15882284
D001241_D007676 CID background_0\NN\4921011 :_1\:\1740 studies_2\NNS\635850 on_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 the_7\DT\1740 long-term_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 <e1>aspirin</e1>_11\NN\2707683 and_12\CC\1740 other_13\JJ\1740 analgesic_14\NN\3740161 and_15\CC\1740 nonsteroidal_16\JJ\1740 anti-inflammatory_17\JJ\1740 drugs_18\NNS\14778436 (_19\-LRB-\1740 nsaids_20\NNS\2721538 )_21\-RRB-\1740 and_22\CC\1740 <e2>end-stage_23\JJ\1740 renal_24\JJ\1740 disease</e2>_25\NN\14061805 (_26\-LRB-\1740 esrd_27\NN\1740 )_28\-RRB-\1740 have_29\VBP\2108377 given_30\VBN\2327200 conflicting_31\JJ\1740 results_32\NNS\34213 ._33\.\1740
D001241_D007676 CID background_0\NN\4921011 :_1\:\1740 studies_2\NNS\635850 on_3\IN\1740 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 the_7\DT\1740 long-term_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 <e1>aspirin</e1>_11\NN\2707683 and_12\CC\1740 other_13\JJ\1740 analgesic_14\NN\3740161 and_15\CC\1740 nonsteroidal_16\JJ\1740 anti-inflammatory_17\JJ\1740 drugs_18\NNS\14778436 (_19\-LRB-\1740 nsaids_20\NNS\2721538 )_21\-RRB-\1740 and_22\CC\1740 end-stage_23\JJ\1740 renal_24\JJ\1740 disease_25\NN\14061805 (_26\-LRB-\1740 <e2>esrd</e2>_27\NN\1740 )_28\-RRB-\1740 have_29\VBP\2108377 given_30\VBN\2327200 conflicting_31\JJ\1740 results_32\NNS\34213 ._33\.\1740
D001241_D007676 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 <e2>esrd</e2>_3\NN\1740 associated_4\VBN\628491 with_5\IN\1740 <e1>aspirin</e1>_6\NN\2707683 was_7\VBD\836236 related_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 cumulated_11\JJ\1740 dose_12\NN\3740161 and_13\CC\1740 duration_14\NN\15113229 of_15\IN\1740 use_16\NN\407535 ,_17\,\1740 and_18\CC\1740 it_19\PRP\6125041 was_20\VBD\836236 particularly_21\RB\1740 high_22\JJ\1740 among_23\IN\1740 the_24\DT\1740 subset_25\NN\7999699 of_26\IN\1740 patients_27\NNS\9898892 with_28\IN\1740 vascular_29\JJ\1740 nephropathy_30\NN\14573196 as_31\IN\14622893 underlying_32\VBG\2604760 disease_33\NN\14061805 [_34\-LRB-\1740 2.35_35\CD\1740 (_36\-LRB-\1740 1.17_37\CD\1740 -_38\SYM\1740 4.72_39\CD\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 ._42\.\1740
D001241_D007676 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 chronic_3\JJ\1740 use_4\NN\407535 of_5\IN\1740 <e1>aspirin</e1>_6\NN\2707683 may_7\MD\15209706 increase_8\VB\169651 the_9\DT\1740 risk_10\NN\14541044 of_11\IN\1740 <e2>esrd</e2>_12\NN\1740 ._13\.\1740
D001241_D007674 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 esrd_3\NN\1740 associated_4\VBN\628491 with_5\IN\1740 <e1>aspirin</e1>_6\NN\2707683 was_7\VBD\836236 related_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 cumulated_11\JJ\1740 dose_12\NN\3740161 and_13\CC\1740 duration_14\NN\15113229 of_15\IN\1740 use_16\NN\407535 ,_17\,\1740 and_18\CC\1740 it_19\PRP\6125041 was_20\VBD\836236 particularly_21\RB\1740 high_22\JJ\1740 among_23\IN\1740 the_24\DT\1740 subset_25\NN\7999699 of_26\IN\1740 patients_27\NNS\9898892 with_28\IN\1740 vascular_29\JJ\1740 <e2>nephropathy</e2>_30\NN\14573196 as_31\IN\14622893 underlying_32\VBG\2604760 disease_33\NN\14061805 [_34\-LRB-\1740 2.35_35\CD\1740 (_36\-LRB-\1740 1.17_37\CD\1740 -_38\SYM\1740 4.72_39\CD\1740 )_40\-RRB-\1740 ]_41\-RRB-\1740 ._42\.\1740
17159032
D006886_D014786 CID early_0\JJ\1740 paracentral_1\JJ\1740 <e2>visual_2\JJ\1740 field_3\NN\8673395 loss</e2>_4\NN\13252973 in_5\IN\13603305 patients_6\NNS\9898892 taking_7\VBG\2367363 <e1>hydroxychloroquine</e1>_8\NN\2721538 ._9\.\1740
D006886_D014786 CID thirty-five_0\JJ\1740 patients_1\NNS\9898892 (_2\-LRB-\1740 13.4_3\CD\1740 %_4\NN\1740 )_5\-RRB-\1740 had_6\VBD\2108377 <e2>visual_7\JJ\1740 field_8\NN\8673395 abnormalities</e2>_9\NNS\14034177 ,_10\,\1740 which_11\WDT\1740 were_12\VBD\836236 attributed_13\VBN\670261 to_14\TO\1740 <e1>hydroxychloroquine</e1>_15\NN\2721538 treatment_16\NN\654885 in_17\IN\13603305 4_18\CD\13741022 patients_19\NNS\9898892 (_20\-LRB-\1740 1.5_21\CD\1740 %_22\NN\1740 )_23\-RRB-\1740 ._24\.\1740
7018927
D006220_D006966 CID pituitary_0\JJ\1740 response_1\NN\11410625 to_2\TO\1740 luteinizing_3\VBG\1740 hormone-releasing_4\JJ\1740 hormone_5\NN\5404728 during_6\IN\1740 <e1>haloperidol-induced</e1>_7\JJ\1740 <e2>hyperprolactinemia</e2>_8\NN\1740 ._9\.\1740
D006220_D006966 CID during_0\IN\1740 the_1\DT\1740 course_2\NN\883297 of_3\IN\1740 <e1>haloperidol</e1>_4\NN\3713736 infusions_5\NNS\14589223 ,_6\,\1740 significant_7\JJ\1740 <e2>hyperprolactinemia</e2>_8\NN\1740 was_9\VBD\836236 found_10\VBN\2426171 ,_11\,\1740 together_12\RB\1740 with_13\IN\1740 an_14\DT\6697703 abolished_15\VBN\1740 pituitary_16\JJ\1740 response_17\NN\11410625 to_18\TO\1740 lh-rh_19\NN\1740 ,_20\,\1740 as_21\IN\14622893 compared_22\VBN\644583 with_23\IN\1740 responses_24\NNS\11410625 of_25\IN\1740 control_26\JJ\1740 subjects_27\NNS\6598915 ._28\.\1740
6305660
2553470
D016291_D013226 NONE anticonvulsant_0\JJ\1740 actions_1\NNS\30358 of_2\IN\1740 <e1>mk-801</e1>_3\NN\1740 on_4\IN\1740 the_5\DT\1740 lithium-pilocarpine_6\NN\1740 model_7\NN\5888929 of_8\IN\1740 <e2>status_9\NN\24720 epilepticus</e2>_10\NN\1740 in_11\IN\13603305 rats_12\NNS\2329401 ._13\.\1740
D016291_D013226 NONE administration_0\NN\1133281 of_1\IN\1740 <e1>mk-801</e1>_2\NN\1740 30_3\CD\13745420 or_4\CC\3541091 60_5\CD\13745420 min_6\NN\15154774 after_7\IN\1740 pilocarpine_8\NN\14712692 ,_9\,\1740 i.e._10\FW\1740 ,_11\,\1740 during_12\IN\1740 <e2>status_13\NN\24720 epilepticus</e2>_14\NN\1740 ,_15\,\1740 gradually_16\RB\1740 reduced_17\VBN\441445 electrical_18\JJ\1740 and_19\CC\1740 behavioral_20\JJ\1740 seizure_21\NN\14081375 activity_22\NN\30358 and_23\CC\1740 greatly_24\RB\1740 enhanced_25\VBD\227165 the_26\DT\1740 survival_27\NN\13961642 rate_28\NN\13815152 ._29\.\1740
D008094_D013226 CID anticonvulsant_0\JJ\1740 actions_1\NNS\30358 of_2\IN\1740 mk-801_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e1>lithium-pilocarpine</e1>_6\NN\1740 model_7\NN\5888929 of_8\IN\1740 <e2>status_9\NN\24720 epilepticus</e2>_10\NN\1740 in_11\IN\13603305 rats_12\NNS\2329401 ._13\.\1740
D008094_D013226 CID third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 seizures_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 <e1>lithium</e1>_12\NN\14625458 and_13\CC\1740 pilocarpine_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 pilocarpine_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 <e2>status_30\NN\24720 epilepticus</e2>_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 seizures_38\NNS\14081375 ._39\.\1740
D008094_D013226 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 activation_4\NN\13561719 of_5\IN\1740 nmda_6\NN\1740 receptors_7\NNS\5225602 plays_8\VBZ\1072262 an_9\DT\6697703 important_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 <e2>status_13\NN\24720 epilepticus</e2>_14\NN\1740 and_15\CC\1740 brain_16\NN\5462674 damage_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 <e1>lithium-pilocarpine</e1>_20\NN\1740 model_21\NN\5888929 ._22\.\1740
D010862_D013226 CID anticonvulsant_0\JJ\1740 actions_1\NNS\30358 of_2\IN\1740 mk-801_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e1>lithium-pilocarpine</e1>_6\NN\1740 model_7\NN\5888929 of_8\IN\1740 <e2>status_9\NN\24720 epilepticus</e2>_10\NN\1740 in_11\IN\13603305 rats_12\NNS\2329401 ._13\.\1740
D010862_D013226 CID third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 seizures_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 lithium_12\NN\14625458 and_13\CC\1740 <e1>pilocarpine</e1>_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 pilocarpine_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 <e2>status_30\NN\24720 epilepticus</e2>_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 seizures_38\NNS\14081375 ._39\.\1740
D010862_D013226 CID third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 seizures_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 lithium_12\NN\14625458 and_13\CC\1740 pilocarpine_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 <e1>pilocarpine</e1>_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 <e2>status_30\NN\24720 epilepticus</e2>_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 seizures_38\NNS\14081375 ._39\.\1740
D010862_D013226 CID administration_0\NN\1133281 of_1\IN\1740 mk-801_2\NN\1740 30_3\CD\13745420 or_4\CC\3541091 60_5\CD\13745420 min_6\NN\15154774 after_7\IN\1740 <e1>pilocarpine</e1>_8\NN\14712692 ,_9\,\1740 i.e._10\FW\1740 ,_11\,\1740 during_12\IN\1740 <e2>status_13\NN\24720 epilepticus</e2>_14\NN\1740 ,_15\,\1740 gradually_16\RB\1740 reduced_17\VBN\441445 electrical_18\JJ\1740 and_19\CC\1740 behavioral_20\JJ\1740 seizure_21\NN\14081375 activity_22\NN\30358 and_23\CC\1740 greatly_24\RB\1740 enhanced_25\VBD\227165 the_26\DT\1740 survival_27\NN\13961642 rate_28\NN\13815152 ._29\.\1740
D010862_D013226 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 activation_4\NN\13561719 of_5\IN\1740 nmda_6\NN\1740 receptors_7\NNS\5225602 plays_8\VBZ\1072262 an_9\DT\6697703 important_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 <e2>status_13\NN\24720 epilepticus</e2>_14\NN\1740 and_15\CC\1740 brain_16\NN\5462674 damage_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 <e1>lithium-pilocarpine</e1>_20\NN\1740 model_21\NN\5888929 ._22\.\1740
D010862_D013226 CID this_0\DT\1740 was_1\VBD\836236 further_2\RBR\1740 supported_3\VBN\2199590 by_4\IN\1740 results_5\NNS\34213 showing_6\VBG\2137132 that_7\IN\1740 nonconvulsive_8\JJ\1740 doses_9\NNS\3740161 of_10\IN\1740 nmda_11\NN\1740 and_12\CC\1740 <e1>pilocarpine</e1>_13\NN\14712692 were_14\VBD\836236 synergistic_15\JJ\1740 ,_16\,\1740 resulting_17\VBG\2633881 in_18\IN\13603305 <e2>status_19\NN\24720 epilepticus</e2>_20\NN\1740 and_21\CC\1740 subsequent_22\JJ\1740 mortality_23\NN\5054863 ._24\.\1740
D016291_D012640 NONE <e1>mk-801</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 noncompetitive_3\JJ\1740 n-methyl-d-aspartate_4\NN\1740 (_5\-LRB-\1740 nmda_6\NN\1740 )_7\-RRB-\1740 receptor_8\NN\5225602 antagonist_9\NN\7846 ,_10\,\1740 was_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 in_16\IN\13603305 rats_17\NNS\2329401 using_18\VBG\1156834 two_19\CD\13741022 <e2>seizure</e2>_20\NN\14081375 models_21\NNS\5888929 ,_22\,\1740 coadministration_23\NN\1740 of_24\IN\1740 lithium_25\NN\14625458 and_26\CC\1740 pilocarpine_27\NN\14712692 and_28\CC\1740 administration_29\NN\1133281 of_30\IN\1740 a_31\DT\13649268 high_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 pilocarpine_35\NN\14712692 alone_36\RB\1740 ._37\.\1740
D016291_D012640 NONE first_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 <e1>mk-801</e1>_4\NN\1740 produced_5\VBD\1617192 an_6\DT\6697703 effective_7\JJ\1740 and_8\CC\1740 dose-dependent_9\JJ\1740 anticonvulsant_10\JJ\1740 action_11\NN\30358 with_12\IN\1740 the_13\DT\1740 lithium-pilocarpine_14\NN\1740 model_15\NN\5888929 but_16\CC\1740 not_17\RB\1740 with_18\IN\1740 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 pilocarpine_22\NN\14712692 alone_23\RB\1740 ,_24\,\1740 suggesting_25\VBG\1010118 that_26\IN\1740 different_27\JJ\1740 biochemical_28\JJ\1740 mechanisms_29\NNS\13446390 control_30\VBP\2422663 <e2>seizures</e2>_31\NNS\14081375 in_32\IN\13603305 these_33\DT\1740 two_34\CD\13741022 models_35\NNS\5888929 ._36\.\1740
D016291_D012640 NONE second_0\RB\1740 ,_1\,\1740 the_2\DT\1740 anticonvulsant_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 <e1>mk-801</e1>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 lithium-pilocarpine_9\NN\1740 model_10\NN\5888929 only_11\RB\1740 occurred_12\VBD\2623529 after_13\IN\1740 initial_14\JJ\1740 periods_15\NNS\13575869 of_16\IN\1740 <e2>seizure</e2>_17\JJ\1740 activity_18\NN\30358 ._19\.\1740
D016291_D012640 NONE administration_0\NN\1133281 of_1\IN\1740 <e1>mk-801</e1>_2\NN\1740 30_3\CD\13745420 or_4\CC\3541091 60_5\CD\13745420 min_6\NN\15154774 after_7\IN\1740 pilocarpine_8\NN\14712692 ,_9\,\1740 i.e._10\FW\1740 ,_11\,\1740 during_12\IN\1740 status_13\NN\24720 epilepticus_14\NN\1740 ,_15\,\1740 gradually_16\RB\1740 reduced_17\VBN\441445 electrical_18\JJ\1740 and_19\CC\1740 behavioral_20\JJ\1740 <e2>seizure</e2>_21\NN\14081375 activity_22\NN\30358 and_23\CC\1740 greatly_24\RB\1740 enhanced_25\VBD\227165 the_26\DT\1740 survival_27\NN\13961642 rate_28\NN\13815152 ._29\.\1740
D016202_D012640 NONE mk-801_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 noncompetitive_3\JJ\1740 <e1>n-methyl-d-aspartate</e1>_4\NN\1740 (_5\-LRB-\1740 nmda_6\NN\1740 )_7\-RRB-\1740 receptor_8\NN\5225602 antagonist_9\NN\7846 ,_10\,\1740 was_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 in_16\IN\13603305 rats_17\NNS\2329401 using_18\VBG\1156834 two_19\CD\13741022 <e2>seizure</e2>_20\NN\14081375 models_21\NNS\5888929 ,_22\,\1740 coadministration_23\NN\1740 of_24\IN\1740 lithium_25\NN\14625458 and_26\CC\1740 pilocarpine_27\NN\14712692 and_28\CC\1740 administration_29\NN\1133281 of_30\IN\1740 a_31\DT\13649268 high_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 pilocarpine_35\NN\14712692 alone_36\RB\1740 ._37\.\1740
D016202_D012640 NONE mk-801_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 noncompetitive_3\JJ\1740 n-methyl-d-aspartate_4\NN\1740 (_5\-LRB-\1740 <e1>nmda</e1>_6\NN\1740 )_7\-RRB-\1740 receptor_8\NN\5225602 antagonist_9\NN\7846 ,_10\,\1740 was_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 in_16\IN\13603305 rats_17\NNS\2329401 using_18\VBG\1156834 two_19\CD\13741022 <e2>seizure</e2>_20\NN\14081375 models_21\NNS\5888929 ,_22\,\1740 coadministration_23\NN\1740 of_24\IN\1740 lithium_25\NN\14625458 and_26\CC\1740 pilocarpine_27\NN\14712692 and_28\CC\1740 administration_29\NN\1133281 of_30\IN\1740 a_31\DT\13649268 high_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 pilocarpine_35\NN\14712692 alone_36\RB\1740 ._37\.\1740
D008094_D012640 NONE mk-801_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 noncompetitive_3\JJ\1740 n-methyl-d-aspartate_4\NN\1740 (_5\-LRB-\1740 nmda_6\NN\1740 )_7\-RRB-\1740 receptor_8\NN\5225602 antagonist_9\NN\7846 ,_10\,\1740 was_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 in_16\IN\13603305 rats_17\NNS\2329401 using_18\VBG\1156834 two_19\CD\13741022 <e2>seizure</e2>_20\NN\14081375 models_21\NNS\5888929 ,_22\,\1740 coadministration_23\NN\1740 of_24\IN\1740 <e1>lithium</e1>_25\NN\14625458 and_26\CC\1740 pilocarpine_27\NN\14712692 and_28\CC\1740 administration_29\NN\1133281 of_30\IN\1740 a_31\DT\13649268 high_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 pilocarpine_35\NN\14712692 alone_36\RB\1740 ._37\.\1740
D008094_D012640 NONE first_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 mk-801_4\NN\1740 produced_5\VBD\1617192 an_6\DT\6697703 effective_7\JJ\1740 and_8\CC\1740 dose-dependent_9\JJ\1740 anticonvulsant_10\JJ\1740 action_11\NN\30358 with_12\IN\1740 the_13\DT\1740 <e1>lithium-pilocarpine</e1>_14\NN\1740 model_15\NN\5888929 but_16\CC\1740 not_17\RB\1740 with_18\IN\1740 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 pilocarpine_22\NN\14712692 alone_23\RB\1740 ,_24\,\1740 suggesting_25\VBG\1010118 that_26\IN\1740 different_27\JJ\1740 biochemical_28\JJ\1740 mechanisms_29\NNS\13446390 control_30\VBP\2422663 <e2>seizures</e2>_31\NNS\14081375 in_32\IN\13603305 these_33\DT\1740 two_34\CD\13741022 models_35\NNS\5888929 ._36\.\1740
D008094_D012640 NONE second_0\RB\1740 ,_1\,\1740 the_2\DT\1740 anticonvulsant_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 mk-801_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 <e1>lithium-pilocarpine</e1>_9\NN\1740 model_10\NN\5888929 only_11\RB\1740 occurred_12\VBD\2623529 after_13\IN\1740 initial_14\JJ\1740 periods_15\NNS\13575869 of_16\IN\1740 <e2>seizure</e2>_17\JJ\1740 activity_18\NN\30358 ._19\.\1740
D008094_D012640 NONE third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 <e2>seizures</e2>_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 <e1>lithium</e1>_12\NN\14625458 and_13\CC\1740 pilocarpine_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 pilocarpine_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 status_30\NN\24720 epilepticus_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 seizures_38\NNS\14081375 ._39\.\1740
D008094_D012640 NONE third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 seizures_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 <e1>lithium</e1>_12\NN\14625458 and_13\CC\1740 pilocarpine_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 pilocarpine_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 status_30\NN\24720 epilepticus_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 <e2>seizures</e2>_38\NNS\14081375 ._39\.\1740
D010862_D012640 NONE mk-801_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 noncompetitive_3\JJ\1740 n-methyl-d-aspartate_4\NN\1740 (_5\-LRB-\1740 nmda_6\NN\1740 )_7\-RRB-\1740 receptor_8\NN\5225602 antagonist_9\NN\7846 ,_10\,\1740 was_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 in_16\IN\13603305 rats_17\NNS\2329401 using_18\VBG\1156834 two_19\CD\13741022 <e2>seizure</e2>_20\NN\14081375 models_21\NNS\5888929 ,_22\,\1740 coadministration_23\NN\1740 of_24\IN\1740 lithium_25\NN\14625458 and_26\CC\1740 <e1>pilocarpine</e1>_27\NN\14712692 and_28\CC\1740 administration_29\NN\1133281 of_30\IN\1740 a_31\DT\13649268 high_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 pilocarpine_35\NN\14712692 alone_36\RB\1740 ._37\.\1740
D010862_D012640 NONE mk-801_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 noncompetitive_3\JJ\1740 n-methyl-d-aspartate_4\NN\1740 (_5\-LRB-\1740 nmda_6\NN\1740 )_7\-RRB-\1740 receptor_8\NN\5225602 antagonist_9\NN\7846 ,_10\,\1740 was_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 in_16\IN\13603305 rats_17\NNS\2329401 using_18\VBG\1156834 two_19\CD\13741022 <e2>seizure</e2>_20\NN\14081375 models_21\NNS\5888929 ,_22\,\1740 coadministration_23\NN\1740 of_24\IN\1740 lithium_25\NN\14625458 and_26\CC\1740 pilocarpine_27\NN\14712692 and_28\CC\1740 administration_29\NN\1133281 of_30\IN\1740 a_31\DT\13649268 high_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 <e1>pilocarpine</e1>_35\NN\14712692 alone_36\RB\1740 ._37\.\1740
D010862_D012640 NONE first_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 mk-801_4\NN\1740 produced_5\VBD\1617192 an_6\DT\6697703 effective_7\JJ\1740 and_8\CC\1740 dose-dependent_9\JJ\1740 anticonvulsant_10\JJ\1740 action_11\NN\30358 with_12\IN\1740 the_13\DT\1740 <e1>lithium-pilocarpine</e1>_14\NN\1740 model_15\NN\5888929 but_16\CC\1740 not_17\RB\1740 with_18\IN\1740 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 pilocarpine_22\NN\14712692 alone_23\RB\1740 ,_24\,\1740 suggesting_25\VBG\1010118 that_26\IN\1740 different_27\JJ\1740 biochemical_28\JJ\1740 mechanisms_29\NNS\13446390 control_30\VBP\2422663 <e2>seizures</e2>_31\NNS\14081375 in_32\IN\13603305 these_33\DT\1740 two_34\CD\13741022 models_35\NNS\5888929 ._36\.\1740
D010862_D012640 NONE first_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 mk-801_4\NN\1740 produced_5\VBD\1617192 an_6\DT\6697703 effective_7\JJ\1740 and_8\CC\1740 dose-dependent_9\JJ\1740 anticonvulsant_10\JJ\1740 action_11\NN\30358 with_12\IN\1740 the_13\DT\1740 lithium-pilocarpine_14\NN\1740 model_15\NN\5888929 but_16\CC\1740 not_17\RB\1740 with_18\IN\1740 rats_19\NNS\2329401 treated_20\VBN\2376958 with_21\IN\1740 <e1>pilocarpine</e1>_22\NN\14712692 alone_23\RB\1740 ,_24\,\1740 suggesting_25\VBG\1010118 that_26\IN\1740 different_27\JJ\1740 biochemical_28\JJ\1740 mechanisms_29\NNS\13446390 control_30\VBP\2422663 <e2>seizures</e2>_31\NNS\14081375 in_32\IN\13603305 these_33\DT\1740 two_34\CD\13741022 models_35\NNS\5888929 ._36\.\1740
D010862_D012640 NONE second_0\RB\1740 ,_1\,\1740 the_2\DT\1740 anticonvulsant_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 mk-801_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 <e1>lithium-pilocarpine</e1>_9\NN\1740 model_10\NN\5888929 only_11\RB\1740 occurred_12\VBD\2623529 after_13\IN\1740 initial_14\JJ\1740 periods_15\NNS\13575869 of_16\IN\1740 <e2>seizure</e2>_17\JJ\1740 activity_18\NN\30358 ._19\.\1740
D010862_D012640 NONE third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 <e2>seizures</e2>_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 lithium_12\NN\14625458 and_13\CC\1740 <e1>pilocarpine</e1>_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 pilocarpine_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 status_30\NN\24720 epilepticus_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 seizures_38\NNS\14081375 ._39\.\1740
D010862_D012640 NONE third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 seizures_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 lithium_12\NN\14625458 and_13\CC\1740 <e1>pilocarpine</e1>_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 pilocarpine_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 status_30\NN\24720 epilepticus_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 <e2>seizures</e2>_38\NNS\14081375 ._39\.\1740
D010862_D012640 NONE third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 <e2>seizures</e2>_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 lithium_12\NN\14625458 and_13\CC\1740 pilocarpine_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 <e1>pilocarpine</e1>_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 status_30\NN\24720 epilepticus_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 seizures_38\NNS\14081375 ._39\.\1740
D010862_D012640 NONE third_0\RB\1740 ,_1\,\1740 although_2\IN\1740 it_3\PRP\6125041 is_4\VBZ\836236 relatively_5\RB\1740 easy_6\JJ\1740 to_7\TO\1740 block_8\VB\1476483 seizures_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 lithium_12\NN\14625458 and_13\CC\1740 pilocarpine_14\NN\14712692 by_15\IN\1740 administration_16\NN\1133281 of_17\IN\1740 anticonvulsants_18\NNS\3740161 prior_19\RB\1740 to_20\TO\1740 <e1>pilocarpine</e1>_21\NN\14712692 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 more_25\RBR\1740 difficult_26\JJ\1740 to_27\TO\1740 terminate_28\VB\126264 ongoing_29\JJ\1740 status_30\NN\24720 epilepticus_31\NN\1740 and_32\CC\1740 block_33\VBP\1476483 the_34\DT\1740 lethality_35\NN\4790449 of_36\IN\1740 the_37\DT\1740 <e2>seizures</e2>_38\NNS\14081375 ._39\.\1740
D010862_D012640 NONE administration_0\NN\1133281 of_1\IN\1740 mk-801_2\NN\1740 30_3\CD\13745420 or_4\CC\3541091 60_5\CD\13745420 min_6\NN\15154774 after_7\IN\1740 <e1>pilocarpine</e1>_8\NN\14712692 ,_9\,\1740 i.e._10\FW\1740 ,_11\,\1740 during_12\IN\1740 status_13\NN\24720 epilepticus_14\NN\1740 ,_15\,\1740 gradually_16\RB\1740 reduced_17\VBN\441445 electrical_18\JJ\1740 and_19\CC\1740 behavioral_20\JJ\1740 <e2>seizure</e2>_21\NN\14081375 activity_22\NN\30358 and_23\CC\1740 greatly_24\RB\1740 enhanced_25\VBD\227165 the_26\DT\1740 survival_27\NN\13961642 rate_28\NN\13815152 ._29\.\1740
D016202_D013226 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 activation_4\NN\13561719 of_5\IN\1740 <e1>nmda</e1>_6\NN\1740 receptors_7\NNS\5225602 plays_8\VBZ\1072262 an_9\DT\6697703 important_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 <e2>status_13\NN\24720 epilepticus</e2>_14\NN\1740 and_15\CC\1740 brain_16\NN\5462674 damage_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 lithium-pilocarpine_20\NN\1740 model_21\NN\5888929 ._22\.\1740
D016202_D013226 NONE this_0\DT\1740 was_1\VBD\836236 further_2\RBR\1740 supported_3\VBN\2199590 by_4\IN\1740 results_5\NNS\34213 showing_6\VBG\2137132 that_7\IN\1740 nonconvulsive_8\JJ\1740 doses_9\NNS\3740161 of_10\IN\1740 <e1>nmda</e1>_11\NN\1740 and_12\CC\1740 pilocarpine_13\NN\14712692 were_14\VBD\836236 synergistic_15\JJ\1740 ,_16\,\1740 resulting_17\VBG\2633881 in_18\IN\13603305 <e2>status_19\NN\24720 epilepticus</e2>_20\NN\1740 and_21\CC\1740 subsequent_22\JJ\1740 mortality_23\NN\5054863 ._24\.\1740
D016202_D001930 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 activation_4\NN\13561719 of_5\IN\1740 <e1>nmda</e1>_6\NN\1740 receptors_7\NNS\5225602 plays_8\VBZ\1072262 an_9\DT\6697703 important_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 status_13\NN\24720 epilepticus_14\NN\1740 and_15\CC\1740 <e2>brain_16\NN\5462674 damage</e2>_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 lithium-pilocarpine_20\NN\1740 model_21\NN\5888929 ._22\.\1740
D008094_D001930 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 activation_4\NN\13561719 of_5\IN\1740 nmda_6\NN\1740 receptors_7\NNS\5225602 plays_8\VBZ\1072262 an_9\DT\6697703 important_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 status_13\NN\24720 epilepticus_14\NN\1740 and_15\CC\1740 <e2>brain_16\NN\5462674 damage</e2>_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 <e1>lithium-pilocarpine</e1>_20\NN\1740 model_21\NN\5888929 ._22\.\1740
D010862_D001930 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 activation_4\NN\13561719 of_5\IN\1740 nmda_6\NN\1740 receptors_7\NNS\5225602 plays_8\VBZ\1072262 an_9\DT\6697703 important_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 status_13\NN\24720 epilepticus_14\NN\1740 and_15\CC\1740 <e2>brain_16\NN\5462674 damage</e2>_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 <e1>lithium-pilocarpine</e1>_20\NN\1740 model_21\NN\5888929 ._22\.\1740
9132810
D008727_D056784 CID this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 unique_3\JJ\1740 contrast_4\NN\13854649 enhancement_5\NN\248977 of_6\IN\1740 the_7\DT\1740 white_8\JJ\1740 matter_9\NN\5670710 on_10\IN\1740 t1-weighted_11\JJ\1740 magnetic_12\JJ\1740 resonance_13\NN\11419404 images_14\NNS\5926676 of_15\IN\1740 two_16\CD\13741022 patients_17\NNS\9898892 with_18\IN\1740 disseminated_19\VBN\954608 necrotizing_20\NN\1740 <e2>leukoencephalopathy</e2>_21\IN\1740 ,_22\,\1740 which_23\WDT\1740 developed_24\VBD\1753788 from_25\IN\1740 acute_26\JJ\1740 lymphoblastic_27\JJ\1740 leukemia_28\NN\14239918 treated_29\VBN\2376958 with_30\IN\1740 high-dose_31\JJ\1740 <e1>methotrexate</e1>_32\NN\2722166 ._33\.\1740
D008727_D054198 NONE this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 unique_3\JJ\1740 contrast_4\NN\13854649 enhancement_5\NN\248977 of_6\IN\1740 the_7\DT\1740 white_8\JJ\1740 matter_9\NN\5670710 on_10\IN\1740 t1-weighted_11\JJ\1740 magnetic_12\JJ\1740 resonance_13\NN\11419404 images_14\NNS\5926676 of_15\IN\1740 two_16\CD\13741022 patients_17\NNS\9898892 with_18\IN\1740 disseminated_19\VBN\954608 necrotizing_20\NN\1740 leukoencephalopathy_21\IN\1740 ,_22\,\1740 which_23\WDT\1740 developed_24\VBD\1753788 from_25\IN\1740 <e2>acute_26\JJ\1740 lymphoblastic_27\JJ\1740 leukemia</e2>_28\NN\14239918 treated_29\VBN\2376958 with_30\IN\1740 high-dose_31\JJ\1740 <e1>methotrexate</e1>_32\NN\2722166 ._33\.\1740
10219427
12828076
D000082_D017114 CID increased_0\VBN\169651 serum_1\NN\5397468 soluble_2\JJ\1740 fas_3\NN\14304060 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 <e2>acute_7\JJ\1740 liver_8\NN\5298729 failure</e2>_9\NN\66216 due_10\JJ\1740 to_11\TO\1740 <e1>paracetamol</e1>_12\NN\1740 overdose_13\NN\1740 ._14\.\1740
D000082_D017114 CID levels_0\NNS\4916342 were_1\VBD\836236 significantly_2\RB\1740 greater_3\JJR\1740 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 <e2>acute_7\JJ\1740 liver_8\NN\5298729 failure</e2>_9\NN\66216 due_10\JJ\1740 to_11\TO\1740 <e1>paracetamol</e1>_12\NN\1740 overdose_13\NN\1740 (_14\-LRB-\1740 median_15\NN\6021761 ,_16\,\1740 28.7_17\CD\1740 u/ml_18\NN\1740 ;_19\:\1740 range_20\VB\2604760 ,_21\,\1740 12.8_22\CD\1740 -_23\SYM\1740 52.7_24\CD\1740 u/ml_25\NN\1740 ,_26\,\1740 n_27\NN\14622893 =_28\JJ\1740 17_29\CD\13745420 )_30\-RRB-\1740 than_31\IN\1740 those_32\DT\1740 due_33\JJ\1740 to_34\IN\1740 non-a_35\NN\1740 to_36\TO\1740 e_37\NN\14724645 hepatitis_38\NN\14127211 (_39\-LRB-\1740 median_40\NN\6021761 ,_41\,\1740 12.5_42\CD\1740 u/ml_43\NN\1740 ;_44\:\1740 range_45\VB\2604760 ,_46\,\1740 6.9_47\CD\1740 -_48\HYPH\1740 46.0_49\CD\1740 u/ml_50\NN\1740 ,_51\,\1740 n_52\NN\14622893 =_53\JJ\1740 7_54\CD\13741022 ,_55\,\1740 p_56\NN\14622893 <_57\XX\1740 0.01_58\CD\1740 )_59\-RRB-\1740 ._60\.\1740
D000082_D062787 NONE increased_0\VBN\169651 serum_1\NN\5397468 soluble_2\JJ\1740 fas_3\NN\14304060 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 acute_7\JJ\1740 liver_8\NN\5298729 failure_9\NN\66216 due_10\JJ\1740 to_11\TO\1740 <e1>paracetamol</e1>_12\NN\1740 <e2>overdose</e2>_13\NN\1740 ._14\.\1740
D000082_D062787 NONE levels_0\NNS\4916342 were_1\VBD\836236 significantly_2\RB\1740 greater_3\JJR\1740 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 acute_7\JJ\1740 liver_8\NN\5298729 failure_9\NN\66216 due_10\JJ\1740 to_11\TO\1740 <e1>paracetamol</e1>_12\NN\1740 <e2>overdose</e2>_13\NN\1740 (_14\-LRB-\1740 median_15\NN\6021761 ,_16\,\1740 28.7_17\CD\1740 u/ml_18\NN\1740 ;_19\:\1740 range_20\VB\2604760 ,_21\,\1740 12.8_22\CD\1740 -_23\SYM\1740 52.7_24\CD\1740 u/ml_25\NN\1740 ,_26\,\1740 n_27\NN\14622893 =_28\JJ\1740 17_29\CD\13745420 )_30\-RRB-\1740 than_31\IN\1740 those_32\DT\1740 due_33\JJ\1740 to_34\IN\1740 non-a_35\NN\1740 to_36\TO\1740 e_37\NN\14724645 hepatitis_38\NN\14127211 (_39\-LRB-\1740 median_40\NN\6021761 ,_41\,\1740 12.5_42\CD\1740 u/ml_43\NN\1740 ;_44\:\1740 range_45\VB\2604760 ,_46\,\1740 6.9_47\CD\1740 -_48\HYPH\1740 46.0_49\CD\1740 u/ml_50\NN\1740 ,_51\,\1740 n_52\NN\14622893 =_53\JJ\1740 7_54\CD\13741022 ,_55\,\1740 p_56\NN\14622893 <_57\XX\1740 0.01_58\CD\1740 )_59\-RRB-\1740 ._60\.\1740
D000082_D056486 NONE levels_0\NNS\4916342 were_1\VBD\836236 significantly_2\RB\1740 greater_3\JJR\1740 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 acute_7\JJ\1740 liver_8\NN\5298729 failure_9\NN\66216 due_10\JJ\1740 to_11\TO\1740 <e1>paracetamol</e1>_12\NN\1740 overdose_13\NN\1740 (_14\-LRB-\1740 median_15\NN\6021761 ,_16\,\1740 28.7_17\CD\1740 u/ml_18\NN\1740 ;_19\:\1740 range_20\VB\2604760 ,_21\,\1740 12.8_22\CD\1740 -_23\SYM\1740 52.7_24\CD\1740 u/ml_25\NN\1740 ,_26\,\1740 n_27\NN\14622893 =_28\JJ\1740 17_29\CD\13745420 )_30\-RRB-\1740 than_31\IN\1740 those_32\DT\1740 due_33\JJ\1740 to_34\IN\1740 non-a_35\NN\1740 to_36\TO\1740 e_37\NN\14724645 <e2>hepatitis</e2>_38\NN\14127211 (_39\-LRB-\1740 median_40\NN\6021761 ,_41\,\1740 12.5_42\CD\1740 u/ml_43\NN\1740 ;_44\:\1740 range_45\VB\2604760 ,_46\,\1740 6.9_47\CD\1740 -_48\HYPH\1740 46.0_49\CD\1740 u/ml_50\NN\1740 ,_51\,\1740 n_52\NN\14622893 =_53\JJ\1740 7_54\CD\13741022 ,_55\,\1740 p_56\NN\14622893 <_57\XX\1740 0.01_58\CD\1740 )_59\-RRB-\1740 ._60\.\1740
11229942
D003042_D066126 NONE <e1>cocaine</e1>_0\NNP\3492717 ,_1\,\1740 ethanol_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 cocaethylene_5\NN\1740 <e2>cardiotoxity</e2>_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse_15\NN\418025 ._16\.\1740
D003042_D066126 NONE their_0\PRP$\1740 combined_1\JJ\1740 <e2>cardiac_2\JJ\1740 toxicity</e2>_3\NN\13576101 may_4\MD\15209706 be_5\VB\836236 due_6\JJ\1740 to_7\TO\1740 independent_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 each_11\DT\1740 drug_12\NN\14778436 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 they_16\PRP\1740 may_17\MD\15209706 also_18\RB\1740 be_19\VB\836236 due_20\JJ\1740 to_21\TO\1740 cocaethylene_22\NN\1740 (_23\-LRB-\1740 ce_24\NN\14625458 )_25\-RRB-\1740 ,_26\,\1740 a_27\DT\13649268 <e1>cocaine</e1>_28\NN\3492717 metabolite_29\NN\20090 formed_30\VBN\1617192 only_31\RB\1740 in_32\IN\13603305 the_33\DT\1740 presence_34\NN\13954253 of_35\IN\1740 ethanol_36\NN\14708720 ._37\.\1740
D003042_D066126 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 delineate_7\VB\2137132 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 ce_11\NN\14625458 in_12\IN\13603305 the_13\DT\1740 combined_14\JJ\1740 <e2>cardiotoxicity</e2>_15\NN\1740 of_16\IN\1740 <e1>cocaine</e1>_17\NN\3492717 and_18\CC\1740 ethanol_19\NN\14708720 in_20\IN\13603305 a_21\DT\13649268 model_22\NN\5888929 simulating_23\VBG\1736822 their_24\PRP$\1740 abuse_25\NN\418025 ._26\.\1740
D003042_D019970 NONE <e1>cocaine</e1>_0\NNP\3492717 ,_1\,\1740 ethanol_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 cocaethylene_5\NN\1740 cardiotoxity_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e2>cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse</e2>_15\NN\418025 ._16\.\1740
D003042_D000437 NONE <e1>cocaine</e1>_0\NNP\3492717 ,_1\,\1740 ethanol_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 cocaethylene_5\NN\1740 cardiotoxity_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e2>cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse</e2>_15\NN\418025 ._16\.\1740
D000431_D066126 NONE cocaine_0\NNP\3492717 ,_1\,\1740 <e1>ethanol</e1>_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 cocaethylene_5\NN\1740 <e2>cardiotoxity</e2>_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse_15\NN\418025 ._16\.\1740
D000431_D066126 NONE their_0\PRP$\1740 combined_1\JJ\1740 <e2>cardiac_2\JJ\1740 toxicity</e2>_3\NN\13576101 may_4\MD\15209706 be_5\VB\836236 due_6\JJ\1740 to_7\TO\1740 independent_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 each_11\DT\1740 drug_12\NN\14778436 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 they_16\PRP\1740 may_17\MD\15209706 also_18\RB\1740 be_19\VB\836236 due_20\JJ\1740 to_21\TO\1740 cocaethylene_22\NN\1740 (_23\-LRB-\1740 ce_24\NN\14625458 )_25\-RRB-\1740 ,_26\,\1740 a_27\DT\13649268 cocaine_28\NN\3492717 metabolite_29\NN\20090 formed_30\VBN\1617192 only_31\RB\1740 in_32\IN\13603305 the_33\DT\1740 presence_34\NN\13954253 of_35\IN\1740 <e1>ethanol</e1>_36\NN\14708720 ._37\.\1740
D000431_D066126 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 delineate_7\VB\2137132 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 ce_11\NN\14625458 in_12\IN\13603305 the_13\DT\1740 combined_14\JJ\1740 <e2>cardiotoxicity</e2>_15\NN\1740 of_16\IN\1740 cocaine_17\NN\3492717 and_18\CC\1740 <e1>ethanol</e1>_19\NN\14708720 in_20\IN\13603305 a_21\DT\13649268 model_22\NN\5888929 simulating_23\VBG\1736822 their_24\PRP$\1740 abuse_25\NN\418025 ._26\.\1740
D000431_D019970 NONE cocaine_0\NNP\3492717 ,_1\,\1740 <e1>ethanol</e1>_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 cocaethylene_5\NN\1740 cardiotoxity_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e2>cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse</e2>_15\NN\418025 ._16\.\1740
D000431_D000437 NONE cocaine_0\NNP\3492717 ,_1\,\1740 <e1>ethanol</e1>_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 cocaethylene_5\NN\1740 cardiotoxity_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e2>cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse</e2>_15\NN\418025 ._16\.\1740
C066444_D066126 NONE cocaine_0\NNP\3492717 ,_1\,\1740 ethanol_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 <e1>cocaethylene</e1>_5\NN\1740 <e2>cardiotoxity</e2>_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse_15\NN\418025 ._16\.\1740
C066444_D066126 NONE their_0\PRP$\1740 combined_1\JJ\1740 <e2>cardiac_2\JJ\1740 toxicity</e2>_3\NN\13576101 may_4\MD\15209706 be_5\VB\836236 due_6\JJ\1740 to_7\TO\1740 independent_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 each_11\DT\1740 drug_12\NN\14778436 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 they_16\PRP\1740 may_17\MD\15209706 also_18\RB\1740 be_19\VB\836236 due_20\JJ\1740 to_21\TO\1740 <e1>cocaethylene</e1>_22\NN\1740 (_23\-LRB-\1740 ce_24\NN\14625458 )_25\-RRB-\1740 ,_26\,\1740 a_27\DT\13649268 cocaine_28\NN\3492717 metabolite_29\NN\20090 formed_30\VBN\1617192 only_31\RB\1740 in_32\IN\13603305 the_33\DT\1740 presence_34\NN\13954253 of_35\IN\1740 ethanol_36\NN\14708720 ._37\.\1740
C066444_D066126 NONE their_0\PRP$\1740 combined_1\JJ\1740 <e2>cardiac_2\JJ\1740 toxicity</e2>_3\NN\13576101 may_4\MD\15209706 be_5\VB\836236 due_6\JJ\1740 to_7\TO\1740 independent_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 each_11\DT\1740 drug_12\NN\14778436 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 they_16\PRP\1740 may_17\MD\15209706 also_18\RB\1740 be_19\VB\836236 due_20\JJ\1740 to_21\TO\1740 cocaethylene_22\NN\1740 (_23\-LRB-\1740 <e1>ce</e1>_24\NN\14625458 )_25\-RRB-\1740 ,_26\,\1740 a_27\DT\13649268 cocaine_28\NN\3492717 metabolite_29\NN\20090 formed_30\VBN\1617192 only_31\RB\1740 in_32\IN\13603305 the_33\DT\1740 presence_34\NN\13954253 of_35\IN\1740 ethanol_36\NN\14708720 ._37\.\1740
C066444_D066126 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 delineate_7\VB\2137132 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 <e1>ce</e1>_11\NN\14625458 in_12\IN\13603305 the_13\DT\1740 combined_14\JJ\1740 <e2>cardiotoxicity</e2>_15\NN\1740 of_16\IN\1740 cocaine_17\NN\3492717 and_18\CC\1740 ethanol_19\NN\14708720 in_20\IN\13603305 a_21\DT\13649268 model_22\NN\5888929 simulating_23\VBG\1736822 their_24\PRP$\1740 abuse_25\NN\418025 ._26\.\1740
C066444_D019970 NONE cocaine_0\NNP\3492717 ,_1\,\1740 ethanol_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 <e1>cocaethylene</e1>_5\NN\1740 cardiotoxity_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e2>cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse</e2>_15\NN\418025 ._16\.\1740
C066444_D000437 NONE cocaine_0\NNP\3492717 ,_1\,\1740 ethanol_2\NN\14708720 ,_3\,\1740 and_4\CC\1740 <e1>cocaethylene</e1>_5\NN\1740 cardiotoxity_6\NN\1740 in_7\IN\13603305 an_8\DT\6697703 animal_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e2>cocaine_12\NN\3492717 and_13\CC\1740 ethanol_14\NN\14708720 abuse</e2>_15\NN\418025 ._16\.\1740
C066444_D002303 CID peak_0\JJ\1740 <e1>ce</e1>_1\NN\14625458 levels_2\NNS\4916342 were_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 a_6\DT\13649268 45_7\CD\1740 %_8\NN\1740 (_9\-LRB-\1740 sd_10\NN\1740 +/-_11\CC\1740 22_12\CD\13745420 %_13\NN\1740 ,_14\,\1740 95_15\CD\1740 %_16\NN\1740 ci_17\NN\13635336 =_18\JJ\1740 22_19\CD\13745420 %_20\NN\1740 to_21\IN\1740 69_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 <e2>decrease_25\NN\7296428 in_26\IN\13603305 cardiac_27\JJ\1740 output</e2>_28\NN\4007894 (_29\-LRB-\1740 p_30\NN\14622893 <_31\XX\1740 0.05_32\CD\1740 )_33\-RRB-\1740 ,_34\,\1740 a_35\DT\13649268 56_36\CD\1740 %_37\NN\1740 (_38\-LRB-\1740 sd_39\NN\1740 +/-_40\CC\1740 23_41\CD\13745420 %_42\NN\1740 ,_43\,\1740 95_44\CD\1740 %_45\NN\1740 ci_46\NN\13635336 =_47\JJ\1740 32_48\CD\1740 %_49\NN\1740 to_50\TO\1740 80_51\CD\13745420 %_52\NN\1740 )_53\-RRB-\1740 decrease_54\NN\7296428 in_55\IN\13603305 dp/dt(max_56\NN\1740 )_57\-RRB-\1740 (_58\-LRB-\1740 p_59\NN\14622893 <_60\XX\1740 .006_61\CD\1740 )_62\-RRB-\1740 ,_63\,\1740 and_64\CC\1740 a_65\DT\13649268 23_66\CD\13745420 %_67\NN\1740 (_68\-LRB-\1740 sd_69\NN\1740 +/-_70\CC\1740 15_71\CD\13745420 %_72\NN\1740 ,_73\,\1740 95_74\CD\1740 %_75\NN\1740 ci_76\NN\13635336 =_77\JJ\1740 7_78\CD\13741022 %_79\NN\1740 to_80\TO\1740 49_81\CD\1740 %_82\NN\1740 )_83\-RRB-\1740 decrease_84\NN\7296428 in_85\IN\13603305 svo(2_86\NN\1740 )_87\-RRB-\1740 (_88\-LRB-\1740 p_89\NN\14622893 <_90\XX\1740 0.025_91\CD\1740 )_92\-RRB-\1740 ._93\.\1740
C066444_D009202 NONE peak_0\JJ\1740 serum_1\NN\5397468 <e1>cocaethylene</e1>_2\NN\1740 concentrations_3\NNS\4916342 were_4\VBD\836236 associated_5\VBN\628491 with_6\IN\1740 prolonged_7\JJ\1740 <e2>myocardial_8\JJ\1740 depression</e2>_9\NN\14373582 ._10\.\1740
12487093
D004837_D006973 CID <e1>adrenaline-induced</e1>_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 was_2\VBD\836236 used_3\VBN\1156834 to_4\TO\1740 destroy_5\VB\1619231 the_6\DT\1740 bbb_7\NNP\1740 ,_8\,\1740 which_9\WDT\1740 was_10\VBD\836236 evaluated_11\VBN\670261 using_12\VBG\1156834 triphenyltetrazolium_13\NN\1740 (_14\-LRB-\1740 ttc_15\NN\1740 )_16\-RRB-\1740 staining_17\NN\275424 of_18\IN\1740 the_19\DT\1740 brain_20\NN\5462674 slices_21\NNS\13285176 just_22\RB\1740 after_23\IN\1740 giving_24\VBG\2327200 adrenaline_25\NN\14807929 for_26\IN\1740 30_27\CD\13745420 s._28\NN\1740 in_29\IN\13603305 normal_30\JJ\1740 rats_31\NNS\2329401 ,_32\,\1740 the_33\DT\1740 whole_34\JJ\1740 brain_35\NN\5462674 sections_36\NNS\7020895 exhibited_37\VBD\2632167 complete_38\JJ\1740 staining_39\NN\275424 with_40\IN\1740 ttc_41\NN\1740 ._42\.\1740
D004837_D006973 CID adrenaline-induced_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 was_2\VBD\836236 used_3\VBN\1156834 to_4\TO\1740 destroy_5\VB\1619231 the_6\DT\1740 bbb_7\NNP\1740 ,_8\,\1740 which_9\WDT\1740 was_10\VBD\836236 evaluated_11\VBN\670261 using_12\VBG\1156834 triphenyltetrazolium_13\NN\1740 (_14\-LRB-\1740 ttc_15\NN\1740 )_16\-RRB-\1740 staining_17\NN\275424 of_18\IN\1740 the_19\DT\1740 brain_20\NN\5462674 slices_21\NNS\13285176 just_22\RB\1740 after_23\IN\1740 giving_24\VBG\2327200 <e1>adrenaline</e1>_25\NN\14807929 for_26\IN\1740 30_27\CD\13745420 s._28\NN\1740 in_29\IN\13603305 normal_30\JJ\1740 rats_31\NNS\2329401 ,_32\,\1740 the_33\DT\1740 whole_34\JJ\1740 brain_35\NN\5462674 sections_36\NNS\7020895 exhibited_37\VBD\2632167 complete_38\JJ\1740 staining_39\NN\275424 with_40\IN\1740 ttc_41\NN\1740 ._42\.\1740
C009591_D006973 NONE adrenaline-induced_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 was_2\VBD\836236 used_3\VBN\1156834 to_4\TO\1740 destroy_5\VB\1619231 the_6\DT\1740 bbb_7\NNP\1740 ,_8\,\1740 which_9\WDT\1740 was_10\VBD\836236 evaluated_11\VBN\670261 using_12\VBG\1156834 <e1>triphenyltetrazolium</e1>_13\NN\1740 (_14\-LRB-\1740 ttc_15\NN\1740 )_16\-RRB-\1740 staining_17\NN\275424 of_18\IN\1740 the_19\DT\1740 brain_20\NN\5462674 slices_21\NNS\13285176 just_22\RB\1740 after_23\IN\1740 giving_24\VBG\2327200 adrenaline_25\NN\14807929 for_26\IN\1740 30_27\CD\13745420 s._28\NN\1740 in_29\IN\13603305 normal_30\JJ\1740 rats_31\NNS\2329401 ,_32\,\1740 the_33\DT\1740 whole_34\JJ\1740 brain_35\NN\5462674 sections_36\NNS\7020895 exhibited_37\VBD\2632167 complete_38\JJ\1740 staining_39\NN\275424 with_40\IN\1740 ttc_41\NN\1740 ._42\.\1740
C009591_D006973 NONE adrenaline-induced_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 was_2\VBD\836236 used_3\VBN\1156834 to_4\TO\1740 destroy_5\VB\1619231 the_6\DT\1740 bbb_7\NNP\1740 ,_8\,\1740 which_9\WDT\1740 was_10\VBD\836236 evaluated_11\VBN\670261 using_12\VBG\1156834 triphenyltetrazolium_13\NN\1740 (_14\-LRB-\1740 <e1>ttc</e1>_15\NN\1740 )_16\-RRB-\1740 staining_17\NN\275424 of_18\IN\1740 the_19\DT\1740 brain_20\NN\5462674 slices_21\NNS\13285176 just_22\RB\1740 after_23\IN\1740 giving_24\VBG\2327200 adrenaline_25\NN\14807929 for_26\IN\1740 30_27\CD\13745420 s._28\NN\1740 in_29\IN\13603305 normal_30\JJ\1740 rats_31\NNS\2329401 ,_32\,\1740 the_33\DT\1740 whole_34\JJ\1740 brain_35\NN\5462674 sections_36\NNS\7020895 exhibited_37\VBD\2632167 complete_38\JJ\1740 staining_39\NN\275424 with_40\IN\1740 ttc_41\NN\1740 ._42\.\1740
C009591_D006973 NONE adrenaline-induced_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 was_2\VBD\836236 used_3\VBN\1156834 to_4\TO\1740 destroy_5\VB\1619231 the_6\DT\1740 bbb_7\NNP\1740 ,_8\,\1740 which_9\WDT\1740 was_10\VBD\836236 evaluated_11\VBN\670261 using_12\VBG\1156834 triphenyltetrazolium_13\NN\1740 (_14\-LRB-\1740 ttc_15\NN\1740 )_16\-RRB-\1740 staining_17\NN\275424 of_18\IN\1740 the_19\DT\1740 brain_20\NN\5462674 slices_21\NNS\13285176 just_22\RB\1740 after_23\IN\1740 giving_24\VBG\2327200 adrenaline_25\NN\14807929 for_26\IN\1740 30_27\CD\13745420 s._28\NN\1740 in_29\IN\13603305 normal_30\JJ\1740 rats_31\NNS\2329401 ,_32\,\1740 the_33\DT\1740 whole_34\JJ\1740 brain_35\NN\5462674 sections_36\NNS\7020895 exhibited_37\VBD\2632167 complete_38\JJ\1740 staining_39\NN\275424 with_40\IN\1740 <e1>ttc</e1>_41\NN\1740 ._42\.\1740
256433
D014031_D007239 NONE continuous_0\JJ\1740 infusion_1\NN\14589223 <e1>tobramycin</e1>_2\NN\2716866 combined_3\JJ\1740 with_4\IN\1740 carbenicillin_5\NN\1740 for_6\IN\1740 <e2>infections</e2>_7\NNS\14052046 in_8\IN\13603305 cancer_9\NN\14239425 patients_10\NNS\9898892 ._11\.\1740
D014031_D009369 NONE continuous_0\JJ\1740 infusion_1\NN\14589223 <e1>tobramycin</e1>_2\NN\2716866 combined_3\JJ\1740 with_4\IN\1740 carbenicillin_5\NN\1740 for_6\IN\1740 infections_7\NNS\14052046 in_8\IN\13603305 <e2>cancer</e2>_9\NN\14239425 patients_10\NNS\9898892 ._11\.\1740
D002228_D007239 NONE continuous_0\JJ\1740 infusion_1\NN\14589223 tobramycin_2\NN\2716866 combined_3\JJ\1740 with_4\IN\1740 <e1>carbenicillin</e1>_5\NN\1740 for_6\IN\1740 <e2>infections</e2>_7\NNS\14052046 in_8\IN\13603305 cancer_9\NN\14239425 patients_10\NNS\9898892 ._11\.\1740
D002228_D009369 NONE continuous_0\JJ\1740 infusion_1\NN\14589223 tobramycin_2\NN\2716866 combined_3\JJ\1740 with_4\IN\1740 <e1>carbenicillin</e1>_5\NN\1740 for_6\IN\1740 infections_7\NNS\14052046 in_8\IN\13603305 <e2>cancer</e2>_9\NN\14239425 patients_10\NNS\9898892 ._11\.\1740
D014031_D009503 NONE to_0\TO\1740 overcome_1\VB\1101913 the_2\DT\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e2>neutropenia</e2>_6\NN\14196405 ,_7\,\1740 <e1>tobramycin</e1>_8\NN\2716866 was_9\VBD\836236 given_10\VBN\2327200 by_11\IN\1740 continuous_12\JJ\1740 infusion_13\NN\14589223 and_14\CC\1740 combined_15\VBN\2630189 with_16\IN\1740 intermittent_17\JJ\1740 carbenicillin_18\NN\1740 ._19\.\1740
D002228_D009503 NONE to_0\TO\1740 overcome_1\VB\1101913 the_2\DT\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e2>neutropenia</e2>_6\NN\14196405 ,_7\,\1740 tobramycin_8\NN\2716866 was_9\VBD\836236 given_10\VBN\2327200 by_11\IN\1740 continuous_12\JJ\1740 infusion_13\NN\14589223 and_14\CC\1740 combined_15\VBN\2630189 with_16\IN\1740 intermittent_17\JJ\1740 <e1>carbenicillin</e1>_18\NN\1740 ._19\.\1740
D003404_D053099 NONE major_0\JJ\1740 <e2>azotemia</e2>_1\NN\14204950 (_2\-LRB-\1740 serum_3\NN\5397468 <e1>creatinine</e1>_4\NN\1740 greater_5\JJR\1740 than_6\IN\1740 2.5_7\CD\1740 mg/dl_8\NN\1740 or_9\CC\3541091 bun_10\NN\7679356 greater_11\JJR\1740 than_12\IN\1740 50_13\CD\13745420 mg/dl_14\NN\1740 )_15\-RRB-\1740 occurred_16\VBD\2623529 in_17\IN\13603305 only_18\RB\1740 2_19\CD\13741022 %_20\NN\1740 ._21\.\1740
D014031_D053099 CID <e2>azotemia</e2>_0\NNP\14204950 was_1\VBD\836236 not_2\RB\1740 related_3\JJ\1740 to_4\TO\1740 duration_5\NN\15113229 of_6\IN\1740 therapy_7\NN\657604 or_8\CC\3541091 serum_9\NN\5397468 <e1>tobramycin</e1>_10\NN\2716866 concentration_11\NN\4916342 ._12\.\1740
612112
D005045_D009207 CID it_0\PRP\6125041 is_1\VBZ\836236 considered_2\VBN\689344 unlikely_3\JJ\1740 that_4\IN\1740 <e1>etomidate</e1>_5\NN\1740 will_6\MD\5650329 prove_7\VB\2604760 to_8\TO\1740 be_9\VB\836236 the_10\DT\1740 hypnotic_11\NN\3247620 of_12\IN\1740 choice_13\NN\5788149 for_14\IN\1740 a_15\DT\13649268 totally_16\RB\1740 intravenous_17\JJ\1740 anesthetic_18\JJ\1740 technique_19\NN\5660268 in_20\IN\13603305 adults_21\NNS\7846 because_22\IN\1740 of_23\IN\1740 the_24\DT\1740 high_25\JJ\1740 incidence_26\NN\13821570 of_27\IN\1740 <e2>myoclonia</e2>_28\NN\1740 after_29\IN\1740 prolonged_30\JJ\1740 administration_31\NN\1133281 ._32\.\1740
12752472
D010862_D004827 CID here_0\RB\1740 we_1\PRP\1740 sought_2\VBD\1825237 to_3\TO\1740 generate_4\VB\1617192 information_5\NN\6598915 with_6\IN\1740 regard_7\NN\5817845 to_8\TO\1740 the_9\DT\1740 interictal_10\JJ\1740 period_11\NN\13575869 in_12\IN\13603305 animals_13\NNS\4475 with_14\IN\1740 <e1>pilocarpine-induced</e1>_15\JJ\1740 <e2>epilepsy</e2>_16\NN\14085708 ._17\.\1740
D010862_D006985 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 <e2>hyperventilation</e2>_3\NN\831191 maneuver_4\NN\955060 caused_5\VBD\1617192 a_6\DT\13649268 decrease_7\NN\7296428 in_8\IN\13603305 spontaneous_9\JJ\1740 ventilation_10\NN\248977 in_11\IN\13603305 <e1>pilocarpine-treated</e1>_12\JJ\1740 and_13\CC\1740 control_14\NN\5190804 rats_15\NNS\2329401 ._16\.\1740
15096374
D016559_D003872 NONE induction_0\NN\7450842 of_1\IN\1740 rosaceiform_2\NN\1740 <e2>dermatitis</e2>_3\NN\14226056 during_4\IN\1740 treatment_5\NN\654885 of_6\IN\1740 facial_7\JJ\1740 inflammatory_8\JJ\1740 dermatoses_9\NNS\14219661 with_10\IN\1740 <e1>tacrolimus</e1>_11\NN\1740 ointment_12\NN\4074482 ._13\.\1740
D016559_D003872 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 rosaceiform_3\NN\1740 <e2>dermatitis</e2>_4\NN\14226056 as_5\IN\14622893 a_6\DT\13649268 complication_7\NN\1073995 of_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 <e1>tacrolimus</e1>_11\NN\1740 ointment_12\NN\4074482 ._13\.\1740
D016559_D003872 NONE conclusions_0\NNS\5837957 :_1\:\1740 our_2\PRP$\1740 observations_3\NNS\996969 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 spectrum_7\NN\7939382 of_8\IN\1740 rosaceiform_9\NN\1740 <e2>dermatitis</e2>_10\NN\14226056 as_11\IN\14622893 a_12\DT\13649268 complication_13\NN\1073995 of_14\IN\1740 treatment_15\NN\654885 with_16\IN\1740 <e1>tacrolimus</e1>_17\NN\1740 ointment_18\NN\4074482 is_19\VBZ\836236 heterogeneous_20\JJ\1740 ._21\.\1740
D016559_D005148 NONE induction_0\NN\7450842 of_1\IN\1740 rosaceiform_2\NN\1740 dermatitis_3\NN\14226056 during_4\IN\1740 treatment_5\NN\654885 of_6\IN\1740 <e2>facial_7\JJ\1740 inflammatory_8\JJ\1740 dermatoses</e2>_9\NNS\14219661 with_10\IN\1740 <e1>tacrolimus</e1>_11\NN\1740 ointment_12\NN\4074482 ._13\.\1740
D016559_D005148 NONE observations_0\NN\996969 :_1\:\1740 six_2\CD\13741022 adult_3\JJ\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>inflammatory_6\JJ\1740 facial_7\JJ\1740 dermatoses</e2>_8\NNS\14219661 were_9\VBD\836236 treated_10\VBN\2376958 with_11\IN\1740 <e1>tacrolimus</e1>_12\NN\1740 ointment_13\JJ\1740 because_14\IN\1740 of_15\IN\1740 the_16\DT\1740 ineffectiveness_17\NN\5204637 of_18\IN\1740 standard_19\JJ\1740 treatments_20\NNS\654885 ._21\.\1740
D016559_D012393 CID background_0\NN\4921011 :_1\:\1740 <e1>tacrolimus</e1>_2\NN\1740 ointment_3\NN\4074482 is_4\VBZ\836236 increasingly_5\RB\1740 used_6\VBN\1156834 for_7\IN\1740 anti-inflammatory_8\JJ\1740 treatment_9\NN\654885 of_10\IN\1740 sensitive_11\JJ\1740 areas_12\NNS\8630985 such_13\JJ\1740 as_14\IN\14622893 the_15\DT\1740 face_16\NN\5225090 ,_17\,\1740 and_18\CC\1740 recent_19\JJ\1740 observations_20\NNS\996969 indicate_21\VBP\952524 that_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 is_25\VBZ\836236 effective_26\JJ\1740 in_27\IN\13603305 steroid-aggravated_28\JJ\1740 <e2>rosacea</e2>_29\NN\14222112 and_30\CC\1740 perioral_31\JJ\1740 dermatitis_32\NN\14226056 ._33\.\1740
D016559_D019557 NONE background_0\NN\4921011 :_1\:\1740 <e1>tacrolimus</e1>_2\NN\1740 ointment_3\NN\4074482 is_4\VBZ\836236 increasingly_5\RB\1740 used_6\VBN\1156834 for_7\IN\1740 anti-inflammatory_8\JJ\1740 treatment_9\NN\654885 of_10\IN\1740 sensitive_11\JJ\1740 areas_12\NNS\8630985 such_13\JJ\1740 as_14\IN\14622893 the_15\DT\1740 face_16\NN\5225090 ,_17\,\1740 and_18\CC\1740 recent_19\JJ\1740 observations_20\NNS\996969 indicate_21\VBP\952524 that_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 is_25\VBZ\836236 effective_26\JJ\1740 in_27\IN\13603305 steroid-aggravated_28\JJ\1740 rosacea_29\NN\14222112 and_30\CC\1740 <e2>perioral_31\JJ\1740 dermatitis</e2>_32\NN\14226056 ._33\.\1740
D013256_D012393 NONE background_0\NN\4921011 :_1\:\1740 tacrolimus_2\NN\1740 ointment_3\NN\4074482 is_4\VBZ\836236 increasingly_5\RB\1740 used_6\VBN\1156834 for_7\IN\1740 anti-inflammatory_8\JJ\1740 treatment_9\NN\654885 of_10\IN\1740 sensitive_11\JJ\1740 areas_12\NNS\8630985 such_13\JJ\1740 as_14\IN\14622893 the_15\DT\1740 face_16\NN\5225090 ,_17\,\1740 and_18\CC\1740 recent_19\JJ\1740 observations_20\NNS\996969 indicate_21\VBP\952524 that_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 is_25\VBZ\836236 effective_26\JJ\1740 in_27\IN\13603305 <e1>steroid-aggravated</e1>_28\JJ\1740 <e2>rosacea</e2>_29\NN\14222112 and_30\CC\1740 perioral_31\JJ\1740 dermatitis_32\NN\14226056 ._33\.\1740
D013256_D019557 NONE background_0\NN\4921011 :_1\:\1740 tacrolimus_2\NN\1740 ointment_3\NN\4074482 is_4\VBZ\836236 increasingly_5\RB\1740 used_6\VBN\1156834 for_7\IN\1740 anti-inflammatory_8\JJ\1740 treatment_9\NN\654885 of_10\IN\1740 sensitive_11\JJ\1740 areas_12\NNS\8630985 such_13\JJ\1740 as_14\IN\14622893 the_15\DT\1740 face_16\NN\5225090 ,_17\,\1740 and_18\CC\1740 recent_19\JJ\1740 observations_20\NNS\996969 indicate_21\VBP\952524 that_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 is_25\VBZ\836236 effective_26\JJ\1740 in_27\IN\13603305 <e1>steroid-aggravated</e1>_28\JJ\1740 rosacea_29\NN\14222112 and_30\CC\1740 <e2>perioral_31\JJ\1740 dermatitis</e2>_32\NN\14226056 ._33\.\1740
20495512
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 :_2\:\1740 a_3\DT\13649268 practical_4\JJ\1740 review_5\NN\5733583 ._6\.\1740
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 (_2\-LRB-\1740 hit_3\NN\36762 )_4\-RRB-\1740 remains_5\VBZ\2604760 under-recognized_6\JJ\1740 despite_7\IN\7501545 its_8\PRP$\6125041 potentially_9\RB\1740 devastating_10\VBG\1564144 outcomes_11\NNS\7291312 ._12\.\1740
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 thrombocytopenia_1\NN\14189204 (_2\-LRB-\1740 <e2>hit</e2>_3\NN\36762 )_4\-RRB-\1740 remains_5\VBZ\2604760 under-recognized_6\JJ\1740 despite_7\IN\7501545 its_8\PRP$\6125041 potentially_9\RB\1740 devastating_10\VBG\1564144 outcomes_11\NNS\7291312 ._12\.\1740
D006493_D013921 CID <e2>hit</e2>_0\NN\36762 must_1\MD\9367203 be_2\VB\836236 acknowledged_3\VBN\822367 for_4\IN\1740 its_5\PRP$\6125041 intense_6\JJ\1740 predilection_7\NN\6200178 for_8\IN\1740 thrombosis_9\NN\14100769 and_10\CC\1740 suspected_11\VBN\916909 whenever_12\WRB\1740 thrombosis_13\NN\14100769 occurs_14\VBZ\2623529 after_15\IN\1740 <e1>heparin</e1>_16\NN\2718259 exposure_17\NN\5042871 ._18\.\1740
D006493_D013921 CID the_0\DT\1740 treatment_1\NN\654885 of_2\IN\1740 <e2>hit</e2>_3\NN\36762 mandates_4\VBZ\2391803 an_5\DT\6697703 immediate_6\JJ\1740 cessation_7\NN\7365849 of_8\IN\1740 all_9\DT\1740 <e1>heparin</e1>_10\NN\2718259 exposure_11\NN\5042871 and_12\CC\1740 the_13\DT\1740 institution_14\NN\8008335 of_15\IN\1740 an_16\DT\6697703 antithrombotic_17\JJ\1740 therapy_18\NN\657604 ,_19\,\1740 most_20\RBS\1740 commonly_21\RB\1740 using_22\VBG\1156834 a_23\DT\13649268 direct_24\JJ\1740 thrombin_25\NN\14735953 inhibitor_26\NN\20090 ._27\.\1740
D006493_D013921 CID direct_0\JJ\1740 thrombin_1\NN\14735953 inhibitors_2\NNS\20090 are_3\VBP\836236 appropriate_4\JJ\1740 ,_5\,\1740 evidence-based_6\JJ\1740 alternatives_7\NNS\5788149 to_8\TO\1740 <e1>heparin</e1>_9\NN\2718259 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 a_13\DT\13649268 history_14\NN\15120823 of_15\IN\1740 <e2>hit</e2>_16\NN\36762 ,_17\,\1740 who_18\WP\8299493 need_19\VBP\2604760 to_20\TO\1740 undergo_21\VB\109660 percutaneous_22\JJ\1740 coronary_23\JJ\1740 intervention_24\NN\1239064 ._25\.\1740
D006493_D013921 CID as_0\IN\14622893 <e1>heparin</e1>_1\NN\2718259 remains_2\VBZ\2604760 one_3\CD\13741022 of_4\IN\1740 the_5\DT\1740 most_6\RBS\1740 frequently_7\RB\1740 used_8\VBN\1156834 medications_9\NNS\3247620 today_10\NN\15119536 with_11\IN\1740 potential_12\NN\14481929 for_13\IN\1740 <e2>hit</e2>_14\NN\36762 with_15\IN\1740 every_16\DT\1740 heparin_17\NN\2718259 exposure_18\NN\5042871 ,_19\,\1740 a_20\DT\13649268 close_21\JJ\1740 vigilance_22\NN\5650579 of_23\IN\1740 platelet_24\NN\5432736 counts_25\NNS\13582013 must_26\MD\9367203 be_27\VB\836236 practiced_28\VBN\599992 whenever_29\WRB\1740 heparin_30\NN\2718259 is_31\VBZ\836236 initiated_32\VBN\1617192 ._33\.\1740
D006493_D013921 CID as_0\IN\14622893 heparin_1\NN\2718259 remains_2\VBZ\2604760 one_3\CD\13741022 of_4\IN\1740 the_5\DT\1740 most_6\RBS\1740 frequently_7\RB\1740 used_8\VBN\1156834 medications_9\NNS\3247620 today_10\NN\15119536 with_11\IN\1740 potential_12\NN\14481929 for_13\IN\1740 <e2>hit</e2>_14\NN\36762 with_15\IN\1740 every_16\DT\1740 <e1>heparin</e1>_17\NN\2718259 exposure_18\NN\5042871 ,_19\,\1740 a_20\DT\13649268 close_21\JJ\1740 vigilance_22\NN\5650579 of_23\IN\1740 platelet_24\NN\5432736 counts_25\NNS\13582013 must_26\MD\9367203 be_27\VB\836236 practiced_28\VBN\599992 whenever_29\WRB\1740 heparin_30\NN\2718259 is_31\VBZ\836236 initiated_32\VBN\1617192 ._33\.\1740
D006493_D013921 CID as_0\IN\14622893 heparin_1\NN\2718259 remains_2\VBZ\2604760 one_3\CD\13741022 of_4\IN\1740 the_5\DT\1740 most_6\RBS\1740 frequently_7\RB\1740 used_8\VBN\1156834 medications_9\NNS\3247620 today_10\NN\15119536 with_11\IN\1740 potential_12\NN\14481929 for_13\IN\1740 <e2>hit</e2>_14\NN\36762 with_15\IN\1740 every_16\DT\1740 heparin_17\NN\2718259 exposure_18\NN\5042871 ,_19\,\1740 a_20\DT\13649268 close_21\JJ\1740 vigilance_22\NN\5650579 of_23\IN\1740 platelet_24\NN\5432736 counts_25\NNS\13582013 must_26\MD\9367203 be_27\VB\836236 practiced_28\VBN\599992 whenever_29\WRB\1740 <e1>heparin</e1>_30\NN\2718259 is_31\VBZ\836236 initiated_32\VBN\1617192 ._33\.\1740
D006493_D013927 CID hit_0\NN\36762 must_1\MD\9367203 be_2\VB\836236 acknowledged_3\VBN\822367 for_4\IN\1740 its_5\PRP$\6125041 intense_6\JJ\1740 predilection_7\NN\6200178 for_8\IN\1740 <e2>thrombosis</e2>_9\NN\14100769 and_10\CC\1740 suspected_11\VBN\916909 whenever_12\WRB\1740 thrombosis_13\NN\14100769 occurs_14\VBZ\2623529 after_15\IN\1740 <e1>heparin</e1>_16\NN\2718259 exposure_17\NN\5042871 ._18\.\1740
D006493_D013927 CID hit_0\NN\36762 must_1\MD\9367203 be_2\VB\836236 acknowledged_3\VBN\822367 for_4\IN\1740 its_5\PRP$\6125041 intense_6\JJ\1740 predilection_7\NN\6200178 for_8\IN\1740 thrombosis_9\NN\14100769 and_10\CC\1740 suspected_11\VBN\916909 whenever_12\WRB\1740 <e2>thrombosis</e2>_13\NN\14100769 occurs_14\VBZ\2623529 after_15\IN\1740 <e1>heparin</e1>_16\NN\2718259 exposure_17\NN\5042871 ._18\.\1740
D000991_D013921 NONE the_0\DT\1740 treatment_1\NN\654885 of_2\IN\1740 <e2>hit</e2>_3\NN\36762 mandates_4\VBZ\2391803 an_5\DT\6697703 immediate_6\JJ\1740 cessation_7\NN\7365849 of_8\IN\1740 all_9\DT\1740 heparin_10\NN\2718259 exposure_11\NN\5042871 and_12\CC\1740 the_13\DT\1740 institution_14\NN\8008335 of_15\IN\1740 an_16\DT\6697703 antithrombotic_17\JJ\1740 therapy_18\NN\657604 ,_19\,\1740 most_20\RBS\1740 commonly_21\RB\1740 using_22\VBG\1156834 a_23\DT\13649268 <e1>direct_24\JJ\1740 thrombin_25\NN\14735953 inhibitor</e1>_26\NN\20090 ._27\.\1740
D000991_D013921 NONE <e1>direct_0\JJ\1740 thrombin_1\NN\14735953 inhibitors</e1>_2\NNS\20090 are_3\VBP\836236 appropriate_4\JJ\1740 ,_5\,\1740 evidence-based_6\JJ\1740 alternatives_7\NNS\5788149 to_8\TO\1740 heparin_9\NN\2718259 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 a_13\DT\13649268 history_14\NN\15120823 of_15\IN\1740 <e2>hit</e2>_16\NN\36762 ,_17\,\1740 who_18\WP\8299493 need_19\VBP\2604760 to_20\TO\1740 undergo_21\VB\109660 percutaneous_22\JJ\1740 coronary_23\JJ\1740 intervention_24\NN\1239064 ._25\.\1740
8825380
D011692_D007674 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 recombinant_3\JJ\1740 human_4\JJ\1740 insulin-like_5\JJ\1740 growth_6\NN\13526110 factor-i_7\NN\1740 on_8\IN\1740 chronic_9\JJ\1740 <e1>puromycin_10\NN\1740 aminonucleoside</e1>_11\NN\1740 <e2>nephropathy</e2>_12\NN\14573196 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
D011692_D007674 CID we_0\PRP\1740 recently_1\RB\1740 demonstrated_2\VBD\2137132 that_3\IN\1740 recombinant_4\JJ\1740 hgh_5\NN\1740 exacerbates_6\NNS\1740 renal_7\JJ\1740 functional_8\JJ\1740 and_9\CC\1740 structural_10\JJ\1740 injury_11\NN\14052046 in_12\IN\13603305 chronic_13\JJ\1740 <e1>puromycin_14\NN\1740 aminonucleoside</e1>_15\NN\1740 (_16\-LRB-\1740 pan_17\NN\3101986 )_18\-RRB-\1740 <e2>nephropathy</e2>_19\RB\1740 ,_20\,\1740 an_21\DT\6697703 experimental_22\JJ\1740 model_23\NN\5888929 of_24\IN\1740 glomerular_25\JJ\1740 disease_26\NN\14061805 ._27\.\1740
D011692_D007674 CID we_0\PRP\1740 recently_1\RB\1740 demonstrated_2\VBD\2137132 that_3\IN\1740 recombinant_4\JJ\1740 hgh_5\NN\1740 exacerbates_6\NNS\1740 renal_7\JJ\1740 functional_8\JJ\1740 and_9\CC\1740 structural_10\JJ\1740 injury_11\NN\14052046 in_12\IN\13603305 chronic_13\JJ\1740 <e1>puromycin_14\NN\1740 aminonucleoside</e1>_15\NN\1740 (_16\-LRB-\1740 pan_17\NN\3101986 )_18\-RRB-\1740 nephropathy_19\RB\1740 ,_20\,\1740 an_21\DT\6697703 experimental_22\JJ\1740 model_23\NN\5888929 of_24\IN\1740 <e2>glomerular_25\JJ\1740 disease</e2>_26\NN\14061805 ._27\.\1740
D011692_D007674 CID we_0\PRP\1740 recently_1\RB\1740 demonstrated_2\VBD\2137132 that_3\IN\1740 recombinant_4\JJ\1740 hgh_5\NN\1740 exacerbates_6\NNS\1740 renal_7\JJ\1740 functional_8\JJ\1740 and_9\CC\1740 structural_10\JJ\1740 injury_11\NN\14052046 in_12\IN\13603305 chronic_13\JJ\1740 puromycin_14\NN\1740 aminonucleoside_15\NN\1740 (_16\-LRB-\1740 <e1>pan</e1>_17\NN\3101986 )_18\-RRB-\1740 <e2>nephropathy</e2>_19\RB\1740 ,_20\,\1740 an_21\DT\6697703 experimental_22\JJ\1740 model_23\NN\5888929 of_24\IN\1740 glomerular_25\JJ\1740 disease_26\NN\14061805 ._27\.\1740
D011692_D007674 CID we_0\PRP\1740 recently_1\RB\1740 demonstrated_2\VBD\2137132 that_3\IN\1740 recombinant_4\JJ\1740 hgh_5\NN\1740 exacerbates_6\NNS\1740 renal_7\JJ\1740 functional_8\JJ\1740 and_9\CC\1740 structural_10\JJ\1740 injury_11\NN\14052046 in_12\IN\13603305 chronic_13\JJ\1740 puromycin_14\NN\1740 aminonucleoside_15\NN\1740 (_16\-LRB-\1740 <e1>pan</e1>_17\NN\3101986 )_18\-RRB-\1740 nephropathy_19\RB\1740 ,_20\,\1740 an_21\DT\6697703 experimental_22\JJ\1740 model_23\NN\5888929 of_24\IN\1740 <e2>glomerular_25\JJ\1740 disease</e2>_26\NN\14061805 ._27\.\1740
D011692_D007674 CID therefore_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 examined_3\VBD\789138 whether_4\IN\1740 recombinant_5\JJ\1740 human_6\JJ\1740 (_7\-LRB-\1740 rh_8\NN\15037339 )_9\-RRB-\1740 igf-i_10\NN\1740 is_11\VBZ\836236 a_12\DT\13649268 safer_13\JJR\1740 alternative_14\NN\5788149 for_15\IN\1740 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 growth_19\NN\13526110 failure_20\NN\66216 in_21\IN\13603305 rats_22\NNS\2329401 with_23\IN\1740 chronic_24\JJ\1740 <e1>pan</e1>_25\NN\3101986 <e2>nephropathy</e2>_26\NN\14573196 ._27\.\1740
D011692_D007674 CID the_0\DT\1740 <e2>glomerulopathy</e2>_1\NN\1740 was_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 seven_5\CD\13741022 serial_6\JJ\1740 injections_7\NNS\320852 of_8\IN\1740 <e1>pan</e1>_9\NN\3101986 over_10\IN\5867413 12_11\CD\13745420 wk_12\NN\1740 ._13\.\1740
D011692_D007674 CID urinary_0\JJ\1740 protein_1\NN\14944888 excretion_2\NN\13466586 was_3\VBD\836236 unaltered_4\JJ\1740 by_5\IN\1740 rhigf-i_6\NN\1740 treatment_7\NN\654885 in_8\IN\13603305 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 <e1>pan</e1>_12\NN\3101986 <e2>nephropathy</e2>_13\NN\14573196 ._14\.\1740
D011692_D007674 CID after_0\IN\1740 12_1\CD\13745420 wk_2\NN\1740 ,_3\,\1740 the_4\DT\1740 inulin_5\JJ\1740 clearance_6\NN\5089947 was_7\VBD\836236 higher_8\JJR\1740 in_9\IN\13603305 rhigf-i-treated_10\VBN\1740 rats_11\NNS\2329401 ,_12\,\1740 0.48_13\CD\1740 +/-_14\CC\1740 0.08_15\CD\1740 versus_16\CC\1740 0.24_17\CD\1740 +/-_18\CC\1740 0.06_19\CD\1740 ml/min/100_20\NN\1740 g_21\NN\13717155 of_22\IN\1740 body_23\NN\19128 weight_24\NN\5009170 in_25\IN\13603305 untreated_26\JJ\1740 <e1>pan</e1>_27\NN\3101986 <e2>nephropathy</e2>_28\JJ\1740 animals_29\NNS\4475 ,_30\,\1740 p_31\NN\14622893 <_32\XX\1740 0.05_33\CD\1740 ._34\.\1740
D011692_D007674 CID in_0\IN\13603305 rats_1\NNS\2329401 with_2\IN\1740 <e1>pan</e1>_3\NN\3101986 <e2>nephropathy</e2>_4\NN\14573196 ,_5\,\1740 administration_6\NN\1133281 of_7\IN\1740 rhigf-i_8\NN\1740 increased_9\VBD\169651 igf-i_10\NN\1740 and_11\CC\1740 gh_12\NN\1740 receptor_13\NN\5225602 gene_14\NN\8459252 expression_15\NN\4679549 ,_16\,\1740 without_17\IN\1740 altering_18\VBG\126264 the_19\DT\1740 steady_20\JJ\1740 state_21\NN\8491826 level_22\NN\4916342 of_23\IN\1740 igf-i_24\NN\1740 receptor_25\NN\5225602 mrna_26\NN\14832193 ._27\.\1740
D011692_D007674 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 :_3\:\1740 1_4\LS\13741022 )_5\-RRB-\1740 administration_6\NN\1133281 of_7\IN\1740 rhigf-i_8\NN\1740 improves_9\NNS\1740 growth_10\NN\13526110 and_11\CC\1740 gfr_12\NN\1740 in_13\IN\13603305 rats_14\NNS\2329401 with_15\IN\1740 chronic_16\JJ\1740 <e1>pan</e1>_17\NN\3101986 <e2>nephropathy</e2>_18\NN\14573196 and_19\CC\1740 2_20\CD\13741022 )_21\-RRB-\1740 unlike_22\IN\1740 rhgh_23\NN\1740 ,_24\,\1740 long-term_25\JJ\1740 use_26\NN\407535 of_27\IN\1740 rhigf-i_28\NN\1740 does_29\VBZ\1640855 not_30\RB\1740 worsen_31\VBN\146138 renal_32\JJ\1740 functional_33\JJ\1740 and_34\CC\1740 structural_35\JJ\1740 injury_36\NN\14052046 in_37\IN\13603305 this_38\DT\1740 disease_39\NN\14061805 model_40\NN\5888929 ._41\.\1740
D011692_D006130 NONE therefore_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 examined_3\VBD\789138 whether_4\IN\1740 recombinant_5\JJ\1740 human_6\JJ\1740 (_7\-LRB-\1740 rh_8\NN\15037339 )_9\-RRB-\1740 igf-i_10\NN\1740 is_11\VBZ\836236 a_12\DT\13649268 safer_13\JJR\1740 alternative_14\NN\5788149 for_15\IN\1740 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 <e2>growth_19\NN\13526110 failure</e2>_20\NN\66216 in_21\IN\13603305 rats_22\NNS\2329401 with_23\IN\1740 chronic_24\JJ\1740 <e1>pan</e1>_25\NN\3101986 nephropathy_26\NN\14573196 ._27\.\1740
D008315_D007674 NONE the_0\DT\1740 improvement_1\NN\7359599 in_2\IN\13603305 gfr_3\NN\1740 was_4\VBD\836236 not_5\RB\1740 associated_6\VBN\628491 with_7\IN\1740 enhanced_8\VBN\227165 <e2>glomerular_9\JJ\1740 hypertrophy</e2>_10\NN\14365950 or_11\CC\3541091 increased_12\VBN\169651 segmental_13\JJ\1740 glomerulosclerosis_14\NN\1740 ,_15\,\1740 tubulointerstitial_16\JJ\1740 injury_17\NN\14052046 ,_18\,\1740 or_19\CC\3541091 renal_20\JJ\1740 cortical_21\JJ\1740 <e1>malondialdehyde</e1>_22\NN\1740 content_23\NN\7951464 ._24\.\1740
D008315_D007674 NONE in_0\IN\13603305 normal_1\JJ\1740 rats_2\NNS\2329401 with_3\IN\1740 intact_4\JJ\1740 kidneys_5\NNS\5333259 ,_6\,\1740 rhigf-i_7\NN\1740 administration_8\NN\1133281 (_9\-LRB-\1740 n_10\NN\14622893 =_11\JJ\1740 4_12\CD\13741022 )_13\-RRB-\1740 did_14\VBD\1640855 not_15\RB\1740 alter_16\VB\126264 weight_17\NN\5009170 gain_18\NN\13576355 ,_19\,\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 proteinuria_23\NN\14299637 ,_24\,\1740 gfr_25\NN\1740 ,_26\,\1740 glomerular_27\JJ\1740 planar_28\NN\1740 area_29\NN\8630985 ,_30\,\1740 renal_31\JJ\1740 cortical_32\JJ\1740 <e1>malondialdehyde</e1>_33\NN\1740 content_34\NN\7951464 ,_35\,\1740 or_36\CC\3541091 glomerular_37\JJ\1740 or_38\CC\3541091 <e2>tubulointerstitial_39\JJ\1740 damage</e2>_40\NN\7296428 ,_41\,\1740 compared_42\VBN\644583 with_43\IN\1740 untreated_44\JJ\1740 animals_45\NNS\4475 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 4_49\CD\13741022 )_50\-RRB-\1740 ._51\.\1740
D008315_D005921 NONE the_0\DT\1740 improvement_1\NN\7359599 in_2\IN\13603305 gfr_3\NN\1740 was_4\VBD\836236 not_5\RB\1740 associated_6\VBN\628491 with_7\IN\1740 enhanced_8\VBN\227165 glomerular_9\JJ\1740 hypertrophy_10\NN\14365950 or_11\CC\3541091 increased_12\VBN\169651 segmental_13\JJ\1740 <e2>glomerulosclerosis</e2>_14\NN\1740 ,_15\,\1740 tubulointerstitial_16\JJ\1740 injury_17\NN\14052046 ,_18\,\1740 or_19\CC\3541091 renal_20\JJ\1740 cortical_21\JJ\1740 <e1>malondialdehyde</e1>_22\NN\1740 content_23\NN\7951464 ._24\.\1740
D008315_-1 NONE the_0\DT\1740 improvement_1\NN\7359599 in_2\IN\13603305 gfr_3\NN\1740 was_4\VBD\836236 not_5\RB\1740 associated_6\VBN\628491 with_7\IN\1740 enhanced_8\VBN\227165 glomerular_9\JJ\1740 hypertrophy_10\NN\14365950 or_11\CC\3541091 increased_12\VBN\169651 segmental_13\JJ\1740 glomerulosclerosis_14\NN\1740 ,_15\,\1740 <e2>tubulointerstitial_16\JJ\1740 injury</e2>_17\NN\14052046 ,_18\,\1740 or_19\CC\3541091 renal_20\JJ\1740 cortical_21\JJ\1740 <e1>malondialdehyde</e1>_22\NN\1740 content_23\NN\7951464 ._24\.\1740
D008315_D011507 NONE in_0\IN\13603305 normal_1\JJ\1740 rats_2\NNS\2329401 with_3\IN\1740 intact_4\JJ\1740 kidneys_5\NNS\5333259 ,_6\,\1740 rhigf-i_7\NN\1740 administration_8\NN\1133281 (_9\-LRB-\1740 n_10\NN\14622893 =_11\JJ\1740 4_12\CD\13741022 )_13\-RRB-\1740 did_14\VBD\1640855 not_15\RB\1740 alter_16\VB\126264 weight_17\NN\5009170 gain_18\NN\13576355 ,_19\,\1740 blood_20\NN\5397468 pressure_21\NN\11419404 ,_22\,\1740 <e2>proteinuria</e2>_23\NN\14299637 ,_24\,\1740 gfr_25\NN\1740 ,_26\,\1740 glomerular_27\JJ\1740 planar_28\NN\1740 area_29\NN\8630985 ,_30\,\1740 renal_31\JJ\1740 cortical_32\JJ\1740 <e1>malondialdehyde</e1>_33\NN\1740 content_34\NN\7951464 ,_35\,\1740 or_36\CC\3541091 glomerular_37\JJ\1740 or_38\CC\3541091 tubulointerstitial_39\JJ\1740 damage_40\NN\7296428 ,_41\,\1740 compared_42\VBN\644583 with_43\IN\1740 untreated_44\JJ\1740 animals_45\NNS\4475 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 4_49\CD\13741022 )_50\-RRB-\1740 ._51\.\1740
20192893
D003287_D007674 CID <e1>contrast_0\NN\13854649 medium</e1>_1\JJ\1740 <e2>nephrotoxicity</e2>_2\NN\1740 after_3\IN\1740 renal_4\JJ\1740 artery_5\NN\5417975 and_6\CC\1740 coronary_7\JJ\1740 angioplasty_8\NN\671351 ._9\.\1740
D003287_D007674 CID background_0\NN\4921011 :_1\:\1740 <e2>renal_2\JJ\1740 dysfunction</e2>_3\NN\14204950 induced_4\VBN\1627355 by_5\IN\1740 iodinated_6\JJ\1740 <e1>contrast_7\NN\13854649 medium</e1>_8\NN\3575240 (_9\-LRB-\1740 cm_10\NN\13649268 )_11\-RRB-\1740 administration_12\NN\1133281 can_13\MD\3094503 minimize_14\VB\441445 the_15\DT\1740 benefit_16\NN\13278375 of_17\IN\1740 the_18\DT\1740 interventional_19\JJ\1740 procedure_20\NN\407535 in_21\IN\13603305 patients_22\NNS\9898892 undergoing_23\VBG\109660 renal_24\JJ\1740 angioplasty_25\NN\671351 (_26\-LRB-\1740 ptra_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D003287_D007674 CID background_0\NN\4921011 :_1\:\1740 <e2>renal_2\JJ\1740 dysfunction</e2>_3\NN\14204950 induced_4\VBN\1627355 by_5\IN\1740 iodinated_6\JJ\1740 contrast_7\NN\13854649 medium_8\NN\3575240 (_9\-LRB-\1740 <e1>cm</e1>_10\NN\13649268 )_11\-RRB-\1740 administration_12\NN\1133281 can_13\MD\3094503 minimize_14\VB\441445 the_15\DT\1740 benefit_16\NN\13278375 of_17\IN\1740 the_18\DT\1740 interventional_19\JJ\1740 procedure_20\NN\407535 in_21\IN\13603305 patients_22\NNS\9898892 undergoing_23\VBG\109660 renal_24\JJ\1740 angioplasty_25\NN\671351 (_26\-LRB-\1740 ptra_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D003287_D007674 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 compare_3\VB\644583 the_4\DT\1740 susceptibility_5\NN\13920835 to_6\TO\1740 <e2>nephrotoxic</e2>_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>cm</e1>_10\NN\13649268 in_11\IN\13603305 patients_12\NNS\9898892 undergoing_13\VBG\109660 ptra_14\NN\1740 with_15\IN\1740 that_16\DT\1740 of_17\IN\1740 patients_18\NNS\9898892 submitted_19\VBN\1952898 to_20\TO\1740 percutaneous_21\JJ\1740 coronary_22\JJ\1740 intervention_23\NN\1239064 (_24\-LRB-\1740 pci_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D003287_D007674 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 preliminary_4\JJ\1740 study_5\NN\635850 patients_6\NNS\9898892 submitted_7\VBN\1952898 to_8\TO\1740 ptra_9\NN\1740 showed_10\VBD\2137132 a_11\DT\13649268 lower_12\JJR\1740 susceptibility_13\NN\13920835 to_14\TO\1740 <e2>renal_15\JJ\1740 damage</e2>_16\NN\7296428 induced_17\VBN\1627355 by_18\IN\1740 <e1>cm</e1>_19\NN\13649268 administration_20\NN\1133281 than_21\IN\1740 pci_22\NN\1740 patients_23\NNS\9898892 ._24\.\1740
D003287_D064420 NONE the_0\DT\1740 effectiveness_1\NN\5190804 of_2\IN\1740 ptra_3\NN\1740 on_4\IN\1740 renal_5\JJ\1740 function_6\NN\13783581 seems_7\VBZ\2604760 to_8\TO\1740 be_9\VB\836236 barely_10\RB\1740 influenced_11\VBN\137313 by_12\IN\1740 <e1>cm</e1>_13\NN\13649268 <e2>toxicity</e2>_14\NN\13576101 ._15\.\1740
7739955
D002220_D009205 CID three_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 acute_3\JJ\1740 viral_4\JJ\1740 <e2>myocarditis</e2>_5\NN\14338942 ,_6\,\1740 one_7\NN\13741022 had_8\VBD\2108377 a_9\DT\13649268 <e1>carbamazepine-induced</e1>_10\JJ\1740 acute_11\JJ\1740 eosinophilic_12\JJ\1740 myocarditis_13\NN\14338942 ,_14\,\1740 and_15\CC\1740 one_16\NN\13741022 had_17\VBD\2108377 cardiac_18\JJ\1740 hemosiderosis_19\NN\14299637 resulting_20\VBG\2633881 in_21\IN\13603305 acute_22\JJ\1740 cardiogenic_23\JJ\1740 shock_24\NN\7510495 ._25\.\1740
D002220_D009205 CID three_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 acute_3\JJ\1740 viral_4\JJ\1740 myocarditis_5\NN\14338942 ,_6\,\1740 one_7\NN\13741022 had_8\VBD\2108377 a_9\DT\13649268 <e1>carbamazepine-induced</e1>_10\JJ\1740 acute_11\JJ\1740 <e2>eosinophilic_12\JJ\1740 myocarditis</e2>_13\NN\14338942 ,_14\,\1740 and_15\CC\1740 one_16\NN\13741022 had_17\VBD\2108377 cardiac_18\JJ\1740 hemosiderosis_19\NN\14299637 resulting_20\VBG\2633881 in_21\IN\13603305 acute_22\JJ\1740 cardiogenic_23\JJ\1740 shock_24\NN\7510495 ._25\.\1740
D002220_D004802 CID three_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 acute_3\JJ\1740 viral_4\JJ\1740 myocarditis_5\NN\14338942 ,_6\,\1740 one_7\NN\13741022 had_8\VBD\2108377 a_9\DT\13649268 <e1>carbamazepine-induced</e1>_10\JJ\1740 acute_11\JJ\1740 <e2>eosinophilic_12\JJ\1740 myocarditis</e2>_13\NN\14338942 ,_14\,\1740 and_15\CC\1740 one_16\NN\13741022 had_17\VBD\2108377 cardiac_18\JJ\1740 hemosiderosis_19\NN\14299637 resulting_20\VBG\2633881 in_21\IN\13603305 acute_22\JJ\1740 cardiogenic_23\JJ\1740 shock_24\NN\7510495 ._25\.\1740
D002220_D012770 NONE three_0\CD\13741022 patients_1\NNS\9898892 had_2\VBD\2108377 acute_3\JJ\1740 viral_4\JJ\1740 myocarditis_5\NN\14338942 ,_6\,\1740 one_7\NN\13741022 had_8\VBD\2108377 a_9\DT\13649268 <e1>carbamazepine-induced</e1>_10\JJ\1740 acute_11\JJ\1740 eosinophilic_12\JJ\1740 myocarditis_13\NN\14338942 ,_14\,\1740 and_15\CC\1740 one_16\NN\13741022 had_17\VBD\2108377 cardiac_18\JJ\1740 hemosiderosis_19\NN\14299637 resulting_20\VBG\2633881 in_21\IN\13603305 acute_22\JJ\1740 <e2>cardiogenic_23\JJ\1740 shock</e2>_24\NN\7510495 ._25\.\1740
24653743
C042288_D016757 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>sudden_3\NNP\1740 cardiac_4\NNP\1740 death</e2>_5\NNP\7296428 due_6\JJ\1740 to_7\IN\1740 <e1>pilsicainide-induced</e1>_8\JJ\1740 torsades_9\NNP\1740 de_10\NNP\1740 pointes_11\NNP\1740 ._12\.\1740
C042288_D016757 CID an_0\DT\6697703 84-year-old_1\JJ\1740 male_2\JJ\1740 received_3\VBD\2210855 oral_4\JJ\1740 <e1>pilsicainide</e1>_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 pure_8\JJ\1740 sodium_9\NN\14625458 channel_10\NN\6251781 blocker_11\NN\10101634 with_12\IN\1740 slow_13\JJ\1740 recovery_14\NN\7357388 kinetics_15\NNS\6100236 ,_16\,\1740 to_17\TO\1740 convert_18\VB\126264 his_19\PRP$\1740 paroxysmal_20\JJ\1740 atrial_21\JJ\1740 fibrillation_22\NN\14361664 to_23\IN\1740 a_24\DT\13649268 sinus_25\NN\5248181 rhythm_26\NN\15122011 ;_27\:\1740 the_28\DT\1740 patient_29\NN\9898892 developed_30\VBD\1753788 <e2>sudden_31\JJ\1740 cardiac_32\JJ\1740 death</e2>_33\NN\7296428 two_34\CD\13741022 days_35\NNS\15140892 later_36\RB\1740 ._37\.\1740
C042288_D016171 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 sudden_3\NNP\1740 cardiac_4\NNP\1740 death_5\NNP\7296428 due_6\JJ\1740 to_7\IN\1740 <e1>pilsicainide-induced</e1>_8\JJ\1740 <e2>torsades_9\NNP\1740 de_10\NNP\1740 pointes</e2>_11\NNP\1740 ._12\.\1740
C042288_D016171 CID although_0\IN\1740 the_1\DT\1740 patient_2\NN\9898892 's_3\POS\1740 renal_4\JJ\1740 function_5\NN\13783581 was_6\VBD\836236 not_7\RB\1740 highly_8\RB\1740 impaired_9\JJ\1740 and_10\CC\1740 the_11\DT\1740 dose_12\NN\3740161 of_13\IN\1740 <e1>pilsicainide</e1>_14\NN\1740 was_15\VBD\836236 low_16\JJ\1740 ,_17\,\1740 the_18\DT\1740 plasma_19\NN\5398023 concentration_20\NN\4916342 of_21\IN\1740 pilsicainide_22\NN\1740 may_23\MD\15209706 have_24\VB\2108377 been_25\VBN\836236 high_26\JJ\1740 ,_27\,\1740 which_28\WDT\1740 can_29\MD\3094503 produce_30\VB\1617192 <e2>torsades_31\NNS\1740 de_32\IN\1740 pointes</e2>_33\NNS\1740 in_34\IN\13603305 the_35\DT\1740 octogenarian_36\NN\10376523 ._37\.\1740
C042288_D016171 CID although_0\IN\1740 the_1\DT\1740 patient_2\NN\9898892 's_3\POS\1740 renal_4\JJ\1740 function_5\NN\13783581 was_6\VBD\836236 not_7\RB\1740 highly_8\RB\1740 impaired_9\JJ\1740 and_10\CC\1740 the_11\DT\1740 dose_12\NN\3740161 of_13\IN\1740 pilsicainide_14\NN\1740 was_15\VBD\836236 low_16\JJ\1740 ,_17\,\1740 the_18\DT\1740 plasma_19\NN\5398023 concentration_20\NN\4916342 of_21\IN\1740 <e1>pilsicainide</e1>_22\NN\1740 may_23\MD\15209706 have_24\VB\2108377 been_25\VBN\836236 high_26\JJ\1740 ,_27\,\1740 which_28\WDT\1740 can_29\MD\3094503 produce_30\VB\1617192 <e2>torsades_31\NNS\1740 de_32\IN\1740 pointes</e2>_33\NNS\1740 in_34\IN\13603305 the_35\DT\1740 octogenarian_36\NN\10376523 ._37\.\1740
C042288_D001281 NONE an_0\DT\6697703 84-year-old_1\JJ\1740 male_2\JJ\1740 received_3\VBD\2210855 oral_4\JJ\1740 <e1>pilsicainide</e1>_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 pure_8\JJ\1740 sodium_9\NN\14625458 channel_10\NN\6251781 blocker_11\NN\10101634 with_12\IN\1740 slow_13\JJ\1740 recovery_14\NN\7357388 kinetics_15\NNS\6100236 ,_16\,\1740 to_17\TO\1740 convert_18\VB\126264 his_19\PRP$\1740 paroxysmal_20\JJ\1740 <e2>atrial_21\JJ\1740 fibrillation</e2>_22\NN\14361664 to_23\IN\1740 a_24\DT\13649268 sinus_25\NN\5248181 rhythm_26\NN\15122011 ;_27\:\1740 the_28\DT\1740 patient_29\NN\9898892 developed_30\VBD\1753788 sudden_31\JJ\1740 cardiac_32\JJ\1740 death_33\NN\7296428 two_34\CD\13741022 days_35\NNS\15140892 later_36\RB\1740 ._37\.\1740
C042288_D001281 NONE although_0\IN\1740 the_1\DT\1740 oral_2\JJ\1740 administration_3\NN\1133281 of_4\IN\1740 class_5\NN\7951464 ic_6\NN\8339454 drugs_7\NNS\14778436 ,_8\,\1740 including_9\VBG\690614 <e1>pilsicainide</e1>_10\NN\1740 ,_11\,\1740 is_12\VBZ\836236 effective_13\JJ\1740 to_14\TO\1740 terminate_15\VB\126264 <e2>atrial_16\JJ\1740 fibrillation</e2>_17\NN\14361664 ,_18\,\1740 careful_19\JJ\1740 consideration_20\NN\5770926 must_21\MD\9367203 be_22\VB\836236 taken_23\VBN\2367363 before_24\IN\1740 giving_25\VBG\2327200 these_26\DT\1740 drugs_27\NNS\14778436 to_28\TO\1740 octogenarians_29\NNS\10376523 ._30\.\1740
D012964_D001281 NONE an_0\DT\6697703 84-year-old_1\JJ\1740 male_2\JJ\1740 received_3\VBD\2210855 oral_4\JJ\1740 pilsicainide_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 pure_8\JJ\1740 <e1>sodium</e1>_9\NN\14625458 channel_10\NN\6251781 blocker_11\NN\10101634 with_12\IN\1740 slow_13\JJ\1740 recovery_14\NN\7357388 kinetics_15\NNS\6100236 ,_16\,\1740 to_17\TO\1740 convert_18\VB\126264 his_19\PRP$\1740 paroxysmal_20\JJ\1740 <e2>atrial_21\JJ\1740 fibrillation</e2>_22\NN\14361664 to_23\IN\1740 a_24\DT\13649268 sinus_25\NN\5248181 rhythm_26\NN\15122011 ;_27\:\1740 the_28\DT\1740 patient_29\NN\9898892 developed_30\VBD\1753788 sudden_31\JJ\1740 cardiac_32\JJ\1740 death_33\NN\7296428 two_34\CD\13741022 days_35\NNS\15140892 later_36\RB\1740 ._37\.\1740
D012964_D016757 NONE an_0\DT\6697703 84-year-old_1\JJ\1740 male_2\JJ\1740 received_3\VBD\2210855 oral_4\JJ\1740 pilsicainide_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 pure_8\JJ\1740 <e1>sodium</e1>_9\NN\14625458 channel_10\NN\6251781 blocker_11\NN\10101634 with_12\IN\1740 slow_13\JJ\1740 recovery_14\NN\7357388 kinetics_15\NNS\6100236 ,_16\,\1740 to_17\TO\1740 convert_18\VB\126264 his_19\PRP$\1740 paroxysmal_20\JJ\1740 atrial_21\JJ\1740 fibrillation_22\NN\14361664 to_23\IN\1740 a_24\DT\13649268 sinus_25\NN\5248181 rhythm_26\NN\15122011 ;_27\:\1740 the_28\DT\1740 patient_29\NN\9898892 developed_30\VBD\1753788 <e2>sudden_31\JJ\1740 cardiac_32\JJ\1740 death</e2>_33\NN\7296428 two_34\CD\13741022 days_35\NNS\15140892 later_36\RB\1740 ._37\.\1740
9071336
D017239_D001943 NONE <e1>paclitaxel</e1>_0\NN\1740 ,_1\,\1740 5-fluorouracil_2\NN\1740 ,_3\,\1740 and_4\CC\1740 folinic_5\JJ\1740 acid_6\NN\14818238 in_7\IN\13603305 metastatic_8\JJ\1740 <e2>breast_9\NN\5225090 cancer</e2>_10\NN\14239425 :_11\:\1740 bre-26_12\NN\1740 ,_13\,\1740 a_14\DT\13649268 phase_15\NN\15113229 ii_16\CD\13741022 trial_17\NN\786195 ._18\.\1740
D017239_D001943 NONE 5-fluorouracil_0\NN\1740 plus_1\CC\4723816 folinic_2\JJ\1740 acid_3\NN\14818238 and_4\CC\1740 <e1>paclitaxel</e1>_5\NN\1740 (_6\-LRB-\1740 taxol_7\NN\1740 ;_8\:\1740 bristol-myers_9\NNP\1740 squibb_10\NNP\1740 company_11\NNP\8053576 ,_12\,\1740 princeton_13\NNP\1740 ,_14\,\1740 nj_15\NNP\1740 )_16\-RRB-\1740 are_17\VBP\836236 effective_18\JJ\1740 salvage_19\NN\3076708 therapies_20\NNS\657604 for_21\IN\1740 metastatic_22\JJ\1740 <e2>breast_23\NN\5225090 cancer</e2>_24\NN\14239425 patients_25\NNS\9898892 ._26\.\1740
D017239_D001943 NONE 5-fluorouracil_0\NN\1740 plus_1\CC\4723816 folinic_2\JJ\1740 acid_3\NN\14818238 and_4\CC\1740 paclitaxel_5\NN\1740 (_6\-LRB-\1740 <e1>taxol</e1>_7\NN\1740 ;_8\:\1740 bristol-myers_9\NNP\1740 squibb_10\NNP\1740 company_11\NNP\8053576 ,_12\,\1740 princeton_13\NNP\1740 ,_14\,\1740 nj_15\NNP\1740 )_16\-RRB-\1740 are_17\VBP\836236 effective_18\JJ\1740 salvage_19\NN\3076708 therapies_20\NNS\657604 for_21\IN\1740 metastatic_22\JJ\1740 <e2>breast_23\NN\5225090 cancer</e2>_24\NN\14239425 patients_25\NNS\9898892 ._26\.\1740
D017239_D001943 NONE we_0\PRP\1740 performed_1\VBD\2367363 a_2\DT\13649268 phase_3\NN\15113229 ii_4\CD\13741022 trial_5\NN\786195 of_6\IN\1740 <e1>paclitaxel</e1>_7\NN\1740 175_8\CD\1740 mg/m2_9\NN\1740 over_10\IN\5867413 3_11\CD\13741022 hours_12\NNS\15118228 on_13\IN\1740 day_14\NN\15154774 i_15\PRP\14622893 followed_16\VBD\1835496 by_17\IN\1740 folinic_18\JJ\1740 acid_19\NN\14818238 300_20\CD\1740 mg_21\NN\13717155 over_22\IN\5867413 1_23\CD\13741022 hour_24\NN\15154774 before_25\IN\1740 5-fluorouracil_26\NN\1740 350_27\CD\1740 mg/m2_28\NN\1740 on_29\IN\1740 days_30\NNS\15140892 1_31\CD\13741022 to_32\TO\1740 3_33\CD\13741022 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 (_37\-LRB-\1740 tfl_38\NN\1740 )_39\-RRB-\1740 in_40\IN\13603305 women_41\NNS\9605289 with_42\IN\1740 metastatic_43\JJ\1740 <e2>breast_44\NN\5225090 cancer</e2>_45\NN\14239425 ._46\.\1740
D005472_D001943 NONE paclitaxel_0\NN\1740 ,_1\,\1740 <e1>5-fluorouracil</e1>_2\NN\1740 ,_3\,\1740 and_4\CC\1740 folinic_5\JJ\1740 acid_6\NN\14818238 in_7\IN\13603305 metastatic_8\JJ\1740 <e2>breast_9\NN\5225090 cancer</e2>_10\NN\14239425 :_11\:\1740 bre-26_12\NN\1740 ,_13\,\1740 a_14\DT\13649268 phase_15\NN\15113229 ii_16\CD\13741022 trial_17\NN\786195 ._18\.\1740
D005472_D001943 NONE <e1>5-fluorouracil</e1>_0\NN\1740 plus_1\CC\4723816 folinic_2\JJ\1740 acid_3\NN\14818238 and_4\CC\1740 paclitaxel_5\NN\1740 (_6\-LRB-\1740 taxol_7\NN\1740 ;_8\:\1740 bristol-myers_9\NNP\1740 squibb_10\NNP\1740 company_11\NNP\8053576 ,_12\,\1740 princeton_13\NNP\1740 ,_14\,\1740 nj_15\NNP\1740 )_16\-RRB-\1740 are_17\VBP\836236 effective_18\JJ\1740 salvage_19\NN\3076708 therapies_20\NNS\657604 for_21\IN\1740 metastatic_22\JJ\1740 <e2>breast_23\NN\5225090 cancer</e2>_24\NN\14239425 patients_25\NNS\9898892 ._26\.\1740
D005472_D001943 NONE we_0\PRP\1740 performed_1\VBD\2367363 a_2\DT\13649268 phase_3\NN\15113229 ii_4\CD\13741022 trial_5\NN\786195 of_6\IN\1740 paclitaxel_7\NN\1740 175_8\CD\1740 mg/m2_9\NN\1740 over_10\IN\5867413 3_11\CD\13741022 hours_12\NNS\15118228 on_13\IN\1740 day_14\NN\15154774 i_15\PRP\14622893 followed_16\VBD\1835496 by_17\IN\1740 folinic_18\JJ\1740 acid_19\NN\14818238 300_20\CD\1740 mg_21\NN\13717155 over_22\IN\5867413 1_23\CD\13741022 hour_24\NN\15154774 before_25\IN\1740 <e1>5-fluorouracil</e1>_26\NN\1740 350_27\CD\1740 mg/m2_28\NN\1740 on_29\IN\1740 days_30\NNS\15140892 1_31\CD\13741022 to_32\TO\1740 3_33\CD\13741022 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 (_37\-LRB-\1740 tfl_38\NN\1740 )_39\-RRB-\1740 in_40\IN\13603305 women_41\NNS\9605289 with_42\IN\1740 metastatic_43\JJ\1740 <e2>breast_44\NN\5225090 cancer</e2>_45\NN\14239425 ._46\.\1740
D002955_D001943 NONE paclitaxel_0\NN\1740 ,_1\,\1740 5-fluorouracil_2\NN\1740 ,_3\,\1740 and_4\CC\1740 <e1>folinic_5\JJ\1740 acid</e1>_6\NN\14818238 in_7\IN\13603305 metastatic_8\JJ\1740 <e2>breast_9\NN\5225090 cancer</e2>_10\NN\14239425 :_11\:\1740 bre-26_12\NN\1740 ,_13\,\1740 a_14\DT\13649268 phase_15\NN\15113229 ii_16\CD\13741022 trial_17\NN\786195 ._18\.\1740
D002955_D001943 NONE 5-fluorouracil_0\NN\1740 plus_1\CC\4723816 <e1>folinic_2\JJ\1740 acid</e1>_3\NN\14818238 and_4\CC\1740 paclitaxel_5\NN\1740 (_6\-LRB-\1740 taxol_7\NN\1740 ;_8\:\1740 bristol-myers_9\NNP\1740 squibb_10\NNP\1740 company_11\NNP\8053576 ,_12\,\1740 princeton_13\NNP\1740 ,_14\,\1740 nj_15\NNP\1740 )_16\-RRB-\1740 are_17\VBP\836236 effective_18\JJ\1740 salvage_19\NN\3076708 therapies_20\NNS\657604 for_21\IN\1740 metastatic_22\JJ\1740 <e2>breast_23\NN\5225090 cancer</e2>_24\NN\14239425 patients_25\NNS\9898892 ._26\.\1740
D002955_D001943 NONE we_0\PRP\1740 performed_1\VBD\2367363 a_2\DT\13649268 phase_3\NN\15113229 ii_4\CD\13741022 trial_5\NN\786195 of_6\IN\1740 paclitaxel_7\NN\1740 175_8\CD\1740 mg/m2_9\NN\1740 over_10\IN\5867413 3_11\CD\13741022 hours_12\NNS\15118228 on_13\IN\1740 day_14\NN\15154774 i_15\PRP\14622893 followed_16\VBD\1835496 by_17\IN\1740 <e1>folinic_18\JJ\1740 acid</e1>_19\NN\14818238 300_20\CD\1740 mg_21\NN\13717155 over_22\IN\5867413 1_23\CD\13741022 hour_24\NN\15154774 before_25\IN\1740 5-fluorouracil_26\NN\1740 350_27\CD\1740 mg/m2_28\NN\1740 on_29\IN\1740 days_30\NNS\15140892 1_31\CD\13741022 to_32\TO\1740 3_33\CD\13741022 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 (_37\-LRB-\1740 tfl_38\NN\1740 )_39\-RRB-\1740 in_40\IN\13603305 women_41\NNS\9605289 with_42\IN\1740 metastatic_43\JJ\1740 <e2>breast_44\NN\5225090 cancer</e2>_45\NN\14239425 ._46\.\1740
D017239_D064420 NONE <e1>paclitaxel</e1>_0\NN\1740 and_1\CC\1740 5-fluorouracil_2\NN\1740 have_3\VBP\2108377 additive_4\JJ\1740 <e2>cytotoxicity</e2>_5\NN\13583478 in_6\IN\13603305 mcf-7_7\NN\1740 cell_8\NN\3080309 lines_9\NNS\8426461 ._10\.\1740
D005472_D064420 NONE paclitaxel_0\NN\1740 and_1\CC\1740 <e1>5-fluorouracil</e1>_2\NN\1740 have_3\VBP\2108377 additive_4\JJ\1740 <e2>cytotoxicity</e2>_5\NN\13583478 in_6\IN\13603305 mcf-7_7\NN\1740 cell_8\NN\3080309 lines_9\NNS\8426461 ._10\.\1740
D016179_D009503 NONE analysis_0\NN\633864 is_1\VBZ\836236 reported_2\VBN\831651 on_3\IN\1740 37_4\CD\1740 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 minimum_8\NN\13653902 of_9\IN\1740 6_10\CD\13741022 months_11\NNS\15113229 follow-up_12\JJ\1740 who_13\WP\8299493 received_14\VBD\2210855 a_15\DT\13649268 total_16\NN\3553 of_17\IN\1740 192_18\CD\1740 cycles_19\NNS\15269513 of_20\IN\1740 tfl_21\NN\1740 :_22\:\1740 nine_23\CD\13741022 cycles_24\NNS\15269513 (_25\-LRB-\1740 5_26\CD\13741022 %_27\NN\1740 )_28\-RRB-\1740 were_29\VBD\836236 associated_30\VBN\628491 with_31\IN\1740 grade_32\NN\7975026 3/4_33\CD\1740 <e2>neutropenia</e2>_34\NN\14196405 requiring_35\VBG\754942 hospitalization_36\NN\15113229 ;_37\:\1740 seven_38\CD\13741022 (_39\-LRB-\1740 4_40\CD\13741022 %_41\NN\1740 )_42\-RRB-\1740 cycles_43\NNS\15269513 in_44\IN\13603305 two_45\CD\13741022 patients_46\NNS\9898892 required_47\VBD\754942 <e1>granulocyte_48\NN\5449959 colony-stimulating_49\JJ\1740 factor</e1>_50\NN\7326557 due_51\JJ\1740 to_52\TO\1740 neutropenia_53\NN\14196405 ;_54\:\1740 no_55\DT\7204911 patient_56\NN\9898892 required_57\VBD\754942 platelet_58\NN\5432736 transfusions_59\NNS\320852 ._60\.\1740
D016179_D009503 NONE analysis_0\NN\633864 is_1\VBZ\836236 reported_2\VBN\831651 on_3\IN\1740 37_4\CD\1740 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 minimum_8\NN\13653902 of_9\IN\1740 6_10\CD\13741022 months_11\NNS\15113229 follow-up_12\JJ\1740 who_13\WP\8299493 received_14\VBD\2210855 a_15\DT\13649268 total_16\NN\3553 of_17\IN\1740 192_18\CD\1740 cycles_19\NNS\15269513 of_20\IN\1740 tfl_21\NN\1740 :_22\:\1740 nine_23\CD\13741022 cycles_24\NNS\15269513 (_25\-LRB-\1740 5_26\CD\13741022 %_27\NN\1740 )_28\-RRB-\1740 were_29\VBD\836236 associated_30\VBN\628491 with_31\IN\1740 grade_32\NN\7975026 3/4_33\CD\1740 neutropenia_34\NN\14196405 requiring_35\VBG\754942 hospitalization_36\NN\15113229 ;_37\:\1740 seven_38\CD\13741022 (_39\-LRB-\1740 4_40\CD\13741022 %_41\NN\1740 )_42\-RRB-\1740 cycles_43\NNS\15269513 in_44\IN\13603305 two_45\CD\13741022 patients_46\NNS\9898892 required_47\VBD\754942 <e1>granulocyte_48\NN\5449959 colony-stimulating_49\JJ\1740 factor</e1>_50\NN\7326557 due_51\JJ\1740 to_52\TO\1740 <e2>neutropenia</e2>_53\NN\14196405 ;_54\:\1740 no_55\DT\7204911 patient_56\NN\9898892 required_57\VBD\754942 platelet_58\NN\5432736 transfusions_59\NNS\320852 ._60\.\1740
19967075
D012964_D007674 NONE decreased_0\VBD\169651 expression_1\NN\4679549 of_2\IN\1740 <e1>na/k-atpase</e1>_3\NN\1740 ,_4\,\1740 nhe3_5\NN\1740 ,_6\,\1740 nbc1_7\NN\1740 ,_8\,\1740 aqp1_9\NN\1740 and_10\CC\1740 oat_11\NN\12141495 in_12\IN\13603305 gentamicin-induced_13\JJ\1740 <e2>nephropathy</e2>_14\NNP\14573196 ._15\.\1740
D012964_D007674 NONE gentamicin-induced_0\JJ\1740 <e2>nephropathy</e2>_1\NN\14573196 may_2\MD\15209706 at_3\IN\14622893 least_4\JJS\1740 in_5\IN\13603305 part_6\NN\31921 be_7\VB\836236 causally_8\RB\1740 related_9\JJ\1740 with_10\IN\1740 a_11\DT\13649268 decreased_12\VBN\169651 expression_13\NN\4679549 of_14\IN\1740 <e1>na(+)/k(+)-atpase</e1>_15\NN\1740 ,_16\,\1740 nhe3_17\NN\1740 ,_18\,\1740 nbc1_19\NN\1740 ,_20\,\1740 aqp1_21\NN\1740 and_22\CC\1740 oat_23\NN\12141495 ._24\.\1740
D011188_D007674 NONE decreased_0\VBD\169651 expression_1\NN\4679549 of_2\IN\1740 <e1>na/k-atpase</e1>_3\NN\1740 ,_4\,\1740 nhe3_5\NN\1740 ,_6\,\1740 nbc1_7\NN\1740 ,_8\,\1740 aqp1_9\NN\1740 and_10\CC\1740 oat_11\NN\12141495 in_12\IN\13603305 gentamicin-induced_13\JJ\1740 <e2>nephropathy</e2>_14\NNP\14573196 ._15\.\1740
D011188_D007674 NONE gentamicin-induced_0\JJ\1740 <e2>nephropathy</e2>_1\NN\14573196 may_2\MD\15209706 at_3\IN\14622893 least_4\JJS\1740 in_5\IN\13603305 part_6\NN\31921 be_7\VB\836236 causally_8\RB\1740 related_9\JJ\1740 with_10\IN\1740 a_11\DT\13649268 decreased_12\VBN\169651 expression_13\NN\4679549 of_14\IN\1740 <e1>na(+)/k(+)-atpase</e1>_15\NN\1740 ,_16\,\1740 nhe3_17\NN\1740 ,_18\,\1740 nbc1_19\NN\1740 ,_20\,\1740 aqp1_21\NN\1740 and_22\CC\1740 oat_23\NN\12141495 ._24\.\1740
D005839_D007674 CID decreased_0\VBD\169651 expression_1\NN\4679549 of_2\IN\1740 na/k-atpase_3\NN\1740 ,_4\,\1740 nhe3_5\NN\1740 ,_6\,\1740 nbc1_7\NN\1740 ,_8\,\1740 aqp1_9\NN\1740 and_10\CC\1740 oat_11\NN\12141495 in_12\IN\13603305 <e1>gentamicin-induced</e1>_13\JJ\1740 <e2>nephropathy</e2>_14\NNP\14573196 ._15\.\1740
D005839_D007674 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 aimed_4\VBN\1987160 to_5\TO\1740 determine_6\VB\1645601 whether_7\IN\1740 there_8\EX\27167 is_9\VBZ\836236 an_10\DT\6697703 altered_11\JJ\1740 regulation_12\NN\6652242 of_13\IN\1740 tubular_14\JJ\1740 transporters_15\NNS\4490091 in_16\IN\13603305 <e1>gentamicin-induced</e1>_17\JJ\1740 <e2>nephropathy</e2>_18\NN\14573196 ._19\.\1740
D005839_D007674 CID <e1>gentamicin-induced</e1>_0\JJ\1740 <e2>nephropathy</e2>_1\NN\14573196 may_2\MD\15209706 at_3\IN\14622893 least_4\JJS\1740 in_5\IN\13603305 part_6\NN\31921 be_7\VB\836236 causally_8\RB\1740 related_9\JJ\1740 with_10\IN\1740 a_11\DT\13649268 decreased_12\VBN\169651 expression_13\NN\4679549 of_14\IN\1740 na(+)/k(+)-atpase_15\NN\1740 ,_16\,\1740 nhe3_17\NN\1740 ,_18\,\1740 nbc1_19\NN\1740 ,_20\,\1740 aqp1_21\NN\1740 and_22\CC\1740 oat_23\NN\12141495 ._24\.\1740
17879100
D001241_D005334 NONE he_0\PRP\14622893 was_1\VBD\836236 put_2\VBN\1850315 on_3\IN\1740 <e1>aspirin</e1>_4\NN\2707683 following_5\VBG\1835496 surgery_6\NN\6045562 and_7\CC\1740 took_8\VBD\2367363 ibuprofen_9\NN\3828465 for_10\IN\1740 <e2>fever</e2>_11\NN\14299637 for_12\IN\1740 nearly_13\RB\1740 a_14\DT\13649268 week_15\NN\15113229 prior_16\RB\1740 to_17\IN\1740 presentation_18\NN\1027379 ._19\.\1740
D007052_D005334 NONE he_0\PRP\14622893 was_1\VBD\836236 put_2\VBN\1850315 on_3\IN\1740 aspirin_4\NN\2707683 following_5\VBG\1835496 surgery_6\NN\6045562 and_7\CC\1740 took_8\VBD\2367363 <e1>ibuprofen</e1>_9\NN\3828465 for_10\IN\1740 <e2>fever</e2>_11\NN\14299637 for_12\IN\1740 nearly_13\RB\1740 a_14\DT\13649268 week_15\NN\15113229 prior_16\RB\1740 to_17\IN\1740 presentation_18\NN\1027379 ._19\.\1740
24999722
D005446_C537630 NONE safety_0\NN\13920835 and_1\CC\1740 efficacy_2\NN\5199286 of_3\IN\1740 <e1>fluocinolone_4\NN\1740 acetonide</e1>_5\NN\1740 intravitreal_6\VBP\1740 implant_7\NN\4013729 (_8\-LRB-\1740 0.59_9\CD\1740 mg_10\NN\13717155 )_11\-RRB-\1740 in_12\IN\13603305 <e2>birdshot_13\NN\1740 retinochoroidopathy</e2>_14\NN\1740 ._15\.\1740
D005446_C537630 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 the_4\DT\1740 treatment_5\NN\654885 outcomes_6\NNS\7291312 of_7\IN\1740 the_8\DT\1740 <e1>fluocinolone_9\NN\1740 acetonide</e1>_10\NN\1740 intravitreal_11\VBP\1740 implant_12\NN\4013729 (_13\-LRB-\1740 0.59_14\CD\1740 mg_15\NN\13717155 )_16\-RRB-\1740 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 <e2>birdshot_20\NN\1740 retinochoroidopathy</e2>_21\VBD\1740 whose_22\WP$\1740 disease_23\NN\14061805 is_24\VBZ\836236 refractory_25\JJ\1740 or_26\CC\3541091 intolerant_27\JJ\1740 to_28\TO\1740 conventional_29\JJ\1740 immunomodulatory_30\NN\1740 therapy_31\NN\657604 ._32\.\1740
D005446_C537630 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 <e1>fluocinolone_6\NN\1740 acetonide</e1>_7\NN\1740 implant_8\NN\4013729 (_9\-LRB-\1740 0.59_10\CD\1740 mg_11\NN\13717155 )_12\-RRB-\1740 helps_13\VBZ\2556126 to_14\TO\1740 control_15\VB\2422663 inflammation_16\NN\14299637 in_17\IN\13603305 otherwise_18\JJ\1740 treatment-refractory_19\JJ\1740 cases_20\NNS\7283608 of_21\IN\1740 <e2>birdshot_22\JJ\1740 retinochoroidopathy</e2>_23\NN\1740 ._24\.\1740
D005446_D007249 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 <e1>fluocinolone_6\NN\1740 acetonide</e1>_7\NN\1740 implant_8\NN\4013729 (_9\-LRB-\1740 0.59_10\CD\1740 mg_11\NN\13717155 )_12\-RRB-\1740 helps_13\VBZ\2556126 to_14\TO\1740 control_15\VB\2422663 <e2>inflammation</e2>_16\NN\14299637 in_17\IN\13603305 otherwise_18\JJ\1740 treatment-refractory_19\JJ\1740 cases_20\NNS\7283608 of_21\IN\1740 birdshot_22\JJ\1740 retinochoroidopathy_23\NN\1740 ._24\.\1740
9323412
D017294_D003866 NONE acute_0\JJ\1740 severe_1\JJ\1740 <e2>depression</e2>_2\NN\14373582 following_3\VBG\1835496 peri-operative_4\JJ\1740 <e1>ondansetron</e1>_5\NN\1740 ._6\.\1740
D017294_D020250 NONE a_0\DT\13649268 41-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 a_4\DT\13649268 strong_5\JJ\1740 history_6\NN\15120823 of_7\IN\1740 <e2>postoperative_8\JJ\1740 nausea_9\NN\14299637 and_10\CC\1740 vomiting</e2>_11\NN\116687 presented_12\VBN\2137132 for_13\IN\1740 abdominal_14\JJ\1740 hysterectomy_15\NN\393369 3_16\CD\13741022 months_17\NNS\15113229 after_18\IN\1740 a_19\DT\13649268 previous_20\JJ\1740 anaesthetic_21\JJ\1740 where_22\WRB\1740 <e1>ondansetron</e1>_23\JJ\1740 prophylaxis_24\NN\1077350 had_25\VBD\2108377 been_26\VBN\836236 used_27\VBN\1156834 ._28\.\1740
D012701_D003865 NONE she_0\PRP\1740 had_1\VBD\2108377 developed_2\VBN\1753788 a_3\DT\13649268 severe_4\JJ\1740 acute_5\JJ\1740 <e2>major_6\JJ\1740 depression_7\NN\14373582 disorder</e2>_8\NN\14034177 almost_9\RB\1740 immediately_10\RB\1740 thereafter_11\RB\1740 ,_12\,\1740 possibly_13\RB\1740 related_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 use_17\NN\407535 of_18\IN\1740 a_19\DT\13649268 <e1>serotonin</e1>_20\NN\14807737 antagonist_21\NN\7846 ._22\.\1740
D015742_D009325 NONE anaesthesia_0\NN\14034177 with_1\IN\1740 a_2\DT\13649268 <e1>propofol</e1>_3\NN\1740 infusion_4\NN\14589223 and_5\CC\1740 avoidance_6\NN\203342 of_7\IN\1740 serotonin_8\NN\14807737 antagonists_9\NNS\7846 provided_10\VBN\2199590 a_11\DT\13649268 <e2>nausea-free</e2>_12\JJ\1740 postoperative_13\JJ\1740 course_14\NN\883297 without_15\IN\1740 exacerbation_16\NN\374224 of_17\IN\1740 the_18\DT\1740 depression_19\NN\14373582 disorder_20\NN\14034177 ._21\.\1740
D015742_D003866 NONE anaesthesia_0\NN\14034177 with_1\IN\1740 a_2\DT\13649268 <e1>propofol</e1>_3\NN\1740 infusion_4\NN\14589223 and_5\CC\1740 avoidance_6\NN\203342 of_7\IN\1740 serotonin_8\NN\14807737 antagonists_9\NNS\7846 provided_10\VBN\2199590 a_11\DT\13649268 nausea-free_12\JJ\1740 postoperative_13\JJ\1740 course_14\NN\883297 without_15\IN\1740 exacerbation_16\NN\374224 of_17\IN\1740 the_18\DT\1740 <e2>depression_19\NN\14373582 disorder</e2>_20\NN\14034177 ._21\.\1740
D012701_D009325 NONE anaesthesia_0\NN\14034177 with_1\IN\1740 a_2\DT\13649268 propofol_3\NN\1740 infusion_4\NN\14589223 and_5\CC\1740 avoidance_6\NN\203342 of_7\IN\1740 <e1>serotonin</e1>_8\NN\14807737 antagonists_9\NNS\7846 provided_10\VBN\2199590 a_11\DT\13649268 <e2>nausea-free</e2>_12\JJ\1740 postoperative_13\JJ\1740 course_14\NN\883297 without_15\IN\1740 exacerbation_16\NN\374224 of_17\IN\1740 the_18\DT\1740 depression_19\NN\14373582 disorder_20\NN\14034177 ._21\.\1740
D012701_D003866 NONE anaesthesia_0\NN\14034177 with_1\IN\1740 a_2\DT\13649268 propofol_3\NN\1740 infusion_4\NN\14589223 and_5\CC\1740 avoidance_6\NN\203342 of_7\IN\1740 <e1>serotonin</e1>_8\NN\14807737 antagonists_9\NNS\7846 provided_10\VBN\2199590 a_11\DT\13649268 nausea-free_12\JJ\1740 postoperative_13\JJ\1740 course_14\NN\883297 without_15\IN\1740 exacerbation_16\NN\374224 of_17\IN\1740 the_18\DT\1740 <e2>depression_19\NN\14373582 disorder</e2>_20\NN\14034177 ._21\.\1740
2131034
D013852_D011115 CID severe_0\JJ\1740 <e2>polyneuropathy</e2>_1\JJ\1740 and_2\CC\1740 motor_3\NN\3699975 loss_4\NN\13252973 after_5\IN\1740 intrathecal_6\JJ\1740 <e1>thiotepa</e1>_7\NN\2722458 combination_8\NN\7951464 chemotherapy_9\NN\661091 :_10\:\1740 description_11\NN\6722453 of_12\IN\1740 two_13\CD\13741022 cases_14\NNS\7283608 ._15\.\1740
D013852_D020258 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 severe_3\JJ\1740 delayed_4\VBN\439958 <e2>neurologic_5\JJ\1740 toxicity</e2>_6\NN\13576101 related_7\JJ\1740 to_8\TO\1740 the_9\DT\1740 administration_10\NN\1133281 of_11\IN\1740 intrathecal_12\JJ\1740 (_13\-LRB-\1740 it_14\NN\6125041 )_15\-RRB-\1740 combination_16\NN\7951464 chemotherapy_17\NN\661091 including_18\VBG\690614 <e1>thiotepa</e1>_19\NN\2722458 (_20\-LRB-\1740 tspa_21\NN\1740 )_22\-RRB-\1740 are_23\VBP\836236 presented_24\VBN\2137132 ._25\.\1740
D013852_D020258 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 severe_3\JJ\1740 delayed_4\VBN\439958 <e2>neurologic_5\JJ\1740 toxicity</e2>_6\NN\13576101 related_7\JJ\1740 to_8\TO\1740 the_9\DT\1740 administration_10\NN\1133281 of_11\IN\1740 intrathecal_12\JJ\1740 (_13\-LRB-\1740 it_14\NN\6125041 )_15\-RRB-\1740 combination_16\NN\7951464 chemotherapy_17\NN\661091 including_18\VBG\690614 thiotepa_19\NN\2722458 (_20\-LRB-\1740 <e1>tspa</e1>_21\NN\1740 )_22\-RRB-\1740 are_23\VBP\836236 presented_24\VBN\2137132 ._25\.\1740
D013852_D020258 CID <e2>neurologic_0\JJ\1740 toxicities</e2>_1\NNS\13576101 have_2\VBP\2108377 been_3\VBN\836236 described_4\VBN\1001294 with_5\IN\1740 it-methotrexate_6\NN\1740 ,_7\,\1740 it-cytosine_8\NN\1740 arabinoside_9\NN\1740 and_10\CC\1740 <e1>it-tspa</e1>_11\NN\1740 ._12\.\1740
D013852_D020258 CID in_0\IN\13603305 spite_1\NN\7550369 of_2\IN\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 <e1>tspa</e1>_6\NNP\1740 is_7\VBZ\836236 a_8\DT\13649268 useful_9\JJ\1740 it_10\NN\6125041 agent_11\NN\7347 ,_12\,\1740 its_13\PRP$\6125041 combination_14\NN\7951464 with_15\IN\1740 mtx_16\NN\1740 ,_17\,\1740 ara-c_18\JJ\1740 and_19\CC\1740 radiotherapy_20\NN\661091 could_21\MD\1740 cause_22\VB\1617192 severe_23\JJ\1740 <e2>neurotoxicity</e2>_24\NN\1740 ._25\.\1740
D008727_D020258 CID <e2>neurologic_0\JJ\1740 toxicities</e2>_1\NNS\13576101 have_2\VBP\2108377 been_3\VBN\836236 described_4\VBN\1001294 with_5\IN\1740 <e1>it-methotrexate</e1>_6\NN\1740 ,_7\,\1740 it-cytosine_8\NN\1740 arabinoside_9\NN\1740 and_10\CC\1740 it-tspa_11\NN\1740 ._12\.\1740
D008727_D020258 CID in_0\IN\13603305 spite_1\NN\7550369 of_2\IN\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 tspa_6\NNP\1740 is_7\VBZ\836236 a_8\DT\13649268 useful_9\JJ\1740 it_10\NN\6125041 agent_11\NN\7347 ,_12\,\1740 its_13\PRP$\6125041 combination_14\NN\7951464 with_15\IN\1740 <e1>mtx</e1>_16\NN\1740 ,_17\,\1740 ara-c_18\JJ\1740 and_19\CC\1740 radiotherapy_20\NN\661091 could_21\MD\1740 cause_22\VB\1617192 severe_23\JJ\1740 <e2>neurotoxicity</e2>_24\NN\1740 ._25\.\1740
D003561_D020258 CID <e2>neurologic_0\JJ\1740 toxicities</e2>_1\NNS\13576101 have_2\VBP\2108377 been_3\VBN\836236 described_4\VBN\1001294 with_5\IN\1740 it-methotrexate_6\NN\1740 ,_7\,\1740 <e1>it-cytosine_8\NN\1740 arabinoside</e1>_9\NN\1740 and_10\CC\1740 it-tspa_11\NN\1740 ._12\.\1740
D003561_D020258 CID in_0\IN\13603305 spite_1\NN\7550369 of_2\IN\1740 the_3\DT\1740 fact_4\NN\5816287 that_5\IN\1740 tspa_6\NNP\1740 is_7\VBZ\836236 a_8\DT\13649268 useful_9\JJ\1740 it_10\NN\6125041 agent_11\NN\7347 ,_12\,\1740 its_13\PRP$\6125041 combination_14\NN\7951464 with_15\IN\1740 mtx_16\NN\1740 ,_17\,\1740 <e1>ara-c</e1>_18\JJ\1740 and_19\CC\1740 radiotherapy_20\NN\661091 could_21\MD\1740 cause_22\VB\1617192 severe_23\JJ\1740 <e2>neurotoxicity</e2>_24\NN\1740 ._25\.\1740
10672628
D009569_D002375 NONE sub-chronic_0\JJ\1740 inhibition_1\NN\1068773 of_2\IN\1740 <e1>nitric-oxide</e1>_3\JJ\1740 synthesis_4\NN\13446390 modifies_5\VBZ\109660 haloperidol-induced_6\JJ\1740 <e2>catalepsy</e2>_7\NN\14023236 and_8\CC\1740 the_9\DT\1740 number_10\NN\5107765 of_11\IN\1740 nadph-diaphorase_12\JJ\1740 neurons_13\NNS\5430628 in_14\IN\13603305 mice_15\NNS\2329401 ._16\.\1740
D009569_D002375 NONE rationale_0\NN\5793000 :_1\:\1740 ng-nitro-l-arginine_2\NN\1740 (_3\-LRB-\1740 l-noarg_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 an_7\DT\6697703 inhibitor_8\NN\20090 of_9\IN\1740 <e1>nitric-oxide</e1>_10\JJ\1740 synthase_11\NN\1740 (_12\-LRB-\1740 nos_13\NN\7204911 )_14\-RRB-\1740 ,_15\,\1740 induces_16\VBZ\1627355 <e2>catalepsy</e2>_17\NN\14023236 in_18\IN\13603305 mice_19\NNS\2329401 ._20\.\1740
D006220_D002375 CID sub-chronic_0\JJ\1740 inhibition_1\NN\1068773 of_2\IN\1740 nitric-oxide_3\JJ\1740 synthesis_4\NN\13446390 modifies_5\VBZ\109660 <e1>haloperidol-induced</e1>_6\JJ\1740 <e2>catalepsy</e2>_7\NN\14023236 and_8\CC\1740 the_9\DT\1740 number_10\NN\5107765 of_11\IN\1740 nadph-diaphorase_12\JJ\1740 neurons_13\NNS\5430628 in_14\IN\13603305 mice_15\NNS\2329401 ._16\.\1740
D006220_D002375 CID neuroleptic_0\JJ\1740 drugs_1\NNS\14778436 such_2\JJ\1740 as_3\IN\14622893 <e1>haloperidol</e1>_4\NN\3713736 ,_5\,\1740 which_6\WDT\1740 block_7\VBP\1476483 dopamine_8\NN\14807737 receptors_9\NNS\5225602 ,_10\,\1740 also_11\RB\1740 cause_12\VBP\1617192 <e2>catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rodents_15\NNS\1886756 ._16\.\1740
D006220_D002375 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 investigate_3\VB\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 subchronic_7\JJ\1740 l-noarg_8\NN\1740 treatment_9\NN\654885 in_10\IN\13603305 <e1>haloperidol-induced</e1>_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 and_13\CC\1740 the_14\DT\1740 number_15\NN\5107765 of_16\IN\1740 nos_17\NN\7204911 neurons_18\NNS\5430628 in_19\IN\13603305 areas_20\NNS\8630985 related_21\JJ\1740 to_22\TO\1740 motor_23\NN\3699975 control_24\NN\5190804 ._25\.\1740
D006220_D002375 CID results_0\NNS\34213 :_1\:\1740 l-noarg_2\JJ\1740 sub-chronic_3\JJ\1740 administration_4\NN\1133281 produced_5\VBD\1617192 tolerance_6\NN\5032565 of_7\IN\1740 l-noarg_8\NN\1740 and_9\CC\1740 of_10\IN\1740 <e1>haloperidol-induced</e1>_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D009249_D002375 NONE sub-chronic_0\JJ\1740 inhibition_1\NN\1068773 of_2\IN\1740 nitric-oxide_3\JJ\1740 synthesis_4\NN\13446390 modifies_5\VBZ\109660 haloperidol-induced_6\JJ\1740 <e2>catalepsy</e2>_7\NN\14023236 and_8\CC\1740 the_9\DT\1740 number_10\NN\5107765 of_11\IN\1740 <e1>nadph-diaphorase</e1>_12\JJ\1740 neurons_13\NNS\5430628 in_14\IN\13603305 mice_15\NNS\2329401 ._16\.\1740
D019335_D002375 NONE rationale_0\NN\5793000 :_1\:\1740 <e1>ng-nitro-l-arginine</e1>_2\NN\1740 (_3\-LRB-\1740 l-noarg_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 an_7\DT\6697703 inhibitor_8\NN\20090 of_9\IN\1740 nitric-oxide_10\JJ\1740 synthase_11\NN\1740 (_12\-LRB-\1740 nos_13\NN\7204911 )_14\-RRB-\1740 ,_15\,\1740 induces_16\VBZ\1627355 <e2>catalepsy</e2>_17\NN\14023236 in_18\IN\13603305 mice_19\NNS\2329401 ._20\.\1740
D019335_D002375 NONE rationale_0\NN\5793000 :_1\:\1740 ng-nitro-l-arginine_2\NN\1740 (_3\-LRB-\1740 <e1>l-noarg</e1>_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 an_7\DT\6697703 inhibitor_8\NN\20090 of_9\IN\1740 nitric-oxide_10\JJ\1740 synthase_11\NN\1740 (_12\-LRB-\1740 nos_13\NN\7204911 )_14\-RRB-\1740 ,_15\,\1740 induces_16\VBZ\1627355 <e2>catalepsy</e2>_17\NN\14023236 in_18\IN\13603305 mice_19\NNS\2329401 ._20\.\1740
D019335_D002375 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 investigate_3\VB\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 subchronic_7\JJ\1740 <e1>l-noarg</e1>_8\NN\1740 treatment_9\NN\654885 in_10\IN\13603305 haloperidol-induced_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 and_13\CC\1740 the_14\DT\1740 number_15\NN\5107765 of_16\IN\1740 nos_17\NN\7204911 neurons_18\NNS\5430628 in_19\IN\13603305 areas_20\NNS\8630985 related_21\JJ\1740 to_22\TO\1740 motor_23\NN\3699975 control_24\NN\5190804 ._25\.\1740
D019335_D002375 NONE results_0\NNS\34213 :_1\:\1740 <e1>l-noarg</e1>_2\JJ\1740 sub-chronic_3\JJ\1740 administration_4\NN\1133281 produced_5\VBD\1617192 tolerance_6\NN\5032565 of_7\IN\1740 l-noarg_8\NN\1740 and_9\CC\1740 of_10\IN\1740 haloperidol-induced_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D019335_D002375 NONE results_0\NNS\34213 :_1\:\1740 l-noarg_2\JJ\1740 sub-chronic_3\JJ\1740 administration_4\NN\1133281 produced_5\VBD\1617192 tolerance_6\NN\5032565 of_7\IN\1740 <e1>l-noarg</e1>_8\NN\1740 and_9\CC\1740 of_10\IN\1740 haloperidol-induced_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D004298_D002375 NONE neuroleptic_0\JJ\1740 drugs_1\NNS\14778436 such_2\JJ\1740 as_3\IN\14622893 haloperidol_4\NN\3713736 ,_5\,\1740 which_6\WDT\1740 block_7\VBP\1476483 <e1>dopamine</e1>_8\NN\14807737 receptors_9\NNS\5225602 ,_10\,\1740 also_11\RB\1740 cause_12\VBP\1617192 <e2>catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rodents_15\NNS\1886756 ._16\.\1740
3711722
D003035_D009202 CID in_0\IN\13603305 the_1\DT\1740 first_2\JJ\1740 ,_3\,\1740 <e1>cobalt</e1>_4\NN\14625458 <e2>cardiomyopathy</e2>_5\NN\14103288 was_6\VBD\836236 induced_7\VBN\1627355 in_8\IN\13603305 eight_9\CD\13741022 dogs_10\NNS\2083346 ;_11\:\1740 vip_12\NN\10200781 (_13\-LRB-\1740 by_14\IN\1740 radioimmunoassay_15\NN\5740560 )_16\-RRB-\1740 decreased_17\VBD\169651 from_18\IN\1740 35_19\CD\1740 +/-_20\CC\1740 11_21\CD\13745420 pg/mg_22\NN\1740 protein_23\NN\14944888 (_24\-LRB-\1740 mean_25\NN\6021761 +/-_26\CC\1740 sd_27\NN\1740 )_28\-RRB-\1740 to_29\TO\1740 5_30\CD\13741022 +/-_31\CC\1740 4_32\CD\13741022 pg/mg_33\NN\1740 protein_34\NN\14944888 (_35\-LRB-\1740 p_36\NN\14622893 less_37\JJR\1740 than_38\IN\1740 0.05_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D004317_D006333 CID in_0\IN\13603305 six_1\CD\13741022 dogs_2\NNS\2083346 with_3\IN\1740 <e1>doxorubicin-induced</e1>_4\JJ\1740 <e2>heart_5\NN\5919034 failure</e2>_6\NN\66216 ,_7\,\1740 vip_8\NN\10200781 decreased_9\VBD\169651 from_10\IN\1740 31_11\CD\1740 +/-_12\CC\1740 7_13\CD\13741022 to_14\TO\1740 11_15\CD\13745420 +/-_16\CC\1740 4_17\CD\13741022 pg/mg_18\NN\1740 protein_19\NN\14944888 (_20\-LRB-\1740 p_21\NN\14622893 less_22\JJR\1740 than_23\IN\1740 0.05_24\CD\1740 )_25\-RRB-\1740 ._26\.\1740
19020118
11988250
D007052_D006976 CID <e2>pulmonary_0\JJ\1740 hypertension</e2>_1\NN\14057371 after_2\IN\1740 <e1>ibuprofen</e1>_3\NN\3828465 prophylaxis_4\NN\1077350 in_5\IN\13603305 very_6\JJ\1740 preterm_7\NN\1740 infants_8\NNS\9918248 ._9\.\1740
D007052_D000860 CID we_0\PRP\1740 report_1\VBP\831651 three_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 severe_5\JJ\1740 <e2>hypoxaemia</e2>_6\NN\1740 after_7\IN\1740 <e1>ibuprofen</e1>_8\NN\3828465 administration_9\NN\1133281 during_10\IN\1740 a_11\DT\13649268 randomised_12\VBN\278117 controlled_13\VBN\2422663 trial_14\NN\786195 of_15\IN\1740 prophylactic_16\JJ\1740 treatment_17\NN\654885 of_18\IN\1740 patent_19\NN\6470073 ductus_20\NN\1740 arteriosus_21\NN\1740 with_22\IN\1740 ibuprofen_23\NN\3828465 in_24\IN\13603305 premature_25\JJ\1740 infants_26\NNS\9918248 born_27\VBN\2630189 at_28\IN\14622893 less_29\JJR\1740 than_30\IN\1740 28_31\CD\13745420 weeks_32\NNS\15113229 of_33\IN\1740 gestation_34\NN\15116532 ._35\.\1740
D007052_D000860 CID we_0\PRP\1740 report_1\VBP\831651 three_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 severe_5\JJ\1740 <e2>hypoxaemia</e2>_6\NN\1740 after_7\IN\1740 ibuprofen_8\NN\3828465 administration_9\NN\1133281 during_10\IN\1740 a_11\DT\13649268 randomised_12\VBN\278117 controlled_13\VBN\2422663 trial_14\NN\786195 of_15\IN\1740 prophylactic_16\JJ\1740 treatment_17\NN\654885 of_18\IN\1740 patent_19\NN\6470073 ductus_20\NN\1740 arteriosus_21\NN\1740 with_22\IN\1740 <e1>ibuprofen</e1>_23\NN\3828465 in_24\IN\13603305 premature_25\JJ\1740 infants_26\NNS\9918248 born_27\VBN\2630189 at_28\IN\14622893 less_29\JJR\1740 than_30\IN\1740 28_31\CD\13745420 weeks_32\NNS\15113229 of_33\IN\1740 gestation_34\NN\15116532 ._35\.\1740
D007052_D000860 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 investigators_3\NNS\10560637 involved_4\VBN\2676054 in_5\IN\13603305 similar_6\JJ\1740 trials_7\NNS\786195 pay_8\VBP\2199590 close_9\JJ\1740 attention_10\NN\5701944 to_11\IN\1740 pulmonary_12\JJ\1740 pressure_13\NN\11419404 if_14\IN\1740 <e2>hypoxaemia</e2>_15\NN\1740 occurs_16\VBZ\2623529 after_17\IN\1740 prophylactic_18\JJ\1740 administration_19\NN\1133281 of_20\IN\1740 <e1>ibuprofen</e1>_21\NN\3828465 ._22\.\1740
D007052_D004374 NONE we_0\PRP\1740 report_1\VBP\831651 three_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 severe_5\JJ\1740 hypoxaemia_6\NN\1740 after_7\IN\1740 <e1>ibuprofen</e1>_8\NN\3828465 administration_9\NN\1133281 during_10\IN\1740 a_11\DT\13649268 randomised_12\VBN\278117 controlled_13\VBN\2422663 trial_14\NN\786195 of_15\IN\1740 prophylactic_16\JJ\1740 treatment_17\NN\654885 of_18\IN\1740 <e2>patent_19\NN\6470073 ductus_20\NN\1740 arteriosus</e2>_21\NN\1740 with_22\IN\1740 ibuprofen_23\NN\3828465 in_24\IN\13603305 premature_25\JJ\1740 infants_26\NNS\9918248 born_27\VBN\2630189 at_28\IN\14622893 less_29\JJR\1740 than_30\IN\1740 28_31\CD\13745420 weeks_32\NNS\15113229 of_33\IN\1740 gestation_34\NN\15116532 ._35\.\1740
D007052_D004374 NONE we_0\PRP\1740 report_1\VBP\831651 three_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 severe_5\JJ\1740 hypoxaemia_6\NN\1740 after_7\IN\1740 ibuprofen_8\NN\3828465 administration_9\NN\1133281 during_10\IN\1740 a_11\DT\13649268 randomised_12\VBN\278117 controlled_13\VBN\2422663 trial_14\NN\786195 of_15\IN\1740 prophylactic_16\JJ\1740 treatment_17\NN\654885 of_18\IN\1740 <e2>patent_19\NN\6470073 ductus_20\NN\1740 arteriosus</e2>_21\NN\1740 with_22\IN\1740 <e1>ibuprofen</e1>_23\NN\3828465 in_24\IN\13603305 premature_25\JJ\1740 infants_26\NNS\9918248 born_27\VBN\2630189 at_28\IN\14622893 less_29\JJR\1740 than_30\IN\1740 28_31\CD\13745420 weeks_32\NNS\15113229 of_33\IN\1740 gestation_34\NN\15116532 ._35\.\1740
D009569_D000860 NONE <e2>hypoxaemia</e2>_0\NNP\1740 resolved_1\VBD\352826 quickly_2\RB\1740 on_3\IN\1740 inhaled_4\VBN\1198101 <e1>nitric_5\JJ\1740 oxide</e1>_6\NN\14818238 therapy_7\NN\657604 ._8\.\1740
17351238
D005996_D007022 CID a_0\DT\13649268 dramatic_1\JJ\1740 <e2>drop_2\NN\13899200 in_3\IN\13603305 blood_4\NN\5397468 pressure</e2>_5\NN\11419404 following_6\VBG\1835496 prehospital_7\JJ\1740 <e1>gtn</e1>_8\NN\1740 administration_9\NN\1133281 ._10\.\1740
D005996_D007022 CID several_0\JJ\1740 minutes_1\NNS\6502378 after_2\IN\1740 the_3\DT\1740 <e1>gtn</e1>_4\NN\1740 the_5\DT\1740 patient_6\NN\9898892 experienced_7\VBD\2108377 a_8\DT\13649268 sudden_9\JJ\1740 <e2>drop_10\NN\13899200 in_11\IN\13603305 blood_12\NN\5397468 pressure</e2>_13\NN\11419404 and_14\CC\1740 heart_15\NN\5919034 rate_16\NN\13815152 ,_17\,\1740 this_18\DT\1740 was_19\VBD\836236 rectified_20\VBN\918872 by_21\IN\1740 atropine_22\NN\14712692 sulphate_23\NN\15010703 and_24\CC\1740 a_25\DT\13649268 fluid_26\NN\19613 challenge_27\NN\13927383 ._28\.\1740
D001285_D007022 NONE several_0\JJ\1740 minutes_1\NNS\6502378 after_2\IN\1740 the_3\DT\1740 gtn_4\NN\1740 the_5\DT\1740 patient_6\NN\9898892 experienced_7\VBD\2108377 a_8\DT\13649268 sudden_9\JJ\1740 <e2>drop_10\NN\13899200 in_11\IN\13603305 blood_12\NN\5397468 pressure</e2>_13\NN\11419404 and_14\CC\1740 heart_15\NN\5919034 rate_16\NN\13815152 ,_17\,\1740 this_18\DT\1740 was_19\VBD\836236 rectified_20\VBN\918872 by_21\IN\1740 <e1>atropine_22\NN\14712692 sulphate</e1>_23\NN\15010703 and_24\CC\1740 a_25\DT\13649268 fluid_26\NN\19613 challenge_27\NN\13927383 ._28\.\1740
17223814
D015251_D054537 CID peri-operative_0\JJ\1740 <e2>atrioventricular_1\JJ\1740 block</e2>_2\NN\21939 as_3\IN\14622893 a_4\DT\13649268 result_5\NN\34213 of_6\IN\1740 chemotherapy_7\NN\661091 with_8\IN\1740 <e1>epirubicin</e1>_9\NN\1740 and_10\CC\1740 paclitaxel_11\NN\1740 ._12\.\1740
D017239_D054537 CID peri-operative_0\JJ\1740 <e2>atrioventricular_1\JJ\1740 block</e2>_2\NN\21939 as_3\IN\14622893 a_4\DT\13649268 result_5\NN\34213 of_6\IN\1740 chemotherapy_7\NN\661091 with_8\IN\1740 epirubicin_9\NN\1740 and_10\CC\1740 <e1>paclitaxel</e1>_11\NN\1740 ._12\.\1740
7457821
25031906
D017311_D004408 CID is_0\VBZ\836236 <e2>dysguesia</e2>_1\NNP\1740 going_2\VBG\2367363 to_3\TO\1740 be_4\VB\836236 a_5\DT\13649268 rare_6\JJ\1740 or_7\CC\3541091 a_8\DT\13649268 common_9\JJ\1740 side-effect_10\NN\1740 of_11\IN\1740 <e1>amlodipine</e1>_12\NN\1740 ?_13\.\1740
D017311_D004408 CID a_0\DT\13649268 very_1\RB\1740 rare_2\JJ\1740 side-effect_3\NN\1740 of_4\IN\1740 <e1>amlodipine</e1>_5\NN\1740 is_6\VBZ\836236 <e2>dysguesia</e2>_7\VBN\1740 ._8\.\1740
D017311_D004408 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>amlodipine</e1>_3\NN\1740 can_4\MD\3094503 cause_5\VB\1617192 <e2>dysguesia</e2>_6\NN\1740 ._7\.\1740
D017311_D004408 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 the_4\DT\1740 clinical_5\JJ\1740 presentation_6\NN\1027379 and_7\CC\1740 review_8\VB\644583 the_9\DT\1740 relevant_10\JJ\1740 literature_11\NN\6362953 on_12\IN\1740 <e1>amlodipine</e1>_13\NN\1740 and_14\CC\1740 <e2>dysguesia</e2>_15\NN\1740 ._16\.\1740
D017311_D006973 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 about_4\IN\1740 a_5\DT\13649268 female_6\NN\15388 with_7\IN\1740 essential_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 on_10\IN\1740 drug_11\NN\14778436 treatment_12\NN\654885 with_13\IN\1740 <e1>amlodipine</e1>_14\NN\1740 developed_15\VBD\1753788 loss_16\NN\13252973 of_17\IN\1740 taste_18\NN\5712076 sensation_19\NN\5708432 ._20\.\1740
D017311_D012678 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 about_4\IN\1740 a_5\DT\13649268 female_6\NN\15388 with_7\IN\1740 essential_8\JJ\1740 hypertension_9\NN\14057371 on_10\IN\1740 drug_11\NN\14778436 treatment_12\NN\654885 with_13\IN\1740 <e1>amlodipine</e1>_14\NN\1740 developed_15\VBD\1753788 <e2>loss_16\NN\13252973 of_17\IN\1740 taste_18\NN\5712076 sensation</e2>_19\NN\5708432 ._20\.\1740
4082192
C026729_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>p-aminophenol</e1>_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 nephrotoxicity_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
C026729_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>p-aminophenol</e1>_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 nephrotoxicity_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 <e2>nephrotoxicity</e2>_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
C026729_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 <e1>p-aminophenol</e1>_16\NN\1740 nephrotoxicity_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
C026729_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 nephrotoxicity_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 <e1>p-aminophenol</e1>_16\NN\1740 <e2>nephrotoxicity</e2>_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
C026729_D007674 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 determine_7\VB\1645601 if_8\IN\1740 <e1>pap</e1>_9\NN\6612266 formation_10\NN\7938773 is_11\VBZ\836236 a_12\DT\13649268 requisite_13\JJ\1740 step_14\NN\168237 in_15\IN\13603305 apap-induced_16\JJ\1740 <e2>nephrotoxicity</e2>_17\NN\1740 ._18\.\1740
C026729_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 bis(p-nitrophenyl_5\NN\1740 )_6\-RRB-\1740 phosphate_7\NN\15010703 (_8\-LRB-\1740 bnpp_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 an_12\DT\6697703 acylamidase_13\NN\1740 inhibitor_14\NN\20090 ,_15\,\1740 on_16\IN\1740 apap_17\NN\1740 and_18\CC\1740 <e1>pap</e1>_19\NN\6612266 <e2>nephrotoxicity</e2>_20\NN\1740 and_21\CC\1740 metabolism_22\NN\13526110 was_23\VBD\836236 determined_24\VBN\1645601 ._25\.\1740
C026729_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 <e1>pap</e1>_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 <e2>nephrotoxicity</e2>_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 nephrotoxicity_25\NN\1740 ._26\.\1740
C026729_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 <e1>pap</e1>_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 nephrotoxicity_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
C026729_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 <e2>nephrotoxicity</e2>_21\NN\1740 but_22\CC\1740 not_23\RB\1740 <e1>pap</e1>_24\NN\6612266 nephrotoxicity_25\NN\1740 ._26\.\1740
C026729_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 nephrotoxicity_21\NN\1740 but_22\CC\1740 not_23\RB\1740 <e1>pap</e1>_24\NN\6612266 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
D000082_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 <e1>acetaminophen-induced</e1>_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 nephrotoxicity_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
D000082_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 <e1>acetaminophen-induced</e1>_5\JJ\1740 nephrotoxicity_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 <e2>nephrotoxicity</e2>_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
D000082_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 <e1>acetaminophen</e1>_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 nephrotoxicity_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
D000082_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 nephrotoxicity_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate_12\NN\15010703 on_13\IN\1740 <e1>acetaminophen</e1>_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 <e2>nephrotoxicity</e2>_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
D000082_D007674 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 determine_7\VB\1645601 if_8\IN\1740 pap_9\NN\6612266 formation_10\NN\7938773 is_11\VBZ\836236 a_12\DT\13649268 requisite_13\JJ\1740 step_14\NN\168237 in_15\IN\13603305 <e1>apap-induced</e1>_16\JJ\1740 <e2>nephrotoxicity</e2>_17\NN\1740 ._18\.\1740
D000082_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 bis(p-nitrophenyl_5\NN\1740 )_6\-RRB-\1740 phosphate_7\NN\15010703 (_8\-LRB-\1740 bnpp_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 an_12\DT\6697703 acylamidase_13\NN\1740 inhibitor_14\NN\20090 ,_15\,\1740 on_16\IN\1740 <e1>apap</e1>_17\NN\1740 and_18\CC\1740 pap_19\NN\6612266 <e2>nephrotoxicity</e2>_20\NN\1740 and_21\CC\1740 metabolism_22\NN\13526110 was_23\VBD\836236 determined_24\VBN\1645601 ._25\.\1740
D000082_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 <e1>apap</e1>_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 <e2>nephrotoxicity</e2>_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 nephrotoxicity_25\NN\1740 ._26\.\1740
D000082_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 <e1>apap</e1>_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 nephrotoxicity_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
D000082_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 <e1>apap</e1>_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 <e2>nephrotoxicity</e2>_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 nephrotoxicity_25\NN\1740 ._26\.\1740
D000082_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 bnpp_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 <e1>apap</e1>_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 nephrotoxicity_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
D000082_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 bnpp-induced_3\JJ\1740 reduction_4\NN\351485 in_5\IN\13603305 <e1>apap-induced</e1>_6\JJ\1740 <e2>nephrotoxicity</e2>_7\NN\1740 appears_8\VBZ\2604760 to_9\TO\1740 be_10\VB\836236 due_11\JJ\1740 to_12\TO\1740 inhibition_13\NN\1068773 of_14\IN\1740 apap_15\NN\1740 deacetylation_16\NN\1740 ._17\.\1740
D000082_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 bnpp-induced_3\JJ\1740 reduction_4\NN\351485 in_5\IN\13603305 apap-induced_6\JJ\1740 <e2>nephrotoxicity</e2>_7\NN\1740 appears_8\VBZ\2604760 to_9\TO\1740 be_10\VB\836236 due_11\JJ\1740 to_12\TO\1740 inhibition_13\NN\1068773 of_14\IN\1740 <e1>apap</e1>_15\NN\1740 deacetylation_16\NN\1740 ._17\.\1740
C002887_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 <e1>bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate</e1>_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 nephrotoxicity_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
C002887_D007674 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 p-aminophenol_3\NN\1740 in_4\IN\13603305 acetaminophen-induced_5\JJ\1740 nephrotoxicity_6\NN\1740 :_7\:\1740 effect_8\NN\34213 of_9\IN\1740 <e1>bis(p-nitrophenyl_10\NN\1740 )_11\-RRB-\1740 phosphate</e1>_12\NN\15010703 on_13\IN\1740 acetaminophen_14\NN\2707683 and_15\CC\1740 p-aminophenol_16\NN\1740 <e2>nephrotoxicity</e2>_17\NN\1740 and_18\CC\1740 metabolism_19\NN\13526110 in_20\IN\13603305 fischer_21\NNP\1740 344_22\CD\1740 rats_23\NNS\2329401 ._24\.\1740
C002887_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 <e1>bis(p-nitrophenyl_5\NN\1740 )_6\-RRB-\1740 phosphate</e1>_7\NN\15010703 (_8\-LRB-\1740 bnpp_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 an_12\DT\6697703 acylamidase_13\NN\1740 inhibitor_14\NN\20090 ,_15\,\1740 on_16\IN\1740 apap_17\NN\1740 and_18\CC\1740 pap_19\NN\6612266 <e2>nephrotoxicity</e2>_20\NN\1740 and_21\CC\1740 metabolism_22\NN\13526110 was_23\VBD\836236 determined_24\VBN\1645601 ._25\.\1740
C002887_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 bis(p-nitrophenyl_5\NN\1740 )_6\-RRB-\1740 phosphate_7\NN\15010703 (_8\-LRB-\1740 <e1>bnpp</e1>_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 an_12\DT\6697703 acylamidase_13\NN\1740 inhibitor_14\NN\20090 ,_15\,\1740 on_16\IN\1740 apap_17\NN\1740 and_18\CC\1740 pap_19\NN\6612266 <e2>nephrotoxicity</e2>_20\NN\1740 and_21\CC\1740 metabolism_22\NN\13526110 was_23\VBD\836236 determined_24\VBN\1645601 ._25\.\1740
C002887_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 <e1>bnpp</e1>_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 <e2>nephrotoxicity</e2>_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 nephrotoxicity_25\NN\1740 ._26\.\1740
C002887_D007674 NONE pretreatment_0\NN\1740 of_1\IN\1740 animals_2\NNS\4475 with_3\IN\1740 <e1>bnpp</e1>_4\NN\1740 prior_5\RB\1740 to_6\TO\1740 apap_7\NN\1740 or_8\CC\3541091 pap_9\NN\6612266 administration_10\NN\1133281 resulted_11\VBD\2633881 in_12\IN\13603305 marked_13\JJ\1740 reduction_14\NN\351485 of_15\IN\1740 apap_16\NN\1740 (_17\-LRB-\1740 900_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 nephrotoxicity_21\NN\1740 but_22\CC\1740 not_23\RB\1740 pap_24\NN\6612266 <e2>nephrotoxicity</e2>_25\NN\1740 ._26\.\1740
C002887_D007674 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e1>bnpp-induced</e1>_3\JJ\1740 reduction_4\NN\351485 in_5\IN\13603305 apap-induced_6\JJ\1740 <e2>nephrotoxicity</e2>_7\NN\1740 appears_8\VBZ\2604760 to_9\TO\1740 be_10\VB\836236 due_11\JJ\1740 to_12\TO\1740 inhibition_13\NN\1068773 of_14\IN\1740 apap_15\NN\1740 deacetylation_16\NN\1740 ._17\.\1740
D000082_D007683 CID <e1>acetaminophen</e1>_0\NN\2707683 (_1\-LRB-\1740 apap_2\NN\1740 )_3\-RRB-\1740 produces_4\VBZ\1617192 proximal_5\JJ\1740 <e2>tubular_6\JJ\1740 necrosis</e2>_7\NN\11444117 in_8\IN\13603305 fischer_9\NNP\1740 344_10\CD\1740 (_11\-LRB-\1740 f344_12\NN\1740 )_13\-RRB-\1740 rats_14\NNS\2329401 ._15\.\1740
D000082_D007683 CID acetaminophen_0\NN\2707683 (_1\-LRB-\1740 <e1>apap</e1>_2\NN\1740 )_3\-RRB-\1740 produces_4\VBZ\1617192 proximal_5\JJ\1740 <e2>tubular_6\JJ\1740 necrosis</e2>_7\NN\11444117 in_8\IN\13603305 fischer_9\NNP\1740 344_10\CD\1740 (_11\-LRB-\1740 f344_12\NN\1740 )_13\-RRB-\1740 rats_14\NNS\2329401 ._15\.\1740
D000082_D007683 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 pap_4\NN\6612266 formation_5\NN\7938773 ,_6\,\1740 in_7\FW\13603305 vivo_8\FW\1740 ,_9\,\1740 accounts_10\NNS\6647206 ,_11\,\1740 at_12\IN\14622893 least_13\JJS\1740 in_14\IN\13603305 part_15\NN\31921 ,_16\,\1740 for_17\IN\1740 <e1>apap-induced</e1>_18\JJ\1740 <e2>renal_19\JJ\1740 tubular_20\JJ\1740 necrosis</e2>_21\NN\11444117 ._22\.\1740
C026729_D007683 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>pap</e1>_4\NN\6612266 formation_5\NN\7938773 ,_6\,\1740 in_7\FW\13603305 vivo_8\FW\1740 ,_9\,\1740 accounts_10\NNS\6647206 ,_11\,\1740 at_12\IN\14622893 least_13\JJS\1740 in_14\IN\13603305 part_15\NN\31921 ,_16\,\1740 for_17\IN\1740 apap-induced_18\JJ\1740 <e2>renal_19\JJ\1740 tubular_20\JJ\1740 necrosis</e2>_21\NN\11444117 ._22\.\1740
6299641
D001262_D013610 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 single_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 50_8\CD\13745420 mg_9\NN\13717155 <e1>atenolol</e1>_10\NNS\2832168 (_11\-LRB-\1740 cardioselective_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 40_15\CD\13745420 mg_16\NN\13717155 propranolol_17\NN\1740 (_18\-LRB-\1740 nonselective_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 placebo_23\VB\1740 on_24\RP\1740 both_25\CC\1740 exercise-_26\JJ\1740 and_27\CC\1740 isoproterenol-induced_28\JJ\1740 <e2>tachycardia</e2>_29\NN\14110674 in_30\IN\13603305 two_31\CD\13741022 experiments_32\NNS\641820 involving_33\VBG\2676054 nine_34\CD\13741022 normal_35\JJ\1740 subjects_36\NNS\6598915 ._37\.\1740
D011433_D013610 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 single_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 50_8\CD\13745420 mg_9\NN\13717155 atenolol_10\NNS\2832168 (_11\-LRB-\1740 cardioselective_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 40_15\CD\13745420 mg_16\NN\13717155 <e1>propranolol</e1>_17\NN\1740 (_18\-LRB-\1740 nonselective_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 placebo_23\VB\1740 on_24\RP\1740 both_25\CC\1740 exercise-_26\JJ\1740 and_27\CC\1740 isoproterenol-induced_28\JJ\1740 <e2>tachycardia</e2>_29\NN\14110674 in_30\IN\13603305 two_31\CD\13741022 experiments_32\NNS\641820 involving_33\VBG\2676054 nine_34\CD\13741022 normal_35\JJ\1740 subjects_36\NNS\6598915 ._37\.\1740
D007545_D013610 CID we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 single_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 50_8\CD\13745420 mg_9\NN\13717155 atenolol_10\NNS\2832168 (_11\-LRB-\1740 cardioselective_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 40_15\CD\13745420 mg_16\NN\13717155 propranolol_17\NN\1740 (_18\-LRB-\1740 nonselective_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 placebo_23\VB\1740 on_24\RP\1740 both_25\CC\1740 exercise-_26\JJ\1740 and_27\CC\1740 <e1>isoproterenol-induced</e1>_28\JJ\1740 <e2>tachycardia</e2>_29\NN\14110674 in_30\IN\13603305 two_31\CD\13741022 experiments_32\NNS\641820 involving_33\VBG\2676054 nine_34\CD\13741022 normal_35\JJ\1740 subjects_36\NNS\6598915 ._37\.\1740
D007545_D013610 CID the_0\DT\1740 effects_1\NNS\13245626 on_2\IN\1740 <e1>isoproterenol</e1>_3\JJ\1740 <e2>tachycardia</e2>_4\NN\14110674 were_5\VBD\836236 determined_6\VBN\1645601 before_7\IN\1740 and_8\CC\1740 after_9\IN\1740 atropine_10\NN\14712692 (_11\-LRB-\1740 0.04_12\CD\1740 mg/kg_13\NN\1740 iv_14\CD\13741022 )_15\-RRB-\1740 ._16\.\1740
D007545_D013610 CID these_0\DT\1740 data_1\NNS\7951464 are_2\VBP\836236 consistent_3\JJ\1740 with_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 exercise-induced_8\JJ\1740 <e2>tachycardia</e2>_9\NN\14110674 results_10\VBZ\2633881 largely_11\RB\1740 from_12\IN\1740 beta_13\NN\6828818 1-receptor_14\NN\1740 activation_15\NN\13561719 that_16\WDT\1740 is_17\VBZ\836236 blocked_18\VBN\1476483 by_19\IN\1740 both_20\CC\1740 cardioselective_21\JJ\1740 and_22\CC\1740 nonselective_23\JJ\1740 drugs_24\NNS\14778436 ,_25\,\1740 whereas_26\IN\1740 <e1>isoproterenol</e1>_27\NN\3740161 activates_28\VBZ\1641914 both_29\CC\1740 beta_30\NN\6828818 1-_31\CD\1740 and_32\CC\1740 beta_33\NN\6828818 2-receptors_34\NNS\1740 so_35\IN\6868043 that_36\IN\1740 after_37\IN\1740 cardioselective_38\JJ\1740 blockade_39\NN\952963 there_40\EX\27167 remains_41\VBZ\2604760 a_42\DT\13649268 beta_43\NN\6828818 2-component_44\NN\1740 that_45\WDT\1740 can_46\MD\3094503 be_47\VB\836236 blocked_48\VBN\1476483 with_49\IN\1740 a_50\DT\13649268 nonselective_51\JJ\1740 drug_52\NN\14778436 ._53\.\1740
D001285_D013610 NONE the_0\DT\1740 effects_1\NNS\13245626 on_2\IN\1740 isoproterenol_3\JJ\1740 <e2>tachycardia</e2>_4\NN\14110674 were_5\VBD\836236 determined_6\VBN\1645601 before_7\IN\1740 and_8\CC\1740 after_9\IN\1740 <e1>atropine</e1>_10\NN\14712692 (_11\-LRB-\1740 0.04_12\CD\1740 mg/kg_13\NN\1740 iv_14\CD\13741022 )_15\-RRB-\1740 ._16\.\1740
24132704
C029036_D006949 NONE <e1>crocin</e1>_0\NN\1740 reduced_1\VBD\441445 inhibition_2\NN\1068773 of_3\IN\1740 erk_4\NN\1740 activation_5\NN\13561719 and_6\CC\1740 diazinon-induced_7\JJ\1740 <e2>hyperlipemia</e2>_8\NN\14299637 and_9\CC\1740 increased_10\VBD\169651 levels_11\NNS\4916342 of_12\IN\1740 ldlr_13\NN\1740 transcript_14\NN\6362953 ._15\.\1740
C029036_D006949 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>crocin</e1>_2\NN\1740 may_3\MD\15209706 be_4\VB\836236 considered_5\VBN\689344 as_6\IN\14622893 a_7\DT\13649268 novel_8\JJ\1740 protective_9\JJ\1740 agent_10\NN\7347 in_11\IN\13603305 diazinon-induced_12\JJ\1740 <e2>hyperlipemia</e2>_13\NN\14299637 through_14\IN\1740 modulating_15\NN\1740 of_16\IN\1740 erk_17\NN\1740 pathway_18\NN\5483677 and_19\CC\1740 increase_20\NN\13576355 of_21\IN\1740 ldlr_22\NN\1740 expression_23\NN\4679549 ._24\.\1740
D003976_D006949 CID crocin_0\NN\1740 reduced_1\VBD\441445 inhibition_2\NN\1068773 of_3\IN\1740 erk_4\NN\1740 activation_5\NN\13561719 and_6\CC\1740 <e1>diazinon-induced</e1>_7\JJ\1740 <e2>hyperlipemia</e2>_8\NN\14299637 and_9\CC\1740 increased_10\VBD\169651 levels_11\NNS\4916342 of_12\IN\1740 ldlr_13\NN\1740 transcript_14\NN\6362953 ._15\.\1740
D003976_D006949 CID conclusions_0\NNS\5837957 :_1\:\1740 crocin_2\NN\1740 may_3\MD\15209706 be_4\VB\836236 considered_5\VBN\689344 as_6\IN\14622893 a_7\DT\13649268 novel_8\JJ\1740 protective_9\JJ\1740 agent_10\NN\7347 in_11\IN\13603305 <e1>diazinon-induced</e1>_12\JJ\1740 <e2>hyperlipemia</e2>_13\NN\14299637 through_14\IN\1740 modulating_15\NN\1740 of_16\IN\1740 erk_17\NN\1740 pathway_18\NN\5483677 and_19\CC\1740 increase_20\NN\13576355 of_21\IN\1740 ldlr_22\NN\1740 expression_23\NN\4679549 ._24\.\1740
6321816
D014667_D006973 NONE <e1>vasopressin</e1>_0\VB\1740 as_1\IN\14622893 a_2\DT\13649268 possible_3\JJ\1740 contributor_4\NN\10025730 to_5\TO\1740 <e2>hypertension</e2>_6\NN\14057371 ._7\.\1740
D014667_D006973 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>vasopressin</e1>_3\NN\5407119 as_4\IN\14622893 a_5\DT\13649268 pressor_6\NN\9190918 agent_7\NN\7347 to_8\TO\1740 the_9\DT\1740 <e2>hypertensive</e2>_10\JJ\1740 process_11\NN\407535 was_12\VBD\836236 examined_13\VBN\789138 ._14\.\1740
D014667_D006973 NONE <e1>vasopressin</e1>_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 doca-salt_9\JJ\1740 <e2>hypertension</e2>_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 lithium-treated_25\JJ\1740 diabetes_26\NNS\14075199 insipidus_27\NN\1740 after_28\IN\1740 doca-salt_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D014667_D006973 NONE furthermore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 pressor_3\NN\9190918 action_4\NN\30358 of_5\IN\1740 <e1>vasopressin</e1>_6\NN\5407119 appears_7\VBZ\2604760 to_8\TO\1740 be_9\VB\836236 important_10\JJ\1740 in_11\IN\13603305 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 this_15\DT\1740 model_16\NN\5888929 of_17\IN\1740 <e2>hypertension</e2>_18\NN\14057371 ,_19\,\1740 since_20\IN\1740 the_21\DT\1740 enhanced_22\VBN\227165 pressor_23\NN\9190918 responsiveness_24\NN\5652926 to_25\TO\1740 the_26\DT\1740 hormone_27\NN\5404728 was_28\VBD\836236 observed_29\VBN\2163746 in_30\IN\13603305 the_31\DT\1740 initial_32\JJ\1740 stage_33\NN\15113229 of_34\IN\1740 hypertension_35\NN\14057371 ._36\.\1740
D014667_D006973 NONE furthermore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 pressor_3\NN\9190918 action_4\NN\30358 of_5\IN\1740 <e1>vasopressin</e1>_6\NN\5407119 appears_7\VBZ\2604760 to_8\TO\1740 be_9\VB\836236 important_10\JJ\1740 in_11\IN\13603305 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 this_15\DT\1740 model_16\NN\5888929 of_17\IN\1740 hypertension_18\NN\14057371 ,_19\,\1740 since_20\IN\1740 the_21\DT\1740 enhanced_22\VBN\227165 pressor_23\NN\9190918 responsiveness_24\NN\5652926 to_25\TO\1740 the_26\DT\1740 hormone_27\NN\5404728 was_28\VBD\836236 observed_29\VBN\2163746 in_30\IN\13603305 the_31\DT\1740 initial_32\JJ\1740 stage_33\NN\15113229 of_34\IN\1740 <e2>hypertension</e2>_35\NN\14057371 ._36\.\1740
D014667_D006973 NONE increased_0\VBN\169651 secretion_1\NN\13526110 of_2\IN\1740 <e1>vasopressin</e1>_3\NN\5407119 from_4\IN\1740 neurohypophysis_5\NN\5329735 also_6\RB\1740 promotes_7\VBZ\2556126 the_8\DT\1740 function_9\NN\13783581 of_10\IN\1740 the_11\DT\1740 hormone_12\NN\5404728 as_13\IN\14622893 a_14\DT\13649268 pathogenetic_15\JJ\1740 factor_16\NN\7326557 in_17\IN\13603305 <e2>hypertension</e2>_18\NN\14057371 ._19\.\1740
D014667_D006973 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 <e1>vasopressin</e1>_5\NN\5407119 remains_6\VBZ\2604760 to_7\TO\1740 be_8\VB\836236 determined_9\VBN\1645601 in_10\IN\13603305 human_11\JJ\1740 essential_12\JJ\1740 <e2>hypertension</e2>_13\NN\14057371 ._14\.\1740
D014667_D003919 NONE <e1>vasopressin</e1>_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 doca-salt_9\JJ\1740 hypertension_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 lithium-treated_25\JJ\1740 <e2>diabetes_26\NNS\14075199 insipidus</e2>_27\NN\1740 after_28\IN\1740 doca-salt_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D003900_D006973 CID vasopressin_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 <e1>doca-salt</e1>_9\JJ\1740 <e2>hypertension</e2>_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 lithium-treated_25\JJ\1740 diabetes_26\NNS\14075199 insipidus_27\NN\1740 after_28\IN\1740 doca-salt_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D003900_D006973 CID vasopressin_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 doca-salt_9\JJ\1740 <e2>hypertension</e2>_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 lithium-treated_25\JJ\1740 diabetes_26\NNS\14075199 insipidus_27\NN\1740 after_28\IN\1740 <e1>doca-salt</e1>_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D003900_D003919 NONE vasopressin_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 <e1>doca-salt</e1>_9\JJ\1740 hypertension_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 lithium-treated_25\JJ\1740 <e2>diabetes_26\NNS\14075199 insipidus</e2>_27\NN\1740 after_28\IN\1740 doca-salt_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D003900_D003919 NONE vasopressin_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 doca-salt_9\JJ\1740 hypertension_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 lithium-treated_25\JJ\1740 <e2>diabetes_26\NNS\14075199 insipidus</e2>_27\NN\1740 after_28\IN\1740 <e1>doca-salt</e1>_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D008094_D006973 NONE vasopressin_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 doca-salt_9\JJ\1740 <e2>hypertension</e2>_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 <e1>lithium-treated</e1>_25\JJ\1740 diabetes_26\NNS\14075199 insipidus_27\NN\1740 after_28\IN\1740 doca-salt_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
D008094_D003919 CID vasopressin_0\NN\5407119 plays_1\VBZ\1072262 a_2\DT\13649268 major_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 the_6\DT\1740 pathogenesis_7\NN\13533470 of_8\IN\1740 doca-salt_9\JJ\1740 hypertension_10\NN\14057371 ,_11\,\1740 since_12\IN\1740 the_13\DT\1740 elevation_14\NN\7445480 of_15\IN\1740 blood_16\NN\5397468 pressure_17\NN\11419404 was_18\VBD\836236 not_19\RB\1740 substantial_20\JJ\1740 in_21\IN\13603305 the_22\DT\1740 rats_23\NNS\2329401 with_24\IN\1740 <e1>lithium-treated</e1>_25\JJ\1740 <e2>diabetes_26\NNS\14075199 insipidus</e2>_27\NN\1740 after_28\IN\1740 doca-salt_29\JJ\1740 treatment_30\NN\654885 ._31\.\1740
6884395
D003276_D000784 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 nontraumatic_3\JJ\1740 <e2>dissecting_4\NN\1740 aneurysm</e2>_5\NN\14057371 of_6\IN\1740 the_7\DT\1740 basilar_8\JJ\1740 artery_9\NN\5417975 in_10\IN\13603305 association_11\NN\8008335 with_12\IN\1740 hypertension_13\NN\14057371 ,_14\,\1740 smoke_15\NN\11422597 ,_16\,\1740 and_17\CC\1740 <e1>oral_18\JJ\1740 contraceptives</e1>_19\NNS\3183080 is_20\VBZ\836236 reported_21\VBN\831651 in_22\IN\13603305 a_23\DT\13649268 young_24\JJ\1740 female_25\JJ\1740 patient_26\NN\9898892 with_27\IN\1740 a_28\DT\13649268 locked-in_29\JJ\1740 syndrome_30\NN\5870365 ._31\.\1740
D003276_D006973 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 nontraumatic_3\JJ\1740 dissecting_4\NN\1740 aneurysm_5\NN\14057371 of_6\IN\1740 the_7\DT\1740 basilar_8\JJ\1740 artery_9\NN\5417975 in_10\IN\13603305 association_11\NN\8008335 with_12\IN\1740 <e2>hypertension</e2>_13\NN\14057371 ,_14\,\1740 smoke_15\NN\11422597 ,_16\,\1740 and_17\CC\1740 <e1>oral_18\JJ\1740 contraceptives</e1>_19\NNS\3183080 is_20\VBZ\836236 reported_21\VBN\831651 in_22\IN\13603305 a_23\DT\13649268 young_24\JJ\1740 female_25\JJ\1740 patient_26\NN\9898892 with_27\IN\1740 a_28\DT\13649268 locked-in_29\JJ\1740 syndrome_30\NN\5870365 ._31\.\1740
D003276_D011782 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 nontraumatic_3\JJ\1740 dissecting_4\NN\1740 aneurysm_5\NN\14057371 of_6\IN\1740 the_7\DT\1740 basilar_8\JJ\1740 artery_9\NN\5417975 in_10\IN\13603305 association_11\NN\8008335 with_12\IN\1740 hypertension_13\NN\14057371 ,_14\,\1740 smoke_15\NN\11422597 ,_16\,\1740 and_17\CC\1740 <e1>oral_18\JJ\1740 contraceptives</e1>_19\NNS\3183080 is_20\VBZ\836236 reported_21\VBN\831651 in_22\IN\13603305 a_23\DT\13649268 young_24\JJ\1740 female_25\JJ\1740 patient_26\NN\9898892 with_27\IN\1740 a_28\DT\13649268 <e2>locked-in_29\JJ\1740 syndrome</e2>_30\NN\5870365 ._31\.\1740
24739405
D003687_D012559 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>dehydroepiandrosterone</e1>_2\NN\1740 in_3\IN\13603305 amphetamine-induced_4\JJ\1740 <e2>schizophrenia</e2>_5\NN\14398067 models_6\NNS\5888929 in_7\IN\13603305 mice_8\NNS\2329401 ._9\.\1740
D003687_D012559 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 examine_3\VB\789138 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>dehydroepiandrosterone</e1>_7\NN\1740 (_8\-LRB-\1740 dhea_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 animal_12\JJ\1740 models_13\NNS\5888929 of_14\IN\1740 <e2>schizophrenia</e2>_15\NN\14398067 ._16\.\1740
D003687_D012559 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 examine_3\VB\789138 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 dehydroepiandrosterone_7\NN\1740 (_8\-LRB-\1740 <e1>dhea</e1>_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 animal_12\JJ\1740 models_13\NNS\5888929 of_14\IN\1740 <e2>schizophrenia</e2>_15\NN\14398067 ._16\.\1740
D003687_D012559 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 <e1>dhea</e1>_3\NN\1740 displays_4\VBZ\2137132 typical_5\JJ\1740 neuroleptic-like_6\JJ\1740 effects_7\NNS\13245626 ,_8\,\1740 and_9\CC\1740 may_10\MD\15209706 be_11\VB\836236 used_12\VBN\1156834 in_13\IN\13603305 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>schizophrenia</e2>_17\NN\14398067 ._18\.\1740
D000661_D012559 CID effects_0\NNS\13245626 of_1\IN\1740 dehydroepiandrosterone_2\NN\1740 in_3\IN\13603305 <e1>amphetamine-induced</e1>_4\JJ\1740 <e2>schizophrenia</e2>_5\NN\14398067 models_6\NNS\5888929 in_7\IN\13603305 mice_8\NNS\2329401 ._9\.\1740
D000661_D012559 CID <e1>amphetamine</e1>_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 hyper_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 apomorphine_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 haloperidol_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 catalepsy_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 <e2>schizophrenia</e2>_38\NN\14398067 ._39\.\1740
D000661_D006948 NONE <e1>amphetamine</e1>_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 <e2>hyper</e2>_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 apomorphine_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 haloperidol_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 catalepsy_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 schizophrenia_38\NN\14398067 ._39\.\1740
D000661_D002375 NONE <e1>amphetamine</e1>_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 hyper_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 apomorphine_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 haloperidol_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 <e2>catalepsy</e2>_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 schizophrenia_38\NN\14398067 ._39\.\1740
D001058_D006948 NONE amphetamine_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 <e2>hyper</e2>_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 <e1>apomorphine</e1>_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 haloperidol_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 catalepsy_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 schizophrenia_38\NN\14398067 ._39\.\1740
D001058_D002375 NONE amphetamine_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 hyper_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 <e1>apomorphine</e1>_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 haloperidol_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 <e2>catalepsy</e2>_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 schizophrenia_38\NN\14398067 ._39\.\1740
D001058_D012559 CID amphetamine_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 hyper_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 <e1>apomorphine</e1>_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 haloperidol_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 catalepsy_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 <e2>schizophrenia</e2>_38\NN\14398067 ._39\.\1740
D006220_D006948 NONE amphetamine_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 <e2>hyper</e2>_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 apomorphine_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 <e1>haloperidol</e1>_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 catalepsy_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 schizophrenia_38\NN\14398067 ._39\.\1740
D006220_D002375 CID amphetamine_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 hyper_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 apomorphine_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 <e1>haloperidol</e1>_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 <e2>catalepsy</e2>_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 schizophrenia_38\NN\14398067 ._39\.\1740
D006220_D002375 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 between_5\IN\1740 groups_6\NNS\2137 in_7\IN\13603305 the_8\DT\1740 <e1>haloperidol-induced</e1>_9\JJ\1740 <e2>catalepsy</e2>_10\NN\14023236 test_11\NN\5798043 (_12\-LRB-\1740 p<0.05_13\NN\1740 )_14\-RRB-\1740 ._15\.\1740
D006220_D012559 CID amphetamine_0\NN\3248958 (_1\-LRB-\1740 3_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\VBN\1627355 hyper_7\NN\1740 locomotion_8\NN\4773351 ,_9\,\1740 apomorphine_10\NN\3786417 (_11\-LRB-\1740 1.5_12\CD\1740 mg/kg_13\NN\1740 subcutaneously_14\RB\1740 [_15\-LRB-\1740 sc_16\FW\14625458 ]_17\-RRB-\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 climbing_20\NN\7445480 ,_21\,\1740 and_22\CC\1740 <e1>haloperidol</e1>_23\NN\3713736 (_24\-LRB-\1740 1.5_25\CD\1740 mg/kg_26\NN\1740 sc_27\NN\14625458 )_28\-RRB-\1740 induced_29\JJ\1740 catalepsy_30\NN\14023236 tests_31\NNS\5798043 were_32\VBD\836236 used_33\VBN\1156834 as_34\IN\14622893 animal_35\JJ\1740 models_36\NNS\5888929 of_37\IN\1740 <e2>schizophrenia</e2>_38\NN\14398067 ._39\.\1740
D003687_D002375 NONE conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 observed_3\VBD\2163746 that_4\IN\1740 <e1>dhea</e1>_5\NN\1740 reduced_6\VBD\441445 locomotor_7\NN\1740 activity_8\NN\30358 and_9\CC\1740 increased_10\VBN\169651 <e2>catalepsy</e2>_11\NN\14023236 at_12\IN\14622893 both_13\DT\1740 doses_14\NNS\3740161 ,_15\,\1740 while_16\IN\15122231 it_17\PRP\6125041 had_18\VBD\2108377 no_19\DT\7204911 effect_20\NN\34213 on_21\IN\1740 climbing_22\NN\7445480 behavior_23\NN\407535 ._24\.\1740
23871786
C006780_D001008 CID pubertal_0\JJ\1740 exposure_1\NN\5042871 to_2\TO\1740 <e1>bisphenol_3\NN\1740 a</e1>_4\NN\13649268 increases_5\VBZ\169651 <e2>anxiety-like</e2>_6\JJ\1740 behavior_7\NN\407535 and_8\CC\1740 decreases_9\VBZ\169651 acetylcholinesterase_10\NN\1740 activity_11\NN\30358 of_12\IN\1740 hippocampus_13\NN\5462674 in_14\IN\13603305 adult_15\JJ\1740 male_16\JJ\1740 mice_17\NNS\2329401 ._18\.\1740
C006780_D001008 CID results_0\NNS\34213 from_1\IN\1740 our_2\PRP$\1740 behavioral_3\JJ\1740 phenotyping_4\NN\1740 indicated_5\VBD\952524 that_6\IN\1740 <e2>anxiety-like</e2>_7\JJ\1740 behavior_8\NN\407535 was_9\VBD\836236 increased_10\VBN\169651 in_11\IN\13603305 mice_12\NNS\2329401 exposed_13\VBN\2110927 to_14\TO\1740 <e1>bpa</e1>_15\NN\1740 ._16\.\1740
C006780_D001008 CID our_0\PRP$\1740 findings_1\NNS\7951464 showed_2\VBD\2137132 that_3\IN\1740 pubertal_4\JJ\1740 <e1>bpa</e1>_5\NN\1740 exposure_6\NN\5042871 increased_7\VBD\169651 <e2>anxiety-like</e2>_8\JJ\1740 behavior_9\NN\407535 ,_10\,\1740 which_11\WDT\1740 may_12\MD\15209706 be_13\VB\836236 associated_14\VBN\628491 with_15\IN\1740 decreased_16\VBN\169651 ache_17\NN\14322699 activity_18\NN\30358 of_19\IN\1740 the_20\DT\1740 hippocampus_21\NN\5462674 in_22\IN\13603305 adult_23\JJ\1740 male_24\JJ\1740 mice_25\NNS\2329401 ._26\.\1740
12699527
D002712_D009224 NONE <e2>myotonia_0\NN\14544672 congenita</e2>_1\NN\1740 (_2\-LRB-\1740 mc_3\NN\15286249 )_4\-RRB-\1740 is_5\VBZ\836236 caused_6\VBN\1617192 by_7\IN\1740 a_8\DT\13649268 defect_9\NN\14462666 in_10\IN\13603305 the_11\DT\1740 skeletal_12\JJ\1740 muscle_13\NN\5289601 <e1>chloride</e1>_14\NN\14818238 channel_15\NN\6251781 function_16\NN\13783581 ,_17\,\1740 which_18\WDT\1740 may_19\MD\15209706 cause_20\VB\1617192 sustained_21\JJ\1740 membrane_22\NN\4188643 depolarisation_23\NN\11412727 ._24\.\1740
D002712_D009224 NONE myotonia_0\NN\14544672 congenita_1\NN\1740 (_2\-LRB-\1740 <e2>mc</e2>_3\NN\15286249 )_4\-RRB-\1740 is_5\VBZ\836236 caused_6\VBN\1617192 by_7\IN\1740 a_8\DT\13649268 defect_9\NN\14462666 in_10\IN\13603305 the_11\DT\1740 skeletal_12\JJ\1740 muscle_13\NN\5289601 <e1>chloride</e1>_14\NN\14818238 channel_15\NN\6251781 function_16\NN\13783581 ,_17\,\1740 which_18\WDT\1740 may_19\MD\15209706 cause_20\VB\1617192 sustained_21\JJ\1740 membrane_22\NN\4188643 depolarisation_23\NN\11412727 ._24\.\1740
D002712_-1 NONE myotonia_0\NN\14544672 congenita_1\NN\1740 (_2\-LRB-\1740 mc_3\NN\15286249 )_4\-RRB-\1740 is_5\VBZ\836236 caused_6\VBN\1617192 by_7\IN\1740 a_8\DT\13649268 defect_9\NN\14462666 in_10\IN\13603305 the_11\DT\1740 skeletal_12\JJ\1740 muscle_13\NN\5289601 <e1>chloride</e1>_14\NN\14818238 channel_15\NN\6251781 function_16\NN\13783581 ,_17\,\1740 which_18\WDT\1740 may_19\MD\15209706 cause_20\VB\1617192 <e2>sustained_21\JJ\1740 membrane_22\NN\4188643 depolarisation</e2>_23\NN\11412727 ._24\.\1740
D013390_D013035 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 previously_3\RB\1740 healthy_4\JJ\1740 32-year-old_5\JJ\1740 woman_6\NN\9605289 who_7\WP\8299493 developed_8\VBD\1753788 a_9\DT\13649268 life-threatening_10\JJ\1740 <e2>muscle_11\NN\5289601 spasm</e2>_12\NN\14299637 and_13\CC\1740 secondary_14\JJ\1740 ventilation_15\NN\248977 difficulties_16\NNS\621627 following_17\VBG\1835496 a_18\DT\13649268 preoperative_19\JJ\1740 injection_20\NN\320852 of_21\IN\1740 <e1>suxamethonium</e1>_22\NN\1740 ._23\.\1740
7315949
D009638_D013035 CID medial_0\JJ\1740 changes_1\NNS\7283608 in_2\IN\13603305 arterial_3\JJ\1740 <e2>spasm</e2>_4\NN\14299637 induced_5\VBN\1627355 by_6\IN\1740 <e1>l-norepinephrine</e1>_7\NN\1740 ._8\.\1740
D009638_D006547 NONE in_0\IN\13603305 the_1\DT\1740 media_2\NNS\3575240 of_3\IN\1740 the_4\DT\1740 saphenous_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 its_8\PRP$\6125041 distal_9\JJ\1740 branch_10\NN\8220714 ,_11\,\1740 vasoconstriction_12\NN\1149911 induced_13\VBN\1627355 by_14\IN\1740 <e1>l-norepinephrine</e1>_15\NN\1740 produced_16\VBD\1617192 many_17\JJ\1740 cell-to-cell_18\JJ\1740 <e2>hernias</e2>_19\NNS\14295248 within_20\IN\1740 15_21\CD\13745420 minutes_22\NNS\6502378 ._23\.\1740
3439580
D007099_D006973 CID <e2>hypertension</e2>_0\NN\14057371 in_1\IN\13603305 neuroblastoma_2\NN\14239425 induced_3\VBN\1627355 by_4\IN\1740 <e1>imipramine</e1>_5\NN\4482543 ._6\.\1740
D007099_D006973 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 occurrence_3\NN\29378 of_4\IN\1740 severe_5\JJ\1740 <e2>hypertension</e2>_6\NN\14057371 (_7\-LRB-\1740 blood_8\NN\5397468 pressure_9\NN\11419404 190/160_10\CD\1740 )_11\-RRB-\1740 in_12\IN\13603305 a_13\DT\13649268 4-year-old_14\JJ\1740 girl_15\NN\10787470 with_16\IN\1740 neuroblastoma_17\NN\14239425 who_18\WP\8299493 was_19\VBD\836236 given_20\VBN\2327200 <e1>imipramine</e1>_21\NNP\4482543 to_22\TO\1740 control_23\VB\2422663 a_24\DT\13649268 behavior_25\NN\407535 disorder_26\NN\14034177 ._27\.\1740
D007099_D006973 CID since_0\IN\1740 she_1\PRP\1740 had_2\VBD\2108377 no_3\DT\7204911 blood_4\NN\5397468 pressure_5\NN\11419404 elevation_6\NN\7445480 at_7\IN\14622893 initial_8\JJ\1740 diagnosis_9\NN\152018 and_10\CC\1740 none_11\NN\15228378 following_12\VBG\1835496 discontinuation_13\NN\209943 of_14\IN\1740 the_15\DT\1740 <e1>imipramine</e1>_16\NNP\4482543 (_17\-LRB-\1740 when_18\WRB\1740 she_19\PRP\1740 was_20\VBD\836236 in_21\IN\13603305 florid_22\NN\1740 relapse_23\NN\66636 )_24\-RRB-\1740 ,_25\,\1740 we_26\PRP\1740 believe_27\VBP\686447 that_28\IN\1740 this_29\DT\1740 drug_30\NN\14778436 rather_31\RB\1740 than_32\IN\1740 her_33\PRP$\1740 underlying_34\VBG\2604760 disease_35\NN\14061805 alone_36\RB\1740 caused_37\VBD\1617192 her_38\PRP$\1740 <e2>hypertension</e2>_39\NN\14057371 ._40\.\1740
D007099_D009447 NONE hypertension_0\NN\14057371 in_1\IN\13603305 <e2>neuroblastoma</e2>_2\NN\14239425 induced_3\VBN\1627355 by_4\IN\1740 <e1>imipramine</e1>_5\NN\4482543 ._6\.\1740
D007099_D009447 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 occurrence_3\NN\29378 of_4\IN\1740 severe_5\JJ\1740 hypertension_6\NN\14057371 (_7\-LRB-\1740 blood_8\NN\5397468 pressure_9\NN\11419404 190/160_10\CD\1740 )_11\-RRB-\1740 in_12\IN\13603305 a_13\DT\13649268 4-year-old_14\JJ\1740 girl_15\NN\10787470 with_16\IN\1740 <e2>neuroblastoma</e2>_17\NN\14239425 who_18\WP\8299493 was_19\VBD\836236 given_20\VBN\2327200 <e1>imipramine</e1>_21\NNP\4482543 to_22\TO\1740 control_23\VB\2422663 a_24\DT\13649268 behavior_25\NN\407535 disorder_26\NN\14034177 ._27\.\1740
D007099_D002653 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 occurrence_3\NN\29378 of_4\IN\1740 severe_5\JJ\1740 hypertension_6\NN\14057371 (_7\-LRB-\1740 blood_8\NN\5397468 pressure_9\NN\11419404 190/160_10\CD\1740 )_11\-RRB-\1740 in_12\IN\13603305 a_13\DT\13649268 4-year-old_14\JJ\1740 girl_15\NN\10787470 with_16\IN\1740 neuroblastoma_17\NN\14239425 who_18\WP\8299493 was_19\VBD\836236 given_20\VBN\2327200 <e1>imipramine</e1>_21\NNP\4482543 to_22\TO\1740 control_23\VB\2422663 a_24\DT\13649268 <e2>behavior_25\NN\407535 disorder</e2>_26\NN\14034177 ._27\.\1740
17151160
C076029_D012559 NONE randomized_0\JJ\1740 comparison_1\NN\635850 of_2\IN\1740 <e1>olanzapine</e1>_3\NN\1740 versus_4\CC\1740 risperidone_5\NN\1740 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 first-episode_10\JJ\1740 <e2>schizophrenia</e2>_11\NN\14398067 :_12\:\1740 4-month_13\JJ\1740 outcomes_14\NNS\7291312 ._15\.\1740
C076029_D012559 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 authors_3\NNS\9610660 compared_4\VBD\644583 4-month_5\JJ\1740 treatment_6\NN\654885 outcomes_7\NNS\7291312 for_8\IN\1740 <e1>olanzapine</e1>_9\NN\1740 versus_10\CC\1740 risperidone_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 first-episode_15\JJ\1740 <e2>schizophrenia</e2>_16\NN\14398067 spectrum_17\NN\7939382 disorders_18\NNS\14034177 ._19\.\1740
C076029_D012559 NONE method_0\NNP\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 twelve_4\CD\13745420 subjects_5\NNS\6598915 (_6\-LRB-\1740 70_7\CD\13745420 %_8\NN\1740 male_9\JJ\1740 ;_10\:\1740 mean_11\JJ\1740 age=23.3_12\JJ\1740 years_13\NNS\15144371 [_14\-LRB-\1740 sd_15\NN\1740 =_16\JJ\1740 5.1_17\CD\1740 ]_18\-RRB-\1740 )_19\-RRB-\1740 with_20\IN\1740 first-episode_21\JJ\1740 <e2>schizophrenia</e2>_22\NN\14398067 (_23\-LRB-\1740 75_24\CD\1740 %_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 schizophreniform_28\NN\1740 disorder_29\NN\14034177 (_30\-LRB-\1740 17_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 schizoaffective_36\JJ\1740 disorder_37\NN\14034177 (_38\-LRB-\1740 8_39\CD\13741022 %_40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 randomly_43\RB\1740 assigned_44\VBN\2475922 to_45\TO\1740 treatment_46\NN\654885 with_47\IN\1740 <e1>olanzapine</e1>_48\NN\1740 (_49\-LRB-\1740 2.5_50\CD\1740 -_51\SYM\1740 20_52\CD\13745420 mg/day_53\NN\1740 )_54\-RRB-\1740 or_55\CC\3541091 risperidone_56\NN\1740 (_57\-LRB-\1740 1_58\CD\13741022 -_59\SYM\1740 6_60\CD\13741022 mg/day_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
D018967_D012559 NONE randomized_0\JJ\1740 comparison_1\NN\635850 of_2\IN\1740 olanzapine_3\NN\1740 versus_4\CC\1740 <e1>risperidone</e1>_5\NN\1740 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 first-episode_10\JJ\1740 <e2>schizophrenia</e2>_11\NN\14398067 :_12\:\1740 4-month_13\JJ\1740 outcomes_14\NNS\7291312 ._15\.\1740
D018967_D012559 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 authors_3\NNS\9610660 compared_4\VBD\644583 4-month_5\JJ\1740 treatment_6\NN\654885 outcomes_7\NNS\7291312 for_8\IN\1740 olanzapine_9\NN\1740 versus_10\CC\1740 <e1>risperidone</e1>_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 first-episode_15\JJ\1740 <e2>schizophrenia</e2>_16\NN\14398067 spectrum_17\NN\7939382 disorders_18\NNS\14034177 ._19\.\1740
D018967_D012559 NONE method_0\NNP\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 twelve_4\CD\13745420 subjects_5\NNS\6598915 (_6\-LRB-\1740 70_7\CD\13745420 %_8\NN\1740 male_9\JJ\1740 ;_10\:\1740 mean_11\JJ\1740 age=23.3_12\JJ\1740 years_13\NNS\15144371 [_14\-LRB-\1740 sd_15\NN\1740 =_16\JJ\1740 5.1_17\CD\1740 ]_18\-RRB-\1740 )_19\-RRB-\1740 with_20\IN\1740 first-episode_21\JJ\1740 <e2>schizophrenia</e2>_22\NN\14398067 (_23\-LRB-\1740 75_24\CD\1740 %_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 schizophreniform_28\NN\1740 disorder_29\NN\14034177 (_30\-LRB-\1740 17_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 schizoaffective_36\JJ\1740 disorder_37\NN\14034177 (_38\-LRB-\1740 8_39\CD\13741022 %_40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 randomly_43\RB\1740 assigned_44\VBN\2475922 to_45\TO\1740 treatment_46\NN\654885 with_47\IN\1740 olanzapine_48\NN\1740 (_49\-LRB-\1740 2.5_50\CD\1740 -_51\SYM\1740 20_52\CD\13745420 mg/day_53\NN\1740 )_54\-RRB-\1740 or_55\CC\3541091 <e1>risperidone</e1>_56\NN\1740 (_57\-LRB-\1740 1_58\CD\13741022 -_59\SYM\1740 6_60\CD\13741022 mg/day_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
C076029_D011618 NONE method_0\NNP\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 twelve_4\CD\13745420 subjects_5\NNS\6598915 (_6\-LRB-\1740 70_7\CD\13745420 %_8\NN\1740 male_9\JJ\1740 ;_10\:\1740 mean_11\JJ\1740 age=23.3_12\JJ\1740 years_13\NNS\15144371 [_14\-LRB-\1740 sd_15\NN\1740 =_16\JJ\1740 5.1_17\CD\1740 ]_18\-RRB-\1740 )_19\-RRB-\1740 with_20\IN\1740 first-episode_21\JJ\1740 schizophrenia_22\NN\14398067 (_23\-LRB-\1740 75_24\CD\1740 %_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 <e2>schizophreniform_28\NN\1740 disorder</e2>_29\NN\14034177 (_30\-LRB-\1740 17_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 schizoaffective_36\JJ\1740 disorder_37\NN\14034177 (_38\-LRB-\1740 8_39\CD\13741022 %_40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 randomly_43\RB\1740 assigned_44\VBN\2475922 to_45\TO\1740 treatment_46\NN\654885 with_47\IN\1740 <e1>olanzapine</e1>_48\NN\1740 (_49\-LRB-\1740 2.5_50\CD\1740 -_51\SYM\1740 20_52\CD\13745420 mg/day_53\NN\1740 )_54\-RRB-\1740 or_55\CC\3541091 risperidone_56\NN\1740 (_57\-LRB-\1740 1_58\CD\13741022 -_59\SYM\1740 6_60\CD\13741022 mg/day_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
C076029_D011618 NONE method_0\NNP\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 twelve_4\CD\13745420 subjects_5\NNS\6598915 (_6\-LRB-\1740 70_7\CD\13745420 %_8\NN\1740 male_9\JJ\1740 ;_10\:\1740 mean_11\JJ\1740 age=23.3_12\JJ\1740 years_13\NNS\15144371 [_14\-LRB-\1740 sd_15\NN\1740 =_16\JJ\1740 5.1_17\CD\1740 ]_18\-RRB-\1740 )_19\-RRB-\1740 with_20\IN\1740 first-episode_21\JJ\1740 schizophrenia_22\NN\14398067 (_23\-LRB-\1740 75_24\CD\1740 %_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 schizophreniform_28\NN\1740 disorder_29\NN\14034177 (_30\-LRB-\1740 17_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 <e2>schizoaffective_36\JJ\1740 disorder</e2>_37\NN\14034177 (_38\-LRB-\1740 8_39\CD\13741022 %_40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 randomly_43\RB\1740 assigned_44\VBN\2475922 to_45\TO\1740 treatment_46\NN\654885 with_47\IN\1740 <e1>olanzapine</e1>_48\NN\1740 (_49\-LRB-\1740 2.5_50\CD\1740 -_51\SYM\1740 20_52\CD\13745420 mg/day_53\NN\1740 )_54\-RRB-\1740 or_55\CC\3541091 risperidone_56\NN\1740 (_57\-LRB-\1740 1_58\CD\13741022 -_59\SYM\1740 6_60\CD\13741022 mg/day_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
D018967_D011618 NONE method_0\NNP\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 twelve_4\CD\13745420 subjects_5\NNS\6598915 (_6\-LRB-\1740 70_7\CD\13745420 %_8\NN\1740 male_9\JJ\1740 ;_10\:\1740 mean_11\JJ\1740 age=23.3_12\JJ\1740 years_13\NNS\15144371 [_14\-LRB-\1740 sd_15\NN\1740 =_16\JJ\1740 5.1_17\CD\1740 ]_18\-RRB-\1740 )_19\-RRB-\1740 with_20\IN\1740 first-episode_21\JJ\1740 schizophrenia_22\NN\14398067 (_23\-LRB-\1740 75_24\CD\1740 %_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 <e2>schizophreniform_28\NN\1740 disorder</e2>_29\NN\14034177 (_30\-LRB-\1740 17_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 schizoaffective_36\JJ\1740 disorder_37\NN\14034177 (_38\-LRB-\1740 8_39\CD\13741022 %_40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 randomly_43\RB\1740 assigned_44\VBN\2475922 to_45\TO\1740 treatment_46\NN\654885 with_47\IN\1740 olanzapine_48\NN\1740 (_49\-LRB-\1740 2.5_50\CD\1740 -_51\SYM\1740 20_52\CD\13745420 mg/day_53\NN\1740 )_54\-RRB-\1740 or_55\CC\3541091 <e1>risperidone</e1>_56\NN\1740 (_57\-LRB-\1740 1_58\CD\13741022 -_59\SYM\1740 6_60\CD\13741022 mg/day_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
D018967_D011618 NONE method_0\NNP\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 twelve_4\CD\13745420 subjects_5\NNS\6598915 (_6\-LRB-\1740 70_7\CD\13745420 %_8\NN\1740 male_9\JJ\1740 ;_10\:\1740 mean_11\JJ\1740 age=23.3_12\JJ\1740 years_13\NNS\15144371 [_14\-LRB-\1740 sd_15\NN\1740 =_16\JJ\1740 5.1_17\CD\1740 ]_18\-RRB-\1740 )_19\-RRB-\1740 with_20\IN\1740 first-episode_21\JJ\1740 schizophrenia_22\NN\14398067 (_23\-LRB-\1740 75_24\CD\1740 %_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 schizophreniform_28\NN\1740 disorder_29\NN\14034177 (_30\-LRB-\1740 17_31\CD\13745420 %_32\NN\1740 )_33\-RRB-\1740 ,_34\,\1740 or_35\CC\3541091 <e2>schizoaffective_36\JJ\1740 disorder</e2>_37\NN\14034177 (_38\-LRB-\1740 8_39\CD\13741022 %_40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 randomly_43\RB\1740 assigned_44\VBN\2475922 to_45\TO\1740 treatment_46\NN\654885 with_47\IN\1740 olanzapine_48\NN\1740 (_49\-LRB-\1740 2.5_50\CD\1740 -_51\SYM\1740 20_52\CD\13745420 mg/day_53\NN\1740 )_54\-RRB-\1740 or_55\CC\3541091 <e1>risperidone</e1>_56\NN\1740 (_57\-LRB-\1740 1_58\CD\13741022 -_59\SYM\1740 6_60\CD\13741022 mg/day_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
D018967_D010302 NONE negative_0\JJ\1740 symptom_1\NN\5823932 outcomes_2\NNS\7291312 and_3\CC\1740 measures_4\NNS\168237 of_5\IN\1740 <e2>parkinsonism</e2>_6\NN\14085708 and_7\CC\1740 akathisia_8\NN\1740 did_9\VBD\1640855 not_10\RB\1740 differ_11\VB\1740 between_12\IN\1740 medications._13\JJ\1740 extrapyramidal_14\JJ\1740 symptom_15\NN\5823932 severity_16\NN\5036394 scores_17\NNS\13757724 were_18\VBD\836236 1.4_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci=1.2_23\NN\1740 -_24\HYPH\1740 1.6_25\CD\1740 )_26\-RRB-\1740 with_27\IN\1740 <e1>risperidone</e1>_28\NN\1740 and_29\CC\1740 1.2_30\CD\1740 (_31\-LRB-\1740 95_32\CD\1740 %_33\NN\1740 ci=1.0_34\NNP\1740 -_35\HYPH\1740 1.4_36\CD\1740 )_37\-RRB-\1740 with_38\IN\1740 olanzapine_39\NN\1740 ._40\.\1740
D018967_D017109 NONE negative_0\JJ\1740 symptom_1\NN\5823932 outcomes_2\NNS\7291312 and_3\CC\1740 measures_4\NNS\168237 of_5\IN\1740 parkinsonism_6\NN\14085708 and_7\CC\1740 <e2>akathisia</e2>_8\NN\1740 did_9\VBD\1640855 not_10\RB\1740 differ_11\VB\1740 between_12\IN\1740 medications._13\JJ\1740 extrapyramidal_14\JJ\1740 symptom_15\NN\5823932 severity_16\NN\5036394 scores_17\NNS\13757724 were_18\VBD\836236 1.4_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci=1.2_23\NN\1740 -_24\HYPH\1740 1.6_25\CD\1740 )_26\-RRB-\1740 with_27\IN\1740 <e1>risperidone</e1>_28\NN\1740 and_29\CC\1740 1.2_30\CD\1740 (_31\-LRB-\1740 95_32\CD\1740 %_33\NN\1740 ci=1.0_34\NNP\1740 -_35\HYPH\1740 1.4_36\CD\1740 )_37\-RRB-\1740 with_38\IN\1740 olanzapine_39\NN\1740 ._40\.\1740
D018967_D001480 CID negative_0\JJ\1740 symptom_1\NN\5823932 outcomes_2\NNS\7291312 and_3\CC\1740 measures_4\NNS\168237 of_5\IN\1740 parkinsonism_6\NN\14085708 and_7\CC\1740 akathisia_8\NN\1740 did_9\VBD\1640855 not_10\RB\1740 differ_11\VB\1740 between_12\IN\1740 medications._13\JJ\1740 <e2>extrapyramidal_14\JJ\1740 symptom</e2>_15\NN\5823932 severity_16\NN\5036394 scores_17\NNS\13757724 were_18\VBD\836236 1.4_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci=1.2_23\NN\1740 -_24\HYPH\1740 1.6_25\CD\1740 )_26\-RRB-\1740 with_27\IN\1740 <e1>risperidone</e1>_28\NN\1740 and_29\CC\1740 1.2_30\CD\1740 (_31\-LRB-\1740 95_32\CD\1740 %_33\NN\1740 ci=1.0_34\NNP\1740 -_35\HYPH\1740 1.4_36\CD\1740 )_37\-RRB-\1740 with_38\IN\1740 olanzapine_39\NN\1740 ._40\.\1740
C076029_D010302 NONE negative_0\JJ\1740 symptom_1\NN\5823932 outcomes_2\NNS\7291312 and_3\CC\1740 measures_4\NNS\168237 of_5\IN\1740 <e2>parkinsonism</e2>_6\NN\14085708 and_7\CC\1740 akathisia_8\NN\1740 did_9\VBD\1640855 not_10\RB\1740 differ_11\VB\1740 between_12\IN\1740 medications._13\JJ\1740 extrapyramidal_14\JJ\1740 symptom_15\NN\5823932 severity_16\NN\5036394 scores_17\NNS\13757724 were_18\VBD\836236 1.4_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci=1.2_23\NN\1740 -_24\HYPH\1740 1.6_25\CD\1740 )_26\-RRB-\1740 with_27\IN\1740 risperidone_28\NN\1740 and_29\CC\1740 1.2_30\CD\1740 (_31\-LRB-\1740 95_32\CD\1740 %_33\NN\1740 ci=1.0_34\NNP\1740 -_35\HYPH\1740 1.4_36\CD\1740 )_37\-RRB-\1740 with_38\IN\1740 <e1>olanzapine</e1>_39\NN\1740 ._40\.\1740
C076029_D017109 NONE negative_0\JJ\1740 symptom_1\NN\5823932 outcomes_2\NNS\7291312 and_3\CC\1740 measures_4\NNS\168237 of_5\IN\1740 parkinsonism_6\NN\14085708 and_7\CC\1740 <e2>akathisia</e2>_8\NN\1740 did_9\VBD\1640855 not_10\RB\1740 differ_11\VB\1740 between_12\IN\1740 medications._13\JJ\1740 extrapyramidal_14\JJ\1740 symptom_15\NN\5823932 severity_16\NN\5036394 scores_17\NNS\13757724 were_18\VBD\836236 1.4_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci=1.2_23\NN\1740 -_24\HYPH\1740 1.6_25\CD\1740 )_26\-RRB-\1740 with_27\IN\1740 risperidone_28\NN\1740 and_29\CC\1740 1.2_30\CD\1740 (_31\-LRB-\1740 95_32\CD\1740 %_33\NN\1740 ci=1.0_34\NNP\1740 -_35\HYPH\1740 1.4_36\CD\1740 )_37\-RRB-\1740 with_38\IN\1740 <e1>olanzapine</e1>_39\NN\1740 ._40\.\1740
C076029_D001480 CID negative_0\JJ\1740 symptom_1\NN\5823932 outcomes_2\NNS\7291312 and_3\CC\1740 measures_4\NNS\168237 of_5\IN\1740 parkinsonism_6\NN\14085708 and_7\CC\1740 akathisia_8\NN\1740 did_9\VBD\1640855 not_10\RB\1740 differ_11\VB\1740 between_12\IN\1740 medications._13\JJ\1740 <e2>extrapyramidal_14\JJ\1740 symptom</e2>_15\NN\5823932 severity_16\NN\5036394 scores_17\NNS\13757724 were_18\VBD\836236 1.4_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci=1.2_23\NN\1740 -_24\HYPH\1740 1.6_25\CD\1740 )_26\-RRB-\1740 with_27\IN\1740 risperidone_28\NN\1740 and_29\CC\1740 1.2_30\CD\1740 (_31\-LRB-\1740 95_32\CD\1740 %_33\NN\1740 ci=1.0_34\NNP\1740 -_35\HYPH\1740 1.4_36\CD\1740 )_37\-RRB-\1740 with_38\IN\1740 <e1>olanzapine</e1>_39\NN\1740 ._40\.\1740
C076029_D015430 CID significantly_0\RB\1740 more_1\JJR\1740 <e2>weight_2\NN\5009170 gain</e2>_3\NN\13576355 occurred_4\VBD\2623529 with_5\IN\1740 <e1>olanzapine</e1>_6\NN\1740 than_7\IN\1740 with_8\IN\1740 risperidone_9\NN\1740 :_10\:\1740 the_11\DT\1740 increase_12\NN\13576355 in_13\IN\13603305 weight_14\NN\5009170 at_15\IN\14622893 4_16\CD\13741022 months_17\NNS\15113229 relative_18\JJ\1740 to_19\TO\1740 baseline_20\NN\7260623 weight_21\NN\5009170 was_22\VBD\836236 17.3_23\CD\1740 %_24\NN\1740 (_25\-LRB-\1740 95_26\CD\1740 %_27\NN\1740 ci=14.2%-20.5_28\NN\1740 %_29\NN\1740 )_30\-RRB-\1740 with_31\IN\1740 olanzapine_32\NN\1740 and_33\CC\1740 11.3_34\CD\1740 %_35\NN\1740 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 ci=8.4%-14.3_39\NN\1740 %_40\NN\1740 )_41\-RRB-\1740 with_42\IN\1740 risperidone_43\NN\1740 ._44\.\1740
C076029_D015430 CID significantly_0\RB\1740 more_1\JJR\1740 <e2>weight_2\NN\5009170 gain</e2>_3\NN\13576355 occurred_4\VBD\2623529 with_5\IN\1740 olanzapine_6\NN\1740 than_7\IN\1740 with_8\IN\1740 risperidone_9\NN\1740 :_10\:\1740 the_11\DT\1740 increase_12\NN\13576355 in_13\IN\13603305 weight_14\NN\5009170 at_15\IN\14622893 4_16\CD\13741022 months_17\NNS\15113229 relative_18\JJ\1740 to_19\TO\1740 baseline_20\NN\7260623 weight_21\NN\5009170 was_22\VBD\836236 17.3_23\CD\1740 %_24\NN\1740 (_25\-LRB-\1740 95_26\CD\1740 %_27\NN\1740 ci=14.2%-20.5_28\NN\1740 %_29\NN\1740 )_30\-RRB-\1740 with_31\IN\1740 <e1>olanzapine</e1>_32\NN\1740 and_33\CC\1740 11.3_34\CD\1740 %_35\NN\1740 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 ci=8.4%-14.3_39\NN\1740 %_40\NN\1740 )_41\-RRB-\1740 with_42\IN\1740 risperidone_43\NN\1740 ._44\.\1740
C076029_D015430 CID both_0\DT\1740 medications_1\NNS\3247620 caused_2\VBD\1617192 substantial_3\JJ\1740 rapid_4\JJ\1740 <e2>weight_5\NN\5009170 gain</e2>_6\NN\13576355 ,_7\,\1740 but_8\CC\1740 weight_9\NN\5009170 gain_10\NN\13576355 was_11\VBD\836236 greater_12\JJR\1740 with_13\IN\1740 <e1>olanzapine</e1>_14\NN\1740 ._15\.\1740
C076029_D015430 CID both_0\DT\1740 medications_1\NNS\3247620 caused_2\VBD\1617192 substantial_3\JJ\1740 rapid_4\JJ\1740 weight_5\NN\5009170 gain_6\NN\13576355 ,_7\,\1740 but_8\CC\1740 <e2>weight_9\NN\5009170 gain</e2>_10\NN\13576355 was_11\VBD\836236 greater_12\JJR\1740 with_13\IN\1740 <e1>olanzapine</e1>_14\NN\1740 ._15\.\1740
D018967_D015430 CID significantly_0\RB\1740 more_1\JJR\1740 <e2>weight_2\NN\5009170 gain</e2>_3\NN\13576355 occurred_4\VBD\2623529 with_5\IN\1740 olanzapine_6\NN\1740 than_7\IN\1740 with_8\IN\1740 <e1>risperidone</e1>_9\NN\1740 :_10\:\1740 the_11\DT\1740 increase_12\NN\13576355 in_13\IN\13603305 weight_14\NN\5009170 at_15\IN\14622893 4_16\CD\13741022 months_17\NNS\15113229 relative_18\JJ\1740 to_19\TO\1740 baseline_20\NN\7260623 weight_21\NN\5009170 was_22\VBD\836236 17.3_23\CD\1740 %_24\NN\1740 (_25\-LRB-\1740 95_26\CD\1740 %_27\NN\1740 ci=14.2%-20.5_28\NN\1740 %_29\NN\1740 )_30\-RRB-\1740 with_31\IN\1740 olanzapine_32\NN\1740 and_33\CC\1740 11.3_34\CD\1740 %_35\NN\1740 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 ci=8.4%-14.3_39\NN\1740 %_40\NN\1740 )_41\-RRB-\1740 with_42\IN\1740 risperidone_43\NN\1740 ._44\.\1740
D018967_D015430 CID significantly_0\RB\1740 more_1\JJR\1740 <e2>weight_2\NN\5009170 gain</e2>_3\NN\13576355 occurred_4\VBD\2623529 with_5\IN\1740 olanzapine_6\NN\1740 than_7\IN\1740 with_8\IN\1740 risperidone_9\NN\1740 :_10\:\1740 the_11\DT\1740 increase_12\NN\13576355 in_13\IN\13603305 weight_14\NN\5009170 at_15\IN\14622893 4_16\CD\13741022 months_17\NNS\15113229 relative_18\JJ\1740 to_19\TO\1740 baseline_20\NN\7260623 weight_21\NN\5009170 was_22\VBD\836236 17.3_23\CD\1740 %_24\NN\1740 (_25\-LRB-\1740 95_26\CD\1740 %_27\NN\1740 ci=14.2%-20.5_28\NN\1740 %_29\NN\1740 )_30\-RRB-\1740 with_31\IN\1740 olanzapine_32\NN\1740 and_33\CC\1740 11.3_34\CD\1740 %_35\NN\1740 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 ci=8.4%-14.3_39\NN\1740 %_40\NN\1740 )_41\-RRB-\1740 with_42\IN\1740 <e1>risperidone</e1>_43\NN\1740 ._44\.\1740
439781
D007213_D007022 CID <e1>indomethacin</e1>_0\NN\3828465 induced_1\VBD\1627355 <e2>hypotension</e2>_2\NN\14057371 in_3\IN\13603305 sodium_4\NN\14625458 and_5\CC\1740 volume_6\NN\33615 depleted_7\VBN\2267060 rats_8\NNS\2329401 ._9\.\1740
D012964_D007022 NONE indomethacin_0\NN\3828465 induced_1\VBD\1627355 <e2>hypotension</e2>_2\NN\14057371 in_3\IN\13603305 <e1>sodium</e1>_4\NN\14625458 and_5\CC\1740 volume_6\NN\33615 depleted_7\VBN\2267060 rats_8\NNS\2329401 ._9\.\1740
19419794
D016627_D004409 NONE increased_0\VBN\169651 vulnerability_1\NN\14540765 to_2\TO\1740 <e1>6-hydroxydopamine</e1>_3\NN\1740 lesion_4\NN\14204950 and_5\CC\1740 reduced_6\VBD\441445 development_7\NN\248977 of_8\IN\1740 <e2>dyskinesias</e2>_9\NNS\14084880 in_10\IN\13603305 mice_11\NNS\2329401 lacking_12\VBG\1740 cb1_13\NN\1740 cannabinoid_14\NN\1740 receptors_15\NNS\5225602 ._16\.\1740
C005177_D004409 NONE treatment_0\NN\654885 with_1\IN\1740 <e1>l-dopa+benserazide</e1>_2\NN\1740 (_3\-LRB-\1740 12_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 resulted_7\VBD\2633881 in_8\IN\13603305 less_9\RBR\1740 severe_10\JJ\1740 <e2>dyskinesias</e2>_11\NNS\14084880 in_12\IN\13603305 cb1_13\NN\1740 ko_14\NNP\1173038 than_15\IN\1740 in_16\IN\13603305 wt_17\NN\1740 mice_18\NNS\2329401 ._19\.\1740
D004298_D004409 NONE the_0\DT\1740 results_1\NNS\34213 revealed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 lack_5\NN\14449126 of_6\IN\1740 cannabinoid_7\JJ\1740 cb1_8\NN\1740 receptors_9\NNS\5225602 increased_10\VBD\169651 the_11\DT\1740 severity_12\NN\5036394 of_13\IN\1740 motor_14\NN\3699975 impairment_15\NN\7296428 and_16\CC\1740 <e1>da</e1>_17\NN\10484858 lesion_18\NN\14204950 ,_19\,\1740 and_20\CC\1740 reduced_21\VBD\441445 l-dopa-induced_22\JJ\1740 <e2>dyskinesias</e2>_23\NNS\14084880 ._24\.\1740
D007980_D004409 CID the_0\DT\1740 results_1\NNS\34213 revealed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 lack_5\NN\14449126 of_6\IN\1740 cannabinoid_7\JJ\1740 cb1_8\NN\1740 receptors_9\NNS\5225602 increased_10\VBD\169651 the_11\DT\1740 severity_12\NN\5036394 of_13\IN\1740 motor_14\NN\3699975 impairment_15\NN\7296428 and_16\CC\1740 da_17\NN\10484858 lesion_18\NN\14204950 ,_19\,\1740 and_20\CC\1740 reduced_21\VBD\441445 <e1>l-dopa-induced</e1>_22\JJ\1740 <e2>dyskinesias</e2>_23\NNS\14084880 ._24\.\1740
D007980_D004409 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 activation_4\NN\13561719 of_5\IN\1740 cb1_6\NN\1740 receptors_7\NNS\5225602 offers_8\VBZ\2327200 neuroprotection_9\NN\1740 against_10\IN\1740 dopaminergic_11\JJ\1740 lesion_12\NN\14204950 and_13\CC\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 <e1>l-dopa-induced</e1>_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 ._19\.\1740
23864035
C400082_D009101 NONE <e1>bortezomib</e1>_0\NNP\1740 and_1\CC\1740 dexamethasone_2\NN\2721538 as_3\IN\14622893 salvage_4\NN\3076708 therapy_5\NN\657604 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 relapsed/refractory_9\JJ\1740 <e2>multiple_10\JJ\1740 myeloma</e2>_11\NN\14239425 :_12\:\1740 analysis_13\NN\633864 of_14\IN\1740 long-term_15\JJ\1740 clinical_16\JJ\1740 outcomes_17\NNS\7291312 ._18\.\1740
C400082_D009101 NONE <e1>bortezomib</e1>_0\NN\1740 (bort)-dexamethasone_1\NN\1740 (_2\-LRB-\1740 dex_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 <e2>multiple_14\JJ\1740 myeloma</e2>_15\NN\14239425 (_16\-LRB-\1740 mm_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
C400082_D009101 NONE <e1>bortezomib</e1>_0\NN\1740 (bort)-dexamethasone_1\NN\1740 (_2\-LRB-\1740 dex_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 multiple_14\JJ\1740 myeloma_15\NN\14239425 (_16\-LRB-\1740 <e2>mm</e2>_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
C400082_D009101 NONE bortezomib_0\NN\1740 <e1>(bort)-dexamethasone</e1>_1\NN\1740 (_2\-LRB-\1740 dex_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 <e2>multiple_14\JJ\1740 myeloma</e2>_15\NN\14239425 (_16\-LRB-\1740 mm_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
C400082_D009101 NONE bortezomib_0\NN\1740 <e1>(bort)-dexamethasone</e1>_1\NN\1740 (_2\-LRB-\1740 dex_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 multiple_14\JJ\1740 myeloma_15\NN\14239425 (_16\-LRB-\1740 <e2>mm</e2>_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
C400082_D009101 NONE 3_0\CD\13741022 weeks_1\NNS\15113229 )_2\-RRB-\1740 and_3\CC\1740 dex_4\NN\1740 (_5\-LRB-\1740 20_6\CD\13745420 mg_7\NN\13717155 on_8\IN\1740 the_9\DT\1740 day_10\NN\15154774 of_11\IN\1740 and_12\CC\1740 the_13\DT\1740 day_14\NN\15154774 after_15\IN\1740 <e1>bort</e1>_16\FW\1740 )_17\-RRB-\1740 as_18\IN\14622893 salvage_19\NN\3076708 treatment_20\NN\654885 in_21\IN\13603305 85_22\CD\1740 patients_23\NNS\9898892 with_24\IN\1740 r/r_25\NN\1740 <e2>mm</e2>_26\NN\13649268 after_27\IN\1740 prior_28\JJ\1740 autologous_29\JJ\1740 stem_30\NN\6290637 cell_31\NN\3080309 transplantation_32\NN\671351 or_33\CC\3541091 conventional_34\JJ\1740 chemotherapy_35\NN\661091 ._36\.\1740
C400082_D009101 NONE <e1>bort-dex</e1>_0\NN\1740 was_1\VBD\836236 an_2\DT\6697703 effective_3\JJ\1740 salvage_4\NN\3076708 treatment_5\NN\654885 for_6\IN\1740 <e2>mm</e2>_7\NN\13649268 patients_8\NNS\9898892 ,_9\,\1740 particularly_10\RB\1740 for_11\IN\1740 those_12\DT\1740 in_13\IN\13603305 first_14\JJ\1740 relapse_15\NN\66636 ._16\.\1740
D003907_D009101 NONE bortezomib_0\NNP\1740 and_1\CC\1740 <e1>dexamethasone</e1>_2\NN\2721538 as_3\IN\14622893 salvage_4\NN\3076708 therapy_5\NN\657604 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 relapsed/refractory_9\JJ\1740 <e2>multiple_10\JJ\1740 myeloma</e2>_11\NN\14239425 :_12\:\1740 analysis_13\NN\633864 of_14\IN\1740 long-term_15\JJ\1740 clinical_16\JJ\1740 outcomes_17\NNS\7291312 ._18\.\1740
D003907_D009101 NONE bortezomib_0\NN\1740 <e1>(bort)-dexamethasone</e1>_1\NN\1740 (_2\-LRB-\1740 dex_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 <e2>multiple_14\JJ\1740 myeloma</e2>_15\NN\14239425 (_16\-LRB-\1740 mm_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
D003907_D009101 NONE bortezomib_0\NN\1740 <e1>(bort)-dexamethasone</e1>_1\NN\1740 (_2\-LRB-\1740 dex_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 multiple_14\JJ\1740 myeloma_15\NN\14239425 (_16\-LRB-\1740 <e2>mm</e2>_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
D003907_D009101 NONE bortezomib_0\NN\1740 (bort)-dexamethasone_1\NN\1740 (_2\-LRB-\1740 <e1>dex</e1>_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 <e2>multiple_14\JJ\1740 myeloma</e2>_15\NN\14239425 (_16\-LRB-\1740 mm_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
D003907_D009101 NONE bortezomib_0\NN\1740 (bort)-dexamethasone_1\NN\1740 (_2\-LRB-\1740 <e1>dex</e1>_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 effective_7\JJ\1740 therapy_8\NN\657604 for_9\IN\1740 relapsed/refractory_10\JJ\1740 (_11\-LRB-\1740 r/r_12\NN\1740 )_13\-RRB-\1740 multiple_14\JJ\1740 myeloma_15\NN\14239425 (_16\-LRB-\1740 <e2>mm</e2>_17\NN\13649268 )_18\-RRB-\1740 ._19\.\1740
D003907_D009101 NONE 3_0\CD\13741022 weeks_1\NNS\15113229 )_2\-RRB-\1740 and_3\CC\1740 <e1>dex</e1>_4\NN\1740 (_5\-LRB-\1740 20_6\CD\13745420 mg_7\NN\13717155 on_8\IN\1740 the_9\DT\1740 day_10\NN\15154774 of_11\IN\1740 and_12\CC\1740 the_13\DT\1740 day_14\NN\15154774 after_15\IN\1740 bort_16\FW\1740 )_17\-RRB-\1740 as_18\IN\14622893 salvage_19\NN\3076708 treatment_20\NN\654885 in_21\IN\13603305 85_22\CD\1740 patients_23\NNS\9898892 with_24\IN\1740 r/r_25\NN\1740 <e2>mm</e2>_26\NN\13649268 after_27\IN\1740 prior_28\JJ\1740 autologous_29\JJ\1740 stem_30\NN\6290637 cell_31\NN\3080309 transplantation_32\NN\671351 or_33\CC\3541091 conventional_34\JJ\1740 chemotherapy_35\NN\661091 ._36\.\1740
D003907_D009101 NONE <e1>bort-dex</e1>_0\NN\1740 was_1\VBD\836236 an_2\DT\6697703 effective_3\JJ\1740 salvage_4\NN\3076708 treatment_5\NN\654885 for_6\IN\1740 <e2>mm</e2>_7\NN\13649268 patients_8\NNS\9898892 ,_9\,\1740 particularly_10\RB\1740 for_11\IN\1740 those_12\DT\1740 in_13\IN\13603305 first_14\JJ\1740 relapse_15\NN\66636 ._16\.\1740
7931490
D017829_D009325 NONE efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 <e1>granisetron</e1>_4\NN\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 5-hydroxytryptamine-3_8\JJ\1740 receptor_9\NN\5225602 antagonist_10\NN\7846 ,_11\,\1740 in_12\IN\13603305 the_13\DT\1740 prevention_14\NN\1073995 of_15\IN\1740 <e2>nausea</e2>_16\NN\14299637 and_17\CC\1740 vomiting_18\NN\116687 induced_19\VBN\1627355 by_20\IN\1740 high-dose_21\JJ\1740 cisplatin_22\NN\1740 ._23\.\1740
D017829_D009325 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 antiemetic_5\JJ\1740 effects_6\NNS\13245626 and_7\CC\1740 safety_8\NN\13920835 profile_9\NN\6999802 of_10\IN\1740 four_11\CD\13741022 different_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 <e1>granisetron</e1>_15\NN\1740 (_16\-LRB-\1740 kytril_17\NNP\1740 ;_18\:\1740 smithkline_19\NNP\1740 beecham_20\NNP\1740 pharmaceuticals_21\NNP\3740161 ,_22\,\1740 philadelphia_23\NNP\1740 ,_24\,\1740 pa_25\NNP\10080869 )_26\-RRB-\1740 when_27\WRB\1740 administered_28\VBN\2436349 as_29\IN\14622893 a_30\DT\13649268 single_31\JJ\1740 intravenous_32\JJ\1740 (_33\-LRB-\1740 iv_34\CD\13741022 )_35\-RRB-\1740 dose_36\NN\3740161 for_37\IN\1740 prophylaxis_38\NN\1077350 of_39\IN\1740 cisplatin-induced_40\JJ\1740 <e2>nausea</e2>_41\NN\14299637 and_42\CC\1740 vomiting_43\NN\116687 ._44\.\1740
D017829_D009325 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 antiemetic_5\JJ\1740 effects_6\NNS\13245626 and_7\CC\1740 safety_8\NN\13920835 profile_9\NN\6999802 of_10\IN\1740 four_11\CD\13741022 different_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 granisetron_15\NN\1740 (_16\-LRB-\1740 <e1>kytril</e1>_17\NNP\1740 ;_18\:\1740 smithkline_19\NNP\1740 beecham_20\NNP\1740 pharmaceuticals_21\NNP\3740161 ,_22\,\1740 philadelphia_23\NNP\1740 ,_24\,\1740 pa_25\NNP\10080869 )_26\-RRB-\1740 when_27\WRB\1740 administered_28\VBN\2436349 as_29\IN\14622893 a_30\DT\13649268 single_31\JJ\1740 intravenous_32\JJ\1740 (_33\-LRB-\1740 iv_34\CD\13741022 )_35\-RRB-\1740 dose_36\NN\3740161 for_37\IN\1740 prophylaxis_38\NN\1077350 of_39\IN\1740 cisplatin-induced_40\JJ\1740 <e2>nausea</e2>_41\NN\14299637 and_42\CC\1740 vomiting_43\NN\116687 ._44\.\1740
D017829_D014839 NONE efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 <e1>granisetron</e1>_4\NN\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 5-hydroxytryptamine-3_8\JJ\1740 receptor_9\NN\5225602 antagonist_10\NN\7846 ,_11\,\1740 in_12\IN\13603305 the_13\DT\1740 prevention_14\NN\1073995 of_15\IN\1740 nausea_16\NN\14299637 and_17\CC\1740 <e2>vomiting</e2>_18\NN\116687 induced_19\VBN\1627355 by_20\IN\1740 high-dose_21\JJ\1740 cisplatin_22\NN\1740 ._23\.\1740
D017829_D014839 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 antiemetic_5\JJ\1740 effects_6\NNS\13245626 and_7\CC\1740 safety_8\NN\13920835 profile_9\NN\6999802 of_10\IN\1740 four_11\CD\13741022 different_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 <e1>granisetron</e1>_15\NN\1740 (_16\-LRB-\1740 kytril_17\NNP\1740 ;_18\:\1740 smithkline_19\NNP\1740 beecham_20\NNP\1740 pharmaceuticals_21\NNP\3740161 ,_22\,\1740 philadelphia_23\NNP\1740 ,_24\,\1740 pa_25\NNP\10080869 )_26\-RRB-\1740 when_27\WRB\1740 administered_28\VBN\2436349 as_29\IN\14622893 a_30\DT\13649268 single_31\JJ\1740 intravenous_32\JJ\1740 (_33\-LRB-\1740 iv_34\CD\13741022 )_35\-RRB-\1740 dose_36\NN\3740161 for_37\IN\1740 prophylaxis_38\NN\1077350 of_39\IN\1740 cisplatin-induced_40\JJ\1740 nausea_41\NN\14299637 and_42\CC\1740 <e2>vomiting</e2>_43\NN\116687 ._44\.\1740
D017829_D014839 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 antiemetic_5\JJ\1740 effects_6\NNS\13245626 and_7\CC\1740 safety_8\NN\13920835 profile_9\NN\6999802 of_10\IN\1740 four_11\CD\13741022 different_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 granisetron_15\NN\1740 (_16\-LRB-\1740 <e1>kytril</e1>_17\NNP\1740 ;_18\:\1740 smithkline_19\NNP\1740 beecham_20\NNP\1740 pharmaceuticals_21\NNP\3740161 ,_22\,\1740 philadelphia_23\NNP\1740 ,_24\,\1740 pa_25\NNP\10080869 )_26\-RRB-\1740 when_27\WRB\1740 administered_28\VBN\2436349 as_29\IN\14622893 a_30\DT\13649268 single_31\JJ\1740 intravenous_32\JJ\1740 (_33\-LRB-\1740 iv_34\CD\13741022 )_35\-RRB-\1740 dose_36\NN\3740161 for_37\IN\1740 prophylaxis_38\NN\1077350 of_39\IN\1740 cisplatin-induced_40\JJ\1740 nausea_41\NN\14299637 and_42\CC\1740 <e2>vomiting</e2>_43\NN\116687 ._44\.\1740
D017829_D014839 NONE results_0\NNS\34213 :_1\:\1740 after_2\IN\1740 <e1>granisetron</e1>_3\NN\1740 doses_4\NNS\3740161 of_5\IN\1740 5_6\CD\13741022 ,_7\,\1740 10_8\CD\13745420 ,_9\,\1740 20_10\CD\13745420 ,_11\,\1740 and_12\CC\1740 40_13\CD\13745420 micrograms/kg_14\NNS\1740 ,_15\,\1740 a_16\DT\13649268 major_17\JJ\1740 response_18\NN\11410625 (_19\-LRB-\1740 <_20\CD\1740 or_21\CC\3541091 =_22\JJ\1740 two_23\CD\13741022 <e2>vomiting</e2>_24\NN\116687 or_25\CC\3541091 retching_26\NN\1740 episodes_27\NNS\7283608 ,_28\,\1740 and_29\CC\1740 no_30\DT\7204911 antiemetic_31\JJ\1740 rescue_32\NN\45907 )_33\-RRB-\1740 was_34\VBD\836236 recorded_35\VBN\2225492 in_36\IN\13603305 23_37\CD\13745420 %_38\NN\1740 ,_39\,\1740 57_40\CD\1740 %_41\NN\1740 ,_42\,\1740 58_43\CD\1740 %_44\NN\1740 ,_45\,\1740 and_46\CC\1740 60_47\CD\13745420 %_48\NN\1740 of_49\IN\1740 patients_50\NNS\9898892 ,_51\,\1740 respectively_52\RB\1740 ,_53\,\1740 and_54\CC\1740 a_55\DT\13649268 complete_56\JJ\1740 response_57\NN\11410625 (_58\-LRB-\1740 no_59\DT\7204911 vomiting_60\NN\116687 or_61\CC\3541091 retching_62\NN\1740 ,_63\,\1740 and_64\CC\1740 no_65\DT\7204911 antiemetic_66\JJ\1740 rescue_67\NN\45907 )_68\-RRB-\1740 in_69\IN\13603305 18_70\CD\13745420 %_71\NN\1740 ,_72\,\1740 41_73\CD\1740 %_74\NN\1740 ,_75\,\1740 40_76\CD\13745420 %_77\NN\1740 ,_78\,\1740 and_79\CC\1740 47_80\CD\1740 %_81\NN\1740 of_82\IN\1740 patients_83\NNS\9898892 ,_84\,\1740 respectively_85\RB\1740 ._86\.\1740
D017829_D014839 NONE results_0\NNS\34213 :_1\:\1740 after_2\IN\1740 <e1>granisetron</e1>_3\NN\1740 doses_4\NNS\3740161 of_5\IN\1740 5_6\CD\13741022 ,_7\,\1740 10_8\CD\13745420 ,_9\,\1740 20_10\CD\13745420 ,_11\,\1740 and_12\CC\1740 40_13\CD\13745420 micrograms/kg_14\NNS\1740 ,_15\,\1740 a_16\DT\13649268 major_17\JJ\1740 response_18\NN\11410625 (_19\-LRB-\1740 <_20\CD\1740 or_21\CC\3541091 =_22\JJ\1740 two_23\CD\13741022 vomiting_24\NN\116687 or_25\CC\3541091 retching_26\NN\1740 episodes_27\NNS\7283608 ,_28\,\1740 and_29\CC\1740 no_30\DT\7204911 antiemetic_31\JJ\1740 rescue_32\NN\45907 )_33\-RRB-\1740 was_34\VBD\836236 recorded_35\VBN\2225492 in_36\IN\13603305 23_37\CD\13745420 %_38\NN\1740 ,_39\,\1740 57_40\CD\1740 %_41\NN\1740 ,_42\,\1740 58_43\CD\1740 %_44\NN\1740 ,_45\,\1740 and_46\CC\1740 60_47\CD\13745420 %_48\NN\1740 of_49\IN\1740 patients_50\NNS\9898892 ,_51\,\1740 respectively_52\RB\1740 ,_53\,\1740 and_54\CC\1740 a_55\DT\13649268 complete_56\JJ\1740 response_57\NN\11410625 (_58\-LRB-\1740 no_59\DT\7204911 <e2>vomiting</e2>_60\NN\116687 or_61\CC\3541091 retching_62\NN\1740 ,_63\,\1740 and_64\CC\1740 no_65\DT\7204911 antiemetic_66\JJ\1740 rescue_67\NN\45907 )_68\-RRB-\1740 in_69\IN\13603305 18_70\CD\13745420 %_71\NN\1740 ,_72\,\1740 41_73\CD\1740 %_74\NN\1740 ,_75\,\1740 40_76\CD\13745420 %_77\NN\1740 ,_78\,\1740 and_79\CC\1740 47_80\CD\1740 %_81\NN\1740 of_82\IN\1740 patients_83\NNS\9898892 ,_84\,\1740 respectively_85\RB\1740 ._86\.\1740
D017829_D014839 NONE conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 single_3\JJ\1740 10-_4\CD\1740 ,_5\,\1740 20-_6\CD\1740 ,_7\,\1740 or_8\CC\3541091 40-micrograms/kg_9\NN\1740 dose_10\NN\3740161 of_11\IN\1740 <e1>granisetron</e1>_12\NN\1740 was_13\VBD\836236 effective_14\JJ\1740 in_15\IN\13603305 controlling_16\VBG\2422663 <e2>vomiting</e2>_17\NN\116687 in_18\IN\13603305 57_19\CD\1740 %_20\NN\1740 to_21\IN\1740 60_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 who_26\WP\8299493 received_27\VBD\2210855 cisplatin_28\NN\1740 at_29\IN\14622893 doses_30\NNS\3740161 greater_31\JJR\1740 than_32\IN\1740 81_33\CD\1740 mg/m2_34\NN\1740 and_35\CC\1740 totally_36\RB\1740 prevented_37\VBD\1740 vomiting_38\NN\116687 in_39\IN\13603305 40_40\CD\13745420 %_41\NN\1740 to_42\IN\1740 47_43\CD\1740 %_44\NN\1740 of_45\IN\1740 patients_46\NNS\9898892 ._47\.\1740
D017829_D014839 NONE conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 single_3\JJ\1740 10-_4\CD\1740 ,_5\,\1740 20-_6\CD\1740 ,_7\,\1740 or_8\CC\3541091 40-micrograms/kg_9\NN\1740 dose_10\NN\3740161 of_11\IN\1740 <e1>granisetron</e1>_12\NN\1740 was_13\VBD\836236 effective_14\JJ\1740 in_15\IN\13603305 controlling_16\VBG\2422663 vomiting_17\NN\116687 in_18\IN\13603305 57_19\CD\1740 %_20\NN\1740 to_21\IN\1740 60_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 who_26\WP\8299493 received_27\VBD\2210855 cisplatin_28\NN\1740 at_29\IN\14622893 doses_30\NNS\3740161 greater_31\JJR\1740 than_32\IN\1740 81_33\CD\1740 mg/m2_34\NN\1740 and_35\CC\1740 totally_36\RB\1740 prevented_37\VBD\1740 <e2>vomiting</e2>_38\NN\116687 in_39\IN\13603305 40_40\CD\13745420 %_41\NN\1740 to_42\IN\1740 47_43\CD\1740 %_44\NN\1740 of_45\IN\1740 patients_46\NNS\9898892 ._47\.\1740
D012701_D009325 NONE efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 granisetron_4\NN\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 <e1>5-hydroxytryptamine-3</e1>_8\JJ\1740 receptor_9\NN\5225602 antagonist_10\NN\7846 ,_11\,\1740 in_12\IN\13603305 the_13\DT\1740 prevention_14\NN\1073995 of_15\IN\1740 <e2>nausea</e2>_16\NN\14299637 and_17\CC\1740 vomiting_18\NN\116687 induced_19\VBN\1627355 by_20\IN\1740 high-dose_21\JJ\1740 cisplatin_22\NN\1740 ._23\.\1740
D012701_D014839 NONE efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 granisetron_4\NN\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 <e1>5-hydroxytryptamine-3</e1>_8\JJ\1740 receptor_9\NN\5225602 antagonist_10\NN\7846 ,_11\,\1740 in_12\IN\13603305 the_13\DT\1740 prevention_14\NN\1073995 of_15\IN\1740 nausea_16\NN\14299637 and_17\CC\1740 <e2>vomiting</e2>_18\NN\116687 induced_19\VBN\1627355 by_20\IN\1740 high-dose_21\JJ\1740 cisplatin_22\NN\1740 ._23\.\1740
D002945_D009325 CID efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 granisetron_4\NN\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 5-hydroxytryptamine-3_8\JJ\1740 receptor_9\NN\5225602 antagonist_10\NN\7846 ,_11\,\1740 in_12\IN\13603305 the_13\DT\1740 prevention_14\NN\1073995 of_15\IN\1740 <e2>nausea</e2>_16\NN\14299637 and_17\CC\1740 vomiting_18\NN\116687 induced_19\VBN\1627355 by_20\IN\1740 high-dose_21\JJ\1740 <e1>cisplatin</e1>_22\NN\1740 ._23\.\1740
D002945_D009325 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 antiemetic_5\JJ\1740 effects_6\NNS\13245626 and_7\CC\1740 safety_8\NN\13920835 profile_9\NN\6999802 of_10\IN\1740 four_11\CD\13741022 different_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 granisetron_15\NN\1740 (_16\-LRB-\1740 kytril_17\NNP\1740 ;_18\:\1740 smithkline_19\NNP\1740 beecham_20\NNP\1740 pharmaceuticals_21\NNP\3740161 ,_22\,\1740 philadelphia_23\NNP\1740 ,_24\,\1740 pa_25\NNP\10080869 )_26\-RRB-\1740 when_27\WRB\1740 administered_28\VBN\2436349 as_29\IN\14622893 a_30\DT\13649268 single_31\JJ\1740 intravenous_32\JJ\1740 (_33\-LRB-\1740 iv_34\CD\13741022 )_35\-RRB-\1740 dose_36\NN\3740161 for_37\IN\1740 prophylaxis_38\NN\1077350 of_39\IN\1740 <e1>cisplatin-induced</e1>_40\JJ\1740 <e2>nausea</e2>_41\NN\14299637 and_42\CC\1740 vomiting_43\NN\116687 ._44\.\1740
D002945_D014839 CID efficacy_0\NNP\5199286 and_1\CC\1740 safety_2\NN\13920835 of_3\IN\1740 granisetron_4\NN\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 5-hydroxytryptamine-3_8\JJ\1740 receptor_9\NN\5225602 antagonist_10\NN\7846 ,_11\,\1740 in_12\IN\13603305 the_13\DT\1740 prevention_14\NN\1073995 of_15\IN\1740 nausea_16\NN\14299637 and_17\CC\1740 <e2>vomiting</e2>_18\NN\116687 induced_19\VBN\1627355 by_20\IN\1740 high-dose_21\JJ\1740 <e1>cisplatin</e1>_22\NN\1740 ._23\.\1740
D002945_D014839 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 the_4\DT\1740 antiemetic_5\JJ\1740 effects_6\NNS\13245626 and_7\CC\1740 safety_8\NN\13920835 profile_9\NN\6999802 of_10\IN\1740 four_11\CD\13741022 different_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 granisetron_15\NN\1740 (_16\-LRB-\1740 kytril_17\NNP\1740 ;_18\:\1740 smithkline_19\NNP\1740 beecham_20\NNP\1740 pharmaceuticals_21\NNP\3740161 ,_22\,\1740 philadelphia_23\NNP\1740 ,_24\,\1740 pa_25\NNP\10080869 )_26\-RRB-\1740 when_27\WRB\1740 administered_28\VBN\2436349 as_29\IN\14622893 a_30\DT\13649268 single_31\JJ\1740 intravenous_32\JJ\1740 (_33\-LRB-\1740 iv_34\CD\13741022 )_35\-RRB-\1740 dose_36\NN\3740161 for_37\IN\1740 prophylaxis_38\NN\1077350 of_39\IN\1740 <e1>cisplatin-induced</e1>_40\JJ\1740 nausea_41\NN\14299637 and_42\CC\1740 <e2>vomiting</e2>_43\NN\116687 ._44\.\1740
D002945_D014839 CID conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 single_3\JJ\1740 10-_4\CD\1740 ,_5\,\1740 20-_6\CD\1740 ,_7\,\1740 or_8\CC\3541091 40-micrograms/kg_9\NN\1740 dose_10\NN\3740161 of_11\IN\1740 granisetron_12\NN\1740 was_13\VBD\836236 effective_14\JJ\1740 in_15\IN\13603305 controlling_16\VBG\2422663 <e2>vomiting</e2>_17\NN\116687 in_18\IN\13603305 57_19\CD\1740 %_20\NN\1740 to_21\IN\1740 60_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 who_26\WP\8299493 received_27\VBD\2210855 <e1>cisplatin</e1>_28\NN\1740 at_29\IN\14622893 doses_30\NNS\3740161 greater_31\JJR\1740 than_32\IN\1740 81_33\CD\1740 mg/m2_34\NN\1740 and_35\CC\1740 totally_36\RB\1740 prevented_37\VBD\1740 vomiting_38\NN\116687 in_39\IN\13603305 40_40\CD\13745420 %_41\NN\1740 to_42\IN\1740 47_43\CD\1740 %_44\NN\1740 of_45\IN\1740 patients_46\NNS\9898892 ._47\.\1740
D002945_D014839 CID conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 single_3\JJ\1740 10-_4\CD\1740 ,_5\,\1740 20-_6\CD\1740 ,_7\,\1740 or_8\CC\3541091 40-micrograms/kg_9\NN\1740 dose_10\NN\3740161 of_11\IN\1740 granisetron_12\NN\1740 was_13\VBD\836236 effective_14\JJ\1740 in_15\IN\13603305 controlling_16\VBG\2422663 vomiting_17\NN\116687 in_18\IN\13603305 57_19\CD\1740 %_20\NN\1740 to_21\IN\1740 60_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 who_26\WP\8299493 received_27\VBD\2210855 <e1>cisplatin</e1>_28\NN\1740 at_29\IN\14622893 doses_30\NNS\3740161 greater_31\JJR\1740 than_32\IN\1740 81_33\CD\1740 mg/m2_34\NN\1740 and_35\CC\1740 totally_36\RB\1740 prevented_37\VBD\1740 <e2>vomiting</e2>_38\NN\116687 in_39\IN\13603305 40_40\CD\13745420 %_41\NN\1740 to_42\IN\1740 47_43\CD\1740 %_44\NN\1740 of_45\IN\1740 patients_46\NNS\9898892 ._47\.\1740
931801
D005937_D007674 NONE effect_0\NN\34213 of_1\IN\1740 <e1>d-glucarates</e1>_2\NN\1740 on_3\IN\1740 basic_4\JJ\1740 antibiotic-induced_5\JJ\1740 <e2>renal_6\JJ\1740 damage</e2>_7\NN\7296428 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
D005937_D007674 NONE <e1>d-glucarates</e1>_0\NN\1740 were_1\VBD\836236 effective_2\JJ\1740 against_3\IN\1740 <e2>renal_4\JJ\1740 damage</e2>_5\NN\7296428 induced_6\VBN\1627355 by_7\IN\1740 peptide_8\NN\14724264 antibiotics_9\NNS\2716205 as_10\RB\1740 well_11\RB\1740 as_12\IN\14622893 various_13\JJ\1740 aminoglycoside_14\NN\1740 antibitocis_15\NN\1740 ._16\.\1740
D005937_D007674 NONE with_0\IN\1740 a_1\DT\13649268 <e1>d-glucarate</e1>_2\NN\1740 of_3\IN\1740 a_4\DT\13649268 fixed_5\JJ\1740 size_6\NN\5090441 of_7\IN\1740 dose_8\NN\3740161 ,_9\,\1740 approximately_10\RB\1740 the_11\DT\1740 same_12\JJ\1740 degree_13\NN\4916342 of_14\IN\1740 protection_15\NN\407535 was_16\VBD\836236 obtained_17\VBN\2210855 against_18\IN\1740 <e2>renal_19\JJ\1740 damages</e2>_20\NNS\13282550 induced_21\VBN\1627355 by_22\IN\1740 different_23\JJ\1740 basic_24\JJ\1740 antibiotics_25\NNS\2716205 despite_26\IN\7501545 large_27\JJ\1740 disparities_28\NNS\4752221 in_29\IN\13603305 administration_30\NN\1133281 doses_31\NNS\3740161 of_32\IN\1740 different_33\JJ\1740 antibiotics_34\NNS\2716205 ._35\.\1740
D005937_D007674 NONE <e1>d-glucarates</e1>_0\NN\1740 had_1\VBD\2108377 the_2\DT\1740 ability_3\NN\4723816 to_4\TO\1740 prevent_5\VB\1740 <e2>renal_6\JJ\1740 damage</e2>_7\NN\7296428 but_8\CC\1740 not_9\RB\1740 to_10\TO\1740 cure_11\VB\82081 it_12\PRP\6125041 ._13\.\1740
D005937_D007674 NONE the_0\DT\1740 reduction_1\NN\351485 effect_2\NN\34213 of_3\IN\1740 <e1>d-glucarates</e1>_4\NNS\1740 against_5\IN\1740 <e2>nephrotoxicity</e2>_6\NN\1740 of_7\IN\1740 basic_8\JJ\1740 antibiotics_9\NNS\2716205 was_10\VBD\836236 discussed_11\VBN\1033527 ._12\.\1740
D000617_D003681 NONE <e2>dehydrated</e2>_0\JJ\1740 rats_1\NNS\2329401 regularly_2\RB\1740 develop_3\VBP\1753788 acute_4\JJ\1740 renal_5\JJ\1740 failure_6\NN\66216 following_7\VBG\1835496 single_8\JJ\1740 injection_9\NN\320852 of_10\IN\1740 <e1>aminoglycoside</e1>_11\JJ\1740 antibiotics_12\NNS\2716205 combined_13\VBN\2630189 with_14\IN\1740 dextran_15\NN\1740 or_16\CC\3541091 of_17\IN\1740 antibiotics_18\NNS\2716205 only_19\RB\1740 ._20\.\1740
D000617_D058186 CID dehydrated_0\JJ\1740 rats_1\NNS\2329401 regularly_2\RB\1740 develop_3\VBP\1753788 <e2>acute_4\JJ\1740 renal_5\JJ\1740 failure</e2>_6\NN\66216 following_7\VBG\1835496 single_8\JJ\1740 injection_9\NN\320852 of_10\IN\1740 <e1>aminoglycoside</e1>_11\JJ\1740 antibiotics_12\NNS\2716205 combined_13\VBN\2630189 with_14\IN\1740 dextran_15\NN\1740 or_16\CC\3541091 of_17\IN\1740 antibiotics_18\NNS\2716205 only_19\RB\1740 ._20\.\1740
C038936_D051437 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>2,5-di-o-acetyl-d-glucaro-1,4_3\CD\1740 -_4\HYPH\1740 6,3-dilactone</e1>_5\NN\1740 protected_6\VBD\1127795 rats_7\NNS\2329401 against_8\IN\1740 <e2>renal_9\JJ\1740 failure</e2>_10\NN\66216 induced_11\VBN\1627355 by_12\IN\1740 kanamycin-dextran_13\NN\1740 ._14\.\1740
D007612_D051437 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 2,5-di-o-acetyl-d-glucaro-1,4_3\CD\1740 -_4\HYPH\1740 6,3-dilactone_5\NN\1740 protected_6\VBD\1127795 rats_7\NNS\2329401 against_8\IN\1740 <e2>renal_9\JJ\1740 failure</e2>_10\NN\66216 induced_11\VBN\1627355 by_12\IN\1740 <e1>kanamycin-dextran</e1>_13\NN\1740 ._14\.\1740
D000617_D007674 NONE d-glucarates_0\NN\1740 were_1\VBD\836236 effective_2\JJ\1740 against_3\IN\1740 <e2>renal_4\JJ\1740 damage</e2>_5\NN\7296428 induced_6\VBN\1627355 by_7\IN\1740 peptide_8\NN\14724264 antibiotics_9\NNS\2716205 as_10\RB\1740 well_11\RB\1740 as_12\IN\14622893 various_13\JJ\1740 <e1>aminoglycoside</e1>_14\NN\1740 antibitocis_15\NN\1740 ._16\.\1740
D009005_D007674 NONE rats_0\NNS\2329401 excreted_1\VBD\104868 acidic_2\JJ\1740 urine_3\NN\14853947 when_4\WRB\1740 they_5\PRP\1740 were_6\VBD\836236 spared_7\VBN\2725714 from_8\IN\1740 <e2>renal_9\JJ\1740 lesions</e2>_10\NNS\14204950 by_11\IN\1740 <e1>monosaccharides</e1>_12\NNS\14792703 ._13\.\1740
7967231
C059447_D020195 NONE <e1>s-312</e1>_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 <e1>s-312-d</e1>_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 <e1>s-312-d</e1>_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D012640 NONE <e1>s-312</e1>_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D012640 NONE <e1>s-312</e1>_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 <e1>s-312-d</e1>_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 <e1>s-312-d</e1>_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 <e1>s-312-d</e1>_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 <e1>s-312-d</e1>_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
-1_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 <e1>s-312-l</e1>_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
-1_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 <e1>s-312-l</e1>_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
-1_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 <e1>s-312-l</e1>_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D002118_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 <e1>calcium</e1>_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D002118_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 <e1>calcium</e1>_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D002118_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 <e1>calcium</e1>_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D005444_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 <e1>flunarizine</e1>_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D005444_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 <e1>flunarizine</e1>_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D005444_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 <e1>flunarizine</e1>_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D010433_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 <e1>pentylenetetrazole</e1>_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D010433_D012640 CID s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 <e1>pentylenetetrazole</e1>_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D010433_D012640 CID s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 <e1>pentylenetetrazole</e1>_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D001534_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 <e1>bemegride</e1>_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D001534_D012640 CID s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 <e1>bemegride</e1>_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D001534_D012640 CID s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 <e1>bemegride</e1>_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D016202_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 <e1>n-methyl-d-aspartate</e1>_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D016202_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 <e1>n-methyl-d-aspartate</e1>_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D016202_D012640 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 <e1>n-methyl-d-aspartate</e1>_107\NN\1740 ,_108\,\1740 picrotoxin_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D010852_D020195 NONE s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 <e2>audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions</e2>_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 <e1>picrotoxin</e1>_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D010852_D012640 CID s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 <e2>convulsions</e2>_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 convulsions_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 <e1>picrotoxin</e1>_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
D010852_D012640 CID s-312_0\NN\1740 ,_1\,\1740 s-312-d_2\NN\1740 ,_3\,\1740 but_4\CC\1740 not_5\RB\1740 s-312-l_6\NN\1740 ,_7\,\1740 l-type_8\NN\1740 calcium_9\NN\14625458 channel_10\NN\6251781 antagonists_11\NNS\7846 ,_12\,\1740 showed_13\VBD\2137132 anticonvulsant_14\JJ\1740 effects_15\NNS\13245626 on_16\IN\1740 the_17\DT\1740 audiogenic_18\JJ\1740 tonic_19\JJ\1740 convulsions_20\NNS\14081375 in_21\IN\13603305 dba/2_22\NN\1740 mice_23\NNS\2329401 ;_24\:\1740 and_25\CC\1740 their_26\PRP$\1740 ed50_27\NN\1740 values_28\NNS\5941423 were_29\VBD\836236 18.4_30\CD\1740 (_31\-LRB-\1740 12.8_32\CD\1740 -_33\SYM\1740 27.1_34\CD\1740 )_35\-RRB-\1740 mg/kg_36\NN\1740 ,_37\,\1740 p.o._38\NN\10360747 and_39\CC\1740 15.0_40\CD\1740 (_41\-LRB-\1740 10.2_42\CD\1740 -_43\SYM\1740 23.7_44\CD\1740 )_45\-RRB-\1740 mg/kg_46\NN\1740 ,_47\,\1740 p.o._48\NN\10360747 ,_49\,\1740 respectively_50\RB\1740 ,_51\,\1740 while_52\IN\15122231 that_53\DT\1740 of_54\IN\1740 flunarizine_55\NN\1740 was_56\VBD\836236 34.0_57\CD\1740 (_58\-LRB-\1740 26.0_59\CD\1740 -_60\SYM\1740 44.8_61\CD\1740 )_62\-RRB-\1740 mg/kg_63\NN\1740 ,_64\,\1740 p.o._65\NN\10360747 although_66\IN\1740 moderate_67\JJ\1740 anticonvulsant_68\JJ\1740 effects_69\NNS\13245626 of_70\IN\1740 s-312-d_71\NN\1740 in_72\IN\13603305 higher_73\JJR\1740 doses_74\NNS\3740161 were_75\VBD\836236 observed_76\VBN\2163746 against_77\IN\1740 the_78\DT\1740 clonic_79\JJ\1740 convulsions_80\NNS\14081375 induced_81\VBN\1627355 by_82\IN\1740 pentylenetetrazole_83\NN\1740 (_84\-LRB-\1740 85_85\CD\1740 mg/kg_86\NN\1740 ,_87\,\1740 s.c._88\NN\1740 )_89\-RRB-\1740 or_90\CC\3541091 bemegride_91\NN\1740 (_92\-LRB-\1740 40_93\CD\13745420 mg/kg_94\NN\1740 ,_95\,\1740 s.c._96\FW\1740 )_97\-RRB-\1740 ,_98\,\1740 no_99\DT\7204911 effects_100\NNS\13245626 were_101\VBD\836236 observed_102\VBN\2163746 in_103\IN\13603305 <e2>convulsions</e2>_104\NNS\14081375 induced_105\VBN\1627355 by_106\IN\1740 n-methyl-d-aspartate_107\NN\1740 ,_108\,\1740 <e1>picrotoxin</e1>_109\NN\1740 ,_110\,\1740 or_111\CC\3541091 electroshock_112\NN\662681 in_113\IN\13603305 slc_114\NN\1740 :_115\:\1740 ddy_116\CD\1740 mice_117\NNS\2329401 ._118\.\1740
C059447_D004827 NONE <e1>s-312-d</e1>_0\NN\1740 may_1\MD\15209706 be_2\VB\836236 useful_3\JJ\1740 in_4\IN\13603305 the_5\DT\1740 therapy_6\NN\657604 of_7\IN\1740 certain_8\JJ\1740 types_9\NNS\5839024 of_10\IN\1740 human_11\JJ\1740 <e2>epilepsy</e2>_12\NN\14085708 ._13\.\1740
17828434
C002647_D012640 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 <e1>mip</e1>_4\NN\1740 synthase_5\NN\1740 inhibition_6\NN\1068773 does_7\VBZ\1640855 not_8\RB\1740 replicate_9\VB\2035919 or_10\CC\3541091 augment_11\VBP\153263 the_12\DT\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 in_16\IN\13603305 the_17\DT\1740 inositol_18\NN\15090742 sensitive_19\JJ\1740 pilocarpine-induced_20\JJ\1740 <e2>seizures</e2>_21\NNS\14081375 model_22\NN\5888929 ._23\.\1740
D008094_D012640 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 mip_4\NN\1740 synthase_5\NN\1740 inhibition_6\NN\1068773 does_7\VBZ\1640855 not_8\RB\1740 replicate_9\VB\2035919 or_10\CC\3541091 augment_11\VBP\153263 the_12\DT\1740 effects_13\NNS\13245626 of_14\IN\1740 <e1>lithium</e1>_15\NN\14625458 in_16\IN\13603305 the_17\DT\1740 inositol_18\NN\15090742 sensitive_19\JJ\1740 pilocarpine-induced_20\JJ\1740 <e2>seizures</e2>_21\NNS\14081375 model_22\NN\5888929 ._23\.\1740
D007294_D012640 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 mip_4\NN\1740 synthase_5\NN\1740 inhibition_6\NN\1068773 does_7\VBZ\1640855 not_8\RB\1740 replicate_9\VB\2035919 or_10\CC\3541091 augment_11\VBP\153263 the_12\DT\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 in_16\IN\13603305 the_17\DT\1740 <e1>inositol</e1>_18\NN\15090742 sensitive_19\JJ\1740 pilocarpine-induced_20\JJ\1740 <e2>seizures</e2>_21\NNS\14081375 model_22\NN\5888929 ._23\.\1740
D010862_D012640 CID this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 mip_4\NN\1740 synthase_5\NN\1740 inhibition_6\NN\1068773 does_7\VBZ\1640855 not_8\RB\1740 replicate_9\VB\2035919 or_10\CC\3541091 augment_11\VBP\153263 the_12\DT\1740 effects_13\NNS\13245626 of_14\IN\1740 lithium_15\NN\14625458 in_16\IN\13603305 the_17\DT\1740 inositol_18\NN\15090742 sensitive_19\JJ\1740 <e1>pilocarpine-induced</e1>_20\JJ\1740 <e2>seizures</e2>_21\NNS\14081375 model_22\NN\5888929 ._23\.\1740
20859899
D000809_D013575 NONE <e2>syncope</e2>_0\NNP\7478169 caused_1\VBN\1617192 by_2\IN\1740 hyperkalemia_3\NN\14299637 during_4\IN\1740 use_5\NN\407535 of_6\IN\1740 a_7\DT\13649268 combined_8\JJ\1740 therapy_9\NN\657604 with_10\IN\1740 the_11\DT\1740 <e1>angiotensin-converting</e1>_12\JJ\1740 enzyme_13\NN\14723628 inhibitor_14\NN\20090 and_15\CC\1740 spironolactone_16\NN\2721160 ._17\.\1740
D000809_D006947 NONE syncope_0\NNP\7478169 caused_1\VBN\1617192 by_2\IN\1740 <e2>hyperkalemia</e2>_3\NN\14299637 during_4\IN\1740 use_5\NN\407535 of_6\IN\1740 a_7\DT\13649268 combined_8\JJ\1740 therapy_9\NN\657604 with_10\IN\1740 the_11\DT\1740 <e1>angiotensin-converting</e1>_12\JJ\1740 enzyme_13\NN\14723628 inhibitor_14\NN\20090 and_15\CC\1740 spironolactone_16\NN\2721160 ._17\.\1740
D013148_D013575 NONE <e2>syncope</e2>_0\NNP\7478169 caused_1\VBN\1617192 by_2\IN\1740 hyperkalemia_3\NN\14299637 during_4\IN\1740 use_5\NN\407535 of_6\IN\1740 a_7\DT\13649268 combined_8\JJ\1740 therapy_9\NN\657604 with_10\IN\1740 the_11\DT\1740 angiotensin-converting_12\JJ\1740 enzyme_13\NN\14723628 inhibitor_14\NN\20090 and_15\CC\1740 <e1>spironolactone</e1>_16\NN\2721160 ._17\.\1740
D013148_D006947 CID syncope_0\NNP\7478169 caused_1\VBN\1617192 by_2\IN\1740 <e2>hyperkalemia</e2>_3\NN\14299637 during_4\IN\1740 use_5\NN\407535 of_6\IN\1740 a_7\DT\13649268 combined_8\JJ\1740 therapy_9\NN\657604 with_10\IN\1740 the_11\DT\1740 angiotensin-converting_12\JJ\1740 enzyme_13\NN\14723628 inhibitor_14\NN\20090 and_15\CC\1740 <e1>spironolactone</e1>_16\NN\2721160 ._17\.\1740
D013148_D006947 CID the_0\DT\1740 cause_1\NN\7323922 of_2\IN\1740 <e2>hyperkalemia</e2>_3\NN\14299637 was_4\VBD\836236 considered_5\VBN\689344 to_6\TO\1740 be_7\VB\836236 several_8\JJ\1740 doses_9\NNS\3740161 of_10\IN\1740 <e1>spiranolactone</e1>_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 aldosterone_14\NN\14751863 antagonist_15\NN\7846 ,_16\,\1740 in_17\IN\13603305 addition_18\NN\3081021 to_19\TO\1740 the_20\DT\1740 long-term_21\JJ\1740 intake_22\NN\13440063 of_23\IN\1740 ramipril_24\NN\2673637 ,_25\,\1740 an_26\DT\6697703 ace_27\NN\13741022 inhibitor_28\NN\20090 ._29\.\1740
D000450_D006947 NONE the_0\DT\1740 cause_1\NN\7323922 of_2\IN\1740 <e2>hyperkalemia</e2>_3\NN\14299637 was_4\VBD\836236 considered_5\VBN\689344 to_6\TO\1740 be_7\VB\836236 several_8\JJ\1740 doses_9\NNS\3740161 of_10\IN\1740 spiranolactone_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 <e1>aldosterone</e1>_14\NN\14751863 antagonist_15\NN\7846 ,_16\,\1740 in_17\IN\13603305 addition_18\NN\3081021 to_19\TO\1740 the_20\DT\1740 long-term_21\JJ\1740 intake_22\NN\13440063 of_23\IN\1740 ramipril_24\NN\2673637 ,_25\,\1740 an_26\DT\6697703 ace_27\NN\13741022 inhibitor_28\NN\20090 ._29\.\1740
D017257_D006947 CID the_0\DT\1740 cause_1\NN\7323922 of_2\IN\1740 <e2>hyperkalemia</e2>_3\NN\14299637 was_4\VBD\836236 considered_5\VBN\689344 to_6\TO\1740 be_7\VB\836236 several_8\JJ\1740 doses_9\NNS\3740161 of_10\IN\1740 spiranolactone_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 aldosterone_14\NN\14751863 antagonist_15\NN\7846 ,_16\,\1740 in_17\IN\13603305 addition_18\NN\3081021 to_19\TO\1740 the_20\DT\1740 long-term_21\JJ\1740 intake_22\NN\13440063 of_23\IN\1740 <e1>ramipril</e1>_24\NN\2673637 ,_25\,\1740 an_26\DT\6697703 ace_27\NN\13741022 inhibitor_28\NN\20090 ._29\.\1740
D011188_D006947 NONE clinicians_0\NNS\10462860 should_1\MD\1740 be_2\VB\836236 alert_3\JJ\1740 to_4\TO\1740 the_5\DT\1740 possibility_6\NN\5944958 of_7\IN\1740 <e2>hyperkalemia</e2>_8\NN\14299637 ,_9\,\1740 especially_10\RB\1740 in_11\IN\13603305 elderly_12\JJ\1740 patients_13\NNS\9898892 using_14\VBG\1156834 ace/arb_15\NN\1740 in_16\IN\13603305 combination_17\NN\7951464 with_18\IN\1740 <e1>potassium</e1>_19\NN\14625458 sparing_20\NN\1740 agents_21\NNS\7347 and_22\CC\1740 who_23\WP\8299493 have_24\VBP\2108377 mild_25\JJ\1740 renal_26\JJ\1740 disturbance_27\NN\407535 ._28\.\1740
D011188_D007674 NONE clinicians_0\NNS\10462860 should_1\MD\1740 be_2\VB\836236 alert_3\JJ\1740 to_4\TO\1740 the_5\DT\1740 possibility_6\NN\5944958 of_7\IN\1740 hyperkalemia_8\NN\14299637 ,_9\,\1740 especially_10\RB\1740 in_11\IN\13603305 elderly_12\JJ\1740 patients_13\NNS\9898892 using_14\VBG\1156834 ace/arb_15\NN\1740 in_16\IN\13603305 combination_17\NN\7951464 with_18\IN\1740 <e1>potassium</e1>_19\NN\14625458 sparing_20\NN\1740 agents_21\NNS\7347 and_22\CC\1740 who_23\WP\8299493 have_24\VBP\2108377 mild_25\JJ\1740 <e2>renal_26\JJ\1740 disturbance</e2>_27\NN\407535 ._28\.\1740
26115410
D001152_D009369 CID there_0\EX\27167 is_1\VBZ\836236 considerable_2\JJ\1740 interest_3\NN\5682570 in_4\IN\13603305 identifying_5\VBG\699815 the_6\DT\1740 molecular_7\JJ\1740 mechanisms_8\NNS\13446390 that_9\WDT\1740 relate_10\VBP\628491 early-life_11\JJ\1740 <e1>ias</e1>_12\NN\1740 exposure_13\NN\5042871 to_14\TO\1740 the_15\DT\1740 development_16\NN\248977 of_17\IN\1740 these_18\DT\1740 latent_19\JJ\1740 diseases_20\NNS\14061805 ,_21\,\1740 particularly_22\RB\1740 in_23\IN\13603305 relationship_24\NN\31921 to_25\TO\1740 <e2>cancer</e2>_26\NN\14239425 ._27\.\1740
D001152_D009369 CID objectives_0\NNS\5980875 :_1\:\1740 this_2\DT\1740 work_3\NN\407535 summarizes_4\VBZ\958334 research_5\NN\633864 on_6\IN\1740 the_7\DT\1740 molecular_8\JJ\1740 mechanisms_9\NNS\13446390 that_10\WDT\1740 underlie_11\VBP\2604760 the_12\DT\1740 increased_13\VBN\169651 risk_14\NN\14541044 of_15\IN\1740 <e2>cancer</e2>_16\NN\14239425 development_17\NN\248977 in_18\IN\13603305 adulthood_19\NN\15144371 that_20\WDT\1740 is_21\VBZ\836236 associated_22\VBN\628491 with_23\IN\1740 early-life_24\JJ\1740 <e1>ias</e1>_25\NN\1740 exposure_26\NN\5042871 ._27\.\1740
D001152_D009369 CID discussion_0\NN\6252138 :_1\:\1740 epigenetic_2\JJ\1740 reprogramming_3\VBG\1740 that_4\WDT\1740 imparts_5\VBZ\952524 functional_6\JJ\1740 changes_7\NNS\7283608 in_8\IN\13603305 gene_9\NN\8459252 expression_10\NN\4679549 ,_11\,\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 <e2>cancer</e2>_15\NN\14239425 stem_16\NN\6290637 cells_17\NNS\3080309 ,_18\,\1740 and_19\CC\1740 immunomodulation_20\NN\1740 are_21\VBP\836236 plausible_22\JJ\1740 underlying_23\VBG\2604760 mechanisms_24\NNS\13446390 by_25\IN\1740 which_26\WDT\1740 early-life_27\JJ\1740 <e1>ias</e1>_28\NN\1740 exposure_29\NN\5042871 elicits_30\VBZ\1617192 latent_31\JJ\1740 carcinogenic_32\JJ\1740 effects_33\NNS\13245626 ._34\.\1740
D001152_D009369 CID conclusions_0\NNS\5837957 :_1\:\1740 evidence_2\NN\5816287 is_3\VBZ\836236 mounting_4\VBG\1296462 that_5\WDT\1740 relates_6\VBZ\628491 early-life_7\JJ\1740 <e1>ias</e1>_8\NN\1740 exposure_9\NN\5042871 and_10\CC\1740 <e2>cancer</e2>_11\NN\14239425 development_12\NN\248977 later_13\RBR\1740 in_14\IN\13603305 life_15\NN\13954253 ._16\.\1740
1359137
D014150_D006966 CID <e1>neuroleptic-associated</e1>_0\JJ\1740 <e2>hyperprolactinemia</e2>_1\NN\1740 ._2\.\1740
D014150_D006966 CID six_0\CD\13741022 stable_1\JJ\1740 psychiatric_2\JJ\1740 outpatients_3\NNS\10405694 with_4\IN\1740 <e2>hyperprolactinemia</e2>_5\NN\1740 and_6\CC\1740 amenorrhea/oligomenorrhea_7\NN\1740 associated_8\VBN\628491 with_9\IN\1740 their_10\PRP$\1740 <e1>neuroleptic_11\JJ\1740 medications</e1>_12\NNS\3247620 were_13\VBD\836236 treated_14\VBN\2376958 with_15\IN\1740 bromocriptine_16\NN\1740 ._17\.\1740
D014150_D006966 CID this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 bromocriptine_3\NN\1740 should_4\MD\1740 be_5\VB\836236 further_6\RB\1740 evaluated_7\VBN\670261 as_8\IN\14622893 potential_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 <e1>neuroleptic-associated</e1>_12\JJ\1740 <e2>hyperprolactinemia</e2>_13\NN\1740 and_14\CC\1740 amenorrhea/galactorrhea_15\NN\1740 ._16\.\1740
D014150_D000568 CID six_0\CD\13741022 stable_1\JJ\1740 psychiatric_2\JJ\1740 outpatients_3\NNS\10405694 with_4\IN\1740 hyperprolactinemia_5\NN\1740 and_6\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>_7\NN\1740 associated_8\VBN\628491 with_9\IN\1740 their_10\PRP$\1740 <e1>neuroleptic_11\JJ\1740 medications</e1>_12\NNS\3247620 were_13\VBD\836236 treated_14\VBN\2376958 with_15\IN\1740 bromocriptine_16\NN\1740 ._17\.\1740
D014150_D000568 CID this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 bromocriptine_3\NN\1740 should_4\MD\1740 be_5\VB\836236 further_6\RB\1740 evaluated_7\VBN\670261 as_8\IN\14622893 potential_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 <e1>neuroleptic-associated</e1>_12\JJ\1740 hyperprolactinemia_13\NN\1740 and_14\CC\1740 <e2>amenorrhea/galactorrhea</e2>_15\NN\1740 ._16\.\1740
D014150_D009839 CID six_0\CD\13741022 stable_1\JJ\1740 psychiatric_2\JJ\1740 outpatients_3\NNS\10405694 with_4\IN\1740 hyperprolactinemia_5\NN\1740 and_6\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>_7\NN\1740 associated_8\VBN\628491 with_9\IN\1740 their_10\PRP$\1740 <e1>neuroleptic_11\JJ\1740 medications</e1>_12\NNS\3247620 were_13\VBD\836236 treated_14\VBN\2376958 with_15\IN\1740 bromocriptine_16\NN\1740 ._17\.\1740
D001971_D006966 NONE six_0\CD\13741022 stable_1\JJ\1740 psychiatric_2\JJ\1740 outpatients_3\NNS\10405694 with_4\IN\1740 <e2>hyperprolactinemia</e2>_5\NN\1740 and_6\CC\1740 amenorrhea/oligomenorrhea_7\NN\1740 associated_8\VBN\628491 with_9\IN\1740 their_10\PRP$\1740 neuroleptic_11\JJ\1740 medications_12\NNS\3247620 were_13\VBD\836236 treated_14\VBN\2376958 with_15\IN\1740 <e1>bromocriptine</e1>_16\NN\1740 ._17\.\1740
D001971_D006966 NONE this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 <e1>bromocriptine</e1>_3\NN\1740 should_4\MD\1740 be_5\VB\836236 further_6\RB\1740 evaluated_7\VBN\670261 as_8\IN\14622893 potential_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 neuroleptic-associated_12\JJ\1740 <e2>hyperprolactinemia</e2>_13\NN\1740 and_14\CC\1740 amenorrhea/galactorrhea_15\NN\1740 ._16\.\1740
D001971_D000568 NONE six_0\CD\13741022 stable_1\JJ\1740 psychiatric_2\JJ\1740 outpatients_3\NNS\10405694 with_4\IN\1740 hyperprolactinemia_5\NN\1740 and_6\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>_7\NN\1740 associated_8\VBN\628491 with_9\IN\1740 their_10\PRP$\1740 neuroleptic_11\JJ\1740 medications_12\NNS\3247620 were_13\VBD\836236 treated_14\VBN\2376958 with_15\IN\1740 <e1>bromocriptine</e1>_16\NN\1740 ._17\.\1740
D001971_D000568 NONE this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 <e1>bromocriptine</e1>_3\NN\1740 should_4\MD\1740 be_5\VB\836236 further_6\RB\1740 evaluated_7\VBN\670261 as_8\IN\14622893 potential_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 neuroleptic-associated_12\JJ\1740 hyperprolactinemia_13\NN\1740 and_14\CC\1740 <e2>amenorrhea/galactorrhea</e2>_15\NN\1740 ._16\.\1740
D001971_D009839 NONE six_0\CD\13741022 stable_1\JJ\1740 psychiatric_2\JJ\1740 outpatients_3\NNS\10405694 with_4\IN\1740 hyperprolactinemia_5\NN\1740 and_6\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>_7\NN\1740 associated_8\VBN\628491 with_9\IN\1740 their_10\PRP$\1740 neuroleptic_11\JJ\1740 medications_12\NNS\3247620 were_13\VBD\836236 treated_14\VBN\2376958 with_15\IN\1740 <e1>bromocriptine</e1>_16\NN\1740 ._17\.\1740
D001971_D011618 CID one_0\CD\13741022 woman_1\NN\9605289 ,_2\,\1740 however_3\RB\1740 ,_4\,\1740 developed_5\VBD\1753788 worsened_6\VBN\146138 <e2>psychiatric_7\JJ\1740 symptoms</e2>_8\NNS\5823932 while_9\IN\15122231 taking_10\VBG\2367363 <e1>bromocriptine</e1>_11\NN\1740 ,_12\,\1740 and_13\CC\1740 it_14\PRP\6125041 was_15\VBD\836236 discontinued_16\VBN\2609764 ._17\.\1740
D001971_D005687 NONE this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 <e1>bromocriptine</e1>_3\NN\1740 should_4\MD\1740 be_5\VB\836236 further_6\RB\1740 evaluated_7\VBN\670261 as_8\IN\14622893 potential_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 neuroleptic-associated_12\JJ\1740 hyperprolactinemia_13\NN\1740 and_14\CC\1740 <e2>amenorrhea/galactorrhea</e2>_15\NN\1740 ._16\.\1740
D014150_D005687 NONE this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 bromocriptine_3\NN\1740 should_4\MD\1740 be_5\VB\836236 further_6\RB\1740 evaluated_7\VBN\670261 as_8\IN\14622893 potential_9\JJ\1740 therapy_10\NN\657604 for_11\IN\1740 <e1>neuroleptic-associated</e1>_12\JJ\1740 hyperprolactinemia_13\NN\1740 and_14\CC\1740 <e2>amenorrhea/galactorrhea</e2>_15\NN\1740 ._16\.\1740
24067251
C418563_D007674 NONE an_0\DT\6697703 investigation_1\NN\5797597 of_2\IN\1740 the_3\DT\1740 pattern_4\NN\5726345 of_5\IN\1740 <e2>kidney_6\NN\5333259 injury</e2>_7\NN\14052046 in_8\IN\13603305 hiv-positive_9\JJ\1740 persons_10\NNS\7347 exposed_11\VBN\2110927 to_12\TO\1740 <e1>tenofovir_13\NN\1740 disoproxil_14\NN\1740 fumarate</e1>_15\NN\1740 :_16\:\1740 an_17\DT\6697703 examination_18\NN\633864 of_19\IN\1740 a_20\DT\13649268 large_21\JJ\1740 population_22\NN\7942152 database_23\NN\6634376 (_24\-LRB-\1740 mhra_25\NN\1740 database_26\NN\6634376 )_27\-RRB-\1740 ._28\.\1740
C418563_D007674 NONE of_0\IN\1740 the_1\DT\1740 407_2\CD\1740 yellow_3\NNP\4959672 card_4\NNP\14974264 records_5\NNS\6643408 analysed_6\VBN\78760 ,_7\,\1740 106_8\CD\1740 satisfied_9\JJ\1740 criteria_10\NNS\13577171 for_11\IN\1740 <e1>tdf-related</e1>_12\JJ\1740 <e2>kidney_13\NN\5333259 disease</e2>_14\NN\14061805 ,_15\,\1740 of_16\IN\1740 which_17\WDT\1740 53_18\CD\1740 (_19\-LRB-\1740 50_20\CD\13745420 %_21\NN\1740 )_22\-RRB-\1740 had_23\VBD\2108377 features_24\NNS\5849040 of_25\IN\1740 kidney_26\NN\5333259 tubular_27\JJ\1740 dysfunction_28\NN\14204950 ,_29\,\1740 35_30\CD\1740 (_31\-LRB-\1740 33_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 were_35\VBD\836236 found_36\VBN\2426171 to_37\TO\1740 have_38\VB\2108377 features_39\NNS\5849040 of_40\IN\1740 glomerular_41\JJ\1740 dysfunction_42\NN\14204950 and_43\CC\1740 18_44\CD\13745420 (_45\-LRB-\1740 17_46\CD\13745420 %_47\NN\1740 )_48\-RRB-\1740 had_49\VBD\2108377 fanconi_50\NN\1740 syndrome_51\NN\5870365 ._52\.\1740
C418563_D007674 NONE of_0\IN\1740 the_1\DT\1740 407_2\CD\1740 yellow_3\NNP\4959672 card_4\NNP\14974264 records_5\NNS\6643408 analysed_6\VBN\78760 ,_7\,\1740 106_8\CD\1740 satisfied_9\JJ\1740 criteria_10\NNS\13577171 for_11\IN\1740 <e1>tdf-related</e1>_12\JJ\1740 kidney_13\NN\5333259 disease_14\NN\14061805 ,_15\,\1740 of_16\IN\1740 which_17\WDT\1740 53_18\CD\1740 (_19\-LRB-\1740 50_20\CD\13745420 %_21\NN\1740 )_22\-RRB-\1740 had_23\VBD\2108377 features_24\NNS\5849040 of_25\IN\1740 <e2>kidney_26\NN\5333259 tubular_27\JJ\1740 dysfunction</e2>_28\NN\14204950 ,_29\,\1740 35_30\CD\1740 (_31\-LRB-\1740 33_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 were_35\VBD\836236 found_36\VBN\2426171 to_37\TO\1740 have_38\VB\2108377 features_39\NNS\5849040 of_40\IN\1740 glomerular_41\JJ\1740 dysfunction_42\NN\14204950 and_43\CC\1740 18_44\CD\13745420 (_45\-LRB-\1740 17_46\CD\13745420 %_47\NN\1740 )_48\-RRB-\1740 had_49\VBD\2108377 fanconi_50\NN\1740 syndrome_51\NN\5870365 ._52\.\1740
C418563_D007674 NONE of_0\IN\1740 the_1\DT\1740 407_2\CD\1740 yellow_3\NNP\4959672 card_4\NNP\14974264 records_5\NNS\6643408 analysed_6\VBN\78760 ,_7\,\1740 106_8\CD\1740 satisfied_9\JJ\1740 criteria_10\NNS\13577171 for_11\IN\1740 <e1>tdf-related</e1>_12\JJ\1740 kidney_13\NN\5333259 disease_14\NN\14061805 ,_15\,\1740 of_16\IN\1740 which_17\WDT\1740 53_18\CD\1740 (_19\-LRB-\1740 50_20\CD\13745420 %_21\NN\1740 )_22\-RRB-\1740 had_23\VBD\2108377 features_24\NNS\5849040 of_25\IN\1740 kidney_26\NN\5333259 tubular_27\JJ\1740 dysfunction_28\NN\14204950 ,_29\,\1740 35_30\CD\1740 (_31\-LRB-\1740 33_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 were_35\VBD\836236 found_36\VBN\2426171 to_37\TO\1740 have_38\VB\2108377 features_39\NNS\5849040 of_40\IN\1740 <e2>glomerular_41\JJ\1740 dysfunction</e2>_42\NN\14204950 and_43\CC\1740 18_44\CD\13745420 (_45\-LRB-\1740 17_46\CD\13745420 %_47\NN\1740 )_48\-RRB-\1740 had_49\VBD\2108377 fanconi_50\NN\1740 syndrome_51\NN\5870365 ._52\.\1740
C418563_D005198 CID of_0\IN\1740 the_1\DT\1740 407_2\CD\1740 yellow_3\NNP\4959672 card_4\NNP\14974264 records_5\NNS\6643408 analysed_6\VBN\78760 ,_7\,\1740 106_8\CD\1740 satisfied_9\JJ\1740 criteria_10\NNS\13577171 for_11\IN\1740 <e1>tdf-related</e1>_12\JJ\1740 kidney_13\NN\5333259 disease_14\NN\14061805 ,_15\,\1740 of_16\IN\1740 which_17\WDT\1740 53_18\CD\1740 (_19\-LRB-\1740 50_20\CD\13745420 %_21\NN\1740 )_22\-RRB-\1740 had_23\VBD\2108377 features_24\NNS\5849040 of_25\IN\1740 kidney_26\NN\5333259 tubular_27\JJ\1740 dysfunction_28\NN\14204950 ,_29\,\1740 35_30\CD\1740 (_31\-LRB-\1740 33_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 were_35\VBD\836236 found_36\VBN\2426171 to_37\TO\1740 have_38\VB\2108377 features_39\NNS\5849040 of_40\IN\1740 glomerular_41\JJ\1740 dysfunction_42\NN\14204950 and_43\CC\1740 18_44\CD\13745420 (_45\-LRB-\1740 17_46\CD\13745420 %_47\NN\1740 )_48\-RRB-\1740 had_49\VBD\2108377 <e2>fanconi_50\NN\1740 syndrome</e2>_51\NN\5870365 ._52\.\1740
C418563_D005198 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 hospitalisation_3\NN\657604 for_4\IN\1740 <e1>tdf</e1>_5\NN\1740 kidney_6\NN\5333259 adverse_7\JJ\1740 effects_8\NNS\13245626 was_9\VBD\836236 high_10\JJ\1740 ,_11\,\1740 particularly_12\RB\1740 amongst_13\IN\1740 patients_14\NNS\9898892 with_15\IN\1740 features_16\NNS\5849040 of_17\IN\1740 <e2>fanconi_18\NNP\1740 syndrome</e2>_19\NN\5870365 ._20\.\1740
8659767
D002045_D001145 NONE since_0\IN\1740 <e1>bupivacaine</e1>_1\NN\1740 and_2\CC\1740 epinephrine_3\NN\14807929 may_4\MD\15209706 both_5\CC\1740 precipitate_6\JJ\1740 <e2>dysrhythmias</e2>_7\NNS\1740 ,_8\,\1740 circulating_9\VBG\1835496 bupivacaine_10\NN\1740 during_11\IN\1740 regional_12\JJ\1740 anesthesia_13\NN\14034177 could_14\MD\1740 potentiate_15\VB\229605 dysrhythmogenic_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 epinephrine_19\NN\14807929 ._20\.\1740
D002045_D001145 NONE since_0\IN\1740 bupivacaine_1\NN\1740 and_2\CC\1740 epinephrine_3\NN\14807929 may_4\MD\15209706 both_5\CC\1740 precipitate_6\JJ\1740 <e2>dysrhythmias</e2>_7\NNS\1740 ,_8\,\1740 circulating_9\VBG\1835496 <e1>bupivacaine</e1>_10\NN\1740 during_11\IN\1740 regional_12\JJ\1740 anesthesia_13\NN\14034177 could_14\MD\1740 potentiate_15\VB\229605 dysrhythmogenic_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 epinephrine_19\NN\14807929 ._20\.\1740
D002045_D001145 NONE <e1>bupivacaine</e1>_0\NN\1740 antagonizes_1\VBZ\1787955 epinephrine_2\NN\14807929 dysrhythmogenicity_3\NN\1740 in_4\IN\13603305 conscious_5\JJ\1740 dogs_6\NNS\2083346 susceptible_7\JJ\1740 to_8\TO\1740 vt_9\NN\1740 and_10\CC\1740 in_11\IN\13603305 anesthetized_12\VBN\84738 dogs_13\NNS\2083346 with_14\IN\1740 spontaneous_15\JJ\1740 postinfarct_16\NN\1740 <e2>dysrhythmias</e2>_17\NNS\1740 ._18\.\1740
D004837_D001145 NONE since_0\IN\1740 bupivacaine_1\NN\1740 and_2\CC\1740 <e1>epinephrine</e1>_3\NN\14807929 may_4\MD\15209706 both_5\CC\1740 precipitate_6\JJ\1740 <e2>dysrhythmias</e2>_7\NNS\1740 ,_8\,\1740 circulating_9\VBG\1835496 bupivacaine_10\NN\1740 during_11\IN\1740 regional_12\JJ\1740 anesthesia_13\NN\14034177 could_14\MD\1740 potentiate_15\VB\229605 dysrhythmogenic_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 epinephrine_19\NN\14807929 ._20\.\1740
D004837_D001145 NONE since_0\IN\1740 bupivacaine_1\NN\1740 and_2\CC\1740 epinephrine_3\NN\14807929 may_4\MD\15209706 both_5\CC\1740 precipitate_6\JJ\1740 <e2>dysrhythmias</e2>_7\NNS\1740 ,_8\,\1740 circulating_9\VBG\1835496 bupivacaine_10\NN\1740 during_11\IN\1740 regional_12\JJ\1740 anesthesia_13\NN\14034177 could_14\MD\1740 potentiate_15\VB\229605 dysrhythmogenic_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 <e1>epinephrine</e1>_19\NN\14807929 ._20\.\1740
D004837_D001145 NONE bupivacaine_0\NN\1740 antagonizes_1\VBZ\1787955 <e1>epinephrine</e1>_2\NN\14807929 dysrhythmogenicity_3\NN\1740 in_4\IN\13603305 conscious_5\JJ\1740 dogs_6\NNS\2083346 susceptible_7\JJ\1740 to_8\TO\1740 vt_9\NN\1740 and_10\CC\1740 in_11\IN\13603305 anesthetized_12\VBN\84738 dogs_13\NNS\2083346 with_14\IN\1740 spontaneous_15\JJ\1740 postinfarct_16\NN\1740 <e2>dysrhythmias</e2>_17\NNS\1740 ._18\.\1740
D002045_D009203 NONE we_0\PRP\1740 therefore_1\RB\1740 examined_2\VBD\789138 whether_3\IN\1740 <e1>bupivacaine</e1>_4\NN\1740 alters_5\VBZ\126264 the_6\DT\1740 dysrhythmogenicity_7\NN\1740 of_8\IN\1740 subsequent_9\JJ\1740 administration_10\NN\1133281 of_11\IN\1740 epinephrine_12\NN\14807929 in_13\IN\13603305 conscious_14\JJ\1740 ,_15\,\1740 healthy_16\JJ\1740 dogs_17\NNS\2083346 and_18\CC\1740 in_19\IN\13603305 anesthetized_20\VBN\84738 dogs_21\NNS\2083346 with_22\IN\1740 <e2>myocardial_23\JJ\1740 infarction</e2>_24\NN\14204950 ._25\.\1740
D004837_D009203 NONE we_0\PRP\1740 therefore_1\RB\1740 examined_2\VBD\789138 whether_3\IN\1740 bupivacaine_4\NN\1740 alters_5\VBZ\126264 the_6\DT\1740 dysrhythmogenicity_7\NN\1740 of_8\IN\1740 subsequent_9\JJ\1740 administration_10\NN\1133281 of_11\IN\1740 <e1>epinephrine</e1>_12\NN\14807929 in_13\IN\13603305 conscious_14\JJ\1740 ,_15\,\1740 healthy_16\JJ\1740 dogs_17\NNS\2083346 and_18\CC\1740 in_19\IN\13603305 anesthetized_20\VBN\84738 dogs_21\NNS\2083346 with_22\IN\1740 <e2>myocardial_23\JJ\1740 infarction</e2>_24\NN\14204950 ._25\.\1740
D004837_D009203 NONE one_0\CD\13741022 day_1\NN\15154774 after_2\IN\1740 experimental_3\JJ\1740 <e2>myocardial_4\JJ\1740 infarction</e2>_5\NN\14204950 ,_6\,\1740 six_7\CD\13741022 additional_8\JJ\1740 halothane-anesthetized_9\JJ\1740 dogs_10\NNS\2083346 received_11\VBD\2210855 4_12\CD\13741022 micrograms.kg-1.min-1_13\NN\1740 <e1>epinephrine</e1>_14\NN\14807929 until_15\IN\1740 vt_16\NN\1740 appeared_17\VBD\2604760 ._18\.\1740
D006221_D009203 NONE one_0\CD\13741022 day_1\NN\15154774 after_2\IN\1740 experimental_3\JJ\1740 <e2>myocardial_4\JJ\1740 infarction</e2>_5\NN\14204950 ,_6\,\1740 six_7\CD\13741022 additional_8\JJ\1740 <e1>halothane-anesthetized</e1>_9\JJ\1740 dogs_10\NNS\2083346 received_11\VBD\2210855 4_12\CD\13741022 micrograms.kg-1.min-1_13\NN\1740 epinephrine_14\NN\14807929 until_15\IN\1740 vt_16\NN\1740 appeared_17\VBD\2604760 ._18\.\1740
D006221_D017180 NONE one_0\CD\13741022 day_1\NN\15154774 after_2\IN\1740 experimental_3\JJ\1740 myocardial_4\JJ\1740 infarction_5\NN\14204950 ,_6\,\1740 six_7\CD\13741022 additional_8\JJ\1740 <e1>halothane-anesthetized</e1>_9\JJ\1740 dogs_10\NNS\2083346 received_11\VBD\2210855 4_12\CD\13741022 micrograms.kg-1.min-1_13\NN\1740 epinephrine_14\NN\14807929 until_15\IN\1740 <e2>vt</e2>_16\NN\1740 appeared_17\VBD\2604760 ._18\.\1740
D004837_D017180 CID one_0\CD\13741022 day_1\NN\15154774 after_2\IN\1740 experimental_3\JJ\1740 myocardial_4\JJ\1740 infarction_5\NN\14204950 ,_6\,\1740 six_7\CD\13741022 additional_8\JJ\1740 halothane-anesthetized_9\JJ\1740 dogs_10\NNS\2083346 received_11\VBD\2210855 4_12\CD\13741022 micrograms.kg-1.min-1_13\NN\1740 <e1>epinephrine</e1>_14\NN\14807929 until_15\IN\1740 <e2>vt</e2>_16\NN\1740 appeared_17\VBD\2604760 ._18\.\1740
D004837_D017180 CID bupivacaine_0\NN\1740 antagonizes_1\VBZ\1787955 <e1>epinephrine</e1>_2\NN\14807929 dysrhythmogenicity_3\NN\1740 in_4\IN\13603305 conscious_5\JJ\1740 dogs_6\NNS\2083346 susceptible_7\JJ\1740 to_8\TO\1740 <e2>vt</e2>_9\NN\1740 and_10\CC\1740 in_11\IN\13603305 anesthetized_12\VBN\84738 dogs_13\NNS\2083346 with_14\IN\1740 spontaneous_15\JJ\1740 postinfarct_16\NN\1740 dysrhythmias_17\NNS\1740 ._18\.\1740
D002045_D017180 NONE <e1>bupivacaine</e1>_0\NN\1740 antagonizes_1\VBZ\1787955 epinephrine_2\NN\14807929 dysrhythmogenicity_3\NN\1740 in_4\IN\13603305 conscious_5\JJ\1740 dogs_6\NNS\2083346 susceptible_7\JJ\1740 to_8\TO\1740 <e2>vt</e2>_9\NN\1740 and_10\CC\1740 in_11\IN\13603305 anesthetized_12\VBN\84738 dogs_13\NNS\2083346 with_14\IN\1740 spontaneous_15\JJ\1740 postinfarct_16\NN\1740 dysrhythmias_17\NNS\1740 ._18\.\1740
12678199
D000638_D016171 CID <e1>amiodarone-induced</e1>_0\JJ\1740 <e2>torsade_1\NN\1740 de_2\FW\1740 pointes</e2>_3\NNS\1740 during_4\IN\1740 bladder_5\NN\5515670 irrigation_6\NN\1057200 :_7\:\1740 an_8\DT\6697703 unusual_9\JJ\1740 presentation_10\NN\1027379 --_11\:\1740 a_12\DT\13649268 case_13\NN\7283608 report_14\NN\6470073 ._15\.\1740
D000638_D016171 CID the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 early_6\JJ\1740 (_7\-LRB-\1740 within_8\IN\1740 4_9\CD\13741022 days_10\NNS\15140892 )_11\-RRB-\1740 development_12\NN\248977 of_13\IN\1740 <e2>torsade_14\NN\1740 de_15\IN\1740 pointes</e2>_16\NNS\1740 (_17\-LRB-\1740 tdp_18\NN\1740 )_19\-RRB-\1740 associated_20\VBN\628491 with_21\IN\1740 oral_22\JJ\1740 <e1>amiodarone</e1>_23\NN\2715941 therapy_24\NN\657604 ._25\.\1740
D000638_D016171 CID the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 early_6\JJ\1740 (_7\-LRB-\1740 within_8\IN\1740 4_9\CD\13741022 days_10\NNS\15140892 )_11\-RRB-\1740 development_12\NN\248977 of_13\IN\1740 torsade_14\NN\1740 de_15\IN\1740 pointes_16\NNS\1740 (_17\-LRB-\1740 <e2>tdp</e2>_18\NN\1740 )_19\-RRB-\1740 associated_20\VBN\628491 with_21\IN\1740 oral_22\JJ\1740 <e1>amiodarone</e1>_23\NN\2715941 therapy_24\NN\657604 ._25\.\1740
D000638_D016171 CID transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 <e2>tdp.</e2>_12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 bradycardia_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 tdp._21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 <e1>amiodarone</e1>_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 amiodarone-induced_46\JJ\1740 proarrhythmia_47\NN\1740 ._48\.\1740
D000638_D016171 CID transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 tdp._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 bradycardia_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 <e2>tdp.</e2>_21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 <e1>amiodarone</e1>_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 amiodarone-induced_46\JJ\1740 proarrhythmia_47\NN\1740 ._48\.\1740
D000638_D016171 CID transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 <e2>tdp.</e2>_12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 bradycardia_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 tdp._21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 amiodarone_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 <e1>amiodarone-induced</e1>_46\JJ\1740 proarrhythmia_47\NN\1740 ._48\.\1740
D000638_D016171 CID transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 tdp._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 bradycardia_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 <e2>tdp.</e2>_21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 amiodarone_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 <e1>amiodarone-induced</e1>_46\JJ\1740 proarrhythmia_47\NN\1740 ._48\.\1740
D000638_D016171 CID in_0\IN\13603305 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 therapy_5\NN\657604 ,_6\,\1740 a_7\DT\13649268 second_8\JJ\1740 bladder_9\NN\5515670 irrigation_10\NN\1057200 did_11\VBD\1640855 not_12\RB\1740 induce_13\VB\1627355 <e2>tdp</e2>_14\NN\1740 despite_15\IN\7501545 hypokalemia_16\NN\14299637 and_17\CC\1740 hypomagnesemia_18\NN\1740 ._19\.\1740
D004077_D016171 NONE consistent_0\JJ\1740 with_1\IN\1740 other_2\JJ\1740 reports_3\NNS\6470073 this_4\DT\1740 case_5\NN\7283608 of_6\IN\1740 <e2>tdp</e2>_7\NN\1740 occurred_8\VBD\2623529 in_9\IN\13603305 the_10\DT\1740 context_11\NN\6284777 of_12\IN\1740 multiple_13\JJ\1740 exacerbating_14\NN\1740 factors_15\NNS\7326557 including_16\VBG\690614 hypokalemia_17\NN\14299637 and_18\CC\1740 <e1>digoxin</e1>_19\NN\15060131 excess_20\JJ\1740 ._21\.\1740
D004077_D007008 NONE consistent_0\JJ\1740 with_1\IN\1740 other_2\JJ\1740 reports_3\NNS\6470073 this_4\DT\1740 case_5\NN\7283608 of_6\IN\1740 tdp_7\NN\1740 occurred_8\VBD\2623529 in_9\IN\13603305 the_10\DT\1740 context_11\NN\6284777 of_12\IN\1740 multiple_13\JJ\1740 exacerbating_14\NN\1740 factors_15\NNS\7326557 including_16\VBG\690614 <e2>hypokalemia</e2>_17\NN\14299637 and_18\CC\1740 <e1>digoxin</e1>_19\NN\15060131 excess_20\JJ\1740 ._21\.\1740
D000638_D001919 NONE transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 tdp._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 <e2>bradycardia</e2>_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 tdp._21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 <e1>amiodarone</e1>_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 amiodarone-induced_46\JJ\1740 proarrhythmia_47\NN\1740 ._48\.\1740
D000638_D001919 NONE transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 tdp._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 <e2>bradycardia</e2>_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 tdp._21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 amiodarone_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 <e1>amiodarone-induced</e1>_46\JJ\1740 proarrhythmia_47\NN\1740 ._48\.\1740
D000638_-1 NONE transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 tdp._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 bradycardia_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 tdp._21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 <e1>amiodarone</e1>_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 amiodarone-induced_46\JJ\1740 <e2>proarrhythmia</e2>_47\NN\1740 ._48\.\1740
D000638_-1 NONE transient_0\JJ\1740 prolongation_1\NN\1017987 of_2\IN\1740 the_3\DT\1740 qt_4\NNP\1740 during_5\IN\1740 bladder_6\NN\5515670 irrigation_7\NN\1057200 prompted_8\VBD\1645601 the_9\DT\1740 episode_10\NN\7283608 of_11\IN\1740 tdp._12\NN\1740 it_13\PRP\6125041 is_14\VBZ\836236 well_15\RB\1740 known_16\VBN\2110220 that_17\IN\1740 bradycardia_18\NN\14110674 exacerbates_19\NNS\1740 acquired_20\VBD\109660 tdp._21\NN\1740 the_22\DT\1740 authors_23\NNS\9610660 speculate_24\VBP\719734 that_25\IN\1740 the_26\DT\1740 increased_27\VBN\169651 vagal_28\JJ\1740 tone_29\NN\7071483 during_30\IN\1740 bladder_31\NN\5515670 irrigation_32\NN\1057200 ,_33\,\1740 a_34\DT\13649268 vagal_35\JJ\1740 maneuver_36\NN\955060 ,_37\,\1740 in_38\IN\13603305 the_39\DT\1740 context_40\NN\6284777 of_41\IN\1740 amiodarone_42\NN\2715941 therapy_43\NN\657604 resulted_44\VBD\2633881 in_45\IN\13603305 <e1>amiodarone-induced</e1>_46\JJ\1740 <e2>proarrhythmia</e2>_47\NN\1740 ._48\.\1740
D000638_D007008 NONE in_0\IN\13603305 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 therapy_5\NN\657604 ,_6\,\1740 a_7\DT\13649268 second_8\JJ\1740 bladder_9\NN\5515670 irrigation_10\NN\1057200 did_11\VBD\1640855 not_12\RB\1740 induce_13\VB\1627355 tdp_14\NN\1740 despite_15\IN\7501545 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 hypomagnesemia_18\NN\1740 ._19\.\1740
D000638_C537153 NONE in_0\IN\13603305 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 therapy_5\NN\657604 ,_6\,\1740 a_7\DT\13649268 second_8\JJ\1740 bladder_9\NN\5515670 irrigation_10\NN\1057200 did_11\VBD\1640855 not_12\RB\1740 induce_13\VB\1627355 tdp_14\NN\1740 despite_15\IN\7501545 hypokalemia_16\NN\14299637 and_17\CC\1740 <e2>hypomagnesemia</e2>_18\NN\1740 ._19\.\1740
20828385
C401859_D020522 NONE cytostatic_0\JJ\1740 and_1\CC\1740 anti-angiogenic_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>temsirolimus</e1>_5\NN\1740 in_6\IN\13603305 refractory_7\JJ\1740 <e2>mantle_8\NN\6806469 cell_9\NN\3080309 lymphoma</e2>_10\NN\14239918 ._11\.\1740
C401859_D020522 NONE however_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 38_3\CD\1740 %_4\NN\1740 remission_5\NN\7368256 rate_6\NN\13815152 has_7\VBZ\2108377 been_8\VBN\836236 recently_9\RB\1740 reported_10\VBN\831651 in_11\IN\13603305 refractory_12\JJ\1740 <e2>mcl</e2>_13\NN\1740 treated_14\VBN\2376958 with_15\IN\1740 <e1>temsirolimus</e1>_16\NN\1740 ,_17\,\1740 a_18\DT\13649268 mtor_19\NN\1740 inhibitor_20\NN\20090 ._21\.\1740
C401859_D020522 NONE here_0\RB\1740 we_1\PRP\1740 had_2\VBD\2108377 the_3\DT\1740 opportunity_4\NN\14481929 to_5\TO\1740 study_6\VB\630380 a_7\DT\13649268 case_8\NN\7283608 of_9\IN\1740 refractory_10\JJ\1740 <e2>mcl</e2>_11\NN\1740 who_12\WP\8299493 had_13\VBD\2108377 tumor_14\NN\14234074 regression_15\NN\14501726 two_16\CD\13741022 months_17\NNS\15113229 after_18\IN\1740 <e1>temsirolimus</e1>_19\NN\1740 treatment_20\NN\654885 ,_21\,\1740 and_22\CC\1740 a_23\DT\13649268 progression-free_24\JJ\1740 survival_25\NN\13961642 of_26\IN\1740 10_27\CD\13745420 months_28\NNS\15113229 ._29\.\1740
C401859_D020522 NONE this_0\DT\1740 dual_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>temsirolimus</e1>_4\NN\1740 on_5\IN\1740 tumor_6\NN\14234074 tissue_7\NN\5220461 could_8\MD\1740 contribute_9\VB\126264 to_10\TO\1740 its_11\PRP$\6125041 recently_12\RB\1740 reported_13\VBN\831651 efficiency_14\NN\13819207 in_15\IN\13603305 refractory_16\JJ\1740 <e2>mcl</e2>_17\NN\1740 resistant_18\JJ\1740 to_19\TO\1740 conventional_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
C401859_D009369 NONE here_0\RB\1740 we_1\PRP\1740 had_2\VBD\2108377 the_3\DT\1740 opportunity_4\NN\14481929 to_5\TO\1740 study_6\VB\630380 a_7\DT\13649268 case_8\NN\7283608 of_9\IN\1740 refractory_10\JJ\1740 mcl_11\NN\1740 who_12\WP\8299493 had_13\VBD\2108377 <e2>tumor</e2>_14\NN\14234074 regression_15\NN\14501726 two_16\CD\13741022 months_17\NNS\15113229 after_18\IN\1740 <e1>temsirolimus</e1>_19\NN\1740 treatment_20\NN\654885 ,_21\,\1740 and_22\CC\1740 a_23\DT\13649268 progression-free_24\JJ\1740 survival_25\NN\13961642 of_26\IN\1740 10_27\CD\13745420 months_28\NNS\15113229 ._29\.\1740
C401859_D009369 NONE comparison_0\NN\635850 of_1\IN\1740 the_2\DT\1740 two_3\CD\13741022 biopsies_4\NNS\5739043 showed_5\VBD\2137132 that_6\IN\1740 <e1>temsirolimus</e1>_7\NN\1740 inhibited_8\VBD\2510337 <e2>tumor</e2>_9\NN\14234074 cell_10\NN\3080309 proliferation_11\NN\13489037 through_12\IN\1740 cell_13\NN\3080309 cycle_14\NN\15269513 arrest_15\NN\88481 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 not_19\RB\1740 induce_20\VB\1627355 any_21\DT\1740 change_22\NN\7283608 in_23\IN\13603305 the_24\DT\1740 number_25\NN\5107765 of_26\IN\1740 apoptotic_27\JJ\1740 tumor_28\NN\14234074 cells_29\NNS\3080309 ._30\.\1740
C401859_D009369 NONE comparison_0\NN\635850 of_1\IN\1740 the_2\DT\1740 two_3\CD\13741022 biopsies_4\NNS\5739043 showed_5\VBD\2137132 that_6\IN\1740 <e1>temsirolimus</e1>_7\NN\1740 inhibited_8\VBD\2510337 tumor_9\NN\14234074 cell_10\NN\3080309 proliferation_11\NN\13489037 through_12\IN\1740 cell_13\NN\3080309 cycle_14\NN\15269513 arrest_15\NN\88481 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 not_19\RB\1740 induce_20\VB\1627355 any_21\DT\1740 change_22\NN\7283608 in_23\IN\13603305 the_24\DT\1740 number_25\NN\5107765 of_26\IN\1740 apoptotic_27\JJ\1740 <e2>tumor</e2>_28\NN\14234074 cells_29\NNS\3080309 ._30\.\1740
C401859_D009369 NONE apart_0\RB\1740 from_1\IN\1740 this_2\DT\1740 cytostatic_3\JJ\1740 effect_4\NN\34213 ,_5\,\1740 <e1>temsirolimus</e1>_6\NN\1740 had_7\VBD\2108377 an_8\DT\6697703 antiangiogenic_9\JJ\1740 effect_10\NN\34213 with_11\IN\1740 decrease_12\NN\7296428 of_13\IN\1740 <e2>tumor</e2>_14\NN\14234074 microvessel_15\NN\1740 density_16\NN\4941325 and_17\CC\1740 of_18\IN\1740 vegf_19\NN\1740 expression_20\NN\4679549 ._21\.\1740
C401859_D009369 NONE thus_0\RB\1740 ,_1\,\1740 <e1>temsirolimus</e1>_2\NN\1740 reduced_3\VBD\441445 <e2>tumor</e2>_4\NN\14234074 burden_5\NN\5832264 through_6\IN\1740 associated_7\VBN\628491 cytostatic_8\NN\1740 and_9\CC\1740 anti-angiogenic_10\JJ\1740 effects_11\NNS\13245626 ._12\.\1740
C401859_D009369 NONE this_0\DT\1740 dual_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>temsirolimus</e1>_4\NN\1740 on_5\IN\1740 <e2>tumor</e2>_6\NN\14234074 tissue_7\NN\5220461 could_8\MD\1740 contribute_9\VB\126264 to_10\TO\1740 its_11\PRP$\6125041 recently_12\RB\1740 reported_13\VBN\831651 efficiency_14\NN\13819207 in_15\IN\13603305 refractory_16\JJ\1740 mcl_17\NN\1740 resistant_18\JJ\1740 to_19\TO\1740 conventional_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
C401859_D009336 CID moreover_0\RB\1740 ,_1\,\1740 numerous_2\JJ\1740 patchy_3\NN\1740 ,_4\,\1740 well-limited_5\JJ\1740 fibrotic_6\JJ\1740 areas_7\NNS\8630985 ,_8\,\1740 compatible_9\JJ\1740 with_10\IN\1740 <e2>post-necrotic</e2>_11\JJ\1740 tissue_12\NN\5220461 repair_13\NN\248977 ,_14\,\1740 were_15\VBD\836236 found_16\VBN\2426171 after_17\IN\1740 6-month_18\JJ\1740 <e1>temsirolimus</e1>_19\NN\1740 therapy_20\NN\657604 ._21\.\1740
15696449
D008558_D058186 CID <e2>acute_0\JJ\1740 renal_1\JJ\1740 insufficiency</e2>_2\NN\14462946 after_3\IN\1740 high-dose_4\JJ\1740 <e1>melphalan</e1>_5\NN\2722458 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 primary_9\JJ\1740 systemic_10\JJ\1740 amyloidosis_11\NN\14061805 during_12\IN\1740 stem_13\NN\6290637 cell_14\NN\3080309 transplantation_15\NN\671351 ._16\.\1740
D008558_D058186 CID the_0\DT\1740 authors_1\NNS\9610660 have_2\VBP\2108377 noted_3\VBN\1009240 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 <e2>acute_7\JJ\1740 renal_8\JJ\1740 insufficiency</e2>_9\NN\14462946 immediately_10\RB\1740 after_11\IN\1740 <e1>melphalan</e1>_12\NN\2722458 conditioning_13\NN\5752544 ._14\.\1740
D008558_D058186 CID <e2>acute_0\JJ\1740 renal_1\JJ\1740 insufficiency</e2>_2\NN\14462946 (_3\-LRB-\1740 ari_4\NN\1740 )_5\-RRB-\1740 after_6\IN\1740 high-dose_7\JJ\1740 <e1>melphalan</e1>_8\NN\2722458 was_9\VBD\836236 defined_10\VBN\2604760 by_11\IN\1740 a_12\DT\13649268 minimum_13\JJ\1740 increase_14\NN\13576355 of_15\IN\1740 0.5_16\CD\1740 mg/dl_17\NN\1740 (_18\-LRB-\1740 44_19\CD\1740 micromol/l_20\NN\1740 )_21\-RRB-\1740 in_22\IN\13603305 the_23\DT\1740 serum_24\NN\5397468 creatinine_25\NN\1740 level_26\NN\4916342 that_27\WDT\1740 is_28\VBZ\836236 greater_29\JJR\1740 than_30\IN\1740 50_31\CD\13745420 %_32\NN\1740 of_33\IN\1740 baseline_34\NN\7260623 immediately_35\RB\1740 after_36\IN\1740 conditioning_37\NN\5752544 ._38\.\1740
D008558_D058186 CID acute_0\JJ\1740 renal_1\JJ\1740 insufficiency_2\NN\14462946 (_3\-LRB-\1740 <e2>ari</e2>_4\NN\1740 )_5\-RRB-\1740 after_6\IN\1740 high-dose_7\JJ\1740 <e1>melphalan</e1>_8\NN\2722458 was_9\VBD\836236 defined_10\VBN\2604760 by_11\IN\1740 a_12\DT\13649268 minimum_13\JJ\1740 increase_14\NN\13576355 of_15\IN\1740 0.5_16\CD\1740 mg/dl_17\NN\1740 (_18\-LRB-\1740 44_19\CD\1740 micromol/l_20\NN\1740 )_21\-RRB-\1740 in_22\IN\13603305 the_23\DT\1740 serum_24\NN\5397468 creatinine_25\NN\1740 level_26\NN\4916342 that_27\WDT\1740 is_28\VBZ\836236 greater_29\JJR\1740 than_30\IN\1740 50_31\CD\13745420 %_32\NN\1740 of_33\IN\1740 baseline_34\NN\7260623 immediately_35\RB\1740 after_36\IN\1740 conditioning_37\NN\5752544 ._38\.\1740
D008558_D058186 CID results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 the_3\DT\1740 80_4\CD\13745420 patients_5\NNS\9898892 studied_6\VBN\630380 ,_7\,\1740 <e2>ari</e2>_8\NN\1740 developed_9\VBD\1753788 in_10\IN\13603305 18.8_11\CD\1740 %_12\NN\1740 of_13\IN\1740 the_14\DT\1740 patients_15\NNS\9898892 after_16\IN\1740 high-dose_17\JJ\1740 <e1>melphalan</e1>_18\NN\2722458 ._19\.\1740
D008558_D058186 CID patients_0\NNS\9898892 who_1\WP\8299493 had_2\VBD\2108377 <e2>ari</e2>_3\NN\1740 after_4\IN\1740 high-dose_5\JJ\1740 <e1>melphalan</e1>_6\NN\2722458 underwent_7\VBD\109660 dialysis_8\NN\646833 more_9\RBR\1740 often_10\RB\1740 (_11\-LRB-\1740 p_12\NN\14622893 =_13\JJ\1740 0.007_14\CD\1740 )_15\-RRB-\1740 ,_16\,\1740 and_17\CC\1740 had_18\VBD\2108377 a_19\DT\13649268 worse_20\JJR\1740 1-year_21\JJ\1740 survival_22\NN\13961642 (_23\-LRB-\1740 p_24\NN\14622893 =_25\JJ\1740 0.03_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D008558_D058186 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 timing_3\NN\5044673 of_4\IN\1740 <e2>renal_5\JJ\1740 injury</e2>_6\NN\14052046 strongly_7\RB\1740 suggests_8\VBZ\1010118 <e1>melphalan</e1>_9\NN\2722458 as_10\IN\14622893 the_11\DT\1740 causative_12\JJ\1740 agent_13\NN\7347 ._14\.\1740
D008558_D058186 CID ongoing_0\JJ\1740 tubular_1\JJ\1740 injury_2\NN\14052046 may_3\MD\15209706 be_4\VB\836236 a_5\DT\13649268 prerequisite_6\NN\1129920 for_7\IN\1740 <e2>renal_8\JJ\1740 injury</e2>_9\NN\14052046 by_10\IN\1740 <e1>melphalan</e1>_11\NN\2722458 as_12\IN\14622893 evidenced_13\VBN\1015244 by_14\IN\1740 the_15\DT\1740 active_16\JJ\1740 urinary_17\JJ\1740 sediment_18\NN\20827 ._19\.\1740
D008558_C531616 NONE acute_0\JJ\1740 renal_1\JJ\1740 insufficiency_2\NN\14462946 after_3\IN\1740 high-dose_4\JJ\1740 <e1>melphalan</e1>_5\NN\2722458 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 <e2>primary_9\JJ\1740 systemic_10\JJ\1740 amyloidosis</e2>_11\NN\14061805 during_12\IN\1740 stem_13\NN\6290637 cell_14\NN\3080309 transplantation_15\NN\671351 ._16\.\1740
D003404_D058186 NONE <e2>acute_0\JJ\1740 renal_1\JJ\1740 insufficiency</e2>_2\NN\14462946 (_3\-LRB-\1740 ari_4\NN\1740 )_5\-RRB-\1740 after_6\IN\1740 high-dose_7\JJ\1740 melphalan_8\NN\2722458 was_9\VBD\836236 defined_10\VBN\2604760 by_11\IN\1740 a_12\DT\13649268 minimum_13\JJ\1740 increase_14\NN\13576355 of_15\IN\1740 0.5_16\CD\1740 mg/dl_17\NN\1740 (_18\-LRB-\1740 44_19\CD\1740 micromol/l_20\NN\1740 )_21\-RRB-\1740 in_22\IN\13603305 the_23\DT\1740 serum_24\NN\5397468 <e1>creatinine</e1>_25\NN\1740 level_26\NN\4916342 that_27\WDT\1740 is_28\VBZ\836236 greater_29\JJR\1740 than_30\IN\1740 50_31\CD\13745420 %_32\NN\1740 of_33\IN\1740 baseline_34\NN\7260623 immediately_35\RB\1740 after_36\IN\1740 conditioning_37\NN\5752544 ._38\.\1740
D003404_D058186 NONE acute_0\JJ\1740 renal_1\JJ\1740 insufficiency_2\NN\14462946 (_3\-LRB-\1740 <e2>ari</e2>_4\NN\1740 )_5\-RRB-\1740 after_6\IN\1740 high-dose_7\JJ\1740 melphalan_8\NN\2722458 was_9\VBD\836236 defined_10\VBN\2604760 by_11\IN\1740 a_12\DT\13649268 minimum_13\JJ\1740 increase_14\NN\13576355 of_15\IN\1740 0.5_16\CD\1740 mg/dl_17\NN\1740 (_18\-LRB-\1740 44_19\CD\1740 micromol/l_20\NN\1740 )_21\-RRB-\1740 in_22\IN\13603305 the_23\DT\1740 serum_24\NN\5397468 <e1>creatinine</e1>_25\NN\1740 level_26\NN\4916342 that_27\WDT\1740 is_28\VBZ\836236 greater_29\JJR\1740 than_30\IN\1740 50_31\CD\13745420 %_32\NN\1740 of_33\IN\1740 baseline_34\NN\7260623 immediately_35\RB\1740 after_36\IN\1740 conditioning_37\NN\5752544 ._38\.\1740
D008558_-1 NONE ongoing_0\JJ\1740 <e2>tubular_1\JJ\1740 injury</e2>_2\NN\14052046 may_3\MD\15209706 be_4\VB\836236 a_5\DT\13649268 prerequisite_6\NN\1129920 for_7\IN\1740 renal_8\JJ\1740 injury_9\NN\14052046 by_10\IN\1740 <e1>melphalan</e1>_11\NN\2722458 as_12\IN\14622893 evidenced_13\VBN\1015244 by_14\IN\1740 the_15\DT\1740 active_16\JJ\1740 urinary_17\JJ\1740 sediment_18\NN\20827 ._19\.\1740
19139825
D019772_D005909 NONE <e1>topotecan</e1>_0\NN\1740 in_1\IN\13603305 combination_2\NN\7951464 with_3\IN\1740 radiotherapy_4\NN\661091 in_5\IN\13603305 unresectable_6\JJ\1740 <e2>glioblastoma</e2>_7\NN\14236743 :_8\:\1740 a_9\DT\13649268 phase_10\NN\15113229 2_11\CD\13741022 study_12\NN\635850 ._13\.\1740
D019772_D005909 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 assessed_3\VBD\670261 the_4\DT\1740 combination_5\NN\7951464 of_6\IN\1740 radiotherapy_7\NN\661091 (_8\-LRB-\1740 60_9\CD\13745420 gy/30_10\NN\1740 fractions/40_11\NN\1740 days_12\NNS\15140892 )_13\-RRB-\1740 and_14\CC\1740 <e1>topotecan</e1>_15\JJ\1740 (_16\-LRB-\1740 0.9_17\CD\1740 mg/m(2)/day_18\CD\1740 on_19\IN\1740 days_20\NNS\15140892 1_21\CD\13741022 -_22\SYM\1740 5_23\CD\13741022 on_24\IN\1740 weeks_25\NNS\15113229 1_26\CD\13741022 ,_27\,\1740 3_28\CD\13741022 and_29\CC\1740 5_30\CD\13741022 )_31\-RRB-\1740 in_32\IN\13603305 50_33\CD\13745420 adults_34\NNS\7846 with_35\IN\1740 histologically_36\RB\1740 proven_37\VBN\2604760 and_38\CC\1740 untreated_39\JJ\1740 <e2>gbm</e2>_40\NN\1740 ._41\.\1740
D019772_D005910 NONE <e1>topotecan</e1>_0\NN\1740 is_1\VBZ\836236 an_2\DT\6697703 attractive_3\JJ\1740 option_4\NN\6480506 as_5\IN\14622893 it_6\PRP\6125041 exhibits_7\VBZ\2632167 growth_8\NN\13526110 inhibition_9\NN\1068773 of_10\IN\1740 human_11\JJ\1740 <e2>glioma</e2>_12\NN\14236743 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 brain_16\NN\5462674 penetration_17\NN\972621 ._18\.\1740
3383127
D002945_D007022 CID <e2>hypotension</e2>_0\NN\14057371 as_1\IN\14622893 a_2\DT\13649268 manifestation_3\NN\7321772 of_4\IN\1740 cardiotoxicity_5\NN\1740 in_6\IN\13603305 three_7\CD\13741022 patients_8\NNS\9898892 receiving_9\VBG\2210855 <e1>cisplatin</e1>_10\NN\1740 and_11\CC\1740 5-fluorouracil_12\NN\1740 ._13\.\1740
D002945_D007022 CID cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 <e2>hypotension</e2>_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 colorectal_12\JJ\1740 carcinoma_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 <e1>cisplatin</e1>_18\NN\1740 (_19\-LRB-\1740 cddp_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 5-fluorouracil_23\NN\1740 (_24\-LRB-\1740 5-fu_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D002945_D007022 CID cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 <e2>hypotension</e2>_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 colorectal_12\JJ\1740 carcinoma_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 cisplatin_18\NN\1740 (_19\-LRB-\1740 <e1>cddp</e1>_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 5-fluorouracil_23\NN\1740 (_24\-LRB-\1740 5-fu_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D002945_D066126 NONE hypotension_0\NN\14057371 as_1\IN\14622893 a_2\DT\13649268 manifestation_3\NN\7321772 of_4\IN\1740 <e2>cardiotoxicity</e2>_5\NN\1740 in_6\IN\13603305 three_7\CD\13741022 patients_8\NNS\9898892 receiving_9\VBG\2210855 <e1>cisplatin</e1>_10\NN\1740 and_11\CC\1740 5-fluorouracil_12\NN\1740 ._13\.\1740
D002945_D066126 NONE the_0\DT\1740 presentation_1\NN\1027379 and_2\CC\1740 cardiac_3\JJ\1740 evaluation_4\NN\874067 (_5\-LRB-\1740 hemodynamic_6\JJ\1740 ,_7\,\1740 echocardiographic_8\JJ\1740 ,_9\,\1740 and_10\CC\1740 scintigraphic_11\JJ\1740 )_12\-RRB-\1740 of_13\IN\1740 these_14\DT\1740 patients_15\NNS\9898892 suggest_16\VBP\1010118 new_17\JJ\1740 manifestations_18\NNS\7321772 of_19\IN\1740 5-fu_20\NN\1740 <e2>cardiotoxicity</e2>_21\NN\1740 that_22\WDT\1740 may_23\MD\15209706 be_24\VB\836236 influenced_25\VBN\137313 by_26\IN\1740 <e1>cddp</e1>_27\NN\1740 ._28\.\1740
D005472_D007022 CID <e2>hypotension</e2>_0\NN\14057371 as_1\IN\14622893 a_2\DT\13649268 manifestation_3\NN\7321772 of_4\IN\1740 cardiotoxicity_5\NN\1740 in_6\IN\13603305 three_7\CD\13741022 patients_8\NNS\9898892 receiving_9\VBG\2210855 cisplatin_10\NN\1740 and_11\CC\1740 <e1>5-fluorouracil</e1>_12\NN\1740 ._13\.\1740
D005472_D007022 CID cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 <e2>hypotension</e2>_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 colorectal_12\JJ\1740 carcinoma_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 cisplatin_18\NN\1740 (_19\-LRB-\1740 cddp_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 <e1>5-fluorouracil</e1>_23\NN\1740 (_24\-LRB-\1740 5-fu_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D005472_D007022 CID cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 <e2>hypotension</e2>_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 colorectal_12\JJ\1740 carcinoma_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 cisplatin_18\NN\1740 (_19\-LRB-\1740 cddp_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 5-fluorouracil_23\NN\1740 (_24\-LRB-\1740 <e1>5-fu</e1>_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D005472_D066126 NONE hypotension_0\NN\14057371 as_1\IN\14622893 a_2\DT\13649268 manifestation_3\NN\7321772 of_4\IN\1740 <e2>cardiotoxicity</e2>_5\NN\1740 in_6\IN\13603305 three_7\CD\13741022 patients_8\NNS\9898892 receiving_9\VBG\2210855 cisplatin_10\NN\1740 and_11\CC\1740 <e1>5-fluorouracil</e1>_12\NN\1740 ._13\.\1740
D005472_D066126 NONE the_0\DT\1740 presentation_1\NN\1027379 and_2\CC\1740 cardiac_3\JJ\1740 evaluation_4\NN\874067 (_5\-LRB-\1740 hemodynamic_6\JJ\1740 ,_7\,\1740 echocardiographic_8\JJ\1740 ,_9\,\1740 and_10\CC\1740 scintigraphic_11\JJ\1740 )_12\-RRB-\1740 of_13\IN\1740 these_14\DT\1740 patients_15\NNS\9898892 suggest_16\VBP\1010118 new_17\JJ\1740 manifestations_18\NNS\7321772 of_19\IN\1740 <e1>5-fu</e1>_20\NN\1740 <e2>cardiotoxicity</e2>_21\NN\1740 that_22\WDT\1740 may_23\MD\15209706 be_24\VB\836236 influenced_25\VBN\137313 by_26\IN\1740 cddp_27\NN\1740 ._28\.\1740
D002945_D015179 NONE cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 hypotension_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 <e2>colorectal_12\JJ\1740 carcinoma</e2>_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 <e1>cisplatin</e1>_18\NN\1740 (_19\-LRB-\1740 cddp_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 5-fluorouracil_23\NN\1740 (_24\-LRB-\1740 5-fu_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D002945_D015179 NONE cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 hypotension_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 <e2>colorectal_12\JJ\1740 carcinoma</e2>_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 cisplatin_18\NN\1740 (_19\-LRB-\1740 <e1>cddp</e1>_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 5-fluorouracil_23\NN\1740 (_24\-LRB-\1740 5-fu_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D005472_D015179 NONE cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 hypotension_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 <e2>colorectal_12\JJ\1740 carcinoma</e2>_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 cisplatin_18\NN\1740 (_19\-LRB-\1740 cddp_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 <e1>5-fluorouracil</e1>_23\NN\1740 (_24\-LRB-\1740 5-fu_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D005472_D015179 NONE cardiac_0\JJ\1740 symptoms_1\NNS\5823932 ,_2\,\1740 including_3\VBG\690614 hypotension_4\NN\14057371 ,_5\,\1740 developed_6\VBD\1753788 in_7\IN\13603305 three_8\CD\13741022 patients_9\NNS\9898892 with_10\IN\1740 advanced_11\JJ\1740 <e2>colorectal_12\JJ\1740 carcinoma</e2>_13\NN\14239918 while_14\IN\15122231 being_15\VBG\836236 treated_16\VBN\2376958 with_17\IN\1740 cisplatin_18\NN\1740 (_19\-LRB-\1740 cddp_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 5-fluorouracil_23\NN\1740 (_24\-LRB-\1740 <e1>5-fu</e1>_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
20431083
D014859_D002543 CID results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pooled_4\JJ\1740 analysis_5\NN\633864 of_6\IN\1740 1460_7\CD\1740 <e2>ich</e2>_8\NN\1740 and_9\CC\1740 3817_10\CD\1740 is/tia_11\NN\1740 ,_12\,\1740 mb_13\NN\13601596 were_14\VBD\836236 more_15\RBR\1740 frequent_16\JJ\1740 in_17\IN\13603305 ich_18\NN\1740 vs_19\CC\13634784 is/tia_20\NN\1740 in_21\IN\13603305 all_22\DT\1740 treatment_23\NN\654885 groups_24\NNS\2137 ,_25\,\1740 but_26\CC\1740 the_27\DT\1740 excess_28\NN\5119367 increased_29\VBD\169651 from_30\IN\1740 2.8_31\CD\1740 (_32\-LRB-\1740 odds_33\NNS\4756635 ratio_34\NN\13815152 ;_35\:\1740 range_36\NN\5123416 ,_37\,\1740 2.3_38\CD\1740 -_39\SYM\1740 3.5_40\CD\1740 )_41\-RRB-\1740 in_42\IN\13603305 nonantithrombotic_43\JJ\1740 users_44\NNS\7846 to_45\TO\1740 5.7_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 3.4_50\CD\1740 -_51\SYM\1740 9.7_52\CD\1740 )_53\-RRB-\1740 in_54\IN\13603305 antiplatelet_55\NN\1740 users_56\NNS\7846 and_57\CC\1740 8.0_58\CD\1740 (_59\-LRB-\1740 range_60\NN\5123416 ,_61\,\1740 3.5_62\CD\1740 -_63\SYM\1740 17.8_64\CD\1740 )_65\-RRB-\1740 in_66\IN\13603305 <e1>warfarin</e1>_67\NN\2718259 users_68\NNS\7846 (_69\-LRB-\1740 p_70\NN\14622893 difference=0.01_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D014859_D002543 CID results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pooled_4\JJ\1740 analysis_5\NN\633864 of_6\IN\1740 1460_7\CD\1740 ich_8\NN\1740 and_9\CC\1740 3817_10\CD\1740 is/tia_11\NN\1740 ,_12\,\1740 mb_13\NN\13601596 were_14\VBD\836236 more_15\RBR\1740 frequent_16\JJ\1740 in_17\IN\13603305 <e2>ich</e2>_18\NN\1740 vs_19\CC\13634784 is/tia_20\NN\1740 in_21\IN\13603305 all_22\DT\1740 treatment_23\NN\654885 groups_24\NNS\2137 ,_25\,\1740 but_26\CC\1740 the_27\DT\1740 excess_28\NN\5119367 increased_29\VBD\169651 from_30\IN\1740 2.8_31\CD\1740 (_32\-LRB-\1740 odds_33\NNS\4756635 ratio_34\NN\13815152 ;_35\:\1740 range_36\NN\5123416 ,_37\,\1740 2.3_38\CD\1740 -_39\SYM\1740 3.5_40\CD\1740 )_41\-RRB-\1740 in_42\IN\13603305 nonantithrombotic_43\JJ\1740 users_44\NNS\7846 to_45\TO\1740 5.7_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 3.4_50\CD\1740 -_51\SYM\1740 9.7_52\CD\1740 )_53\-RRB-\1740 in_54\IN\13603305 antiplatelet_55\NN\1740 users_56\NNS\7846 and_57\CC\1740 8.0_58\CD\1740 (_59\-LRB-\1740 range_60\NN\5123416 ,_61\,\1740 3.5_62\CD\1740 -_63\SYM\1740 17.8_64\CD\1740 )_65\-RRB-\1740 in_66\IN\13603305 <e1>warfarin</e1>_67\NN\2718259 users_68\NNS\7846 (_69\-LRB-\1740 p_70\NN\14622893 difference=0.01_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D014859_D002543 CID there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 mb_6\NN\13601596 in_7\IN\13603305 <e1>warfarin</e1>_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 <e2>ich</e2>_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 warfarin_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 is/tia_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_D002543 CID there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 mb_6\NN\13601596 in_7\IN\13603305 warfarin_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 <e2>ich</e2>_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 <e1>warfarin</e1>_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 is/tia_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_D002543 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 mb_5\NN\13601596 in_6\IN\13603305 <e1>warfarin</e1>_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 <e2>ich</e2>_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 mb_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 warfarin-associated_22\JJ\1740 ich_23\NN\1740 ._24\.\1740
D014859_D002543 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 mb_5\NN\13601596 in_6\IN\13603305 <e1>warfarin</e1>_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 ich_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 mb_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 warfarin-associated_22\JJ\1740 <e2>ich</e2>_23\NN\1740 ._24\.\1740
D014859_D002543 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 mb_5\NN\13601596 in_6\IN\13603305 warfarin_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 <e2>ich</e2>_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 mb_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 <e1>warfarin-associated</e1>_22\JJ\1740 ich_23\NN\1740 ._24\.\1740
D014859_D002543 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 mb_5\NN\13601596 in_6\IN\13603305 warfarin_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 ich_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 mb_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 <e1>warfarin-associated</e1>_22\JJ\1740 <e2>ich</e2>_23\NN\1740 ._24\.\1740
D014859_D002544 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pooled_4\JJ\1740 analysis_5\NN\633864 of_6\IN\1740 1460_7\CD\1740 ich_8\NN\1740 and_9\CC\1740 3817_10\CD\1740 <e2>is/tia</e2>_11\NN\1740 ,_12\,\1740 mb_13\NN\13601596 were_14\VBD\836236 more_15\RBR\1740 frequent_16\JJ\1740 in_17\IN\13603305 ich_18\NN\1740 vs_19\CC\13634784 is/tia_20\NN\1740 in_21\IN\13603305 all_22\DT\1740 treatment_23\NN\654885 groups_24\NNS\2137 ,_25\,\1740 but_26\CC\1740 the_27\DT\1740 excess_28\NN\5119367 increased_29\VBD\169651 from_30\IN\1740 2.8_31\CD\1740 (_32\-LRB-\1740 odds_33\NNS\4756635 ratio_34\NN\13815152 ;_35\:\1740 range_36\NN\5123416 ,_37\,\1740 2.3_38\CD\1740 -_39\SYM\1740 3.5_40\CD\1740 )_41\-RRB-\1740 in_42\IN\13603305 nonantithrombotic_43\JJ\1740 users_44\NNS\7846 to_45\TO\1740 5.7_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 3.4_50\CD\1740 -_51\SYM\1740 9.7_52\CD\1740 )_53\-RRB-\1740 in_54\IN\13603305 antiplatelet_55\NN\1740 users_56\NNS\7846 and_57\CC\1740 8.0_58\CD\1740 (_59\-LRB-\1740 range_60\NN\5123416 ,_61\,\1740 3.5_62\CD\1740 -_63\SYM\1740 17.8_64\CD\1740 )_65\-RRB-\1740 in_66\IN\13603305 <e1>warfarin</e1>_67\NN\2718259 users_68\NNS\7846 (_69\-LRB-\1740 p_70\NN\14622893 difference=0.01_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D014859_D002544 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pooled_4\JJ\1740 analysis_5\NN\633864 of_6\IN\1740 1460_7\CD\1740 ich_8\NN\1740 and_9\CC\1740 3817_10\CD\1740 is/tia_11\NN\1740 ,_12\,\1740 mb_13\NN\13601596 were_14\VBD\836236 more_15\RBR\1740 frequent_16\JJ\1740 in_17\IN\13603305 ich_18\NN\1740 vs_19\CC\13634784 <e2>is/tia</e2>_20\NN\1740 in_21\IN\13603305 all_22\DT\1740 treatment_23\NN\654885 groups_24\NNS\2137 ,_25\,\1740 but_26\CC\1740 the_27\DT\1740 excess_28\NN\5119367 increased_29\VBD\169651 from_30\IN\1740 2.8_31\CD\1740 (_32\-LRB-\1740 odds_33\NNS\4756635 ratio_34\NN\13815152 ;_35\:\1740 range_36\NN\5123416 ,_37\,\1740 2.3_38\CD\1740 -_39\SYM\1740 3.5_40\CD\1740 )_41\-RRB-\1740 in_42\IN\13603305 nonantithrombotic_43\JJ\1740 users_44\NNS\7846 to_45\TO\1740 5.7_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 3.4_50\CD\1740 -_51\SYM\1740 9.7_52\CD\1740 )_53\-RRB-\1740 in_54\IN\13603305 antiplatelet_55\NN\1740 users_56\NNS\7846 and_57\CC\1740 8.0_58\CD\1740 (_59\-LRB-\1740 range_60\NN\5123416 ,_61\,\1740 3.5_62\CD\1740 -_63\SYM\1740 17.8_64\CD\1740 )_65\-RRB-\1740 in_66\IN\13603305 <e1>warfarin</e1>_67\NN\2718259 users_68\NNS\7846 (_69\-LRB-\1740 p_70\NN\14622893 difference=0.01_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D014859_D002544 NONE there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 mb_6\NN\13601596 in_7\IN\13603305 <e1>warfarin</e1>_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 ich_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 warfarin_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 <e2>is/tia</e2>_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_D002544 NONE there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 mb_6\NN\13601596 in_7\IN\13603305 warfarin_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 ich_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 <e1>warfarin</e1>_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 <e2>is/tia</e2>_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_D002546 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pooled_4\JJ\1740 analysis_5\NN\633864 of_6\IN\1740 1460_7\CD\1740 ich_8\NN\1740 and_9\CC\1740 3817_10\CD\1740 <e2>is/tia</e2>_11\NN\1740 ,_12\,\1740 mb_13\NN\13601596 were_14\VBD\836236 more_15\RBR\1740 frequent_16\JJ\1740 in_17\IN\13603305 ich_18\NN\1740 vs_19\CC\13634784 is/tia_20\NN\1740 in_21\IN\13603305 all_22\DT\1740 treatment_23\NN\654885 groups_24\NNS\2137 ,_25\,\1740 but_26\CC\1740 the_27\DT\1740 excess_28\NN\5119367 increased_29\VBD\169651 from_30\IN\1740 2.8_31\CD\1740 (_32\-LRB-\1740 odds_33\NNS\4756635 ratio_34\NN\13815152 ;_35\:\1740 range_36\NN\5123416 ,_37\,\1740 2.3_38\CD\1740 -_39\SYM\1740 3.5_40\CD\1740 )_41\-RRB-\1740 in_42\IN\13603305 nonantithrombotic_43\JJ\1740 users_44\NNS\7846 to_45\TO\1740 5.7_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 3.4_50\CD\1740 -_51\SYM\1740 9.7_52\CD\1740 )_53\-RRB-\1740 in_54\IN\13603305 antiplatelet_55\NN\1740 users_56\NNS\7846 and_57\CC\1740 8.0_58\CD\1740 (_59\-LRB-\1740 range_60\NN\5123416 ,_61\,\1740 3.5_62\CD\1740 -_63\SYM\1740 17.8_64\CD\1740 )_65\-RRB-\1740 in_66\IN\13603305 <e1>warfarin</e1>_67\NN\2718259 users_68\NNS\7846 (_69\-LRB-\1740 p_70\NN\14622893 difference=0.01_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D014859_D002546 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pooled_4\JJ\1740 analysis_5\NN\633864 of_6\IN\1740 1460_7\CD\1740 ich_8\NN\1740 and_9\CC\1740 3817_10\CD\1740 is/tia_11\NN\1740 ,_12\,\1740 mb_13\NN\13601596 were_14\VBD\836236 more_15\RBR\1740 frequent_16\JJ\1740 in_17\IN\13603305 ich_18\NN\1740 vs_19\CC\13634784 <e2>is/tia</e2>_20\NN\1740 in_21\IN\13603305 all_22\DT\1740 treatment_23\NN\654885 groups_24\NNS\2137 ,_25\,\1740 but_26\CC\1740 the_27\DT\1740 excess_28\NN\5119367 increased_29\VBD\169651 from_30\IN\1740 2.8_31\CD\1740 (_32\-LRB-\1740 odds_33\NNS\4756635 ratio_34\NN\13815152 ;_35\:\1740 range_36\NN\5123416 ,_37\,\1740 2.3_38\CD\1740 -_39\SYM\1740 3.5_40\CD\1740 )_41\-RRB-\1740 in_42\IN\13603305 nonantithrombotic_43\JJ\1740 users_44\NNS\7846 to_45\TO\1740 5.7_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 3.4_50\CD\1740 -_51\SYM\1740 9.7_52\CD\1740 )_53\-RRB-\1740 in_54\IN\13603305 antiplatelet_55\NN\1740 users_56\NNS\7846 and_57\CC\1740 8.0_58\CD\1740 (_59\-LRB-\1740 range_60\NN\5123416 ,_61\,\1740 3.5_62\CD\1740 -_63\SYM\1740 17.8_64\CD\1740 )_65\-RRB-\1740 in_66\IN\13603305 <e1>warfarin</e1>_67\NN\2718259 users_68\NNS\7846 (_69\-LRB-\1740 p_70\NN\14622893 difference=0.01_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D014859_D002546 NONE there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 mb_6\NN\13601596 in_7\IN\13603305 <e1>warfarin</e1>_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 ich_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 warfarin_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 <e2>is/tia</e2>_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_D002546 NONE there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 mb_6\NN\13601596 in_7\IN\13603305 warfarin_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 ich_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 <e1>warfarin</e1>_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 <e2>is/tia</e2>_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_-1 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pooled_4\JJ\1740 analysis_5\NN\633864 of_6\IN\1740 1460_7\CD\1740 ich_8\NN\1740 and_9\CC\1740 3817_10\CD\1740 is/tia_11\NN\1740 ,_12\,\1740 <e2>mb</e2>_13\NN\13601596 were_14\VBD\836236 more_15\RBR\1740 frequent_16\JJ\1740 in_17\IN\13603305 ich_18\NN\1740 vs_19\CC\13634784 is/tia_20\NN\1740 in_21\IN\13603305 all_22\DT\1740 treatment_23\NN\654885 groups_24\NNS\2137 ,_25\,\1740 but_26\CC\1740 the_27\DT\1740 excess_28\NN\5119367 increased_29\VBD\169651 from_30\IN\1740 2.8_31\CD\1740 (_32\-LRB-\1740 odds_33\NNS\4756635 ratio_34\NN\13815152 ;_35\:\1740 range_36\NN\5123416 ,_37\,\1740 2.3_38\CD\1740 -_39\SYM\1740 3.5_40\CD\1740 )_41\-RRB-\1740 in_42\IN\13603305 nonantithrombotic_43\JJ\1740 users_44\NNS\7846 to_45\TO\1740 5.7_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 3.4_50\CD\1740 -_51\SYM\1740 9.7_52\CD\1740 )_53\-RRB-\1740 in_54\IN\13603305 antiplatelet_55\NN\1740 users_56\NNS\7846 and_57\CC\1740 8.0_58\CD\1740 (_59\-LRB-\1740 range_60\NN\5123416 ,_61\,\1740 3.5_62\CD\1740 -_63\SYM\1740 17.8_64\CD\1740 )_65\-RRB-\1740 in_66\IN\13603305 <e1>warfarin</e1>_67\NN\2718259 users_68\NNS\7846 (_69\-LRB-\1740 p_70\NN\14622893 difference=0.01_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D014859_-1 NONE there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 <e2>mb</e2>_6\NN\13601596 in_7\IN\13603305 <e1>warfarin</e1>_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 ich_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 warfarin_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 is/tia_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_-1 NONE there_0\EX\27167 was_1\VBD\836236 also_2\RB\1740 an_3\DT\6697703 excess_4\NN\5119367 of_5\IN\1740 <e2>mb</e2>_6\NN\13601596 in_7\IN\13603305 warfarin_8\NN\2718259 users_9\NNS\7846 vs_10\CC\13634784 nonusers_11\NNS\1740 with_12\IN\1740 ich_13\NN\1740 (_14\-LRB-\1740 or_15\NN\3541091 ,_16\,\1740 2.7_17\CD\1740 ;_18\:\1740 95_19\CD\1740 %_20\NN\1740 ci_21\NN\13635336 ,_22\,\1740 1.6_23\CD\1740 -_24\SYM\1740 4.4_25\CD\1740 ;_26\:\1740 p<0.001_27\NN\1740 )_28\-RRB-\1740 but_29\CC\1740 none_30\NN\15228378 in_31\IN\13603305 <e1>warfarin</e1>_32\NN\2718259 users_33\NNS\7846 with_34\IN\1740 is/tia_35\NN\1740 (_36\-LRB-\1740 or_37\NN\3541091 ,_38\,\1740 1.3_39\CD\1740 ;_40\:\1740 95_41\CD\1740 %_42\NN\1740 ci_43\NN\13635336 ,_44\,\1740 0.9_45\CD\1740 -_46\SYM\1740 1.7_47\CD\1740 ;_48\:\1740 p=0.33_49\NN\1740 ;_50\:\1740 p_51\NN\14622893 difference=0.01_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D014859_-1 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 <e2>mb</e2>_5\NN\13601596 in_6\IN\13603305 <e1>warfarin</e1>_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 ich_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 mb_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 warfarin-associated_22\JJ\1740 ich_23\NN\1740 ._24\.\1740
D014859_-1 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 mb_5\NN\13601596 in_6\IN\13603305 <e1>warfarin</e1>_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 ich_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 <e2>mb</e2>_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 warfarin-associated_22\JJ\1740 ich_23\NN\1740 ._24\.\1740
D014859_-1 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 <e2>mb</e2>_5\NN\13601596 in_6\IN\13603305 warfarin_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 ich_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 mb_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 <e1>warfarin-associated</e1>_22\JJ\1740 ich_23\NN\1740 ._24\.\1740
D014859_-1 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 excess_3\NN\5119367 of_4\IN\1740 mb_5\NN\13601596 in_6\IN\13603305 warfarin_7\NN\2718259 users_8\NNS\7846 with_9\IN\1740 ich_10\NN\1740 compared_11\VBN\644583 to_12\TO\1740 other_13\JJ\1740 groups_14\NNS\2137 suggests_15\VBZ\1010118 that_16\IN\1740 <e2>mb</e2>_17\NN\13601596 increase_18\VBP\169651 the_19\DT\1740 risk_20\NN\14541044 of_21\IN\1740 <e1>warfarin-associated</e1>_22\JJ\1740 ich_23\NN\1740 ._24\.\1740
16920333
C416835_D012640 NONE anticonvulsant_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>eslicarbazepine_3\NN\1740 acetate</e1>_4\NN\15010703 (_5\-LRB-\1740 bia_6\NN\1740 2_7\CD\13741022 -_8\SYM\1740 093_9\CD\1740 )_10\-RRB-\1740 on_11\IN\1740 <e2>seizures</e2>_12\NNS\14081375 induced_13\VBN\1627355 by_14\IN\1740 microperfusion_15\NN\1740 of_16\IN\1740 picrotoxin_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 hippocampus_20\NN\5462674 of_21\IN\1740 freely_22\RB\1740 moving_23\VBG\2367363 rats_24\NNS\2329401 ._25\.\1740
C416835_D012640 NONE anticonvulsant_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 eslicarbazepine_3\NN\1740 acetate_4\NN\15010703 (_5\-LRB-\1740 <e1>bia_6\NN\1740 2_7\CD\13741022 -_8\SYM\1740 093</e1>_9\CD\1740 )_10\-RRB-\1740 on_11\IN\1740 <e2>seizures</e2>_12\NNS\14081375 induced_13\VBN\1627355 by_14\IN\1740 microperfusion_15\NN\1740 of_16\IN\1740 picrotoxin_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 hippocampus_20\NN\5462674 of_21\IN\1740 freely_22\RB\1740 moving_23\VBG\2367363 rats_24\NNS\2329401 ._25\.\1740
C416835_D012640 NONE we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 oral_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 <e1>eslicarbazepine_9\NN\1740 acetate</e1>_10\NN\15010703 on_11\IN\1740 a_12\DT\13649268 whole-animal_13\JJ\1740 model_14\NN\5888929 in_15\IN\13603305 which_16\WDT\1740 partial_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 can_19\MD\3094503 be_20\VB\836236 elicited_21\VBN\1617192 repeatedly_22\RB\1740 on_23\IN\1740 different_24\JJ\1740 days_25\NNS\15140892 without_26\IN\1740 changes_27\NNS\7283608 in_28\IN\13603305 threshold_29\NN\15265518 or_30\CC\3541091 seizure_31\VB\1740 patterns_32\NNS\5726345 ._33\.\1740
C416835_D012640 NONE we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 oral_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 <e1>eslicarbazepine_9\NN\1740 acetate</e1>_10\NN\15010703 on_11\IN\1740 a_12\DT\13649268 whole-animal_13\JJ\1740 model_14\NN\5888929 in_15\IN\13603305 which_16\WDT\1740 partial_17\JJ\1740 seizures_18\NNS\14081375 can_19\MD\3094503 be_20\VB\836236 elicited_21\VBN\1617192 repeatedly_22\RB\1740 on_23\IN\1740 different_24\JJ\1740 days_25\NNS\15140892 without_26\IN\1740 changes_27\NNS\7283608 in_28\IN\13603305 threshold_29\NN\15265518 or_30\CC\3541091 <e2>seizure</e2>_31\VB\1740 patterns_32\NNS\5726345 ._33\.\1740
D010852_D012640 CID anticonvulsant_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 eslicarbazepine_3\NN\1740 acetate_4\NN\15010703 (_5\-LRB-\1740 bia_6\NN\1740 2_7\CD\13741022 -_8\SYM\1740 093_9\CD\1740 )_10\-RRB-\1740 on_11\IN\1740 <e2>seizures</e2>_12\NNS\14081375 induced_13\VBN\1627355 by_14\IN\1740 microperfusion_15\NN\1740 of_16\IN\1740 <e1>picrotoxin</e1>_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 hippocampus_20\NN\5462674 of_21\IN\1740 freely_22\RB\1740 moving_23\VBG\2367363 rats_24\NNS\2329401 ._25\.\1740
D010852_D012640 CID in_0\IN\13603305 the_1\DT\1740 animals_2\NNS\4475 treated_3\VBN\2376958 with_4\IN\1740 threshold_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 <e1>picrotoxin</e1>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 average_11\JJ\1740 number_12\NN\5107765 of_13\IN\1740 <e2>seizures</e2>_14\NNS\14081375 was_15\VBD\836236 2.3+/-1.2_16\CD\1740 ,_17\,\1740 and_18\CC\1740 average_19\JJ\1740 seizure_20\NN\14081375 duration_21\NN\15113229 was_22\VBD\836236 39.5+/-8.4s_23\CD\1740 ._24\.\1740
D010852_D012640 CID in_0\IN\13603305 the_1\DT\1740 animals_2\NNS\4475 treated_3\VBN\2376958 with_4\IN\1740 threshold_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 <e1>picrotoxin</e1>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 average_11\JJ\1740 number_12\NN\5107765 of_13\IN\1740 seizures_14\NNS\14081375 was_15\VBD\836236 2.3+/-1.2_16\CD\1740 ,_17\,\1740 and_18\CC\1740 average_19\JJ\1740 <e2>seizure</e2>_20\NN\14081375 duration_21\NN\15113229 was_22\VBD\836236 39.5+/-8.4s_23\CD\1740 ._24\.\1740
D010852_D012640 CID pre-treatment_0\JJ\1740 with_1\IN\1740 a_2\DT\13649268 dose_3\NN\3740161 of_4\IN\1740 30_5\CD\13745420 mg/kg_6\NN\1740 2h_7\NN\1740 before_8\IN\1740 <e1>picrotoxin</e1>_9\NN\1740 microperfusion_10\NN\1740 prevented_11\VBD\1740 <e2>seizures</e2>_12\NNS\14081375 in_13\IN\13603305 the_14\DT\1740 75_15\CD\1740 %_16\NN\1740 of_17\IN\1740 the_18\DT\1740 rats_19\NNS\2329401 ._20\.\1740
15482540
D012254_D000740 NONE factors_0\NNS\7326557 contributing_1\VBG\126264 to_2\TO\1740 <e1>ribavirin-induced</e1>_3\JJ\1740 <e2>anemia</e2>_4\NN\14189204 ._5\.\1740
D012254_D000740 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 conducted_3\VBN\2436349 to_4\TO\1740 identify_5\VB\699815 the_6\DT\1740 factors_7\NNS\7326557 contributing_8\VBG\126264 to_9\TO\1740 <e1>ribavirin-induced</e1>_10\JJ\1740 <e2>anemia</e2>_11\NN\14189204 ._12\.\1740
D012254_D000740 NONE a_0\DT\13649268 hemoglobin_1\NN\14888884 concentration_2\NN\4916342 of_3\IN\1740 <_4\XX\1740 10_5\CD\13745420 g/dl_6\NN\1740 was_7\VBD\836236 defined_8\VBN\2604760 as_9\IN\14622893 <e1>ribavirin-induced</e1>_10\JJ\1740 <e2>anemia</e2>_11\NN\14189204 ._12\.\1740
D012254_D000740 NONE results_0\NNS\34213 :_1\:\1740 <e1>ribavirin-induced</e1>_2\JJ\1740 <e2>anemia</e2>_3\NN\14189204 occurred_4\VBD\2623529 in_5\IN\13603305 18_6\CD\13745420 (_7\-LRB-\1740 20.5_8\CD\1740 %_9\NN\1740 )_10\-RRB-\1740 patients_11\NNS\9898892 during_12\IN\1740 treatment_13\NN\654885 ._14\.\1740
D016898_D019698 NONE background_0\NN\4921011 and_1\CC\1740 aim_2\NN\5980875 :_3\:\1740 <e1>interferon</e1>_4\NN\2725367 and_5\CC\1740 ribavirin_6\NN\2725367 combination_7\NN\7951464 therapy_8\NN\657604 for_9\IN\1740 <e2>chronic_10\JJ\1740 hepatitis_11\NN\14127211 c</e2>_12\NN\13714184 produces_13\VBZ\1617192 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ._16\.\1740
D016898_D019698 NONE methods_0\NNS\5616786 :_1\:\1740 eighty-eight_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 <e2>chronic_5\JJ\1740 hepatitis_6\NN\14127211 c</e2>_7\NN\13714184 who_8\WP\8299493 received_9\VBD\2210855 <e1>interferon-alpha-2b</e1>_10\CD\1740 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 of_14\IN\1740 6_15\CD\13741022 mu_16\NN\6828818 administered_17\VBN\2436349 intramuscularly_18\RB\1740 for_19\IN\1740 24_20\CD\13745420 weeks_21\NNS\15113229 in_22\IN\13603305 combination_23\NN\7951464 with_24\IN\1740 ribavirin_25\NN\2725367 administered_26\VBN\2436349 orally_27\RB\1740 at_28\IN\14622893 a_29\DT\13649268 dose_30\NN\3740161 of_31\IN\1740 600_32\CD\1740 mg_33\NN\13717155 or_34\CC\3541091 800_35\CD\1740 mg_36\NN\13717155 participated_37\VBN\2367363 in_38\IN\13603305 the_39\DT\1740 study_40\NN\635850 ._41\.\1740
D016898_D000743 CID background_0\NN\4921011 and_1\CC\1740 aim_2\NN\5980875 :_3\:\1740 <e1>interferon</e1>_4\NN\2725367 and_5\CC\1740 ribavirin_6\NN\2725367 combination_7\NN\7951464 therapy_8\NN\657604 for_9\IN\1740 chronic_10\JJ\1740 hepatitis_11\NN\14127211 c_12\NN\13714184 produces_13\VBZ\1617192 <e2>hemolytic_14\JJ\1740 anemia</e2>_15\NN\14189204 ._16\.\1740
D012254_D019698 NONE background_0\NN\4921011 and_1\CC\1740 aim_2\NN\5980875 :_3\:\1740 interferon_4\NN\2725367 and_5\CC\1740 <e1>ribavirin</e1>_6\NN\2725367 combination_7\NN\7951464 therapy_8\NN\657604 for_9\IN\1740 <e2>chronic_10\JJ\1740 hepatitis_11\NN\14127211 c</e2>_12\NN\13714184 produces_13\VBZ\1617192 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ._16\.\1740
D012254_D019698 NONE methods_0\NNS\5616786 :_1\:\1740 eighty-eight_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 <e2>chronic_5\JJ\1740 hepatitis_6\NN\14127211 c</e2>_7\NN\13714184 who_8\WP\8299493 received_9\VBD\2210855 interferon-alpha-2b_10\CD\1740 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 of_14\IN\1740 6_15\CD\13741022 mu_16\NN\6828818 administered_17\VBN\2436349 intramuscularly_18\RB\1740 for_19\IN\1740 24_20\CD\13745420 weeks_21\NNS\15113229 in_22\IN\13603305 combination_23\NN\7951464 with_24\IN\1740 <e1>ribavirin</e1>_25\NN\2725367 administered_26\VBN\2436349 orally_27\RB\1740 at_28\IN\14622893 a_29\DT\13649268 dose_30\NN\3740161 of_31\IN\1740 600_32\CD\1740 mg_33\NN\13717155 or_34\CC\3541091 800_35\CD\1740 mg_36\NN\13717155 participated_37\VBN\2367363 in_38\IN\13603305 the_39\DT\1740 study_40\NN\635850 ._41\.\1740
D012254_D000743 CID background_0\NN\4921011 and_1\CC\1740 aim_2\NN\5980875 :_3\:\1740 interferon_4\NN\2725367 and_5\CC\1740 <e1>ribavirin</e1>_6\NN\2725367 combination_7\NN\7951464 therapy_8\NN\657604 for_9\IN\1740 chronic_10\JJ\1740 hepatitis_11\NN\14127211 c_12\NN\13714184 produces_13\VBZ\1617192 <e2>hemolytic_14\JJ\1740 anemia</e2>_15\NN\14189204 ._16\.\1740
19549709
C107135_D002289 NONE efficacy_0\NNP\5199286 of_1\IN\1740 <e1>everolimus</e1>_2\NN\1740 (_3\-LRB-\1740 rad001_4\NN\1740 )_5\-RRB-\1740 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 advanced_9\JJ\1740 <e2>nsclc</e2>_10\NN\1740 previously_11\RB\1740 treated_12\VBN\2376958 with_13\IN\1740 chemotherapy_14\NN\661091 alone_15\RB\1740 or_16\CC\3541091 with_17\IN\1740 chemotherapy_18\NN\661091 and_19\CC\1740 egfr_20\NN\1740 inhibitors_21\NNS\20090 ._22\.\1740
C107135_D002289 NONE efficacy_0\NNP\5199286 of_1\IN\1740 everolimus_2\NN\1740 (_3\-LRB-\1740 <e1>rad001</e1>_4\NN\1740 )_5\-RRB-\1740 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 advanced_9\JJ\1740 <e2>nsclc</e2>_10\NN\1740 previously_11\RB\1740 treated_12\VBN\2376958 with_13\IN\1740 chemotherapy_14\NN\661091 alone_15\RB\1740 or_16\CC\3541091 with_17\IN\1740 chemotherapy_18\NN\661091 and_19\CC\1740 egfr_20\NN\1740 inhibitors_21\NNS\20090 ._22\.\1740
C107135_D002289 NONE <e1>rad001</e1>_0\NN\1740 ,_1\,\1740 an_2\DT\6697703 oral_3\JJ\1740 inhibitor_4\NN\20090 of_5\IN\1740 the_6\DT\1740 mammalian_7\JJ\1740 target_8\NN\7258332 of_9\IN\1740 rapamycin_10\NN\1740 (_11\-LRB-\1740 mtor_12\NN\1740 )_13\-RRB-\1740 ,_14\,\1740 has_15\VBZ\2108377 shown_16\VBN\2137132 phase_17\NN\15113229 i_18\CD\14622893 efficacy_19\NN\5199286 in_20\IN\13603305 <e2>nsclc</e2>_21\NN\1740 ._22\.\1740
C107135_D002289 NONE methods_0\NNS\5616786 :_1\:\1740 stage_2\NN\15113229 iiib_3\NNS\1740 or_4\CC\3541091 iv_5\CD\13741022 <e2>nsclc</e2>_6\NN\1740 patients_7\NNS\9898892 ,_8\,\1740 with_9\IN\1740 two_10\CD\13741022 or_11\CC\3541091 fewer_12\JJR\1740 prior_13\JJ\1740 chemotherapy_14\NN\661091 regimens_15\NNS\5898568 ,_16\,\1740 one_17\CD\13741022 platinum_18\NN\14627081 based_19\VBN\2694933 (_20\-LRB-\1740 stratum_21\NN\8591680 1_22\CD\13741022 )_23\-RRB-\1740 or_24\CC\3541091 both_25\CC\1740 chemotherapy_26\NN\661091 and_27\CC\1740 epidermal_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 receptor_31\NN\5225602 tyrosine_32\NN\14601829 kinase_33\NN\14732946 inhibitors_34\NNS\20090 (_35\-LRB-\1740 stratum_36\NN\8591680 2_37\CD\13741022 )_38\-RRB-\1740 ,_39\,\1740 received_40\VBD\2210855 <e1>rad001</e1>_41\NN\1740 10_42\CD\13745420 mg/day_43\NN\1740 until_44\IN\1740 progression_45\NN\8457976 or_46\CC\3541091 unacceptable_47\JJ\1740 toxicity_48\NN\13576101 ._49\.\1740
C107135_D002289 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>rad001</e1>_2\NN\1740 10_3\CD\13745420 mg/day_4\NN\1740 was_5\VBD\836236 well_6\RB\1740 tolerated_7\VBN\802318 ,_8\,\1740 showing_9\VBG\2137132 modest_10\JJ\1740 clinical_11\JJ\1740 activity_12\NN\30358 in_13\IN\13603305 pretreated_14\JJ\1740 <e2>nsclc</e2>_15\NN\1740 ._16\.\1740
C107135_D002289 NONE evaluation_0\NN\874067 of_1\IN\1740 <e1>rad001</e1>_2\NN\1740 plus_3\CC\4723816 standard_4\JJ\1740 therapy_5\NN\657604 for_6\IN\1740 metastatic_7\JJ\1740 <e2>nsclc</e2>_8\NN\1740 continues_9\VBZ\2367363 ._10\.\1740
D020123_D002289 NONE rad001_0\NN\1740 ,_1\,\1740 an_2\DT\6697703 oral_3\JJ\1740 inhibitor_4\NN\20090 of_5\IN\1740 the_6\DT\1740 mammalian_7\JJ\1740 target_8\NN\7258332 of_9\IN\1740 <e1>rapamycin</e1>_10\NN\1740 (_11\-LRB-\1740 mtor_12\NN\1740 )_13\-RRB-\1740 ,_14\,\1740 has_15\VBZ\2108377 shown_16\VBN\2137132 phase_17\NN\15113229 i_18\CD\14622893 efficacy_19\NN\5199286 in_20\IN\13603305 <e2>nsclc</e2>_21\NN\1740 ._22\.\1740
D010984_D002289 NONE methods_0\NNS\5616786 :_1\:\1740 stage_2\NN\15113229 iiib_3\NNS\1740 or_4\CC\3541091 iv_5\CD\13741022 <e2>nsclc</e2>_6\NN\1740 patients_7\NNS\9898892 ,_8\,\1740 with_9\IN\1740 two_10\CD\13741022 or_11\CC\3541091 fewer_12\JJR\1740 prior_13\JJ\1740 chemotherapy_14\NN\661091 regimens_15\NNS\5898568 ,_16\,\1740 one_17\CD\13741022 <e1>platinum</e1>_18\NN\14627081 based_19\VBN\2694933 (_20\-LRB-\1740 stratum_21\NN\8591680 1_22\CD\13741022 )_23\-RRB-\1740 or_24\CC\3541091 both_25\CC\1740 chemotherapy_26\NN\661091 and_27\CC\1740 epidermal_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 receptor_31\NN\5225602 tyrosine_32\NN\14601829 kinase_33\NN\14732946 inhibitors_34\NNS\20090 (_35\-LRB-\1740 stratum_36\NN\8591680 2_37\CD\13741022 )_38\-RRB-\1740 ,_39\,\1740 received_40\VBD\2210855 rad001_41\NN\1740 10_42\CD\13745420 mg/day_43\NN\1740 until_44\IN\1740 progression_45\NN\8457976 or_46\CC\3541091 unacceptable_47\JJ\1740 toxicity_48\NN\13576101 ._49\.\1740
D010984_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 stage_2\NN\15113229 iiib_3\NNS\1740 or_4\CC\3541091 iv_5\CD\13741022 nsclc_6\NN\1740 patients_7\NNS\9898892 ,_8\,\1740 with_9\IN\1740 two_10\CD\13741022 or_11\CC\3541091 fewer_12\JJR\1740 prior_13\JJ\1740 chemotherapy_14\NN\661091 regimens_15\NNS\5898568 ,_16\,\1740 one_17\CD\13741022 <e1>platinum</e1>_18\NN\14627081 based_19\VBN\2694933 (_20\-LRB-\1740 stratum_21\NN\8591680 1_22\CD\13741022 )_23\-RRB-\1740 or_24\CC\3541091 both_25\CC\1740 chemotherapy_26\NN\661091 and_27\CC\1740 epidermal_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 receptor_31\NN\5225602 tyrosine_32\NN\14601829 kinase_33\NN\14732946 inhibitors_34\NNS\20090 (_35\-LRB-\1740 stratum_36\NN\8591680 2_37\CD\13741022 )_38\-RRB-\1740 ,_39\,\1740 received_40\VBD\2210855 rad001_41\NN\1740 10_42\CD\13745420 mg/day_43\NN\1740 until_44\IN\1740 progression_45\NN\8457976 or_46\CC\3541091 unacceptable_47\JJ\1740 <e2>toxicity</e2>_48\NN\13576101 ._49\.\1740
D014443_D002289 NONE methods_0\NNS\5616786 :_1\:\1740 stage_2\NN\15113229 iiib_3\NNS\1740 or_4\CC\3541091 iv_5\CD\13741022 <e2>nsclc</e2>_6\NN\1740 patients_7\NNS\9898892 ,_8\,\1740 with_9\IN\1740 two_10\CD\13741022 or_11\CC\3541091 fewer_12\JJR\1740 prior_13\JJ\1740 chemotherapy_14\NN\661091 regimens_15\NNS\5898568 ,_16\,\1740 one_17\CD\13741022 platinum_18\NN\14627081 based_19\VBN\2694933 (_20\-LRB-\1740 stratum_21\NN\8591680 1_22\CD\13741022 )_23\-RRB-\1740 or_24\CC\3541091 both_25\CC\1740 chemotherapy_26\NN\661091 and_27\CC\1740 epidermal_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 receptor_31\NN\5225602 <e1>tyrosine</e1>_32\NN\14601829 kinase_33\NN\14732946 inhibitors_34\NNS\20090 (_35\-LRB-\1740 stratum_36\NN\8591680 2_37\CD\13741022 )_38\-RRB-\1740 ,_39\,\1740 received_40\VBD\2210855 rad001_41\NN\1740 10_42\CD\13745420 mg/day_43\NN\1740 until_44\IN\1740 progression_45\NN\8457976 or_46\CC\3541091 unacceptable_47\JJ\1740 toxicity_48\NN\13576101 ._49\.\1740
D014443_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 stage_2\NN\15113229 iiib_3\NNS\1740 or_4\CC\3541091 iv_5\CD\13741022 nsclc_6\NN\1740 patients_7\NNS\9898892 ,_8\,\1740 with_9\IN\1740 two_10\CD\13741022 or_11\CC\3541091 fewer_12\JJR\1740 prior_13\JJ\1740 chemotherapy_14\NN\661091 regimens_15\NNS\5898568 ,_16\,\1740 one_17\CD\13741022 platinum_18\NN\14627081 based_19\VBN\2694933 (_20\-LRB-\1740 stratum_21\NN\8591680 1_22\CD\13741022 )_23\-RRB-\1740 or_24\CC\3541091 both_25\CC\1740 chemotherapy_26\NN\661091 and_27\CC\1740 epidermal_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 receptor_31\NN\5225602 <e1>tyrosine</e1>_32\NN\14601829 kinase_33\NN\14732946 inhibitors_34\NNS\20090 (_35\-LRB-\1740 stratum_36\NN\8591680 2_37\CD\13741022 )_38\-RRB-\1740 ,_39\,\1740 received_40\VBD\2210855 rad001_41\NN\1740 10_42\CD\13745420 mg/day_43\NN\1740 until_44\IN\1740 progression_45\NN\8457976 or_46\CC\3541091 unacceptable_47\JJ\1740 <e2>toxicity</e2>_48\NN\13576101 ._49\.\1740
C107135_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 stage_2\NN\15113229 iiib_3\NNS\1740 or_4\CC\3541091 iv_5\CD\13741022 nsclc_6\NN\1740 patients_7\NNS\9898892 ,_8\,\1740 with_9\IN\1740 two_10\CD\13741022 or_11\CC\3541091 fewer_12\JJR\1740 prior_13\JJ\1740 chemotherapy_14\NN\661091 regimens_15\NNS\5898568 ,_16\,\1740 one_17\CD\13741022 platinum_18\NN\14627081 based_19\VBN\2694933 (_20\-LRB-\1740 stratum_21\NN\8591680 1_22\CD\13741022 )_23\-RRB-\1740 or_24\CC\3541091 both_25\CC\1740 chemotherapy_26\NN\661091 and_27\CC\1740 epidermal_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 receptor_31\NN\5225602 tyrosine_32\NN\14601829 kinase_33\NN\14732946 inhibitors_34\NNS\20090 (_35\-LRB-\1740 stratum_36\NN\8591680 2_37\CD\13741022 )_38\-RRB-\1740 ,_39\,\1740 received_40\VBD\2210855 <e1>rad001</e1>_41\NN\1740 10_42\CD\13745420 mg/day_43\NN\1740 until_44\IN\1740 progression_45\NN\8457976 or_46\CC\3541091 unacceptable_47\JJ\1740 <e2>toxicity</e2>_48\NN\13576101 ._49\.\1740
7671401
D000806_D000799 CID increased_0\VBN\169651 frequency_1\NN\15286249 and_2\CC\1740 severity_3\NN\5036394 of_4\IN\1740 <e2>angio-oedema</e2>_5\NN\1740 related_6\JJ\1740 to_7\TO\1740 long-term_8\JJ\1740 therapy_9\NN\657604 with_10\IN\1740 <e1>angiotensin-converting_11\JJ\1740 enzyme_12\NN\14723628 inhibitor</e1>_13\NN\20090 in_14\IN\13603305 two_15\CD\13741022 patients_16\NNS\9898892 ._17\.\1740
D000806_D000799 CID soon_0\RB\1740 after_1\IN\1740 the_2\DT\1740 introduction_3\NN\235435 of_4\IN\1740 <e1>ace_5\NN\13741022 inhibitors</e1>_6\NNS\20090 ,_7\,\1740 acute_8\JJ\1740 bouts_9\NNS\5867413 of_10\IN\1740 <e2>angio-oedema</e2>_11\NN\1740 were_12\VBD\836236 reported_13\VBN\831651 in_14\IN\13603305 association_15\NN\8008335 with_16\IN\1740 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 these_20\DT\1740 drugs_21\NNS\14778436 ._22\.\1740
D000806_D000799 CID we_0\PRP\1740 wish_1\VBP\1825237 to_2\TO\1740 draw_3\VB\1850315 attention_4\NN\5701944 to_5\IN\1740 the_6\DT\1740 possibility_7\NN\5944958 of_8\IN\1740 adverse_9\JJ\1740 reactions_10\NNS\13446390 to_11\TO\1740 <e1>ace_12\NN\13741022 inhibitors</e1>_13\NNS\20090 after_14\IN\1740 long-term_15\JJ\1740 use_16\NN\407535 and_17\CC\1740 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 pre-existing_21\JJ\1740 <e2>angio-oedema</e2>_22\NN\1740 ._23\.\1740
D000806_D006973 NONE <e1>angiotensin-converting_0\JJ\1740 enzyme_1\NN\14723628 (_2\-LRB-\1740 ace_3\NN\13741022 )_4\-RRB-\1740 inhibitors</e1>_5\NNS\20090 ,_6\,\1740 used_7\VBN\1156834 to_8\TO\1740 treat_9\VB\2376958 <e2>hypertension</e2>_10\NN\14057371 and_11\CC\1740 congestive_12\JJ\1740 heart_13\NN\5919034 failure_14\NN\66216 ,_15\,\1740 were_16\VBD\836236 introduced_17\VBN\831651 in_18\IN\13603305 europe_19\NNP\8294696 in_20\IN\13603305 the_21\DT\1740 middle_22\NN\8497294 of_23\IN\1740 the_24\DT\1740 eighties_25\NNS\15204983 ,_26\,\1740 and_27\CC\1740 the_28\DT\1740 use_29\NN\407535 of_30\IN\1740 these_31\DT\1740 drugs_32\NNS\14778436 has_33\VBZ\2108377 increased_34\VBN\169651 progressively_35\RB\1740 ._36\.\1740
D000806_D006333 NONE <e1>angiotensin-converting_0\JJ\1740 enzyme_1\NN\14723628 (_2\-LRB-\1740 ace_3\NN\13741022 )_4\-RRB-\1740 inhibitors</e1>_5\NNS\20090 ,_6\,\1740 used_7\VBN\1156834 to_8\TO\1740 treat_9\VB\2376958 hypertension_10\NN\14057371 and_11\CC\1740 <e2>congestive_12\JJ\1740 heart_13\NN\5919034 failure</e2>_14\NN\66216 ,_15\,\1740 were_16\VBD\836236 introduced_17\VBN\831651 in_18\IN\13603305 europe_19\NNP\8294696 in_20\IN\13603305 the_21\DT\1740 middle_22\NN\8497294 of_23\IN\1740 the_24\DT\1740 eighties_25\NNS\15204983 ,_26\,\1740 and_27\CC\1740 the_28\DT\1740 use_29\NN\407535 of_30\IN\1740 these_31\DT\1740 drugs_32\NNS\14778436 has_33\VBZ\2108377 increased_34\VBN\169651 progressively_35\RB\1740 ._36\.\1740
24464946
D015251_D066126 CID two-dimensional_0\JJ\1740 speckle_1\NN\4680285 tracking_2\NN\319939 echocardiography_3\NN\177127 combined_4\JJ\1740 with_5\IN\1740 high-sensitive_6\JJ\1740 cardiac_7\NN\1740 troponin_8\NN\1740 t_9\NN\14999913 in_10\IN\13603305 early_11\JJ\1740 detection_12\NN\5708432 and_13\CC\1740 prediction_14\NN\5772356 of_15\IN\1740 <e2>cardiotoxicity</e2>_16\NN\1740 during_17\IN\1740 <e1>epirubicine-based</e1>_18\JJ\1740 chemotherapy_19\NN\661091 ._20\.\1740
D015251_D009202 NONE aims_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 investigate_3\VB\644583 whether_4\IN\1740 alterations_5\NNS\7283608 of_6\IN\1740 <e2>myocardial_7\JJ\1740 strain</e2>_8\NN\7358060 and_9\CC\1740 high-sensitive_10\JJ\1740 cardiac_11\JJ\1740 troponin_12\NN\1740 t_13\NN\14999913 (_14\-LRB-\1740 ctnt_15\NN\1740 )_16\-RRB-\1740 could_17\MD\1740 predict_18\VB\916909 future_19\JJ\1740 cardiac_20\JJ\1740 dysfunction_21\NN\14204950 in_22\IN\13603305 patients_23\NNS\9898892 after_24\IN\1740 <e1>epirubicin</e1>_25\NN\1740 exposure_26\NN\5042871 ._27\.\1740
D015251_D006331 NONE aims_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 investigate_3\VB\644583 whether_4\IN\1740 alterations_5\NNS\7283608 of_6\IN\1740 myocardial_7\JJ\1740 strain_8\NN\7358060 and_9\CC\1740 high-sensitive_10\JJ\1740 cardiac_11\JJ\1740 troponin_12\NN\1740 t_13\NN\14999913 (_14\-LRB-\1740 ctnt_15\NN\1740 )_16\-RRB-\1740 could_17\MD\1740 predict_18\VB\916909 future_19\JJ\1740 <e2>cardiac_20\JJ\1740 dysfunction</e2>_21\NN\14204950 in_22\IN\13603305 patients_23\NNS\9898892 after_24\IN\1740 <e1>epirubicin</e1>_25\NN\1740 exposure_26\NN\5042871 ._27\.\1740
D015251_D008228 NONE methods_0\NNS\5616786 :_1\:\1740 seventy-five_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 <e2>non-hodgkin_5\JJ\1740 lymphoma</e2>_6\NN\14239918 treated_7\VBN\2376958 with_8\IN\1740 <e1>epirubicin</e1>_9\NN\1740 were_10\VBD\836236 studied_11\VBN\630380 ._12\.\1740
D018943_D006331 NONE conclusions_0\NNS\5837957 :_1\:\1740 gls_2\NN\1740 combined_3\VBN\2630189 with_4\IN\1740 ctnt_5\NN\1740 may_6\MD\15209706 provide_7\VB\2199590 a_8\DT\13649268 reliable_9\JJ\1740 and_10\CC\1740 non-invasive_11\JJ\1740 method_12\NN\5616786 to_13\TO\1740 predict_14\VB\916909 <e2>cardiac_15\JJ\1740 dysfunction</e2>_16\NN\14204950 in_17\IN\13603305 patients_18\NNS\9898892 receiving_19\VBG\2210855 <e1>anthracycline-based</e1>_20\JJ\1740 chemotherapy_21\NN\661091 ._22\.\1740
1756784
D010862_D001930 CID <e2>damage_0\NN\7296428 of_1\IN\1740 substantia_2\RB\1740 nigra_3\JJ\1740 pars_4\NNS\13594585 reticulata</e2>_5\VBZ\1740 during_6\IN\1740 <e1>pilocarpine-induced</e1>_7\JJ\1740 status_8\NN\24720 epilepticus_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 rat_12\NN\2329401 :_13\:\1740 immunohistochemical_14\JJ\1740 study_15\NN\635850 of_16\IN\1740 neurons_17\NNS\5430628 ,_18\,\1740 astrocytes_19\NNS\5467432 and_20\CC\1740 serum-protein_21\JJ\1740 extravasation_22\NN\14940100 ._23\.\1740
D010862_D013226 CID damage_0\NN\7296428 of_1\IN\1740 substantia_2\RB\1740 nigra_3\JJ\1740 pars_4\NNS\13594585 reticulata_5\VBZ\1740 during_6\IN\1740 <e1>pilocarpine-induced</e1>_7\JJ\1740 <e2>status_8\NN\24720 epilepticus</e2>_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 rat_12\NN\2329401 :_13\:\1740 immunohistochemical_14\JJ\1740 study_15\NN\635850 of_16\IN\1740 neurons_17\NNS\5430628 ,_18\,\1740 astrocytes_19\NNS\5467432 and_20\CC\1740 serum-protein_21\JJ\1740 extravasation_22\NN\14940100 ._23\.\1740
D010862_D013226 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 <e2>status_4\NN\24720 epilepticus</e2>_5\NN\1740 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 systemic_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 <e1>pilocarpine</e1>_12\NN\14712692 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
D002118_D009422 NONE nissl-staining_0\JJ\1740 and_1\CC\1740 antibodies_2\NNS\14728724 against_3\IN\1740 the_4\DT\1740 neuron-specific_5\JJ\1740 <e1>calcium-binding</e1>_6\JJ\1740 protein_7\NN\14944888 ,_8\,\1740 parvalbumin_9\NN\1740 ,_10\,\1740 served_11\VBD\2669789 to_12\TO\1740 detect_13\VB\2163746 <e2>neuronal_14\JJ\1740 damage</e2>_15\NN\7296428 in_16\IN\13603305 snr_17\NN\1740 ._18\.\1740
9570197
D003042_D018487 CID background_0\NN\4921011 :_1\:\1740 in_2\IN\13603305 dogs_3\NNS\2083346 ,_4\,\1740 a_5\DT\13649268 large_6\JJ\1740 amount_7\NN\13329641 of_8\IN\1740 intravenous_9\JJ\1740 <e1>cocaine</e1>_10\NN\3492717 causes_11\VBZ\1617192 a_12\DT\13649268 profound_13\JJ\1740 <e2>deterioration_14\NN\14560612 of_15\IN\1740 left_16\JJ\1740 ventricular_17\NN\1740 (_18\-LRB-\1740 lv_19\JJ\1740 )_20\-RRB-\1740 systolic_21\JJ\1740 function</e2>_22\NN\13783581 and_23\CC\1740 an_24\DT\6697703 increase_25\NN\13576355 in_26\IN\13603305 lv_27\JJ\1740 end-diastolic_28\JJ\1740 pressure_29\NN\11419404 ._30\.\1740
D003042_D018487 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 humans_3\NNS\31264 ,_4\,\1740 the_5\DT\1740 intracoronary_6\JJ\1740 infusion_7\NN\14589223 of_8\IN\1740 <e1>cocaine</e1>_9\NN\3492717 sufficient_10\JJ\1740 in_11\IN\13603305 amount_12\NN\13329641 to_13\TO\1740 achieve_14\VB\2524171 a_15\DT\13649268 high_16\JJ\1740 drug_17\NN\14778436 concentration_18\NN\4916342 in_19\IN\13603305 coronary_20\JJ\1740 sinus_21\NN\5248181 blood_22\NN\5397468 causes_23\VBZ\1617192 a_24\DT\13649268 <e2>deterioration_25\NN\14560612 of_26\IN\1740 lv_27\JJ\1740 systolic_28\NN\1740 and_29\CC\1740 diastolic_30\JJ\1740 performance</e2>_31\NN\6619065 ._32\.\1740
D003042_D002637 NONE methods_0\NNS\5616786 and_1\CC\1740 results_2\NNS\34213 :_3\:\1740 in_4\IN\13603305 20_5\CD\13745420 patients_6\NNS\9898892 (_7\-LRB-\1740 14_8\CD\13745420 men_9\NNS\8208016 and_10\CC\1740 6_11\CD\13741022 women_12\NNS\9605289 aged_13\JJ\1740 39_14\CD\1740 to_15\TO\1740 72_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 referred_19\VBN\730052 for_20\IN\1740 cardiac_21\JJ\1740 catheterization_22\NN\671351 for_23\IN\1740 the_24\DT\1740 evaluation_25\NN\874067 of_26\IN\1740 <e2>chest_27\JJ\1740 pain</e2>_28\NN\14299637 ,_29\,\1740 we_30\PRP\1740 measured_31\VBD\697589 heart_32\NN\5919034 rate_33\NN\13815152 ,_34\,\1740 systemic_35\JJ\1740 arterial_36\JJ\1740 pressure_37\NN\11419404 ,_38\,\1740 lv_39\JJ\1740 pressure_40\NN\11419404 and_41\CC\1740 its_42\PRP$\6125041 first_43\JJ\1740 derivative_44\JJ\1740 (_45\-LRB-\1740 dp/dt_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 lv_50\JJ\1740 volumes_51\NNS\33615 and_52\CC\1740 ejection_53\NN\45250 fraction_54\NN\14806838 before_55\IN\1740 and_56\CC\1740 during_57\IN\1740 the_58\DT\1740 final_59\JJ\1740 2_60\CD\13741022 to_61\TO\1740 3_62\CD\13741022 minutes_63\NNS\6502378 of_64\IN\1740 a_65\DT\13649268 15-minute_66\JJ\1740 intracoronary_67\JJ\1740 infusion_68\NN\14589223 of_69\IN\1740 saline_70\NN\14849367 (_71\-LRB-\1740 n=10_72\NN\1740 ,_73\,\1740 control_74\JJ\1740 subjects_75\NNS\6598915 )_76\-RRB-\1740 or_77\CC\3541091 <e1>cocaine_78\NN\3492717 hydrochloride</e1>_79\NN\14817592 1_80\CD\13741022 mg/min_81\NN\1740 (_82\-LRB-\1740 n=10_83\NN\1740 )_84\-RRB-\1740 ._85\.\1740
24691439
D003907_D012173 NONE treatment_0\NN\654885 of_1\IN\1740 wt_2\NN\1740 mice_3\NNS\2329401 with_4\IN\1740 topical_5\JJ\1740 ocular_6\JJ\1740 0.1_7\CD\1740 %_8\NN\1740 <e1>dexamethasone</e1>_9\NN\2721538 led_10\VBD\1752884 to_11\TO\1740 elevation_12\NN\7445480 of_13\IN\1740 intraocular_14\JJ\1740 pressure_15\NN\11419404 (_16\-LRB-\1740 iop_17\NNS\11495041 )_18\-RRB-\1740 ,_19\,\1740 functional_20\JJ\1740 and_21\CC\1740 structural_22\JJ\1740 loss_23\NN\13252973 of_24\IN\1740 <e2>retinal_25\JJ\1740 ganglion</e2>_26\NN\5462674 cells_27\NNS\3080309 ,_28\,\1740 and_29\CC\1740 axonal_30\JJ\1740 degeneration_31\NN\29677 ,_32\,\1740 resembling_33\VBG\2657219 glucocorticoid-induced_34\JJ\1740 glaucoma_35\NN\14252864 in_36\IN\13603305 human_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D003907_D009410 CID treatment_0\NN\654885 of_1\IN\1740 wt_2\NN\1740 mice_3\NNS\2329401 with_4\IN\1740 topical_5\JJ\1740 ocular_6\JJ\1740 0.1_7\CD\1740 %_8\NN\1740 <e1>dexamethasone</e1>_9\NN\2721538 led_10\VBD\1752884 to_11\TO\1740 elevation_12\NN\7445480 of_13\IN\1740 intraocular_14\JJ\1740 pressure_15\NN\11419404 (_16\-LRB-\1740 iop_17\NNS\11495041 )_18\-RRB-\1740 ,_19\,\1740 functional_20\JJ\1740 and_21\CC\1740 structural_22\JJ\1740 loss_23\NN\13252973 of_24\IN\1740 retinal_25\JJ\1740 ganglion_26\NN\5462674 cells_27\NNS\3080309 ,_28\,\1740 and_29\CC\1740 <e2>axonal_30\JJ\1740 degeneration</e2>_31\NN\29677 ,_32\,\1740 resembling_33\VBG\2657219 glucocorticoid-induced_34\JJ\1740 glaucoma_35\NN\14252864 in_36\IN\13603305 human_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D003907_D005901 CID treatment_0\NN\654885 of_1\IN\1740 wt_2\NN\1740 mice_3\NNS\2329401 with_4\IN\1740 topical_5\JJ\1740 ocular_6\JJ\1740 0.1_7\CD\1740 %_8\NN\1740 <e1>dexamethasone</e1>_9\NN\2721538 led_10\VBD\1752884 to_11\TO\1740 elevation_12\NN\7445480 of_13\IN\1740 intraocular_14\JJ\1740 pressure_15\NN\11419404 (_16\-LRB-\1740 iop_17\NNS\11495041 )_18\-RRB-\1740 ,_19\,\1740 functional_20\JJ\1740 and_21\CC\1740 structural_22\JJ\1740 loss_23\NN\13252973 of_24\IN\1740 retinal_25\JJ\1740 ganglion_26\NN\5462674 cells_27\NNS\3080309 ,_28\,\1740 and_29\CC\1740 axonal_30\JJ\1740 degeneration_31\NN\29677 ,_32\,\1740 resembling_33\VBG\2657219 glucocorticoid-induced_34\JJ\1740 <e2>glaucoma</e2>_35\NN\14252864 in_36\IN\13603305 human_37\JJ\1740 patients_38\NNS\9898892 ._39\.\1740
D003907_D009798 CID furthermore_0\RB\1740 ,_1\,\1740 <e1>dexamethasone-induced</e1>_2\JJ\1740 <e2>ocular_3\JJ\1740 hypertension</e2>_4\NN\14057371 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 chronic_8\JJ\1740 er_9\NN\14625458 stress_10\NN\7083732 of_11\IN\1740 the_12\DT\1740 trabecular_13\JJ\1740 meshwork_14\NN\3309808 (_15\-LRB-\1740 tm_16\NN\14625458 )_17\-RRB-\1740 ._18\.\1740
D003907_D009798 CID <e1>dexamethasone</e1>_0\NN\2721538 induced_1\VBD\1627355 the_2\DT\1740 transcriptional_3\JJ\1740 factor_4\NN\7326557 chop_5\NN\11419404 ,_6\,\1740 a_7\DT\13649268 marker_8\NN\21939 for_9\IN\1740 chronic_10\JJ\1740 er_11\NN\14625458 stress_12\NN\7083732 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 anterior_16\JJ\1740 segment_17\NN\3892891 tissues_18\NNS\5220461 ,_19\,\1740 and_20\CC\1740 chop_21\NN\11419404 deletion_22\NN\13508333 reduced_23\VBD\441445 er_24\NN\14625458 stress_25\NN\7083732 in_26\IN\13603305 these_27\DT\1740 tissues_28\NNS\5220461 and_29\CC\1740 prevented_30\VBD\1740 dexamethasone-induced_31\JJ\1740 <e2>ocular_32\JJ\1740 hypertension</e2>_33\NN\14057371 ._34\.\1740
D003907_D009798 CID dexamethasone_0\NN\2721538 induced_1\VBD\1627355 the_2\DT\1740 transcriptional_3\JJ\1740 factor_4\NN\7326557 chop_5\NN\11419404 ,_6\,\1740 a_7\DT\13649268 marker_8\NN\21939 for_9\IN\1740 chronic_10\JJ\1740 er_11\NN\14625458 stress_12\NN\7083732 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 anterior_16\JJ\1740 segment_17\NN\3892891 tissues_18\NNS\5220461 ,_19\,\1740 and_20\CC\1740 chop_21\NN\11419404 deletion_22\NN\13508333 reduced_23\VBD\441445 er_24\NN\14625458 stress_25\NN\7083732 in_26\IN\13603305 these_27\DT\1740 tissues_28\NNS\5220461 and_29\CC\1740 prevented_30\VBD\1740 <e1>dexamethasone-induced</e1>_31\JJ\1740 <e2>ocular_32\JJ\1740 hypertension</e2>_33\NN\14057371 ._34\.\1740
D003907_D009798 CID furthermore_0\RB\1740 ,_1\,\1740 reduction_2\NN\351485 of_3\IN\1740 er_4\NN\14625458 stress_5\NN\7083732 in_6\IN\13603305 the_7\DT\1740 tm_8\NN\14625458 with_9\IN\1740 sodium_10\NN\14625458 4-phenylbutyrate_11\NN\1740 prevented_12\VBD\1740 <e1>dexamethasone-induced</e1>_13\JJ\1740 <e2>ocular_14\JJ\1740 hypertension</e2>_15\NN\14057371 in_16\IN\13603305 wt_17\NN\1740 mice_18\NNS\2329401 ._19\.\1740
C075773_D009798 NONE furthermore_0\RB\1740 ,_1\,\1740 reduction_2\NN\351485 of_3\IN\1740 er_4\NN\14625458 stress_5\NN\7083732 in_6\IN\13603305 the_7\DT\1740 tm_8\NN\14625458 with_9\IN\1740 <e1>sodium_10\NN\14625458 4-phenylbutyrate</e1>_11\NN\1740 prevented_12\VBD\1740 dexamethasone-induced_13\JJ\1740 <e2>ocular_14\JJ\1740 hypertension</e2>_15\NN\14057371 in_16\IN\13603305 wt_17\NN\1740 mice_18\NNS\2329401 ._19\.\1740
24971338
D020123_D007674 NONE conversion_0\NN\7359599 to_1\TO\1740 <e1>sirolimus</e1>_2\NN\1740 ameliorates_3\VBZ\126264 cyclosporine-induced_4\JJ\1740 <e2>nephropathy</e2>_5\NN\14573196 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 :_9\:\1740 focus_10\NN\5704266 on_11\IN\1740 serum_12\NN\5397468 ,_13\,\1740 urine_14\NN\14853947 ,_15\,\1740 gene_16\NN\8459252 ,_17\,\1740 and_18\CC\1740 protein_19\NN\14944888 renal_20\JJ\1740 expression_21\NN\4679549 biomarkers_22\NNS\1740 ._23\.\1740
D020123_D007674 NONE protocols_0\NNS\6652242 of_1\IN\1740 conversion_2\NN\7359599 from_3\IN\1740 cyclosporin_4\NN\1740 a_5\NN\13649268 (_6\-LRB-\1740 csa_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 <e1>sirolimus</e1>_10\NN\1740 (_11\-LRB-\1740 srl_12\NN\1740 )_13\-RRB-\1740 have_14\VBP\2108377 been_15\VBN\836236 widely_16\RB\1740 used_17\VBN\1156834 in_18\IN\13603305 immunotherapy_19\NN\661091 after_20\IN\1740 transplantation_21\NN\671351 to_22\TO\1740 prevent_23\VB\1740 csa-induced_24\JJ\1740 <e2>nephropathy</e2>_25\NN\14573196 ,_26\,\1740 but_27\CC\1740 the_28\DT\1740 molecular_29\JJ\1740 mechanisms_30\NNS\13446390 underlying_31\VBG\2604760 these_32\DT\1740 protocols_33\NNS\6652242 remain_34\VBP\2604760 nuclear_35\JJ\1740 ._36\.\1740
D020123_D007674 NONE protocols_0\NNS\6652242 of_1\IN\1740 conversion_2\NN\7359599 from_3\IN\1740 cyclosporin_4\NN\1740 a_5\NN\13649268 (_6\-LRB-\1740 csa_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 sirolimus_10\NN\1740 (_11\-LRB-\1740 <e1>srl</e1>_12\NN\1740 )_13\-RRB-\1740 have_14\VBP\2108377 been_15\VBN\836236 widely_16\RB\1740 used_17\VBN\1156834 in_18\IN\13603305 immunotherapy_19\NN\661091 after_20\IN\1740 transplantation_21\NN\671351 to_22\TO\1740 prevent_23\VB\1740 csa-induced_24\JJ\1740 <e2>nephropathy</e2>_25\NN\14573196 ,_26\,\1740 but_27\CC\1740 the_28\DT\1740 molecular_29\JJ\1740 mechanisms_30\NNS\13446390 underlying_31\VBG\2604760 these_32\DT\1740 protocols_33\NNS\6652242 remain_34\VBP\2604760 nuclear_35\JJ\1740 ._36\.\1740
D020123_D007674 NONE <e1>srl-treated</e1>_0\JJ\1740 rats_1\NNS\2329401 presented_2\VBD\2137132 proteinuria_3\NN\14299637 and_4\CC\1740 ngal_5\NN\1740 (_6\-LRB-\1740 serum_7\NN\5397468 and_8\CC\1740 urinary_9\JJ\1740 )_10\-RRB-\1740 as_11\IN\14622893 the_12\DT\1740 best_13\JJS\1740 markers_14\NNS\21939 of_15\IN\1740 <e2>renal_16\JJ\1740 impairment</e2>_17\NN\7296428 ._18\.\1740
D020123_D007674 NONE conversion_0\NN\7359599 to_1\TO\1740 <e1>srl</e1>_2\NN\1740 prevented_3\VBD\1740 csa-induced_4\JJ\1740 <e2>renal_5\JJ\1740 damage</e2>_6\NN\7296428 evolution_7\NN\29677 (_8\-LRB-\1740 absent/mild_9\JJ\1740 grade_10\NN\7975026 lesions_11\NNS\14204950 )_12\-RRB-\1740 ,_13\,\1740 while_14\IN\15122231 ngal_15\NN\1740 (_16\-LRB-\1740 serum_17\NN\5397468 versus_18\CC\1740 urine_19\NN\14853947 )_20\-RRB-\1740 seems_21\VBZ\2604760 to_22\TO\1740 be_23\VB\836236 a_24\DT\13649268 feasible_25\JJ\1740 biomarker_26\NN\1740 of_27\IN\1740 csa_28\NN\1740 replacement_29\NN\196485 to_30\TO\1740 srl_31\NNP\1740 ._32\.\1740
D020123_D007674 NONE conversion_0\NN\7359599 to_1\TO\1740 srl_2\NN\1740 prevented_3\VBD\1740 csa-induced_4\JJ\1740 <e2>renal_5\JJ\1740 damage</e2>_6\NN\7296428 evolution_7\NN\29677 (_8\-LRB-\1740 absent/mild_9\JJ\1740 grade_10\NN\7975026 lesions_11\NNS\14204950 )_12\-RRB-\1740 ,_13\,\1740 while_14\IN\15122231 ngal_15\NN\1740 (_16\-LRB-\1740 serum_17\NN\5397468 versus_18\CC\1740 urine_19\NN\14853947 )_20\-RRB-\1740 seems_21\VBZ\2604760 to_22\TO\1740 be_23\VB\836236 a_24\DT\13649268 feasible_25\JJ\1740 biomarker_26\NN\1740 of_27\IN\1740 csa_28\NN\1740 replacement_29\NN\196485 to_30\TO\1740 <e1>srl</e1>_31\NNP\1740 ._32\.\1740
D016572_D007674 CID conversion_0\NN\7359599 to_1\TO\1740 sirolimus_2\NN\1740 ameliorates_3\VBZ\126264 <e1>cyclosporine-induced</e1>_4\JJ\1740 <e2>nephropathy</e2>_5\NN\14573196 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 :_9\:\1740 focus_10\NN\5704266 on_11\IN\1740 serum_12\NN\5397468 ,_13\,\1740 urine_14\NN\14853947 ,_15\,\1740 gene_16\NN\8459252 ,_17\,\1740 and_18\CC\1740 protein_19\NN\14944888 renal_20\JJ\1740 expression_21\NN\4679549 biomarkers_22\NNS\1740 ._23\.\1740
D016572_D007674 CID protocols_0\NNS\6652242 of_1\IN\1740 conversion_2\NN\7359599 from_3\IN\1740 <e1>cyclosporin_4\NN\1740 a</e1>_5\NN\13649268 (_6\-LRB-\1740 csa_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 sirolimus_10\NN\1740 (_11\-LRB-\1740 srl_12\NN\1740 )_13\-RRB-\1740 have_14\VBP\2108377 been_15\VBN\836236 widely_16\RB\1740 used_17\VBN\1156834 in_18\IN\13603305 immunotherapy_19\NN\661091 after_20\IN\1740 transplantation_21\NN\671351 to_22\TO\1740 prevent_23\VB\1740 csa-induced_24\JJ\1740 <e2>nephropathy</e2>_25\NN\14573196 ,_26\,\1740 but_27\CC\1740 the_28\DT\1740 molecular_29\JJ\1740 mechanisms_30\NNS\13446390 underlying_31\VBG\2604760 these_32\DT\1740 protocols_33\NNS\6652242 remain_34\VBP\2604760 nuclear_35\JJ\1740 ._36\.\1740
D016572_D007674 CID protocols_0\NNS\6652242 of_1\IN\1740 conversion_2\NN\7359599 from_3\IN\1740 cyclosporin_4\NN\1740 a_5\NN\13649268 (_6\-LRB-\1740 <e1>csa</e1>_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 sirolimus_10\NN\1740 (_11\-LRB-\1740 srl_12\NN\1740 )_13\-RRB-\1740 have_14\VBP\2108377 been_15\VBN\836236 widely_16\RB\1740 used_17\VBN\1156834 in_18\IN\13603305 immunotherapy_19\NN\661091 after_20\IN\1740 transplantation_21\NN\671351 to_22\TO\1740 prevent_23\VB\1740 csa-induced_24\JJ\1740 <e2>nephropathy</e2>_25\NN\14573196 ,_26\,\1740 but_27\CC\1740 the_28\DT\1740 molecular_29\JJ\1740 mechanisms_30\NNS\13446390 underlying_31\VBG\2604760 these_32\DT\1740 protocols_33\NNS\6652242 remain_34\VBP\2604760 nuclear_35\JJ\1740 ._36\.\1740
D016572_D007674 CID protocols_0\NNS\6652242 of_1\IN\1740 conversion_2\NN\7359599 from_3\IN\1740 cyclosporin_4\NN\1740 a_5\NN\13649268 (_6\-LRB-\1740 csa_7\NN\1740 )_8\-RRB-\1740 to_9\TO\1740 sirolimus_10\NN\1740 (_11\-LRB-\1740 srl_12\NN\1740 )_13\-RRB-\1740 have_14\VBP\2108377 been_15\VBN\836236 widely_16\RB\1740 used_17\VBN\1156834 in_18\IN\13603305 immunotherapy_19\NN\661091 after_20\IN\1740 transplantation_21\NN\671351 to_22\TO\1740 prevent_23\VB\1740 <e1>csa-induced</e1>_24\JJ\1740 <e2>nephropathy</e2>_25\NN\14573196 ,_26\,\1740 but_27\CC\1740 the_28\DT\1740 molecular_29\JJ\1740 mechanisms_30\NNS\13446390 underlying_31\VBG\2604760 these_32\DT\1740 protocols_33\NNS\6652242 remain_34\VBP\2604760 nuclear_35\JJ\1740 ._36\.\1740
D016572_D007674 CID short_0\JJ\1740 <e1>csa</e1>_1\NN\1740 treatment_2\NN\654885 presented_3\VBD\2137132 slight_4\JJ\1740 or_5\CC\3541091 even_6\RB\1740 absent_7\JJ\1740 <e2>kidney_8\NN\5333259 lesions</e2>_9\NNS\14204950 and_10\CC\1740 tgf-b_11\NN\1740 ,_12\,\1740 nf-_13\NN\1740 kb_14\NN\13601596 ,_15\,\1740 mtor_16\NN\1740 ,_17\,\1740 pcna_18\NN\1740 ,_19\,\1740 tp53_20\NN\1740 ,_21\,\1740 kim-1_22\NN\1740 ,_23\,\1740 and_24\CC\1740 ctgf_25\NN\1740 as_26\IN\14622893 relevant_27\JJ\1740 gene_28\NN\8459252 and_29\CC\1740 protein_30\NN\14944888 changes_31\NNS\7283608 ._32\.\1740
D016572_D007674 CID prolonged_0\JJ\1740 <e1>csa</e1>_1\NN\1740 exposure_2\NN\5042871 aggravated_3\VBD\126264 <e2>renal_4\JJ\1740 damage</e2>_5\NN\7296428 ,_6\,\1740 without_7\IN\1740 clear_8\JJ\1740 changes_9\NNS\7283608 on_10\IN\1740 the_11\DT\1740 traditional_12\JJ\1740 markers_13\NNS\21939 ,_14\,\1740 but_15\CC\1740 with_16\IN\1740 changes_17\NNS\7283608 in_18\IN\13603305 serums_19\NN\5397468 tgf-_20\NN\1740 b_21\NN\1355326 and_22\CC\1740 il-7_23\NN\1740 ,_24\,\1740 tbars_25\NNS\1740 clearance_26\NN\5089947 ,_27\,\1740 and_28\CC\1740 kidney_29\NN\5333259 tgf-b_30\NN\1740 and_31\CC\1740 mtor_32\NN\1740 ._33\.\1740
D016572_D007674 CID conversion_0\NN\7359599 to_1\TO\1740 srl_2\NN\1740 prevented_3\VBD\1740 <e1>csa-induced</e1>_4\JJ\1740 <e2>renal_5\JJ\1740 damage</e2>_6\NN\7296428 evolution_7\NN\29677 (_8\-LRB-\1740 absent/mild_9\JJ\1740 grade_10\NN\7975026 lesions_11\NNS\14204950 )_12\-RRB-\1740 ,_13\,\1740 while_14\IN\15122231 ngal_15\NN\1740 (_16\-LRB-\1740 serum_17\NN\5397468 versus_18\CC\1740 urine_19\NN\14853947 )_20\-RRB-\1740 seems_21\VBZ\2604760 to_22\TO\1740 be_23\VB\836236 a_24\DT\13649268 feasible_25\JJ\1740 biomarker_26\NN\1740 of_27\IN\1740 csa_28\NN\1740 replacement_29\NN\196485 to_30\TO\1740 srl_31\NNP\1740 ._32\.\1740
D016572_D007674 CID conversion_0\NN\7359599 to_1\TO\1740 srl_2\NN\1740 prevented_3\VBD\1740 csa-induced_4\JJ\1740 <e2>renal_5\JJ\1740 damage</e2>_6\NN\7296428 evolution_7\NN\29677 (_8\-LRB-\1740 absent/mild_9\JJ\1740 grade_10\NN\7975026 lesions_11\NNS\14204950 )_12\-RRB-\1740 ,_13\,\1740 while_14\IN\15122231 ngal_15\NN\1740 (_16\-LRB-\1740 serum_17\NN\5397468 versus_18\CC\1740 urine_19\NN\14853947 )_20\-RRB-\1740 seems_21\VBZ\2604760 to_22\TO\1740 be_23\VB\836236 a_24\DT\13649268 feasible_25\JJ\1740 biomarker_26\NN\1740 of_27\IN\1740 <e1>csa</e1>_28\NN\1740 replacement_29\NN\196485 to_30\TO\1740 srl_31\NNP\1740 ._32\.\1740
D006416_D007674 NONE <e2>renal_0\JJ\1740 lesions</e2>_1\NNS\14204950 were_2\VBD\836236 analyzed_3\VBN\78760 in_4\IN\13603305 <e1>hematoxylin</e1>_5\NN\1740 and_6\CC\1740 eosin_7\NN\14987695 ,_8\,\1740 periodic_9\JJ\1740 acid-schiff_10\NN\1740 ,_11\,\1740 and_12\CC\1740 masson_13\NNP\1740 's_14\POS\1740 trichrome_15\NN\1740 stains_16\NNS\4673965 ._17\.\1740
D004801_D007674 NONE <e2>renal_0\JJ\1740 lesions</e2>_1\NNS\14204950 were_2\VBD\836236 analyzed_3\VBN\78760 in_4\IN\13603305 hematoxylin_5\NN\1740 and_6\CC\1740 <e1>eosin</e1>_7\NN\14987695 ,_8\,\1740 periodic_9\JJ\1740 acid-schiff_10\NN\1740 ,_11\,\1740 and_12\CC\1740 masson_13\NNP\1740 's_14\POS\1740 trichrome_15\NN\1740 stains_16\NNS\4673965 ._17\.\1740
D020123_D011507 CID <e1>srl-treated</e1>_0\JJ\1740 rats_1\NNS\2329401 presented_2\VBD\2137132 <e2>proteinuria</e2>_3\NN\14299637 and_4\CC\1740 ngal_5\NN\1740 (_6\-LRB-\1740 serum_7\NN\5397468 and_8\CC\1740 urinary_9\JJ\1740 )_10\-RRB-\1740 as_11\IN\14622893 the_12\DT\1740 best_13\JJS\1740 markers_14\NNS\21939 of_15\IN\1740 renal_16\JJ\1740 impairment_17\NN\7296428 ._18\.\1740
24671324
C400082_D019115 CID <e2>necrotising_0\VBG\1740 fasciitis</e2>_1\NN\1740 after_2\IN\1740 <e1>bortezomib</e1>_3\NN\1740 and_4\CC\1740 dexamethasone-containing_5\JJ\1740 regimen_6\NN\5898568 in_7\IN\13603305 an_8\DT\6697703 elderly_9\JJ\1740 patient_10\NN\9898892 of_11\IN\1740 waldenstrom_12\NN\1740 macroglobulinaemia_13\NN\1740 ._14\.\1740
C400082_D019115 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 76-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 waldenstrom_9\NN\1740 macroglobulinaemia_10\NN\1740 who_11\WP\8299493 suffered_12\VBD\2110220 <e2>necrotising_13\JJ\1740 fasciitis</e2>_14\NN\1740 without_15\IN\1740 neutropenia_16\NN\14196405 after_17\IN\1740 the_18\DT\1740 combination_19\NN\7951464 treatment_20\NN\654885 with_21\IN\1740 <e1>bortezomib</e1>_22\NN\1740 ,_23\,\1740 high-dose_24\JJ\1740 dexamethasone_25\NN\2721538 and_26\CC\1740 rituximab_27\NN\1740 ._28\.\1740
C400082_D008258 NONE necrotising_0\VBG\1740 fasciitis_1\NN\1740 after_2\IN\1740 <e1>bortezomib</e1>_3\NN\1740 and_4\CC\1740 dexamethasone-containing_5\JJ\1740 regimen_6\NN\5898568 in_7\IN\13603305 an_8\DT\6697703 elderly_9\JJ\1740 patient_10\NN\9898892 of_11\IN\1740 <e2>waldenstrom_12\NN\1740 macroglobulinaemia</e2>_13\NN\1740 ._14\.\1740
C400082_D008258 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 76-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 <e2>waldenstrom_9\NN\1740 macroglobulinaemia</e2>_10\NN\1740 who_11\WP\8299493 suffered_12\VBD\2110220 necrotising_13\JJ\1740 fasciitis_14\NN\1740 without_15\IN\1740 neutropenia_16\NN\14196405 after_17\IN\1740 the_18\DT\1740 combination_19\NN\7951464 treatment_20\NN\654885 with_21\IN\1740 <e1>bortezomib</e1>_22\NN\1740 ,_23\,\1740 high-dose_24\JJ\1740 dexamethasone_25\NN\2721538 and_26\CC\1740 rituximab_27\NN\1740 ._28\.\1740
D003907_D019115 CID <e2>necrotising_0\VBG\1740 fasciitis</e2>_1\NN\1740 after_2\IN\1740 bortezomib_3\NN\1740 and_4\CC\1740 <e1>dexamethasone-containing</e1>_5\JJ\1740 regimen_6\NN\5898568 in_7\IN\13603305 an_8\DT\6697703 elderly_9\JJ\1740 patient_10\NN\9898892 of_11\IN\1740 waldenstrom_12\NN\1740 macroglobulinaemia_13\NN\1740 ._14\.\1740
D003907_D019115 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 76-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 waldenstrom_9\NN\1740 macroglobulinaemia_10\NN\1740 who_11\WP\8299493 suffered_12\VBD\2110220 <e2>necrotising_13\JJ\1740 fasciitis</e2>_14\NN\1740 without_15\IN\1740 neutropenia_16\NN\14196405 after_17\IN\1740 the_18\DT\1740 combination_19\NN\7951464 treatment_20\NN\654885 with_21\IN\1740 bortezomib_22\NN\1740 ,_23\,\1740 high-dose_24\JJ\1740 <e1>dexamethasone</e1>_25\NN\2721538 and_26\CC\1740 rituximab_27\NN\1740 ._28\.\1740
D003907_D008258 NONE necrotising_0\VBG\1740 fasciitis_1\NN\1740 after_2\IN\1740 bortezomib_3\NN\1740 and_4\CC\1740 <e1>dexamethasone-containing</e1>_5\JJ\1740 regimen_6\NN\5898568 in_7\IN\13603305 an_8\DT\6697703 elderly_9\JJ\1740 patient_10\NN\9898892 of_11\IN\1740 <e2>waldenstrom_12\NN\1740 macroglobulinaemia</e2>_13\NN\1740 ._14\.\1740
D003907_D008258 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 76-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 <e2>waldenstrom_9\NN\1740 macroglobulinaemia</e2>_10\NN\1740 who_11\WP\8299493 suffered_12\VBD\2110220 necrotising_13\JJ\1740 fasciitis_14\NN\1740 without_15\IN\1740 neutropenia_16\NN\14196405 after_17\IN\1740 the_18\DT\1740 combination_19\NN\7951464 treatment_20\NN\654885 with_21\IN\1740 bortezomib_22\NN\1740 ,_23\,\1740 high-dose_24\JJ\1740 <e1>dexamethasone</e1>_25\NN\2721538 and_26\CC\1740 rituximab_27\NN\1740 ._28\.\1740
C400082_D001424 NONE <e1>bortezomib</e1>_0\NNP\1740 and_1\CC\1740 high-dose_2\JJ\1740 dexamethasone-containing_3\JJ\1740 regimens_4\NNS\5898568 are_5\VBP\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 generally_9\RB\1740 tolerable_10\JJ\1740 with_11\IN\1740 few_12\JJ\1740 severe_13\JJ\1740 <e2>bacterial_14\JJ\1740 infections</e2>_15\NNS\14052046 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 b-cell_19\NN\1740 malignancies_20\NNS\14070360 ._21\.\1740
C400082_D001424 NONE physicians_0\NNS\10305802 should_1\MD\1740 recognise_2\VB\2256109 the_3\DT\1740 possibility_4\NN\5944958 of_5\IN\1740 fatal_6\JJ\1740 <e2>bacterial_7\JJ\1740 infections</e2>_8\NNS\14052046 related_9\VBN\628491 to_10\TO\1740 <e1>bortezomib</e1>_11\NN\1740 plus_12\CC\4723816 high-dose_13\JJ\1740 dexamethasone_14\NN\2721538 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 ,_18\,\1740 and_19\CC\1740 we_20\PRP\1740 believe_21\VBP\686447 this_22\DT\1740 case_23\NN\7283608 warrants_24\VBZ\1012073 further_25\JJ\1740 investigation_26\NN\5797597 ._27\.\1740
C400082_D009369 NONE <e1>bortezomib</e1>_0\NNP\1740 and_1\CC\1740 high-dose_2\JJ\1740 dexamethasone-containing_3\JJ\1740 regimens_4\NNS\5898568 are_5\VBP\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 generally_9\RB\1740 tolerable_10\JJ\1740 with_11\IN\1740 few_12\JJ\1740 severe_13\JJ\1740 bacterial_14\JJ\1740 infections_15\NNS\14052046 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 b-cell_19\NN\1740 <e2>malignancies</e2>_20\NNS\14070360 ._21\.\1740
D003907_D001424 NONE bortezomib_0\NNP\1740 and_1\CC\1740 high-dose_2\JJ\1740 <e1>dexamethasone-containing</e1>_3\JJ\1740 regimens_4\NNS\5898568 are_5\VBP\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 generally_9\RB\1740 tolerable_10\JJ\1740 with_11\IN\1740 few_12\JJ\1740 severe_13\JJ\1740 <e2>bacterial_14\JJ\1740 infections</e2>_15\NNS\14052046 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 b-cell_19\NN\1740 malignancies_20\NNS\14070360 ._21\.\1740
D003907_D001424 NONE physicians_0\NNS\10305802 should_1\MD\1740 recognise_2\VB\2256109 the_3\DT\1740 possibility_4\NN\5944958 of_5\IN\1740 fatal_6\JJ\1740 <e2>bacterial_7\JJ\1740 infections</e2>_8\NNS\14052046 related_9\VBN\628491 to_10\TO\1740 bortezomib_11\NN\1740 plus_12\CC\4723816 high-dose_13\JJ\1740 <e1>dexamethasone</e1>_14\NN\2721538 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 ,_18\,\1740 and_19\CC\1740 we_20\PRP\1740 believe_21\VBP\686447 this_22\DT\1740 case_23\NN\7283608 warrants_24\VBZ\1012073 further_25\JJ\1740 investigation_26\NN\5797597 ._27\.\1740
D003907_D009369 NONE bortezomib_0\NNP\1740 and_1\CC\1740 high-dose_2\JJ\1740 <e1>dexamethasone-containing</e1>_3\JJ\1740 regimens_4\NNS\5898568 are_5\VBP\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 generally_9\RB\1740 tolerable_10\JJ\1740 with_11\IN\1740 few_12\JJ\1740 severe_13\JJ\1740 bacterial_14\JJ\1740 infections_15\NNS\14052046 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 b-cell_19\NN\1740 <e2>malignancies</e2>_20\NNS\14070360 ._21\.\1740
C400082_D009503 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 76-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 waldenstrom_9\NN\1740 macroglobulinaemia_10\NN\1740 who_11\WP\8299493 suffered_12\VBD\2110220 necrotising_13\JJ\1740 fasciitis_14\NN\1740 without_15\IN\1740 <e2>neutropenia</e2>_16\NN\14196405 after_17\IN\1740 the_18\DT\1740 combination_19\NN\7951464 treatment_20\NN\654885 with_21\IN\1740 <e1>bortezomib</e1>_22\NN\1740 ,_23\,\1740 high-dose_24\JJ\1740 dexamethasone_25\NN\2721538 and_26\CC\1740 rituximab_27\NN\1740 ._28\.\1740
D003907_D009503 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 76-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 waldenstrom_9\NN\1740 macroglobulinaemia_10\NN\1740 who_11\WP\8299493 suffered_12\VBD\2110220 necrotising_13\JJ\1740 fasciitis_14\NN\1740 without_15\IN\1740 <e2>neutropenia</e2>_16\NN\14196405 after_17\IN\1740 the_18\DT\1740 combination_19\NN\7951464 treatment_20\NN\654885 with_21\IN\1740 bortezomib_22\NN\1740 ,_23\,\1740 high-dose_24\JJ\1740 <e1>dexamethasone</e1>_25\NN\2721538 and_26\CC\1740 rituximab_27\NN\1740 ._28\.\1740
16801510
D008691_D008133 CID drug-induced_0\JJ\1740 <e2>long_1\JJ\1740 qt_2\NN\1740 syndrome</e2>_3\NN\5870365 in_4\IN\13603305 injection_5\NN\320852 drug_6\NN\14778436 users_7\NNS\7846 receiving_8\VBG\2210855 <e1>methadone</e1>_9\NN\3808564 :_10\:\1740 high_11\JJ\1740 frequency_12\NN\15286249 in_13\IN\13603305 hospitalized_14\VBN\2348568 patients_15\NNS\9898892 and_16\CC\1740 risk_17\NN\14541044 factors_18\NNS\7326557 ._19\.\1740
D008691_D008133 CID in_0\IN\13603305 the_1\DT\1740 inpatient_2\JJ\1740 setting_3\NN\8567235 ,_4\,\1740 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 <e2>qt_8\NN\1740 interval_9\NN\33615 prolongation</e2>_10\NN\1017987 with_11\IN\1740 <e1>methadone</e1>_12\NN\3808564 treatment_13\NN\654885 ,_14\,\1740 its_15\PRP$\6125041 dose_16\NN\3740161 dependence_17\NN\24720 ,_18\,\1740 and_19\CC\1740 the_20\DT\1740 importance_21\NN\5138488 of_22\IN\1740 cofactors_23\NNS\14818238 such_24\JJ\1740 as_25\IN\14622893 drug-drug_26\JJ\1740 interactions_27\NNS\37396 remain_28\VBP\2604760 unknown_29\JJ\1740 ._30\.\1740
D008691_D008133 CID in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 <e1>methadone</e1>_3\NN\3808564 dose_4\NN\3740161 ,_5\,\1740 15_6\CD\13745420 demographic_7\JJ\1740 ,_8\,\1740 biological_9\JJ\1740 ,_10\,\1740 and_11\CC\1740 pharmacological_12\JJ\1740 variables_13\NNS\2452 were_14\VBD\836236 considered_15\VBN\689344 as_16\IN\14622893 potential_17\JJ\1740 risk_18\NN\14541044 factors_19\NNS\7326557 for_20\IN\1740 <e2>qt_21\NN\1740 prolongation</e2>_22\NN\1017987 ._23\.\1740
D008691_D008133 CID conclusions_0\NNS\5837957 :_1\:\1740 <e2>qt_2\NN\1740 interval_3\NN\33615 prolongation</e2>_4\NN\1017987 in_5\IN\13603305 <e1>methadone</e1>_6\NN\3808564 maintenance_7\NN\266806 patients_8\NNS\9898892 hospitalized_9\VBN\2348568 in_10\IN\13603305 a_11\DT\13649268 tertiary_12\JJ\1740 care_13\NN\575741 center_14\NN\8497294 is_15\VBZ\836236 a_16\DT\13649268 frequent_17\JJ\1740 finding_18\NN\43195 ._19\.\1740
D008691_D008133 CID <e1>methadone</e1>_0\NN\3808564 dose_1\NN\3740161 ,_2\,\1740 presence_3\NN\13954253 of_4\IN\1740 cytochrome_5\NN\14888884 p-450_6\NN\1740 3a4_7\NN\1740 inhibitors_8\NNS\20090 ,_9\,\1740 potassium_10\NN\14625458 level_11\NN\4916342 ,_12\,\1740 and_13\CC\1740 liver_14\NN\5298729 function_15\NN\13783581 contribute_16\VBP\126264 to_17\TO\1740 <e2>qt_18\NN\1740 prolongation</e2>_19\NN\1017987 ._20\.\1740
D008691_D008133 CID <e2>long_0\JJ\1740 qt_1\NN\1740 syndrome</e2>_2\NN\5870365 can_3\MD\3094503 occur_4\VB\2623529 with_5\IN\1740 low_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>methadone</e1>_9\NN\3808564 ._10\.\1740
D008691_D016171 NONE six_0\CD\13741022 patients_1\NNS\9898892 (_2\-LRB-\1740 3.6_3\CD\1740 %_4\NN\1740 )_5\-RRB-\1740 in_6\IN\13603305 the_7\DT\1740 <e1>methadone</e1>_8\NN\3808564 group_9\NN\2137 presented_10\VBD\2137132 <e2>torsades_11\NNS\1740 de_12\IN\1740 pointes</e2>_13\NNS\1740 ._14\.\1740
D008691_D007008 NONE multivariate_0\JJ\1740 regression_1\NN\14501726 analysis_2\NN\633864 allowed_3\VBD\797697 attribution_4\NN\5732756 of_5\IN\1740 31.8_6\CD\1740 %_7\NN\1740 of_8\IN\1740 qtc_9\NN\1740 variability_10\NN\4733640 to_11\TO\1740 <e1>methadone</e1>_12\NN\3808564 dose_13\NN\3740161 ,_14\,\1740 cytochrome_15\NN\14888884 p-450_16\NN\1740 3a4_17\NN\1740 drug-drug_18\NN\1740 interactions_19\NNS\37396 ,_20\,\1740 <e2>hypokalemia</e2>_21\NN\14299637 ,_22\,\1740 and_23\CC\1740 altered_24\JJ\1740 liver_25\NN\5298729 function_26\NN\13783581 ._27\.\1740
D011188_D008133 NONE methadone_0\NN\3808564 dose_1\NN\3740161 ,_2\,\1740 presence_3\NN\13954253 of_4\IN\1740 cytochrome_5\NN\14888884 p-450_6\NN\1740 3a4_7\NN\1740 inhibitors_8\NNS\20090 ,_9\,\1740 <e1>potassium</e1>_10\NN\14625458 level_11\NN\4916342 ,_12\,\1740 and_13\CC\1740 liver_14\NN\5298729 function_15\NN\13783581 contribute_16\VBP\126264 to_17\TO\1740 <e2>qt_18\NN\1740 prolongation</e2>_19\NN\1017987 ._20\.\1740
24158386
C056507_D006689 NONE <e1>gem-p</e1>_0\NN\1740 chemotherapy_1\NN\661091 is_2\VBZ\836236 active_3\JJ\1740 in_4\IN\13603305 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 relapsed_8\JJ\1740 <e2>hodgkin_9\NN\1740 lymphoma</e2>_10\NN\14239918 ._11\.\1740
C056507_D006689 NONE <e1>gemcitabine</e1>_0\NN\1740 and_1\CC\1740 cisplatin_2\NN\1740 have_3\VBP\2108377 activity_4\NN\30358 in_5\IN\13603305 <e2>hl</e2>_6\NN\13616054 ,_7\,\1740 non-overlapping_8\JJ\1740 toxicity_9\NN\13576101 with_10\IN\1740 first-line_11\JJ\1740 chemotherapeutics_12\NNS\1740 ,_13\,\1740 and_14\CC\1740 may_15\MD\15209706 be_16\VB\836236 delivered_17\VBN\941990 in_18\IN\13603305 an_19\DT\6697703 outpatient_20\JJ\1740 setting_21\NN\8567235 ._22\.\1740
C056507_D006689 NONE in_0\IN\13603305 this_1\DT\1740 retrospective_2\JJ\1740 single-centre_3\JJ\1740 analysis_4\NN\633864 ,_5\,\1740 patients_6\NNS\9898892 with_7\IN\1740 relapsed_8\JJ\1740 or_9\CC\3541091 refractory_10\JJ\1740 <e2>hl</e2>_11\NN\13616054 treated_12\VBN\2376958 with_13\IN\1740 <e1>gemcitabine</e1>_14\NN\1740 1,000_15\CD\1740 mg/m(2_16\NN\1740 )_17\-RRB-\1740 day_18\NN\15154774 (d)1_19\-LRB-\1740 ,_20\,\1740 d8_21\NN\1740 and_22\CC\1740 d15_23\NN\1740 ;_24\:\1740 methylprednisolone_25\NN\1740 1,000_26\CD\1740 mg_27\NN\13717155 d1_28\NN\1740 -_29\HYPH\1740 5_30\CD\13741022 ;_31\:\1740 and_32\CC\1740 cisplatin_33\NN\1740 100_34\CD\13745420 mg/m(2_35\NN\1740 )_36\-RRB-\1740 d15_37\NN\1740 ,_38\,\1740 every_39\DT\1740 28_40\CD\13745420 days_41\NNS\15140892 (_42\-LRB-\1740 gem-p_43\NN\1740 )_44\-RRB-\1740 were_45\VBD\836236 included_46\VBN\690614 ._47\.\1740
C056507_D006689 NONE in_0\IN\13603305 this_1\DT\1740 retrospective_2\JJ\1740 single-centre_3\JJ\1740 analysis_4\NN\633864 ,_5\,\1740 patients_6\NNS\9898892 with_7\IN\1740 relapsed_8\JJ\1740 or_9\CC\3541091 refractory_10\JJ\1740 <e2>hl</e2>_11\NN\13616054 treated_12\VBN\2376958 with_13\IN\1740 gemcitabine_14\NN\1740 1,000_15\CD\1740 mg/m(2_16\NN\1740 )_17\-RRB-\1740 day_18\NN\15154774 (d)1_19\-LRB-\1740 ,_20\,\1740 d8_21\NN\1740 and_22\CC\1740 d15_23\NN\1740 ;_24\:\1740 methylprednisolone_25\NN\1740 1,000_26\CD\1740 mg_27\NN\13717155 d1_28\NN\1740 -_29\HYPH\1740 5_30\CD\13741022 ;_31\:\1740 and_32\CC\1740 cisplatin_33\NN\1740 100_34\CD\13745420 mg/m(2_35\NN\1740 )_36\-RRB-\1740 d15_37\NN\1740 ,_38\,\1740 every_39\DT\1740 28_40\CD\13745420 days_41\NNS\15140892 (_42\-LRB-\1740 <e1>gem-p</e1>_43\NN\1740 )_44\-RRB-\1740 were_45\VBD\836236 included_46\VBN\690614 ._47\.\1740
C056507_D006689 NONE <e1>gem-p</e1>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 salvage_3\JJ\1740 chemotherapy_4\NN\661091 with_5\IN\1740 relatively_6\RB\1740 high_7\JJ\1740 response_8\NN\11410625 rates_9\NNS\13308999 ,_10\,\1740 leading_11\VBG\1752884 to_12\TO\1740 successful_13\JJ\1740 transplantation_14\NN\671351 in_15\IN\13603305 appropriate_16\JJ\1740 patients_17\NNS\9898892 ,_18\,\1740 in_19\IN\13603305 the_20\DT\1740 treatment_21\NN\654885 of_22\IN\1740 relapsed_23\JJ\1740 or_24\CC\3541091 refractory_25\JJ\1740 <e2>hl</e2>_26\NN\13616054 ._27\.\1740
C056507_D064420 NONE <e1>gemcitabine</e1>_0\NN\1740 and_1\CC\1740 cisplatin_2\NN\1740 have_3\VBP\2108377 activity_4\NN\30358 in_5\IN\13603305 hl_6\NN\13616054 ,_7\,\1740 non-overlapping_8\JJ\1740 <e2>toxicity</e2>_9\NN\13576101 with_10\IN\1740 first-line_11\JJ\1740 chemotherapeutics_12\NNS\1740 ,_13\,\1740 and_14\CC\1740 may_15\MD\15209706 be_16\VB\836236 delivered_17\VBN\941990 in_18\IN\13603305 an_19\DT\6697703 outpatient_20\JJ\1740 setting_21\NN\8567235 ._22\.\1740
D002945_D006689 NONE gemcitabine_0\NN\1740 and_1\CC\1740 <e1>cisplatin</e1>_2\NN\1740 have_3\VBP\2108377 activity_4\NN\30358 in_5\IN\13603305 <e2>hl</e2>_6\NN\13616054 ,_7\,\1740 non-overlapping_8\JJ\1740 toxicity_9\NN\13576101 with_10\IN\1740 first-line_11\JJ\1740 chemotherapeutics_12\NNS\1740 ,_13\,\1740 and_14\CC\1740 may_15\MD\15209706 be_16\VB\836236 delivered_17\VBN\941990 in_18\IN\13603305 an_19\DT\6697703 outpatient_20\JJ\1740 setting_21\NN\8567235 ._22\.\1740
D002945_D006689 NONE in_0\IN\13603305 this_1\DT\1740 retrospective_2\JJ\1740 single-centre_3\JJ\1740 analysis_4\NN\633864 ,_5\,\1740 patients_6\NNS\9898892 with_7\IN\1740 relapsed_8\JJ\1740 or_9\CC\3541091 refractory_10\JJ\1740 <e2>hl</e2>_11\NN\13616054 treated_12\VBN\2376958 with_13\IN\1740 gemcitabine_14\NN\1740 1,000_15\CD\1740 mg/m(2_16\NN\1740 )_17\-RRB-\1740 day_18\NN\15154774 (d)1_19\-LRB-\1740 ,_20\,\1740 d8_21\NN\1740 and_22\CC\1740 d15_23\NN\1740 ;_24\:\1740 methylprednisolone_25\NN\1740 1,000_26\CD\1740 mg_27\NN\13717155 d1_28\NN\1740 -_29\HYPH\1740 5_30\CD\13741022 ;_31\:\1740 and_32\CC\1740 <e1>cisplatin</e1>_33\NN\1740 100_34\CD\13745420 mg/m(2_35\NN\1740 )_36\-RRB-\1740 d15_37\NN\1740 ,_38\,\1740 every_39\DT\1740 28_40\CD\13745420 days_41\NNS\15140892 (_42\-LRB-\1740 gem-p_43\NN\1740 )_44\-RRB-\1740 were_45\VBD\836236 included_46\VBN\690614 ._47\.\1740
D002945_D064420 NONE gemcitabine_0\NN\1740 and_1\CC\1740 <e1>cisplatin</e1>_2\NN\1740 have_3\VBP\2108377 activity_4\NN\30358 in_5\IN\13603305 hl_6\NN\13616054 ,_7\,\1740 non-overlapping_8\JJ\1740 <e2>toxicity</e2>_9\NN\13576101 with_10\IN\1740 first-line_11\JJ\1740 chemotherapeutics_12\NNS\1740 ,_13\,\1740 and_14\CC\1740 may_15\MD\15209706 be_16\VB\836236 delivered_17\VBN\941990 in_18\IN\13603305 an_19\DT\6697703 outpatient_20\JJ\1740 setting_21\NN\8567235 ._22\.\1740
D008775_D006689 NONE in_0\IN\13603305 this_1\DT\1740 retrospective_2\JJ\1740 single-centre_3\JJ\1740 analysis_4\NN\633864 ,_5\,\1740 patients_6\NNS\9898892 with_7\IN\1740 relapsed_8\JJ\1740 or_9\CC\3541091 refractory_10\JJ\1740 <e2>hl</e2>_11\NN\13616054 treated_12\VBN\2376958 with_13\IN\1740 gemcitabine_14\NN\1740 1,000_15\CD\1740 mg/m(2_16\NN\1740 )_17\-RRB-\1740 day_18\NN\15154774 (d)1_19\-LRB-\1740 ,_20\,\1740 d8_21\NN\1740 and_22\CC\1740 d15_23\NN\1740 ;_24\:\1740 <e1>methylprednisolone</e1>_25\NN\1740 1,000_26\CD\1740 mg_27\NN\13717155 d1_28\NN\1740 -_29\HYPH\1740 5_30\CD\13741022 ;_31\:\1740 and_32\CC\1740 cisplatin_33\NN\1740 100_34\CD\13745420 mg/m(2_35\NN\1740 )_36\-RRB-\1740 d15_37\NN\1740 ,_38\,\1740 every_39\DT\1740 28_40\CD\13745420 days_41\NNS\15140892 (_42\-LRB-\1740 gem-p_43\NN\1740 )_44\-RRB-\1740 were_45\VBD\836236 included_46\VBN\690614 ._47\.\1740
2931989
D015474_D000152 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 261_3\CD\1740 adverse_4\JJ\1740 ocular_5\JJ\1740 reactions_6\NNS\13446390 occurred_7\VBD\2623529 in_8\IN\13603305 237_9\CD\1740 patients_10\NNS\9898892 who_11\WP\8299493 received_12\VBD\2210855 <e1>isotretinoin</e1>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 commonly_16\RB\1740 used_17\VBN\1156834 drug_18\NN\14778436 in_19\IN\13603305 the_20\DT\1740 treatment_21\NN\654885 of_22\IN\1740 severe_23\JJ\1740 cystic_24\JJ\1740 <e2>acne</e2>_25\NN\14171682 ._26\.\1740
D015474_D000013 NONE <e1>isotretinoin</e1>_0\NN\1740 is_1\VBZ\836236 contraindicated_2\VBN\872886 in_3\IN\13603305 pregnancy_4\NN\14034177 because_5\IN\1740 of_6\IN\1740 the_7\DT\1740 many_8\JJ\1740 reported_9\VBN\831651 <e2>congenital_10\JJ\1740 abnormalities</e2>_11\NNS\14034177 after_12\IN\1740 maternal_13\JJ\1740 use_14\NN\407535 (_15\-LRB-\1740 including_16\VBG\690614 microphthalmos_17\NN\1740 ,_18\,\1740 orbital_19\JJ\1740 hypertelorism_20\NN\1740 ,_21\,\1740 and_22\CC\1740 optic_23\JJ\1740 nerve_24\NN\5475681 hypoplasia_25\NN\14365950 )_26\-RRB-\1740 ._27\.\1740
D015474_D008850 NONE <e1>isotretinoin</e1>_0\NN\1740 is_1\VBZ\836236 contraindicated_2\VBN\872886 in_3\IN\13603305 pregnancy_4\NN\14034177 because_5\IN\1740 of_6\IN\1740 the_7\DT\1740 many_8\JJ\1740 reported_9\VBN\831651 congenital_10\JJ\1740 abnormalities_11\NNS\14034177 after_12\IN\1740 maternal_13\JJ\1740 use_14\NN\407535 (_15\-LRB-\1740 including_16\VBG\690614 <e2>microphthalmos</e2>_17\NN\1740 ,_18\,\1740 orbital_19\JJ\1740 hypertelorism_20\NN\1740 ,_21\,\1740 and_22\CC\1740 optic_23\JJ\1740 nerve_24\NN\5475681 hypoplasia_25\NN\14365950 )_26\-RRB-\1740 ._27\.\1740
D015474_D006972 NONE <e1>isotretinoin</e1>_0\NN\1740 is_1\VBZ\836236 contraindicated_2\VBN\872886 in_3\IN\13603305 pregnancy_4\NN\14034177 because_5\IN\1740 of_6\IN\1740 the_7\DT\1740 many_8\JJ\1740 reported_9\VBN\831651 congenital_10\JJ\1740 abnormalities_11\NNS\14034177 after_12\IN\1740 maternal_13\JJ\1740 use_14\NN\407535 (_15\-LRB-\1740 including_16\VBG\690614 microphthalmos_17\NN\1740 ,_18\,\1740 orbital_19\JJ\1740 <e2>hypertelorism</e2>_20\NN\1740 ,_21\,\1740 and_22\CC\1740 optic_23\JJ\1740 nerve_24\NN\5475681 hypoplasia_25\NN\14365950 )_26\-RRB-\1740 ._27\.\1740
D015474_C563492 NONE <e1>isotretinoin</e1>_0\NN\1740 is_1\VBZ\836236 contraindicated_2\VBN\872886 in_3\IN\13603305 pregnancy_4\NN\14034177 because_5\IN\1740 of_6\IN\1740 the_7\DT\1740 many_8\JJ\1740 reported_9\VBN\831651 congenital_10\JJ\1740 abnormalities_11\NNS\14034177 after_12\IN\1740 maternal_13\JJ\1740 use_14\NN\407535 (_15\-LRB-\1740 including_16\VBG\690614 microphthalmos_17\NN\1740 ,_18\,\1740 orbital_19\JJ\1740 hypertelorism_20\NN\1740 ,_21\,\1740 and_22\CC\1740 <e2>optic_23\JJ\1740 nerve_24\NN\5475681 hypoplasia</e2>_25\NN\14365950 )_26\-RRB-\1740 ._27\.\1740
18987260
D004317_D007674 NONE reduced_0\VBN\441445 progression_1\NN\8457976 of_2\IN\1740 <e1>adriamycin</e1>_3\NN\1740 <e2>nephropathy</e2>_4\JJ\1740 in_5\IN\13603305 spontaneously_6\JJ\1740 hypertensive_7\JJ\1740 rats_8\NNS\2329401 treated_9\VBN\2376958 by_10\IN\1740 losartan_11\NN\1740 ._12\.\1740
D004317_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 <e2>renal_28\JJ\1740 disease</e2>_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 <e1>adriamycin</e1>_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D004317_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 <e1>adriamycin</e1>_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 <e2>nephropathy</e2>_43\RB\1740 ._44\.\1740
D004317_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 <e2>renal_28\JJ\1740 disease</e2>_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 <e1>adr</e1>_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D004317_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 <e1>adr</e1>_41\NN\1740 )_42\-RRB-\1740 <e2>nephropathy</e2>_43\RB\1740 ._44\.\1740
D004317_D007674 NONE losartan_0\NNP\1740 reduced_1\VBD\441445 uraemia_2\NN\14204950 and_3\CC\1740 increased_4\VBN\169651 urea_5\NN\14727670 clearance_6\NN\5089947 in_7\IN\13603305 advanced_8\JJ\1740 <e1>adr</e1>_9\NN\1740 <e2>nephropathy</e2>_10\NN\14573196 in_11\IN\13603305 shr_12\NN\1740 ._13\.\1740
D004317_D007674 NONE histological_0\JJ\1740 examination_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 losartan_4\NN\1740 could_5\MD\1740 prevent_6\VB\1740 tubular_7\JJ\1740 atrophy_8\NN\14299637 ,_9\,\1740 interstitial_10\JJ\1740 infiltration_11\NN\975452 and_12\CC\1740 fibrosis_13\NN\14204950 in_14\IN\13603305 <e1>adr</e1>_15\NN\1740 <e2>nephropathy</e2>_16\NN\14573196 ._17\.\1740
D004317_D006973 NONE reduced_0\VBN\441445 progression_1\NN\8457976 of_2\IN\1740 <e1>adriamycin</e1>_3\NN\1740 nephropathy_4\JJ\1740 in_5\IN\13603305 spontaneously_6\JJ\1740 <e2>hypertensive</e2>_7\JJ\1740 rats_8\NNS\2329401 treated_9\VBN\2376958 by_10\IN\1740 losartan_11\NN\1740 ._12\.\1740
D004317_D006973 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 <e2>hypertensive</e2>_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 <e1>adriamycin</e1>_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D004317_D006973 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 <e2>hypertensive</e2>_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 <e1>adr</e1>_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D019808_D007674 NONE reduced_0\VBN\441445 progression_1\NN\8457976 of_2\IN\1740 adriamycin_3\NN\1740 <e2>nephropathy</e2>_4\JJ\1740 in_5\IN\13603305 spontaneously_6\JJ\1740 hypertensive_7\JJ\1740 rats_8\NNS\2329401 treated_9\VBN\2376958 by_10\IN\1740 <e1>losartan</e1>_11\NN\1740 ._12\.\1740
D019808_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 <e1>losartan</e1>_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 <e2>renal_28\JJ\1740 disease</e2>_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D019808_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 <e1>losartan</e1>_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 <e2>nephropathy</e2>_43\RB\1740 ._44\.\1740
D019808_D007674 NONE <e1>losartan</e1>_0\NNP\1740 reduced_1\VBD\441445 uraemia_2\NN\14204950 and_3\CC\1740 increased_4\VBN\169651 urea_5\NN\14727670 clearance_6\NN\5089947 in_7\IN\13603305 advanced_8\JJ\1740 adr_9\NN\1740 <e2>nephropathy</e2>_10\NN\14573196 in_11\IN\13603305 shr_12\NN\1740 ._13\.\1740
D019808_D007674 NONE histological_0\JJ\1740 examination_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 <e1>losartan</e1>_4\NN\1740 could_5\MD\1740 prevent_6\VB\1740 tubular_7\JJ\1740 atrophy_8\NN\14299637 ,_9\,\1740 interstitial_10\JJ\1740 infiltration_11\NN\975452 and_12\CC\1740 fibrosis_13\NN\14204950 in_14\IN\13603305 adr_15\NN\1740 <e2>nephropathy</e2>_16\NN\14573196 ._17\.\1740
D019808_D006973 NONE reduced_0\VBN\441445 progression_1\NN\8457976 of_2\IN\1740 adriamycin_3\NN\1740 nephropathy_4\JJ\1740 in_5\IN\13603305 spontaneously_6\JJ\1740 <e2>hypertensive</e2>_7\JJ\1740 rats_8\NNS\2329401 treated_9\VBN\2376958 by_10\IN\1740 <e1>losartan</e1>_11\NN\1740 ._12\.\1740
D019808_D006973 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 angiotensin_14\NN\4522421 ii_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 <e1>losartan</e1>_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 <e2>hypertensive</e2>_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D000804_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 <e1>angiotensin_14\NN\4522421 ii</e1>_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 <e2>renal_28\JJ\1740 disease</e2>_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D000804_D007674 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 <e1>angiotensin_14\NN\4522421 ii</e1>_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 hypertensive_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 <e2>nephropathy</e2>_43\RB\1740 ._44\.\1740
D000804_D006973 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 the_10\DT\1740 antihypertensive_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 <e1>angiotensin_14\NN\4522421 ii</e1>_15\CD\13741022 type-1_16\NN\1740 receptor_17\NN\5225602 blocker_18\NN\10101634 ,_19\,\1740 losartan_20\RB\1740 ,_21\,\1740 and_22\CC\1740 its_23\PRP$\6125041 potential_24\NN\14481929 in_25\IN\13603305 slowing_26\VBG\151689 down_27\RP\1740 renal_28\JJ\1740 disease_29\NN\14061805 progression_30\NN\8457976 in_31\IN\13603305 spontaneously_32\JJ\1740 <e2>hypertensive</e2>_33\JJ\1740 rats_34\NNS\2329401 (_35\-LRB-\1740 shr_36\NN\1740 )_37\-RRB-\1740 with_38\IN\1740 adriamycin_39\NN\1740 (_40\-LRB-\1740 adr_41\NN\1740 )_42\-RRB-\1740 nephropathy_43\RB\1740 ._44\.\1740
D019808_D005921 NONE results_0\NNS\34213 :_1\:\1740 short-term_2\JJ\1740 <e1>losartan</e1>_3\JJ\1740 treatment_4\NN\654885 ,_5\,\1740 besides_6\IN\1740 antihypertensive_7\JJ\1740 effect_8\NN\34213 ,_9\,\1740 improved_10\VBD\126264 glomerular_11\JJ\1740 filtration_12\NN\13518963 rate_13\NN\13815152 and_14\CC\1740 ameliorated_15\VBD\126264 <e2>glomerulosclerosis</e2>_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 decreased_19\VBN\169651 proteinuria_20\NN\14299637 ._21\.\1740
D019808_D005921 NONE prolonged_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>losartan</e1>_3\NN\1740 showed_4\VBD\2137132 further_5\JJ\1740 reduction_6\NN\351485 of_7\IN\1740 <e2>glomerulosclerosis</e2>_8\NN\1740 associated_9\VBN\628491 with_10\IN\1740 reduced_11\VBN\441445 progression_12\NN\8457976 of_13\IN\1740 tubular_14\JJ\1740 atrophy_15\NN\14299637 and_16\CC\1740 interstitial_17\JJ\1740 fibrosis_18\NN\14204950 ,_19\,\1740 thus_20\RB\1740 preventing_21\VBG\1740 heavy_22\JJ\1740 proteinuria_23\NN\14299637 and_24\CC\1740 chronic_25\JJ\1740 renal_26\JJ\1740 failure_27\NN\66216 ._28\.\1740
D019808_D011507 NONE results_0\NNS\34213 :_1\:\1740 short-term_2\JJ\1740 <e1>losartan</e1>_3\JJ\1740 treatment_4\NN\654885 ,_5\,\1740 besides_6\IN\1740 antihypertensive_7\JJ\1740 effect_8\NN\34213 ,_9\,\1740 improved_10\VBD\126264 glomerular_11\JJ\1740 filtration_12\NN\13518963 rate_13\NN\13815152 and_14\CC\1740 ameliorated_15\VBD\126264 glomerulosclerosis_16\NN\1740 resulting_17\VBG\2633881 in_18\IN\13603305 decreased_19\VBN\169651 <e2>proteinuria</e2>_20\NN\14299637 ._21\.\1740
D019808_D011507 NONE prolonged_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>losartan</e1>_3\NN\1740 showed_4\VBD\2137132 further_5\JJ\1740 reduction_6\NN\351485 of_7\IN\1740 glomerulosclerosis_8\NN\1740 associated_9\VBN\628491 with_10\IN\1740 reduced_11\VBN\441445 progression_12\NN\8457976 of_13\IN\1740 tubular_14\JJ\1740 atrophy_15\NN\14299637 and_16\CC\1740 interstitial_17\JJ\1740 fibrosis_18\NN\14204950 ,_19\,\1740 thus_20\RB\1740 preventing_21\VBG\1740 heavy_22\JJ\1740 <e2>proteinuria</e2>_23\NN\14299637 and_24\CC\1740 chronic_25\JJ\1740 renal_26\JJ\1740 failure_27\NN\66216 ._28\.\1740
D019808_D001284 NONE prolonged_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>losartan</e1>_3\NN\1740 showed_4\VBD\2137132 further_5\JJ\1740 reduction_6\NN\351485 of_7\IN\1740 glomerulosclerosis_8\NN\1740 associated_9\VBN\628491 with_10\IN\1740 reduced_11\VBN\441445 progression_12\NN\8457976 of_13\IN\1740 tubular_14\JJ\1740 <e2>atrophy</e2>_15\NN\14299637 and_16\CC\1740 interstitial_17\JJ\1740 fibrosis_18\NN\14204950 ,_19\,\1740 thus_20\RB\1740 preventing_21\VBG\1740 heavy_22\JJ\1740 proteinuria_23\NN\14299637 and_24\CC\1740 chronic_25\JJ\1740 renal_26\JJ\1740 failure_27\NN\66216 ._28\.\1740
D019808_D001284 NONE histological_0\JJ\1740 examination_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 <e1>losartan</e1>_4\NN\1740 could_5\MD\1740 prevent_6\VB\1740 tubular_7\JJ\1740 <e2>atrophy</e2>_8\NN\14299637 ,_9\,\1740 interstitial_10\JJ\1740 infiltration_11\NN\975452 and_12\CC\1740 fibrosis_13\NN\14204950 in_14\IN\13603305 adr_15\NN\1740 nephropathy_16\NN\14573196 ._17\.\1740
D019808_D005355 NONE prolonged_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>losartan</e1>_3\NN\1740 showed_4\VBD\2137132 further_5\JJ\1740 reduction_6\NN\351485 of_7\IN\1740 glomerulosclerosis_8\NN\1740 associated_9\VBN\628491 with_10\IN\1740 reduced_11\VBN\441445 progression_12\NN\8457976 of_13\IN\1740 tubular_14\JJ\1740 atrophy_15\NN\14299637 and_16\CC\1740 <e2>interstitial_17\JJ\1740 fibrosis</e2>_18\NN\14204950 ,_19\,\1740 thus_20\RB\1740 preventing_21\VBG\1740 heavy_22\JJ\1740 proteinuria_23\NN\14299637 and_24\CC\1740 chronic_25\JJ\1740 renal_26\JJ\1740 failure_27\NN\66216 ._28\.\1740
D019808_D005355 NONE histological_0\JJ\1740 examination_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 <e1>losartan</e1>_4\NN\1740 could_5\MD\1740 prevent_6\VB\1740 tubular_7\JJ\1740 atrophy_8\NN\14299637 ,_9\,\1740 interstitial_10\JJ\1740 infiltration_11\NN\975452 and_12\CC\1740 <e2>fibrosis</e2>_13\NN\14204950 in_14\IN\13603305 adr_15\NN\1740 nephropathy_16\NN\14573196 ._17\.\1740
D019808_D007676 NONE prolonged_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>losartan</e1>_3\NN\1740 showed_4\VBD\2137132 further_5\JJ\1740 reduction_6\NN\351485 of_7\IN\1740 glomerulosclerosis_8\NN\1740 associated_9\VBN\628491 with_10\IN\1740 reduced_11\VBN\441445 progression_12\NN\8457976 of_13\IN\1740 tubular_14\JJ\1740 atrophy_15\NN\14299637 and_16\CC\1740 interstitial_17\JJ\1740 fibrosis_18\NN\14204950 ,_19\,\1740 thus_20\RB\1740 preventing_21\VBG\1740 heavy_22\JJ\1740 proteinuria_23\NN\14299637 and_24\CC\1740 <e2>chronic_25\JJ\1740 renal_26\JJ\1740 failure</e2>_27\NN\66216 ._28\.\1740
D019808_D007676 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>losartan</e1>_2\NNP\1740 reduces_3\VBZ\441445 the_4\DT\1740 rate_5\NN\13815152 of_6\IN\1740 progression_7\NN\8457976 of_8\IN\1740 adr-induced_9\JJ\1740 focal_10\JJ\1740 segmental_11\JJ\1740 glomerulosclerosis_12\NN\1740 to_13\TO\1740 <e2>end-stage_14\JJ\1740 renal_15\JJ\1740 disease</e2>_16\NN\14061805 in_17\IN\13603305 shr_18\NN\1740 ._19\.\1740
D019808_D014511 NONE <e1>losartan</e1>_0\NNP\1740 reduced_1\VBD\441445 <e2>uraemia</e2>_2\NN\14204950 and_3\CC\1740 increased_4\VBN\169651 urea_5\NN\14727670 clearance_6\NN\5089947 in_7\IN\13603305 advanced_8\JJ\1740 adr_9\NN\1740 nephropathy_10\NN\14573196 in_11\IN\13603305 shr_12\NN\1740 ._13\.\1740
D014508_D014511 NONE losartan_0\NNP\1740 reduced_1\VBD\441445 <e2>uraemia</e2>_2\NN\14204950 and_3\CC\1740 increased_4\VBN\169651 <e1>urea</e1>_5\NN\14727670 clearance_6\NN\5089947 in_7\IN\13603305 advanced_8\JJ\1740 adr_9\NN\1740 nephropathy_10\NN\14573196 in_11\IN\13603305 shr_12\NN\1740 ._13\.\1740
D014508_D007674 NONE losartan_0\NNP\1740 reduced_1\VBD\441445 uraemia_2\NN\14204950 and_3\CC\1740 increased_4\VBN\169651 <e1>urea</e1>_5\NN\14727670 clearance_6\NN\5089947 in_7\IN\13603305 advanced_8\JJ\1740 adr_9\NN\1740 <e2>nephropathy</e2>_10\NN\14573196 in_11\IN\13603305 shr_12\NN\1740 ._13\.\1740
D004317_D014511 CID losartan_0\NNP\1740 reduced_1\VBD\441445 <e2>uraemia</e2>_2\NN\14204950 and_3\CC\1740 increased_4\VBN\169651 urea_5\NN\14727670 clearance_6\NN\5089947 in_7\IN\13603305 advanced_8\JJ\1740 <e1>adr</e1>_9\NN\1740 nephropathy_10\NN\14573196 in_11\IN\13603305 shr_12\NN\1740 ._13\.\1740
D004317_D001284 NONE histological_0\JJ\1740 examination_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 losartan_4\NN\1740 could_5\MD\1740 prevent_6\VB\1740 tubular_7\JJ\1740 <e2>atrophy</e2>_8\NN\14299637 ,_9\,\1740 interstitial_10\JJ\1740 infiltration_11\NN\975452 and_12\CC\1740 fibrosis_13\NN\14204950 in_14\IN\13603305 <e1>adr</e1>_15\NN\1740 nephropathy_16\NN\14573196 ._17\.\1740
D004317_D005355 NONE histological_0\JJ\1740 examination_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 losartan_4\NN\1740 could_5\MD\1740 prevent_6\VB\1740 tubular_7\JJ\1740 atrophy_8\NN\14299637 ,_9\,\1740 interstitial_10\JJ\1740 infiltration_11\NN\975452 and_12\CC\1740 <e2>fibrosis</e2>_13\NN\14204950 in_14\IN\13603305 <e1>adr</e1>_15\NN\1740 nephropathy_16\NN\14573196 ._17\.\1740
D019808_D005923 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>losartan</e1>_2\NNP\1740 reduces_3\VBZ\441445 the_4\DT\1740 rate_5\NN\13815152 of_6\IN\1740 progression_7\NN\8457976 of_8\IN\1740 adr-induced_9\JJ\1740 <e2>focal_10\JJ\1740 segmental_11\JJ\1740 glomerulosclerosis</e2>_12\NN\1740 to_13\TO\1740 end-stage_14\JJ\1740 renal_15\JJ\1740 disease_16\NN\14061805 in_17\IN\13603305 shr_18\NN\1740 ._19\.\1740
D004317_D005923 CID conclusion_0\NN\5837957 :_1\:\1740 losartan_2\NNP\1740 reduces_3\VBZ\441445 the_4\DT\1740 rate_5\NN\13815152 of_6\IN\1740 progression_7\NN\8457976 of_8\IN\1740 <e1>adr-induced</e1>_9\JJ\1740 <e2>focal_10\JJ\1740 segmental_11\JJ\1740 glomerulosclerosis</e2>_12\NN\1740 to_13\TO\1740 end-stage_14\JJ\1740 renal_15\JJ\1740 disease_16\NN\14061805 in_17\IN\13603305 shr_18\NN\1740 ._19\.\1740
D004317_D007676 NONE conclusion_0\NN\5837957 :_1\:\1740 losartan_2\NNP\1740 reduces_3\VBZ\441445 the_4\DT\1740 rate_5\NN\13815152 of_6\IN\1740 progression_7\NN\8457976 of_8\IN\1740 <e1>adr-induced</e1>_9\JJ\1740 focal_10\JJ\1740 segmental_11\JJ\1740 glomerulosclerosis_12\NN\1740 to_13\TO\1740 <e2>end-stage_14\JJ\1740 renal_15\JJ\1740 disease</e2>_16\NN\14061805 in_17\IN\13603305 shr_18\NN\1740 ._19\.\1740
1522360
D012293_D006461 CID intravascular_0\JJ\1740 <e2>hemolysis</e2>_1\NN\13509528 and_2\CC\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 following_6\VBG\1835496 intermittent_7\JJ\1740 <e1>rifampin</e1>_8\NN\2716205 therapy_9\NN\657604 ._10\.\1740
D012293_D006461 CID intravascular_0\JJ\1740 <e2>hemolysis</e2>_1\NN\13509528 leading_2\VBG\1752884 to_3\TO\1740 acute_4\JJ\1740 renal_5\JJ\1740 failure_6\NN\66216 following_7\VBG\1835496 <e1>rifampin</e1>_8\NN\2716205 therapy_9\NN\657604 is_10\VBZ\836236 extremely_11\RB\1740 rare_12\JJ\1740 ._13\.\1740
D012293_D006461 CID two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 leprosy_3\NN\14127211 who_4\WP\8299493 developed_5\VBD\1753788 <e2>hemolysis</e2>_6\NN\13509528 and_7\CC\1740 acute_8\JJ\1740 renal_9\JJ\1740 failure_10\NN\66216 following_11\VBG\1835496 <e1>rifampin</e1>_12\NN\2716205 are_13\VBP\836236 reported_14\VBN\831651 ._15\.\1740
D012293_D058186 CID intravascular_0\JJ\1740 hemolysis_1\NN\13509528 and_2\CC\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 following_6\VBG\1835496 intermittent_7\JJ\1740 <e1>rifampin</e1>_8\NN\2716205 therapy_9\NN\657604 ._10\.\1740
D012293_D058186 CID intravascular_0\JJ\1740 hemolysis_1\NN\13509528 leading_2\VBG\1752884 to_3\TO\1740 <e2>acute_4\JJ\1740 renal_5\JJ\1740 failure</e2>_6\NN\66216 following_7\VBG\1835496 <e1>rifampin</e1>_8\NN\2716205 therapy_9\NN\657604 is_10\VBZ\836236 extremely_11\RB\1740 rare_12\JJ\1740 ._13\.\1740
D012293_D058186 CID two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 leprosy_3\NN\14127211 who_4\WP\8299493 developed_5\VBD\1753788 hemolysis_6\NN\13509528 and_7\CC\1740 <e2>acute_8\JJ\1740 renal_9\JJ\1740 failure</e2>_10\NN\66216 following_11\VBG\1835496 <e1>rifampin</e1>_12\NN\2716205 are_13\VBP\836236 reported_14\VBN\831651 ._15\.\1740
D012293_D051437 NONE <e2>renal_0\JJ\1740 failure</e2>_1\NN\66216 is_2\VBZ\836236 a_3\DT\13649268 rare_4\JJ\1740 complication_5\NN\1073995 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>rifampin</e1>_11\NN\2716205 ._12\.\1740
D012293_D007918 NONE two_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>leprosy</e2>_3\NN\14127211 who_4\WP\8299493 developed_5\VBD\1753788 hemolysis_6\NN\13509528 and_7\CC\1740 acute_8\JJ\1740 renal_9\JJ\1740 failure_10\NN\66216 following_11\VBG\1835496 <e1>rifampin</e1>_12\NN\2716205 are_13\VBP\836236 reported_14\VBN\831651 ._15\.\1740
24283660
D016559_D012640 CID <e1>tacrolimus-related</e1>_0\JJ\1740 <e2>seizure</e2>_1\NN\14081375 after_2\IN\1740 pediatric_3\JJ\1740 liver_4\NN\5298729 transplantation_5\NN\671351 --_6\:\1740 a_7\DT\13649268 single-center_8\NN\1740 experience_9\NN\5984287 ._10\.\1740
D016559_D012640 CID univariate_0\NN\1740 analysis_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 risk_5\NN\14541044 factors_6\NNS\7326557 associated_7\VBN\628491 with_8\IN\1740 <e2>seizures</e2>_9\NNS\14081375 after_10\IN\1740 pediatric_11\JJ\1740 lt_12\NN\1740 included_13\VBD\690614 gender_14\NN\6309383 ,_15\,\1740 pediatric_16\JJ\1740 end-stage_17\JJ\1740 liver_18\NN\5298729 disease_19\NN\14061805 score_20\NN\5736149 before_21\IN\1740 surgery_22\NN\6045562 ,_23\,\1740 child-pugh_24\JJ\1740 score_25\NN\5736149 before_26\IN\1740 surgery_27\NN\6045562 ,_28\,\1740 serum_29\NN\5397468 total_30\JJ\1740 bilirubin_31\NN\14756039 after_32\IN\1740 surgery_33\NN\6045562 ,_34\,\1740 and_35\CC\1740 trough_36\NN\9366017 <e1>tac</e1>_37\NN\1740 level_38\NN\4916342 ._39\.\1740
D016559_D012640 CID multivariate_0\JJ\1740 analysis_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 trough_4\NN\9366017 <e1>tac</e1>_5\NN\1740 level_6\NN\4916342 was_7\VBD\836236 the_8\DT\1740 only_9\JJ\1740 independent_10\JJ\1740 risk_11\NN\14541044 factor_12\NN\7326557 associated_13\VBN\628491 with_14\IN\1740 the_15\DT\1740 <e2>seizures</e2>_16\NNS\14081375 ._17\.\1740
D016559_D012640 CID high_0\JJ\1740 trough_1\NN\9366017 <e1>tac</e1>_2\NN\1740 level_3\NN\4916342 was_4\VBD\836236 the_5\DT\1740 predominant_6\JJ\1740 factor_7\NN\7326557 that_8\WDT\1740 contributed_9\VBD\126264 to_10\TO\1740 <e2>seizures</e2>_11\NNS\14081375 in_12\IN\13603305 the_13\DT\1740 early_14\JJ\1740 post-operative_15\JJ\1740 period_16\NN\13575869 after_17\IN\1740 pediatric_18\JJ\1740 lt_19\NN\1740 ._20\.\1740
D016559_D012640 CID high_0\JJ\1740 peld_1\NN\1740 and_2\CC\1740 child-pugh_3\JJ\1740 scores_4\NNS\13757724 before_5\IN\1740 lt_6\NN\1740 and_7\CC\1740 high_8\JJ\1740 post-operative_9\JJ\1740 serum_10\NN\5397468 tbil_11\NN\1740 may_12\MD\15209706 be_13\VB\836236 contributory_14\JJ\1740 risk_15\NN\14541044 factors_16\NNS\7326557 for_17\IN\1740 <e1>tac-related</e1>_18\JJ\1740 <e2>seizures</e2>_19\NNS\14081375 ._20\.\1740
D001663_D012640 NONE univariate_0\NN\1740 analysis_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 risk_5\NN\14541044 factors_6\NNS\7326557 associated_7\VBN\628491 with_8\IN\1740 <e2>seizures</e2>_9\NNS\14081375 after_10\IN\1740 pediatric_11\JJ\1740 lt_12\NN\1740 included_13\VBD\690614 gender_14\NN\6309383 ,_15\,\1740 pediatric_16\JJ\1740 end-stage_17\JJ\1740 liver_18\NN\5298729 disease_19\NN\14061805 score_20\NN\5736149 before_21\IN\1740 surgery_22\NN\6045562 ,_23\,\1740 child-pugh_24\JJ\1740 score_25\NN\5736149 before_26\IN\1740 surgery_27\NN\6045562 ,_28\,\1740 serum_29\NN\5397468 total_30\JJ\1740 <e1>bilirubin</e1>_31\NN\14756039 after_32\IN\1740 surgery_33\NN\6045562 ,_34\,\1740 and_35\CC\1740 trough_36\NN\9366017 tac_37\NN\1740 level_38\NN\4916342 ._39\.\1740
D001663_D058625 NONE univariate_0\NN\1740 analysis_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 risk_5\NN\14541044 factors_6\NNS\7326557 associated_7\VBN\628491 with_8\IN\1740 seizures_9\NNS\14081375 after_10\IN\1740 pediatric_11\JJ\1740 lt_12\NN\1740 included_13\VBD\690614 gender_14\NN\6309383 ,_15\,\1740 pediatric_16\JJ\1740 <e2>end-stage_17\JJ\1740 liver_18\NN\5298729 disease</e2>_19\NN\14061805 score_20\NN\5736149 before_21\IN\1740 surgery_22\NN\6045562 ,_23\,\1740 child-pugh_24\JJ\1740 score_25\NN\5736149 before_26\IN\1740 surgery_27\NN\6045562 ,_28\,\1740 serum_29\NN\5397468 total_30\JJ\1740 <e1>bilirubin</e1>_31\NN\14756039 after_32\IN\1740 surgery_33\NN\6045562 ,_34\,\1740 and_35\CC\1740 trough_36\NN\9366017 tac_37\NN\1740 level_38\NN\4916342 ._39\.\1740
D016559_D058625 NONE univariate_0\NN\1740 analysis_1\NN\633864 showed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 risk_5\NN\14541044 factors_6\NNS\7326557 associated_7\VBN\628491 with_8\IN\1740 seizures_9\NNS\14081375 after_10\IN\1740 pediatric_11\JJ\1740 lt_12\NN\1740 included_13\VBD\690614 gender_14\NN\6309383 ,_15\,\1740 pediatric_16\JJ\1740 <e2>end-stage_17\JJ\1740 liver_18\NN\5298729 disease</e2>_19\NN\14061805 score_20\NN\5736149 before_21\IN\1740 surgery_22\NN\6045562 ,_23\,\1740 child-pugh_24\JJ\1740 score_25\NN\5736149 before_26\IN\1740 surgery_27\NN\6045562 ,_28\,\1740 serum_29\NN\5397468 total_30\JJ\1740 bilirubin_31\NN\14756039 after_32\IN\1740 surgery_33\NN\6045562 ,_34\,\1740 and_35\CC\1740 trough_36\NN\9366017 <e1>tac</e1>_37\NN\1740 level_38\NN\4916342 ._39\.\1740
2453942
D001556_D020258 NONE <e1>lindane</e1>_0\NN\14919948 (_1\-LRB-\1740 gamma-hexachlorocyclohexane_2\JJ\1740 )_3\-RRB-\1740 is_4\VBZ\836236 an_5\DT\6697703 organochlorine_6\NN\1740 insecticide_7\NN\14980215 with_8\IN\1740 known_9\JJ\1740 <e2>neurotoxic</e2>_10\JJ\1740 effects_11\NNS\13245626 ._12\.\1740
D001556_D020258 NONE lindane_0\NN\14919948 (_1\-LRB-\1740 <e1>gamma-hexachlorocyclohexane</e1>_2\JJ\1740 )_3\-RRB-\1740 is_4\VBZ\836236 an_5\DT\6697703 organochlorine_6\NN\1740 insecticide_7\NN\14980215 with_8\IN\1740 known_9\JJ\1740 <e2>neurotoxic</e2>_10\JJ\1740 effects_11\NNS\13245626 ._12\.\1740
D001556_D012640 CID we_0\PRP\1740 studied_1\VBD\630380 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 <e1>lindane</e1>_5\NN\14919948 (_6\-LRB-\1740 150_7\CD\1740 mg/kg_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 the_11\DT\1740 gabaergic_12\JJ\1740 and_13\CC\1740 dopaminergic_14\JJ\1740 systems_15\NNS\3575240 by_16\IN\1740 measuring_17\VBG\697589 the_18\DT\1740 concentration_19\NN\4916342 of_20\IN\1740 gaba_21\NN\14601829 ,_22\,\1740 dopamine_23\NN\14807737 and_24\CC\1740 its_25\PRP$\6125041 metabolites_26\NNS\20090 in_27\IN\13603305 7_28\CD\13741022 brain_29\NN\5462674 areas_30\NNS\8630985 at_31\IN\14622893 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 <e2>seizures</e2>_35\NNS\14081375 ._36\.\1740
D001556_D012640 CID all_0\DT\1740 animals_1\NNS\4475 suffered_2\VBD\2110220 tonic_3\JJ\1740 <e2>convulsions</e2>_4\NNS\14081375 at_5\IN\14622893 18.3_6\CD\1740 +/-_7\CC\1740 1.4_8\CD\1740 min_9\NN\15154774 after_10\IN\1740 <e1>lindane</e1>_11\JJ\1740 administration_12\NN\1133281 ._13\.\1740
D005680_D012640 NONE we_0\PRP\1740 studied_1\VBD\630380 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 lindane_5\NN\14919948 (_6\-LRB-\1740 150_7\CD\1740 mg/kg_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 the_11\DT\1740 gabaergic_12\JJ\1740 and_13\CC\1740 dopaminergic_14\JJ\1740 systems_15\NNS\3575240 by_16\IN\1740 measuring_17\VBG\697589 the_18\DT\1740 concentration_19\NN\4916342 of_20\IN\1740 <e1>gaba</e1>_21\NN\14601829 ,_22\,\1740 dopamine_23\NN\14807737 and_24\CC\1740 its_25\PRP$\6125041 metabolites_26\NNS\20090 in_27\IN\13603305 7_28\CD\13741022 brain_29\NN\5462674 areas_30\NNS\8630985 at_31\IN\14622893 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 <e2>seizures</e2>_35\NNS\14081375 ._36\.\1740
D004298_D012640 NONE we_0\PRP\1740 studied_1\VBD\630380 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 lindane_5\NN\14919948 (_6\-LRB-\1740 150_7\CD\1740 mg/kg_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 the_11\DT\1740 gabaergic_12\JJ\1740 and_13\CC\1740 dopaminergic_14\JJ\1740 systems_15\NNS\3575240 by_16\IN\1740 measuring_17\VBG\697589 the_18\DT\1740 concentration_19\NN\4916342 of_20\IN\1740 gaba_21\NN\14601829 ,_22\,\1740 <e1>dopamine</e1>_23\NN\14807737 and_24\CC\1740 its_25\PRP$\6125041 metabolites_26\NNS\20090 in_27\IN\13603305 7_28\CD\13741022 brain_29\NN\5462674 areas_30\NNS\8630985 at_31\IN\14622893 the_32\DT\1740 onset_33\NN\7325190 of_34\IN\1740 <e2>seizures</e2>_35\NNS\14081375 ._36\.\1740
20009434
D008727_D058186 CID <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 after_3\IN\1740 high-dose_4\JJ\1740 <e1>methotrexate</e1>_5\NN\2722166 therapy_6\NN\657604 in_7\IN\13603305 a_8\DT\13649268 patient_9\NN\9898892 with_10\IN\1740 ileostomy_11\NN\689550 ._12\.\1740
D008727_D058186 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>acute_5\JJ\1740 renal_6\JJ\1740 failure</e2>_7\NN\66216 after_8\IN\1740 <e1>hd-mtx</e1>_9\NN\1740 therapy_10\NN\657604 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 ileostomy_15\NN\689550 ,_16\,\1740 the_17\DT\1740 patient_18\NN\9898892 was_19\VBD\836236 a_20\DT\13649268 3-year-old_21\JJ\1740 boy_22\NN\9624168 who_23\WP\8299493 had_24\VBD\2108377 received_25\VBN\2210855 a_26\DT\13649268 living-related_27\JJ\1740 liver_28\NN\5298729 transplantation_29\NN\671351 for_30\IN\1740 congenital_31\JJ\1740 biliary_32\JJ\1740 atresia_33\NN\14501726 ._34\.\1740
D008727_D058186 CID subsequent_0\JJ\1740 <e1>hd-mtx</e1>_1\NN\1740 therapy_2\NN\657604 caused_3\VBD\1617192 <e2>acute_4\JJ\1740 renal_5\JJ\1740 failure</e2>_6\NN\66216 that_7\WDT\1740 required_8\VBD\754942 continuous_9\JJ\1740 hemodialysis_10\NN\649760 ._11\.\1740
D008727_D002051 NONE high-dose_0\JJ\1740 <e1>methotrexate</e1>_1\NN\2722166 (_2\-LRB-\1740 hd-mtx_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 important_7\JJ\1740 treatment_8\NN\654885 for_9\IN\1740 <e2>burkitt_10\NN\1740 lymphoma</e2>_11\NN\14239918 ,_12\,\1740 but_13\CC\1740 can_14\MD\3094503 cause_15\VB\1617192 hepatic_16\JJ\1740 and_17\CC\1740 renal_18\JJ\1740 toxicity_19\NN\13576101 when_20\WRB\1740 its_21\PRP$\6125041 clearance_22\NN\5089947 is_23\VBZ\836236 delayed_24\VBN\439958 ._25\.\1740
D008727_D002051 NONE high-dose_0\JJ\1740 methotrexate_1\NN\2722166 (_2\-LRB-\1740 <e1>hd-mtx</e1>_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 important_7\JJ\1740 treatment_8\NN\654885 for_9\IN\1740 <e2>burkitt_10\NN\1740 lymphoma</e2>_11\NN\14239918 ,_12\,\1740 but_13\CC\1740 can_14\MD\3094503 cause_15\VB\1617192 hepatic_16\JJ\1740 and_17\CC\1740 renal_18\JJ\1740 toxicity_19\NN\13576101 when_20\WRB\1740 its_21\PRP$\6125041 clearance_22\NN\5089947 is_23\VBZ\836236 delayed_24\VBN\439958 ._25\.\1740
D008727_D056486 NONE high-dose_0\JJ\1740 <e1>methotrexate</e1>_1\NN\2722166 (_2\-LRB-\1740 hd-mtx_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 important_7\JJ\1740 treatment_8\NN\654885 for_9\IN\1740 burkitt_10\NN\1740 lymphoma_11\NN\14239918 ,_12\,\1740 but_13\CC\1740 can_14\MD\3094503 cause_15\VB\1617192 <e2>hepatic_16\JJ\1740 and_17\CC\1740 renal_18\JJ\1740 toxicity</e2>_19\NN\13576101 when_20\WRB\1740 its_21\PRP$\6125041 clearance_22\NN\5089947 is_23\VBZ\836236 delayed_24\VBN\439958 ._25\.\1740
D008727_D056486 NONE high-dose_0\JJ\1740 methotrexate_1\NN\2722166 (_2\-LRB-\1740 <e1>hd-mtx</e1>_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 important_7\JJ\1740 treatment_8\NN\654885 for_9\IN\1740 burkitt_10\NN\1740 lymphoma_11\NN\14239918 ,_12\,\1740 but_13\CC\1740 can_14\MD\3094503 cause_15\VB\1617192 <e2>hepatic_16\JJ\1740 and_17\CC\1740 renal_18\JJ\1740 toxicity</e2>_19\NN\13576101 when_20\WRB\1740 its_21\PRP$\6125041 clearance_22\NN\5089947 is_23\VBZ\836236 delayed_24\VBN\439958 ._25\.\1740
D008727_D007674 NONE high-dose_0\JJ\1740 <e1>methotrexate</e1>_1\NN\2722166 (_2\-LRB-\1740 hd-mtx_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 important_7\JJ\1740 treatment_8\NN\654885 for_9\IN\1740 burkitt_10\NN\1740 lymphoma_11\NN\14239918 ,_12\,\1740 but_13\CC\1740 can_14\MD\3094503 cause_15\VB\1617192 <e2>hepatic_16\JJ\1740 and_17\CC\1740 renal_18\JJ\1740 toxicity</e2>_19\NN\13576101 when_20\WRB\1740 its_21\PRP$\6125041 clearance_22\NN\5089947 is_23\VBZ\836236 delayed_24\VBN\439958 ._25\.\1740
D008727_D007674 NONE high-dose_0\JJ\1740 methotrexate_1\NN\2722166 (_2\-LRB-\1740 <e1>hd-mtx</e1>_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 important_7\JJ\1740 treatment_8\NN\654885 for_9\IN\1740 burkitt_10\NN\1740 lymphoma_11\NN\14239918 ,_12\,\1740 but_13\CC\1740 can_14\MD\3094503 cause_15\VB\1617192 <e2>hepatic_16\JJ\1740 and_17\CC\1740 renal_18\JJ\1740 toxicity</e2>_19\NN\13576101 when_20\WRB\1740 its_21\PRP$\6125041 clearance_22\NN\5089947 is_23\VBZ\836236 delayed_24\VBN\439958 ._25\.\1740
D008727_D001656 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 renal_6\JJ\1740 failure_7\NN\66216 after_8\IN\1740 <e1>hd-mtx</e1>_9\NN\1740 therapy_10\NN\657604 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 ileostomy_15\NN\689550 ,_16\,\1740 the_17\DT\1740 patient_18\NN\9898892 was_19\VBD\836236 a_20\DT\13649268 3-year-old_21\JJ\1740 boy_22\NN\9624168 who_23\WP\8299493 had_24\VBD\2108377 received_25\VBN\2210855 a_26\DT\13649268 living-related_27\JJ\1740 liver_28\NN\5298729 transplantation_29\NN\671351 for_30\IN\1740 congenital_31\JJ\1740 <e2>biliary_32\JJ\1740 atresia</e2>_33\NN\14501726 ._34\.\1740
14616590
D015742_D010146 CID <e2>pain</e2>_0\NN\14299637 on_1\IN\1740 injection_2\NN\320852 (_3\-LRB-\1740 80_4\CD\13745420 vs._5\CC\1740 20_6\CD\13745420 %_7\NN\1740 ,_8\,\1740 p_9\NN\14622893 <_10\XX\1740 0.01_11\CD\1740 )_12\-RRB-\1740 and_13\CC\1740 thrombophlebitis_14\NN\14352890 (_15\-LRB-\1740 93.3_16\CD\1740 vs._17\CC\1740 6.6_18\CD\1740 %_19\NN\1740 ,_20\,\1740 p_21\NN\14622893 <_22\XX\1740 0.001_23\CD\1740 )_24\-RRB-\1740 occurred_25\VBD\2623529 more_26\RBR\1740 frequently_27\RB\1740 with_28\IN\1740 am149_29\NN\1740 than_30\IN\1740 with_31\IN\1740 <e1>disoprivan</e1>_32\NNP\1740 ._33\.\1740
D015742_D013924 CID pain_0\NN\14299637 on_1\IN\1740 injection_2\NN\320852 (_3\-LRB-\1740 80_4\CD\13745420 vs._5\CC\1740 20_6\CD\13745420 %_7\NN\1740 ,_8\,\1740 p_9\NN\14622893 <_10\XX\1740 0.01_11\CD\1740 )_12\-RRB-\1740 and_13\CC\1740 <e2>thrombophlebitis</e2>_14\NN\14352890 (_15\-LRB-\1740 93.3_16\CD\1740 vs._17\CC\1740 6.6_18\CD\1740 %_19\NN\1740 ,_20\,\1740 p_21\NN\14622893 <_22\XX\1740 0.001_23\CD\1740 )_24\-RRB-\1740 occurred_25\VBD\2623529 more_26\RBR\1740 frequently_27\RB\1740 with_28\IN\1740 am149_29\NN\1740 than_30\IN\1740 with_31\IN\1740 <e1>disoprivan</e1>_32\NNP\1740 ._33\.\1740
23846525
C055162_D056486 CID acute_0\JJ\1740 <e2>hepatitis</e2>_1\NN\14127211 associated_2\VBN\628491 with_3\IN\1740 <e1>clopidogrel</e1>_4\NN\1740 :_5\:\1740 a_6\DT\13649268 case_7\NN\7283608 report_8\NN\6470073 and_9\CC\1740 review_10\NN\5733583 of_11\IN\1740 the_12\DT\1740 literature_13\NN\6362953 ._14\.\1740
C055162_D056486 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e1>clopidogrel-related</e1>_5\JJ\1740 acute_6\JJ\1740 <e2>hepatitis</e2>_7\NN\14127211 ._8\.\1740
C055162_D056486 CID reports_0\NNS\6470073 about_1\IN\1740 cases_2\NNS\7283608 of_3\IN\1740 <e2>hepatotoxicity</e2>_4\NN\1740 due_5\IN\5174653 to_6\IN\1740 <e1>clopidogrel</e1>_7\NN\1740 are_8\VBP\836236 increasing_9\VBG\169651 in_10\IN\13603305 the_11\DT\1740 last_12\JJ\1740 few_13\JJ\1740 years_14\NNS\15144371 ,_15\,\1740 after_16\IN\1740 the_17\DT\1740 increased_18\VBN\169651 use_19\NN\407535 of_20\IN\1740 this_21\DT\1740 drug_22\NN\14778436 ._23\.\1740
C055162_D056486 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 we_3\PRP\1740 believe_4\VBP\686447 that_5\IN\1740 physicians_6\NNS\10305802 should_7\MD\1740 carefully_8\RB\1740 consider_9\VB\689344 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 drug-induced_13\JJ\1740 <e2>hepatic_14\JJ\1740 injury</e2>_15\NN\14052046 when_16\WRB\1740 <e1>clopidogrel</e1>_17\NN\1740 is_18\VBZ\836236 prescribed_19\VBN\748282 ._20\.\1740
1779253
D002211_D051474 NONE topical_0\JJ\1740 0.025_1\CD\1740 %_2\NN\1740 <e1>capsaicin</e1>_3\NN\15032661 in_4\IN\13603305 chronic_5\JJ\1740 <e2>post-herpetic_6\JJ\1740 neuralgia</e2>_7\NN\14322699 :_8\:\1740 efficacy_9\NN\5199286 ,_10\,\1740 predictors_11\NNS\10756433 of_12\IN\1740 response_13\NN\11410625 and_14\CC\1740 long-term_15\JJ\1740 course_16\NN\883297 ._17\.\1740
D002211_D051474 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 efficacy_5\NN\5199286 ,_6\,\1740 time-course_7\RB\1740 of_8\IN\1740 action_9\NN\30358 and_10\CC\1740 predictors_11\NNS\10756433 of_12\IN\1740 response_13\NN\11410625 to_14\TO\1740 topical_15\JJ\1740 <e1>capsaicin</e1>_16\NN\15032661 ,_17\,\1740 39_18\CD\1740 patients_19\NNS\9898892 with_20\IN\1740 chronic_21\JJ\1740 <e2>post-herpetic_22\JJ\1740 neuralgia</e2>_23\NN\14322699 (_24\-LRB-\1740 phn_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 median_28\JJ\1740 duration_29\NN\15113229 24_30\CD\13745420 months_31\NNS\15113229 ,_32\,\1740 were_33\VBD\836236 treated_34\VBN\2376958 with_35\IN\1740 0.025_36\CD\1740 %_37\NN\1740 capsaicin_38\NN\15032661 cream_39\NN\8386555 for_40\IN\1740 8_41\CD\13741022 weeks_42\NNS\15113229 ._43\.\1740
D002211_D051474 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 efficacy_5\NN\5199286 ,_6\,\1740 time-course_7\RB\1740 of_8\IN\1740 action_9\NN\30358 and_10\CC\1740 predictors_11\NNS\10756433 of_12\IN\1740 response_13\NN\11410625 to_14\TO\1740 topical_15\JJ\1740 <e1>capsaicin</e1>_16\NN\15032661 ,_17\,\1740 39_18\CD\1740 patients_19\NNS\9898892 with_20\IN\1740 chronic_21\JJ\1740 post-herpetic_22\JJ\1740 neuralgia_23\NN\14322699 (_24\-LRB-\1740 <e2>phn</e2>_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 median_28\JJ\1740 duration_29\NN\15113229 24_30\CD\13745420 months_31\NNS\15113229 ,_32\,\1740 were_33\VBD\836236 treated_34\VBN\2376958 with_35\IN\1740 0.025_36\CD\1740 %_37\NN\1740 capsaicin_38\NN\15032661 cream_39\NN\8386555 for_40\IN\1740 8_41\CD\13741022 weeks_42\NNS\15113229 ._43\.\1740
D002211_D051474 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 efficacy_5\NN\5199286 ,_6\,\1740 time-course_7\RB\1740 of_8\IN\1740 action_9\NN\30358 and_10\CC\1740 predictors_11\NNS\10756433 of_12\IN\1740 response_13\NN\11410625 to_14\TO\1740 topical_15\JJ\1740 capsaicin_16\NN\15032661 ,_17\,\1740 39_18\CD\1740 patients_19\NNS\9898892 with_20\IN\1740 chronic_21\JJ\1740 <e2>post-herpetic_22\JJ\1740 neuralgia</e2>_23\NN\14322699 (_24\-LRB-\1740 phn_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 median_28\JJ\1740 duration_29\NN\15113229 24_30\CD\13745420 months_31\NNS\15113229 ,_32\,\1740 were_33\VBD\836236 treated_34\VBN\2376958 with_35\IN\1740 0.025_36\CD\1740 %_37\NN\1740 <e1>capsaicin</e1>_38\NN\15032661 cream_39\NN\8386555 for_40\IN\1740 8_41\CD\13741022 weeks_42\NNS\15113229 ._43\.\1740
D002211_D051474 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 efficacy_5\NN\5199286 ,_6\,\1740 time-course_7\RB\1740 of_8\IN\1740 action_9\NN\30358 and_10\CC\1740 predictors_11\NNS\10756433 of_12\IN\1740 response_13\NN\11410625 to_14\TO\1740 topical_15\JJ\1740 capsaicin_16\NN\15032661 ,_17\,\1740 39_18\CD\1740 patients_19\NNS\9898892 with_20\IN\1740 chronic_21\JJ\1740 post-herpetic_22\JJ\1740 neuralgia_23\NN\14322699 (_24\-LRB-\1740 <e2>phn</e2>_25\NN\1740 )_26\-RRB-\1740 ,_27\,\1740 median_28\JJ\1740 duration_29\NN\15113229 24_30\CD\13745420 months_31\NNS\15113229 ,_32\,\1740 were_33\VBD\836236 treated_34\VBN\2376958 with_35\IN\1740 0.025_36\CD\1740 %_37\NN\1740 <e1>capsaicin</e1>_38\NN\15032661 cream_39\NN\8386555 for_40\IN\1740 8_41\CD\13741022 weeks_42\NNS\15113229 ._43\.\1740
D002211_D051474 NONE if_0\IN\1740 confirmed_1\VBD\1011725 in_2\IN\13603305 controlled_3\VBN\2422663 trials_4\NNS\786195 ,_5\,\1740 the_6\DT\1740 long-term_7\JJ\1740 results_8\NNS\34213 of_9\IN\1740 this_10\DT\1740 open_11\JJ\1740 ,_12\,\1740 non-randomized_13\JJ\1740 study_14\NN\635850 might_15\MD\5029706 indicate_16\VB\952524 that_17\IN\1740 the_18\DT\1740 analgesic_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 <e1>capsaicin</e1>_22\NN\15032661 in_23\IN\13603305 <e2>phn</e2>_24\NN\1740 is_25\VBZ\836236 mediated_26\VBN\761713 by_27\IN\1740 both_28\CC\1740 interference_29\NN\6660942 with_30\IN\1740 neuropeptide_31\NN\1740 metabolism_32\NN\13526110 and_33\CC\1740 morphological_34\JJ\1740 changes_35\NNS\7283608 (_36\-LRB-\1740 perhaps_37\RB\1740 degeneration_38\NN\29677 )_39\-RRB-\1740 of_40\IN\1740 nociceptive_41\JJ\1740 afferents_42\NNS\5474346 ._43\.\1740
D002211_D008413 CID nineteen_0\CD\13745420 patients_1\NNS\9898892 (_2\-LRB-\1740 48.7_3\CD\1740 %_4\NN\1740 )_5\-RRB-\1740 substantially_6\RB\1740 improved_7\VBN\126264 after_8\IN\1740 the_9\DT\1740 8-week_10\JJ\1740 trial_11\NN\786195 ;_12\:\1740 5_13\CD\13741022 (_14\-LRB-\1740 12.8_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 discontinued_18\VBD\2609764 therapy_19\NN\657604 due_20\JJ\1740 to_21\TO\1740 side-effects_22\NNS\1740 such_23\JJ\1740 as_24\IN\14622893 intolerable_25\JJ\1740 <e1>capsaicin-induced</e1>_26\JJ\1740 burning_27\NN\376063 sensations_28\NNS\5708432 (_29\-LRB-\1740 4_30\CD\13741022 )_31\-RRB-\1740 or_32\CC\3541091 <e2>mastitis</e2>_33\NN\14336539 (_34\-LRB-\1740 1_35\CD\13741022 )_36\-RRB-\1740 ;_37\:\1740 15_38\CD\13745420 (_39\-LRB-\1740 38.5_40\CD\1740 %_41\NN\1740 )_42\-RRB-\1740 reported_43\VBD\831651 no_44\DT\7204911 benefit_45\NN\13278375 ._46\.\1740
573555
D011433_D007003 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 previously_3\RB\1740 reported_4\VBD\831651 <e2>hypoglycemia</e2>_5\NN\14299637 ,_6\,\1740 hyperbilirubinemia_7\NN\14204950 ,_8\,\1740 polycythemia_9\NN\14189204 ,_10\,\1740 neonatal_11\JJ\1740 apnea_12\NN\14299637 ,_13\,\1740 and_14\CC\1740 bradycardia_15\NN\14110674 are_16\VBP\836236 not_17\RB\1740 invariable_18\JJ\1740 and_19\CC\1740 can_20\MD\3094503 not_21\RB\1740 be_22\VB\836236 statistically_23\RB\1740 correlated_24\VBN\2657219 with_25\IN\1740 chronic_26\JJ\1740 <e1>propranolol</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
D011433_D006932 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 previously_3\RB\1740 reported_4\VBD\831651 hypoglycemia_5\NN\14299637 ,_6\,\1740 <e2>hyperbilirubinemia</e2>_7\NN\14204950 ,_8\,\1740 polycythemia_9\NN\14189204 ,_10\,\1740 neonatal_11\JJ\1740 apnea_12\NN\14299637 ,_13\,\1740 and_14\CC\1740 bradycardia_15\NN\14110674 are_16\VBP\836236 not_17\RB\1740 invariable_18\JJ\1740 and_19\CC\1740 can_20\MD\3094503 not_21\RB\1740 be_22\VB\836236 statistically_23\RB\1740 correlated_24\VBN\2657219 with_25\IN\1740 chronic_26\JJ\1740 <e1>propranolol</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
D011433_D011086 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 previously_3\RB\1740 reported_4\VBD\831651 hypoglycemia_5\NN\14299637 ,_6\,\1740 hyperbilirubinemia_7\NN\14204950 ,_8\,\1740 <e2>polycythemia</e2>_9\NN\14189204 ,_10\,\1740 neonatal_11\JJ\1740 apnea_12\NN\14299637 ,_13\,\1740 and_14\CC\1740 bradycardia_15\NN\14110674 are_16\VBP\836236 not_17\RB\1740 invariable_18\JJ\1740 and_19\CC\1740 can_20\MD\3094503 not_21\RB\1740 be_22\VB\836236 statistically_23\RB\1740 correlated_24\VBN\2657219 with_25\IN\1740 chronic_26\JJ\1740 <e1>propranolol</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
D011433_D001049 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 previously_3\RB\1740 reported_4\VBD\831651 hypoglycemia_5\NN\14299637 ,_6\,\1740 hyperbilirubinemia_7\NN\14204950 ,_8\,\1740 polycythemia_9\NN\14189204 ,_10\,\1740 <e2>neonatal_11\JJ\1740 apnea</e2>_12\NN\14299637 ,_13\,\1740 and_14\CC\1740 bradycardia_15\NN\14110674 are_16\VBP\836236 not_17\RB\1740 invariable_18\JJ\1740 and_19\CC\1740 can_20\MD\3094503 not_21\RB\1740 be_22\VB\836236 statistically_23\RB\1740 correlated_24\VBN\2657219 with_25\IN\1740 chronic_26\JJ\1740 <e1>propranolol</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
D011433_D001919 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 previously_3\RB\1740 reported_4\VBD\831651 hypoglycemia_5\NN\14299637 ,_6\,\1740 hyperbilirubinemia_7\NN\14204950 ,_8\,\1740 polycythemia_9\NN\14189204 ,_10\,\1740 neonatal_11\JJ\1740 apnea_12\NN\14299637 ,_13\,\1740 and_14\CC\1740 <e2>bradycardia</e2>_15\NN\14110674 are_16\VBP\836236 not_17\RB\1740 invariable_18\JJ\1740 and_19\CC\1740 can_20\MD\3094503 not_21\RB\1740 be_22\VB\836236 statistically_23\RB\1740 correlated_24\VBN\2657219 with_25\IN\1740 chronic_26\JJ\1740 <e1>propranolol</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
7173007
C025504_D009325 CID the_0\DT\1740 <e1>dimer-x</e1>_1\NN\1740 group_2\NN\2137 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 incidence_6\NN\13821570 of_7\IN\1740 <e2>nausea</e2>_8\NN\14299637 and_9\CC\1740 dizziness_10\JJ\1740 ._11\.\1740
C025504_D004244 CID the_0\DT\1740 <e1>dimer-x</e1>_1\NN\1740 group_2\NN\2137 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 incidence_6\NN\13821570 of_7\IN\1740 nausea_8\NN\14299637 and_9\CC\1740 <e2>dizziness</e2>_10\JJ\1740 ._11\.\1740
C006753_D015746 CID the_0\DT\1740 <e1>endografine</e1>_1\NNP\1740 group_2\NN\2137 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 incidence_6\NN\13821570 of_7\IN\1740 <e2>abdominal_8\JJ\1740 pain</e2>_9\NN\14299637 ._10\.\1740
D007485_D064420 NONE <e1>hexabrix</e1>_0\NN\1740 and_1\CC\1740 vasurix_2\NN\1740 polyvidone_3\NN\1740 are_4\VBP\836236 considered_5\VBN\689344 the_6\DT\1740 best_7\JJS\1740 contrast_8\NN\13854649 media_9\NNS\3575240 for_10\IN\1740 hysterosalpingography_11\NN\1740 and_12\CC\1740 perhaps_13\RB\1740 because_14\IN\1740 of_15\IN\1740 its_16\PRP$\6125041 low_17\JJ\1740 <e2>toxicity</e2>_18\NN\13576101 hexabrix_19\NNP\1740 should_20\MD\1740 be_21\VB\836236 preferred_22\VBN\1777210 ._23\.\1740
D007485_D064420 NONE hexabrix_0\NN\1740 and_1\CC\1740 vasurix_2\NN\1740 polyvidone_3\NN\1740 are_4\VBP\836236 considered_5\VBN\689344 the_6\DT\1740 best_7\JJS\1740 contrast_8\NN\13854649 media_9\NNS\3575240 for_10\IN\1740 hysterosalpingography_11\NN\1740 and_12\CC\1740 perhaps_13\RB\1740 because_14\IN\1740 of_15\IN\1740 its_16\PRP$\6125041 low_17\JJ\1740 <e2>toxicity</e2>_18\NN\13576101 <e1>hexabrix</e1>_19\NNP\1740 should_20\MD\1740 be_21\VB\836236 preferred_22\VBN\1777210 ._23\.\1740
D000100_D064420 NONE hexabrix_0\NN\1740 and_1\CC\1740 <e1>vasurix_2\NN\1740 polyvidone</e1>_3\NN\1740 are_4\VBP\836236 considered_5\VBN\689344 the_6\DT\1740 best_7\JJS\1740 contrast_8\NN\13854649 media_9\NNS\3575240 for_10\IN\1740 hysterosalpingography_11\NN\1740 and_12\CC\1740 perhaps_13\RB\1740 because_14\IN\1740 of_15\IN\1740 its_16\PRP$\6125041 low_17\JJ\1740 <e2>toxicity</e2>_18\NN\13576101 hexabrix_19\NNP\1740 should_20\MD\1740 be_21\VB\836236 preferred_22\VBN\1777210 ._23\.\1740
D003287_D064420 NONE hexabrix_0\NN\1740 and_1\CC\1740 vasurix_2\NN\1740 polyvidone_3\NN\1740 are_4\VBP\836236 considered_5\VBN\689344 the_6\DT\1740 best_7\JJS\1740 <e1>contrast_8\NN\13854649 media</e1>_9\NNS\3575240 for_10\IN\1740 hysterosalpingography_11\NN\1740 and_12\CC\1740 perhaps_13\RB\1740 because_14\IN\1740 of_15\IN\1740 its_16\PRP$\6125041 low_17\JJ\1740 <e2>toxicity</e2>_18\NN\13576101 hexabrix_19\NNP\1740 should_20\MD\1740 be_21\VB\836236 preferred_22\VBN\1777210 ._23\.\1740
1449452
D004077_D001281 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>atrial_3\JJ\1740 fibrillation</e2>_4\NN\14361664 <e1>digoxin</e1>_5\NN\15060131 is_6\VBZ\836236 beneficial_7\JJ\1740 for_8\IN\1740 ventricular_9\JJ\1740 rate_10\NN\13815152 control_11\NN\5190804 ._12\.\1740
D004077_D001145 CID also_0\RB\1740 ,_1\,\1740 <e1>digoxin</e1>_2\NN\15060131 has_3\VBZ\2108377 undesirable_4\JJ\1740 effects_5\NNS\13245626 such_6\JJ\1740 as_7\IN\14622893 increasing_8\VBG\169651 peripheral_9\JJ\1740 resistance_10\NN\37396 and_11\CC\1740 myocardial_12\JJ\1740 demands_13\NNS\6513366 ,_14\,\1740 and_15\CC\1740 causing_16\VBG\1617192 <e2>arrhythmias</e2>_17\NNS\14103288 ._18\.\1740
D004077_D009203 NONE pooled_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 other_6\JJ\1740 inotropic_7\JJ\1740 drugs_8\NNS\14778436 shows_9\VBZ\2137132 an_10\DT\6697703 excess_11\JJ\1740 mortality_12\NN\5054863 and_13\CC\1740 there_14\EX\27167 is_15\VBZ\836236 a_16\DT\13649268 possibility_17\NN\5944958 that_18\IN\1740 <e1>digoxin</e1>_19\NN\15060131 may_20\MD\15209706 increase_21\VB\169651 mortality_22\NN\5054863 after_23\IN\1740 <e2>myocardial_24\JJ\1740 infarction</e2>_25\NN\14204950 (_26\-LRB-\1740 mi_27\NN\14207561 )_28\-RRB-\1740 ._29\.\1740
D004077_D009203 NONE pooled_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 other_6\JJ\1740 inotropic_7\JJ\1740 drugs_8\NNS\14778436 shows_9\VBZ\2137132 an_10\DT\6697703 excess_11\JJ\1740 mortality_12\NN\5054863 and_13\CC\1740 there_14\EX\27167 is_15\VBZ\836236 a_16\DT\13649268 possibility_17\NN\5944958 that_18\IN\1740 <e1>digoxin</e1>_19\NN\15060131 may_20\MD\15209706 increase_21\VB\169651 mortality_22\NN\5054863 after_23\IN\1740 myocardial_24\JJ\1740 infarction_25\NN\14204950 (_26\-LRB-\1740 <e2>mi</e2>_27\NN\14207561 )_28\-RRB-\1740 ._29\.\1740
9197951
D003042_D001714 NONE a_0\DT\13649268 30-year-old_1\JJ\1740 <e1>cocaine-dependent</e1>_2\JJ\1740 man_3\NN\9605289 who_4\WP\8299493 was_5\VBD\836236 a_6\DT\13649268 subject_7\NN\6598915 in_8\IN\13603305 a_9\DT\13649268 study_10\NN\635850 evaluating_11\VBG\670261 the_12\DT\1740 anticraving_13\VBG\1740 efficacy_14\NN\5199286 of_15\IN\1740 the_16\DT\1740 stimulant_17\JJ\1740 medication_18\NN\3247620 diethylpropion_19\NN\1740 (_20\-LRB-\1740 dep_21\NN\1740 )_22\-RRB-\1740 became_23\VBD\146138 <e2>manic</e2>_24\JJ\1740 during_25\IN\1740 his_26\PRP$\1740 second_27\JJ\1740 week_28\NN\15113229 on_29\IN\1740 the_30\DT\1740 study_31\NN\635850 drug_32\NN\14778436 ._33\.\1740
D004053_D001714 CID a_0\DT\13649268 30-year-old_1\JJ\1740 cocaine-dependent_2\JJ\1740 man_3\NN\9605289 who_4\WP\8299493 was_5\VBD\836236 a_6\DT\13649268 subject_7\NN\6598915 in_8\IN\13603305 a_9\DT\13649268 study_10\NN\635850 evaluating_11\VBG\670261 the_12\DT\1740 anticraving_13\VBG\1740 efficacy_14\NN\5199286 of_15\IN\1740 the_16\DT\1740 stimulant_17\JJ\1740 medication_18\NN\3247620 <e1>diethylpropion</e1>_19\NN\1740 (_20\-LRB-\1740 dep_21\NN\1740 )_22\-RRB-\1740 became_23\VBD\146138 <e2>manic</e2>_24\JJ\1740 during_25\IN\1740 his_26\PRP$\1740 second_27\JJ\1740 week_28\NN\15113229 on_29\IN\1740 the_30\DT\1740 study_31\NN\635850 drug_32\NN\14778436 ._33\.\1740
D004053_D001714 CID a_0\DT\13649268 30-year-old_1\JJ\1740 cocaine-dependent_2\JJ\1740 man_3\NN\9605289 who_4\WP\8299493 was_5\VBD\836236 a_6\DT\13649268 subject_7\NN\6598915 in_8\IN\13603305 a_9\DT\13649268 study_10\NN\635850 evaluating_11\VBG\670261 the_12\DT\1740 anticraving_13\VBG\1740 efficacy_14\NN\5199286 of_15\IN\1740 the_16\DT\1740 stimulant_17\JJ\1740 medication_18\NN\3247620 diethylpropion_19\NN\1740 (_20\-LRB-\1740 <e1>dep</e1>_21\NN\1740 )_22\-RRB-\1740 became_23\VBD\146138 <e2>manic</e2>_24\JJ\1740 during_25\IN\1740 his_26\PRP$\1740 second_27\JJ\1740 week_28\NN\15113229 on_29\IN\1740 the_30\DT\1740 study_31\NN\635850 drug_32\NN\14778436 ._33\.\1740
D004053_D001714 CID pupillometric_0\JJ\1740 changes_1\NNS\7283608 while_2\IN\15122231 on_3\IN\1740 <e1>dep</e1>_4\NN\1740 ,_5\,\1740 especially_6\RB\1740 changes_7\NNS\7283608 in_8\IN\13603305 the_9\DT\1740 total_10\JJ\1740 power_11\NN\4723816 of_12\IN\1740 pupillary_13\JJ\1740 oscillation_14\NN\13518963 ,_15\,\1740 were_16\VBD\836236 dramatically_17\RB\1740 different_18\JJ\1740 than_19\IN\1740 those_20\DT\1740 observed_21\VBN\2163746 in_22\IN\13603305 the_23\DT\1740 eight_24\CD\13741022 other_25\JJ\1740 study_26\NN\635850 subjects_27\NNS\6598915 who_28\WP\8299493 did_29\VBD\1640855 not_30\RB\1740 become_31\VB\146138 <e2>manic</e2>_32\JJ\1740 ._33\.\1740
D004053_D011681 NONE pupillometric_0\JJ\1740 changes_1\NNS\7283608 while_2\IN\15122231 on_3\IN\1740 <e1>dep</e1>_4\NN\1740 ,_5\,\1740 especially_6\RB\1740 changes_7\NNS\7283608 in_8\IN\13603305 the_9\DT\1740 total_10\JJ\1740 power_11\NN\4723816 of_12\IN\1740 <e2>pupillary_13\JJ\1740 oscillation</e2>_14\NN\13518963 ,_15\,\1740 were_16\VBD\836236 dramatically_17\RB\1740 different_18\JJ\1740 than_19\IN\1740 those_20\DT\1740 observed_21\VBN\2163746 in_22\IN\13603305 the_23\DT\1740 eight_24\CD\13741022 other_25\JJ\1740 study_26\NN\635850 subjects_27\NNS\6598915 who_28\WP\8299493 did_29\VBD\1640855 not_30\RB\1740 become_31\VB\146138 manic_32\JJ\1740 ._33\.\1740
25006961
D008094_D018500 CID absence_0\NN\14449405 of_1\IN\1740 pkc-alpha_2\NN\1740 attenuates_3\VBZ\224901 <e1>lithium-induced</e1>_4\JJ\1740 <e2>nephrogenic_5\JJ\1740 diabetes_6\NNS\14075199 insipidus</e2>_7\NN\1740 ._8\.\1740
D008094_D018500 CID <e1>lithium</e1>_0\FW\14625458 ,_1\,\1740 an_2\DT\6697703 effective_3\JJ\1740 antipsychotic_4\JJ\1740 ,_5\,\1740 induces_6\VBZ\1627355 <e2>nephrogenic_7\JJ\1740 diabetes_8\NN\14075199 insipidus</e2>_9\NN\1740 (_10\-LRB-\1740 ndi_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 40_14\CD\13745420 %_15\NN\1740 of_16\IN\1740 patients_17\NNS\9898892 ._18\.\1740
D008094_D018500 CID <e1>lithium</e1>_0\FW\14625458 ,_1\,\1740 an_2\DT\6697703 effective_3\JJ\1740 antipsychotic_4\JJ\1740 ,_5\,\1740 induces_6\VBZ\1627355 nephrogenic_7\JJ\1740 diabetes_8\NN\14075199 insipidus_9\NN\1740 (_10\-LRB-\1740 <e2>ndi</e2>_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 40_14\CD\13745420 %_15\NN\1740 of_16\IN\1740 patients_17\NNS\9898892 ._18\.\1740
D008094_D018500 CID our_0\PRP$\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 ablation_4\NN\671351 of_5\IN\1740 pkca_6\NN\1740 preserves_7\VBZ\2681795 aqp2_8\NN\1740 and_9\CC\1740 ut-a1_10\NN\1740 protein_11\NN\14944888 expression_12\NN\4679549 and_13\CC\1740 localization_14\NN\151497 in_15\IN\13603305 <e1>lithium-induced</e1>_16\JJ\1740 <e2>ndi</e2>_17\NN\1740 ,_18\,\1740 and_19\CC\1740 prevents_20\VBZ\1740 the_21\DT\1740 development_22\NN\248977 of_23\IN\1740 the_24\DT\1740 severe_25\JJ\1740 polyuria_26\NN\14113228 associated_27\VBN\628491 with_28\IN\1740 lithium_29\NN\14625458 therapy_30\NN\657604 ._31\.\1740
D008094_D018500 CID our_0\PRP$\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 ablation_4\NN\671351 of_5\IN\1740 pkca_6\NN\1740 preserves_7\VBZ\2681795 aqp2_8\NN\1740 and_9\CC\1740 ut-a1_10\NN\1740 protein_11\NN\14944888 expression_12\NN\4679549 and_13\CC\1740 localization_14\NN\151497 in_15\IN\13603305 lithium-induced_16\JJ\1740 <e2>ndi</e2>_17\NN\1740 ,_18\,\1740 and_19\CC\1740 prevents_20\VBZ\1740 the_21\DT\1740 development_22\NN\248977 of_23\IN\1740 the_24\DT\1740 severe_25\JJ\1740 polyuria_26\NN\14113228 associated_27\VBN\628491 with_28\IN\1740 <e1>lithium</e1>_29\NN\14625458 therapy_30\NN\657604 ._31\.\1740
D008094_D011141 CID targeting_0\VBG\1151110 an_1\DT\6697703 alternative_2\JJ\1740 signaling_3\NN\33020 pathway_4\NN\5483677 ,_5\,\1740 such_6\JJ\1740 as_7\IN\14622893 pkc-mediated_8\JJ\1740 signaling_9\NN\33020 ,_10\,\1740 may_11\MD\15209706 be_12\VB\836236 an_13\DT\6697703 effective_14\JJ\1740 method_15\NN\5616786 of_16\IN\1740 treating_17\VBG\2376958 <e1>lithium-induced</e1>_18\JJ\1740 <e2>polyuria</e2>_19\NN\14113228 ._20\.\1740
D008094_D011141 CID our_0\PRP$\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 ablation_4\NN\671351 of_5\IN\1740 pkca_6\NN\1740 preserves_7\VBZ\2681795 aqp2_8\NN\1740 and_9\CC\1740 ut-a1_10\NN\1740 protein_11\NN\14944888 expression_12\NN\4679549 and_13\CC\1740 localization_14\NN\151497 in_15\IN\13603305 <e1>lithium-induced</e1>_16\JJ\1740 ndi_17\NN\1740 ,_18\,\1740 and_19\CC\1740 prevents_20\VBZ\1740 the_21\DT\1740 development_22\NN\248977 of_23\IN\1740 the_24\DT\1740 severe_25\JJ\1740 <e2>polyuria</e2>_26\NN\14113228 associated_27\VBN\628491 with_28\IN\1740 lithium_29\NN\14625458 therapy_30\NN\657604 ._31\.\1740
D008094_D011141 CID our_0\PRP$\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 ablation_4\NN\671351 of_5\IN\1740 pkca_6\NN\1740 preserves_7\VBZ\2681795 aqp2_8\NN\1740 and_9\CC\1740 ut-a1_10\NN\1740 protein_11\NN\14944888 expression_12\NN\4679549 and_13\CC\1740 localization_14\NN\151497 in_15\IN\13603305 lithium-induced_16\JJ\1740 ndi_17\NN\1740 ,_18\,\1740 and_19\CC\1740 prevents_20\VBZ\1740 the_21\DT\1740 development_22\NN\248977 of_23\IN\1740 the_24\DT\1740 severe_25\JJ\1740 <e2>polyuria</e2>_26\NN\14113228 associated_27\VBN\628491 with_28\IN\1740 <e1>lithium</e1>_29\NN\14625458 therapy_30\NN\657604 ._31\.\1740
6316193
D010852_D012640 CID structure-activity_0\JJ\1740 and_1\CC\1740 dose-effect_2\JJ\1740 relationships_3\NNS\31921 of_4\IN\1740 the_5\DT\1740 antagonism_6\NN\24720 of_7\IN\1740 <e1>picrotoxin-induced</e1>_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 by_10\IN\1740 cholecystokinin_11\NN\5408684 ,_12\,\1740 fragments_13\NNS\9385911 and_14\CC\1740 analogues_15\NNS\4743605 of_16\IN\1740 cholecystokinin_17\NN\5408684 in_18\IN\13603305 mice_19\NNS\2329401 ._20\.\1740
D010852_D012640 CID intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 cholecystokinin_3\NN\5408684 octapeptide_4\NN\1740 sulphate_5\NN\15010703 ester_6\NN\14727670 (_7\-LRB-\1740 cck-8-se_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 nonsulphated_11\VBN\1740 cholecystokinin_12\NN\5408684 octapeptide_13\NN\1740 (_14\-LRB-\1740 cck-8-ns_15\NN\1740 )_16\-RRB-\1740 enhanced_17\VBD\227165 the_18\DT\1740 latency_19\NN\15269513 of_20\IN\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 <e1>picrotoxin</e1>_24\NN\1740 in_25\IN\13603305 mice_26\NNS\2329401 ._27\.\1740
D010852_D012640 CID the_0\DT\1740 peptide_1\NN\14724264 cck-5_2\NN\1740 -_3\:\1740 8_4\CD\13741022 had_5\VBD\2108377 weak_6\JJ\1740 anticonvulsant_7\JJ\1740 activity_8\NN\30358 in_9\IN\13603305 comparison_10\NN\635850 to_11\IN\1740 the_12\DT\1740 octapeptides_13\NNS\1740 ,_14\,\1740 3.2_15\CD\1740 mumol/kg_16\NNS\1740 and_17\CC\1740 larger_18\JJR\1740 doses_19\NNS\3740161 of_20\IN\1740 the_21\DT\1740 reference_22\NN\6765044 drug_23\NN\14778436 ,_24\,\1740 diazepam_25\NN\2830852 ,_26\,\1740 totally_27\RB\1740 prevented_28\VBD\1740 <e1>picrotoxin-induced</e1>_29\JJ\1740 <e2>seizures</e2>_30\NNS\14081375 and_31\CC\1740 mortality_32\NN\5054863 ._33\.\1740
D002766_D012640 NONE structure-activity_0\JJ\1740 and_1\CC\1740 dose-effect_2\JJ\1740 relationships_3\NNS\31921 of_4\IN\1740 the_5\DT\1740 antagonism_6\NN\24720 of_7\IN\1740 picrotoxin-induced_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 by_10\IN\1740 <e1>cholecystokinin</e1>_11\NN\5408684 ,_12\,\1740 fragments_13\NNS\9385911 and_14\CC\1740 analogues_15\NNS\4743605 of_16\IN\1740 cholecystokinin_17\NN\5408684 in_18\IN\13603305 mice_19\NNS\2329401 ._20\.\1740
D002766_D012640 NONE structure-activity_0\JJ\1740 and_1\CC\1740 dose-effect_2\JJ\1740 relationships_3\NNS\31921 of_4\IN\1740 the_5\DT\1740 antagonism_6\NN\24720 of_7\IN\1740 picrotoxin-induced_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 by_10\IN\1740 cholecystokinin_11\NN\5408684 ,_12\,\1740 fragments_13\NNS\9385911 and_14\CC\1740 analogues_15\NNS\4743605 of_16\IN\1740 <e1>cholecystokinin</e1>_17\NN\5408684 in_18\IN\13603305 mice_19\NNS\2329401 ._20\.\1740
D012844_D012640 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>cholecystokinin_3\NN\5408684 octapeptide</e1>_4\NN\1740 sulphate_5\NN\15010703 ester_6\NN\14727670 (_7\-LRB-\1740 cck-8-se_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 nonsulphated_11\VBN\1740 cholecystokinin_12\NN\5408684 octapeptide_13\NN\1740 (_14\-LRB-\1740 cck-8-ns_15\NN\1740 )_16\-RRB-\1740 enhanced_17\VBD\227165 the_18\DT\1740 latency_19\NN\15269513 of_20\IN\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 picrotoxin_24\NN\1740 in_25\IN\13603305 mice_26\NNS\2329401 ._27\.\1740
D012844_D012640 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 cholecystokinin_3\NN\5408684 octapeptide_4\NN\1740 sulphate_5\NN\15010703 ester_6\NN\14727670 (_7\-LRB-\1740 <e1>cck-8-se</e1>_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 nonsulphated_11\VBN\1740 cholecystokinin_12\NN\5408684 octapeptide_13\NN\1740 (_14\-LRB-\1740 cck-8-ns_15\NN\1740 )_16\-RRB-\1740 enhanced_17\VBD\227165 the_18\DT\1740 latency_19\NN\15269513 of_20\IN\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 picrotoxin_24\NN\1740 in_25\IN\13603305 mice_26\NNS\2329401 ._27\.\1740
D012844_D012640 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 cholecystokinin_3\NN\5408684 octapeptide_4\NN\1740 sulphate_5\NN\15010703 ester_6\NN\14727670 (_7\-LRB-\1740 cck-8-se_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 nonsulphated_11\VBN\1740 <e1>cholecystokinin_12\NN\5408684 octapeptide</e1>_13\NN\1740 (_14\-LRB-\1740 cck-8-ns_15\NN\1740 )_16\-RRB-\1740 enhanced_17\VBD\227165 the_18\DT\1740 latency_19\NN\15269513 of_20\IN\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 picrotoxin_24\NN\1740 in_25\IN\13603305 mice_26\NNS\2329401 ._27\.\1740
D012844_D012640 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 cholecystokinin_3\NN\5408684 octapeptide_4\NN\1740 sulphate_5\NN\15010703 ester_6\NN\14727670 (_7\-LRB-\1740 cck-8-se_8\NN\1740 )_9\-RRB-\1740 and_10\CC\1740 nonsulphated_11\VBN\1740 cholecystokinin_12\NN\5408684 octapeptide_13\NN\1740 (_14\-LRB-\1740 <e1>cck-8-ns</e1>_15\NN\1740 )_16\-RRB-\1740 enhanced_17\VBD\227165 the_18\DT\1740 latency_19\NN\15269513 of_20\IN\1740 <e2>seizures</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 picrotoxin_24\NN\1740 in_25\IN\13603305 mice_26\NNS\2329401 ._27\.\1740
D003975_D012640 NONE the_0\DT\1740 peptide_1\NN\14724264 cck-5_2\NN\1740 -_3\:\1740 8_4\CD\13741022 had_5\VBD\2108377 weak_6\JJ\1740 anticonvulsant_7\JJ\1740 activity_8\NN\30358 in_9\IN\13603305 comparison_10\NN\635850 to_11\IN\1740 the_12\DT\1740 octapeptides_13\NNS\1740 ,_14\,\1740 3.2_15\CD\1740 mumol/kg_16\NNS\1740 and_17\CC\1740 larger_18\JJR\1740 doses_19\NNS\3740161 of_20\IN\1740 the_21\DT\1740 reference_22\NN\6765044 drug_23\NN\14778436 ,_24\,\1740 <e1>diazepam</e1>_25\NN\2830852 ,_26\,\1740 totally_27\RB\1740 prevented_28\VBD\1740 picrotoxin-induced_29\JJ\1740 <e2>seizures</e2>_30\NNS\14081375 and_31\CC\1740 mortality_32\NN\5054863 ._33\.\1740
4631913
D014750_D011552 CID effect_0\NN\34213 of_1\IN\1740 <e1>vincristine_2\NN\3917455 sulfate</e1>_3\NN\15010703 on_4\IN\1740 <e2>pseudomonas_5\NN\1352574 infections</e2>_6\NNS\14052046 in_7\IN\13603305 monkeys_8\NNS\2469914 ._9\.\1740
D014750_D007970 CID intravenous_0\JJ\1740 or_1\CC\3541091 intratracheal_2\JJ\1740 inoculation_3\NN\828990 of_4\IN\1740 2.0_5\CD\1740 to_6\TO\1740 2.5_7\CD\1740 mg_8\NN\13717155 of_9\IN\1740 <e1>vincristine_10\NN\3917455 sulfate</e1>_11\NN\15010703 was_12\VBD\836236 followed_13\VBN\1835496 by_14\IN\1740 <e2>leukopenia</e2>_15\NN\14189204 in_16\IN\13603305 4_17\CD\13741022 to_18\TO\1740 5_19\CD\13741022 days_20\NNS\15140892 ._21\.\1740
D014750_D007239 NONE intravenous_0\JJ\1740 inoculation_1\NN\828990 of_2\IN\1740 4.2_3\CD\1740 x_4\CC\13745420 10(10_5\CD\1740 )_6\-RRB-\1740 to_7\TO\1740 7.8_8\CD\1740 x_9\CC\13745420 10(10_10\CD\1740 )_11\-RRB-\1740 pyocin_12\NN\1740 type_13\NN\5839024 6_14\CD\13741022 pseudomonas_15\NN\1352574 organisms_16\NNS\4258 in_17\IN\13603305 monkeys_18\NNS\2469914 given_19\VBD\2327200 <e1>vincristine_20\NN\3917455 sulfate</e1>_21\NN\15010703 4_22\CD\13741022 days_23\NNS\15140892 previously_24\RB\1740 resulted_25\VBD\2633881 in_26\IN\13603305 fatal_27\JJ\1740 <e2>infection</e2>_28\NN\14052046 in_29\IN\13603305 11_30\CD\13745420 of_31\IN\1740 14_32\CD\13745420 monkeys_33\NNS\2469914 ,_34\,\1740 whereas_35\IN\1740 none_36\NN\15228378 of_37\IN\1740 four_38\CD\13741022 receiving_39\VBG\2210855 pseudomonas_40\NNP\1352574 alone_41\RB\1740 died_42\VBD\146138 ._43\.\1740
19681452
D003042_D002543 NONE bilateral_0\JJ\1740 <e2>haemorrhagic_1\JJ\1740 infarction_2\NN\14204950 of_3\IN\1740 the_4\DT\1740 globus_5\NN\1740 pallidus</e2>_6\NN\1740 after_7\IN\1740 <e1>cocaine</e1>_8\NN\3492717 and_9\CC\1740 alcohol_10\NN\7881800 intoxication_11\NN\14034177 ._12\.\1740
D003042_D020520 NONE bilateral_0\JJ\1740 <e2>haemorrhagic_1\JJ\1740 infarction_2\NN\14204950 of_3\IN\1740 the_4\DT\1740 globus_5\NN\1740 pallidus</e2>_6\NN\1740 after_7\IN\1740 <e1>cocaine</e1>_8\NN\3492717 and_9\CC\1740 alcohol_10\NN\7881800 intoxication_11\NN\14034177 ._12\.\1740
D003042_D020520 NONE bilateral_0\JJ\1740 <e2>basal_1\JJ\1740 ganglia_2\NN\5462674 infarcts</e2>_3\NNS\14204950 after_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 <e1>cocaine</e1>_8\NN\3492717 ,_9\,\1740 without_10\IN\1740 concurrent_11\JJ\1740 heroin_12\NN\3492717 use_13\NN\407535 ,_14\,\1740 have_15\VBP\2108377 never_16\RB\1740 been_17\VBN\836236 reported_18\VBN\831651 ._19\.\1740
D000431_D002543 NONE bilateral_0\JJ\1740 <e2>haemorrhagic_1\JJ\1740 infarction_2\NN\14204950 of_3\IN\1740 the_4\DT\1740 globus_5\NN\1740 pallidus</e2>_6\NN\1740 after_7\IN\1740 cocaine_8\NN\3492717 and_9\CC\1740 <e1>alcohol</e1>_10\NN\7881800 intoxication_11\NN\14034177 ._12\.\1740
D000431_D020520 NONE bilateral_0\JJ\1740 <e2>haemorrhagic_1\JJ\1740 infarction_2\NN\14204950 of_3\IN\1740 the_4\DT\1740 globus_5\NN\1740 pallidus</e2>_6\NN\1740 after_7\IN\1740 cocaine_8\NN\3492717 and_9\CC\1740 <e1>alcohol</e1>_10\NN\7881800 intoxication_11\NN\14034177 ._12\.\1740
D003042_D002544 NONE <e1>cocaine</e1>_0\NNP\3492717 is_1\VBZ\836236 a_2\DT\13649268 risk_3\NN\14541044 factor_4\NN\7326557 for_5\IN\1740 both_6\CC\1740 <e2>ischemic_7\JJ\1740 and_8\CC\1740 haemorrhagic_9\JJ\1740 stroke</e2>_10\NN\556313 ._11\.\1740
D003042_D020521 NONE <e1>cocaine</e1>_0\NNP\3492717 is_1\VBZ\836236 a_2\DT\13649268 risk_3\NN\14541044 factor_4\NN\7326557 for_5\IN\1740 both_6\CC\1740 <e2>ischemic_7\JJ\1740 and_8\CC\1740 haemorrhagic_9\JJ\1740 stroke</e2>_10\NN\556313 ._11\.\1740
D000431_D002545 NONE we_0\PRP\1740 present_1\VBP\2137132 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 31-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 bilateral_9\JJ\1740 <e2>ischemia_10\NN\14195315 of_11\IN\1740 the_12\DT\1740 globus_13\NN\1740 pallidus</e2>_14\NN\1740 after_15\IN\1740 excessive_16\JJ\1740 <e1>alcohol</e1>_17\NN\7881800 and_18\CC\1740 intranasal_19\JJ\1740 cocaine_20\NN\3492717 use_21\NN\407535 ._22\.\1740
D003042_D002545 CID we_0\PRP\1740 present_1\VBP\2137132 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 31-year-old_6\JJ\1740 man_7\NN\9605289 with_8\IN\1740 bilateral_9\JJ\1740 <e2>ischemia_10\NN\14195315 of_11\IN\1740 the_12\DT\1740 globus_13\NN\1740 pallidus</e2>_14\NN\1740 after_15\IN\1740 excessive_16\JJ\1740 alcohol_17\NN\7881800 and_18\CC\1740 intranasal_19\JJ\1740 <e1>cocaine</e1>_20\NN\3492717 use_21\NN\407535 ._22\.\1740
D003932_D020520 CID drug-related_0\JJ\1740 <e2>globus_1\NN\1740 pallidus_2\NN\1740 infarctions</e2>_3\NNS\14204950 are_4\VBP\836236 most_5\RBS\1740 often_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 <e1>heroin</e1>_9\NN\3492717 ._10\.\1740
D003932_D020520 CID bilateral_0\JJ\1740 <e2>basal_1\JJ\1740 ganglia_2\NN\5462674 infarcts</e2>_3\NNS\14204950 after_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 cocaine_8\NN\3492717 ,_9\,\1740 without_10\IN\1740 concurrent_11\JJ\1740 <e1>heroin</e1>_12\NN\3492717 use_13\NN\407535 ,_14\,\1740 have_15\VBP\2108377 never_16\RB\1740 been_17\VBN\836236 reported_18\VBN\831651 ._19\.\1740
D003042_D001145 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 transient_4\JJ\1740 <e2>cardiac_5\JJ\1740 arrhythmia</e2>_6\NN\14103288 or_7\CC\3541091 respiratory_8\JJ\1740 dysfunction_9\NN\14204950 related_10\JJ\1740 to_11\TO\1740 <e1>cocaine</e1>_12\NN\3492717 and/or_13\CC\1740 ethanol_14\NN\14708720 use_15\NN\407535 were_16\VBD\836236 the_17\DT\1740 most_18\RBS\1740 likely_19\JJ\1740 causes_20\NNS\7323922 of_21\IN\1740 cerebral_22\JJ\1740 hypoperfusion_23\NN\1740 ._24\.\1740
D003042_D012131 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 transient_4\JJ\1740 cardiac_5\JJ\1740 arrhythmia_6\NN\14103288 or_7\CC\3541091 <e2>respiratory_8\JJ\1740 dysfunction</e2>_9\NN\14204950 related_10\JJ\1740 to_11\TO\1740 <e1>cocaine</e1>_12\NN\3492717 and/or_13\CC\1740 ethanol_14\NN\14708720 use_15\NN\407535 were_16\VBD\836236 the_17\DT\1740 most_18\RBS\1740 likely_19\JJ\1740 causes_20\NNS\7323922 of_21\IN\1740 cerebral_22\JJ\1740 hypoperfusion_23\NN\1740 ._24\.\1740
D003042_-1 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 transient_4\JJ\1740 cardiac_5\JJ\1740 arrhythmia_6\NN\14103288 or_7\CC\3541091 respiratory_8\JJ\1740 dysfunction_9\NN\14204950 related_10\JJ\1740 to_11\TO\1740 <e1>cocaine</e1>_12\NN\3492717 and/or_13\CC\1740 ethanol_14\NN\14708720 use_15\NN\407535 were_16\VBD\836236 the_17\DT\1740 most_18\RBS\1740 likely_19\JJ\1740 causes_20\NNS\7323922 of_21\IN\1740 <e2>cerebral_22\JJ\1740 hypoperfusion</e2>_23\NN\1740 ._24\.\1740
D000431_D001145 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 transient_4\JJ\1740 <e2>cardiac_5\JJ\1740 arrhythmia</e2>_6\NN\14103288 or_7\CC\3541091 respiratory_8\JJ\1740 dysfunction_9\NN\14204950 related_10\JJ\1740 to_11\TO\1740 cocaine_12\NN\3492717 and/or_13\CC\1740 <e1>ethanol</e1>_14\NN\14708720 use_15\NN\407535 were_16\VBD\836236 the_17\DT\1740 most_18\RBS\1740 likely_19\JJ\1740 causes_20\NNS\7323922 of_21\IN\1740 cerebral_22\JJ\1740 hypoperfusion_23\NN\1740 ._24\.\1740
D000431_D012131 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 transient_4\JJ\1740 cardiac_5\JJ\1740 arrhythmia_6\NN\14103288 or_7\CC\3541091 <e2>respiratory_8\JJ\1740 dysfunction</e2>_9\NN\14204950 related_10\JJ\1740 to_11\TO\1740 cocaine_12\NN\3492717 and/or_13\CC\1740 <e1>ethanol</e1>_14\NN\14708720 use_15\NN\407535 were_16\VBD\836236 the_17\DT\1740 most_18\RBS\1740 likely_19\JJ\1740 causes_20\NNS\7323922 of_21\IN\1740 cerebral_22\JJ\1740 hypoperfusion_23\NN\1740 ._24\.\1740
D000431_-1 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 transient_4\JJ\1740 cardiac_5\JJ\1740 arrhythmia_6\NN\14103288 or_7\CC\3541091 respiratory_8\JJ\1740 dysfunction_9\NN\14204950 related_10\JJ\1740 to_11\TO\1740 cocaine_12\NN\3492717 and/or_13\CC\1740 <e1>ethanol</e1>_14\NN\14708720 use_15\NN\407535 were_16\VBD\836236 the_17\DT\1740 most_18\RBS\1740 likely_19\JJ\1740 causes_20\NNS\7323922 of_21\IN\1740 <e2>cerebral_22\JJ\1740 hypoperfusion</e2>_23\NN\1740 ._24\.\1740
2320485
D008750_D000743 CID <e1>methyldopa-induced</e1>_0\JJ\1740 <e2>hemolytic_1\JJ\1740 anemia</e2>_2\NN\14189204 in_3\IN\13603305 a_4\DT\13649268 15_5\CD\13745420 year_6\NN\15113229 old_7\JJ\1740 presenting_8\NN\1740 as_9\RB\1740 near-syncope_10\JJ\1740 ._11\.\1740
D008750_D000743 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e1>methyldopa-induced</e1>_5\JJ\1740 <e2>hemolytic_6\JJ\1740 anemia</e2>_7\NN\14189204 in_8\IN\13603305 a_9\DT\13649268 15-year-old_10\JJ\1740 boy_11\NN\9624168 who_12\WP\8299493 presented_13\VBD\2137132 to_14\IN\1740 the_15\DT\1740 emergency_16\NN\7417644 department_17\NN\8220714 with_18\IN\1740 near-syncope_19\NN\1740 ._20\.\1740
D008750_D013575 NONE <e1>methyldopa-induced</e1>_0\JJ\1740 hemolytic_1\JJ\1740 anemia_2\NN\14189204 in_3\IN\13603305 a_4\DT\13649268 15_5\CD\13745420 year_6\NN\15113229 old_7\JJ\1740 presenting_8\NN\1740 as_9\RB\1740 <e2>near-syncope</e2>_10\JJ\1740 ._11\.\1740
D008750_D013575 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e1>methyldopa-induced</e1>_5\JJ\1740 hemolytic_6\JJ\1740 anemia_7\NN\14189204 in_8\IN\13603305 a_9\DT\13649268 15-year-old_10\JJ\1740 boy_11\NN\9624168 who_12\WP\8299493 presented_13\VBD\2137132 to_14\IN\1740 the_15\DT\1740 emergency_16\NN\7417644 department_17\NN\8220714 with_18\IN\1740 <e2>near-syncope</e2>_19\NN\1740 ._20\.\1740
D008750_D000744 NONE <e1>methyldopa</e1>_0\NNP\2721160 causes_1\VBZ\1617192 an_2\DT\6697703 <e2>autoimmune_3\JJ\1740 hemolytic_4\JJ\1740 anemia</e2>_5\NN\14189204 in_6\IN\13603305 a_7\DT\13649268 small_8\JJ\1740 percentage_9\NN\13815742 of_10\IN\1740 patients_11\NNS\9898892 who_12\WP\8299493 take_13\VBP\2367363 the_14\DT\1740 drug_15\NN\14778436 ._16\.\1740
D008750_D004630 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e1>methyldopa-induced</e1>_5\JJ\1740 hemolytic_6\JJ\1740 anemia_7\NN\14189204 in_8\IN\13603305 a_9\DT\13649268 15-year-old_10\JJ\1740 boy_11\NN\9624168 who_12\WP\8299493 presented_13\VBD\2137132 to_14\IN\1740 the_15\DT\1740 <e2>emergency_16\NN\7417644 department</e2>_17\NN\8220714 with_18\IN\1740 near-syncope_19\NN\1740 ._20\.\1740
D008750_D014947 NONE the_0\DT\1740 boy_1\NN\9624168 had_2\VBD\2108377 been_3\VBN\836236 treated_4\VBN\2376958 with_5\IN\1740 intravenous_6\JJ\1740 <e1>methyldopa</e1>_7\NN\2721160 during_8\IN\1740 a_9\DT\13649268 <e2>trauma</e2>_10\NN\14052046 admission_11\NN\49003 seven_12\CD\13741022 weeks_13\NNS\15113229 prior_14\RB\1740 to_15\IN\1740 presentation_16\NN\1027379 ._17\.\1740
16092435
D012266_D066126 NONE morphological_0\JJ\1740 evaluation_1\NN\874067 of_2\IN\1740 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 <e1>d-ribose</e1>_6\NN\1740 on_7\IN\1740 adriamycin-evoked_8\JJ\1740 <e2>cardiotoxicity</e2>_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D012266_D066126 NONE <e1>d-ribose</e1>_0\NN\1740 in_1\IN\13603305 the_2\DT\1740 multiple_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 200_6\CD\1740 mg/kg_7\NN\1740 did_8\VBD\1640855 not_9\RB\1740 influence_10\VB\137313 adr_11\NN\1740 <e2>cardiotoxicity</e2>_12\NN\1740 ._13\.\1740
D004317_D066126 NONE morphological_0\JJ\1740 evaluation_1\NN\874067 of_2\IN\1740 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 d-ribose_6\NN\1740 on_7\IN\1740 <e1>adriamycin-evoked</e1>_8\JJ\1740 <e2>cardiotoxicity</e2>_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D004317_D066126 NONE <e1>adriamycin</e1>_0\NN\1740 in_1\IN\13603305 the_2\DT\1740 cumulative_3\JJ\1740 dose_4\NN\3740161 of_5\IN\1740 25_6\CD\13745420 mg/kg_7\NN\1740 evoked_8\VBD\1617192 fully_9\RB\1740 developed_10\VBD\1753788 <e2>cardiac_11\JJ\1740 toxicity</e2>_12\NN\13576101 ._13\.\1740
D004317_D066126 NONE d-ribose_0\NN\1740 in_1\IN\13603305 the_2\DT\1740 multiple_3\JJ\1740 doses_4\NNS\3740161 of_5\IN\1740 200_6\CD\1740 mg/kg_7\NN\1740 did_8\VBD\1640855 not_9\RB\1740 influence_10\VB\137313 <e1>adr</e1>_11\NN\1740 <e2>cardiotoxicity</e2>_12\NN\1740 ._13\.\1740
D012266_D009202 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 <e1>d-ribose</e1>_3\NN\1740 on_4\IN\1740 adriamycin-induced_5\JJ\1740 <e2>myocardiopathy</e2>_6\NN\14103288 in_7\IN\13603305 rats_8\NNS\2329401 was_9\VBD\836236 studied_10\VBN\630380 ._11\.\1740
D004317_D009202 CID the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 d-ribose_3\NN\1740 on_4\IN\1740 <e1>adriamycin-induced</e1>_5\JJ\1740 <e2>myocardiopathy</e2>_6\NN\14103288 in_7\IN\13603305 rats_8\NNS\2329401 was_9\VBD\836236 studied_10\VBN\630380 ._11\.\1740
2782734
D000420_D001249 NONE tachyphylaxis_0\NN\1740 to_1\TO\1740 systemic_2\VB\1740 but_3\CC\1740 not_4\RB\1740 to_5\TO\1740 airway_6\NN\3253398 responses_7\NNS\11410625 during_8\IN\1740 prolonged_9\JJ\1740 therapy_10\NN\657604 with_11\IN\1740 high_12\JJ\1740 dose_13\NN\3740161 inhaled_14\VBD\1198101 <e1>salbutamol</e1>_15\NN\1740 in_16\IN\13603305 <e2>asthmatics</e2>_17\NNS\7846 ._18\.\1740
D000420_D001249 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 inhaled_3\VBN\1198101 <e1>salbutamol</e1>_4\NN\1740 produce_5\VBP\1617192 substantial_6\JJ\1740 improvements_7\NNS\7359599 in_8\IN\13603305 airway_9\NN\3253398 response_10\NN\11410625 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>asthma</e2>_14\NN\14145095 ,_15\,\1740 and_16\CC\1740 are_17\VBP\836236 associated_18\VBN\628491 with_19\IN\1740 dose-dependent_20\JJ\1740 systemic_21\JJ\1740 beta-adrenoceptor_22\NN\5608868 responses_23\NNS\11410625 ._24\.\1740
D000420_D001249 NONE twelve_0\CD\13745420 <e2>asthmatic</e2>_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 fev1_4\NN\1740 ,_5\,\1740 81_6\CD\1740 +/-_7\CC\1740 4_8\CD\13741022 %_9\NN\1740 predicted_10\VBN\916909 )_11\-RRB-\1740 ,_12\,\1740 requiring_13\VBG\754942 only_14\RB\1740 occasional_15\JJ\1740 inhaled_16\VBN\1198101 beta-agonists_17\NNS\1740 as_18\IN\14622893 their_19\PRP$\1740 sole_20\NN\8511241 therapy_21\NN\657604 ,_22\,\1740 were_23\VBD\836236 given_24\VBN\2327200 a_25\DT\13649268 14-day_26\JJ\1740 treatment_27\NN\654885 with_28\IN\1740 high_29\JJ\1740 dose_30\NN\3740161 inhaled_31\VBD\1198101 <e1>salbutamol</e1>_32\NN\1740 (_33\-LRB-\1740 hds_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 4,000_37\CD\1740 micrograms_38\NNS\13717155 daily_39\RB\1740 ,_40\,\1740 low_41\JJ\1740 dose_42\NN\3740161 inhaled_43\VBD\1198101 salbutamol_44\NN\1740 (_45\-LRB-\1740 lds_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 800_49\CD\1740 micrograms_50\NNS\13717155 daily_51\RB\1740 ,_52\,\1740 or_53\CC\3541091 placebo_54\NN\3740161 (_55\-LRB-\1740 pi_56\NN\13730756 )_57\-RRB-\1740 by_58\IN\1740 metered-dose_59\JJ\1740 inhaler_60\NN\3210683 in_61\IN\13603305 a_62\DT\13649268 double-blind_63\JJ\1740 ,_64\,\1740 randomized_65\JJ\1740 crossover_66\NN\13526110 design_67\NN\927261 ._68\.\1740
D000420_D001249 NONE twelve_0\CD\13745420 <e2>asthmatic</e2>_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 fev1_4\NN\1740 ,_5\,\1740 81_6\CD\1740 +/-_7\CC\1740 4_8\CD\13741022 %_9\NN\1740 predicted_10\VBN\916909 )_11\-RRB-\1740 ,_12\,\1740 requiring_13\VBG\754942 only_14\RB\1740 occasional_15\JJ\1740 inhaled_16\VBN\1198101 beta-agonists_17\NNS\1740 as_18\IN\14622893 their_19\PRP$\1740 sole_20\NN\8511241 therapy_21\NN\657604 ,_22\,\1740 were_23\VBD\836236 given_24\VBN\2327200 a_25\DT\13649268 14-day_26\JJ\1740 treatment_27\NN\654885 with_28\IN\1740 high_29\JJ\1740 dose_30\NN\3740161 inhaled_31\VBD\1198101 salbutamol_32\NN\1740 (_33\-LRB-\1740 hds_34\NN\1740 )_35\-RRB-\1740 ,_36\,\1740 4,000_37\CD\1740 micrograms_38\NNS\13717155 daily_39\RB\1740 ,_40\,\1740 low_41\JJ\1740 dose_42\NN\3740161 inhaled_43\VBD\1198101 <e1>salbutamol</e1>_44\NN\1740 (_45\-LRB-\1740 lds_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 800_49\CD\1740 micrograms_50\NNS\13717155 daily_51\RB\1740 ,_52\,\1740 or_53\CC\3541091 placebo_54\NN\3740161 (_55\-LRB-\1740 pi_56\NN\13730756 )_57\-RRB-\1740 by_58\IN\1740 metered-dose_59\JJ\1740 inhaler_60\NN\3210683 in_61\IN\13603305 a_62\DT\13649268 double-blind_63\JJ\1740 ,_64\,\1740 randomized_65\JJ\1740 crossover_66\NN\13526110 design_67\NN\927261 ._68\.\1740
D011188_D014202 NONE at_0\IN\14622893 the_1\DT\1740 end_2\NN\8568978 of_3\IN\1740 each_4\DT\1740 14-day_5\JJ\1740 treatment_6\NN\654885 ,_7\,\1740 a_8\DT\13649268 dose-response_9\JJ\1740 curve_10\NN\13863771 (_11\-LRB-\1740 drc_12\NN\1740 )_13\-RRB-\1740 was_14\VBD\836236 performed_15\VBN\2367363 ,_16\,\1740 and_17\CC\1740 airway_18\NN\3253398 (_19\-LRB-\1740 fev1_20\NN\1740 ,_21\,\1740 fef25_22\NN\1740 -_23\HYPH\1740 75_24\CD\1740 )_25\-RRB-\1740 chronotropic_26\JJ\1740 (_27\-LRB-\1740 hr_28\NN\15154774 )_29\-RRB-\1740 ,_30\,\1740 <e2>tremor</e2>_31\NN\345926 ,_32\,\1740 and_33\CC\1740 metabolic_34\JJ\1740 (_35\-LRB-\1740 <e1>k</e1>_36\NN\13608598 ,_37\,\1740 glu_38\NN\1740 )_39\-RRB-\1740 responses_40\NNS\11410625 were_41\VBD\836236 measured_42\VBN\697589 at_43\IN\14622893 each_44\DT\1740 step_45\NN\168237 (_46\-LRB-\1740 from_47\IN\1740 100_48\CD\13745420 to_49\TO\1740 4,000_50\CD\1740 micrograms_51\NNS\13717155 )_52\-RRB-\1740 ._53\.\1740
D005947_D014202 NONE at_0\IN\14622893 the_1\DT\1740 end_2\NN\8568978 of_3\IN\1740 each_4\DT\1740 14-day_5\JJ\1740 treatment_6\NN\654885 ,_7\,\1740 a_8\DT\13649268 dose-response_9\JJ\1740 curve_10\NN\13863771 (_11\-LRB-\1740 drc_12\NN\1740 )_13\-RRB-\1740 was_14\VBD\836236 performed_15\VBN\2367363 ,_16\,\1740 and_17\CC\1740 airway_18\NN\3253398 (_19\-LRB-\1740 fev1_20\NN\1740 ,_21\,\1740 fef25_22\NN\1740 -_23\HYPH\1740 75_24\CD\1740 )_25\-RRB-\1740 chronotropic_26\JJ\1740 (_27\-LRB-\1740 hr_28\NN\15154774 )_29\-RRB-\1740 ,_30\,\1740 <e2>tremor</e2>_31\NN\345926 ,_32\,\1740 and_33\CC\1740 metabolic_34\JJ\1740 (_35\-LRB-\1740 k_36\NN\13608598 ,_37\,\1740 <e1>glu</e1>_38\NN\1740 )_39\-RRB-\1740 responses_40\NNS\11410625 were_41\VBD\836236 measured_42\VBN\697589 at_43\IN\14622893 each_44\DT\1740 step_45\NN\168237 (_46\-LRB-\1740 from_47\IN\1740 100_48\CD\13745420 to_49\TO\1740 4,000_50\CD\1740 micrograms_51\NNS\13717155 )_52\-RRB-\1740 ._53\.\1740
24675088
D004317_D066126 NONE an_0\DT\6697703 integrated_1\JJ\1740 characterization_2\NN\6724763 of_3\IN\1740 serological_4\JJ\1740 ,_5\,\1740 pathological_6\JJ\1740 ,_7\,\1740 and_8\CC\1740 functional_9\JJ\1740 events_10\NNS\23100 in_11\IN\13603305 <e1>doxorubicin-induced</e1>_12\JJ\1740 <e2>cardiotoxicity</e2>_13\NN\1740 ._14\.\1740
D004317_D009202 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 have_5\VBP\2108377 utilized_6\VBN\161225 a_7\DT\13649268 rat_8\NN\2329401 model_9\NN\5888929 of_10\IN\1740 progressive_11\JJ\1740 <e1>doxorubicin</e1>_12\NN\2716866 (dox)-induced_13\NN\1740 <e2>cardiomyopathy</e2>_14\JJ\1740 ,_15\,\1740 applying_16\VBG\2676054 multiple_17\JJ\1740 approaches_18\NNS\940842 ,_19\,\1740 including_20\VBG\690614 cardiac_21\JJ\1740 magnetic_22\JJ\1740 resonance_23\NN\11419404 imaging_24\NN\5765159 (_25\-LRB-\1740 mri_26\NN\901083 )_27\-RRB-\1740 ,_28\,\1740 to_29\TO\1740 provide_30\VB\2199590 the_31\DT\1740 most_32\RBS\1740 comprehensive_33\JJ\1740 characterization_34\NN\6724763 to_35\IN\1740 date_36\NN\15155220 of_37\IN\1740 the_38\DT\1740 timecourse_39\NN\1740 of_40\IN\1740 serological_41\JJ\1740 ,_42\,\1740 pathological_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 functional_46\JJ\1740 events_47\NNS\23100 underlying_48\VBG\2604760 this_49\DT\1740 toxicity_50\NN\13576101 ._51\.\1740
D004317_D009202 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 have_5\VBP\2108377 utilized_6\VBN\161225 a_7\DT\13649268 rat_8\NN\2329401 model_9\NN\5888929 of_10\IN\1740 progressive_11\JJ\1740 doxorubicin_12\NN\2716866 <e1>(dox)-induced</e1>_13\NN\1740 <e2>cardiomyopathy</e2>_14\JJ\1740 ,_15\,\1740 applying_16\VBG\2676054 multiple_17\JJ\1740 approaches_18\NNS\940842 ,_19\,\1740 including_20\VBG\690614 cardiac_21\JJ\1740 magnetic_22\JJ\1740 resonance_23\NN\11419404 imaging_24\NN\5765159 (_25\-LRB-\1740 mri_26\NN\901083 )_27\-RRB-\1740 ,_28\,\1740 to_29\TO\1740 provide_30\VB\2199590 the_31\DT\1740 most_32\RBS\1740 comprehensive_33\JJ\1740 characterization_34\NN\6724763 to_35\IN\1740 date_36\NN\15155220 of_37\IN\1740 the_38\DT\1740 timecourse_39\NN\1740 of_40\IN\1740 serological_41\JJ\1740 ,_42\,\1740 pathological_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 functional_46\JJ\1740 events_47\NNS\23100 underlying_48\VBG\2604760 this_49\DT\1740 toxicity_50\NN\13576101 ._51\.\1740
D004317_D064420 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 have_5\VBP\2108377 utilized_6\VBN\161225 a_7\DT\13649268 rat_8\NN\2329401 model_9\NN\5888929 of_10\IN\1740 progressive_11\JJ\1740 <e1>doxorubicin</e1>_12\NN\2716866 (dox)-induced_13\NN\1740 cardiomyopathy_14\JJ\1740 ,_15\,\1740 applying_16\VBG\2676054 multiple_17\JJ\1740 approaches_18\NNS\940842 ,_19\,\1740 including_20\VBG\690614 cardiac_21\JJ\1740 magnetic_22\JJ\1740 resonance_23\NN\11419404 imaging_24\NN\5765159 (_25\-LRB-\1740 mri_26\NN\901083 )_27\-RRB-\1740 ,_28\,\1740 to_29\TO\1740 provide_30\VB\2199590 the_31\DT\1740 most_32\RBS\1740 comprehensive_33\JJ\1740 characterization_34\NN\6724763 to_35\IN\1740 date_36\NN\15155220 of_37\IN\1740 the_38\DT\1740 timecourse_39\NN\1740 of_40\IN\1740 serological_41\JJ\1740 ,_42\,\1740 pathological_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 functional_46\JJ\1740 events_47\NNS\23100 underlying_48\VBG\2604760 this_49\DT\1740 <e2>toxicity</e2>_50\NN\13576101 ._51\.\1740
D004317_D064420 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 have_5\VBP\2108377 utilized_6\VBN\161225 a_7\DT\13649268 rat_8\NN\2329401 model_9\NN\5888929 of_10\IN\1740 progressive_11\JJ\1740 doxorubicin_12\NN\2716866 <e1>(dox)-induced</e1>_13\NN\1740 cardiomyopathy_14\JJ\1740 ,_15\,\1740 applying_16\VBG\2676054 multiple_17\JJ\1740 approaches_18\NNS\940842 ,_19\,\1740 including_20\VBG\690614 cardiac_21\JJ\1740 magnetic_22\JJ\1740 resonance_23\NN\11419404 imaging_24\NN\5765159 (_25\-LRB-\1740 mri_26\NN\901083 )_27\-RRB-\1740 ,_28\,\1740 to_29\TO\1740 provide_30\VB\2199590 the_31\DT\1740 most_32\RBS\1740 comprehensive_33\JJ\1740 characterization_34\NN\6724763 to_35\IN\1740 date_36\NN\15155220 of_37\IN\1740 the_38\DT\1740 timecourse_39\NN\1740 of_40\IN\1740 serological_41\JJ\1740 ,_42\,\1740 pathological_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 functional_46\JJ\1740 events_47\NNS\23100 underlying_48\VBG\2604760 this_49\DT\1740 <e2>toxicity</e2>_50\NN\13576101 ._51\.\1740
D005682_D018754 NONE troponin_0\NN\1740 i_1\PRP\14622893 levels_2\NNS\4916342 positively_3\RB\1740 correlated_4\VBD\2657219 with_5\IN\1740 delayed_6\VBN\439958 and_7\CC\1740 peak_8\NN\13758296 <e1>gadolinium</e1>_9\NN\14625458 contrast_10\NN\13854649 enhancement_11\NN\248977 ,_12\,\1740 histopathological_13\JJ\1740 grading_14\NN\1009871 ,_15\,\1740 and_16\CC\1740 <e2>diastolic_17\JJ\1740 dysfunction</e2>_18\NN\14204950 ._19\.\1740
24100055
D006493_D013921 CID incidence_0\NN\13821570 of_1\IN\1740 <e1>heparin-induced</e1>_2\JJ\1740 <e2>thrombocytopenia_3\NN\14189204 type_4\NN\5839024 ii</e2>_5\CD\13741022 and_6\CC\1740 postoperative_7\JJ\1740 recovery_8\NN\7357388 of_9\IN\1740 platelet_10\NN\5432736 count_11\NN\13582013 in_12\IN\13603305 liver_13\NN\5298729 graft_14\NN\5267548 recipients_15\NNS\9764201 :_16\:\1740 a_17\DT\13649268 retrospective_18\JJ\1740 cohort_19\NN\8184861 analysis_20\NN\633864 ._21\.\1740
D006493_D013921 CID the_0\DT\1740 impact_1\NN\7339329 of_2\IN\1740 immune-mediated_3\JJ\1740 <e1>heparin-induced</e1>_4\JJ\1740 <e2>thrombocytopenia_5\NN\14189204 type_6\NN\5839024 ii</e2>_7\CD\13741022 (_8\-LRB-\1740 hit_9\NN\36762 type_10\NN\5839024 ii_11\CD\13741022 )_12\-RRB-\1740 as_13\IN\14622893 a_14\DT\13649268 cause_15\NN\7323922 of_16\IN\1740 thrombocytopenia_17\NN\14189204 after_18\IN\1740 liver_19\NN\5298729 transplantation_20\NN\671351 is_21\VBZ\836236 not_22\RB\1740 yet_23\RB\1740 understood_24\VBN\588888 ,_25\,\1740 with_26\IN\1740 few_27\JJ\1740 literature_28\NN\6362953 citations_29\NNS\6696483 reporting_30\VBG\831651 contradictory_31\JJ\1740 results_32\NNS\34213 ._33\.\1740
D006493_D013921 CID the_0\DT\1740 impact_1\NN\7339329 of_2\IN\1740 immune-mediated_3\JJ\1740 <e1>heparin-induced</e1>_4\JJ\1740 thrombocytopenia_5\NN\14189204 type_6\NN\5839024 ii_7\CD\13741022 (_8\-LRB-\1740 <e2>hit_9\NN\36762 type_10\NN\5839024 ii</e2>_11\CD\13741022 )_12\-RRB-\1740 as_13\IN\14622893 a_14\DT\13649268 cause_15\NN\7323922 of_16\IN\1740 thrombocytopenia_17\NN\14189204 after_18\IN\1740 liver_19\NN\5298729 transplantation_20\NN\671351 is_21\VBZ\836236 not_22\RB\1740 yet_23\RB\1740 understood_24\VBN\588888 ,_25\,\1740 with_26\IN\1740 few_27\JJ\1740 literature_28\NN\6362953 citations_29\NNS\6696483 reporting_30\VBG\831651 contradictory_31\JJ\1740 results_32\NNS\34213 ._33\.\1740
D006493_D013921 CID the_0\DT\1740 impact_1\NN\7339329 of_2\IN\1740 immune-mediated_3\JJ\1740 <e1>heparin-induced</e1>_4\JJ\1740 thrombocytopenia_5\NN\14189204 type_6\NN\5839024 ii_7\CD\13741022 (_8\-LRB-\1740 hit_9\NN\36762 type_10\NN\5839024 ii_11\CD\13741022 )_12\-RRB-\1740 as_13\IN\14622893 a_14\DT\13649268 cause_15\NN\7323922 of_16\IN\1740 <e2>thrombocytopenia</e2>_17\NN\14189204 after_18\IN\1740 liver_19\NN\5298729 transplantation_20\NN\671351 is_21\VBZ\836236 not_22\RB\1740 yet_23\RB\1740 understood_24\VBN\588888 ,_25\,\1740 with_26\IN\1740 few_27\JJ\1740 literature_28\NN\6362953 citations_29\NNS\6696483 reporting_30\VBG\831651 contradictory_31\JJ\1740 results_32\NNS\34213 ._33\.\1740
D006493_D013921 CID for_0\IN\1740 further_1\JJ\1740 reduction_2\NN\351485 of_3\IN\1740 <e2>hit_4\NN\36762 type_5\NN\5839024 ii</e2>_6\CD\13741022 ,_7\,\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 intravenous_11\JJ\1740 <e1>heparin</e1>_12\NN\2718259 should_13\MD\1740 be_14\VB\836236 avoided_15\VBN\2452885 and_16\CC\1740 the_17\DT\1740 prophylactic_18\JJ\1740 anticoagulation_19\NN\657604 should_20\MD\1740 be_21\VB\836236 performed_22\VBN\2367363 with_23\IN\1740 low-molecular-weight_24\JJ\1740 heparin_25\NN\2718259 after_26\IN\1740 normalization_27\NN\1123598 of_28\IN\1740 platelet_29\NN\5432736 count_30\NN\13582013 ._31\.\1740
D006493_D013921 CID for_0\IN\1740 further_1\JJ\1740 reduction_2\NN\351485 of_3\IN\1740 <e2>hit_4\NN\36762 type_5\NN\5839024 ii</e2>_6\CD\13741022 ,_7\,\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 intravenous_11\JJ\1740 heparin_12\NN\2718259 should_13\MD\1740 be_14\VB\836236 avoided_15\VBN\2452885 and_16\CC\1740 the_17\DT\1740 prophylactic_18\JJ\1740 anticoagulation_19\NN\657604 should_20\MD\1740 be_21\VB\836236 performed_22\VBN\2367363 with_23\IN\1740 low-molecular-weight_24\JJ\1740 <e1>heparin</e1>_25\NN\2718259 after_26\IN\1740 normalization_27\NN\1123598 of_28\IN\1740 platelet_29\NN\5432736 count_30\NN\13582013 ._31\.\1740
1837756
D012701_D010259 NONE <e1>serotonin</e1>_0\NN\14807737 reuptake_1\NN\13571580 inhibitors_2\NNS\20090 ,_3\,\1740 <e2>paranoia</e2>_4\RB\1740 ,_5\,\1740 and_6\CC\1740 the_7\DT\1740 ventral_8\JJ\1740 basal_9\JJ\1740 ganglia_10\NN\5462674 ._11\.\1740
D012701_D010259 NONE five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>paranoid</e2>_3\JJ\1740 exacerbation_4\NN\374224 with_5\IN\1740 the_6\DT\1740 <e1>serotonin</e1>_7\NN\14807737 reuptake_8\NN\13571580 inhibitors_9\NNS\20090 fluoxetine_10\NN\4169152 and_11\CC\1740 amitriptyline_12\NN\4482543 are_13\VBP\836236 reported_14\VBN\831651 here_15\RB\1740 ._16\.\1740
D012701_D010259 NONE complicated_0\JJ\1740 depressive_1\JJ\1740 disorders_2\NNS\14034177 (_3\-LRB-\1740 including_4\VBG\690614 atypicality_5\NN\14501726 of_6\IN\1740 course_7\NN\883297 and_8\CC\1740 symptomatology_9\NN\1740 ,_10\,\1740 chronicity_11\NN\1740 ,_12\,\1740 psychosis_13\NN\14380140 ,_14\,\1740 bipolarity_15\NN\1740 ,_16\,\1740 and_17\CC\1740 secondary_18\JJ\1740 onset_19\NN\7325190 in_20\IN\13603305 the_21\DT\1740 course_22\NN\883297 of_23\IN\1740 a_24\DT\13649268 primary_25\JJ\1740 psychosis_26\NN\14380140 )_27\-RRB-\1740 may_28\MD\15209706 present_29\VB\2137132 particular_30\JJ\1740 vulnerability_31\NN\14540765 to_32\TO\1740 <e2>paranoid</e2>_33\NN\10490141 exacerbations_34\NNS\374224 associated_35\VBN\628491 with_36\IN\1740 <e1>serotonin</e1>_37\NN\14807737 reuptake_38\NN\13571580 inhibitors_39\NNS\20090 ._40\.\1740
D012701_D010259 NONE these_0\DT\1740 cases_1\NNS\7283608 call_2\VBP\1029852 attention_3\NN\5701944 to_4\IN\1740 possible_5\JJ\1740 <e2>paranoid</e2>_6\JJ\1740 exacerbations_7\NNS\374224 with_8\IN\1740 <e1>serotonin</e1>_9\NN\14807737 reuptake_10\NN\13571580 blockers_11\NNS\10101634 in_12\IN\13603305 select_13\JJ\1740 patients_14\NNS\9898892 and_15\CC\1740 raise_16\VBP\153263 neurobiological_17\JJ\1740 considerations_18\NNS\5770926 regarding_19\VBG\689344 paranoia_20\NN\14398067 ._21\.\1740
D012701_D010259 NONE these_0\DT\1740 cases_1\NNS\7283608 call_2\VBP\1029852 attention_3\NN\5701944 to_4\IN\1740 possible_5\JJ\1740 paranoid_6\JJ\1740 exacerbations_7\NNS\374224 with_8\IN\1740 <e1>serotonin</e1>_9\NN\14807737 reuptake_10\NN\13571580 blockers_11\NNS\10101634 in_12\IN\13603305 select_13\JJ\1740 patients_14\NNS\9898892 and_15\CC\1740 raise_16\VBP\153263 neurobiological_17\JJ\1740 considerations_18\NNS\5770926 regarding_19\VBG\689344 <e2>paranoia</e2>_20\NN\14398067 ._21\.\1740
D005473_D010259 CID five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>paranoid</e2>_3\JJ\1740 exacerbation_4\NN\374224 with_5\IN\1740 the_6\DT\1740 serotonin_7\NN\14807737 reuptake_8\NN\13571580 inhibitors_9\NNS\20090 <e1>fluoxetine</e1>_10\NN\4169152 and_11\CC\1740 amitriptyline_12\NN\4482543 are_13\VBP\836236 reported_14\VBN\831651 here_15\RB\1740 ._16\.\1740
D000639_D010259 CID five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>paranoid</e2>_3\JJ\1740 exacerbation_4\NN\374224 with_5\IN\1740 the_6\DT\1740 serotonin_7\NN\14807737 reuptake_8\NN\13571580 inhibitors_9\NNS\20090 fluoxetine_10\NN\4169152 and_11\CC\1740 <e1>amitriptyline</e1>_12\NN\4482543 are_13\VBP\836236 reported_14\VBN\831651 here_15\RB\1740 ._16\.\1740
D012701_D003866 NONE complicated_0\JJ\1740 <e2>depressive_1\JJ\1740 disorders</e2>_2\NNS\14034177 (_3\-LRB-\1740 including_4\VBG\690614 atypicality_5\NN\14501726 of_6\IN\1740 course_7\NN\883297 and_8\CC\1740 symptomatology_9\NN\1740 ,_10\,\1740 chronicity_11\NN\1740 ,_12\,\1740 psychosis_13\NN\14380140 ,_14\,\1740 bipolarity_15\NN\1740 ,_16\,\1740 and_17\CC\1740 secondary_18\JJ\1740 onset_19\NN\7325190 in_20\IN\13603305 the_21\DT\1740 course_22\NN\883297 of_23\IN\1740 a_24\DT\13649268 primary_25\JJ\1740 psychosis_26\NN\14380140 )_27\-RRB-\1740 may_28\MD\15209706 present_29\VB\2137132 particular_30\JJ\1740 vulnerability_31\NN\14540765 to_32\TO\1740 paranoid_33\NN\10490141 exacerbations_34\NNS\374224 associated_35\VBN\628491 with_36\IN\1740 <e1>serotonin</e1>_37\NN\14807737 reuptake_38\NN\13571580 inhibitors_39\NNS\20090 ._40\.\1740
D012701_D011605 NONE complicated_0\JJ\1740 depressive_1\JJ\1740 disorders_2\NNS\14034177 (_3\-LRB-\1740 including_4\VBG\690614 atypicality_5\NN\14501726 of_6\IN\1740 course_7\NN\883297 and_8\CC\1740 symptomatology_9\NN\1740 ,_10\,\1740 chronicity_11\NN\1740 ,_12\,\1740 <e2>psychosis</e2>_13\NN\14380140 ,_14\,\1740 bipolarity_15\NN\1740 ,_16\,\1740 and_17\CC\1740 secondary_18\JJ\1740 onset_19\NN\7325190 in_20\IN\13603305 the_21\DT\1740 course_22\NN\883297 of_23\IN\1740 a_24\DT\13649268 primary_25\JJ\1740 psychosis_26\NN\14380140 )_27\-RRB-\1740 may_28\MD\15209706 present_29\VB\2137132 particular_30\JJ\1740 vulnerability_31\NN\14540765 to_32\TO\1740 paranoid_33\NN\10490141 exacerbations_34\NNS\374224 associated_35\VBN\628491 with_36\IN\1740 <e1>serotonin</e1>_37\NN\14807737 reuptake_38\NN\13571580 inhibitors_39\NNS\20090 ._40\.\1740
D012701_D011605 NONE complicated_0\JJ\1740 depressive_1\JJ\1740 disorders_2\NNS\14034177 (_3\-LRB-\1740 including_4\VBG\690614 atypicality_5\NN\14501726 of_6\IN\1740 course_7\NN\883297 and_8\CC\1740 symptomatology_9\NN\1740 ,_10\,\1740 chronicity_11\NN\1740 ,_12\,\1740 psychosis_13\NN\14380140 ,_14\,\1740 bipolarity_15\NN\1740 ,_16\,\1740 and_17\CC\1740 secondary_18\JJ\1740 onset_19\NN\7325190 in_20\IN\13603305 the_21\DT\1740 course_22\NN\883297 of_23\IN\1740 a_24\DT\13649268 primary_25\JJ\1740 <e2>psychosis</e2>_26\NN\14380140 )_27\-RRB-\1740 may_28\MD\15209706 present_29\VB\2137132 particular_30\JJ\1740 vulnerability_31\NN\14540765 to_32\TO\1740 paranoid_33\NN\10490141 exacerbations_34\NNS\374224 associated_35\VBN\628491 with_36\IN\1740 <e1>serotonin</e1>_37\NN\14807737 reuptake_38\NN\13571580 inhibitors_39\NNS\20090 ._40\.\1740
D004298_D010259 NONE although_0\IN\1740 the_1\DT\1740 pharmacology_2\NN\6043075 and_3\CC\1740 neurobiology_4\NN\6037666 of_5\IN\1740 <e2>paranoia</e2>_6\RB\1740 remain_7\VBP\2604760 cryptic_8\JJ\1740 ,_9\,\1740 several_10\JJ\1740 mechanisms_11\NNS\13446390 ,_12\,\1740 including_13\VBG\690614 5ht3_14\NN\1740 receptor-mediated_15\JJ\1740 <e1>dopamine</e1>_16\NN\14807737 release_17\NN\3748886 ,_18\,\1740 beta-noradrenergic_19\JJ\1740 receptor_20\NN\5225602 downregulation_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 gabab_24\NN\1740 receptor_25\NN\5225602 upregulation_26\NN\1740 acting_27\VBG\1619354 in_28\IN\13603305 the_29\DT\1740 vicinity_30\NN\8648322 of_31\IN\1740 the_32\DT\1740 ventral_33\JJ\1740 basal_34\JJ\1740 ganglia_35\NN\5462674 (_36\-LRB-\1740 possibly_37\RB\1740 in_38\IN\13603305 lateral_39\JJ\1740 orbitofrontal_40\JJ\1740 or_41\CC\3541091 anterior_42\JJ\1740 cingulate_43\NN\1740 circuits_44\NNS\3269401 )_45\-RRB-\1740 ,_46\,\1740 might_47\MD\5029706 apply_48\VB\2676054 to_49\IN\1740 this_50\DT\1740 phenomenon_51\NN\29677 ._52\.\1740
3297909
D013827_D001649 NONE progressive_0\JJ\1740 <e2>bile_1\NN\5405946 duct_2\NN\5248181 injury</e2>_3\NN\14052046 after_4\IN\1740 <e1>thiabendazole</e1>_5\NN\2720201 administration_6\NN\1133281 ._7\.\1740
D013827_D007565 NONE a_0\DT\13649268 27-yr-old_1\JJ\1740 man_2\NN\9605289 developed_3\VBD\1753788 <e2>jaundice</e2>_4\NN\14299637 2_5\CD\13741022 wk_6\NN\1740 after_7\IN\1740 exposure_8\NN\5042871 to_9\TO\1740 <e1>thiabendazole</e1>_10\NN\2720201 ._11\.\1740
6106951
D005479_D064420 NONE signs_0\NNS\6643763 of_1\IN\1740 <e1>fzp</e1>_2\NN\1740 <e2>toxocity</e2>_3\NN\1740 in_4\IN\13603305 cats_5\NNS\2120997 included_6\VBD\690614 excessive_7\JJ\1740 salivation_8\NN\13553916 ,_9\,\1740 extreme_10\JJ\1740 apprehensive_11\JJ\1740 behavior_12\NN\407535 ,_13\,\1740 retching_14\NN\1740 ,_15\,\1740 muscle_16\NN\5289601 tremors_17\NNS\345926 and_18\CC\1740 convulsions_19\NNS\14081375 ._20\.\1740
D005479_D012798 NONE signs_0\NNS\6643763 of_1\IN\1740 <e1>fzp</e1>_2\NN\1740 toxocity_3\NN\1740 in_4\IN\13603305 cats_5\NNS\2120997 included_6\VBD\690614 excessive_7\JJ\1740 <e2>salivation</e2>_8\NN\13553916 ,_9\,\1740 extreme_10\JJ\1740 apprehensive_11\JJ\1740 behavior_12\NN\407535 ,_13\,\1740 retching_14\NN\1740 ,_15\,\1740 muscle_16\NN\5289601 tremors_17\NNS\345926 and_18\CC\1740 convulsions_19\NNS\14081375 ._20\.\1740
D005479_D014202 NONE signs_0\NNS\6643763 of_1\IN\1740 <e1>fzp</e1>_2\NN\1740 toxocity_3\NN\1740 in_4\IN\13603305 cats_5\NNS\2120997 included_6\VBD\690614 excessive_7\JJ\1740 salivation_8\NN\13553916 ,_9\,\1740 extreme_10\JJ\1740 apprehensive_11\JJ\1740 behavior_12\NN\407535 ,_13\,\1740 retching_14\NN\1740 ,_15\,\1740 <e2>muscle_16\NN\5289601 tremors</e2>_17\NNS\345926 and_18\CC\1740 convulsions_19\NNS\14081375 ._20\.\1740
D005479_D012640 CID signs_0\NNS\6643763 of_1\IN\1740 <e1>fzp</e1>_2\NN\1740 toxocity_3\NN\1740 in_4\IN\13603305 cats_5\NNS\2120997 included_6\VBD\690614 excessive_7\JJ\1740 salivation_8\NN\13553916 ,_9\,\1740 extreme_10\JJ\1740 apprehensive_11\JJ\1740 behavior_12\NN\407535 ,_13\,\1740 retching_14\NN\1740 ,_15\,\1740 muscle_16\NN\5289601 tremors_17\NNS\345926 and_18\CC\1740 <e2>convulsions</e2>_19\NNS\14081375 ._20\.\1740
D005479_D012640 CID as_0\IN\14622893 a_1\DT\13649268 function_2\NN\13783581 of_3\IN\1740 dose_4\NN\3740161 ,_5\,\1740 <e1>fzp</e1>_6\NN\1740 first_7\RB\1740 protected_8\VBD\1127795 against_9\IN\1740 <e2>convulsions</e2>_10\NNS\14081375 and_11\CC\1740 death_12\NN\7296428
D005479_D012640 CID these_0\DT\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>fzp</e1>_3\NN\1740 were_4\VBD\836236 lower_5\JJR\1740 than_6\IN\1740 those_7\DT\1740 that_8\WDT\1740 would_9\MD\1740 alone_10\RB\1740 cause_11\VB\1617192 <e2>convulsions</e2>_12\NNS\14081375 ._13\.\1740
D005479_D004827 NONE these_0\DT\1740 results_1\NNS\34213 may_2\MD\15209706 be_3\VB\836236 relevant_4\JJ\1740 to_5\TO\1740 the_6\DT\1740 use_7\NN\407535 of_8\IN\1740 <e1>fzp</e1>_9\NN\1740 in_10\IN\13603305 clinical_11\JJ\1740 situations_12\NNS\24720 in_13\IN\13603305 which_14\WDT\1740 there_15\EX\27167 is_16\VBZ\836236 increased_17\VBN\169651 neural_18\JJ\1740 excitability_19\NN\5653575 ,_20\,\1740 such_21\JJ\1740 as_22\IN\14622893 <e2>epilepsy</e2>_23\NN\14085708 or_24\CC\3541091 sedative-hypnotic_25\JJ\1740 drug_26\NN\14778436 withdrawal_27\NN\7206096 ._28\.\1740
44072
C024986_D001145 CID four_0\CD\13741022 types_1\NNS\5839024 of_2\IN\1740 experimental_3\JJ\1740 <e2>arrhythmia</e2>_4\NN\14103288 are_5\VBP\836236 used_6\VBN\1156834 --_7\:\1740 with_8\IN\1740 <e1>bacl2</e1>_9\NN\1740 ,_10\,\1740 with_11\IN\1740 chloroform-adrenaline_12\NN\1740 ,_13\,\1740 with_14\IN\1740 strophantine_15\JJ\1740 g_16\NN\13717155 and_17\CC\1740 with_18\IN\1740 aconitine_19\NN\1740 ._20\.\1740
C024986_D001145 CID the_0\DT\1740 compound_1\NN\5869584 manifests_2\VBZ\1015244 antiarrhythmic_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 all_6\DT\1740 models_7\NNS\5888929 of_8\IN\1740 experimental_9\JJ\1740 <e2>arrhythmia</e2>_10\NN\14103288 used_11\VBN\1156834 ,_12\,\1740 causing_13\VBG\1617192 greatest_14\JJS\1740 inhibition_15\NN\1068773 on_16\IN\1740 the_17\DT\1740 arrhythmia_18\NN\14103288 induced_19\VBN\1627355 by_20\IN\1740 chloroform-adrenaline_21\NN\1740 (_22\-LRB-\1740 in_23\IN\13603305 90_24\CD\13745420 per_25\NN\1740 cent_26\NN\13662703 )_27\-RRB-\1740 and_28\CC\1740 with_29\IN\1740 <e1>bacl2</e1>_30\NN\1740 (_31\-LRB-\1740 in_32\IN\13603305 84_33\CD\1740 per_34\IN\1740 cent_35\NN\13662703 )_36\-RRB-\1740 ._37\.\1740
C024986_D001145 CID the_0\DT\1740 compound_1\NN\5869584 manifests_2\VBZ\1015244 antiarrhythmic_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 all_6\DT\1740 models_7\NNS\5888929 of_8\IN\1740 experimental_9\JJ\1740 arrhythmia_10\NN\14103288 used_11\VBN\1156834 ,_12\,\1740 causing_13\VBG\1617192 greatest_14\JJS\1740 inhibition_15\NN\1068773 on_16\IN\1740 the_17\DT\1740 <e2>arrhythmia</e2>_18\NN\14103288 induced_19\VBN\1627355 by_20\IN\1740 chloroform-adrenaline_21\NN\1740 (_22\-LRB-\1740 in_23\IN\13603305 90_24\CD\13745420 per_25\NN\1740 cent_26\NN\13662703 )_27\-RRB-\1740 and_28\CC\1740 with_29\IN\1740 <e1>bacl2</e1>_30\NN\1740 (_31\-LRB-\1740 in_32\IN\13603305 84_33\CD\1740 per_34\IN\1740 cent_35\NN\13662703 )_36\-RRB-\1740 ._37\.\1740
D002725_D001145 CID four_0\CD\13741022 types_1\NNS\5839024 of_2\IN\1740 experimental_3\JJ\1740 <e2>arrhythmia</e2>_4\NN\14103288 are_5\VBP\836236 used_6\VBN\1156834 --_7\:\1740 with_8\IN\1740 bacl2_9\NN\1740 ,_10\,\1740 with_11\IN\1740 <e1>chloroform-adrenaline</e1>_12\NN\1740 ,_13\,\1740 with_14\IN\1740 strophantine_15\JJ\1740 g_16\NN\13717155 and_17\CC\1740 with_18\IN\1740 aconitine_19\NN\1740 ._20\.\1740
D002725_D001145 CID the_0\DT\1740 compound_1\NN\5869584 manifests_2\VBZ\1015244 antiarrhythmic_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 all_6\DT\1740 models_7\NNS\5888929 of_8\IN\1740 experimental_9\JJ\1740 <e2>arrhythmia</e2>_10\NN\14103288 used_11\VBN\1156834 ,_12\,\1740 causing_13\VBG\1617192 greatest_14\JJS\1740 inhibition_15\NN\1068773 on_16\IN\1740 the_17\DT\1740 arrhythmia_18\NN\14103288 induced_19\VBN\1627355 by_20\IN\1740 <e1>chloroform-adrenaline</e1>_21\NN\1740 (_22\-LRB-\1740 in_23\IN\13603305 90_24\CD\13745420 per_25\NN\1740 cent_26\NN\13662703 )_27\-RRB-\1740 and_28\CC\1740 with_29\IN\1740 bacl2_30\NN\1740 (_31\-LRB-\1740 in_32\IN\13603305 84_33\CD\1740 per_34\IN\1740 cent_35\NN\13662703 )_36\-RRB-\1740 ._37\.\1740
D002725_D001145 CID the_0\DT\1740 compound_1\NN\5869584 manifests_2\VBZ\1015244 antiarrhythmic_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 all_6\DT\1740 models_7\NNS\5888929 of_8\IN\1740 experimental_9\JJ\1740 arrhythmia_10\NN\14103288 used_11\VBN\1156834 ,_12\,\1740 causing_13\VBG\1617192 greatest_14\JJS\1740 inhibition_15\NN\1068773 on_16\IN\1740 the_17\DT\1740 <e2>arrhythmia</e2>_18\NN\14103288 induced_19\VBN\1627355 by_20\IN\1740 <e1>chloroform-adrenaline</e1>_21\NN\1740 (_22\-LRB-\1740 in_23\IN\13603305 90_24\CD\13745420 per_25\NN\1740 cent_26\NN\13662703 )_27\-RRB-\1740 and_28\CC\1740 with_29\IN\1740 bacl2_30\NN\1740 (_31\-LRB-\1740 in_32\IN\13603305 84_33\CD\1740 per_34\IN\1740 cent_35\NN\13662703 )_36\-RRB-\1740 ._37\.\1740
D004837_D001145 CID four_0\CD\13741022 types_1\NNS\5839024 of_2\IN\1740 experimental_3\JJ\1740 <e2>arrhythmia</e2>_4\NN\14103288 are_5\VBP\836236 used_6\VBN\1156834 --_7\:\1740 with_8\IN\1740 bacl2_9\NN\1740 ,_10\,\1740 with_11\IN\1740 <e1>chloroform-adrenaline</e1>_12\NN\1740 ,_13\,\1740 with_14\IN\1740 strophantine_15\JJ\1740 g_16\NN\13717155 and_17\CC\1740 with_18\IN\1740 aconitine_19\NN\1740 ._20\.\1740
D004837_D001145 CID the_0\DT\1740 compound_1\NN\5869584 manifests_2\VBZ\1015244 antiarrhythmic_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 all_6\DT\1740 models_7\NNS\5888929 of_8\IN\1740 experimental_9\JJ\1740 <e2>arrhythmia</e2>_10\NN\14103288 used_11\VBN\1156834 ,_12\,\1740 causing_13\VBG\1617192 greatest_14\JJS\1740 inhibition_15\NN\1068773 on_16\IN\1740 the_17\DT\1740 arrhythmia_18\NN\14103288 induced_19\VBN\1627355 by_20\IN\1740 <e1>chloroform-adrenaline</e1>_21\NN\1740 (_22\-LRB-\1740 in_23\IN\13603305 90_24\CD\13745420 per_25\NN\1740 cent_26\NN\13662703 )_27\-RRB-\1740 and_28\CC\1740 with_29\IN\1740 bacl2_30\NN\1740 (_31\-LRB-\1740 in_32\IN\13603305 84_33\CD\1740 per_34\IN\1740 cent_35\NN\13662703 )_36\-RRB-\1740 ._37\.\1740
D004837_D001145 CID the_0\DT\1740 compound_1\NN\5869584 manifests_2\VBZ\1015244 antiarrhythmic_3\JJ\1740 activity_4\NN\30358 in_5\IN\13603305 all_6\DT\1740 models_7\NNS\5888929 of_8\IN\1740 experimental_9\JJ\1740 arrhythmia_10\NN\14103288 used_11\VBN\1156834 ,_12\,\1740 causing_13\VBG\1617192 greatest_14\JJS\1740 inhibition_15\NN\1068773 on_16\IN\1740 the_17\DT\1740 <e2>arrhythmia</e2>_18\NN\14103288 induced_19\VBN\1627355 by_20\IN\1740 <e1>chloroform-adrenaline</e1>_21\NN\1740 (_22\-LRB-\1740 in_23\IN\13603305 90_24\CD\13745420 per_25\NN\1740 cent_26\NN\13662703 )_27\-RRB-\1740 and_28\CC\1740 with_29\IN\1740 bacl2_30\NN\1740 (_31\-LRB-\1740 in_32\IN\13603305 84_33\CD\1740 per_34\IN\1740 cent_35\NN\13662703 )_36\-RRB-\1740 ._37\.\1740
D010042_D001145 CID four_0\CD\13741022 types_1\NNS\5839024 of_2\IN\1740 experimental_3\JJ\1740 <e2>arrhythmia</e2>_4\NN\14103288 are_5\VBP\836236 used_6\VBN\1156834 --_7\:\1740 with_8\IN\1740 bacl2_9\NN\1740 ,_10\,\1740 with_11\IN\1740 chloroform-adrenaline_12\NN\1740 ,_13\,\1740 with_14\IN\1740 <e1>strophantine_15\JJ\1740 g</e1>_16\NN\13717155 and_17\CC\1740 with_18\IN\1740 aconitine_19\NN\1740 ._20\.\1740
D000157_D001145 CID four_0\CD\13741022 types_1\NNS\5839024 of_2\IN\1740 experimental_3\JJ\1740 <e2>arrhythmia</e2>_4\NN\14103288 are_5\VBP\836236 used_6\VBN\1156834 --_7\:\1740 with_8\IN\1740 bacl2_9\NN\1740 ,_10\,\1740 with_11\IN\1740 chloroform-adrenaline_12\NN\1740 ,_13\,\1740 with_14\IN\1740 strophantine_15\JJ\1740 g_16\NN\13717155 and_17\CC\1740 with_18\IN\1740 <e1>aconitine</e1>_19\NN\1740 ._20\.\1740
10087562
D004280_D016171 CID <e2>torsade_0\NNP\1740 de_1\NNP\1740 pointes</e2>_2\VBZ\831651 ventricular_3\JJ\1740 tachycardia_4\NN\14110674 during_5\IN\1740 low_6\JJ\1740 dose_7\NN\3740161 intermittent_8\NN\1740 <e1>dobutamine</e1>_9\NN\1740 treatment_10\NN\654885 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 dilated_15\JJ\1740 cardiomyopathy_16\JJ\1740 and_17\CC\1740 congestive_18\JJ\1740 heart_19\NN\5919034 failure_20\NN\66216 ._21\.\1740
D004280_D016171 CID the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 56-year-old_7\JJ\1740 woman_8\NN\9605289 with_9\IN\1740 chronic_10\JJ\1740 ,_11\,\1740 severe_12\JJ\1740 heart_13\NN\5919034 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 dilated_17\VBN\303465 cardiomyopathy_18\JJ\1740 and_19\CC\1740 absence_20\NN\14449405 of_21\IN\1740 significant_22\JJ\1740 ventricular_23\NN\1740 arrhythmias_24\NNS\14103288 who_25\WP\8299493 developed_26\VBD\1753788 qt_27\NN\1740 prolongation_28\NN\1017987 and_29\CC\1740 <e2>torsade_30\VB\1740 de_31\NN\1740 pointes</e2>_32\VBZ\831651 ventricular_33\JJ\1740 tachycardia_34\NN\14110674 during_35\IN\1740 one_36\CD\13741022 cycle_37\NN\15269513 of_38\IN\1740 intermittent_39\JJ\1740 low_40\JJ\1740 dose_41\NN\3740161 (_42\-LRB-\1740 2.5_43\CD\1740 mcg/kg_44\NN\1740 per_45\IN\1740 min_46\NN\15154774 )_47\-RRB-\1740 <e1>dobutamine</e1>_48\NN\1740 ._49\.\1740
D004280_D016171 CID this_0\DT\1740 report_1\NN\6470073 of_2\IN\1740 <e2>torsade_3\NN\1740 de_4\FW\1740 pointes</e2>_5\VBZ\831651 ventricular_6\JJ\1740 tachycardia_7\NN\14110674 during_8\IN\1740 intermittent_9\JJ\1740 <e1>dobutamine</e1>_10\NN\1740 supports_11\VBZ\2199590 the_12\DT\1740 hypothesis_13\NN\7162194 that_14\IN\1740 unpredictable_15\JJ\1740 fatal_16\JJ\1740 arrhythmias_17\NNS\14103288 may_18\MD\15209706 occur_19\VB\2623529 even_20\RB\1740 with_21\IN\1740 low_22\JJ\1740 doses_23\NNS\3740161 and_24\CC\1740 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 no_28\DT\7204911 history_29\NN\15120823 of_30\IN\1740 significant_31\JJ\1740 rhythm_32\NN\15122011 disturbances_33\NNS\407535 ._34\.\1740
D004280_D017180 NONE torsade_0\NNP\1740 de_1\NNP\1740 pointes_2\VBZ\831651 <e2>ventricular_3\JJ\1740 tachycardia</e2>_4\NN\14110674 during_5\IN\1740 low_6\JJ\1740 dose_7\NN\3740161 intermittent_8\NN\1740 <e1>dobutamine</e1>_9\NN\1740 treatment_10\NN\654885 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 dilated_15\JJ\1740 cardiomyopathy_16\JJ\1740 and_17\CC\1740 congestive_18\JJ\1740 heart_19\NN\5919034 failure_20\NN\66216 ._21\.\1740
D004280_D017180 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 56-year-old_7\JJ\1740 woman_8\NN\9605289 with_9\IN\1740 chronic_10\JJ\1740 ,_11\,\1740 severe_12\JJ\1740 heart_13\NN\5919034 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 dilated_17\VBN\303465 cardiomyopathy_18\JJ\1740 and_19\CC\1740 absence_20\NN\14449405 of_21\IN\1740 significant_22\JJ\1740 ventricular_23\NN\1740 arrhythmias_24\NNS\14103288 who_25\WP\8299493 developed_26\VBD\1753788 qt_27\NN\1740 prolongation_28\NN\1017987 and_29\CC\1740 torsade_30\VB\1740 de_31\NN\1740 pointes_32\VBZ\831651 <e2>ventricular_33\JJ\1740 tachycardia</e2>_34\NN\14110674 during_35\IN\1740 one_36\CD\13741022 cycle_37\NN\15269513 of_38\IN\1740 intermittent_39\JJ\1740 low_40\JJ\1740 dose_41\NN\3740161 (_42\-LRB-\1740 2.5_43\CD\1740 mcg/kg_44\NN\1740 per_45\IN\1740 min_46\NN\15154774 )_47\-RRB-\1740 <e1>dobutamine</e1>_48\NN\1740 ._49\.\1740
D004280_D017180 NONE this_0\DT\1740 report_1\NN\6470073 of_2\IN\1740 torsade_3\NN\1740 de_4\FW\1740 pointes_5\VBZ\831651 <e2>ventricular_6\JJ\1740 tachycardia</e2>_7\NN\14110674 during_8\IN\1740 intermittent_9\JJ\1740 <e1>dobutamine</e1>_10\NN\1740 supports_11\VBZ\2199590 the_12\DT\1740 hypothesis_13\NN\7162194 that_14\IN\1740 unpredictable_15\JJ\1740 fatal_16\JJ\1740 arrhythmias_17\NNS\14103288 may_18\MD\15209706 occur_19\VB\2623529 even_20\RB\1740 with_21\IN\1740 low_22\JJ\1740 doses_23\NNS\3740161 and_24\CC\1740 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 no_28\DT\7204911 history_29\NN\15120823 of_30\IN\1740 significant_31\JJ\1740 rhythm_32\NN\15122011 disturbances_33\NNS\407535 ._34\.\1740
D004280_D002311 NONE torsade_0\NNP\1740 de_1\NNP\1740 pointes_2\VBZ\831651 ventricular_3\JJ\1740 tachycardia_4\NN\14110674 during_5\IN\1740 low_6\JJ\1740 dose_7\NN\3740161 intermittent_8\NN\1740 <e1>dobutamine</e1>_9\NN\1740 treatment_10\NN\654885 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 <e2>dilated_15\JJ\1740 cardiomyopathy</e2>_16\JJ\1740 and_17\CC\1740 congestive_18\JJ\1740 heart_19\NN\5919034 failure_20\NN\66216 ._21\.\1740
D004280_D002311 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 56-year-old_7\JJ\1740 woman_8\NN\9605289 with_9\IN\1740 chronic_10\JJ\1740 ,_11\,\1740 severe_12\JJ\1740 heart_13\NN\5919034 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 <e2>dilated_17\VBN\303465 cardiomyopathy</e2>_18\JJ\1740 and_19\CC\1740 absence_20\NN\14449405 of_21\IN\1740 significant_22\JJ\1740 ventricular_23\NN\1740 arrhythmias_24\NNS\14103288 who_25\WP\8299493 developed_26\VBD\1753788 qt_27\NN\1740 prolongation_28\NN\1017987 and_29\CC\1740 torsade_30\VB\1740 de_31\NN\1740 pointes_32\VBZ\831651 ventricular_33\JJ\1740 tachycardia_34\NN\14110674 during_35\IN\1740 one_36\CD\13741022 cycle_37\NN\15269513 of_38\IN\1740 intermittent_39\JJ\1740 low_40\JJ\1740 dose_41\NN\3740161 (_42\-LRB-\1740 2.5_43\CD\1740 mcg/kg_44\NN\1740 per_45\IN\1740 min_46\NN\15154774 )_47\-RRB-\1740 <e1>dobutamine</e1>_48\NN\1740 ._49\.\1740
D004280_D006333 NONE torsade_0\NNP\1740 de_1\NNP\1740 pointes_2\VBZ\831651 ventricular_3\JJ\1740 tachycardia_4\NN\14110674 during_5\IN\1740 low_6\JJ\1740 dose_7\NN\3740161 intermittent_8\NN\1740 <e1>dobutamine</e1>_9\NN\1740 treatment_10\NN\654885 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 with_14\IN\1740 dilated_15\JJ\1740 cardiomyopathy_16\JJ\1740 and_17\CC\1740 <e2>congestive_18\JJ\1740 heart_19\NN\5919034 failure</e2>_20\NN\66216 ._21\.\1740
D004280_D006333 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 56-year-old_7\JJ\1740 woman_8\NN\9605289 with_9\IN\1740 chronic_10\JJ\1740 ,_11\,\1740 severe_12\JJ\1740 <e2>heart_13\NN\5919034 failure</e2>_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 dilated_17\VBN\303465 cardiomyopathy_18\JJ\1740 and_19\CC\1740 absence_20\NN\14449405 of_21\IN\1740 significant_22\JJ\1740 ventricular_23\NN\1740 arrhythmias_24\NNS\14103288 who_25\WP\8299493 developed_26\VBD\1753788 qt_27\NN\1740 prolongation_28\NN\1017987 and_29\CC\1740 torsade_30\VB\1740 de_31\NN\1740 pointes_32\VBZ\831651 ventricular_33\JJ\1740 tachycardia_34\NN\14110674 during_35\IN\1740 one_36\CD\13741022 cycle_37\NN\15269513 of_38\IN\1740 intermittent_39\JJ\1740 low_40\JJ\1740 dose_41\NN\3740161 (_42\-LRB-\1740 2.5_43\CD\1740 mcg/kg_44\NN\1740 per_45\IN\1740 min_46\NN\15154774 )_47\-RRB-\1740 <e1>dobutamine</e1>_48\NN\1740 ._49\.\1740
D004280_D001145 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 56-year-old_7\JJ\1740 woman_8\NN\9605289 with_9\IN\1740 chronic_10\JJ\1740 ,_11\,\1740 severe_12\JJ\1740 heart_13\NN\5919034 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 dilated_17\VBN\303465 cardiomyopathy_18\JJ\1740 and_19\CC\1740 absence_20\NN\14449405 of_21\IN\1740 significant_22\JJ\1740 <e2>ventricular_23\NN\1740 arrhythmias</e2>_24\NNS\14103288 who_25\WP\8299493 developed_26\VBD\1753788 qt_27\NN\1740 prolongation_28\NN\1017987 and_29\CC\1740 torsade_30\VB\1740 de_31\NN\1740 pointes_32\VBZ\831651 ventricular_33\JJ\1740 tachycardia_34\NN\14110674 during_35\IN\1740 one_36\CD\13741022 cycle_37\NN\15269513 of_38\IN\1740 intermittent_39\JJ\1740 low_40\JJ\1740 dose_41\NN\3740161 (_42\-LRB-\1740 2.5_43\CD\1740 mcg/kg_44\NN\1740 per_45\IN\1740 min_46\NN\15154774 )_47\-RRB-\1740 <e1>dobutamine</e1>_48\NN\1740 ._49\.\1740
D004280_D001145 NONE this_0\DT\1740 report_1\NN\6470073 of_2\IN\1740 torsade_3\NN\1740 de_4\FW\1740 pointes_5\VBZ\831651 ventricular_6\JJ\1740 tachycardia_7\NN\14110674 during_8\IN\1740 intermittent_9\JJ\1740 <e1>dobutamine</e1>_10\NN\1740 supports_11\VBZ\2199590 the_12\DT\1740 hypothesis_13\NN\7162194 that_14\IN\1740 unpredictable_15\JJ\1740 fatal_16\JJ\1740 <e2>arrhythmias</e2>_17\NNS\14103288 may_18\MD\15209706 occur_19\VB\2623529 even_20\RB\1740 with_21\IN\1740 low_22\JJ\1740 doses_23\NNS\3740161 and_24\CC\1740 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 no_28\DT\7204911 history_29\NN\15120823 of_30\IN\1740 significant_31\JJ\1740 rhythm_32\NN\15122011 disturbances_33\NNS\407535 ._34\.\1740
D004280_D008133 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 56-year-old_7\JJ\1740 woman_8\NN\9605289 with_9\IN\1740 chronic_10\JJ\1740 ,_11\,\1740 severe_12\JJ\1740 heart_13\NN\5919034 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 dilated_17\VBN\303465 cardiomyopathy_18\JJ\1740 and_19\CC\1740 absence_20\NN\14449405 of_21\IN\1740 significant_22\JJ\1740 ventricular_23\NN\1740 arrhythmias_24\NNS\14103288 who_25\WP\8299493 developed_26\VBD\1753788 <e2>qt_27\NN\1740 prolongation</e2>_28\NN\1017987 and_29\CC\1740 torsade_30\VB\1740 de_31\NN\1740 pointes_32\VBZ\831651 ventricular_33\JJ\1740 tachycardia_34\NN\14110674 during_35\IN\1740 one_36\CD\13741022 cycle_37\NN\15269513 of_38\IN\1740 intermittent_39\JJ\1740 low_40\JJ\1740 dose_41\NN\3740161 (_42\-LRB-\1740 2.5_43\CD\1740 mcg/kg_44\NN\1740 per_45\IN\1740 min_46\NN\15154774 )_47\-RRB-\1740 <e1>dobutamine</e1>_48\NN\1740 ._49\.\1740
3083835
D010406_D000707 CID <e1>penicillin</e1>_0\NNP\2716866 <e2>anaphylaxis</e2>_1\NN\14533203 ._2\.\1740
D010406_D000707 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 oral_3\JJ\1740 <e1>penicillin</e1>_4\NN\2716866 <e2>anaphylaxis</e2>_5\NN\14533203 is_6\VBZ\836236 described_7\VBN\1001294 ,_8\,\1740 and_9\CC\1740 the_10\DT\1740 terminology_11\NN\6286395 ,_12\,\1740 occurrence_13\NN\29378 ,_14\,\1740 clinical_15\JJ\1740 manifestations_16\NNS\7321772 ,_17\,\1740 pathogenesis_18\NN\13533470 ,_19\,\1740 prevention_20\NN\1073995 ,_21\,\1740 and_22\CC\1740 treatment_23\NN\654885 of_24\IN\1740 anaphylaxis_25\NN\14533203 are_26\VBP\836236 reviewed_27\VBN\644583 ._28\.\1740
D010406_D000707 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 oral_3\JJ\1740 <e1>penicillin</e1>_4\NN\2716866 anaphylaxis_5\NN\14533203 is_6\VBZ\836236 described_7\VBN\1001294 ,_8\,\1740 and_9\CC\1740 the_10\DT\1740 terminology_11\NN\6286395 ,_12\,\1740 occurrence_13\NN\29378 ,_14\,\1740 clinical_15\JJ\1740 manifestations_16\NNS\7321772 ,_17\,\1740 pathogenesis_18\NN\13533470 ,_19\,\1740 prevention_20\NN\1073995 ,_21\,\1740 and_22\CC\1740 treatment_23\NN\654885 of_24\IN\1740 <e2>anaphylaxis</e2>_25\NN\14533203 are_26\VBP\836236 reviewed_27\VBN\644583 ._28\.\1740
D010406_D000707 CID emergency_0\NN\7417644 physicians_1\NNS\10305802 should_2\MD\1740 be_3\VB\836236 aware_4\JJ\1740 of_5\IN\1740 oral_6\JJ\1740 <e1>penicillin</e1>_7\NN\2716866 <e2>anaphylaxis</e2>_8\NN\14533203 in_9\IN\13603305 order_10\NN\7168131 to_11\TO\1740 prevent_12\VB\1740 its_13\PRP$\6125041 occurrence_14\NN\29378 by_15\IN\1740 prescribing_16\VBG\748282 the_17\DT\1740 antibiotic_18\JJ\1740 judiciously_19\NN\1740 and_20\CC\1740 knowledgeably_21\NN\1740 and_22\CC\1740 to_23\TO\1740 offer_24\VB\2327200 optimal_25\JJ\1740 medical_26\JJ\1740 therapy_27\NN\657604 once_28\IN\1740 this_29\DT\1740 life-threatening_30\JJ\1740 reaction_31\NN\13446390 has_32\VBZ\2108377 begun_33\VBN\941990 ._34\.\1740
2767010
C043114_D012640 NONE <e1>acc-9653</e1>_0\NN\1740 and_1\CC\1740 phenytoin_2\NN\3550533 sodium_3\NN\14625458 have_4\VBP\2108377 equivalent_5\JJ\1740 anticonvulsant_6\JJ\1740 activity_7\NN\30358 against_8\IN\1740 <e2>seizures</e2>_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 maximal_12\JJ\1740 electroshock_13\NN\662681 (_14\-LRB-\1740 mes_15\NN\1740 )_16\-RRB-\1740 in_17\IN\13603305 mice_18\NNS\2329401 following_19\VBG\1835496 i.p._20\RB\1740 ,_21\,\1740 oral_22\JJ\1740 ,_23\,\1740 or_24\CC\3541091 i.v._25\NN\1740 administration_26\NN\1133281 ._27\.\1740
C043114_D012640 NONE acc-9653_0\NN\1740 and_1\CC\1740 <e1>phenytoin_2\NN\3550533 sodium</e1>_3\NN\14625458 have_4\VBP\2108377 equivalent_5\JJ\1740 anticonvulsant_6\JJ\1740 activity_7\NN\30358 against_8\IN\1740 <e2>seizures</e2>_9\NNS\14081375 induced_10\VBN\1627355 by_11\IN\1740 maximal_12\JJ\1740 electroshock_13\NN\662681 (_14\-LRB-\1740 mes_15\NN\1740 )_16\-RRB-\1740 in_17\IN\13603305 mice_18\NNS\2329401 following_19\VBG\1835496 i.p._20\RB\1740 ,_21\,\1740 oral_22\JJ\1740 ,_23\,\1740 or_24\CC\3541091 i.v._25\NN\1740 administration_26\NN\1133281 ._27\.\1740
C043114_D017180 NONE <e1>acc-9653</e1>_0\NN\1740 and_1\CC\1740 phenytoin_2\NN\3550533 sodium_3\NN\14625458 have_4\VBP\2108377 similar_5\JJ\1740 antiarrhythmic_6\JJ\1740 activity_7\NN\30358 against_8\IN\1740 ouabain-induced_9\JJ\1740 <e2>ventricular_10\JJ\1740 tachycardia</e2>_11\NN\14110674 in_12\IN\13603305 anesthetized_13\VBN\84738 dogs_14\NNS\2083346 ._15\.\1740
C043114_D017180 NONE acc-9653_0\NN\1740 and_1\CC\1740 <e1>phenytoin_2\NN\3550533 sodium</e1>_3\NN\14625458 have_4\VBP\2108377 similar_5\JJ\1740 antiarrhythmic_6\JJ\1740 activity_7\NN\30358 against_8\IN\1740 ouabain-induced_9\JJ\1740 <e2>ventricular_10\JJ\1740 tachycardia</e2>_11\NN\14110674 in_12\IN\13603305 anesthetized_13\VBN\84738 dogs_14\NNS\2083346 ._15\.\1740
D010042_D017180 CID acc-9653_0\NN\1740 and_1\CC\1740 phenytoin_2\NN\3550533 sodium_3\NN\14625458 have_4\VBP\2108377 similar_5\JJ\1740 antiarrhythmic_6\JJ\1740 activity_7\NN\30358 against_8\IN\1740 <e1>ouabain-induced</e1>_9\JJ\1740 <e2>ventricular_10\JJ\1740 tachycardia</e2>_11\NN\14110674 in_12\IN\13603305 anesthetized_13\VBN\84738 dogs_14\NNS\2083346 ._15\.\1740
C043114_D001145 NONE the_0\DT\1740 total_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 <e1>acc-9653</e1>_4\NN\1740 or_5\CC\3541091 phenytoin_6\NN\3550533 sodium_7\NN\14625458 necessary_8\JJ\1740 to_9\TO\1740 convert_10\VB\126264 the_11\DT\1740 <e2>arrhythmia</e2>_12\NN\14103288 to_13\IN\1740 a_14\DT\13649268 normal_15\JJ\1740 sinus_16\NN\5248181 rhythm_17\NN\15122011 were_18\VBD\836236 24_19\CD\13745420 +/-_20\CC\1740 6_21\CD\13741022 and_22\CC\1740 14_23\CD\13745420 +/-_24\CC\1740 3_25\CD\13741022 mg/kg_26\NN\1740 ,_27\,\1740 respectively_28\RB\1740 ._29\.\1740
C043114_D001145 NONE the_0\DT\1740 total_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 acc-9653_4\NN\1740 or_5\CC\3541091 <e1>phenytoin_6\NN\3550533 sodium</e1>_7\NN\14625458 necessary_8\JJ\1740 to_9\TO\1740 convert_10\VB\126264 the_11\DT\1740 <e2>arrhythmia</e2>_12\NN\14103288 to_13\IN\1740 a_14\DT\13649268 normal_15\JJ\1740 sinus_16\NN\5248181 rhythm_17\NN\15122011 were_18\VBD\836236 24_19\CD\13745420 +/-_20\CC\1740 6_21\CD\13741022 and_22\CC\1740 14_23\CD\13745420 +/-_24\CC\1740 3_25\CD\13741022 mg/kg_26\NN\1740 ,_27\,\1740 respectively_28\RB\1740 ._29\.\1740
C043114_D001145 NONE only_0\RB\1740 <e1>phenytoin_1\JJ\1740 sodium</e1>_2\NN\14625458 displayed_3\VBD\2137132 in_4\FW\13603305 vitro_5\FW\1740 antiarrhythmic_6\JJ\1740 activity_7\NN\30358 against_8\IN\1740 strophanthidin-induced_9\JJ\1740 <e2>arrhythmias</e2>_10\NNS\14103288 in_11\IN\13603305 guinea_12\NN\13388245 pig_13\NN\2395003 right_14\RB\1740 atria_15\RB\1740 ._16\.\1740
D013327_D001145 CID only_0\RB\1740 phenytoin_1\JJ\1740 sodium_2\NN\14625458 displayed_3\VBD\2137132 in_4\FW\13603305 vitro_5\FW\1740 antiarrhythmic_6\JJ\1740 activity_7\NN\30358 against_8\IN\1740 <e1>strophanthidin-induced</e1>_9\JJ\1740 <e2>arrhythmias</e2>_10\NNS\14103288 in_11\IN\13603305 guinea_12\NN\13388245 pig_13\NN\2395003 right_14\RB\1740 atria_15\RB\1740 ._16\.\1740
C043114_D064420 NONE acute_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 studies_2\NNS\635850 of_3\IN\1740 <e1>acc-9653</e1>_4\NN\1740 and_5\CC\1740 phenytoin_6\NN\3550533 sodium_7\NN\14625458 were_8\VBD\836236 carried_9\VBN\1850315 out_10\RP\1740 in_11\IN\13603305 mice_12\NNS\2329401 ,_13\,\1740 rats_14\NNS\2329401 ,_15\,\1740 rabbits_16\VBZ\1143838 ,_17\,\1740 and_18\CC\1740 dogs_19\NNS\2083346 by_20\IN\1740 i.v._21\NN\1740 ,_22\,\1740 i.m._23\RB\1740 ,_24\,\1740 and_25\CC\1740 i.p._26\RB\1740 routes_27\NNS\8593262 of_28\IN\1740 administration_29\NN\1133281 ._30\.\1740
C043114_D064420 NONE acute_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 studies_2\NNS\635850 of_3\IN\1740 acc-9653_4\NN\1740 and_5\CC\1740 <e1>phenytoin_6\NN\3550533 sodium</e1>_7\NN\14625458 were_8\VBD\836236 carried_9\VBN\1850315 out_10\RP\1740 in_11\IN\13603305 mice_12\NNS\2329401 ,_13\,\1740 rats_14\NNS\2329401 ,_15\,\1740 rabbits_16\VBZ\1143838 ,_17\,\1740 and_18\CC\1740 dogs_19\NNS\2083346 by_20\IN\1740 i.v._21\NN\1740 ,_22\,\1740 i.m._23\RB\1740 ,_24\,\1740 and_25\CC\1740 i.p._26\RB\1740 routes_27\NNS\8593262 of_28\IN\1740 administration_29\NN\1133281 ._30\.\1740
9272404
D002245_D010146 NONE phasic_0\JJ\1740 <e2>pain</e2>_1\NN\14299637 was_2\VBD\836236 applied_3\VBN\2676054 by_4\IN\1740 means_5\NNS\44150 of_6\IN\1740 short_7\JJ\1740 pulses_8\NNS\7345593 of_9\IN\1740 <e1>co2</e1>_10\NN\14836127 to_11\TO\1740 the_12\DT\1740 nasal_13\JJ\1740 mucosa_14\NN\5426243 (_15\-LRB-\1740 stimulus_16\NN\5816287 duration_17\NN\15113229 500_18\CD\13745420 ms_19\NN\14187378 ,_20\,\1740 interval_21\NN\33615 approximately_22\RB\1740 60_23\CD\13745420 s_24\NNS\15154774 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 tonic_28\JJ\1740 pain_29\NN\14299637 was_30\VBD\836236 induced_31\VBN\1627355 in_32\IN\13603305 the_33\DT\1740 nasal_34\JJ\1740 cavity_35\NN\9304750 by_36\IN\1740 means_37\NNS\44150 of_38\IN\1740 dry_39\JJ\1740 air_40\NN\14877585 of_41\IN\1740 controlled_42\VBN\2422663 temperature_43\NN\13575869 ,_44\,\1740 humidity_45\NN\14534696 and_46\CC\1740 flow_47\NN\7311115 rate_48\NN\13815152 (_49\-LRB-\1740 22_50\CD\13745420 degrees_51\NNS\4916342 c_52\NN\13714184 ,_53\,\1740 0_54\CD\13741022 %_55\NN\1740 relative_56\JJ\1740 humidity_57\NN\14534696 ,_58\,\1740 145_59\CD\1740 ml.s-1_60\NNS\1740 )_61\-RRB-\1740 ._62\.\1740
D002245_D010146 NONE phasic_0\JJ\1740 pain_1\NN\14299637 was_2\VBD\836236 applied_3\VBN\2676054 by_4\IN\1740 means_5\NNS\44150 of_6\IN\1740 short_7\JJ\1740 pulses_8\NNS\7345593 of_9\IN\1740 <e1>co2</e1>_10\NN\14836127 to_11\TO\1740 the_12\DT\1740 nasal_13\JJ\1740 mucosa_14\NN\5426243 (_15\-LRB-\1740 stimulus_16\NN\5816287 duration_17\NN\15113229 500_18\CD\13745420 ms_19\NN\14187378 ,_20\,\1740 interval_21\NN\33615 approximately_22\RB\1740 60_23\CD\13745420 s_24\NNS\15154774 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 tonic_28\JJ\1740 <e2>pain</e2>_29\NN\14299637 was_30\VBD\836236 induced_31\VBN\1627355 in_32\IN\13603305 the_33\DT\1740 nasal_34\JJ\1740 cavity_35\NN\9304750 by_36\IN\1740 means_37\NNS\44150 of_38\IN\1740 dry_39\JJ\1740 air_40\NN\14877585 of_41\IN\1740 controlled_42\VBN\2422663 temperature_43\NN\13575869 ,_44\,\1740 humidity_45\NN\14534696 and_46\CC\1740 flow_47\NN\7311115 rate_48\NN\13815152 (_49\-LRB-\1740 22_50\CD\13745420 degrees_51\NNS\4916342 c_52\NN\13714184 ,_53\,\1740 0_54\CD\13741022 %_55\NN\1740 relative_56\JJ\1740 humidity_57\NN\14534696 ,_58\,\1740 145_59\CD\1740 ml.s-1_60\NNS\1740 )_61\-RRB-\1740 ._62\.\1740
D002245_D010146 NONE both_0\CC\1740 csseps_1\NNS\1740 as_2\IN\14622893 central_3\JJ\1740 and_4\CC\1740 nmps_5\NNS\1740 as_6\IN\14622893 peripheral_7\JJ\1740 correlates_8\NNS\5857459 of_9\IN\1740 <e2>pain</e2>_10\NN\14299637 were_11\VBD\836236 obtained_12\VBN\2210855 in_13\IN\13603305 response_14\NN\11410625 to_15\TO\1740 the_16\DT\1740 <e1>co2</e1>_17\NN\14836127 stimuli_18\NNS\5816287 ._19\.\1740
D007052_D010146 CID results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 described_3\VBN\1001294 earlier_4\RBR\1740 ,_5\,\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>ibuprofen</e1>_8\NN\3828465 was_9\VBD\836236 followed_10\VBN\1835496 by_11\IN\1740 a_12\DT\13649268 decrease_13\NN\7296428 in_14\IN\13603305 tonic_15\JJ\1740 <e2>pain</e2>_16\NN\14299637 but-relative_17\JJ\1740 to_18\TO\1740 placebo-an_19\JJ\1740 increase_20\NN\13576355 in_21\IN\13603305 correlates_22\NNS\5857459 of_23\IN\1740 phasic_24\JJ\1740 pain_25\NN\14299637 ,_26\,\1740 indicating_27\VBG\952524 a_28\DT\13649268 specific_29\JJ\1740 effect_30\NN\34213 of_31\IN\1740 ibuprofen_32\NN\3828465 on_33\IN\1740 the_34\DT\1740 interaction_35\NN\37396 between_36\IN\1740 the_37\DT\1740 pain_38\NN\14299637 stimuli_39\NNS\5816287 under_40\IN\1740 these_41\DT\1740 special_42\JJ\1740 experimental_43\JJ\1740 conditions_44\NNS\14512817 ._45\.\1740
D007052_D010146 CID results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 described_3\VBN\1001294 earlier_4\RBR\1740 ,_5\,\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>ibuprofen</e1>_8\NN\3828465 was_9\VBD\836236 followed_10\VBN\1835496 by_11\IN\1740 a_12\DT\13649268 decrease_13\NN\7296428 in_14\IN\13603305 tonic_15\JJ\1740 pain_16\NN\14299637 but-relative_17\JJ\1740 to_18\TO\1740 placebo-an_19\JJ\1740 increase_20\NN\13576355 in_21\IN\13603305 correlates_22\NNS\5857459 of_23\IN\1740 phasic_24\JJ\1740 <e2>pain</e2>_25\NN\14299637 ,_26\,\1740 indicating_27\VBG\952524 a_28\DT\13649268 specific_29\JJ\1740 effect_30\NN\34213 of_31\IN\1740 ibuprofen_32\NN\3828465 on_33\IN\1740 the_34\DT\1740 interaction_35\NN\37396 between_36\IN\1740 the_37\DT\1740 pain_38\NN\14299637 stimuli_39\NNS\5816287 under_40\IN\1740 these_41\DT\1740 special_42\JJ\1740 experimental_43\JJ\1740 conditions_44\NNS\14512817 ._45\.\1740
D007052_D010146 CID results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 described_3\VBN\1001294 earlier_4\RBR\1740 ,_5\,\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>ibuprofen</e1>_8\NN\3828465 was_9\VBD\836236 followed_10\VBN\1835496 by_11\IN\1740 a_12\DT\13649268 decrease_13\NN\7296428 in_14\IN\13603305 tonic_15\JJ\1740 pain_16\NN\14299637 but-relative_17\JJ\1740 to_18\TO\1740 placebo-an_19\JJ\1740 increase_20\NN\13576355 in_21\IN\13603305 correlates_22\NNS\5857459 of_23\IN\1740 phasic_24\JJ\1740 pain_25\NN\14299637 ,_26\,\1740 indicating_27\VBG\952524 a_28\DT\13649268 specific_29\JJ\1740 effect_30\NN\34213 of_31\IN\1740 ibuprofen_32\NN\3828465 on_33\IN\1740 the_34\DT\1740 interaction_35\NN\37396 between_36\IN\1740 the_37\DT\1740 <e2>pain</e2>_38\NN\14299637 stimuli_39\NNS\5816287 under_40\IN\1740 these_41\DT\1740 special_42\JJ\1740 experimental_43\JJ\1740 conditions_44\NNS\14512817 ._45\.\1740
D007052_D010146 CID results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 described_3\VBN\1001294 earlier_4\RBR\1740 ,_5\,\1740 administration_6\NN\1133281 of_7\IN\1740 ibuprofen_8\NN\3828465 was_9\VBD\836236 followed_10\VBN\1835496 by_11\IN\1740 a_12\DT\13649268 decrease_13\NN\7296428 in_14\IN\13603305 tonic_15\JJ\1740 <e2>pain</e2>_16\NN\14299637 but-relative_17\JJ\1740 to_18\TO\1740 placebo-an_19\JJ\1740 increase_20\NN\13576355 in_21\IN\13603305 correlates_22\NNS\5857459 of_23\IN\1740 phasic_24\JJ\1740 pain_25\NN\14299637 ,_26\,\1740 indicating_27\VBG\952524 a_28\DT\13649268 specific_29\JJ\1740 effect_30\NN\34213 of_31\IN\1740 <e1>ibuprofen</e1>_32\NN\3828465 on_33\IN\1740 the_34\DT\1740 interaction_35\NN\37396 between_36\IN\1740 the_37\DT\1740 pain_38\NN\14299637 stimuli_39\NNS\5816287 under_40\IN\1740 these_41\DT\1740 special_42\JJ\1740 experimental_43\JJ\1740 conditions_44\NNS\14512817 ._45\.\1740
D007052_D010146 CID results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 described_3\VBN\1001294 earlier_4\RBR\1740 ,_5\,\1740 administration_6\NN\1133281 of_7\IN\1740 ibuprofen_8\NN\3828465 was_9\VBD\836236 followed_10\VBN\1835496 by_11\IN\1740 a_12\DT\13649268 decrease_13\NN\7296428 in_14\IN\13603305 tonic_15\JJ\1740 pain_16\NN\14299637 but-relative_17\JJ\1740 to_18\TO\1740 placebo-an_19\JJ\1740 increase_20\NN\13576355 in_21\IN\13603305 correlates_22\NNS\5857459 of_23\IN\1740 phasic_24\JJ\1740 <e2>pain</e2>_25\NN\14299637 ,_26\,\1740 indicating_27\VBG\952524 a_28\DT\13649268 specific_29\JJ\1740 effect_30\NN\34213 of_31\IN\1740 <e1>ibuprofen</e1>_32\NN\3828465 on_33\IN\1740 the_34\DT\1740 interaction_35\NN\37396 between_36\IN\1740 the_37\DT\1740 pain_38\NN\14299637 stimuli_39\NNS\5816287 under_40\IN\1740 these_41\DT\1740 special_42\JJ\1740 experimental_43\JJ\1740 conditions_44\NNS\14512817 ._45\.\1740
D007052_D010146 CID results_0\NNS\34213 :_1\:\1740 as_2\IN\14622893 described_3\VBN\1001294 earlier_4\RBR\1740 ,_5\,\1740 administration_6\NN\1133281 of_7\IN\1740 ibuprofen_8\NN\3828465 was_9\VBD\836236 followed_10\VBN\1835496 by_11\IN\1740 a_12\DT\13649268 decrease_13\NN\7296428 in_14\IN\13603305 tonic_15\JJ\1740 pain_16\NN\14299637 but-relative_17\JJ\1740 to_18\TO\1740 placebo-an_19\JJ\1740 increase_20\NN\13576355 in_21\IN\13603305 correlates_22\NNS\5857459 of_23\IN\1740 phasic_24\JJ\1740 pain_25\NN\14299637 ,_26\,\1740 indicating_27\VBG\952524 a_28\DT\13649268 specific_29\JJ\1740 effect_30\NN\34213 of_31\IN\1740 <e1>ibuprofen</e1>_32\NN\3828465 on_33\IN\1740 the_34\DT\1740 interaction_35\NN\37396 between_36\IN\1740 the_37\DT\1740 <e2>pain</e2>_38\NN\14299637 stimuli_39\NNS\5816287 under_40\IN\1740 these_41\DT\1740 special_42\JJ\1740 experimental_43\JJ\1740 conditions_44\NNS\14512817 ._45\.\1740
18340638
D001379_D000740 CID the_0\DT\1740 side_1\NN\8630039 effects_2\NNS\13245626 of_3\IN\1740 <e1>azathioprine</e1>_4\NN\3740161 include_5\VBP\690614 <e2>anemia</e2>_6\NN\14189204 ,_7\,\1740 which_8\WDT\1740 has_9\VBZ\2108377 been_10\VBN\836236 attributed_11\VBN\670261 to_12\TO\1740 bone_13\NN\5286536 marrow_14\NN\5286536 suppression_15\NN\13489037 ._16\.\1740
D001379_D000740 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>azathioprine</e1>_2\NN\3740161 triggers_3\VBZ\1641914 suicidal_4\JJ\1740 erythrocyte_5\NN\5449268 death_6\NN\7296428 ,_7\,\1740 an_8\DT\6697703 effect_9\NN\34213 presumably_10\RB\1740 contributing_11\VBG\126264 to_12\TO\1740 azathioprine-induced_13\JJ\1740 <e2>anemia</e2>_14\NN\14189204 ._15\.\1740
D001379_D000740 CID conclusions_0\NNS\5837957 :_1\:\1740 azathioprine_2\NN\3740161 triggers_3\VBZ\1641914 suicidal_4\JJ\1740 erythrocyte_5\NN\5449268 death_6\NN\7296428 ,_7\,\1740 an_8\DT\6697703 effect_9\NN\34213 presumably_10\RB\1740 contributing_11\VBG\126264 to_12\TO\1740 <e1>azathioprine-induced</e1>_13\JJ\1740 <e2>anemia</e2>_14\NN\14189204 ._15\.\1740
D010718_D000740 NONE alternatively_0\RB\1740 ,_1\,\1740 <e2>anemia</e2>_2\NN\14189204 could_3\MD\1740 result_4\VB\2633881 from_5\IN\1740 accelerated_6\VBN\226566 suicidal_7\JJ\1740 erythrocyte_8\NN\5449268 death_9\NN\7296428 or_10\CC\3541091 eryptosis_11\NN\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 characterized_15\VBN\609683 by_16\IN\1740 exposure_17\NN\5042871 of_18\IN\1740 <e1>phosphatidylserine</e1>_19\NN\1740 (_20\-LRB-\1740 ps_21\NN\6763273 )_22\-RRB-\1740 at_23\IN\14622893 the_24\DT\1740 erythrocyte_25\NN\5449268 surface_26\NN\21939 and_27\CC\1740 by_28\IN\1740 cell_29\NN\3080309 shrinkage_30\NN\7355887 ._31\.\1740
D010718_D000740 NONE alternatively_0\RB\1740 ,_1\,\1740 <e2>anemia</e2>_2\NN\14189204 could_3\MD\1740 result_4\VB\2633881 from_5\IN\1740 accelerated_6\VBN\226566 suicidal_7\JJ\1740 erythrocyte_8\NN\5449268 death_9\NN\7296428 or_10\CC\3541091 eryptosis_11\NN\1740 ,_12\,\1740 which_13\WDT\1740 is_14\VBZ\836236 characterized_15\VBN\609683 by_16\IN\1740 exposure_17\NN\5042871 of_18\IN\1740 phosphatidylserine_19\NN\1740 (_20\-LRB-\1740 <e1>ps</e1>_21\NN\6763273 )_22\-RRB-\1740 at_23\IN\14622893 the_24\DT\1740 erythrocyte_25\NN\5449268 surface_26\NN\21939 and_27\CC\1740 by_28\IN\1740 cell_29\NN\3080309 shrinkage_30\NN\7355887 ._31\.\1740
10726030
D006493_D013921 CID clinical_0\JJ\1740 aspects_1\NNS\5849789 of_2\IN\1740 <e1>heparin-induced</e1>_3\JJ\1740 <e2>thrombocytopenia</e2>_4\NN\14189204 and_5\CC\1740 thrombosis_6\NN\14100769 and_7\CC\1740 other_8\JJ\1740 side_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 heparin_12\NN\2718259 therapy_13\NN\657604 ._14\.\1740
D006493_D013921 CID clinical_0\JJ\1740 aspects_1\NNS\5849789 of_2\IN\1740 heparin-induced_3\JJ\1740 <e2>thrombocytopenia</e2>_4\NN\14189204 and_5\CC\1740 thrombosis_6\NN\14100769 and_7\CC\1740 other_8\JJ\1740 side_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 <e1>heparin</e1>_12\NN\2718259 therapy_13\NN\657604 ._14\.\1740
D006493_D013921 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 <e2>thrombocytopenia</e2>_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D013921 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 <e2>thrombocytopenia</e2>_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D013921 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 <e2>thrombocytopenia</e2>_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D013921 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 <e2>thrombocytopenia</e2>_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D013921 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 <e2>thrombocytopenia</e2>_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D013921 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 <e2>thrombocytopenia</e2>_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D013921 NONE these_0\DT\1740 side_1\NN\8630039 effects_2\NNS\13245626 are_3\VBP\836236 relatively_4\RB\1740 rare_5\JJ\1740 in_6\IN\13603305 a_7\DT\13649268 given_8\VBN\2327200 individual_9\JJ\1740 ,_10\,\1740 but_11\CC\1740 given_12\VBN\2327200 the_13\DT\1740 extremely_14\RB\1740 widespread_15\JJ\1740 use_16\NN\407535 of_17\IN\1740 <e1>heparin</e1>_18\NN\2718259 ,_19\,\1740 some_20\DT\1740 are_21\VBP\836236 quite_22\RB\1740 common_23\JJ\1740 ,_24\,\1740 particularly_25\RB\1740 <e2>hitt</e2>_26\NN\1740 and_27\CC\1740 osteoporosis_28\NN\14204950 ._29\.\1740
D006493_D013927 NONE clinical_0\JJ\1740 aspects_1\NNS\5849789 of_2\IN\1740 <e1>heparin-induced</e1>_3\JJ\1740 thrombocytopenia_4\NN\14189204 and_5\CC\1740 <e2>thrombosis</e2>_6\NN\14100769 and_7\CC\1740 other_8\JJ\1740 side_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 heparin_12\NN\2718259 therapy_13\NN\657604 ._14\.\1740
D006493_D013927 NONE clinical_0\JJ\1740 aspects_1\NNS\5849789 of_2\IN\1740 heparin-induced_3\JJ\1740 thrombocytopenia_4\NN\14189204 and_5\CC\1740 <e2>thrombosis</e2>_6\NN\14100769 and_7\CC\1740 other_8\JJ\1740 side_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 <e1>heparin</e1>_12\NN\2718259 therapy_13\NN\657604 ._14\.\1740
D006493_D013927 NONE <e1>heparin</e1>_0\NN\2718259 ,_1\,\1740 first_2\RB\1740 used_3\VBN\1156834 to_4\TO\1740 prevent_5\VB\1740 the_6\DT\1740 clotting_7\NN\13518963 of_8\IN\1740 blood_9\NN\5397468 in_10\FW\13603305 vitro_11\FW\1740 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 clinically_15\RB\1740 used_16\VBN\1156834 to_17\TO\1740 treat_18\VB\2376958 <e2>thrombosis</e2>_19\NN\14100769 for_20\IN\1740 more_21\JJR\1740 than_22\IN\1740 50_23\CD\13745420 years_24\NNS\15144371 ._25\.\1740
D006493_D013927 NONE although_0\IN\1740 several_1\JJ\1740 new_2\JJ\1740 anticoagulant_3\JJ\1740 drugs_4\NNS\14778436 are_5\VBP\836236 in_6\IN\13603305 development_7\NN\248977 ,_8\,\1740 <e1>heparin</e1>_9\NN\2718259 remains_10\VBZ\2604760 the_11\DT\1740 anticoagulant_12\NN\3740161 of_13\IN\1740 choice_14\NN\5788149 to_15\TO\1740 treat_16\VB\2376958 acute_17\JJ\1740 <e2>thrombotic</e2>_18\JJ\1740 episodes_19\NNS\7283608 ._20\.\1740
D006493_D013927 NONE these_0\DT\1740 side_1\NN\8630039 effects_2\NNS\13245626 are_3\VBP\836236 relatively_4\RB\1740 rare_5\JJ\1740 in_6\IN\13603305 a_7\DT\13649268 given_8\VBN\2327200 individual_9\JJ\1740 ,_10\,\1740 but_11\CC\1740 given_12\VBN\2327200 the_13\DT\1740 extremely_14\RB\1740 widespread_15\JJ\1740 use_16\NN\407535 of_17\IN\1740 <e1>heparin</e1>_18\NN\2718259 ,_19\,\1740 some_20\DT\1740 are_21\VBP\836236 quite_22\RB\1740 common_23\JJ\1740 ,_24\,\1740 particularly_25\RB\1740 <e2>hitt</e2>_26\NN\1740 and_27\CC\1740 osteoporosis_28\NN\14204950 ._29\.\1740
D006493_D006470 NONE <e2>bleeding</e2>_0\NN\14285662 is_1\VBZ\836236 the_2\DT\1740 primary_3\JJ\1740 untoward_4\JJ\1740 effect_5\NN\34213 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 ._8\.\1740
D006493_D006470 NONE major_0\JJ\1740 <e2>bleeding</e2>_1\NN\14285662 is_2\VBZ\836236 of_3\IN\1740 primary_4\JJ\1740 concern_5\NN\5682950 in_6\IN\13603305 patients_7\NNS\9898892 receiving_8\VBG\2210855 <e1>heparin</e1>_9\NN\2718259 therapy_10\NN\657604 ._11\.\1740
D006493_D010024 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 <e2>osteoporosis</e2>_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D010024 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 <e2>osteoporosis</e2>_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D010024 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 <e2>osteoporosis</e2>_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D010024 CID these_0\DT\1740 side_1\NN\8630039 effects_2\NNS\13245626 are_3\VBP\836236 relatively_4\RB\1740 rare_5\JJ\1740 in_6\IN\13603305 a_7\DT\13649268 given_8\VBN\2327200 individual_9\JJ\1740 ,_10\,\1740 but_11\CC\1740 given_12\VBN\2327200 the_13\DT\1740 extremely_14\RB\1740 widespread_15\JJ\1740 use_16\NN\407535 of_17\IN\1740 <e1>heparin</e1>_18\NN\2718259 ,_19\,\1740 some_20\DT\1740 are_21\VBP\836236 quite_22\RB\1740 common_23\JJ\1740 ,_24\,\1740 particularly_25\RB\1740 hitt_26\NN\1740 and_27\CC\1740 <e2>osteoporosis</e2>_28\NN\14204950 ._29\.\1740
D006493_D004802 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 <e2>eosinophilia</e2>_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D004802 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 <e2>eosinophilia</e2>_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D004802 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 <e2>eosinophilia</e2>_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D012871 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 <e2>skin_18\NN\5237755 reactions</e2>_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D012871 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 <e2>skin_18\NN\5237755 reactions</e2>_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D012871 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 <e2>skin_18\NN\5237755 reactions</e2>_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D004342 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 <e2>allergic_21\JJ\1740 reactions</e2>_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D004342 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 <e2>allergic_21\JJ\1740 reactions</e2>_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D004342 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 <e2>allergic_21\JJ\1740 reactions</e2>_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D000505 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 <e2>alopecia</e2>_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D000505 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 <e2>alopecia</e2>_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D000505 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 <e2>alopecia</e2>_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D006947 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 <e2>hyperkalemia</e2>_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D006947 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 <e2>hyperkalemia</e2>_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D006947 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 <e2>hyperkalemia</e2>_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D006994 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 <e2>hypoaldosteronism</e2>_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D006994 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 <e2>hypoaldosteronism</e2>_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D006994 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 <e2>hypoaldosteronism</e2>_33\NN\1740 ,_34\,\1740 and_35\CC\1740 priapism_36\NN\14204950 ._37\.\1740
D006493_D011317 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>heparin</e1>_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 <e2>priapism</e2>_36\NN\14204950 ._37\.\1740
D006493_D011317 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 heparin-associated_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 <e2>priapism</e2>_36\NN\14204950 ._37\.\1740
D006493_D011317 CID however_0\RB\1740 ,_1\,\1740 additional_2\JJ\1740 important_3\JJ\1740 untoward_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 heparin_7\NN\2718259 therapy_8\NN\657604 include_9\VBP\690614 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 ,_12\,\1740 <e1>heparin-associated</e1>_13\JJ\1740 osteoporosis_14\NN\14204950 ,_15\,\1740 eosinophilia_16\NN\14299637 ,_17\,\1740 skin_18\NN\5237755 reactions_19\NNS\13446390 ,_20\,\1740 allergic_21\JJ\1740 reactions_22\NNS\13446390 other_23\JJ\1740 than_24\IN\1740 thrombocytopenia_25\NN\14189204 ,_26\,\1740 alopecia_27\NN\14457041 ,_28\,\1740 transaminasemia_29\NN\1740 ,_30\,\1740 hyperkalemia_31\NN\14299637 ,_32\,\1740 hypoaldosteronism_33\NN\1740 ,_34\,\1740 and_35\CC\1740 <e2>priapism</e2>_36\NN\14204950 ._37\.\1740
10427794
C065757_D056486 CID <e1>meloxicam-induced</e1>_0\JJ\1740 <e2>liver_1\NN\5298729 toxicity</e2>_2\NN\13576101 ._3\.\1740
C065757_D056486 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 female_6\JJ\1740 patient_7\NN\9898892 with_8\IN\1740 rheumatoid_9\JJ\1740 arthritis_10\NN\14171682 who_11\WP\8299493 developed_12\VBD\1753788 acute_13\JJ\1740 cytolytic_14\JJ\1740 <e2>hepatitis</e2>_15\NN\14127211 due_16\JJ\1740 to_17\TO\1740 <e1>meloxicam</e1>_18\VB\1740 ._19\.\1740
C065757_D056486 CID the_0\DT\1740 acute_1\JJ\1740 cytolytic_2\JJ\1740 <e2>hepatitis</e2>_3\NN\14127211 occurred_4\VBD\2623529 rapidly_5\RB\1740 after_6\IN\1740 <e1>meloxicam</e1>_7\JJ\1740 administration_8\NN\1133281 and_9\CC\1740 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 the_13\DT\1740 development_14\NN\248977 of_15\IN\1740 antinuclear_16\JJ\1740 antibodies_17\NNS\14728724 suggesting_18\VBG\1010118 a_19\DT\13649268 hypersensitivity_20\NN\14531772 mechanism_21\NN\13446390 ._22\.\1740
C065757_D056486 CID this_0\DT\1740 first_1\JJ\1740 case_2\NN\7283608 of_3\IN\1740 <e1>meloxicam</e1>_4\NN\1740 related_5\JJ\1740 <e2>liver_6\NN\5298729 toxicity</e2>_7\NN\13576101 demonstrates_8\VBZ\2137132 the_9\DT\1740 potential_10\NN\14481929 of_11\IN\1740 this_12\DT\1740 drug_13\NN\14778436 to_14\TO\1740 induce_15\VB\1627355 hepatic_16\JJ\1740 damage_17\NN\7296428 ._18\.\1740
C065757_D056486 CID this_0\DT\1740 first_1\JJ\1740 case_2\NN\7283608 of_3\IN\1740 <e1>meloxicam</e1>_4\NN\1740 related_5\JJ\1740 liver_6\NN\5298729 toxicity_7\NN\13576101 demonstrates_8\VBZ\2137132 the_9\DT\1740 potential_10\NN\14481929 of_11\IN\1740 this_12\DT\1740 drug_13\NN\14778436 to_14\TO\1740 induce_15\VB\1627355 <e2>hepatic_16\JJ\1740 damage</e2>_17\NN\7296428 ._18\.\1740
C065757_D001172 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 female_6\JJ\1740 patient_7\NN\9898892 with_8\IN\1740 <e2>rheumatoid_9\JJ\1740 arthritis</e2>_10\NN\14171682 who_11\WP\8299493 developed_12\VBD\1753788 acute_13\JJ\1740 cytolytic_14\JJ\1740 hepatitis_15\NN\14127211 due_16\JJ\1740 to_17\TO\1740 <e1>meloxicam</e1>_18\VB\1740 ._19\.\1740
C065757_D004342 CID the_0\DT\1740 acute_1\JJ\1740 cytolytic_2\JJ\1740 hepatitis_3\NN\14127211 occurred_4\VBD\2623529 rapidly_5\RB\1740 after_6\IN\1740 <e1>meloxicam</e1>_7\JJ\1740 administration_8\NN\1133281 and_9\CC\1740 was_10\VBD\836236 associated_11\VBN\628491 with_12\IN\1740 the_13\DT\1740 development_14\NN\248977 of_15\IN\1740 antinuclear_16\JJ\1740 antibodies_17\NNS\14728724 suggesting_18\VBG\1010118 a_19\DT\13649268 <e2>hypersensitivity</e2>_20\NN\14531772 mechanism_21\NN\13446390 ._22\.\1740
19184102
D014635_D065626 CID <e2>nonalcoholic_0\JJ\1740 fatty_1\JJ\1740 liver_2\NN\5298729 disease</e2>_3\NN\14061805 during_4\IN\1740 <e1>valproate</e1>_5\NN\1740 therapy_6\NN\657604 ._7\.\1740
D014635_D065626 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>nonalcoholic_5\JJ\1740 fatty_6\JJ\1740 liver_7\NN\5298729 disease</e2>_8\NN\14061805 (_9\-LRB-\1740 nafld_10\NN\1740 )_11\-RRB-\1740 arising_12\VBG\2623529 in_13\IN\13603305 a_14\DT\13649268 child_15\NN\9622049 who_16\WP\8299493 developed_17\VBD\1753788 obesity_18\NN\4999401 during_19\IN\1740 <e1>vpa</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D014635_D065626 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 nonalcoholic_5\JJ\1740 fatty_6\JJ\1740 liver_7\NN\5298729 disease_8\NN\14061805 (_9\-LRB-\1740 <e2>nafld</e2>_10\NN\1740 )_11\-RRB-\1740 arising_12\VBG\2623529 in_13\IN\13603305 a_14\DT\13649268 child_15\NN\9622049 who_16\WP\8299493 developed_17\VBD\1753788 obesity_18\NN\4999401 during_19\IN\1740 <e1>vpa</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D014635_D065626 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 obesity_5\NN\4999401 ,_6\,\1740 hyperinsulinemia_7\NN\1740 ,_8\,\1740 insulin_9\NN\5407119 resistance_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>vpa</e1>_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 <e2>nafld</e2>_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 vpa_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
D014635_D065626 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 obesity_5\NN\4999401 ,_6\,\1740 hyperinsulinemia_7\NN\1740 ,_8\,\1740 insulin_9\NN\5407119 resistance_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 vpa_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 <e2>nafld</e2>_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 <e1>vpa</e1>_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
D014635_D004827 NONE <e1>valproic_0\JJ\1740 acid</e1>_1\NN\14818238 (_2\-LRB-\1740 vpa_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 effective_6\JJ\1740 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 many_11\JJ\1740 types_12\NNS\5839024 of_13\IN\1740 <e2>epilepsy</e2>_14\NN\14085708 ,_15\,\1740 but_16\CC\1740 its_17\PRP$\6125041 use_18\NN\407535 can_19\MD\3094503 be_20\VB\836236 associated_21\VBN\628491 with_22\IN\1740 an_23\DT\6697703 increase_24\NN\13576355 in_25\IN\13603305 body_26\NN\19128 weight_27\NN\5009170 ._28\.\1740
D014635_D004827 NONE valproic_0\JJ\1740 acid_1\NN\14818238 (_2\-LRB-\1740 <e1>vpa</e1>_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 effective_6\JJ\1740 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 many_11\JJ\1740 types_12\NNS\5839024 of_13\IN\1740 <e2>epilepsy</e2>_14\NN\14085708 ,_15\,\1740 but_16\CC\1740 its_17\PRP$\6125041 use_18\NN\407535 can_19\MD\3094503 be_20\VB\836236 associated_21\VBN\628491 with_22\IN\1740 an_23\DT\6697703 increase_24\NN\13576355 in_25\IN\13603305 body_26\NN\19128 weight_27\NN\5009170 ._28\.\1740
D014635_D009765 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 nonalcoholic_5\JJ\1740 fatty_6\JJ\1740 liver_7\NN\5298729 disease_8\NN\14061805 (_9\-LRB-\1740 nafld_10\NN\1740 )_11\-RRB-\1740 arising_12\VBG\2623529 in_13\IN\13603305 a_14\DT\13649268 child_15\NN\9622049 who_16\WP\8299493 developed_17\VBD\1753788 <e2>obesity</e2>_18\NN\4999401 during_19\IN\1740 <e1>vpa</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D014635_D009765 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 <e2>obesity</e2>_5\NN\4999401 ,_6\,\1740 hyperinsulinemia_7\NN\1740 ,_8\,\1740 insulin_9\NN\5407119 resistance_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>vpa</e1>_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 nafld_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 vpa_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
D014635_D009765 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 <e2>obesity</e2>_5\NN\4999401 ,_6\,\1740 hyperinsulinemia_7\NN\1740 ,_8\,\1740 insulin_9\NN\5407119 resistance_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 vpa_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 nafld_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 <e1>vpa</e1>_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
D014635_D015431 NONE after_0\IN\1740 the_1\DT\1740 withdrawal_2\NN\7206096 of_3\IN\1740 <e1>vpa</e1>_4\NN\1740 therapy_5\NN\657604 ,_6\,\1740 our_7\PRP$\1740 patient_8\NN\9898892 showed_9\VBD\2137132 a_10\DT\13649268 significant_11\JJ\1740 <e2>weight_12\NN\5009170 loss</e2>_13\NN\13252973 ,_14\,\1740 a_15\DT\13649268 decrease_16\NN\7296428 of_17\IN\1740 body_18\NN\19128 mass_19\NN\13575869 index_20\NN\13850304 ,_21\,\1740 and_22\CC\1740 normalization_23\NN\1123598 of_24\IN\1740 metabolic_25\JJ\1740 and_26\CC\1740 endocrine_27\JJ\1740 parameters_28\NNS\5858936 ;_29\:\1740 moreover_30\RB\1740 ,_31\,\1740 ultrasound_32\JJ\1740 measurements_33\NNS\407535 showed_34\VBD\2137132 a_35\DT\13649268 complete_36\JJ\1740 normalization_37\NN\1123598 ._38\.\1740
D014635_D006946 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 obesity_5\NN\4999401 ,_6\,\1740 <e2>hyperinsulinemia</e2>_7\NN\1740 ,_8\,\1740 insulin_9\NN\5407119 resistance_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>vpa</e1>_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 nafld_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 vpa_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
D014635_D006946 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 obesity_5\NN\4999401 ,_6\,\1740 <e2>hyperinsulinemia</e2>_7\NN\1740 ,_8\,\1740 insulin_9\NN\5407119 resistance_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 vpa_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 nafld_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 <e1>vpa</e1>_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
D014635_D007333 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 obesity_5\NN\4999401 ,_6\,\1740 hyperinsulinemia_7\NN\1740 ,_8\,\1740 <e2>insulin_9\NN\5407119 resistance</e2>_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>vpa</e1>_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 nafld_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 vpa_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
D014635_D007333 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 suggests_3\VBZ\1010118 that_4\IN\1740 obesity_5\NN\4999401 ,_6\,\1740 hyperinsulinemia_7\NN\1740 ,_8\,\1740 <e2>insulin_9\NN\5407119 resistance</e2>_10\NN\37396 ,_11\,\1740 and_12\CC\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 vpa_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 all_19\DT\1740 associated_20\VBN\628491 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 nafld_25\NN\1740 ;_26\:\1740 this_27\DT\1740 side_28\NN\8630039 effect_29\NN\34213 is_30\VBZ\836236 reversible_31\JJ\1740 after_32\IN\1740 <e1>vpa</e1>_33\NN\1740 withdrawal_34\NN\7206096 ._35\.\1740
18399341
D004837_D007022 NONE four_0\CD\13741022 (_1\-LRB-\1740 10.8_2\CD\1740 %_3\NN\1740 )_4\-RRB-\1740 patients_5\NNS\9898892 in_6\IN\13603305 the_7\DT\1740 conventional_8\JJ\1740 group_9\NN\2137 and_10\CC\1740 1_11\CD\13741022 (_12\-LRB-\1740 2.7_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 the_17\DT\1740 unilateral_18\JJ\1740 group_19\NN\2137 ,_20\,\1740 p=_21\NN\1740 0.17_22\CD\1740 required_23\VBD\754942 <e1>epinephrine</e1>_24\NN\14807929 infusion_25\NN\14589223 to_26\TO\1740 treat_27\VB\2376958 <e2>hypotension</e2>_28\NN\14057371 ._29\.\1740
24742750
D016593_D016171 CID finally_0\RB\1740 ,_1\,\1740 the_2\DT\1740 ikr_3\NN\1740 blockers_4\NNS\10101634 ,_5\,\1740 <e1>terfenadine</e1>_6\NNP\1740 and_7\CC\1740 citalopram_8\NNP\1740 ,_9\,\1740 which_10\WDT\1740 are_11\VBP\836236 reported_12\VBN\831651 to_13\TO\1740 cause_14\VB\1617192 <e2>torsade_15\NNP\1740 de_16\NNP\1740 pointes</e2>_17\NNP\1740 (_18\-LRB-\1740 tdp_19\NN\1740 )_20\-RRB-\1740 in_21\IN\13603305 clinical_22\JJ\1740 practice_23\NN\407535 ,_24\,\1740 produced_25\VBN\1617192 early_26\JJ\1740 afterdepolarization_27\NN\1740 (_28\-LRB-\1740 ead_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D016593_D016171 CID finally_0\RB\1740 ,_1\,\1740 the_2\DT\1740 ikr_3\NN\1740 blockers_4\NNS\10101634 ,_5\,\1740 <e1>terfenadine</e1>_6\NNP\1740 and_7\CC\1740 citalopram_8\NNP\1740 ,_9\,\1740 which_10\WDT\1740 are_11\VBP\836236 reported_12\VBN\831651 to_13\TO\1740 cause_14\VB\1617192 torsade_15\NNP\1740 de_16\NNP\1740 pointes_17\NNP\1740 (_18\-LRB-\1740 <e2>tdp</e2>_19\NN\1740 )_20\-RRB-\1740 in_21\IN\13603305 clinical_22\JJ\1740 practice_23\NN\407535 ,_24\,\1740 produced_25\VBN\1617192 early_26\JJ\1740 afterdepolarization_27\NN\1740 (_28\-LRB-\1740 ead_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D015283_D016171 CID finally_0\RB\1740 ,_1\,\1740 the_2\DT\1740 ikr_3\NN\1740 blockers_4\NNS\10101634 ,_5\,\1740 terfenadine_6\NNP\1740 and_7\CC\1740 <e1>citalopram</e1>_8\NNP\1740 ,_9\,\1740 which_10\WDT\1740 are_11\VBP\836236 reported_12\VBN\831651 to_13\TO\1740 cause_14\VB\1617192 <e2>torsade_15\NNP\1740 de_16\NNP\1740 pointes</e2>_17\NNP\1740 (_18\-LRB-\1740 tdp_19\NN\1740 )_20\-RRB-\1740 in_21\IN\13603305 clinical_22\JJ\1740 practice_23\NN\407535 ,_24\,\1740 produced_25\VBN\1617192 early_26\JJ\1740 afterdepolarization_27\NN\1740 (_28\-LRB-\1740 ead_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D015283_D016171 CID finally_0\RB\1740 ,_1\,\1740 the_2\DT\1740 ikr_3\NN\1740 blockers_4\NNS\10101634 ,_5\,\1740 terfenadine_6\NNP\1740 and_7\CC\1740 <e1>citalopram</e1>_8\NNP\1740 ,_9\,\1740 which_10\WDT\1740 are_11\VBP\836236 reported_12\VBN\831651 to_13\TO\1740 cause_14\VB\1617192 torsade_15\NNP\1740 de_16\NNP\1740 pointes_17\NNP\1740 (_18\-LRB-\1740 <e2>tdp</e2>_19\NN\1740 )_20\-RRB-\1740 in_21\IN\13603305 clinical_22\JJ\1740 practice_23\NN\407535 ,_24\,\1740 produced_25\VBN\1617192 early_26\JJ\1740 afterdepolarization_27\NN\1740 (_28\-LRB-\1740 ead_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
2358093
D003613_D054179 NONE the_0\DT\1740 long-term_1\JJ\1740 safety_2\NN\13920835 of_3\IN\1740 <e1>danazol</e1>_4\NN\1740 in_5\IN\13603305 women_6\NNS\9605289 with_7\IN\1740 <e2>hereditary_8\JJ\1740 angioedema</e2>_9\NN\14316714 ._10\.\1740
D003613_D054179 NONE we_0\PRP\1740 therefore_1\RB\1740 investigated_2\VBD\644583 the_3\DT\1740 long-term_4\JJ\1740 safety_5\NN\13920835 of_6\IN\1740 <e1>danazol</e1>_7\NN\1740 by_8\IN\1740 performing_9\VBG\2367363 a_10\DT\13649268 retrospective_11\JJ\1740 chart_12\NN\6873252 review_13\NN\5733583 of_14\IN\1740 60_15\CD\13745420 female_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 <e2>hereditary_19\JJ\1740 angioedema</e2>_20\NN\14316714 treated_21\VBN\2376958 with_22\IN\1740 danazol_23\NN\1740 for_24\IN\1740 a_25\DT\13649268 continuous_26\JJ\1740 period_27\NN\13575869 of_28\IN\1740 6_29\CD\13741022 months_30\NNS\15113229 or_31\CC\3541091 longer_32\RBR\1740 ._33\.\1740
D003613_D054179 NONE we_0\PRP\1740 therefore_1\RB\1740 investigated_2\VBD\644583 the_3\DT\1740 long-term_4\JJ\1740 safety_5\NN\13920835 of_6\IN\1740 danazol_7\NN\1740 by_8\IN\1740 performing_9\VBG\2367363 a_10\DT\13649268 retrospective_11\JJ\1740 chart_12\NN\6873252 review_13\NN\5733583 of_14\IN\1740 60_15\CD\13745420 female_16\JJ\1740 patients_17\NNS\9898892 with_18\IN\1740 <e2>hereditary_19\JJ\1740 angioedema</e2>_20\NN\14316714 treated_21\VBN\2376958 with_22\IN\1740 <e1>danazol</e1>_23\NN\1740 for_24\IN\1740 a_25\DT\13649268 continuous_26\JJ\1740 period_27\NN\13575869 of_28\IN\1740 6_29\CD\13741022 months_30\NNS\15113229 or_31\CC\3541091 longer_32\RBR\1740 ._33\.\1740
15859361
C105934_D003875 NONE safety_0\NN\13920835 of_1\IN\1740 <e1>celecoxib</e1>_2\NN\3124700 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 adverse_6\JJ\1740 <e2>skin_7\NN\5237755 reactions</e2>_8\NNS\13446390 to_9\TO\1740 acetaminophen_10\VB\1740 (_11\-LRB-\1740 paracetamol_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 nimesulide_15\NN\1740 associated_16\VBN\628491 or_17\CC\3541091 not_18\RB\1740 with_19\IN\1740 common_20\JJ\1740 non-steroidal_21\JJ\1740 anti-inflammatory_22\JJ\1740 drugs_23\NNS\14778436 ._24\.\1740
C105934_D003875 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 evaluated_3\VBD\670261 the_4\DT\1740 tolerability_5\NN\1740 of_6\IN\1740 <e1>ce</e1>_7\NN\14625458 in_8\IN\13603305 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 patients_12\NNS\9898892 with_13\IN\1740 documented_14\VBN\1000214 history_15\NN\15120823 of_16\IN\1740 adverse_17\JJ\1740 <e2>cutaneous_18\JJ\1740 reactions</e2>_19\NNS\13446390 to_20\TO\1740 p_21\NN\14622893 and_22\CC\1740 n_23\NN\14622893 associated_24\VBN\628491 or_25\CC\3541091 not_26\RB\1740 to_27\TO\1740 classic_28\JJ\1740 nsaids_29\NNS\2721538 ._30\.\1740
D000082_D003875 CID safety_0\NN\13920835 of_1\IN\1740 celecoxib_2\NN\3124700 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 adverse_6\JJ\1740 <e2>skin_7\NN\5237755 reactions</e2>_8\NNS\13446390 to_9\TO\1740 <e1>acetaminophen</e1>_10\VB\1740 (_11\-LRB-\1740 paracetamol_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 nimesulide_15\NN\1740 associated_16\VBN\628491 or_17\CC\3541091 not_18\RB\1740 with_19\IN\1740 common_20\JJ\1740 non-steroidal_21\JJ\1740 anti-inflammatory_22\JJ\1740 drugs_23\NNS\14778436 ._24\.\1740
D000082_D003875 CID safety_0\NN\13920835 of_1\IN\1740 celecoxib_2\NN\3124700 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 adverse_6\JJ\1740 <e2>skin_7\NN\5237755 reactions</e2>_8\NNS\13446390 to_9\TO\1740 acetaminophen_10\VB\1740 (_11\-LRB-\1740 <e1>paracetamol</e1>_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 nimesulide_15\NN\1740 associated_16\VBN\628491 or_17\CC\3541091 not_18\RB\1740 with_19\IN\1740 common_20\JJ\1740 non-steroidal_21\JJ\1740 anti-inflammatory_22\JJ\1740 drugs_23\NNS\14778436 ._24\.\1740
D000082_D003875 CID objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 evaluated_3\VBD\670261 the_4\DT\1740 tolerability_5\NN\1740 of_6\IN\1740 ce_7\NN\14625458 in_8\IN\13603305 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 patients_12\NNS\9898892 with_13\IN\1740 documented_14\VBN\1000214 history_15\NN\15120823 of_16\IN\1740 adverse_17\JJ\1740 <e2>cutaneous_18\JJ\1740 reactions</e2>_19\NNS\13446390 to_20\TO\1740 <e1>p</e1>_21\NN\14622893 and_22\CC\1740 n_23\NN\14622893 associated_24\VBN\628491 or_25\CC\3541091 not_26\RB\1740 to_27\TO\1740 classic_28\JJ\1740 nsaids_29\NNS\2721538 ._30\.\1740
D000082_D003875 CID the_0\DT\1740 diagnosis_1\NN\152018 of_2\IN\1740 <e1>p</e1>_3\NN\14622893 and_4\CC\1740 n-induced_5\JJ\1740 <e2>skin_6\NN\5237755 reactions</e2>_7\NNS\13446390 was_8\VBD\836236 based_9\VBN\2694933 in_10\FW\13603305 vivo_11\FW\1740 challenge_12\NN\13927383 ._13\.\1740
C012655_D003875 CID safety_0\NN\13920835 of_1\IN\1740 celecoxib_2\NN\3124700 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 adverse_6\JJ\1740 <e2>skin_7\NN\5237755 reactions</e2>_8\NNS\13446390 to_9\TO\1740 acetaminophen_10\VB\1740 (_11\-LRB-\1740 paracetamol_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 <e1>nimesulide</e1>_15\NN\1740 associated_16\VBN\628491 or_17\CC\3541091 not_18\RB\1740 with_19\IN\1740 common_20\JJ\1740 non-steroidal_21\JJ\1740 anti-inflammatory_22\JJ\1740 drugs_23\NNS\14778436 ._24\.\1740
C012655_D003875 CID objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 evaluated_3\VBD\670261 the_4\DT\1740 tolerability_5\NN\1740 of_6\IN\1740 ce_7\NN\14625458 in_8\IN\13603305 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 patients_12\NNS\9898892 with_13\IN\1740 documented_14\VBN\1000214 history_15\NN\15120823 of_16\IN\1740 adverse_17\JJ\1740 <e2>cutaneous_18\JJ\1740 reactions</e2>_19\NNS\13446390 to_20\TO\1740 p_21\NN\14622893 and_22\CC\1740 <e1>n</e1>_23\NN\14622893 associated_24\VBN\628491 or_25\CC\3541091 not_26\RB\1740 to_27\TO\1740 classic_28\JJ\1740 nsaids_29\NNS\2721538 ._30\.\1740
C012655_D003875 CID the_0\DT\1740 diagnosis_1\NN\152018 of_2\IN\1740 p_3\NN\14622893 and_4\CC\1740 <e1>n-induced</e1>_5\JJ\1740 <e2>skin_6\NN\5237755 reactions</e2>_7\NNS\13446390 was_8\VBD\836236 based_9\VBN\2694933 in_10\FW\13603305 vivo_11\FW\1740 challenge_12\NN\13927383 ._13\.\1740
D000082_D004342 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 studied_3\VBD\630380 9_4\CD\13741022 patients_5\NNS\9898892 with_6\IN\1740 <e2>hypersensitivity</e2>_7\NN\14531772 to_8\TO\1740 <e1>p</e1>_9\NN\14622893 and_10\CC\1740 n_11\NN\14622893 with_12\IN\1740 or_13\CC\3541091 without_14\IN\1740 associated_15\VBN\628491 reactions_16\NNS\13446390 to_17\TO\1740 classic_18\JJ\1740 nsaids_19\NNS\2721538 ._20\.\1740
D000082_D004342 NONE conclusion_0\NN\5837957 :_1\:\1740 only_2\RB\1740 one_3\CD\13741022 <e2>hypersensitivity</e2>_4\NN\14531772 reaction_5\NN\13446390 to_6\TO\1740 ce_7\NN\14625458 was_8\VBD\836236 documented_9\VBN\1000214 among_10\IN\1740 9_11\CD\13741022 <e1>p</e1>_12\NN\14622893 and_13\CC\1740 n-highly_14\JJ\1740 nsaids_15\NN\2721538 intolerant_16\JJ\1740 patients_17\NNS\9898892 ._18\.\1740
C012655_D004342 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 studied_3\VBD\630380 9_4\CD\13741022 patients_5\NNS\9898892 with_6\IN\1740 <e2>hypersensitivity</e2>_7\NN\14531772 to_8\TO\1740 p_9\NN\14622893 and_10\CC\1740 <e1>n</e1>_11\NN\14622893 with_12\IN\1740 or_13\CC\3541091 without_14\IN\1740 associated_15\VBN\628491 reactions_16\NNS\13446390 to_17\TO\1740 classic_18\JJ\1740 nsaids_19\NNS\2721538 ._20\.\1740
C012655_D004342 NONE conclusion_0\NN\5837957 :_1\:\1740 only_2\RB\1740 one_3\CD\13741022 <e2>hypersensitivity</e2>_4\NN\14531772 reaction_5\NN\13446390 to_6\TO\1740 ce_7\NN\14625458 was_8\VBD\836236 documented_9\VBN\1000214 among_10\IN\1740 9_11\CD\13741022 p_12\NN\14622893 and_13\CC\1740 <e1>n-highly</e1>_14\JJ\1740 nsaids_15\NN\2721538 intolerant_16\JJ\1740 patients_17\NNS\9898892 ._18\.\1740
C105934_D004342 NONE conclusion_0\NN\5837957 :_1\:\1740 only_2\RB\1740 one_3\CD\13741022 <e2>hypersensitivity</e2>_4\NN\14531772 reaction_5\NN\13446390 to_6\TO\1740 <e1>ce</e1>_7\NN\14625458 was_8\VBD\836236 documented_9\VBN\1000214 among_10\IN\1740 9_11\CD\13741022 p_12\NN\14622893 and_13\CC\1740 n-highly_14\JJ\1740 nsaids_15\NN\2721538 intolerant_16\JJ\1740 patients_17\NNS\9898892 ._18\.\1740
3088653
D012601_D000647 CID reversal_0\NN\199130 of_1\IN\1740 <e1>scopolamine-induced</e1>_2\JJ\1740 <e2>amnesia</e2>_3\NN\5669934 of_4\IN\1740 passive_5\JJ\1740 avoidance_6\NN\203342 by_7\IN\1740 pre-_8\JJ\1740 and_9\CC\1740 post-training_10\JJ\1740 naloxone_11\NN\3808977 ._12\.\1740
D012601_D000647 CID <e1>scopolamine</e1>_0\NN\14712692 ,_1\,\1740 but_2\CC\1740 not_3\RB\1740 methyl_4\NN\14617189 scopolamine_5\NN\14712692 (_6\-LRB-\1740 1_7\CD\13741022 and_8\CC\1740 3_9\CD\13741022 mg/kg_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 induced_13\VBD\1627355 an_14\DT\6697703 <e2>amnesia</e2>_15\NN\5669934 as_16\IN\14622893 measured_17\VBN\697589 by_18\IN\1740 latency_19\NN\15269513 and_20\CC\1740 duration_21\NN\15113229 parameters_22\NNS\5858936 ._23\.\1740
D012601_D000647 CID post-training_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 naloxone_3\NN\3808977 (_4\-LRB-\1740 3_5\CD\13741022 mg/kg_6\NN\1740 )_7\-RRB-\1740 as_8\IN\14622893 a_9\DT\13649268 single_10\JJ\1740 or_11\CC\3541091 as_12\IN\14622893 a_13\DT\13649268 split_14\JJ\1740 dose_15\NN\3740161 also_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 <e1>scopolamine-induced</e1>_19\JJ\1740 <e2>amnesia</e2>_20\NN\5669934 ._21\.\1740
D009270_D000647 NONE reversal_0\NN\199130 of_1\IN\1740 scopolamine-induced_2\JJ\1740 <e2>amnesia</e2>_3\NN\5669934 of_4\IN\1740 passive_5\JJ\1740 avoidance_6\NN\203342 by_7\IN\1740 pre-_8\JJ\1740 and_9\CC\1740 post-training_10\JJ\1740 <e1>naloxone</e1>_11\NN\3808977 ._12\.\1740
D009270_D000647 NONE post-training_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>naloxone</e1>_3\NN\3808977 (_4\-LRB-\1740 3_5\CD\13741022 mg/kg_6\NN\1740 )_7\-RRB-\1740 as_8\IN\14622893 a_9\DT\13649268 single_10\JJ\1740 or_11\CC\3541091 as_12\IN\14622893 a_13\DT\13649268 split_14\JJ\1740 dose_15\NN\3740161 also_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 scopolamine-induced_19\JJ\1740 <e2>amnesia</e2>_20\NN\5669934 ._21\.\1740
D009270_D008569 NONE in_0\IN\13603305 a_1\DT\13649268 series_2\NN\8456993 of_3\IN\1740 five_4\CD\13741022 experiments_5\NNS\641820 ,_6\,\1740 the_7\DT\1740 modulating_8\VBG\1724459 role_9\NN\719494 of_10\IN\1740 <e1>naloxone</e1>_11\NN\3808977 on_12\IN\1740 a_13\DT\13649268 scopolamine-induced_14\JJ\1740 <e2>retention_15\NN\809465 deficit</e2>_16\NN\5113133 in_17\IN\13603305 a_18\DT\13649268 passive_19\JJ\1740 avoidance_20\NN\203342 paradigm_21\NN\13803782 was_22\VBD\836236 investigated_23\VBN\644583 in_24\IN\13603305 mice_25\NNS\2329401 ._26\.\1740
D009270_D008569 NONE <e1>naloxone</e1>_0\NN\3808977 (_1\-LRB-\1740 0.3_2\CD\1740 ,_3\,\1740 1_4\CD\13741022 ,_5\,\1740 3_6\CD\13741022 ,_7\,\1740 and_8\CC\1740 10_9\CD\13745420 mg/kg_10\NN\1740 )_11\-RRB-\1740 injected_12\VBN\81072 prior_13\RB\1740 to_14\IN\1740 training_15\NN\407535 attenuated_16\VBD\224901 the_17\DT\1740 <e2>retention_18\NN\809465 deficit</e2>_19\NN\5113133 with_20\IN\1740 a_21\DT\13649268 peak_22\NN\13758296 of_23\IN\1740 activity_24\NN\30358 at_25\IN\14622893 3_26\CD\13741022 mg/kg_27\NN\1740 ._28\.\1740
D009270_D008569 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 pain_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 <e1>naloxone</e1>_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 naloxone_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 naloxone_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 scopolamine-induced_34\JJ\1740 <e2>retention_35\NN\809465 deficit</e2>_36\NN\5113133 ._37\.\1740
D009270_D008569 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 pain_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 naloxone_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 <e1>naloxone</e1>_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 naloxone_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 scopolamine-induced_34\JJ\1740 <e2>retention_35\NN\809465 deficit</e2>_36\NN\5113133 ._37\.\1740
D009270_D008569 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 pain_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 naloxone_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 naloxone_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 <e1>naloxone</e1>_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 scopolamine-induced_34\JJ\1740 <e2>retention_35\NN\809465 deficit</e2>_36\NN\5113133 ._37\.\1740
D012601_D008569 NONE in_0\IN\13603305 a_1\DT\13649268 series_2\NN\8456993 of_3\IN\1740 five_4\CD\13741022 experiments_5\NNS\641820 ,_6\,\1740 the_7\DT\1740 modulating_8\VBG\1724459 role_9\NN\719494 of_10\IN\1740 naloxone_11\NN\3808977 on_12\IN\1740 a_13\DT\13649268 <e1>scopolamine-induced</e1>_14\JJ\1740 <e2>retention_15\NN\809465 deficit</e2>_16\NN\5113133 in_17\IN\13603305 a_18\DT\13649268 passive_19\JJ\1740 avoidance_20\NN\203342 paradigm_21\NN\13803782 was_22\VBD\836236 investigated_23\VBN\644583 in_24\IN\13603305 mice_25\NNS\2329401 ._26\.\1740
D012601_D008569 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 pain_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 naloxone_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 naloxone_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 naloxone_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 <e1>scopolamine-induced</e1>_34\JJ\1740 <e2>retention_35\NN\809465 deficit</e2>_36\NN\5113133 ._37\.\1740
D019832_D000647 NONE scopolamine_0\NN\14712692 ,_1\,\1740 but_2\CC\1740 not_3\RB\1740 <e1>methyl_4\NN\14617189 scopolamine</e1>_5\NN\14712692 (_6\-LRB-\1740 1_7\CD\13741022 and_8\CC\1740 3_9\CD\13741022 mg/kg_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 induced_13\VBD\1627355 an_14\DT\6697703 <e2>amnesia</e2>_15\NN\5669934 as_16\IN\14622893 measured_17\VBN\697589 by_18\IN\1740 latency_19\NN\15269513 and_20\CC\1740 duration_21\NN\15113229 parameters_22\NNS\5858936 ._23\.\1740
D009270_D010146 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 <e2>pain</e2>_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 <e1>naloxone</e1>_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 naloxone_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 naloxone_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 scopolamine-induced_34\JJ\1740 retention_35\NN\809465 deficit_36\NN\5113133 ._37\.\1740
D009270_D010146 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 <e2>pain</e2>_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 naloxone_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 <e1>naloxone</e1>_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 naloxone_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 scopolamine-induced_34\JJ\1740 retention_35\NN\809465 deficit_36\NN\5113133 ._37\.\1740
D009270_D010146 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 <e2>pain</e2>_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 naloxone_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 naloxone_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 <e1>naloxone</e1>_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 scopolamine-induced_34\JJ\1740 retention_35\NN\809465 deficit_36\NN\5113133 ._37\.\1740
D012601_D010146 NONE control_0\NN\5190804 experiments_1\NNS\641820 indicated_2\VBD\952524 that_3\IN\1740 neither_4\CC\1740 an_5\DT\6697703 increase_6\NN\13576355 in_7\IN\13603305 <e2>pain</e2>_8\NN\14299637 sensitivity_9\NN\5651971 (_10\-LRB-\1740 pre-training_11\JJ\1740 naloxone_12\NN\3808977 )_13\-RRB-\1740 nor_14\CC\1740 an_15\DT\6697703 induced_16\VBN\1627355 aversive_17\JJ\1740 state_18\NN\8491826 (_19\-LRB-\1740 post-training_20\JJ\1740 naloxone_21\NN\3808977 )_22\-RRB-\1740 appear_23\VBP\2604760 to_24\TO\1740 be_25\VB\836236 responsible_26\JJ\1740 for_27\IN\1740 the_28\DT\1740 influence_29\NN\5190804 of_30\IN\1740 naloxone_31\NN\3808977 on_32\IN\1740 the_33\DT\1740 <e1>scopolamine-induced</e1>_34\JJ\1740 retention_35\NN\809465 deficit_36\NN\5113133 ._37\.\1740
8808730
D009569_D001745 NONE increased_0\VBN\169651 expression_1\NN\4679549 of_2\IN\1740 neuronal_3\JJ\1740 <e1>nitric_4\JJ\1740 oxide</e1>_5\NN\14818238 synthase_6\NN\1740 in_7\IN\13603305 bladder_8\NN\5515670 afferent_9\JJ\1740 pathways_10\NNS\5483677 following_11\VBG\1835496 chronic_12\JJ\1740 <e2>bladder_13\NN\5515670 irritation</e2>_14\NN\14373582 ._15\.\1740
D009569_D014570 NONE immunocytochemical_0\JJ\1740 techniques_1\NNS\5660268 were_2\VBD\836236 used_3\VBN\1156834 to_4\TO\1740 examine_5\VB\789138 alterations_6\NNS\7283608 in_7\IN\13603305 the_8\DT\1740 expression_9\NN\4679549 of_10\IN\1740 neuronal_11\JJ\1740 <e1>nitric_12\JJ\1740 oxide</e1>_13\NN\14818238 synthase_14\NN\1740 (_15\-LRB-\1740 nos_16\NN\7204911 )_17\-RRB-\1740 in_18\IN\13603305 bladder_19\NN\5515670 pathways_20\NNS\5483677 following_21\VBG\1835496 acute_22\JJ\1740 and_23\CC\1740 chronic_24\JJ\1740 <e2>irritation_25\NN\14373582 of_26\IN\1740 the_27\DT\1740 urinary_28\JJ\1740 tract</e2>_29\NN\8574314 of_30\IN\1740 the_31\DT\1740 rat_32\NN\2329401 ._33\.\1740
D003520_D003556 CID chemical_0\JJ\1740 <e2>cystitis</e2>_1\NN\14566129 was_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 <e1>cyclophosphamide</e1>_5\NN\1740 (_6\-LRB-\1740 cyp_7\NN\1740 )_8\-RRB-\1740 which_9\WDT\1740 is_10\VBZ\836236 metabolized_11\VBN\1740 to_12\TO\1740 acrolein_13\NN\14584765 ,_14\,\1740 an_15\DT\6697703 irritant_16\NN\5830059 eliminated_17\VBN\1619929 in_18\IN\13603305 the_19\DT\1740 urine_20\NN\14853947 ._21\.\1740
D003520_D003556 CID chemical_0\JJ\1740 <e2>cystitis</e2>_1\NN\14566129 was_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 cyclophosphamide_5\NN\1740 (_6\-LRB-\1740 <e1>cyp</e1>_7\NN\1740 )_8\-RRB-\1740 which_9\WDT\1740 is_10\VBZ\836236 metabolized_11\VBN\1740 to_12\TO\1740 acrolein_13\NN\14584765 ,_14\,\1740 an_15\DT\6697703 irritant_16\NN\5830059 eliminated_17\VBN\1619929 in_18\IN\13603305 the_19\DT\1740 urine_20\NN\14853947 ._21\.\1740
D000171_D003556 NONE chemical_0\JJ\1740 <e2>cystitis</e2>_1\NN\14566129 was_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 cyclophosphamide_5\NN\1740 (_6\-LRB-\1740 cyp_7\NN\1740 )_8\-RRB-\1740 which_9\WDT\1740 is_10\VBZ\836236 metabolized_11\VBN\1740 to_12\TO\1740 <e1>acrolein</e1>_13\NN\14584765 ,_14\,\1740 an_15\DT\6697703 irritant_16\NN\5830059 eliminated_17\VBN\1619929 in_18\IN\13603305 the_19\DT\1740 urine_20\NN\14853947 ._21\.\1740
24753331
C106487_D020964 CID background_0\NN\4921011 :_1\:\1740 <e1>s-53482</e1>_2\NN\1740 and_3\CC\1740 s-23121_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 <e2>embryolethality</e2>_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C106487_D064793 CID background_0\NN\4921011 :_1\:\1740 <e1>s-53482</e1>_2\NN\1740 and_3\CC\1740 s-23121_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 <e2>teratogenicity</e2>_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C106487_D064793 CID conclusions_0\NNS\5837957 :_1\:\1740 based_2\VBN\2694933 on_3\IN\1740 the_4\DT\1740 results_5\NNS\34213 ,_6\,\1740 <e1>s-53482</e1>_7\NN\1740 and_8\CC\1740 s-23121_9\NN\1740 were_10\VBD\836236 <e2>teratogenic</e2>_11\JJ\1740 when_12\WRB\1740 administered_13\VBN\2436349 dermally_14\RB\1740 to_15\TO\1740 pregnant_16\JJ\1740 rats_17\NNS\2329401 as_18\IN\14622893 were_19\VBD\836236 the_20\DT\1740 compounds_21\NNS\5869584 administered_22\VBN\2436349 orally_23\RB\1740 ._24\.\1740
C106487_D006345 CID background_0\NN\4921011 :_1\:\1740 <e1>s-53482</e1>_2\NN\1740 and_3\CC\1740 s-23121_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 <e2>ventricular_15\JJ\1740 septal_16\JJ\1740 defects</e2>_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C106487_D005317 CID background_0\NN\4921011 :_1\:\1740 <e1>s-53482</e1>_2\NN\1740 and_3\CC\1740 s-23121_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 <e2>growth_24\NN\13526110 retardation</e2>_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C106487_D064420 NONE background_0\NN\4921011 :_1\:\1740 <e1>s-53482</e1>_2\NN\1740 and_3\CC\1740 s-23121_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 <e2>toxicity</e2>_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C106487_D064420 NONE results_0\NNS\34213 :_1\:\1740 dermal_2\JJ\1740 exposure_3\NN\5042871 of_4\IN\1740 rats_5\NNS\2329401 to_6\TO\1740 <e1>s-53482</e1>_7\NN\1740 at_8\IN\14622893 300_9\CD\1740 mg/kg_10\NN\1740 produced_11\VBD\1617192 patterns_12\NNS\5726345 of_13\IN\1740 developmental_14\JJ\1740 <e2>toxicity</e2>_15\NN\13576101 similar_16\JJ\1740 to_17\TO\1740 those_18\DT\1740 resulting_19\VBG\2633881 from_20\IN\1740 oral_21\JJ\1740 exposure_22\NN\5042871 ._23\.\1740
C083440_D020964 CID background_0\NN\4921011 :_1\:\1740 s-53482_2\NN\1740 and_3\CC\1740 <e1>s-23121</e1>_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 <e2>embryolethality</e2>_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C083440_D020964 CID dermal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>s-23121</e1>_3\NN\1740 at_4\IN\14622893 800_5\CD\1740 mg/kg_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 an_9\DT\6697703 increased_10\VBN\169651 incidence_11\NN\13821570 of_12\IN\1740 <e2>embryonic_13\JJ\1740 death</e2>_14\NN\7296428 and_15\CC\1740 ventricular_16\JJ\1740 septal_17\JJ\1740 defect_18\NN\14462666 ,_19\,\1740 but_20\CC\1740 retarded_21\VBD\438495 fetal_22\JJ\1740 growth_23\NN\13526110 was_24\VBD\836236 not_25\RB\1740 observed_26\VBN\2163746 as_27\IN\14622893 it_28\PRP\6125041 was_29\VBD\836236 following_30\VBG\1835496 oral_31\JJ\1740 exposure_32\NN\5042871 to_33\IN\1740 s-23121_34\NN\1740 ._35\.\1740
C083440_D020964 CID dermal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 s-23121_3\NN\1740 at_4\IN\14622893 800_5\CD\1740 mg/kg_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 an_9\DT\6697703 increased_10\VBN\169651 incidence_11\NN\13821570 of_12\IN\1740 <e2>embryonic_13\JJ\1740 death</e2>_14\NN\7296428 and_15\CC\1740 ventricular_16\JJ\1740 septal_17\JJ\1740 defect_18\NN\14462666 ,_19\,\1740 but_20\CC\1740 retarded_21\VBD\438495 fetal_22\JJ\1740 growth_23\NN\13526110 was_24\VBD\836236 not_25\RB\1740 observed_26\VBN\2163746 as_27\IN\14622893 it_28\PRP\6125041 was_29\VBD\836236 following_30\VBG\1835496 oral_31\JJ\1740 exposure_32\NN\5042871 to_33\IN\1740 <e1>s-23121</e1>_34\NN\1740 ._35\.\1740
C083440_D064793 CID background_0\NN\4921011 :_1\:\1740 s-53482_2\NN\1740 and_3\CC\1740 <e1>s-23121</e1>_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 <e2>teratogenicity</e2>_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C083440_D064793 CID conclusions_0\NNS\5837957 :_1\:\1740 based_2\VBN\2694933 on_3\IN\1740 the_4\DT\1740 results_5\NNS\34213 ,_6\,\1740 s-53482_7\NN\1740 and_8\CC\1740 <e1>s-23121</e1>_9\NN\1740 were_10\VBD\836236 <e2>teratogenic</e2>_11\JJ\1740 when_12\WRB\1740 administered_13\VBN\2436349 dermally_14\RB\1740 to_15\TO\1740 pregnant_16\JJ\1740 rats_17\NNS\2329401 as_18\IN\14622893 were_19\VBD\836236 the_20\DT\1740 compounds_21\NNS\5869584 administered_22\VBN\2436349 orally_23\RB\1740 ._24\.\1740
C083440_D006345 CID background_0\NN\4921011 :_1\:\1740 s-53482_2\NN\1740 and_3\CC\1740 <e1>s-23121</e1>_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 <e2>ventricular_15\JJ\1740 septal_16\JJ\1740 defects</e2>_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C083440_D006345 CID dermal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>s-23121</e1>_3\NN\1740 at_4\IN\14622893 800_5\CD\1740 mg/kg_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 an_9\DT\6697703 increased_10\VBN\169651 incidence_11\NN\13821570 of_12\IN\1740 embryonic_13\JJ\1740 death_14\NN\7296428 and_15\CC\1740 <e2>ventricular_16\JJ\1740 septal_17\JJ\1740 defect</e2>_18\NN\14462666 ,_19\,\1740 but_20\CC\1740 retarded_21\VBD\438495 fetal_22\JJ\1740 growth_23\NN\13526110 was_24\VBD\836236 not_25\RB\1740 observed_26\VBN\2163746 as_27\IN\14622893 it_28\PRP\6125041 was_29\VBD\836236 following_30\VBG\1835496 oral_31\JJ\1740 exposure_32\NN\5042871 to_33\IN\1740 s-23121_34\NN\1740 ._35\.\1740
C083440_D006345 CID dermal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 s-23121_3\NN\1740 at_4\IN\14622893 800_5\CD\1740 mg/kg_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 an_9\DT\6697703 increased_10\VBN\169651 incidence_11\NN\13821570 of_12\IN\1740 embryonic_13\JJ\1740 death_14\NN\7296428 and_15\CC\1740 <e2>ventricular_16\JJ\1740 septal_17\JJ\1740 defect</e2>_18\NN\14462666 ,_19\,\1740 but_20\CC\1740 retarded_21\VBD\438495 fetal_22\JJ\1740 growth_23\NN\13526110 was_24\VBD\836236 not_25\RB\1740 observed_26\VBN\2163746 as_27\IN\14622893 it_28\PRP\6125041 was_29\VBD\836236 following_30\VBG\1835496 oral_31\JJ\1740 exposure_32\NN\5042871 to_33\IN\1740 <e1>s-23121</e1>_34\NN\1740 ._35\.\1740
C083440_D005317 CID background_0\NN\4921011 :_1\:\1740 s-53482_2\NN\1740 and_3\CC\1740 <e1>s-23121</e1>_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 <e2>growth_24\NN\13526110 retardation</e2>_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 toxicity_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
C083440_D064420 NONE background_0\NN\4921011 :_1\:\1740 s-53482_2\NN\1740 and_3\CC\1740 <e1>s-23121</e1>_4\NN\1740 are_5\VBP\836236 n-phenylimide_6\JJ\1740 herbicides_7\NNS\14806838 and_8\CC\1740 produced_9\VBD\1617192 embryolethality_10\NN\1740 ,_11\,\1740 teratogenicity_12\NN\1740 (_13\-LRB-\1740 mainly_14\RB\1740 ventricular_15\JJ\1740 septal_16\JJ\1740 defects_17\NNS\14462666 and_18\CC\1740 wavy_19\JJ\1740 ribs_20\NNS\4359589 )_21\-RRB-\1740 ,_22\,\1740 and_23\CC\1740 growth_24\NN\13526110 retardation_25\NN\7296428 in_26\IN\13603305 rats_27\NNS\2329401 in_28\IN\13603305 conventional_29\JJ\1740 oral_30\JJ\1740 developmental_31\JJ\1740 <e2>toxicity</e2>_32\NN\13576101 studies_33\NNS\635850 ._34\.\1740
24209900
D007069_D001927 NONE <e1>ifosfamide</e1>_0\NN\1740 related_1\JJ\1740 <e2>encephalopathy</e2>_2\RB\1740 :_3\:\1740 the_4\DT\1740 need_5\NN\13920835 for_6\IN\1740 a_7\DT\13649268 timely_8\RB\1740 eeg_9\NN\7000195 evaluation_10\NN\874067 ._11\.\1740
D007069_D001927 NONE <e2>encephalopathy</e2>_0\NNP\14084880 has_1\VBZ\2108377 been_2\VBN\836236 reported_3\VBN\831651 in_4\IN\13603305 10_5\CD\13745420 -_6\SYM\1740 40_7\CD\13745420 %_8\NN\1740 of_9\IN\1740 patients_10\NNS\9898892 receiving_11\VBG\2210855 high-dose_12\JJ\1740 iv_13\CD\13741022 <e1>ifosfamide</e1>_14\NN\1740 ._15\.\1740
D007069_D001927 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 highlight_3\VB\514463 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 electroencephalogram_7\NN\7000195 (_8\-LRB-\1740 eeg_9\NN\7000195 )_10\-RRB-\1740 in_11\IN\13603305 the_12\DT\1740 early_13\JJ\1740 detection_14\NN\5708432 and_15\CC\1740 management_16\NN\1123598 of_17\IN\1740 <e1>ifosfamide</e1>_18\NN\1740 related_19\JJ\1740 <e2>encephalopathy</e2>_20\JJ\1740 ._21\.\1740
D007069_D001927 NONE methods_0\NNS\5616786 :_1\:\1740 retrospective_2\JJ\1740 chart_3\NN\6873252 review_4\NN\5733583 including_5\VBG\690614 clinical_6\JJ\1740 data_7\NNS\7951464 and_8\CC\1740 eeg_9\NN\7000195 recordings_10\NNS\6791372 was_11\VBD\836236 done_12\VBN\1640855 on_13\IN\1740 five_14\CD\13741022 patients_15\NNS\9898892 ,_16\,\1740 admitted_17\VBN\822367 to_18\IN\1740 md_19\NNP\14622893 anderson_20\NNP\1740 cancer_21\NNP\14239425 center_22\NNP\8497294 between_23\IN\1740 years_24\NNS\15144371 2009_25\CD\1740 and_26\CC\1740 2012_27\CD\1740 ,_28\,\1740 who_29\WP\8299493 developed_30\VBD\1753788 <e1>ifosfamide</e1>_31\NN\1740 related_32\JJ\1740 acute_33\JJ\1740 <e2>encephalopathy</e2>_34\JJ\1740 ._35\.\1740
D007069_D001927 NONE results_0\NNS\34213 :_1\:\1740 all_2\DT\1740 five_3\CD\13741022 patients_4\NNS\9898892 experienced_5\VBD\2108377 symptoms_6\NNS\5823932 of_7\IN\1740 <e2>encephalopathy</e2>_8\JJ\1740 soon_9\RB\1740 after_10\IN\1740 (_11\-LRB-\1740 within_12\IN\1740 12_13\CD\13745420 h-2_14\NN\1740 days_15\NNS\15140892 )_16\-RRB-\1740 receiving_17\VBG\2210855 <e1>ifosfamide</e1>_18\NN\1740 ._19\.\1740
D007069_D001927 NONE conclusions_0\NNS\5837957 :_1\:\1740 severity_2\NN\5036394 of_3\IN\1740 <e1>ifosfamide</e1>_4\NN\1740 related_5\JJ\1740 <e2>encephalopathy</e2>_6\JJ\1740 correlates_7\VBZ\2657219 with_8\IN\1740 eeg_9\NN\7000195 changes_10\NNS\7283608 ._11\.\1740
D007069_D001927 NONE we_0\PRP\1740 suggest_1\VBP\1010118 a_2\DT\13649268 timely_3\RB\1740 eeg_4\NN\7000195 evaluation_5\NN\874067 for_6\IN\1740 patients_7\NNS\9898892 receiving_8\VBG\2210855 <e1>ifosfamide</e1>_9\NN\1740 who_10\WP\8299493 develop_11\VBP\1753788 features_12\NNS\5849040 of_13\IN\1740 <e2>encephalopathy</e2>_14\JJ\1740 ._15\.\1740
D007069_D009369 NONE background_0\NN\4921011 :_1\:\1740 <e1>ifosfamide</e1>_2\NNP\1740 is_3\VBZ\836236 an_4\DT\6697703 alkylating_5\VBG\1740 agent_6\NN\7347 useful_7\JJ\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 a_12\DT\13649268 wide_13\JJ\1740 range_14\NN\5123416 of_15\IN\1740 <e2>cancers</e2>_16\NNS\14239425 including_17\VBG\690614 sarcomas_18\NNS\14239918 ,_19\,\1740 lymphoma_20\NN\14239918 ,_21\,\1740 gynecologic_22\NN\1740 and_23\CC\1740 testicular_24\JJ\1740 cancers_25\NNS\14239425 ._26\.\1740
D007069_D009369 NONE background_0\NN\4921011 :_1\:\1740 <e1>ifosfamide</e1>_2\NNP\1740 is_3\VBZ\836236 an_4\DT\6697703 alkylating_5\VBG\1740 agent_6\NN\7347 useful_7\JJ\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 a_12\DT\13649268 wide_13\JJ\1740 range_14\NN\5123416 of_15\IN\1740 cancers_16\NNS\14239425 including_17\VBG\690614 sarcomas_18\NNS\14239918 ,_19\,\1740 lymphoma_20\NN\14239918 ,_21\,\1740 <e2>gynecologic_22\NN\1740 and_23\CC\1740 testicular_24\JJ\1740 cancers</e2>_25\NNS\14239425 ._26\.\1740
D007069_D009369 NONE methods_0\NNS\5616786 :_1\:\1740 retrospective_2\JJ\1740 chart_3\NN\6873252 review_4\NN\5733583 including_5\VBG\690614 clinical_6\JJ\1740 data_7\NNS\7951464 and_8\CC\1740 eeg_9\NN\7000195 recordings_10\NNS\6791372 was_11\VBD\836236 done_12\VBN\1640855 on_13\IN\1740 five_14\CD\13741022 patients_15\NNS\9898892 ,_16\,\1740 admitted_17\VBN\822367 to_18\IN\1740 md_19\NNP\14622893 anderson_20\NNP\1740 <e2>cancer</e2>_21\NNP\14239425 center_22\NNP\8497294 between_23\IN\1740 years_24\NNS\15144371 2009_25\CD\1740 and_26\CC\1740 2012_27\CD\1740 ,_28\,\1740 who_29\WP\8299493 developed_30\VBD\1753788 <e1>ifosfamide</e1>_31\NN\1740 related_32\JJ\1740 acute_33\JJ\1740 encephalopathy_34\JJ\1740 ._35\.\1740
D007069_D012509 NONE background_0\NN\4921011 :_1\:\1740 <e1>ifosfamide</e1>_2\NNP\1740 is_3\VBZ\836236 an_4\DT\6697703 alkylating_5\VBG\1740 agent_6\NN\7347 useful_7\JJ\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 a_12\DT\13649268 wide_13\JJ\1740 range_14\NN\5123416 of_15\IN\1740 cancers_16\NNS\14239425 including_17\VBG\690614 <e2>sarcomas</e2>_18\NNS\14239918 ,_19\,\1740 lymphoma_20\NN\14239918 ,_21\,\1740 gynecologic_22\NN\1740 and_23\CC\1740 testicular_24\JJ\1740 cancers_25\NNS\14239425 ._26\.\1740
D007069_D008223 NONE background_0\NN\4921011 :_1\:\1740 <e1>ifosfamide</e1>_2\NNP\1740 is_3\VBZ\836236 an_4\DT\6697703 alkylating_5\VBG\1740 agent_6\NN\7347 useful_7\JJ\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 a_12\DT\13649268 wide_13\JJ\1740 range_14\NN\5123416 of_15\IN\1740 cancers_16\NNS\14239425 including_17\VBG\690614 sarcomas_18\NNS\14239918 ,_19\,\1740 <e2>lymphoma</e2>_20\NN\14239918 ,_21\,\1740 gynecologic_22\NN\1740 and_23\CC\1740 testicular_24\JJ\1740 cancers_25\NNS\14239425 ._26\.\1740
24733133
C031942_D055499 NONE use_0\NN\407535 of_1\IN\1740 <e1>argatroban</e1>_2\NN\1740 and_3\CC\1740 catheter-directed_4\JJ\1740 <e2>thrombolysis</e2>_5\NN\13509528 with_6\IN\1740 alteplase_7\NN\1740 in_8\IN\13603305 an_9\DT\6697703 oncology_10\NN\6043075 patient_11\NN\9898892 with_12\IN\1740 heparin-induced_13\JJ\1740 thrombocytopenia_14\NN\14189204 with_15\IN\1740 thrombosis_16\NN\14100769 ._17\.\1740
C031942_D055499 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 hitt_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>argatroban</e1>_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 <e2>thrombolysis</e2>_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
C031942_D013921 NONE use_0\NN\407535 of_1\IN\1740 <e1>argatroban</e1>_2\NN\1740 and_3\CC\1740 catheter-directed_4\JJ\1740 thrombolysis_5\NN\13509528 with_6\IN\1740 alteplase_7\NN\1740 in_8\IN\13603305 an_9\DT\6697703 oncology_10\NN\6043075 patient_11\NN\9898892 with_12\IN\1740 heparin-induced_13\JJ\1740 <e2>thrombocytopenia</e2>_14\NN\14189204 with_15\IN\1740 thrombosis_16\NN\14100769 ._17\.\1740
C031942_D013921 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 heparin-induced_10\JJ\1740 <e2>thrombocytopenia</e2>_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 hitt_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>argatroban</e1>_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
C031942_D013921 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 <e2>hitt</e2>_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>argatroban</e1>_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
C031942_D013921 NONE conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 man_4\NN\9605289 with_5\IN\1740 renal_6\JJ\1740 amyloidosis_7\NN\14061805 and_8\CC\1740 svc_9\NN\1740 syndrome_10\NN\5870365 secondary_11\JJ\1740 to_12\TO\1740 <e2>hitt</e2>_13\NN\1740 was_14\VBD\836236 successfully_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 <e1>argatroban</e1>_18\NN\1740 and_19\CC\1740 cdt_20\NN\1740 with_21\IN\1740 alteplase_22\NN\1740 ._23\.\1740
C031942_D013927 NONE use_0\NN\407535 of_1\IN\1740 <e1>argatroban</e1>_2\NN\1740 and_3\CC\1740 catheter-directed_4\JJ\1740 thrombolysis_5\NN\13509528 with_6\IN\1740 alteplase_7\NN\1740 in_8\IN\13603305 an_9\DT\6697703 oncology_10\NN\6043075 patient_11\NN\9898892 with_12\IN\1740 heparin-induced_13\JJ\1740 thrombocytopenia_14\NN\14189204 with_15\IN\1740 <e2>thrombosis</e2>_16\NN\14100769 ._17\.\1740
C031942_D013927 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 <e2>thrombosis</e2>_13\NN\14100769 (_14\-LRB-\1740 hitt_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>argatroban</e1>_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
C031942_D013927 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 heparin-induced_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 <e2>hitt</e2>_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>argatroban</e1>_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
C031942_D013927 NONE conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 man_4\NN\9605289 with_5\IN\1740 renal_6\JJ\1740 amyloidosis_7\NN\14061805 and_8\CC\1740 svc_9\NN\1740 syndrome_10\NN\5870365 secondary_11\JJ\1740 to_12\TO\1740 <e2>hitt</e2>_13\NN\1740 was_14\VBD\836236 successfully_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 <e1>argatroban</e1>_18\NN\1740 and_19\CC\1740 cdt_20\NN\1740 with_21\IN\1740 alteplase_22\NN\1740 ._23\.\1740
D006493_D055499 NONE use_0\NN\407535 of_1\IN\1740 argatroban_2\NN\1740 and_3\CC\1740 catheter-directed_4\JJ\1740 <e2>thrombolysis</e2>_5\NN\13509528 with_6\IN\1740 alteplase_7\NN\1740 in_8\IN\13603305 an_9\DT\6697703 oncology_10\NN\6043075 patient_11\NN\9898892 with_12\IN\1740 <e1>heparin-induced</e1>_13\JJ\1740 thrombocytopenia_14\NN\14189204 with_15\IN\1740 thrombosis_16\NN\14100769 ._17\.\1740
D006493_D055499 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 hitt_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 argatroban_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 <e2>thrombolysis</e2>_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
D006493_D013921 CID use_0\NN\407535 of_1\IN\1740 argatroban_2\NN\1740 and_3\CC\1740 catheter-directed_4\JJ\1740 thrombolysis_5\NN\13509528 with_6\IN\1740 alteplase_7\NN\1740 in_8\IN\13603305 an_9\DT\6697703 oncology_10\NN\6043075 patient_11\NN\9898892 with_12\IN\1740 <e1>heparin-induced</e1>_13\JJ\1740 <e2>thrombocytopenia</e2>_14\NN\14189204 with_15\IN\1740 thrombosis_16\NN\14100769 ._17\.\1740
D006493_D013921 CID purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 <e1>heparin-induced</e1>_10\JJ\1740 <e2>thrombocytopenia</e2>_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 hitt_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 argatroban_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
D006493_D013921 CID summary_0\NN\6722453 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 caucasian_4\JJ\1740 man_5\NN\9605289 with_6\IN\1740 renal_7\JJ\1740 amyloidosis_8\NN\14061805 undergoing_9\VBG\109660 peripheral_10\JJ\1740 blood_11\NN\5397468 stem_12\NN\6290637 cell_13\NN\3080309 collection_14\NN\31264 for_15\IN\1740 an_16\DT\6697703 autologous_17\JJ\1740 stem_18\NN\6290637 cell_19\NN\3080309 transplant_20\NN\5267548 developed_21\VBD\1753788 extensive_22\JJ\1740 bilateral_23\JJ\1740 upper-extremity_24\NN\1740 deep_25\JJ\1740 venous_26\JJ\1740 thrombosis_27\NN\14100769 (_28\-LRB-\1740 dvt_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pulmonary_32\JJ\1740 embolism_33\NN\15269513 secondary_34\JJ\1740 to_35\TO\1740 <e1>heparin-induced</e1>_36\JJ\1740 <e2>thrombocytopenia</e2>_37\NN\14189204 ._38\.\1740
D006493_D013921 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 <e2>hitt</e2>_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 argatroban_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
D006493_D013927 NONE use_0\NN\407535 of_1\IN\1740 argatroban_2\NN\1740 and_3\CC\1740 catheter-directed_4\JJ\1740 thrombolysis_5\NN\13509528 with_6\IN\1740 alteplase_7\NN\1740 in_8\IN\13603305 an_9\DT\6697703 oncology_10\NN\6043075 patient_11\NN\9898892 with_12\IN\1740 <e1>heparin-induced</e1>_13\JJ\1740 thrombocytopenia_14\NN\14189204 with_15\IN\1740 <e2>thrombosis</e2>_16\NN\14100769 ._17\.\1740
D006493_D013927 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 <e2>thrombosis</e2>_13\NN\14100769 (_14\-LRB-\1740 hitt_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 argatroban_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
D006493_D013927 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 oncology_6\NN\6043075 patient_7\NN\9898892 who_8\WP\8299493 developed_9\VBD\1753788 <e1>heparin-induced</e1>_10\JJ\1740 thrombocytopenia_11\NN\14189204 with_12\IN\1740 thrombosis_13\NN\14100769 (_14\-LRB-\1740 <e2>hitt</e2>_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 was_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 argatroban_21\NN\1740 plus_22\CC\4723816 catheter-directed_23\JJ\1740 thrombolysis_24\NN\13509528 (_25\-LRB-\1740 cdt_26\NN\1740 )_27\-RRB-\1740 with_28\IN\1740 alteplase_29\NN\1740 is_30\VBZ\836236 presented_31\VBN\2137132 ._32\.\1740
D006493_D000686 NONE summary_0\NN\6722453 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 caucasian_4\JJ\1740 man_5\NN\9605289 with_6\IN\1740 renal_7\JJ\1740 <e2>amyloidosis</e2>_8\NN\14061805 undergoing_9\VBG\109660 peripheral_10\JJ\1740 blood_11\NN\5397468 stem_12\NN\6290637 cell_13\NN\3080309 collection_14\NN\31264 for_15\IN\1740 an_16\DT\6697703 autologous_17\JJ\1740 stem_18\NN\6290637 cell_19\NN\3080309 transplant_20\NN\5267548 developed_21\VBD\1753788 extensive_22\JJ\1740 bilateral_23\JJ\1740 upper-extremity_24\NN\1740 deep_25\JJ\1740 venous_26\JJ\1740 thrombosis_27\NN\14100769 (_28\-LRB-\1740 dvt_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pulmonary_32\JJ\1740 embolism_33\NN\15269513 secondary_34\JJ\1740 to_35\TO\1740 <e1>heparin-induced</e1>_36\JJ\1740 thrombocytopenia_37\NN\14189204 ._38\.\1740
D006493_D056824 NONE summary_0\NN\6722453 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 caucasian_4\JJ\1740 man_5\NN\9605289 with_6\IN\1740 renal_7\JJ\1740 amyloidosis_8\NN\14061805 undergoing_9\VBG\109660 peripheral_10\JJ\1740 blood_11\NN\5397468 stem_12\NN\6290637 cell_13\NN\3080309 collection_14\NN\31264 for_15\IN\1740 an_16\DT\6697703 autologous_17\JJ\1740 stem_18\NN\6290637 cell_19\NN\3080309 transplant_20\NN\5267548 developed_21\VBD\1753788 extensive_22\JJ\1740 bilateral_23\JJ\1740 <e2>upper-extremity_24\NN\1740 deep_25\JJ\1740 venous_26\JJ\1740 thrombosis</e2>_27\NN\14100769 (_28\-LRB-\1740 dvt_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pulmonary_32\JJ\1740 embolism_33\NN\15269513 secondary_34\JJ\1740 to_35\TO\1740 <e1>heparin-induced</e1>_36\JJ\1740 thrombocytopenia_37\NN\14189204 ._38\.\1740
D006493_D020246 CID summary_0\NN\6722453 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 caucasian_4\JJ\1740 man_5\NN\9605289 with_6\IN\1740 renal_7\JJ\1740 amyloidosis_8\NN\14061805 undergoing_9\VBG\109660 peripheral_10\JJ\1740 blood_11\NN\5397468 stem_12\NN\6290637 cell_13\NN\3080309 collection_14\NN\31264 for_15\IN\1740 an_16\DT\6697703 autologous_17\JJ\1740 stem_18\NN\6290637 cell_19\NN\3080309 transplant_20\NN\5267548 developed_21\VBD\1753788 extensive_22\JJ\1740 bilateral_23\JJ\1740 upper-extremity_24\NN\1740 deep_25\JJ\1740 venous_26\JJ\1740 thrombosis_27\NN\14100769 (_28\-LRB-\1740 <e2>dvt</e2>_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pulmonary_32\JJ\1740 embolism_33\NN\15269513 secondary_34\JJ\1740 to_35\TO\1740 <e1>heparin-induced</e1>_36\JJ\1740 thrombocytopenia_37\NN\14189204 ._38\.\1740
D006493_D011655 CID summary_0\NN\6722453 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 caucasian_4\JJ\1740 man_5\NN\9605289 with_6\IN\1740 renal_7\JJ\1740 amyloidosis_8\NN\14061805 undergoing_9\VBG\109660 peripheral_10\JJ\1740 blood_11\NN\5397468 stem_12\NN\6290637 cell_13\NN\3080309 collection_14\NN\31264 for_15\IN\1740 an_16\DT\6697703 autologous_17\JJ\1740 stem_18\NN\6290637 cell_19\NN\3080309 transplant_20\NN\5267548 developed_21\VBD\1753788 extensive_22\JJ\1740 bilateral_23\JJ\1740 upper-extremity_24\NN\1740 deep_25\JJ\1740 venous_26\JJ\1740 thrombosis_27\NN\14100769 (_28\-LRB-\1740 dvt_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 <e2>pulmonary_32\JJ\1740 embolism</e2>_33\NN\15269513 secondary_34\JJ\1740 to_35\TO\1740 <e1>heparin-induced</e1>_36\JJ\1740 thrombocytopenia_37\NN\14189204 ._38\.\1740
C031942_D004844 NONE the_0\DT\1740 <e2>epistaxis</e2>_1\NN\14288235 resolved_2\VBD\352826 the_3\DT\1740 next_4\JJ\1740 day_5\NN\15154774 ,_6\,\1740 and_7\CC\1740 the_8\DT\1740 patient_9\NN\9898892 was_10\VBD\836236 restarted_11\VBN\1857717 on_12\IN\1740 <e1>argatroban</e1>_13\NN\1740 ._14\.\1740
C031942_D000686 NONE conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 man_4\NN\9605289 with_5\IN\1740 renal_6\JJ\1740 <e2>amyloidosis</e2>_7\NN\14061805 and_8\CC\1740 svc_9\NN\1740 syndrome_10\NN\5870365 secondary_11\JJ\1740 to_12\TO\1740 hitt_13\NN\1740 was_14\VBD\836236 successfully_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 <e1>argatroban</e1>_18\NN\1740 and_19\CC\1740 cdt_20\NN\1740 with_21\IN\1740 alteplase_22\NN\1740 ._23\.\1740
C031942_D013479 NONE conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 63-year-old_3\JJ\1740 man_4\NN\9605289 with_5\IN\1740 renal_6\JJ\1740 amyloidosis_7\NN\14061805 and_8\CC\1740 <e2>svc_9\NN\1740 syndrome</e2>_10\NN\5870365 secondary_11\JJ\1740 to_12\TO\1740 hitt_13\NN\1740 was_14\VBD\836236 successfully_15\RB\1740 treated_16\VBN\2376958 with_17\IN\1740 <e1>argatroban</e1>_18\NN\1740 and_19\CC\1740 cdt_20\NN\1740 with_21\IN\1740 alteplase_22\NN\1740 ._23\.\1740
24928523
C400082_D009101 NONE combination_0\NN\7951464 of_1\IN\1740 <e1>bortezomib</e1>_2\NN\1740 ,_3\,\1740 thalidomide_4\VBP\1740 ,_5\,\1740 and_6\CC\1740 dexamethasone_7\NN\2721538 (_8\-LRB-\1740 vtd_9\NN\1740 )_10\-RRB-\1740 as_11\IN\14622893 a_12\DT\13649268 consolidation_13\NN\7373803 therapy_14\NN\657604 after_15\IN\1740 autologous_16\JJ\1740 stem_17\NN\6290637 cell_18\NN\3080309 transplantation_19\NN\671351 for_20\IN\1740 symptomatic_21\JJ\1740 <e2>multiple_22\JJ\1740 myeloma</e2>_23\NN\14239425 in_24\IN\13603305 japanese_25\JJ\1740 patients_26\NNS\9898892 ._27\.\1740
C400082_D009101 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 retrospectively_5\RB\1740 analyzed_6\VBD\78760 the_7\DT\1740 safety_8\NN\13920835 and_9\CC\1740 efficacy_10\NN\5199286 of_11\IN\1740 combination_12\NN\7951464 regimen_13\NN\5898568 of_14\IN\1740 <e1>bortezomib</e1>_15\NN\1740 ,_16\,\1740 thalidomide_17\VBP\1740 ,_18\,\1740 and_19\CC\1740 dexamethasone_20\NN\2721538 (_21\-LRB-\1740 vtd_22\NN\1740 )_23\-RRB-\1740 as_24\IN\14622893 consolidation_25\NN\7373803 therapy_26\NN\657604 in_27\IN\13603305 24_28\CD\13745420 japanese_29\JJ\1740 patients_30\NNS\9898892 with_31\IN\1740 newly_32\RB\1740 diagnosed_33\VBN\644583 <e2>mm</e2>_34\NN\13649268 ._35\.\1740
D013792_D009101 NONE combination_0\NN\7951464 of_1\IN\1740 bortezomib_2\NN\1740 ,_3\,\1740 <e1>thalidomide</e1>_4\VBP\1740 ,_5\,\1740 and_6\CC\1740 dexamethasone_7\NN\2721538 (_8\-LRB-\1740 vtd_9\NN\1740 )_10\-RRB-\1740 as_11\IN\14622893 a_12\DT\13649268 consolidation_13\NN\7373803 therapy_14\NN\657604 after_15\IN\1740 autologous_16\JJ\1740 stem_17\NN\6290637 cell_18\NN\3080309 transplantation_19\NN\671351 for_20\IN\1740 symptomatic_21\JJ\1740 <e2>multiple_22\JJ\1740 myeloma</e2>_23\NN\14239425 in_24\IN\13603305 japanese_25\JJ\1740 patients_26\NNS\9898892 ._27\.\1740
D013792_D009101 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 retrospectively_5\RB\1740 analyzed_6\VBD\78760 the_7\DT\1740 safety_8\NN\13920835 and_9\CC\1740 efficacy_10\NN\5199286 of_11\IN\1740 combination_12\NN\7951464 regimen_13\NN\5898568 of_14\IN\1740 bortezomib_15\NN\1740 ,_16\,\1740 <e1>thalidomide</e1>_17\VBP\1740 ,_18\,\1740 and_19\CC\1740 dexamethasone_20\NN\2721538 (_21\-LRB-\1740 vtd_22\NN\1740 )_23\-RRB-\1740 as_24\IN\14622893 consolidation_25\NN\7373803 therapy_26\NN\657604 in_27\IN\13603305 24_28\CD\13745420 japanese_29\JJ\1740 patients_30\NNS\9898892 with_31\IN\1740 newly_32\RB\1740 diagnosed_33\VBN\644583 <e2>mm</e2>_34\NN\13649268 ._35\.\1740
D003907_D009101 NONE combination_0\NN\7951464 of_1\IN\1740 bortezomib_2\NN\1740 ,_3\,\1740 thalidomide_4\VBP\1740 ,_5\,\1740 and_6\CC\1740 <e1>dexamethasone</e1>_7\NN\2721538 (_8\-LRB-\1740 vtd_9\NN\1740 )_10\-RRB-\1740 as_11\IN\14622893 a_12\DT\13649268 consolidation_13\NN\7373803 therapy_14\NN\657604 after_15\IN\1740 autologous_16\JJ\1740 stem_17\NN\6290637 cell_18\NN\3080309 transplantation_19\NN\671351 for_20\IN\1740 symptomatic_21\JJ\1740 <e2>multiple_22\JJ\1740 myeloma</e2>_23\NN\14239425 in_24\IN\13603305 japanese_25\JJ\1740 patients_26\NNS\9898892 ._27\.\1740
D003907_D009101 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 retrospectively_5\RB\1740 analyzed_6\VBD\78760 the_7\DT\1740 safety_8\NN\13920835 and_9\CC\1740 efficacy_10\NN\5199286 of_11\IN\1740 combination_12\NN\7951464 regimen_13\NN\5898568 of_14\IN\1740 bortezomib_15\NN\1740 ,_16\,\1740 thalidomide_17\VBP\1740 ,_18\,\1740 and_19\CC\1740 <e1>dexamethasone</e1>_20\NN\2721538 (_21\-LRB-\1740 vtd_22\NN\1740 )_23\-RRB-\1740 as_24\IN\14622893 consolidation_25\NN\7373803 therapy_26\NN\657604 in_27\IN\13603305 24_28\CD\13745420 japanese_29\JJ\1740 patients_30\NNS\9898892 with_31\IN\1740 newly_32\RB\1740 diagnosed_33\VBN\644583 <e2>mm</e2>_34\NN\13649268 ._35\.\1740
2904523
D004837_D006973 CID support_0\NN\407535 for_1\IN\1740 <e2><e1>adrenaline-hypertension</e1></e2>_2\JJ\1740 hypothesis_3\NN\7162194 :_4\:\1740 18_5\CD\13745420 hour_6\NN\15154774 pressor_7\NN\9190918 effect_8\NN\34213 after_9\IN\1740 6_10\CD\13741022 hours_11\NNS\15118228 adrenaline_12\NN\14807929 infusion_13\NN\14589223 ._14\.\1740
D004837_D006973 CID support_0\NN\407535 for_1\IN\1740 <e2>adrenaline-hypertension</e2>_2\JJ\1740 hypothesis_3\NN\7162194 :_4\:\1740 18_5\CD\13745420 hour_6\NN\15154774 pressor_7\NN\9190918 effect_8\NN\34213 after_9\IN\1740 6_10\CD\13741022 hours_11\NNS\15118228 <e1>adrenaline</e1>_12\NN\14807929 infusion_13\NN\14589223 ._14\.\1740
D004837_D006973 CID these_0\DT\1740 findings_1\NNS\7951464 are_2\VBP\836236 strong_3\JJ\1740 support_4\NN\407535 for_5\IN\1740 the_6\DT\1740 <e2><e1>adrenaline-hypertension</e1></e2>_7\JJ\1740 hypothesis_8\NN\7162194 in_9\IN\13603305 man_10\NN\9605289 ._11\.\1740
24114426
D018817_D003866 CID <e2>depression</e2>_0\NNP\14373582 ,_1\,\1740 impulsiveness_2\NN\4661706 ,_3\,\1740 sleep_4\NN\14034177 ,_5\,\1740 and_6\CC\1740 memory_7\NN\5926676 in_8\IN\13603305 past_9\JJ\1740 and_10\CC\1740 present_11\JJ\1740 polydrug_12\NN\1740 users_13\NNS\7846 of_14\IN\1740 <e1>3,4-methylenedioxymethamphetamine</e1>_15\NN\1740 (_16\-LRB-\1740 mdma_17\NN\3054098 ,_18\,\1740 ecstasy_19\NN\13985818 )_20\-RRB-\1740 ._21\.\1740
D018817_D003866 CID <e2>depression</e2>_0\NNP\14373582 ,_1\,\1740 impulsiveness_2\NN\4661706 ,_3\,\1740 sleep_4\NN\14034177 ,_5\,\1740 and_6\CC\1740 memory_7\NN\5926676 in_8\IN\13603305 past_9\JJ\1740 and_10\CC\1740 present_11\JJ\1740 polydrug_12\NN\1740 users_13\NNS\7846 of_14\IN\1740 3,4-methylenedioxymethamphetamine_15\NN\1740 (_16\-LRB-\1740 <e1>mdma</e1>_17\NN\3054098 ,_18\,\1740 ecstasy_19\NN\13985818 )_20\-RRB-\1740 ._21\.\1740
D018817_D003866 CID <e2>depression</e2>_0\NNP\14373582 ,_1\,\1740 impulsiveness_2\NN\4661706 ,_3\,\1740 sleep_4\NN\14034177 ,_5\,\1740 and_6\CC\1740 memory_7\NN\5926676 in_8\IN\13603305 past_9\JJ\1740 and_10\CC\1740 present_11\JJ\1740 polydrug_12\NN\1740 users_13\NNS\7846 of_14\IN\1740 3,4-methylenedioxymethamphetamine_15\NN\1740 (_16\-LRB-\1740 mdma_17\NN\3054098 ,_18\,\1740 <e1>ecstasy</e1>_19\NN\13985818 )_20\-RRB-\1740 ._21\.\1740
D018817_D003866 CID conclusions_0\NNS\5837957 :_1\:\1740 given_2\VBN\2327200 this_3\DT\1740 record_4\NN\6643408 of_5\IN\1740 impaired_6\JJ\1740 memory_7\NN\5926676 and_8\CC\1740 clinically_9\RB\1740 significant_10\JJ\1740 levels_11\NNS\4916342 of_12\IN\1740 <e2>depression</e2>_13\NN\14373582 ,_14\,\1740 impulsiveness_15\NN\4661706 ,_16\,\1740 and_17\CC\1740 sleep_18\NN\14034177 disturbance_19\NN\407535 ,_20\,\1740 the_21\DT\1740 prognosis_22\NN\6748969 for_23\IN\1740 the_24\DT\1740 current_25\JJ\1740 generation_26\NN\7942152 of_27\IN\1740 <e1>ecstasy</e1>_28\NN\13985818 users_29\NNS\7846 is_30\VBZ\836236 a_31\DT\13649268 major_32\JJ\1740 cause_33\NN\7323922 for_34\IN\1740 concern_35\NN\5682950 ._36\.\1740
D018817_D010554 CID depression_0\NNP\14373582 ,_1\,\1740 <e2>impulsiveness</e2>_2\NN\4661706 ,_3\,\1740 sleep_4\NN\14034177 ,_5\,\1740 and_6\CC\1740 memory_7\NN\5926676 in_8\IN\13603305 past_9\JJ\1740 and_10\CC\1740 present_11\JJ\1740 polydrug_12\NN\1740 users_13\NNS\7846 of_14\IN\1740 <e1>3,4-methylenedioxymethamphetamine</e1>_15\NN\1740 (_16\-LRB-\1740 mdma_17\NN\3054098 ,_18\,\1740 ecstasy_19\NN\13985818 )_20\-RRB-\1740 ._21\.\1740
D018817_D010554 CID depression_0\NNP\14373582 ,_1\,\1740 <e2>impulsiveness</e2>_2\NN\4661706 ,_3\,\1740 sleep_4\NN\14034177 ,_5\,\1740 and_6\CC\1740 memory_7\NN\5926676 in_8\IN\13603305 past_9\JJ\1740 and_10\CC\1740 present_11\JJ\1740 polydrug_12\NN\1740 users_13\NNS\7846 of_14\IN\1740 3,4-methylenedioxymethamphetamine_15\NN\1740 (_16\-LRB-\1740 <e1>mdma</e1>_17\NN\3054098 ,_18\,\1740 ecstasy_19\NN\13985818 )_20\-RRB-\1740 ._21\.\1740
D018817_D010554 CID depression_0\NNP\14373582 ,_1\,\1740 <e2>impulsiveness</e2>_2\NN\4661706 ,_3\,\1740 sleep_4\NN\14034177 ,_5\,\1740 and_6\CC\1740 memory_7\NN\5926676 in_8\IN\13603305 past_9\JJ\1740 and_10\CC\1740 present_11\JJ\1740 polydrug_12\NN\1740 users_13\NNS\7846 of_14\IN\1740 3,4-methylenedioxymethamphetamine_15\NN\1740 (_16\-LRB-\1740 mdma_17\NN\3054098 ,_18\,\1740 <e1>ecstasy</e1>_19\NN\13985818 )_20\-RRB-\1740 ._21\.\1740
D018817_D010554 CID conclusions_0\NNS\5837957 :_1\:\1740 given_2\VBN\2327200 this_3\DT\1740 record_4\NN\6643408 of_5\IN\1740 impaired_6\JJ\1740 memory_7\NN\5926676 and_8\CC\1740 clinically_9\RB\1740 significant_10\JJ\1740 levels_11\NNS\4916342 of_12\IN\1740 depression_13\NN\14373582 ,_14\,\1740 <e2>impulsiveness</e2>_15\NN\4661706 ,_16\,\1740 and_17\CC\1740 sleep_18\NN\14034177 disturbance_19\NN\407535 ,_20\,\1740 the_21\DT\1740 prognosis_22\NN\6748969 for_23\IN\1740 the_24\DT\1740 current_25\JJ\1740 generation_26\NN\7942152 of_27\IN\1740 <e1>ecstasy</e1>_28\NN\13985818 users_29\NNS\7846 is_30\VBZ\836236 a_31\DT\13649268 major_32\JJ\1740 cause_33\NN\7323922 for_34\IN\1740 concern_35\NN\5682950 ._36\.\1740
D018817_D008569 NONE conclusions_0\NNS\5837957 :_1\:\1740 given_2\VBN\2327200 this_3\DT\1740 record_4\NN\6643408 of_5\IN\1740 <e2>impaired_6\JJ\1740 memory</e2>_7\NN\5926676 and_8\CC\1740 clinically_9\RB\1740 significant_10\JJ\1740 levels_11\NNS\4916342 of_12\IN\1740 depression_13\NN\14373582 ,_14\,\1740 impulsiveness_15\NN\4661706 ,_16\,\1740 and_17\CC\1740 sleep_18\NN\14034177 disturbance_19\NN\407535 ,_20\,\1740 the_21\DT\1740 prognosis_22\NN\6748969 for_23\IN\1740 the_24\DT\1740 current_25\JJ\1740 generation_26\NN\7942152 of_27\IN\1740 <e1>ecstasy</e1>_28\NN\13985818 users_29\NNS\7846 is_30\VBZ\836236 a_31\DT\13649268 major_32\JJ\1740 cause_33\NN\7323922 for_34\IN\1740 concern_35\NN\5682950 ._36\.\1740
D018817_D020920 CID conclusions_0\NNS\5837957 :_1\:\1740 given_2\VBN\2327200 this_3\DT\1740 record_4\NN\6643408 of_5\IN\1740 impaired_6\JJ\1740 memory_7\NN\5926676 and_8\CC\1740 clinically_9\RB\1740 significant_10\JJ\1740 levels_11\NNS\4916342 of_12\IN\1740 depression_13\NN\14373582 ,_14\,\1740 impulsiveness_15\NN\4661706 ,_16\,\1740 and_17\CC\1740 <e2>sleep_18\NN\14034177 disturbance</e2>_19\NN\407535 ,_20\,\1740 the_21\DT\1740 prognosis_22\NN\6748969 for_23\IN\1740 the_24\DT\1740 current_25\JJ\1740 generation_26\NN\7942152 of_27\IN\1740 <e1>ecstasy</e1>_28\NN\13985818 users_29\NNS\7846 is_30\VBZ\836236 a_31\DT\13649268 major_32\JJ\1740 cause_33\NN\7323922 for_34\IN\1740 concern_35\NN\5682950 ._36\.\1740
978847
D006145_D006973 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 <e1>guanethidine</e1>_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 <e2>enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure</e2>_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 tachycardia_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D006145_D013610 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 <e1>guanethidine</e1>_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 <e2>tachycardia</e2>_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D018738_D006973 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 <e1>hexamethonium</e1>_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 <e2>enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure</e2>_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 tachycardia_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D018738_D013610 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 <e1>hexamethonium</e1>_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 <e2>tachycardia</e2>_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D010646_D006973 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 <e1>phentolamine</e1>_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 <e2>enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure</e2>_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 tachycardia_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D010646_D013610 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 <e1>phentolamine</e1>_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 <e2>tachycardia</e2>_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D003891_D006973 CID this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 <e1>desmethylimipramine</e1>_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 <e2>enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure</e2>_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 tachycardia_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D003891_D013610 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 <e1>desmethylimipramine</e1>_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 <e2>tachycardia</e2>_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D011433_D006973 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 <e1>propranolol</e1>_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 <e2>enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure</e2>_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 tachycardia_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D011433_D013610 NONE this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 <e1>propranolol</e1>_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 <e2>tachycardia</e2>_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 carbachol_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D002217_D006973 CID this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 <e2>enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure</e2>_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 tachycardia_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 <e1>carbachol</e1>_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
D002217_D013610 CID this_0\DT\1740 response_1\NN\11410625 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 by_5\IN\1740 the_6\DT\1740 intravenous_7\JJ\1740 (_8\-LRB-\1740 i.v._9\NN\1740 )_10\-RRB-\1740 injection_11\NN\320852 of_12\IN\1740 guanethidine_13\NN\1740 (_14\-LRB-\1740 5_15\CD\13741022 mg_16\NN\13717155 )_17\-RRB-\1740 ,_18\,\1740 hexamethonium_19\NN\1740 (_20\-LRB-\1740 10_21\CD\13745420 mg_22\NN\13717155 )_23\-RRB-\1740 or_24\CC\3541091 phentolamine_25\NN\4537602 (_26\-LRB-\1740 5_27\CD\13741022 mg_28\NN\13717155 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 conversely_32\RB\1740 ,_33\,\1740 potentiated_34\VBD\229605 by_35\IN\1740 i.v._36\NN\1740 desmethylimipramine_37\NN\1740 (_38\-LRB-\1740 0.3_39\CD\1740 mg_40\NN\13717155 )_41\-RRB-\1740 ,_42\,\1740 while_43\IN\15122231 propranolol_44\NN\1740 (_45\-LRB-\1740 0.5_46\CD\1740 mg_47\NN\13717155 )_48\-RRB-\1740 i.v._49\RBR\1740 selectively_50\RB\1740 inhibited_51\VBD\2510337 the_52\DT\1740 enlargement_53\NN\363260 of_54\IN\1740 pulse_55\NN\7345593 pressure_56\NN\11419404 and_57\CC\1740 the_58\DT\1740 <e2>tachycardia</e2>_59\NN\14110674 following_60\VBG\1835496 i.c._61\JJ\1740 <e1>carbachol</e1>_62\NN\1740 (_63\-LRB-\1740 1_64\CD\13741022 mug_65\NN\13756125 )_66\-RRB-\1740 ._67\.\1740
8392553
C056595_D006331 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>clentiazem</e1>_3\NN\1740 against_4\IN\1740 epinephrine-induced_5\JJ\1740 <e2>cardiac_6\JJ\1740 injury</e2>_7\NN\14052046 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
C056595_D006331 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>clentiazem</e1>_3\NN\1740 attenuated_4\VBD\224901 epinephrine-induced_5\JJ\1740 <e2>cardiac_6\JJ\1740 injury</e2>_7\NN\14052046 ,_8\,\1740 possibly_9\RB\1740 through_10\IN\1740 its_11\PRP$\6125041 effect_12\NN\34213 on_13\IN\1740 the_14\DT\1740 adrenergic_15\JJ\1740 pathway_16\NN\5483677 ._17\.\1740
D004837_D006331 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 clentiazem_3\NN\1740 against_4\IN\1740 <e1>epinephrine-induced</e1>_5\JJ\1740 <e2>cardiac_6\JJ\1740 injury</e2>_7\NN\14052046 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
D004837_D006331 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 clentiazem_3\NN\1740 attenuated_4\VBD\224901 <e1>epinephrine-induced</e1>_5\JJ\1740 <e2>cardiac_6\JJ\1740 injury</e2>_7\NN\14052046 ,_8\,\1740 possibly_9\RB\1740 through_10\IN\1740 its_11\PRP$\6125041 effect_12\NN\34213 on_13\IN\1740 the_14\DT\1740 adrenergic_15\JJ\1740 pathway_16\NN\5483677 ._17\.\1740
C056595_D009202 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>clentiazem</e1>_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 1,5-benzothiazepine_8\NN\1740 calcium_9\NN\14625458 antagonist_10\NN\7846 ,_11\,\1740 on_12\IN\1740 epinephrine-induced_13\JJ\1740 <e2>cardiomyopathy</e2>_14\NN\14103288 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
C106746_D009202 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 clentiazem_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 <e1>1,5-benzothiazepine</e1>_8\NN\1740 calcium_9\NN\14625458 antagonist_10\NN\7846 ,_11\,\1740 on_12\IN\1740 epinephrine-induced_13\JJ\1740 <e2>cardiomyopathy</e2>_14\NN\14103288 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D002118_D009202 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 clentiazem_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 1,5-benzothiazepine_8\NN\1740 <e1>calcium</e1>_9\NN\14625458 antagonist_10\NN\7846 ,_11\,\1740 on_12\IN\1740 epinephrine-induced_13\JJ\1740 <e2>cardiomyopathy</e2>_14\NN\14103288 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D004837_D009202 CID we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 clentiazem_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 1,5-benzothiazepine_8\NN\1740 calcium_9\NN\14625458 antagonist_10\NN\7846 ,_11\,\1740 on_12\IN\1740 <e1>epinephrine-induced</e1>_13\JJ\1740 <e2>cardiomyopathy</e2>_14\NN\14103288 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D004837_D007511 NONE with_0\IN\1740 2-week_1\JJ\1740 chronic_2\JJ\1740 <e1>epinephrine</e1>_3\NN\14807929 infusion_4\NN\14589223 ,_5\,\1740 16_6\CD\13745420 of_7\IN\1740 30_8\CD\13745420 rats_9\NNS\2329401 died_10\VBD\146138 within_11\IN\1740 4_12\CD\13741022 days_13\NNS\15140892 ,_14\,\1740 and_15\CC\1740 severe_16\JJ\1740 <e2>ischemic_17\JJ\1740 lesions</e2>_18\NNS\14204950 and_19\CC\1740 fibrosis_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 left_23\JJ\1740 ventricles_24\NNS\5303402 were_25\VBD\836236 observed_26\VBN\2163746 ._27\.\1740
D004837_D007511 NONE treatment_0\NN\654885 with_1\IN\1740 clentiazem_2\NN\1740 prevented_3\VBD\1740 <e1>epinephrine-induced</e1>_4\JJ\1740 death_5\NN\7296428 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 .05_9\CD\1740 )_10\-RRB-\1740 ,_11\,\1740 and_12\CC\1740 attenuated_13\VBD\224901 the_14\DT\1740 ventricular_15\JJ\1740 <e2>ischemic_16\JJ\1740 lesions</e2>_17\NNS\14204950 and_18\CC\1740 fibrosis_19\NN\14204950 ,_20\,\1740 in_21\IN\13603305 a_22\DT\13649268 dose-dependent_23\JJ\1740 manner_24\NN\4916342 ._25\.\1740
D004837_D005355 NONE with_0\IN\1740 2-week_1\JJ\1740 chronic_2\JJ\1740 <e1>epinephrine</e1>_3\NN\14807929 infusion_4\NN\14589223 ,_5\,\1740 16_6\CD\13745420 of_7\IN\1740 30_8\CD\13745420 rats_9\NNS\2329401 died_10\VBD\146138 within_11\IN\1740 4_12\CD\13741022 days_13\NNS\15140892 ,_14\,\1740 and_15\CC\1740 severe_16\JJ\1740 ischemic_17\JJ\1740 lesions_18\NNS\14204950 and_19\CC\1740 <e2>fibrosis</e2>_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 left_23\JJ\1740 ventricles_24\NNS\5303402 were_25\VBD\836236 observed_26\VBN\2163746 ._27\.\1740
D004837_D005355 NONE treatment_0\NN\654885 with_1\IN\1740 clentiazem_2\NN\1740 prevented_3\VBD\1740 <e1>epinephrine-induced</e1>_4\JJ\1740 death_5\NN\7296428 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 .05_9\CD\1740 )_10\-RRB-\1740 ,_11\,\1740 and_12\CC\1740 attenuated_13\VBD\224901 the_14\DT\1740 ventricular_15\JJ\1740 ischemic_16\JJ\1740 lesions_17\NNS\14204950 and_18\CC\1740 <e2>fibrosis</e2>_19\NN\14204950 ,_20\,\1740 in_21\IN\13603305 a_22\DT\13649268 dose-dependent_23\JJ\1740 manner_24\NN\4916342 ._25\.\1740
C056595_D007511 NONE treatment_0\NN\654885 with_1\IN\1740 <e1>clentiazem</e1>_2\NN\1740 prevented_3\VBD\1740 epinephrine-induced_4\JJ\1740 death_5\NN\7296428 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 .05_9\CD\1740 )_10\-RRB-\1740 ,_11\,\1740 and_12\CC\1740 attenuated_13\VBD\224901 the_14\DT\1740 ventricular_15\JJ\1740 <e2>ischemic_16\JJ\1740 lesions</e2>_17\NNS\14204950 and_18\CC\1740 fibrosis_19\NN\14204950 ,_20\,\1740 in_21\IN\13603305 a_22\DT\13649268 dose-dependent_23\JJ\1740 manner_24\NN\4916342 ._25\.\1740
C056595_D005355 NONE treatment_0\NN\654885 with_1\IN\1740 <e1>clentiazem</e1>_2\NN\1740 prevented_3\VBD\1740 epinephrine-induced_4\JJ\1740 death_5\NN\7296428 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 .05_9\CD\1740 )_10\-RRB-\1740 ,_11\,\1740 and_12\CC\1740 attenuated_13\VBD\224901 the_14\DT\1740 ventricular_15\JJ\1740 ischemic_16\JJ\1740 lesions_17\NNS\14204950 and_18\CC\1740 <e2>fibrosis</e2>_19\NN\14204950 ,_20\,\1740 in_21\IN\13603305 a_22\DT\13649268 dose-dependent_23\JJ\1740 manner_24\NN\4916342 ._25\.\1740
7369302
D011803_D000550 CID abnormalities_0\NNS\14034177 of_1\IN\1740 the_2\DT\1740 pupil_3\NN\10059162 and_4\CC\1740 visual-evoked_5\JJ\1740 potential_6\NN\14481929 in_7\IN\13603305 <e1>quinine</e1>_8\NN\2721948 <e2>amblyopia</e2>_9\NN\14552802 ._10\.\1740
D011803_D001766 CID total_0\JJ\1740 <e2>blindness</e2>_1\NN\14552802 with_2\IN\1740 a_3\DT\13649268 transient_4\JJ\1740 tonic_5\JJ\1740 pupillary_6\JJ\1740 response_7\NN\11410625 ,_8\,\1740 denervation_9\NN\1740 supersensitivity_10\NN\1740 ,_11\,\1740 and_12\CC\1740 abnormal_13\JJ\1740 visual-evoked_14\JJ\1740 potentials_15\NNS\14481929 developed_16\VBD\1753788 in_17\IN\13603305 a_18\DT\13649268 54-year-old_19\JJ\1740 man_20\NN\9605289 after_21\IN\1740 the_22\DT\1740 use_23\NN\407535 of_24\IN\1740 <e1>quinine_25\NN\2721948 sulfate</e1>_26\NN\15010703 for_27\IN\1740 leg_28\NN\5560244 cramps_29\NNS\14299637 ._30\.\1740
D011803_D015845 CID total_0\JJ\1740 blindness_1\NN\14552802 with_2\IN\1740 a_3\DT\13649268 transient_4\JJ\1740 <e2>tonic_5\JJ\1740 pupillary</e2>_6\JJ\1740 response_7\NN\11410625 ,_8\,\1740 denervation_9\NN\1740 supersensitivity_10\NN\1740 ,_11\,\1740 and_12\CC\1740 abnormal_13\JJ\1740 visual-evoked_14\JJ\1740 potentials_15\NNS\14481929 developed_16\VBD\1753788 in_17\IN\13603305 a_18\DT\13649268 54-year-old_19\JJ\1740 man_20\NN\9605289 after_21\IN\1740 the_22\DT\1740 use_23\NN\407535 of_24\IN\1740 <e1>quinine_25\NN\2721948 sulfate</e1>_26\NN\15010703 for_27\IN\1740 leg_28\NN\5560244 cramps_29\NNS\14299637 ._30\.\1740
D011803_D015845 CID a_0\DT\13649268 transient_1\JJ\1740 <e2>tonic_2\JJ\1740 pupillary</e2>_3\JJ\1740 response_4\NN\11410625 ,_5\,\1740 denervation_6\NN\1740 supersensitivity_7\NN\1740 ,_8\,\1740 and_9\CC\1740 abnormal_10\JJ\1740 visual-evoked_11\JJ\1740 potentials_12\NNS\14481929 in_13\IN\13603305 <e1>quinine</e1>_14\NN\2721948 toxicity_15\NN\13576101 ,_16\,\1740 to_17\IN\1740 our_18\PRP$\1740 knowledge_19\NN\23100 ,_20\,\1740 have_21\VBP\2108377 not_22\RB\1740 been_23\VBN\836236 previously_24\RB\1740 reported_25\VBN\831651 ._26\.\1740
D011803_D009120 NONE total_0\JJ\1740 blindness_1\NN\14552802 with_2\IN\1740 a_3\DT\13649268 transient_4\JJ\1740 tonic_5\JJ\1740 pupillary_6\JJ\1740 response_7\NN\11410625 ,_8\,\1740 denervation_9\NN\1740 supersensitivity_10\NN\1740 ,_11\,\1740 and_12\CC\1740 abnormal_13\JJ\1740 visual-evoked_14\JJ\1740 potentials_15\NNS\14481929 developed_16\VBD\1753788 in_17\IN\13603305 a_18\DT\13649268 54-year-old_19\JJ\1740 man_20\NN\9605289 after_21\IN\1740 the_22\DT\1740 use_23\NN\407535 of_24\IN\1740 <e1>quinine_25\NN\2721948 sulfate</e1>_26\NN\15010703 for_27\IN\1740 <e2>leg_28\NN\5560244 cramps</e2>_29\NNS\14299637 ._30\.\1740
D011803_D064420 NONE a_0\DT\13649268 transient_1\JJ\1740 tonic_2\JJ\1740 pupillary_3\JJ\1740 response_4\NN\11410625 ,_5\,\1740 denervation_6\NN\1740 supersensitivity_7\NN\1740 ,_8\,\1740 and_9\CC\1740 abnormal_10\JJ\1740 visual-evoked_11\JJ\1740 potentials_12\NNS\14481929 in_13\IN\13603305 <e1>quinine</e1>_14\NN\2721948 <e2>toxicity</e2>_15\NN\13576101 ,_16\,\1740 to_17\IN\1740 our_18\PRP$\1740 knowledge_19\NN\23100 ,_20\,\1740 have_21\VBP\2108377 not_22\RB\1740 been_23\VBN\836236 previously_24\RB\1740 reported_25\VBN\831651 ._26\.\1740
3812624
D002220_D009759 NONE two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>downbeat_3\JJ\1740 nystagmus</e2>_4\NN\337486 and_5\CC\1740 oscillopsia_6\NN\1740 associated_7\VBN\628491 with_8\IN\1740 <e1>carbamazepine</e1>_9\NN\1740 ._10\.\1740
D002220_D009759 NONE we_0\PRP\1740 recorded_1\VBD\2225492 the_2\DT\1740 eye_3\NN\5299178 movements_4\NNS\191142 of_5\IN\1740 two_6\CD\13741022 patients_7\NNS\9898892 with_8\IN\1740 reversible_9\JJ\1740 <e2>downbeat_10\JJ\1740 nystagmus</e2>_11\NN\337486 related_12\JJ\1740 to_13\TO\1740 <e1>carbamazepine</e1>_14\NN\1740 therapy_15\NN\657604 ._16\.\1740
D002220_D009759 NONE the_0\DT\1740 <e2>nystagmus</e2>_1\NN\337486 of_2\IN\1740 both_3\DT\1740 patients_4\NNS\9898892 resolved_5\VBN\352826 after_6\IN\1740 reduction_7\NN\351485 of_8\IN\1740 the_9\DT\1740 serum_10\NN\5397468 <e1>carbamazepine</e1>_11\NN\1740 levels_12\NNS\4916342 ._13\.\1740
D002220_D015835 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 downbeat_3\JJ\1740 nystagmus_4\NN\337486 and_5\CC\1740 <e2>oscillopsia</e2>_6\NN\1740 associated_7\VBN\628491 with_8\IN\1740 <e1>carbamazepine</e1>_9\NN\1740 ._10\.\1740
3798047
D008775_D001919 CID <e2>bradycardia</e2>_0\NN\14110674 after_1\IN\1740 high-dose_2\JJ\1740 intravenous_3\JJ\1740 <e1>methylprednisolone</e1>_4\NN\1740 therapy_5\NN\657604 ._6\.\1740
D008775_D001172 NONE in_0\IN\13603305 5_1\CD\13741022 consecutive_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 <e2>rheumatoid_5\JJ\1740 arthritis</e2>_6\NN\14171682 who_7\WP\8299493 received_8\VBD\2210855 intravenous_9\JJ\1740 high-dose_10\JJ\1740 <e1>methylprednisolone</e1>_11\NN\1740 (_12\-LRB-\1740 mp_13\NN\10249459 )_14\-RRB-\1740 therapy_15\NN\657604 (_16\-LRB-\1740 1_17\CD\13741022 g_18\NN\13717155 daily_19\RB\1740 for_20\IN\1740 2_21\CD\13741022 or_22\CC\3541091 3_23\CD\13741022 consecutive_24\JJ\1740 days_25\NNS\15140892 )_26\-RRB-\1740 ,_27\,\1740 a_28\DT\13649268 decline_29\NN\13458571 in_30\IN\13603305 pulse_31\NN\7345593 rate_32\NN\13815152 was_33\VBD\836236 observed_34\VBN\2163746 ,_35\,\1740 most_36\RBS\1740 pronounced_37\VBN\822367 on_38\IN\1740 day_39\NN\15154774 4_40\CD\13741022 ._41\.\1740
D008775_D001172 NONE in_0\IN\13603305 5_1\CD\13741022 consecutive_2\JJ\1740 patients_3\NNS\9898892 with_4\IN\1740 <e2>rheumatoid_5\JJ\1740 arthritis</e2>_6\NN\14171682 who_7\WP\8299493 received_8\VBD\2210855 intravenous_9\JJ\1740 high-dose_10\JJ\1740 methylprednisolone_11\NN\1740 (_12\-LRB-\1740 <e1>mp</e1>_13\NN\10249459 )_14\-RRB-\1740 therapy_15\NN\657604 (_16\-LRB-\1740 1_17\CD\13741022 g_18\NN\13717155 daily_19\RB\1740 for_20\IN\1740 2_21\CD\13741022 or_22\CC\3541091 3_23\CD\13741022 consecutive_24\JJ\1740 days_25\NNS\15140892 )_26\-RRB-\1740 ,_27\,\1740 a_28\DT\13649268 decline_29\NN\13458571 in_30\IN\13603305 pulse_31\NN\7345593 rate_32\NN\13815152 was_33\VBD\836236 observed_34\VBN\2163746 ,_35\,\1740 most_36\RBS\1740 pronounced_37\VBN\822367 on_38\IN\1740 day_39\NN\15154774 4_40\CD\13741022 ._41\.\1740
D008775_D006331 NONE high-dose_0\JJ\1740 <e1>mp</e1>_1\NN\10249459 may_2\MD\15209706 be_3\VB\836236 contraindicated_4\VBN\872886 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 known_8\JJ\1740 <e2>heart_9\NN\5919034 disease</e2>_10\NN\14061805 ._11\.\1740
17721298
D016578_D003320 CID <e2>corneal_0\NN\1740 ulcers</e2>_1\NNS\14211294 associated_2\VBN\628491 with_3\IN\1740 aerosolized_4\JJ\1740 <e1>crack_5\NN\9379111 cocaine</e1>_6\NN\3492717 use_7\NN\407535 ._8\.\1740
D016578_D003320 CID results_0\NNS\34213 :_1\:\1740 four_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 <e2>corneal_5\NN\1740 ulcers</e2>_6\NNS\14211294 associated_7\VBN\628491 with_8\IN\1740 <e1>crack_9\NN\9379111 cocaine</e1>_10\NN\3492717 use_11\NN\407535 were_12\VBD\836236 reviewed_13\VBN\644583 ._14\.\1740
D016578_D003320 CID conclusions_0\NNS\5837957 :_1\:\1740 aerosolized_2\VBN\1376245 <e1>crack_3\NN\9379111 cocaine</e1>_4\NN\3492717 use_5\NN\407535 can_6\MD\3094503 be_7\VB\836236 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 development_11\NN\248977 of_12\IN\1740 <e2>corneal_13\NN\1740 ulcers</e2>_14\NNS\14211294 ._15\.\1740
1655018
D000728_D006528 CID <e2>hepatocellular_0\JJ\1740 carcinoma</e2>_1\NN\14239918 in_2\IN\13603305 fanconi_3\NNP\1740 's_4\POS\1740 anemia_5\NN\14189204 treated_6\VBN\2376958 with_7\IN\1740 <e1>androgen</e1>_8\NN\14745635 and_9\CC\1740 corticosteroid_10\NN\14745635 ._11\.\1740
D000728_D005199 NONE hepatocellular_0\JJ\1740 carcinoma_1\NN\14239918 in_2\IN\13603305 <e2>fanconi_3\NNP\1740 's_4\POS\1740 anemia</e2>_5\NN\14189204 treated_6\VBN\2376958 with_7\IN\1740 <e1>androgen</e1>_8\NN\14745635 and_9\CC\1740 corticosteroid_10\NN\14745635 ._11\.\1740
D000728_D005199 NONE the_0\DT\1740 case_1\NN\7283608 of_2\IN\1740 an_3\DT\6697703 11-year-old_4\JJ\1740 boy_5\NN\9624168 is_6\VBZ\836236 reported_7\VBN\831651 who_8\WP\8299493 was_9\VBD\836236 known_10\VBN\2110220 to_11\TO\1740 have_12\VB\2108377 <e2>fanconi_13\NNP\1740 's_14\POS\1740 anemia</e2>_15\NN\14189204 for_16\IN\1740 3_17\CD\13741022 years_18\NNS\15144371 and_19\CC\1740 was_20\VBD\836236 treated_21\VBN\2376958 with_22\IN\1740 <e1>androgens</e1>_23\NNS\14745635 ,_24\,\1740 corticosteroids_25\NNS\14745635 and_26\CC\1740 transfusions_27\NNS\320852 ._28\.\1740
D000728_D005199 NONE this_0\DT\1740 case_1\NN\7283608 contributes_2\VBZ\126264 to_3\TO\1740 the_4\DT\1740 previous_5\JJ\1740 observations_6\NNS\996969 that_7\IN\1740 non-metastasizing_8\JJ\1740 hepatic_9\JJ\1740 neoplasms_10\NNS\14234074 and_11\CC\1740 peliosis_12\NN\14189204 can_13\MD\3094503 develop_14\VB\1753788 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e1>androgen-</e1>_18\NN\1740 and_19\CC\1740 corticosteroid-treated_20\JJ\1740 <e2>fanconi_21\NNP\1740 's_22\POS\1740 anemia</e2>_23\NN\14189204 ._24\.\1740
D000305_D006528 CID <e2>hepatocellular_0\JJ\1740 carcinoma</e2>_1\NN\14239918 in_2\IN\13603305 fanconi_3\NNP\1740 's_4\POS\1740 anemia_5\NN\14189204 treated_6\VBN\2376958 with_7\IN\1740 androgen_8\NN\14745635 and_9\CC\1740 <e1>corticosteroid</e1>_10\NN\14745635 ._11\.\1740
D000305_D005199 NONE hepatocellular_0\JJ\1740 carcinoma_1\NN\14239918 in_2\IN\13603305 <e2>fanconi_3\NNP\1740 's_4\POS\1740 anemia</e2>_5\NN\14189204 treated_6\VBN\2376958 with_7\IN\1740 androgen_8\NN\14745635 and_9\CC\1740 <e1>corticosteroid</e1>_10\NN\14745635 ._11\.\1740
D000305_D005199 NONE the_0\DT\1740 case_1\NN\7283608 of_2\IN\1740 an_3\DT\6697703 11-year-old_4\JJ\1740 boy_5\NN\9624168 is_6\VBZ\836236 reported_7\VBN\831651 who_8\WP\8299493 was_9\VBD\836236 known_10\VBN\2110220 to_11\TO\1740 have_12\VB\2108377 <e2>fanconi_13\NNP\1740 's_14\POS\1740 anemia</e2>_15\NN\14189204 for_16\IN\1740 3_17\CD\13741022 years_18\NNS\15144371 and_19\CC\1740 was_20\VBD\836236 treated_21\VBN\2376958 with_22\IN\1740 androgens_23\NNS\14745635 ,_24\,\1740 <e1>corticosteroids</e1>_25\NNS\14745635 and_26\CC\1740 transfusions_27\NNS\320852 ._28\.\1740
D000305_D005199 NONE this_0\DT\1740 case_1\NN\7283608 contributes_2\VBZ\126264 to_3\TO\1740 the_4\DT\1740 previous_5\JJ\1740 observations_6\NNS\996969 that_7\IN\1740 non-metastasizing_8\JJ\1740 hepatic_9\JJ\1740 neoplasms_10\NNS\14234074 and_11\CC\1740 peliosis_12\NN\14189204 can_13\MD\3094503 develop_14\VB\1753788 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 androgen-_18\NN\1740 and_19\CC\1740 <e1>corticosteroid-treated</e1>_20\JJ\1740 <e2>fanconi_21\NNP\1740 's_22\POS\1740 anemia</e2>_23\NN\14189204 ._24\.\1740
D000728_D008113 NONE this_0\DT\1740 case_1\NN\7283608 contributes_2\VBZ\126264 to_3\TO\1740 the_4\DT\1740 previous_5\JJ\1740 observations_6\NNS\996969 that_7\IN\1740 non-metastasizing_8\JJ\1740 <e2>hepatic_9\JJ\1740 neoplasms</e2>_10\NNS\14234074 and_11\CC\1740 peliosis_12\NN\14189204 can_13\MD\3094503 develop_14\VB\1753788 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e1>androgen-</e1>_18\NN\1740 and_19\CC\1740 corticosteroid-treated_20\JJ\1740 fanconi_21\NNP\1740 's_22\POS\1740 anemia_23\NN\14189204 ._24\.\1740
D000728_D010382 CID this_0\DT\1740 case_1\NN\7283608 contributes_2\VBZ\126264 to_3\TO\1740 the_4\DT\1740 previous_5\JJ\1740 observations_6\NNS\996969 that_7\IN\1740 non-metastasizing_8\JJ\1740 hepatic_9\JJ\1740 neoplasms_10\NNS\14234074 and_11\CC\1740 <e2>peliosis</e2>_12\NN\14189204 can_13\MD\3094503 develop_14\VB\1753788 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e1>androgen-</e1>_18\NN\1740 and_19\CC\1740 corticosteroid-treated_20\JJ\1740 fanconi_21\NNP\1740 's_22\POS\1740 anemia_23\NN\14189204 ._24\.\1740
D000305_D008113 NONE this_0\DT\1740 case_1\NN\7283608 contributes_2\VBZ\126264 to_3\TO\1740 the_4\DT\1740 previous_5\JJ\1740 observations_6\NNS\996969 that_7\IN\1740 non-metastasizing_8\JJ\1740 <e2>hepatic_9\JJ\1740 neoplasms</e2>_10\NNS\14234074 and_11\CC\1740 peliosis_12\NN\14189204 can_13\MD\3094503 develop_14\VB\1753788 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 androgen-_18\NN\1740 and_19\CC\1740 <e1>corticosteroid-treated</e1>_20\JJ\1740 fanconi_21\NNP\1740 's_22\POS\1740 anemia_23\NN\14189204 ._24\.\1740
D000305_D010382 CID this_0\DT\1740 case_1\NN\7283608 contributes_2\VBZ\126264 to_3\TO\1740 the_4\DT\1740 previous_5\JJ\1740 observations_6\NNS\996969 that_7\IN\1740 non-metastasizing_8\JJ\1740 hepatic_9\JJ\1740 neoplasms_10\NNS\14234074 and_11\CC\1740 <e2>peliosis</e2>_12\NN\14189204 can_13\MD\3094503 develop_14\VB\1753788 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 androgen-_18\NN\1740 and_19\CC\1740 <e1>corticosteroid-treated</e1>_20\JJ\1740 fanconi_21\NNP\1740 's_22\POS\1740 anemia_23\NN\14189204 ._24\.\1740
10975596
C118667_D009203 NONE hemodynamic_0\JJ\1740 and_1\CC\1740 antiadrenergic_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>dronedarone</e1>_5\NN\1740 and_6\CC\1740 amiodarone_7\JJ\1740 in_8\IN\13603305 animals_9\NNS\4475 with_10\IN\1740 a_11\DT\13649268 healed_12\VBN\205046 <e2>myocardial_13\JJ\1740 infarction</e2>_14\NN\14204950 ._15\.\1740
C118667_D009203 NONE the_0\DT\1740 hemodynamic_1\JJ\1740 and_2\CC\1740 antiadrenergic_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>dronedarone</e1>_6\NN\1740 ,_7\,\1740 a_8\DT\13649268 noniodinated_9\JJ\1740 compound_10\NN\5869584 structurally_11\RB\1740 related_12\JJ\1740 to_13\TO\1740 amiodarone_14\NN\2715941 ,_15\,\1740 were_16\VBD\836236 compared_17\VBN\644583 with_18\IN\1740 those_19\DT\1740 of_20\IN\1740 amiodarone_21\NN\2715941 after_22\IN\1740 prolonged_23\JJ\1740 oral_24\JJ\1740 administration_25\NN\1133281 ,_26\,\1740 both_27\CC\1740 at_28\IN\14622893 rest_29\NN\13809207 and_30\CC\1740 during_31\IN\1740 sympathetic_32\JJ\1740 stimulation_33\NN\242808 in_34\IN\13603305 conscious_35\JJ\1740 dogs_36\NNS\2083346 with_37\IN\1740 a_38\DT\13649268 healed_39\VBN\205046 <e2>myocardial_40\JJ\1740 infarction</e2>_41\NN\14204950 ._42\.\1740
D000638_D009203 NONE hemodynamic_0\JJ\1740 and_1\CC\1740 antiadrenergic_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 dronedarone_5\NN\1740 and_6\CC\1740 <e1>amiodarone</e1>_7\JJ\1740 in_8\IN\13603305 animals_9\NNS\4475 with_10\IN\1740 a_11\DT\13649268 healed_12\VBN\205046 <e2>myocardial_13\JJ\1740 infarction</e2>_14\NN\14204950 ._15\.\1740
D000638_D009203 NONE the_0\DT\1740 hemodynamic_1\JJ\1740 and_2\CC\1740 antiadrenergic_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 dronedarone_6\NN\1740 ,_7\,\1740 a_8\DT\13649268 noniodinated_9\JJ\1740 compound_10\NN\5869584 structurally_11\RB\1740 related_12\JJ\1740 to_13\TO\1740 <e1>amiodarone</e1>_14\NN\2715941 ,_15\,\1740 were_16\VBD\836236 compared_17\VBN\644583 with_18\IN\1740 those_19\DT\1740 of_20\IN\1740 amiodarone_21\NN\2715941 after_22\IN\1740 prolonged_23\JJ\1740 oral_24\JJ\1740 administration_25\NN\1133281 ,_26\,\1740 both_27\CC\1740 at_28\IN\14622893 rest_29\NN\13809207 and_30\CC\1740 during_31\IN\1740 sympathetic_32\JJ\1740 stimulation_33\NN\242808 in_34\IN\13603305 conscious_35\JJ\1740 dogs_36\NNS\2083346 with_37\IN\1740 a_38\DT\13649268 healed_39\VBN\205046 <e2>myocardial_40\JJ\1740 infarction</e2>_41\NN\14204950 ._42\.\1740
D000638_D009203 NONE the_0\DT\1740 hemodynamic_1\JJ\1740 and_2\CC\1740 antiadrenergic_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 dronedarone_6\NN\1740 ,_7\,\1740 a_8\DT\13649268 noniodinated_9\JJ\1740 compound_10\NN\5869584 structurally_11\RB\1740 related_12\JJ\1740 to_13\TO\1740 amiodarone_14\NN\2715941 ,_15\,\1740 were_16\VBD\836236 compared_17\VBN\644583 with_18\IN\1740 those_19\DT\1740 of_20\IN\1740 <e1>amiodarone</e1>_21\NN\2715941 after_22\IN\1740 prolonged_23\JJ\1740 oral_24\JJ\1740 administration_25\NN\1133281 ,_26\,\1740 both_27\CC\1740 at_28\IN\14622893 rest_29\NN\13809207 and_30\CC\1740 during_31\IN\1740 sympathetic_32\JJ\1740 stimulation_33\NN\242808 in_34\IN\13603305 conscious_35\JJ\1740 dogs_36\NNS\2083346 with_37\IN\1740 a_38\DT\13649268 healed_39\VBN\205046 <e2>myocardial_40\JJ\1740 infarction</e2>_41\NN\14204950 ._42\.\1740
C118667_D013610 NONE both_0\CC\1740 <e1>dronedarone</e1>_1\NN\1740 and_2\CC\1740 amiodarone_3\NN\2715941 significantly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 exercise-induced_7\JJ\1740 <e2>tachycardia</e2>_8\NN\14110674 and_9\CC\1740 ,_10\,\1740 at_11\IN\14622893 the_12\DT\1740 highest_13\JJS\1740 dose_14\NN\3740161 ,_15\,\1740 decreased_16\VBD\169651 the_17\DT\1740 isoproterenol-induced_18\JJ\1740 tachycardia_19\NN\14110674 ._20\.\1740
C118667_D013610 NONE both_0\CC\1740 <e1>dronedarone</e1>_1\NN\1740 and_2\CC\1740 amiodarone_3\NN\2715941 significantly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 exercise-induced_7\JJ\1740 tachycardia_8\NN\14110674 and_9\CC\1740 ,_10\,\1740 at_11\IN\14622893 the_12\DT\1740 highest_13\JJS\1740 dose_14\NN\3740161 ,_15\,\1740 decreased_16\VBD\169651 the_17\DT\1740 isoproterenol-induced_18\JJ\1740 <e2>tachycardia</e2>_19\NN\14110674 ._20\.\1740
D000638_D013610 NONE both_0\CC\1740 dronedarone_1\NN\1740 and_2\CC\1740 <e1>amiodarone</e1>_3\NN\2715941 significantly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 exercise-induced_7\JJ\1740 <e2>tachycardia</e2>_8\NN\14110674 and_9\CC\1740 ,_10\,\1740 at_11\IN\14622893 the_12\DT\1740 highest_13\JJS\1740 dose_14\NN\3740161 ,_15\,\1740 decreased_16\VBD\169651 the_17\DT\1740 isoproterenol-induced_18\JJ\1740 tachycardia_19\NN\14110674 ._20\.\1740
D000638_D013610 NONE both_0\CC\1740 dronedarone_1\NN\1740 and_2\CC\1740 <e1>amiodarone</e1>_3\NN\2715941 significantly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 exercise-induced_7\JJ\1740 tachycardia_8\NN\14110674 and_9\CC\1740 ,_10\,\1740 at_11\IN\14622893 the_12\DT\1740 highest_13\JJS\1740 dose_14\NN\3740161 ,_15\,\1740 decreased_16\VBD\169651 the_17\DT\1740 isoproterenol-induced_18\JJ\1740 <e2>tachycardia</e2>_19\NN\14110674 ._20\.\1740
D007545_D013610 CID both_0\CC\1740 dronedarone_1\NN\1740 and_2\CC\1740 amiodarone_3\NN\2715941 significantly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 exercise-induced_7\JJ\1740 <e2>tachycardia</e2>_8\NN\14110674 and_9\CC\1740 ,_10\,\1740 at_11\IN\14622893 the_12\DT\1740 highest_13\JJS\1740 dose_14\NN\3740161 ,_15\,\1740 decreased_16\VBD\169651 the_17\DT\1740 <e1>isoproterenol-induced</e1>_18\JJ\1740 tachycardia_19\NN\14110674 ._20\.\1740
D007545_D013610 CID both_0\CC\1740 dronedarone_1\NN\1740 and_2\CC\1740 amiodarone_3\NN\2715941 significantly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 exercise-induced_7\JJ\1740 tachycardia_8\NN\14110674 and_9\CC\1740 ,_10\,\1740 at_11\IN\14622893 the_12\DT\1740 highest_13\JJS\1740 dose_14\NN\3740161 ,_15\,\1740 decreased_16\VBD\169651 the_17\DT\1740 <e1>isoproterenol-induced</e1>_18\JJ\1740 <e2>tachycardia</e2>_19\NN\14110674 ._20\.\1740
C118667_D001145 NONE consequently_0\RB\1740 ,_1\,\1740 <e1>dronedarone</e1>_2\NN\1740 might_3\MD\5029706 be_4\VB\836236 particularly_5\RB\1740 suitable_6\JJ\1740 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 and_10\CC\1740 prevention_11\NN\1073995 of_12\IN\1740 various_13\JJ\1740 clinical_14\JJ\1740 <e2>arrhythmias</e2>_15\NNS\14103288 ,_16\,\1740 without_17\IN\1740 compromising_18\VBG\1035530 the_19\DT\1740 left_20\JJ\1740 ventricular_21\JJ\1740 function_22\NN\13783581 ._23\.\1740
24618873
D008614_D002526 NONE <e2>cerebellar_0\JJ\1740 and_1\CC\1740 oculomotor_2\NN\5476256 dysfunction</e2>_3\NN\14204950 induced_4\VBN\1627355 by_5\IN\1740 rapid_6\JJ\1740 infusion_7\NN\14589223 of_8\IN\1740 <e1>pethidine</e1>_9\NN\1740 ._10\.\1740
D008614_D005128 NONE <e2>cerebellar_0\JJ\1740 and_1\CC\1740 oculomotor_2\NN\5476256 dysfunction</e2>_3\NN\14204950 induced_4\VBN\1627355 by_5\IN\1740 rapid_6\JJ\1740 infusion_7\NN\14589223 of_8\IN\1740 <e1>pethidine</e1>_9\NN\1740 ._10\.\1740
D008614_D010146 NONE <e1>pethidine</e1>_0\NNP\1740 is_1\VBZ\836236 an_2\DT\6697703 opioid_3\NN\1740 that_4\WDT\1740 gains_5\VBZ\2238085 its_6\PRP$\6125041 popularity_7\NN\4723816 for_8\IN\1740 the_9\DT\1740 effective_10\JJ\1740 <e2>pain</e2>_11\NN\14299637 control_12\NN\5190804 through_13\IN\1740 acting_14\VBG\1619354 on_15\IN\1740 the_16\DT\1740 opioid-receptors_17\NNS\1740 ._18\.\1740
D008614_D010146 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 <e2>pain</e2>_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 <e1>pethidine</e1>_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 norpethidine_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
D008614_D051437 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function</e2>_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 <e1>pethidine</e1>_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 norpethidine_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
D008614_D017093 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function</e2>_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 <e1>pethidine</e1>_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 norpethidine_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
D008614_D020258 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 <e1>pethidine</e1>_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 <e2>neurotoxic</e2>_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 norpethidine_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
D008614_D001523 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 <e1>pethidine</e1>_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 norpethidine_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 <e2>irritability</e2>_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
D008614_D012640 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 <e1>pethidine</e1>_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 norpethidine_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 <e2>seizure</e2>_39\VB\1740 attack_40\NN\955060 ._41\.\1740
C002752_D051437 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function</e2>_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 pethidine_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 <e1>norpethidine</e1>_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
C002752_D017093 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function</e2>_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 pethidine_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 <e1>norpethidine</e1>_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
C002752_D010146 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 <e2>pain</e2>_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 pethidine_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 <e1>norpethidine</e1>_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
C002752_D020258 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 pethidine_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 <e2>neurotoxic</e2>_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 <e1>norpethidine</e1>_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
C002752_D001523 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 pethidine_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 <e1>norpethidine</e1>_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 <e2>irritability</e2>_37\NN\7552087 and_38\CC\1740 seizure_39\VB\1740 attack_40\NN\955060 ._41\.\1740
C002752_D012640 CID in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 impaired_3\JJ\1740 renal_4\JJ\1740 and_5\CC\1740 liver_6\NN\5298729 function_7\NN\13783581 ,_8\,\1740 and_9\CC\1740 those_10\DT\1740 who_11\WP\8299493 need_12\VBP\2604760 long-term_13\JJ\1740 pain_14\NN\14299637 control_15\NN\5190804 ,_16\,\1740 pethidine_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 excitatory_20\NN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 (_24\-LRB-\1740 cns_25\NN\5237227 )_26\-RRB-\1740 effects_27\NNS\13245626 through_28\IN\1740 its_29\PRP$\6125041 neurotoxic_30\JJ\1740 metabolite_31\NN\20090 ,_32\,\1740 <e1>norpethidine</e1>_33\NN\1740 ,_34\,\1740 resulting_35\VBG\2633881 in_36\IN\13603305 irritability_37\NN\7552087 and_38\CC\1740 <e2>seizure</e2>_39\VB\1740 attack_40\NN\955060 ._41\.\1740
7411769
D007213_D006947 CID <e1>indomethacin-induced</e1>_0\JJ\1740 <e2>hyperkalemia</e2>_1\NN\14299637 in_2\IN\13603305 three_3\CD\13741022 patients_4\NNS\9898892 with_5\IN\1740 gouty_6\NN\1740 arthritis_7\NN\14171682 ._8\.\1740
D007213_D006947 CID we_0\PRP\1740 describe_1\VBP\1001294 three_2\CD\13741022 patients_3\NNS\9898892 in_4\IN\13603305 whom_5\WP\1740 severe_6\JJ\1740 ,_7\,\1740 life-threatening_8\JJ\1740 <e2>hyperkalemia</e2>_9\NN\14299637 and_10\CC\1740 renal_11\JJ\1740 insufficiency_12\NN\14462946 developed_13\VBD\1753788 after_14\IN\1740 treatment_15\NN\654885 of_16\IN\1740 acute_17\JJ\1740 gouty_18\NN\1740 arthritis_19\NN\14171682 with_20\IN\1740 <e1>indomethacin</e1>_21\NN\3828465 ._22\.\1740
D007213_D015210 NONE <e1>indomethacin-induced</e1>_0\JJ\1740 hyperkalemia_1\NN\14299637 in_2\IN\13603305 three_3\CD\13741022 patients_4\NNS\9898892 with_5\IN\1740 <e2>gouty_6\NN\1740 arthritis</e2>_7\NN\14171682 ._8\.\1740
D007213_D015210 NONE we_0\PRP\1740 describe_1\VBP\1001294 three_2\CD\13741022 patients_3\NNS\9898892 in_4\IN\13603305 whom_5\WP\1740 severe_6\JJ\1740 ,_7\,\1740 life-threatening_8\JJ\1740 hyperkalemia_9\NN\14299637 and_10\CC\1740 renal_11\JJ\1740 insufficiency_12\NN\14462946 developed_13\VBD\1753788 after_14\IN\1740 treatment_15\NN\654885 of_16\IN\1740 acute_17\JJ\1740 <e2>gouty_18\NN\1740 arthritis</e2>_19\NN\14171682 with_20\IN\1740 <e1>indomethacin</e1>_21\NN\3828465 ._22\.\1740
D007213_D051437 CID we_0\PRP\1740 describe_1\VBP\1001294 three_2\CD\13741022 patients_3\NNS\9898892 in_4\IN\13603305 whom_5\WP\1740 severe_6\JJ\1740 ,_7\,\1740 life-threatening_8\JJ\1740 hyperkalemia_9\NN\14299637 and_10\CC\1740 <e2>renal_11\JJ\1740 insufficiency</e2>_12\NN\14462946 developed_13\VBD\1753788 after_14\IN\1740 treatment_15\NN\654885 of_16\IN\1740 acute_17\JJ\1740 gouty_18\NN\1740 arthritis_19\NN\14171682 with_20\IN\1740 <e1>indomethacin</e1>_21\NN\3828465 ._22\.\1740
D011453_D006994 NONE this_0\DT\1740 complication_1\NN\1073995 may_2\MD\15209706 result_3\VB\2633881 from_4\IN\1740 an_5\DT\6697703 inhibition_6\NN\1068773 of_7\IN\1740 <e1>prostaglandin</e1>_8\NN\5414534 synthesis_9\NN\13446390 and_10\CC\1740 consequent_11\JJ\1740 <e2>hyporeninemic_12\JJ\1740 hypoaidosteronism</e2>_13\NN\1740 ._14\.\1740
D011188_D003920 NONE careful_0\JJ\1740 attention_1\NN\5701944 to_2\IN\1740 renal_3\JJ\1740 function_4\NN\13783581 and_5\CC\1740 <e1>potassium</e1>_6\NN\14625458 balance_7\NN\13934900 in_8\IN\13603305 patients_9\NNS\9898892 receiving_10\VBG\2210855 indomethacin_11\NN\3828465 or_12\CC\3541091 other_13\JJ\1740 nonsteroidal_14\JJ\1740 anti-inflammatory_15\JJ\1740 agents_16\NNS\7347 ,_17\,\1740 particularly_18\RB\1740 in_19\IN\13603305 those_20\DT\1740 patients_21\NNS\9898892 with_22\IN\1740 <e2>diabetes_23\NN\14075199 mellitus</e2>_24\NN\1740 or_25\CC\3541091 preexisting_26\JJ\1740 renal_27\JJ\1740 disease_28\NN\14061805 ,_29\,\1740 will_30\MD\5650329 help_31\VB\2556126 prevent_32\VB\1740 this_33\DT\1740 potentially_34\RB\1740 serious_35\JJ\1740 complication_36\NN\1073995 ._37\.\1740
D011188_D007674 NONE careful_0\JJ\1740 attention_1\NN\5701944 to_2\IN\1740 renal_3\JJ\1740 function_4\NN\13783581 and_5\CC\1740 <e1>potassium</e1>_6\NN\14625458 balance_7\NN\13934900 in_8\IN\13603305 patients_9\NNS\9898892 receiving_10\VBG\2210855 indomethacin_11\NN\3828465 or_12\CC\3541091 other_13\JJ\1740 nonsteroidal_14\JJ\1740 anti-inflammatory_15\JJ\1740 agents_16\NNS\7347 ,_17\,\1740 particularly_18\RB\1740 in_19\IN\13603305 those_20\DT\1740 patients_21\NNS\9898892 with_22\IN\1740 diabetes_23\NN\14075199 mellitus_24\NN\1740 or_25\CC\3541091 preexisting_26\JJ\1740 <e2>renal_27\JJ\1740 disease</e2>_28\NN\14061805 ,_29\,\1740 will_30\MD\5650329 help_31\VB\2556126 prevent_32\VB\1740 this_33\DT\1740 potentially_34\RB\1740 serious_35\JJ\1740 complication_36\NN\1073995 ._37\.\1740
D007213_D003920 NONE careful_0\JJ\1740 attention_1\NN\5701944 to_2\IN\1740 renal_3\JJ\1740 function_4\NN\13783581 and_5\CC\1740 potassium_6\NN\14625458 balance_7\NN\13934900 in_8\IN\13603305 patients_9\NNS\9898892 receiving_10\VBG\2210855 <e1>indomethacin</e1>_11\NN\3828465 or_12\CC\3541091 other_13\JJ\1740 nonsteroidal_14\JJ\1740 anti-inflammatory_15\JJ\1740 agents_16\NNS\7347 ,_17\,\1740 particularly_18\RB\1740 in_19\IN\13603305 those_20\DT\1740 patients_21\NNS\9898892 with_22\IN\1740 <e2>diabetes_23\NN\14075199 mellitus</e2>_24\NN\1740 or_25\CC\3541091 preexisting_26\JJ\1740 renal_27\JJ\1740 disease_28\NN\14061805 ,_29\,\1740 will_30\MD\5650329 help_31\VB\2556126 prevent_32\VB\1740 this_33\DT\1740 potentially_34\RB\1740 serious_35\JJ\1740 complication_36\NN\1073995 ._37\.\1740
D007213_D007674 NONE careful_0\JJ\1740 attention_1\NN\5701944 to_2\IN\1740 renal_3\JJ\1740 function_4\NN\13783581 and_5\CC\1740 potassium_6\NN\14625458 balance_7\NN\13934900 in_8\IN\13603305 patients_9\NNS\9898892 receiving_10\VBG\2210855 <e1>indomethacin</e1>_11\NN\3828465 or_12\CC\3541091 other_13\JJ\1740 nonsteroidal_14\JJ\1740 anti-inflammatory_15\JJ\1740 agents_16\NNS\7347 ,_17\,\1740 particularly_18\RB\1740 in_19\IN\13603305 those_20\DT\1740 patients_21\NNS\9898892 with_22\IN\1740 diabetes_23\NN\14075199 mellitus_24\NN\1740 or_25\CC\3541091 preexisting_26\JJ\1740 <e2>renal_27\JJ\1740 disease</e2>_28\NN\14061805 ,_29\,\1740 will_30\MD\5650329 help_31\VB\2556126 prevent_32\VB\1740 this_33\DT\1740 potentially_34\RB\1740 serious_35\JJ\1740 complication_36\NN\1073995 ._37\.\1740
9061777
D016291_D012640 CID <e1>mk-801</e1>_0\NN\1740 augments_1\VBZ\153263 pilocarpine-induced_2\JJ\1740 electrographic_3\NN\1740 <e2>seizure</e2>_4\NN\14081375 but_5\CC\1740 protects_6\VBZ\1127795 against_7\IN\1740 brain_8\NN\5462674 damage_9\NN\7296428 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D016291_D012640 CID the_0\DT\1740 authors_1\NNS\9610660 examined_2\VBD\789138 the_3\DT\1740 anticonvulsant_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>mk-801</e1>_7\NN\1740 on_8\IN\1740 the_9\DT\1740 pilocarpine-induced_10\JJ\1740 <e2>seizure</e2>_11\NN\14081375 model_12\NN\5888929 ._13\.\1740
D016291_D012640 CID scopolamine_0\NN\14712692 (_1\-LRB-\1740 10_2\CD\13745420 mg/kg_3\NN\1740 )_4\-RRB-\1740 and_5\CC\1740 pentobarbital_6\JJ\1740 (_7\-LRB-\1740 5_8\CD\13741022 mg/kg_9\NN\1740 )_10\-RRB-\1740 prevented_11\VBD\1740 development_12\NN\248977 of_13\IN\1740 pilocarpine-induced_14\JJ\1740 behavioral_15\JJ\1740 <e2>seizure</e2>_16\NN\14081375 but_17\CC\1740 <e1>mk-801</e1>_18\NN\1740 (_19\-LRB-\1740 0.5_20\CD\1740 mg/kg_21\NN\1740 )_22\-RRB-\1740 did_23\VBD\1640855 not_24\RB\1740 ._25\.\1740
D016291_D012640 CID scopolamine_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 <e2>seizure</e2>_7\NN\14081375 ,_8\,\1740 <e1>mk-801</e1>_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 seizure_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D016291_D012640 CID scopolamine_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 seizure_7\NN\14081375 ,_8\,\1740 <e1>mk-801</e1>_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 <e2>seizure</e2>_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D016291_D001930 NONE <e1>mk-801</e1>_0\NN\1740 augments_1\VBZ\153263 pilocarpine-induced_2\JJ\1740 electrographic_3\NN\1740 seizure_4\NN\14081375 but_5\CC\1740 protects_6\VBZ\1127795 against_7\IN\1740 <e2>brain_8\NN\5462674 damage</e2>_9\NN\7296428 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D016291_D001930 NONE pentobarbital_0\JJ\1740 ,_1\,\1740 scopolamine_2\NN\14712692 and_3\CC\1740 <e1>mk-801</e1>_4\NN\1740 protected_5\VBD\1127795 the_6\DT\1740 <e2>brain_7\NN\5462674 damage</e2>_8\NN\7296428 by_9\IN\1740 pilocarpine_10\NN\14712692 ,_11\,\1740 though_12\IN\1740 in_13\IN\13603305 the_14\DT\1740 mk-801-treated_15\JJ\1740 group_16\NN\2137 ,_17\,\1740 the_18\DT\1740 pyramidal_19\JJ\1740 cells_20\NNS\3080309 of_21\IN\1740 hippocampus_22\NN\5462674 appeared_23\VBD\2604760 darker_24\JJR\1740 than_25\IN\1740 normal_26\JJ\1740 ._27\.\1740
D016291_D001930 NONE pentobarbital_0\JJ\1740 ,_1\,\1740 scopolamine_2\NN\14712692 and_3\CC\1740 mk-801_4\NN\1740 protected_5\VBD\1127795 the_6\DT\1740 <e2>brain_7\NN\5462674 damage</e2>_8\NN\7296428 by_9\IN\1740 pilocarpine_10\NN\14712692 ,_11\,\1740 though_12\IN\1740 in_13\IN\13603305 the_14\DT\1740 <e1>mk-801-treated</e1>_15\JJ\1740 group_16\NN\2137 ,_17\,\1740 the_18\DT\1740 pyramidal_19\JJ\1740 cells_20\NNS\3080309 of_21\IN\1740 hippocampus_22\NN\5462674 appeared_23\VBD\2604760 darker_24\JJR\1740 than_25\IN\1740 normal_26\JJ\1740 ._27\.\1740
D010862_D012640 CID mk-801_0\NN\1740 augments_1\VBZ\153263 <e1>pilocarpine-induced</e1>_2\JJ\1740 electrographic_3\NN\1740 <e2>seizure</e2>_4\NN\14081375 but_5\CC\1740 protects_6\VBZ\1127795 against_7\IN\1740 brain_8\NN\5462674 damage_9\NN\7296428 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D010862_D012640 CID the_0\DT\1740 authors_1\NNS\9610660 examined_2\VBD\789138 the_3\DT\1740 anticonvulsant_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 mk-801_7\NN\1740 on_8\IN\1740 the_9\DT\1740 <e1>pilocarpine-induced</e1>_10\JJ\1740 <e2>seizure</e2>_11\NN\14081375 model_12\NN\5888929 ._13\.\1740
D010862_D012640 CID intraperitoneal_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 <e1>pilocarpine</e1>_3\NN\14712692 (_4\-LRB-\1740 400_5\CD\1740 mg/kg_6\NN\1740 )_7\-RRB-\1740 induced_8\VBD\1627355 <e2>tonic_9\JJ\1740 and_10\CC\1740 clonic_11\NN\1740 seizure</e2>_12\NN\14081375 ._13\.\1740
D010862_D012640 CID scopolamine_0\NN\14712692 (_1\-LRB-\1740 10_2\CD\13745420 mg/kg_3\NN\1740 )_4\-RRB-\1740 and_5\CC\1740 pentobarbital_6\JJ\1740 (_7\-LRB-\1740 5_8\CD\13741022 mg/kg_9\NN\1740 )_10\-RRB-\1740 prevented_11\VBD\1740 development_12\NN\248977 of_13\IN\1740 <e1>pilocarpine-induced</e1>_14\JJ\1740 behavioral_15\JJ\1740 <e2>seizure</e2>_16\NN\14081375 but_17\CC\1740 mk-801_18\NN\1740 (_19\-LRB-\1740 0.5_20\CD\1740 mg/kg_21\NN\1740 )_22\-RRB-\1740 did_23\VBD\1640855 not_24\RB\1740 ._25\.\1740
D010862_D012640 CID 2_0\LS\13741022 ._1\.\1740 an_2\DT\6697703 electrical_3\JJ\1740 <e2>seizure</e2>_4\NN\14081375 measured_5\VBN\697589 with_6\IN\1740 hippocampal_7\NN\1740 eeg_8\NN\7000195 appeared_9\VBD\2604760 in_10\IN\13603305 the_11\DT\1740 <e1>pilocarpine-treated</e1>_12\JJ\1740 group_13\NN\2137 ._14\.\1740
D010862_D012640 CID scopolamine_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 <e1>pilocarpine-induced</e1>_5\JJ\1740 electrographic_6\NN\1740 <e2>seizure</e2>_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 seizure_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D010862_D012640 CID scopolamine_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 <e1>pilocarpine-induced</e1>_5\JJ\1740 electrographic_6\NN\1740 seizure_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 <e2>seizure</e2>_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D010862_D012640 CID scopolamine_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 <e2>seizure</e2>_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 seizure_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 <e1>pilocarpine</e1>_17\NN\14712692 ._18\.\1740
D010862_D012640 CID scopolamine_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 seizure_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 <e2>seizure</e2>_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 <e1>pilocarpine</e1>_17\NN\14712692 ._18\.\1740
D010862_D001930 NONE mk-801_0\NN\1740 augments_1\VBZ\153263 <e1>pilocarpine-induced</e1>_2\JJ\1740 electrographic_3\NN\1740 seizure_4\NN\14081375 but_5\CC\1740 protects_6\VBZ\1127795 against_7\IN\1740 <e2>brain_8\NN\5462674 damage</e2>_9\NN\7296428 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D010862_D001930 NONE pentobarbital_0\JJ\1740 ,_1\,\1740 scopolamine_2\NN\14712692 and_3\CC\1740 mk-801_4\NN\1740 protected_5\VBD\1127795 the_6\DT\1740 <e2>brain_7\NN\5462674 damage</e2>_8\NN\7296428 by_9\IN\1740 <e1>pilocarpine</e1>_10\NN\14712692 ,_11\,\1740 though_12\IN\1740 in_13\IN\13603305 the_14\DT\1740 mk-801-treated_15\JJ\1740 group_16\NN\2137 ,_17\,\1740 the_18\DT\1740 pyramidal_19\JJ\1740 cells_20\NNS\3080309 of_21\IN\1740 hippocampus_22\NN\5462674 appeared_23\VBD\2604760 darker_24\JJR\1740 than_25\IN\1740 normal_26\JJ\1740 ._27\.\1740
D010862_D001930 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 status_4\NN\24720 epilepticus_5\NN\1740 induced_6\VBN\1627355 by_7\IN\1740 <e1>pilocarpine</e1>_8\NN\14712692 is_9\VBZ\836236 initiated_10\VBN\1617192 by_11\IN\1740 cholinergic_12\JJ\1740 overstimulation_13\NN\1740 and_14\CC\1740 propagated_15\VBN\2230247 by_16\IN\1740 glutamatergic_17\JJ\1740 transmission_18\NN\121166 ,_19\,\1740 the_20\DT\1740 elevation_21\NN\7445480 of_22\IN\1740 which_23\WDT\1740 may_24\MD\15209706 cause_25\VB\1617192 <e2>brain_26\NN\5462674 damage</e2>_27\NN\7296428 through_28\IN\1740 an_29\DT\6697703 excitatory_30\JJ\1740 nmda_31\NN\1740 receptor-mediated_32\JJ\1740 mechanism_33\NN\13446390 ._34\.\1740
D012601_D012640 NONE <e1>scopolamine</e1>_0\NN\14712692 (_1\-LRB-\1740 10_2\CD\13745420 mg/kg_3\NN\1740 )_4\-RRB-\1740 and_5\CC\1740 pentobarbital_6\JJ\1740 (_7\-LRB-\1740 5_8\CD\13741022 mg/kg_9\NN\1740 )_10\-RRB-\1740 prevented_11\VBD\1740 development_12\NN\248977 of_13\IN\1740 pilocarpine-induced_14\JJ\1740 behavioral_15\JJ\1740 <e2>seizure</e2>_16\NN\14081375 but_17\CC\1740 mk-801_18\NN\1740 (_19\-LRB-\1740 0.5_20\CD\1740 mg/kg_21\NN\1740 )_22\-RRB-\1740 did_23\VBD\1640855 not_24\RB\1740 ._25\.\1740
D012601_D012640 NONE <e1>scopolamine</e1>_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 <e2>seizure</e2>_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 seizure_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D012601_D012640 NONE <e1>scopolamine</e1>_0\NN\14712692 and_1\CC\1740 pentobarbital_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 seizure_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 <e2>seizure</e2>_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D010424_D012640 NONE scopolamine_0\NN\14712692 (_1\-LRB-\1740 10_2\CD\13745420 mg/kg_3\NN\1740 )_4\-RRB-\1740 and_5\CC\1740 <e1>pentobarbital</e1>_6\JJ\1740 (_7\-LRB-\1740 5_8\CD\13741022 mg/kg_9\NN\1740 )_10\-RRB-\1740 prevented_11\VBD\1740 development_12\NN\248977 of_13\IN\1740 pilocarpine-induced_14\JJ\1740 behavioral_15\JJ\1740 <e2>seizure</e2>_16\NN\14081375 but_17\CC\1740 mk-801_18\NN\1740 (_19\-LRB-\1740 0.5_20\CD\1740 mg/kg_21\NN\1740 )_22\-RRB-\1740 did_23\VBD\1640855 not_24\RB\1740 ._25\.\1740
D010424_D012640 NONE scopolamine_0\NN\14712692 and_1\CC\1740 <e1>pentobarbital</e1>_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 <e2>seizure</e2>_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 seizure_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D010424_D012640 NONE scopolamine_0\NN\14712692 and_1\CC\1740 <e1>pentobarbital</e1>_2\NN\2792049 blocked_3\VBD\1476483 the_4\DT\1740 pilocarpine-induced_5\JJ\1740 electrographic_6\NN\1740 seizure_7\NN\14081375 ,_8\,\1740 mk-801_9\NN\1740 treatment_10\NN\654885 augmented_11\VBD\153263 the_12\DT\1740 electrographic_13\JJ\1740 <e2>seizure</e2>_14\NN\14081375 induced_15\VBN\1627355 by_16\IN\1740 pilocarpine_17\NN\14712692 ._18\.\1740
D010862_D009410 CID <e1>pilocarpine</e1>_0\NN\14712692 produced_1\VBD\1617192 <e2>neuronal_2\JJ\1740 death</e2>_3\NN\7296428 in_4\IN\13603305 the_5\DT\1740 hippocampus_6\NN\5462674 ,_7\,\1740 which_8\WDT\1740 showed_9\VBD\2137132 pyknotic_10\JJ\1740 changes_11\NNS\7283608 ._12\.\1740
D010424_D001930 NONE <e1>pentobarbital</e1>_0\JJ\1740 ,_1\,\1740 scopolamine_2\NN\14712692 and_3\CC\1740 mk-801_4\NN\1740 protected_5\VBD\1127795 the_6\DT\1740 <e2>brain_7\NN\5462674 damage</e2>_8\NN\7296428 by_9\IN\1740 pilocarpine_10\NN\14712692 ,_11\,\1740 though_12\IN\1740 in_13\IN\13603305 the_14\DT\1740 mk-801-treated_15\JJ\1740 group_16\NN\2137 ,_17\,\1740 the_18\DT\1740 pyramidal_19\JJ\1740 cells_20\NNS\3080309 of_21\IN\1740 hippocampus_22\NN\5462674 appeared_23\VBD\2604760 darker_24\JJR\1740 than_25\IN\1740 normal_26\JJ\1740 ._27\.\1740
D012601_D001930 NONE pentobarbital_0\JJ\1740 ,_1\,\1740 <e1>scopolamine</e1>_2\NN\14712692 and_3\CC\1740 mk-801_4\NN\1740 protected_5\VBD\1127795 the_6\DT\1740 <e2>brain_7\NN\5462674 damage</e2>_8\NN\7296428 by_9\IN\1740 pilocarpine_10\NN\14712692 ,_11\,\1740 though_12\IN\1740 in_13\IN\13603305 the_14\DT\1740 mk-801-treated_15\JJ\1740 group_16\NN\2137 ,_17\,\1740 the_18\DT\1740 pyramidal_19\JJ\1740 cells_20\NNS\3080309 of_21\IN\1740 hippocampus_22\NN\5462674 appeared_23\VBD\2604760 darker_24\JJR\1740 than_25\IN\1740 normal_26\JJ\1740 ._27\.\1740
D010862_D013226 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e2>status_4\NN\24720 epilepticus</e2>_5\NN\1740 induced_6\VBN\1627355 by_7\IN\1740 <e1>pilocarpine</e1>_8\NN\14712692 is_9\VBZ\836236 initiated_10\VBN\1617192 by_11\IN\1740 cholinergic_12\JJ\1740 overstimulation_13\NN\1740 and_14\CC\1740 propagated_15\VBN\2230247 by_16\IN\1740 glutamatergic_17\JJ\1740 transmission_18\NN\121166 ,_19\,\1740 the_20\DT\1740 elevation_21\NN\7445480 of_22\IN\1740 which_23\WDT\1740 may_24\MD\15209706 cause_25\VB\1617192 brain_26\NN\5462674 damage_27\NN\7296428 through_28\IN\1740 an_29\DT\6697703 excitatory_30\JJ\1740 nmda_31\NN\1740 receptor-mediated_32\JJ\1740 mechanism_33\NN\13446390 ._34\.\1740
D016202_D013226 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e2>status_4\NN\24720 epilepticus</e2>_5\NN\1740 induced_6\VBN\1627355 by_7\IN\1740 pilocarpine_8\NN\14712692 is_9\VBZ\836236 initiated_10\VBN\1617192 by_11\IN\1740 cholinergic_12\JJ\1740 overstimulation_13\NN\1740 and_14\CC\1740 propagated_15\VBN\2230247 by_16\IN\1740 glutamatergic_17\JJ\1740 transmission_18\NN\121166 ,_19\,\1740 the_20\DT\1740 elevation_21\NN\7445480 of_22\IN\1740 which_23\WDT\1740 may_24\MD\15209706 cause_25\VB\1617192 brain_26\NN\5462674 damage_27\NN\7296428 through_28\IN\1740 an_29\DT\6697703 excitatory_30\JJ\1740 <e1>nmda</e1>_31\NN\1740 receptor-mediated_32\JJ\1740 mechanism_33\NN\13446390 ._34\.\1740
D016202_D001930 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 status_4\NN\24720 epilepticus_5\NN\1740 induced_6\VBN\1627355 by_7\IN\1740 pilocarpine_8\NN\14712692 is_9\VBZ\836236 initiated_10\VBN\1617192 by_11\IN\1740 cholinergic_12\JJ\1740 overstimulation_13\NN\1740 and_14\CC\1740 propagated_15\VBN\2230247 by_16\IN\1740 glutamatergic_17\JJ\1740 transmission_18\NN\121166 ,_19\,\1740 the_20\DT\1740 elevation_21\NN\7445480 of_22\IN\1740 which_23\WDT\1740 may_24\MD\15209706 cause_25\VB\1617192 <e2>brain_26\NN\5462674 damage</e2>_27\NN\7296428 through_28\IN\1740 an_29\DT\6697703 excitatory_30\JJ\1740 <e1>nmda</e1>_31\NN\1740 receptor-mediated_32\JJ\1740 mechanism_33\NN\13446390 ._34\.\1740
24881749
D013747_D009459 CID <e2>neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome</e2>_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 with_7\IN\1740 <e1>tetrabenazine</e1>_8\NN\1740 and_9\CC\1740 tiapride_10\NN\1740 in_11\IN\13603305 a_12\DT\13649268 japanese_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 huntington_16\NNP\1740 's_17\POS\1740 disease_18\NN\14061805 at_19\IN\14622893 the_20\DT\1740 terminal_21\JJ\1740 stage_22\NN\15113229 of_23\IN\1740 recurrent_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D013747_D009459 CID we_0\PRP\1740 herein_1\RB\1740 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 an_6\DT\6697703 81-year-old_7\JJ\1740 japanese_8\JJ\1740 woman_9\NN\9605289 with_10\IN\1740 <e2>neuroleptic_11\JJ\1740 malignant_12\JJ\1740 syndrome</e2>_13\NN\5870365 that_14\WDT\1740 occurred_15\VBD\2623529 36_16\CD\1740 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 combination_22\NN\7951464 therapy_23\NN\657604 with_24\IN\1740 tiapride_25\NN\1740 (_26\-LRB-\1740 75_27\CD\1740 mg/day_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 <e1>tetrabenazine</e1>_31\NN\1740 (_32\-LRB-\1740 12.5_33\CD\1740 mg/day_34\NN\1740 )_35\-RRB-\1740 for_36\IN\1740 huntington_37\NNP\1740 's_38\POS\1740 disease_39\NN\14061805 ._40\.\1740
D013747_D009459 CID to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 ,_6\,\1740 the_7\DT\1740 occurrence_8\NN\29378 of_9\IN\1740 <e2>neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome</e2>_12\NN\5870365 due_13\JJ\1740 to_14\TO\1740 combination_15\NN\7951464 therapy_16\NN\657604 with_17\IN\1740 <e1>tetrabenazine</e1>_18\NN\1740 and_19\CC\1740 tiapride_20\NN\1740 has_21\VBZ\2108377 not_22\RB\1740 been_23\VBN\836236 previously_24\RB\1740 reported_25\VBN\831651 ._26\.\1740
D013747_D006816 NONE neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 with_7\IN\1740 <e1>tetrabenazine</e1>_8\NN\1740 and_9\CC\1740 tiapride_10\NN\1740 in_11\IN\13603305 a_12\DT\13649268 japanese_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 <e2>huntington_16\NNP\1740 's_17\POS\1740 disease</e2>_18\NN\14061805 at_19\IN\14622893 the_20\DT\1740 terminal_21\JJ\1740 stage_22\NN\15113229 of_23\IN\1740 recurrent_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D013747_D006816 NONE we_0\PRP\1740 herein_1\RB\1740 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 an_6\DT\6697703 81-year-old_7\JJ\1740 japanese_8\JJ\1740 woman_9\NN\9605289 with_10\IN\1740 neuroleptic_11\JJ\1740 malignant_12\JJ\1740 syndrome_13\NN\5870365 that_14\WDT\1740 occurred_15\VBD\2623529 36_16\CD\1740 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 combination_22\NN\7951464 therapy_23\NN\657604 with_24\IN\1740 tiapride_25\NN\1740 (_26\-LRB-\1740 75_27\CD\1740 mg/day_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 <e1>tetrabenazine</e1>_31\NN\1740 (_32\-LRB-\1740 12.5_33\CD\1740 mg/day_34\NN\1740 )_35\-RRB-\1740 for_36\IN\1740 <e2>huntington_37\NNP\1740 's_38\POS\1740 disease</e2>_39\NN\14061805 ._40\.\1740
D013747_D001943 NONE neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 with_7\IN\1740 <e1>tetrabenazine</e1>_8\NN\1740 and_9\CC\1740 tiapride_10\NN\1740 in_11\IN\13603305 a_12\DT\13649268 japanese_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 huntington_16\NNP\1740 's_17\POS\1740 disease_18\NN\14061805 at_19\IN\14622893 the_20\DT\1740 terminal_21\JJ\1740 stage_22\NN\15113229 of_23\IN\1740 recurrent_24\JJ\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 ._27\.\1740
D063325_D009459 CID <e2>neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome</e2>_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 with_7\IN\1740 tetrabenazine_8\NN\1740 and_9\CC\1740 <e1>tiapride</e1>_10\NN\1740 in_11\IN\13603305 a_12\DT\13649268 japanese_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 huntington_16\NNP\1740 's_17\POS\1740 disease_18\NN\14061805 at_19\IN\14622893 the_20\DT\1740 terminal_21\JJ\1740 stage_22\NN\15113229 of_23\IN\1740 recurrent_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D063325_D009459 CID we_0\PRP\1740 herein_1\RB\1740 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 an_6\DT\6697703 81-year-old_7\JJ\1740 japanese_8\JJ\1740 woman_9\NN\9605289 with_10\IN\1740 <e2>neuroleptic_11\JJ\1740 malignant_12\JJ\1740 syndrome</e2>_13\NN\5870365 that_14\WDT\1740 occurred_15\VBD\2623529 36_16\CD\1740 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 combination_22\NN\7951464 therapy_23\NN\657604 with_24\IN\1740 <e1>tiapride</e1>_25\NN\1740 (_26\-LRB-\1740 75_27\CD\1740 mg/day_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tetrabenazine_31\NN\1740 (_32\-LRB-\1740 12.5_33\CD\1740 mg/day_34\NN\1740 )_35\-RRB-\1740 for_36\IN\1740 huntington_37\NNP\1740 's_38\POS\1740 disease_39\NN\14061805 ._40\.\1740
D063325_D009459 CID to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 ,_6\,\1740 the_7\DT\1740 occurrence_8\NN\29378 of_9\IN\1740 <e2>neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome</e2>_12\NN\5870365 due_13\JJ\1740 to_14\TO\1740 combination_15\NN\7951464 therapy_16\NN\657604 with_17\IN\1740 tetrabenazine_18\NN\1740 and_19\CC\1740 <e1>tiapride</e1>_20\NN\1740 has_21\VBZ\2108377 not_22\RB\1740 been_23\VBN\836236 previously_24\RB\1740 reported_25\VBN\831651 ._26\.\1740
D063325_D006816 NONE neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 with_7\IN\1740 tetrabenazine_8\NN\1740 and_9\CC\1740 <e1>tiapride</e1>_10\NN\1740 in_11\IN\13603305 a_12\DT\13649268 japanese_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 <e2>huntington_16\NNP\1740 's_17\POS\1740 disease</e2>_18\NN\14061805 at_19\IN\14622893 the_20\DT\1740 terminal_21\JJ\1740 stage_22\NN\15113229 of_23\IN\1740 recurrent_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D063325_D006816 NONE we_0\PRP\1740 herein_1\RB\1740 describe_2\VBP\1001294 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 an_6\DT\6697703 81-year-old_7\JJ\1740 japanese_8\JJ\1740 woman_9\NN\9605289 with_10\IN\1740 neuroleptic_11\JJ\1740 malignant_12\JJ\1740 syndrome_13\NN\5870365 that_14\WDT\1740 occurred_15\VBD\2623529 36_16\CD\1740 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 combination_22\NN\7951464 therapy_23\NN\657604 with_24\IN\1740 <e1>tiapride</e1>_25\NN\1740 (_26\-LRB-\1740 75_27\CD\1740 mg/day_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tetrabenazine_31\NN\1740 (_32\-LRB-\1740 12.5_33\CD\1740 mg/day_34\NN\1740 )_35\-RRB-\1740 for_36\IN\1740 <e2>huntington_37\NNP\1740 's_38\POS\1740 disease</e2>_39\NN\14061805 ._40\.\1740
D063325_D001943 NONE neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 combination_5\NN\7951464 therapy_6\NN\657604 with_7\IN\1740 tetrabenazine_8\NN\1740 and_9\CC\1740 <e1>tiapride</e1>_10\NN\1740 in_11\IN\13603305 a_12\DT\13649268 japanese_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 huntington_16\NNP\1740 's_17\POS\1740 disease_18\NN\14061805 at_19\IN\14622893 the_20\DT\1740 terminal_21\JJ\1740 stage_22\NN\15113229 of_23\IN\1740 recurrent_24\JJ\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 ._27\.\1740
3155884
D007545_D066126 NONE acute_0\JJ\1740 insulin_1\NN\5407119 treatment_2\NN\654885 normalizes_3\VBZ\109660 the_4\DT\1740 resistance_5\NN\37396 to_6\TO\1740 the_7\DT\1740 <e2>cardiotoxic</e2>_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 <e1>isoproterenol</e1>_11\NN\3740161 in_12\IN\13603305 streptozotocin_13\NN\1740 diabetic_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D007545_D066126 NONE the_0\DT\1740 acute_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 on_6\IN\1740 the_7\DT\1740 earlier_8\RBR\1740 reported_9\VBN\831651 protective_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 streptozotocin_13\NN\1740 diabetes_14\NNS\14075199 against_15\IN\1740 the_16\DT\1740 <e2>cardiotoxic</e2>_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 high_20\JJ\1740 doses_21\NNS\3740161 of_22\IN\1740 <e1>isoproterenol</e1>_23\NN\3740161 (_24\-LRB-\1740 iso_25\NN\1740 )_26\-RRB-\1740 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D007545_D066126 NONE the_0\DT\1740 acute_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 on_6\IN\1740 the_7\DT\1740 earlier_8\RBR\1740 reported_9\VBN\831651 protective_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 streptozotocin_13\NN\1740 diabetes_14\NNS\14075199 against_15\IN\1740 the_16\DT\1740 <e2>cardiotoxic</e2>_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 high_20\JJ\1740 doses_21\NNS\3740161 of_22\IN\1740 isoproterenol_23\NN\3740161 (_24\-LRB-\1740 <e1>iso</e1>_25\NN\1740 )_26\-RRB-\1740 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D007545_D003920 NONE acute_0\JJ\1740 insulin_1\NN\5407119 treatment_2\NN\654885 normalizes_3\VBZ\109660 the_4\DT\1740 resistance_5\NN\37396 to_6\TO\1740 the_7\DT\1740 cardiotoxic_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 <e1>isoproterenol</e1>_11\NN\3740161 in_12\IN\13603305 streptozotocin_13\NN\1740 <e2>diabetic</e2>_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D007545_D003920 NONE the_0\DT\1740 acute_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 on_6\IN\1740 the_7\DT\1740 earlier_8\RBR\1740 reported_9\VBN\831651 protective_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 streptozotocin_13\NN\1740 <e2>diabetes</e2>_14\NNS\14075199 against_15\IN\1740 the_16\DT\1740 cardiotoxic_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 high_20\JJ\1740 doses_21\NNS\3740161 of_22\IN\1740 <e1>isoproterenol</e1>_23\NN\3740161 (_24\-LRB-\1740 iso_25\NN\1740 )_26\-RRB-\1740 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D007545_D003920 NONE the_0\DT\1740 acute_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 on_6\IN\1740 the_7\DT\1740 earlier_8\RBR\1740 reported_9\VBN\831651 protective_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 streptozotocin_13\NN\1740 <e2>diabetes</e2>_14\NNS\14075199 against_15\IN\1740 the_16\DT\1740 cardiotoxic_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 high_20\JJ\1740 doses_21\NNS\3740161 of_22\IN\1740 isoproterenol_23\NN\3740161 (_24\-LRB-\1740 <e1>iso</e1>_25\NN\1740 )_26\-RRB-\1740 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D007545_D003920 NONE the_0\DT\1740 rapid_1\JJ\1740 reversion_2\NN\13286801 after_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 excludes_6\VBZ\471711 the_7\DT\1740 possibility_8\NN\5944958 that_9\IN\1740 streptozotocin_10\NN\1740 in_11\IN\13603305 itself_12\PRP\1740 causes_13\VBZ\1617192 the_14\DT\1740 <e1>iso</e1>_15\NN\1740 resistance_16\NN\37396 and_17\CC\1740 points_18\VBZ\831651 towards_19\IN\1740 a_20\DT\13649268 direct_21\JJ\1740 insulin_22\NN\5407119 effect_23\NN\34213 on_24\IN\1740 myocardial_25\JJ\1740 catecholamine_26\NN\5407119 sensitivity_27\NN\5651971 in_28\IN\13603305 <e2>diabetic</e2>_29\JJ\1740 rats_30\NNS\2329401 ._31\.\1740
D013311_D066126 NONE acute_0\JJ\1740 insulin_1\NN\5407119 treatment_2\NN\654885 normalizes_3\VBZ\109660 the_4\DT\1740 resistance_5\NN\37396 to_6\TO\1740 the_7\DT\1740 <e2>cardiotoxic</e2>_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 isoproterenol_11\NN\3740161 in_12\IN\13603305 <e1>streptozotocin</e1>_13\NN\1740 diabetic_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D013311_D066126 NONE the_0\DT\1740 acute_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 on_6\IN\1740 the_7\DT\1740 earlier_8\RBR\1740 reported_9\VBN\831651 protective_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 <e1>streptozotocin</e1>_13\NN\1740 diabetes_14\NNS\14075199 against_15\IN\1740 the_16\DT\1740 <e2>cardiotoxic</e2>_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 high_20\JJ\1740 doses_21\NNS\3740161 of_22\IN\1740 isoproterenol_23\NN\3740161 (_24\-LRB-\1740 iso_25\NN\1740 )_26\-RRB-\1740 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D013311_D003920 CID acute_0\JJ\1740 insulin_1\NN\5407119 treatment_2\NN\654885 normalizes_3\VBZ\109660 the_4\DT\1740 resistance_5\NN\37396 to_6\TO\1740 the_7\DT\1740 cardiotoxic_8\JJ\1740 effect_9\NN\34213 of_10\IN\1740 isoproterenol_11\NN\3740161 in_12\IN\13603305 <e1>streptozotocin</e1>_13\NN\1740 <e2>diabetic</e2>_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D013311_D003920 CID the_0\DT\1740 acute_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 on_6\IN\1740 the_7\DT\1740 earlier_8\RBR\1740 reported_9\VBN\831651 protective_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 <e1>streptozotocin</e1>_13\NN\1740 <e2>diabetes</e2>_14\NNS\14075199 against_15\IN\1740 the_16\DT\1740 cardiotoxic_17\JJ\1740 effect_18\NN\34213 of_19\IN\1740 high_20\JJ\1740 doses_21\NNS\3740161 of_22\IN\1740 isoproterenol_23\NN\3740161 (_24\-LRB-\1740 iso_25\NN\1740 )_26\-RRB-\1740 was_27\VBD\836236 investigated_28\VBN\644583 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D013311_D003920 CID the_0\DT\1740 rapid_1\JJ\1740 reversion_2\NN\13286801 after_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 excludes_6\VBZ\471711 the_7\DT\1740 possibility_8\NN\5944958 that_9\IN\1740 <e1>streptozotocin</e1>_10\NN\1740 in_11\IN\13603305 itself_12\PRP\1740 causes_13\VBZ\1617192 the_14\DT\1740 iso_15\NN\1740 resistance_16\NN\37396 and_17\CC\1740 points_18\VBZ\831651 towards_19\IN\1740 a_20\DT\13649268 direct_21\JJ\1740 insulin_22\NN\5407119 effect_23\NN\34213 on_24\IN\1740 myocardial_25\JJ\1740 catecholamine_26\NN\5407119 sensitivity_27\NN\5651971 in_28\IN\13603305 <e2>diabetic</e2>_29\JJ\1740 rats_30\NNS\2329401 ._31\.\1740
D007545_D005355 CID a_0\DT\13649268 morphometric_1\JJ\1740 study_2\NN\635850 of_3\IN\1740 <e1>isoproterenol</e1>_4\NN\3740161 induced_5\JJ\1740 myocardial_6\JJ\1740 <e2>fibrosis</e2>_7\NN\14204950 ._8\.\1740
D007545_D005355 CID thirty_0\CD\13745420 to_1\TO\1740 135_2\CD\1740 min_3\NN\15154774 after_4\IN\1740 the_5\DT\1740 injection_6\NN\320852 of_7\IN\1740 crystalline_8\NN\1740 insulin_9\NN\5407119 ,_10\,\1740 <e1>iso</e1>_11\NN\1740 was_12\VBD\836236 given_13\VBN\2327200 subcutaneously_14\RB\1740 and_15\CC\1740 when_16\WRB\1740 iso_17\NN\1740 induced_18\VBD\1627355 <e2>fibrosis</e2>_19\NN\14204950 in_20\IN\13603305 the_21\DT\1740 myocardium_22\NN\5389939 was_23\VBD\836236 morphometrically_24\RB\1740 analyzed_25\VBN\78760 7_26\CD\13741022 days_27\NNS\15140892 later_28\RB\1740 ,_29\,\1740 a_30\DT\13649268 highly_31\RB\1740 significant_32\JJ\1740 correlation_33\NN\13841213 (_34\-LRB-\1740 r_35\NN\13635336 =_36\JJ\1740 0.83_37\CD\1740 ,_38\,\1740 2_39\CD\13741022 p_40\NN\14622893 =_41\JJ\1740 0.006_42\CD\1740 )_43\-RRB-\1740 to_44\TO\1740 the_45\DT\1740 slope_46\NN\9287968 of_47\IN\1740 the_48\DT\1740 fall_49\NN\15236475 in_50\IN\13603305 blood_51\NN\5397468 glucose_52\NN\14710501 after_53\IN\1740 insulin_54\NN\5407119 treatment_55\NN\654885 appeared_56\VBD\2604760 ._57\.\1740
D007545_D005355 CID thirty_0\CD\13745420 to_1\TO\1740 135_2\CD\1740 min_3\NN\15154774 after_4\IN\1740 the_5\DT\1740 injection_6\NN\320852 of_7\IN\1740 crystalline_8\NN\1740 insulin_9\NN\5407119 ,_10\,\1740 iso_11\NN\1740 was_12\VBD\836236 given_13\VBN\2327200 subcutaneously_14\RB\1740 and_15\CC\1740 when_16\WRB\1740 <e1>iso</e1>_17\NN\1740 induced_18\VBD\1627355 <e2>fibrosis</e2>_19\NN\14204950 in_20\IN\13603305 the_21\DT\1740 myocardium_22\NN\5389939 was_23\VBD\836236 morphometrically_24\RB\1740 analyzed_25\VBN\78760 7_26\CD\13741022 days_27\NNS\15140892 later_28\RB\1740 ,_29\,\1740 a_30\DT\13649268 highly_31\RB\1740 significant_32\JJ\1740 correlation_33\NN\13841213 (_34\-LRB-\1740 r_35\NN\13635336 =_36\JJ\1740 0.83_37\CD\1740 ,_38\,\1740 2_39\CD\13741022 p_40\NN\14622893 =_41\JJ\1740 0.006_42\CD\1740 )_43\-RRB-\1740 to_44\TO\1740 the_45\DT\1740 slope_46\NN\9287968 of_47\IN\1740 the_48\DT\1740 fall_49\NN\15236475 in_50\IN\13603305 blood_51\NN\5397468 glucose_52\NN\14710501 after_53\IN\1740 insulin_54\NN\5407119 treatment_55\NN\654885 appeared_56\VBD\2604760 ._57\.\1740
D005947_D005355 NONE thirty_0\CD\13745420 to_1\TO\1740 135_2\CD\1740 min_3\NN\15154774 after_4\IN\1740 the_5\DT\1740 injection_6\NN\320852 of_7\IN\1740 crystalline_8\NN\1740 insulin_9\NN\5407119 ,_10\,\1740 iso_11\NN\1740 was_12\VBD\836236 given_13\VBN\2327200 subcutaneously_14\RB\1740 and_15\CC\1740 when_16\WRB\1740 iso_17\NN\1740 induced_18\VBD\1627355 <e2>fibrosis</e2>_19\NN\14204950 in_20\IN\13603305 the_21\DT\1740 myocardium_22\NN\5389939 was_23\VBD\836236 morphometrically_24\RB\1740 analyzed_25\VBN\78760 7_26\CD\13741022 days_27\NNS\15140892 later_28\RB\1740 ,_29\,\1740 a_30\DT\13649268 highly_31\RB\1740 significant_32\JJ\1740 correlation_33\NN\13841213 (_34\-LRB-\1740 r_35\NN\13635336 =_36\JJ\1740 0.83_37\CD\1740 ,_38\,\1740 2_39\CD\13741022 p_40\NN\14622893 =_41\JJ\1740 0.006_42\CD\1740 )_43\-RRB-\1740 to_44\TO\1740 the_45\DT\1740 slope_46\NN\9287968 of_47\IN\1740 the_48\DT\1740 fall_49\NN\15236475 in_50\IN\13603305 blood_51\NN\5397468 <e1>glucose</e1>_52\NN\14710501 after_53\IN\1740 insulin_54\NN\5407119 treatment_55\NN\654885 appeared_56\VBD\2604760 ._57\.\1740
D002395_D003920 NONE the_0\DT\1740 myocardial_1\JJ\1740 content_2\NN\7951464 of_3\IN\1740 <e1>catecholamines</e1>_4\NNS\5407119 was_5\VBD\836236 estimated_6\VBN\637259 in_7\IN\13603305 these_8\DT\1740 8_9\CD\13741022 day_10\NN\15154774 <e2>diabetic</e2>_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D002395_D003920 NONE the_0\DT\1740 rapid_1\JJ\1740 reversion_2\NN\13286801 after_3\IN\1740 insulin_4\NN\5407119 treatment_5\NN\654885 excludes_6\VBZ\471711 the_7\DT\1740 possibility_8\NN\5944958 that_9\IN\1740 streptozotocin_10\NN\1740 in_11\IN\13603305 itself_12\PRP\1740 causes_13\VBZ\1617192 the_14\DT\1740 iso_15\NN\1740 resistance_16\NN\37396 and_17\CC\1740 points_18\VBZ\831651 towards_19\IN\1740 a_20\DT\13649268 direct_21\JJ\1740 insulin_22\NN\5407119 effect_23\NN\34213 on_24\IN\1740 myocardial_25\JJ\1740 <e1>catecholamine</e1>_26\NN\5407119 sensitivity_27\NN\5651971 in_28\IN\13603305 <e2>diabetic</e2>_29\JJ\1740 rats_30\NNS\2329401 ._31\.\1740
25096313
D013256_D009422 NONE lateral_0\JJ\1740 antebrachial_1\NN\1740 cutaneous_2\JJ\1740 <e2>neuropathy</e2>_3\NN\14204950 after_4\IN\1740 <e1>steroid</e1>_5\NN\14727670 injection_6\NN\320852 at_7\IN\14622893 lateral_8\JJ\1740 epicondyle_9\NN\5470189 ._10\.\1740
D013256_D009422 NONE background_0\NN\4921011 and_1\CC\1740 objectives_2\NNS\5980875 :_3\:\1740 this_4\DT\1740 report_5\NN\6470073 aimed_6\VBN\1987160 to_7\TO\1740 present_8\VB\2137132 a_9\DT\13649268 case_10\NN\7283608 of_11\IN\1740 lateral_12\JJ\1740 antebrachial_13\JJ\1740 cutaneous_14\JJ\1740 <e2>neuropathy</e2>_15\NN\14204950 (_16\-LRB-\1740 lacnp_17\NN\1740 )_18\-RRB-\1740 that_19\WDT\1740 occurred_20\VBD\2623529 after_21\IN\1740 a_22\DT\13649268 <e1>steroid</e1>_23\NN\14727670 injection_24\NN\320852 in_25\IN\13603305 the_26\DT\1740 lateral_27\JJ\1740 epicondyle_28\NN\5470189 to_29\TO\1740 treat_30\VB\2376958 lateral_31\JJ\1740 epicondylitis_32\NN\14336539 in_33\IN\13603305 a_34\DT\13649268 40-year-old_35\JJ\1740 woman_36\NN\9605289 ._37\.\1740
D013256_D013716 NONE background_0\NN\4921011 and_1\CC\1740 objectives_2\NNS\5980875 :_3\:\1740 this_4\DT\1740 report_5\NN\6470073 aimed_6\VBN\1987160 to_7\TO\1740 present_8\VB\2137132 a_9\DT\13649268 case_10\NN\7283608 of_11\IN\1740 lateral_12\JJ\1740 antebrachial_13\JJ\1740 cutaneous_14\JJ\1740 neuropathy_15\NN\14204950 (_16\-LRB-\1740 lacnp_17\NN\1740 )_18\-RRB-\1740 that_19\WDT\1740 occurred_20\VBD\2623529 after_21\IN\1740 a_22\DT\13649268 <e1>steroid</e1>_23\NN\14727670 injection_24\NN\320852 in_25\IN\13603305 the_26\DT\1740 lateral_27\JJ\1740 epicondyle_28\NN\5470189 to_29\TO\1740 treat_30\VB\2376958 <e2>lateral_31\JJ\1740 epicondylitis</e2>_32\NN\14336539 in_33\IN\13603305 a_34\DT\13649268 40-year-old_35\JJ\1740 woman_36\NN\9605289 ._37\.\1740
D013256_D013716 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 report_3\NN\6470073 describes_4\VBZ\1001294 the_5\DT\1740 case_6\NN\7283608 of_7\IN\1740 a_8\DT\13649268 woman_9\NN\9605289 with_10\IN\1740 lacnp_11\NN\1740 that_12\WDT\1740 developed_13\VBD\1753788 after_14\IN\1740 a_15\DT\13649268 <e1>steroid</e1>_16\NN\14727670 injection_17\NN\320852 for_18\IN\1740 the_19\DT\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>lateral_22\JJ\1740 epicondylitis</e2>_23\NN\14336539 ._24\.\1740
D013256_D010292 CID material_0\NN\19613 and_1\CC\1740 method_2\NN\5616786 :_3\:\1740 a_4\DT\13649268 40-year-old_5\JJ\1740 woman_6\NN\9605289 presented_7\VBN\2137132 with_8\IN\1740 decreased_9\VBN\169651 sensation_10\NN\5708432 and_11\CC\1740 <e2>paresthesia</e2>_12\VBD\1740 over_13\IN\5867413 her_14\PRP$\1740 right_15\JJ\1740 lateral_16\JJ\1740 forearm_17\NN\5560244 ;_18\:\1740 the_19\DT\1740 paresthesia_20\NN\14299637 had_21\VBD\2108377 occurred_22\VBN\2623529 after_23\IN\1740 a_24\DT\13649268 <e1>steroid</e1>_25\NN\14727670 injection_26\NN\320852 in_27\IN\13603305 the_28\DT\1740 right_29\JJ\1740 lateral_30\JJ\1740 epicondyle_31\NN\5470189 3_32\CD\13741022 months_33\NNS\15113229 before_34\RB\1740 ._35\.\1740
D013256_D010292 CID material_0\NN\19613 and_1\CC\1740 method_2\NN\5616786 :_3\:\1740 a_4\DT\13649268 40-year-old_5\JJ\1740 woman_6\NN\9605289 presented_7\VBN\2137132 with_8\IN\1740 decreased_9\VBN\169651 sensation_10\NN\5708432 and_11\CC\1740 paresthesia_12\VBD\1740 over_13\IN\5867413 her_14\PRP$\1740 right_15\JJ\1740 lateral_16\JJ\1740 forearm_17\NN\5560244 ;_18\:\1740 the_19\DT\1740 <e2>paresthesia</e2>_20\NN\14299637 had_21\VBD\2108377 occurred_22\VBN\2623529 after_23\IN\1740 a_24\DT\13649268 <e1>steroid</e1>_25\NN\14727670 injection_26\NN\320852 in_27\IN\13603305 the_28\DT\1740 right_29\JJ\1740 lateral_30\JJ\1740 epicondyle_31\NN\5470189 3_32\CD\13741022 months_33\NNS\15113229 before_34\RB\1740 ._35\.\1740
24664478
C104457_D020258 NONE <e1>nelarabine</e1>_0\JJ\1740 <e2>neurotoxicity</e2>_1\NN\1740 with_2\IN\1740 concurrent_3\JJ\1740 intrathecal_4\JJ\1740 chemotherapy_5\NN\661091 :_6\:\1740 case_7\NN\7283608 report_8\NN\6470073 and_9\CC\1740 review_10\NN\5733583 of_11\IN\1740 literature_12\NN\6362953 ._13\.\1740
C104457_D020258 NONE severe_0\JJ\1740 <e1>nelarabine</e1>_1\JJ\1740 <e2>neurotoxicity</e2>_2\NN\1740 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 who_6\WP\8299493 received_7\VBD\2210855 concurrent_8\JJ\1740 intrathecal_9\JJ\1740 (_10\-LRB-\1740 it_11\NN\6125041 )_12\-RRB-\1740 chemotherapy_13\NN\661091 is_14\VBZ\836236 reported_15\VBN\831651 ._16\.\1740
C104457_D020258 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 published_8\VBN\1621555 case_9\NN\7283608 report_10\NN\6470073 of_11\IN\1740 severe_12\JJ\1740 <e2>neurotoxicity</e2>_13\NN\1740 caused_14\VBN\1617192 by_15\IN\1740 <e1>nelarabine</e1>_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 patient_19\NN\9898892 who_20\WP\8299493 received_21\VBD\2210855 concurrent_22\JJ\1740 it_23\NN\6125041 chemotherapy_24\NN\661091 ._25\.\1740
24659727
D008130_D008223 NONE tolerability_0\NN\1740 of_1\IN\1740 <e1>lomustine</e1>_2\NN\2722458 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 cyclophosphamide_6\NN\1740 in_7\IN\13603305 dogs_8\NNS\2083346 with_9\IN\1740 <e2>lymphoma</e2>_10\NN\14239918 ._11\.\1740
D008130_D008223 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 toxicity_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 <e1>lomustine</e1>_10\NN\2722458 (_11\-LRB-\1740 ccnu_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 cyclophosphamide_15\NN\1740 (_16\-LRB-\1740 ctx_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 <e2>lymphoma</e2>_22\NN\14239918 ._23\.\1740
D008130_D008223 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 toxicity_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 lomustine_10\NN\2722458 (_11\-LRB-\1740 <e1>ccnu</e1>_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 cyclophosphamide_15\NN\1740 (_16\-LRB-\1740 ctx_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 <e2>lymphoma</e2>_22\NN\14239918 ._23\.\1740
D003520_D008223 NONE tolerability_0\NN\1740 of_1\IN\1740 lomustine_2\NN\2722458 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 <e1>cyclophosphamide</e1>_6\NN\1740 in_7\IN\13603305 dogs_8\NNS\2083346 with_9\IN\1740 <e2>lymphoma</e2>_10\NN\14239918 ._11\.\1740
D003520_D008223 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 toxicity_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 lomustine_10\NN\2722458 (_11\-LRB-\1740 ccnu_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 <e1>cyclophosphamide</e1>_15\NN\1740 (_16\-LRB-\1740 ctx_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 <e2>lymphoma</e2>_22\NN\14239918 ._23\.\1740
D003520_D008223 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 toxicity_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 lomustine_10\NN\2722458 (_11\-LRB-\1740 ccnu_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 cyclophosphamide_15\NN\1740 (_16\-LRB-\1740 <e1>ctx</e1>_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 <e2>lymphoma</e2>_22\NN\14239918 ._23\.\1740
D008130_D064420 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 <e2>toxicity</e2>_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 <e1>lomustine</e1>_10\NN\2722458 (_11\-LRB-\1740 ccnu_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 cyclophosphamide_15\NN\1740 (_16\-LRB-\1740 ctx_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 lymphoma_22\NN\14239918 ._23\.\1740
D008130_D064420 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 <e2>toxicity</e2>_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 lomustine_10\NN\2722458 (_11\-LRB-\1740 <e1>ccnu</e1>_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 cyclophosphamide_15\NN\1740 (_16\-LRB-\1740 ctx_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 lymphoma_22\NN\14239918 ._23\.\1740
D003520_D064420 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 <e2>toxicity</e2>_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 lomustine_10\NN\2722458 (_11\-LRB-\1740 ccnu_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 <e1>cyclophosphamide</e1>_15\NN\1740 (_16\-LRB-\1740 ctx_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 lymphoma_22\NN\14239918 ._23\.\1740
D003520_D064420 NONE this_0\DT\1740 retrospective_1\JJ\1740 study_2\NN\635850 describes_3\VBZ\1001294 <e2>toxicity</e2>_4\NN\13576101 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 protocol_8\NN\6652242 of_9\IN\1740 lomustine_10\NN\2722458 (_11\-LRB-\1740 ccnu_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 cyclophosphamide_15\NN\1740 (_16\-LRB-\1740 <e1>ctx</e1>_17\NN\1740 )_18\-RRB-\1740 in_19\IN\13603305 dogs_20\NNS\2083346 with_21\IN\1740 lymphoma_22\NN\14239918 ._23\.\1740
D008130_D009503 CID <e2>neutropenia</e2>_0\NNP\14196405 was_1\VBD\836236 the_2\DT\1740 principal_3\JJ\1740 toxic_4\JJ\1740 effect_5\NN\34213 ,_6\,\1740 and_7\CC\1740 the_8\DT\1740 overall_9\JJ\1740 frequency_10\NN\15286249 of_11\IN\1740 grade_12\NN\7975026 4_13\CD\13741022 neutropenia_14\NN\14196405 after_15\IN\1740 the_16\DT\1740 first_17\JJ\1740 treatment_18\NN\654885 of_19\IN\1740 <e1>ccnu/ctx</e1>_20\NN\1740 was_21\VBD\836236 30_22\CD\13745420 %_23\NN\1740 (_24\-LRB-\1740 95_25\CD\1740 %_26\NN\1740 confidence_27\NN\5697135 interval_28\NN\33615 ,_29\,\1740 19_30\CD\13745420 -_31\SYM\1740 43_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 ._35\.\1740
D008130_D009503 CID neutropenia_0\NNP\14196405 was_1\VBD\836236 the_2\DT\1740 principal_3\JJ\1740 toxic_4\JJ\1740 effect_5\NN\34213 ,_6\,\1740 and_7\CC\1740 the_8\DT\1740 overall_9\JJ\1740 frequency_10\NN\15286249 of_11\IN\1740 grade_12\NN\7975026 4_13\CD\13741022 <e2>neutropenia</e2>_14\NN\14196405 after_15\IN\1740 the_16\DT\1740 first_17\JJ\1740 treatment_18\NN\654885 of_19\IN\1740 <e1>ccnu/ctx</e1>_20\NN\1740 was_21\VBD\836236 30_22\CD\13745420 %_23\NN\1740 (_24\-LRB-\1740 95_25\CD\1740 %_26\NN\1740 confidence_27\NN\5697135 interval_28\NN\33615 ,_29\,\1740 19_30\CD\13745420 -_31\SYM\1740 43_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 ._35\.\1740
D003520_D009503 CID <e2>neutropenia</e2>_0\NNP\14196405 was_1\VBD\836236 the_2\DT\1740 principal_3\JJ\1740 toxic_4\JJ\1740 effect_5\NN\34213 ,_6\,\1740 and_7\CC\1740 the_8\DT\1740 overall_9\JJ\1740 frequency_10\NN\15286249 of_11\IN\1740 grade_12\NN\7975026 4_13\CD\13741022 neutropenia_14\NN\14196405 after_15\IN\1740 the_16\DT\1740 first_17\JJ\1740 treatment_18\NN\654885 of_19\IN\1740 <e1>ccnu/ctx</e1>_20\NN\1740 was_21\VBD\836236 30_22\CD\13745420 %_23\NN\1740 (_24\-LRB-\1740 95_25\CD\1740 %_26\NN\1740 confidence_27\NN\5697135 interval_28\NN\33615 ,_29\,\1740 19_30\CD\13745420 -_31\SYM\1740 43_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 ._35\.\1740
D003520_D009503 CID neutropenia_0\NNP\14196405 was_1\VBD\836236 the_2\DT\1740 principal_3\JJ\1740 toxic_4\JJ\1740 effect_5\NN\34213 ,_6\,\1740 and_7\CC\1740 the_8\DT\1740 overall_9\JJ\1740 frequency_10\NN\15286249 of_11\IN\1740 grade_12\NN\7975026 4_13\CD\13741022 <e2>neutropenia</e2>_14\NN\14196405 after_15\IN\1740 the_16\DT\1740 first_17\JJ\1740 treatment_18\NN\654885 of_19\IN\1740 <e1>ccnu/ctx</e1>_20\NN\1740 was_21\VBD\836236 30_22\CD\13745420 %_23\NN\1740 (_24\-LRB-\1740 95_25\CD\1740 %_26\NN\1740 confidence_27\NN\5697135 interval_28\NN\33615 ,_29\,\1740 19_30\CD\13745420 -_31\SYM\1740 43_32\CD\1740 %_33\NN\1740 )_34\-RRB-\1740 ._35\.\1740
D008130_D009369 NONE on_0\IN\1740 the_1\DT\1740 basis_2\NN\13790712 of_3\IN\1740 the_4\DT\1740 findings_5\NNS\7951464 reported_6\VBN\831651 herein_7\RB\1740 ,_8\,\1740 a_9\DT\13649268 dose_10\NN\3740161 of_11\IN\1740 60_12\CD\13745420 mg/m(2_13\NN\1740 )_14\-RRB-\1740 of_15\IN\1740 <e1>ccnu</e1>_16\NN\1740 combined_17\VBN\2630189 with_18\IN\1740 250_19\CD\1740 mg/m(2_20\NN\1740 )_21\-RRB-\1740 of_22\IN\1740 ctx_23\NN\1740 (_24\-LRB-\1740 divided_25\VBN\140123 over_26\RB\1740 5_27\CD\13741022 days_28\NNS\15140892 )_29\-RRB-\1740 q_30\DT\6828818 4_31\CD\13741022 wk_32\NN\1740 is_33\VBZ\836236 tolerable_34\JJ\1740 in_35\IN\13603305 <e2>tumor-bearing</e2>_36\JJ\1740 dogs_37\NNS\2083346 ._38\.\1740
D003520_D009369 NONE on_0\IN\1740 the_1\DT\1740 basis_2\NN\13790712 of_3\IN\1740 the_4\DT\1740 findings_5\NNS\7951464 reported_6\VBN\831651 herein_7\RB\1740 ,_8\,\1740 a_9\DT\13649268 dose_10\NN\3740161 of_11\IN\1740 60_12\CD\13745420 mg/m(2_13\NN\1740 )_14\-RRB-\1740 of_15\IN\1740 ccnu_16\NN\1740 combined_17\VBN\2630189 with_18\IN\1740 250_19\CD\1740 mg/m(2_20\NN\1740 )_21\-RRB-\1740 of_22\IN\1740 <e1>ctx</e1>_23\NN\1740 (_24\-LRB-\1740 divided_25\VBN\140123 over_26\RB\1740 5_27\CD\13741022 days_28\NNS\15140892 )_29\-RRB-\1740 q_30\DT\6828818 4_31\CD\13741022 wk_32\NN\1740 is_33\VBZ\836236 tolerable_34\JJ\1740 in_35\IN\13603305 <e2>tumor-bearing</e2>_36\JJ\1740 dogs_37\NNS\2083346 ._38\.\1740
15991002
D009538_D001008 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 investigates_5\VBZ\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>nicotine</e1>_9\NN\14712692 on_10\IN\1740 <e2>anxiety</e2>_11\NN\14373582 induced_12\VBN\1627355 by_13\IN\1740 caffeine_14\NN\14712692 and_15\CC\1740 another_16\DT\1740 anxiogenic_17\JJ\1740 drug_18\NN\14778436 ,_19\,\1740 pentylenetetrazole_20\NN\1740 ,_21\,\1740 in_22\IN\13603305 mice_23\NNS\2329401 ._24\.\1740
D009538_D001008 NONE <e1>nicotine</e1>_0\NN\14712692 (_1\-LRB-\1740 0.25_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 pretreatment_5\NN\1740 blocked_6\VBD\1476483 the_7\DT\1740 caffeine-_8\NN\1740 but_9\CC\1740 not_10\RB\1740 pentylenetetrazole-induced_11\JJ\1740 <e2>anxiety</e2>_12\NN\14373582 ._13\.\1740
D009538_D001008 NONE conclusions_0\NNS\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 antagonistic_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>nicotine</e1>_10\NN\14712692 on_11\IN\1740 caffeine-induced_12\JJ\1740 <e2>anxiety</e2>_13\NN\14373582 is_14\VBZ\836236 specific_15\JJ\1740 to_16\TO\1740 caffeine_17\NN\14712692 ,_18\,\1740 instead_19\RB\1740 of_20\IN\1740 a_21\DT\13649268 non-specific_22\JJ\1740 anxiolytic_23\JJ\1740 effect_24\NN\34213 ._25\.\1740
D002110_D001008 CID objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 investigates_5\VBZ\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 nicotine_9\NN\14712692 on_10\IN\1740 <e2>anxiety</e2>_11\NN\14373582 induced_12\VBN\1627355 by_13\IN\1740 <e1>caffeine</e1>_14\NN\14712692 and_15\CC\1740 another_16\DT\1740 anxiogenic_17\JJ\1740 drug_18\NN\14778436 ,_19\,\1740 pentylenetetrazole_20\NN\1740 ,_21\,\1740 in_22\IN\13603305 mice_23\NNS\2329401 ._24\.\1740
D002110_D001008 CID nicotine_0\NN\14712692 (_1\-LRB-\1740 0.25_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 pretreatment_5\NN\1740 blocked_6\VBD\1476483 the_7\DT\1740 <e1>caffeine-</e1>_8\NN\1740 but_9\CC\1740 not_10\RB\1740 pentylenetetrazole-induced_11\JJ\1740 <e2>anxiety</e2>_12\NN\14373582 ._13\.\1740
D002110_D001008 CID conclusions_0\NNS\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 antagonistic_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 nicotine_10\NN\14712692 on_11\IN\1740 <e1>caffeine-induced</e1>_12\JJ\1740 <e2>anxiety</e2>_13\NN\14373582 is_14\VBZ\836236 specific_15\JJ\1740 to_16\TO\1740 caffeine_17\NN\14712692 ,_18\,\1740 instead_19\RB\1740 of_20\IN\1740 a_21\DT\13649268 non-specific_22\JJ\1740 anxiolytic_23\JJ\1740 effect_24\NN\34213 ._25\.\1740
D002110_D001008 CID conclusions_0\NNS\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 antagonistic_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 nicotine_10\NN\14712692 on_11\IN\1740 caffeine-induced_12\JJ\1740 <e2>anxiety</e2>_13\NN\14373582 is_14\VBZ\836236 specific_15\JJ\1740 to_16\TO\1740 <e1>caffeine</e1>_17\NN\14712692 ,_18\,\1740 instead_19\RB\1740 of_20\IN\1740 a_21\DT\13649268 non-specific_22\JJ\1740 anxiolytic_23\JJ\1740 effect_24\NN\34213 ._25\.\1740
D010433_D001008 CID objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 investigates_5\VBZ\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 nicotine_9\NN\14712692 on_10\IN\1740 <e2>anxiety</e2>_11\NN\14373582 induced_12\VBN\1627355 by_13\IN\1740 caffeine_14\NN\14712692 and_15\CC\1740 another_16\DT\1740 anxiogenic_17\JJ\1740 drug_18\NN\14778436 ,_19\,\1740 <e1>pentylenetetrazole</e1>_20\NN\1740 ,_21\,\1740 in_22\IN\13603305 mice_23\NNS\2329401 ._24\.\1740
D010433_D001008 CID nicotine_0\NN\14712692 (_1\-LRB-\1740 0.25_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 pretreatment_5\NN\1740 blocked_6\VBD\1476483 the_7\DT\1740 caffeine-_8\NN\1740 but_9\CC\1740 not_10\RB\1740 <e1>pentylenetetrazole-induced</e1>_11\JJ\1740 <e2>anxiety</e2>_12\NN\14373582 ._13\.\1740
3987172
D011433_D006973 NONE <e1>propranolol</e1>_0\JJ\1740 antagonism_1\NN\24720 of_2\IN\1740 phenylpropanolamine-induced_3\JJ\1740 <e2>hypertension</e2>_4\NN\14057371 ._5\.\1740
D011433_D006973 NONE we_0\PRP\1740 studied_1\VBD\630380 the_2\DT\1740 efficacy_3\NN\5199286 and_4\CC\1740 safety_5\NN\13920835 of_6\IN\1740 <e1>propranolol</e1>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 ppa-induced_12\JJ\1740 <e2>hypertension</e2>_13\NN\14057371 ._14\.\1740
D010665_D006973 CID propranolol_0\JJ\1740 antagonism_1\NN\24720 of_2\IN\1740 <e1>phenylpropanolamine-induced</e1>_3\JJ\1740 <e2>hypertension</e2>_4\NN\14057371 ._5\.\1740
D010665_D006973 CID <e1>phenylpropanolamine</e1>_0\NN\2682038 (_1\-LRB-\1740 ppa_2\NN\1740 )_3\-RRB-\1740 overdose_4\NN\1740 can_5\MD\3094503 cause_6\VB\1617192 severe_7\JJ\1740 <e2>hypertension</e2>_8\NN\14057371 ,_9\,\1740 intracerebral_10\JJ\1740 hemorrhage_11\NN\14285662 ,_12\,\1740 and_13\CC\1740 death_14\NN\7296428 ._15\.\1740
D010665_D006973 CID phenylpropanolamine_0\NN\2682038 (_1\-LRB-\1740 <e1>ppa</e1>_2\NN\1740 )_3\-RRB-\1740 overdose_4\NN\1740 can_5\MD\3094503 cause_6\VB\1617192 severe_7\JJ\1740 <e2>hypertension</e2>_8\NN\14057371 ,_9\,\1740 intracerebral_10\JJ\1740 hemorrhage_11\NN\14285662 ,_12\,\1740 and_13\CC\1740 death_14\NN\7296428 ._15\.\1740
D010665_D006973 CID we_0\PRP\1740 studied_1\VBD\630380 the_2\DT\1740 efficacy_3\NN\5199286 and_4\CC\1740 safety_5\NN\13920835 of_6\IN\1740 propranolol_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 <e1>ppa-induced</e1>_12\JJ\1740 <e2>hypertension</e2>_13\NN\14057371 ._14\.\1740
D010665_D062787 NONE <e1>phenylpropanolamine</e1>_0\NN\2682038 (_1\-LRB-\1740 ppa_2\NN\1740 )_3\-RRB-\1740 <e2>overdose</e2>_4\NN\1740 can_5\MD\3094503 cause_6\VB\1617192 severe_7\JJ\1740 hypertension_8\NN\14057371 ,_9\,\1740 intracerebral_10\JJ\1740 hemorrhage_11\NN\14285662 ,_12\,\1740 and_13\CC\1740 death_14\NN\7296428 ._15\.\1740
D010665_D062787 NONE phenylpropanolamine_0\NN\2682038 (_1\-LRB-\1740 <e1>ppa</e1>_2\NN\1740 )_3\-RRB-\1740 <e2>overdose</e2>_4\NN\1740 can_5\MD\3094503 cause_6\VB\1617192 severe_7\JJ\1740 hypertension_8\NN\14057371 ,_9\,\1740 intracerebral_10\JJ\1740 hemorrhage_11\NN\14285662 ,_12\,\1740 and_13\CC\1740 death_14\NN\7296428 ._15\.\1740
D010665_D002543 NONE <e1>phenylpropanolamine</e1>_0\NN\2682038 (_1\-LRB-\1740 ppa_2\NN\1740 )_3\-RRB-\1740 overdose_4\NN\1740 can_5\MD\3094503 cause_6\VB\1617192 severe_7\JJ\1740 hypertension_8\NN\14057371 ,_9\,\1740 <e2>intracerebral_10\JJ\1740 hemorrhage</e2>_11\NN\14285662 ,_12\,\1740 and_13\CC\1740 death_14\NN\7296428 ._15\.\1740
D010665_D002543 NONE phenylpropanolamine_0\NN\2682038 (_1\-LRB-\1740 <e1>ppa</e1>_2\NN\1740 )_3\-RRB-\1740 overdose_4\NN\1740 can_5\MD\3094503 cause_6\VB\1617192 severe_7\JJ\1740 hypertension_8\NN\14057371 ,_9\,\1740 <e2>intracerebral_10\JJ\1740 hemorrhage</e2>_11\NN\14285662 ,_12\,\1740 and_13\CC\1740 death_14\NN\7296428 ._15\.\1740
D010665_D020521 NONE left_0\JJ\1740 ventricular_1\JJ\1740 function_2\NN\13783581 (_3\-LRB-\1740 assessed_4\VBN\670261 by_5\IN\1740 echocardiography_6\NN\177127 )_7\-RRB-\1740 showed_8\VBD\2137132 that_9\IN\1740 <e1>ppa</e1>_10\NN\1740 increased_11\VBD\169651 the_12\DT\1740 <e2>stroke</e2>_13\NN\556313 volume_14\NN\33615 30_15\CD\13745420 %_16\NN\1740 (_17\-LRB-\1740 from_18\IN\1740 62.5_19\CD\1740 +/-_20\CC\1740 20.9_21\CD\1740 to_22\TO\1740 80.8_23\CD\1740 +/-_24\CC\1740 22.4_25\CD\1740 ml_26\NN\13616054 )_27\-RRB-\1740 ,_28\,\1740 the_29\DT\1740 ejection_30\NN\45250 fraction_31\NN\14806838 9_32\CD\13741022 %_33\NN\1740 (_34\-LRB-\1740 from_35\IN\1740 64_36\CD\1740 %_37\NN\1740 +/-_38\CC\1740 10_39\CD\13745420 %_40\NN\1740 to_41\IN\1740 70_42\CD\13745420 %_43\NN\1740 +/-_44\CC\1740 7_45\CD\13741022 %_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 cardiac_50\JJ\1740 output_51\NN\4007894 14_52\CD\13745420 %_53\NN\1740 (_54\-LRB-\1740 from_55\IN\1740 3.6_56\CD\1740 +/-_57\CC\1740 0.6_58\CD\1740 to_59\TO\1740 4.1_60\CD\1740 +/-_61\CC\1740 1.0_62\CD\1740 l/min_63\NN\1740 )_64\-RRB-\1740 ._65\.\1740
20408947
D000082_D017114 CID medical_0\JJ\1740 and_1\CC\1740 psychiatric_2\JJ\1740 outcomes_3\NNS\7291312 for_4\IN\1740 patients_5\NNS\9898892 transplanted_6\VBN\2013571 for_7\IN\1740 <e1>acetaminophen-induced</e1>_8\JJ\1740 <e2>acute_9\JJ\1740 liver_10\NN\5298729 failure</e2>_11\NN\66216 :_12\:\1740 a_13\DT\13649268 case-control_14\JJ\1740 study_15\NN\635850 ._16\.\1740
D000082_D017114 CID background_0\NN\4921011 :_1\:\1740 <e1>acetaminophen-induced</e1>_2\JJ\1740 hepatotoxicity_3\NN\1740 is_4\VBZ\836236 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 cause_8\NN\7323922 of_9\IN\1740 <e2>acute_10\JJ\1740 liver_11\NN\5298729 failure</e2>_12\NN\66216 (_13\-LRB-\1740 alf_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 the_17\DT\1740 uk_18\NNP\1740 ._19\.\1740
D000082_D017114 CID background_0\NN\4921011 :_1\:\1740 <e1>acetaminophen-induced</e1>_2\JJ\1740 hepatotoxicity_3\NN\1740 is_4\VBZ\836236 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 cause_8\NN\7323922 of_9\IN\1740 acute_10\JJ\1740 liver_11\NN\5298729 failure_12\NN\66216 (_13\-LRB-\1740 <e2>alf</e2>_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 the_17\DT\1740 uk_18\NNP\1740 ._19\.\1740
D000082_D017114 CID aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 <e1>acetaminophen-induced</e1>_36\JJ\1740 <e2>alf</e2>_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 non-acetaminophen-induced_50\JJ\1740 alf_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 chronic_59\JJ\1740 liver_60\NN\5298729 disease_61\NN\14061805 (_62\-LRB-\1740 cld_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D017114 CID aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 <e1>acetaminophen-induced</e1>_36\JJ\1740 alf_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 non-acetaminophen-induced_50\JJ\1740 <e2>alf</e2>_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 chronic_59\JJ\1740 liver_60\NN\5298729 disease_61\NN\14061805 (_62\-LRB-\1740 cld_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D017114 CID aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 acetaminophen-induced_36\JJ\1740 <e2>alf</e2>_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 <e1>non-acetaminophen-induced</e1>_50\JJ\1740 alf_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 chronic_59\JJ\1740 liver_60\NN\5298729 disease_61\NN\14061805 (_62\-LRB-\1740 cld_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D017114 CID aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 acetaminophen-induced_36\JJ\1740 alf_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 <e1>non-acetaminophen-induced</e1>_50\JJ\1740 <e2>alf</e2>_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 chronic_59\JJ\1740 liver_60\NN\5298729 disease_61\NN\14061805 (_62\-LRB-\1740 cld_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D017114 CID results_0\NNS\34213 :_1\:\1740 <e1>acetaminophen-induced</e1>_2\JJ\1740 <e2>alf</e2>_3\NN\1740 patients_4\NNS\9898892 undergoing_5\VBG\109660 lt_6\NN\1740 had_7\VBD\2108377 a_8\DT\13649268 greater_9\JJR\1740 severity_10\NN\5036394 of_11\IN\1740 pre-lt_12\JJ\1740 illness_13\NN\14052046 reflected_14\VBN\923793 by_15\IN\1740 higher_16\JJR\1740 acute_17\NNP\6822198 physiology_18\NNP\6037666 and_19\CC\1740 chronic_20\NNP\1740 health_21\NN\14447525 evaluation_22\NN\874067 ii_23\CD\13741022 scores_24\NNS\13757724 and_25\CC\1740 requirement_26\NN\1129920 for_27\IN\1740 organ_28\JJ\1740 support_29\NN\407535 compared_30\VBN\644583 with_31\IN\1740 the_32\DT\1740 other_33\JJ\1740 two_34\CD\13741022 groups_35\NNS\2137 ._36\.\1740
D000082_D017114 CID twenty_0\CD\13745420 (_1\-LRB-\1740 56_2\CD\1740 %_3\NN\1740 )_4\-RRB-\1740 <e1>acetaminophen-induced</e1>_5\JJ\1740 <e2>alf</e2>_6\NN\1740 patients_7\NNS\9898892 had_8\VBD\2108377 a_9\DT\13649268 formal_10\JJ\1740 psychiatric_11\JJ\1740 diagnosis_12\NN\152018 before_13\IN\1740 lt_14\NN\1740 (_15\-LRB-\1740 non-acetaminophen-induced_16\JJ\1740 alf=0/35_17\NN\1740 ,_18\,\1740 cld=2/34_19\JJ\1740 ;_20\:\1740 p<0.01_21\NN\1740 for_22\IN\1740 all_23\DT\1740 )_24\-RRB-\1740 and_25\CC\1740 nine_26\CD\13741022 (_27\-LRB-\1740 25_28\CD\13745420 %_29\NN\1740 )_30\-RRB-\1740 had_31\VBD\2108377 a_32\DT\13649268 previous_33\JJ\1740 suicide_34\NN\219012 attempt_35\NN\407535 ._36\.\1740
D000082_D017114 CID twenty_0\CD\13745420 (_1\-LRB-\1740 56_2\CD\1740 %_3\NN\1740 )_4\-RRB-\1740 <e1>acetaminophen-induced</e1>_5\JJ\1740 alf_6\NN\1740 patients_7\NNS\9898892 had_8\VBD\2108377 a_9\DT\13649268 formal_10\JJ\1740 psychiatric_11\JJ\1740 diagnosis_12\NN\152018 before_13\IN\1740 lt_14\NN\1740 (_15\-LRB-\1740 non-acetaminophen-induced_16\JJ\1740 <e2>alf=0/35</e2>_17\NN\1740 ,_18\,\1740 cld=2/34_19\JJ\1740 ;_20\:\1740 p<0.01_21\NN\1740 for_22\IN\1740 all_23\DT\1740 )_24\-RRB-\1740 and_25\CC\1740 nine_26\CD\13741022 (_27\-LRB-\1740 25_28\CD\13745420 %_29\NN\1740 )_30\-RRB-\1740 had_31\VBD\2108377 a_32\DT\13649268 previous_33\JJ\1740 suicide_34\NN\219012 attempt_35\NN\407535 ._36\.\1740
D000082_D017114 CID twenty_0\CD\13745420 (_1\-LRB-\1740 56_2\CD\1740 %_3\NN\1740 )_4\-RRB-\1740 acetaminophen-induced_5\JJ\1740 <e2>alf</e2>_6\NN\1740 patients_7\NNS\9898892 had_8\VBD\2108377 a_9\DT\13649268 formal_10\JJ\1740 psychiatric_11\JJ\1740 diagnosis_12\NN\152018 before_13\IN\1740 lt_14\NN\1740 (_15\-LRB-\1740 <e1>non-acetaminophen-induced</e1>_16\JJ\1740 alf=0/35_17\NN\1740 ,_18\,\1740 cld=2/34_19\JJ\1740 ;_20\:\1740 p<0.01_21\NN\1740 for_22\IN\1740 all_23\DT\1740 )_24\-RRB-\1740 and_25\CC\1740 nine_26\CD\13741022 (_27\-LRB-\1740 25_28\CD\13745420 %_29\NN\1740 )_30\-RRB-\1740 had_31\VBD\2108377 a_32\DT\13649268 previous_33\JJ\1740 suicide_34\NN\219012 attempt_35\NN\407535 ._36\.\1740
D000082_D017114 CID twenty_0\CD\13745420 (_1\-LRB-\1740 56_2\CD\1740 %_3\NN\1740 )_4\-RRB-\1740 acetaminophen-induced_5\JJ\1740 alf_6\NN\1740 patients_7\NNS\9898892 had_8\VBD\2108377 a_9\DT\13649268 formal_10\JJ\1740 psychiatric_11\JJ\1740 diagnosis_12\NN\152018 before_13\IN\1740 lt_14\NN\1740 (_15\-LRB-\1740 <e1>non-acetaminophen-induced</e1>_16\JJ\1740 <e2>alf=0/35</e2>_17\NN\1740 ,_18\,\1740 cld=2/34_19\JJ\1740 ;_20\:\1740 p<0.01_21\NN\1740 for_22\IN\1740 all_23\DT\1740 )_24\-RRB-\1740 and_25\CC\1740 nine_26\CD\13741022 (_27\-LRB-\1740 25_28\CD\13745420 %_29\NN\1740 )_30\-RRB-\1740 had_31\VBD\2108377 a_32\DT\13649268 previous_33\JJ\1740 suicide_34\NN\219012 attempt_35\NN\407535 ._36\.\1740
D000082_D017114 CID during_0\IN\1740 follow-up_1\JJ\1740 (_2\-LRB-\1740 median_3\JJ\1740 5_4\CD\13741022 years_5\NNS\15144371 )_6\-RRB-\1740 ,_7\,\1740 there_8\EX\27167 were_9\VBD\836236 no_10\DT\7204911 significant_11\JJ\1740 differences_12\NNS\4723816 in_13\IN\13603305 rejection_14\NN\30358 (_15\-LRB-\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 graft_21\NN\5267548 failure_22\NN\66216 or_23\CC\3541091 survival_24\NN\13961642 between_25\IN\1740 the_26\DT\1740 groups_27\NNS\2137 (_28\-LRB-\1740 <e1>acetaminophen-induced</e1>_29\JJ\1740 <e2>alf</e2>_30\NN\1740 1_31\CD\13741022 year_32\NN\15113229 87_33\CD\1740 %_34\NN\1740 ,_35\,\1740 5_36\CD\13741022 years_37\NNS\15144371 75_38\CD\1740 %_39\NN\1740 ;_40\:\1740 non-acetaminophen-induced_41\JJ\1740 alf_42\NN\1740 88_43\CD\1740 %_44\NN\1740 ,_45\,\1740 78_46\CD\13745420 %_47\NN\1740 ;_48\:\1740 cld_49\NN\1740 93_50\CD\1740 %_51\NN\1740 ,_52\,\1740 82_53\CD\1740 %_54\NN\1740 :_55\:\1740 p>0.6_56\NN\1740 log_57\NN\15098161 rank_58\NN\8430568 )_59\-RRB-\1740 ._60\.\1740
D000082_D017114 CID during_0\IN\1740 follow-up_1\JJ\1740 (_2\-LRB-\1740 median_3\JJ\1740 5_4\CD\13741022 years_5\NNS\15144371 )_6\-RRB-\1740 ,_7\,\1740 there_8\EX\27167 were_9\VBD\836236 no_10\DT\7204911 significant_11\JJ\1740 differences_12\NNS\4723816 in_13\IN\13603305 rejection_14\NN\30358 (_15\-LRB-\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 graft_21\NN\5267548 failure_22\NN\66216 or_23\CC\3541091 survival_24\NN\13961642 between_25\IN\1740 the_26\DT\1740 groups_27\NNS\2137 (_28\-LRB-\1740 <e1>acetaminophen-induced</e1>_29\JJ\1740 alf_30\NN\1740 1_31\CD\13741022 year_32\NN\15113229 87_33\CD\1740 %_34\NN\1740 ,_35\,\1740 5_36\CD\13741022 years_37\NNS\15144371 75_38\CD\1740 %_39\NN\1740 ;_40\:\1740 non-acetaminophen-induced_41\JJ\1740 <e2>alf</e2>_42\NN\1740 88_43\CD\1740 %_44\NN\1740 ,_45\,\1740 78_46\CD\13745420 %_47\NN\1740 ;_48\:\1740 cld_49\NN\1740 93_50\CD\1740 %_51\NN\1740 ,_52\,\1740 82_53\CD\1740 %_54\NN\1740 :_55\:\1740 p>0.6_56\NN\1740 log_57\NN\15098161 rank_58\NN\8430568 )_59\-RRB-\1740 ._60\.\1740
D000082_D017114 CID during_0\IN\1740 follow-up_1\JJ\1740 (_2\-LRB-\1740 median_3\JJ\1740 5_4\CD\13741022 years_5\NNS\15144371 )_6\-RRB-\1740 ,_7\,\1740 there_8\EX\27167 were_9\VBD\836236 no_10\DT\7204911 significant_11\JJ\1740 differences_12\NNS\4723816 in_13\IN\13603305 rejection_14\NN\30358 (_15\-LRB-\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 graft_21\NN\5267548 failure_22\NN\66216 or_23\CC\3541091 survival_24\NN\13961642 between_25\IN\1740 the_26\DT\1740 groups_27\NNS\2137 (_28\-LRB-\1740 acetaminophen-induced_29\JJ\1740 <e2>alf</e2>_30\NN\1740 1_31\CD\13741022 year_32\NN\15113229 87_33\CD\1740 %_34\NN\1740 ,_35\,\1740 5_36\CD\13741022 years_37\NNS\15144371 75_38\CD\1740 %_39\NN\1740 ;_40\:\1740 <e1>non-acetaminophen-induced</e1>_41\JJ\1740 alf_42\NN\1740 88_43\CD\1740 %_44\NN\1740 ,_45\,\1740 78_46\CD\13745420 %_47\NN\1740 ;_48\:\1740 cld_49\NN\1740 93_50\CD\1740 %_51\NN\1740 ,_52\,\1740 82_53\CD\1740 %_54\NN\1740 :_55\:\1740 p>0.6_56\NN\1740 log_57\NN\15098161 rank_58\NN\8430568 )_59\-RRB-\1740 ._60\.\1740
D000082_D017114 CID during_0\IN\1740 follow-up_1\JJ\1740 (_2\-LRB-\1740 median_3\JJ\1740 5_4\CD\13741022 years_5\NNS\15144371 )_6\-RRB-\1740 ,_7\,\1740 there_8\EX\27167 were_9\VBD\836236 no_10\DT\7204911 significant_11\JJ\1740 differences_12\NNS\4723816 in_13\IN\13603305 rejection_14\NN\30358 (_15\-LRB-\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 graft_21\NN\5267548 failure_22\NN\66216 or_23\CC\3541091 survival_24\NN\13961642 between_25\IN\1740 the_26\DT\1740 groups_27\NNS\2137 (_28\-LRB-\1740 acetaminophen-induced_29\JJ\1740 alf_30\NN\1740 1_31\CD\13741022 year_32\NN\15113229 87_33\CD\1740 %_34\NN\1740 ,_35\,\1740 5_36\CD\13741022 years_37\NNS\15144371 75_38\CD\1740 %_39\NN\1740 ;_40\:\1740 <e1>non-acetaminophen-induced</e1>_41\JJ\1740 <e2>alf</e2>_42\NN\1740 88_43\CD\1740 %_44\NN\1740 ,_45\,\1740 78_46\CD\13745420 %_47\NN\1740 ;_48\:\1740 cld_49\NN\1740 93_50\CD\1740 %_51\NN\1740 ,_52\,\1740 82_53\CD\1740 %_54\NN\1740 :_55\:\1740 p>0.6_56\NN\1740 log_57\NN\15098161 rank_58\NN\8430568 )_59\-RRB-\1740 ._60\.\1740
D000082_D017114 CID two_0\CD\13741022 <e1>acetaminophen-induced</e1>_1\JJ\1740 <e2>alf</e2>_2\NN\1740 patients_3\NNS\9898892 reattempted_4\VBD\1740 suicide_5\NN\219012 post-lt_6\NN\1740 (_7\-LRB-\1740 one_8\CD\13741022 died_9\VBD\146138 8_10\CD\13741022 years_11\NNS\15144371 post-lt_12\JJ\1740 )_13\-RRB-\1740 ._14\.\1740
D000082_D017114 CID conclusions_0\NNS\5837957 :_1\:\1740 despite_2\IN\7501545 a_3\DT\13649268 high_4\JJ\1740 prevalence_5\NN\4764412 of_6\IN\1740 psychiatric_7\JJ\1740 disturbance_8\NN\407535 ,_9\,\1740 outcomes_10\NNS\7291312 for_11\IN\1740 patients_12\NNS\9898892 transplanted_13\VBN\2013571 emergently_14\RB\1740 for_15\IN\1740 <e1>acetaminophen-induced</e1>_16\JJ\1740 <e2>alf</e2>_17\NN\1740 were_18\VBD\836236 comparable_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 transplanted_22\VBN\2013571 for_23\IN\1740 non-acetaminophen-induced_24\JJ\1740 alf_25\NN\1740 and_26\CC\1740 electively_27\RB\1740 for_28\IN\1740 cld_29\NN\1740 ._30\.\1740
D000082_D017114 CID conclusions_0\NNS\5837957 :_1\:\1740 despite_2\IN\7501545 a_3\DT\13649268 high_4\JJ\1740 prevalence_5\NN\4764412 of_6\IN\1740 psychiatric_7\JJ\1740 disturbance_8\NN\407535 ,_9\,\1740 outcomes_10\NNS\7291312 for_11\IN\1740 patients_12\NNS\9898892 transplanted_13\VBN\2013571 emergently_14\RB\1740 for_15\IN\1740 <e1>acetaminophen-induced</e1>_16\JJ\1740 alf_17\NN\1740 were_18\VBD\836236 comparable_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 transplanted_22\VBN\2013571 for_23\IN\1740 non-acetaminophen-induced_24\JJ\1740 <e2>alf</e2>_25\NN\1740 and_26\CC\1740 electively_27\RB\1740 for_28\IN\1740 cld_29\NN\1740 ._30\.\1740
D000082_D017114 CID conclusions_0\NNS\5837957 :_1\:\1740 despite_2\IN\7501545 a_3\DT\13649268 high_4\JJ\1740 prevalence_5\NN\4764412 of_6\IN\1740 psychiatric_7\JJ\1740 disturbance_8\NN\407535 ,_9\,\1740 outcomes_10\NNS\7291312 for_11\IN\1740 patients_12\NNS\9898892 transplanted_13\VBN\2013571 emergently_14\RB\1740 for_15\IN\1740 acetaminophen-induced_16\JJ\1740 <e2>alf</e2>_17\NN\1740 were_18\VBD\836236 comparable_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 transplanted_22\VBN\2013571 for_23\IN\1740 <e1>non-acetaminophen-induced</e1>_24\JJ\1740 alf_25\NN\1740 and_26\CC\1740 electively_27\RB\1740 for_28\IN\1740 cld_29\NN\1740 ._30\.\1740
D000082_D017114 CID conclusions_0\NNS\5837957 :_1\:\1740 despite_2\IN\7501545 a_3\DT\13649268 high_4\JJ\1740 prevalence_5\NN\4764412 of_6\IN\1740 psychiatric_7\JJ\1740 disturbance_8\NN\407535 ,_9\,\1740 outcomes_10\NNS\7291312 for_11\IN\1740 patients_12\NNS\9898892 transplanted_13\VBN\2013571 emergently_14\RB\1740 for_15\IN\1740 acetaminophen-induced_16\JJ\1740 alf_17\NN\1740 were_18\VBD\836236 comparable_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 transplanted_22\VBN\2013571 for_23\IN\1740 <e1>non-acetaminophen-induced</e1>_24\JJ\1740 <e2>alf</e2>_25\NN\1740 and_26\CC\1740 electively_27\RB\1740 for_28\IN\1740 cld_29\NN\1740 ._30\.\1740
D000082_D056486 CID background_0\NN\4921011 :_1\:\1740 <e1>acetaminophen-induced</e1>_2\JJ\1740 <e2>hepatotoxicity</e2>_3\NN\1740 is_4\VBZ\836236 the_5\DT\1740 most_6\RBS\1740 common_7\JJ\1740 cause_8\NN\7323922 of_9\IN\1740 acute_10\JJ\1740 liver_11\NN\5298729 failure_12\NN\66216 (_13\-LRB-\1740 alf_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 the_17\DT\1740 uk_18\NNP\1740 ._19\.\1740
D000082_D008107 NONE aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 <e1>acetaminophen-induced</e1>_36\JJ\1740 alf_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 non-acetaminophen-induced_50\JJ\1740 alf_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 <e2>chronic_59\JJ\1740 liver_60\NN\5298729 disease</e2>_61\NN\14061805 (_62\-LRB-\1740 cld_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D008107 NONE aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 <e1>acetaminophen-induced</e1>_36\JJ\1740 alf_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 non-acetaminophen-induced_50\JJ\1740 alf_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 chronic_59\JJ\1740 liver_60\NN\5298729 disease_61\NN\14061805 (_62\-LRB-\1740 <e2>cld</e2>_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D008107 NONE aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 acetaminophen-induced_36\JJ\1740 alf_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 <e1>non-acetaminophen-induced</e1>_50\JJ\1740 alf_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 <e2>chronic_59\JJ\1740 liver_60\NN\5298729 disease</e2>_61\NN\14061805 (_62\-LRB-\1740 cld_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D008107 NONE aims_0\NNS\5980875 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 compared_5\VBD\644583 the_6\DT\1740 severity_7\NN\5036394 of_8\IN\1740 pretransplant_9\JJ\1740 illness_10\NN\14052046 ,_11\,\1740 psychiatric_12\JJ\1740 co-morbidity_13\NN\1740 ,_14\,\1740 medical_15\JJ\1740 and_16\CC\1740 psychosocial_17\JJ\1740 outcomes_18\NNS\7291312 of_19\IN\1740 all_20\DT\1740 patients_21\NNS\9898892 who_22\WP\8299493 had_23\VBD\2108377 undergone_24\VBN\109660 liver_25\NN\5298729 transplantation_26\NN\671351 (_27\-LRB-\1740 lt_28\NN\1740 )_29\-RRB-\1740 emergently_30\RB\1740 between_31\IN\1740 1999_32\CD\1740 -_33\SYM\1740 2004_34\CD\1740 for_35\IN\1740 acetaminophen-induced_36\JJ\1740 alf_37\NN\1740 (_38\-LRB-\1740 n=36_39\NN\1740 )_40\-RRB-\1740 with_41\IN\1740 age-_42\NN\1740 and_43\CC\1740 sex-matched_44\JJ\1740 patients_45\NNS\9898892 undergoing_46\VBG\109660 emergent_47\NN\1740 lt_48\NN\1740 for_49\IN\1740 <e1>non-acetaminophen-induced</e1>_50\JJ\1740 alf_51\NN\1740 (_52\-LRB-\1740 n=35_53\NN\1740 )_54\-RRB-\1740 and_55\CC\1740 elective_56\JJ\1740 lt_57\NN\1740 for_58\IN\1740 chronic_59\JJ\1740 liver_60\NN\5298729 disease_61\NN\14061805 (_62\-LRB-\1740 <e2>cld</e2>_63\NN\1740 ,_64\,\1740 n=34_65\NN\1740 )_66\-RRB-\1740 ._67\.\1740
D000082_D008107 NONE twenty_0\CD\13745420 (_1\-LRB-\1740 56_2\CD\1740 %_3\NN\1740 )_4\-RRB-\1740 <e1>acetaminophen-induced</e1>_5\JJ\1740 alf_6\NN\1740 patients_7\NNS\9898892 had_8\VBD\2108377 a_9\DT\13649268 formal_10\JJ\1740 psychiatric_11\JJ\1740 diagnosis_12\NN\152018 before_13\IN\1740 lt_14\NN\1740 (_15\-LRB-\1740 non-acetaminophen-induced_16\JJ\1740 alf=0/35_17\NN\1740 ,_18\,\1740 <e2>cld=2/34</e2>_19\JJ\1740 ;_20\:\1740 p<0.01_21\NN\1740 for_22\IN\1740 all_23\DT\1740 )_24\-RRB-\1740 and_25\CC\1740 nine_26\CD\13741022 (_27\-LRB-\1740 25_28\CD\13745420 %_29\NN\1740 )_30\-RRB-\1740 had_31\VBD\2108377 a_32\DT\13649268 previous_33\JJ\1740 suicide_34\NN\219012 attempt_35\NN\407535 ._36\.\1740
D000082_D008107 NONE twenty_0\CD\13745420 (_1\-LRB-\1740 56_2\CD\1740 %_3\NN\1740 )_4\-RRB-\1740 acetaminophen-induced_5\JJ\1740 alf_6\NN\1740 patients_7\NNS\9898892 had_8\VBD\2108377 a_9\DT\13649268 formal_10\JJ\1740 psychiatric_11\JJ\1740 diagnosis_12\NN\152018 before_13\IN\1740 lt_14\NN\1740 (_15\-LRB-\1740 <e1>non-acetaminophen-induced</e1>_16\JJ\1740 alf=0/35_17\NN\1740 ,_18\,\1740 <e2>cld=2/34</e2>_19\JJ\1740 ;_20\:\1740 p<0.01_21\NN\1740 for_22\IN\1740 all_23\DT\1740 )_24\-RRB-\1740 and_25\CC\1740 nine_26\CD\13741022 (_27\-LRB-\1740 25_28\CD\13745420 %_29\NN\1740 )_30\-RRB-\1740 had_31\VBD\2108377 a_32\DT\13649268 previous_33\JJ\1740 suicide_34\NN\219012 attempt_35\NN\407535 ._36\.\1740
D000082_D008107 NONE during_0\IN\1740 follow-up_1\JJ\1740 (_2\-LRB-\1740 median_3\JJ\1740 5_4\CD\13741022 years_5\NNS\15144371 )_6\-RRB-\1740 ,_7\,\1740 there_8\EX\27167 were_9\VBD\836236 no_10\DT\7204911 significant_11\JJ\1740 differences_12\NNS\4723816 in_13\IN\13603305 rejection_14\NN\30358 (_15\-LRB-\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 graft_21\NN\5267548 failure_22\NN\66216 or_23\CC\3541091 survival_24\NN\13961642 between_25\IN\1740 the_26\DT\1740 groups_27\NNS\2137 (_28\-LRB-\1740 <e1>acetaminophen-induced</e1>_29\JJ\1740 alf_30\NN\1740 1_31\CD\13741022 year_32\NN\15113229 87_33\CD\1740 %_34\NN\1740 ,_35\,\1740 5_36\CD\13741022 years_37\NNS\15144371 75_38\CD\1740 %_39\NN\1740 ;_40\:\1740 non-acetaminophen-induced_41\JJ\1740 alf_42\NN\1740 88_43\CD\1740 %_44\NN\1740 ,_45\,\1740 78_46\CD\13745420 %_47\NN\1740 ;_48\:\1740 <e2>cld</e2>_49\NN\1740 93_50\CD\1740 %_51\NN\1740 ,_52\,\1740 82_53\CD\1740 %_54\NN\1740 :_55\:\1740 p>0.6_56\NN\1740 log_57\NN\15098161 rank_58\NN\8430568 )_59\-RRB-\1740 ._60\.\1740
D000082_D008107 NONE during_0\IN\1740 follow-up_1\JJ\1740 (_2\-LRB-\1740 median_3\JJ\1740 5_4\CD\13741022 years_5\NNS\15144371 )_6\-RRB-\1740 ,_7\,\1740 there_8\EX\27167 were_9\VBD\836236 no_10\DT\7204911 significant_11\JJ\1740 differences_12\NNS\4723816 in_13\IN\13603305 rejection_14\NN\30358 (_15\-LRB-\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 )_19\-RRB-\1740 ,_20\,\1740 graft_21\NN\5267548 failure_22\NN\66216 or_23\CC\3541091 survival_24\NN\13961642 between_25\IN\1740 the_26\DT\1740 groups_27\NNS\2137 (_28\-LRB-\1740 acetaminophen-induced_29\JJ\1740 alf_30\NN\1740 1_31\CD\13741022 year_32\NN\15113229 87_33\CD\1740 %_34\NN\1740 ,_35\,\1740 5_36\CD\13741022 years_37\NNS\15144371 75_38\CD\1740 %_39\NN\1740 ;_40\:\1740 <e1>non-acetaminophen-induced</e1>_41\JJ\1740 alf_42\NN\1740 88_43\CD\1740 %_44\NN\1740 ,_45\,\1740 78_46\CD\13745420 %_47\NN\1740 ;_48\:\1740 <e2>cld</e2>_49\NN\1740 93_50\CD\1740 %_51\NN\1740 ,_52\,\1740 82_53\CD\1740 %_54\NN\1740 :_55\:\1740 p>0.6_56\NN\1740 log_57\NN\15098161 rank_58\NN\8430568 )_59\-RRB-\1740 ._60\.\1740
D000082_D008107 NONE conclusions_0\NNS\5837957 :_1\:\1740 despite_2\IN\7501545 a_3\DT\13649268 high_4\JJ\1740 prevalence_5\NN\4764412 of_6\IN\1740 psychiatric_7\JJ\1740 disturbance_8\NN\407535 ,_9\,\1740 outcomes_10\NNS\7291312 for_11\IN\1740 patients_12\NNS\9898892 transplanted_13\VBN\2013571 emergently_14\RB\1740 for_15\IN\1740 <e1>acetaminophen-induced</e1>_16\JJ\1740 alf_17\NN\1740 were_18\VBD\836236 comparable_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 transplanted_22\VBN\2013571 for_23\IN\1740 non-acetaminophen-induced_24\JJ\1740 alf_25\NN\1740 and_26\CC\1740 electively_27\RB\1740 for_28\IN\1740 <e2>cld</e2>_29\NN\1740 ._30\.\1740
D000082_D008107 NONE conclusions_0\NNS\5837957 :_1\:\1740 despite_2\IN\7501545 a_3\DT\13649268 high_4\JJ\1740 prevalence_5\NN\4764412 of_6\IN\1740 psychiatric_7\JJ\1740 disturbance_8\NN\407535 ,_9\,\1740 outcomes_10\NNS\7291312 for_11\IN\1740 patients_12\NNS\9898892 transplanted_13\VBN\2013571 emergently_14\RB\1740 for_15\IN\1740 acetaminophen-induced_16\JJ\1740 alf_17\NN\1740 were_18\VBD\836236 comparable_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 transplanted_22\VBN\2013571 for_23\IN\1740 <e1>non-acetaminophen-induced</e1>_24\JJ\1740 alf_25\NN\1740 and_26\CC\1740 electively_27\RB\1740 for_28\IN\1740 <e2>cld</e2>_29\NN\1740 ._30\.\1740
1423336
D007980_D007022 CID pharmacodynamics_0\NNS\1740 of_1\IN\1740 the_2\DT\1740 <e2>hypotensive</e2>_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 <e1>levodopa</e1>_6\NN\14604959 in_7\IN\13603305 parkinsonian_8\JJ\1740 patients_9\NNS\9898892 ._10\.\1740
D007980_D007022 CID the_0\DT\1740 magnitude_1\NN\4916342 of_2\IN\1740 the_3\DT\1740 <e2>hypotensive</e2>_4\JJ\1740 effect_5\NN\34213 of_6\IN\1740 <e1>levodopa</e1>_7\NN\14604959 was_8\VBD\836236 concentration_9\NN\4916342 dependent_10\JJ\1740 and_11\CC\1740 was_12\VBD\836236 fit_13\JJ\1740 to_14\TO\1740 an_15\DT\6697703 emax_16\NN\1740 model_17\NN\5888929 in_18\IN\13603305 fluctuating_19\VBG\1850315 responders_20\NNS\9610660 ._21\.\1740
D007980_D007022 CID phenylalanine_0\NNP\14605787 ,_1\,\1740 a_2\DT\13649268 large_3\JJ\1740 neutral_4\JJ\1740 amino_5\NN\14621446 acid_6\NN\14818238 (_7\-LRB-\1740 lnaa_8\NN\1740 )_9\-RRB-\1740 competing_10\VBG\1740 with_11\IN\1740 <e1>levodopa</e1>_12\NN\14604959 for_13\IN\1740 transport_14\NN\3575240 across_15\IN\1740 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 reduced_20\VBD\441445 the_21\DT\1740 <e2>hypotensive</e2>_22\JJ\1740 and_23\CC\1740 antiparkinsonian_24\JJ\1740 effects_25\NNS\13245626 of_26\IN\1740 levodopa_27\NN\14604959 ._28\.\1740
D007980_D007022 CID phenylalanine_0\NNP\14605787 ,_1\,\1740 a_2\DT\13649268 large_3\JJ\1740 neutral_4\JJ\1740 amino_5\NN\14621446 acid_6\NN\14818238 (_7\-LRB-\1740 lnaa_8\NN\1740 )_9\-RRB-\1740 competing_10\VBG\1740 with_11\IN\1740 levodopa_12\NN\14604959 for_13\IN\1740 transport_14\NN\3575240 across_15\IN\1740 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 reduced_20\VBD\441445 the_21\DT\1740 <e2>hypotensive</e2>_22\JJ\1740 and_23\CC\1740 antiparkinsonian_24\JJ\1740 effects_25\NNS\13245626 of_26\IN\1740 <e1>levodopa</e1>_27\NN\14604959 ._28\.\1740
D007980_D007022 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>levodopa</e1>_3\NN\14604959 has_4\VBZ\2108377 a_5\DT\13649268 central_6\JJ\1740 <e2>hypotensive</e2>_7\JJ\1740 action_8\NN\30358 that_9\WDT\1740 parallels_10\VBZ\2657219 the_11\DT\1740 motor_12\NN\3699975 effects_13\NNS\13245626 in_14\IN\13603305 fluctuating_15\VBG\1850315 patients_16\NNS\9898892 ._17\.\1740
D007980_D010300 NONE pharmacodynamics_0\NNS\1740 of_1\IN\1740 the_2\DT\1740 hypotensive_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 <e1>levodopa</e1>_6\NN\14604959 in_7\IN\13603305 <e2>parkinsonian</e2>_8\JJ\1740 patients_9\NNS\9898892 ._10\.\1740
D007980_D010300 NONE blood_0\NN\5397468 pressure_1\NN\11419404 effects_2\NNS\13245626 of_3\IN\1740 i.v._4\NN\1740 <e1>levodopa</e1>_5\NN\14604959 were_6\VBD\836236 examined_7\VBN\789138 in_8\IN\13603305 <e2>parkinsonian</e2>_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 stable_12\JJ\1740 and_13\CC\1740 fluctuating_14\VBG\1850315 responses_15\NNS\11410625 to_16\TO\1740 levodopa_17\VB\1740 ._18\.\1740
D007980_D010300 NONE blood_0\NN\5397468 pressure_1\NN\11419404 effects_2\NNS\13245626 of_3\IN\1740 i.v._4\NN\1740 levodopa_5\NN\14604959 were_6\VBD\836236 examined_7\VBN\789138 in_8\IN\13603305 <e2>parkinsonian</e2>_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 stable_12\JJ\1740 and_13\CC\1740 fluctuating_14\VBG\1850315 responses_15\NNS\11410625 to_16\TO\1740 <e1>levodopa</e1>_17\VB\1740 ._18\.\1740
D010649_D007022 NONE <e1>phenylalanine</e1>_0\NNP\14605787 ,_1\,\1740 a_2\DT\13649268 large_3\JJ\1740 neutral_4\JJ\1740 amino_5\NN\14621446 acid_6\NN\14818238 (_7\-LRB-\1740 lnaa_8\NN\1740 )_9\-RRB-\1740 competing_10\VBG\1740 with_11\IN\1740 levodopa_12\NN\14604959 for_13\IN\1740 transport_14\NN\3575240 across_15\IN\1740 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 reduced_20\VBD\441445 the_21\DT\1740 <e2>hypotensive</e2>_22\JJ\1740 and_23\CC\1740 antiparkinsonian_24\JJ\1740 effects_25\NNS\13245626 of_26\IN\1740 levodopa_27\NN\14604959 ._28\.\1740
D000596_D007022 NONE phenylalanine_0\NNP\14605787 ,_1\,\1740 a_2\DT\13649268 large_3\JJ\1740 neutral_4\JJ\1740 <e1>amino_5\NN\14621446 acid</e1>_6\NN\14818238 (_7\-LRB-\1740 lnaa_8\NN\1740 )_9\-RRB-\1740 competing_10\VBG\1740 with_11\IN\1740 levodopa_12\NN\14604959 for_13\IN\1740 transport_14\NN\3575240 across_15\IN\1740 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 reduced_20\VBD\441445 the_21\DT\1740 <e2>hypotensive</e2>_22\JJ\1740 and_23\CC\1740 antiparkinsonian_24\JJ\1740 effects_25\NNS\13245626 of_26\IN\1740 levodopa_27\NN\14604959 ._28\.\1740
16906379
D008911_D014657 NONE <e1>minocycline-induced</e1>_0\JJ\1740 <e2>vasculitis</e2>_1\NN\14336539 fulfilling_2\VBG\484166 the_3\DT\1740 criteria_4\NNS\13577171 of_5\IN\1740 polyarteritis_6\NN\14258609 nodosa_7\NNS\1740 ._8\.\1740
D008911_D014657 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 second_7\JJ\1740 case_8\NN\7283608 of_9\IN\1740 <e1>minocycline-induced</e1>_10\JJ\1740 <e2>vasculitis</e2>_11\NN\14336539 satisfying_12\VBG\2667900 the_13\DT\1740 criteria_14\NNS\13577171 ._15\.\1740
D008911_D010488 CID <e1>minocycline-induced</e1>_0\JJ\1740 vasculitis_1\NN\14336539 fulfilling_2\VBG\484166 the_3\DT\1740 criteria_4\NNS\13577171 of_5\IN\1740 <e2>polyarteritis_6\NN\14258609 nodosa</e2>_7\NNS\1740 ._8\.\1740
D008911_D011565 NONE a_0\DT\13649268 47-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 had_4\VBD\2108377 been_5\VBN\836236 taking_6\VBG\2367363 <e1>minocycline</e1>_7\NN\4416530 for_8\IN\1740 <e2>palmoplantar_9\NN\1740 pustulosis</e2>_10\NN\1740 developed_11\VBD\1753788 fever_12\NN\14299637 ,_13\,\1740 myalgias_14\NNS\14322699 ,_15\,\1740 polyneuropathy_16\JJ\1740 ,_17\,\1740 and_18\CC\1740 testicular_19\JJ\1740 pain_20\NN\14299637 ,_21\,\1740 with_22\IN\1740 elevated_23\JJ\1740 c-reactive_24\JJ\1740 protein_25\NN\14944888 (_26\-LRB-\1740 crp_27\NN\14732116 )_28\-RRB-\1740 ._29\.\1740
D008911_D005334 NONE a_0\DT\13649268 47-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 had_4\VBD\2108377 been_5\VBN\836236 taking_6\VBG\2367363 <e1>minocycline</e1>_7\NN\4416530 for_8\IN\1740 palmoplantar_9\NN\1740 pustulosis_10\NN\1740 developed_11\VBD\1753788 <e2>fever</e2>_12\NN\14299637 ,_13\,\1740 myalgias_14\NNS\14322699 ,_15\,\1740 polyneuropathy_16\JJ\1740 ,_17\,\1740 and_18\CC\1740 testicular_19\JJ\1740 pain_20\NN\14299637 ,_21\,\1740 with_22\IN\1740 elevated_23\JJ\1740 c-reactive_24\JJ\1740 protein_25\NN\14944888 (_26\-LRB-\1740 crp_27\NN\14732116 )_28\-RRB-\1740 ._29\.\1740
D008911_D063806 NONE a_0\DT\13649268 47-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 had_4\VBD\2108377 been_5\VBN\836236 taking_6\VBG\2367363 <e1>minocycline</e1>_7\NN\4416530 for_8\IN\1740 palmoplantar_9\NN\1740 pustulosis_10\NN\1740 developed_11\VBD\1753788 fever_12\NN\14299637 ,_13\,\1740 <e2>myalgias</e2>_14\NNS\14322699 ,_15\,\1740 polyneuropathy_16\JJ\1740 ,_17\,\1740 and_18\CC\1740 testicular_19\JJ\1740 pain_20\NN\14299637 ,_21\,\1740 with_22\IN\1740 elevated_23\JJ\1740 c-reactive_24\JJ\1740 protein_25\NN\14944888 (_26\-LRB-\1740 crp_27\NN\14732116 )_28\-RRB-\1740 ._29\.\1740
D008911_D011115 NONE a_0\DT\13649268 47-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 had_4\VBD\2108377 been_5\VBN\836236 taking_6\VBG\2367363 <e1>minocycline</e1>_7\NN\4416530 for_8\IN\1740 palmoplantar_9\NN\1740 pustulosis_10\NN\1740 developed_11\VBD\1753788 fever_12\NN\14299637 ,_13\,\1740 myalgias_14\NNS\14322699 ,_15\,\1740 <e2>polyneuropathy</e2>_16\JJ\1740 ,_17\,\1740 and_18\CC\1740 testicular_19\JJ\1740 pain_20\NN\14299637 ,_21\,\1740 with_22\IN\1740 elevated_23\JJ\1740 c-reactive_24\JJ\1740 protein_25\NN\14944888 (_26\-LRB-\1740 crp_27\NN\14732116 )_28\-RRB-\1740 ._29\.\1740
D008911_D013733 NONE a_0\DT\13649268 47-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 had_4\VBD\2108377 been_5\VBN\836236 taking_6\VBG\2367363 <e1>minocycline</e1>_7\NN\4416530 for_8\IN\1740 palmoplantar_9\NN\1740 pustulosis_10\NN\1740 developed_11\VBD\1753788 fever_12\NN\14299637 ,_13\,\1740 myalgias_14\NNS\14322699 ,_15\,\1740 polyneuropathy_16\JJ\1740 ,_17\,\1740 and_18\CC\1740 <e2>testicular_19\JJ\1740 pain</e2>_20\NN\14299637 ,_21\,\1740 with_22\IN\1740 elevated_23\JJ\1740 c-reactive_24\JJ\1740 protein_25\NN\14944888 (_26\-LRB-\1740 crp_27\NN\14732116 )_28\-RRB-\1740 ._29\.\1740
12523489
D003042_D006948 NONE <e1>cocaine-induced</e1>_0\JJ\1740 <e2>hyperactivity</e2>_1\NN\14052403 is_2\VBZ\836236 more_3\RBR\1740 influenced_4\VBN\137313 by_5\IN\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 than_9\IN\1740 amphetamine-induced_10\JJ\1740 hyperactivity_11\NN\14052403 ._12\.\1740
D003042_D006948 NONE <e1>cocaine-induced</e1>_0\JJ\1740 hyperactivity_1\NN\14052403 is_2\VBZ\836236 more_3\RBR\1740 influenced_4\VBN\137313 by_5\IN\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 than_9\IN\1740 amphetamine-induced_10\JJ\1740 <e2>hyperactivity</e2>_11\NN\14052403 ._12\.\1740
D003042_D006948 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 adenosine_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 and_6\CC\1740 antagonists_7\NNS\7846 on_8\IN\1740 <e1>cocaine-and</e1>_9\NN\1740 amphetamine-induced_10\JJ\1740 <e2>hyperactivity</e2>_11\NN\14052403 was_12\VBD\836236 examined_13\VBN\789138 in_14\IN\13603305 mice_15\NNS\2329401 ._16\.\1740
D003042_D006948 NONE similarly_0\RB\1740 ,_1\,\1740 all_2\DT\1740 adenosine_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 decreased_6\VBD\169651 amphetamine-induced_7\JJ\1740 <e2>hyperactivity</e2>_8\NN\14052403 ,_9\,\1740 but_10\CC\1740 at_11\IN\14622893 the_12\DT\1740 higher_13\JJR\1740 doses_14\NNS\3740161 than_15\IN\1740 those_16\DT\1740 which_17\WDT\1740 were_18\VBD\836236 active_19\JJ\1740 in_20\IN\13603305 <e1>cocaine-induced</e1>_21\JJ\1740 hyperactivity_22\NN\14052403 ._23\.\1740
D003042_D006948 NONE similarly_0\RB\1740 ,_1\,\1740 all_2\DT\1740 adenosine_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 decreased_6\VBD\169651 amphetamine-induced_7\JJ\1740 hyperactivity_8\NN\14052403 ,_9\,\1740 but_10\CC\1740 at_11\IN\14622893 the_12\DT\1740 higher_13\JJR\1740 doses_14\NNS\3740161 than_15\IN\1740 those_16\DT\1740 which_17\WDT\1740 were_18\VBD\836236 active_19\JJ\1740 in_20\IN\13603305 <e1>cocaine-induced</e1>_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 ._23\.\1740
D003042_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 <e1>cocaine-</e1>_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 hyperactivity_39\NN\14052403 ._40\.\1740
D003042_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 <e1>cocaine-</e1>_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 hyperactivity_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 <e2>hyperactivity</e2>_39\NN\14052403 ._40\.\1740
D003042_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 <e1>cocaine-induced</e1>_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 hyperactivity_39\NN\14052403 ._40\.\1740
D003042_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 <e1>cocaine-induced</e1>_23\JJ\1740 hyperactivity_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 <e2>hyperactivity</e2>_39\NN\14052403 ._40\.\1740
D000241_D006948 NONE cocaine-induced_0\JJ\1740 <e2>hyperactivity</e2>_1\NN\14052403 is_2\VBZ\836236 more_3\RBR\1740 influenced_4\VBN\137313 by_5\IN\1740 <e1>adenosine</e1>_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 than_9\IN\1740 amphetamine-induced_10\JJ\1740 hyperactivity_11\NN\14052403 ._12\.\1740
D000241_D006948 NONE cocaine-induced_0\JJ\1740 hyperactivity_1\NN\14052403 is_2\VBZ\836236 more_3\RBR\1740 influenced_4\VBN\137313 by_5\IN\1740 <e1>adenosine</e1>_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 than_9\IN\1740 amphetamine-induced_10\JJ\1740 <e2>hyperactivity</e2>_11\NN\14052403 ._12\.\1740
D000241_D006948 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 <e1>adenosine</e1>_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 and_6\CC\1740 antagonists_7\NNS\7846 on_8\IN\1740 cocaine-and_9\NN\1740 amphetamine-induced_10\JJ\1740 <e2>hyperactivity</e2>_11\NN\14052403 was_12\VBD\836236 examined_13\VBN\789138 in_14\IN\13603305 mice_15\NNS\2329401 ._16\.\1740
D000241_D006948 NONE similarly_0\RB\1740 ,_1\,\1740 all_2\DT\1740 <e1>adenosine</e1>_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 decreased_6\VBD\169651 amphetamine-induced_7\JJ\1740 <e2>hyperactivity</e2>_8\NN\14052403 ,_9\,\1740 but_10\CC\1740 at_11\IN\14622893 the_12\DT\1740 higher_13\JJR\1740 doses_14\NNS\3740161 than_15\IN\1740 those_16\DT\1740 which_17\WDT\1740 were_18\VBD\836236 active_19\JJ\1740 in_20\IN\13603305 cocaine-induced_21\JJ\1740 hyperactivity_22\NN\14052403 ._23\.\1740
D000241_D006948 NONE similarly_0\RB\1740 ,_1\,\1740 all_2\DT\1740 <e1>adenosine</e1>_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 decreased_6\VBD\169651 amphetamine-induced_7\JJ\1740 hyperactivity_8\NN\14052403 ,_9\,\1740 but_10\CC\1740 at_11\IN\14622893 the_12\DT\1740 higher_13\JJR\1740 doses_14\NNS\3740161 than_15\IN\1740 those_16\DT\1740 which_17\WDT\1740 were_18\VBD\836236 active_19\JJ\1740 in_20\IN\13603305 cocaine-induced_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 ._23\.\1740
D000241_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 <e1>adenosine</e1>_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 hyperactivity_39\NN\14052403 ._40\.\1740
D000241_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 <e1>adenosine</e1>_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 hyperactivity_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 <e2>hyperactivity</e2>_39\NN\14052403 ._40\.\1740
D000241_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 <e1>adenosine</e1>_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 hyperactivity_39\NN\14052403 ._40\.\1740
D000241_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 hyperactivity_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 <e1>adenosine</e1>_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 <e2>hyperactivity</e2>_39\NN\14052403 ._40\.\1740
D000661_D006948 NONE cocaine-induced_0\JJ\1740 <e2>hyperactivity</e2>_1\NN\14052403 is_2\VBZ\836236 more_3\RBR\1740 influenced_4\VBN\137313 by_5\IN\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 than_9\IN\1740 <e1>amphetamine-induced</e1>_10\JJ\1740 hyperactivity_11\NN\14052403 ._12\.\1740
D000661_D006948 NONE cocaine-induced_0\JJ\1740 hyperactivity_1\NN\14052403 is_2\VBZ\836236 more_3\RBR\1740 influenced_4\VBN\137313 by_5\IN\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 than_9\IN\1740 <e1>amphetamine-induced</e1>_10\JJ\1740 <e2>hyperactivity</e2>_11\NN\14052403 ._12\.\1740
D000661_D006948 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 adenosine_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 and_6\CC\1740 antagonists_7\NNS\7846 on_8\IN\1740 cocaine-and_9\NN\1740 <e1>amphetamine-induced</e1>_10\JJ\1740 <e2>hyperactivity</e2>_11\NN\14052403 was_12\VBD\836236 examined_13\VBN\789138 in_14\IN\13603305 mice_15\NNS\2329401 ._16\.\1740
D000661_D006948 NONE similarly_0\RB\1740 ,_1\,\1740 all_2\DT\1740 adenosine_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 decreased_6\VBD\169651 <e1>amphetamine-induced</e1>_7\JJ\1740 <e2>hyperactivity</e2>_8\NN\14052403 ,_9\,\1740 but_10\CC\1740 at_11\IN\14622893 the_12\DT\1740 higher_13\JJR\1740 doses_14\NNS\3740161 than_15\IN\1740 those_16\DT\1740 which_17\WDT\1740 were_18\VBD\836236 active_19\JJ\1740 in_20\IN\13603305 cocaine-induced_21\JJ\1740 hyperactivity_22\NN\14052403 ._23\.\1740
D000661_D006948 NONE similarly_0\RB\1740 ,_1\,\1740 all_2\DT\1740 adenosine_3\NN\14964367 receptor_4\NN\5225602 agonists_5\NNS\9613191 decreased_6\VBD\169651 <e1>amphetamine-induced</e1>_7\JJ\1740 hyperactivity_8\NN\14052403 ,_9\,\1740 but_10\CC\1740 at_11\IN\14622893 the_12\DT\1740 higher_13\JJR\1740 doses_14\NNS\3740161 than_15\IN\1740 those_16\DT\1740 which_17\WDT\1740 were_18\VBD\836236 active_19\JJ\1740 in_20\IN\13603305 cocaine-induced_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 ._23\.\1740
D000661_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 <e1>amphetamine-induced</e1>_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 hyperactivity_39\NN\14052403 ._40\.\1740
D000661_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 <e1>amphetamine-induced</e1>_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 hyperactivity_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 amphetamine-induced_38\JJ\1740 <e2>hyperactivity</e2>_39\NN\14052403 ._40\.\1740
D000661_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 <e1>amphetamine-induced</e1>_38\JJ\1740 hyperactivity_39\NN\14052403 ._40\.\1740
D000661_D006948 NONE our_0\PRP$\1740 results_1\NNS\34213 have_2\VBP\2108377 shown_3\VBN\2137132 that_4\IN\1740 all_5\DT\1740 adenosine_6\NN\14964367 receptor_7\NN\5225602 agonists_8\NNS\9613191 (_9\-LRB-\1740 a1_10\NN\1740 and_11\CC\1740 a2_12\NN\1740 )_13\-RRB-\1740 reduce_14\VBP\441445 cocaine-_15\NN\1740 and_16\CC\1740 amphetamine-induced_17\JJ\1740 locomotor_18\NN\1740 activity_19\NN\30358 and_20\CC\1740 indicate_21\VBP\952524 that_22\IN\1740 cocaine-induced_23\JJ\1740 hyperactivity_24\NN\14052403 is_25\VBZ\836236 more_26\RBR\1740 influenced_27\VBN\137313 by_28\IN\1740 adenosine_29\NN\14964367 receptor_30\NN\5225602 agonists_31\NNS\9613191 (_32\-LRB-\1740 particularly_33\RB\1740 a1_34\NN\1740 receptors_35\NNS\5225602 )_36\-RRB-\1740 than_37\IN\1740 <e1>amphetamine-induced</e1>_38\JJ\1740 <e2>hyperactivity</e2>_39\NN\14052403 ._40\.\1740
D000241_D004409 NONE all_0\DT\1740 <e1>adenosine</e1>_1\NN\14964367 receptor_2\NN\5225602 agonists_3\NNS\9613191 significantly_4\RB\1740 <e2>decreased_5\VBD\169651 the_6\DT\1740 locomotor_7\NN\1740 activity</e2>_8\NN\30358 in_9\IN\13603305 mice_10\NNS\2329401 ,_11\,\1740 and_12\CC\1740 the_13\DT\1740 effects_14\NNS\13245626 were_15\VBD\836236 dose-dependent_16\JJ\1740 ._17\.\1740
6453500
D004221_D056486 CID <e2>toxic_0\JJ\1740 hepatitis</e2>_1\NN\14127211 induced_2\VBN\1627355 by_3\IN\1740 <e1>disulfiram</e1>_4\NN\3740161 in_5\IN\13603305 a_6\DT\13649268 non-alcoholic_7\JJ\1740 ._8\.\1740
D004221_D056486 CID a_0\DT\13649268 reversible_1\JJ\1740 <e2>toxic_2\JJ\1740 liver_3\NN\5298729 damage</e2>_4\NN\7296428 was_5\VBD\836236 observed_6\VBN\2163746 in_7\IN\13603305 a_8\DT\13649268 non-alcoholic_9\JJ\1740 woman_10\NN\9605289 treated_11\VBN\2376958 with_12\IN\1740 <e1>disulfiram</e1>_13\NN\3740161 ._14\.\1740
146391
D010672_D012010 CID <e2>pure_0\JJ\1740 red_1\JJ\1740 cell_2\NN\3080309 aplasia</e2>_3\NN\14365950 ,_4\,\1740 toxic_5\JJ\1740 dermatitis_6\NN\14226056 and_7\CC\1740 lymphadenopathy_8\NN\14204950 in_9\IN\13603305 a_10\DT\13649268 patient_11\NN\9898892 taking_12\VBG\2367363 <e1>diphenylhydantoin</e1>_13\NN\3550533 ._14\.\1740
D010672_D012010 CID a_0\DT\13649268 patient_1\NN\9898892 taking_2\VBG\2367363 <e1>diphenylhydantoin</e1>_3\NN\3550533 for_4\IN\1740 3_5\CD\13741022 weeks_6\NNS\15113229 developed_7\VBD\1753788 a_8\DT\13649268 generalized_9\JJ\1740 skin_10\NN\5237755 rash_11\NN\14321469 ,_12\,\1740 lymphadenopathy_13\NN\14204950 and_14\CC\1740 <e2>pure_15\JJ\1740 red_16\JJ\1740 cell_17\NN\3080309 aplasia</e2>_18\NN\14365950 ._19\.\1740
D010672_D012010 CID <e2>pure_0\JJ\1740 red_1\JJ\1740 cell_2\NN\3080309 aplasia</e2>_3\NN\14365950 associated_4\VBN\628491 with_5\IN\1740 <e1>diphenylhydantoin</e1>_6\NN\3550533 medication_7\NN\3247620 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 in_11\IN\13603305 3_12\CD\13741022 patients_13\NNS\9898892 ._14\.\1740
D010672_D012010 CID in_0\IN\13603305 this_1\DT\1740 patient_2\NN\9898892 the_3\DT\1740 time_4\NN\7308889 relation_5\NN\2137 between_6\IN\1740 the_7\DT\1740 ingestion_8\NN\13440063 of_9\IN\1740 <e1>diphenylhydantoin</e1>_10\NN\3550533 and_11\CC\1740 the_12\DT\1740 occurrence_13\NN\29378 of_14\IN\1740 the_15\DT\1740 skin_16\NN\5237755 rash_17\NN\14321469 ,_18\,\1740 lymphadenopathy_19\NN\14204950 and_20\CC\1740 <e2>pure_21\JJ\1740 red_22\JJ\1740 cell_23\NN\3080309 aplasia</e2>_24\NN\14365950 is_25\VBZ\836236 very_26\RB\1740 suggestive_27\JJ\1740 of_28\IN\1740 a_29\DT\13649268 direct_30\JJ\1740 connection_31\NN\31921 ._32\.\1740
D010672_D003875 CID pure_0\JJ\1740 red_1\JJ\1740 cell_2\NN\3080309 aplasia_3\NN\14365950 ,_4\,\1740 <e2>toxic_5\JJ\1740 dermatitis</e2>_6\NN\14226056 and_7\CC\1740 lymphadenopathy_8\NN\14204950 in_9\IN\13603305 a_10\DT\13649268 patient_11\NN\9898892 taking_12\VBG\2367363 <e1>diphenylhydantoin</e1>_13\NN\3550533 ._14\.\1740
D010672_D008206 CID pure_0\JJ\1740 red_1\JJ\1740 cell_2\NN\3080309 aplasia_3\NN\14365950 ,_4\,\1740 toxic_5\JJ\1740 dermatitis_6\NN\14226056 and_7\CC\1740 <e2>lymphadenopathy</e2>_8\NN\14204950 in_9\IN\13603305 a_10\DT\13649268 patient_11\NN\9898892 taking_12\VBG\2367363 <e1>diphenylhydantoin</e1>_13\NN\3550533 ._14\.\1740
D010672_D008206 CID a_0\DT\13649268 patient_1\NN\9898892 taking_2\VBG\2367363 <e1>diphenylhydantoin</e1>_3\NN\3550533 for_4\IN\1740 3_5\CD\13741022 weeks_6\NNS\15113229 developed_7\VBD\1753788 a_8\DT\13649268 generalized_9\JJ\1740 skin_10\NN\5237755 rash_11\NN\14321469 ,_12\,\1740 <e2>lymphadenopathy</e2>_13\NN\14204950 and_14\CC\1740 pure_15\JJ\1740 red_16\JJ\1740 cell_17\NN\3080309 aplasia_18\NN\14365950 ._19\.\1740
D010672_D008206 CID skin_0\NN\5237755 rash_1\NN\14321469 is_2\VBZ\836236 a_3\DT\13649268 well-known_4\JJ\1740 complication_5\NN\1073995 of_6\IN\1740 <e1>diphenylhydantoin</e1>_7\NN\3550533 treatment_8\NN\654885 as_9\IN\14622893 is_10\VBZ\836236 benign_11\JJ\1740 and_12\CC\1740 malignant_13\JJ\1740 <e2>lymphadenopathy</e2>_14\NN\14204950 ._15\.\1740
D010672_D008206 CID in_0\IN\13603305 this_1\DT\1740 patient_2\NN\9898892 the_3\DT\1740 time_4\NN\7308889 relation_5\NN\2137 between_6\IN\1740 the_7\DT\1740 ingestion_8\NN\13440063 of_9\IN\1740 <e1>diphenylhydantoin</e1>_10\NN\3550533 and_11\CC\1740 the_12\DT\1740 occurrence_13\NN\29378 of_14\IN\1740 the_15\DT\1740 skin_16\NN\5237755 rash_17\NN\14321469 ,_18\,\1740 <e2>lymphadenopathy</e2>_19\NN\14204950 and_20\CC\1740 pure_21\JJ\1740 red_22\JJ\1740 cell_23\NN\3080309 aplasia_24\NN\14365950 is_25\VBZ\836236 very_26\RB\1740 suggestive_27\JJ\1740 of_28\IN\1740 a_29\DT\13649268 direct_30\JJ\1740 connection_31\NN\31921 ._32\.\1740
D010672_D005076 NONE a_0\DT\13649268 patient_1\NN\9898892 taking_2\VBG\2367363 <e1>diphenylhydantoin</e1>_3\NN\3550533 for_4\IN\1740 3_5\CD\13741022 weeks_6\NNS\15113229 developed_7\VBD\1753788 a_8\DT\13649268 generalized_9\JJ\1740 <e2>skin_10\NN\5237755 rash</e2>_11\NN\14321469 ,_12\,\1740 lymphadenopathy_13\NN\14204950 and_14\CC\1740 pure_15\JJ\1740 red_16\JJ\1740 cell_17\NN\3080309 aplasia_18\NN\14365950 ._19\.\1740
D010672_D005076 NONE <e2>skin_0\NN\5237755 rash</e2>_1\NN\14321469 is_2\VBZ\836236 a_3\DT\13649268 well-known_4\JJ\1740 complication_5\NN\1073995 of_6\IN\1740 <e1>diphenylhydantoin</e1>_7\NN\3550533 treatment_8\NN\654885 as_9\IN\14622893 is_10\VBZ\836236 benign_11\JJ\1740 and_12\CC\1740 malignant_13\JJ\1740 lymphadenopathy_14\NN\14204950 ._15\.\1740
D010672_D005076 NONE in_0\IN\13603305 this_1\DT\1740 patient_2\NN\9898892 the_3\DT\1740 time_4\NN\7308889 relation_5\NN\2137 between_6\IN\1740 the_7\DT\1740 ingestion_8\NN\13440063 of_9\IN\1740 <e1>diphenylhydantoin</e1>_10\NN\3550533 and_11\CC\1740 the_12\DT\1740 occurrence_13\NN\29378 of_14\IN\1740 the_15\DT\1740 <e2>skin_16\NN\5237755 rash</e2>_17\NN\14321469 ,_18\,\1740 lymphadenopathy_19\NN\14204950 and_20\CC\1740 pure_21\JJ\1740 red_22\JJ\1740 cell_23\NN\3080309 aplasia_24\NN\14365950 is_25\VBZ\836236 very_26\RB\1740 suggestive_27\JJ\1740 of_28\IN\1740 a_29\DT\13649268 direct_30\JJ\1740 connection_31\NN\31921 ._32\.\1740
6673474
D009599_D007022 CID coronary_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 ,_3\,\1740 cardiac_4\JJ\1740 work_5\NN\407535 and_6\CC\1740 metabolism_7\NN\13526110 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 under_12\IN\1740 <e1>sodium_13\NN\14625458 nitroprusside</e1>_14\NN\1740 (_15\-LRB-\1740 snp_16\NN\11493266 )_17\-RRB-\1740 and_18\CC\1740 trimetaphan_19\NN\1740 (_20\-LRB-\1740 tmp_21\NN\1740 )_22\-RRB-\1740 deliberate_23\VBP\813978 <e2>hypotension</e2>_24\NN\14057371 (_25\-LRB-\1740 20_26\CD\13745420 %_27\NN\1740 and_28\CC\1740 40_29\CD\13745420 %_30\NN\1740 mean_31\NN\6021761 pressure_32\NN\11419404 decrease_33\NN\7296428 from_34\IN\1740 baseline_35\NN\7260623 )_36\-RRB-\1740 ._37\.\1740
D009599_D007022 CID coronary_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 ,_3\,\1740 cardiac_4\JJ\1740 work_5\NN\407535 and_6\CC\1740 metabolism_7\NN\13526110 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 under_12\IN\1740 sodium_13\NN\14625458 nitroprusside_14\NN\1740 (_15\-LRB-\1740 <e1>snp</e1>_16\NN\11493266 )_17\-RRB-\1740 and_18\CC\1740 trimetaphan_19\NN\1740 (_20\-LRB-\1740 tmp_21\NN\1740 )_22\-RRB-\1740 deliberate_23\VBP\813978 <e2>hypotension</e2>_24\NN\14057371 (_25\-LRB-\1740 20_26\CD\13745420 %_27\NN\1740 and_28\CC\1740 40_29\CD\13745420 %_30\NN\1740 mean_31\NN\6021761 pressure_32\NN\11419404 decrease_33\NN\7296428 from_34\IN\1740 baseline_35\NN\7260623 )_36\-RRB-\1740 ._37\.\1740
D009599_D007022 CID regarding_0\VBG\689344 the_1\DT\1740 effects_2\NNS\13245626 of_3\IN\1740 drug-induced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 on_6\IN\1740 coronary_7\JJ\1740 blood_8\NN\5397468 flow_9\NN\7311115 ,_10\,\1740 aortic_11\JJ\1740 and_12\CC\1740 coronary_13\JJ\1740 sinus_14\NN\5248181 metabolic_15\JJ\1740 data_16\NNS\7951464 (_17\-LRB-\1740 ph_18\NN\5038959 ,_19\,\1740 po2_20\FW\1740 ,_21\,\1740 pco2_22\NN\1740 )_23\-RRB-\1740 we_24\PRP\1740 could_25\MD\1740 confirm_26\VB\1011725 that_27\IN\1740 <e1>nitroprusside</e1>_28\NN\1740 hypotension_29\NN\14057371 could_30\MD\1740 be_31\VB\836236 safely_32\RB\1740 used_33\VBN\1156834 to_34\IN\1740 30_35\CD\13745420 %_36\NN\1740 mean_37\NN\6021761 blood_38\NN\5397468 pressure_39\NN\11419404 decrease_40\NN\7296428 from_41\IN\1740 control_42\NN\5190804 ,_43\,\1740 trimetaphan_44\JJ\1740 hypotension_45\NN\14057371 to_46\TO\1740 20_47\CD\13745420 %_48\NN\1740 mean_49\NN\6021761 blood_50\NN\5397468 pressure_51\NN\11419404 decrease_52\NN\7296428 ._53\.\1740
D009599_D007022 CID regarding_0\VBG\689344 the_1\DT\1740 effects_2\NNS\13245626 of_3\IN\1740 drug-induced_4\JJ\1740 hypotension_5\NN\14057371 on_6\IN\1740 coronary_7\JJ\1740 blood_8\NN\5397468 flow_9\NN\7311115 ,_10\,\1740 aortic_11\JJ\1740 and_12\CC\1740 coronary_13\JJ\1740 sinus_14\NN\5248181 metabolic_15\JJ\1740 data_16\NNS\7951464 (_17\-LRB-\1740 ph_18\NN\5038959 ,_19\,\1740 po2_20\FW\1740 ,_21\,\1740 pco2_22\NN\1740 )_23\-RRB-\1740 we_24\PRP\1740 could_25\MD\1740 confirm_26\VB\1011725 that_27\IN\1740 <e1>nitroprusside</e1>_28\NN\1740 <e2>hypotension</e2>_29\NN\14057371 could_30\MD\1740 be_31\VB\836236 safely_32\RB\1740 used_33\VBN\1156834 to_34\IN\1740 30_35\CD\13745420 %_36\NN\1740 mean_37\NN\6021761 blood_38\NN\5397468 pressure_39\NN\11419404 decrease_40\NN\7296428 from_41\IN\1740 control_42\NN\5190804 ,_43\,\1740 trimetaphan_44\JJ\1740 hypotension_45\NN\14057371 to_46\TO\1740 20_47\CD\13745420 %_48\NN\1740 mean_49\NN\6021761 blood_50\NN\5397468 pressure_51\NN\11419404 decrease_52\NN\7296428 ._53\.\1740
D009599_D007022 CID regarding_0\VBG\689344 the_1\DT\1740 effects_2\NNS\13245626 of_3\IN\1740 drug-induced_4\JJ\1740 hypotension_5\NN\14057371 on_6\IN\1740 coronary_7\JJ\1740 blood_8\NN\5397468 flow_9\NN\7311115 ,_10\,\1740 aortic_11\JJ\1740 and_12\CC\1740 coronary_13\JJ\1740 sinus_14\NN\5248181 metabolic_15\JJ\1740 data_16\NNS\7951464 (_17\-LRB-\1740 ph_18\NN\5038959 ,_19\,\1740 po2_20\FW\1740 ,_21\,\1740 pco2_22\NN\1740 )_23\-RRB-\1740 we_24\PRP\1740 could_25\MD\1740 confirm_26\VB\1011725 that_27\IN\1740 <e1>nitroprusside</e1>_28\NN\1740 hypotension_29\NN\14057371 could_30\MD\1740 be_31\VB\836236 safely_32\RB\1740 used_33\VBN\1156834 to_34\IN\1740 30_35\CD\13745420 %_36\NN\1740 mean_37\NN\6021761 blood_38\NN\5397468 pressure_39\NN\11419404 decrease_40\NN\7296428 from_41\IN\1740 control_42\NN\5190804 ,_43\,\1740 trimetaphan_44\JJ\1740 <e2>hypotension</e2>_45\NN\14057371 to_46\TO\1740 20_47\CD\13745420 %_48\NN\1740 mean_49\NN\6021761 blood_50\NN\5397468 pressure_51\NN\11419404 decrease_52\NN\7296428 ._53\.\1740
D009599_D007022 CID cardiac_0\JJ\1740 work_1\NN\407535 was_2\VBD\836236 significantly_3\RB\1740 reduced_4\VBN\441445 during_5\IN\1740 <e1>snp</e1>_6\NN\11493266 <e2>hypotension</e2>_7\NN\14057371 ._8\.\1740
D014294_D007022 CID coronary_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 ,_3\,\1740 cardiac_4\JJ\1740 work_5\NN\407535 and_6\CC\1740 metabolism_7\NN\13526110 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 under_12\IN\1740 sodium_13\NN\14625458 nitroprusside_14\NN\1740 (_15\-LRB-\1740 snp_16\NN\11493266 )_17\-RRB-\1740 and_18\CC\1740 <e1>trimetaphan</e1>_19\NN\1740 (_20\-LRB-\1740 tmp_21\NN\1740 )_22\-RRB-\1740 deliberate_23\VBP\813978 <e2>hypotension</e2>_24\NN\14057371 (_25\-LRB-\1740 20_26\CD\13745420 %_27\NN\1740 and_28\CC\1740 40_29\CD\13745420 %_30\NN\1740 mean_31\NN\6021761 pressure_32\NN\11419404 decrease_33\NN\7296428 from_34\IN\1740 baseline_35\NN\7260623 )_36\-RRB-\1740 ._37\.\1740
D014294_D007022 CID coronary_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 ,_3\,\1740 cardiac_4\JJ\1740 work_5\NN\407535 and_6\CC\1740 metabolism_7\NN\13526110 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 under_12\IN\1740 sodium_13\NN\14625458 nitroprusside_14\NN\1740 (_15\-LRB-\1740 snp_16\NN\11493266 )_17\-RRB-\1740 and_18\CC\1740 trimetaphan_19\NN\1740 (_20\-LRB-\1740 <e1>tmp</e1>_21\NN\1740 )_22\-RRB-\1740 deliberate_23\VBP\813978 <e2>hypotension</e2>_24\NN\14057371 (_25\-LRB-\1740 20_26\CD\13745420 %_27\NN\1740 and_28\CC\1740 40_29\CD\13745420 %_30\NN\1740 mean_31\NN\6021761 pressure_32\NN\11419404 decrease_33\NN\7296428 from_34\IN\1740 baseline_35\NN\7260623 )_36\-RRB-\1740 ._37\.\1740
D014294_D007022 CID regarding_0\VBG\689344 the_1\DT\1740 effects_2\NNS\13245626 of_3\IN\1740 drug-induced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 on_6\IN\1740 coronary_7\JJ\1740 blood_8\NN\5397468 flow_9\NN\7311115 ,_10\,\1740 aortic_11\JJ\1740 and_12\CC\1740 coronary_13\JJ\1740 sinus_14\NN\5248181 metabolic_15\JJ\1740 data_16\NNS\7951464 (_17\-LRB-\1740 ph_18\NN\5038959 ,_19\,\1740 po2_20\FW\1740 ,_21\,\1740 pco2_22\NN\1740 )_23\-RRB-\1740 we_24\PRP\1740 could_25\MD\1740 confirm_26\VB\1011725 that_27\IN\1740 nitroprusside_28\NN\1740 hypotension_29\NN\14057371 could_30\MD\1740 be_31\VB\836236 safely_32\RB\1740 used_33\VBN\1156834 to_34\IN\1740 30_35\CD\13745420 %_36\NN\1740 mean_37\NN\6021761 blood_38\NN\5397468 pressure_39\NN\11419404 decrease_40\NN\7296428 from_41\IN\1740 control_42\NN\5190804 ,_43\,\1740 <e1>trimetaphan</e1>_44\JJ\1740 hypotension_45\NN\14057371 to_46\TO\1740 20_47\CD\13745420 %_48\NN\1740 mean_49\NN\6021761 blood_50\NN\5397468 pressure_51\NN\11419404 decrease_52\NN\7296428 ._53\.\1740
D014294_D007022 CID regarding_0\VBG\689344 the_1\DT\1740 effects_2\NNS\13245626 of_3\IN\1740 drug-induced_4\JJ\1740 hypotension_5\NN\14057371 on_6\IN\1740 coronary_7\JJ\1740 blood_8\NN\5397468 flow_9\NN\7311115 ,_10\,\1740 aortic_11\JJ\1740 and_12\CC\1740 coronary_13\JJ\1740 sinus_14\NN\5248181 metabolic_15\JJ\1740 data_16\NNS\7951464 (_17\-LRB-\1740 ph_18\NN\5038959 ,_19\,\1740 po2_20\FW\1740 ,_21\,\1740 pco2_22\NN\1740 )_23\-RRB-\1740 we_24\PRP\1740 could_25\MD\1740 confirm_26\VB\1011725 that_27\IN\1740 nitroprusside_28\NN\1740 <e2>hypotension</e2>_29\NN\14057371 could_30\MD\1740 be_31\VB\836236 safely_32\RB\1740 used_33\VBN\1156834 to_34\IN\1740 30_35\CD\13745420 %_36\NN\1740 mean_37\NN\6021761 blood_38\NN\5397468 pressure_39\NN\11419404 decrease_40\NN\7296428 from_41\IN\1740 control_42\NN\5190804 ,_43\,\1740 <e1>trimetaphan</e1>_44\JJ\1740 hypotension_45\NN\14057371 to_46\TO\1740 20_47\CD\13745420 %_48\NN\1740 mean_49\NN\6021761 blood_50\NN\5397468 pressure_51\NN\11419404 decrease_52\NN\7296428 ._53\.\1740
D014294_D007022 CID regarding_0\VBG\689344 the_1\DT\1740 effects_2\NNS\13245626 of_3\IN\1740 drug-induced_4\JJ\1740 hypotension_5\NN\14057371 on_6\IN\1740 coronary_7\JJ\1740 blood_8\NN\5397468 flow_9\NN\7311115 ,_10\,\1740 aortic_11\JJ\1740 and_12\CC\1740 coronary_13\JJ\1740 sinus_14\NN\5248181 metabolic_15\JJ\1740 data_16\NNS\7951464 (_17\-LRB-\1740 ph_18\NN\5038959 ,_19\,\1740 po2_20\FW\1740 ,_21\,\1740 pco2_22\NN\1740 )_23\-RRB-\1740 we_24\PRP\1740 could_25\MD\1740 confirm_26\VB\1011725 that_27\IN\1740 nitroprusside_28\NN\1740 hypotension_29\NN\14057371 could_30\MD\1740 be_31\VB\836236 safely_32\RB\1740 used_33\VBN\1156834 to_34\IN\1740 30_35\CD\13745420 %_36\NN\1740 mean_37\NN\6021761 blood_38\NN\5397468 pressure_39\NN\11419404 decrease_40\NN\7296428 from_41\IN\1740 control_42\NN\5190804 ,_43\,\1740 <e1>trimetaphan</e1>_44\JJ\1740 <e2>hypotension</e2>_45\NN\14057371 to_46\TO\1740 20_47\CD\13745420 %_48\NN\1740 mean_49\NN\6021761 blood_50\NN\5397468 pressure_51\NN\11419404 decrease_52\NN\7296428 ._53\.\1740
20046642
D008668_D003072 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 explore_5\VB\789138 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 <e1>mt</e1>_9\NN\14622893 induction_10\NN\7450842 on_11\IN\1740 carmustine_12\NN\1740 (bcnu)-induced_13\JJ\1740 hippocampal_14\NN\1740 <e2>cognitive_15\JJ\1740 dysfunction</e2>_16\NN\14204950 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D002330_D003072 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 explore_5\VB\789138 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 mt_9\NN\14622893 induction_10\NN\7450842 on_11\IN\1740 <e1>carmustine</e1>_12\NN\1740 (bcnu)-induced_13\JJ\1740 hippocampal_14\NN\1740 <e2>cognitive_15\JJ\1740 dysfunction</e2>_16\NN\14204950 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D002330_D003072 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 explore_5\VB\789138 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 mt_9\NN\14622893 induction_10\NN\7450842 on_11\IN\1740 carmustine_12\NN\1740 <e1>(bcnu)-induced</e1>_13\JJ\1740 hippocampal_14\NN\1740 <e2>cognitive_15\JJ\1740 dysfunction</e2>_16\NN\14204950 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D019287_D007859 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 <e1>znso(4_7\NN\1740 )</e1>_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D019287_D008569 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 <e1>znso(4_7\NN\1740 )</e1>_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D002330_D007859 CID fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 <e1>bcnu</e1>_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D002330_D007859 CID fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 <e1>bcnu</e1>_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D002330_D008569 CID fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 <e1>bcnu</e1>_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D002330_D008569 CID fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 <e1>bcnu</e1>_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D005978_D007859 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 <e1>glutathione</e1>_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D005978_D007859 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 <e1>glutathione</e1>_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D005978_D007859 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 <e1>gsh</e1>_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D005978_D008569 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 <e1>glutathione</e1>_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D005978_D008569 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 <e1>glutathione</e1>_71\NN\1740 (_72\-LRB-\1740 gsh_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D005978_D008569 NONE fourth_0\JJ\1740 group_1\NN\2137 received_2\VBD\2210855 a_3\DT\13649268 single_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 znso(4_7\NN\1740 )_8\-RRB-\1740 (_9\-LRB-\1740 0.1_10\CD\1740 micromol/10_11\NN\1740 microl_12\NN\1740 normal_13\JJ\1740 saline_14\NN\14849367 ,_15\,\1740 i.c.v_16\NN\1740 )_17\-RRB-\1740 then_18\RB\1740 bcnu_19\NNS\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg/kg_22\NN\1740 ,_23\,\1740 i.v_24\NNS\1740 ,_25\,\1740 once_26\RB\1740 )_27\-RRB-\1740 after_28\IN\1740 24_29\CD\13745420 h._30\NN\1740 the_31\DT\1740 obtained_32\VBN\2210855 data_33\NNS\7951464 revealed_34\VBD\2137132 that_35\IN\1740 bcnu_36\NN\1740 administration_37\NN\1133281 resulted_38\VBD\2633881 in_39\IN\13603305 <e2>deterioration_40\NN\14560612 of_41\IN\1740 learning_42\NN\5701944 and_43\CC\1740 short-term_44\JJ\1740 memory</e2>_45\NN\5926676 (_46\-LRB-\1740 stm_47\NN\5760202 )_48\-RRB-\1740 ,_49\,\1740 as_50\IN\14622893 measured_51\VBN\697589 by_52\IN\1740 using_53\VBG\1156834 radial_54\JJ\1740 arm_55\NN\5560244 water_56\NN\14618834 maze_57\NN\4377057 ,_58\,\1740 accompanied_59\VBN\1835496 with_60\IN\1740 decreased_61\VBN\169651 hippocampal_62\NN\1740 glutathione_63\NN\1740 reductase_64\NN\14732946 (_65\-LRB-\1740 gr_66\NN\1740 )_67\-RRB-\1740 activity_68\NN\30358 and_69\CC\1740 reduced_70\VBN\441445 glutathione_71\NN\1740 (_72\-LRB-\1740 <e1>gsh</e1>_73\NN\1740 )_74\-RRB-\1740 content_75\NN\7951464 ._76\.\1740
D002330_D009369 NONE also_0\RB\1740 ,_1\,\1740 <e1>bcnu</e1>_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 <e2>tumor</e2>_6\NN\14234074 necrosis_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 mt_14\NN\14622893 and_15\CC\1740 malondialdehyde_16\NN\1740 (_17\-LRB-\1740 mda_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D002330_D009336 NONE also_0\RB\1740 ,_1\,\1740 <e1>bcnu</e1>_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 tumor_6\NN\14234074 <e2>necrosis</e2>_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 mt_14\NN\14622893 and_15\CC\1740 malondialdehyde_16\NN\1740 (_17\-LRB-\1740 mda_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D008668_D009369 NONE also_0\RB\1740 ,_1\,\1740 bcnu_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 <e2>tumor</e2>_6\NN\14234074 necrosis_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 <e1>mt</e1>_14\NN\14622893 and_15\CC\1740 malondialdehyde_16\NN\1740 (_17\-LRB-\1740 mda_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D008668_D009336 NONE also_0\RB\1740 ,_1\,\1740 bcnu_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 tumor_6\NN\14234074 <e2>necrosis</e2>_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 <e1>mt</e1>_14\NN\14622893 and_15\CC\1740 malondialdehyde_16\NN\1740 (_17\-LRB-\1740 mda_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D008315_D009369 NONE also_0\RB\1740 ,_1\,\1740 bcnu_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 <e2>tumor</e2>_6\NN\14234074 necrosis_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 mt_14\NN\14622893 and_15\CC\1740 <e1>malondialdehyde</e1>_16\NN\1740 (_17\-LRB-\1740 mda_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D008315_D009369 NONE also_0\RB\1740 ,_1\,\1740 bcnu_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 <e2>tumor</e2>_6\NN\14234074 necrosis_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 mt_14\NN\14622893 and_15\CC\1740 malondialdehyde_16\NN\1740 (_17\-LRB-\1740 <e1>mda</e1>_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D008315_D009336 NONE also_0\RB\1740 ,_1\,\1740 bcnu_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 tumor_6\NN\14234074 <e2>necrosis</e2>_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 mt_14\NN\14622893 and_15\CC\1740 <e1>malondialdehyde</e1>_16\NN\1740 (_17\-LRB-\1740 mda_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D008315_D009336 NONE also_0\RB\1740 ,_1\,\1740 bcnu_2\NNP\1740 administration_3\NN\1133281 increased_4\VBD\169651 serum_5\NN\5397468 tumor_6\NN\14234074 <e2>necrosis</e2>_7\NN\11444117 factor-alpha_8\NN\1740 (_9\-LRB-\1740 tnfalpha_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 hippocampal_13\VBP\1740 mt_14\NN\14622893 and_15\CC\1740 malondialdehyde_16\NN\1740 (_17\-LRB-\1740 <e1>mda</e1>_18\NN\1740 )_19\-RRB-\1740 contents_20\NNS\6481320 as_21\RB\1740 well_22\RB\1740 as_23\IN\14622893 caspase-3_24\NN\1740 activity_25\NN\30358 in_26\IN\13603305 addition_27\NN\3081021 to_28\TO\1740 histological_29\JJ\1740 alterations_30\NNS\7283608 ._31\.\1740
D008668_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>mt</e1>_3\NN\14622893 induction_4\NN\7450842 halts_5\VBZ\1859221 bcnu-induced_6\JJ\1740 hippocampal_7\NN\1740 <e2>toxicity</e2>_8\NN\13576101 as_9\IN\14622893 it_10\PRP\6125041 prevented_11\VBD\1740 gr_12\NN\1740 inhibition_13\NN\1068773 and_14\CC\1740 gsh_15\NN\1740 depletion_16\NN\351638 and_17\CC\1740 counteracted_18\VBD\2367363 the_19\DT\1740 increased_20\VBN\169651 levels_21\NNS\4916342 of_22\IN\1740 tnfalpha_23\NN\1740 ,_24\,\1740 mda_25\NN\1740 and_26\CC\1740 caspase-3_27\NN\1740 activity_28\NN\30358 with_29\IN\1740 subsequent_30\JJ\1740 preservation_31\NN\817680 of_32\IN\1740 cognition_33\NN\23100 ._34\.\1740
D002330_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 mt_3\NN\14622893 induction_4\NN\7450842 halts_5\VBZ\1859221 <e1>bcnu-induced</e1>_6\JJ\1740 hippocampal_7\NN\1740 <e2>toxicity</e2>_8\NN\13576101 as_9\IN\14622893 it_10\PRP\6125041 prevented_11\VBD\1740 gr_12\NN\1740 inhibition_13\NN\1068773 and_14\CC\1740 gsh_15\NN\1740 depletion_16\NN\351638 and_17\CC\1740 counteracted_18\VBD\2367363 the_19\DT\1740 increased_20\VBN\169651 levels_21\NNS\4916342 of_22\IN\1740 tnfalpha_23\NN\1740 ,_24\,\1740 mda_25\NN\1740 and_26\CC\1740 caspase-3_27\NN\1740 activity_28\NN\30358 with_29\IN\1740 subsequent_30\JJ\1740 preservation_31\NN\817680 of_32\IN\1740 cognition_33\NN\23100 ._34\.\1740
D005978_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 mt_3\NN\14622893 induction_4\NN\7450842 halts_5\VBZ\1859221 bcnu-induced_6\JJ\1740 hippocampal_7\NN\1740 <e2>toxicity</e2>_8\NN\13576101 as_9\IN\14622893 it_10\PRP\6125041 prevented_11\VBD\1740 gr_12\NN\1740 inhibition_13\NN\1068773 and_14\CC\1740 <e1>gsh</e1>_15\NN\1740 depletion_16\NN\351638 and_17\CC\1740 counteracted_18\VBD\2367363 the_19\DT\1740 increased_20\VBN\169651 levels_21\NNS\4916342 of_22\IN\1740 tnfalpha_23\NN\1740 ,_24\,\1740 mda_25\NN\1740 and_26\CC\1740 caspase-3_27\NN\1740 activity_28\NN\30358 with_29\IN\1740 subsequent_30\JJ\1740 preservation_31\NN\817680 of_32\IN\1740 cognition_33\NN\23100 ._34\.\1740
D008315_D064420 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 mt_3\NN\14622893 induction_4\NN\7450842 halts_5\VBZ\1859221 bcnu-induced_6\JJ\1740 hippocampal_7\NN\1740 <e2>toxicity</e2>_8\NN\13576101 as_9\IN\14622893 it_10\PRP\6125041 prevented_11\VBD\1740 gr_12\NN\1740 inhibition_13\NN\1068773 and_14\CC\1740 gsh_15\NN\1740 depletion_16\NN\351638 and_17\CC\1740 counteracted_18\VBD\2367363 the_19\DT\1740 increased_20\VBN\169651 levels_21\NNS\4916342 of_22\IN\1740 tnfalpha_23\NN\1740 ,_24\,\1740 <e1>mda</e1>_25\NN\1740 and_26\CC\1740 caspase-3_27\NN\1740 activity_28\NN\30358 with_29\IN\1740 subsequent_30\JJ\1740 preservation_31\NN\817680 of_32\IN\1740 cognition_33\NN\23100 ._34\.\1740
24438483
D002045_D002318 NONE pre-treatment_0\JJ\1740 of_1\IN\1740 <e1>bupivacaine-induced</e1>_2\JJ\1740 <e2>cardiovascular_3\JJ\1740 depression</e2>_4\NN\14373582 using_5\VBG\1156834 different_6\JJ\1740 lipid_7\NN\14944888 formulations_8\NNS\14818238 of_9\IN\1740 propofol_10\NN\1740 ._11\.\1740
D015742_D002318 NONE pre-treatment_0\JJ\1740 of_1\IN\1740 bupivacaine-induced_2\JJ\1740 <e2>cardiovascular_3\JJ\1740 depression</e2>_4\NN\14373582 using_5\VBG\1156834 different_6\JJ\1740 lipid_7\NN\14944888 formulations_8\NNS\14818238 of_9\IN\1740 <e1>propofol</e1>_10\NN\1740 ._11\.\1740
D002045_D066126 CID background_0\NN\4921011 :_1\:\1740 pre-treatment_2\JJ\1740 with_3\IN\1740 lipid_4\NN\14944888 emulsions_5\NNS\14588219 has_6\VBZ\2108377 been_7\VBN\836236 shown_8\VBN\2137132 to_9\TO\1740 increase_10\VB\169651 lethal_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 <e1>bupivacaine</e1>_14\NN\1740 ,_15\,\1740 and_16\CC\1740 the_17\DT\1740 lipid_18\NN\14944888 content_19\NN\7951464 of_20\IN\1740 propofol_21\NN\1740 may_22\MD\15209706 alleviate_23\VB\205885 bupivacaine-induced_24\JJ\1740 <e2>cardiotoxicity</e2>_25\NN\1740 ._26\.\1740
D002045_D066126 CID background_0\NN\4921011 :_1\:\1740 pre-treatment_2\JJ\1740 with_3\IN\1740 lipid_4\NN\14944888 emulsions_5\NNS\14588219 has_6\VBZ\2108377 been_7\VBN\836236 shown_8\VBN\2137132 to_9\TO\1740 increase_10\VB\169651 lethal_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 bupivacaine_14\NN\1740 ,_15\,\1740 and_16\CC\1740 the_17\DT\1740 lipid_18\NN\14944888 content_19\NN\7951464 of_20\IN\1740 propofol_21\NN\1740 may_22\MD\15209706 alleviate_23\VB\205885 <e1>bupivacaine-induced</e1>_24\JJ\1740 <e2>cardiotoxicity</e2>_25\NN\1740 ._26\.\1740
D002045_D066126 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 investigate_7\VB\644583 the_8\DT\1740 effects_9\NNS\13245626 of_10\IN\1740 propofol_11\NN\1740 in_12\IN\13603305 intralipid_13\NN\1740 or_14\CC\3541091 medialipid_15\NN\1740 emulsions_16\NNS\14588219 on_17\IN\1740 <e1>bupivacaine-induced</e1>_18\JJ\1740 <e2>cardiotoxicity</e2>_19\NN\1740 ._20\.\1740
D002045_D066126 CID the_0\DT\1740 cumulative_1\JJ\1740 <e1>bupivacaine</e1>_2\NN\1740 dose_3\NN\3740161 given_4\VBN\2327200 at_5\IN\14622893 those_6\DT\1740 time_7\NN\7308889 points_8\NNS\5868954 was_9\VBD\836236 higher_10\JJR\1740 in_11\IN\13603305 group_12\NNP\2137 p._13\NNP\1740 plasma_14\NNP\5398023 bupivacaine_15\NN\1740 levels_16\NNS\4916342 were_17\VBD\836236 significantly_18\RB\1740 lower_19\JJR\1740 in_20\IN\13603305 group_21\NN\2137 p_22\NN\14622893 than_23\IN\1740 in_24\IN\13603305 group_25\NNP\2137 c._26\NNP\1740 bupivacaine_27\NNP\1740 levels_28\NNS\4916342 in_29\IN\13603305 the_30\DT\1740 brain_31\NN\5462674 and_32\CC\1740 heart_33\NN\5919034 were_34\VBD\836236 significantly_35\RB\1740 lower_36\JJR\1740 in_37\IN\13603305 group_38\NN\2137 p_39\NN\14622893 and_40\CC\1740 group_41\NNP\2137 l_42\NN\13616054 than_43\IN\1740 in_44\IN\13603305 group_45\NNP\2137 c._46\NNP\1740 conclusion_47\NN\5837957 :_48\:\1740 we_49\PRP\1740 conclude_50\VBP\628491 that_51\IN\1740 pre-treatment_52\NN\1740 with_53\IN\1740 propofol_54\NN\1740 in_55\IN\13603305 intralipid_56\NN\1740 ,_57\,\1740 compared_58\VBN\644583 with_59\IN\1740 propofol_60\NN\1740 in_61\IN\13603305 medialipid_62\NN\1740 or_63\CC\3541091 saline_64\NN\14849367 ,_65\,\1740 delayed_66\VBD\439958 the_67\DT\1740 onset_68\NN\7325190 of_69\IN\1740 bupivacaine-induced_70\JJ\1740 <e2>cardiotoxic</e2>_71\JJ\1740 effects_72\NNS\13245626 as_73\RB\1740 well_74\RB\1740 as_75\IN\14622893 reduced_76\VBN\441445 plasma_77\NN\5398023 bupivacaine_78\NN\1740 levels_79\NNS\4916342 ._80\.\1740
D002045_D066126 CID the_0\DT\1740 cumulative_1\JJ\1740 bupivacaine_2\NN\1740 dose_3\NN\3740161 given_4\VBN\2327200 at_5\IN\14622893 those_6\DT\1740 time_7\NN\7308889 points_8\NNS\5868954 was_9\VBD\836236 higher_10\JJR\1740 in_11\IN\13603305 group_12\NNP\2137 p._13\NNP\1740 plasma_14\NNP\5398023 <e1>bupivacaine</e1>_15\NN\1740 levels_16\NNS\4916342 were_17\VBD\836236 significantly_18\RB\1740 lower_19\JJR\1740 in_20\IN\13603305 group_21\NN\2137 p_22\NN\14622893 than_23\IN\1740 in_24\IN\13603305 group_25\NNP\2137 c._26\NNP\1740 bupivacaine_27\NNP\1740 levels_28\NNS\4916342 in_29\IN\13603305 the_30\DT\1740 brain_31\NN\5462674 and_32\CC\1740 heart_33\NN\5919034 were_34\VBD\836236 significantly_35\RB\1740 lower_36\JJR\1740 in_37\IN\13603305 group_38\NN\2137 p_39\NN\14622893 and_40\CC\1740 group_41\NNP\2137 l_42\NN\13616054 than_43\IN\1740 in_44\IN\13603305 group_45\NNP\2137 c._46\NNP\1740 conclusion_47\NN\5837957 :_48\:\1740 we_49\PRP\1740 conclude_50\VBP\628491 that_51\IN\1740 pre-treatment_52\NN\1740 with_53\IN\1740 propofol_54\NN\1740 in_55\IN\13603305 intralipid_56\NN\1740 ,_57\,\1740 compared_58\VBN\644583 with_59\IN\1740 propofol_60\NN\1740 in_61\IN\13603305 medialipid_62\NN\1740 or_63\CC\3541091 saline_64\NN\14849367 ,_65\,\1740 delayed_66\VBD\439958 the_67\DT\1740 onset_68\NN\7325190 of_69\IN\1740 bupivacaine-induced_70\JJ\1740 <e2>cardiotoxic</e2>_71\JJ\1740 effects_72\NNS\13245626 as_73\RB\1740 well_74\RB\1740 as_75\IN\14622893 reduced_76\VBN\441445 plasma_77\NN\5398023 bupivacaine_78\NN\1740 levels_79\NNS\4916342 ._80\.\1740
D002045_D066126 CID the_0\DT\1740 cumulative_1\JJ\1740 bupivacaine_2\NN\1740 dose_3\NN\3740161 given_4\VBN\2327200 at_5\IN\14622893 those_6\DT\1740 time_7\NN\7308889 points_8\NNS\5868954 was_9\VBD\836236 higher_10\JJR\1740 in_11\IN\13603305 group_12\NNP\2137 p._13\NNP\1740 plasma_14\NNP\5398023 bupivacaine_15\NN\1740 levels_16\NNS\4916342 were_17\VBD\836236 significantly_18\RB\1740 lower_19\JJR\1740 in_20\IN\13603305 group_21\NN\2137 p_22\NN\14622893 than_23\IN\1740 in_24\IN\13603305 group_25\NNP\2137 c._26\NNP\1740 <e1>bupivacaine</e1>_27\NNP\1740 levels_28\NNS\4916342 in_29\IN\13603305 the_30\DT\1740 brain_31\NN\5462674 and_32\CC\1740 heart_33\NN\5919034 were_34\VBD\836236 significantly_35\RB\1740 lower_36\JJR\1740 in_37\IN\13603305 group_38\NN\2137 p_39\NN\14622893 and_40\CC\1740 group_41\NNP\2137 l_42\NN\13616054 than_43\IN\1740 in_44\IN\13603305 group_45\NNP\2137 c._46\NNP\1740 conclusion_47\NN\5837957 :_48\:\1740 we_49\PRP\1740 conclude_50\VBP\628491 that_51\IN\1740 pre-treatment_52\NN\1740 with_53\IN\1740 propofol_54\NN\1740 in_55\IN\13603305 intralipid_56\NN\1740 ,_57\,\1740 compared_58\VBN\644583 with_59\IN\1740 propofol_60\NN\1740 in_61\IN\13603305 medialipid_62\NN\1740 or_63\CC\3541091 saline_64\NN\14849367 ,_65\,\1740 delayed_66\VBD\439958 the_67\DT\1740 onset_68\NN\7325190 of_69\IN\1740 bupivacaine-induced_70\JJ\1740 <e2>cardiotoxic</e2>_71\JJ\1740 effects_72\NNS\13245626 as_73\RB\1740 well_74\RB\1740 as_75\IN\14622893 reduced_76\VBN\441445 plasma_77\NN\5398023 bupivacaine_78\NN\1740 levels_79\NNS\4916342 ._80\.\1740
D002045_D066126 CID the_0\DT\1740 cumulative_1\JJ\1740 bupivacaine_2\NN\1740 dose_3\NN\3740161 given_4\VBN\2327200 at_5\IN\14622893 those_6\DT\1740 time_7\NN\7308889 points_8\NNS\5868954 was_9\VBD\836236 higher_10\JJR\1740 in_11\IN\13603305 group_12\NNP\2137 p._13\NNP\1740 plasma_14\NNP\5398023 bupivacaine_15\NN\1740 levels_16\NNS\4916342 were_17\VBD\836236 significantly_18\RB\1740 lower_19\JJR\1740 in_20\IN\13603305 group_21\NN\2137 p_22\NN\14622893 than_23\IN\1740 in_24\IN\13603305 group_25\NNP\2137 c._26\NNP\1740 bupivacaine_27\NNP\1740 levels_28\NNS\4916342 in_29\IN\13603305 the_30\DT\1740 brain_31\NN\5462674 and_32\CC\1740 heart_33\NN\5919034 were_34\VBD\836236 significantly_35\RB\1740 lower_36\JJR\1740 in_37\IN\13603305 group_38\NN\2137 p_39\NN\14622893 and_40\CC\1740 group_41\NNP\2137 l_42\NN\13616054 than_43\IN\1740 in_44\IN\13603305 group_45\NNP\2137 c._46\NNP\1740 conclusion_47\NN\5837957 :_48\:\1740 we_49\PRP\1740 conclude_50\VBP\628491 that_51\IN\1740 pre-treatment_52\NN\1740 with_53\IN\1740 propofol_54\NN\1740 in_55\IN\13603305 intralipid_56\NN\1740 ,_57\,\1740 compared_58\VBN\644583 with_59\IN\1740 propofol_60\NN\1740 in_61\IN\13603305 medialipid_62\NN\1740 or_63\CC\3541091 saline_64\NN\14849367 ,_65\,\1740 delayed_66\VBD\439958 the_67\DT\1740 onset_68\NN\7325190 of_69\IN\1740 <e1>bupivacaine-induced</e1>_70\JJ\1740 <e2>cardiotoxic</e2>_71\JJ\1740 effects_72\NNS\13245626 as_73\RB\1740 well_74\RB\1740 as_75\IN\14622893 reduced_76\VBN\441445 plasma_77\NN\5398023 bupivacaine_78\NN\1740 levels_79\NNS\4916342 ._80\.\1740
D002045_D066126 CID the_0\DT\1740 cumulative_1\JJ\1740 bupivacaine_2\NN\1740 dose_3\NN\3740161 given_4\VBN\2327200 at_5\IN\14622893 those_6\DT\1740 time_7\NN\7308889 points_8\NNS\5868954 was_9\VBD\836236 higher_10\JJR\1740 in_11\IN\13603305 group_12\NNP\2137 p._13\NNP\1740 plasma_14\NNP\5398023 bupivacaine_15\NN\1740 levels_16\NNS\4916342 were_17\VBD\836236 significantly_18\RB\1740 lower_19\JJR\1740 in_20\IN\13603305 group_21\NN\2137 p_22\NN\14622893 than_23\IN\1740 in_24\IN\13603305 group_25\NNP\2137 c._26\NNP\1740 bupivacaine_27\NNP\1740 levels_28\NNS\4916342 in_29\IN\13603305 the_30\DT\1740 brain_31\NN\5462674 and_32\CC\1740 heart_33\NN\5919034 were_34\VBD\836236 significantly_35\RB\1740 lower_36\JJR\1740 in_37\IN\13603305 group_38\NN\2137 p_39\NN\14622893 and_40\CC\1740 group_41\NNP\2137 l_42\NN\13616054 than_43\IN\1740 in_44\IN\13603305 group_45\NNP\2137 c._46\NNP\1740 conclusion_47\NN\5837957 :_48\:\1740 we_49\PRP\1740 conclude_50\VBP\628491 that_51\IN\1740 pre-treatment_52\NN\1740 with_53\IN\1740 propofol_54\NN\1740 in_55\IN\13603305 intralipid_56\NN\1740 ,_57\,\1740 compared_58\VBN\644583 with_59\IN\1740 propofol_60\NN\1740 in_61\IN\13603305 medialipid_62\NN\1740 or_63\CC\3541091 saline_64\NN\14849367 ,_65\,\1740 delayed_66\VBD\439958 the_67\DT\1740 onset_68\NN\7325190 of_69\IN\1740 bupivacaine-induced_70\JJ\1740 <e2>cardiotoxic</e2>_71\JJ\1740 effects_72\NNS\13245626 as_73\RB\1740 well_74\RB\1740 as_75\IN\14622893 reduced_76\VBN\441445 plasma_77\NN\5398023 <e1>bupivacaine</e1>_78\NN\1740 levels_79\NNS\4916342 ._80\.\1740
D015742_D066126 NONE background_0\NN\4921011 :_1\:\1740 pre-treatment_2\JJ\1740 with_3\IN\1740 lipid_4\NN\14944888 emulsions_5\NNS\14588219 has_6\VBZ\2108377 been_7\VBN\836236 shown_8\VBN\2137132 to_9\TO\1740 increase_10\VB\169651 lethal_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 bupivacaine_14\NN\1740 ,_15\,\1740 and_16\CC\1740 the_17\DT\1740 lipid_18\NN\14944888 content_19\NN\7951464 of_20\IN\1740 <e1>propofol</e1>_21\NN\1740 may_22\MD\15209706 alleviate_23\VB\205885 bupivacaine-induced_24\JJ\1740 <e2>cardiotoxicity</e2>_25\NN\1740 ._26\.\1740
D015742_D066126 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 is_5\VBZ\836236 to_6\TO\1740 investigate_7\VB\644583 the_8\DT\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>propofol</e1>_11\NN\1740 in_12\IN\13603305 intralipid_13\NN\1740 or_14\CC\3541091 medialipid_15\NN\1740 emulsions_16\NNS\14588219 on_17\IN\1740 bupivacaine-induced_18\JJ\1740 <e2>cardiotoxicity</e2>_19\NN\1740 ._20\.\1740
D015742_D066126 NONE the_0\DT\1740 cumulative_1\JJ\1740 bupivacaine_2\NN\1740 dose_3\NN\3740161 given_4\VBN\2327200 at_5\IN\14622893 those_6\DT\1740 time_7\NN\7308889 points_8\NNS\5868954 was_9\VBD\836236 higher_10\JJR\1740 in_11\IN\13603305 group_12\NNP\2137 p._13\NNP\1740 plasma_14\NNP\5398023 bupivacaine_15\NN\1740 levels_16\NNS\4916342 were_17\VBD\836236 significantly_18\RB\1740 lower_19\JJR\1740 in_20\IN\13603305 group_21\NN\2137 p_22\NN\14622893 than_23\IN\1740 in_24\IN\13603305 group_25\NNP\2137 c._26\NNP\1740 bupivacaine_27\NNP\1740 levels_28\NNS\4916342 in_29\IN\13603305 the_30\DT\1740 brain_31\NN\5462674 and_32\CC\1740 heart_33\NN\5919034 were_34\VBD\836236 significantly_35\RB\1740 lower_36\JJR\1740 in_37\IN\13603305 group_38\NN\2137 p_39\NN\14622893 and_40\CC\1740 group_41\NNP\2137 l_42\NN\13616054 than_43\IN\1740 in_44\IN\13603305 group_45\NNP\2137 c._46\NNP\1740 conclusion_47\NN\5837957 :_48\:\1740 we_49\PRP\1740 conclude_50\VBP\628491 that_51\IN\1740 pre-treatment_52\NN\1740 with_53\IN\1740 <e1>propofol</e1>_54\NN\1740 in_55\IN\13603305 intralipid_56\NN\1740 ,_57\,\1740 compared_58\VBN\644583 with_59\IN\1740 propofol_60\NN\1740 in_61\IN\13603305 medialipid_62\NN\1740 or_63\CC\3541091 saline_64\NN\14849367 ,_65\,\1740 delayed_66\VBD\439958 the_67\DT\1740 onset_68\NN\7325190 of_69\IN\1740 bupivacaine-induced_70\JJ\1740 <e2>cardiotoxic</e2>_71\JJ\1740 effects_72\NNS\13245626 as_73\RB\1740 well_74\RB\1740 as_75\IN\14622893 reduced_76\VBN\441445 plasma_77\NN\5398023 bupivacaine_78\NN\1740 levels_79\NNS\4916342 ._80\.\1740
D015742_D066126 NONE the_0\DT\1740 cumulative_1\JJ\1740 bupivacaine_2\NN\1740 dose_3\NN\3740161 given_4\VBN\2327200 at_5\IN\14622893 those_6\DT\1740 time_7\NN\7308889 points_8\NNS\5868954 was_9\VBD\836236 higher_10\JJR\1740 in_11\IN\13603305 group_12\NNP\2137 p._13\NNP\1740 plasma_14\NNP\5398023 bupivacaine_15\NN\1740 levels_16\NNS\4916342 were_17\VBD\836236 significantly_18\RB\1740 lower_19\JJR\1740 in_20\IN\13603305 group_21\NN\2137 p_22\NN\14622893 than_23\IN\1740 in_24\IN\13603305 group_25\NNP\2137 c._26\NNP\1740 bupivacaine_27\NNP\1740 levels_28\NNS\4916342 in_29\IN\13603305 the_30\DT\1740 brain_31\NN\5462674 and_32\CC\1740 heart_33\NN\5919034 were_34\VBD\836236 significantly_35\RB\1740 lower_36\JJR\1740 in_37\IN\13603305 group_38\NN\2137 p_39\NN\14622893 and_40\CC\1740 group_41\NNP\2137 l_42\NN\13616054 than_43\IN\1740 in_44\IN\13603305 group_45\NNP\2137 c._46\NNP\1740 conclusion_47\NN\5837957 :_48\:\1740 we_49\PRP\1740 conclude_50\VBP\628491 that_51\IN\1740 pre-treatment_52\NN\1740 with_53\IN\1740 propofol_54\NN\1740 in_55\IN\13603305 intralipid_56\NN\1740 ,_57\,\1740 compared_58\VBN\644583 with_59\IN\1740 <e1>propofol</e1>_60\NN\1740 in_61\IN\13603305 medialipid_62\NN\1740 or_63\CC\3541091 saline_64\NN\14849367 ,_65\,\1740 delayed_66\VBD\439958 the_67\DT\1740 onset_68\NN\7325190 of_69\IN\1740 bupivacaine-induced_70\JJ\1740 <e2>cardiotoxic</e2>_71\JJ\1740 effects_72\NNS\13245626 as_73\RB\1740 well_74\RB\1740 as_75\IN\14622893 reduced_76\VBN\441445 plasma_77\NN\5398023 bupivacaine_78\NN\1740 levels_79\NNS\4916342 ._80\.\1740
D002045_D001145 NONE we_0\PRP\1740 recorded_1\VBD\2225492 time_2\NN\7308889 to_3\IN\1740 first_4\JJ\1740 <e2>dysrhythmia</e2>_5\NN\1740 occurrence_6\NN\29378 ,_7\,\1740 respective_8\JJ\1740 times_9\NNS\15113229 to_10\IN\1740 25_11\CD\13745420 %_12\NN\1740 and_13\CC\1740 50_14\CD\13745420 %_15\NN\1740 reduction_16\NN\351485 of_17\IN\1740 the_18\DT\1740 heart_19\NN\5919034 rate_20\NN\13815152 (_21\-LRB-\1740 hr_22\NN\15154774 )_23\-RRB-\1740 and_24\CC\1740 mean_25\VB\928630 arterial_26\JJ\1740 pressure_27\NN\11419404 ,_28\,\1740 and_29\CC\1740 time_30\NN\7308889 to_31\TO\1740 asystole_32\VB\1740 and_33\CC\1740 total_34\JJ\1740 amount_35\NN\13329641 of_36\IN\1740 <e1>bupivacaine</e1>_37\NN\1740 consumption_38\NN\13440063 ._39\.\1740
D002045_D006323 CID we_0\PRP\1740 recorded_1\VBD\2225492 time_2\NN\7308889 to_3\IN\1740 first_4\JJ\1740 dysrhythmia_5\NN\1740 occurrence_6\NN\29378 ,_7\,\1740 respective_8\JJ\1740 times_9\NNS\15113229 to_10\IN\1740 25_11\CD\13745420 %_12\NN\1740 and_13\CC\1740 50_14\CD\13745420 %_15\NN\1740 reduction_16\NN\351485 of_17\IN\1740 the_18\DT\1740 heart_19\NN\5919034 rate_20\NN\13815152 (_21\-LRB-\1740 hr_22\NN\15154774 )_23\-RRB-\1740 and_24\CC\1740 mean_25\VB\928630 arterial_26\JJ\1740 pressure_27\NN\11419404 ,_28\,\1740 and_29\CC\1740 time_30\NN\7308889 to_31\TO\1740 <e2>asystole</e2>_32\VB\1740 and_33\CC\1740 total_34\JJ\1740 amount_35\NN\13329641 of_36\IN\1740 <e1>bupivacaine</e1>_37\NN\1740 consumption_38\NN\13440063 ._39\.\1740
6695685
D014700_D001145 CID <e2>accelerated_0\VBN\226566 junctional_1\JJ\1740 rhythms</e2>_2\NNS\15122011 during_3\IN\1740 oral_4\JJ\1740 <e1>verapamil</e1>_5\NN\2938514 therapy_6\NN\657604 ._7\.\1740
D014700_D001145 CID this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 frequency_4\NN\15286249 of_5\IN\1740 atrioventricular_6\JJ\1740 (_7\-LRB-\1740 av_8\NN\15214068 )_9\-RRB-\1740 dissociation_10\NN\383606 and_11\CC\1740 <e2>accelerated_12\VBD\226566 junctional_13\JJ\1740 rhythms</e2>_14\NNS\15122011 in_15\IN\13603305 59_16\CD\1740 patients_17\NNS\9898892 receiving_18\VBG\2210855 oral_19\JJ\1740 <e1>verapamil</e1>_20\NN\2938514 ._21\.\1740
D014700_D002637 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 various_3\JJ\1740 <e2>chest_4\JJ\1740 pain</e2>_5\NN\14299637 syndromes_6\NNS\5870365 ,_7\,\1740 <e1>verapamil</e1>_8\RB\1740 neither_9\CC\1740 increased_10\VBD\169651 the_11\DT\1740 frequency_12\NN\15286249 of_13\IN\1740 junctional_14\JJ\1740 rhythms_15\NNS\15122011 nor_16\CC\1740 suppressed_17\VBD\2510337 their_18\PRP$\1740 role_19\NN\719494 as_20\IN\14622893 escape_21\NN\46177 rhythms_22\NNS\15122011 under_23\IN\1740 physiologically_24\RB\1740 appropriate_25\JJ\1740 circumstances_26\NNS\13920429 ._27\.\1740
7176945
D013390_D010146 CID <e1>post-suxamethonium</e1>_0\JJ\1740 <e2>pains</e2>_1\VBZ\64643 in_2\IN\13603305 nigerian_3\JJ\1740 surgical_4\JJ\1740 patients_5\NNS\9898892 ._6\.\1740
D013390_D010146 CID contrary_0\JJ\1740 to_1\IN\1740 an_2\DT\6697703 earlier_3\JJR\1740 report_4\NN\6470073 by_5\IN\1740 coxon_6\NNP\1740 ,_7\,\1740 <e1>scoline</e1>_8\NN\1740 <e2>pain</e2>_9\NN\14299637 occurs_10\VBZ\2623529 in_11\IN\13603305 african_12\JJ\1740 negroes_13\NNS\7846 ._14\.\1740
D013390_D010146 CID about_0\RB\1740 62_1\CD\1740 %_2\NN\1740 of_3\IN\1740 the_4\DT\1740 out-patients_5\JJ\1740 developed_6\VBD\1753788 <e1>scoline</e1>_7\NN\1740 <e2>pain</e2>_8\NN\14299637 as_9\IN\14622893 compared_10\VBN\644583 with_11\IN\1740 about_12\RB\1740 26_13\CD\13745420 %_14\NN\1740 among_15\IN\1740 the_16\DT\1740 in-patients_17\NNS\1740 ._18\.\1740
D013390_D010146 CID the_0\DT\1740 abolition_1\NN\209943 of_2\IN\1740 muscle_3\NN\5289601 fasciculations_4\NNS\14361664 (_5\-LRB-\1740 by_6\IN\1740 0.075mg/kg_7\NN\1740 dose_8\NN\3740161 of_9\IN\1740 fazadinium_10\NNP\1740 )_11\-RRB-\1740 did_12\VBD\1640855 not_13\RB\1740 influence_14\VB\137313 the_15\DT\1740 occurrence_16\NN\29378 of_17\IN\1740 <e1>scoline</e1>_18\JJ\1740 <e2>pain</e2>_19\NN\14299637 ._20\.\1740
D013390_D010146 CID neither_0\CC\1740 the_1\DT\1740 type_2\NN\5839024 of_3\IN\1740 induction_4\NN\7450842 agent_5\NN\7347 (_6\-LRB-\1740 althesin_7\NN\1740 or_8\CC\3541091 thiopentone_9\NN\1740 )_10\-RRB-\1740 nor_11\CC\1740 the_12\DT\1740 salt_13\NN\14818238 preparation_14\NN\407535 of_15\IN\1740 <e1>suxamethonium</e1>_16\NN\1740 used_17\VBN\1156834 (_18\-LRB-\1740 chloride_19\NN\14818238 or_20\CC\3541091 bromide_21\NN\14904359 )_22\-RRB-\1740 ,_23\,\1740 affected_24\VBD\126264 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 scoline_28\JJ\1740 <e2>pain</e2>_29\NN\14299637 ._30\.\1740
D013390_D010146 CID neither_0\CC\1740 the_1\DT\1740 type_2\NN\5839024 of_3\IN\1740 induction_4\NN\7450842 agent_5\NN\7347 (_6\-LRB-\1740 althesin_7\NN\1740 or_8\CC\3541091 thiopentone_9\NN\1740 )_10\-RRB-\1740 nor_11\CC\1740 the_12\DT\1740 salt_13\NN\14818238 preparation_14\NN\407535 of_15\IN\1740 suxamethonium_16\NN\1740 used_17\VBN\1156834 (_18\-LRB-\1740 chloride_19\NN\14818238 or_20\CC\3541091 bromide_21\NN\14904359 )_22\-RRB-\1740 ,_23\,\1740 affected_24\VBD\126264 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 <e1>scoline</e1>_28\JJ\1740 <e2>pain</e2>_29\NN\14299637 ._30\.\1740
C084773_D005207 NONE the_0\DT\1740 abolition_1\NN\209943 of_2\IN\1740 muscle_3\NN\5289601 <e2>fasciculations</e2>_4\NNS\14361664 (_5\-LRB-\1740 by_6\IN\1740 0.075mg/kg_7\NN\1740 dose_8\NN\3740161 of_9\IN\1740 <e1>fazadinium</e1>_10\NNP\1740 )_11\-RRB-\1740 did_12\VBD\1640855 not_13\RB\1740 influence_14\VB\137313 the_15\DT\1740 occurrence_16\NN\29378 of_17\IN\1740 scoline_18\JJ\1740 pain_19\NN\14299637 ._20\.\1740
C084773_D010146 NONE the_0\DT\1740 abolition_1\NN\209943 of_2\IN\1740 muscle_3\NN\5289601 fasciculations_4\NNS\14361664 (_5\-LRB-\1740 by_6\IN\1740 0.075mg/kg_7\NN\1740 dose_8\NN\3740161 of_9\IN\1740 <e1>fazadinium</e1>_10\NNP\1740 )_11\-RRB-\1740 did_12\VBD\1640855 not_13\RB\1740 influence_14\VB\137313 the_15\DT\1740 occurrence_16\NN\29378 of_17\IN\1740 scoline_18\JJ\1740 <e2>pain</e2>_19\NN\14299637 ._20\.\1740
D013390_D005207 CID the_0\DT\1740 abolition_1\NN\209943 of_2\IN\1740 muscle_3\NN\5289601 <e2>fasciculations</e2>_4\NNS\14361664 (_5\-LRB-\1740 by_6\IN\1740 0.075mg/kg_7\NN\1740 dose_8\NN\3740161 of_9\IN\1740 fazadinium_10\NNP\1740 )_11\-RRB-\1740 did_12\VBD\1640855 not_13\RB\1740 influence_14\VB\137313 the_15\DT\1740 occurrence_16\NN\29378 of_17\IN\1740 <e1>scoline</e1>_18\JJ\1740 pain_19\NN\14299637 ._20\.\1740
D000530_D010146 NONE neither_0\CC\1740 the_1\DT\1740 type_2\NN\5839024 of_3\IN\1740 induction_4\NN\7450842 agent_5\NN\7347 (_6\-LRB-\1740 <e1>althesin</e1>_7\NN\1740 or_8\CC\3541091 thiopentone_9\NN\1740 )_10\-RRB-\1740 nor_11\CC\1740 the_12\DT\1740 salt_13\NN\14818238 preparation_14\NN\407535 of_15\IN\1740 suxamethonium_16\NN\1740 used_17\VBN\1156834 (_18\-LRB-\1740 chloride_19\NN\14818238 or_20\CC\3541091 bromide_21\NN\14904359 )_22\-RRB-\1740 ,_23\,\1740 affected_24\VBD\126264 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 scoline_28\JJ\1740 <e2>pain</e2>_29\NN\14299637 ._30\.\1740
D013874_D010146 NONE neither_0\CC\1740 the_1\DT\1740 type_2\NN\5839024 of_3\IN\1740 induction_4\NN\7450842 agent_5\NN\7347 (_6\-LRB-\1740 althesin_7\NN\1740 or_8\CC\3541091 <e1>thiopentone</e1>_9\NN\1740 )_10\-RRB-\1740 nor_11\CC\1740 the_12\DT\1740 salt_13\NN\14818238 preparation_14\NN\407535 of_15\IN\1740 suxamethonium_16\NN\1740 used_17\VBN\1156834 (_18\-LRB-\1740 chloride_19\NN\14818238 or_20\CC\3541091 bromide_21\NN\14904359 )_22\-RRB-\1740 ,_23\,\1740 affected_24\VBD\126264 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 scoline_28\JJ\1740 <e2>pain</e2>_29\NN\14299637 ._30\.\1740
D002712_D010146 NONE neither_0\CC\1740 the_1\DT\1740 type_2\NN\5839024 of_3\IN\1740 induction_4\NN\7450842 agent_5\NN\7347 (_6\-LRB-\1740 althesin_7\NN\1740 or_8\CC\3541091 thiopentone_9\NN\1740 )_10\-RRB-\1740 nor_11\CC\1740 the_12\DT\1740 salt_13\NN\14818238 preparation_14\NN\407535 of_15\IN\1740 suxamethonium_16\NN\1740 used_17\VBN\1156834 (_18\-LRB-\1740 <e1>chloride</e1>_19\NN\14818238 or_20\CC\3541091 bromide_21\NN\14904359 )_22\-RRB-\1740 ,_23\,\1740 affected_24\VBD\126264 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 scoline_28\JJ\1740 <e2>pain</e2>_29\NN\14299637 ._30\.\1740
D001965_D010146 NONE neither_0\CC\1740 the_1\DT\1740 type_2\NN\5839024 of_3\IN\1740 induction_4\NN\7450842 agent_5\NN\7347 (_6\-LRB-\1740 althesin_7\NN\1740 or_8\CC\3541091 thiopentone_9\NN\1740 )_10\-RRB-\1740 nor_11\CC\1740 the_12\DT\1740 salt_13\NN\14818238 preparation_14\NN\407535 of_15\IN\1740 suxamethonium_16\NN\1740 used_17\VBN\1156834 (_18\-LRB-\1740 chloride_19\NN\14818238 or_20\CC\3541091 <e1>bromide</e1>_21\NN\14904359 )_22\-RRB-\1740 ,_23\,\1740 affected_24\VBD\126264 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 scoline_28\JJ\1740 <e2>pain</e2>_29\NN\14299637 ._30\.\1740
26033014
C051786_D009369 NONE <e2>cancer</e2>_0\NN\14239425 incidence_1\NN\13821570 and_2\CC\1740 <e1>metolachlor</e1>_3\NN\1740 use_4\NN\407535 in_5\IN\13603305 the_6\DT\1740 agricultural_7\NNP\1740 health_8\NNP\14447525 study_9\NNP\635850 :_10\:\1740 an_11\DT\6697703 update_12\NN\6642138 ._13\.\1740
C051786_D009369 NONE we_0\PRP\1740 evaluated_1\VBD\670261 <e2>cancer</e2>_2\NN\14239425 incidence_3\NN\13821570 through_4\IN\1740 2010/2011_5\NN\1740 (_6\-LRB-\1740 nc/ia_7\NN\1740 )_8\-RRB-\1740 for_9\IN\1740 49,616_10\CD\1740 applicators_11\NNS\3183080 ,_12\,\1740 53_13\CD\1740 %_14\NN\1740 of_15\IN\1740 whom_16\WP\1740 reported_17\VBD\831651 ever_18\RB\1740 using_19\VBG\1156834 <e1>metolachlor</e1>_20\NN\1740 ._21\.\1740
C051786_D009369 NONE we_0\PRP\1740 used_1\VBD\1156834 poisson_2\NNP\1740 regression_3\NN\14501726 to_4\TO\1740 evaluate_5\VB\670261 relations_6\NNS\32823 between_7\IN\1740 two_8\CD\13741022 metrics_9\NNS\6169932 of_10\IN\1740 <e1>metolachlor</e1>_11\NN\1740 use_12\NN\407535 (_13\-LRB-\1740 lifetime_14\NN\15113229 days_15\NNS\15140892 ,_16\,\1740 intensity-weighted_17\JJ\1740 lifetime_18\NN\15113229 days_19\NNS\15140892 )_20\-RRB-\1740 and_21\CC\1740 <e2>cancer</e2>_22\NN\14239425 incidence_23\NN\13821570 ._24\.\1740
C051786_D009369 NONE we_0\PRP\1740 saw_1\VBD\1552519 no_2\DT\7204911 association_3\NN\8008335 between_4\IN\1740 <e1>metolachlor</e1>_5\NN\1740 use_6\NN\407535 and_7\CC\1740 incidence_8\NN\13821570 of_9\IN\1740 all_10\DT\1740 <e2>cancers</e2>_11\NNS\14239425 combined_12\JJ\1740 (_13\-LRB-\1740 n_14\NN\14622893 =_15\JJ\1740 5,701_16\CD\1740 with_17\IN\1740 a_18\DT\13649268 5-year_19\JJ\1740 lag_20\NN\1066163 )_21\-RRB-\1740 or_22\CC\3541091 most_23\JJS\1740 site-specific_24\JJ\1740 cancers_25\NNS\14239425 ._26\.\1740
C051786_D009369 NONE we_0\PRP\1740 saw_1\VBD\1552519 no_2\DT\7204911 association_3\NN\8008335 between_4\IN\1740 <e1>metolachlor</e1>_5\NN\1740 use_6\NN\407535 and_7\CC\1740 incidence_8\NN\13821570 of_9\IN\1740 all_10\DT\1740 cancers_11\NNS\14239425 combined_12\JJ\1740 (_13\-LRB-\1740 n_14\NN\14622893 =_15\JJ\1740 5,701_16\CD\1740 with_17\IN\1740 a_18\DT\13649268 5-year_19\JJ\1740 lag_20\NN\1066163 )_21\-RRB-\1740 or_22\CC\3541091 most_23\JJS\1740 site-specific_24\JJ\1740 <e2>cancers</e2>_25\NNS\14239425 ._26\.\1740
C051786_D008113 CID unassigned_0\NNS\1740 :_1\:\1740 <e1>metolachlor</e1>_2\NNP\1740 ,_3\,\1740 a_4\DT\13649268 widely_5\RB\1740 used_6\VBN\1156834 herbicide_7\NN\14806838 ,_8\,\1740 is_9\VBZ\836236 classified_10\VBN\657260 as_11\IN\14622893 a_12\DT\13649268 group_13\NN\2137 c_14\NN\13714184 carcinogen_15\NN\20090 by_16\IN\1740 the_17\DT\1740 u.s._18\NNP\8052549 environmental_19\NNP\1740 protection_20\NNP\407535 agency_21\NNP\8077292 based_22\VBN\2694933 on_23\IN\1740 increased_24\VBN\169651 <e2>liver_25\NN\5298729 neoplasms</e2>_26\NNS\14234074 in_27\IN\13603305 female_28\JJ\1740 rats_29\NNS\2329401 ._30\.\1740
C051786_D008113 CID this_0\DT\1740 suggestion_1\NN\5833840 of_2\IN\1740 an_3\DT\6697703 association_4\NN\8008335 between_5\IN\1740 <e1>metolachlor</e1>_6\NN\1740 and_7\CC\1740 <e2>liver_8\NN\5298729 cancer</e2>_9\NN\14239425 among_10\IN\1740 pesticide_11\NN\14806838 applicators_12\NNS\3183080 is_13\VBZ\836236 a_14\DT\13649268 novel_15\JJ\1740 finding_16\NN\43195 and_17\CC\1740 echoes_18\VBZ\983824 observation_19\NN\996969 of_20\IN\1740 increased_21\VBN\169651 liver_22\NN\5298729 neoplasms_23\NNS\14234074 in_24\IN\13603305 some_25\DT\1740 animal_26\JJ\1740 studies_27\NNS\635850 ._28\.\1740
C051786_D008113 CID this_0\DT\1740 suggestion_1\NN\5833840 of_2\IN\1740 an_3\DT\6697703 association_4\NN\8008335 between_5\IN\1740 <e1>metolachlor</e1>_6\NN\1740 and_7\CC\1740 liver_8\NN\5298729 cancer_9\NN\14239425 among_10\IN\1740 pesticide_11\NN\14806838 applicators_12\NNS\3183080 is_13\VBZ\836236 a_14\DT\13649268 novel_15\JJ\1740 finding_16\NN\43195 and_17\CC\1740 echoes_18\VBZ\983824 observation_19\NN\996969 of_20\IN\1740 increased_21\VBN\169651 <e2>liver_22\NN\5298729 neoplasms</e2>_23\NNS\14234074 in_24\IN\13603305 some_25\DT\1740 animal_26\JJ\1740 studies_27\NNS\635850 ._28\.\1740
C051786_D008113 CID however_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 findings_3\NNS\7951464 for_4\IN\1740 both_5\CC\1740 <e2>liver_6\NN\5298729 cancer</e2>_7\NN\14239425 and_8\CC\1740 follicular_9\JJ\1740 cell_10\NN\3080309 lymphoma_11\NN\14239918 warrant_12\NN\6552984 follow-up_13\NN\4599396 to_14\TO\1740 better_15\RBR\1740 differentiate_16\VB\618878 effects_17\NNS\13245626 of_18\IN\1740 <e1>metolachlor</e1>_19\NN\1740 use_20\NN\407535 from_21\IN\1740 other_22\JJ\1740 factors_23\NNS\7326557 ._24\.\1740
C051786_D008175 NONE an_0\DT\6697703 earlier_1\JJR\1740 suggestion_2\NN\5833840 of_3\IN\1740 increased_4\VBN\169651 <e2>lung_5\NN\5528060 cancer</e2>_6\NN\14239425 risk_7\NN\14541044 at_8\IN\14622893 high_9\JJ\1740 levels_10\NNS\4916342 of_11\IN\1740 <e1>metolachlor</e1>_12\NN\1740 use_13\NN\407535 in_14\IN\13603305 this_15\DT\1740 cohort_16\NN\8184861 was_17\VBD\836236 not_18\RB\1740 confirmed_19\VBN\1011725 in_20\IN\13603305 this_21\DT\1740 update_22\NN\6642138 ._23\.\1740
C051786_D008223 NONE however_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 findings_3\NNS\7951464 for_4\IN\1740 both_5\CC\1740 liver_6\NN\5298729 cancer_7\NN\14239425 and_8\CC\1740 follicular_9\JJ\1740 cell_10\NN\3080309 <e2>lymphoma</e2>_11\NN\14239918 warrant_12\NN\6552984 follow-up_13\NN\4599396 to_14\TO\1740 better_15\RBR\1740 differentiate_16\VB\618878 effects_17\NNS\13245626 of_18\IN\1740 <e1>metolachlor</e1>_19\NN\1740 use_20\NN\407535 from_21\IN\1740 other_22\JJ\1740 factors_23\NNS\7326557 ._24\.\1740
3895875
D008012_D009203 NONE prophylactic_0\JJ\1740 <e1>lidocaine</e1>_1\NN\3681148 in_2\IN\13603305 the_3\DT\1740 early_4\JJ\1740 phase_5\NN\15113229 of_6\IN\1740 suspected_7\VBN\916909 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 ._10\.\1740
D008012_D009203 NONE four_0\CD\13741022 hundred_1\CD\13745420 two_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 suspected_5\VBN\916909 <e2>myocardial_6\JJ\1740 infarction</e2>_7\NN\14204950 seen_8\VBN\2106506 within_9\IN\1740 6_10\CD\13741022 hours_11\NNS\15118228 of_12\IN\1740 the_13\DT\1740 onset_14\NN\7325190 of_15\IN\1740 symptoms_16\NNS\5823932 entered_17\VBD\2471690 a_18\DT\13649268 double-blind_19\JJ\1740 randomized_20\JJ\1740 trial_21\NN\786195 of_22\IN\1740 <e1>lidocaine</e1>_23\NN\3681148 vs_24\CC\13634784 placebo_25\NN\3740161 ._26\.\1740
D008012_D009203 NONE the_0\DT\1740 average_1\JJ\1740 plasma_2\NN\5398023 <e1>lidocaine</e1>_3\NN\3681148 level_4\NN\4916342 10_5\CD\13745420 minutes_6\NNS\6502378 after_7\IN\1740 administration_8\NN\1133281 for_9\IN\1740 patients_10\NNS\9898892 without_11\IN\1740 a_12\DT\13649268 <e2>myocardial_13\JJ\1740 infarction</e2>_14\NN\14204950 was_15\VBD\836236 significantly_16\RB\1740 higher_17\JJR\1740 than_18\IN\1740 that_19\DT\1740 for_20\IN\1740 patients_21\NNS\9898892 with_22\IN\1740 an_23\DT\6697703 acute_24\JJ\1740 infarction_25\NN\14204950 ._26\.\1740
D008012_D009203 NONE we_0\PRP\1740 can_1\MD\3094503 not_2\RB\1740 advocate_3\VB\875394 the_4\DT\1740 administration_5\NN\1133281 of_6\IN\1740 <e1>lidocaine</e1>_7\NN\3681148 prophylactically_8\RB\1740 in_9\IN\13603305 the_10\DT\1740 early_11\JJ\1740 hours_12\NNS\15118228 of_13\IN\1740 suspected_14\VBN\916909 <e2>myocardial_15\JJ\1740 infarction</e2>_16\NN\14204950 ._17\.\1740
D008012_D017180 NONE <e1>lidocaine</e1>_0\NN\3681148 ,_1\,\1740 given_2\VBN\2327200 in_3\IN\13603305 a_4\DT\13649268 300_5\CD\1740 mg_6\NN\13717155 dose_7\NN\3740161 intramuscularly_8\RB\1740 followed_9\VBN\1835496 by_10\IN\1740 100_11\CD\13745420 mg_12\NN\13717155 intravenously_13\RB\1740 ,_14\,\1740 did_15\VBD\1640855 not_16\RB\1740 prevent_17\VB\1740 sustained_18\JJ\1740 <e2>ventricular_19\JJ\1740 tachycardia</e2>_20\NN\14110674 ,_21\,\1740 although_22\IN\1740 there_23\EX\27167 was_24\VBD\836236 a_25\DT\13649268 significant_26\JJ\1740 reduction_27\NN\351485 in_28\IN\13603305 the_29\DT\1740 number_30\NN\5107765 of_31\IN\1740 patients_32\NNS\9898892 with_33\IN\1740 warning_34\NN\7212190 arrhythmias_35\NNS\14103288 between_36\IN\1740 15_37\CD\13745420 and_38\CC\1740 45_39\CD\1740 minutes_40\NNS\6502378 after_41\IN\1740 the_42\DT\1740 administration_43\NN\1133281 of_44\IN\1740 lidocaine_45\NN\3681148 (_46\-LRB-\1740 p_47\NN\14622893 less_48\JJR\1740 than_49\IN\1740 0.05_50\CD\1740 )_51\-RRB-\1740 ._52\.\1740
D008012_D017180 NONE lidocaine_0\NN\3681148 ,_1\,\1740 given_2\VBN\2327200 in_3\IN\13603305 a_4\DT\13649268 300_5\CD\1740 mg_6\NN\13717155 dose_7\NN\3740161 intramuscularly_8\RB\1740 followed_9\VBN\1835496 by_10\IN\1740 100_11\CD\13745420 mg_12\NN\13717155 intravenously_13\RB\1740 ,_14\,\1740 did_15\VBD\1640855 not_16\RB\1740 prevent_17\VB\1740 sustained_18\JJ\1740 <e2>ventricular_19\JJ\1740 tachycardia</e2>_20\NN\14110674 ,_21\,\1740 although_22\IN\1740 there_23\EX\27167 was_24\VBD\836236 a_25\DT\13649268 significant_26\JJ\1740 reduction_27\NN\351485 in_28\IN\13603305 the_29\DT\1740 number_30\NN\5107765 of_31\IN\1740 patients_32\NNS\9898892 with_33\IN\1740 warning_34\NN\7212190 arrhythmias_35\NNS\14103288 between_36\IN\1740 15_37\CD\13745420 and_38\CC\1740 45_39\CD\1740 minutes_40\NNS\6502378 after_41\IN\1740 the_42\DT\1740 administration_43\NN\1133281 of_44\IN\1740 <e1>lidocaine</e1>_45\NN\3681148 (_46\-LRB-\1740 p_47\NN\14622893 less_48\JJR\1740 than_49\IN\1740 0.05_50\CD\1740 )_51\-RRB-\1740 ._52\.\1740
D008012_D001145 NONE <e1>lidocaine</e1>_0\NN\3681148 ,_1\,\1740 given_2\VBN\2327200 in_3\IN\13603305 a_4\DT\13649268 300_5\CD\1740 mg_6\NN\13717155 dose_7\NN\3740161 intramuscularly_8\RB\1740 followed_9\VBN\1835496 by_10\IN\1740 100_11\CD\13745420 mg_12\NN\13717155 intravenously_13\RB\1740 ,_14\,\1740 did_15\VBD\1640855 not_16\RB\1740 prevent_17\VB\1740 sustained_18\JJ\1740 ventricular_19\JJ\1740 tachycardia_20\NN\14110674 ,_21\,\1740 although_22\IN\1740 there_23\EX\27167 was_24\VBD\836236 a_25\DT\13649268 significant_26\JJ\1740 reduction_27\NN\351485 in_28\IN\13603305 the_29\DT\1740 number_30\NN\5107765 of_31\IN\1740 patients_32\NNS\9898892 with_33\IN\1740 warning_34\NN\7212190 <e2>arrhythmias</e2>_35\NNS\14103288 between_36\IN\1740 15_37\CD\13745420 and_38\CC\1740 45_39\CD\1740 minutes_40\NNS\6502378 after_41\IN\1740 the_42\DT\1740 administration_43\NN\1133281 of_44\IN\1740 lidocaine_45\NN\3681148 (_46\-LRB-\1740 p_47\NN\14622893 less_48\JJR\1740 than_49\IN\1740 0.05_50\CD\1740 )_51\-RRB-\1740 ._52\.\1740
D008012_D001145 NONE lidocaine_0\NN\3681148 ,_1\,\1740 given_2\VBN\2327200 in_3\IN\13603305 a_4\DT\13649268 300_5\CD\1740 mg_6\NN\13717155 dose_7\NN\3740161 intramuscularly_8\RB\1740 followed_9\VBN\1835496 by_10\IN\1740 100_11\CD\13745420 mg_12\NN\13717155 intravenously_13\RB\1740 ,_14\,\1740 did_15\VBD\1640855 not_16\RB\1740 prevent_17\VB\1740 sustained_18\JJ\1740 ventricular_19\JJ\1740 tachycardia_20\NN\14110674 ,_21\,\1740 although_22\IN\1740 there_23\EX\27167 was_24\VBD\836236 a_25\DT\13649268 significant_26\JJ\1740 reduction_27\NN\351485 in_28\IN\13603305 the_29\DT\1740 number_30\NN\5107765 of_31\IN\1740 patients_32\NNS\9898892 with_33\IN\1740 warning_34\NN\7212190 <e2>arrhythmias</e2>_35\NNS\14103288 between_36\IN\1740 15_37\CD\13745420 and_38\CC\1740 45_39\CD\1740 minutes_40\NNS\6502378 after_41\IN\1740 the_42\DT\1740 administration_43\NN\1133281 of_44\IN\1740 <e1>lidocaine</e1>_45\NN\3681148 (_46\-LRB-\1740 p_47\NN\14622893 less_48\JJR\1740 than_49\IN\1740 0.05_50\CD\1740 )_51\-RRB-\1740 ._52\.\1740
D008012_D007238 NONE the_0\DT\1740 average_1\JJ\1740 plasma_2\NN\5398023 <e1>lidocaine</e1>_3\NN\3681148 level_4\NN\4916342 10_5\CD\13745420 minutes_6\NNS\6502378 after_7\IN\1740 administration_8\NN\1133281 for_9\IN\1740 patients_10\NNS\9898892 without_11\IN\1740 a_12\DT\13649268 myocardial_13\JJ\1740 infarction_14\NN\14204950 was_15\VBD\836236 significantly_16\RB\1740 higher_17\JJR\1740 than_18\IN\1740 that_19\DT\1740 for_20\IN\1740 patients_21\NNS\9898892 with_22\IN\1740 an_23\DT\6697703 acute_24\JJ\1740 <e2>infarction</e2>_25\NN\14204950 ._26\.\1740
D008012_D007022 CID during_0\IN\1740 the_1\DT\1740 1-hour_2\CD\1740 study_3\NN\635850 period_4\NN\13575869 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 central_9\JJ\1740 nervous_10\JJ\1740 system_11\NN\3575240 side_12\NN\8630039 effects_13\NNS\13245626 was_14\VBD\836236 significantly_15\RB\1740 greater_16\JJR\1740 in_17\IN\13603305 the_18\DT\1740 <e1>lidocaine</e1>_19\NN\3681148 group_20\NN\2137 ,_21\,\1740 <e2>hypotension</e2>_22\NN\14057371 occurred_23\VBD\2623529 in_24\IN\13603305 11_25\CD\13745420 patients_26\NNS\9898892 ,_27\,\1740 nine_28\CD\13741022 of_29\IN\1740 whom_30\WP\1740 had_31\VBD\2108377 received_32\VBN\2210855 lidocaine_33\NN\3681148 ,_34\,\1740 and_35\CC\1740 four_36\CD\13741022 patients_37\NNS\9898892 died_38\VBD\146138 from_39\IN\1740 asystole_40\NN\14204950 ,_41\,\1740 three_42\CD\13741022 of_43\IN\1740 whom_44\WP\1740 had_45\VBD\2108377 had_46\VBN\2108377 lidocaine_47\NN\3681148 ._48\.\1740
D008012_D007022 CID during_0\IN\1740 the_1\DT\1740 1-hour_2\CD\1740 study_3\NN\635850 period_4\NN\13575869 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 central_9\JJ\1740 nervous_10\JJ\1740 system_11\NN\3575240 side_12\NN\8630039 effects_13\NNS\13245626 was_14\VBD\836236 significantly_15\RB\1740 greater_16\JJR\1740 in_17\IN\13603305 the_18\DT\1740 lidocaine_19\NN\3681148 group_20\NN\2137 ,_21\,\1740 <e2>hypotension</e2>_22\NN\14057371 occurred_23\VBD\2623529 in_24\IN\13603305 11_25\CD\13745420 patients_26\NNS\9898892 ,_27\,\1740 nine_28\CD\13741022 of_29\IN\1740 whom_30\WP\1740 had_31\VBD\2108377 received_32\VBN\2210855 <e1>lidocaine</e1>_33\NN\3681148 ,_34\,\1740 and_35\CC\1740 four_36\CD\13741022 patients_37\NNS\9898892 died_38\VBD\146138 from_39\IN\1740 asystole_40\NN\14204950 ,_41\,\1740 three_42\CD\13741022 of_43\IN\1740 whom_44\WP\1740 had_45\VBD\2108377 had_46\VBN\2108377 lidocaine_47\NN\3681148 ._48\.\1740
D008012_D007022 CID during_0\IN\1740 the_1\DT\1740 1-hour_2\CD\1740 study_3\NN\635850 period_4\NN\13575869 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 central_9\JJ\1740 nervous_10\JJ\1740 system_11\NN\3575240 side_12\NN\8630039 effects_13\NNS\13245626 was_14\VBD\836236 significantly_15\RB\1740 greater_16\JJR\1740 in_17\IN\13603305 the_18\DT\1740 lidocaine_19\NN\3681148 group_20\NN\2137 ,_21\,\1740 <e2>hypotension</e2>_22\NN\14057371 occurred_23\VBD\2623529 in_24\IN\13603305 11_25\CD\13745420 patients_26\NNS\9898892 ,_27\,\1740 nine_28\CD\13741022 of_29\IN\1740 whom_30\WP\1740 had_31\VBD\2108377 received_32\VBN\2210855 lidocaine_33\NN\3681148 ,_34\,\1740 and_35\CC\1740 four_36\CD\13741022 patients_37\NNS\9898892 died_38\VBD\146138 from_39\IN\1740 asystole_40\NN\14204950 ,_41\,\1740 three_42\CD\13741022 of_43\IN\1740 whom_44\WP\1740 had_45\VBD\2108377 had_46\VBN\2108377 <e1>lidocaine</e1>_47\NN\3681148 ._48\.\1740
D008012_D006323 NONE during_0\IN\1740 the_1\DT\1740 1-hour_2\CD\1740 study_3\NN\635850 period_4\NN\13575869 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 central_9\JJ\1740 nervous_10\JJ\1740 system_11\NN\3575240 side_12\NN\8630039 effects_13\NNS\13245626 was_14\VBD\836236 significantly_15\RB\1740 greater_16\JJR\1740 in_17\IN\13603305 the_18\DT\1740 <e1>lidocaine</e1>_19\NN\3681148 group_20\NN\2137 ,_21\,\1740 hypotension_22\NN\14057371 occurred_23\VBD\2623529 in_24\IN\13603305 11_25\CD\13745420 patients_26\NNS\9898892 ,_27\,\1740 nine_28\CD\13741022 of_29\IN\1740 whom_30\WP\1740 had_31\VBD\2108377 received_32\VBN\2210855 lidocaine_33\NN\3681148 ,_34\,\1740 and_35\CC\1740 four_36\CD\13741022 patients_37\NNS\9898892 died_38\VBD\146138 from_39\IN\1740 <e2>asystole</e2>_40\NN\14204950 ,_41\,\1740 three_42\CD\13741022 of_43\IN\1740 whom_44\WP\1740 had_45\VBD\2108377 had_46\VBN\2108377 lidocaine_47\NN\3681148 ._48\.\1740
D008012_D006323 NONE during_0\IN\1740 the_1\DT\1740 1-hour_2\CD\1740 study_3\NN\635850 period_4\NN\13575869 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 central_9\JJ\1740 nervous_10\JJ\1740 system_11\NN\3575240 side_12\NN\8630039 effects_13\NNS\13245626 was_14\VBD\836236 significantly_15\RB\1740 greater_16\JJR\1740 in_17\IN\13603305 the_18\DT\1740 lidocaine_19\NN\3681148 group_20\NN\2137 ,_21\,\1740 hypotension_22\NN\14057371 occurred_23\VBD\2623529 in_24\IN\13603305 11_25\CD\13745420 patients_26\NNS\9898892 ,_27\,\1740 nine_28\CD\13741022 of_29\IN\1740 whom_30\WP\1740 had_31\VBD\2108377 received_32\VBN\2210855 <e1>lidocaine</e1>_33\NN\3681148 ,_34\,\1740 and_35\CC\1740 four_36\CD\13741022 patients_37\NNS\9898892 died_38\VBD\146138 from_39\IN\1740 <e2>asystole</e2>_40\NN\14204950 ,_41\,\1740 three_42\CD\13741022 of_43\IN\1740 whom_44\WP\1740 had_45\VBD\2108377 had_46\VBN\2108377 lidocaine_47\NN\3681148 ._48\.\1740
D008012_D006323 NONE during_0\IN\1740 the_1\DT\1740 1-hour_2\CD\1740 study_3\NN\635850 period_4\NN\13575869 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 central_9\JJ\1740 nervous_10\JJ\1740 system_11\NN\3575240 side_12\NN\8630039 effects_13\NNS\13245626 was_14\VBD\836236 significantly_15\RB\1740 greater_16\JJR\1740 in_17\IN\13603305 the_18\DT\1740 lidocaine_19\NN\3681148 group_20\NN\2137 ,_21\,\1740 hypotension_22\NN\14057371 occurred_23\VBD\2623529 in_24\IN\13603305 11_25\CD\13745420 patients_26\NNS\9898892 ,_27\,\1740 nine_28\CD\13741022 of_29\IN\1740 whom_30\WP\1740 had_31\VBD\2108377 received_32\VBN\2210855 lidocaine_33\NN\3681148 ,_34\,\1740 and_35\CC\1740 four_36\CD\13741022 patients_37\NNS\9898892 died_38\VBD\146138 from_39\IN\1740 <e2>asystole</e2>_40\NN\14204950 ,_41\,\1740 three_42\CD\13741022 of_43\IN\1740 whom_44\WP\1740 had_45\VBD\2108377 had_46\VBN\2108377 <e1>lidocaine</e1>_47\NN\3681148 ._48\.\1740
16880771
D004298_D020521 NONE administration_0\NN\1133281 of_1\IN\1740 the_2\DT\1740 <e1>dopamine</e1>_3\NN\14807737 precursor_4\NN\14580897 levodopa_5\NN\14604959 enhances_6\VBZ\227165 learning_7\NN\5701944 in_8\IN\13603305 healthy_9\JJ\1740 subjects_10\NNS\6598915 and_11\CC\1740 <e2>stroke</e2>_12\NN\556313 patients_13\NNS\9898892 ._14\.\1740
D004298_D020521 NONE thus_0\RB\1740 ,_1\,\1740 phasic_2\JJ\1740 signaling_3\NN\33020 seems_4\VBZ\2604760 to_5\TO\1740 be_6\VB\836236 the_7\DT\1740 critical_8\JJ\1740 mechanism_9\NN\13446390 by_10\IN\1740 which_11\WDT\1740 <e1>dopamine</e1>_12\NN\14807737 enhances_13\VBZ\227165 associative_14\JJ\1740 learning_15\NN\5701944 in_16\IN\13603305 healthy_17\JJ\1740 subjects_18\NNS\6598915 and_19\CC\1740 <e2>stroke</e2>_20\NN\556313 patients_21\NNS\9898892 ._22\.\1740
D007980_D020521 NONE administration_0\NN\1133281 of_1\IN\1740 the_2\DT\1740 dopamine_3\NN\14807737 precursor_4\NN\14580897 <e1>levodopa</e1>_5\NN\14604959 enhances_6\VBZ\227165 learning_7\NN\5701944 in_8\IN\13603305 healthy_9\JJ\1740 subjects_10\NNS\6598915 and_11\CC\1740 <e2>stroke</e2>_12\NN\556313 patients_13\NNS\9898892 ._14\.\1740
D004298_D007859 NONE the_0\DT\1740 <e1>dopamine</e1>_1\NN\14807737 agonist_2\NN\9613191 significantly_3\RB\1740 <e2>impaired_4\VBD\258857 novel_5\JJ\1740 word_6\NN\6284225 learning</e2>_7\NN\5701944 compared_8\VBN\644583 to_9\TO\1740 placebo_10\NN\3740161 ._11\.\1740
7248895
D003520_D010386 NONE invasive_0\JJ\1740 <e2>carcinoma_1\NN\14239918 of_2\IN\1740 the_3\DT\1740 renal_4\JJ\1740 pelvis</e2>_5\NN\5578911 following_6\VBG\1835496 <e1>cyclophosphamide</e1>_7\NN\1740 therapy_8\NN\657604 for_9\IN\1740 nonmalignant_10\JJ\1740 disease_11\NN\14061805 ._12\.\1740
D003520_D010386 NONE the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 is_3\VBZ\836236 the_4\DT\1740 first_5\JJ\1740 <e2>carcinoma_6\NN\14239918 of_7\IN\1740 the_8\DT\1740 renal_9\JJ\1740 pelvis</e2>_10\NN\5578911 reported_11\VBN\831651 in_12\IN\13603305 association_13\NN\8008335 with_14\IN\1740 <e1>cyclophosphamide</e1>_15\NN\1740 treatment_16\NN\654885 ._17\.\1740
D003520_D006869 NONE a_0\DT\13649268 47-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 right_4\JJ\1740 <e2>hydroureteronephrosis</e2>_5\NN\1740 due_6\IN\5174653 to_7\TO\1740 ureterovesical_8\JJ\1740 junction_9\NN\8664443 obstruction_10\NN\4341686 had_11\VBD\2108377 gross_12\JJ\1740 hematuria_13\NN\14299637 after_14\IN\1740 being_15\VBG\836236 treated_16\VBN\2376958 for_17\IN\1740 five_18\CD\13741022 years_19\NNS\15144371 wtih_20\NN\1740 <e1>cyclophosphamide</e1>_21\NN\1740 for_22\IN\1740 cerebral_23\JJ\1740 vasculitis_24\NN\14336539 ._25\.\1740
D003520_D006869 NONE the_0\DT\1740 association_1\NN\8008335 of_2\IN\1740 the_3\DT\1740 tumor_4\NN\14234074 with_5\IN\1740 preexisting_6\JJ\1740 <e2>hydroureteronephrosis</e2>_7\NN\1740 suggests_8\VBZ\1010118 that_9\IN\1740 stasis_10\NN\14204950 prolonged_11\VBD\317700 and_12\CC\1740 intensified_13\VBD\153263 exposure_14\NN\5042871 of_15\IN\1740 upper_16\JJ\1740 urinary_17\JJ\1740 tract_18\NN\8574314 epithelium_19\NN\5267548 to_20\TO\1740 <e1>cyclophosphamide</e1>_21\NN\1740 ._22\.\1740
D003520_D006417 CID a_0\DT\13649268 47-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 right_4\JJ\1740 hydroureteronephrosis_5\NN\1740 due_6\IN\5174653 to_7\TO\1740 ureterovesical_8\JJ\1740 junction_9\NN\8664443 obstruction_10\NN\4341686 had_11\VBD\2108377 gross_12\JJ\1740 <e2>hematuria</e2>_13\NN\14299637 after_14\IN\1740 being_15\VBG\836236 treated_16\VBN\2376958 for_17\IN\1740 five_18\CD\13741022 years_19\NNS\15144371 wtih_20\NN\1740 <e1>cyclophosphamide</e1>_21\NN\1740 for_22\IN\1740 cerebral_23\JJ\1740 vasculitis_24\NN\14336539 ._25\.\1740
D003520_D020293 NONE a_0\DT\13649268 47-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 right_4\JJ\1740 hydroureteronephrosis_5\NN\1740 due_6\IN\5174653 to_7\TO\1740 ureterovesical_8\JJ\1740 junction_9\NN\8664443 obstruction_10\NN\4341686 had_11\VBD\2108377 gross_12\JJ\1740 hematuria_13\NN\14299637 after_14\IN\1740 being_15\VBG\836236 treated_16\VBN\2376958 for_17\IN\1740 five_18\CD\13741022 years_19\NNS\15144371 wtih_20\NN\1740 <e1>cyclophosphamide</e1>_21\NN\1740 for_22\IN\1740 <e2>cerebral_23\JJ\1740 vasculitis</e2>_24\NN\14336539 ._25\.\1740
D003520_D006470 NONE although_0\IN\1740 the_1\DT\1740 ability_2\NN\4723816 of_3\IN\1740 <e1>cyclophosphamide</e1>_4\NN\1740 to_5\TO\1740 cause_6\VB\1617192 <e2>hemorrhagic_7\JJ\1740 cystitis</e2>_8\NN\14566129 and_9\CC\1740 urine_10\NN\14853947 cytologic_11\JJ\1740 abnormalities_12\NNS\14034177 indistinguishable_13\JJ\1740 from_14\IN\1740 high_15\JJ\1740 grade_16\NN\7975026 carcinoma_17\NN\14239918 is_18\VBZ\836236 well_19\RB\1740 known_20\VBN\2110220 ,_21\,\1740 it_22\PRP\6125041 is_23\VBZ\836236 less_24\RBR\1740 widely_25\RB\1740 appreciated_26\JJ\1740 that_27\IN\1740 it_28\PRP\6125041 is_29\VBZ\836236 also_30\RB\1740 associated_31\VBN\628491 with_32\IN\1740 carcinoma_33\NN\14239918 of_34\IN\1740 the_35\DT\1740 urinary_36\JJ\1740 tract_37\NN\8574314 ._38\.\1740
D003520_D003556 NONE although_0\IN\1740 the_1\DT\1740 ability_2\NN\4723816 of_3\IN\1740 <e1>cyclophosphamide</e1>_4\NN\1740 to_5\TO\1740 cause_6\VB\1617192 <e2>hemorrhagic_7\JJ\1740 cystitis</e2>_8\NN\14566129 and_9\CC\1740 urine_10\NN\14853947 cytologic_11\JJ\1740 abnormalities_12\NNS\14034177 indistinguishable_13\JJ\1740 from_14\IN\1740 high_15\JJ\1740 grade_16\NN\7975026 carcinoma_17\NN\14239918 is_18\VBZ\836236 well_19\RB\1740 known_20\VBN\2110220 ,_21\,\1740 it_22\PRP\6125041 is_23\VBZ\836236 less_24\RBR\1740 widely_25\RB\1740 appreciated_26\JJ\1740 that_27\IN\1740 it_28\PRP\6125041 is_29\VBZ\836236 also_30\RB\1740 associated_31\VBN\628491 with_32\IN\1740 carcinoma_33\NN\14239918 of_34\IN\1740 the_35\DT\1740 urinary_36\JJ\1740 tract_37\NN\8574314 ._38\.\1740
D003520_D002277 CID although_0\IN\1740 the_1\DT\1740 ability_2\NN\4723816 of_3\IN\1740 <e1>cyclophosphamide</e1>_4\NN\1740 to_5\TO\1740 cause_6\VB\1617192 hemorrhagic_7\JJ\1740 cystitis_8\NN\14566129 and_9\CC\1740 urine_10\NN\14853947 cytologic_11\JJ\1740 abnormalities_12\NNS\14034177 indistinguishable_13\JJ\1740 from_14\IN\1740 high_15\JJ\1740 grade_16\NN\7975026 <e2>carcinoma</e2>_17\NN\14239918 is_18\VBZ\836236 well_19\RB\1740 known_20\VBN\2110220 ,_21\,\1740 it_22\PRP\6125041 is_23\VBZ\836236 less_24\RBR\1740 widely_25\RB\1740 appreciated_26\JJ\1740 that_27\IN\1740 it_28\PRP\6125041 is_29\VBZ\836236 also_30\RB\1740 associated_31\VBN\628491 with_32\IN\1740 carcinoma_33\NN\14239918 of_34\IN\1740 the_35\DT\1740 urinary_36\JJ\1740 tract_37\NN\8574314 ._38\.\1740
D003520_D014571 NONE although_0\IN\1740 the_1\DT\1740 ability_2\NN\4723816 of_3\IN\1740 <e1>cyclophosphamide</e1>_4\NN\1740 to_5\TO\1740 cause_6\VB\1617192 hemorrhagic_7\JJ\1740 cystitis_8\NN\14566129 and_9\CC\1740 urine_10\NN\14853947 cytologic_11\JJ\1740 abnormalities_12\NNS\14034177 indistinguishable_13\JJ\1740 from_14\IN\1740 high_15\JJ\1740 grade_16\NN\7975026 carcinoma_17\NN\14239918 is_18\VBZ\836236 well_19\RB\1740 known_20\VBN\2110220 ,_21\,\1740 it_22\PRP\6125041 is_23\VBZ\836236 less_24\RBR\1740 widely_25\RB\1740 appreciated_26\JJ\1740 that_27\IN\1740 it_28\PRP\6125041 is_29\VBZ\836236 also_30\RB\1740 associated_31\VBN\628491 with_32\IN\1740 <e2>carcinoma_33\NN\14239918 of_34\IN\1740 the_35\DT\1740 urinary_36\JJ\1740 tract</e2>_37\NN\8574314 ._38\.\1740
D003520_D014571 NONE it_0\PRP\6125041 is_1\VBZ\836236 the_2\DT\1740 third_3\JJ\1740 <e2>urinary_4\JJ\1740 tract_5\NN\8574314 cancer</e2>_6\NN\14239425 reported_7\VBN\831651 in_8\IN\13603305 association_9\NN\8008335 with_10\IN\1740 <e1>cyclophosphamide</e1>_11\NN\1740 treatment_12\NN\654885 for_13\IN\1740 nonmalignant_14\JJ\1740 disease_15\NN\14061805 ._16\.\1740
D003520_D009369 NONE the_0\DT\1740 association_1\NN\8008335 of_2\IN\1740 the_3\DT\1740 <e2>tumor</e2>_4\NN\14234074 with_5\IN\1740 preexisting_6\JJ\1740 hydroureteronephrosis_7\NN\1740 suggests_8\VBZ\1010118 that_9\IN\1740 stasis_10\NN\14204950 prolonged_11\VBD\317700 and_12\CC\1740 intensified_13\VBD\153263 exposure_14\NN\5042871 of_15\IN\1740 upper_16\JJ\1740 urinary_17\JJ\1740 tract_18\NN\8574314 epithelium_19\NN\5267548 to_20\TO\1740 <e1>cyclophosphamide</e1>_21\NN\1740 ._22\.\1740
D003520_-1 NONE patients_0\NNS\9898892 who_1\WP\8299493 are_2\VBP\836236 candidates_3\NNS\10450303 for_4\IN\1740 long-term_5\JJ\1740 <e1>cyclophosphamide</e1>_6\NN\1740 treatment_7\NN\654885 should_8\MD\1740 be_9\VB\836236 routinely_10\RB\1740 evaluated_11\VBN\670261 for_12\IN\1740 <e2>obstructive_13\JJ\1740 uropathy</e2>_14\JJ\1740 ._15\.\1740
24345882
D008727_D054198 NONE neurocognitive_0\JJ\1740 and_1\CC\1740 neuroradiologic_2\NN\1740 central_3\JJ\1740 nervous_4\JJ\1740 system_5\NN\3575240 late_6\JJ\1740 effects_7\NNS\13245626 in_8\IN\13603305 children_9\NNS\9622049 treated_10\VBN\2376958 on_11\IN\1740 pediatric_12\NNP\1740 oncology_13\NNP\6043075 group_14\NNP\2137 (_15\-LRB-\1740 pog_16\NN\1740 )_17\-RRB-\1740 p9605_18\NN\1740 (_19\-LRB-\1740 standard_20\JJ\1740 risk_21\NN\14541044 )_22\-RRB-\1740 and_23\CC\1740 p9201_24\NN\1740 (_25\-LRB-\1740 lesser_26\JJR\1740 risk_27\NN\14541044 )_28\-RRB-\1740 <e2>acute_29\JJ\1740 lymphoblastic_30\JJ\1740 leukemia</e2>_31\NN\14239918 protocols_32\NNS\6652242 (_33\-LRB-\1740 accl0131_34\NN\1740 ):_35\NFP\1740 a_36\DT\13649268 <e1>methotrexate</e1>_37\JJ\1740 consequence_38\NN\34213 ?_39\.\1740
D008727_D054198 NONE concerns_0\NNS\5682950 about_1\IN\1740 long-term_2\JJ\1740 <e1>methotrexate</e1>_3\NN\2722166 (_4\-LRB-\1740 mtx_5\NN\1740 )_6\-RRB-\1740 neurotoxicity_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 1990s_10\NNS\15204983 led_11\VBD\1752884 to_12\TO\1740 modifications_13\NNS\191142 in_14\IN\13603305 intrathecal_15\JJ\1740 (_16\-LRB-\1740 it_17\NN\6125041 )_18\-RRB-\1740 therapy_19\NN\657604 ,_20\,\1740 leucovorin_21\NN\1740 rescue_22\NN\45907 ,_23\,\1740 and_24\CC\1740 frequency_25\NN\15286249 of_26\IN\1740 systemic_27\JJ\1740 mtx_28\NN\1740 administration_29\NN\1133281 in_30\IN\13603305 children_31\NNS\9622049 with_32\IN\1740 <e2>acute_33\JJ\1740 lymphoblastic_34\JJ\1740 leukemia</e2>_35\NN\14239918 ._36\.\1740
D008727_D054198 NONE concerns_0\NNS\5682950 about_1\IN\1740 long-term_2\JJ\1740 methotrexate_3\NN\2722166 (_4\-LRB-\1740 <e1>mtx</e1>_5\NN\1740 )_6\-RRB-\1740 neurotoxicity_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 1990s_10\NNS\15204983 led_11\VBD\1752884 to_12\TO\1740 modifications_13\NNS\191142 in_14\IN\13603305 intrathecal_15\JJ\1740 (_16\-LRB-\1740 it_17\NN\6125041 )_18\-RRB-\1740 therapy_19\NN\657604 ,_20\,\1740 leucovorin_21\NN\1740 rescue_22\NN\45907 ,_23\,\1740 and_24\CC\1740 frequency_25\NN\15286249 of_26\IN\1740 systemic_27\JJ\1740 mtx_28\NN\1740 administration_29\NN\1133281 in_30\IN\13603305 children_31\NNS\9622049 with_32\IN\1740 <e2>acute_33\JJ\1740 lymphoblastic_34\JJ\1740 leukemia</e2>_35\NN\14239918 ._36\.\1740
D008727_D054198 NONE concerns_0\NNS\5682950 about_1\IN\1740 long-term_2\JJ\1740 methotrexate_3\NN\2722166 (_4\-LRB-\1740 mtx_5\NN\1740 )_6\-RRB-\1740 neurotoxicity_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 1990s_10\NNS\15204983 led_11\VBD\1752884 to_12\TO\1740 modifications_13\NNS\191142 in_14\IN\13603305 intrathecal_15\JJ\1740 (_16\-LRB-\1740 it_17\NN\6125041 )_18\-RRB-\1740 therapy_19\NN\657604 ,_20\,\1740 leucovorin_21\NN\1740 rescue_22\NN\45907 ,_23\,\1740 and_24\CC\1740 frequency_25\NN\15286249 of_26\IN\1740 systemic_27\JJ\1740 <e1>mtx</e1>_28\NN\1740 administration_29\NN\1133281 in_30\IN\13603305 children_31\NNS\9622049 with_32\IN\1740 <e2>acute_33\JJ\1740 lymphoblastic_34\JJ\1740 leukemia</e2>_35\NN\14239918 ._36\.\1740
D008727_D020258 NONE concerns_0\NNS\5682950 about_1\IN\1740 long-term_2\JJ\1740 <e1>methotrexate</e1>_3\NN\2722166 (_4\-LRB-\1740 mtx_5\NN\1740 )_6\-RRB-\1740 <e2>neurotoxicity</e2>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 1990s_10\NNS\15204983 led_11\VBD\1752884 to_12\TO\1740 modifications_13\NNS\191142 in_14\IN\13603305 intrathecal_15\JJ\1740 (_16\-LRB-\1740 it_17\NN\6125041 )_18\-RRB-\1740 therapy_19\NN\657604 ,_20\,\1740 leucovorin_21\NN\1740 rescue_22\NN\45907 ,_23\,\1740 and_24\CC\1740 frequency_25\NN\15286249 of_26\IN\1740 systemic_27\JJ\1740 mtx_28\NN\1740 administration_29\NN\1133281 in_30\IN\13603305 children_31\NNS\9622049 with_32\IN\1740 acute_33\JJ\1740 lymphoblastic_34\JJ\1740 leukemia_35\NN\14239918 ._36\.\1740
D008727_D020258 NONE concerns_0\NNS\5682950 about_1\IN\1740 long-term_2\JJ\1740 methotrexate_3\NN\2722166 (_4\-LRB-\1740 <e1>mtx</e1>_5\NN\1740 )_6\-RRB-\1740 <e2>neurotoxicity</e2>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 1990s_10\NNS\15204983 led_11\VBD\1752884 to_12\TO\1740 modifications_13\NNS\191142 in_14\IN\13603305 intrathecal_15\JJ\1740 (_16\-LRB-\1740 it_17\NN\6125041 )_18\-RRB-\1740 therapy_19\NN\657604 ,_20\,\1740 leucovorin_21\NN\1740 rescue_22\NN\45907 ,_23\,\1740 and_24\CC\1740 frequency_25\NN\15286249 of_26\IN\1740 systemic_27\JJ\1740 mtx_28\NN\1740 administration_29\NN\1133281 in_30\IN\13603305 children_31\NNS\9622049 with_32\IN\1740 acute_33\JJ\1740 lymphoblastic_34\JJ\1740 leukemia_35\NN\14239918 ._36\.\1740
D008727_D020258 NONE concerns_0\NNS\5682950 about_1\IN\1740 long-term_2\JJ\1740 methotrexate_3\NN\2722166 (_4\-LRB-\1740 mtx_5\NN\1740 )_6\-RRB-\1740 <e2>neurotoxicity</e2>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 1990s_10\NNS\15204983 led_11\VBD\1752884 to_12\TO\1740 modifications_13\NNS\191142 in_14\IN\13603305 intrathecal_15\JJ\1740 (_16\-LRB-\1740 it_17\NN\6125041 )_18\-RRB-\1740 therapy_19\NN\657604 ,_20\,\1740 leucovorin_21\NN\1740 rescue_22\NN\45907 ,_23\,\1740 and_24\CC\1740 frequency_25\NN\15286249 of_26\IN\1740 systemic_27\JJ\1740 <e1>mtx</e1>_28\NN\1740 administration_29\NN\1133281 in_30\IN\13603305 children_31\NNS\9622049 with_32\IN\1740 acute_33\JJ\1740 lymphoblastic_34\JJ\1740 leukemia_35\NN\14239918 ._36\.\1740
18945509
-1_D003324 NONE risk_0\NN\14541044 of_1\IN\1740 <e2>coronary_2\JJ\1740 artery_3\NN\5417975 disease</e2>_4\NN\14061805 associated_5\VBN\628491 with_6\IN\1740 initial_7\JJ\1740 <e1>sulphonylurea</e1>_8\NN\1740 treatment_9\NN\654885 of_10\IN\1740 patients_11\NNS\9898892 with_12\IN\1740 type_13\NN\5839024 2_14\CD\13741022 diabetes_15\NNS\14075199 :_16\:\1740 a_17\DT\13649268 matched_18\VBN\2664769 case-control_19\NN\1740 study_20\NN\635850 ._21\.\1740
-1_D003324 NONE aims_0\NNS\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 sought_4\VBD\1825237 to_5\TO\1740 assess_6\VB\670261 the_7\DT\1740 risk_8\NN\14541044 of_9\IN\1740 developing_10\VBG\1753788 <e2>coronary_11\JJ\1740 artery_12\NN\5417975 disease</e2>_13\NN\14061805 (_14\-LRB-\1740 cad_15\NN\10753546 )_16\-RRB-\1740 associated_17\VBN\628491 with_18\IN\1740 initial_19\JJ\1740 treatment_20\NN\654885 of_21\IN\1740 type_22\NN\5839024 2_23\CD\13741022 diabetes_24\NNS\14075199 with_25\IN\1740 different_26\JJ\1740 <e1>sulphonylureas</e1>_27\NNS\1740 ._28\.\1740
-1_D003324 NONE aims_0\NNS\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 sought_4\VBD\1825237 to_5\TO\1740 assess_6\VB\670261 the_7\DT\1740 risk_8\NN\14541044 of_9\IN\1740 developing_10\VBG\1753788 coronary_11\JJ\1740 artery_12\NN\5417975 disease_13\NN\14061805 (_14\-LRB-\1740 <e2>cad</e2>_15\NN\10753546 )_16\-RRB-\1740 associated_17\VBN\628491 with_18\IN\1740 initial_19\JJ\1740 treatment_20\NN\654885 of_21\IN\1740 type_22\NN\5839024 2_23\CD\13741022 diabetes_24\NNS\14075199 with_25\IN\1740 different_26\JJ\1740 <e1>sulphonylureas</e1>_27\NNS\1740 ._28\.\1740
-1_D003924 NONE risk_0\NN\14541044 of_1\IN\1740 coronary_2\JJ\1740 artery_3\NN\5417975 disease_4\NN\14061805 associated_5\VBN\628491 with_6\IN\1740 initial_7\JJ\1740 <e1>sulphonylurea</e1>_8\NN\1740 treatment_9\NN\654885 of_10\IN\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>type_13\NN\5839024 2_14\CD\13741022 diabetes</e2>_15\NNS\14075199 :_16\:\1740 a_17\DT\13649268 matched_18\VBN\2664769 case-control_19\NN\1740 study_20\NN\635850 ._21\.\1740
-1_D003924 NONE aims_0\NNS\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 sought_4\VBD\1825237 to_5\TO\1740 assess_6\VB\670261 the_7\DT\1740 risk_8\NN\14541044 of_9\IN\1740 developing_10\VBG\1753788 coronary_11\JJ\1740 artery_12\NN\5417975 disease_13\NN\14061805 (_14\-LRB-\1740 cad_15\NN\10753546 )_16\-RRB-\1740 associated_17\VBN\628491 with_18\IN\1740 initial_19\JJ\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>type_22\NN\5839024 2_23\CD\13741022 diabetes</e2>_24\NNS\14075199 with_25\IN\1740 different_26\JJ\1740 <e1>sulphonylureas</e1>_27\NNS\1740 ._28\.\1740
D005905_D003324 CID the_0\DT\1740 hazard_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 <e2>cad</e2>_4\NN\10753546 (_5\-LRB-\1740 95_6\CD\1740 %_7\NN\1740 ci_8\NN\13635336 )_9\-RRB-\1740 associated_10\VBN\628491 with_11\IN\1740 initial_12\JJ\1740 treatment_13\NN\654885 increased_14\VBN\169651 by_15\IN\1740 2.4-fold_16\JJ\1740 (_17\-LRB-\1740 1.3_18\CD\1740 -_19\SYM\1740 4.3_20\CD\1740 ,_21\,\1740 p=0.004_22\NN\1740 )_23\-RRB-\1740 with_24\IN\1740 <e1>glibenclamide</e1>_25\NN\1740 ;_26\:\1740 2-fold_27\JJ\1740 (_28\-LRB-\1740 0.9_29\CD\1740 -_30\SYM\1740 4.6_31\CD\1740 ,_32\,\1740 p=0.099_33\NN\1740 )_34\-RRB-\1740 with_35\IN\1740 glipizide_36\NN\2719105 ;_37\:\1740 2.9-fold_38\RB\1740 (_39\-LRB-\1740 1.6_40\CD\1740 -_41\SYM\1740 5.1_42\CD\1740 ,_43\,\1740 p=0.000_44\NN\1740 )_45\-RRB-\1740 with_46\IN\1740 either_47\RB\1740 ,_48\,\1740 and_49\CC\1740 was_50\VBD\836236 unchanged_51\JJ\1740 with_52\IN\1740 metformin_53\NN\2719105 ._54\.\1740
D005905_D003324 CID conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 type_5\NN\5839024 2_6\CD\13741022 diabetes_7\NNS\14075199 with_8\IN\1740 <e1>glibenclamide</e1>_9\NN\1740 or_10\CC\3541091 glipizide_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 <e2>cad</e2>_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 gliclazide_22\VB\1740 or_23\CC\3541091 glimepiride_24\NN\1740 ._25\.\1740
D005913_D003324 NONE the_0\DT\1740 hazard_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 <e2>cad</e2>_4\NN\10753546 (_5\-LRB-\1740 95_6\CD\1740 %_7\NN\1740 ci_8\NN\13635336 )_9\-RRB-\1740 associated_10\VBN\628491 with_11\IN\1740 initial_12\JJ\1740 treatment_13\NN\654885 increased_14\VBN\169651 by_15\IN\1740 2.4-fold_16\JJ\1740 (_17\-LRB-\1740 1.3_18\CD\1740 -_19\SYM\1740 4.3_20\CD\1740 ,_21\,\1740 p=0.004_22\NN\1740 )_23\-RRB-\1740 with_24\IN\1740 glibenclamide_25\NN\1740 ;_26\:\1740 2-fold_27\JJ\1740 (_28\-LRB-\1740 0.9_29\CD\1740 -_30\SYM\1740 4.6_31\CD\1740 ,_32\,\1740 p=0.099_33\NN\1740 )_34\-RRB-\1740 with_35\IN\1740 <e1>glipizide</e1>_36\NN\2719105 ;_37\:\1740 2.9-fold_38\RB\1740 (_39\-LRB-\1740 1.6_40\CD\1740 -_41\SYM\1740 5.1_42\CD\1740 ,_43\,\1740 p=0.000_44\NN\1740 )_45\-RRB-\1740 with_46\IN\1740 either_47\RB\1740 ,_48\,\1740 and_49\CC\1740 was_50\VBD\836236 unchanged_51\JJ\1740 with_52\IN\1740 metformin_53\NN\2719105 ._54\.\1740
D005913_D003324 NONE conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 type_5\NN\5839024 2_6\CD\13741022 diabetes_7\NNS\14075199 with_8\IN\1740 glibenclamide_9\NN\1740 or_10\CC\3541091 <e1>glipizide</e1>_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 <e2>cad</e2>_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 gliclazide_22\VB\1740 or_23\CC\3541091 glimepiride_24\NN\1740 ._25\.\1740
D008687_D003324 NONE the_0\DT\1740 hazard_1\NN\14541044 of_2\IN\1740 developing_3\VBG\1753788 <e2>cad</e2>_4\NN\10753546 (_5\-LRB-\1740 95_6\CD\1740 %_7\NN\1740 ci_8\NN\13635336 )_9\-RRB-\1740 associated_10\VBN\628491 with_11\IN\1740 initial_12\JJ\1740 treatment_13\NN\654885 increased_14\VBN\169651 by_15\IN\1740 2.4-fold_16\JJ\1740 (_17\-LRB-\1740 1.3_18\CD\1740 -_19\SYM\1740 4.3_20\CD\1740 ,_21\,\1740 p=0.004_22\NN\1740 )_23\-RRB-\1740 with_24\IN\1740 glibenclamide_25\NN\1740 ;_26\:\1740 2-fold_27\JJ\1740 (_28\-LRB-\1740 0.9_29\CD\1740 -_30\SYM\1740 4.6_31\CD\1740 ,_32\,\1740 p=0.099_33\NN\1740 )_34\-RRB-\1740 with_35\IN\1740 glipizide_36\NN\2719105 ;_37\:\1740 2.9-fold_38\RB\1740 (_39\-LRB-\1740 1.6_40\CD\1740 -_41\SYM\1740 5.1_42\CD\1740 ,_43\,\1740 p=0.000_44\NN\1740 )_45\-RRB-\1740 with_46\IN\1740 either_47\RB\1740 ,_48\,\1740 and_49\CC\1740 was_50\VBD\836236 unchanged_51\JJ\1740 with_52\IN\1740 <e1>metformin</e1>_53\NN\2719105 ._54\.\1740
D005905_D003924 NONE conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 <e2>type_5\NN\5839024 2_6\CD\13741022 diabetes</e2>_7\NNS\14075199 with_8\IN\1740 <e1>glibenclamide</e1>_9\NN\1740 or_10\CC\3541091 glipizide_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 cad_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 gliclazide_22\VB\1740 or_23\CC\3541091 glimepiride_24\NN\1740 ._25\.\1740
D005913_D003924 NONE conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 <e2>type_5\NN\5839024 2_6\CD\13741022 diabetes</e2>_7\NNS\14075199 with_8\IN\1740 glibenclamide_9\NN\1740 or_10\CC\3541091 <e1>glipizide</e1>_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 cad_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 gliclazide_22\VB\1740 or_23\CC\3541091 glimepiride_24\NN\1740 ._25\.\1740
D005907_D003924 NONE conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 <e2>type_5\NN\5839024 2_6\CD\13741022 diabetes</e2>_7\NNS\14075199 with_8\IN\1740 glibenclamide_9\NN\1740 or_10\CC\3541091 glipizide_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 cad_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 <e1>gliclazide</e1>_22\VB\1740 or_23\CC\3541091 glimepiride_24\NN\1740 ._25\.\1740
D005907_D003324 NONE conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 type_5\NN\5839024 2_6\CD\13741022 diabetes_7\NNS\14075199 with_8\IN\1740 glibenclamide_9\NN\1740 or_10\CC\3541091 glipizide_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 <e2>cad</e2>_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 <e1>gliclazide</e1>_22\VB\1740 or_23\CC\3541091 glimepiride_24\NN\1740 ._25\.\1740
C057619_D003924 NONE conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 <e2>type_5\NN\5839024 2_6\CD\13741022 diabetes</e2>_7\NNS\14075199 with_8\IN\1740 glibenclamide_9\NN\1740 or_10\CC\3541091 glipizide_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 cad_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 gliclazide_22\VB\1740 or_23\CC\3541091 <e1>glimepiride</e1>_24\NN\1740 ._25\.\1740
C057619_D003324 NONE conclusions_0\NNS\5837957 :_1\:\1740 initiating_2\VBG\1617192 treatment_3\NN\654885 of_4\IN\1740 type_5\NN\5839024 2_6\CD\13741022 diabetes_7\NNS\14075199 with_8\IN\1740 glibenclamide_9\NN\1740 or_10\CC\3541091 glipizide_11\NN\2719105 is_12\VBZ\836236 associated_13\VBN\628491 with_14\IN\1740 increased_15\VBN\169651 risk_16\NN\14541044 of_17\IN\1740 <e2>cad</e2>_18\NN\10753546 in_19\IN\13603305 comparison_20\NN\635850 to_21\TO\1740 gliclazide_22\VB\1740 or_23\CC\3541091 <e1>glimepiride</e1>_24\NN\1740 ._25\.\1740
15627798
D005839_D009395 CID inhibition_0\NN\1068773 of_1\IN\1740 nuclear_2\JJ\1740 factor-kappab_3\NN\1740 activation_4\NN\13561719 attenuates_5\VBZ\224901 <e2>tubulointerstitial_6\JJ\1740 nephritis</e2>_7\NN\14113228 induced_8\VBN\1627355 by_9\IN\1740 <e1>gentamicin</e1>_10\NN\2716866 ._11\.\1740
D005839_D009395 CID conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 data_3\NNS\7951464 show_4\VBP\2137132 that_5\IN\1740 inhibition_6\NN\1068773 of_7\IN\1740 nf-kappab_8\NN\1740 activation_9\NN\13561719 attenuates_10\VBZ\224901 <e2>tubulointerstitial_11\JJ\1740 nephritis</e2>_12\NN\14113228 induced_13\VBN\1627355 by_14\IN\1740 <e1>gentamicin</e1>_15\NN\2716866 ._16\.\1740
D005839_D005355 NONE background_0\NN\4921011 :_1\:\1740 animals_2\NNS\4475 treated_3\VBN\2376958 with_4\IN\1740 <e1>gentamicin</e1>_5\NN\2716866 can_6\MD\3094503 show_7\VB\2137132 residual_8\JJ\1740 areas_9\NNS\8630985 of_10\IN\1740 interstitial_11\JJ\1740 <e2>fibrosis</e2>_12\NN\14204950 in_13\IN\13603305 the_14\DT\1740 renal_15\JJ\1740 cortex_16\NN\5462674 ._17\.\1740
16731636
D007545_D006332 CID enhanced_0\VBN\227165 <e1>isoproterenol-induced</e1>_1\JJ\1740 <e2>cardiac_2\JJ\1740 hypertrophy</e2>_3\NN\14365950 in_4\IN\13603305 transgenic_5\JJ\1740 rats_6\NNS\2329401 with_7\IN\1740 low_8\JJ\1740 brain_9\NN\5462674 angiotensinogen_10\NN\1740 ._11\.\1740
D007545_D006332 CID <e2>lv_0\JJ\1740 hypertrophy</e2>_1\NN\14365950 induced_2\VBN\1627355 by_3\IN\1740 <e1>iso</e1>_4\NN\1740 treatment_5\NN\654885 was_6\VBD\836236 significantly_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 tgr_10\NNP\1740 than_11\IN\1740 in_12\IN\13603305 sd_13\NN\1740 rats_14\NNS\2329401 (_15\-LRB-\1740 in_16\IN\13603305 g_17\NN\13717155 lv_18\NN\1740 wt/100_19\CD\1740 g_20\NN\13717155 body_21\NN\19128 wt_22\NN\1740 ,_23\,\1740 0.28_24\CD\1740 +/-_25\CC\1740 0.004_26\CD\1740 vs._27\CC\1740 0.24_28\CD\1740 +/-_29\CC\1740 0.004_30\CD\1740 ,_31\,\1740 respectively_32\RB\1740 )_33\-RRB-\1740 ._34\.\1740
6985498
D008733_D056486 CID <e2>hepatitis</e2>_0\NN\14127211 and_1\CC\1740 renal_2\JJ\1740 tubular_3\JJ\1740 acidosis_4\NN\14204950 after_5\IN\1740 anesthesia_6\NN\14034177 with_7\IN\1740 <e1>methoxyflurane</e1>_8\NN\1740 ._9\.\1740
D008733_D000141 CID hepatitis_0\NN\14127211 and_1\CC\1740 <e2>renal_2\JJ\1740 tubular_3\JJ\1740 acidosis</e2>_4\NN\14204950 after_5\IN\1740 anesthesia_6\NN\14034177 with_7\IN\1740 <e1>methoxyflurane</e1>_8\NN\1740 ._9\.\1740
D008733_D000141 CID a_0\DT\13649268 69-year-old_1\JJ\1740 man_2\NN\9605289 operated_3\VBD\2439501 for_4\IN\1740 acute_5\JJ\1740 cholecystitis_6\NN\14336539 under_7\IN\1740 <e1>methoxyflurane</e1>_8\JJ\1740 anesthesia_9\NN\14034177 developed_10\VBD\1753788 postoperatively_11\RB\1740 a_12\DT\13649268 hepatic_13\JJ\1740 insufficiency_14\NN\14462946 syndrome_15\NN\5870365 and_16\CC\1740 <e2>renal_17\JJ\1740 tubular_18\JJ\1740 acidosis</e2>_19\NN\14204950 ._20\.\1740
D008733_D041881 NONE a_0\DT\13649268 69-year-old_1\JJ\1740 man_2\NN\9605289 operated_3\VBD\2439501 for_4\IN\1740 <e2>acute_5\JJ\1740 cholecystitis</e2>_6\NN\14336539 under_7\IN\1740 <e1>methoxyflurane</e1>_8\JJ\1740 anesthesia_9\NN\14034177 developed_10\VBD\1753788 postoperatively_11\RB\1740 a_12\DT\13649268 hepatic_13\JJ\1740 insufficiency_14\NN\14462946 syndrome_15\NN\5870365 and_16\CC\1740 renal_17\JJ\1740 tubular_18\JJ\1740 acidosis_19\NN\14204950 ._20\.\1740
D008733_D048550 NONE a_0\DT\13649268 69-year-old_1\JJ\1740 man_2\NN\9605289 operated_3\VBD\2439501 for_4\IN\1740 acute_5\JJ\1740 cholecystitis_6\NN\14336539 under_7\IN\1740 <e1>methoxyflurane</e1>_8\JJ\1740 anesthesia_9\NN\14034177 developed_10\VBD\1753788 postoperatively_11\RB\1740 a_12\DT\13649268 <e2>hepatic_13\JJ\1740 insufficiency_14\NN\14462946 syndrome</e2>_15\NN\5870365 and_16\CC\1740 renal_17\JJ\1740 tubular_18\JJ\1740 acidosis_19\NN\14204950 ._20\.\1740
8819482
D002118_D017202 NONE effects_0\NNS\13245626 of_1\IN\1740 a_2\DT\13649268 new_3\JJ\1740 <e1>calcium</e1>_4\NN\14625458 antagonist_5\NN\7846 ,_6\,\1740 cd-832_7\NN\1740 ,_8\,\1740 on_9\IN\1740 isoproterenol-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 ischemia</e2>_12\NN\14195315 in_13\IN\13603305 dogs_14\NNS\2083346 with_15\IN\1740 partial_16\JJ\1740 coronary_17\JJ\1740 stenosis_18\NN\14204950 ._19\.\1740
D002118_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 a_2\DT\13649268 new_3\JJ\1740 <e1>calcium</e1>_4\NN\14625458 antagonist_5\NN\7846 ,_6\,\1740 cd-832_7\NN\1740 ,_8\,\1740 on_9\IN\1740 isoproterenol-induced_10\JJ\1740 myocardial_11\JJ\1740 ischemia_12\NN\14195315 in_13\IN\13603305 dogs_14\NNS\2083346 with_15\IN\1740 partial_16\JJ\1740 <e2>coronary_17\JJ\1740 stenosis</e2>_18\NN\14204950 ._19\.\1740
C082828_D017202 NONE effects_0\NNS\13245626 of_1\IN\1740 a_2\DT\13649268 new_3\JJ\1740 calcium_4\NN\14625458 antagonist_5\NN\7846 ,_6\,\1740 <e1>cd-832</e1>_7\NN\1740 ,_8\,\1740 on_9\IN\1740 isoproterenol-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 ischemia</e2>_12\NN\14195315 in_13\IN\13603305 dogs_14\NNS\2083346 with_15\IN\1740 partial_16\JJ\1740 coronary_17\JJ\1740 stenosis_18\NN\14204950 ._19\.\1740
C082828_D017202 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>cd-832</e1>_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 (iso)-induced_5\VBN\1740 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 coronary_14\JJ\1740 stenosis_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
C082828_D017202 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 <e1>cd-832</e1>_4\NN\1740 improves_5\VBZ\126264 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 during_8\IN\1740 iso_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 stenosis_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 cd-832_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 cd-832_31\NN\1740 ._32\.\1740
C082828_D017202 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 cd-832_4\NN\1740 improves_5\VBZ\126264 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 during_8\IN\1740 iso_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 stenosis_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 <e1>cd-832</e1>_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 cd-832_31\NN\1740 ._32\.\1740
C082828_D017202 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 cd-832_4\NN\1740 improves_5\VBZ\126264 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 during_8\IN\1740 iso_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 stenosis_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 cd-832_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 <e1>cd-832</e1>_31\NN\1740 ._32\.\1740
C082828_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 a_2\DT\13649268 new_3\JJ\1740 calcium_4\NN\14625458 antagonist_5\NN\7846 ,_6\,\1740 <e1>cd-832</e1>_7\NN\1740 ,_8\,\1740 on_9\IN\1740 isoproterenol-induced_10\JJ\1740 myocardial_11\JJ\1740 ischemia_12\NN\14195315 in_13\IN\13603305 dogs_14\NNS\2083346 with_15\IN\1740 partial_16\JJ\1740 <e2>coronary_17\JJ\1740 stenosis</e2>_18\NN\14204950 ._19\.\1740
C082828_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>cd-832</e1>_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 (iso)-induced_5\VBN\1740 myocardial_6\JJ\1740 ischemia_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 <e2>coronary_14\JJ\1740 stenosis</e2>_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
D007545_D017202 CID effects_0\NNS\13245626 of_1\IN\1740 a_2\DT\13649268 new_3\JJ\1740 calcium_4\NN\14625458 antagonist_5\NN\7846 ,_6\,\1740 cd-832_7\NN\1740 ,_8\,\1740 on_9\IN\1740 <e1>isoproterenol-induced</e1>_10\JJ\1740 <e2>myocardial_11\JJ\1740 ischemia</e2>_12\NN\14195315 in_13\IN\13603305 dogs_14\NNS\2083346 with_15\IN\1740 partial_16\JJ\1740 coronary_17\JJ\1740 stenosis_18\NN\14204950 ._19\.\1740
D007545_D017202 CID effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 <e1>isoproterenol</e1>_4\NN\3740161 (iso)-induced_5\VBN\1740 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 coronary_14\JJ\1740 stenosis_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
D007545_D017202 CID effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 <e1>(iso)-induced</e1>_5\VBN\1740 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 coronary_14\JJ\1740 stenosis_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
D007545_D017202 CID these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 cd-832_4\NN\1740 improves_5\VBZ\126264 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 during_8\IN\1740 <e1>iso</e1>_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 stenosis_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 cd-832_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 cd-832_31\NN\1740 ._32\.\1740
D007545_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 a_2\DT\13649268 new_3\JJ\1740 calcium_4\NN\14625458 antagonist_5\NN\7846 ,_6\,\1740 cd-832_7\NN\1740 ,_8\,\1740 on_9\IN\1740 <e1>isoproterenol-induced</e1>_10\JJ\1740 myocardial_11\JJ\1740 ischemia_12\NN\14195315 in_13\IN\13603305 dogs_14\NNS\2083346 with_15\IN\1740 partial_16\JJ\1740 <e2>coronary_17\JJ\1740 stenosis</e2>_18\NN\14204950 ._19\.\1740
D007545_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 <e1>isoproterenol</e1>_4\NN\3740161 (iso)-induced_5\VBN\1740 myocardial_6\JJ\1740 ischemia_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 <e2>coronary_14\JJ\1740 stenosis</e2>_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
D007545_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 <e1>(iso)-induced</e1>_5\VBN\1740 myocardial_6\JJ\1740 ischemia_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 <e2>coronary_14\JJ\1740 stenosis</e2>_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
D007545_D023921 NONE in_0\IN\13603305 the_1\DT\1740 presence_2\NN\13954253 of_3\IN\1740 <e2>coronary_4\JJ\1740 artery_5\NN\5417975 stenosis</e2>_6\NN\14204950 ,_7\,\1740 3-min_8\JJ\1740 periods_9\NNS\13575869 of_10\IN\1740 intracoronary_11\JJ\1740 <e1>iso</e1>_12\NN\1740 infusion_13\NN\14589223 (_14\-LRB-\1740 10_15\CD\13745420 ng/kg/min_16\NN\1740 )_17\-RRB-\1740 increased_18\VBD\169651 heart_19\NN\5919034 rate_20\NN\13815152 and_21\CC\1740 maximal_22\JJ\1740 rate_23\NN\13815152 of_24\IN\1740 left_25\JJ\1740 ventricular_26\JJ\1740 pressure_27\NN\11419404 rise_28\NN\7324673 ,_29\,\1740 which_30\WDT\1740 resulted_31\VBD\2633881 in_32\IN\13603305 a_33\DT\13649268 decrease_34\NN\7296428 in_35\IN\13603305 percentage_36\NN\13815742 segmental_37\JJ\1740 shortening_38\NN\7672135 and_39\CC\1740 st-segment_40\JJ\1740 elevation_41\NN\7445480 of_42\IN\1740 the_43\DT\1740 epicardial_44\JJ\1740 electrocardiogram_45\NN\7000195 ._46\.\1740
D009543_D017202 NONE effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 (iso)-induced_5\VBN\1740 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 coronary_14\JJ\1740 stenosis_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 <e1>nifedipine</e1>_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
D009543_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 (iso)-induced_5\VBN\1740 myocardial_6\JJ\1740 ischemia_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 <e2>coronary_14\JJ\1740 stenosis</e2>_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 <e1>nifedipine</e1>_29\NN\2938514 or_30\CC\3541091 diltiazem_31\NN\2938514 ._32\.\1740
D004110_D017202 NONE effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 (iso)-induced_5\VBN\1740 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 coronary_14\JJ\1740 stenosis_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 <e1>diltiazem</e1>_31\NN\2938514 ._32\.\1740
D004110_D023921 NONE effects_0\NNS\13245626 of_1\IN\1740 cd-832_2\NN\1740 on_3\IN\1740 isoproterenol_4\NN\3740161 (iso)-induced_5\VBN\1740 myocardial_6\JJ\1740 ischemia_7\NN\14195315 were_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 dogs_11\NNS\2083346 with_12\IN\1740 partial_13\JJ\1740 <e2>coronary_14\JJ\1740 stenosis</e2>_15\NN\14204950 of_16\IN\1740 the_17\DT\1740 left_18\JJ\1740 circumflex_19\JJ\1740 coronary_20\JJ\1740 artery_21\NN\5417975 and_22\CC\1740 findings_23\NNS\7951464 were_24\VBD\836236 compared_25\VBN\644583 with_26\IN\1740 those_27\DT\1740 for_28\IN\1740 nifedipine_29\NN\2938514 or_30\CC\3541091 <e1>diltiazem</e1>_31\NN\2938514 ._32\.\1740
D007545_D003251 NONE after_0\IN\1740 the_1\DT\1740 control_2\NN\5190804 <e1>iso</e1>_3\NN\1740 infusion_4\NN\14589223 with_5\IN\1740 <e2>stenosis</e2>_6\NN\14204950 was_7\VBD\836236 performed_8\VBN\2367363 ,_9\,\1740 equihypotensive_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 cd-832_13\NN\1740 (_14\-LRB-\1740 3_15\CD\13741022 and_16\CC\1740 10_17\CD\13745420 micrograms/kg/min_18\NN\1740 ,_19\,\1740 n_20\NN\14622893 =_21\JJ\1740 7_22\CD\13741022 )_23\-RRB-\1740 ,_24\,\1740 nifedipine_25\NN\2938514 (_26\-LRB-\1740 1_27\CD\13741022 and_28\CC\1740 3_29\CD\13741022 micrograms/kg/min_30\NN\1740 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 9_34\CD\13741022 )_35\-RRB-\1740 or_36\CC\3541091 diltiazem_37\NN\2938514 (_38\-LRB-\1740 10_39\CD\13745420 and_40\CC\1740 30_41\CD\13745420 micrograms/kg/min_42\NN\1740 ,_43\,\1740 n_44\NN\14622893 =_45\JJ\1740 7_46\CD\13741022 )_47\-RRB-\1740 were_48\VBD\836236 infused_49\VBN\606335 5_50\CD\13741022 min_51\NN\15154774 before_52\IN\1740 and_53\CC\1740 during_54\IN\1740 the_55\DT\1740 second_56\JJ\1740 and_57\CC\1740 third_58\JJ\1740 iso_59\NN\1740 infusion_60\NN\14589223 ._61\.\1740
D007545_D003251 NONE after_0\IN\1740 the_1\DT\1740 control_2\NN\5190804 iso_3\NN\1740 infusion_4\NN\14589223 with_5\IN\1740 <e2>stenosis</e2>_6\NN\14204950 was_7\VBD\836236 performed_8\VBN\2367363 ,_9\,\1740 equihypotensive_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 cd-832_13\NN\1740 (_14\-LRB-\1740 3_15\CD\13741022 and_16\CC\1740 10_17\CD\13745420 micrograms/kg/min_18\NN\1740 ,_19\,\1740 n_20\NN\14622893 =_21\JJ\1740 7_22\CD\13741022 )_23\-RRB-\1740 ,_24\,\1740 nifedipine_25\NN\2938514 (_26\-LRB-\1740 1_27\CD\13741022 and_28\CC\1740 3_29\CD\13741022 micrograms/kg/min_30\NN\1740 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 9_34\CD\13741022 )_35\-RRB-\1740 or_36\CC\3541091 diltiazem_37\NN\2938514 (_38\-LRB-\1740 10_39\CD\13745420 and_40\CC\1740 30_41\CD\13745420 micrograms/kg/min_42\NN\1740 ,_43\,\1740 n_44\NN\14622893 =_45\JJ\1740 7_46\CD\13741022 )_47\-RRB-\1740 were_48\VBD\836236 infused_49\VBN\606335 5_50\CD\13741022 min_51\NN\15154774 before_52\IN\1740 and_53\CC\1740 during_54\IN\1740 the_55\DT\1740 second_56\JJ\1740 and_57\CC\1740 third_58\JJ\1740 <e1>iso</e1>_59\NN\1740 infusion_60\NN\14589223 ._61\.\1740
D007545_D003251 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 nifedipine_3\NN\2938514 ,_4\,\1740 cd-832_5\NN\1740 (_6\-LRB-\1740 10_7\CD\13745420 micrograms/kg/min_8\NN\1740 )_9\-RRB-\1740 prevented_10\VBD\1740 the_11\DT\1740 decrease_12\NN\7296428 in_13\IN\13603305 percentage_14\NN\13815742 segmental_15\JJ\1740 shortening_16\NN\7672135 from_17\IN\1740 32_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 %_21\NN\1740 to_22\TO\1740 115_23\CD\1740 +/-_24\CC\1740 26_25\CD\13745420 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 control_29\NN\5190804 value_30\NN\5856066 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 .01_34\CD\1740 )_35\-RRB-\1740 and_36\CC\1740 st-segment_37\JJ\1740 elevation_38\NN\7445480 from_39\IN\1740 5.6_40\CD\1740 +/-_41\CC\1740 1.0_42\CD\1740 mv_43\NN\13634784 to_44\IN\1740 1.6_45\CD\1740 +/-_46\CC\1740 1.3_47\CD\1740 mv_48\NN\13634784 (_49\-LRB-\1740 p_50\NN\14622893 <_51\XX\1740 .01_52\CD\1740 )_53\-RRB-\1740 at_54\IN\14622893 3_55\CD\13741022 min_56\NN\15154774 after_57\IN\1740 <e1>iso</e1>_58\NN\1740 infusion_59\NN\14589223 with_60\IN\1740 <e2>stenosis</e2>_61\NN\14204950 ._62\.\1740
D007545_D003251 NONE diltiazem_0\NNP\2938514 (_1\-LRB-\1740 30_2\CD\13745420 micrograms/kg/min_3\NN\1740 )_4\-RRB-\1740 also_5\RB\1740 prevented_6\VBD\1740 the_7\DT\1740 decrease_8\NN\7296428 in_9\IN\13603305 percentage_10\NN\13815742 segmental_11\JJ\1740 shortening_12\NN\7672135 from_13\IN\1740 34_14\CD\1740 +/-_15\CC\1740 14_16\CD\13745420 %_17\NN\1740 to_18\TO\1740 63_19\CD\1740 +/-_20\CC\1740 18_21\CD\13745420 %_22\NN\1740 of_23\IN\1740 the_24\DT\1740 control_25\NN\5190804 value_26\NN\5856066 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 .05_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 st-segment_33\JJ\1740 elevation_34\NN\7445480 from_35\IN\1740 4.7_36\CD\1740 +/-_37\CC\1740 0.7_38\CD\1740 mv_39\NN\13634784 to_40\TO\1740 2.1_41\CD\1740 +/-_42\CC\1740 0.7_43\CD\1740 mv_44\NN\13634784 (_45\-LRB-\1740 p_46\NN\14622893 <_47\XX\1740 .01_48\CD\1740 )_49\-RRB-\1740 at_50\IN\14622893 3_51\CD\13741022 min_52\NN\15154774 after_53\IN\1740 <e1>iso</e1>_54\NN\1740 infusion_55\NN\14589223 with_56\IN\1740 <e2>stenosis</e2>_57\NN\14204950 ._58\.\1740
D007545_D003251 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 cd-832_4\NN\1740 improves_5\VBZ\126264 myocardial_6\JJ\1740 ischemia_7\NN\14195315 during_8\IN\1740 <e1>iso</e1>_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 <e2>stenosis</e2>_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 cd-832_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 cd-832_31\NN\1740 ._32\.\1740
C082828_D003251 NONE after_0\IN\1740 the_1\DT\1740 control_2\NN\5190804 iso_3\NN\1740 infusion_4\NN\14589223 with_5\IN\1740 <e2>stenosis</e2>_6\NN\14204950 was_7\VBD\836236 performed_8\VBN\2367363 ,_9\,\1740 equihypotensive_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 <e1>cd-832</e1>_13\NN\1740 (_14\-LRB-\1740 3_15\CD\13741022 and_16\CC\1740 10_17\CD\13745420 micrograms/kg/min_18\NN\1740 ,_19\,\1740 n_20\NN\14622893 =_21\JJ\1740 7_22\CD\13741022 )_23\-RRB-\1740 ,_24\,\1740 nifedipine_25\NN\2938514 (_26\-LRB-\1740 1_27\CD\13741022 and_28\CC\1740 3_29\CD\13741022 micrograms/kg/min_30\NN\1740 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 9_34\CD\13741022 )_35\-RRB-\1740 or_36\CC\3541091 diltiazem_37\NN\2938514 (_38\-LRB-\1740 10_39\CD\13745420 and_40\CC\1740 30_41\CD\13745420 micrograms/kg/min_42\NN\1740 ,_43\,\1740 n_44\NN\14622893 =_45\JJ\1740 7_46\CD\13741022 )_47\-RRB-\1740 were_48\VBD\836236 infused_49\VBN\606335 5_50\CD\13741022 min_51\NN\15154774 before_52\IN\1740 and_53\CC\1740 during_54\IN\1740 the_55\DT\1740 second_56\JJ\1740 and_57\CC\1740 third_58\JJ\1740 iso_59\NN\1740 infusion_60\NN\14589223 ._61\.\1740
C082828_D003251 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 nifedipine_3\NN\2938514 ,_4\,\1740 <e1>cd-832</e1>_5\NN\1740 (_6\-LRB-\1740 10_7\CD\13745420 micrograms/kg/min_8\NN\1740 )_9\-RRB-\1740 prevented_10\VBD\1740 the_11\DT\1740 decrease_12\NN\7296428 in_13\IN\13603305 percentage_14\NN\13815742 segmental_15\JJ\1740 shortening_16\NN\7672135 from_17\IN\1740 32_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 %_21\NN\1740 to_22\TO\1740 115_23\CD\1740 +/-_24\CC\1740 26_25\CD\13745420 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 control_29\NN\5190804 value_30\NN\5856066 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 .01_34\CD\1740 )_35\-RRB-\1740 and_36\CC\1740 st-segment_37\JJ\1740 elevation_38\NN\7445480 from_39\IN\1740 5.6_40\CD\1740 +/-_41\CC\1740 1.0_42\CD\1740 mv_43\NN\13634784 to_44\IN\1740 1.6_45\CD\1740 +/-_46\CC\1740 1.3_47\CD\1740 mv_48\NN\13634784 (_49\-LRB-\1740 p_50\NN\14622893 <_51\XX\1740 .01_52\CD\1740 )_53\-RRB-\1740 at_54\IN\14622893 3_55\CD\13741022 min_56\NN\15154774 after_57\IN\1740 iso_58\NN\1740 infusion_59\NN\14589223 with_60\IN\1740 <e2>stenosis</e2>_61\NN\14204950 ._62\.\1740
C082828_D003251 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 <e1>cd-832</e1>_4\NN\1740 improves_5\VBZ\126264 myocardial_6\JJ\1740 ischemia_7\NN\14195315 during_8\IN\1740 iso_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 <e2>stenosis</e2>_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 cd-832_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 cd-832_31\NN\1740 ._32\.\1740
C082828_D003251 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 cd-832_4\NN\1740 improves_5\VBZ\126264 myocardial_6\JJ\1740 ischemia_7\NN\14195315 during_8\IN\1740 iso_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 <e2>stenosis</e2>_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 <e1>cd-832</e1>_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 cd-832_31\NN\1740 ._32\.\1740
C082828_D003251 NONE these_0\DT\1740 data_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 cd-832_4\NN\1740 improves_5\VBZ\126264 myocardial_6\JJ\1740 ischemia_7\NN\14195315 during_8\IN\1740 iso_9\NN\1740 infusion_10\NN\14589223 with_11\IN\1740 <e2>stenosis</e2>_12\NN\14204950 and_13\CC\1740 suggest_14\VBP\1010118 that_15\IN\1740 the_16\DT\1740 negative_17\JJ\1740 chronotropic_18\JJ\1740 property_19\NN\32613 of_20\IN\1740 cd-832_21\NN\1740 plays_22\VBZ\1072262 a_23\DT\13649268 major_24\JJ\1740 role_25\NN\719494 in_26\IN\13603305 the_27\DT\1740 beneficial_28\JJ\1740 effects_29\NNS\13245626 of_30\IN\1740 <e1>cd-832</e1>_31\NN\1740 ._32\.\1740
D009543_D003251 NONE after_0\IN\1740 the_1\DT\1740 control_2\NN\5190804 iso_3\NN\1740 infusion_4\NN\14589223 with_5\IN\1740 <e2>stenosis</e2>_6\NN\14204950 was_7\VBD\836236 performed_8\VBN\2367363 ,_9\,\1740 equihypotensive_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 cd-832_13\NN\1740 (_14\-LRB-\1740 3_15\CD\13741022 and_16\CC\1740 10_17\CD\13745420 micrograms/kg/min_18\NN\1740 ,_19\,\1740 n_20\NN\14622893 =_21\JJ\1740 7_22\CD\13741022 )_23\-RRB-\1740 ,_24\,\1740 <e1>nifedipine</e1>_25\NN\2938514 (_26\-LRB-\1740 1_27\CD\13741022 and_28\CC\1740 3_29\CD\13741022 micrograms/kg/min_30\NN\1740 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 9_34\CD\13741022 )_35\-RRB-\1740 or_36\CC\3541091 diltiazem_37\NN\2938514 (_38\-LRB-\1740 10_39\CD\13745420 and_40\CC\1740 30_41\CD\13745420 micrograms/kg/min_42\NN\1740 ,_43\,\1740 n_44\NN\14622893 =_45\JJ\1740 7_46\CD\13741022 )_47\-RRB-\1740 were_48\VBD\836236 infused_49\VBN\606335 5_50\CD\13741022 min_51\NN\15154774 before_52\IN\1740 and_53\CC\1740 during_54\IN\1740 the_55\DT\1740 second_56\JJ\1740 and_57\CC\1740 third_58\JJ\1740 iso_59\NN\1740 infusion_60\NN\14589223 ._61\.\1740
D009543_D003251 NONE in_0\IN\13603305 contrast_1\NN\13854649 to_2\TO\1740 <e1>nifedipine</e1>_3\NN\2938514 ,_4\,\1740 cd-832_5\NN\1740 (_6\-LRB-\1740 10_7\CD\13745420 micrograms/kg/min_8\NN\1740 )_9\-RRB-\1740 prevented_10\VBD\1740 the_11\DT\1740 decrease_12\NN\7296428 in_13\IN\13603305 percentage_14\NN\13815742 segmental_15\JJ\1740 shortening_16\NN\7672135 from_17\IN\1740 32_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 %_21\NN\1740 to_22\TO\1740 115_23\CD\1740 +/-_24\CC\1740 26_25\CD\13745420 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 control_29\NN\5190804 value_30\NN\5856066 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 .01_34\CD\1740 )_35\-RRB-\1740 and_36\CC\1740 st-segment_37\JJ\1740 elevation_38\NN\7445480 from_39\IN\1740 5.6_40\CD\1740 +/-_41\CC\1740 1.0_42\CD\1740 mv_43\NN\13634784 to_44\IN\1740 1.6_45\CD\1740 +/-_46\CC\1740 1.3_47\CD\1740 mv_48\NN\13634784 (_49\-LRB-\1740 p_50\NN\14622893 <_51\XX\1740 .01_52\CD\1740 )_53\-RRB-\1740 at_54\IN\14622893 3_55\CD\13741022 min_56\NN\15154774 after_57\IN\1740 iso_58\NN\1740 infusion_59\NN\14589223 with_60\IN\1740 <e2>stenosis</e2>_61\NN\14204950 ._62\.\1740
D004110_D003251 NONE after_0\IN\1740 the_1\DT\1740 control_2\NN\5190804 iso_3\NN\1740 infusion_4\NN\14589223 with_5\IN\1740 <e2>stenosis</e2>_6\NN\14204950 was_7\VBD\836236 performed_8\VBN\2367363 ,_9\,\1740 equihypotensive_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 cd-832_13\NN\1740 (_14\-LRB-\1740 3_15\CD\13741022 and_16\CC\1740 10_17\CD\13745420 micrograms/kg/min_18\NN\1740 ,_19\,\1740 n_20\NN\14622893 =_21\JJ\1740 7_22\CD\13741022 )_23\-RRB-\1740 ,_24\,\1740 nifedipine_25\NN\2938514 (_26\-LRB-\1740 1_27\CD\13741022 and_28\CC\1740 3_29\CD\13741022 micrograms/kg/min_30\NN\1740 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 9_34\CD\13741022 )_35\-RRB-\1740 or_36\CC\3541091 <e1>diltiazem</e1>_37\NN\2938514 (_38\-LRB-\1740 10_39\CD\13745420 and_40\CC\1740 30_41\CD\13745420 micrograms/kg/min_42\NN\1740 ,_43\,\1740 n_44\NN\14622893 =_45\JJ\1740 7_46\CD\13741022 )_47\-RRB-\1740 were_48\VBD\836236 infused_49\VBN\606335 5_50\CD\13741022 min_51\NN\15154774 before_52\IN\1740 and_53\CC\1740 during_54\IN\1740 the_55\DT\1740 second_56\JJ\1740 and_57\CC\1740 third_58\JJ\1740 iso_59\NN\1740 infusion_60\NN\14589223 ._61\.\1740
D004110_D003251 NONE <e1>diltiazem</e1>_0\NNP\2938514 (_1\-LRB-\1740 30_2\CD\13745420 micrograms/kg/min_3\NN\1740 )_4\-RRB-\1740 also_5\RB\1740 prevented_6\VBD\1740 the_7\DT\1740 decrease_8\NN\7296428 in_9\IN\13603305 percentage_10\NN\13815742 segmental_11\JJ\1740 shortening_12\NN\7672135 from_13\IN\1740 34_14\CD\1740 +/-_15\CC\1740 14_16\CD\13745420 %_17\NN\1740 to_18\TO\1740 63_19\CD\1740 +/-_20\CC\1740 18_21\CD\13745420 %_22\NN\1740 of_23\IN\1740 the_24\DT\1740 control_25\NN\5190804 value_26\NN\5856066 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 .05_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 st-segment_33\JJ\1740 elevation_34\NN\7445480 from_35\IN\1740 4.7_36\CD\1740 +/-_37\CC\1740 0.7_38\CD\1740 mv_39\NN\13634784 to_40\TO\1740 2.1_41\CD\1740 +/-_42\CC\1740 0.7_43\CD\1740 mv_44\NN\13634784 (_45\-LRB-\1740 p_46\NN\14622893 <_47\XX\1740 .01_48\CD\1740 )_49\-RRB-\1740 at_50\IN\14622893 3_51\CD\13741022 min_52\NN\15154774 after_53\IN\1740 iso_54\NN\1740 infusion_55\NN\14589223 with_56\IN\1740 <e2>stenosis</e2>_57\NN\14204950 ._58\.\1740
12165618
D019469_-1 NONE persistent_0\JJ\1740 sterile_1\JJ\1740 <e2>leukocyturia</e2>_2\NN\1740 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 impaired_6\JJ\1740 renal_7\JJ\1740 function_8\NN\13783581 in_9\IN\13603305 human_10\JJ\1740 immunodeficiency_11\NN\13973990 virus_12\NN\9312843 type_13\NN\5839024 1-infected_14\JJ\1740 children_15\NNS\9622049 treated_16\VBN\2376958 with_17\IN\1740 <e1>indinavir</e1>_18\NN\4013993 ._19\.\1740
D019469_-1 NONE a_0\DT\13649268 higher_1\JJR\1740 cumulative_2\JJ\1740 incidence_3\NN\13821570 of_4\IN\1740 persistent_5\JJ\1740 <e2>leukocyturia</e2>_6\NN\1740 was_7\VBD\836236 found_8\VBN\2426171 in_9\IN\13603305 children_10\NNS\9622049 with_11\IN\1740 an_12\DT\6697703 area_13\NN\8630985 under_14\IN\1740 the_15\DT\1740 curve_16\NN\13863771 >_17\$\1740 19_18\CD\13745420 mg/l_19\NN\1740 x_20\NN\13745420 h_21\NN\14622893 or_22\CC\3541091 a_23\DT\13649268 peak_24\JJ\1740 serum_25\NN\5397468 level_26\NN\4916342 of_27\IN\1740 <e1>indinavir</e1>_28\NN\4013993 >_29\$\1740 12_30\CD\13745420 mg/l._31\NNS\1740 in_32\IN\13603305 4_33\CD\13741022 children_34\NNS\9622049 ,_35\,\1740 indinavir_36\NN\4013993 was_37\VBD\836236 discontinued_38\VBN\2609764 because_39\IN\1740 of_40\IN\1740 nephrotoxicity_41\NN\1740 ._42\.\1740
D019469_-1 NONE a_0\DT\13649268 higher_1\JJR\1740 cumulative_2\JJ\1740 incidence_3\NN\13821570 of_4\IN\1740 persistent_5\JJ\1740 <e2>leukocyturia</e2>_6\NN\1740 was_7\VBD\836236 found_8\VBN\2426171 in_9\IN\13603305 children_10\NNS\9622049 with_11\IN\1740 an_12\DT\6697703 area_13\NN\8630985 under_14\IN\1740 the_15\DT\1740 curve_16\NN\13863771 >_17\$\1740 19_18\CD\13745420 mg/l_19\NN\1740 x_20\NN\13745420 h_21\NN\14622893 or_22\CC\3541091 a_23\DT\13649268 peak_24\JJ\1740 serum_25\NN\5397468 level_26\NN\4916342 of_27\IN\1740 indinavir_28\NN\4013993 >_29\$\1740 12_30\CD\13745420 mg/l._31\NNS\1740 in_32\IN\13603305 4_33\CD\13741022 children_34\NNS\9622049 ,_35\,\1740 <e1>indinavir</e1>_36\NN\4013993 was_37\VBD\836236 discontinued_38\VBN\2609764 because_39\IN\1740 of_40\IN\1740 nephrotoxicity_41\NN\1740 ._42\.\1740
D019469_-1 NONE conclusions_0\NNS\5837957 :_1\:\1740 children_2\NNS\9622049 treated_3\VBN\2376958 with_4\IN\1740 <e1>indinavir</e1>_5\NN\4013993 have_6\VBP\2108377 a_7\DT\13649268 high_8\JJ\1740 cumulative_9\JJ\1740 incidence_10\NN\13821570 of_11\IN\1740 persistent_12\JJ\1740 sterile_13\JJ\1740 <e2>leukocyturia</e2>_14\NN\1740 ._15\.\1740
D019469_-1 NONE <e1>indinavir-associated</e1>_0\JJ\1740 nephrotoxicity_1\NN\1740 must_2\MD\9367203 be_3\VB\836236 monitored_4\VBN\2169352 closely_5\RB\1740 ,_6\,\1740 especially_7\RB\1740 in_8\IN\13603305 children_9\NNS\9622049 with_10\IN\1740 risk_11\NN\14541044 factors_12\NNS\7326557 such_13\JJ\1740 as_14\IN\14622893 persistent_15\JJ\1740 sterile_16\JJ\1740 <e2>leukocyturia</e2>_17\NN\1740 ,_18\,\1740 age_19\NN\4916342 <_20\NN\1740 5.6_21\CD\1740 years_22\NNS\15144371 ,_23\,\1740 an_24\DT\6697703 area_25\NN\8630985 under_26\IN\1740 the_27\DT\1740 curve_28\NN\13863771 of_29\IN\1740 indinavir_30\NN\4013993 >_31\NNS\1740 19_32\CD\13745420 mg/l_33\NN\1740 x_34\NN\13745420 h_35\NN\14622893 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 c(max_39\NN\1740 )_40\-RRB-\1740 >_41\NN\1740 12_42\CD\13745420 mg/l._43\NNS\1740
D019469_-1 NONE indinavir-associated_0\JJ\1740 nephrotoxicity_1\NN\1740 must_2\MD\9367203 be_3\VB\836236 monitored_4\VBN\2169352 closely_5\RB\1740 ,_6\,\1740 especially_7\RB\1740 in_8\IN\13603305 children_9\NNS\9622049 with_10\IN\1740 risk_11\NN\14541044 factors_12\NNS\7326557 such_13\JJ\1740 as_14\IN\14622893 persistent_15\JJ\1740 sterile_16\JJ\1740 <e2>leukocyturia</e2>_17\NN\1740 ,_18\,\1740 age_19\NN\4916342 <_20\NN\1740 5.6_21\CD\1740 years_22\NNS\15144371 ,_23\,\1740 an_24\DT\6697703 area_25\NN\8630985 under_26\IN\1740 the_27\DT\1740 curve_28\NN\13863771 of_29\IN\1740 <e1>indinavir</e1>_30\NN\4013993 >_31\NNS\1740 19_32\CD\13745420 mg/l_33\NN\1740 x_34\NN\13745420 h_35\NN\14622893 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 c(max_39\NN\1740 )_40\-RRB-\1740 >_41\NN\1740 12_42\CD\13745420 mg/l._43\NNS\1740
D019469_D007674 CID persistent_0\JJ\1740 sterile_1\JJ\1740 leukocyturia_2\NN\1740 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 <e2>impaired_6\JJ\1740 renal_7\JJ\1740 function</e2>_8\NN\13783581 in_9\IN\13603305 human_10\JJ\1740 immunodeficiency_11\NN\13973990 virus_12\NN\9312843 type_13\NN\5839024 1-infected_14\JJ\1740 children_15\NNS\9622049 treated_16\VBN\2376958 with_17\IN\1740 <e1>indinavir</e1>_18\NN\4013993 ._19\.\1740
D019469_D007674 CID design_0\NN\927261 :_1\:\1740 a_2\DT\13649268 prospective_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 monitor_6\VB\2169352 <e1>indinavir-related</e1>_7\JJ\1740 <e2>nephrotoxicity</e2>_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 cohort_11\NN\8184861 of_12\IN\1740 30_13\CD\13745420 human_14\JJ\1740 immunodeficiency_15\NN\13973990 virus_16\NN\9312843 type_17\NN\5839024 1-infected_18\JJ\1740 children_19\NNS\9622049 treated_20\VBN\2376958 with_21\IN\1740 indinavir_22\NN\4013993 ._23\.\1740
D019469_D007674 CID design_0\NN\927261 :_1\:\1740 a_2\DT\13649268 prospective_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 monitor_6\VB\2169352 indinavir-related_7\JJ\1740 <e2>nephrotoxicity</e2>_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 cohort_11\NN\8184861 of_12\IN\1740 30_13\CD\13745420 human_14\JJ\1740 immunodeficiency_15\NN\13973990 virus_16\NN\9312843 type_17\NN\5839024 1-infected_18\JJ\1740 children_19\NNS\9622049 treated_20\VBN\2376958 with_21\IN\1740 <e1>indinavir</e1>_22\NN\4013993 ._23\.\1740
D019469_D007674 CID a_0\DT\13649268 higher_1\JJR\1740 cumulative_2\JJ\1740 incidence_3\NN\13821570 of_4\IN\1740 persistent_5\JJ\1740 leukocyturia_6\NN\1740 was_7\VBD\836236 found_8\VBN\2426171 in_9\IN\13603305 children_10\NNS\9622049 with_11\IN\1740 an_12\DT\6697703 area_13\NN\8630985 under_14\IN\1740 the_15\DT\1740 curve_16\NN\13863771 >_17\$\1740 19_18\CD\13745420 mg/l_19\NN\1740 x_20\NN\13745420 h_21\NN\14622893 or_22\CC\3541091 a_23\DT\13649268 peak_24\JJ\1740 serum_25\NN\5397468 level_26\NN\4916342 of_27\IN\1740 <e1>indinavir</e1>_28\NN\4013993 >_29\$\1740 12_30\CD\13745420 mg/l._31\NNS\1740 in_32\IN\13603305 4_33\CD\13741022 children_34\NNS\9622049 ,_35\,\1740 indinavir_36\NN\4013993 was_37\VBD\836236 discontinued_38\VBN\2609764 because_39\IN\1740 of_40\IN\1740 <e2>nephrotoxicity</e2>_41\NN\1740 ._42\.\1740
D019469_D007674 CID a_0\DT\13649268 higher_1\JJR\1740 cumulative_2\JJ\1740 incidence_3\NN\13821570 of_4\IN\1740 persistent_5\JJ\1740 leukocyturia_6\NN\1740 was_7\VBD\836236 found_8\VBN\2426171 in_9\IN\13603305 children_10\NNS\9622049 with_11\IN\1740 an_12\DT\6697703 area_13\NN\8630985 under_14\IN\1740 the_15\DT\1740 curve_16\NN\13863771 >_17\$\1740 19_18\CD\13745420 mg/l_19\NN\1740 x_20\NN\13745420 h_21\NN\14622893 or_22\CC\3541091 a_23\DT\13649268 peak_24\JJ\1740 serum_25\NN\5397468 level_26\NN\4916342 of_27\IN\1740 indinavir_28\NN\4013993 >_29\$\1740 12_30\CD\13745420 mg/l._31\NNS\1740 in_32\IN\13603305 4_33\CD\13741022 children_34\NNS\9622049 ,_35\,\1740 <e1>indinavir</e1>_36\NN\4013993 was_37\VBD\836236 discontinued_38\VBN\2609764 because_39\IN\1740 of_40\IN\1740 <e2>nephrotoxicity</e2>_41\NN\1740 ._42\.\1740
D019469_D007674 CID <e1>indinavir-associated</e1>_0\JJ\1740 <e2>nephrotoxicity</e2>_1\NN\1740 must_2\MD\9367203 be_3\VB\836236 monitored_4\VBN\2169352 closely_5\RB\1740 ,_6\,\1740 especially_7\RB\1740 in_8\IN\13603305 children_9\NNS\9622049 with_10\IN\1740 risk_11\NN\14541044 factors_12\NNS\7326557 such_13\JJ\1740 as_14\IN\14622893 persistent_15\JJ\1740 sterile_16\JJ\1740 leukocyturia_17\NN\1740 ,_18\,\1740 age_19\NN\4916342 <_20\NN\1740 5.6_21\CD\1740 years_22\NNS\15144371 ,_23\,\1740 an_24\DT\6697703 area_25\NN\8630985 under_26\IN\1740 the_27\DT\1740 curve_28\NN\13863771 of_29\IN\1740 indinavir_30\NN\4013993 >_31\NNS\1740 19_32\CD\13745420 mg/l_33\NN\1740 x_34\NN\13745420 h_35\NN\14622893 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 c(max_39\NN\1740 )_40\-RRB-\1740 >_41\NN\1740 12_42\CD\13745420 mg/l._43\NNS\1740
D019469_D007674 CID indinavir-associated_0\JJ\1740 <e2>nephrotoxicity</e2>_1\NN\1740 must_2\MD\9367203 be_3\VB\836236 monitored_4\VBN\2169352 closely_5\RB\1740 ,_6\,\1740 especially_7\RB\1740 in_8\IN\13603305 children_9\NNS\9622049 with_10\IN\1740 risk_11\NN\14541044 factors_12\NNS\7326557 such_13\JJ\1740 as_14\IN\14622893 persistent_15\JJ\1740 sterile_16\JJ\1740 leukocyturia_17\NN\1740 ,_18\,\1740 age_19\NN\4916342 <_20\NN\1740 5.6_21\CD\1740 years_22\NNS\15144371 ,_23\,\1740 an_24\DT\6697703 area_25\NN\8630985 under_26\IN\1740 the_27\DT\1740 curve_28\NN\13863771 of_29\IN\1740 <e1>indinavir</e1>_30\NN\4013993 >_31\NNS\1740 19_32\CD\13745420 mg/l_33\NN\1740 x_34\NN\13745420 h_35\NN\14622893 ,_36\,\1740 and_37\CC\1740 a_38\DT\13649268 c(max_39\NN\1740 )_40\-RRB-\1740 >_41\NN\1740 12_42\CD\13745420 mg/l._43\NNS\1740
D019469_D015658 NONE persistent_0\JJ\1740 sterile_1\JJ\1740 leukocyturia_2\NN\1740 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 impaired_6\JJ\1740 renal_7\JJ\1740 function_8\NN\13783581 in_9\IN\13603305 <e2>human_10\JJ\1740 immunodeficiency_11\NN\13973990 virus_12\NN\9312843 type_13\NN\5839024 1-infected</e2>_14\JJ\1740 children_15\NNS\9622049 treated_16\VBN\2376958 with_17\IN\1740 <e1>indinavir</e1>_18\NN\4013993 ._19\.\1740
D019469_D015658 NONE design_0\NN\927261 :_1\:\1740 a_2\DT\13649268 prospective_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 monitor_6\VB\2169352 <e1>indinavir-related</e1>_7\JJ\1740 nephrotoxicity_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 cohort_11\NN\8184861 of_12\IN\1740 30_13\CD\13745420 <e2>human_14\JJ\1740 immunodeficiency_15\NN\13973990 virus_16\NN\9312843 type_17\NN\5839024 1-infected</e2>_18\JJ\1740 children_19\NNS\9622049 treated_20\VBN\2376958 with_21\IN\1740 indinavir_22\NN\4013993 ._23\.\1740
D019469_D015658 NONE design_0\NN\927261 :_1\:\1740 a_2\DT\13649268 prospective_3\JJ\1740 study_4\NN\635850 to_5\TO\1740 monitor_6\VB\2169352 indinavir-related_7\JJ\1740 nephrotoxicity_8\NN\1740 in_9\IN\13603305 a_10\DT\13649268 cohort_11\NN\8184861 of_12\IN\1740 30_13\CD\13745420 <e2>human_14\JJ\1740 immunodeficiency_15\NN\13973990 virus_16\NN\9312843 type_17\NN\5839024 1-infected</e2>_18\JJ\1740 children_19\NNS\9622049 treated_20\VBN\2376958 with_21\IN\1740 <e1>indinavir</e1>_22\NN\4013993 ._23\.\1740
D003404_-1 NONE persistent_0\JJ\1740 sterile_1\JJ\1740 <e2>leukocyturia</e2>_2\NN\1740 was_3\VBD\836236 frequently_4\RB\1740 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 mild_8\JJ\1740 increase_9\NN\13576355 in_10\IN\13603305 the_11\DT\1740 urine_12\NN\14853947 <e1>albumin/creatinine</e1>_13\NN\1740 ratio_14\NN\13815152 and_15\CC\1740 by_16\IN\1740 microscopic_17\JJ\1740 hematuria_18\NN\14299637 ._19\.\1740
D003404_-1 NONE children_0\NNS\9622049 with_1\IN\1740 persistent_2\JJ\1740 sterile_3\JJ\1740 <e2>leukocyturia</e2>_4\NN\1740 more_5\RBR\1740 frequently_6\RB\1740 had_7\VBD\2108377 serum_8\NN\5397468 <e1>creatinine</e1>_9\NN\1740 levels_10\NNS\4916342 of_11\IN\1740 50_12\CD\13745420 %_13\NN\1740 above_14\IN\6392001 normal_15\JJ\1740 than_16\IN\1740 those_17\DT\1740 children_18\NNS\9622049 without_19\IN\1740 persistent_20\JJ\1740 sterile_21\JJ\1740 leukocyturia_22\NN\1740 ._23\.\1740
D003404_-1 NONE children_0\NNS\9622049 with_1\IN\1740 persistent_2\JJ\1740 sterile_3\JJ\1740 leukocyturia_4\NN\1740 more_5\RBR\1740 frequently_6\RB\1740 had_7\VBD\2108377 serum_8\NN\5397468 <e1>creatinine</e1>_9\NN\1740 levels_10\NNS\4916342 of_11\IN\1740 50_12\CD\13745420 %_13\NN\1740 above_14\IN\6392001 normal_15\JJ\1740 than_16\IN\1740 those_17\DT\1740 children_18\NNS\9622049 without_19\IN\1740 persistent_20\JJ\1740 sterile_21\JJ\1740 <e2>leukocyturia</e2>_22\NN\1740 ._23\.\1740
D003404_-1 NONE subsequently_0\RB\1740 ,_1\,\1740 the_2\DT\1740 serum_3\NN\5397468 <e1>creatinine</e1>_4\NN\1740 levels_5\NNS\4916342 decreased_6\VBD\169651 ,_7\,\1740 the_8\DT\1740 urine_9\NN\14853947 albumin/creatinine_10\NN\1740 ratios_11\NNS\13815152 returned_12\VBD\1835496 to_13\IN\1740 zero_14\CD\13576982 ,_15\,\1740 and_16\CC\1740 the_17\DT\1740 <e2>leukocyturia</e2>_18\NN\1740 disappeared_19\VBD\2609764 within_20\IN\1740 3_21\CD\13741022 months_22\NNS\15113229 ._23\.\1740
D003404_-1 NONE subsequently_0\RB\1740 ,_1\,\1740 the_2\DT\1740 serum_3\NN\5397468 creatinine_4\NN\1740 levels_5\NNS\4916342 decreased_6\VBD\169651 ,_7\,\1740 the_8\DT\1740 urine_9\NN\14853947 <e1>albumin/creatinine</e1>_10\NN\1740 ratios_11\NNS\13815152 returned_12\VBD\1835496 to_13\IN\1740 zero_14\CD\13576982 ,_15\,\1740 and_16\CC\1740 the_17\DT\1740 <e2>leukocyturia</e2>_18\NN\1740 disappeared_19\VBD\2609764 within_20\IN\1740 3_21\CD\13741022 months_22\NNS\15113229 ._23\.\1740
D003404_-1 NONE children_0\NNS\9622049 with_1\IN\1740 persistent_2\JJ\1740 sterile_3\JJ\1740 <e2>leukocyturia</e2>_4\NN\1740 more_5\RBR\1740 frequently_6\RB\1740 had_7\VBD\2108377 an_8\DT\6697703 increase_9\NN\13576355 in_10\IN\13603305 serum_11\NN\5397468 <e1>creatinine</e1>_12\NN\1740 levels_13\NNS\4916342 of_14\IN\1740 >_15\NN\1740 50_16\CD\13745420 %_17\NN\1740 above_18\IN\6392001 normal_19\JJ\1740 ._20\.\1740
D003404_D006417 NONE persistent_0\JJ\1740 sterile_1\JJ\1740 leukocyturia_2\NN\1740 was_3\VBD\836236 frequently_4\RB\1740 associated_5\VBN\628491 with_6\IN\1740 a_7\DT\13649268 mild_8\JJ\1740 increase_9\NN\13576355 in_10\IN\13603305 the_11\DT\1740 urine_12\NN\14853947 <e1>albumin/creatinine</e1>_13\NN\1740 ratio_14\NN\13815152 and_15\CC\1740 by_16\IN\1740 microscopic_17\JJ\1740 <e2>hematuria</e2>_18\NN\14299637 ._19\.\1740
16083708
D001663_D017114 NONE factors_0\NNS\7326557 associated_1\VBN\628491 with_2\IN\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 <e2>fulminant_6\JJ\1740 hepatic_7\JJ\1740 failure</e2>_8\NN\66216 were_9\VBD\836236 female_10\JJ\1740 sex_11\NN\13440063 (_12\-LRB-\1740 or_13\NN\3541091 =_14\JJ\1740 25_15\CD\13745420 ;_16\:\1740 95_17\CD\1740 %_18\NN\1740 ci_19\NN\13635336 :_20\:\1740 4.1_21\CD\1740 -_22\SYM\1740 151_23\CD\1740 ;_24\:\1740 p_25\NN\14622893 <_26\XX\1740 .0001_27\CD\1740 )_28\-RRB-\1740 ,_29\,\1740 hepatocellular_30\JJ\1740 damage_31\NN\7296428 (_32\-LRB-\1740 or_33\NN\3541091 =_34\JJ\1740 7.9_35\CD\1740 ;_36\:\1740 95_37\CD\1740 %_38\NN\1740 ci_39\NN\13635336 :_40\:\1740 1.6_41\CD\1740 -_42\SYM\1740 37_43\CD\1740 ;_44\:\1740 p_45\NN\14622893 <_46\XX\1740 .009_47\CD\1740 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 higher_51\JJR\1740 baseline_52\NN\7260623 plasma_53\NN\5398023 <e1>bilirubin</e1>_54\NN\14756039 value_55\NN\5856066 (_56\-LRB-\1740 or_57\NN\3541091 =_58\JJ\1740 1.15_59\CD\1740 ;_60\:\1740 95_61\CD\1740 %_62\NN\1740 ci_63\NN\13635336 :_64\:\1740 1.09_65\CD\1740 -_66\SYM\1740 1.22_67\CD\1740 ;_68\:\1740 p_69\NN\14622893 <_70\XX\1740 .0001_71\CD\1740 )_72\-RRB-\1740 ._73\.\1740
D019980_D056486 CID <e1>amoxicillin-clavulanate</e1>_0\NN\1740 stands_1\VBZ\1545883 out_2\RP\1740 as_3\IN\14622893 the_4\DT\1740 most_5\RBS\1740 common_6\JJ\1740 drug_7\NN\14778436 related_8\JJ\1740 to_9\TO\1740 <e2>dili</e2>_10\NN\1740 ._11\.\1740
23872883
D007545_D066126 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 the_9\DT\1740 protective_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 the_13\DT\1740 solidago_14\NNP\11579418 virgaurea_15\NN\1740 extract_16\NN\14589223 on_17\IN\1740 <e1>isoproterenol-induced</e1>_18\JJ\1740 <e2>cardiotoxicity</e2>_19\NN\1740 in_20\IN\13603305 rats_21\NNS\2329401 ._22\.\1740
3833372
D013999_D006973 NONE a_0\DT\13649268 postmarketing_1\NN\1740 surveillance_2\NN\635012 study_3\NN\635850 was_4\VBD\836236 conducted_5\VBN\2436349 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 safety_9\NN\13920835 and_10\CC\1740 efficacy_11\NN\5199286 of_12\IN\1740 a_13\DT\13649268 fixed-ratio_14\JJ\1740 combination_15\NN\7951464 containing_16\VBG\2632940 10_17\CD\13745420 mg_18\NN\13717155 of_19\IN\1740 <e1>timolol_20\CD\2832168 maleate</e1>_21\NN\2718811 and_22\CC\1740 25_23\CD\13745420 mg_24\NN\13717155 of_25\IN\1740 hydrochlorothiazide_26\NN\4423288 ,_27\,\1740 administered_28\VBN\2436349 twice_29\RB\1740 daily_30\RB\1740 for_31\IN\1740 one_32\CD\13741022 month_33\NN\15113229 to_34\IN\1740 <e2>hypertensive</e2>_35\JJ\1740 patients_36\NNS\9898892 ._37\.\1740
D006852_D006973 NONE a_0\DT\13649268 postmarketing_1\NN\1740 surveillance_2\NN\635012 study_3\NN\635850 was_4\VBD\836236 conducted_5\VBN\2436349 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 safety_9\NN\13920835 and_10\CC\1740 efficacy_11\NN\5199286 of_12\IN\1740 a_13\DT\13649268 fixed-ratio_14\JJ\1740 combination_15\NN\7951464 containing_16\VBG\2632940 10_17\CD\13745420 mg_18\NN\13717155 of_19\IN\1740 timolol_20\CD\2832168 maleate_21\NN\2718811 and_22\CC\1740 25_23\CD\13745420 mg_24\NN\13717155 of_25\IN\1740 <e1>hydrochlorothiazide</e1>_26\NN\4423288 ,_27\,\1740 administered_28\VBN\2436349 twice_29\RB\1740 daily_30\RB\1740 for_31\IN\1740 one_32\CD\13741022 month_33\NN\15113229 to_34\IN\1740 <e2>hypertensive</e2>_35\JJ\1740 patients_36\NNS\9898892 ._37\.\1740
25041770
D019821_D012206 CID <e2>rhabdomyolysis</e2>_0\NN\1740 in_1\IN\13603305 association_2\NN\8008335 with_3\IN\1740 <e1>simvastatin</e1>_4\NN\3676175 and_5\CC\1740 dosage_6\NN\13576355 increment_7\NN\29677 in_8\IN\13603305 clarithromycin_9\NN\1740 ._10\.\1740
D019821_D012206 CID our_0\PRP$\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 that_3\IN\1740 troponin_4\NN\1740 elevation_5\NN\7445480 could_6\MD\1740 be_7\VB\836236 associated_8\VBN\628491 with_9\IN\1740 <e1>statin</e1>_10\NN\3740161 induced_11\JJ\1740 <e2>rhabdomyolysis</e2>_12\NN\1740 ,_13\,\1740 which_14\WDT\1740 may_15\MD\15209706 warrant_16\VB\1012073 further_17\JJ\1740 studies_18\NNS\635850 ._19\.\1740
D017291_D012206 CID <e2>rhabdomyolysis</e2>_0\NN\1740 in_1\IN\13603305 association_2\NN\8008335 with_3\IN\1740 simvastatin_4\NN\3676175 and_5\CC\1740 dosage_6\NN\13576355 increment_7\NN\29677 in_8\IN\13603305 <e1>clarithromycin</e1>_9\NN\1740 ._10\.\1740
D017291_D012206 CID this_0\DT\1740 particular_1\JJ\1740 case_2\NN\7283608 is_3\VBZ\836236 of_4\IN\1740 interest_5\NN\5682570 as_6\IN\14622893 <e2>rhabdomyolysis</e2>_7\NN\1740 only_8\RB\1740 occurred_9\VBD\2623529 after_10\IN\1740 an_11\DT\6697703 increase_12\NN\13576355 in_13\IN\13603305 the_14\DT\1740 dose_15\NN\3740161 of_16\IN\1740 <e1>clarithromycin</e1>_17\NN\1740 ._18\.\1740
11835460
D007980_D015835 CID <e1>levodopa-induced</e1>_0\JJ\1740 <e2>ocular_1\JJ\1740 dyskinesias</e2>_2\NNS\14084880 in_3\IN\13603305 parkinson_4\NN\1740 's_5\POS\1740 disease_6\NN\14061805 ._7\.\1740
D007980_D015835 CID <e1>levodopa-induced</e1>_0\JJ\1740 <e2>ocular_1\JJ\1740 dyskinesias</e2>_2\NNS\14084880 are_3\VBP\836236 very_4\RB\1740 uncommon_5\JJ\1740 ._6\.\1740
D007980_D015835 CID we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 leftward_6\NN\1740 and_7\CC\1740 upward_8\JJ\1740 deviations_9\NNS\7337390 of_10\IN\1740 gaze_11\NN\878456 during_12\IN\1740 the_13\DT\1740 peak_14\NN\13758296 effect_15\NN\34213 of_16\IN\1740 <e1>levodopa</e1>_17\NN\14604959 ,_18\,\1740 and_19\CC\1740 hypothesize_20\VB\719734 that_21\IN\1740 a_22\DT\13649268 severe_23\JJ\1740 dopaminergic_24\JJ\1740 denervation_25\NN\1740 in_26\IN\13603305 the_27\DT\1740 caudate_28\NN\5497363 nucleus_29\NN\5445668 is_30\VBZ\836236 needed_31\VBN\2604760 for_32\IN\1740 the_33\DT\1740 appearance_34\NN\4723816 of_35\IN\1740 these_36\DT\1740 levodopa-induce_37\JJ\1740 <e2>ocular_38\JJ\1740 dyskinesias</e2>_39\NNS\14084880 ._40\.\1740
D007980_D015835 CID we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 leftward_6\NN\1740 and_7\CC\1740 upward_8\JJ\1740 deviations_9\NNS\7337390 of_10\IN\1740 gaze_11\NN\878456 during_12\IN\1740 the_13\DT\1740 peak_14\NN\13758296 effect_15\NN\34213 of_16\IN\1740 levodopa_17\NN\14604959 ,_18\,\1740 and_19\CC\1740 hypothesize_20\VB\719734 that_21\IN\1740 a_22\DT\13649268 severe_23\JJ\1740 dopaminergic_24\JJ\1740 denervation_25\NN\1740 in_26\IN\13603305 the_27\DT\1740 caudate_28\NN\5497363 nucleus_29\NN\5445668 is_30\VBZ\836236 needed_31\VBN\2604760 for_32\IN\1740 the_33\DT\1740 appearance_34\NN\4723816 of_35\IN\1740 these_36\DT\1740 <e1>levodopa-induce</e1>_37\JJ\1740 <e2>ocular_38\JJ\1740 dyskinesias</e2>_39\NNS\14084880 ._40\.\1740
D007980_D010300 NONE <e1>levodopa-induced</e1>_0\JJ\1740 ocular_1\JJ\1740 dyskinesias_2\NNS\14084880 in_3\IN\13603305 <e2>parkinson_4\NN\1740 's_5\POS\1740 disease</e2>_6\NN\14061805 ._7\.\1740
9759693
D018170_D017091 CID <e2>ischemic_0\JJ\1740 colitis</e2>_1\NN\14336539 and_2\CC\1740 <e1>sumatriptan</e1>_3\JJ\1740 use_4\NN\407535 ._5\.\1740
D018170_D017091 CID we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 8_6\CD\13741022 serious_7\JJ\1740 cases_8\NNS\7283608 of_9\IN\1740 <e2>ischemic_10\JJ\1740 colitis</e2>_11\NN\14336539 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 migraine_15\NN\14326607 treated_16\VBN\2376958 with_17\IN\1740 <e1>sumatriptan</e1>_18\NN\1740 ._19\.\1740
D018170_D003329 NONE cases_0\NNS\7283608 have_1\VBP\2108377 been_2\VBN\836236 published_3\VBN\1621555 of_4\IN\1740 <e2>coronary_5\JJ\1740 vasospasm</e2>_6\NN\1740 ,_7\,\1740 myocardial_8\JJ\1740 ischemia_9\NN\14195315 ,_10\,\1740 and_11\CC\1740 myocardial_12\JJ\1740 infarction_13\NN\14204950 occurring_14\VBG\2623529 after_15\IN\1740 <e1>sumatriptan</e1>_16\JJ\1740 use_17\NN\407535 ._18\.\1740
D018170_D017202 NONE cases_0\NNS\7283608 have_1\VBP\2108377 been_2\VBN\836236 published_3\VBN\1621555 of_4\IN\1740 coronary_5\JJ\1740 vasospasm_6\NN\1740 ,_7\,\1740 <e2>myocardial_8\JJ\1740 ischemia</e2>_9\NN\14195315 ,_10\,\1740 and_11\CC\1740 myocardial_12\JJ\1740 infarction_13\NN\14204950 occurring_14\VBG\2623529 after_15\IN\1740 <e1>sumatriptan</e1>_16\JJ\1740 use_17\NN\407535 ._18\.\1740
D018170_D009203 NONE cases_0\NNS\7283608 have_1\VBP\2108377 been_2\VBN\836236 published_3\VBN\1621555 of_4\IN\1740 coronary_5\JJ\1740 vasospasm_6\NN\1740 ,_7\,\1740 myocardial_8\JJ\1740 ischemia_9\NN\14195315 ,_10\,\1740 and_11\CC\1740 <e2>myocardial_12\JJ\1740 infarction</e2>_13\NN\14204950 occurring_14\VBG\2623529 after_15\IN\1740 <e1>sumatriptan</e1>_16\JJ\1740 use_17\NN\407535 ._18\.\1740
D018170_D008881 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 8_6\CD\13741022 serious_7\JJ\1740 cases_8\NNS\7283608 of_9\IN\1740 ischemic_10\JJ\1740 colitis_11\NN\14336539 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>migraine</e2>_15\NN\14326607 treated_16\VBN\2376958 with_17\IN\1740 <e1>sumatriptan</e1>_18\NN\1740 ._19\.\1740
9382023
D004280_D006973 CID <e2>hypertensive</e2>_0\JJ\1740 response_1\NN\11410625 during_2\IN\1740 <e1>dobutamine</e1>_3\NN\1740 stress_4\NN\7083732 echocardiography_5\NN\177127 ._6\.\1740
D004280_D006973 CID among_0\IN\1740 3,129_1\CD\1740 <e1>dobutamine</e1>_2\NN\1740 stress_3\NN\7083732 echocardiographic_4\JJ\1740 studies_5\NNS\635850 ,_6\,\1740 a_7\DT\13649268 <e2>hypertensive</e2>_8\JJ\1740 response_9\NN\11410625 ,_10\,\1740 defined_11\VBN\2604760 as_12\IN\14622893 systolic_13\JJ\1740 blood_14\NN\5397468 pressure_15\NN\11419404 (_16\-LRB-\1740 bp_17\NN\1740 )_18\-RRB-\1740 >_19\NN\1740 or_20\CC\3541091 =_21\JJ\1740 220_22\CD\1740 mm_23\NN\13649268 hg_24\NN\14625458 and/or_25\CC\1740 diastolic_26\JJ\1740 bp_27\NN\1740 >_28\NN\1740 or_29\CC\3541091 =_30\JJ\1740 110_31\CD\1740 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 occurred_35\VBD\2623529 in_36\IN\13603305 30_37\CD\13745420 patients_38\NNS\9898892 (_39\-LRB-\1740 1_40\CD\13741022 %_41\NN\1740 )_42\-RRB-\1740 ._43\.\1740
D004280_D006973 CID patients_0\NNS\9898892 with_1\IN\1740 this_2\DT\1740 response_3\NN\11410625 more_4\RBR\1740 often_5\RB\1740 had_6\VBD\2108377 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 <e2>hypertension</e2>_10\NN\14057371 and_11\CC\1740 had_12\VBD\2108377 higher_13\JJR\1740 resting_14\VBG\2604760 systolic_15\NN\1740 and_16\CC\1740 diastolic_17\JJ\1740 bp_18\NN\1740 before_19\IN\1740 <e1>dobutamine</e1>_20\NN\1740 infusion_21\NN\14589223 ._22\.\1740
9125676
D013015_-1 NONE efficacy_0\NNP\5199286 and_1\CC\1740 <e2>proarrhythmia</e2>_2\VB\1740 with_3\IN\1740 the_4\DT\1740 use_5\NN\407535 of_6\IN\1740 <e1>d_7\NN\15089472 ,_8\,\1740 l-sotalol</e1>_9\NN\1740 for_10\IN\1740 sustained_11\JJ\1740 ventricular_12\JJ\1740 tachyarrhythmias_13\NNS\1740 ._14\.\1740
D013015_D017180 NONE efficacy_0\NNP\5199286 and_1\CC\1740 proarrhythmia_2\VB\1740 with_3\IN\1740 the_4\DT\1740 use_5\NN\407535 of_6\IN\1740 <e1>d_7\NN\15089472 ,_8\,\1740 l-sotalol</e1>_9\NN\1740 for_10\IN\1740 sustained_11\JJ\1740 <e2>ventricular_12\JJ\1740 tachyarrhythmias</e2>_13\NNS\1740 ._14\.\1740
D013015_D017180 NONE this_0\DT\1740 study_1\NN\635850 prospectively_2\RB\1740 evaluated_3\VBD\670261 the_4\DT\1740 clinical_5\JJ\1740 efficacy_6\NN\5199286 ,_7\,\1740 the_8\DT\1740 incidence_9\NN\13821570 of_10\IN\1740 torsades_11\NNS\1740 de_12\IN\1740 pointes_13\NNS\1740 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 presumable_17\JJ\1740 risk_18\NN\14541044 factors_19\NNS\7326557 for_20\IN\1740 torsades_21\NNS\1740 de_22\IN\1740 pointes_23\NNS\1740 in_24\IN\13603305 patients_25\NNS\9898892 treated_26\VBN\2376958 with_27\IN\1740 <e1>d_28\NN\15089472 ,_29\,\1740 l-sotalol</e1>_30\NN\1740 for_31\IN\1740 sustained_32\JJ\1740 <e2>ventricular_33\JJ\1740 tachyarrhythmias</e2>_34\NNS\1740 ._35\.\1740
D013015_D017180 NONE eighty-one_0\CD\1740 consecutive_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 54_4\CD\1740 with_5\IN\1740 coronary_6\JJ\1740 artery_7\NN\5417975 disease_8\NN\14061805 ,_9\,\1740 and_10\CC\1740 20_11\CD\13745420 with_12\IN\1740 dilated_13\VBN\303465 cardiomyopathy_14\JJ\1740 )_15\-RRB-\1740 with_16\IN\1740 inducible_17\JJ\1740 sustained_18\JJ\1740 <e2>ventricular_19\JJ\1740 tachycardia</e2>_20\NN\14110674 or_21\CC\3541091 ventricular_22\JJ\1740 fibrillation_23\NN\14361664 received_24\VBD\2210855 oral_25\JJ\1740 <e1>d_26\NN\15089472 ,_27\,\1740 l-sotalol</e1>_28\NN\1740 to_29\TO\1740 prevent_30\VB\1740 induction_31\NN\7450842 of_32\IN\1740 the_33\DT\1740 ventricular_34\JJ\1740 tachyarrhythmia_35\NN\1740 ._36\.\1740
D013015_D017180 NONE eighty-one_0\CD\1740 consecutive_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 54_4\CD\1740 with_5\IN\1740 coronary_6\JJ\1740 artery_7\NN\5417975 disease_8\NN\14061805 ,_9\,\1740 and_10\CC\1740 20_11\CD\13745420 with_12\IN\1740 dilated_13\VBN\303465 cardiomyopathy_14\JJ\1740 )_15\-RRB-\1740 with_16\IN\1740 inducible_17\JJ\1740 sustained_18\JJ\1740 ventricular_19\JJ\1740 tachycardia_20\NN\14110674 or_21\CC\3541091 ventricular_22\JJ\1740 fibrillation_23\NN\14361664 received_24\VBD\2210855 oral_25\JJ\1740 <e1>d_26\NN\15089472 ,_27\,\1740 l-sotalol</e1>_28\NN\1740 to_29\TO\1740 prevent_30\VB\1740 induction_31\NN\7450842 of_32\IN\1740 the_33\DT\1740 <e2>ventricular_34\JJ\1740 tachyarrhythmia</e2>_35\NN\1740 ._36\.\1740
D013015_D017180 NONE those_0\DT\1740 patients_1\NNS\9898892 in_2\IN\13603305 whom_3\WP\1740 <e1>d_4\NN\15089472 ,_5\,\1740 l-sotalol</e1>_6\NN\1740 prevented_7\VBD\1740 induction_8\NN\7450842 of_9\IN\1740 <e2>ventricular_10\JJ\1740 tachycardia</e2>_11\NN\14110674 or_12\CC\3541091 ventricular_13\JJ\1740 fibrillation_14\NN\14361664 were_15\VBD\836236 discharged_16\VBN\1640855 with_17\IN\1740 the_18\DT\1740 drug_19\NN\14778436 and_20\CC\1740 followed_21\VBD\1835496 up_22\RP\1740 on_23\IN\1740 an_24\DT\6697703 outpatient_25\JJ\1740 basis_26\NN\13790712 for_27\IN\1740 21_28\CD\13745420 +/-_29\CC\1740 18_30\CD\13745420 months_31\NNS\15113229 ._32\.\1740
D013015_D017180 NONE induction_0\NN\7450842 of_1\IN\1740 the_2\DT\1740 <e2>ventricular_3\NN\1740 tachyarrhythmia</e2>_4\NN\1740 was_5\VBD\836236 prevented_6\VBN\1740 by_7\IN\1740 oral_8\JJ\1740 <e1>d_9\NN\15089472 ,_10\,\1740 l-sotalol</e1>_11\NN\1740 in_12\IN\13603305 35_13\CD\1740 (_14\-LRB-\1740 43_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 patients_18\NNS\9898892 ;_19\:\1740 the_20\DT\1740 ventricular_21\JJ\1740 tachyarrhythmia_22\NN\1740 remained_23\VBD\2604760 inducible_24\JJ\1740 in_25\IN\13603305 40_26\CD\13745420 (_27\-LRB-\1740 49_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 patients_31\NNS\9898892 ;_32\:\1740 and_33\CC\1740 two_34\CD\13741022 (_35\-LRB-\1740 2.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 patients_39\NNS\9898892 did_40\VBD\1640855 not_41\RB\1740 tolerate_42\VB\802318 even_43\RB\1740 40_44\CD\13745420 mg_45\NN\13717155 of_46\IN\1740 d_47\NN\15089472 ,_48\,\1740 l-sotalol_49\NN\1740 once_50\RB\1740 daily_51\RB\1740 ._52\.\1740
D013015_D017180 NONE induction_0\NN\7450842 of_1\IN\1740 the_2\DT\1740 ventricular_3\NN\1740 tachyarrhythmia_4\NN\1740 was_5\VBD\836236 prevented_6\VBN\1740 by_7\IN\1740 oral_8\JJ\1740 <e1>d_9\NN\15089472 ,_10\,\1740 l-sotalol</e1>_11\NN\1740 in_12\IN\13603305 35_13\CD\1740 (_14\-LRB-\1740 43_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 patients_18\NNS\9898892 ;_19\:\1740 the_20\DT\1740 <e2>ventricular_21\JJ\1740 tachyarrhythmia</e2>_22\NN\1740 remained_23\VBD\2604760 inducible_24\JJ\1740 in_25\IN\13603305 40_26\CD\13745420 (_27\-LRB-\1740 49_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 patients_31\NNS\9898892 ;_32\:\1740 and_33\CC\1740 two_34\CD\13741022 (_35\-LRB-\1740 2.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 patients_39\NNS\9898892 did_40\VBD\1640855 not_41\RB\1740 tolerate_42\VB\802318 even_43\RB\1740 40_44\CD\13745420 mg_45\NN\13717155 of_46\IN\1740 d_47\NN\15089472 ,_48\,\1740 l-sotalol_49\NN\1740 once_50\RB\1740 daily_51\RB\1740 ._52\.\1740
D013015_D017180 NONE induction_0\NN\7450842 of_1\IN\1740 the_2\DT\1740 <e2>ventricular_3\NN\1740 tachyarrhythmia</e2>_4\NN\1740 was_5\VBD\836236 prevented_6\VBN\1740 by_7\IN\1740 oral_8\JJ\1740 d_9\NN\15089472 ,_10\,\1740 l-sotalol_11\NN\1740 in_12\IN\13603305 35_13\CD\1740 (_14\-LRB-\1740 43_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 patients_18\NNS\9898892 ;_19\:\1740 the_20\DT\1740 ventricular_21\JJ\1740 tachyarrhythmia_22\NN\1740 remained_23\VBD\2604760 inducible_24\JJ\1740 in_25\IN\13603305 40_26\CD\13745420 (_27\-LRB-\1740 49_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 patients_31\NNS\9898892 ;_32\:\1740 and_33\CC\1740 two_34\CD\13741022 (_35\-LRB-\1740 2.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 patients_39\NNS\9898892 did_40\VBD\1640855 not_41\RB\1740 tolerate_42\VB\802318 even_43\RB\1740 40_44\CD\13745420 mg_45\NN\13717155 of_46\IN\1740 <e1>d_47\NN\15089472 ,_48\,\1740 l-sotalol</e1>_49\NN\1740 once_50\RB\1740 daily_51\RB\1740 ._52\.\1740
D013015_D017180 NONE induction_0\NN\7450842 of_1\IN\1740 the_2\DT\1740 ventricular_3\NN\1740 tachyarrhythmia_4\NN\1740 was_5\VBD\836236 prevented_6\VBN\1740 by_7\IN\1740 oral_8\JJ\1740 d_9\NN\15089472 ,_10\,\1740 l-sotalol_11\NN\1740 in_12\IN\13603305 35_13\CD\1740 (_14\-LRB-\1740 43_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 patients_18\NNS\9898892 ;_19\:\1740 the_20\DT\1740 <e2>ventricular_21\JJ\1740 tachyarrhythmia</e2>_22\NN\1740 remained_23\VBD\2604760 inducible_24\JJ\1740 in_25\IN\13603305 40_26\CD\13745420 (_27\-LRB-\1740 49_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 patients_31\NNS\9898892 ;_32\:\1740 and_33\CC\1740 two_34\CD\13741022 (_35\-LRB-\1740 2.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 patients_39\NNS\9898892 did_40\VBD\1640855 not_41\RB\1740 tolerate_42\VB\802318 even_43\RB\1740 40_44\CD\13745420 mg_45\NN\13717155 of_46\IN\1740 <e1>d_47\NN\15089472 ,_48\,\1740 l-sotalol</e1>_49\NN\1740 once_50\RB\1740 daily_51\RB\1740 ._52\.\1740
D013015_D016171 CID this_0\DT\1740 study_1\NN\635850 prospectively_2\RB\1740 evaluated_3\VBD\670261 the_4\DT\1740 clinical_5\JJ\1740 efficacy_6\NN\5199286 ,_7\,\1740 the_8\DT\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>torsades_11\NNS\1740 de_12\IN\1740 pointes</e2>_13\NNS\1740 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 presumable_17\JJ\1740 risk_18\NN\14541044 factors_19\NNS\7326557 for_20\IN\1740 torsades_21\NNS\1740 de_22\IN\1740 pointes_23\NNS\1740 in_24\IN\13603305 patients_25\NNS\9898892 treated_26\VBN\2376958 with_27\IN\1740 <e1>d_28\NN\15089472 ,_29\,\1740 l-sotalol</e1>_30\NN\1740 for_31\IN\1740 sustained_32\JJ\1740 ventricular_33\JJ\1740 tachyarrhythmias_34\NNS\1740 ._35\.\1740
D013015_D016171 CID this_0\DT\1740 study_1\NN\635850 prospectively_2\RB\1740 evaluated_3\VBD\670261 the_4\DT\1740 clinical_5\JJ\1740 efficacy_6\NN\5199286 ,_7\,\1740 the_8\DT\1740 incidence_9\NN\13821570 of_10\IN\1740 torsades_11\NNS\1740 de_12\IN\1740 pointes_13\NNS\1740 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 presumable_17\JJ\1740 risk_18\NN\14541044 factors_19\NNS\7326557 for_20\IN\1740 <e2>torsades_21\NNS\1740 de_22\IN\1740 pointes</e2>_23\NNS\1740 in_24\IN\13603305 patients_25\NNS\9898892 treated_26\VBN\2376958 with_27\IN\1740 <e1>d_28\NN\15089472 ,_29\,\1740 l-sotalol</e1>_30\NN\1740 for_31\IN\1740 sustained_32\JJ\1740 ventricular_33\JJ\1740 tachyarrhythmias_34\NNS\1740 ._35\.\1740
D013015_D016171 CID four_0\CD\13741022 (_1\-LRB-\1740 5_2\CD\13741022 %_3\NN\1740 )_4\-RRB-\1740 patients_5\NNS\9898892 had_6\VBD\2108377 from_7\IN\1740 <e2>torsades_8\NNS\1740 de_9\IN\1740 pointes</e2>_10\NNS\1740 during_11\IN\1740 the_12\DT\1740 initial_13\JJ\1740 oral_14\JJ\1740 treatment_15\NN\654885 with_16\IN\1740 <e1>d_17\NN\15089472 ,_18\,\1740 l-sotalol</e1>_19\NN\1740 ._20\.\1740
D013015_D016171 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 oral_3\JJ\1740 dose_4\NN\3740161 of_5\IN\1740 <e1>d_6\NN\15089472 ,_7\,\1740 l-sotalol</e1>_8\NN\1740 was_9\VBD\836236 significantly_10\RB\1740 lower_11\JJR\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>torsades_15\NNS\1740 de_16\IN\1740 pointes</e2>_17\NNS\1740 (_18\-LRB-\1740 200_19\CD\1740 +/-_20\CC\1740 46_21\CD\1740 vs._22\CC\1740 328_23\CD\1740 +/-_24\CC\1740 53_25\CD\1740 mg/day_26\NN\1740 ;_27\:\1740 p_28\NN\14622893 =_29\JJ\1740 0.0017_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D013015_D016171 CID one_0\CD\13741022 female_1\JJ\1740 patient_2\NN\9898892 with_3\IN\1740 stable_4\JJ\1740 cardiac_5\JJ\1740 disease_6\NN\14061805 had_7\VBD\2108377 recurrent_8\JJ\1740 <e2>torsades_9\NNS\1740 de_10\IN\1740 pointes</e2>_11\NNS\1740 after_12\IN\1740 2_13\CD\13741022 years_14\NNS\15144371 of_15\IN\1740 successful_16\JJ\1740 treatment_17\NN\654885 with_18\IN\1740 <e1>d_19\NN\15089472 ,_20\,\1740 l-sotalol</e1>_21\NN\1740 ._22\.\1740
D013015_D016171 CID <e2>torsades_0\NNS\1740 de_1\IN\1740 pointes</e2>_2\NNS\1740 occurred_3\VBD\2623529 early_4\JJ\1740 during_5\IN\1740 treatment_6\NN\654885 even_7\RB\1740 with_8\IN\1740 low_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 oral_12\JJ\1740 <e1>d_13\NN\15089472 ,_14\,\1740 l-sotalol</e1>_15\NN\1740 ._16\.\1740
D013015_D016171 CID pronounced_0\JJ\1740 changes_1\NNS\7283608 in_2\IN\13603305 the_3\DT\1740 surface_4\NN\21939 ecg_5\NN\7000195 (_6\-LRB-\1740 cycle_7\NN\15269513 length_8\NN\5093581 ,_9\,\1740 qt_10\NN\1740 ,_11\,\1740 and_12\CC\1740 qtc_13\NNS\1740 )_14\-RRB-\1740 in_15\IN\13603305 relation_16\NN\2137 to_17\TO\1740 the_18\DT\1740 dose_19\NN\3740161 of_20\IN\1740 oral_21\JJ\1740 <e1>d_22\NN\15089472 ,_23\,\1740 l-sotalol</e1>_24\NN\1740 might_25\MD\5029706 identify_26\VB\699815 a_27\DT\13649268 subgroup_28\NN\31264 of_29\IN\1740 patients_30\NNS\9898892 with_31\IN\1740 an_32\DT\6697703 increased_33\VBN\169651 risk_34\NN\14541044 for_35\IN\1740 <e2>torsades_36\NNS\1740 de_37\IN\1740 pointes</e2>_38\NNS\1740 ._39\.\1740
D013015_D016171 CID other_0\JJ\1740 ecg_1\NN\7000195 parameters_2\NNS\5858936 before_3\IN\1740 the_4\DT\1740 application_5\NN\947128 of_6\IN\1740 <e1>d_7\NN\15089472 ,_8\,\1740 l-sotalol</e1>_9\NN\1740 did_10\VBD\1640855 not_11\RB\1740 identify_12\VB\699815 patients_13\NNS\9898892 at_14\IN\14622893 increased_15\VBN\169651 risk_16\NN\14541044 for_17\IN\1740 <e2>torsades_18\NNS\1740 de_19\IN\1740 pointes</e2>_20\NNS\1740 ._21\.\1740
D013015_D003324 NONE eighty-one_0\CD\1740 consecutive_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 54_4\CD\1740 with_5\IN\1740 <e2>coronary_6\JJ\1740 artery_7\NN\5417975 disease</e2>_8\NN\14061805 ,_9\,\1740 and_10\CC\1740 20_11\CD\13745420 with_12\IN\1740 dilated_13\VBN\303465 cardiomyopathy_14\JJ\1740 )_15\-RRB-\1740 with_16\IN\1740 inducible_17\JJ\1740 sustained_18\JJ\1740 ventricular_19\JJ\1740 tachycardia_20\NN\14110674 or_21\CC\3541091 ventricular_22\JJ\1740 fibrillation_23\NN\14361664 received_24\VBD\2210855 oral_25\JJ\1740 <e1>d_26\NN\15089472 ,_27\,\1740 l-sotalol</e1>_28\NN\1740 to_29\TO\1740 prevent_30\VB\1740 induction_31\NN\7450842 of_32\IN\1740 the_33\DT\1740 ventricular_34\JJ\1740 tachyarrhythmia_35\NN\1740 ._36\.\1740
D013015_D002311 NONE eighty-one_0\CD\1740 consecutive_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 54_4\CD\1740 with_5\IN\1740 coronary_6\JJ\1740 artery_7\NN\5417975 disease_8\NN\14061805 ,_9\,\1740 and_10\CC\1740 20_11\CD\13745420 with_12\IN\1740 <e2>dilated_13\VBN\303465 cardiomyopathy</e2>_14\JJ\1740 )_15\-RRB-\1740 with_16\IN\1740 inducible_17\JJ\1740 sustained_18\JJ\1740 ventricular_19\JJ\1740 tachycardia_20\NN\14110674 or_21\CC\3541091 ventricular_22\JJ\1740 fibrillation_23\NN\14361664 received_24\VBD\2210855 oral_25\JJ\1740 <e1>d_26\NN\15089472 ,_27\,\1740 l-sotalol</e1>_28\NN\1740 to_29\TO\1740 prevent_30\VB\1740 induction_31\NN\7450842 of_32\IN\1740 the_33\DT\1740 ventricular_34\JJ\1740 tachyarrhythmia_35\NN\1740 ._36\.\1740
D013015_D014693 NONE eighty-one_0\CD\1740 consecutive_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 54_4\CD\1740 with_5\IN\1740 coronary_6\JJ\1740 artery_7\NN\5417975 disease_8\NN\14061805 ,_9\,\1740 and_10\CC\1740 20_11\CD\13745420 with_12\IN\1740 dilated_13\VBN\303465 cardiomyopathy_14\JJ\1740 )_15\-RRB-\1740 with_16\IN\1740 inducible_17\JJ\1740 sustained_18\JJ\1740 ventricular_19\JJ\1740 tachycardia_20\NN\14110674 or_21\CC\3541091 <e2>ventricular_22\JJ\1740 fibrillation</e2>_23\NN\14361664 received_24\VBD\2210855 oral_25\JJ\1740 <e1>d_26\NN\15089472 ,_27\,\1740 l-sotalol</e1>_28\NN\1740 to_29\TO\1740 prevent_30\VB\1740 induction_31\NN\7450842 of_32\IN\1740 the_33\DT\1740 ventricular_34\JJ\1740 tachyarrhythmia_35\NN\1740 ._36\.\1740
D013015_D014693 NONE those_0\DT\1740 patients_1\NNS\9898892 in_2\IN\13603305 whom_3\WP\1740 <e1>d_4\NN\15089472 ,_5\,\1740 l-sotalol</e1>_6\NN\1740 prevented_7\VBD\1740 induction_8\NN\7450842 of_9\IN\1740 ventricular_10\JJ\1740 tachycardia_11\NN\14110674 or_12\CC\3541091 <e2>ventricular_13\JJ\1740 fibrillation</e2>_14\NN\14361664 were_15\VBD\836236 discharged_16\VBN\1640855 with_17\IN\1740 the_18\DT\1740 drug_19\NN\14778436 and_20\CC\1740 followed_21\VBD\1835496 up_22\RP\1740 on_23\IN\1740 an_24\DT\6697703 outpatient_25\JJ\1740 basis_26\NN\13790712 for_27\IN\1740 21_28\CD\13745420 +/-_29\CC\1740 18_30\CD\13745420 months_31\NNS\15113229 ._32\.\1740
D013015_D006331 NONE one_0\CD\13741022 female_1\JJ\1740 patient_2\NN\9898892 with_3\IN\1740 stable_4\JJ\1740 <e2>cardiac_5\JJ\1740 disease</e2>_6\NN\14061805 had_7\VBD\2108377 recurrent_8\JJ\1740 torsades_9\NNS\1740 de_10\IN\1740 pointes_11\NNS\1740 after_12\IN\1740 2_13\CD\13741022 years_14\NNS\15144371 of_15\IN\1740 successful_16\JJ\1740 treatment_17\NN\654885 with_18\IN\1740 <e1>d_19\NN\15089472 ,_20\,\1740 l-sotalol</e1>_21\NN\1740 ._22\.\1740
1735570
D014294_D007022 CID the_0\DT\1740 <e1>trimethaphan-induced</e1>_1\JJ\1740 <e2>hypotension</e2>_2\NN\14057371 was_3\VBD\836236 accompanied_4\VBN\1835496 by_5\IN\1740 a_6\DT\13649268 significant_7\JJ\1740 bradycardia_8\NN\14110674 in_9\IN\13603305 lesioned_10\JJ\1740 rats_11\NNS\2329401 (_12\-LRB-\1740 -32_13\CD\1740 +/-_14\CC\1740 13_15\CD\13745420 beats_16\NNS\8289449 per_17\IN\1740 minute_18\NN\15154774 )_19\-RRB-\1740 but_20\CC\1740 a_21\DT\13649268 tachycardia_22\NN\14110674 in_23\IN\13603305 sham_24\NN\3562126 rats_25\NNS\2329401 (_26\-LRB-\1740 +_27\CC\1740 33_28\CD\1740 +/-_29\CC\1740 12_30\CD\13745420 beats_31\NNS\8289449 per_32\IN\1740 minute_33\NN\15154774 )_34\-RRB-\1740 1_35\CD\13741022 day_36\NN\15154774 postlesion_37\NN\1740 ._38\.\1740
D014294_D001919 NONE the_0\DT\1740 <e1>trimethaphan-induced</e1>_1\JJ\1740 hypotension_2\NN\14057371 was_3\VBD\836236 accompanied_4\VBN\1835496 by_5\IN\1740 a_6\DT\13649268 significant_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 in_9\IN\13603305 lesioned_10\JJ\1740 rats_11\NNS\2329401 (_12\-LRB-\1740 -32_13\CD\1740 +/-_14\CC\1740 13_15\CD\13745420 beats_16\NNS\8289449 per_17\IN\1740 minute_18\NN\15154774 )_19\-RRB-\1740 but_20\CC\1740 a_21\DT\13649268 tachycardia_22\NN\14110674 in_23\IN\13603305 sham_24\NN\3562126 rats_25\NNS\2329401 (_26\-LRB-\1740 +_27\CC\1740 33_28\CD\1740 +/-_29\CC\1740 12_30\CD\13745420 beats_31\NNS\8289449 per_32\IN\1740 minute_33\NN\15154774 )_34\-RRB-\1740 1_35\CD\13741022 day_36\NN\15154774 postlesion_37\NN\1740 ._38\.\1740
D014294_D013610 CID the_0\DT\1740 <e1>trimethaphan-induced</e1>_1\JJ\1740 hypotension_2\NN\14057371 was_3\VBD\836236 accompanied_4\VBN\1835496 by_5\IN\1740 a_6\DT\13649268 significant_7\JJ\1740 bradycardia_8\NN\14110674 in_9\IN\13603305 lesioned_10\JJ\1740 rats_11\NNS\2329401 (_12\-LRB-\1740 -32_13\CD\1740 +/-_14\CC\1740 13_15\CD\13745420 beats_16\NNS\8289449 per_17\IN\1740 minute_18\NN\15154774 )_19\-RRB-\1740 but_20\CC\1740 a_21\DT\13649268 <e2>tachycardia</e2>_22\NN\14110674 in_23\IN\13603305 sham_24\NN\3562126 rats_25\NNS\2329401 (_26\-LRB-\1740 +_27\CC\1740 33_28\CD\1740 +/-_29\CC\1740 12_30\CD\13745420 beats_31\NNS\8289449 per_32\IN\1740 minute_33\NN\15154774 )_34\-RRB-\1740 1_35\CD\13741022 day_36\NN\15154774 postlesion_37\NN\1740 ._38\.\1740
20169779
D015632_D010302 NONE neuropsychiatric_0\JJ\1740 behaviors_1\NNS\407535 in_2\IN\13603305 the_3\DT\1740 <e1>mptp</e1>_4\NN\1740 marmoset_5\NN\2489589 model_6\NN\5888929 of_7\IN\1740 <e2>parkinson_8\NN\1740 's_9\POS\1740 disease</e2>_10\NN\14061805 ._11\.\1740
D015632_D010302 NONE the_0\DT\1740 levodopa-treated_1\JJ\1740 <e1>mptp-lesioned</e1>_2\JJ\1740 marmoset_3\NN\2489589 was_4\VBD\836236 used_5\VBN\1156834 as_6\IN\14622893 a_7\DT\13649268 model_8\NN\5888929 of_9\IN\1740 neuropsychiatric_10\JJ\1740 symptoms_11\NNS\5823932 in_12\IN\13603305 <e2>pd</e2>_13\NN\14625458 patients_14\NNS\9898892 ._15\.\1740
D015632_D010302 NONE methods_0\NNS\5616786 :_1\:\1740 marmosets_2\NNS\2489589 were_3\VBD\836236 administered_4\VBN\2436349 <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>_5\CD\1740 (_6\-LRB-\1740 2.0_7\CD\1740 mg/kg_8\NN\1740 s.c._9\NN\1740 )_10\-RRB-\1740 for_11\IN\1740 five_12\CD\13741022 days_13\NNS\15140892 ,_14\,\1740 resulting_15\VBG\2633881 in_16\IN\13603305 stable_17\JJ\1740 <e2>parkinsonism</e2>_18\NN\14085708 ._19\.\1740
D007980_D001523 NONE the_0\DT\1740 <e1>levodopa-treated</e1>_1\JJ\1740 mptp-lesioned_2\JJ\1740 marmoset_3\NN\2489589 was_4\VBD\836236 used_5\VBN\1156834 as_6\IN\14622893 a_7\DT\13649268 model_8\NN\5888929 of_9\IN\1740 <e2>neuropsychiatric_10\JJ\1740 symptoms</e2>_11\NNS\5823932 in_12\IN\13603305 pd_13\NN\14625458 patients_14\NNS\9898892 ._15\.\1740
D007980_D001523 NONE here_0\RB\1740 we_1\PRP\1740 compare_2\VBP\644583 the_3\DT\1740 time_4\NN\7308889 course_5\NN\883297 of_6\IN\1740 <e1>levodopa-induced</e1>_7\JJ\1740 motor_8\NN\3699975 fluctuations_9\NNS\7345593 and_10\CC\1740 <e2>neuropsychiatric-like_11\JJ\1740 behaviors</e2>_12\NNS\407535 to_13\TO\1740 determine_14\VB\1645601 the_15\DT\1740 relationship_16\NN\31921 between_17\IN\1740 duration_18\NN\15113229 of_19\IN\1740 treatment_20\NN\654885 and_21\CC\1740 onset_22\NN\7325190 of_23\IN\1740 symptoms_24\NNS\5823932 ._25\.\1740
D007980_D001523 NONE animals_0\NNS\4475 were_1\VBD\836236 evaluated_2\VBN\670261 for_3\IN\1740 parkinsonian_4\JJ\1740 disability_5\NN\14547369 ,_6\,\1740 dyskinesia_7\NN\14084880 and_8\CC\1740 on-time_9\NN\1740 (_10\-LRB-\1740 motor_11\NN\3699975 fluctuations_12\NNS\7345593 )_13\-RRB-\1740 and_14\CC\1740 <e2>neuropsychiatric-like_15\JJ\1740 behaviors</e2>_16\NNS\407535 on_17\IN\1740 day_18\NN\15154774 0_19\CD\13741022 (_20\-LRB-\1740 prior_21\JJ\1740 to_22\TO\1740 <e1>levodopa</e1>_23\NN\14604959 )_24\-RRB-\1740 and_25\CC\1740 on_26\IN\1740 days_27\NNS\15140892 1_28\CD\13741022 ,_29\,\1740 7_30\CD\13741022 ,_31\,\1740 13_32\CD\13745420 ,_33\,\1740 27_34\CD\13745420 and_35\CC\1740 30_36\CD\13745420 of_37\IN\1740 treatment_38\NN\654885 using_39\VBG\1156834 post_40\NN\8621598 hoc_41\NN\1740 dvd_42\NN\3851787 analysis_43\NN\633864 by_44\IN\1740 a_45\DT\13649268 trained_46\VBN\829107 rater_47\NN\1740 ,_48\,\1740 blind_49\JJ\1740 to_50\IN\1740 the_51\DT\1740 treatment_52\NN\654885 day_53\NN\15154774 ._54\.\1740
D007980_D001523 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>levodopa-induced</e1>_3\JJ\1740 <e2>neuropsychiatric-like_4\JJ\1740 behaviors</e2>_5\NNS\407535 were_6\VBD\836236 present_7\JJ\1740 on_8\IN\1740 day_9\NN\15154774 1_10\CD\13741022 of_11\IN\1740 levodopa_12\NN\14604959 treatment_13\NN\654885 and_14\CC\1740 their_15\PRP$\1740 severity_16\NN\5036394 did_17\VBD\1640855 not_18\RB\1740 correlate_19\VB\2657219 with_20\IN\1740 duration_21\NN\15113229 of_22\IN\1740 treatment_23\NN\654885 ._24\.\1740
D007980_D001523 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 levodopa-induced_3\JJ\1740 <e2>neuropsychiatric-like_4\JJ\1740 behaviors</e2>_5\NNS\407535 were_6\VBD\836236 present_7\JJ\1740 on_8\IN\1740 day_9\NN\15154774 1_10\CD\13741022 of_11\IN\1740 <e1>levodopa</e1>_12\NN\14604959 treatment_13\NN\654885 and_14\CC\1740 their_15\PRP$\1740 severity_16\NN\5036394 did_17\VBD\1640855 not_18\RB\1740 correlate_19\VB\2657219 with_20\IN\1740 duration_21\NN\15113229 of_22\IN\1740 treatment_23\NN\654885 ._24\.\1740
D007980_D001523 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 <e2>neuropsychiatric_6\JJ\1740 disorders</e2>_7\NNS\14034177 in_8\IN\13603305 pd_9\NN\14625458 are_10\VBP\836236 more_11\RBR\1740 likely_12\JJ\1740 an_13\DT\6697703 interaction_14\NN\37396 between_15\IN\1740 <e1>levodopa</e1>_16\NN\14604959 and_17\CC\1740 the_18\DT\1740 disease_19\NN\14061805 state_20\NN\8491826 than_21\IN\1740 a_22\DT\13649268 consequence_23\NN\34213 of_24\IN\1740 sensitisation_25\NN\14531772 to_26\TO\1740 repeated_27\VBN\952524 dopaminergic_28\JJ\1740 therapy_29\NN\657604 ._30\.\1740
D007980_D010302 NONE the_0\DT\1740 <e1>levodopa-treated</e1>_1\JJ\1740 mptp-lesioned_2\JJ\1740 marmoset_3\NN\2489589 was_4\VBD\836236 used_5\VBN\1156834 as_6\IN\14622893 a_7\DT\13649268 model_8\NN\5888929 of_9\IN\1740 neuropsychiatric_10\JJ\1740 symptoms_11\NNS\5823932 in_12\IN\13603305 <e2>pd</e2>_13\NN\14625458 patients_14\NNS\9898892 ._15\.\1740
D007980_D010302 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 neuropsychiatric_6\JJ\1740 disorders_7\NNS\14034177 in_8\IN\13603305 <e2>pd</e2>_9\NN\14625458 are_10\VBP\836236 more_11\RBR\1740 likely_12\JJ\1740 an_13\DT\6697703 interaction_14\NN\37396 between_15\IN\1740 <e1>levodopa</e1>_16\NN\14604959 and_17\CC\1740 the_18\DT\1740 disease_19\NN\14061805 state_20\NN\8491826 than_21\IN\1740 a_22\DT\13649268 consequence_23\NN\34213 of_24\IN\1740 sensitisation_25\NN\14531772 to_26\TO\1740 repeated_27\VBN\952524 dopaminergic_28\JJ\1740 therapy_29\NN\657604 ._30\.\1740
D015632_D001523 NONE the_0\DT\1740 levodopa-treated_1\JJ\1740 <e1>mptp-lesioned</e1>_2\JJ\1740 marmoset_3\NN\2489589 was_4\VBD\836236 used_5\VBN\1156834 as_6\IN\14622893 a_7\DT\13649268 model_8\NN\5888929 of_9\IN\1740 <e2>neuropsychiatric_10\JJ\1740 symptoms</e2>_11\NNS\5823932 in_12\IN\13603305 pd_13\NN\14625458 patients_14\NNS\9898892 ._15\.\1740
D007980_D020734 NONE animals_0\NNS\4475 were_1\VBD\836236 evaluated_2\VBN\670261 for_3\IN\1740 <e2>parkinsonian_4\JJ\1740 disability</e2>_5\NN\14547369 ,_6\,\1740 dyskinesia_7\NN\14084880 and_8\CC\1740 on-time_9\NN\1740 (_10\-LRB-\1740 motor_11\NN\3699975 fluctuations_12\NNS\7345593 )_13\-RRB-\1740 and_14\CC\1740 neuropsychiatric-like_15\JJ\1740 behaviors_16\NNS\407535 on_17\IN\1740 day_18\NN\15154774 0_19\CD\13741022 (_20\-LRB-\1740 prior_21\JJ\1740 to_22\TO\1740 <e1>levodopa</e1>_23\NN\14604959 )_24\-RRB-\1740 and_25\CC\1740 on_26\IN\1740 days_27\NNS\15140892 1_28\CD\13741022 ,_29\,\1740 7_30\CD\13741022 ,_31\,\1740 13_32\CD\13745420 ,_33\,\1740 27_34\CD\13745420 and_35\CC\1740 30_36\CD\13745420 of_37\IN\1740 treatment_38\NN\654885 using_39\VBG\1156834 post_40\NN\8621598 hoc_41\NN\1740 dvd_42\NN\3851787 analysis_43\NN\633864 by_44\IN\1740 a_45\DT\13649268 trained_46\VBN\829107 rater_47\NN\1740 ,_48\,\1740 blind_49\JJ\1740 to_50\IN\1740 the_51\DT\1740 treatment_52\NN\654885 day_53\NN\15154774 ._54\.\1740
D007980_D004409 CID animals_0\NNS\4475 were_1\VBD\836236 evaluated_2\VBN\670261 for_3\IN\1740 parkinsonian_4\JJ\1740 disability_5\NN\14547369 ,_6\,\1740 <e2>dyskinesia</e2>_7\NN\14084880 and_8\CC\1740 on-time_9\NN\1740 (_10\-LRB-\1740 motor_11\NN\3699975 fluctuations_12\NNS\7345593 )_13\-RRB-\1740 and_14\CC\1740 neuropsychiatric-like_15\JJ\1740 behaviors_16\NNS\407535 on_17\IN\1740 day_18\NN\15154774 0_19\CD\13741022 (_20\-LRB-\1740 prior_21\JJ\1740 to_22\TO\1740 <e1>levodopa</e1>_23\NN\14604959 )_24\-RRB-\1740 and_25\CC\1740 on_26\IN\1740 days_27\NNS\15140892 1_28\CD\13741022 ,_29\,\1740 7_30\CD\13741022 ,_31\,\1740 13_32\CD\13745420 ,_33\,\1740 27_34\CD\13745420 and_35\CC\1740 30_36\CD\13745420 of_37\IN\1740 treatment_38\NN\654885 using_39\VBG\1156834 post_40\NN\8621598 hoc_41\NN\1740 dvd_42\NN\3851787 analysis_43\NN\633864 by_44\IN\1740 a_45\DT\13649268 trained_46\VBN\829107 rater_47\NN\1740 ,_48\,\1740 blind_49\JJ\1740 to_50\IN\1740 the_51\DT\1740 treatment_52\NN\654885 day_53\NN\15154774 ._54\.\1740
D007980_D004409 CID as_0\IN\14622893 anticipated_1\VBN\670261 ,_2\,\1740 animals_3\NNS\4475 exhibited_4\VBD\2632167 a_5\DT\13649268 progressive_6\JJ\1740 increase_7\NN\13576355 in_8\IN\13603305 <e1>levodopa-induced</e1>_9\JJ\1740 motor_10\NN\3699975 fluctuations_11\NNS\7345593 ,_12\,\1740 <e2>dyskinesia</e2>_13\NN\14084880 and_14\CC\1740 wearing-off_15\NN\1740 ,_16\,\1740 that_17\WDT\1740 correlated_18\VBD\2657219 with_19\IN\1740 the_20\DT\1740 duration_21\NN\15113229 of_22\IN\1740 levodopa_23\NN\14604959 therapy_24\NN\657604 ._25\.\1740
D007980_D004409 CID as_0\IN\14622893 anticipated_1\VBN\670261 ,_2\,\1740 animals_3\NNS\4475 exhibited_4\VBD\2632167 a_5\DT\13649268 progressive_6\JJ\1740 increase_7\NN\13576355 in_8\IN\13603305 levodopa-induced_9\JJ\1740 motor_10\NN\3699975 fluctuations_11\NNS\7345593 ,_12\,\1740 <e2>dyskinesia</e2>_13\NN\14084880 and_14\CC\1740 wearing-off_15\NN\1740 ,_16\,\1740 that_17\WDT\1740 correlated_18\VBD\2657219 with_19\IN\1740 the_20\DT\1740 duration_21\NN\15113229 of_22\IN\1740 <e1>levodopa</e1>_23\NN\14604959 therapy_24\NN\657604 ._25\.\1740
24641119
D007654_-1 NONE <e2>baboon_0\NNP\2484473 syndrome</e2>_1\NN\5870365 induced_2\VBN\1627355 by_3\IN\1740 <e1>ketoconazole</e1>_4\NN\1740 ._5\.\1740
D007654_-1 NONE the_0\DT\1740 patient_1\NN\9898892 was_2\VBD\836236 diagnosed_3\VBN\644583 with_4\IN\1740 drug-induced_5\JJ\1740 <e2>baboon_6\NN\2484473 syndrome</e2>_7\NN\5870365 based_8\VBN\2694933 on_9\IN\1740 his_10\PRP$\1740 history_11\NN\15120823 ,_12\,\1740 which_13\WDT\1740 included_14\VBD\690614 prior_15\JJ\1740 sensitivity_16\NN\5651971 to_17\TO\1740 topical_18\JJ\1740 <e1>ketoconazole</e1>_19\NN\1740 ,_20\,\1740 a_21\DT\13649268 physical_22\JJ\1740 examination_23\NN\633864 ,_24\,\1740 and_25\CC\1740 histopathological_26\JJ\1740 findings_27\NNS\7951464 ._28\.\1740
D007654_-1 NONE to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 ,_6\,\1740 this_7\DT\1740 is_8\VBZ\836236 the_9\DT\1740 first_10\JJ\1740 reported_11\VBN\831651 case_12\NN\7283608 of_13\IN\1740 <e1>ketoconazole-induced</e1>_14\JJ\1740 <e2>baboon_15\NN\2484473 syndrome</e2>_16\NN\5870365 in_17\IN\13603305 the_18\DT\1740 english_19\NNP\6946823 literature_20\NN\6362953 ._21\.\1740
D007654_D003875 CID a_0\DT\13649268 27-year-old_1\JJ\1740 male_2\JJ\1740 patient_3\NN\9898892 presented_4\VBN\2137132 with_5\IN\1740 a_6\DT\13649268 <e2>maculopapular_7\JJ\1740 eruption</e2>_8\NN\7307754 on_9\IN\1740 the_10\DT\1740 flexural_11\JJ\1740 areas_12\NNS\8630985 and_13\CC\1740 buttocks_14\NNS\5220461 after_15\IN\1740 using_16\VBG\1156834 oral_17\JJ\1740 <e1>ketoconazole</e1>_18\NN\1740 ._19\.\1740
24840785
D000157_D001145 CID <e1>aconitine-induced</e1>_0\JJ\1740 ca2_1\NN\1740 +_2\CC\1740 overload_3\NN\3679986 causes_4\VBZ\1617192 <e2>arrhythmia</e2>_5\NN\14103288 and_6\CC\1740 triggers_7\VBZ\1641914 apoptosis_8\NN\11486178 through_9\IN\1740 p38_10\NN\1740 mapk_11\NN\1740 signaling_12\NN\33020 pathway_13\NN\5483677 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D000157_D001145 CID hence_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 <e1>aconitine</e1>_6\NN\1740 significantly_7\RB\1740 aggravates_8\VBZ\126264 ca(2_9\NN\1740 +_10\CC\1740 )_11\-RRB-\1740 overload_12\NN\3679986 and_13\CC\1740 causes_14\VBZ\1617192 <e2>arrhythmia</e2>_15\NN\14103288 and_16\CC\1740 finally_17\RB\1740 promotes_18\VBZ\2556126 apoptotic_19\JJ\1740 development_20\NN\248977 via_21\IN\1740 phosphorylation_22\NN\1740 of_23\IN\1740 p38_24\NN\1740 mitogen-activated_25\JJ\1740 protein_26\NN\14944888 kinase_27\NN\14732946 ._28\.\1740
D002118_D001145 NONE aconitine-induced_0\JJ\1740 <e1>ca2</e1>_1\NN\1740 +_2\CC\1740 overload_3\NN\3679986 causes_4\VBZ\1617192 <e2>arrhythmia</e2>_5\NN\14103288 and_6\CC\1740 triggers_7\VBZ\1641914 apoptosis_8\NN\11486178 through_9\IN\1740 p38_10\NN\1740 mapk_11\NN\1740 signaling_12\NN\33020 pathway_13\NN\5483677 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D002118_D001145 NONE we_0\PRP\1740 found_1\VBD\2426171 that_2\IN\1740 <e1>ca(2</e1>_3\NN\1740 +_4\CC\1740 )_5\-RRB-\1740 overload_6\NN\3679986 lead_7\VBP\1752884 to_8\TO\1740 accelerated_9\VBN\226566 beating_10\NN\1170962 rhythm_11\NN\15122011 in_12\IN\13603305 adult_13\JJ\1740 rat_14\NN\2329401 ventricular_15\NN\1740 myocytes_16\NNS\1740 and_17\CC\1740 caused_18\VBD\1617192 <e2>arrhythmia</e2>_19\NN\14103288 in_20\IN\13603305 conscious_21\JJ\1740 freely_22\RB\1740 moving_23\VBG\2367363 rats_24\NNS\2329401 ._25\.\1740
D002118_D001145 NONE hence_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 aconitine_6\NN\1740 significantly_7\RB\1740 aggravates_8\VBZ\126264 <e1>ca(2</e1>_9\NN\1740 +_10\CC\1740 )_11\-RRB-\1740 overload_12\NN\3679986 and_13\CC\1740 causes_14\VBZ\1617192 <e2>arrhythmia</e2>_15\NN\14103288 and_16\CC\1740 finally_17\RB\1740 promotes_18\VBZ\2556126 apoptotic_19\JJ\1740 development_20\NN\248977 via_21\IN\1740 phosphorylation_22\NN\1740 of_23\IN\1740 p38_24\NN\1740 mitogen-activated_25\JJ\1740 protein_26\NN\14944888 kinase_27\NN\14732946 ._28\.\1740
D012964_D066126 NONE emerging_0\VBG\422090 evidence_1\NN\5816287 indicates_2\VBZ\952524 that_3\IN\1740 voltage-dependent_4\JJ\1740 <e1>na(+</e1>_5\CD\1740 )_6\-RRB-\1740 channels_7\NNS\6251781 have_8\VBP\2108377 pivotal_9\JJ\1740 roles_10\NNS\719494 in_11\IN\13603305 the_12\DT\1740 <e2>cardiotoxicity</e2>_13\NN\1740 of_14\IN\1740 aconitine_15\NN\1740 ._16\.\1740
D000157_D066126 CID emerging_0\VBG\422090 evidence_1\NN\5816287 indicates_2\VBZ\952524 that_3\IN\1740 voltage-dependent_4\JJ\1740 na(+_5\CD\1740 )_6\-RRB-\1740 channels_7\NNS\6251781 have_8\VBP\2108377 pivotal_9\JJ\1740 roles_10\NNS\719494 in_11\IN\13603305 the_12\DT\1740 <e2>cardiotoxicity</e2>_13\NN\1740 of_14\IN\1740 <e1>aconitine</e1>_15\NN\1740 ._16\.\1740
D002118_D011041 NONE however_0\RB\1740 ,_1\,\1740 no_2\DT\7204911 reports_3\NNS\6470073 are_4\VBP\836236 available_5\JJ\1740 on_6\IN\1740 the_7\DT\1740 role_8\NN\719494 of_9\IN\1740 <e1>ca(2</e1>_10\NN\1740 +_11\CC\1740 )_12\-RRB-\1740 in_13\IN\13603305 aconitine_14\NN\1740 <e2>poisoning</e2>_15\NN\14034177 ._16\.\1740
D002118_D011041 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 explored_5\VBD\789138 the_6\DT\1740 importance_7\NN\5138488 of_8\IN\1740 pathological_9\JJ\1740 <e1>ca(2</e1>_10\NN\1740 +_11\CC\1740 )_12\-RRB-\1740 signaling_13\NN\33020 in_14\IN\13603305 aconitine_15\NN\1740 <e2>poisoning</e2>_16\NN\14034177 in_17\FW\13603305 vitro_18\FW\1740 and_19\CC\1740 in_20\FW\13603305 vivo_21\FW\1740 ._22\.\1740
D000157_D011041 CID however_0\RB\1740 ,_1\,\1740 no_2\DT\7204911 reports_3\NNS\6470073 are_4\VBP\836236 available_5\JJ\1740 on_6\IN\1740 the_7\DT\1740 role_8\NN\719494 of_9\IN\1740 ca(2_10\NN\1740 +_11\CC\1740 )_12\-RRB-\1740 in_13\IN\13603305 <e1>aconitine</e1>_14\NN\1740 <e2>poisoning</e2>_15\NN\14034177 ._16\.\1740
D000157_D011041 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 explored_5\VBD\789138 the_6\DT\1740 importance_7\NN\5138488 of_8\IN\1740 pathological_9\JJ\1740 ca(2_10\NN\1740 +_11\CC\1740 )_12\-RRB-\1740 signaling_13\NN\33020 in_14\IN\13603305 <e1>aconitine</e1>_15\NN\1740 <e2>poisoning</e2>_16\NN\14034177 in_17\FW\13603305 vitro_18\FW\1740 and_19\CC\1740 in_20\FW\13603305 vivo_21\FW\1740 ._22\.\1740
D000157_D009202 NONE to_0\TO\1740 investigate_1\VB\644583 effects_2\NNS\13245626 of_3\IN\1740 <e1>aconitine</e1>_4\NN\1740 on_5\IN\1740 <e2>myocardial_6\JJ\1740 injury</e2>_7\NN\14052046 ,_8\,\1740 we_9\PRP\1740 performed_10\VBD\2367363 cytotoxicity_11\NN\13583478 assay_12\NN\5733583 in_13\IN\13603305 neonatal_14\JJ\1740 rat_15\NN\2329401 ventricular_16\NN\1740 myocytes_17\NNS\1740 (_18\-LRB-\1740 nrvms_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 as_22\RB\1740 well_23\RB\1740 as_24\IN\14622893 measured_25\VBN\697589 lactate_26\NN\14850483 dehydrogenase_27\NN\1740 level_28\NN\4916342 in_29\IN\13603305 the_30\DT\1740 culture_31\NN\7966140 medium_32\NN\3575240 of_33\IN\1740 nrvms_34\NN\1740 and_35\CC\1740 activities_36\NNS\30358 of_37\IN\1740 serum_38\NN\5397468 cardiac_39\JJ\1740 enzymes_40\NNS\14723628 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
D000157_D009202 NONE the_0\DT\1740 results_1\NNS\34213 showed_2\VBD\2137132 that_3\IN\1740 <e1>aconitine</e1>_4\NN\1740 resulted_5\VBD\2633881 in_6\IN\13603305 <e2>myocardial_7\JJ\1740 injury</e2>_8\NN\14052046 and_9\CC\1740 reduced_10\VBD\441445 nrvms_11\NN\1740 viability_12\NN\4916342 dose-dependently_13\RB\1740 ._14\.\1740
D000157_D064420 NONE to_0\TO\1740 investigate_1\VB\644583 effects_2\NNS\13245626 of_3\IN\1740 <e1>aconitine</e1>_4\NN\1740 on_5\IN\1740 myocardial_6\JJ\1740 injury_7\NN\14052046 ,_8\,\1740 we_9\PRP\1740 performed_10\VBD\2367363 <e2>cytotoxicity</e2>_11\NN\13583478 assay_12\NN\5733583 in_13\IN\13603305 neonatal_14\JJ\1740 rat_15\NN\2329401 ventricular_16\NN\1740 myocytes_17\NNS\1740 (_18\-LRB-\1740 nrvms_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 as_22\RB\1740 well_23\RB\1740 as_24\IN\14622893 measured_25\VBN\697589 lactate_26\NN\14850483 dehydrogenase_27\NN\1740 level_28\NN\4916342 in_29\IN\13603305 the_30\DT\1740 culture_31\NN\7966140 medium_32\NN\3575240 of_33\IN\1740 nrvms_34\NN\1740 and_35\CC\1740 activities_36\NNS\30358 of_37\IN\1740 serum_38\NN\5397468 cardiac_39\JJ\1740 enzymes_40\NNS\14723628 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
D019344_D009202 NONE to_0\TO\1740 investigate_1\VB\644583 effects_2\NNS\13245626 of_3\IN\1740 aconitine_4\NN\1740 on_5\IN\1740 <e2>myocardial_6\JJ\1740 injury</e2>_7\NN\14052046 ,_8\,\1740 we_9\PRP\1740 performed_10\VBD\2367363 cytotoxicity_11\NN\13583478 assay_12\NN\5733583 in_13\IN\13603305 neonatal_14\JJ\1740 rat_15\NN\2329401 ventricular_16\NN\1740 myocytes_17\NNS\1740 (_18\-LRB-\1740 nrvms_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 as_22\RB\1740 well_23\RB\1740 as_24\IN\14622893 measured_25\VBN\697589 <e1>lactate</e1>_26\NN\14850483 dehydrogenase_27\NN\1740 level_28\NN\4916342 in_29\IN\13603305 the_30\DT\1740 culture_31\NN\7966140 medium_32\NN\3575240 of_33\IN\1740 nrvms_34\NN\1740 and_35\CC\1740 activities_36\NNS\30358 of_37\IN\1740 serum_38\NN\5397468 cardiac_39\JJ\1740 enzymes_40\NNS\14723628 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
D019344_D064420 NONE to_0\TO\1740 investigate_1\VB\644583 effects_2\NNS\13245626 of_3\IN\1740 aconitine_4\NN\1740 on_5\IN\1740 myocardial_6\JJ\1740 injury_7\NN\14052046 ,_8\,\1740 we_9\PRP\1740 performed_10\VBD\2367363 <e2>cytotoxicity</e2>_11\NN\13583478 assay_12\NN\5733583 in_13\IN\13603305 neonatal_14\JJ\1740 rat_15\NN\2329401 ventricular_16\NN\1740 myocytes_17\NNS\1740 (_18\-LRB-\1740 nrvms_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 as_22\RB\1740 well_23\RB\1740 as_24\IN\14622893 measured_25\VBN\697589 <e1>lactate</e1>_26\NN\14850483 dehydrogenase_27\NN\1740 level_28\NN\4916342 in_29\IN\13603305 the_30\DT\1740 culture_31\NN\7966140 medium_32\NN\3575240 of_33\IN\1740 nrvms_34\NN\1740 and_35\CC\1740 activities_36\NNS\30358 of_37\IN\1740 serum_38\NN\5397468 cardiac_39\JJ\1740 enzymes_40\NNS\14723628 in_41\IN\13603305 rats_42\NNS\2329401 ._43\.\1740
24975837
D002945_D058186 CID kinin_0\NN\14744841 b2_1\NN\1740 receptor_2\NN\5225602 deletion_3\NN\13508333 and_4\CC\1740 blockage_5\NN\14034177 ameliorates_6\VBZ\126264 <e1>cisplatin-induced</e1>_7\JJ\1740 <e2>acute_8\JJ\1740 renal_9\JJ\1740 injury</e2>_10\NN\14052046 ._11\.\1740
D002945_D058186 CID <e1>cisplatin</e1>_0\NN\1740 treatment_1\NN\654885 has_2\VBZ\2108377 been_3\VBN\836236 adopted_4\VBN\674607 in_5\IN\13603305 some_6\DT\1740 chemotherapies_7\NNS\661091 ;_8\:\1740 however_9\RB\1740 ,_10\,\1740 this_11\DT\1740 drug_12\NN\14778436 can_13\MD\3094503 induce_14\VB\1627355 <e2>acute_15\JJ\1740 kidney_16\NN\5333259 injury</e2>_17\NN\14052046 due_18\IN\5174653 its_19\PRP$\6125041 ability_20\NN\4723816 to_21\TO\1740 negatively_22\RB\1740 affect_23\VB\126264 renal_24\JJ\1740 function_25\NN\13783581 ,_26\,\1740 augment_27\VBP\153263 serum_28\NN\5397468 levels_29\NNS\4916342 of_30\IN\1740 creatinine_31\NN\1740 and_32\CC\1740 urea_33\NN\14727670 ,_34\,\1740 increase_35\VB\169651 the_36\DT\1740 acute_37\JJ\1740 tubular_38\JJ\1740 necrosis_39\NN\11444117 score_40\NN\5736149 and_41\CC\1740 up-regulate_42\VBP\1740 cytokines_43\NNS\14728724 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 il-1b_47\NN\1740 and_48\CC\1740 tnf-a_49\NN\1740 )_50\-RRB-\1740 ._51\.\1740
D002945_D058186 CID to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 the_5\DT\1740 kinin_6\NN\14744841 b2_7\NN\1740 receptor_8\NN\5225602 in_9\IN\13603305 <e1>cisplatin-induced</e1>_10\JJ\1740 <e2>acute_11\JJ\1740 kidney_12\NN\5333259 injury</e2>_13\NN\14052046 ,_14\,\1740 kinin_15\NN\14744841 b2_16\NN\1740 receptor_17\NN\5225602 knockout_18\JJ\1740 mice_19\NNS\2329401 were_20\VBD\836236 challenged_21\VBN\869596 with_22\IN\1740 cisplatin_23\NN\1740 ._24\.\1740
D002945_D058186 CID to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 the_5\DT\1740 kinin_6\NN\14744841 b2_7\NN\1740 receptor_8\NN\5225602 in_9\IN\13603305 cisplatin-induced_10\JJ\1740 <e2>acute_11\JJ\1740 kidney_12\NN\5333259 injury</e2>_13\NN\14052046 ,_14\,\1740 kinin_15\NN\14744841 b2_16\NN\1740 receptor_17\NN\5225602 knockout_18\JJ\1740 mice_19\NNS\2329401 were_20\VBD\836236 challenged_21\VBN\869596 with_22\IN\1740 <e1>cisplatin</e1>_23\NN\1740 ._24\.\1740
D002945_D058186 CID thus_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b2_8\NN\1740 receptor_9\NN\5225602 is_10\VBZ\836236 involved_11\VBN\2676054 in_12\IN\13603305 <e1>cisplatin-induced</e1>_13\JJ\1740 <e2>acute_14\JJ\1740 kidney_15\NN\5333259 injury</e2>_16\NN\14052046 by_17\IN\1740 mediating_18\VBG\761713 the_19\DT\1740 necrotic_20\JJ\1740 process_21\NN\407535 and_22\CC\1740 the_23\DT\1740 expression_24\NN\4679549 of_25\IN\1740 inflammatory_26\JJ\1740 cytokines_27\NNS\14728724 ,_28\,\1740 thus_29\RB\1740 resulting_30\VBG\2633881 in_31\IN\13603305 declined_32\VBN\146138 renal_33\JJ\1740 function_34\NN\13783581 ._35\.\1740
D002945_D007683 CID <e1>cisplatin</e1>_0\NN\1740 treatment_1\NN\654885 has_2\VBZ\2108377 been_3\VBN\836236 adopted_4\VBN\674607 in_5\IN\13603305 some_6\DT\1740 chemotherapies_7\NNS\661091 ;_8\:\1740 however_9\RB\1740 ,_10\,\1740 this_11\DT\1740 drug_12\NN\14778436 can_13\MD\3094503 induce_14\VB\1627355 acute_15\JJ\1740 kidney_16\NN\5333259 injury_17\NN\14052046 due_18\IN\5174653 its_19\PRP$\6125041 ability_20\NN\4723816 to_21\TO\1740 negatively_22\RB\1740 affect_23\VB\126264 renal_24\JJ\1740 function_25\NN\13783581 ,_26\,\1740 augment_27\VBP\153263 serum_28\NN\5397468 levels_29\NNS\4916342 of_30\IN\1740 creatinine_31\NN\1740 and_32\CC\1740 urea_33\NN\14727670 ,_34\,\1740 increase_35\VB\169651 the_36\DT\1740 <e2>acute_37\JJ\1740 tubular_38\JJ\1740 necrosis</e2>_39\NN\11444117 score_40\NN\5736149 and_41\CC\1740 up-regulate_42\VBP\1740 cytokines_43\NNS\14728724 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 il-1b_47\NN\1740 and_48\CC\1740 tnf-a_49\NN\1740 )_50\-RRB-\1740 ._51\.\1740
D003404_D058186 NONE cisplatin_0\NN\1740 treatment_1\NN\654885 has_2\VBZ\2108377 been_3\VBN\836236 adopted_4\VBN\674607 in_5\IN\13603305 some_6\DT\1740 chemotherapies_7\NNS\661091 ;_8\:\1740 however_9\RB\1740 ,_10\,\1740 this_11\DT\1740 drug_12\NN\14778436 can_13\MD\3094503 induce_14\VB\1627355 <e2>acute_15\JJ\1740 kidney_16\NN\5333259 injury</e2>_17\NN\14052046 due_18\IN\5174653 its_19\PRP$\6125041 ability_20\NN\4723816 to_21\TO\1740 negatively_22\RB\1740 affect_23\VB\126264 renal_24\JJ\1740 function_25\NN\13783581 ,_26\,\1740 augment_27\VBP\153263 serum_28\NN\5397468 levels_29\NNS\4916342 of_30\IN\1740 <e1>creatinine</e1>_31\NN\1740 and_32\CC\1740 urea_33\NN\14727670 ,_34\,\1740 increase_35\VB\169651 the_36\DT\1740 acute_37\JJ\1740 tubular_38\JJ\1740 necrosis_39\NN\11444117 score_40\NN\5736149 and_41\CC\1740 up-regulate_42\VBP\1740 cytokines_43\NNS\14728724 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 il-1b_47\NN\1740 and_48\CC\1740 tnf-a_49\NN\1740 )_50\-RRB-\1740 ._51\.\1740
D003404_D007683 NONE cisplatin_0\NN\1740 treatment_1\NN\654885 has_2\VBZ\2108377 been_3\VBN\836236 adopted_4\VBN\674607 in_5\IN\13603305 some_6\DT\1740 chemotherapies_7\NNS\661091 ;_8\:\1740 however_9\RB\1740 ,_10\,\1740 this_11\DT\1740 drug_12\NN\14778436 can_13\MD\3094503 induce_14\VB\1627355 acute_15\JJ\1740 kidney_16\NN\5333259 injury_17\NN\14052046 due_18\IN\5174653 its_19\PRP$\6125041 ability_20\NN\4723816 to_21\TO\1740 negatively_22\RB\1740 affect_23\VB\126264 renal_24\JJ\1740 function_25\NN\13783581 ,_26\,\1740 augment_27\VBP\153263 serum_28\NN\5397468 levels_29\NNS\4916342 of_30\IN\1740 <e1>creatinine</e1>_31\NN\1740 and_32\CC\1740 urea_33\NN\14727670 ,_34\,\1740 increase_35\VB\169651 the_36\DT\1740 <e2>acute_37\JJ\1740 tubular_38\JJ\1740 necrosis</e2>_39\NN\11444117 score_40\NN\5736149 and_41\CC\1740 up-regulate_42\VBP\1740 cytokines_43\NNS\14728724 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 il-1b_47\NN\1740 and_48\CC\1740 tnf-a_49\NN\1740 )_50\-RRB-\1740 ._51\.\1740
D014508_D058186 NONE cisplatin_0\NN\1740 treatment_1\NN\654885 has_2\VBZ\2108377 been_3\VBN\836236 adopted_4\VBN\674607 in_5\IN\13603305 some_6\DT\1740 chemotherapies_7\NNS\661091 ;_8\:\1740 however_9\RB\1740 ,_10\,\1740 this_11\DT\1740 drug_12\NN\14778436 can_13\MD\3094503 induce_14\VB\1627355 <e2>acute_15\JJ\1740 kidney_16\NN\5333259 injury</e2>_17\NN\14052046 due_18\IN\5174653 its_19\PRP$\6125041 ability_20\NN\4723816 to_21\TO\1740 negatively_22\RB\1740 affect_23\VB\126264 renal_24\JJ\1740 function_25\NN\13783581 ,_26\,\1740 augment_27\VBP\153263 serum_28\NN\5397468 levels_29\NNS\4916342 of_30\IN\1740 creatinine_31\NN\1740 and_32\CC\1740 <e1>urea</e1>_33\NN\14727670 ,_34\,\1740 increase_35\VB\169651 the_36\DT\1740 acute_37\JJ\1740 tubular_38\JJ\1740 necrosis_39\NN\11444117 score_40\NN\5736149 and_41\CC\1740 up-regulate_42\VBP\1740 cytokines_43\NNS\14728724 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 il-1b_47\NN\1740 and_48\CC\1740 tnf-a_49\NN\1740 )_50\-RRB-\1740 ._51\.\1740
D014508_D007683 NONE cisplatin_0\NN\1740 treatment_1\NN\654885 has_2\VBZ\2108377 been_3\VBN\836236 adopted_4\VBN\674607 in_5\IN\13603305 some_6\DT\1740 chemotherapies_7\NNS\661091 ;_8\:\1740 however_9\RB\1740 ,_10\,\1740 this_11\DT\1740 drug_12\NN\14778436 can_13\MD\3094503 induce_14\VB\1627355 acute_15\JJ\1740 kidney_16\NN\5333259 injury_17\NN\14052046 due_18\IN\5174653 its_19\PRP$\6125041 ability_20\NN\4723816 to_21\TO\1740 negatively_22\RB\1740 affect_23\VB\126264 renal_24\JJ\1740 function_25\NN\13783581 ,_26\,\1740 augment_27\VBP\153263 serum_28\NN\5397468 levels_29\NNS\4916342 of_30\IN\1740 creatinine_31\NN\1740 and_32\CC\1740 <e1>urea</e1>_33\NN\14727670 ,_34\,\1740 increase_35\VB\169651 the_36\DT\1740 <e2>acute_37\JJ\1740 tubular_38\JJ\1740 necrosis</e2>_39\NN\11444117 score_40\NN\5736149 and_41\CC\1740 up-regulate_42\VBP\1740 cytokines_43\NNS\14728724 (_44\-LRB-\1740 e.g._45\FW\1740 ,_46\,\1740 il-1b_47\NN\1740 and_48\CC\1740 tnf-a_49\NN\1740 )_50\-RRB-\1740 ._51\.\1740
D002945_D009336 NONE thus_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b2_8\NN\1740 receptor_9\NN\5225602 is_10\VBZ\836236 involved_11\VBN\2676054 in_12\IN\13603305 <e1>cisplatin-induced</e1>_13\JJ\1740 acute_14\JJ\1740 kidney_15\NN\5333259 injury_16\NN\14052046 by_17\IN\1740 mediating_18\VBG\761713 the_19\DT\1740 <e2>necrotic</e2>_20\JJ\1740 process_21\NN\407535 and_22\CC\1740 the_23\DT\1740 expression_24\NN\4679549 of_25\IN\1740 inflammatory_26\JJ\1740 cytokines_27\NNS\14728724 ,_28\,\1740 thus_29\RB\1740 resulting_30\VBG\2633881 in_31\IN\13603305 declined_32\VBN\146138 renal_33\JJ\1740 function_34\NN\13783581 ._35\.\1740
D002945_D007674 NONE these_0\DT\1740 results_1\NNS\34213 highlight_2\VBP\514463 the_3\DT\1740 kinin_4\NN\14744841 b2_5\NN\1740 receptor_6\NN\5225602 antagonist_7\NN\7846 treatment_8\NN\654885 in_9\IN\13603305 amelioration_10\NN\248977 of_11\IN\1740 <e2>nephrotoxicity</e2>_12\NN\1740 induced_13\VBN\1627355 by_14\IN\1740 <e1>cisplatin</e1>_15\NN\1740 therapy_16\NN\657604 ._17\.\1740
1556529
D015215_D056486 CID <e1>zidovudine-induced</e1>_0\JJ\1740 <e2>hepatitis</e2>_1\NN\14127211 ._2\.\1740
D015215_D056486 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 <e2>hepatitis</e2>_4\NN\14127211 induced_5\VBN\1627355 by_6\IN\1740 <e1>zidovudine</e1>_7\NN\3834836 in_8\IN\13603305 a_9\DT\13649268 38-year-old_10\JJ\1740 patient_11\NN\9898892 with_12\IN\1740 aids_13\NN\13974317 is_14\VBZ\836236 presented_15\VBN\2137132 ._16\.\1740
D015215_D000163 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 hepatitis_4\NN\14127211 induced_5\VBN\1627355 by_6\IN\1740 <e1>zidovudine</e1>_7\NN\3834836 in_8\IN\13603305 a_9\DT\13649268 38-year-old_10\JJ\1740 patient_11\NN\9898892 with_12\IN\1740 <e2>aids</e2>_13\NN\13974317 is_14\VBZ\836236 presented_15\VBN\2137132 ._16\.\1740
8667442
D002117_D006934 CID <e2>milk-alkali_0\JJ\1740 syndrome</e2>_1\NN\5870365 induced_2\VBN\1627355 by_3\IN\1740 <e1>1,25(oh)2d</e1>_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 hypoparathyroidism_9\NN\14059928 ._10\.\1740
D002117_D006934 CID this_0\DT\1740 article_1\NN\6367571 presents_2\VBZ\2137132 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 hypoparathyroidism_6\NN\14059928 who_7\WP\8299493 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 calcium_11\NN\14625458 carbonate_12\NN\15010703 and_13\CC\1740 <e1>calcitriol</e1>_14\NN\1740 resulting_15\VBG\2633881 in_16\IN\13603305 two_17\CD\13741022 admissions_18\NNS\49003 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 for_22\IN\1740 <e2>milk-alkali_23\JJ\1740 syndrome</e2>_24\NN\5870365 ._25\.\1740
D002117_D007011 NONE milk-alkali_0\JJ\1740 syndrome_1\NN\5870365 induced_2\VBN\1627355 by_3\IN\1740 <e1>1,25(oh)2d</e1>_4\NN\1740 in_5\IN\13603305 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 <e2>hypoparathyroidism</e2>_9\NN\14059928 ._10\.\1740
D002117_D007011 NONE this_0\DT\1740 article_1\NN\6367571 presents_2\VBZ\2137132 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 <e2>hypoparathyroidism</e2>_6\NN\14059928 who_7\WP\8299493 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 calcium_11\NN\14625458 carbonate_12\NN\15010703 and_13\CC\1740 <e1>calcitriol</e1>_14\NN\1740 resulting_15\VBG\2633881 in_16\IN\13603305 two_17\CD\13741022 admissions_18\NNS\49003 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 for_22\IN\1740 milk-alkali_23\JJ\1740 syndrome_24\NN\5870365 ._25\.\1740
D002118_D006934 CID <e2>milk-alkali_0\JJ\1740 syndrome</e2>_1\NN\5870365 was_2\VBD\836236 first_3\RB\1740 described_4\VBN\1001294 70_5\CD\13745420 years_6\NNS\15144371 ago_7\RB\1740 in_8\IN\13603305 the_9\DT\1740 context_10\NN\6284777 of_11\IN\1740 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 peptic_15\JJ\1740 ulcer_16\NN\14211294 disease_17\NN\14061805 with_18\IN\1740 large_19\JJ\1740 amounts_20\NNS\13329641 of_21\IN\1740 <e1>calcium</e1>_22\NN\14625458 and_23\CC\1740 alkali_24\JJ\1740 ._25\.\1740
D002118_D010437 NONE milk-alkali_0\JJ\1740 syndrome_1\NN\5870365 was_2\VBD\836236 first_3\RB\1740 described_4\VBN\1001294 70_5\CD\13745420 years_6\NNS\15144371 ago_7\RB\1740 in_8\IN\13603305 the_9\DT\1740 context_10\NN\6284777 of_11\IN\1740 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 <e2>peptic_15\JJ\1740 ulcer_16\NN\14211294 disease</e2>_17\NN\14061805 with_18\IN\1740 large_19\JJ\1740 amounts_20\NNS\13329641 of_21\IN\1740 <e1>calcium</e1>_22\NN\14625458 and_23\CC\1740 alkali_24\JJ\1740 ._25\.\1740
D000468_D006934 CID <e2>milk-alkali_0\JJ\1740 syndrome</e2>_1\NN\5870365 was_2\VBD\836236 first_3\RB\1740 described_4\VBN\1001294 70_5\CD\13745420 years_6\NNS\15144371 ago_7\RB\1740 in_8\IN\13603305 the_9\DT\1740 context_10\NN\6284777 of_11\IN\1740 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 peptic_15\JJ\1740 ulcer_16\NN\14211294 disease_17\NN\14061805 with_18\IN\1740 large_19\JJ\1740 amounts_20\NNS\13329641 of_21\IN\1740 calcium_22\NN\14625458 and_23\CC\1740 <e1>alkali</e1>_24\JJ\1740 ._25\.\1740
D000468_D010437 NONE milk-alkali_0\JJ\1740 syndrome_1\NN\5870365 was_2\VBD\836236 first_3\RB\1740 described_4\VBN\1001294 70_5\CD\13745420 years_6\NNS\15144371 ago_7\RB\1740 in_8\IN\13603305 the_9\DT\1740 context_10\NN\6284777 of_11\IN\1740 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 <e2>peptic_15\JJ\1740 ulcer_16\NN\14211294 disease</e2>_17\NN\14061805 with_18\IN\1740 large_19\JJ\1740 amounts_20\NNS\13329641 of_21\IN\1740 calcium_22\NN\14625458 and_23\CC\1740 <e1>alkali</e1>_24\JJ\1740 ._25\.\1740
D009853_D014456 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 <e2>ulcer</e2>_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 <e1>omeprazole</e1>_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 sucralfate_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D009853_D006934 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 <e1>omeprazole</e1>_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 sucralfate_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 <e2>milk-alkali_18\JJ\1740 syndrome</e2>_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D009853_D006934 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 <e1>omeprazole</e1>_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 sucralfate_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 <e2>hypercalcemia</e2>_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D009853_D000471 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 <e1>omeprazole</e1>_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 sucralfate_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 <e2>alkalosis</e2>_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D009853_D051437 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 <e1>omeprazole</e1>_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 sucralfate_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 <e2>renal_33\JJ\1740 impairment</e2>_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D013392_D014456 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 <e2>ulcer</e2>_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 omeprazole_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 <e1>sucralfate</e1>_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D013392_D006934 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 omeprazole_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 <e1>sucralfate</e1>_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 <e2>milk-alkali_18\JJ\1740 syndrome</e2>_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D013392_D006934 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 omeprazole_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 <e1>sucralfate</e1>_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 <e2>hypercalcemia</e2>_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D013392_D000471 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 omeprazole_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 <e1>sucralfate</e1>_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 <e2>alkalosis</e2>_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 renal_33\JJ\1740 impairment_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D013392_D051437 NONE although_0\IN\1740 with_1\IN\1740 current_2\JJ\1740 ulcer_3\NN\14211294 therapy_4\NN\657604 (_5\-LRB-\1740 h-2_6\NN\1740 blockers_7\NNS\10101634 ,_8\,\1740 omeprazole_9\NN\14778019 ,_10\,\1740 and_11\CC\1740 <e1>sucralfate</e1>_12\JJ\1740 )_13\-RRB-\1740 ,_14\,\1740 the_15\DT\1740 frequency_16\NN\15286249 of_17\IN\1740 milk-alkali_18\JJ\1740 syndrome_19\NN\5870365 has_20\VBZ\2108377 decreased_21\VBN\169651 significantly_22\RB\1740 ,_23\,\1740 the_24\DT\1740 classic_25\JJ\1740 triad_26\NN\13741022 of_27\IN\1740 hypercalcemia_28\NN\14299637 ,_29\,\1740 alkalosis_30\NN\14204950 ,_31\,\1740 and_32\CC\1740 <e2>renal_33\JJ\1740 impairment</e2>_34\NN\7296428 remains_35\VBZ\2604760 the_36\DT\1740 hallmark_37\NN\4731497 of_38\IN\1740 the_39\DT\1740 syndrome_40\NN\5870365 ._41\.\1740
D002119_D007011 NONE this_0\DT\1740 article_1\NN\6367571 presents_2\VBZ\2137132 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 <e2>hypoparathyroidism</e2>_6\NN\14059928 who_7\WP\8299493 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 <e1>calcium_11\NN\14625458 carbonate</e1>_12\NN\15010703 and_13\CC\1740 calcitriol_14\NN\1740 resulting_15\VBG\2633881 in_16\IN\13603305 two_17\CD\13741022 admissions_18\NNS\49003 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 for_22\IN\1740 milk-alkali_23\JJ\1740 syndrome_24\NN\5870365 ._25\.\1740
D002119_D006934 CID this_0\DT\1740 article_1\NN\6367571 presents_2\VBZ\2137132 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 hypoparathyroidism_6\NN\14059928 who_7\WP\8299493 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 <e1>calcium_11\NN\14625458 carbonate</e1>_12\NN\15010703 and_13\CC\1740 calcitriol_14\NN\1740 resulting_15\VBG\2633881 in_16\IN\13603305 two_17\CD\13741022 admissions_18\NNS\49003 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 for_22\IN\1740 <e2>milk-alkali_23\JJ\1740 syndrome</e2>_24\NN\5870365 ._25\.\1740
C019248_D006934 NONE this_0\DT\1740 illustrates_1\VBZ\955601 intravenous_2\JJ\1740 <e1>pamidronate</e1>_3\NN\1740 as_4\IN\14622893 a_5\DT\13649268 valuable_6\JJ\1740 therapeutic_7\JJ\1740 tool_8\NN\3563967 when_9\WRB\1740 <e2>milk-alkali_10\JJ\1740 syndrome</e2>_11\NN\5870365 presents_12\VBZ\2137132 as_13\IN\14622893 hypercalcemic_14\JJ\1740 emergency_15\NN\7417644 ._16\.\1740
C019248_D006934 NONE this_0\DT\1740 illustrates_1\VBZ\955601 intravenous_2\JJ\1740 <e1>pamidronate</e1>_3\NN\1740 as_4\IN\14622893 a_5\DT\13649268 valuable_6\JJ\1740 therapeutic_7\JJ\1740 tool_8\NN\3563967 when_9\WRB\1740 milk-alkali_10\JJ\1740 syndrome_11\NN\5870365 presents_12\VBZ\2137132 as_13\IN\14622893 <e2>hypercalcemic_14\JJ\1740 emergency</e2>_15\NN\7417644 ._16\.\1740
10986547
C076029_D001714 NONE efficacy_0\NNP\5199286 of_1\IN\1740 <e1>olanzapine</e1>_2\NN\1740 in_3\IN\13603305 acute_4\JJ\1740 <e2>bipolar_5\JJ\1740 mania</e2>_6\NN\9180259 :_7\:\1740 a_8\DT\13649268 double-blind_9\JJ\1740 ,_10\,\1740 placebo-controlled_11\JJ\1740 study_12\NN\635850 ._13\.\1740
C076029_D001714 NONE background_0\NN\4921011 :_1\:\1740 we_2\PRP\1740 compared_3\VBD\644583 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 safety_7\NN\13920835 of_8\IN\1740 <e1>olanzapine</e1>_9\NN\1740 vs_10\CC\13634784 placebo_11\VB\1740 for_12\IN\1740 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 acute_16\JJ\1740 <e2>bipolar_17\JJ\1740 mania</e2>_18\NN\9180259 ._19\.\1740
C076029_D001714 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 115_3\CD\1740 patients_4\NNS\9898892 with_5\IN\1740 a_6\DT\13649268 dsm-iv_7\NN\1740 diagnosis_8\NN\152018 of_9\IN\1740 <e2>bipolar_10\JJ\1740 disorder</e2>_11\NN\14034177 ,_12\,\1740 manic_13\JJ\1740 or_14\CC\3541091 mixed_15\JJ\1740 ,_16\,\1740 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 <e1>olanzapine</e1>_20\NN\1740 ,_21\,\1740 5_22\CD\13741022 to_23\TO\1740 20_24\CD\13745420 mg/d_25\NN\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 55_29\CD\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 placebo_33\NN\3740161 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 60_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
C076029_D001714 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 115_3\CD\1740 patients_4\NNS\9898892 with_5\IN\1740 a_6\DT\13649268 dsm-iv_7\NN\1740 diagnosis_8\NN\152018 of_9\IN\1740 bipolar_10\JJ\1740 disorder_11\NN\14034177 ,_12\,\1740 <e2>manic</e2>_13\JJ\1740 or_14\CC\3541091 mixed_15\JJ\1740 ,_16\,\1740 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 <e1>olanzapine</e1>_20\NN\1740 ,_21\,\1740 5_22\CD\13741022 to_23\TO\1740 20_24\CD\13745420 mg/d_25\NN\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 55_29\CD\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 placebo_33\NN\3740161 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 60_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
C076029_D001714 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>olanzapine</e1>_2\NNP\1740 demonstrated_3\VBD\2137132 greater_4\JJR\1740 efficacy_5\NN\5199286 than_6\IN\1740 placebo_7\NN\3740161 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 acute_12\JJ\1740 <e2>bipolar_13\JJ\1740 mania</e2>_14\NN\9180259 and_15\CC\1740 was_16\VBD\836236 generally_17\RB\1740 well_18\RB\1740 tolerated_19\VBN\802318 ._20\.\1740
C076029_D015430 CID however_0\RB\1740 ,_1\,\1740 <e1>olanzapine-treated</e1>_2\JJ\1740 patients_3\NNS\9898892 had_4\VBD\2108377 a_5\DT\13649268 statistically_6\RB\1740 significant_7\JJ\1740 greater_8\JJR\1740 mean_9\NN\6021761 (_10\-LRB-\1740 +/-_11\CC\1740 sd_12\NN\1740 )_13\-RRB-\1740 <e2>weight_14\NN\5009170 gain</e2>_15\NN\13576355 than_16\IN\1740 placebo-treated_17\JJ\1740 patients_18\NNS\9898892 (_19\-LRB-\1740 2.1_20\CD\1740 +/-_21\CC\1740 2.8_22\CD\1740 vs_23\CC\13634784 0.45_24\CD\1740 +/-_25\CC\1740 2.3_26\CD\1740 kg_27\NN\13717155 ,_28\,\1740 respectively_29\RB\1740 )_30\-RRB-\1740 and_31\CC\1740 also_32\RB\1740 experienced_33\VBD\2108377 more_34\RBR\1740 treatment-emergent_35\JJ\1740 somnolence_36\NN\14015731 (_37\-LRB-\1740 21_38\CD\13745420 patients_39\NNS\9898892 [_40\-LRB-\1740 38.2_41\CD\1740 %_42\NN\1740 ]_43\-RRB-\1740 vs_44\CC\13634784 5_45\CD\13741022 [_46\-LRB-\1740 8.3_47\CD\1740 %_48\NN\1740 ]_49\-RRB-\1740 ,_50\,\1740 respectively_51\RB\1740 )_52\-RRB-\1740 ._53\.\1740
C076029_D006970 CID however_0\RB\1740 ,_1\,\1740 <e1>olanzapine-treated</e1>_2\JJ\1740 patients_3\NNS\9898892 had_4\VBD\2108377 a_5\DT\13649268 statistically_6\RB\1740 significant_7\JJ\1740 greater_8\JJR\1740 mean_9\NN\6021761 (_10\-LRB-\1740 +/-_11\CC\1740 sd_12\NN\1740 )_13\-RRB-\1740 weight_14\NN\5009170 gain_15\NN\13576355 than_16\IN\1740 placebo-treated_17\JJ\1740 patients_18\NNS\9898892 (_19\-LRB-\1740 2.1_20\CD\1740 +/-_21\CC\1740 2.8_22\CD\1740 vs_23\CC\13634784 0.45_24\CD\1740 +/-_25\CC\1740 2.3_26\CD\1740 kg_27\NN\13717155 ,_28\,\1740 respectively_29\RB\1740 )_30\-RRB-\1740 and_31\CC\1740 also_32\RB\1740 experienced_33\VBD\2108377 more_34\RBR\1740 treatment-emergent_35\JJ\1740 <e2>somnolence</e2>_36\NN\14015731 (_37\-LRB-\1740 21_38\CD\13745420 patients_39\NNS\9898892 [_40\-LRB-\1740 38.2_41\CD\1740 %_42\NN\1740 ]_43\-RRB-\1740 vs_44\CC\13634784 5_45\CD\13741022 [_46\-LRB-\1740 8.3_47\CD\1740 %_48\NN\1740 ]_49\-RRB-\1740 ,_50\,\1740 respectively_51\RB\1740 )_52\-RRB-\1740 ._53\.\1740
17356399
C042705_D020803 NONE <e2>acute_0\JJ\1740 encephalopathy</e2>_1\JJ\1740 and_2\CC\1740 cerebral_3\JJ\1740 vasospasm_4\NN\1740 after_5\IN\1740 multiagent_6\JJ\1740 chemotherapy_7\NN\661091 including_8\VBG\690614 <e1>peg-asparaginase</e1>_9\NN\1740 and_10\CC\1740 intrathecal_11\JJ\1740 cytarabine_12\NN\1740 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 acute_17\JJ\1740 lymphoblastic_18\JJ\1740 leukemia_19\NN\14239918 ._20\.\1740
C042705_D020301 CID acute_0\JJ\1740 encephalopathy_1\JJ\1740 and_2\CC\1740 <e2>cerebral_3\JJ\1740 vasospasm</e2>_4\NN\1740 after_5\IN\1740 multiagent_6\JJ\1740 chemotherapy_7\NN\661091 including_8\VBG\690614 <e1>peg-asparaginase</e1>_9\NN\1740 and_10\CC\1740 intrathecal_11\JJ\1740 cytarabine_12\NN\1740 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 acute_17\JJ\1740 lymphoblastic_18\JJ\1740 leukemia_19\NN\14239918 ._20\.\1740
C042705_D054198 NONE acute_0\JJ\1740 encephalopathy_1\JJ\1740 and_2\CC\1740 cerebral_3\JJ\1740 vasospasm_4\NN\1740 after_5\IN\1740 multiagent_6\JJ\1740 chemotherapy_7\NN\661091 including_8\VBG\690614 <e1>peg-asparaginase</e1>_9\NN\1740 and_10\CC\1740 intrathecal_11\JJ\1740 cytarabine_12\NN\1740 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>acute_17\JJ\1740 lymphoblastic_18\JJ\1740 leukemia</e2>_19\NN\14239918 ._20\.\1740
D003561_D020803 NONE <e2>acute_0\JJ\1740 encephalopathy</e2>_1\JJ\1740 and_2\CC\1740 cerebral_3\JJ\1740 vasospasm_4\NN\1740 after_5\IN\1740 multiagent_6\JJ\1740 chemotherapy_7\NN\661091 including_8\VBG\690614 peg-asparaginase_9\NN\1740 and_10\CC\1740 intrathecal_11\JJ\1740 <e1>cytarabine</e1>_12\NN\1740 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 acute_17\JJ\1740 lymphoblastic_18\JJ\1740 leukemia_19\NN\14239918 ._20\.\1740
D003561_D020803 NONE the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 <e2>acute_3\JJ\1740 encephalopathy</e2>_4\RB\1740 evidenced_5\VBN\1015244 by_6\IN\1740 behavioral_7\JJ\1740 changes_8\NNS\7283608 ,_9\,\1740 aphasia_10\NN\14085708 ,_11\,\1740 incontinence_12\NN\13473097 ,_13\,\1740 visual_14\JJ\1740 hallucinations_15\NNS\14376855 ,_16\,\1740 and_17\CC\1740 right-sided_18\JJ\1740 weakness_19\NN\14462666 with_20\IN\1740 diffuse_21\JJ\1740 cerebral_22\JJ\1740 vasospasm_23\NN\1740 on_24\IN\1740 magnetic_25\JJ\1740 resonance_26\NN\11419404 angiography_27\NN\904623 after_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 intrathecal_32\JJ\1740 <e1>cytarabine</e1>_33\NN\1740 ._34\.\1740
D003561_D020301 CID acute_0\JJ\1740 encephalopathy_1\JJ\1740 and_2\CC\1740 <e2>cerebral_3\JJ\1740 vasospasm</e2>_4\NN\1740 after_5\IN\1740 multiagent_6\JJ\1740 chemotherapy_7\NN\661091 including_8\VBG\690614 peg-asparaginase_9\NN\1740 and_10\CC\1740 intrathecal_11\JJ\1740 <e1>cytarabine</e1>_12\NN\1740 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 acute_17\JJ\1740 lymphoblastic_18\JJ\1740 leukemia_19\NN\14239918 ._20\.\1740
D003561_D020301 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 encephalopathy_4\RB\1740 evidenced_5\VBN\1015244 by_6\IN\1740 behavioral_7\JJ\1740 changes_8\NNS\7283608 ,_9\,\1740 aphasia_10\NN\14085708 ,_11\,\1740 incontinence_12\NN\13473097 ,_13\,\1740 visual_14\JJ\1740 hallucinations_15\NNS\14376855 ,_16\,\1740 and_17\CC\1740 right-sided_18\JJ\1740 weakness_19\NN\14462666 with_20\IN\1740 diffuse_21\JJ\1740 <e2>cerebral_22\JJ\1740 vasospasm</e2>_23\NN\1740 on_24\IN\1740 magnetic_25\JJ\1740 resonance_26\NN\11419404 angiography_27\NN\904623 after_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 intrathecal_32\JJ\1740 <e1>cytarabine</e1>_33\NN\1740 ._34\.\1740
D003561_D054198 NONE acute_0\JJ\1740 encephalopathy_1\JJ\1740 and_2\CC\1740 cerebral_3\JJ\1740 vasospasm_4\NN\1740 after_5\IN\1740 multiagent_6\JJ\1740 chemotherapy_7\NN\661091 including_8\VBG\690614 peg-asparaginase_9\NN\1740 and_10\CC\1740 intrathecal_11\JJ\1740 <e1>cytarabine</e1>_12\NN\1740 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>acute_17\JJ\1740 lymphoblastic_18\JJ\1740 leukemia</e2>_19\NN\14239918 ._20\.\1740
D003561_D001037 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 encephalopathy_4\RB\1740 evidenced_5\VBN\1015244 by_6\IN\1740 behavioral_7\JJ\1740 changes_8\NNS\7283608 ,_9\,\1740 <e2>aphasia</e2>_10\NN\14085708 ,_11\,\1740 incontinence_12\NN\13473097 ,_13\,\1740 visual_14\JJ\1740 hallucinations_15\NNS\14376855 ,_16\,\1740 and_17\CC\1740 right-sided_18\JJ\1740 weakness_19\NN\14462666 with_20\IN\1740 diffuse_21\JJ\1740 cerebral_22\JJ\1740 vasospasm_23\NN\1740 on_24\IN\1740 magnetic_25\JJ\1740 resonance_26\NN\11419404 angiography_27\NN\904623 after_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 intrathecal_32\JJ\1740 <e1>cytarabine</e1>_33\NN\1740 ._34\.\1740
D003561_D014549 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 encephalopathy_4\RB\1740 evidenced_5\VBN\1015244 by_6\IN\1740 behavioral_7\JJ\1740 changes_8\NNS\7283608 ,_9\,\1740 aphasia_10\NN\14085708 ,_11\,\1740 <e2>incontinence</e2>_12\NN\13473097 ,_13\,\1740 visual_14\JJ\1740 hallucinations_15\NNS\14376855 ,_16\,\1740 and_17\CC\1740 right-sided_18\JJ\1740 weakness_19\NN\14462666 with_20\IN\1740 diffuse_21\JJ\1740 cerebral_22\JJ\1740 vasospasm_23\NN\1740 on_24\IN\1740 magnetic_25\JJ\1740 resonance_26\NN\11419404 angiography_27\NN\904623 after_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 intrathecal_32\JJ\1740 <e1>cytarabine</e1>_33\NN\1740 ._34\.\1740
D003561_D006212 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 encephalopathy_4\RB\1740 evidenced_5\VBN\1015244 by_6\IN\1740 behavioral_7\JJ\1740 changes_8\NNS\7283608 ,_9\,\1740 aphasia_10\NN\14085708 ,_11\,\1740 incontinence_12\NN\13473097 ,_13\,\1740 <e2>visual_14\JJ\1740 hallucinations</e2>_15\NNS\14376855 ,_16\,\1740 and_17\CC\1740 right-sided_18\JJ\1740 weakness_19\NN\14462666 with_20\IN\1740 diffuse_21\JJ\1740 cerebral_22\JJ\1740 vasospasm_23\NN\1740 on_24\IN\1740 magnetic_25\JJ\1740 resonance_26\NN\11419404 angiography_27\NN\904623 after_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 intrathecal_32\JJ\1740 <e1>cytarabine</e1>_33\NN\1740 ._34\.\1740
D003561_D018908 CID the_0\DT\1740 patient_1\NN\9898892 developed_2\VBD\1753788 acute_3\JJ\1740 encephalopathy_4\RB\1740 evidenced_5\VBN\1015244 by_6\IN\1740 behavioral_7\JJ\1740 changes_8\NNS\7283608 ,_9\,\1740 aphasia_10\NN\14085708 ,_11\,\1740 incontinence_12\NN\13473097 ,_13\,\1740 visual_14\JJ\1740 hallucinations_15\NNS\14376855 ,_16\,\1740 and_17\CC\1740 right-sided_18\JJ\1740 <e2>weakness</e2>_19\NN\14462666 with_20\IN\1740 diffuse_21\JJ\1740 cerebral_22\JJ\1740 vasospasm_23\NN\1740 on_24\IN\1740 magnetic_25\JJ\1740 resonance_26\NN\11419404 angiography_27\NN\904623 after_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 intrathecal_32\JJ\1740 <e1>cytarabine</e1>_33\NN\1740 ._34\.\1740
3533179
D003520_D066126 NONE <e1>cyclophosphamide</e1>_0\JJ\1740 <e2>cardiotoxicity</e2>_1\NN\1740 :_2\:\1740 an_3\DT\6697703 analysis_4\NN\633864 of_5\IN\1740 dosing_6\NN\1740 as_7\IN\14622893 a_8\DT\13649268 risk_9\NN\14541044 factor_10\NN\7326557 ._11\.\1740
D003520_D066126 NONE at_0\IN\14622893 these_1\DT\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>cya</e1>_5\NN\1740 ,_6\,\1740 serious_7\JJ\1740 <e2>cardiotoxicity</e2>_8\NN\1740 may_9\MD\15209706 occur_10\VB\2623529 ,_11\,\1740 but_12\CC\1740 definitive_13\JJ\1740 risk_14\NN\14541044 factors_15\NNS\7326557 for_16\IN\1740 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 such_20\JJ\1740 cardiotoxicity_21\NN\1740 have_22\VBP\2108377 not_23\RB\1740 been_24\VBN\836236 described_25\VBN\1001294 ._26\.\1740
D003520_D066126 NONE at_0\IN\14622893 these_1\DT\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>cya</e1>_5\NN\1740 ,_6\,\1740 serious_7\JJ\1740 cardiotoxicity_8\NN\1740 may_9\MD\15209706 occur_10\VB\2623529 ,_11\,\1740 but_12\CC\1740 definitive_13\JJ\1740 risk_14\NN\14541044 factors_15\NNS\7326557 for_16\IN\1740 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 such_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 have_22\VBP\2108377 not_23\RB\1740 been_24\VBN\836236 described_25\VBN\1001294 ._26\.\1740
D003520_D066126 NONE since_0\IN\1740 chemotherapeutic_1\JJ\1740 agent_2\NN\7347 toxicity_3\NN\13576101 generally_4\RB\1740 correlates_5\VBZ\2657219 with_6\IN\1740 dose_7\NN\3740161 per_8\IN\1740 body_9\NN\19128 surface_10\NN\21939 area_11\NN\8630985 ,_12\,\1740 we_13\PRP\1740 retrospectively_14\RB\1740 calculated_15\VBD\632627 the_16\DT\1740 dose_17\NN\3740161 of_18\IN\1740 <e1>cya</e1>_19\NN\1740 in_20\IN\13603305 patients_21\NNS\9898892 transplanted_22\VBN\2013571 at_23\IN\14622893 our_24\PRP$\1740 institution_25\NN\8008335 to_26\TO\1740 determine_27\VB\1645601 whether_28\IN\1740 the_29\DT\1740 incidence_30\NN\13821570 of_31\IN\1740 cya_32\NN\1740 <e2>cardiotoxicity</e2>_33\NN\1740 correlated_34\VBD\2657219 with_35\IN\1740 the_36\DT\1740 dose_37\NN\3740161 per_38\IN\1740 body_39\NN\19128 surface_40\NN\21939 area_41\NN\8630985 ._42\.\1740
D003520_D066126 NONE since_0\IN\1740 chemotherapeutic_1\JJ\1740 agent_2\NN\7347 toxicity_3\NN\13576101 generally_4\RB\1740 correlates_5\VBZ\2657219 with_6\IN\1740 dose_7\NN\3740161 per_8\IN\1740 body_9\NN\19128 surface_10\NN\21939 area_11\NN\8630985 ,_12\,\1740 we_13\PRP\1740 retrospectively_14\RB\1740 calculated_15\VBD\632627 the_16\DT\1740 dose_17\NN\3740161 of_18\IN\1740 cya_19\NN\1740 in_20\IN\13603305 patients_21\NNS\9898892 transplanted_22\VBN\2013571 at_23\IN\14622893 our_24\PRP$\1740 institution_25\NN\8008335 to_26\TO\1740 determine_27\VB\1645601 whether_28\IN\1740 the_29\DT\1740 incidence_30\NN\13821570 of_31\IN\1740 <e1>cya</e1>_32\NN\1740 <e2>cardiotoxicity</e2>_33\NN\1740 correlated_34\VBD\2657219 with_35\IN\1740 the_36\DT\1740 dose_37\NN\3740161 per_38\IN\1740 body_39\NN\19128 surface_40\NN\21939 area_41\NN\8630985 ._42\.\1740
D003520_D066126 NONE fourteen_0\CD\13745420 of_1\IN\1740 84_2\CD\1740 (_3\-LRB-\1740 17_4\CD\13745420 %_5\NN\1740 )_6\-RRB-\1740 patients_7\NNS\9898892 had_8\VBD\2108377 symptoms_9\NNS\5823932 and_10\CC\1740 signs_11\NNS\6643763 consistent_12\JJ\1740 with_13\IN\1740 <e1>cya</e1>_14\NN\1740 <e2>cardiotoxicity</e2>_15\NN\1740 within_16\IN\1740 ten_17\CD\13745420 days_18\NNS\15140892 of_19\IN\1740 receiving_20\VBG\2210855 1_21\CD\13741022 to_22\TO\1740 4_23\CD\13741022 doses_24\NNS\3740161 of_25\IN\1740 cya_26\NNP\1740 ._27\.\1740
D003520_D066126 NONE fourteen_0\CD\13745420 of_1\IN\1740 84_2\CD\1740 (_3\-LRB-\1740 17_4\CD\13745420 %_5\NN\1740 )_6\-RRB-\1740 patients_7\NNS\9898892 had_8\VBD\2108377 symptoms_9\NNS\5823932 and_10\CC\1740 signs_11\NNS\6643763 consistent_12\JJ\1740 with_13\IN\1740 cya_14\NN\1740 <e2>cardiotoxicity</e2>_15\NN\1740 within_16\IN\1740 ten_17\CD\13745420 days_18\NNS\15140892 of_19\IN\1740 receiving_20\VBG\2210855 1_21\CD\13741022 to_22\TO\1740 4_23\CD\13741022 doses_24\NNS\3740161 of_25\IN\1740 <e1>cya</e1>_26\NNP\1740 ._27\.\1740
D003520_D066126 NONE <e2>cardiotoxicity</e2>_0\NN\1740 that_1\WDT\1740 was_2\VBD\836236 thought_3\VBN\670261 to_4\TO\1740 be_5\VB\836236 related_6\JJ\1740 to_7\TO\1740 <e1>cya</e1>_8\NN\1740 occurred_9\VBD\2623529 in_10\IN\13603305 1/32_11\CD\1740 (_12\-LRB-\1740 3_13\CD\13741022 %_14\NN\1740 )_15\-RRB-\1740 of_16\IN\1740 patients_17\NNS\9898892 in_18\IN\13603305 group_19\NN\2137 1_20\CD\13741022 and_21\CC\1740 in_22\IN\13603305 13/52_23\CD\1740 (_24\-LRB-\1740 25_25\CD\13745420 %_26\NN\1740 )_27\-RRB-\1740 patients_28\NNS\9898892 in_29\IN\13603305 group_30\NN\2137 2_31\CD\13741022 (_32\-LRB-\1740 p_33\NN\14622893 less_34\JJR\1740 than_35\IN\1740 0.025_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 <e1>cya</e1>_4\NN\1740 <e2>cardiotoxicity</e2>_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 <e1>cya</e1>_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 <e2>cardiotoxicity</e2>_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 <e2>cardiotoxicity</e2>_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 <e1>cya</e1>_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 <e1>cya</e1>_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 <e2>cardiotoxicity</e2>_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 <e2>cardiotoxicity</e2>_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 <e1>cya</e1>_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 <e1>cya</e1>_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 <e2>cardiotoxicity</e2>_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 <e2>cardiotoxicity</e2>_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 <e1>cya</e1>_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D066126 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 <e2>cardiotoxicity</e2>_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 <e1>cya</e1>_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D064420 NONE since_0\IN\1740 chemotherapeutic_1\JJ\1740 agent_2\NN\7347 <e2>toxicity</e2>_3\NN\13576101 generally_4\RB\1740 correlates_5\VBZ\2657219 with_6\IN\1740 dose_7\NN\3740161 per_8\IN\1740 body_9\NN\19128 surface_10\NN\21939 area_11\NN\8630985 ,_12\,\1740 we_13\PRP\1740 retrospectively_14\RB\1740 calculated_15\VBD\632627 the_16\DT\1740 dose_17\NN\3740161 of_18\IN\1740 <e1>cya</e1>_19\NN\1740 in_20\IN\13603305 patients_21\NNS\9898892 transplanted_22\VBN\2013571 at_23\IN\14622893 our_24\PRP$\1740 institution_25\NN\8008335 to_26\TO\1740 determine_27\VB\1645601 whether_28\IN\1740 the_29\DT\1740 incidence_30\NN\13821570 of_31\IN\1740 cya_32\NN\1740 cardiotoxicity_33\NN\1740 correlated_34\VBD\2657219 with_35\IN\1740 the_36\DT\1740 dose_37\NN\3740161 per_38\IN\1740 body_39\NN\19128 surface_40\NN\21939 area_41\NN\8630985 ._42\.\1740
D003520_D064420 NONE since_0\IN\1740 chemotherapeutic_1\JJ\1740 agent_2\NN\7347 <e2>toxicity</e2>_3\NN\13576101 generally_4\RB\1740 correlates_5\VBZ\2657219 with_6\IN\1740 dose_7\NN\3740161 per_8\IN\1740 body_9\NN\19128 surface_10\NN\21939 area_11\NN\8630985 ,_12\,\1740 we_13\PRP\1740 retrospectively_14\RB\1740 calculated_15\VBD\632627 the_16\DT\1740 dose_17\NN\3740161 of_18\IN\1740 cya_19\NN\1740 in_20\IN\13603305 patients_21\NNS\9898892 transplanted_22\VBN\2013571 at_23\IN\14622893 our_24\PRP$\1740 institution_25\NN\8008335 to_26\TO\1740 determine_27\VB\1645601 whether_28\IN\1740 the_29\DT\1740 incidence_30\NN\13821570 of_31\IN\1740 <e1>cya</e1>_32\NN\1740 cardiotoxicity_33\NN\1740 correlated_34\VBD\2657219 with_35\IN\1740 the_36\DT\1740 dose_37\NN\3740161 per_38\IN\1740 body_39\NN\19128 surface_40\NN\21939 area_41\NN\8630985 ._42\.\1740
D003520_D000741 NONE eighty_0\CD\13745420 patients_1\NNS\9898892 who_2\WP\8299493 were_3\VBD\836236 to_4\TO\1740 receive_5\VB\2210855 <e1>cya</e1>_6\NN\1740 50_7\CD\13745420 mg/kg/d_8\NN\1740 for_9\IN\1740 four_10\CD\13741022 days_11\NNS\15140892 as_12\IN\14622893 preparation_13\NN\407535 for_14\IN\1740 marrow_15\NN\5286536 grafting_16\NN\379422 underwent_17\VBD\109660 a_18\DT\13649268 total_19\NN\3553 of_20\IN\1740 84_21\CD\1740 transplants_22\NNS\5267548 for_23\IN\1740 <e2>aplastic_24\JJ\1740 anemia</e2>_25\NN\14189204 ,_26\,\1740 wiskott-aldrich_27\NN\1740 syndrome_28\NN\5870365 ,_29\,\1740 or_30\CC\3541091 severe_31\JJ\1740 combined_32\JJ\1740 immunodeficiency_33\NN\13973990 syndrome_34\NN\5870365 ._35\.\1740
D003520_D000741 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 <e1>cya</e1>_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 <e2>aplastic_21\JJ\1740 anemia</e2>_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D000741 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 <e1>cya</e1>_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 <e2>aplastic_21\JJ\1740 anemia</e2>_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D000741 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 <e2>aplastic_21\JJ\1740 anemia</e2>_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 <e1>cya</e1>_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D000741 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 <e2>aplastic_21\JJ\1740 anemia</e2>_22\NN\14189204 and_23\CC\1740 immunodeficiencies_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 <e1>cya</e1>_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D014923 NONE eighty_0\CD\13745420 patients_1\NNS\9898892 who_2\WP\8299493 were_3\VBD\836236 to_4\TO\1740 receive_5\VB\2210855 <e1>cya</e1>_6\NN\1740 50_7\CD\13745420 mg/kg/d_8\NN\1740 for_9\IN\1740 four_10\CD\13741022 days_11\NNS\15140892 as_12\IN\14622893 preparation_13\NN\407535 for_14\IN\1740 marrow_15\NN\5286536 grafting_16\NN\379422 underwent_17\VBD\109660 a_18\DT\13649268 total_19\NN\3553 of_20\IN\1740 84_21\CD\1740 transplants_22\NNS\5267548 for_23\IN\1740 aplastic_24\JJ\1740 anemia_25\NN\14189204 ,_26\,\1740 <e2>wiskott-aldrich_27\NN\1740 syndrome</e2>_28\NN\5870365 ,_29\,\1740 or_30\CC\3541091 severe_31\JJ\1740 combined_32\JJ\1740 immunodeficiency_33\NN\13973990 syndrome_34\NN\5870365 ._35\.\1740
D003520_D016511 NONE eighty_0\CD\13745420 patients_1\NNS\9898892 who_2\WP\8299493 were_3\VBD\836236 to_4\TO\1740 receive_5\VB\2210855 <e1>cya</e1>_6\NN\1740 50_7\CD\13745420 mg/kg/d_8\NN\1740 for_9\IN\1740 four_10\CD\13741022 days_11\NNS\15140892 as_12\IN\14622893 preparation_13\NN\407535 for_14\IN\1740 marrow_15\NN\5286536 grafting_16\NN\379422 underwent_17\VBD\109660 a_18\DT\13649268 total_19\NN\3553 of_20\IN\1740 84_21\CD\1740 transplants_22\NNS\5267548 for_23\IN\1740 aplastic_24\JJ\1740 anemia_25\NN\14189204 ,_26\,\1740 wiskott-aldrich_27\NN\1740 syndrome_28\NN\5870365 ,_29\,\1740 or_30\CC\3541091 <e2>severe_31\JJ\1740 combined_32\JJ\1740 immunodeficiency_33\NN\13973990 syndrome</e2>_34\NN\5870365 ._35\.\1740
D003520_D007153 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 <e1>cya</e1>_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 <e2>immunodeficiencies</e2>_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D007153 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 <e1>cya</e1>_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 <e2>immunodeficiencies</e2>_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D007153 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 <e2>immunodeficiencies</e2>_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 <e1>cya</e1>_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 cya_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
D003520_D007153 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 cya_4\NN\1740 cardiotoxicity_5\NN\1740 correlates_6\VBZ\2657219 with_7\IN\1740 cya_8\NN\1740 dosage_9\NN\13576355 as_10\IN\14622893 calculated_11\VBN\632627 by_12\IN\1740 body_13\NN\19128 surface_14\NN\21939 area_15\NN\8630985 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 patients_19\NNS\9898892 with_20\IN\1740 aplastic_21\JJ\1740 anemia_22\NN\14189204 and_23\CC\1740 <e2>immunodeficiencies</e2>_24\NNS\13973990 can_25\MD\3094503 be_26\VB\836236 effectively_27\RB\1740 prepared_28\VBN\126264 for_29\IN\1740 bone_30\NN\5286536 marrow_31\NN\5286536 grafting_32\VBG\1291069 at_33\IN\14622893 a_34\DT\13649268 cya_35\NN\1740 dose_36\NN\3740161 of_37\IN\1740 1.55_38\CD\1740 g/m2/d_39\NN\1740 for_40\IN\1740 four_41\CD\13741022 days_42\NNS\15140892 with_43\IN\1740 a_44\DT\13649268 lower_45\JJR\1740 incidence_46\NN\13821570 of_47\IN\1740 cardiotoxicity_48\NN\1740 than_49\IN\1740 patients_50\NNS\9898892 whose_51\WP$\1740 <e1>cya</e1>_52\NN\1740 dosage_53\NN\13576355 is_54\VBZ\836236 calculated_55\VBN\632627 based_56\VBN\2694933 on_57\IN\1740 weight_58\NN\5009170 ._59\.\1740
20589632
D014295_D000743 CID <e1>trimethoprim-induced</e1>_0\JJ\1740 immune_1\JJ\1740 <e2>hemolytic_2\JJ\1740 anemia</e2>_3\NN\14189204 in_4\IN\13603305 a_5\DT\13649268 pediatric_6\JJ\1740 oncology_7\NN\6043075 patient_8\NN\9898892 presenting_9\VBG\2137132 as_10\IN\14622893 an_11\DT\6697703 acute_12\JJ\1740 hemolytic_13\JJ\1740 transfusion_14\NN\320852 reaction_15\NN\13446390 ._16\.\1740
15018178
D015662_D000743 CID we_0\PRP\1740 present_1\VBP\2137132 magnetic_2\JJ\1740 resonance_3\NN\11419404 imaging_4\NN\5765159 findings_5\NNS\7951464 of_6\IN\1740 a_7\DT\13649268 5-year-old_8\JJ\1740 girl_9\NN\10787470 who_10\WP\8299493 had_11\VBD\2108377 a_12\DT\13649268 rapidly_13\RB\1740 installing_14\VBG\1494310 <e2>hemolytic_15\JJ\1740 anemia</e2>_16\NN\14189204 crisis_17\NN\14411243 induced_18\VBN\1627355 by_19\IN\1740 <e1>trimethoprim-sulfomethoxazole</e1>_20\NN\1740 ,_21\,\1740 resulting_22\VBG\2633881 in_23\IN\13603305 cerebral_24\JJ\1740 anoxia_25\NN\14041256 leading_26\VBG\1752884 to_27\TO\1740 permanent_28\JJ\1740 damage_29\NN\7296428 ._30\.\1740
D015662_D002534 NONE we_0\PRP\1740 present_1\VBP\2137132 magnetic_2\JJ\1740 resonance_3\NN\11419404 imaging_4\NN\5765159 findings_5\NNS\7951464 of_6\IN\1740 a_7\DT\13649268 5-year-old_8\JJ\1740 girl_9\NN\10787470 who_10\WP\8299493 had_11\VBD\2108377 a_12\DT\13649268 rapidly_13\RB\1740 installing_14\VBG\1494310 hemolytic_15\JJ\1740 anemia_16\NN\14189204 crisis_17\NN\14411243 induced_18\VBN\1627355 by_19\IN\1740 <e1>trimethoprim-sulfomethoxazole</e1>_20\NN\1740 ,_21\,\1740 resulting_22\VBG\2633881 in_23\IN\13603305 <e2>cerebral_24\JJ\1740 anoxia</e2>_25\NN\14041256 leading_26\VBG\1752884 to_27\TO\1740 permanent_28\JJ\1740 damage_29\NN\7296428 ._30\.\1740
23666265
D003520_D003556 CID the_0\DT\1740 function_1\NN\13783581 of_2\IN\1740 p2x3_3\NN\1740 receptor_4\NN\5225602 and_5\CC\1740 nk1_6\NN\1740 receptor_7\NN\5225602 antagonists_8\NNS\7846 on_9\IN\1740 <e1>cyclophosphamide-induced</e1>_10\JJ\1740 <e2>cystitis</e2>_11\NN\14566129 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
D003520_D003556 CID purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 is_7\VBZ\836236 to_8\TO\1740 explore_9\VB\789138 the_10\DT\1740 function_11\NN\13783581 of_12\IN\1740 p2x3_13\NN\1740 and_14\CC\1740 nk1_15\NN\1740 receptors_16\NNS\5225602 antagonists_17\NNS\7846 on_18\IN\1740 <e1>cyclophosphamide</e1>_19\NN\1740 (cyp)-induced_20\JJ\1740 <e2>cystitis</e2>_21\NN\14566129 in_22\IN\13603305 rats_23\NNS\2329401 ._24\.\1740
D003520_D003556 CID purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 study_6\NN\635850 is_7\VBZ\836236 to_8\TO\1740 explore_9\VB\789138 the_10\DT\1740 function_11\NN\13783581 of_12\IN\1740 p2x3_13\NN\1740 and_14\CC\1740 nk1_15\NN\1740 receptors_16\NNS\5225602 antagonists_17\NNS\7846 on_18\IN\1740 cyclophosphamide_19\NN\1740 <e1>(cyp)-induced</e1>_20\JJ\1740 <e2>cystitis</e2>_21\NN\14566129 in_22\IN\13603305 rats_23\NNS\2329401 ._24\.\1740
D003520_D003556 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 <e1>cyp-induced</e1>_3\JJ\1740 <e2>cystitis</e2>_4\NN\14566129 ,_5\,\1740 the_6\DT\1740 expression_7\NN\4679549 of_8\IN\1740 p2x3_9\NN\1740 and_10\CC\1740 nk1_11\NN\1740 receptors_12\NNS\5225602 increased_13\VBD\169651 in_14\IN\13603305 urothelium_15\NN\1740 and/or_16\CC\1740 suburothelium_17\NN\1740 ._18\.\1740
D003520_D010146 CID spontaneous_0\JJ\1740 <e2>pain</e2>_1\NN\14299637 behaviors_2\NNS\407535 following_3\VBG\1835496 the_4\DT\1740 administration_5\NN\1133281 of_6\IN\1740 <e1>cyp</e1>_7\NN\1740 were_8\VBD\836236 observed_9\VBN\2163746 ._10\.\1740
D003520_D010146 CID results_0\NNS\34213 :_1\:\1740 <e1>cyclophosphamide</e1>_2\NN\1740 treatment_3\NN\654885 increased_4\VBD\169651 the_5\DT\1740 spontaneous_6\JJ\1740 <e2>pain</e2>_7\NN\14299637 behaviors_8\NNS\407535 scores_9\NNS\13757724 ._10\.\1740
9578276
15366550
D008094_D059606 NONE the_0\DT\1740 nursing_1\NN\654885 staff_2\NN\8208016 ,_3\,\1740 by_4\IN\1740 reviewing_5\VBG\644583 the_6\DT\1740 patient_7\NN\9898892 's_8\POS\1740 health_9\NN\14447525 history_10\NN\15120823 with_11\IN\1740 his_12\PRP$\1740 family_13\NN\8189659 ,_14\,\1740 discovered_15\VBD\2163746 a_16\DT\13649268 history_17\NN\15120823 of_18\IN\1740 <e2>polydipsia</e2>_19\NN\14040660 and_20\CC\1740 long-standing_21\JJ\1740 <e1>lithium</e1>_22\NN\14625458 use_23\NN\407535 ._24\.\1740
D008094_D018500 CID <e1>lithium</e1>_0\NNP\14625458 is_1\VBZ\836236 implicated_2\VBN\2677097 in_3\IN\13603305 drug-induced_4\JJ\1740 <e2>nephrogenic_5\JJ\1740 di</e2>_6\NN\1740 ,_7\,\1740 and_8\CC\1740 because_9\IN\1740 the_10\DT\1740 patient_11\NN\9898892 had_12\VBD\2108377 not_13\RB\1740 received_14\VBN\2210855 lithium_15\NN\14625458 since_16\IN\1740 being_17\VBG\836236 admitted_18\VBN\822367 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 ,_22\,\1740 his_23\PRP$\1740 treatment_24\NN\654885 changed_25\VBN\46534 to_26\TO\1740 focus_27\VB\628491 on_28\IN\1740 nephrogenic_29\JJ\1740 di_30\NN\1740 ._31\.\1740
D008094_D018500 CID <e1>lithium</e1>_0\NNP\14625458 is_1\VBZ\836236 implicated_2\VBN\2677097 in_3\IN\13603305 drug-induced_4\JJ\1740 nephrogenic_5\JJ\1740 di_6\NN\1740 ,_7\,\1740 and_8\CC\1740 because_9\IN\1740 the_10\DT\1740 patient_11\NN\9898892 had_12\VBD\2108377 not_13\RB\1740 received_14\VBN\2210855 lithium_15\NN\14625458 since_16\IN\1740 being_17\VBG\836236 admitted_18\VBN\822367 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 ,_22\,\1740 his_23\PRP$\1740 treatment_24\NN\654885 changed_25\VBN\46534 to_26\TO\1740 focus_27\VB\628491 on_28\IN\1740 <e2>nephrogenic_29\JJ\1740 di</e2>_30\NN\1740 ._31\.\1740
D008094_D018500 CID lithium_0\NNP\14625458 is_1\VBZ\836236 implicated_2\VBN\2677097 in_3\IN\13603305 drug-induced_4\JJ\1740 <e2>nephrogenic_5\JJ\1740 di</e2>_6\NN\1740 ,_7\,\1740 and_8\CC\1740 because_9\IN\1740 the_10\DT\1740 patient_11\NN\9898892 had_12\VBD\2108377 not_13\RB\1740 received_14\VBN\2210855 <e1>lithium</e1>_15\NN\14625458 since_16\IN\1740 being_17\VBG\836236 admitted_18\VBN\822367 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 ,_22\,\1740 his_23\PRP$\1740 treatment_24\NN\654885 changed_25\VBN\46534 to_26\TO\1740 focus_27\VB\628491 on_28\IN\1740 nephrogenic_29\JJ\1740 di_30\NN\1740 ._31\.\1740
D008094_D018500 CID lithium_0\NNP\14625458 is_1\VBZ\836236 implicated_2\VBN\2677097 in_3\IN\13603305 drug-induced_4\JJ\1740 nephrogenic_5\JJ\1740 di_6\NN\1740 ,_7\,\1740 and_8\CC\1740 because_9\IN\1740 the_10\DT\1740 patient_11\NN\9898892 had_12\VBD\2108377 not_13\RB\1740 received_14\VBN\2210855 <e1>lithium</e1>_15\NN\14625458 since_16\IN\1740 being_17\VBG\836236 admitted_18\VBN\822367 to_19\IN\1740 the_20\DT\1740 hospital_21\NN\3739518 ,_22\,\1740 his_23\PRP$\1740 treatment_24\NN\654885 changed_25\VBN\46534 to_26\TO\1740 focus_27\VB\628491 on_28\IN\1740 <e2>nephrogenic_29\JJ\1740 di</e2>_30\NN\1740 ._31\.\1740
D008094_D018500 CID by_0\IN\1740 combining_1\VBG\2630189 information_2\NN\6598915 from_3\IN\1740 the_4\DT\1740 patient_5\NN\9898892 history_6\NN\15120823 ,_7\,\1740 the_8\DT\1740 physical_9\JJ\1740 examination_10\NN\633864 ,_11\,\1740 and_12\CC\1740 radiologic_13\JJ\1740 and_14\CC\1740 laboratory_15\NN\4602044 studies_16\NNS\635850 ,_17\,\1740 the_18\DT\1740 critical_19\JJ\1740 care_20\NN\575741 team_21\NN\8189659 demonstrated_22\VBD\2137132 that_23\IN\1740 the_24\DT\1740 patient_25\NN\9898892 had_26\VBD\2108377 been_27\VBN\836236 self-treating_28\JJ\1740 his_29\PRP$\1740 <e1>lithium-induced</e1>_30\JJ\1740 <e2>nephrogenic_31\JJ\1740 di</e2>_32\NN\1740 and_33\CC\1740 developed_34\VBD\1753788 neurogenic_35\JJ\1740 di_36\NN\1740 secondary_37\JJ\1740 to_38\TO\1740 brain_39\NN\5462674 trauma_40\NN\14052046 ._41\.\1740
D008094_D018500 CID by_0\IN\1740 combining_1\VBG\2630189 information_2\NN\6598915 from_3\IN\1740 the_4\DT\1740 patient_5\NN\9898892 history_6\NN\15120823 ,_7\,\1740 the_8\DT\1740 physical_9\JJ\1740 examination_10\NN\633864 ,_11\,\1740 and_12\CC\1740 radiologic_13\JJ\1740 and_14\CC\1740 laboratory_15\NN\4602044 studies_16\NNS\635850 ,_17\,\1740 the_18\DT\1740 critical_19\JJ\1740 care_20\NN\575741 team_21\NN\8189659 demonstrated_22\VBD\2137132 that_23\IN\1740 the_24\DT\1740 patient_25\NN\9898892 had_26\VBD\2108377 been_27\VBN\836236 self-treating_28\JJ\1740 his_29\PRP$\1740 <e1>lithium-induced</e1>_30\JJ\1740 nephrogenic_31\JJ\1740 di_32\NN\1740 and_33\CC\1740 developed_34\VBD\1753788 <e2>neurogenic_35\JJ\1740 di</e2>_36\NN\1740 secondary_37\JJ\1740 to_38\TO\1740 brain_39\NN\5462674 trauma_40\NN\14052046 ._41\.\1740
D008094_D001930 NONE by_0\IN\1740 combining_1\VBG\2630189 information_2\NN\6598915 from_3\IN\1740 the_4\DT\1740 patient_5\NN\9898892 history_6\NN\15120823 ,_7\,\1740 the_8\DT\1740 physical_9\JJ\1740 examination_10\NN\633864 ,_11\,\1740 and_12\CC\1740 radiologic_13\JJ\1740 and_14\CC\1740 laboratory_15\NN\4602044 studies_16\NNS\635850 ,_17\,\1740 the_18\DT\1740 critical_19\JJ\1740 care_20\NN\575741 team_21\NN\8189659 demonstrated_22\VBD\2137132 that_23\IN\1740 the_24\DT\1740 patient_25\NN\9898892 had_26\VBD\2108377 been_27\VBN\836236 self-treating_28\JJ\1740 his_29\PRP$\1740 <e1>lithium-induced</e1>_30\JJ\1740 nephrogenic_31\JJ\1740 di_32\NN\1740 and_33\CC\1740 developed_34\VBD\1753788 neurogenic_35\JJ\1740 di_36\NN\1740 secondary_37\JJ\1740 to_38\TO\1740 <e2>brain_39\NN\5462674 trauma</e2>_40\NN\14052046 ._41\.\1740
10713017
D005277_D006976 CID however_0\RB\1740 ,_1\,\1740 of_2\IN\1740 the_3\DT\1740 medications_4\NNS\3247620 surveyed_5\VBN\644583 ,_6\,\1740 only_7\RB\1740 the_8\DT\1740 <e1>fenfluramines</e1>_9\NNS\1740 had_10\VBD\2108377 a_11\DT\13649268 significant_12\JJ\1740 preferential_13\JJ\1740 association_14\NN\8008335 with_15\IN\1740 <e2>pph</e2>_16\NN\1740 as_17\IN\14622893 compared_18\VBN\644583 with_19\IN\1740 sph_20\NN\1740 (_21\-LRB-\1740 adjusted_22\VBN\126264 odds_23\NNS\4756635 ratio_24\NN\13815152 for_25\IN\1740 use_26\NN\407535 >_27\NN\1740 6_28\CD\13741022 months_29\NNS\15113229 ,_30\,\1740 7.5_31\CD\1740 ;_32\:\1740 95_33\CD\1740 %_34\NN\1740 confidence_35\NN\5697135 interval_36\NN\33615 ,_37\,\1740 1.7_38\CD\1740 to_39\TO\1740 32.4_40\CD\1740 )_41\-RRB-\1740 ._42\.\1740
D005277_D006976 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 magnitude_3\NN\4916342 of_4\IN\1740 the_5\DT\1740 association_6\NN\8008335 with_7\IN\1740 <e2>pph</e2>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 increase_11\NN\13576355 of_12\IN\1740 association_13\NN\8008335 with_14\IN\1740 increasing_15\VBG\169651 duration_16\NN\15113229 of_17\IN\1740 use_18\NN\407535 ,_19\,\1740 and_20\CC\1740 the_21\DT\1740 specificity_22\NN\4762633 for_23\IN\1740 <e1>fenfluramines</e1>_24\NNS\1740 are_25\VBP\836236 consistent_26\JJ\1740 with_27\IN\1740 previous_28\JJ\1740 studies_29\NNS\635850 indicating_30\VBG\952524 that_31\IN\1740 fenfluramines_32\NNS\1740 are_33\VBP\836236 causally_34\RB\1740 related_35\JJ\1740 to_36\TO\1740 pph_37\NN\1740 ._38\.\1740
D005277_D006976 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 magnitude_3\NN\4916342 of_4\IN\1740 the_5\DT\1740 association_6\NN\8008335 with_7\IN\1740 pph_8\NN\1740 ,_9\,\1740 the_10\DT\1740 increase_11\NN\13576355 of_12\IN\1740 association_13\NN\8008335 with_14\IN\1740 increasing_15\VBG\169651 duration_16\NN\15113229 of_17\IN\1740 use_18\NN\407535 ,_19\,\1740 and_20\CC\1740 the_21\DT\1740 specificity_22\NN\4762633 for_23\IN\1740 <e1>fenfluramines</e1>_24\NNS\1740 are_25\VBP\836236 consistent_26\JJ\1740 with_27\IN\1740 previous_28\JJ\1740 studies_29\NNS\635850 indicating_30\VBG\952524 that_31\IN\1740 fenfluramines_32\NNS\1740 are_33\VBP\836236 causally_34\RB\1740 related_35\JJ\1740 to_36\TO\1740 <e2>pph</e2>_37\NN\1740 ._38\.\1740
D005277_D006976 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 magnitude_3\NN\4916342 of_4\IN\1740 the_5\DT\1740 association_6\NN\8008335 with_7\IN\1740 <e2>pph</e2>_8\NN\1740 ,_9\,\1740 the_10\DT\1740 increase_11\NN\13576355 of_12\IN\1740 association_13\NN\8008335 with_14\IN\1740 increasing_15\VBG\169651 duration_16\NN\15113229 of_17\IN\1740 use_18\NN\407535 ,_19\,\1740 and_20\CC\1740 the_21\DT\1740 specificity_22\NN\4762633 for_23\IN\1740 fenfluramines_24\NNS\1740 are_25\VBP\836236 consistent_26\JJ\1740 with_27\IN\1740 previous_28\JJ\1740 studies_29\NNS\635850 indicating_30\VBG\952524 that_31\IN\1740 <e1>fenfluramines</e1>_32\NNS\1740 are_33\VBP\836236 causally_34\RB\1740 related_35\JJ\1740 to_36\TO\1740 pph_37\NN\1740 ._38\.\1740
D005277_D006976 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 magnitude_3\NN\4916342 of_4\IN\1740 the_5\DT\1740 association_6\NN\8008335 with_7\IN\1740 pph_8\NN\1740 ,_9\,\1740 the_10\DT\1740 increase_11\NN\13576355 of_12\IN\1740 association_13\NN\8008335 with_14\IN\1740 increasing_15\VBG\169651 duration_16\NN\15113229 of_17\IN\1740 use_18\NN\407535 ,_19\,\1740 and_20\CC\1740 the_21\DT\1740 specificity_22\NN\4762633 for_23\IN\1740 fenfluramines_24\NNS\1740 are_25\VBP\836236 consistent_26\JJ\1740 with_27\IN\1740 previous_28\JJ\1740 studies_29\NNS\635850 indicating_30\VBG\952524 that_31\IN\1740 <e1>fenfluramines</e1>_32\NNS\1740 are_33\VBP\836236 causally_34\RB\1740 related_35\JJ\1740 to_36\TO\1740 <e2>pph</e2>_37\NN\1740 ._38\.\1740
2818777
D010672_D056486 NONE <e1>phenytoin</e1>_0\NN\3550533 induced_1\VBD\1627355 fatal_2\JJ\1740 <e2>hepatic_3\JJ\1740 injury</e2>_4\NN\14052046 ._5\.\1740
D010672_D017093 CID a_0\DT\13649268 61_1\CD\1740 year_2\NN\15113229 old_3\JJ\1740 female_4\NN\15388 developed_5\VBD\1753788 fatal_6\JJ\1740 <e2>hepatic_7\JJ\1740 failure</e2>_8\NN\66216 after_9\IN\1740 <e1>phenytoin</e1>_10\NN\3550533 administration_11\NN\1133281 ._12\.\1740
25986755
D002110_D005921 NONE low_0\JJ\1740 functional_1\JJ\1740 programming_2\NN\1144133 of_3\IN\1740 renal_4\JJ\1740 at2r_5\NN\1740 mediates_6\VBZ\761713 the_7\DT\1740 developmental_8\JJ\1740 origin_9\NN\8620061 of_10\IN\1740 <e2>glomerulosclerosis</e2>_11\NN\1740 in_12\IN\13603305 adult_13\JJ\1740 offspring_14\NN\10235549 induced_15\VBN\1627355 by_16\IN\1740 prenatal_17\JJ\1740 <e1>caffeine</e1>_18\NN\14712692 exposure_19\NN\5042871 ._20\.\1740
D002110_D005317 CID unassigned_0\NNS\1740 :_1\:\1740 our_2\PRP$\1740 previous_3\JJ\1740 study_4\NN\635850 has_5\VBZ\2108377 indicated_6\VBN\952524 that_7\IN\1740 prenatal_8\JJ\1740 <e1>caffeine</e1>_9\NN\14712692 exposure_10\NN\5042871 (_11\-LRB-\1740 pce_12\NN\1740 )_13\-RRB-\1740 could_14\MD\1740 induce_15\VB\1627355 <e2>intrauterine_16\NN\1740 growth_17\NN\13526110 retardation</e2>_18\NN\7296428 (_19\-LRB-\1740 iugr_20\NN\1740 )_21\-RRB-\1740 of_22\IN\1740 offspring_23\NN\10235549 ._24\.\1740
D002110_D005317 CID unassigned_0\NNS\1740 :_1\:\1740 our_2\PRP$\1740 previous_3\JJ\1740 study_4\NN\635850 has_5\VBZ\2108377 indicated_6\VBN\952524 that_7\IN\1740 prenatal_8\JJ\1740 <e1>caffeine</e1>_9\NN\14712692 exposure_10\NN\5042871 (_11\-LRB-\1740 pce_12\NN\1740 )_13\-RRB-\1740 could_14\MD\1740 induce_15\VB\1627355 intrauterine_16\NN\1740 growth_17\NN\13526110 retardation_18\NN\7296428 (_19\-LRB-\1740 <e2>iugr</e2>_20\NN\1740 )_21\-RRB-\1740 of_22\IN\1740 offspring_23\NN\10235549 ._24\.\1740
D003404_D005921 NONE the_0\DT\1740 results_1\NNS\34213 revealed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 adult_5\JJ\1740 offspring_6\NN\10235549 kidneys_7\NNS\5333259 in_8\IN\13603305 the_9\DT\1740 pce_10\NN\1740 group_11\NN\2137 exhibited_12\VBD\2632167 <e2>glomerulosclerosis</e2>_13\NN\1740 as_14\RB\1740 well_15\RB\1740 as_16\IN\14622893 interstitial_17\JJ\1740 fibrosis_18\NN\14204950 ,_19\,\1740 accompanied_20\VBN\1835496 by_21\IN\1740 elevated_22\JJ\1740 levels_23\NNS\4916342 of_24\IN\1740 serum_25\NN\5397468 <e1>creatinine</e1>_26\NN\1740 and_27\CC\1740 urine_28\NN\14853947 protein_29\NN\14944888 ._30\.\1740
D003404_D005355 NONE the_0\DT\1740 results_1\NNS\34213 revealed_2\VBD\2137132 that_3\IN\1740 the_4\DT\1740 adult_5\JJ\1740 offspring_6\NN\10235549 kidneys_7\NNS\5333259 in_8\IN\13603305 the_9\DT\1740 pce_10\NN\1740 group_11\NN\2137 exhibited_12\VBD\2632167 glomerulosclerosis_13\NN\1740 as_14\RB\1740 well_15\RB\1740 as_16\IN\14622893 <e2>interstitial_17\JJ\1740 fibrosis</e2>_18\NN\14204950 ,_19\,\1740 accompanied_20\VBN\1835496 by_21\IN\1740 elevated_22\JJ\1740 levels_23\NNS\4916342 of_24\IN\1740 serum_25\NN\5397468 <e1>creatinine</e1>_26\NN\1740 and_27\CC\1740 urine_28\NN\14853947 protein_29\NN\14944888 ._30\.\1740
2217015
D008528_D009503 CID <e1>mefenamic_0\JJ\1740 acid-induced</e1>_1\JJ\1740 <e2>neutropenia</e2>_2\NN\14196405 and_3\CC\1740 renal_4\JJ\1740 failure_5\NN\66216 in_6\IN\13603305 elderly_7\JJ\1740 females_8\NNS\15388 with_9\IN\1740 hypothyroidism_10\NN\14059928 ._11\.\1740
D008528_D009503 CID we_0\PRP\1740 report_1\VBP\831651 <e1>mefenamic_2\JJ\1740 acid-induced</e1>_3\JJ\1740 non-oliguric_4\JJ\1740 renal_5\JJ\1740 failure_6\NN\66216 and_7\CC\1740 severe_8\JJ\1740 <e2>neutropenia</e2>_9\NN\14196405 occurring_10\VBG\2623529 simultaneously_11\RB\1740 in_12\IN\13603305 two_13\CD\13741022 elderly_14\JJ\1740 females_15\NNS\15388 ._16\.\1740
D008528_D051437 CID <e1>mefenamic_0\JJ\1740 acid-induced</e1>_1\JJ\1740 neutropenia_2\NN\14196405 and_3\CC\1740 <e2>renal_4\JJ\1740 failure</e2>_5\NN\66216 in_6\IN\13603305 elderly_7\JJ\1740 females_8\NNS\15388 with_9\IN\1740 hypothyroidism_10\NN\14059928 ._11\.\1740
D008528_D051437 CID we_0\PRP\1740 report_1\VBP\831651 <e1>mefenamic_2\JJ\1740 acid-induced</e1>_3\JJ\1740 non-oliguric_4\JJ\1740 <e2>renal_5\JJ\1740 failure</e2>_6\NN\66216 and_7\CC\1740 severe_8\JJ\1740 neutropenia_9\NN\14196405 occurring_10\VBG\2623529 simultaneously_11\RB\1740 in_12\IN\13603305 two_13\CD\13741022 elderly_14\JJ\1740 females_15\NNS\15388 ._16\.\1740
D008528_D007037 NONE <e1>mefenamic_0\JJ\1740 acid-induced</e1>_1\JJ\1740 neutropenia_2\NN\14196405 and_3\CC\1740 renal_4\JJ\1740 failure_5\NN\66216 in_6\IN\13603305 elderly_7\JJ\1740 females_8\NNS\15388 with_9\IN\1740 <e2>hypothyroidism</e2>_10\NN\14059928 ._11\.\1740
D008528_D007037 NONE however_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 would_3\MD\1740 seem_4\VB\2604760 prudent_5\JJ\1740 not_6\RB\1740 to_7\TO\1740 use_8\VB\1156834 <e1>mefenamic_9\JJ\1740 acid</e1>_10\NN\14818238 in_11\IN\13603305 <e2>hypothyroid</e2>_12\JJ\1740 patients_13\NNS\9898892 until_14\IN\1740 the_15\DT\1740 hypothyroidism_16\NN\14059928 has_17\VBZ\2108377 been_18\VBN\836236 corrected_19\VBN\138508 ._20\.\1740
D008528_D007037 NONE however_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 would_3\MD\1740 seem_4\VB\2604760 prudent_5\JJ\1740 not_6\RB\1740 to_7\TO\1740 use_8\VB\1156834 <e1>mefenamic_9\JJ\1740 acid</e1>_10\NN\14818238 in_11\IN\13603305 hypothyroid_12\JJ\1740 patients_13\NNS\9898892 until_14\IN\1740 the_15\DT\1740 <e2>hypothyroidism</e2>_16\NN\14059928 has_17\VBZ\2108377 been_18\VBN\836236 corrected_19\VBN\138508 ._20\.\1740
15609701
D013015_D003329 CID <e1>sotalol-induced</e1>_0\JJ\1740 <e2>coronary_1\JJ\1740 spasm</e2>_2\NN\14299637 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 dilated_7\JJ\1740 cardiomyopathy_8\NN\14103288 associated_9\VBN\628491 with_10\IN\1740 sustained_11\JJ\1740 ventricular_12\JJ\1740 tachycardia_13\NN\14110674 ._14\.\1740
D013015_D003329 CID <e2>coronary_0\JJ\1740 vasospasm</e2>_1\NN\1740 may_2\MD\15209706 be_3\VB\836236 induced_4\VBN\1627355 by_5\IN\1740 the_6\DT\1740 non-selective_7\JJ\1740 beta-blocking_8\JJ\1740 properties_9\NNS\32613 of_10\IN\1740 <e1>sotalol</e1>_11\NNS\1740 ._12\.\1740
D013015_D002311 NONE <e1>sotalol-induced</e1>_0\JJ\1740 coronary_1\JJ\1740 spasm_2\NN\14299637 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 <e2>dilated_7\JJ\1740 cardiomyopathy</e2>_8\NN\14103288 associated_9\VBN\628491 with_10\IN\1740 sustained_11\JJ\1740 ventricular_12\JJ\1740 tachycardia_13\NN\14110674 ._14\.\1740
D013015_D017180 NONE <e1>sotalol-induced</e1>_0\JJ\1740 coronary_1\JJ\1740 spasm_2\NN\14299637 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 dilated_7\JJ\1740 cardiomyopathy_8\NN\14103288 associated_9\VBN\628491 with_10\IN\1740 sustained_11\JJ\1740 <e2>ventricular_12\JJ\1740 tachycardia</e2>_13\NN\14110674 ._14\.\1740
D013015_D017180 NONE an_0\DT\6697703 alternate_1\JJ\1740 class_2\NN\7951464 iii_3\CD\13741022 agent_4\NN\7347 ,_5\,\1740 <e1>sotalol</e1>_6\NNS\1740 ,_7\,\1740 was_8\VBD\836236 also_9\RB\1740 effective_10\JJ\1740 for_11\IN\1740 the_12\DT\1740 prevention_13\NN\1073995 of_14\IN\1740 <e2>vt</e2>_15\NN\1740 ._16\.\1740
C076259_D017180 NONE after_0\IN\1740 the_1\DT\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>nifekalant_4\JJ\1740 hydrochloride</e1>_5\NN\14817592 ,_6\,\1740 sustained_7\JJ\1740 <e2>vt</e2>_8\NN\1740 was_9\VBD\836236 terminated_10\VBN\126264 ._11\.\1740
23433219
D008694_D011605 CID the_0\DT\1740 risk_1\NN\14541044 and_2\CC\1740 associated_3\VBN\628491 factors_4\NNS\7326557 of_5\IN\1740 <e1>methamphetamine</e1>_6\JJ\1740 <e2>psychosis</e2>_7\NN\14380140 in_8\IN\13603305 methamphetamine-dependent_9\JJ\1740 patients_10\NNS\9898892 in_11\IN\13603305 malaysia_12\NNP\1740 ._13\.\1740
D008694_D011605 CID the_0\DT\1740 risk_1\NN\14541044 and_2\CC\1740 associated_3\VBN\628491 factors_4\NNS\7326557 of_5\IN\1740 methamphetamine_6\JJ\1740 <e2>psychosis</e2>_7\NN\14380140 in_8\IN\13603305 <e1>methamphetamine-dependent</e1>_9\JJ\1740 patients_10\NNS\9898892 in_11\IN\13603305 malaysia_12\NNP\1740 ._13\.\1740
D008694_D011605 CID objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 lifetime_13\NN\15113229 and_14\CC\1740 current_15\JJ\1740 <e1>methamphetamine-induced</e1>_16\JJ\1740 <e2>psychosis</e2>_17\NN\14380140 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 methamphetamine_21\NN\2704153 dependence_22\NN\24720 ._23\.\1740
D008694_D011605 CID objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 lifetime_13\NN\15113229 and_14\CC\1740 current_15\JJ\1740 methamphetamine-induced_16\JJ\1740 <e2>psychosis</e2>_17\NN\14380140 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e1>methamphetamine</e1>_21\NN\2704153 dependence_22\NN\24720 ._23\.\1740
D008694_D011605 CID the_0\DT\1740 association_1\NN\8008335 between_2\IN\1740 psychiatric_3\JJ\1740 co-morbidity_4\NN\1740 and_5\CC\1740 <e1>methamphetamine-induced</e1>_6\JJ\1740 <e2>psychosis</e2>_7\NN\14380140 was_8\VBD\836236 also_9\RB\1740 studied_10\VBN\630380 ._11\.\1740
D008694_D011605 CID patients_0\NNS\9898892 with_1\IN\1740 the_2\DT\1740 diagnosis_3\NN\152018 of_4\IN\1740 <e1>methamphetamine</e1>_5\NN\2704153 based_6\VBN\2694933 on_7\IN\1740 dsm-iv_8\NN\1740 were_9\VBD\836236 interviewed_10\VBN\964694 using_11\VBG\1156834 the_12\DT\1740 mini_13\NNP\4230808 international_14\NNP\8366202 neuropsychiatric_15\NNP\1740 interview_16\NNP\7193958 (_17\-LRB-\1740 m.i.n.i._18\NNP\1740 )_19\-RRB-\1740 for_20\IN\1740 methamphetamine-induced_21\JJ\1740 <e2>psychosis</e2>_22\NN\14380140 and_23\CC\1740 other_24\JJ\1740 axis_25\NN\8593262 i_26\CD\14622893 psychiatric_27\JJ\1740 disorders_28\NNS\14034177 ._29\.\1740
D008694_D011605 CID patients_0\NNS\9898892 with_1\IN\1740 the_2\DT\1740 diagnosis_3\NN\152018 of_4\IN\1740 methamphetamine_5\NN\2704153 based_6\VBN\2694933 on_7\IN\1740 dsm-iv_8\NN\1740 were_9\VBD\836236 interviewed_10\VBN\964694 using_11\VBG\1156834 the_12\DT\1740 mini_13\NNP\4230808 international_14\NNP\8366202 neuropsychiatric_15\NNP\1740 interview_16\NNP\7193958 (_17\-LRB-\1740 m.i.n.i._18\NNP\1740 )_19\-RRB-\1740 for_20\IN\1740 <e1>methamphetamine-induced</e1>_21\JJ\1740 <e2>psychosis</e2>_22\NN\14380140 and_23\CC\1740 other_24\JJ\1740 axis_25\NN\8593262 i_26\CD\14622893 psychiatric_27\JJ\1740 disorders_28\NNS\14034177 ._29\.\1740
D008694_D011605 CID co-morbid_0\JJ\1740 major_1\JJ\1740 depressive_2\JJ\1740 disorder_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 bipolar_13\JJ\1740 disorder_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 antisocial_24\JJ\1740 personality_25\NN\24264 disorder_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 <e1>methamphetamine</e1>_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 methamphetamine-induced_44\JJ\1740 <e2>psychosis</e2>_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D011605 CID co-morbid_0\JJ\1740 major_1\JJ\1740 depressive_2\JJ\1740 disorder_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 bipolar_13\JJ\1740 disorder_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 antisocial_24\JJ\1740 personality_25\NN\24264 disorder_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 methamphetamine_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 <e1>methamphetamine-induced</e1>_44\JJ\1740 <e2>psychosis</e2>_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D011605 CID conclusion_0\NN\5837957 :_1\:\1740 there_2\EX\27167 was_3\VBD\836236 a_4\DT\13649268 high_5\JJ\1740 risk_6\NN\14541044 of_7\IN\1740 <e2>psychosis</e2>_8\NN\14380140 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 <e1>methamphetamine</e1>_12\NN\2704153 dependence_13\NN\24720 ._14\.\1740
D008694_D011605 CID it_0\PRP\6125041 is_1\VBZ\836236 recommended_2\VBN\875394 that_3\IN\1740 all_4\DT\1740 cases_5\NNS\7283608 of_6\IN\1740 <e1>methamphetamine</e1>_7\NN\2704153 dependence_8\NN\24720 should_9\MD\1740 be_10\VB\836236 screened_11\VBN\2533282 for_12\IN\1740 <e2>psychotic_13\JJ\1740 symptoms</e2>_14\NNS\5823932 ._15\.\1740
D008694_D001523 NONE patients_0\NNS\9898892 with_1\IN\1740 the_2\DT\1740 diagnosis_3\NN\152018 of_4\IN\1740 <e1>methamphetamine</e1>_5\NN\2704153 based_6\VBN\2694933 on_7\IN\1740 dsm-iv_8\NN\1740 were_9\VBD\836236 interviewed_10\VBN\964694 using_11\VBG\1156834 the_12\DT\1740 mini_13\NNP\4230808 international_14\NNP\8366202 neuropsychiatric_15\NNP\1740 interview_16\NNP\7193958 (_17\-LRB-\1740 m.i.n.i._18\NNP\1740 )_19\-RRB-\1740 for_20\IN\1740 methamphetamine-induced_21\JJ\1740 psychosis_22\NN\14380140 and_23\CC\1740 other_24\JJ\1740 axis_25\NN\8593262 i_26\CD\14622893 <e2>psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D008694_D001523 NONE patients_0\NNS\9898892 with_1\IN\1740 the_2\DT\1740 diagnosis_3\NN\152018 of_4\IN\1740 methamphetamine_5\NN\2704153 based_6\VBN\2694933 on_7\IN\1740 dsm-iv_8\NN\1740 were_9\VBD\836236 interviewed_10\VBN\964694 using_11\VBG\1156834 the_12\DT\1740 mini_13\NNP\4230808 international_14\NNP\8366202 neuropsychiatric_15\NNP\1740 interview_16\NNP\7193958 (_17\-LRB-\1740 m.i.n.i._18\NNP\1740 )_19\-RRB-\1740 for_20\IN\1740 <e1>methamphetamine-induced</e1>_21\JJ\1740 psychosis_22\NN\14380140 and_23\CC\1740 other_24\JJ\1740 axis_25\NN\8593262 i_26\CD\14622893 <e2>psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D008694_D003866 NONE co-morbid_0\JJ\1740 major_1\JJ\1740 <e2>depressive_2\JJ\1740 disorder</e2>_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 bipolar_13\JJ\1740 disorder_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 antisocial_24\JJ\1740 personality_25\NN\24264 disorder_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 <e1>methamphetamine</e1>_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 methamphetamine-induced_44\JJ\1740 psychosis_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D003866 NONE co-morbid_0\JJ\1740 major_1\JJ\1740 <e2>depressive_2\JJ\1740 disorder</e2>_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 bipolar_13\JJ\1740 disorder_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 antisocial_24\JJ\1740 personality_25\NN\24264 disorder_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 methamphetamine_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 <e1>methamphetamine-induced</e1>_44\JJ\1740 psychosis_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D001714 CID co-morbid_0\JJ\1740 major_1\JJ\1740 depressive_2\JJ\1740 disorder_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 <e2>bipolar_13\JJ\1740 disorder</e2>_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 antisocial_24\JJ\1740 personality_25\NN\24264 disorder_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 <e1>methamphetamine</e1>_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 methamphetamine-induced_44\JJ\1740 psychosis_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D001714 CID co-morbid_0\JJ\1740 major_1\JJ\1740 depressive_2\JJ\1740 disorder_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 <e2>bipolar_13\JJ\1740 disorder</e2>_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 antisocial_24\JJ\1740 personality_25\NN\24264 disorder_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 methamphetamine_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 <e1>methamphetamine-induced</e1>_44\JJ\1740 psychosis_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D000987 CID co-morbid_0\JJ\1740 major_1\JJ\1740 depressive_2\JJ\1740 disorder_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 bipolar_13\JJ\1740 disorder_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 <e2>antisocial_24\JJ\1740 personality_25\NN\24264 disorder</e2>_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 <e1>methamphetamine</e1>_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 methamphetamine-induced_44\JJ\1740 psychosis_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D000987 CID co-morbid_0\JJ\1740 major_1\JJ\1740 depressive_2\JJ\1740 disorder_3\NN\14034177 (_4\-LRB-\1740 or=7.18_5\NN\1740 ,_6\,\1740 95_7\CD\1740 ci=2.612_8\NN\1740 -_9\HYPH\1740 19.708_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 bipolar_13\JJ\1740 disorder_14\NN\14034177 (_15\-LRB-\1740 or=13.807_16\NN\1740 ,_17\,\1740 95_18\CD\1740 ci=5.194_19\CD\1740 -_20\HYPH\1740 36.706_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 <e2>antisocial_24\JJ\1740 personality_25\NN\24264 disorder</e2>_26\NN\14034177 (_27\-LRB-\1740 or=12.619_28\NN\1740 ,_29\,\1740 95_30\CD\1740 ci=6.702_31\CD\1740 -_32\:\1740 23.759_33\CD\1740 )_34\-RRB-\1740 and_35\CC\1740 heavy_36\JJ\1740 methamphetamine_37\NN\2704153 uses_38\NNS\407535 were_39\VBD\836236 significantly_40\RB\1740 associated_41\VBN\628491 with_42\IN\1740 lifetime_43\NN\15113229 <e1>methamphetamine-induced</e1>_44\JJ\1740 psychosis_45\NN\14380140 after_46\IN\1740 adjusted_47\VBN\126264 for_48\IN\1740 other_49\JJ\1740 factors_50\NNS\7326557 ._51\.\1740
D008694_D000987 CID it_0\PRP\6125041 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 co-morbid_4\JJ\1740 affective_5\JJ\1740 disorder_6\NN\14034177 ,_7\,\1740 <e2>antisocial_8\JJ\1740 personality</e2>_9\NN\24264 ,_10\,\1740 and_11\CC\1740 heavy_12\JJ\1740 <e1>methamphetamine</e1>_13\NN\2704153 use_14\NN\407535 ._15\.\1740
D008694_D019964 NONE it_0\PRP\6125041 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 co-morbid_4\JJ\1740 <e2>affective_5\JJ\1740 disorder</e2>_6\NN\14034177 ,_7\,\1740 antisocial_8\JJ\1740 personality_9\NN\24264 ,_10\,\1740 and_11\CC\1740 heavy_12\JJ\1740 <e1>methamphetamine</e1>_13\NN\2704153 use_14\NN\407535 ._15\.\1740
16112787
D014640_D007674 CID in_0\FW\13603305 vivo_1\FW\1740 evidences_2\NNS\5816287 suggesting_3\VBG\1010118 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 oxidative_7\JJ\1740 stress_8\NN\7083732 in_9\IN\13603305 pathogenesis_10\NN\13533470 of_11\IN\1740 <e1>vancomycin-induced</e1>_12\JJ\1740 <e2>nephrotoxicity</e2>_13\NN\1740 :_14\:\1740 protection_15\NN\407535 by_16\IN\1740 erdosteine_17\NN\1740 ._18\.\1740
D014640_D007674 CID the_0\DT\1740 aims_1\NNS\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 <e1>vancomycin</e1>_8\NN\2716866 (vcm)-induced_9\JJ\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 that_12\WDT\1740 promotes_13\VBZ\2556126 production_14\NN\30358 of_15\IN\1740 reactive_16\JJ\1740 oxygen_17\NN\14622893 species_18\NNS\7992450 (_19\-LRB-\1740 ros_20\NN\6894544 )_21\-RRB-\1740 and_22\CC\1740 to_23\TO\1740 investigate_24\VB\644583 the_25\DT\1740 role_26\NN\719494 of_27\IN\1740 erdosteine_28\NN\1740 ,_29\,\1740 an_30\DT\6697703 expectorant_31\JJ\1740 agent_32\NN\7347 ,_33\,\1740 which_34\WDT\1740 has_35\VBZ\2108377 also_36\RB\1740 antioxidant_37\JJ\1740 properties_38\NNS\32613 ,_39\,\1740 on_40\IN\1740 kidney_41\NN\5333259 tissue_42\NN\5220461 against_43\IN\1740 the_44\DT\1740 possible_45\JJ\1740 vcm-induced_46\JJ\1740 <e2>renal_47\JJ\1740 impairment</e2>_48\NN\7296428 in_49\IN\13603305 rats_50\NNS\2329401 ._51\.\1740
D014640_D007674 CID the_0\DT\1740 aims_1\NNS\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 vancomycin_8\NN\2716866 <e1>(vcm)-induced</e1>_9\JJ\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 that_12\WDT\1740 promotes_13\VBZ\2556126 production_14\NN\30358 of_15\IN\1740 reactive_16\JJ\1740 oxygen_17\NN\14622893 species_18\NNS\7992450 (_19\-LRB-\1740 ros_20\NN\6894544 )_21\-RRB-\1740 and_22\CC\1740 to_23\TO\1740 investigate_24\VB\644583 the_25\DT\1740 role_26\NN\719494 of_27\IN\1740 erdosteine_28\NN\1740 ,_29\,\1740 an_30\DT\6697703 expectorant_31\JJ\1740 agent_32\NN\7347 ,_33\,\1740 which_34\WDT\1740 has_35\VBZ\2108377 also_36\RB\1740 antioxidant_37\JJ\1740 properties_38\NNS\32613 ,_39\,\1740 on_40\IN\1740 kidney_41\NN\5333259 tissue_42\NN\5220461 against_43\IN\1740 the_44\DT\1740 possible_45\JJ\1740 vcm-induced_46\JJ\1740 <e2>renal_47\JJ\1740 impairment</e2>_48\NN\7296428 in_49\IN\13603305 rats_50\NNS\2329401 ._51\.\1740
D014640_D007674 CID the_0\DT\1740 aims_1\NNS\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 vancomycin_8\NN\2716866 (vcm)-induced_9\JJ\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 that_12\WDT\1740 promotes_13\VBZ\2556126 production_14\NN\30358 of_15\IN\1740 reactive_16\JJ\1740 oxygen_17\NN\14622893 species_18\NNS\7992450 (_19\-LRB-\1740 ros_20\NN\6894544 )_21\-RRB-\1740 and_22\CC\1740 to_23\TO\1740 investigate_24\VB\644583 the_25\DT\1740 role_26\NN\719494 of_27\IN\1740 erdosteine_28\NN\1740 ,_29\,\1740 an_30\DT\6697703 expectorant_31\JJ\1740 agent_32\NN\7347 ,_33\,\1740 which_34\WDT\1740 has_35\VBZ\2108377 also_36\RB\1740 antioxidant_37\JJ\1740 properties_38\NNS\32613 ,_39\,\1740 on_40\IN\1740 kidney_41\NN\5333259 tissue_42\NN\5220461 against_43\IN\1740 the_44\DT\1740 possible_45\JJ\1740 <e1>vcm-induced</e1>_46\JJ\1740 <e2>renal_47\JJ\1740 impairment</e2>_48\NN\7296428 in_49\IN\13603305 rats_50\NNS\2329401 ._51\.\1740
D014640_D007674 CID <e1>vcm</e1>_0\NN\1740 administration_1\NN\1133281 to_2\TO\1740 control_3\NN\5190804 rats_4\NNS\2329401 significantly_5\RB\1740 increased_6\VBD\169651 renal_7\JJ\1740 malondialdehyde_8\NN\1740 (_9\-LRB-\1740 mda_10\NN\1740 )_11\-RRB-\1740 and_12\CC\1740 urinary_13\JJ\1740 n-acetyl-beta-d-glucosaminidase_14\NN\1740 (_15\-LRB-\1740 nag_16\NN\9631463 ,_17\,\1740 a_18\DT\13649268 marker_19\NN\21939 of_20\IN\1740 <e2>renal_21\JJ\1740 tubular_22\JJ\1740 injury</e2>_23\NN\14052046 )_24\-RRB-\1740 excretion_25\NN\13466586 but_26\CC\1740 decreased_27\VBD\169651 superoxide_28\NN\14971519 dismutase_29\NN\1740 (_30\-LRB-\1740 sod_31\NN\9335240 )_32\-RRB-\1740 and_33\CC\1740 catalase_34\NN\14732946 (_35\-LRB-\1740 cat_36\NN\2120997 )_37\-RRB-\1740 activities_38\NNS\30358 ._39\.\1740
D014640_D007674 CID erdosteine_0\NNP\1740 showed_1\VBD\2137132 histopathological_2\JJ\1740 protection_3\NN\407535 against_4\IN\1740 <e1>vcm-induced</e1>_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 ._7\.\1740
D014640_D007674 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 oxidative_4\JJ\1740 tubular_5\JJ\1740 damage_6\NN\7296428 plays_7\VBZ\1072262 an_8\DT\6697703 important_9\JJ\1740 role_10\NN\719494 in_11\IN\13603305 the_12\DT\1740 <e1>vcm-induced</e1>_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 and_15\CC\1740 the_16\DT\1740 modulation_17\NN\7044917 of_18\IN\1740 oxidative_19\JJ\1740 stress_20\NN\7083732 with_21\IN\1740 erdosteine_22\NN\1740 reduces_23\VBZ\441445 the_24\DT\1740 vcm-induced_25\JJ\1740 kidney_26\NN\5333259 damage_27\NN\7296428 both_28\CC\1740 at_29\IN\14622893 the_30\DT\1740 biochemical_31\JJ\1740 and_32\CC\1740 histological_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
D014640_D007674 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 oxidative_4\JJ\1740 tubular_5\JJ\1740 damage_6\NN\7296428 plays_7\VBZ\1072262 an_8\DT\6697703 important_9\JJ\1740 role_10\NN\719494 in_11\IN\13603305 the_12\DT\1740 <e1>vcm-induced</e1>_13\JJ\1740 nephrotoxicity_14\NN\1740 and_15\CC\1740 the_16\DT\1740 modulation_17\NN\7044917 of_18\IN\1740 oxidative_19\JJ\1740 stress_20\NN\7083732 with_21\IN\1740 erdosteine_22\NN\1740 reduces_23\VBZ\441445 the_24\DT\1740 vcm-induced_25\JJ\1740 <e2>kidney_26\NN\5333259 damage</e2>_27\NN\7296428 both_28\CC\1740 at_29\IN\14622893 the_30\DT\1740 biochemical_31\JJ\1740 and_32\CC\1740 histological_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
D014640_D007674 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 oxidative_4\JJ\1740 tubular_5\JJ\1740 damage_6\NN\7296428 plays_7\VBZ\1072262 an_8\DT\6697703 important_9\JJ\1740 role_10\NN\719494 in_11\IN\13603305 the_12\DT\1740 vcm-induced_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 and_15\CC\1740 the_16\DT\1740 modulation_17\NN\7044917 of_18\IN\1740 oxidative_19\JJ\1740 stress_20\NN\7083732 with_21\IN\1740 erdosteine_22\NN\1740 reduces_23\VBZ\441445 the_24\DT\1740 <e1>vcm-induced</e1>_25\JJ\1740 kidney_26\NN\5333259 damage_27\NN\7296428 both_28\CC\1740 at_29\IN\14622893 the_30\DT\1740 biochemical_31\JJ\1740 and_32\CC\1740 histological_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
D014640_D007674 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 oxidative_4\JJ\1740 tubular_5\JJ\1740 damage_6\NN\7296428 plays_7\VBZ\1072262 an_8\DT\6697703 important_9\JJ\1740 role_10\NN\719494 in_11\IN\13603305 the_12\DT\1740 vcm-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 and_15\CC\1740 the_16\DT\1740 modulation_17\NN\7044917 of_18\IN\1740 oxidative_19\JJ\1740 stress_20\NN\7083732 with_21\IN\1740 erdosteine_22\NN\1740 reduces_23\VBZ\441445 the_24\DT\1740 <e1>vcm-induced</e1>_25\JJ\1740 <e2>kidney_26\NN\5333259 damage</e2>_27\NN\7296428 both_28\CC\1740 at_29\IN\14622893 the_30\DT\1740 biochemical_31\JJ\1740 and_32\CC\1740 histological_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
C048498_D007674 NONE in_0\FW\13603305 vivo_1\FW\1740 evidences_2\NNS\5816287 suggesting_3\VBG\1010118 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 oxidative_7\JJ\1740 stress_8\NN\7083732 in_9\IN\13603305 pathogenesis_10\NN\13533470 of_11\IN\1740 vancomycin-induced_12\JJ\1740 <e2>nephrotoxicity</e2>_13\NN\1740 :_14\:\1740 protection_15\NN\407535 by_16\IN\1740 <e1>erdosteine</e1>_17\NN\1740 ._18\.\1740
C048498_D007674 NONE the_0\DT\1740 aims_1\NNS\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 vancomycin_8\NN\2716866 (vcm)-induced_9\JJ\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 that_12\WDT\1740 promotes_13\VBZ\2556126 production_14\NN\30358 of_15\IN\1740 reactive_16\JJ\1740 oxygen_17\NN\14622893 species_18\NNS\7992450 (_19\-LRB-\1740 ros_20\NN\6894544 )_21\-RRB-\1740 and_22\CC\1740 to_23\TO\1740 investigate_24\VB\644583 the_25\DT\1740 role_26\NN\719494 of_27\IN\1740 <e1>erdosteine</e1>_28\NN\1740 ,_29\,\1740 an_30\DT\6697703 expectorant_31\JJ\1740 agent_32\NN\7347 ,_33\,\1740 which_34\WDT\1740 has_35\VBZ\2108377 also_36\RB\1740 antioxidant_37\JJ\1740 properties_38\NNS\32613 ,_39\,\1740 on_40\IN\1740 kidney_41\NN\5333259 tissue_42\NN\5220461 against_43\IN\1740 the_44\DT\1740 possible_45\JJ\1740 vcm-induced_46\JJ\1740 <e2>renal_47\JJ\1740 impairment</e2>_48\NN\7296428 in_49\IN\13603305 rats_50\NNS\2329401 ._51\.\1740
C048498_D007674 NONE <e1>erdosteine</e1>_0\NNP\1740 showed_1\VBD\2137132 histopathological_2\JJ\1740 protection_3\NN\407535 against_4\IN\1740 vcm-induced_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 ._7\.\1740
C048498_D007674 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 oxidative_4\JJ\1740 tubular_5\JJ\1740 damage_6\NN\7296428 plays_7\VBZ\1072262 an_8\DT\6697703 important_9\JJ\1740 role_10\NN\719494 in_11\IN\13603305 the_12\DT\1740 vcm-induced_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 and_15\CC\1740 the_16\DT\1740 modulation_17\NN\7044917 of_18\IN\1740 oxidative_19\JJ\1740 stress_20\NN\7083732 with_21\IN\1740 <e1>erdosteine</e1>_22\NN\1740 reduces_23\VBZ\441445 the_24\DT\1740 vcm-induced_25\JJ\1740 kidney_26\NN\5333259 damage_27\NN\7296428 both_28\CC\1740 at_29\IN\14622893 the_30\DT\1740 biochemical_31\JJ\1740 and_32\CC\1740 histological_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
C048498_D007674 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 oxidative_4\JJ\1740 tubular_5\JJ\1740 damage_6\NN\7296428 plays_7\VBZ\1072262 an_8\DT\6697703 important_9\JJ\1740 role_10\NN\719494 in_11\IN\13603305 the_12\DT\1740 vcm-induced_13\JJ\1740 nephrotoxicity_14\NN\1740 and_15\CC\1740 the_16\DT\1740 modulation_17\NN\7044917 of_18\IN\1740 oxidative_19\JJ\1740 stress_20\NN\7083732 with_21\IN\1740 <e1>erdosteine</e1>_22\NN\1740 reduces_23\VBZ\441445 the_24\DT\1740 vcm-induced_25\JJ\1740 <e2>kidney_26\NN\5333259 damage</e2>_27\NN\7296428 both_28\CC\1740 at_29\IN\14622893 the_30\DT\1740 biochemical_31\JJ\1740 and_32\CC\1740 histological_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
D010100_D007674 NONE the_0\DT\1740 aims_1\NNS\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 vancomycin_8\NN\2716866 (vcm)-induced_9\JJ\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 that_12\WDT\1740 promotes_13\VBZ\2556126 production_14\NN\30358 of_15\IN\1740 reactive_16\JJ\1740 <e1>oxygen</e1>_17\NN\14622893 species_18\NNS\7992450 (_19\-LRB-\1740 ros_20\NN\6894544 )_21\-RRB-\1740 and_22\CC\1740 to_23\TO\1740 investigate_24\VB\644583 the_25\DT\1740 role_26\NN\719494 of_27\IN\1740 erdosteine_28\NN\1740 ,_29\,\1740 an_30\DT\6697703 expectorant_31\JJ\1740 agent_32\NN\7347 ,_33\,\1740 which_34\WDT\1740 has_35\VBZ\2108377 also_36\RB\1740 antioxidant_37\JJ\1740 properties_38\NNS\32613 ,_39\,\1740 on_40\IN\1740 kidney_41\NN\5333259 tissue_42\NN\5220461 against_43\IN\1740 the_44\DT\1740 possible_45\JJ\1740 vcm-induced_46\JJ\1740 <e2>renal_47\JJ\1740 impairment</e2>_48\NN\7296428 in_49\IN\13603305 rats_50\NNS\2329401 ._51\.\1740
D008315_D007674 NONE vcm_0\NN\1740 administration_1\NN\1133281 to_2\TO\1740 control_3\NN\5190804 rats_4\NNS\2329401 significantly_5\RB\1740 increased_6\VBD\169651 renal_7\JJ\1740 <e1>malondialdehyde</e1>_8\NN\1740 (_9\-LRB-\1740 mda_10\NN\1740 )_11\-RRB-\1740 and_12\CC\1740 urinary_13\JJ\1740 n-acetyl-beta-d-glucosaminidase_14\NN\1740 (_15\-LRB-\1740 nag_16\NN\9631463 ,_17\,\1740 a_18\DT\13649268 marker_19\NN\21939 of_20\IN\1740 <e2>renal_21\JJ\1740 tubular_22\JJ\1740 injury</e2>_23\NN\14052046 )_24\-RRB-\1740 excretion_25\NN\13466586 but_26\CC\1740 decreased_27\VBD\169651 superoxide_28\NN\14971519 dismutase_29\NN\1740 (_30\-LRB-\1740 sod_31\NN\9335240 )_32\-RRB-\1740 and_33\CC\1740 catalase_34\NN\14732946 (_35\-LRB-\1740 cat_36\NN\2120997 )_37\-RRB-\1740 activities_38\NNS\30358 ._39\.\1740
D008315_D007674 NONE vcm_0\NN\1740 administration_1\NN\1133281 to_2\TO\1740 control_3\NN\5190804 rats_4\NNS\2329401 significantly_5\RB\1740 increased_6\VBD\169651 renal_7\JJ\1740 malondialdehyde_8\NN\1740 (_9\-LRB-\1740 <e1>mda</e1>_10\NN\1740 )_11\-RRB-\1740 and_12\CC\1740 urinary_13\JJ\1740 n-acetyl-beta-d-glucosaminidase_14\NN\1740 (_15\-LRB-\1740 nag_16\NN\9631463 ,_17\,\1740 a_18\DT\13649268 marker_19\NN\21939 of_20\IN\1740 <e2>renal_21\JJ\1740 tubular_22\JJ\1740 injury</e2>_23\NN\14052046 )_24\-RRB-\1740 excretion_25\NN\13466586 but_26\CC\1740 decreased_27\VBD\169651 superoxide_28\NN\14971519 dismutase_29\NN\1740 (_30\-LRB-\1740 sod_31\NN\9335240 )_32\-RRB-\1740 and_33\CC\1740 catalase_34\NN\14732946 (_35\-LRB-\1740 cat_36\NN\2120997 )_37\-RRB-\1740 activities_38\NNS\30358 ._39\.\1740
D013481_D007674 NONE vcm_0\NN\1740 administration_1\NN\1133281 to_2\TO\1740 control_3\NN\5190804 rats_4\NNS\2329401 significantly_5\RB\1740 increased_6\VBD\169651 renal_7\JJ\1740 malondialdehyde_8\NN\1740 (_9\-LRB-\1740 mda_10\NN\1740 )_11\-RRB-\1740 and_12\CC\1740 urinary_13\JJ\1740 n-acetyl-beta-d-glucosaminidase_14\NN\1740 (_15\-LRB-\1740 nag_16\NN\9631463 ,_17\,\1740 a_18\DT\13649268 marker_19\NN\21939 of_20\IN\1740 <e2>renal_21\JJ\1740 tubular_22\JJ\1740 injury</e2>_23\NN\14052046 )_24\-RRB-\1740 excretion_25\NN\13466586 but_26\CC\1740 decreased_27\VBD\169651 <e1>superoxide</e1>_28\NN\14971519 dismutase_29\NN\1740 (_30\-LRB-\1740 sod_31\NN\9335240 )_32\-RRB-\1740 and_33\CC\1740 catalase_34\NN\14732946 (_35\-LRB-\1740 cat_36\NN\2120997 )_37\-RRB-\1740 activities_38\NNS\30358 ._39\.\1740
D014640_D001284 NONE there_0\EX\27167 were_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 dilatation_4\NN\14034177 of_5\IN\1740 tubular_6\JJ\1740 lumens_7\NNS\13639927 ,_8\,\1740 extensive_9\JJ\1740 epithelial_10\JJ\1740 cell_11\NN\3080309 vacuolization_12\NN\13920835 ,_13\,\1740 <e2>atrophy</e2>_14\NN\14299637 ,_15\,\1740 desquamation_16\NN\11418750 ,_17\,\1740 and_18\CC\1740 necrosis_19\NN\11444117 in_20\IN\13603305 <e1>vcm-treated</e1>_21\JJ\1740 rats_22\NNS\2329401 more_23\JJR\1740 than_24\IN\1740 those_25\DT\1740 of_26\IN\1740 the_27\DT\1740 control_28\NN\5190804 and_29\CC\1740 the_30\DT\1740 erdosteine_31\NN\1740 groups_32\NNS\2137 ._33\.\1740
D014640_-1 NONE there_0\EX\27167 were_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 dilatation_4\NN\14034177 of_5\IN\1740 tubular_6\JJ\1740 lumens_7\NNS\13639927 ,_8\,\1740 extensive_9\JJ\1740 epithelial_10\JJ\1740 cell_11\NN\3080309 vacuolization_12\NN\13920835 ,_13\,\1740 atrophy_14\NN\14299637 ,_15\,\1740 <e2>desquamation</e2>_16\NN\11418750 ,_17\,\1740 and_18\CC\1740 necrosis_19\NN\11444117 in_20\IN\13603305 <e1>vcm-treated</e1>_21\JJ\1740 rats_22\NNS\2329401 more_23\JJR\1740 than_24\IN\1740 those_25\DT\1740 of_26\IN\1740 the_27\DT\1740 control_28\NN\5190804 and_29\CC\1740 the_30\DT\1740 erdosteine_31\NN\1740 groups_32\NNS\2137 ._33\.\1740
D014640_D009336 NONE there_0\EX\27167 were_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 dilatation_4\NN\14034177 of_5\IN\1740 tubular_6\JJ\1740 lumens_7\NNS\13639927 ,_8\,\1740 extensive_9\JJ\1740 epithelial_10\JJ\1740 cell_11\NN\3080309 vacuolization_12\NN\13920835 ,_13\,\1740 atrophy_14\NN\14299637 ,_15\,\1740 desquamation_16\NN\11418750 ,_17\,\1740 and_18\CC\1740 <e2>necrosis</e2>_19\NN\11444117 in_20\IN\13603305 <e1>vcm-treated</e1>_21\JJ\1740 rats_22\NNS\2329401 more_23\JJR\1740 than_24\IN\1740 those_25\DT\1740 of_26\IN\1740 the_27\DT\1740 control_28\NN\5190804 and_29\CC\1740 the_30\DT\1740 erdosteine_31\NN\1740 groups_32\NNS\2137 ._33\.\1740
C048498_D001284 NONE there_0\EX\27167 were_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 dilatation_4\NN\14034177 of_5\IN\1740 tubular_6\JJ\1740 lumens_7\NNS\13639927 ,_8\,\1740 extensive_9\JJ\1740 epithelial_10\JJ\1740 cell_11\NN\3080309 vacuolization_12\NN\13920835 ,_13\,\1740 <e2>atrophy</e2>_14\NN\14299637 ,_15\,\1740 desquamation_16\NN\11418750 ,_17\,\1740 and_18\CC\1740 necrosis_19\NN\11444117 in_20\IN\13603305 vcm-treated_21\JJ\1740 rats_22\NNS\2329401 more_23\JJR\1740 than_24\IN\1740 those_25\DT\1740 of_26\IN\1740 the_27\DT\1740 control_28\NN\5190804 and_29\CC\1740 the_30\DT\1740 <e1>erdosteine</e1>_31\NN\1740 groups_32\NNS\2137 ._33\.\1740
C048498_-1 NONE there_0\EX\27167 were_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 dilatation_4\NN\14034177 of_5\IN\1740 tubular_6\JJ\1740 lumens_7\NNS\13639927 ,_8\,\1740 extensive_9\JJ\1740 epithelial_10\JJ\1740 cell_11\NN\3080309 vacuolization_12\NN\13920835 ,_13\,\1740 atrophy_14\NN\14299637 ,_15\,\1740 <e2>desquamation</e2>_16\NN\11418750 ,_17\,\1740 and_18\CC\1740 necrosis_19\NN\11444117 in_20\IN\13603305 vcm-treated_21\JJ\1740 rats_22\NNS\2329401 more_23\JJR\1740 than_24\IN\1740 those_25\DT\1740 of_26\IN\1740 the_27\DT\1740 control_28\NN\5190804 and_29\CC\1740 the_30\DT\1740 <e1>erdosteine</e1>_31\NN\1740 groups_32\NNS\2137 ._33\.\1740
C048498_D009336 NONE there_0\EX\27167 were_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 dilatation_4\NN\14034177 of_5\IN\1740 tubular_6\JJ\1740 lumens_7\NNS\13639927 ,_8\,\1740 extensive_9\JJ\1740 epithelial_10\JJ\1740 cell_11\NN\3080309 vacuolization_12\NN\13920835 ,_13\,\1740 atrophy_14\NN\14299637 ,_15\,\1740 desquamation_16\NN\11418750 ,_17\,\1740 and_18\CC\1740 <e2>necrosis</e2>_19\NN\11444117 in_20\IN\13603305 vcm-treated_21\JJ\1740 rats_22\NNS\2329401 more_23\JJR\1740 than_24\IN\1740 those_25\DT\1740 of_26\IN\1740 the_27\DT\1740 control_28\NN\5190804 and_29\CC\1740 the_30\DT\1740 <e1>erdosteine</e1>_31\NN\1740 groups_32\NNS\2137 ._33\.\1740
11439380
D013792_D009422 NONE <e1>thalidomide</e1>_0\VB\1740 <e2>neuropathy</e2>_1\NN\14204950 in_2\IN\13603305 patients_3\NNS\9898892 treated_4\VBN\2376958 for_5\IN\1740 metastatic_6\JJ\1740 prostate_7\NN\5329735 cancer_8\NN\14239425 ._9\.\1740
D013792_D009422 NONE we_0\PRP\1740 prospectively_1\RB\1740 evaluated_2\VBD\670261 <e1>thalidomide-induced</e1>_3\JJ\1740 <e2>neuropathy</e2>_4\JJ\1740 using_5\VBG\1156834 electrodiagnostic_6\JJ\1740 studies_7\NNS\635850 ._8\.\1740
D013792_D009422 NONE <e2>neuropathy</e2>_0\NNP\14204950 may_1\MD\15209706 thus_2\RB\1740 be_3\VB\836236 a_4\DT\13649268 common_5\JJ\1740 complication_6\NN\1073995 of_7\IN\1740 <e1>thalidomide</e1>_8\NN\4166841 in_9\IN\13603305 older_10\JJR\1740 patients_11\NNS\9898892 ._12\.\1740
D013792_D011471 NONE <e1>thalidomide</e1>_0\VB\1740 neuropathy_1\NN\14204950 in_2\IN\13603305 patients_3\NNS\9898892 treated_4\VBN\2376958 for_5\IN\1740 metastatic_6\JJ\1740 <e2>prostate_7\NN\5329735 cancer</e2>_8\NN\14239425 ._9\.\1740
D013792_D011471 NONE sixty-seven_0\JJ\1740 men_1\NNS\8208016 with_2\IN\1740 metastatic_3\JJ\1740 androgen-independent_4\JJ\1740 <e2>prostate_5\NN\5329735 cancer</e2>_6\NN\14239425 in_7\IN\13603305 an_8\DT\6697703 open-label_9\JJ\1740 trial_10\NN\786195 of_11\IN\1740 oral_12\JJ\1740 <e1>thalidomide</e1>_13\NN\4166841 underwent_14\VBD\109660 neurologic_15\JJ\1740 examinations_16\NNS\633864 and_17\CC\1740 nerve_18\NN\5475681 conduction_19\NN\11419404 studies_20\NNS\635850 (_21\-LRB-\1740 ncs_22\NN\1740 )_23\-RRB-\1740 prior_24\RB\1740 to_25\TO\1740 and_26\CC\1740 at_27\IN\14622893 3-month_28\JJ\1740 intervals_29\NNS\33615 during_30\IN\1740 treatment_31\NN\654885 ._32\.\1740
D000728_D011471 NONE sixty-seven_0\JJ\1740 men_1\NNS\8208016 with_2\IN\1740 metastatic_3\JJ\1740 <e1>androgen-independent</e1>_4\JJ\1740 <e2>prostate_5\NN\5329735 cancer</e2>_6\NN\14239425 in_7\IN\13603305 an_8\DT\6697703 open-label_9\JJ\1740 trial_10\NN\786195 of_11\IN\1740 oral_12\JJ\1740 thalidomide_13\NN\4166841 underwent_14\VBD\109660 neurologic_15\JJ\1740 examinations_16\NNS\633864 and_17\CC\1740 nerve_18\NN\5475681 conduction_19\NN\11419404 studies_20\NNS\635850 (_21\-LRB-\1740 ncs_22\NN\1740 )_23\-RRB-\1740 prior_24\RB\1740 to_25\TO\1740 and_26\CC\1740 at_27\IN\14622893 3-month_28\JJ\1740 intervals_29\NNS\33615 during_30\IN\1740 treatment_31\NN\654885 ._32\.\1740
24842192
D008687_D018487 NONE chronic_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>metformin</e1>_3\NN\2719105 suppresses_4\VBZ\2510337 toll-like_5\JJ\1740 receptor_6\NN\5225602 4_7\CD\13741022 signaling_8\NN\33020 and_9\CC\1740 attenuates_10\VBZ\224901 <e2>left_11\JJ\1740 ventricular_12\NN\1740 dysfunction</e2>_13\NN\14204950 following_14\VBG\1835496 myocardial_15\JJ\1740 infarction_16\NN\14204950 ._17\.\1740
D008687_D018487 NONE the_0\DT\1740 <e2>left_1\JJ\1740 ventricular_2\NN\1740 dysfunction</e2>_3\NN\14204950 was_4\VBD\836236 significantly_5\RB\1740 lower_6\JJR\1740 in_7\IN\13603305 the_8\DT\1740 groups_9\NNS\2137 treated_10\VBN\2376958 with_11\IN\1740 25_12\CD\13745420 and_13\CC\1740 50mg/kg_14\NN\1740 of_15\IN\1740 <e1>metformin</e1>_16\NN\2719105 ._17\.\1740
D008687_D009203 NONE chronic_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>metformin</e1>_3\NN\2719105 suppresses_4\VBZ\2510337 toll-like_5\JJ\1740 receptor_6\NN\5225602 4_7\CD\13741022 signaling_8\NN\33020 and_9\CC\1740 attenuates_10\VBZ\224901 left_11\JJ\1740 ventricular_12\NN\1740 dysfunction_13\NN\14204950 following_14\VBG\1835496 <e2>myocardial_15\JJ\1740 infarction</e2>_16\NN\14204950 ._17\.\1740
D008687_D009203 NONE acute_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>metformin</e1>_3\NN\2719105 has_4\VBZ\2108377 a_5\DT\13649268 protective_6\JJ\1740 effect_7\NN\34213 in_8\IN\13603305 <e2>myocardial_9\JJ\1740 infarction</e2>_10\NN\14204950 by_11\IN\1740 suppression_12\NN\13489037 of_13\IN\1740 inflammatory_14\JJ\1740 responses_15\NNS\11410625 due_16\JJ\1740 to_17\TO\1740 activation_18\NN\13561719 of_19\IN\1740 amp-activated_20\JJ\1740 protein_21\NN\14944888 kinase_22\NN\14732946 (_23\-LRB-\1740 ampk_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D008687_D009203 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 chronic_8\JJ\1740 pre-treatment_9\NN\1740 with_10\IN\1740 <e1>metformin</e1>_11\NN\2719105 on_12\IN\1740 cardiac_13\JJ\1740 dysfunction_14\NN\14204950 and_15\CC\1740 toll-like_16\JJ\1740 receptor_17\NN\5225602 4_18\CD\13741022 (_19\-LRB-\1740 tlr4_20\NN\1740 )_21\-RRB-\1740 activities_22\NNS\30358 following_23\VBG\1835496 <e2>myocardial_24\JJ\1740 infarction</e2>_25\NN\14204950 and_26\CC\1740 their_27\PRP$\1740 relation_28\NN\2137 with_29\IN\1740 ampk_30\NN\1740 were_31\VBD\836236 assessed_32\VBN\670261 ._33\.\1740
D008687_D009203 NONE chronic_0\JJ\1740 pre-treatment_1\NN\1740 with_2\IN\1740 <e1>metformin</e1>_3\NN\2719105 reduces_4\VBZ\441445 <e2>post-myocardial_5\JJ\1740 infarction</e2>_6\NN\14204950 cardiac_7\NN\1740 dysfunction_8\NN\14204950 and_9\CC\1740 suppresses_10\VBZ\2510337 inflammatory_11\JJ\1740 responses_12\NNS\11410625 ,_13\,\1740 possibly_14\RB\1740 through_15\IN\1740 inhibition_16\NN\1068773 of_17\IN\1740 tlr4_18\NN\1740 activities_19\NNS\30358 ._20\.\1740
D000667_D009203 NONE acute_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 metformin_3\NN\2719105 has_4\VBZ\2108377 a_5\DT\13649268 protective_6\JJ\1740 effect_7\NN\34213 in_8\IN\13603305 <e2>myocardial_9\JJ\1740 infarction</e2>_10\NN\14204950 by_11\IN\1740 suppression_12\NN\13489037 of_13\IN\1740 inflammatory_14\JJ\1740 responses_15\NNS\11410625 due_16\JJ\1740 to_17\TO\1740 activation_18\NN\13561719 of_19\IN\1740 <e1>amp-activated</e1>_20\JJ\1740 protein_21\NN\14944888 kinase_22\NN\14732946 (_23\-LRB-\1740 ampk_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D008687_D006331 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 chronic_8\JJ\1740 pre-treatment_9\NN\1740 with_10\IN\1740 <e1>metformin</e1>_11\NN\2719105 on_12\IN\1740 <e2>cardiac_13\JJ\1740 dysfunction</e2>_14\NN\14204950 and_15\CC\1740 toll-like_16\JJ\1740 receptor_17\NN\5225602 4_18\CD\13741022 (_19\-LRB-\1740 tlr4_20\NN\1740 )_21\-RRB-\1740 activities_22\NNS\30358 following_23\VBG\1835496 myocardial_24\JJ\1740 infarction_25\NN\14204950 and_26\CC\1740 their_27\PRP$\1740 relation_28\NN\2137 with_29\IN\1740 ampk_30\NN\1740 were_31\VBD\836236 assessed_32\VBN\670261 ._33\.\1740
D007545_D009203 CID <e1>isoproterenol</e1>_0\NN\3740161 (_1\-LRB-\1740 100mg/kg_2\NN\1740 )_3\-RRB-\1740 was_4\VBD\836236 injected_5\VBN\81072 subcutaneously_6\RB\1740 on_7\IN\1740 the_8\DT\1740 13th_9\NN\1740 and_10\CC\1740 14th_11\JJ\1740 days_12\NNS\15140892 to_13\TO\1740 induce_14\VB\1627355 <e2>acute_15\JJ\1740 myocardial_16\JJ\1740 infarction</e2>_17\NN\14204950 ._18\.\1740
D007545_D009369 NONE metfromin_0\NN\1740 markedly_1\RB\1740 lowered_2\VBD\1850315 <e1>isoproterenol-induced</e1>_3\JJ\1740 elevation_4\NN\7445480 in_5\IN\13603305 the_6\DT\1740 levels_7\NNS\4916342 of_8\IN\1740 tlr4_9\NN\1740 mrna_10\NN\14832193 ,_11\,\1740 myeloid_12\JJ\1740 differentiation_13\NN\5748054 protein_14\NN\14944888 88_15\CD\1740 (_16\-LRB-\1740 myd88_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 <e2>tumor</e2>_20\NN\14234074 necrosis_21\NN\11444117 factor-alpha_22\NN\1740 (_23\-LRB-\1740 tnf-a_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 interleukin_28\NN\14943950 6_29\CD\13741022 (_30\-LRB-\1740 il-6_31\NN\1740 )_32\-RRB-\1740 in_33\IN\13603305 the_34\DT\1740 heart_35\NN\5919034 tissues_36\NNS\5220461 ._37\.\1740
D007545_D009336 NONE metfromin_0\NN\1740 markedly_1\RB\1740 lowered_2\VBD\1850315 <e1>isoproterenol-induced</e1>_3\JJ\1740 elevation_4\NN\7445480 in_5\IN\13603305 the_6\DT\1740 levels_7\NNS\4916342 of_8\IN\1740 tlr4_9\NN\1740 mrna_10\NN\14832193 ,_11\,\1740 myeloid_12\JJ\1740 differentiation_13\NN\5748054 protein_14\NN\14944888 88_15\CD\1740 (_16\-LRB-\1740 myd88_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 tumor_20\NN\14234074 <e2>necrosis</e2>_21\NN\11444117 factor-alpha_22\NN\1740 (_23\-LRB-\1740 tnf-a_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 interleukin_28\NN\14943950 6_29\CD\13741022 (_30\-LRB-\1740 il-6_31\NN\1740 )_32\-RRB-\1740 in_33\IN\13603305 the_34\DT\1740 heart_35\NN\5919034 tissues_36\NNS\5220461 ._37\.\1740
9646784
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 ,_2\,\1740 paradoxical_3\JJ\1740 thromboembolism_4\NN\14100769 ,_5\,\1740 and_6\CC\1740 other_7\JJ\1740 side_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 heparin_11\NN\2718259 therapy_12\NN\657604 ._13\.\1740
D006493_D013921 CID heparin-induced_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 ,_2\,\1740 paradoxical_3\JJ\1740 thromboembolism_4\NN\14100769 ,_5\,\1740 and_6\CC\1740 other_7\JJ\1740 side_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>heparin</e1>_11\NN\2718259 therapy_12\NN\657604 ._13\.\1740
D006493_D013921 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 <e2>thrombocytopenia</e2>_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D013921 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 <e2>thrombocytopenia</e2>_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D013921 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 <e1>heparin-induced</e1>_7\JJ\1740 <e2>thrombocytopenia</e2>_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D013921 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 <e1>heparin-induced</e1>_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 <e2>thrombocytopenia</e2>_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D013921 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 <e2>thrombocytopenia</e2>_8\NN\14189204 ,_9\,\1740 <e1>heparin-associated</e1>_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D013921 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 <e1>heparin-associated</e1>_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 <e2>thrombocytopenia</e2>_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D013923 CID <e1>heparin-induced</e1>_0\JJ\1740 thrombocytopenia_1\NN\14189204 ,_2\,\1740 paradoxical_3\JJ\1740 <e2>thromboembolism</e2>_4\NN\14100769 ,_5\,\1740 and_6\CC\1740 other_7\JJ\1740 side_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 heparin_11\NN\2718259 therapy_12\NN\657604 ._13\.\1740
D006493_D013923 CID heparin-induced_0\JJ\1740 thrombocytopenia_1\NN\14189204 ,_2\,\1740 paradoxical_3\JJ\1740 <e2>thromboembolism</e2>_4\NN\14100769 ,_5\,\1740 and_6\CC\1740 other_7\JJ\1740 side_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>heparin</e1>_11\NN\2718259 therapy_12\NN\657604 ._13\.\1740
D006493_D010024 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 <e2>osteoporosis</e2>_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D010024 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 <e1>heparin-induced</e1>_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 <e2>osteoporosis</e2>_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D010024 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 <e1>heparin-associated</e1>_10\JJ\1740 <e2>osteoporosis</e2>_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D004802 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 <e2>eosinophilia</e2>_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D004802 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 <e1>heparin-induced</e1>_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 <e2>eosinophilia</e2>_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D004802 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 <e1>heparin-associated</e1>_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 <e2>eosinophilia</e2>_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D012871 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 <e2>skin_15\NN\5237755 reactions</e2>_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D012871 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 <e1>heparin-induced</e1>_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 <e2>skin_15\NN\5237755 reactions</e2>_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D012871 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 <e1>heparin-associated</e1>_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 <e2>skin_15\NN\5237755 reactions</e2>_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D004342 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 <e2>allergic_18\JJ\1740 reactions</e2>_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D004342 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 <e1>heparin-induced</e1>_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 <e2>allergic_18\JJ\1740 reactions</e2>_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D004342 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 <e1>heparin-associated</e1>_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 <e2>allergic_18\JJ\1740 reactions</e2>_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 alopecia_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D000505 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>heparin</e1>_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 <e2>alopecia</e2>_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D000505 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 <e1>heparin-induced</e1>_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 heparin-associated_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 <e2>alopecia</e2>_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
D006493_D000505 CID important_0\JJ\1740 untoward_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 heparin_4\NN\2718259 therapy_5\NN\657604 including_6\VBG\690614 heparin-induced_7\JJ\1740 thrombocytopenia_8\NN\14189204 ,_9\,\1740 <e1>heparin-associated</e1>_10\JJ\1740 osteoporosis_11\NN\14204950 ,_12\,\1740 eosinophilia_13\NN\14299637 ,_14\,\1740 skin_15\NN\5237755 reactions_16\NNS\13446390 ,_17\,\1740 allergic_18\JJ\1740 reactions_19\NNS\13446390 other_20\JJ\1740 than_21\IN\1740 thrombocytopenia_22\NN\14189204 and_23\CC\1740 <e2>alopecia</e2>_24\NN\14457041 will_25\MD\5650329 be_26\VB\836236 discussed_27\VBN\1033527 in_28\IN\13603305 this_29\DT\1740 article_30\NN\6367571 ._31\.\1740
24582773
C069541_D011595 CID paradoxical_0\JJ\1740 severe_1\JJ\1740 <e2>agitation</e2>_2\NN\14373582 induced_3\VBN\1627355 by_4\IN\1740 add-on_5\JJ\1740 high-doses_6\JJ\1740 <e1>quetiapine</e1>_7\NN\1740 in_8\IN\13603305 schizo-affective_9\JJ\1740 disorder_10\NN\14034177 ._11\.\1740
C069541_D011595 CID within_0\IN\1740 the_1\DT\1740 48_2\CD\1740 h_3\NN\14622893 following_4\VBG\1835496 the_5\DT\1740 gradual_6\JJ\1740 introduction_7\NN\235435 of_8\IN\1740 <e1>quetiapine</e1>_9\NN\1740 (_10\-LRB-\1740 up_11\RB\1740 to_12\TO\1740 600_13\CD\1740 mg/day_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 the_17\DT\1740 patient_18\NN\9898892 presented_19\VBD\2137132 severe_20\JJ\1740 <e2>agitation</e2>_21\NN\14373582 without_22\IN\1740 an_23\DT\6697703 environmental_24\JJ\1740 explanation_25\NN\6722453 ,_26\,\1740 contrasting_27\VBG\650353 with_28\IN\1740 the_29\DT\1740 absence_30\NN\14449405 of_31\IN\1740 a_32\DT\13649268 history_33\NN\15120823 of_34\IN\1740 aggressiveness_35\NN\4835724 or_36\CC\3541091 personality_37\NN\24264 disorder_38\NN\14034177 ._39\.\1740
C069541_D011595 CID the_0\DT\1740 withdrawal_1\NN\7206096 and_2\CC\1740 the_3\DT\1740 gradual_4\JJ\1740 reintroduction_5\NN\7217349 of_6\IN\1740 <e1>quetiapine</e1>_7\NN\1740 2_8\CD\13741022 weeks_9\NNS\15113229 later_10\RBR\1740 ,_11\,\1740 which_12\WDT\1740 led_13\VBD\1752884 to_14\IN\1740 another_15\DT\1740 severe_16\JJ\1740 <e2>agitation</e2>_17\NN\14373582 ,_18\,\1740 enabled_19\VBD\126264 us_20\PRP\14964590 to_21\TO\1740 attribute_22\VB\670261 the_23\DT\1740 agitation_24\NN\14373582 specifically_25\RB\1740 to_26\TO\1740 quetiapine_27\NN\1740 ._28\.\1740
C069541_D011595 CID the_0\DT\1740 withdrawal_1\NN\7206096 and_2\CC\1740 the_3\DT\1740 gradual_4\JJ\1740 reintroduction_5\NN\7217349 of_6\IN\1740 <e1>quetiapine</e1>_7\NN\1740 2_8\CD\13741022 weeks_9\NNS\15113229 later_10\RBR\1740 ,_11\,\1740 which_12\WDT\1740 led_13\VBD\1752884 to_14\IN\1740 another_15\DT\1740 severe_16\JJ\1740 agitation_17\NN\14373582 ,_18\,\1740 enabled_19\VBD\126264 us_20\PRP\14964590 to_21\TO\1740 attribute_22\VB\670261 the_23\DT\1740 <e2>agitation</e2>_24\NN\14373582 specifically_25\RB\1740 to_26\TO\1740 quetiapine_27\NN\1740 ._28\.\1740
C069541_D011595 CID the_0\DT\1740 withdrawal_1\NN\7206096 and_2\CC\1740 the_3\DT\1740 gradual_4\JJ\1740 reintroduction_5\NN\7217349 of_6\IN\1740 quetiapine_7\NN\1740 2_8\CD\13741022 weeks_9\NNS\15113229 later_10\RBR\1740 ,_11\,\1740 which_12\WDT\1740 led_13\VBD\1752884 to_14\IN\1740 another_15\DT\1740 severe_16\JJ\1740 <e2>agitation</e2>_17\NN\14373582 ,_18\,\1740 enabled_19\VBD\126264 us_20\PRP\14964590 to_21\TO\1740 attribute_22\VB\670261 the_23\DT\1740 agitation_24\NN\14373582 specifically_25\RB\1740 to_26\TO\1740 <e1>quetiapine</e1>_27\NN\1740 ._28\.\1740
C069541_D011595 CID the_0\DT\1740 withdrawal_1\NN\7206096 and_2\CC\1740 the_3\DT\1740 gradual_4\JJ\1740 reintroduction_5\NN\7217349 of_6\IN\1740 quetiapine_7\NN\1740 2_8\CD\13741022 weeks_9\NNS\15113229 later_10\RBR\1740 ,_11\,\1740 which_12\WDT\1740 led_13\VBD\1752884 to_14\IN\1740 another_15\DT\1740 severe_16\JJ\1740 agitation_17\NN\14373582 ,_18\,\1740 enabled_19\VBD\126264 us_20\PRP\14964590 to_21\TO\1740 attribute_22\VB\670261 the_23\DT\1740 <e2>agitation</e2>_24\NN\14373582 specifically_25\RB\1740 to_26\TO\1740 <e1>quetiapine</e1>_27\NN\1740 ._28\.\1740
C069541_D011618 NONE paradoxical_0\JJ\1740 severe_1\JJ\1740 agitation_2\NN\14373582 induced_3\VBN\1627355 by_4\IN\1740 add-on_5\JJ\1740 high-doses_6\JJ\1740 <e1>quetiapine</e1>_7\NN\1740 in_8\IN\13603305 <e2>schizo-affective_9\JJ\1740 disorder</e2>_10\NN\14034177 ._11\.\1740
D003006_D011618 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 35-year-old_6\JJ\1740 patient_7\NN\9898892 suffering_8\VBG\2110220 from_9\IN\1740 <e2>schizo-affective_10\JJ\1740 disorder</e2>_11\NN\14034177 since_12\IN\1740 the_13\DT\1740 age_14\NN\4916342 of_15\IN\1740 19_16\CD\13745420 years_17\NNS\15144371 ,_18\,\1740 treated_19\VBN\2376958 by_20\IN\1740 a_21\DT\13649268 combination_22\NN\7951464 of_23\IN\1740 first-generation_24\NN\1740 antipsychotics_25\NNS\4470232 ,_26\,\1740 <e1>zuclopenthixol</e1>_27\NN\1740 (_28\-LRB-\1740 100_29\CD\13745420 mg/day_30\NN\1740 )_31\-RRB-\1740 and_32\CC\1740 lithium_33\NN\14625458 (_34\-LRB-\1740 1200_35\CD\1740 mg/day_36\NN\1740 )_37\-RRB-\1740 (_38\-LRB-\1740 serum_39\NN\5397468 lithium=0.85_40\NN\1740 meq/l_41\NN\1740 )_42\-RRB-\1740 ._43\.\1740
D008094_D011618 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 35-year-old_6\JJ\1740 patient_7\NN\9898892 suffering_8\VBG\2110220 from_9\IN\1740 <e2>schizo-affective_10\JJ\1740 disorder</e2>_11\NN\14034177 since_12\IN\1740 the_13\DT\1740 age_14\NN\4916342 of_15\IN\1740 19_16\CD\13745420 years_17\NNS\15144371 ,_18\,\1740 treated_19\VBN\2376958 by_20\IN\1740 a_21\DT\13649268 combination_22\NN\7951464 of_23\IN\1740 first-generation_24\NN\1740 antipsychotics_25\NNS\4470232 ,_26\,\1740 zuclopenthixol_27\NN\1740 (_28\-LRB-\1740 100_29\CD\13745420 mg/day_30\NN\1740 )_31\-RRB-\1740 and_32\CC\1740 <e1>lithium</e1>_33\NN\14625458 (_34\-LRB-\1740 1200_35\CD\1740 mg/day_36\NN\1740 )_37\-RRB-\1740 (_38\-LRB-\1740 serum_39\NN\5397468 lithium=0.85_40\NN\1740 meq/l_41\NN\1740 )_42\-RRB-\1740 ._43\.\1740
D008094_D011618 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 35-year-old_6\JJ\1740 patient_7\NN\9898892 suffering_8\VBG\2110220 from_9\IN\1740 <e2>schizo-affective_10\JJ\1740 disorder</e2>_11\NN\14034177 since_12\IN\1740 the_13\DT\1740 age_14\NN\4916342 of_15\IN\1740 19_16\CD\13745420 years_17\NNS\15144371 ,_18\,\1740 treated_19\VBN\2376958 by_20\IN\1740 a_21\DT\13649268 combination_22\NN\7951464 of_23\IN\1740 first-generation_24\NN\1740 antipsychotics_25\NNS\4470232 ,_26\,\1740 zuclopenthixol_27\NN\1740 (_28\-LRB-\1740 100_29\CD\13745420 mg/day_30\NN\1740 )_31\-RRB-\1740 and_32\CC\1740 lithium_33\NN\14625458 (_34\-LRB-\1740 1200_35\CD\1740 mg/day_36\NN\1740 )_37\-RRB-\1740 (_38\-LRB-\1740 serum_39\NN\5397468 <e1>lithium=0.85</e1>_40\NN\1740 meq/l_41\NN\1740 )_42\-RRB-\1740 ._43\.\1740
C069541_D010554 NONE within_0\IN\1740 the_1\DT\1740 48_2\CD\1740 h_3\NN\14622893 following_4\VBG\1835496 the_5\DT\1740 gradual_6\JJ\1740 introduction_7\NN\235435 of_8\IN\1740 <e1>quetiapine</e1>_9\NN\1740 (_10\-LRB-\1740 up_11\RB\1740 to_12\TO\1740 600_13\CD\1740 mg/day_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 the_17\DT\1740 patient_18\NN\9898892 presented_19\VBD\2137132 severe_20\JJ\1740 agitation_21\NN\14373582 without_22\IN\1740 an_23\DT\6697703 environmental_24\JJ\1740 explanation_25\NN\6722453 ,_26\,\1740 contrasting_27\VBG\650353 with_28\IN\1740 the_29\DT\1740 absence_30\NN\14449405 of_31\IN\1740 a_32\DT\13649268 history_33\NN\15120823 of_34\IN\1740 <e2>aggressiveness</e2>_35\NN\4835724 or_36\CC\3541091 personality_37\NN\24264 disorder_38\NN\14034177 ._39\.\1740
C069541_D010554 NONE within_0\IN\1740 the_1\DT\1740 48_2\CD\1740 h_3\NN\14622893 following_4\VBG\1835496 the_5\DT\1740 gradual_6\JJ\1740 introduction_7\NN\235435 of_8\IN\1740 <e1>quetiapine</e1>_9\NN\1740 (_10\-LRB-\1740 up_11\RB\1740 to_12\TO\1740 600_13\CD\1740 mg/day_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 the_17\DT\1740 patient_18\NN\9898892 presented_19\VBD\2137132 severe_20\JJ\1740 agitation_21\NN\14373582 without_22\IN\1740 an_23\DT\6697703 environmental_24\JJ\1740 explanation_25\NN\6722453 ,_26\,\1740 contrasting_27\VBG\650353 with_28\IN\1740 the_29\DT\1740 absence_30\NN\14449405 of_31\IN\1740 a_32\DT\13649268 history_33\NN\15120823 of_34\IN\1740 aggressiveness_35\NN\4835724 or_36\CC\3541091 <e2>personality_37\NN\24264 disorder</e2>_38\NN\14034177 ._39\.\1740
24459006
D015725_D000380 CID <e1>fluconazole</e1>_0\NNP\1740 associated_1\VBD\628491 <e2>agranulocytosis</e2>_2\NN\14189204 and_3\CC\1740 thrombocytopenia_4\NN\14189204 ._5\.\1740
D015725_D000380 CID case_0\LS\7283608 :_1\:\1740 we_2\PRP\1740 describe_3\VBP\1001294 a_4\DT\13649268 second_5\JJ\1740 case_6\NN\7283608 of_7\IN\1740 <e1>fluconazole</e1>_8\NN\1740 associated_9\VBN\628491 <e2>agranulocytosis</e2>_10\NN\14189204 with_11\IN\1740 thrombocytopenia_12\NN\14189204 and_13\CC\1740 recovery_14\NN\7357388 upon_15\IN\1740 discontinuation_16\NN\209943 of_17\IN\1740 therapy_18\NN\657604 ._19\.\1740
D015725_D000380 CID conclusion_0\NN\5837957 :_1\:\1740 according_2\VBG\2657219 to_3\IN\1740 naranjo_4\NNP\1740 's_5\POS\1740 algorithm_6\NN\5846932 the_7\DT\1740 likelihood_8\NN\4756172 that_9\IN\1740 our_10\PRP$\1740 patient_11\NN\9898892 's_12\POS\1740 <e2>agranulocytosis</e2>_13\NN\14189204 and_14\CC\1740 thrombocytopenia_15\NN\14189204 occurred_16\VBD\2623529 as_17\IN\14622893 a_18\DT\13649268 result_19\NN\34213 of_20\IN\1740 therapy_21\NN\657604 with_22\IN\1740 <e1>fluconazole</e1>_23\NN\1740 is_24\VBZ\836236 probable_25\JJ\1740 ,_26\,\1740 with_27\IN\1740 a_28\DT\13649268 total_29\NN\3553 of_30\IN\1740 six_31\CD\13741022 points_32\NNS\5868954 ._33\.\1740
D015725_D013921 CID <e1>fluconazole</e1>_0\NNP\1740 associated_1\VBD\628491 agranulocytosis_2\NN\14189204 and_3\CC\1740 <e2>thrombocytopenia</e2>_4\NN\14189204 ._5\.\1740
D015725_D013921 CID case_0\LS\7283608 :_1\:\1740 we_2\PRP\1740 describe_3\VBP\1001294 a_4\DT\13649268 second_5\JJ\1740 case_6\NN\7283608 of_7\IN\1740 <e1>fluconazole</e1>_8\NN\1740 associated_9\VBN\628491 agranulocytosis_10\NN\14189204 with_11\IN\1740 <e2>thrombocytopenia</e2>_12\NN\14189204 and_13\CC\1740 recovery_14\NN\7357388 upon_15\IN\1740 discontinuation_16\NN\209943 of_17\IN\1740 therapy_18\NN\657604 ._19\.\1740
D015725_D013921 CID conclusion_0\NN\5837957 :_1\:\1740 according_2\VBG\2657219 to_3\IN\1740 naranjo_4\NNP\1740 's_5\POS\1740 algorithm_6\NN\5846932 the_7\DT\1740 likelihood_8\NN\4756172 that_9\IN\1740 our_10\PRP$\1740 patient_11\NN\9898892 's_12\POS\1740 agranulocytosis_13\NN\14189204 and_14\CC\1740 <e2>thrombocytopenia</e2>_15\NN\14189204 occurred_16\VBD\2623529 as_17\IN\14622893 a_18\DT\13649268 result_19\NN\34213 of_20\IN\1740 therapy_21\NN\657604 with_22\IN\1740 <e1>fluconazole</e1>_23\NN\1740 is_24\VBZ\836236 probable_25\JJ\1740 ,_26\,\1740 with_27\IN\1740 a_28\DT\13649268 total_29\NN\3553 of_30\IN\1740 six_31\CD\13741022 points_32\NNS\5868954 ._33\.\1740
D015725_D001855 NONE in_0\IN\13603305 particular_1\JJ\1740 the_2\DT\1740 temporal_3\JJ\1740 relationship_4\NN\31921 of_5\IN\1740 <e2>bone_6\NN\5286536 marrow_7\NN\5286536 suppression</e2>_8\NN\13489037 to_9\TO\1740 the_10\DT\1740 initiation_11\NN\7450842 of_12\IN\1740 <e1>fluconazole</e1>_13\NN\1740 and_14\CC\1740 the_15\DT\1740 abatement_16\NN\7367812 of_17\IN\1740 symptoms_18\NNS\5823932 that_19\WDT\1740 rapidly_20\RB\1740 reversed_21\VBD\109660 immediately_22\RB\1740 following_23\VBG\1835496 discontinuation_24\NN\209943 ._25\.\1740
24234943
C086816_D007177 CID <e2>syndrome_0\NN\5870365 of_1\IN\1740 inappropriate_2\JJ\1740 antidiuretic_3\JJ\1740 hormone</e2>_4\NN\5404728 secretion_5\NN\13526110 associated_6\VBN\628491 with_7\IN\1740 <e1>desvenlafaxine</e1>_8\NN\1740 ._9\.\1740
C086816_D007177 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e2>syndrome_7\NN\5870365 of_8\IN\1740 inappropriate_9\JJ\1740 anti-diuretic_10\JJ\1740 hormone</e2>_11\NN\5404728 (_12\-LRB-\1740 siadh_13\NN\1740 )_14\-RRB-\1740 secretion_15\NN\13526110 associated_16\VBN\628491 with_17\IN\1740 <e1>desvenlafaxine</e1>_18\NN\1740 ._19\.\1740
C086816_D007177 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 syndrome_7\NN\5870365 of_8\IN\1740 inappropriate_9\JJ\1740 anti-diuretic_10\JJ\1740 hormone_11\NN\5404728 (_12\-LRB-\1740 <e2>siadh</e2>_13\NN\1740 )_14\-RRB-\1740 secretion_15\NN\13526110 associated_16\VBN\628491 with_17\IN\1740 <e1>desvenlafaxine</e1>_18\NN\1740 ._19\.\1740
C086816_D009325 CID her_0\PRP$\1740 medications_1\NNS\3247620 included_2\VBD\690614 <e1>desvenlafaxine</e1>_3\NN\1740 ,_4\,\1740 and_5\CC\1740 symptoms_6\NNS\5823932 included_7\VBD\690614 <e2>nausea</e2>_8\NN\14299637 ,_9\,\1740 anxiety_10\NN\14373582 and_11\CC\1740 confusion_12\NN\13972797 ._13\.\1740
C086816_D001008 CID her_0\PRP$\1740 medications_1\NNS\3247620 included_2\VBD\690614 <e1>desvenlafaxine</e1>_3\NN\1740 ,_4\,\1740 and_5\CC\1740 symptoms_6\NNS\5823932 included_7\VBD\690614 nausea_8\NN\14299637 ,_9\,\1740 <e2>anxiety</e2>_10\NN\14373582 and_11\CC\1740 confusion_12\NN\13972797 ._13\.\1740
C086816_D003221 CID her_0\PRP$\1740 medications_1\NNS\3247620 included_2\VBD\690614 <e1>desvenlafaxine</e1>_3\NN\1740 ,_4\,\1740 and_5\CC\1740 symptoms_6\NNS\5823932 included_7\VBD\690614 nausea_8\NN\14299637 ,_9\,\1740 anxiety_10\NN\14373582 and_11\CC\1740 <e2>confusion</e2>_12\NN\13972797 ._13\.\1740
D012964_D007177 NONE the_0\DT\1740 serum_1\NN\5397468 <e1>sodium</e1>_2\NN\14625458 at_3\IN\14622893 this_4\DT\1740 time_5\NN\7308889 was_6\VBD\836236 120_7\CD\13745420 mmol/l_8\NN\1740 ,_9\,\1740 serum_10\NN\5397468 osmolality_11\NN\1740 was_12\VBD\836236 263_13\CD\1740 mosmol/kg_14\NNS\1740 ,_15\,\1740 urine_16\NN\14853947 osmolality_17\NN\1740 410_18\CD\1740 mosmol/kg_19\NN\1740 and_20\CC\1740 urine_21\NN\14853947 sodium_22\NN\14625458 63_23\CD\1740 mmol/l_24\NN\1740 ,_25\,\1740 consistent_26\JJ\1740 with_27\IN\1740 a_28\DT\13649268 diagnosis_29\NN\152018 of_30\IN\1740 <e2>siadh</e2>_31\NN\1740 ._32\.\1740
D012964_D007177 NONE the_0\DT\1740 serum_1\NN\5397468 sodium_2\NN\14625458 at_3\IN\14622893 this_4\DT\1740 time_5\NN\7308889 was_6\VBD\836236 120_7\CD\13745420 mmol/l_8\NN\1740 ,_9\,\1740 serum_10\NN\5397468 osmolality_11\NN\1740 was_12\VBD\836236 263_13\CD\1740 mosmol/kg_14\NNS\1740 ,_15\,\1740 urine_16\NN\14853947 osmolality_17\NN\1740 410_18\CD\1740 mosmol/kg_19\NN\1740 and_20\CC\1740 urine_21\NN\14853947 <e1>sodium</e1>_22\NN\14625458 63_23\CD\1740 mmol/l_24\NN\1740 ,_25\,\1740 consistent_26\JJ\1740 with_27\IN\1740 a_28\DT\13649268 diagnosis_29\NN\152018 of_30\IN\1740 <e2>siadh</e2>_31\NN\1740 ._32\.\1740
C086816_D007010 CID this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 suggests_3\VBZ\1010118 that_4\IN\1740 <e1>desvenlafaxine</e1>_5\NN\1740 might_6\MD\5029706 cause_7\VB\1617192 clinically_8\RB\1740 significant_9\JJ\1740 <e2>hyponatremia</e2>_10\NN\14299637 ._11\.\1740
8829135
C058876_D000647 NONE <e1>nefiracetam</e1>_0\NN\1740 (_1\-LRB-\1740 dm-9384_2\NN\1740 )_3\-RRB-\1740 reverses_4\VBZ\109660 apomorphine-induced_5\JJ\1740 <e2>amnesia</e2>_6\NN\5669934 of_7\IN\1740 a_8\DT\13649268 passive_9\JJ\1740 avoidance_10\NN\203342 response_11\NN\11410625 :_12\:\1740 delayed_13\VBN\439958 emergence_14\NN\7290905 of_15\IN\1740 the_16\DT\1740 memory_17\NN\5926676 retention_18\NN\809465 effects_19\NNS\13245626 ._20\.\1740
C058876_D000647 NONE nefiracetam_0\NN\1740 (_1\-LRB-\1740 <e1>dm-9384</e1>_2\NN\1740 )_3\-RRB-\1740 reverses_4\VBZ\109660 apomorphine-induced_5\JJ\1740 <e2>amnesia</e2>_6\NN\5669934 of_7\IN\1740 a_8\DT\13649268 passive_9\JJ\1740 avoidance_10\NN\203342 response_11\NN\11410625 :_12\:\1740 delayed_13\VBN\439958 emergence_14\NN\7290905 of_15\IN\1740 the_16\DT\1740 memory_17\NN\5926676 retention_18\NN\809465 effects_19\NNS\13245626 ._20\.\1740
C058876_D000647 NONE given_0\VBN\2327200 that_1\DT\1740 apomorphine_2\NN\3786417 inhibits_3\VBZ\2510337 passive_4\JJ\1740 avoidance_5\NN\203342 retention_6\NN\809465 when_7\WRB\1740 given_8\VBN\2327200 during_9\IN\1740 training_10\NN\407535 or_11\CC\3541091 in_12\IN\13603305 a_13\DT\13649268 defined_14\VBN\2604760 10_15\CD\13745420 -_16\HYPH\1740 12h_17\NN\1740 post-training_18\JJ\1740 period_19\NN\13575869 ,_20\,\1740 we_21\PRP\1740 evaluated_22\VBD\670261 the_23\DT\1740 ability_24\NN\4723816 of_25\IN\1740 <e1>nefiracetam</e1>_26\NN\1740 to_27\TO\1740 attenuate_28\VB\224901 <e2>amnesia</e2>_29\NN\5669934 induced_30\VBN\1627355 by_31\IN\1740 dopaminergic_32\JJ\1740 agonism_33\NN\1740 ._34\.\1740
C058876_D000647 NONE however_0\RB\1740 ,_1\,\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>nefiracetam</e1>_4\NN\1740 during_5\IN\1740 training_6\NN\407535 completely_7\RB\1740 reversed_8\VBD\109660 the_9\DT\1740 <e2>amnesia</e2>_10\NN\5669934 induced_11\VBN\1627355 by_12\IN\1740 apomorphine_13\NN\3786417 at_14\IN\14622893 the_15\DT\1740 10h_16\NN\1740 post-training_17\JJ\1740 time_18\NN\7308889 and_19\CC\1740 the_20\DT\1740 converse_21\NN\6750804 was_22\VBD\836236 also_23\RB\1740 true_24\JJ\1740 ._25\.\1740
D001058_D000647 CID nefiracetam_0\NN\1740 (_1\-LRB-\1740 dm-9384_2\NN\1740 )_3\-RRB-\1740 reverses_4\VBZ\109660 <e1>apomorphine-induced</e1>_5\JJ\1740 <e2>amnesia</e2>_6\NN\5669934 of_7\IN\1740 a_8\DT\13649268 passive_9\JJ\1740 avoidance_10\NN\203342 response_11\NN\11410625 :_12\:\1740 delayed_13\VBN\439958 emergence_14\NN\7290905 of_15\IN\1740 the_16\DT\1740 memory_17\NN\5926676 retention_18\NN\809465 effects_19\NNS\13245626 ._20\.\1740
D001058_D000647 CID given_0\VBN\2327200 that_1\DT\1740 <e1>apomorphine</e1>_2\NN\3786417 inhibits_3\VBZ\2510337 passive_4\JJ\1740 avoidance_5\NN\203342 retention_6\NN\809465 when_7\WRB\1740 given_8\VBN\2327200 during_9\IN\1740 training_10\NN\407535 or_11\CC\3541091 in_12\IN\13603305 a_13\DT\13649268 defined_14\VBN\2604760 10_15\CD\13745420 -_16\HYPH\1740 12h_17\NN\1740 post-training_18\JJ\1740 period_19\NN\13575869 ,_20\,\1740 we_21\PRP\1740 evaluated_22\VBD\670261 the_23\DT\1740 ability_24\NN\4723816 of_25\IN\1740 nefiracetam_26\NN\1740 to_27\TO\1740 attenuate_28\VB\224901 <e2>amnesia</e2>_29\NN\5669934 induced_30\VBN\1627355 by_31\IN\1740 dopaminergic_32\JJ\1740 agonism_33\NN\1740 ._34\.\1740
D001058_D000647 CID however_0\RB\1740 ,_1\,\1740 administration_2\NN\1133281 of_3\IN\1740 nefiracetam_4\NN\1740 during_5\IN\1740 training_6\NN\407535 completely_7\RB\1740 reversed_8\VBD\109660 the_9\DT\1740 <e2>amnesia</e2>_10\NN\5669934 induced_11\VBN\1627355 by_12\IN\1740 <e1>apomorphine</e1>_13\NN\3786417 at_14\IN\14622893 the_15\DT\1740 10h_16\NN\1740 post-training_17\JJ\1740 time_18\NN\7308889 and_19\CC\1740 the_20\DT\1740 converse_21\NN\6750804 was_22\VBD\836236 also_23\RB\1740 true_24\JJ\1740 ._25\.\1740
C058876_D007859 NONE <e1>nefiracetam</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 novel_3\JJ\1740 pyrrolidone_4\NN\1740 derivative_5\JJ\1740 which_6\WDT\1740 attenuates_7\VBZ\224901 scopolamine-induced_8\JJ\1740 <e2>learning_9\NN\5701944 and_10\CC\1740 post-training_11\JJ\1740 consolidation_12\NN\7373803 deficits</e2>_13\NNS\5113133 ._14\.\1740
D011760_D007859 NONE nefiracetam_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 novel_3\JJ\1740 <e1>pyrrolidone</e1>_4\NN\1740 derivative_5\JJ\1740 which_6\WDT\1740 attenuates_7\VBZ\224901 scopolamine-induced_8\JJ\1740 <e2>learning_9\NN\5701944 and_10\CC\1740 post-training_11\JJ\1740 consolidation_12\NN\7373803 deficits</e2>_13\NNS\5113133 ._14\.\1740
D012601_D007859 CID nefiracetam_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 novel_3\JJ\1740 pyrrolidone_4\NN\1740 derivative_5\JJ\1740 which_6\WDT\1740 attenuates_7\VBZ\224901 <e1>scopolamine-induced</e1>_8\JJ\1740 <e2>learning_9\NN\5701944 and_10\CC\1740 post-training_11\JJ\1740 consolidation_12\NN\7373803 deficits</e2>_13\NNS\5113133 ._14\.\1740
24709919
D036145_D006930 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>ginsenosides</e1>_2\NNS\1740 on_3\IN\1740 opioid-induced_4\JJ\1740 <e2>hyperalgesia</e2>_5\NN\1740 in_6\IN\13603305 mice_7\NNS\2329401 ._8\.\1740
C049864_D006930 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 investigated_5\VBD\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>re_9\NN\14625458 ,_10\,\1740 rg1_11\NN\1740 ,_12\,\1740 and_13\CC\1740 rb1_14\NN\1740 ginsenosides</e1>_15\VBZ\1740 ,_16\,\1740 the_17\DT\1740 bioactive_18\JJ\1740 components_19\NNS\5867413 of_20\IN\1740 ginseng_21\NN\13125117 ,_22\,\1740 on_23\IN\1740 <e2>oih</e2>_24\NNP\1740 ._25\.\1740
C049864_D006930 NONE <e1>re</e1>_0\IN\14625458 (_1\-LRB-\1740 300_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 inhibited_5\VBD\2510337 <e2>oih</e2>_6\NN\1740 in_7\IN\13603305 both_8\CC\1740 the_9\DT\1740 thermal_10\JJ\1740 sensitivity_11\NN\5651971 test_12\NN\5798043 and_13\CC\1740 the_14\DT\1740 acetic_15\JJ\1740 acid-induced_16\JJ\1740 writhing_17\NN\1740 test_18\NN\5798043 ._19\.\1740
C049864_D006930 NONE our_0\PRP$\1740 data_1\NNS\7951464 suggested_2\VBD\1010118 that_3\IN\1740 the_4\DT\1740 <e1>ginsenoside_5\NN\1740 re</e1>_6\IN\14625458 ,_7\,\1740 but_8\CC\1740 not_9\RB\1740 rg1_10\NN\1740 or_11\CC\3541091 rb1_12\NN\1740 ,_13\,\1740 may_14\MD\15209706 contribute_15\VB\126264 toward_16\IN\1740 reversal_17\NN\199130 of_18\IN\1740 <e2>oih</e2>_19\NNP\1740 ._20\.\1740
C035054_D006930 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 investigated_5\VBD\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>re_9\NN\14625458 ,_10\,\1740 rg1_11\NN\1740 ,_12\,\1740 and_13\CC\1740 rb1_14\NN\1740 ginsenosides</e1>_15\VBZ\1740 ,_16\,\1740 the_17\DT\1740 bioactive_18\JJ\1740 components_19\NNS\5867413 of_20\IN\1740 ginseng_21\NN\13125117 ,_22\,\1740 on_23\IN\1740 <e2>oih</e2>_24\NNP\1740 ._25\.\1740
C035054_D006930 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e1>rg1_3\NN\1740 and_4\CC\1740 rb1_5\NN\1740 ginsenosides</e1>_6\VBZ\1740 failed_7\VBD\1798936 to_8\TO\1740 prevent_9\VB\1740 <e2>oih</e2>_10\NNP\1740 in_11\IN\13603305 either_12\DT\1740 test_13\NN\5798043 ._14\.\1740
C035054_D006930 NONE furthermore_0\RB\1740 ,_1\,\1740 <e1>rg1</e1>_2\NN\1740 showed_3\VBD\2137132 a_4\DT\13649268 tendency_5\NN\6193203 to_6\TO\1740 aggravate_7\VB\126264 <e2>oih</e2>_8\NNP\1740 in_9\IN\13603305 the_10\DT\1740 acetic_11\JJ\1740 acid-induced_12\JJ\1740 writhing_13\NN\1740 test_14\NN\5798043 ._15\.\1740
C035054_D006930 NONE our_0\PRP$\1740 data_1\NNS\7951464 suggested_2\VBD\1010118 that_3\IN\1740 the_4\DT\1740 ginsenoside_5\NN\1740 re_6\IN\14625458 ,_7\,\1740 but_8\CC\1740 not_9\RB\1740 <e1>rg1</e1>_10\NN\1740 or_11\CC\3541091 rb1_12\NN\1740 ,_13\,\1740 may_14\MD\15209706 contribute_15\VB\126264 toward_16\IN\1740 reversal_17\NN\199130 of_18\IN\1740 <e2>oih</e2>_19\NNP\1740 ._20\.\1740
C442759_D006930 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 investigated_5\VBD\644583 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>re_9\NN\14625458 ,_10\,\1740 rg1_11\NN\1740 ,_12\,\1740 and_13\CC\1740 rb1_14\NN\1740 ginsenosides</e1>_15\VBZ\1740 ,_16\,\1740 the_17\DT\1740 bioactive_18\JJ\1740 components_19\NNS\5867413 of_20\IN\1740 ginseng_21\NN\13125117 ,_22\,\1740 on_23\IN\1740 <e2>oih</e2>_24\NNP\1740 ._25\.\1740
C442759_D006930 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e1>rg1_3\NN\1740 and_4\CC\1740 rb1_5\NN\1740 ginsenosides</e1>_6\VBZ\1740 failed_7\VBD\1798936 to_8\TO\1740 prevent_9\VB\1740 <e2>oih</e2>_10\NNP\1740 in_11\IN\13603305 either_12\DT\1740 test_13\NN\5798043 ._14\.\1740
C442759_D006930 NONE our_0\PRP$\1740 data_1\NNS\7951464 suggested_2\VBD\1010118 that_3\IN\1740 the_4\DT\1740 ginsenoside_5\NN\1740 re_6\IN\14625458 ,_7\,\1740 but_8\CC\1740 not_9\RB\1740 rg1_10\NN\1740 or_11\CC\3541091 <e1>rb1</e1>_12\NN\1740 ,_13\,\1740 may_14\MD\15209706 contribute_15\VB\126264 toward_16\IN\1740 reversal_17\NN\199130 of_18\IN\1740 <e2>oih</e2>_19\NNP\1740 ._20\.\1740
D009020_D006930 CID <e2>oih</e2>_0\NNP\1740 was_1\VBD\836236 achieved_2\VBN\2524171 in_3\IN\13603305 mice_4\NNS\2329401 after_5\IN\1740 subcutaneous_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>morphine</e1>_9\NN\2707683 for_10\IN\1740 7_11\CD\13741022 consecutive_12\JJ\1740 days_13\NNS\15140892 three_14\CD\13741022 times_15\NNS\15113229 per_16\IN\1740 day_17\NN\15154774 ._18\.\1740
D019342_D006930 NONE re_0\IN\14625458 (_1\-LRB-\1740 300_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 inhibited_5\VBD\2510337 <e2>oih</e2>_6\NN\1740 in_7\IN\13603305 both_8\CC\1740 the_9\DT\1740 thermal_10\JJ\1740 sensitivity_11\NN\5651971 test_12\NN\5798043 and_13\CC\1740 the_14\DT\1740 <e1>acetic_15\JJ\1740 acid-induced</e1>_16\JJ\1740 writhing_17\NN\1740 test_18\NN\5798043 ._19\.\1740
D019342_D006930 NONE furthermore_0\RB\1740 ,_1\,\1740 rg1_2\NN\1740 showed_3\VBD\2137132 a_4\DT\13649268 tendency_5\NN\6193203 to_6\TO\1740 aggravate_7\VB\126264 <e2>oih</e2>_8\NNP\1740 in_9\IN\13603305 the_10\DT\1740 <e1>acetic_11\JJ\1740 acid-induced</e1>_12\JJ\1740 writhing_13\NN\1740 test_14\NN\5798043 ._15\.\1740
689020
D005280_D014202 CID after_0\IN\1740 the_1\DT\1740 end_2\NN\8568978 of_3\IN\1740 <e1>fenoterol-hydrobromide</e1>_4\JJ\1740 infusion_5\NN\14589223 ,_6\,\1740 <e2>tremor</e2>_7\NN\345926 amplitudes_8\NNS\7444668 decreased_9\VBD\169651 significantly_10\RB\1740 faster_11\JJR\1740 than_12\IN\1740 those_13\DT\1740 following_14\VBG\1835496 ritodrin-hcl_15\NN\1740 infusion_16\NN\14589223 ._17\.\1740
D012312_D014202 CID after_0\IN\1740 the_1\DT\1740 end_2\NN\8568978 of_3\IN\1740 fenoterol-hydrobromide_4\JJ\1740 infusion_5\NN\14589223 ,_6\,\1740 <e2>tremor</e2>_7\NN\345926 amplitudes_8\NNS\7444668 decreased_9\VBD\169651 significantly_10\RB\1740 faster_11\JJR\1740 than_12\IN\1740 those_13\DT\1740 following_14\VBG\1835496 <e1>ritodrin-hcl</e1>_15\NN\1740 infusion_16\NN\14589223 ._17\.\1740
19392810
D003932_D012206 CID <e2>rhabdomyolysis</e2>_0\NN\1740 and_1\CC\1740 brain_2\NN\5462674 ischemic_3\JJ\1740 stroke_4\NN\556313 in_5\IN\13603305 a_6\DT\13649268 <e1>heroin-dependent</e1>_7\JJ\1740 male_8\NN\15388 under_9\IN\1740 methadone_10\NN\3808564 maintenance_11\NN\266806 therapy_12\NN\657604 ._13\.\1740
D003932_D012206 CID results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 33-year-old_3\JJ\1740 man_4\NN\9605289 presented_5\VBN\2137132 with_6\IN\1740 <e2>rhabdomyolysis</e2>_7\NN\1740 and_8\CC\1740 cerebral_9\JJ\1740 ischemic_10\JJ\1740 stroke_11\NN\556313 after_12\IN\1740 intravenous_13\JJ\1740 <e1>heroin</e1>_14\NN\3492717 ._15\.\1740
D003932_D012206 CID conclusion_0\NN\5837957 :_1\:\1740 those_2\DT\1740 using_3\VBG\1156834 methadone_4\NN\3808564 and_5\CC\1740 <e1>heroin</e1>_6\NN\3492717 simultaneously_7\RB\1740 may_8\MD\15209706 increase_9\VB\169651 risk_10\NN\14541044 of_11\IN\1740 <e2>rhabdomyolysis</e2>_12\NN\1740 and_13\CC\1740 ischemic_14\JJ\1740 stroke_15\NN\556313 ._16\.\1740
D003932_D012206 CID hypotheses_0\NNS\7162194 of_1\IN\1740 <e1>heroin-related</e1>_2\JJ\1740 <e2>rhabdomyolysis</e2>_3\NN\1740 and_4\CC\1740 stroke_5\NN\556313 in_6\IN\13603305 heroin_7\NN\3492717 abusers_8\NNS\9633969 are_9\VBP\836236 discussed_10\VBN\1033527 ._11\.\1740
D003932_D012206 CID hypotheses_0\NNS\7162194 of_1\IN\1740 heroin-related_2\JJ\1740 <e2>rhabdomyolysis</e2>_3\NN\1740 and_4\CC\1740 stroke_5\NN\556313 in_6\IN\13603305 <e1>heroin</e1>_7\NN\3492717 abusers_8\NNS\9633969 are_9\VBP\836236 discussed_10\VBN\1033527 ._11\.\1740
D003932_D002544 NONE rhabdomyolysis_0\NN\1740 and_1\CC\1740 brain_2\NN\5462674 <e2>ischemic_3\JJ\1740 stroke</e2>_4\NN\556313 in_5\IN\13603305 a_6\DT\13649268 <e1>heroin-dependent</e1>_7\JJ\1740 male_8\NN\15388 under_9\IN\1740 methadone_10\NN\3808564 maintenance_11\NN\266806 therapy_12\NN\657604 ._13\.\1740
D003932_D002544 NONE results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 33-year-old_3\JJ\1740 man_4\NN\9605289 presented_5\VBN\2137132 with_6\IN\1740 rhabdomyolysis_7\NN\1740 and_8\CC\1740 cerebral_9\JJ\1740 <e2>ischemic_10\JJ\1740 stroke</e2>_11\NN\556313 after_12\IN\1740 intravenous_13\JJ\1740 <e1>heroin</e1>_14\NN\3492717 ._15\.\1740
D003932_D002544 NONE conclusion_0\NN\5837957 :_1\:\1740 those_2\DT\1740 using_3\VBG\1156834 methadone_4\NN\3808564 and_5\CC\1740 <e1>heroin</e1>_6\NN\3492717 simultaneously_7\RB\1740 may_8\MD\15209706 increase_9\VB\169651 risk_10\NN\14541044 of_11\IN\1740 rhabdomyolysis_12\NN\1740 and_13\CC\1740 <e2>ischemic_14\JJ\1740 stroke</e2>_15\NN\556313 ._16\.\1740
D008691_D012206 CID <e2>rhabdomyolysis</e2>_0\NN\1740 and_1\CC\1740 brain_2\NN\5462674 ischemic_3\JJ\1740 stroke_4\NN\556313 in_5\IN\13603305 a_6\DT\13649268 heroin-dependent_7\JJ\1740 male_8\NN\15388 under_9\IN\1740 <e1>methadone</e1>_10\NN\3808564 maintenance_11\NN\266806 therapy_12\NN\657604 ._13\.\1740
D008691_D012206 CID conclusion_0\NN\5837957 :_1\:\1740 those_2\DT\1740 using_3\VBG\1156834 <e1>methadone</e1>_4\NN\3808564 and_5\CC\1740 heroin_6\NN\3492717 simultaneously_7\RB\1740 may_8\MD\15209706 increase_9\VB\169651 risk_10\NN\14541044 of_11\IN\1740 <e2>rhabdomyolysis</e2>_12\NN\1740 and_13\CC\1740 ischemic_14\JJ\1740 stroke_15\NN\556313 ._16\.\1740
D008691_D002544 NONE rhabdomyolysis_0\NN\1740 and_1\CC\1740 brain_2\NN\5462674 <e2>ischemic_3\JJ\1740 stroke</e2>_4\NN\556313 in_5\IN\13603305 a_6\DT\13649268 heroin-dependent_7\JJ\1740 male_8\NN\15388 under_9\IN\1740 <e1>methadone</e1>_10\NN\3808564 maintenance_11\NN\266806 therapy_12\NN\657604 ._13\.\1740
D008691_D002544 NONE conclusion_0\NN\5837957 :_1\:\1740 those_2\DT\1740 using_3\VBG\1156834 <e1>methadone</e1>_4\NN\3808564 and_5\CC\1740 heroin_6\NN\3492717 simultaneously_7\RB\1740 may_8\MD\15209706 increase_9\VB\169651 risk_10\NN\14541044 of_11\IN\1740 rhabdomyolysis_12\NN\1740 and_13\CC\1740 <e2>ischemic_14\JJ\1740 stroke</e2>_15\NN\556313 ._16\.\1740
D003932_D020521 CID hypotheses_0\NNS\7162194 of_1\IN\1740 <e1>heroin-related</e1>_2\JJ\1740 rhabdomyolysis_3\NN\1740 and_4\CC\1740 <e2>stroke</e2>_5\NN\556313 in_6\IN\13603305 heroin_7\NN\3492717 abusers_8\NNS\9633969 are_9\VBP\836236 discussed_10\VBN\1033527 ._11\.\1740
D003932_D020521 CID hypotheses_0\NNS\7162194 of_1\IN\1740 heroin-related_2\JJ\1740 rhabdomyolysis_3\NN\1740 and_4\CC\1740 <e2>stroke</e2>_5\NN\556313 in_6\IN\13603305 <e1>heroin</e1>_7\NN\3492717 abusers_8\NNS\9633969 are_9\VBP\836236 discussed_10\VBN\1033527 ._11\.\1740
24451297
C065180_D056486 CID <e2>drug-induced_0\JJ\1740 acute_1\NNP\6822198 liver_2\NNP\5298729 injury</e2>_3\NNP\14052046 within_4\IN\1740 12_5\CD\13745420 hours_6\NNS\15118228 after_7\IN\1740 <e1>fluvastatin</e1>_8\NNP\3676175 therapy_9\NNP\657604 ._10\.\1740
C065180_D056486 CID a_0\DT\13649268 52-year-old_1\JJ\1740 chinese_2\JJ\1740 man_3\NN\9605289 reported_4\VBN\831651 with_5\IN\1740 <e2>liver_6\NN\5298729 damage</e2>_7\NN\7296428 ,_8\,\1740 which_9\WDT\1740 appeared_10\VBD\2604760 12_11\CD\13745420 hours_12\NNS\15118228 after_13\IN\1740 beginning_14\VBG\941990 treatment_15\NN\654885 with_16\IN\1740 <e1>fluvastatin</e1>_17\NN\3676175 ._18\.\1740
D019161_D056486 NONE although_0\IN\1740 <e1>statins</e1>_1\NNS\3740161 are_2\VBP\836236 generally_3\RB\1740 well-tolerated_4\JJ\1740 drugs_5\NNS\14778436 ,_6\,\1740 recent_7\JJ\1740 cases_8\NNS\7283608 of_9\IN\1740 <e2>drug-induced_10\JJ\1740 liver_11\NN\5298729 injury</e2>_12\NN\14052046 associated_13\VBN\628491 with_14\IN\1740 their_15\PRP$\1740 use_16\NN\407535 have_17\VBP\2108377 been_18\VBN\836236 reported_19\VBN\831651 ._20\.\1740
15229250
D008694_D001930 CID we_0\PRP\1740 visualize_1\VBP\1636397 ,_2\,\1740 for_3\IN\1740 the_4\DT\1740 first_5\JJ\1740 time_6\NN\7308889 ,_7\,\1740 the_8\DT\1740 profile_9\NN\6999802 of_10\IN\1740 <e2>structural_11\JJ\1740 deficits_12\NNS\5113133 in_13\IN\13603305 the_14\DT\1740 human_15\JJ\1740 brain</e2>_16\NN\5462674 associated_17\VBN\628491 with_18\IN\1740 chronic_19\JJ\1740 <e1>methamphetamine</e1>_20\NN\2704153 (_21\-LRB-\1740 ma_22\NN\10332385 )_23\-RRB-\1740 abuse_24\NN\418025 ._25\.\1740
D008694_D001930 CID we_0\PRP\1740 visualize_1\VBP\1636397 ,_2\,\1740 for_3\IN\1740 the_4\DT\1740 first_5\JJ\1740 time_6\NN\7308889 ,_7\,\1740 the_8\DT\1740 profile_9\NN\6999802 of_10\IN\1740 <e2>structural_11\JJ\1740 deficits_12\NNS\5113133 in_13\IN\13603305 the_14\DT\1740 human_15\JJ\1740 brain</e2>_16\NN\5462674 associated_17\VBN\628491 with_18\IN\1740 chronic_19\JJ\1740 methamphetamine_20\NN\2704153 (_21\-LRB-\1740 <e1>ma</e1>_22\NN\10332385 )_23\-RRB-\1740 abuse_24\NN\418025 ._25\.\1740
D008694_D001930 CID we_0\PRP\1740 used_1\VBD\1156834 high-resolution_2\JJ\1740 mri_3\NN\901083 and_4\CC\1740 surface-based_5\JJ\1740 computational_6\JJ\1740 image_7\NN\5926676 analyses_8\NNS\633864 to_9\TO\1740 map_10\VB\1686132 regional_11\JJ\1740 <e2>abnormalities_12\NNS\14034177 in_13\IN\13603305 the_14\DT\1740 cortex_15\NN\5462674 ,_16\,\1740 hippocampus_17\NN\5462674 ,_18\,\1740 white_19\JJ\1740 matter_20\NN\5670710 ,_21\,\1740 and_22\CC\1740 ventricles</e2>_23\NNS\5303402 in_24\IN\13603305 22_25\CD\13745420 human_26\JJ\1740 subjects_27\NNS\6598915 who_28\WP\8299493 used_29\VBD\1156834 <e1>ma</e1>_30\NN\10332385 and_31\CC\1740 21_32\CD\13745420 age-matched_33\JJ\1740 ,_34\,\1740 healthy_35\JJ\1740 controls_36\NNS\5190804 ._37\.\1740
D008694_D001930 CID these_0\DT\1740 brain_1\NN\5462674 substrates_2\NNS\19613 may_3\MD\15209706 help_4\VB\2556126 account_5\NN\6647206 for_6\IN\1740 the_7\DT\1740 symptoms_8\NNS\5823932 of_9\IN\1740 <e1>ma</e1>_10\NN\10332385 abuse_11\NN\418025 ,_12\,\1740 providing_13\VBG\2199590 therapeutic_14\JJ\1740 targets_15\NNS\7258332 for_16\IN\1740 drug-induced_17\JJ\1740 <e2>brain_18\NN\5462674 injury</e2>_19\NN\14052046 ._20\.\1740
D008694_D008659 NONE studies_0\NNS\635850 of_1\IN\1740 human_2\JJ\1740 subjects_3\NNS\6598915 who_4\WP\8299493 have_5\VBP\2108377 used_6\VBN\1156834 <e1>ma</e1>_7\NNP\10332385 chronically_8\RB\1740 have_9\VBP\2108377 revealed_10\VBN\2137132 deficits_11\NNS\5113133 in_12\IN\13603305 dopaminergic_13\JJ\1740 and_14\CC\1740 serotonergic_15\JJ\1740 systems_16\NNS\3575240 and_17\CC\1740 cerebral_18\JJ\1740 <e2>metabolic_19\JJ\1740 abnormalities</e2>_20\NNS\14034177 ._21\.\1740
D008694_D003072 NONE using_0\VBG\1156834 magnetic_1\JJ\1740 resonance_2\NN\11419404 imaging_3\NN\5765159 (_4\-LRB-\1740 mri_5\NN\901083 )_6\-RRB-\1740 and_7\CC\1740 new_8\JJ\1740 computational_9\JJ\1740 brain-mapping_10\JJ\1740 techniques_11\NNS\5660268 ,_12\,\1740 we_13\PRP\1740 determined_14\VBD\1645601 the_15\DT\1740 pattern_16\NN\5726345 of_17\IN\1740 structural_18\JJ\1740 brain_19\NN\5462674 alterations_20\NNS\7283608 associated_21\VBN\628491 with_22\IN\1740 chronic_23\JJ\1740 <e1>ma</e1>_24\NN\10332385 abuse_25\NN\418025 in_26\IN\13603305 human_27\JJ\1740 subjects_28\NNS\6598915 and_29\CC\1740 related_30\VBN\628491 these_31\DT\1740 deficits_32\NNS\5113133 to_33\TO\1740 <e2>cognitive_34\JJ\1740 impairment</e2>_35\NN\7296428 ._36\.\1740
D008694_D006984 NONE on_0\IN\1740 average_1\JJ\1740 ,_2\,\1740 <e1>ma</e1>_3\NN\10332385 abusers_4\NNS\9633969 had_5\VBD\2108377 7.8_6\CD\1740 %_7\NN\1740 smaller_8\JJR\1740 hippocampal_9\NN\1740 volumes_10\NNS\33615 than_11\IN\1740 control_12\JJ\1740 subjects_13\NNS\6598915 (_14\-LRB-\1740 p_15\NN\14622893 <_16\XX\1740 0.01_17\CD\1740 ;_18\:\1740 left_19\VBN\120316 ,_20\,\1740 p_21\NN\14622893 =_22\JJ\1740 0.01_23\CD\1740 ;_24\:\1740 right_25\UH\5854150 ,_26\,\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 and_31\CC\1740 significant_32\JJ\1740 white-matter_33\NN\1740 <e2>hypertrophy</e2>_34\NN\14365950 (_35\-LRB-\1740 7.0_36\CD\1740 %_37\NN\1740 ;_38\:\1740 p_39\NN\14622893 <_40\XX\1740 0.01_41\CD\1740 )_42\-RRB-\1740 ._43\.\1740
D008694_D008569 CID mri-based_0\JJ\1740 maps_1\NNS\4076846 suggest_2\VBP\1010118 that_3\IN\1740 chronic_4\JJ\1740 <e1>methamphetamine</e1>_5\NN\2704153 abuse_6\NN\418025 causes_7\VBZ\1617192 a_8\DT\13649268 selective_9\JJ\1740 pattern_10\NN\5726345 of_11\IN\1740 cerebral_12\JJ\1740 deterioration_13\NN\14560612 that_14\WDT\1740 contributes_15\VBZ\126264 to_16\TO\1740 <e2>impaired_17\JJ\1740 memory_18\NN\5926676 performance</e2>_19\NN\6619065 ._20\.\1740
16867246
D002746_D001480 CID association_0\NN\8008335 of_1\IN\1740 drd2_2\NN\1740 polymorphisms_3\NNS\11418750 and_4\CC\1740 <e1>chlorpromazine-induced</e1>_5\JJ\1740 <e2>extrapyramidal_6\JJ\1740 syndrome</e2>_7\NN\5870365 in_8\IN\13603305 chinese_9\JJ\1740 schizophrenic_10\JJ\1740 patients_11\NNS\9898892 ._12\.\1740
D002746_D001480 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 evaluate_5\VBP\670261 the_6\DT\1740 role_7\NN\719494 drd2_8\NN\1740 plays_9\VBZ\1072262 in_10\IN\13603305 <e1>chlorpromazine-induced</e1>_11\JJ\1740 <e2>eps</e2>_12\NN\1740 in_13\IN\13603305 schizophrenic_14\JJ\1740 patients_15\NNS\9898892 ._16\.\1740
D002746_D001480 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 identified_3\VBD\699815 seven_4\CD\13741022 snp(single_5\NN\1740 nucleotide_6\NN\14850483 polymorphism_7\NN\11418750 )_8\-RRB-\1740 (_9\-LRB-\1740 -141cins_10\NNS\1740 >_11\NN\1740 del_12\NN\1740 ,_13\,\1740 taqib_14\FW\1740 ,_15\,\1740 taqid_16\NN\1740 ,_17\,\1740 ser311cys_18\NNP\1740 ,_19\,\1740 rs6275_20\NN\1740 ,_21\,\1740 rs6277_22\NN\1740 and_23\CC\1740 taqia_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 the_27\DT\1740 drd2_28\NN\1740 gene_29\NN\8459252 in_30\IN\13603305 146_31\CD\1740 schizophrenic_32\JJ\1740 inpatients_33\NNS\10405694 (_34\-LRB-\1740 59_35\CD\1740 with_36\IN\1740 <e2>eps</e2>_37\NN\1740 and_38\CC\1740 87_39\CD\1740 without_40\IN\1740 eps_41\NN\1740 according_42\VBG\2657219 to_43\IN\1740 the_44\DT\1740 simpson-angus_45\JJ\1740 scale_46\NN\7260623 )_47\-RRB-\1740 treated_48\VBN\2376958 with_49\IN\1740 <e1>chlorpromazine</e1>_50\NN\3713736 after_51\IN\1740 8_52\CD\13741022 weeks_53\NNS\15113229 ._54\.\1740
D002746_D001480 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 identified_3\VBD\699815 seven_4\CD\13741022 snp(single_5\NN\1740 nucleotide_6\NN\14850483 polymorphism_7\NN\11418750 )_8\-RRB-\1740 (_9\-LRB-\1740 -141cins_10\NNS\1740 >_11\NN\1740 del_12\NN\1740 ,_13\,\1740 taqib_14\FW\1740 ,_15\,\1740 taqid_16\NN\1740 ,_17\,\1740 ser311cys_18\NNP\1740 ,_19\,\1740 rs6275_20\NN\1740 ,_21\,\1740 rs6277_22\NN\1740 and_23\CC\1740 taqia_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 the_27\DT\1740 drd2_28\NN\1740 gene_29\NN\8459252 in_30\IN\13603305 146_31\CD\1740 schizophrenic_32\JJ\1740 inpatients_33\NNS\10405694 (_34\-LRB-\1740 59_35\CD\1740 with_36\IN\1740 eps_37\NN\1740 and_38\CC\1740 87_39\CD\1740 without_40\IN\1740 <e2>eps</e2>_41\NN\1740 according_42\VBG\2657219 to_43\IN\1740 the_44\DT\1740 simpson-angus_45\JJ\1740 scale_46\NN\7260623 )_47\-RRB-\1740 treated_48\VBN\2376958 with_49\IN\1740 <e1>chlorpromazine</e1>_50\NN\3713736 after_51\IN\1740 8_52\CD\13741022 weeks_53\NNS\15113229 ._54\.\1740
D002746_D012559 NONE association_0\NN\8008335 of_1\IN\1740 drd2_2\NN\1740 polymorphisms_3\NNS\11418750 and_4\CC\1740 <e1>chlorpromazine-induced</e1>_5\JJ\1740 extrapyramidal_6\JJ\1740 syndrome_7\NN\5870365 in_8\IN\13603305 chinese_9\JJ\1740 <e2>schizophrenic</e2>_10\JJ\1740 patients_11\NNS\9898892 ._12\.\1740
D002746_D012559 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 evaluate_5\VBP\670261 the_6\DT\1740 role_7\NN\719494 drd2_8\NN\1740 plays_9\VBZ\1072262 in_10\IN\13603305 <e1>chlorpromazine-induced</e1>_11\JJ\1740 eps_12\NN\1740 in_13\IN\13603305 <e2>schizophrenic</e2>_14\JJ\1740 patients_15\NNS\9898892 ._16\.\1740
D002746_D012559 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 identified_3\VBD\699815 seven_4\CD\13741022 snp(single_5\NN\1740 nucleotide_6\NN\14850483 polymorphism_7\NN\11418750 )_8\-RRB-\1740 (_9\-LRB-\1740 -141cins_10\NNS\1740 >_11\NN\1740 del_12\NN\1740 ,_13\,\1740 taqib_14\FW\1740 ,_15\,\1740 taqid_16\NN\1740 ,_17\,\1740 ser311cys_18\NNP\1740 ,_19\,\1740 rs6275_20\NN\1740 ,_21\,\1740 rs6277_22\NN\1740 and_23\CC\1740 taqia_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 the_27\DT\1740 drd2_28\NN\1740 gene_29\NN\8459252 in_30\IN\13603305 146_31\CD\1740 <e2>schizophrenic</e2>_32\JJ\1740 inpatients_33\NNS\10405694 (_34\-LRB-\1740 59_35\CD\1740 with_36\IN\1740 eps_37\NN\1740 and_38\CC\1740 87_39\CD\1740 without_40\IN\1740 eps_41\NN\1740 according_42\VBG\2657219 to_43\IN\1740 the_44\DT\1740 simpson-angus_45\JJ\1740 scale_46\NN\7260623 )_47\-RRB-\1740 treated_48\VBN\2376958 with_49\IN\1740 <e1>chlorpromazine</e1>_50\NN\3713736 after_51\IN\1740 8_52\CD\13741022 weeks_53\NNS\15113229 ._54\.\1740
D002746_D012559 NONE conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 did_4\VBD\1640855 not_5\RB\1740 lend_6\VB\126264 strong_7\JJ\1740 support_8\NN\407535 to_9\IN\1740 the_10\DT\1740 view_11\NN\6208021 that_12\IN\1740 the_13\DT\1740 genetic_14\JJ\1740 variation_15\NN\7296428 of_16\IN\1740 the_17\DT\1740 drd2_18\NN\1740 gene_19\NN\8459252 plays_20\VBZ\1072262 a_21\DT\13649268 major_22\JJ\1740 role_23\NN\719494 in_24\IN\13603305 the_25\DT\1740 individually_26\RB\1740 variable_27\JJ\1740 adverse_28\JJ\1740 effect_29\NN\34213 induced_30\VBN\1627355 by_31\IN\1740 <e1>chlorpromazine</e1>_32\NN\3713736 ,_33\,\1740 at_34\IN\14622893 least_35\JJS\1740 in_36\IN\13603305 chinese_37\JJ\1740 patients_38\NNS\9898892 with_39\IN\1740 <e2>schizophrenia</e2>_40\NN\14398067 ._41\.\1740
611664
D011433_C544351 NONE use_0\NN\407535 of_1\IN\1740 <e1>propranolol</e1>_2\NN\1740 in_3\IN\13603305 the_4\DT\1740 treatment_5\NN\654885 of_6\IN\1740 <e2>idiopathic_7\JJ\1740 orthostatic_8\JJ\1740 hypotension</e2>_9\NN\14057371 ._10\.\1740
D011433_C544351 NONE the_0\DT\1740 studies_1\NNS\635850 suggest_2\VBP\1010118 that_3\IN\1740 <e1>propranolol</e1>_4\NN\1740 is_5\VBZ\836236 a_6\DT\13649268 useful_7\JJ\1740 drug_8\NN\14778436 in_9\IN\13603305 selected_10\VBN\697589 patients_11\NNS\9898892 with_12\IN\1740 severe_13\JJ\1740 <e2>idiopathic_14\JJ\1740 orthostatic_15\JJ\1740 hypotension</e2>_16\NN\14057371 ._17\.\1740
D002395_D004342 NONE they_0\PRP\1740 all_1\DT\1740 exhibited_2\VBD\2632167 markedly_3\RB\1740 reduced_4\VBN\441445 plasma_5\NN\5398023 <e1>catecholamines</e1>_6\NNS\5407119 and_7\CC\1740 plasma_8\NN\5398023 renin_9\NN\14999106 activity_10\NN\30358 in_11\IN\13603305 both_12\CC\1740 recumbent_13\JJ\1740 and_14\CC\1740 upright_15\JJ\1740 positions_16\NNS\8620061 and_17\CC\1740 had_18\VBD\2108377 marked_19\JJ\1740 <e2>hypersensitivity</e2>_20\NN\14531772 to_21\TO\1740 the_22\DT\1740 pressor_23\NN\9190918 effects_24\NNS\13245626 of_25\IN\1740 infused_26\JJ\1740 norepinephrine_27\NN\14807929 ._28\.\1740
D009638_D004342 NONE they_0\PRP\1740 all_1\DT\1740 exhibited_2\VBD\2632167 markedly_3\RB\1740 reduced_4\VBN\441445 plasma_5\NN\5398023 catecholamines_6\NNS\5407119 and_7\CC\1740 plasma_8\NN\5398023 renin_9\NN\14999106 activity_10\NN\30358 in_11\IN\13603305 both_12\CC\1740 recumbent_13\JJ\1740 and_14\CC\1740 upright_15\JJ\1740 positions_16\NNS\8620061 and_17\CC\1740 had_18\VBD\2108377 marked_19\JJ\1740 <e2>hypersensitivity</e2>_20\NN\14531772 to_21\TO\1740 the_22\DT\1740 pressor_23\NN\9190918 effects_24\NNS\13245626 of_25\IN\1740 infused_26\JJ\1740 <e1>norepinephrine</e1>_27\NN\14807929 ._28\.\1740
D011433_D006973 CID in_0\IN\13603305 1_1\CD\13741022 patient_2\NN\9898892 ,_3\,\1740 marked_4\JJ\1740 <e2>hypertension</e2>_5\NN\14057371 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 <e1>propranolol</e1>_9\NN\1740 and_10\CC\1740 the_11\DT\1740 drug_12\NN\14778436 had_13\VBD\2108377 to_14\TO\1740 be_15\VB\836236 withdrawn_16\VBN\1835496 ._17\.\1740
20513036
C542870_D010243 NONE abductor_0\JJ\1740 <e2>paralysis</e2>_1\NN\14557898 after_2\IN\1740 <e1>botox</e1>_3\NN\14587688 injection_4\NN\320852 for_5\IN\1740 adductor_6\NN\5289861 spasmodic_7\NN\1740 dysphonia_8\NN\14400677 ._9\.\1740
C542870_D010243 NONE here_0\RB\1740 we_1\PRP\1740 report_2\VBP\831651 multiple_3\JJ\1740 cases_4\NNS\7283608 of_5\IN\1740 bilateral_6\JJ\1740 abductor_7\JJ\1740 <e2>paralysis</e2>_8\NN\14557898 following_9\VBG\1835496 <e1>botox</e1>_10\NNP\14587688 injections_11\NNS\320852 for_12\IN\1740 adsd_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 complication_16\NN\1073995 previously_17\RB\1740 unreported_18\VBD\1740 ._19\.\1740
C542870_D010243 NONE for_0\IN\1740 patients_1\NNS\9898892 with_2\IN\1740 bilateral_3\JJ\1740 abductor_4\NN\9609561 <e2>paralysis</e2>_5\NN\14557898 ,_6\,\1740 age_7\NN\4916342 ,_8\,\1740 sex_9\NN\13440063 ,_10\,\1740 paralytic_11\JJ\1740 <e1>botox</e1>_12\NN\14587688 dose_13\NN\3740161 ,_14\,\1740 prior_15\JJ\1740 botox_16\NNP\14587688 dose_17\NN\3740161 ,_18\,\1740 and_19\CC\1740 course_20\NN\883297 following_21\VBG\1835496 paralysis_22\NN\14557898 were_23\VBD\836236 noted_24\VBN\1009240 ._25\.\1740
C542870_D010243 NONE for_0\IN\1740 patients_1\NNS\9898892 with_2\IN\1740 bilateral_3\JJ\1740 abductor_4\NN\9609561 paralysis_5\NN\14557898 ,_6\,\1740 age_7\NN\4916342 ,_8\,\1740 sex_9\NN\13440063 ,_10\,\1740 paralytic_11\JJ\1740 <e1>botox</e1>_12\NN\14587688 dose_13\NN\3740161 ,_14\,\1740 prior_15\JJ\1740 botox_16\NNP\14587688 dose_17\NN\3740161 ,_18\,\1740 and_19\CC\1740 course_20\NN\883297 following_21\VBG\1835496 <e2>paralysis</e2>_22\NN\14557898 were_23\VBD\836236 noted_24\VBN\1009240 ._25\.\1740
C542870_D010243 NONE for_0\IN\1740 patients_1\NNS\9898892 with_2\IN\1740 bilateral_3\JJ\1740 abductor_4\NN\9609561 <e2>paralysis</e2>_5\NN\14557898 ,_6\,\1740 age_7\NN\4916342 ,_8\,\1740 sex_9\NN\13440063 ,_10\,\1740 paralytic_11\JJ\1740 botox_12\NN\14587688 dose_13\NN\3740161 ,_14\,\1740 prior_15\JJ\1740 <e1>botox</e1>_16\NNP\14587688 dose_17\NN\3740161 ,_18\,\1740 and_19\CC\1740 course_20\NN\883297 following_21\VBG\1835496 paralysis_22\NN\14557898 were_23\VBD\836236 noted_24\VBN\1009240 ._25\.\1740
C542870_D010243 NONE for_0\IN\1740 patients_1\NNS\9898892 with_2\IN\1740 bilateral_3\JJ\1740 abductor_4\NN\9609561 paralysis_5\NN\14557898 ,_6\,\1740 age_7\NN\4916342 ,_8\,\1740 sex_9\NN\13440063 ,_10\,\1740 paralytic_11\JJ\1740 botox_12\NN\14587688 dose_13\NN\3740161 ,_14\,\1740 prior_15\JJ\1740 <e1>botox</e1>_16\NNP\14587688 dose_17\NN\3740161 ,_18\,\1740 and_19\CC\1740 course_20\NN\883297 following_21\VBG\1835496 <e2>paralysis</e2>_22\NN\14557898 were_23\VBD\836236 noted_24\VBN\1009240 ._25\.\1740
C542870_D010243 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 abductor_3\JJ\1740 <e2>paralysis</e2>_4\NN\14557898 after_5\IN\1740 <e1>botox</e1>_6\NNP\14587688 injection_7\NN\320852 for_8\IN\1740 adsd_9\NN\1740 was_10\VBD\836236 0.34_11\CD\1740 %_12\NN\1740 ._13\.\1740
C542870_D010243 NONE conclusions_0\NNS\5837957 :_1\:\1740 bilateral_2\JJ\1740 abductor_3\JJ\1740 <e2>paralysis</e2>_4\NN\14557898 is_5\VBZ\836236 a_6\DT\13649268 rare_7\JJ\1740 complication_8\NN\1073995 of_9\IN\1740 <e1>botox</e1>_10\NNP\14587688 injections_11\NNS\320852 for_12\IN\1740 adsd_13\NN\1740 ,_14\,\1740 causing_15\VBG\1617192 difficulty_16\NN\621627 with_17\IN\1740 breathing_18\NN\13440063 upon_19\IN\1740 exertion_20\NN\620752 ._21\.\1740
C542870_D010243 NONE the_0\DT\1740 likely_1\JJ\1740 mechanism_2\NN\13446390 of_3\IN\1740 <e2>paralysis</e2>_4\NN\14557898 is_5\VBZ\836236 diffusion_6\NN\13518963 of_7\IN\1740 <e1>botox</e1>_8\NNP\14587688 around_9\IN\1740 the_10\DT\1740 muscular_11\JJ\1740 process_12\NN\407535 of_13\IN\1740 the_14\DT\1740 arytenoid_15\NN\5288091 to_16\IN\1740 the_17\DT\1740 posterior_18\JJ\1740 cricoarytenoid_19\JJ\1740 muscles_20\NNS\5289601 ._21\.\1740
C542870_D014826 CID abductor_0\JJ\1740 paralysis_1\NN\14557898 after_2\IN\1740 <e1>botox</e1>_3\NN\14587688 injection_4\NN\320852 for_5\IN\1740 <e2>adductor_6\NN\5289861 spasmodic_7\NN\1740 dysphonia</e2>_8\NN\14400677 ._9\.\1740
C542870_D014826 CID objectives/hypothesis_0\JJ\1740 :_1\:\1740 botulinum_2\NN\1355326 toxin_3\NN\15032376 (_4\-LRB-\1740 <e1>botox</e1>_5\NN\14587688 )_6\-RRB-\1740 injections_7\NNS\320852 into_8\IN\1740 the_9\DT\1740 thyroarytenoid_10\JJ\1740 muscles_11\NNS\5289601 are_12\VBP\836236 the_13\DT\1740 current_14\JJ\1740 standard_15\NN\13577171 of_16\IN\1740 care_17\NN\575741 for_18\IN\1740 <e2>adductor_19\NN\5289861 spasmodic_20\JJ\1740 dysphonia</e2>_21\NN\14400677 (_22\-LRB-\1740 adsd_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
C542870_D014826 CID objectives/hypothesis_0\JJ\1740 :_1\:\1740 botulinum_2\NN\1355326 toxin_3\NN\15032376 (_4\-LRB-\1740 <e1>botox</e1>_5\NN\14587688 )_6\-RRB-\1740 injections_7\NNS\320852 into_8\IN\1740 the_9\DT\1740 thyroarytenoid_10\JJ\1740 muscles_11\NNS\5289601 are_12\VBP\836236 the_13\DT\1740 current_14\JJ\1740 standard_15\NN\13577171 of_16\IN\1740 care_17\NN\575741 for_18\IN\1740 adductor_19\NN\5289861 spasmodic_20\JJ\1740 dysphonia_21\NN\14400677 (_22\-LRB-\1740 <e2>adsd</e2>_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
C542870_D014826 CID here_0\RB\1740 we_1\PRP\1740 report_2\VBP\831651 multiple_3\JJ\1740 cases_4\NNS\7283608 of_5\IN\1740 bilateral_6\JJ\1740 abductor_7\JJ\1740 paralysis_8\NN\14557898 following_9\VBG\1835496 <e1>botox</e1>_10\NNP\14587688 injections_11\NNS\320852 for_12\IN\1740 <e2>adsd</e2>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 complication_16\NN\1073995 previously_17\RB\1740 unreported_18\VBD\1740 ._19\.\1740
C542870_D014826 CID results_0\NNS\34213 :_1\:\1740 from_2\IN\1740 a_3\DT\13649268 database_4\NN\6634376 of_5\IN\1740 452_6\CD\1740 patients_7\NNS\9898892 receiving_8\VBG\2210855 <e1>botox</e1>_9\NNP\14587688 ,_10\,\1740 352_11\CD\1740 patients_12\NNS\9898892 had_13\VBD\2108377 been_14\VBN\836236 diagnosed_15\VBN\644583 with_16\IN\1740 <e2>adsd</e2>_17\NN\1740 ._18\.\1740
C542870_D014826 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 abductor_3\JJ\1740 paralysis_4\NN\14557898 after_5\IN\1740 <e1>botox</e1>_6\NNP\14587688 injection_7\NN\320852 for_8\IN\1740 <e2>adsd</e2>_9\NN\1740 was_10\VBD\836236 0.34_11\CD\1740 %_12\NN\1740 ._13\.\1740
C542870_D014826 CID conclusions_0\NNS\5837957 :_1\:\1740 bilateral_2\JJ\1740 abductor_3\JJ\1740 paralysis_4\NN\14557898 is_5\VBZ\836236 a_6\DT\13649268 rare_7\JJ\1740 complication_8\NN\1073995 of_9\IN\1740 <e1>botox</e1>_10\NNP\14587688 injections_11\NNS\320852 for_12\IN\1740 <e2>adsd</e2>_13\NN\1740 ,_14\,\1740 causing_15\VBG\1617192 difficulty_16\NN\621627 with_17\IN\1740 breathing_18\NN\13440063 upon_19\IN\1740 exertion_20\NN\620752 ._21\.\1740
C542870_D055154 NONE methods_0\NNS\5616786 :_1\:\1740 patients_2\NNS\9898892 that_3\WDT\1740 received_4\VBD\2210855 <e1>botox</e1>_5\NNP\14587688 injections_6\NNS\320852 for_7\IN\1740 <e2>spasmodic_8\JJ\1740 dysphonia</e2>_9\NN\14400677 between_10\IN\1740 january_11\NNP\15209706 2000_12\CD\1740 and_13\CC\1740 october_14\NNP\15209706 2009_15\CD\1740 were_16\VBD\836236 evaluated_17\VBN\670261 ._18\.\1740
2614930
D009543_D001919 CID <e1>nifedipine</e1>_0\NN\2938514 induced_1\VBD\1627355 <e2>bradycardia</e2>_2\NN\14110674 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 autonomic_7\JJ\1740 neuropathy_8\NN\14204950 ._9\.\1740
D009543_D009422 NONE <e1>nifedipine</e1>_0\NN\2938514 induced_1\VBD\1627355 bradycardia_2\NN\14110674 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 <e2>autonomic_7\JJ\1740 neuropathy</e2>_8\NN\14204950 ._9\.\1740
D009543_D001282 NONE he_0\PRP\14622893 was_1\VBD\836236 found_2\VBN\2426171 to_3\TO\1740 have_4\VB\2108377 <e2>atrial_5\JJ\1740 flutter</e2>_6\NN\331950 at_7\IN\14622893 a_8\DT\13649268 ventricular_9\JJ\1740 rate_10\NN\13815152 of_11\IN\1740 70/min_12\NN\1740 which_13\WDT\1740 slowed_14\VBD\151689 down_15\RP\1740 to_16\IN\1740 30_17\CD\13745420 -_18\HYPH\1740 40/min_19\NN\1740 when_20\WRB\1740 <e1>nifedipine</e1>_21\NN\2938514 (_22\-LRB-\1740 60_23\CD\13745420 mg_24\NN\13717155 )_25\-RRB-\1740 in_26\IN\13603305 3_27\CD\13741022 divided_28\JJ\1740 doses_29\NNS\3740161 ,_30\,\1740 during_31\IN\1740 which_32\WDT\1740 he_33\PRP\14622893 was_34\VBD\836236 paced_35\VBN\1904930 at_36\IN\14622893 a_37\DT\13649268 rate_38\NN\13815152 of_39\IN\1740 70/min_40\NNP\1740 ._41\.\1740
D009543_D013610 CID this_0\DT\1740 is_1\VBZ\836236 inconsistent_2\JJ\1740 with_3\IN\1740 the_4\DT\1740 well-established_5\JJ\1740 finding_6\NN\43195 that_7\IN\1740 <e1>nifedipine</e1>_8\NN\2938514 induces_9\VBZ\1627355 <e2>tachycardia</e2>_10\NN\14110674 in_11\IN\13603305 normally_12\RB\1740 innervated_13\VBN\2327200 hearts_14\NNS\496167 ._15\.\1740
24614773
D014635_D001927 NONE normoammonemic_0\JJ\1740 <e2>encephalopathy</e2>_1\JJ\1740 :_2\:\1740 solely_3\RB\1740 <e1>valproate</e1>_4\VBP\1740 induced_5\VBN\1627355 or_6\CC\3541091 multiple_7\JJ\1740 mechanisms_8\NNS\13446390 ?_9\.\1740
D014635_D001927 NONE the_0\DT\1740 possible_1\JJ\1740 aetiologies_2\NNS\7326557 of_3\IN\1740 <e1>valproate-induced</e1>_4\JJ\1740 <e2>encephalopathy</e2>_5\JJ\1740 and_6\CC\1740 nmda_7\NN\1740 receptor-associated_8\JJ\1740 encephalitis_9\NN\14336539 present_10\VBP\2137132 a_11\DT\13649268 diagnostic_12\JJ\1740 dilemma_13\NN\5685363 ._14\.\1740
D014635_D010291 NONE in_0\IN\13603305 the_1\DT\1740 preceding_2\VBG\2690708 months_3\NNS\15113229 ,_4\,\1740 the_5\DT\1740 patient_6\NN\9898892 had_7\VBD\2108377 a_8\DT\13649268 number_9\NN\5107765 of_10\IN\1740 admissions_11\NNS\49003 with_12\IN\1740 transient_13\JJ\1740 unilateral_14\JJ\1740 <e2>hemiparesis</e2>_15\NN\1740 with_16\IN\1740 facial_17\JJ\1740 droop_18\NN\13896369 ,_19\,\1740 and_20\CC\1740 had_21\VBD\2108377 been_22\VBN\836236 started_23\VBN\2009433 on_24\IN\1740 <e1>valproate</e1>_25\NN\1740 for_26\IN\1740 presumed_27\VBN\719734 hemiplegic_28\JJ\1740 migraine_29\NN\14326607 ._30\.\1740
D014635_D020325 NONE in_0\IN\13603305 the_1\DT\1740 preceding_2\VBG\2690708 months_3\NNS\15113229 ,_4\,\1740 the_5\DT\1740 patient_6\NN\9898892 had_7\VBD\2108377 a_8\DT\13649268 number_9\NN\5107765 of_10\IN\1740 admissions_11\NNS\49003 with_12\IN\1740 transient_13\JJ\1740 unilateral_14\JJ\1740 hemiparesis_15\NN\1740 with_16\IN\1740 facial_17\JJ\1740 droop_18\NN\13896369 ,_19\,\1740 and_20\CC\1740 had_21\VBD\2108377 been_22\VBN\836236 started_23\VBN\2009433 on_24\IN\1740 <e1>valproate</e1>_25\NN\1740 for_26\IN\1740 presumed_27\VBN\719734 <e2>hemiplegic_28\JJ\1740 migraine</e2>_29\NN\14326607 ._30\.\1740
D016202_D001927 NONE eeg_0\NN\7000195 undertaken_1\VBN\1641914 during_2\IN\1740 inpatient_3\JJ\1740 stay_4\NN\30358 showed_5\VBD\2137132 changes_6\NNS\7283608 consistent_7\JJ\1740 with_8\IN\1740 <e2>encephalopathy</e2>_9\JJ\1740 ,_10\,\1740 and_11\CC\1740 low_12\JJ\1740 titre_13\NN\5038593 <e1>n-methyl-d-aspartate</e1>_14\NN\1740 (_15\-LRB-\1740 nmda_16\NN\1740 )_17\-RRB-\1740 receptor_18\NN\5225602 antibodies_19\NNS\14728724 were_20\VBD\836236 present_21\JJ\1740 in_22\IN\13603305 this_23\DT\1740 patient_24\NN\9898892 ._25\.\1740
D016202_D001927 NONE eeg_0\NN\7000195 undertaken_1\VBN\1641914 during_2\IN\1740 inpatient_3\JJ\1740 stay_4\NN\30358 showed_5\VBD\2137132 changes_6\NNS\7283608 consistent_7\JJ\1740 with_8\IN\1740 <e2>encephalopathy</e2>_9\JJ\1740 ,_10\,\1740 and_11\CC\1740 low_12\JJ\1740 titre_13\NN\5038593 n-methyl-d-aspartate_14\NN\1740 (_15\-LRB-\1740 <e1>nmda</e1>_16\NN\1740 )_17\-RRB-\1740 receptor_18\NN\5225602 antibodies_19\NNS\14728724 were_20\VBD\836236 present_21\JJ\1740 in_22\IN\13603305 this_23\DT\1740 patient_24\NN\9898892 ._25\.\1740
D016202_D001927 NONE the_0\DT\1740 possible_1\JJ\1740 aetiologies_2\NNS\7326557 of_3\IN\1740 valproate-induced_4\JJ\1740 <e2>encephalopathy</e2>_5\JJ\1740 and_6\CC\1740 <e1>nmda</e1>_7\NN\1740 receptor-associated_8\JJ\1740 encephalitis_9\NN\14336539 present_10\VBP\2137132 a_11\DT\13649268 diagnostic_12\JJ\1740 dilemma_13\NN\5685363 ._14\.\1740
D014635_D004660 NONE the_0\DT\1740 possible_1\JJ\1740 aetiologies_2\NNS\7326557 of_3\IN\1740 <e1>valproate-induced</e1>_4\JJ\1740 encephalopathy_5\JJ\1740 and_6\CC\1740 nmda_7\NN\1740 receptor-associated_8\JJ\1740 <e2>encephalitis</e2>_9\NN\14336539 present_10\VBP\2137132 a_11\DT\13649268 diagnostic_12\JJ\1740 dilemma_13\NN\5685363 ._14\.\1740
D016202_D004660 NONE the_0\DT\1740 possible_1\JJ\1740 aetiologies_2\NNS\7326557 of_3\IN\1740 valproate-induced_4\JJ\1740 encephalopathy_5\JJ\1740 and_6\CC\1740 <e1>nmda</e1>_7\NN\1740 receptor-associated_8\JJ\1740 <e2>encephalitis</e2>_9\NN\14336539 present_10\VBP\2137132 a_11\DT\13649268 diagnostic_12\JJ\1740 dilemma_13\NN\5685363 ._14\.\1740
17042797
D010862_D013226 CID stereological_0\JJ\1740 methods_1\NNS\5616786 reveal_2\VBP\2137132 the_3\DT\1740 robust_4\JJ\1740 size_5\NN\5090441 and_6\CC\1740 stability_7\NN\4777852 of_8\IN\1740 ectopic_9\JJ\1740 hilar_10\JJ\1740 granule_11\NN\9290777 cells_12\NNS\3080309 after_13\IN\1740 <e1>pilocarpine-induced</e1>_14\JJ\1740 <e2>status_15\NN\24720 epilepticus</e2>_16\NN\1740 in_17\IN\13603305 the_18\DT\1740 adult_19\JJ\1740 rat_20\NN\2329401 ._21\.\1740
D010862_D013226 CID to_0\TO\1740 quantify_1\VB\947077 this_2\DT\1740 population_3\NN\7942152 ,_4\,\1740 the_5\DT\1740 total_6\JJ\1740 number_7\NN\5107765 of_8\IN\1740 ectopic_9\JJ\1740 hilar_10\JJ\1740 granule_11\NN\9290777 cells_12\NNS\3080309 was_13\VBD\836236 estimated_14\VBN\637259 using_15\VBG\1156834 unbiased_16\JJ\1740 stereology_17\NN\1740 at_18\IN\14622893 different_19\JJ\1740 times_20\NNS\15113229 after_21\IN\1740 <e1>pilocarpine-induced</e1>_22\JJ\1740 <e2>status_23\NN\24720 epilepticus</e2>_24\NN\1740 ._25\.\1740
D010862_D004833 CID the_0\DT\1740 results_1\NNS\34213 provide_2\VBP\2199590 new_3\JJ\1740 insight_4\NN\5710020 into_5\IN\1740 the_6\DT\1740 potential_7\JJ\1740 role_8\NN\719494 of_9\IN\1740 ectopic_10\JJ\1740 hilar_11\JJ\1740 granule_12\NN\9290777 cells_13\NNS\3080309 in_14\IN\13603305 the_15\DT\1740 <e1>pilocarpine</e1>_16\NN\14712692 model_17\NN\5888929 of_18\IN\1740 <e2>temporal_19\JJ\1740 lobe_20\JJ\1740 epilepsy</e2>_21\NN\14085708 ._22\.\1740
7378868
D013390_D014313 CID <e1>suxamethonium-induced</e1>_0\JJ\1740 <e2>jaw_1\NN\5269901 stiffness</e2>_2\NN\5023233 and_3\CC\1740 myalgia_4\NN\14322699 associated_5\VBN\628491 with_6\IN\1740 atypical_7\JJ\1740 cholinesterase_8\NN\14732946 :_9\:\1740 case_10\NN\7283608 report_11\NN\6470073 ._12\.\1740
D013390_D014313 CID the_0\DT\1740 case_1\NN\7283608 shows_2\VBZ\2137132 that_3\IN\1740 <e2>prolonged_4\JJ\1740 jaw_5\NN\5269901 rigidity</e2>_6\NN\5023233 and_7\CC\1740 myalgia_8\NN\14322699 may_9\MD\15209706 occur_10\VB\2623529 after_11\IN\1740 <e1>suxamethonium</e1>_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 atypical_16\JJ\1740 cholinesterase_17\NN\14732946 despite_18\IN\7501545 pretreatment_19\NN\1740 with_20\IN\1740 pancuronium_21\NN\1740 ._22\.\1740
D013390_D063806 CID <e1>suxamethonium-induced</e1>_0\JJ\1740 jaw_1\NN\5269901 stiffness_2\NN\5023233 and_3\CC\1740 <e2>myalgia</e2>_4\NN\14322699 associated_5\VBN\628491 with_6\IN\1740 atypical_7\JJ\1740 cholinesterase_8\NN\14732946 :_9\:\1740 case_10\NN\7283608 report_11\NN\6470073 ._12\.\1740
D013390_D063806 CID the_0\DT\1740 case_1\NN\7283608 shows_2\VBZ\2137132 that_3\IN\1740 prolonged_4\JJ\1740 jaw_5\NN\5269901 rigidity_6\NN\5023233 and_7\CC\1740 <e2>myalgia</e2>_8\NN\14322699 may_9\MD\15209706 occur_10\VB\2623529 after_11\IN\1740 <e1>suxamethonium</e1>_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 atypical_16\JJ\1740 cholinesterase_17\NN\14732946 despite_18\IN\7501545 pretreatment_19\NN\1740 with_20\IN\1740 pancuronium_21\NN\1740 ._22\.\1740
D010197_D014313 NONE the_0\DT\1740 case_1\NN\7283608 shows_2\VBZ\2137132 that_3\IN\1740 <e2>prolonged_4\JJ\1740 jaw_5\NN\5269901 rigidity</e2>_6\NN\5023233 and_7\CC\1740 myalgia_8\NN\14322699 may_9\MD\15209706 occur_10\VB\2623529 after_11\IN\1740 suxamethonium_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 atypical_16\JJ\1740 cholinesterase_17\NN\14732946 despite_18\IN\7501545 pretreatment_19\NN\1740 with_20\IN\1740 <e1>pancuronium</e1>_21\NN\1740 ._22\.\1740
D010197_D063806 NONE the_0\DT\1740 case_1\NN\7283608 shows_2\VBZ\2137132 that_3\IN\1740 prolonged_4\JJ\1740 jaw_5\NN\5269901 rigidity_6\NN\5023233 and_7\CC\1740 <e2>myalgia</e2>_8\NN\14322699 may_9\MD\15209706 occur_10\VB\2623529 after_11\IN\1740 suxamethonium_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 atypical_16\JJ\1740 cholinesterase_17\NN\14732946 despite_18\IN\7501545 pretreatment_19\NN\1740 with_20\IN\1740 <e1>pancuronium</e1>_21\NN\1740 ._22\.\1740
9869655
D004997_D002780 CID this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 <e1>17alpha-ethinylestradiol</e1>_4\NN\1740 (ee)-induced_5\VBD\1740 <e2>intrahepatic_6\JJ\1740 cholestasis</e2>_7\NN\14052403 in_8\IN\13603305 rats_9\NNS\2329401 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 selective_13\JJ\1740 inhibition_14\NN\1068773 of_15\IN\1740 the_16\DT\1740 neutral_17\JJ\1740 pathway_18\NN\5483677 of_19\IN\1740 bile_20\NN\5405946 salt_21\NN\14818238 (_22\-LRB-\1740 bs_23\NN\6698252 )_24\-RRB-\1740 synthesis_25\NN\13446390 ._26\.\1740
D004997_D002780 CID this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 17alpha-ethinylestradiol_4\NN\1740 <e1>(ee)-induced</e1>_5\VBD\1740 <e2>intrahepatic_6\JJ\1740 cholestasis</e2>_7\NN\14052403 in_8\IN\13603305 rats_9\NNS\2329401 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 selective_13\JJ\1740 inhibition_14\NN\1068773 of_15\IN\1740 the_16\DT\1740 neutral_17\JJ\1740 pathway_18\NN\5483677 of_19\IN\1740 bile_20\NN\5405946 salt_21\NN\14818238 (_22\-LRB-\1740 bs_23\NN\6698252 )_24\-RRB-\1740 synthesis_25\NN\13446390 ._26\.\1740
D001647_D002780 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 17alpha-ethinylestradiol_4\NN\1740 (ee)-induced_5\VBD\1740 <e2>intrahepatic_6\JJ\1740 cholestasis</e2>_7\NN\14052403 in_8\IN\13603305 rats_9\NNS\2329401 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 selective_13\JJ\1740 inhibition_14\NN\1068773 of_15\IN\1740 the_16\DT\1740 neutral_17\JJ\1740 pathway_18\NN\5483677 of_19\IN\1740 <e1>bile_20\NN\5405946 salt</e1>_21\NN\14818238 (_22\-LRB-\1740 bs_23\NN\6698252 )_24\-RRB-\1740 synthesis_25\NN\13446390 ._26\.\1740
D001647_D002780 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 17alpha-ethinylestradiol_4\NN\1740 (ee)-induced_5\VBD\1740 <e2>intrahepatic_6\JJ\1740 cholestasis</e2>_7\NN\14052403 in_8\IN\13603305 rats_9\NNS\2329401 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 selective_13\JJ\1740 inhibition_14\NN\1068773 of_15\IN\1740 the_16\DT\1740 neutral_17\JJ\1740 pathway_18\NN\5483677 of_19\IN\1740 bile_20\NN\5405946 salt_21\NN\14818238 (_22\-LRB-\1740 <e1>bs</e1>_23\NN\6698252 )_24\-RRB-\1740 synthesis_25\NN\13446390 ._26\.\1740
11366874
D019888_D001145 NONE <e1>viracept</e1>_0\NNP\4013993 and_1\CC\1740 <e2>irregular_2\JJ\1740 heartbeat</e2>_3\NN\7296190 warning_4\NN\7212190 ._5\.\1740
D019888_D001145 NONE a_0\DT\13649268 group_1\NN\2137 of_2\IN\1740 doctors_3\NNS\10305802 in_4\IN\13603305 boston_5\NNP\1740 warn_6\VBP\831651 that_7\IN\1740 the_8\DT\1740 protease_9\NN\14732946 inhibitor_10\NN\20090 <e1>viracept</e1>_11\NNP\4013993 may_12\MD\15209706 cause_13\VB\1617192 an_14\DT\6697703 <e2>irregular_15\JJ\1740 heart_16\NN\5919034 beat</e2>_17\VBN\1108148 ,_18\,\1740 known_19\VBN\2110220 as_20\IN\14622893 bradycardia_21\NN\14110674 ,_22\,\1740 in_23\IN\13603305 people_24\NNS\31264 with_25\IN\1740 hiv_26\NN\14186340 ._27\.\1740
D019888_D001919 CID a_0\DT\13649268 group_1\NN\2137 of_2\IN\1740 doctors_3\NNS\10305802 in_4\IN\13603305 boston_5\NNP\1740 warn_6\VBP\831651 that_7\IN\1740 the_8\DT\1740 protease_9\NN\14732946 inhibitor_10\NN\20090 <e1>viracept</e1>_11\NNP\4013993 may_12\MD\15209706 cause_13\VB\1617192 an_14\DT\6697703 irregular_15\JJ\1740 heart_16\NN\5919034 beat_17\VBN\1108148 ,_18\,\1740 known_19\VBN\2110220 as_20\IN\14622893 <e2>bradycardia</e2>_21\NN\14110674 ,_22\,\1740 in_23\IN\13603305 people_24\NNS\31264 with_25\IN\1740 hiv_26\NN\14186340 ._27\.\1740
D019888_D001919 CID <e2>bradycardia</e2>_0\NNP\14110674 occurred_1\VBD\2623529 in_2\IN\13603305 a_3\DT\13649268 45-year-old_4\JJ\1740 male_5\JJ\1740 patient_6\NN\9898892 who_7\WP\8299493 was_8\VBD\836236 <e1>viracept</e1>_9\NNP\4013993 in_10\IN\13603305 combination_11\NN\7951464 with_12\IN\1740 other_13\JJ\1740 anti-hiv_14\JJ\1740 drugs_15\NNS\14778436 ._16\.\1740
11423811
D004280_D002637 NONE a_0\DT\13649268 pilot_1\NN\9826204 study_2\NN\635850 to_3\TO\1740 assess_4\VB\670261 the_5\DT\1740 safety_6\NN\13920835 of_7\IN\1740 <e1>dobutamine</e1>_8\NN\1740 stress_9\NN\7083732 echocardiography_10\NN\177127 in_11\IN\13603305 the_12\DT\1740 emergency_13\NN\7417644 department_14\NN\8220714 evaluation_15\NN\874067 of_16\IN\1740 cocaine-associated_17\JJ\1740 <e2>chest_18\NN\5220461 pain</e2>_19\NN\14299637 ._20\.\1740
D004280_D002637 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 theoretical_3\JJ\1740 concern_4\NN\5682950 regarding_5\VBG\689344 administration_6\NN\1133281 of_7\IN\1740 <e1>dobutamine</e1>_8\NN\1740 in_9\IN\13603305 the_10\DT\1740 setting_11\NN\8567235 of_12\IN\1740 cocaine_13\NN\3492717 use_14\NN\407535 ,_15\,\1740 we_16\PRP\1740 conducted_17\VBD\2436349 a_18\DT\13649268 pilot_19\NN\9826204 study_20\NN\635850 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 safety_24\NN\13920835 of_25\IN\1740 dse_26\NN\1740 in_27\IN\13603305 emergency_28\NN\7417644 department_29\NN\8220714 patients_30\NNS\9898892 with_31\IN\1740 cocaine-associated_32\JJ\1740 <e2>chest_33\NN\5220461 pain</e2>_34\NN\14299637 ._35\.\1740
D004280_D002637 NONE conclusion_0\NN\5837957 :_1\:\1740 no_2\DT\7204911 exaggerated_3\JJ\1740 adrenergic_4\JJ\1740 response_5\NN\11410625 was_6\VBD\836236 detected_7\VBN\2163746 when_8\WRB\1740 <e1>dobutamine</e1>_9\NN\1740 was_10\VBD\836236 administered_11\VBN\2436349 to_12\TO\1740 patients_13\NNS\9898892 with_14\IN\1740 cocaine-related_15\JJ\1740 <e2>chest_16\NN\5220461 pain</e2>_17\NN\14299637 ._18\.\1740
D003042_D002637 CID a_0\DT\13649268 pilot_1\NN\9826204 study_2\NN\635850 to_3\TO\1740 assess_4\VB\670261 the_5\DT\1740 safety_6\NN\13920835 of_7\IN\1740 dobutamine_8\NN\1740 stress_9\NN\7083732 echocardiography_10\NN\177127 in_11\IN\13603305 the_12\DT\1740 emergency_13\NN\7417644 department_14\NN\8220714 evaluation_15\NN\874067 of_16\IN\1740 <e1>cocaine-associated</e1>_17\JJ\1740 <e2>chest_18\NN\5220461 pain</e2>_19\NN\14299637 ._20\.\1740
D003042_D002637 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 <e2>chest_3\JJ\1740 pain</e2>_4\NN\14299637 in_5\IN\13603305 the_6\DT\1740 setting_7\NN\8567235 of_8\IN\1740 <e1>cocaine</e1>_9\NN\3492717 use_10\NN\407535 poses_11\NNS\4787763 a_12\DT\13649268 diagnostic_13\JJ\1740 dilemma_14\NN\5685363 ._15\.\1740
D003042_D002637 CID because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 theoretical_3\JJ\1740 concern_4\NN\5682950 regarding_5\VBG\689344 administration_6\NN\1133281 of_7\IN\1740 dobutamine_8\NN\1740 in_9\IN\13603305 the_10\DT\1740 setting_11\NN\8567235 of_12\IN\1740 <e1>cocaine</e1>_13\NN\3492717 use_14\NN\407535 ,_15\,\1740 we_16\PRP\1740 conducted_17\VBD\2436349 a_18\DT\13649268 pilot_19\NN\9826204 study_20\NN\635850 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 safety_24\NN\13920835 of_25\IN\1740 dse_26\NN\1740 in_27\IN\13603305 emergency_28\NN\7417644 department_29\NN\8220714 patients_30\NNS\9898892 with_31\IN\1740 cocaine-associated_32\JJ\1740 <e2>chest_33\NN\5220461 pain</e2>_34\NN\14299637 ._35\.\1740
D003042_D002637 CID because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 theoretical_3\JJ\1740 concern_4\NN\5682950 regarding_5\VBG\689344 administration_6\NN\1133281 of_7\IN\1740 dobutamine_8\NN\1740 in_9\IN\13603305 the_10\DT\1740 setting_11\NN\8567235 of_12\IN\1740 cocaine_13\NN\3492717 use_14\NN\407535 ,_15\,\1740 we_16\PRP\1740 conducted_17\VBD\2436349 a_18\DT\13649268 pilot_19\NN\9826204 study_20\NN\635850 to_21\TO\1740 assess_22\VB\670261 the_23\DT\1740 safety_24\NN\13920835 of_25\IN\1740 dse_26\NN\1740 in_27\IN\13603305 emergency_28\NN\7417644 department_29\NN\8220714 patients_30\NNS\9898892 with_31\IN\1740 <e1>cocaine-associated</e1>_32\JJ\1740 <e2>chest_33\NN\5220461 pain</e2>_34\NN\14299637 ._35\.\1740
D003042_D002637 CID patients_0\NNS\9898892 were_1\VBD\836236 eligible_2\JJ\1740 for_3\IN\1740 dse_4\NN\1740 if_5\IN\1740 they_6\PRP\1740 had_7\VBD\2108377 used_8\VBN\1156834 <e1>cocaine</e1>_9\NN\3492717 within_10\IN\1740 24_11\CD\13745420 hours_12\NNS\15118228 preceding_13\VBG\2690708 the_14\DT\1740 onset_15\NN\7325190 of_16\IN\1740 <e2>chest_17\JJ\1740 pain</e2>_18\NN\14299637 and_19\CC\1740 had_20\VBD\2108377 a_21\DT\13649268 normal_22\JJ\1740 ecg_23\NN\7000195 and_24\CC\1740 tropinin_25\NN\1740
D003042_D002637 CID conclusion_0\NN\5837957 :_1\:\1740 no_2\DT\7204911 exaggerated_3\JJ\1740 adrenergic_4\JJ\1740 response_5\NN\11410625 was_6\VBD\836236 detected_7\VBN\2163746 when_8\WRB\1740 dobutamine_9\NN\1740 was_10\VBD\836236 administered_11\VBN\2436349 to_12\TO\1740 patients_13\NNS\9898892 with_14\IN\1740 <e1>cocaine-related</e1>_15\JJ\1740 <e2>chest_16\NN\5220461 pain</e2>_17\NN\14299637 ._18\.\1740
D004280_D007511 NONE <e1>dobutamine</e1>_0\JJ\1740 stress_1\NN\7083732 echocardiography_2\NN\177127 (_3\-LRB-\1740 dse_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 widely_8\RB\1740 available_9\JJ\1740 and_10\CC\1740 sensitive_11\JJ\1740 test_12\NN\5798043 for_13\IN\1740 evaluating_14\VBG\670261 cardiac_15\JJ\1740 <e2>ischemia</e2>_16\NN\14195315 ._17\.\1740
D003042_D064420 NONE patients_0\NNS\9898892 exhibiting_1\VBG\2632167 signs_2\NNS\6643763 of_3\IN\1740 continuing_4\VBG\2367363 <e1>cocaine</e1>_5\NN\3492717 <e2>toxicity</e2>_6\NN\13576101 were_7\VBD\836236 excluded_8\VBN\471711 from_9\IN\1740 the_10\DT\1740 study_11\NN\635850 ._12\.\1740
17255138
D052246_D009203 CID objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>acute_5\JJ\1740 myocardial_6\JJ\1740 infarction</e2>_7\NN\14204950 (_8\-LRB-\1740 ami_9\NN\1740 )_10\-RRB-\1740 with_11\IN\1740 <e1>cox-2_12\NN\14737847 inhibitors</e1>_13\NNS\20090 may_14\MD\15209706 offset_15\VB\2673134 their_16\PRP$\1740 gastrointestinal_17\NN\1740 (_18\-LRB-\1740 gi_19\NN\13634615 )_20\-RRB-\1740 benefit_21\NN\13278375 compared_22\VBN\644583 with_23\IN\1740 non-selective_24\JJ\1740 (_25\-LRB-\1740 ns_26\NN\14622893 )_27\-RRB-\1740 non-steroidal_28\JJ\1740 anti-inflammatory_29\JJ\1740 drugs_30\NNS\14778436 (_31\-LRB-\1740 nsaids_32\NNS\2721538 )_33\-RRB-\1740 ._34\.\1740
D052246_D009203 CID objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 acute_5\JJ\1740 myocardial_6\JJ\1740 infarction_7\NN\14204950 (_8\-LRB-\1740 <e2>ami</e2>_9\NN\1740 )_10\-RRB-\1740 with_11\IN\1740 <e1>cox-2_12\NN\14737847 inhibitors</e1>_13\NNS\20090 may_14\MD\15209706 offset_15\VB\2673134 their_16\PRP$\1740 gastrointestinal_17\NN\1740 (_18\-LRB-\1740 gi_19\NN\13634615 )_20\-RRB-\1740 benefit_21\NN\13278375 compared_22\VBN\644583 with_23\IN\1740 non-selective_24\JJ\1740 (_25\-LRB-\1740 ns_26\NN\14622893 )_27\-RRB-\1740 non-steroidal_28\JJ\1740 anti-inflammatory_29\JJ\1740 drugs_30\NNS\14778436 (_31\-LRB-\1740 nsaids_32\NNS\2721538 )_33\-RRB-\1740 ._34\.\1740
D052246_D009203 CID we_0\PRP\1740 aimed_1\VBD\1987160 to_2\TO\1740 compare_3\VB\644583 the_4\DT\1740 risks_5\NNS\14541044 of_6\IN\1740 hospitalization_7\NN\15113229 for_8\IN\1740 <e2>ami</e2>_9\NN\1740 and_10\CC\1740 gi_11\NN\13634615 bleeding_12\VBG\104868 among_13\IN\1740 elderly_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 <e1>cox-2_17\NN\14737847 inhibitors</e1>_18\NNS\20090 ,_19\,\1740 ns-nsaids_20\NN\1740 and_21\CC\1740 acetaminophen_22\RB\1740 ._23\.\1740
D000894_D009203 CID objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>acute_5\JJ\1740 myocardial_6\JJ\1740 infarction</e2>_7\NN\14204950 (_8\-LRB-\1740 ami_9\NN\1740 )_10\-RRB-\1740 with_11\IN\1740 cox-2_12\NN\14737847 inhibitors_13\NNS\20090 may_14\MD\15209706 offset_15\VB\2673134 their_16\PRP$\1740 gastrointestinal_17\NN\1740 (_18\-LRB-\1740 gi_19\NN\13634615 )_20\-RRB-\1740 benefit_21\NN\13278375 compared_22\VBN\644583 with_23\IN\1740 non-selective_24\JJ\1740 (_25\-LRB-\1740 ns_26\NN\14622893 )_27\-RRB-\1740 <e1>non-steroidal_28\JJ\1740 anti-inflammatory_29\JJ\1740 drugs</e1>_30\NNS\14778436 (_31\-LRB-\1740 nsaids_32\NNS\2721538 )_33\-RRB-\1740 ._34\.\1740
D000894_D009203 CID objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 acute_5\JJ\1740 myocardial_6\JJ\1740 infarction_7\NN\14204950 (_8\-LRB-\1740 <e2>ami</e2>_9\NN\1740 )_10\-RRB-\1740 with_11\IN\1740 cox-2_12\NN\14737847 inhibitors_13\NNS\20090 may_14\MD\15209706 offset_15\VB\2673134 their_16\PRP$\1740 gastrointestinal_17\NN\1740 (_18\-LRB-\1740 gi_19\NN\13634615 )_20\-RRB-\1740 benefit_21\NN\13278375 compared_22\VBN\644583 with_23\IN\1740 non-selective_24\JJ\1740 (_25\-LRB-\1740 ns_26\NN\14622893 )_27\-RRB-\1740 <e1>non-steroidal_28\JJ\1740 anti-inflammatory_29\JJ\1740 drugs</e1>_30\NNS\14778436 (_31\-LRB-\1740 nsaids_32\NNS\2721538 )_33\-RRB-\1740 ._34\.\1740
D052246_D006471 NONE we_0\PRP\1740 aimed_1\VBD\1987160 to_2\TO\1740 compare_3\VB\644583 the_4\DT\1740 risks_5\NNS\14541044 of_6\IN\1740 hospitalization_7\NN\15113229 for_8\IN\1740 ami_9\NN\1740 and_10\CC\1740 <e2>gi_11\NN\13634615 bleeding</e2>_12\VBG\104868 among_13\IN\1740 elderly_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 <e1>cox-2_17\NN\14737847 inhibitors</e1>_18\NNS\20090 ,_19\,\1740 ns-nsaids_20\NN\1740 and_21\CC\1740 acetaminophen_22\RB\1740 ._23\.\1740
D000082_D009203 NONE we_0\PRP\1740 aimed_1\VBD\1987160 to_2\TO\1740 compare_3\VB\644583 the_4\DT\1740 risks_5\NNS\14541044 of_6\IN\1740 hospitalization_7\NN\15113229 for_8\IN\1740 <e2>ami</e2>_9\NN\1740 and_10\CC\1740 gi_11\NN\13634615 bleeding_12\VBG\104868 among_13\IN\1740 elderly_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 cox-2_17\NN\14737847 inhibitors_18\NNS\20090 ,_19\,\1740 ns-nsaids_20\NN\1740 and_21\CC\1740 <e1>acetaminophen</e1>_22\RB\1740 ._23\.\1740
D000082_D009203 NONE among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 aspirin_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 <e1>acetaminophen</e1>_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 aspirin_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 rofecoxib_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 celecoxib_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 naproxen_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 diclofenac_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 ibuprofen_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D000082_D009203 NONE the_0\DT\1740 <e2>ami/gi</e2>_1\NN\1740 toxicity_2\NN\13576101 of_3\IN\1740 celecoxib_4\NN\3124700 was_5\VBD\836236 similar_6\JJ\1740 to_7\TO\1740 that_8\DT\1740 of_9\IN\1740 <e1>acetaminophen</e1>_10\NN\2707683 and_11\CC\1740 seemed_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 better_15\JJR\1740 than_16\IN\1740 those_17\DT\1740 of_18\IN\1740 rofecoxib_19\NN\3124700 and_20\CC\1740 ns-nsaids_21\NN\1740 ._22\.\1740
D000082_D006471 NONE we_0\PRP\1740 aimed_1\VBD\1987160 to_2\TO\1740 compare_3\VB\644583 the_4\DT\1740 risks_5\NNS\14541044 of_6\IN\1740 hospitalization_7\NN\15113229 for_8\IN\1740 ami_9\NN\1740 and_10\CC\1740 <e2>gi_11\NN\13634615 bleeding</e2>_12\VBG\104868 among_13\IN\1740 elderly_14\JJ\1740 patients_15\NNS\9898892 using_16\VBG\1156834 cox-2_17\NN\14737847 inhibitors_18\NNS\20090 ,_19\,\1740 ns-nsaids_20\NN\1740 and_21\CC\1740 <e1>acetaminophen</e1>_22\RB\1740 ._23\.\1740
D001241_D009203 NONE among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 <e1>aspirin</e1>_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 acetaminophen_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 aspirin_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 rofecoxib_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 celecoxib_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 naproxen_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 diclofenac_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 ibuprofen_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D001241_D009203 NONE among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 aspirin_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 acetaminophen_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 <e1>aspirin</e1>_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 rofecoxib_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 celecoxib_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 naproxen_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 diclofenac_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 ibuprofen_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D001241_D009203 NONE conclusion_0\NN\5837957 :_1\:\1740 among_2\IN\1740 non-users_3\NNS\1740 of_4\IN\1740 <e1>aspirin</e1>_5\NN\2707683 ,_6\,\1740 naproxen_7\NN\3828465 seemed_8\VBD\2604760 to_9\TO\1740 carry_10\VB\1850315 the_11\DT\1740 highest_12\JJS\1740 risk_13\NN\14541044 for_14\IN\1740 <e2>ami/gi</e2>_15\NN\1740 bleeding_16\VBG\104868 ._17\.\1740
C116926_D009203 CID among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 aspirin_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 acetaminophen_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 aspirin_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 <e1>rofecoxib</e1>_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 celecoxib_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 naproxen_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 diclofenac_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 ibuprofen_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
C116926_D009203 CID the_0\DT\1740 <e2>ami/gi</e2>_1\NN\1740 toxicity_2\NN\13576101 of_3\IN\1740 celecoxib_4\NN\3124700 was_5\VBD\836236 similar_6\JJ\1740 to_7\TO\1740 that_8\DT\1740 of_9\IN\1740 acetaminophen_10\NN\2707683 and_11\CC\1740 seemed_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 better_15\JJR\1740 than_16\IN\1740 those_17\DT\1740 of_18\IN\1740 <e1>rofecoxib</e1>_19\NN\3124700 and_20\CC\1740 ns-nsaids_21\NN\1740 ._22\.\1740
C105934_D009203 NONE among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 aspirin_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 acetaminophen_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 aspirin_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 rofecoxib_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 <e1>celecoxib</e1>_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 naproxen_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 diclofenac_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 ibuprofen_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
C105934_D009203 NONE the_0\DT\1740 <e2>ami/gi</e2>_1\NN\1740 toxicity_2\NN\13576101 of_3\IN\1740 <e1>celecoxib</e1>_4\NN\3124700 was_5\VBD\836236 similar_6\JJ\1740 to_7\TO\1740 that_8\DT\1740 of_9\IN\1740 acetaminophen_10\NN\2707683 and_11\CC\1740 seemed_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 better_15\JJR\1740 than_16\IN\1740 those_17\DT\1740 of_18\IN\1740 rofecoxib_19\NN\3124700 and_20\CC\1740 ns-nsaids_21\NN\1740 ._22\.\1740
D009288_D009203 CID among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 aspirin_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 acetaminophen_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 aspirin_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 rofecoxib_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 celecoxib_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 <e1>naproxen</e1>_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 diclofenac_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 ibuprofen_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D009288_D009203 CID conclusion_0\NN\5837957 :_1\:\1740 among_2\IN\1740 non-users_3\NNS\1740 of_4\IN\1740 aspirin_5\NN\2707683 ,_6\,\1740 <e1>naproxen</e1>_7\NN\3828465 seemed_8\VBD\2604760 to_9\TO\1740 carry_10\VB\1850315 the_11\DT\1740 highest_12\JJS\1740 risk_13\NN\14541044 for_14\IN\1740 <e2>ami/gi</e2>_15\NN\1740 bleeding_16\VBG\104868 ._17\.\1740
D004008_D009203 NONE among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 aspirin_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 acetaminophen_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 aspirin_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 rofecoxib_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 celecoxib_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 naproxen_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 <e1>diclofenac</e1>_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 ibuprofen_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D007052_D009203 NONE among_0\IN\1740 non-users_1\NNS\1740 of_2\IN\1740 aspirin_3\NN\2707683 ,_4\,\1740 the_5\DT\1740 adjusted_6\VBN\126264 hazard_7\NN\14541044 ratios_8\NNS\13815152 (_9\-LRB-\1740 95_10\CD\1740 %_11\NN\1740 confidence_12\NN\5697135 interval_13\NN\33615 )_14\-RRB-\1740 of_15\IN\1740 hospitalization_16\NN\15113229 for_17\IN\1740 <e2>ami/gi</e2>_18\NN\1740 vs_19\CC\13634784 the_20\DT\1740 acetaminophen_21\NN\2707683 (_22\-LRB-\1740 with_23\IN\1740 no_24\DT\7204911 aspirin_25\NN\2707683 )_26\-RRB-\1740 group_27\NN\2137 were_28\VBD\836236 :_29\:\1740 rofecoxib_30\NN\3124700 1.27_31\CD\1740 (_32\-LRB-\1740 1.13_33\CD\1740 ,_34\,\1740 1.42_35\CD\1740 )_36\-RRB-\1740 ,_37\,\1740 celecoxib_38\NN\3124700 0.93_39\CD\1740 (_40\-LRB-\1740 0.83_41\CD\1740 ,_42\,\1740 1.03_43\CD\1740 )_44\-RRB-\1740 ,_45\,\1740 naproxen_46\NN\3828465 1.59_47\CD\1740 (_48\-LRB-\1740 1.31_49\CD\1740 ,_50\,\1740 1.93_51\CD\1740 )_52\-RRB-\1740 ,_53\,\1740 diclofenac_54\VBD\1740 1.17_55\CD\1740 (_56\-LRB-\1740 0.99_57\CD\1740 ,_58\,\1740 1.38_59\CD\1740 )_60\-RRB-\1740 and_61\CC\1740 <e1>ibuprofen</e1>_62\NN\3828465 1.05_63\CD\1740 (_64\-LRB-\1740 0.74_65\CD\1740 ,_66\,\1740 1.51_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D001241_D006471 NONE conclusion_0\NN\5837957 :_1\:\1740 among_2\IN\1740 non-users_3\NNS\1740 of_4\IN\1740 <e1>aspirin</e1>_5\NN\2707683 ,_6\,\1740 naproxen_7\NN\3828465 seemed_8\VBD\2604760 to_9\TO\1740 carry_10\VB\1850315 the_11\DT\1740 highest_12\JJS\1740 risk_13\NN\14541044 for_14\IN\1740 <e2>ami/gi_15\NN\1740 bleeding</e2>_16\VBG\104868 ._17\.\1740
D009288_D006471 CID conclusion_0\NN\5837957 :_1\:\1740 among_2\IN\1740 non-users_3\NNS\1740 of_4\IN\1740 aspirin_5\NN\2707683 ,_6\,\1740 <e1>naproxen</e1>_7\NN\3828465 seemed_8\VBD\2604760 to_9\TO\1740 carry_10\VB\1850315 the_11\DT\1740 highest_12\JJS\1740 risk_13\NN\14541044 for_14\IN\1740 <e2>ami/gi_15\NN\1740 bleeding</e2>_16\VBG\104868 ._17\.\1740
C105934_D064420 NONE the_0\DT\1740 ami/gi_1\NN\1740 <e2>toxicity</e2>_2\NN\13576101 of_3\IN\1740 <e1>celecoxib</e1>_4\NN\3124700 was_5\VBD\836236 similar_6\JJ\1740 to_7\TO\1740 that_8\DT\1740 of_9\IN\1740 acetaminophen_10\NN\2707683 and_11\CC\1740 seemed_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 better_15\JJR\1740 than_16\IN\1740 those_17\DT\1740 of_18\IN\1740 rofecoxib_19\NN\3124700 and_20\CC\1740 ns-nsaids_21\NN\1740 ._22\.\1740
D000082_D064420 NONE the_0\DT\1740 ami/gi_1\NN\1740 <e2>toxicity</e2>_2\NN\13576101 of_3\IN\1740 celecoxib_4\NN\3124700 was_5\VBD\836236 similar_6\JJ\1740 to_7\TO\1740 that_8\DT\1740 of_9\IN\1740 <e1>acetaminophen</e1>_10\NN\2707683 and_11\CC\1740 seemed_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 better_15\JJR\1740 than_16\IN\1740 those_17\DT\1740 of_18\IN\1740 rofecoxib_19\NN\3124700 and_20\CC\1740 ns-nsaids_21\NN\1740 ._22\.\1740
C116926_D064420 NONE the_0\DT\1740 ami/gi_1\NN\1740 <e2>toxicity</e2>_2\NN\13576101 of_3\IN\1740 celecoxib_4\NN\3124700 was_5\VBD\836236 similar_6\JJ\1740 to_7\TO\1740 that_8\DT\1740 of_9\IN\1740 acetaminophen_10\NN\2707683 and_11\CC\1740 seemed_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 better_15\JJR\1740 than_16\IN\1740 those_17\DT\1740 of_18\IN\1740 <e1>rofecoxib</e1>_19\NN\3124700 and_20\CC\1740 ns-nsaids_21\NN\1740 ._22\.\1740
15953230
C012052_D062787 NONE two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e1>amisulpride</e1>_3\JJ\1740 <e2>overdose</e2>_4\NN\1740 :_5\:\1740 a_6\DT\13649268 cause_7\NN\7323922 for_8\IN\1740 prolonged_9\JJ\1740 qt_10\NN\1740 syndrome_11\NN\5870365 ._12\.\1740
C012052_D008133 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e1>amisulpride</e1>_3\JJ\1740 overdose_4\NN\1740 :_5\:\1740 a_6\DT\13649268 cause_7\NN\7323922 for_8\IN\1740 <e2>prolonged_9\JJ\1740 qt_10\NN\1740 syndrome</e2>_11\NN\5870365 ._12\.\1740
C012052_D011041 NONE two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 deliberate_3\NN\1740 <e2>self-poisoning</e2>_4\NN\1740 with_5\IN\1740 5_6\CD\13741022 g_7\NN\13717155 and_8\CC\1740 3.6_9\CD\1740 g_10\NN\13717155 of_11\IN\1740 <e1>amisulpride</e1>_12\RB\1740 ,_13\,\1740 respectively_14\RB\1740 ,_15\,\1740 are_16\VBP\836236 reported_17\VBN\831651 ._18\.\1740
D002125_D008133 NONE the_0\DT\1740 <e2>qt_1\NNP\1740 prolongation</e2>_2\NN\1017987 appeared_3\VBD\2604760 to_4\TO\1740 respond_5\VB\2367363 to_6\TO\1740 administration_7\NN\1133281 of_8\IN\1740 i.v._9\NN\1740 <e1>calcium_10\NN\14625458 gluconate</e1>_11\NN\1740 ._12\.\1740
12498738
C043211_D009202 NONE <e1>carvedilol</e1>_0\NNP\2832168 protects_1\VBZ\1127795 against_2\IN\1740 doxorubicin-induced_3\JJ\1740 mitochondrial_4\JJ\1740 <e2>cardiomyopathy</e2>_5\JJ\1740 ._6\.\1740
C043211_D009202 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 this_4\DT\1740 protection_5\NN\407535 by_6\IN\1740 <e1>carvedilol</e1>_7\NNS\2832168 against_8\IN\1740 both_9\CC\1740 the_10\DT\1740 structural_11\JJ\1740 and_12\CC\1740 functional_13\JJ\1740 cardiac_14\JJ\1740 tissue_15\NN\5220461 damage_16\NN\7296428 may_17\MD\15209706 afford_18\VB\2267060 significant_19\JJ\1740 clinical_20\JJ\1740 advantage_21\NN\5154517 in_22\IN\13603305 minimizing_23\VBG\441445 the_24\DT\1740 dose-limiting_25\JJ\1740 mitochondrial_26\JJ\1740 dysfunction_27\NN\14204950 and_28\CC\1740 <e2>cardiomyopathy</e2>_29\NN\14103288 that_30\WDT\1740 accompanies_31\VBZ\1835496 long-term_32\JJ\1740 doxorubicin_33\NN\2716866 therapy_34\NN\657604 in_35\IN\13603305 cancer_36\NN\14239425 patients_37\NNS\9898892 ._38\.\1740
D004317_D009202 CID carvedilol_0\NNP\2832168 protects_1\VBZ\1127795 against_2\IN\1740 <e1>doxorubicin-induced</e1>_3\JJ\1740 mitochondrial_4\JJ\1740 <e2>cardiomyopathy</e2>_5\JJ\1740 ._6\.\1740
D004317_D009202 CID several_0\JJ\1740 cytopathic_1\JJ\1740 mechanisms_2\NNS\13446390 have_3\VBP\2108377 been_4\VBN\836236 suggested_5\VBN\1010118 to_6\TO\1740 mediate_7\VB\761713 the_8\DT\1740 dose-limiting_9\JJ\1740 cumulative_10\JJ\1740 and_11\CC\1740 irreversible_12\JJ\1740 <e2>cardiomyopathy</e2>_13\NN\14103288 caused_14\VBN\1617192 by_15\IN\1740 <e1>doxorubicin</e1>_16\NN\2716866 ._17\.\1740
D004317_D009202 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 this_4\DT\1740 protection_5\NN\407535 by_6\IN\1740 carvedilol_7\NNS\2832168 against_8\IN\1740 both_9\CC\1740 the_10\DT\1740 structural_11\JJ\1740 and_12\CC\1740 functional_13\JJ\1740 cardiac_14\JJ\1740 tissue_15\NN\5220461 damage_16\NN\7296428 may_17\MD\15209706 afford_18\VB\2267060 significant_19\JJ\1740 clinical_20\JJ\1740 advantage_21\NN\5154517 in_22\IN\13603305 minimizing_23\VBG\441445 the_24\DT\1740 dose-limiting_25\JJ\1740 mitochondrial_26\JJ\1740 dysfunction_27\NN\14204950 and_28\CC\1740 <e2>cardiomyopathy</e2>_29\NN\14103288 that_30\WDT\1740 accompanies_31\VBZ\1835496 long-term_32\JJ\1740 <e1>doxorubicin</e1>_33\NN\2716866 therapy_34\NN\657604 in_35\IN\13603305 cancer_36\NN\14239425 patients_37\NNS\9898892 ._38\.\1740
C043211_D064420 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 investigation_4\NN\5797597 was_5\VBD\836236 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 hypothesis_9\NN\7162194 that_10\IN\1740 <e1>carvedilol</e1>_11\NN\2832168 ,_12\,\1740 a_13\DT\13649268 nonselective_14\JJ\1740 beta-adrenergic_15\JJ\1740 receptor_16\NN\5225602 antagonist_17\NN\7846 with_18\IN\1740 potent_19\JJ\1740 antioxidant_20\JJ\1740 properties_21\NNS\32613 ,_22\,\1740 protects_23\VBZ\1127795 against_24\IN\1740 the_25\DT\1740 cardiac_26\JJ\1740 and_27\CC\1740 hepatic_28\JJ\1740 mitochondrial_29\JJ\1740 bioenergetic_30\JJ\1740 dysfunction_31\NN\14204950 associated_32\VBN\628491 with_33\IN\1740 subchronic_34\JJ\1740 doxorubicin_35\NN\2716866 <e2>toxicity</e2>_36\NN\13576101 ._37\.\1740
D004317_D064420 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 investigation_4\NN\5797597 was_5\VBD\836236 to_6\TO\1740 test_7\VB\670261 the_8\DT\1740 hypothesis_9\NN\7162194 that_10\IN\1740 carvedilol_11\NN\2832168 ,_12\,\1740 a_13\DT\13649268 nonselective_14\JJ\1740 beta-adrenergic_15\JJ\1740 receptor_16\NN\5225602 antagonist_17\NN\7846 with_18\IN\1740 potent_19\JJ\1740 antioxidant_20\JJ\1740 properties_21\NNS\32613 ,_22\,\1740 protects_23\VBZ\1127795 against_24\IN\1740 the_25\DT\1740 cardiac_26\JJ\1740 and_27\CC\1740 hepatic_28\JJ\1740 mitochondrial_29\JJ\1740 bioenergetic_30\JJ\1740 dysfunction_31\NN\14204950 associated_32\VBN\628491 with_33\IN\1740 subchronic_34\JJ\1740 <e1>doxorubicin</e1>_35\NN\2716866 <e2>toxicity</e2>_36\NN\13576101 ._37\.\1740
C043211_D028361 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 this_4\DT\1740 protection_5\NN\407535 by_6\IN\1740 <e1>carvedilol</e1>_7\NNS\2832168 against_8\IN\1740 both_9\CC\1740 the_10\DT\1740 structural_11\JJ\1740 and_12\CC\1740 functional_13\JJ\1740 cardiac_14\JJ\1740 tissue_15\NN\5220461 damage_16\NN\7296428 may_17\MD\15209706 afford_18\VB\2267060 significant_19\JJ\1740 clinical_20\JJ\1740 advantage_21\NN\5154517 in_22\IN\13603305 minimizing_23\VBG\441445 the_24\DT\1740 dose-limiting_25\JJ\1740 <e2>mitochondrial_26\JJ\1740 dysfunction</e2>_27\NN\14204950 and_28\CC\1740 cardiomyopathy_29\NN\14103288 that_30\WDT\1740 accompanies_31\VBZ\1835496 long-term_32\JJ\1740 doxorubicin_33\NN\2716866 therapy_34\NN\657604 in_35\IN\13603305 cancer_36\NN\14239425 patients_37\NNS\9898892 ._38\.\1740
C043211_D009369 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 this_4\DT\1740 protection_5\NN\407535 by_6\IN\1740 <e1>carvedilol</e1>_7\NNS\2832168 against_8\IN\1740 both_9\CC\1740 the_10\DT\1740 structural_11\JJ\1740 and_12\CC\1740 functional_13\JJ\1740 cardiac_14\JJ\1740 tissue_15\NN\5220461 damage_16\NN\7296428 may_17\MD\15209706 afford_18\VB\2267060 significant_19\JJ\1740 clinical_20\JJ\1740 advantage_21\NN\5154517 in_22\IN\13603305 minimizing_23\VBG\441445 the_24\DT\1740 dose-limiting_25\JJ\1740 mitochondrial_26\JJ\1740 dysfunction_27\NN\14204950 and_28\CC\1740 cardiomyopathy_29\NN\14103288 that_30\WDT\1740 accompanies_31\VBZ\1835496 long-term_32\JJ\1740 doxorubicin_33\NN\2716866 therapy_34\NN\657604 in_35\IN\13603305 <e2>cancer</e2>_36\NN\14239425 patients_37\NNS\9898892 ._38\.\1740
D004317_D028361 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 this_4\DT\1740 protection_5\NN\407535 by_6\IN\1740 carvedilol_7\NNS\2832168 against_8\IN\1740 both_9\CC\1740 the_10\DT\1740 structural_11\JJ\1740 and_12\CC\1740 functional_13\JJ\1740 cardiac_14\JJ\1740 tissue_15\NN\5220461 damage_16\NN\7296428 may_17\MD\15209706 afford_18\VB\2267060 significant_19\JJ\1740 clinical_20\JJ\1740 advantage_21\NN\5154517 in_22\IN\13603305 minimizing_23\VBG\441445 the_24\DT\1740 dose-limiting_25\JJ\1740 <e2>mitochondrial_26\JJ\1740 dysfunction</e2>_27\NN\14204950 and_28\CC\1740 cardiomyopathy_29\NN\14103288 that_30\WDT\1740 accompanies_31\VBZ\1835496 long-term_32\JJ\1740 <e1>doxorubicin</e1>_33\NN\2716866 therapy_34\NN\657604 in_35\IN\13603305 cancer_36\NN\14239425 patients_37\NNS\9898892 ._38\.\1740
D004317_D009369 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 this_4\DT\1740 protection_5\NN\407535 by_6\IN\1740 carvedilol_7\NNS\2832168 against_8\IN\1740 both_9\CC\1740 the_10\DT\1740 structural_11\JJ\1740 and_12\CC\1740 functional_13\JJ\1740 cardiac_14\JJ\1740 tissue_15\NN\5220461 damage_16\NN\7296428 may_17\MD\15209706 afford_18\VB\2267060 significant_19\JJ\1740 clinical_20\JJ\1740 advantage_21\NN\5154517 in_22\IN\13603305 minimizing_23\VBG\441445 the_24\DT\1740 dose-limiting_25\JJ\1740 mitochondrial_26\JJ\1740 dysfunction_27\NN\14204950 and_28\CC\1740 cardiomyopathy_29\NN\14103288 that_30\WDT\1740 accompanies_31\VBZ\1835496 long-term_32\JJ\1740 <e1>doxorubicin</e1>_33\NN\2716866 therapy_34\NN\657604 in_35\IN\13603305 <e2>cancer</e2>_36\NN\14239425 patients_37\NNS\9898892 ._38\.\1740
19515070
D019343_D064420 NONE systemic_0\JJ\1740 anticoagulation_1\NN\657604 is_2\VBZ\836236 unsafe_3\JJ\1740 and_4\CC\1740 regional_5\JJ\1740 <e1>citrate</e1>_6\NN\14850483 anticoagulation_7\NN\657604 in_8\IN\13603305 the_9\DT\1740 absence_10\NN\14449405 of_11\IN\1740 a_12\DT\13649268 functional_13\JJ\1740 liver_14\NN\5298729 carries_15\VBZ\1850315 the_16\DT\1740 risk_17\NN\14541044 of_18\IN\1740 citrate_19\NN\14850483 <e2>toxicity</e2>_20\NN\13576101 ._21\.\1740
D019343_D064420 NONE systemic_0\JJ\1740 anticoagulation_1\NN\657604 is_2\VBZ\836236 unsafe_3\JJ\1740 and_4\CC\1740 regional_5\JJ\1740 citrate_6\NN\14850483 anticoagulation_7\NN\657604 in_8\IN\13603305 the_9\DT\1740 absence_10\NN\14449405 of_11\IN\1740 a_12\DT\13649268 functional_13\JJ\1740 liver_14\NN\5298729 carries_15\VBZ\1850315 the_16\DT\1740 risk_17\NN\14541044 of_18\IN\1740 <e1>citrate</e1>_19\NN\14850483 <e2>toxicity</e2>_20\NN\13576101 ._21\.\1740
D019343_D064420 NONE the_0\DT\1740 patient_1\NN\9898892 tolerated_2\VBD\802318 the_3\DT\1740 procedure_4\NN\407535 well_5\RB\1740 without_6\IN\1740 any_7\DT\1740 signs_8\NNS\6643763 of_9\IN\1740 <e1>citrate</e1>_10\NN\14850483 <e2>toxicity</e2>_11\NN\13576101 and_12\CC\1740 maintained_13\VBD\2202928 adequate_14\JJ\1740 anticoagulation_15\NN\657604 for_16\IN\1740 patency_17\NN\5083905 of_18\IN\1740 the_19\DT\1740 dialysis_20\NN\646833 circuit_21\NN\3269401 ._22\.\1740
D000082_D017114 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 40-year-old_6\JJ\1740 female_7\NN\15388 with_8\IN\1740 <e1>acetaminophen-induced</e1>_9\JJ\1740 <e2>fulminant_10\JJ\1740 liver_11\NN\5298729 failure</e2>_12\NN\66216 with_13\IN\1740 associated_14\VBN\628491 aki_15\NN\1740 who_16\WP\8299493 underwent_17\VBD\109660 intraoperative_18\JJ\1740 dialytic_19\JJ\1740 support_20\NN\407535 during_21\IN\1740 liver_22\NN\5298729 transplantation_23\NN\671351 anticoagulated_24\VBN\1740 with_25\IN\1740 citrate_26\NN\14850483 dialysate_27\NN\1740 during_28\IN\1740 the_29\DT\1740 entire_30\JJ\1740 procedure_31\NN\407535 ._32\.\1740
D000082_D058186 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 40-year-old_6\JJ\1740 female_7\NN\15388 with_8\IN\1740 <e1>acetaminophen-induced</e1>_9\JJ\1740 fulminant_10\JJ\1740 liver_11\NN\5298729 failure_12\NN\66216 with_13\IN\1740 associated_14\VBN\628491 <e2>aki</e2>_15\NN\1740 who_16\WP\8299493 underwent_17\VBD\109660 intraoperative_18\JJ\1740 dialytic_19\JJ\1740 support_20\NN\407535 during_21\IN\1740 liver_22\NN\5298729 transplantation_23\NN\671351 anticoagulated_24\VBN\1740 with_25\IN\1740 citrate_26\NN\14850483 dialysate_27\NN\1740 during_28\IN\1740 the_29\DT\1740 entire_30\JJ\1740 procedure_31\NN\407535 ._32\.\1740
D019343_D017114 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 40-year-old_6\JJ\1740 female_7\NN\15388 with_8\IN\1740 acetaminophen-induced_9\JJ\1740 <e2>fulminant_10\JJ\1740 liver_11\NN\5298729 failure</e2>_12\NN\66216 with_13\IN\1740 associated_14\VBN\628491 aki_15\NN\1740 who_16\WP\8299493 underwent_17\VBD\109660 intraoperative_18\JJ\1740 dialytic_19\JJ\1740 support_20\NN\407535 during_21\IN\1740 liver_22\NN\5298729 transplantation_23\NN\671351 anticoagulated_24\VBN\1740 with_25\IN\1740 <e1>citrate</e1>_26\NN\14850483 dialysate_27\NN\1740 during_28\IN\1740 the_29\DT\1740 entire_30\JJ\1740 procedure_31\NN\407535 ._32\.\1740
D019343_D017114 NONE <e1>citrate</e1>_0\NN\14850483 dialysate_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 safe_4\JJ\1740 alternative_5\NN\5788149 for_6\IN\1740 intradialytic_7\JJ\1740 support_8\NN\407535 of_9\IN\1740 liver_10\NN\5298729 transplantation_11\NN\671351 in_12\IN\13603305 <e2>fulminant_13\JJ\1740 liver_14\NN\5298729 failure</e2>_15\NN\66216 ._16\.\1740
D019343_D058186 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 40-year-old_6\JJ\1740 female_7\NN\15388 with_8\IN\1740 acetaminophen-induced_9\JJ\1740 fulminant_10\JJ\1740 liver_11\NN\5298729 failure_12\NN\66216 with_13\IN\1740 associated_14\VBN\628491 <e2>aki</e2>_15\NN\1740 who_16\WP\8299493 underwent_17\VBD\109660 intraoperative_18\JJ\1740 dialytic_19\JJ\1740 support_20\NN\407535 during_21\IN\1740 liver_22\NN\5298729 transplantation_23\NN\671351 anticoagulated_24\VBN\1740 with_25\IN\1740 <e1>citrate</e1>_26\NN\14850483 dialysate_27\NN\1740 during_28\IN\1740 the_29\DT\1740 entire_30\JJ\1740 procedure_31\NN\407535 ._32\.\1740
9889429
D009543_D006973 NONE long-term_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 adverse_3\JJ\1740 event_4\NN\23100 of_5\IN\1740 <e1>nifedipine</e1>_6\NN\2938514 sustained-release_7\NN\1740 tablets_8\NNS\4233405 for_9\IN\1740 cyclosporin_10\NN\1740 a-induced_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 psoriasis_16\NN\14219661 ._17\.\1740
D009543_D006973 NONE thirteen_0\CD\13745420 psoriatic_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 <e2>hypertension</e2>_4\NN\14057371 during_5\IN\1740 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 cyclosporin_9\NN\1740 a_10\NN\13649268 therapy_11\NN\657604 were_12\VBD\836236 treated_13\VBN\2376958 for_14\IN\1740 25_15\CD\13745420 months_16\NNS\15113229 with_17\IN\1740 a_18\DT\13649268 calcium_19\NN\14625458 channel_20\NN\6251781 blocker_21\NN\10101634 ,_22\,\1740 sustained-release_23\JJ\1740 <e1>nifedipine</e1>_24\NN\2938514 ,_25\,\1740 to_26\TO\1740 study_27\VB\630380 the_28\DT\1740 clinical_29\JJ\1740 antihypertensive_30\JJ\1740 effects_31\NNS\13245626 and_32\CC\1740 adverse_33\JJ\1740 events_34\NNS\23100 during_35\IN\1740 treatment_36\NN\654885 with_37\IN\1740 both_38\DT\1740 drugs_39\NNS\14778436 ._40\.\1740
D009543_D006973 NONE our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 sustained-release_4\JJ\1740 <e1>nifedipine</e1>_5\NN\2938514 is_6\VBZ\836236 useful_7\JJ\1740 for_8\IN\1740 <e2>hypertensive</e2>_9\JJ\1740 psoriatic_10\JJ\1740 patients_11\NNS\9898892 under_12\IN\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 cyclosporin_16\NN\1740 a_17\NN\13649268 ,_18\,\1740 but_19\CC\1740 that_20\IN\1740 these_21\DT\1740 patients_22\NNS\9898892 should_23\MD\1740 be_24\VB\836236 monitored_25\VBN\2169352 for_26\IN\1740 gingival_27\JJ\1740 hyperplasia_28\NN\14365950 ._29\.\1740
D009543_D011565 NONE long-term_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 adverse_3\JJ\1740 event_4\NN\23100 of_5\IN\1740 <e1>nifedipine</e1>_6\NN\2938514 sustained-release_7\NN\1740 tablets_8\NNS\4233405 for_9\IN\1740 cyclosporin_10\NN\1740 a-induced_11\JJ\1740 hypertension_12\NN\14057371 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 <e2>psoriasis</e2>_16\NN\14219661 ._17\.\1740
D009543_D011565 NONE thirteen_0\CD\13745420 <e2>psoriatic</e2>_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 hypertension_4\NN\14057371 during_5\IN\1740 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 cyclosporin_9\NN\1740 a_10\NN\13649268 therapy_11\NN\657604 were_12\VBD\836236 treated_13\VBN\2376958 for_14\IN\1740 25_15\CD\13745420 months_16\NNS\15113229 with_17\IN\1740 a_18\DT\13649268 calcium_19\NN\14625458 channel_20\NN\6251781 blocker_21\NN\10101634 ,_22\,\1740 sustained-release_23\JJ\1740 <e1>nifedipine</e1>_24\NN\2938514 ,_25\,\1740 to_26\TO\1740 study_27\VB\630380 the_28\DT\1740 clinical_29\JJ\1740 antihypertensive_30\JJ\1740 effects_31\NNS\13245626 and_32\CC\1740 adverse_33\JJ\1740 events_34\NNS\23100 during_35\IN\1740 treatment_36\NN\654885 with_37\IN\1740 both_38\DT\1740 drugs_39\NNS\14778436 ._40\.\1740
D009543_D011565 NONE our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 sustained-release_4\JJ\1740 <e1>nifedipine</e1>_5\NN\2938514 is_6\VBZ\836236 useful_7\JJ\1740 for_8\IN\1740 hypertensive_9\JJ\1740 <e2>psoriatic</e2>_10\JJ\1740 patients_11\NNS\9898892 under_12\IN\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 cyclosporin_16\NN\1740 a_17\NN\13649268 ,_18\,\1740 but_19\CC\1740 that_20\IN\1740 these_21\DT\1740 patients_22\NNS\9898892 should_23\MD\1740 be_24\VB\836236 monitored_25\VBN\2169352 for_26\IN\1740 gingival_27\JJ\1740 hyperplasia_28\NN\14365950 ._29\.\1740
D016572_D006973 CID long-term_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 adverse_3\JJ\1740 event_4\NN\23100 of_5\IN\1740 nifedipine_6\NN\2938514 sustained-release_7\NN\1740 tablets_8\NNS\4233405 for_9\IN\1740 <e1>cyclosporin_10\NN\1740 a-induced</e1>_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 psoriasis_16\NN\14219661 ._17\.\1740
D016572_D006973 CID thirteen_0\CD\13745420 psoriatic_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 <e2>hypertension</e2>_4\NN\14057371 during_5\IN\1740 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 <e1>cyclosporin_9\NN\1740 a</e1>_10\NN\13649268 therapy_11\NN\657604 were_12\VBD\836236 treated_13\VBN\2376958 for_14\IN\1740 25_15\CD\13745420 months_16\NNS\15113229 with_17\IN\1740 a_18\DT\13649268 calcium_19\NN\14625458 channel_20\NN\6251781 blocker_21\NN\10101634 ,_22\,\1740 sustained-release_23\JJ\1740 nifedipine_24\NN\2938514 ,_25\,\1740 to_26\TO\1740 study_27\VB\630380 the_28\DT\1740 clinical_29\JJ\1740 antihypertensive_30\JJ\1740 effects_31\NNS\13245626 and_32\CC\1740 adverse_33\JJ\1740 events_34\NNS\23100 during_35\IN\1740 treatment_36\NN\654885 with_37\IN\1740 both_38\DT\1740 drugs_39\NNS\14778436 ._40\.\1740
D016572_D006973 CID seven_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 13_3\CD\13745420 patients_4\NNS\9898892 had_5\VBD\2108377 exhibited_6\VBN\2632167 a_7\DT\13649268 subclinical_8\JJ\1740 <e2>hypertensive</e2>_9\NN\10405694 state_10\NN\8491826 before_11\IN\1740 <e1>cyclosporin_12\NN\1740 a</e1>_13\NN\13649268 therapy_14\NN\657604 ._15\.\1740
D016572_D006973 CID our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 sustained-release_4\JJ\1740 nifedipine_5\NN\2938514 is_6\VBZ\836236 useful_7\JJ\1740 for_8\IN\1740 <e2>hypertensive</e2>_9\JJ\1740 psoriatic_10\JJ\1740 patients_11\NNS\9898892 under_12\IN\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>cyclosporin_16\NN\1740 a</e1>_17\NN\13649268 ,_18\,\1740 but_19\CC\1740 that_20\IN\1740 these_21\DT\1740 patients_22\NNS\9898892 should_23\MD\1740 be_24\VB\836236 monitored_25\VBN\2169352 for_26\IN\1740 gingival_27\JJ\1740 hyperplasia_28\NN\14365950 ._29\.\1740
D016572_D011565 NONE long-term_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 adverse_3\JJ\1740 event_4\NN\23100 of_5\IN\1740 nifedipine_6\NN\2938514 sustained-release_7\NN\1740 tablets_8\NNS\4233405 for_9\IN\1740 <e1>cyclosporin_10\NN\1740 a-induced</e1>_11\JJ\1740 hypertension_12\NN\14057371 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 <e2>psoriasis</e2>_16\NN\14219661 ._17\.\1740
D016572_D011565 NONE thirteen_0\CD\13745420 <e2>psoriatic</e2>_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 hypertension_4\NN\14057371 during_5\IN\1740 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 <e1>cyclosporin_9\NN\1740 a</e1>_10\NN\13649268 therapy_11\NN\657604 were_12\VBD\836236 treated_13\VBN\2376958 for_14\IN\1740 25_15\CD\13745420 months_16\NNS\15113229 with_17\IN\1740 a_18\DT\13649268 calcium_19\NN\14625458 channel_20\NN\6251781 blocker_21\NN\10101634 ,_22\,\1740 sustained-release_23\JJ\1740 nifedipine_24\NN\2938514 ,_25\,\1740 to_26\TO\1740 study_27\VB\630380 the_28\DT\1740 clinical_29\JJ\1740 antihypertensive_30\JJ\1740 effects_31\NNS\13245626 and_32\CC\1740 adverse_33\JJ\1740 events_34\NNS\23100 during_35\IN\1740 treatment_36\NN\654885 with_37\IN\1740 both_38\DT\1740 drugs_39\NNS\14778436 ._40\.\1740
D016572_D011565 NONE our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 sustained-release_4\JJ\1740 nifedipine_5\NN\2938514 is_6\VBZ\836236 useful_7\JJ\1740 for_8\IN\1740 hypertensive_9\JJ\1740 <e2>psoriatic</e2>_10\JJ\1740 patients_11\NNS\9898892 under_12\IN\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>cyclosporin_16\NN\1740 a</e1>_17\NN\13649268 ,_18\,\1740 but_19\CC\1740 that_20\IN\1740 these_21\DT\1740 patients_22\NNS\9898892 should_23\MD\1740 be_24\VB\836236 monitored_25\VBN\2169352 for_26\IN\1740 gingival_27\JJ\1740 hyperplasia_28\NN\14365950 ._29\.\1740
D002118_D011565 NONE thirteen_0\CD\13745420 <e2>psoriatic</e2>_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 hypertension_4\NN\14057371 during_5\IN\1740 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 cyclosporin_9\NN\1740 a_10\NN\13649268 therapy_11\NN\657604 were_12\VBD\836236 treated_13\VBN\2376958 for_14\IN\1740 25_15\CD\13745420 months_16\NNS\15113229 with_17\IN\1740 a_18\DT\13649268 <e1>calcium</e1>_19\NN\14625458 channel_20\NN\6251781 blocker_21\NN\10101634 ,_22\,\1740 sustained-release_23\JJ\1740 nifedipine_24\NN\2938514 ,_25\,\1740 to_26\TO\1740 study_27\VB\630380 the_28\DT\1740 clinical_29\JJ\1740 antihypertensive_30\JJ\1740 effects_31\NNS\13245626 and_32\CC\1740 adverse_33\JJ\1740 events_34\NNS\23100 during_35\IN\1740 treatment_36\NN\654885 with_37\IN\1740 both_38\DT\1740 drugs_39\NNS\14778436 ._40\.\1740
D002118_D006973 NONE thirteen_0\CD\13745420 psoriatic_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 <e2>hypertension</e2>_4\NN\14057371 during_5\IN\1740 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 cyclosporin_9\NN\1740 a_10\NN\13649268 therapy_11\NN\657604 were_12\VBD\836236 treated_13\VBN\2376958 for_14\IN\1740 25_15\CD\13745420 months_16\NNS\15113229 with_17\IN\1740 a_18\DT\13649268 <e1>calcium</e1>_19\NN\14625458 channel_20\NN\6251781 blocker_21\NN\10101634 ,_22\,\1740 sustained-release_23\JJ\1740 nifedipine_24\NN\2938514 ,_25\,\1740 to_26\TO\1740 study_27\VB\630380 the_28\DT\1740 clinical_29\JJ\1740 antihypertensive_30\JJ\1740 effects_31\NNS\13245626 and_32\CC\1740 adverse_33\JJ\1740 events_34\NNS\23100 during_35\IN\1740 treatment_36\NN\654885 with_37\IN\1740 both_38\DT\1740 drugs_39\NNS\14778436 ._40\.\1740
D016572_D005885 CID the_0\DT\1740 adverse_1\JJ\1740 events_2\NNS\23100 during_3\IN\1740 combined_4\JJ\1740 therapy_5\NN\657604 with_6\IN\1740 <e1>cyclosporin_7\NN\1740 a</e1>_8\NN\13649268 and_9\CC\1740 nifedipine_10\NN\2938514 included_11\VBD\690614 an_12\DT\6697703 increase_13\NN\13576355 in_14\IN\13603305 blood_15\NN\5397468 urea_16\NN\14727670 nitrogen_17\NN\14622893 levels_18\NNS\4916342 in_19\IN\13603305 9_20\CD\13741022 of_21\IN\1740 the_22\DT\1740 13_23\CD\13745420 patients_24\NNS\9898892 and_25\CC\1740 development_26\NN\248977 of_27\IN\1740 <e2>gingival_28\JJ\1740 hyperplasia</e2>_29\NN\14365950 in_30\IN\13603305 2_31\CD\13741022 of_32\IN\1740 the_33\DT\1740 13_34\CD\13745420 patients_35\NNS\9898892 ._36\.\1740
D016572_D005885 CID our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 sustained-release_4\JJ\1740 nifedipine_5\NN\2938514 is_6\VBZ\836236 useful_7\JJ\1740 for_8\IN\1740 hypertensive_9\JJ\1740 psoriatic_10\JJ\1740 patients_11\NNS\9898892 under_12\IN\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>cyclosporin_16\NN\1740 a</e1>_17\NN\13649268 ,_18\,\1740 but_19\CC\1740 that_20\IN\1740 these_21\DT\1740 patients_22\NNS\9898892 should_23\MD\1740 be_24\VB\836236 monitored_25\VBN\2169352 for_26\IN\1740 <e2>gingival_27\JJ\1740 hyperplasia</e2>_28\NN\14365950 ._29\.\1740
D009543_D005885 CID the_0\DT\1740 adverse_1\JJ\1740 events_2\NNS\23100 during_3\IN\1740 combined_4\JJ\1740 therapy_5\NN\657604 with_6\IN\1740 cyclosporin_7\NN\1740 a_8\NN\13649268 and_9\CC\1740 <e1>nifedipine</e1>_10\NN\2938514 included_11\VBD\690614 an_12\DT\6697703 increase_13\NN\13576355 in_14\IN\13603305 blood_15\NN\5397468 urea_16\NN\14727670 nitrogen_17\NN\14622893 levels_18\NNS\4916342 in_19\IN\13603305 9_20\CD\13741022 of_21\IN\1740 the_22\DT\1740 13_23\CD\13745420 patients_24\NNS\9898892 and_25\CC\1740 development_26\NN\248977 of_27\IN\1740 <e2>gingival_28\JJ\1740 hyperplasia</e2>_29\NN\14365950 in_30\IN\13603305 2_31\CD\13741022 of_32\IN\1740 the_33\DT\1740 13_34\CD\13745420 patients_35\NNS\9898892 ._36\.\1740
D009543_D005885 CID our_0\PRP$\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 sustained-release_4\JJ\1740 <e1>nifedipine</e1>_5\NN\2938514 is_6\VBZ\836236 useful_7\JJ\1740 for_8\IN\1740 hypertensive_9\JJ\1740 psoriatic_10\JJ\1740 patients_11\NNS\9898892 under_12\IN\1740 long-term_13\JJ\1740 treatment_14\NN\654885 with_15\IN\1740 cyclosporin_16\NN\1740 a_17\NN\13649268 ,_18\,\1740 but_19\CC\1740 that_20\IN\1740 these_21\DT\1740 patients_22\NNS\9898892 should_23\MD\1740 be_24\VB\836236 monitored_25\VBN\2169352 for_26\IN\1740 <e2>gingival_27\JJ\1740 hyperplasia</e2>_28\NN\14365950 ._29\.\1740
D001806_D005885 NONE the_0\DT\1740 adverse_1\JJ\1740 events_2\NNS\23100 during_3\IN\1740 combined_4\JJ\1740 therapy_5\NN\657604 with_6\IN\1740 cyclosporin_7\NN\1740 a_8\NN\13649268 and_9\CC\1740 nifedipine_10\NN\2938514 included_11\VBD\690614 an_12\DT\6697703 increase_13\NN\13576355 in_14\IN\13603305 <e1>blood_15\NN\5397468 urea_16\NN\14727670 nitrogen</e1>_17\NN\14622893 levels_18\NNS\4916342 in_19\IN\13603305 9_20\CD\13741022 of_21\IN\1740 the_22\DT\1740 13_23\CD\13745420 patients_24\NNS\9898892 and_25\CC\1740 development_26\NN\248977 of_27\IN\1740 <e2>gingival_28\JJ\1740 hyperplasia</e2>_29\NN\14365950 in_30\IN\13603305 2_31\CD\13741022 of_32\IN\1740 the_33\DT\1740 13_34\CD\13745420 patients_35\NNS\9898892 ._36\.\1740
17554526
D003042_D001925 CID <e2>impaired_0\JJ\1740 fear_1\NN\7480068 recognition</e2>_2\NN\13932421 in_3\IN\13603305 regular_4\JJ\1740 recreational_5\JJ\1740 <e1>cocaine</e1>_6\NN\3492717 users_7\NNS\7846 ._8\.\1740
D003042_D001925 CID the_0\DT\1740 selective_1\JJ\1740 <e2>deficit_2\NN\5113133 in_3\IN\13603305 fear_4\NN\7480068 recognition</e2>_5\NN\13932421 accuracy_6\NN\4723816 manifested_7\VBN\1015244 by_8\IN\1740 the_9\DT\1740 rc_10\NN\1740 group_11\NN\2137 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 explained_15\VBN\831651 by_16\IN\1740 the_17\DT\1740 subacute_18\NN\1740 effects_19\NNS\13245626 of_20\IN\1740 <e1>cocaine</e1>_21\NN\3492717 ,_22\,\1740 or_23\CC\3541091 ecstasy_24\VB\1740 ,_25\,\1740 because_26\IN\1740 recent_27\JJ\1740 and_28\CC\1740 less_29\RBR\1740 recent_30\JJ\1740 users_31\NNS\7846 of_32\IN\1740 these_33\DT\1740 drugs_34\NNS\14778436 within_35\IN\1740 this_36\DT\1740 group_37\NN\2137 were_38\VBD\836236 similarly_39\RB\1740 impaired_40\JJ\1740 ._41\.\1740
D018817_D001925 NONE the_0\DT\1740 selective_1\JJ\1740 <e2>deficit_2\NN\5113133 in_3\IN\13603305 fear_4\NN\7480068 recognition</e2>_5\NN\13932421 accuracy_6\NN\4723816 manifested_7\VBN\1015244 by_8\IN\1740 the_9\DT\1740 rc_10\NN\1740 group_11\NN\2137 can_12\MD\3094503 not_13\RB\1740 be_14\VB\836236 explained_15\VBN\831651 by_16\IN\1740 the_17\DT\1740 subacute_18\NN\1740 effects_19\NNS\13245626 of_20\IN\1740 cocaine_21\NN\3492717 ,_22\,\1740 or_23\CC\3541091 <e1>ecstasy</e1>_24\VB\1740 ,_25\,\1740 because_26\IN\1740 recent_27\JJ\1740 and_28\CC\1740 less_29\RBR\1740 recent_30\JJ\1740 users_31\NNS\7846 of_32\IN\1740 these_33\DT\1740 drugs_34\NNS\14778436 within_35\IN\1740 this_36\DT\1740 group_37\NN\2137 were_38\VBD\836236 similarly_39\RB\1740 impaired_40\JJ\1740 ._41\.\1740
920167
D014859_D005315 NONE the_0\DT\1740 baby_1\NN\9918248 showed_2\VBD\2137132 <e1>warfarin-induced</e1>_3\JJ\1740 <e2>embryopathy</e2>_4\NN\1740 with_5\IN\1740 nasal_6\JJ\1740 hypoplasia_7\NN\14365950 and_8\CC\1740 stippled_9\JJ\1740 epiphyses_10\NNS\5275651 (_11\-LRB-\1740 chondrodysplasia_12\NN\1740 punctata_13\NNS\1740 )_14\-RRB-\1740 ._15\.\1740
D014859_-1 NONE the_0\DT\1740 baby_1\NN\9918248 showed_2\VBD\2137132 <e1>warfarin-induced</e1>_3\JJ\1740 embryopathy_4\NN\1740 with_5\IN\1740 <e2>nasal_6\JJ\1740 hypoplasia</e2>_7\NN\14365950 and_8\CC\1740 stippled_9\JJ\1740 epiphyses_10\NNS\5275651 (_11\-LRB-\1740 chondrodysplasia_12\NN\1740 punctata_13\NNS\1740 )_14\-RRB-\1740 ._15\.\1740
D014859_-1 NONE <e2>nasal_0\JJ\1740 hypoplasia</e2>_1\NN\14365950 with_2\IN\1740 or_3\CC\3541091 without_4\IN\1740 stippled_5\JJ\1740 epiphyses_6\NNS\5275651 has_7\VBZ\2108377 now_8\RB\1740 been_9\VBN\836236 reported_10\VBN\831651 in_11\IN\13603305 11_12\CD\13745420 infants_13\NNS\9918248 born_14\VBN\2630189 to_15\TO\1740 mothers_16\NNS\10399491 treated_17\VBN\2376958 with_18\IN\1740 <e1>warfarin</e1>_19\NN\2718259 during_20\IN\1740 the_21\DT\1740 first_22\JJ\1740 trimester_23\NN\15113229 ,_24\,\1740 and_25\CC\1740 a_26\DT\13649268 causal_27\JJ\1740 association_28\NN\8008335 is_29\VBZ\836236 probable_30\JJ\1740 ._31\.\1740
D014859_D002806 CID the_0\DT\1740 baby_1\NN\9918248 showed_2\VBD\2137132 <e1>warfarin-induced</e1>_3\JJ\1740 embryopathy_4\NN\1740 with_5\IN\1740 nasal_6\JJ\1740 hypoplasia_7\NN\14365950 and_8\CC\1740 <e2>stippled_9\JJ\1740 epiphyses</e2>_10\NNS\5275651 (_11\-LRB-\1740 chondrodysplasia_12\NN\1740 punctata_13\NNS\1740 )_14\-RRB-\1740 ._15\.\1740
D014859_D002806 CID the_0\DT\1740 baby_1\NN\9918248 showed_2\VBD\2137132 <e1>warfarin-induced</e1>_3\JJ\1740 embryopathy_4\NN\1740 with_5\IN\1740 nasal_6\JJ\1740 hypoplasia_7\NN\14365950 and_8\CC\1740 stippled_9\JJ\1740 epiphyses_10\NNS\5275651 (_11\-LRB-\1740 <e2>chondrodysplasia_12\NN\1740 punctata</e2>_13\NNS\1740 )_14\-RRB-\1740 ._15\.\1740
D014859_D002806 CID nasal_0\JJ\1740 hypoplasia_1\NN\14365950 with_2\IN\1740 or_3\CC\3541091 without_4\IN\1740 <e2>stippled_5\JJ\1740 epiphyses</e2>_6\NNS\5275651 has_7\VBZ\2108377 now_8\RB\1740 been_9\VBN\836236 reported_10\VBN\831651 in_11\IN\13603305 11_12\CD\13745420 infants_13\NNS\9918248 born_14\VBN\2630189 to_15\TO\1740 mothers_16\NNS\10399491 treated_17\VBN\2376958 with_18\IN\1740 <e1>warfarin</e1>_19\NN\2718259 during_20\IN\1740 the_21\DT\1740 first_22\JJ\1740 trimester_23\NN\15113229 ,_24\,\1740 and_25\CC\1740 a_26\DT\13649268 causal_27\JJ\1740 association_28\NN\8008335 is_29\VBZ\836236 probable_30\JJ\1740 ._31\.\1740
25054547
D013390_D001049 CID characterization_0\NN\6724763 of_1\IN\1740 a_2\DT\13649268 novel_3\JJ\1740 bche_4\NN\1740 "_5\``\1740 silent_6\JJ\1740 "_7\''\1740 allele_8\NN\5436752 :_9\:\1740 point_10\NN\5868954 mutation_11\NN\4475 (_12\-LRB-\1740 p._13\NN\1740 val204asp_14\NN\1740 )_15\-RRB-\1740 causes_16\VBZ\1617192 loss_17\NN\13252973 of_18\IN\1740 activity_19\NN\30358 and_20\CC\1740 prolonged_21\VBD\317700 <e2>apnea</e2>_22\NN\14299637 with_23\IN\1740 <e1>suxamethonium</e1>_24\NN\1740 ._25\.\1740
D013390_D001049 CID butyrylcholinesterase_0\NN\1740 deficiency_1\NN\14449126 is_2\VBZ\836236 characterized_3\VBN\609683 by_4\IN\1740 prolonged_5\JJ\1740 <e2>apnea</e2>_6\NN\14299637 after_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 muscle_11\NN\5289601 relaxants_12\NNS\3247620 (_13\-LRB-\1740 <e1>suxamethonium</e1>_14\NN\1740 or_15\CC\3541091 mivacurium_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 patients_19\NNS\9898892 who_20\WP\8299493 have_21\VBP\2108377 mutations_22\NNS\4475 in_23\IN\13603305 the_24\DT\1740 bche_25\NN\1740 gene_26\NN\8459252 ._27\.\1740
D013390_C537417 CID <e2>butyrylcholinesterase_0\NN\1740 deficiency</e2>_1\NN\14449126 is_2\VBZ\836236 characterized_3\VBN\609683 by_4\IN\1740 prolonged_5\JJ\1740 apnea_6\NN\14299637 after_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 muscle_11\NN\5289601 relaxants_12\NNS\3247620 (_13\-LRB-\1740 <e1>suxamethonium</e1>_14\NN\1740 or_15\CC\3541091 mivacurium_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 patients_19\NNS\9898892 who_20\WP\8299493 have_21\VBP\2108377 mutations_22\NNS\4475 in_23\IN\13603305 the_24\DT\1740 bche_25\NN\1740 gene_26\NN\8459252 ._27\.\1740
C049430_C537417 CID <e2>butyrylcholinesterase_0\NN\1740 deficiency</e2>_1\NN\14449126 is_2\VBZ\836236 characterized_3\VBN\609683 by_4\IN\1740 prolonged_5\JJ\1740 apnea_6\NN\14299637 after_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 muscle_11\NN\5289601 relaxants_12\NNS\3247620 (_13\-LRB-\1740 suxamethonium_14\NN\1740 or_15\CC\3541091 <e1>mivacurium</e1>_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 patients_19\NNS\9898892 who_20\WP\8299493 have_21\VBP\2108377 mutations_22\NNS\4475 in_23\IN\13603305 the_24\DT\1740 bche_25\NN\1740 gene_26\NN\8459252 ._27\.\1740
C049430_D001049 CID butyrylcholinesterase_0\NN\1740 deficiency_1\NN\14449126 is_2\VBZ\836236 characterized_3\VBN\609683 by_4\IN\1740 prolonged_5\JJ\1740 <e2>apnea</e2>_6\NN\14299637 after_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 muscle_11\NN\5289601 relaxants_12\NNS\3247620 (_13\-LRB-\1740 suxamethonium_14\NN\1740 or_15\CC\3541091 <e1>mivacurium</e1>_16\NN\1740 )_17\-RRB-\1740 in_18\IN\13603305 patients_19\NNS\9898892 who_20\WP\8299493 have_21\VBP\2108377 mutations_22\NNS\4475 in_23\IN\13603305 the_24\DT\1740 bche_25\NN\1740 gene_26\NN\8459252 ._27\.\1740
10677406
D004280_D018487 CID prolonged_0\JJ\1740 <e2>left_1\VBD\120316 ventricular_2\NN\1740 dysfunction</e2>_3\NN\14204950 occurs_4\VBZ\2623529 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 coronary_8\JJ\1740 artery_9\NN\5417975 disease_10\NN\14061805 after_11\IN\1740 both_12\CC\1740 <e1>dobutamine</e1>_13\NN\1740 and_14\CC\1740 exercise_15\NN\621627 induced_16\JJ\1740 myocardial_17\JJ\1740 ischaemia_18\NN\14195315 ._19\.\1740
D004280_D018487 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 disease_7\NN\14061805 ,_8\,\1740 <e1>dobutamine</e1>_9\NN\1740 induced_10\VBD\1627355 ischaemia_11\NN\14195315 results_12\NNS\34213 in_13\IN\13603305 prolonged_14\JJ\1740 reversible_15\JJ\1740 <e2>left_16\JJ\1740 ventricular_17\NN\1740 dysfunction</e2>_18\NN\14204950 ,_19\,\1740 presumed_20\VBN\719734 to_21\TO\1740 be_22\VB\836236 myocardial_23\JJ\1740 stunning_24\JJ\1740 ,_25\,\1740 similar_26\JJ\1740 to_27\TO\1740 that_28\DT\1740 seen_29\VBN\2106506 after_30\IN\1740 exercise_31\NN\621627 ._32\.\1740
D004280_D003324 NONE prolonged_0\JJ\1740 left_1\VBD\120316 ventricular_2\NN\1740 dysfunction_3\NN\14204950 occurs_4\VBZ\2623529 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>coronary_8\JJ\1740 artery_9\NN\5417975 disease</e2>_10\NN\14061805 after_11\IN\1740 both_12\CC\1740 <e1>dobutamine</e1>_13\NN\1740 and_14\CC\1740 exercise_15\NN\621627 induced_16\JJ\1740 myocardial_17\JJ\1740 ischaemia_18\NN\14195315 ._19\.\1740
D004280_D003324 NONE conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 <e2>coronary_5\JJ\1740 artery_6\NN\5417975 disease</e2>_7\NN\14061805 ,_8\,\1740 <e1>dobutamine</e1>_9\NN\1740 induced_10\VBD\1627355 ischaemia_11\NN\14195315 results_12\NNS\34213 in_13\IN\13603305 prolonged_14\JJ\1740 reversible_15\JJ\1740 left_16\JJ\1740 ventricular_17\NN\1740 dysfunction_18\NN\14204950 ,_19\,\1740 presumed_20\VBN\719734 to_21\TO\1740 be_22\VB\836236 myocardial_23\JJ\1740 stunning_24\JJ\1740 ,_25\,\1740 similar_26\JJ\1740 to_27\TO\1740 that_28\DT\1740 seen_29\VBN\2106506 after_30\IN\1740 exercise_31\NN\621627 ._32\.\1740
D004280_D003324 NONE <e1>dobutamine</e1>_0\NNP\1740 induced_1\VBD\1627355 ischaemia_2\NN\14195315 could_3\MD\1740 therefore_4\RB\1740 be_5\VB\836236 used_6\VBN\1156834 to_7\TO\1740 study_8\VB\630380 the_9\DT\1740 pathophysiology_10\NN\1740 of_11\IN\1740 this_12\DT\1740 phenomenon_13\NN\29677 further_14\RBR\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>coronary_18\JJ\1740 artery_19\NN\5417975 disease</e2>_20\NN\14061805 ._21\.\1740
D004280_D017202 NONE prolonged_0\JJ\1740 left_1\VBD\120316 ventricular_2\NN\1740 dysfunction_3\NN\14204950 occurs_4\VBZ\2623529 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 coronary_8\JJ\1740 artery_9\NN\5417975 disease_10\NN\14061805 after_11\IN\1740 both_12\CC\1740 <e1>dobutamine</e1>_13\NN\1740 and_14\CC\1740 exercise_15\NN\621627 induced_16\JJ\1740 <e2>myocardial_17\JJ\1740 ischaemia</e2>_18\NN\14195315 ._19\.\1740
D004280_D007511 NONE design_0\NN\927261 :_1\:\1740 a_2\DT\13649268 randomised_3\JJ\1740 crossover_4\NN\13526110 study_5\NN\635850 of_6\IN\1740 recovery_7\NN\7357388 time_8\NN\7308889 of_9\IN\1740 systolic_10\JJ\1740 and_11\CC\1740 diastolic_12\JJ\1740 left_13\JJ\1740 ventricular_14\JJ\1740 function_15\NN\13783581 after_16\IN\1740 exercise_17\NN\621627 and_18\CC\1740 <e1>dobutamine</e1>_19\NN\1740 induced_20\JJ\1740 <e2>ischaemia</e2>_21\NN\14195315 ._22\.\1740
D004280_D007511 NONE conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 disease_7\NN\14061805 ,_8\,\1740 <e1>dobutamine</e1>_9\NN\1740 induced_10\VBD\1627355 <e2>ischaemia</e2>_11\NN\14195315 results_12\NNS\34213 in_13\IN\13603305 prolonged_14\JJ\1740 reversible_15\JJ\1740 left_16\JJ\1740 ventricular_17\NN\1740 dysfunction_18\NN\14204950 ,_19\,\1740 presumed_20\VBN\719734 to_21\TO\1740 be_22\VB\836236 myocardial_23\JJ\1740 stunning_24\JJ\1740 ,_25\,\1740 similar_26\JJ\1740 to_27\TO\1740 that_28\DT\1740 seen_29\VBN\2106506 after_30\IN\1740 exercise_31\NN\621627 ._32\.\1740
D004280_D007511 NONE <e1>dobutamine</e1>_0\NNP\1740 induced_1\VBD\1627355 <e2>ischaemia</e2>_2\NN\14195315 could_3\MD\1740 therefore_4\RB\1740 be_5\VB\836236 used_6\VBN\1156834 to_7\TO\1740 study_8\VB\630380 the_9\DT\1740 pathophysiology_10\NN\1740 of_11\IN\1740 this_12\DT\1740 phenomenon_13\NN\29677 further_14\RBR\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 coronary_18\JJ\1740 artery_19\NN\5417975 disease_20\NN\14061805 ._21\.\1740
D004280_D017682 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 disease_7\NN\14061805 ,_8\,\1740 <e1>dobutamine</e1>_9\NN\1740 induced_10\VBD\1627355 ischaemia_11\NN\14195315 results_12\NNS\34213 in_13\IN\13603305 prolonged_14\JJ\1740 reversible_15\JJ\1740 left_16\JJ\1740 ventricular_17\NN\1740 dysfunction_18\NN\14204950 ,_19\,\1740 presumed_20\VBN\719734 to_21\TO\1740 be_22\VB\836236 <e2>myocardial_23\JJ\1740 stunning</e2>_24\JJ\1740 ,_25\,\1740 similar_26\JJ\1740 to_27\TO\1740 that_28\DT\1740 seen_29\VBN\2106506 after_30\IN\1740 exercise_31\NN\621627 ._32\.\1740
1361574
D002243_D012640 NONE moreover_0\RB\1740 ,_1\,\1740 0.05_2\CD\1740 mg/kg_3\NN\1740 of_4\IN\1740 this_5\DT\1740 <e1>beta-carboline</e1>_6\NN\1740 reduced_7\VBD\441445 markedly_8\RB\1740 the_9\DT\1740 increase_10\NN\13576355 of_11\IN\1740 [35s]tbps_12\NN\1740 binding_13\NN\4688246 and_14\CC\1740 the_15\DT\1740 <e2>convulsions</e2>_16\NNS\14081375 induced_17\VBN\1627355 by_18\IN\1740 isoniazid_19\NNS\2716205 (_20\-LRB-\1740 200_21\CD\1740 mg/kg_22\NN\1740 s.c._23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
C037476_D012640 NONE moreover_0\RB\1740 ,_1\,\1740 0.05_2\CD\1740 mg/kg_3\NN\1740 of_4\IN\1740 this_5\DT\1740 beta-carboline_6\NN\1740 reduced_7\VBD\441445 markedly_8\RB\1740 the_9\DT\1740 increase_10\NN\13576355 of_11\IN\1740 <e1>[35s]tbps</e1>_12\NN\1740 binding_13\NN\4688246 and_14\CC\1740 the_15\DT\1740 <e2>convulsions</e2>_16\NNS\14081375 induced_17\VBN\1627355 by_18\IN\1740 isoniazid_19\NNS\2716205 (_20\-LRB-\1740 200_21\CD\1740 mg/kg_22\NN\1740 s.c._23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D007538_D012640 CID moreover_0\RB\1740 ,_1\,\1740 0.05_2\CD\1740 mg/kg_3\NN\1740 of_4\IN\1740 this_5\DT\1740 beta-carboline_6\NN\1740 reduced_7\VBD\441445 markedly_8\RB\1740 the_9\DT\1740 increase_10\NN\13576355 of_11\IN\1740 [35s]tbps_12\NN\1740 binding_13\NN\4688246 and_14\CC\1740 the_15\DT\1740 <e2>convulsions</e2>_16\NNS\14081375 induced_17\VBN\1627355 by_18\IN\1740 <e1>isoniazid</e1>_19\NNS\2716205 (_20\-LRB-\1740 200_21\CD\1740 mg/kg_22\NN\1740 s.c._23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
6687006
D003913_D006948 CID the_0\DT\1740 <e2>hyperactivity</e2>_1\NN\14052403 induced_2\VBN\1627355 by_3\IN\1740 <e1>d-amphetamine</e1>_4\NN\1740 (_5\-LRB-\1740 10_6\CD\13745420 mumol/kg_7\NNS\1740 )_8\-RRB-\1740 was_9\VBD\836236 significantly_10\RB\1740 reduced_11\VBN\441445 by_12\IN\1740 dsp4_13\NN\1740 pretreatment_14\NN\1740 ._15\.\1740
C012102_D006948 NONE the_0\DT\1740 <e2>hyperactivity</e2>_1\NN\14052403 induced_2\VBN\1627355 by_3\IN\1740 d-amphetamine_4\NN\1740 (_5\-LRB-\1740 10_6\CD\13745420 mumol/kg_7\NNS\1740 )_8\-RRB-\1740 was_9\VBD\836236 significantly_10\RB\1740 reduced_11\VBN\441445 by_12\IN\1740 <e1>dsp4</e1>_13\NN\1740 pretreatment_14\NN\1740 ._15\.\1740
C012102_D006948 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 <e2>hyperactivity</e2>_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 <e1>dsp4</e1>_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 neurotoxic_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
C012102_D006948 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 <e2>hyperactivity</e2>_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 neurotoxic_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 <e1>dsp4</e1>_26\NN\1740 ._27\.\1740
D000661_D019956 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 increased_3\VBN\169651 rearings_4\NNS\4921754 and_5\CC\1740 the_6\DT\1740 <e1>amphetamine-induced</e1>_7\JJ\1740 <e2>stereotypies</e2>_8\NNS\1740 were_9\VBD\836236 not_10\RB\1740 blocked_11\VBN\1476483 by_12\IN\1740 pretreatment_13\NN\1740 with_14\IN\1740 dsp4_15\NN\1740 ._16\.\1740
C012102_D019956 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 increased_3\VBN\169651 rearings_4\NNS\4921754 and_5\CC\1740 the_6\DT\1740 amphetamine-induced_7\JJ\1740 <e2>stereotypies</e2>_8\NNS\1740 were_9\VBD\836236 not_10\RB\1740 blocked_11\VBN\1476483 by_12\IN\1740 pretreatment_13\NN\1740 with_14\IN\1740 <e1>dsp4</e1>_15\NN\1740 ._16\.\1740
D000661_D006948 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 <e1>amphetamine</e1>_3\NN\3248958 <e2>hyperactivity</e2>_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 neurotoxic_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
D000661_D020258 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 <e1>amphetamine</e1>_3\NN\3248958 hyperactivity_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 <e2>neurotoxic</e2>_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
C012102_D020258 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 hyperactivity_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 <e1>dsp4</e1>_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 <e2>neurotoxic</e2>_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
C012102_D020258 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 hyperactivity_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 <e2>neurotoxic</e2>_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 <e1>dsp4</e1>_26\NN\1740 ._27\.\1740
D009638_D006948 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 <e2>hyperactivity</e2>_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 <e1>noradrenaline-uptake</e1>_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 neurotoxic_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
D009638_D020258 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 hyperactivity_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 <e1>noradrenaline-uptake</e1>_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 desipramine_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 <e2>neurotoxic</e2>_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
D003891_D006948 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 <e2>hyperactivity</e2>_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 <e1>desipramine</e1>_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 neurotoxic_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
D003891_D020258 NONE the_0\DT\1740 reduction_1\NN\351485 of_2\IN\1740 amphetamine_3\NN\3248958 hyperactivity_4\NN\14052403 induced_5\VBN\1627355 by_6\IN\1740 dsp4_7\NN\1740 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 pretreatment_11\NN\1740 with_12\IN\1740 the_13\DT\1740 noradrenaline-uptake_14\JJ\1740 blocking_15\NN\562280 agent_16\NN\7347 ,_17\,\1740 <e1>desipramine</e1>_18\NN\4482543 ,_19\,\1740 which_20\WDT\1740 prevents_21\VBZ\1740 the_22\DT\1740 <e2>neurotoxic</e2>_23\JJ\1740 action_24\NN\30358 of_25\IN\1740 dsp4_26\NN\1740 ._27\.\1740
10770468
D008094_D001714 NONE recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 <e2>bipolar</e2>_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 <e1>lithium</e1>_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 lithium-associated_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D001714 NONE recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 <e1>lithium</e1>_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 <e2>bipolar</e2>_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 lithium-associated_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D001714 NONE recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 <e2>bipolar</e2>_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 lithium_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 <e1>lithium-associated</e1>_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D001714 NONE recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 lithium_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 <e2>bipolar</e2>_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 <e1>lithium-associated</e1>_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D001714 NONE thus_0\RB\1740 ,_1\,\1740 two_2\CD\13741022 control_3\NN\5190804 groups_4\NNS\2137 were_5\VBD\836236 generated_6\VBN\1617192 :_7\:\1740 group_8\NN\2137 c1_9\NN\1740 ,_10\,\1740 which_11\WDT\1740 included_12\VBD\690614 age-_13\NN\1740 and_14\CC\1740 sex-comparable_15\JJ\1740 <e1>lithium-treated</e1>_16\JJ\1740 <e2>bipolar</e2>_17\JJ\1740 normocalcemic_18\JJ\1740 patients_19\NNS\9898892 ,_20\,\1740 and_21\CC\1740 group_22\NN\2137 c2_23\NN\1740 ,_24\,\1740 which_25\WDT\1740 included_26\VBD\690614 bipolar_27\JJ\1740 normocalcemic_28\JJ\1740 patients_29\NNS\9898892 treated_30\VBN\2376958 with_31\IN\1740 anticonvulsant_32\JJ\1740 mood_33\NN\26192 stabilizers_34\NNS\14806838 ._35\.\1740
D008094_D001714 NONE thus_0\RB\1740 ,_1\,\1740 two_2\CD\13741022 control_3\NN\5190804 groups_4\NNS\2137 were_5\VBD\836236 generated_6\VBN\1617192 :_7\:\1740 group_8\NN\2137 c1_9\NN\1740 ,_10\,\1740 which_11\WDT\1740 included_12\VBD\690614 age-_13\NN\1740 and_14\CC\1740 sex-comparable_15\JJ\1740 <e1>lithium-treated</e1>_16\JJ\1740 bipolar_17\JJ\1740 normocalcemic_18\JJ\1740 patients_19\NNS\9898892 ,_20\,\1740 and_21\CC\1740 group_22\NN\2137 c2_23\NN\1740 ,_24\,\1740 which_25\WDT\1740 included_26\VBD\690614 <e2>bipolar</e2>_27\JJ\1740 normocalcemic_28\JJ\1740 patients_29\NNS\9898892 treated_30\VBN\2376958 with_31\IN\1740 anticonvulsant_32\JJ\1740 mood_33\NN\26192 stabilizers_34\NNS\14806838 ._35\.\1740
D008094_D001714 NONE patients_0\NNS\9898892 with_1\IN\1740 hypercalcemia_2\NN\14299637 resulting_3\VBG\2633881 from_4\IN\1740 medical_5\JJ\1740 diseases_6\NNS\14061805 and_7\CC\1740 <e2>bipolar</e2>_8\JJ\1740 patients_9\NNS\9898892 with_10\IN\1740 <e1>lithium-associated</e1>_11\JJ\1740 hypercalcemia_12\NN\14299637 had_13\VBD\2108377 significantly_14\RB\1740 higher_15\JJR\1740 frequencies_16\NNS\15286249 of_17\IN\1740 conduction_18\NN\11419404 defects_19\NNS\14462666 ._20\.\1740
D008094_D006934 CID recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 <e1>lithium</e1>_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 <e2>hypercalcemia</e2>_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 lithium-associated_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D006934 CID recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 <e1>lithium</e1>_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 lithium-associated_28\JJ\1740 <e2>hypercalcemia</e2>_29\NN\14299637 ._30\.\1740
D008094_D006934 CID recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 lithium_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 <e2>hypercalcemia</e2>_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 <e1>lithium-associated</e1>_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D006934 CID recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 lithium_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 bradyarrhythmia_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 <e1>lithium-associated</e1>_28\JJ\1740 <e2>hypercalcemia</e2>_29\NN\14299637 ._30\.\1740
D008094_D006934 CID after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 <e2>hypercalcemias</e2>_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 <e1>non-lithium-treated</e1>_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 hypercalcemias_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 malignancies_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 lithium-associated_34\JJ\1740 hypercalcemia_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
D008094_D006934 CID after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 hypercalcemias_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 <e1>non-lithium-treated</e1>_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 <e2>hypercalcemias</e2>_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 malignancies_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 lithium-associated_34\JJ\1740 hypercalcemia_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
D008094_D006934 CID after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 hypercalcemias_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 <e1>non-lithium-treated</e1>_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 hypercalcemias_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 malignancies_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 lithium-associated_34\JJ\1740 <e2>hypercalcemia</e2>_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
D008094_D006934 CID after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 <e2>hypercalcemias</e2>_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 non-lithium-treated_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 hypercalcemias_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 malignancies_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 <e1>lithium-associated</e1>_34\JJ\1740 hypercalcemia_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
D008094_D006934 CID after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 hypercalcemias_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 non-lithium-treated_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 <e2>hypercalcemias</e2>_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 malignancies_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 <e1>lithium-associated</e1>_34\JJ\1740 hypercalcemia_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
D008094_D006934 CID after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 hypercalcemias_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 non-lithium-treated_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 hypercalcemias_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 malignancies_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 <e1>lithium-associated</e1>_34\JJ\1740 <e2>hypercalcemia</e2>_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
D008094_D006934 CID patients_0\NNS\9898892 with_1\IN\1740 <e2>hypercalcemia</e2>_2\NN\14299637 resulting_3\VBG\2633881 from_4\IN\1740 medical_5\JJ\1740 diseases_6\NNS\14061805 and_7\CC\1740 bipolar_8\JJ\1740 patients_9\NNS\9898892 with_10\IN\1740 <e1>lithium-associated</e1>_11\JJ\1740 hypercalcemia_12\NN\14299637 had_13\VBD\2108377 significantly_14\RB\1740 higher_15\JJR\1740 frequencies_16\NNS\15286249 of_17\IN\1740 conduction_18\NN\11419404 defects_19\NNS\14462666 ._20\.\1740
D008094_D006934 CID patients_0\NNS\9898892 with_1\IN\1740 hypercalcemia_2\NN\14299637 resulting_3\VBG\2633881 from_4\IN\1740 medical_5\JJ\1740 diseases_6\NNS\14061805 and_7\CC\1740 bipolar_8\JJ\1740 patients_9\NNS\9898892 with_10\IN\1740 <e1>lithium-associated</e1>_11\JJ\1740 <e2>hypercalcemia</e2>_12\NN\14299637 had_13\VBD\2108377 significantly_14\RB\1740 higher_15\JJR\1740 frequencies_16\NNS\15286249 of_17\IN\1740 conduction_18\NN\11419404 defects_19\NNS\14462666 ._20\.\1740
D008094_D001919 NONE recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 <e1>lithium</e1>_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 <e2>bradyarrhythmia</e2>_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 lithium-associated_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D001919 NONE recent_0\JJ\1740 findings_1\NNS\7951464 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 receiving_6\VBG\2210855 maintenance_7\NN\266806 lithium_8\NN\14625458 therapy_9\NN\657604 who_10\WP\8299493 developed_11\VBD\1753788 hypercalcemia_12\NN\14299637 and_13\CC\1740 severe_14\JJ\1740 <e2>bradyarrhythmia</e2>_15\NN\1740 prompted_16\VBD\1645601 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 conduct_20\VB\2436349 a_21\DT\13649268 retrospective_22\JJ\1740 study_23\NN\635850 of_24\IN\1740 bipolar_25\JJ\1740 patients_26\NNS\9898892 with_27\IN\1740 <e1>lithium-associated</e1>_28\JJ\1740 hypercalcemia_29\NN\14299637 ._30\.\1740
D008094_D009369 NONE after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 hypercalcemias_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 <e1>non-lithium-treated</e1>_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 hypercalcemias_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 <e2>malignancies</e2>_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 lithium-associated_34\JJ\1740 hypercalcemia_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
D008094_D009369 NONE after_0\IN\1740 eliminating_1\VBG\1619929 spurious_2\JJ\1740 hypercalcemias_3\NNS\14299637 or_4\CC\3541091 those_5\DT\1740 associated_6\VBN\628491 with_7\IN\1740 intravenous_8\JJ\1740 fluids_9\NNS\19613 ,_10\,\1740 the_11\DT\1740 authors_12\NNS\9610660 identified_13\VBD\699815 18_14\CD\13745420 non-lithium-treated_15\JJ\1740 patients_16\NNS\9898892 with_17\IN\1740 hypercalcemias_18\NNS\14299637 related_19\JJ\1740 to_20\TO\1740 <e2>malignancies</e2>_21\NNS\14070360 and_22\CC\1740 other_23\JJ\1740 medical_24\JJ\1740 conditions_25\NNS\14512817 (_26\-LRB-\1740 group_27\NN\2137 a_28\NN\13649268 )_29\-RRB-\1740 and_30\CC\1740 12_31\CD\13745420 patients_32\NNS\9898892 with_33\IN\1740 <e1>lithium-associated</e1>_34\JJ\1740 hypercalcemia_35\NN\14299637 (_36\-LRB-\1740 group_37\NN\2137 b_38\NN\1355326 )_39\-RRB-\1740 ._40\.\1740
18025637
D005473_D012170 CID branch_0\NN\8220714 <e2>retinal_1\JJ\1740 vein_2\NN\5417975 occlusion</e2>_3\NN\14081375 and_4\CC\1740 <e1>fluoxetine</e1>_5\NN\4169152 ._6\.\1740
D005473_D012170 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 branch_3\NN\8220714 <e2>retinal_4\JJ\1740 vein_5\NN\5417975 occlusion</e2>_6\NN\14081375 associated_7\VBN\628491 with_8\IN\1740 <e1>fluoxetine-induced</e1>_9\JJ\1740 secondary_10\JJ\1740 hypertension_11\NN\14057371 is_12\VBZ\836236 described_13\VBN\1001294 ._14\.\1740
D005473_D006973 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 branch_3\NN\8220714 retinal_4\JJ\1740 vein_5\NN\5417975 occlusion_6\NN\14081375 associated_7\VBN\628491 with_8\IN\1740 <e1>fluoxetine-induced</e1>_9\JJ\1740 secondary_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 is_12\VBZ\836236 described_13\VBN\1001294 ._14\.\1740
D012701_D006973 NONE although_0\IN\1740 an_1\DT\6697703 infrequent_2\JJ\1740 complication_3\NN\1073995 of_4\IN\1740 selective_5\JJ\1740 <e1>serotonin</e1>_6\NN\14807737 reuptake_7\NN\13571580 inhibitor_8\NN\20090 therapy_9\NN\657604 ,_10\,\1740 it_11\PRP\6125041 is_12\VBZ\836236 important_13\JJ\1740 that_14\IN\1740 ophthalmologists_15\NNS\10632576 are_16\VBP\836236 aware_17\JJ\1740 that_18\IN\1740 these_19\DT\1740 agents_20\NNS\7347 can_21\MD\3094503 cause_22\VB\1617192 <e2>hypertension</e2>_23\NN\14057371 because_24\IN\1740 this_25\DT\1740 class_26\NN\7951464 of_27\IN\1740 drugs_28\NNS\14778436 is_29\VBZ\836236 widely_30\RB\1740 prescribed_31\VBN\748282 ._32\.\1740
16309808
D004294_D012148 NONE does_0\VBZ\1640855 <e1>domperidone</e1>_1\RB\1740 potentiate_2\VB\229605 mirtazapine-associated_3\JJ\1740 <e2>restless_4\NN\1740 legs_5\NNS\5032918 syndrome</e2>_6\NN\5870365 ?_7\.\1740
D004294_D012148 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 there_4\EX\27167 is_5\VBZ\836236 no_6\DT\7204911 previous_7\JJ\1740 report_8\NN\6470073 regarding_9\VBG\689344 whether_10\IN\1740 <e1>domperidone</e1>_11\NN\1740 ,_12\,\1740 a_13\DT\13649268 peripheral_14\JJ\1740 dopamine_15\NN\14807737 d2_16\NN\1740 receptor_17\NN\5225602 antagonist_18\NN\7846 ,_19\,\1740 can_20\MD\3094503 also_21\RB\1740 induce_22\VB\1627355 or_23\CC\3541091 aggravate_24\JJ\1740 symptoms_25\NNS\5823932 of_26\IN\1740 <e2>rls</e2>_27\NNP\1740 ._28\.\1740
D004294_D012148 NONE the_0\DT\1740 authors_1\NNS\9610660 report_2\VBP\831651 here_3\RB\1740 a_4\DT\13649268 depressed_5\JJ\1740 patient_6\NN\9898892 comorbid_7\NN\1740 with_8\IN\1740 postprandial_9\JJ\1740 dyspepsia_10\NN\14299637 who_11\WP\8299493 developed_12\VBD\1753788 <e2>rls</e2>_13\NN\1740 after_14\IN\1740 mirtazapine_15\NN\1740 had_16\VBD\2108377 been_17\VBN\836236 added_18\VBN\156601 to_19\IN\1740 his_20\PRP$\1740 <e1>domperidone</e1>_21\NN\1740 therapy_22\NN\657604 ._23\.\1740
D004294_D012148 NONE such_0\JJ\1740 a_1\DT\13649268 temporal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 mirtazapine_8\NN\1740 and_9\CC\1740 the_10\DT\1740 symptoms_11\NNS\5823932 of_12\IN\1740 <e2>rls</e2>_13\NN\1740 in_14\IN\13603305 our_15\PRP$\1740 patient_16\NN\9898892 did_17\VBD\1640855 not_18\RB\1740 support_19\VB\2199590 a_20\DT\13649268 potentiating_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 <e1>domperione</e1>_24\NN\1740 on_25\IN\1740 mirtazapine-associated_26\JJ\1740 rls_27\NN\1740 ._28\.\1740
D004294_D012148 NONE such_0\JJ\1740 a_1\DT\13649268 temporal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 mirtazapine_8\NN\1740 and_9\CC\1740 the_10\DT\1740 symptoms_11\NNS\5823932 of_12\IN\1740 rls_13\NN\1740 in_14\IN\13603305 our_15\PRP$\1740 patient_16\NN\9898892 did_17\VBD\1640855 not_18\RB\1740 support_19\VB\2199590 a_20\DT\13649268 potentiating_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 <e1>domperione</e1>_24\NN\1740 on_25\IN\1740 mirtazapine-associated_26\JJ\1740 <e2>rls</e2>_27\NN\1740 ._28\.\1740
C035133_D012148 CID does_0\VBZ\1640855 domperidone_1\RB\1740 potentiate_2\VB\229605 <e1>mirtazapine-associated</e1>_3\JJ\1740 <e2>restless_4\NN\1740 legs_5\NNS\5032918 syndrome</e2>_6\NN\5870365 ?_7\.\1740
C035133_D012148 CID <e1>mirtazapine</e1>_0\NNP\1740 ,_1\,\1740 the_2\DT\1740 first_3\JJ\1740 noradrenergic_4\JJ\1740 and_5\CC\1740 specific_6\JJ\1740 serotonergic_7\NN\1740 antidepressant_8\NN\3740161 (_9\-LRB-\1740 nassa_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 has_13\VBZ\2108377 been_14\VBN\836236 associated_15\VBN\628491 with_16\IN\1740 <e2>rls</e2>_17\NN\1740 in_18\IN\13603305 several_19\JJ\1740 recent_20\JJ\1740 publications_21\NNS\4599396 ._22\.\1740
C035133_D012148 CID the_0\DT\1740 authors_1\NNS\9610660 report_2\VBP\831651 here_3\RB\1740 a_4\DT\13649268 depressed_5\JJ\1740 patient_6\NN\9898892 comorbid_7\NN\1740 with_8\IN\1740 postprandial_9\JJ\1740 dyspepsia_10\NN\14299637 who_11\WP\8299493 developed_12\VBD\1753788 <e2>rls</e2>_13\NN\1740 after_14\IN\1740 <e1>mirtazapine</e1>_15\NN\1740 had_16\VBD\2108377 been_17\VBN\836236 added_18\VBN\156601 to_19\IN\1740 his_20\PRP$\1740 domperidone_21\NN\1740 therapy_22\NN\657604 ._23\.\1740
C035133_D012148 CID our_0\PRP$\1740 patient_1\NN\9898892 started_2\VBD\2009433 to_3\TO\1740 have_4\VB\2108377 symptoms_5\NNS\5823932 of_6\IN\1740 <e2>rls</e2>_7\NN\1740 only_8\RB\1740 after_9\IN\1740 he_10\PRP\14622893 had_11\VBD\2108377 been_12\VBN\836236 treated_13\VBN\2376958 with_14\IN\1740 <e1>mirtazapine</e1>_15\NN\1740 ,_16\,\1740 and_17\CC\1740 his_18\PRP$\1740 rls_19\NN\1740 symptoms_20\NNS\5823932 resolved_21\VBD\352826 completely_22\RB\1740 upon_23\IN\1740 discontinuation_24\NN\209943 of_25\IN\1740 his_26\PRP$\1740 mirtazapine_27\NN\1740 ._28\.\1740
C035133_D012148 CID our_0\PRP$\1740 patient_1\NN\9898892 started_2\VBD\2009433 to_3\TO\1740 have_4\VB\2108377 symptoms_5\NNS\5823932 of_6\IN\1740 rls_7\NN\1740 only_8\RB\1740 after_9\IN\1740 he_10\PRP\14622893 had_11\VBD\2108377 been_12\VBN\836236 treated_13\VBN\2376958 with_14\IN\1740 <e1>mirtazapine</e1>_15\NN\1740 ,_16\,\1740 and_17\CC\1740 his_18\PRP$\1740 <e2>rls</e2>_19\NN\1740 symptoms_20\NNS\5823932 resolved_21\VBD\352826 completely_22\RB\1740 upon_23\IN\1740 discontinuation_24\NN\209943 of_25\IN\1740 his_26\PRP$\1740 mirtazapine_27\NN\1740 ._28\.\1740
C035133_D012148 CID our_0\PRP$\1740 patient_1\NN\9898892 started_2\VBD\2009433 to_3\TO\1740 have_4\VB\2108377 symptoms_5\NNS\5823932 of_6\IN\1740 <e2>rls</e2>_7\NN\1740 only_8\RB\1740 after_9\IN\1740 he_10\PRP\14622893 had_11\VBD\2108377 been_12\VBN\836236 treated_13\VBN\2376958 with_14\IN\1740 mirtazapine_15\NN\1740 ,_16\,\1740 and_17\CC\1740 his_18\PRP$\1740 rls_19\NN\1740 symptoms_20\NNS\5823932 resolved_21\VBD\352826 completely_22\RB\1740 upon_23\IN\1740 discontinuation_24\NN\209943 of_25\IN\1740 his_26\PRP$\1740 <e1>mirtazapine</e1>_27\NN\1740 ._28\.\1740
C035133_D012148 CID our_0\PRP$\1740 patient_1\NN\9898892 started_2\VBD\2009433 to_3\TO\1740 have_4\VB\2108377 symptoms_5\NNS\5823932 of_6\IN\1740 rls_7\NN\1740 only_8\RB\1740 after_9\IN\1740 he_10\PRP\14622893 had_11\VBD\2108377 been_12\VBN\836236 treated_13\VBN\2376958 with_14\IN\1740 mirtazapine_15\NN\1740 ,_16\,\1740 and_17\CC\1740 his_18\PRP$\1740 <e2>rls</e2>_19\NN\1740 symptoms_20\NNS\5823932 resolved_21\VBD\352826 completely_22\RB\1740 upon_23\IN\1740 discontinuation_24\NN\209943 of_25\IN\1740 his_26\PRP$\1740 <e1>mirtazapine</e1>_27\NN\1740 ._28\.\1740
C035133_D012148 CID such_0\JJ\1740 a_1\DT\13649268 temporal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 <e1>mirtazapine</e1>_8\NN\1740 and_9\CC\1740 the_10\DT\1740 symptoms_11\NNS\5823932 of_12\IN\1740 <e2>rls</e2>_13\NN\1740 in_14\IN\13603305 our_15\PRP$\1740 patient_16\NN\9898892 did_17\VBD\1640855 not_18\RB\1740 support_19\VB\2199590 a_20\DT\13649268 potentiating_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 domperione_24\NN\1740 on_25\IN\1740 mirtazapine-associated_26\JJ\1740 rls_27\NN\1740 ._28\.\1740
C035133_D012148 CID such_0\JJ\1740 a_1\DT\13649268 temporal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 <e1>mirtazapine</e1>_8\NN\1740 and_9\CC\1740 the_10\DT\1740 symptoms_11\NNS\5823932 of_12\IN\1740 rls_13\NN\1740 in_14\IN\13603305 our_15\PRP$\1740 patient_16\NN\9898892 did_17\VBD\1640855 not_18\RB\1740 support_19\VB\2199590 a_20\DT\13649268 potentiating_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 domperione_24\NN\1740 on_25\IN\1740 mirtazapine-associated_26\JJ\1740 <e2>rls</e2>_27\NN\1740 ._28\.\1740
C035133_D012148 CID such_0\JJ\1740 a_1\DT\13649268 temporal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 mirtazapine_8\NN\1740 and_9\CC\1740 the_10\DT\1740 symptoms_11\NNS\5823932 of_12\IN\1740 <e2>rls</e2>_13\NN\1740 in_14\IN\13603305 our_15\PRP$\1740 patient_16\NN\9898892 did_17\VBD\1640855 not_18\RB\1740 support_19\VB\2199590 a_20\DT\13649268 potentiating_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 domperione_24\NN\1740 on_25\IN\1740 <e1>mirtazapine-associated</e1>_26\JJ\1740 rls_27\NN\1740 ._28\.\1740
C035133_D012148 CID such_0\JJ\1740 a_1\DT\13649268 temporal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 mirtazapine_8\NN\1740 and_9\CC\1740 the_10\DT\1740 symptoms_11\NNS\5823932 of_12\IN\1740 rls_13\NN\1740 in_14\IN\13603305 our_15\PRP$\1740 patient_16\NN\9898892 did_17\VBD\1640855 not_18\RB\1740 support_19\VB\2199590 a_20\DT\13649268 potentiating_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 domperione_24\NN\1740 on_25\IN\1740 <e1>mirtazapine-associated</e1>_26\JJ\1740 <e2>rls</e2>_27\NN\1740 ._28\.\1740
C035133_D012148 CID however_0\RB\1740 ,_1\,\1740 physicians_2\NNS\10305802 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 of_6\IN\1740 the_7\DT\1740 possibility_8\NN\5944958 that_9\IN\1740 <e1>mirtazapine</e1>_10\NN\1740 can_11\MD\3094503 be_12\VB\836236 associated_13\VBN\628491 with_14\IN\1740 <e2>rls</e2>_15\NN\1740 in_16\IN\13603305 some_17\DT\1740 individuals_18\NNS\7347 ,_19\,\1740 especially_20\RB\1740 those_21\DT\1740 receiving_22\VBG\2210855 concomitant_23\JJ\1740 dopamine_24\NN\14807737 d2_25\NN\1740 receptor_26\NN\5225602 antagonists_27\NNS\7846 ._28\.\1740
D007980_D012148 NONE for_0\IN\1740 example_1\NN\5816287 ,_2\,\1740 the_3\DT\1740 symptoms_4\NNS\5823932 of_5\IN\1740 <e2>rls</e2>_6\NN\1740 can_7\MD\3094503 be_8\VB\836236 dramatically_9\RB\1740 improved_10\VBN\126264 by_11\IN\1740 <e1>levodopa</e1>_12\NN\14604959 and_13\CC\1740 dopamine_14\NN\14807737 agonists_15\NNS\9613191 ,_16\,\1740 whereas_17\IN\1740 central_18\JJ\1740 dopamine_19\NN\14807737 d2_20\NN\1740 receptor_21\NN\5225602 antagonists_22\NNS\7846 can_23\MD\3094503 induce_24\VB\1627355 or_25\CC\3541091 aggravate_26\JJ\1740 rls_27\NN\1740 symptoms_28\NNS\5823932 ._29\.\1740
D007980_D012148 NONE for_0\IN\1740 example_1\NN\5816287 ,_2\,\1740 the_3\DT\1740 symptoms_4\NNS\5823932 of_5\IN\1740 rls_6\NN\1740 can_7\MD\3094503 be_8\VB\836236 dramatically_9\RB\1740 improved_10\VBN\126264 by_11\IN\1740 <e1>levodopa</e1>_12\NN\14604959 and_13\CC\1740 dopamine_14\NN\14807737 agonists_15\NNS\9613191 ,_16\,\1740 whereas_17\IN\1740 central_18\JJ\1740 dopamine_19\NN\14807737 d2_20\NN\1740 receptor_21\NN\5225602 antagonists_22\NNS\7846 can_23\MD\3094503 induce_24\VB\1627355 or_25\CC\3541091 aggravate_26\JJ\1740 <e2>rls</e2>_27\NN\1740 symptoms_28\NNS\5823932 ._29\.\1740
D004298_D012148 NONE for_0\IN\1740 example_1\NN\5816287 ,_2\,\1740 the_3\DT\1740 symptoms_4\NNS\5823932 of_5\IN\1740 <e2>rls</e2>_6\NN\1740 can_7\MD\3094503 be_8\VB\836236 dramatically_9\RB\1740 improved_10\VBN\126264 by_11\IN\1740 levodopa_12\NN\14604959 and_13\CC\1740 <e1>dopamine</e1>_14\NN\14807737 agonists_15\NNS\9613191 ,_16\,\1740 whereas_17\IN\1740 central_18\JJ\1740 dopamine_19\NN\14807737 d2_20\NN\1740 receptor_21\NN\5225602 antagonists_22\NNS\7846 can_23\MD\3094503 induce_24\VB\1627355 or_25\CC\3541091 aggravate_26\JJ\1740 rls_27\NN\1740 symptoms_28\NNS\5823932 ._29\.\1740
D004298_D012148 NONE for_0\IN\1740 example_1\NN\5816287 ,_2\,\1740 the_3\DT\1740 symptoms_4\NNS\5823932 of_5\IN\1740 rls_6\NN\1740 can_7\MD\3094503 be_8\VB\836236 dramatically_9\RB\1740 improved_10\VBN\126264 by_11\IN\1740 levodopa_12\NN\14604959 and_13\CC\1740 <e1>dopamine</e1>_14\NN\14807737 agonists_15\NNS\9613191 ,_16\,\1740 whereas_17\IN\1740 central_18\JJ\1740 dopamine_19\NN\14807737 d2_20\NN\1740 receptor_21\NN\5225602 antagonists_22\NNS\7846 can_23\MD\3094503 induce_24\VB\1627355 or_25\CC\3541091 aggravate_26\JJ\1740 <e2>rls</e2>_27\NN\1740 symptoms_28\NNS\5823932 ._29\.\1740
D004298_D012148 NONE for_0\IN\1740 example_1\NN\5816287 ,_2\,\1740 the_3\DT\1740 symptoms_4\NNS\5823932 of_5\IN\1740 <e2>rls</e2>_6\NN\1740 can_7\MD\3094503 be_8\VB\836236 dramatically_9\RB\1740 improved_10\VBN\126264 by_11\IN\1740 levodopa_12\NN\14604959 and_13\CC\1740 dopamine_14\NN\14807737 agonists_15\NNS\9613191 ,_16\,\1740 whereas_17\IN\1740 central_18\JJ\1740 <e1>dopamine</e1>_19\NN\14807737 d2_20\NN\1740 receptor_21\NN\5225602 antagonists_22\NNS\7846 can_23\MD\3094503 induce_24\VB\1627355 or_25\CC\3541091 aggravate_26\JJ\1740 rls_27\NN\1740 symptoms_28\NNS\5823932 ._29\.\1740
D004298_D012148 NONE for_0\IN\1740 example_1\NN\5816287 ,_2\,\1740 the_3\DT\1740 symptoms_4\NNS\5823932 of_5\IN\1740 rls_6\NN\1740 can_7\MD\3094503 be_8\VB\836236 dramatically_9\RB\1740 improved_10\VBN\126264 by_11\IN\1740 levodopa_12\NN\14604959 and_13\CC\1740 dopamine_14\NN\14807737 agonists_15\NNS\9613191 ,_16\,\1740 whereas_17\IN\1740 central_18\JJ\1740 <e1>dopamine</e1>_19\NN\14807737 d2_20\NN\1740 receptor_21\NN\5225602 antagonists_22\NNS\7846 can_23\MD\3094503 induce_24\VB\1627355 or_25\CC\3541091 aggravate_26\JJ\1740 <e2>rls</e2>_27\NN\1740 symptoms_28\NNS\5823932 ._29\.\1740
D004298_D012148 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 there_4\EX\27167 is_5\VBZ\836236 no_6\DT\7204911 previous_7\JJ\1740 report_8\NN\6470073 regarding_9\VBG\689344 whether_10\IN\1740 domperidone_11\NN\1740 ,_12\,\1740 a_13\DT\13649268 peripheral_14\JJ\1740 <e1>dopamine</e1>_15\NN\14807737 d2_16\NN\1740 receptor_17\NN\5225602 antagonist_18\NN\7846 ,_19\,\1740 can_20\MD\3094503 also_21\RB\1740 induce_22\VB\1627355 or_23\CC\3541091 aggravate_24\JJ\1740 symptoms_25\NNS\5823932 of_26\IN\1740 <e2>rls</e2>_27\NNP\1740 ._28\.\1740
D004298_D012148 NONE however_0\RB\1740 ,_1\,\1740 physicians_2\NNS\10305802 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 of_6\IN\1740 the_7\DT\1740 possibility_8\NN\5944958 that_9\IN\1740 mirtazapine_10\NN\1740 can_11\MD\3094503 be_12\VB\836236 associated_13\VBN\628491 with_14\IN\1740 <e2>rls</e2>_15\NN\1740 in_16\IN\13603305 some_17\DT\1740 individuals_18\NNS\7347 ,_19\,\1740 especially_20\RB\1740 those_21\DT\1740 receiving_22\VBG\2210855 concomitant_23\JJ\1740 <e1>dopamine</e1>_24\NN\14807737 d2_25\NN\1740 receptor_26\NN\5225602 antagonists_27\NNS\7846 ._28\.\1740
C035133_D004415 NONE the_0\DT\1740 authors_1\NNS\9610660 report_2\VBP\831651 here_3\RB\1740 a_4\DT\13649268 depressed_5\JJ\1740 patient_6\NN\9898892 comorbid_7\NN\1740 with_8\IN\1740 <e2>postprandial_9\JJ\1740 dyspepsia</e2>_10\NN\14299637 who_11\WP\8299493 developed_12\VBD\1753788 rls_13\NN\1740 after_14\IN\1740 <e1>mirtazapine</e1>_15\NN\1740 had_16\VBD\2108377 been_17\VBN\836236 added_18\VBN\156601 to_19\IN\1740 his_20\PRP$\1740 domperidone_21\NN\1740 therapy_22\NN\657604 ._23\.\1740
D004294_D004415 NONE the_0\DT\1740 authors_1\NNS\9610660 report_2\VBP\831651 here_3\RB\1740 a_4\DT\13649268 depressed_5\JJ\1740 patient_6\NN\9898892 comorbid_7\NN\1740 with_8\IN\1740 <e2>postprandial_9\JJ\1740 dyspepsia</e2>_10\NN\14299637 who_11\WP\8299493 developed_12\VBD\1753788 rls_13\NN\1740 after_14\IN\1740 mirtazapine_15\NN\1740 had_16\VBD\2108377 been_17\VBN\836236 added_18\VBN\156601 to_19\IN\1740 his_20\PRP$\1740 <e1>domperidone</e1>_21\NN\1740 therapy_22\NN\657604 ._23\.\1740
3832950
D002998_D004827 NONE <e1>clonazepam</e1>_0\NN\1740 monotherapy_1\NN\1740 for_2\IN\1740 <e2>epilepsy</e2>_3\NN\14085708 in_4\IN\13603305 childhood_5\NN\15144371 ._6\.\1740
D002998_D004827 NONE sixty_0\CD\13745420 patients_1\NNS\9898892 (_2\-LRB-\1740 age-range_3\JJ\1740 one_4\CD\13741022 month_5\NN\15113229 to_6\IN\1740 14_7\CD\13745420 years_8\NNS\15144371 )_9\-RRB-\1740 with_10\IN\1740 other_11\JJ\1740 types_12\NNS\5839024 of_13\IN\1740 <e2>epilepsy</e2>_14\NN\14085708 than_15\IN\1740 infantile_16\JJ\1740 spasms_17\NNS\14299637 were_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>clonazepam</e1>_21\NN\1740 ._22\.\1740
D002998_D013036 NONE sixty_0\CD\13745420 patients_1\NNS\9898892 (_2\-LRB-\1740 age-range_3\JJ\1740 one_4\CD\13741022 month_5\NN\15113229 to_6\IN\1740 14_7\CD\13745420 years_8\NNS\15144371 )_9\-RRB-\1740 with_10\IN\1740 other_11\JJ\1740 types_12\NNS\5839024 of_13\IN\1740 epilepsy_14\NN\14085708 than_15\IN\1740 <e2>infantile_16\JJ\1740 spasms</e2>_17\NNS\14299637 were_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>clonazepam</e1>_21\NN\1740 ._22\.\1740
4010471
D009538_D012640 CID relationship_0\NN\31921 between_1\IN\1740 <e1>nicotine-induced</e1>_2\JJ\1740 <e2>seizures</e2>_3\NNS\14081375 and_4\CC\1740 hippocampal_5\NN\1740 nicotinic_6\JJ\1740 receptors_7\NNS\5225602 ._8\.\1740
D009538_D012640 CID using_0\VBG\1156834 mice_1\NNS\2329401 derived_2\VBN\634472 from_3\IN\1740 a_4\DT\13649268 classical_5\JJ\1740 f2_6\NN\1740 and_7\CC\1740 backcross_8\NN\1740 genetic_9\JJ\1740 design_10\NN\927261 ,_11\,\1740 a_12\DT\13649268 relationship_13\NN\31921 between_14\IN\1740 <e1>nicotine-induced</e1>_15\JJ\1740 <e2>seizures</e2>_16\NNS\14081375 and_17\CC\1740 alpha-bungarotoxin_18\JJ\1740 nicotinic_19\JJ\1740 receptor_20\NN\5225602 concentration_21\NN\4916342 was_22\VBD\836236 found_23\VBN\2426171 ._24\.\1740
D009538_D012640 CID mice_0\NNS\2329401 sensitive_1\JJ\1740 to_2\TO\1740 the_3\DT\1740 convulsant_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>nicotine</e1>_7\NN\14712692 had_8\VBD\2108377 greater_9\JJR\1740 alpha-bungarotoxin_10\NN\1740 binding_11\NN\4688246 in_12\IN\13603305 the_13\DT\1740 hippocampus_14\NN\5462674 than_15\IN\1740 <e2>seizure</e2>_16\JJ\1740 insensitive_17\JJ\1740 mice_18\NNS\2329401 ._19\.\1740
D004229_D012640 NONE the_0\DT\1740 binding_1\VBG\1290422 sites_2\NNS\8673395 from_3\IN\1740 <e2>seizure</e2>_4\JJ\1740 sensitive_5\JJ\1740 and_6\CC\1740 resistant_7\JJ\1740 mice_8\NNS\2329401 were_9\VBD\836236 equally_10\RB\1740 affected_11\VBN\126264 by_12\IN\1740 treatment_13\NN\654885 with_14\IN\1740 <e1>dithiothreitol</e1>_15\NN\1740 ,_16\,\1740 trypsin_17\NN\14732946 or_18\CC\3541091 heat_19\NN\11452218 ._20\.\1740
7644931
D017239_D002289 NONE <e1>paclitaxel</e1>_0\NN\1740 (_1\-LRB-\1740 taxol_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 by_12\IN\1740 3-hour_13\CD\1740 infusion_14\NN\14589223 was_15\VBD\836236 combined_16\VBN\2630189 with_17\IN\1740 carboplatin_18\NN\1740 in_19\IN\13603305 a_20\DT\13649268 phase_21\NN\15113229 i/ii_22\NN\1740 study_23\NN\635850 directed_24\VBN\746718 to_25\TO\1740 patients_26\NNS\9898892 with_27\IN\1740 <e2>non-small_28\JJ\1740 cell_29\NN\3080309 lung_30\NN\5528060 cancer</e2>_31\NN\14239425 ._32\.\1740
D017239_D002289 NONE paclitaxel_0\NN\1740 (_1\-LRB-\1740 <e1>taxol</e1>_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 by_12\IN\1740 3-hour_13\CD\1740 infusion_14\NN\14589223 was_15\VBD\836236 combined_16\VBN\2630189 with_17\IN\1740 carboplatin_18\NN\1740 in_19\IN\13603305 a_20\DT\13649268 phase_21\NN\15113229 i/ii_22\NN\1740 study_23\NN\635850 directed_24\VBN\746718 to_25\TO\1740 patients_26\NNS\9898892 with_27\IN\1740 <e2>non-small_28\JJ\1740 cell_29\NN\3080309 lung_30\NN\5528060 cancer</e2>_31\NN\14239425 ._32\.\1740
D016190_D002289 NONE paclitaxel_0\NN\1740 (_1\-LRB-\1740 taxol_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 by_12\IN\1740 3-hour_13\CD\1740 infusion_14\NN\14589223 was_15\VBD\836236 combined_16\VBN\2630189 with_17\IN\1740 <e1>carboplatin</e1>_18\NN\1740 in_19\IN\13603305 a_20\DT\13649268 phase_21\NN\15113229 i/ii_22\NN\1740 study_23\NN\635850 directed_24\VBN\746718 to_25\TO\1740 patients_26\NNS\9898892 with_27\IN\1740 <e2>non-small_28\JJ\1740 cell_29\NN\3080309 lung_30\NN\5528060 cancer</e2>_31\NN\14239425 ._32\.\1740
D017239_D064420 NONE <e2>toxicities</e2>_0\NNS\13576101 were_1\VBD\836236 compared_2\VBN\644583 with_3\IN\1740 a_4\DT\13649268 cohort_5\NN\8184861 of_6\IN\1740 patients_7\NNS\9898892 in_8\IN\13603305 a_9\DT\13649268 phase_10\NN\15113229 i_11\CD\14622893 trial_12\NN\786195 of_13\IN\1740 <e1>paclitaxel</e1>_14\NN\1740 alone_15\RB\1740 at_16\IN\14622893 identical_17\JJ\1740 dose_18\NN\3740161 levels_19\NNS\4916342 ._20\.\1740
D016190_D006402 NONE <e1>carboplatin</e1>_0\NNP\1740 did_1\VBD\1640855 not_2\RB\1740 appear_3\VB\2604760 to_4\TO\1740 add_5\VB\156601 to_6\IN\1740 the_7\DT\1740 <e2>hematologic_8\JJ\1740 toxicities</e2>_9\NNS\13576101 observed_10\VBN\2163746 ,_11\,\1740 and_12\CC\1740 the_13\DT\1740 paclitaxel/carboplatin_14\NN\1740 combination_15\NN\7951464 could_16\MD\1740 be_17\VB\836236 dosed_18\VBN\515154 every_19\DT\1740 3_20\CD\13741022 weeks_21\NNS\15113229 ._22\.\1740
D016190_D006402 NONE carboplatin_0\NNP\1740 did_1\VBD\1640855 not_2\RB\1740 appear_3\VB\2604760 to_4\TO\1740 add_5\VB\156601 to_6\IN\1740 the_7\DT\1740 <e2>hematologic_8\JJ\1740 toxicities</e2>_9\NNS\13576101 observed_10\VBN\2163746 ,_11\,\1740 and_12\CC\1740 the_13\DT\1740 <e1>paclitaxel/carboplatin</e1>_14\NN\1740 combination_15\NN\7951464 could_16\MD\1740 be_17\VB\836236 dosed_18\VBN\515154 every_19\DT\1740 3_20\CD\13741022 weeks_21\NNS\15113229 ._22\.\1740
D017239_D006402 CID carboplatin_0\NNP\1740 did_1\VBD\1640855 not_2\RB\1740 appear_3\VB\2604760 to_4\TO\1740 add_5\VB\156601 to_6\IN\1740 the_7\DT\1740 <e2>hematologic_8\JJ\1740 toxicities</e2>_9\NNS\13576101 observed_10\VBN\2163746 ,_11\,\1740 and_12\CC\1740 the_13\DT\1740 <e1>paclitaxel/carboplatin</e1>_14\NN\1740 combination_15\NN\7951464 could_16\MD\1740 be_17\VB\836236 dosed_18\VBN\515154 every_19\DT\1740 3_20\CD\13741022 weeks_21\NNS\15113229 ._22\.\1740
1280054
D014750_D001927 CID fatal_0\JJ\1740 <e2>myeloencephalopathy</e2>_1\NN\1740 due_2\JJ\1740 to_3\TO\1740 intrathecal_4\JJ\1740 <e1>vincristine</e1>_5\NN\3917455 administration_6\NN\1133281 ._7\.\1740
D014750_D001927 CID <e1>vincristine</e1>_0\NN\3917455 was_1\VBD\836236 accidentally_2\RB\1740 given_3\VBN\2327200 intrathecally_4\RB\1740 to_5\IN\1740 a_6\DT\13649268 child_7\NN\9622049 with_8\IN\1740 leukaemia_9\NN\14239918 ,_10\,\1740 producing_11\VBG\1617192 sensory_12\JJ\1740 and_13\CC\1740 motor_14\NN\3699975 dysfunction_15\NN\14204950 followed_16\VBN\1835496 by_17\IN\1740 <e2>encephalopathy</e2>_18\JJ\1740 and_19\CC\1740 death_20\NN\7296428 ._21\.\1740
D014750_D007938 NONE <e1>vincristine</e1>_0\NN\3917455 was_1\VBD\836236 accidentally_2\RB\1740 given_3\VBN\2327200 intrathecally_4\RB\1740 to_5\IN\1740 a_6\DT\13649268 child_7\NN\9622049 with_8\IN\1740 <e2>leukaemia</e2>_9\NN\14239918 ,_10\,\1740 producing_11\VBG\1617192 sensory_12\JJ\1740 and_13\CC\1740 motor_14\NN\3699975 dysfunction_15\NN\14204950 followed_16\VBN\1835496 by_17\IN\1740 encephalopathy_18\JJ\1740 and_19\CC\1740 death_20\NN\7296428 ._21\.\1740
D014750_D007049 CID <e1>vincristine</e1>_0\NN\3917455 was_1\VBD\836236 accidentally_2\RB\1740 given_3\VBN\2327200 intrathecally_4\RB\1740 to_5\IN\1740 a_6\DT\13649268 child_7\NN\9622049 with_8\IN\1740 leukaemia_9\NN\14239918 ,_10\,\1740 producing_11\VBG\1617192 <e2>sensory_12\JJ\1740 and_13\CC\1740 motor_14\NN\3699975 dysfunction</e2>_15\NN\14204950 followed_16\VBN\1835496 by_17\IN\1740 encephalopathy_18\JJ\1740 and_19\CC\1740 death_20\NN\7296428 ._21\.\1740
895432
D007545_D009203 CID effects_0\NNS\13245626 of_1\IN\1740 exercise_2\NN\621627 on_3\IN\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 <e1>isoproterenol-induced</e1>_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 ._10\.\1740
D007545_D009203 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 exercise_3\NN\621627 on_4\IN\1740 the_5\DT\1740 severity_6\NN\5036394 of_7\IN\1740 <e1>isoproterenol-induced</e1>_8\JJ\1740 <e2>myocardial_9\JJ\1740 infarction</e2>_10\NN\14204950 was_11\VBD\836236 studied_12\VBN\630380 in_13\IN\13603305 male_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D007545_D007238 NONE the_0\DT\1740 results_1\NNS\34213 indicated_2\VBD\952524 that_3\IN\1740 exercise_4\NN\621627 reduced_5\VBD\441445 the_6\DT\1740 mortality_7\NN\5054863 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 effects_11\NNS\13245626 of_12\IN\1740 large_13\JJ\1740 dosages_14\NNS\13576355 of_15\IN\1740 <e1>isoproterenol</e1>_16\NN\3740161 but_17\CC\1740 had_18\VBD\2108377 little_19\JJ\1740 on_20\IN\1740 the_21\DT\1740 severity_22\NN\5036394 of_23\IN\1740 the_24\DT\1740 <e2>infarction</e2>_25\NN\14204950 ._26\.\1740
19815465
D020888_D014786 CID <e2>binasal_0\JJ\1740 visual_1\JJ\1740 field_2\NN\8673395 defects</e2>_3\NNS\14462666 are_4\VBP\836236 not_5\RB\1740 specific_6\JJ\1740 to_7\TO\1740 <e1>vigabatrin</e1>_8\NN\1740 ._9\.\1740
D020888_D014786 CID this_0\DT\1740 study_1\NN\635850 investigated_2\VBD\644583 the_3\DT\1740 <e2>visual_4\JJ\1740 defects</e2>_5\NNS\14462666 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 antiepileptic_9\JJ\1740 drug_10\NN\14778436 <e1>vigabatrin</e1>_11\NN\1740 (_12\-LRB-\1740 vgb_13\NN\1740 )_14\-RRB-\1740 ._15\.\1740
D020888_D014786 CID this_0\DT\1740 study_1\NN\635850 investigated_2\VBD\644583 the_3\DT\1740 <e2>visual_4\JJ\1740 defects</e2>_5\NNS\14462666 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 antiepileptic_9\JJ\1740 drug_10\NN\14778436 vigabatrin_11\NN\1740 (_12\-LRB-\1740 <e1>vgb</e1>_13\NN\1740 )_14\-RRB-\1740 ._15\.\1740
D020888_D004827 NONE two_0\CD\13741022 hundred_1\CD\13745420 four_2\CD\13741022 people_3\NNS\31264 with_4\IN\1740 <e2>epilepsy</e2>_5\NN\14085708 were_6\VBD\836236 grouped_7\VBN\654625 on_8\IN\1740 the_9\DT\1740 basis_10\NN\13790712 of_11\IN\1740 antiepileptic_12\JJ\1740 drug_13\NN\14778436 therapy_14\NN\657604 (_15\-LRB-\1740 current_16\JJ\1740 ,_17\,\1740 previous_18\JJ\1740 ,_19\,\1740 or_20\CC\3541091 no_21\DT\7204911 exposure_22\NN\5042871 to_23\TO\1740 <e1>vgb</e1>_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D020888_D012164 CID assessment_0\NN\5732756 by_1\IN\1740 conventional_2\JJ\1740 static_3\JJ\1740 perimetry_4\NN\1740 may_5\MD\15209706 neither_6\CC\1740 be_7\VB\836236 sufficiently_8\RB\1740 sensitive_9\JJ\1740 nor_10\CC\1740 specific_11\JJ\1740 to_12\TO\1740 reliably_13\RB\1740 identify_14\VB\699815 <e2>retinal_15\JJ\1740 toxicity</e2>_16\NN\13576101 associated_17\VBN\628491 with_18\IN\1740 <e1>vgb</e1>_19\NN\1740 ._20\.\1740
16565833
C522803_D066126 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 the_3\DT\1740 time_4\NN\7308889 interval_5\NN\33615 between_6\IN\1740 <e1>monoher</e1>_7\NN\1740 and_8\CC\1740 doxorubicin_9\NN\2716866 administration_10\NN\1133281 on_11\IN\1740 the_12\DT\1740 protection_13\NN\407535 against_14\IN\1740 doxorubicin-induced_15\JJ\1740 <e2>cardiotoxicity</e2>_16\NN\1740 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
C522803_D066126 NONE the_0\DT\1740 semisynthetic_1\JJ\1740 flavonoid_2\NN\14983143 <e1>monohydroxyethylrutoside</e1>_3\NN\1740 (_4\-LRB-\1740 monoher_5\NN\1740 )_6\-RRB-\1740 showed_7\VBD\2137132 cardioprotection_8\NN\1740 against_9\IN\1740 dox-induced_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 through_12\IN\1740 its_13\PRP$\6125041 radical_14\JJ\1740 scavenging_15\NN\1740 and_16\CC\1740 iron_17\NN\14625458 chelating_18\NN\1740 properties_19\NNS\32613 ._20\.\1740
C522803_D066126 NONE the_0\DT\1740 semisynthetic_1\JJ\1740 flavonoid_2\NN\14983143 monohydroxyethylrutoside_3\NN\1740 (_4\-LRB-\1740 <e1>monoher</e1>_5\NN\1740 )_6\-RRB-\1740 showed_7\VBD\2137132 cardioprotection_8\NN\1740 against_9\IN\1740 dox-induced_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 through_12\IN\1740 its_13\PRP$\6125041 radical_14\JJ\1740 scavenging_15\NN\1740 and_16\CC\1740 iron_17\NN\14625458 chelating_18\NN\1740 properties_19\NNS\32613 ._20\.\1740
D004317_D066126 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 the_3\DT\1740 time_4\NN\7308889 interval_5\NN\33615 between_6\IN\1740 monoher_7\NN\1740 and_8\CC\1740 <e1>doxorubicin</e1>_9\NN\2716866 administration_10\NN\1133281 on_11\IN\1740 the_12\DT\1740 protection_13\NN\407535 against_14\IN\1740 doxorubicin-induced_15\JJ\1740 <e2>cardiotoxicity</e2>_16\NN\1740 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
D004317_D066126 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 the_3\DT\1740 time_4\NN\7308889 interval_5\NN\33615 between_6\IN\1740 monoher_7\NN\1740 and_8\CC\1740 doxorubicin_9\NN\2716866 administration_10\NN\1133281 on_11\IN\1740 the_12\DT\1740 protection_13\NN\407535 against_14\IN\1740 <e1>doxorubicin-induced</e1>_15\JJ\1740 <e2>cardiotoxicity</e2>_16\NN\1740 in_17\IN\13603305 mice_18\NNS\2329401 ._19\.\1740
D004317_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 despite_2\IN\7501545 its_3\PRP$\6125041 well-known_4\JJ\1740 <e2>cardiotoxicity</e2>_5\NN\1740 ,_6\,\1740 the_7\DT\1740 anthracyclin_8\JJ\1740 <e1>doxorubicin</e1>_9\NN\2716866 (_10\-LRB-\1740 dox_11\NN\1740 )_12\-RRB-\1740 continues_13\VBZ\2367363 to_14\TO\1740 be_15\VB\836236 an_16\DT\6697703 effective_17\JJ\1740 and_18\CC\1740 widely_19\RB\1740 used_20\VBN\1156834 chemotherapeutic_21\JJ\1740 agent_22\NN\7347 ._23\.\1740
D004317_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 despite_2\IN\7501545 its_3\PRP$\6125041 well-known_4\JJ\1740 <e2>cardiotoxicity</e2>_5\NN\1740 ,_6\,\1740 the_7\DT\1740 anthracyclin_8\JJ\1740 doxorubicin_9\NN\2716866 (_10\-LRB-\1740 <e1>dox</e1>_11\NN\1740 )_12\-RRB-\1740 continues_13\VBZ\2367363 to_14\TO\1740 be_15\VB\836236 an_16\DT\6697703 effective_17\JJ\1740 and_18\CC\1740 widely_19\RB\1740 used_20\VBN\1156834 chemotherapeutic_21\JJ\1740 agent_22\NN\7347 ._23\.\1740
D004317_D066126 NONE the_0\DT\1740 semisynthetic_1\JJ\1740 flavonoid_2\NN\14983143 monohydroxyethylrutoside_3\NN\1740 (_4\-LRB-\1740 monoher_5\NN\1740 )_6\-RRB-\1740 showed_7\VBD\2137132 cardioprotection_8\NN\1740 against_9\IN\1740 <e1>dox-induced</e1>_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 through_12\IN\1740 its_13\PRP$\6125041 radical_14\JJ\1740 scavenging_15\NN\1740 and_16\CC\1740 iron_17\NN\14625458 chelating_18\NN\1740 properties_19\NNS\32613 ._20\.\1740
D004317_D006331 NONE <e1>dox-induced</e1>_0\JJ\1740 <e2>cardiac_1\JJ\1740 damage</e2>_2\NN\7296428 presumably_3\RB\1740 results_4\VBZ\2633881 from_5\IN\1740 the_6\DT\1740 formation_7\NN\7938773 of_8\IN\1740 free_9\JJ\1740 radicals_10\NNS\9465459 by_11\IN\1740 dox_12\NN\1740 ._13\.\1740
D004317_D006331 NONE dox-induced_0\JJ\1740 <e2>cardiac_1\JJ\1740 damage</e2>_2\NN\7296428 presumably_3\RB\1740 results_4\VBZ\2633881 from_5\IN\1740 the_6\DT\1740 formation_7\NN\7938773 of_8\IN\1740 free_9\JJ\1740 radicals_10\NNS\9465459 by_11\IN\1740 <e1>dox</e1>_12\NN\1740 ._13\.\1740
D004317_D006331 NONE microscopic_0\JJ\1740 evaluation_1\NN\874067 revealed_2\VBD\2137132 that_3\IN\1740 treatment_4\NN\654885 with_5\IN\1740 <e1>dox</e1>_6\NN\1740 alone_7\RB\1740 induced_8\VBD\1627355 significant_9\JJ\1740 <e2>cardiac_10\JJ\1740 damage</e2>_11\NN\7296428 in_12\IN\13603305 comparison_13\NN\635850 to_14\TO\1740 the_15\DT\1740 saline_16\NN\14849367 control_17\NN\5190804 group_18\NN\2137 (_19\-LRB-\1740 p<0.001_20\NN\1740 )_21\-RRB-\1740 ._22\.\1740
D005419_D066126 NONE the_0\DT\1740 semisynthetic_1\JJ\1740 <e1>flavonoid</e1>_2\NN\14983143 monohydroxyethylrutoside_3\NN\1740 (_4\-LRB-\1740 monoher_5\NN\1740 )_6\-RRB-\1740 showed_7\VBD\2137132 cardioprotection_8\NN\1740 against_9\IN\1740 dox-induced_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 through_12\IN\1740 its_13\PRP$\6125041 radical_14\JJ\1740 scavenging_15\NN\1740 and_16\CC\1740 iron_17\NN\14625458 chelating_18\NN\1740 properties_19\NNS\32613 ._20\.\1740
D007501_D066126 NONE the_0\DT\1740 semisynthetic_1\JJ\1740 flavonoid_2\NN\14983143 monohydroxyethylrutoside_3\NN\1740 (_4\-LRB-\1740 monoher_5\NN\1740 )_6\-RRB-\1740 showed_7\VBD\2137132 cardioprotection_8\NN\1740 against_9\IN\1740 dox-induced_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 through_12\IN\1740 its_13\PRP$\6125041 radical_14\JJ\1740 scavenging_15\NN\1740 and_16\CC\1740 <e1>iron</e1>_17\NN\14625458 chelating_18\NN\1740 properties_19\NNS\32613 ._20\.\1740
20682692
D013311_D003928 CID blockade_0\NN\952963 of_1\IN\1740 endothelial-mesenchymal_2\JJ\1740 transition_3\NN\199130 by_4\IN\1740 a_5\DT\13649268 smad3_6\NN\1740 inhibitor_7\NN\20090 delays_8\VBZ\439958 the_9\DT\1740 early_10\JJ\1740 development_11\NN\248977 of_12\IN\1740 <e1>streptozotocin-induced</e1>_13\JJ\1740 <e2>diabetic_14\JJ\1740 nephropathy</e2>_15\NN\14573196 ._16\.\1740
D013311_D003928 CID blocking_0\NN\562280 studies_1\NNS\635850 using_2\VBG\1156834 receptor_3\NN\5225602 for_4\IN\1740 age_5\NN\4916342 sirna_6\NN\1740 and_7\CC\1740 a_8\DT\13649268 specific_9\JJ\1740 inhibitor_10\NN\20090 of_11\IN\1740 smad3_12\NN\1740 (_13\-LRB-\1740 sis3_14\NN\1740 )_15\-RRB-\1740 were_16\VBD\836236 performed_17\VBN\2367363 in_18\IN\13603305 mmecs_19\NNS\1740 and_20\CC\1740 in_21\IN\13603305 <e1>stz-induced</e1>_22\JJ\1740 <e2>diabetic_23\JJ\1740 nephropathy</e2>_24\NN\14573196 in_25\IN\13603305 tie2-cre;loxp-egfp_26\NN\1740 mice_27\NNS\2329401 ._28\.\1740
D013311_D003928 CID immunoprecipitation/western_0\NN\1740 blotting_1\NN\1740 showed_2\VBD\2137132 that_3\IN\1740 smad3_4\NN\1740 was_5\VBD\836236 activated_6\VBN\1641914 by_7\IN\1740 ages_8\NN\4916342 but_9\CC\1740 was_10\VBD\836236 inhibited_11\VBN\2510337 by_12\IN\1740 sis3_13\NN\1740 in_14\IN\13603305 mmecs_15\NNS\1740 and_16\CC\1740 in_17\IN\13603305 <e1>stz-induced</e1>_18\JJ\1740 <e2>diabetic_19\JJ\1740 nephropathy</e2>_20\NN\14573196 ._21\.\1740
D000804_D003922 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 multicenter_3\NN\1740 ,_4\,\1740 controlled_5\VBN\2422663 trial_6\NN\786195 showed_7\VBD\2137132 that_8\IN\1740 early_9\JJ\1740 blockade_10\NN\952963 of_11\IN\1740 the_12\DT\1740 <e1>renin-angiotensin</e1>_13\JJ\1740 system_14\NN\3575240 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>type_18\NN\5839024 1_19\CD\13741022 diabetes</e2>_20\NNS\14075199 and_21\CC\1740 normoalbuminuria_22\NN\1740 did_23\VBD\1640855 not_24\RB\1740 retard_25\VB\438495 the_26\DT\1740 progression_27\NN\8457976 of_28\IN\1740 nephropathy_29\NN\14573196 ,_30\,\1740 suggesting_31\VBG\1010118 that_32\IN\1740 other_33\JJ\1740 mechanism(s_34\NN\1740 )_35\-RRB-\1740 are_36\VBP\836236 involved_37\VBN\2676054 in_38\IN\13603305 the_39\DT\1740 pathogenesis_40\NN\13533470 of_41\IN\1740 early_42\JJ\1740 diabetic_43\JJ\1740 nephropathy_44\NN\14573196 (_45\-LRB-\1740 diabetic_46\JJ\1740 nephropathy_47\NN\14573196 )_48\-RRB-\1740 ._49\.\1740
D000804_D007674 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 multicenter_3\NN\1740 ,_4\,\1740 controlled_5\VBN\2422663 trial_6\NN\786195 showed_7\VBD\2137132 that_8\IN\1740 early_9\JJ\1740 blockade_10\NN\952963 of_11\IN\1740 the_12\DT\1740 <e1>renin-angiotensin</e1>_13\JJ\1740 system_14\NN\3575240 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 type_18\NN\5839024 1_19\CD\13741022 diabetes_20\NNS\14075199 and_21\CC\1740 normoalbuminuria_22\NN\1740 did_23\VBD\1640855 not_24\RB\1740 retard_25\VB\438495 the_26\DT\1740 progression_27\NN\8457976 of_28\IN\1740 <e2>nephropathy</e2>_29\NN\14573196 ,_30\,\1740 suggesting_31\VBG\1010118 that_32\IN\1740 other_33\JJ\1740 mechanism(s_34\NN\1740 )_35\-RRB-\1740 are_36\VBP\836236 involved_37\VBN\2676054 in_38\IN\13603305 the_39\DT\1740 pathogenesis_40\NN\13533470 of_41\IN\1740 early_42\JJ\1740 diabetic_43\JJ\1740 nephropathy_44\NN\14573196 (_45\-LRB-\1740 diabetic_46\JJ\1740 nephropathy_47\NN\14573196 )_48\-RRB-\1740 ._49\.\1740
D000804_D003928 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 multicenter_3\NN\1740 ,_4\,\1740 controlled_5\VBN\2422663 trial_6\NN\786195 showed_7\VBD\2137132 that_8\IN\1740 early_9\JJ\1740 blockade_10\NN\952963 of_11\IN\1740 the_12\DT\1740 <e1>renin-angiotensin</e1>_13\JJ\1740 system_14\NN\3575240 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 type_18\NN\5839024 1_19\CD\13741022 diabetes_20\NNS\14075199 and_21\CC\1740 normoalbuminuria_22\NN\1740 did_23\VBD\1640855 not_24\RB\1740 retard_25\VB\438495 the_26\DT\1740 progression_27\NN\8457976 of_28\IN\1740 nephropathy_29\NN\14573196 ,_30\,\1740 suggesting_31\VBG\1010118 that_32\IN\1740 other_33\JJ\1740 mechanism(s_34\NN\1740 )_35\-RRB-\1740 are_36\VBP\836236 involved_37\VBN\2676054 in_38\IN\13603305 the_39\DT\1740 pathogenesis_40\NN\13533470 of_41\IN\1740 early_42\JJ\1740 <e2>diabetic_43\JJ\1740 nephropathy</e2>_44\NN\14573196 (_45\-LRB-\1740 diabetic_46\JJ\1740 nephropathy_47\NN\14573196 )_48\-RRB-\1740 ._49\.\1740
D000804_D003928 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 multicenter_3\NN\1740 ,_4\,\1740 controlled_5\VBN\2422663 trial_6\NN\786195 showed_7\VBD\2137132 that_8\IN\1740 early_9\JJ\1740 blockade_10\NN\952963 of_11\IN\1740 the_12\DT\1740 <e1>renin-angiotensin</e1>_13\JJ\1740 system_14\NN\3575240 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 type_18\NN\5839024 1_19\CD\13741022 diabetes_20\NNS\14075199 and_21\CC\1740 normoalbuminuria_22\NN\1740 did_23\VBD\1640855 not_24\RB\1740 retard_25\VB\438495 the_26\DT\1740 progression_27\NN\8457976 of_28\IN\1740 nephropathy_29\NN\14573196 ,_30\,\1740 suggesting_31\VBG\1010118 that_32\IN\1740 other_33\JJ\1740 mechanism(s_34\NN\1740 )_35\-RRB-\1740 are_36\VBP\836236 involved_37\VBN\2676054 in_38\IN\13603305 the_39\DT\1740 pathogenesis_40\NN\13533470 of_41\IN\1740 early_42\JJ\1740 diabetic_43\JJ\1740 nephropathy_44\NN\14573196 (_45\-LRB-\1740 <e2>diabetic_46\JJ\1740 nephropathy</e2>_47\NN\14573196 )_48\-RRB-\1740 ._49\.\1740
D013311_D005355 NONE we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 demonstrated_3\VBN\2137132 that_4\IN\1740 endothelial-mesenchymal-transition_5\NN\1740 (_6\-LRB-\1740 endomt_7\NN\1740 )_8\-RRB-\1740 contributes_9\VBZ\126264 to_10\TO\1740 the_11\DT\1740 early_12\JJ\1740 development_13\NN\248977 of_14\IN\1740 renal_15\JJ\1740 interstitial_16\JJ\1740 <e2>fibrosis</e2>_17\NN\14204950 independently_18\RB\1740 of_19\IN\1740 microalbuminuria_20\NN\1740 in_21\IN\13603305 mice_22\NNS\2329401 with_23\IN\1740 <e1>streptozotocin</e1>_24\NN\1740 (stz)-induced_25\VBN\1740 diabetes_26\NNS\14075199 ._27\.\1740
D013311_D005355 NONE we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 demonstrated_3\VBN\2137132 that_4\IN\1740 endothelial-mesenchymal-transition_5\NN\1740 (_6\-LRB-\1740 endomt_7\NN\1740 )_8\-RRB-\1740 contributes_9\VBZ\126264 to_10\TO\1740 the_11\DT\1740 early_12\JJ\1740 development_13\NN\248977 of_14\IN\1740 renal_15\JJ\1740 interstitial_16\JJ\1740 <e2>fibrosis</e2>_17\NN\14204950 independently_18\RB\1740 of_19\IN\1740 microalbuminuria_20\NN\1740 in_21\IN\13603305 mice_22\NNS\2329401 with_23\IN\1740 streptozotocin_24\NN\1740 <e1>(stz)-induced</e1>_25\VBN\1740 diabetes_26\NNS\14075199 ._27\.\1740
D013311_D003920 NONE we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 demonstrated_3\VBN\2137132 that_4\IN\1740 endothelial-mesenchymal-transition_5\NN\1740 (_6\-LRB-\1740 endomt_7\NN\1740 )_8\-RRB-\1740 contributes_9\VBZ\126264 to_10\TO\1740 the_11\DT\1740 early_12\JJ\1740 development_13\NN\248977 of_14\IN\1740 renal_15\JJ\1740 interstitial_16\JJ\1740 fibrosis_17\NN\14204950 independently_18\RB\1740 of_19\IN\1740 microalbuminuria_20\NN\1740 in_21\IN\13603305 mice_22\NNS\2329401 with_23\IN\1740 <e1>streptozotocin</e1>_24\NN\1740 (stz)-induced_25\VBN\1740 <e2>diabetes</e2>_26\NNS\14075199 ._27\.\1740
D013311_D003920 NONE we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 demonstrated_3\VBN\2137132 that_4\IN\1740 endothelial-mesenchymal-transition_5\NN\1740 (_6\-LRB-\1740 endomt_7\NN\1740 )_8\-RRB-\1740 contributes_9\VBZ\126264 to_10\TO\1740 the_11\DT\1740 early_12\JJ\1740 development_13\NN\248977 of_14\IN\1740 renal_15\JJ\1740 interstitial_16\JJ\1740 fibrosis_17\NN\14204950 independently_18\RB\1740 of_19\IN\1740 microalbuminuria_20\NN\1740 in_21\IN\13603305 mice_22\NNS\2329401 with_23\IN\1740 streptozotocin_24\NN\1740 <e1>(stz)-induced</e1>_25\VBN\1740 <e2>diabetes</e2>_26\NNS\14075199 ._27\.\1740
18189308
D003520_D003556 CID p75ntr_0\NN\1740 expression_1\NN\4679549 in_2\IN\13603305 rat_3\NN\2329401 urinary_4\JJ\1740 bladder_5\NN\5515670 sensory_6\JJ\1740 neurons_7\NNS\5430628 and_8\CC\1740 spinal_9\JJ\1740 cord_10\NN\3670849 with_11\IN\1740 <e1>cyclophosphamide-induced</e1>_12\JJ\1740 <e2>cystitis</e2>_13\NN\14566129 ._14\.\1740
D003520_D003556 CID the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 examine_3\VBP\789138 the_4\DT\1740 expression_5\NN\4679549 and_6\CC\1740 regulation_7\NN\6652242 of_8\IN\1740 another_9\DT\1740 receptor_10\NN\5225602 known_11\VBN\2110220 to_12\TO\1740 bind_13\VB\1290422 ngf_14\NN\14734348 ,_15\,\1740 p75(ntr_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 after_19\IN\1740 various_20\JJ\1740 durations_21\NNS\15113229 of_22\IN\1740 <e2>bladder_23\NN\5515670 inflammation</e2>_24\NN\14299637 induced_25\VBN\1627355 by_26\IN\1740 <e1>cyclophosphamide</e1>_27\NN\1740 (_28\-LRB-\1740 cyp_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D003520_D003556 CID the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 examine_3\VBP\789138 the_4\DT\1740 expression_5\NN\4679549 and_6\CC\1740 regulation_7\NN\6652242 of_8\IN\1740 another_9\DT\1740 receptor_10\NN\5225602 known_11\VBN\2110220 to_12\TO\1740 bind_13\VB\1290422 ngf_14\NN\14734348 ,_15\,\1740 p75(ntr_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 after_19\IN\1740 various_20\JJ\1740 durations_21\NNS\15113229 of_22\IN\1740 <e2>bladder_23\NN\5515670 inflammation</e2>_24\NN\14299637 induced_25\VBN\1627355 by_26\IN\1740 cyclophosphamide_27\NN\1740 (_28\-LRB-\1740 <e1>cyp</e1>_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D003520_D003556 CID <e1>cyp-induced</e1>_0\JJ\1740 <e2>cystitis</e2>_1\NN\14566129 increased_2\VBD\169651 (_3\-LRB-\1740 p_4\NN\14622893 <_5\NN\1740 or_6\CC\3541091 =_7\JJ\1740 0.001_8\CD\1740 )_9\-RRB-\1740 p75(ntr_10\FW\1740 )_11\-RRB-\1740 expression_12\NN\4679549 in_13\IN\13603305 the_14\DT\1740 superficial_15\JJ\1740 lateral_16\JJ\1740 and_17\CC\1740 medial_18\JJ\1740 dorsal_19\NN\1740 horn_20\NN\3827536 in_21\IN\13603305 l1-l2_22\NN\1740 and_23\CC\1740 l6-s1_24\JJ\1740 spinal_25\JJ\1740 segments_26\NNS\3892891 ._27\.\1740
D003520_D003556 CID the_0\DT\1740 number_1\NN\5107765 of_2\IN\1740 p75(ntr)-immunoreactive_3\NN\1740 (_4\-LRB-\1740 -ir_5\NN\1740 )_6\-RRB-\1740 cells_7\NNS\3080309 in_8\IN\13603305 the_9\DT\1740 lumbosacral_10\JJ\1740 dorsal_11\NN\1740 root_12\NN\13087625 ganglia_13\NN\5462674 (_14\-LRB-\1740 drg_15\NN\1740 )_16\-RRB-\1740 also_17\RB\1740 increased_18\VBD\169651 (_19\-LRB-\1740 p_20\NN\14622893 <_21\NN\1740 or_22\CC\3541091 =_23\JJ\1740 0.05_24\CD\1740 )_25\-RRB-\1740 with_26\IN\1740 <e1>cyp-induced</e1>_27\JJ\1740 <e2>cystitis</e2>_28\NN\14566129 (_29\-LRB-\1740 acute_30\JJ\1740 ,_31\,\1740 intermediate_32\JJ\1740 ,_33\,\1740 and_34\CC\1740 chronic_35\JJ\1740 )_36\-RRB-\1740 ._37\.\1740
D003520_D003556 CID quantitative_0\JJ\1740 ,_1\,\1740 real-time_2\JJ\1740 polymerase_3\NN\14732946 chain_4\NN\8457976 reaction_5\NN\13446390 also_6\RB\1740 demonstrated_7\VBD\2137132 significant_8\JJ\1740 increases_9\NNS\13576355 (_10\-LRB-\1740 p_11\NN\14622893 <_12\NN\1740 or_13\CC\3541091 =_14\JJ\1740 0.01_15\CD\1740 )_16\-RRB-\1740 in_17\IN\13603305 p75(ntr_18\NN\1740 )_19\-RRB-\1740 mrna_20\NN\14832193 in_21\IN\13603305 drg_22\NN\1740 with_23\IN\1740 intermediate_24\JJ\1740 and_25\CC\1740 chronic_26\JJ\1740 <e1>cyp-induced</e1>_27\JJ\1740 <e2>cystitis</e2>_28\NN\14566129 ._29\.\1740
D014443_D003556 NONE previous_0\JJ\1740 studies_1\NNS\635850 have_2\VBP\2108377 examined_3\VBN\789138 the_4\DT\1740 expression_5\NN\4679549 and_6\CC\1740 regulation_7\NN\6652242 of_8\IN\1740 <e1>tyrosine</e1>_9\NN\14601829 kinase_10\NN\14732946 receptors_11\NNS\5225602 (_12\-LRB-\1740 trks_13\NNS\1740 )_14\-RRB-\1740 in_15\IN\13603305 micturition_16\NN\13473097 reflexes_17\NNS\859001 with_18\IN\1740 <e2>urinary_19\JJ\1740 bladder_20\NN\5515670 inflammation</e2>_21\NN\14299637 ._22\.\1740
9428298
D000420_D001249 NONE continuously_0\RB\1740 nebulized_1\JJ\1740 <e1>albuterol</e1>_2\NN\2905612 in_3\IN\13603305 severe_4\JJ\1740 exacerbations_5\NNS\374224 of_6\IN\1740 <e2>asthma</e2>_7\NN\14145095 in_8\IN\13603305 adults_9\NNS\7846 :_10\:\1740 a_11\DT\13649268 case-controlled_12\JJ\1740 study_13\NN\635850 ._14\.\1740
D000420_D001249 NONE a_0\DT\13649268 retrospective_1\JJ\1740 ,_2\,\1740 case-controlled_3\JJ\1740 analysis_4\NN\633864 comparing_5\VBG\644583 patients_6\NNS\9898892 admitted_7\VBN\822367 to_8\TO\1740 a_9\DT\13649268 medical_10\JJ\1740 intensive_11\JJ\1740 care_12\NN\575741 unit_13\NN\13576101 with_14\IN\1740 severe_15\JJ\1740 exacerbations_16\NNS\374224 of_17\IN\1740 <e2>asthma</e2>_18\NN\14145095 who_19\WP\8299493 received_20\VBD\2210855 continuously_21\RB\1740 nebulized_22\JJ\1740 <e1>albuterol</e1>_23\NN\2905612 (_24\-LRB-\1740 cna_25\NN\1740 )_26\-RRB-\1740 versus_27\CC\1740 intermittent_28\JJ\1740 albuterol_29\NN\2905612 (_30\-LRB-\1740 ina_31\NN\1740 )_32\-RRB-\1740 treatments_33\NNS\654885 is_34\VBZ\836236 reported_35\VBN\831651 ._36\.\1740
D000420_D001249 NONE a_0\DT\13649268 retrospective_1\JJ\1740 ,_2\,\1740 case-controlled_3\JJ\1740 analysis_4\NN\633864 comparing_5\VBG\644583 patients_6\NNS\9898892 admitted_7\VBN\822367 to_8\TO\1740 a_9\DT\13649268 medical_10\JJ\1740 intensive_11\JJ\1740 care_12\NN\575741 unit_13\NN\13576101 with_14\IN\1740 severe_15\JJ\1740 exacerbations_16\NNS\374224 of_17\IN\1740 <e2>asthma</e2>_18\NN\14145095 who_19\WP\8299493 received_20\VBD\2210855 continuously_21\RB\1740 nebulized_22\JJ\1740 albuterol_23\NN\2905612 (_24\-LRB-\1740 cna_25\NN\1740 )_26\-RRB-\1740 versus_27\CC\1740 intermittent_28\JJ\1740 <e1>albuterol</e1>_29\NN\2905612 (_30\-LRB-\1740 ina_31\NN\1740 )_32\-RRB-\1740 treatments_33\NNS\654885 is_34\VBZ\836236 reported_35\VBN\831651 ._36\.\1740
16369751
D005472_D066126 NONE <e1>5-fluorouracil</e1>_0\NN\1740 <e2>cardiotoxicity</e2>_1\NN\1740 induced_2\VBN\1627355 by_3\IN\1740 alpha-fluoro-beta-alanine_4\NN\1740 ._5\.\1740
D005472_D066126 NONE <e2>cardiotoxicity</e2>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 rare_3\JJ\1740 complication_4\NN\1073995 occurring_5\VBG\2623529 during_6\IN\1740 <e1>5-fluorouracil</e1>_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 treatment_11\NN\654885 for_12\IN\1740 malignancies_13\NNS\14070360 ._14\.\1740
D005472_D066126 NONE <e2>cardiotoxicity</e2>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 rare_3\JJ\1740 complication_4\NN\1073995 occurring_5\VBG\2623529 during_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 <e1>5-fu</e1>_9\NN\1740 )_10\-RRB-\1740 treatment_11\NN\654885 for_12\IN\1740 malignancies_13\NNS\14070360 ._14\.\1740
D005472_D066126 NONE we_0\PRP\1740 herein_1\RB\1740 report_2\VBP\831651 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 70-year-old_7\JJ\1740 man_8\NN\9605289 with_9\IN\1740 <e1>5-fu-induced</e1>_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 ,_12\,\1740 in_13\IN\13603305 whom_14\WP\1740 a_15\DT\13649268 high_16\JJ\1740 serum_17\NN\5397468 level_18\NN\4916342 of_19\IN\1740 alpha-fluoro-beta-alanine_20\NN\1740 (_21\-LRB-\1740 fbal_22\RB\1740 )_23\-RRB-\1740 was_24\VBD\836236 observed_25\VBN\2163746 ._26\.\1740
D005472_D066126 NONE as_0\IN\14622893 the_1\DT\1740 precordial_2\JJ\1740 pain_3\NN\14299637 in_4\IN\13603305 this_5\DT\1740 patient_6\NN\9898892 was_7\VBD\836236 considered_8\VBN\689344 to_9\TO\1740 have_10\VB\2108377 been_11\VBN\836236 due_12\JJ\1740 to_13\TO\1740 <e1>5-fu-induced</e1>_14\JJ\1740 <e2>cardiotoxicity</e2>_15\NN\1740 ,_16\,\1740 the_17\DT\1740 administration_18\NN\1133281 of_19\IN\1740 5-fu_20\NN\1740 was_21\VBD\836236 abandoned_22\VBN\2222318 ._23\.\1740
D005472_D066126 NONE as_0\IN\14622893 the_1\DT\1740 precordial_2\JJ\1740 pain_3\NN\14299637 in_4\IN\13603305 this_5\DT\1740 patient_6\NN\9898892 was_7\VBD\836236 considered_8\VBN\689344 to_9\TO\1740 have_10\VB\2108377 been_11\VBN\836236 due_12\JJ\1740 to_13\TO\1740 5-fu-induced_14\JJ\1740 <e2>cardiotoxicity</e2>_15\NN\1740 ,_16\,\1740 the_17\DT\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>5-fu</e1>_20\NN\1740 was_21\VBD\836236 abandoned_22\VBN\2222318 ._23\.\1740
D005472_D066126 NONE the_0\DT\1740 experience_1\NN\5984287 of_2\IN\1740 this_3\DT\1740 case_4\NN\7283608 ,_5\,\1740 together_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 review_9\NN\5733583 of_10\IN\1740 the_11\DT\1740 literature_12\NN\6362953 ,_13\,\1740 suggests_14\VBZ\1010118 that_15\IN\1740 fbal_16\DT\1740 is_17\VBZ\836236 related_18\JJ\1740 to_19\TO\1740 <e1>5-fu-induced</e1>_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 ._22\.\1740
D005472_D066126 NONE s-1_0\NN\1740 may_1\MD\15209706 be_2\VB\836236 administered_3\VBN\2436349 safely_4\RB\1740 to_5\TO\1740 patients_6\NNS\9898892 with_7\IN\1740 <e1>5-fu-induced</e1>_8\JJ\1740 <e2>cardiotoxicity</e2>_9\NN\1740 ._10\.\1740
C032348_D066126 NONE 5-fluorouracil_0\NN\1740 <e2>cardiotoxicity</e2>_1\NN\1740 induced_2\VBN\1627355 by_3\IN\1740 <e1>alpha-fluoro-beta-alanine</e1>_4\NN\1740 ._5\.\1740
C032348_D066126 NONE we_0\PRP\1740 herein_1\RB\1740 report_2\VBP\831651 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 70-year-old_7\JJ\1740 man_8\NN\9605289 with_9\IN\1740 5-fu-induced_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 ,_12\,\1740 in_13\IN\13603305 whom_14\WP\1740 a_15\DT\13649268 high_16\JJ\1740 serum_17\NN\5397468 level_18\NN\4916342 of_19\IN\1740 <e1>alpha-fluoro-beta-alanine</e1>_20\NN\1740 (_21\-LRB-\1740 fbal_22\RB\1740 )_23\-RRB-\1740 was_24\VBD\836236 observed_25\VBN\2163746 ._26\.\1740
C032348_D066126 NONE we_0\PRP\1740 herein_1\RB\1740 report_2\VBP\831651 the_3\DT\1740 case_4\NN\7283608 of_5\IN\1740 a_6\DT\13649268 70-year-old_7\JJ\1740 man_8\NN\9605289 with_9\IN\1740 5-fu-induced_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 ,_12\,\1740 in_13\IN\13603305 whom_14\WP\1740 a_15\DT\13649268 high_16\JJ\1740 serum_17\NN\5397468 level_18\NN\4916342 of_19\IN\1740 alpha-fluoro-beta-alanine_20\NN\1740 (_21\-LRB-\1740 <e1>fbal</e1>_22\RB\1740 )_23\-RRB-\1740 was_24\VBD\836236 observed_25\VBN\2163746 ._26\.\1740
C032348_D066126 NONE the_0\DT\1740 experience_1\NN\5984287 of_2\IN\1740 this_3\DT\1740 case_4\NN\7283608 ,_5\,\1740 together_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 review_9\NN\5733583 of_10\IN\1740 the_11\DT\1740 literature_12\NN\6362953 ,_13\,\1740 suggests_14\VBZ\1010118 that_15\IN\1740 <e1>fbal</e1>_16\DT\1740 is_17\VBZ\836236 related_18\JJ\1740 to_19\TO\1740 5-fu-induced_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 ._22\.\1740
D005472_D009369 NONE cardiotoxicity_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 rare_3\JJ\1740 complication_4\NN\1073995 occurring_5\VBG\2623529 during_6\IN\1740 <e1>5-fluorouracil</e1>_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 treatment_11\NN\654885 for_12\IN\1740 <e2>malignancies</e2>_13\NNS\14070360 ._14\.\1740
D005472_D009369 NONE cardiotoxicity_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 rare_3\JJ\1740 complication_4\NN\1073995 occurring_5\VBG\2623529 during_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 <e1>5-fu</e1>_9\NN\1740 )_10\-RRB-\1740 treatment_11\NN\654885 for_12\IN\1740 <e2>malignancies</e2>_13\NNS\14070360 ._14\.\1740
D005472_D002637 CID after_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 the_3\DT\1740 patient_4\NN\9898892 received_5\VBD\2210855 a_6\DT\13649268 continuous_7\JJ\1740 intravenous_8\JJ\1740 infusion_9\NN\14589223 of_10\IN\1740 <e1>5-fu</e1>_11\NN\1740 (_12\-LRB-\1740 1000_13\CD\13745420 mg/day_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 during_17\IN\1740 which_18\WDT\1740 <e2>precordial_19\JJ\1740 pain</e2>_20\NN\14299637 with_21\IN\1740 right_22\JJ\1740 bundle_23\NN\7951464 branch_24\NN\8220714 block_25\NN\21939 occurred_26\VBD\2623529 concomitantly_27\RB\1740 with_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 serum_31\NN\5397468 fbal_32\NN\1740 concentration_33\NN\4916342 of_34\IN\1740 1955_35\CD\1740 ng/ml_36\NN\1740 ._37\.\1740
D005472_D002637 CID both_0\CC\1740 the_1\DT\1740 <e2>precordial_2\JJ\1740 pain</e2>_3\NN\14299637 and_4\CC\1740 the_5\DT\1740 electrocardiographic_6\JJ\1740 changes_7\NNS\7283608 disappeared_8\VBD\2609764 spontaneously_9\RB\1740 after_10\IN\1740 the_11\DT\1740 discontinuation_12\NN\209943 of_13\IN\1740 <e1>5-fu</e1>_14\NN\1740 ._15\.\1740
D005472_D002637 CID as_0\IN\14622893 the_1\DT\1740 <e2>precordial_2\JJ\1740 pain</e2>_3\NN\14299637 in_4\IN\13603305 this_5\DT\1740 patient_6\NN\9898892 was_7\VBD\836236 considered_8\VBN\689344 to_9\TO\1740 have_10\VB\2108377 been_11\VBN\836236 due_12\JJ\1740 to_13\TO\1740 <e1>5-fu-induced</e1>_14\JJ\1740 cardiotoxicity_15\NN\1740 ,_16\,\1740 the_17\DT\1740 administration_18\NN\1133281 of_19\IN\1740 5-fu_20\NN\1740 was_21\VBD\836236 abandoned_22\VBN\2222318 ._23\.\1740
D005472_D002637 CID as_0\IN\14622893 the_1\DT\1740 <e2>precordial_2\JJ\1740 pain</e2>_3\NN\14299637 in_4\IN\13603305 this_5\DT\1740 patient_6\NN\9898892 was_7\VBD\836236 considered_8\VBN\689344 to_9\TO\1740 have_10\VB\2108377 been_11\VBN\836236 due_12\JJ\1740 to_13\TO\1740 5-fu-induced_14\JJ\1740 cardiotoxicity_15\NN\1740 ,_16\,\1740 the_17\DT\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>5-fu</e1>_20\NN\1740 was_21\VBD\836236 abandoned_22\VBN\2222318 ._23\.\1740
D005472_D002037 CID after_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 the_3\DT\1740 patient_4\NN\9898892 received_5\VBD\2210855 a_6\DT\13649268 continuous_7\JJ\1740 intravenous_8\JJ\1740 infusion_9\NN\14589223 of_10\IN\1740 <e1>5-fu</e1>_11\NN\1740 (_12\-LRB-\1740 1000_13\CD\13745420 mg/day_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 during_17\IN\1740 which_18\WDT\1740 precordial_19\JJ\1740 pain_20\NN\14299637 with_21\IN\1740 <e2>right_22\JJ\1740 bundle_23\NN\7951464 branch_24\NN\8220714 block</e2>_25\NN\21939 occurred_26\VBD\2623529 concomitantly_27\RB\1740 with_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 serum_31\NN\5397468 fbal_32\NN\1740 concentration_33\NN\4916342 of_34\IN\1740 1955_35\CD\1740 ng/ml_36\NN\1740 ._37\.\1740
C032348_D002637 NONE after_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 the_3\DT\1740 patient_4\NN\9898892 received_5\VBD\2210855 a_6\DT\13649268 continuous_7\JJ\1740 intravenous_8\JJ\1740 infusion_9\NN\14589223 of_10\IN\1740 5-fu_11\NN\1740 (_12\-LRB-\1740 1000_13\CD\13745420 mg/day_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 during_17\IN\1740 which_18\WDT\1740 <e2>precordial_19\JJ\1740 pain</e2>_20\NN\14299637 with_21\IN\1740 right_22\JJ\1740 bundle_23\NN\7951464 branch_24\NN\8220714 block_25\NN\21939 occurred_26\VBD\2623529 concomitantly_27\RB\1740 with_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 serum_31\NN\5397468 <e1>fbal</e1>_32\NN\1740 concentration_33\NN\4916342 of_34\IN\1740 1955_35\CD\1740 ng/ml_36\NN\1740 ._37\.\1740
C032348_D002037 NONE after_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 the_3\DT\1740 patient_4\NN\9898892 received_5\VBD\2210855 a_6\DT\13649268 continuous_7\JJ\1740 intravenous_8\JJ\1740 infusion_9\NN\14589223 of_10\IN\1740 5-fu_11\NN\1740 (_12\-LRB-\1740 1000_13\CD\13745420 mg/day_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 during_17\IN\1740 which_18\WDT\1740 precordial_19\JJ\1740 pain_20\NN\14299637 with_21\IN\1740 <e2>right_22\JJ\1740 bundle_23\NN\7951464 branch_24\NN\8220714 block</e2>_25\NN\21939 occurred_26\VBD\2623529 concomitantly_27\RB\1740 with_28\IN\1740 a_29\DT\13649268 high_30\JJ\1740 serum_31\NN\5397468 <e1>fbal</e1>_32\NN\1740 concentration_33\NN\4916342 of_34\IN\1740 1955_35\CD\1740 ng/ml_36\NN\1740 ._37\.\1740
3708328
D010862_D012640 CID susceptibility_0\NN\13920835 to_1\TO\1740 <e2>seizures</e2>_2\NNS\14081375 produced_3\VBN\1617192 by_4\IN\1740 <e1>pilocarpine</e1>_5\NN\14712692 in_6\IN\13603305 rats_7\NNS\2329401 after_8\IN\1740 microinjection_9\NN\1740 of_10\IN\1740 isoniazid_11\NNS\2716205 or_12\CC\3541091 gamma-vinyl-gaba_13\NN\1740 into_14\IN\1740 the_15\DT\1740 substantia_16\NN\1740 nigra_17\JJ\1740 ._18\.\1740
D010862_D012640 CID <e1>pilocarpine</e1>_0\NN\14712692 ,_1\,\1740 given_2\VBN\2327200 intraperitoneally_3\RB\1740 to_4\TO\1740 rats_5\NNS\2329401 ,_6\,\1740 reproduces_7\VBZ\1621555 the_8\DT\1740 neuropathological_9\JJ\1740 sequelae_10\NN\14501726 of_11\IN\1740 temporal_12\JJ\1740 lobe_13\VBN\1740 epilepsy_14\NN\14085708 and_15\CC\1740 provides_16\VBZ\2199590 a_17\DT\13649268 relevant_18\JJ\1740 animal_19\NN\4475 model_20\NN\5888929 for_21\IN\1740 studying_22\VBG\630380 mechanisms_23\NNS\13446390 of_24\IN\1740 buildup_25\NN\372013 of_26\IN\1740 <e2>convulsive</e2>_27\JJ\1740 activity_28\NN\30358 and_29\CC\1740 pathways_30\NNS\5483677 operative_31\JJ\1740 in_32\IN\13603305 the_33\DT\1740 generalization_34\NN\5764197 and_35\CC\1740 propagation_36\NN\6253140 of_37\IN\1740 seizures_38\NNS\14081375 within_39\IN\1740 the_40\DT\1740 forebrain_41\NN\5462674 ._42\.\1740
D010862_D012640 CID <e1>pilocarpine</e1>_0\NN\14712692 ,_1\,\1740 given_2\VBN\2327200 intraperitoneally_3\RB\1740 to_4\TO\1740 rats_5\NNS\2329401 ,_6\,\1740 reproduces_7\VBZ\1621555 the_8\DT\1740 neuropathological_9\JJ\1740 sequelae_10\NN\14501726 of_11\IN\1740 temporal_12\JJ\1740 lobe_13\VBN\1740 epilepsy_14\NN\14085708 and_15\CC\1740 provides_16\VBZ\2199590 a_17\DT\13649268 relevant_18\JJ\1740 animal_19\NN\4475 model_20\NN\5888929 for_21\IN\1740 studying_22\VBG\630380 mechanisms_23\NNS\13446390 of_24\IN\1740 buildup_25\NN\372013 of_26\IN\1740 convulsive_27\JJ\1740 activity_28\NN\30358 and_29\CC\1740 pathways_30\NNS\5483677 operative_31\JJ\1740 in_32\IN\13603305 the_33\DT\1740 generalization_34\NN\5764197 and_35\CC\1740 propagation_36\NN\6253140 of_37\IN\1740 <e2>seizures</e2>_38\NNS\14081375 within_39\IN\1740 the_40\DT\1740 forebrain_41\NN\5462674 ._42\.\1740
D010862_D012640 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 manipulating_8\VBG\2536557 the_9\DT\1740 activity_10\NN\30358 of_11\IN\1740 the_12\DT\1740 gamma-aminobutyric_13\JJ\1740 acid_14\NN\14818238 (gaba)-mediated_15\JJ\1740 synaptic_16\JJ\1740 inhibition_17\NN\1068773 within_18\IN\1740 the_19\DT\1740 substantia_20\NN\1740 nigra_21\JJ\1740 on_22\IN\1740 <e2>seizures</e2>_23\NNS\14081375 produced_24\VBN\1617192 by_25\IN\1740 <e1>pilocarpine</e1>_26\NN\14712692 in_27\IN\13603305 rats_28\NNS\2329401 ,_29\,\1740 were_30\VBD\836236 investigated_31\VBN\644583 ._32\.\1740
D010862_D012640 CID in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 isoniazid_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 gaba-synthesizing_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 l-glutamic_20\JJ\1740 acid_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 <e1>pilocarpine</e1>_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 <e2>seizures</e2>_51\NNS\14081375 and_52\CC\1740 status_53\NN\24720 epilepticus_54\NN\1740 ._55\.\1740
D010862_D012640 CID electroencephalographic_0\NNP\1740 and_1\CC\1740 behavioral_2\JJ\1740 monitoring_3\NN\879759 revealed_4\VBD\2137132 a_5\DT\13649268 profound_6\JJ\1740 reduction_7\NN\351485 of_8\IN\1740 the_9\DT\1740 threshold_10\NN\15265518 for_11\IN\1740 <e1>pilocarpine-induced</e1>_12\JJ\1740 <e2>convulsions</e2>_13\NNS\14081375 ._14\.\1740
D010862_D012640 CID morphological_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 frontal_3\JJ\1740 forebrain_4\NN\5462674 sections_5\NNS\7020895 with_6\IN\1740 light_7\JJ\1740 microscopy_8\NN\636921 revealed_9\VBD\2137132 <e2>seizure-related</e2>_10\JJ\1740 damage_11\NN\7296428 to_12\IN\1740 the_13\DT\1740 hippocampal_14\NN\1740 formation_15\NN\7938773 ,_16\,\1740 thalamus_17\NN\5462674 ,_18\,\1740 amygdala_19\JJ\1740 ,_20\,\1740 olfactory_21\JJ\1740 cortex_22\NN\5462674 ,_23\,\1740 substantia_24\RB\1740 nigra_25\JJ\1740 and_26\CC\1740 neocortex_27\NN\5486510 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 typically_31\RB\1740 observed_32\VBN\2163746 with_33\IN\1740 <e1>pilocarpine</e1>_34\NN\14712692 in_35\IN\13603305 doses_36\NNS\3740161 exceeding_37\VBG\2673965 350_38\CD\1740 mg/kg_39\NN\1740 ._40\.\1740
D010862_D012640 CID bilateral_0\JJ\1740 intrastriatal_1\JJ\1740 injections_2\NNS\320852 of_3\IN\1740 isoniazid_4\NNS\2716205 did_5\VBD\1640855 not_6\RB\1740 augment_7\VB\153263 <e2>seizures</e2>_8\NNS\14081375 produced_9\VBN\1617192 by_10\IN\1740 <e1>pilocarpine</e1>_11\NN\14712692 ,_12\,\1740 200_13\CD\1740 mg/kg_14\NN\1740 ._15\.\1740
D010862_D012640 CID application_0\NN\947128 of_1\IN\1740 an_2\DT\6697703 irreversible_3\JJ\1740 inhibitor_4\NN\20090 of_5\IN\1740 gaba_6\NN\14601829 transaminase_7\NN\15077571 ,_8\,\1740 gamma-vinyl-gaba_9\NN\1740 (_10\-LRB-\1740 d_11\NN\15089472 ,_12\,\1740 l-4-amino-hex-5-enoic_13\JJ\1740 acid_14\NN\14818238 )_15\-RRB-\1740 ,_16\,\1740 5_17\CD\13741022 micrograms_18\NNS\13717155 ,_19\,\1740 into_20\IN\1740 the_21\DT\1740 snr_22\NN\1740 ,_23\,\1740 bilaterally_24\RB\1740 ,_25\,\1740 suppressed_26\VBD\2510337 the_27\DT\1740 appearance_28\NN\4723816 of_29\IN\1740 electrographic_30\JJ\1740 and_31\CC\1740 behavioral_32\JJ\1740 <e2>seizures</e2>_33\NNS\14081375 produced_34\VBN\1617192 by_35\IN\1740 <e1>pilocarpine</e1>_36\NN\14712692 ,_37\,\1740 380_38\CD\1740 mg/kg_39\NN\1740 ._40\.\1740
D010862_D012640 CID microinjections_0\NNS\1740 of_1\IN\1740 gamma-vinyl-gaba_2\NN\1740 ,_3\,\1740 5_4\CD\13741022 micrograms_5\NNS\13717155 ,_6\,\1740 into_7\IN\1740 the_8\DT\1740 dorsal_9\NN\1740 striatum_10\NN\5497363 ,_11\,\1740 bilaterally_12\RB\1740 ,_13\,\1740 failed_14\VBD\1798936 to_15\TO\1740 prevent_16\VB\1740 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 <e2>convulsions</e2>_20\NNS\14081375 produced_21\VBN\1617192 by_22\IN\1740 <e1>pilocarpine</e1>_23\NN\14712692 ,_24\,\1740 380_25\CD\1740 mg/kg_26\NN\1740 ._27\.\1740
D010862_D012640 CID the_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 threshold_5\NN\15265518 for_6\IN\1740 <e1>pilocarpine-induced</e1>_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 in_9\IN\13603305 rats_10\NNS\2329401 is_11\VBZ\836236 subjected_12\VBN\137313 to_13\TO\1740 the_14\DT\1740 regulation_15\NN\6652242 of_16\IN\1740 the_17\DT\1740 gaba-mediated_18\JJ\1740 synaptic_19\JJ\1740 inhibition_20\NN\1068773 within_21\IN\1740 the_22\DT\1740 substantia_23\RB\1740 nigra_24\JJ\1740 ._25\.\1740
D007538_D012640 NONE susceptibility_0\NN\13920835 to_1\TO\1740 <e2>seizures</e2>_2\NNS\14081375 produced_3\VBN\1617192 by_4\IN\1740 pilocarpine_5\NN\14712692 in_6\IN\13603305 rats_7\NNS\2329401 after_8\IN\1740 microinjection_9\NN\1740 of_10\IN\1740 <e1>isoniazid</e1>_11\NNS\2716205 or_12\CC\3541091 gamma-vinyl-gaba_13\NN\1740 into_14\IN\1740 the_15\DT\1740 substantia_16\NN\1740 nigra_17\JJ\1740 ._18\.\1740
D007538_D012640 NONE in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 <e1>isoniazid</e1>_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 gaba-synthesizing_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 l-glutamic_20\JJ\1740 acid_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 pilocarpine_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 <e2>seizures</e2>_51\NNS\14081375 and_52\CC\1740 status_53\NN\24720 epilepticus_54\NN\1740 ._55\.\1740
D007538_D012640 NONE bilateral_0\JJ\1740 intrastriatal_1\JJ\1740 injections_2\NNS\320852 of_3\IN\1740 <e1>isoniazid</e1>_4\NNS\2716205 did_5\VBD\1640855 not_6\RB\1740 augment_7\VB\153263 <e2>seizures</e2>_8\NNS\14081375 produced_9\VBN\1617192 by_10\IN\1740 pilocarpine_11\NN\14712692 ,_12\,\1740 200_13\CD\1740 mg/kg_14\NN\1740 ._15\.\1740
D020888_D012640 NONE susceptibility_0\NN\13920835 to_1\TO\1740 <e2>seizures</e2>_2\NNS\14081375 produced_3\VBN\1617192 by_4\IN\1740 pilocarpine_5\NN\14712692 in_6\IN\13603305 rats_7\NNS\2329401 after_8\IN\1740 microinjection_9\NN\1740 of_10\IN\1740 isoniazid_11\NNS\2716205 or_12\CC\3541091 <e1>gamma-vinyl-gaba</e1>_13\NN\1740 into_14\IN\1740 the_15\DT\1740 substantia_16\NN\1740 nigra_17\JJ\1740 ._18\.\1740
D020888_D012640 NONE application_0\NN\947128 of_1\IN\1740 an_2\DT\6697703 irreversible_3\JJ\1740 inhibitor_4\NN\20090 of_5\IN\1740 gaba_6\NN\14601829 transaminase_7\NN\15077571 ,_8\,\1740 <e1>gamma-vinyl-gaba</e1>_9\NN\1740 (_10\-LRB-\1740 d_11\NN\15089472 ,_12\,\1740 l-4-amino-hex-5-enoic_13\JJ\1740 acid_14\NN\14818238 )_15\-RRB-\1740 ,_16\,\1740 5_17\CD\13741022 micrograms_18\NNS\13717155 ,_19\,\1740 into_20\IN\1740 the_21\DT\1740 snr_22\NN\1740 ,_23\,\1740 bilaterally_24\RB\1740 ,_25\,\1740 suppressed_26\VBD\2510337 the_27\DT\1740 appearance_28\NN\4723816 of_29\IN\1740 electrographic_30\JJ\1740 and_31\CC\1740 behavioral_32\JJ\1740 <e2>seizures</e2>_33\NNS\14081375 produced_34\VBN\1617192 by_35\IN\1740 pilocarpine_36\NN\14712692 ,_37\,\1740 380_38\CD\1740 mg/kg_39\NN\1740 ._40\.\1740
D020888_D012640 NONE application_0\NN\947128 of_1\IN\1740 an_2\DT\6697703 irreversible_3\JJ\1740 inhibitor_4\NN\20090 of_5\IN\1740 gaba_6\NN\14601829 transaminase_7\NN\15077571 ,_8\,\1740 gamma-vinyl-gaba_9\NN\1740 (_10\-LRB-\1740 <e1>d_11\NN\15089472 ,_12\,\1740 l-4-amino-hex-5-enoic_13\JJ\1740 acid</e1>_14\NN\14818238 )_15\-RRB-\1740 ,_16\,\1740 5_17\CD\13741022 micrograms_18\NNS\13717155 ,_19\,\1740 into_20\IN\1740 the_21\DT\1740 snr_22\NN\1740 ,_23\,\1740 bilaterally_24\RB\1740 ,_25\,\1740 suppressed_26\VBD\2510337 the_27\DT\1740 appearance_28\NN\4723816 of_29\IN\1740 electrographic_30\JJ\1740 and_31\CC\1740 behavioral_32\JJ\1740 <e2>seizures</e2>_33\NNS\14081375 produced_34\VBN\1617192 by_35\IN\1740 pilocarpine_36\NN\14712692 ,_37\,\1740 380_38\CD\1740 mg/kg_39\NN\1740 ._40\.\1740
D020888_D012640 NONE microinjections_0\NNS\1740 of_1\IN\1740 <e1>gamma-vinyl-gaba</e1>_2\NN\1740 ,_3\,\1740 5_4\CD\13741022 micrograms_5\NNS\13717155 ,_6\,\1740 into_7\IN\1740 the_8\DT\1740 dorsal_9\NN\1740 striatum_10\NN\5497363 ,_11\,\1740 bilaterally_12\RB\1740 ,_13\,\1740 failed_14\VBD\1798936 to_15\TO\1740 prevent_16\VB\1740 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 <e2>convulsions</e2>_20\NNS\14081375 produced_21\VBN\1617192 by_22\IN\1740 pilocarpine_23\NN\14712692 ,_24\,\1740 380_25\CD\1740 mg/kg_26\NN\1740 ._27\.\1740
D010862_D004833 NONE <e1>pilocarpine</e1>_0\NN\14712692 ,_1\,\1740 given_2\VBN\2327200 intraperitoneally_3\RB\1740 to_4\TO\1740 rats_5\NNS\2329401 ,_6\,\1740 reproduces_7\VBZ\1621555 the_8\DT\1740 neuropathological_9\JJ\1740 sequelae_10\NN\14501726 of_11\IN\1740 <e2>temporal_12\JJ\1740 lobe_13\VBN\1740 epilepsy</e2>_14\NN\14085708 and_15\CC\1740 provides_16\VBZ\2199590 a_17\DT\13649268 relevant_18\JJ\1740 animal_19\NN\4475 model_20\NN\5888929 for_21\IN\1740 studying_22\VBG\630380 mechanisms_23\NNS\13446390 of_24\IN\1740 buildup_25\NN\372013 of_26\IN\1740 convulsive_27\JJ\1740 activity_28\NN\30358 and_29\CC\1740 pathways_30\NNS\5483677 operative_31\JJ\1740 in_32\IN\13603305 the_33\DT\1740 generalization_34\NN\5764197 and_35\CC\1740 propagation_36\NN\6253140 of_37\IN\1740 seizures_38\NNS\14081375 within_39\IN\1740 the_40\DT\1740 forebrain_41\NN\5462674 ._42\.\1740
D005680_D012640 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 manipulating_8\VBG\2536557 the_9\DT\1740 activity_10\NN\30358 of_11\IN\1740 the_12\DT\1740 <e1>gamma-aminobutyric_13\JJ\1740 acid</e1>_14\NN\14818238 (gaba)-mediated_15\JJ\1740 synaptic_16\JJ\1740 inhibition_17\NN\1068773 within_18\IN\1740 the_19\DT\1740 substantia_20\NN\1740 nigra_21\JJ\1740 on_22\IN\1740 <e2>seizures</e2>_23\NNS\14081375 produced_24\VBN\1617192 by_25\IN\1740 pilocarpine_26\NN\14712692 in_27\IN\13603305 rats_28\NNS\2329401 ,_29\,\1740 were_30\VBD\836236 investigated_31\VBN\644583 ._32\.\1740
D005680_D012640 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 manipulating_8\VBG\2536557 the_9\DT\1740 activity_10\NN\30358 of_11\IN\1740 the_12\DT\1740 gamma-aminobutyric_13\JJ\1740 acid_14\NN\14818238 <e1>(gaba)-mediated</e1>_15\JJ\1740 synaptic_16\JJ\1740 inhibition_17\NN\1068773 within_18\IN\1740 the_19\DT\1740 substantia_20\NN\1740 nigra_21\JJ\1740 on_22\IN\1740 <e2>seizures</e2>_23\NNS\14081375 produced_24\VBN\1617192 by_25\IN\1740 pilocarpine_26\NN\14712692 in_27\IN\13603305 rats_28\NNS\2329401 ,_29\,\1740 were_30\VBD\836236 investigated_31\VBN\644583 ._32\.\1740
D005680_D012640 NONE in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 isoniazid_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 <e1>gaba-synthesizing</e1>_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 l-glutamic_20\JJ\1740 acid_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 pilocarpine_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 <e2>seizures</e2>_51\NNS\14081375 and_52\CC\1740 status_53\NN\24720 epilepticus_54\NN\1740 ._55\.\1740
D005680_D012640 NONE application_0\NN\947128 of_1\IN\1740 an_2\DT\6697703 irreversible_3\JJ\1740 inhibitor_4\NN\20090 of_5\IN\1740 <e1>gaba</e1>_6\NN\14601829 transaminase_7\NN\15077571 ,_8\,\1740 gamma-vinyl-gaba_9\NN\1740 (_10\-LRB-\1740 d_11\NN\15089472 ,_12\,\1740 l-4-amino-hex-5-enoic_13\JJ\1740 acid_14\NN\14818238 )_15\-RRB-\1740 ,_16\,\1740 5_17\CD\13741022 micrograms_18\NNS\13717155 ,_19\,\1740 into_20\IN\1740 the_21\DT\1740 snr_22\NN\1740 ,_23\,\1740 bilaterally_24\RB\1740 ,_25\,\1740 suppressed_26\VBD\2510337 the_27\DT\1740 appearance_28\NN\4723816 of_29\IN\1740 electrographic_30\JJ\1740 and_31\CC\1740 behavioral_32\JJ\1740 <e2>seizures</e2>_33\NNS\14081375 produced_34\VBN\1617192 by_35\IN\1740 pilocarpine_36\NN\14712692 ,_37\,\1740 380_38\CD\1740 mg/kg_39\NN\1740 ._40\.\1740
D005680_D012640 NONE the_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 threshold_5\NN\15265518 for_6\IN\1740 pilocarpine-induced_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 in_9\IN\13603305 rats_10\NNS\2329401 is_11\VBZ\836236 subjected_12\VBN\137313 to_13\TO\1740 the_14\DT\1740 regulation_15\NN\6652242 of_16\IN\1740 the_17\DT\1740 <e1>gaba-mediated</e1>_18\JJ\1740 synaptic_19\JJ\1740 inhibition_20\NN\1068773 within_21\IN\1740 the_22\DT\1740 substantia_23\RB\1740 nigra_24\JJ\1740 ._25\.\1740
D007538_D013226 NONE in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 <e1>isoniazid</e1>_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 gaba-synthesizing_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 l-glutamic_20\JJ\1740 acid_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 pilocarpine_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 seizures_51\NNS\14081375 and_52\CC\1740 <e2>status_53\NN\24720 epilepticus</e2>_54\NN\1740 ._55\.\1740
D005680_D013226 NONE in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 isoniazid_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 <e1>gaba-synthesizing</e1>_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 l-glutamic_20\JJ\1740 acid_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 pilocarpine_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 seizures_51\NNS\14081375 and_52\CC\1740 <e2>status_53\NN\24720 epilepticus</e2>_54\NN\1740 ._55\.\1740
D018698_D012640 NONE in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 isoniazid_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 gaba-synthesizing_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 <e1>l-glutamic_20\JJ\1740 acid</e1>_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 pilocarpine_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 <e2>seizures</e2>_51\NNS\14081375 and_52\CC\1740 status_53\NN\24720 epilepticus_54\NN\1740 ._55\.\1740
D018698_D013226 NONE in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 isoniazid_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 gaba-synthesizing_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 <e1>l-glutamic_20\JJ\1740 acid</e1>_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 pilocarpine_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 seizures_51\NNS\14081375 and_52\CC\1740 <e2>status_53\NN\24720 epilepticus</e2>_54\NN\1740 ._55\.\1740
D010862_D013226 NONE in_0\IN\13603305 animals_1\NNS\4475 pretreated_2\VBN\1740 with_3\IN\1740 microinjections_4\NNS\1740 of_5\IN\1740 isoniazid_6\NNS\2716205 ,_7\,\1740 150_8\CD\1740 micrograms_9\NNS\13717155 ,_10\,\1740 an_11\DT\6697703 inhibitor_12\NN\20090 of_13\IN\1740 activity_14\NN\30358 of_15\IN\1740 the_16\DT\1740 gaba-synthesizing_17\JJ\1740 enzyme_18\NN\14723628 ,_19\,\1740 l-glutamic_20\JJ\1740 acid_21\NN\14818238 decarboxylase_22\NN\14732946 ,_23\,\1740 into_24\IN\1740 the_25\DT\1740 substantia_26\RB\1740 nigra_27\JJ\1740 pars_28\NNS\13594585 reticulata_29\NN\1740 (_30\-LRB-\1740 snr_31\NN\1740 )_32\-RRB-\1740 ,_33\,\1740 bilaterally_34\RB\1740 ,_35\,\1740 non-convulsant_36\JJ\1740 doses_37\NNS\3740161 of_38\IN\1740 <e1>pilocarpine</e1>_39\NN\14712692 ,_40\,\1740 100_41\CD\13745420 and_42\CC\1740 200_43\CD\1740 mg/kg_44\NN\1740 ,_45\,\1740 resulted_46\VBD\2633881 in_47\IN\13603305 severe_48\JJ\1740 motor_49\NN\3699975 limbic_50\JJ\1740 seizures_51\NNS\14081375 and_52\CC\1740 <e2>status_53\NN\24720 epilepticus</e2>_54\NN\1740 ._55\.\1740
4082466
D009020_D012640 CID <e1>morphine-induced</e1>_0\JJ\1740 <e2>seizures</e2>_1\NNS\14081375 in_2\IN\13603305 newborn_3\JJ\1740 infants_4\NNS\9918248 ._5\.\1740
D009020_D012640 CID two_0\CD\13741022 neonates_1\NNS\9827683 suffered_2\VBN\2110220 from_3\IN\1740 generalized_4\JJ\1740 <e2>seizures</e2>_5\NNS\14081375 during_6\IN\1740 the_7\DT\1740 course_8\NN\883297 of_9\IN\1740 intravenous_10\JJ\1740 <e1>morphine_11\NN\2707683 sulfate</e1>_12\NN\15010703 for_13\IN\1740 post-operative_14\JJ\1740 analgesia_15\NN\14034177 ._16\.\1740
D009020_D012640 CID they_0\PRP\1740 received_1\VBD\2210855 <e1>morphine</e1>_2\NN\2707683 in_3\IN\13603305 doses_4\NNS\3740161 of_5\IN\1740 32_6\CD\1740 micrograms/kg/hr_7\NN\1740 and_8\CC\1740 40_9\CD\13745420 micrograms/kg/hr_10\NN\1740 larger_11\JJR\1740 than_12\IN\1740 a_13\DT\13649268 group_14\NN\2137 of_15\IN\1740 10_16\CD\13745420 neonates_17\NNS\9827683 who_18\WP\8299493 received_19\VBD\2210855 6_20\CD\13741022 -_21\SYM\1740 24_22\CD\13745420 micrograms/kg/hr_23\NN\1740 and_24\CC\1740 had_25\VBD\2108377 no_26\DT\7204911 <e2>seizures</e2>_27\NNS\14081375 ._28\.\1740
D009020_D012640 CID other_0\JJ\1740 known_1\JJ\1740 reasons_2\NNS\9178821 for_3\IN\1740 <e2>seizures</e2>_4\NNS\14081375 were_5\VBD\836236 ruled_6\VBN\2441022 out_7\RP\1740 and_8\CC\1740 the_9\DT\1740 convulsions_10\NNS\14081375 stopped_11\VBD\2452885 a_12\DT\13649268 few_13\JJ\1740 hours_14\NNS\15118228 after_15\IN\1740 cessation_16\NN\7365849 of_17\IN\1740 <e1>morphine</e1>_18\NN\2707683 and_19\CC\1740 did_20\VBD\1640855 not_21\RB\1740 reoccur_22\VB\1740 in_23\IN\13603305 the_24\DT\1740 subsequent_25\JJ\1740 8_26\CD\13741022 months_27\NNS\15113229 ._28\.\1740
D009020_D012640 CID other_0\JJ\1740 known_1\JJ\1740 reasons_2\NNS\9178821 for_3\IN\1740 seizures_4\NNS\14081375 were_5\VBD\836236 ruled_6\VBN\2441022 out_7\RP\1740 and_8\CC\1740 the_9\DT\1740 <e2>convulsions</e2>_10\NNS\14081375 stopped_11\VBD\2452885 a_12\DT\13649268 few_13\JJ\1740 hours_14\NNS\15118228 after_15\IN\1740 cessation_16\NN\7365849 of_17\IN\1740 <e1>morphine</e1>_18\NN\2707683 and_19\CC\1740 did_20\VBD\1640855 not_21\RB\1740 reoccur_22\VB\1740 in_23\IN\13603305 the_24\DT\1740 subsequent_25\JJ\1740 8_26\CD\13741022 months_27\NNS\15113229 ._28\.\1740
2933998
D017265_D001249 NONE <e1>procaterol</e1>_0\NN\1740 and_1\CC\1740 terbutaline_2\NN\1740 in_3\IN\13603305 <e2>bronchial_4\JJ\1740 asthma</e2>_5\NN\14145095 ._6\.\1740
D017265_D001249 NONE <e1>procaterol</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 new_3\JJ\1740 beta-2_4\NN\1740 adrenoceptor_5\NN\1740 stimulant_6\JJ\1740 ,_7\,\1740 was_8\VBD\836236 studied_9\VBN\630380 in_10\IN\13603305 a_11\DT\13649268 double-blind_12\JJ\1740 ,_13\,\1740 placebo-controlled_14\JJ\1740 ,_15\,\1740 cross-over_16\JJ\1740 trial_17\NN\786195 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>bronchial_21\JJ\1740 asthma</e2>_22\NN\14145095 ._23\.\1740
D017265_D001249 NONE both_0\CC\1740 <e2>anti-asthmatic</e2>_1\JJ\1740 and_2\CC\1740 tremorgenic_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>procaterol</e1>_6\NN\1740 were_7\VBD\836236 dose-related_8\JJ\1740 ._9\.\1740
D013726_D001249 NONE procaterol_0\NN\1740 and_1\CC\1740 <e1>terbutaline</e1>_2\NN\1740 in_3\IN\13603305 <e2>bronchial_4\JJ\1740 asthma</e2>_5\NN\14145095 ._6\.\1740
D017265_D014202 CID both_0\CC\1740 anti-asthmatic_1\JJ\1740 and_2\CC\1740 <e2>tremorgenic</e2>_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>procaterol</e1>_6\NN\1740 were_7\VBD\836236 dose-related_8\JJ\1740 ._9\.\1740
24778426
D002945_D007674 NONE rates_0\NNS\13308999 of_1\IN\1740 <e2>renal_2\NNP\1740 toxicity</e2>_3\NNP\13576101 in_4\IN\13603305 cancer_5\NN\14239425 patients_6\NNS\9898892 receiving_7\NNP\1740 <e1>cisplatin</e1>_8\NNP\1740 with_9\IN\1740 and_10\CC\1740 without_11\IN\1740 mannitol_12\NNP\3214670 ._13\.\1740
D002945_D007674 NONE one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 major_3\JJ\1740 complications_4\NNS\1073995 of_5\IN\1740 <e1>cisplatin</e1>_6\NN\1740 use_7\NN\407535 is_8\VBZ\836236 dose-limiting_9\JJ\1740 <e2>nephrotoxicity</e2>_10\NN\1740 ._11\.\1740
D002945_D007674 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 aimed_3\VBD\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 rates_7\NNS\13308999 of_8\IN\1740 <e1>cisplatin-induced</e1>_9\JJ\1740 <e2>nephrotoxicity</e2>_10\NN\1740 in_11\IN\13603305 cancer_12\NN\14239425 patients_13\NNS\9898892 receiving_14\VBG\2210855 single-agent_15\JJ\1740 cisplatin_16\NN\1740 with_17\IN\1740 and_18\CC\1740 without_19\IN\1740 mannitol_20\NN\3214670 ._21\.\1740
D002945_D007674 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 aimed_3\VBD\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 rates_7\NNS\13308999 of_8\IN\1740 cisplatin-induced_9\JJ\1740 <e2>nephrotoxicity</e2>_10\NN\1740 in_11\IN\13603305 cancer_12\NN\14239425 patients_13\NNS\9898892 receiving_14\VBG\2210855 single-agent_15\JJ\1740 <e1>cisplatin</e1>_16\NN\1740 with_17\IN\1740 and_18\CC\1740 without_19\IN\1740 mannitol_20\NN\3214670 ._21\.\1740
D002945_D007674 NONE our_0\PRP$\1740 analysis_1\NN\633864 suggests_2\VBZ\1010118 that_3\IN\1740 those_4\DT\1740 patients_5\NNS\9898892 receiving_6\VBG\2210855 the_7\DT\1740 dosing_8\NN\1740 schedule_9\NN\5898568 of_10\IN\1740 100_11\CD\13745420 mg/m(2_12\NN\1740 )_13\-RRB-\1740 <e1>cisplatin</e1>_14\NN\1740 every_15\DT\1740 3_16\CD\13741022 weeks_17\NNS\15113229 and_18\CC\1740 those_19\DT\1740 with_20\IN\1740 hypertension_21\NN\14057371 are_22\VBP\836236 at_23\IN\14622893 the_24\DT\1740 greatest_25\JJS\1740 risk_26\NN\14541044 of_27\IN\1740 <e2>nephrotoxicity</e2>_28\NN\1740 and_29\CC\1740 would_30\MD\1740 benefit_31\VB\2210855 from_32\IN\1740 the_33\DT\1740 addition_34\NN\3081021 of_35\IN\1740 mannitol_36\NN\3214670 ._37\.\1740
D002945_D009369 NONE rates_0\NNS\13308999 of_1\IN\1740 renal_2\NNP\1740 toxicity_3\NNP\13576101 in_4\IN\13603305 <e2>cancer</e2>_5\NN\14239425 patients_6\NNS\9898892 receiving_7\NNP\1740 <e1>cisplatin</e1>_8\NNP\1740 with_9\IN\1740 and_10\CC\1740 without_11\IN\1740 mannitol_12\NNP\3214670 ._13\.\1740
D002945_D009369 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 aimed_3\VBD\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 rates_7\NNS\13308999 of_8\IN\1740 <e1>cisplatin-induced</e1>_9\JJ\1740 nephrotoxicity_10\NN\1740 in_11\IN\13603305 <e2>cancer</e2>_12\NN\14239425 patients_13\NNS\9898892 receiving_14\VBG\2210855 single-agent_15\JJ\1740 cisplatin_16\NN\1740 with_17\IN\1740 and_18\CC\1740 without_19\IN\1740 mannitol_20\NN\3214670 ._21\.\1740
D002945_D009369 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 aimed_3\VBD\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 rates_7\NNS\13308999 of_8\IN\1740 cisplatin-induced_9\JJ\1740 nephrotoxicity_10\NN\1740 in_11\IN\13603305 <e2>cancer</e2>_12\NN\14239425 patients_13\NNS\9898892 receiving_14\VBG\2210855 single-agent_15\JJ\1740 <e1>cisplatin</e1>_16\NN\1740 with_17\IN\1740 and_18\CC\1740 without_19\IN\1740 mannitol_20\NN\3214670 ._21\.\1740
D002945_D009369 NONE data_0\NNS\7951464 were_1\VBD\836236 collected_2\VBN\2281093 on_3\IN\1740 adult_4\JJ\1740 <e2>cancer</e2>_5\NN\14239425 patients_6\NNS\9898892 receiving_7\VBG\2210855 single-agent_8\JJ\1740 <e1>cisplatin</e1>_9\NN\1740 as_10\IN\14622893 an_11\DT\6697703 outpatient_12\NN\10405694 from_13\IN\1740 january_14\NNP\15209706 2011_15\CD\1740 to_16\IN\1740 september_17\NNP\15209706 2012_18\CD\1740 ._19\.\1740
D002945_D009369 NONE results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 evaluated_3\VBD\670261 143_4\CD\1740 patients_5\NNS\9898892 who_6\WP\8299493 received_7\VBD\2210855 single-agent_8\JJ\1740 <e1>cisplatin</e1>_9\NN\1740 ;_10\:\1740 97.2_11\CD\1740 %_12\NN\1740 of_13\IN\1740 patients_14\NNS\9898892 had_15\VBD\2108377 head_16\NN\5225090 and_17\CC\1740 neck_18\NN\5225090 cancer_19\NN\14239425 as_20\IN\14622893 their_21\PRP$\1740 primary_22\JJ\1740 <e2>malignancy</e2>_23\NN\14070360 ._24\.\1740
D008353_D007674 NONE rates_0\NNS\13308999 of_1\IN\1740 <e2>renal_2\NNP\1740 toxicity</e2>_3\NNP\13576101 in_4\IN\13603305 cancer_5\NN\14239425 patients_6\NNS\9898892 receiving_7\NNP\1740 cisplatin_8\NNP\1740 with_9\IN\1740 and_10\CC\1740 without_11\IN\1740 <e1>mannitol</e1>_12\NNP\3214670 ._13\.\1740
D008353_D007674 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 aimed_3\VBD\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 rates_7\NNS\13308999 of_8\IN\1740 cisplatin-induced_9\JJ\1740 <e2>nephrotoxicity</e2>_10\NN\1740 in_11\IN\13603305 cancer_12\NN\14239425 patients_13\NNS\9898892 receiving_14\VBG\2210855 single-agent_15\JJ\1740 cisplatin_16\NN\1740 with_17\IN\1740 and_18\CC\1740 without_19\IN\1740 <e1>mannitol</e1>_20\NN\3214670 ._21\.\1740
D008353_D007674 NONE patients_0\NNS\9898892 who_1\WP\8299493 did_2\VBD\1640855 not_3\RB\1740 receive_4\VB\2210855 <e1>mannitol</e1>_5\NN\3214670 were_6\VBD\836236 more_7\RBR\1740 likely_8\JJ\1740 to_9\TO\1740 develop_10\VB\1753788 <e2>nephrotoxicity</e2>_11\NN\1740 :_12\:\1740 odds_13\NNS\4756635 ratio_14\NN\13815152 [_15\-LRB-\1740 or_16\NN\3541091 ]_17\-RRB-\1740 =_18\JJ\1740 2.646_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci_23\NN\13635336 =_24\JJ\1740 1.008_25\CD\1740 ,_26\,\1740 6.944_27\CD\1740 ;_28\:\1740 p_29\NN\14622893 =_30\JJ\1740 0.048_31\CD\1740 )_32\-RRB-\1740 ._33\.\1740
D008353_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 when_2\WRB\1740 limited_3\JJ\1740 quantities_4\NNS\2137 of_5\IN\1740 <e1>mannitol</e1>_6\NN\3214670 are_7\VBP\836236 available_8\JJ\1740 ,_9\,\1740 it_10\PRP\6125041 should_11\MD\1740 preferentially_12\RB\1740 be_13\VB\836236 given_14\VBN\2327200 to_15\TO\1740 patients_16\NNS\9898892 at_17\IN\14622893 particularly_18\RB\1740 high_19\JJ\1740 risk_20\NN\14541044 of_21\IN\1740 <e2>nephrotoxicity</e2>_22\NN\1740 ._23\.\1740
D008353_D007674 NONE our_0\PRP$\1740 analysis_1\NN\633864 suggests_2\VBZ\1010118 that_3\IN\1740 those_4\DT\1740 patients_5\NNS\9898892 receiving_6\VBG\2210855 the_7\DT\1740 dosing_8\NN\1740 schedule_9\NN\5898568 of_10\IN\1740 100_11\CD\13745420 mg/m(2_12\NN\1740 )_13\-RRB-\1740 cisplatin_14\NN\1740 every_15\DT\1740 3_16\CD\13741022 weeks_17\NNS\15113229 and_18\CC\1740 those_19\DT\1740 with_20\IN\1740 hypertension_21\NN\14057371 are_22\VBP\836236 at_23\IN\14622893 the_24\DT\1740 greatest_25\JJS\1740 risk_26\NN\14541044 of_27\IN\1740 <e2>nephrotoxicity</e2>_28\NN\1740 and_29\CC\1740 would_30\MD\1740 benefit_31\VB\2210855 from_32\IN\1740 the_33\DT\1740 addition_34\NN\3081021 of_35\IN\1740 <e1>mannitol</e1>_36\NN\3214670 ._37\.\1740
D008353_D009369 NONE rates_0\NNS\13308999 of_1\IN\1740 renal_2\NNP\1740 toxicity_3\NNP\13576101 in_4\IN\13603305 <e2>cancer</e2>_5\NN\14239425 patients_6\NNS\9898892 receiving_7\NNP\1740 cisplatin_8\NNP\1740 with_9\IN\1740 and_10\CC\1740 without_11\IN\1740 <e1>mannitol</e1>_12\NNP\3214670 ._13\.\1740
D008353_D009369 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 aimed_3\VBD\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 rates_7\NNS\13308999 of_8\IN\1740 cisplatin-induced_9\JJ\1740 nephrotoxicity_10\NN\1740 in_11\IN\13603305 <e2>cancer</e2>_12\NN\14239425 patients_13\NNS\9898892 receiving_14\VBG\2210855 single-agent_15\JJ\1740 cisplatin_16\NN\1740 with_17\IN\1740 and_18\CC\1740 without_19\IN\1740 <e1>mannitol</e1>_20\NN\3214670 ._21\.\1740
D008353_D064420 NONE there_0\EX\27167 are_1\VBP\836236 many_2\JJ\1740 strategies_3\NNS\5902545 to_4\TO\1740 prevent_5\VB\1740 this_6\DT\1740 <e2>toxicity</e2>_7\NN\13576101 ,_8\,\1740 including_9\VBG\690614 the_10\DT\1740 use_11\NN\407535 of_12\IN\1740 <e1>mannitol</e1>_13\NN\3214670 as_14\IN\14622893 a_15\DT\13649268 nephroprotectant_16\NN\1740 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 hydration_20\NN\13435152 ._21\.\1740
D002945_D006258 NONE results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 evaluated_3\VBD\670261 143_4\CD\1740 patients_5\NNS\9898892 who_6\WP\8299493 received_7\VBD\2210855 single-agent_8\JJ\1740 <e1>cisplatin</e1>_9\NN\1740 ;_10\:\1740 97.2_11\CD\1740 %_12\NN\1740 of_13\IN\1740 patients_14\NNS\9898892 had_15\VBD\2108377 <e2>head_16\NN\5225090 and_17\CC\1740 neck_18\NN\5225090 cancer</e2>_19\NN\14239425 as_20\IN\14622893 their_21\PRP$\1740 primary_22\JJ\1740 malignancy_23\NN\14070360 ._24\.\1740
D002945_D006973 NONE our_0\PRP$\1740 analysis_1\NN\633864 suggests_2\VBZ\1010118 that_3\IN\1740 those_4\DT\1740 patients_5\NNS\9898892 receiving_6\VBG\2210855 the_7\DT\1740 dosing_8\NN\1740 schedule_9\NN\5898568 of_10\IN\1740 100_11\CD\13745420 mg/m(2_12\NN\1740 )_13\-RRB-\1740 <e1>cisplatin</e1>_14\NN\1740 every_15\DT\1740 3_16\CD\13741022 weeks_17\NNS\15113229 and_18\CC\1740 those_19\DT\1740 with_20\IN\1740 <e2>hypertension</e2>_21\NN\14057371 are_22\VBP\836236 at_23\IN\14622893 the_24\DT\1740 greatest_25\JJS\1740 risk_26\NN\14541044 of_27\IN\1740 nephrotoxicity_28\NN\1740 and_29\CC\1740 would_30\MD\1740 benefit_31\VB\2210855 from_32\IN\1740 the_33\DT\1740 addition_34\NN\3081021 of_35\IN\1740 mannitol_36\NN\3214670 ._37\.\1740
D008353_D006973 NONE our_0\PRP$\1740 analysis_1\NN\633864 suggests_2\VBZ\1010118 that_3\IN\1740 those_4\DT\1740 patients_5\NNS\9898892 receiving_6\VBG\2210855 the_7\DT\1740 dosing_8\NN\1740 schedule_9\NN\5898568 of_10\IN\1740 100_11\CD\13745420 mg/m(2_12\NN\1740 )_13\-RRB-\1740 cisplatin_14\NN\1740 every_15\DT\1740 3_16\CD\13741022 weeks_17\NNS\15113229 and_18\CC\1740 those_19\DT\1740 with_20\IN\1740 <e2>hypertension</e2>_21\NN\14057371 are_22\VBP\836236 at_23\IN\14622893 the_24\DT\1740 greatest_25\JJS\1740 risk_26\NN\14541044 of_27\IN\1740 nephrotoxicity_28\NN\1740 and_29\CC\1740 would_30\MD\1740 benefit_31\VB\2210855 from_32\IN\1740 the_33\DT\1740 addition_34\NN\3081021 of_35\IN\1740 <e1>mannitol</e1>_36\NN\3214670 ._37\.\1740
20447294
D009020_D009437 NONE studies_0\NNS\635850 of_1\IN\1740 synergy_2\NN\13518963 between_3\IN\1740 <e1>morphine</e1>_4\NN\2707683 and_5\CC\1740 a_6\DT\13649268 novel_7\JJ\1740 sodium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 ,_11\,\1740 cnsb002_12\NN\1740 ,_13\,\1740 in_14\IN\13603305 rat_15\NN\2329401 models_16\NNS\5888929 of_17\IN\1740 inflammatory_18\JJ\1740 and_19\CC\1740 <e2>neuropathic_20\JJ\1740 pain</e2>_21\NN\14299637 ._22\.\1740
D009020_D009437 NONE objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 determined_4\VBD\1645601 the_5\DT\1740 antihyperalgesic_6\JJ\1740 effect_7\NN\34213 of_8\IN\1740 cnsb002_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 sodium_12\NN\14625458 channel_13\NN\6251781 blocker_14\NN\10101634 with_15\IN\1740 antioxidant_16\JJ\1740 properties_17\NNS\32613 given_18\VBN\2327200 alone_19\RB\1740 and_20\CC\1740 in_21\IN\13603305 combinations_22\NNS\7951464 with_23\IN\1740 <e1>morphine</e1>_24\NN\2707683 in_25\IN\13603305 rat_26\NN\2329401 models_27\NNS\5888929 of_28\IN\1740 inflammatory_29\JJ\1740 and_30\CC\1740 <e2>neuropathic_31\JJ\1740 pain</e2>_32\NN\14299637 ._33\.\1740
D012964_D009437 NONE studies_0\NNS\635850 of_1\IN\1740 synergy_2\NN\13518963 between_3\IN\1740 morphine_4\NN\2707683 and_5\CC\1740 a_6\DT\13649268 novel_7\JJ\1740 <e1>sodium</e1>_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 ,_11\,\1740 cnsb002_12\NN\1740 ,_13\,\1740 in_14\IN\13603305 rat_15\NN\2329401 models_16\NNS\5888929 of_17\IN\1740 inflammatory_18\JJ\1740 and_19\CC\1740 <e2>neuropathic_20\JJ\1740 pain</e2>_21\NN\14299637 ._22\.\1740
D012964_D009437 NONE objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 determined_4\VBD\1645601 the_5\DT\1740 antihyperalgesic_6\JJ\1740 effect_7\NN\34213 of_8\IN\1740 cnsb002_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 <e1>sodium</e1>_12\NN\14625458 channel_13\NN\6251781 blocker_14\NN\10101634 with_15\IN\1740 antioxidant_16\JJ\1740 properties_17\NNS\32613 given_18\VBN\2327200 alone_19\RB\1740 and_20\CC\1740 in_21\IN\13603305 combinations_22\NNS\7951464 with_23\IN\1740 morphine_24\NN\2707683 in_25\IN\13603305 rat_26\NN\2329401 models_27\NNS\5888929 of_28\IN\1740 inflammatory_29\JJ\1740 and_30\CC\1740 <e2>neuropathic_31\JJ\1740 pain</e2>_32\NN\14299637 ._33\.\1740
C401121_D009437 NONE studies_0\NNS\635850 of_1\IN\1740 synergy_2\NN\13518963 between_3\IN\1740 morphine_4\NN\2707683 and_5\CC\1740 a_6\DT\13649268 novel_7\JJ\1740 sodium_8\NN\14625458 channel_9\NN\6251781 blocker_10\NN\10101634 ,_11\,\1740 <e1>cnsb002</e1>_12\NN\1740 ,_13\,\1740 in_14\IN\13603305 rat_15\NN\2329401 models_16\NNS\5888929 of_17\IN\1740 inflammatory_18\JJ\1740 and_19\CC\1740 <e2>neuropathic_20\JJ\1740 pain</e2>_21\NN\14299637 ._22\.\1740
C401121_D009437 NONE objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 determined_4\VBD\1645601 the_5\DT\1740 antihyperalgesic_6\JJ\1740 effect_7\NN\34213 of_8\IN\1740 <e1>cnsb002</e1>_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 sodium_12\NN\14625458 channel_13\NN\6251781 blocker_14\NN\10101634 with_15\IN\1740 antioxidant_16\JJ\1740 properties_17\NNS\32613 given_18\VBN\2327200 alone_19\RB\1740 and_20\CC\1740 in_21\IN\13603305 combinations_22\NNS\7951464 with_23\IN\1740 morphine_24\NN\2707683 in_25\IN\13603305 rat_26\NN\2329401 models_27\NNS\5888929 of_28\IN\1740 inflammatory_29\JJ\1740 and_30\CC\1740 <e2>neuropathic_31\JJ\1740 pain</e2>_32\NN\14299637 ._33\.\1740
D009020_D010146 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>morphine</e1>_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 <e2>pain</e2>_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D009020_D007249 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>morphine</e1>_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 <e2>inflammation</e2>_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D009020_D003929 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>morphine</e1>_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 <e2>diabetic_42\JJ\1740 neuropathy</e2>_43\JJ\1740 ._44\.\1740
C401121_D010146 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 <e1>cnsb002</e1>_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 <e2>pain</e2>_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
C401121_D007249 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 <e1>cnsb002</e1>_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 <e2>inflammation</e2>_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
C401121_D003929 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 <e1>cnsb002</e1>_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 <e2>diabetic_42\JJ\1740 neuropathy</e2>_43\JJ\1740 ._44\.\1740
D002351_D010146 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 <e2>pain</e2>_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 <e1>carrageenan-induced</e1>_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D002351_D007249 CID design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 <e1>carrageenan-induced</e1>_36\JJ\1740 paw_37\NN\2153445 <e2>inflammation</e2>_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D002351_D003929 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 <e1>carrageenan-induced</e1>_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 (stz)-induced_41\JJ\1740 <e2>diabetic_42\JJ\1740 neuropathy</e2>_43\JJ\1740 ._44\.\1740
D013311_D010146 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 <e2>pain</e2>_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 <e1>streptozotocin</e1>_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D013311_D010146 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 <e2>pain</e2>_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 <e1>(stz)-induced</e1>_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D013311_D007249 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 <e2>inflammation</e2>_38\NN\14299637 and_39\CC\1740 <e1>streptozotocin</e1>_40\NN\1740 (stz)-induced_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D013311_D007249 NONE design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 <e2>inflammation</e2>_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 <e1>(stz)-induced</e1>_41\JJ\1740 diabetic_42\JJ\1740 neuropathy_43\JJ\1740 ._44\.\1740
D013311_D003929 CID design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 <e1>streptozotocin</e1>_40\NN\1740 (stz)-induced_41\JJ\1740 <e2>diabetic_42\JJ\1740 neuropathy</e2>_43\JJ\1740 ._44\.\1740
D013311_D003929 CID design_0\NN\927261 :_1\:\1740 dose_2\NN\3740161 response_3\NN\11410625 curves_4\NNS\13863771 for_5\IN\1740 nonsedating_6\NN\1740 doses_7\NNS\3740161 of_8\IN\1740 morphine_9\NN\2707683 and_10\CC\1740 cnsb002_11\NN\1740 given_12\VBN\2327200 intraperitoneally_13\RB\1740 alone_14\RB\1740 and_15\CC\1740 together_16\RB\1740 in_17\IN\13603305 combinations_18\NNS\7951464 were_19\VBD\836236 constructed_20\VBN\1617192 for_21\IN\1740 antihyperalgesic_22\JJ\1740 effect_23\NN\34213 using_24\VBG\1156834 paw_25\NN\2153445 withdrawal_26\NN\7206096 from_27\IN\1740 noxious_28\JJ\1740 heat_29\NN\11452218 in_30\IN\13603305 two_31\CD\13741022 rat_32\NN\2329401 pain_33\NN\14299637 models_34\NNS\5888929 :_35\:\1740 carrageenan-induced_36\JJ\1740 paw_37\NN\2153445 inflammation_38\NN\14299637 and_39\CC\1740 streptozotocin_40\NN\1740 <e1>(stz)-induced</e1>_41\JJ\1740 <e2>diabetic_42\JJ\1740 neuropathy</e2>_43\JJ\1740 ._44\.\1740
D002351_D006930 CID the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 <e2>hyperalgesia</e2>_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 <e1>carrageenan</e1>_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 stz-induced_39\JJ\1740 neuropathy_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 cnsb002_43\NN\1740 and_44\CC\1740 morphine_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D002351_D009422 NONE the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 hyperalgesia_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 <e1>carrageenan</e1>_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 stz-induced_39\JJ\1740 <e2>neuropathy</e2>_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 cnsb002_43\NN\1740 and_44\CC\1740 morphine_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D002351_D009422 NONE the_0\DT\1740 ed50_1\NN\1740 values_2\NNS\5941423 for_3\IN\1740 morphine_4\NN\2707683 when_5\WRB\1740 given_6\VBN\2327200 in_7\IN\13603305 combination_8\NN\7951464 with_9\IN\1740 cnsb002_10\NN\1740 (_11\-LRB-\1740 5_12\CD\13741022 mg/kg_13\NN\1740 )_14\-RRB-\1740 were_15\VBD\836236 less_16\JJR\1740 than_17\IN\1740 the_18\DT\1740 maximum_19\NN\13653902 nonsedating_20\NN\1740 dose_21\NN\3740161 :_22\:\1740 0.56_23\CD\1740 (_24\-LRB-\1740 1.55_25\CD\1740 )_26\-RRB-\1740 in_27\IN\13603305 the_28\DT\1740 <e1>carrageenan</e1>_29\NN\14898470 model_30\NN\5888929 and_31\CC\1740 1.37_32\CD\1740 (_33\-LRB-\1740 1.23_34\CD\1740 )_35\-RRB-\1740 in_36\IN\13603305 the_37\DT\1740 <e2>neuropathy</e2>_38\JJ\1740 model_39\NN\5888929 (_40\-LRB-\1740 mg/kg_41\NN\1740 ;_42\:\1740 mean_43\NN\6021761 ,_44\,\1740 sem_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D013311_D006930 CID the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 <e2>hyperalgesia</e2>_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 carrageenan_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 <e1>stz-induced</e1>_39\JJ\1740 neuropathy_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 cnsb002_43\NN\1740 and_44\CC\1740 morphine_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D013311_D009422 NONE the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 hyperalgesia_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 carrageenan_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 <e1>stz-induced</e1>_39\JJ\1740 <e2>neuropathy</e2>_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 cnsb002_43\NN\1740 and_44\CC\1740 morphine_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
C401121_D006930 NONE the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 <e2>hyperalgesia</e2>_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 carrageenan_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 stz-induced_39\JJ\1740 neuropathy_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 <e1>cnsb002</e1>_43\NN\1740 and_44\CC\1740 morphine_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
C401121_D006930 NONE the_0\DT\1740 antinociception_1\NN\1740 after_2\IN\1740 morphine_3\NN\2707683 (_4\-LRB-\1740 3.2_5\CD\1740 mg/kg_6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 increased_9\VBN\169651 by_10\IN\1740 co-administration_11\NN\1740 with_12\IN\1740 <e1>cnsb002</e1>_13\NN\1740 from_14\IN\1740 28.0_15\CD\1740 and_16\CC\1740 31.7_17\CD\1740 %_18\NN\1740 to_19\IN\1740 114.6_20\CD\1740 and_21\CC\1740 56.9_22\CD\1740 %_23\NN\1740 reversal_24\NN\199130 of_25\IN\1740 <e2>hyperalgesia</e2>_26\NN\1740 in_27\IN\13603305 the_28\DT\1740 inflammatory_29\JJ\1740 and_30\CC\1740 neuropathic_31\JJ\1740 models_32\NNS\5888929 ,_33\,\1740 respectively_34\RB\1740 (_35\-LRB-\1740 p_36\NN\14622893 <_37\XX\1740 0.01_38\CD\1740 ;_39\:\1740 one-way_40\JJ\1740 analysis_41\NN\633864 of_42\IN\1740 variance-significantly_43\RB\1740 greater_44\JJR\1740 than_45\IN\1740 either_46\DT\1740 drug_47\NN\14778436 given_48\VBN\2327200 alone_49\RB\1740 )_50\-RRB-\1740 ._51\.\1740
C401121_D009422 NONE the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 hyperalgesia_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 carrageenan_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 stz-induced_39\JJ\1740 <e2>neuropathy</e2>_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 <e1>cnsb002</e1>_43\NN\1740 and_44\CC\1740 morphine_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
C401121_D009422 NONE the_0\DT\1740 ed50_1\NN\1740 values_2\NNS\5941423 for_3\IN\1740 morphine_4\NN\2707683 when_5\WRB\1740 given_6\VBN\2327200 in_7\IN\13603305 combination_8\NN\7951464 with_9\IN\1740 <e1>cnsb002</e1>_10\NN\1740 (_11\-LRB-\1740 5_12\CD\13741022 mg/kg_13\NN\1740 )_14\-RRB-\1740 were_15\VBD\836236 less_16\JJR\1740 than_17\IN\1740 the_18\DT\1740 maximum_19\NN\13653902 nonsedating_20\NN\1740 dose_21\NN\3740161 :_22\:\1740 0.56_23\CD\1740 (_24\-LRB-\1740 1.55_25\CD\1740 )_26\-RRB-\1740 in_27\IN\13603305 the_28\DT\1740 carrageenan_29\NN\14898470 model_30\NN\5888929 and_31\CC\1740 1.37_32\CD\1740 (_33\-LRB-\1740 1.23_34\CD\1740 )_35\-RRB-\1740 in_36\IN\13603305 the_37\DT\1740 <e2>neuropathy</e2>_38\JJ\1740 model_39\NN\5888929 (_40\-LRB-\1740 mg/kg_41\NN\1740 ;_42\:\1740 mean_43\NN\6021761 ,_44\,\1740 sem_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
C401121_D009422 NONE the_0\DT\1740 antinociception_1\NN\1740 after_2\IN\1740 morphine_3\NN\2707683 (_4\-LRB-\1740 3.2_5\CD\1740 mg/kg_6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 increased_9\VBN\169651 by_10\IN\1740 co-administration_11\NN\1740 with_12\IN\1740 <e1>cnsb002</e1>_13\NN\1740 from_14\IN\1740 28.0_15\CD\1740 and_16\CC\1740 31.7_17\CD\1740 %_18\NN\1740 to_19\IN\1740 114.6_20\CD\1740 and_21\CC\1740 56.9_22\CD\1740 %_23\NN\1740 reversal_24\NN\199130 of_25\IN\1740 hyperalgesia_26\NN\1740 in_27\IN\13603305 the_28\DT\1740 inflammatory_29\JJ\1740 and_30\CC\1740 <e2>neuropathic</e2>_31\JJ\1740 models_32\NNS\5888929 ,_33\,\1740 respectively_34\RB\1740 (_35\-LRB-\1740 p_36\NN\14622893 <_37\XX\1740 0.01_38\CD\1740 ;_39\:\1740 one-way_40\JJ\1740 analysis_41\NN\633864 of_42\IN\1740 variance-significantly_43\RB\1740 greater_44\JJR\1740 than_45\IN\1740 either_46\DT\1740 drug_47\NN\14778436 given_48\VBN\2327200 alone_49\RB\1740 )_50\-RRB-\1740 ._51\.\1740
D009020_D006930 NONE the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 <e2>hyperalgesia</e2>_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 carrageenan_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 stz-induced_39\JJ\1740 neuropathy_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 cnsb002_43\NN\1740 and_44\CC\1740 <e1>morphine</e1>_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D009020_D006930 NONE the_0\DT\1740 antinociception_1\NN\1740 after_2\IN\1740 <e1>morphine</e1>_3\NN\2707683 (_4\-LRB-\1740 3.2_5\CD\1740 mg/kg_6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 increased_9\VBN\169651 by_10\IN\1740 co-administration_11\NN\1740 with_12\IN\1740 cnsb002_13\NN\1740 from_14\IN\1740 28.0_15\CD\1740 and_16\CC\1740 31.7_17\CD\1740 %_18\NN\1740 to_19\IN\1740 114.6_20\CD\1740 and_21\CC\1740 56.9_22\CD\1740 %_23\NN\1740 reversal_24\NN\199130 of_25\IN\1740 <e2>hyperalgesia</e2>_26\NN\1740 in_27\IN\13603305 the_28\DT\1740 inflammatory_29\JJ\1740 and_30\CC\1740 neuropathic_31\JJ\1740 models_32\NNS\5888929 ,_33\,\1740 respectively_34\RB\1740 (_35\-LRB-\1740 p_36\NN\14622893 <_37\XX\1740 0.01_38\CD\1740 ;_39\:\1740 one-way_40\JJ\1740 analysis_41\NN\633864 of_42\IN\1740 variance-significantly_43\RB\1740 greater_44\JJR\1740 than_45\IN\1740 either_46\DT\1740 drug_47\NN\14778436 given_48\VBN\2327200 alone_49\RB\1740 )_50\-RRB-\1740 ._51\.\1740
D009020_D009422 NONE the_0\DT\1740 doses_1\NNS\3740161 calculated_2\VBN\632627 to_3\TO\1740 cause_4\VB\1617192 50_5\CD\13745420 %_6\NN\1740 reversal_7\NN\199130 of_8\IN\1740 hyperalgesia_9\NN\1740 (_10\-LRB-\1740 ed50_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 7.54_14\CD\1740 (_15\-LRB-\1740 1.81_16\CD\1740 )_17\-RRB-\1740 and_18\CC\1740 4.83_19\CD\1740 (_20\-LRB-\1740 1.54_21\CD\1740 )_22\-RRB-\1740 in_23\IN\13603305 the_24\DT\1740 carrageenan_25\NN\14898470 model_26\NN\5888929 and_27\CC\1740 44.18_28\CD\1740 (_29\-LRB-\1740 1.37_30\CD\1740 )_31\-RRB-\1740 and_32\CC\1740 9.14_33\CD\1740 (_34\-LRB-\1740 1.24_35\CD\1740 )_36\-RRB-\1740 in_37\IN\13603305 the_38\DT\1740 stz-induced_39\JJ\1740 <e2>neuropathy</e2>_40\JJ\1740 model_41\NN\5888929 for_42\IN\1740 cnsb002_43\NN\1740 and_44\CC\1740 <e1>morphine</e1>_45\NN\2707683 ,_46\,\1740 respectively_47\RB\1740 (_48\-LRB-\1740 mg/kg_49\NN\1740 ;_50\:\1740 mean_51\NN\6021761 ,_52\,\1740 sem_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D009020_D009422 NONE the_0\DT\1740 ed50_1\NN\1740 values_2\NNS\5941423 for_3\IN\1740 <e1>morphine</e1>_4\NN\2707683 when_5\WRB\1740 given_6\VBN\2327200 in_7\IN\13603305 combination_8\NN\7951464 with_9\IN\1740 cnsb002_10\NN\1740 (_11\-LRB-\1740 5_12\CD\13741022 mg/kg_13\NN\1740 )_14\-RRB-\1740 were_15\VBD\836236 less_16\JJR\1740 than_17\IN\1740 the_18\DT\1740 maximum_19\NN\13653902 nonsedating_20\NN\1740 dose_21\NN\3740161 :_22\:\1740 0.56_23\CD\1740 (_24\-LRB-\1740 1.55_25\CD\1740 )_26\-RRB-\1740 in_27\IN\13603305 the_28\DT\1740 carrageenan_29\NN\14898470 model_30\NN\5888929 and_31\CC\1740 1.37_32\CD\1740 (_33\-LRB-\1740 1.23_34\CD\1740 )_35\-RRB-\1740 in_36\IN\13603305 the_37\DT\1740 <e2>neuropathy</e2>_38\JJ\1740 model_39\NN\5888929 (_40\-LRB-\1740 mg/kg_41\NN\1740 ;_42\:\1740 mean_43\NN\6021761 ,_44\,\1740 sem_45\NN\1740 )_46\-RRB-\1740 ._47\.\1740
D009020_D009422 NONE the_0\DT\1740 antinociception_1\NN\1740 after_2\IN\1740 <e1>morphine</e1>_3\NN\2707683 (_4\-LRB-\1740 3.2_5\CD\1740 mg/kg_6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 increased_9\VBN\169651 by_10\IN\1740 co-administration_11\NN\1740 with_12\IN\1740 cnsb002_13\NN\1740 from_14\IN\1740 28.0_15\CD\1740 and_16\CC\1740 31.7_17\CD\1740 %_18\NN\1740 to_19\IN\1740 114.6_20\CD\1740 and_21\CC\1740 56.9_22\CD\1740 %_23\NN\1740 reversal_24\NN\199130 of_25\IN\1740 hyperalgesia_26\NN\1740 in_27\IN\13603305 the_28\DT\1740 inflammatory_29\JJ\1740 and_30\CC\1740 <e2>neuropathic</e2>_31\JJ\1740 models_32\NNS\5888929 ,_33\,\1740 respectively_34\RB\1740 (_35\-LRB-\1740 p_36\NN\14622893 <_37\XX\1740 0.01_38\CD\1740 ;_39\:\1740 one-way_40\JJ\1740 analysis_41\NN\633864 of_42\IN\1740 variance-significantly_43\RB\1740 greater_44\JJR\1740 than_45\IN\1740 either_46\DT\1740 drug_47\NN\14778436 given_48\VBN\2327200 alone_49\RB\1740 )_50\-RRB-\1740 ._51\.\1740
22836123
D016559_D007674 NONE late-onset_0\JJ\1740 <e2>scleroderma_1\NN\14187378 renal_2\JJ\1740 crisis</e2>_3\NN\14411243 induced_4\VBN\1627355 by_5\IN\1740 <e1>tacrolimus</e1>_6\NN\1740 and_7\CC\1740 prednisolone_8\NN\2721538 :_9\:\1740 a_10\DT\13649268 case_11\NN\7283608 report_12\NN\6470073 ._13\.\1740
D016559_D007674 NONE in_0\IN\13603305 this_1\DT\1740 article_2\NN\6367571 ,_3\,\1740 we_4\PRP\1740 report_5\VBP\831651 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 <e2>src</e2>_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 <e1>tacrolimus</e1>_12\NN\1740 and_13\CC\1740 corticosteroids_14\NNS\14745635 ._15\.\1740
D011239_D007674 NONE late-onset_0\JJ\1740 <e2>scleroderma_1\NN\14187378 renal_2\JJ\1740 crisis</e2>_3\NN\14411243 induced_4\VBN\1627355 by_5\IN\1740 tacrolimus_6\NN\1740 and_7\CC\1740 <e1>prednisolone</e1>_8\NN\2721538 :_9\:\1740 a_10\DT\13649268 case_11\NN\7283608 report_12\NN\6470073 ._13\.\1740
D000305_D007674 NONE moderate_0\JJ\1740 to_1\TO\1740 high_2\JJ\1740 dose_3\NN\3740161 <e1>corticosteroid</e1>_4\NN\14745635 use_5\NN\407535 is_6\VBZ\836236 recognized_7\VBN\686447 as_8\IN\14622893 a_9\DT\13649268 major_10\JJ\1740 risk_11\NN\14541044 factor_12\NN\7326557 for_13\IN\1740 <e2>src</e2>_14\NN\1740 ._15\.\1740
D000305_D007674 NONE in_0\IN\13603305 this_1\DT\1740 article_2\NN\6367571 ,_3\,\1740 we_4\PRP\1740 report_5\VBP\831651 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 <e2>src</e2>_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 tacrolimus_12\NN\1740 and_13\CC\1740 <e1>corticosteroids</e1>_14\NNS\14745635 ._15\.\1740
D016572_D057049 CID furthermore_0\RB\1740 ,_1\,\1740 there_2\EX\27167 have_3\VBP\2108377 been_4\VBN\836236 reports_5\NNS\6470073 of_6\IN\1740 <e2>thrombotic_7\JJ\1740 microangiopathy</e2>_8\NN\1740 precipitated_9\VBN\1642924 by_10\IN\1740 <e1>cyclosporine</e1>_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 ssc_15\NN\1740 ._16\.\1740
D016572_D012595 NONE furthermore_0\RB\1740 ,_1\,\1740 there_2\EX\27167 have_3\VBP\2108377 been_4\VBN\836236 reports_5\NNS\6470073 of_6\IN\1740 thrombotic_7\JJ\1740 microangiopathy_8\NN\1740 precipitated_9\VBN\1642924 by_10\IN\1740 <e1>cyclosporine</e1>_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>ssc</e2>_15\NN\1740 ._16\.\1740
D016559_D012595 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 work_4\NN\407535 is_5\VBZ\836236 to_6\TO\1740 call_7\VB\1029852 attention_8\NN\5701944 to_9\IN\1740 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 <e1>tacrolimus</e1>_13\NN\1740 use_14\NN\407535 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>ssc</e2>_18\NN\1740 ._19\.\1740
12559315
D007213_D018856 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>indomethacin</e1>_2\NN\3828465 resulted_3\VBD\2633881 in_4\IN\13603305 histopathologic_5\JJ\1740 findings_6\NNS\7951464 typical_7\JJ\1740 of_8\IN\1740 <e2>interstitial_9\JJ\1740 cystitis</e2>_10\NN\14566129 ,_11\,\1740 such_12\JJ\1740 as_13\IN\14622893 leaky_14\NNS\1740 bladder_15\NN\5515670 epithelium_16\NN\5267548 and_17\CC\1740 mucosal_18\JJ\1740 mastocytosis_19\NN\1740 ._20\.\1740
D007213_D008415 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>indomethacin</e1>_2\NN\3828465 resulted_3\VBD\2633881 in_4\IN\13603305 histopathologic_5\JJ\1740 findings_6\NNS\7951464 typical_7\JJ\1740 of_8\IN\1740 interstitial_9\JJ\1740 cystitis_10\NN\14566129 ,_11\,\1740 such_12\JJ\1740 as_13\IN\14622893 leaky_14\NNS\1740 bladder_15\NN\5515670 epithelium_16\NN\5267548 and_17\CC\1740 mucosal_18\JJ\1740 <e2>mastocytosis</e2>_19\NN\1740 ._20\.\1740
753803
D014810_D009135 NONE <e2>myopathy</e2>_0\NNP\14204950 due_1\JJ\1740 to_2\TO\1740 lack_3\NN\14449126 of_4\IN\1740 <e1>vitamin_5\NN\7570720 e</e1>_6\NN\14724645 and_7\CC\1740 myopathy_8\NN\14204950 induced_9\VBN\1627355 by_10\IN\1740 certain_11\JJ\1740 viruses_12\NNS\9312843 have_13\VBP\2108377 much_14\JJ\1740 in_15\IN\13603305 common_16\JJ\1740 anatomically_17\RB\1740 and_18\CC\1740 pathologically_19\RB\1740 with_20\IN\1740 the_21\DT\1740 human_22\JJ\1740 form_23\NN\6286395 ._24\.\1740
D014810_D009135 NONE myopathy_0\NNP\14204950 due_1\JJ\1740 to_2\TO\1740 lack_3\NN\14449126 of_4\IN\1740 <e1>vitamin_5\NN\7570720 e</e1>_6\NN\14724645 and_7\CC\1740 <e2>myopathy</e2>_8\NN\14204950 induced_9\VBN\1627355 by_10\IN\1740 certain_11\JJ\1740 viruses_12\NNS\9312843 have_13\VBP\2108377 much_14\JJ\1740 in_15\IN\13603305 common_16\JJ\1740 anatomically_17\RB\1740 and_18\CC\1740 pathologically_19\RB\1740 with_20\IN\1740 the_21\DT\1740 human_22\JJ\1740 form_23\NN\6286395 ._24\.\1740
D014810_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 <e2>myopathic</e2>_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 <e1>vitamin_45\NN\7570720 e.</e1>_46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D014810_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 <e2>myopathic</e2>_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 <e1>vitamin_45\NN\7570720 e.</e1>_46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D014810_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 <e1>vitamin_45\NN\7570720 e.</e1>_46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 <e2>myopathic</e2>_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D014810_D009135 NONE the_0\DT\1740 authors_1\NNS\9610660 conclude_2\VBP\628491 by_3\IN\1740 affirming_4\VBG\1010118 the_5\DT\1740 undoubted_6\JJ\1740 efficacy_7\NN\5199286 of_8\IN\1740 the_9\DT\1740 anabolizing_10\NN\1740 steroids_11\NNS\14727670 in_12\IN\13603305 experimental_13\JJ\1740 <e2>myopathic_14\JJ\1740 disease</e2>_15\NN\14061805 ,_16\,\1740 but_17\CC\1740 they_18\PRP\1740 have_19\VBP\2108377 reservations_20\NNS\8491826 as_21\IN\14622893 to_22\IN\1740 the_23\DT\1740 transfer_24\NN\280586 of_25\IN\1740 the_26\DT\1740 results_27\NNS\34213 into_28\IN\1740 the_29\DT\1740 human_30\JJ\1740 field_31\NN\8673395 ,_32\,\1740 where_33\WRB\1740 high_34\JJ\1740 dosage_35\NN\13576355 can_36\MD\3094503 not_37\RB\1740 be_38\VB\836236 carried_39\VBN\1850315 out_40\RP\1740 continuously_41\RB\1740 because_42\IN\1740 of_43\IN\1740 the_44\DT\1740 effects_45\NNS\13245626 of_46\IN\1740 the_47\DT\1740 drug_48\NN\14778436 on_49\IN\1740 virility_50\NN\5008227 ;_51\:\1740 because_52\IN\1740 the_53\DT\1740 tissue_54\NN\5220461 injury_55\NN\14052046 too_56\RB\1740 often_57\RB\1740 occurs_58\VBZ\2623529 at_59\IN\14622893 an_60\DT\6697703 irreversible_61\JJ\1740 stage_62\NN\15113229 vis-a-vis_63\FW\5695554 the_64\DT\1740 "_65\``\1740 regeneration_66\NN\13526110 "_67\''\1740 of_68\IN\1740 the_69\DT\1740 muscle_70\NN\5289601 tissue_71\NN\5220461 ;_72\:\1740 and_73\CC\1740 finally_74\RB\1740 because_75\IN\1740 the_76\DT\1740 dystrophic_77\JJ\1740 injurious_78\JJ\1740 agent_79\NN\7347 is_80\VBZ\836236 certainly_81\RB\1740 not_82\RB\1740 the_83\DT\1740 lack_84\NN\14449126 of_85\IN\1740 <e1>vitamin_86\NN\7570720 e</e1>_87\NN\14724645 but_88\CC\1740 something_89\NN\1740 as_90\IN\14622893 yet_91\RB\1740 unknown_92\JJ\1740 ._93\.\1740
D014810_D009136 CID the_0\DT\1740 authors_1\NNS\9610660 induced_2\VBD\1627355 <e2>myodystrophy</e2>_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 rat_6\NN\2329401 by_7\IN\1740 giving_8\VBG\2327200 it_9\PRP\6125041 a_10\DT\13649268 diet_11\NN\7560652 lacking_12\VBG\1740 in_13\IN\13603305 <e1>vitamin_14\NN\7570720 e.</e1>_15\NN\1740 the_16\DT\1740 pharmacological_17\JJ\1740 characteristics_18\NNS\5849040 of_19\IN\1740 vitamin_20\NN\7570720 e_21\NN\14724645 and_22\CC\1740 the_23\DT\1740 degenerative_24\JJ\1740 changes_25\NNS\7283608 brought_26\VBN\1449974 about_27\RB\1740 by_28\IN\1740 its_29\PRP$\6125041 deficiency_30\NN\14449126 ,_31\,\1740 especially_32\RB\1740 in_33\IN\13603305 the_34\DT\1740 muscles_35\NNS\5289601 ,_36\,\1740 are_37\VBP\836236 illustrated_38\VBN\955601 ._39\.\1740
D014810_D009136 CID the_0\DT\1740 authors_1\NNS\9610660 induced_2\VBD\1627355 <e2>myodystrophy</e2>_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 rat_6\NN\2329401 by_7\IN\1740 giving_8\VBG\2327200 it_9\PRP\6125041 a_10\DT\13649268 diet_11\NN\7560652 lacking_12\VBG\1740 in_13\IN\13603305 vitamin_14\NN\7570720 e._15\NN\1740 the_16\DT\1740 pharmacological_17\JJ\1740 characteristics_18\NNS\5849040 of_19\IN\1740 <e1>vitamin_20\NN\7570720 e</e1>_21\NN\14724645 and_22\CC\1740 the_23\DT\1740 degenerative_24\JJ\1740 changes_25\NNS\7283608 brought_26\VBN\1449974 about_27\RB\1740 by_28\IN\1740 its_29\PRP$\6125041 deficiency_30\NN\14449126 ,_31\,\1740 especially_32\RB\1740 in_33\IN\13603305 the_34\DT\1740 muscles_35\NNS\5289601 ,_36\,\1740 are_37\VBP\836236 illustrated_38\VBN\955601 ._39\.\1740
D013256_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 <e2>myopathic</e2>_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 <e1>steroids</e1>_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D013256_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 <e1>steroids</e1>_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 <e2>myopathic</e2>_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D013256_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 <e1>steroids</e1>_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 <e2>myopathic</e2>_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D013256_D009135 NONE the_0\DT\1740 authors_1\NNS\9610660 conclude_2\VBP\628491 by_3\IN\1740 affirming_4\VBG\1010118 the_5\DT\1740 undoubted_6\JJ\1740 efficacy_7\NN\5199286 of_8\IN\1740 the_9\DT\1740 anabolizing_10\NN\1740 <e1>steroids</e1>_11\NNS\14727670 in_12\IN\13603305 experimental_13\JJ\1740 <e2>myopathic_14\JJ\1740 disease</e2>_15\NN\14061805 ,_16\,\1740 but_17\CC\1740 they_18\PRP\1740 have_19\VBP\2108377 reservations_20\NNS\8491826 as_21\IN\14622893 to_22\IN\1740 the_23\DT\1740 transfer_24\NN\280586 of_25\IN\1740 the_26\DT\1740 results_27\NNS\34213 into_28\IN\1740 the_29\DT\1740 human_30\JJ\1740 field_31\NN\8673395 ,_32\,\1740 where_33\WRB\1740 high_34\JJ\1740 dosage_35\NN\13576355 can_36\MD\3094503 not_37\RB\1740 be_38\VB\836236 carried_39\VBN\1850315 out_40\RP\1740 continuously_41\RB\1740 because_42\IN\1740 of_43\IN\1740 the_44\DT\1740 effects_45\NNS\13245626 of_46\IN\1740 the_47\DT\1740 drug_48\NN\14778436 on_49\IN\1740 virility_50\NN\5008227 ;_51\:\1740 because_52\IN\1740 the_53\DT\1740 tissue_54\NN\5220461 injury_55\NN\14052046 too_56\RB\1740 often_57\RB\1740 occurs_58\VBZ\2623529 at_59\IN\14622893 an_60\DT\6697703 irreversible_61\JJ\1740 stage_62\NN\15113229 vis-a-vis_63\FW\5695554 the_64\DT\1740 "_65\``\1740 regeneration_66\NN\13526110 "_67\''\1740 of_68\IN\1740 the_69\DT\1740 muscle_70\NN\5289601 tissue_71\NN\5220461 ;_72\:\1740 and_73\CC\1740 finally_74\RB\1740 because_75\IN\1740 the_76\DT\1740 dystrophic_77\JJ\1740 injurious_78\JJ\1740 agent_79\NN\7347 is_80\VBZ\836236 certainly_81\RB\1740 not_82\RB\1740 the_83\DT\1740 lack_84\NN\14449126 of_85\IN\1740 vitamin_86\NN\7570720 e_87\NN\14724645 but_88\CC\1740 something_89\NN\1740 as_90\IN\14622893 yet_91\RB\1740 unknown_92\JJ\1740 ._93\.\1740
D008696_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 <e2>myopathic</e2>_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 <e1>dianabol</e1>_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D008696_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 <e1>dianabol</e1>_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 <e2>myopathic</e2>_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
D008696_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 <e1>dianabol</e1>_29\NN\1740 ,_30\,\1740 ciba_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 <e2>myopathic</e2>_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
-1_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 <e2>myopathic</e2>_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 <e1>ciba</e1>_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
-1_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 <e1>ciba</e1>_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 <e2>myopathic</e2>_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 myopathic_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
-1_D009135 NONE the_0\DT\1740 encouraging_1\JJ\1740 results_2\NNS\34213 obtained_3\VBN\2210855 in_4\IN\13603305 various_5\JJ\1740 authoratative_6\JJ\1740 departments_7\NNS\8220714 in_8\IN\13603305 myopathic_9\JJ\1740 patients_10\NNS\9898892 by_11\IN\1740 using_12\VBG\1156834 anabolizing_13\NN\1740 steroids_14\NNS\14727670 have_15\VBP\2108377 encouraged_16\VBN\2556126 the_17\DT\1740 authors_18\NNS\9610660 to_19\TO\1740 investigate_20\VB\644583 the_21\DT\1740 beneficial_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 one_25\CD\13741022 anabolizing_26\NN\1740 agent_27\NN\7347 (_28\-LRB-\1740 dianabol_29\NN\1740 ,_30\,\1740 <e1>ciba</e1>_31\NNP\1740 )_32\-RRB-\1740 at_33\IN\14622893 high_34\JJ\1740 doses_35\NNS\3740161 in_36\IN\13603305 rats_37\NNS\2329401 rendered_38\VBN\120316 myopathic_39\JJ\1740 by_40\IN\1740 a_41\DT\13649268 diet_42\JJ\1740 deficient_43\NN\1740 in_44\IN\13603305 vitamin_45\NN\7570720 e._46\NN\1740 in_47\IN\13603305 this_48\DT\1740 way_49\NN\4916342 they_50\PRP\1740 obtained_51\VBD\2210855 appreciable_52\JJ\1740 changes_53\NNS\7283608 in_54\IN\13603305 body_55\NN\19128 weight_56\NN\5009170 (_57\-LRB-\1740 increased_58\VBD\169651 from_59\IN\1740 50_60\CD\13745420 to_61\TO\1740 70_62\CD\13745420 g_63\NN\13717155 after_64\IN\1740 forty_65\CD\13745420 days_66\NNS\15140892 at_67\IN\14622893 a_68\DT\13649268 dose_69\NN\3740161 of_70\IN\1740 5_71\CD\13741022 mg_72\NN\13717155 per_73\IN\1740 day_74\NN\15154774 of_75\IN\1740 anabolizing_76\VBG\1740 agent_77\NN\7347 )_78\-RRB-\1740 ,_79\,\1740 but_80\CC\1740 most_81\JJS\1740 of_82\IN\1740 all_83\DT\1740 they_84\PRP\1740 found_85\VBD\2426171 histological_86\JJ\1740 changes_87\NNS\7283608 due_88\JJ\1740 to_89\TO\1740 "_90\``\1740 regenerative_91\JJ\1740 "_92\''\1740 changes_93\NNS\7283608 in_94\IN\13603305 the_95\DT\1740 muscle_96\NN\5289601 tissue_97\NN\5220461 ,_98\,\1740 which_99\WDT\1740 however_100\RB\1740 maintained_101\VBD\2202928 its_102\PRP$\6125041 <e2>myopathic</e2>_103\JJ\1740 characteristics_104\NNS\5849040 in_105\IN\13603305 the_106\DT\1740 control_107\NN\5190804 animals_108\NNS\4475 that_109\WDT\1740 were_110\VBD\836236 not_111\RB\1740 treated_112\VBN\2376958 with_113\IN\1740 the_114\DT\1740 anabolizing_115\NN\1740 agent_116\NN\7347 ._117\.\1740
1760851
D004317_D066126 CID reduced_0\VBN\441445 <e2>cardiotoxicity</e2>_1\NN\1740 of_2\IN\1740 <e1>doxorubicin</e1>_3\NN\2716866 given_4\VBN\2327200 in_5\IN\13603305 the_6\DT\1740 form_7\NN\6286395 of_8\IN\1740 n-(2-hydroxypropyl)methacrylamide_9\NN\1740 conjugates_10\NNS\14589223 :_11\:\1740 and_12\CC\1740 experimental_13\JJ\1740 study_14\NN\635850 in_15\IN\13603305 the_16\DT\1740 rat_17\NN\2329401 ._18\.\1740
D004317_D066126 CID a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 toxicity_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 <e2>cardiotoxicity</e2>_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 <e1>doxorubicin</e1>_18\NN\2716866 (_19\-LRB-\1740 dox_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 n-(2-hydroxypropyl)methacrylamide_33\NN\1740 (_34\-LRB-\1740 hpma_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
D004317_D066126 CID a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 toxicity_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 <e2>cardiotoxicity</e2>_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 doxorubicin_18\NN\2716866 (_19\-LRB-\1740 <e1>dox</e1>_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 n-(2-hydroxypropyl)methacrylamide_33\NN\1740 (_34\-LRB-\1740 hpma_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
D004317_D066126 CID throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 <e2>cardiotoxicity</e2>_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 <e1>dox</e1>_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 hpma_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 dox_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 dox-induced_48\JJ\1740 cardiotoxicity_49\NN\1740 ._50\.\1740
D004317_D066126 CID throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 cardiotoxicity_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 <e1>dox</e1>_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 hpma_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 dox_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 dox-induced_48\JJ\1740 <e2>cardiotoxicity</e2>_49\NN\1740 ._50\.\1740
D004317_D066126 CID throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 <e2>cardiotoxicity</e2>_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 dox_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 hpma_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 <e1>dox</e1>_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 dox-induced_48\JJ\1740 cardiotoxicity_49\NN\1740 ._50\.\1740
D004317_D066126 CID throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 cardiotoxicity_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 dox_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 hpma_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 <e1>dox</e1>_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 dox-induced_48\JJ\1740 <e2>cardiotoxicity</e2>_49\NN\1740 ._50\.\1740
D004317_D066126 CID throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 <e2>cardiotoxicity</e2>_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 dox_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 hpma_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 dox_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 <e1>dox-induced</e1>_48\JJ\1740 cardiotoxicity_49\NN\1740 ._50\.\1740
D004317_D066126 CID throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 cardiotoxicity_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 dox_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 hpma_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 dox_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 <e1>dox-induced</e1>_48\JJ\1740 <e2>cardiotoxicity</e2>_49\NN\1740 ._50\.\1740
C032976_D066126 NONE reduced_0\VBN\441445 <e2>cardiotoxicity</e2>_1\NN\1740 of_2\IN\1740 doxorubicin_3\NN\2716866 given_4\VBN\2327200 in_5\IN\13603305 the_6\DT\1740 form_7\NN\6286395 of_8\IN\1740 <e1>n-(2-hydroxypropyl)methacrylamide</e1>_9\NN\1740 conjugates_10\NNS\14589223 :_11\:\1740 and_12\CC\1740 experimental_13\JJ\1740 study_14\NN\635850 in_15\IN\13603305 the_16\DT\1740 rat_17\NN\2329401 ._18\.\1740
C032976_D066126 NONE a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 toxicity_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 <e2>cardiotoxicity</e2>_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 doxorubicin_18\NN\2716866 (_19\-LRB-\1740 dox_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 <e1>n-(2-hydroxypropyl)methacrylamide</e1>_33\NN\1740 (_34\-LRB-\1740 hpma_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
C032976_D066126 NONE a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 toxicity_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 <e2>cardiotoxicity</e2>_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 doxorubicin_18\NN\2716866 (_19\-LRB-\1740 dox_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 n-(2-hydroxypropyl)methacrylamide_33\NN\1740 (_34\-LRB-\1740 <e1>hpma</e1>_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
C032976_D066126 NONE throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 <e2>cardiotoxicity</e2>_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 dox_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 <e1>hpma</e1>_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 dox_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 dox-induced_48\JJ\1740 cardiotoxicity_49\NN\1740 ._50\.\1740
C032976_D066126 NONE throughout_0\IN\1740 the_1\DT\1740 study_2\NN\635850 (_3\-LRB-\1740 20_4\CD\13745420 weeks_5\NNS\15113229 )_6\-RRB-\1740 ,_7\,\1740 deaths_8\NNS\7296428 related_9\JJ\1740 to_10\TO\1740 cardiotoxicity_11\NN\1740 were_12\VBD\836236 observed_13\VBN\2163746 only_14\RB\1740 in_15\IN\13603305 animals_16\NNS\4475 that_17\WDT\1740 received_18\VBD\2210855 either_19\CC\1740 free_20\JJ\1740 dox_21\NN\1740 or_22\CC\3541091 the_23\DT\1740 mixture_24\NN\19613 of_25\IN\1740 <e1>hpma</e1>_26\NN\1740 copolymer_27\NN\14994328 and_28\CC\1740 free_29\JJ\1740 dox_30\NN\1740 ;_31\:\1740 in_32\IN\13603305 these_33\DT\1740 cases_34\NNS\7283608 ,_35\,\1740 histological_36\JJ\1740 investigations_37\NNS\5797597 revealed_38\VBD\2137132 marked_39\JJ\1740 changes_40\NNS\7283608 in_41\IN\13603305 the_42\DT\1740 heart_43\NN\5919034 that_44\WDT\1740 were_45\VBD\836236 consistent_46\JJ\1740 with_47\IN\1740 dox-induced_48\JJ\1740 <e2>cardiotoxicity</e2>_49\NN\1740 ._50\.\1740
D004317_D064420 NONE a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 cardiotoxicity_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 <e1>doxorubicin</e1>_18\NN\2716866 (_19\-LRB-\1740 dox_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 n-(2-hydroxypropyl)methacrylamide_33\NN\1740 (_34\-LRB-\1740 hpma_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
D004317_D064420 NONE a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 cardiotoxicity_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 doxorubicin_18\NN\2716866 (_19\-LRB-\1740 <e1>dox</e1>_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 n-(2-hydroxypropyl)methacrylamide_33\NN\1740 (_34\-LRB-\1740 hpma_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
C032976_D064420 NONE a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 cardiotoxicity_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 doxorubicin_18\NN\2716866 (_19\-LRB-\1740 dox_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 <e1>n-(2-hydroxypropyl)methacrylamide</e1>_33\NN\1740 (_34\-LRB-\1740 hpma_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
C032976_D064420 NONE a_0\DT\13649268 rat_1\NN\2329401 model_2\NN\5888929 was_3\VBD\836236 used_4\VBN\1156834 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 general_8\JJ\1740 acute_9\JJ\1740 <e2>toxicity</e2>_10\NN\13576101 and_11\CC\1740 the_12\DT\1740 late_13\JJ\1740 cardiotoxicity_14\NN\1740 of_15\IN\1740 4_16\CD\13741022 mg/kg_17\NN\1740 doxorubicin_18\NN\2716866 (_19\-LRB-\1740 dox_20\NN\1740 )_21\-RRB-\1740 given_22\VBN\2327200 either_23\CC\1740 as_24\IN\14622893 free_25\JJ\1740 drug_26\NN\14778436 or_27\CC\3541091 in_28\IN\13603305 the_29\DT\1740 form_30\NN\6286395 of_31\IN\1740 three_32\CD\13741022 n-(2-hydroxypropyl)methacrylamide_33\NN\1740 (_34\-LRB-\1740 <e1>hpma</e1>_35\NN\1740 )_36\-RRB-\1740 copolymer_37\NN\14994328 conjugates_38\NNS\14589223 ._39\.\1740
17879217
D012293_D005921 CID <e1>rifampicin-associated</e1>_0\JJ\1740 segmental_1\JJ\1740 necrotizing_2\NN\1740 <e2>glomerulonephritis</e2>_3\NN\14113798 in_4\IN\13603305 staphylococcal_5\JJ\1740 endocarditis_6\NN\14338942 ._7\.\1740
D012293_D005921 CID segmental_0\JJ\1740 necrotising_1\JJ\1740 <e2>glomerulonephritis</e2>_2\NN\14113798 has_3\VBZ\2108377 been_4\VBN\836236 reported_5\VBN\831651 as_6\IN\14622893 complication_7\NN\1073995 of_8\IN\1740 <e1>rifampicin</e1>_9\NN\1740 therapy_10\NN\657604 in_11\IN\13603305 patients_12\NNS\9898892 receiving_13\VBG\2210855 treatment_14\NN\654885 for_15\IN\1740 tuberculosis_16\NN\14127211 ._17\.\1740
D012293_D005921 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 staphylococcal_8\JJ\1740 ie_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 acute_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 <e2>glomerulonephritis</e2>_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 <e1>rifampicin</e1>_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 rifampicin_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012293_D005921 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 staphylococcal_8\JJ\1740 ie_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 acute_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 <e2>glomerulonephritis</e2>_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 rifampicin_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 <e1>rifampicin</e1>_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012293_D013203 NONE <e1>rifampicin-associated</e1>_0\JJ\1740 segmental_1\JJ\1740 necrotizing_2\NN\1740 glomerulonephritis_3\NN\14113798 in_4\IN\13603305 <e2>staphylococcal_5\JJ\1740 endocarditis</e2>_6\NN\14338942 ._7\.\1740
D012293_D013203 NONE changing_0\VBG\46534 epidemiology_1\NN\6043075 of_2\IN\1740 infections_3\NNS\14052046 such_4\JJ\1740 as_5\IN\14622893 infective_6\JJ\1740 endocarditis_7\NN\14338942 (_8\-LRB-\1740 ie_9\NN\1740 )_10\-RRB-\1740 has_11\VBZ\2108377 led_12\VBN\1752884 to_13\TO\1740 an_14\DT\6697703 increase_15\NN\13576355 in_16\IN\13603305 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 <e1>rifampicin</e1>_20\NN\1740 for_21\IN\1740 <e2>staphylococcal_22\JJ\1740 infections</e2>_23\NNS\14052046 ._24\.\1740
D012293_D013203 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>staphylococcal_8\JJ\1740 ie</e2>_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 acute_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 glomerulonephritis_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 <e1>rifampicin</e1>_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 rifampicin_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012293_D013203 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>staphylococcal_8\JJ\1740 ie</e2>_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 acute_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 glomerulonephritis_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 rifampicin_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 <e1>rifampicin</e1>_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012293_D004696 NONE <e1>rifampicin-associated</e1>_0\JJ\1740 segmental_1\JJ\1740 necrotizing_2\NN\1740 glomerulonephritis_3\NN\14113798 in_4\IN\13603305 <e2>staphylococcal_5\JJ\1740 endocarditis</e2>_6\NN\14338942 ._7\.\1740
D012293_D004696 NONE changing_0\VBG\46534 epidemiology_1\NN\6043075 of_2\IN\1740 infections_3\NNS\14052046 such_4\JJ\1740 as_5\IN\14622893 <e2>infective_6\JJ\1740 endocarditis</e2>_7\NN\14338942 (_8\-LRB-\1740 ie_9\NN\1740 )_10\-RRB-\1740 has_11\VBZ\2108377 led_12\VBN\1752884 to_13\TO\1740 an_14\DT\6697703 increase_15\NN\13576355 in_16\IN\13603305 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 <e1>rifampicin</e1>_20\NN\1740 for_21\IN\1740 staphylococcal_22\JJ\1740 infections_23\NNS\14052046 ._24\.\1740
D012293_D004696 NONE changing_0\VBG\46534 epidemiology_1\NN\6043075 of_2\IN\1740 infections_3\NNS\14052046 such_4\JJ\1740 as_5\IN\14622893 infective_6\JJ\1740 endocarditis_7\NN\14338942 (_8\-LRB-\1740 <e2>ie</e2>_9\NN\1740 )_10\-RRB-\1740 has_11\VBZ\2108377 led_12\VBN\1752884 to_13\TO\1740 an_14\DT\6697703 increase_15\NN\13576355 in_16\IN\13603305 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 <e1>rifampicin</e1>_20\NN\1740 for_21\IN\1740 staphylococcal_22\JJ\1740 infections_23\NNS\14052046 ._24\.\1740
D012293_D004696 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>staphylococcal_8\JJ\1740 ie</e2>_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 acute_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 glomerulonephritis_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 <e1>rifampicin</e1>_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 rifampicin_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012293_D004696 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>staphylococcal_8\JJ\1740 ie</e2>_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 acute_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 glomerulonephritis_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 rifampicin_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 <e1>rifampicin</e1>_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012293_D014376 NONE segmental_0\JJ\1740 necrotising_1\JJ\1740 glomerulonephritis_2\NN\14113798 has_3\VBZ\2108377 been_4\VBN\836236 reported_5\VBN\831651 as_6\IN\14622893 complication_7\NN\1073995 of_8\IN\1740 <e1>rifampicin</e1>_9\NN\1740 therapy_10\NN\657604 in_11\IN\13603305 patients_12\NNS\9898892 receiving_13\VBG\2210855 treatment_14\NN\654885 for_15\IN\1740 <e2>tuberculosis</e2>_16\NN\14127211 ._17\.\1740
D012293_D007239 NONE changing_0\VBG\46534 epidemiology_1\NN\6043075 of_2\IN\1740 <e2>infections</e2>_3\NNS\14052046 such_4\JJ\1740 as_5\IN\14622893 infective_6\JJ\1740 endocarditis_7\NN\14338942 (_8\-LRB-\1740 ie_9\NN\1740 )_10\-RRB-\1740 has_11\VBZ\2108377 led_12\VBN\1752884 to_13\TO\1740 an_14\DT\6697703 increase_15\NN\13576355 in_16\IN\13603305 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 <e1>rifampicin</e1>_20\NN\1740 for_21\IN\1740 staphylococcal_22\JJ\1740 infections_23\NNS\14052046 ._24\.\1740
D012293_D058186 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 staphylococcal_8\JJ\1740 ie_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 <e2>acute_12\JJ\1740 renal_13\JJ\1740 failure</e2>_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 glomerulonephritis_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 <e1>rifampicin</e1>_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 rifampicin_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
D012293_D058186 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 staphylococcal_8\JJ\1740 ie_9\NN\1740 who_10\WP\8299493 developed_11\VBD\1753788 <e2>acute_12\JJ\1740 renal_13\JJ\1740 failure</e2>_14\NN\66216 secondary_15\JJ\1740 to_16\TO\1740 a_17\DT\13649268 segmental_18\JJ\1740 necrotising_19\JJ\1740 glomerulonephritis_20\NN\14113798 while_21\IN\15122231 being_22\VBG\836236 treated_23\VBN\2376958 with_24\IN\1740 rifampicin_25\NN\1740 ,_26\,\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 literature_30\NN\6362953 regarding_31\VBG\689344 this_32\DT\1740 complication_33\NN\1073995 of_34\IN\1740 <e1>rifampicin</e1>_35\NN\1740 therapy_36\NN\657604 ._37\.\1740
8957205
D000324_D006935 NONE human_0\JJ\1740 <e1>corticotropin-releasing</e1>_1\JJ\1740 hormone_2\NN\5404728 and_3\CC\1740 thyrotropin-releasing_4\JJ\1740 hormone_5\NN\5404728 modulate_6\VBP\1724459 the_7\DT\1740 <e2>hypercapnic</e2>_8\JJ\1740 ventilatory_9\JJ\1740 response_10\NN\11410625 in_11\IN\13603305 humans_12\NNS\31264 ._13\.\1740
D013972_D006935 NONE human_0\JJ\1740 corticotropin-releasing_1\JJ\1740 hormone_2\NN\5404728 and_3\CC\1740 <e1>thyrotropin-releasing</e1>_4\JJ\1740 hormone_5\NN\5404728 modulate_6\VBP\1724459 the_7\DT\1740 <e2>hypercapnic</e2>_8\JJ\1740 ventilatory_9\JJ\1740 response_10\NN\11410625 in_11\IN\13603305 humans_12\NNS\31264 ._13\.\1740
24816962
D008795_D001927 CID <e1>metronidazole-induced</e1>_0\JJ\1740 <e2>encephalopathy</e2>_1\RB\1740 :_2\:\1740 an_3\DT\6697703 uncommon_4\JJ\1740 scenario_5\NN\7009946 ._6\.\1740
D008795_D001927 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 where_4\WRB\1740 a_5\DT\13649268 patient_6\NN\9898892 developed_7\VBD\1753788 features_8\NNS\5849040 of_9\IN\1740 <e2>encephalopathy</e2>_10\JJ\1740 following_11\VBG\1835496 prolonged_12\JJ\1740 <e1>metronidazole</e1>_13\NN\2723292 intake_14\NN\13440063 ._15\.\1740
D008795_D064420 NONE the_0\DT\1740 diagnosis_1\NN\152018 of_2\IN\1740 <e1>metronidazole</e1>_3\NN\2723292 <e2>toxicity</e2>_4\NN\13576101 was_5\VBD\836236 made_6\VBN\126264 by_7\IN\1740 the_8\DT\1740 mri_9\NN\901083 findings_10\NNS\7951464 and_11\CC\1740 supported_12\VBD\2199590 clinically_13\RB\1740 ._14\.\1740
12950111
D006024_D013547 NONE treatment_0\NN\654885 of_1\IN\1740 compensatory_2\JJ\1740 <e2>gustatory_3\NN\1740 hyperhidrosis</e2>_4\NN\13535261 with_5\IN\1740 topical_6\JJ\1740 <e1>glycopyrrolate</e1>_7\NN\1740 ._8\.\1740
D006024_D013547 NONE after_0\IN\1740 applying_1\VBG\2676054 topical_2\JJ\1740 <e1>glycopyrrolate</e1>_3\NN\1740 ,_4\,\1740 the_5\DT\1740 subjective_6\JJ\1740 effect_7\NN\34213 was_8\VBD\836236 excellent_9\JJ\1740 (_10\-LRB-\1740 no_11\DT\7204911 <e2>sweating</e2>_12\NN\13440063 after_13\IN\1740 eating_14\VBG\1156834 hot_15\JJ\1740 spicy_16\JJ\1740 food_17\NN\20090 )_18\-RRB-\1740 in_19\IN\13603305 10_20\CD\13745420 patients_21\NNS\9898892 (_22\-LRB-\1740 77_23\CD\1740 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 fair_28\JJ\1740 (_29\-LRB-\1740 clearly_30\RB\1740 reduced_31\VBN\441445 sweating_32\NN\13440063 )_33\-RRB-\1740 in_34\IN\13603305 3_35\CD\13741022 patients_36\NNS\9898892 (_37\-LRB-\1740 23_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D006024_D013547 NONE after_0\IN\1740 applying_1\VBG\2676054 topical_2\JJ\1740 <e1>glycopyrrolate</e1>_3\NN\1740 ,_4\,\1740 the_5\DT\1740 subjective_6\JJ\1740 effect_7\NN\34213 was_8\VBD\836236 excellent_9\JJ\1740 (_10\-LRB-\1740 no_11\DT\7204911 sweating_12\NN\13440063 after_13\IN\1740 eating_14\VBG\1156834 hot_15\JJ\1740 spicy_16\JJ\1740 food_17\NN\20090 )_18\-RRB-\1740 in_19\IN\13603305 10_20\CD\13745420 patients_21\NNS\9898892 (_22\-LRB-\1740 77_23\CD\1740 %_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 fair_28\JJ\1740 (_29\-LRB-\1740 clearly_30\RB\1740 reduced_31\VBN\441445 <e2>sweating</e2>_32\NN\13440063 )_33\-RRB-\1740 in_34\IN\13603305 3_35\CD\13741022 patients_36\NNS\9898892 (_37\-LRB-\1740 23_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D006024_D013547 NONE the_0\DT\1740 topical_1\JJ\1740 application_2\NN\947128 of_3\IN\1740 a_4\DT\13649268 <e1>glycopyrrolate</e1>_5\NN\1740 pad_6\NN\14974264 appeared_7\VBD\2604760 to_8\TO\1740 be_9\VB\836236 safe_10\JJ\1740 ,_11\,\1740 efficacious_12\JJ\1740 ,_13\,\1740 well_14\RB\1740 tolerated_15\VBN\802318 ,_16\,\1740 and_17\CC\1740 a_18\DT\13649268 convenient_19\JJ\1740 method_20\NN\5616786 of_21\IN\1740 treatment_22\NN\654885 for_23\IN\1740 moderate_24\JJ\1740 to_25\IN\1740 severe_26\JJ\1740 symptoms_27\NNS\5823932 of_28\IN\1740 <e2>gustatory_29\JJ\1740 hyperhidrosis</e2>_30\NN\13535261 in_31\IN\13603305 post_32\NN\8621598 transthoracic_33\NN\1740 endoscopic_34\JJ\1740 sympathectomy_35\NN\393369 or_36\CC\3541091 sympathicotomy_37\NN\1740 patients_38\NNS\9898892 ,_39\,\1740 with_40\IN\1740 few_41\JJ\1740 side_42\NN\8630039 effects_43\NNS\13245626 ._44\.\1740
D006024_D014987 NONE adverse_0\JJ\1740 effects_1\NNS\13245626 included_2\VBD\690614 a_3\DT\13649268 mildly_4\RB\1740 <e2>dry_5\JJ\1740 mouth</e2>_6\NN\5610008 and_7\CC\1740 a_8\DT\13649268 sore_9\JJ\1740 throat_10\NN\5548726 in_11\IN\13603305 2_12\CD\13741022 patients_13\NNS\9898892 (_14\-LRB-\1740 2_15\CD\13741022 %_16\NN\1740 <e1>glycopyrrolate</e1>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 light_21\JJ\1740 headache_22\NN\5829480 in_23\IN\13603305 1_24\CD\13741022 patient_25\NN\9898892 (_26\-LRB-\1740 1.5_27\CD\1740 %_28\NN\1740 glycopyrrolate_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D006024_D014987 NONE adverse_0\JJ\1740 effects_1\NNS\13245626 included_2\VBD\690614 a_3\DT\13649268 mildly_4\RB\1740 <e2>dry_5\JJ\1740 mouth</e2>_6\NN\5610008 and_7\CC\1740 a_8\DT\13649268 sore_9\JJ\1740 throat_10\NN\5548726 in_11\IN\13603305 2_12\CD\13741022 patients_13\NNS\9898892 (_14\-LRB-\1740 2_15\CD\13741022 %_16\NN\1740 glycopyrrolate_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 light_21\JJ\1740 headache_22\NN\5829480 in_23\IN\13603305 1_24\CD\13741022 patient_25\NN\9898892 (_26\-LRB-\1740 1.5_27\CD\1740 %_28\NN\1740 <e1>glycopyrrolate</e1>_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D006024_D010612 CID adverse_0\JJ\1740 effects_1\NNS\13245626 included_2\VBD\690614 a_3\DT\13649268 mildly_4\RB\1740 dry_5\JJ\1740 mouth_6\NN\5610008 and_7\CC\1740 a_8\DT\13649268 <e2>sore_9\JJ\1740 throat</e2>_10\NN\5548726 in_11\IN\13603305 2_12\CD\13741022 patients_13\NNS\9898892 (_14\-LRB-\1740 2_15\CD\13741022 %_16\NN\1740 <e1>glycopyrrolate</e1>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 light_21\JJ\1740 headache_22\NN\5829480 in_23\IN\13603305 1_24\CD\13741022 patient_25\NN\9898892 (_26\-LRB-\1740 1.5_27\CD\1740 %_28\NN\1740 glycopyrrolate_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D006024_D010612 CID adverse_0\JJ\1740 effects_1\NNS\13245626 included_2\VBD\690614 a_3\DT\13649268 mildly_4\RB\1740 dry_5\JJ\1740 mouth_6\NN\5610008 and_7\CC\1740 a_8\DT\13649268 <e2>sore_9\JJ\1740 throat</e2>_10\NN\5548726 in_11\IN\13603305 2_12\CD\13741022 patients_13\NNS\9898892 (_14\-LRB-\1740 2_15\CD\13741022 %_16\NN\1740 glycopyrrolate_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 light_21\JJ\1740 headache_22\NN\5829480 in_23\IN\13603305 1_24\CD\13741022 patient_25\NN\9898892 (_26\-LRB-\1740 1.5_27\CD\1740 %_28\NN\1740 <e1>glycopyrrolate</e1>_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D006024_D006261 CID adverse_0\JJ\1740 effects_1\NNS\13245626 included_2\VBD\690614 a_3\DT\13649268 mildly_4\RB\1740 dry_5\JJ\1740 mouth_6\NN\5610008 and_7\CC\1740 a_8\DT\13649268 sore_9\JJ\1740 throat_10\NN\5548726 in_11\IN\13603305 2_12\CD\13741022 patients_13\NNS\9898892 (_14\-LRB-\1740 2_15\CD\13741022 %_16\NN\1740 <e1>glycopyrrolate</e1>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 light_21\JJ\1740 <e2>headache</e2>_22\NN\5829480 in_23\IN\13603305 1_24\CD\13741022 patient_25\NN\9898892 (_26\-LRB-\1740 1.5_27\CD\1740 %_28\NN\1740 glycopyrrolate_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D006024_D006261 CID adverse_0\JJ\1740 effects_1\NNS\13245626 included_2\VBD\690614 a_3\DT\13649268 mildly_4\RB\1740 dry_5\JJ\1740 mouth_6\NN\5610008 and_7\CC\1740 a_8\DT\13649268 sore_9\JJ\1740 throat_10\NN\5548726 in_11\IN\13603305 2_12\CD\13741022 patients_13\NNS\9898892 (_14\-LRB-\1740 2_15\CD\13741022 %_16\NN\1740 glycopyrrolate_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 a_20\DT\13649268 light_21\JJ\1740 <e2>headache</e2>_22\NN\5829480 in_23\IN\13603305 1_24\CD\13741022 patient_25\NN\9898892 (_26\-LRB-\1740 1.5_27\CD\1740 %_28\NN\1740 <e1>glycopyrrolate</e1>_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
20024739
D000431_D015658 NONE longitudinal_0\JJ\1740 association_1\NN\8008335 of_2\IN\1740 <e1>alcohol</e1>_3\NN\7881800 use_4\NN\407535 with_5\IN\1740 <e2>hiv_6\NN\14186340 disease</e2>_7\NN\14061805 progression_8\NN\8457976 and_9\CC\1740 psychological_10\JJ\1740 health_11\NN\14447525 of_12\IN\1740 women_13\NNS\9605289 with_14\IN\1740 hiv_15\NN\14186340 ._16\.\1740
D000431_D015658 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 association_3\NN\8008335 of_4\IN\1740 <e1>alcohol</e1>_5\NN\7881800 consumption_6\NN\13440063 and_7\CC\1740 depression_8\NN\14373582 ,_9\,\1740 and_10\CC\1740 their_11\PRP$\1740 effects_12\NNS\13245626 on_13\IN\1740 <e2>hiv_14\NN\14186340 disease</e2>_15\NN\14061805 progression_16\NN\8457976 among_17\IN\1740 women_18\NNS\9605289 with_19\IN\1740 hiv_20\NN\14186340 ._21\.\1740
D000431_D003866 CID we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 association_3\NN\8008335 of_4\IN\1740 <e1>alcohol</e1>_5\NN\7881800 consumption_6\NN\13440063 and_7\CC\1740 <e2>depression</e2>_8\NN\14373582 ,_9\,\1740 and_10\CC\1740 their_11\PRP$\1740 effects_12\NNS\13245626 on_13\IN\1740 hiv_14\NN\14186340 disease_15\NN\14061805 progression_16\NN\8457976 among_17\IN\1740 women_18\NNS\9605289 with_19\IN\1740 hiv_20\NN\14186340 ._21\.\1740
D000431_D003866 CID the_0\DT\1740 participants_1\NNS\9816771 had_2\VBD\2108377 physical_3\JJ\1740 examination_4\NN\633864 ,_5\,\1740 medical_6\JJ\1740 record_7\NN\6643408 extraction_8\NN\13518963 ,_9\,\1740 and_10\CC\1740 venipuncture_11\VB\1740 ,_12\,\1740 cd4+t-cell_13\JJ\1740 counts_14\NNS\13582013 determination_15\NN\43195 ,_16\,\1740 measurement_17\NN\407535 of_18\IN\1740 <e2>depression</e2>_19\NN\14373582 symptoms_20\NNS\5823932 (_21\-LRB-\1740 using_22\VBG\1156834 the_23\DT\1740 self-report_24\JJ\1740 center_25\NNP\8497294 for_26\IN\1740 epidemiological_27\NNP\1740 studies-depression_28\NN\1740 scale_29\NN\7260623 )_30\-RRB-\1740 ,_31\,\1740 and_32\CC\1740 <e1>alcohol</e1>_33\NN\7881800 use_34\VBP\1156834 assessment_35\NN\5732756 at_36\IN\14622893 enrollment_37\NN\49003 ,_38\,\1740 and_39\CC\1740 semiannually_40\RB\1740 until_41\IN\1740 march_42\NNP\15209706 2000_43\CD\1740 ._44\.\1740
D000431_D003866 CID the_0\DT\1740 participants_1\NNS\9816771 had_2\VBD\2108377 physical_3\JJ\1740 examination_4\NN\633864 ,_5\,\1740 medical_6\JJ\1740 record_7\NN\6643408 extraction_8\NN\13518963 ,_9\,\1740 and_10\CC\1740 venipuncture_11\VB\1740 ,_12\,\1740 cd4+t-cell_13\JJ\1740 counts_14\NNS\13582013 determination_15\NN\43195 ,_16\,\1740 measurement_17\NN\407535 of_18\IN\1740 depression_19\NN\14373582 symptoms_20\NNS\5823932 (_21\-LRB-\1740 using_22\VBG\1156834 the_23\DT\1740 self-report_24\JJ\1740 center_25\NNP\8497294 for_26\IN\1740 epidemiological_27\NNP\1740 <e2>studies-depression</e2>_28\NN\1740 scale_29\NN\7260623 )_30\-RRB-\1740 ,_31\,\1740 and_32\CC\1740 <e1>alcohol</e1>_33\NN\7881800 use_34\VBP\1156834 assessment_35\NN\5732756 at_36\IN\14622893 enrollment_37\NN\49003 ,_38\,\1740 and_39\CC\1740 semiannually_40\RB\1740 until_41\IN\1740 march_42\NNP\15209706 2000_43\CD\1740 ._44\.\1740
D000431_D003866 CID the_0\DT\1740 association_1\NN\8008335 between_2\IN\1740 <e1>alcohol</e1>_3\NN\7881800 consumption_4\NN\13440063 and_5\CC\1740 <e2>depression</e2>_6\NN\14373582 was_7\VBD\836236 significant_8\JJ\1740 (_9\-LRB-\1740 p<0.001_10\NN\1740 )_11\-RRB-\1740 ._12\.\1740
D000431_D003866 CID our_0\PRP$\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>alcohol</e1>_4\NN\7881800 consumption_5\NN\13440063 has_6\VBZ\2108377 a_7\DT\13649268 direct_8\JJ\1740 association_9\NN\8008335 with_10\IN\1740 <e2>depression</e2>_11\NN\14373582 ._12\.\1740
24717468
D020927_D007022 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 <e2>hypotension</e2>_3\NN\14057371 and_4\CC\1740 bradycardia_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 <e1>dexmedetomidine</e1>_16\NN\1740 or_17\CC\3541091 propofol_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 hypotension_27\NN\14057371 or_28\CC\3541091 bradycardia_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
D020927_D007022 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 hypotension_3\NN\14057371 and_4\CC\1740 bradycardia_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 <e1>dexmedetomidine</e1>_16\NN\1740 or_17\CC\3541091 propofol_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 <e2>hypotension</e2>_27\NN\14057371 or_28\CC\3541091 bradycardia_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
D020927_D001919 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 hypotension_3\NN\14057371 and_4\CC\1740 <e2>bradycardia</e2>_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 <e1>dexmedetomidine</e1>_16\NN\1740 or_17\CC\3541091 propofol_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 hypotension_27\NN\14057371 or_28\CC\3541091 bradycardia_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
D020927_D001919 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 hypotension_3\NN\14057371 and_4\CC\1740 bradycardia_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 <e1>dexmedetomidine</e1>_16\NN\1740 or_17\CC\3541091 propofol_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 hypotension_27\NN\14057371 or_28\CC\3541091 <e2>bradycardia</e2>_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
D015742_D007022 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 <e2>hypotension</e2>_3\NN\14057371 and_4\CC\1740 bradycardia_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 dexmedetomidine_16\NN\1740 or_17\CC\3541091 <e1>propofol</e1>_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 hypotension_27\NN\14057371 or_28\CC\3541091 bradycardia_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
D015742_D007022 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 hypotension_3\NN\14057371 and_4\CC\1740 bradycardia_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 dexmedetomidine_16\NN\1740 or_17\CC\3541091 <e1>propofol</e1>_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 <e2>hypotension</e2>_27\NN\14057371 or_28\CC\3541091 bradycardia_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
D015742_D001919 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 hypotension_3\NN\14057371 and_4\CC\1740 <e2>bradycardia</e2>_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 dexmedetomidine_16\NN\1740 or_17\CC\3541091 <e1>propofol</e1>_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 hypotension_27\NN\14057371 or_28\CC\3541091 bradycardia_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
D015742_D001919 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 hypotension_3\NN\14057371 and_4\CC\1740 bradycardia_5\NN\14110674 occur_6\VBP\2623529 at_7\IN\14622893 similar_8\JJ\1740 prevalence_9\NN\4764412 in_10\IN\13603305 neurocritical_11\JJ\1740 care_12\NN\575741 patients_13\NNS\9898892 who_14\WP\8299493 receive_15\VBP\2210855 dexmedetomidine_16\NN\1740 or_17\CC\3541091 <e1>propofol</e1>_18\NN\1740 ._19\.\1740 providers_20\NNS\9882716 should_21\MD\1740 similarly_22\RB\1740 consider_23\VB\689344 the_24\DT\1740 likelihood_25\NN\4756172 of_26\IN\1740 hypotension_27\NN\14057371 or_28\CC\3541091 <e2>bradycardia</e2>_29\NN\14110674 before_30\IN\1740 starting_31\VBG\2009433 either_32\CC\1740 sedative_33\JJ\1740 ._34\.\1740
8985298
D019259_D006509 NONE <e1>lamivudine</e1>_0\NN\3834836 is_1\VBZ\836236 effective_2\JJ\1740 in_3\IN\13603305 suppressing_4\VBG\2510337 <e2>hepatitis_5\NN\14127211 b</e2>_6\NN\1355326 virus_7\NN\9312843 dna_8\NN\14994328 in_9\IN\13603305 chinese_10\JJ\1740 hepatitis_11\NN\14127211 b_12\NN\1355326 surface_13\NN\21939 antigen_14\NN\20090 carriers_15\NNS\9629752 :_16\:\1740 a_17\DT\13649268 placebo-controlled_18\JJ\1740 trial_19\NN\786195 ._20\.\1740
D019259_D006509 NONE <e1>lamivudine</e1>_0\NN\3834836 is_1\VBZ\836236 a_2\DT\13649268 novel_3\JJ\1740 2',3'-dideoxy_4\NN\1740 cytosine_5\NN\14999913 analogue_6\NN\4743605 that_7\WDT\1740 has_8\VBZ\2108377 potent_9\JJ\1740 inhibitory_10\JJ\1740 effects_11\NNS\13245626 on_12\IN\1740 <e2>hepatitis_13\NN\14127211 b</e2>_14\NN\1355326 virus_15\NN\9312843 replication_16\NN\1019524 in_17\FW\13603305 vitro_18\FW\1740 and_19\CC\1740 in_20\FW\13603305 vivo_21\FW\1740 ._22\.\1740
D019259_D006509 NONE lamivudine_0\NN\3834836 is_1\VBZ\836236 a_2\DT\13649268 novel_3\JJ\1740 <e1>2',3'-dideoxy_4\NN\1740 cytosine</e1>_5\NN\14999913 analogue_6\NN\4743605 that_7\WDT\1740 has_8\VBZ\2108377 potent_9\JJ\1740 inhibitory_10\JJ\1740 effects_11\NNS\13245626 on_12\IN\1740 <e2>hepatitis_13\NN\14127211 b</e2>_14\NN\1355326 virus_15\NN\9312843 replication_16\NN\1019524 in_17\FW\13603305 vitro_18\FW\1740 and_19\CC\1740 in_20\FW\13603305 vivo_21\FW\1740 ._22\.\1740
D019259_D006509 NONE all_0\DT\1740 36_1\CD\1740 patients_2\NNS\9898892 receiving_3\VBG\2210855 <e1>lamivudine</e1>_4\NN\3834836 had_5\VBD\2108377 a_6\DT\13649268 decrease_7\NN\7296428 in_8\IN\13603305 <e2>hepatitis_9\NN\14127211 b</e2>_10\NN\1355326 virus_11\NN\9312843 (_12\-LRB-\1740 hbv_13\NN\1740 )_14\-RRB-\1740 dna_15\NN\14994328 values_16\NNS\5941423 of_17\IN\1740 >_18\NN\1740 90_19\CD\13745420 %_20\NN\1740 (_21\-LRB-\1740 p_22\NN\14622893 <_23\XX\1740 .001_24\CD\1740 compared_25\VBN\644583 with_26\IN\1740 placebo_27\NN\3740161 )_28\-RRB-\1740 ._29\.\1740
D006514_D006509 CID lamivudine_0\NN\3834836 is_1\VBZ\836236 effective_2\JJ\1740 in_3\IN\13603305 suppressing_4\VBG\2510337 <e2>hepatitis_5\NN\14127211 b</e2>_6\NN\1355326 virus_7\NN\9312843 dna_8\NN\14994328 in_9\IN\13603305 chinese_10\JJ\1740 <e1>hepatitis_11\NN\14127211 b_12\NN\1355326 surface_13\NN\21939 antigen</e1>_14\NN\20090 carriers_15\NNS\9629752 :_16\:\1740 a_17\DT\13649268 placebo-controlled_18\JJ\1740 trial_19\NN\786195 ._20\.\1740
24927617
C486464_D012206 CID <e2>rhabdomyolysis</e2>_0\NN\1740 in_1\IN\13603305 a_2\DT\13649268 hepatitis_3\NN\14127211 c_4\NN\13714184 virus_5\NN\9312843 infected_6\JJ\1740 patient_7\NN\9898892 treated_8\VBN\2376958 with_9\IN\1740 <e1>telaprevir</e1>_10\NN\1740 and_11\CC\1740 simvastatin_12\NN\3676175 ._13\.\1740
C486464_D006526 NONE rhabdomyolysis_0\NN\1740 in_1\IN\13603305 a_2\DT\13649268 <e2>hepatitis_3\NN\14127211 c_4\NN\13714184 virus_5\NN\9312843 infected</e2>_6\JJ\1740 patient_7\NN\9898892 treated_8\VBN\2376958 with_9\IN\1740 <e1>telaprevir</e1>_10\NN\1740 and_11\CC\1740 simvastatin_12\NN\3676175 ._13\.\1740
C486464_D006526 NONE a_0\DT\13649268 46-year_1\JJ\1740 old_2\JJ\1740 man_3\NN\9605289 with_4\IN\1740 a_5\DT\13649268 chronic_6\JJ\1740 <e2>hepatitis_7\NN\14127211 c_8\NN\13714184 virus_9\NN\9312843 infection</e2>_10\NN\14052046 received_11\VBD\2210855 triple_12\JJ\1740 therapy_13\NN\657604 with_14\IN\1740 ribavirin_15\NN\2725367 ,_16\,\1740 pegylated_17\JJ\1740 interferon_18\NN\2725367 and_19\CC\1740 <e1>telaprevir</e1>_20\NN\1740 ._21\.\1740
D019821_D012206 CID <e2>rhabdomyolysis</e2>_0\NN\1740 in_1\IN\13603305 a_2\DT\13649268 hepatitis_3\NN\14127211 c_4\NN\13714184 virus_5\NN\9312843 infected_6\JJ\1740 patient_7\NN\9898892 treated_8\VBN\2376958 with_9\IN\1740 telaprevir_10\NN\1740 and_11\CC\1740 <e1>simvastatin</e1>_12\NN\3676175 ._13\.\1740
D019821_D006526 NONE rhabdomyolysis_0\NN\1740 in_1\IN\13603305 a_2\DT\13649268 <e2>hepatitis_3\NN\14127211 c_4\NN\13714184 virus_5\NN\9312843 infected</e2>_6\JJ\1740 patient_7\NN\9898892 treated_8\VBN\2376958 with_9\IN\1740 telaprevir_10\NN\1740 and_11\CC\1740 <e1>simvastatin</e1>_12\NN\3676175 ._13\.\1740
D012254_D006526 NONE a_0\DT\13649268 46-year_1\JJ\1740 old_2\JJ\1740 man_3\NN\9605289 with_4\IN\1740 a_5\DT\13649268 chronic_6\JJ\1740 <e2>hepatitis_7\NN\14127211 c_8\NN\13714184 virus_9\NN\9312843 infection</e2>_10\NN\14052046 received_11\VBD\2210855 triple_12\JJ\1740 therapy_13\NN\657604 with_14\IN\1740 <e1>ribavirin</e1>_15\NN\2725367 ,_16\,\1740 pegylated_17\JJ\1740 interferon_18\NN\2725367 and_19\CC\1740 telaprevir_20\NN\1740 ._21\.\1740
C417083_D006526 NONE a_0\DT\13649268 46-year_1\JJ\1740 old_2\JJ\1740 man_3\NN\9605289 with_4\IN\1740 a_5\DT\13649268 chronic_6\JJ\1740 <e2>hepatitis_7\NN\14127211 c_8\NN\13714184 virus_9\NN\9312843 infection</e2>_10\NN\14052046 received_11\VBD\2210855 triple_12\JJ\1740 therapy_13\NN\657604 with_14\IN\1740 ribavirin_15\NN\2725367 ,_16\,\1740 <e1>pegylated_17\JJ\1740 interferon</e1>_18\NN\2725367 and_19\CC\1740 telaprevir_20\NN\1740 ._21\.\1740
D019821_D064420 NONE at_0\IN\14622893 admission_1\NN\49003 <e1>simvastatin</e1>_2\NN\3676175 and_3\CC\1740 all_4\DT\1740 antiviral_5\JJ\1740 drugs_6\NNS\14778436 were_7\VBD\836236 discontinued_8\VBN\2609764 because_9\IN\1740 <e2>toxicity</e2>_10\NN\13576101 due_11\IN\5174653 to_12\TO\1740 a_13\DT\13649268 drug-drug_14\JJ\1740 interaction_15\NN\37396 was_16\VBD\836236 suspected_17\VBN\916909 ._18\.\1740
D019821_D009135 CID <e1>simvastatin</e1>_0\JJ\1740 plasma_1\NN\5398023 concentration_2\NN\4916342 increased_3\VBD\169651 30_4\CD\13745420 times_5\NNS\15113229 in_6\IN\13603305 this_7\DT\1740 patient_8\NN\9898892 and_9\CC\1740 statin_10\NN\3740161 induced_11\JJ\1740 <e2>muscle_12\NN\5289601 toxicity</e2>_13\NN\13576101 is_14\VBZ\836236 related_15\JJ\1740 to_16\TO\1740 the_17\DT\1740 concentration_18\NN\4916342 of_19\IN\1740 the_20\DT\1740 statin_21\NN\3740161 in_22\IN\13603305 blood_23\NN\5397468 ._24\.\1740
D019821_D009135 CID simvastatin_0\JJ\1740 plasma_1\NN\5398023 concentration_2\NN\4916342 increased_3\VBD\169651 30_4\CD\13745420 times_5\NNS\15113229 in_6\IN\13603305 this_7\DT\1740 patient_8\NN\9898892 and_9\CC\1740 <e1>statin</e1>_10\NN\3740161 induced_11\JJ\1740 <e2>muscle_12\NN\5289601 toxicity</e2>_13\NN\13576101 is_14\VBZ\836236 related_15\JJ\1740 to_16\TO\1740 the_17\DT\1740 concentration_18\NN\4916342 of_19\IN\1740 the_20\DT\1740 statin_21\NN\3740161 in_22\IN\13603305 blood_23\NN\5397468 ._24\.\1740
D019821_D009135 CID simvastatin_0\JJ\1740 plasma_1\NN\5398023 concentration_2\NN\4916342 increased_3\VBD\169651 30_4\CD\13745420 times_5\NNS\15113229 in_6\IN\13603305 this_7\DT\1740 patient_8\NN\9898892 and_9\CC\1740 statin_10\NN\3740161 induced_11\JJ\1740 <e2>muscle_12\NN\5289601 toxicity</e2>_13\NN\13576101 is_14\VBZ\836236 related_15\JJ\1740 to_16\TO\1740 the_17\DT\1740 concentration_18\NN\4916342 of_19\IN\1740 the_20\DT\1740 <e1>statin</e1>_21\NN\3740161 in_22\IN\13603305 blood_23\NN\5397468 ._24\.\1740
11474137
D003300_D034381 NONE overexpression_0\NN\1740 of_1\IN\1740 <e1>copper/zinc-superoxide</e1>_2\JJ\1740 dismutase_3\NN\1740 protects_4\VBZ\1127795 from_5\IN\1740 kanamycin-induced_6\JJ\1740 <e2>hearing_7\NN\1184814 loss</e2>_8\NN\13252973 ._9\.\1740
D015032_D034381 NONE overexpression_0\NN\1740 of_1\IN\1740 <e1>copper/zinc-superoxide</e1>_2\JJ\1740 dismutase_3\NN\1740 protects_4\VBZ\1127795 from_5\IN\1740 kanamycin-induced_6\JJ\1740 <e2>hearing_7\NN\1184814 loss</e2>_8\NN\13252973 ._9\.\1740
D013481_D034381 NONE overexpression_0\NN\1740 of_1\IN\1740 <e1>copper/zinc-superoxide</e1>_2\JJ\1740 dismutase_3\NN\1740 protects_4\VBZ\1127795 from_5\IN\1740 kanamycin-induced_6\JJ\1740 <e2>hearing_7\NN\1184814 loss</e2>_8\NN\13252973 ._9\.\1740
D007612_D034381 CID overexpression_0\NN\1740 of_1\IN\1740 copper/zinc-superoxide_2\JJ\1740 dismutase_3\NN\1740 protects_4\VBZ\1127795 from_5\IN\1740 <e1>kanamycin-induced</e1>_6\JJ\1740 <e2>hearing_7\NN\1184814 loss</e2>_8\NN\13252973 ._9\.\1740
D010100_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 <e1>oxygen</e1>_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 <e2>ototoxicity</e2>_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 aminoglycoside-iron_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 ototoxicity_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D010100_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 <e1>oxygen</e1>_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 ototoxicity_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 aminoglycoside-iron_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 <e2>ototoxicity</e2>_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D000617_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 <e1>aminoglycoside-induced</e1>_7\JJ\1740 <e2>ototoxicity</e2>_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 aminoglycoside-iron_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 ototoxicity_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D000617_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 <e1>aminoglycoside-induced</e1>_7\JJ\1740 ototoxicity_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 aminoglycoside-iron_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 <e2>ototoxicity</e2>_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D000617_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 <e2>ototoxicity</e2>_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 <e1>aminoglycoside-iron</e1>_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 ototoxicity_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D000617_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 ototoxicity_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 <e1>aminoglycoside-iron</e1>_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 <e2>ototoxicity</e2>_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D000617_D006311 NONE the_0\DT\1740 protection_1\NN\407535 by_2\IN\1740 overexpression_3\NN\1740 of_4\IN\1740 superoxide_5\NN\14971519 dismutase_6\NN\1740 supports_7\VBZ\2199590 the_8\DT\1740 hypothesis_9\NN\7162194 that_10\IN\1740 oxidant_11\JJ\1740 stress_12\NN\7083732 plays_13\VBZ\1072262 a_14\DT\13649268 significant_15\JJ\1740 role_16\NN\719494 in_17\IN\13603305 <e1>aminoglycoside-induced</e1>_18\JJ\1740 <e2>ototoxicity</e2>_19\NN\1740 ._20\.\1740
D007501_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 <e2>ototoxicity</e2>_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 <e1>aminoglycoside-iron</e1>_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 ototoxicity_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D007501_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 ototoxicity_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 <e1>aminoglycoside-iron</e1>_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 superoxide_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 <e2>ototoxicity</e2>_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D013481_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 <e2>ototoxicity</e2>_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 aminoglycoside-iron_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 <e1>superoxide</e1>_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 ototoxicity_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D013481_D006311 NONE the_0\DT\1740 participation_1\NN\1080366 of_2\IN\1740 reactive_3\JJ\1740 oxygen_4\NN\14622893 species_5\NNS\7992450 in_6\IN\13603305 aminoglycoside-induced_7\JJ\1740 ototoxicity_8\NN\1740 has_9\VBZ\2108377 been_10\VBN\836236 deduced_11\VBN\634472 from_12\IN\1740 observations_13\NNS\996969 that_14\IN\1740 aminoglycoside-iron_15\JJ\1740 complexes_16\NNS\5869584 catalyze_17\VBP\146138 the_18\DT\1740 formation_19\NN\7938773 of_20\IN\1740 <e1>superoxide</e1>_21\NN\14971519 radicals_22\NNS\9465459 in_23\FW\13603305 vitro_24\FW\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 attenuate_28\VBP\224901 <e2>ototoxicity</e2>_29\NN\1740 in_30\FW\13603305 vivo_31\FW\1740 ._32\.\1740
D013481_D006311 NONE we_0\PRP\1740 therefore_1\RB\1740 hypothesized_2\VBD\719734 that_3\IN\1740 overexpression_4\NN\1740 of_5\IN\1740 <e1>cu/zn-superoxide</e1>_6\JJ\1740 dismutase_7\NN\1740 (_8\-LRB-\1740 h-sod1_9\NN\1740 )_10\-RRB-\1740 should_11\MD\1740 protect_12\VB\1127795 transgenic_13\JJ\1740 mice_14\NNS\2329401 from_15\IN\1740 <e2>ototoxicity</e2>_16\NN\1740 ._17\.\1740
D013481_D006311 NONE the_0\DT\1740 protection_1\NN\407535 by_2\IN\1740 overexpression_3\NN\1740 of_4\IN\1740 <e1>superoxide</e1>_5\NN\14971519 dismutase_6\NN\1740 supports_7\VBZ\2199590 the_8\DT\1740 hypothesis_9\NN\7162194 that_10\IN\1740 oxidant_11\JJ\1740 stress_12\NN\7083732 plays_13\VBZ\1072262 a_14\DT\13649268 significant_15\JJ\1740 role_16\NN\719494 in_17\IN\13603305 aminoglycoside-induced_18\JJ\1740 <e2>ototoxicity</e2>_19\NN\1740 ._20\.\1740
D003300_D006311 NONE we_0\PRP\1740 therefore_1\RB\1740 hypothesized_2\VBD\719734 that_3\IN\1740 overexpression_4\NN\1740 of_5\IN\1740 <e1>cu/zn-superoxide</e1>_6\JJ\1740 dismutase_7\NN\1740 (_8\-LRB-\1740 h-sod1_9\NN\1740 )_10\-RRB-\1740 should_11\MD\1740 protect_12\VB\1127795 transgenic_13\JJ\1740 mice_14\NNS\2329401 from_15\IN\1740 <e2>ototoxicity</e2>_16\NN\1740 ._17\.\1740
D015032_D006311 NONE we_0\PRP\1740 therefore_1\RB\1740 hypothesized_2\VBD\719734 that_3\IN\1740 overexpression_4\NN\1740 of_5\IN\1740 <e1>cu/zn-superoxide</e1>_6\JJ\1740 dismutase_7\NN\1740 (_8\-LRB-\1740 h-sod1_9\NN\1740 )_10\-RRB-\1740 should_11\MD\1740 protect_12\VB\1127795 transgenic_13\JJ\1740 mice_14\NNS\2329401 from_15\IN\1740 <e2>ototoxicity</e2>_16\NN\1740 ._17\.\1740
24897009
D004977_D010523 NONE optochiasmatic_0\JJ\1740 and_1\CC\1740 <e2>peripheral_2\JJ\1740 neuropathy</e2>_3\NN\14204950 due_4\JJ\1740 to_5\IN\1740 <e1>ethambutol</e1>_6\JJ\1740 overtreatment_7\NN\1740 ._8\.\1740
D004977_D009901 CID <e1>ethambutol</e1>_0\NNP\1740 is_1\VBZ\836236 known_2\VBN\2110220 to_3\TO\1740 cause_4\VB\1617192 <e2>optic_5\JJ\1740 neuropathy</e2>_6\JJ\1740 and_7\CC\1740 ,_8\,\1740 more_9\RBR\1740 rarely_10\RB\1740 ,_11\,\1740 axonal_12\JJ\1740 polyneuropathy_13\NN\1740 ._14\.\1740
D004977_D011115 CID <e1>ethambutol</e1>_0\NNP\1740 is_1\VBZ\836236 known_2\VBN\2110220 to_3\TO\1740 cause_4\VB\1617192 optic_5\JJ\1740 neuropathy_6\JJ\1740 and_7\CC\1740 ,_8\,\1740 more_9\RBR\1740 rarely_10\RB\1740 ,_11\,\1740 axonal_12\JJ\1740 <e2>polyneuropathy</e2>_13\NN\1740 ._14\.\1740
D004977_D014786 CID we_0\PRP\1740 characterize_1\VBP\609683 the_2\DT\1740 clinical_3\JJ\1740 ,_4\,\1740 neurophysiological_5\JJ\1740 ,_6\,\1740 and_7\CC\1740 neuroimaging_8\JJ\1740 findings_9\NNS\7951464 in_10\IN\13603305 a_11\DT\13649268 72-year-old_12\JJ\1740 man_13\NN\9605289 who_14\WP\8299493 developed_15\VBD\1753788 <e2>visual_16\JJ\1740 loss</e2>_17\NN\13252973 and_18\CC\1740 paresthesias_19\NNS\14299637 after_20\IN\1740 11_21\CD\13745420 weeks_22\NNS\15113229 of_23\IN\1740 exposure_24\NN\5042871 to_25\TO\1740 a_26\DT\13649268 supratherapeutic_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 <e1>ethambutol</e1>_30\NN\1740 ._31\.\1740
D004977_D010292 CID we_0\PRP\1740 characterize_1\VBP\609683 the_2\DT\1740 clinical_3\JJ\1740 ,_4\,\1740 neurophysiological_5\JJ\1740 ,_6\,\1740 and_7\CC\1740 neuroimaging_8\JJ\1740 findings_9\NNS\7951464 in_10\IN\13603305 a_11\DT\13649268 72-year-old_12\JJ\1740 man_13\NN\9605289 who_14\WP\8299493 developed_15\VBD\1753788 visual_16\JJ\1740 loss_17\NN\13252973 and_18\CC\1740 <e2>paresthesias</e2>_19\NNS\14299637 after_20\IN\1740 11_21\CD\13745420 weeks_22\NNS\15113229 of_23\IN\1740 exposure_24\NN\5042871 to_25\TO\1740 a_26\DT\13649268 supratherapeutic_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 <e1>ethambutol</e1>_30\NN\1740 ._31\.\1740
D004977_D064420 NONE this_0\DT\1740 case_1\NN\7283608 demonstrates_2\VBZ\2137132 the_3\DT\1740 selective_4\JJ\1740 vulnerability_5\NN\14540765 of_6\IN\1740 the_7\DT\1740 anterior_8\JJ\1740 visual_9\JJ\1740 pathways_10\NNS\5483677 and_11\CC\1740 peripheral_12\JJ\1740 nerves_13\NNS\14373582 to_14\TO\1740 <e1>ethambutol</e1>_15\JJ\1740 <e2>toxicity</e2>_16\NN\13576101 ._17\.\1740
25071004
C039726_D000740 NONE delayed_0\VBN\439958 <e2>anemia</e2>_1\NN\14189204 after_2\IN\1740 treatment_3\NN\654885 with_4\IN\1740 injectable_5\JJ\1740 <e1>artesunate</e1>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 democratic_9\NNP\1740 republic_10\NNP\8367880 of_11\IN\1740 the_12\DT\1740 congo_13\NNP\7934530 :_14\:\1740 a_15\DT\13649268 manageable_16\JJ\1740 issue_17\NN\5809192 ._18\.\1740
C039726_D000743 CID cases_0\NNS\7283608 of_1\IN\1740 delayed_2\VBN\439958 <e2>hemolytic_3\JJ\1740 anemia</e2>_4\NN\14189204 have_5\VBP\2108377 been_6\VBN\836236 described_7\VBN\1001294 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 injectable_11\JJ\1740 <e1>artesunate</e1>_12\NN\1740 ,_13\,\1740 the_14\DT\1740 current_15\JJ\1740 world_16\NNP\19128 health_17\NNP\14447525 organization_18\NNP\7950920 (who)-recommended_19\VBD\1740 first-line_20\JJ\1740 drug_21\NN\14778436 for_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 severe_26\JJ\1740 malaria_27\NN\14178913 ._28\.\1740
C039726_D008288 NONE cases_0\NNS\7283608 of_1\IN\1740 delayed_2\VBN\439958 hemolytic_3\JJ\1740 anemia_4\NN\14189204 have_5\VBP\2108377 been_6\VBN\836236 described_7\VBN\1001294 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 injectable_11\JJ\1740 <e1>artesunate</e1>_12\NN\1740 ,_13\,\1740 the_14\DT\1740 current_15\JJ\1740 world_16\NNP\19128 health_17\NNP\14447525 organization_18\NNP\7950920 (who)-recommended_19\VBD\1740 first-line_20\JJ\1740 drug_21\NN\14778436 for_22\IN\1740 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 severe_26\JJ\1740 <e2>malaria</e2>_27\NN\14178913 ._28\.\1740
C039726_D008288 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 350_3\CD\1740 patients_4\NNS\9898892 (_5\-LRB-\1740 215_6\CD\1740 [_7\-LRB-\1740 61.4_8\CD\1740 %_9\NN\1740 ]_10\-RRB-\1740 <_11\XX\1740 5_12\CD\13741022 years_13\NNS\15144371 of_14\IN\1740 age_15\NN\4916342 and_16\CC\1740 135_17\CD\1740 [_18\-LRB-\1740 38.6_19\CD\1740 %_20\NN\1740 ]_21\-RRB-\1740 >_22\NNS\1740 5_23\CD\13741022 years_24\NNS\15144371 of_25\IN\1740 age_26\NN\4916342 )_27\-RRB-\1740 were_28\VBD\836236 followed-up_29\JJ\1740 after_30\IN\1740 treatment_31\NN\654885 with_32\IN\1740 injectable_33\JJ\1740 <e1>artesunate</e1>_34\NN\1740 for_35\IN\1740 severe_36\JJ\1740 <e2>malaria</e2>_37\NN\14178913 in_38\IN\13603305 hospitals_39\NNS\3739518 and_40\CC\1740 health_41\NN\14447525 centers_42\NNS\8497294 of_43\IN\1740 the_44\DT\1740 democratic_45\NNP\1740 republic_46\NNP\8367880 of_47\IN\1740 the_48\DT\1740 congo_49\NNP\7934530 ._50\.\1740
19914299
D005473_D008569 NONE <e1>fluoxetine</e1>_0\NN\4169152 improves_1\VBZ\126264 the_2\DT\1740 <e2>memory_3\NN\5926676 deficits</e2>_4\NNS\5113133 caused_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 chemotherapy_8\NN\661091 agent_9\NN\7347 5-fluorouracil_10\NN\1740 ._11\.\1740
D005472_D008569 CID fluoxetine_0\NN\4169152 improves_1\VBZ\126264 the_2\DT\1740 <e2>memory_3\NN\5926676 deficits</e2>_4\NNS\5113133 caused_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 chemotherapy_8\NN\661091 agent_9\NN\7347 <e1>5-fluorouracil</e1>_10\NN\1740 ._11\.\1740
11745287
D016190_D002294 NONE phase_0\NN\15113229 ii_1\CD\13741022 study_2\NN\635850 of_3\IN\1740 <e1>carboplatin</e1>_4\NN\1740 and_5\CC\1740 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 recurrent_11\JJ\1740 <e2>squamous_12\JJ\1740 cell_13\NN\3080309 carcinoma_14\NN\14239918 of_15\IN\1740 the_16\DT\1740 cervix</e2>_17\NN\5225090 ._18\.\1740
D016190_D002294 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 <e1>carboplatin</e1>_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 doxil_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 <e2>squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma</e2>_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 toxicity_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D016190_D002583 NONE phase_0\NN\15113229 ii_1\CD\13741022 study_2\NN\635850 of_3\IN\1740 <e1>carboplatin</e1>_4\NN\1740 and_5\CC\1740 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 recurrent_11\JJ\1740 <e2>squamous_12\JJ\1740 cell_13\NN\3080309 carcinoma_14\NN\14239918 of_15\IN\1740 the_16\DT\1740 cervix</e2>_17\NN\5225090 ._18\.\1740
D016190_D002583 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 activity_3\NN\30358 of_4\IN\1740 the_5\DT\1740 combination_6\NN\7951464 of_7\IN\1740 <e1>carboplatin</e1>_8\NN\1740 and_9\CC\1740 liposomal_10\JJ\1740 doxorubicin_11\NN\2716866 was_12\VBD\836236 tested_13\VBN\670261 in_14\IN\13603305 a_15\DT\13649268 phase_16\NN\15113229 ii_17\CD\13741022 study_18\NN\635850 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 recurrent_22\JJ\1740 <e2>cervical_23\JJ\1740 carcinoma</e2>_24\NN\14239918 ._25\.\1740
D016190_D002583 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 <e1>carboplatin</e1>_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 doxil_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 <e2>squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma</e2>_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 toxicity_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D016190_D002583 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 <e1>carboplatin</e1>_5\NN\1740 and_6\CC\1740 liposomal_7\JJ\1740 doxorubicin_8\NN\2716866 has_9\VBZ\2108377 modest_10\JJ\1740 activity_11\NN\30358 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 recurrent_15\JJ\1740 <e2>cervical_16\JJ\1740 carcinoma</e2>_17\NN\14239918 ._18\.\1740
D004317_D002294 NONE phase_0\NN\15113229 ii_1\CD\13741022 study_2\NN\635850 of_3\IN\1740 carboplatin_4\NN\1740 and_5\CC\1740 liposomal_6\JJ\1740 <e1>doxorubicin</e1>_7\NN\2716866 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 recurrent_11\JJ\1740 <e2>squamous_12\JJ\1740 cell_13\NN\3080309 carcinoma_14\NN\14239918 of_15\IN\1740 the_16\DT\1740 cervix</e2>_17\NN\5225090 ._18\.\1740
D004317_D002294 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 carboplatin_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 <e1>doxorubicin</e1>_20\NN\2716866 (_21\-LRB-\1740 doxil_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 <e2>squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma</e2>_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 toxicity_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D004317_D002294 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 carboplatin_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 <e1>doxil</e1>_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 <e2>squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma</e2>_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 toxicity_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D004317_D002583 NONE phase_0\NN\15113229 ii_1\CD\13741022 study_2\NN\635850 of_3\IN\1740 carboplatin_4\NN\1740 and_5\CC\1740 liposomal_6\JJ\1740 <e1>doxorubicin</e1>_7\NN\2716866 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 recurrent_11\JJ\1740 <e2>squamous_12\JJ\1740 cell_13\NN\3080309 carcinoma_14\NN\14239918 of_15\IN\1740 the_16\DT\1740 cervix</e2>_17\NN\5225090 ._18\.\1740
D004317_D002583 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 activity_3\NN\30358 of_4\IN\1740 the_5\DT\1740 combination_6\NN\7951464 of_7\IN\1740 carboplatin_8\NN\1740 and_9\CC\1740 liposomal_10\JJ\1740 <e1>doxorubicin</e1>_11\NN\2716866 was_12\VBD\836236 tested_13\VBN\670261 in_14\IN\13603305 a_15\DT\13649268 phase_16\NN\15113229 ii_17\CD\13741022 study_18\NN\635850 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 recurrent_22\JJ\1740 <e2>cervical_23\JJ\1740 carcinoma</e2>_24\NN\14239918 ._25\.\1740
D004317_D002583 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 carboplatin_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 <e1>doxorubicin</e1>_20\NN\2716866 (_21\-LRB-\1740 doxil_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 <e2>squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma</e2>_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 toxicity_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D004317_D002583 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 carboplatin_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 <e1>doxil</e1>_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 <e2>squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma</e2>_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 toxicity_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D004317_D002583 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 carboplatin_5\NN\1740 and_6\CC\1740 liposomal_7\JJ\1740 <e1>doxorubicin</e1>_8\NN\2716866 has_9\VBZ\2108377 modest_10\JJ\1740 activity_11\NN\30358 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 recurrent_15\JJ\1740 <e2>cervical_16\JJ\1740 carcinoma</e2>_17\NN\14239918 ._18\.\1740
D016190_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 <e1>carboplatin</e1>_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 doxil_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 <e2>toxicity</e2>_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D004317_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 carboplatin_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 <e1>doxorubicin</e1>_20\NN\2716866 (_21\-LRB-\1740 doxil_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 <e2>toxicity</e2>_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
D004317_D064420 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 carboplatin_5\NN\1740 (_6\-LRB-\1740 area_7\NN\8630985 under_8\IN\1740 the_9\DT\1740 concentration_10\NN\4916342 curve_11\NN\13863771 [_12\-LRB-\1740 auc_13\NN\1740 ]_14\-RRB-\1740 ,_15\,\1740 5_16\LS\13741022 )_17\-RRB-\1740 and_18\CC\1740 liposomal_19\JJ\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 <e1>doxil</e1>_22\NN\1740 ;_23\:\1740 starting_24\VBG\2009433 dose_25\NN\3740161 ,_26\,\1740 40_27\CD\13745420 mg/m(2_28\NN\1740 )_29\-RRB-\1740 )_30\-RRB-\1740 was_31\VBD\836236 administered_32\VBN\2436349 intravenously_33\RB\1740 every_34\DT\1740 28_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 37_38\CD\1740 patients_39\NNS\9898892 with_40\IN\1740 recurrent_41\JJ\1740 squamous_42\JJ\1740 cell_43\NN\3080309 cervical_44\JJ\1740 carcinoma_45\NN\14239918 to_46\TO\1740 determine_47\VB\1645601 antitumor_48\NN\1740 activity_49\NN\30358 and_50\CC\1740 <e2>toxicity</e2>_51\NN\13576101 profile_52\NN\6999802 ._53\.\1740
10510854
D006220_D002375 CID 7e_0\NNP\1740 exhibits_1\VBZ\2632167 a_2\DT\13649268 high_3\JJ\1740 reversal_4\NN\199130 of_5\IN\1740 <e2>catalepsy</e2>_6\NN\14023236 induced_7\VBN\1627355 by_8\IN\1740 <e1>haloperidol</e1>_9\NN\3713736 indicating_10\VBG\952524 its_11\PRP$\6125041 atypical_12\JJ\1740 antipsychotic_13\JJ\1740 nature_14\NN\4723816 ._15\.\1740
1943082
D005978_D007511 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 hepatic_5\JJ\1740 tissue_6\NN\5220461 total_7\JJ\1740 <e1>glutathione</e1>_8\NN\1740 following_9\VBG\1835496 intestinal_10\JJ\1740 <e2>ischemia-reperfusion</e2>_11\NN\1740 injury_12\NN\14052046 ._13\.\1740
D005978_D015427 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 hepatic_5\JJ\1740 tissue_6\NN\5220461 total_7\JJ\1740 <e1>glutathione</e1>_8\NN\1740 following_9\VBG\1835496 intestinal_10\JJ\1740 <e2>ischemia-reperfusion_11\NN\1740 injury</e2>_12\NN\14052046 ._13\.\1740
3074291
C017590_D001249 NONE comparison_0\NN\635850 of_1\IN\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 <e1>oxitropium_5\NN\1740 bromide</e1>_6\NN\14904359 and_7\CC\1740 of_8\IN\1740 slow-release_9\JJ\1740 theophylline_10\NN\2905612 on_11\IN\1740 nocturnal_12\JJ\1740 <e2>asthma</e2>_13\NN\14145095 ._14\.\1740
C017590_D001249 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 a_3\DT\13649268 new_4\JJ\1740 inhaled_5\VBN\1198101 antimuscarinic_6\JJ\1740 drug_7\NN\14778436 ,_8\,\1740 <e1>oxitropium_9\NN\1740 bromide</e1>_10\NN\14904359 ,_11\,\1740 and_12\CC\1740 of_13\IN\1740 a_14\DT\13649268 slow-release_15\JJ\1740 theophylline_16\NN\2905612 preparation_17\NN\407535 upon_18\IN\1740 nocturnal_19\JJ\1740 <e2>asthma</e2>_20\NN\14145095 were_21\VBD\836236 compared_22\VBN\644583 in_23\IN\13603305 a_24\DT\13649268 placebo-controlled_25\JJ\1740 double-blind_26\JJ\1740 study_27\NN\635850 ._28\.\1740
C017590_D001249 NONE <e1>oxitropium</e1>_0\NN\1740 proves_1\VBZ\2604760 to_2\TO\1740 be_3\VB\836236 a_4\DT\13649268 valuable_5\JJ\1740 alternative_6\NN\5788149 to_7\IN\1740 theophylline_8\NN\2905612 in_9\IN\13603305 nocturnal_10\JJ\1740 <e2>asthma</e2>_11\NN\14145095 ,_12\,\1740 since_13\IN\1740 it_14\PRP\6125041 is_15\VBZ\836236 equally_16\RB\1740 potent_17\JJ\1740 ,_18\,\1740 safer_19\JJR\1740 and_20\CC\1740 does_21\VBZ\1640855 not_22\RB\1740 require_23\VB\754942 the_24\DT\1740 titration_25\NN\647713 of_26\IN\1740 dosage_27\NN\13576355 ._28\.\1740
D013806_D001249 NONE comparison_0\NN\635850 of_1\IN\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 oxitropium_5\NN\1740 bromide_6\NN\14904359 and_7\CC\1740 of_8\IN\1740 slow-release_9\JJ\1740 <e1>theophylline</e1>_10\NN\2905612 on_11\IN\1740 nocturnal_12\JJ\1740 <e2>asthma</e2>_13\NN\14145095 ._14\.\1740
D013806_D001249 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 a_3\DT\13649268 new_4\JJ\1740 inhaled_5\VBN\1198101 antimuscarinic_6\JJ\1740 drug_7\NN\14778436 ,_8\,\1740 oxitropium_9\NN\1740 bromide_10\NN\14904359 ,_11\,\1740 and_12\CC\1740 of_13\IN\1740 a_14\DT\13649268 slow-release_15\JJ\1740 <e1>theophylline</e1>_16\NN\2905612 preparation_17\NN\407535 upon_18\IN\1740 nocturnal_19\JJ\1740 <e2>asthma</e2>_20\NN\14145095 were_21\VBD\836236 compared_22\VBN\644583 in_23\IN\13603305 a_24\DT\13649268 placebo-controlled_25\JJ\1740 double-blind_26\JJ\1740 study_27\NN\635850 ._28\.\1740
D013806_D001249 NONE oxitropium_0\NN\1740 proves_1\VBZ\2604760 to_2\TO\1740 be_3\VB\836236 a_4\DT\13649268 valuable_5\JJ\1740 alternative_6\NN\5788149 to_7\IN\1740 <e1>theophylline</e1>_8\NN\2905612 in_9\IN\13603305 nocturnal_10\JJ\1740 <e2>asthma</e2>_11\NN\14145095 ,_12\,\1740 since_13\IN\1740 it_14\PRP\6125041 is_15\VBZ\836236 equally_16\RB\1740 potent_17\JJ\1740 ,_18\,\1740 safer_19\JJR\1740 and_20\CC\1740 does_21\VBZ\1640855 not_22\RB\1740 require_23\VB\754942 the_24\DT\1740 titration_25\NN\647713 of_26\IN\1740 dosage_27\NN\13576355 ._28\.\1740
C017590_D009325 NONE no_0\DT\7204911 subject_1\NN\6598915 reported_2\VBD\831651 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>oxitropium</e1>_6\NN\1740 ,_7\,\1740 as_8\IN\14622893 compared_9\VBN\644583 to_10\TO\1740 three_11\CD\13741022 subjects_12\NNS\6598915 reporting_13\VBG\831651 <e2>nausea</e2>_14\NN\14299637 ,_15\,\1740 vomiting_16\NN\116687 and_17\CC\1740 tremors_18\NNS\345926 after_19\IN\1740 theophylline_20\NN\2905612 ._21\.\1740
C017590_D014839 NONE no_0\DT\7204911 subject_1\NN\6598915 reported_2\VBD\831651 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>oxitropium</e1>_6\NN\1740 ,_7\,\1740 as_8\IN\14622893 compared_9\VBN\644583 to_10\TO\1740 three_11\CD\13741022 subjects_12\NNS\6598915 reporting_13\VBG\831651 nausea_14\NN\14299637 ,_15\,\1740 <e2>vomiting</e2>_16\NN\116687 and_17\CC\1740 tremors_18\NNS\345926 after_19\IN\1740 theophylline_20\NN\2905612 ._21\.\1740
C017590_D014202 NONE no_0\DT\7204911 subject_1\NN\6598915 reported_2\VBD\831651 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>oxitropium</e1>_6\NN\1740 ,_7\,\1740 as_8\IN\14622893 compared_9\VBN\644583 to_10\TO\1740 three_11\CD\13741022 subjects_12\NNS\6598915 reporting_13\VBG\831651 nausea_14\NN\14299637 ,_15\,\1740 vomiting_16\NN\116687 and_17\CC\1740 <e2>tremors</e2>_18\NNS\345926 after_19\IN\1740 theophylline_20\NN\2905612 ._21\.\1740
D013806_D009325 CID no_0\DT\7204911 subject_1\NN\6598915 reported_2\VBD\831651 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 oxitropium_6\NN\1740 ,_7\,\1740 as_8\IN\14622893 compared_9\VBN\644583 to_10\TO\1740 three_11\CD\13741022 subjects_12\NNS\6598915 reporting_13\VBG\831651 <e2>nausea</e2>_14\NN\14299637 ,_15\,\1740 vomiting_16\NN\116687 and_17\CC\1740 tremors_18\NNS\345926 after_19\IN\1740 <e1>theophylline</e1>_20\NN\2905612 ._21\.\1740
D013806_D014839 CID no_0\DT\7204911 subject_1\NN\6598915 reported_2\VBD\831651 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 oxitropium_6\NN\1740 ,_7\,\1740 as_8\IN\14622893 compared_9\VBN\644583 to_10\TO\1740 three_11\CD\13741022 subjects_12\NNS\6598915 reporting_13\VBG\831651 nausea_14\NN\14299637 ,_15\,\1740 <e2>vomiting</e2>_16\NN\116687 and_17\CC\1740 tremors_18\NNS\345926 after_19\IN\1740 <e1>theophylline</e1>_20\NN\2905612 ._21\.\1740
D013806_D014202 CID no_0\DT\7204911 subject_1\NN\6598915 reported_2\VBD\831651 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 oxitropium_6\NN\1740 ,_7\,\1740 as_8\IN\14622893 compared_9\VBN\644583 to_10\TO\1740 three_11\CD\13741022 subjects_12\NNS\6598915 reporting_13\VBG\831651 nausea_14\NN\14299637 ,_15\,\1740 vomiting_16\NN\116687 and_17\CC\1740 <e2>tremors</e2>_18\NNS\345926 after_19\IN\1740 <e1>theophylline</e1>_20\NN\2905612 ._21\.\1740
19263707
D002231_D056648 CID <e1>carbimazole</e1>_0\NNP\1740 induced_1\VBD\1627355 <e2>anca_2\NN\1740 positive_3\JJ\1740 vasculitis</e2>_4\NN\14336539 ._5\.\1740
D013956_D006980 NONE <e1>anti-thyroid_0\JJ\1740 drugs</e1>_1\NNS\14778436 ,_2\,\1740 like_3\UH\5839024 carbimazole_4\NN\1740 and_5\CC\1740 propylthiouracil_6\NN\14727670 (_7\-LRB-\1740 ptu_8\NN\1740 )_9\-RRB-\1740 are_10\VBP\836236 commonly_11\RB\1740 prescribed_12\VBN\748282 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>hyperthyroidism</e2>_17\NN\14059928 ._18\.\1740
D002231_D006980 NONE anti-thyroid_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 like_3\UH\5839024 <e1>carbimazole</e1>_4\NN\1740 and_5\CC\1740 propylthiouracil_6\NN\14727670 (_7\-LRB-\1740 ptu_8\NN\1740 )_9\-RRB-\1740 are_10\VBP\836236 commonly_11\RB\1740 prescribed_12\VBN\748282 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>hyperthyroidism</e2>_17\NN\14059928 ._18\.\1740
D011441_D006980 NONE anti-thyroid_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 like_3\UH\5839024 carbimazole_4\NN\1740 and_5\CC\1740 <e1>propylthiouracil</e1>_6\NN\14727670 (_7\-LRB-\1740 ptu_8\NN\1740 )_9\-RRB-\1740 are_10\VBP\836236 commonly_11\RB\1740 prescribed_12\VBN\748282 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>hyperthyroidism</e2>_17\NN\14059928 ._18\.\1740
D011441_D006980 NONE anti-thyroid_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 like_3\UH\5839024 carbimazole_4\NN\1740 and_5\CC\1740 propylthiouracil_6\NN\14727670 (_7\-LRB-\1740 <e1>ptu</e1>_8\NN\1740 )_9\-RRB-\1740 are_10\VBP\836236 commonly_11\RB\1740 prescribed_12\VBN\748282 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>hyperthyroidism</e2>_17\NN\14059928 ._18\.\1740
D013956_D056648 CID one_0\PRP\13741022 should_1\MD\1740 be_2\VB\836236 aware_3\JJ\1740 of_4\IN\1740 the_5\DT\1740 side_6\NN\8630039 effects_7\NNS\13245626 of_8\IN\1740 <e1>antithyroid_9\NN\1740 medications.</e1>_10\NN\1740 <e2>antineutrophil_11\NN\1740 cytoplasmic_12\JJ\1740 antibody_13\NN\14728724 (anca)--associated_14\-LRB-\1740 vasculitis</e2>_15\NN\14336539 is_16\VBZ\836236 a_17\DT\13649268 potentially_18\RB\1740 life-threatening_19\JJ\1740 adverse_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 antithyroidmedications_23\NNS\1740 ._24\.\1740
D013956_D056648 CID one_0\PRP\13741022 should_1\MD\1740 be_2\VB\836236 aware_3\JJ\1740 of_4\IN\1740 the_5\DT\1740 side_6\NN\8630039 effects_7\NNS\13245626 of_8\IN\1740 antithyroid_9\NN\1740 medications._10\NN\1740 <e2>antineutrophil_11\NN\1740 cytoplasmic_12\JJ\1740 antibody_13\NN\14728724 (anca)--associated_14\-LRB-\1740 vasculitis</e2>_15\NN\14336539 is_16\VBZ\836236 a_17\DT\13649268 potentially_18\RB\1740 life-threatening_19\JJ\1740 adverse_20\JJ\1740 effect_21\NN\34213 of_22\IN\1740 <e1>antithyroidmedications</e1>_23\NNS\1740 ._24\.\1740
D002231_D006111 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 <e2>graves_5\NN\15143477 '_6\POS\1740 disease</e2>_7\NN\14061805 who_8\WP\8299493 developed_9\VBD\1753788 anca_10\NN\1740 positive_11\JJ\1740 <e1>carbimazole</e1>_12\NN\1740 induced_13\JJ\1740 vasculitis_14\NN\14336539 ._15\.\1740
D002231_D014657 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 graves_5\NN\15143477 '_6\POS\1740 disease_7\NN\14061805 who_8\WP\8299493 developed_9\VBD\1753788 anca_10\NN\1740 positive_11\JJ\1740 <e1>carbimazole</e1>_12\NN\1740 induced_13\JJ\1740 <e2>vasculitis</e2>_14\NN\14336539 ._15\.\1740
D002231_D014657 NONE to_0\IN\1740 the_1\DT\1740 best_2\JJS\1740 of_3\IN\1740 our_4\PRP$\1740 knowledge_5\NN\23100 this_6\DT\1740 is_7\VBZ\836236 the_8\DT\1740 first_9\JJ\1740 anca_10\NN\1740 positive_11\JJ\1740 <e1>carbimazole</e1>_12\NN\1740 induced_13\JJ\1740 <e2>vasculitis</e2>_14\NN\14336539 case_15\NN\7283608 reported_16\VBN\831651 from_17\IN\1740 india_18\NNP\1740 ._19\.\1740
816141
D002512_D000743 CID <e1>cephalothin-induced</e1>_0\JJ\1740 immune_1\JJ\1740 <e2>hemolytic_2\JJ\1740 anemia</e2>_3\NN\14189204 ._4\.\1740
D002512_D000743 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 renal_3\JJ\1740 disease_4\NN\14061805 developed_5\VBD\1753788 coombs-positive_6\JJ\1740 <e2>hemolytic_7\JJ\1740 anemia</e2>_8\NN\14189204 while_9\IN\15122231 receiving_10\VBG\2210855 <e1>cephalothin</e1>_11\NN\2996840 therapy_12\NN\657604 ._13\.\1740
D002512_D007674 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>renal_3\JJ\1740 disease</e2>_4\NN\14061805 developed_5\VBD\1753788 coombs-positive_6\JJ\1740 hemolytic_7\JJ\1740 anemia_8\NN\14189204 while_9\IN\15122231 receiving_10\VBG\2210855 <e1>cephalothin</e1>_11\NN\2996840 therapy_12\NN\657604 ._13\.\1740
10960401
D009020_D009759 CID <e2>downbeat_0\JJ\1740 nystagmus</e2>_1\NN\337486 associated_2\VBN\628491 with_3\IN\1740 intravenous_4\JJ\1740 patient-controlled_5\JJ\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>morphine</e1>_8\NN\2707683 ._9\.\1740
D009020_D009759 CID implications_0\NN\5774614 :_1\:\1740 this_2\DT\1740 case_3\NN\7283608 documents_4\VBZ\1000214 a_5\DT\13649268 patient_6\NN\9898892 who_7\WP\8299493 developed_8\VBD\1753788 dizziness_9\NN\14299637 with_10\IN\1740 <e2>downbeating_11\VBG\1740 nystagmus</e2>_12\NN\337486 while_13\IN\15122231 receiving_14\VBG\2210855 a_15\DT\13649268 relatively_16\RB\1740 large_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 iv_20\CD\13741022 patient-controlled_21\JJ\1740 analgesia_22\NN\14034177 <e1>morphine</e1>_23\NN\2707683 ._24\.\1740
D009020_D004244 CID implications_0\NN\5774614 :_1\:\1740 this_2\DT\1740 case_3\NN\7283608 documents_4\VBZ\1000214 a_5\DT\13649268 patient_6\NN\9898892 who_7\WP\8299493 developed_8\VBD\1753788 <e2>dizziness</e2>_9\NN\14299637 with_10\IN\1740 downbeating_11\VBG\1740 nystagmus_12\NN\337486 while_13\IN\15122231 receiving_14\VBG\2210855 a_15\DT\13649268 relatively_16\RB\1740 large_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 iv_20\CD\13741022 patient-controlled_21\JJ\1740 analgesia_22\NN\14034177 <e1>morphine</e1>_23\NN\2707683 ._24\.\1740
891494
D010672_D001927 CID <e1>phenytoin</e1>_0\NN\3550533 <e2>encephalopathy</e2>_1\JJ\1740 as_2\IN\14622893 probable_3\JJ\1740 idiosyncratic_4\JJ\1740 reaction_5\NN\13446390 :_6\:\1740 case_7\NN\7283608 report_8\NN\6470073 ._9\.\1740
D010672_D001927 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e1>phenytoin</e1>_3\NN\3550533 (_4\-LRB-\1740 dph_5\NN\6702458 )_6\-RRB-\1740 <e2>encephalopathy</e2>_7\RB\1740 with_8\IN\1740 increasing_9\VBG\169651 seizures_10\NNS\14081375 and_11\CC\1740 eeg_12\NN\7000195 and_13\CC\1740 mental_14\JJ\1740 changes_15\NNS\7283608 is_16\VBZ\836236 described_17\VBN\1001294 ._18\.\1740
D010672_D001927 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 phenytoin_3\NN\3550533 (_4\-LRB-\1740 <e1>dph</e1>_5\NN\6702458 )_6\-RRB-\1740 <e2>encephalopathy</e2>_7\RB\1740 with_8\IN\1740 increasing_9\VBG\169651 seizures_10\NNS\14081375 and_11\CC\1740 eeg_12\NN\7000195 and_13\CC\1740 mental_14\JJ\1740 changes_15\NNS\7283608 is_16\VBZ\836236 described_17\VBN\1001294 ._18\.\1740
D010672_D012640 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e1>phenytoin</e1>_3\NN\3550533 (_4\-LRB-\1740 dph_5\NN\6702458 )_6\-RRB-\1740 encephalopathy_7\RB\1740 with_8\IN\1740 increasing_9\VBG\169651 <e2>seizures</e2>_10\NNS\14081375 and_11\CC\1740 eeg_12\NN\7000195 and_13\CC\1740 mental_14\JJ\1740 changes_15\NNS\7283608 is_16\VBZ\836236 described_17\VBN\1001294 ._18\.\1740
D010672_D012640 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 phenytoin_3\NN\3550533 (_4\-LRB-\1740 <e1>dph</e1>_5\NN\6702458 )_6\-RRB-\1740 encephalopathy_7\RB\1740 with_8\IN\1740 increasing_9\VBG\169651 <e2>seizures</e2>_10\NNS\14081375 and_11\CC\1740 eeg_12\NN\7000195 and_13\CC\1740 mental_14\JJ\1740 changes_15\NNS\7283608 is_16\VBZ\836236 described_17\VBN\1001294 ._18\.\1740
D010672_D012640 NONE the_0\DT\1740 authors_1\NNS\9610660 conclude_2\VBP\628491 that_3\IN\1740 in_4\IN\13603305 a_5\DT\13649268 patient_6\NN\9898892 starting_7\VBG\2009433 <e1>dph</e1>_8\NN\6702458 treatment_9\NN\654885 an_10\DT\6697703 unexpected_11\JJ\1740 increase_12\NN\13576355 in_13\IN\13603305 <e2>seizures</e2>_14\NNS\14081375 ,_15\,\1740 with_16\IN\1740 eeg_17\NN\7000195 and_18\CC\1740 mental_19\JJ\1740 changes_20\NNS\7283608 occurring_21\VBG\2623529 simultaneously_22\RB\1740 ,_23\,\1740 should_24\MD\1740 alert_25\VB\870213 the_26\DT\1740 physician_27\NN\10305802 to_28\IN\1740 the_29\DT\1740 possible_30\JJ\1740 need_31\NN\13920835 for_32\IN\1740 eliminating_33\VBG\1619929 dph_34\NN\6702458 from_35\IN\1740 the_36\DT\1740 therapeutic_37\JJ\1740 regimen_38\NN\5898568 ,_39\,\1740 even_40\RB\1740 if_41\IN\1740 plasma_42\NN\5398023 concentrations_43\NNS\4916342 are_44\VBP\836236 low_45\JJ\1740 ._46\.\1740
D010672_D012640 NONE the_0\DT\1740 authors_1\NNS\9610660 conclude_2\VBP\628491 that_3\IN\1740 in_4\IN\13603305 a_5\DT\13649268 patient_6\NN\9898892 starting_7\VBG\2009433 dph_8\NN\6702458 treatment_9\NN\654885 an_10\DT\6697703 unexpected_11\JJ\1740 increase_12\NN\13576355 in_13\IN\13603305 <e2>seizures</e2>_14\NNS\14081375 ,_15\,\1740 with_16\IN\1740 eeg_17\NN\7000195 and_18\CC\1740 mental_19\JJ\1740 changes_20\NNS\7283608 occurring_21\VBG\2623529 simultaneously_22\RB\1740 ,_23\,\1740 should_24\MD\1740 alert_25\VB\870213 the_26\DT\1740 physician_27\NN\10305802 to_28\IN\1740 the_29\DT\1740 possible_30\JJ\1740 need_31\NN\13920835 for_32\IN\1740 eliminating_33\VBG\1619929 <e1>dph</e1>_34\NN\6702458 from_35\IN\1740 the_36\DT\1740 therapeutic_37\JJ\1740 regimen_38\NN\5898568 ,_39\,\1740 even_40\RB\1740 if_41\IN\1740 plasma_42\NN\5398023 concentrations_43\NNS\4916342 are_44\VBP\836236 low_45\JJ\1740 ._46\.\1740
D010672_D005076 NONE in_0\IN\13603305 fact_1\NN\5816287 the_2\DT\1740 concentration_3\NN\4916342 of_4\IN\1740 free_5\JJ\1740 <e1>dph</e1>_6\NN\6702458 was_7\VBD\836236 normal_8\JJ\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 presented_12\VBD\2137132 a_13\DT\13649268 retarded_14\VBN\438495 morbilliform_15\NN\1740 <e2>rash</e2>_16\NN\14321469 during_17\IN\1740 dph_18\NN\6702458 treatment_19\NN\654885 ,_20\,\1740 the_21\DT\1740 protidogram_22\NN\1740 was_23\VBD\836236 normal_24\JJ\1740 ,_25\,\1740 and_26\CC\1740 an_27\DT\6697703 intradermic_28\JJ\1740 dph_29\NN\6702458 injection_30\NN\320852 had_31\VBD\2108377 no_32\DT\7204911 local_33\JJ\1740 effect_34\NN\34213 ._35\.\1740
D010672_D005076 NONE in_0\IN\13603305 fact_1\NN\5816287 the_2\DT\1740 concentration_3\NN\4916342 of_4\IN\1740 free_5\JJ\1740 dph_6\NN\6702458 was_7\VBD\836236 normal_8\JJ\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 presented_12\VBD\2137132 a_13\DT\13649268 retarded_14\VBN\438495 morbilliform_15\NN\1740 <e2>rash</e2>_16\NN\14321469 during_17\IN\1740 <e1>dph</e1>_18\NN\6702458 treatment_19\NN\654885 ,_20\,\1740 the_21\DT\1740 protidogram_22\NN\1740 was_23\VBD\836236 normal_24\JJ\1740 ,_25\,\1740 and_26\CC\1740 an_27\DT\6697703 intradermic_28\JJ\1740 dph_29\NN\6702458 injection_30\NN\320852 had_31\VBD\2108377 no_32\DT\7204911 local_33\JJ\1740 effect_34\NN\34213 ._35\.\1740
D010672_D005076 NONE in_0\IN\13603305 fact_1\NN\5816287 the_2\DT\1740 concentration_3\NN\4916342 of_4\IN\1740 free_5\JJ\1740 dph_6\NN\6702458 was_7\VBD\836236 normal_8\JJ\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 presented_12\VBD\2137132 a_13\DT\13649268 retarded_14\VBN\438495 morbilliform_15\NN\1740 <e2>rash</e2>_16\NN\14321469 during_17\IN\1740 dph_18\NN\6702458 treatment_19\NN\654885 ,_20\,\1740 the_21\DT\1740 protidogram_22\NN\1740 was_23\VBD\836236 normal_24\JJ\1740 ,_25\,\1740 and_26\CC\1740 an_27\DT\6697703 intradermic_28\JJ\1740 <e1>dph</e1>_29\NN\6702458 injection_30\NN\320852 had_31\VBD\2108377 no_32\DT\7204911 local_33\JJ\1740 effect_34\NN\34213 ._35\.\1740
11915580
D005996_D004412 NONE a_0\DT\13649268 comparison_1\NN\635850 of_2\IN\1740 <e1>glyceryl_3\NN\14621446 trinitrate</e1>_4\NN\1740 with_5\IN\1740 diclofenac_6\NN\1740 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 primary_11\JJ\1740 <e2>dysmenorrhea</e2>_12\NN\14322699 :_13\:\1740 an_14\DT\6697703 open_15\JJ\1740 ,_16\,\1740 randomized_17\JJ\1740 ,_18\,\1740 cross-over_19\JJ\1740 trial_20\NN\786195 ._21\.\1740
D005996_D004412 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 efficacy_10\NN\5199286 of_11\IN\1740 <e1>glyceryl_12\NN\14621446 trinitrate</e1>_13\NN\1740 (_14\-LRB-\1740 gtn_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 an_18\DT\6697703 no_19\NN\7204911 donor_20\NN\9608709 ,_21\,\1740 in_22\IN\13603305 the_23\DT\1740 resolution_24\NN\6470073 of_25\IN\1740 primary_26\JJ\1740 <e2>dysmenorrhea</e2>_27\NN\14322699 in_28\IN\13603305 comparison_29\NN\635850 with_30\IN\1740 diclofenac_31\NN\1740 (_32\-LRB-\1740 dcf_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
D005996_D004412 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 efficacy_10\NN\5199286 of_11\IN\1740 glyceryl_12\NN\14621446 trinitrate_13\NN\1740 (_14\-LRB-\1740 <e1>gtn</e1>_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 an_18\DT\6697703 no_19\NN\7204911 donor_20\NN\9608709 ,_21\,\1740 in_22\IN\13603305 the_23\DT\1740 resolution_24\NN\6470073 of_25\IN\1740 primary_26\JJ\1740 <e2>dysmenorrhea</e2>_27\NN\14322699 in_28\IN\13603305 comparison_29\NN\635850 with_30\IN\1740 diclofenac_31\NN\1740 (_32\-LRB-\1740 dcf_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
D005996_D004412 NONE these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>gtn</e1>_4\NN\1740 has_5\VBZ\2108377 a_6\DT\13649268 reduced_7\VBN\441445 efficacy_8\NN\5199286 and_9\CC\1740 tolerability_10\NN\1740 by_11\IN\1740 comparison_12\NN\635850 with_13\IN\1740 dcf_14\NN\1740 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 primary_19\JJ\1740 <e2>dysmenorrhea</e2>_20\NN\14322699 ._21\.\1740
D004008_D004412 NONE a_0\DT\13649268 comparison_1\NN\635850 of_2\IN\1740 glyceryl_3\NN\14621446 trinitrate_4\NN\1740 with_5\IN\1740 <e1>diclofenac</e1>_6\NN\1740 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 primary_11\JJ\1740 <e2>dysmenorrhea</e2>_12\NN\14322699 :_13\:\1740 an_14\DT\6697703 open_15\JJ\1740 ,_16\,\1740 randomized_17\JJ\1740 ,_18\,\1740 cross-over_19\JJ\1740 trial_20\NN\786195 ._21\.\1740
D004008_D004412 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 efficacy_10\NN\5199286 of_11\IN\1740 glyceryl_12\NN\14621446 trinitrate_13\NN\1740 (_14\-LRB-\1740 gtn_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 an_18\DT\6697703 no_19\NN\7204911 donor_20\NN\9608709 ,_21\,\1740 in_22\IN\13603305 the_23\DT\1740 resolution_24\NN\6470073 of_25\IN\1740 primary_26\JJ\1740 <e2>dysmenorrhea</e2>_27\NN\14322699 in_28\IN\13603305 comparison_29\NN\635850 with_30\IN\1740 <e1>diclofenac</e1>_31\NN\1740 (_32\-LRB-\1740 dcf_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
D004008_D004412 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 efficacy_10\NN\5199286 of_11\IN\1740 glyceryl_12\NN\14621446 trinitrate_13\NN\1740 (_14\-LRB-\1740 gtn_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 an_18\DT\6697703 no_19\NN\7204911 donor_20\NN\9608709 ,_21\,\1740 in_22\IN\13603305 the_23\DT\1740 resolution_24\NN\6470073 of_25\IN\1740 primary_26\JJ\1740 <e2>dysmenorrhea</e2>_27\NN\14322699 in_28\IN\13603305 comparison_29\NN\635850 with_30\IN\1740 diclofenac_31\NN\1740 (_32\-LRB-\1740 <e1>dcf</e1>_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
D004008_D004412 NONE these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 gtn_4\NN\1740 has_5\VBZ\2108377 a_6\DT\13649268 reduced_7\VBN\441445 efficacy_8\NN\5199286 and_9\CC\1740 tolerability_10\NN\1740 by_11\IN\1740 comparison_12\NN\635850 with_13\IN\1740 <e1>dcf</e1>_14\NN\1740 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 primary_19\JJ\1740 <e2>dysmenorrhea</e2>_20\NN\14322699 ._21\.\1740
D011453_D004412 NONE primary_0\JJ\1740 <e2>dysmenorrhea</e2>_1\NN\14322699 is_2\VBZ\836236 a_3\DT\13649268 syndrome_4\NN\5870365 characterized_5\VBN\609683 by_6\IN\1740 painful_7\JJ\1740 uterine_8\NN\1740 contractility_9\NN\5200169 caused_10\VBN\1617192 by_11\IN\1740 a_12\DT\13649268 hypersecretion_13\NN\13553916 of_14\IN\1740 endometrial_15\JJ\1740 <e1>prostaglandins</e1>_16\NNS\5414534 ;_17\:\1740 non-steroidal_18\JJ\1740 anti-inflammatory_19\JJ\1740 drugs_20\NNS\14778436 are_21\VBP\836236 the_22\DT\1740 first_23\JJ\1740 choice_24\NN\5788149 for_25\IN\1740 its_26\PRP$\6125041 treatment_27\NN\654885 ._28\.\1740
D009569_D004412 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 efficacy_10\NN\5199286 of_11\IN\1740 glyceryl_12\NN\14621446 trinitrate_13\NN\1740 (_14\-LRB-\1740 gtn_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 an_18\DT\6697703 <e1>no</e1>_19\NN\7204911 donor_20\NN\9608709 ,_21\,\1740 in_22\IN\13603305 the_23\DT\1740 resolution_24\NN\6470073 of_25\IN\1740 primary_26\JJ\1740 <e2>dysmenorrhea</e2>_27\NN\14322699 in_28\IN\13603305 comparison_29\NN\635850 with_30\IN\1740 diclofenac_31\NN\1740 (_32\-LRB-\1740 dcf_33\NNP\1740 )_34\-RRB-\1740 ._35\.\1740
D004008_D017699 NONE however_0\RB\1740 ,_1\,\1740 <e1>dcf</e1>_2\NNP\1740 continued_3\VBD\2367363 to_4\TO\1740 be_5\VB\836236 effective_6\JJ\1740 in_7\IN\13603305 reducing_8\VBG\441445 <e2>pelvic_9\JJ\1740 pain</e2>_10\NN\14299637 for_11\IN\1740 two_12\CD\13741022 hours_13\NNS\15118228 ,_14\,\1740 whereas_15\IN\1740 gtn_16\NN\1740 scores_17\NNS\13757724 remained_18\VBD\2604760 more_19\RBR\1740 or_20\CC\3541091 less_21\RBR\1740 stable_22\JJ\1740 after_23\IN\1740 30_24\CD\13745420 min_25\NN\15154774 and_26\CC\1740 significantly_27\RB\1740 higher_28\JJR\1740 than_29\IN\1740 those_30\DT\1740 for_31\IN\1740 dfc_32\NN\1740 (_33\-LRB-\1740 after_34\IN\1740 one_35\CD\13741022 hour_36\NN\15154774 :_37\:\1740 gtn_38\NN\1740 ,_39\,\1740 -12.8_40\NN\1740 +/-_41\CC\1740 17.9_42\CD\1740 ;_43\:\1740 dfc_44\NN\1740 ,_45\,\1740 -18.9_46\NN\1740 +/-_47\CC\1740 16.6_48\CD\1740 and_49\CC\1740 after_50\IN\1740 two_51\CD\13741022 hours_52\NNS\15118228 :_53\:\1740 gtn_54\NN\1740 ,_55\,\1740 -23.7_56\NNS\1740 +/-_57\CC\1740 20.5_58\CD\1740 ;_59\:\1740 dfc_60\NN\1740 ,_61\,\1740 -59.7_62\CD\1740 +/-_63\CC\1740 17.9_64\CD\1740 ,_65\,\1740 p_66\NN\14622893 =_67\JJ\1740 0.0001_68\CD\1740 )_69\-RRB-\1740 ._70\.\1740
D005996_D017699 NONE however_0\RB\1740 ,_1\,\1740 dcf_2\NNP\1740 continued_3\VBD\2367363 to_4\TO\1740 be_5\VB\836236 effective_6\JJ\1740 in_7\IN\13603305 reducing_8\VBG\441445 <e2>pelvic_9\JJ\1740 pain</e2>_10\NN\14299637 for_11\IN\1740 two_12\CD\13741022 hours_13\NNS\15118228 ,_14\,\1740 whereas_15\IN\1740 <e1>gtn</e1>_16\NN\1740 scores_17\NNS\13757724 remained_18\VBD\2604760 more_19\RBR\1740 or_20\CC\3541091 less_21\RBR\1740 stable_22\JJ\1740 after_23\IN\1740 30_24\CD\13745420 min_25\NN\15154774 and_26\CC\1740 significantly_27\RB\1740 higher_28\JJR\1740 than_29\IN\1740 those_30\DT\1740 for_31\IN\1740 dfc_32\NN\1740 (_33\-LRB-\1740 after_34\IN\1740 one_35\CD\13741022 hour_36\NN\15154774 :_37\:\1740 gtn_38\NN\1740 ,_39\,\1740 -12.8_40\NN\1740 +/-_41\CC\1740 17.9_42\CD\1740 ;_43\:\1740 dfc_44\NN\1740 ,_45\,\1740 -18.9_46\NN\1740 +/-_47\CC\1740 16.6_48\CD\1740 and_49\CC\1740 after_50\IN\1740 two_51\CD\13741022 hours_52\NNS\15118228 :_53\:\1740 gtn_54\NN\1740 ,_55\,\1740 -23.7_56\NNS\1740 +/-_57\CC\1740 20.5_58\CD\1740 ;_59\:\1740 dfc_60\NN\1740 ,_61\,\1740 -59.7_62\CD\1740 +/-_63\CC\1740 17.9_64\CD\1740 ,_65\,\1740 p_66\NN\14622893 =_67\JJ\1740 0.0001_68\CD\1740 )_69\-RRB-\1740 ._70\.\1740
D005996_D017699 NONE however_0\RB\1740 ,_1\,\1740 dcf_2\NNP\1740 continued_3\VBD\2367363 to_4\TO\1740 be_5\VB\836236 effective_6\JJ\1740 in_7\IN\13603305 reducing_8\VBG\441445 <e2>pelvic_9\JJ\1740 pain</e2>_10\NN\14299637 for_11\IN\1740 two_12\CD\13741022 hours_13\NNS\15118228 ,_14\,\1740 whereas_15\IN\1740 gtn_16\NN\1740 scores_17\NNS\13757724 remained_18\VBD\2604760 more_19\RBR\1740 or_20\CC\3541091 less_21\RBR\1740 stable_22\JJ\1740 after_23\IN\1740 30_24\CD\13745420 min_25\NN\15154774 and_26\CC\1740 significantly_27\RB\1740 higher_28\JJR\1740 than_29\IN\1740 those_30\DT\1740 for_31\IN\1740 dfc_32\NN\1740 (_33\-LRB-\1740 after_34\IN\1740 one_35\CD\13741022 hour_36\NN\15154774 :_37\:\1740 <e1>gtn</e1>_38\NN\1740 ,_39\,\1740 -12.8_40\NN\1740 +/-_41\CC\1740 17.9_42\CD\1740 ;_43\:\1740 dfc_44\NN\1740 ,_45\,\1740 -18.9_46\NN\1740 +/-_47\CC\1740 16.6_48\CD\1740 and_49\CC\1740 after_50\IN\1740 two_51\CD\13741022 hours_52\NNS\15118228 :_53\:\1740 gtn_54\NN\1740 ,_55\,\1740 -23.7_56\NNS\1740 +/-_57\CC\1740 20.5_58\CD\1740 ;_59\:\1740 dfc_60\NN\1740 ,_61\,\1740 -59.7_62\CD\1740 +/-_63\CC\1740 17.9_64\CD\1740 ,_65\,\1740 p_66\NN\14622893 =_67\JJ\1740 0.0001_68\CD\1740 )_69\-RRB-\1740 ._70\.\1740
D005996_D017699 NONE however_0\RB\1740 ,_1\,\1740 dcf_2\NNP\1740 continued_3\VBD\2367363 to_4\TO\1740 be_5\VB\836236 effective_6\JJ\1740 in_7\IN\13603305 reducing_8\VBG\441445 <e2>pelvic_9\JJ\1740 pain</e2>_10\NN\14299637 for_11\IN\1740 two_12\CD\13741022 hours_13\NNS\15118228 ,_14\,\1740 whereas_15\IN\1740 gtn_16\NN\1740 scores_17\NNS\13757724 remained_18\VBD\2604760 more_19\RBR\1740 or_20\CC\3541091 less_21\RBR\1740 stable_22\JJ\1740 after_23\IN\1740 30_24\CD\13745420 min_25\NN\15154774 and_26\CC\1740 significantly_27\RB\1740 higher_28\JJR\1740 than_29\IN\1740 those_30\DT\1740 for_31\IN\1740 dfc_32\NN\1740 (_33\-LRB-\1740 after_34\IN\1740 one_35\CD\13741022 hour_36\NN\15154774 :_37\:\1740 gtn_38\NN\1740 ,_39\,\1740 -12.8_40\NN\1740 +/-_41\CC\1740 17.9_42\CD\1740 ;_43\:\1740 dfc_44\NN\1740 ,_45\,\1740 -18.9_46\NN\1740 +/-_47\CC\1740 16.6_48\CD\1740 and_49\CC\1740 after_50\IN\1740 two_51\CD\13741022 hours_52\NNS\15118228 :_53\:\1740 <e1>gtn</e1>_54\NN\1740 ,_55\,\1740 -23.7_56\NNS\1740 +/-_57\CC\1740 20.5_58\CD\1740 ;_59\:\1740 dfc_60\NN\1740 ,_61\,\1740 -59.7_62\CD\1740 +/-_63\CC\1740 17.9_64\CD\1740 ,_65\,\1740 p_66\NN\14622893 =_67\JJ\1740 0.0001_68\CD\1740 )_69\-RRB-\1740 ._70\.\1740
D005996_D006261 CID <e2>headache</e2>_0\NNP\5829480 was_1\VBD\836236 significantly_2\RB\1740 increased_3\VBN\169651 by_4\IN\1740 <e1>gtn</e1>_5\NN\1740 but_6\CC\1740 not_7\RB\1740 by_8\IN\1740 dcf_9\NNP\1740 ._10\.\1740
D005996_D006261 CID eight_0\CD\13741022 patients_1\NNS\9898892 stopped_2\VBD\2452885 using_3\VBG\1156834 <e1>gtn</e1>_4\NN\1740 because_5\IN\1740 <e2>headache</e2>_6\NN\5829480 --_7\:\1740 attributed_8\VBN\670261 to_9\TO\1740 its_10\PRP$\6125041 use_11\NN\407535 --_12\:\1740 became_13\VBD\146138 intolerable_14\JJ\1740 ._15\.\1740
D004008_D006261 NONE <e2>headache</e2>_0\NNP\5829480 was_1\VBD\836236 significantly_2\RB\1740 increased_3\VBN\169651 by_4\IN\1740 gtn_5\NN\1740 but_6\CC\1740 not_7\RB\1740 by_8\IN\1740 <e1>dcf</e1>_9\NNP\1740 ._10\.\1740
24190587
D018817_D008107 NONE rationale_0\NN\5793000 :_1\:\1740 <e1>ecstasy</e1>_2\NNP\13985818 (_3\-LRB-\1740 mdma_4\NNP\3054098 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 psychostimulant_8\NN\1740 drug_9\NN\14778436 which_10\WDT\1740 is_11\VBZ\836236 increasingly_12\RB\1740 associated_13\VBN\628491 with_14\IN\1740 <e2>psychobiological_15\JJ\1740 dysfunction</e2>_16\NN\14204950 ._17\.\1740
D018817_D008107 NONE rationale_0\NN\5793000 :_1\:\1740 ecstasy_2\NNP\13985818 (_3\-LRB-\1740 <e1>mdma</e1>_4\NNP\3054098 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 psychostimulant_8\NN\1740 drug_9\NN\14778436 which_10\WDT\1740 is_11\VBZ\836236 increasingly_12\RB\1740 associated_13\VBN\628491 with_14\IN\1740 <e2>psychobiological_15\JJ\1740 dysfunction</e2>_16\NN\14204950 ._17\.\1740
D018817_D001008 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 increases_3\NNS\13576355 in_4\IN\13603305 <e2>anxiety</e2>_5\NN\14373582 and_6\CC\1740 depression_7\NN\14373582 are_8\VBP\836236 in_9\IN\13603305 line_10\NN\8426461 with_11\IN\1740 previous_12\JJ\1740 observations_13\NNS\996969 in_14\IN\13603305 recreational_15\JJ\1740 <e1>ecstasy-polydrug</e1>_16\JJ\1740 users_17\NNS\7846 ._18\.\1740
D018817_D003866 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 increases_3\NNS\13576355 in_4\IN\13603305 anxiety_5\NN\14373582 and_6\CC\1740 <e2>depression</e2>_7\NN\14373582 are_8\VBP\836236 in_9\IN\13603305 line_10\NN\8426461 with_11\IN\1740 previous_12\JJ\1740 observations_13\NNS\996969 in_14\IN\13603305 recreational_15\JJ\1740 <e1>ecstasy-polydrug</e1>_16\JJ\1740 users_17\NNS\7846 ._18\.\1740
35781
D003000_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>clonidine</e1>_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D003000_D002375 CID codeine_0\NN\2707683 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 increased_3\VBN\169651 by_4\IN\1740 <e1>clonidine</e1>_5\NN\2721160 and_6\CC\1740 decreased_7\VBN\169651 by_8\IN\1740 naphazoline_9\NN\3809939 and_10\CC\1740 xylometazoline_11\NN\1740 ._12\.\1740
D009278_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 <e1>naphazoline</e1>_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D009278_D002375 CID codeine_0\NN\2707683 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 increased_3\VBN\169651 by_4\IN\1740 clonidine_5\NN\2721160 and_6\CC\1740 decreased_7\VBN\169651 by_8\IN\1740 <e1>naphazoline</e1>_9\NN\3809939 and_10\CC\1740 xylometazoline_11\NN\1740 ._12\.\1740
C009695_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 <e1>xylometazoline</e1>_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
C009695_D002375 CID codeine_0\NN\2707683 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 increased_3\VBN\169651 by_4\IN\1740 clonidine_5\NN\2721160 and_6\CC\1740 decreased_7\VBN\169651 by_8\IN\1740 naphazoline_9\NN\3809939 and_10\CC\1740 <e1>xylometazoline</e1>_11\NN\1740 ._12\.\1740
D009020_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 <e1>morphine</e1>_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D009020_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 <e1>morphine</e1>_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D009020_D002375 CID it_0\PRP\6125041 was_1\VBD\836236 found_2\VBN\2426171 that_3\IN\1740 three_4\CD\13741022 drugs_5\NNS\14778436 stimulating_6\VBG\137313 central_7\JJ\1740 na_8\NN\14625458 receptors_9\NNS\5225602 failed_10\VBD\1798936 to_11\TO\1740 affect_12\VB\126264 the_13\DT\1740 analgesic_14\JJ\1740 ed50_15\NN\1740 of_16\IN\1740 all_17\DT\1740 antinociceptive_18\JJ\1740 agents_19\NNS\7347 and_20\CC\1740 they_21\PRP\1740 enhanced_22\VBD\227165 <e2>catalepsy</e2>_23\NN\14023236 induced_24\VBN\1627355 by_25\IN\1740 <e1>morphine</e1>_26\NN\2707683 and_27\CC\1740 fentanyl_28\NN\2707683 ._29\.\1740
D003061_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 <e1>codeine</e1>_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D003061_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 <e1>codine</e1>_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D003061_D002375 CID <e1>codeine</e1>_0\NN\2707683 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 increased_3\VBN\169651 by_4\IN\1740 clonidine_5\NN\2721160 and_6\CC\1740 decreased_7\VBN\169651 by_8\IN\1740 naphazoline_9\NN\3809939 and_10\CC\1740 xylometazoline_11\NN\1740 ._12\.\1740
D005283_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 <e1>fentanyl</e1>_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D005283_D002375 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 pentazocine_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 <e1>fentanyl</e1>_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D005283_D002375 CID it_0\PRP\6125041 was_1\VBD\836236 found_2\VBN\2426171 that_3\IN\1740 three_4\CD\13741022 drugs_5\NNS\14778436 stimulating_6\VBG\137313 central_7\JJ\1740 na_8\NN\14625458 receptors_9\NNS\5225602 failed_10\VBD\1798936 to_11\TO\1740 affect_12\VB\126264 the_13\DT\1740 analgesic_14\JJ\1740 ed50_15\NN\1740 of_16\IN\1740 all_17\DT\1740 antinociceptive_18\JJ\1740 agents_19\NNS\7347 and_20\CC\1740 they_21\PRP\1740 enhanced_22\VBD\227165 <e2>catalepsy</e2>_23\NN\14023236 induced_24\VBN\1627355 by_25\IN\1740 morphine_26\NN\2707683 and_27\CC\1740 <e1>fentanyl</e1>_28\NN\2707683 ._29\.\1740
D010423_D002375 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 clonidine_3\NN\2721160 ,_4\,\1740 naphazoline_5\NN\3809939 and_6\CC\1740 xylometazoline_7\NN\1740 on_8\IN\1740 analgesia_9\NN\14034177 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 codeine_14\NN\2707683 ,_15\,\1740 fentanyl_16\NN\2707683 and_17\CC\1740 <e1>pentazocine</e1>_18\NN\2707683 ,_19\,\1740 and_20\CC\1740 on_21\IN\1740 <e2>cataleptic</e2>_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 codine_27\NN\1740 and_28\CC\1740 fentanyl_29\NN\2707683 was_30\VBD\836236 studied_31\VBN\630380 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D009638_D002375 NONE it_0\PRP\6125041 was_1\VBD\836236 found_2\VBN\2426171 that_3\IN\1740 three_4\CD\13741022 drugs_5\NNS\14778436 stimulating_6\VBG\137313 central_7\JJ\1740 <e1>na</e1>_8\NN\14625458 receptors_9\NNS\5225602 failed_10\VBD\1798936 to_11\TO\1740 affect_12\VB\126264 the_13\DT\1740 analgesic_14\JJ\1740 ed50_15\NN\1740 of_16\IN\1740 all_17\DT\1740 antinociceptive_18\JJ\1740 agents_19\NNS\7347 and_20\CC\1740 they_21\PRP\1740 enhanced_22\VBD\227165 <e2>catalepsy</e2>_23\NN\14023236 induced_24\VBN\1627355 by_25\IN\1740 morphine_26\NN\2707683 and_27\CC\1740 fentanyl_28\NN\2707683 ._29\.\1740
6310832
D016572_D007239 CID early_0\JJ\1740 <e2>infections</e2>_1\NNS\14052046 in_2\IN\13603305 kidney_3\NN\5333259 ,_4\,\1740 heart_5\NN\5919034 ,_6\,\1740 and_7\CC\1740 liver_8\NN\5298729 transplant_9\NN\5267548 recipients_10\NNS\9764201 on_11\IN\1740 <e1>cyclosporine</e1>_12\NN\1740 ._13\.\1740
D016572_D007239 CID the_0\DT\1740 randomized_1\JJ\1740 aza_2\NN\1740 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\RBR\1740 overall_6\JJ\1740 <e2>infections</e2>_7\NNS\14052046 (_8\-LRB-\1740 p_9\NN\14622893 less_10\JJR\1740 than_11\IN\1740 0.05_12\CD\1740 )_13\-RRB-\1740 and_14\CC\1740 more_15\JJR\1740 nonviral_16\JJ\1740 infections_17\NNS\14052046 (_18\-LRB-\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.02_22\CD\1740 )_23\-RRB-\1740 than_24\IN\1740 the_25\DT\1740 randomized_26\VBN\278117 <e1>cyclosporine</e1>_27\NN\1740 patients_28\NNS\9898892 ._29\.\1740
D016572_D007239 CID the_0\DT\1740 randomized_1\JJ\1740 aza_2\NN\1740 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\RBR\1740 overall_6\JJ\1740 infections_7\NNS\14052046 (_8\-LRB-\1740 p_9\NN\14622893 less_10\JJR\1740 than_11\IN\1740 0.05_12\CD\1740 )_13\-RRB-\1740 and_14\CC\1740 more_15\JJR\1740 nonviral_16\JJ\1740 <e2>infections</e2>_17\NNS\14052046 (_18\-LRB-\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.02_22\CD\1740 )_23\-RRB-\1740 than_24\IN\1740 the_25\DT\1740 randomized_26\VBN\278117 <e1>cyclosporine</e1>_27\NN\1740 patients_28\NNS\9898892 ._29\.\1740
D016572_D007239 CID heart_0\NNP\5919034 and_1\CC\1740 liver_2\NN\5298729 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\JJR\1740 <e2>infections</e2>_6\NNS\14052046 than_7\IN\1740 <e1>cyclosporine</e1>_8\NN\1740 renal_9\JJ\1740 patients_10\NNS\9898892 but_11\CC\1740 fewer_12\JJR\1740 infections_13\NNS\14052046 than_14\IN\1740 the_15\DT\1740 aza_16\NN\1740 renal_17\JJ\1740 patients_18\NNS\9898892 ._19\.\1740
D016572_D007239 CID heart_0\NNP\5919034 and_1\CC\1740 liver_2\NN\5298729 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\JJR\1740 infections_6\NNS\14052046 than_7\IN\1740 <e1>cyclosporine</e1>_8\NN\1740 renal_9\JJ\1740 patients_10\NNS\9898892 but_11\CC\1740 fewer_12\JJR\1740 <e2>infections</e2>_13\NNS\14052046 than_14\IN\1740 the_15\DT\1740 aza_16\NN\1740 renal_17\JJ\1740 patients_18\NNS\9898892 ._19\.\1740
D016572_D007239 CID there_0\EX\27167 were_1\VBD\836236 no_2\DT\7204911 infectious_3\JJ\1740 deaths_4\NNS\7296428 in_5\IN\13603305 renal_6\JJ\1740 transplant_7\NN\5267548 patients_8\NNS\9898892 on_9\IN\1740 <e1>cyclosporine</e1>_10\NN\1740 or_11\CC\3541091 aza_12\NN\1740 ,_13\,\1740 but_14\CC\1740 <e2>infection</e2>_15\NN\14052046 played_16\VBD\1072262 a_17\DT\13649268 major_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 3_21\CD\13741022 out_22\IN\66636 of_23\IN\1740 6_24\CD\13741022 cardiac_25\JJ\1740 transplant_26\NN\5267548 deaths_27\NNS\7296428 and_28\CC\1740 in_29\IN\13603305 8_30\CD\13741022 out_31\IN\66636 of_32\IN\1740 9_33\CD\13741022 liver_34\NN\5298729 transplant_35\NN\5267548 deaths_36\NNS\7296428 ._37\.\1740
D016572_D007239 CID pulmonary_0\JJ\1740 <e2>infections</e2>_1\NNS\14052046 were_2\VBD\836236 less_3\RBR\1740 common_4\JJ\1740 in_5\IN\13603305 <e1>cyclosporine-treated</e1>_6\JJ\1740 renal_7\JJ\1740 patients_8\NNS\9898892 than_9\IN\1740 in_10\IN\13603305 aza-treated_11\JJ\1740 patients_12\NNS\9898892 (_13\-LRB-\1740 p_14\NN\14622893 less_15\JJR\1740 than_16\IN\1740 0.05_17\CD\1740 )_18\-RRB-\1740 ._19\.\1740
D001379_D007239 CID the_0\DT\1740 randomized_1\JJ\1740 <e1>aza</e1>_2\NN\1740 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\RBR\1740 overall_6\JJ\1740 <e2>infections</e2>_7\NNS\14052046 (_8\-LRB-\1740 p_9\NN\14622893 less_10\JJR\1740 than_11\IN\1740 0.05_12\CD\1740 )_13\-RRB-\1740 and_14\CC\1740 more_15\JJR\1740 nonviral_16\JJ\1740 infections_17\NNS\14052046 (_18\-LRB-\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.02_22\CD\1740 )_23\-RRB-\1740 than_24\IN\1740 the_25\DT\1740 randomized_26\VBN\278117 cyclosporine_27\NN\1740 patients_28\NNS\9898892 ._29\.\1740
D001379_D007239 CID the_0\DT\1740 randomized_1\JJ\1740 <e1>aza</e1>_2\NN\1740 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\RBR\1740 overall_6\JJ\1740 infections_7\NNS\14052046 (_8\-LRB-\1740 p_9\NN\14622893 less_10\JJR\1740 than_11\IN\1740 0.05_12\CD\1740 )_13\-RRB-\1740 and_14\CC\1740 more_15\JJR\1740 nonviral_16\JJ\1740 <e2>infections</e2>_17\NNS\14052046 (_18\-LRB-\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.02_22\CD\1740 )_23\-RRB-\1740 than_24\IN\1740 the_25\DT\1740 randomized_26\VBN\278117 cyclosporine_27\NN\1740 patients_28\NNS\9898892 ._29\.\1740
D001379_D007239 CID heart_0\NNP\5919034 and_1\CC\1740 liver_2\NN\5298729 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\JJR\1740 <e2>infections</e2>_6\NNS\14052046 than_7\IN\1740 cyclosporine_8\NN\1740 renal_9\JJ\1740 patients_10\NNS\9898892 but_11\CC\1740 fewer_12\JJR\1740 infections_13\NNS\14052046 than_14\IN\1740 the_15\DT\1740 <e1>aza</e1>_16\NN\1740 renal_17\JJ\1740 patients_18\NNS\9898892 ._19\.\1740
D001379_D007239 CID heart_0\NNP\5919034 and_1\CC\1740 liver_2\NN\5298729 patients_3\NNS\9898892 had_4\VBD\2108377 more_5\JJR\1740 infections_6\NNS\14052046 than_7\IN\1740 cyclosporine_8\NN\1740 renal_9\JJ\1740 patients_10\NNS\9898892 but_11\CC\1740 fewer_12\JJR\1740 <e2>infections</e2>_13\NNS\14052046 than_14\IN\1740 the_15\DT\1740 <e1>aza</e1>_16\NN\1740 renal_17\JJ\1740 patients_18\NNS\9898892 ._19\.\1740
D001379_D007239 CID there_0\EX\27167 were_1\VBD\836236 no_2\DT\7204911 infectious_3\JJ\1740 deaths_4\NNS\7296428 in_5\IN\13603305 renal_6\JJ\1740 transplant_7\NN\5267548 patients_8\NNS\9898892 on_9\IN\1740 cyclosporine_10\NN\1740 or_11\CC\3541091 <e1>aza</e1>_12\NN\1740 ,_13\,\1740 but_14\CC\1740 <e2>infection</e2>_15\NN\14052046 played_16\VBD\1072262 a_17\DT\13649268 major_18\JJ\1740 role_19\NN\719494 in_20\IN\13603305 3_21\CD\13741022 out_22\IN\66636 of_23\IN\1740 6_24\CD\13741022 cardiac_25\JJ\1740 transplant_26\NN\5267548 deaths_27\NNS\7296428 and_28\CC\1740 in_29\IN\13603305 8_30\CD\13741022 out_31\IN\66636 of_32\IN\1740 9_33\CD\13741022 liver_34\NN\5298729 transplant_35\NN\5267548 deaths_36\NNS\7296428 ._37\.\1740
D001379_D007239 CID pulmonary_0\JJ\1740 <e2>infections</e2>_1\NNS\14052046 were_2\VBD\836236 less_3\RBR\1740 common_4\JJ\1740 in_5\IN\13603305 cyclosporine-treated_6\JJ\1740 renal_7\JJ\1740 patients_8\NNS\9898892 than_9\IN\1740 in_10\IN\13603305 <e1>aza-treated</e1>_11\JJ\1740 patients_12\NNS\9898892 (_13\-LRB-\1740 p_14\NN\14622893 less_15\JJR\1740 than_16\IN\1740 0.05_17\CD\1740 )_18\-RRB-\1740 ._19\.\1740
D016572_D016470 NONE renal_0\JJ\1740 patients_1\NNS\9898892 on_2\IN\1740 <e1>cyclosporine</e1>_3\NN\1740 had_4\VBD\2108377 the_5\DT\1740 fewest_6\JJS\1740 <e2>bacteremias</e2>_7\NNS\14204950 ._8\.\1740
D001379_D013203 NONE <e1>aza</e1>_0\NN\1740 patients_1\NNS\9898892 had_2\VBD\2108377 significantly_3\RB\1740 more_4\RBR\1740 <e2>staphylococcal_5\JJ\1740 infections</e2>_6\NNS\14052046 than_7\IN\1740 all_8\DT\1740 other_9\JJ\1740 transplant_10\NN\5267548 groups_11\NNS\2137 (_12\-LRB-\1740 p_13\NN\14622893 less_14\JJR\1740 than_15\IN\1740 0.005_16\CD\1740 )_17\-RRB-\1740 ,_18\,\1740 and_19\CC\1740 systemic_20\JJ\1740 fungal_21\JJ\1740 infections_22\NNS\14052046 occurred_23\VBD\2623529 only_24\RB\1740 in_25\IN\13603305 the_26\DT\1740 liver_27\NN\5298729 transplant_28\NN\5267548 group_29\NN\2137 ._30\.\1740
D001379_D009181 NONE <e1>aza</e1>_0\NN\1740 patients_1\NNS\9898892 had_2\VBD\2108377 significantly_3\RB\1740 more_4\RBR\1740 staphylococcal_5\JJ\1740 infections_6\NNS\14052046 than_7\IN\1740 all_8\DT\1740 other_9\JJ\1740 transplant_10\NN\5267548 groups_11\NNS\2137 (_12\-LRB-\1740 p_13\NN\14622893 less_14\JJR\1740 than_15\IN\1740 0.005_16\CD\1740 )_17\-RRB-\1740 ,_18\,\1740 and_19\CC\1740 systemic_20\JJ\1740 <e2>fungal_21\JJ\1740 infections</e2>_22\NNS\14052046 occurred_23\VBD\2623529 only_24\RB\1740 in_25\IN\13603305 the_26\DT\1740 liver_27\NN\5298729 transplant_28\NN\5267548 group_29\NN\2137 ._30\.\1740
D016572_D003586 NONE of_0\IN\1740 the_1\DT\1740 <e1>cyclosporine</e1>_2\NN\1740 patients_3\NNS\9898892 ,_4\,\1740 15_5\CD\13745420 %_6\NN\1740 had_7\VBD\2108377 symptoms_8\NNS\5823932 related_9\JJ\1740 to_10\TO\1740 <e2>cmv_11\NN\1338685 infection</e2>_12\NN\14052046 ._13\.\1740
D016572_D020031 NONE serological_0\JJ\1740 evidence_1\NN\5816287 for_2\IN\1740 <e2>epstein_3\NN\1740 barr_4\NN\1740 virus_5\NN\9312843 infection</e2>_6\NN\14052046 was_7\VBD\836236 found_8\VBN\2426171 in_9\IN\13603305 20_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 65_13\CD\1740 <e1>cyclosporine</e1>_14\NN\1740 patients_15\NNS\9898892 studied_16\VBN\630380 ._17\.\1740
8096565
D018170_D009203 CID transmural_0\JJ\1740 <e2>myocardial_1\JJ\1740 infarction</e2>_2\NN\14204950 with_3\IN\1740 <e1>sumatriptan</e1>_4\NN\1740 ._5\.\1740
D018170_D009203 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 47-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 an_6\DT\6697703 acute_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 after_10\IN\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>sumatriptan</e1>_13\NN\1740 6_14\CD\13741022 mg_15\NN\13717155 subcutaneously_16\RB\1740 for_17\IN\1740 cluster_18\NN\7959269 headache_19\NN\5829480 ._20\.\1740
D018170_D003027 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 47-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 an_6\DT\6697703 acute_7\JJ\1740 myocardial_8\JJ\1740 infarction_9\NN\14204950 after_10\IN\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>sumatriptan</e1>_13\NN\1740 6_14\CD\13741022 mg_15\NN\13717155 subcutaneously_16\RB\1740 for_17\IN\1740 <e2>cluster_18\NN\7959269 headache</e2>_19\NN\5829480 ._20\.\1740
16876986
D010862_D012640 CID physical_0\JJ\1740 training_1\NN\407535 decreases_2\VBZ\169651 susceptibility_3\NN\13920835 to_4\TO\1740 subsequent_5\JJ\1740 <e1>pilocarpine-induced</e1>_6\JJ\1740 <e2>seizures</e2>_7\NNS\14081375 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D010862_D012640 CID thereafter_0\RB\1740 ,_1\,\1740 <e2>seizures</e2>_2\NNS\14081375 were_3\VBD\836236 induced_4\VBN\1627355 by_5\IN\1740 <e1>pilocarpine</e1>_6\NN\14712692 injections_7\NNS\320852 in_8\IN\13603305 trained_9\VBN\829107 and_10\CC\1740 non-trained_11\JJ\1740 control_12\NN\5190804 groups_13\NNS\2137 ._14\.\1740
946593
D008727_D010264 CID <e2>paraplegia</e2>_0\NNP\14558226 following_1\VBG\1835496 intrathecal_2\JJ\1740 <e1>methotrexate</e1>_3\NN\2722166 :_4\:\1740 report_5\NN\6470073 of_6\IN\1740 a_7\DT\13649268 case_8\NN\7283608 and_9\CC\1740 review_10\NN\5733583 of_11\IN\1740 the_12\DT\1740 literature_13\NN\6362953 ._14\.\1740
D008727_D010264 CID a_0\DT\13649268 patient_1\NN\9898892 who_2\WP\8299493 developed_3\VBD\1753788 <e2>paraplegia</e2>_4\NN\14558226 following_5\VBG\1835496 the_6\DT\1740 intrathecal_7\JJ\1740 instillation_8\NN\320852 of_9\IN\1740 <e1>methotrexate</e1>_10\NN\2722166 is_11\VBZ\836236 discribed_12\VBN\1740 ._13\.\1740
D008727_D002493 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 <e2>central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia</e2>_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 <e1>methothexate</e1>_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 methotrexate_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 neurotoxic_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 methotrexate_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 methotrexate_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D002493 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 <e2>central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia</e2>_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 methothexate_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 <e1>methotrexate</e1>_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 neurotoxic_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 methotrexate_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 methotrexate_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D002493 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 <e2>central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia</e2>_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 methothexate_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 methotrexate_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 neurotoxic_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 <e1>methotrexate</e1>_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 methotrexate_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D002493 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 <e2>central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia</e2>_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 methothexate_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 methotrexate_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 neurotoxic_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 methotrexate_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 <e1>methotrexate</e1>_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D002493 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 neurotoxicity_3\NN\1740 may_4\MD\15209706 be_5\VB\836236 reduced_6\VBN\441445 by_7\IN\1740 employing_8\VBG\1740 lower_9\JJR\1740 doses_10\NNS\3740161 of_11\IN\1740 <e1>methotrexate</e1>_12\NN\2722166 in_13\IN\13603305 the_14\DT\1740 presence_15\NN\13954253 of_16\IN\1740 <e2>central_17\JJ\1740 nervous_18\JJ\1740 system_19\NN\3575240 leukemia</e2>_20\NN\14239918 ,_21\,\1740 in_22\IN\13603305 older_23\JJR\1740 children_24\NNS\9622049 and_25\CC\1740 adults_26\NNS\7846 ,_27\,\1740 and_28\CC\1740 in_29\IN\13603305 the_30\DT\1740 presence_31\NN\13954253 of_32\IN\1740 epidural_33\JJ\1740 leakage_34\NN\7407777 ._35\.\1740
D008727_D020258 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 <e1>methothexate</e1>_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 methotrexate_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 <e2>neurotoxic</e2>_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 methotrexate_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 methotrexate_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D020258 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 methothexate_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 <e1>methotrexate</e1>_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 <e2>neurotoxic</e2>_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 methotrexate_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 methotrexate_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D020258 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 methothexate_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 methotrexate_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 <e2>neurotoxic</e2>_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 <e1>methotrexate</e1>_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 methotrexate_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D020258 NONE the_0\DT\1740 following_1\VBG\1835496 factors_2\NNS\7326557 appear_3\VBP\2604760 to_4\TO\1740 predispose_5\VB\680841 to_6\TO\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 this_10\DT\1740 complication_11\NN\1073995 :_12\:\1740 abnormal_13\JJ\1740 cerebrospinal_14\JJ\1740 dynamics_15\NNS\6100236 related_16\JJ\1740 to_17\TO\1740 the_18\DT\1740 presence_19\NN\13954253 of_20\IN\1740 central_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 leukemia_24\NN\14239918 ,_25\,\1740 and_26\CC\1740 epidural_27\JJ\1740 cerebrospinal_28\JJ\1740 leakage_29\NN\7407777 ;_30\:\1740 elevated_31\JJ\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 methothexate_34\NN\1740 concentration_35\NN\4916342 related_36\JJ\1740 to_37\TO\1740 abnormal_38\JJ\1740 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 dynamics_41\NNS\6100236 and_42\CC\1740 to_43\TO\1740 inappropriately_44\RB\1740 high_45\JJ\1740 methotrexate_46\NN\2722166 doses_47\NNS\3740161 based_48\VBN\2694933 on_49\IN\1740 body_50\NN\19128 surface_51\NN\21939 area_52\NN\8630985 calculations_53\NNS\1023820 in_54\IN\13603305 older_55\JJR\1740 children_56\NNS\9622049 and_57\CC\1740 adults_58\NNS\7846 ;_59\:\1740 the_60\DT\1740 presence_61\NN\13954253 of_62\IN\1740 <e2>neurotoxic</e2>_63\JJ\1740 preservatives_64\NNS\14818238 in_65\IN\13603305 commercially_66\RB\1740 available_67\JJ\1740 methotrexate_68\NN\2722166 preparations_69\NNS\407535 and_70\CC\1740 diluents_71\NNS\14778436 ;_72\:\1740 and_73\CC\1740 the_74\DT\1740 use_75\NN\407535 of_76\IN\1740 <e1>methotrexate</e1>_77\JJ\1740 diluents_78\NNS\14778436 of_79\IN\1740 unphysiologic_80\JJ\1740 ph_81\NN\5038959 ,_82\,\1740 ionic_83\JJ\1740 content_84\NN\7951464 and_85\CC\1740 osmolarity_86\NN\1740 ._87\.\1740
D008727_D020258 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>neurotoxicity</e2>_3\NN\1740 may_4\MD\15209706 be_5\VB\836236 reduced_6\VBN\441445 by_7\IN\1740 employing_8\VBG\1740 lower_9\JJR\1740 doses_10\NNS\3740161 of_11\IN\1740 <e1>methotrexate</e1>_12\NN\2722166 in_13\IN\13603305 the_14\DT\1740 presence_15\NN\13954253 of_16\IN\1740 central_17\JJ\1740 nervous_18\JJ\1740 system_19\NN\3575240 leukemia_20\NN\14239918 ,_21\,\1740 in_22\IN\13603305 older_23\JJR\1740 children_24\NNS\9622049 and_25\CC\1740 adults_26\NNS\7846 ,_27\,\1740 and_28\CC\1740 in_29\IN\13603305 the_30\DT\1740 presence_31\NN\13954253 of_32\IN\1740 epidural_33\JJ\1740 leakage_34\NN\7407777 ._35\.\1740
D008727_D020258 NONE periodic_0\JJ\1740 monitoring_1\NN\879759 of_2\IN\1740 cerebruspinal_3\JJ\1740 fluid_4\NN\19613 <e1>methotrexate</e1>_5\NN\2722166 levels_6\NNS\4916342 may_7\MD\15209706 be_8\VB\836236 predictive_9\JJ\1740 of_10\IN\1740 the_11\DT\1740 development_12\NN\248977 of_13\IN\1740 serious_14\JJ\1740 <e2>neurotoxicity</e2>_15\NN\1740 ._16\.\1740
D008727_C536409 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>methotrexate</e1>_3\JJ\1740 contaminants_4\NNS\14580897 ,_5\,\1740 local_6\JJ\1740 <e2>folate_7\NN\15090742 deficiency</e2>_8\NN\14449126 ,_9\,\1740 and_10\CC\1740 cranial_11\JJ\1740 irradiation_12\NN\13920835 in_13\IN\13603305 the_14\DT\1740 pathogenesis_15\NN\13533470 of_16\IN\1740 intrathecal_17\JJ\1740 methotrexate_18\NN\2722166 toxicity_19\NN\13576101 is_20\VBZ\836236 unclear_21\JJ\1740 ._22\.\1740
D008727_C536409 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 methotrexate_3\JJ\1740 contaminants_4\NNS\14580897 ,_5\,\1740 local_6\JJ\1740 <e2>folate_7\NN\15090742 deficiency</e2>_8\NN\14449126 ,_9\,\1740 and_10\CC\1740 cranial_11\JJ\1740 irradiation_12\NN\13920835 in_13\IN\13603305 the_14\DT\1740 pathogenesis_15\NN\13533470 of_16\IN\1740 intrathecal_17\JJ\1740 <e1>methotrexate</e1>_18\NN\2722166 toxicity_19\NN\13576101 is_20\VBZ\836236 unclear_21\JJ\1740 ._22\.\1740
D008727_D064420 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>methotrexate</e1>_3\JJ\1740 contaminants_4\NNS\14580897 ,_5\,\1740 local_6\JJ\1740 folate_7\NN\15090742 deficiency_8\NN\14449126 ,_9\,\1740 and_10\CC\1740 cranial_11\JJ\1740 irradiation_12\NN\13920835 in_13\IN\13603305 the_14\DT\1740 pathogenesis_15\NN\13533470 of_16\IN\1740 intrathecal_17\JJ\1740 methotrexate_18\NN\2722166 <e2>toxicity</e2>_19\NN\13576101 is_20\VBZ\836236 unclear_21\JJ\1740 ._22\.\1740
D008727_D064420 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 methotrexate_3\JJ\1740 contaminants_4\NNS\14580897 ,_5\,\1740 local_6\JJ\1740 folate_7\NN\15090742 deficiency_8\NN\14449126 ,_9\,\1740 and_10\CC\1740 cranial_11\JJ\1740 irradiation_12\NN\13920835 in_13\IN\13603305 the_14\DT\1740 pathogenesis_15\NN\13533470 of_16\IN\1740 intrathecal_17\JJ\1740 <e1>methotrexate</e1>_18\NN\2722166 <e2>toxicity</e2>_19\NN\13576101 is_20\VBZ\836236 unclear_21\JJ\1740 ._22\.\1740
16034922
D004967_D020521 CID long-term_0\JJ\1740 <e1>oestrogen-only</e1>_1\JJ\1740 ht_2\NN\1740 also_3\RB\1740 significantly_4\RB\1740 increased_5\VBD\169651 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>stroke</e2>_9\NN\556313 and_10\CC\1740 gallbladder_11\NN\5512139 disease_12\NN\14061805 ._13\.\1740
D004967_D005705 CID long-term_0\JJ\1740 <e1>oestrogen-only</e1>_1\JJ\1740 ht_2\NN\1740 also_3\RB\1740 significantly_4\RB\1740 increased_5\VBD\169651 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 stroke_9\NN\556313 and_10\CC\1740 <e2>gallbladder_11\NN\5512139 disease</e2>_12\NN\14061805 ._13\.\1740
17445520
D002110_D016584 CID <e1>caffeine</e1>_0\NN\14712692 challenge_1\NN\13927383 test_2\NN\5798043 in_3\IN\13603305 <e2>panic_4\JJ\1740 disorder</e2>_5\NN\14034177 and_6\CC\1740 depression_7\NN\14373582 with_8\IN\1740 panic_9\NN\7519253 attacks_10\NNS\955060 ._11\.\1740
D002110_D016584 CID <e1>caffeine</e1>_0\NN\14712692 challenge_1\NN\13927383 test_2\NN\5798043 in_3\IN\13603305 panic_4\JJ\1740 disorder_5\NN\14034177 and_6\CC\1740 depression_7\NN\14373582 with_8\IN\1740 <e2>panic_9\NN\7519253 attacks</e2>_10\NNS\955060 ._11\.\1740
D002110_D016584 CID our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 <e2>panic_8\JJ\1740 disorder</e2>_9\NN\14034177 (_10\-LRB-\1740 pd_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 major_16\JJ\1740 depression_17\NN\14373582 with_18\IN\1740 panic_19\NN\7519253 attacks_20\NNS\955060 (_21\-LRB-\1740 mdp_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 mental_30\NNP\1740 disorders_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 panic_46\NN\7519253 attacks_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D016584 CID our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 panic_8\JJ\1740 disorder_9\NN\14034177 (_10\-LRB-\1740 <e2>pd</e2>_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 major_16\JJ\1740 depression_17\NN\14373582 with_18\IN\1740 panic_19\NN\7519253 attacks_20\NNS\955060 (_21\-LRB-\1740 mdp_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 mental_30\NNP\1740 disorders_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 panic_46\NN\7519253 attacks_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D016584 CID our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 panic_8\JJ\1740 disorder_9\NN\14034177 (_10\-LRB-\1740 pd_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 major_16\JJ\1740 depression_17\NN\14373582 with_18\IN\1740 <e2>panic_19\NN\7519253 attacks</e2>_20\NNS\955060 (_21\-LRB-\1740 mdp_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 mental_30\NNP\1740 disorders_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 panic_46\NN\7519253 attacks_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D016584 CID our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 panic_8\JJ\1740 disorder_9\NN\14034177 (_10\-LRB-\1740 pd_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 major_16\JJ\1740 depression_17\NN\14373582 with_18\IN\1740 panic_19\NN\7519253 attacks_20\NNS\955060 (_21\-LRB-\1740 mdp_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 mental_30\NNP\1740 disorders_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 <e2>panic_46\NN\7519253 attacks</e2>_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D016584 CID a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 58.6_3\CD\1740 %_4\NN\1740 (_5\-LRB-\1740 n_6\NN\14622893 =_7\JJ\1740 17_8\CD\13745420 )_9\-RRB-\1740 of_10\IN\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>pd</e2>_13\NN\14625458 ,_14\,\1740 44.4_15\CD\1740 %_16\NN\1740 (_17\-LRB-\1740 n_18\NN\14622893 =_19\JJ\1740 12_20\CD\13745420 )_21\-RRB-\1740 of_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 mdp_25\NN\1740 ,_26\,\1740 12.0_27\CD\1740 %_28\NN\1740 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 3_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 patients_35\NNS\9898892 with_36\IN\1740 md_37\NN\14622893 ,_38\,\1740 and_39\CC\1740 7.1_40\CD\1740 %_41\NN\1740 (_42\-LRB-\1740 n=_43\NN\1740 2_44\CD\13741022 )_45\-RRB-\1740 of_46\IN\1740 control_47\JJ\1740 subjects_48\NNS\6598915 had_49\VBD\2108377 a_50\DT\13649268 panic_51\NN\7519253 attack_52\NN\955060 after_53\IN\1740 the_54\DT\1740 480-mg_55\NN\1740 <e1>caffeine</e1>_56\NN\14712692 challenge_57\NN\13927383 test_58\NN\5798043 (_59\-LRB-\1740 chi(2)(3_60\NN\1740 )_61\-RRB-\1740 =_62\JJ\1740 16.22_63\CD\1740 ,_64\,\1740 p_65\NN\14622893 =_66\JJ\1740 .001_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D002110_D016584 CID a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 58.6_3\CD\1740 %_4\NN\1740 (_5\-LRB-\1740 n_6\NN\14622893 =_7\JJ\1740 17_8\CD\13745420 )_9\-RRB-\1740 of_10\IN\1740 patients_11\NNS\9898892 with_12\IN\1740 pd_13\NN\14625458 ,_14\,\1740 44.4_15\CD\1740 %_16\NN\1740 (_17\-LRB-\1740 n_18\NN\14622893 =_19\JJ\1740 12_20\CD\13745420 )_21\-RRB-\1740 of_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 mdp_25\NN\1740 ,_26\,\1740 12.0_27\CD\1740 %_28\NN\1740 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 3_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 patients_35\NNS\9898892 with_36\IN\1740 md_37\NN\14622893 ,_38\,\1740 and_39\CC\1740 7.1_40\CD\1740 %_41\NN\1740 (_42\-LRB-\1740 n=_43\NN\1740 2_44\CD\13741022 )_45\-RRB-\1740 of_46\IN\1740 control_47\JJ\1740 subjects_48\NNS\6598915 had_49\VBD\2108377 a_50\DT\13649268 <e2>panic_51\NN\7519253 attack</e2>_52\NN\955060 after_53\IN\1740 the_54\DT\1740 480-mg_55\NN\1740 <e1>caffeine</e1>_56\NN\14712692 challenge_57\NN\13927383 test_58\NN\5798043 (_59\-LRB-\1740 chi(2)(3_60\NN\1740 )_61\-RRB-\1740 =_62\JJ\1740 16.22_63\CD\1740 ,_64\,\1740 p_65\NN\14622893 =_66\JJ\1740 .001_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D002110_D016584 CID the_0\DT\1740 patients_1\NNS\9898892 with_2\IN\1740 <e2>pd</e2>_3\NN\14625458 and_4\CC\1740 mdp_5\NN\1740 were_6\VBD\836236 more_7\RBR\1740 sensitive_8\JJ\1740 to_9\TO\1740 <e1>caffeine</e1>_10\NN\14712692 than_11\IN\1740 were_12\VBD\836236 patients_13\NNS\9898892 with_14\IN\1740 md_15\NN\14622893 and_16\CC\1740 healthy_17\JJ\1740 volunteers_18\NNS\10582746 ._19\.\1740
D002110_D016584 CID no_0\DT\7204911 <e2>panic_1\NN\7519253 attack</e2>_2\NN\955060 was_3\VBD\836236 observed_4\VBN\2163746 after_5\IN\1740 the_6\DT\1740 <e1>caffeine-free</e1>_7\JJ\1740 solution_8\NN\14586258 intake_9\NN\13440063 ._10\.\1740
D002110_D016584 CID our_0\PRP$\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 there_4\EX\27167 is_5\VBZ\836236 an_6\DT\6697703 association_7\NN\8008335 between_8\IN\1740 <e2>panic_9\NN\7519253 attacks</e2>_10\NNS\955060 ,_11\,\1740 no_12\RB\1740 matter_13\RB\1740 if_14\IN\1740 associated_15\VBN\628491 with_16\IN\1740 pd_17\NN\14625458 or_18\CC\3541091 mdp_19\NN\1740 ,_20\,\1740 and_21\CC\1740 hyperreactivity_22\NN\1740 to_23\TO\1740 an_24\DT\6697703 oral_25\JJ\1740 <e1>caffeine</e1>_26\NN\14712692 challenge_27\NN\13927383 test_28\NN\5798043 ._29\.\1740
D002110_D016584 CID our_0\PRP$\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 there_4\EX\27167 is_5\VBZ\836236 an_6\DT\6697703 association_7\NN\8008335 between_8\IN\1740 panic_9\NN\7519253 attacks_10\NNS\955060 ,_11\,\1740 no_12\RB\1740 matter_13\RB\1740 if_14\IN\1740 associated_15\VBN\628491 with_16\IN\1740 <e2>pd</e2>_17\NN\14625458 or_18\CC\3541091 mdp_19\NN\1740 ,_20\,\1740 and_21\CC\1740 hyperreactivity_22\NN\1740 to_23\TO\1740 an_24\DT\6697703 oral_25\JJ\1740 <e1>caffeine</e1>_26\NN\14712692 challenge_27\NN\13927383 test_28\NN\5798043 ._29\.\1740
D002110_D016584 NONE our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 panic_8\JJ\1740 disorder_9\NN\14034177 (_10\-LRB-\1740 pd_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 major_16\JJ\1740 depression_17\NN\14373582 with_18\IN\1740 panic_19\NN\7519253 attacks_20\NNS\955060 (_21\-LRB-\1740 <e2>mdp</e2>_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 mental_30\NNP\1740 disorders_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 panic_46\NN\7519253 attacks_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D016584 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 58.6_3\CD\1740 %_4\NN\1740 (_5\-LRB-\1740 n_6\NN\14622893 =_7\JJ\1740 17_8\CD\13745420 )_9\-RRB-\1740 of_10\IN\1740 patients_11\NNS\9898892 with_12\IN\1740 pd_13\NN\14625458 ,_14\,\1740 44.4_15\CD\1740 %_16\NN\1740 (_17\-LRB-\1740 n_18\NN\14622893 =_19\JJ\1740 12_20\CD\13745420 )_21\-RRB-\1740 of_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 <e2>mdp</e2>_25\NN\1740 ,_26\,\1740 12.0_27\CD\1740 %_28\NN\1740 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 3_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 patients_35\NNS\9898892 with_36\IN\1740 md_37\NN\14622893 ,_38\,\1740 and_39\CC\1740 7.1_40\CD\1740 %_41\NN\1740 (_42\-LRB-\1740 n=_43\NN\1740 2_44\CD\13741022 )_45\-RRB-\1740 of_46\IN\1740 control_47\JJ\1740 subjects_48\NNS\6598915 had_49\VBD\2108377 a_50\DT\13649268 panic_51\NN\7519253 attack_52\NN\955060 after_53\IN\1740 the_54\DT\1740 480-mg_55\NN\1740 <e1>caffeine</e1>_56\NN\14712692 challenge_57\NN\13927383 test_58\NN\5798043 (_59\-LRB-\1740 chi(2)(3_60\NN\1740 )_61\-RRB-\1740 =_62\JJ\1740 16.22_63\CD\1740 ,_64\,\1740 p_65\NN\14622893 =_66\JJ\1740 .001_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D002110_D016584 NONE the_0\DT\1740 patients_1\NNS\9898892 with_2\IN\1740 pd_3\NN\14625458 and_4\CC\1740 <e2>mdp</e2>_5\NN\1740 were_6\VBD\836236 more_7\RBR\1740 sensitive_8\JJ\1740 to_9\TO\1740 <e1>caffeine</e1>_10\NN\14712692 than_11\IN\1740 were_12\VBD\836236 patients_13\NNS\9898892 with_14\IN\1740 md_15\NN\14622893 and_16\CC\1740 healthy_17\JJ\1740 volunteers_18\NNS\10582746 ._19\.\1740
D002110_D016584 NONE our_0\PRP$\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 there_4\EX\27167 is_5\VBZ\836236 an_6\DT\6697703 association_7\NN\8008335 between_8\IN\1740 panic_9\NN\7519253 attacks_10\NNS\955060 ,_11\,\1740 no_12\RB\1740 matter_13\RB\1740 if_14\IN\1740 associated_15\VBN\628491 with_16\IN\1740 pd_17\NN\14625458 or_18\CC\3541091 <e2>mdp</e2>_19\NN\1740 ,_20\,\1740 and_21\CC\1740 hyperreactivity_22\NN\1740 to_23\TO\1740 an_24\DT\6697703 oral_25\JJ\1740 <e1>caffeine</e1>_26\NN\14712692 challenge_27\NN\13927383 test_28\NN\5798043 ._29\.\1740
D002110_D003866 NONE <e1>caffeine</e1>_0\NN\14712692 challenge_1\NN\13927383 test_2\NN\5798043 in_3\IN\13603305 panic_4\JJ\1740 disorder_5\NN\14034177 and_6\CC\1740 <e2>depression</e2>_7\NN\14373582 with_8\IN\1740 panic_9\NN\7519253 attacks_10\NNS\955060 ._11\.\1740
D002110_D003865 NONE our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 panic_8\JJ\1740 disorder_9\NN\14034177 (_10\-LRB-\1740 pd_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 <e2>major_16\JJ\1740 depression</e2>_17\NN\14373582 with_18\IN\1740 panic_19\NN\7519253 attacks_20\NNS\955060 (_21\-LRB-\1740 mdp_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 mental_30\NNP\1740 disorders_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 panic_46\NN\7519253 attacks_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D003865 NONE our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 panic_8\JJ\1740 disorder_9\NN\14034177 (_10\-LRB-\1740 pd_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 major_16\JJ\1740 depression_17\NN\14373582 with_18\IN\1740 panic_19\NN\7519253 attacks_20\NNS\955060 (_21\-LRB-\1740 <e2>mdp</e2>_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 mental_30\NNP\1740 disorders_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 panic_46\NN\7519253 attacks_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D003865 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 58.6_3\CD\1740 %_4\NN\1740 (_5\-LRB-\1740 n_6\NN\14622893 =_7\JJ\1740 17_8\CD\13745420 )_9\-RRB-\1740 of_10\IN\1740 patients_11\NNS\9898892 with_12\IN\1740 pd_13\NN\14625458 ,_14\,\1740 44.4_15\CD\1740 %_16\NN\1740 (_17\-LRB-\1740 n_18\NN\14622893 =_19\JJ\1740 12_20\CD\13745420 )_21\-RRB-\1740 of_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 <e2>mdp</e2>_25\NN\1740 ,_26\,\1740 12.0_27\CD\1740 %_28\NN\1740 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 3_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 patients_35\NNS\9898892 with_36\IN\1740 md_37\NN\14622893 ,_38\,\1740 and_39\CC\1740 7.1_40\CD\1740 %_41\NN\1740 (_42\-LRB-\1740 n=_43\NN\1740 2_44\CD\13741022 )_45\-RRB-\1740 of_46\IN\1740 control_47\JJ\1740 subjects_48\NNS\6598915 had_49\VBD\2108377 a_50\DT\13649268 panic_51\NN\7519253 attack_52\NN\955060 after_53\IN\1740 the_54\DT\1740 480-mg_55\NN\1740 <e1>caffeine</e1>_56\NN\14712692 challenge_57\NN\13927383 test_58\NN\5798043 (_59\-LRB-\1740 chi(2)(3_60\NN\1740 )_61\-RRB-\1740 =_62\JJ\1740 16.22_63\CD\1740 ,_64\,\1740 p_65\NN\14622893 =_66\JJ\1740 .001_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D002110_D003865 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 58.6_3\CD\1740 %_4\NN\1740 (_5\-LRB-\1740 n_6\NN\14622893 =_7\JJ\1740 17_8\CD\13745420 )_9\-RRB-\1740 of_10\IN\1740 patients_11\NNS\9898892 with_12\IN\1740 pd_13\NN\14625458 ,_14\,\1740 44.4_15\CD\1740 %_16\NN\1740 (_17\-LRB-\1740 n_18\NN\14622893 =_19\JJ\1740 12_20\CD\13745420 )_21\-RRB-\1740 of_22\IN\1740 patients_23\NNS\9898892 with_24\IN\1740 mdp_25\NN\1740 ,_26\,\1740 12.0_27\CD\1740 %_28\NN\1740 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 3_32\CD\13741022 )_33\-RRB-\1740 of_34\IN\1740 patients_35\NNS\9898892 with_36\IN\1740 <e2>md</e2>_37\NN\14622893 ,_38\,\1740 and_39\CC\1740 7.1_40\CD\1740 %_41\NN\1740 (_42\-LRB-\1740 n=_43\NN\1740 2_44\CD\13741022 )_45\-RRB-\1740 of_46\IN\1740 control_47\JJ\1740 subjects_48\NNS\6598915 had_49\VBD\2108377 a_50\DT\13649268 panic_51\NN\7519253 attack_52\NN\955060 after_53\IN\1740 the_54\DT\1740 480-mg_55\NN\1740 <e1>caffeine</e1>_56\NN\14712692 challenge_57\NN\13927383 test_58\NN\5798043 (_59\-LRB-\1740 chi(2)(3_60\NN\1740 )_61\-RRB-\1740 =_62\JJ\1740 16.22_63\CD\1740 ,_64\,\1740 p_65\NN\14622893 =_66\JJ\1740 .001_67\CD\1740 )_68\-RRB-\1740 ._69\.\1740
D002110_D003865 NONE the_0\DT\1740 patients_1\NNS\9898892 with_2\IN\1740 pd_3\NN\14625458 and_4\CC\1740 <e2>mdp</e2>_5\NN\1740 were_6\VBD\836236 more_7\RBR\1740 sensitive_8\JJ\1740 to_9\TO\1740 <e1>caffeine</e1>_10\NN\14712692 than_11\IN\1740 were_12\VBD\836236 patients_13\NNS\9898892 with_14\IN\1740 md_15\NN\14622893 and_16\CC\1740 healthy_17\JJ\1740 volunteers_18\NNS\10582746 ._19\.\1740
D002110_D003865 NONE the_0\DT\1740 patients_1\NNS\9898892 with_2\IN\1740 pd_3\NN\14625458 and_4\CC\1740 mdp_5\NN\1740 were_6\VBD\836236 more_7\RBR\1740 sensitive_8\JJ\1740 to_9\TO\1740 <e1>caffeine</e1>_10\NN\14712692 than_11\IN\1740 were_12\VBD\836236 patients_13\NNS\9898892 with_14\IN\1740 <e2>md</e2>_15\NN\14622893 and_16\CC\1740 healthy_17\JJ\1740 volunteers_18\NNS\10582746 ._19\.\1740
D002110_D003865 NONE our_0\PRP$\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 there_4\EX\27167 is_5\VBZ\836236 an_6\DT\6697703 association_7\NN\8008335 between_8\IN\1740 panic_9\NN\7519253 attacks_10\NNS\955060 ,_11\,\1740 no_12\RB\1740 matter_13\RB\1740 if_14\IN\1740 associated_15\VBN\628491 with_16\IN\1740 pd_17\NN\14625458 or_18\CC\3541091 <e2>mdp</e2>_19\NN\1740 ,_20\,\1740 and_21\CC\1740 hyperreactivity_22\NN\1740 to_23\TO\1740 an_24\DT\6697703 oral_25\JJ\1740 <e1>caffeine</e1>_26\NN\14712692 challenge_27\NN\13927383 test_28\NN\5798043 ._29\.\1740
D002110_D001523 NONE our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 observe_4\VB\2163746 if_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 panic_8\JJ\1740 disorder_9\NN\14034177 (_10\-LRB-\1740 pd_11\NN\14625458 )_12\-RRB-\1740 and_13\CC\1740 patients_14\NNS\9898892 with_15\IN\1740 major_16\JJ\1740 depression_17\NN\14373582 with_18\IN\1740 panic_19\NN\7519253 attacks_20\NNS\955060 (_21\-LRB-\1740 mdp_22\NN\1740 )_23\-RRB-\1740 (_24\-LRB-\1740 diagnostic_25\NNP\1740 and_26\CC\1740 statistical_27\NNP\1740 manual_28\NNP\6421301 of_29\IN\1740 <e2>mental_30\NNP\1740 disorders</e2>_31\NNPS\14034177 ,_32\,\1740 fourth_33\NNP\14429985 edition_34\NNP\6590210 criteria_35\NNS\13577171 )_36\-RRB-\1740 respond_37\VBP\2367363 in_38\IN\13603305 a_39\DT\13649268 similar_40\JJ\1740 way_41\NN\4916342 to_42\IN\1740 the_43\DT\1740 induction_44\NN\7450842 of_45\IN\1740 panic_46\NN\7519253 attacks_47\NNS\955060 by_48\IN\1740 an_49\DT\6697703 oral_50\JJ\1740 <e1>caffeine</e1>_51\NN\14712692 challenge_52\NN\13927383 test_53\NN\5798043 ._54\.\1740
D002110_D001008 NONE in_0\IN\13603305 a_1\DT\13649268 randomized_2\JJ\1740 double-blind_3\JJ\1740 experiment_4\NN\641820 performed_5\VBN\2367363 in_6\IN\13603305 2_7\CD\13741022 occasions_8\NNS\5983801 7_9\CD\13741022 days_10\NNS\15140892 apart_11\RB\1740 ,_12\,\1740 480_13\CD\1740 mg_14\NN\13717155 <e1>caffeine</e1>_15\NN\14712692 and_16\CC\1740 a_17\DT\13649268 caffeine-free_18\NN\1740 (_19\-LRB-\1740 placebo_20\NN\3740161 )_21\-RRB-\1740 solution_22\NN\14586258 were_23\VBD\836236 administered_24\VBN\2436349 in_25\IN\13603305 a_26\DT\13649268 coffee_27\NN\7881800 form_28\NN\6286395 and_29\CC\1740 <e2>anxiety</e2>_30\NN\14373582 scales_31\NNS\7260623 were_32\VBD\836236 applied_33\VBN\2676054 before_34\IN\1740 and_35\CC\1740 after_36\IN\1740 each_37\DT\1740 test_38\NN\5798043 ._39\.\1740
D002110_D001008 NONE in_0\IN\13603305 a_1\DT\13649268 randomized_2\JJ\1740 double-blind_3\JJ\1740 experiment_4\NN\641820 performed_5\VBN\2367363 in_6\IN\13603305 2_7\CD\13741022 occasions_8\NNS\5983801 7_9\CD\13741022 days_10\NNS\15140892 apart_11\RB\1740 ,_12\,\1740 480_13\CD\1740 mg_14\NN\13717155 caffeine_15\NN\14712692 and_16\CC\1740 a_17\DT\13649268 <e1>caffeine-free</e1>_18\NN\1740 (_19\-LRB-\1740 placebo_20\NN\3740161 )_21\-RRB-\1740 solution_22\NN\14586258 were_23\VBD\836236 administered_24\VBN\2436349 in_25\IN\13603305 a_26\DT\13649268 coffee_27\NN\7881800 form_28\NN\6286395 and_29\CC\1740 <e2>anxiety</e2>_30\NN\14373582 scales_31\NNS\7260623 were_32\VBD\836236 applied_33\VBN\2676054 before_34\IN\1740 and_35\CC\1740 after_36\IN\1740 each_37\DT\1740 test_38\NN\5798043 ._39\.\1740
10462057
D017330_D000741 CID induction_0\NN\7450842 of_1\IN\1740 apoptosis_2\NN\11486178 by_3\IN\1740 <e1>remoxipride</e1>_4\NN\1740 metabolites_5\NNS\20090 in_6\IN\13603305 hl60_7\NN\1740 and_8\CC\1740 cd34+/cd19-_9\NN\1740 human_10\JJ\1740 bone_11\NN\5286536 marrow_12\NN\5286536 progenitor_13\NN\9792555 cells_14\NNS\3080309 :_15\:\1740 potential_16\JJ\1740 relevance_17\NN\13791389 to_18\TO\1740 remoxipride-induced_19\JJ\1740 <e2>aplastic_20\JJ\1740 anemia</e2>_21\NN\14189204 ._22\.\1740
D017330_D000741 CID induction_0\NN\7450842 of_1\IN\1740 apoptosis_2\NN\11486178 by_3\IN\1740 remoxipride_4\NN\1740 metabolites_5\NNS\20090 in_6\IN\13603305 hl60_7\NN\1740 and_8\CC\1740 cd34+/cd19-_9\NN\1740 human_10\JJ\1740 bone_11\NN\5286536 marrow_12\NN\5286536 progenitor_13\NN\9792555 cells_14\NNS\3080309 :_15\:\1740 potential_16\JJ\1740 relevance_17\NN\13791389 to_18\TO\1740 <e1>remoxipride-induced</e1>_19\JJ\1740 <e2>aplastic_20\JJ\1740 anemia</e2>_21\NN\14189204 ._22\.\1740
D017330_D000741 CID the_0\DT\1740 antipsychotic_1\JJ\1740 agent_2\NN\7347 ,_3\,\1740 <e1>remoxipride</e1>_4\NN\1740 [_5\-LRB-\1740 (s)-(-)-3-bromo-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz_6\FW\1740 amide_7\NN\14727670 ]_8\-RRB-\1740 has_9\VBZ\2108377 been_10\VBN\836236 associated_11\VBN\628491 with_12\IN\1740 acquired_13\VBN\109660 <e2>aplastic_14\JJ\1740 anemia</e2>_15\NN\14189204 ._16\.\1740
D017330_D000741 CID the_0\DT\1740 antipsychotic_1\JJ\1740 agent_2\NN\7347 ,_3\,\1740 remoxipride_4\NN\1740 [_5\-LRB-\1740 <e1>(s)-(-)-3-bromo-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz_6\FW\1740 amide</e1>_7\NN\14727670 ]_8\-RRB-\1740 has_9\VBZ\2108377 been_10\VBN\836236 associated_11\VBN\628491 with_12\IN\1740 acquired_13\VBN\109660 <e2>aplastic_14\JJ\1740 anemia</e2>_15\NN\14189204 ._16\.\1740
D017330_D000741 CID we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 <e1>remoxipride</e1>_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 <e2>aplastic_8\JJ\1740 anemia</e2>_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 aplastic_37\JJ\1740 anemia_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
D017330_D000741 CID we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 <e1>remoxipride</e1>_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 aplastic_8\JJ\1740 anemia_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 <e2>aplastic_37\JJ\1740 anemia</e2>_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
D017330_D000741 CID we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 <e2>aplastic_8\JJ\1740 anemia</e2>_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 aplastic_37\JJ\1740 anemia_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 <e1>remoxipride</e1>_44\NN\1740 ._45\.\1740
D017330_D000741 CID we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 aplastic_8\JJ\1740 anemia_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 <e2>aplastic_37\JJ\1740 anemia</e2>_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 <e1>remoxipride</e1>_44\NN\1740 ._45\.\1740
C084325_D009336 NONE no_0\DT\7204911 <e2>necrosis</e2>_1\NN\11444117 was_2\VBD\836236 observed_3\VBN\2163746 in_4\IN\13603305 cells_5\NNS\3080309 treated_6\VBN\2376958 with_7\IN\1740 <e1>ncq436</e1>_8\NN\1740 but_9\CC\1740 ncq344_10\NN\1740 had_11\VBD\2108377 a_12\DT\13649268 biphasic_13\JJ\1740 effect_14\NN\34213 in_15\IN\13603305 both_16\DT\1740 cell_17\NN\3080309 types_18\NNS\5839024 ,_19\,\1740 inducing_20\VBG\1627355 apoptosis_21\NN\11486178 at_22\IN\14622893 lower_23\JJR\1740 concentrations_24\NNS\4916342 and_25\CC\1740 necrosis_26\NN\11444117 at_27\IN\14622893 higher_28\JJR\1740 concentrations_29\NNS\4916342 ._30\.\1740
C084325_D009336 NONE no_0\DT\7204911 necrosis_1\NN\11444117 was_2\VBD\836236 observed_3\VBN\2163746 in_4\IN\13603305 cells_5\NNS\3080309 treated_6\VBN\2376958 with_7\IN\1740 <e1>ncq436</e1>_8\NN\1740 but_9\CC\1740 ncq344_10\NN\1740 had_11\VBD\2108377 a_12\DT\13649268 biphasic_13\JJ\1740 effect_14\NN\34213 in_15\IN\13603305 both_16\DT\1740 cell_17\NN\3080309 types_18\NNS\5839024 ,_19\,\1740 inducing_20\VBG\1627355 apoptosis_21\NN\11486178 at_22\IN\14622893 lower_23\JJR\1740 concentrations_24\NNS\4916342 and_25\CC\1740 <e2>necrosis</e2>_26\NN\11444117 at_27\IN\14622893 higher_28\JJR\1740 concentrations_29\NNS\4916342 ._30\.\1740
C112341_D009336 NONE no_0\DT\7204911 <e2>necrosis</e2>_1\NN\11444117 was_2\VBD\836236 observed_3\VBN\2163746 in_4\IN\13603305 cells_5\NNS\3080309 treated_6\VBN\2376958 with_7\IN\1740 ncq436_8\NN\1740 but_9\CC\1740 <e1>ncq344</e1>_10\NN\1740 had_11\VBD\2108377 a_12\DT\13649268 biphasic_13\JJ\1740 effect_14\NN\34213 in_15\IN\13603305 both_16\DT\1740 cell_17\NN\3080309 types_18\NNS\5839024 ,_19\,\1740 inducing_20\VBG\1627355 apoptosis_21\NN\11486178 at_22\IN\14622893 lower_23\JJR\1740 concentrations_24\NNS\4916342 and_25\CC\1740 necrosis_26\NN\11444117 at_27\IN\14622893 higher_28\JJR\1740 concentrations_29\NNS\4916342 ._30\.\1740
C112341_D009336 NONE no_0\DT\7204911 necrosis_1\NN\11444117 was_2\VBD\836236 observed_3\VBN\2163746 in_4\IN\13603305 cells_5\NNS\3080309 treated_6\VBN\2376958 with_7\IN\1740 ncq436_8\NN\1740 but_9\CC\1740 <e1>ncq344</e1>_10\NN\1740 had_11\VBD\2108377 a_12\DT\13649268 biphasic_13\JJ\1740 effect_14\NN\34213 in_15\IN\13603305 both_16\DT\1740 cell_17\NN\3080309 types_18\NNS\5839024 ,_19\,\1740 inducing_20\VBG\1627355 apoptosis_21\NN\11486178 at_22\IN\14622893 lower_23\JJR\1740 concentrations_24\NNS\4916342 and_25\CC\1740 <e2>necrosis</e2>_26\NN\11444117 at_27\IN\14622893 higher_28\JJR\1740 concentrations_29\NNS\4916342 ._30\.\1740
D001554_D000741 CID we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 <e1>benzene</e1>_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 <e2>aplastic_8\JJ\1740 anemia</e2>_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 aplastic_37\JJ\1740 anemia_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
D001554_D000741 CID we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 <e1>benzene</e1>_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 aplastic_8\JJ\1740 anemia_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 <e2>aplastic_37\JJ\1740 anemia</e2>_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
C084325_D000741 NONE we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 <e2>aplastic_8\JJ\1740 anemia</e2>_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 <e1>ncq436</e1>_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 aplastic_37\JJ\1740 anemia_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
C084325_D000741 NONE we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 aplastic_8\JJ\1740 anemia_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 <e1>ncq436</e1>_21\NN\1740 and_22\CC\1740 ncq344_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 <e2>aplastic_37\JJ\1740 anemia</e2>_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
C112341_D000741 NONE we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 <e2>aplastic_8\JJ\1740 anemia</e2>_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 <e1>ncq344</e1>_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 aplastic_37\JJ\1740 anemia_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
C112341_D000741 NONE we_0\PRP\1740 propose_1\VBP\1010118 that_2\IN\1740 remoxipride_3\NN\1740 and_4\CC\1740 benzene_5\NN\14767996 may_6\MD\15209706 induce_7\VB\1627355 aplastic_8\JJ\1740 anemia_9\NN\14189204 via_10\IN\1740 production_11\NN\30358 of_12\IN\1740 similar_13\JJ\1740 reactive_14\JJ\1740 metabolites_15\NNS\20090 and_16\CC\1740 that_17\IN\1740 the_18\DT\1740 ability_19\NN\4723816 of_20\IN\1740 ncq436_21\NN\1740 and_22\CC\1740 <e1>ncq344</e1>_23\NN\1740 to_24\TO\1740 induce_25\VB\1627355 apoptosis_26\NN\11486178 in_27\IN\13603305 hbmp_28\NN\1740 cells_29\NNS\3080309 may_30\MD\15209706 contribute_31\VB\126264 to_32\TO\1740 the_33\DT\1740 mechanism_34\NN\13446390 underlying_35\VBG\2604760 acquired_36\VBN\109660 <e2>aplastic_37\JJ\1740 anemia</e2>_38\NN\14189204 that_39\WDT\1740 has_40\VBZ\2108377 been_41\VBN\836236 associated_42\VBN\628491 with_43\IN\1740 remoxipride_44\NN\1740 ._45\.\1740
6627074
D013390_D001049 CID <e1>succinylcholine</e1>_0\NN\3800001 <e2>apnoea</e2>_1\NN\1740 :_2\:\1740 attempted_3\VBN\2367363 reversal_4\NN\199130 with_5\IN\1740 anticholinesterases_6\NNS\3740161 ._7\.\1740
D013390_D001049 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 anticholinesterases_4\NNS\3740161 are_5\VBP\836236 only_6\RB\1740 partially_7\RB\1740 effective_8\JJ\1740 in_9\IN\13603305 restoring_10\VBG\1631072 neuromuscular_11\JJ\1740 function_12\NN\13783581 in_13\IN\13603305 <e1>succinylcholine</e1>_14\NN\3800001 <e2>apnoea</e2>_15\NN\1740 despite_16\IN\7501545 muscle_17\NN\5289601 twitch_18\NN\14360459 activity_19\NN\30358 typical_20\JJ\1740 of_21\IN\1740 phase_22\NN\15113229 ii_23\CD\13741022 block_24\NN\21939 ._25\.\1740
D013390_D020879 NONE anticholinesterases_0\NNS\3740161 were_1\VBD\836236 administered_2\VBN\2436349 in_3\IN\13603305 an_4\DT\6697703 attempt_5\NN\407535 to_6\TO\1740 antagonize_7\VB\1787955 prolonged_8\JJ\1740 <e2>neuromuscular_9\JJ\1740 blockade</e2>_10\NN\952963 following_11\VBG\1835496 the_12\DT\1740 administration_13\NN\1133281 of_14\IN\1740 <e1>succinylcholine</e1>_15\NN\3800001 in_16\IN\13603305 a_17\DT\13649268 patient_18\NN\9898892 later_19\RBR\1740 found_20\VBD\2426171 to_21\TO\1740 be_22\VB\836236 homozygous_23\JJ\1740 for_24\IN\1740 atypical_25\JJ\1740 plasma_26\NN\5398023 cholinesterase_27\NN\14732946 ._28\.\1740
3323599
D011692_D009401 NONE the_0\DT\1740 enhancement_1\NN\248977 of_2\IN\1740 <e1>aminonucleoside</e1>_3\NN\1740 <e2>nephrosis</e2>_4\NN\14304060 by_5\IN\1740 the_6\DT\1740 co-administration_7\NN\1740 of_8\IN\1740 protamine_9\NN\14736972 ._10\.\1740
D011692_D005923 CID an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 <e2>focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis</e2>_7\NN\14204950 (_8\-LRB-\1740 fsgs_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>puromycin-aminonucleoside</e1>_20\NN\1740 (_21\-LRB-\1740 amns_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 protamine_25\NN\14736972 sulfate_26\NN\15010703 (_27\-LRB-\1740 ps_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011692_D005923 CID an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis_7\NN\14204950 (_8\-LRB-\1740 <e2>fsgs</e2>_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>puromycin-aminonucleoside</e1>_20\NN\1740 (_21\-LRB-\1740 amns_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 protamine_25\NN\14736972 sulfate_26\NN\15010703 (_27\-LRB-\1740 ps_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011692_D005923 CID an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 <e2>focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis</e2>_7\NN\14204950 (_8\-LRB-\1740 fsgs_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 puromycin-aminonucleoside_20\NN\1740 (_21\-LRB-\1740 <e1>amns</e1>_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 protamine_25\NN\14736972 sulfate_26\NN\15010703 (_27\-LRB-\1740 ps_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011692_D005923 CID an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis_7\NN\14204950 (_8\-LRB-\1740 <e2>fsgs</e2>_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 puromycin-aminonucleoside_20\NN\1740 (_21\-LRB-\1740 <e1>amns</e1>_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 protamine_25\NN\14736972 sulfate_26\NN\15010703 (_27\-LRB-\1740 ps_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011692_D005923 CID therefore_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 suggested_4\VBN\1010118 that_5\IN\1740 the_6\DT\1740 administration_7\NN\1133281 of_8\IN\1740 ps_9\NN\6763273 enhances_10\VBZ\227165 the_11\DT\1740 toxicity_12\NN\13576101 of_13\IN\1740 <e1>amns</e1>_14\NN\1740 on_15\IN\1740 the_16\DT\1740 glomerulus_17\NN\5425910 and_18\CC\1740 readily_19\RB\1740 produces_20\VBZ\1617192 progressive_21\JJ\1740 <e2>fsgs</e2>_22\NNS\1740 in_23\IN\13603305 rats_24\NNS\2329401 resulting_25\VBG\2633881 in_26\IN\13603305 the_27\DT\1740 end-stage_28\JJ\1740 renal_29\JJ\1740 disease_30\NN\14061805 ._31\.\1740
D011479_D005923 NONE an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 <e2>focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis</e2>_7\NN\14204950 (_8\-LRB-\1740 fsgs_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 puromycin-aminonucleoside_20\NN\1740 (_21\-LRB-\1740 amns_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 <e1>protamine_25\NN\14736972 sulfate</e1>_26\NN\15010703 (_27\-LRB-\1740 ps_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011479_D005923 NONE an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis_7\NN\14204950 (_8\-LRB-\1740 <e2>fsgs</e2>_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 puromycin-aminonucleoside_20\NN\1740 (_21\-LRB-\1740 amns_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 <e1>protamine_25\NN\14736972 sulfate</e1>_26\NN\15010703 (_27\-LRB-\1740 ps_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011479_D005923 NONE an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 <e2>focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis</e2>_7\NN\14204950 (_8\-LRB-\1740 fsgs_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 puromycin-aminonucleoside_20\NN\1740 (_21\-LRB-\1740 amns_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 protamine_25\NN\14736972 sulfate_26\NN\15010703 (_27\-LRB-\1740 <e1>ps</e1>_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011479_D005923 NONE an_0\DT\6697703 experimental_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 focal_4\JJ\1740 segmental_5\JJ\1740 glomerular_6\JJ\1740 sclerosis_7\NN\14204950 (_8\-LRB-\1740 <e2>fsgs</e2>_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 developed_12\VBN\1753788 in_13\IN\13603305 rats_14\NNS\2329401 by_15\IN\1740 the_16\DT\1740 combined_17\JJ\1740 administration_18\NN\1133281 of_19\IN\1740 puromycin-aminonucleoside_20\NN\1740 (_21\-LRB-\1740 amns_22\NN\1740 )_23\-RRB-\1740 and_24\CC\1740 protamine_25\NN\14736972 sulfate_26\NN\15010703 (_27\-LRB-\1740 <e1>ps</e1>_28\NN\6763273 )_29\-RRB-\1740 ._30\.\1740
D011479_D005923 NONE therefore_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 suggested_4\VBN\1010118 that_5\IN\1740 the_6\DT\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>ps</e1>_9\NN\6763273 enhances_10\VBZ\227165 the_11\DT\1740 toxicity_12\NN\13576101 of_13\IN\1740 amns_14\NN\1740 on_15\IN\1740 the_16\DT\1740 glomerulus_17\NN\5425910 and_18\CC\1740 readily_19\RB\1740 produces_20\VBZ\1617192 progressive_21\JJ\1740 <e2>fsgs</e2>_22\NNS\1740 in_23\IN\13603305 rats_24\NNS\2329401 resulting_25\VBG\2633881 in_26\IN\13603305 the_27\DT\1740 end-stage_28\JJ\1740 renal_29\JJ\1740 disease_30\NN\14061805 ._31\.\1740
D011479_D064420 NONE therefore_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 suggested_4\VBN\1010118 that_5\IN\1740 the_6\DT\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>ps</e1>_9\NN\6763273 enhances_10\VBZ\227165 the_11\DT\1740 <e2>toxicity</e2>_12\NN\13576101 of_13\IN\1740 amns_14\NN\1740 on_15\IN\1740 the_16\DT\1740 glomerulus_17\NN\5425910 and_18\CC\1740 readily_19\RB\1740 produces_20\VBZ\1617192 progressive_21\JJ\1740 fsgs_22\NNS\1740 in_23\IN\13603305 rats_24\NNS\2329401 resulting_25\VBG\2633881 in_26\IN\13603305 the_27\DT\1740 end-stage_28\JJ\1740 renal_29\JJ\1740 disease_30\NN\14061805 ._31\.\1740
D011479_D007676 NONE therefore_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 suggested_4\VBN\1010118 that_5\IN\1740 the_6\DT\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>ps</e1>_9\NN\6763273 enhances_10\VBZ\227165 the_11\DT\1740 toxicity_12\NN\13576101 of_13\IN\1740 amns_14\NN\1740 on_15\IN\1740 the_16\DT\1740 glomerulus_17\NN\5425910 and_18\CC\1740 readily_19\RB\1740 produces_20\VBZ\1617192 progressive_21\JJ\1740 fsgs_22\NNS\1740 in_23\IN\13603305 rats_24\NNS\2329401 resulting_25\VBG\2633881 in_26\IN\13603305 the_27\DT\1740 <e2>end-stage_28\JJ\1740 renal_29\JJ\1740 disease</e2>_30\NN\14061805 ._31\.\1740
D011692_D064420 NONE therefore_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 suggested_4\VBN\1010118 that_5\IN\1740 the_6\DT\1740 administration_7\NN\1133281 of_8\IN\1740 ps_9\NN\6763273 enhances_10\VBZ\227165 the_11\DT\1740 <e2>toxicity</e2>_12\NN\13576101 of_13\IN\1740 <e1>amns</e1>_14\NN\1740 on_15\IN\1740 the_16\DT\1740 glomerulus_17\NN\5425910 and_18\CC\1740 readily_19\RB\1740 produces_20\VBZ\1617192 progressive_21\JJ\1740 fsgs_22\NNS\1740 in_23\IN\13603305 rats_24\NNS\2329401 resulting_25\VBG\2633881 in_26\IN\13603305 the_27\DT\1740 end-stage_28\JJ\1740 renal_29\JJ\1740 disease_30\NN\14061805 ._31\.\1740
D011692_D007676 CID therefore_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 suggested_4\VBN\1010118 that_5\IN\1740 the_6\DT\1740 administration_7\NN\1133281 of_8\IN\1740 ps_9\NN\6763273 enhances_10\VBZ\227165 the_11\DT\1740 toxicity_12\NN\13576101 of_13\IN\1740 <e1>amns</e1>_14\NN\1740 on_15\IN\1740 the_16\DT\1740 glomerulus_17\NN\5425910 and_18\CC\1740 readily_19\RB\1740 produces_20\VBZ\1617192 progressive_21\JJ\1740 fsgs_22\NNS\1740 in_23\IN\13603305 rats_24\NNS\2329401 resulting_25\VBG\2633881 in_26\IN\13603305 the_27\DT\1740 <e2>end-stage_28\JJ\1740 renal_29\JJ\1740 disease</e2>_30\NN\14061805 ._31\.\1740
24658375
D014212_D009220 CID <e1>all-trans_0\JJ\1740 retinoic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 inflammatory_3\JJ\1740 <e2>myositis</e2>_4\NN\14336539 in_5\IN\13603305 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 acute_9\JJ\1740 promyelocytic_10\JJ\1740 leukemia_11\NN\14239918 ._12\.\1740
D014212_D009220 CID only_0\RB\1740 a_1\DT\13649268 handful_2\NN\13760316 of_3\IN\1740 cases_4\NNS\7283608 of_5\IN\1740 <e1>atra-induced</e1>_6\JJ\1740 <e2>myositis</e2>_7\NN\14336539 in_8\IN\13603305 children_9\NNS\9622049 have_10\VBP\2108377 been_11\VBN\836236 reported_12\VBN\831651 ,_13\,\1740 and_14\CC\1740 none_15\NN\15228378 in_16\IN\13603305 the_17\DT\1740 radiology_18\NN\6045562 literature_19\NN\6362953 ._20\.\1740
D014212_D015473 NONE <e1>all-trans_0\JJ\1740 retinoic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 inflammatory_3\JJ\1740 myositis_4\NN\14336539 in_5\IN\13603305 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 <e2>acute_9\JJ\1740 promyelocytic_10\JJ\1740 leukemia</e2>_11\NN\14239918 ._12\.\1740
D014212_D015473 NONE <e1>all-trans_0\JJ\1740 retinoic_1\JJ\1740 acid</e1>_2\NN\14818238 (_3\-LRB-\1740 atra_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 component_8\NN\5867413 of_9\IN\1740 standard_10\JJ\1740 therapy_11\NN\657604 for_12\IN\1740 <e2>acute_13\JJ\1740 promyelocytic_14\JJ\1740 leukemia</e2>_15\NN\14239918 (_16\-LRB-\1740 apl_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 is_20\VBZ\836236 associated_21\VBN\628491 with_22\IN\1740 potentially_23\RB\1740 serious_24\JJ\1740 but_25\CC\1740 treatable_26\JJ\1740 adverse_27\JJ\1740 effects_28\NNS\13245626 involving_29\VBG\2676054 numerous_30\JJ\1740 organ_31\NN\5220461 systems_32\NNS\3575240 ,_33\,\1740 including_34\VBG\690614 rare_35\JJ\1740 skeletal_36\JJ\1740 muscle_37\NN\5289601 involvement_38\NN\1080366 ._39\.\1740
D014212_D015473 NONE <e1>all-trans_0\JJ\1740 retinoic_1\JJ\1740 acid</e1>_2\NN\14818238 (_3\-LRB-\1740 atra_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 component_8\NN\5867413 of_9\IN\1740 standard_10\JJ\1740 therapy_11\NN\657604 for_12\IN\1740 acute_13\JJ\1740 promyelocytic_14\JJ\1740 leukemia_15\NN\14239918 (_16\-LRB-\1740 <e2>apl</e2>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 is_20\VBZ\836236 associated_21\VBN\628491 with_22\IN\1740 potentially_23\RB\1740 serious_24\JJ\1740 but_25\CC\1740 treatable_26\JJ\1740 adverse_27\JJ\1740 effects_28\NNS\13245626 involving_29\VBG\2676054 numerous_30\JJ\1740 organ_31\NN\5220461 systems_32\NNS\3575240 ,_33\,\1740 including_34\VBG\690614 rare_35\JJ\1740 skeletal_36\JJ\1740 muscle_37\NN\5289601 involvement_38\NN\1080366 ._39\.\1740
D014212_D015473 NONE all-trans_0\JJ\1740 retinoic_1\JJ\1740 acid_2\NN\14818238 (_3\-LRB-\1740 <e1>atra</e1>_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 component_8\NN\5867413 of_9\IN\1740 standard_10\JJ\1740 therapy_11\NN\657604 for_12\IN\1740 <e2>acute_13\JJ\1740 promyelocytic_14\JJ\1740 leukemia</e2>_15\NN\14239918 (_16\-LRB-\1740 apl_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 is_20\VBZ\836236 associated_21\VBN\628491 with_22\IN\1740 potentially_23\RB\1740 serious_24\JJ\1740 but_25\CC\1740 treatable_26\JJ\1740 adverse_27\JJ\1740 effects_28\NNS\13245626 involving_29\VBG\2676054 numerous_30\JJ\1740 organ_31\NN\5220461 systems_32\NNS\3575240 ,_33\,\1740 including_34\VBG\690614 rare_35\JJ\1740 skeletal_36\JJ\1740 muscle_37\NN\5289601 involvement_38\NN\1080366 ._39\.\1740
D014212_D015473 NONE all-trans_0\JJ\1740 retinoic_1\JJ\1740 acid_2\NN\14818238 (_3\-LRB-\1740 <e1>atra</e1>_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 a_7\DT\13649268 component_8\NN\5867413 of_9\IN\1740 standard_10\JJ\1740 therapy_11\NN\657604 for_12\IN\1740 acute_13\JJ\1740 promyelocytic_14\JJ\1740 leukemia_15\NN\14239918 (_16\-LRB-\1740 <e2>apl</e2>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 is_20\VBZ\836236 associated_21\VBN\628491 with_22\IN\1740 potentially_23\RB\1740 serious_24\JJ\1740 but_25\CC\1740 treatable_26\JJ\1740 adverse_27\JJ\1740 effects_28\NNS\13245626 involving_29\VBG\2676054 numerous_30\JJ\1740 organ_31\NN\5220461 systems_32\NNS\3575240 ,_33\,\1740 including_34\VBG\690614 rare_35\JJ\1740 skeletal_36\JJ\1740 muscle_37\NN\5289601 involvement_38\NN\1080366 ._39\.\1740
12535818
D000638_D001919 CID <e1>amiodarone</e1>_0\NN\2715941 and_1\CC\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>bradyarrhythmia</e2>_5\NN\1740 requiring_6\VBG\754942 permanent_7\JJ\1740 pacemaker_8\NN\5925366 in_9\IN\13603305 elderly_10\JJ\1740 patients_11\NNS\9898892 with_12\IN\1740 atrial_13\JJ\1740 fibrillation_14\NN\14361664 and_15\CC\1740 prior_16\JJ\1740 myocardial_17\JJ\1740 infarction_18\NN\14204950 ._19\.\1740
D000638_D001919 CID objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 whether_10\IN\1740 the_11\DT\1740 use_12\NN\407535 of_13\IN\1740 <e1>amiodarone</e1>_14\NN\2715941 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 atrial_18\JJ\1740 fibrillation_19\NN\14361664 (_20\-LRB-\1740 af_21\NN\1740 )_22\-RRB-\1740 increases_23\VBZ\169651 the_24\DT\1740 risk_25\NN\14541044 of_26\IN\1740 <e2>bradyarrhythmia</e2>_27\NN\1740 requiring_28\VBG\754942 a_29\DT\13649268 permanent_30\JJ\1740 pacemaker_31\NN\5925366 ._32\.\1740
D000638_D001919 CID background_0\NN\4921011 :_1\:\1740 reports_2\NNS\6470073 of_3\IN\1740 severe_4\JJ\1740 <e2>bradyarrhythmia</e2>_5\NN\1740 during_6\IN\1740 <e1>amiodarone</e1>_7\NN\2715941 therapy_8\NN\657604 are_9\VBP\836236 infrequent_10\JJ\1740 and_11\CC\1740 limited_12\VBN\2510337 to_13\IN\1740 studies_14\NNS\635850 assessing_15\VBG\670261 the_16\DT\1740 therapy_17\NN\657604 's_18\POS\1740 use_19\NN\407535 in_20\IN\13603305 the_21\DT\1740 management_22\NN\1123598 of_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 ventricular_26\NN\1740 arrhythmias_27\NNS\14103288 ._28\.\1740
D000638_D001919 CID conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 suggests_4\VBZ\1010118 that_5\IN\1740 the_6\DT\1740 use_7\NN\407535 of_8\IN\1740 <e1>amiodarone</e1>_9\NN\2715941 in_10\IN\13603305 elderly_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 af_14\NN\1740 and_15\CC\1740 a_16\DT\13649268 previous_17\JJ\1740 mi_18\NN\14207561 increases_19\VBZ\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 <e2>bradyarrhythmia</e2>_23\NN\1740 requiring_24\VBG\754942 a_25\DT\13649268 permanent_26\JJ\1740 pacemaker_27\NN\5925366 ._28\.\1740
D000638_D001281 NONE <e1>amiodarone</e1>_0\NN\2715941 and_1\CC\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 bradyarrhythmia_5\NN\1740 requiring_6\VBG\754942 permanent_7\JJ\1740 pacemaker_8\NN\5925366 in_9\IN\13603305 elderly_10\JJ\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>atrial_13\JJ\1740 fibrillation</e2>_14\NN\14361664 and_15\CC\1740 prior_16\JJ\1740 myocardial_17\JJ\1740 infarction_18\NN\14204950 ._19\.\1740
D000638_D001281 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 whether_10\IN\1740 the_11\DT\1740 use_12\NN\407535 of_13\IN\1740 <e1>amiodarone</e1>_14\NN\2715941 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>atrial_18\JJ\1740 fibrillation</e2>_19\NN\14361664 (_20\-LRB-\1740 af_21\NN\1740 )_22\-RRB-\1740 increases_23\VBZ\169651 the_24\DT\1740 risk_25\NN\14541044 of_26\IN\1740 bradyarrhythmia_27\NN\1740 requiring_28\VBG\754942 a_29\DT\13649268 permanent_30\JJ\1740 pacemaker_31\NN\5925366 ._32\.\1740
D000638_D001281 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 whether_10\IN\1740 the_11\DT\1740 use_12\NN\407535 of_13\IN\1740 <e1>amiodarone</e1>_14\NN\2715941 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 atrial_18\JJ\1740 fibrillation_19\NN\14361664 (_20\-LRB-\1740 <e2>af</e2>_21\NN\1740 )_22\-RRB-\1740 increases_23\VBZ\169651 the_24\DT\1740 risk_25\NN\14541044 of_26\IN\1740 bradyarrhythmia_27\NN\1740 requiring_28\VBG\754942 a_29\DT\13649268 permanent_30\JJ\1740 pacemaker_31\NN\5925366 ._32\.\1740
D000638_D001281 NONE conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 suggests_4\VBZ\1010118 that_5\IN\1740 the_6\DT\1740 use_7\NN\407535 of_8\IN\1740 <e1>amiodarone</e1>_9\NN\2715941 in_10\IN\13603305 elderly_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>af</e2>_14\NN\1740 and_15\CC\1740 a_16\DT\13649268 previous_17\JJ\1740 mi_18\NN\14207561 increases_19\VBZ\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 bradyarrhythmia_23\NN\1740 requiring_24\VBG\754942 a_25\DT\13649268 permanent_26\JJ\1740 pacemaker_27\NN\5925366 ._28\.\1740
D000638_D009203 NONE <e1>amiodarone</e1>_0\NN\2715941 and_1\CC\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 bradyarrhythmia_5\NN\1740 requiring_6\VBG\754942 permanent_7\JJ\1740 pacemaker_8\NN\5925366 in_9\IN\13603305 elderly_10\JJ\1740 patients_11\NNS\9898892 with_12\IN\1740 atrial_13\JJ\1740 fibrillation_14\NN\14361664 and_15\CC\1740 prior_16\JJ\1740 <e2>myocardial_17\JJ\1740 infarction</e2>_18\NN\14204950 ._19\.\1740
D000638_D009203 NONE conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 suggests_4\VBZ\1010118 that_5\IN\1740 the_6\DT\1740 use_7\NN\407535 of_8\IN\1740 <e1>amiodarone</e1>_9\NN\2715941 in_10\IN\13603305 elderly_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 af_14\NN\1740 and_15\CC\1740 a_16\DT\13649268 previous_17\JJ\1740 <e2>mi</e2>_18\NN\14207561 increases_19\VBZ\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 bradyarrhythmia_23\NN\1740 requiring_24\VBG\754942 a_25\DT\13649268 permanent_26\JJ\1740 pacemaker_27\NN\5925366 ._28\.\1740
D000638_D001145 NONE background_0\NN\4921011 :_1\:\1740 reports_2\NNS\6470073 of_3\IN\1740 severe_4\JJ\1740 bradyarrhythmia_5\NN\1740 during_6\IN\1740 <e1>amiodarone</e1>_7\NN\2715941 therapy_8\NN\657604 are_9\VBP\836236 infrequent_10\JJ\1740 and_11\CC\1740 limited_12\VBN\2510337 to_13\IN\1740 studies_14\NNS\635850 assessing_15\VBG\670261 the_16\DT\1740 therapy_17\NN\657604 's_18\POS\1740 use_19\NN\407535 in_20\IN\13603305 the_21\DT\1740 management_22\NN\1123598 of_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 <e2>ventricular_26\NN\1740 arrhythmias</e2>_27\NNS\14103288 ._28\.\1740
2429800
D006632_D007022 NONE <e1>histamine</e1>_0\NN\14739004 antagonists_1\NNS\7846 and_2\CC\1740 d-tubocurarine-induced_3\JJ\1740 <e2>hypotension</e2>_4\NN\14057371 in_5\IN\13603305 cardiac_6\JJ\1740 surgical_7\JJ\1740 patients_8\NNS\9898892 ._9\.\1740
D014403_D007022 CID histamine_0\NN\14739004 antagonists_1\NNS\7846 and_2\CC\1740 <e1>d-tubocurarine-induced</e1>_3\JJ\1740 <e2>hypotension</e2>_4\NN\14057371 in_5\IN\13603305 cardiac_6\JJ\1740 surgical_7\JJ\1740 patients_8\NNS\9898892 ._9\.\1740
2765447
D019793_D012640 NONE <e2>convulsion</e2>_0\NN\14081375 following_1\VBG\1835496 intravenous_2\JJ\1740 <e1>fluorescein</e1>_3\NN\14598383 angiography_4\NN\904623 ._5\.\1740
D019793_D004830 CID <e2>tonic-clonic_0\JJ\1740 seizures</e2>_1\NNS\14081375 followed_2\VBD\1835496 intravenous_3\JJ\1740 <e1>fluorescein</e1>_4\NN\14598383 injection_5\NN\320852 for_6\IN\1740 fundus_7\NN\5225602 angiography_8\NN\904623 in_9\IN\13603305 a_10\DT\13649268 47-year-old_11\JJ\1740 male_12\JJ\1740 ._13\.\1740
3685052
D005481_D012640 NONE <e1>flurothyl</e1>_0\NN\1740 <e2>seizure</e2>_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 monosodium_12\NN\1740 glutamate_13\NN\15010703 (_14\-LRB-\1740 msg_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 flurothyl_22\NN\1740 seizure_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D005481_D012640 NONE <e1>flurothyl</e1>_0\NN\1740 seizure_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 monosodium_12\NN\1740 glutamate_13\NN\15010703 (_14\-LRB-\1740 msg_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 flurothyl_22\NN\1740 <e2>seizure</e2>_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D005481_D012640 NONE flurothyl_0\NN\1740 <e2>seizure</e2>_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 monosodium_12\NN\1740 glutamate_13\NN\15010703 (_14\-LRB-\1740 msg_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 <e1>flurothyl</e1>_22\NN\1740 seizure_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D005481_D012640 NONE flurothyl_0\NN\1740 seizure_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 monosodium_12\NN\1740 glutamate_13\NN\15010703 (_14\-LRB-\1740 msg_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 <e1>flurothyl</e1>_22\NN\1740 <e2>seizure</e2>_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D005481_D012640 NONE a_0\DT\13649268 <e1>flurothyl</e1>_1\NN\1740 ether_2\RB\1740 <e2>seizure</e2>_3\VBP\1740 screening_4\NN\6887726 technique_5\NN\5660268 was_6\VBD\836236 used_7\VBN\1156834 to_8\TO\1740 evaluate_9\VB\670261 seizure_10\JJ\1740 susceptibility_11\NN\13920835 in_12\IN\13603305 adult_13\JJ\1740 mice_14\NNS\2329401 that_15\WDT\1740 received_16\VBD\2210855 neonatal_17\JJ\1740 injections_18\NNS\320852 of_19\IN\1740 msg_20\NN\7809368 (_21\-LRB-\1740 4_22\CD\13741022 mg/g_23\NN\1740 and_24\CC\1740 1_25\CD\13741022 mg/g_26\NN\1740 )_27\-RRB-\1740 ._28\.\1740
D005481_D012640 NONE a_0\DT\13649268 <e1>flurothyl</e1>_1\NN\1740 ether_2\RB\1740 seizure_3\VBP\1740 screening_4\NN\6887726 technique_5\NN\5660268 was_6\VBD\836236 used_7\VBN\1156834 to_8\TO\1740 evaluate_9\VB\670261 <e2>seizure</e2>_10\JJ\1740 susceptibility_11\NN\13920835 in_12\IN\13603305 adult_13\JJ\1740 mice_14\NNS\2329401 that_15\WDT\1740 received_16\VBD\2210855 neonatal_17\JJ\1740 injections_18\NNS\320852 of_19\IN\1740 msg_20\NN\7809368 (_21\-LRB-\1740 4_22\CD\13741022 mg/g_23\NN\1740 and_24\CC\1740 1_25\CD\13741022 mg/g_26\NN\1740 )_27\-RRB-\1740 ._28\.\1740
D005481_D012640 NONE <e1>flurothyl</e1>_0\NN\1740 ether_1\NN\14840755 produced_2\VBD\1617192 hypothermia_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 flurothyl_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 hypothermia_19\NN\14034177 to_20\TO\1740 <e2>seizure</e2>_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D005481_D012640 NONE flurothyl_0\NN\1740 ether_1\NN\14840755 produced_2\VBD\1617192 hypothermia_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 <e1>flurothyl</e1>_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 hypothermia_19\NN\14034177 to_20\TO\1740 <e2>seizure</e2>_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D005481_D012640 NONE <e1>flurothyl</e1>_0\NN\1740 <e2>seizure</e2>_1\NN\14081375 testing_2\NN\639556 proved_3\VBD\2604760 to_4\TO\1740 be_5\VB\836236 a_6\DT\13649268 rapid_7\JJ\1740 and_8\CC\1740 reliable_9\JJ\1740 technique_10\NN\5660268 with_11\IN\1740 which_12\WDT\1740 to_13\TO\1740 evaluate_14\VB\670261 seizure_15\JJ\1740 susceptibility_16\NN\13920835 ._17\.\1740
D005481_D012640 NONE <e1>flurothyl</e1>_0\NN\1740 seizure_1\NN\14081375 testing_2\NN\639556 proved_3\VBD\2604760 to_4\TO\1740 be_5\VB\836236 a_6\DT\13649268 rapid_7\JJ\1740 and_8\CC\1740 reliable_9\JJ\1740 technique_10\NN\5660268 with_11\IN\1740 which_12\WDT\1740 to_13\TO\1740 evaluate_14\VB\670261 <e2>seizure</e2>_15\JJ\1740 susceptibility_16\NN\13920835 ._17\.\1740
D012970_D012640 NONE flurothyl_0\NN\1740 <e2>seizure</e2>_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 <e1>monosodium_12\NN\1740 glutamate</e1>_13\NN\15010703 (_14\-LRB-\1740 msg_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 flurothyl_22\NN\1740 seizure_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D012970_D012640 NONE flurothyl_0\NN\1740 seizure_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 <e1>monosodium_12\NN\1740 glutamate</e1>_13\NN\15010703 (_14\-LRB-\1740 msg_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 flurothyl_22\NN\1740 <e2>seizure</e2>_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D012970_D012640 NONE flurothyl_0\NN\1740 <e2>seizure</e2>_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 monosodium_12\NN\1740 glutamate_13\NN\15010703 (_14\-LRB-\1740 <e1>msg</e1>_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 flurothyl_22\NN\1740 seizure_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D012970_D012640 NONE flurothyl_0\NN\1740 seizure_1\VBD\1740 thresholds_2\NNS\15265518 in_3\IN\13603305 mice_4\NNS\2329401 treated_5\VBN\2376958 neonatally_6\RB\1740 with_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 monosodium_12\NN\1740 glutamate_13\NN\15010703 (_14\-LRB-\1740 <e1>msg</e1>_15\NN\7809368 ):_16\-RRB-\1740 evaluation_17\NN\874067 of_18\IN\1740 experimental_19\JJ\1740 parameters_20\NNS\5858936 in_21\IN\13603305 flurothyl_22\NN\1740 <e2>seizure</e2>_23\JJ\1740 testing_24\NN\639556 ._25\.\1740
D012970_D012640 NONE <e1>monosodium_0\NN\1740 glutamate</e1>_1\NN\15010703 (_2\-LRB-\1740 msg_3\NN\7809368 )_4\-RRB-\1740 administration_5\NN\1133281 to_6\TO\1740 neonatal_7\JJ\1740 rodents_8\NNS\1886756 produces_9\VBZ\1617192 <e2>convulsions</e2>_10\NNS\14081375 and_11\CC\1740 results_12\VBZ\2633881 in_13\IN\13603305 numerous_14\JJ\1740 biochemical_15\JJ\1740 and_16\CC\1740 behavioral_17\JJ\1740 deficits_18\NNS\5113133 ._19\.\1740
D012970_D012640 NONE monosodium_0\NN\1740 glutamate_1\NN\15010703 (_2\-LRB-\1740 <e1>msg</e1>_3\NN\7809368 )_4\-RRB-\1740 administration_5\NN\1133281 to_6\TO\1740 neonatal_7\JJ\1740 rodents_8\NNS\1886756 produces_9\VBZ\1617192 <e2>convulsions</e2>_10\NNS\14081375 and_11\CC\1740 results_12\VBZ\2633881 in_13\IN\13603305 numerous_14\JJ\1740 biochemical_15\JJ\1740 and_16\CC\1740 behavioral_17\JJ\1740 deficits_18\NNS\5113133 ._19\.\1740
D012970_D012640 NONE these_0\DT\1740 studies_1\NNS\635850 were_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 determine_5\VB\1645601 if_6\IN\1740 neonatal_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>msg</e1>_10\NN\7809368 produced_11\VBD\1617192 permanent_12\JJ\1740 alterations_13\NNS\7283608 in_14\IN\13603305 <e2>seizure</e2>_15\JJ\1740 susceptibility_16\NN\13920835 ,_17\,\1740 since_18\IN\1740 previous_19\JJ\1740 investigations_20\NNS\5797597 were_21\VBD\836236 inconclusive_22\JJ\1740 ._23\.\1740
D012970_D012640 NONE a_0\DT\13649268 flurothyl_1\NN\1740 ether_2\RB\1740 <e2>seizure</e2>_3\VBP\1740 screening_4\NN\6887726 technique_5\NN\5660268 was_6\VBD\836236 used_7\VBN\1156834 to_8\TO\1740 evaluate_9\VB\670261 seizure_10\JJ\1740 susceptibility_11\NN\13920835 in_12\IN\13603305 adult_13\JJ\1740 mice_14\NNS\2329401 that_15\WDT\1740 received_16\VBD\2210855 neonatal_17\JJ\1740 injections_18\NNS\320852 of_19\IN\1740 <e1>msg</e1>_20\NN\7809368 (_21\-LRB-\1740 4_22\CD\13741022 mg/g_23\NN\1740 and_24\CC\1740 1_25\CD\13741022 mg/g_26\NN\1740 )_27\-RRB-\1740 ._28\.\1740
D012970_D012640 NONE a_0\DT\13649268 flurothyl_1\NN\1740 ether_2\RB\1740 seizure_3\VBP\1740 screening_4\NN\6887726 technique_5\NN\5660268 was_6\VBD\836236 used_7\VBN\1156834 to_8\TO\1740 evaluate_9\VB\670261 <e2>seizure</e2>_10\JJ\1740 susceptibility_11\NN\13920835 in_12\IN\13603305 adult_13\JJ\1740 mice_14\NNS\2329401 that_15\WDT\1740 received_16\VBD\2210855 neonatal_17\JJ\1740 injections_18\NNS\320852 of_19\IN\1740 <e1>msg</e1>_20\NN\7809368 (_21\-LRB-\1740 4_22\CD\13741022 mg/g_23\NN\1740 and_24\CC\1740 1_25\CD\13741022 mg/g_26\NN\1740 )_27\-RRB-\1740 ._28\.\1740
D012970_D012640 NONE <e1>msg</e1>_0\NN\7809368 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 significant_4\JJ\1740 reductions_5\NNS\351485 in_6\IN\13603305 whole_7\JJ\1740 brain_8\NN\5462674 weight_9\NN\5009170 but_10\CC\1740 did_11\VBD\1640855 not_12\RB\1740 alter_13\VB\126264 <e2>seizure</e2>_14\JJ\1740 threshold_15\NN\15265518 ._16\.\1740
D012970_D012640 NONE a_0\DT\13649268 naloxone_1\NN\3808977 (_2\-LRB-\1740 5_3\CD\13741022 mg/kg_4\NN\1740 )_5\-RRB-\1740 challenge_6\NN\13927383 was_7\VBD\836236 also_8\RB\1740 ineffective_9\JJ\1740 in_10\IN\13603305 altering_11\VBG\126264 the_12\DT\1740 <e2>seizure</e2>_13\JJ\1740 thresholds_14\NNS\15265518 of_15\IN\1740 either_16\CC\1740 control_17\NN\5190804 of_18\IN\1740 <e1>msg-treated</e1>_19\JJ\1740 mice_20\NNS\2329401 ._21\.\1740
D004986_D012640 NONE a_0\DT\13649268 flurothyl_1\NN\1740 <e1>ether</e1>_2\RB\1740 <e2>seizure</e2>_3\VBP\1740 screening_4\NN\6887726 technique_5\NN\5660268 was_6\VBD\836236 used_7\VBN\1156834 to_8\TO\1740 evaluate_9\VB\670261 seizure_10\JJ\1740 susceptibility_11\NN\13920835 in_12\IN\13603305 adult_13\JJ\1740 mice_14\NNS\2329401 that_15\WDT\1740 received_16\VBD\2210855 neonatal_17\JJ\1740 injections_18\NNS\320852 of_19\IN\1740 msg_20\NN\7809368 (_21\-LRB-\1740 4_22\CD\13741022 mg/g_23\NN\1740 and_24\CC\1740 1_25\CD\13741022 mg/g_26\NN\1740 )_27\-RRB-\1740 ._28\.\1740
D004986_D012640 NONE a_0\DT\13649268 flurothyl_1\NN\1740 <e1>ether</e1>_2\RB\1740 seizure_3\VBP\1740 screening_4\NN\6887726 technique_5\NN\5660268 was_6\VBD\836236 used_7\VBN\1156834 to_8\TO\1740 evaluate_9\VB\670261 <e2>seizure</e2>_10\JJ\1740 susceptibility_11\NN\13920835 in_12\IN\13603305 adult_13\JJ\1740 mice_14\NNS\2329401 that_15\WDT\1740 received_16\VBD\2210855 neonatal_17\JJ\1740 injections_18\NNS\320852 of_19\IN\1740 msg_20\NN\7809368 (_21\-LRB-\1740 4_22\CD\13741022 mg/g_23\NN\1740 and_24\CC\1740 1_25\CD\13741022 mg/g_26\NN\1740 )_27\-RRB-\1740 ._28\.\1740
D004986_D012640 NONE flurothyl_0\NN\1740 <e1>ether</e1>_1\NN\14840755 produced_2\VBD\1617192 hypothermia_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 flurothyl_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 hypothermia_19\NN\14034177 to_20\TO\1740 <e2>seizure</e2>_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D009270_D012640 NONE a_0\DT\13649268 <e1>naloxone</e1>_1\NN\3808977 (_2\-LRB-\1740 5_3\CD\13741022 mg/kg_4\NN\1740 )_5\-RRB-\1740 challenge_6\NN\13927383 was_7\VBD\836236 also_8\RB\1740 ineffective_9\JJ\1740 in_10\IN\13603305 altering_11\VBG\126264 the_12\DT\1740 <e2>seizure</e2>_13\JJ\1740 thresholds_14\NNS\15265518 of_15\IN\1740 either_16\CC\1740 control_17\NN\5190804 of_18\IN\1740 msg-treated_19\JJ\1740 mice_20\NNS\2329401 ._21\.\1740
D005481_D007035 CID <e1>flurothyl</e1>_0\NN\1740 ether_1\NN\14840755 produced_2\VBD\1617192 <e2>hypothermia</e2>_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 flurothyl_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 hypothermia_19\NN\14034177 to_20\TO\1740 seizure_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D005481_D007035 CID <e1>flurothyl</e1>_0\NN\1740 ether_1\NN\14840755 produced_2\VBD\1617192 hypothermia_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 flurothyl_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 <e2>hypothermia</e2>_19\NN\14034177 to_20\TO\1740 seizure_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D005481_D007035 CID flurothyl_0\NN\1740 ether_1\NN\14840755 produced_2\VBD\1617192 <e2>hypothermia</e2>_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 <e1>flurothyl</e1>_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 hypothermia_19\NN\14034177 to_20\TO\1740 seizure_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D005481_D007035 CID flurothyl_0\NN\1740 ether_1\NN\14840755 produced_2\VBD\1617192 hypothermia_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 <e1>flurothyl</e1>_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 <e2>hypothermia</e2>_19\NN\14034177 to_20\TO\1740 seizure_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D004986_D007035 NONE flurothyl_0\NN\1740 <e1>ether</e1>_1\NN\14840755 produced_2\VBD\1617192 <e2>hypothermia</e2>_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 flurothyl_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 hypothermia_19\NN\14034177 to_20\TO\1740 seizure_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
D004986_D007035 NONE flurothyl_0\NN\1740 <e1>ether</e1>_1\NN\14840755 produced_2\VBD\1617192 hypothermia_3\NN\14034177 which_4\WDT\1740 was_5\VBD\836236 correlated_6\VBN\2657219 with_7\IN\1740 the_8\DT\1740 duration_9\NN\15113229 of_10\IN\1740 flurothyl_11\NN\1740 exposure_12\NN\5042871 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 the_16\DT\1740 relationship_17\NN\31921 of_18\IN\1740 <e2>hypothermia</e2>_19\NN\14034177 to_20\TO\1740 seizure_21\VB\1740 induction_22\NN\7450842 was_23\VBD\836236 unclear_24\JJ\1740 ._25\.\1740
1360900
D004976_D012640 CID <e1>ethacrynic_0\JJ\1740 acid-induced</e1>_1\JJ\1740 <e2>convulsions</e2>_2\NNS\14081375 and_3\CC\1740 brain_4\NN\5462674 neurotransmitters_5\NNS\14807410 in_6\IN\13603305 mice_7\NNS\2329401 ._8\.\1740
D004976_D012640 CID intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 <e1>ethacrynic_3\JJ\1740 acid</e1>_4\NN\14818238 (_5\-LRB-\1740 50_6\CD\13745420 %_7\NN\1740 <e2>convulsive</e2>_8\JJ\1740 dose_9\NN\3740161 ;_10\:\1740 50_11\CD\13745420 micrograms/mouse_12\NN\1740 )_13\-RRB-\1740 accelerated_14\VBD\226566 the_15\DT\1740 synthesis/turnover_16\NN\1740 of_17\IN\1740 5-hydroxytryptamine_18\NN\14807737 (_19\-LRB-\1740 5-ht_20\NN\1740 )_21\-RRB-\1740 but_22\CC\1740 suppressed_23\VBD\2510337 the_24\DT\1740 synthesis_25\NN\13446390 of_26\IN\1740 gamma-aminobutyric_27\JJ\1740 acid_28\NN\14818238 and_29\CC\1740 acetylcholine_30\NN\14807558 in_31\IN\13603305 mouse_32\NN\2329401 brain_33\NN\5462674 ._34\.\1740
D004976_D012640 CID in_0\IN\13603305 <e1>ethacrynic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 <e2>convulsions</e2>_3\NNS\14081375 ,_4\,\1740 these_5\DT\1740 neurotransmitter_6\NN\14807410 systems_7\NNS\3575240 may_8\MD\15209706 be_9\VB\836236 differentially_10\RB\1740 modulated_11\VBN\1724459 ,_12\,\1740 probably_13\RB\1740 through_14\IN\1740 activation_15\NN\13561719 of_16\IN\1740 glutaminergic_17\JJ\1740 neurons_18\NNS\5430628 in_19\IN\13603305 the_20\DT\1740 brain_21\NN\5462674 ._22\.\1740
D012701_D012640 NONE intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 ethacrynic_3\JJ\1740 acid_4\NN\14818238 (_5\-LRB-\1740 50_6\CD\13745420 %_7\NN\1740 <e2>convulsive</e2>_8\JJ\1740 dose_9\NN\3740161 ;_10\:\1740 50_11\CD\13745420 micrograms/mouse_12\NN\1740 )_13\-RRB-\1740 accelerated_14\VBD\226566 the_15\DT\1740 synthesis/turnover_16\NN\1740 of_17\IN\1740 <e1>5-hydroxytryptamine</e1>_18\NN\14807737 (_19\-LRB-\1740 5-ht_20\NN\1740 )_21\-RRB-\1740 but_22\CC\1740 suppressed_23\VBD\2510337 the_24\DT\1740 synthesis_25\NN\13446390 of_26\IN\1740 gamma-aminobutyric_27\JJ\1740 acid_28\NN\14818238 and_29\CC\1740 acetylcholine_30\NN\14807558 in_31\IN\13603305 mouse_32\NN\2329401 brain_33\NN\5462674 ._34\.\1740
D012701_D012640 NONE intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 ethacrynic_3\JJ\1740 acid_4\NN\14818238 (_5\-LRB-\1740 50_6\CD\13745420 %_7\NN\1740 <e2>convulsive</e2>_8\JJ\1740 dose_9\NN\3740161 ;_10\:\1740 50_11\CD\13745420 micrograms/mouse_12\NN\1740 )_13\-RRB-\1740 accelerated_14\VBD\226566 the_15\DT\1740 synthesis/turnover_16\NN\1740 of_17\IN\1740 5-hydroxytryptamine_18\NN\14807737 (_19\-LRB-\1740 <e1>5-ht</e1>_20\NN\1740 )_21\-RRB-\1740 but_22\CC\1740 suppressed_23\VBD\2510337 the_24\DT\1740 synthesis_25\NN\13446390 of_26\IN\1740 gamma-aminobutyric_27\JJ\1740 acid_28\NN\14818238 and_29\CC\1740 acetylcholine_30\NN\14807558 in_31\IN\13603305 mouse_32\NN\2329401 brain_33\NN\5462674 ._34\.\1740
D005680_D012640 NONE intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 ethacrynic_3\JJ\1740 acid_4\NN\14818238 (_5\-LRB-\1740 50_6\CD\13745420 %_7\NN\1740 <e2>convulsive</e2>_8\JJ\1740 dose_9\NN\3740161 ;_10\:\1740 50_11\CD\13745420 micrograms/mouse_12\NN\1740 )_13\-RRB-\1740 accelerated_14\VBD\226566 the_15\DT\1740 synthesis/turnover_16\NN\1740 of_17\IN\1740 5-hydroxytryptamine_18\NN\14807737 (_19\-LRB-\1740 5-ht_20\NN\1740 )_21\-RRB-\1740 but_22\CC\1740 suppressed_23\VBD\2510337 the_24\DT\1740 synthesis_25\NN\13446390 of_26\IN\1740 <e1>gamma-aminobutyric_27\JJ\1740 acid</e1>_28\NN\14818238 and_29\CC\1740 acetylcholine_30\NN\14807558 in_31\IN\13603305 mouse_32\NN\2329401 brain_33\NN\5462674 ._34\.\1740
D000109_D012640 NONE intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 ethacrynic_3\JJ\1740 acid_4\NN\14818238 (_5\-LRB-\1740 50_6\CD\13745420 %_7\NN\1740 <e2>convulsive</e2>_8\JJ\1740 dose_9\NN\3740161 ;_10\:\1740 50_11\CD\13745420 micrograms/mouse_12\NN\1740 )_13\-RRB-\1740 accelerated_14\VBD\226566 the_15\DT\1740 synthesis/turnover_16\NN\1740 of_17\IN\1740 5-hydroxytryptamine_18\NN\14807737 (_19\-LRB-\1740 5-ht_20\NN\1740 )_21\-RRB-\1740 but_22\CC\1740 suppressed_23\VBD\2510337 the_24\DT\1740 synthesis_25\NN\13446390 of_26\IN\1740 gamma-aminobutyric_27\JJ\1740 acid_28\NN\14818238 and_29\CC\1740 <e1>acetylcholine</e1>_30\NN\14807558 in_31\IN\13603305 mouse_32\NN\2329401 brain_33\NN\5462674 ._34\.\1740
11026989
D014331_D015878 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e2>pupil_3\NN\10059162 dilation</e2>_4\NN\7138085 with_5\IN\1740 <e1>tropicamide</e1>_6\NN\1740 on_7\IN\1740 vision_8\NN\5767733 and_9\CC\1740 driving_10\NN\571609 simulator_11\NN\3699975 performance_12\NN\6619065 ._13\.\1740
D014331_D015878 CID methods_0\NNS\5616786 :_1\:\1740 a_2\DT\13649268 series_3\NN\8456993 of_4\IN\1740 tests_5\NNS\5798043 on_6\IN\1740 various_7\JJ\1740 parameters_8\NNS\5858936 of_9\IN\1740 visual_10\JJ\1740 function_11\NN\13783581 and_12\CC\1740 driving_13\NN\571609 simulator_14\NN\3699975 performance_15\NN\6619065 were_16\VBD\836236 performed_17\VBN\2367363 on_18\IN\1740 12_19\CD\13745420 healthy_20\JJ\1740 drivers_21\NNS\10378412 ,_22\,\1740 before_23\IN\1740 and_24\CC\1740 after_25\IN\1740 <e2>pupil_26\NN\10059162 dilation</e2>_27\NN\7138085 using_28\VBG\1156834 guttae_29\NN\1740 <e1>tropicamide</e1>_30\NN\1740 1_31\CD\13741022 %_32\NN\1740 ._33\.\1740
24729111
D000638_D007037 CID <e1>amiodarone-induced</e1>_0\JJ\1740 <e2>myxoedema_1\NN\14121276 coma</e2>_2\NN\5678932 ._3\.\1740
D000638_D007037 CID the_0\DT\1740 only_1\JJ\1740 two_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 <e1>amiodarone-induced</e1>_5\JJ\1740 <e2>myxoedema_6\NN\14121276 coma</e2>_7\NN\5678932 in_8\IN\13603305 the_9\DT\1740 literature_10\NN\6362953 report_11\NN\6470073 patient_12\NN\9898892 death_13\NN\7296428 despite_14\IN\7501545 supportive_15\JJ\1740 therapy_16\NN\657604 and_17\CC\1740 thyroid_18\NN\5329735 hormone_19\NN\5404728 replacement_20\NN\196485 ._21\.\1740
D000638_D007037 CID this_0\DT\1740 case_1\NN\7283608 represents_2\VBZ\2664769 the_3\DT\1740 most_4\RBS\1740 thoroughly_5\RB\1740 investigated_6\VBN\644583 case_7\NN\7283608 of_8\IN\1740 <e1>amiodarone-induced</e1>_9\JJ\1740 <e2>myxoedema_10\NN\14121276 coma</e2>_11\NN\5678932 with_12\IN\1740 a_13\DT\13649268 history_14\NN\15120823 significant_15\JJ\1740 for_16\IN\1740 subclinical_17\JJ\1740 thyroid_18\NN\5329735 disease_19\NN\14061805 ._20\.\1740
D000638_D003128 CID <e1>amiodarone-induced</e1>_0\JJ\1740 <e2>myxoedema_1\NN\14121276 coma</e2>_2\NN\5678932 ._3\.\1740
D000638_D003128 CID the_0\DT\1740 only_1\JJ\1740 two_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 <e1>amiodarone-induced</e1>_5\JJ\1740 <e2>myxoedema_6\NN\14121276 coma</e2>_7\NN\5678932 in_8\IN\13603305 the_9\DT\1740 literature_10\NN\6362953 report_11\NN\6470073 patient_12\NN\9898892 death_13\NN\7296428 despite_14\IN\7501545 supportive_15\JJ\1740 therapy_16\NN\657604 and_17\CC\1740 thyroid_18\NN\5329735 hormone_19\NN\5404728 replacement_20\NN\196485 ._21\.\1740
D000638_D003128 CID this_0\DT\1740 case_1\NN\7283608 represents_2\VBZ\2664769 the_3\DT\1740 most_4\RBS\1740 thoroughly_5\RB\1740 investigated_6\VBN\644583 case_7\NN\7283608 of_8\IN\1740 <e1>amiodarone-induced</e1>_9\JJ\1740 <e2>myxoedema_10\NN\14121276 coma</e2>_11\NN\5678932 with_12\IN\1740 a_13\DT\13649268 history_14\NN\15120823 significant_15\JJ\1740 for_16\IN\1740 subclinical_17\JJ\1740 thyroid_18\NN\5329735 disease_19\NN\14061805 ._20\.\1740
D000638_D001919 CID a_0\DT\13649268 62-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 found_4\VBN\2426171 to_5\TO\1740 have_6\VB\2108377 <e2>bradycardia</e2>_7\NN\14110674 ,_8\,\1740 hypothermia_9\NN\14034177 and_10\CC\1740 respiratory_11\JJ\1740 failure_12\NN\66216 3_13\CD\13741022 weeks_14\NNS\15113229 after_15\IN\1740 initiation_16\NN\7450842 of_17\IN\1740 <e1>amiodarone</e1>_18\NN\2715941 therapy_19\NN\657604 for_20\IN\1740 atrial_21\JJ\1740 fibrillation_22\NN\14361664 ._23\.\1740
D000638_D007035 CID a_0\DT\13649268 62-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 found_4\VBN\2426171 to_5\TO\1740 have_6\VB\2108377 bradycardia_7\NN\14110674 ,_8\,\1740 <e2>hypothermia</e2>_9\NN\14034177 and_10\CC\1740 respiratory_11\JJ\1740 failure_12\NN\66216 3_13\CD\13741022 weeks_14\NNS\15113229 after_15\IN\1740 initiation_16\NN\7450842 of_17\IN\1740 <e1>amiodarone</e1>_18\NN\2715941 therapy_19\NN\657604 for_20\IN\1740 atrial_21\JJ\1740 fibrillation_22\NN\14361664 ._23\.\1740
D000638_D012131 CID a_0\DT\13649268 62-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 found_4\VBN\2426171 to_5\TO\1740 have_6\VB\2108377 bradycardia_7\NN\14110674 ,_8\,\1740 hypothermia_9\NN\14034177 and_10\CC\1740 <e2>respiratory_11\JJ\1740 failure</e2>_12\NN\66216 3_13\CD\13741022 weeks_14\NNS\15113229 after_15\IN\1740 initiation_16\NN\7450842 of_17\IN\1740 <e1>amiodarone</e1>_18\NN\2715941 therapy_19\NN\657604 for_20\IN\1740 atrial_21\JJ\1740 fibrillation_22\NN\14361664 ._23\.\1740
D000638_D001281 NONE a_0\DT\13649268 62-year-old_1\JJ\1740 man_2\NN\9605289 was_3\VBD\836236 found_4\VBN\2426171 to_5\TO\1740 have_6\VB\2108377 bradycardia_7\NN\14110674 ,_8\,\1740 hypothermia_9\NN\14034177 and_10\CC\1740 respiratory_11\JJ\1740 failure_12\NN\66216 3_13\CD\13741022 weeks_14\NNS\15113229 after_15\IN\1740 initiation_16\NN\7450842 of_17\IN\1740 <e1>amiodarone</e1>_18\NN\2715941 therapy_19\NN\657604 for_20\IN\1740 <e2>atrial_21\JJ\1740 fibrillation</e2>_22\NN\14361664 ._23\.\1740
D000638_D013959 NONE this_0\DT\1740 case_1\NN\7283608 represents_2\VBZ\2664769 the_3\DT\1740 most_4\RBS\1740 thoroughly_5\RB\1740 investigated_6\VBN\644583 case_7\NN\7283608 of_8\IN\1740 <e1>amiodarone-induced</e1>_9\JJ\1740 myxoedema_10\NN\14121276 coma_11\NN\5678932 with_12\IN\1740 a_13\DT\13649268 history_14\NN\15120823 significant_15\JJ\1740 for_16\IN\1740 subclinical_17\JJ\1740 <e2>thyroid_18\NN\5329735 disease</e2>_19\NN\14061805 ._20\.\1740
15282950
D010936_D009202 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>terminalia_3\NNP\1740 chebula</e1>_4\NN\1740 against_5\IN\1740 experimental_6\JJ\1740 <e2>myocardial_7\JJ\1740 injury</e2>_8\NN\14052046 induced_9\VBN\1627355 by_10\IN\1740 isoproterenol_11\NN\3740161 ._12\.\1740
D010936_D009202 NONE cardioprotective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>ethanolic_3\JJ\1740 extract_4\NN\14589223 of_5\IN\1740 terminalia_6\NNP\1740 chebula_7\NN\1740 fruits</e1>_8\NNS\11675842 (_9\-LRB-\1740 500_10\CD\13745420 mg/kg_11\NN\1740 body_12\NN\19128 wt_13\NN\1740 )_14\-RRB-\1740 was_15\VBD\836236 examined_16\VBN\789138 in_17\IN\13603305 isoproterenol_18\NN\3740161 (_19\-LRB-\1740 200_20\CD\1740 mg/kg_21\NN\1740 body_22\NN\19128 wt_23\NN\1740 )_24\-RRB-\1740 induced_25\VBD\1627355 <e2>myocardial_26\JJ\1740 damage</e2>_27\NN\7296428 in_28\IN\13603305 rats_29\NNS\2329401 ._30\.\1740
D007545_D009202 CID protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 terminalia_3\NNP\1740 chebula_4\NN\1740 against_5\IN\1740 experimental_6\JJ\1740 <e2>myocardial_7\JJ\1740 injury</e2>_8\NN\14052046 induced_9\VBN\1627355 by_10\IN\1740 <e1>isoproterenol</e1>_11\NN\3740161 ._12\.\1740
D007545_D009202 CID cardioprotective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 ethanolic_3\JJ\1740 extract_4\NN\14589223 of_5\IN\1740 terminalia_6\NNP\1740 chebula_7\NN\1740 fruits_8\NNS\11675842 (_9\-LRB-\1740 500_10\CD\13745420 mg/kg_11\NN\1740 body_12\NN\19128 wt_13\NN\1740 )_14\-RRB-\1740 was_15\VBD\836236 examined_16\VBN\789138 in_17\IN\13603305 <e1>isoproterenol</e1>_18\NN\3740161 (_19\-LRB-\1740 200_20\CD\1740 mg/kg_21\NN\1740 body_22\NN\19128 wt_23\NN\1740 )_24\-RRB-\1740 induced_25\VBD\1627355 <e2>myocardial_26\JJ\1740 damage</e2>_27\NN\7296428 in_28\IN\13603305 rats_29\NNS\2329401 ._30\.\1740
11105626
D015474_D065817 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 newborn_3\JJ\1740 infant_4\NN\9918248 with_5\IN\1740 multiple_6\JJ\1740 congenital_7\JJ\1740 anomalies_8\NNS\14501726 (_9\-LRB-\1740 <e2>anotia</e2>_10\NN\1740 and_11\CC\1740 taussig-bing_12\JJ\1740 malformation_13\NN\14213199 )_14\-RRB-\1740 due_15\JJ\1740 to_16\TO\1740 exposure_17\NN\5042871 to_18\TO\1740 <e1>isotretinoin</e1>_19\VB\1740 within_20\IN\1740 the_21\DT\1740 first_22\JJ\1740 trimester_23\NN\15113229 ._24\.\1740
D015474_D004310 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 newborn_3\JJ\1740 infant_4\NN\9918248 with_5\IN\1740 multiple_6\JJ\1740 congenital_7\JJ\1740 anomalies_8\NNS\14501726 (_9\-LRB-\1740 anotia_10\NN\1740 and_11\CC\1740 <e2>taussig-bing_12\JJ\1740 malformation</e2>_13\NN\14213199 )_14\-RRB-\1740 due_15\JJ\1740 to_16\TO\1740 exposure_17\NN\5042871 to_18\TO\1740 <e1>isotretinoin</e1>_19\VB\1740 within_20\IN\1740 the_21\DT\1740 first_22\JJ\1740 trimester_23\NN\15113229 ._24\.\1740
1420650
D002220_D020820 NONE <e2>asterixis</e2>_0\NN\1740 induced_1\VBN\1627355 by_2\IN\1740 <e1>carbamazepine</e1>_3\NN\1740 therapy_4\NN\657604 ._5\.\1740
D002220_D020820 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 we_3\PRP\1740 present_4\VBP\2137132 four_5\CD\13741022 patients_6\NNS\9898892 treated_7\VBN\2376958 with_8\IN\1740 a_9\DT\13649268 combination_10\NN\7951464 of_11\IN\1740 different_12\JJ\1740 psychotropic_13\JJ\1740 drugs_14\NNS\14778436 ,_15\,\1740 in_16\IN\13603305 whom_17\WP\1740 <e2>asterixis</e2>_18\NN\1740 was_19\VBD\836236 triggered_20\VBN\1641914 either_21\CC\1740 by_22\IN\1740 adding_23\VBG\156601 <e1>carbamazepine</e1>_24\NN\1740 (_25\-LRB-\1740 cbz_26\NN\1740 )_27\-RRB-\1740 to_28\TO\1740 a_29\DT\13649268 treatment_30\NN\654885 regimen_31\NN\5898568 ,_32\,\1740 or_33\CC\3541091 by_34\IN\1740 increasing_35\VBG\169651 its_36\PRP$\6125041 dosage_37\NN\13576355 ._38\.\1740
D002220_D020820 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 we_3\PRP\1740 present_4\VBP\2137132 four_5\CD\13741022 patients_6\NNS\9898892 treated_7\VBN\2376958 with_8\IN\1740 a_9\DT\13649268 combination_10\NN\7951464 of_11\IN\1740 different_12\JJ\1740 psychotropic_13\JJ\1740 drugs_14\NNS\14778436 ,_15\,\1740 in_16\IN\13603305 whom_17\WP\1740 <e2>asterixis</e2>_18\NN\1740 was_19\VBD\836236 triggered_20\VBN\1641914 either_21\CC\1740 by_22\IN\1740 adding_23\VBG\156601 carbamazepine_24\NN\1740 (_25\-LRB-\1740 <e1>cbz</e1>_26\NN\1740 )_27\-RRB-\1740 to_28\TO\1740 a_29\DT\13649268 treatment_30\NN\654885 regimen_31\NN\5898568 ,_32\,\1740 or_33\CC\3541091 by_34\IN\1740 increasing_35\VBG\169651 its_36\PRP$\6125041 dosage_37\NN\13576355 ._38\.\1740
D002220_D020820 NONE we_0\PRP\1740 consider_1\VBP\689344 <e2>asterixis</e2>_2\NN\1740 to_3\TO\1740 be_4\VB\836236 an_5\DT\6697703 easily_6\RB\1740 overlooked_7\VBN\2127853 sign_8\NN\6643763 of_9\IN\1740 neurotoxicity_10\NN\1740 ,_11\,\1740 which_12\WDT\1740 may_13\MD\15209706 occur_14\VB\2623529 even_15\RB\1740 at_16\IN\14622893 low_17\JJ\1740 or_18\CC\3541091 moderate_19\JJ\1740 dosage_20\NN\13576355 levels_21\NNS\4916342 ,_22\,\1740 if_23\IN\1740 certain_24\JJ\1740 drugs_25\NNS\14778436 as_26\IN\14622893 lithium_27\NN\14625458 or_28\CC\3541091 clozapine_29\NN\3713736 are_30\VBP\836236 used_31\VBN\1156834 in_32\IN\13603305 combination_33\NN\7951464 with_34\IN\1740 <e1>cbz</e1>_35\NN\1740 ._36\.\1740
D008094_D020820 CID we_0\PRP\1740 consider_1\VBP\689344 <e2>asterixis</e2>_2\NN\1740 to_3\TO\1740 be_4\VB\836236 an_5\DT\6697703 easily_6\RB\1740 overlooked_7\VBN\2127853 sign_8\NN\6643763 of_9\IN\1740 neurotoxicity_10\NN\1740 ,_11\,\1740 which_12\WDT\1740 may_13\MD\15209706 occur_14\VB\2623529 even_15\RB\1740 at_16\IN\14622893 low_17\JJ\1740 or_18\CC\3541091 moderate_19\JJ\1740 dosage_20\NN\13576355 levels_21\NNS\4916342 ,_22\,\1740 if_23\IN\1740 certain_24\JJ\1740 drugs_25\NNS\14778436 as_26\IN\14622893 <e1>lithium</e1>_27\NN\14625458 or_28\CC\3541091 clozapine_29\NN\3713736 are_30\VBP\836236 used_31\VBN\1156834 in_32\IN\13603305 combination_33\NN\7951464 with_34\IN\1740 cbz_35\NN\1740 ._36\.\1740
D008094_D020258 NONE we_0\PRP\1740 consider_1\VBP\689344 asterixis_2\NN\1740 to_3\TO\1740 be_4\VB\836236 an_5\DT\6697703 easily_6\RB\1740 overlooked_7\VBN\2127853 sign_8\NN\6643763 of_9\IN\1740 <e2>neurotoxicity</e2>_10\NN\1740 ,_11\,\1740 which_12\WDT\1740 may_13\MD\15209706 occur_14\VB\2623529 even_15\RB\1740 at_16\IN\14622893 low_17\JJ\1740 or_18\CC\3541091 moderate_19\JJ\1740 dosage_20\NN\13576355 levels_21\NNS\4916342 ,_22\,\1740 if_23\IN\1740 certain_24\JJ\1740 drugs_25\NNS\14778436 as_26\IN\14622893 <e1>lithium</e1>_27\NN\14625458 or_28\CC\3541091 clozapine_29\NN\3713736 are_30\VBP\836236 used_31\VBN\1156834 in_32\IN\13603305 combination_33\NN\7951464 with_34\IN\1740 cbz_35\NN\1740 ._36\.\1740
D003024_D020820 CID we_0\PRP\1740 consider_1\VBP\689344 <e2>asterixis</e2>_2\NN\1740 to_3\TO\1740 be_4\VB\836236 an_5\DT\6697703 easily_6\RB\1740 overlooked_7\VBN\2127853 sign_8\NN\6643763 of_9\IN\1740 neurotoxicity_10\NN\1740 ,_11\,\1740 which_12\WDT\1740 may_13\MD\15209706 occur_14\VB\2623529 even_15\RB\1740 at_16\IN\14622893 low_17\JJ\1740 or_18\CC\3541091 moderate_19\JJ\1740 dosage_20\NN\13576355 levels_21\NNS\4916342 ,_22\,\1740 if_23\IN\1740 certain_24\JJ\1740 drugs_25\NNS\14778436 as_26\IN\14622893 lithium_27\NN\14625458 or_28\CC\3541091 <e1>clozapine</e1>_29\NN\3713736 are_30\VBP\836236 used_31\VBN\1156834 in_32\IN\13603305 combination_33\NN\7951464 with_34\IN\1740 cbz_35\NN\1740 ._36\.\1740
D003024_D020258 NONE we_0\PRP\1740 consider_1\VBP\689344 asterixis_2\NN\1740 to_3\TO\1740 be_4\VB\836236 an_5\DT\6697703 easily_6\RB\1740 overlooked_7\VBN\2127853 sign_8\NN\6643763 of_9\IN\1740 <e2>neurotoxicity</e2>_10\NN\1740 ,_11\,\1740 which_12\WDT\1740 may_13\MD\15209706 occur_14\VB\2623529 even_15\RB\1740 at_16\IN\14622893 low_17\JJ\1740 or_18\CC\3541091 moderate_19\JJ\1740 dosage_20\NN\13576355 levels_21\NNS\4916342 ,_22\,\1740 if_23\IN\1740 certain_24\JJ\1740 drugs_25\NNS\14778436 as_26\IN\14622893 lithium_27\NN\14625458 or_28\CC\3541091 <e1>clozapine</e1>_29\NN\3713736 are_30\VBP\836236 used_31\VBN\1156834 in_32\IN\13603305 combination_33\NN\7951464 with_34\IN\1740 cbz_35\NN\1740 ._36\.\1740
D002220_D020258 NONE we_0\PRP\1740 consider_1\VBP\689344 asterixis_2\NN\1740 to_3\TO\1740 be_4\VB\836236 an_5\DT\6697703 easily_6\RB\1740 overlooked_7\VBN\2127853 sign_8\NN\6643763 of_9\IN\1740 <e2>neurotoxicity</e2>_10\NN\1740 ,_11\,\1740 which_12\WDT\1740 may_13\MD\15209706 occur_14\VB\2623529 even_15\RB\1740 at_16\IN\14622893 low_17\JJ\1740 or_18\CC\3541091 moderate_19\JJ\1740 dosage_20\NN\13576355 levels_21\NNS\4916342 ,_22\,\1740 if_23\IN\1740 certain_24\JJ\1740 drugs_25\NNS\14778436 as_26\IN\14622893 lithium_27\NN\14625458 or_28\CC\3541091 clozapine_29\NN\3713736 are_30\VBP\836236 used_31\VBN\1156834 in_32\IN\13603305 combination_33\NN\7951464 with_34\IN\1740 <e1>cbz</e1>_35\NN\1740 ._36\.\1740
3746148
D004176_D003324 NONE non-invasive_0\JJ\1740 detection_1\NN\5708432 of_2\IN\1740 <e2>coronary_3\JJ\1740 artery_4\NN\5417975 disease</e2>_5\NN\14061805 by_6\IN\1740 body_7\NN\19128 surface_8\NN\21939 electrocardiographic_9\JJ\1740 mapping_10\NN\13783581 after_11\IN\1740 <e1>dipyridamole</e1>_12\NN\1740 infusion_13\NN\14589223 ._14\.\1740
D004176_D003324 NONE electrocardiographic_0\JJ\1740 changes_1\NNS\7283608 after_2\IN\1740 <e1>dipyridamole</e1>_3\NN\1740 infusion_4\NN\14589223 (_5\-LRB-\1740 0.568_6\CD\1740 mg/kg/4_7\NN\1740 min_8\NN\15154774 )_9\-RRB-\1740 were_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 41_13\CD\1740 patients_14\NNS\9898892 with_15\IN\1740 <e2>coronary_16\JJ\1740 artery_17\NN\5417975 disease</e2>_18\NN\14061805 and_19\CC\1740 compared_20\VBN\644583 with_21\IN\1740 those_22\DT\1740 after_23\IN\1740 submaximal_24\JJ\1740 treadmill_25\NN\3302790 exercise_26\NN\621627 by_27\IN\1740 use_28\NN\407535 of_29\IN\1740 the_30\DT\1740 body_31\NN\19128 surface_32\NN\21939 mapping_33\NN\13783581 technique_34\NN\5660268 ._35\.\1740
D004176_D003324 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 <e1>dipyridamole</e1>_4\NN\1740 ecg_5\NNP\7000195 test_6\NN\5798043 is_7\VBZ\836236 as_8\RB\1740 useful_9\JJ\1740 as_10\IN\14622893 the_11\DT\1740 exercise_12\NN\621627 ecg_13\NNP\7000195 test_14\NN\5798043 for_15\IN\1740 the_16\DT\1740 assessment_17\NN\5732756 of_18\IN\1740 <e2>coronary_19\JJ\1740 artery_20\NN\5417975 disease</e2>_21\NN\14061805 ._22\.\1740
D004176_D007511 NONE after_0\IN\1740 <e1>dipyridamole</e1>_1\NN\1740 ,_2\,\1740 <e2>ischemic</e2>_3\JJ\1740 st-segment_4\JJ\1740 depression_5\NN\14373582 (_6\-LRB-\1740 0.05_7\CD\1740 mv_8\NN\13634784 or_9\CC\3541091 more_10\JJR\1740 )_11\-RRB-\1740 was_12\VBD\836236 observed_13\VBN\2163746 in_14\IN\13603305 84_15\CD\1740 %_16\NN\1740 of_17\IN\1740 the_18\DT\1740 non-mi_19\JJ\1740 group_20\NN\2137 ,_21\,\1740 29_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 ant-mi_26\NN\1740 group_27\NN\2137 ,_28\,\1740 63_29\CD\1740 %_30\NN\1740 of_31\IN\1740 the_32\DT\1740 inf-mi_33\NN\1740 group_34\NN\2137 and_35\CC\1740 61_36\CD\1740 %_37\NN\1740 of_38\IN\1740 the_39\DT\1740 total_40\JJ\1740 population_41\NN\7942152 ._42\.\1740
D004176_D003866 NONE after_0\IN\1740 <e1>dipyridamole</e1>_1\NN\1740 ,_2\,\1740 ischemic_3\JJ\1740 st-segment_4\JJ\1740 <e2>depression</e2>_5\NN\14373582 (_6\-LRB-\1740 0.05_7\CD\1740 mv_8\NN\13634784 or_9\CC\3541091 more_10\JJR\1740 )_11\-RRB-\1740 was_12\VBD\836236 observed_13\VBN\2163746 in_14\IN\13603305 84_15\CD\1740 %_16\NN\1740 of_17\IN\1740 the_18\DT\1740 non-mi_19\JJ\1740 group_20\NN\2137 ,_21\,\1740 29_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 ant-mi_26\NN\1740 group_27\NN\2137 ,_28\,\1740 63_29\CD\1740 %_30\NN\1740 of_31\IN\1740 the_32\DT\1740 inf-mi_33\NN\1740 group_34\NN\2137 and_35\CC\1740 61_36\CD\1740 %_37\NN\1740 of_38\IN\1740 the_39\DT\1740 total_40\JJ\1740 population_41\NN\7942152 ._42\.\1740
D004176_D009203 NONE after_0\IN\1740 <e1>dipyridamole</e1>_1\NN\1740 ,_2\,\1740 ischemic_3\JJ\1740 st-segment_4\JJ\1740 depression_5\NN\14373582 (_6\-LRB-\1740 0.05_7\CD\1740 mv_8\NN\13634784 or_9\CC\3541091 more_10\JJR\1740 )_11\-RRB-\1740 was_12\VBD\836236 observed_13\VBN\2163746 in_14\IN\13603305 84_15\CD\1740 %_16\NN\1740 of_17\IN\1740 the_18\DT\1740 <e2>non-mi</e2>_19\JJ\1740 group_20\NN\2137 ,_21\,\1740 29_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 ant-mi_26\NN\1740 group_27\NN\2137 ,_28\,\1740 63_29\CD\1740 %_30\NN\1740 of_31\IN\1740 the_32\DT\1740 inf-mi_33\NN\1740 group_34\NN\2137 and_35\CC\1740 61_36\CD\1740 %_37\NN\1740 of_38\IN\1740 the_39\DT\1740 total_40\JJ\1740 population_41\NN\7942152 ._42\.\1740
D004176_D056988 NONE after_0\IN\1740 <e1>dipyridamole</e1>_1\NN\1740 ,_2\,\1740 ischemic_3\JJ\1740 st-segment_4\JJ\1740 depression_5\NN\14373582 (_6\-LRB-\1740 0.05_7\CD\1740 mv_8\NN\13634784 or_9\CC\3541091 more_10\JJR\1740 )_11\-RRB-\1740 was_12\VBD\836236 observed_13\VBN\2163746 in_14\IN\13603305 84_15\CD\1740 %_16\NN\1740 of_17\IN\1740 the_18\DT\1740 non-mi_19\JJ\1740 group_20\NN\2137 ,_21\,\1740 29_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 <e2>ant-mi</e2>_26\NN\1740 group_27\NN\2137 ,_28\,\1740 63_29\CD\1740 %_30\NN\1740 of_31\IN\1740 the_32\DT\1740 inf-mi_33\NN\1740 group_34\NN\2137 and_35\CC\1740 61_36\CD\1740 %_37\NN\1740 of_38\IN\1740 the_39\DT\1740 total_40\JJ\1740 population_41\NN\7942152 ._42\.\1740
D004176_D056989 NONE after_0\IN\1740 <e1>dipyridamole</e1>_1\NN\1740 ,_2\,\1740 ischemic_3\JJ\1740 st-segment_4\JJ\1740 depression_5\NN\14373582 (_6\-LRB-\1740 0.05_7\CD\1740 mv_8\NN\13634784 or_9\CC\3541091 more_10\JJR\1740 )_11\-RRB-\1740 was_12\VBD\836236 observed_13\VBN\2163746 in_14\IN\13603305 84_15\CD\1740 %_16\NN\1740 of_17\IN\1740 the_18\DT\1740 non-mi_19\JJ\1740 group_20\NN\2137 ,_21\,\1740 29_22\CD\13745420 %_23\NN\1740 of_24\IN\1740 the_25\DT\1740 ant-mi_26\NN\1740 group_27\NN\2137 ,_28\,\1740 63_29\CD\1740 %_30\NN\1740 of_31\IN\1740 the_32\DT\1740 <e2>inf-mi</e2>_33\NN\1740 group_34\NN\2137 and_35\CC\1740 61_36\CD\1740 %_37\NN\1740 of_38\IN\1740 the_39\DT\1740 total_40\JJ\1740 population_41\NN\7942152 ._42\.\1740
D004176_D017202 CID the_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 <e1>dipyridamole-induced</e1>_5\JJ\1740 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 is_8\VBZ\836236 caused_9\VBN\1617192 by_10\IN\1740 the_11\DT\1740 inhomogenous_12\JJ\1740 distribution_13\NN\5726596 of_14\IN\1740 myocardial_15\JJ\1740 blood_16\NN\5397468 flow_17\NN\7311115 ._18\.\1740
24055495
D005690_D003072 CID long-term_0\JJ\1740 oral_1\JJ\1740 <e1>galactose</e1>_2\VBP\1740 treatment_3\NN\654885 prevents_4\VBZ\1740 <e2>cognitive_5\JJ\1740 deficits</e2>_6\NNS\5113133 in_7\IN\13603305 male_8\JJ\1740 wistar_9\NNP\1740 rats_10\NNS\2329401 treated_11\VBN\2376958 intracerebroventricularly_12\RB\1740 with_13\IN\1740 streptozotocin_14\NN\1740 ._15\.\1740
D005690_D003072 CID we_0\PRP\1740 have_1\VBP\2108377 investigated_2\VBN\644583 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 continuous_6\JJ\1740 daily_7\RB\1740 oral_8\JJ\1740 <e1>galactose</e1>_9\NN\15062778 (_10\-LRB-\1740 200_11\CD\1740 mg/kg/day_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 on_15\IN\1740 <e2>cognitive_16\JJ\1740 deficits</e2>_17\NNS\5113133 in_18\IN\13603305 streptozotocin-induced_19\JJ\1740 (_20\-LRB-\1740 stz-icv_21\NN\1740 )_22\-RRB-\1740 rat_23\NN\2329401 model_24\NN\5888929 of_25\IN\1740 sad_26\NN\1740 ,_27\,\1740 tested_28\VBN\670261 by_29\IN\1740 morris_30\NNP\1740 water_31\NNP\14618834 maze_32\NNP\4377057 and_33\CC\1740 passive_34\NNP\13802920 avoidance_35\NNP\203342 test_36\NN\5798043 ,_37\,\1740 respectively_38\RB\1740 ._39\.\1740
D005690_D003072 CID one_0\CD\13741022 month_1\NN\15113229 of_2\IN\1740 oral_3\JJ\1740 <e1>galactose</e1>_4\JJ\1740 treatment_5\NN\654885 initiated_6\VBN\1617192 immediately_7\RB\1740 after_8\IN\1740 the_9\DT\1740 stz-icv_10\NN\1740 administration_11\NN\1133281 ,_12\,\1740 successfully_13\RB\1740 prevented_14\VBD\1740 development_15\NN\248977 of_16\IN\1740 the_17\DT\1740 stz-icv-induced_18\VBN\1740 <e2>cognitive_19\JJ\1740 deficits</e2>_20\NNS\5113133 ._21\.\1740
D005690_D003072 CID oral_0\JJ\1740 <e1>galactose</e1>_1\JJ\1740 exposure_2\NN\5042871 might_3\MD\5029706 have_4\VB\2108377 beneficial_5\JJ\1740 effects_6\NNS\13245626 on_7\IN\1740 learning_8\NN\5701944 and_9\CC\1740 memory_10\NN\5926676 ability_11\NN\4723816 and_12\CC\1740 could_13\MD\1740 be_14\VB\836236 worth_15\JJ\1740 investigating_16\VBG\644583 for_17\IN\1740 improvement_18\NN\7359599 of_19\IN\1740 <e2>cognitive_20\JJ\1740 deficits</e2>_21\NNS\5113133 associated_22\VBN\628491 with_23\IN\1740 glucose_24\NN\14710501 hypometabolism_25\NN\1740 in_26\IN\13603305 ad_27\NN\7247071 ._28\.\1740
D013311_D003072 CID long-term_0\JJ\1740 oral_1\JJ\1740 galactose_2\VBP\1740 treatment_3\NN\654885 prevents_4\VBZ\1740 <e2>cognitive_5\JJ\1740 deficits</e2>_6\NNS\5113133 in_7\IN\13603305 male_8\JJ\1740 wistar_9\NNP\1740 rats_10\NNS\2329401 treated_11\VBN\2376958 intracerebroventricularly_12\RB\1740 with_13\IN\1740 <e1>streptozotocin</e1>_14\NN\1740 ._15\.\1740
D013311_D003072 CID we_0\PRP\1740 have_1\VBP\2108377 investigated_2\VBN\644583 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 continuous_6\JJ\1740 daily_7\RB\1740 oral_8\JJ\1740 galactose_9\NN\15062778 (_10\-LRB-\1740 200_11\CD\1740 mg/kg/day_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 on_15\IN\1740 <e2>cognitive_16\JJ\1740 deficits</e2>_17\NNS\5113133 in_18\IN\13603305 <e1>streptozotocin-induced</e1>_19\JJ\1740 (_20\-LRB-\1740 stz-icv_21\NN\1740 )_22\-RRB-\1740 rat_23\NN\2329401 model_24\NN\5888929 of_25\IN\1740 sad_26\NN\1740 ,_27\,\1740 tested_28\VBN\670261 by_29\IN\1740 morris_30\NNP\1740 water_31\NNP\14618834 maze_32\NNP\4377057 and_33\CC\1740 passive_34\NNP\13802920 avoidance_35\NNP\203342 test_36\NN\5798043 ,_37\,\1740 respectively_38\RB\1740 ._39\.\1740
D013311_D003072 CID we_0\PRP\1740 have_1\VBP\2108377 investigated_2\VBN\644583 the_3\DT\1740 effects_4\NNS\13245626 of_5\IN\1740 continuous_6\JJ\1740 daily_7\RB\1740 oral_8\JJ\1740 galactose_9\NN\15062778 (_10\-LRB-\1740 200_11\CD\1740 mg/kg/day_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 on_15\IN\1740 <e2>cognitive_16\JJ\1740 deficits</e2>_17\NNS\5113133 in_18\IN\13603305 streptozotocin-induced_19\JJ\1740 (_20\-LRB-\1740 <e1>stz-icv</e1>_21\NN\1740 )_22\-RRB-\1740 rat_23\NN\2329401 model_24\NN\5888929 of_25\IN\1740 sad_26\NN\1740 ,_27\,\1740 tested_28\VBN\670261 by_29\IN\1740 morris_30\NNP\1740 water_31\NNP\14618834 maze_32\NNP\4377057 and_33\CC\1740 passive_34\NNP\13802920 avoidance_35\NNP\203342 test_36\NN\5798043 ,_37\,\1740 respectively_38\RB\1740 ._39\.\1740
D013311_D003072 CID one_0\CD\13741022 month_1\NN\15113229 of_2\IN\1740 oral_3\JJ\1740 galactose_4\JJ\1740 treatment_5\NN\654885 initiated_6\VBN\1617192 immediately_7\RB\1740 after_8\IN\1740 the_9\DT\1740 <e1>stz-icv</e1>_10\NN\1740 administration_11\NN\1133281 ,_12\,\1740 successfully_13\RB\1740 prevented_14\VBD\1740 development_15\NN\248977 of_16\IN\1740 the_17\DT\1740 stz-icv-induced_18\VBN\1740 <e2>cognitive_19\JJ\1740 deficits</e2>_20\NNS\5113133 ._21\.\1740
D013311_D003072 CID one_0\CD\13741022 month_1\NN\15113229 of_2\IN\1740 oral_3\JJ\1740 galactose_4\JJ\1740 treatment_5\NN\654885 initiated_6\VBN\1617192 immediately_7\RB\1740 after_8\IN\1740 the_9\DT\1740 stz-icv_10\NN\1740 administration_11\NN\1133281 ,_12\,\1740 successfully_13\RB\1740 prevented_14\VBD\1740 development_15\NN\248977 of_16\IN\1740 the_17\DT\1740 <e1>stz-icv-induced</e1>_18\VBN\1740 <e2>cognitive_19\JJ\1740 deficits</e2>_20\NNS\5113133 ._21\.\1740
D005947_D003704 NONE basic_0\JJ\1740 and_1\CC\1740 clinical_2\JJ\1740 research_3\NN\633864 has_4\VBZ\2108377 demonstrated_5\VBN\2137132 that_6\IN\1740 <e2>dementia</e2>_7\NN\14395018 of_8\IN\1740 sporadic_9\JJ\1740 alzheimer_10\NN\1740 's_11\POS\1740 disease_12\NN\14061805 (_13\-LRB-\1740 sad_14\NN\1740 )_15\-RRB-\1740 type_16\NN\5839024 is_17\VBZ\836236 associated_18\VBN\628491 with_19\IN\1740 dysfunction_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 insulin-receptor_23\NN\1740 (_24\-LRB-\1740 ir_25\NN\14625458 )_26\-RRB-\1740 system_27\NN\3575240 followed_28\VBN\1835496 by_29\IN\1740 decreased_30\VBN\169651 <e1>glucose</e1>_31\NN\14710501 transport_32\NN\3575240 via_33\IN\1740 glucose_34\NN\14710501 transporter_35\NN\4490091 glut4_36\NN\1740 and_37\CC\1740 decreased_38\VBD\169651 glucose_39\NN\14710501 metabolism_40\NN\13526110 in_41\IN\13603305 brain_42\NN\5462674 cells_43\NNS\3080309 ._44\.\1740
D005947_D003704 NONE basic_0\JJ\1740 and_1\CC\1740 clinical_2\JJ\1740 research_3\NN\633864 has_4\VBZ\2108377 demonstrated_5\VBN\2137132 that_6\IN\1740 <e2>dementia</e2>_7\NN\14395018 of_8\IN\1740 sporadic_9\JJ\1740 alzheimer_10\NN\1740 's_11\POS\1740 disease_12\NN\14061805 (_13\-LRB-\1740 sad_14\NN\1740 )_15\-RRB-\1740 type_16\NN\5839024 is_17\VBZ\836236 associated_18\VBN\628491 with_19\IN\1740 dysfunction_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 insulin-receptor_23\NN\1740 (_24\-LRB-\1740 ir_25\NN\14625458 )_26\-RRB-\1740 system_27\NN\3575240 followed_28\VBN\1835496 by_29\IN\1740 decreased_30\VBN\169651 glucose_31\NN\14710501 transport_32\NN\3575240 via_33\IN\1740 <e1>glucose</e1>_34\NN\14710501 transporter_35\NN\4490091 glut4_36\NN\1740 and_37\CC\1740 decreased_38\VBD\169651 glucose_39\NN\14710501 metabolism_40\NN\13526110 in_41\IN\13603305 brain_42\NN\5462674 cells_43\NNS\3080309 ._44\.\1740
D005947_D003704 NONE basic_0\JJ\1740 and_1\CC\1740 clinical_2\JJ\1740 research_3\NN\633864 has_4\VBZ\2108377 demonstrated_5\VBN\2137132 that_6\IN\1740 <e2>dementia</e2>_7\NN\14395018 of_8\IN\1740 sporadic_9\JJ\1740 alzheimer_10\NN\1740 's_11\POS\1740 disease_12\NN\14061805 (_13\-LRB-\1740 sad_14\NN\1740 )_15\-RRB-\1740 type_16\NN\5839024 is_17\VBZ\836236 associated_18\VBN\628491 with_19\IN\1740 dysfunction_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 insulin-receptor_23\NN\1740 (_24\-LRB-\1740 ir_25\NN\14625458 )_26\-RRB-\1740 system_27\NN\3575240 followed_28\VBN\1835496 by_29\IN\1740 decreased_30\VBN\169651 glucose_31\NN\14710501 transport_32\NN\3575240 via_33\IN\1740 glucose_34\NN\14710501 transporter_35\NN\4490091 glut4_36\NN\1740 and_37\CC\1740 decreased_38\VBD\169651 <e1>glucose</e1>_39\NN\14710501 metabolism_40\NN\13526110 in_41\IN\13603305 brain_42\NN\5462674 cells_43\NNS\3080309 ._44\.\1740
D005947_D000544 CID basic_0\JJ\1740 and_1\CC\1740 clinical_2\JJ\1740 research_3\NN\633864 has_4\VBZ\2108377 demonstrated_5\VBN\2137132 that_6\IN\1740 dementia_7\NN\14395018 of_8\IN\1740 sporadic_9\JJ\1740 <e2>alzheimer_10\NN\1740 's_11\POS\1740 disease</e2>_12\NN\14061805 (_13\-LRB-\1740 sad_14\NN\1740 )_15\-RRB-\1740 type_16\NN\5839024 is_17\VBZ\836236 associated_18\VBN\628491 with_19\IN\1740 dysfunction_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 insulin-receptor_23\NN\1740 (_24\-LRB-\1740 ir_25\NN\14625458 )_26\-RRB-\1740 system_27\NN\3575240 followed_28\VBN\1835496 by_29\IN\1740 decreased_30\VBN\169651 <e1>glucose</e1>_31\NN\14710501 transport_32\NN\3575240 via_33\IN\1740 glucose_34\NN\14710501 transporter_35\NN\4490091 glut4_36\NN\1740 and_37\CC\1740 decreased_38\VBD\169651 glucose_39\NN\14710501 metabolism_40\NN\13526110 in_41\IN\13603305 brain_42\NN\5462674 cells_43\NNS\3080309 ._44\.\1740
D005947_D000544 CID basic_0\JJ\1740 and_1\CC\1740 clinical_2\JJ\1740 research_3\NN\633864 has_4\VBZ\2108377 demonstrated_5\VBN\2137132 that_6\IN\1740 dementia_7\NN\14395018 of_8\IN\1740 sporadic_9\JJ\1740 <e2>alzheimer_10\NN\1740 's_11\POS\1740 disease</e2>_12\NN\14061805 (_13\-LRB-\1740 sad_14\NN\1740 )_15\-RRB-\1740 type_16\NN\5839024 is_17\VBZ\836236 associated_18\VBN\628491 with_19\IN\1740 dysfunction_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 insulin-receptor_23\NN\1740 (_24\-LRB-\1740 ir_25\NN\14625458 )_26\-RRB-\1740 system_27\NN\3575240 followed_28\VBN\1835496 by_29\IN\1740 decreased_30\VBN\169651 glucose_31\NN\14710501 transport_32\NN\3575240 via_33\IN\1740 <e1>glucose</e1>_34\NN\14710501 transporter_35\NN\4490091 glut4_36\NN\1740 and_37\CC\1740 decreased_38\VBD\169651 glucose_39\NN\14710501 metabolism_40\NN\13526110 in_41\IN\13603305 brain_42\NN\5462674 cells_43\NNS\3080309 ._44\.\1740
D005947_D000544 CID basic_0\JJ\1740 and_1\CC\1740 clinical_2\JJ\1740 research_3\NN\633864 has_4\VBZ\2108377 demonstrated_5\VBN\2137132 that_6\IN\1740 dementia_7\NN\14395018 of_8\IN\1740 sporadic_9\JJ\1740 <e2>alzheimer_10\NN\1740 's_11\POS\1740 disease</e2>_12\NN\14061805 (_13\-LRB-\1740 sad_14\NN\1740 )_15\-RRB-\1740 type_16\NN\5839024 is_17\VBZ\836236 associated_18\VBN\628491 with_19\IN\1740 dysfunction_20\NN\14204950 of_21\IN\1740 the_22\DT\1740 insulin-receptor_23\NN\1740 (_24\-LRB-\1740 ir_25\NN\14625458 )_26\-RRB-\1740 system_27\NN\3575240 followed_28\VBN\1835496 by_29\IN\1740 decreased_30\VBN\169651 glucose_31\NN\14710501 transport_32\NN\3575240 via_33\IN\1740 glucose_34\NN\14710501 transporter_35\NN\4490091 glut4_36\NN\1740 and_37\CC\1740 decreased_38\VBD\169651 <e1>glucose</e1>_39\NN\14710501 metabolism_40\NN\13526110 in_41\IN\13603305 brain_42\NN\5462674 cells_43\NNS\3080309 ._44\.\1740
D005690_D008569 NONE exclusively_0\RB\1740 parenteral_1\JJ\1740 daily_2\JJ\1740 injections_3\NNS\320852 of_4\IN\1740 <e1>galactose</e1>_5\JJ\1740 induce_6\NN\1740 <e2>memory_7\NN\5926676 deterioration</e2>_8\NN\14560612 in_9\IN\13603305 rodents_10\NNS\1886756 and_11\CC\1740 are_12\VBP\836236 used_13\VBN\1156834 to_14\TO\1740 generate_15\VB\1617192 animal_16\JJ\1740 aging_17\NN\13526110 model_18\NN\5888929 ,_19\,\1740 but_20\CC\1740 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 oral_24\JJ\1740 galactose_25\VBP\1740 treatment_26\NN\654885 on_27\IN\1740 cognitive_28\JJ\1740 functions_29\NNS\13783581 have_30\VBP\2108377 never_31\RB\1740 been_32\VBN\836236 tested_33\VBN\670261 ._34\.\1740
D005690_D008569 NONE exclusively_0\RB\1740 parenteral_1\JJ\1740 daily_2\JJ\1740 injections_3\NNS\320852 of_4\IN\1740 galactose_5\JJ\1740 induce_6\NN\1740 <e2>memory_7\NN\5926676 deterioration</e2>_8\NN\14560612 in_9\IN\13603305 rodents_10\NNS\1886756 and_11\CC\1740 are_12\VBP\836236 used_13\VBN\1156834 to_14\TO\1740 generate_15\VB\1617192 animal_16\JJ\1740 aging_17\NN\13526110 model_18\NN\5888929 ,_19\,\1740 but_20\CC\1740 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 oral_24\JJ\1740 <e1>galactose</e1>_25\VBP\1740 treatment_26\NN\654885 on_27\IN\1740 cognitive_28\JJ\1740 functions_29\NNS\13783581 have_30\VBP\2108377 never_31\RB\1740 been_32\VBN\836236 tested_33\VBN\670261 ._34\.\1740
D005690_D018149 NONE oral_0\JJ\1740 <e1>galactose</e1>_1\JJ\1740 exposure_2\NN\5042871 might_3\MD\5029706 have_4\VB\2108377 beneficial_5\JJ\1740 effects_6\NNS\13245626 on_7\IN\1740 learning_8\NN\5701944 and_9\CC\1740 memory_10\NN\5926676 ability_11\NN\4723816 and_12\CC\1740 could_13\MD\1740 be_14\VB\836236 worth_15\JJ\1740 investigating_16\VBG\644583 for_17\IN\1740 improvement_18\NN\7359599 of_19\IN\1740 cognitive_20\JJ\1740 deficits_21\NNS\5113133 associated_22\VBN\628491 with_23\IN\1740 <e2>glucose_24\NN\14710501 hypometabolism</e2>_25\NN\1740 in_26\IN\13603305 ad_27\NN\7247071 ._28\.\1740
D005690_D000544 NONE oral_0\JJ\1740 <e1>galactose</e1>_1\JJ\1740 exposure_2\NN\5042871 might_3\MD\5029706 have_4\VB\2108377 beneficial_5\JJ\1740 effects_6\NNS\13245626 on_7\IN\1740 learning_8\NN\5701944 and_9\CC\1740 memory_10\NN\5926676 ability_11\NN\4723816 and_12\CC\1740 could_13\MD\1740 be_14\VB\836236 worth_15\JJ\1740 investigating_16\VBG\644583 for_17\IN\1740 improvement_18\NN\7359599 of_19\IN\1740 cognitive_20\JJ\1740 deficits_21\NNS\5113133 associated_22\VBN\628491 with_23\IN\1740 glucose_24\NN\14710501 hypometabolism_25\NN\1740 in_26\IN\13603305 <e2>ad</e2>_27\NN\7247071 ._28\.\1740
24220752
D003287_D007674 CID incidence_0\NN\13821570 of_1\IN\1740 <e1>contrast-induced</e1>_2\JJ\1740 <e2>nephropathy</e2>_3\NN\14573196 in_4\IN\13603305 hospitalised_5\VBN\2348568 patients_6\NNS\9898892 with_7\IN\1740 cancer_8\NN\14239425 ._9\.\1740
D003287_D007674 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 frequency_5\NN\15286249 of_6\IN\1740 and_7\CC\1740 possible_8\JJ\1740 factors_9\NNS\7326557 related_10\JJ\1740 to_11\TO\1740 <e1>contrast-induced</e1>_12\JJ\1740 <e2>nephropathy</e2>_13\NN\14573196 (_14\-LRB-\1740 cin_15\NN\1740 )_16\-RRB-\1740 in_17\IN\13603305 hospitalised_18\VBN\2348568 patients_19\NNS\9898892 with_20\IN\1740 cancer_21\NN\14239425 ._22\.\1740
D003287_D007674 CID <e1>contrast-induced</e1>_0\JJ\1740 <e2>nephropathy</e2>_1\NN\14573196 (_2\-LRB-\1740 cin_3\NN\1740 )_4\-RRB-\1740 is_5\VBZ\836236 a_6\DT\13649268 concern_7\NN\5682950 for_8\IN\1740 oncological_9\JJ\1740 patients_10\NNS\9898892 undergoing_11\VBG\109660 ct_12\NN\901316 ._13\.\1740 ._14\.\1740
D003287_D009369 NONE incidence_0\NN\13821570 of_1\IN\1740 <e1>contrast-induced</e1>_2\JJ\1740 nephropathy_3\NN\14573196 in_4\IN\13603305 hospitalised_5\VBN\2348568 patients_6\NNS\9898892 with_7\IN\1740 <e2>cancer</e2>_8\NN\14239425 ._9\.\1740
D003287_D009369 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 frequency_5\NN\15286249 of_6\IN\1740 and_7\CC\1740 possible_8\JJ\1740 factors_9\NNS\7326557 related_10\JJ\1740 to_11\TO\1740 <e1>contrast-induced</e1>_12\JJ\1740 nephropathy_13\NN\14573196 (_14\-LRB-\1740 cin_15\NN\1740 )_16\-RRB-\1740 in_17\IN\13603305 hospitalised_18\VBN\2348568 patients_19\NNS\9898892 with_20\IN\1740 <e2>cancer</e2>_21\NN\14239425 ._22\.\1740
-1_D006973 NONE cin_0\NN\1740 was_1\VBD\836236 significantly_2\RB\1740 more_3\JJR\1740 after_4\IN\1740 treatment_5\NN\654885 with_6\IN\1740 <e1>bevacizumab/irinotecan</e1>_7\NN\1740 (_8\-LRB-\1740 p_9\NN\14622893 =_10\JJ\1740 0.021_11\CD\1740 )_12\-RRB-\1740 and_13\CC\1740 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 <e2>hypertension</e2>_17\NN\14057371 (_18\-LRB-\1740 p_19\NN\14622893 =_20\JJ\1740 0.044_21\CD\1740 )_22\-RRB-\1740 ._23\.\1740
-1_D006973 NONE <e2>hypertension</e2>_0\NN\14057371 and_1\CC\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 <e1>bevacizumab/irinotecan</e1>_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 additional_8\JJ\1740 risk_9\NN\14541044 factors_10\NNS\7326557 for_11\IN\1740 cin_12\NN\1740 development_13\NN\248977 ._14\.\1740
-1_D006973 NONE <e2>hypertension</e2>_0\NN\14057371 and_1\CC\1740 treatment_2\NN\654885 with_3\IN\1740 <e1>bevacizumab</e1>_4\NN\1740 appear_5\VBP\2604760 to_6\TO\1740 be_7\VB\836236 additional_8\JJ\1740 risk_9\NN\14541044 factors_10\NNS\7326557 ._11\.\1740
C051890_D006973 NONE cin_0\NN\1740 was_1\VBD\836236 significantly_2\RB\1740 more_3\JJR\1740 after_4\IN\1740 treatment_5\NN\654885 with_6\IN\1740 <e1>bevacizumab/irinotecan</e1>_7\NN\1740 (_8\-LRB-\1740 p_9\NN\14622893 =_10\JJ\1740 0.021_11\CD\1740 )_12\-RRB-\1740 and_13\CC\1740 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 <e2>hypertension</e2>_17\NN\14057371 (_18\-LRB-\1740 p_19\NN\14622893 =_20\JJ\1740 0.044_21\CD\1740 )_22\-RRB-\1740 ._23\.\1740
C051890_D006973 NONE <e2>hypertension</e2>_0\NN\14057371 and_1\CC\1740 the_2\DT\1740 combination_3\NN\7951464 of_4\IN\1740 <e1>bevacizumab/irinotecan</e1>_5\NN\1740 may_6\MD\15209706 be_7\VB\836236 additional_8\JJ\1740 risk_9\NN\14541044 factors_10\NNS\7326557 for_11\IN\1740 cin_12\NN\1740 development_13\NN\248977 ._14\.\1740
17069550
D005702_D001321 NONE a_0\DT\13649268 prospective_1\JJ\1740 ,_2\,\1740 open-label_3\JJ\1740 trial_4\NN\786195 of_5\IN\1740 <e1>galantamine</e1>_6\NN\1740 in_7\IN\13603305 <e2>autistic_8\JJ\1740 disorder</e2>_9\NN\14034177 ._10\.\1740
D005702_D001321 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 assess_7\VB\670261 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>galantamine</e1>_11\NN\1740 ,_12\,\1740 an_13\DT\6697703 acetylcholinesterase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 nicotinic_17\JJ\1740 receptor_18\NN\5225602 modulator_19\NN\1740 ,_20\,\1740 in_21\IN\13603305 the_22\DT\1740 treatment_23\NN\654885 of_24\IN\1740 interfering_25\VBG\2451370 behaviors_26\NNS\407535 in_27\IN\13603305 children_28\NNS\9622049 with_29\IN\1740 <e2>autism</e2>_30\NN\14304060 ._31\.\1740
D005702_D001321 NONE methods_0\NNS\5616786 :_1\:\1740 thirteen_2\CD\13745420 medication-free_3\JJ\1740 children_4\NNS\9622049 with_5\IN\1740 <e2>autism</e2>_6\NN\14304060 (_7\-LRB-\1740 mean_8\NN\6021761 age_9\NN\4916342 ,_10\,\1740 8.8_11\CD\1740 +/-_12\CC\1740 3.5_13\CD\1740 years_14\NNS\15144371 )_15\-RRB-\1740 participated_16\VBN\2367363 in_17\IN\13603305 a_18\DT\13649268 12-week_19\JJ\1740 ,_20\,\1740 open-label_21\JJ\1740 trial_22\NN\786195 of_23\IN\1740 <e1>galantamine</e1>_24\NN\1740 ._25\.\1740
D005702_D001321 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 open_4\JJ\1740 trial_5\NN\786195 ,_6\,\1740 <e1>galantamine</e1>_7\NN\1740 was_8\VBD\836236 well-tolerated_9\JJ\1740 and_10\CC\1740 appeared_11\VBD\2604760 to_12\TO\1740 be_13\VB\836236 beneficial_14\JJ\1740 for_15\IN\1740 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 interfering_19\VBG\2451370 behaviors_20\NNS\407535 in_21\IN\13603305 children_22\NNS\9622049 with_23\IN\1740 <e2>autism</e2>_24\NN\14304060 ,_25\,\1740 particularly_26\RB\1740 aggression_27\NN\4657876 ,_28\,\1740 behavioral_29\JJ\1740 dyscontrol_30\NN\1740 ,_31\,\1740 and_32\CC\1740 inattention_33\NN\5701944 ._34\.\1740
D005702_D006261 CID overall_0\RB\1740 ,_1\,\1740 <e1>galantamine</e1>_2\NN\1740 was_3\VBD\836236 well-tolerated_4\JJ\1740 ,_5\,\1740 with_6\IN\1740 no_7\DT\7204911 significant_8\JJ\1740 adverse_9\JJ\1740 effects_10\NNS\13245626 apart_11\RB\1740 from_12\IN\1740 <e2>headaches</e2>_13\NNS\5829480 in_14\IN\13603305 one_15\CD\13741022 patient_16\NN\9898892 ._17\.\1740
D005702_D001523 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 open_4\JJ\1740 trial_5\NN\786195 ,_6\,\1740 <e1>galantamine</e1>_7\NN\1740 was_8\VBD\836236 well-tolerated_9\JJ\1740 and_10\CC\1740 appeared_11\VBD\2604760 to_12\TO\1740 be_13\VB\836236 beneficial_14\JJ\1740 for_15\IN\1740 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 interfering_19\VBG\2451370 behaviors_20\NNS\407535 in_21\IN\13603305 children_22\NNS\9622049 with_23\IN\1740 autism_24\NN\14304060 ,_25\,\1740 particularly_26\RB\1740 <e2>aggression</e2>_27\NN\4657876 ,_28\,\1740 behavioral_29\JJ\1740 dyscontrol_30\NN\1740 ,_31\,\1740 and_32\CC\1740 inattention_33\NN\5701944 ._34\.\1740
D005702_D002653 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 open_4\JJ\1740 trial_5\NN\786195 ,_6\,\1740 <e1>galantamine</e1>_7\NN\1740 was_8\VBD\836236 well-tolerated_9\JJ\1740 and_10\CC\1740 appeared_11\VBD\2604760 to_12\TO\1740 be_13\VB\836236 beneficial_14\JJ\1740 for_15\IN\1740 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 interfering_19\VBG\2451370 behaviors_20\NNS\407535 in_21\IN\13603305 children_22\NNS\9622049 with_23\IN\1740 autism_24\NN\14304060 ,_25\,\1740 particularly_26\RB\1740 aggression_27\NN\4657876 ,_28\,\1740 <e2>behavioral_29\JJ\1740 dyscontrol</e2>_30\NN\1740 ,_31\,\1740 and_32\CC\1740 inattention_33\NN\5701944 ._34\.\1740
D005702_D019958 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 open_4\JJ\1740 trial_5\NN\786195 ,_6\,\1740 <e1>galantamine</e1>_7\NN\1740 was_8\VBD\836236 well-tolerated_9\JJ\1740 and_10\CC\1740 appeared_11\VBD\2604760 to_12\TO\1740 be_13\VB\836236 beneficial_14\JJ\1740 for_15\IN\1740 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 interfering_19\VBG\2451370 behaviors_20\NNS\407535 in_21\IN\13603305 children_22\NNS\9622049 with_23\IN\1740 autism_24\NN\14304060 ,_25\,\1740 particularly_26\RB\1740 aggression_27\NN\4657876 ,_28\,\1740 behavioral_29\JJ\1740 dyscontrol_30\NN\1740 ,_31\,\1740 and_32\CC\1740 <e2>inattention</e2>_33\NN\5701944 ._34\.\1740
20595935
D014700_D006966 NONE <e1>verapamil</e1>_0\NN\2938514 stimulation_1\NN\242808 test_2\NN\5798043 in_3\IN\13603305 <e2>hyperprolactinemia</e2>_4\NN\1740 :_5\:\1740 loss_6\NN\13252973 of_7\IN\1740 prolactin_8\NN\5410315 response_9\NN\11410625 in_10\IN\13603305 anatomic_11\JJ\1740 or_12\CC\3541091 functional_13\JJ\1740 stalk_14\NN\14991712 effect_15\NN\34213 ._16\.\1740
D014700_D006966 NONE aim_0\NN\5980875 :_1\:\1740 <e1>verapamil</e1>_2\NN\2938514 stimulation_3\NN\242808 test_4\NN\5798043 was_5\VBD\836236 previously_6\RB\1740 investigated_7\VBN\644583 as_8\IN\14622893 a_9\DT\13649268 tool_10\NN\3563967 for_11\IN\1740 differential_12\JJ\1740 diagnosis_13\NN\152018 of_14\IN\1740 <e2>hyperprolactinemia</e2>_15\NN\1740 ,_16\,\1740 but_17\CC\1740 with_18\IN\1740 conflicting_19\VBG\2666882 results_20\NNS\34213 ._21\.\1740
D014700_D006966 NONE prolactin_0\NN\5410315 responses_1\NNS\11410625 to_2\TO\1740 <e1>verapamil</e1>_3\NNS\2938514 in_4\IN\13603305 65_5\CD\1740 female_6\JJ\1740 patients_7\NNS\9898892 (_8\-LRB-\1740 age_9\NN\4916342 :_10\:\1740 29.9_11\CD\1740 +/-_12\CC\1740 8.1_13\CD\1740 years_14\NNS\15144371 )_15\-RRB-\1740 with_16\IN\1740 <e2>hyperprolactinemia</e2>_17\NN\1740 were_18\VBD\836236 tested_19\VBN\670261 in_20\IN\13603305 a_21\DT\13649268 descriptive_22\JJ\1740 ,_23\,\1740 matched_24\VBN\2664769 case-control_25\NN\1740 study_26\NN\635850 ._27\.\1740
D014700_D006966 NONE results_0\NNS\34213 :_1\:\1740 <e1>verapamil</e1>_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 risperidone-induced_68\JJ\1740 <e2>hyperprolactinemia</e2>_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D014700_D006966 NONE roc_0\NNP\9492123 curve_1\NN\13863771 analysis_2\NN\633864 revealed_3\VBD\2137132 that_4\IN\1740 unresponsiveness_5\NN\4723816 to_6\TO\1740 <e1>verapamil</e1>_7\RB\1740 defined_8\VBN\2604760 as_9\IN\14622893 prl_10\NN\1740 <_11\XX\1740 7_12\CD\13741022 %_13\NN\1740 ,_14\,\1740 discriminated_15\VBD\650353 anatomical_16\JJ\1740 or_17\CC\3541091 functional_18\JJ\1740 stalk_19\NN\14991712 effect_20\NN\34213 (_21\-LRB-\1740 sensitivity_22\NN\5651971 :_23\:\1740 74_24\CD\1740 %_25\NN\1740 ,_26\,\1740 specificity_27\NN\4762633 :_28\:\1740 73_29\CD\1740 %_30\NN\1740 ,_31\,\1740 auc_32\NN\1740 :_33\:\1740 0.855+/-0.04_34\NN\1740 ,_35\,\1740 p_36\NN\14622893 <_37\XX\1740 0.001_38\CD\1740 ,_39\,\1740 ci_40\NN\13635336 :_41\:\1740 0.768_42\CD\1740 -_43\SYM\1740 0.942_44\CD\1740 )_45\-RRB-\1740 associated_46\VBN\628491 with_47\IN\1740 pseudoprolactinoma_48\NN\1740 or_49\CC\3541091 risperidone-induced_50\JJ\1740 <e2>hyperprolactinemia</e2>_51\NN\1740 ,_52\,\1740 respectively_53\RB\1740 ._54\.\1740
D014700_D006966 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>verapamil</e1>_2\NN\2938514 responsiveness_3\NN\5652926 is_4\VBZ\836236 not_5\RB\1740 a_6\DT\13649268 reliable_7\JJ\1740 finding_8\NN\43195 for_9\IN\1740 the_10\DT\1740 differential_11\JJ\1740 diagnosis_12\NN\152018 of_13\IN\1740 <e2>hyperprolactinemia</e2>_14\NN\1740 ._15\.\1740
D014700_D006966 NONE however_0\RB\1740 ,_1\,\1740 <e1>verapamil</e1>_2\VBZ\1740 unresponsiveness_3\JJ\1740 discriminates_4\NNS\1740 stalk_5\NN\14991712 effect_6\NN\34213 (_7\-LRB-\1740 i.e._8\FW\1740 ,_9\,\1740 anatomically_10\RB\1740 or_11\CC\3541091 functionally_12\RB\1740 inhibited_13\VBN\2510337 dopaminergic_14\JJ\1740 tonus_15\NN\14544335 )_16\-RRB-\1740 from_17\IN\1740 other_18\JJ\1740 causes_19\NNS\7323922 of_20\IN\1740 <e2>hyperprolactinemia</e2>_21\NN\1740 with_22\IN\1740 varying_23\VBG\2666239 degrees_24\NNS\4916342 of_25\IN\1740 responsiveness_26\NN\5652926 ._27\.\1740
D014700_D015175 NONE here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 aimed_3\VBD\1987160 to_4\TO\1740 re-investigate_5\VB\1740 the_6\DT\1740 diagnostic_7\JJ\1740 value_8\NN\5856066 of_9\IN\1740 <e1>verapamil</e1>_10\NN\2938514 in_11\IN\13603305 a_12\DT\13649268 population_13\NN\7942152 who_14\WP\8299493 were_15\VBD\836236 all_16\DT\1740 screened_17\VBN\2533282 for_18\IN\1740 <e2>macroprolactinemia</e2>_19\NN\1740 ._20\.\1740
D014700_D015175 NONE results_0\NNS\34213 :_1\:\1740 <e1>verapamil</e1>_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 <e2>macroprolactinoma</e2>_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 risperidone-induced_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D014700_D015175 NONE results_0\NNS\34213 :_1\:\1740 <e1>verapamil</e1>_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 <e2>microprolactinoma</e2>_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 risperidone-induced_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D014700_D015175 NONE results_0\NNS\34213 :_1\:\1740 <e1>verapamil</e1>_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 <e2>macroprolactinemia</e2>_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 risperidone-induced_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D014700_-1 NONE results_0\NNS\34213 :_1\:\1740 <e1>verapamil</e1>_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 <e2>pseudoprolactinoma</e2>_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 risperidone-induced_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D014700_-1 NONE roc_0\NNP\9492123 curve_1\NN\13863771 analysis_2\NN\633864 revealed_3\VBD\2137132 that_4\IN\1740 unresponsiveness_5\NN\4723816 to_6\TO\1740 <e1>verapamil</e1>_7\RB\1740 defined_8\VBN\2604760 as_9\IN\14622893 prl_10\NN\1740 <_11\XX\1740 7_12\CD\13741022 %_13\NN\1740 ,_14\,\1740 discriminated_15\VBD\650353 anatomical_16\JJ\1740 or_17\CC\3541091 functional_18\JJ\1740 stalk_19\NN\14991712 effect_20\NN\34213 (_21\-LRB-\1740 sensitivity_22\NN\5651971 :_23\:\1740 74_24\CD\1740 %_25\NN\1740 ,_26\,\1740 specificity_27\NN\4762633 :_28\:\1740 73_29\CD\1740 %_30\NN\1740 ,_31\,\1740 auc_32\NN\1740 :_33\:\1740 0.855+/-0.04_34\NN\1740 ,_35\,\1740 p_36\NN\14622893 <_37\XX\1740 0.001_38\CD\1740 ,_39\,\1740 ci_40\NN\13635336 :_41\:\1740 0.768_42\CD\1740 -_43\SYM\1740 0.942_44\CD\1740 )_45\-RRB-\1740 associated_46\VBN\628491 with_47\IN\1740 <e2>pseudoprolactinoma</e2>_48\NN\1740 or_49\CC\3541091 risperidone-induced_50\JJ\1740 hyperprolactinemia_51\NN\1740 ,_52\,\1740 respectively_53\RB\1740 ._54\.\1740
D018967_D015175 NONE results_0\NNS\34213 :_1\:\1740 verapamil_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 <e2>macroprolactinoma</e2>_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 <e1>risperidone-induced</e1>_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D018967_D015175 NONE results_0\NNS\34213 :_1\:\1740 verapamil_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 <e2>microprolactinoma</e2>_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 <e1>risperidone-induced</e1>_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D018967_D015175 NONE results_0\NNS\34213 :_1\:\1740 verapamil_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 <e2>macroprolactinemia</e2>_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 <e1>risperidone-induced</e1>_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D018967_-1 NONE results_0\NNS\34213 :_1\:\1740 verapamil_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 <e2>pseudoprolactinoma</e2>_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 <e1>risperidone-induced</e1>_68\JJ\1740 hyperprolactinemia_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D018967_-1 NONE roc_0\NNP\9492123 curve_1\NN\13863771 analysis_2\NN\633864 revealed_3\VBD\2137132 that_4\IN\1740 unresponsiveness_5\NN\4723816 to_6\TO\1740 verapamil_7\RB\1740 defined_8\VBN\2604760 as_9\IN\14622893 prl_10\NN\1740 <_11\XX\1740 7_12\CD\13741022 %_13\NN\1740 ,_14\,\1740 discriminated_15\VBD\650353 anatomical_16\JJ\1740 or_17\CC\3541091 functional_18\JJ\1740 stalk_19\NN\14991712 effect_20\NN\34213 (_21\-LRB-\1740 sensitivity_22\NN\5651971 :_23\:\1740 74_24\CD\1740 %_25\NN\1740 ,_26\,\1740 specificity_27\NN\4762633 :_28\:\1740 73_29\CD\1740 %_30\NN\1740 ,_31\,\1740 auc_32\NN\1740 :_33\:\1740 0.855+/-0.04_34\NN\1740 ,_35\,\1740 p_36\NN\14622893 <_37\XX\1740 0.001_38\CD\1740 ,_39\,\1740 ci_40\NN\13635336 :_41\:\1740 0.768_42\CD\1740 -_43\SYM\1740 0.942_44\CD\1740 )_45\-RRB-\1740 associated_46\VBN\628491 with_47\IN\1740 <e2>pseudoprolactinoma</e2>_48\NN\1740 or_49\CC\3541091 <e1>risperidone-induced</e1>_50\JJ\1740 hyperprolactinemia_51\NN\1740 ,_52\,\1740 respectively_53\RB\1740 ._54\.\1740
D018967_D006966 CID results_0\NNS\34213 :_1\:\1740 verapamil_2\NNS\2938514 significantly_3\RB\1740 increased_4\VBD\169651 prl_5\NN\1740 levels_6\NNS\4916342 in_7\IN\13603305 healthy_8\JJ\1740 controls_9\NNS\5190804 (_10\-LRB-\1740 n._11\NN\1740 8_12\CD\13741022 ,_13\,\1740 prl_14\NN\1740 :_15\:\1740 183_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 macroprolactinoma_20\NN\1740 (_21\-LRB-\1740 n._22\NN\1740 8_23\CD\13741022 ,_24\,\1740 prl_25\NN\1740 :_26\:\1740 7_27\CD\13741022 %_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 microprolactinoma_31\NN\1740 (_32\-LRB-\1740 n._33\NN\1740 19_34\CD\13745420 ,_35\,\1740 prl_36\NN\1740 :_37\:\1740 21_38\CD\13745420 %_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 macroprolactinemia_42\NN\1740 (_43\-LRB-\1740 n._44\NN\1740 23_45\CD\13745420 ,_46\,\1740 prl_47\NN\1740 :_48\:\1740 126_49\CD\1740 %_50\NN\1740 )_51\-RRB-\1740 ,_52\,\1740 but_53\CC\1740 not_54\RB\1740 in_55\IN\13603305 pseudoprolactinoma_56\NN\1740 (_57\-LRB-\1740 n._58\NN\1740 8_59\CD\13741022 ,_60\,\1740 prl_61\NN\1740 :_62\:\1740 0.8_63\CD\1740 %_64\NN\1740 )_65\-RRB-\1740 ,_66\,\1740 and_67\CC\1740 <e1>risperidone-induced</e1>_68\JJ\1740 <e2>hyperprolactinemia</e2>_69\NN\1740 (_70\-LRB-\1740 n._71\NN\1740 7_72\CD\13741022 ,_73\,\1740 prl_74\NN\1740 :_75\:\1740 3_76\CD\13741022 %_77\NN\1740 )_78\-RRB-\1740 ._79\.\1740
D018967_D006966 CID roc_0\NNP\9492123 curve_1\NN\13863771 analysis_2\NN\633864 revealed_3\VBD\2137132 that_4\IN\1740 unresponsiveness_5\NN\4723816 to_6\TO\1740 verapamil_7\RB\1740 defined_8\VBN\2604760 as_9\IN\14622893 prl_10\NN\1740 <_11\XX\1740 7_12\CD\13741022 %_13\NN\1740 ,_14\,\1740 discriminated_15\VBD\650353 anatomical_16\JJ\1740 or_17\CC\3541091 functional_18\JJ\1740 stalk_19\NN\14991712 effect_20\NN\34213 (_21\-LRB-\1740 sensitivity_22\NN\5651971 :_23\:\1740 74_24\CD\1740 %_25\NN\1740 ,_26\,\1740 specificity_27\NN\4762633 :_28\:\1740 73_29\CD\1740 %_30\NN\1740 ,_31\,\1740 auc_32\NN\1740 :_33\:\1740 0.855+/-0.04_34\NN\1740 ,_35\,\1740 p_36\NN\14622893 <_37\XX\1740 0.001_38\CD\1740 ,_39\,\1740 ci_40\NN\13635336 :_41\:\1740 0.768_42\CD\1740 -_43\SYM\1740 0.942_44\CD\1740 )_45\-RRB-\1740 associated_46\VBN\628491 with_47\IN\1740 pseudoprolactinoma_48\NN\1740 or_49\CC\3541091 <e1>risperidone-induced</e1>_50\JJ\1740 <e2>hyperprolactinemia</e2>_51\NN\1740 ,_52\,\1740 respectively_53\RB\1740 ._54\.\1740
3339945
D013806_D020258 NONE <e1>theophylline</e1>_0\NN\2905612 <e2>neurotoxicity</e2>_1\NN\1740 in_2\IN\13603305 pregnant_3\JJ\1740 rats_4\NNS\2329401 ._5\.\1740
D013806_D020258 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 investigation_4\NN\5797597 was_5\VBD\836236 to_6\TO\1740 determine_7\VB\1645601 whether_8\IN\1740 the_9\DT\1740 <e2>neurotoxicity</e2>_10\NN\1740 of_11\IN\1740 <e1>theophylline</e1>_12\NN\2905612 is_13\VBZ\836236 altered_14\VBN\126264 in_15\IN\13603305 advanced_16\JJ\1740 pregnancy_17\NN\14034177 ._18\.\1740
D013806_D020258 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 advanced_4\JJ\1740 pregnancy_5\NN\14034177 has_6\VBZ\2108377 a_7\DT\13649268 negligible_8\JJ\1740 effect_9\NN\34213 on_10\IN\1740 the_11\DT\1740 <e2>neurotoxic</e2>_12\JJ\1740 response_13\NN\11410625 to_14\TO\1740 <e1>theophylline</e1>_15\NN\2905612 in_16\IN\13603305 rats_17\NNS\2329401 ._18\.\1740
D000628_D012640 CID sprague-dawley_0\NN\1740 rats_1\NNS\2329401 that_2\WDT\1740 were_3\VBD\836236 20_4\CD\13745420 days_5\NNS\15140892 pregnant_6\JJ\1740 and_7\CC\1740 nonpregnant_8\JJ\1740 rats_9\NNS\2329401 of_10\IN\1740 the_11\DT\1740 same_12\JJ\1740 age_13\NN\4916342 and_14\CC\1740 strain_15\NN\7358060 received_16\VBD\2210855 infusions_17\NNS\14589223 of_18\IN\1740 <e1>aminophylline</e1>_19\NN\2905612 until_20\IN\1740 onset_21\NN\7325190 of_22\IN\1740 maximal_23\JJ\1740 <e2>seizures</e2>_24\NNS\14081375 which_25\WDT\1740 occurred_26\VBD\2623529 after_27\IN\1740 28_28\CD\13745420 and_29\CC\1740 30_30\CD\13745420 minutes_31\NNS\6502378 respectively_32\RB\1740 ._33\.\1740
6893265
D011441_D056486 CID <e1>propylthiouracil-induced</e1>_0\JJ\1740 <e2>hepatic_1\JJ\1740 damage</e2>_2\NN\7296428 ._3\.\1740
D011441_D056486 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e1>propylthiouracil-induced</e1>_3\JJ\1740 <e2>liver_4\NN\5298729 damage</e2>_5\NN\7296428 have_6\VBP\2108377 been_7\VBN\836236 observed_8\VBN\2163746 ._9\.\1740
16810074
D009569_D006973 CID mechanisms_0\NNS\13446390 of_1\IN\1740 <e2>hypertension</e2>_2\NN\14057371 induced_3\VBN\1627355 by_4\IN\1740 <e1>nitric_5\JJ\1740 oxide</e1>_6\NN\14818238 (_7\-LRB-\1740 no_8\NN\7204911 )_9\-RRB-\1740 deficiency_10\NN\14449126 :_11\:\1740 focus_12\VB\628491 on_13\IN\1740 venous_14\JJ\1740 function_15\NN\13783581 ._16\.\1740
D009569_D006973 CID mechanisms_0\NNS\13446390 of_1\IN\1740 <e2>hypertension</e2>_2\NN\14057371 induced_3\VBN\1627355 by_4\IN\1740 nitric_5\JJ\1740 oxide_6\NN\14818238 (_7\-LRB-\1740 <e1>no</e1>_8\NN\7204911 )_9\-RRB-\1740 deficiency_10\NN\14449126 :_11\:\1740 focus_12\VB\628491 on_13\IN\1740 venous_14\JJ\1740 function_15\NN\13783581 ._16\.\1740
D009569_D006973 CID loss_0\NN\13252973 of_1\IN\1740 endothelial_2\JJ\1740 cell-derived_3\JJ\1740 <e1>nitric_4\JJ\1740 oxide</e1>_5\NN\14818238 (_6\-LRB-\1740 no_7\NN\7204911 )_8\-RRB-\1740 in_9\IN\13603305 <e2>hypertension</e2>_10\NN\14057371 is_11\VBZ\836236 a_12\DT\13649268 hallmark_13\NN\4731497 of_14\IN\1740 arterial_15\JJ\1740 dysfunction_16\NN\14204950 ._17\.\1740
D009569_D006973 CID loss_0\NN\13252973 of_1\IN\1740 endothelial_2\JJ\1740 cell-derived_3\JJ\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 (_6\-LRB-\1740 <e1>no</e1>_7\NN\7204911 )_8\-RRB-\1740 in_9\IN\13603305 <e2>hypertension</e2>_10\NN\14057371 is_11\VBZ\836236 a_12\DT\13649268 hallmark_13\NN\4731497 of_14\IN\1740 arterial_15\JJ\1740 dysfunction_16\NN\14204950 ._17\.\1740
D009569_D006973 CID experimental_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 created_2\VBN\2367363 by_3\IN\1740 the_4\DT\1740 removal_5\NN\383606 of_6\IN\1740 <e1>no</e1>_7\NN\7204911 ,_8\,\1740 however_9\RB\1740 ,_10\,\1740 involves_11\VBZ\2676054 mechanisms_12\NNS\13446390 in_13\IN\13603305 addition_14\NN\3081021 to_15\TO\1740 decreased_16\VBN\169651 arterial_17\JJ\1740 vasodilator_18\NN\3198383 activity_19\NN\30358 ._20\.\1740
D009569_D006973 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 while_4\IN\15122231 <e1>no</e1>_5\DT\7204911 deficiency_6\NN\14449126 increases_7\VBZ\169651 oxidative_8\JJ\1740 stress_9\NN\7083732 and_10\CC\1740 sympathetic_11\JJ\1740 activity_12\NN\30358 in_13\IN\13603305 both_14\CC\1740 arterial_15\JJ\1740 and_16\CC\1740 venous_17\JJ\1740 vessels_18\NNS\5246511 ,_19\,\1740 the_20\DT\1740 impact_21\NN\7339329 on_22\IN\1740 veins_23\NNS\5417975 does_24\VBZ\1640855 not_25\RB\1740 make_26\VB\126264 a_27\DT\13649268 major_28\JJ\1740 contribution_29\NN\786195 to_30\TO\1740 this_31\DT\1740 form_32\NN\6286395 of_33\IN\1740 <e2>hypertension</e2>_34\NN\14057371 ._35\.\1740
D009569_D018754 NONE loss_0\NN\13252973 of_1\IN\1740 endothelial_2\JJ\1740 cell-derived_3\JJ\1740 <e1>nitric_4\JJ\1740 oxide</e1>_5\NN\14818238 (_6\-LRB-\1740 no_7\NN\7204911 )_8\-RRB-\1740 in_9\IN\13603305 hypertension_10\NN\14057371 is_11\VBZ\836236 a_12\DT\13649268 hallmark_13\NN\4731497 of_14\IN\1740 <e2>arterial_15\JJ\1740 dysfunction</e2>_16\NN\14204950 ._17\.\1740
D009569_D018754 NONE loss_0\NN\13252973 of_1\IN\1740 endothelial_2\JJ\1740 cell-derived_3\JJ\1740 nitric_4\JJ\1740 oxide_5\NN\14818238 (_6\-LRB-\1740 <e1>no</e1>_7\NN\7204911 )_8\-RRB-\1740 in_9\IN\13603305 hypertension_10\NN\14057371 is_11\VBZ\836236 a_12\DT\13649268 hallmark_13\NN\4731497 of_14\IN\1740 <e2>arterial_15\JJ\1740 dysfunction</e2>_16\NN\14204950 ._17\.\1740
D019335_D006973 NONE we_0\PRP\1740 hypothesized_1\VBD\719734 that_2\IN\1740 increased_3\VBD\169651 venous_4\JJ\1740 smooth_5\JJ\1740 muscle_6\NN\5289601 (_7\-LRB-\1740 venomotor_8\NN\1740 )_9\-RRB-\1740 tone_10\NN\7071483 plays_11\VBZ\1072262 a_12\DT\13649268 role_13\NN\719494 in_14\IN\13603305 <e1>nomega-nitro-l-arginine</e1>_15\NN\1740 (_16\-LRB-\1740 lnna_17\NN\1740 )_18\-RRB-\1740 <e2>hypertension</e2>_19\NN\14057371 through_20\IN\1740 these_21\DT\1740 mechanisms_22\NNS\13446390 ._23\.\1740
D019335_D006973 NONE we_0\PRP\1740 hypothesized_1\VBD\719734 that_2\IN\1740 increased_3\VBD\169651 venous_4\JJ\1740 smooth_5\JJ\1740 muscle_6\NN\5289601 (_7\-LRB-\1740 venomotor_8\NN\1740 )_9\-RRB-\1740 tone_10\NN\7071483 plays_11\VBZ\1072262 a_12\DT\13649268 role_13\NN\719494 in_14\IN\13603305 nomega-nitro-l-arginine_15\NN\1740 (_16\-LRB-\1740 <e1>lnna</e1>_17\NN\1740 )_18\-RRB-\1740 <e2>hypertension</e2>_19\NN\14057371 through_20\IN\1740 these_21\DT\1740 mechanisms_22\NNS\13446390 ._23\.\1740
D019335_D006973 NONE mean_0\VB\928630 circulatory_1\JJ\1740 filling_2\NN\14580897 pressure_3\NN\11419404 ,_4\,\1740 an_5\DT\6697703 in_6\FW\13603305 vivo_7\FW\1740 measure_8\NN\168237 of_9\IN\1740 venomotor_10\NN\1740 tone_11\NN\7071483 ,_12\,\1740 was_13\VBD\836236 not_14\RB\1740 elevated_15\JJ\1740 in_16\IN\13603305 <e1>lnna</e1>_17\NN\1740 <e2>hypertension</e2>_18\NN\14057371 at_19\IN\14622893 1_20\CD\13741022 or_21\CC\3541091 2_22\CD\13741022 weeks_23\NNS\15113229 after_24\IN\1740 lnna_25\NNP\1740 ._26\.\1740
D019335_D006973 NONE mean_0\VB\928630 circulatory_1\JJ\1740 filling_2\NN\14580897 pressure_3\NN\11419404 ,_4\,\1740 an_5\DT\6697703 in_6\FW\13603305 vivo_7\FW\1740 measure_8\NN\168237 of_9\IN\1740 venomotor_10\NN\1740 tone_11\NN\7071483 ,_12\,\1740 was_13\VBD\836236 not_14\RB\1740 elevated_15\JJ\1740 in_16\IN\13603305 lnna_17\NN\1740 <e2>hypertension</e2>_18\NN\14057371 at_19\IN\14622893 1_20\CD\13741022 or_21\CC\3541091 2_22\CD\13741022 weeks_23\NNS\15113229 after_24\IN\1740 <e1>lnna</e1>_25\NNP\1740 ._26\.\1740
D019335_D006973 NONE similarly_0\RB\1740 ,_1\,\1740 ganglionic_2\JJ\1740 blockade_3\NN\952963 with_4\IN\1740 hexamethonium_5\NN\1740 caused_6\VBD\1617192 a_7\DT\13649268 significantly_8\RB\1740 greater_9\JJR\1740 fall_10\NN\15236475 in_11\IN\13603305 <e1>lnna</e1>_12\NN\1740 <e2>hypertensive</e2>_13\NN\10405694 rats_14\NNS\2329401 (_15\-LRB-\1740 76_16\CD\1740 +/-_17\CC\1740 9_18\CD\13741022 mm_19\NN\13649268 hg_20\NN\14625458 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 control_24\JJ\1740 rats_25\NNS\2329401 (_26\-LRB-\1740 35_27\CD\1740 +/-_28\CC\1740 10_29\CD\13745420 mm_30\NN\13649268 hg_31\NNP\14625458 )_32\-RRB-\1740 ._33\.\1740
D018738_D006973 NONE similarly_0\RB\1740 ,_1\,\1740 ganglionic_2\JJ\1740 blockade_3\NN\952963 with_4\IN\1740 <e1>hexamethonium</e1>_5\NN\1740 caused_6\VBD\1617192 a_7\DT\13649268 significantly_8\RB\1740 greater_9\JJR\1740 fall_10\NN\15236475 in_11\IN\13603305 lnna_12\NN\1740 <e2>hypertensive</e2>_13\NN\10405694 rats_14\NNS\2329401 (_15\-LRB-\1740 76_16\CD\1740 +/-_17\CC\1740 9_18\CD\13741022 mm_19\NN\13649268 hg_20\NN\14625458 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 control_24\JJ\1740 rats_25\NNS\2329401 (_26\-LRB-\1740 35_27\CD\1740 +/-_28\CC\1740 10_29\CD\13745420 mm_30\NN\13649268 hg_31\NNP\14625458 )_32\-RRB-\1740 ._33\.\1740
1563460
D014859_D020758 CID <e2>thoracic_0\NN\1740 hematomyelia</e2>_1\NN\1740 secondary_2\JJ\1740 to_3\TO\1740 <e1>coumadin</e1>_4\NN\2718259 anticoagulant_5\NN\3740161 therapy_6\NN\657604 :_7\:\1740 a_8\DT\13649268 case_9\NN\7283608 report_10\NN\6470073 ._11\.\1740
6529939
D011433_D001146 CID <e2>alternating_0\VBG\123170 sinus_1\NN\5248181 rhythm</e2>_2\NN\15122011 and_3\CC\1740 intermittent_4\JJ\1740 sinoatrial_5\NN\1740 block_6\NN\21939 induced_7\VBN\1627355 by_8\IN\1740 <e1>propranolol</e1>_9\NN\1740 ._10\.\1740
D011433_D001146 CID <e2>alternating_0\VBG\123170 sinus_1\NN\5248181 rhythm</e2>_2\NN\15122011 and_3\CC\1740 intermittent_4\JJ\1740 sinoatrial_5\NN\1740 (_6\-LRB-\1740 s-a_7\NN\1740 )_8\-RRB-\1740 block_9\NN\21939 was_10\VBD\836236 observed_11\VBN\2163746 in_12\IN\13603305 a_13\DT\13649268 57-year-old_14\JJ\1740 woman_15\NN\9605289 ,_16\,\1740 under_17\IN\1740 treatment_18\NN\654885 for_19\IN\1740 angina_20\NN\14171682 with_21\IN\1740 80_22\CD\13745420 mg_23\NN\13717155 <e1>propranolol</e1>_24\NN\1740 daily_25\RB\1740 ._26\.\1740
D011433_D012848 CID alternating_0\VBG\123170 sinus_1\NN\5248181 rhythm_2\NN\15122011 and_3\CC\1740 intermittent_4\JJ\1740 <e2>sinoatrial_5\NN\1740 block</e2>_6\NN\21939 induced_7\VBN\1627355 by_8\IN\1740 <e1>propranolol</e1>_9\NN\1740 ._10\.\1740
D011433_D012848 CID alternating_0\VBG\123170 sinus_1\NN\5248181 rhythm_2\NN\15122011 and_3\CC\1740 intermittent_4\JJ\1740 <e2>sinoatrial_5\NN\1740 (_6\-LRB-\1740 s-a_7\NN\1740 )_8\-RRB-\1740 block</e2>_9\NN\21939 was_10\VBD\836236 observed_11\VBN\2163746 in_12\IN\13603305 a_13\DT\13649268 57-year-old_14\JJ\1740 woman_15\NN\9605289 ,_16\,\1740 under_17\IN\1740 treatment_18\NN\654885 for_19\IN\1740 angina_20\NN\14171682 with_21\IN\1740 80_22\CD\13745420 mg_23\NN\13717155 <e1>propranolol</e1>_24\NN\1740 daily_25\RB\1740 ._26\.\1740
D011433_D012848 CID the_0\DT\1740 abnormal_1\JJ\1740 rhythm_2\NN\15122011 disappeared_3\VBD\2609764 with_4\IN\1740 the_5\DT\1740 withdrawal_6\NN\7206096 of_7\IN\1740 <e1>propranolol</e1>_8\NN\1740 and_9\CC\1740 when_10\WRB\1740 the_11\DT\1740 drug_12\NN\14778436 was_13\VBD\836236 restarted_14\VBN\1857717 a_15\DT\13649268 2/1_16\CD\1740 <e2>s-a_17\JJ\1740 block</e2>_18\NN\21939 was_19\VBD\836236 seen_20\VBN\2106506 ._21\.\1740
D011433_D000787 NONE alternating_0\VBG\123170 sinus_1\NN\5248181 rhythm_2\NN\15122011 and_3\CC\1740 intermittent_4\JJ\1740 sinoatrial_5\NN\1740 (_6\-LRB-\1740 s-a_7\NN\1740 )_8\-RRB-\1740 block_9\NN\21939 was_10\VBD\836236 observed_11\VBN\2163746 in_12\IN\13603305 a_13\DT\13649268 57-year-old_14\JJ\1740 woman_15\NN\9605289 ,_16\,\1740 under_17\IN\1740 treatment_18\NN\654885 for_19\IN\1740 <e2>angina</e2>_20\NN\14171682 with_21\IN\1740 80_22\CD\13745420 mg_23\NN\13717155 <e1>propranolol</e1>_24\NN\1740 daily_25\RB\1740 ._26\.\1740
D011433_D019955 NONE this_0\DT\1740 was_1\VBD\836236 accepted_2\VBN\670261 as_3\IN\14622893 evidence_4\NN\5816287 for_5\IN\1740 <e1>propranolol</e1>_6\NN\1740 being_7\VBG\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 this_11\DT\1740 <e2>conduction_12\NN\11419404 disorder</e2>_13\NN\14034177 ._14\.\1740
24812279
D018943_D066126 NONE p53_0\NN\1740 inhibition_1\NN\1068773 exacerbates_2\VBZ\126264 late-stage_3\NN\1740 <e1>anthracycline</e1>_4\NN\1740 <e2>cardiotoxicity</e2>_5\NN\1740 ._6\.\1740
D004317_D009369 NONE aims_0\NNS\5980875 :_1\:\1740 <e1>doxorubicin</e1>_2\NN\2716866 (_3\-LRB-\1740 dox_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 an_7\DT\6697703 effective_8\JJ\1740 <e2>anti-cancer</e2>_9\NN\1740 therapeutic_10\JJ\1740 ,_11\,\1740 but_12\CC\1740 is_13\VBZ\836236 associated_14\VBN\628491 with_15\IN\1740 both_16\CC\1740 acute_17\JJ\1740 and_18\CC\1740 late-stage_19\NN\1740 cardiotoxicity_20\NN\1740 ._21\.\1740
D004317_D009369 NONE aims_0\NNS\5980875 :_1\:\1740 doxorubicin_2\NN\2716866 (_3\-LRB-\1740 <e1>dox</e1>_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 an_7\DT\6697703 effective_8\JJ\1740 <e2>anti-cancer</e2>_9\NN\1740 therapeutic_10\JJ\1740 ,_11\,\1740 but_12\CC\1740 is_13\VBZ\836236 associated_14\VBN\628491 with_15\IN\1740 both_16\CC\1740 acute_17\JJ\1740 and_18\CC\1740 late-stage_19\NN\1740 cardiotoxicity_20\NN\1740 ._21\.\1740
D004317_D066126 NONE aims_0\NNS\5980875 :_1\:\1740 <e1>doxorubicin</e1>_2\NN\2716866 (_3\-LRB-\1740 dox_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 an_7\DT\6697703 effective_8\JJ\1740 anti-cancer_9\NN\1740 therapeutic_10\JJ\1740 ,_11\,\1740 but_12\CC\1740 is_13\VBZ\836236 associated_14\VBN\628491 with_15\IN\1740 both_16\CC\1740 acute_17\JJ\1740 and_18\CC\1740 late-stage_19\NN\1740 <e2>cardiotoxicity</e2>_20\NN\1740 ._21\.\1740
D004317_D066126 NONE aims_0\NNS\5980875 :_1\:\1740 doxorubicin_2\NN\2716866 (_3\-LRB-\1740 <e1>dox</e1>_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 an_7\DT\6697703 effective_8\JJ\1740 anti-cancer_9\NN\1740 therapeutic_10\JJ\1740 ,_11\,\1740 but_12\CC\1740 is_13\VBZ\836236 associated_14\VBN\628491 with_15\IN\1740 both_16\CC\1740 acute_17\JJ\1740 and_18\CC\1740 late-stage_19\NN\1740 <e2>cardiotoxicity</e2>_20\NN\1740 ._21\.\1740
D004317_D066126 NONE here_0\RB\1740 ,_1\,\1740 the_2\DT\1740 impact_3\NN\7339329 of_4\IN\1740 p53_5\NN\1740 inhibition_6\NN\1068773 on_7\IN\1740 acute_8\JJ\1740 vs._9\CC\1740 late-stage_10\NN\1740 <e1>dox</e1>_11\NN\1740 <e2>cardiotoxicity</e2>_12\NN\1740 was_13\VBD\836236 examined_14\VBN\789138 in_15\IN\13603305 a_16\DT\13649268 juvenile_17\NN\7846 model_18\NN\5888929 ._19\.\1740
D004317_D006333 CID children_0\NNS\9622049 are_1\VBP\836236 particularly_2\RB\1740 sensitive_3\JJ\1740 to_4\TO\1740 <e1>dox-induced</e1>_5\JJ\1740 <e2>heart_6\NN\5919034 failure</e2>_7\NN\66216 ._8\.\1740
3538855
D000617_D007674 CID studies_0\NNS\635850 of_1\IN\1740 risk_2\NN\14541044 factors_3\NNS\7326557 for_4\IN\1740 <e1>aminoglycoside</e1>_5\JJ\1740 <e2>nephrotoxicity</e2>_6\NN\1740 ._7\.\1740
D000617_D007674 CID the_0\DT\1740 epidemiology_1\NN\6043075 of_2\IN\1740 <e1>aminoglycoside-induced</e1>_3\JJ\1740 <e2>nephrotoxicity</e2>_4\NN\1740 is_5\VBZ\836236 not_6\RB\1740 fully_7\RB\1740 understood_8\VBN\588888 ._9\.\1740
D000617_D007674 CID experimental_0\JJ\1740 studies_1\NNS\635850 in_2\IN\13603305 healthy_3\JJ\1740 human_4\JJ\1740 volunteers_5\NNS\10582746 indicate_6\VBP\952524 <e1>aminoglycosides</e1>_7\NNS\1740 cause_8\VBP\1617192 proximal_9\JJ\1740 tubular_10\JJ\1740 damage_11\NN\7296428 in_12\IN\13603305 most_13\JJS\1740 patients_14\NNS\9898892 ,_15\,\1740 but_16\CC\1740 rarely_17\RB\1740 ,_18\,\1740 if_19\IN\1740 ever_20\RB\1740 ,_21\,\1740 cause_22\VB\1617192 <e2>glomerular_23\JJ\1740 or_24\CC\3541091 tubular_25\JJ\1740 dysfunction</e2>_26\NN\14204950 ._27\.\1740
D000617_D007674 CID further_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 these_3\DT\1740 data_4\NNS\7951464 suggests_5\VBZ\1010118 that_6\IN\1740 the_7\DT\1740 duration_8\NN\15113229 of_9\IN\1740 therapy_10\NN\657604 ,_11\,\1740 plasma_12\NN\5398023 <e1>aminoglycoside</e1>_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 liver_16\NN\5298729 disease_17\NN\14061805 ,_18\,\1740 advanced_19\JJ\1740 age_20\NN\4916342 ,_21\,\1740 high_22\JJ\1740 initial_23\JJ\1740 estimated_24\VBN\637259 creatinine_25\NN\1740 clearance_26\NN\5089947 and_27\CC\1740 ,_28\,\1740 possibly_29\RB\1740 ,_30\,\1740 female_31\JJ\1740 gender_32\NN\6309383 all_33\DT\1740 increase_34\VBP\169651 the_35\DT\1740 risk_36\NN\14541044 for_37\IN\1740 <e2>nephrotoxicity</e2>_38\NN\1740 ._39\.\1740
D000617_D007674 CID these_0\DT\1740 models_1\NNS\5888929 may_2\MD\15209706 also_3\RB\1740 be_4\VB\836236 useful_5\JJ\1740 in_6\IN\13603305 developing_7\VBG\1753788 insights_8\NNS\5710020 into_9\IN\1740 the_10\DT\1740 pathophysiology_11\NN\1740 of_12\IN\1740 <e1>aminoglycoside-induced</e1>_13\JJ\1740 <e2>nephrotoxicity</e2>_14\NN\1740 ._15\.\1740
D000617_D058186 NONE clinical_0\JJ\1740 trials_1\NNS\786195 of_2\IN\1740 <e1>aminoglycosides</e1>_3\NNS\1740 in_4\IN\13603305 seriously_5\RB\1740 ill_6\JJ\1740 patients_7\NNS\9898892 indicate_8\VBP\952524 that_9\IN\1740 the_10\DT\1740 relative_11\JJ\1740 risk_12\NN\14541044 for_13\IN\1740 developing_14\VBG\1753788 <e2>acute_15\JJ\1740 renal_16\JJ\1740 failure</e2>_17\NN\66216 during_18\IN\1740 therapy_19\NN\657604 ranges_20\VBZ\2604760 from_21\IN\1740 8_22\CD\13741022 to_23\TO\1740 10_24\CD\13745420 and_25\CC\1740 that_26\IN\1740 the_27\DT\1740 attributable_28\JJ\1740 risk_29\NN\14541044 is_30\VBZ\836236 70_31\CD\13745420 %_32\NN\1740 to_33\TO\1740 80_34\CD\13745420 %_35\NN\1740 ._36\.\1740
D000617_D008107 NONE further_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 these_3\DT\1740 data_4\NNS\7951464 suggests_5\VBZ\1010118 that_6\IN\1740 the_7\DT\1740 duration_8\NN\15113229 of_9\IN\1740 therapy_10\NN\657604 ,_11\,\1740 plasma_12\NN\5398023 <e1>aminoglycoside</e1>_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 <e2>liver_16\NN\5298729 disease</e2>_17\NN\14061805 ,_18\,\1740 advanced_19\JJ\1740 age_20\NN\4916342 ,_21\,\1740 high_22\JJ\1740 initial_23\JJ\1740 estimated_24\VBN\637259 creatinine_25\NN\1740 clearance_26\NN\5089947 and_27\CC\1740 ,_28\,\1740 possibly_29\RB\1740 ,_30\,\1740 female_31\JJ\1740 gender_32\NN\6309383 all_33\DT\1740 increase_34\VBP\169651 the_35\DT\1740 risk_36\NN\14541044 for_37\IN\1740 nephrotoxicity_38\NN\1740 ._39\.\1740
D003404_D008107 NONE further_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 these_3\DT\1740 data_4\NNS\7951464 suggests_5\VBZ\1010118 that_6\IN\1740 the_7\DT\1740 duration_8\NN\15113229 of_9\IN\1740 therapy_10\NN\657604 ,_11\,\1740 plasma_12\NN\5398023 aminoglycoside_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 <e2>liver_16\NN\5298729 disease</e2>_17\NN\14061805 ,_18\,\1740 advanced_19\JJ\1740 age_20\NN\4916342 ,_21\,\1740 high_22\JJ\1740 initial_23\JJ\1740 estimated_24\VBN\637259 <e1>creatinine</e1>_25\NN\1740 clearance_26\NN\5089947 and_27\CC\1740 ,_28\,\1740 possibly_29\RB\1740 ,_30\,\1740 female_31\JJ\1740 gender_32\NN\6309383 all_33\DT\1740 increase_34\VBP\169651 the_35\DT\1740 risk_36\NN\14541044 for_37\IN\1740 nephrotoxicity_38\NN\1740 ._39\.\1740
D003404_D007674 NONE further_0\JJ\1740 analysis_1\NN\633864 of_2\IN\1740 these_3\DT\1740 data_4\NNS\7951464 suggests_5\VBZ\1010118 that_6\IN\1740 the_7\DT\1740 duration_8\NN\15113229 of_9\IN\1740 therapy_10\NN\657604 ,_11\,\1740 plasma_12\NN\5398023 aminoglycoside_13\NN\1740 levels_14\NNS\4916342 ,_15\,\1740 liver_16\NN\5298729 disease_17\NN\14061805 ,_18\,\1740 advanced_19\JJ\1740 age_20\NN\4916342 ,_21\,\1740 high_22\JJ\1740 initial_23\JJ\1740 estimated_24\VBN\637259 <e1>creatinine</e1>_25\NN\1740 clearance_26\NN\5089947 and_27\CC\1740 ,_28\,\1740 possibly_29\RB\1740 ,_30\,\1740 female_31\JJ\1740 gender_32\NN\6309383 all_33\DT\1740 increase_34\VBP\169651 the_35\DT\1740 risk_36\NN\14541044 for_37\IN\1740 <e2>nephrotoxicity</e2>_38\NN\1740 ._39\.\1740
15817013
D014859_D001281 NONE people_0\NNS\31264 aged_1\VBD\252019 over_2\IN\5867413 75_3\CD\1740 in_4\IN\13603305 <e2>atrial_5\JJ\1740 fibrillation</e2>_6\NN\14361664 on_7\IN\1740 <e1>warfarin</e1>_8\NN\2718259 :_9\:\1740 the_10\DT\1740 rate_11\NN\13815152 of_12\IN\1740 major_13\JJ\1740 hemorrhage_14\NN\14285662 and_15\CC\1740 stroke_16\VB\1206218 in_17\IN\13603305 more_18\JJR\1740 than_19\IN\1740 500_20\CD\13745420 patient-years_21\NNS\1740 of_22\IN\1740 follow-up_23\NN\4599396 ._24\.\1740
D014859_D001281 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 major_7\JJ\1740 hemorrhage_8\NN\14285662 and_9\CC\1740 stroke_10\VB\1206218 in_11\IN\13603305 people_12\NNS\31264 aged_13\JJ\1740 76_14\CD\1740 and_15\CC\1740 older_16\JJR\1740 with_17\IN\1740 <e2>atrial_18\JJ\1740 fibrillation</e2>_19\NN\14361664 on_20\IN\1740 adjusted-dose_21\JJ\1740 <e1>warfarin</e1>_22\NN\2718259 who_23\WP\8299493 had_24\VBD\2108377 been_25\VBN\836236 recently_26\RB\1740 been_27\VBN\836236 admitted_28\VBN\822367 to_29\IN\1740 hospital_30\NN\3739518 ._31\.\1740
D014859_D001281 NONE participants_0\NNS\9816771 :_1\:\1740 two_2\CD\13741022 hundred_3\CD\13745420 thirty-five_4\JJ\1740 patients_5\NNS\9898892 aged_6\JJ\1740 76_7\CD\1740 and_8\CC\1740 older_9\JJR\1740 admitted_10\VBN\822367 to_11\TO\1740 a_12\DT\13649268 major_13\JJ\1740 healthcare_14\NN\654885 network_15\NN\8435388 between_16\IN\1740 july_17\NNP\15209706 1_18\CD\13741022 ,_19\,\1740 2001_20\CD\1740 ,_21\,\1740 and_22\CC\1740 june_23\NNP\15209706 30_24\CD\13745420 ,_25\,\1740 2002_26\CD\1740 ,_27\,\1740 with_28\IN\1740 <e2>atrial_29\JJ\1740 fibrillation</e2>_30\NN\14361664 on_31\IN\1740 <e1>warfarin</e1>_32\NN\2718259 were_33\VBD\836236 enrolled_34\VBN\2471690 ._35\.\1740
D014859_D006470 CID people_0\NNS\31264 aged_1\VBD\252019 over_2\IN\5867413 75_3\CD\1740 in_4\IN\13603305 atrial_5\JJ\1740 fibrillation_6\NN\14361664 on_7\IN\1740 <e1>warfarin</e1>_8\NN\2718259 :_9\:\1740 the_10\DT\1740 rate_11\NN\13815152 of_12\IN\1740 major_13\JJ\1740 <e2>hemorrhage</e2>_14\NN\14285662 and_15\CC\1740 stroke_16\VB\1206218 in_17\IN\13603305 more_18\JJR\1740 than_19\IN\1740 500_20\CD\13745420 patient-years_21\NNS\1740 of_22\IN\1740 follow-up_23\NN\4599396 ._24\.\1740
D014859_D006470 CID objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 major_7\JJ\1740 <e2>hemorrhage</e2>_8\NN\14285662 and_9\CC\1740 stroke_10\VB\1206218 in_11\IN\13603305 people_12\NNS\31264 aged_13\JJ\1740 76_14\CD\1740 and_15\CC\1740 older_16\JJR\1740 with_17\IN\1740 atrial_18\JJ\1740 fibrillation_19\NN\14361664 on_20\IN\1740 adjusted-dose_21\JJ\1740 <e1>warfarin</e1>_22\NN\2718259 who_23\WP\8299493 had_24\VBD\2108377 been_25\VBN\836236 recently_26\RB\1740 been_27\VBN\836236 admitted_28\VBN\822367 to_29\IN\1740 hospital_30\NN\3739518 ._31\.\1740
D014859_D006470 CID measurements_0\NNS\407535 :_1\:\1740 information_2\NN\6598915 regarding_3\VBG\689344 major_4\JJ\1740 <e2>bleeding</e2>_5\JJ\1740 episodes_6\NNS\7283608 ,_7\,\1740 strokes_8\NNS\556313 ,_9\,\1740 and_10\CC\1740 <e1>warfarin</e1>_11\NN\2718259 use_12\NN\407535 was_13\VBD\836236 obtained_14\VBN\2210855 from_15\IN\1740 patients_16\NNS\9898892 ,_17\,\1740 relatives_18\NNS\7846 ,_19\,\1740 primary_20\JJ\1740 physicians_21\NNS\10305802 ,_22\,\1740 and_23\CC\1740 medical_24\JJ\1740 records_25\NNS\6643408 ._26\.\1740
D014859_D006470 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 major_5\JJ\1740 <e2>hemorrhage</e2>_6\NN\14285662 was_7\VBD\836236 high_8\JJ\1740 in_9\IN\13603305 this_10\DT\1740 old_11\JJ\1740 ,_12\,\1740 frail_13\NN\13608788 group_14\NN\2137 ,_15\,\1740 but_16\CC\1740 excluding_17\VBG\471711 fatalities_18\NNS\7355491 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 no_22\DT\7204911 long-term_23\JJ\1740 sequelae_24\NN\14501726 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 stroke_28\NN\556313 rate_29\NN\13815152 on_30\IN\1740 <e1>warfarin</e1>_31\NN\2718259 was_32\VBD\836236 low_33\JJ\1740 ,_34\,\1740 demonstrating_35\VBG\2137132 how_36\WRB\1740 effective_37\JJ\1740 warfarin_38\NN\2718259 treatment_39\NN\654885 is_40\VBZ\836236 ._41\.\1740
D014859_D006470 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 major_5\JJ\1740 <e2>hemorrhage</e2>_6\NN\14285662 was_7\VBD\836236 high_8\JJ\1740 in_9\IN\13603305 this_10\DT\1740 old_11\JJ\1740 ,_12\,\1740 frail_13\NN\13608788 group_14\NN\2137 ,_15\,\1740 but_16\CC\1740 excluding_17\VBG\471711 fatalities_18\NNS\7355491 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 no_22\DT\7204911 long-term_23\JJ\1740 sequelae_24\NN\14501726 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 stroke_28\NN\556313 rate_29\NN\13815152 on_30\IN\1740 warfarin_31\NN\2718259 was_32\VBD\836236 low_33\JJ\1740 ,_34\,\1740 demonstrating_35\VBG\2137132 how_36\WRB\1740 effective_37\JJ\1740 <e1>warfarin</e1>_38\NN\2718259 treatment_39\NN\654885 is_40\VBZ\836236 ._41\.\1740
D014859_D020521 NONE people_0\NNS\31264 aged_1\VBD\252019 over_2\IN\5867413 75_3\CD\1740 in_4\IN\13603305 atrial_5\JJ\1740 fibrillation_6\NN\14361664 on_7\IN\1740 <e1>warfarin</e1>_8\NN\2718259 :_9\:\1740 the_10\DT\1740 rate_11\NN\13815152 of_12\IN\1740 major_13\JJ\1740 hemorrhage_14\NN\14285662 and_15\CC\1740 <e2>stroke</e2>_16\VB\1206218 in_17\IN\13603305 more_18\JJR\1740 than_19\IN\1740 500_20\CD\13745420 patient-years_21\NNS\1740 of_22\IN\1740 follow-up_23\NN\4599396 ._24\.\1740
D014859_D020521 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 major_7\JJ\1740 hemorrhage_8\NN\14285662 and_9\CC\1740 <e2>stroke</e2>_10\VB\1206218 in_11\IN\13603305 people_12\NNS\31264 aged_13\JJ\1740 76_14\CD\1740 and_15\CC\1740 older_16\JJR\1740 with_17\IN\1740 atrial_18\JJ\1740 fibrillation_19\NN\14361664 on_20\IN\1740 adjusted-dose_21\JJ\1740 <e1>warfarin</e1>_22\NN\2718259 who_23\WP\8299493 had_24\VBD\2108377 been_25\VBN\836236 recently_26\RB\1740 been_27\VBN\836236 admitted_28\VBN\822367 to_29\IN\1740 hospital_30\NN\3739518 ._31\.\1740
D014859_D020521 NONE measurements_0\NNS\407535 :_1\:\1740 information_2\NN\6598915 regarding_3\VBG\689344 major_4\JJ\1740 bleeding_5\JJ\1740 episodes_6\NNS\7283608 ,_7\,\1740 <e2>strokes</e2>_8\NNS\556313 ,_9\,\1740 and_10\CC\1740 <e1>warfarin</e1>_11\NN\2718259 use_12\NN\407535 was_13\VBD\836236 obtained_14\VBN\2210855 from_15\IN\1740 patients_16\NNS\9898892 ,_17\,\1740 relatives_18\NNS\7846 ,_19\,\1740 primary_20\JJ\1740 physicians_21\NNS\10305802 ,_22\,\1740 and_23\CC\1740 medical_24\JJ\1740 records_25\NNS\6643408 ._26\.\1740
D014859_D020521 NONE the_0\DT\1740 annual_1\JJ\1740 <e2>stroke</e2>_2\NN\556313 rate_3\NN\13815152 after_4\IN\1740 initiation_5\NN\7450842 of_6\IN\1740 <e1>warfarin</e1>_7\NN\2718259 was_8\VBD\836236 2.6_9\CD\1740 %_10\NN\1740 ._11\.\1740
D014859_D020521 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 major_5\JJ\1740 hemorrhage_6\NN\14285662 was_7\VBD\836236 high_8\JJ\1740 in_9\IN\13603305 this_10\DT\1740 old_11\JJ\1740 ,_12\,\1740 frail_13\NN\13608788 group_14\NN\2137 ,_15\,\1740 but_16\CC\1740 excluding_17\VBG\471711 fatalities_18\NNS\7355491 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 no_22\DT\7204911 long-term_23\JJ\1740 sequelae_24\NN\14501726 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 <e2>stroke</e2>_28\NN\556313 rate_29\NN\13815152 on_30\IN\1740 <e1>warfarin</e1>_31\NN\2718259 was_32\VBD\836236 low_33\JJ\1740 ,_34\,\1740 demonstrating_35\VBG\2137132 how_36\WRB\1740 effective_37\JJ\1740 warfarin_38\NN\2718259 treatment_39\NN\654885 is_40\VBZ\836236 ._41\.\1740
D014859_D020521 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 rate_3\NN\13815152 of_4\IN\1740 major_5\JJ\1740 hemorrhage_6\NN\14285662 was_7\VBD\836236 high_8\JJ\1740 in_9\IN\13603305 this_10\DT\1740 old_11\JJ\1740 ,_12\,\1740 frail_13\NN\13608788 group_14\NN\2137 ,_15\,\1740 but_16\CC\1740 excluding_17\VBG\471711 fatalities_18\NNS\7355491 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 no_22\DT\7204911 long-term_23\JJ\1740 sequelae_24\NN\14501726 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 <e2>stroke</e2>_28\NN\556313 rate_29\NN\13815152 on_30\IN\1740 warfarin_31\NN\2718259 was_32\VBD\836236 low_33\JJ\1740 ,_34\,\1740 demonstrating_35\VBG\2137132 how_36\WRB\1740 effective_37\JJ\1740 <e1>warfarin</e1>_38\NN\2718259 treatment_39\NN\654885 is_40\VBZ\836236 ._41\.\1740
19178808
D015742_D006470 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 compare_9\VB\644583 surgical_10\JJ\1740 conditions_11\NNS\14512817 ,_12\,\1740 including_13\VBG\690614 the_14\DT\1740 amount_15\NN\13329641 of_16\IN\1740 intraoperative_17\JJ\1740 <e2>bleeding</e2>_18\NN\14285662 as_19\RB\1740 well_20\RB\1740 as_21\IN\14622893 intraoperative_22\JJ\1740 blood_23\NN\5397468 pressure_24\NN\11419404 ,_25\,\1740 during_26\IN\1740 functional_27\JJ\1740 endoscopic_28\JJ\1740 sinus_29\NN\5248181 surgery_30\NN\6045562 (_31\-LRB-\1740 fess_32\NN\3853734 )_33\-RRB-\1740 using_34\VBG\1156834 flexible_35\JJ\1740 reinforced_36\VBN\220869 laryngeal_37\NN\1740 mask_38\NN\3122748 airway_39\NN\3253398 (_40\-LRB-\1740 frlma_41\NN\1740 )_42\-RRB-\1740 versus_43\CC\1740 endotracheal_44\NN\1740 tube_45\NN\3089014 (_46\-LRB-\1740 ett_47\NN\1740 )_48\-RRB-\1740 in_49\IN\13603305 maintaining_50\VBG\2202928 controlled_51\VBN\2422663 hypotension_52\NN\14057371 anesthesia_53\NN\14034177 induced_54\VBN\1627355 by_55\IN\1740 <e1>propofol-remifentanil</e1>_56\JJ\1740 total_57\JJ\1740 i.v._58\NN\1740 anesthesia_59\NN\14034177 (_60\-LRB-\1740 tiva_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
D015742_D007022 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 compare_9\VB\644583 surgical_10\JJ\1740 conditions_11\NNS\14512817 ,_12\,\1740 including_13\VBG\690614 the_14\DT\1740 amount_15\NN\13329641 of_16\IN\1740 intraoperative_17\JJ\1740 bleeding_18\NN\14285662 as_19\RB\1740 well_20\RB\1740 as_21\IN\14622893 intraoperative_22\JJ\1740 blood_23\NN\5397468 pressure_24\NN\11419404 ,_25\,\1740 during_26\IN\1740 functional_27\JJ\1740 endoscopic_28\JJ\1740 sinus_29\NN\5248181 surgery_30\NN\6045562 (_31\-LRB-\1740 fess_32\NN\3853734 )_33\-RRB-\1740 using_34\VBG\1156834 flexible_35\JJ\1740 reinforced_36\VBN\220869 laryngeal_37\NN\1740 mask_38\NN\3122748 airway_39\NN\3253398 (_40\-LRB-\1740 frlma_41\NN\1740 )_42\-RRB-\1740 versus_43\CC\1740 endotracheal_44\NN\1740 tube_45\NN\3089014 (_46\-LRB-\1740 ett_47\NN\1740 )_48\-RRB-\1740 in_49\IN\13603305 maintaining_50\VBG\2202928 controlled_51\VBN\2422663 <e2>hypotension</e2>_52\NN\14057371 anesthesia_53\NN\14034177 induced_54\VBN\1627355 by_55\IN\1740 <e1>propofol-remifentanil</e1>_56\JJ\1740 total_57\JJ\1740 i.v._58\NN\1740 anesthesia_59\NN\14034177 (_60\-LRB-\1740 tiva_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
D015742_D007022 CID methods_0\NNS\5616786 :_1\:\1740 sixty_2\CD\13745420 normotensive_3\NN\1740 american_4\NNP\9620078 society_5\NNP\7950920 of_6\IN\1740 anesthesiologists_7\NNP\10632576 i-ii_8\CD\1740 adult_9\JJ\1740 patients_10\NNS\9898892 undergoing_11\VBG\109660 fess_12\NN\3853734 under_13\IN\1740 controlled_14\VBN\2422663 <e2>hypotension</e2>_15\NN\14057371 anesthesia_16\NN\14034177 caused_17\VBN\1617192 by_18\IN\1740 <e1>propofol-remifentanil-tiva</e1>_19\NN\1740 were_20\VBD\836236 randomly_21\RB\1740 assigned_22\VBN\2475922 into_23\IN\1740 two_24\CD\13741022 groups_25\NNS\2137 :_26\:\1740 group_27\NN\2137 i_28\CD\14622893 ,_29\,\1740 frlma_30\NN\1740 ;_31\:\1740 group_32\NN\2137 ii_33\CD\13741022 ,_34\,\1740 ett_35\NN\1740 ._36\.\1740
C071741_D006470 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 compare_9\VB\644583 surgical_10\JJ\1740 conditions_11\NNS\14512817 ,_12\,\1740 including_13\VBG\690614 the_14\DT\1740 amount_15\NN\13329641 of_16\IN\1740 intraoperative_17\JJ\1740 <e2>bleeding</e2>_18\NN\14285662 as_19\RB\1740 well_20\RB\1740 as_21\IN\14622893 intraoperative_22\JJ\1740 blood_23\NN\5397468 pressure_24\NN\11419404 ,_25\,\1740 during_26\IN\1740 functional_27\JJ\1740 endoscopic_28\JJ\1740 sinus_29\NN\5248181 surgery_30\NN\6045562 (_31\-LRB-\1740 fess_32\NN\3853734 )_33\-RRB-\1740 using_34\VBG\1156834 flexible_35\JJ\1740 reinforced_36\VBN\220869 laryngeal_37\NN\1740 mask_38\NN\3122748 airway_39\NN\3253398 (_40\-LRB-\1740 frlma_41\NN\1740 )_42\-RRB-\1740 versus_43\CC\1740 endotracheal_44\NN\1740 tube_45\NN\3089014 (_46\-LRB-\1740 ett_47\NN\1740 )_48\-RRB-\1740 in_49\IN\13603305 maintaining_50\VBG\2202928 controlled_51\VBN\2422663 hypotension_52\NN\14057371 anesthesia_53\NN\14034177 induced_54\VBN\1627355 by_55\IN\1740 <e1>propofol-remifentanil</e1>_56\JJ\1740 total_57\JJ\1740 i.v._58\NN\1740 anesthesia_59\NN\14034177 (_60\-LRB-\1740 tiva_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
C071741_D007022 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 purpose_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 compare_9\VB\644583 surgical_10\JJ\1740 conditions_11\NNS\14512817 ,_12\,\1740 including_13\VBG\690614 the_14\DT\1740 amount_15\NN\13329641 of_16\IN\1740 intraoperative_17\JJ\1740 bleeding_18\NN\14285662 as_19\RB\1740 well_20\RB\1740 as_21\IN\14622893 intraoperative_22\JJ\1740 blood_23\NN\5397468 pressure_24\NN\11419404 ,_25\,\1740 during_26\IN\1740 functional_27\JJ\1740 endoscopic_28\JJ\1740 sinus_29\NN\5248181 surgery_30\NN\6045562 (_31\-LRB-\1740 fess_32\NN\3853734 )_33\-RRB-\1740 using_34\VBG\1156834 flexible_35\JJ\1740 reinforced_36\VBN\220869 laryngeal_37\NN\1740 mask_38\NN\3122748 airway_39\NN\3253398 (_40\-LRB-\1740 frlma_41\NN\1740 )_42\-RRB-\1740 versus_43\CC\1740 endotracheal_44\NN\1740 tube_45\NN\3089014 (_46\-LRB-\1740 ett_47\NN\1740 )_48\-RRB-\1740 in_49\IN\13603305 maintaining_50\VBG\2202928 controlled_51\VBN\2422663 <e2>hypotension</e2>_52\NN\14057371 anesthesia_53\NN\14034177 induced_54\VBN\1627355 by_55\IN\1740 <e1>propofol-remifentanil</e1>_56\JJ\1740 total_57\JJ\1740 i.v._58\NN\1740 anesthesia_59\NN\14034177 (_60\-LRB-\1740 tiva_61\NN\1740 )_62\-RRB-\1740 ._63\.\1740
C071741_D007022 CID methods_0\NNS\5616786 :_1\:\1740 sixty_2\CD\13745420 normotensive_3\NN\1740 american_4\NNP\9620078 society_5\NNP\7950920 of_6\IN\1740 anesthesiologists_7\NNP\10632576 i-ii_8\CD\1740 adult_9\JJ\1740 patients_10\NNS\9898892 undergoing_11\VBG\109660 fess_12\NN\3853734 under_13\IN\1740 controlled_14\VBN\2422663 <e2>hypotension</e2>_15\NN\14057371 anesthesia_16\NN\14034177 caused_17\VBN\1617192 by_18\IN\1740 <e1>propofol-remifentanil-tiva</e1>_19\NN\1740 were_20\VBD\836236 randomly_21\RB\1740 assigned_22\VBN\2475922 into_23\IN\1740 two_24\CD\13741022 groups_25\NNS\2137 :_26\:\1740 group_27\NN\2137 i_28\CD\14622893 ,_29\,\1740 frlma_30\NN\1740 ;_31\:\1740 group_32\NN\2137 ii_33\CD\13741022 ,_34\,\1740 ett_35\NN\1740 ._36\.\1740
C071741_D007022 CID results_0\NNS\34213 :_1\:\1740 controlled_2\VBN\2422663 <e2>hypotension</e2>_3\NN\14057371 was_4\VBD\836236 achieved_5\VBN\2524171 within_6\IN\1740 a_7\DT\13649268 shorter_8\JJR\1740 period_9\NN\13575869 using_10\VBG\1156834 laryngeal_11\JJ\1740 mask_12\NN\3122748 using_13\VBG\1156834 lower_14\JJR\1740 rates_15\NNS\13308999 of_16\IN\1740 <e1>remifentanil</e1>_17\NN\1740 infusion_18\NN\14589223 and_19\CC\1740 lower_20\JJR\1740 total_21\JJ\1740 dose_22\NN\3740161 of_23\IN\1740 remifentanil_24\NN\1740 ._25\.\1740
C071741_D007022 CID results_0\NNS\34213 :_1\:\1740 controlled_2\VBN\2422663 <e2>hypotension</e2>_3\NN\14057371 was_4\VBD\836236 achieved_5\VBN\2524171 within_6\IN\1740 a_7\DT\13649268 shorter_8\JJR\1740 period_9\NN\13575869 using_10\VBG\1156834 laryngeal_11\JJ\1740 mask_12\NN\3122748 using_13\VBG\1156834 lower_14\JJR\1740 rates_15\NNS\13308999 of_16\IN\1740 remifentanil_17\NN\1740 infusion_18\NN\14589223 and_19\CC\1740 lower_20\JJR\1740 total_21\JJ\1740 dose_22\NN\3740161 of_23\IN\1740 <e1>remifentanil</e1>_24\NN\1740 ._25\.\1740
C071741_D007022 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 summary_3\NN\6722453 ,_4\,\1740 our_5\PRP$\1740 results_6\NNS\34213 indicate_7\VBP\952524 that_8\IN\1740 airway_9\NN\3253398 management_10\NN\1123598 using_11\VBG\1156834 frlma_12\NN\1740 during_13\IN\1740 controlled_14\VBN\2422663 <e2>hypotension</e2>_15\NN\14057371 anesthesia_16\NN\14034177 provided_17\VBD\2199590 better_18\JJR\1740 surgical_19\JJ\1740 conditions_20\NNS\14512817 in_21\IN\13603305 terms_22\NNS\13945919 of_23\IN\1740 quality_24\NN\24264 of_25\IN\1740 operative_26\JJ\1740 field_27\NN\8673395 and_28\CC\1740 blood_29\NN\5397468 loss_30\NN\13252973 and_31\CC\1740 allowed_32\VBD\797697 for_33\IN\1740 convenient_34\JJ\1740 induced_35\VBN\1627355 hypotension_36\NN\14057371 with_37\IN\1740 low_38\JJ\1740 doses_39\NNS\3740161 of_40\IN\1740 <e1>remifentanil</e1>_41\NN\1740 during_42\IN\1740 tiva_43\NN\1740 in_44\IN\13603305 patients_45\NNS\9898892 undergoing_46\VBG\109660 fess_47\NN\3853734 ._48\.\1740
C071741_D007022 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 summary_3\NN\6722453 ,_4\,\1740 our_5\PRP$\1740 results_6\NNS\34213 indicate_7\VBP\952524 that_8\IN\1740 airway_9\NN\3253398 management_10\NN\1123598 using_11\VBG\1156834 frlma_12\NN\1740 during_13\IN\1740 controlled_14\VBN\2422663 hypotension_15\NN\14057371 anesthesia_16\NN\14034177 provided_17\VBD\2199590 better_18\JJR\1740 surgical_19\JJ\1740 conditions_20\NNS\14512817 in_21\IN\13603305 terms_22\NNS\13945919 of_23\IN\1740 quality_24\NN\24264 of_25\IN\1740 operative_26\JJ\1740 field_27\NN\8673395 and_28\CC\1740 blood_29\NN\5397468 loss_30\NN\13252973 and_31\CC\1740 allowed_32\VBD\797697 for_33\IN\1740 convenient_34\JJ\1740 induced_35\VBN\1627355 <e2>hypotension</e2>_36\NN\14057371 with_37\IN\1740 low_38\JJ\1740 doses_39\NNS\3740161 of_40\IN\1740 <e1>remifentanil</e1>_41\NN\1740 during_42\IN\1740 tiva_43\NN\1740 in_44\IN\13603305 patients_45\NNS\9898892 undergoing_46\VBG\109660 fess_47\NN\3853734 ._48\.\1740
7121659
D012293_D051437 NONE antirifampicin_0\NN\1740 antibodies_1\NNS\14728724 in_2\IN\13603305 acute_3\JJ\1740 <e1>rifampicin-associated</e1>_4\JJ\1740 <e2>renal_5\JJ\1740 failure</e2>_6\NN\66216 ._7\.\1740
D012293_D058186 NONE 5_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 (_6\-LRB-\1740 3_7\CD\13741022 with_8\IN\1740 thrombopenia_9\NN\14189204 and_10\CC\1740 hemolysis_11\NN\13509528 )_12\-RRB-\1740 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 reintroduction_16\NN\7217349 of_17\IN\1740 <e1>rifampicin</e1>_18\NN\1740 are_19\VBP\836236 described_20\VBN\1001294 ._21\.\1740
D012293_D013921 CID 5_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 3_7\CD\13741022 with_8\IN\1740 <e2>thrombopenia</e2>_9\NN\14189204 and_10\CC\1740 hemolysis_11\NN\13509528 )_12\-RRB-\1740 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 reintroduction_16\NN\7217349 of_17\IN\1740 <e1>rifampicin</e1>_18\NN\1740 are_19\VBP\836236 described_20\VBN\1001294 ._21\.\1740
D012293_D006461 CID 5_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 3_7\CD\13741022 with_8\IN\1740 thrombopenia_9\NN\14189204 and_10\CC\1740 <e2>hemolysis</e2>_11\NN\13509528 )_12\-RRB-\1740 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 reintroduction_16\NN\7217349 of_17\IN\1740 <e1>rifampicin</e1>_18\NN\1740 are_19\VBP\836236 described_20\VBN\1001294 ._21\.\1740
12644816
D013792_D011471 NONE an_0\DT\6697703 open-label_1\JJ\1740 phase_2\NN\15113229 ii_3\CD\13741022 study_4\NN\635850 of_5\IN\1740 low-dose_6\JJ\1740 <e1>thalidomide</e1>_7\NN\4166841 in_8\IN\13603305 androgen-independent_9\JJ\1740 <e2>prostate_10\NN\5329735 cancer</e2>_11\NN\14239425 ._12\.\1740
D013792_D011471 NONE we_0\PRP\1740 undertook_1\VBD\1641914 an_2\DT\6697703 open-label_3\JJ\1740 study_4\NN\635850 using_5\VBG\1156834 <e1>thalidomide</e1>_6\NN\4166841 100_7\CD\13745420 mg_8\NN\13717155 once_9\RB\1740 daily_10\RB\1740 for_11\IN\1740 up_12\RB\1740 to_13\TO\1740 6_14\CD\13741022 months_15\NNS\15113229 in_16\IN\13603305 20_17\CD\13745420 men_18\NNS\8208016 with_19\IN\1740 androgen-independent_20\JJ\1740 <e2>prostate_21\NN\5329735 cancer</e2>_22\NN\14239425 ._23\.\1740
D000728_D011471 NONE an_0\DT\6697703 open-label_1\JJ\1740 phase_2\NN\15113229 ii_3\CD\13741022 study_4\NN\635850 of_5\IN\1740 low-dose_6\JJ\1740 thalidomide_7\NN\4166841 in_8\IN\13603305 <e1>androgen-independent</e1>_9\JJ\1740 <e2>prostate_10\NN\5329735 cancer</e2>_11\NN\14239425 ._12\.\1740
D000728_D011471 NONE we_0\PRP\1740 undertook_1\VBD\1641914 an_2\DT\6697703 open-label_3\JJ\1740 study_4\NN\635850 using_5\VBG\1156834 thalidomide_6\NN\4166841 100_7\CD\13745420 mg_8\NN\13717155 once_9\RB\1740 daily_10\RB\1740 for_11\IN\1740 up_12\RB\1740 to_13\TO\1740 6_14\CD\13741022 months_15\NNS\15113229 in_16\IN\13603305 20_17\CD\13745420 men_18\NNS\8208016 with_19\IN\1740 <e1>androgen-independent</e1>_20\JJ\1740 <e2>prostate_21\NN\5329735 cancer</e2>_22\NN\14239425 ._23\.\1740
D013792_D019337 NONE the_0\DT\1740 antiangiogenic_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>thalidomide</e1>_4\NN\4166841 have_5\VBP\2108377 been_6\VBN\836236 assessed_7\VBN\670261 in_8\IN\13603305 clinical_9\JJ\1740 trials_10\NNS\786195 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 various_14\JJ\1740 solid_15\JJ\1740 and_16\CC\1740 <e2>haematological_17\JJ\1740 malignancies</e2>_18\NNS\14070360 ._19\.\1740
D013792_D010523 CID in_0\IN\13603305 the_1\DT\1740 seven_2\CD\13741022 men_3\NNS\8208016 who_4\WP\8299493 completed_5\VBD\352826 six_6\CD\13741022 months_7\NNS\15113229 on_8\IN\1740 <e1>thalidomide</e1>_9\NN\4166841 ,_10\,\1740 subclinical_11\JJ\1740 evidence_12\NN\5816287 of_13\IN\1740 <e2>peripheral_14\JJ\1740 neuropathy</e2>_15\NN\14204950 was_16\VBD\836236 found_17\VBN\2426171 in_18\IN\13603305 four_19\CD\13741022 before_20\IN\1740 treatment_21\NN\654885 ,_22\,\1740 but_23\CC\1740 in_24\IN\13603305 all_25\DT\1740 seven_26\CD\13741022 at_27\IN\14622893 repeat_28\NN\7296190 testing_29\NN\639556 ._30\.\1740
D013792_D010523 CID the_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>thalidomide</e1>_4\NN\4166841 may_5\MD\15209706 be_6\VB\836236 an_7\DT\6697703 option_8\NN\6480506 for_9\IN\1740 patients_10\NNS\9898892 who_11\WP\8299493 have_12\VBP\2108377 failed_13\VBN\1798936 other_14\JJ\1740 forms_15\NNS\6286395 of_16\IN\1740 therapy_17\NN\657604 ,_18\,\1740 provided_19\VBN\2199590 close_20\JJ\1740 follow-up_21\NN\4599396 is_22\VBZ\836236 maintained_23\VBN\2202928 for_24\IN\1740 development_25\NN\248977 of_26\IN\1740 <e2>peripheral_27\JJ\1740 neuropathy</e2>_28\NN\14204950 ._29\.\1740
3990093
D011692_D007674 NONE mesangial_0\JJ\1740 function_1\NN\13783581 and_2\CC\1740 <e2>glomerular_3\JJ\1740 sclerosis</e2>_4\NN\14204950 in_5\IN\13603305 rats_6\NNS\2329401 with_7\IN\1740 <e1>aminonucleoside</e1>_8\NN\1740 nephrosis_9\NN\14304060 ._10\.\1740
D011692_D007674 NONE the_0\DT\1740 possible_1\JJ\1740 relationship_2\NN\31921 between_3\IN\1740 <e2>mesangial_4\JJ\1740 dysfunction</e2>_5\NN\14204950 and_6\CC\1740 development_7\NN\248977 of_8\IN\1740 glomerular_9\JJ\1740 sclerosis_10\NN\14204950 was_11\VBD\836236 studied_12\VBN\630380 in_13\IN\13603305 the_14\DT\1740 <e1>puromycin_15\NN\1740 aminonucleoside</e1>_16\NN\1740 (_17\-LRB-\1740 pan_18\NN\3101986 )_19\-RRB-\1740 model_20\NN\5888929 ._21\.\1740
D011692_D007674 NONE the_0\DT\1740 possible_1\JJ\1740 relationship_2\NN\31921 between_3\IN\1740 mesangial_4\JJ\1740 dysfunction_5\NN\14204950 and_6\CC\1740 development_7\NN\248977 of_8\IN\1740 <e2>glomerular_9\JJ\1740 sclerosis</e2>_10\NN\14204950 was_11\VBD\836236 studied_12\VBN\630380 in_13\IN\13603305 the_14\DT\1740 <e1>puromycin_15\NN\1740 aminonucleoside</e1>_16\NN\1740 (_17\-LRB-\1740 pan_18\NN\3101986 )_19\-RRB-\1740 model_20\NN\5888929 ._21\.\1740
D011692_D007674 NONE the_0\DT\1740 possible_1\JJ\1740 relationship_2\NN\31921 between_3\IN\1740 <e2>mesangial_4\JJ\1740 dysfunction</e2>_5\NN\14204950 and_6\CC\1740 development_7\NN\248977 of_8\IN\1740 glomerular_9\JJ\1740 sclerosis_10\NN\14204950 was_11\VBD\836236 studied_12\VBN\630380 in_13\IN\13603305 the_14\DT\1740 puromycin_15\NN\1740 aminonucleoside_16\NN\1740 (_17\-LRB-\1740 <e1>pan</e1>_18\NN\3101986 )_19\-RRB-\1740 model_20\NN\5888929 ._21\.\1740
D011692_D007674 NONE the_0\DT\1740 possible_1\JJ\1740 relationship_2\NN\31921 between_3\IN\1740 mesangial_4\JJ\1740 dysfunction_5\NN\14204950 and_6\CC\1740 development_7\NN\248977 of_8\IN\1740 <e2>glomerular_9\JJ\1740 sclerosis</e2>_10\NN\14204950 was_11\VBD\836236 studied_12\VBN\630380 in_13\IN\13603305 the_14\DT\1740 puromycin_15\NN\1740 aminonucleoside_16\NN\1740 (_17\-LRB-\1740 <e1>pan</e1>_18\NN\3101986 )_19\-RRB-\1740 model_20\NN\5888929 ._21\.\1740
D011692_D007674 NONE at_0\IN\14622893 5_1\CD\13741022 months_2\NNS\15113229 <e2>glomerular_3\JJ\1740 sclerosis</e2>_4\NN\14204950 was_5\VBD\836236 found_6\VBN\2426171 in_7\IN\13603305 7.6_8\CD\1740 +/-_9\CC\1740 3.4_10\CD\1740 %_11\NN\1740 of_12\IN\1740 the_13\DT\1740 glomeruli_14\NNS\5425910 of_15\IN\1740 <e1>pan</e1>_16\NN\3101986 rats_17\NNS\2329401 ;_18\:\1740 glomeruli_19\NNS\5425910 of_20\IN\1740 the_21\DT\1740 controls_22\NNS\5190804 were_23\VBD\836236 normal_24\JJ\1740 ._25\.\1740
D011692_D007674 NONE similar_0\JJ\1740 to_1\TO\1740 the_2\DT\1740 remnant_3\JJ\1740 kidney_4\NN\5333259 model_5\NN\5888929 in_6\IN\13603305 <e1>pan</e1>_7\NN\3101986 nephrosis_8\NN\14304060 the_9\DT\1740 development_10\NN\248977 of_11\IN\1740 <e2>glomerular_12\JJ\1740 sclerosis</e2>_13\NN\14204950 may_14\MD\15209706 be_15\VB\836236 related_16\JJ\1740 to_17\TO\1740 "_18\``\1740 mesangial_19\JJ\1740 overloading_20\NN\1740 ._21\.\1740 "_22\''\1740
D011692_D009401 NONE mesangial_0\JJ\1740 function_1\NN\13783581 and_2\CC\1740 glomerular_3\JJ\1740 sclerosis_4\NN\14204950 in_5\IN\13603305 rats_6\NNS\2329401 with_7\IN\1740 <e1>aminonucleoside</e1>_8\NN\1740 <e2>nephrosis</e2>_9\NN\14304060 ._10\.\1740
D011692_D009401 NONE similar_0\JJ\1740 to_1\TO\1740 the_2\DT\1740 remnant_3\JJ\1740 kidney_4\NN\5333259 model_5\NN\5888929 in_6\IN\13603305 <e1>pan</e1>_7\NN\3101986 <e2>nephrosis</e2>_8\NN\14304060 the_9\DT\1740 development_10\NN\248977 of_11\IN\1740 glomerular_12\JJ\1740 sclerosis_13\NN\14204950 may_14\MD\15209706 be_15\VB\836236 related_16\JJ\1740 to_17\TO\1740 "_18\``\1740 mesangial_19\JJ\1740 overloading_20\NN\1740 ._21\.\1740 "_22\''\1740
D011692_D011507 CID after_0\IN\1740 4_1\CD\13741022 weeks_2\NNS\15113229 the_3\DT\1740 <e1>pan</e1>_4\NN\3101986 rats_5\NNS\2329401 were_6\VBD\836236 severely_7\RB\1740 <e2>proteinuric</e2>_8\JJ\1740 (_9\-LRB-\1740 190_10\CD\1740 +/-_11\CC\1740 80_12\CD\13745420 mg/24_13\NNS\1740 hr_14\NN\15154774 )_15\-RRB-\1740 ,_16\,\1740 and_17\CC\1740 all_18\DT\1740 rats_19\NNS\2329401 were_20\VBD\836236 given_21\VBN\2327200 colloidal_22\JJ\1740 carbon_23\NN\14622893 (_24\-LRB-\1740 cc_25\NN\13616054 )_26\-RRB-\1740 intravenously_27\RB\1740 ._28\.\1740
D002244_D011507 NONE after_0\IN\1740 4_1\CD\13741022 weeks_2\NNS\15113229 the_3\DT\1740 pan_4\NN\3101986 rats_5\NNS\2329401 were_6\VBD\836236 severely_7\RB\1740 <e2>proteinuric</e2>_8\JJ\1740 (_9\-LRB-\1740 190_10\CD\1740 +/-_11\CC\1740 80_12\CD\13745420 mg/24_13\NNS\1740 hr_14\NN\15154774 )_15\-RRB-\1740 ,_16\,\1740 and_17\CC\1740 all_18\DT\1740 rats_19\NNS\2329401 were_20\VBD\836236 given_21\VBN\2327200 colloidal_22\JJ\1740 <e1>carbon</e1>_23\NN\14622893 (_24\-LRB-\1740 cc_25\NN\13616054 )_26\-RRB-\1740 intravenously_27\RB\1740 ._28\.\1740
D011692_D012598 NONE since_0\IN\1740 mesangial_1\JJ\1740 cc_2\NN\13616054 clearance_3\NN\5089947 from_4\IN\1740 the_5\DT\1740 mesangium_6\NN\1740 did_7\VBD\1640855 not_8\RB\1740 change_9\VB\46534 during_10\IN\1740 chronic_11\JJ\1740 <e1>pan</e1>_12\NN\3101986 treatment_13\NN\654885 ,_14\,\1740 we_15\PRP\1740 conclude_16\VBP\628491 that_17\IN\1740 this_18\DT\1740 preferential_19\JJ\1740 cc_20\NN\13616054 localization_21\NN\151497 within_22\IN\1740 the_23\DT\1740 lesions_24\NNS\14204950 is_25\VBZ\836236 caused_26\VBN\1617192 by_27\IN\1740 an_28\DT\6697703 increased_29\VBN\169651 cc_30\NN\13616054 uptake_31\NN\13440063 shortly_32\RB\1740 after_33\IN\1740 injection_34\NN\320852 in_35\IN\13603305 apparent_36\JJ\1740 vulnerable_37\JJ\1740 areas_38\NNS\8630985 where_39\WRB\1740 <e2>sclerosis</e2>_40\NN\14204950 will_41\MD\5650329 develop_42\VB\1753788 subsequently_43\RB\1740 ._44\.\1740
17346443
D010396_D017512 CID <e1>penicillamine-related</e1>_0\JJ\1740 <e2>lichenoid_1\JJ\1740 dermatitis</e2>_2\NN\14226056 and_3\CC\1740 utility_4\NN\8186047 of_5\IN\1740 zinc_6\NN\14625458 acetate_7\NN\15010703 in_8\IN\13603305 a_9\DT\13649268 wilson_10\NN\1740 disease_11\NN\14061805 patient_12\NN\9898892 with_13\IN\1740 hepatic_14\JJ\1740 presentation_15\NN\1027379 ,_16\,\1740 anxiety_17\NN\14373582 and_18\CC\1740 spect_19\NN\1740 abnormalities_20\NNS\14034177 ._21\.\1740
D010396_D017512 CID during_0\IN\1740 the_1\DT\1740 follow-up_2\NN\4599396 of_3\IN\1740 our_4\PRP$\1740 patient_5\NN\9898892 ,_6\,\1740 <e1>penicillamine</e1>_7\NN\3740161 was_8\VBD\836236 interrupted_9\JJ\1740 after_10\IN\1740 the_11\DT\1740 appearance_12\NN\4723816 of_13\IN\1740 a_14\DT\13649268 <e2>lichenoid_15\JJ\1740 dermatitis</e2>_16\NN\14226056 ,_17\,\1740 and_18\CC\1740 zinc_19\NN\14625458 acetate_20\NN\15010703 permitted_21\VBD\797697 to_22\TO\1740 continue_23\VB\2367363 the_24\DT\1740 successful_25\JJ\1740 treatment_26\NN\654885 of_27\IN\1740 the_28\DT\1740 patient_29\NN\9898892 without_30\IN\1740 side-effects_31\NNS\1740 ._32\.\1740
D010396_D006527 NONE <e1>penicillamine-related</e1>_0\JJ\1740 lichenoid_1\JJ\1740 dermatitis_2\NN\14226056 and_3\CC\1740 utility_4\NN\8186047 of_5\IN\1740 zinc_6\NN\14625458 acetate_7\NN\15010703 in_8\IN\13603305 a_9\DT\13649268 <e2>wilson_10\NN\1740 disease</e2>_11\NN\14061805 patient_12\NN\9898892 with_13\IN\1740 hepatic_14\JJ\1740 presentation_15\NN\1027379 ,_16\,\1740 anxiety_17\NN\14373582 and_18\CC\1740 spect_19\NN\1740 abnormalities_20\NNS\14034177 ._21\.\1740
D010396_D006527 NONE in_0\IN\13603305 our_1\PRP$\1740 case_2\NN\7283608 the_3\DT\1740 therapy_4\NN\657604 with_5\IN\1740 zinc_6\NN\14625458 acetate_7\NN\15010703 represented_8\VBD\2664769 an_9\DT\6697703 effective_10\JJ\1740 treatment_11\NN\654885 for_12\IN\1740 a_13\DT\13649268 <e2>wilson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 patient_17\NN\9898892 in_18\IN\13603305 which_19\WDT\1740 <e1>penicillamine-related</e1>_20\JJ\1740 side_21\NN\8630039 effects_22\NNS\13245626 appeared_23\VBD\2604760 ._24\.\1740
D010396_D006527 NONE since_0\IN\1740 most_1\JJS\1740 of_2\IN\1740 <e2>wilson_3\NN\1740 's_4\POS\1740 disease</e2>_5\NN\14061805 <e1>penicillamine-treated</e1>_6\JJ\1740 patients_7\NNS\9898892 do_8\VBP\1640855 not_9\RB\1740 seem_10\VB\2604760 to_11\TO\1740 develop_12\VB\1753788 this_13\DT\1740 skin_14\NN\5237755 lesion_15\NN\14204950 ,_16\,\1740 it_17\PRP\6125041 could_18\MD\1740 be_19\VB\836236 conceivable_20\JJ\1740 that_21\IN\1740 a_22\DT\13649268 specific_23\JJ\1740 genetic_24\JJ\1740 factor_25\NN\7326557 is_26\VBZ\836236 involved_27\VBN\2676054 in_28\IN\13603305 drug_29\NN\14778436 response_30\NN\11410625 ._31\.\1740
D010396_D001008 NONE <e1>penicillamine-related</e1>_0\JJ\1740 lichenoid_1\JJ\1740 dermatitis_2\NN\14226056 and_3\CC\1740 utility_4\NN\8186047 of_5\IN\1740 zinc_6\NN\14625458 acetate_7\NN\15010703 in_8\IN\13603305 a_9\DT\13649268 wilson_10\NN\1740 disease_11\NN\14061805 patient_12\NN\9898892 with_13\IN\1740 hepatic_14\JJ\1740 presentation_15\NN\1027379 ,_16\,\1740 <e2>anxiety</e2>_17\NN\14373582 and_18\CC\1740 spect_19\NN\1740 abnormalities_20\NNS\14034177 ._21\.\1740
D019345_D017512 NONE penicillamine-related_0\JJ\1740 <e2>lichenoid_1\JJ\1740 dermatitis</e2>_2\NN\14226056 and_3\CC\1740 utility_4\NN\8186047 of_5\IN\1740 <e1>zinc_6\NN\14625458 acetate</e1>_7\NN\15010703 in_8\IN\13603305 a_9\DT\13649268 wilson_10\NN\1740 disease_11\NN\14061805 patient_12\NN\9898892 with_13\IN\1740 hepatic_14\JJ\1740 presentation_15\NN\1027379 ,_16\,\1740 anxiety_17\NN\14373582 and_18\CC\1740 spect_19\NN\1740 abnormalities_20\NNS\14034177 ._21\.\1740
D019345_D017512 NONE during_0\IN\1740 the_1\DT\1740 follow-up_2\NN\4599396 of_3\IN\1740 our_4\PRP$\1740 patient_5\NN\9898892 ,_6\,\1740 penicillamine_7\NN\3740161 was_8\VBD\836236 interrupted_9\JJ\1740 after_10\IN\1740 the_11\DT\1740 appearance_12\NN\4723816 of_13\IN\1740 a_14\DT\13649268 <e2>lichenoid_15\JJ\1740 dermatitis</e2>_16\NN\14226056 ,_17\,\1740 and_18\CC\1740 <e1>zinc_19\NN\14625458 acetate</e1>_20\NN\15010703 permitted_21\VBD\797697 to_22\TO\1740 continue_23\VB\2367363 the_24\DT\1740 successful_25\JJ\1740 treatment_26\NN\654885 of_27\IN\1740 the_28\DT\1740 patient_29\NN\9898892 without_30\IN\1740 side-effects_31\NNS\1740 ._32\.\1740
D019345_D006527 NONE penicillamine-related_0\JJ\1740 lichenoid_1\JJ\1740 dermatitis_2\NN\14226056 and_3\CC\1740 utility_4\NN\8186047 of_5\IN\1740 <e1>zinc_6\NN\14625458 acetate</e1>_7\NN\15010703 in_8\IN\13603305 a_9\DT\13649268 <e2>wilson_10\NN\1740 disease</e2>_11\NN\14061805 patient_12\NN\9898892 with_13\IN\1740 hepatic_14\JJ\1740 presentation_15\NN\1027379 ,_16\,\1740 anxiety_17\NN\14373582 and_18\CC\1740 spect_19\NN\1740 abnormalities_20\NNS\14034177 ._21\.\1740
D019345_D006527 NONE in_0\IN\13603305 our_1\PRP$\1740 case_2\NN\7283608 the_3\DT\1740 therapy_4\NN\657604 with_5\IN\1740 <e1>zinc_6\NN\14625458 acetate</e1>_7\NN\15010703 represented_8\VBD\2664769 an_9\DT\6697703 effective_10\JJ\1740 treatment_11\NN\654885 for_12\IN\1740 a_13\DT\13649268 <e2>wilson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 patient_17\NN\9898892 in_18\IN\13603305 which_19\WDT\1740 penicillamine-related_20\JJ\1740 side_21\NN\8630039 effects_22\NNS\13245626 appeared_23\VBD\2604760 ._24\.\1740
D019345_D006527 NONE the_0\DT\1740 safety_1\NN\13920835 of_2\IN\1740 the_3\DT\1740 <e1>zinc_4\NN\14625458 acetate</e1>_5\NN\15010703 allowed_6\VBD\797697 us_7\PRP\14964590 to_8\TO\1740 avoid_9\VB\2452885 other_10\JJ\1740 potentially_11\RB\1740 toxic_12\JJ\1740 chelating_13\NN\1740 drugs_14\NNS\14778436 ;_15\:\1740 this_16\DT\1740 observation_17\NN\996969 is_18\VBZ\836236 in_19\IN\13603305 line_20\NN\8426461 with_21\IN\1740 the_22\DT\1740 growing_23\VBG\109660 evidence_24\NN\5816287 on_25\IN\1740 the_26\DT\1740 efficacy_27\NN\5199286 of_28\IN\1740 the_29\DT\1740 drug_30\NN\14778436 in_31\IN\13603305 the_32\DT\1740 treatment_33\NN\654885 of_34\IN\1740 <e2>wilson_35\NN\1740 's_36\POS\1740 disease</e2>_37\NN\14061805 ._38\.\1740
D019345_D001008 NONE penicillamine-related_0\JJ\1740 lichenoid_1\JJ\1740 dermatitis_2\NN\14226056 and_3\CC\1740 utility_4\NN\8186047 of_5\IN\1740 <e1>zinc_6\NN\14625458 acetate</e1>_7\NN\15010703 in_8\IN\13603305 a_9\DT\13649268 wilson_10\NN\1740 disease_11\NN\14061805 patient_12\NN\9898892 with_13\IN\1740 hepatic_14\JJ\1740 presentation_15\NN\1027379 ,_16\,\1740 <e2>anxiety</e2>_17\NN\14373582 and_18\CC\1740 spect_19\NN\1740 abnormalities_20\NNS\14034177 ._21\.\1740
D003300_D006527 NONE <e2>wilson_0\NN\1740 's_1\POS\1740 disease</e2>_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 <e1>copper</e1>_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 copper_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders_28\NNS\14034177 ._29\.\1740
D003300_D006527 NONE <e2>wilson_0\NN\1740 's_1\POS\1740 disease</e2>_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 copper_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 <e1>copper</e1>_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders_28\NNS\14034177 ._29\.\1740
D003300_D064420 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 <e1>copper</e1>_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 copper_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 <e2>toxicity</e2>_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders_28\NNS\14034177 ._29\.\1740
D003300_D064420 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 copper_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 <e1>copper</e1>_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 <e2>toxicity</e2>_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders_28\NNS\14034177 ._29\.\1740
D003300_D056486 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 <e1>copper</e1>_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 copper_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 <e2>hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D003300_D056486 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 copper_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 <e1>copper</e1>_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 <e2>hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D003300_D009422 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 <e1>copper</e1>_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 copper_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 <e2>hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D003300_D009422 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 copper_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 <e1>copper</e1>_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 <e2>hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D003300_D001523 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 <e1>copper</e1>_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 copper_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 <e2>hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D003300_D001523 NONE wilson_0\NN\1740 's_1\POS\1740 disease_2\NN\14061805 is_3\VBZ\836236 an_4\DT\6697703 autosomal_5\JJ\1740 recessive_6\JJ\1740 disorder_7\NN\14034177 of_8\IN\1740 hepatic_9\JJ\1740 copper_10\NN\14821043 metabolism_11\NN\13526110 with_12\IN\1740 consequent_13\JJ\1740 <e1>copper</e1>_14\NN\14821043 accumulation_15\NN\13497135 and_16\CC\1740 toxicity_17\NN\13576101 in_18\IN\13603305 many_19\JJ\1740 tissues_20\NNS\5220461 and_21\CC\1740 consequent_22\JJ\1740 <e2>hepatic_23\JJ\1740 ,_24\,\1740 neurologic_25\JJ\1740 and_26\CC\1740 psychiatric_27\JJ\1740 disorders</e2>_28\NNS\14034177 ._29\.\1740
D010396_D012871 NONE since_0\IN\1740 most_1\JJS\1740 of_2\IN\1740 wilson_3\NN\1740 's_4\POS\1740 disease_5\NN\14061805 <e1>penicillamine-treated</e1>_6\JJ\1740 patients_7\NNS\9898892 do_8\VBP\1640855 not_9\RB\1740 seem_10\VB\2604760 to_11\TO\1740 develop_12\VB\1753788 this_13\DT\1740 <e2>skin_14\NN\5237755 lesion</e2>_15\NN\14204950 ,_16\,\1740 it_17\PRP\6125041 could_18\MD\1740 be_19\VB\836236 conceivable_20\JJ\1740 that_21\IN\1740 a_22\DT\13649268 specific_23\JJ\1740 genetic_24\JJ\1740 factor_25\NN\7326557 is_26\VBZ\836236 involved_27\VBN\2676054 in_28\IN\13603305 drug_29\NN\14778436 response_30\NN\11410625 ._31\.\1740
3975902
D010424_D002318 NONE <e2>cardiovascular_0\JJ\1740 dysfunction</e2>_1\NN\14204950 and_2\CC\1740 hypersensitivity_3\NN\14531772 to_4\TO\1740 <e1>sodium_5\NN\14625458 pentobarbital</e1>_6\NN\2792049 induced_7\VBN\1627355 by_8\IN\1740 chronic_9\JJ\1740 barium_10\NN\14625458 chloride_11\NN\14818238 ingestion_12\NN\13440063 ._13\.\1740
D010424_D004342 NONE cardiovascular_0\JJ\1740 dysfunction_1\NN\14204950 and_2\CC\1740 <e2>hypersensitivity</e2>_3\NN\14531772 to_4\TO\1740 <e1>sodium_5\NN\14625458 pentobarbital</e1>_6\NN\2792049 induced_7\VBN\1627355 by_8\IN\1740 chronic_9\JJ\1740 barium_10\NN\14625458 chloride_11\NN\14818238 ingestion_12\NN\13440063 ._13\.\1740
D010424_D004342 NONE the_0\DT\1740 most_1\RBS\1740 distinctive_2\JJ\1740 aspect_3\NN\5849789 of_4\IN\1740 the_5\DT\1740 barium_6\NN\14625458 effect_7\NN\34213 was_8\VBD\836236 a_9\DT\13649268 demonstrated_10\VBN\2137132 <e2>hypersensitivity</e2>_11\NN\14531772 of_12\IN\1740 the_13\DT\1740 cardiovascular_14\JJ\1740 system_15\NN\3575240 to_16\TO\1740 <e1>sodium_17\NN\14625458 pentobarbital</e1>_18\JJ\1740 ._19\.\1740
D010424_D004342 NONE overall_0\RB\1740 ,_1\,\1740 the_2\DT\1740 altered_3\JJ\1740 cardiac_4\JJ\1740 contractility_5\NN\5200169 and_6\CC\1740 excitability_7\NN\5653575 characteristics_8\NNS\5849040 ,_9\,\1740 the_10\DT\1740 myocardial_11\JJ\1740 metabolic_12\JJ\1740 disturbances_13\NNS\407535 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 <e2>hypersensitivity</e2>_17\NN\14531772 of_18\IN\1740 the_19\DT\1740 cardiovascular_20\JJ\1740 system_21\NN\3575240 to_22\TO\1740 <e1>sodium_23\NN\14625458 pentobarbital</e1>_24\NN\2792049 suggest_25\VBP\1010118 the_26\DT\1740 existence_27\NN\24720 of_28\IN\1740 a_29\DT\13649268 heretofore_30\RB\1740 undescribed_31\JJ\1740 cardiomyopathic_32\JJ\1740 disorder_33\NN\14034177 induced_34\VBN\1627355 by_35\IN\1740 chronic_36\JJ\1740 barium_37\NN\14625458 exposure_38\NN\5042871 ._39\.\1740
C024986_D002318 NONE <e2>cardiovascular_0\JJ\1740 dysfunction</e2>_1\NN\14204950 and_2\CC\1740 hypersensitivity_3\NN\14531772 to_4\TO\1740 sodium_5\NN\14625458 pentobarbital_6\NN\2792049 induced_7\VBN\1627355 by_8\IN\1740 chronic_9\JJ\1740 <e1>barium_10\NN\14625458 chloride</e1>_11\NN\14818238 ingestion_12\NN\13440063 ._13\.\1740
C024986_D004342 NONE cardiovascular_0\JJ\1740 dysfunction_1\NN\14204950 and_2\CC\1740 <e2>hypersensitivity</e2>_3\NN\14531772 to_4\TO\1740 sodium_5\NN\14625458 pentobarbital_6\NN\2792049 induced_7\VBN\1627355 by_8\IN\1740 chronic_9\JJ\1740 <e1>barium_10\NN\14625458 chloride</e1>_11\NN\14818238 ingestion_12\NN\13440063 ._13\.\1740
D001464_D006973 NONE <e1>barium-supplemented</e1>_0\JJ\1740 long-evans_1\NNPS\1740 hooded_2\VBD\1332730 rats_3\NNS\2329401 were_4\VBD\836236 characterized_5\VBN\609683 by_6\IN\1740 a_7\DT\13649268 persistent_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 that_10\WDT\1740 was_11\VBD\836236 evident_12\JJ\1740 after_13\IN\1740 1_14\CD\13741022 month_15\NN\15113229 of_16\IN\1740 barium_17\NN\14625458 (_18\-LRB-\1740 100_19\CD\13745420 micrograms/ml_20\NNS\1740 mineral_21\NN\14580897 fortified_22\VBD\126264 water_23\NN\14618834 )_24\-RRB-\1740 treatment_25\NN\654885 ._26\.\1740
D001464_D006973 NONE barium-supplemented_0\JJ\1740 long-evans_1\NNPS\1740 hooded_2\VBD\1332730 rats_3\NNS\2329401 were_4\VBD\836236 characterized_5\VBN\609683 by_6\IN\1740 a_7\DT\13649268 persistent_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 that_10\WDT\1740 was_11\VBD\836236 evident_12\JJ\1740 after_13\IN\1740 1_14\CD\13741022 month_15\NN\15113229 of_16\IN\1740 <e1>barium</e1>_17\NN\14625458 (_18\-LRB-\1740 100_19\CD\13745420 micrograms/ml_20\NNS\1740 mineral_21\NN\14580897 fortified_22\VBD\126264 water_23\NN\14618834 )_24\-RRB-\1740 treatment_25\NN\654885 ._26\.\1740
D001464_D002318 NONE analysis_0\NN\633864 of_1\IN\1740 in_2\FW\13603305 vivo_3\FW\1740 myocardial_4\JJ\1740 excitability_5\NN\5653575 ,_6\,\1740 contractility_7\NN\5200169 ,_8\,\1740 and_9\CC\1740 metabolic_10\JJ\1740 characteristics_11\NNS\5849040 at_12\IN\14622893 16_13\CD\13745420 months_14\NNS\15113229 revealed_15\VBD\2137132 other_16\JJ\1740 significant_17\JJ\1740 <e1>barium-induced</e1>_18\JJ\1740 <e2>disturbances_19\NNS\407535 within_20\IN\1740 the_21\DT\1740 cardiovascular_22\JJ\1740 system</e2>_23\NN\3575240 ._24\.\1740
D001464_D004342 NONE the_0\DT\1740 most_1\RBS\1740 distinctive_2\JJ\1740 aspect_3\NN\5849789 of_4\IN\1740 the_5\DT\1740 <e1>barium</e1>_6\NN\14625458 effect_7\NN\34213 was_8\VBD\836236 a_9\DT\13649268 demonstrated_10\VBN\2137132 <e2>hypersensitivity</e2>_11\NN\14531772 of_12\IN\1740 the_13\DT\1740 cardiovascular_14\JJ\1740 system_15\NN\3575240 to_16\TO\1740 sodium_17\NN\14625458 pentobarbital_18\JJ\1740 ._19\.\1740
D001464_D004342 NONE overall_0\RB\1740 ,_1\,\1740 the_2\DT\1740 altered_3\JJ\1740 cardiac_4\JJ\1740 contractility_5\NN\5200169 and_6\CC\1740 excitability_7\NN\5653575 characteristics_8\NNS\5849040 ,_9\,\1740 the_10\DT\1740 myocardial_11\JJ\1740 metabolic_12\JJ\1740 disturbances_13\NNS\407535 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 <e2>hypersensitivity</e2>_17\NN\14531772 of_18\IN\1740 the_19\DT\1740 cardiovascular_20\JJ\1740 system_21\NN\3575240 to_22\TO\1740 sodium_23\NN\14625458 pentobarbital_24\NN\2792049 suggest_25\VBP\1010118 the_26\DT\1740 existence_27\NN\24720 of_28\IN\1740 a_29\DT\13649268 heretofore_30\RB\1740 undescribed_31\JJ\1740 cardiomyopathic_32\JJ\1740 disorder_33\NN\14034177 induced_34\VBN\1627355 by_35\IN\1740 chronic_36\JJ\1740 <e1>barium</e1>_37\NN\14625458 exposure_38\NN\5042871 ._39\.\1740
D010424_D008659 NONE overall_0\RB\1740 ,_1\,\1740 the_2\DT\1740 altered_3\JJ\1740 cardiac_4\JJ\1740 contractility_5\NN\5200169 and_6\CC\1740 excitability_7\NN\5653575 characteristics_8\NNS\5849040 ,_9\,\1740 the_10\DT\1740 myocardial_11\JJ\1740 <e2>metabolic_12\JJ\1740 disturbances</e2>_13\NNS\407535 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 hypersensitivity_17\NN\14531772 of_18\IN\1740 the_19\DT\1740 cardiovascular_20\JJ\1740 system_21\NN\3575240 to_22\TO\1740 <e1>sodium_23\NN\14625458 pentobarbital</e1>_24\NN\2792049 suggest_25\VBP\1010118 the_26\DT\1740 existence_27\NN\24720 of_28\IN\1740 a_29\DT\13649268 heretofore_30\RB\1740 undescribed_31\JJ\1740 cardiomyopathic_32\JJ\1740 disorder_33\NN\14034177 induced_34\VBN\1627355 by_35\IN\1740 chronic_36\JJ\1740 barium_37\NN\14625458 exposure_38\NN\5042871 ._39\.\1740
D010424_D009202 NONE overall_0\RB\1740 ,_1\,\1740 the_2\DT\1740 altered_3\JJ\1740 cardiac_4\JJ\1740 contractility_5\NN\5200169 and_6\CC\1740 excitability_7\NN\5653575 characteristics_8\NNS\5849040 ,_9\,\1740 the_10\DT\1740 myocardial_11\JJ\1740 metabolic_12\JJ\1740 disturbances_13\NNS\407535 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 hypersensitivity_17\NN\14531772 of_18\IN\1740 the_19\DT\1740 cardiovascular_20\JJ\1740 system_21\NN\3575240 to_22\TO\1740 <e1>sodium_23\NN\14625458 pentobarbital</e1>_24\NN\2792049 suggest_25\VBP\1010118 the_26\DT\1740 existence_27\NN\24720 of_28\IN\1740 a_29\DT\13649268 heretofore_30\RB\1740 undescribed_31\JJ\1740 <e2>cardiomyopathic_32\JJ\1740 disorder</e2>_33\NN\14034177 induced_34\VBN\1627355 by_35\IN\1740 chronic_36\JJ\1740 barium_37\NN\14625458 exposure_38\NN\5042871 ._39\.\1740
D001464_D008659 NONE overall_0\RB\1740 ,_1\,\1740 the_2\DT\1740 altered_3\JJ\1740 cardiac_4\JJ\1740 contractility_5\NN\5200169 and_6\CC\1740 excitability_7\NN\5653575 characteristics_8\NNS\5849040 ,_9\,\1740 the_10\DT\1740 myocardial_11\JJ\1740 <e2>metabolic_12\JJ\1740 disturbances</e2>_13\NNS\407535 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 hypersensitivity_17\NN\14531772 of_18\IN\1740 the_19\DT\1740 cardiovascular_20\JJ\1740 system_21\NN\3575240 to_22\TO\1740 sodium_23\NN\14625458 pentobarbital_24\NN\2792049 suggest_25\VBP\1010118 the_26\DT\1740 existence_27\NN\24720 of_28\IN\1740 a_29\DT\13649268 heretofore_30\RB\1740 undescribed_31\JJ\1740 cardiomyopathic_32\JJ\1740 disorder_33\NN\14034177 induced_34\VBN\1627355 by_35\IN\1740 chronic_36\JJ\1740 <e1>barium</e1>_37\NN\14625458 exposure_38\NN\5042871 ._39\.\1740
D001464_D009202 NONE overall_0\RB\1740 ,_1\,\1740 the_2\DT\1740 altered_3\JJ\1740 cardiac_4\JJ\1740 contractility_5\NN\5200169 and_6\CC\1740 excitability_7\NN\5653575 characteristics_8\NNS\5849040 ,_9\,\1740 the_10\DT\1740 myocardial_11\JJ\1740 metabolic_12\JJ\1740 disturbances_13\NNS\407535 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 hypersensitivity_17\NN\14531772 of_18\IN\1740 the_19\DT\1740 cardiovascular_20\JJ\1740 system_21\NN\3575240 to_22\TO\1740 sodium_23\NN\14625458 pentobarbital_24\NN\2792049 suggest_25\VBP\1010118 the_26\DT\1740 existence_27\NN\24720 of_28\IN\1740 a_29\DT\13649268 heretofore_30\RB\1740 undescribed_31\JJ\1740 <e2>cardiomyopathic_32\JJ\1740 disorder</e2>_33\NN\14034177 induced_34\VBN\1627355 by_35\IN\1740 chronic_36\JJ\1740 <e1>barium</e1>_37\NN\14625458 exposure_38\NN\5042871 ._39\.\1740
17379047
C081489_D006973 NONE comparison_0\NN\635850 of_1\IN\1740 <e1>valsartan/hydrochlorothiazide</e1>_2\JJ\1740 combination_3\NN\7951464 therapy_4\NN\657604 at_5\IN\14622893 doses_6\NNS\3740161 up_7\IN\1740 to_8\TO\1740 320/25_9\NN\1740 mg_10\NN\13717155 versus_11\CC\1740 monotherapy_12\NN\1740 :_13\:\1740 a_14\DT\13649268 double-blind_15\JJ\1740 ,_16\,\1740 placebo-controlled_17\JJ\1740 study_18\NN\635850 followed_19\VBN\1835496 by_20\IN\1740 long-term_21\JJ\1740 combination_22\NN\7951464 therapy_23\NN\657604 in_24\IN\13603305 <e2>hypertensive</e2>_25\JJ\1740 adults_26\NNS\7846 ._27\.\1740
D006852_D006973 NONE comparison_0\NN\635850 of_1\IN\1740 <e1>valsartan/hydrochlorothiazide</e1>_2\JJ\1740 combination_3\NN\7951464 therapy_4\NN\657604 at_5\IN\14622893 doses_6\NNS\3740161 up_7\IN\1740 to_8\TO\1740 320/25_9\NN\1740 mg_10\NN\13717155 versus_11\CC\1740 monotherapy_12\NN\1740 :_13\:\1740 a_14\DT\13649268 double-blind_15\JJ\1740 ,_16\,\1740 placebo-controlled_17\JJ\1740 study_18\NN\635850 followed_19\VBN\1835496 by_20\IN\1740 long-term_21\JJ\1740 combination_22\NN\7951464 therapy_23\NN\657604 in_24\IN\13603305 <e2>hypertensive</e2>_25\JJ\1740 adults_26\NNS\7846 ._27\.\1740
C081489_C562386 NONE objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 investigated_4\VBD\644583 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 tolerability_8\NN\1740 of_9\IN\1740 <e1>valsartan</e1>_10\NN\2712393 (_11\-LRB-\1740 val_12\NN\1740 )_13\-RRB-\1740 or_14\CC\3541091 hydrochlorothiazide_15\JJ\1740 (hctz)-monotherapy_16\NN\1740 and_17\CC\1740 higher-dose_18\JJ\1740 combinations_19\NNS\7951464 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 <e2>essential_23\JJ\1740 hypertension</e2>_24\NN\14057371 ._25\.\1740
C081489_C562386 NONE objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 investigated_4\VBD\644583 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 tolerability_8\NN\1740 of_9\IN\1740 valsartan_10\NN\2712393 (_11\-LRB-\1740 <e1>val</e1>_12\NN\1740 )_13\-RRB-\1740 or_14\CC\3541091 hydrochlorothiazide_15\JJ\1740 (hctz)-monotherapy_16\NN\1740 and_17\CC\1740 higher-dose_18\JJ\1740 combinations_19\NNS\7951464 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 <e2>essential_23\JJ\1740 hypertension</e2>_24\NN\14057371 ._25\.\1740
C081489_C562386 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>essential_2\JJ\1740 hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 mean_5\NN\6021761 sitting_6\VBG\2655135 diastolic_7\JJ\1740 bp_8\NN\1740 [_9\-LRB-\1740 msdbp_10\NN\1740 ]_11\-RRB-\1740 ,_12\,\1740 >_13\NN\1740 or_14\CC\3541091 =_15\JJ\1740 95_16\CD\1740 mm_17\NN\13649268 hg_18\NNP\14625458 and_19\CC\1740 <_20\XX\1740 110_21\CD\1740 mm_22\NN\13649268 hg_23\NN\14625458 )_24\-RRB-\1740 were_25\VBD\836236 randomized_26\VBN\278117 to_27\TO\1740 1_28\CD\13741022 of_29\IN\1740 8_30\CD\13741022 treatment_31\NN\654885 groups_32\NNS\2137 :_33\:\1740 <e1>val</e1>_34\NN\1740 160_35\CD\1740 or_36\CC\3541091 320_37\CD\1740 mg_38\NN\13717155 ;_39\:\1740 hctz_40\NN\1740 12.5_41\CD\1740 or_42\CC\3541091 25_43\CD\13745420 mg_44\NN\13717155 ;_45\:\1740 val/hctz_46\NN\1740 160/12.5_47\NN\1740 ,_48\,\1740 320/12.5_49\NN\1740 ,_50\,\1740 or_51\CC\3541091 320/25_52\NN\1740 mg_53\NN\13717155 ;_54\:\1740 or_55\CC\3541091 placebo_56\NN\3740161 ._57\.\1740
C081489_C562386 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>essential_2\JJ\1740 hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 mean_5\NN\6021761 sitting_6\VBG\2655135 diastolic_7\JJ\1740 bp_8\NN\1740 [_9\-LRB-\1740 msdbp_10\NN\1740 ]_11\-RRB-\1740 ,_12\,\1740 >_13\NN\1740 or_14\CC\3541091 =_15\JJ\1740 95_16\CD\1740 mm_17\NN\13649268 hg_18\NNP\14625458 and_19\CC\1740 <_20\XX\1740 110_21\CD\1740 mm_22\NN\13649268 hg_23\NN\14625458 )_24\-RRB-\1740 were_25\VBD\836236 randomized_26\VBN\278117 to_27\TO\1740 1_28\CD\13741022 of_29\IN\1740 8_30\CD\13741022 treatment_31\NN\654885 groups_32\NNS\2137 :_33\:\1740 val_34\NN\1740 160_35\CD\1740 or_36\CC\3541091 320_37\CD\1740 mg_38\NN\13717155 ;_39\:\1740 hctz_40\NN\1740 12.5_41\CD\1740 or_42\CC\3541091 25_43\CD\13745420 mg_44\NN\13717155 ;_45\:\1740 <e1>val/hctz</e1>_46\NN\1740 160/12.5_47\NN\1740 ,_48\,\1740 320/12.5_49\NN\1740 ,_50\,\1740 or_51\CC\3541091 320/25_52\NN\1740 mg_53\NN\13717155 ;_54\:\1740 or_55\CC\3541091 placebo_56\NN\3740161 ._57\.\1740
D006852_C562386 NONE objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 investigated_4\VBD\644583 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 tolerability_8\NN\1740 of_9\IN\1740 valsartan_10\NN\2712393 (_11\-LRB-\1740 val_12\NN\1740 )_13\-RRB-\1740 or_14\CC\3541091 <e1>hydrochlorothiazide</e1>_15\JJ\1740 (hctz)-monotherapy_16\NN\1740 and_17\CC\1740 higher-dose_18\JJ\1740 combinations_19\NNS\7951464 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 <e2>essential_23\JJ\1740 hypertension</e2>_24\NN\14057371 ._25\.\1740
D006852_C562386 NONE objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 investigated_4\VBD\644583 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 tolerability_8\NN\1740 of_9\IN\1740 valsartan_10\NN\2712393 (_11\-LRB-\1740 val_12\NN\1740 )_13\-RRB-\1740 or_14\CC\3541091 hydrochlorothiazide_15\JJ\1740 <e1>(hctz)-monotherapy</e1>_16\NN\1740 and_17\CC\1740 higher-dose_18\JJ\1740 combinations_19\NNS\7951464 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 <e2>essential_23\JJ\1740 hypertension</e2>_24\NN\14057371 ._25\.\1740
D006852_C562386 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>essential_2\JJ\1740 hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 mean_5\NN\6021761 sitting_6\VBG\2655135 diastolic_7\JJ\1740 bp_8\NN\1740 [_9\-LRB-\1740 msdbp_10\NN\1740 ]_11\-RRB-\1740 ,_12\,\1740 >_13\NN\1740 or_14\CC\3541091 =_15\JJ\1740 95_16\CD\1740 mm_17\NN\13649268 hg_18\NNP\14625458 and_19\CC\1740 <_20\XX\1740 110_21\CD\1740 mm_22\NN\13649268 hg_23\NN\14625458 )_24\-RRB-\1740 were_25\VBD\836236 randomized_26\VBN\278117 to_27\TO\1740 1_28\CD\13741022 of_29\IN\1740 8_30\CD\13741022 treatment_31\NN\654885 groups_32\NNS\2137 :_33\:\1740 val_34\NN\1740 160_35\CD\1740 or_36\CC\3541091 320_37\CD\1740 mg_38\NN\13717155 ;_39\:\1740 <e1>hctz</e1>_40\NN\1740 12.5_41\CD\1740 or_42\CC\3541091 25_43\CD\13745420 mg_44\NN\13717155 ;_45\:\1740 val/hctz_46\NN\1740 160/12.5_47\NN\1740 ,_48\,\1740 320/12.5_49\NN\1740 ,_50\,\1740 or_51\CC\3541091 320/25_52\NN\1740 mg_53\NN\13717155 ;_54\:\1740 or_55\CC\3541091 placebo_56\NN\3740161 ._57\.\1740
D006852_C562386 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>essential_2\JJ\1740 hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 mean_5\NN\6021761 sitting_6\VBG\2655135 diastolic_7\JJ\1740 bp_8\NN\1740 [_9\-LRB-\1740 msdbp_10\NN\1740 ]_11\-RRB-\1740 ,_12\,\1740 >_13\NN\1740 or_14\CC\3541091 =_15\JJ\1740 95_16\CD\1740 mm_17\NN\13649268 hg_18\NNP\14625458 and_19\CC\1740 <_20\XX\1740 110_21\CD\1740 mm_22\NN\13649268 hg_23\NN\14625458 )_24\-RRB-\1740 were_25\VBD\836236 randomized_26\VBN\278117 to_27\TO\1740 1_28\CD\13741022 of_29\IN\1740 8_30\CD\13741022 treatment_31\NN\654885 groups_32\NNS\2137 :_33\:\1740 val_34\NN\1740 160_35\CD\1740 or_36\CC\3541091 320_37\CD\1740 mg_38\NN\13717155 ;_39\:\1740 hctz_40\NN\1740 12.5_41\CD\1740 or_42\CC\3541091 25_43\CD\13745420 mg_44\NN\13717155 ;_45\:\1740 <e1>val/hctz</e1>_46\NN\1740 160/12.5_47\NN\1740 ,_48\,\1740 320/12.5_49\NN\1740 ,_50\,\1740 or_51\CC\3541091 320/25_52\NN\1740 mg_53\NN\13717155 ;_54\:\1740 or_55\CC\3541091 placebo_56\NN\3740161 ._57\.\1740
C081489_D007008 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>hypokalemia</e2>_3\NN\14299637 was_4\VBD\836236 lower_5\JJR\1740 with_6\IN\1740 <e1>val/hctz</e1>_7\JJ\1740 combinations_8\NNS\7951464 (_9\-LRB-\1740 1.8%-6.1_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 than_13\IN\1740 with_14\IN\1740 hctz_15\NN\1740 monotherapies_16\NNS\1740 (_17\-LRB-\1740 7.1%-13.3_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ._21\.\1740
C081489_D007008 NONE conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 population_5\NN\7942152 ,_6\,\1740 combination_7\NN\7951464 therapies_8\NNS\657604 with_9\IN\1740 <e1>val/hctz</e1>_10\NN\1740 were_11\VBD\836236 associated_12\VBN\628491 with_13\IN\1740 significantly_14\RB\1740 greater_15\JJR\1740 bp_16\NN\1740 reductions_17\NNS\351485 compared_18\VBN\644583 with_19\IN\1740 either_20\CC\1740 monotherapy_21\NN\1740 ,_22\,\1740 were_23\VBD\836236 well_24\RB\1740 tolerated_25\VBN\802318 ,_26\,\1740 and_27\CC\1740 were_28\VBD\836236 associated_29\VBN\628491 with_30\IN\1740 less_31\JJR\1740 <e2>hypokalemia</e2>_32\NN\14299637 than_33\IN\1740 hctz_34\NN\1740 alone_35\RB\1740 ._36\.\1740
D006852_D007008 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>hypokalemia</e2>_3\NN\14299637 was_4\VBD\836236 lower_5\JJR\1740 with_6\IN\1740 <e1>val/hctz</e1>_7\JJ\1740 combinations_8\NNS\7951464 (_9\-LRB-\1740 1.8%-6.1_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 than_13\IN\1740 with_14\IN\1740 hctz_15\NN\1740 monotherapies_16\NNS\1740 (_17\-LRB-\1740 7.1%-13.3_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ._21\.\1740
D006852_D007008 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>hypokalemia</e2>_3\NN\14299637 was_4\VBD\836236 lower_5\JJR\1740 with_6\IN\1740 val/hctz_7\JJ\1740 combinations_8\NNS\7951464 (_9\-LRB-\1740 1.8%-6.1_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 than_13\IN\1740 with_14\IN\1740 <e1>hctz</e1>_15\NN\1740 monotherapies_16\NNS\1740 (_17\-LRB-\1740 7.1%-13.3_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ._21\.\1740
D006852_D007008 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 population_5\NN\7942152 ,_6\,\1740 combination_7\NN\7951464 therapies_8\NNS\657604 with_9\IN\1740 <e1>val/hctz</e1>_10\NN\1740 were_11\VBD\836236 associated_12\VBN\628491 with_13\IN\1740 significantly_14\RB\1740 greater_15\JJR\1740 bp_16\NN\1740 reductions_17\NNS\351485 compared_18\VBN\644583 with_19\IN\1740 either_20\CC\1740 monotherapy_21\NN\1740 ,_22\,\1740 were_23\VBD\836236 well_24\RB\1740 tolerated_25\VBN\802318 ,_26\,\1740 and_27\CC\1740 were_28\VBD\836236 associated_29\VBN\628491 with_30\IN\1740 less_31\JJR\1740 <e2>hypokalemia</e2>_32\NN\14299637 than_33\IN\1740 hctz_34\NN\1740 alone_35\RB\1740 ._36\.\1740
D006852_D007008 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 population_5\NN\7942152 ,_6\,\1740 combination_7\NN\7951464 therapies_8\NNS\657604 with_9\IN\1740 val/hctz_10\NN\1740 were_11\VBD\836236 associated_12\VBN\628491 with_13\IN\1740 significantly_14\RB\1740 greater_15\JJR\1740 bp_16\NN\1740 reductions_17\NNS\351485 compared_18\VBN\644583 with_19\IN\1740 either_20\CC\1740 monotherapy_21\NN\1740 ,_22\,\1740 were_23\VBD\836236 well_24\RB\1740 tolerated_25\VBN\802318 ,_26\,\1740 and_27\CC\1740 were_28\VBD\836236 associated_29\VBN\628491 with_30\IN\1740 less_31\JJR\1740 <e2>hypokalemia</e2>_32\NN\14299637 than_33\IN\1740 <e1>hctz</e1>_34\NN\1740 alone_35\RB\1740 ._36\.\1740
24068571
D013874_D003693 CID the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>thiopentone</e1>_3\NN\1740 was_4\VBD\836236 significantly_5\RB\1740 associated_6\VBN\628491 with_7\IN\1740 an_8\DT\6697703 eight-fold-higher_9\NN\1740 risk_10\NN\14541044 for_11\IN\1740 <e2>delirium</e2>_12\NN\14391660 compared_13\VBN\644583 to_14\TO\1740 propofol_15\NN\1740 (_16\-LRB-\1740 57.1_17\CD\1740 %_18\NN\1740 vs._19\CC\1740 7.1_20\CD\1740 %_21\NN\1740 ,_22\,\1740 rr_23\NN\1740 =_24\JJ\1740 8.0_25\CD\1740 ,_26\,\1740 x2_27\NN\1740 =_28\JJ\1740 4.256_29\CD\1740 ;_30\:\1740 df_31\NN\1740 =_32\JJ\1740 1_33\CD\13741022 ;_34\:\1740 0.05_35\CD\1740 <_36\XX\1740 p_37\NN\14622893 <_38\XX\1740 0.02_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D015742_D003693 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 thiopentone_3\NN\1740 was_4\VBD\836236 significantly_5\RB\1740 associated_6\VBN\628491 with_7\IN\1740 an_8\DT\6697703 eight-fold-higher_9\NN\1740 risk_10\NN\14541044 for_11\IN\1740 <e2>delirium</e2>_12\NN\14391660 compared_13\VBN\644583 to_14\TO\1740 <e1>propofol</e1>_15\NN\1740 (_16\-LRB-\1740 57.1_17\CD\1740 %_18\NN\1740 vs._19\CC\1740 7.1_20\CD\1740 %_21\NN\1740 ,_22\,\1740 rr_23\NN\1740 =_24\JJ\1740 8.0_25\CD\1740 ,_26\,\1740 x2_27\NN\1740 =_28\JJ\1740 4.256_29\CD\1740 ;_30\:\1740 df_31\NN\1740 =_32\JJ\1740 1_33\CD\13741022 ;_34\:\1740 0.05_35\CD\1740 <_36\XX\1740 p_37\NN\14622893 <_38\XX\1740 0.02_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
10933650
D000666_D007674 NONE attenuation_0\NN\7427337 of_1\IN\1740 <e2>nephrotoxicity</e2>_2\NN\1740 by_3\IN\1740 a_4\DT\13649268 novel_5\JJ\1740 lipid_6\NN\14944888 nanosphere_7\RB\1740 (_8\-LRB-\1740 ns-718_9\NN\1740 )_10\-RRB-\1740 incorporating_11\VBG\1461328 <e1>amphotericin_12\NN\2716866 b.</e1>_13\NN\1740
D000666_D007674 NONE our_0\PRP$\1740 in_1\FW\13603305 vitro_2\FW\1740 and_3\CC\1740 in_4\FW\13603305 vivo_5\FW\1740 results_6\NNS\34213 suggest_7\VBP\1010118 that_8\IN\1740 incorporation_9\NN\1237415 of_10\IN\1740 <e1>amphotericin_11\NN\2716866 b</e1>_12\NN\1355326 into_13\IN\1740 lipid_14\NN\14944888 nanospheres_15\NNS\1740 of_16\IN\1740 ns-718_17\NN\1740 attenuates_18\VBZ\224901 the_19\DT\1740 <e2>nephrotoxicity</e2>_20\NN\1740 of_21\IN\1740 amphotericin_22\NN\2716866 b._23\NN\1740
D000666_D007674 NONE our_0\PRP$\1740 in_1\FW\13603305 vitro_2\FW\1740 and_3\CC\1740 in_4\FW\13603305 vivo_5\FW\1740 results_6\NNS\34213 suggest_7\VBP\1010118 that_8\IN\1740 incorporation_9\NN\1237415 of_10\IN\1740 amphotericin_11\NN\2716866 b_12\NN\1355326 into_13\IN\1740 lipid_14\NN\14944888 nanospheres_15\NNS\1740 of_16\IN\1740 ns-718_17\NN\1740 attenuates_18\VBZ\224901 the_19\DT\1740 <e2>nephrotoxicity</e2>_20\NN\1740 of_21\IN\1740 <e1>amphotericin_22\NN\2716866 b.</e1>_23\NN\1740
D000666_D064420 NONE ns-718_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 lipid_3\NN\14944888 nanosphere_4\RB\1740 incorporating_5\VBG\1461328 <e1>amphotericin_6\NN\2716866 b</e1>_7\NN\1355326 ,_8\,\1740 is_9\VBZ\836236 effective_10\JJ\1740 against_11\IN\1740 pathogenic_12\JJ\1740 fungi_13\NN\7940552 and_14\CC\1740 has_15\VBZ\2108377 low_16\JJ\1740 <e2>toxicity</e2>_17\NN\13576101 ._18\.\1740
D000666_D064420 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 ns-718_5\NN\1740 with_6\IN\1740 that_7\DT\1740 of_8\IN\1740 <e1>fungizone</e1>_9\NN\1740 (_10\-LRB-\1740 amphotericin_11\NN\2716866 b-sodium_12\NN\1740 deoxycholate_13\VBP\1740 ;_14\:\1740 d-amb_15\NN\1740 )_16\-RRB-\1740 in_17\FW\13603305 vitro_18\FW\1740 using_19\VBG\1156834 renal_20\JJ\1740 cell_21\NN\3080309 cultures_22\NNS\7966140 and_23\CC\1740 in_24\FW\13603305 vivo_25\FW\1740 by_26\IN\1740 biochemical_27\JJ\1740 analysis_28\NN\633864 ,_29\,\1740 histopathological_30\JJ\1740 study_31\NN\635850 of_32\IN\1740 the_33\DT\1740 kidney_34\NN\5333259 and_35\CC\1740 pharmacokinetic_36\JJ\1740 study_37\NN\635850 of_38\IN\1740 amphotericin_39\NN\2716866 b_40\NN\1355326 following_41\VBG\1835496 intravenous_42\JJ\1740 infusion_43\NN\14589223 of_44\IN\1740 the_45\DT\1740 formulation_46\NN\14818238 in_47\IN\13603305 rats_48\NNS\2329401 ._49\.\1740
D000666_D064420 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 ns-718_5\NN\1740 with_6\IN\1740 that_7\DT\1740 of_8\IN\1740 fungizone_9\NN\1740 (_10\-LRB-\1740 amphotericin_11\NN\2716866 b-sodium_12\NN\1740 deoxycholate_13\VBP\1740 ;_14\:\1740 d-amb_15\NN\1740 )_16\-RRB-\1740 in_17\FW\13603305 vitro_18\FW\1740 using_19\VBG\1156834 renal_20\JJ\1740 cell_21\NN\3080309 cultures_22\NNS\7966140 and_23\CC\1740 in_24\FW\13603305 vivo_25\FW\1740 by_26\IN\1740 biochemical_27\JJ\1740 analysis_28\NN\633864 ,_29\,\1740 histopathological_30\JJ\1740 study_31\NN\635850 of_32\IN\1740 the_33\DT\1740 kidney_34\NN\5333259 and_35\CC\1740 pharmacokinetic_36\JJ\1740 study_37\NN\635850 of_38\IN\1740 <e1>amphotericin_39\NN\2716866 b</e1>_40\NN\1355326 following_41\VBG\1835496 intravenous_42\JJ\1740 infusion_43\NN\14589223 of_44\IN\1740 the_45\DT\1740 formulation_46\NN\14818238 in_47\IN\13603305 rats_48\NNS\2329401 ._49\.\1740
C059765_D064420 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 ns-718_5\NN\1740 with_6\IN\1740 that_7\DT\1740 of_8\IN\1740 fungizone_9\NN\1740 (_10\-LRB-\1740 <e1>amphotericin_11\NN\2716866 b-sodium_12\NN\1740 deoxycholate</e1>_13\VBP\1740 ;_14\:\1740 d-amb_15\NN\1740 )_16\-RRB-\1740 in_17\FW\13603305 vitro_18\FW\1740 using_19\VBG\1156834 renal_20\JJ\1740 cell_21\NN\3080309 cultures_22\NNS\7966140 and_23\CC\1740 in_24\FW\13603305 vivo_25\FW\1740 by_26\IN\1740 biochemical_27\JJ\1740 analysis_28\NN\633864 ,_29\,\1740 histopathological_30\JJ\1740 study_31\NN\635850 of_32\IN\1740 the_33\DT\1740 kidney_34\NN\5333259 and_35\CC\1740 pharmacokinetic_36\JJ\1740 study_37\NN\635850 of_38\IN\1740 amphotericin_39\NN\2716866 b_40\NN\1355326 following_41\VBG\1835496 intravenous_42\JJ\1740 infusion_43\NN\14589223 of_44\IN\1740 the_45\DT\1740 formulation_46\NN\14818238 in_47\IN\13603305 rats_48\NNS\2329401 ._49\.\1740
C059765_D064420 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 ns-718_5\NN\1740 with_6\IN\1740 that_7\DT\1740 of_8\IN\1740 fungizone_9\NN\1740 (_10\-LRB-\1740 amphotericin_11\NN\2716866 b-sodium_12\NN\1740 deoxycholate_13\VBP\1740 ;_14\:\1740 <e1>d-amb</e1>_15\NN\1740 )_16\-RRB-\1740 in_17\FW\13603305 vitro_18\FW\1740 using_19\VBG\1156834 renal_20\JJ\1740 cell_21\NN\3080309 cultures_22\NNS\7966140 and_23\CC\1740 in_24\FW\13603305 vivo_25\FW\1740 by_26\IN\1740 biochemical_27\JJ\1740 analysis_28\NN\633864 ,_29\,\1740 histopathological_30\JJ\1740 study_31\NN\635850 of_32\IN\1740 the_33\DT\1740 kidney_34\NN\5333259 and_35\CC\1740 pharmacokinetic_36\JJ\1740 study_37\NN\635850 of_38\IN\1740 amphotericin_39\NN\2716866 b_40\NN\1355326 following_41\VBG\1835496 intravenous_42\JJ\1740 infusion_43\NN\14589223 of_44\IN\1740 the_45\DT\1740 formulation_46\NN\14818238 in_47\IN\13603305 rats_48\NNS\2329401 ._49\.\1740
C059765_D007683 CID histopathological_0\JJ\1740 examination_1\NN\633864 of_2\IN\1740 the_3\DT\1740 kidney_4\NN\5333259 showed_5\VBD\2137132 <e2>tubular_6\JJ\1740 necrosis</e2>_7\NN\11444117 in_8\IN\13603305 <e1>d-amb-treated</e1>_9\JJ\1740 rats_10\NNS\2329401 but_11\CC\1740 no_12\DT\7204911 change_13\NN\7283608 in_14\IN\13603305 ns-718-treated_15\JJ\1740 rats_16\NNS\2329401 ._17\.\1740
9881641
D005905_D007022 NONE <e1>glibenclamide-sensitive</e1>_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 produced_2\VBN\1617192 by_3\IN\1740 helodermin_4\NN\1740 assessed_5\VBN\670261 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 ._9\.\1740
D005905_D007022 NONE <e2>hypotension</e2>_0\NN\14057371 induced_1\VBN\1627355 by_2\IN\1740 both_3\DT\1740 peptides_4\NNS\14724264 was_5\VBD\836236 significantly_6\RB\1740 attenuated_7\VBN\224901 by_8\IN\1740 <e1>glibenclamide</e1>_9\NN\1740 ,_10\,\1740 which_11\WDT\1740 abolished_12\VBD\1740 a_13\DT\13649268 levcromakalim-produced_14\JJ\1740 decrease_15\NN\7296428 in_16\IN\13603305 arterial_17\JJ\1740 blood_18\NN\5397468 pressure_19\NN\11419404 ._20\.\1740
D005905_D007022 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 helodermin-produced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 is_6\VBZ\836236 partly_7\RB\1740 attributable_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 activation_11\NN\13561719 of_12\IN\1740 <e1>glibenclamide-sensitive</e1>_13\JJ\1740 k+_14\NN\1740 channels_15\NNS\6251781 (_16\-LRB-\1740 k(atp_17\JJ\1740 )_18\-RRB-\1740 channels_19\NNS\6251781 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 presumably_23\RB\1740 exist_24\VBP\1740 on_25\IN\1740 arterial_26\JJ\1740 smooth_27\JJ\1740 muscle_28\NN\5289601 cells_29\NNS\3080309 ._30\.\1740
C040442_D007022 CID glibenclamide-sensitive_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 produced_2\VBN\1617192 by_3\IN\1740 <e1>helodermin</e1>_4\NN\1740 assessed_5\VBN\670261 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 ._9\.\1740
C040442_D007022 CID <e1>helodermin</e1>_0\NNP\1740 produced_1\VBD\1617192 <e2>hypotension</e2>_2\NN\14057371 in_3\IN\13603305 a_4\DT\13649268 dose-dependent_5\JJ\1740 manner_6\NN\4916342 with_7\IN\1740 approximately_8\RB\1740 similar_9\JJ\1740 potency_10\NN\5196375 and_11\CC\1740 duration_12\NN\15113229 to_13\TO\1740 vip_14\NN\10200781 ._15\.\1740
C040442_D007022 CID oxyhemoglobin_0\NN\15024240 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 <e1>helodermin-induced</e1>_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 ,_6\,\1740 whereas_7\IN\1740 it_8\PRP\6125041 shortened_9\VBD\429060 the_10\DT\1740 duration_11\NN\15113229 of_12\IN\1740 acetylcholine_13\NN\14807558 (ach)-produced_14\VBN\1740 hypotension_15\NN\14057371 ._16\.\1740
C040442_D007022 CID oxyhemoglobin_0\NN\15024240 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 <e1>helodermin-induced</e1>_4\JJ\1740 hypotension_5\NN\14057371 ,_6\,\1740 whereas_7\IN\1740 it_8\PRP\6125041 shortened_9\VBD\429060 the_10\DT\1740 duration_11\NN\15113229 of_12\IN\1740 acetylcholine_13\NN\14807558 (ach)-produced_14\VBN\1740 <e2>hypotension</e2>_15\NN\14057371 ._16\.\1740
C040442_D007022 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>helodermin-produced</e1>_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 is_6\VBZ\836236 partly_7\RB\1740 attributable_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 activation_11\NN\13561719 of_12\IN\1740 glibenclamide-sensitive_13\JJ\1740 k+_14\NN\1740 channels_15\NNS\6251781 (_16\-LRB-\1740 k(atp_17\JJ\1740 )_18\-RRB-\1740 channels_19\NNS\6251781 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 presumably_23\RB\1740 exist_24\VBP\1740 on_25\IN\1740 arterial_26\JJ\1740 smooth_27\JJ\1740 muscle_28\NN\5289601 cells_29\NNS\3080309 ._30\.\1740
D019806_D007022 CID <e2>hypotension</e2>_0\NN\14057371 induced_1\VBN\1627355 by_2\IN\1740 both_3\DT\1740 peptides_4\NNS\14724264 was_5\VBD\836236 significantly_6\RB\1740 attenuated_7\VBN\224901 by_8\IN\1740 glibenclamide_9\NN\1740 ,_10\,\1740 which_11\WDT\1740 abolished_12\VBD\1740 a_13\DT\13649268 <e1>levcromakalim-produced</e1>_14\JJ\1740 decrease_15\NN\7296428 in_16\IN\13603305 arterial_17\JJ\1740 blood_18\NN\5397468 pressure_19\NN\11419404 ._20\.\1740
D000109_D007022 CID oxyhemoglobin_0\NN\15024240 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 helodermin-induced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 ,_6\,\1740 whereas_7\IN\1740 it_8\PRP\6125041 shortened_9\VBD\429060 the_10\DT\1740 duration_11\NN\15113229 of_12\IN\1740 <e1>acetylcholine</e1>_13\NN\14807558 (ach)-produced_14\VBN\1740 hypotension_15\NN\14057371 ._16\.\1740
D000109_D007022 CID oxyhemoglobin_0\NN\15024240 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 helodermin-induced_4\JJ\1740 hypotension_5\NN\14057371 ,_6\,\1740 whereas_7\IN\1740 it_8\PRP\6125041 shortened_9\VBD\429060 the_10\DT\1740 duration_11\NN\15113229 of_12\IN\1740 <e1>acetylcholine</e1>_13\NN\14807558 (ach)-produced_14\VBN\1740 <e2>hypotension</e2>_15\NN\14057371 ._16\.\1740
D000109_D007022 CID oxyhemoglobin_0\NN\15024240 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 helodermin-induced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 ,_6\,\1740 whereas_7\IN\1740 it_8\PRP\6125041 shortened_9\VBD\429060 the_10\DT\1740 duration_11\NN\15113229 of_12\IN\1740 acetylcholine_13\NN\14807558 <e1>(ach)-produced</e1>_14\VBN\1740 hypotension_15\NN\14057371 ._16\.\1740
D000109_D007022 CID oxyhemoglobin_0\NN\15024240 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 helodermin-induced_4\JJ\1740 hypotension_5\NN\14057371 ,_6\,\1740 whereas_7\IN\1740 it_8\PRP\6125041 shortened_9\VBD\429060 the_10\DT\1740 duration_11\NN\15113229 of_12\IN\1740 acetylcholine_13\NN\14807558 <e1>(ach)-produced</e1>_14\VBN\1740 <e2>hypotension</e2>_15\NN\14057371 ._16\.\1740
D011188_D007022 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 helodermin-produced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 is_6\VBZ\836236 partly_7\RB\1740 attributable_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 activation_11\NN\13561719 of_12\IN\1740 glibenclamide-sensitive_13\JJ\1740 <e1>k+</e1>_14\NN\1740 channels_15\NNS\6251781 (_16\-LRB-\1740 k(atp_17\JJ\1740 )_18\-RRB-\1740 channels_19\NNS\6251781 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 presumably_23\RB\1740 exist_24\VBP\1740 on_25\IN\1740 arterial_26\JJ\1740 smooth_27\JJ\1740 muscle_28\NN\5289601 cells_29\NNS\3080309 ._30\.\1740
D011188_D007022 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 helodermin-produced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 is_6\VBZ\836236 partly_7\RB\1740 attributable_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 activation_11\NN\13561719 of_12\IN\1740 glibenclamide-sensitive_13\JJ\1740 k+_14\NN\1740 channels_15\NNS\6251781 (_16\-LRB-\1740 <e1>k(atp</e1>_17\JJ\1740 )_18\-RRB-\1740 channels_19\NNS\6251781 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 presumably_23\RB\1740 exist_24\VBP\1740 on_25\IN\1740 arterial_26\JJ\1740 smooth_27\JJ\1740 muscle_28\NN\5289601 cells_29\NNS\3080309 ._30\.\1740
D000255_D007022 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 helodermin-produced_4\JJ\1740 <e2>hypotension</e2>_5\NN\14057371 is_6\VBZ\836236 partly_7\RB\1740 attributable_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 activation_11\NN\13561719 of_12\IN\1740 glibenclamide-sensitive_13\JJ\1740 k+_14\NN\1740 channels_15\NNS\6251781 (_16\-LRB-\1740 <e1>k(atp</e1>_17\JJ\1740 )_18\-RRB-\1740 channels_19\NNS\6251781 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 presumably_23\RB\1740 exist_24\VBP\1740 on_25\IN\1740 arterial_26\JJ\1740 smooth_27\JJ\1740 muscle_28\NN\5289601 cells_29\NNS\3080309 ._30\.\1740
D009569_D007022 NONE edrf_0\NN\1740 (_1\-LRB-\1740 endothelium-derived_2\JJ\1740 relaxing_3\VBG\146138 <e1>factor)/nitric_4\NN\1740 oxide</e1>_5\NN\14818238 does_6\VBZ\1640855 not_7\RB\1740 seem_8\VB\2604760 to_9\TO\1740 play_10\VB\1072262 an_11\DT\6697703 important_12\JJ\1740 role_13\NN\719494 in_14\IN\13603305 the_15\DT\1740 peptide-produced_16\JJ\1740 <e2>hypotension</e2>_17\NN\14057371 ._18\.\1740
1158089
D013752_D005234 CID <e2>fatty_0\JJ\1740 liver</e2>_1\NN\5298729 induced_2\VBN\1627355 by_3\IN\1740 <e1>tetracycline</e1>_4\NN\2716205 in_5\IN\13603305 the_6\DT\1740 rat_7\NN\2329401 ._8\.\1740
D013752_D005234 CID dose-response_0\JJ\1740 relationships_1\NNS\31921 ,_2\,\1740 biochemical_3\JJ\1740 mechanisms_4\NNS\13446390 ,_5\,\1740 and_6\CC\1740 sex_7\NN\13440063 differences_8\NNS\4723816 in_9\IN\13603305 the_10\DT\1740 experimental_11\JJ\1740 <e2>fatty_12\JJ\1740 liver</e2>_13\NN\5298729 induced_14\VBN\1627355 by_15\IN\1740 <e1>tetracycline</e1>_16\NN\2716205 were_17\VBD\836236 studied_18\VBN\630380 in_19\IN\13603305 the_20\DT\1740 intact_21\JJ\1740 rat_22\NN\2329401 and_23\CC\1740 with_24\IN\1740 the_25\DT\1740 isolated_26\VBN\2512305 perfused_27\JJ\1740 rat_28\NN\2329401 liver_29\NN\5298729 in_30\FW\13603305 vitro_31\FW\1740 ._32\.\1740
D013752_D005234 CID depressed_0\JJ\1740 hepatic_1\JJ\1740 secretion_2\NN\13526110 of_3\IN\1740 triglyceride_4\NN\14885088 accounted_5\VBD\2604760 only_6\RB\1740 for_7\IN\1740 30_8\CD\13745420 to_9\TO\1740 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 accumulated_13\VBN\2281093 hepatic_14\JJ\1740 triglyceride_15\NN\14885088 ,_16\,\1740 indicating_17\VBG\952524 that_18\IN\1740 additional_19\JJ\1740 mechanisms_20\NNS\13446390 must_21\MD\9367203 be_22\VB\836236 involved_23\VBN\2676054 in_24\IN\13603305 the_25\DT\1740 production_26\NN\30358 of_27\IN\1740 the_28\DT\1740 triglyceride-rich_29\JJ\1740 <e2>fatty_30\JJ\1740 liver</e2>_31\NN\5298729 in_32\IN\13603305 response_33\NN\11410625 to_34\TO\1740 <e1>tetracycline</e1>_35\NN\2716205 ._36\.\1740
D019301_D003866 NONE with_0\IN\1740 provision_1\NN\6755568 of_2\IN\1740 adequate_3\JJ\1740 <e1>oleic_4\JJ\1740 acid</e1>_5\NN\14818238 as_6\IN\14622893 a_7\DT\13649268 substrate_8\NN\19613 for_9\IN\1740 the_10\DT\1740 isolated_11\VBN\2512305 perfused_12\JJ\1740 liver_13\NN\5298729 ,_14\,\1740 a_15\DT\13649268 direct_16\JJ\1740 relationship_17\NN\31921 was_18\VBD\836236 observed_19\VBN\2163746 between_20\IN\1740 dose_21\NN\3740161 of_22\IN\1740 tetracycline_23\NN\2716205 and_24\CC\1740 both_25\CC\1740 accumulation_26\NN\13497135 of_27\IN\1740 triglyceride_28\NN\14885088 in_29\IN\13603305 the_30\DT\1740 liver_31\NN\5298729 and_32\CC\1740 <e2>depression</e2>_33\NN\14373582 of_34\IN\1740 output_35\NN\4007894 of_36\IN\1740 triglyceride_37\NN\14885088 by_38\IN\1740 livers_39\NNS\5298729 from_40\IN\1740 male_41\JJ\1740 and_42\CC\1740 female_43\JJ\1740 rats_44\NNS\2329401 ._45\.\1740
D013752_D003866 NONE with_0\IN\1740 provision_1\NN\6755568 of_2\IN\1740 adequate_3\JJ\1740 oleic_4\JJ\1740 acid_5\NN\14818238 as_6\IN\14622893 a_7\DT\13649268 substrate_8\NN\19613 for_9\IN\1740 the_10\DT\1740 isolated_11\VBN\2512305 perfused_12\JJ\1740 liver_13\NN\5298729 ,_14\,\1740 a_15\DT\13649268 direct_16\JJ\1740 relationship_17\NN\31921 was_18\VBD\836236 observed_19\VBN\2163746 between_20\IN\1740 dose_21\NN\3740161 of_22\IN\1740 <e1>tetracycline</e1>_23\NN\2716205 and_24\CC\1740 both_25\CC\1740 accumulation_26\NN\13497135 of_27\IN\1740 triglyceride_28\NN\14885088 in_29\IN\13603305 the_30\DT\1740 liver_31\NN\5298729 and_32\CC\1740 <e2>depression</e2>_33\NN\14373582 of_34\IN\1740 output_35\NN\4007894 of_36\IN\1740 triglyceride_37\NN\14885088 by_38\IN\1740 livers_39\NNS\5298729 from_40\IN\1740 male_41\JJ\1740 and_42\CC\1740 female_43\JJ\1740 rats_44\NNS\2329401 ._45\.\1740
D013752_D003866 NONE however_0\RB\1740 ,_1\,\1740 livers_2\NNS\5298729 from_3\IN\1740 female_4\NN\15388 ,_5\,\1740 and_6\CC\1740 especially_7\RB\1740 pregnant_8\JJ\1740 female_9\JJ\1740 rats_10\NNS\2329401 ,_11\,\1740 were_12\VBD\836236 strikingly_13\RB\1740 resistant_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 effects_17\NNS\13245626 of_18\IN\1740 <e1>tetracycline</e1>_19\NN\2716205 on_20\IN\1740 <e2>depression</e2>_21\NN\14373582 of_22\IN\1740 output_23\NN\4007894 of_24\IN\1740 triglyceride_25\NN\14885088 under_26\IN\1740 these_27\DT\1740 experimental_28\JJ\1740 conditions_29\NNS\14512817 ._30\.\1740
D014280_D003866 NONE with_0\IN\1740 provision_1\NN\6755568 of_2\IN\1740 adequate_3\JJ\1740 oleic_4\JJ\1740 acid_5\NN\14818238 as_6\IN\14622893 a_7\DT\13649268 substrate_8\NN\19613 for_9\IN\1740 the_10\DT\1740 isolated_11\VBN\2512305 perfused_12\JJ\1740 liver_13\NN\5298729 ,_14\,\1740 a_15\DT\13649268 direct_16\JJ\1740 relationship_17\NN\31921 was_18\VBD\836236 observed_19\VBN\2163746 between_20\IN\1740 dose_21\NN\3740161 of_22\IN\1740 tetracycline_23\NN\2716205 and_24\CC\1740 both_25\CC\1740 accumulation_26\NN\13497135 of_27\IN\1740 <e1>triglyceride</e1>_28\NN\14885088 in_29\IN\13603305 the_30\DT\1740 liver_31\NN\5298729 and_32\CC\1740 <e2>depression</e2>_33\NN\14373582 of_34\IN\1740 output_35\NN\4007894 of_36\IN\1740 triglyceride_37\NN\14885088 by_38\IN\1740 livers_39\NNS\5298729 from_40\IN\1740 male_41\JJ\1740 and_42\CC\1740 female_43\JJ\1740 rats_44\NNS\2329401 ._45\.\1740
D014280_D003866 NONE with_0\IN\1740 provision_1\NN\6755568 of_2\IN\1740 adequate_3\JJ\1740 oleic_4\JJ\1740 acid_5\NN\14818238 as_6\IN\14622893 a_7\DT\13649268 substrate_8\NN\19613 for_9\IN\1740 the_10\DT\1740 isolated_11\VBN\2512305 perfused_12\JJ\1740 liver_13\NN\5298729 ,_14\,\1740 a_15\DT\13649268 direct_16\JJ\1740 relationship_17\NN\31921 was_18\VBD\836236 observed_19\VBN\2163746 between_20\IN\1740 dose_21\NN\3740161 of_22\IN\1740 tetracycline_23\NN\2716205 and_24\CC\1740 both_25\CC\1740 accumulation_26\NN\13497135 of_27\IN\1740 triglyceride_28\NN\14885088 in_29\IN\13603305 the_30\DT\1740 liver_31\NN\5298729 and_32\CC\1740 <e2>depression</e2>_33\NN\14373582 of_34\IN\1740 output_35\NN\4007894 of_36\IN\1740 <e1>triglyceride</e1>_37\NN\14885088 by_38\IN\1740 livers_39\NNS\5298729 from_40\IN\1740 male_41\JJ\1740 and_42\CC\1740 female_43\JJ\1740 rats_44\NNS\2329401 ._45\.\1740
D014280_D003866 NONE however_0\RB\1740 ,_1\,\1740 livers_2\NNS\5298729 from_3\IN\1740 female_4\NN\15388 ,_5\,\1740 and_6\CC\1740 especially_7\RB\1740 pregnant_8\JJ\1740 female_9\JJ\1740 rats_10\NNS\2329401 ,_11\,\1740 were_12\VBD\836236 strikingly_13\RB\1740 resistant_14\JJ\1740 to_15\TO\1740 the_16\DT\1740 effects_17\NNS\13245626 of_18\IN\1740 tetracycline_19\NN\2716205 on_20\IN\1740 <e2>depression</e2>_21\NN\14373582 of_22\IN\1740 output_23\NN\4007894 of_24\IN\1740 <e1>triglyceride</e1>_25\NN\14885088 under_26\IN\1740 these_27\DT\1740 experimental_28\JJ\1740 conditions_29\NNS\14512817 ._30\.\1740
D014280_D005234 NONE depressed_0\JJ\1740 hepatic_1\JJ\1740 secretion_2\NN\13526110 of_3\IN\1740 <e1>triglyceride</e1>_4\NN\14885088 accounted_5\VBD\2604760 only_6\RB\1740 for_7\IN\1740 30_8\CD\13745420 to_9\TO\1740 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 accumulated_13\VBN\2281093 hepatic_14\JJ\1740 triglyceride_15\NN\14885088 ,_16\,\1740 indicating_17\VBG\952524 that_18\IN\1740 additional_19\JJ\1740 mechanisms_20\NNS\13446390 must_21\MD\9367203 be_22\VB\836236 involved_23\VBN\2676054 in_24\IN\13603305 the_25\DT\1740 production_26\NN\30358 of_27\IN\1740 the_28\DT\1740 triglyceride-rich_29\JJ\1740 <e2>fatty_30\JJ\1740 liver</e2>_31\NN\5298729 in_32\IN\13603305 response_33\NN\11410625 to_34\TO\1740 tetracycline_35\NN\2716205 ._36\.\1740
D014280_D005234 NONE depressed_0\JJ\1740 hepatic_1\JJ\1740 secretion_2\NN\13526110 of_3\IN\1740 triglyceride_4\NN\14885088 accounted_5\VBD\2604760 only_6\RB\1740 for_7\IN\1740 30_8\CD\13745420 to_9\TO\1740 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 accumulated_13\VBN\2281093 hepatic_14\JJ\1740 <e1>triglyceride</e1>_15\NN\14885088 ,_16\,\1740 indicating_17\VBG\952524 that_18\IN\1740 additional_19\JJ\1740 mechanisms_20\NNS\13446390 must_21\MD\9367203 be_22\VB\836236 involved_23\VBN\2676054 in_24\IN\13603305 the_25\DT\1740 production_26\NN\30358 of_27\IN\1740 the_28\DT\1740 triglyceride-rich_29\JJ\1740 <e2>fatty_30\JJ\1740 liver</e2>_31\NN\5298729 in_32\IN\13603305 response_33\NN\11410625 to_34\TO\1740 tetracycline_35\NN\2716205 ._36\.\1740
D014280_D005234 NONE depressed_0\JJ\1740 hepatic_1\JJ\1740 secretion_2\NN\13526110 of_3\IN\1740 triglyceride_4\NN\14885088 accounted_5\VBD\2604760 only_6\RB\1740 for_7\IN\1740 30_8\CD\13745420 to_9\TO\1740 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 accumulated_13\VBN\2281093 hepatic_14\JJ\1740 triglyceride_15\NN\14885088 ,_16\,\1740 indicating_17\VBG\952524 that_18\IN\1740 additional_19\JJ\1740 mechanisms_20\NNS\13446390 must_21\MD\9367203 be_22\VB\836236 involved_23\VBN\2676054 in_24\IN\13603305 the_25\DT\1740 production_26\NN\30358 of_27\IN\1740 the_28\DT\1740 <e1>triglyceride-rich</e1>_29\JJ\1740 <e2>fatty_30\JJ\1740 liver</e2>_31\NN\5298729 in_32\IN\13603305 response_33\NN\11410625 to_34\TO\1740 tetracycline_35\NN\2716205 ._36\.\1740
1289188
D003676_D058186 NONE <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 occurring_3\VBG\2623529 during_4\IN\1740 intravenous_5\JJ\1740 <e1>desferrioxamine</e1>_6\NN\1740 therapy_7\NN\657604 :_8\:\1740 recovery_9\NN\7357388 after_10\IN\1740 haemodialysis_11\NN\649760 ._12\.\1740
D003676_D058186 NONE from_0\IN\1740 the_1\DT\1740 results_2\NNS\34213 obtained_3\VBN\2210855 ,_4\,\1740 haemodialysis_5\NN\649760 can_6\MD\3094503 therefore_7\RB\1740 be_8\VB\836236 suggested_9\VBN\1010118 as_10\IN\14622893 a_11\DT\13649268 useful_12\JJ\1740 therapy_13\NN\657604 in_14\IN\13603305 rare_15\JJ\1740 cases_16\NNS\7283608 of_17\IN\1740 progressive_18\JJ\1740 <e2>acute_19\JJ\1740 renal_20\JJ\1740 failure</e2>_21\NN\66216 caused_22\VBN\1617192 by_23\IN\1740 <e1>desferrioxamine</e1>_24\NN\1740 ._25\.\1740
D003676_D013789 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 transfusion-dependent_3\JJ\1740 <e2>thalassemia</e2>_4\NN\14165544 was_5\VBD\836236 undergoing_6\VBG\109660 home_7\NN\8558963 intravenous_8\JJ\1740 <e1>desferrioxamine</e1>_9\NN\1740 (_10\-LRB-\1740 dfx_11\NN\1740 )_12\-RRB-\1740 treatment_13\NN\654885 by_14\IN\1740 means_15\NNS\44150 of_16\IN\1740 a_17\DT\13649268 totally_18\RB\1740 implanted_19\JJ\1740 system_20\NN\3575240 because_21\IN\1740 of_22\IN\1740 his_23\PRP$\1740 poor_24\JJ\1740 compliance_25\NN\1202904 with_26\IN\1740 the_27\DT\1740 nightly_28\RB\1740 subcutaneous_29\JJ\1740 therapy_30\NN\657604 ._31\.\1740
D003676_D013789 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 transfusion-dependent_3\JJ\1740 <e2>thalassemia</e2>_4\NN\14165544 was_5\VBD\836236 undergoing_6\VBG\109660 home_7\NN\8558963 intravenous_8\JJ\1740 desferrioxamine_9\NN\1740 (_10\-LRB-\1740 <e1>dfx</e1>_11\NN\1740 )_12\-RRB-\1740 treatment_13\NN\654885 by_14\IN\1740 means_15\NNS\44150 of_16\IN\1740 a_17\DT\13649268 totally_18\RB\1740 implanted_19\JJ\1740 system_20\NN\3575240 because_21\IN\1740 of_22\IN\1740 his_23\PRP$\1740 poor_24\JJ\1740 compliance_25\NN\1202904 with_26\IN\1740 the_27\DT\1740 nightly_28\RB\1740 subcutaneous_29\JJ\1740 therapy_30\NN\657604 ._31\.\1740
24309294
D012844_D000647 NONE we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 reported_3\VBN\831651 that_4\IN\1740 <e1>cck-8</e1>_5\NN\1740 significantly_6\RB\1740 alleviated_7\VBD\205885 morphine-induced_8\JJ\1740 <e2>amnesia</e2>_9\NN\5669934 and_10\CC\1740 reversed_11\VBN\109660 spine_12\NN\5585665 density_13\NN\4941325 decreases_14\VBZ\169651 in_15\IN\13603305 the_16\DT\1740 ca1_17\NN\1740 region_18\NN\27167 of_19\IN\1740 the_20\DT\1740 hippocampus_21\NN\5462674 in_22\IN\13603305 morphine-treated_23\JJ\1740 animals_24\NNS\4475 ._25\.\1740
D009020_D000647 CID we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 reported_3\VBN\831651 that_4\IN\1740 cck-8_5\NN\1740 significantly_6\RB\1740 alleviated_7\VBD\205885 <e1>morphine-induced</e1>_8\JJ\1740 <e2>amnesia</e2>_9\NN\5669934 and_10\CC\1740 reversed_11\VBN\109660 spine_12\NN\5585665 density_13\NN\4941325 decreases_14\VBZ\169651 in_15\IN\13603305 the_16\DT\1740 ca1_17\NN\1740 region_18\NN\27167 of_19\IN\1740 the_20\DT\1740 hippocampus_21\NN\5462674 in_22\IN\13603305 morphine-treated_23\JJ\1740 animals_24\NNS\4475 ._25\.\1740
D009020_D000647 CID we_0\PRP\1740 have_1\VBP\2108377 previously_2\RB\1740 reported_3\VBN\831651 that_4\IN\1740 cck-8_5\NN\1740 significantly_6\RB\1740 alleviated_7\VBD\205885 morphine-induced_8\JJ\1740 <e2>amnesia</e2>_9\NN\5669934 and_10\CC\1740 reversed_11\VBN\109660 spine_12\NN\5585665 density_13\NN\4941325 decreases_14\VBZ\169651 in_15\IN\13603305 the_16\DT\1740 ca1_17\NN\1740 region_18\NN\27167 of_19\IN\1740 the_20\DT\1740 hippocampus_21\NN\5462674 in_22\IN\13603305 <e1>morphine-treated</e1>_23\JJ\1740 animals_24\NNS\4475 ._25\.\1740
D012844_D008569 NONE the_0\DT\1740 present_1\JJ\1740 results_2\NNS\34213 demonstrate_3\VBP\2137132 that_4\IN\1740 <e1>cck-8</e1>_5\NN\1740 attenuates_6\VBZ\224901 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 morphine_10\NN\2707683 on_11\IN\1740 hippocampal_12\NN\1740 ltp_13\NNP\1740 through_14\IN\1740 cck2_15\NN\1740 receptors_16\NNS\5225602 and_17\CC\1740 suggest_18\VBP\1010118 an_19\DT\6697703 ameliorative_20\JJ\1740 function_21\NN\13783581 of_22\IN\1740 cck-8_23\NN\1740 on_24\IN\1740 morphine-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
D012844_D008569 NONE the_0\DT\1740 present_1\JJ\1740 results_2\NNS\34213 demonstrate_3\VBP\2137132 that_4\IN\1740 cck-8_5\NN\1740 attenuates_6\VBZ\224901 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 morphine_10\NN\2707683 on_11\IN\1740 hippocampal_12\NN\1740 ltp_13\NNP\1740 through_14\IN\1740 cck2_15\NN\1740 receptors_16\NNS\5225602 and_17\CC\1740 suggest_18\VBP\1010118 an_19\DT\6697703 ameliorative_20\JJ\1740 function_21\NN\13783581 of_22\IN\1740 <e1>cck-8</e1>_23\NN\1740 on_24\IN\1740 morphine-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
D009020_D008569 NONE the_0\DT\1740 present_1\JJ\1740 results_2\NNS\34213 demonstrate_3\VBP\2137132 that_4\IN\1740 cck-8_5\NN\1740 attenuates_6\VBZ\224901 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 <e1>morphine</e1>_10\NN\2707683 on_11\IN\1740 hippocampal_12\NN\1740 ltp_13\NNP\1740 through_14\IN\1740 cck2_15\NN\1740 receptors_16\NNS\5225602 and_17\CC\1740 suggest_18\VBP\1010118 an_19\DT\6697703 ameliorative_20\JJ\1740 function_21\NN\13783581 of_22\IN\1740 cck-8_23\NN\1740 on_24\IN\1740 morphine-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
D009020_D008569 NONE the_0\DT\1740 present_1\JJ\1740 results_2\NNS\34213 demonstrate_3\VBP\2137132 that_4\IN\1740 cck-8_5\NN\1740 attenuates_6\VBZ\224901 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 morphine_10\NN\2707683 on_11\IN\1740 hippocampal_12\NN\1740 ltp_13\NNP\1740 through_14\IN\1740 cck2_15\NN\1740 receptors_16\NNS\5225602 and_17\CC\1740 suggest_18\VBP\1010118 an_19\DT\6697703 ameliorative_20\JJ\1740 function_21\NN\13783581 of_22\IN\1740 cck-8_23\NN\1740 on_24\IN\1740 <e1>morphine-induced</e1>_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
15630069
D005947_D012559 NONE <e1>glucose</e1>_0\NN\14710501 metabolism_1\NN\13526110 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 <e2>schizophrenia</e2>_5\NN\14398067 treated_6\VBN\2376958 with_7\IN\1740 atypical_8\JJ\1740 antipsychotic_9\JJ\1740 agents_10\NNS\7347 :_11\:\1740 a_12\DT\13649268 frequently_13\RB\1740 sampled_14\VBN\1156834 intravenous_15\JJ\1740 glucose_16\NN\14710501 tolerance_17\NN\5032565 test_18\NN\5798043 and_19\CC\1740 minimal_20\JJ\1740 model_21\NN\5888929 analysis_22\NN\633864 ._23\.\1740
D005947_D012559 NONE glucose_0\NN\14710501 metabolism_1\NN\13526110 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 <e2>schizophrenia</e2>_5\NN\14398067 treated_6\VBN\2376958 with_7\IN\1740 atypical_8\JJ\1740 antipsychotic_9\JJ\1740 agents_10\NNS\7347 :_11\:\1740 a_12\DT\13649268 frequently_13\RB\1740 sampled_14\VBN\1156834 intravenous_15\JJ\1740 <e1>glucose</e1>_16\NN\14710501 tolerance_17\NN\5032565 test_18\NN\5798043 and_19\CC\1740 minimal_20\JJ\1740 model_21\NN\5888929 analysis_22\NN\633864 ._23\.\1740
D005947_D012559 NONE background_0\NN\4921011 :_1\:\1740 while_2\IN\15122231 the_3\DT\1740 incidence_4\NN\13821570 of_5\IN\1740 new-onset_6\JJ\1740 diabetes_7\NN\14075199 mellitus_8\NN\1740 may_9\MD\15209706 be_10\VB\836236 increasing_11\VBG\169651 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>schizophrenia</e2>_15\NN\14398067 treated_16\VBN\2376958 with_17\IN\1740 certain_18\JJ\1740 atypical_19\JJ\1740 antipsychotic_20\JJ\1740 agents_21\NNS\7347 ,_22\,\1740 it_23\PRP\6125041 remains_24\VBZ\2604760 unclear_25\JJ\1740 whether_26\IN\1740 atypical_27\JJ\1740 agents_28\NNS\7347 are_29\VBP\836236 directly_30\RB\1740 affecting_31\VBG\126264 <e1>glucose</e1>_32\NN\14710501 metabolism_33\NN\13526110 or_34\CC\3541091 simply_35\RB\1740 increasing_36\VBG\169651 known_37\JJ\1740 risk_38\NN\14541044 factors_39\NNS\7326557 for_40\IN\1740 diabetes_41\NNS\14075199 ._42\.\1740
D005947_D012559 NONE design_0\NN\927261 :_1\:\1740 a_2\DT\13649268 cross-sectional_3\JJ\1740 design_4\NN\927261 in_5\IN\13603305 stable_6\JJ\1740 ,_7\,\1740 treated_8\VBN\2376958 patients_9\NNS\9898892 with_10\IN\1740 <e2>schizophrenia</e2>_11\NN\14398067 evaluated_12\VBN\670261 using_13\VBG\1156834 a_14\DT\13649268 frequently_15\RB\1740 sampled_16\VBN\1156834 intravenous_17\JJ\1740 <e1>glucose</e1>_18\NN\14710501 tolerance_19\NN\5032565 test_20\NN\5798043 and_21\CC\1740 the_22\DT\1740 bergman_23\NNP\1740 minimal_24\JJ\1740 model_25\NN\5888929 analysis_26\NN\633864 ._27\.\1740
D005947_D003920 NONE background_0\NN\4921011 :_1\:\1740 while_2\IN\15122231 the_3\DT\1740 incidence_4\NN\13821570 of_5\IN\1740 new-onset_6\JJ\1740 <e2>diabetes_7\NN\14075199 mellitus</e2>_8\NN\1740 may_9\MD\15209706 be_10\VB\836236 increasing_11\VBG\169651 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 schizophrenia_15\NN\14398067 treated_16\VBN\2376958 with_17\IN\1740 certain_18\JJ\1740 atypical_19\JJ\1740 antipsychotic_20\JJ\1740 agents_21\NNS\7347 ,_22\,\1740 it_23\PRP\6125041 remains_24\VBZ\2604760 unclear_25\JJ\1740 whether_26\IN\1740 atypical_27\JJ\1740 agents_28\NNS\7347 are_29\VBP\836236 directly_30\RB\1740 affecting_31\VBG\126264 <e1>glucose</e1>_32\NN\14710501 metabolism_33\NN\13526110 or_34\CC\3541091 simply_35\RB\1740 increasing_36\VBG\169651 known_37\JJ\1740 risk_38\NN\14541044 factors_39\NNS\7326557 for_40\IN\1740 diabetes_41\NNS\14075199 ._42\.\1740
D005947_D003920 NONE background_0\NN\4921011 :_1\:\1740 while_2\IN\15122231 the_3\DT\1740 incidence_4\NN\13821570 of_5\IN\1740 new-onset_6\JJ\1740 diabetes_7\NN\14075199 mellitus_8\NN\1740 may_9\MD\15209706 be_10\VB\836236 increasing_11\VBG\169651 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 schizophrenia_15\NN\14398067 treated_16\VBN\2376958 with_17\IN\1740 certain_18\JJ\1740 atypical_19\JJ\1740 antipsychotic_20\JJ\1740 agents_21\NNS\7347 ,_22\,\1740 it_23\PRP\6125041 remains_24\VBZ\2604760 unclear_25\JJ\1740 whether_26\IN\1740 atypical_27\JJ\1740 agents_28\NNS\7347 are_29\VBP\836236 directly_30\RB\1740 affecting_31\VBG\126264 <e1>glucose</e1>_32\NN\14710501 metabolism_33\NN\13526110 or_34\CC\3541091 simply_35\RB\1740 increasing_36\VBG\169651 known_37\JJ\1740 risk_38\NN\14541044 factors_39\NNS\7326557 for_40\IN\1740 <e2>diabetes</e2>_41\NNS\14075199 ._42\.\1740
D003024_D012559 NONE thirty-six_0\CD\1740 nonobese_1\JJ\1740 subjects_2\NNS\6598915 with_3\IN\1740 <e2>schizophrenia</e2>_4\NN\14398067 or_5\CC\3541091 schizoaffective_6\JJ\1740 disorder_7\NN\14034177 ,_8\,\1740 matched_9\VBN\2664769 by_10\IN\1740 body_11\NN\19128 mass_12\NN\13575869 index_13\NN\13850304 and_14\CC\1740 treated_15\VBN\2376958 with_16\IN\1740 either_17\DT\1740 <e1>clozapine</e1>_18\NN\3713736 ,_19\,\1740 olanzapine_20\NN\1740 ,_21\,\1740 or_22\CC\3541091 risperidone_23\NN\1740 ,_24\,\1740 were_25\VBD\836236 included_26\VBN\690614 in_27\IN\13603305 the_28\DT\1740 analysis_29\NN\633864 ._30\.\1740
D003024_D011618 NONE thirty-six_0\CD\1740 nonobese_1\JJ\1740 subjects_2\NNS\6598915 with_3\IN\1740 schizophrenia_4\NN\14398067 or_5\CC\3541091 <e2>schizoaffective_6\JJ\1740 disorder</e2>_7\NN\14034177 ,_8\,\1740 matched_9\VBN\2664769 by_10\IN\1740 body_11\NN\19128 mass_12\NN\13575869 index_13\NN\13850304 and_14\CC\1740 treated_15\VBN\2376958 with_16\IN\1740 either_17\DT\1740 <e1>clozapine</e1>_18\NN\3713736 ,_19\,\1740 olanzapine_20\NN\1740 ,_21\,\1740 or_22\CC\3541091 risperidone_23\NN\1740 ,_24\,\1740 were_25\VBD\836236 included_26\VBN\690614 in_27\IN\13603305 the_28\DT\1740 analysis_29\NN\633864 ._30\.\1740
C076029_D012559 NONE thirty-six_0\CD\1740 nonobese_1\JJ\1740 subjects_2\NNS\6598915 with_3\IN\1740 <e2>schizophrenia</e2>_4\NN\14398067 or_5\CC\3541091 schizoaffective_6\JJ\1740 disorder_7\NN\14034177 ,_8\,\1740 matched_9\VBN\2664769 by_10\IN\1740 body_11\NN\19128 mass_12\NN\13575869 index_13\NN\13850304 and_14\CC\1740 treated_15\VBN\2376958 with_16\IN\1740 either_17\DT\1740 clozapine_18\NN\3713736 ,_19\,\1740 <e1>olanzapine</e1>_20\NN\1740 ,_21\,\1740 or_22\CC\3541091 risperidone_23\NN\1740 ,_24\,\1740 were_25\VBD\836236 included_26\VBN\690614 in_27\IN\13603305 the_28\DT\1740 analysis_29\NN\633864 ._30\.\1740
C076029_D011618 NONE thirty-six_0\CD\1740 nonobese_1\JJ\1740 subjects_2\NNS\6598915 with_3\IN\1740 schizophrenia_4\NN\14398067 or_5\CC\3541091 <e2>schizoaffective_6\JJ\1740 disorder</e2>_7\NN\14034177 ,_8\,\1740 matched_9\VBN\2664769 by_10\IN\1740 body_11\NN\19128 mass_12\NN\13575869 index_13\NN\13850304 and_14\CC\1740 treated_15\VBN\2376958 with_16\IN\1740 either_17\DT\1740 clozapine_18\NN\3713736 ,_19\,\1740 <e1>olanzapine</e1>_20\NN\1740 ,_21\,\1740 or_22\CC\3541091 risperidone_23\NN\1740 ,_24\,\1740 were_25\VBD\836236 included_26\VBN\690614 in_27\IN\13603305 the_28\DT\1740 analysis_29\NN\633864 ._30\.\1740
D018967_D012559 NONE thirty-six_0\CD\1740 nonobese_1\JJ\1740 subjects_2\NNS\6598915 with_3\IN\1740 <e2>schizophrenia</e2>_4\NN\14398067 or_5\CC\3541091 schizoaffective_6\JJ\1740 disorder_7\NN\14034177 ,_8\,\1740 matched_9\VBN\2664769 by_10\IN\1740 body_11\NN\19128 mass_12\NN\13575869 index_13\NN\13850304 and_14\CC\1740 treated_15\VBN\2376958 with_16\IN\1740 either_17\DT\1740 clozapine_18\NN\3713736 ,_19\,\1740 olanzapine_20\NN\1740 ,_21\,\1740 or_22\CC\3541091 <e1>risperidone</e1>_23\NN\1740 ,_24\,\1740 were_25\VBD\836236 included_26\VBN\690614 in_27\IN\13603305 the_28\DT\1740 analysis_29\NN\633864 ._30\.\1740
D018967_D011618 NONE thirty-six_0\CD\1740 nonobese_1\JJ\1740 subjects_2\NNS\6598915 with_3\IN\1740 schizophrenia_4\NN\14398067 or_5\CC\3541091 <e2>schizoaffective_6\JJ\1740 disorder</e2>_7\NN\14034177 ,_8\,\1740 matched_9\VBN\2664769 by_10\IN\1740 body_11\NN\19128 mass_12\NN\13575869 index_13\NN\13850304 and_14\CC\1740 treated_15\VBN\2376958 with_16\IN\1740 either_17\DT\1740 clozapine_18\NN\3713736 ,_19\,\1740 olanzapine_20\NN\1740 ,_21\,\1740 or_22\CC\3541091 <e1>risperidone</e1>_23\NN\1740 ,_24\,\1740 were_25\VBD\836236 included_26\VBN\690614 in_27\IN\13603305 the_28\DT\1740 analysis_29\NN\633864 ._30\.\1740
D005947_D007333 NONE main_0\NNP\9225146 outcome_1\NN\7291312 measures_2\NN\168237 :_3\:\1740 fasting_4\VBG\1196037 plasma_5\NN\5398023 <e1>glucose</e1>_6\NN\14710501 and_7\CC\1740 fasting_8\VBG\1196037 serum_9\NN\5397468 insulin_10\NN\5407119 levels_11\NNS\4916342 ,_12\,\1740 <e2>insulin_13\NN\5407119 sensitivity</e2>_14\NN\5651971 index_15\NN\13850304 ,_16\,\1740 homeostasis_17\NN\13934900 model_18\NN\5888929 assessment_19\NN\5732756 of_20\IN\1740 insulin_21\NN\5407119 resistance_22\NN\37396 ,_23\,\1740 and_24\CC\1740 glucose_25\NN\14710501 effectiveness_26\NN\5190804 ._27\.\1740
D005947_D007333 NONE main_0\NNP\9225146 outcome_1\NN\7291312 measures_2\NN\168237 :_3\:\1740 fasting_4\VBG\1196037 plasma_5\NN\5398023 <e1>glucose</e1>_6\NN\14710501 and_7\CC\1740 fasting_8\VBG\1196037 serum_9\NN\5397468 insulin_10\NN\5407119 levels_11\NNS\4916342 ,_12\,\1740 insulin_13\NN\5407119 sensitivity_14\NN\5651971 index_15\NN\13850304 ,_16\,\1740 homeostasis_17\NN\13934900 model_18\NN\5888929 assessment_19\NN\5732756 of_20\IN\1740 <e2>insulin_21\NN\5407119 resistance</e2>_22\NN\37396 ,_23\,\1740 and_24\CC\1740 glucose_25\NN\14710501 effectiveness_26\NN\5190804 ._27\.\1740
D005947_D007333 NONE main_0\NNP\9225146 outcome_1\NN\7291312 measures_2\NN\168237 :_3\:\1740 fasting_4\VBG\1196037 plasma_5\NN\5398023 glucose_6\NN\14710501 and_7\CC\1740 fasting_8\VBG\1196037 serum_9\NN\5397468 insulin_10\NN\5407119 levels_11\NNS\4916342 ,_12\,\1740 <e2>insulin_13\NN\5407119 sensitivity</e2>_14\NN\5651971 index_15\NN\13850304 ,_16\,\1740 homeostasis_17\NN\13934900 model_18\NN\5888929 assessment_19\NN\5732756 of_20\IN\1740 insulin_21\NN\5407119 resistance_22\NN\37396 ,_23\,\1740 and_24\CC\1740 <e1>glucose</e1>_25\NN\14710501 effectiveness_26\NN\5190804 ._27\.\1740
D005947_D007333 NONE main_0\NNP\9225146 outcome_1\NN\7291312 measures_2\NN\168237 :_3\:\1740 fasting_4\VBG\1196037 plasma_5\NN\5398023 glucose_6\NN\14710501 and_7\CC\1740 fasting_8\VBG\1196037 serum_9\NN\5397468 insulin_10\NN\5407119 levels_11\NNS\4916342 ,_12\,\1740 insulin_13\NN\5407119 sensitivity_14\NN\5651971 index_15\NN\13850304 ,_16\,\1740 homeostasis_17\NN\13934900 model_18\NN\5888929 assessment_19\NN\5732756 of_20\IN\1740 <e2>insulin_21\NN\5407119 resistance</e2>_22\NN\37396 ,_23\,\1740 and_24\CC\1740 <e1>glucose</e1>_25\NN\14710501 effectiveness_26\NN\5190804 ._27\.\1740
D005947_D007333 NONE conclusions_0\NNS\5837957 :_1\:\1740 both_2\DT\1740 nonobese_3\JJ\1740 clozapine-_4\NN\1740 and_5\CC\1740 olanzapine-treated_6\JJ\1740 groups_7\NNS\2137 displayed_8\VBD\2137132 significant_9\JJ\1740 <e2>insulin_10\NN\5407119 resistance</e2>_11\NN\37396 and_12\CC\1740 impairment_13\NN\7296428 of_14\IN\1740 <e1>glucose</e1>_15\NN\14710501 effectiveness_16\NN\5190804 compared_17\VBN\644583 with_18\IN\1740 risperidone-treated_19\JJ\1740 subjects_20\NNS\6598915 ._21\.\1740
D003024_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 <e1>clozapine</e1>_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D003024_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 <e1>clozapine</e1>_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D003024_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 <e1>clozapine</e1>_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D003024_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 <e1>clozapine</e1>_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D003024_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 <e1>clozapine</e1>_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D003024_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 <e1>clozapine</e1>_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D003024_D007333 CID the_0\DT\1740 homeostasis_1\NN\13934900 model_2\NN\5888929 assessment_3\NN\5732756 of_4\IN\1740 <e2>insulin_5\NN\5407119 resistance</e2>_6\NN\37396 also_7\RB\1740 differed_8\VBD\1740 significantly_9\RB\1740 among_10\IN\1740 groups_11\NNS\2137 (_12\-LRB-\1740 f(33_13\NN\1740 )_14\-RRB-\1740 =_15\JJ\1740 4.92_16\CD\1740 ;_17\:\1740 p_18\NN\14622893 =_19\JJ\1740 .01_20\CD\1740 )_21\-RRB-\1740 (_22\-LRB-\1740 <e1>clozapine</e1>_23\NN\3713736 >_24\NN\1740 olanzapine_25\NN\1740 >_26\NN\1740 risperidone_27\NN\1740 )_28\-RRB-\1740 (_29\-LRB-\1740 clozapine_30\NN\3713736 vs_31\CC\13634784 risperidone_32\NN\1740 ,_33\,\1740 t(33_34\NN\1740 )_35\-RRB-\1740 =_36\JJ\1740 2.94_37\CD\1740 ;_38\:\1740 p_39\NN\14622893 =_40\JJ\1740 .006_41\CD\1740 ;_42\:\1740 olanzapine_43\NN\1740 vs_44\CC\13634784 risperidone_45\NN\1740 ,_46\,\1740 t(33_47\NN\1740 )_48\-RRB-\1740 =_49\JJ\1740 2.42_50\CD\1740 ;_51\:\1740 p_52\NN\14622893 =_53\JJ\1740 .02_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
D003024_D007333 CID the_0\DT\1740 homeostasis_1\NN\13934900 model_2\NN\5888929 assessment_3\NN\5732756 of_4\IN\1740 <e2>insulin_5\NN\5407119 resistance</e2>_6\NN\37396 also_7\RB\1740 differed_8\VBD\1740 significantly_9\RB\1740 among_10\IN\1740 groups_11\NNS\2137 (_12\-LRB-\1740 f(33_13\NN\1740 )_14\-RRB-\1740 =_15\JJ\1740 4.92_16\CD\1740 ;_17\:\1740 p_18\NN\14622893 =_19\JJ\1740 .01_20\CD\1740 )_21\-RRB-\1740 (_22\-LRB-\1740 clozapine_23\NN\3713736 >_24\NN\1740 olanzapine_25\NN\1740 >_26\NN\1740 risperidone_27\NN\1740 )_28\-RRB-\1740 (_29\-LRB-\1740 <e1>clozapine</e1>_30\NN\3713736 vs_31\CC\13634784 risperidone_32\NN\1740 ,_33\,\1740 t(33_34\NN\1740 )_35\-RRB-\1740 =_36\JJ\1740 2.94_37\CD\1740 ;_38\:\1740 p_39\NN\14622893 =_40\JJ\1740 .006_41\CD\1740 ;_42\:\1740 olanzapine_43\NN\1740 vs_44\CC\13634784 risperidone_45\NN\1740 ,_46\,\1740 t(33_47\NN\1740 )_48\-RRB-\1740 =_49\JJ\1740 2.42_50\CD\1740 ;_51\:\1740 p_52\NN\14622893 =_53\JJ\1740 .02_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
D003024_D007333 CID conclusions_0\NNS\5837957 :_1\:\1740 both_2\DT\1740 nonobese_3\JJ\1740 <e1>clozapine-</e1>_4\NN\1740 and_5\CC\1740 olanzapine-treated_6\JJ\1740 groups_7\NNS\2137 displayed_8\VBD\2137132 significant_9\JJ\1740 <e2>insulin_10\NN\5407119 resistance</e2>_11\NN\37396 and_12\CC\1740 impairment_13\NN\7296428 of_14\IN\1740 glucose_15\NN\14710501 effectiveness_16\NN\5190804 compared_17\VBN\644583 with_18\IN\1740 risperidone-treated_19\JJ\1740 subjects_20\NNS\6598915 ._21\.\1740
D003024_D007333 CID patients_0\NNS\9898892 taking_1\VBG\2367363 <e1>clozapine</e1>_2\NN\3713736 and_3\CC\1740 olanzapine_4\NN\1740 must_5\MD\9367203 be_6\VB\836236 examined_7\VBN\789138 for_8\IN\1740 <e2>insulin_9\NN\5407119 resistance</e2>_10\NN\37396 and_11\CC\1740 its_12\PRP$\6125041 consequences_13\NNS\34213 ._14\.\1740
C076029_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 <e1>olanzapine</e1>_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
C076029_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 <e1>olanzapine</e1>_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
C076029_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 <e1>olanzapine</e1>_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
C076029_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 <e1>olanzapine</e1>_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
C076029_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 <e1>olanzapine</e1>_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
C076029_D007333 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 <e1>olanzapine</e1>_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
C076029_D007333 CID the_0\DT\1740 homeostasis_1\NN\13934900 model_2\NN\5888929 assessment_3\NN\5732756 of_4\IN\1740 <e2>insulin_5\NN\5407119 resistance</e2>_6\NN\37396 also_7\RB\1740 differed_8\VBD\1740 significantly_9\RB\1740 among_10\IN\1740 groups_11\NNS\2137 (_12\-LRB-\1740 f(33_13\NN\1740 )_14\-RRB-\1740 =_15\JJ\1740 4.92_16\CD\1740 ;_17\:\1740 p_18\NN\14622893 =_19\JJ\1740 .01_20\CD\1740 )_21\-RRB-\1740 (_22\-LRB-\1740 clozapine_23\NN\3713736 >_24\NN\1740 <e1>olanzapine</e1>_25\NN\1740 >_26\NN\1740 risperidone_27\NN\1740 )_28\-RRB-\1740 (_29\-LRB-\1740 clozapine_30\NN\3713736 vs_31\CC\13634784 risperidone_32\NN\1740 ,_33\,\1740 t(33_34\NN\1740 )_35\-RRB-\1740 =_36\JJ\1740 2.94_37\CD\1740 ;_38\:\1740 p_39\NN\14622893 =_40\JJ\1740 .006_41\CD\1740 ;_42\:\1740 olanzapine_43\NN\1740 vs_44\CC\13634784 risperidone_45\NN\1740 ,_46\,\1740 t(33_47\NN\1740 )_48\-RRB-\1740 =_49\JJ\1740 2.42_50\CD\1740 ;_51\:\1740 p_52\NN\14622893 =_53\JJ\1740 .02_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
C076029_D007333 CID the_0\DT\1740 homeostasis_1\NN\13934900 model_2\NN\5888929 assessment_3\NN\5732756 of_4\IN\1740 <e2>insulin_5\NN\5407119 resistance</e2>_6\NN\37396 also_7\RB\1740 differed_8\VBD\1740 significantly_9\RB\1740 among_10\IN\1740 groups_11\NNS\2137 (_12\-LRB-\1740 f(33_13\NN\1740 )_14\-RRB-\1740 =_15\JJ\1740 4.92_16\CD\1740 ;_17\:\1740 p_18\NN\14622893 =_19\JJ\1740 .01_20\CD\1740 )_21\-RRB-\1740 (_22\-LRB-\1740 clozapine_23\NN\3713736 >_24\NN\1740 olanzapine_25\NN\1740 >_26\NN\1740 risperidone_27\NN\1740 )_28\-RRB-\1740 (_29\-LRB-\1740 clozapine_30\NN\3713736 vs_31\CC\13634784 risperidone_32\NN\1740 ,_33\,\1740 t(33_34\NN\1740 )_35\-RRB-\1740 =_36\JJ\1740 2.94_37\CD\1740 ;_38\:\1740 p_39\NN\14622893 =_40\JJ\1740 .006_41\CD\1740 ;_42\:\1740 <e1>olanzapine</e1>_43\NN\1740 vs_44\CC\13634784 risperidone_45\NN\1740 ,_46\,\1740 t(33_47\NN\1740 )_48\-RRB-\1740 =_49\JJ\1740 2.42_50\CD\1740 ;_51\:\1740 p_52\NN\14622893 =_53\JJ\1740 .02_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
C076029_D007333 CID conclusions_0\NNS\5837957 :_1\:\1740 both_2\DT\1740 nonobese_3\JJ\1740 clozapine-_4\NN\1740 and_5\CC\1740 <e1>olanzapine-treated</e1>_6\JJ\1740 groups_7\NNS\2137 displayed_8\VBD\2137132 significant_9\JJ\1740 <e2>insulin_10\NN\5407119 resistance</e2>_11\NN\37396 and_12\CC\1740 impairment_13\NN\7296428 of_14\IN\1740 glucose_15\NN\14710501 effectiveness_16\NN\5190804 compared_17\VBN\644583 with_18\IN\1740 risperidone-treated_19\JJ\1740 subjects_20\NNS\6598915 ._21\.\1740
C076029_D007333 CID patients_0\NNS\9898892 taking_1\VBG\2367363 clozapine_2\NN\3713736 and_3\CC\1740 <e1>olanzapine</e1>_4\NN\1740 must_5\MD\9367203 be_6\VB\836236 examined_7\VBN\789138 for_8\IN\1740 <e2>insulin_9\NN\5407119 resistance</e2>_10\NN\37396 and_11\CC\1740 its_12\PRP$\6125041 consequences_13\NNS\34213 ._14\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 <e1>risperidone</e1>_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 <e1>risperidone</e1>_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 <e1>risperidone</e1>_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 <e1>risperidone</e1>_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 <e1>risperidone</e1>_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 <e1>risperidone</e1>_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 risperidone_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 <e2>insulin_6\NN\5407119 sensitivity</e2>_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 insulin_36\NN\5407119 resistance_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 <e1>risperidone</e1>_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 insulin_6\NN\5407119 sensitivity_7\NN\5651971 index_8\NN\13850304 among_9\IN\1740 groups_10\NNS\2137 (_11\-LRB-\1740 f(33_12\NN\1740 )_13\-RRB-\1740 =_14\JJ\1740 10.66_15\CD\1740 ;_16\:\1740 p<.001_17\NN\1740 )_18\-RRB-\1740 (_19\-LRB-\1740 clozapine_20\NN\3713736 <_21\XX\1740 olanzapine_22\NN\1740 <_23\XX\1740 risperidone_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 with_27\IN\1740 subjects_28\NNS\6598915 who_29\WP\8299493 received_30\VBD\2210855 clozapine_31\NN\3713736 and_32\CC\1740 olanzapine_33\NN\1740 exhibiting_34\VBG\2632167 significant_35\JJ\1740 <e2>insulin_36\NN\5407119 resistance</e2>_37\NN\37396 compared_38\VBN\644583 with_39\IN\1740 subjects_40\NNS\6598915 who_41\WP\8299493 were_42\VBD\836236 treated_43\VBN\2376958 with_44\IN\1740 risperidone_45\NN\1740 (_46\-LRB-\1740 clozapine_47\NN\3713736 vs_48\CC\13634784 risperidone_49\NN\1740 ,_50\,\1740 t(33_51\NN\1740 )_52\-RRB-\1740 =_53\JJ\1740 -4.29_54\CD\1740 ;_55\:\1740 p<.001_56\NN\1740 ;_57\:\1740 olanzapine_58\NN\1740 vs_59\CC\13634784 <e1>risperidone</e1>_60\NN\1740 ,_61\,\1740 t(33_62\NN\1740 )_63\-RRB-\1740 =_64\JJ\1740 -3.62_65\NN\1740 ;_66\:\1740 p_67\NN\14622893 =_68\JJ\1740 .001_69\CD\1740 [_70\-LRB-\1740 p<.001_71\NN\1740 ]_72\-RRB-\1740 )_73\-RRB-\1740 ._74\.\1740
D018967_D007333 NONE the_0\DT\1740 homeostasis_1\NN\13934900 model_2\NN\5888929 assessment_3\NN\5732756 of_4\IN\1740 <e2>insulin_5\NN\5407119 resistance</e2>_6\NN\37396 also_7\RB\1740 differed_8\VBD\1740 significantly_9\RB\1740 among_10\IN\1740 groups_11\NNS\2137 (_12\-LRB-\1740 f(33_13\NN\1740 )_14\-RRB-\1740 =_15\JJ\1740 4.92_16\CD\1740 ;_17\:\1740 p_18\NN\14622893 =_19\JJ\1740 .01_20\CD\1740 )_21\-RRB-\1740 (_22\-LRB-\1740 clozapine_23\NN\3713736 >_24\NN\1740 olanzapine_25\NN\1740 >_26\NN\1740 <e1>risperidone</e1>_27\NN\1740 )_28\-RRB-\1740 (_29\-LRB-\1740 clozapine_30\NN\3713736 vs_31\CC\13634784 risperidone_32\NN\1740 ,_33\,\1740 t(33_34\NN\1740 )_35\-RRB-\1740 =_36\JJ\1740 2.94_37\CD\1740 ;_38\:\1740 p_39\NN\14622893 =_40\JJ\1740 .006_41\CD\1740 ;_42\:\1740 olanzapine_43\NN\1740 vs_44\CC\13634784 risperidone_45\NN\1740 ,_46\,\1740 t(33_47\NN\1740 )_48\-RRB-\1740 =_49\JJ\1740 2.42_50\CD\1740 ;_51\:\1740 p_52\NN\14622893 =_53\JJ\1740 .02_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
D018967_D007333 NONE the_0\DT\1740 homeostasis_1\NN\13934900 model_2\NN\5888929 assessment_3\NN\5732756 of_4\IN\1740 <e2>insulin_5\NN\5407119 resistance</e2>_6\NN\37396 also_7\RB\1740 differed_8\VBD\1740 significantly_9\RB\1740 among_10\IN\1740 groups_11\NNS\2137 (_12\-LRB-\1740 f(33_13\NN\1740 )_14\-RRB-\1740 =_15\JJ\1740 4.92_16\CD\1740 ;_17\:\1740 p_18\NN\14622893 =_19\JJ\1740 .01_20\CD\1740 )_21\-RRB-\1740 (_22\-LRB-\1740 clozapine_23\NN\3713736 >_24\NN\1740 olanzapine_25\NN\1740 >_26\NN\1740 risperidone_27\NN\1740 )_28\-RRB-\1740 (_29\-LRB-\1740 clozapine_30\NN\3713736 vs_31\CC\13634784 <e1>risperidone</e1>_32\NN\1740 ,_33\,\1740 t(33_34\NN\1740 )_35\-RRB-\1740 =_36\JJ\1740 2.94_37\CD\1740 ;_38\:\1740 p_39\NN\14622893 =_40\JJ\1740 .006_41\CD\1740 ;_42\:\1740 olanzapine_43\NN\1740 vs_44\CC\13634784 risperidone_45\NN\1740 ,_46\,\1740 t(33_47\NN\1740 )_48\-RRB-\1740 =_49\JJ\1740 2.42_50\CD\1740 ;_51\:\1740 p_52\NN\14622893 =_53\JJ\1740 .02_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
D018967_D007333 NONE the_0\DT\1740 homeostasis_1\NN\13934900 model_2\NN\5888929 assessment_3\NN\5732756 of_4\IN\1740 <e2>insulin_5\NN\5407119 resistance</e2>_6\NN\37396 also_7\RB\1740 differed_8\VBD\1740 significantly_9\RB\1740 among_10\IN\1740 groups_11\NNS\2137 (_12\-LRB-\1740 f(33_13\NN\1740 )_14\-RRB-\1740 =_15\JJ\1740 4.92_16\CD\1740 ;_17\:\1740 p_18\NN\14622893 =_19\JJ\1740 .01_20\CD\1740 )_21\-RRB-\1740 (_22\-LRB-\1740 clozapine_23\NN\3713736 >_24\NN\1740 olanzapine_25\NN\1740 >_26\NN\1740 risperidone_27\NN\1740 )_28\-RRB-\1740 (_29\-LRB-\1740 clozapine_30\NN\3713736 vs_31\CC\13634784 risperidone_32\NN\1740 ,_33\,\1740 t(33_34\NN\1740 )_35\-RRB-\1740 =_36\JJ\1740 2.94_37\CD\1740 ;_38\:\1740 p_39\NN\14622893 =_40\JJ\1740 .006_41\CD\1740 ;_42\:\1740 olanzapine_43\NN\1740 vs_44\CC\13634784 <e1>risperidone</e1>_45\NN\1740 ,_46\,\1740 t(33_47\NN\1740 )_48\-RRB-\1740 =_49\JJ\1740 2.42_50\CD\1740 ;_51\:\1740 p_52\NN\14622893 =_53\JJ\1740 .02_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
D018967_D007333 NONE conclusions_0\NNS\5837957 :_1\:\1740 both_2\DT\1740 nonobese_3\JJ\1740 clozapine-_4\NN\1740 and_5\CC\1740 olanzapine-treated_6\JJ\1740 groups_7\NNS\2137 displayed_8\VBD\2137132 significant_9\JJ\1740 <e2>insulin_10\NN\5407119 resistance</e2>_11\NN\37396 and_12\CC\1740 impairment_13\NN\7296428 of_14\IN\1740 glucose_15\NN\14710501 effectiveness_16\NN\5190804 compared_17\VBN\644583 with_18\IN\1740 <e1>risperidone-treated</e1>_19\JJ\1740 subjects_20\NNS\6598915 ._21\.\1740
19841052
D016578_D015658 NONE smoking_0\NN\831191 of_1\IN\1740 <e1>crack_2\NN\9379111 cocaine</e1>_3\NN\3492717 as_4\IN\14622893 a_5\DT\13649268 risk_6\NN\14541044 factor_7\NN\7326557 for_8\IN\1740 <e2>hiv_9\NN\14186340 infection</e2>_10\NN\14052046 among_11\IN\1740 people_12\NNS\31264 who_13\WP\8299493 use_14\VBP\1156834 injection_15\NN\320852 drugs_16\NNS\14778436 ._17\.\1740
D016578_D015658 NONE background_0\NN\4921011 :_1\:\1740 little_2\JJ\1740 is_3\VBZ\836236 known_4\VBN\2110220 about_5\IN\1740 the_6\DT\1740 possible_7\JJ\1740 role_8\NN\719494 that_9\WDT\1740 smoking_10\VBG\1156834 <e1>crack_11\NN\9379111 cocaine</e1>_12\NN\3492717 has_13\VBZ\2108377 on_14\IN\1740 the_15\DT\1740 incidence_16\NN\13821570 of_17\IN\1740 <e2>hiv_18\NN\14186340 infection</e2>_19\NN\14052046 ._20\.\1740
D016578_D015658 NONE given_0\VBN\2327200 the_1\DT\1740 increasing_2\VBG\169651 use_3\NN\407535 of_4\IN\1740 <e1>crack_5\NN\9379111 cocaine</e1>_6\NN\3492717 ,_7\,\1740 we_8\PRP\1740 sought_9\VBD\1825237 to_10\TO\1740 examine_11\VB\789138 whether_12\IN\1740 use_13\NN\407535 of_14\IN\1740 this_15\DT\1740 illicit_16\NN\1740 drug_17\NN\14778436 has_18\VBZ\2108377 become_19\VBN\146138 a_20\DT\13649268 risk_21\NN\14541044 factor_22\NN\7326557 for_23\IN\1740 <e2>hiv_24\NN\14186340 infection</e2>_25\NN\14052046 ._26\.\1740
D016578_D006679 CID to_0\TO\1740 determine_1\VB\1645601 whether_2\IN\1740 the_3\DT\1740 risk_4\NN\14541044 of_5\IN\1740 <e2>hiv_6\NN\14186340 seroconversion</e2>_7\NN\1740 among_8\IN\1740 daily_9\JJ\1740 smokers_10\NNS\9612848 of_11\IN\1740 <e1>crack_12\NN\9379111 cocaine</e1>_13\NN\3492717 changed_14\VBD\46534 over_15\IN\5867413 time_16\NN\7308889 ,_17\,\1740 we_18\PRP\1740 used_19\VBD\1156834 cox_20\NN\14732946 proportional_21\JJ\1740 hazards_22\NNS\14541044 regression_23\NN\14501726 and_24\CC\1740 divided_25\VBD\140123 the_26\DT\1740 study_27\NN\635850 into_28\IN\1740 3_29\CD\13741022 periods_30\NNS\13575869 :_31\:\1740 may_32\NNP\15209706 1_33\CD\13741022 ,_34\,\1740 1996-nov_35\NN\1740 ._36\.\1740
D016578_D006679 CID after_0\IN\1740 adjusting_1\VBG\126264 for_2\IN\1740 potential_3\JJ\1740 confounders_4\NNS\1740 ,_5\,\1740 we_6\PRP\1740 found_7\VBD\2426171 that_8\IN\1740 the_9\DT\1740 risk_10\NN\14541044 of_11\IN\1740 <e2>hiv_12\NN\14186340 seroconversion</e2>_13\NN\1740 among_14\IN\1740 participants_15\NNS\9816771 who_16\WP\8299493 were_17\VBD\836236 daily_18\RB\1740 smokers_19\NNS\9612848 of_20\IN\1740 <e1>crack_21\NN\9379111 cocaine</e1>_22\NN\3492717 increased_23\VBD\169651 over_24\IN\5867413 time_25\NN\7308889 (_26\-LRB-\1740 period_27\NN\13575869 1_28\CD\13741022 :_29\:\1740 hazard_30\NN\14541044 ratio_31\NN\13815152 [_32\-LRB-\1740 hr_33\NNP\15154774 ]_34\-RRB-\1740 1.03_35\CD\1740 ,_36\,\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 [_41\-LRB-\1740 ci_42\NNP\13635336 ]_43\-RRB-\1740 0.57_44\CD\1740 -_45\SYM\1740 1.85_46\CD\1740 ;_47\:\1740 period_48\NN\13575869 2_49\CD\13741022 :_50\:\1740 hr_51\NNP\15154774 1.68_52\CD\1740 ,_53\,\1740 95_54\CD\1740 %_55\NN\1740 ci_56\NN\13635336 1.01_57\CD\1740 -_58\SYM\1740 2.80_59\CD\1740 ;_60\:\1740 and_61\CC\1740 period_62\NN\13575869 3_63\CD\13741022 :_64\:\1740 hr_65\NN\15154774 2.74_66\CD\1740 ,_67\,\1740 95_68\CD\1740 %_69\NN\1740 ci_70\NNP\13635336 1.06_71\CD\1740 -_72\SYM\1740 7.11_73\CD\1740 )_74\-RRB-\1740 ._75\.\1740
D016578_D006679 CID interpretation_0\NN\5926676 :_1\:\1740 smoking_2\NN\831191 of_3\IN\1740 <e1>crack_4\NN\9379111 cocaine</e1>_5\NN\3492717 was_6\VBD\836236 found_7\VBN\2426171 to_8\TO\1740 be_9\VB\836236 an_10\DT\6697703 independent_11\JJ\1740 risk_12\NN\14541044 factor_13\NN\7326557 for_14\IN\1740 <e2>hiv_15\NN\14186340 seroconversion</e2>_16\NN\1740 among_17\IN\1740 people_18\NNS\31264 who_19\WP\8299493 were_20\VBD\836236 injection_21\NN\320852 drug_22\NN\14778436 users_23\NNS\7846 ._24\.\1740
851038
D007980_D010300 NONE kaliuretic_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>l-dopa</e1>_3\JJ\1740 treatment_4\NN\654885 in_5\IN\13603305 <e2>parkinsonian</e2>_6\JJ\1740 patients_7\NNS\9898892 ._8\.\1740
D007980_D010300 NONE hypokalemia_0\NNP\14299637 ,_1\,\1740 sometimes_2\RB\1740 severe_3\JJ\1740 ,_4\,\1740 was_5\VBD\836236 observed_6\VBN\2163746 in_7\IN\13603305 some_8\DT\1740 <e1>l-dopa-treated</e1>_9\JJ\1740 <e2>parkinsonian</e2>_10\JJ\1740 patients_11\NNS\9898892 ._12\.\1740
D007980_D007008 CID <e2>hypokalemia</e2>_0\NNP\14299637 ,_1\,\1740 sometimes_2\RB\1740 severe_3\JJ\1740 ,_4\,\1740 was_5\VBD\836236 observed_6\VBN\2163746 in_7\IN\13603305 some_8\DT\1740 <e1>l-dopa-treated</e1>_9\JJ\1740 parkinsonian_10\JJ\1740 patients_11\NNS\9898892 ._12\.\1740
D007980_D007008 CID the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 <e1>l-dopa</e1>_3\NN\14604959 on_4\IN\1740 the_5\DT\1740 renal_6\JJ\1740 excretion_7\NN\13466586 of_8\IN\1740 potassium_9\NN\14625458 was_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 3_13\CD\13741022 patients_14\NNS\9898892 with_15\IN\1740 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 in_18\IN\13603305 5_19\CD\13741022 normokalemic_20\JJ\1740 patients_21\NNS\9898892 by_22\IN\1740 determination_23\NN\43195 of_24\IN\1740 renal_25\JJ\1740 plasma_26\NN\5398023 flow_27\NN\7311115 ,_28\,\1740 glomerular_29\JJ\1740 filtration_30\NN\13518963 rate_31\NN\13815152 ,_32\,\1740 plasma_33\NN\5398023 concentration_34\NN\4916342 of_35\IN\1740 potassium_36\NN\14625458 and_37\CC\1740 sodium_38\NN\14625458 as_39\RB\1740 well_40\RB\1740 as_41\IN\14622893 urinary_42\JJ\1740 excretion_43\NN\13466586 of_44\IN\1740 potassium_45\NN\14625458 ,_46\,\1740 sodium_47\NN\14625458 and_48\CC\1740 aldosterone_49\NN\14751863 ._50\.\1740
D011188_D007008 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 l-dopa_3\NN\14604959 on_4\IN\1740 the_5\DT\1740 renal_6\JJ\1740 excretion_7\NN\13466586 of_8\IN\1740 <e1>potassium</e1>_9\NN\14625458 was_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 3_13\CD\13741022 patients_14\NNS\9898892 with_15\IN\1740 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 in_18\IN\13603305 5_19\CD\13741022 normokalemic_20\JJ\1740 patients_21\NNS\9898892 by_22\IN\1740 determination_23\NN\43195 of_24\IN\1740 renal_25\JJ\1740 plasma_26\NN\5398023 flow_27\NN\7311115 ,_28\,\1740 glomerular_29\JJ\1740 filtration_30\NN\13518963 rate_31\NN\13815152 ,_32\,\1740 plasma_33\NN\5398023 concentration_34\NN\4916342 of_35\IN\1740 potassium_36\NN\14625458 and_37\CC\1740 sodium_38\NN\14625458 as_39\RB\1740 well_40\RB\1740 as_41\IN\14622893 urinary_42\JJ\1740 excretion_43\NN\13466586 of_44\IN\1740 potassium_45\NN\14625458 ,_46\,\1740 sodium_47\NN\14625458 and_48\CC\1740 aldosterone_49\NN\14751863 ._50\.\1740
D011188_D007008 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 l-dopa_3\NN\14604959 on_4\IN\1740 the_5\DT\1740 renal_6\JJ\1740 excretion_7\NN\13466586 of_8\IN\1740 potassium_9\NN\14625458 was_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 3_13\CD\13741022 patients_14\NNS\9898892 with_15\IN\1740 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 in_18\IN\13603305 5_19\CD\13741022 normokalemic_20\JJ\1740 patients_21\NNS\9898892 by_22\IN\1740 determination_23\NN\43195 of_24\IN\1740 renal_25\JJ\1740 plasma_26\NN\5398023 flow_27\NN\7311115 ,_28\,\1740 glomerular_29\JJ\1740 filtration_30\NN\13518963 rate_31\NN\13815152 ,_32\,\1740 plasma_33\NN\5398023 concentration_34\NN\4916342 of_35\IN\1740 <e1>potassium</e1>_36\NN\14625458 and_37\CC\1740 sodium_38\NN\14625458 as_39\RB\1740 well_40\RB\1740 as_41\IN\14622893 urinary_42\JJ\1740 excretion_43\NN\13466586 of_44\IN\1740 potassium_45\NN\14625458 ,_46\,\1740 sodium_47\NN\14625458 and_48\CC\1740 aldosterone_49\NN\14751863 ._50\.\1740
D011188_D007008 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 l-dopa_3\NN\14604959 on_4\IN\1740 the_5\DT\1740 renal_6\JJ\1740 excretion_7\NN\13466586 of_8\IN\1740 potassium_9\NN\14625458 was_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 3_13\CD\13741022 patients_14\NNS\9898892 with_15\IN\1740 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 in_18\IN\13603305 5_19\CD\13741022 normokalemic_20\JJ\1740 patients_21\NNS\9898892 by_22\IN\1740 determination_23\NN\43195 of_24\IN\1740 renal_25\JJ\1740 plasma_26\NN\5398023 flow_27\NN\7311115 ,_28\,\1740 glomerular_29\JJ\1740 filtration_30\NN\13518963 rate_31\NN\13815152 ,_32\,\1740 plasma_33\NN\5398023 concentration_34\NN\4916342 of_35\IN\1740 potassium_36\NN\14625458 and_37\CC\1740 sodium_38\NN\14625458 as_39\RB\1740 well_40\RB\1740 as_41\IN\14622893 urinary_42\JJ\1740 excretion_43\NN\13466586 of_44\IN\1740 <e1>potassium</e1>_45\NN\14625458 ,_46\,\1740 sodium_47\NN\14625458 and_48\CC\1740 aldosterone_49\NN\14751863 ._50\.\1740
D012964_D007008 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 l-dopa_3\NN\14604959 on_4\IN\1740 the_5\DT\1740 renal_6\JJ\1740 excretion_7\NN\13466586 of_8\IN\1740 potassium_9\NN\14625458 was_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 3_13\CD\13741022 patients_14\NNS\9898892 with_15\IN\1740 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 in_18\IN\13603305 5_19\CD\13741022 normokalemic_20\JJ\1740 patients_21\NNS\9898892 by_22\IN\1740 determination_23\NN\43195 of_24\IN\1740 renal_25\JJ\1740 plasma_26\NN\5398023 flow_27\NN\7311115 ,_28\,\1740 glomerular_29\JJ\1740 filtration_30\NN\13518963 rate_31\NN\13815152 ,_32\,\1740 plasma_33\NN\5398023 concentration_34\NN\4916342 of_35\IN\1740 potassium_36\NN\14625458 and_37\CC\1740 <e1>sodium</e1>_38\NN\14625458 as_39\RB\1740 well_40\RB\1740 as_41\IN\14622893 urinary_42\JJ\1740 excretion_43\NN\13466586 of_44\IN\1740 potassium_45\NN\14625458 ,_46\,\1740 sodium_47\NN\14625458 and_48\CC\1740 aldosterone_49\NN\14751863 ._50\.\1740
D012964_D007008 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 l-dopa_3\NN\14604959 on_4\IN\1740 the_5\DT\1740 renal_6\JJ\1740 excretion_7\NN\13466586 of_8\IN\1740 potassium_9\NN\14625458 was_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 3_13\CD\13741022 patients_14\NNS\9898892 with_15\IN\1740 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 in_18\IN\13603305 5_19\CD\13741022 normokalemic_20\JJ\1740 patients_21\NNS\9898892 by_22\IN\1740 determination_23\NN\43195 of_24\IN\1740 renal_25\JJ\1740 plasma_26\NN\5398023 flow_27\NN\7311115 ,_28\,\1740 glomerular_29\JJ\1740 filtration_30\NN\13518963 rate_31\NN\13815152 ,_32\,\1740 plasma_33\NN\5398023 concentration_34\NN\4916342 of_35\IN\1740 potassium_36\NN\14625458 and_37\CC\1740 sodium_38\NN\14625458 as_39\RB\1740 well_40\RB\1740 as_41\IN\14622893 urinary_42\JJ\1740 excretion_43\NN\13466586 of_44\IN\1740 potassium_45\NN\14625458 ,_46\,\1740 <e1>sodium</e1>_47\NN\14625458 and_48\CC\1740 aldosterone_49\NN\14751863 ._50\.\1740
D000450_D007008 NONE the_0\DT\1740 influence_1\NN\5190804 of_2\IN\1740 l-dopa_3\NN\14604959 on_4\IN\1740 the_5\DT\1740 renal_6\JJ\1740 excretion_7\NN\13466586 of_8\IN\1740 potassium_9\NN\14625458 was_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 3_13\CD\13741022 patients_14\NNS\9898892 with_15\IN\1740 <e2>hypokalemia</e2>_16\NN\14299637 and_17\CC\1740 in_18\IN\13603305 5_19\CD\13741022 normokalemic_20\JJ\1740 patients_21\NNS\9898892 by_22\IN\1740 determination_23\NN\43195 of_24\IN\1740 renal_25\JJ\1740 plasma_26\NN\5398023 flow_27\NN\7311115 ,_28\,\1740 glomerular_29\JJ\1740 filtration_30\NN\13518963 rate_31\NN\13815152 ,_32\,\1740 plasma_33\NN\5398023 concentration_34\NN\4916342 of_35\IN\1740 potassium_36\NN\14625458 and_37\CC\1740 sodium_38\NN\14625458 as_39\RB\1740 well_40\RB\1740 as_41\IN\14622893 urinary_42\JJ\1740 excretion_43\NN\13466586 of_44\IN\1740 potassium_45\NN\14625458 ,_46\,\1740 sodium_47\NN\14625458 and_48\CC\1740 <e1>aldosterone</e1>_49\NN\14751863 ._50\.\1740
20129423
D002220_D004802 CID fatal_0\JJ\1740 <e1>carbamazepine</e1>_1\NN\1740 induced_2\JJ\1740 <e2>fulminant_3\JJ\1740 eosinophilic</e2>_4\JJ\1740 (_5\-LRB-\1740 hypersensitivity_6\NN\14531772 )_7\-RRB-\1740 myocarditis_8\NN\14338942 :_9\:\1740 emphasis_10\NN\14434681 on_11\IN\1740 anatomical_12\JJ\1740 and_13\CC\1740 histological_14\JJ\1740 characteristics_15\NNS\5849040 ,_16\,\1740 mechanisms_17\NNS\13446390 and_18\CC\1740 genetics_19\NNS\6037666 of_20\IN\1740 drug_21\NN\14778436 hypersensitivity_22\NN\14531772 and_23\CC\1740 differential_24\JJ\1740 diagnosis_25\NN\152018 ._26\.\1740
D002220_D004342 CID fatal_0\JJ\1740 <e1>carbamazepine</e1>_1\NN\1740 induced_2\JJ\1740 fulminant_3\JJ\1740 eosinophilic_4\JJ\1740 (_5\-LRB-\1740 <e2>hypersensitivity</e2>_6\NN\14531772 )_7\-RRB-\1740 myocarditis_8\NN\14338942 :_9\:\1740 emphasis_10\NN\14434681 on_11\IN\1740 anatomical_12\JJ\1740 and_13\CC\1740 histological_14\JJ\1740 characteristics_15\NNS\5849040 ,_16\,\1740 mechanisms_17\NNS\13446390 and_18\CC\1740 genetics_19\NNS\6037666 of_20\IN\1740 drug_21\NN\14778436 hypersensitivity_22\NN\14531772 and_23\CC\1740 differential_24\JJ\1740 diagnosis_25\NN\152018 ._26\.\1740
D002220_D004342 CID fatal_0\JJ\1740 <e1>carbamazepine</e1>_1\NN\1740 induced_2\JJ\1740 fulminant_3\JJ\1740 eosinophilic_4\JJ\1740 (_5\-LRB-\1740 hypersensitivity_6\NN\14531772 )_7\-RRB-\1740 myocarditis_8\NN\14338942 :_9\:\1740 emphasis_10\NN\14434681 on_11\IN\1740 anatomical_12\JJ\1740 and_13\CC\1740 histological_14\JJ\1740 characteristics_15\NNS\5849040 ,_16\,\1740 mechanisms_17\NNS\13446390 and_18\CC\1740 genetics_19\NNS\6037666 of_20\IN\1740 <e2>drug_21\NN\14778436 hypersensitivity</e2>_22\NN\14531772 and_23\CC\1740 differential_24\JJ\1740 diagnosis_25\NN\152018 ._26\.\1740
D002220_D004342 CID a_0\DT\13649268 frequently_1\RB\1740 fatal_2\JJ\1740 ,_3\,\1740 although_4\IN\1740 exceptionally_5\RB\1740 rare_6\JJ\1740 side_7\NN\8630039 effect_8\NN\34213 of_9\IN\1740 <e1>carbamazepine</e1>_10\NN\1740 is_11\VBZ\836236 necrotizing_12\VBG\1740 eosinophilic_13\JJ\1740 (_14\-LRB-\1740 <e2>hypersensitivity</e2>_15\NN\14531772 )_16\-RRB-\1740 myocarditis_17\NN\14338942 ._18\.\1740
D002220_D004342 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>hypersensitivity</e2>_5\NN\14531772 myocarditis_6\NN\14338942 secondary_7\JJ\1740 to_8\TO\1740 administration_9\NN\1133281 of_10\IN\1740 <e1>carbamazepine</e1>_11\NN\1740 ._12\.\1740
D002220_D009205 CID fatal_0\JJ\1740 <e1>carbamazepine</e1>_1\NN\1740 induced_2\JJ\1740 fulminant_3\JJ\1740 eosinophilic_4\JJ\1740 (_5\-LRB-\1740 hypersensitivity_6\NN\14531772 )_7\-RRB-\1740 <e2>myocarditis</e2>_8\NN\14338942 :_9\:\1740 emphasis_10\NN\14434681 on_11\IN\1740 anatomical_12\JJ\1740 and_13\CC\1740 histological_14\JJ\1740 characteristics_15\NNS\5849040 ,_16\,\1740 mechanisms_17\NNS\13446390 and_18\CC\1740 genetics_19\NNS\6037666 of_20\IN\1740 drug_21\NN\14778436 hypersensitivity_22\NN\14531772 and_23\CC\1740 differential_24\JJ\1740 diagnosis_25\NN\152018 ._26\.\1740
D002220_D009205 CID a_0\DT\13649268 frequently_1\RB\1740 fatal_2\JJ\1740 ,_3\,\1740 although_4\IN\1740 exceptionally_5\RB\1740 rare_6\JJ\1740 side_7\NN\8630039 effect_8\NN\34213 of_9\IN\1740 <e1>carbamazepine</e1>_10\NN\1740 is_11\VBZ\836236 necrotizing_12\VBG\1740 eosinophilic_13\JJ\1740 (_14\-LRB-\1740 hypersensitivity_15\NN\14531772 )_16\-RRB-\1740 <e2>myocarditis</e2>_17\NN\14338942 ._18\.\1740
D002220_D009205 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 hypersensitivity_5\NN\14531772 <e2>myocarditis</e2>_6\NN\14338942 secondary_7\JJ\1740 to_8\TO\1740 administration_9\NN\1133281 of_10\IN\1740 <e1>carbamazepine</e1>_11\NN\1740 ._12\.\1740
D002220_D009205 CID to_0\TO\1740 best_1\JJS\1740 of_2\IN\1740 our_3\PRP$\1740 knowledge_4\NN\23100 this_5\DT\1740 is_6\VBZ\836236 the_7\DT\1740 second_8\JJ\1740 case_9\NN\7283608 of_10\IN\1740 fatal_11\JJ\1740 <e1>carbamazepine</e1>_12\NN\1740 induced_13\JJ\1740 <e2>myocarditis</e2>_14\NN\14338942 reported_15\VBN\831651 in_16\IN\13603305 english_17\NNP\6946823 literature_18\NN\6362953 ._19\.\1740
10327032
D005472_D022124 CID risk_0\NN\14541044 of_1\IN\1740 transient_2\JJ\1740 <e2>hyperammonemic_3\JJ\1740 encephalopathy</e2>_4\JJ\1740 in_5\IN\13603305 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 received_9\VBD\2210855 continuous_10\JJ\1740 infusion_11\NN\14589223 of_12\IN\1740 <e1>5-fluorouracil</e1>_13\NN\1740 with_14\IN\1740 the_15\DT\1740 complication_16\NN\1073995 of_17\IN\1740 dehydration_18\NN\14536438 and_19\CC\1740 infection_20\NN\14052046 ._21\.\1740
D005472_D022124 CID from_0\IN\1740 1986_1\CD\1740 to_2\IN\1740 1998_3\CD\1740 ,_4\,\1740 29_5\CD\13745420 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 had_9\VBD\2108377 32_10\CD\1740 episodes_11\NNS\7283608 of_12\IN\1740 transient_13\JJ\1740 <e2>hyperammonemic_14\JJ\1740 encephalopathy</e2>_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 continuous_18\JJ\1740 infusion_19\NN\14589223 of_20\IN\1740 <e1>5-fluorouracil</e1>_21\NN\1740 (_22\-LRB-\1740 5-fu_23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 identified_26\VBN\699815 ._27\.\1740
D005472_D022124 CID from_0\IN\1740 1986_1\CD\1740 to_2\IN\1740 1998_3\CD\1740 ,_4\,\1740 29_5\CD\13745420 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 had_9\VBD\2108377 32_10\CD\1740 episodes_11\NNS\7283608 of_12\IN\1740 transient_13\JJ\1740 <e2>hyperammonemic_14\JJ\1740 encephalopathy</e2>_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 continuous_18\JJ\1740 infusion_19\NN\14589223 of_20\IN\1740 5-fluorouracil_21\NN\1740 (_22\-LRB-\1740 <e1>5-fu</e1>_23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 identified_26\VBN\699815 ._27\.\1740
D005472_D022124 CID higher_0\JJR\1740 plasma_1\NN\5398023 ammonium_2\NN\14743582 levels_3\NNS\4916342 and_4\CC\1740 more_5\RBR\1740 rapid_6\JJ\1740 onset_7\NN\7325190 of_8\IN\1740 <e2>hyperammonemia</e2>_9\NN\1740 were_10\VBD\836236 seen_11\VBN\2106506 in_12\IN\13603305 18_13\CD\13745420 patients_14\NNS\9898892 with_15\IN\1740 bacterial_16\JJ\1740 infections_17\NNS\14052046 (_18\-LRB-\1740 p=0.003_19\NN\1740 and_20\CC\1740 0.0006_21\CD\1740 ,_22\,\1740 respectively_23\RB\1740 )_24\-RRB-\1740 and_25\CC\1740 in_26\IN\13603305 nine_27\CD\13741022 patients_28\NNS\9898892 receiving_29\VBG\2210855 high_30\JJ\1740 daily_31\JJ\1740 doses_32\NNS\3740161 (_33\-LRB-\1740 2600_34\CD\1740 or_35\CC\3541091 1800_36\CD\1740 mg/m2_37\NN\1740 )_38\-RRB-\1740 of_39\IN\1740 <e1>5-fu</e1>_40\NN\1740 (_41\-LRB-\1740 p=0.0001_42\NN\1740 and_43\CC\1740 <_44\XX\1740 0.0001_45\CD\1740 ,_46\,\1740 respectively_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D005472_D022124 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e2>hyperammonemic_3\JJ\1740 encephalopathy</e2>_4\JJ\1740 can_5\MD\3094503 occur_6\VB\2623529 in_7\IN\13603305 patients_8\NNS\9898892 receiving_9\VBG\2210855 continuous_10\JJ\1740 infusion_11\NN\14589223 of_12\IN\1740 <e1>5-fu</e1>_13\NN\1740 ._14\.\1740
D005472_D001927 CID risk_0\NN\14541044 of_1\IN\1740 transient_2\JJ\1740 <e2>hyperammonemic_3\JJ\1740 encephalopathy</e2>_4\JJ\1740 in_5\IN\13603305 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 received_9\VBD\2210855 continuous_10\JJ\1740 infusion_11\NN\14589223 of_12\IN\1740 <e1>5-fluorouracil</e1>_13\NN\1740 with_14\IN\1740 the_15\DT\1740 complication_16\NN\1073995 of_17\IN\1740 dehydration_18\NN\14536438 and_19\CC\1740 infection_20\NN\14052046 ._21\.\1740
D005472_D001927 CID from_0\IN\1740 1986_1\CD\1740 to_2\IN\1740 1998_3\CD\1740 ,_4\,\1740 29_5\CD\13745420 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 had_9\VBD\2108377 32_10\CD\1740 episodes_11\NNS\7283608 of_12\IN\1740 transient_13\JJ\1740 <e2>hyperammonemic_14\JJ\1740 encephalopathy</e2>_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 continuous_18\JJ\1740 infusion_19\NN\14589223 of_20\IN\1740 <e1>5-fluorouracil</e1>_21\NN\1740 (_22\-LRB-\1740 5-fu_23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 identified_26\VBN\699815 ._27\.\1740
D005472_D001927 CID from_0\IN\1740 1986_1\CD\1740 to_2\IN\1740 1998_3\CD\1740 ,_4\,\1740 29_5\CD\13745420 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 had_9\VBD\2108377 32_10\CD\1740 episodes_11\NNS\7283608 of_12\IN\1740 transient_13\JJ\1740 <e2>hyperammonemic_14\JJ\1740 encephalopathy</e2>_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 continuous_18\JJ\1740 infusion_19\NN\14589223 of_20\IN\1740 5-fluorouracil_21\NN\1740 (_22\-LRB-\1740 <e1>5-fu</e1>_23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 identified_26\VBN\699815 ._27\.\1740
D005472_D001927 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e2>hyperammonemic_3\JJ\1740 encephalopathy</e2>_4\JJ\1740 can_5\MD\3094503 occur_6\VB\2623529 in_7\IN\13603305 patients_8\NNS\9898892 receiving_9\VBG\2210855 continuous_10\JJ\1740 infusion_11\NN\14589223 of_12\IN\1740 <e1>5-fu</e1>_13\NN\1740 ._14\.\1740
D005472_D009369 NONE risk_0\NN\14541044 of_1\IN\1740 transient_2\JJ\1740 hyperammonemic_3\JJ\1740 encephalopathy_4\JJ\1740 in_5\IN\13603305 <e2>cancer</e2>_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 received_9\VBD\2210855 continuous_10\JJ\1740 infusion_11\NN\14589223 of_12\IN\1740 <e1>5-fluorouracil</e1>_13\NN\1740 with_14\IN\1740 the_15\DT\1740 complication_16\NN\1073995 of_17\IN\1740 dehydration_18\NN\14536438 and_19\CC\1740 infection_20\NN\14052046 ._21\.\1740
D005472_D009369 NONE from_0\IN\1740 1986_1\CD\1740 to_2\IN\1740 1998_3\CD\1740 ,_4\,\1740 29_5\CD\13745420 <e2>cancer</e2>_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 had_9\VBD\2108377 32_10\CD\1740 episodes_11\NNS\7283608 of_12\IN\1740 transient_13\JJ\1740 hyperammonemic_14\JJ\1740 encephalopathy_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 continuous_18\JJ\1740 infusion_19\NN\14589223 of_20\IN\1740 <e1>5-fluorouracil</e1>_21\NN\1740 (_22\-LRB-\1740 5-fu_23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 identified_26\VBN\699815 ._27\.\1740
D005472_D009369 NONE from_0\IN\1740 1986_1\CD\1740 to_2\IN\1740 1998_3\CD\1740 ,_4\,\1740 29_5\CD\13745420 <e2>cancer</e2>_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 had_9\VBD\2108377 32_10\CD\1740 episodes_11\NNS\7283608 of_12\IN\1740 transient_13\JJ\1740 hyperammonemic_14\JJ\1740 encephalopathy_15\RB\1740 related_16\JJ\1740 to_17\TO\1740 continuous_18\JJ\1740 infusion_19\NN\14589223 of_20\IN\1740 5-fluorouracil_21\NN\1740 (_22\-LRB-\1740 <e1>5-fu</e1>_23\NN\1740 )_24\-RRB-\1740 were_25\VBD\836236 identified_26\VBN\699815 ._27\.\1740
D005472_D003681 NONE risk_0\NN\14541044 of_1\IN\1740 transient_2\JJ\1740 hyperammonemic_3\JJ\1740 encephalopathy_4\JJ\1740 in_5\IN\13603305 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 received_9\VBD\2210855 continuous_10\JJ\1740 infusion_11\NN\14589223 of_12\IN\1740 <e1>5-fluorouracil</e1>_13\NN\1740 with_14\IN\1740 the_15\DT\1740 complication_16\NN\1073995 of_17\IN\1740 <e2>dehydration</e2>_18\NN\14536438 and_19\CC\1740 infection_20\NN\14052046 ._21\.\1740
D005472_D007239 NONE risk_0\NN\14541044 of_1\IN\1740 transient_2\JJ\1740 hyperammonemic_3\JJ\1740 encephalopathy_4\JJ\1740 in_5\IN\13603305 cancer_6\NN\14239425 patients_7\NNS\9898892 who_8\WP\8299493 received_9\VBD\2210855 continuous_10\JJ\1740 infusion_11\NN\14589223 of_12\IN\1740 <e1>5-fluorouracil</e1>_13\NN\1740 with_14\IN\1740 the_15\DT\1740 complication_16\NN\1073995 of_17\IN\1740 dehydration_18\NN\14536438 and_19\CC\1740 <e2>infection</e2>_20\NN\14052046 ._21\.\1740
D000644_D022124 NONE higher_0\JJR\1740 plasma_1\NN\5398023 <e1>ammonium</e1>_2\NN\14743582 levels_3\NNS\4916342 and_4\CC\1740 more_5\RBR\1740 rapid_6\JJ\1740 onset_7\NN\7325190 of_8\IN\1740 <e2>hyperammonemia</e2>_9\NN\1740 were_10\VBD\836236 seen_11\VBN\2106506 in_12\IN\13603305 18_13\CD\13745420 patients_14\NNS\9898892 with_15\IN\1740 bacterial_16\JJ\1740 infections_17\NNS\14052046 (_18\-LRB-\1740 p=0.003_19\NN\1740 and_20\CC\1740 0.0006_21\CD\1740 ,_22\,\1740 respectively_23\RB\1740 )_24\-RRB-\1740 and_25\CC\1740 in_26\IN\13603305 nine_27\CD\13741022 patients_28\NNS\9898892 receiving_29\VBG\2210855 high_30\JJ\1740 daily_31\JJ\1740 doses_32\NNS\3740161 (_33\-LRB-\1740 2600_34\CD\1740 or_35\CC\3541091 1800_36\CD\1740 mg/m2_37\NN\1740 )_38\-RRB-\1740 of_39\IN\1740 5-fu_40\NN\1740 (_41\-LRB-\1740 p=0.0001_42\NN\1740 and_43\CC\1740 <_44\XX\1740 0.0001_45\CD\1740 ,_46\,\1740 respectively_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D000644_D001424 NONE higher_0\JJR\1740 plasma_1\NN\5398023 <e1>ammonium</e1>_2\NN\14743582 levels_3\NNS\4916342 and_4\CC\1740 more_5\RBR\1740 rapid_6\JJ\1740 onset_7\NN\7325190 of_8\IN\1740 hyperammonemia_9\NN\1740 were_10\VBD\836236 seen_11\VBN\2106506 in_12\IN\13603305 18_13\CD\13745420 patients_14\NNS\9898892 with_15\IN\1740 <e2>bacterial_16\JJ\1740 infections</e2>_17\NNS\14052046 (_18\-LRB-\1740 p=0.003_19\NN\1740 and_20\CC\1740 0.0006_21\CD\1740 ,_22\,\1740 respectively_23\RB\1740 )_24\-RRB-\1740 and_25\CC\1740 in_26\IN\13603305 nine_27\CD\13741022 patients_28\NNS\9898892 receiving_29\VBG\2210855 high_30\JJ\1740 daily_31\JJ\1740 doses_32\NNS\3740161 (_33\-LRB-\1740 2600_34\CD\1740 or_35\CC\3541091 1800_36\CD\1740 mg/m2_37\NN\1740 )_38\-RRB-\1740 of_39\IN\1740 5-fu_40\NN\1740 (_41\-LRB-\1740 p=0.0001_42\NN\1740 and_43\CC\1740 <_44\XX\1740 0.0001_45\CD\1740 ,_46\,\1740 respectively_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
D005472_D001424 NONE higher_0\JJR\1740 plasma_1\NN\5398023 ammonium_2\NN\14743582 levels_3\NNS\4916342 and_4\CC\1740 more_5\RBR\1740 rapid_6\JJ\1740 onset_7\NN\7325190 of_8\IN\1740 hyperammonemia_9\NN\1740 were_10\VBD\836236 seen_11\VBN\2106506 in_12\IN\13603305 18_13\CD\13745420 patients_14\NNS\9898892 with_15\IN\1740 <e2>bacterial_16\JJ\1740 infections</e2>_17\NNS\14052046 (_18\-LRB-\1740 p=0.003_19\NN\1740 and_20\CC\1740 0.0006_21\CD\1740 ,_22\,\1740 respectively_23\RB\1740 )_24\-RRB-\1740 and_25\CC\1740 in_26\IN\13603305 nine_27\CD\13741022 patients_28\NNS\9898892 receiving_29\VBG\2210855 high_30\JJ\1740 daily_31\JJ\1740 doses_32\NNS\3740161 (_33\-LRB-\1740 2600_34\CD\1740 or_35\CC\3541091 1800_36\CD\1740 mg/m2_37\NN\1740 )_38\-RRB-\1740 of_39\IN\1740 <e1>5-fu</e1>_40\NN\1740 (_41\-LRB-\1740 p=0.0001_42\NN\1740 and_43\CC\1740 <_44\XX\1740 0.0001_45\CD\1740 ,_46\,\1740 respectively_47\RB\1740 )_48\-RRB-\1740 ._49\.\1740
3109094
D003520_D001745 CID electron_0\NN\9338013 microscopic_1\JJ\1740 investigations_2\NNS\5797597 of_3\IN\1740 the_4\DT\1740 <e1>cyclophosphamide-induced</e1>_5\JJ\1740 <e2>lesions_6\NNS\14204950 of_7\IN\1740 the_8\DT\1740 urinary_9\JJ\1740 bladder</e2>_10\NN\5515670 of_11\IN\1740 the_12\DT\1740 rat_13\NN\2329401 and_14\CC\1740 their_15\PRP$\1740 prevention_16\NN\1073995 by_17\IN\1740 mesna_18\NN\1740 ._19\.\1740
D015080_D001745 NONE electron_0\NN\9338013 microscopic_1\JJ\1740 investigations_2\NNS\5797597 of_3\IN\1740 the_4\DT\1740 cyclophosphamide-induced_5\JJ\1740 <e2>lesions_6\NNS\14204950 of_7\IN\1740 the_8\DT\1740 urinary_9\JJ\1740 bladder</e2>_10\NN\5515670 of_11\IN\1740 the_12\DT\1740 rat_13\NN\2329401 and_14\CC\1740 their_15\PRP$\1740 prevention_16\NN\1073995 by_17\IN\1740 <e1>mesna</e1>_18\NN\1740 ._19\.\1740
D003520_D003556 NONE fully_0\RB\1740 developed_1\VBN\1753788 <e1>cyclophosphamide-induced</e1>_2\JJ\1740 <e2>cystitis</e2>_3\NN\14566129 is_4\VBZ\836236 characterized_5\VBN\609683 by_6\IN\1740 nearly_7\RB\1740 complete_8\JJ\1740 detachment_9\NN\7505676 of_10\IN\1740 the_11\DT\1740 urothelium_12\NN\1740 ,_13\,\1740 severe_14\JJ\1740 submucosal_15\NN\1740 edema_16\NN\14315192 owing_17\VBG\2663643 to_18\TO\1740 damage_19\NN\7296428 to_20\IN\1740 the_21\DT\1740 microvascular_22\JJ\1740 bed_23\NN\2821943 and_24\CC\1740 focal_25\JJ\1740 muscle_26\NN\5289601 necroses_27\NNS\1740 ._28\.\1740
D003520_D004487 NONE fully_0\RB\1740 developed_1\VBN\1753788 <e1>cyclophosphamide-induced</e1>_2\JJ\1740 cystitis_3\NN\14566129 is_4\VBZ\836236 characterized_5\VBN\609683 by_6\IN\1740 nearly_7\RB\1740 complete_8\JJ\1740 detachment_9\NN\7505676 of_10\IN\1740 the_11\DT\1740 urothelium_12\NN\1740 ,_13\,\1740 severe_14\JJ\1740 submucosal_15\NN\1740 <e2>edema</e2>_16\NN\14315192 owing_17\VBG\2663643 to_18\TO\1740 damage_19\NN\7296428 to_20\IN\1740 the_21\DT\1740 microvascular_22\JJ\1740 bed_23\NN\2821943 and_24\CC\1740 focal_25\JJ\1740 muscle_26\NN\5289601 necroses_27\NNS\1740 ._28\.\1740
D003520_D009336 NONE fully_0\RB\1740 developed_1\VBN\1753788 <e1>cyclophosphamide-induced</e1>_2\JJ\1740 cystitis_3\NN\14566129 is_4\VBZ\836236 characterized_5\VBN\609683 by_6\IN\1740 nearly_7\RB\1740 complete_8\JJ\1740 detachment_9\NN\7505676 of_10\IN\1740 the_11\DT\1740 urothelium_12\NN\1740 ,_13\,\1740 severe_14\JJ\1740 submucosal_15\NN\1740 edema_16\NN\14315192 owing_17\VBG\2663643 to_18\TO\1740 damage_19\NN\7296428 to_20\IN\1740 the_21\DT\1740 microvascular_22\JJ\1740 bed_23\NN\2821943 and_24\CC\1740 focal_25\JJ\1740 muscle_26\NN\5289601 <e2>necroses</e2>_27\NNS\1740 ._28\.\1740
11380496
D011441_D006111 NONE frequency_0\NN\15286249 of_1\IN\1740 appearance_2\NN\4723816 of_3\IN\1740 myeloperoxidase-antineutrophil_4\NN\1740 cytoplasmic_5\JJ\1740 antibody_6\NN\14728724 (_7\-LRB-\1740 mpo-anca_8\NN\1740 )_9\-RRB-\1740 in_10\IN\13603305 <e2>graves_11\NN\15143477 '_12\POS\1740 disease</e2>_13\NN\14061805 patients_14\NNS\9898892 treated_15\VBN\2376958 with_16\IN\1740 <e1>propylthiouracil</e1>_17\NN\14727670 and_18\CC\1740 the_19\DT\1740 relationship_20\NN\31921 between_21\IN\1740 mpo-anca_22\NN\1740 and_23\CC\1740 clinical_24\JJ\1740 manifestations_25\NNS\7321772 ._26\.\1740
D011441_D006111 NONE objective_0\NN\5980875 :_1\:\1740 myeloperoxidase_2\NN\1740 antineutrophil_3\NN\1740 cytoplasmic_4\JJ\1740 antibody_5\NN\14728724 (mpo-anca)-positive_6\JJ\1740 vasculitis_7\NN\14336539 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>graves_14\NN\15143477 '_15\POS\1740 disease</e2>_16\NN\14061805 who_17\WP\8299493 were_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>propylthiouracil</e1>_21\NN\14727670 (_22\-LRB-\1740 ptu_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D011441_D006111 NONE objective_0\NN\5980875 :_1\:\1740 myeloperoxidase_2\NN\1740 antineutrophil_3\NN\1740 cytoplasmic_4\JJ\1740 antibody_5\NN\14728724 (mpo-anca)-positive_6\JJ\1740 vasculitis_7\NN\14336539 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>graves_14\NN\15143477 '_15\POS\1740 disease</e2>_16\NN\14061805 who_17\WP\8299493 were_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 propylthiouracil_21\NN\14727670 (_22\-LRB-\1740 <e1>ptu</e1>_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D011441_D006111 NONE nevertheless_0\RB\1740 ,_1\,\1740 there_2\EX\27167 have_3\VBP\2108377 been_4\VBN\836236 no_5\DT\7204911 studies_6\NNS\635850 on_7\IN\1740 the_8\DT\1740 temporal_9\JJ\1740 relationship_10\NN\31921 between_11\IN\1740 the_12\DT\1740 appearance_13\NN\4723816 of_14\IN\1740 mpo-anca_15\NN\1740 and_16\CC\1740 vasculitis_17\NN\14336539 during_18\IN\1740 <e1>ptu</e1>_19\NN\1740 therapy_20\NN\657604 ,_21\,\1740 or_22\CC\3541091 on_23\IN\1740 the_24\DT\1740 incidence_25\NN\13821570 of_26\IN\1740 mpo-anca_27\NN\1740 in_28\IN\13603305 untreated_29\JJ\1740 <e2>graves_30\NN\15143477 '_31\POS\1740 disease</e2>_32\NN\14061805 patients_33\NNS\9898892 ._34\.\1740
D011441_D006111 NONE patients_0\NNS\9898892 :_1\:\1740 we_2\PRP\1740 investigated_3\VBD\644583 102_4\CD\1740 untreated_5\JJ\1740 patients_6\NNS\9898892 with_7\IN\1740 hyperthyroidism_8\NN\14059928 due_9\IN\5174653 to_10\IN\1740 <e2>graves_11\NN\15143477 '_12\POS\1740 disease</e2>_13\NN\14061805 for_14\IN\1740 the_15\DT\1740 presence_16\NN\13954253 of_17\IN\1740 mpo-anca_18\NN\1740 ,_19\,\1740 and_20\CC\1740 for_21\IN\1740 the_22\DT\1740 development_23\NN\248977 vasculitis_24\NN\14336539 after_25\IN\1740 starting_26\VBG\2009433 <e1>ptu</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
D011441_D014657 NONE objective_0\NN\5980875 :_1\:\1740 myeloperoxidase_2\NN\1740 antineutrophil_3\NN\1740 cytoplasmic_4\JJ\1740 antibody_5\NN\14728724 (mpo-anca)-positive_6\JJ\1740 <e2>vasculitis</e2>_7\NN\14336539 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 graves_14\NN\15143477 '_15\POS\1740 disease_16\NN\14061805 who_17\WP\8299493 were_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 <e1>propylthiouracil</e1>_21\NN\14727670 (_22\-LRB-\1740 ptu_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D011441_D014657 NONE objective_0\NN\5980875 :_1\:\1740 myeloperoxidase_2\NN\1740 antineutrophil_3\NN\1740 cytoplasmic_4\JJ\1740 antibody_5\NN\14728724 (mpo-anca)-positive_6\JJ\1740 <e2>vasculitis</e2>_7\NN\14336539 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 graves_14\NN\15143477 '_15\POS\1740 disease_16\NN\14061805 who_17\WP\8299493 were_18\VBD\836236 treated_19\VBN\2376958 with_20\IN\1740 propylthiouracil_21\NN\14727670 (_22\-LRB-\1740 <e1>ptu</e1>_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D011441_D014657 NONE nevertheless_0\RB\1740 ,_1\,\1740 there_2\EX\27167 have_3\VBP\2108377 been_4\VBN\836236 no_5\DT\7204911 studies_6\NNS\635850 on_7\IN\1740 the_8\DT\1740 temporal_9\JJ\1740 relationship_10\NN\31921 between_11\IN\1740 the_12\DT\1740 appearance_13\NN\4723816 of_14\IN\1740 mpo-anca_15\NN\1740 and_16\CC\1740 <e2>vasculitis</e2>_17\NN\14336539 during_18\IN\1740 <e1>ptu</e1>_19\NN\1740 therapy_20\NN\657604 ,_21\,\1740 or_22\CC\3541091 on_23\IN\1740 the_24\DT\1740 incidence_25\NN\13821570 of_26\IN\1740 mpo-anca_27\NN\1740 in_28\IN\13603305 untreated_29\JJ\1740 graves_30\NN\15143477 '_31\POS\1740 disease_32\NN\14061805 patients_33\NNS\9898892 ._34\.\1740
D011441_D014657 NONE patients_0\NNS\9898892 :_1\:\1740 we_2\PRP\1740 investigated_3\VBD\644583 102_4\CD\1740 untreated_5\JJ\1740 patients_6\NNS\9898892 with_7\IN\1740 hyperthyroidism_8\NN\14059928 due_9\IN\5174653 to_10\IN\1740 graves_11\NN\15143477 '_12\POS\1740 disease_13\NN\14061805 for_14\IN\1740 the_15\DT\1740 presence_16\NN\13954253 of_17\IN\1740 mpo-anca_18\NN\1740 ,_19\,\1740 and_20\CC\1740 for_21\IN\1740 the_22\DT\1740 development_23\NN\248977 <e2>vasculitis</e2>_24\NN\14336539 after_25\IN\1740 starting_26\VBG\2009433 <e1>ptu</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
D011441_D014657 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>ptu</e1>_2\NN\1740 therapy_3\NN\657604 may_4\MD\15209706 be_5\VB\836236 related_6\JJ\1740 to_7\TO\1740 the_8\DT\1740 appearance_9\NN\4723816 of_10\IN\1740 mpo-anca_11\NN\1740 ,_12\,\1740 but_13\CC\1740 mpo-anca_14\NN\1740 does_15\VBZ\1640855 not_16\RB\1740 appear_17\VB\2604760 to_18\TO\1740 be_19\VB\836236 closely_20\RB\1740 related_21\JJ\1740 to_22\TO\1740 <e2>vasculitis</e2>_23\NN\14336539 ._24\.\1740
D011441_D006980 NONE patients_0\NNS\9898892 :_1\:\1740 we_2\PRP\1740 investigated_3\VBD\644583 102_4\CD\1740 untreated_5\JJ\1740 patients_6\NNS\9898892 with_7\IN\1740 <e2>hyperthyroidism</e2>_8\NN\14059928 due_9\IN\5174653 to_10\IN\1740 graves_11\NN\15143477 '_12\POS\1740 disease_13\NN\14061805 for_14\IN\1740 the_15\DT\1740 presence_16\NN\13954253 of_17\IN\1740 mpo-anca_18\NN\1740 ,_19\,\1740 and_20\CC\1740 for_21\IN\1740 the_22\DT\1740 development_23\NN\248977 vasculitis_24\NN\14336539 after_25\IN\1740 starting_26\VBG\2009433 <e1>ptu</e1>_27\NN\1740 therapy_28\NN\657604 ._29\.\1740
D011441_D014652 NONE in_0\IN\13603305 two_1\CD\13741022 of_2\IN\1740 them_3\PRP\1740 ,_4\,\1740 the_5\DT\1740 mpo-anca_6\NN\1740 titres_7\NNS\5038593 transiently_8\RB\1740 increased_9\VBD\169651 to_10\TO\1740 12.8_11\CD\1740 and_12\CC\1740 15.0_13\CD\1740 u/ml_14\NN\1740 ,_15\,\1740 respectively_16\RB\1740 ,_17\,\1740 despite_18\IN\7501545 continued_19\JJ\1740 <e1>ptu</e1>_20\NN\1740 therapy_21\NN\657604 ,_22\,\1740 but_23\CC\1740 no_24\DT\7204911 <e2>vasculitic_25\JJ\1740 disorders</e2>_26\NNS\14034177 developed_27\VBD\1753788 ._28\.\1740
D011441_D005334 CID in_0\IN\13603305 the_1\DT\1740 third_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 the_5\DT\1740 mpo-anca_6\NN\1740 titre_7\NN\5038593 increased_8\VBD\169651 to_9\TO\1740 204_10\CD\1740 u/ml_11\NN\1740 and_12\CC\1740 she_13\PRP\1740 developed_14\VBD\1753788 a_15\DT\13649268 higher_16\JJR\1740 <e2>fever</e2>_17\NN\14299637 ,_18\,\1740 oral_19\JJ\1740 ulcers_20\NNS\14211294 and_21\CC\1740 polyarthralgia_22\NN\1740 ,_23\,\1740 but_24\CC\1740 the_25\DT\1740 symptoms_26\NNS\5823932 resolved_27\VBD\352826 2_28\CD\13741022 weeks_29\NNS\15113229 after_30\IN\1740 stopping_31\VBG\2452885 <e1>ptu</e1>_32\NN\1740 therapy_33\NN\657604 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 mpo-anca_37\NN\1740 titre_38\NN\5038593 decreased_39\VBD\169651 to_40\TO\1740 20.7_41\CD\1740 u/ml_42\NN\1740 by_43\IN\1740 4_44\CD\13741022 months_45\NNS\15113229 after_46\IN\1740 discontinuing_47\VBG\2609764 ptu_48\NN\1740 ._49\.\1740
D011441_D005334 CID in_0\IN\13603305 the_1\DT\1740 third_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 the_5\DT\1740 mpo-anca_6\NN\1740 titre_7\NN\5038593 increased_8\VBD\169651 to_9\TO\1740 204_10\CD\1740 u/ml_11\NN\1740 and_12\CC\1740 she_13\PRP\1740 developed_14\VBD\1753788 a_15\DT\13649268 higher_16\JJR\1740 <e2>fever</e2>_17\NN\14299637 ,_18\,\1740 oral_19\JJ\1740 ulcers_20\NNS\14211294 and_21\CC\1740 polyarthralgia_22\NN\1740 ,_23\,\1740 but_24\CC\1740 the_25\DT\1740 symptoms_26\NNS\5823932 resolved_27\VBD\352826 2_28\CD\13741022 weeks_29\NNS\15113229 after_30\IN\1740 stopping_31\VBG\2452885 ptu_32\NN\1740 therapy_33\NN\657604 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 mpo-anca_37\NN\1740 titre_38\NN\5038593 decreased_39\VBD\169651 to_40\TO\1740 20.7_41\CD\1740 u/ml_42\NN\1740 by_43\IN\1740 4_44\CD\13741022 months_45\NNS\15113229 after_46\IN\1740 discontinuing_47\VBG\2609764 <e1>ptu</e1>_48\NN\1740 ._49\.\1740
D011441_D019226 CID in_0\IN\13603305 the_1\DT\1740 third_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 the_5\DT\1740 mpo-anca_6\NN\1740 titre_7\NN\5038593 increased_8\VBD\169651 to_9\TO\1740 204_10\CD\1740 u/ml_11\NN\1740 and_12\CC\1740 she_13\PRP\1740 developed_14\VBD\1753788 a_15\DT\13649268 higher_16\JJR\1740 fever_17\NN\14299637 ,_18\,\1740 <e2>oral_19\JJ\1740 ulcers</e2>_20\NNS\14211294 and_21\CC\1740 polyarthralgia_22\NN\1740 ,_23\,\1740 but_24\CC\1740 the_25\DT\1740 symptoms_26\NNS\5823932 resolved_27\VBD\352826 2_28\CD\13741022 weeks_29\NNS\15113229 after_30\IN\1740 stopping_31\VBG\2452885 <e1>ptu</e1>_32\NN\1740 therapy_33\NN\657604 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 mpo-anca_37\NN\1740 titre_38\NN\5038593 decreased_39\VBD\169651 to_40\TO\1740 20.7_41\CD\1740 u/ml_42\NN\1740 by_43\IN\1740 4_44\CD\13741022 months_45\NNS\15113229 after_46\IN\1740 discontinuing_47\VBG\2609764 ptu_48\NN\1740 ._49\.\1740
D011441_D019226 CID in_0\IN\13603305 the_1\DT\1740 third_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 the_5\DT\1740 mpo-anca_6\NN\1740 titre_7\NN\5038593 increased_8\VBD\169651 to_9\TO\1740 204_10\CD\1740 u/ml_11\NN\1740 and_12\CC\1740 she_13\PRP\1740 developed_14\VBD\1753788 a_15\DT\13649268 higher_16\JJR\1740 fever_17\NN\14299637 ,_18\,\1740 <e2>oral_19\JJ\1740 ulcers</e2>_20\NNS\14211294 and_21\CC\1740 polyarthralgia_22\NN\1740 ,_23\,\1740 but_24\CC\1740 the_25\DT\1740 symptoms_26\NNS\5823932 resolved_27\VBD\352826 2_28\CD\13741022 weeks_29\NNS\15113229 after_30\IN\1740 stopping_31\VBG\2452885 ptu_32\NN\1740 therapy_33\NN\657604 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 mpo-anca_37\NN\1740 titre_38\NN\5038593 decreased_39\VBD\169651 to_40\TO\1740 20.7_41\CD\1740 u/ml_42\NN\1740 by_43\IN\1740 4_44\CD\13741022 months_45\NNS\15113229 after_46\IN\1740 discontinuing_47\VBG\2609764 <e1>ptu</e1>_48\NN\1740 ._49\.\1740
D011441_D018771 CID in_0\IN\13603305 the_1\DT\1740 third_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 the_5\DT\1740 mpo-anca_6\NN\1740 titre_7\NN\5038593 increased_8\VBD\169651 to_9\TO\1740 204_10\CD\1740 u/ml_11\NN\1740 and_12\CC\1740 she_13\PRP\1740 developed_14\VBD\1753788 a_15\DT\13649268 higher_16\JJR\1740 fever_17\NN\14299637 ,_18\,\1740 oral_19\JJ\1740 ulcers_20\NNS\14211294 and_21\CC\1740 <e2>polyarthralgia</e2>_22\NN\1740 ,_23\,\1740 but_24\CC\1740 the_25\DT\1740 symptoms_26\NNS\5823932 resolved_27\VBD\352826 2_28\CD\13741022 weeks_29\NNS\15113229 after_30\IN\1740 stopping_31\VBG\2452885 <e1>ptu</e1>_32\NN\1740 therapy_33\NN\657604 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 mpo-anca_37\NN\1740 titre_38\NN\5038593 decreased_39\VBD\169651 to_40\TO\1740 20.7_41\CD\1740 u/ml_42\NN\1740 by_43\IN\1740 4_44\CD\13741022 months_45\NNS\15113229 after_46\IN\1740 discontinuing_47\VBG\2609764 ptu_48\NN\1740 ._49\.\1740
D011441_D018771 CID in_0\IN\13603305 the_1\DT\1740 third_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 the_5\DT\1740 mpo-anca_6\NN\1740 titre_7\NN\5038593 increased_8\VBD\169651 to_9\TO\1740 204_10\CD\1740 u/ml_11\NN\1740 and_12\CC\1740 she_13\PRP\1740 developed_14\VBD\1753788 a_15\DT\13649268 higher_16\JJR\1740 fever_17\NN\14299637 ,_18\,\1740 oral_19\JJ\1740 ulcers_20\NNS\14211294 and_21\CC\1740 <e2>polyarthralgia</e2>_22\NN\1740 ,_23\,\1740 but_24\CC\1740 the_25\DT\1740 symptoms_26\NNS\5823932 resolved_27\VBD\352826 2_28\CD\13741022 weeks_29\NNS\15113229 after_30\IN\1740 stopping_31\VBG\2452885 ptu_32\NN\1740 therapy_33\NN\657604 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 mpo-anca_37\NN\1740 titre_38\NN\5038593 decreased_39\VBD\169651 to_40\TO\1740 20.7_41\CD\1740 u/ml_42\NN\1740 by_43\IN\1740 4_44\CD\13741022 months_45\NNS\15113229 after_46\IN\1740 discontinuing_47\VBG\2609764 <e1>ptu</e1>_48\NN\1740 ._49\.\1740
11176729
D000806_D006333 NONE toleration_0\NN\4637923 of_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>angiotensin-converting_5\JJ\1740 enzyme_6\NN\14723628 inhibitors</e1>_7\NNS\20090 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 chronic_11\JJ\1740 <e2>heart_12\NN\5919034 failure</e2>_13\NN\66216 :_14\:\1740 results_15\NNS\34213 from_16\IN\1740 the_17\DT\1740 atlas_18\NN\6417598 trial_19\NN\786195 ._20\.\1740
D000806_D006333 NONE background_0\NN\4921011 :_1\:\1740 treatment_2\NN\654885 with_3\IN\1740 <e1>angiotensin-converting_4\JJ\1740 enzyme_5\NN\14723628 (_6\-LRB-\1740 ace_7\NN\13741022 )_8\-RRB-\1740 inhibitors</e1>_9\NNS\20090 reduces_10\VBZ\441445 mortality_11\NN\5054863 and_12\CC\1740 morbidity_13\NN\13826959 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 chronic_17\JJ\1740 <e2>heart_18\NN\5919034 failure</e2>_19\NN\66216 (_20\-LRB-\1740 chf_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 but_24\CC\1740 most_25\JJS\1740 affected_26\VBN\126264 patients_27\NNS\9898892 are_28\VBP\836236 not_29\RB\1740 receiving_30\VBG\2210855 these_31\DT\1740 agents_32\NNS\7347 or_33\CC\3541091 are_34\VBP\836236 being_35\VBG\836236 treated_36\VBN\2376958 with_37\IN\1740 doses_38\NNS\3740161 lower_39\JJR\1740 than_40\IN\1740 those_41\DT\1740 found_42\VBN\2426171 to_43\TO\1740 be_44\VB\836236 efficacious_45\JJ\1740 in_46\IN\13603305 trials_47\NNS\786195 ,_48\,\1740 primarily_49\RB\1740 because_50\IN\1740 of_51\IN\1740 concerns_52\NNS\5682950 about_53\IN\1740 the_54\DT\1740 safety_55\NN\13920835 and_56\CC\1740 tolerability_57\NN\1740 of_58\IN\1740 these_59\DT\1740 agents_60\NNS\7347 ,_61\,\1740 especially_62\RB\1740 at_63\IN\14622893 the_64\DT\1740 recommended_65\VBN\875394 doses_66\NNS\3740161 ._67\.\1740
D000806_D006333 NONE background_0\NN\4921011 :_1\:\1740 treatment_2\NN\654885 with_3\IN\1740 <e1>angiotensin-converting_4\JJ\1740 enzyme_5\NN\14723628 (_6\-LRB-\1740 ace_7\NN\13741022 )_8\-RRB-\1740 inhibitors</e1>_9\NNS\20090 reduces_10\VBZ\441445 mortality_11\NN\5054863 and_12\CC\1740 morbidity_13\NN\13826959 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 chronic_17\JJ\1740 heart_18\NN\5919034 failure_19\NN\66216 (_20\-LRB-\1740 <e2>chf</e2>_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 but_24\CC\1740 most_25\JJS\1740 affected_26\VBN\126264 patients_27\NNS\9898892 are_28\VBP\836236 not_29\RB\1740 receiving_30\VBG\2210855 these_31\DT\1740 agents_32\NNS\7347 or_33\CC\3541091 are_34\VBP\836236 being_35\VBG\836236 treated_36\VBN\2376958 with_37\IN\1740 doses_38\NNS\3740161 lower_39\JJR\1740 than_40\IN\1740 those_41\DT\1740 found_42\VBN\2426171 to_43\TO\1740 be_44\VB\836236 efficacious_45\JJ\1740 in_46\IN\13603305 trials_47\NNS\786195 ,_48\,\1740 primarily_49\RB\1740 because_50\IN\1740 of_51\IN\1740 concerns_52\NNS\5682950 about_53\IN\1740 the_54\DT\1740 safety_55\NN\13920835 and_56\CC\1740 tolerability_57\NN\1740 of_58\IN\1740 these_59\DT\1740 agents_60\NNS\7347 ,_61\,\1740 especially_62\RB\1740 at_63\IN\14622893 the_64\DT\1740 recommended_65\VBN\875394 doses_66\NNS\3740161 ._67\.\1740
D000806_D006333 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 findings_3\NNS\7951464 demonstrate_4\VBP\2137132 that_5\IN\1740 <e1>ace_6\NN\13741022 inhibitor</e1>_7\NN\20090 therapy_8\NN\657604 in_9\IN\13603305 most_10\JJS\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>chf</e2>_13\NN\1740 can_14\MD\3094503 be_15\VB\836236 successfully_16\RB\1740 titrated_17\VBN\489837 to_18\IN\1740 and_19\CC\1740 maintained_20\VBN\2202928 at_21\IN\14622893 high_22\JJ\1740 doses_23\NNS\3740161 ,_24\,\1740 and_25\CC\1740 that_26\IN\1740 more_27\RBR\1740 aggressive_28\JJ\1740 use_29\NN\407535 of_30\IN\1740 these_31\DT\1740 agents_32\NNS\7347 is_33\VBZ\836236 warranted_34\VBN\1012073 ._35\.\1740
D017706_D006333 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 examines_3\VBZ\789138 the_4\DT\1740 safety_5\NN\13920835 and_6\CC\1740 tolerability_7\NN\1740 of_8\IN\1740 high-_9\NN\1740 compared_10\VBN\644583 with_11\IN\1740 low-dose_12\JJ\1740 <e1>lisinopril</e1>_13\NN\2673637 in_14\IN\13603305 <e2>chf</e2>_15\NN\1740 ._16\.\1740
D000806_D007022 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 405_3\CD\1740 patients_4\NNS\9898892 not_5\RB\1740 previously_6\RB\1740 receiving_7\VBG\2210855 an_8\DT\6697703 <e1>ace_9\NN\13741022 inhibitor</e1>_10\NN\20090 ,_11\,\1740 doses_12\NNS\3740161 in_13\IN\13603305 only_14\RB\1740 4.2_15\CD\1740 %_16\NN\1740 could_17\MD\1740 not_18\RB\1740 be_19\VB\836236 titrated_20\VBN\489837 to_21\TO\1740 the_22\DT\1740 medium_23\NN\3575240 doses_24\NNS\3740161 required_25\VBN\754942 for_26\IN\1740 randomization_27\NN\1008378 because_28\IN\1740 of_29\IN\1740 symptoms_30\NNS\5823932 possibly_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 <e2>hypotension</e2>_34\NN\14057371 (_35\-LRB-\1740 2.0_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 or_39\CC\3541091 because_40\IN\1740 of_41\IN\1740 renal_42\JJ\1740 dysfunction_43\NN\14204950 or_44\CC\3541091 hyperkalemia_45\NN\14299637 (_46\-LRB-\1740 2.3_47\CD\1740 %_48\NN\1740 )_49\-RRB-\1740 ._50\.\1740
D000806_D007674 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 405_3\CD\1740 patients_4\NNS\9898892 not_5\RB\1740 previously_6\RB\1740 receiving_7\VBG\2210855 an_8\DT\6697703 <e1>ace_9\NN\13741022 inhibitor</e1>_10\NN\20090 ,_11\,\1740 doses_12\NNS\3740161 in_13\IN\13603305 only_14\RB\1740 4.2_15\CD\1740 %_16\NN\1740 could_17\MD\1740 not_18\RB\1740 be_19\VB\836236 titrated_20\VBN\489837 to_21\TO\1740 the_22\DT\1740 medium_23\NN\3575240 doses_24\NNS\3740161 required_25\VBN\754942 for_26\IN\1740 randomization_27\NN\1008378 because_28\IN\1740 of_29\IN\1740 symptoms_30\NNS\5823932 possibly_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 hypotension_34\NN\14057371 (_35\-LRB-\1740 2.0_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 or_39\CC\3541091 because_40\IN\1740 of_41\IN\1740 <e2>renal_42\JJ\1740 dysfunction</e2>_43\NN\14204950 or_44\CC\3541091 hyperkalemia_45\NN\14299637 (_46\-LRB-\1740 2.3_47\CD\1740 %_48\NN\1740 )_49\-RRB-\1740 ._50\.\1740
D000806_D006947 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 405_3\CD\1740 patients_4\NNS\9898892 not_5\RB\1740 previously_6\RB\1740 receiving_7\VBG\2210855 an_8\DT\6697703 <e1>ace_9\NN\13741022 inhibitor</e1>_10\NN\20090 ,_11\,\1740 doses_12\NNS\3740161 in_13\IN\13603305 only_14\RB\1740 4.2_15\CD\1740 %_16\NN\1740 could_17\MD\1740 not_18\RB\1740 be_19\VB\836236 titrated_20\VBN\489837 to_21\TO\1740 the_22\DT\1740 medium_23\NN\3575240 doses_24\NNS\3740161 required_25\VBN\754942 for_26\IN\1740 randomization_27\NN\1008378 because_28\IN\1740 of_29\IN\1740 symptoms_30\NNS\5823932 possibly_31\RB\1740 related_32\JJ\1740 to_33\TO\1740 hypotension_34\NN\14057371 (_35\-LRB-\1740 2.0_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 or_39\CC\3541091 because_40\IN\1740 of_41\IN\1740 renal_42\JJ\1740 dysfunction_43\NN\14204950 or_44\CC\3541091 <e2>hyperkalemia</e2>_45\NN\14299637 (_46\-LRB-\1740 2.3_47\CD\1740 %_48\NN\1740 )_49\-RRB-\1740 ._50\.\1740
D000806_D003920 NONE subgroups_0\NNS\31264 presumed_1\VBD\719734 to_2\TO\1740 be_3\VB\836236 at_4\IN\14622893 higher_5\JJR\1740 risk_6\NN\14541044 for_7\IN\1740 <e1>ace_8\NN\13741022 inhibitor</e1>_9\NN\20090 intolerance_10\NN\4642596 (_11\-LRB-\1740 blood_12\NN\5397468 pressure_13\NN\11419404 ,_14\,\1740 <_15\XX\1740 120_16\CD\13745420 mm_17\NN\13649268 hg_18\NN\14625458 ;_19\:\1740 creatinine_20\NN\1740 ,_21\,\1740 >_22\NN\1740 or_23\CC\3541091 =_24\JJ\1740 132.6_25\CD\1740 micromol/l_26\NN\1740 [_27\-LRB-\1740 >_28\CD\1740 or_29\CC\3541091 =_30\JJ\1740 1.5_31\CD\1740 mg/dl_32\NN\1740 ]_33\-RRB-\1740 ;_34\:\1740 age_35\NN\4916342 ,_36\,\1740 >_37\NN\1740 or_38\CC\3541091 =_39\JJ\1740 70_40\CD\13745420 years_41\NNS\15144371 ;_42\:\1740 and_43\CC\1740 patients_44\NNS\9898892 with_45\IN\1740 <e2>diabetes</e2>_46\NNS\14075199 )_47\-RRB-\1740 generally_48\RB\1740 tolerated_49\VBD\802318 the_50\DT\1740 high-dose_51\JJ\1740 strategy_52\NN\5902545 ._53\.\1740
D003404_D003920 NONE subgroups_0\NNS\31264 presumed_1\VBD\719734 to_2\TO\1740 be_3\VB\836236 at_4\IN\14622893 higher_5\JJR\1740 risk_6\NN\14541044 for_7\IN\1740 ace_8\NN\13741022 inhibitor_9\NN\20090 intolerance_10\NN\4642596 (_11\-LRB-\1740 blood_12\NN\5397468 pressure_13\NN\11419404 ,_14\,\1740 <_15\XX\1740 120_16\CD\13745420 mm_17\NN\13649268 hg_18\NN\14625458 ;_19\:\1740 <e1>creatinine</e1>_20\NN\1740 ,_21\,\1740 >_22\NN\1740 or_23\CC\3541091 =_24\JJ\1740 132.6_25\CD\1740 micromol/l_26\NN\1740 [_27\-LRB-\1740 >_28\CD\1740 or_29\CC\3541091 =_30\JJ\1740 1.5_31\CD\1740 mg/dl_32\NN\1740 ]_33\-RRB-\1740 ;_34\:\1740 age_35\NN\4916342 ,_36\,\1740 >_37\NN\1740 or_38\CC\3541091 =_39\JJ\1740 70_40\CD\13745420 years_41\NNS\15144371 ;_42\:\1740 and_43\CC\1740 patients_44\NNS\9898892 with_45\IN\1740 <e2>diabetes</e2>_46\NNS\14075199 )_47\-RRB-\1740 generally_48\RB\1740 tolerated_49\VBD\802318 the_50\DT\1740 high-dose_51\JJ\1740 strategy_52\NN\5902545 ._53\.\1740
2383364
C048279_D002056 NONE patient_0\NN\9898892 tolerance_1\NN\5032565 study_2\NN\635850 of_3\IN\1740 topical_4\JJ\1740 <e1>chlorhexidine_5\NN\2724207 diphosphanilate</e1>_6\NN\1740 :_7\:\1740 a_8\DT\13649268 new_9\JJ\1740 topical_10\JJ\1740 agent_11\NN\7347 for_12\IN\1740 <e2>burns</e2>_13\NNS\14322699 ._14\.\1740
C048279_D002056 NONE <e1>chlorhexidine_0\NN\2724207 phosphanilate</e1>_1\NN\1740 (_2\-LRB-\1740 chp_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 new_7\JJ\1740 broad-spectrum_8\NN\1740 antimicrobial_9\JJ\1740 agent_10\NN\7347 ,_11\,\1740 has_12\VBZ\2108377 been_13\VBN\836236 evaluated_14\VBN\670261 as_15\IN\14622893 a_16\DT\13649268 topical_17\JJ\1740 <e2>burn</e2>_18\NN\14322699 wound_19\NN\14285662 dressing_20\VBG\109660 in_21\IN\13603305 cream_22\NN\8386555 form_23\NN\6286395 ,_24\,\1740 but_25\CC\1740 preliminary_26\JJ\1740 clinical_27\JJ\1740 trials_28\NNS\786195 reported_29\VBD\831651 that_30\IN\1740 it_31\PRP\6125041 was_32\VBD\836236 painful_33\JJ\1740 upon_34\IN\1740 application_35\NN\947128 ._36\.\1740
C048279_D002056 NONE chlorhexidine_0\NN\2724207 phosphanilate_1\NN\1740 (_2\-LRB-\1740 <e1>chp</e1>_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 new_7\JJ\1740 broad-spectrum_8\NN\1740 antimicrobial_9\JJ\1740 agent_10\NN\7347 ,_11\,\1740 has_12\VBZ\2108377 been_13\VBN\836236 evaluated_14\VBN\670261 as_15\IN\14622893 a_16\DT\13649268 topical_17\JJ\1740 <e2>burn</e2>_18\NN\14322699 wound_19\NN\14285662 dressing_20\VBG\109660 in_21\IN\13603305 cream_22\NN\8386555 form_23\NN\6286395 ,_24\,\1740 but_25\CC\1740 preliminary_26\JJ\1740 clinical_27\JJ\1740 trials_28\NNS\786195 reported_29\VBD\831651 that_30\IN\1740 it_31\PRP\6125041 was_32\VBD\836236 painful_33\JJ\1740 upon_34\IN\1740 application_35\NN\947128 ._36\.\1740
C048279_D002056 NONE one_0\CD\13741022 <e2>burn</e2>_1\NN\14322699 site_2\NN\8673395 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 each_6\DT\1740 of_7\IN\1740 four_8\CD\13741022 different_9\JJ\1740 <e1>chp</e1>_10\NN\1740 concentrations_11\NNS\4916342 ,_12\,\1740 from_13\IN\1740 0.25_14\CD\1740 per_15\IN\1740 cent_16\NN\13662703 to_17\IN\1740 2_18\CD\13741022 per_19\NN\1740 cent_20\NN\13662703 ,_21\,\1740 their_22\PRP$\1740 vehicle_23\NN\3100490 ,_24\,\1740 and_25\CC\1740 1_26\CD\13741022 per_27\NN\1740 cent_28\NN\13662703 silver_29\NN\14821043 sulphadiazine_30\NN\1740 (_31\-LRB-\1740 agsd_32\NN\1740 )_33\-RRB-\1740 cream_34\NN\8386555 ,_35\,\1740 an_36\DT\6697703 antimicrobial_37\JJ\1740 agent_38\NN\7347 frequently_39\RB\1740 used_40\VBN\1156834 for_41\IN\1740 topical_42\JJ\1740 treatment_43\NN\654885 of_44\IN\1740 burn_45\NN\14322699 wounds_46\NNS\14285662 ._47\.\1740
C048279_D002056 NONE one_0\CD\13741022 burn_1\NN\14322699 site_2\NN\8673395 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 each_6\DT\1740 of_7\IN\1740 four_8\CD\13741022 different_9\JJ\1740 <e1>chp</e1>_10\NN\1740 concentrations_11\NNS\4916342 ,_12\,\1740 from_13\IN\1740 0.25_14\CD\1740 per_15\IN\1740 cent_16\NN\13662703 to_17\IN\1740 2_18\CD\13741022 per_19\NN\1740 cent_20\NN\13662703 ,_21\,\1740 their_22\PRP$\1740 vehicle_23\NN\3100490 ,_24\,\1740 and_25\CC\1740 1_26\CD\13741022 per_27\NN\1740 cent_28\NN\13662703 silver_29\NN\14821043 sulphadiazine_30\NN\1740 (_31\-LRB-\1740 agsd_32\NN\1740 )_33\-RRB-\1740 cream_34\NN\8386555 ,_35\,\1740 an_36\DT\6697703 antimicrobial_37\JJ\1740 agent_38\NN\7347 frequently_39\RB\1740 used_40\VBN\1156834 for_41\IN\1740 topical_42\JJ\1740 treatment_43\NN\654885 of_44\IN\1740 <e2>burn</e2>_45\NN\14322699 wounds_46\NNS\14285662 ._47\.\1740
D012837_D002056 NONE one_0\CD\13741022 <e2>burn</e2>_1\NN\14322699 site_2\NN\8673395 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 each_6\DT\1740 of_7\IN\1740 four_8\CD\13741022 different_9\JJ\1740 chp_10\NN\1740 concentrations_11\NNS\4916342 ,_12\,\1740 from_13\IN\1740 0.25_14\CD\1740 per_15\IN\1740 cent_16\NN\13662703 to_17\IN\1740 2_18\CD\13741022 per_19\NN\1740 cent_20\NN\13662703 ,_21\,\1740 their_22\PRP$\1740 vehicle_23\NN\3100490 ,_24\,\1740 and_25\CC\1740 1_26\CD\13741022 per_27\NN\1740 cent_28\NN\13662703 <e1>silver_29\NN\14821043 sulphadiazine</e1>_30\NN\1740 (_31\-LRB-\1740 agsd_32\NN\1740 )_33\-RRB-\1740 cream_34\NN\8386555 ,_35\,\1740 an_36\DT\6697703 antimicrobial_37\JJ\1740 agent_38\NN\7347 frequently_39\RB\1740 used_40\VBN\1156834 for_41\IN\1740 topical_42\JJ\1740 treatment_43\NN\654885 of_44\IN\1740 burn_45\NN\14322699 wounds_46\NNS\14285662 ._47\.\1740
D012837_D002056 NONE one_0\CD\13741022 burn_1\NN\14322699 site_2\NN\8673395 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 each_6\DT\1740 of_7\IN\1740 four_8\CD\13741022 different_9\JJ\1740 chp_10\NN\1740 concentrations_11\NNS\4916342 ,_12\,\1740 from_13\IN\1740 0.25_14\CD\1740 per_15\IN\1740 cent_16\NN\13662703 to_17\IN\1740 2_18\CD\13741022 per_19\NN\1740 cent_20\NN\13662703 ,_21\,\1740 their_22\PRP$\1740 vehicle_23\NN\3100490 ,_24\,\1740 and_25\CC\1740 1_26\CD\13741022 per_27\NN\1740 cent_28\NN\13662703 <e1>silver_29\NN\14821043 sulphadiazine</e1>_30\NN\1740 (_31\-LRB-\1740 agsd_32\NN\1740 )_33\-RRB-\1740 cream_34\NN\8386555 ,_35\,\1740 an_36\DT\6697703 antimicrobial_37\JJ\1740 agent_38\NN\7347 frequently_39\RB\1740 used_40\VBN\1156834 for_41\IN\1740 topical_42\JJ\1740 treatment_43\NN\654885 of_44\IN\1740 <e2>burn</e2>_45\NN\14322699 wounds_46\NNS\14285662 ._47\.\1740
D012837_D002056 NONE one_0\CD\13741022 <e2>burn</e2>_1\NN\14322699 site_2\NN\8673395 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 each_6\DT\1740 of_7\IN\1740 four_8\CD\13741022 different_9\JJ\1740 chp_10\NN\1740 concentrations_11\NNS\4916342 ,_12\,\1740 from_13\IN\1740 0.25_14\CD\1740 per_15\IN\1740 cent_16\NN\13662703 to_17\IN\1740 2_18\CD\13741022 per_19\NN\1740 cent_20\NN\13662703 ,_21\,\1740 their_22\PRP$\1740 vehicle_23\NN\3100490 ,_24\,\1740 and_25\CC\1740 1_26\CD\13741022 per_27\NN\1740 cent_28\NN\13662703 silver_29\NN\14821043 sulphadiazine_30\NN\1740 (_31\-LRB-\1740 <e1>agsd</e1>_32\NN\1740 )_33\-RRB-\1740 cream_34\NN\8386555 ,_35\,\1740 an_36\DT\6697703 antimicrobial_37\JJ\1740 agent_38\NN\7347 frequently_39\RB\1740 used_40\VBN\1156834 for_41\IN\1740 topical_42\JJ\1740 treatment_43\NN\654885 of_44\IN\1740 burn_45\NN\14322699 wounds_46\NNS\14285662 ._47\.\1740
D012837_D002056 NONE one_0\CD\13741022 burn_1\NN\14322699 site_2\NN\8673395 was_3\VBD\836236 treated_4\VBN\2376958 with_5\IN\1740 each_6\DT\1740 of_7\IN\1740 four_8\CD\13741022 different_9\JJ\1740 chp_10\NN\1740 concentrations_11\NNS\4916342 ,_12\,\1740 from_13\IN\1740 0.25_14\CD\1740 per_15\IN\1740 cent_16\NN\13662703 to_17\IN\1740 2_18\CD\13741022 per_19\NN\1740 cent_20\NN\13662703 ,_21\,\1740 their_22\PRP$\1740 vehicle_23\NN\3100490 ,_24\,\1740 and_25\CC\1740 1_26\CD\13741022 per_27\NN\1740 cent_28\NN\13662703 silver_29\NN\14821043 sulphadiazine_30\NN\1740 (_31\-LRB-\1740 <e1>agsd</e1>_32\NN\1740 )_33\-RRB-\1740 cream_34\NN\8386555 ,_35\,\1740 an_36\DT\6697703 antimicrobial_37\JJ\1740 agent_38\NN\7347 frequently_39\RB\1740 used_40\VBN\1156834 for_41\IN\1740 topical_42\JJ\1740 treatment_43\NN\654885 of_44\IN\1740 <e2>burn</e2>_45\NN\14322699 wounds_46\NNS\14285662 ._47\.\1740
C048279_D010146 CID there_0\EX\27167 was_1\VBD\836236 a_2\DT\13649268 direct_3\JJ\1740 relationship_4\NN\31921 between_5\IN\1740 <e1>chp</e1>_6\NN\1740 concentration_7\NN\4916342 and_8\CC\1740 patients_9\NNS\9898892 '_10\POS\1740 ratings_11\NNS\5733583 of_12\IN\1740 <e2>pain</e2>_13\NN\14299637 on_14\IN\1740 an_15\DT\6697703 analogue_16\NN\4743605 scale_17\NN\7260623 ._18\.\1740
C048279_D010146 CID the_0\DT\1740 0.25_1\CD\1740 per_2\IN\1740 cent_3\NN\13662703 <e1>chp</e1>_4\NN\1740 cream_5\NN\8386555 was_6\VBD\836236 closest_7\JJR\1740 to_8\TO\1740 agsd_9\NN\1740 in_10\IN\13603305 <e2>pain</e2>_11\NN\14299637 tolerance_12\NN\5032565 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 none_16\NN\15228378 of_17\IN\1740 the_18\DT\1740 treatments_19\NNS\654885 differed_20\VBD\1740 statistically_21\RB\1740 from_22\IN\1740 agsd_23\NN\1740 or_24\CC\3541091 from_25\IN\1740 each_26\DT\1740 other_27\JJ\1740 ._28\.\1740
D012837_D010146 NONE the_0\DT\1740 0.25_1\CD\1740 per_2\IN\1740 cent_3\NN\13662703 chp_4\NN\1740 cream_5\NN\8386555 was_6\VBD\836236 closest_7\JJR\1740 to_8\TO\1740 <e1>agsd</e1>_9\NN\1740 in_10\IN\13603305 <e2>pain</e2>_11\NN\14299637 tolerance_12\NN\5032565 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 none_16\NN\15228378 of_17\IN\1740 the_18\DT\1740 treatments_19\NNS\654885 differed_20\VBD\1740 statistically_21\RB\1740 from_22\IN\1740 agsd_23\NN\1740 or_24\CC\3541091 from_25\IN\1740 each_26\DT\1740 other_27\JJ\1740 ._28\.\1740
D012837_D010146 NONE the_0\DT\1740 0.25_1\CD\1740 per_2\IN\1740 cent_3\NN\13662703 chp_4\NN\1740 cream_5\NN\8386555 was_6\VBD\836236 closest_7\JJR\1740 to_8\TO\1740 agsd_9\NN\1740 in_10\IN\13603305 <e2>pain</e2>_11\NN\14299637 tolerance_12\NN\5032565 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 none_16\NN\15228378 of_17\IN\1740 the_18\DT\1740 treatments_19\NNS\654885 differed_20\VBD\1740 statistically_21\RB\1740 from_22\IN\1740 <e1>agsd</e1>_23\NN\1740 or_24\CC\3541091 from_25\IN\1740 each_26\DT\1740 other_27\JJ\1740 ._28\.\1740
9725303
D019469_D014517 NONE nonopaque_0\JJ\1740 crystal_1\JJ\1740 deposition_2\NN\13424865 causing_3\VBG\1617192 <e2>ureteric_4\JJ\1740 obstruction</e2>_5\NN\4341686 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 hiv_9\NN\14186340 undergoing_10\VBG\109660 <e1>indinavir</e1>_11\NN\4013993 therapy_12\NN\657604 ._13\.\1740
D019469_D014517 NONE conclusion_0\NN\5837957 :_1\:\1740 <e2>ureteric_2\NNP\1740 obstruction</e2>_3\NN\4341686 caused_4\VBN\1617192 by_5\IN\1740 precipitated_6\VBN\1642924 <e1>indinavir</e1>_7\NN\4013993 crystals_8\NNS\15046900 may_9\MD\15209706 be_10\VB\836236 difficult_11\JJ\1740 to_12\TO\1740 diagnose_13\VB\644583 with_14\IN\1740 unenhanced_15\JJ\1740 ct_16\NN\901316 ._17\.\1740
D019469_D014517 NONE images_0\NNS\5926676 may_1\MD\15209706 need_2\VB\2604760 to_3\TO\1740 be_4\VB\836236 obtained_5\VBN\2210855 using_6\VBG\1156834 i.v._7\NN\1740 contrast_8\NN\13854649 material_9\NN\19613 to_10\TO\1740 enable_11\VB\126264 diagnosis_12\NN\152018 of_13\IN\1740 <e2>ureteric_14\JJ\1740 stones_15\NNS\19128 or_16\CC\3541091 obstruction</e2>_17\NN\4341686 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 hiv_21\NN\14186340 infection_22\NN\14052046 who_23\WP\8299493 receive_24\VBP\2210855 <e1>indinavir</e1>_25\NN\4013993 therapy_26\NN\657604 ._27\.\1740
D019469_D014514 CID objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 describe_3\VBP\1001294 the_4\DT\1740 unique_5\JJ\1740 ct_6\NN\901316 features_7\NNS\5849040 of_8\IN\1740 <e2>ureteric_9\JJ\1740 calculi</e2>_10\NNS\9416076 in_11\IN\13603305 six_12\CD\13741022 hiv-infected_13\JJ\1740 patients_14\NNS\9898892 receiving_15\VBG\2210855 <e1>indinavir</e1>_16\NN\4013993 ,_17\,\1740 the_18\DT\1740 most_19\RBS\1740 commonly_20\RB\1740 used_21\VBN\1156834 hiv_22\NN\14186340 protease_23\NN\14732946 inhibitor_24\NN\20090 ,_25\,\1740 which_26\WDT\1740 is_27\VBZ\836236 associated_28\VBN\628491 with_29\IN\1740 an_30\DT\6697703 increased_31\VBN\169651 incidence_32\NN\13821570 of_33\IN\1740 urolithiasis_34\NN\1740 ._35\.\1740
D019469_D014514 NONE images_0\NNS\5926676 may_1\MD\15209706 need_2\VB\2604760 to_3\TO\1740 be_4\VB\836236 obtained_5\VBN\2210855 using_6\VBG\1156834 i.v._7\NN\1740 contrast_8\NN\13854649 material_9\NN\19613 to_10\TO\1740 enable_11\VB\126264 diagnosis_12\NN\152018 of_13\IN\1740 <e2>ureteric_14\JJ\1740 stones_15\NNS\19128 or_16\CC\3541091 obstruction</e2>_17\NN\4341686 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 hiv_21\NN\14186340 infection_22\NN\14052046 who_23\WP\8299493 receive_24\VBP\2210855 <e1>indinavir</e1>_25\NN\4013993 therapy_26\NN\657604 ._27\.\1740
D019469_D015658 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 describe_3\VBP\1001294 the_4\DT\1740 unique_5\JJ\1740 ct_6\NN\901316 features_7\NNS\5849040 of_8\IN\1740 ureteric_9\JJ\1740 calculi_10\NNS\9416076 in_11\IN\13603305 six_12\CD\13741022 <e2>hiv-infected</e2>_13\JJ\1740 patients_14\NNS\9898892 receiving_15\VBG\2210855 <e1>indinavir</e1>_16\NN\4013993 ,_17\,\1740 the_18\DT\1740 most_19\RBS\1740 commonly_20\RB\1740 used_21\VBN\1156834 hiv_22\NN\14186340 protease_23\NN\14732946 inhibitor_24\NN\20090 ,_25\,\1740 which_26\WDT\1740 is_27\VBZ\836236 associated_28\VBN\628491 with_29\IN\1740 an_30\DT\6697703 increased_31\VBN\169651 incidence_32\NN\13821570 of_33\IN\1740 urolithiasis_34\NN\1740 ._35\.\1740
D019469_D015658 NONE images_0\NNS\5926676 may_1\MD\15209706 need_2\VB\2604760 to_3\TO\1740 be_4\VB\836236 obtained_5\VBN\2210855 using_6\VBG\1156834 i.v._7\NN\1740 contrast_8\NN\13854649 material_9\NN\19613 to_10\TO\1740 enable_11\VB\126264 diagnosis_12\NN\152018 of_13\IN\1740 ureteric_14\JJ\1740 stones_15\NNS\19128 or_16\CC\3541091 obstruction_17\NN\4341686 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 <e2>hiv_21\NN\14186340 infection</e2>_22\NN\14052046 who_23\WP\8299493 receive_24\VBP\2210855 <e1>indinavir</e1>_25\NN\4013993 therapy_26\NN\657604 ._27\.\1740
D019469_D052878 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 describe_3\VBP\1001294 the_4\DT\1740 unique_5\JJ\1740 ct_6\NN\901316 features_7\NNS\5849040 of_8\IN\1740 ureteric_9\JJ\1740 calculi_10\NNS\9416076 in_11\IN\13603305 six_12\CD\13741022 hiv-infected_13\JJ\1740 patients_14\NNS\9898892 receiving_15\VBG\2210855 <e1>indinavir</e1>_16\NN\4013993 ,_17\,\1740 the_18\DT\1740 most_19\RBS\1740 commonly_20\RB\1740 used_21\VBN\1156834 hiv_22\NN\14186340 protease_23\NN\14732946 inhibitor_24\NN\20090 ,_25\,\1740 which_26\WDT\1740 is_27\VBZ\836236 associated_28\VBN\628491 with_29\IN\1740 an_30\DT\6697703 increased_31\VBN\169651 incidence_32\NN\13821570 of_33\IN\1740 <e2>urolithiasis</e2>_34\NN\1740 ._35\.\1740
10401555
C096012_D007859 NONE <e1>nociceptin/orphanin</e1>_0\NN\1740 fq_1\NN\1740 and_2\CC\1740 nocistatin_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 scopolamine_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
C096012_D007859 NONE <e1>nociceptin/orphanin_0\NN\1740 fq</e1>_1\NN\1740 and_2\CC\1740 nocistatin_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 scopolamine_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
C096012_D007859 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 <e1>nociceptin/orphanin</e1>_8\NN\1740 fq_9\NN\1740 and_10\CC\1740 nocistatin_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 scopolamine_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
C096012_D007859 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 <e1>nociceptin/orphanin_8\NN\1740 fq</e1>_9\NN\1740 and_10\CC\1740 nocistatin_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 scopolamine_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
C096012_D008569 NONE <e1>nociceptin/orphanin</e1>_0\NN\1740 fq_1\NN\1740 and_2\CC\1740 nocistatin_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 scopolamine_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
C096012_D008569 NONE <e1>nociceptin/orphanin_0\NN\1740 fq</e1>_1\NN\1740 and_2\CC\1740 nocistatin_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 scopolamine_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
C096012_D008569 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 <e1>nociceptin/orphanin</e1>_8\NN\1740 fq_9\NN\1740 and_10\CC\1740 nocistatin_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 scopolamine_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
C096012_D008569 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 <e1>nociceptin/orphanin_8\NN\1740 fq</e1>_9\NN\1740 and_10\CC\1740 nocistatin_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 scopolamine_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
C111148_D007859 NONE nociceptin/orphanin_0\NN\1740 fq_1\NN\1740 and_2\CC\1740 <e1>nocistatin</e1>_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 scopolamine_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
C111148_D007859 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 nociceptin/orphanin_8\NN\1740 fq_9\NN\1740 and_10\CC\1740 <e1>nocistatin</e1>_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 scopolamine_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
C111148_D008569 NONE nociceptin/orphanin_0\NN\1740 fq_1\NN\1740 and_2\CC\1740 <e1>nocistatin</e1>_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 scopolamine_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
C111148_D008569 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 nociceptin/orphanin_8\NN\1740 fq_9\NN\1740 and_10\CC\1740 <e1>nocistatin</e1>_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 scopolamine_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
D012601_D007859 CID nociceptin/orphanin_0\NN\1740 fq_1\NN\1740 and_2\CC\1740 nocistatin_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 <e1>scopolamine</e1>_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
D012601_D007859 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 nociceptin/orphanin_8\NN\1740 fq_9\NN\1740 and_10\CC\1740 nocistatin_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 <e1>scopolamine</e1>_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
D012601_D008569 CID nociceptin/orphanin_0\NN\1740 fq_1\NN\1740 and_2\CC\1740 nocistatin_3\NN\1740 on_4\IN\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairment</e2>_8\NN\7296428 induced_9\VBN\1627355 by_10\IN\1740 <e1>scopolamine</e1>_11\NN\14712692 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
D012601_D008569 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 whether_7\IN\1740 nociceptin/orphanin_8\NN\1740 fq_9\NN\1740 and_10\CC\1740 nocistatin_11\NN\1740 could_12\MD\1740 modulate_13\VB\1724459 <e2>impairment_14\NN\7296428 of_15\IN\1740 learning_16\NN\5701944 and_17\CC\1740 memory</e2>_18\NN\5926676 induced_19\VBN\1627355 by_20\IN\1740 <e1>scopolamine</e1>_21\NN\14712692 ,_22\,\1740 a_23\DT\13649268 muscarinic_24\JJ\1740 cholinergic_25\NN\1740 receptor_26\NN\5225602 antagonist_27\NN\7846 ,_28\,\1740 using_29\VBG\1156834 spontaneous_30\JJ\1740 alternation_31\NN\1010458 of_32\IN\1740 y-maze_33\JJ\1740 and_34\CC\1740 step-down_35\JJ\1740 type_36\NN\5839024 passive_37\JJ\1740 avoidance_38\NN\203342 tasks_39\NNS\575741 in_40\IN\13603305 mice_41\NNS\2329401 ._42\.\1740
C111148_D006930 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e1>nocistatin</e1>_5\NN\1740 is_6\VBZ\836236 recently_7\RB\1740 isolated_8\VBN\2512305 from_9\IN\1740 the_10\DT\1740 same_11\JJ\1740 precursor_12\NN\14580897 as_13\IN\14622893 nociceptin_14\NN\1740 and_15\CC\1740 blocks_16\VBZ\1476483 nociceptin-induced_17\JJ\1740 <e2>allodynia</e2>_18\NN\1740 and_19\CC\1740 hyperalgesia_20\NN\1740 ._21\.\1740
C111148_D006930 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e1>nocistatin</e1>_5\NN\1740 is_6\VBZ\836236 recently_7\RB\1740 isolated_8\VBN\2512305 from_9\IN\1740 the_10\DT\1740 same_11\JJ\1740 precursor_12\NN\14580897 as_13\IN\14622893 nociceptin_14\NN\1740 and_15\CC\1740 blocks_16\VBZ\1476483 nociceptin-induced_17\JJ\1740 allodynia_18\NN\1740 and_19\CC\1740 <e2>hyperalgesia</e2>_20\NN\1740 ._21\.\1740
C096012_D006930 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 nocistatin_5\NN\1740 is_6\VBZ\836236 recently_7\RB\1740 isolated_8\VBN\2512305 from_9\IN\1740 the_10\DT\1740 same_11\JJ\1740 precursor_12\NN\14580897 as_13\IN\14622893 <e1>nociceptin</e1>_14\NN\1740 and_15\CC\1740 blocks_16\VBZ\1476483 nociceptin-induced_17\JJ\1740 <e2>allodynia</e2>_18\NN\1740 and_19\CC\1740 hyperalgesia_20\NN\1740 ._21\.\1740
C096012_D006930 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 nocistatin_5\NN\1740 is_6\VBZ\836236 recently_7\RB\1740 isolated_8\VBN\2512305 from_9\IN\1740 the_10\DT\1740 same_11\JJ\1740 precursor_12\NN\14580897 as_13\IN\14622893 <e1>nociceptin</e1>_14\NN\1740 and_15\CC\1740 blocks_16\VBZ\1476483 nociceptin-induced_17\JJ\1740 allodynia_18\NN\1740 and_19\CC\1740 <e2>hyperalgesia</e2>_20\NN\1740 ._21\.\1740
C096012_D006930 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 nocistatin_5\NN\1740 is_6\VBZ\836236 recently_7\RB\1740 isolated_8\VBN\2512305 from_9\IN\1740 the_10\DT\1740 same_11\JJ\1740 precursor_12\NN\14580897 as_13\IN\14622893 nociceptin_14\NN\1740 and_15\CC\1740 blocks_16\VBZ\1476483 <e1>nociceptin-induced</e1>_17\JJ\1740 <e2>allodynia</e2>_18\NN\1740 and_19\CC\1740 hyperalgesia_20\NN\1740 ._21\.\1740
C096012_D006930 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 nocistatin_5\NN\1740 is_6\VBZ\836236 recently_7\RB\1740 isolated_8\VBN\2512305 from_9\IN\1740 the_10\DT\1740 same_11\JJ\1740 precursor_12\NN\14580897 as_13\IN\14622893 nociceptin_14\NN\1740 and_15\CC\1740 blocks_16\VBZ\1476483 <e1>nociceptin-induced</e1>_17\JJ\1740 allodynia_18\NN\1740 and_19\CC\1740 <e2>hyperalgesia</e2>_20\NN\1740 ._21\.\1740
3323259
D002118_D002318 NONE increasing_0\VBG\169651 recognition_1\NN\13932421 of_2\IN\1740 the_3\DT\1740 importance_4\NN\5138488 of_5\IN\1740 <e1>calcium</e1>_6\NN\14625458 in_7\IN\13603305 the_8\DT\1740 pathogenesis_9\NN\13533470 of_10\IN\1740 <e2>cardiovascular_11\JJ\1740 disease</e2>_12\NN\14061805 has_13\VBZ\2108377 stimulated_14\VBN\137313 research_15\NN\633864 into_16\IN\1740 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 calcium_20\NN\14625458 channel_21\NN\6251781 blocking_22\NN\562280 agents_23\NNS\7347 for_24\IN\1740 treatment_25\NN\654885 of_26\IN\1740 a_27\DT\13649268 variety_28\NN\7951464 of_29\IN\1740 cardiovascular_30\JJ\1740 diseases_31\NNS\14061805 ._32\.\1740
D002118_D002318 NONE increasing_0\VBG\169651 recognition_1\NN\13932421 of_2\IN\1740 the_3\DT\1740 importance_4\NN\5138488 of_5\IN\1740 <e1>calcium</e1>_6\NN\14625458 in_7\IN\13603305 the_8\DT\1740 pathogenesis_9\NN\13533470 of_10\IN\1740 cardiovascular_11\JJ\1740 disease_12\NN\14061805 has_13\VBZ\2108377 stimulated_14\VBN\137313 research_15\NN\633864 into_16\IN\1740 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 calcium_20\NN\14625458 channel_21\NN\6251781 blocking_22\NN\562280 agents_23\NNS\7347 for_24\IN\1740 treatment_25\NN\654885 of_26\IN\1740 a_27\DT\13649268 variety_28\NN\7951464 of_29\IN\1740 <e2>cardiovascular_30\JJ\1740 diseases</e2>_31\NNS\14061805 ._32\.\1740
D002121_D002318 NONE increasing_0\VBG\169651 recognition_1\NN\13932421 of_2\IN\1740 the_3\DT\1740 importance_4\NN\5138488 of_5\IN\1740 calcium_6\NN\14625458 in_7\IN\13603305 the_8\DT\1740 pathogenesis_9\NN\13533470 of_10\IN\1740 <e2>cardiovascular_11\JJ\1740 disease</e2>_12\NN\14061805 has_13\VBZ\2108377 stimulated_14\VBN\137313 research_15\NN\633864 into_16\IN\1740 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 <e1>calcium_20\NN\14625458 channel_21\NN\6251781 blocking_22\NN\562280 agents</e1>_23\NNS\7347 for_24\IN\1740 treatment_25\NN\654885 of_26\IN\1740 a_27\DT\13649268 variety_28\NN\7951464 of_29\IN\1740 cardiovascular_30\JJ\1740 diseases_31\NNS\14061805 ._32\.\1740
D002121_D002318 NONE increasing_0\VBG\169651 recognition_1\NN\13932421 of_2\IN\1740 the_3\DT\1740 importance_4\NN\5138488 of_5\IN\1740 calcium_6\NN\14625458 in_7\IN\13603305 the_8\DT\1740 pathogenesis_9\NN\13533470 of_10\IN\1740 cardiovascular_11\JJ\1740 disease_12\NN\14061805 has_13\VBZ\2108377 stimulated_14\VBN\137313 research_15\NN\633864 into_16\IN\1740 the_17\DT\1740 use_18\NN\407535 of_19\IN\1740 <e1>calcium_20\NN\14625458 channel_21\NN\6251781 blocking_22\NN\562280 agents</e1>_23\NNS\7347 for_24\IN\1740 treatment_25\NN\654885 of_26\IN\1740 a_27\DT\13649268 variety_28\NN\7951464 of_29\IN\1740 <e2>cardiovascular_30\JJ\1740 diseases</e2>_31\NNS\14061805 ._32\.\1740
C038806_D000787 NONE as_0\IN\14622893 the_1\DT\1740 first_2\JJ\1740 <e1>dihydropyridine</e1>_3\NN\1740 available_4\JJ\1740 for_5\IN\1740 use_6\NN\407535 in_7\IN\13603305 the_8\DT\1740 united_9\NNP\1740 states_10\NNP\8491826 ,_11\,\1740 nifedipine_12\NN\2938514 controls_13\VBZ\2422663 <e2>angina</e2>_14\NN\14171682 and_15\CC\1740 hypertension_16\NN\14057371 with_17\IN\1740 minimal_18\JJ\1740 depression_19\NN\14373582 of_20\IN\1740 cardiac_21\JJ\1740 function_22\NN\13783581 ._23\.\1740
C038806_D006973 NONE as_0\IN\14622893 the_1\DT\1740 first_2\JJ\1740 <e1>dihydropyridine</e1>_3\NN\1740 available_4\JJ\1740 for_5\IN\1740 use_6\NN\407535 in_7\IN\13603305 the_8\DT\1740 united_9\NNP\1740 states_10\NNP\8491826 ,_11\,\1740 nifedipine_12\NN\2938514 controls_13\VBZ\2422663 angina_14\NN\14171682 and_15\CC\1740 <e2>hypertension</e2>_16\NN\14057371 with_17\IN\1740 minimal_18\JJ\1740 depression_19\NN\14373582 of_20\IN\1740 cardiac_21\JJ\1740 function_22\NN\13783581 ._23\.\1740
D009543_D000787 NONE as_0\IN\14622893 the_1\DT\1740 first_2\JJ\1740 dihydropyridine_3\NN\1740 available_4\JJ\1740 for_5\IN\1740 use_6\NN\407535 in_7\IN\13603305 the_8\DT\1740 united_9\NNP\1740 states_10\NNP\8491826 ,_11\,\1740 <e1>nifedipine</e1>_12\NN\2938514 controls_13\VBZ\2422663 <e2>angina</e2>_14\NN\14171682 and_15\CC\1740 hypertension_16\NN\14057371 with_17\IN\1740 minimal_18\JJ\1740 depression_19\NN\14373582 of_20\IN\1740 cardiac_21\JJ\1740 function_22\NN\13783581 ._23\.\1740
D009543_D006973 NONE as_0\IN\14622893 the_1\DT\1740 first_2\JJ\1740 dihydropyridine_3\NN\1740 available_4\JJ\1740 for_5\IN\1740 use_6\NN\407535 in_7\IN\13603305 the_8\DT\1740 united_9\NNP\1740 states_10\NNP\8491826 ,_11\,\1740 <e1>nifedipine</e1>_12\NN\2938514 controls_13\VBZ\2422663 angina_14\NN\14171682 and_15\CC\1740 <e2>hypertension</e2>_16\NN\14057371 with_17\IN\1740 minimal_18\JJ\1740 depression_19\NN\14373582 of_20\IN\1740 cardiac_21\JJ\1740 function_22\NN\13783581 ._23\.\1740
D009568_D006973 NONE once_0\RB\1740 or_1\CC\3541091 twice_2\RB\1740 daily_3\RB\1740 dosage_4\NN\13576355 possible_5\JJ\1740 with_6\IN\1740 <e1>nitrendipine</e1>_7\JJ\1740 and_8\CC\1740 nisoldipine_9\NN\1740 offers_10\VBZ\2327200 a_11\DT\13649268 convenient_12\JJ\1740 administration_13\NN\1133281 schedule_14\NN\5898568 ,_15\,\1740 which_16\WDT\1740 encourages_17\VBZ\2556126 patient_18\NN\9898892 compliance_19\NN\1202904 in_20\IN\13603305 long-term_21\JJ\1740 therapy_22\NN\657604 of_23\IN\1740 <e2>hypertension</e2>_24\NN\14057371 ._25\.\1740
D015737_D006973 NONE once_0\RB\1740 or_1\CC\3541091 twice_2\RB\1740 daily_3\RB\1740 dosage_4\NN\13576355 possible_5\JJ\1740 with_6\IN\1740 nitrendipine_7\JJ\1740 and_8\CC\1740 <e1>nisoldipine</e1>_9\NN\1740 offers_10\VBZ\2327200 a_11\DT\13649268 convenient_12\JJ\1740 administration_13\NN\1133281 schedule_14\NN\5898568 ,_15\,\1740 which_16\WDT\1740 encourages_17\VBZ\2556126 patient_18\NN\9898892 compliance_19\NN\1202904 in_20\IN\13603305 long-term_21\JJ\1740 therapy_22\NN\657604 of_23\IN\1740 <e2>hypertension</e2>_24\NN\14057371 ._25\.\1740
D015737_D000787 NONE the_0\DT\1740 coronary_1\JJ\1740 vasodilating_2\NN\1740 properties_3\NNS\32613 of_4\IN\1740 <e1>nisoldipine</e1>_5\NN\1740 have_6\VBP\2108377 led_7\VBN\1752884 to_8\TO\1740 the_9\DT\1740 investigation_10\NN\5797597 of_11\IN\1740 this_12\DT\1740 agent_13\NN\7347 for_14\IN\1740 use_15\NN\407535 in_16\IN\13603305 <e2>angina</e2>_17\NN\14171682 ._18\.\1740
D009553_D013345 NONE selectivity_0\NN\4916342 for_1\IN\1740 the_2\DT\1740 cerebrovascular_3\JJ\1740 bed_4\NN\2821943 makes_5\VBZ\126264 <e1>nimodipine</e1>_6\NN\1740 potentially_7\RB\1740 useful_8\JJ\1740 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 <e2>subarachnoid_13\JJ\1740 hemorrhage</e2>_14\NN\14285662 ,_15\,\1740 migraine_16\NN\14326607 headache_17\NN\5829480 ,_18\,\1740 dementia_19\NN\14395018 ,_20\,\1740 and_21\CC\1740 stroke_22\RB\1740 ._23\.\1740
D009553_D008881 NONE selectivity_0\NN\4916342 for_1\IN\1740 the_2\DT\1740 cerebrovascular_3\JJ\1740 bed_4\NN\2821943 makes_5\VBZ\126264 <e1>nimodipine</e1>_6\NN\1740 potentially_7\RB\1740 useful_8\JJ\1740 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 subarachnoid_13\JJ\1740 hemorrhage_14\NN\14285662 ,_15\,\1740 <e2>migraine_16\NN\14326607 headache</e2>_17\NN\5829480 ,_18\,\1740 dementia_19\NN\14395018 ,_20\,\1740 and_21\CC\1740 stroke_22\RB\1740 ._23\.\1740
D009553_D003704 NONE selectivity_0\NN\4916342 for_1\IN\1740 the_2\DT\1740 cerebrovascular_3\JJ\1740 bed_4\NN\2821943 makes_5\VBZ\126264 <e1>nimodipine</e1>_6\NN\1740 potentially_7\RB\1740 useful_8\JJ\1740 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 subarachnoid_13\JJ\1740 hemorrhage_14\NN\14285662 ,_15\,\1740 migraine_16\NN\14326607 headache_17\NN\5829480 ,_18\,\1740 <e2>dementia</e2>_19\NN\14395018 ,_20\,\1740 and_21\CC\1740 stroke_22\RB\1740 ._23\.\1740
D009553_D020521 NONE selectivity_0\NN\4916342 for_1\IN\1740 the_2\DT\1740 cerebrovascular_3\JJ\1740 bed_4\NN\2821943 makes_5\VBZ\126264 <e1>nimodipine</e1>_6\NN\1740 potentially_7\RB\1740 useful_8\JJ\1740 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 subarachnoid_13\JJ\1740 hemorrhage_14\NN\14285662 ,_15\,\1740 migraine_16\NN\14326607 headache_17\NN\5829480 ,_18\,\1740 dementia_19\NN\14395018 ,_20\,\1740 and_21\CC\1740 <e2>stroke</e2>_22\RB\1740 ._23\.\1740
C038806_D006261 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 <e1>dihydropyridine</e1>_4\NN\1740 calcium_5\NN\14625458 channel_6\NN\6251781 blockers_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 <e2>headache</e2>_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
C038806_D005483 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 <e1>dihydropyridine</e1>_4\NN\1740 calcium_5\NN\14625458 channel_6\NN\6251781 blockers_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 <e2>flushing</e2>_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
C038806_-1 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 <e1>dihydropyridine</e1>_4\NN\1740 calcium_5\NN\14625458 channel_6\NN\6251781 blockers_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 <e2>palpitations</e2>_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
C038806_D004487 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 <e1>dihydropyridine</e1>_4\NN\1740 calcium_5\NN\14625458 channel_6\NN\6251781 blockers_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 <e2>edema</e2>_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
C038806_D009325 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 <e1>dihydropyridine</e1>_4\NN\1740 calcium_5\NN\14625458 channel_6\NN\6251781 blockers_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 <e2>nausea</e2>_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
C038806_D000855 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 <e1>dihydropyridine</e1>_4\NN\1740 calcium_5\NN\14625458 channel_6\NN\6251781 blockers_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 <e2>anorexia</e2>_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
C038806_D004244 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 <e1>dihydropyridine</e1>_4\NN\1740 calcium_5\NN\14625458 channel_6\NN\6251781 blockers_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 <e2>dizziness</e2>_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
D002121_D006261 CID in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 dihydropyridine_4\NN\1740 <e1>calcium_5\NN\14625458 channel_6\NN\6251781 blockers</e1>_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 <e2>headache</e2>_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
D002121_D005483 CID in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 dihydropyridine_4\NN\1740 <e1>calcium_5\NN\14625458 channel_6\NN\6251781 blockers</e1>_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 <e2>flushing</e2>_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
D002121_-1 NONE in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 dihydropyridine_4\NN\1740 <e1>calcium_5\NN\14625458 channel_6\NN\6251781 blockers</e1>_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 <e2>palpitations</e2>_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
D002121_D004487 CID in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 dihydropyridine_4\NN\1740 <e1>calcium_5\NN\14625458 channel_6\NN\6251781 blockers</e1>_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 <e2>edema</e2>_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
D002121_D009325 CID in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 dihydropyridine_4\NN\1740 <e1>calcium_5\NN\14625458 channel_6\NN\6251781 blockers</e1>_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 <e2>nausea</e2>_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
D002121_D000855 CID in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 dihydropyridine_4\NN\1740 <e1>calcium_5\NN\14625458 channel_6\NN\6251781 blockers</e1>_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 <e2>anorexia</e2>_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 dizziness_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
D002121_D004244 CID in_0\IN\13603305 general_1\JJ\1740 ,_2\,\1740 the_3\DT\1740 dihydropyridine_4\NN\1740 <e1>calcium_5\NN\14625458 channel_6\NN\6251781 blockers</e1>_7\NNS\10101634 are_8\VBP\836236 usually_9\RB\1740 well_10\RB\1740 tolerated_11\VBN\802318 ,_12\,\1740 with_13\IN\1740 headache_14\NN\5829480 ,_15\,\1740 facial_16\JJ\1740 flushing_17\NN\1740 ,_18\,\1740 palpitations_19\NNS\14299637 ,_20\,\1740 edema_21\NN\14315192 ,_22\,\1740 nausea_23\NN\14299637 ,_24\,\1740 anorexia_25\NN\14055623 ,_26\,\1740 and_27\CC\1740 <e2>dizziness</e2>_28\VB\1740 being_29\VBG\836236 the_30\DT\1740 more_31\RBR\1740 common_32\JJ\1740 adverse_33\JJ\1740 effects_34\NNS\13245626 ._35\.\1740
2884595
D006632_D014917 NONE blockade_0\NN\952963 of_1\IN\1740 <e1>histamine</e1>_2\NN\14739004 h1_3\NN\1740 receptors_4\NNS\5225602 may_5\MD\15209706 reduce_6\VB\441445 mortality_7\NN\5054863 in_8\IN\13603305 <e2>pertussis</e2>_9\NN\14127211 immunization-induced_10\JJ\1740 encephalopathy_11\JJ\1740 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
D006632_D001927 NONE blockade_0\NN\952963 of_1\IN\1740 <e1>histamine</e1>_2\NN\14739004 h1_3\NN\1740 receptors_4\NNS\5225602 may_5\MD\15209706 reduce_6\VB\441445 mortality_7\NN\5054863 in_8\IN\13603305 pertussis_9\NN\14127211 immunization-induced_10\JJ\1740 <e2>encephalopathy</e2>_11\JJ\1740 in_12\IN\13603305 mice_13\NNS\2329401 ._14\.\1740
2710809
D001712_D001919 CID <e2>bradycardia</e2>_0\NNP\14110674 due_1\IN\5174653 to_2\IN\1740 <e1>biperiden</e1>_3\JJ\1740 ._4\.\1740
D001712_D001919 CID <e2>bradycardia</e2>_0\NNP\14110674 induced_1\VBN\1627355 by_2\IN\1740 <e1>biperiden</e1>_3\NN\1740 is_4\VBZ\836236 attributed_5\VBN\670261 to_6\TO\1740 the_7\DT\1740 speed_8\NN\15286249 of_9\IN\1740 injection_10\NN\320852 and_11\CC\1740 to_12\TO\1740 a_13\DT\13649268 dose-related_14\JJ\1740 dual_15\JJ\1740 effect_16\NN\34213 of_17\IN\1740 atropine-like_18\JJ\1740 drugs_19\NNS\14778436 on_20\IN\1740 muscarine_21\NN\1740 receptors_22\NNS\5225602 ._23\.\1740
C036432_D006562 NONE in_0\IN\13603305 a_1\DT\13649268 38-year-old_2\JJ\1740 male_3\JJ\1740 patient_4\NN\9898892 suffering_5\VBG\2110220 from_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 <e2>postzosteric</e2>_9\JJ\1740 trigeminal_10\JJ\1740 neuralgia_11\NN\14322699 ,_12\,\1740 intravenous_13\JJ\1740 application_14\NN\947128 of_15\IN\1740 10_16\CD\13745420 mg_17\NN\13717155 <e1>biperiden_18\JJ\1740 lactate</e1>_19\NN\14850483 led_20\VBD\1752884 to_21\TO\1740 a_22\DT\13649268 long-lasting_23\JJ\1740 paradoxical_24\JJ\1740 reaction_25\NN\13446390 characterized_26\VBN\609683 by_27\IN\1740 considerable_28\JJ\1740 bradycardia_29\NN\14110674 ,_30\,\1740 dysarthria_31\NN\14400677 ,_32\,\1740 and_33\CC\1740 dysphagia_34\NN\14052403 ._35\.\1740
C036432_D014277 NONE in_0\IN\13603305 a_1\DT\13649268 38-year-old_2\JJ\1740 male_3\JJ\1740 patient_4\NN\9898892 suffering_5\VBG\2110220 from_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 postzosteric_9\JJ\1740 <e2>trigeminal_10\JJ\1740 neuralgia</e2>_11\NN\14322699 ,_12\,\1740 intravenous_13\JJ\1740 application_14\NN\947128 of_15\IN\1740 10_16\CD\13745420 mg_17\NN\13717155 <e1>biperiden_18\JJ\1740 lactate</e1>_19\NN\14850483 led_20\VBD\1752884 to_21\TO\1740 a_22\DT\13649268 long-lasting_23\JJ\1740 paradoxical_24\JJ\1740 reaction_25\NN\13446390 characterized_26\VBN\609683 by_27\IN\1740 considerable_28\JJ\1740 bradycardia_29\NN\14110674 ,_30\,\1740 dysarthria_31\NN\14400677 ,_32\,\1740 and_33\CC\1740 dysphagia_34\NN\14052403 ._35\.\1740
C036432_D001919 NONE in_0\IN\13603305 a_1\DT\13649268 38-year-old_2\JJ\1740 male_3\JJ\1740 patient_4\NN\9898892 suffering_5\VBG\2110220 from_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 postzosteric_9\JJ\1740 trigeminal_10\JJ\1740 neuralgia_11\NN\14322699 ,_12\,\1740 intravenous_13\JJ\1740 application_14\NN\947128 of_15\IN\1740 10_16\CD\13745420 mg_17\NN\13717155 <e1>biperiden_18\JJ\1740 lactate</e1>_19\NN\14850483 led_20\VBD\1752884 to_21\TO\1740 a_22\DT\13649268 long-lasting_23\JJ\1740 paradoxical_24\JJ\1740 reaction_25\NN\13446390 characterized_26\VBN\609683 by_27\IN\1740 considerable_28\JJ\1740 <e2>bradycardia</e2>_29\NN\14110674 ,_30\,\1740 dysarthria_31\NN\14400677 ,_32\,\1740 and_33\CC\1740 dysphagia_34\NN\14052403 ._35\.\1740
C036432_D004401 NONE in_0\IN\13603305 a_1\DT\13649268 38-year-old_2\JJ\1740 male_3\JJ\1740 patient_4\NN\9898892 suffering_5\VBG\2110220 from_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 postzosteric_9\JJ\1740 trigeminal_10\JJ\1740 neuralgia_11\NN\14322699 ,_12\,\1740 intravenous_13\JJ\1740 application_14\NN\947128 of_15\IN\1740 10_16\CD\13745420 mg_17\NN\13717155 <e1>biperiden_18\JJ\1740 lactate</e1>_19\NN\14850483 led_20\VBD\1752884 to_21\TO\1740 a_22\DT\13649268 long-lasting_23\JJ\1740 paradoxical_24\JJ\1740 reaction_25\NN\13446390 characterized_26\VBN\609683 by_27\IN\1740 considerable_28\JJ\1740 bradycardia_29\NN\14110674 ,_30\,\1740 <e2>dysarthria</e2>_31\NN\14400677 ,_32\,\1740 and_33\CC\1740 dysphagia_34\NN\14052403 ._35\.\1740
C036432_D003680 NONE in_0\IN\13603305 a_1\DT\13649268 38-year-old_2\JJ\1740 male_3\JJ\1740 patient_4\NN\9898892 suffering_5\VBG\2110220 from_6\IN\1740 a_7\DT\13649268 severe_8\JJ\1740 postzosteric_9\JJ\1740 trigeminal_10\JJ\1740 neuralgia_11\NN\14322699 ,_12\,\1740 intravenous_13\JJ\1740 application_14\NN\947128 of_15\IN\1740 10_16\CD\13745420 mg_17\NN\13717155 <e1>biperiden_18\JJ\1740 lactate</e1>_19\NN\14850483 led_20\VBD\1752884 to_21\TO\1740 a_22\DT\13649268 long-lasting_23\JJ\1740 paradoxical_24\JJ\1740 reaction_25\NN\13446390 characterized_26\VBN\609683 by_27\IN\1740 considerable_28\JJ\1740 bradycardia_29\NN\14110674 ,_30\,\1740 dysarthria_31\NN\14400677 ,_32\,\1740 and_33\CC\1740 <e2>dysphagia</e2>_34\NN\14052403 ._35\.\1740
D001285_D001919 NONE <e2>bradycardia</e2>_0\NNP\14110674 induced_1\VBN\1627355 by_2\IN\1740 biperiden_3\NN\1740 is_4\VBZ\836236 attributed_5\VBN\670261 to_6\TO\1740 the_7\DT\1740 speed_8\NN\15286249 of_9\IN\1740 injection_10\NN\320852 and_11\CC\1740 to_12\TO\1740 a_13\DT\13649268 dose-related_14\JJ\1740 dual_15\JJ\1740 effect_16\NN\34213 of_17\IN\1740 <e1>atropine-like</e1>_18\JJ\1740 drugs_19\NNS\14778436 on_20\IN\1740 muscarine_21\NN\1740 receptors_22\NNS\5225602 ._23\.\1740
D009116_D001919 NONE <e2>bradycardia</e2>_0\NNP\14110674 induced_1\VBN\1627355 by_2\IN\1740 biperiden_3\NN\1740 is_4\VBZ\836236 attributed_5\VBN\670261 to_6\TO\1740 the_7\DT\1740 speed_8\NN\15286249 of_9\IN\1740 injection_10\NN\320852 and_11\CC\1740 to_12\TO\1740 a_13\DT\13649268 dose-related_14\JJ\1740 dual_15\JJ\1740 effect_16\NN\34213 of_17\IN\1740 atropine-like_18\JJ\1740 drugs_19\NNS\14778436 on_20\IN\1740 <e1>muscarine</e1>_21\NN\1740 receptors_22\NNS\5225602 ._23\.\1740
12865514
D007980_D010300 NONE method_0\NN\5616786 :_1\:\1740 twenty-three_2\JJ\1740 patients_3\NNS\9898892 suffering_4\VBG\2110220 from_5\IN\1740 severe_6\JJ\1740 <e2>parkinson_7\NNP\1740 's_8\POS\1740 disease</e2>_9\NN\14061805 (_10\-LRB-\1740 stages_11\NNS\15113229 iii-v_12\NN\1740 on_13\IN\1740 hoehn_14\NNP\1740 and_15\CC\1740 yahr_16\NNP\1740 scale_17\NN\7260623 )_18\-RRB-\1740 and_19\CC\1740 ,_20\,\1740 particularly_21\RB\1740 bradykinesia_22\NN\1740 ,_23\,\1740 rigidity_24\NN\5023233 ,_25\,\1740 and_26\CC\1740 <e1>levodopa-induced</e1>_27\JJ\1740 dyskinesias_28\NNS\14084880 underwent_29\VBD\109660 bilateral_30\JJ\1740 implantation_31\NN\13526110 of_32\IN\1740 electrodes_33\NNS\3088707 in_34\IN\13603305 the_35\DT\1740 stn_36\NN\1740 ._37\.\1740
D007980_D018476 NONE method_0\NN\5616786 :_1\:\1740 twenty-three_2\JJ\1740 patients_3\NNS\9898892 suffering_4\VBG\2110220 from_5\IN\1740 severe_6\JJ\1740 parkinson_7\NNP\1740 's_8\POS\1740 disease_9\NN\14061805 (_10\-LRB-\1740 stages_11\NNS\15113229 iii-v_12\NN\1740 on_13\IN\1740 hoehn_14\NNP\1740 and_15\CC\1740 yahr_16\NNP\1740 scale_17\NN\7260623 )_18\-RRB-\1740 and_19\CC\1740 ,_20\,\1740 particularly_21\RB\1740 <e2>bradykinesia</e2>_22\NN\1740 ,_23\,\1740 rigidity_24\NN\5023233 ,_25\,\1740 and_26\CC\1740 <e1>levodopa-induced</e1>_27\JJ\1740 dyskinesias_28\NNS\14084880 underwent_29\VBD\109660 bilateral_30\JJ\1740 implantation_31\NN\13526110 of_32\IN\1740 electrodes_33\NNS\3088707 in_34\IN\13603305 the_35\DT\1740 stn_36\NN\1740 ._37\.\1740
D007980_D009127 NONE method_0\NN\5616786 :_1\:\1740 twenty-three_2\JJ\1740 patients_3\NNS\9898892 suffering_4\VBG\2110220 from_5\IN\1740 severe_6\JJ\1740 parkinson_7\NNP\1740 's_8\POS\1740 disease_9\NN\14061805 (_10\-LRB-\1740 stages_11\NNS\15113229 iii-v_12\NN\1740 on_13\IN\1740 hoehn_14\NNP\1740 and_15\CC\1740 yahr_16\NNP\1740 scale_17\NN\7260623 )_18\-RRB-\1740 and_19\CC\1740 ,_20\,\1740 particularly_21\RB\1740 bradykinesia_22\NN\1740 ,_23\,\1740 <e2>rigidity</e2>_24\NN\5023233 ,_25\,\1740 and_26\CC\1740 <e1>levodopa-induced</e1>_27\JJ\1740 dyskinesias_28\NNS\14084880 underwent_29\VBD\109660 bilateral_30\JJ\1740 implantation_31\NN\13526110 of_32\IN\1740 electrodes_33\NNS\3088707 in_34\IN\13603305 the_35\DT\1740 stn_36\NN\1740 ._37\.\1740
D007980_D004409 CID method_0\NN\5616786 :_1\:\1740 twenty-three_2\JJ\1740 patients_3\NNS\9898892 suffering_4\VBG\2110220 from_5\IN\1740 severe_6\JJ\1740 parkinson_7\NNP\1740 's_8\POS\1740 disease_9\NN\14061805 (_10\-LRB-\1740 stages_11\NNS\15113229 iii-v_12\NN\1740 on_13\IN\1740 hoehn_14\NNP\1740 and_15\CC\1740 yahr_16\NNP\1740 scale_17\NN\7260623 )_18\-RRB-\1740 and_19\CC\1740 ,_20\,\1740 particularly_21\RB\1740 bradykinesia_22\NN\1740 ,_23\,\1740 rigidity_24\NN\5023233 ,_25\,\1740 and_26\CC\1740 <e1>levodopa-induced</e1>_27\JJ\1740 <e2>dyskinesias</e2>_28\NNS\14084880 underwent_29\VBD\109660 bilateral_30\JJ\1740 implantation_31\NN\13526110 of_32\IN\1740 electrodes_33\NNS\3088707 in_34\IN\13603305 the_35\DT\1740 stn_36\NN\1740 ._37\.\1740
D007980_D004409 CID the_0\DT\1740 reduction_1\NN\351485 in_2\IN\13603305 the_3\DT\1740 <e1>levodopa</e1>_4\NN\14604959 dose_5\NN\3740161 is_6\VBZ\836236 useful_7\JJ\1740 in_8\IN\13603305 controlling_9\VBG\2422663 <e2>drug-induced_10\JJ\1740 dyskinesias</e2>_11\NNS\14084880 ._12\.\1740
16323982
D002784_D011471 NONE materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 studied_5\VBD\630380 with_6\IN\1740 a_7\DT\13649268 2.5_8\CD\1740 years_9\NNS\15144371 follow-up_10\VBD\1740 the_11\DT\1740 changes_12\NNS\7283608 in_13\IN\13603305 plasma_14\NN\5398023 <e1>cholesterols</e1>_15\NNS\15058310 (_16\-LRB-\1740 c_17\NN\13714184 )_18\-RRB-\1740 ,_19\,\1740 triglycerides_20\NNS\14885088 (_21\-LRB-\1740 tg_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 lipoproteins_25\NNS\14731135 (_26\-LRB-\1740 lp_27\NN\3924069 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 apolipoproteins_31\NNS\1740 (_32\-LRB-\1740 apo_33\NN\1740 )_34\-RRB-\1740 b-100_35\NN\1740 ,_36\,\1740 a-i_37\NN\1740 ,_38\,\1740 and_39\CC\1740 a-ii_40\JJ\1740 pro_41\JJ\1740 fi_42\NN\1740 les_43\NN\14187378 in_44\IN\13603305 24_45\CD\13745420 patients_46\NNS\9898892 of_47\IN\1740 mean_48\NN\6021761 age_49\NN\4916342 60_50\CD\13745420 years_51\NNS\15144371 with_52\IN\1740 low_53\JJ\1740 risk_54\NN\14541044 <e2>prostate_55\NN\5329735 cancer</e2>_56\NN\14239425 (_57\-LRB-\1740 stage_58\NN\15113229 :_59\:\1740 t1cn0m0_60\NN\1740 ,_61\,\1740 gleason_62\NN\1740 score_63\NN\5736149 :_64\:\1740 2_65\CD\13741022 -_66\SYM\1740 5_67\CD\13741022 )_68\-RRB-\1740 during_69\IN\1740 treatment_70\NN\654885 with_71\IN\1740 cyproterone_72\NN\1740 acetate_73\NN\15010703 (_74\-LRB-\1740 cpa_75\NN\9761403 )_76\-RRB-\1740 without_77\IN\1740 surgical_78\JJ\1740 management_79\NN\1123598 or_80\CC\3541091 radiation_81\NN\11452218 therapy_82\NN\657604 ._83\.\1740
D002784_D011471 NONE materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 studied_5\VBD\630380 with_6\IN\1740 a_7\DT\13649268 2.5_8\CD\1740 years_9\NNS\15144371 follow-up_10\VBD\1740 the_11\DT\1740 changes_12\NNS\7283608 in_13\IN\13603305 plasma_14\NN\5398023 cholesterols_15\NNS\15058310 (_16\-LRB-\1740 <e1>c</e1>_17\NN\13714184 )_18\-RRB-\1740 ,_19\,\1740 triglycerides_20\NNS\14885088 (_21\-LRB-\1740 tg_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 lipoproteins_25\NNS\14731135 (_26\-LRB-\1740 lp_27\NN\3924069 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 apolipoproteins_31\NNS\1740 (_32\-LRB-\1740 apo_33\NN\1740 )_34\-RRB-\1740 b-100_35\NN\1740 ,_36\,\1740 a-i_37\NN\1740 ,_38\,\1740 and_39\CC\1740 a-ii_40\JJ\1740 pro_41\JJ\1740 fi_42\NN\1740 les_43\NN\14187378 in_44\IN\13603305 24_45\CD\13745420 patients_46\NNS\9898892 of_47\IN\1740 mean_48\NN\6021761 age_49\NN\4916342 60_50\CD\13745420 years_51\NNS\15144371 with_52\IN\1740 low_53\JJ\1740 risk_54\NN\14541044 <e2>prostate_55\NN\5329735 cancer</e2>_56\NN\14239425 (_57\-LRB-\1740 stage_58\NN\15113229 :_59\:\1740 t1cn0m0_60\NN\1740 ,_61\,\1740 gleason_62\NN\1740 score_63\NN\5736149 :_64\:\1740 2_65\CD\13741022 -_66\SYM\1740 5_67\CD\13741022 )_68\-RRB-\1740 during_69\IN\1740 treatment_70\NN\654885 with_71\IN\1740 cyproterone_72\NN\1740 acetate_73\NN\15010703 (_74\-LRB-\1740 cpa_75\NN\9761403 )_76\-RRB-\1740 without_77\IN\1740 surgical_78\JJ\1740 management_79\NN\1123598 or_80\CC\3541091 radiation_81\NN\11452218 therapy_82\NN\657604 ._83\.\1740
D014280_D011471 NONE materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 studied_5\VBD\630380 with_6\IN\1740 a_7\DT\13649268 2.5_8\CD\1740 years_9\NNS\15144371 follow-up_10\VBD\1740 the_11\DT\1740 changes_12\NNS\7283608 in_13\IN\13603305 plasma_14\NN\5398023 cholesterols_15\NNS\15058310 (_16\-LRB-\1740 c_17\NN\13714184 )_18\-RRB-\1740 ,_19\,\1740 <e1>triglycerides</e1>_20\NNS\14885088 (_21\-LRB-\1740 tg_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 lipoproteins_25\NNS\14731135 (_26\-LRB-\1740 lp_27\NN\3924069 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 apolipoproteins_31\NNS\1740 (_32\-LRB-\1740 apo_33\NN\1740 )_34\-RRB-\1740 b-100_35\NN\1740 ,_36\,\1740 a-i_37\NN\1740 ,_38\,\1740 and_39\CC\1740 a-ii_40\JJ\1740 pro_41\JJ\1740 fi_42\NN\1740 les_43\NN\14187378 in_44\IN\13603305 24_45\CD\13745420 patients_46\NNS\9898892 of_47\IN\1740 mean_48\NN\6021761 age_49\NN\4916342 60_50\CD\13745420 years_51\NNS\15144371 with_52\IN\1740 low_53\JJ\1740 risk_54\NN\14541044 <e2>prostate_55\NN\5329735 cancer</e2>_56\NN\14239425 (_57\-LRB-\1740 stage_58\NN\15113229 :_59\:\1740 t1cn0m0_60\NN\1740 ,_61\,\1740 gleason_62\NN\1740 score_63\NN\5736149 :_64\:\1740 2_65\CD\13741022 -_66\SYM\1740 5_67\CD\13741022 )_68\-RRB-\1740 during_69\IN\1740 treatment_70\NN\654885 with_71\IN\1740 cyproterone_72\NN\1740 acetate_73\NN\15010703 (_74\-LRB-\1740 cpa_75\NN\9761403 )_76\-RRB-\1740 without_77\IN\1740 surgical_78\JJ\1740 management_79\NN\1123598 or_80\CC\3541091 radiation_81\NN\11452218 therapy_82\NN\657604 ._83\.\1740
D014280_D011471 NONE materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 studied_5\VBD\630380 with_6\IN\1740 a_7\DT\13649268 2.5_8\CD\1740 years_9\NNS\15144371 follow-up_10\VBD\1740 the_11\DT\1740 changes_12\NNS\7283608 in_13\IN\13603305 plasma_14\NN\5398023 cholesterols_15\NNS\15058310 (_16\-LRB-\1740 c_17\NN\13714184 )_18\-RRB-\1740 ,_19\,\1740 triglycerides_20\NNS\14885088 (_21\-LRB-\1740 <e1>tg</e1>_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 lipoproteins_25\NNS\14731135 (_26\-LRB-\1740 lp_27\NN\3924069 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 apolipoproteins_31\NNS\1740 (_32\-LRB-\1740 apo_33\NN\1740 )_34\-RRB-\1740 b-100_35\NN\1740 ,_36\,\1740 a-i_37\NN\1740 ,_38\,\1740 and_39\CC\1740 a-ii_40\JJ\1740 pro_41\JJ\1740 fi_42\NN\1740 les_43\NN\14187378 in_44\IN\13603305 24_45\CD\13745420 patients_46\NNS\9898892 of_47\IN\1740 mean_48\NN\6021761 age_49\NN\4916342 60_50\CD\13745420 years_51\NNS\15144371 with_52\IN\1740 low_53\JJ\1740 risk_54\NN\14541044 <e2>prostate_55\NN\5329735 cancer</e2>_56\NN\14239425 (_57\-LRB-\1740 stage_58\NN\15113229 :_59\:\1740 t1cn0m0_60\NN\1740 ,_61\,\1740 gleason_62\NN\1740 score_63\NN\5736149 :_64\:\1740 2_65\CD\13741022 -_66\SYM\1740 5_67\CD\13741022 )_68\-RRB-\1740 during_69\IN\1740 treatment_70\NN\654885 with_71\IN\1740 cyproterone_72\NN\1740 acetate_73\NN\15010703 (_74\-LRB-\1740 cpa_75\NN\9761403 )_76\-RRB-\1740 without_77\IN\1740 surgical_78\JJ\1740 management_79\NN\1123598 or_80\CC\3541091 radiation_81\NN\11452218 therapy_82\NN\657604 ._83\.\1740
D017373_D011471 NONE materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 studied_5\VBD\630380 with_6\IN\1740 a_7\DT\13649268 2.5_8\CD\1740 years_9\NNS\15144371 follow-up_10\VBD\1740 the_11\DT\1740 changes_12\NNS\7283608 in_13\IN\13603305 plasma_14\NN\5398023 cholesterols_15\NNS\15058310 (_16\-LRB-\1740 c_17\NN\13714184 )_18\-RRB-\1740 ,_19\,\1740 triglycerides_20\NNS\14885088 (_21\-LRB-\1740 tg_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 lipoproteins_25\NNS\14731135 (_26\-LRB-\1740 lp_27\NN\3924069 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 apolipoproteins_31\NNS\1740 (_32\-LRB-\1740 apo_33\NN\1740 )_34\-RRB-\1740 b-100_35\NN\1740 ,_36\,\1740 a-i_37\NN\1740 ,_38\,\1740 and_39\CC\1740 a-ii_40\JJ\1740 pro_41\JJ\1740 fi_42\NN\1740 les_43\NN\14187378 in_44\IN\13603305 24_45\CD\13745420 patients_46\NNS\9898892 of_47\IN\1740 mean_48\NN\6021761 age_49\NN\4916342 60_50\CD\13745420 years_51\NNS\15144371 with_52\IN\1740 low_53\JJ\1740 risk_54\NN\14541044 <e2>prostate_55\NN\5329735 cancer</e2>_56\NN\14239425 (_57\-LRB-\1740 stage_58\NN\15113229 :_59\:\1740 t1cn0m0_60\NN\1740 ,_61\,\1740 gleason_62\NN\1740 score_63\NN\5736149 :_64\:\1740 2_65\CD\13741022 -_66\SYM\1740 5_67\CD\13741022 )_68\-RRB-\1740 during_69\IN\1740 treatment_70\NN\654885 with_71\IN\1740 <e1>cyproterone_72\NN\1740 acetate</e1>_73\NN\15010703 (_74\-LRB-\1740 cpa_75\NN\9761403 )_76\-RRB-\1740 without_77\IN\1740 surgical_78\JJ\1740 management_79\NN\1123598 or_80\CC\3541091 radiation_81\NN\11452218 therapy_82\NN\657604 ._83\.\1740
D017373_D011471 NONE materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 studied_5\VBD\630380 with_6\IN\1740 a_7\DT\13649268 2.5_8\CD\1740 years_9\NNS\15144371 follow-up_10\VBD\1740 the_11\DT\1740 changes_12\NNS\7283608 in_13\IN\13603305 plasma_14\NN\5398023 cholesterols_15\NNS\15058310 (_16\-LRB-\1740 c_17\NN\13714184 )_18\-RRB-\1740 ,_19\,\1740 triglycerides_20\NNS\14885088 (_21\-LRB-\1740 tg_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 lipoproteins_25\NNS\14731135 (_26\-LRB-\1740 lp_27\NN\3924069 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 apolipoproteins_31\NNS\1740 (_32\-LRB-\1740 apo_33\NN\1740 )_34\-RRB-\1740 b-100_35\NN\1740 ,_36\,\1740 a-i_37\NN\1740 ,_38\,\1740 and_39\CC\1740 a-ii_40\JJ\1740 pro_41\JJ\1740 fi_42\NN\1740 les_43\NN\14187378 in_44\IN\13603305 24_45\CD\13745420 patients_46\NNS\9898892 of_47\IN\1740 mean_48\NN\6021761 age_49\NN\4916342 60_50\CD\13745420 years_51\NNS\15144371 with_52\IN\1740 low_53\JJ\1740 risk_54\NN\14541044 <e2>prostate_55\NN\5329735 cancer</e2>_56\NN\14239425 (_57\-LRB-\1740 stage_58\NN\15113229 :_59\:\1740 t1cn0m0_60\NN\1740 ,_61\,\1740 gleason_62\NN\1740 score_63\NN\5736149 :_64\:\1740 2_65\CD\13741022 -_66\SYM\1740 5_67\CD\13741022 )_68\-RRB-\1740 during_69\IN\1740 treatment_70\NN\654885 with_71\IN\1740 cyproterone_72\NN\1740 acetate_73\NN\15010703 (_74\-LRB-\1740 <e1>cpa</e1>_75\NN\9761403 )_76\-RRB-\1740 without_77\IN\1740 surgical_78\JJ\1740 management_79\NN\1123598 or_80\CC\3541091 radiation_81\NN\11452218 therapy_82\NN\657604 ._83\.\1740
D017373_D003327 NONE after_0\IN\1740 a_1\DT\13649268 period_2\NN\13575869 of_3\IN\1740 2.5_4\CD\1740 years_5\NNS\15144371 on_6\IN\1740 <e1>cpa</e1>_7\NN\9761403 treatment_8\NN\654885 ,_9\,\1740 four_10\CD\13741022 patients_11\NNS\9898892 out_12\IN\66636 of_13\IN\1740 twenty-four_14\NN\13745420 were_15\VBD\836236 found_16\VBN\2426171 to_17\TO\1740 be_18\VB\836236 affected_19\VBN\126264 by_20\IN\1740 <e2>coronary_21\JJ\1740 heart_22\NN\5919034 disease</e2>_23\NN\14061805 ._24\.\1740
D017373_D003324 CID conclusions_0\NNS\5837957 :_1\:\1740 ischaemic_2\JJ\1740 <e2>coronary_3\JJ\1740 arteriosclerosis</e2>_4\NN\14110411 with_5\IN\1740 an_6\DT\6697703 incidence_7\NN\13821570 rate_8\NN\13815152 of_9\IN\1740 16.6_10\CD\1740 %_11\NN\1740 as_12\IN\14622893 caused_13\VBN\1617192 by_14\IN\1740 prolonged_15\JJ\1740 <e1>cpa</e1>_16\NN\9761403 therapy_17\NN\657604 is_18\VBZ\836236 mediated_19\VBN\761713 through_20\IN\1740 changes_21\NNS\7283608 in_22\IN\13603305 hdl_23\NN\14939230 cholesterol_24\NN\15058310 ,_25\,\1740 apo_26\NN\1740 a-i_27\NN\1740 and_28\CC\1740 apo_29\JJ\1740 a-ii_30\NN\1740 pro_31\JJ\1740 fi_32\NN\1740 les_33\NN\14187378 ,_34\,\1740 other_35\JJ\1740 than_36\IN\1740 the_37\DT\1740 well-known_38\JJ\1740 hyperglyceridemic_39\JJ\1740 effect_40\NN\34213 caused_41\VBN\1617192 by_42\IN\1740 estrogen_43\NN\14745635 ._44\.\1740
D017373_D050171 CID conclusions_0\NNS\5837957 :_1\:\1740 ischaemic_2\JJ\1740 coronary_3\JJ\1740 arteriosclerosis_4\NN\14110411 with_5\IN\1740 an_6\DT\6697703 incidence_7\NN\13821570 rate_8\NN\13815152 of_9\IN\1740 16.6_10\CD\1740 %_11\NN\1740 as_12\IN\14622893 caused_13\VBN\1617192 by_14\IN\1740 prolonged_15\JJ\1740 <e1>cpa</e1>_16\NN\9761403 therapy_17\NN\657604 is_18\VBZ\836236 mediated_19\VBN\761713 through_20\IN\1740 changes_21\NNS\7283608 in_22\IN\13603305 hdl_23\NN\14939230 cholesterol_24\NN\15058310 ,_25\,\1740 apo_26\NN\1740 a-i_27\NN\1740 and_28\CC\1740 apo_29\JJ\1740 a-ii_30\NN\1740 pro_31\JJ\1740 fi_32\NN\1740 les_33\NN\14187378 ,_34\,\1740 other_35\JJ\1740 than_36\IN\1740 the_37\DT\1740 well-known_38\JJ\1740 <e2>hyperglyceridemic_39\JJ\1740 effect</e2>_40\NN\34213 caused_41\VBN\1617192 by_42\IN\1740 estrogen_43\NN\14745635 ._44\.\1740
D002784_D003324 NONE conclusions_0\NNS\5837957 :_1\:\1740 ischaemic_2\JJ\1740 <e2>coronary_3\JJ\1740 arteriosclerosis</e2>_4\NN\14110411 with_5\IN\1740 an_6\DT\6697703 incidence_7\NN\13821570 rate_8\NN\13815152 of_9\IN\1740 16.6_10\CD\1740 %_11\NN\1740 as_12\IN\14622893 caused_13\VBN\1617192 by_14\IN\1740 prolonged_15\JJ\1740 cpa_16\NN\9761403 therapy_17\NN\657604 is_18\VBZ\836236 mediated_19\VBN\761713 through_20\IN\1740 changes_21\NNS\7283608 in_22\IN\13603305 hdl_23\NN\14939230 <e1>cholesterol</e1>_24\NN\15058310 ,_25\,\1740 apo_26\NN\1740 a-i_27\NN\1740 and_28\CC\1740 apo_29\JJ\1740 a-ii_30\NN\1740 pro_31\JJ\1740 fi_32\NN\1740 les_33\NN\14187378 ,_34\,\1740 other_35\JJ\1740 than_36\IN\1740 the_37\DT\1740 well-known_38\JJ\1740 hyperglyceridemic_39\JJ\1740 effect_40\NN\34213 caused_41\VBN\1617192 by_42\IN\1740 estrogen_43\NN\14745635 ._44\.\1740
D002784_D050171 NONE conclusions_0\NNS\5837957 :_1\:\1740 ischaemic_2\JJ\1740 coronary_3\JJ\1740 arteriosclerosis_4\NN\14110411 with_5\IN\1740 an_6\DT\6697703 incidence_7\NN\13821570 rate_8\NN\13815152 of_9\IN\1740 16.6_10\CD\1740 %_11\NN\1740 as_12\IN\14622893 caused_13\VBN\1617192 by_14\IN\1740 prolonged_15\JJ\1740 cpa_16\NN\9761403 therapy_17\NN\657604 is_18\VBZ\836236 mediated_19\VBN\761713 through_20\IN\1740 changes_21\NNS\7283608 in_22\IN\13603305 hdl_23\NN\14939230 <e1>cholesterol</e1>_24\NN\15058310 ,_25\,\1740 apo_26\NN\1740 a-i_27\NN\1740 and_28\CC\1740 apo_29\JJ\1740 a-ii_30\NN\1740 pro_31\JJ\1740 fi_32\NN\1740 les_33\NN\14187378 ,_34\,\1740 other_35\JJ\1740 than_36\IN\1740 the_37\DT\1740 well-known_38\JJ\1740 <e2>hyperglyceridemic_39\JJ\1740 effect</e2>_40\NN\34213 caused_41\VBN\1617192 by_42\IN\1740 estrogen_43\NN\14745635 ._44\.\1740
D004967_D003324 NONE conclusions_0\NNS\5837957 :_1\:\1740 ischaemic_2\JJ\1740 <e2>coronary_3\JJ\1740 arteriosclerosis</e2>_4\NN\14110411 with_5\IN\1740 an_6\DT\6697703 incidence_7\NN\13821570 rate_8\NN\13815152 of_9\IN\1740 16.6_10\CD\1740 %_11\NN\1740 as_12\IN\14622893 caused_13\VBN\1617192 by_14\IN\1740 prolonged_15\JJ\1740 cpa_16\NN\9761403 therapy_17\NN\657604 is_18\VBZ\836236 mediated_19\VBN\761713 through_20\IN\1740 changes_21\NNS\7283608 in_22\IN\13603305 hdl_23\NN\14939230 cholesterol_24\NN\15058310 ,_25\,\1740 apo_26\NN\1740 a-i_27\NN\1740 and_28\CC\1740 apo_29\JJ\1740 a-ii_30\NN\1740 pro_31\JJ\1740 fi_32\NN\1740 les_33\NN\14187378 ,_34\,\1740 other_35\JJ\1740 than_36\IN\1740 the_37\DT\1740 well-known_38\JJ\1740 hyperglyceridemic_39\JJ\1740 effect_40\NN\34213 caused_41\VBN\1617192 by_42\IN\1740 <e1>estrogen</e1>_43\NN\14745635 ._44\.\1740
D004967_D050171 NONE conclusions_0\NNS\5837957 :_1\:\1740 ischaemic_2\JJ\1740 coronary_3\JJ\1740 arteriosclerosis_4\NN\14110411 with_5\IN\1740 an_6\DT\6697703 incidence_7\NN\13821570 rate_8\NN\13815152 of_9\IN\1740 16.6_10\CD\1740 %_11\NN\1740 as_12\IN\14622893 caused_13\VBN\1617192 by_14\IN\1740 prolonged_15\JJ\1740 cpa_16\NN\9761403 therapy_17\NN\657604 is_18\VBZ\836236 mediated_19\VBN\761713 through_20\IN\1740 changes_21\NNS\7283608 in_22\IN\13603305 hdl_23\NN\14939230 cholesterol_24\NN\15058310 ,_25\,\1740 apo_26\NN\1740 a-i_27\NN\1740 and_28\CC\1740 apo_29\JJ\1740 a-ii_30\NN\1740 pro_31\JJ\1740 fi_32\NN\1740 les_33\NN\14187378 ,_34\,\1740 other_35\JJ\1740 than_36\IN\1740 the_37\DT\1740 well-known_38\JJ\1740 <e2>hyperglyceridemic_39\JJ\1740 effect</e2>_40\NN\34213 caused_41\VBN\1617192 by_42\IN\1740 <e1>estrogen</e1>_43\NN\14745635 ._44\.\1740
16723784
D015764_D001281 NONE clinical_0\JJ\1740 evaluation_1\NN\874067 of_2\IN\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 during_5\IN\1740 <e1>bepridil</e1>_6\JJ\1740 administration_7\NN\1133281 for_8\IN\1740 <e2>atrial_9\JJ\1740 fibrillation_10\NN\14361664 and_11\CC\1740 flutter</e2>_12\NN\331950 ._13\.\1740
D015764_D001281 NONE background_0\NN\4921011 :_1\:\1740 <e1>bepridil_2\NNP\1740 hydrochloride</e1>_3\NN\14817592 (_4\-LRB-\1740 bpd_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 <e2>atrial_15\JJ\1740 fibrillation</e2>_16\NN\14361664 (_17\-LRB-\1740 af_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 atrial_21\JJ\1740 flutter_22\NN\331950 (_23\-LRB-\1740 afl_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001281 NONE background_0\NN\4921011 :_1\:\1740 <e1>bepridil_2\NNP\1740 hydrochloride</e1>_3\NN\14817592 (_4\-LRB-\1740 bpd_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 atrial_15\JJ\1740 fibrillation_16\NN\14361664 (_17\-LRB-\1740 <e2>af</e2>_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 atrial_21\JJ\1740 flutter_22\NN\331950 (_23\-LRB-\1740 afl_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001281 NONE background_0\NN\4921011 :_1\:\1740 bepridil_2\NNP\1740 hydrochloride_3\NN\14817592 (_4\-LRB-\1740 <e1>bpd</e1>_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 <e2>atrial_15\JJ\1740 fibrillation</e2>_16\NN\14361664 (_17\-LRB-\1740 af_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 atrial_21\JJ\1740 flutter_22\NN\331950 (_23\-LRB-\1740 afl_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001281 NONE background_0\NN\4921011 :_1\:\1740 bepridil_2\NNP\1740 hydrochloride_3\NN\14817592 (_4\-LRB-\1740 <e1>bpd</e1>_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 atrial_15\JJ\1740 fibrillation_16\NN\14361664 (_17\-LRB-\1740 <e2>af</e2>_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 atrial_21\JJ\1740 flutter_22\NN\331950 (_23\-LRB-\1740 afl_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001281 NONE <e1>bpd</e1>_0\NN\1740 was_1\VBD\836236 administered_2\VBN\2436349 to_3\TO\1740 459_4\CD\1740 patients_5\NNS\9898892 (_6\-LRB-\1740 361_7\CD\1740 males_8\NNS\15388 ,_9\,\1740 63+/-12_10\CD\1740 years_11\NNS\15144371 old_12\JJ\1740 )_13\-RRB-\1740 comprising_14\VBG\2604760 378_15\CD\1740 <e2>af</e2>_16\NN\1740 and_17\CC\1740 81_18\CD\1740 afl_19\NN\8303504 cases_20\NNS\7283608 ._21\.\1740
D015764_D001282 NONE clinical_0\JJ\1740 evaluation_1\NN\874067 of_2\IN\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 during_5\IN\1740 <e1>bepridil</e1>_6\JJ\1740 administration_7\NN\1133281 for_8\IN\1740 <e2>atrial_9\JJ\1740 fibrillation_10\NN\14361664 and_11\CC\1740 flutter</e2>_12\NN\331950 ._13\.\1740
D015764_D001282 NONE background_0\NN\4921011 :_1\:\1740 <e1>bepridil_2\NNP\1740 hydrochloride</e1>_3\NN\14817592 (_4\-LRB-\1740 bpd_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 atrial_15\JJ\1740 fibrillation_16\NN\14361664 (_17\-LRB-\1740 af_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 <e2>atrial_21\JJ\1740 flutter</e2>_22\NN\331950 (_23\-LRB-\1740 afl_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001282 NONE background_0\NN\4921011 :_1\:\1740 <e1>bepridil_2\NNP\1740 hydrochloride</e1>_3\NN\14817592 (_4\-LRB-\1740 bpd_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 atrial_15\JJ\1740 fibrillation_16\NN\14361664 (_17\-LRB-\1740 af_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 atrial_21\JJ\1740 flutter_22\NN\331950 (_23\-LRB-\1740 <e2>afl</e2>_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001282 NONE background_0\NN\4921011 :_1\:\1740 bepridil_2\NNP\1740 hydrochloride_3\NN\14817592 (_4\-LRB-\1740 <e1>bpd</e1>_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 atrial_15\JJ\1740 fibrillation_16\NN\14361664 (_17\-LRB-\1740 af_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 <e2>atrial_21\JJ\1740 flutter</e2>_22\NN\331950 (_23\-LRB-\1740 afl_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001282 NONE background_0\NN\4921011 :_1\:\1740 bepridil_2\NNP\1740 hydrochloride_3\NN\14817592 (_4\-LRB-\1740 <e1>bpd</e1>_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 attracted_8\VBN\1448100 attention_9\NN\5701944 as_10\IN\14622893 an_11\DT\6697703 effective_12\JJ\1740 drug_13\NN\14778436 for_14\IN\1740 atrial_15\JJ\1740 fibrillation_16\NN\14361664 (_17\-LRB-\1740 af_18\NN\1740 )_19\-RRB-\1740 and_20\CC\1740 atrial_21\JJ\1740 flutter_22\NN\331950 (_23\-LRB-\1740 <e2>afl</e2>_24\NN\8303504 )_25\-RRB-\1740 ._26\.\1740
D015764_D001282 NONE <e1>bpd</e1>_0\NN\1740 was_1\VBD\836236 administered_2\VBN\2436349 to_3\TO\1740 459_4\CD\1740 patients_5\NNS\9898892 (_6\-LRB-\1740 361_7\CD\1740 males_8\NNS\15388 ,_9\,\1740 63+/-12_10\CD\1740 years_11\NNS\15144371 old_12\JJ\1740 )_13\-RRB-\1740 comprising_14\VBG\2604760 378_15\CD\1740 af_16\NN\1740 and_17\CC\1740 81_18\CD\1740 <e2>afl</e2>_19\NN\8303504 cases_20\NNS\7283608 ._21\.\1740
15321332
D004329_D001008 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 postoperative_3\JJ\1740 <e2>anxiety</e2>_4\NN\14373582 due_5\IN\5174653 to_6\TO\1740 low_7\JJ\1740 dose_8\NN\3740161 <e1>droperidol</e1>_9\NN\1740 used_10\VBN\1156834 with_11\IN\1740 patient-controlled_12\JJ\1740 analgesia_13\NN\14034177 ._14\.\1740
D004329_D001008 CID the_0\DT\1740 diagnosis_1\NN\152018 of_2\IN\1740 <e1>droperidol-induced</e1>_3\JJ\1740 <e2>psychological_4\JJ\1740 disturbance</e2>_5\NN\407535 was_6\VBD\836236 not_7\RB\1740 made_8\VBN\126264 straight_9\RB\1740 away_10\RB\1740 although_11\IN\1740 on_12\IN\1740 subsequent_13\JJ\1740 close_14\NN\15266911 questioning_15\VBG\868591 the_16\DT\1740 patient_17\NN\9898892 gave_18\VBD\2327200 a_19\DT\13649268 very_20\RB\1740 clear_21\JJ\1740 history_22\NN\15120823 ._23\.\1740
19920070
D010634_D006529 CID liver-specific_0\JJ\1740 ablation_1\NN\671351 of_2\IN\1740 integrin-linked_3\JJ\1740 kinase_4\NN\14732946 in_5\IN\13603305 mice_6\NNS\2329401 results_7\VBZ\2633881 in_8\IN\13603305 enhanced_9\VBN\227165 and_10\CC\1740 prolonged_11\JJ\1740 cell_12\NN\3080309 proliferation_13\NN\13489037 and_14\CC\1740 <e2>hepatomegaly</e2>_15\NN\14501726 after_16\IN\1740 <e1>phenobarbital</e1>_17\JJ\1740 administration_18\NN\1133281 ._19\.\1740
6806735
D002945_D010051 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>ovarian_2\JJ\1740 cancer</e2>_3\NN\14239425 with_4\IN\1740 a_5\DT\13649268 combination_6\NN\7951464 of_7\IN\1740 <e1>cis-platinum</e1>_8\NN\1740 ,_9\,\1740 adriamycin_10\NN\1740 ,_11\,\1740 cyclophosphamide_12\NN\1740 and_13\CC\1740 hexamethylmelamine_14\NN\1740 ._15\.\1740
D002945_D010051 NONE during_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 2_3\CD\13741022 1/2_4\CD\1740 years_5\NNS\15144371 ,_6\,\1740 38_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 a_15\DT\13649268 combination_16\NN\7951464 of_17\IN\1740 <e1>cisplatinum</e1>_18\NN\1740 (_19\-LRB-\1740 cpdd_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 50_23\CD\13745420 mg/m2_24\NN\1740 ,_25\,\1740 adriamycin_26\NN\1740 ,_27\,\1740 30_28\CD\13745420 mg/m2_29\NN\1740 ,_30\,\1740 cyclophosphamide_31\NN\1740 ,_32\,\1740 300_33\CD\1740 mg/m2_34\NN\1740 ,_35\,\1740 on_36\IN\1740 day_37\NN\15154774 1_38\CD\13741022 ;_39\:\1740 and_40\CC\1740 hexamethylmelamine_41\NN\1740 (_42\-LRB-\1740 hmm_43\NN\1740 )_44\-RRB-\1740 ,_45\,\1740 6_46\CD\13741022 mg/kg_47\NN\1740 daily_48\RB\1740 ,_49\,\1740 for_50\IN\1740 14_51\CD\13745420 days_52\NNS\15140892 ._53\.\1740
D004317_D010051 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>ovarian_2\JJ\1740 cancer</e2>_3\NN\14239425 with_4\IN\1740 a_5\DT\13649268 combination_6\NN\7951464 of_7\IN\1740 cis-platinum_8\NN\1740 ,_9\,\1740 <e1>adriamycin</e1>_10\NN\1740 ,_11\,\1740 cyclophosphamide_12\NN\1740 and_13\CC\1740 hexamethylmelamine_14\NN\1740 ._15\.\1740
D004317_D010051 NONE during_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 2_3\CD\13741022 1/2_4\CD\1740 years_5\NNS\15144371 ,_6\,\1740 38_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 a_15\DT\13649268 combination_16\NN\7951464 of_17\IN\1740 cisplatinum_18\NN\1740 (_19\-LRB-\1740 cpdd_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 50_23\CD\13745420 mg/m2_24\NN\1740 ,_25\,\1740 <e1>adriamycin</e1>_26\NN\1740 ,_27\,\1740 30_28\CD\13745420 mg/m2_29\NN\1740 ,_30\,\1740 cyclophosphamide_31\NN\1740 ,_32\,\1740 300_33\CD\1740 mg/m2_34\NN\1740 ,_35\,\1740 on_36\IN\1740 day_37\NN\15154774 1_38\CD\13741022 ;_39\:\1740 and_40\CC\1740 hexamethylmelamine_41\NN\1740 (_42\-LRB-\1740 hmm_43\NN\1740 )_44\-RRB-\1740 ,_45\,\1740 6_46\CD\13741022 mg/kg_47\NN\1740 daily_48\RB\1740 ,_49\,\1740 for_50\IN\1740 14_51\CD\13745420 days_52\NNS\15140892 ._53\.\1740
D003520_D010051 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>ovarian_2\JJ\1740 cancer</e2>_3\NN\14239425 with_4\IN\1740 a_5\DT\13649268 combination_6\NN\7951464 of_7\IN\1740 cis-platinum_8\NN\1740 ,_9\,\1740 adriamycin_10\NN\1740 ,_11\,\1740 <e1>cyclophosphamide</e1>_12\NN\1740 and_13\CC\1740 hexamethylmelamine_14\NN\1740 ._15\.\1740
D003520_D010051 NONE during_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 2_3\CD\13741022 1/2_4\CD\1740 years_5\NNS\15144371 ,_6\,\1740 38_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 a_15\DT\13649268 combination_16\NN\7951464 of_17\IN\1740 cisplatinum_18\NN\1740 (_19\-LRB-\1740 cpdd_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 50_23\CD\13745420 mg/m2_24\NN\1740 ,_25\,\1740 adriamycin_26\NN\1740 ,_27\,\1740 30_28\CD\13745420 mg/m2_29\NN\1740 ,_30\,\1740 <e1>cyclophosphamide</e1>_31\NN\1740 ,_32\,\1740 300_33\CD\1740 mg/m2_34\NN\1740 ,_35\,\1740 on_36\IN\1740 day_37\NN\15154774 1_38\CD\13741022 ;_39\:\1740 and_40\CC\1740 hexamethylmelamine_41\NN\1740 (_42\-LRB-\1740 hmm_43\NN\1740 )_44\-RRB-\1740 ,_45\,\1740 6_46\CD\13741022 mg/kg_47\NN\1740 daily_48\RB\1740 ,_49\,\1740 for_50\IN\1740 14_51\CD\13745420 days_52\NNS\15140892 ._53\.\1740
D006585_D010051 NONE treatment_0\NN\654885 of_1\IN\1740 <e2>ovarian_2\JJ\1740 cancer</e2>_3\NN\14239425 with_4\IN\1740 a_5\DT\13649268 combination_6\NN\7951464 of_7\IN\1740 cis-platinum_8\NN\1740 ,_9\,\1740 adriamycin_10\NN\1740 ,_11\,\1740 cyclophosphamide_12\NN\1740 and_13\CC\1740 <e1>hexamethylmelamine</e1>_14\NN\1740 ._15\.\1740
D006585_D010051 NONE during_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 2_3\CD\13741022 1/2_4\CD\1740 years_5\NNS\15144371 ,_6\,\1740 38_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 a_15\DT\13649268 combination_16\NN\7951464 of_17\IN\1740 cisplatinum_18\NN\1740 (_19\-LRB-\1740 cpdd_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 50_23\CD\13745420 mg/m2_24\NN\1740 ,_25\,\1740 adriamycin_26\NN\1740 ,_27\,\1740 30_28\CD\13745420 mg/m2_29\NN\1740 ,_30\,\1740 cyclophosphamide_31\NN\1740 ,_32\,\1740 300_33\CD\1740 mg/m2_34\NN\1740 ,_35\,\1740 on_36\IN\1740 day_37\NN\15154774 1_38\CD\13741022 ;_39\:\1740 and_40\CC\1740 <e1>hexamethylmelamine</e1>_41\NN\1740 (_42\-LRB-\1740 hmm_43\NN\1740 )_44\-RRB-\1740 ,_45\,\1740 6_46\CD\13741022 mg/kg_47\NN\1740 daily_48\RB\1740 ,_49\,\1740 for_50\IN\1740 14_51\CD\13745420 days_52\NNS\15140892 ._53\.\1740
D006585_D010051 NONE during_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 2_3\CD\13741022 1/2_4\CD\1740 years_5\NNS\15144371 ,_6\,\1740 38_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 a_15\DT\13649268 combination_16\NN\7951464 of_17\IN\1740 cisplatinum_18\NN\1740 (_19\-LRB-\1740 cpdd_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 50_23\CD\13745420 mg/m2_24\NN\1740 ,_25\,\1740 adriamycin_26\NN\1740 ,_27\,\1740 30_28\CD\13745420 mg/m2_29\NN\1740 ,_30\,\1740 cyclophosphamide_31\NN\1740 ,_32\,\1740 300_33\CD\1740 mg/m2_34\NN\1740 ,_35\,\1740 on_36\IN\1740 day_37\NN\15154774 1_38\CD\13741022 ;_39\:\1740 and_40\CC\1740 hexamethylmelamine_41\NN\1740 (_42\-LRB-\1740 <e1>hmm</e1>_43\NN\1740 )_44\-RRB-\1740 ,_45\,\1740 6_46\CD\13741022 mg/kg_47\NN\1740 daily_48\RB\1740 ,_49\,\1740 for_50\IN\1740 14_51\CD\13745420 days_52\NNS\15140892 ._53\.\1740
C034868_D010051 NONE during_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 2_3\CD\13741022 1/2_4\CD\1740 years_5\NNS\15144371 ,_6\,\1740 38_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 a_15\DT\13649268 combination_16\NN\7951464 of_17\IN\1740 cisplatinum_18\NN\1740 (_19\-LRB-\1740 <e1>cpdd</e1>_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 50_23\CD\13745420 mg/m2_24\NN\1740 ,_25\,\1740 adriamycin_26\NN\1740 ,_27\,\1740 30_28\CD\13745420 mg/m2_29\NN\1740 ,_30\,\1740 cyclophosphamide_31\NN\1740 ,_32\,\1740 300_33\CD\1740 mg/m2_34\NN\1740 ,_35\,\1740 on_36\IN\1740 day_37\NN\15154774 1_38\CD\13741022 ;_39\:\1740 and_40\CC\1740 hexamethylmelamine_41\NN\1740 (_42\-LRB-\1740 hmm_43\NN\1740 )_44\-RRB-\1740 ,_45\,\1740 6_46\CD\13741022 mg/kg_47\NN\1740 daily_48\RB\1740 ,_49\,\1740 for_50\IN\1740 14_51\CD\13745420 days_52\NNS\15140892 ._53\.\1740
D006585_D005767 NONE <e1>hmm</e1>_0\NN\1740 <e2>gastrointestinal_1\NN\1740 toxicity</e2>_2\NN\13576101 necessitated_3\JJ\1740 discontinuation_4\NN\209943 of_5\IN\1740 the_6\DT\1740 drug_7\NN\14778436 in_8\IN\13603305 5_9\CD\13741022 patients_10\NNS\9898892 ._11\.\1740
24275640
D004317_D066126 CID oxidative_0\JJ\1740 stress_1\NN\7083732 on_2\IN\1740 <e2>cardiotoxicity</e2>_3\NN\1740 after_4\IN\1740 treatment_5\NN\654885 with_6\IN\1740 single_7\JJ\1740 and_8\CC\1740 multiple_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 <e1>doxorubicin</e1>_12\NN\2716866 ._13\.\1740
D004317_D066126 CID the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 <e1>doxorubicin</e1>_3\NN\2716866 (dox)-induced_4\JJ\1740 <e2>cardiotoxicity</e2>_5\NN\1740 remains_6\VBZ\2604760 controversial_7\JJ\1740 ._8\.\1740
D004317_D066126 CID the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 doxorubicin_3\NN\2716866 <e1>(dox)-induced</e1>_4\JJ\1740 <e2>cardiotoxicity</e2>_5\NN\1740 remains_6\VBZ\2604760 controversial_7\JJ\1740 ._8\.\1740
D004317_D066126 CID our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 oxidative_4\JJ\1740 damage_5\NN\7296428 is_6\VBZ\836236 associated_7\VBN\628491 with_8\IN\1740 acute_9\JJ\1740 <e2>cardiotoxicity</e2>_10\NN\1740 induced_11\VBN\1627355 by_12\IN\1740 a_13\DT\13649268 single_14\JJ\1740 dose_15\NN\3740161 of_16\IN\1740 <e1>dox</e1>_17\NN\1740 only_18\RB\1740 ._19\.\1740
D004317_D006331 NONE single_0\JJ\1740 dose_1\NN\3740161 of_2\IN\1740 <e1>dox</e1>_3\NN\1740 was_4\VBD\836236 associated_5\VBN\628491 with_6\IN\1740 increased_7\VBN\169651 <e2>cardiac_8\JJ\1740 disarrangement</e2>_9\NN\14499262 ,_10\,\1740 necrosis_11\NN\11444117 ,_12\,\1740 and_13\CC\1740 dna_14\NN\14994328 damage_15\NN\7296428 (_16\-LRB-\1740 strand_17\NN\5930736 breaks_18\NNS\7283608 (_19\-LRB-\1740 sbs_20\NNS\14625458 )_21\-RRB-\1740 and_22\CC\1740 oxidized_23\VBN\109660 pyrimidines_24\NNS\14618253 )_25\-RRB-\1740 and_26\CC\1740 decreased_27\VBD\169651 tap_28\NN\7371293 ._29\.\1740
D004317_D009336 CID single_0\JJ\1740 dose_1\NN\3740161 of_2\IN\1740 <e1>dox</e1>_3\NN\1740 was_4\VBD\836236 associated_5\VBN\628491 with_6\IN\1740 increased_7\VBN\169651 cardiac_8\JJ\1740 disarrangement_9\NN\14499262 ,_10\,\1740 <e2>necrosis</e2>_11\NN\11444117 ,_12\,\1740 and_13\CC\1740 dna_14\NN\14994328 damage_15\NN\7296428 (_16\-LRB-\1740 strand_17\NN\5930736 breaks_18\NNS\7283608 (_19\-LRB-\1740 sbs_20\NNS\14625458 )_21\-RRB-\1740 and_22\CC\1740 oxidized_23\VBN\109660 pyrimidines_24\NNS\14618253 )_25\-RRB-\1740 and_26\CC\1740 decreased_27\VBD\169651 tap_28\NN\7371293 ._29\.\1740
3409843
D002220_D000741 CID fatal_0\JJ\1740 <e2>aplastic_1\JJ\1740 anemia</e2>_2\NN\14189204 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 treated_6\VBN\2376958 with_7\IN\1740 <e1>carbamazepine</e1>_8\NN\1740 ._9\.\1740
D002220_D000741 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 fatal_3\JJ\1740 <e2>aplastic_4\JJ\1740 anemia</e2>_5\NN\14189204 due_6\JJ\1740 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 treatment_9\NN\654885 in_10\IN\13603305 an_11\DT\6697703 epileptic_12\JJ\1740 woman_13\NN\9605289 is_14\VBZ\836236 reported_15\VBN\831651 ._16\.\1740
D002220_D004827 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 fatal_3\JJ\1740 aplastic_4\JJ\1740 anemia_5\NN\14189204 due_6\JJ\1740 to_7\TO\1740 <e1>carbamazepine</e1>_8\NN\1740 treatment_9\NN\654885 in_10\IN\13603305 an_11\DT\6697703 <e2>epileptic</e2>_12\JJ\1740 woman_13\NN\9605289 is_14\VBZ\836236 reported_15\VBN\831651 ._16\.\1740
D002220_D001855 NONE despite_0\IN\7501545 concerns_1\NNS\5682950 of_2\IN\1740 fatal_3\JJ\1740 <e2>bone_4\NN\5286536 marrow_5\NN\5286536 toxicity</e2>_6\NN\13576101 due_7\IN\5174653 to_8\TO\1740 <e1>carbamazepine</e1>_9\NN\1740 ,_10\,\1740 this_11\DT\1740 is_12\VBZ\836236 only_13\RB\1740 the_14\DT\1740 fourth_15\JJ\1740 documented_16\VBN\1000214 and_17\CC\1740 published_18\VBN\1621555 report_19\NN\6470073 ._20\.\1740
2021990
D002927_D007022 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 an_3\DT\6697703 h1_4\NN\1740 antagonist_5\NN\7846 may_6\MD\15209706 be_7\VB\836236 useful_8\JJ\1740 in_9\IN\13603305 preventing_10\VBG\1740 <e2>hypotension</e2>_11\NN\14057371 caused_12\VBN\1617192 by_13\IN\1740 iv_14\NN\13741022 <e1>cimetidine</e1>_15\NN\14778019 ,_16\,\1740 since_17\IN\1740 the_18\DT\1740 vasodilating_19\NN\1740 activity_20\NN\30358 of_21\IN\1740 cimetidine_22\NN\14778019 is_23\VBZ\836236 mediated_24\VBN\761713 ,_25\,\1740 in_26\IN\13603305 part_27\NN\31921 ,_28\,\1740 through_29\IN\1740 the_30\DT\1740 h1_31\NN\1740 receptor_32\NN\5225602 ._33\.\1740
D002927_D007022 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 an_3\DT\6697703 h1_4\NN\1740 antagonist_5\NN\7846 may_6\MD\15209706 be_7\VB\836236 useful_8\JJ\1740 in_9\IN\13603305 preventing_10\VBG\1740 <e2>hypotension</e2>_11\NN\14057371 caused_12\VBN\1617192 by_13\IN\1740 iv_14\NN\13741022 cimetidine_15\NN\14778019 ,_16\,\1740 since_17\IN\1740 the_18\DT\1740 vasodilating_19\NN\1740 activity_20\NN\30358 of_21\IN\1740 <e1>cimetidine</e1>_22\NN\14778019 is_23\VBZ\836236 mediated_24\VBN\761713 ,_25\,\1740 in_26\IN\13603305 part_27\NN\31921 ,_28\,\1740 through_29\IN\1740 the_30\DT\1740 h1_31\NN\1740 receptor_32\NN\5225602 ._33\.\1740
8996419
D003276_D054556 CID population-based_0\JJ\1740 study_1\NN\635850 of_2\IN\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>venous_5\JJ\1740 thromboembolism</e2>_6\NN\14100769 associated_7\VBN\628491 with_8\IN\1740 various_9\JJ\1740 <e1>oral_10\JJ\1740 contraceptives</e1>_11\NNS\3183080 ._12\.\1740
D003276_D054556 CID background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>venous_15\JJ\1740 thromboembolism</e2>_16\NN\14100769 (_17\-LRB-\1740 vte_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 <e1>oral_26\JJ\1740 contraceptives</e1>_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D003276_D054556 CID background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 venous_15\JJ\1740 thromboembolism_16\NN\14100769 (_17\-LRB-\1740 <e2>vte</e2>_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 <e1>oral_26\JJ\1740 contraceptives</e1>_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D003276_D054556 CID background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>venous_15\JJ\1740 thromboembolism</e2>_16\NN\14100769 (_17\-LRB-\1740 vte_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 <e1>ocs</e1>_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D003276_D054556 CID background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 venous_15\JJ\1740 thromboembolism_16\NN\14100769 (_17\-LRB-\1740 <e2>vte</e2>_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 <e1>ocs</e1>_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D003276_D054556 CID background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>venous_15\JJ\1740 thromboembolism</e2>_16\NN\14100769 (_17\-LRB-\1740 vte_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 <e1>ocs</e1>_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D003276_D054556 CID background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 venous_15\JJ\1740 thromboembolism_16\NN\14100769 (_17\-LRB-\1740 <e2>vte</e2>_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 <e1>ocs</e1>_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D003276_D054556 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 our_3\PRP$\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 re-examine_7\VB\788564 the_8\DT\1740 association_9\NN\8008335 between_10\IN\1740 risk_11\NN\14541044 of_12\IN\1740 <e2>vte</e2>_13\NN\1740 and_14\CC\1740 <e1>oc</e1>_15\NN\1740 use_16\NN\407535 with_17\IN\1740 a_18\DT\13649268 different_19\JJ\1740 study_20\NN\635850 design_21\NN\927261 and_22\CC\1740 analysis_23\NN\633864 to_24\TO\1740 avoid_25\VB\2452885 some_26\DT\1740 of_27\IN\1740 the_28\DT\1740 bias_29\NN\6201136 and_30\CC\1740 confounding_31\NN\1740 of_32\IN\1740 the_33\DT\1740 earlier_34\JJR\1740 studies_35\NNS\635850 ._36\.\1740
D003276_D054556 CID we_0\PRP\1740 did_1\VBD\1640855 a_2\DT\13649268 cohort_3\NN\8184861 analysis_4\NN\633864 to_5\TO\1740 estimate_6\VB\637259 and_7\CC\1740 compare_8\VB\644583 incidence_9\NN\13821570 of_10\IN\1740 <e2>vte</e2>_11\NN\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 the_15\DT\1740 main_16\JJ\1740 <e1>oc</e1>_17\NN\1740 preparations_18\NNS\407535 ,_19\,\1740 and_20\CC\1740 a_21\DT\13649268 nested_22\JJ\1740 case-control_23\NN\1740 study_24\NN\635850 to_25\TO\1740 calculate_26\VB\632627 the_27\DT\1740 odds_28\NNS\4756635 ratios_29\NNS\13815152 of_30\IN\1740 vte_31\NN\1740 associated_32\VBN\628491 with_33\IN\1740 use_34\NN\407535 of_35\IN\1740 different_36\JJ\1740 types_37\NNS\5839024 of_38\IN\1740 oc_39\NN\1740 ,_40\,\1740 after_41\IN\1740 adjustment_42\NN\7357388 for_43\IN\1740 potential_44\JJ\1740 confounding_45\VBG\2604760 factors_46\NNS\7326557 ._47\.\1740
D003276_D054556 CID we_0\PRP\1740 did_1\VBD\1640855 a_2\DT\13649268 cohort_3\NN\8184861 analysis_4\NN\633864 to_5\TO\1740 estimate_6\VB\637259 and_7\CC\1740 compare_8\VB\644583 incidence_9\NN\13821570 of_10\IN\1740 vte_11\NN\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 the_15\DT\1740 main_16\JJ\1740 <e1>oc</e1>_17\NN\1740 preparations_18\NNS\407535 ,_19\,\1740 and_20\CC\1740 a_21\DT\13649268 nested_22\JJ\1740 case-control_23\NN\1740 study_24\NN\635850 to_25\TO\1740 calculate_26\VB\632627 the_27\DT\1740 odds_28\NNS\4756635 ratios_29\NNS\13815152 of_30\IN\1740 <e2>vte</e2>_31\NN\1740 associated_32\VBN\628491 with_33\IN\1740 use_34\NN\407535 of_35\IN\1740 different_36\JJ\1740 types_37\NNS\5839024 of_38\IN\1740 oc_39\NN\1740 ,_40\,\1740 after_41\IN\1740 adjustment_42\NN\7357388 for_43\IN\1740 potential_44\JJ\1740 confounding_45\VBG\2604760 factors_46\NNS\7326557 ._47\.\1740
D003276_D054556 CID we_0\PRP\1740 did_1\VBD\1640855 a_2\DT\13649268 cohort_3\NN\8184861 analysis_4\NN\633864 to_5\TO\1740 estimate_6\VB\637259 and_7\CC\1740 compare_8\VB\644583 incidence_9\NN\13821570 of_10\IN\1740 <e2>vte</e2>_11\NN\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 the_15\DT\1740 main_16\JJ\1740 oc_17\NN\1740 preparations_18\NNS\407535 ,_19\,\1740 and_20\CC\1740 a_21\DT\13649268 nested_22\JJ\1740 case-control_23\NN\1740 study_24\NN\635850 to_25\TO\1740 calculate_26\VB\632627 the_27\DT\1740 odds_28\NNS\4756635 ratios_29\NNS\13815152 of_30\IN\1740 vte_31\NN\1740 associated_32\VBN\628491 with_33\IN\1740 use_34\NN\407535 of_35\IN\1740 different_36\JJ\1740 types_37\NNS\5839024 of_38\IN\1740 <e1>oc</e1>_39\NN\1740 ,_40\,\1740 after_41\IN\1740 adjustment_42\NN\7357388 for_43\IN\1740 potential_44\JJ\1740 confounding_45\VBG\2604760 factors_46\NNS\7326557 ._47\.\1740
D003276_D054556 CID we_0\PRP\1740 did_1\VBD\1640855 a_2\DT\13649268 cohort_3\NN\8184861 analysis_4\NN\633864 to_5\TO\1740 estimate_6\VB\637259 and_7\CC\1740 compare_8\VB\644583 incidence_9\NN\13821570 of_10\IN\1740 vte_11\NN\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 the_15\DT\1740 main_16\JJ\1740 oc_17\NN\1740 preparations_18\NNS\407535 ,_19\,\1740 and_20\CC\1740 a_21\DT\13649268 nested_22\JJ\1740 case-control_23\NN\1740 study_24\NN\635850 to_25\TO\1740 calculate_26\VB\632627 the_27\DT\1740 odds_28\NNS\4756635 ratios_29\NNS\13815152 of_30\IN\1740 <e2>vte</e2>_31\NN\1740 associated_32\VBN\628491 with_33\IN\1740 use_34\NN\407535 of_35\IN\1740 different_36\JJ\1740 types_37\NNS\5839024 of_38\IN\1740 <e1>oc</e1>_39\NN\1740 ,_40\,\1740 after_41\IN\1740 adjustment_42\NN\7357388 for_43\IN\1740 potential_44\JJ\1740 confounding_45\VBG\2604760 factors_46\NNS\7326557 ._47\.\1740
D003276_D054556 CID findings_0\NNS\7951464 :_1\:\1740 85_2\CD\1740 women_3\NNS\9605289 met_4\VBD\1182709 the_5\DT\1740 inclusion_6\NN\13927383 criteria_7\NNS\13577171 for_8\IN\1740 <e2>vte</e2>_9\NN\1740 ,_10\,\1740 two_11\CD\13741022 of_12\IN\1740 whom_13\WP\1740 were_14\VBD\836236 users_15\NNS\7846 of_16\IN\1740 progestagen-only_17\JJ\1740 <e1>ocs</e1>_18\NN\1740 ._19\.\1740
D003276_D054556 CID of_0\IN\1740 the_1\DT\1740 83_2\CD\1740 cases_3\NNS\7283608 of_4\IN\1740 <e2>vte</e2>_5\NN\1740 associated_6\VBN\628491 with_7\IN\1740 use_8\NN\407535 of_9\IN\1740 combined_10\JJ\1740 <e1>ocs</e1>_11\NN\1740 ,_12\,\1740 43_13\CD\1740 were_14\VBD\836236 recorded_15\VBN\2225492 as_16\IN\14622893 deep-vein_17\JJ\1740 thrombosis_18\NN\14100769 ,_19\,\1740 35_20\CD\1740 as_21\IN\14622893 pulmonary_22\JJ\1740 thrombosis_23\NN\14100769 ,_24\,\1740 and_25\CC\1740 five_26\CD\13741022 as_27\IN\14622893 venous_28\JJ\1740 thrombosis_29\NN\14100769 not_30\RB\1740 otherwise_31\RB\1740 specified_32\VBD\888786 ._33\.\1740
D003276_D054556 CID the_0\DT\1740 crude_1\JJ\1740 rate_2\NN\13815152 of_3\IN\1740 <e2>vte</e2>_4\NN\1740 per_5\IN\1740 10,000_6\CD\1740 woman-years_7\NNS\1740 was_8\VBD\836236 4.10_9\CD\1740 in_10\IN\13603305 current_11\JJ\1740 users_12\NNS\7846 of_13\IN\1740 any_14\DT\1740 <e1>oc</e1>_15\NNP\1740 ,_16\,\1740 3.10_17\CD\1740 in_18\IN\13603305 users_19\NNS\7846 of_20\IN\1740 second-generation_21\JJ\1740 ocs_22\NN\1740 ,_23\,\1740 and_24\CC\1740 4.96_25\CD\1740 in_26\IN\13603305 users_27\NNS\7846 of_28\IN\1740 third-generation_29\JJ\1740 preparations_30\NNS\407535 ._31\.\1740
D003276_D054556 CID the_0\DT\1740 crude_1\JJ\1740 rate_2\NN\13815152 of_3\IN\1740 <e2>vte</e2>_4\NN\1740 per_5\IN\1740 10,000_6\CD\1740 woman-years_7\NNS\1740 was_8\VBD\836236 4.10_9\CD\1740 in_10\IN\13603305 current_11\JJ\1740 users_12\NNS\7846 of_13\IN\1740 any_14\DT\1740 oc_15\NNP\1740 ,_16\,\1740 3.10_17\CD\1740 in_18\IN\13603305 users_19\NNS\7846 of_20\IN\1740 second-generation_21\JJ\1740 <e1>ocs</e1>_22\NN\1740 ,_23\,\1740 and_24\CC\1740 4.96_25\CD\1740 in_26\IN\13603305 users_27\NNS\7846 of_28\IN\1740 third-generation_29\JJ\1740 preparations_30\NNS\407535 ._31\.\1740
D003276_D054556 CID after_0\IN\1740 adjustment_1\NN\7357388 for_2\IN\1740 age_3\NN\4916342 ,_4\,\1740 the_5\DT\1740 rate_6\NN\13815152 ratio_7\NN\13815152 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 in_10\IN\13603305 users_11\NNS\7846 of_12\IN\1740 third-generation_13\NN\1740 relative_14\JJ\1740 to_15\TO\1740 second-generation_16\JJ\1740 <e1>ocs</e1>_17\NN\1740 was_18\VBD\836236 1.68_19\CD\1740 (_20\-LRB-\1740 95_21\CD\1740 %_22\NN\1740 ci_23\NN\13635336 1.04_24\CD\1740 -_25\HYPH\1740 2.75_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D003276_D054556 CID logistic_0\JJ\1740 regression_1\NN\14501726 showed_2\VBD\2137132 no_3\DT\7204911 significant_4\JJ\1740 difference_5\NN\4723816 in_6\IN\13603305 the_7\DT\1740 risk_8\NN\14541044 of_9\IN\1740 <e2>vte</e2>_10\NN\1740 between_11\IN\1740 users_12\NNS\7846 of_13\IN\1740 third-generation_14\NN\1740 and_15\CC\1740 second-generation_16\JJ\1740 <e1>ocs</e1>_17\NN\1740 ._18\.\1740
D003276_D054556 CID with_0\IN\1740 all_1\DT\1740 second-generation_2\JJ\1740 <e1>ocs</e1>_3\NN\1740 as_4\IN\14622893 the_5\DT\1740 reference_6\NN\6765044 ,_7\,\1740 the_8\DT\1740 odds_9\NNS\4756635 ratios_10\NNS\13815152 for_11\IN\1740 <e2>vte</e2>_12\NN\1740 were_13\VBD\836236 3.49_14\CD\1740 (_15\-LRB-\1740 1.21_16\CD\1740 -_17\SYM\1740 10.12_18\CD\1740 )_19\-RRB-\1740 for_20\IN\1740 desogestrel_21\NN\1740 plus_22\CC\4723816 20_23\CD\13745420 g_24\NN\13717155 ethinyloestradiol_25\NN\1740 and_26\CC\1740 1.18_27\CD\1740 (_28\-LRB-\1740 0.66_29\CD\1740 -_30\SYM\1740 2.17_31\CD\1740 )_32\-RRB-\1740 for_33\IN\1740 the_34\DT\1740 other_35\JJ\1740 third-generation_36\NN\1740 progestagens_37\NNS\1740 ._38\.\1740
D011374_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>venous_15\JJ\1740 thromboembolism</e2>_16\NN\14100769 (_17\-LRB-\1740 vte_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 <e1>progestagens</e1>_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D011374_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 venous_15\JJ\1740 thromboembolism_16\NN\14100769 (_17\-LRB-\1740 <e2>vte</e2>_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 <e1>progestagens</e1>_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D011374_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>venous_15\JJ\1740 thromboembolism</e2>_16\NN\14100769 (_17\-LRB-\1740 vte_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 <e1>progestagens</e1>_45\NNS\1740 ._46\.\1740
D011374_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 venous_15\JJ\1740 thromboembolism_16\NN\14100769 (_17\-LRB-\1740 <e2>vte</e2>_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 <e1>progestagens</e1>_45\NNS\1740 ._46\.\1740
D011374_D054556 NONE among_0\IN\1740 users_1\NNS\7846 of_2\IN\1740 third-generation_3\NN\1740 <e1>progestagens</e1>_4\NNS\1740 ,_5\,\1740 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 was_10\VBD\836236 higher_11\JJR\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 desogestrel_15\NN\1740 with_16\IN\1740 20_17\CD\13745420 g_18\NN\13717155 ethinyloestradiol_19\NN\1740 than_20\IN\1740 in_21\IN\13603305 users_22\NNS\7846 of_23\IN\1740 gestodene_24\NN\1740 or_25\CC\3541091 desogestrel_26\NN\1740 with_27\IN\1740 30_28\CD\13745420 g_29\NN\13717155 ethinyloestradiol_30\NN\1740 ._31\.\1740
D011374_D054556 NONE with_0\IN\1740 all_1\DT\1740 second-generation_2\JJ\1740 ocs_3\NN\1740 as_4\IN\14622893 the_5\DT\1740 reference_6\NN\6765044 ,_7\,\1740 the_8\DT\1740 odds_9\NNS\4756635 ratios_10\NNS\13815152 for_11\IN\1740 <e2>vte</e2>_12\NN\1740 were_13\VBD\836236 3.49_14\CD\1740 (_15\-LRB-\1740 1.21_16\CD\1740 -_17\SYM\1740 10.12_18\CD\1740 )_19\-RRB-\1740 for_20\IN\1740 desogestrel_21\NN\1740 plus_22\CC\4723816 20_23\CD\13745420 g_24\NN\13717155 ethinyloestradiol_25\NN\1740 and_26\CC\1740 1.18_27\CD\1740 (_28\-LRB-\1740 0.66_29\CD\1740 -_30\SYM\1740 2.17_31\CD\1740 )_32\-RRB-\1740 for_33\IN\1740 the_34\DT\1740 other_35\JJ\1740 third-generation_36\NN\1740 <e1>progestagens</e1>_37\NNS\1740 ._38\.\1740
C033273_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>venous_15\JJ\1740 thromboembolism</e2>_16\NN\14100769 (_17\-LRB-\1740 vte_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 <e1>gestodene</e1>_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
C033273_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 venous_15\JJ\1740 thromboembolism_16\NN\14100769 (_17\-LRB-\1740 <e2>vte</e2>_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 <e1>gestodene</e1>_35\NN\1740 or_36\CC\3541091 desogestrel_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
C033273_D054556 NONE among_0\IN\1740 users_1\NNS\7846 of_2\IN\1740 third-generation_3\NN\1740 progestagens_4\NNS\1740 ,_5\,\1740 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 was_10\VBD\836236 higher_11\JJR\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 desogestrel_15\NN\1740 with_16\IN\1740 20_17\CD\13745420 g_18\NN\13717155 ethinyloestradiol_19\NN\1740 than_20\IN\1740 in_21\IN\13603305 users_22\NNS\7846 of_23\IN\1740 <e1>gestodene</e1>_24\NN\1740 or_25\CC\3541091 desogestrel_26\NN\1740 with_27\IN\1740 30_28\CD\13745420 g_29\NN\13717155 ethinyloestradiol_30\NN\1740 ._31\.\1740
D017135_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>venous_15\JJ\1740 thromboembolism</e2>_16\NN\14100769 (_17\-LRB-\1740 vte_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 <e1>desogestrel</e1>_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D017135_D054556 NONE background_0\NN\4921011 :_1\:\1740 four_2\CD\13741022 studies_3\NNS\635850 published_4\VBN\1621555 since_5\IN\1740 december_6\NNP\15209706 ,_7\,\1740 1995_8\CD\1740 ,_9\,\1740 reported_10\VBD\831651 that_11\IN\1740 the_12\DT\1740 incidence_13\NN\13821570 of_14\IN\1740 venous_15\JJ\1740 thromboembolism_16\NN\14100769 (_17\-LRB-\1740 <e2>vte</e2>_18\NN\1740 )_19\-RRB-\1740 was_20\VBD\836236 higher_21\JJR\1740 in_22\IN\13603305 women_23\NNS\9605289 who_24\WP\8299493 used_25\VBD\1156834 oral_26\JJ\1740 contraceptives_27\NNS\3183080 (_28\-LRB-\1740 ocs_29\NNS\1740 )_30\-RRB-\1740 containing_31\VBG\2632940 the_32\DT\1740 third-generation_33\NN\1740 progestagens_34\NNS\1740 gestodene_35\NN\1740 or_36\CC\3541091 <e1>desogestrel</e1>_37\NN\1740 than_38\IN\1740 in_39\IN\13603305 users_40\NNS\7846 of_41\IN\1740 ocs_42\NN\1740 containing_43\VBG\2632940 second-generation_44\NN\1740 progestagens_45\NNS\1740 ._46\.\1740
D017135_D054556 NONE among_0\IN\1740 users_1\NNS\7846 of_2\IN\1740 third-generation_3\NN\1740 progestagens_4\NNS\1740 ,_5\,\1740 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 was_10\VBD\836236 higher_11\JJR\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 <e1>desogestrel</e1>_15\NN\1740 with_16\IN\1740 20_17\CD\13745420 g_18\NN\13717155 ethinyloestradiol_19\NN\1740 than_20\IN\1740 in_21\IN\13603305 users_22\NNS\7846 of_23\IN\1740 gestodene_24\NN\1740 or_25\CC\3541091 desogestrel_26\NN\1740 with_27\IN\1740 30_28\CD\13745420 g_29\NN\13717155 ethinyloestradiol_30\NN\1740 ._31\.\1740
D017135_D054556 NONE among_0\IN\1740 users_1\NNS\7846 of_2\IN\1740 third-generation_3\NN\1740 progestagens_4\NNS\1740 ,_5\,\1740 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 was_10\VBD\836236 higher_11\JJR\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 desogestrel_15\NN\1740 with_16\IN\1740 20_17\CD\13745420 g_18\NN\13717155 ethinyloestradiol_19\NN\1740 than_20\IN\1740 in_21\IN\13603305 users_22\NNS\7846 of_23\IN\1740 gestodene_24\NN\1740 or_25\CC\3541091 <e1>desogestrel</e1>_26\NN\1740 with_27\IN\1740 30_28\CD\13745420 g_29\NN\13717155 ethinyloestradiol_30\NN\1740 ._31\.\1740
D017135_D054556 NONE with_0\IN\1740 all_1\DT\1740 second-generation_2\JJ\1740 ocs_3\NN\1740 as_4\IN\14622893 the_5\DT\1740 reference_6\NN\6765044 ,_7\,\1740 the_8\DT\1740 odds_9\NNS\4756635 ratios_10\NNS\13815152 for_11\IN\1740 <e2>vte</e2>_12\NN\1740 were_13\VBD\836236 3.49_14\CD\1740 (_15\-LRB-\1740 1.21_16\CD\1740 -_17\SYM\1740 10.12_18\CD\1740 )_19\-RRB-\1740 for_20\IN\1740 <e1>desogestrel</e1>_21\NN\1740 plus_22\CC\4723816 20_23\CD\13745420 g_24\NN\13717155 ethinyloestradiol_25\NN\1740 and_26\CC\1740 1.18_27\CD\1740 (_28\-LRB-\1740 0.66_29\CD\1740 -_30\SYM\1740 2.17_31\CD\1740 )_32\-RRB-\1740 for_33\IN\1740 the_34\DT\1740 other_35\JJ\1740 third-generation_36\NN\1740 progestagens_37\NNS\1740 ._38\.\1740
D011372_D054556 NONE findings_0\NNS\7951464 :_1\:\1740 85_2\CD\1740 women_3\NNS\9605289 met_4\VBD\1182709 the_5\DT\1740 inclusion_6\NN\13927383 criteria_7\NNS\13577171 for_8\IN\1740 <e2>vte</e2>_9\NN\1740 ,_10\,\1740 two_11\CD\13741022 of_12\IN\1740 whom_13\WP\1740 were_14\VBD\836236 users_15\NNS\7846 of_16\IN\1740 <e1>progestagen-only</e1>_17\JJ\1740 ocs_18\NN\1740 ._19\.\1740
D003276_D020246 NONE of_0\IN\1740 the_1\DT\1740 83_2\CD\1740 cases_3\NNS\7283608 of_4\IN\1740 vte_5\NN\1740 associated_6\VBN\628491 with_7\IN\1740 use_8\NN\407535 of_9\IN\1740 combined_10\JJ\1740 <e1>ocs</e1>_11\NN\1740 ,_12\,\1740 43_13\CD\1740 were_14\VBD\836236 recorded_15\VBN\2225492 as_16\IN\14622893 <e2>deep-vein_17\JJ\1740 thrombosis</e2>_18\NN\14100769 ,_19\,\1740 35_20\CD\1740 as_21\IN\14622893 pulmonary_22\JJ\1740 thrombosis_23\NN\14100769 ,_24\,\1740 and_25\CC\1740 five_26\CD\13741022 as_27\IN\14622893 venous_28\JJ\1740 thrombosis_29\NN\14100769 not_30\RB\1740 otherwise_31\RB\1740 specified_32\VBD\888786 ._33\.\1740
D003276_D020246 NONE of_0\IN\1740 the_1\DT\1740 83_2\CD\1740 cases_3\NNS\7283608 of_4\IN\1740 vte_5\NN\1740 associated_6\VBN\628491 with_7\IN\1740 use_8\NN\407535 of_9\IN\1740 combined_10\JJ\1740 <e1>ocs</e1>_11\NN\1740 ,_12\,\1740 43_13\CD\1740 were_14\VBD\836236 recorded_15\VBN\2225492 as_16\IN\14622893 deep-vein_17\JJ\1740 thrombosis_18\NN\14100769 ,_19\,\1740 35_20\CD\1740 as_21\IN\14622893 pulmonary_22\JJ\1740 thrombosis_23\NN\14100769 ,_24\,\1740 and_25\CC\1740 five_26\CD\13741022 as_27\IN\14622893 <e2>venous_28\JJ\1740 thrombosis</e2>_29\NN\14100769 not_30\RB\1740 otherwise_31\RB\1740 specified_32\VBD\888786 ._33\.\1740
D003276_D013927 NONE of_0\IN\1740 the_1\DT\1740 83_2\CD\1740 cases_3\NNS\7283608 of_4\IN\1740 vte_5\NN\1740 associated_6\VBN\628491 with_7\IN\1740 use_8\NN\407535 of_9\IN\1740 combined_10\JJ\1740 <e1>ocs</e1>_11\NN\1740 ,_12\,\1740 43_13\CD\1740 were_14\VBD\836236 recorded_15\VBN\2225492 as_16\IN\14622893 deep-vein_17\JJ\1740 thrombosis_18\NN\14100769 ,_19\,\1740 35_20\CD\1740 as_21\IN\14622893 pulmonary_22\JJ\1740 <e2>thrombosis</e2>_23\NN\14100769 ,_24\,\1740 and_25\CC\1740 five_26\CD\13741022 as_27\IN\14622893 venous_28\JJ\1740 thrombosis_29\NN\14100769 not_30\RB\1740 otherwise_31\RB\1740 specified_32\VBD\888786 ._33\.\1740
D004997_D054556 NONE among_0\IN\1740 users_1\NNS\7846 of_2\IN\1740 third-generation_3\NN\1740 progestagens_4\NNS\1740 ,_5\,\1740 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 was_10\VBD\836236 higher_11\JJR\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 desogestrel_15\NN\1740 with_16\IN\1740 20_17\CD\13745420 g_18\NN\13717155 <e1>ethinyloestradiol</e1>_19\NN\1740 than_20\IN\1740 in_21\IN\13603305 users_22\NNS\7846 of_23\IN\1740 gestodene_24\NN\1740 or_25\CC\3541091 desogestrel_26\NN\1740 with_27\IN\1740 30_28\CD\13745420 g_29\NN\13717155 ethinyloestradiol_30\NN\1740 ._31\.\1740
D004997_D054556 NONE among_0\IN\1740 users_1\NNS\7846 of_2\IN\1740 third-generation_3\NN\1740 progestagens_4\NNS\1740 ,_5\,\1740 the_6\DT\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 was_10\VBD\836236 higher_11\JJR\1740 in_12\IN\13603305 users_13\NNS\7846 of_14\IN\1740 desogestrel_15\NN\1740 with_16\IN\1740 20_17\CD\13745420 g_18\NN\13717155 ethinyloestradiol_19\NN\1740 than_20\IN\1740 in_21\IN\13603305 users_22\NNS\7846 of_23\IN\1740 gestodene_24\NN\1740 or_25\CC\3541091 desogestrel_26\NN\1740 with_27\IN\1740 30_28\CD\13745420 g_29\NN\13717155 <e1>ethinyloestradiol</e1>_30\NN\1740 ._31\.\1740
D004997_D054556 NONE with_0\IN\1740 all_1\DT\1740 second-generation_2\JJ\1740 ocs_3\NN\1740 as_4\IN\14622893 the_5\DT\1740 reference_6\NN\6765044 ,_7\,\1740 the_8\DT\1740 odds_9\NNS\4756635 ratios_10\NNS\13815152 for_11\IN\1740 <e2>vte</e2>_12\NN\1740 were_13\VBD\836236 3.49_14\CD\1740 (_15\-LRB-\1740 1.21_16\CD\1740 -_17\SYM\1740 10.12_18\CD\1740 )_19\-RRB-\1740 for_20\IN\1740 desogestrel_21\NN\1740 plus_22\CC\4723816 20_23\CD\13745420 g_24\NN\13717155 <e1>ethinyloestradiol</e1>_25\NN\1740 and_26\CC\1740 1.18_27\CD\1740 (_28\-LRB-\1740 0.66_29\CD\1740 -_30\SYM\1740 2.17_31\CD\1740 )_32\-RRB-\1740 for_33\IN\1740 the_34\DT\1740 other_35\JJ\1740 third-generation_36\NN\1740 progestagens_37\NNS\1740 ._38\.\1740
18422462
D000409_D000740 NONE clinically_0\RB\1740 significant_1\JJ\1740 <e2>anemia</e2>_2\NN\14189204 (_3\-LRB-\1740 hemoglobin_4\NN\14888884 <_5\XX\1740 7_6\CD\13741022 g/dl_7\NN\1740 )_8\-RRB-\1740 was_9\VBD\836236 observed_10\VBN\2163746 in_11\IN\13603305 5.4_12\CD\1740 %_13\NN\1740 of_14\IN\1740 patients_15\NNS\9898892 (_16\-LRB-\1740 cd4_17\NN\14888310 ,_18\,\1740 165_19\CD\1740 cells/microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 hepatitis_23\NN\14127211 (_24\-LRB-\1740 clinical_25\JJ\1740 jaundice_26\NN\14299637 with_27\IN\1740 <e1>alanine</e1>_28\NN\14601829 aminotransferase_29\NN\15077571 >_30\NN\1740 5_31\CD\13741022 times_32\NNS\15113229 upper_33\JJ\1740 limits_34\NNS\5123416 of_35\IN\1740 normal_36\JJ\1740 )_37\-RRB-\1740 in_38\IN\13603305 3.5_39\CD\1740 %_40\NN\1740 of_41\IN\1740 patients_42\NNS\9898892 (_43\-LRB-\1740 cd4_44\NN\14888310 ,_45\,\1740 260_46\CD\1740 cells/microl_47\CD\1740 )_48\-RRB-\1740 ._49\.\1740
D000409_D056486 NONE clinically_0\RB\1740 significant_1\JJ\1740 anemia_2\NN\14189204 (_3\-LRB-\1740 hemoglobin_4\NN\14888884 <_5\XX\1740 7_6\CD\13741022 g/dl_7\NN\1740 )_8\-RRB-\1740 was_9\VBD\836236 observed_10\VBN\2163746 in_11\IN\13603305 5.4_12\CD\1740 %_13\NN\1740 of_14\IN\1740 patients_15\NNS\9898892 (_16\-LRB-\1740 cd4_17\NN\14888310 ,_18\,\1740 165_19\CD\1740 cells/microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 <e2>hepatitis</e2>_23\NN\14127211 (_24\-LRB-\1740 clinical_25\JJ\1740 jaundice_26\NN\14299637 with_27\IN\1740 <e1>alanine</e1>_28\NN\14601829 aminotransferase_29\NN\15077571 >_30\NN\1740 5_31\CD\13741022 times_32\NNS\15113229 upper_33\JJ\1740 limits_34\NNS\5123416 of_35\IN\1740 normal_36\JJ\1740 )_37\-RRB-\1740 in_38\IN\13603305 3.5_39\CD\1740 %_40\NN\1740 of_41\IN\1740 patients_42\NNS\9898892 (_43\-LRB-\1740 cd4_44\NN\14888310 ,_45\,\1740 260_46\CD\1740 cells/microl_47\CD\1740 )_48\-RRB-\1740 ._49\.\1740
D000409_D007565 NONE clinically_0\RB\1740 significant_1\JJ\1740 anemia_2\NN\14189204 (_3\-LRB-\1740 hemoglobin_4\NN\14888884 <_5\XX\1740 7_6\CD\13741022 g/dl_7\NN\1740 )_8\-RRB-\1740 was_9\VBD\836236 observed_10\VBN\2163746 in_11\IN\13603305 5.4_12\CD\1740 %_13\NN\1740 of_14\IN\1740 patients_15\NNS\9898892 (_16\-LRB-\1740 cd4_17\NN\14888310 ,_18\,\1740 165_19\CD\1740 cells/microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 hepatitis_23\NN\14127211 (_24\-LRB-\1740 clinical_25\JJ\1740 <e2>jaundice</e2>_26\NN\14299637 with_27\IN\1740 <e1>alanine</e1>_28\NN\14601829 aminotransferase_29\NN\15077571 >_30\NN\1740 5_31\CD\13741022 times_32\NNS\15113229 upper_33\JJ\1740 limits_34\NNS\5123416 of_35\IN\1740 normal_36\JJ\1740 )_37\-RRB-\1740 in_38\IN\13603305 3.5_39\CD\1740 %_40\NN\1740 of_41\IN\1740 patients_42\NNS\9898892 (_43\-LRB-\1740 cd4_44\NN\14888310 ,_45\,\1740 260_46\CD\1740 cells/microl_47\CD\1740 )_48\-RRB-\1740 ._49\.\1740
D019829_D005076 CID among_0\IN\1740 the_1\DT\1740 patients_2\NNS\9898892 with_3\IN\1740 1_4\CD\13741022 year_5\NN\15113229 of_6\IN\1740 follow-up_7\NN\4599396 ,_8\,\1740 <e1>nvp</e1>_9\NN\1740 therapy_10\NN\657604 was_11\VBD\836236 significantly_12\RB\1740 associated_13\VBN\628491 with_14\IN\1740 developing_15\VBG\1753788 <e2>rash</e2>_16\NN\14321469 and_17\CC\1740 d4_18\NN\1740 t_19\NN\14999913 therapy_20\NN\657604 with_21\IN\1740 developing_22\VBG\1753788 peripheral_23\JJ\1740 neuropathy_24\NN\14204950 (_25\-LRB-\1740 p_26\NN\14622893 <_27\XX\1740 0.05_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D019829_D010523 NONE among_0\IN\1740 the_1\DT\1740 patients_2\NNS\9898892 with_3\IN\1740 1_4\CD\13741022 year_5\NN\15113229 of_6\IN\1740 follow-up_7\NN\4599396 ,_8\,\1740 <e1>nvp</e1>_9\NN\1740 therapy_10\NN\657604 was_11\VBD\836236 significantly_12\RB\1740 associated_13\VBN\628491 with_14\IN\1740 developing_15\VBG\1753788 rash_16\NN\14321469 and_17\CC\1740 d4_18\NN\1740 t_19\NN\14999913 therapy_20\NN\657604 with_21\IN\1740 developing_22\VBG\1753788 <e2>peripheral_23\JJ\1740 neuropathy</e2>_24\NN\14204950 (_25\-LRB-\1740 p_26\NN\14622893 <_27\XX\1740 0.05_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D018119_D005076 NONE among_0\IN\1740 the_1\DT\1740 patients_2\NNS\9898892 with_3\IN\1740 1_4\CD\13741022 year_5\NN\15113229 of_6\IN\1740 follow-up_7\NN\4599396 ,_8\,\1740 nvp_9\NN\1740 therapy_10\NN\657604 was_11\VBD\836236 significantly_12\RB\1740 associated_13\VBN\628491 with_14\IN\1740 developing_15\VBG\1753788 <e2>rash</e2>_16\NN\14321469 and_17\CC\1740 <e1>d4_18\NN\1740 t</e1>_19\NN\14999913 therapy_20\NN\657604 with_21\IN\1740 developing_22\VBG\1753788 peripheral_23\JJ\1740 neuropathy_24\NN\14204950 (_25\-LRB-\1740 p_26\NN\14622893 <_27\XX\1740 0.05_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D018119_D010523 CID among_0\IN\1740 the_1\DT\1740 patients_2\NNS\9898892 with_3\IN\1740 1_4\CD\13741022 year_5\NN\15113229 of_6\IN\1740 follow-up_7\NN\4599396 ,_8\,\1740 nvp_9\NN\1740 therapy_10\NN\657604 was_11\VBD\836236 significantly_12\RB\1740 associated_13\VBN\628491 with_14\IN\1740 developing_15\VBG\1753788 rash_16\NN\14321469 and_17\CC\1740 <e1>d4_18\NN\1740 t</e1>_19\NN\14999913 therapy_20\NN\657604 with_21\IN\1740 developing_22\VBG\1753788 <e2>peripheral_23\JJ\1740 neuropathy</e2>_24\NN\14204950 (_25\-LRB-\1740 p_26\NN\14622893 <_27\XX\1740 0.05_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
18450790
D013792_D010523 CID <e1>thalidomide</e1>_0\NN\4166841 and_1\CC\1740 <e2>sensory_2\JJ\1740 neurotoxicity</e2>_3\NN\1740 :_4\:\1740 a_5\DT\13649268 neurophysiological_6\JJ\1740 study_7\NN\635850 ._8\.\1740
D013792_D010523 CID background_0\NN\4921011 :_1\:\1740 recent_2\JJ\1740 studies_3\NNS\635850 confirmed_4\VBD\1011725 a_5\DT\13649268 high_6\JJ\1740 incidence_7\NN\13821570 of_8\IN\1740 <e2>sensory_9\JJ\1740 axonal_10\JJ\1740 neuropathy</e2>_11\NN\14204950 in_12\IN\13603305 patients_13\NNS\9898892 treated_14\VBN\2376958 with_15\IN\1740 different_16\JJ\1740 doses_17\NNS\3740161 of_18\IN\1740 <e1>thalidomide</e1>_19\NN\4166841 ._20\.\1740
D013792_D008178 NONE the_0\DT\1740 study_1\NN\635850 's_2\POS\1740 aims_3\NNS\5980875 were_4\VBD\836236 to_5\TO\1740 measure_6\VB\697589 variations_7\NNS\7296428 in_8\IN\13603305 sural_9\JJ\1740 nerve_10\NN\5475681 sensory_11\JJ\1740 action_12\NN\30358 potential_13\NN\14481929 (_14\-LRB-\1740 sap_15\NN\14589223 )_16\-RRB-\1740 amplitude_17\NN\7444668 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 refractory_21\JJ\1740 <e2>cutaneous_22\JJ\1740 lupus_23\NN\14219661 erythematosus</e2>_24\NN\1740 (_25\-LRB-\1740 cle_26\NN\1740 )_27\-RRB-\1740 treated_28\VBN\2376958 with_29\IN\1740 <e1>thalidomide</e1>_30\NN\4166841 and_31\CC\1740 use_32\VB\1156834 these_33\DT\1740 findings_34\NNS\7951464 to_35\TO\1740 identify_36\VB\699815 the_37\DT\1740 neurotoxic_38\JJ\1740 potential_39\NN\14481929 of_40\IN\1740 thalidomide_41\NN\4166841 and_42\CC\1740 the_43\DT\1740 recovery_44\NN\7357388 capacity_45\NN\5202497 of_46\IN\1740 sensory_47\JJ\1740 fibres_48\NNS\14580897 after_49\IN\1740 discontinuation_50\NN\209943 of_51\IN\1740 treatment_52\NN\654885 ._53\.\1740
D013792_D008178 NONE the_0\DT\1740 study_1\NN\635850 's_2\POS\1740 aims_3\NNS\5980875 were_4\VBD\836236 to_5\TO\1740 measure_6\VB\697589 variations_7\NNS\7296428 in_8\IN\13603305 sural_9\JJ\1740 nerve_10\NN\5475681 sensory_11\JJ\1740 action_12\NN\30358 potential_13\NN\14481929 (_14\-LRB-\1740 sap_15\NN\14589223 )_16\-RRB-\1740 amplitude_17\NN\7444668 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 refractory_21\JJ\1740 cutaneous_22\JJ\1740 lupus_23\NN\14219661 erythematosus_24\NN\1740 (_25\-LRB-\1740 <e2>cle</e2>_26\NN\1740 )_27\-RRB-\1740 treated_28\VBN\2376958 with_29\IN\1740 <e1>thalidomide</e1>_30\NN\4166841 and_31\CC\1740 use_32\VB\1156834 these_33\DT\1740 findings_34\NNS\7951464 to_35\TO\1740 identify_36\VB\699815 the_37\DT\1740 neurotoxic_38\JJ\1740 potential_39\NN\14481929 of_40\IN\1740 thalidomide_41\NN\4166841 and_42\CC\1740 the_43\DT\1740 recovery_44\NN\7357388 capacity_45\NN\5202497 of_46\IN\1740 sensory_47\JJ\1740 fibres_48\NNS\14580897 after_49\IN\1740 discontinuation_50\NN\209943 of_51\IN\1740 treatment_52\NN\654885 ._53\.\1740
D013792_D008178 NONE the_0\DT\1740 study_1\NN\635850 's_2\POS\1740 aims_3\NNS\5980875 were_4\VBD\836236 to_5\TO\1740 measure_6\VB\697589 variations_7\NNS\7296428 in_8\IN\13603305 sural_9\JJ\1740 nerve_10\NN\5475681 sensory_11\JJ\1740 action_12\NN\30358 potential_13\NN\14481929 (_14\-LRB-\1740 sap_15\NN\14589223 )_16\-RRB-\1740 amplitude_17\NN\7444668 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 refractory_21\JJ\1740 <e2>cutaneous_22\JJ\1740 lupus_23\NN\14219661 erythematosus</e2>_24\NN\1740 (_25\-LRB-\1740 cle_26\NN\1740 )_27\-RRB-\1740 treated_28\VBN\2376958 with_29\IN\1740 thalidomide_30\NN\4166841 and_31\CC\1740 use_32\VB\1156834 these_33\DT\1740 findings_34\NNS\7951464 to_35\TO\1740 identify_36\VB\699815 the_37\DT\1740 neurotoxic_38\JJ\1740 potential_39\NN\14481929 of_40\IN\1740 <e1>thalidomide</e1>_41\NN\4166841 and_42\CC\1740 the_43\DT\1740 recovery_44\NN\7357388 capacity_45\NN\5202497 of_46\IN\1740 sensory_47\JJ\1740 fibres_48\NNS\14580897 after_49\IN\1740 discontinuation_50\NN\209943 of_51\IN\1740 treatment_52\NN\654885 ._53\.\1740
D013792_D008178 NONE the_0\DT\1740 study_1\NN\635850 's_2\POS\1740 aims_3\NNS\5980875 were_4\VBD\836236 to_5\TO\1740 measure_6\VB\697589 variations_7\NNS\7296428 in_8\IN\13603305 sural_9\JJ\1740 nerve_10\NN\5475681 sensory_11\JJ\1740 action_12\NN\30358 potential_13\NN\14481929 (_14\-LRB-\1740 sap_15\NN\14589223 )_16\-RRB-\1740 amplitude_17\NN\7444668 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 refractory_21\JJ\1740 cutaneous_22\JJ\1740 lupus_23\NN\14219661 erythematosus_24\NN\1740 (_25\-LRB-\1740 <e2>cle</e2>_26\NN\1740 )_27\-RRB-\1740 treated_28\VBN\2376958 with_29\IN\1740 thalidomide_30\NN\4166841 and_31\CC\1740 use_32\VB\1156834 these_33\DT\1740 findings_34\NNS\7951464 to_35\TO\1740 identify_36\VB\699815 the_37\DT\1740 neurotoxic_38\JJ\1740 potential_39\NN\14481929 of_40\IN\1740 <e1>thalidomide</e1>_41\NN\4166841 and_42\CC\1740 the_43\DT\1740 recovery_44\NN\7357388 capacity_45\NN\5202497 of_46\IN\1740 sensory_47\JJ\1740 fibres_48\NNS\14580897 after_49\IN\1740 discontinuation_50\NN\209943 of_51\IN\1740 treatment_52\NN\654885 ._53\.\1740
D013792_D008178 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 clinical_4\JJ\1740 and_5\CC\1740 electrophysiological_6\JJ\1740 data_7\NNS\7951464 in_8\IN\13603305 12_9\CD\13745420 female_10\JJ\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>cle</e2>_13\NN\1740 during_14\IN\1740 treatment_15\NN\654885 with_16\IN\1740 <e1>thalidomide</e1>_17\NN\4166841 and_18\CC\1740 up_19\IN\1740 to_20\TO\1740 47_21\CD\1740 months_22\NNS\15113229 after_23\IN\1740 discontinuation_24\NN\209943 of_25\IN\1740 treatment_26\NN\654885 were_27\VBD\836236 analysed_28\VBN\78760 ._29\.\1740
D013792_D020258 NONE the_0\DT\1740 study_1\NN\635850 's_2\POS\1740 aims_3\NNS\5980875 were_4\VBD\836236 to_5\TO\1740 measure_6\VB\697589 variations_7\NNS\7296428 in_8\IN\13603305 sural_9\JJ\1740 nerve_10\NN\5475681 sensory_11\JJ\1740 action_12\NN\30358 potential_13\NN\14481929 (_14\-LRB-\1740 sap_15\NN\14589223 )_16\-RRB-\1740 amplitude_17\NN\7444668 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 refractory_21\JJ\1740 cutaneous_22\JJ\1740 lupus_23\NN\14219661 erythematosus_24\NN\1740 (_25\-LRB-\1740 cle_26\NN\1740 )_27\-RRB-\1740 treated_28\VBN\2376958 with_29\IN\1740 <e1>thalidomide</e1>_30\NN\4166841 and_31\CC\1740 use_32\VB\1156834 these_33\DT\1740 findings_34\NNS\7951464 to_35\TO\1740 identify_36\VB\699815 the_37\DT\1740 <e2>neurotoxic</e2>_38\JJ\1740 potential_39\NN\14481929 of_40\IN\1740 thalidomide_41\NN\4166841 and_42\CC\1740 the_43\DT\1740 recovery_44\NN\7357388 capacity_45\NN\5202497 of_46\IN\1740 sensory_47\JJ\1740 fibres_48\NNS\14580897 after_49\IN\1740 discontinuation_50\NN\209943 of_51\IN\1740 treatment_52\NN\654885 ._53\.\1740
D013792_D020258 NONE the_0\DT\1740 study_1\NN\635850 's_2\POS\1740 aims_3\NNS\5980875 were_4\VBD\836236 to_5\TO\1740 measure_6\VB\697589 variations_7\NNS\7296428 in_8\IN\13603305 sural_9\JJ\1740 nerve_10\NN\5475681 sensory_11\JJ\1740 action_12\NN\30358 potential_13\NN\14481929 (_14\-LRB-\1740 sap_15\NN\14589223 )_16\-RRB-\1740 amplitude_17\NN\7444668 in_18\IN\13603305 patients_19\NNS\9898892 with_20\IN\1740 refractory_21\JJ\1740 cutaneous_22\JJ\1740 lupus_23\NN\14219661 erythematosus_24\NN\1740 (_25\-LRB-\1740 cle_26\NN\1740 )_27\-RRB-\1740 treated_28\VBN\2376958 with_29\IN\1740 thalidomide_30\NN\4166841 and_31\CC\1740 use_32\VB\1156834 these_33\DT\1740 findings_34\NNS\7951464 to_35\TO\1740 identify_36\VB\699815 the_37\DT\1740 <e2>neurotoxic</e2>_38\JJ\1740 potential_39\NN\14481929 of_40\IN\1740 <e1>thalidomide</e1>_41\NN\4166841 and_42\CC\1740 the_43\DT\1740 recovery_44\NN\7357388 capacity_45\NN\5202497 of_46\IN\1740 sensory_47\JJ\1740 fibres_48\NNS\14580897 after_49\IN\1740 discontinuation_50\NN\209943 of_51\IN\1740 treatment_52\NN\654885 ._53\.\1740
D013792_D020258 NONE at_0\IN\14622893 detection_1\NN\5708432 of_2\IN\1740 reduction_3\NN\351485 in_4\IN\13603305 sural_5\JJ\1740 nerve_6\NN\5475681 sap_7\NN\14589223 amplitude_8\NN\7444668 ,_9\,\1740 the_10\DT\1740 median_11\JJ\1740 <e1>thalidomide</e1>_12\NN\4166841 cumulative_13\JJ\1740 dose_14\NN\3740161 was_15\VBD\836236 21.4_16\CD\1740 g._17\NN\1740 the_18\DT\1740 threshold_19\JJ\1740 <e2>neurotoxic</e2>_20\JJ\1740 dosage_21\NN\13576355 is_22\VBZ\836236 lower_23\JJR\1740 than_24\IN\1740 previously_25\RB\1740 reported_26\VBN\831651 ._27\.\1740
D013792_D020258 NONE this_0\DT\1740 electrophysiological_1\JJ\1740 parameter_2\NN\5858936 provides_3\VBZ\2199590 information_4\NN\6598915 about_5\IN\1740 subclinical_6\JJ\1740 <e2>neurotoxic</e2>_7\JJ\1740 potential_8\NN\14481929 of_9\IN\1740 <e1>thalidomide</e1>_10\NN\4166841 but_11\CC\1740 is_12\VBZ\836236 not_13\RB\1740 helpful_14\JJ\1740 in_15\IN\13603305 predicting_16\VBG\916909 the_17\DT\1740 appearance_18\NN\4723816 of_19\IN\1740 sensory_20\JJ\1740 symptoms_21\NNS\5823932 ._22\.\1740
24894748
D008790_D001919 CID a_0\DT\13649268 <e1>metoprolol-terbinafine</e1>_1\JJ\1740 combination_2\NN\7951464 induced_3\JJ\1740 <e2>bradycardia</e2>_4\NN\14110674 ._5\.\1740
C041359_D001919 CID a_0\DT\13649268 <e1>metoprolol-terbinafine</e1>_1\JJ\1740 combination_2\NN\7951464 induced_3\JJ\1740 <e2>bradycardia</e2>_4\NN\14110674 ._5\.\1740
D008790_D012804 NONE to_0\TO\1740 report_1\VB\831651 a_2\DT\13649268 <e2>sinus_3\NN\5248181 bradycardia</e2>_4\NN\14110674 induced_5\VBN\1627355 by_6\IN\1740 <e1>metoprolol</e1>_7\NN\2832168 and_8\CC\1740 terbinafine_9\JJ\1740 drug-drug_10\JJ\1740 interaction_11\NN\37396 and_12\CC\1740 its_13\PRP$\6125041 management_14\NN\1123598 ._15\.\1740
D008790_D012804 NONE a_0\DT\13649268 score_1\NN\5736149 of_2\IN\1740 7_3\CD\13741022 on_4\IN\1740 the_5\DT\1740 naranjo_6\NNP\1740 adverse_7\JJ\1740 drug_8\NN\14778436 reaction_9\NN\13446390 probability_10\NN\33615 scale_11\NN\7260623 indicates_12\VBZ\952524 a_13\DT\13649268 probable_14\JJ\1740 relationship_15\NN\31921 between_16\IN\1740 the_17\DT\1740 patient_18\NN\9898892 's_19\POS\1740 <e2>sinus_20\NN\5248181 bradycardia</e2>_21\NN\14110674 and_22\CC\1740 the_23\DT\1740 drug_24\NN\14778436 interaction_25\NN\37396 between_26\IN\1740 <e1>metoprolol</e1>_27\NN\2832168 and_28\CC\1740 terbinafine_29\NN\2720201 ._30\.\1740
D008790_D012804 NONE by_0\IN\1740 inhibiting_1\VBG\2510337 the_2\DT\1740 cytochrome_3\NN\14888884 p450_4\NN\1740 2d6_5\NN\1740 ,_6\,\1740 terbinafine_7\NN\2720201 had_8\VBD\2108377 decreased_9\VBN\169651 <e1>metoprolol</e1>_10\NN\2832168 's_11\POS\1740 clearance_12\NN\5089947 ,_13\,\1740 leading_14\VBG\1752884 in_15\IN\13603305 metoprolol_16\NN\2832168 accumulation_17\NN\13497135 which_18\WDT\1740 has_19\VBZ\2108377 resulted_20\VBN\2633881 in_21\IN\13603305 clinically_22\RB\1740 significant_23\JJ\1740 <e2>sinus_24\NN\5248181 bradycardia</e2>_25\NN\14110674 ._26\.\1740
D008790_D012804 NONE by_0\IN\1740 inhibiting_1\VBG\2510337 the_2\DT\1740 cytochrome_3\NN\14888884 p450_4\NN\1740 2d6_5\NN\1740 ,_6\,\1740 terbinafine_7\NN\2720201 had_8\VBD\2108377 decreased_9\VBN\169651 metoprolol_10\NN\2832168 's_11\POS\1740 clearance_12\NN\5089947 ,_13\,\1740 leading_14\VBG\1752884 in_15\IN\13603305 <e1>metoprolol</e1>_16\NN\2832168 accumulation_17\NN\13497135 which_18\WDT\1740 has_19\VBZ\2108377 resulted_20\VBN\2633881 in_21\IN\13603305 clinically_22\RB\1740 significant_23\JJ\1740 <e2>sinus_24\NN\5248181 bradycardia</e2>_25\NN\14110674 ._26\.\1740
C041359_D012804 NONE to_0\TO\1740 report_1\VB\831651 a_2\DT\13649268 <e2>sinus_3\NN\5248181 bradycardia</e2>_4\NN\14110674 induced_5\VBN\1627355 by_6\IN\1740 metoprolol_7\NN\2832168 and_8\CC\1740 <e1>terbinafine</e1>_9\JJ\1740 drug-drug_10\JJ\1740 interaction_11\NN\37396 and_12\CC\1740 its_13\PRP$\6125041 management_14\NN\1123598 ._15\.\1740
C041359_D012804 NONE a_0\DT\13649268 score_1\NN\5736149 of_2\IN\1740 7_3\CD\13741022 on_4\IN\1740 the_5\DT\1740 naranjo_6\NNP\1740 adverse_7\JJ\1740 drug_8\NN\14778436 reaction_9\NN\13446390 probability_10\NN\33615 scale_11\NN\7260623 indicates_12\VBZ\952524 a_13\DT\13649268 probable_14\JJ\1740 relationship_15\NN\31921 between_16\IN\1740 the_17\DT\1740 patient_18\NN\9898892 's_19\POS\1740 <e2>sinus_20\NN\5248181 bradycardia</e2>_21\NN\14110674 and_22\CC\1740 the_23\DT\1740 drug_24\NN\14778436 interaction_25\NN\37396 between_26\IN\1740 metoprolol_27\NN\2832168 and_28\CC\1740 <e1>terbinafine</e1>_29\NN\2720201 ._30\.\1740
C041359_D012804 NONE by_0\IN\1740 inhibiting_1\VBG\2510337 the_2\DT\1740 cytochrome_3\NN\14888884 p450_4\NN\1740 2d6_5\NN\1740 ,_6\,\1740 <e1>terbinafine</e1>_7\NN\2720201 had_8\VBD\2108377 decreased_9\VBN\169651 metoprolol_10\NN\2832168 's_11\POS\1740 clearance_12\NN\5089947 ,_13\,\1740 leading_14\VBG\1752884 in_15\IN\13603305 metoprolol_16\NN\2832168 accumulation_17\NN\13497135 which_18\WDT\1740 has_19\VBZ\2108377 resulted_20\VBN\2633881 in_21\IN\13603305 clinically_22\RB\1740 significant_23\JJ\1740 <e2>sinus_24\NN\5248181 bradycardia</e2>_25\NN\14110674 ._26\.\1740
D008790_D003324 NONE a_0\DT\13649268 63_1\CD\1740 year-old_2\NN\1740 caucasian_3\JJ\1740 man_4\NN\9605289 on_5\IN\1740 <e1>metoprolol</e1>_6\NN\2832168 200_7\CD\1740 mg/day_8\NN\1740 for_9\IN\1740 stable_10\JJ\1740 <e2>coronary_11\JJ\1740 artery_12\NN\5417975 disease</e2>_13\NN\14061805 was_14\VBD\836236 prescribed_15\VBN\748282 a_16\DT\13649268 90-day_17\JJ\1740 course_18\NN\883297 of_19\IN\1740 oral_20\JJ\1740 terbinafine_21\NN\2720201 250_22\CD\1740 mg/day_23\NN\1740 for_24\IN\1740 onychomycosis_25\NN\1740 ._26\.\1740
D008790_D014009 NONE a_0\DT\13649268 63_1\CD\1740 year-old_2\NN\1740 caucasian_3\JJ\1740 man_4\NN\9605289 on_5\IN\1740 <e1>metoprolol</e1>_6\NN\2832168 200_7\CD\1740 mg/day_8\NN\1740 for_9\IN\1740 stable_10\JJ\1740 coronary_11\JJ\1740 artery_12\NN\5417975 disease_13\NN\14061805 was_14\VBD\836236 prescribed_15\VBN\748282 a_16\DT\13649268 90-day_17\JJ\1740 course_18\NN\883297 of_19\IN\1740 oral_20\JJ\1740 terbinafine_21\NN\2720201 250_22\CD\1740 mg/day_23\NN\1740 for_24\IN\1740 <e2>onychomycosis</e2>_25\NN\1740 ._26\.\1740
C041359_D003324 NONE a_0\DT\13649268 63_1\CD\1740 year-old_2\NN\1740 caucasian_3\JJ\1740 man_4\NN\9605289 on_5\IN\1740 metoprolol_6\NN\2832168 200_7\CD\1740 mg/day_8\NN\1740 for_9\IN\1740 stable_10\JJ\1740 <e2>coronary_11\JJ\1740 artery_12\NN\5417975 disease</e2>_13\NN\14061805 was_14\VBD\836236 prescribed_15\VBN\748282 a_16\DT\13649268 90-day_17\JJ\1740 course_18\NN\883297 of_19\IN\1740 oral_20\JJ\1740 <e1>terbinafine</e1>_21\NN\2720201 250_22\CD\1740 mg/day_23\NN\1740 for_24\IN\1740 onychomycosis_25\NN\1740 ._26\.\1740
C041359_D014009 NONE a_0\DT\13649268 63_1\CD\1740 year-old_2\NN\1740 caucasian_3\JJ\1740 man_4\NN\9605289 on_5\IN\1740 metoprolol_6\NN\2832168 200_7\CD\1740 mg/day_8\NN\1740 for_9\IN\1740 stable_10\JJ\1740 coronary_11\JJ\1740 artery_12\NN\5417975 disease_13\NN\14061805 was_14\VBD\836236 prescribed_15\VBN\748282 a_16\DT\13649268 90-day_17\JJ\1740 course_18\NN\883297 of_19\IN\1740 oral_20\JJ\1740 <e1>terbinafine</e1>_21\NN\2720201 250_22\CD\1740 mg/day_23\NN\1740 for_24\IN\1740 <e2>onychomycosis</e2>_25\NN\1740 ._26\.\1740
C041359_D003221 NONE on_0\IN\1740 the_1\DT\1740 49th_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 <e1>terbinafine</e1>_5\NN\2720201 therapy_6\NN\657604 ,_7\,\1740 he_8\PRP\14622893 was_9\VBD\836236 brought_10\VBN\1449974 to_11\IN\1740 the_12\DT\1740 emergency_13\NN\7417644 room_14\NN\2735688 for_15\IN\1740 a_16\DT\13649268 decrease_17\NN\7296428 of_18\IN\1740 his_19\PRP$\1740 global_20\JJ\1740 health_21\NN\14447525 status_22\NN\24720 ,_23\,\1740 <e2>confusion</e2>_24\NN\13972797 and_25\CC\1740 falls_26\VBZ\1835496 ._27\.\1740
D008790_D064420 NONE a_0\DT\13649268 score_1\NN\5736149 of_2\IN\1740 7_3\CD\13741022 on_4\IN\1740 the_5\DT\1740 naranjo_6\NNP\1740 <e2>adverse_7\JJ\1740 drug_8\NN\14778436 reaction</e2>_9\NN\13446390 probability_10\NN\33615 scale_11\NN\7260623 indicates_12\VBZ\952524 a_13\DT\13649268 probable_14\JJ\1740 relationship_15\NN\31921 between_16\IN\1740 the_17\DT\1740 patient_18\NN\9898892 's_19\POS\1740 sinus_20\NN\5248181 bradycardia_21\NN\14110674 and_22\CC\1740 the_23\DT\1740 drug_24\NN\14778436 interaction_25\NN\37396 between_26\IN\1740 <e1>metoprolol</e1>_27\NN\2832168 and_28\CC\1740 terbinafine_29\NN\2720201 ._30\.\1740
C041359_D064420 NONE a_0\DT\13649268 score_1\NN\5736149 of_2\IN\1740 7_3\CD\13741022 on_4\IN\1740 the_5\DT\1740 naranjo_6\NNP\1740 <e2>adverse_7\JJ\1740 drug_8\NN\14778436 reaction</e2>_9\NN\13446390 probability_10\NN\33615 scale_11\NN\7260623 indicates_12\VBZ\952524 a_13\DT\13649268 probable_14\JJ\1740 relationship_15\NN\31921 between_16\IN\1740 the_17\DT\1740 patient_18\NN\9898892 's_19\POS\1740 sinus_20\NN\5248181 bradycardia_21\NN\14110674 and_22\CC\1740 the_23\DT\1740 drug_24\NN\14778436 interaction_25\NN\37396 between_26\IN\1740 metoprolol_27\NN\2832168 and_28\CC\1740 <e1>terbinafine</e1>_29\NN\2720201 ._30\.\1740
19715529
12051122
D014750_D007010 CID <e2>hyponatremia</e2>_0\NN\14299637 and_1\CC\1740 syndrome_2\NN\5870365 of_3\IN\1740 inappropriate_4\JJ\1740 anti-diuretic_5\JJ\1740 hormone_6\NN\5404728 reported_7\VBN\831651 with_8\IN\1740 the_9\DT\1740 use_10\NN\407535 of_11\IN\1740 <e1>vincristine</e1>_12\NN\3917455 :_13\:\1740 an_14\DT\6697703 over-representation_15\NN\1740 of_16\IN\1740 asians_17\NNPS\9620078 ?_18\.\1740
D014750_D007010 CID purpose_0\NNP\5980875 :_1\:\1740 this_2\DT\1740 retrospective_3\JJ\1740 study_4\NN\635850 used_5\VBD\1156834 a_6\DT\13649268 pharmaceutical_7\JJ\1740 company_8\NN\8053576 's_9\POS\1740 global_10\JJ\1740 safety_11\NN\13920835 database_12\NN\6634376 to_13\TO\1740 determine_14\VB\1645601 the_15\DT\1740 reporting_16\NN\6681177 rate_17\NN\13815152 of_18\IN\1740 <e2>hyponatremia</e2>_19\NN\14299637 and/or_20\CC\1740 syndrome_21\NN\5870365 of_22\IN\1740 inappropriate_23\JJ\1740 secretion_24\NN\13526110 of_25\IN\1740 anti-diuretic_26\JJ\1740 hormone_27\NN\5404728 (_28\-LRB-\1740 siadh_29\NN\1740 )_30\-RRB-\1740 among_31\IN\1740 <e1>vincristine-treated</e1>_32\JJ\1740 patients_33\NNS\9898892 and_34\CC\1740 to_35\TO\1740 explore_36\VB\789138 the_37\DT\1740 possibility_38\NN\5944958 of_39\IN\1740 at-risk_40\JJ\1740 population_41\NN\7942152 subgroups_42\NNS\31264 ._43\.\1740
D014750_D007010 CID method_0\NNP\5616786 :_1\:\1740 we_2\PRP\1740 searched_3\VBD\2131279 the_4\DT\1740 eli_5\NNP\1740 lilly_6\NNP\1740 and_7\CC\1740 company_8\NNP\8053576 's_9\POS\1740 computerized_10\VBN\2327200 adverse_11\JJ\1740 event_12\NN\23100 database_13\NN\6634376 for_14\IN\1740 all_15\DT\1740 reported_16\VBN\831651 cases_17\NNS\7283608 of_18\IN\1740 <e2>hyponatremia</e2>_19\NN\14299637 and/or_20\CC\1740 siadh_21\NN\1740 as_22\IN\14622893 of_23\IN\1740 1_24\CD\13741022 november_25\NNP\15209706 1999_26\CD\1740 that_27\WDT\1740 had_28\VBD\2108377 been_29\VBN\836236 reported_30\VBN\831651 during_31\IN\1740 the_32\DT\1740 use_33\NN\407535 of_34\IN\1740 <e1>vincristine</e1>_35\NN\3917455 ._36\.\1740
D014750_D007010 CID results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 total_3\NN\3553 of_4\IN\1740 76_5\CD\1740 cases_6\NNS\7283608 of_7\IN\1740 <e2>hyponatremia</e2>_8\NN\14299637 and/or_9\CC\1740 siadh_10\NN\1740 associated_11\VBN\628491 with_12\IN\1740 <e1>vincristine</e1>_13\NN\3917455 use_14\NN\407535 were_15\VBD\836236 identified_16\VBN\699815 ._17\.\1740
D014750_D007010 CID conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 asian_6\JJ\1740 patients_7\NNS\9898892 may_8\MD\15209706 be_9\VB\836236 at_10\IN\14622893 increased_11\VBN\169651 risk_12\NN\14541044 of_13\IN\1740 <e2>hyponatremia</e2>_14\NN\14299637 and/or_15\CC\1740 siadh_16\NN\1740 associated_17\VBN\628491 with_18\IN\1740 <e1>vincristine</e1>_19\NN\3917455 use_20\NN\407535 ._21\.\1740
D014750_D007177 CID hyponatremia_0\NN\14299637 and_1\CC\1740 <e2>syndrome_2\NN\5870365 of_3\IN\1740 inappropriate_4\JJ\1740 anti-diuretic_5\JJ\1740 hormone</e2>_6\NN\5404728 reported_7\VBN\831651 with_8\IN\1740 the_9\DT\1740 use_10\NN\407535 of_11\IN\1740 <e1>vincristine</e1>_12\NN\3917455 :_13\:\1740 an_14\DT\6697703 over-representation_15\NN\1740 of_16\IN\1740 asians_17\NNPS\9620078 ?_18\.\1740
D014750_D007177 CID purpose_0\NNP\5980875 :_1\:\1740 this_2\DT\1740 retrospective_3\JJ\1740 study_4\NN\635850 used_5\VBD\1156834 a_6\DT\13649268 pharmaceutical_7\JJ\1740 company_8\NN\8053576 's_9\POS\1740 global_10\JJ\1740 safety_11\NN\13920835 database_12\NN\6634376 to_13\TO\1740 determine_14\VB\1645601 the_15\DT\1740 reporting_16\NN\6681177 rate_17\NN\13815152 of_18\IN\1740 hyponatremia_19\NN\14299637 and/or_20\CC\1740 <e2>syndrome_21\NN\5870365 of_22\IN\1740 inappropriate_23\JJ\1740 secretion_24\NN\13526110 of_25\IN\1740 anti-diuretic_26\JJ\1740 hormone</e2>_27\NN\5404728 (_28\-LRB-\1740 siadh_29\NN\1740 )_30\-RRB-\1740 among_31\IN\1740 <e1>vincristine-treated</e1>_32\JJ\1740 patients_33\NNS\9898892 and_34\CC\1740 to_35\TO\1740 explore_36\VB\789138 the_37\DT\1740 possibility_38\NN\5944958 of_39\IN\1740 at-risk_40\JJ\1740 population_41\NN\7942152 subgroups_42\NNS\31264 ._43\.\1740
D014750_D007177 CID purpose_0\NNP\5980875 :_1\:\1740 this_2\DT\1740 retrospective_3\JJ\1740 study_4\NN\635850 used_5\VBD\1156834 a_6\DT\13649268 pharmaceutical_7\JJ\1740 company_8\NN\8053576 's_9\POS\1740 global_10\JJ\1740 safety_11\NN\13920835 database_12\NN\6634376 to_13\TO\1740 determine_14\VB\1645601 the_15\DT\1740 reporting_16\NN\6681177 rate_17\NN\13815152 of_18\IN\1740 hyponatremia_19\NN\14299637 and/or_20\CC\1740 syndrome_21\NN\5870365 of_22\IN\1740 inappropriate_23\JJ\1740 secretion_24\NN\13526110 of_25\IN\1740 anti-diuretic_26\JJ\1740 hormone_27\NN\5404728 (_28\-LRB-\1740 <e2>siadh</e2>_29\NN\1740 )_30\-RRB-\1740 among_31\IN\1740 <e1>vincristine-treated</e1>_32\JJ\1740 patients_33\NNS\9898892 and_34\CC\1740 to_35\TO\1740 explore_36\VB\789138 the_37\DT\1740 possibility_38\NN\5944958 of_39\IN\1740 at-risk_40\JJ\1740 population_41\NN\7942152 subgroups_42\NNS\31264 ._43\.\1740
D014750_D007177 CID method_0\NNP\5616786 :_1\:\1740 we_2\PRP\1740 searched_3\VBD\2131279 the_4\DT\1740 eli_5\NNP\1740 lilly_6\NNP\1740 and_7\CC\1740 company_8\NNP\8053576 's_9\POS\1740 computerized_10\VBN\2327200 adverse_11\JJ\1740 event_12\NN\23100 database_13\NN\6634376 for_14\IN\1740 all_15\DT\1740 reported_16\VBN\831651 cases_17\NNS\7283608 of_18\IN\1740 hyponatremia_19\NN\14299637 and/or_20\CC\1740 <e2>siadh</e2>_21\NN\1740 as_22\IN\14622893 of_23\IN\1740 1_24\CD\13741022 november_25\NNP\15209706 1999_26\CD\1740 that_27\WDT\1740 had_28\VBD\2108377 been_29\VBN\836236 reported_30\VBN\831651 during_31\IN\1740 the_32\DT\1740 use_33\NN\407535 of_34\IN\1740 <e1>vincristine</e1>_35\NN\3917455 ._36\.\1740
D014750_D007177 CID results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 total_3\NN\3553 of_4\IN\1740 76_5\CD\1740 cases_6\NNS\7283608 of_7\IN\1740 hyponatremia_8\NN\14299637 and/or_9\CC\1740 <e2>siadh</e2>_10\NN\1740 associated_11\VBN\628491 with_12\IN\1740 <e1>vincristine</e1>_13\NN\3917455 use_14\NN\407535 were_15\VBD\836236 identified_16\VBN\699815 ._17\.\1740
D014750_D007177 CID conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 data_3\NNS\7951464 suggest_4\VBP\1010118 that_5\IN\1740 asian_6\JJ\1740 patients_7\NNS\9898892 may_8\MD\15209706 be_9\VB\836236 at_10\IN\14622893 increased_11\VBN\169651 risk_12\NN\14541044 of_13\IN\1740 hyponatremia_14\NN\14299637 and/or_15\CC\1740 <e2>siadh</e2>_16\NN\1740 associated_17\VBN\628491 with_18\IN\1740 <e1>vincristine</e1>_19\NN\3917455 use_20\NN\407535 ._21\.\1740
D014750_D007177 CID although_0\IN\1740 the_1\DT\1740 overall_2\JJ\1740 reported_3\VBN\831651 rate_4\NN\13815152 of_5\IN\1740 <e2>siadh</e2>_6\NN\1740 associated_7\VBN\628491 with_8\IN\1740 <e1>vincristine</e1>_9\NN\3917455 is_10\VBZ\836236 very_11\RB\1740 low_12\JJ\1740 ,_13\,\1740 physicians_14\NNS\10305802 caring_15\VBG\1821996 for_16\IN\1740 asian_17\JJ\1740 oncology_18\NN\6043075 patients_19\NNS\9898892 should_20\MD\1740 be_21\VB\836236 aware_22\JJ\1740 of_23\IN\1740 this_24\DT\1740 potential_25\JJ\1740 serious_26\JJ\1740 but_27\CC\1740 reversible_28\JJ\1740 adverse_29\JJ\1740 event_30\NN\23100 ._31\.\1740
15605432
D004317_D028361 CID oxidative_0\JJ\1740 damage_1\NN\7296428 precedes_2\VBZ\2690708 nitrative_3\JJ\1740 damage_4\NN\7296428 in_5\IN\13603305 <e1>adriamycin-induced</e1>_6\JJ\1740 cardiac_7\JJ\1740 <e2>mitochondrial_8\JJ\1740 injury</e2>_9\NN\14052046 ._10\.\1740
D004317_D028361 CID our_0\PRP$\1740 data_1\NNS\7951464 showed_2\VBD\2137132 <e1>adr</e1>_3\NN\1740 induced_4\JJ\1740 4hne-protein_5\NN\1740 adducts_6\NNS\14818238 in_7\IN\13603305 mitochondria_8\NN\5445668 at_9\IN\14622893 the_10\DT\1740 same_11\JJ\1740 time_12\NN\7308889 point_13\NN\5868954 as_14\IN\14622893 when_15\WRB\1740 <e2>mitochondrial_16\JJ\1740 injury</e2>_17\NN\14052046 initially_18\RB\1740 appeared_19\VBD\2604760 ._20\.\1740
D010100_D066126 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 if_9\IN\1740 elevated_10\JJ\1740 reactive_11\JJ\1740 <e1>oxygen</e1>_12\NN\14622893 (ros)/nitrogen_13\NN\1740 species_14\NNS\7992450 (_15\-LRB-\1740 rns_16\NN\14622893 )_17\-RRB-\1740 reported_18\VBD\831651 to_19\TO\1740 be_20\VB\836236 present_21\JJ\1740 in_22\IN\13603305 adriamycin_23\NN\1740 (adr)-induced_24\:\1740 <e2>cardiotoxicity</e2>_25\NN\1740 actually_26\RB\1740 resulted_27\VBD\2633881 in_28\IN\13603305 cardiomyocyte_29\NN\1740 oxidative/nitrative_30\JJ\1740 damage_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 to_34\TO\1740 quantitatively_35\RB\1740 determine_36\VB\1645601 the_37\DT\1740 time_38\NN\7308889 course_39\NN\883297 and_40\CC\1740 subcellular_41\JJ\1740 localization_42\NN\151497 of_43\IN\1740 these_44\DT\1740 postulated_45\VBN\756338 damage_46\NN\7296428 products_47\NNS\3076708 using_48\VBG\1156834 an_49\DT\6697703 in_50\FW\13603305 vivo_51\FW\1740 approach_52\NN\940842 ._53\.\1740
D009584_D066126 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 if_9\IN\1740 elevated_10\JJ\1740 reactive_11\JJ\1740 oxygen_12\NN\14622893 <e1>(ros)/nitrogen</e1>_13\NN\1740 species_14\NNS\7992450 (_15\-LRB-\1740 rns_16\NN\14622893 )_17\-RRB-\1740 reported_18\VBD\831651 to_19\TO\1740 be_20\VB\836236 present_21\JJ\1740 in_22\IN\13603305 adriamycin_23\NN\1740 (adr)-induced_24\:\1740 <e2>cardiotoxicity</e2>_25\NN\1740 actually_26\RB\1740 resulted_27\VBD\2633881 in_28\IN\13603305 cardiomyocyte_29\NN\1740 oxidative/nitrative_30\JJ\1740 damage_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 to_34\TO\1740 quantitatively_35\RB\1740 determine_36\VB\1645601 the_37\DT\1740 time_38\NN\7308889 course_39\NN\883297 and_40\CC\1740 subcellular_41\JJ\1740 localization_42\NN\151497 of_43\IN\1740 these_44\DT\1740 postulated_45\VBN\756338 damage_46\NN\7296428 products_47\NNS\3076708 using_48\VBG\1156834 an_49\DT\6697703 in_50\FW\13603305 vivo_51\FW\1740 approach_52\NN\940842 ._53\.\1740
D004317_D066126 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 if_9\IN\1740 elevated_10\JJ\1740 reactive_11\JJ\1740 oxygen_12\NN\14622893 (ros)/nitrogen_13\NN\1740 species_14\NNS\7992450 (_15\-LRB-\1740 rns_16\NN\14622893 )_17\-RRB-\1740 reported_18\VBD\831651 to_19\TO\1740 be_20\VB\836236 present_21\JJ\1740 in_22\IN\13603305 <e1>adriamycin</e1>_23\NN\1740 (adr)-induced_24\:\1740 <e2>cardiotoxicity</e2>_25\NN\1740 actually_26\RB\1740 resulted_27\VBD\2633881 in_28\IN\13603305 cardiomyocyte_29\NN\1740 oxidative/nitrative_30\JJ\1740 damage_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 to_34\TO\1740 quantitatively_35\RB\1740 determine_36\VB\1645601 the_37\DT\1740 time_38\NN\7308889 course_39\NN\883297 and_40\CC\1740 subcellular_41\JJ\1740 localization_42\NN\151497 of_43\IN\1740 these_44\DT\1740 postulated_45\VBN\756338 damage_46\NN\7296428 products_47\NNS\3076708 using_48\VBG\1156834 an_49\DT\6697703 in_50\FW\13603305 vivo_51\FW\1740 approach_52\NN\940842 ._53\.\1740
D004317_D066126 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 if_9\IN\1740 elevated_10\JJ\1740 reactive_11\JJ\1740 oxygen_12\NN\14622893 (ros)/nitrogen_13\NN\1740 species_14\NNS\7992450 (_15\-LRB-\1740 rns_16\NN\14622893 )_17\-RRB-\1740 reported_18\VBD\831651 to_19\TO\1740 be_20\VB\836236 present_21\JJ\1740 in_22\IN\13603305 adriamycin_23\NN\1740 <e1>(adr)-induced</e1>_24\:\1740 <e2>cardiotoxicity</e2>_25\NN\1740 actually_26\RB\1740 resulted_27\VBD\2633881 in_28\IN\13603305 cardiomyocyte_29\NN\1740 oxidative/nitrative_30\JJ\1740 damage_31\NN\7296428 ,_32\,\1740 and_33\CC\1740 to_34\TO\1740 quantitatively_35\RB\1740 determine_36\VB\1645601 the_37\DT\1740 time_38\NN\7308889 course_39\NN\883297 and_40\CC\1740 subcellular_41\JJ\1740 localization_42\NN\151497 of_43\IN\1740 these_44\DT\1740 postulated_45\VBN\756338 damage_46\NN\7296428 products_47\NNS\3076708 using_48\VBG\1156834 an_49\DT\6697703 in_50\FW\13603305 vivo_51\FW\1740 approach_52\NN\940842 ._53\.\1740
C027576_D028361 NONE our_0\PRP$\1740 data_1\NNS\7951464 showed_2\VBD\2137132 adr_3\NN\1740 induced_4\JJ\1740 <e1>4hne-protein</e1>_5\NN\1740 adducts_6\NNS\14818238 in_7\IN\13603305 mitochondria_8\NN\5445668 at_9\IN\14622893 the_10\DT\1740 same_11\JJ\1740 time_12\NN\7308889 point_13\NN\5868954 as_14\IN\14622893 when_15\WRB\1740 <e2>mitochondrial_16\JJ\1740 injury</e2>_17\NN\14052046 initially_18\RB\1740 appeared_19\VBD\2604760 ._20\.\1740
8184922
D007545_D006332 CID these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 adult_4\JJ\1740 mouse_5\NN\2329401 atrial_6\JJ\1740 and_7\CC\1740 ventricular_8\JJ\1740 cardiomyocytes_9\NNS\1740 do_10\VBP\1640855 not_11\RB\1740 synthesize_12\VB\193486 dna_13\NN\14994328 in_14\IN\13603305 response_15\NN\11410625 to_16\TO\1740 <e1>isoproterenol-induced</e1>_17\JJ\1740 <e2>cardiac_18\JJ\1740 hypertrophy</e2>_19\NN\14365950 ._20\.\1740
20959502
D017576_D008581 NONE cerebrospinal_0\JJ\1740 fluid_1\NN\19613 penetration_2\NN\972621 of_3\IN\1740 high-dose_4\JJ\1740 <e1>daptomycin</e1>_5\NN\1740 in_6\IN\13603305 suspected_7\VBN\916909 staphylococcus_8\FW\1350855 aureus_9\FW\1740 <e2>meningitis</e2>_10\NN\14127211 ._11\.\1740
D017576_D008581 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 methicillin-sensitive_7\JJ\1740 staphylococcus_8\FW\1350855 aureus_9\FW\1740 (_10\-LRB-\1740 mssa_11\JJ\1740 )_12\-RRB-\1740 bacteremia_13\NN\14204950 with_14\IN\1740 suspected_15\VBN\916909 mssa_16\NN\1740 <e2>meningitis</e2>_17\NN\14127211 treated_18\VBN\2376958 with_19\IN\1740 high-dose_20\JJ\1740 <e1>daptomycin</e1>_21\NN\1740 assessed_22\VBN\670261 with_23\IN\1740 concurrent_24\JJ\1740 serum_25\NN\5397468 and_26\CC\1740 cerebrospinal_27\JJ\1740 fluid_28\NN\19613 (_29\-LRB-\1740 csf_30\NN\1740 )_31\-RRB-\1740 concentrations_32\NNS\4916342 ._33\.\1740
D017576_D008581 NONE nafcillin_0\NNP\3910417 was_1\VBD\836236 discontinued_2\VBN\2609764 and_3\CC\1740 <e1>daptomycin</e1>_4\NN\1740 9_5\CD\13741022 mg/kg_6\NN\1740 daily_7\RB\1740 was_8\VBD\836236 initiated_9\VBN\1617192 for_10\IN\1740 suspected_11\VBN\916909 <e2>meningitis</e2>_12\NN\14127211 and_13\CC\1740 was_14\VBD\836236 continued_15\VBN\2367363 until_16\IN\1740 the_17\DT\1740 patient_18\NN\9898892 's_19\POS\1740 death_20\NN\7296428 on_21\IN\1740 day_22\NN\15154774 16_23\CD\13745420 ._24\.\1740
D008712_D016470 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>methicillin-sensitive</e1>_7\JJ\1740 staphylococcus_8\FW\1350855 aureus_9\FW\1740 (_10\-LRB-\1740 mssa_11\JJ\1740 )_12\-RRB-\1740 <e2>bacteremia</e2>_13\NN\14204950 with_14\IN\1740 suspected_15\VBN\916909 mssa_16\NN\1740 meningitis_17\NN\14127211 treated_18\VBN\2376958 with_19\IN\1740 high-dose_20\JJ\1740 daptomycin_21\NN\1740 assessed_22\VBN\670261 with_23\IN\1740 concurrent_24\JJ\1740 serum_25\NN\5397468 and_26\CC\1740 cerebrospinal_27\JJ\1740 fluid_28\NN\19613 (_29\-LRB-\1740 csf_30\NN\1740 )_31\-RRB-\1740 concentrations_32\NNS\4916342 ._33\.\1740
D008712_D008581 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>methicillin-sensitive</e1>_7\JJ\1740 staphylococcus_8\FW\1350855 aureus_9\FW\1740 (_10\-LRB-\1740 mssa_11\JJ\1740 )_12\-RRB-\1740 bacteremia_13\NN\14204950 with_14\IN\1740 suspected_15\VBN\916909 mssa_16\NN\1740 <e2>meningitis</e2>_17\NN\14127211 treated_18\VBN\2376958 with_19\IN\1740 high-dose_20\JJ\1740 daptomycin_21\NN\1740 assessed_22\VBN\670261 with_23\IN\1740 concurrent_24\JJ\1740 serum_25\NN\5397468 and_26\CC\1740 cerebrospinal_27\JJ\1740 fluid_28\NN\19613 (_29\-LRB-\1740 csf_30\NN\1740 )_31\-RRB-\1740 concentrations_32\NNS\4916342 ._33\.\1740
D017576_D016470 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 methicillin-sensitive_7\JJ\1740 staphylococcus_8\FW\1350855 aureus_9\FW\1740 (_10\-LRB-\1740 mssa_11\JJ\1740 )_12\-RRB-\1740 <e2>bacteremia</e2>_13\NN\14204950 with_14\IN\1740 suspected_15\VBN\916909 mssa_16\NN\1740 meningitis_17\NN\14127211 treated_18\VBN\2376958 with_19\IN\1740 high-dose_20\JJ\1740 <e1>daptomycin</e1>_21\NN\1740 assessed_22\VBN\670261 with_23\IN\1740 concurrent_24\JJ\1740 serum_25\NN\5397468 and_26\CC\1740 cerebrospinal_27\JJ\1740 fluid_28\NN\19613 (_29\-LRB-\1740 csf_30\NN\1740 )_31\-RRB-\1740 concentrations_32\NNS\4916342 ._33\.\1740
D017576_D016470 NONE discussion_0\NN\6252138 :_1\:\1740 <e1>daptomycin</e1>_2\NNP\1740 was_3\VBD\836236 initiated_4\VBN\1617192 in_5\IN\13603305 our_6\PRP$\1740 patient_7\NN\9898892 secondary_8\JJ\1740 to_9\TO\1740 possible_10\JJ\1740 nafcillin-induced_11\JJ\1740 acute_12\JJ\1740 interstitial_13\JJ\1740 nephritis_14\NN\14113228 and_15\CC\1740 relapsing_16\VBG\146138 <e2>bacteremia</e2>_17\NN\14204950 ._18\.\1740
D017576_D016470 NONE conclusions_0\NNS\5837957 :_1\:\1740 high-dose_2\JJ\1740 <e1>daptomycin</e1>_3\NN\1740 may_4\MD\15209706 be_5\VB\836236 an_6\DT\6697703 alternative_7\JJ\1740 option_8\NN\6480506 for_9\IN\1740 mssa_10\JJ\1740 <e2>bacteremia</e2>_11\NN\14204950 with_12\IN\1740 or_13\CC\3541091 without_14\IN\1740 a_15\DT\13649268 cns_16\NN\5237227 source_17\NN\8620061 in_18\IN\13603305 patients_19\NNS\9898892 who_20\WP\8299493 have_21\VBP\2108377 failed_22\VBN\1798936 or_23\CC\3541091 can_24\MD\3094503 not_25\RB\1740 tolerate_26\VB\802318 standard_27\JJ\1740 therapy_28\NN\657604 ._29\.\1740
D003404_D058186 NONE on_0\IN\1740 day_1\NN\15154774 8_2\CD\13741022 ,_3\,\1740 the_4\DT\1740 patient_5\NN\9898892 developed_6\VBD\1753788 <e2>acute_7\JJ\1740 renal_8\JJ\1740 failure</e2>_9\NN\66216 (_10\-LRB-\1740 serum_11\NN\5397468 <e1>creatinine</e1>_12\NN\1740 1.9_13\CD\1740 mg/dl_14\NN\1740 ,_15\,\1740 increased_16\VBD\169651 from_17\IN\1740 1.2_18\CD\1740 mg/dl_19\NN\1740 the_20\DT\1740 previous_21\JJ\1740 day_22\NN\15154774 and_23\CC\1740 0.8_24\CD\1740 mg/dl_25\NN\1740 on_26\IN\1740 admission_27\NN\49003 )_28\-RRB-\1740 ._29\.\1740
D009254_D008581 NONE <e1>nafcillin</e1>_0\NNP\3910417 was_1\VBD\836236 discontinued_2\VBN\2609764 and_3\CC\1740 daptomycin_4\NN\1740 9_5\CD\13741022 mg/kg_6\NN\1740 daily_7\RB\1740 was_8\VBD\836236 initiated_9\VBN\1617192 for_10\IN\1740 suspected_11\VBN\916909 <e2>meningitis</e2>_12\NN\14127211 and_13\CC\1740 was_14\VBD\836236 continued_15\VBN\2367363 until_16\IN\1740 the_17\DT\1740 patient_18\NN\9898892 's_19\POS\1740 death_20\NN\7296428 on_21\IN\1740 day_22\NN\15154774 16_23\CD\13745420 ._24\.\1740
D017576_D009395 NONE discussion_0\NN\6252138 :_1\:\1740 <e1>daptomycin</e1>_2\NNP\1740 was_3\VBD\836236 initiated_4\VBN\1617192 in_5\IN\13603305 our_6\PRP$\1740 patient_7\NN\9898892 secondary_8\JJ\1740 to_9\TO\1740 possible_10\JJ\1740 nafcillin-induced_11\JJ\1740 acute_12\JJ\1740 <e2>interstitial_13\JJ\1740 nephritis</e2>_14\NN\14113228 and_15\CC\1740 relapsing_16\VBG\146138 bacteremia_17\NN\14204950 ._18\.\1740
D009254_D009395 CID discussion_0\NN\6252138 :_1\:\1740 daptomycin_2\NNP\1740 was_3\VBD\836236 initiated_4\VBN\1617192 in_5\IN\13603305 our_6\PRP$\1740 patient_7\NN\9898892 secondary_8\JJ\1740 to_9\TO\1740 possible_10\JJ\1740 <e1>nafcillin-induced</e1>_11\JJ\1740 acute_12\JJ\1740 <e2>interstitial_13\JJ\1740 nephritis</e2>_14\NN\14113228 and_15\CC\1740 relapsing_16\VBG\146138 bacteremia_17\NN\14204950 ._18\.\1740
D009254_D016470 NONE discussion_0\NN\6252138 :_1\:\1740 daptomycin_2\NNP\1740 was_3\VBD\836236 initiated_4\VBN\1617192 in_5\IN\13603305 our_6\PRP$\1740 patient_7\NN\9898892 secondary_8\JJ\1740 to_9\TO\1740 possible_10\JJ\1740 <e1>nafcillin-induced</e1>_11\JJ\1740 acute_12\JJ\1740 interstitial_13\JJ\1740 nephritis_14\NN\14113228 and_15\CC\1740 relapsing_16\VBG\146138 <e2>bacteremia</e2>_17\NN\14204950 ._18\.\1740
89511
D004967_D014591 NONE prevention_0\NN\1073995 and_1\CC\1740 treatment_2\NN\654885 of_3\IN\1740 <e2>endometrial_4\JJ\1740 disease</e2>_5\NN\14061805 in_6\IN\13603305 climacteric_7\JJ\1740 women_8\NNS\9605289 receiving_9\VBG\2210855 <e1>oestrogen</e1>_10\NN\14745635 therapy_11\NN\657604 ._12\.\1740
D004967_D014591 NONE the_0\DT\1740 treatment_1\NN\654885 regimens_2\NNS\5898568 are_3\VBP\836236 described_4\VBN\1001294 in_5\IN\13603305 74_6\CD\1740 patients_7\NNS\9898892 with_8\IN\1740 <e2>endometrial_9\JJ\1740 disease</e2>_10\NN\14061805 among_11\IN\1740 850_12\CD\1740 climacteric_13\JJ\1740 women_14\NNS\9605289 receiving_15\VBG\2210855 <e1>oestrogen</e1>_16\NN\14745635 therapy_17\NN\657604 ._18\.\1740
D004967_D006965 CID cystic_0\JJ\1740 <e2>hyperplasia</e2>_1\NN\14365950 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 unopposed_5\JJ\1740 <e1>oestrogen</e1>_6\NN\14745635 therapy_7\NN\657604 without_8\IN\1740 progestagen_9\NN\1740 ._10\.\1740
D004967_D006965 CID 4_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 endometrial_3\JJ\1740 carcinoma_4\NN\14239918 referred_5\VBN\730052 from_6\IN\1740 elsewhere_7\RB\1740 demonstrated_8\VBD\2137132 the_9\DT\1740 problems_10\NNS\14408086 of_11\IN\1740 inappropriate_12\JJ\1740 and_13\CC\1740 unsupervised_14\VBD\1740 unopposed_15\JJ\1740 <e1>oestrogen</e1>_16\NN\14745635 therapy_17\NN\657604 and_18\CC\1740 the_19\DT\1740 difficulty_20\NN\621627 in_21\IN\13603305 distinguishing_22\VBG\618878 severe_23\JJ\1740 <e2>hyperplasia</e2>_24\NN\14365950 from_25\IN\1740 malignancy_26\NN\14070360 ._27\.\1740
D011372_D006965 NONE cystic_0\JJ\1740 <e2>hyperplasia</e2>_1\NN\14365950 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 unopposed_5\JJ\1740 oestrogen_6\NN\14745635 therapy_7\NN\657604 without_8\IN\1740 <e1>progestagen</e1>_9\NN\1740 ._10\.\1740
D009640_D006965 NONE two_0\CD\13741022 courses_1\NNS\883297 of_2\IN\1740 21_3\CD\13745420 days_4\NNS\15140892 of_5\IN\1740 5_6\CD\13741022 mg_7\NN\13717155 <e1>norethisterone</e1>_8\JJ\1740 daily_9\RB\1740 caused_10\VBD\1617192 reversion_11\NN\13286801 to_12\TO\1740 normal_13\JJ\1740 in_14\IN\13603305 all_15\DT\1740 57_16\CD\1740 cases_17\NNS\7283608 of_18\IN\1740 cystic_19\JJ\1740 <e2>hyperplasia</e2>_20\NN\14365950 and_21\CC\1740 6_22\CD\13741022 of_23\IN\1740 the_24\DT\1740 8_25\CD\13741022 cases_26\NNS\7283608 of_27\IN\1740 atypical_28\JJ\1740 hyperplasia_29\NN\14365950 ._30\.\1740
D009640_D006965 NONE two_0\CD\13741022 courses_1\NNS\883297 of_2\IN\1740 21_3\CD\13745420 days_4\NNS\15140892 of_5\IN\1740 5_6\CD\13741022 mg_7\NN\13717155 <e1>norethisterone</e1>_8\JJ\1740 daily_9\RB\1740 caused_10\VBD\1617192 reversion_11\NN\13286801 to_12\TO\1740 normal_13\JJ\1740 in_14\IN\13603305 all_15\DT\1740 57_16\CD\1740 cases_17\NNS\7283608 of_18\IN\1740 cystic_19\JJ\1740 hyperplasia_20\NN\14365950 and_21\CC\1740 6_22\CD\13741022 of_23\IN\1740 the_24\DT\1740 8_25\CD\13741022 cases_26\NNS\7283608 of_27\IN\1740 atypical_28\JJ\1740 <e2>hyperplasia</e2>_29\NN\14365950 ._30\.\1740
D004967_D016889 NONE 4_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>endometrial_3\JJ\1740 carcinoma</e2>_4\NN\14239918 referred_5\VBN\730052 from_6\IN\1740 elsewhere_7\RB\1740 demonstrated_8\VBD\2137132 the_9\DT\1740 problems_10\NNS\14408086 of_11\IN\1740 inappropriate_12\JJ\1740 and_13\CC\1740 unsupervised_14\VBD\1740 unopposed_15\JJ\1740 <e1>oestrogen</e1>_16\NN\14745635 therapy_17\NN\657604 and_18\CC\1740 the_19\DT\1740 difficulty_20\NN\621627 in_21\IN\13603305 distinguishing_22\VBG\618878 severe_23\JJ\1740 hyperplasia_24\NN\14365950 from_25\IN\1740 malignancy_26\NN\14070360 ._27\.\1740
D004967_D009369 NONE 4_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 endometrial_3\JJ\1740 carcinoma_4\NN\14239918 referred_5\VBN\730052 from_6\IN\1740 elsewhere_7\RB\1740 demonstrated_8\VBD\2137132 the_9\DT\1740 problems_10\NNS\14408086 of_11\IN\1740 inappropriate_12\JJ\1740 and_13\CC\1740 unsupervised_14\VBD\1740 unopposed_15\JJ\1740 <e1>oestrogen</e1>_16\NN\14745635 therapy_17\NN\657604 and_18\CC\1740 the_19\DT\1740 difficulty_20\NN\621627 in_21\IN\13603305 distinguishing_22\VBG\618878 severe_23\JJ\1740 hyperplasia_24\NN\14365950 from_25\IN\1740 <e2>malignancy</e2>_26\NN\14070360 ._27\.\1740
D004967_D004714 NONE cyclical_0\JJ\1740 low-dose_1\JJ\1740 <e1>oestrogen</e1>_2\NN\14745635 therapy_3\NN\657604 with_4\IN\1740 7_5\CD\13741022 -_6\HYPH\1740 -13_7\CD\1740 days_8\NNS\15140892 of_9\IN\1740 progestagen_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 seem_13\VB\2604760 to_14\TO\1740 increase_15\VB\169651 the_16\DT\1740 risk_17\NN\14541044 of_18\IN\1740 <e2>endometrial_19\JJ\1740 hyperplasia</e2>_20\NN\14365950 or_21\CC\3541091 carcinoma_22\NN\14239918 ._23\.\1740
D004967_D002277 NONE cyclical_0\JJ\1740 low-dose_1\JJ\1740 <e1>oestrogen</e1>_2\NN\14745635 therapy_3\NN\657604 with_4\IN\1740 7_5\CD\13741022 -_6\HYPH\1740 -13_7\CD\1740 days_8\NNS\15140892 of_9\IN\1740 progestagen_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 seem_13\VB\2604760 to_14\TO\1740 increase_15\VB\169651 the_16\DT\1740 risk_17\NN\14541044 of_18\IN\1740 endometrial_19\JJ\1740 hyperplasia_20\NN\14365950 or_21\CC\3541091 <e2>carcinoma</e2>_22\NN\14239918 ._23\.\1740
D011372_D004714 NONE cyclical_0\JJ\1740 low-dose_1\JJ\1740 oestrogen_2\NN\14745635 therapy_3\NN\657604 with_4\IN\1740 7_5\CD\13741022 -_6\HYPH\1740 -13_7\CD\1740 days_8\NNS\15140892 of_9\IN\1740 <e1>progestagen</e1>_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 seem_13\VB\2604760 to_14\TO\1740 increase_15\VB\169651 the_16\DT\1740 risk_17\NN\14541044 of_18\IN\1740 <e2>endometrial_19\JJ\1740 hyperplasia</e2>_20\NN\14365950 or_21\CC\3541091 carcinoma_22\NN\14239918 ._23\.\1740
D011372_D002277 NONE cyclical_0\JJ\1740 low-dose_1\JJ\1740 oestrogen_2\NN\14745635 therapy_3\NN\657604 with_4\IN\1740 7_5\CD\13741022 -_6\HYPH\1740 -13_7\CD\1740 days_8\NNS\15140892 of_9\IN\1740 <e1>progestagen</e1>_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 seem_13\VB\2604760 to_14\TO\1740 increase_15\VB\169651 the_16\DT\1740 risk_17\NN\14541044 of_18\IN\1740 endometrial_19\JJ\1740 hyperplasia_20\NN\14365950 or_21\CC\3541091 <e2>carcinoma</e2>_22\NN\14239918 ._23\.\1740
8748050
D000639_D001927 CID <e2>encephalopathy</e2>_0\RB\1740 during_1\IN\1740 <e1>amitriptyline</e1>_2\NN\4482543 therapy_3\NN\657604 :_4\:\1740 are_5\VBP\836236 neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome_8\NN\5870365 and_9\CC\1740 serotonin_10\NN\14807737 syndrome_11\NN\5870365 spectrum_12\NN\7939382 disorders_13\NNS\14034177 ?_14\.\1740
D000639_D001927 CID this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 <e2>encephalopathy</e2>_6\JJ\1740 developed_7\VBN\1753788 in_8\IN\13603305 the_9\DT\1740 course_10\NN\883297 of_11\IN\1740 <e1>amitriptyline</e1>_12\NN\4482543 therapy_13\NN\657604 ,_14\,\1740 during_15\IN\1740 a_16\DT\13649268 remission_17\NN\7368256 of_18\IN\1740 unipolar_19\JJ\1740 depression_20\NN\14373582 ._21\.\1740
D000639_D009459 NONE encephalopathy_0\RB\1740 during_1\IN\1740 <e1>amitriptyline</e1>_2\NN\4482543 therapy_3\NN\657604 :_4\:\1740 are_5\VBP\836236 <e2>neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome</e2>_8\NN\5870365 and_9\CC\1740 serotonin_10\NN\14807737 syndrome_11\NN\5870365 spectrum_12\NN\7939382 disorders_13\NNS\14034177 ?_14\.\1740
D000639_D020230 NONE encephalopathy_0\RB\1740 during_1\IN\1740 <e1>amitriptyline</e1>_2\NN\4482543 therapy_3\NN\657604 :_4\:\1740 are_5\VBP\836236 neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome_8\NN\5870365 and_9\CC\1740 <e2>serotonin_10\NN\14807737 syndrome</e2>_11\NN\5870365 spectrum_12\NN\7939382 disorders_13\NNS\14034177 ?_14\.\1740
D000639_D003866 NONE this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 encephalopathy_6\JJ\1740 developed_7\VBN\1753788 in_8\IN\13603305 the_9\DT\1740 course_10\NN\883297 of_11\IN\1740 <e1>amitriptyline</e1>_12\NN\4482543 therapy_13\NN\657604 ,_14\,\1740 during_15\IN\1740 a_16\DT\13649268 remission_17\NN\7368256 of_18\IN\1740 <e2>unipolar_19\JJ\1740 depression</e2>_20\NN\14373582 ._21\.\1740
24535067
D005045_D009207 CID prevention_0\NN\1073995 of_1\IN\1740 <e1>etomidate-induced</e1>_2\JJ\1740 <e2>myoclonus</e2>_3\NN\14360459 :_4\:\1740 which_5\WDT\1740 is_6\VBZ\836236 superior_7\JJ\1740 :_8\:\1740 fentanyl_9\NNP\2707683 ,_10\,\1740 midazolam_11\NN\2830852 ,_12\,\1740 or_13\CC\3541091 a_14\DT\13649268 combination_15\NN\7951464 ?_16\.\1740
D005045_D009207 CID background_0\NN\4921011 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 retrospective_4\JJ\1740 comparative_5\JJ\1740 study_6\NN\635850 ,_7\,\1740 we_8\PRP\1740 aimed_9\VBD\1987160 to_10\TO\1740 compare_11\VB\644583 the_12\DT\1740 effectiveness_13\NN\5190804 of_14\IN\1740 fentanyl_15\NN\2707683 ,_16\,\1740 midazolam_17\NN\2830852 ,_18\,\1740 and_19\CC\1740 a_20\DT\13649268 combination_21\NN\7951464 of_22\IN\1740 fentanyl_23\NN\2707683 and_24\CC\1740 midazolam_25\NNS\2830852 to_26\TO\1740 prevent_27\VB\1740 <e1>etomidate-induced</e1>_28\JJ\1740 <e2>myoclonus</e2>_29\NN\14360459 ._30\.\1740
D005045_D009207 CID conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 fentanyl_7\NN\2707683 or_8\CC\3541091 combination_9\NN\7951464 of_10\IN\1740 fentanyl_11\NN\2707683 and_12\CC\1740 midazolam_13\NN\2830852 was_14\VBD\836236 effective_15\JJ\1740 in_16\IN\13603305 preventing_17\VBG\1740 <e1>etomidate-induced</e1>_18\JJ\1740 <e2>myoclonus</e2>_19\NN\14360459 ._20\.\1740
D005283_D009207 NONE prevention_0\NN\1073995 of_1\IN\1740 etomidate-induced_2\JJ\1740 <e2>myoclonus</e2>_3\NN\14360459 :_4\:\1740 which_5\WDT\1740 is_6\VBZ\836236 superior_7\JJ\1740 :_8\:\1740 <e1>fentanyl</e1>_9\NNP\2707683 ,_10\,\1740 midazolam_11\NN\2830852 ,_12\,\1740 or_13\CC\3541091 a_14\DT\13649268 combination_15\NN\7951464 ?_16\.\1740
D005283_D009207 NONE background_0\NN\4921011 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 retrospective_4\JJ\1740 comparative_5\JJ\1740 study_6\NN\635850 ,_7\,\1740 we_8\PRP\1740 aimed_9\VBD\1987160 to_10\TO\1740 compare_11\VB\644583 the_12\DT\1740 effectiveness_13\NN\5190804 of_14\IN\1740 <e1>fentanyl</e1>_15\NN\2707683 ,_16\,\1740 midazolam_17\NN\2830852 ,_18\,\1740 and_19\CC\1740 a_20\DT\13649268 combination_21\NN\7951464 of_22\IN\1740 fentanyl_23\NN\2707683 and_24\CC\1740 midazolam_25\NNS\2830852 to_26\TO\1740 prevent_27\VB\1740 etomidate-induced_28\JJ\1740 <e2>myoclonus</e2>_29\NN\14360459 ._30\.\1740
D005283_D009207 NONE background_0\NN\4921011 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 retrospective_4\JJ\1740 comparative_5\JJ\1740 study_6\NN\635850 ,_7\,\1740 we_8\PRP\1740 aimed_9\VBD\1987160 to_10\TO\1740 compare_11\VB\644583 the_12\DT\1740 effectiveness_13\NN\5190804 of_14\IN\1740 fentanyl_15\NN\2707683 ,_16\,\1740 midazolam_17\NN\2830852 ,_18\,\1740 and_19\CC\1740 a_20\DT\13649268 combination_21\NN\7951464 of_22\IN\1740 <e1>fentanyl</e1>_23\NN\2707683 and_24\CC\1740 midazolam_25\NNS\2830852 to_26\TO\1740 prevent_27\VB\1740 etomidate-induced_28\JJ\1740 <e2>myoclonus</e2>_29\NN\14360459 ._30\.\1740
D005283_D009207 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 <e1>fentanyl</e1>_7\NN\2707683 or_8\CC\3541091 combination_9\NN\7951464 of_10\IN\1740 fentanyl_11\NN\2707683 and_12\CC\1740 midazolam_13\NN\2830852 was_14\VBD\836236 effective_15\JJ\1740 in_16\IN\13603305 preventing_17\VBG\1740 etomidate-induced_18\JJ\1740 <e2>myoclonus</e2>_19\NN\14360459 ._20\.\1740
D005283_D009207 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 fentanyl_7\NN\2707683 or_8\CC\3541091 combination_9\NN\7951464 of_10\IN\1740 <e1>fentanyl</e1>_11\NN\2707683 and_12\CC\1740 midazolam_13\NN\2830852 was_14\VBD\836236 effective_15\JJ\1740 in_16\IN\13603305 preventing_17\VBG\1740 etomidate-induced_18\JJ\1740 <e2>myoclonus</e2>_19\NN\14360459 ._20\.\1740
D008874_D009207 NONE prevention_0\NN\1073995 of_1\IN\1740 etomidate-induced_2\JJ\1740 <e2>myoclonus</e2>_3\NN\14360459 :_4\:\1740 which_5\WDT\1740 is_6\VBZ\836236 superior_7\JJ\1740 :_8\:\1740 fentanyl_9\NNP\2707683 ,_10\,\1740 <e1>midazolam</e1>_11\NN\2830852 ,_12\,\1740 or_13\CC\3541091 a_14\DT\13649268 combination_15\NN\7951464 ?_16\.\1740
D008874_D009207 NONE background_0\NN\4921011 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 retrospective_4\JJ\1740 comparative_5\JJ\1740 study_6\NN\635850 ,_7\,\1740 we_8\PRP\1740 aimed_9\VBD\1987160 to_10\TO\1740 compare_11\VB\644583 the_12\DT\1740 effectiveness_13\NN\5190804 of_14\IN\1740 fentanyl_15\NN\2707683 ,_16\,\1740 <e1>midazolam</e1>_17\NN\2830852 ,_18\,\1740 and_19\CC\1740 a_20\DT\13649268 combination_21\NN\7951464 of_22\IN\1740 fentanyl_23\NN\2707683 and_24\CC\1740 midazolam_25\NNS\2830852 to_26\TO\1740 prevent_27\VB\1740 etomidate-induced_28\JJ\1740 <e2>myoclonus</e2>_29\NN\14360459 ._30\.\1740
D008874_D009207 NONE background_0\NN\4921011 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 retrospective_4\JJ\1740 comparative_5\JJ\1740 study_6\NN\635850 ,_7\,\1740 we_8\PRP\1740 aimed_9\VBD\1987160 to_10\TO\1740 compare_11\VB\644583 the_12\DT\1740 effectiveness_13\NN\5190804 of_14\IN\1740 fentanyl_15\NN\2707683 ,_16\,\1740 midazolam_17\NN\2830852 ,_18\,\1740 and_19\CC\1740 a_20\DT\13649268 combination_21\NN\7951464 of_22\IN\1740 fentanyl_23\NN\2707683 and_24\CC\1740 <e1>midazolam</e1>_25\NNS\2830852 to_26\TO\1740 prevent_27\VB\1740 etomidate-induced_28\JJ\1740 <e2>myoclonus</e2>_29\NN\14360459 ._30\.\1740
D008874_D009207 NONE conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 fentanyl_7\NN\2707683 or_8\CC\3541091 combination_9\NN\7951464 of_10\IN\1740 fentanyl_11\NN\2707683 and_12\CC\1740 <e1>midazolam</e1>_13\NN\2830852 was_14\VBD\836236 effective_15\JJ\1740 in_16\IN\13603305 preventing_17\VBG\1740 etomidate-induced_18\JJ\1740 <e2>myoclonus</e2>_19\NN\14360459 ._20\.\1740
D005045_D009069 NONE <e2>myoclonic_0\JJ\1740 movements</e2>_1\NNS\191142 are_2\VBP\836236 evaluated_3\VBN\670261 ,_4\,\1740 which_5\WDT\1740 were_6\VBD\836236 observed_7\VBN\2163746 and_8\CC\1740 graded_9\VBN\670261 according_10\VBG\2657219 to_11\IN\1740 clinical_12\JJ\1740 severity_13\NN\5036394 during_14\IN\1740 the_15\DT\1740 2_16\CD\13741022 minutes_17\NNS\6502378 after_18\IN\1740 <e1>etomidate</e1>_19\NN\1740 injection_20\NN\320852 ._21\.\1740
D005045_D010146 NONE the_0\DT\1740 severity_1\NN\5036394 of_2\IN\1740 <e2>pain</e2>_3\NN\14299637 due_4\JJ\1740 to_5\TO\1740 <e1>etomidate</e1>_6\JJ\1740 injection_7\NN\320852 ,_8\,\1740 mean_9\VBP\928630 arterial_10\JJ\1740 pressure_11\NN\11419404 ,_12\,\1740 heart_13\NN\5919034 rate_14\NN\13815152 ,_15\,\1740 and_16\CC\1740 adverse_17\JJ\1740 effects_18\NNS\13245626 were_19\VBD\836236 also_20\RB\1740 evaluated_21\VBN\670261 ._22\.\1740
24802403
D008687_D012640 NONE <e1>metformin</e1>_0\NN\2719105 protects_1\VBZ\1127795 against_2\IN\1740 <e2>seizures</e2>_3\NNS\14081375 ,_4\,\1740 learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairments_8\NNS\7296428 and_9\CC\1740 oxidative_10\JJ\1740 damage_11\NN\7296428 induced_12\VBN\1627355 by_13\IN\1740 pentylenetetrazole-induced_14\JJ\1740 kindling_15\NN\15101361 in_16\IN\13603305 mice_17\NNS\2329401 ._18\.\1740
D008687_D012640 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 ameliorative_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>metformin</e1>_10\NN\2719105 on_11\IN\1740 <e2>seizures</e2>_12\NNS\14081375 ,_13\,\1740 cognitive_14\JJ\1740 impairment_15\NN\7296428 and_16\CC\1740 brain_17\NN\5462674 oxidative_18\JJ\1740 stress_19\NN\7083732 markers_20\NNS\21939 observed_21\VBN\2163746 in_22\IN\13603305 pentylenetetrazole-induced_23\JJ\1740 kindling_24\NN\15101361 animals_25\NNS\4475 ._26\.\1740
D008687_D012640 NONE thus_0\RB\1740 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 concluded_4\VBD\628491 that_5\IN\1740 <e1>metformin</e1>_6\NN\2719105 may_7\MD\15209706 be_8\VB\836236 a_9\DT\13649268 potential_10\JJ\1740 agent_11\NN\7347 for_12\IN\1740 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 epilepsy_16\NN\14085708 as_17\RB\1740 well_18\RB\1740 as_19\IN\14622893 a_20\DT\13649268 protective_21\JJ\1740 medicine_22\NN\6045562 against_23\IN\1740 cognitive_24\JJ\1740 impairment_25\NN\7296428 induced_26\VBN\1627355 by_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 ._29\.\1740
D008687_D007859 NONE <e1>metformin</e1>_0\NN\2719105 protects_1\VBZ\1127795 against_2\IN\1740 seizures_3\NNS\14081375 ,_4\,\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairments</e2>_8\NNS\7296428 and_9\CC\1740 oxidative_10\JJ\1740 damage_11\NN\7296428 induced_12\VBN\1627355 by_13\IN\1740 pentylenetetrazole-induced_14\JJ\1740 kindling_15\NN\15101361 in_16\IN\13603305 mice_17\NNS\2329401 ._18\.\1740
D008687_D008569 NONE <e1>metformin</e1>_0\NN\2719105 protects_1\VBZ\1127795 against_2\IN\1740 seizures_3\NNS\14081375 ,_4\,\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairments</e2>_8\NNS\7296428 and_9\CC\1740 oxidative_10\JJ\1740 damage_11\NN\7296428 induced_12\VBN\1627355 by_13\IN\1740 pentylenetetrazole-induced_14\JJ\1740 kindling_15\NN\15101361 in_16\IN\13603305 mice_17\NNS\2329401 ._18\.\1740
D010433_D012640 CID metformin_0\NN\2719105 protects_1\VBZ\1127795 against_2\IN\1740 <e2>seizures</e2>_3\NNS\14081375 ,_4\,\1740 learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairments_8\NNS\7296428 and_9\CC\1740 oxidative_10\JJ\1740 damage_11\NN\7296428 induced_12\VBN\1627355 by_13\IN\1740 <e1>pentylenetetrazole-induced</e1>_14\JJ\1740 kindling_15\NN\15101361 in_16\IN\13603305 mice_17\NNS\2329401 ._18\.\1740
D010433_D012640 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 ameliorative_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 metformin_10\NN\2719105 on_11\IN\1740 <e2>seizures</e2>_12\NNS\14081375 ,_13\,\1740 cognitive_14\JJ\1740 impairment_15\NN\7296428 and_16\CC\1740 brain_17\NN\5462674 oxidative_18\JJ\1740 stress_19\NN\7083732 markers_20\NNS\21939 observed_21\VBN\2163746 in_22\IN\13603305 <e1>pentylenetetrazole-induced</e1>_23\JJ\1740 kindling_24\NN\15101361 animals_25\NNS\4475 ._26\.\1740
D010433_D007859 CID metformin_0\NN\2719105 protects_1\VBZ\1127795 against_2\IN\1740 seizures_3\NNS\14081375 ,_4\,\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairments</e2>_8\NNS\7296428 and_9\CC\1740 oxidative_10\JJ\1740 damage_11\NN\7296428 induced_12\VBN\1627355 by_13\IN\1740 <e1>pentylenetetrazole-induced</e1>_14\JJ\1740 kindling_15\NN\15101361 in_16\IN\13603305 mice_17\NNS\2329401 ._18\.\1740
D010433_D008569 CID metformin_0\NN\2719105 protects_1\VBZ\1127795 against_2\IN\1740 seizures_3\NNS\14081375 ,_4\,\1740 <e2>learning_5\NN\5701944 and_6\CC\1740 memory_7\NN\5926676 impairments</e2>_8\NNS\7296428 and_9\CC\1740 oxidative_10\JJ\1740 damage_11\NN\7296428 induced_12\VBN\1627355 by_13\IN\1740 <e1>pentylenetetrazole-induced</e1>_14\JJ\1740 kindling_15\NN\15101361 in_16\IN\13603305 mice_17\NNS\2329401 ._18\.\1740
D008687_D003072 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 ameliorative_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>metformin</e1>_10\NN\2719105 on_11\IN\1740 seizures_12\NNS\14081375 ,_13\,\1740 <e2>cognitive_14\JJ\1740 impairment</e2>_15\NN\7296428 and_16\CC\1740 brain_17\NN\5462674 oxidative_18\JJ\1740 stress_19\NN\7083732 markers_20\NNS\21939 observed_21\VBN\2163746 in_22\IN\13603305 pentylenetetrazole-induced_23\JJ\1740 kindling_24\NN\15101361 animals_25\NNS\4475 ._26\.\1740
D008687_D003072 NONE we_0\PRP\1740 found_1\VBD\2426171 that_2\IN\1740 <e1>metformin</e1>_3\NN\2719105 suppressed_4\VBD\2510337 the_5\DT\1740 progression_6\NN\8457976 of_7\IN\1740 kindling_8\NN\15101361 ,_9\,\1740 ameliorated_10\VBD\126264 the_11\DT\1740 <e2>cognitive_12\JJ\1740 impairment</e2>_13\NN\7296428 and_14\CC\1740 decreased_15\VBD\169651 brain_16\NN\5462674 oxidative_17\JJ\1740 stress_18\NN\7083732 ._19\.\1740
D008687_D003072 NONE thus_0\RB\1740 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 concluded_4\VBD\628491 that_5\IN\1740 <e1>metformin</e1>_6\NN\2719105 may_7\MD\15209706 be_8\VB\836236 a_9\DT\13649268 potential_10\JJ\1740 agent_11\NN\7347 for_12\IN\1740 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 epilepsy_16\NN\14085708 as_17\RB\1740 well_18\RB\1740 as_19\IN\14622893 a_20\DT\13649268 protective_21\JJ\1740 medicine_22\NN\6045562 against_23\IN\1740 <e2>cognitive_24\JJ\1740 impairment</e2>_25\NN\7296428 induced_26\VBN\1627355 by_27\IN\1740 seizures_28\NNS\14081375 ._29\.\1740
D010433_D003072 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 ameliorative_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 metformin_10\NN\2719105 on_11\IN\1740 seizures_12\NNS\14081375 ,_13\,\1740 <e2>cognitive_14\JJ\1740 impairment</e2>_15\NN\7296428 and_16\CC\1740 brain_17\NN\5462674 oxidative_18\JJ\1740 stress_19\NN\7083732 markers_20\NNS\21939 observed_21\VBN\2163746 in_22\IN\13603305 <e1>pentylenetetrazole-induced</e1>_23\JJ\1740 kindling_24\NN\15101361 animals_25\NNS\4475 ._26\.\1740
D008687_D004827 NONE thus_0\RB\1740 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 concluded_4\VBD\628491 that_5\IN\1740 <e1>metformin</e1>_6\NN\2719105 may_7\MD\15209706 be_8\VB\836236 a_9\DT\13649268 potential_10\JJ\1740 agent_11\NN\7347 for_12\IN\1740 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 <e2>epilepsy</e2>_16\NN\14085708 as_17\RB\1740 well_18\RB\1740 as_19\IN\14622893 a_20\DT\13649268 protective_21\JJ\1740 medicine_22\NN\6045562 against_23\IN\1740 cognitive_24\JJ\1740 impairment_25\NN\7296428 induced_26\VBN\1627355 by_27\IN\1740 seizures_28\NNS\14081375 ._29\.\1740
25006369
C061870_D005207 NONE optimal_0\JJ\1740 precurarizing_1\VBG\1740 dose_2\NN\3740161 of_3\IN\1740 <e1>rocuronium</e1>_4\NN\1740 to_5\TO\1740 decrease_6\VB\169651 <e2>fasciculation</e2>_7\NN\14361664 and_8\CC\1740 myalgia_9\NN\14322699 following_10\VBG\1835496 succinylcholine_11\NN\3800001 administration_12\NN\1133281 ._13\.\1740
C061870_D005207 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>rocuronium</e1>_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 succinylcholine-induced_11\JJ\1740 <e2>fasciculation</e2>_12\NN\14361664 and_13\CC\1740 myalgia_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 rocuronium_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 succinylcholine_28\NN\3800001 ._29\.\1740
C061870_D005207 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 rocuronium_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 succinylcholine-induced_11\JJ\1740 <e2>fasciculation</e2>_12\NN\14361664 and_13\CC\1740 myalgia_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 <e1>rocuronium</e1>_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 succinylcholine_28\NN\3800001 ._29\.\1740
C061870_D005207 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 incidence_3\NN\13821570 and_4\CC\1740 severity_5\NN\5036394 of_6\IN\1740 visible_7\JJ\1740 <e2>muscle_8\NN\5289601 fasciculation</e2>_9\NN\14361664 was_10\VBD\836236 significantly_11\RB\1740 less_12\JJR\1740 with_13\IN\1740 increasing_14\VBG\169651 the_15\DT\1740 amount_16\NN\13329641 of_17\IN\1740 precurarizing_18\VBG\1740 dose_19\NN\3740161 of_20\IN\1740 <e1>rocuronium</e1>_21\NN\1740 (_22\-LRB-\1740 p_23\NN\14622893 <_24\XX\1740 0.001_25\CD\1740 )_26\-RRB-\1740 ._27\.\1740
C061870_D005207 NONE conclusions_0\NNS\5837957 :_1\:\1740 precurarization_2\NN\1740 with_3\IN\1740 0.04_4\CD\1740 mg/kg_5\NN\1740 <e1>rocuronium</e1>_6\NN\1740 was_7\VBD\836236 the_8\DT\1740 optimal_9\JJ\1740 dose_10\NN\3740161 considering_11\VBG\689344 the_12\DT\1740 reduction_13\NN\351485 in_14\IN\13603305 the_15\DT\1740 incidence_16\NN\13821570 and_17\CC\1740 severity_18\NN\5036394 of_19\IN\1740 <e2>fasciculation</e2>_20\NN\14361664 and_21\CC\1740 myalgia_22\NN\14322699 with_23\IN\1740 acceptable_24\JJ\1740 onset_25\NN\7325190 time_26\NN\7308889 ,_27\,\1740 and_28\CC\1740 the_29\DT\1740 safe_30\JJ\1740 and_31\CC\1740 effective_32\JJ\1740 precurarization_33\NN\1740 ._34\.\1740
C061870_D063806 NONE optimal_0\JJ\1740 precurarizing_1\VBG\1740 dose_2\NN\3740161 of_3\IN\1740 <e1>rocuronium</e1>_4\NN\1740 to_5\TO\1740 decrease_6\VB\169651 fasciculation_7\NN\14361664 and_8\CC\1740 <e2>myalgia</e2>_9\NN\14322699 following_10\VBG\1835496 succinylcholine_11\NN\3800001 administration_12\NN\1133281 ._13\.\1740
C061870_D063806 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>rocuronium</e1>_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 succinylcholine-induced_11\JJ\1740 fasciculation_12\NN\14361664 and_13\CC\1740 <e2>myalgia</e2>_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 rocuronium_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 succinylcholine_28\NN\3800001 ._29\.\1740
C061870_D063806 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 rocuronium_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 succinylcholine-induced_11\JJ\1740 fasciculation_12\NN\14361664 and_13\CC\1740 <e2>myalgia</e2>_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 <e1>rocuronium</e1>_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 succinylcholine_28\NN\3800001 ._29\.\1740
C061870_D063806 NONE those_0\DT\1740 of_1\IN\1740 <e2>myalgia</e2>_2\NN\14322699 tend_3\VBP\2604760 to_4\TO\1740 decrease_5\VB\169651 according_6\VBG\2657219 to_7\IN\1740 increasing_8\VBG\169651 the_9\DT\1740 amount_10\NN\13329641 of_11\IN\1740 precurarizing_12\VBG\1740 dose_13\NN\3740161 of_14\IN\1740 <e1>rocuronium</e1>_15\NN\1740 ,_16\,\1740 but_17\CC\1740 there_18\EX\27167 was_19\VBD\836236 no_20\DT\7204911 significance_21\NN\5168261 (_22\-LRB-\1740 p_23\NN\14622893 =_24\JJ\1740 0.072_25\CD\1740 )_26\-RRB-\1740 ._27\.\1740
C061870_D063806 NONE conclusions_0\NNS\5837957 :_1\:\1740 precurarization_2\NN\1740 with_3\IN\1740 0.04_4\CD\1740 mg/kg_5\NN\1740 <e1>rocuronium</e1>_6\NN\1740 was_7\VBD\836236 the_8\DT\1740 optimal_9\JJ\1740 dose_10\NN\3740161 considering_11\VBG\689344 the_12\DT\1740 reduction_13\NN\351485 in_14\IN\13603305 the_15\DT\1740 incidence_16\NN\13821570 and_17\CC\1740 severity_18\NN\5036394 of_19\IN\1740 fasciculation_20\NN\14361664 and_21\CC\1740 <e2>myalgia</e2>_22\NN\14322699 with_23\IN\1740 acceptable_24\JJ\1740 onset_25\NN\7325190 time_26\NN\7308889 ,_27\,\1740 and_28\CC\1740 the_29\DT\1740 safe_30\JJ\1740 and_31\CC\1740 effective_32\JJ\1740 precurarization_33\NN\1740 ._34\.\1740
D013390_D005207 CID optimal_0\JJ\1740 precurarizing_1\VBG\1740 dose_2\NN\3740161 of_3\IN\1740 rocuronium_4\NN\1740 to_5\TO\1740 decrease_6\VB\169651 <e2>fasciculation</e2>_7\NN\14361664 and_8\CC\1740 myalgia_9\NN\14322699 following_10\VBG\1835496 <e1>succinylcholine</e1>_11\NN\3800001 administration_12\NN\1133281 ._13\.\1740
D013390_D005207 CID background_0\NN\4921011 :_1\:\1740 <e1>succinylcholine</e1>_2\NN\3800001 commonly_3\RB\1740 produces_4\VBZ\1617192 frequent_5\JJ\1740 adverse_6\JJ\1740 effects_7\NNS\13245626 ,_8\,\1740 including_9\VBG\690614 <e2>muscle_10\NN\5289601 fasciculation</e2>_11\NN\14361664 and_12\CC\1740 myalgia_13\NN\14322699 ._14\.\1740
D013390_D005207 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 rocuronium_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 <e1>succinylcholine-induced</e1>_11\JJ\1740 <e2>fasciculation</e2>_12\NN\14361664 and_13\CC\1740 myalgia_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 rocuronium_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 succinylcholine_28\NN\3800001 ._29\.\1740
D013390_D005207 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 rocuronium_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 succinylcholine-induced_11\JJ\1740 <e2>fasciculation</e2>_12\NN\14361664 and_13\CC\1740 myalgia_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 rocuronium_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 <e1>succinylcholine</e1>_28\NN\3800001 ._29\.\1740
D013390_D005207 CID all_0\DT\1740 patients_1\NNS\9898892 received_2\VBD\2210855 <e1>succinylcholine</e1>_3\NN\3800001 1.5_4\CD\1740 mg/kg_5\NN\1740 at_6\IN\14622893 2_7\CD\13741022 minutes_8\NNS\6502378 after_9\IN\1740 the_10\DT\1740 precurarization_11\NN\1740 ,_12\,\1740 and_13\CC\1740 were_14\VBD\836236 assessed_15\VBN\670261 the_16\DT\1740 incidence_17\NN\13821570 and_18\CC\1740 severity_19\NN\5036394 of_20\IN\1740 <e2>fasciculations</e2>_21\NNS\14361664 ,_22\,\1740 while_23\IN\15122231 myalgia_24\NN\14322699 was_25\VBD\836236 assessed_26\VBN\670261 at_27\IN\14622893 24_28\CD\13745420 hours_29\NNS\15118228 after_30\IN\1740 surgery_31\NN\6045562 ._32\.\1740
D013390_D063806 CID optimal_0\JJ\1740 precurarizing_1\VBG\1740 dose_2\NN\3740161 of_3\IN\1740 rocuronium_4\NN\1740 to_5\TO\1740 decrease_6\VB\169651 fasciculation_7\NN\14361664 and_8\CC\1740 <e2>myalgia</e2>_9\NN\14322699 following_10\VBG\1835496 <e1>succinylcholine</e1>_11\NN\3800001 administration_12\NN\1133281 ._13\.\1740
D013390_D063806 CID background_0\NN\4921011 :_1\:\1740 <e1>succinylcholine</e1>_2\NN\3800001 commonly_3\RB\1740 produces_4\VBZ\1617192 frequent_5\JJ\1740 adverse_6\JJ\1740 effects_7\NNS\13245626 ,_8\,\1740 including_9\VBG\690614 muscle_10\NN\5289601 fasciculation_11\NN\14361664 and_12\CC\1740 <e2>myalgia</e2>_13\NN\14322699 ._14\.\1740
D013390_D063806 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 rocuronium_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 <e1>succinylcholine-induced</e1>_11\JJ\1740 fasciculation_12\NN\14361664 and_13\CC\1740 <e2>myalgia</e2>_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 rocuronium_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 succinylcholine_28\NN\3800001 ._29\.\1740
D013390_D063806 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 identified_3\VBD\699815 the_4\DT\1740 optimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 rocuronium_8\NN\1740 to_9\TO\1740 prevent_10\VB\1740 succinylcholine-induced_11\JJ\1740 fasciculation_12\NN\14361664 and_13\CC\1740 <e2>myalgia</e2>_14\NN\14322699 and_15\CC\1740 evaluated_16\VBD\670261 the_17\DT\1740 influence_18\NN\5190804 of_19\IN\1740 rocuronium_20\NN\1740 on_21\IN\1740 the_22\DT\1740 speed_23\NN\15286249 of_24\IN\1740 onset_25\NN\7325190 produced_26\VBN\1617192 by_27\IN\1740 <e1>succinylcholine</e1>_28\NN\3800001 ._29\.\1740
D013390_D063806 CID all_0\DT\1740 patients_1\NNS\9898892 received_2\VBD\2210855 <e1>succinylcholine</e1>_3\NN\3800001 1.5_4\CD\1740 mg/kg_5\NN\1740 at_6\IN\14622893 2_7\CD\13741022 minutes_8\NNS\6502378 after_9\IN\1740 the_10\DT\1740 precurarization_11\NN\1740 ,_12\,\1740 and_13\CC\1740 were_14\VBD\836236 assessed_15\VBN\670261 the_16\DT\1740 incidence_17\NN\13821570 and_18\CC\1740 severity_19\NN\5036394 of_20\IN\1740 fasciculations_21\NNS\14361664 ,_22\,\1740 while_23\IN\15122231 <e2>myalgia</e2>_24\NN\14322699 was_25\VBD\836236 assessed_26\VBN\670261 at_27\IN\14622893 24_28\CD\13745420 hours_29\NNS\15118228 after_30\IN\1740 surgery_31\NN\6045562 ._32\.\1740
8188982
D001127_D006973 CID central_0\JJ\1740 cardiovascular_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>avp</e1>_4\NN\1740 and_5\CC\1740 anp_6\NN\1740 in_7\IN\13603305 normotensive_8\NN\1740 and_9\CC\1740 spontaneously_10\JJ\1740 <e2>hypertensive</e2>_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D001127_D006973 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 compare_8\VB\644583 influence_9\NN\5190804 of_10\IN\1740 central_11\JJ\1740 <e1>arginine_12\NN\14605787 vasopressin</e1>_13\NN\5407119 (_14\-LRB-\1740 avp_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 of_18\IN\1740 atrial_19\JJ\1740 natriuretic_20\JJ\1740 peptide_21\NN\14724264 (_22\-LRB-\1740 anp_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 control_26\NN\5190804 of_27\IN\1740 arterial_28\JJ\1740 blood_29\NN\5397468 pressure_30\NN\11419404 (_31\-LRB-\1740 map_32\NN\4076846 )_33\-RRB-\1740 and_34\CC\1740 heart_35\NN\5919034 rate_36\NN\13815152 (_37\-LRB-\1740 hr_38\NN\15154774 )_39\-RRB-\1740 in_40\IN\13603305 normotensive_41\NN\1740 (_42\-LRB-\1740 wky_43\NN\1740 )_44\-RRB-\1740 and_45\CC\1740 spontaneously_46\JJ\1740 <e2>hypertensive</e2>_47\NN\10405694 (_48\-LRB-\1740 shr_49\NN\1740 )_50\-RRB-\1740 rats_51\NNS\2329401 ._52\.\1740
D001127_D006973 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 compare_8\VB\644583 influence_9\NN\5190804 of_10\IN\1740 central_11\JJ\1740 arginine_12\NN\14605787 vasopressin_13\NN\5407119 (_14\-LRB-\1740 <e1>avp</e1>_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 of_18\IN\1740 atrial_19\JJ\1740 natriuretic_20\JJ\1740 peptide_21\NN\14724264 (_22\-LRB-\1740 anp_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 control_26\NN\5190804 of_27\IN\1740 arterial_28\JJ\1740 blood_29\NN\5397468 pressure_30\NN\11419404 (_31\-LRB-\1740 map_32\NN\4076846 )_33\-RRB-\1740 and_34\CC\1740 heart_35\NN\5919034 rate_36\NN\13815152 (_37\-LRB-\1740 hr_38\NN\15154774 )_39\-RRB-\1740 in_40\IN\13603305 normotensive_41\NN\1740 (_42\-LRB-\1740 wky_43\NN\1740 )_44\-RRB-\1740 and_45\CC\1740 spontaneously_46\JJ\1740 <e2>hypertensive</e2>_47\NN\10405694 (_48\-LRB-\1740 shr_49\NN\1740 )_50\-RRB-\1740 rats_51\NNS\2329401 ._52\.\1740
D010656_D006973 CID sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 <e1>phenylephrine</e1>_36\NN\2682038 (phe)-induced_37\JJ\1740 <e2>hypertension</e2>_38\NN\14057371 and_39\CC\1740 sodium_40\NN\14625458 nitroprusside_41\NN\1740 (sn)-induced_42\VBD\1740 hypotension_43\NN\14057371 ._44\.\1740
D010656_D006973 CID sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 phenylephrine_36\NN\2682038 <e1>(phe)-induced</e1>_37\JJ\1740 <e2>hypertension</e2>_38\NN\14057371 and_39\CC\1740 sodium_40\NN\14625458 nitroprusside_41\NN\1740 (sn)-induced_42\VBD\1740 hypotension_43\NN\14057371 ._44\.\1740
D010656_D007022 NONE sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 <e1>phenylephrine</e1>_36\NN\2682038 (phe)-induced_37\JJ\1740 hypertension_38\NN\14057371 and_39\CC\1740 sodium_40\NN\14625458 nitroprusside_41\NN\1740 (sn)-induced_42\VBD\1740 <e2>hypotension</e2>_43\NN\14057371 ._44\.\1740
D010656_D007022 NONE sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 phenylephrine_36\NN\2682038 <e1>(phe)-induced</e1>_37\JJ\1740 hypertension_38\NN\14057371 and_39\CC\1740 sodium_40\NN\14625458 nitroprusside_41\NN\1740 (sn)-induced_42\VBD\1740 <e2>hypotension</e2>_43\NN\14057371 ._44\.\1740
D009599_D006973 NONE sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 phenylephrine_36\NN\2682038 (phe)-induced_37\JJ\1740 <e2>hypertension</e2>_38\NN\14057371 and_39\CC\1740 <e1>sodium_40\NN\14625458 nitroprusside</e1>_41\NN\1740 (sn)-induced_42\VBD\1740 hypotension_43\NN\14057371 ._44\.\1740
D009599_D006973 NONE sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 phenylephrine_36\NN\2682038 (phe)-induced_37\JJ\1740 <e2>hypertension</e2>_38\NN\14057371 and_39\CC\1740 sodium_40\NN\14625458 nitroprusside_41\NN\1740 <e1>(sn)-induced</e1>_42\VBD\1740 hypotension_43\NN\14057371 ._44\.\1740
D009599_D007022 CID sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 phenylephrine_36\NN\2682038 (phe)-induced_37\JJ\1740 hypertension_38\NN\14057371 and_39\CC\1740 <e1>sodium_40\NN\14625458 nitroprusside</e1>_41\NN\1740 (sn)-induced_42\VBD\1740 <e2>hypotension</e2>_43\NN\14057371 ._44\.\1740
D009599_D007022 CID sensitivity_0\NN\5651971 of_1\IN\1740 cardiac_2\JJ\1740 component_3\NN\5867413 of_4\IN\1740 baroreflex_5\NN\1740 (_6\-LRB-\1740 ccb_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 expressed_10\VBN\928630 as_11\IN\14622893 a_12\DT\13649268 slope_13\NN\9287968 of_14\IN\1740 the_15\DT\1740 regression_16\NN\14501726 line_17\NN\8426461 was_18\VBD\836236 determined_19\VBN\1645601 from_20\IN\1740 relationships_21\NNS\31921 between_22\IN\1740 systolic_23\JJ\1740 arterial_24\JJ\1740 pressure_25\NN\11419404 (_26\-LRB-\1740 sap_27\NN\14589223 )_28\-RRB-\1740 and_29\CC\1740 hr_30\NN\15154774 period_31\NN\13575869 (_32\-LRB-\1740 hrp_33\NNS\1740 )_34\-RRB-\1740 during_35\IN\1740 phenylephrine_36\NN\2682038 (phe)-induced_37\JJ\1740 hypertension_38\NN\14057371 and_39\CC\1740 sodium_40\NN\14625458 nitroprusside_41\NN\1740 <e1>(sn)-induced</e1>_42\VBD\1740 <e2>hypotension</e2>_43\NN\14057371 ._44\.\1740
D009599_D007022 CID ccb_0\NN\1740 was_1\VBD\836236 reduced_2\VBN\441445 in_3\IN\13603305 wky_4\NN\1740 and_5\CC\1740 shr_6\NN\1740 after_7\IN\1740 lv_8\JJ\1740 administration_9\NN\1133281 of_10\IN\1740 avp_11\NN\1740 during_12\IN\1740 <e1>sn-induced</e1>_13\JJ\1740 <e2>hypotension</e2>_14\NN\14057371 ._15\.\1740
D001127_D007022 NONE ccb_0\NN\1740 was_1\VBD\836236 reduced_2\VBN\441445 in_3\IN\13603305 wky_4\NN\1740 and_5\CC\1740 shr_6\NN\1740 after_7\IN\1740 lv_8\JJ\1740 administration_9\NN\1133281 of_10\IN\1740 <e1>avp</e1>_11\NN\1740 during_12\IN\1740 sn-induced_13\JJ\1740 <e2>hypotension</e2>_14\NN\14057371 ._15\.\1740
23892921
C467567_D009101 NONE "_0\``\1740 real-world_1\JJ\1740 "_2\''\1740 data_3\NNS\7951464 on_4\IN\1740 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 safety_8\NN\13920835 of_9\IN\1740 <e1>lenalidomide</e1>_10\NN\1740 and_11\CC\1740 dexamethasone_12\NN\2721538 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 relapsed/refractory_16\JJ\1740 <e2>multiple_17\JJ\1740 myeloma</e2>_18\NN\14239425 who_19\WP\8299493 were_20\VBD\836236 treated_21\VBN\2376958 according_22\VBG\2657219 to_23\IN\1740 the_24\DT\1740 standard_25\JJ\1740 clinical_26\JJ\1740 practice_27\NN\407535 :_28\:\1740 a_29\DT\13649268 study_30\NN\635850 of_31\IN\1740 the_32\DT\1740 greek_33\NNP\6941644 myeloma_34\NNP\14239425 study_35\NNP\635850 group_36\NNP\2137 ._37\.\1740
C467567_D009101 NONE "_0\``\1740 real-world_1\JJ\1740 "_2\''\1740 data_3\NNS\7951464 on_4\IN\1740 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 safety_8\NN\13920835 of_9\IN\1740 <e1>lenalidomide</e1>_10\NN\1740 and_11\CC\1740 dexamethasone_12\NN\2721538 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 relapsed/refractory_16\JJ\1740 multiple_17\JJ\1740 myeloma_18\NN\14239425 who_19\WP\8299493 were_20\VBD\836236 treated_21\VBN\2376958 according_22\VBG\2657219 to_23\IN\1740 the_24\DT\1740 standard_25\JJ\1740 clinical_26\JJ\1740 practice_27\NN\407535 :_28\:\1740 a_29\DT\13649268 study_30\NN\635850 of_31\IN\1740 the_32\DT\1740 greek_33\NNP\6941644 <e2>myeloma</e2>_34\NNP\14239425 study_35\NNP\635850 group_36\NNP\2137 ._37\.\1740
C467567_D009101 NONE <e1>lenalidomide</e1>_0\NN\1740 and_1\CC\1740 dexamethasone_2\NN\2721538 (_3\-LRB-\1740 rd_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 <e2>multiple_13\JJ\1740 myeloma</e2>_14\NN\14239425 (_15\-LRB-\1740 rrmm_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
C467567_D009101 NONE <e1>lenalidomide</e1>_0\NN\1740 and_1\CC\1740 dexamethasone_2\NN\2721538 (_3\-LRB-\1740 rd_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 multiple_13\JJ\1740 myeloma_14\NN\14239425 (_15\-LRB-\1740 <e2>rrmm</e2>_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
C467567_D009101 NONE lenalidomide_0\NN\1740 and_1\CC\1740 dexamethasone_2\NN\2721538 (_3\-LRB-\1740 <e1>rd</e1>_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 <e2>multiple_13\JJ\1740 myeloma</e2>_14\NN\14239425 (_15\-LRB-\1740 rrmm_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
C467567_D009101 NONE lenalidomide_0\NN\1740 and_1\CC\1740 dexamethasone_2\NN\2721538 (_3\-LRB-\1740 <e1>rd</e1>_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 multiple_13\JJ\1740 myeloma_14\NN\14239425 (_15\-LRB-\1740 <e2>rrmm</e2>_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
C467567_D009101 NONE we_0\PRP\1740 studied_1\VBD\630380 212_2\CD\1740 <e2>rrmm</e2>_3\NN\1740 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 <e1>rd</e1>_7\NNP\1740 in_8\IN\13603305 rw_9\NN\1740 ._10\.\1740
C467567_D009101 NONE our_0\PRP$\1740 study_1\NN\635850 confirms_2\VBZ\1011725 that_3\IN\1740 <e1>rd</e1>_4\NNP\1740 is_5\VBZ\836236 effective_6\JJ\1740 and_7\CC\1740 safe_8\JJ\1740 in_9\IN\13603305 <e2>rrmm</e2>_10\NN\1740 in_11\IN\13603305 the_12\DT\1740 rw_13\NN\1740 ;_14\:\1740 it_15\PRP\6125041 produces_16\VBZ\1617192 durable_17\JJ\1740 responses_18\NNS\11410625 especially_19\RB\1740 in_20\IN\13603305 patients_21\NNS\9898892 who_22\WP\8299493 continue_23\VBP\2367363 on_24\IN\1740 treatment_25\NN\654885 till_26\IN\14844693 progression_27\NN\8457976 and_28\CC\1740 improves_29\VBZ\126264 humoral_30\JJ\1740 immunity_31\NN\13920835 even_32\RB\1740 in_33\IN\13603305 patients_34\NNS\9898892 with_35\IN\1740 stable_36\JJ\1740 disease_37\NN\14061805 ._38\.\1740
D003907_D009101 NONE "_0\``\1740 real-world_1\JJ\1740 "_2\''\1740 data_3\NNS\7951464 on_4\IN\1740 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 safety_8\NN\13920835 of_9\IN\1740 lenalidomide_10\NN\1740 and_11\CC\1740 <e1>dexamethasone</e1>_12\NN\2721538 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 relapsed/refractory_16\JJ\1740 <e2>multiple_17\JJ\1740 myeloma</e2>_18\NN\14239425 who_19\WP\8299493 were_20\VBD\836236 treated_21\VBN\2376958 according_22\VBG\2657219 to_23\IN\1740 the_24\DT\1740 standard_25\JJ\1740 clinical_26\JJ\1740 practice_27\NN\407535 :_28\:\1740 a_29\DT\13649268 study_30\NN\635850 of_31\IN\1740 the_32\DT\1740 greek_33\NNP\6941644 myeloma_34\NNP\14239425 study_35\NNP\635850 group_36\NNP\2137 ._37\.\1740
D003907_D009101 NONE "_0\``\1740 real-world_1\JJ\1740 "_2\''\1740 data_3\NNS\7951464 on_4\IN\1740 the_5\DT\1740 efficacy_6\NN\5199286 and_7\CC\1740 safety_8\NN\13920835 of_9\IN\1740 lenalidomide_10\NN\1740 and_11\CC\1740 <e1>dexamethasone</e1>_12\NN\2721538 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 relapsed/refractory_16\JJ\1740 multiple_17\JJ\1740 myeloma_18\NN\14239425 who_19\WP\8299493 were_20\VBD\836236 treated_21\VBN\2376958 according_22\VBG\2657219 to_23\IN\1740 the_24\DT\1740 standard_25\JJ\1740 clinical_26\JJ\1740 practice_27\NN\407535 :_28\:\1740 a_29\DT\13649268 study_30\NN\635850 of_31\IN\1740 the_32\DT\1740 greek_33\NNP\6941644 <e2>myeloma</e2>_34\NNP\14239425 study_35\NNP\635850 group_36\NNP\2137 ._37\.\1740
D003907_D009101 NONE lenalidomide_0\NN\1740 and_1\CC\1740 <e1>dexamethasone</e1>_2\NN\2721538 (_3\-LRB-\1740 rd_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 <e2>multiple_13\JJ\1740 myeloma</e2>_14\NN\14239425 (_15\-LRB-\1740 rrmm_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
D003907_D009101 NONE lenalidomide_0\NN\1740 and_1\CC\1740 <e1>dexamethasone</e1>_2\NN\2721538 (_3\-LRB-\1740 rd_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 multiple_13\JJ\1740 myeloma_14\NN\14239425 (_15\-LRB-\1740 <e2>rrmm</e2>_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
D003907_D009101 NONE lenalidomide_0\NN\1740 and_1\CC\1740 dexamethasone_2\NN\2721538 (_3\-LRB-\1740 <e1>rd</e1>_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 <e2>multiple_13\JJ\1740 myeloma</e2>_14\NN\14239425 (_15\-LRB-\1740 rrmm_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
D003907_D009101 NONE lenalidomide_0\NN\1740 and_1\CC\1740 dexamethasone_2\NN\2721538 (_3\-LRB-\1740 <e1>rd</e1>_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 standard_8\NN\13577171 of_9\IN\1740 care_10\NN\575741 for_11\IN\1740 relapsed/refractory_12\JJ\1740 multiple_13\JJ\1740 myeloma_14\NN\14239425 (_15\-LRB-\1740 <e2>rrmm</e2>_16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 but_19\CC\1740 there_20\EX\27167 is_21\VBZ\836236 limited_22\JJ\1740 published_23\VBN\1621555 data_24\NNS\7951464 on_25\IN\1740 its_26\PRP$\6125041 efficacy_27\NN\5199286 and_28\CC\1740 safety_29\NN\13920835 in_30\IN\13603305 the_31\DT\1740 "_32\``\1740 real_33\JJ\1740 world_34\NN\19128 "_35\''\1740 (_36\-LRB-\1740 rw_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 according_40\VBG\2657219 to_41\IN\1740 the_42\DT\1740 international_43\NNP\8366202 society_44\NNP\7950920 of_45\IN\1740 pharmacoeconomics_46\NNPS\1740 and_47\CC\1740 outcomes_48\NNP\7291312 research_49\NNP\633864 definition_50\NN\6738281 ._51\.\1740
D003907_D009101 NONE we_0\PRP\1740 studied_1\VBD\630380 212_2\CD\1740 <e2>rrmm</e2>_3\NN\1740 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 <e1>rd</e1>_7\NNP\1740 in_8\IN\13603305 rw_9\NN\1740 ._10\.\1740
D003907_D009101 NONE our_0\PRP$\1740 study_1\NN\635850 confirms_2\VBZ\1011725 that_3\IN\1740 <e1>rd</e1>_4\NNP\1740 is_5\VBZ\836236 effective_6\JJ\1740 and_7\CC\1740 safe_8\JJ\1740 in_9\IN\13603305 <e2>rrmm</e2>_10\NN\1740 in_11\IN\13603305 the_12\DT\1740 rw_13\NN\1740 ;_14\:\1740 it_15\PRP\6125041 produces_16\VBZ\1617192 durable_17\JJ\1740 responses_18\NNS\11410625 especially_19\RB\1740 in_20\IN\13603305 patients_21\NNS\9898892 who_22\WP\8299493 continue_23\VBP\2367363 on_24\IN\1740 treatment_25\NN\654885 till_26\IN\14844693 progression_27\NN\8457976 and_28\CC\1740 improves_29\VBZ\126264 humoral_30\JJ\1740 immunity_31\NN\13920835 even_32\RB\1740 in_33\IN\13603305 patients_34\NNS\9898892 with_35\IN\1740 stable_36\JJ\1740 disease_37\NN\14061805 ._38\.\1740
12359538
D003042_D002637 NONE utility_0\NN\8186047 of_1\IN\1740 troponin_2\NN\1740 i_3\NN\14622893 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 <e1>cocaine-associated</e1>_7\JJ\1740 <e2>chest_8\NN\5220461 pain</e2>_9\NN\14299637 ._10\.\1740
D003042_D002637 NONE baseline_0\NN\7260623 electrocardiogram_1\NN\7000195 abnormalities_2\NNS\14034177 and_3\CC\1740 market_4\NN\407535 elevations_5\NNS\7445480 not_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 myocardial_9\JJ\1740 necrosis_10\NN\11444117 make_11\VB\126264 accurate_12\JJ\1740 diagnosis_13\NN\152018 of_14\IN\1740 myocardial_15\JJ\1740 infarction_16\NN\14204950 (_17\-LRB-\1740 mi_18\NN\14207561 )_19\-RRB-\1740 difficult_20\JJ\1740 in_21\IN\13603305 patients_22\NNS\9898892 with_23\IN\1740 <e1>cocaine-associated</e1>_24\JJ\1740 <e2>chest_25\NN\5220461 pain</e2>_26\NN\14299637 ._27\.\1740
D003042_D002637 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 outcomes_4\NNS\7291312 based_5\VBN\2694933 on_6\IN\1740 troponin_7\NN\1740 positivity_8\NN\13856574 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 <e1>cocaine</e1>_12\NN\3492717 <e2>chest_13\NN\5220461 pain</e2>_14\NN\14299637 admitted_15\VBN\822367 for_16\IN\1740 exclusion_17\NN\13927383 of_18\IN\1740 mi_19\NNP\14207561 ._20\.\1740
D003042_D002637 NONE troponin_0\NNP\1740 appears_1\VBZ\2604760 to_2\TO\1740 have_3\VB\2108377 an_4\DT\6697703 equivalent_5\JJ\1740 diagnostic_6\JJ\1740 accuracy_7\NN\4723816 compared_8\VBN\644583 with_9\IN\1740 ck-mb_10\NN\1740 for_11\IN\1740 diagnosing_12\VBG\644583 necrosis_13\NN\11444117 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 <e1>cocaine-associated</e1>_17\JJ\1740 <e2>chest_18\JJ\1740 pain</e2>_19\NN\14299637 and_20\CC\1740 suspected_21\VBN\916909 mi_22\NN\14207561 ._23\.\1740
D003042_D009202 NONE baseline_0\NN\7260623 electrocardiogram_1\NN\7000195 abnormalities_2\NNS\14034177 and_3\CC\1740 market_4\NN\407535 elevations_5\NNS\7445480 not_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 <e2>myocardial_9\JJ\1740 necrosis</e2>_10\NN\11444117 make_11\VB\126264 accurate_12\JJ\1740 diagnosis_13\NN\152018 of_14\IN\1740 myocardial_15\JJ\1740 infarction_16\NN\14204950 (_17\-LRB-\1740 mi_18\NN\14207561 )_19\-RRB-\1740 difficult_20\JJ\1740 in_21\IN\13603305 patients_22\NNS\9898892 with_23\IN\1740 <e1>cocaine-associated</e1>_24\JJ\1740 chest_25\NN\5220461 pain_26\NN\14299637 ._27\.\1740
D003042_D009203 CID baseline_0\NN\7260623 electrocardiogram_1\NN\7000195 abnormalities_2\NNS\14034177 and_3\CC\1740 market_4\NN\407535 elevations_5\NNS\7445480 not_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 myocardial_9\JJ\1740 necrosis_10\NN\11444117 make_11\VB\126264 accurate_12\JJ\1740 diagnosis_13\NN\152018 of_14\IN\1740 <e2>myocardial_15\JJ\1740 infarction</e2>_16\NN\14204950 (_17\-LRB-\1740 mi_18\NN\14207561 )_19\-RRB-\1740 difficult_20\JJ\1740 in_21\IN\13603305 patients_22\NNS\9898892 with_23\IN\1740 <e1>cocaine-associated</e1>_24\JJ\1740 chest_25\NN\5220461 pain_26\NN\14299637 ._27\.\1740
D003042_D009203 CID baseline_0\NN\7260623 electrocardiogram_1\NN\7000195 abnormalities_2\NNS\14034177 and_3\CC\1740 market_4\NN\407535 elevations_5\NNS\7445480 not_6\RB\1740 associated_7\VBN\628491 with_8\IN\1740 myocardial_9\JJ\1740 necrosis_10\NN\11444117 make_11\VB\126264 accurate_12\JJ\1740 diagnosis_13\NN\152018 of_14\IN\1740 myocardial_15\JJ\1740 infarction_16\NN\14204950 (_17\-LRB-\1740 <e2>mi</e2>_18\NN\14207561 )_19\-RRB-\1740 difficult_20\JJ\1740 in_21\IN\13603305 patients_22\NNS\9898892 with_23\IN\1740 <e1>cocaine-associated</e1>_24\JJ\1740 chest_25\NN\5220461 pain_26\NN\14299637 ._27\.\1740
D003042_D009203 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 outcomes_4\NNS\7291312 based_5\VBN\2694933 on_6\IN\1740 troponin_7\NN\1740 positivity_8\NN\13856574 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 <e1>cocaine</e1>_12\NN\3492717 chest_13\NN\5220461 pain_14\NN\14299637 admitted_15\VBN\822367 for_16\IN\1740 exclusion_17\NN\13927383 of_18\IN\1740 <e2>mi</e2>_19\NNP\14207561 ._20\.\1740
D003042_D009203 CID methods_0\NNS\5616786 :_1\:\1740 outcomes_2\NNS\7291312 were_3\VBD\836236 examined_4\VBN\789138 in_5\IN\13603305 patients_6\NNS\9898892 admitted_7\VBN\822367 for_8\IN\1740 possible_9\JJ\1740 <e2>mi</e2>_10\NN\14207561 after_11\IN\1740 <e1>cocaine</e1>_12\NN\3492717 use_13\NN\407535 ._14\.\1740
D003042_D009203 CID troponin_0\NNP\1740 appears_1\VBZ\2604760 to_2\TO\1740 have_3\VB\2108377 an_4\DT\6697703 equivalent_5\JJ\1740 diagnostic_6\JJ\1740 accuracy_7\NN\4723816 compared_8\VBN\644583 with_9\IN\1740 ck-mb_10\NN\1740 for_11\IN\1740 diagnosing_12\VBG\644583 necrosis_13\NN\11444117 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 <e1>cocaine-associated</e1>_17\JJ\1740 chest_18\JJ\1740 pain_19\NN\14299637 and_20\CC\1740 suspected_21\VBN\916909 <e2>mi</e2>_22\NN\14207561 ._23\.\1740
D003042_D009336 NONE troponin_0\NNP\1740 appears_1\VBZ\2604760 to_2\TO\1740 have_3\VB\2108377 an_4\DT\6697703 equivalent_5\JJ\1740 diagnostic_6\JJ\1740 accuracy_7\NN\4723816 compared_8\VBN\644583 with_9\IN\1740 ck-mb_10\NN\1740 for_11\IN\1740 diagnosing_12\VBG\644583 <e2>necrosis</e2>_13\NN\11444117 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 <e1>cocaine-associated</e1>_17\JJ\1740 chest_18\JJ\1740 pain_19\NN\14299637 and_20\CC\1740 suspected_21\VBN\916909 mi_22\NN\14207561 ._23\.\1740
25080425
D001622_D009202 NONE regulation_0\NN\6652242 of_1\IN\1740 signal_2\NN\33020 transducer_3\NN\3269401 and_4\CC\1740 activator_5\NN\19613 of_6\IN\1740 transcription_7\NN\6349220 3_8\CD\13741022 and_9\CC\1740 apoptotic_10\JJ\1740 pathways_11\NNS\5483677 by_12\IN\1740 <e1>betaine</e1>_13\NN\14712692 attenuates_14\NNS\1740 isoproterenol-induced_15\JJ\1740 acute_16\JJ\1740 <e2>myocardial_17\JJ\1740 injury</e2>_18\NN\14052046 in_19\IN\13603305 rats_20\NNS\2329401 ._21\.\1740
D001622_D009202 NONE the_0\DT\1740 protective_1\JJ\1740 role_2\NN\719494 of_3\IN\1740 <e1>betaine</e1>_4\NN\14712692 on_5\IN\1740 <e2>myocardial_6\JJ\1740 damage</e2>_7\NN\7296428 was_8\VBD\836236 further_9\RB\1740 confirmed_10\VBN\1011725 by_11\IN\1740 histopathological_12\JJ\1740 examination_13\NN\633864 ._14\.\1740
D007545_D009202 NONE regulation_0\NN\6652242 of_1\IN\1740 signal_2\NN\33020 transducer_3\NN\3269401 and_4\CC\1740 activator_5\NN\19613 of_6\IN\1740 transcription_7\NN\6349220 3_8\CD\13741022 and_9\CC\1740 apoptotic_10\JJ\1740 pathways_11\NNS\5483677 by_12\IN\1740 betaine_13\NN\14712692 attenuates_14\NNS\1740 <e1>isoproterenol-induced</e1>_15\JJ\1740 acute_16\JJ\1740 <e2>myocardial_17\JJ\1740 injury</e2>_18\NN\14052046 in_19\IN\13603305 rats_20\NNS\2329401 ._21\.\1740
D001622_D017202 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 cardioprotective_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>betaine</e1>_11\NN\14712692 on_12\IN\1740 acute_13\JJ\1740 <e2>myocardial_14\JJ\1740 ischemia</e2>_15\NN\14195315 induced_16\VBN\1627355 experimentally_17\RB\1740 in_18\IN\13603305 rats_19\NNS\2329401 focusing_20\VBG\628491 on_21\IN\1740 regulation_22\NN\6652242 of_23\IN\1740 signal_24\NN\33020 transducer_25\NN\3269401 and_26\CC\1740 activator_27\NN\19613 of_28\IN\1740 transcription_29\NN\6349220 3_30\CD\13741022 (_31\-LRB-\1740 stat3_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 apoptotic_35\JJ\1740 pathways_36\NNS\5483677 as_37\IN\14622893 the_38\DT\1740 potential_39\JJ\1740 mechanism_40\NN\13446390 underlying_41\VBG\2604760 the_42\DT\1740 drug_43\NN\14778436 effect_44\NN\34213 ._45\.\1740
D001622_D017202 NONE in_0\IN\13603305 summary_1\NN\6722453 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 showed_5\VBD\2137132 that_6\IN\1740 <e1>betaine</e1>_7\NN\14712692 pretreatment_8\NN\1740 attenuated_9\VBD\224901 isoproterenol-induced_10\JJ\1740 acute_11\JJ\1740 <e2>myocardial_12\JJ\1740 ischemia</e2>_13\NN\14195315 via_14\IN\1740 the_15\DT\1740 regulation_16\NN\6652242 of_17\IN\1740 stat3_18\NN\1740 and_19\CC\1740 apoptotic_20\JJ\1740 pathways_21\NNS\5483677 ._22\.\1740
D007545_D017202 CID acute_0\JJ\1740 <e2>myocardial_1\JJ\1740 ischemic_2\JJ\1740 injury</e2>_3\NN\14052046 was_4\VBD\836236 induced_5\VBN\1627355 in_6\IN\13603305 rats_7\NNS\2329401 by_8\IN\1740 subcutaneous_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 <e1>isoproterenol</e1>_12\NN\3740161 (_13\-LRB-\1740 85_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 for_18\IN\1740 two_19\CD\13741022 consecutive_20\JJ\1740 days_21\NNS\15140892 ._22\.\1740
D007545_D017202 CID in_0\IN\13603305 summary_1\NN\6722453 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 showed_5\VBD\2137132 that_6\IN\1740 betaine_7\NN\14712692 pretreatment_8\NN\1740 attenuated_9\VBD\224901 <e1>isoproterenol-induced</e1>_10\JJ\1740 acute_11\JJ\1740 <e2>myocardial_12\JJ\1740 ischemia</e2>_13\NN\14195315 via_14\IN\1740 the_15\DT\1740 regulation_16\NN\6652242 of_17\IN\1740 stat3_18\NN\1740 and_19\CC\1740 apoptotic_20\JJ\1740 pathways_21\NNS\5483677 ._22\.\1740
D001622_D020257 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>betaine</e1>_3\NN\14712692 (_4\-LRB-\1740 200_5\CD\1740 and_6\CC\1740 400_7\CD\1740 mg/kg_8\NN\1740 )_9\-RRB-\1740 significantly_10\RB\1740 reduced_11\VBD\441445 the_12\DT\1740 level_13\NN\4916342 of_14\IN\1740 cardiac_15\JJ\1740 marker_16\NN\21939 enzyme_17\NN\14723628 in_18\IN\13603305 the_19\DT\1740 serum_20\NN\5397468 and_21\CC\1740 prevented_22\VBD\1740 left_23\VBN\120316 <e2>ventricular_24\JJ\1740 remodeling</e2>_25\NN\1740 ._26\.\1740
15614572
D014196_D009062 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 <e1>trazodone</e1>_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 <e2>oral_12\JJ\1740 stereotypies</e2>_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 catalepsy_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D014196_D002375 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 <e1>trazodone</e1>_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 oral_12\JJ\1740 stereotypies_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D014196_D002375 NONE we_0\PRP\1740 also_1\RB\1740 investigated_2\VBD\644583 whether_3\IN\1740 <e1>trazodone</e1>_4\NN\3829085 induces_5\VBZ\1627355 <e2>catalepsy</e2>_6\NN\14023236 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D014196_D002375 NONE results_0\NNS\34213 :_1\:\1740 <e1>trazodone</e1>_2\NN\3829085 at_3\IN\14622893 2.5_4\CD\1740 -_5\SYM\1740 20_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 did_9\VBD\1640855 not_10\RB\1740 induce_11\VB\1627355 <e2>catalepsy</e2>_12\NN\14023236 ,_13\,\1740 and_14\CC\1740 did_15\VBD\1640855 not_16\RB\1740 antagonize_17\VB\1787955 apomorphine_18\NN\3786417 (_19\-LRB-\1740 1.5_20\CD\1740 and_21\CC\1740 3_22\CD\13741022 mg/kg_23\NN\1740 )_24\-RRB-\1740 stereotypy_25\NN\1740 and_26\CC\1740 apomorphine_27\NN\3786417 (_28\-LRB-\1740 0.05_29\CD\1740 mg/kg)-induced_30\JJ\1740 catalepsy_31\NN\14023236 ._32\.\1740
D014196_D002375 NONE results_0\NNS\34213 :_1\:\1740 <e1>trazodone</e1>_2\NN\3829085 at_3\IN\14622893 2.5_4\CD\1740 -_5\SYM\1740 20_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 did_9\VBD\1640855 not_10\RB\1740 induce_11\VB\1627355 catalepsy_12\NN\14023236 ,_13\,\1740 and_14\CC\1740 did_15\VBD\1640855 not_16\RB\1740 antagonize_17\VB\1787955 apomorphine_18\NN\3786417 (_19\-LRB-\1740 1.5_20\CD\1740 and_21\CC\1740 3_22\CD\13741022 mg/kg_23\NN\1740 )_24\-RRB-\1740 stereotypy_25\NN\1740 and_26\CC\1740 apomorphine_27\NN\3786417 (_28\-LRB-\1740 0.05_29\CD\1740 mg/kg)-induced_30\JJ\1740 <e2>catalepsy</e2>_31\NN\14023236 ._32\.\1740
D014196_D002375 NONE however_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 5_4\CD\13741022 ,_5\,\1740 10_6\CD\13745420 and_7\CC\1740 20_8\CD\13745420 mg/kg_9\NN\1740 i.p._10\RB\1740 <e1>trazodone</e1>_11\NN\3829085 enhanced_12\VBD\227165 dexamphetamine_13\NN\1740 stereotypy_14\NN\1740 ,_15\,\1740 and_16\CC\1740 antagonized_17\VBD\1787955 haloperidol_18\NN\3713736 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 ergometrine-induced_21\JJ\1740 wds_22\NN\1740 behavior_23\NN\407535 and_24\CC\1740 fluoxetine-induced_25\JJ\1740 penile_26\NN\1740 erections_27\NNS\14037619 ._28\.\1740
D014196_D002375 NONE <e1>trazodone</e1>_0\NN\3829085 at_1\IN\14622893 30_2\CD\13745420 ,_3\,\1740 40_4\CD\13745420 and_5\CC\1740 50_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 induced_9\VBN\1627355 <e2>catalepsy</e2>_10\NN\14023236 and_11\CC\1740 antagonized_12\JJ\1740 apomorphine_13\NN\3786417 and_14\CC\1740 dexamphetamine_15\NN\1740 stereotypies_16\NNS\1740 ._17\.\1740
D014196_D002375 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 <e1>trazodone</e1>_3\NN\3829085 (_4\-LRB-\1740 5_5\CD\13741022 ,_6\,\1740 10_7\CD\13745420 and_8\CC\1740 20_9\CD\13745420 mg/kg_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 by_13\IN\1740 blocking_14\VBG\1476483 the_15\DT\1740 5-ht_16\NN\1740 2c_17\NN\1740 receptors_18\NNS\5225602 ,_19\,\1740 releases_20\VBZ\1435380 the_21\DT\1740 nigrostriatal_22\JJ\1740 daergic_23\JJ\1740 neurons_24\NNS\5430628 from_25\IN\1740 tonic_26\JJ\1740 inhibition_27\NN\1068773 caused_28\VBN\1617192 by_29\IN\1740 5-ht_30\NN\1740 ,_31\,\1740 and_32\CC\1740 thereby_33\RB\1740 potentiates_34\VBZ\229605 dexamphetamine_35\NN\1740 stereotypy_36\NN\1740 and_37\CC\1740 antagonizes_38\VBZ\1787955 haloperidol_39\NN\3713736 <e2>catalepsy</e2>_40\NN\14023236 ._41\.\1740
D003913_D009062 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 <e1>dexamphetamine-</e1>_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 <e2>oral_12\JJ\1740 stereotypies</e2>_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 catalepsy_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D003913_D002375 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 <e1>dexamphetamine-</e1>_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 oral_12\JJ\1740 stereotypies_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D003913_D002375 NONE however_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 5_4\CD\13741022 ,_5\,\1740 10_6\CD\13745420 and_7\CC\1740 20_8\CD\13745420 mg/kg_9\NN\1740 i.p._10\RB\1740 trazodone_11\NN\3829085 enhanced_12\VBD\227165 <e1>dexamphetamine</e1>_13\NN\1740 stereotypy_14\NN\1740 ,_15\,\1740 and_16\CC\1740 antagonized_17\VBD\1787955 haloperidol_18\NN\3713736 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 ergometrine-induced_21\JJ\1740 wds_22\NN\1740 behavior_23\NN\407535 and_24\CC\1740 fluoxetine-induced_25\JJ\1740 penile_26\NN\1740 erections_27\NNS\14037619 ._28\.\1740
D003913_D002375 NONE trazodone_0\NN\3829085 at_1\IN\14622893 30_2\CD\13745420 ,_3\,\1740 40_4\CD\13745420 and_5\CC\1740 50_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 induced_9\VBN\1627355 <e2>catalepsy</e2>_10\NN\14023236 and_11\CC\1740 antagonized_12\JJ\1740 apomorphine_13\NN\3786417 and_14\CC\1740 <e1>dexamphetamine</e1>_15\NN\1740 stereotypies_16\NNS\1740 ._17\.\1740
D003913_D002375 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 trazodone_3\NN\3829085 (_4\-LRB-\1740 5_5\CD\13741022 ,_6\,\1740 10_7\CD\13745420 and_8\CC\1740 20_9\CD\13745420 mg/kg_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 by_13\IN\1740 blocking_14\VBG\1476483 the_15\DT\1740 5-ht_16\NN\1740 2c_17\NN\1740 receptors_18\NNS\5225602 ,_19\,\1740 releases_20\VBZ\1435380 the_21\DT\1740 nigrostriatal_22\JJ\1740 daergic_23\JJ\1740 neurons_24\NNS\5430628 from_25\IN\1740 tonic_26\JJ\1740 inhibition_27\NN\1068773 caused_28\VBN\1617192 by_29\IN\1740 5-ht_30\NN\1740 ,_31\,\1740 and_32\CC\1740 thereby_33\RB\1740 potentiates_34\VBZ\229605 <e1>dexamphetamine</e1>_35\NN\1740 stereotypy_36\NN\1740 and_37\CC\1740 antagonizes_38\VBZ\1787955 haloperidol_39\NN\3713736 <e2>catalepsy</e2>_40\NN\14023236 ._41\.\1740
D001058_D009062 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 <e1>apomorphine-induced</e1>_11\JJ\1740 <e2>oral_12\JJ\1740 stereotypies</e2>_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 catalepsy_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D001058_D009062 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 <e2>oral_12\JJ\1740 stereotypies</e2>_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 catalepsy_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 <e1>apomorphine</e1>_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D001058_D002375 CID methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 <e1>apomorphine-induced</e1>_11\JJ\1740 oral_12\JJ\1740 stereotypies_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D001058_D002375 CID methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 oral_12\JJ\1740 stereotypies_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 <e1>apomorphine</e1>_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D001058_D002375 CID results_0\NNS\34213 :_1\:\1740 trazodone_2\NN\3829085 at_3\IN\14622893 2.5_4\CD\1740 -_5\SYM\1740 20_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 did_9\VBD\1640855 not_10\RB\1740 induce_11\VB\1627355 <e2>catalepsy</e2>_12\NN\14023236 ,_13\,\1740 and_14\CC\1740 did_15\VBD\1640855 not_16\RB\1740 antagonize_17\VB\1787955 <e1>apomorphine</e1>_18\NN\3786417 (_19\-LRB-\1740 1.5_20\CD\1740 and_21\CC\1740 3_22\CD\13741022 mg/kg_23\NN\1740 )_24\-RRB-\1740 stereotypy_25\NN\1740 and_26\CC\1740 apomorphine_27\NN\3786417 (_28\-LRB-\1740 0.05_29\CD\1740 mg/kg)-induced_30\JJ\1740 catalepsy_31\NN\14023236 ._32\.\1740
D001058_D002375 CID results_0\NNS\34213 :_1\:\1740 trazodone_2\NN\3829085 at_3\IN\14622893 2.5_4\CD\1740 -_5\SYM\1740 20_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 did_9\VBD\1640855 not_10\RB\1740 induce_11\VB\1627355 catalepsy_12\NN\14023236 ,_13\,\1740 and_14\CC\1740 did_15\VBD\1640855 not_16\RB\1740 antagonize_17\VB\1787955 <e1>apomorphine</e1>_18\NN\3786417 (_19\-LRB-\1740 1.5_20\CD\1740 and_21\CC\1740 3_22\CD\13741022 mg/kg_23\NN\1740 )_24\-RRB-\1740 stereotypy_25\NN\1740 and_26\CC\1740 apomorphine_27\NN\3786417 (_28\-LRB-\1740 0.05_29\CD\1740 mg/kg)-induced_30\JJ\1740 <e2>catalepsy</e2>_31\NN\14023236 ._32\.\1740
D001058_D002375 CID results_0\NNS\34213 :_1\:\1740 trazodone_2\NN\3829085 at_3\IN\14622893 2.5_4\CD\1740 -_5\SYM\1740 20_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 did_9\VBD\1640855 not_10\RB\1740 induce_11\VB\1627355 <e2>catalepsy</e2>_12\NN\14023236 ,_13\,\1740 and_14\CC\1740 did_15\VBD\1640855 not_16\RB\1740 antagonize_17\VB\1787955 apomorphine_18\NN\3786417 (_19\-LRB-\1740 1.5_20\CD\1740 and_21\CC\1740 3_22\CD\13741022 mg/kg_23\NN\1740 )_24\-RRB-\1740 stereotypy_25\NN\1740 and_26\CC\1740 <e1>apomorphine</e1>_27\NN\3786417 (_28\-LRB-\1740 0.05_29\CD\1740 mg/kg)-induced_30\JJ\1740 catalepsy_31\NN\14023236 ._32\.\1740
D001058_D002375 CID results_0\NNS\34213 :_1\:\1740 trazodone_2\NN\3829085 at_3\IN\14622893 2.5_4\CD\1740 -_5\SYM\1740 20_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 did_9\VBD\1640855 not_10\RB\1740 induce_11\VB\1627355 catalepsy_12\NN\14023236 ,_13\,\1740 and_14\CC\1740 did_15\VBD\1640855 not_16\RB\1740 antagonize_17\VB\1787955 apomorphine_18\NN\3786417 (_19\-LRB-\1740 1.5_20\CD\1740 and_21\CC\1740 3_22\CD\13741022 mg/kg_23\NN\1740 )_24\-RRB-\1740 stereotypy_25\NN\1740 and_26\CC\1740 <e1>apomorphine</e1>_27\NN\3786417 (_28\-LRB-\1740 0.05_29\CD\1740 mg/kg)-induced_30\JJ\1740 <e2>catalepsy</e2>_31\NN\14023236 ._32\.\1740
D001058_D002375 CID trazodone_0\NN\3829085 at_1\IN\14622893 30_2\CD\13745420 ,_3\,\1740 40_4\CD\13745420 and_5\CC\1740 50_6\CD\13745420 mg/kg_7\NN\1740 i.p._8\RB\1740 induced_9\VBN\1627355 <e2>catalepsy</e2>_10\NN\14023236 and_11\CC\1740 antagonized_12\JJ\1740 <e1>apomorphine</e1>_13\NN\3786417 and_14\CC\1740 dexamphetamine_15\NN\1740 stereotypies_16\NNS\1740 ._17\.\1740
D006220_D009062 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 <e2>oral_12\JJ\1740 stereotypies</e2>_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 catalepsy_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 <e1>haloperidol</e1>_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D006220_D002375 CID methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 oral_12\JJ\1740 stereotypies_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 <e1>haloperidol</e1>_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D006220_D002375 CID however_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 5_4\CD\13741022 ,_5\,\1740 10_6\CD\13745420 and_7\CC\1740 20_8\CD\13745420 mg/kg_9\NN\1740 i.p._10\RB\1740 trazodone_11\NN\3829085 enhanced_12\VBD\227165 dexamphetamine_13\NN\1740 stereotypy_14\NN\1740 ,_15\,\1740 and_16\CC\1740 antagonized_17\VBD\1787955 <e1>haloperidol</e1>_18\NN\3713736 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 ergometrine-induced_21\JJ\1740 wds_22\NN\1740 behavior_23\NN\407535 and_24\CC\1740 fluoxetine-induced_25\JJ\1740 penile_26\NN\1740 erections_27\NNS\14037619 ._28\.\1740
D006220_D002375 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 trazodone_3\NN\3829085 (_4\-LRB-\1740 5_5\CD\13741022 ,_6\,\1740 10_7\CD\13745420 and_8\CC\1740 20_9\CD\13745420 mg/kg_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 by_13\IN\1740 blocking_14\VBG\1476483 the_15\DT\1740 5-ht_16\NN\1740 2c_17\NN\1740 receptors_18\NNS\5225602 ,_19\,\1740 releases_20\VBZ\1435380 the_21\DT\1740 nigrostriatal_22\JJ\1740 daergic_23\JJ\1740 neurons_24\NNS\5430628 from_25\IN\1740 tonic_26\JJ\1740 inhibition_27\NN\1068773 caused_28\VBN\1617192 by_29\IN\1740 5-ht_30\NN\1740 ,_31\,\1740 and_32\CC\1740 thereby_33\RB\1740 potentiates_34\VBZ\229605 dexamphetamine_35\NN\1740 stereotypy_36\NN\1740 and_37\CC\1740 antagonizes_38\VBZ\1787955 <e1>haloperidol</e1>_39\NN\3713736 <e2>catalepsy</e2>_40\NN\14023236 ._41\.\1740
D004874_D009062 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 <e2>oral_12\JJ\1740 stereotypies</e2>_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 catalepsy_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 <e1>ergometrine-induced</e1>_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D004874_D002375 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 oral_12\JJ\1740 stereotypies_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 <e1>ergometrine-induced</e1>_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 fluoxetine-induced_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D004874_D002375 NONE however_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 5_4\CD\13741022 ,_5\,\1740 10_6\CD\13745420 and_7\CC\1740 20_8\CD\13745420 mg/kg_9\NN\1740 i.p._10\RB\1740 trazodone_11\NN\3829085 enhanced_12\VBD\227165 dexamphetamine_13\NN\1740 stereotypy_14\NN\1740 ,_15\,\1740 and_16\CC\1740 antagonized_17\VBD\1787955 haloperidol_18\NN\3713736 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 <e1>ergometrine-induced</e1>_21\JJ\1740 wds_22\NN\1740 behavior_23\NN\407535 and_24\CC\1740 fluoxetine-induced_25\JJ\1740 penile_26\NN\1740 erections_27\NNS\14037619 ._28\.\1740
D005473_D009062 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 <e2>oral_12\JJ\1740 stereotypies</e2>_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 catalepsy_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 <e1>fluoxetine-induced</e1>_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D005473_D002375 NONE methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 effect_3\NN\34213 of_4\IN\1740 pretreatment_5\NN\1740 with_6\IN\1740 trazodone_7\NN\3829085 on_8\IN\1740 dexamphetamine-_9\NN\1740 and_10\CC\1740 apomorphine-induced_11\JJ\1740 oral_12\JJ\1740 stereotypies_13\NNS\1740 ,_14\,\1740 on_15\IN\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 haloperidol_19\NN\3713736 and_20\CC\1740 apomorphine_21\NN\3786417 (_22\-LRB-\1740 0.05_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 i.p._26\RB\1740 )_27\-RRB-\1740 ,_28\,\1740 on_29\IN\1740 ergometrine-induced_30\JJ\1740 wet_31\JJ\1740 dog_32\NN\2083346 shake_33\NN\14786479 (_34\-LRB-\1740 wds_35\NN\1740 )_36\-RRB-\1740 behavior_37\NN\407535 and_38\CC\1740 <e1>fluoxetine-induced</e1>_39\JJ\1740 penile_40\NN\1740 erections_41\NNS\14037619 was_42\VBD\836236 studied_43\VBN\630380 in_44\IN\13603305 rats_45\NNS\2329401 ._46\.\1740
D005473_D002375 NONE however_0\RB\1740 ,_1\,\1740 pretreatment_2\NN\1740 with_3\IN\1740 5_4\CD\13741022 ,_5\,\1740 10_6\CD\13745420 and_7\CC\1740 20_8\CD\13745420 mg/kg_9\NN\1740 i.p._10\RB\1740 trazodone_11\NN\3829085 enhanced_12\VBD\227165 dexamphetamine_13\NN\1740 stereotypy_14\NN\1740 ,_15\,\1740 and_16\CC\1740 antagonized_17\VBD\1787955 haloperidol_18\NN\3713736 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 ergometrine-induced_21\JJ\1740 wds_22\NN\1740 behavior_23\NN\407535 and_24\CC\1740 <e1>fluoxetine-induced</e1>_25\JJ\1740 penile_26\NN\1740 erections_27\NNS\14037619 ._28\.\1740
D012701_D002375 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 trazodone_3\NN\3829085 (_4\-LRB-\1740 5_5\CD\13741022 ,_6\,\1740 10_7\CD\13745420 and_8\CC\1740 20_9\CD\13745420 mg/kg_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 by_13\IN\1740 blocking_14\VBG\1476483 the_15\DT\1740 <e1>5-ht</e1>_16\NN\1740 2c_17\NN\1740 receptors_18\NNS\5225602 ,_19\,\1740 releases_20\VBZ\1435380 the_21\DT\1740 nigrostriatal_22\JJ\1740 daergic_23\JJ\1740 neurons_24\NNS\5430628 from_25\IN\1740 tonic_26\JJ\1740 inhibition_27\NN\1068773 caused_28\VBN\1617192 by_29\IN\1740 5-ht_30\NN\1740 ,_31\,\1740 and_32\CC\1740 thereby_33\RB\1740 potentiates_34\VBZ\229605 dexamphetamine_35\NN\1740 stereotypy_36\NN\1740 and_37\CC\1740 antagonizes_38\VBZ\1787955 haloperidol_39\NN\3713736 <e2>catalepsy</e2>_40\NN\14023236 ._41\.\1740
D012701_D002375 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 trazodone_3\NN\3829085 (_4\-LRB-\1740 5_5\CD\13741022 ,_6\,\1740 10_7\CD\13745420 and_8\CC\1740 20_9\CD\13745420 mg/kg_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 by_13\IN\1740 blocking_14\VBG\1476483 the_15\DT\1740 5-ht_16\NN\1740 2c_17\NN\1740 receptors_18\NNS\5225602 ,_19\,\1740 releases_20\VBZ\1435380 the_21\DT\1740 nigrostriatal_22\JJ\1740 daergic_23\JJ\1740 neurons_24\NNS\5430628 from_25\IN\1740 tonic_26\JJ\1740 inhibition_27\NN\1068773 caused_28\VBN\1617192 by_29\IN\1740 <e1>5-ht</e1>_30\NN\1740 ,_31\,\1740 and_32\CC\1740 thereby_33\RB\1740 potentiates_34\VBZ\229605 dexamphetamine_35\NN\1740 stereotypy_36\NN\1740 and_37\CC\1740 antagonizes_38\VBZ\1787955 haloperidol_39\NN\3713736 <e2>catalepsy</e2>_40\NN\14023236 ._41\.\1740
11425091
D003042_D007235 CID prenatal_0\JJ\1740 <e1>cocaine</e1>_1\NN\3492717 exposure_2\NN\5042871 and_3\CC\1740 cranial_4\JJ\1740 sonographic_5\JJ\1740 findings_6\NNS\7951464 in_7\IN\13603305 <e2>preterm_8\NN\1740 infants</e2>_9\NNS\9918248 ._10\.\1740
D003042_D007235 CID we_0\PRP\1740 sought_1\VBD\1825237 to_2\TO\1740 determine_3\VB\1645601 if_4\IN\1740 prenatal_5\JJ\1740 <e1>cocaine</e1>_6\NN\3492717 exposure_7\NN\5042871 increases_8\VBZ\169651 the_9\DT\1740 incidence_10\NN\13821570 of_11\IN\1740 subependymal_12\JJ\1740 cysts_13\NNS\14204950 in_14\IN\13603305 <e2>preterm_15\NN\1740 infants</e2>_16\NNS\9918248 ._17\.\1740
D003042_D007235 CID conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 found_3\VBD\2426171 an_4\DT\6697703 increased_5\VBN\169651 incidence_6\NN\13821570 of_7\IN\1740 subependymal_8\JJ\1740 cyst_9\NN\14204950 formation_10\NN\7938773 in_11\IN\13603305 <e2>preterm_12\NN\1740 infants</e2>_13\NNS\9918248 who_14\WP\8299493 were_15\VBD\836236 exposed_16\VBN\2110927 to_17\TO\1740 <e1>cocaine</e1>_18\NN\3492717 prenatally_19\RB\1740 ._20\.\1740
D003042_D006470 NONE purpose_0\NNP\5980875 :_1\:\1740 prenatal_2\JJ\1740 <e1>cocaine</e1>_3\NN\3492717 exposure_4\NN\5042871 has_5\VBZ\2108377 been_6\VBN\836236 linked_7\VBN\628491 with_8\IN\1740 subependymal_9\JJ\1740 <e2>hemorrhage</e2>_10\NN\14285662 and_11\CC\1740 the_12\DT\1740 formation_13\NN\7938773 of_14\IN\1740 cysts_15\NNS\14204950 that_16\WDT\1740 are_17\VBP\836236 detectable_18\JJ\1740 on_19\IN\1740 cranial_20\JJ\1740 sonography_21\NN\901083 in_22\IN\13603305 neonates_23\NNS\9827683 born_24\VBN\2630189 at_25\IN\14622893 term_26\NN\6286395 ._27\.\1740
D003042_D003560 CID purpose_0\NNP\5980875 :_1\:\1740 prenatal_2\JJ\1740 <e1>cocaine</e1>_3\NN\3492717 exposure_4\NN\5042871 has_5\VBZ\2108377 been_6\VBN\836236 linked_7\VBN\628491 with_8\IN\1740 subependymal_9\JJ\1740 hemorrhage_10\NN\14285662 and_11\CC\1740 the_12\DT\1740 formation_13\NN\7938773 of_14\IN\1740 <e2>cysts</e2>_15\NNS\14204950 that_16\WDT\1740 are_17\VBP\836236 detectable_18\JJ\1740 on_19\IN\1740 cranial_20\JJ\1740 sonography_21\NN\901083 in_22\IN\13603305 neonates_23\NNS\9827683 born_24\VBN\2630189 at_25\IN\14622893 term_26\NN\6286395 ._27\.\1740
D003042_D003560 CID we_0\PRP\1740 sought_1\VBD\1825237 to_2\TO\1740 determine_3\VB\1645601 if_4\IN\1740 prenatal_5\JJ\1740 <e1>cocaine</e1>_6\NN\3492717 exposure_7\NN\5042871 increases_8\VBZ\169651 the_9\DT\1740 incidence_10\NN\13821570 of_11\IN\1740 <e2>subependymal_12\JJ\1740 cysts</e2>_13\NNS\14204950 in_14\IN\13603305 preterm_15\NN\1740 infants_16\NNS\9918248 ._17\.\1740
D003042_D003560 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>subependymal_3\JJ\1740 cysts</e2>_4\NNS\14204950 in_5\IN\13603305 infants_6\NNS\9918248 exposed_7\VBN\2110927 to_8\TO\1740 <e1>cocaine</e1>_9\NN\3492717 prenatally_10\RB\1740 was_11\VBD\836236 44_12\CD\1740 %_13\NN\1740 (_14\-LRB-\1740 8_15\CD\13741022 of_16\IN\1740 18_17\CD\13745420 )_18\-RRB-\1740 compared_19\VBN\644583 with_20\IN\1740 8_21\CD\13741022 %_22\NN\1740 (_23\-LRB-\1740 8_24\CD\13741022 of_25\IN\1740 99_26\CD\1740 )_27\-RRB-\1740 in_28\IN\13603305 the_29\DT\1740 unexposed_30\JJ\1740 group_31\NN\2137 (_32\-LRB-\1740 p_33\NN\14622893 <_34\XX\1740 0.01_35\CD\1740 )_36\-RRB-\1740 ._37\.\1740
D003042_D003560 CID conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 found_3\VBD\2426171 an_4\DT\6697703 increased_5\VBN\169651 incidence_6\NN\13821570 of_7\IN\1740 <e2>subependymal_8\JJ\1740 cyst</e2>_9\NN\14204950 formation_10\NN\7938773 in_11\IN\13603305 preterm_12\NN\1740 infants_13\NNS\9918248 who_14\WP\8299493 were_15\VBD\836236 exposed_16\VBN\2110927 to_17\TO\1740 <e1>cocaine</e1>_18\NN\3492717 prenatally_19\RB\1740 ._20\.\1740
D003042_D001927 CID we_0\PRP\1740 sought_1\VBD\1825237 to_2\TO\1740 determine_3\VB\1645601 if_4\IN\1740 prenatal_5\JJ\1740 <e1>cocaine</e1>_6\NN\3492717 exposure_7\NN\5042871 increases_8\VBZ\169651 the_9\DT\1740 incidence_10\NN\13821570 of_11\IN\1740 <e2>subependymal_12\JJ\1740 cysts</e2>_13\NNS\14204950 in_14\IN\13603305 preterm_15\NN\1740 infants_16\NNS\9918248 ._17\.\1740
D003042_D001927 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>subependymal_3\JJ\1740 cysts</e2>_4\NNS\14204950 in_5\IN\13603305 infants_6\NNS\9918248 exposed_7\VBN\2110927 to_8\TO\1740 <e1>cocaine</e1>_9\NN\3492717 prenatally_10\RB\1740 was_11\VBD\836236 44_12\CD\1740 %_13\NN\1740 (_14\-LRB-\1740 8_15\CD\13741022 of_16\IN\1740 18_17\CD\13745420 )_18\-RRB-\1740 compared_19\VBN\644583 with_20\IN\1740 8_21\CD\13741022 %_22\NN\1740 (_23\-LRB-\1740 8_24\CD\13741022 of_25\IN\1740 99_26\CD\1740 )_27\-RRB-\1740 in_28\IN\13603305 the_29\DT\1740 unexposed_30\JJ\1740 group_31\NN\2137 (_32\-LRB-\1740 p_33\NN\14622893 <_34\XX\1740 0.01_35\CD\1740 )_36\-RRB-\1740 ._37\.\1740
D003042_D001927 CID conclusions_0\NNS\5837957 :_1\:\1740 we_2\PRP\1740 found_3\VBD\2426171 an_4\DT\6697703 increased_5\VBN\169651 incidence_6\NN\13821570 of_7\IN\1740 <e2>subependymal_8\JJ\1740 cyst</e2>_9\NN\14204950 formation_10\NN\7938773 in_11\IN\13603305 preterm_12\NN\1740 infants_13\NNS\9918248 who_14\WP\8299493 were_15\VBD\836236 exposed_16\VBN\2110927 to_17\TO\1740 <e1>cocaine</e1>_18\NN\3492717 prenatally_19\RB\1740 ._20\.\1740
D003042_D019970 NONE infants_0\NNS\9918248 were_1\VBD\836236 assigned_2\VBN\2475922 to_3\TO\1740 the_4\DT\1740 <e1>cocaine-exposed</e1>_5\JJ\1740 group_6\NN\2137 if_7\IN\1740 there_8\EX\27167 was_9\VBD\836236 a_10\DT\13649268 maternal_11\JJ\1740 history_12\NN\15120823 of_13\IN\1740 <e2>cocaine_14\NN\3492717 abuse</e2>_15\NN\418025 during_16\IN\1740 pregnancy_17\NN\14034177 or_18\CC\3541091 if_19\IN\1740 maternal_20\JJ\1740 or_21\CC\3541091 neonatal_22\JJ\1740 urine_23\NN\14853947 toxicology_24\NN\6054892 results_25\NNS\34213 were_26\VBD\836236 positive_27\JJ\1740 at_28\IN\14622893 the_29\DT\1740 time_30\NN\7308889 of_31\IN\1740 delivery_32\NN\315986 ._33\.\1740
17954033
D019259_D019694 NONE rate_0\NN\13815152 of_1\IN\1740 ymdd_2\NN\1740 motif_3\NN\3178782 mutants_4\NNS\4475 in_5\IN\13603305 <e1>lamivudine-untreated</e1>_6\JJ\1740 iranian_7\JJ\1740 patients_8\NNS\9898892 with_9\IN\1740 <e2>chronic_10\JJ\1740 hepatitis_11\NN\14127211 b_12\NN\1355326 virus_13\NN\9312843 infection</e2>_14\NN\14052046 ._15\.\1740
D019259_D019694 NONE background_0\NN\4921011 :_1\:\1740 <e1>lamivudine</e1>_2\NNP\3834836 is_3\VBZ\836236 used_4\VBN\1156834 for_5\IN\1740 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 <e2>chronic_9\JJ\1740 hepatitis_10\NN\14127211 b</e2>_11\NN\1355326 patients_12\NNS\9898892 ._13\.\1740
D019259_D019694 NONE recent_0\JJ\1740 studies_1\NNS\635850 show_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 ymdd_5\NN\1740 motif_6\NN\3178782 mutants_7\NNS\4475 (_8\-LRB-\1740 resistant_9\JJ\1740 hepatitis_10\NN\14127211 b_11\NN\1355326 virus_12\NN\9312843 )_13\-RRB-\1740 occur_14\VBP\2623529 as_15\IN\14622893 natural_16\JJ\1740 genome_17\NN\8456993 variability_18\NN\4733640 in_19\IN\13603305 <e1>lamivudine-untreated</e1>_20\JJ\1740 <e2>chronic_21\JJ\1740 hepatitis_22\NN\14127211 b</e2>_23\NN\1355326 patients_24\NNS\9898892 ._25\.\1740
D019259_D019694 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 aimed_4\VBD\1987160 to_5\TO\1740 determine_6\VB\1645601 the_7\DT\1740 rate_8\NN\13815152 of_9\IN\1740 ymdd_10\NN\1740 motif_11\NN\3178782 mutants_12\NNS\4475 in_13\IN\13603305 <e1>lamivudine-untreated</e1>_14\JJ\1740 <e2>chronic_15\JJ\1740 hepatitis_16\NN\14127211 b</e2>_17\NN\1355326 patients_18\NNS\9898892 in_19\IN\13603305 iran_20\NNP\1740 ._21\.\1740
D019259_D019694 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 a_4\DT\13649268 total_5\NN\3553 of_6\IN\1740 77_7\CD\1740 <e2>chronic_8\JJ\1740 hepatitis_9\NN\14127211 b</e2>_10\NN\1355326 patients_11\NNS\9898892 who_12\WP\8299493 had_13\VBD\2108377 not_14\RB\1740 been_15\VBN\836236 treated_16\VBN\2376958 with_17\IN\1740 <e1>lamivudine</e1>_18\NN\3834836 were_19\VBD\836236 included_20\VBN\690614 in_21\IN\13603305 the_22\DT\1740 study_23\NN\635850 ._24\.\1740
D019259_D019694 NONE conclusion_0\NN\5837957 :_1\:\1740 although_2\IN\1740 the_3\DT\1740 natural_4\JJ\1740 occurrence_5\NN\29378 of_6\IN\1740 ymdd_7\NN\1740 motif_8\NN\3178782 mutants_9\NNS\4475 in_10\IN\13603305 <e1>lamivudine-untreated</e1>_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>chronic_14\JJ\1740 hepatitis_15\NN\14127211 b</e2>_16\NN\1355326 has_17\VBZ\2108377 been_18\VBN\836236 reported_19\VBN\831651 ,_20\,\1740 these_21\DT\1740 mutants_22\NNS\4475 were_23\VBD\836236 not_24\RB\1740 detected_25\VBN\2163746 in_26\IN\13603305 iranian_27\JJ\1740 lamivudine-untreated_28\JJ\1740 chronic_29\JJ\1740 hepatitis_30\NN\14127211 b_31\NN\1355326 patients_32\NNS\9898892 ._33\.\1740
D019259_D019694 NONE conclusion_0\NN\5837957 :_1\:\1740 although_2\IN\1740 the_3\DT\1740 natural_4\JJ\1740 occurrence_5\NN\29378 of_6\IN\1740 ymdd_7\NN\1740 motif_8\NN\3178782 mutants_9\NNS\4475 in_10\IN\13603305 <e1>lamivudine-untreated</e1>_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 chronic_14\JJ\1740 hepatitis_15\NN\14127211 b_16\NN\1355326 has_17\VBZ\2108377 been_18\VBN\836236 reported_19\VBN\831651 ,_20\,\1740 these_21\DT\1740 mutants_22\NNS\4475 were_23\VBD\836236 not_24\RB\1740 detected_25\VBN\2163746 in_26\IN\13603305 iranian_27\JJ\1740 lamivudine-untreated_28\JJ\1740 <e2>chronic_29\JJ\1740 hepatitis_30\NN\14127211 b</e2>_31\NN\1355326 patients_32\NNS\9898892 ._33\.\1740
D019259_D019694 NONE conclusion_0\NN\5837957 :_1\:\1740 although_2\IN\1740 the_3\DT\1740 natural_4\JJ\1740 occurrence_5\NN\29378 of_6\IN\1740 ymdd_7\NN\1740 motif_8\NN\3178782 mutants_9\NNS\4475 in_10\IN\13603305 lamivudine-untreated_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>chronic_14\JJ\1740 hepatitis_15\NN\14127211 b</e2>_16\NN\1355326 has_17\VBZ\2108377 been_18\VBN\836236 reported_19\VBN\831651 ,_20\,\1740 these_21\DT\1740 mutants_22\NNS\4475 were_23\VBD\836236 not_24\RB\1740 detected_25\VBN\2163746 in_26\IN\13603305 iranian_27\JJ\1740 <e1>lamivudine-untreated</e1>_28\JJ\1740 chronic_29\JJ\1740 hepatitis_30\NN\14127211 b_31\NN\1355326 patients_32\NNS\9898892 ._33\.\1740
D019259_D019694 NONE conclusion_0\NN\5837957 :_1\:\1740 although_2\IN\1740 the_3\DT\1740 natural_4\JJ\1740 occurrence_5\NN\29378 of_6\IN\1740 ymdd_7\NN\1740 motif_8\NN\3178782 mutants_9\NNS\4475 in_10\IN\13603305 lamivudine-untreated_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 chronic_14\JJ\1740 hepatitis_15\NN\14127211 b_16\NN\1355326 has_17\VBZ\2108377 been_18\VBN\836236 reported_19\VBN\831651 ,_20\,\1740 these_21\DT\1740 mutants_22\NNS\4475 were_23\VBD\836236 not_24\RB\1740 detected_25\VBN\2163746 in_26\IN\13603305 iranian_27\JJ\1740 <e1>lamivudine-untreated</e1>_28\JJ\1740 <e2>chronic_29\JJ\1740 hepatitis_30\NN\14127211 b</e2>_31\NN\1355326 patients_32\NNS\9898892 ._33\.\1740
D019259_D006509 NONE recent_0\JJ\1740 studies_1\NNS\635850 show_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 ymdd_5\NN\1740 motif_6\NN\3178782 mutants_7\NNS\4475 (_8\-LRB-\1740 resistant_9\JJ\1740 <e2>hepatitis_10\NN\14127211 b</e2>_11\NN\1355326 virus_12\NN\9312843 )_13\-RRB-\1740 occur_14\VBP\2623529 as_15\IN\14622893 natural_16\JJ\1740 genome_17\NN\8456993 variability_18\NN\4733640 in_19\IN\13603305 <e1>lamivudine-untreated</e1>_20\JJ\1740 chronic_21\JJ\1740 hepatitis_22\NN\14127211 b_23\NN\1355326 patients_24\NNS\9898892 ._25\.\1740
2484903
D011441_D056486 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e1>propylthiouracil-associated</e1>_3\JJ\1740 acute_4\JJ\1740 <e2>hepatitis</e2>_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 methimazole-associated_11\JJ\1740 hepatocellular_12\JJ\1740 necrosis_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 propylthiouracil-associated_18\JJ\1740 lupus-like_19\JJ\1740 syndrome_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D011441_D056486 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 propylthiouracil-associated_3\JJ\1740 acute_4\JJ\1740 <e2>hepatitis</e2>_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 methimazole-associated_11\JJ\1740 hepatocellular_12\JJ\1740 necrosis_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 <e1>propylthiouracil-associated</e1>_18\JJ\1740 lupus-like_19\JJ\1740 syndrome_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D011441_D047508 NONE two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e1>propylthiouracil-associated</e1>_3\JJ\1740 acute_4\JJ\1740 hepatitis_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 methimazole-associated_11\JJ\1740 <e2>hepatocellular_12\JJ\1740 necrosis</e2>_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 propylthiouracil-associated_18\JJ\1740 lupus-like_19\JJ\1740 syndrome_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D011441_D047508 NONE two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 propylthiouracil-associated_3\JJ\1740 acute_4\JJ\1740 hepatitis_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 methimazole-associated_11\JJ\1740 <e2>hepatocellular_12\JJ\1740 necrosis</e2>_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 <e1>propylthiouracil-associated</e1>_18\JJ\1740 lupus-like_19\JJ\1740 syndrome_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D011441_D008180 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e1>propylthiouracil-associated</e1>_3\JJ\1740 acute_4\JJ\1740 hepatitis_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 methimazole-associated_11\JJ\1740 hepatocellular_12\JJ\1740 necrosis_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 propylthiouracil-associated_18\JJ\1740 <e2>lupus-like_19\JJ\1740 syndrome</e2>_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D011441_D008180 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 propylthiouracil-associated_3\JJ\1740 acute_4\JJ\1740 hepatitis_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 methimazole-associated_11\JJ\1740 hepatocellular_12\JJ\1740 necrosis_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 <e1>propylthiouracil-associated</e1>_18\JJ\1740 <e2>lupus-like_19\JJ\1740 syndrome</e2>_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D008713_D056486 NONE two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 propylthiouracil-associated_3\JJ\1740 acute_4\JJ\1740 <e2>hepatitis</e2>_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 <e1>methimazole-associated</e1>_11\JJ\1740 hepatocellular_12\JJ\1740 necrosis_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 propylthiouracil-associated_18\JJ\1740 lupus-like_19\JJ\1740 syndrome_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D008713_D047508 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 propylthiouracil-associated_3\JJ\1740 acute_4\JJ\1740 hepatitis_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 <e1>methimazole-associated</e1>_11\JJ\1740 <e2>hepatocellular_12\JJ\1740 necrosis</e2>_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 propylthiouracil-associated_18\JJ\1740 lupus-like_19\JJ\1740 syndrome_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
D008713_D008180 NONE two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 propylthiouracil-associated_3\JJ\1740 acute_4\JJ\1740 hepatitis_5\NN\14127211 ,_6\,\1740 one_7\CD\13741022 case_8\NN\7283608 of_9\IN\1740 fatal_10\JJ\1740 <e1>methimazole-associated</e1>_11\JJ\1740 hepatocellular_12\JJ\1740 necrosis_13\NN\11444117 and_14\CC\1740 one_15\CD\13741022 case_16\NN\7283608 of_17\IN\1740 propylthiouracil-associated_18\JJ\1740 <e2>lupus-like_19\JJ\1740 syndrome</e2>_20\NN\5870365 are_21\VBP\836236 described_22\VBN\1001294 ._23\.\1740
17484470
D011433_D006333 CID acute_0\JJ\1740 <e2>heart_1\NN\5919034 failure</e2>_2\NN\66216 was_3\VBD\836236 induced_4\VBN\1627355 by_5\IN\1740 <e1>propranolol</e1>_6\NN\1740 and_7\CC\1740 volume_8\NN\33615 loading_9\NN\4571088 after_10\IN\1740 weaning_11\VBG\2313250 from_12\IN\1740 cardiopulmonary_13\JJ\1740 bypass_14\NN\3519981 ;_15\:\1740 an_16\DT\6697703 absence_17\NN\14449405 of_18\IN\1740 mr_19\NN\6339416 was_20\VBD\836236 confirmed_21\VBN\1011725 by_22\IN\1740 echocardiography_23\NN\177127 ._24\.\1740
D011433_D008944 NONE acute_0\JJ\1740 heart_1\NN\5919034 failure_2\NN\66216 was_3\VBD\836236 induced_4\VBN\1627355 by_5\IN\1740 <e1>propranolol</e1>_6\NN\1740 and_7\CC\1740 volume_8\NN\33615 loading_9\NN\4571088 after_10\IN\1740 weaning_11\VBG\2313250 from_12\IN\1740 cardiopulmonary_13\JJ\1740 bypass_14\NN\3519981 ;_15\:\1740 an_16\DT\6697703 absence_17\NN\14449405 of_18\IN\1740 <e2>mr</e2>_19\NN\6339416 was_20\VBD\836236 confirmed_21\VBN\1011725 by_22\IN\1740 echocardiography_23\NN\177127 ._24\.\1740
23535177
D007980_D010300 NONE the_0\DT\1740 plasticity_1\NN\5009170 of_2\IN\1740 primary_3\JJ\1740 motor_4\NN\3699975 cortex_5\NN\5462674 (_6\-LRB-\1740 m1_7\NN\13357178 )_8\-RRB-\1740 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 <e2>parkinson_12\NN\1740 's_13\POS\1740 disease</e2>_14\NN\14061805 (_15\-LRB-\1740 pd_16\NN\14625458 )_17\-RRB-\1740 and_18\CC\1740 <e1>levodopa-induced</e1>_19\JJ\1740 dyskinesias_20\NNS\14084880 (_21\-LRB-\1740 lids_22\NNS\5313679 )_23\-RRB-\1740 is_24\VBZ\836236 severely_25\RB\1740 impaired_26\JJ\1740 ._27\.\1740
D007980_D010300 NONE the_0\DT\1740 plasticity_1\NN\5009170 of_2\IN\1740 primary_3\JJ\1740 motor_4\NN\3699975 cortex_5\NN\5462674 (_6\-LRB-\1740 m1_7\NN\13357178 )_8\-RRB-\1740 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 parkinson_12\NN\1740 's_13\POS\1740 disease_14\NN\14061805 (_15\-LRB-\1740 <e2>pd</e2>_16\NN\14625458 )_17\-RRB-\1740 and_18\CC\1740 <e1>levodopa-induced</e1>_19\JJ\1740 dyskinesias_20\NNS\14084880 (_21\-LRB-\1740 lids_22\NNS\5313679 )_23\-RRB-\1740 is_24\VBZ\836236 severely_25\RB\1740 impaired_26\JJ\1740 ._27\.\1740
D007980_D004409 CID the_0\DT\1740 plasticity_1\NN\5009170 of_2\IN\1740 primary_3\JJ\1740 motor_4\NN\3699975 cortex_5\NN\5462674 (_6\-LRB-\1740 m1_7\NN\13357178 )_8\-RRB-\1740 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 parkinson_12\NN\1740 's_13\POS\1740 disease_14\NN\14061805 (_15\-LRB-\1740 pd_16\NN\14625458 )_17\-RRB-\1740 and_18\CC\1740 <e1>levodopa-induced</e1>_19\JJ\1740 <e2>dyskinesias</e2>_20\NNS\14084880 (_21\-LRB-\1740 lids_22\NNS\5313679 )_23\-RRB-\1740 is_24\VBZ\836236 severely_25\RB\1740 impaired_26\JJ\1740 ._27\.\1740
D007980_D004409 CID the_0\DT\1740 plasticity_1\NN\5009170 of_2\IN\1740 primary_3\JJ\1740 motor_4\NN\3699975 cortex_5\NN\5462674 (_6\-LRB-\1740 m1_7\NN\13357178 )_8\-RRB-\1740 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 parkinson_12\NN\1740 's_13\POS\1740 disease_14\NN\14061805 (_15\-LRB-\1740 pd_16\NN\14625458 )_17\-RRB-\1740 and_18\CC\1740 <e1>levodopa-induced</e1>_19\JJ\1740 dyskinesias_20\NNS\14084880 (_21\-LRB-\1740 <e2>lids</e2>_22\NNS\5313679 )_23\-RRB-\1740 is_24\VBZ\836236 severely_25\RB\1740 impaired_26\JJ\1740 ._27\.\1740
6585590
D004317_D066126 NONE antitumor_0\NN\1740 effect_1\NN\34213 ,_2\,\1740 <e2>cardiotoxicity</e2>_3\NN\1740 ,_4\,\1740 and_5\CC\1740 nephrotoxicity_6\NN\1740 of_7\IN\1740 <e1>doxorubicin</e1>_8\NN\2716866 in_9\IN\13603305 the_10\DT\1740 igm_11\NN\15030481 solid_12\JJ\1740 immunocytoma-bearing_13\JJ\1740 lou/m/wsl_14\NN\1740 rat_15\NN\2329401 ._16\.\1740
D004317_D066126 NONE antitumor_0\NN\1740 activity_1\NN\30358 ,_2\,\1740 <e2>cardiotoxicity</e2>_3\NN\1740 ,_4\,\1740 and_5\CC\1740 nephrotoxicity_6\NN\1740 induced_7\VBN\1627355 by_8\IN\1740 <e1>doxorubicin</e1>_9\NN\2716866 were_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 lou/m/wsl_13\CD\1740 inbred_14\JJ\1740 rats_15\NNS\2329401 each_16\DT\1740 bearing_17\VBG\2630189 a_18\DT\13649268 transplantable_19\JJ\1740 solid_20\JJ\1740 igm_21\NN\15030481 immunocytoma_22\NN\1740 ._23\.\1740
D004317_D066126 NONE histologic_0\JJ\1740 evidence_1\NN\5816287 of_2\IN\1740 <e2>cardiotoxicity</e2>_3\NN\1740 scored_4\VBN\1111028 as_5\IN\14622893 grade_6\NN\7975026 iii_7\CD\13741022 was_8\VBD\836236 only_9\RB\1740 observed_10\VBN\2163746 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 of_14\IN\1740 1.0_15\CD\1740 mg_16\NN\13717155 <e1>doxorubicin/kg</e1>_17\NN\1740 ._18\.\1740
D004317_D007674 NONE antitumor_0\NN\1740 effect_1\NN\34213 ,_2\,\1740 cardiotoxicity_3\NN\1740 ,_4\,\1740 and_5\CC\1740 <e2>nephrotoxicity</e2>_6\NN\1740 of_7\IN\1740 <e1>doxorubicin</e1>_8\NN\2716866 in_9\IN\13603305 the_10\DT\1740 igm_11\NN\15030481 solid_12\JJ\1740 immunocytoma-bearing_13\JJ\1740 lou/m/wsl_14\NN\1740 rat_15\NN\2329401 ._16\.\1740
D004317_D007674 NONE antitumor_0\NN\1740 activity_1\NN\30358 ,_2\,\1740 cardiotoxicity_3\NN\1740 ,_4\,\1740 and_5\CC\1740 <e2>nephrotoxicity</e2>_6\NN\1740 induced_7\VBN\1627355 by_8\IN\1740 <e1>doxorubicin</e1>_9\NN\2716866 were_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 lou/m/wsl_13\CD\1740 inbred_14\JJ\1740 rats_15\NNS\2329401 each_16\DT\1740 bearing_17\VBG\2630189 a_18\DT\13649268 transplantable_19\JJ\1740 solid_20\JJ\1740 igm_21\NN\15030481 immunocytoma_22\NN\1740 ._23\.\1740
D004317_D007674 NONE light_0\JJ\1740 microscopic_1\JJ\1740 evidence_2\NN\5816287 of_3\IN\1740 <e2>renal_4\JJ\1740 damage</e2>_5\NN\7296428 was_6\VBD\836236 seen_7\VBN\2106506 above_8\IN\6392001 a_9\DT\13649268 dose_10\NN\3740161 of_11\IN\1740 0.5_12\CD\1740 mg_13\NN\13717155 <e1>doxorubicin/kg</e1>_14\NN\1740 ,_15\,\1740 which_16\WDT\1740 resulted_17\VBD\2633881 in_18\IN\13603305 albuminuria_19\NN\14299637 and_20\CC\1740 very_21\RB\1740 low_22\JJ\1740 serum_23\NN\5397468 albumin_24\NN\14736972 levels_25\NNS\4916342 ._26\.\1740
D004317_-1 NONE antitumor_0\NN\1740 effect_1\NN\34213 ,_2\,\1740 cardiotoxicity_3\NN\1740 ,_4\,\1740 and_5\CC\1740 nephrotoxicity_6\NN\1740 of_7\IN\1740 <e1>doxorubicin</e1>_8\NN\2716866 in_9\IN\13603305 the_10\DT\1740 igm_11\NN\15030481 solid_12\JJ\1740 <e2>immunocytoma-bearing</e2>_13\JJ\1740 lou/m/wsl_14\NN\1740 rat_15\NN\2329401 ._16\.\1740
D004317_-1 NONE antitumor_0\NN\1740 activity_1\NN\30358 ,_2\,\1740 cardiotoxicity_3\NN\1740 ,_4\,\1740 and_5\CC\1740 nephrotoxicity_6\NN\1740 induced_7\VBN\1627355 by_8\IN\1740 <e1>doxorubicin</e1>_9\NN\2716866 were_10\VBD\836236 studied_11\VBN\630380 in_12\IN\13603305 lou/m/wsl_13\CD\1740 inbred_14\JJ\1740 rats_15\NNS\2329401 each_16\DT\1740 bearing_17\VBG\2630189 a_18\DT\13649268 transplantable_19\JJ\1740 solid_20\JJ\1740 igm_21\NN\15030481 <e2>immunocytoma</e2>_22\NN\1740 ._23\.\1740
D004317_D009369 NONE animals_0\NNS\4475 with_1\IN\1740 a_2\DT\13649268 <e2>tumor</e2>_3\NN\14234074 (_4\-LRB-\1740 diameter_5\NN\5129201 ,_6\,\1740 15.8_7\CD\1740 +/-_8\CC\1740 3.3_9\CD\1740 mm_10\NN\13649268 )_11\-RRB-\1740 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 iv_15\NN\13741022 injections_16\NNS\320852 of_17\IN\1740 <e1>doxorubicin</e1>_18\NN\2716866 on_19\IN\1740 5_20\CD\13741022 consecutive_21\JJ\1740 days_22\NNS\15140892 ,_23\,\1740 followed_24\VBN\1835496 by_25\IN\1740 1_26\CD\13741022 weekly_27\JJ\1740 injection_28\NN\320852 for_29\IN\1740 7_30\CD\13741022 weeks_31\NNS\15113229 (_32\-LRB-\1740 dose_33\NN\3740161 range_34\NN\5123416 ,_35\,\1740 0.015_36\CD\1740 -_37\SYM\1740 4.0_38\CD\1740 mg/kg_39\NN\1740 body_40\NN\19128 wt_41\NN\1740 )_42\-RRB-\1740 ._43\.\1740
D004317_D009369 NONE <e2>tumor</e2>_0\NN\14234074 regression_1\NN\14501726 was_2\VBD\836236 observed_3\VBN\2163746 with_4\IN\1740 0.5_5\CD\1740 mg_6\NN\13717155 <e1>doxorubicin/kg</e1>_7\NN\1740 ._8\.\1740
D004317_D009369 NONE complete_0\JJ\1740 disappearance_1\NN\42757 of_2\IN\1740 the_3\DT\1740 <e2>tumor</e2>_4\NN\14234074 was_5\VBD\836236 induced_6\VBN\1627355 with_7\IN\1740 1.0_8\CD\1740 mg_9\NN\13717155 <e1>doxorubicin/kg</e1>_10\NN\1740 ._11\.\1740
D004317_D000419 CID light_0\JJ\1740 microscopic_1\JJ\1740 evidence_2\NN\5816287 of_3\IN\1740 renal_4\JJ\1740 damage_5\NN\7296428 was_6\VBD\836236 seen_7\VBN\2106506 above_8\IN\6392001 a_9\DT\13649268 dose_10\NN\3740161 of_11\IN\1740 0.5_12\CD\1740 mg_13\NN\13717155 <e1>doxorubicin/kg</e1>_14\NN\1740 ,_15\,\1740 which_16\WDT\1740 resulted_17\VBD\2633881 in_18\IN\13603305 <e2>albuminuria</e2>_19\NN\14299637 and_20\CC\1740 very_21\RB\1740 low_22\JJ\1740 serum_23\NN\5397468 albumin_24\NN\14736972 levels_25\NNS\4916342 ._26\.\1740
2650911
D004967_D002292 NONE autoradiographic_0\JJ\1740 evidence_1\NN\5816287 of_2\IN\1740 <e1>estrogen</e1>_3\NN\14745635 binding_4\NN\4688246 sites_5\NNS\8673395 in_6\IN\13603305 nuclei_7\NNS\5445668 of_8\IN\1740 diethylstilbesterol_9\NN\15058023 induced_10\VBD\1627355 hamster_11\NN\2329401 <e2>renal_12\JJ\1740 carcinomas</e2>_13\NNS\14239918 ._14\.\1740
D004967_D002292 NONE <e1>estrogen</e1>_0\NN\14745635 binding_1\NN\4688246 sites_2\NNS\8673395 were_3\VBD\836236 demonstrated_4\VBN\2137132 by_5\IN\1740 autoradiography_6\NN\13545382 in_7\IN\13603305 one_8\CD\13741022 transplantable_9\NN\1740 and_10\CC\1740 five_11\CD\13741022 primary_12\JJ\1740 diethylstilbesterol_13\NN\15058023 induced_14\JJ\1740 <e2>renal_15\JJ\1740 carcinomas</e2>_16\NNS\14239918 in_17\IN\13603305 three_18\CD\13741022 hamsters_19\NNS\2329401 ._20\.\1740
D004967_D002292 NONE this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 published_4\VBN\1621555 report_5\NN\6470073 documenting_6\VBG\1000214 the_7\DT\1740 preferential_8\JJ\1740 in_9\FW\13603305 vivo_10\FW\1740 binding_11\NN\4688246 of_12\IN\1740 <e1>estrogen</e1>_13\NN\14745635 to_14\TO\1740 nuclei_15\NNS\5445668 of_16\IN\1740 cells_17\NNS\3080309 in_18\IN\13603305 estrogen_19\NN\14745635 induced_20\JJ\1740 hamster_21\NN\2329401 <e2>renal_22\JJ\1740 carcinomas</e2>_23\NNS\14239918 ._24\.\1740
D004967_D002292 NONE this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 published_4\VBN\1621555 report_5\NN\6470073 documenting_6\VBG\1000214 the_7\DT\1740 preferential_8\JJ\1740 in_9\FW\13603305 vivo_10\FW\1740 binding_11\NN\4688246 of_12\IN\1740 estrogen_13\NN\14745635 to_14\TO\1740 nuclei_15\NNS\5445668 of_16\IN\1740 cells_17\NNS\3080309 in_18\IN\13603305 <e1>estrogen</e1>_19\NN\14745635 induced_20\JJ\1740 hamster_21\NN\2329401 <e2>renal_22\JJ\1740 carcinomas</e2>_23\NNS\14239918 ._24\.\1740
D004054_D002292 CID autoradiographic_0\JJ\1740 evidence_1\NN\5816287 of_2\IN\1740 estrogen_3\NN\14745635 binding_4\NN\4688246 sites_5\NNS\8673395 in_6\IN\13603305 nuclei_7\NNS\5445668 of_8\IN\1740 <e1>diethylstilbesterol</e1>_9\NN\15058023 induced_10\VBD\1627355 hamster_11\NN\2329401 <e2>renal_12\JJ\1740 carcinomas</e2>_13\NNS\14239918 ._14\.\1740
D004054_D002292 CID estrogen_0\NN\14745635 binding_1\NN\4688246 sites_2\NNS\8673395 were_3\VBD\836236 demonstrated_4\VBN\2137132 by_5\IN\1740 autoradiography_6\NN\13545382 in_7\IN\13603305 one_8\CD\13741022 transplantable_9\NN\1740 and_10\CC\1740 five_11\CD\13741022 primary_12\JJ\1740 <e1>diethylstilbesterol</e1>_13\NN\15058023 induced_14\JJ\1740 <e2>renal_15\JJ\1740 carcinomas</e2>_16\NNS\14239918 in_17\IN\13603305 three_18\CD\13741022 hamsters_19\NNS\2329401 ._20\.\1740
D004958_D009369 NONE radiolabelling_0\NNP\1740 ,_1\,\1740 following_2\VBG\1835496 the_3\DT\1740 in_4\FW\13603305 vivo_5\FW\1740 injection_6\NN\320852 of_7\IN\1740 3h-17_8\CD\1740 beta_9\NN\6828818 <e1>estradiol</e1>_10\NN\14749794 ,_11\,\1740 was_12\VBD\836236 increased_13\VBN\169651 only_14\RB\1740 over_15\IN\5867413 the_16\DT\1740 nuclei_17\NNS\5445668 of_18\IN\1740 <e2>tumor</e2>_19\NN\14234074 cells_20\NNS\3080309 ;_21\:\1740 stereologic_22\JJ\1740 analysis_23\NN\633864 revealed_24\VBD\2137132 a_25\DT\13649268 4.5-_26\CD\1740 to_27\TO\1740 6.7-times_28\RB\1740 higher_29\JJR\1740 concentration_30\NN\4916342 of_31\IN\1740 reduced_32\VBN\441445 silver_33\JJ\1740 grains_34\NNS\14585519 over_35\IN\5867413 nuclei_36\NNS\5445668 than_37\IN\1740 cytoplasm_38\NN\5432736 of_39\IN\1740 these_40\DT\1740 cells_41\NNS\3080309 ._42\.\1740
D012834_D009369 NONE radiolabelling_0\NNP\1740 ,_1\,\1740 following_2\VBG\1835496 the_3\DT\1740 in_4\FW\13603305 vivo_5\FW\1740 injection_6\NN\320852 of_7\IN\1740 3h-17_8\CD\1740 beta_9\NN\6828818 estradiol_10\NN\14749794 ,_11\,\1740 was_12\VBD\836236 increased_13\VBN\169651 only_14\RB\1740 over_15\IN\5867413 the_16\DT\1740 nuclei_17\NNS\5445668 of_18\IN\1740 <e2>tumor</e2>_19\NN\14234074 cells_20\NNS\3080309 ;_21\:\1740 stereologic_22\JJ\1740 analysis_23\NN\633864 revealed_24\VBD\2137132 a_25\DT\13649268 4.5-_26\CD\1740 to_27\TO\1740 6.7-times_28\RB\1740 higher_29\JJR\1740 concentration_30\NN\4916342 of_31\IN\1740 reduced_32\VBN\441445 <e1>silver</e1>_33\JJ\1740 grains_34\NNS\14585519 over_35\IN\5867413 nuclei_36\NNS\5445668 than_37\IN\1740 cytoplasm_38\NN\5432736 of_39\IN\1740 these_40\DT\1740 cells_41\NNS\3080309 ._42\.\1740
17297207
D011803_D001145 NONE <e1>quinine-induced</e1>_0\JJ\1740 <e2>arrhythmia</e2>_1\NN\14103288 in_2\IN\13603305 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 malaria_7\NN\14178913 ._8\.\1740
D011803_D001145 NONE it_0\PRP\6125041 was_1\VBD\836236 reported_2\VBN\831651 that_3\IN\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 severe_9\JJ\1740 malaria_10\NN\14178913 patient_11\NN\9898892 with_12\IN\1740 jaundice_13\NN\14299637 who_14\WP\8299493 presented_15\VBD\2137132 with_16\IN\1740 <e2>arrhythmia</e2>_17\NN\14103288 (_18\-LRB-\1740 premature_19\JJ\1740 ventricular_20\JJ\1740 contraction_21\NN\358931 )_22\-RRB-\1740 while_23\IN\15122231 getting_24\VBG\146138 <e1>quinine</e1>_25\NN\2721948 infusion_26\NN\14589223 was_27\VBD\836236 reported_28\VBN\831651 ._29\.\1740
D011803_D001145 NONE <e1>quinine</e1>_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 quinidine_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 <e2>anti-arrhythmic</e2>_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011803_D001145 NONE <e1>quinine</e1>_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 quinidine_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 <e2>pro-arrhythmic</e2>_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011803_D001145 NONE <e1>quinine</e1>_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 quinidine_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 <e2>arrhythmias</e2>_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011803_D001145 NONE <e1>quinine</e1>_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 quinidine_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 <e2>arrhythmia</e2>_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011803_D001145 NONE administration_0\NN\1133281 of_1\IN\1740 parenteral_2\JJ\1740 <e1>quinine</e1>_3\NN\2721948 must_4\MD\9367203 be_5\VB\836236 done_6\VBN\1640855 carefully_7\RB\1740 and_8\CC\1740 with_9\IN\1740 good_10\JJ\1740 observation_11\NN\996969 because_12\IN\1740 of_13\IN\1740 its_14\PRP$\6125041 <e2>pro-arrhythmic</e2>_15\JJ\1740 effect_16\NN\34213 ,_17\,\1740 especially_18\RB\1740 in_19\IN\13603305 older_20\JJR\1740 patients_21\NNS\9898892 who_22\WP\8299493 have_23\VBP\2108377 heart_24\NN\5919034 diseases_25\NNS\14061805 or_26\CC\3541091 patients_27\NNS\9898892 with_28\IN\1740 electrolyte_29\NN\14589223 disorder_30\NN\14034177 (_31\-LRB-\1740 hypokalemia_32\NN\14299637 )_33\-RRB-\1740 which_34\WDT\1740 frequently_35\RB\1740 occurs_36\VBZ\2623529 due_37\JJ\1740 to_38\TO\1740 vomiting_39\NN\116687 and_40\CC\1740 or_41\CC\3541091 diarrhea_42\NN\14299637 in_43\IN\13603305 malaria_44\NN\14178913 cases_45\NNS\7283608 ._46\.\1740
D011803_D016778 NONE <e1>quinine-induced</e1>_0\JJ\1740 arrhythmia_1\NN\14103288 in_2\IN\13603305 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 <e2>severe_6\JJ\1740 malaria</e2>_7\NN\14178913 ._8\.\1740
D011803_D016778 NONE it_0\PRP\6125041 was_1\VBD\836236 reported_2\VBN\831651 that_3\IN\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 <e2>severe_9\JJ\1740 malaria</e2>_10\NN\14178913 patient_11\NN\9898892 with_12\IN\1740 jaundice_13\NN\14299637 who_14\WP\8299493 presented_15\VBD\2137132 with_16\IN\1740 arrhythmia_17\NN\14103288 (_18\-LRB-\1740 premature_19\JJ\1740 ventricular_20\JJ\1740 contraction_21\NN\358931 )_22\-RRB-\1740 while_23\IN\15122231 getting_24\VBG\146138 <e1>quinine</e1>_25\NN\2721948 infusion_26\NN\14589223 was_27\VBD\836236 reported_28\VBN\831651 ._29\.\1740
D011803_D016778 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 <e2>severe_37\JJ\1740 malaria</e2>_38\NN\14178913 with_39\IN\1740 jaundice_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 <e1>quinine</e1>_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D011803_D007565 NONE it_0\PRP\6125041 was_1\VBD\836236 reported_2\VBN\831651 that_3\IN\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 severe_9\JJ\1740 malaria_10\NN\14178913 patient_11\NN\9898892 with_12\IN\1740 <e2>jaundice</e2>_13\NN\14299637 who_14\WP\8299493 presented_15\VBD\2137132 with_16\IN\1740 arrhythmia_17\NN\14103288 (_18\-LRB-\1740 premature_19\JJ\1740 ventricular_20\JJ\1740 contraction_21\NN\358931 )_22\-RRB-\1740 while_23\IN\15122231 getting_24\VBG\146138 <e1>quinine</e1>_25\NN\2721948 infusion_26\NN\14589223 was_27\VBD\836236 reported_28\VBN\831651 ._29\.\1740
D011803_D007565 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 severe_37\JJ\1740 malaria_38\NN\14178913 with_39\IN\1740 <e2>jaundice</e2>_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 <e1>quinine</e1>_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D011803_D018879 CID it_0\PRP\6125041 was_1\VBD\836236 reported_2\VBN\831651 that_3\IN\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 severe_9\JJ\1740 malaria_10\NN\14178913 patient_11\NN\9898892 with_12\IN\1740 jaundice_13\NN\14299637 who_14\WP\8299493 presented_15\VBD\2137132 with_16\IN\1740 arrhythmia_17\NN\14103288 (_18\-LRB-\1740 <e2>premature_19\JJ\1740 ventricular_20\JJ\1740 contraction</e2>_21\NN\358931 )_22\-RRB-\1740 while_23\IN\15122231 getting_24\VBG\146138 <e1>quinine</e1>_25\NN\2721948 infusion_26\NN\14589223 was_27\VBD\836236 reported_28\VBN\831651 ._29\.\1740
D011803_D018879 CID after_0\IN\1740 30_1\CD\13745420 hours_2\NNS\15118228 of_3\IN\1740 <e1>quinine</e1>_4\NN\2721948 infusion_5\NN\14589223 the_6\DT\1740 patient_7\NN\9898892 felt_8\VBD\1462928 palpitation_9\NN\14299637 and_10\CC\1740 electrocardiography_11\NN\177127 (_12\-LRB-\1740 ecg_13\NN\7000195 )_14\-RRB-\1740 recording_15\NN\6791372 showed_16\VBD\2137132 <e2>premature_17\JJ\1740 ventricular_18\JJ\1740 contraction</e2>_19\NN\358931 (_20\-LRB-\1740 pvc_21\NN\15088440 )_22\-RRB-\1740 >_23\NN\1740 5_24\CD\13741022 x/minute_25\NN\1740 ,_26\,\1740 trigemini_27\NN\1740 ,_28\,\1740 constant_29\JJ\1740 type_30\NN\5839024 --_31\:\1740 sinoatrial_32\JJ\1740 block_33\NN\21939 ,_34\,\1740 positive_35\JJ\1740 u_36\NN\14964590 wave_37\NN\7309781 ._38\.\1740
D011803_D018879 CID after_0\IN\1740 30_1\CD\13745420 hours_2\NNS\15118228 of_3\IN\1740 <e1>quinine</e1>_4\NN\2721948 infusion_5\NN\14589223 the_6\DT\1740 patient_7\NN\9898892 felt_8\VBD\1462928 palpitation_9\NN\14299637 and_10\CC\1740 electrocardiography_11\NN\177127 (_12\-LRB-\1740 ecg_13\NN\7000195 )_14\-RRB-\1740 recording_15\NN\6791372 showed_16\VBD\2137132 premature_17\JJ\1740 ventricular_18\JJ\1740 contraction_19\NN\358931 (_20\-LRB-\1740 <e2>pvc</e2>_21\NN\15088440 )_22\-RRB-\1740 >_23\NN\1740 5_24\CD\13741022 x/minute_25\NN\1740 ,_26\,\1740 trigemini_27\NN\1740 ,_28\,\1740 constant_29\JJ\1740 type_30\NN\5839024 --_31\:\1740 sinoatrial_32\JJ\1740 block_33\NN\21939 ,_34\,\1740 positive_35\JJ\1740 u_36\NN\14964590 wave_37\NN\7309781 ._38\.\1740
D011803_D018879 CID <e1>quinine</e1>_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 quinidine_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 <e2>pvc</e2>_30\NN\15088440 ._31\.\1740
D001663_D016778 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 <e1>bilirubin</e1>_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 <e2>severe_37\JJ\1740 malaria</e2>_38\NN\14178913 with_39\IN\1740 jaundice_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D001663_D016778 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 <e1>bilirubin</e1>_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 <e2>severe_37\JJ\1740 malaria</e2>_38\NN\14178913 with_39\IN\1740 jaundice_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D001663_D016778 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 <e1>bilirubin</e1>_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 <e2>severe_37\JJ\1740 malaria</e2>_38\NN\14178913 with_39\IN\1740 jaundice_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D001663_D007565 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 <e1>bilirubin</e1>_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 severe_37\JJ\1740 malaria_38\NN\14178913 with_39\IN\1740 <e2>jaundice</e2>_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D001663_D007565 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 <e1>bilirubin</e1>_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 severe_37\JJ\1740 malaria_38\NN\14178913 with_39\IN\1740 <e2>jaundice</e2>_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D001663_D007565 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 <e1>bilirubin</e1>_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 severe_37\JJ\1740 malaria_38\NN\14178913 with_39\IN\1740 <e2>jaundice</e2>_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D011188_D016778 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 <e1>potassium</e1>_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 <e2>severe_37\JJ\1740 malaria</e2>_38\NN\14178913 with_39\IN\1740 jaundice_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D011188_D007565 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 <e1>potassium</e1>_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 severe_37\JJ\1740 malaria_38\NN\14178913 with_39\IN\1740 <e2>jaundice</e2>_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 dextrose_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D005947_D016778 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 <e2>severe_37\JJ\1740 malaria</e2>_38\NN\14178913 with_39\IN\1740 jaundice_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 <e1>dextrose</e1>_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D005947_D007565 NONE on_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 laboratory_3\NN\4602044 examination_4\NN\633864 showed_5\VBD\2137132 plasmodium_6\NN\5432948 falciparum_7\NN\1740 (_8\-LRB-\1740 +_9\CC\1740 +_10\CC\1740 +_11\CC\1740 +_12\CC\1740 )_13\-RRB-\1740 ,_14\,\1740 total_15\JJ\1740 bilirubin_16\NN\14756039 8.25_17\CD\1740 mg/dl_18\NN\1740 ,_19\,\1740 conjugated_20\VBN\394813 bilirubin_21\NN\14756039 4.36_22\CD\1740 mg/dl_23\NN\1740 ,_24\,\1740 unconjugated_25\JJ\1740 bilirubin_26\NN\14756039 3.89_27\CD\1740 mg/dl_28\VBN\1740 ,_29\,\1740 potassium_30\NN\14625458 3.52_31\CD\1740 meq/l_32\NN\1740 patient_33\NN\9898892 was_34\VBD\836236 diagnosed_35\VBN\644583 as_36\IN\14622893 severe_37\JJ\1740 malaria_38\NN\14178913 with_39\IN\1740 <e2>jaundice</e2>_40\NN\14299637 and_41\CC\1740 got_42\VBD\146138 quinine_43\NN\2721948 infusion_44\NN\14589223 in_45\IN\13603305 <e1>dextrose</e1>_46\NN\14884120 5_47\CD\13741022 %_48\NN\1740 500_49\CD\13745420 mg/8_50\NN\1740 hour_51\NN\15154774 ._52\.\1740
D011803_-1 NONE after_0\IN\1740 30_1\CD\13745420 hours_2\NNS\15118228 of_3\IN\1740 <e1>quinine</e1>_4\NN\2721948 infusion_5\NN\14589223 the_6\DT\1740 patient_7\NN\9898892 felt_8\VBD\1462928 <e2>palpitation</e2>_9\NN\14299637 and_10\CC\1740 electrocardiography_11\NN\177127 (_12\-LRB-\1740 ecg_13\NN\7000195 )_14\-RRB-\1740 recording_15\NN\6791372 showed_16\VBD\2137132 premature_17\JJ\1740 ventricular_18\JJ\1740 contraction_19\NN\358931 (_20\-LRB-\1740 pvc_21\NN\15088440 )_22\-RRB-\1740 >_23\NN\1740 5_24\CD\13741022 x/minute_25\NN\1740 ,_26\,\1740 trigemini_27\NN\1740 ,_28\,\1740 constant_29\JJ\1740 type_30\NN\5839024 --_31\:\1740 sinoatrial_32\JJ\1740 block_33\NN\21939 ,_34\,\1740 positive_35\JJ\1740 u_36\NN\14964590 wave_37\NN\7309781 ._38\.\1740
D011803_D012848 NONE after_0\IN\1740 30_1\CD\13745420 hours_2\NNS\15118228 of_3\IN\1740 <e1>quinine</e1>_4\NN\2721948 infusion_5\NN\14589223 the_6\DT\1740 patient_7\NN\9898892 felt_8\VBD\1462928 palpitation_9\NN\14299637 and_10\CC\1740 electrocardiography_11\NN\177127 (_12\-LRB-\1740 ecg_13\NN\7000195 )_14\-RRB-\1740 recording_15\NN\6791372 showed_16\VBD\2137132 premature_17\JJ\1740 ventricular_18\JJ\1740 contraction_19\NN\358931 (_20\-LRB-\1740 pvc_21\NN\15088440 )_22\-RRB-\1740 >_23\NN\1740 5_24\CD\13741022 x/minute_25\NN\1740 ,_26\,\1740 trigemini_27\NN\1740 ,_28\,\1740 constant_29\JJ\1740 type_30\NN\5839024 --_31\:\1740 <e2>sinoatrial_32\JJ\1740 block</e2>_33\NN\21939 ,_34\,\1740 positive_35\JJ\1740 u_36\NN\14964590 wave_37\NN\7309781 ._38\.\1740
D011188_D018879 NONE three_0\CD\13741022 hours_1\NNS\15118228 later_2\RB\1740 the_3\DT\1740 patient_4\NN\9898892 felt_5\VBD\1462928 better_6\RBR\1740 ,_7\,\1740 the_8\DT\1740 frequency_9\NN\15286249 of_10\IN\1740 <e2>pvc</e2>_11\NN\15088440 reduced_12\VBD\441445 to_13\TO\1740 4_14\CD\13741022 -_15\SYM\1740 5_16\CD\13741022 x/minute_17\NN\1740 and_18\CC\1740 on_19\IN\1740 the_20\DT\1740 third_21\JJ\1740 day_22\NN\15154774 ecg_23\NNP\7000195 was_24\VBD\836236 normal_25\JJ\1740 ,_26\,\1740 <e1>potassium</e1>_27\NN\14625458 level_28\NN\4916342 was_29\VBD\836236 3.34_30\CD\1740 meq/l._31\NNS\1740 he_32\PRP\14622893 was_33\VBD\836236 discharged_34\VBN\1640855 on_35\IN\1740 7th_36\JJ\1740 day_37\NN\15154774 in_38\IN\13603305 good_39\JJ\1740 condition_40\NN\24720 ._41\.\1740
D011802_D001145 NONE quinine_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 <e1>quinidine</e1>_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 <e2>anti-arrhythmic</e2>_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011802_D001145 NONE quinine_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 <e1>quinidine</e1>_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 <e2>pro-arrhythmic</e2>_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011802_D001145 NONE quinine_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 <e1>quinidine</e1>_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 <e2>arrhythmias</e2>_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011802_D001145 NONE quinine_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 <e1>quinidine</e1>_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 <e2>arrhythmia</e2>_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 pvc_30\NN\15088440 ._31\.\1740
D011802_D018879 NONE quinine_0\NNP\2721948 ,_1\,\1740 like_2\UH\5839024 <e1>quinidine</e1>_3\NN\2715941 ,_4\,\1740 is_5\VBZ\836236 a_6\DT\13649268 chincona_7\NN\1740 alkaloid_8\NN\14727670 that_9\WDT\1740 has_10\VBZ\2108377 anti-arrhythmic_11\JJ\1740 property_12\NN\32613 ,_13\,\1740 although_14\IN\1740 it_15\PRP\6125041 also_16\RB\1740 pro-arrhythmic_17\JJ\1740 that_18\WDT\1740 can_19\MD\3094503 cause_20\VB\1617192 various_21\JJ\1740 arrhythmias_22\NNS\14103288 ,_23\,\1740 including_24\VBG\690614 severe_25\JJ\1740 arrhythmia_26\NN\14103288 such_27\JJ\1740 as_28\IN\14622893 multiple_29\JJ\1740 <e2>pvc</e2>_30\NN\15088440 ._31\.\1740
D011803_D006331 NONE administration_0\NN\1133281 of_1\IN\1740 parenteral_2\JJ\1740 <e1>quinine</e1>_3\NN\2721948 must_4\MD\9367203 be_5\VB\836236 done_6\VBN\1640855 carefully_7\RB\1740 and_8\CC\1740 with_9\IN\1740 good_10\JJ\1740 observation_11\NN\996969 because_12\IN\1740 of_13\IN\1740 its_14\PRP$\6125041 pro-arrhythmic_15\JJ\1740 effect_16\NN\34213 ,_17\,\1740 especially_18\RB\1740 in_19\IN\13603305 older_20\JJR\1740 patients_21\NNS\9898892 who_22\WP\8299493 have_23\VBP\2108377 <e2>heart_24\NN\5919034 diseases</e2>_25\NNS\14061805 or_26\CC\3541091 patients_27\NNS\9898892 with_28\IN\1740 electrolyte_29\NN\14589223 disorder_30\NN\14034177 (_31\-LRB-\1740 hypokalemia_32\NN\14299637 )_33\-RRB-\1740 which_34\WDT\1740 frequently_35\RB\1740 occurs_36\VBZ\2623529 due_37\JJ\1740 to_38\TO\1740 vomiting_39\NN\116687 and_40\CC\1740 or_41\CC\3541091 diarrhea_42\NN\14299637 in_43\IN\13603305 malaria_44\NN\14178913 cases_45\NNS\7283608 ._46\.\1740
D011803_D014883 NONE administration_0\NN\1133281 of_1\IN\1740 parenteral_2\JJ\1740 <e1>quinine</e1>_3\NN\2721948 must_4\MD\9367203 be_5\VB\836236 done_6\VBN\1640855 carefully_7\RB\1740 and_8\CC\1740 with_9\IN\1740 good_10\JJ\1740 observation_11\NN\996969 because_12\IN\1740 of_13\IN\1740 its_14\PRP$\6125041 pro-arrhythmic_15\JJ\1740 effect_16\NN\34213 ,_17\,\1740 especially_18\RB\1740 in_19\IN\13603305 older_20\JJR\1740 patients_21\NNS\9898892 who_22\WP\8299493 have_23\VBP\2108377 heart_24\NN\5919034 diseases_25\NNS\14061805 or_26\CC\3541091 patients_27\NNS\9898892 with_28\IN\1740 <e2>electrolyte_29\NN\14589223 disorder</e2>_30\NN\14034177 (_31\-LRB-\1740 hypokalemia_32\NN\14299637 )_33\-RRB-\1740 which_34\WDT\1740 frequently_35\RB\1740 occurs_36\VBZ\2623529 due_37\JJ\1740 to_38\TO\1740 vomiting_39\NN\116687 and_40\CC\1740 or_41\CC\3541091 diarrhea_42\NN\14299637 in_43\IN\13603305 malaria_44\NN\14178913 cases_45\NNS\7283608 ._46\.\1740
D011803_D007008 NONE administration_0\NN\1133281 of_1\IN\1740 parenteral_2\JJ\1740 <e1>quinine</e1>_3\NN\2721948 must_4\MD\9367203 be_5\VB\836236 done_6\VBN\1640855 carefully_7\RB\1740 and_8\CC\1740 with_9\IN\1740 good_10\JJ\1740 observation_11\NN\996969 because_12\IN\1740 of_13\IN\1740 its_14\PRP$\6125041 pro-arrhythmic_15\JJ\1740 effect_16\NN\34213 ,_17\,\1740 especially_18\RB\1740 in_19\IN\13603305 older_20\JJR\1740 patients_21\NNS\9898892 who_22\WP\8299493 have_23\VBP\2108377 heart_24\NN\5919034 diseases_25\NNS\14061805 or_26\CC\3541091 patients_27\NNS\9898892 with_28\IN\1740 electrolyte_29\NN\14589223 disorder_30\NN\14034177 (_31\-LRB-\1740 <e2>hypokalemia</e2>_32\NN\14299637 )_33\-RRB-\1740 which_34\WDT\1740 frequently_35\RB\1740 occurs_36\VBZ\2623529 due_37\JJ\1740 to_38\TO\1740 vomiting_39\NN\116687 and_40\CC\1740 or_41\CC\3541091 diarrhea_42\NN\14299637 in_43\IN\13603305 malaria_44\NN\14178913 cases_45\NNS\7283608 ._46\.\1740
D011803_D014839 NONE administration_0\NN\1133281 of_1\IN\1740 parenteral_2\JJ\1740 <e1>quinine</e1>_3\NN\2721948 must_4\MD\9367203 be_5\VB\836236 done_6\VBN\1640855 carefully_7\RB\1740 and_8\CC\1740 with_9\IN\1740 good_10\JJ\1740 observation_11\NN\996969 because_12\IN\1740 of_13\IN\1740 its_14\PRP$\6125041 pro-arrhythmic_15\JJ\1740 effect_16\NN\34213 ,_17\,\1740 especially_18\RB\1740 in_19\IN\13603305 older_20\JJR\1740 patients_21\NNS\9898892 who_22\WP\8299493 have_23\VBP\2108377 heart_24\NN\5919034 diseases_25\NNS\14061805 or_26\CC\3541091 patients_27\NNS\9898892 with_28\IN\1740 electrolyte_29\NN\14589223 disorder_30\NN\14034177 (_31\-LRB-\1740 hypokalemia_32\NN\14299637 )_33\-RRB-\1740 which_34\WDT\1740 frequently_35\RB\1740 occurs_36\VBZ\2623529 due_37\JJ\1740 to_38\TO\1740 <e2>vomiting</e2>_39\NN\116687 and_40\CC\1740 or_41\CC\3541091 diarrhea_42\NN\14299637 in_43\IN\13603305 malaria_44\NN\14178913 cases_45\NNS\7283608 ._46\.\1740
D011803_D003967 NONE administration_0\NN\1133281 of_1\IN\1740 parenteral_2\JJ\1740 <e1>quinine</e1>_3\NN\2721948 must_4\MD\9367203 be_5\VB\836236 done_6\VBN\1640855 carefully_7\RB\1740 and_8\CC\1740 with_9\IN\1740 good_10\JJ\1740 observation_11\NN\996969 because_12\IN\1740 of_13\IN\1740 its_14\PRP$\6125041 pro-arrhythmic_15\JJ\1740 effect_16\NN\34213 ,_17\,\1740 especially_18\RB\1740 in_19\IN\13603305 older_20\JJR\1740 patients_21\NNS\9898892 who_22\WP\8299493 have_23\VBP\2108377 heart_24\NN\5919034 diseases_25\NNS\14061805 or_26\CC\3541091 patients_27\NNS\9898892 with_28\IN\1740 electrolyte_29\NN\14589223 disorder_30\NN\14034177 (_31\-LRB-\1740 hypokalemia_32\NN\14299637 )_33\-RRB-\1740 which_34\WDT\1740 frequently_35\RB\1740 occurs_36\VBZ\2623529 due_37\JJ\1740 to_38\TO\1740 vomiting_39\NN\116687 and_40\CC\1740 or_41\CC\3541091 <e2>diarrhea</e2>_42\NN\14299637 in_43\IN\13603305 malaria_44\NN\14178913 cases_45\NNS\7283608 ._46\.\1740
D011803_D008288 NONE administration_0\NN\1133281 of_1\IN\1740 parenteral_2\JJ\1740 <e1>quinine</e1>_3\NN\2721948 must_4\MD\9367203 be_5\VB\836236 done_6\VBN\1640855 carefully_7\RB\1740 and_8\CC\1740 with_9\IN\1740 good_10\JJ\1740 observation_11\NN\996969 because_12\IN\1740 of_13\IN\1740 its_14\PRP$\6125041 pro-arrhythmic_15\JJ\1740 effect_16\NN\34213 ,_17\,\1740 especially_18\RB\1740 in_19\IN\13603305 older_20\JJR\1740 patients_21\NNS\9898892 who_22\WP\8299493 have_23\VBP\2108377 heart_24\NN\5919034 diseases_25\NNS\14061805 or_26\CC\3541091 patients_27\NNS\9898892 with_28\IN\1740 electrolyte_29\NN\14589223 disorder_30\NN\14034177 (_31\-LRB-\1740 hypokalemia_32\NN\14299637 )_33\-RRB-\1740 which_34\WDT\1740 frequently_35\RB\1740 occurs_36\VBZ\2623529 due_37\JJ\1740 to_38\TO\1740 vomiting_39\NN\116687 and_40\CC\1740 or_41\CC\3541091 diarrhea_42\NN\14299637 in_43\IN\13603305 <e2>malaria</e2>_44\NN\14178913 cases_45\NNS\7283608 ._46\.\1740
3084231
D014635_D003704 CID reversible_0\JJ\1740 <e1>valproic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 <e2>dementia</e2>_3\NN\14395018 :_4\:\1740 a_5\DT\13649268 case_6\NN\7283608 report_7\NN\6470073 ._8\.\1740
D014635_D003704 CID reversible_0\JJ\1740 <e1>valproic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 <e2>dementia</e2>_3\NN\14395018 was_4\VBD\836236 documented_5\VBN\1000214 in_6\IN\13603305 a_7\DT\13649268 21-year-old_8\JJ\1740 man_9\NN\9605289 with_10\IN\1740 epilepsy_11\NN\14085708 who_12\WP\8299493 had_13\VBD\2108377 a_14\DT\13649268 3-year_15\JJ\1740 history_16\NN\15120823 of_17\IN\1740 insidious_18\JJ\1740 progressive_19\JJ\1740 decline_20\NN\13458571 in_21\IN\13603305 global_22\JJ\1740 cognitive_23\JJ\1740 abilities_24\NNS\4723816 documented_25\VBN\1000214 by_26\IN\1740 serial_27\JJ\1740 neuropsychological_28\JJ\1740 studies_29\NNS\635850 ._30\.\1740
D014635_D004827 NONE reversible_0\JJ\1740 <e1>valproic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 dementia_3\NN\14395018 was_4\VBD\836236 documented_5\VBN\1000214 in_6\IN\13603305 a_7\DT\13649268 21-year-old_8\JJ\1740 man_9\NN\9605289 with_10\IN\1740 <e2>epilepsy</e2>_11\NN\14085708 who_12\WP\8299493 had_13\VBD\2108377 a_14\DT\13649268 3-year_15\JJ\1740 history_16\NN\15120823 of_17\IN\1740 insidious_18\JJ\1740 progressive_19\JJ\1740 decline_20\NN\13458571 in_21\IN\13603305 global_22\JJ\1740 cognitive_23\JJ\1740 abilities_24\NNS\4723816 documented_25\VBN\1000214 by_26\IN\1740 serial_27\JJ\1740 neuropsychological_28\JJ\1740 studies_29\NNS\635850 ._30\.\1740
D014635_D022124 CID possible_0\JJ\1740 pathophysiological_1\JJ\1740 mechanisms_2\NNS\13446390 which_3\WDT\1740 may_4\MD\15209706 have_5\VB\2108377 been_6\VBN\836236 operative_7\JJ\1740 in_8\IN\13603305 this_9\DT\1740 case_10\NN\7283608 include_11\VBP\690614 :_12\:\1740 a_13\DT\13649268 direct_14\JJ\1740 central_15\JJ\1740 nervous_16\JJ\1740 system_17\NN\3575240 (_18\-LRB-\1740 cns_19\NN\5237227 )_20\-RRB-\1740 toxic_21\JJ\1740 effect_22\NN\34213 of_23\IN\1740 <e1>valproic_24\JJ\1740 acid</e1>_25\NN\14818238 ;_26\:\1740 a_27\DT\13649268 paradoxical_28\JJ\1740 epileptogenic_29\JJ\1740 effect_30\NN\34213 secondary_31\JJ\1740 to_32\TO\1740 the_33\DT\1740 drug_34\NN\14778436 ;_35\:\1740 and_36\CC\1740 an_37\DT\6697703 indirect_38\JJ\1740 cns_39\NN\5237227 toxic_40\JJ\1740 effect_41\NN\34213 mediated_42\VBN\761713 through_43\IN\1740 valproic_44\JJ\1740 acid-induced_45\JJ\1740 <e2>hyperammonemia</e2>_46\NN\1740 ._47\.\1740
D014635_D022124 CID possible_0\JJ\1740 pathophysiological_1\JJ\1740 mechanisms_2\NNS\13446390 which_3\WDT\1740 may_4\MD\15209706 have_5\VB\2108377 been_6\VBN\836236 operative_7\JJ\1740 in_8\IN\13603305 this_9\DT\1740 case_10\NN\7283608 include_11\VBP\690614 :_12\:\1740 a_13\DT\13649268 direct_14\JJ\1740 central_15\JJ\1740 nervous_16\JJ\1740 system_17\NN\3575240 (_18\-LRB-\1740 cns_19\NN\5237227 )_20\-RRB-\1740 toxic_21\JJ\1740 effect_22\NN\34213 of_23\IN\1740 valproic_24\JJ\1740 acid_25\NN\14818238 ;_26\:\1740 a_27\DT\13649268 paradoxical_28\JJ\1740 epileptogenic_29\JJ\1740 effect_30\NN\34213 secondary_31\JJ\1740 to_32\TO\1740 the_33\DT\1740 drug_34\NN\14778436 ;_35\:\1740 and_36\CC\1740 an_37\DT\6697703 indirect_38\JJ\1740 cns_39\NN\5237227 toxic_40\JJ\1740 effect_41\NN\34213 mediated_42\VBN\761713 through_43\IN\1740 <e1>valproic_44\JJ\1740 acid-induced</e1>_45\JJ\1740 <e2>hyperammonemia</e2>_46\NN\1740 ._47\.\1740
2083961
D012293_D058186 CID <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 due_3\JJ\1740 to_4\TO\1740 <e1>rifampicin</e1>_5\NN\1740 ._6\.\1740
D012293_D009325 NONE <e1>rifampicin</e1>_0\NN\1740 was_1\VBD\836236 administered_2\VBN\2436349 thrice_3\NN\1740 as_4\IN\14622893 one_5\CD\13741022 of_6\IN\1740 the_7\DT\1740 3_8\CD\13741022 -_9\SYM\1740 4_10\CD\13741022 drug_11\NN\14778436 regimen_12\NN\5898568 and_13\CC\1740 each_14\DT\1740 time_15\NN\7308889 he_16\PRP\14622893 developed_17\VBD\1753788 untoward_18\JJ\1740 side_19\NN\8630039 effects_20\NNS\13245626 like_21\IN\5839024 <e2>nausea</e2>_22\NN\14299637 ,_23\,\1740 vomiting_24\NN\116687 and_25\CC\1740 fever_26\NN\14299637 with_27\IN\1740 chills_28\NNS\5015117 and_29\CC\1740 rigors_30\NNS\4709253 ._31\.\1740
D012293_D014839 NONE <e1>rifampicin</e1>_0\NN\1740 was_1\VBD\836236 administered_2\VBN\2436349 thrice_3\NN\1740 as_4\IN\14622893 one_5\CD\13741022 of_6\IN\1740 the_7\DT\1740 3_8\CD\13741022 -_9\SYM\1740 4_10\CD\13741022 drug_11\NN\14778436 regimen_12\NN\5898568 and_13\CC\1740 each_14\DT\1740 time_15\NN\7308889 he_16\PRP\14622893 developed_17\VBD\1753788 untoward_18\JJ\1740 side_19\NN\8630039 effects_20\NNS\13245626 like_21\IN\5839024 nausea_22\NN\14299637 ,_23\,\1740 <e2>vomiting</e2>_24\NN\116687 and_25\CC\1740 fever_26\NN\14299637 with_27\IN\1740 chills_28\NNS\5015117 and_29\CC\1740 rigors_30\NNS\4709253 ._31\.\1740
D012293_D005334 NONE <e1>rifampicin</e1>_0\NN\1740 was_1\VBD\836236 administered_2\VBN\2436349 thrice_3\NN\1740 as_4\IN\14622893 one_5\CD\13741022 of_6\IN\1740 the_7\DT\1740 3_8\CD\13741022 -_9\SYM\1740 4_10\CD\13741022 drug_11\NN\14778436 regimen_12\NN\5898568 and_13\CC\1740 each_14\DT\1740 time_15\NN\7308889 he_16\PRP\14622893 developed_17\VBD\1753788 untoward_18\JJ\1740 side_19\NN\8630039 effects_20\NNS\13245626 like_21\IN\5839024 nausea_22\NN\14299637 ,_23\,\1740 vomiting_24\NN\116687 and_25\CC\1740 <e2>fever</e2>_26\NN\14299637 with_27\IN\1740 chills_28\NNS\5015117 and_29\CC\1740 rigors_30\NNS\4709253 ._31\.\1740
23949582
D015080_D030342 NONE <e1>mesna</e1>_0\NN\1740 significantly_1\RB\1740 reduces_2\VBZ\441445 ifo_3\NN\1740 's_4\POS\1740 <e2>genotoxicity</e2>_5\NN\1740 ,_6\,\1740 while_7\IN\15122231 when_8\WRB\1740 administered_9\VBN\2436349 in_10\IN\13603305 high_11\JJ\1740 concentrations_12\NNS\4916342 it_13\PRP\6125041 acts_14\VBZ\1619354 in_15\IN\13603305 an_16\DT\6697703 inhibitory_17\JJ\1740 fashion_18\NN\4916342 on_19\IN\1740 the_20\DT\1740 cytostatic_21\JJ\1740 action_22\NN\30358 of_23\IN\1740 the_24\DT\1740 drug_25\NN\14778436 ._26\.\1740
D007069_D030342 NONE mesna_0\NN\1740 significantly_1\RB\1740 reduces_2\VBZ\441445 <e1>ifo</e1>_3\NN\1740 's_4\POS\1740 <e2>genotoxicity</e2>_5\NN\1740 ,_6\,\1740 while_7\IN\15122231 when_8\WRB\1740 administered_9\VBN\2436349 in_10\IN\13603305 high_11\JJ\1740 concentrations_12\NNS\4916342 it_13\PRP\6125041 acts_14\VBZ\1619354 in_15\IN\13603305 an_16\DT\6697703 inhibitory_17\JJ\1740 fashion_18\NN\4916342 on_19\IN\1740 the_20\DT\1740 cytostatic_21\JJ\1740 action_22\NN\30358 of_23\IN\1740 the_24\DT\1740 drug_25\NN\14778436 ._26\.\1740
19154241
D008094_D006961 CID long-term_0\JJ\1740 <e1>lithium</e1>_1\NN\14625458 therapy_2\NN\657604 leading_3\VBG\1752884 to_4\TO\1740 <e2>hyperparathyroidism</e2>_5\NN\14059928 :_6\:\1740 a_7\DT\13649268 case_8\NN\7283608 report_9\NN\6470073 ._10\.\1740
D008094_D006934 CID we_0\PRP\1740 examined_1\VBD\789138 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 <e1>lithium-treated</e1>_6\JJ\1740 patient_7\NN\9898892 who_8\WP\8299493 had_9\VBD\2108377 recurrent_10\JJ\1740 <e2>hypercalcemia</e2>_11\NN\14299637 to_12\TO\1740 better_13\RBR\1740 understand_14\VB\588888 the_15\DT\1740 disease_16\NN\14061805 process_17\NN\407535 ._18\.\1740
D008094_D006934 CID practical_0\NN\1740 implications_1\NN\5774614 :_2\:\1740 as_3\RB\1740 much_4\JJ\1740 as_5\IN\14622893 15_6\CD\13745420 %_7\NN\1740 of_8\IN\1740 <e1>lithium-treated</e1>_9\JJ\1740 patients_10\NNS\9898892 become_11\VBP\146138 <e2>hypercalcemic</e2>_12\JJ\1740 ._13\.\1740
D008094_D049950 NONE conclusion_0\NN\5837957 :_1\:\1740 <e2>primary_2\JJ\1740 hyperparathyroidism</e2>_3\NN\14059928 is_4\VBZ\836236 a_5\DT\13649268 rare_6\JJ\1740 but_7\CC\1740 potentially_8\RB\1740 life-threatening_9\JJ\1740 side_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 long-term_13\JJ\1740 <e1>lithium</e1>_14\NN\14625458 therapy_15\NN\657604 ._16\.\1740
8318674
D003561_D011654 CID <e2>pulmonary_0\JJ\1740 edema</e2>_1\NN\14315192 and_2\CC\1740 shock_3\NN\7510495 after_4\IN\1740 high-dose_5\JJ\1740 <e1>aracytine-c</e1>_6\NN\1740 for_7\IN\1740 lymphoma_8\NN\14239918 ;_9\:\1740 possible_10\JJ\1740 role_11\NN\719494 of_12\IN\1740 tnf-alpha_13\NN\1740 and_14\CC\1740 paf_15\NN\1740 ._16\.\1740
D003561_D012769 CID pulmonary_0\JJ\1740 edema_1\NN\14315192 and_2\CC\1740 <e2>shock</e2>_3\NN\7510495 after_4\IN\1740 high-dose_5\JJ\1740 <e1>aracytine-c</e1>_6\NN\1740 for_7\IN\1740 lymphoma_8\NN\14239918 ;_9\:\1740 possible_10\JJ\1740 role_11\NN\719494 of_12\IN\1740 tnf-alpha_13\NN\1740 and_14\CC\1740 paf_15\NN\1740 ._16\.\1740
D003561_D012769 CID as_0\IN\14622893 tnf_1\NN\14828193 and_2\CC\1740 paf_3\NN\1740 are_4\VBP\836236 thought_5\VBN\670261 to_6\TO\1740 be_7\VB\836236 involved_8\VBN\2676054 in_9\IN\13603305 the_10\DT\1740 development_11\NN\248977 of_12\IN\1740 septic_13\JJ\1740 <e2>shock</e2>_14\NN\7510495 and_15\CC\1740 adult_16\JJ\1740 respiratory_17\JJ\1740 distress_18\NN\7494363 syndrome_19\NN\5870365 ,_20\,\1740 we_21\PRP\1740 hypothesize_22\VBP\719734 that_23\IN\1740 high-dose_24\JJ\1740 <e1>ara-c</e1>_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 associated_28\VBN\628491 with_29\IN\1740 cytokine_30\NN\14728724 release_31\NN\3748886 ._32\.\1740
D003561_D008223 NONE pulmonary_0\JJ\1740 edema_1\NN\14315192 and_2\CC\1740 shock_3\NN\7510495 after_4\IN\1740 high-dose_5\JJ\1740 <e1>aracytine-c</e1>_6\NN\1740 for_7\IN\1740 <e2>lymphoma</e2>_8\NN\14239918 ;_9\:\1740 possible_10\JJ\1740 role_11\NN\719494 of_12\IN\1740 tnf-alpha_13\NN\1740 and_14\CC\1740 paf_15\NN\1740 ._16\.\1740
D003561_D008223 NONE four_0\CD\13741022 out_1\IN\66636 of_2\IN\1740 23_3\CD\13745420 consecutive_4\JJ\1740 patients_5\NNS\9898892 treated_6\VBN\2376958 with_7\IN\1740 high-dose_8\JJ\1740 <e1>ara-c</e1>_9\NN\1740 for_10\IN\1740 <e2>lymphomas</e2>_11\NNS\14239918 in_12\IN\13603305 our_13\PRP$\1740 institution_14\NN\8008335 developed_15\VBD\1753788 a_16\DT\13649268 strikingly_17\RB\1740 similar_18\JJ\1740 syndrome_19\NN\5870365 during_20\IN\1740 the_21\DT\1740 perfusion_22\NN\320852 ._23\.\1740
D003561_D012128 NONE as_0\IN\14622893 tnf_1\NN\14828193 and_2\CC\1740 paf_3\NN\1740 are_4\VBP\836236 thought_5\VBN\670261 to_6\TO\1740 be_7\VB\836236 involved_8\VBN\2676054 in_9\IN\13603305 the_10\DT\1740 development_11\NN\248977 of_12\IN\1740 septic_13\JJ\1740 shock_14\NN\7510495 and_15\CC\1740 <e2>adult_16\JJ\1740 respiratory_17\JJ\1740 distress_18\NN\7494363 syndrome</e2>_19\NN\5870365 ,_20\,\1740 we_21\PRP\1740 hypothesize_22\VBP\719734 that_23\IN\1740 high-dose_24\JJ\1740 <e1>ara-c</e1>_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 associated_28\VBN\628491 with_29\IN\1740 cytokine_30\NN\14728724 release_31\NN\3748886 ._32\.\1740
19338378
C031942_D013921 NONE reducing_0\VBG\441445 harm_1\NN\14052046 associated_2\VBN\628491 with_3\IN\1740 anticoagulation_4\NN\657604 :_5\:\1740 practical_6\JJ\1740 considerations_7\NNS\5770926 of_8\IN\1740 <e1>argatroban</e1>_9\NN\1740 therapy_10\NN\657604 in_11\IN\13603305 heparin-induced_12\JJ\1740 <e2>thrombocytopenia</e2>_13\NN\14189204 ._14\.\1740
C031942_D013921 NONE <e1>argatroban</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 thrombosis_15\NN\14100769 in_16\IN\13603305 heparin-induced_17\JJ\1740 <e2>thrombocytopenia</e2>_18\NN\14189204 (_19\-LRB-\1740 hit_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 hit_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
C031942_D013921 NONE <e1>argatroban</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 thrombosis_15\NN\14100769 in_16\IN\13603305 heparin-induced_17\JJ\1740 thrombocytopenia_18\NN\14189204 (_19\-LRB-\1740 <e2>hit</e2>_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 hit_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
C031942_D013921 NONE <e1>argatroban</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 thrombosis_15\NN\14100769 in_16\IN\13603305 heparin-induced_17\JJ\1740 thrombocytopenia_18\NN\14189204 (_19\-LRB-\1740 hit_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 <e2>hit</e2>_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
C031942_D013921 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 review_4\NN\5733583 is_5\VBZ\836236 to_6\TO\1740 summarize_7\VB\958334 practical_8\JJ\1740 considerations_9\NNS\5770926 of_10\IN\1740 <e1>argatroban</e1>_11\NN\1740 therapy_12\NN\657604 in_13\IN\13603305 <e2>hit</e2>_14\NN\36762 ._15\.\1740
C031942_D013921 NONE the_0\DT\1740 us_1\NNP\14964590 fda-recommended_2\JJ\1740 <e1>argatroban</e1>_3\NN\1740 dose_4\NN\3740161 in_5\IN\13603305 <e2>hit</e2>_6\NN\36762 is_7\VBZ\836236 2_8\CD\13741022 microg/kg/min_9\NN\1740 (_10\-LRB-\1740 reduced_11\VBN\441445 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 hepatic_15\JJ\1740 impairment_16\NN\7296428 and_17\CC\1740 in_18\IN\13603305 paediatric_19\JJ\1740 patients_20\NNS\9898892 )_21\-RRB-\1740 ,_22\,\1740 adjusted_23\VBN\126264 to_24\TO\1740 achieve_25\VB\2524171 activated_26\VBN\1641914 partial_27\JJ\1740 thromboplastin_28\NN\15022776 times_29\NNS\15113229 (_30\-LRB-\1740 aptts_31\NNS\1740 )_32\-RRB-\1740 1.5_33\CD\1740 -_34\SYM\1740 3_35\CD\13741022 times_36\NNS\15113229 baseline_37\NN\7260623 (_38\-LRB-\1740 not_39\RB\1740 >_40\NNS\1740 100_41\CD\13745420 seconds_42\NNS\15154774 )_43\-RRB-\1740 ._44\.\1740
C031942_D013921 NONE improved_0\VBN\126264 familiarity_1\NN\5816287 of_2\IN\1740 healthcare_3\NN\654885 professionals_4\NNS\9605289 with_5\IN\1740 <e1>argatroban</e1>_6\JJ\1740 therapy_7\NN\657604 in_8\IN\13603305 <e2>hit</e2>_9\NN\36762 ,_10\,\1740 including_11\VBG\690614 in_12\IN\13603305 special_13\JJ\1740 populations_14\NNS\7942152 and_15\CC\1740 during_16\IN\1740 pci_17\NN\1740 ,_18\,\1740 may_19\MD\15209706 facilitate_20\VB\2547586 reduction_21\NN\351485 of_22\IN\1740 harm_23\NN\14052046 associated_24\VBN\628491 with_25\IN\1740 hit_26\NN\36762 (_27\-LRB-\1740 e.g._28\FW\1740 fewer_29\JJR\1740 thromboses_30\NNS\1740 )_31\-RRB-\1740 or_32\CC\3541091 its_33\PRP$\6125041 treatment_34\NN\654885 (_35\-LRB-\1740 e.g._36\FW\1740 fewer_37\JJR\1740 argatroban_38\JJ\1740 medication_39\NN\3247620 errors_40\NNS\66216 )_41\-RRB-\1740 ._42\.\1740
C031942_D013921 NONE improved_0\VBN\126264 familiarity_1\NN\5816287 of_2\IN\1740 healthcare_3\NN\654885 professionals_4\NNS\9605289 with_5\IN\1740 <e1>argatroban</e1>_6\JJ\1740 therapy_7\NN\657604 in_8\IN\13603305 hit_9\NN\36762 ,_10\,\1740 including_11\VBG\690614 in_12\IN\13603305 special_13\JJ\1740 populations_14\NNS\7942152 and_15\CC\1740 during_16\IN\1740 pci_17\NN\1740 ,_18\,\1740 may_19\MD\15209706 facilitate_20\VB\2547586 reduction_21\NN\351485 of_22\IN\1740 harm_23\NN\14052046 associated_24\VBN\628491 with_25\IN\1740 <e2>hit</e2>_26\NN\36762 (_27\-LRB-\1740 e.g._28\FW\1740 fewer_29\JJR\1740 thromboses_30\NNS\1740 )_31\-RRB-\1740 or_32\CC\3541091 its_33\PRP$\6125041 treatment_34\NN\654885 (_35\-LRB-\1740 e.g._36\FW\1740 fewer_37\JJR\1740 argatroban_38\JJ\1740 medication_39\NN\3247620 errors_40\NNS\66216 )_41\-RRB-\1740 ._42\.\1740
C031942_D013921 NONE improved_0\VBN\126264 familiarity_1\NN\5816287 of_2\IN\1740 healthcare_3\NN\654885 professionals_4\NNS\9605289 with_5\IN\1740 argatroban_6\JJ\1740 therapy_7\NN\657604 in_8\IN\13603305 <e2>hit</e2>_9\NN\36762 ,_10\,\1740 including_11\VBG\690614 in_12\IN\13603305 special_13\JJ\1740 populations_14\NNS\7942152 and_15\CC\1740 during_16\IN\1740 pci_17\NN\1740 ,_18\,\1740 may_19\MD\15209706 facilitate_20\VB\2547586 reduction_21\NN\351485 of_22\IN\1740 harm_23\NN\14052046 associated_24\VBN\628491 with_25\IN\1740 hit_26\NN\36762 (_27\-LRB-\1740 e.g._28\FW\1740 fewer_29\JJR\1740 thromboses_30\NNS\1740 )_31\-RRB-\1740 or_32\CC\3541091 its_33\PRP$\6125041 treatment_34\NN\654885 (_35\-LRB-\1740 e.g._36\FW\1740 fewer_37\JJR\1740 <e1>argatroban</e1>_38\JJ\1740 medication_39\NN\3247620 errors_40\NNS\66216 )_41\-RRB-\1740 ._42\.\1740
C031942_D013921 NONE improved_0\VBN\126264 familiarity_1\NN\5816287 of_2\IN\1740 healthcare_3\NN\654885 professionals_4\NNS\9605289 with_5\IN\1740 argatroban_6\JJ\1740 therapy_7\NN\657604 in_8\IN\13603305 hit_9\NN\36762 ,_10\,\1740 including_11\VBG\690614 in_12\IN\13603305 special_13\JJ\1740 populations_14\NNS\7942152 and_15\CC\1740 during_16\IN\1740 pci_17\NN\1740 ,_18\,\1740 may_19\MD\15209706 facilitate_20\VB\2547586 reduction_21\NN\351485 of_22\IN\1740 harm_23\NN\14052046 associated_24\VBN\628491 with_25\IN\1740 <e2>hit</e2>_26\NN\36762 (_27\-LRB-\1740 e.g._28\FW\1740 fewer_29\JJR\1740 thromboses_30\NNS\1740 )_31\-RRB-\1740 or_32\CC\3541091 its_33\PRP$\6125041 treatment_34\NN\654885 (_35\-LRB-\1740 e.g._36\FW\1740 fewer_37\JJR\1740 <e1>argatroban</e1>_38\JJ\1740 medication_39\NN\3247620 errors_40\NNS\66216 )_41\-RRB-\1740 ._42\.\1740
D006493_D013921 NONE reducing_0\VBG\441445 harm_1\NN\14052046 associated_2\VBN\628491 with_3\IN\1740 anticoagulation_4\NN\657604 :_5\:\1740 practical_6\JJ\1740 considerations_7\NNS\5770926 of_8\IN\1740 argatroban_9\NN\1740 therapy_10\NN\657604 in_11\IN\13603305 <e1>heparin-induced</e1>_12\JJ\1740 <e2>thrombocytopenia</e2>_13\NN\14189204 ._14\.\1740
D006493_D013921 NONE argatroban_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 thrombosis_15\NN\14100769 in_16\IN\13603305 <e1>heparin-induced</e1>_17\JJ\1740 <e2>thrombocytopenia</e2>_18\NN\14189204 (_19\-LRB-\1740 hit_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 hit_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013921 NONE argatroban_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 thrombosis_15\NN\14100769 in_16\IN\13603305 <e1>heparin-induced</e1>_17\JJ\1740 thrombocytopenia_18\NN\14189204 (_19\-LRB-\1740 <e2>hit</e2>_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 hit_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013921 NONE argatroban_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 thrombosis_15\NN\14100769 in_16\IN\13603305 <e1>heparin-induced</e1>_17\JJ\1740 thrombocytopenia_18\NN\14189204 (_19\-LRB-\1740 hit_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 <e2>hit</e2>_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
C031942_D013927 NONE <e1>argatroban</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 <e2>thrombosis</e2>_15\NN\14100769 in_16\IN\13603305 heparin-induced_17\JJ\1740 thrombocytopenia_18\NN\14189204 (_19\-LRB-\1740 hit_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 hit_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
D006493_D013927 NONE argatroban_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 hepatically_3\RB\1740 metabolized_4\VBN\1740 ,_5\,\1740 direct_6\JJ\1740 thrombin_7\NN\14735953 inhibitor_8\NN\20090 used_9\VBN\1156834 for_10\IN\1740 prophylaxis_11\NN\1077350 or_12\CC\3541091 treatment_13\NN\654885 of_14\IN\1740 <e2>thrombosis</e2>_15\NN\14100769 in_16\IN\13603305 <e1>heparin-induced</e1>_17\JJ\1740 thrombocytopenia_18\NN\14189204 (_19\-LRB-\1740 hit_20\NN\36762 )_21\-RRB-\1740 and_22\CC\1740 for_23\IN\1740 patients_24\NNS\9898892 with_25\IN\1740 or_26\CC\3541091 at_27\IN\14622893 risk_28\NN\14541044 of_29\IN\1740 hit_30\NN\36762 undergoing_31\VBG\109660 percutaneous_32\JJ\1740 coronary_33\JJ\1740 intervention_34\NN\1239064 (_35\-LRB-\1740 pci_36\NN\1740 )_37\-RRB-\1740 ._38\.\1740
C031942_D008107 NONE the_0\DT\1740 us_1\NNP\14964590 fda-recommended_2\JJ\1740 <e1>argatroban</e1>_3\NN\1740 dose_4\NN\3740161 in_5\IN\13603305 hit_6\NN\36762 is_7\VBZ\836236 2_8\CD\13741022 microg/kg/min_9\NN\1740 (_10\-LRB-\1740 reduced_11\VBN\441445 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>hepatic_15\JJ\1740 impairment</e2>_16\NN\7296428 and_17\CC\1740 in_18\IN\13603305 paediatric_19\JJ\1740 patients_20\NNS\9898892 )_21\-RRB-\1740 ,_22\,\1740 adjusted_23\VBN\126264 to_24\TO\1740 achieve_25\VB\2524171 activated_26\VBN\1641914 partial_27\JJ\1740 thromboplastin_28\NN\15022776 times_29\NNS\15113229 (_30\-LRB-\1740 aptts_31\NNS\1740 )_32\-RRB-\1740 1.5_33\CD\1740 -_34\SYM\1740 3_35\CD\13741022 times_36\NNS\15113229 baseline_37\NN\7260623 (_38\-LRB-\1740 not_39\RB\1740 >_40\NNS\1740 100_41\CD\13745420 seconds_42\NNS\15154774 )_43\-RRB-\1740 ._44\.\1740
C031942_D009765 NONE the_0\DT\1740 fda-recommended_1\JJ\1740 dose_2\NN\3740161 during_3\IN\1740 pci_4\NN\1740 is_5\VBZ\836236 25_6\CD\13745420 microg/kg/min_7\NN\1740 (_8\-LRB-\1740 350_9\CD\1740 microg/kg_10\NNS\1740 initial_11\JJ\1740 bolus_12\NN\13899404 )_13\-RRB-\1740 ,_14\,\1740 adjusted_15\VBN\126264 to_16\TO\1740 achieve_17\VB\2524171 activated_18\VBN\1641914 clotting_19\NN\13518963 times_20\NNS\15113229 (_21\-LRB-\1740 acts_22\NNS\6479665 )_23\-RRB-\1740 of_24\IN\1740 300_25\CD\1740 -_26\SYM\1740 450_27\CD\1740 sec._28\NN\1740 for_29\IN\1740 pci_30\NN\1740 ,_31\,\1740 <e1>argatroban</e1>_32\NN\1740 has_33\VBZ\2108377 not_34\RB\1740 been_35\VBN\836236 investigated_36\VBN\644583 in_37\IN\13603305 hepatically_38\RB\1740 impaired_39\JJ\1740 patients_40\NNS\9898892 ;_41\:\1740 dose_42\NN\3740161 adjustment_43\NN\7357388 is_44\VBZ\836236 unnecessary_45\JJ\1740 for_46\IN\1740 adult_47\JJ\1740 age_48\NN\4916342 ,_49\,\1740 sex_50\NN\13440063 ,_51\,\1740 race/ethnicity_52\NN\1740 or_53\CC\3541091 <e2>obesity</e2>_54\NN\4999401 ,_55\,\1740 and_56\CC\1740 lesser_57\JJR\1740 doses_58\NNS\3740161 may_59\MD\15209706 be_60\VB\836236 adequate_61\JJ\1740 with_62\IN\1740 concurrent_63\JJ\1740 glycoprotein_64\NN\14731135 iib/iiia_65\NN\1740 inhibition_66\NN\1068773 ._67\.\1740
C031942_D006470 CID major_0\JJ\1740 <e2>bleeding</e2>_1\VBG\104868 with_2\IN\1740 <e1>argatroban</e1>_3\NN\1740 is_4\VBZ\836236 0_5\CD\13741022 -_6\SYM\1740 10_7\CD\13745420 %_8\NN\1740 in_9\IN\13603305 the_10\DT\1740 non-interventional_11\JJ\1740 setting_12\NN\8567235 and_13\CC\1740 0_14\CD\13741022 -_15\SYM\1740 5.8_16\CD\1740 %_17\NN\1740 periprocedurally_18\RB\1740 ._19\.\1740
12948256
D004977_D009901 CID <e1>ethambutol</e1>_0\NNP\1740 and_1\CC\1740 <e2>optic_2\JJ\1740 neuropathy</e2>_3\JJ\1740 ._4\.\1740
D004977_D009901 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 demonstrate_3\VB\2137132 the_4\DT\1740 association_5\NN\8008335 between_6\IN\1740 <e1>ethambutol</e1>_7\NN\1740 and_8\CC\1740 <e2>optic_9\JJ\1740 neuropathy</e2>_10\JJ\1740 ._11\.\1740
D004977_D009901 CID method_0\NNP\5616786 :_1\:\1740 thirteen_2\CD\13745420 patients_3\NNS\9898892 who_4\WP\8299493 developed_5\VBD\1753788 <e2>optic_6\JJ\1740 neuropathy</e2>_7\JJ\1740 after_8\IN\1740 being_9\VBG\836236 treated_10\VBN\2376958 with_11\IN\1740 <e1>ethambutol</e1>_12\NN\1740 for_13\IN\1740 tuberculosis_14\NN\14127211 of_15\IN\1740 the_16\DT\1740 lung_17\NN\5528060 or_18\CC\3541091 lymph_19\NN\5397468 node_20\NN\13870805 at_21\IN\14622893 siriraj_22\NNP\1740 hospital_23\NNP\3739518 between_24\IN\1740 1997_25\CD\1740 and_26\CC\1740 2001_27\CD\1740 were_28\VBD\836236 retrospectively_29\RB\1740 reviewed_30\VBN\644583 ._31\.\1740
D004977_D009901 CID results_0\NNS\34213 :_1\:\1740 all_2\DT\1740 patients_3\NNS\9898892 had_4\VBD\2108377 <e2>optic_5\JJ\1740 neuropathy</e2>_6\JJ\1740 between_7\IN\1740 1_8\CD\13741022 to_9\TO\1740 6_10\CD\13741022 months_11\NNS\15113229 (_12\-LRB-\1740 mean_13\NN\6021761 =_14\JJ\1740 2.9_15\CD\1740 months_16\NNS\15113229 )_17\-RRB-\1740 after_18\IN\1740 starting_19\VBG\2009433 <e1>ethambutol</e1>_20\NN\1740 therapy_21\NN\657604 at_22\IN\14622893 a_23\DT\13649268 dosage_24\NN\13576355 ranging_25\VBG\2604760 from_26\IN\1740 13_27\CD\13745420 to_28\TO\1740 20_29\CD\13745420 mg/kg/day_30\NN\1740 (_31\-LRB-\1740 mean_32\NN\6021761 =_33\JJ\1740 17_34\CD\13745420 mg/kg/day_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
D004977_D009901 CID conclusion_0\NN\5837957 :_1\:\1740 early_2\JJ\1740 recognition_3\NN\13932421 of_4\IN\1740 <e2>optic_5\JJ\1740 neuropathy</e2>_6\NN\14204950 should_7\MD\1740 be_8\VB\836236 considered_9\VBN\689344 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e1>ethambutol</e1>_13\NN\1740 therapy_14\NN\657604 ._15\.\1740
D004977_D014397 NONE method_0\NNP\5616786 :_1\:\1740 thirteen_2\CD\13745420 patients_3\NNS\9898892 who_4\WP\8299493 developed_5\VBD\1753788 optic_6\JJ\1740 neuropathy_7\JJ\1740 after_8\IN\1740 being_9\VBG\836236 treated_10\VBN\2376958 with_11\IN\1740 <e1>ethambutol</e1>_12\NN\1740 for_13\IN\1740 <e2>tuberculosis_14\NN\14127211 of_15\IN\1740 the_16\DT\1740 lung_17\NN\5528060 or_18\CC\3541091 lymph_19\NN\5397468 node</e2>_20\NN\13870805 at_21\IN\14622893 siriraj_22\NNP\1740 hospital_23\NNP\3739518 between_24\IN\1740 1997_25\CD\1740 and_26\CC\1740 2001_27\CD\1740 were_28\VBD\836236 retrospectively_29\RB\1740 reviewed_30\VBN\644583 ._31\.\1740
D004977_D014388 NONE method_0\NNP\5616786 :_1\:\1740 thirteen_2\CD\13745420 patients_3\NNS\9898892 who_4\WP\8299493 developed_5\VBD\1753788 optic_6\JJ\1740 neuropathy_7\JJ\1740 after_8\IN\1740 being_9\VBG\836236 treated_10\VBN\2376958 with_11\IN\1740 <e1>ethambutol</e1>_12\NN\1740 for_13\IN\1740 <e2>tuberculosis_14\NN\14127211 of_15\IN\1740 the_16\DT\1740 lung_17\NN\5528060 or_18\CC\3541091 lymph_19\NN\5397468 node</e2>_20\NN\13870805 at_21\IN\14622893 siriraj_22\NNP\1740 hospital_23\NNP\3739518 between_24\IN\1740 1997_25\CD\1740 and_26\CC\1740 2001_27\CD\1740 were_28\VBD\836236 retrospectively_29\RB\1740 reviewed_30\VBN\644583 ._31\.\1740
8312343
D004317_D002311 NONE indications_0\NNS\33020 for_1\IN\1740 transplantation_2\NN\671351 were_3\VBD\836236 <e2>idiopathic_4\JJ\1740 cardiomyopathy</e2>_5\JJ\1740 (_6\-LRB-\1740 52_7\CD\1740 %_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 congenital_11\JJ\1740 heart_12\NN\5919034 disease_13\NN\14061805 (_14\-LRB-\1740 35_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 with_18\IN\1740 and_19\CC\1740 without_20\IN\1740 prior_21\JJ\1740 repair_22\NN\248977 (_23\-LRB-\1740 71_24\CD\1740 %_25\NN\1740 and_26\CC\1740 29_27\CD\13745420 %_28\NN\1740 ,_29\,\1740 respectively_30\RB\1740 )_31\-RRB-\1740 ,_32\,\1740 hypertrophic_33\JJ\1740 cardiomyopathy_34\JJ\1740 (_35\-LRB-\1740 5_36\CD\13741022 %_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 valvular_40\JJ\1740 heart_41\NN\5919034 disease_42\NN\14061805 (_43\-LRB-\1740 3_44\CD\13741022 %_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 and_48\CC\1740 <e1>doxorubicin</e1>_49\NN\2716866 cardiomyopathy_50\JJ\1740 (_51\-LRB-\1740 5_52\CD\13741022 %_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D004317_D006331 NONE indications_0\NNS\33020 for_1\IN\1740 transplantation_2\NN\671351 were_3\VBD\836236 idiopathic_4\JJ\1740 cardiomyopathy_5\JJ\1740 (_6\-LRB-\1740 52_7\CD\1740 %_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 <e2>congenital_11\JJ\1740 heart_12\NN\5919034 disease</e2>_13\NN\14061805 (_14\-LRB-\1740 35_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 with_18\IN\1740 and_19\CC\1740 without_20\IN\1740 prior_21\JJ\1740 repair_22\NN\248977 (_23\-LRB-\1740 71_24\CD\1740 %_25\NN\1740 and_26\CC\1740 29_27\CD\13745420 %_28\NN\1740 ,_29\,\1740 respectively_30\RB\1740 )_31\-RRB-\1740 ,_32\,\1740 hypertrophic_33\JJ\1740 cardiomyopathy_34\JJ\1740 (_35\-LRB-\1740 5_36\CD\13741022 %_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 valvular_40\JJ\1740 heart_41\NN\5919034 disease_42\NN\14061805 (_43\-LRB-\1740 3_44\CD\13741022 %_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 and_48\CC\1740 <e1>doxorubicin</e1>_49\NN\2716866 cardiomyopathy_50\JJ\1740 (_51\-LRB-\1740 5_52\CD\13741022 %_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D004317_D002312 NONE indications_0\NNS\33020 for_1\IN\1740 transplantation_2\NN\671351 were_3\VBD\836236 idiopathic_4\JJ\1740 cardiomyopathy_5\JJ\1740 (_6\-LRB-\1740 52_7\CD\1740 %_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 congenital_11\JJ\1740 heart_12\NN\5919034 disease_13\NN\14061805 (_14\-LRB-\1740 35_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 with_18\IN\1740 and_19\CC\1740 without_20\IN\1740 prior_21\JJ\1740 repair_22\NN\248977 (_23\-LRB-\1740 71_24\CD\1740 %_25\NN\1740 and_26\CC\1740 29_27\CD\13745420 %_28\NN\1740 ,_29\,\1740 respectively_30\RB\1740 )_31\-RRB-\1740 ,_32\,\1740 <e2>hypertrophic_33\JJ\1740 cardiomyopathy</e2>_34\JJ\1740 (_35\-LRB-\1740 5_36\CD\13741022 %_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 valvular_40\JJ\1740 heart_41\NN\5919034 disease_42\NN\14061805 (_43\-LRB-\1740 3_44\CD\13741022 %_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 and_48\CC\1740 <e1>doxorubicin</e1>_49\NN\2716866 cardiomyopathy_50\JJ\1740 (_51\-LRB-\1740 5_52\CD\13741022 %_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D004317_D006349 NONE indications_0\NNS\33020 for_1\IN\1740 transplantation_2\NN\671351 were_3\VBD\836236 idiopathic_4\JJ\1740 cardiomyopathy_5\JJ\1740 (_6\-LRB-\1740 52_7\CD\1740 %_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 congenital_11\JJ\1740 heart_12\NN\5919034 disease_13\NN\14061805 (_14\-LRB-\1740 35_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 with_18\IN\1740 and_19\CC\1740 without_20\IN\1740 prior_21\JJ\1740 repair_22\NN\248977 (_23\-LRB-\1740 71_24\CD\1740 %_25\NN\1740 and_26\CC\1740 29_27\CD\13745420 %_28\NN\1740 ,_29\,\1740 respectively_30\RB\1740 )_31\-RRB-\1740 ,_32\,\1740 hypertrophic_33\JJ\1740 cardiomyopathy_34\JJ\1740 (_35\-LRB-\1740 5_36\CD\13741022 %_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 <e2>valvular_40\JJ\1740 heart_41\NN\5919034 disease</e2>_42\NN\14061805 (_43\-LRB-\1740 3_44\CD\13741022 %_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 and_48\CC\1740 <e1>doxorubicin</e1>_49\NN\2716866 cardiomyopathy_50\JJ\1740 (_51\-LRB-\1740 5_52\CD\13741022 %_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D004317_D009202 CID indications_0\NNS\33020 for_1\IN\1740 transplantation_2\NN\671351 were_3\VBD\836236 idiopathic_4\JJ\1740 cardiomyopathy_5\JJ\1740 (_6\-LRB-\1740 52_7\CD\1740 %_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 congenital_11\JJ\1740 heart_12\NN\5919034 disease_13\NN\14061805 (_14\-LRB-\1740 35_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 with_18\IN\1740 and_19\CC\1740 without_20\IN\1740 prior_21\JJ\1740 repair_22\NN\248977 (_23\-LRB-\1740 71_24\CD\1740 %_25\NN\1740 and_26\CC\1740 29_27\CD\13745420 %_28\NN\1740 ,_29\,\1740 respectively_30\RB\1740 )_31\-RRB-\1740 ,_32\,\1740 hypertrophic_33\JJ\1740 cardiomyopathy_34\JJ\1740 (_35\-LRB-\1740 5_36\CD\13741022 %_37\NN\1740 )_38\-RRB-\1740 ,_39\,\1740 valvular_40\JJ\1740 heart_41\NN\5919034 disease_42\NN\14061805 (_43\-LRB-\1740 3_44\CD\13741022 %_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 and_48\CC\1740 <e1>doxorubicin</e1>_49\NN\2716866 <e2>cardiomyopathy</e2>_50\JJ\1740 (_51\-LRB-\1740 5_52\CD\13741022 %_53\NN\1740 )_54\-RRB-\1740 ._55\.\1740
D015774_D003586 NONE <e2>cytomegalovirus_0\NN\1338685 infections</e2>_1\NNS\14052046 were_2\VBD\836236 treated_3\VBN\2376958 successfully_4\RB\1740 with_5\IN\1740 <e1>ganciclovir</e1>_6\NN\1740 in_7\IN\13603305 11_8\CD\13745420 patients_9\NNS\9898892 ._10\.\1740
11401944
D013015_D016171 CID background_0\NN\4921011 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 examined_4\VBD\789138 the_5\DT\1740 role_6\NN\719494 of_7\IN\1740 phase_8\NN\15113229 2_9\CD\13741022 early_10\JJ\1740 afterdepolarization_11\NN\1740 (_12\-LRB-\1740 ead_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 producing_16\VBG\1617192 a_17\DT\13649268 trigger_18\NN\3659292 to_19\TO\1740 initiate_20\VB\1617192 <e2>torsade_21\NN\1740 de_22\FW\1740 pointes</e2>_23\NNS\1740 (_24\-LRB-\1740 tdp_25\NN\1740 )_26\-RRB-\1740 with_27\IN\1740 qt_28\NN\1740 prolongation_29\NN\1017987 induced_30\VBN\1627355 by_31\IN\1740 <e1>dl-sotalol</e1>_32\NN\1740 and_33\CC\1740 azimilide_34\NN\1740 ._35\.\1740
D013015_D016171 CID background_0\NN\4921011 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 examined_4\VBD\789138 the_5\DT\1740 role_6\NN\719494 of_7\IN\1740 phase_8\NN\15113229 2_9\CD\13741022 early_10\JJ\1740 afterdepolarization_11\NN\1740 (_12\-LRB-\1740 ead_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 producing_16\VBG\1617192 a_17\DT\13649268 trigger_18\NN\3659292 to_19\TO\1740 initiate_20\VB\1617192 torsade_21\NN\1740 de_22\FW\1740 pointes_23\NNS\1740 (_24\-LRB-\1740 <e2>tdp</e2>_25\NN\1740 )_26\-RRB-\1740 with_27\IN\1740 qt_28\NN\1740 prolongation_29\NN\1017987 induced_30\VBN\1627355 by_31\IN\1740 <e1>dl-sotalol</e1>_32\NN\1740 and_33\CC\1740 azimilide_34\NN\1740 ._35\.\1740
D013015_D016171 CID an_0\DT\6697703 increase_1\NN\13576355 in_2\IN\13603305 tdr_3\NN\1740 by_4\IN\1740 <e1>dl-sotalol</e1>_5\NN\1740 facilitated_6\VBN\2547586 transmural_7\JJ\1740 propagation_8\NN\6253140 of_9\IN\1740 eads_10\NNS\1740 that_11\WDT\1740 initiated_12\VBD\1617192 multiple_13\JJ\1740 episodes_14\NNS\7283608 of_15\IN\1740 spontaneous_16\JJ\1740 <e2>tdp</e2>_17\NN\1740 in_18\IN\13603305 3_19\CD\13741022 of_20\IN\1740 6_21\CD\13741022 rabbit_22\NN\2323902 left_23\VBD\120316 ventricles_24\NNS\5303402 ._25\.\1740
D013015_D008133 CID background_0\NN\4921011 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 examined_4\VBD\789138 the_5\DT\1740 role_6\NN\719494 of_7\IN\1740 phase_8\NN\15113229 2_9\CD\13741022 early_10\JJ\1740 afterdepolarization_11\NN\1740 (_12\-LRB-\1740 ead_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 producing_16\VBG\1617192 a_17\DT\13649268 trigger_18\NN\3659292 to_19\TO\1740 initiate_20\VB\1617192 torsade_21\NN\1740 de_22\FW\1740 pointes_23\NNS\1740 (_24\-LRB-\1740 tdp_25\NN\1740 )_26\-RRB-\1740 with_27\IN\1740 <e2>qt_28\NN\1740 prolongation</e2>_29\NN\1017987 induced_30\VBN\1627355 by_31\IN\1740 <e1>dl-sotalol</e1>_32\NN\1740 and_33\CC\1740 azimilide_34\NN\1740 ._35\.\1740
D013015_D008133 CID <e1>dl-sotalol</e1>_0\NN\1740 preferentially_1\RB\1740 prolonged_2\VBD\317700 action_3\NN\30358 potential_4\JJ\1740 duration_5\NN\15113229 (_6\-LRB-\1740 apd_7\NN\1740 )_8\-RRB-\1740 in_9\IN\13603305 m_10\NN\13649268 cells_11\NNS\3080309 dose-dependently_12\RB\1740 (_13\-LRB-\1740 1_14\CD\13741022 to_15\TO\1740 100_16\CD\13745420 micromol/l_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 leading_20\VBG\1752884 to_21\TO\1740 <e2>qt_22\NN\1740 prolongation</e2>_23\NN\1017987 and_24\CC\1740 an_25\DT\6697703 increase_26\NN\13576355 in_27\IN\13603305 tdr_28\NN\1740 ._29\.\1740
D013015_D008133 CID although_0\IN\1740 both_1\DT\1740 <e1>dl-sotalol</e1>_2\NN\1740 and_3\CC\1740 azimilide_4\NN\1740 rarely_5\RB\1740 induced_6\VBD\1627355 eads_7\NNS\1740 in_8\IN\13603305 canine_9\NN\5282746 left_10\VBD\120316 ventricles_11\NNS\5303402 ,_12\,\1740 they_13\PRP\1740 produced_14\VBD\1617192 frequent_15\JJ\1740 eads_16\NNS\1740 in_17\IN\13603305 rabbits_18\NNS\2323902 ,_19\,\1740 in_20\IN\13603305 which_21\WDT\1740 more_22\RBR\1740 pronounced_23\VBD\822367 <e2>qt_24\NN\1740 prolongation</e2>_25\NN\1017987 was_26\VBD\836236 seen_27\VBN\2106506 ._28\.\1740
C086123_D016171 NONE background_0\NN\4921011 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 examined_4\VBD\789138 the_5\DT\1740 role_6\NN\719494 of_7\IN\1740 phase_8\NN\15113229 2_9\CD\13741022 early_10\JJ\1740 afterdepolarization_11\NN\1740 (_12\-LRB-\1740 ead_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 producing_16\VBG\1617192 a_17\DT\13649268 trigger_18\NN\3659292 to_19\TO\1740 initiate_20\VB\1617192 <e2>torsade_21\NN\1740 de_22\FW\1740 pointes</e2>_23\NNS\1740 (_24\-LRB-\1740 tdp_25\NN\1740 )_26\-RRB-\1740 with_27\IN\1740 qt_28\NN\1740 prolongation_29\NN\1017987 induced_30\VBN\1627355 by_31\IN\1740 dl-sotalol_32\NN\1740 and_33\CC\1740 <e1>azimilide</e1>_34\NN\1740 ._35\.\1740
C086123_D016171 NONE background_0\NN\4921011 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 examined_4\VBD\789138 the_5\DT\1740 role_6\NN\719494 of_7\IN\1740 phase_8\NN\15113229 2_9\CD\13741022 early_10\JJ\1740 afterdepolarization_11\NN\1740 (_12\-LRB-\1740 ead_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 producing_16\VBG\1617192 a_17\DT\13649268 trigger_18\NN\3659292 to_19\TO\1740 initiate_20\VB\1617192 torsade_21\NN\1740 de_22\FW\1740 pointes_23\NNS\1740 (_24\-LRB-\1740 <e2>tdp</e2>_25\NN\1740 )_26\-RRB-\1740 with_27\IN\1740 qt_28\NN\1740 prolongation_29\NN\1017987 induced_30\VBN\1627355 by_31\IN\1740 dl-sotalol_32\NN\1740 and_33\CC\1740 <e1>azimilide</e1>_34\NN\1740 ._35\.\1740
C086123_D008133 NONE background_0\NN\4921011 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 examined_4\VBD\789138 the_5\DT\1740 role_6\NN\719494 of_7\IN\1740 phase_8\NN\15113229 2_9\CD\13741022 early_10\JJ\1740 afterdepolarization_11\NN\1740 (_12\-LRB-\1740 ead_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 producing_16\VBG\1617192 a_17\DT\13649268 trigger_18\NN\3659292 to_19\TO\1740 initiate_20\VB\1617192 torsade_21\NN\1740 de_22\FW\1740 pointes_23\NNS\1740 (_24\-LRB-\1740 tdp_25\NN\1740 )_26\-RRB-\1740 with_27\IN\1740 <e2>qt_28\NN\1740 prolongation</e2>_29\NN\1017987 induced_30\VBN\1627355 by_31\IN\1740 dl-sotalol_32\NN\1740 and_33\CC\1740 <e1>azimilide</e1>_34\NN\1740 ._35\.\1740
C086123_D008133 NONE although_0\IN\1740 both_1\DT\1740 dl-sotalol_2\NN\1740 and_3\CC\1740 <e1>azimilide</e1>_4\NN\1740 rarely_5\RB\1740 induced_6\VBD\1627355 eads_7\NNS\1740 in_8\IN\13603305 canine_9\NN\5282746 left_10\VBD\120316 ventricles_11\NNS\5303402 ,_12\,\1740 they_13\PRP\1740 produced_14\VBD\1617192 frequent_15\JJ\1740 eads_16\NNS\1740 in_17\IN\13603305 rabbits_18\NNS\2323902 ,_19\,\1740 in_20\IN\13603305 which_21\WDT\1740 more_22\RBR\1740 pronounced_23\VBD\822367 <e2>qt_24\NN\1740 prolongation</e2>_25\NN\1017987 was_26\VBD\836236 seen_27\VBN\2106506 ._28\.\1740
6517710
D011796_D003328 CID <e2>atrial_0\JJ\1740 thrombosis</e2>_1\NN\14100769 involving_2\VBG\2676054 the_3\DT\1740 heart_4\NN\5919034 of_5\IN\1740 f-344_6\NN\1740 rats_7\NNS\2329401 ingesting_8\VBG\597915 <e1>quinacrine_9\NN\2721948 hydrochloride</e1>_10\NN\14817592 ._11\.\1740
D011796_D003328 CID rats_0\NNS\2329401 treated_1\VBN\2376958 with_2\IN\1740 500_3\CD\13745420 ppm_4\JJ\1740 <e1>quinacrine_5\NN\2721948 hydrochloride</e1>_6\NN\14817592 in_7\IN\13603305 the_8\DT\1740 diet_9\NN\7560652 all_10\DT\1740 developed_11\VBD\1753788 a_12\DT\13649268 high_13\JJ\1740 incidence_14\NN\13821570 of_15\IN\1740 left_16\JJ\1740 <e2>atrial_17\JJ\1740 thrombosis</e2>_18\NN\14100769 ._19\.\1740
D011796_D003328 CID seventy_0\CD\13745420 percent_1\NN\13815742 of_2\IN\1740 rats_3\NNS\2329401 given_4\VBN\2327200 250_5\CD\1740 ppm_6\NN\1740 <e1>quinacrine_7\NN\2721948 hydrochloride</e1>_8\NN\14817592 and_9\CC\1740 1,000_10\CD\1740 ppm_11\JJ\1740 sodium_12\NN\14625458 nitrite_13\RB\1740 simultaneously_14\RB\1740 in_15\IN\13603305 the_16\DT\1740 diet_17\NN\7560652 had_18\VBD\2108377 thrombosis_19\NN\14100769 of_20\IN\1740 the_21\DT\1740 atria_22\NN\5392744 of_23\IN\1740 the_24\DT\1740 heart_25\NN\5919034 ,_26\,\1740 while_27\IN\15122231 untreated_28\JJ\1740 control_29\NN\5190804 rats_30\NNS\2329401 in_31\IN\13603305 this_32\DT\1740 laboratory_33\NN\4602044 did_34\VBD\1640855 not_35\RB\1740 have_36\VB\2108377 <e2>atrial_37\JJ\1740 thrombosis</e2>_38\NN\14100769 ._39\.\1740
D011796_D013927 NONE seventy_0\CD\13745420 percent_1\NN\13815742 of_2\IN\1740 rats_3\NNS\2329401 given_4\VBN\2327200 250_5\CD\1740 ppm_6\NN\1740 <e1>quinacrine_7\NN\2721948 hydrochloride</e1>_8\NN\14817592 and_9\CC\1740 1,000_10\CD\1740 ppm_11\JJ\1740 sodium_12\NN\14625458 nitrite_13\RB\1740 simultaneously_14\RB\1740 in_15\IN\13603305 the_16\DT\1740 diet_17\NN\7560652 had_18\VBD\2108377 <e2>thrombosis</e2>_19\NN\14100769 of_20\IN\1740 the_21\DT\1740 atria_22\NN\5392744 of_23\IN\1740 the_24\DT\1740 heart_25\NN\5919034 ,_26\,\1740 while_27\IN\15122231 untreated_28\JJ\1740 control_29\NN\5190804 rats_30\NNS\2329401 in_31\IN\13603305 this_32\DT\1740 laboratory_33\NN\4602044 did_34\VBD\1640855 not_35\RB\1740 have_36\VB\2108377 atrial_37\JJ\1740 thrombosis_38\NN\14100769 ._39\.\1740
D012977_D013927 NONE seventy_0\CD\13745420 percent_1\NN\13815742 of_2\IN\1740 rats_3\NNS\2329401 given_4\VBN\2327200 250_5\CD\1740 ppm_6\NN\1740 quinacrine_7\NN\2721948 hydrochloride_8\NN\14817592 and_9\CC\1740 1,000_10\CD\1740 ppm_11\JJ\1740 <e1>sodium_12\NN\14625458 nitrite</e1>_13\RB\1740 simultaneously_14\RB\1740 in_15\IN\13603305 the_16\DT\1740 diet_17\NN\7560652 had_18\VBD\2108377 <e2>thrombosis</e2>_19\NN\14100769 of_20\IN\1740 the_21\DT\1740 atria_22\NN\5392744 of_23\IN\1740 the_24\DT\1740 heart_25\NN\5919034 ,_26\,\1740 while_27\IN\15122231 untreated_28\JJ\1740 control_29\NN\5190804 rats_30\NNS\2329401 in_31\IN\13603305 this_32\DT\1740 laboratory_33\NN\4602044 did_34\VBD\1640855 not_35\RB\1740 have_36\VB\2108377 atrial_37\JJ\1740 thrombosis_38\NN\14100769 ._39\.\1740
D012977_D003328 NONE seventy_0\CD\13745420 percent_1\NN\13815742 of_2\IN\1740 rats_3\NNS\2329401 given_4\VBN\2327200 250_5\CD\1740 ppm_6\NN\1740 quinacrine_7\NN\2721948 hydrochloride_8\NN\14817592 and_9\CC\1740 1,000_10\CD\1740 ppm_11\JJ\1740 <e1>sodium_12\NN\14625458 nitrite</e1>_13\RB\1740 simultaneously_14\RB\1740 in_15\IN\13603305 the_16\DT\1740 diet_17\NN\7560652 had_18\VBD\2108377 thrombosis_19\NN\14100769 of_20\IN\1740 the_21\DT\1740 atria_22\NN\5392744 of_23\IN\1740 the_24\DT\1740 heart_25\NN\5919034 ,_26\,\1740 while_27\IN\15122231 untreated_28\JJ\1740 control_29\NN\5190804 rats_30\NNS\2329401 in_31\IN\13603305 this_32\DT\1740 laboratory_33\NN\4602044 did_34\VBD\1640855 not_35\RB\1740 have_36\VB\2108377 <e2>atrial_37\JJ\1740 thrombosis</e2>_38\NN\14100769 ._39\.\1740
7661171
D016595_D007674 NONE the_0\DT\1740 dose-dependent_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>misoprostol</e1>_4\NN\1740 on_5\IN\1740 indomethacin-induced_6\JJ\1740 <e2>renal_7\JJ\1740 dysfunction</e2>_8\NN\14204950 in_9\IN\13603305 well_10\RB\1740 compensated_11\VBN\2673134 cirrhosis_12\NN\14116321 ._13\.\1740
D016595_D007674 NONE <e1>misoprostol</e1>_0\NN\1740 (_1\-LRB-\1740 200_2\CD\1740 micrograms_3\NNS\13717155 )_4\-RRB-\1740 has_5\VBZ\2108377 been_6\VBN\836236 shown_7\VBN\2137132 to_8\TO\1740 acutely_9\RB\1740 counteract_10\VB\2367363 the_11\DT\1740 indomethacin-induced_12\JJ\1740 <e2>renal_13\JJ\1740 dysfunction</e2>_14\NN\14204950 in_15\IN\13603305 well_16\RB\1740 compensated_17\VBN\2673134 cirrhotic_18\JJ\1740 patients_19\NNS\9898892 ._20\.\1740
D016595_D005355 NONE the_0\DT\1740 dose-dependent_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>misoprostol</e1>_4\NN\1740 on_5\IN\1740 indomethacin-induced_6\JJ\1740 renal_7\JJ\1740 dysfunction_8\NN\14204950 in_9\IN\13603305 well_10\RB\1740 compensated_11\VBN\2673134 <e2>cirrhosis</e2>_12\NN\14116321 ._13\.\1740
D016595_D005355 NONE <e1>misoprostol</e1>_0\NN\1740 (_1\-LRB-\1740 200_2\CD\1740 micrograms_3\NNS\13717155 )_4\-RRB-\1740 has_5\VBZ\2108377 been_6\VBN\836236 shown_7\VBN\2137132 to_8\TO\1740 acutely_9\RB\1740 counteract_10\VB\2367363 the_11\DT\1740 indomethacin-induced_12\JJ\1740 renal_13\JJ\1740 dysfunction_14\NN\14204950 in_15\IN\13603305 well_16\RB\1740 compensated_17\VBN\2673134 <e2>cirrhotic</e2>_18\JJ\1740 patients_19\NNS\9898892 ._20\.\1740
D016595_D005355 NONE parameters_0\NNS\5858936 of_1\IN\1740 renal_2\JJ\1740 hemodynamics_3\NNS\6080522 and_4\CC\1740 tubular_5\JJ\1740 sodium_6\NN\14625458 and_7\CC\1740 water_8\NN\14618834 handling_9\NN\623162 were_10\VBD\836236 assessed_11\VBN\670261 by_12\IN\1740 clearance_13\NN\5089947 techniques_14\NNS\5660268 in_15\IN\13603305 26_16\CD\13745420 well_17\RB\1740 compensated_18\VBN\2673134 <e2>cirrhotic</e2>_19\JJ\1740 patients_20\NNS\9898892 before_21\IN\1740 and_22\CC\1740 after_23\IN\1740 an_24\DT\6697703 oral_25\JJ\1740 combination_26\NN\7951464 of_27\IN\1740 50_28\CD\13745420 mg_29\NN\13717155 of_30\IN\1740 indomethacin_31\NN\3828465 and_32\CC\1740 various_33\JJ\1740 doses_34\NNS\3740161 of_35\IN\1740 <e1>misoprostol</e1>_36\NN\1740 ._37\.\1740
D016595_D005355 NONE however_0\RB\1740 ,_1\,\1740 until_2\IN\1740 this_3\DT\1740 apparent_4\JJ\1740 ability_5\NN\4723816 of_6\IN\1740 200_7\CD\1740 micrograms_8\NNS\13717155 of_9\IN\1740 <e1>misoprostol</e1>_10\NN\1740 to_11\TO\1740 prevent_12\VB\1740 the_13\DT\1740 adverse_14\JJ\1740 effects_15\NNS\13245626 of_16\IN\1740 indomethacin_17\NN\3828465 on_18\IN\1740 renal_19\JJ\1740 function_20\NN\13783581 is_21\VBZ\836236 confirmed_22\VBN\1011725 with_23\IN\1740 chronic_24\JJ\1740 frequent_25\JJ\1740 dosing_26\NN\1740 ,_27\,\1740 it_28\PRP\6125041 would_29\MD\1740 be_30\VB\836236 prudent_31\JJ\1740 to_32\TO\1740 avoid_33\VB\2452885 nonsteroidal_34\JJ\1740 anti-inflammatory_35\JJ\1740 therapy_36\NN\657604 in_37\IN\13603305 patients_38\NNS\9898892 with_39\IN\1740 <e2>cirrhosis</e2>_40\NN\14116321 ._41\.\1740
D007213_D007674 CID the_0\DT\1740 dose-dependent_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 misoprostol_4\NN\1740 on_5\IN\1740 <e1>indomethacin-induced</e1>_6\JJ\1740 <e2>renal_7\JJ\1740 dysfunction</e2>_8\NN\14204950 in_9\IN\13603305 well_10\RB\1740 compensated_11\VBN\2673134 cirrhosis_12\NN\14116321 ._13\.\1740
D007213_D007674 CID misoprostol_0\NN\1740 (_1\-LRB-\1740 200_2\CD\1740 micrograms_3\NNS\13717155 )_4\-RRB-\1740 has_5\VBZ\2108377 been_6\VBN\836236 shown_7\VBN\2137132 to_8\TO\1740 acutely_9\RB\1740 counteract_10\VB\2367363 the_11\DT\1740 <e1>indomethacin-induced</e1>_12\JJ\1740 <e2>renal_13\JJ\1740 dysfunction</e2>_14\NN\14204950 in_15\IN\13603305 well_16\RB\1740 compensated_17\VBN\2673134 cirrhotic_18\JJ\1740 patients_19\NNS\9898892 ._20\.\1740
D007213_D005355 NONE the_0\DT\1740 dose-dependent_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 misoprostol_4\NN\1740 on_5\IN\1740 <e1>indomethacin-induced</e1>_6\JJ\1740 renal_7\JJ\1740 dysfunction_8\NN\14204950 in_9\IN\13603305 well_10\RB\1740 compensated_11\VBN\2673134 <e2>cirrhosis</e2>_12\NN\14116321 ._13\.\1740
D007213_D005355 NONE misoprostol_0\NN\1740 (_1\-LRB-\1740 200_2\CD\1740 micrograms_3\NNS\13717155 )_4\-RRB-\1740 has_5\VBZ\2108377 been_6\VBN\836236 shown_7\VBN\2137132 to_8\TO\1740 acutely_9\RB\1740 counteract_10\VB\2367363 the_11\DT\1740 <e1>indomethacin-induced</e1>_12\JJ\1740 renal_13\JJ\1740 dysfunction_14\NN\14204950 in_15\IN\13603305 well_16\RB\1740 compensated_17\VBN\2673134 <e2>cirrhotic</e2>_18\JJ\1740 patients_19\NNS\9898892 ._20\.\1740
D007213_D005355 NONE parameters_0\NNS\5858936 of_1\IN\1740 renal_2\JJ\1740 hemodynamics_3\NNS\6080522 and_4\CC\1740 tubular_5\JJ\1740 sodium_6\NN\14625458 and_7\CC\1740 water_8\NN\14618834 handling_9\NN\623162 were_10\VBD\836236 assessed_11\VBN\670261 by_12\IN\1740 clearance_13\NN\5089947 techniques_14\NNS\5660268 in_15\IN\13603305 26_16\CD\13745420 well_17\RB\1740 compensated_18\VBN\2673134 <e2>cirrhotic</e2>_19\JJ\1740 patients_20\NNS\9898892 before_21\IN\1740 and_22\CC\1740 after_23\IN\1740 an_24\DT\6697703 oral_25\JJ\1740 combination_26\NN\7951464 of_27\IN\1740 50_28\CD\13745420 mg_29\NN\13717155 of_30\IN\1740 <e1>indomethacin</e1>_31\NN\3828465 and_32\CC\1740 various_33\JJ\1740 doses_34\NNS\3740161 of_35\IN\1740 misoprostol_36\NN\1740 ._37\.\1740
D007213_D005355 NONE however_0\RB\1740 ,_1\,\1740 until_2\IN\1740 this_3\DT\1740 apparent_4\JJ\1740 ability_5\NN\4723816 of_6\IN\1740 200_7\CD\1740 micrograms_8\NNS\13717155 of_9\IN\1740 misoprostol_10\NN\1740 to_11\TO\1740 prevent_12\VB\1740 the_13\DT\1740 adverse_14\JJ\1740 effects_15\NNS\13245626 of_16\IN\1740 <e1>indomethacin</e1>_17\NN\3828465 on_18\IN\1740 renal_19\JJ\1740 function_20\NN\13783581 is_21\VBZ\836236 confirmed_22\VBN\1011725 with_23\IN\1740 chronic_24\JJ\1740 frequent_25\JJ\1740 dosing_26\NN\1740 ,_27\,\1740 it_28\PRP\6125041 would_29\MD\1740 be_30\VB\836236 prudent_31\JJ\1740 to_32\TO\1740 avoid_33\VB\2452885 nonsteroidal_34\JJ\1740 anti-inflammatory_35\JJ\1740 therapy_36\NN\657604 in_37\IN\13603305 patients_38\NNS\9898892 with_39\IN\1740 <e2>cirrhosis</e2>_40\NN\14116321 ._41\.\1740
D012964_D005355 NONE parameters_0\NNS\5858936 of_1\IN\1740 renal_2\JJ\1740 hemodynamics_3\NNS\6080522 and_4\CC\1740 tubular_5\JJ\1740 <e1>sodium</e1>_6\NN\14625458 and_7\CC\1740 water_8\NN\14618834 handling_9\NN\623162 were_10\VBD\836236 assessed_11\VBN\670261 by_12\IN\1740 clearance_13\NN\5089947 techniques_14\NNS\5660268 in_15\IN\13603305 26_16\CD\13745420 well_17\RB\1740 compensated_18\VBN\2673134 <e2>cirrhotic</e2>_19\JJ\1740 patients_20\NNS\9898892 before_21\IN\1740 and_22\CC\1740 after_23\IN\1740 an_24\DT\6697703 oral_25\JJ\1740 combination_26\NN\7951464 of_27\IN\1740 50_28\CD\13745420 mg_29\NN\13717155 of_30\IN\1740 indomethacin_31\NN\3828465 and_32\CC\1740 various_33\JJ\1740 doses_34\NNS\3740161 of_35\IN\1740 misoprostol_36\NN\1740 ._37\.\1740
11385188
D003042_D006331 NONE prevalence_0\NN\4764412 of_1\IN\1740 <e2>heart_2\NN\5919034 disease</e2>_3\NN\14061805 in_4\IN\13603305 asymptomatic_5\JJ\1740 chronic_6\JJ\1740 <e1>cocaine</e1>_7\NN\3492717 users_8\NNS\7846 ._9\.\1740
D003042_D006331 NONE to_0\TO\1740 determine_1\VB\1645601 the_2\DT\1740 prevalence_3\NN\4764412 of_4\IN\1740 <e2>heart_5\NN\5919034 disease</e2>_6\NN\14061805 in_7\IN\13603305 outpatient_8\JJ\1740 young_9\JJ\1740 asymptomatic_10\JJ\1740 chronic_11\JJ\1740 <e1>cocaine</e1>_12\NN\3492717 users_13\NNS\7846 ,_14\,\1740 35_15\CD\1740 cocaine_16\NN\3492717 users_17\NNS\7846 and_18\CC\1740 32_19\CD\1740 age-matched_20\JJ\1740 controls_21\NNS\5190804 underwent_22\VBD\109660 resting_23\VBG\2604760 and_24\CC\1740 exercise_25\NN\621627 electrocardiography_26\NN\177127 (_27\-LRB-\1740 ecg_28\NN\7000195 )_29\-RRB-\1740 and_30\CC\1740 doppler_31\NNP\1740 echocardiography_32\NN\177127 ._33\.\1740
D003042_D006331 NONE to_0\TO\1740 determine_1\VB\1645601 the_2\DT\1740 prevalence_3\NN\4764412 of_4\IN\1740 <e2>heart_5\NN\5919034 disease</e2>_6\NN\14061805 in_7\IN\13603305 outpatient_8\JJ\1740 young_9\JJ\1740 asymptomatic_10\JJ\1740 chronic_11\JJ\1740 cocaine_12\NN\3492717 users_13\NNS\7846 ,_14\,\1740 35_15\CD\1740 <e1>cocaine</e1>_16\NN\3492717 users_17\NNS\7846 and_18\CC\1740 32_19\CD\1740 age-matched_20\JJ\1740 controls_21\NNS\5190804 underwent_22\VBD\109660 resting_23\VBG\2604760 and_24\CC\1740 exercise_25\NN\621627 electrocardiography_26\NN\177127 (_27\-LRB-\1740 ecg_28\NN\7000195 )_29\-RRB-\1740 and_30\CC\1740 doppler_31\NNP\1740 echocardiography_32\NN\177127 ._33\.\1740
D003042_D003324 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e2>coronary_3\JJ\1740 artery_4\NN\5417975 or_5\CC\3541091 myocardial_6\JJ\1740 disease</e2>_7\NN\14061805 is_8\VBZ\836236 common_9\JJ\1740 (_10\-LRB-\1740 38_11\CD\1740 %_12\NN\1740 )_13\-RRB-\1740 in_14\IN\13603305 young_15\JJ\1740 asymptomatic_16\JJ\1740 chronic_17\JJ\1740 <e1>cocaine</e1>_18\NN\3492717 users_19\NNS\7846 ._20\.\1740
D003042_D009202 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e2>coronary_3\JJ\1740 artery_4\NN\5417975 or_5\CC\3541091 myocardial_6\JJ\1740 disease</e2>_7\NN\14061805 is_8\VBZ\836236 common_9\JJ\1740 (_10\-LRB-\1740 38_11\CD\1740 %_12\NN\1740 )_13\-RRB-\1740 in_14\IN\13603305 young_15\JJ\1740 asymptomatic_16\JJ\1740 chronic_17\JJ\1740 <e1>cocaine</e1>_18\NN\3492717 users_19\NNS\7846 ._20\.\1740
24091473
D004837_D066126 NONE resuscitation_0\NN\1047338 with_1\IN\1740 lipid_2\NN\14944888 ,_3\,\1740 <e1>epinephrine</e1>_4\NN\14807929 ,_5\,\1740 or_6\CC\3541091 both_7\CC\1740 in_8\IN\13603305 levobupivacaine-induced_9\JJ\1740 <e2>cardiac_10\JJ\1740 toxicity</e2>_11\NN\13576101 in_12\IN\13603305 newborn_13\JJ\1740 piglets_14\NNS\1321854 ._15\.\1740
C476513_D066126 NONE resuscitation_0\NN\1047338 with_1\IN\1740 lipid_2\NN\14944888 ,_3\,\1740 epinephrine_4\NN\14807929 ,_5\,\1740 or_6\CC\3541091 both_7\CC\1740 in_8\IN\13603305 <e1>levobupivacaine-induced</e1>_9\JJ\1740 <e2>cardiac_10\JJ\1740 toxicity</e2>_11\NN\13576101 in_12\IN\13603305 newborn_13\JJ\1740 piglets_14\NNS\1321854 ._15\.\1740
D004837_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 optimal_3\JJ\1740 dosing_4\NN\1740 regimens_5\NNS\5898568 of_6\IN\1740 lipid_7\NN\14944888 emulsion_8\NN\14588219 ,_9\,\1740 <e1>epinephrine</e1>_10\NN\14807929 ,_11\,\1740 or_12\CC\3541091 both_13\DT\1740 are_14\VBP\836236 not_15\RB\1740 yet_16\RB\1740 determined_17\VBN\1645601 in_18\IN\13603305 neonates_19\NNS\9827683 in_20\IN\13603305 cases_21\NNS\7283608 of_22\IN\1740 local_23\JJ\1740 anaesthetic_24\JJ\1740 systemic_25\JJ\1740 <e2>toxicity</e2>_26\NN\13576101 (_27\-LRB-\1740 last_28\JJ\1740 )_29\-RRB-\1740 ._30\.\1740
C476513_D002318 CID methods_0\NNS\5616786 :_1\:\1740 newborn_2\JJ\1740 piglets_3\NNS\1321854 received_4\VBD\2210855 <e1>levobupivacaine</e1>_5\NN\1740 until_6\IN\1740 <e2>cardiovascular_7\JJ\1740 collapse</e2>_8\NN\14061805 occurred_9\VBD\2623529 ._10\.\1740
16911931
D019259_D006509 NONE intramuscular_0\JJ\1740 <e2>hepatitis_1\NN\14127211 b</e2>_2\NN\1355326 immune_3\JJ\1740 globulin_4\NN\14736972 combined_5\VBN\2630189 with_6\IN\1740 <e1>lamivudine</e1>_7\NN\3834836 in_8\IN\13603305 prevention_9\NN\1073995 of_10\IN\1740 hepatitis_11\NN\14127211 b_12\NN\1355326 recurrence_13\NN\7342049 after_14\IN\1740 liver_15\NN\5298729 transplantation_16\NN\671351 ._17\.\1740
D019259_D006509 NONE intramuscular_0\JJ\1740 hepatitis_1\NN\14127211 b_2\NN\1355326 immune_3\JJ\1740 globulin_4\NN\14736972 combined_5\VBN\2630189 with_6\IN\1740 <e1>lamivudine</e1>_7\NN\3834836 in_8\IN\13603305 prevention_9\NN\1073995 of_10\IN\1740 <e2>hepatitis_11\NN\14127211 b</e2>_12\NN\1355326 recurrence_13\NN\7342049 after_14\IN\1740 liver_15\NN\5298729 transplantation_16\NN\671351 ._17\.\1740
D019259_D006509 NONE background_0\NN\4921011 :_1\:\1740 combined_2\JJ\1740 <e2>hepatitis_3\NN\14127211 b</e2>_4\NN\1355326 immune_5\JJ\1740 globulin_6\NN\14736972 (_7\-LRB-\1740 hbig_8\NNS\1740 )_9\-RRB-\1740 and_10\CC\1740 <e1>lamivudine</e1>_11\NN\3834836 in_12\IN\13603305 prophylaxis_13\NN\1077350 of_14\IN\1740 the_15\DT\1740 recurrence_16\NN\7342049 of_17\IN\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 after_20\IN\1740 liver_21\NN\5298729 transplantation_22\NN\671351 has_23\VBZ\2108377 significantly_24\RB\1740 improved_25\VBN\126264 the_26\DT\1740 survival_27\NN\13961642 of_28\IN\1740 hbsag_29\NN\1740 positive_30\JJ\1740 patients_31\NNS\9898892 ._32\.\1740
D019259_D006509 NONE background_0\NN\4921011 :_1\:\1740 combined_2\JJ\1740 hepatitis_3\NN\14127211 b_4\NN\1355326 immune_5\JJ\1740 globulin_6\NN\14736972 (_7\-LRB-\1740 hbig_8\NNS\1740 )_9\-RRB-\1740 and_10\CC\1740 <e1>lamivudine</e1>_11\NN\3834836 in_12\IN\13603305 prophylaxis_13\NN\1077350 of_14\IN\1740 the_15\DT\1740 recurrence_16\NN\7342049 of_17\IN\1740 <e2>hepatitis_18\NN\14127211 b</e2>_19\NN\1355326 after_20\IN\1740 liver_21\NN\5298729 transplantation_22\NN\671351 has_23\VBZ\2108377 significantly_24\RB\1740 improved_25\VBN\126264 the_26\DT\1740 survival_27\NN\13961642 of_28\IN\1740 hbsag_29\NN\1740 positive_30\JJ\1740 patients_31\NNS\9898892 ._32\.\1740
D006514_D006509 NONE background_0\NN\4921011 :_1\:\1740 combined_2\JJ\1740 <e2>hepatitis_3\NN\14127211 b</e2>_4\NN\1355326 immune_5\JJ\1740 globulin_6\NN\14736972 (_7\-LRB-\1740 hbig_8\NNS\1740 )_9\-RRB-\1740 and_10\CC\1740 lamivudine_11\NN\3834836 in_12\IN\13603305 prophylaxis_13\NN\1077350 of_14\IN\1740 the_15\DT\1740 recurrence_16\NN\7342049 of_17\IN\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 after_20\IN\1740 liver_21\NN\5298729 transplantation_22\NN\671351 has_23\VBZ\2108377 significantly_24\RB\1740 improved_25\VBN\126264 the_26\DT\1740 survival_27\NN\13961642 of_28\IN\1740 <e1>hbsag</e1>_29\NN\1740 positive_30\JJ\1740 patients_31\NNS\9898892 ._32\.\1740
D006514_D006509 NONE background_0\NN\4921011 :_1\:\1740 combined_2\JJ\1740 hepatitis_3\NN\14127211 b_4\NN\1355326 immune_5\JJ\1740 globulin_6\NN\14736972 (_7\-LRB-\1740 hbig_8\NNS\1740 )_9\-RRB-\1740 and_10\CC\1740 lamivudine_11\NN\3834836 in_12\IN\13603305 prophylaxis_13\NN\1077350 of_14\IN\1740 the_15\DT\1740 recurrence_16\NN\7342049 of_17\IN\1740 <e2>hepatitis_18\NN\14127211 b</e2>_19\NN\1355326 after_20\IN\1740 liver_21\NN\5298729 transplantation_22\NN\671351 has_23\VBZ\2108377 significantly_24\RB\1740 improved_25\VBN\126264 the_26\DT\1740 survival_27\NN\13961642 of_28\IN\1740 <e1>hbsag</e1>_29\NN\1740 positive_30\JJ\1740 patients_31\NNS\9898892 ._32\.\1740
20034406
D010862_D013226 CID chemokine_0\NN\1740 ccl2_1\NN\1740 and_2\CC\1740 its_3\PRP$\6125041 receptor_4\NN\5225602 ccr2_5\NN\1740 are_6\VBP\836236 increased_7\VBN\169651 in_8\IN\13603305 the_9\DT\1740 hippocampus_10\NN\5462674 following_11\VBG\1835496 <e1>pilocarpine-induced</e1>_12\JJ\1740 <e2>status_13\NN\24720 epilepticus</e2>_14\NN\1740 ._15\.\1740
D010862_D013226 CID in_0\IN\13603305 this_1\DT\1740 work_2\NN\407535 ccr2_3\NN\1740 and_4\CC\1740 ccl2_5\NN\1740 expression_6\NN\4679549 were_7\VBD\836236 examined_8\VBN\789138 following_9\VBG\1835496 <e2>status_10\NN\24720 epilepticus</e2>_11\NN\1740 (_12\-LRB-\1740 se_13\NN\14724645 )_14\-RRB-\1740 induced_15\VBN\1627355 by_16\IN\1740 <e1>pilocarpine</e1>_17\NN\14712692 injection_18\NN\320852 ._19\.\1740
D010862_D013226 CID in_0\IN\13603305 this_1\DT\1740 work_2\NN\407535 ccr2_3\NN\1740 and_4\CC\1740 ccl2_5\NN\1740 expression_6\NN\4679549 were_7\VBD\836236 examined_8\VBN\789138 following_9\VBG\1835496 status_10\NN\24720 epilepticus_11\NN\1740 (_12\-LRB-\1740 <e2>se</e2>_13\NN\14724645 )_14\-RRB-\1740 induced_15\VBN\1627355 by_16\IN\1740 <e1>pilocarpine</e1>_17\NN\14712692 injection_18\NN\320852 ._19\.\1740
D010862_D013226 CID methods_0\NNS\5616786 :_1\:\1740 <e2>se</e2>_2\NN\14724645 was_3\VBD\836236 induced_4\VBN\1627355 by_5\IN\1740 <e1>pilocarpine</e1>_6\NN\14712692 injection_7\NN\320852 ._8\.\1740
D010862_D013226 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 data_3\NNS\7951464 show_4\VBP\2137132 that_5\IN\1740 ccr2_6\NN\1740 and_7\CC\1740 ccl2_8\NN\1740 are_9\VBP\836236 up-regulated_10\VBN\1740 in_11\IN\13603305 the_12\DT\1740 hippocampus_13\NN\5462674 after_14\IN\1740 <e1>pilocarpine-induced</e1>_15\JJ\1740 <e2>se</e2>_16\NN\14724645 ._17\.\1740
6985297
D015764_D001919 CID studies_0\NNS\635850 on_1\IN\1740 the_2\DT\1740 <e2>bradycardia</e2>_3\NN\14110674 induced_4\VBN\1627355 by_5\IN\1740 <e1>bepridil</e1>_6\NN\1740 ._7\.\1740
D015764_D001919 CID <e1>bepridil</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 novel_3\JJ\1740 active_4\JJ\1740 compound_5\NN\5869584 for_6\IN\1740 prophylactic_7\JJ\1740 treatment_8\NN\654885 of_9\IN\1740 anginal_10\JJ\1740 attacks_11\NNS\955060 ,_12\,\1740 induced_13\VBN\1627355 persistent_14\JJ\1740 <e2>bradycardia</e2>_15\NN\14110674 and_16\CC\1740 a_17\DT\13649268 non-specific_18\JJ\1740 anti-tachycardial_19\JJ\1740 effect_20\NN\34213 ,_21\,\1740 the_22\DT\1740 mechanisms_23\NNS\13446390 of_24\IN\1740 which_25\WDT\1740 were_26\VBD\836236 investigated_27\VBN\644583 in_28\FW\13603305 vitro_29\FW\1740 and_30\CC\1740 in_31\FW\13603305 vivo_32\FW\1740 ._33\.\1740
D015764_D000787 NONE <e1>bepridil</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 novel_3\JJ\1740 active_4\JJ\1740 compound_5\NN\5869584 for_6\IN\1740 prophylactic_7\JJ\1740 treatment_8\NN\654885 of_9\IN\1740 <e2>anginal_10\JJ\1740 attacks</e2>_11\NNS\955060 ,_12\,\1740 induced_13\VBN\1627355 persistent_14\JJ\1740 bradycardia_15\NN\14110674 and_16\CC\1740 a_17\DT\13649268 non-specific_18\JJ\1740 anti-tachycardial_19\JJ\1740 effect_20\NN\34213 ,_21\,\1740 the_22\DT\1740 mechanisms_23\NNS\13446390 of_24\IN\1740 which_25\WDT\1740 were_26\VBD\836236 investigated_27\VBN\644583 in_28\FW\13603305 vitro_29\FW\1740 and_30\CC\1740 in_31\FW\13603305 vivo_32\FW\1740 ._33\.\1740
D015764_D013610 NONE <e1>bepridil</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 novel_3\JJ\1740 active_4\JJ\1740 compound_5\NN\5869584 for_6\IN\1740 prophylactic_7\JJ\1740 treatment_8\NN\654885 of_9\IN\1740 anginal_10\JJ\1740 attacks_11\NNS\955060 ,_12\,\1740 induced_13\VBN\1627355 persistent_14\JJ\1740 bradycardia_15\NN\14110674 and_16\CC\1740 a_17\DT\13649268 non-specific_18\JJ\1740 <e2>anti-tachycardial</e2>_19\JJ\1740 effect_20\NN\34213 ,_21\,\1740 the_22\DT\1740 mechanisms_23\NNS\13446390 of_24\IN\1740 which_25\WDT\1740 were_26\VBD\836236 investigated_27\VBN\644583 in_28\FW\13603305 vitro_29\FW\1740 and_30\CC\1740 in_31\FW\13603305 vivo_32\FW\1740 ._33\.\1740
7949506
D003000_D054537 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 a_7\DT\13649268 possible_8\JJ\1740 adverse_9\JJ\1740 interaction_10\NN\37396 between_11\IN\1740 <e1>clonidine</e1>_12\NN\2721160 and_13\CC\1740 verapamil_14\NN\2938514 resulting_15\VBG\2633881 in_16\IN\13603305 <e2>atrioventricular_17\JJ\1740 (_18\-LRB-\1740 av_19\NN\15214068 )_20\-RRB-\1740 block</e2>_21\NN\21939 in_22\IN\13603305 both_23\CC\1740 patients_24\NNS\9898892 and_25\CC\1740 severe_26\JJ\1740 hypotension_27\NN\14057371 in_28\IN\13603305 one_29\CD\13741022 patient_30\NN\9898892 ._31\.\1740
D003000_D054537 CID after_0\IN\1740 the_1\DT\1740 addition_2\NN\3081021 of_3\IN\1740 a_4\DT\13649268 minimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>clonidine</e1>_8\NN\2721160 (_9\-LRB-\1740 0.15_10\CD\1740 mg_11\NN\13717155 bid_12\NN\7160883 )_13\-RRB-\1740 ,_14\,\1740 she_15\PRP\1740 developed_16\VBD\1753788 complete_17\JJ\1740 <e2>av_18\NN\15214068 block</e2>_19\NN\21939 and_20\CC\1740 severe_21\JJ\1740 hypotension_22\NN\14057371 ,_23\,\1740 which_24\WDT\1740 resolved_25\VBD\352826 upon_26\IN\1740 cessation_27\NN\7365849 of_28\IN\1740 all_29\DT\1740 medications._30\NN\1740 a_31\NN\13649268 65-year-old_32\JJ\1740 woman_33\NN\9605289 was_34\VBD\836236 treated_35\VBN\2376958 with_36\IN\1740 extended-release_37\NN\1740 verapamil_38\NN\2938514 240_39\CD\1740 mg/d_40\NN\1740 ._41\.\1740
D003000_D054537 CID after_0\IN\1740 the_1\DT\1740 addition_2\NN\3081021 of_3\IN\1740 <e1>clonidine</e1>_4\NN\2721160 0.15_5\CD\1740 mg_6\NN\13717155 bid_7\NN\7160883 she_8\PRP\1740 developed_9\VBD\1753788 complete_10\JJ\1740 <e2>av_11\NN\15214068 block</e2>_12\NN\21939 ,_13\,\1740 which_14\WDT\1740 resolved_15\VBD\352826 after_16\IN\1740 all_17\DT\1740 therapy_18\NN\657604 was_19\VBD\836236 stopped_20\VBN\2452885 ._21\.\1740
D003000_D007022 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 a_7\DT\13649268 possible_8\JJ\1740 adverse_9\JJ\1740 interaction_10\NN\37396 between_11\IN\1740 <e1>clonidine</e1>_12\NN\2721160 and_13\CC\1740 verapamil_14\NN\2938514 resulting_15\VBG\2633881 in_16\IN\13603305 atrioventricular_17\JJ\1740 (_18\-LRB-\1740 av_19\NN\15214068 )_20\-RRB-\1740 block_21\NN\21939 in_22\IN\13603305 both_23\CC\1740 patients_24\NNS\9898892 and_25\CC\1740 severe_26\JJ\1740 <e2>hypotension</e2>_27\NN\14057371 in_28\IN\13603305 one_29\CD\13741022 patient_30\NN\9898892 ._31\.\1740
D003000_D007022 CID after_0\IN\1740 the_1\DT\1740 addition_2\NN\3081021 of_3\IN\1740 a_4\DT\13649268 minimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>clonidine</e1>_8\NN\2721160 (_9\-LRB-\1740 0.15_10\CD\1740 mg_11\NN\13717155 bid_12\NN\7160883 )_13\-RRB-\1740 ,_14\,\1740 she_15\PRP\1740 developed_16\VBD\1753788 complete_17\JJ\1740 av_18\NN\15214068 block_19\NN\21939 and_20\CC\1740 severe_21\JJ\1740 <e2>hypotension</e2>_22\NN\14057371 ,_23\,\1740 which_24\WDT\1740 resolved_25\VBD\352826 upon_26\IN\1740 cessation_27\NN\7365849 of_28\IN\1740 all_29\DT\1740 medications._30\NN\1740 a_31\NN\13649268 65-year-old_32\JJ\1740 woman_33\NN\9605289 was_34\VBD\836236 treated_35\VBN\2376958 with_36\IN\1740 extended-release_37\NN\1740 verapamil_38\NN\2938514 240_39\CD\1740 mg/d_40\NN\1740 ._41\.\1740
D014700_D054537 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 a_7\DT\13649268 possible_8\JJ\1740 adverse_9\JJ\1740 interaction_10\NN\37396 between_11\IN\1740 clonidine_12\NN\2721160 and_13\CC\1740 <e1>verapamil</e1>_14\NN\2938514 resulting_15\VBG\2633881 in_16\IN\13603305 <e2>atrioventricular_17\JJ\1740 (_18\-LRB-\1740 av_19\NN\15214068 )_20\-RRB-\1740 block</e2>_21\NN\21939 in_22\IN\13603305 both_23\CC\1740 patients_24\NNS\9898892 and_25\CC\1740 severe_26\JJ\1740 hypotension_27\NN\14057371 in_28\IN\13603305 one_29\CD\13741022 patient_30\NN\9898892 ._31\.\1740
D014700_D054537 CID after_0\IN\1740 the_1\DT\1740 addition_2\NN\3081021 of_3\IN\1740 a_4\DT\13649268 minimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 clonidine_8\NN\2721160 (_9\-LRB-\1740 0.15_10\CD\1740 mg_11\NN\13717155 bid_12\NN\7160883 )_13\-RRB-\1740 ,_14\,\1740 she_15\PRP\1740 developed_16\VBD\1753788 complete_17\JJ\1740 <e2>av_18\NN\15214068 block</e2>_19\NN\21939 and_20\CC\1740 severe_21\JJ\1740 hypotension_22\NN\14057371 ,_23\,\1740 which_24\WDT\1740 resolved_25\VBD\352826 upon_26\IN\1740 cessation_27\NN\7365849 of_28\IN\1740 all_29\DT\1740 medications._30\NN\1740 a_31\NN\13649268 65-year-old_32\JJ\1740 woman_33\NN\9605289 was_34\VBD\836236 treated_35\VBN\2376958 with_36\IN\1740 extended-release_37\NN\1740 <e1>verapamil</e1>_38\NN\2938514 240_39\CD\1740 mg/d_40\NN\1740 ._41\.\1740
D014700_D007022 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 a_7\DT\13649268 possible_8\JJ\1740 adverse_9\JJ\1740 interaction_10\NN\37396 between_11\IN\1740 clonidine_12\NN\2721160 and_13\CC\1740 <e1>verapamil</e1>_14\NN\2938514 resulting_15\VBG\2633881 in_16\IN\13603305 atrioventricular_17\JJ\1740 (_18\-LRB-\1740 av_19\NN\15214068 )_20\-RRB-\1740 block_21\NN\21939 in_22\IN\13603305 both_23\CC\1740 patients_24\NNS\9898892 and_25\CC\1740 severe_26\JJ\1740 <e2>hypotension</e2>_27\NN\14057371 in_28\IN\13603305 one_29\CD\13741022 patient_30\NN\9898892 ._31\.\1740
D014700_D007022 CID after_0\IN\1740 the_1\DT\1740 addition_2\NN\3081021 of_3\IN\1740 a_4\DT\13649268 minimal_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 clonidine_8\NN\2721160 (_9\-LRB-\1740 0.15_10\CD\1740 mg_11\NN\13717155 bid_12\NN\7160883 )_13\-RRB-\1740 ,_14\,\1740 she_15\PRP\1740 developed_16\VBD\1753788 complete_17\JJ\1740 av_18\NN\15214068 block_19\NN\21939 and_20\CC\1740 severe_21\JJ\1740 <e2>hypotension</e2>_22\NN\14057371 ,_23\,\1740 which_24\WDT\1740 resolved_25\VBD\352826 upon_26\IN\1740 cessation_27\NN\7365849 of_28\IN\1740 all_29\DT\1740 medications._30\NN\1740 a_31\NN\13649268 65-year-old_32\JJ\1740 woman_33\NN\9605289 was_34\VBD\836236 treated_35\VBN\2376958 with_36\IN\1740 extended-release_37\NN\1740 <e1>verapamil</e1>_38\NN\2938514 240_39\CD\1740 mg/d_40\NN\1740 ._41\.\1740
D014700_D006929 NONE case_0\NN\7283608 summaries_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 54-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 <e2>hyperaldosteronism</e2>_7\NN\14059928 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 <e1>verapamil</e1>_11\NN\2938514 480_12\CD\1740 mg/d_13\NN\1740 and_14\CC\1740 spironolactone_15\VBD\1740 100_16\CD\13745420 mg/d_17\NN\1740 ._18\.\1740
D013148_D006929 NONE case_0\NN\7283608 summaries_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 54-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 <e2>hyperaldosteronism</e2>_7\NN\14059928 was_8\VBD\836236 treated_9\VBN\2376958 with_10\IN\1740 verapamil_11\NN\2938514 480_12\CD\1740 mg/d_13\NN\1740 and_14\CC\1740 <e1>spironolactone</e1>_15\VBD\1740 100_16\CD\13745420 mg/d_17\NN\1740 ._18\.\1740
11135381
D008729_D014550 NONE effect_0\NN\34213 of_1\IN\1740 <e1>methoxamine</e1>_2\NN\1740 on_3\IN\1740 maximum_4\JJ\1740 urethral_5\JJ\1740 pressure_6\NN\11419404 in_7\IN\13603305 women_8\NNS\9605289 with_9\IN\1740 genuine_10\JJ\1740 <e2>stress_11\NN\7083732 incontinence</e2>_12\NN\13473097 :_13\:\1740 a_14\DT\13649268 placebo-controlled_15\JJ\1740 ,_16\,\1740 double-blind_17\JJ\1740 crossover_18\NN\13526110 study_19\VBP\630380 ._20\.\1740
D008729_D014550 NONE half_0\NN\13732295 log_1\NN\15098161 incremental_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 intravenous_5\JJ\1740 <e1>methoxamine</e1>_6\NN\1740 or_7\CC\3541091 placebo_8\NN\3740161 (_9\-LRB-\1740 saline_10\NN\14849367 )_11\-RRB-\1740 were_12\VBD\836236 administered_13\VBN\2436349 to_14\TO\1740 a_15\DT\13649268 group_16\NN\2137 of_17\IN\1740 women_18\NNS\9605289 with_19\IN\1740 genuine_20\JJ\1740 <e2>stress_21\NN\7083732 incontinence</e2>_22\NN\13473097 while_23\IN\15122231 measuring_24\VBG\697589 maximum_25\NN\13653902 urethral_26\JJ\1740 pressure_27\NN\11419404 (_28\-LRB-\1740 mup_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 blood_32\NN\5397468 pressure_33\NN\11419404 ,_34\,\1740 heart_35\NN\5919034 rate_36\NN\13815152 ,_37\,\1740 and_38\CC\1740 symptomatic_39\JJ\1740 side_40\NN\8630039 effects_41\NNS\13245626 ._42\.\1740
D008729_D006973 CID <e1>methoxamine</e1>_0\NNP\1740 evoked_1\VBD\1617192 non-significant_2\JJ\1740 increases_3\NNS\13576355 in_4\IN\13603305 mup_5\NN\1740 and_6\CC\1740 diastolic_7\JJ\1740 blood_8\NN\5397468 pressure_9\NN\11419404 but_10\CC\1740 caused_11\VBD\1617192 <e2>a_12\DT\13649268 significant_13\JJ\1740 rise_14\NN\7324673 in_15\IN\13603305 systolic_16\JJ\1740 blood_17\NN\5397468 pressure</e2>_18\NN\11419404 and_19\CC\1740 significant_20\JJ\1740 fall_21\NN\15236475 in_22\IN\13603305 heart_23\NN\5919034 rate_24\NN\13815152 at_25\IN\14622893 maximum_26\NN\13653902 dosage_27\NN\13576355 ._28\.\1740
3191389
D010862_D012640 CID differential_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 non-steroidal_3\JJ\1740 anti-inflammatory_4\JJ\1740 drugs_5\NNS\14778436 on_6\IN\1740 <e2>seizures</e2>_7\NNS\14081375 produced_8\VBN\1617192 by_9\IN\1740 <e1>pilocarpine</e1>_10\NN\14712692 in_11\IN\13603305 rats_12\NNS\2329401 ._13\.\1740
D010862_D012640 CID the_0\DT\1740 muscarinic_1\JJ\1740 cholinergic_2\NN\1740 agonist_3\NN\9613191 <e1>pilocarpine</e1>_4\NN\14712692 induces_5\VBZ\1627355 in_6\IN\13603305 rats_7\NNS\2329401 <e2>seizures</e2>_8\NNS\14081375 and_9\CC\1740 status_10\NN\24720 epilepticus_11\NN\1740 followed_12\VBN\1835496 by_13\IN\1740 widespread_14\JJ\1740 damage_15\NN\7296428 to_16\IN\1740 the_17\DT\1740 forebrain_18\NN\5462674 ._19\.\1740
D010862_D012640 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 5_10\CD\13741022 non-steroidal_11\JJ\1740 anti-inflammatory_12\JJ\1740 drugs_13\NNS\14778436 ,_14\,\1740 sodium_15\NN\14625458 salicylate_16\NN\3828465 ,_17\,\1740 phenylbutazone_18\NN\2721538 ,_19\,\1740 indomethacin_20\NN\3828465 ,_21\,\1740 ibuprofen_22\NN\3828465 and_23\CC\1740 mefenamic_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 on_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 produced_29\VBN\1617192 by_30\IN\1740 <e1>pilocarpine</e1>_31\NN\14712692 ._32\.\1740
D010862_D012640 CID indomethacin_0\NN\3828465 ,_1\,\1740 1_2\CD\13741022 -_3\SYM\1740 10_4\CD\13745420 mg/kg_5\NN\1740 ,_6\,\1740 and_7\CC\1740 ibuprofen_8\NN\3828465 ,_9\,\1740 10_10\CD\13745420 -_11\SYM\1740 100_12\CD\13745420 mg/kg_13\NN\1740 ,_14\,\1740 failed_15\VBD\1798936 to_16\TO\1740 modulate_17\VB\1724459 <e2>seizures</e2>_18\NNS\14081375 produced_19\VBN\1617192 by_20\IN\1740 <e1>pilocarpine</e1>_21\NN\14712692 ._22\.\1740
D010862_D012640 CID mefenamic_0\JJ\1740 acid_1\NN\14818238 ,_2\,\1740 26_3\CD\13745420 (_4\-LRB-\1740 22_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 )_8\-RRB-\1740 mg/kg_9\NN\1740 ,_10\,\1740 prevented_11\VBD\1740 <e2>seizures</e2>_12\NNS\14081375 and_13\CC\1740 protected_14\VBD\1127795 rats_15\NNS\2329401 from_16\IN\1740 seizure-related_17\JJ\1740 brain_18\NN\5462674 damage_19\NN\7296428 induced_20\VBN\1627355 by_21\IN\1740 <e1>pilocarpine</e1>_22\NN\14712692 ,_23\,\1740 380_24\CD\1740 mg/kg_25\NN\1740 ._26\.\1740
D010862_D012640 CID mefenamic_0\JJ\1740 acid_1\NN\14818238 ,_2\,\1740 26_3\CD\13745420 (_4\-LRB-\1740 22_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 )_8\-RRB-\1740 mg/kg_9\NN\1740 ,_10\,\1740 prevented_11\VBD\1740 seizures_12\NNS\14081375 and_13\CC\1740 protected_14\VBD\1127795 rats_15\NNS\2329401 from_16\IN\1740 <e2>seizure-related</e2>_17\JJ\1740 brain_18\NN\5462674 damage_19\NN\7296428 induced_20\VBN\1627355 by_21\IN\1740 <e1>pilocarpine</e1>_22\NN\14712692 ,_23\,\1740 380_24\CD\1740 mg/kg_25\NN\1740 ._26\.\1740
D010862_D012640 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 non-steroidal_4\JJ\1740 anti-inflammatory_5\JJ\1740 drugs_6\NNS\14778436 differentially_7\RB\1740 modulate_8\VBP\1724459 the_9\DT\1740 threshold_10\NN\15265518 for_11\IN\1740 <e1>pilocarpine-induced</e1>_12\JJ\1740 <e2>seizures</e2>_13\NNS\14081375 ._14\.\1740
D010862_D013226 CID the_0\DT\1740 muscarinic_1\JJ\1740 cholinergic_2\NN\1740 agonist_3\NN\9613191 <e1>pilocarpine</e1>_4\NN\14712692 induces_5\VBZ\1627355 in_6\IN\13603305 rats_7\NNS\2329401 seizures_8\NNS\14081375 and_9\CC\1740 <e2>status_10\NN\24720 epilepticus</e2>_11\NN\1740 followed_12\VBN\1835496 by_13\IN\1740 widespread_14\JJ\1740 damage_15\NN\7296428 to_16\IN\1740 the_17\DT\1740 forebrain_18\NN\5462674 ._19\.\1740
D012980_D012640 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 5_10\CD\13741022 non-steroidal_11\JJ\1740 anti-inflammatory_12\JJ\1740 drugs_13\NNS\14778436 ,_14\,\1740 <e1>sodium_15\NN\14625458 salicylate</e1>_16\NN\3828465 ,_17\,\1740 phenylbutazone_18\NN\2721538 ,_19\,\1740 indomethacin_20\NN\3828465 ,_21\,\1740 ibuprofen_22\NN\3828465 and_23\CC\1740 mefenamic_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 on_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 produced_29\VBN\1617192 by_30\IN\1740 pilocarpine_31\NN\14712692 ._32\.\1740
D010653_D012640 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 5_10\CD\13741022 non-steroidal_11\JJ\1740 anti-inflammatory_12\JJ\1740 drugs_13\NNS\14778436 ,_14\,\1740 sodium_15\NN\14625458 salicylate_16\NN\3828465 ,_17\,\1740 <e1>phenylbutazone</e1>_18\NN\2721538 ,_19\,\1740 indomethacin_20\NN\3828465 ,_21\,\1740 ibuprofen_22\NN\3828465 and_23\CC\1740 mefenamic_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 on_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 produced_29\VBN\1617192 by_30\IN\1740 pilocarpine_31\NN\14712692 ._32\.\1740
D007213_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 5_10\CD\13741022 non-steroidal_11\JJ\1740 anti-inflammatory_12\JJ\1740 drugs_13\NNS\14778436 ,_14\,\1740 sodium_15\NN\14625458 salicylate_16\NN\3828465 ,_17\,\1740 phenylbutazone_18\NN\2721538 ,_19\,\1740 <e1>indomethacin</e1>_20\NN\3828465 ,_21\,\1740 ibuprofen_22\NN\3828465 and_23\CC\1740 mefenamic_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 on_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 produced_29\VBN\1617192 by_30\IN\1740 pilocarpine_31\NN\14712692 ._32\.\1740
D007213_D012640 NONE <e1>indomethacin</e1>_0\NN\3828465 ,_1\,\1740 1_2\CD\13741022 -_3\SYM\1740 10_4\CD\13745420 mg/kg_5\NN\1740 ,_6\,\1740 and_7\CC\1740 ibuprofen_8\NN\3828465 ,_9\,\1740 10_10\CD\13745420 -_11\SYM\1740 100_12\CD\13745420 mg/kg_13\NN\1740 ,_14\,\1740 failed_15\VBD\1798936 to_16\TO\1740 modulate_17\VB\1724459 <e2>seizures</e2>_18\NNS\14081375 produced_19\VBN\1617192 by_20\IN\1740 pilocarpine_21\NN\14712692 ._22\.\1740
D007052_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 5_10\CD\13741022 non-steroidal_11\JJ\1740 anti-inflammatory_12\JJ\1740 drugs_13\NNS\14778436 ,_14\,\1740 sodium_15\NN\14625458 salicylate_16\NN\3828465 ,_17\,\1740 phenylbutazone_18\NN\2721538 ,_19\,\1740 indomethacin_20\NN\3828465 ,_21\,\1740 <e1>ibuprofen</e1>_22\NN\3828465 and_23\CC\1740 mefenamic_24\JJ\1740 acid_25\NN\14818238 ,_26\,\1740 on_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 produced_29\VBN\1617192 by_30\IN\1740 pilocarpine_31\NN\14712692 ._32\.\1740
D007052_D012640 NONE indomethacin_0\NN\3828465 ,_1\,\1740 1_2\CD\13741022 -_3\SYM\1740 10_4\CD\13745420 mg/kg_5\NN\1740 ,_6\,\1740 and_7\CC\1740 <e1>ibuprofen</e1>_8\NN\3828465 ,_9\,\1740 10_10\CD\13745420 -_11\SYM\1740 100_12\CD\13745420 mg/kg_13\NN\1740 ,_14\,\1740 failed_15\VBD\1798936 to_16\TO\1740 modulate_17\VB\1724459 <e2>seizures</e2>_18\NNS\14081375 produced_19\VBN\1617192 by_20\IN\1740 pilocarpine_21\NN\14712692 ._22\.\1740
D008528_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 investigate_6\VB\644583 the_7\DT\1740 effect_8\NN\34213 of_9\IN\1740 5_10\CD\13741022 non-steroidal_11\JJ\1740 anti-inflammatory_12\JJ\1740 drugs_13\NNS\14778436 ,_14\,\1740 sodium_15\NN\14625458 salicylate_16\NN\3828465 ,_17\,\1740 phenylbutazone_18\NN\2721538 ,_19\,\1740 indomethacin_20\NN\3828465 ,_21\,\1740 ibuprofen_22\NN\3828465 and_23\CC\1740 <e1>mefenamic_24\JJ\1740 acid</e1>_25\NN\14818238 ,_26\,\1740 on_27\IN\1740 <e2>seizures</e2>_28\NNS\14081375 produced_29\VBN\1617192 by_30\IN\1740 pilocarpine_31\NN\14712692 ._32\.\1740
D008528_D012640 NONE <e1>mefenamic_0\JJ\1740 acid</e1>_1\NN\14818238 ,_2\,\1740 26_3\CD\13745420 (_4\-LRB-\1740 22_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 )_8\-RRB-\1740 mg/kg_9\NN\1740 ,_10\,\1740 prevented_11\VBD\1740 <e2>seizures</e2>_12\NNS\14081375 and_13\CC\1740 protected_14\VBD\1127795 rats_15\NNS\2329401 from_16\IN\1740 seizure-related_17\JJ\1740 brain_18\NN\5462674 damage_19\NN\7296428 induced_20\VBN\1627355 by_21\IN\1740 pilocarpine_22\NN\14712692 ,_23\,\1740 380_24\CD\1740 mg/kg_25\NN\1740 ._26\.\1740
D008528_D012640 NONE <e1>mefenamic_0\JJ\1740 acid</e1>_1\NN\14818238 ,_2\,\1740 26_3\CD\13745420 (_4\-LRB-\1740 22_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 )_8\-RRB-\1740 mg/kg_9\NN\1740 ,_10\,\1740 prevented_11\VBD\1740 seizures_12\NNS\14081375 and_13\CC\1740 protected_14\VBD\1127795 rats_15\NNS\2329401 from_16\IN\1740 <e2>seizure-related</e2>_17\JJ\1740 brain_18\NN\5462674 damage_19\NN\7296428 induced_20\VBN\1627355 by_21\IN\1740 pilocarpine_22\NN\14712692 ,_23\,\1740 380_24\CD\1740 mg/kg_25\NN\1740 ._26\.\1740
D008528_D001930 NONE <e1>mefenamic_0\JJ\1740 acid</e1>_1\NN\14818238 ,_2\,\1740 26_3\CD\13745420 (_4\-LRB-\1740 22_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 )_8\-RRB-\1740 mg/kg_9\NN\1740 ,_10\,\1740 prevented_11\VBD\1740 seizures_12\NNS\14081375 and_13\CC\1740 protected_14\VBD\1127795 rats_15\NNS\2329401 from_16\IN\1740 seizure-related_17\JJ\1740 <e2>brain_18\NN\5462674 damage</e2>_19\NN\7296428 induced_20\VBN\1627355 by_21\IN\1740 pilocarpine_22\NN\14712692 ,_23\,\1740 380_24\CD\1740 mg/kg_25\NN\1740 ._26\.\1740
D010862_D001930 NONE mefenamic_0\JJ\1740 acid_1\NN\14818238 ,_2\,\1740 26_3\CD\13745420 (_4\-LRB-\1740 22_5\CD\13745420 -_6\SYM\1740 30_7\CD\13745420 )_8\-RRB-\1740 mg/kg_9\NN\1740 ,_10\,\1740 prevented_11\VBD\1740 seizures_12\NNS\14081375 and_13\CC\1740 protected_14\VBD\1127795 rats_15\NNS\2329401 from_16\IN\1740 seizure-related_17\JJ\1740 <e2>brain_18\NN\5462674 damage</e2>_19\NN\7296428 induced_20\VBN\1627355 by_21\IN\1740 <e1>pilocarpine</e1>_22\NN\14712692 ,_23\,\1740 380_24\CD\1740 mg/kg_25\NN\1740 ._26\.\1740
7147232
D000255_D007022 CID cardiovascular_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e2>hypotension</e2>_3\NN\14057371 induced_4\VBN\1627355 by_5\IN\1740 <e1>adenosine_6\NN\14964367 triphosphate</e1>_7\NN\1740 and_8\CC\1740 sodium_9\NN\14625458 nitroprusside_10\NN\1740 on_11\IN\1740 dogs_12\NNS\2083346 with_13\IN\1740 denervated_14\JJ\1740 hearts_15\NNS\496167 ._16\.\1740
D000255_D007022 CID <e1>adenosine_0\JJ\1740 triphosphate</e1>_1\NN\1740 (_2\-LRB-\1740 atp_3\NN\14964590 )_4\-RRB-\1740 and_5\CC\1740 sodium_6\NN\14625458 nitroprusside_7\NN\1740 (_8\-LRB-\1740 snp_9\NN\11493266 )_10\-RRB-\1740 are_11\VBP\836236 administered_12\VBN\2436349 to_13\TO\1740 patients_14\NNS\9898892 to_15\TO\1740 induce_16\VB\1627355 and_17\CC\1740 control_18\NN\5190804 <e2>hypotension</e2>_19\NN\14057371 during_20\IN\1740 anesthesia_21\NN\14034177 ._22\.\1740
D000255_D007022 CID adenosine_0\JJ\1740 triphosphate_1\NN\1740 (_2\-LRB-\1740 <e1>atp</e1>_3\NN\14964590 )_4\-RRB-\1740 and_5\CC\1740 sodium_6\NN\14625458 nitroprusside_7\NN\1740 (_8\-LRB-\1740 snp_9\NN\11493266 )_10\-RRB-\1740 are_11\VBP\836236 administered_12\VBN\2436349 to_13\TO\1740 patients_14\NNS\9898892 to_15\TO\1740 induce_16\VB\1627355 and_17\CC\1740 control_18\NN\5190804 <e2>hypotension</e2>_19\NN\14057371 during_20\IN\1740 anesthesia_21\NN\14034177 ._22\.\1740
D000255_D007022 CID <e2>hypotension</e2>_0\NN\14057371 induced_1\VBN\1627355 by_2\IN\1740 <e1>atp</e1>_3\NN\14964590 was_4\VBD\836236 accompanied_5\VBN\1835496 by_6\IN\1740 significant_7\JJ\1740 decreases_8\NNS\7296428 in_9\IN\13603305 mean_10\JJ\1740 pulmonary_11\JJ\1740 arterial_12\JJ\1740 pressure_13\NN\11419404 (_14\-LRB-\1740 p_15\NN\14622893 less_16\JJR\1740 than_17\IN\1740 0.001_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 central_21\JJ\1740 venous_22\JJ\1740 pressure_23\NN\11419404 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 0.001_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 left_31\VBD\120316 ventricular_32\JJ\1740 end-diastolic_33\JJ\1740 pressure_34\NN\11419404 (_35\-LRB-\1740 p_36\NN\14622893 less_37\JJR\1740 than_38\IN\1740 0.001_39\CD\1740 )_40\-RRB-\1740 ,_41\,\1740 total_42\JJ\1740 peripheral_43\JJ\1740 resistance_44\NN\37396 (_45\-LRB-\1740 p_46\NN\14622893 less_47\JJR\1740 than_48\IN\1740 0.001_49\CD\1740 )_50\-RRB-\1740 ,_51\,\1740 rate_52\NN\13815152 pressure_53\NN\11419404 product_54\NN\3076708 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 total_62\JJ\1740 body_63\NN\19128 oxygen_64\NN\14622893 consumption_65\NN\13440063 (_66\-LRB-\1740 p_67\NN\14622893 less_68\JJR\1740 than_69\IN\1740 0.05_70\CD\1740 )_71\-RRB-\1740 ,_72\,\1740 and_73\CC\1740 heart_74\NN\5919034 rate_75\NN\13815152 (_76\-LRB-\1740 p_77\NN\14622893 less_78\JJR\1740 than_79\IN\1740 0.001_80\CD\1740 )_81\-RRB-\1740 ;_82\:\1740 all_83\PDT\1740 these_84\DT\1740 variables_85\NNS\2452 returned_86\VBD\1835496 normal_87\JJ\1740 within_88\IN\1740 30_89\CD\13745420 min_90\NN\15154774 after_91\IN\1740 atp_92\NN\14964590 was_93\VBD\836236 stopped_94\VBN\2452885 ._95\.\1740
D000255_D007022 CID <e2>hypotension</e2>_0\NN\14057371 induced_1\VBN\1627355 by_2\IN\1740 atp_3\NN\14964590 was_4\VBD\836236 accompanied_5\VBN\1835496 by_6\IN\1740 significant_7\JJ\1740 decreases_8\NNS\7296428 in_9\IN\13603305 mean_10\JJ\1740 pulmonary_11\JJ\1740 arterial_12\JJ\1740 pressure_13\NN\11419404 (_14\-LRB-\1740 p_15\NN\14622893 less_16\JJR\1740 than_17\IN\1740 0.001_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 central_21\JJ\1740 venous_22\JJ\1740 pressure_23\NN\11419404 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 0.001_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 left_31\VBD\120316 ventricular_32\JJ\1740 end-diastolic_33\JJ\1740 pressure_34\NN\11419404 (_35\-LRB-\1740 p_36\NN\14622893 less_37\JJR\1740 than_38\IN\1740 0.001_39\CD\1740 )_40\-RRB-\1740 ,_41\,\1740 total_42\JJ\1740 peripheral_43\JJ\1740 resistance_44\NN\37396 (_45\-LRB-\1740 p_46\NN\14622893 less_47\JJR\1740 than_48\IN\1740 0.001_49\CD\1740 )_50\-RRB-\1740 ,_51\,\1740 rate_52\NN\13815152 pressure_53\NN\11419404 product_54\NN\3076708 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 total_62\JJ\1740 body_63\NN\19128 oxygen_64\NN\14622893 consumption_65\NN\13440063 (_66\-LRB-\1740 p_67\NN\14622893 less_68\JJR\1740 than_69\IN\1740 0.05_70\CD\1740 )_71\-RRB-\1740 ,_72\,\1740 and_73\CC\1740 heart_74\NN\5919034 rate_75\NN\13815152 (_76\-LRB-\1740 p_77\NN\14622893 less_78\JJR\1740 than_79\IN\1740 0.001_80\CD\1740 )_81\-RRB-\1740 ;_82\:\1740 all_83\PDT\1740 these_84\DT\1740 variables_85\NNS\2452 returned_86\VBD\1835496 normal_87\JJ\1740 within_88\IN\1740 30_89\CD\13745420 min_90\NN\15154774 after_91\IN\1740 <e1>atp</e1>_92\NN\14964590 was_93\VBD\836236 stopped_94\VBN\2452885 ._95\.\1740
D009599_D007022 CID cardiovascular_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e2>hypotension</e2>_3\NN\14057371 induced_4\VBN\1627355 by_5\IN\1740 adenosine_6\NN\14964367 triphosphate_7\NN\1740 and_8\CC\1740 <e1>sodium_9\NN\14625458 nitroprusside</e1>_10\NN\1740 on_11\IN\1740 dogs_12\NNS\2083346 with_13\IN\1740 denervated_14\JJ\1740 hearts_15\NNS\496167 ._16\.\1740
D009599_D007022 CID adenosine_0\JJ\1740 triphosphate_1\NN\1740 (_2\-LRB-\1740 atp_3\NN\14964590 )_4\-RRB-\1740 and_5\CC\1740 <e1>sodium_6\NN\14625458 nitroprusside</e1>_7\NN\1740 (_8\-LRB-\1740 snp_9\NN\11493266 )_10\-RRB-\1740 are_11\VBP\836236 administered_12\VBN\2436349 to_13\TO\1740 patients_14\NNS\9898892 to_15\TO\1740 induce_16\VB\1627355 and_17\CC\1740 control_18\NN\5190804 <e2>hypotension</e2>_19\NN\14057371 during_20\IN\1740 anesthesia_21\NN\14034177 ._22\.\1740
D009599_D007022 CID adenosine_0\JJ\1740 triphosphate_1\NN\1740 (_2\-LRB-\1740 atp_3\NN\14964590 )_4\-RRB-\1740 and_5\CC\1740 sodium_6\NN\14625458 nitroprusside_7\NN\1740 (_8\-LRB-\1740 <e1>snp</e1>_9\NN\11493266 )_10\-RRB-\1740 are_11\VBP\836236 administered_12\VBN\2436349 to_13\TO\1740 patients_14\NNS\9898892 to_15\TO\1740 induce_16\VB\1627355 and_17\CC\1740 control_18\NN\5190804 <e2>hypotension</e2>_19\NN\14057371 during_20\IN\1740 anesthesia_21\NN\14034177 ._22\.\1740
D009599_D007022 CID during_0\IN\1740 <e2>hypotension</e2>_1\NN\14057371 produced_2\VBN\1617192 by_3\IN\1740 <e1>snp</e1>_4\NN\11493266 similar_5\JJ\1740 decreases_6\NNS\7296428 were_7\VBD\836236 observed_8\VBN\2163746 in_9\IN\13603305 mean_10\JJ\1740 pulmonary_11\JJ\1740 arterial_12\JJ\1740 pressure_13\NN\11419404 (_14\-LRB-\1740 p_15\NN\14622893 less_16\JJR\1740 than_17\IN\1740 0.01_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 central_21\JJ\1740 venous_22\JJ\1740 pressure_23\NN\11419404 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 0.001_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 left_31\VBD\120316 ventricular_32\JJ\1740 end-diastolic_33\JJ\1740 pressure_34\NN\11419404 (_35\-LRB-\1740 p_36\NN\14622893 less_37\JJR\1740 than_38\IN\1740 0.01_39\CD\1740 )_40\-RRB-\1740 ,_41\,\1740 total_42\JJ\1740 peripheral_43\JJ\1740 resistance_44\NN\37396 (_45\-LRB-\1740 p_46\NN\14622893 less_47\JJR\1740 than_48\IN\1740 0.001_49\CD\1740 )_50\-RRB-\1740 ,_51\,\1740 rate_52\NN\13815152 pressure_53\NN\11419404 product_54\NN\3076708 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 and_62\CC\1740 oxygen_63\NN\14622893 content_64\NN\7951464 difference_65\NN\4723816 between_66\IN\1740 arterial_67\JJ\1740 and_68\CC\1740 mixed_69\JJ\1740 venous_70\JJ\1740 blood_71\NN\5397468 (_72\-LRB-\1740 p_73\NN\14622893 less_74\JJR\1740 than_75\IN\1740 0.05_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 while_79\IN\15122231 heart_80\NN\5919034 rate_81\NN\13815152 (_82\-LRB-\1740 p_83\NN\14622893 less_84\JJR\1740 than_85\IN\1740 0.001_86\CD\1740 )_87\-RRB-\1740 and_88\CC\1740 cardiac_89\JJ\1740 output_90\NN\4007894 (_91\-LRB-\1740 p_92\NN\14622893 less_93\JJR\1740 than_94\IN\1740 0.05_95\CD\1740 )_96\-RRB-\1740 were_97\VBD\836236 increased_98\VBN\169651 ._99\.\1740
D010100_D007022 NONE <e2>hypotension</e2>_0\NN\14057371 induced_1\VBN\1627355 by_2\IN\1740 atp_3\NN\14964590 was_4\VBD\836236 accompanied_5\VBN\1835496 by_6\IN\1740 significant_7\JJ\1740 decreases_8\NNS\7296428 in_9\IN\13603305 mean_10\JJ\1740 pulmonary_11\JJ\1740 arterial_12\JJ\1740 pressure_13\NN\11419404 (_14\-LRB-\1740 p_15\NN\14622893 less_16\JJR\1740 than_17\IN\1740 0.001_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 central_21\JJ\1740 venous_22\JJ\1740 pressure_23\NN\11419404 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 0.001_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 left_31\VBD\120316 ventricular_32\JJ\1740 end-diastolic_33\JJ\1740 pressure_34\NN\11419404 (_35\-LRB-\1740 p_36\NN\14622893 less_37\JJR\1740 than_38\IN\1740 0.001_39\CD\1740 )_40\-RRB-\1740 ,_41\,\1740 total_42\JJ\1740 peripheral_43\JJ\1740 resistance_44\NN\37396 (_45\-LRB-\1740 p_46\NN\14622893 less_47\JJR\1740 than_48\IN\1740 0.001_49\CD\1740 )_50\-RRB-\1740 ,_51\,\1740 rate_52\NN\13815152 pressure_53\NN\11419404 product_54\NN\3076708 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 total_62\JJ\1740 body_63\NN\19128 <e1>oxygen</e1>_64\NN\14622893 consumption_65\NN\13440063 (_66\-LRB-\1740 p_67\NN\14622893 less_68\JJR\1740 than_69\IN\1740 0.05_70\CD\1740 )_71\-RRB-\1740 ,_72\,\1740 and_73\CC\1740 heart_74\NN\5919034 rate_75\NN\13815152 (_76\-LRB-\1740 p_77\NN\14622893 less_78\JJR\1740 than_79\IN\1740 0.001_80\CD\1740 )_81\-RRB-\1740 ;_82\:\1740 all_83\PDT\1740 these_84\DT\1740 variables_85\NNS\2452 returned_86\VBD\1835496 normal_87\JJ\1740 within_88\IN\1740 30_89\CD\13745420 min_90\NN\15154774 after_91\IN\1740 atp_92\NN\14964590 was_93\VBD\836236 stopped_94\VBN\2452885 ._95\.\1740
D010100_D007022 NONE during_0\IN\1740 <e2>hypotension</e2>_1\NN\14057371 produced_2\VBN\1617192 by_3\IN\1740 snp_4\NN\11493266 similar_5\JJ\1740 decreases_6\NNS\7296428 were_7\VBD\836236 observed_8\VBN\2163746 in_9\IN\13603305 mean_10\JJ\1740 pulmonary_11\JJ\1740 arterial_12\JJ\1740 pressure_13\NN\11419404 (_14\-LRB-\1740 p_15\NN\14622893 less_16\JJR\1740 than_17\IN\1740 0.01_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 central_21\JJ\1740 venous_22\JJ\1740 pressure_23\NN\11419404 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 0.001_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 left_31\VBD\120316 ventricular_32\JJ\1740 end-diastolic_33\JJ\1740 pressure_34\NN\11419404 (_35\-LRB-\1740 p_36\NN\14622893 less_37\JJR\1740 than_38\IN\1740 0.01_39\CD\1740 )_40\-RRB-\1740 ,_41\,\1740 total_42\JJ\1740 peripheral_43\JJ\1740 resistance_44\NN\37396 (_45\-LRB-\1740 p_46\NN\14622893 less_47\JJR\1740 than_48\IN\1740 0.001_49\CD\1740 )_50\-RRB-\1740 ,_51\,\1740 rate_52\NN\13815152 pressure_53\NN\11419404 product_54\NN\3076708 (_55\-LRB-\1740 p_56\NN\14622893 less_57\JJR\1740 than_58\IN\1740 0.001_59\CD\1740 )_60\-RRB-\1740 ,_61\,\1740 and_62\CC\1740 <e1>oxygen</e1>_63\NN\14622893 content_64\NN\7951464 difference_65\NN\4723816 between_66\IN\1740 arterial_67\JJ\1740 and_68\CC\1740 mixed_69\JJ\1740 venous_70\JJ\1740 blood_71\NN\5397468 (_72\-LRB-\1740 p_73\NN\14622893 less_74\JJR\1740 than_75\IN\1740 0.05_76\CD\1740 )_77\-RRB-\1740 ,_78\,\1740 while_79\IN\15122231 heart_80\NN\5919034 rate_81\NN\13815152 (_82\-LRB-\1740 p_83\NN\14622893 less_84\JJR\1740 than_85\IN\1740 0.001_86\CD\1740 )_87\-RRB-\1740 and_88\CC\1740 cardiac_89\JJ\1740 output_90\NN\4007894 (_91\-LRB-\1740 p_92\NN\14622893 less_93\JJR\1740 than_94\IN\1740 0.05_95\CD\1740 )_96\-RRB-\1740 were_97\VBD\836236 increased_98\VBN\169651 ._99\.\1740
24665854
D014635_D022124 CID <e1>valproate-induced</e1>_0\JJ\1740 <e2>hyperammonemic</e2>_1\JJ\1740 encephalopathy_2\JJ\1740 in_3\IN\13603305 a_4\DT\13649268 renal_5\JJ\1740 transplanted_6\VBN\2013571 patient_7\NN\9898892 ._8\.\1740
D014635_D022124 CID <e1>valproate-induced</e1>_0\JJ\1740 <e2>hyperammonemic</e2>_1\JJ\1740 encephalopathy_2\JJ\1740 is_3\VBZ\836236 an_4\DT\6697703 uncommon_5\JJ\1740 but_6\CC\1740 serious_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 valproate_10\NN\1740 treatment_11\NN\654885 ._12\.\1740
D014635_D022124 CID valproate-induced_0\JJ\1740 <e2>hyperammonemic</e2>_1\JJ\1740 encephalopathy_2\JJ\1740 is_3\VBZ\836236 an_4\DT\6697703 uncommon_5\JJ\1740 but_6\CC\1740 serious_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>valproate</e1>_10\NN\1740 treatment_11\NN\654885 ._12\.\1740
D014635_D022124 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 the_4\DT\1740 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 15-year-old_8\JJ\1740 girl_9\NN\10787470 who_10\WP\8299493 was_11\VBD\836236 on_12\IN\1740 a_13\DT\13649268 long-term_14\JJ\1740 therapy_15\NN\657604 with_16\IN\1740 <e1>valproate</e1>_17\NN\1740 due_18\IN\5174653 to_19\IN\1740 epilepsy_20\NN\14085708 and_21\CC\1740 revealed_22\VBD\2137132 impaired_23\JJ\1740 consciousness_24\NN\5669934 with_25\IN\1740 <e2>hyperammonemia</e2>_26\NN\1740 12_27\CD\13745420 days_28\NNS\15140892 after_29\IN\1740 renal_30\JJ\1740 transplantation_31\NN\671351 ._32\.\1740
D014635_D001927 NONE <e1>valproate-induced</e1>_0\JJ\1740 hyperammonemic_1\JJ\1740 <e2>encephalopathy</e2>_2\JJ\1740 in_3\IN\13603305 a_4\DT\13649268 renal_5\JJ\1740 transplanted_6\VBN\2013571 patient_7\NN\9898892 ._8\.\1740
D014635_D001927 NONE <e1>valproate-induced</e1>_0\JJ\1740 hyperammonemic_1\JJ\1740 <e2>encephalopathy</e2>_2\JJ\1740 is_3\VBZ\836236 an_4\DT\6697703 uncommon_5\JJ\1740 but_6\CC\1740 serious_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 valproate_10\NN\1740 treatment_11\NN\654885 ._12\.\1740
D014635_D001927 NONE valproate-induced_0\JJ\1740 hyperammonemic_1\JJ\1740 <e2>encephalopathy</e2>_2\JJ\1740 is_3\VBZ\836236 an_4\DT\6697703 uncommon_5\JJ\1740 but_6\CC\1740 serious_7\JJ\1740 effect_8\NN\34213 of_9\IN\1740 <e1>valproate</e1>_10\NN\1740 treatment_11\NN\654885 ._12\.\1740
D014635_D004827 NONE here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 the_4\DT\1740 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 15-year-old_8\JJ\1740 girl_9\NN\10787470 who_10\WP\8299493 was_11\VBD\836236 on_12\IN\1740 a_13\DT\13649268 long-term_14\JJ\1740 therapy_15\NN\657604 with_16\IN\1740 <e1>valproate</e1>_17\NN\1740 due_18\IN\5174653 to_19\IN\1740 <e2>epilepsy</e2>_20\NN\14085708 and_21\CC\1740 revealed_22\VBD\2137132 impaired_23\JJ\1740 consciousness_24\NN\5669934 with_25\IN\1740 hyperammonemia_26\NN\1740 12_27\CD\13745420 days_28\NNS\15140892 after_29\IN\1740 renal_30\JJ\1740 transplantation_31\NN\671351 ._32\.\1740
D014635_D003244 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 the_4\DT\1740 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 15-year-old_8\JJ\1740 girl_9\NN\10787470 who_10\WP\8299493 was_11\VBD\836236 on_12\IN\1740 a_13\DT\13649268 long-term_14\JJ\1740 therapy_15\NN\657604 with_16\IN\1740 <e1>valproate</e1>_17\NN\1740 due_18\IN\5174653 to_19\IN\1740 epilepsy_20\NN\14085708 and_21\CC\1740 revealed_22\VBD\2137132 <e2>impaired_23\JJ\1740 consciousness</e2>_24\NN\5669934 with_25\IN\1740 hyperammonemia_26\NN\1740 12_27\CD\13745420 days_28\NNS\15140892 after_29\IN\1740 renal_30\JJ\1740 transplantation_31\NN\671351 ._32\.\1740
8603459
D004317_D066126 CID <e1>doxorubicin-induced</e1>_0\JJ\1740 <e2>cardiotoxicity</e2>_1\NN\1740 monitored_2\VBN\2169352 by_3\IN\1740 ecg_4\NNP\7000195 in_5\IN\13603305 freely_6\RB\1740 moving_7\VBG\2367363 mice_8\NNS\2329401 ._9\.\1740
D004317_D066126 CID in_0\IN\13603305 laboratory_1\JJ\1740 animals_2\NNS\4475 ,_3\,\1740 histology_4\NN\6060049 is_5\VBZ\836236 most_6\RBS\1740 commonly_7\RB\1740 used_8\VBN\1156834 to_9\TO\1740 study_10\VB\630380 <e1>doxorubicin-induced</e1>_11\JJ\1740 <e2>cardiotoxicity</e2>_12\NN\1740 ._13\.\1740
D004317_D066126 CID these_0\DT\1740 findings_1\NNS\7951464 result_2\VBP\2633881 in_3\IN\13603305 a_4\DT\13649268 model_5\NN\5888929 that_6\WDT\1740 allows_7\VBZ\797697 the_8\DT\1740 testing_9\NN\639556 of_10\IN\1740 protectors_11\NNS\10466918 against_12\IN\1740 <e1>doxorubicin-induced</e1>_13\JJ\1740 <e2>cardiotoxicity</e2>_14\NN\1740 as_15\IN\14622893 demonstrated_16\VBN\2137132 by_17\IN\1740 the_18\DT\1740 protection_19\NN\407535 provided_20\VBN\2199590 by_21\IN\1740 icrf-187_22\NN\1740 ._23\.\1740
D004317_D006984 NONE after_0\IN\1740 sacrifice_1\NN\30358 the_2\DT\1740 hearts_3\NNS\496167 of_4\IN\1740 <e1>doxorubicin-treated</e1>_5\JJ\1740 animals_6\NNS\4475 were_7\VBD\836236 enlarged_8\VBN\153263 and_9\CC\1740 the_10\DT\1740 atria_11\NN\5392744 were_12\VBD\836236 <e2>hypertrophic</e2>_13\JJ\1740 ._14\.\1740
D064730_D064420 NONE as_0\IN\14622893 this_1\DT\1740 schedule_2\NN\5898568 exerted_3\VBD\1158872 more_4\JJR\1740 <e2>toxicity</e2>_5\NN\13576101 than_6\IN\1740 needed_7\VBN\2604760 to_8\TO\1740 investigate_9\VB\644583 protective_10\JJ\1740 agents_11\NNS\7347 ,_12\,\1740 the_13\DT\1740 protection_14\NN\407535 of_15\IN\1740 <e1>icrf-187</e1>_16\NN\1740 was_17\VBD\836236 determined_18\VBN\1645601 using_19\VBG\1156834 a_20\DT\13649268 dose_21\NN\3740161 schedule_22\NN\5898568 with_23\IN\1740 lower_24\JJR\1740 general_25\JJ\1740 toxicity_26\NN\13576101 (_27\-LRB-\1740 6_28\CD\13741022 weekly_29\JJ\1740 doses_30\NNS\3740161 of_31\IN\1740 4_32\CD\13741022 mg/kg_33\NN\1740 doxorubicin_34\NN\2716866 given_35\VBN\2327200 i.v._36\NN\1740 plus_37\CC\4723816 2_38\CD\13741022 weeks_39\NNS\15113229 of_40\IN\1740 observation_41\NN\996969 )_42\-RRB-\1740 ._43\.\1740
D064730_D064420 NONE as_0\IN\14622893 this_1\DT\1740 schedule_2\NN\5898568 exerted_3\VBD\1158872 more_4\JJR\1740 toxicity_5\NN\13576101 than_6\IN\1740 needed_7\VBN\2604760 to_8\TO\1740 investigate_9\VB\644583 protective_10\JJ\1740 agents_11\NNS\7347 ,_12\,\1740 the_13\DT\1740 protection_14\NN\407535 of_15\IN\1740 <e1>icrf-187</e1>_16\NN\1740 was_17\VBD\836236 determined_18\VBN\1645601 using_19\VBG\1156834 a_20\DT\13649268 dose_21\NN\3740161 schedule_22\NN\5898568 with_23\IN\1740 lower_24\JJR\1740 general_25\JJ\1740 <e2>toxicity</e2>_26\NN\13576101 (_27\-LRB-\1740 6_28\CD\13741022 weekly_29\JJ\1740 doses_30\NNS\3740161 of_31\IN\1740 4_32\CD\13741022 mg/kg_33\NN\1740 doxorubicin_34\NN\2716866 given_35\VBN\2327200 i.v._36\NN\1740 plus_37\CC\4723816 2_38\CD\13741022 weeks_39\NNS\15113229 of_40\IN\1740 observation_41\NN\996969 )_42\-RRB-\1740 ._43\.\1740
D004317_D064420 NONE as_0\IN\14622893 this_1\DT\1740 schedule_2\NN\5898568 exerted_3\VBD\1158872 more_4\JJR\1740 <e2>toxicity</e2>_5\NN\13576101 than_6\IN\1740 needed_7\VBN\2604760 to_8\TO\1740 investigate_9\VB\644583 protective_10\JJ\1740 agents_11\NNS\7347 ,_12\,\1740 the_13\DT\1740 protection_14\NN\407535 of_15\IN\1740 icrf-187_16\NN\1740 was_17\VBD\836236 determined_18\VBN\1645601 using_19\VBG\1156834 a_20\DT\13649268 dose_21\NN\3740161 schedule_22\NN\5898568 with_23\IN\1740 lower_24\JJR\1740 general_25\JJ\1740 toxicity_26\NN\13576101 (_27\-LRB-\1740 6_28\CD\13741022 weekly_29\JJ\1740 doses_30\NNS\3740161 of_31\IN\1740 4_32\CD\13741022 mg/kg_33\NN\1740 <e1>doxorubicin</e1>_34\NN\2716866 given_35\VBN\2327200 i.v._36\NN\1740 plus_37\CC\4723816 2_38\CD\13741022 weeks_39\NNS\15113229 of_40\IN\1740 observation_41\NN\996969 )_42\-RRB-\1740 ._43\.\1740
D004317_D064420 NONE as_0\IN\14622893 this_1\DT\1740 schedule_2\NN\5898568 exerted_3\VBD\1158872 more_4\JJR\1740 toxicity_5\NN\13576101 than_6\IN\1740 needed_7\VBN\2604760 to_8\TO\1740 investigate_9\VB\644583 protective_10\JJ\1740 agents_11\NNS\7347 ,_12\,\1740 the_13\DT\1740 protection_14\NN\407535 of_15\IN\1740 icrf-187_16\NN\1740 was_17\VBD\836236 determined_18\VBN\1645601 using_19\VBG\1156834 a_20\DT\13649268 dose_21\NN\3740161 schedule_22\NN\5898568 with_23\IN\1740 lower_24\JJR\1740 general_25\JJ\1740 <e2>toxicity</e2>_26\NN\13576101 (_27\-LRB-\1740 6_28\CD\13741022 weekly_29\JJ\1740 doses_30\NNS\3740161 of_31\IN\1740 4_32\CD\13741022 mg/kg_33\NN\1740 <e1>doxorubicin</e1>_34\NN\2716866 given_35\VBN\2327200 i.v._36\NN\1740 plus_37\CC\4723816 2_38\CD\13741022 weeks_39\NNS\15113229 of_40\IN\1740 observation_41\NN\996969 )_42\-RRB-\1740 ._43\.\1740
D064730_D066126 NONE these_0\DT\1740 findings_1\NNS\7951464 result_2\VBP\2633881 in_3\IN\13603305 a_4\DT\13649268 model_5\NN\5888929 that_6\WDT\1740 allows_7\VBZ\797697 the_8\DT\1740 testing_9\NN\639556 of_10\IN\1740 protectors_11\NNS\10466918 against_12\IN\1740 doxorubicin-induced_13\JJ\1740 <e2>cardiotoxicity</e2>_14\NN\1740 as_15\IN\14622893 demonstrated_16\VBN\2137132 by_17\IN\1740 the_18\DT\1740 protection_19\NN\407535 provided_20\VBN\2199590 by_21\IN\1740 <e1>icrf-187</e1>_22\NN\1740 ._23\.\1740
21195121
D009569_D012640 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>nitric_3\JJ\1740 oxide</e1>_4\NN\14818238 in_5\IN\13603305 <e2>convulsions</e2>_6\NNS\14081375 induced_7\VBN\1627355 by_8\IN\1740 lindane_9\NN\14919948 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D009569_D012640 NONE these_0\DT\1740 results_1\NNS\34213 support_2\VBP\2199590 the_3\DT\1740 conclusion_4\NN\5837957 that_5\IN\1740 <e1>no</e1>_6\NN\7204911 plays_7\VBZ\1072262 a_8\DT\13649268 role_9\NN\719494 of_10\IN\1740 endogenous_11\JJ\1740 convulsant_12\NN\1740 in_13\IN\13603305 rat_14\NN\2329401 model_15\NN\5888929 of_16\IN\1740 lindane_17\NN\14919948 <e2>seizures</e2>_18\NNS\14081375 ._19\.\1740
D001556_D012640 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 nitric_3\JJ\1740 oxide_4\NN\14818238 in_5\IN\13603305 <e2>convulsions</e2>_6\NNS\14081375 induced_7\VBN\1627355 by_8\IN\1740 <e1>lindane</e1>_9\NN\14919948 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D001556_D012640 CID the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 l-arginine_3\NN\1740 (_4\-LRB-\1740 600_5\CD\1740 ,_6\,\1740 800_7\CD\1740 and_8\CC\1740 1000_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 in_14\IN\13603305 dose-dependent_15\JJ\1740 manner_16\NN\4916342 significantly_17\RB\1740 increased_18\VBD\169651 <e2>convulsion</e2>_19\NN\14081375 incidence_20\NN\13821570 and_21\CC\1740 severity_22\NN\5036394 and_23\CC\1740 shortened_24\VBD\429060 latency_25\NN\15269513 time_26\NN\7308889 to_27\TO\1740 first_28\JJ\1740 convulsion_29\NN\14081375 elicited_30\VBN\1617192 by_31\IN\1740 lower_32\JJR\1740 <e1>lindane</e1>_33\NN\14919948 dose_34\NN\3740161 (_35\-LRB-\1740 4_36\CD\13741022 mg/kg_37\NN\1740 ,_38\,\1740 i.p._39\RB\1740 )_40\-RRB-\1740 ._41\.\1740
D001556_D012640 CID the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 l-arginine_3\NN\1740 (_4\-LRB-\1740 600_5\CD\1740 ,_6\,\1740 800_7\CD\1740 and_8\CC\1740 1000_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 in_14\IN\13603305 dose-dependent_15\JJ\1740 manner_16\NN\4916342 significantly_17\RB\1740 increased_18\VBD\169651 convulsion_19\NN\14081375 incidence_20\NN\13821570 and_21\CC\1740 severity_22\NN\5036394 and_23\CC\1740 shortened_24\VBD\429060 latency_25\NN\15269513 time_26\NN\7308889 to_27\TO\1740 first_28\JJ\1740 <e2>convulsion</e2>_29\NN\14081375 elicited_30\VBN\1617192 by_31\IN\1740 lower_32\JJR\1740 <e1>lindane</e1>_33\NN\14919948 dose_34\NN\3740161 (_35\-LRB-\1740 4_36\CD\13741022 mg/kg_37\NN\1740 ,_38\,\1740 i.p._39\RB\1740 )_40\-RRB-\1740 ._41\.\1740
D001556_D012640 CID on_0\IN\1740 the_1\DT\1740 contrary_2\NN\13854649 ,_3\,\1740 pretreatment_4\NN\1740 with_5\IN\1740 l-name_6\NN\1740 (_7\-LRB-\1740 500_8\CD\13745420 ,_9\,\1740 700_10\CD\1740 and_11\CC\1740 900_12\CD\1740 mg/kg_13\NN\1740 ,_14\,\1740 i.p._15\RB\1740 )_16\-RRB-\1740 decreased_17\VBD\169651 <e2>convulsion</e2>_18\NN\14081375 incidence_19\NN\13821570 and_20\CC\1740 severity_21\NN\5036394 and_22\CC\1740 prolonged_23\JJ\1740 latency_24\NN\15269513 time_25\NN\7308889 to_26\TO\1740 convulsion_27\NN\14081375 following_28\VBG\1835496 injection_29\NN\320852 with_30\IN\1740 a_31\DT\13649268 convulsive_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 <e1>lindane</e1>_35\NN\14919948 (_36\-LRB-\1740 8_37\CD\13741022 mg/kg_38\NN\1740 ,_39\,\1740 i.p._40\RB\1740 )_41\-RRB-\1740 ._42\.\1740
D001556_D012640 CID on_0\IN\1740 the_1\DT\1740 contrary_2\NN\13854649 ,_3\,\1740 pretreatment_4\NN\1740 with_5\IN\1740 l-name_6\NN\1740 (_7\-LRB-\1740 500_8\CD\13745420 ,_9\,\1740 700_10\CD\1740 and_11\CC\1740 900_12\CD\1740 mg/kg_13\NN\1740 ,_14\,\1740 i.p._15\RB\1740 )_16\-RRB-\1740 decreased_17\VBD\169651 convulsion_18\NN\14081375 incidence_19\NN\13821570 and_20\CC\1740 severity_21\NN\5036394 and_22\CC\1740 prolonged_23\JJ\1740 latency_24\NN\15269513 time_25\NN\7308889 to_26\TO\1740 <e2>convulsion</e2>_27\NN\14081375 following_28\VBG\1835496 injection_29\NN\320852 with_30\IN\1740 a_31\DT\13649268 convulsive_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 <e1>lindane</e1>_35\NN\14919948 (_36\-LRB-\1740 8_37\CD\13741022 mg/kg_38\NN\1740 ,_39\,\1740 i.p._40\RB\1740 )_41\-RRB-\1740 ._42\.\1740
D001556_D012640 CID on_0\IN\1740 the_1\DT\1740 contrary_2\NN\13854649 ,_3\,\1740 pretreatment_4\NN\1740 with_5\IN\1740 l-name_6\NN\1740 (_7\-LRB-\1740 500_8\CD\13745420 ,_9\,\1740 700_10\CD\1740 and_11\CC\1740 900_12\CD\1740 mg/kg_13\NN\1740 ,_14\,\1740 i.p._15\RB\1740 )_16\-RRB-\1740 decreased_17\VBD\169651 convulsion_18\NN\14081375 incidence_19\NN\13821570 and_20\CC\1740 severity_21\NN\5036394 and_22\CC\1740 prolonged_23\JJ\1740 latency_24\NN\15269513 time_25\NN\7308889 to_26\TO\1740 convulsion_27\NN\14081375 following_28\VBG\1835496 injection_29\NN\320852 with_30\IN\1740 a_31\DT\13649268 <e2>convulsive</e2>_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 <e1>lindane</e1>_35\NN\14919948 (_36\-LRB-\1740 8_37\CD\13741022 mg/kg_38\NN\1740 ,_39\,\1740 i.p._40\RB\1740 )_41\-RRB-\1740 ._42\.\1740
D001556_D012640 CID these_0\DT\1740 results_1\NNS\34213 support_2\VBP\2199590 the_3\DT\1740 conclusion_4\NN\5837957 that_5\IN\1740 no_6\NN\7204911 plays_7\VBZ\1072262 a_8\DT\13649268 role_9\NN\719494 of_10\IN\1740 endogenous_11\JJ\1740 convulsant_12\NN\1740 in_13\IN\13603305 rat_14\NN\2329401 model_15\NN\5888929 of_16\IN\1740 <e1>lindane</e1>_17\NN\14919948 <e2>seizures</e2>_18\NNS\14081375 ._19\.\1740
D005680_D012640 NONE it_0\PRP\6125041 evokes_1\VBZ\1617192 <e2>convulsions</e2>_2\NNS\14081375 mainly_3\RB\1740 trough_4\VBP\1740 the_5\DT\1740 blockage_6\NN\14034177 of_7\IN\1740 <e1>gaba(a</e1>_8\NN\1740 )_9\-RRB-\1740 receptors_10\NNS\5225602 ._11\.\1740
D009569_D004827 NONE <e1>nitric_0\JJ\1740 oxide</e1>_1\NN\14818238 (_2\-LRB-\1740 no_3\NN\7204911 )_4\-RRB-\1740 ,_5\,\1740 gaseous_6\JJ\1740 neurotransmitter_7\NN\14807410 ,_8\,\1740 has_9\VBZ\2108377 contradictor_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 epileptogenesis_13\NN\1740 due_14\IN\5174653 to_15\TO\1740 opposite_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 l-arginine_19\NN\1740 ,_20\,\1740 precursor_21\NN\14580897 of_22\IN\1740 no_23\NN\7204911 syntheses_24\NNS\13446390 (_25\-LRB-\1740 nos_26\NN\7204911 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 l-name_30\NN\1740 (_31\-LRB-\1740 nos_32\NN\7204911 inhibitor_33\NN\20090 )_34\-RRB-\1740 observed_35\VBN\2163746 in_36\IN\13603305 different_37\JJ\1740 <e2>epilepsy</e2>_38\NN\14085708 models_39\NNS\5888929 ._40\.\1740
D009569_D004827 NONE nitric_0\JJ\1740 oxide_1\NN\14818238 (_2\-LRB-\1740 <e1>no</e1>_3\NN\7204911 )_4\-RRB-\1740 ,_5\,\1740 gaseous_6\JJ\1740 neurotransmitter_7\NN\14807410 ,_8\,\1740 has_9\VBZ\2108377 contradictor_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 epileptogenesis_13\NN\1740 due_14\IN\5174653 to_15\TO\1740 opposite_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 l-arginine_19\NN\1740 ,_20\,\1740 precursor_21\NN\14580897 of_22\IN\1740 no_23\NN\7204911 syntheses_24\NNS\13446390 (_25\-LRB-\1740 nos_26\NN\7204911 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 l-name_30\NN\1740 (_31\-LRB-\1740 nos_32\NN\7204911 inhibitor_33\NN\20090 )_34\-RRB-\1740 observed_35\VBN\2163746 in_36\IN\13603305 different_37\JJ\1740 <e2>epilepsy</e2>_38\NN\14085708 models_39\NNS\5888929 ._40\.\1740
D009569_D004827 NONE nitric_0\JJ\1740 oxide_1\NN\14818238 (_2\-LRB-\1740 no_3\NN\7204911 )_4\-RRB-\1740 ,_5\,\1740 gaseous_6\JJ\1740 neurotransmitter_7\NN\14807410 ,_8\,\1740 has_9\VBZ\2108377 contradictor_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 epileptogenesis_13\NN\1740 due_14\IN\5174653 to_15\TO\1740 opposite_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 l-arginine_19\NN\1740 ,_20\,\1740 precursor_21\NN\14580897 of_22\IN\1740 <e1>no</e1>_23\NN\7204911 syntheses_24\NNS\13446390 (_25\-LRB-\1740 nos_26\NN\7204911 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 l-name_30\NN\1740 (_31\-LRB-\1740 nos_32\NN\7204911 inhibitor_33\NN\20090 )_34\-RRB-\1740 observed_35\VBN\2163746 in_36\IN\13603305 different_37\JJ\1740 <e2>epilepsy</e2>_38\NN\14085708 models_39\NNS\5888929 ._40\.\1740
D009569_D004827 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 current_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 effects_10\NNS\13245626 of_11\IN\1740 <e1>no</e1>_12\NN\7204911 on_13\IN\1740 the_14\DT\1740 behavioral_15\JJ\1740 and_16\CC\1740 eeg_17\NN\7000195 characteristics_18\NNS\5849040 of_19\IN\1740 lindane-induced_20\JJ\1740 <e2>epilepsy</e2>_21\NN\14085708 in_22\IN\13603305 male_23\JJ\1740 wistar_24\NNP\1740 albino_25\NN\9606527 rats_26\NNS\2329401 ._27\.\1740
D001120_D004827 NONE nitric_0\JJ\1740 oxide_1\NN\14818238 (_2\-LRB-\1740 no_3\NN\7204911 )_4\-RRB-\1740 ,_5\,\1740 gaseous_6\JJ\1740 neurotransmitter_7\NN\14807410 ,_8\,\1740 has_9\VBZ\2108377 contradictor_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 epileptogenesis_13\NN\1740 due_14\IN\5174653 to_15\TO\1740 opposite_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 <e1>l-arginine</e1>_19\NN\1740 ,_20\,\1740 precursor_21\NN\14580897 of_22\IN\1740 no_23\NN\7204911 syntheses_24\NNS\13446390 (_25\-LRB-\1740 nos_26\NN\7204911 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 l-name_30\NN\1740 (_31\-LRB-\1740 nos_32\NN\7204911 inhibitor_33\NN\20090 )_34\-RRB-\1740 observed_35\VBN\2163746 in_36\IN\13603305 different_37\JJ\1740 <e2>epilepsy</e2>_38\NN\14085708 models_39\NNS\5888929 ._40\.\1740
D019331_D004827 NONE nitric_0\JJ\1740 oxide_1\NN\14818238 (_2\-LRB-\1740 no_3\NN\7204911 )_4\-RRB-\1740 ,_5\,\1740 gaseous_6\JJ\1740 neurotransmitter_7\NN\14807410 ,_8\,\1740 has_9\VBZ\2108377 contradictor_10\JJ\1740 role_11\NN\719494 in_12\IN\13603305 epileptogenesis_13\NN\1740 due_14\IN\5174653 to_15\TO\1740 opposite_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 l-arginine_19\NN\1740 ,_20\,\1740 precursor_21\NN\14580897 of_22\IN\1740 no_23\NN\7204911 syntheses_24\NNS\13446390 (_25\-LRB-\1740 nos_26\NN\7204911 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 <e1>l-name</e1>_30\NN\1740 (_31\-LRB-\1740 nos_32\NN\7204911 inhibitor_33\NN\20090 )_34\-RRB-\1740 observed_35\VBN\2163746 in_36\IN\13603305 different_37\JJ\1740 <e2>epilepsy</e2>_38\NN\14085708 models_39\NNS\5888929 ._40\.\1740
D001556_D004827 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 current_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 the_9\DT\1740 effects_10\NNS\13245626 of_11\IN\1740 no_12\NN\7204911 on_13\IN\1740 the_14\DT\1740 behavioral_15\JJ\1740 and_16\CC\1740 eeg_17\NN\7000195 characteristics_18\NNS\5849040 of_19\IN\1740 <e1>lindane-induced</e1>_20\JJ\1740 <e2>epilepsy</e2>_21\NN\14085708 in_22\IN\13603305 male_23\JJ\1740 wistar_24\NNP\1740 albino_25\NN\9606527 rats_26\NNS\2329401 ._27\.\1740
D001120_D012640 NONE the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>l-arginine</e1>_3\NN\1740 (_4\-LRB-\1740 600_5\CD\1740 ,_6\,\1740 800_7\CD\1740 and_8\CC\1740 1000_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 in_14\IN\13603305 dose-dependent_15\JJ\1740 manner_16\NN\4916342 significantly_17\RB\1740 increased_18\VBD\169651 <e2>convulsion</e2>_19\NN\14081375 incidence_20\NN\13821570 and_21\CC\1740 severity_22\NN\5036394 and_23\CC\1740 shortened_24\VBD\429060 latency_25\NN\15269513 time_26\NN\7308889 to_27\TO\1740 first_28\JJ\1740 convulsion_29\NN\14081375 elicited_30\VBN\1617192 by_31\IN\1740 lower_32\JJR\1740 lindane_33\NN\14919948 dose_34\NN\3740161 (_35\-LRB-\1740 4_36\CD\13741022 mg/kg_37\NN\1740 ,_38\,\1740 i.p._39\RB\1740 )_40\-RRB-\1740 ._41\.\1740
D001120_D012640 NONE the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>l-arginine</e1>_3\NN\1740 (_4\-LRB-\1740 600_5\CD\1740 ,_6\,\1740 800_7\CD\1740 and_8\CC\1740 1000_9\CD\13745420 mg/kg_10\NN\1740 ,_11\,\1740 i.p._12\RB\1740 )_13\-RRB-\1740 in_14\IN\13603305 dose-dependent_15\JJ\1740 manner_16\NN\4916342 significantly_17\RB\1740 increased_18\VBD\169651 convulsion_19\NN\14081375 incidence_20\NN\13821570 and_21\CC\1740 severity_22\NN\5036394 and_23\CC\1740 shortened_24\VBD\429060 latency_25\NN\15269513 time_26\NN\7308889 to_27\TO\1740 first_28\JJ\1740 <e2>convulsion</e2>_29\NN\14081375 elicited_30\VBN\1617192 by_31\IN\1740 lower_32\JJR\1740 lindane_33\NN\14919948 dose_34\NN\3740161 (_35\-LRB-\1740 4_36\CD\13741022 mg/kg_37\NN\1740 ,_38\,\1740 i.p._39\RB\1740 )_40\-RRB-\1740 ._41\.\1740
D019331_D012640 NONE on_0\IN\1740 the_1\DT\1740 contrary_2\NN\13854649 ,_3\,\1740 pretreatment_4\NN\1740 with_5\IN\1740 <e1>l-name</e1>_6\NN\1740 (_7\-LRB-\1740 500_8\CD\13745420 ,_9\,\1740 700_10\CD\1740 and_11\CC\1740 900_12\CD\1740 mg/kg_13\NN\1740 ,_14\,\1740 i.p._15\RB\1740 )_16\-RRB-\1740 decreased_17\VBD\169651 <e2>convulsion</e2>_18\NN\14081375 incidence_19\NN\13821570 and_20\CC\1740 severity_21\NN\5036394 and_22\CC\1740 prolonged_23\JJ\1740 latency_24\NN\15269513 time_25\NN\7308889 to_26\TO\1740 convulsion_27\NN\14081375 following_28\VBG\1835496 injection_29\NN\320852 with_30\IN\1740 a_31\DT\13649268 convulsive_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 lindane_35\NN\14919948 (_36\-LRB-\1740 8_37\CD\13741022 mg/kg_38\NN\1740 ,_39\,\1740 i.p._40\RB\1740 )_41\-RRB-\1740 ._42\.\1740
D019331_D012640 NONE on_0\IN\1740 the_1\DT\1740 contrary_2\NN\13854649 ,_3\,\1740 pretreatment_4\NN\1740 with_5\IN\1740 <e1>l-name</e1>_6\NN\1740 (_7\-LRB-\1740 500_8\CD\13745420 ,_9\,\1740 700_10\CD\1740 and_11\CC\1740 900_12\CD\1740 mg/kg_13\NN\1740 ,_14\,\1740 i.p._15\RB\1740 )_16\-RRB-\1740 decreased_17\VBD\169651 convulsion_18\NN\14081375 incidence_19\NN\13821570 and_20\CC\1740 severity_21\NN\5036394 and_22\CC\1740 prolonged_23\JJ\1740 latency_24\NN\15269513 time_25\NN\7308889 to_26\TO\1740 <e2>convulsion</e2>_27\NN\14081375 following_28\VBG\1835496 injection_29\NN\320852 with_30\IN\1740 a_31\DT\13649268 convulsive_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 lindane_35\NN\14919948 (_36\-LRB-\1740 8_37\CD\13741022 mg/kg_38\NN\1740 ,_39\,\1740 i.p._40\RB\1740 )_41\-RRB-\1740 ._42\.\1740
D019331_D012640 NONE on_0\IN\1740 the_1\DT\1740 contrary_2\NN\13854649 ,_3\,\1740 pretreatment_4\NN\1740 with_5\IN\1740 <e1>l-name</e1>_6\NN\1740 (_7\-LRB-\1740 500_8\CD\13745420 ,_9\,\1740 700_10\CD\1740 and_11\CC\1740 900_12\CD\1740 mg/kg_13\NN\1740 ,_14\,\1740 i.p._15\RB\1740 )_16\-RRB-\1740 decreased_17\VBD\169651 convulsion_18\NN\14081375 incidence_19\NN\13821570 and_20\CC\1740 severity_21\NN\5036394 and_22\CC\1740 prolonged_23\JJ\1740 latency_24\NN\15269513 time_25\NN\7308889 to_26\TO\1740 convulsion_27\NN\14081375 following_28\VBG\1835496 injection_29\NN\320852 with_30\IN\1740 a_31\DT\13649268 <e2>convulsive</e2>_32\JJ\1740 dose_33\NN\3740161 of_34\IN\1740 lindane_35\NN\14919948 (_36\-LRB-\1740 8_37\CD\13741022 mg/kg_38\NN\1740 ,_39\,\1740 i.p._40\RB\1740 )_41\-RRB-\1740 ._42\.\1740
3864191
D012459_D007674 NONE <e1>salicylate</e1>_0\NN\3828465 <e2>nephropathy</e2>_1\NN\14573196 in_2\IN\13603305 the_3\DT\1740 gunn_4\NNP\1740 rat_5\NN\2329401 :_6\:\1740 potential_7\JJ\1740 role_8\NN\719494 of_9\IN\1740 prostaglandins_10\NNS\5414534 ._11\.\1740
D011453_D007674 NONE salicylate_0\NN\3828465 <e2>nephropathy</e2>_1\NN\14573196 in_2\IN\13603305 the_3\DT\1740 gunn_4\NNP\1740 rat_5\NN\2329401 :_6\:\1740 potential_7\JJ\1740 role_8\NN\719494 of_9\IN\1740 <e1>prostaglandins</e1>_10\NNS\5414534 ._11\.\1740
D011453_D007674 NONE we_0\PRP\1740 examined_1\VBD\789138 the_2\DT\1740 potential_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 <e1>prostaglandins</e1>_6\NNS\5414534 in_7\IN\13603305 the_8\DT\1740 development_9\NN\248977 of_10\IN\1740 analgesic_11\JJ\1740 <e2>nephropathy</e2>_12\NN\14573196 in_13\IN\13603305 the_14\DT\1740 gunn_15\NN\1740 strain_16\NN\7358060 of_17\IN\1740 rat_18\NN\2329401 ._19\.\1740
D011453_D007674 NONE the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 <e1>prostaglandin</e1>_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 <e2>renal_11\JJ\1740 damage</e2>_12\NN\7296428 in_13\IN\13603305 aspirin-treated_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 hematuria_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 creatinine_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 aspirin-treated_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D011453_D007674 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 enhanced_4\VBN\227165 <e1>prostaglandin</e1>_5\NN\5414534 synthesis_6\NN\13446390 contributes_7\VBZ\126264 to_8\TO\1740 maintenance_9\NN\266806 of_10\IN\1740 renal_11\JJ\1740 function_12\NN\13783581 and_13\CC\1740 morphological_14\JJ\1740 integrity_15\NN\24720 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 inhibition_19\NN\1068773 of_20\IN\1740 prostaglandin_21\NN\5414534 synthesis_22\NN\13446390 may_23\MD\15209706 lead_24\VB\1752884 to_25\TO\1740 pathological_26\JJ\1740 renal_27\JJ\1740 medullary_28\JJ\1740 lesions_29\NNS\14204950 and_30\CC\1740 <e2>deterioration_31\NN\14560612 of_32\IN\1740 renal_33\JJ\1740 function</e2>_34\NN\13783581 ._35\.\1740
D011453_D007674 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 enhanced_4\VBN\227165 prostaglandin_5\NN\5414534 synthesis_6\NN\13446390 contributes_7\VBZ\126264 to_8\TO\1740 maintenance_9\NN\266806 of_10\IN\1740 renal_11\JJ\1740 function_12\NN\13783581 and_13\CC\1740 morphological_14\JJ\1740 integrity_15\NN\24720 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 inhibition_19\NN\1068773 of_20\IN\1740 <e1>prostaglandin</e1>_21\NN\5414534 synthesis_22\NN\13446390 may_23\MD\15209706 lead_24\VB\1752884 to_25\TO\1740 pathological_26\JJ\1740 renal_27\JJ\1740 medullary_28\JJ\1740 lesions_29\NNS\14204950 and_30\CC\1740 <e2>deterioration_31\NN\14560612 of_32\IN\1740 renal_33\JJ\1740 function</e2>_34\NN\13783581 ._35\.\1740
-1_D006932 NONE the_0\DT\1740 homozygous_1\JJ\1740 gunn_2\NN\1740 rats_3\NNS\2329401 have_4\VBP\2108377 unconjugated_5\VBN\1740 <e2>hyperbilirubinemia</e2>_6\NN\14204950 due_7\JJ\1740 to_8\TO\1740 the_9\DT\1740 absence_10\NN\14449405 of_11\IN\1740 <e1>glucuronyl</e1>_12\NN\1740 transferase_13\NN\14732946 ,_14\,\1740 leading_15\VBG\1752884 to_16\TO\1740 marked_17\JJ\1740 bilirubin_18\NN\14756039 deposition_19\NN\13424865 in_20\IN\13603305 renal_21\JJ\1740 medulla_22\NN\14864360 and_23\CC\1740 papilla_24\NN\5470189 ._25\.\1740
D001663_D006932 NONE the_0\DT\1740 homozygous_1\JJ\1740 gunn_2\NN\1740 rats_3\NNS\2329401 have_4\VBP\2108377 unconjugated_5\VBN\1740 <e2>hyperbilirubinemia</e2>_6\NN\14204950 due_7\JJ\1740 to_8\TO\1740 the_9\DT\1740 absence_10\NN\14449405 of_11\IN\1740 glucuronyl_12\NN\1740 transferase_13\NN\14732946 ,_14\,\1740 leading_15\VBG\1752884 to_16\TO\1740 marked_17\JJ\1740 <e1>bilirubin</e1>_18\NN\14756039 deposition_19\NN\13424865 in_20\IN\13603305 renal_21\JJ\1740 medulla_22\NN\14864360 and_23\CC\1740 papilla_24\NN\5470189 ._25\.\1740
D011453_D006417 NONE the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 <e1>prostaglandin</e1>_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 renal_11\JJ\1740 damage_12\NN\7296428 in_13\IN\13603305 aspirin-treated_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 <e2>hematuria</e2>_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 creatinine_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 aspirin-treated_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D001241_D007674 CID the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 prostaglandin_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 <e2>renal_11\JJ\1740 damage</e2>_12\NN\7296428 in_13\IN\13603305 <e1>aspirin-treated</e1>_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 hematuria_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 creatinine_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 aspirin-treated_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D001241_D007674 CID the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 prostaglandin_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 <e2>renal_11\JJ\1740 damage</e2>_12\NN\7296428 in_13\IN\13603305 aspirin-treated_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 hematuria_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 creatinine_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 <e1>aspirin-treated</e1>_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D001241_D006417 NONE the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 prostaglandin_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 renal_11\JJ\1740 damage_12\NN\7296428 in_13\IN\13603305 <e1>aspirin-treated</e1>_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 <e2>hematuria</e2>_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 creatinine_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 aspirin-treated_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D001241_D006417 NONE the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 prostaglandin_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 renal_11\JJ\1740 damage_12\NN\7296428 in_13\IN\13603305 aspirin-treated_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 <e2>hematuria</e2>_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 creatinine_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 <e1>aspirin-treated</e1>_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D003404_D007674 NONE the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 prostaglandin_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 <e2>renal_11\JJ\1740 damage</e2>_12\NN\7296428 in_13\IN\13603305 aspirin-treated_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 hematuria_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 <e1>creatinine</e1>_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 aspirin-treated_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D003404_D006417 NONE the_0\DT\1740 changes_1\NNS\7283608 in_2\IN\13603305 renal_3\JJ\1740 prostaglandin_4\NN\5414534 synthesis_5\NN\13446390 were_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 evidence_9\NN\5816287 of_10\IN\1740 renal_11\JJ\1740 damage_12\NN\7296428 in_13\IN\13603305 aspirin-treated_14\JJ\1740 jj_15\NN\1740 but_16\CC\1740 not_17\RB\1740 jj_18\NN\1740 rats_19\NNS\2329401 as_20\IN\14622893 evidenced_21\VBN\1015244 by_22\IN\1740 :_23\:\1740 increased_24\VBN\169651 incidence_25\NN\13821570 and_26\CC\1740 severity_27\NN\5036394 of_28\IN\1740 <e2>hematuria</e2>_29\NN\14299637 (_30\-LRB-\1740 p_31\NN\14622893 less_32\JJR\1740 than_33\IN\1740 0.01_34\CD\1740 )_35\-RRB-\1740 ;_36\:\1740 increased_37\VBN\169651 serum_38\NN\5397468 <e1>creatinine</e1>_39\NN\1740 (_40\-LRB-\1740 p_41\NN\14622893 less_42\JJR\1740 than_43\IN\1740 0.05_44\CD\1740 )_45\-RRB-\1740 ;_46\:\1740 and_47\CC\1740 increase_48\VB\169651 in_49\IN\13603305 outer_50\JJ\1740 medullary_51\JJ\1740 histopathologic_52\JJ\1740 lesions_53\NNS\14204950 (_54\-LRB-\1740 p_55\NN\14622893 less_56\JJR\1740 than_57\IN\1740 0.005_58\CD\1740 compared_59\VBN\644583 to_60\TO\1740 either_61\CC\1740 sham-treated_62\JJ\1740 jj_63\NN\1740 or_64\CC\3541091 aspirin-treated_65\JJ\1740 jj_66\NN\1740 )_67\-RRB-\1740 ._68\.\1740
D011453_D058186 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 enhanced_4\VBN\227165 <e1>prostaglandin</e1>_5\NN\5414534 synthesis_6\NN\13446390 contributes_7\VBZ\126264 to_8\TO\1740 maintenance_9\NN\266806 of_10\IN\1740 renal_11\JJ\1740 function_12\NN\13783581 and_13\CC\1740 morphological_14\JJ\1740 integrity_15\NN\24720 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 inhibition_19\NN\1068773 of_20\IN\1740 prostaglandin_21\NN\5414534 synthesis_22\NN\13446390 may_23\MD\15209706 lead_24\VB\1752884 to_25\TO\1740 <e2>pathological_26\JJ\1740 renal_27\JJ\1740 medullary_28\JJ\1740 lesions</e2>_29\NNS\14204950 and_30\CC\1740 deterioration_31\NN\14560612 of_32\IN\1740 renal_33\JJ\1740 function_34\NN\13783581 ._35\.\1740
D011453_D058186 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 enhanced_4\VBN\227165 prostaglandin_5\NN\5414534 synthesis_6\NN\13446390 contributes_7\VBZ\126264 to_8\TO\1740 maintenance_9\NN\266806 of_10\IN\1740 renal_11\JJ\1740 function_12\NN\13783581 and_13\CC\1740 morphological_14\JJ\1740 integrity_15\NN\24720 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 inhibition_19\NN\1068773 of_20\IN\1740 <e1>prostaglandin</e1>_21\NN\5414534 synthesis_22\NN\13446390 may_23\MD\15209706 lead_24\VB\1752884 to_25\TO\1740 <e2>pathological_26\JJ\1740 renal_27\JJ\1740 medullary_28\JJ\1740 lesions</e2>_29\NNS\14204950 and_30\CC\1740 deterioration_31\NN\14560612 of_32\IN\1740 renal_33\JJ\1740 function_34\NN\13783581 ._35\.\1740
15815446
D010656_D002545 NONE focal_0\JJ\1740 <e2>cerebral_1\JJ\1740 ischemia</e2>_2\NN\14195315 in_3\IN\13603305 rats_4\NNS\2329401 :_5\:\1740 effect_6\NN\34213 of_7\IN\1740 <e1>phenylephrine-induced</e1>_8\JJ\1740 hypertension_9\NN\14057371 during_10\IN\1740 reperfusion_11\NN\1740 ._12\.\1740
D010656_D006973 CID focal_0\JJ\1740 cerebral_1\JJ\1740 ischemia_2\NN\14195315 in_3\IN\13603305 rats_4\NNS\2329401 :_5\:\1740 effect_6\NN\34213 of_7\IN\1740 <e1>phenylephrine-induced</e1>_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 during_10\IN\1740 reperfusion_11\NN\1740 ._12\.\1740
D010656_D006973 CID after_0\IN\1740 180_1\CD\1740 min_2\NN\15154774 of_3\IN\1740 temporary_4\JJ\1740 middle_5\NN\8497294 cerebral_6\JJ\1740 artery_7\NN\5417975 occlusion_8\NN\14081375 in_9\IN\13603305 spontaneously_10\JJ\1740 <e2>hypertensive</e2>_11\JJ\1740 rats_12\NNS\2329401 ,_13\,\1740 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 <e1>phenylephrine-induced</e1>_17\JJ\1740 hypertension_18\NN\14057371 on_19\IN\1740 ischemic_20\JJ\1740 brain_21\NN\5462674 injury_22\NN\14052046 and_23\CC\1740 blood-brain_24\JJ\1740 barrier_25\NN\3839993 permeability_26\NN\4940146 was_27\VBD\836236 determined_28\VBN\1645601 ._29\.\1740
D010656_D006973 CID after_0\IN\1740 180_1\CD\1740 min_2\NN\15154774 of_3\IN\1740 temporary_4\JJ\1740 middle_5\NN\8497294 cerebral_6\JJ\1740 artery_7\NN\5417975 occlusion_8\NN\14081375 in_9\IN\13603305 spontaneously_10\JJ\1740 hypertensive_11\JJ\1740 rats_12\NNS\2329401 ,_13\,\1740 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 <e1>phenylephrine-induced</e1>_17\JJ\1740 <e2>hypertension</e2>_18\NN\14057371 on_19\IN\1740 ischemic_20\JJ\1740 brain_21\NN\5462674 injury_22\NN\14052046 and_23\CC\1740 blood-brain_24\JJ\1740 barrier_25\NN\3839993 permeability_26\NN\4940146 was_27\VBD\836236 determined_28\VBN\1645601 ._29\.\1740
D010656_D020244 NONE after_0\IN\1740 180_1\CD\1740 min_2\NN\15154774 of_3\IN\1740 temporary_4\JJ\1740 <e2>middle_5\NN\8497294 cerebral_6\JJ\1740 artery_7\NN\5417975 occlusion</e2>_8\NN\14081375 in_9\IN\13603305 spontaneously_10\JJ\1740 hypertensive_11\JJ\1740 rats_12\NNS\2329401 ,_13\,\1740 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 <e1>phenylephrine-induced</e1>_17\JJ\1740 hypertension_18\NN\14057371 on_19\IN\1740 ischemic_20\JJ\1740 brain_21\NN\5462674 injury_22\NN\14052046 and_23\CC\1740 blood-brain_24\JJ\1740 barrier_25\NN\3839993 permeability_26\NN\4940146 was_27\VBD\836236 determined_28\VBN\1645601 ._29\.\1740
D010656_D001930 NONE after_0\IN\1740 180_1\CD\1740 min_2\NN\15154774 of_3\IN\1740 temporary_4\JJ\1740 middle_5\NN\8497294 cerebral_6\JJ\1740 artery_7\NN\5417975 occlusion_8\NN\14081375 in_9\IN\13603305 spontaneously_10\JJ\1740 hypertensive_11\JJ\1740 rats_12\NNS\2329401 ,_13\,\1740 the_14\DT\1740 effect_15\NN\34213 of_16\IN\1740 <e1>phenylephrine-induced</e1>_17\JJ\1740 hypertension_18\NN\14057371 on_19\IN\1740 <e2>ischemic_20\JJ\1740 brain_21\NN\5462674 injury</e2>_22\NN\14052046 and_23\CC\1740 blood-brain_24\JJ\1740 barrier_25\NN\3839993 permeability_26\NN\4940146 was_27\VBD\836236 determined_28\VBN\1645601 ._29\.\1740
C009591_D001930 NONE part_0\NN\31921 a_1\NN\13649268 ,_2\,\1740 for_3\IN\1740 eight_4\CD\13741022 rats_5\NNS\2329401 in_6\IN\13603305 each_7\DT\1740 group_8\NN\2137 <e2>brain_9\NN\5462674 injury</e2>_10\NN\14052046 was_11\VBD\836236 evaluated_12\VBN\670261 by_13\IN\1740 staining_14\VBG\283090 tissue_15\NN\5220461 using_16\VBG\1156834 <e1>2,3,5-triphenyltetrazolium_17\NN\1740 chloride</e1>_18\NN\14818238 and_19\CC\1740 edema_20\NN\14315192 was_21\VBD\836236 evaluated_22\VBN\670261 by_23\IN\1740 microgravimetry_24\NN\1740 ._25\.\1740
C009591_D004487 NONE part_0\NN\31921 a_1\NN\13649268 ,_2\,\1740 for_3\IN\1740 eight_4\CD\13741022 rats_5\NNS\2329401 in_6\IN\13603305 each_7\DT\1740 group_8\NN\2137 brain_9\NN\5462674 injury_10\NN\14052046 was_11\VBD\836236 evaluated_12\VBN\670261 by_13\IN\1740 staining_14\VBG\283090 tissue_15\NN\5220461 using_16\VBG\1156834 <e1>2,3,5-triphenyltetrazolium_17\NN\1740 chloride</e1>_18\NN\14818238 and_19\CC\1740 <e2>edema</e2>_20\NN\14315192 was_21\VBD\836236 evaluated_22\VBN\670261 by_23\IN\1740 microgravimetry_24\NN\1740 ._25\.\1740
D005070_D006973 NONE <e1>evans_0\NNP\1740 blue</e1>_1\NNP\4959672 (_2\-LRB-\1740 mug_3\NN\13756125 g-1_4\NN\1740 of_5\IN\1740 brain_6\NN\5462674 tissue_7\NN\5220461 )_8\-RRB-\1740 was_9\VBD\836236 greater_10\JJR\1740 in_11\IN\13603305 the_12\DT\1740 <e2>90/htn</e2>_13\JJ\1740 group_14\NN\2137 (_15\-LRB-\1740 24.4_16\CD\1740 +/-_17\CC\1740 6.0_18\CD\1740 )_19\-RRB-\1740 versus_20\CC\1740 the_21\DT\1740 control_22\NN\5190804 group_23\NN\2137 (_24\-LRB-\1740 12.3_25\CD\1740 +/-_26\CC\1740 4.1_27\CD\1740 )_28\-RRB-\1740 ,_29\,\1740 which_30\WDT\1740 was_31\VBD\836236 in_32\IN\13603305 turn_33\NN\13867641 greater_34\JJR\1740 than_35\IN\1740 the_36\DT\1740 15/htn_37\CD\1740 group_38\NN\2137 (_39\-LRB-\1740 7.3_40\CD\1740 +/-_41\CC\1740 3.2_42\CD\1740 )_43\-RRB-\1740 ._44\.\1740
D005070_D006973 NONE <e1>evans_0\NNP\1740 blue</e1>_1\NNP\4959672 (_2\-LRB-\1740 mug_3\NN\13756125 g-1_4\NN\1740 of_5\IN\1740 brain_6\NN\5462674 tissue_7\NN\5220461 )_8\-RRB-\1740 was_9\VBD\836236 greater_10\JJR\1740 in_11\IN\13603305 the_12\DT\1740 90/htn_13\JJ\1740 group_14\NN\2137 (_15\-LRB-\1740 24.4_16\CD\1740 +/-_17\CC\1740 6.0_18\CD\1740 )_19\-RRB-\1740 versus_20\CC\1740 the_21\DT\1740 control_22\NN\5190804 group_23\NN\2137 (_24\-LRB-\1740 12.3_25\CD\1740 +/-_26\CC\1740 4.1_27\CD\1740 )_28\-RRB-\1740 ,_29\,\1740 which_30\WDT\1740 was_31\VBD\836236 in_32\IN\13603305 turn_33\NN\13867641 greater_34\JJR\1740 than_35\IN\1740 the_36\DT\1740 <e2>15/htn</e2>_37\CD\1740 group_38\NN\2137 (_39\-LRB-\1740 7.3_40\CD\1740 +/-_41\CC\1740 3.2_42\CD\1740 )_43\-RRB-\1740 ._44\.\1740
15276093
C451780_D006937 NONE <e1>niacin_0\NN\15090742 extended-release/lovastatin</e1>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 new_4\JJ\1740 combination_5\NN\7951464 product_6\NN\3076708 approved_7\VBN\803325 for_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 primary_11\JJ\1740 <e2>hypercholesterolemia</e2>_12\NN\14299637 and_13\CC\1740 mixed_14\JJ\1740 dyslipidemia_15\NN\1740 ._16\.\1740
C451780_D050171 NONE <e1>niacin_0\NN\15090742 extended-release/lovastatin</e1>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 new_4\JJ\1740 combination_5\NN\7951464 product_6\NN\3076708 approved_7\VBN\803325 for_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 primary_11\JJ\1740 hypercholesterolemia_12\NN\14299637 and_13\CC\1740 mixed_14\JJ\1740 <e2>dyslipidemia</e2>_15\NN\1740 ._16\.\1740
C451780_D050171 NONE patients_0\NNS\9898892 also_1\RB\1740 received_2\VBD\2210855 dietary_3\JJ\1740 counseling_4\NN\6598915 ,_5\,\1740 educational_6\JJ\1740 materials_7\NNS\19613 ,_8\,\1740 and_9\CC\1740 reminders_10\NNS\6598915 to_11\TO\1740 call_12\VB\1029852 a_13\DT\13649268 toll-free_14\JJ\1740 number_15\NN\5107765 that_16\WDT\1740 provided_17\VBD\2199590 further_18\JJ\1740 education_19\NN\407535 about_20\IN\1740 <e2>dyslipidemia</e2>_21\NN\1740 and_22\CC\1740 <e1>niacin_23\NN\15090742 extended-release/lovastatin</e1>_24\NN\1740 ._25\.\1740
D003401_D009135 NONE an_0\DT\6697703 increase_1\NN\13576355 of_2\IN\1740 <e1>creatine</e1>_3\NN\14601829 phosphokinase_4\NN\1740 to_5\TO\1740 >_6\NNS\1740 5_7\CD\13741022 times_8\NNS\15113229 the_9\DT\1740 upper_10\JJ\1740 limit_11\NN\5123416 of_12\IN\1740 normal_13\JJ\1740 occurred_14\VBD\2623529 in_15\IN\13603305 0.24_16\CD\1740 %_17\NN\1740 of_18\IN\1740 patients_19\NNS\9898892 ,_20\,\1740 and_21\CC\1740 no_22\DT\7204911 cases_23\NNS\7283608 of_24\IN\1740 drug-induced_25\JJ\1740 <e2>myopathy</e2>_26\NN\14204950 were_27\VBD\836236 observed_28\VBN\2163746 ._29\.\1740
7479194
D015662_D064420 NONE a_0\DT\13649268 large_1\JJ\1740 population-based_2\JJ\1740 follow-up_3\NN\4599396 study_4\NN\635850 of_5\IN\1740 <e1>trimethoprim-sulfamethoxazole</e1>_6\JJ\1740 ,_7\,\1740 trimethoprim_8\VBP\1740 ,_9\,\1740 and_10\CC\1740 cephalexin_11\NN\2996840 for_12\IN\1740 uncommon_13\JJ\1740 serious_14\JJ\1740 <e2>drug_15\NN\14778436 toxicity</e2>_16\NN\13576101 ._17\.\1740
D014295_D064420 NONE a_0\DT\13649268 large_1\JJ\1740 population-based_2\JJ\1740 follow-up_3\NN\4599396 study_4\NN\635850 of_5\IN\1740 trimethoprim-sulfamethoxazole_6\JJ\1740 ,_7\,\1740 <e1>trimethoprim</e1>_8\VBP\1740 ,_9\,\1740 and_10\CC\1740 cephalexin_11\NN\2996840 for_12\IN\1740 uncommon_13\JJ\1740 serious_14\JJ\1740 <e2>drug_15\NN\14778436 toxicity</e2>_16\NN\13576101 ._17\.\1740
D002506_D064420 NONE a_0\DT\13649268 large_1\JJ\1740 population-based_2\JJ\1740 follow-up_3\NN\4599396 study_4\NN\635850 of_5\IN\1740 trimethoprim-sulfamethoxazole_6\JJ\1740 ,_7\,\1740 trimethoprim_8\VBP\1740 ,_9\,\1740 and_10\CC\1740 <e1>cephalexin</e1>_11\NN\2996840 for_12\IN\1740 uncommon_13\JJ\1740 serious_14\JJ\1740 <e2>drug_15\NN\14778436 toxicity</e2>_16\NN\13576101 ._17\.\1740
D015662_D008107 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 clinically_3\RB\1740 important_4\JJ\1740 idiopathic_5\JJ\1740 <e2>liver_6\NN\5298729 disease</e2>_7\NN\14061805 was_8\VBD\836236 similar_9\JJ\1740 for_10\IN\1740 persons_11\NNS\7347 prescribed_12\VBN\748282 <e1>tmp-smz</e1>_13\NN\1740 (_14\-LRB-\1740 5.2/100,000_15\JJ\1740 )_16\-RRB-\1740 and_17\CC\1740 those_18\DT\1740 prescribed_19\VBN\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 (_22\-LRB-\1740 3.8/100,000_23\CD\1740 )_24\-RRB-\1740 ._25\.\1740
D015662_D008107 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D008107 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 <e1>tmp-smz</e1>_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D006402 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D006402 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 <e1>tmp-smz</e1>_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D012871 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D012871 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 <e1>tmp-smz</e1>_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D007674 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D007674 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 <e1>tmp-smz</e1>_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D014295_D008107 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 clinically_3\RB\1740 important_4\JJ\1740 idiopathic_5\JJ\1740 <e2>liver_6\NN\5298729 disease</e2>_7\NN\14061805 was_8\VBD\836236 similar_9\JJ\1740 for_10\IN\1740 persons_11\NNS\7347 prescribed_12\VBN\748282 tmp-smz_13\NN\1740 (_14\-LRB-\1740 5.2/100,000_15\JJ\1740 )_16\-RRB-\1740 and_17\CC\1740 those_18\DT\1740 prescribed_19\VBN\748282 <e1>trimethoprim</e1>_20\NN\1740 alone_21\RB\1740 (_22\-LRB-\1740 3.8/100,000_23\CD\1740 )_24\-RRB-\1740 ._25\.\1740
D014295_D008107 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 <e1>trimethoprim</e1>_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D014295_D006402 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 <e1>trimethoprim</e1>_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D014295_D012871 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 <e1>trimethoprim</e1>_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D014295_D007674 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 <e1>trimethoprim</e1>_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 cephalexin_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D002506_D008107 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 <e1>cephalexin</e1>_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D002506_D006402 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 <e1>cephalexin</e1>_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D002506_D012871 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 <e1>cephalexin</e1>_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D002506_D007674 NONE we_0\PRP\1740 conducted_1\VBD\2436349 a_2\DT\13649268 population-based_3\JJ\1740 45-day_4\JJ\1740 follow-up_5\NN\4599396 study_6\NN\635850 of_7\IN\1740 232,390_8\CD\1740 people_9\NNS\31264 who_10\WP\8299493 were_11\VBD\836236 prescribed_12\VBN\748282 trimethoprim-sulfamethoxazole_13\NN\1740 (_14\-LRB-\1740 tmp-smz_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 266,951_18\CD\1740 prescribed_19\VBD\748282 trimethoprim_20\NN\1740 alone_21\RB\1740 ,_22\,\1740 and_23\CC\1740 196,397_24\CD\1740 prescribed_25\VBN\748282 <e1>cephalexin</e1>_26\NNS\2996840 ,_27\,\1740 to_28\TO\1740 estimate_29\VB\637259 the_30\DT\1740 risk_31\NN\14541044 of_32\IN\1740 serious_33\JJ\1740 <e2>liver_34\NN\5298729 ,_35\,\1740 blood_36\NN\5397468 ,_37\,\1740 skin_38\NN\5237755 ,_39\,\1740 and_40\CC\1740 renal_41\JJ\1740 disorders</e2>_42\NNS\14034177 resulting_43\VBG\2633881 in_44\IN\13603305 referral_45\NN\9898892 or_46\CC\3541091 hospitalization_47\NN\15113229 associated_48\VBN\628491 with_49\IN\1740 these_50\DT\1740 drugs_51\NNS\14778436 ._52\.\1740
D015662_D004892 NONE only_0\RB\1740 five_1\CD\13741022 patients_2\NNS\9898892 experienced_3\VBD\2108377 blood_4\NN\5397468 disorders_5\NNS\14034177 ,_6\,\1740 one_7\CD\13741022 of_8\IN\1740 whom_9\WP\1740 was_10\VBD\836236 exposed_11\VBN\2110927 to_12\TO\1740 <e1>tmp-smz</e1>_13\NN\1740 ;_14\:\1740 of_15\IN\1740 seven_16\CD\13741022 with_17\IN\1740 <e2>erythema_18\NN\14227218 multiforme</e2>_19\JJ\1740 and_20\CC\1740 stevens-johnson_21\NN\1740 syndrome_22\NN\5870365 ,_23\,\1740 four_24\CD\13741022 were_25\VBD\836236 exposed_26\VBN\2110927 to_27\TO\1740 tmp-smz_28\NN\1740 ._29\.\1740
D015662_D004892 NONE only_0\RB\1740 five_1\CD\13741022 patients_2\NNS\9898892 experienced_3\VBD\2108377 blood_4\NN\5397468 disorders_5\NNS\14034177 ,_6\,\1740 one_7\CD\13741022 of_8\IN\1740 whom_9\WP\1740 was_10\VBD\836236 exposed_11\VBN\2110927 to_12\TO\1740 tmp-smz_13\NN\1740 ;_14\:\1740 of_15\IN\1740 seven_16\CD\13741022 with_17\IN\1740 <e2>erythema_18\NN\14227218 multiforme</e2>_19\JJ\1740 and_20\CC\1740 stevens-johnson_21\NN\1740 syndrome_22\NN\5870365 ,_23\,\1740 four_24\CD\13741022 were_25\VBD\836236 exposed_26\VBN\2110927 to_27\TO\1740 <e1>tmp-smz</e1>_28\NN\1740 ._29\.\1740
D015662_D013262 CID only_0\RB\1740 five_1\CD\13741022 patients_2\NNS\9898892 experienced_3\VBD\2108377 blood_4\NN\5397468 disorders_5\NNS\14034177 ,_6\,\1740 one_7\CD\13741022 of_8\IN\1740 whom_9\WP\1740 was_10\VBD\836236 exposed_11\VBN\2110927 to_12\TO\1740 <e1>tmp-smz</e1>_13\NN\1740 ;_14\:\1740 of_15\IN\1740 seven_16\CD\13741022 with_17\IN\1740 erythema_18\NN\14227218 multiforme_19\JJ\1740 and_20\CC\1740 <e2>stevens-johnson_21\NN\1740 syndrome</e2>_22\NN\5870365 ,_23\,\1740 four_24\CD\13741022 were_25\VBD\836236 exposed_26\VBN\2110927 to_27\TO\1740 tmp-smz_28\NN\1740 ._29\.\1740
D015662_D013262 CID only_0\RB\1740 five_1\CD\13741022 patients_2\NNS\9898892 experienced_3\VBD\2108377 blood_4\NN\5397468 disorders_5\NNS\14034177 ,_6\,\1740 one_7\CD\13741022 of_8\IN\1740 whom_9\WP\1740 was_10\VBD\836236 exposed_11\VBN\2110927 to_12\TO\1740 tmp-smz_13\NN\1740 ;_14\:\1740 of_15\IN\1740 seven_16\CD\13741022 with_17\IN\1740 erythema_18\NN\14227218 multiforme_19\JJ\1740 and_20\CC\1740 <e2>stevens-johnson_21\NN\1740 syndrome</e2>_22\NN\5870365 ,_23\,\1740 four_24\CD\13741022 were_25\VBD\836236 exposed_26\VBN\2110927 to_27\TO\1740 <e1>tmp-smz</e1>_28\NN\1740 ._29\.\1740
D002506_D013262 CID the_0\DT\1740 one_1\CD\13741022 case_2\NN\7283608 of_3\IN\1740 <e2>toxic_4\JJ\1740 epidermal_5\JJ\1740 necrolysis</e2>_6\NN\13509528 occurred_7\VBD\2623529 in_8\IN\13603305 a_9\DT\13649268 patient_10\NN\9898892 who_11\WP\8299493 took_12\VBD\2367363 <e1>cephalexin</e1>_13\NNS\2996840 ._14\.\1740
8511251
D003042_D017202 CID <e1>cocaine</e1>_0\NN\3492717 induced_1\VBD\1627355 <e2>myocardial_2\JJ\1740 ischemia</e2>_3\NN\14195315 ._4\.\1740
D003042_D017202 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>myocardial_5\JJ\1740 ischemia</e2>_6\NN\14195315 induced_7\VBN\1627355 by_8\IN\1740 <e1>cocaine</e1>_9\NN\3492717 ._10\.\1740
D005996_D007511 NONE the_0\DT\1740 <e2>ischemia</e2>_1\NN\14195315 probably_2\RB\1740 induced_3\VBN\1627355 by_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 spasm_7\NN\14299637 was_8\VBD\836236 reversed_9\VBN\109660 by_10\IN\1740 <e1>nitroglycerin</e1>_11\NN\15015501 and_12\CC\1740 calcium_13\NN\14625458 blocking_14\NN\562280 agents_15\NNS\7347 ._16\.\1740
D005996_D003329 NONE the_0\DT\1740 ischemia_1\NN\14195315 probably_2\RB\1740 induced_3\VBN\1627355 by_4\IN\1740 <e2>coronary_5\JJ\1740 artery_6\NN\5417975 spasm</e2>_7\NN\14299637 was_8\VBD\836236 reversed_9\VBN\109660 by_10\IN\1740 <e1>nitroglycerin</e1>_11\NN\15015501 and_12\CC\1740 calcium_13\NN\14625458 blocking_14\NN\562280 agents_15\NNS\7347 ._16\.\1740
D002118_D007511 NONE the_0\DT\1740 <e2>ischemia</e2>_1\NN\14195315 probably_2\RB\1740 induced_3\VBN\1627355 by_4\IN\1740 coronary_5\JJ\1740 artery_6\NN\5417975 spasm_7\NN\14299637 was_8\VBD\836236 reversed_9\VBN\109660 by_10\IN\1740 nitroglycerin_11\NN\15015501 and_12\CC\1740 <e1>calcium</e1>_13\NN\14625458 blocking_14\NN\562280 agents_15\NNS\7347 ._16\.\1740
D002118_D003329 NONE the_0\DT\1740 ischemia_1\NN\14195315 probably_2\RB\1740 induced_3\VBN\1627355 by_4\IN\1740 <e2>coronary_5\JJ\1740 artery_6\NN\5417975 spasm</e2>_7\NN\14299637 was_8\VBD\836236 reversed_9\VBN\109660 by_10\IN\1740 nitroglycerin_11\NN\15015501 and_12\CC\1740 <e1>calcium</e1>_13\NN\14625458 blocking_14\NN\562280 agents_15\NNS\7347 ._16\.\1740
19447152
D010042_D001714 CID animal_0\JJ\1740 model_1\NN\5888929 of_2\IN\1740 <e2>mania</e2>_3\NN\9180259 induced_4\VBN\1627355 by_5\IN\1740 <e1>ouabain</e1>_6\NN\1740 :_7\:\1740 evidence_8\NN\5816287 of_9\IN\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 in_12\IN\13603305 submitochondrial_13\JJ\1740 particles_14\NNS\14580897 of_15\IN\1740 the_16\DT\1740 rat_17\NN\2329401 brain_18\NN\5462674 ._19\.\1740
D010042_D001714 CID the_0\DT\1740 intracerebroventricular_1\NN\1740 (_2\-LRB-\1740 icv_3\NN\1740 )_4\-RRB-\1740 administration_5\NN\1133281 of_6\IN\1740 <e1>ouabain</e1>_7\NN\1740 (_8\-LRB-\1740 a_9\DT\13649268 na(+)/k(+)-atpase_10\NN\1740 inhibitor_11\NN\20090 )_12\-RRB-\1740 in_13\IN\13603305 rats_14\NNS\2329401 has_15\VBZ\2108377 been_16\VBN\836236 suggested_17\VBN\1010118 to_18\TO\1740 mimic_19\VB\1742886 some_20\DT\1740 symptoms_21\NNS\5823932 of_22\IN\1740 human_23\JJ\1740 <e2>bipolar_24\JJ\1740 mania</e2>_25\NN\9180259 ._26\.\1740
D010042_D001714 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>ouabain-induced</e1>_3\JJ\1740 <e2>mania-like</e2>_4\JJ\1740 behavior_5\NN\407535 may_6\MD\15209706 provide_7\VB\2199590 a_8\DT\13649268 useful_9\JJ\1740 animal_10\NN\4475 model_11\NN\5888929 to_12\TO\1740 test_13\VB\670261 the_14\DT\1740 hypothesis_15\NN\7162194 of_16\IN\1740 the_17\DT\1740 involvement_18\NN\1080366 of_19\IN\1740 oxidative_20\JJ\1740 stress_21\NN\7083732 in_22\IN\13603305 bipolar_23\JJ\1740 disorder_24\NN\14034177 ._25\.\1740
D010042_D001714 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>ouabain-induced</e1>_3\JJ\1740 mania-like_4\JJ\1740 behavior_5\NN\407535 may_6\MD\15209706 provide_7\VB\2199590 a_8\DT\13649268 useful_9\JJ\1740 animal_10\NN\4475 model_11\NN\5888929 to_12\TO\1740 test_13\VB\670261 the_14\DT\1740 hypothesis_15\NN\7162194 of_16\IN\1740 the_17\DT\1740 involvement_18\NN\1080366 of_19\IN\1740 oxidative_20\JJ\1740 stress_21\NN\7083732 in_22\IN\13603305 <e2>bipolar_23\JJ\1740 disorder</e2>_24\NN\14034177 ._25\.\1740
D012964_D001714 NONE the_0\DT\1740 intracerebroventricular_1\NN\1740 (_2\-LRB-\1740 icv_3\NN\1740 )_4\-RRB-\1740 administration_5\NN\1133281 of_6\IN\1740 ouabain_7\NN\1740 (_8\-LRB-\1740 a_9\DT\13649268 <e1>na(+)/k(+)-atpase</e1>_10\NN\1740 inhibitor_11\NN\20090 )_12\-RRB-\1740 in_13\IN\13603305 rats_14\NNS\2329401 has_15\VBZ\2108377 been_16\VBN\836236 suggested_17\VBN\1010118 to_18\TO\1740 mimic_19\VB\1742886 some_20\DT\1740 symptoms_21\NNS\5823932 of_22\IN\1740 human_23\JJ\1740 <e2>bipolar_24\JJ\1740 mania</e2>_25\NN\9180259 ._26\.\1740
D011188_D001714 NONE the_0\DT\1740 intracerebroventricular_1\NN\1740 (_2\-LRB-\1740 icv_3\NN\1740 )_4\-RRB-\1740 administration_5\NN\1133281 of_6\IN\1740 ouabain_7\NN\1740 (_8\-LRB-\1740 a_9\DT\13649268 <e1>na(+)/k(+)-atpase</e1>_10\NN\1740 inhibitor_11\NN\20090 )_12\-RRB-\1740 in_13\IN\13603305 rats_14\NNS\2329401 has_15\VBZ\2108377 been_16\VBN\836236 suggested_17\VBN\1010118 to_18\TO\1740 mimic_19\VB\1742886 some_20\DT\1740 symptoms_21\NNS\5823932 of_22\IN\1740 human_23\JJ\1740 <e2>bipolar_24\JJ\1740 mania</e2>_25\NN\9180259 ._26\.\1740
D010042_D009069 NONE our_0\PRP$\1740 findings_1\NNS\7951464 demonstrated_2\VBD\2137132 that_3\IN\1740 <e1>ouabain</e1>_4\VBP\1740 at_5\IN\14622893 10(-2_6\CD\1740 )_7\-RRB-\1740 and_8\CC\1740 10(-3)m_9\CD\1740 induced_10\VBD\1627355 <e2>hyperlocomotion</e2>_11\NN\1740 in_12\IN\13603305 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 this_16\DT\1740 response_17\NN\11410625 remained_18\VBD\2604760 up_19\RB\1740 to_20\TO\1740 7_21\CD\13741022 days_22\NNS\15140892 following_23\VBG\1835496 a_24\DT\13649268 single_25\JJ\1740 icv_26\NN\1740 injection_27\NN\320852 ._28\.\1740
733189
D000305_D015356 NONE bilateral_0\JJ\1740 <e2>retinal_1\JJ\1740 artery_2\NN\5417975 and_3\CC\1740 choriocapillaris_4\JJ\1740 occlusion</e2>_5\NN\14081375 following_6\VBG\1835496 the_7\DT\1740 injection_8\NN\320852 of_9\IN\1740 long-acting_10\JJ\1740 <e1>corticosteroid</e1>_11\NN\14745635 suspensions_12\NNS\14586258 in_13\IN\13603305 combination_14\NN\7951464 with_15\IN\1740 other_16\JJ\1740 drugs_17\NNS\14778436 :_18\:\1740 i._19\NNP\1740 clinical_20\JJ\1740 studies_21\NNS\635850 ._22\.\1740
C000873_D015356 CID two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 <e2>retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions</e2>_9\NNS\14081375 with_10\IN\1740 blindness_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 <e1>methylprednisolone_19\JJ\1740 acetate</e1>_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 lidocaine_24\NN\3681148 ,_25\,\1740 epinephrine_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 penicillin_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
C000873_D001766 NONE two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions_9\NNS\14081375 with_10\IN\1740 <e2>blindness</e2>_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 <e1>methylprednisolone_19\JJ\1740 acetate</e1>_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 lidocaine_24\NN\3681148 ,_25\,\1740 epinephrine_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 penicillin_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
D008012_D015356 NONE two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 <e2>retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions</e2>_9\NNS\14081375 with_10\IN\1740 blindness_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 methylprednisolone_19\JJ\1740 acetate_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 <e1>lidocaine</e1>_24\NN\3681148 ,_25\,\1740 epinephrine_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 penicillin_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
D008012_D001766 NONE two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions_9\NNS\14081375 with_10\IN\1740 <e2>blindness</e2>_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 methylprednisolone_19\JJ\1740 acetate_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 <e1>lidocaine</e1>_24\NN\3681148 ,_25\,\1740 epinephrine_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 penicillin_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
D004837_D015356 NONE two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 <e2>retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions</e2>_9\NNS\14081375 with_10\IN\1740 blindness_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 methylprednisolone_19\JJ\1740 acetate_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 lidocaine_24\NN\3681148 ,_25\,\1740 <e1>epinephrine</e1>_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 penicillin_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
D004837_D001766 NONE two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions_9\NNS\14081375 with_10\IN\1740 <e2>blindness</e2>_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 methylprednisolone_19\JJ\1740 acetate_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 lidocaine_24\NN\3681148 ,_25\,\1740 <e1>epinephrine</e1>_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 penicillin_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
D010406_D015356 NONE two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 <e2>retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions</e2>_9\NNS\14081375 with_10\IN\1740 blindness_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 methylprednisolone_19\JJ\1740 acetate_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 lidocaine_24\NN\3681148 ,_25\,\1740 epinephrine_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 <e1>penicillin</e1>_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
D010406_D001766 NONE two_0\CD\13741022 well-documented_1\JJ\1740 cases_2\NNS\7283608 of_3\IN\1740 bilateral_4\JJ\1740 retinal_5\JJ\1740 artery_6\NN\5417975 and_7\CC\1740 choriocapillaris_8\NN\1740 occlusions_9\NNS\14081375 with_10\IN\1740 <e2>blindness</e2>_11\NN\14552802 following_12\VBG\1835496 head_13\NN\5225090 and_14\CC\1740 neck_15\NN\5225090 soft-tissue_16\NN\1740 injection_17\NN\320852 with_18\IN\1740 methylprednisolone_19\JJ\1740 acetate_20\NN\15010703 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 lidocaine_24\NN\3681148 ,_25\,\1740 epinephrine_26\NN\14807929 ,_27\,\1740 or_28\CC\3541091 <e1>penicillin</e1>_29\NN\2716866 are_30\VBP\836236 reported_31\VBN\831651 ._32\.\1740
20566328
D003042_D028361 NONE <e2>mitochondrial_0\JJ\1740 impairment</e2>_1\NN\7296428 contributes_2\VBZ\126264 to_3\TO\1740 <e1>cocaine-induced</e1>_4\JJ\1740 cardiac_5\JJ\1740 dysfunction_6\NN\14204950 :_7\:\1740 prevention_8\NN\1073995 by_9\IN\1740 the_10\DT\1740 targeted_11\VBN\1151110 antioxidant_12\JJ\1740 mitoq._13\NN\1740
D003042_D028361 NONE this_0\DT\1740 uncoupling_1\NN\1740 effect_2\NN\34213 on_3\IN\1740 oxidative_4\JJ\1740 phosphorylation_5\NN\1740 was_6\VBD\836236 not_7\RB\1740 detectable_8\JJ\1740 after_9\IN\1740 short-term_10\JJ\1740 exposure_11\NN\5042871 to_12\TO\1740 <e1>cocaine</e1>_13\NN\3492717 ,_14\,\1740 suggesting_15\VBG\1010118 that_16\IN\1740 these_17\DT\1740 <e2>mitochondrial_18\JJ\1740 abnormalities</e2>_19\NNS\14034177 were_20\VBD\836236 a_21\DT\13649268 late_22\JJ\1740 rather_23\RB\1740 than_24\IN\1740 a_25\DT\13649268 primary_26\JJ\1740 event_27\NN\23100 in_28\IN\13603305 the_29\DT\1740 pathological_30\JJ\1740 response_31\NN\11410625 to_32\TO\1740 cocaine_33\NN\3492717 ._34\.\1740
D003042_D028361 NONE this_0\DT\1740 uncoupling_1\NN\1740 effect_2\NN\34213 on_3\IN\1740 oxidative_4\JJ\1740 phosphorylation_5\NN\1740 was_6\VBD\836236 not_7\RB\1740 detectable_8\JJ\1740 after_9\IN\1740 short-term_10\JJ\1740 exposure_11\NN\5042871 to_12\TO\1740 cocaine_13\NN\3492717 ,_14\,\1740 suggesting_15\VBG\1010118 that_16\IN\1740 these_17\DT\1740 <e2>mitochondrial_18\JJ\1740 abnormalities</e2>_19\NNS\14034177 were_20\VBD\836236 a_21\DT\13649268 late_22\JJ\1740 rather_23\RB\1740 than_24\IN\1740 a_25\DT\13649268 primary_26\JJ\1740 event_27\NN\23100 in_28\IN\13603305 the_29\DT\1740 pathological_30\JJ\1740 response_31\NN\11410625 to_32\TO\1740 <e1>cocaine</e1>_33\NN\3492717 ._34\.\1740
D003042_D028361 NONE taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 these_3\DT\1740 results_4\NNS\34213 extend_5\VBP\153263 previous_6\JJ\1740 studies_7\NNS\635850 and_8\CC\1740 demonstrate_9\VBP\2137132 that_10\IN\1740 <e1>cocaine-induced</e1>_11\JJ\1740 cardiac_12\JJ\1740 dysfunction_13\NN\14204950 may_14\MD\15209706 be_15\VB\836236 due_16\JJ\1740 to_17\TO\1740 a_18\DT\13649268 <e2>mitochondrial_19\JJ\1740 defect</e2>_20\NN\14462666 ._21\.\1740
D003042_D006331 CID mitochondrial_0\JJ\1740 impairment_1\NN\7296428 contributes_2\VBZ\126264 to_3\TO\1740 <e1>cocaine-induced</e1>_4\JJ\1740 <e2>cardiac_5\JJ\1740 dysfunction</e2>_6\NN\14204950 :_7\:\1740 prevention_8\NN\1073995 by_9\IN\1740 the_10\DT\1740 targeted_11\VBN\1151110 antioxidant_12\JJ\1740 mitoq._13\NN\1740
D003042_D006331 CID the_0\DT\1740 goal_1\NN\5809192 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 assess_7\VB\670261 mitochondrial_8\JJ\1740 function_9\NN\13783581 and_10\CC\1740 ros_11\NN\6894544 production_12\NN\30358 in_13\IN\13603305 an_14\DT\6697703 experimental_15\JJ\1740 model_16\NN\5888929 of_17\IN\1740 <e1>cocaine-induced</e1>_18\JJ\1740 <e2>cardiac_19\JJ\1740 dysfunction</e2>_20\NN\14204950 ._21\.\1740
D003042_D006331 CID taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 these_3\DT\1740 results_4\NNS\34213 extend_5\VBP\153263 previous_6\JJ\1740 studies_7\NNS\635850 and_8\CC\1740 demonstrate_9\VBP\2137132 that_10\IN\1740 <e1>cocaine-induced</e1>_11\JJ\1740 <e2>cardiac_12\JJ\1740 dysfunction</e2>_13\NN\14204950 may_14\MD\15209706 be_15\VB\836236 due_16\JJ\1740 to_17\TO\1740 a_18\DT\13649268 mitochondrial_19\JJ\1740 defect_20\NN\14462666 ._21\.\1740
C476756_D028361 NONE <e2>mitochondrial_0\JJ\1740 impairment</e2>_1\NN\7296428 contributes_2\VBZ\126264 to_3\TO\1740 cocaine-induced_4\JJ\1740 cardiac_5\JJ\1740 dysfunction_6\NN\14204950 :_7\:\1740 prevention_8\NN\1073995 by_9\IN\1740 the_10\DT\1740 targeted_11\VBN\1151110 antioxidant_12\JJ\1740 <e1>mitoq.</e1>_13\NN\1740
C476756_D028361 NONE <e1>mitoq</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 mitochondrial-targeted_3\JJ\1740 antioxidant_4\NN\14724436 ,_5\,\1740 was_6\VBD\836236 shown_7\VBN\2137132 to_8\TO\1740 completely_9\RB\1740 prevent_10\VB\1740 these_11\DT\1740 <e2>mitochondrial_12\JJ\1740 abnormalities</e2>_13\NNS\14034177 as_14\RB\1740 well_15\RB\1740 as_16\IN\14622893 cardiac_17\JJ\1740 dysfunction_18\NN\14204950 characterized_19\VBN\609683 here_20\RB\1740 by_21\IN\1740 a_22\DT\13649268 diastolic_23\JJ\1740 dysfunction_24\NN\14204950 studied_25\VBN\630380 with_26\IN\1740 a_27\DT\13649268 conductance_28\NN\11449002 catheter_29\NN\4493505 to_30\TO\1740 obtain_31\VB\2210855 pressure-volume_32\JJ\1740 data_33\NNS\7951464 ._34\.\1740
C476756_D006331 NONE mitochondrial_0\JJ\1740 impairment_1\NN\7296428 contributes_2\VBZ\126264 to_3\TO\1740 cocaine-induced_4\JJ\1740 <e2>cardiac_5\JJ\1740 dysfunction</e2>_6\NN\14204950 :_7\:\1740 prevention_8\NN\1073995 by_9\IN\1740 the_10\DT\1740 targeted_11\VBN\1151110 antioxidant_12\JJ\1740 <e1>mitoq.</e1>_13\NN\1740
C476756_D006331 NONE <e1>mitoq</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 mitochondrial-targeted_3\JJ\1740 antioxidant_4\NN\14724436 ,_5\,\1740 was_6\VBD\836236 shown_7\VBN\2137132 to_8\TO\1740 completely_9\RB\1740 prevent_10\VB\1740 these_11\DT\1740 mitochondrial_12\JJ\1740 abnormalities_13\NNS\14034177 as_14\RB\1740 well_15\RB\1740 as_16\IN\14622893 <e2>cardiac_17\JJ\1740 dysfunction</e2>_18\NN\14204950 characterized_19\VBN\609683 here_20\RB\1740 by_21\IN\1740 a_22\DT\13649268 diastolic_23\JJ\1740 dysfunction_24\NN\14204950 studied_25\VBN\630380 with_26\IN\1740 a_27\DT\13649268 conductance_28\NN\11449002 catheter_29\NN\4493505 to_30\TO\1740 obtain_31\VB\2210855 pressure-volume_32\JJ\1740 data_33\NNS\7951464 ._34\.\1740
C476756_-1 NONE <e1>mitoq</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 mitochondrial-targeted_3\JJ\1740 antioxidant_4\NN\14724436 ,_5\,\1740 was_6\VBD\836236 shown_7\VBN\2137132 to_8\TO\1740 completely_9\RB\1740 prevent_10\VB\1740 these_11\DT\1740 mitochondrial_12\JJ\1740 abnormalities_13\NNS\14034177 as_14\RB\1740 well_15\RB\1740 as_16\IN\14622893 cardiac_17\JJ\1740 dysfunction_18\NN\14204950 characterized_19\VBN\609683 here_20\RB\1740 by_21\IN\1740 a_22\DT\13649268 <e2>diastolic_23\JJ\1740 dysfunction</e2>_24\NN\14204950 studied_25\VBN\630380 with_26\IN\1740 a_27\DT\13649268 conductance_28\NN\11449002 catheter_29\NN\4493505 to_30\TO\1740 obtain_31\VB\2210855 pressure-volume_32\JJ\1740 data_33\NNS\7951464 ._34\.\1740
8308951
D014859_D002543 CID cutaneous_0\JJ\1740 exposure_1\NN\5042871 to_2\TO\1740 <e1>warfarin-like</e1>_3\JJ\1740 anticoagulant_4\NN\3740161 causing_5\VBG\1617192 an_6\DT\6697703 <e2>intracerebral_7\JJ\1740 hemorrhage</e2>_8\NN\14285662 :_9\:\1740 a_10\DT\13649268 case_11\NN\7283608 report_12\NN\6470073 ._13\.\1740
D014859_D006406 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 intercerebral_3\JJ\1740 <e2>hematoma</e2>_4\NN\14317720 due_5\JJ\1740 to_6\TO\1740 <e1>warfarin-induced</e1>_7\JJ\1740 coagulopathy_8\NN\1740 is_9\VBZ\836236 presented_10\VBN\2137132 ._11\.\1740
D014859_D001778 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 intercerebral_3\JJ\1740 hematoma_4\NN\14317720 due_5\JJ\1740 to_6\TO\1740 <e1>warfarin-induced</e1>_7\JJ\1740 <e2>coagulopathy</e2>_8\NN\1740 is_9\VBZ\836236 presented_10\VBN\2137132 ._11\.\1740
D014859_D001778 NONE percutaneous_0\JJ\1740 absorption_1\NN\13558490 of_2\IN\1740 <e1>warfarin</e1>_3\NN\2718259 causing_4\VBG\1617192 <e2>coagulopathy</e2>_5\JJ\1740 ,_6\,\1740 reported_7\VBD\831651 three_8\CD\13741022 times_9\NNS\15113229 in_10\IN\13603305 the_11\DT\1740 past_12\NN\28270 ,_13\,\1740 is_14\VBZ\836236 a_15\DT\13649268 significant_16\JJ\1740 risk_17\NN\14541044 if_18\IN\1740 protective_19\JJ\1740 measures_20\NNS\168237 ,_21\,\1740 such_22\JJ\1740 as_23\IN\14622893 gloves_24\NNS\2799897 ,_25\,\1740 are_26\VBP\836236 not_27\RB\1740 used_28\VBN\1156834 ._29\.\1740
D010894_D001778 NONE an_0\DT\6697703 adverse_1\JJ\1740 drug_2\NN\14778436 interaction_3\NN\37396 with_4\IN\1740 <e1>piroxicam</e1>_5\NN\3828465 ,_6\,\1740 which_7\WDT\1740 she_8\PRP\1740 took_9\VBD\2367363 occasionally_10\RB\1740 ,_11\,\1740 may_12\MD\15209706 have_13\VB\2108377 exacerbated_14\VBN\126264 the_15\DT\1740 <e2>coagulopathy</e2>_16\NN\1740 ._17\.\1740
2718706
D007741_D007022 CID deliberate_0\VB\813978 <e2>hypotension</e2>_1\NN\14057371 induced_2\VBN\1627355 by_3\IN\1740 <e1>labetalol</e1>_4\NNS\2721160 with_5\IN\1740 halothane_6\NN\3570838 ,_7\,\1740 enflurane_8\NN\3299929 or_9\CC\3541091 isoflurane_10\NN\3570838 for_11\IN\1740 middle-ear_12\JJ\1740 surgery_13\NN\6045562 ._14\.\1740
D007741_D007022 CID the_0\DT\1740 feasibility_1\NN\5152150 of_2\IN\1740 using_3\VBG\1156834 <e1>labetalol</e1>_4\NNS\2721160 ,_5\,\1740 an_6\DT\6697703 alpha-_7\NN\1740 and_8\CC\1740 beta-adrenergic_9\JJ\1740 blocking_10\NN\562280 agent_11\NN\7347 ,_12\,\1740 as_13\IN\14622893 a_14\DT\13649268 <e2>hypotensive</e2>_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 inhalation_20\NN\835032 anaesthetics_21\NNS\3247620 (_22\-LRB-\1740 halothane_23\NN\3570838 ,_24\,\1740 enflurane_25\NN\3299929 or_26\CC\3541091 isoflurane_27\NN\3570838 )_28\-RRB-\1740 was_29\VBD\836236 studied_30\VBN\630380 in_31\IN\13603305 23_32\CD\13745420 adult_33\JJ\1740 patients_34\NNS\9898892 undergoing_35\VBG\109660 middle-ear_36\JJ\1740 surgery_37\NN\6045562 ._38\.\1740
D007741_D007022 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>labetalol</e1>_4\NN\2721160 induces_5\VBZ\1627355 easily_6\RB\1740 adjustable_7\JJ\1740 <e2>hypotension</e2>_8\NN\14057371 without_9\IN\1740 compensatory_10\JJ\1740 tachycardia_11\NN\14110674 and_12\CC\1740 rebound_13\NN\7309781 hypertension_14\NN\14057371 ._15\.\1740
D006221_D007022 CID deliberate_0\VB\813978 <e2>hypotension</e2>_1\NN\14057371 induced_2\VBN\1627355 by_3\IN\1740 labetalol_4\NNS\2721160 with_5\IN\1740 <e1>halothane</e1>_6\NN\3570838 ,_7\,\1740 enflurane_8\NN\3299929 or_9\CC\3541091 isoflurane_10\NN\3570838 for_11\IN\1740 middle-ear_12\JJ\1740 surgery_13\NN\6045562 ._14\.\1740
D006221_D007022 CID the_0\DT\1740 feasibility_1\NN\5152150 of_2\IN\1740 using_3\VBG\1156834 labetalol_4\NNS\2721160 ,_5\,\1740 an_6\DT\6697703 alpha-_7\NN\1740 and_8\CC\1740 beta-adrenergic_9\JJ\1740 blocking_10\NN\562280 agent_11\NN\7347 ,_12\,\1740 as_13\IN\14622893 a_14\DT\13649268 <e2>hypotensive</e2>_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 inhalation_20\NN\835032 anaesthetics_21\NNS\3247620 (_22\-LRB-\1740 <e1>halothane</e1>_23\NN\3570838 ,_24\,\1740 enflurane_25\NN\3299929 or_26\CC\3541091 isoflurane_27\NN\3570838 )_28\-RRB-\1740 was_29\VBD\836236 studied_30\VBN\630380 in_31\IN\13603305 23_32\CD\13745420 adult_33\JJ\1740 patients_34\NNS\9898892 undergoing_35\VBG\109660 middle-ear_36\JJ\1740 surgery_37\NN\6045562 ._38\.\1740
D006221_D007022 CID the_0\DT\1740 mean_1\NN\6021761 <e1>h</e1>_2\NN\14622893 concentration_3\NN\4916342 during_4\IN\1740 <e2>hypotension</e2>_5\NN\14057371 in_6\IN\13603305 the_7\DT\1740 inspiratory_8\JJ\1740 gas_9\NN\14479615 was_10\VBD\836236 0.7_11\CD\1740 +/-_12\CC\1740 0.1_13\CD\1740 vol%_14\NN\1740 ,_15\,\1740 the_16\DT\1740 mean_17\NN\6021761 e_18\NN\14724645 concentration_19\NN\4916342 1.6_20\CD\1740 +/-_21\CC\1740 0.2_22\CD\1740 vol%_23\NN\1740 ,_24\,\1740 and_25\CC\1740 the_26\DT\1740 mean_27\NN\6021761 i_28\CD\14622893 concentration_29\NN\4916342 1.0_30\CD\1740 +/-_31\CC\1740 0.1_32\CD\1740 vol%_33\NN\1740 ._34\.\1740
D004737_D007022 CID deliberate_0\VB\813978 <e2>hypotension</e2>_1\NN\14057371 induced_2\VBN\1627355 by_3\IN\1740 labetalol_4\NNS\2721160 with_5\IN\1740 halothane_6\NN\3570838 ,_7\,\1740 <e1>enflurane</e1>_8\NN\3299929 or_9\CC\3541091 isoflurane_10\NN\3570838 for_11\IN\1740 middle-ear_12\JJ\1740 surgery_13\NN\6045562 ._14\.\1740
D004737_D007022 CID the_0\DT\1740 feasibility_1\NN\5152150 of_2\IN\1740 using_3\VBG\1156834 labetalol_4\NNS\2721160 ,_5\,\1740 an_6\DT\6697703 alpha-_7\NN\1740 and_8\CC\1740 beta-adrenergic_9\JJ\1740 blocking_10\NN\562280 agent_11\NN\7347 ,_12\,\1740 as_13\IN\14622893 a_14\DT\13649268 <e2>hypotensive</e2>_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 inhalation_20\NN\835032 anaesthetics_21\NNS\3247620 (_22\-LRB-\1740 halothane_23\NN\3570838 ,_24\,\1740 <e1>enflurane</e1>_25\NN\3299929 or_26\CC\3541091 isoflurane_27\NN\3570838 )_28\-RRB-\1740 was_29\VBD\836236 studied_30\VBN\630380 in_31\IN\13603305 23_32\CD\13745420 adult_33\JJ\1740 patients_34\NNS\9898892 undergoing_35\VBG\109660 middle-ear_36\JJ\1740 surgery_37\NN\6045562 ._38\.\1740
D004737_D007022 CID the_0\DT\1740 mean_1\NN\6021761 h_2\NN\14622893 concentration_3\NN\4916342 during_4\IN\1740 <e2>hypotension</e2>_5\NN\14057371 in_6\IN\13603305 the_7\DT\1740 inspiratory_8\JJ\1740 gas_9\NN\14479615 was_10\VBD\836236 0.7_11\CD\1740 +/-_12\CC\1740 0.1_13\CD\1740 vol%_14\NN\1740 ,_15\,\1740 the_16\DT\1740 mean_17\NN\6021761 <e1>e</e1>_18\NN\14724645 concentration_19\NN\4916342 1.6_20\CD\1740 +/-_21\CC\1740 0.2_22\CD\1740 vol%_23\NN\1740 ,_24\,\1740 and_25\CC\1740 the_26\DT\1740 mean_27\NN\6021761 i_28\CD\14622893 concentration_29\NN\4916342 1.0_30\CD\1740 +/-_31\CC\1740 0.1_32\CD\1740 vol%_33\NN\1740 ._34\.\1740
D007530_D007022 CID deliberate_0\VB\813978 <e2>hypotension</e2>_1\NN\14057371 induced_2\VBN\1627355 by_3\IN\1740 labetalol_4\NNS\2721160 with_5\IN\1740 halothane_6\NN\3570838 ,_7\,\1740 enflurane_8\NN\3299929 or_9\CC\3541091 <e1>isoflurane</e1>_10\NN\3570838 for_11\IN\1740 middle-ear_12\JJ\1740 surgery_13\NN\6045562 ._14\.\1740
D007530_D007022 CID the_0\DT\1740 feasibility_1\NN\5152150 of_2\IN\1740 using_3\VBG\1156834 labetalol_4\NNS\2721160 ,_5\,\1740 an_6\DT\6697703 alpha-_7\NN\1740 and_8\CC\1740 beta-adrenergic_9\JJ\1740 blocking_10\NN\562280 agent_11\NN\7347 ,_12\,\1740 as_13\IN\14622893 a_14\DT\13649268 <e2>hypotensive</e2>_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 inhalation_20\NN\835032 anaesthetics_21\NNS\3247620 (_22\-LRB-\1740 halothane_23\NN\3570838 ,_24\,\1740 enflurane_25\NN\3299929 or_26\CC\3541091 <e1>isoflurane</e1>_27\NN\3570838 )_28\-RRB-\1740 was_29\VBD\836236 studied_30\VBN\630380 in_31\IN\13603305 23_32\CD\13745420 adult_33\JJ\1740 patients_34\NNS\9898892 undergoing_35\VBG\109660 middle-ear_36\JJ\1740 surgery_37\NN\6045562 ._38\.\1740
D007530_D007022 CID the_0\DT\1740 mean_1\NN\6021761 h_2\NN\14622893 concentration_3\NN\4916342 during_4\IN\1740 <e2>hypotension</e2>_5\NN\14057371 in_6\IN\13603305 the_7\DT\1740 inspiratory_8\JJ\1740 gas_9\NN\14479615 was_10\VBD\836236 0.7_11\CD\1740 +/-_12\CC\1740 0.1_13\CD\1740 vol%_14\NN\1740 ,_15\,\1740 the_16\DT\1740 mean_17\NN\6021761 e_18\NN\14724645 concentration_19\NN\4916342 1.6_20\CD\1740 +/-_21\CC\1740 0.2_22\CD\1740 vol%_23\NN\1740 ,_24\,\1740 and_25\CC\1740 the_26\DT\1740 mean_27\NN\6021761 <e1>i</e1>_28\CD\14622893 concentration_29\NN\4916342 1.0_30\CD\1740 +/-_31\CC\1740 0.1_32\CD\1740 vol%_33\NN\1740 ._34\.\1740
D007530_D007022 CID during_0\IN\1740 <e2>hypotension</e2>_1\NN\14057371 ,_2\,\1740 the_3\DT\1740 serum_4\NN\5397468 creatinine_5\NN\1740 concentration_6\NN\4916342 rose_7\VBD\1835496 significantly_8\RB\1740 in_9\IN\13603305 all_10\DT\1740 groups_11\NNS\2137 from_12\IN\1740 the_13\DT\1740 values_14\NNS\5941423 before_15\IN\1740 hypotension_16\NN\14057371 and_17\CC\1740 returned_18\VBD\1835496 postoperatively_19\RB\1740 to_20\TO\1740 the_21\DT\1740 initial_22\JJ\1740 level_23\NN\4916342 in_24\IN\13603305 the_25\DT\1740 other_26\JJ\1740 groups_27\NNS\2137 ,_28\,\1740 except_29\IN\1740 the_30\DT\1740 <e1>isoflurane</e1>_31\NN\3570838 group_32\NN\2137 ._33\.\1740
D007530_D007022 CID during_0\IN\1740 hypotension_1\NN\14057371 ,_2\,\1740 the_3\DT\1740 serum_4\NN\5397468 creatinine_5\NN\1740 concentration_6\NN\4916342 rose_7\VBD\1835496 significantly_8\RB\1740 in_9\IN\13603305 all_10\DT\1740 groups_11\NNS\2137 from_12\IN\1740 the_13\DT\1740 values_14\NNS\5941423 before_15\IN\1740 <e2>hypotension</e2>_16\NN\14057371 and_17\CC\1740 returned_18\VBD\1835496 postoperatively_19\RB\1740 to_20\TO\1740 the_21\DT\1740 initial_22\JJ\1740 level_23\NN\4916342 in_24\IN\13603305 the_25\DT\1740 other_26\JJ\1740 groups_27\NNS\2137 ,_28\,\1740 except_29\IN\1740 the_30\DT\1740 <e1>isoflurane</e1>_31\NN\3570838 group_32\NN\2137 ._33\.\1740
D003404_D007022 NONE during_0\IN\1740 <e2>hypotension</e2>_1\NN\14057371 ,_2\,\1740 the_3\DT\1740 serum_4\NN\5397468 <e1>creatinine</e1>_5\NN\1740 concentration_6\NN\4916342 rose_7\VBD\1835496 significantly_8\RB\1740 in_9\IN\13603305 all_10\DT\1740 groups_11\NNS\2137 from_12\IN\1740 the_13\DT\1740 values_14\NNS\5941423 before_15\IN\1740 hypotension_16\NN\14057371 and_17\CC\1740 returned_18\VBD\1835496 postoperatively_19\RB\1740 to_20\TO\1740 the_21\DT\1740 initial_22\JJ\1740 level_23\NN\4916342 in_24\IN\13603305 the_25\DT\1740 other_26\JJ\1740 groups_27\NNS\2137 ,_28\,\1740 except_29\IN\1740 the_30\DT\1740 isoflurane_31\NN\3570838 group_32\NN\2137 ._33\.\1740
D003404_D007022 NONE during_0\IN\1740 hypotension_1\NN\14057371 ,_2\,\1740 the_3\DT\1740 serum_4\NN\5397468 <e1>creatinine</e1>_5\NN\1740 concentration_6\NN\4916342 rose_7\VBD\1835496 significantly_8\RB\1740 in_9\IN\13603305 all_10\DT\1740 groups_11\NNS\2137 from_12\IN\1740 the_13\DT\1740 values_14\NNS\5941423 before_15\IN\1740 <e2>hypotension</e2>_16\NN\14057371 and_17\CC\1740 returned_18\VBD\1835496 postoperatively_19\RB\1740 to_20\TO\1740 the_21\DT\1740 initial_22\JJ\1740 level_23\NN\4916342 in_24\IN\13603305 the_25\DT\1740 other_26\JJ\1740 groups_27\NNS\2137 ,_28\,\1740 except_29\IN\1740 the_30\DT\1740 isoflurane_31\NN\3570838 group_32\NN\2137 ._33\.\1740
D007741_D013610 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>labetalol</e1>_4\NN\2721160 induces_5\VBZ\1627355 easily_6\RB\1740 adjustable_7\JJ\1740 hypotension_8\NN\14057371 without_9\IN\1740 compensatory_10\JJ\1740 <e2>tachycardia</e2>_11\NN\14110674 and_12\CC\1740 rebound_13\NN\7309781 hypertension_14\NN\14057371 ._15\.\1740
D007741_D006973 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>labetalol</e1>_4\NN\2721160 induces_5\VBZ\1627355 easily_6\RB\1740 adjustable_7\JJ\1740 hypotension_8\NN\14057371 without_9\IN\1740 compensatory_10\JJ\1740 tachycardia_11\NN\14110674 and_12\CC\1740 rebound_13\NN\7309781 <e2>hypertension</e2>_14\NN\14057371 ._15\.\1740
2400986
D002066_D020258 NONE dose-dependent_0\JJ\1740 <e2>neurotoxicity</e2>_1\NN\1740 of_2\IN\1740 high-dose_3\JJ\1740 <e1>busulfan</e1>_4\NNS\1740 in_5\IN\13603305 children_6\NNS\9622049 :_7\:\1740 a_8\DT\13649268 clinical_9\JJ\1740 and_10\CC\1740 pharmacological_11\JJ\1740 study_12\NN\635850 ._13\.\1740
D002066_D020258 NONE <e1>busulfan</e1>_0\NNS\1740 is_1\VBZ\836236 known_2\VBN\2110220 to_3\TO\1740 be_4\VB\836236 <e2>neurotoxic</e2>_5\JJ\1740 in_6\IN\13603305 animals_7\NNS\4475 and_8\CC\1740 humans_9\NNS\31264 ,_10\,\1740 but_11\CC\1740 its_12\PRP$\6125041 acute_13\JJ\1740 neurotoxicity_14\NN\1740 remains_15\VBZ\2604760 poorly_16\RB\1740 characterized_17\VBN\609683 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D002066_D020258 NONE <e1>busulfan</e1>_0\NNS\1740 is_1\VBZ\836236 known_2\VBN\2110220 to_3\TO\1740 be_4\VB\836236 neurotoxic_5\JJ\1740 in_6\IN\13603305 animals_7\NNS\4475 and_8\CC\1740 humans_9\NNS\31264 ,_10\,\1740 but_11\CC\1740 its_12\PRP$\6125041 acute_13\JJ\1740 <e2>neurotoxicity</e2>_14\NN\1740 remains_15\VBZ\2604760 poorly_16\RB\1740 characterized_17\VBN\609683 in_18\IN\13603305 children_19\NNS\9622049 ._20\.\1740
D002066_D020258 NONE when_0\WRB\1740 the_1\DT\1740 total_2\JJ\1740 <e1>busulfan</e1>_3\NNS\1740 dose_4\NN\3740161 was_5\VBD\836236 taken_6\VBN\2367363 into_7\IN\1740 account_8\NN\6647206 ,_9\,\1740 there_10\EX\27167 was_11\VBD\836236 a_12\DT\13649268 significant_13\JJ\1740 difference_14\NN\4723816 in_15\IN\13603305 terms_16\NNS\13945919 of_17\IN\1740 <e2>neurotoxicity</e2>_18\NN\1740 incidence_19\NN\13821570 among_20\IN\1740 patients_21\NNS\9898892 under_22\IN\1740 16_23\CD\13745420 mg/kg_24\NN\1740 (_25\-LRB-\1740 1_26\CD\13741022 of_27\IN\1740 57_28\CD\1740 ,_29\,\1740 1.7_30\CD\1740 %_31\NN\1740 )_32\-RRB-\1740 and_33\CC\1740 patients_34\NNS\9898892 under_35\IN\1740 600_36\CD\1740 mg/m2_37\NN\1740 (_38\-LRB-\1740 6_39\CD\13741022 of_40\IN\1740 39_41\CD\1740 ,_42\,\1740 15.4_43\CD\1740 %_44\NN\1740 )_45\-RRB-\1740 (_46\-LRB-\1740 p_47\NN\14622893 less_48\JJR\1740 than_49\IN\1740 0.02_50\CD\1740 )_51\-RRB-\1740 ._52\.\1740
D002066_D020258 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 <e1>busulfan</e1>_4\NNS\1740 <e2>neurotoxicity</e2>_5\NN\1740 is_6\VBZ\836236 dose-dependent_7\JJ\1740 in_8\IN\13603305 children_9\NNS\9622049 and_10\CC\1740 efficiently_11\RB\1740 prevented_12\VBN\1740 by_13\IN\1740 clonazepam_14\NN\1740 ._15\.\1740
D002066_D020258 NONE a_0\DT\13649268 <e1>busulfan</e1>_1\NNS\1740 dose_2\NN\3740161 calculated_3\VBN\632627 on_4\IN\1740 the_5\DT\1740 basis_6\NN\13790712 of_7\IN\1740 body_8\NN\19128 surface_9\NN\21939 area_10\NN\8630985 ,_11\,\1740 resulting_12\VBG\2633881 in_13\IN\13603305 higher_14\JJR\1740 doses_15\NNS\3740161 in_16\IN\13603305 young_17\JJ\1740 children_18\NNS\9622049 ,_19\,\1740 was_20\VBD\836236 followed_21\VBN\1835496 by_22\IN\1740 increased_23\VBN\169651 <e2>neurotoxicity</e2>_24\NN\1740 ,_25\,\1740 close_26\JJ\1740 to_27\IN\1740 neurotoxicity_28\NN\1740 incidence_29\NN\13821570 observed_30\VBN\2163746 in_31\IN\13603305 adults_32\NNS\7846 ._33\.\1740
D002066_D020258 NONE a_0\DT\13649268 <e1>busulfan</e1>_1\NNS\1740 dose_2\NN\3740161 calculated_3\VBN\632627 on_4\IN\1740 the_5\DT\1740 basis_6\NN\13790712 of_7\IN\1740 body_8\NN\19128 surface_9\NN\21939 area_10\NN\8630985 ,_11\,\1740 resulting_12\VBG\2633881 in_13\IN\13603305 higher_14\JJR\1740 doses_15\NNS\3740161 in_16\IN\13603305 young_17\JJ\1740 children_18\NNS\9622049 ,_19\,\1740 was_20\VBD\836236 followed_21\VBN\1835496 by_22\IN\1740 increased_23\VBN\169651 neurotoxicity_24\NN\1740 ,_25\,\1740 close_26\JJ\1740 to_27\IN\1740 <e2>neurotoxicity</e2>_28\NN\1740 incidence_29\NN\13821570 observed_30\VBN\2163746 in_31\IN\13603305 adults_32\NNS\7846 ._33\.\1740
D002066_D009369 NONE we_0\PRP\1740 report_1\VBP\831651 here_2\RB\1740 a_3\DT\13649268 retrospective_4\JJ\1740 study_5\NN\635850 of_6\IN\1740 123_7\CD\1740 children_8\NNS\9622049 (_9\-LRB-\1740 median_10\JJ\1740 age_11\NN\4916342 ,_12\,\1740 6.5_13\CD\1740 years_14\NNS\15144371 )_15\-RRB-\1740 receiving_16\VBG\2210855 high-dose_17\JJ\1740 <e1>busulfan</e1>_18\NNS\1740 in_19\IN\13603305 combined_20\JJ\1740 chemotherapy_21\NN\661091 before_22\IN\1740 bone_23\NN\5286536 marrow_24\NN\5286536 transplantation_25\NN\671351 for_26\IN\1740 malignant_27\JJ\1740 solid_28\JJ\1740 <e2>tumors</e2>_29\NNS\14234074 ,_30\,\1740 brain_31\NN\5462674 tumors_32\NNS\14234074 excluded_33\VBN\471711 ._34\.\1740
D002066_D001932 NONE we_0\PRP\1740 report_1\VBP\831651 here_2\RB\1740 a_3\DT\13649268 retrospective_4\JJ\1740 study_5\NN\635850 of_6\IN\1740 123_7\CD\1740 children_8\NNS\9622049 (_9\-LRB-\1740 median_10\JJ\1740 age_11\NN\4916342 ,_12\,\1740 6.5_13\CD\1740 years_14\NNS\15144371 )_15\-RRB-\1740 receiving_16\VBG\2210855 high-dose_17\JJ\1740 <e1>busulfan</e1>_18\NNS\1740 in_19\IN\13603305 combined_20\JJ\1740 chemotherapy_21\NN\661091 before_22\IN\1740 bone_23\NN\5286536 marrow_24\NN\5286536 transplantation_25\NN\671351 for_26\IN\1740 malignant_27\JJ\1740 solid_28\JJ\1740 tumors_29\NNS\14234074 ,_30\,\1740 <e2>brain_31\NN\5462674 tumors</e2>_32\NNS\14234074 excluded_33\VBN\471711 ._34\.\1740
D002066_D012640 CID ninety-six_0\CD\1740 patients_1\NNS\9898892 were_2\VBD\836236 not_3\RB\1740 given_4\VBN\2327200 anticonvulsive_5\JJ\1740 prophylaxis_6\NN\1077350 ;_7\:\1740 7_8\CD\13741022 (_9\-LRB-\1740 7.5_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 developed_13\VBD\1753788 <e2>seizures</e2>_14\NNS\14081375 during_15\IN\1740 the_16\DT\1740 4_17\CD\13741022 days_18\NNS\15140892 of_19\IN\1740 the_20\DT\1740 <e1>busulfan</e1>_21\NNS\1740 course_22\NN\883297 or_23\CC\3541091 within_24\IN\1740 24_25\CD\13745420 h_26\NN\14622893 after_27\IN\1740 the_28\DT\1740 last_29\JJ\1740 dosing_30\NN\1740 ._31\.\1740
D002066_D009461 NONE twenty-seven_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 given_3\VBN\2327200 a_4\DT\13649268 600-mg/m2_5\CD\1740 <e1>busulfan</e1>_6\NNS\1740 total_7\JJ\1740 dose_8\NN\3740161 with_9\IN\1740 continuous_10\JJ\1740 i.v._11\NN\1740 infusion_12\NN\14589223 of_13\IN\1740 clonazepam_14\NN\1740 ;_15\:\1740 none_16\NN\15228378 had_17\VBD\2108377 any_18\DT\1740 <e2>neurological_19\JJ\1740 symptoms</e2>_20\NNS\5823932 ._21\.\1740
D002998_D009461 NONE twenty-seven_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 given_3\VBN\2327200 a_4\DT\13649268 600-mg/m2_5\CD\1740 busulfan_6\NNS\1740 total_7\JJ\1740 dose_8\NN\3740161 with_9\IN\1740 continuous_10\JJ\1740 i.v._11\NN\1740 infusion_12\NN\14589223 of_13\IN\1740 <e1>clonazepam</e1>_14\NN\1740 ;_15\:\1740 none_16\NN\15228378 had_17\VBD\2108377 any_18\DT\1740 <e2>neurological_19\JJ\1740 symptoms</e2>_20\NNS\5823932 ._21\.\1740
D002066_D002493 NONE <e1>busulfan</e1>_0\NNS\1740 levels_1\NNS\4916342 were_2\VBD\836236 measured_3\VBN\697589 by_4\IN\1740 a_5\DT\13649268 gas_6\NN\14479615 chromatographic-mass_7\NN\1740 spectrometry_8\NN\646833 assay_9\NN\5733583 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 and_13\CC\1740 cerebrospinal_14\JJ\1740 fluid_15\NN\19613 of_16\IN\1740 9_17\CD\13741022 children_18\NNS\9622049 without_19\IN\1740 <e2>central_20\JJ\1740 nervous_21\JJ\1740 system_22\NN\3575240 disease</e2>_23\NN\14061805 under_24\IN\1740 600_25\CD\1740 mg/m2_26\NN\1740 busulfan_27\NNS\1740 with_28\IN\1740 clonazepam_29\NN\1740 :_30\:\1740 busulfan_31\NNS\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 :_34\:\1740 plasma_35\NN\5398023 ratio_36\NN\13815152 was_37\VBD\836236 1.39_38\CD\1740 ._39\.\1740
D002066_D002493 NONE busulfan_0\NNS\1740 levels_1\NNS\4916342 were_2\VBD\836236 measured_3\VBN\697589 by_4\IN\1740 a_5\DT\13649268 gas_6\NN\14479615 chromatographic-mass_7\NN\1740 spectrometry_8\NN\646833 assay_9\NN\5733583 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 and_13\CC\1740 cerebrospinal_14\JJ\1740 fluid_15\NN\19613 of_16\IN\1740 9_17\CD\13741022 children_18\NNS\9622049 without_19\IN\1740 <e2>central_20\JJ\1740 nervous_21\JJ\1740 system_22\NN\3575240 disease</e2>_23\NN\14061805 under_24\IN\1740 600_25\CD\1740 mg/m2_26\NN\1740 <e1>busulfan</e1>_27\NNS\1740 with_28\IN\1740 clonazepam_29\NN\1740 :_30\:\1740 busulfan_31\NNS\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 :_34\:\1740 plasma_35\NN\5398023 ratio_36\NN\13815152 was_37\VBD\836236 1.39_38\CD\1740 ._39\.\1740
D002066_D002493 NONE busulfan_0\NNS\1740 levels_1\NNS\4916342 were_2\VBD\836236 measured_3\VBN\697589 by_4\IN\1740 a_5\DT\13649268 gas_6\NN\14479615 chromatographic-mass_7\NN\1740 spectrometry_8\NN\646833 assay_9\NN\5733583 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 and_13\CC\1740 cerebrospinal_14\JJ\1740 fluid_15\NN\19613 of_16\IN\1740 9_17\CD\13741022 children_18\NNS\9622049 without_19\IN\1740 <e2>central_20\JJ\1740 nervous_21\JJ\1740 system_22\NN\3575240 disease</e2>_23\NN\14061805 under_24\IN\1740 600_25\CD\1740 mg/m2_26\NN\1740 busulfan_27\NNS\1740 with_28\IN\1740 clonazepam_29\NN\1740 :_30\:\1740 <e1>busulfan</e1>_31\NNS\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 :_34\:\1740 plasma_35\NN\5398023 ratio_36\NN\13815152 was_37\VBD\836236 1.39_38\CD\1740 ._39\.\1740
D002998_D002493 NONE busulfan_0\NNS\1740 levels_1\NNS\4916342 were_2\VBD\836236 measured_3\VBN\697589 by_4\IN\1740 a_5\DT\13649268 gas_6\NN\14479615 chromatographic-mass_7\NN\1740 spectrometry_8\NN\646833 assay_9\NN\5733583 in_10\IN\13603305 the_11\DT\1740 plasma_12\NN\5398023 and_13\CC\1740 cerebrospinal_14\JJ\1740 fluid_15\NN\19613 of_16\IN\1740 9_17\CD\13741022 children_18\NNS\9622049 without_19\IN\1740 <e2>central_20\JJ\1740 nervous_21\JJ\1740 system_22\NN\3575240 disease</e2>_23\NN\14061805 under_24\IN\1740 600_25\CD\1740 mg/m2_26\NN\1740 busulfan_27\NNS\1740 with_28\IN\1740 <e1>clonazepam</e1>_29\NN\1740 :_30\:\1740 busulfan_31\NNS\1740 cerebrospinal_32\JJ\1740 fluid_33\NN\19613 :_34\:\1740 plasma_35\NN\5398023 ratio_36\NN\13815152 was_37\VBD\836236 1.39_38\CD\1740 ._39\.\1740
D002998_D020258 NONE this_0\DT\1740 study_1\NN\635850 shows_2\VBZ\2137132 that_3\IN\1740 busulfan_4\NNS\1740 <e2>neurotoxicity</e2>_5\NN\1740 is_6\VBZ\836236 dose-dependent_7\JJ\1740 in_8\IN\13603305 children_9\NNS\9622049 and_10\CC\1740 efficiently_11\RB\1740 prevented_12\VBN\1740 by_13\IN\1740 <e1>clonazepam</e1>_14\NN\1740 ._15\.\1740
9782254
D007980_D010300 NONE 51_0\CD\1740 patients_1\NNS\9898892 with_2\IN\1740 medically_3\RB\1740 refractory_4\JJ\1740 <e2>parkinson_5\NN\1740 's_6\POS\1740 disease</e2>_7\NN\14061805 underwent_8\VBD\109660 stereotactic_9\JJ\1740 posteromedial_10\JJ\1740 pallidotomy_11\NN\1740 between_12\IN\1740 august_13\NNP\15209706 1993_14\CD\1740 and_15\CC\1740 february_16\NNP\15209706 1997_17\CD\1740 for_18\IN\1740 treatment_19\NN\654885 of_20\IN\1740 bradykinesia_21\NN\1740 ,_22\,\1740 rigidity_23\NN\5023233 ,_24\,\1740 and_25\CC\1740 <e1>l-dopa-induced</e1>_26\VBN\1740 dyskinesias_27\NNS\14084880 ._28\.\1740
D007980_D018476 NONE 51_0\CD\1740 patients_1\NNS\9898892 with_2\IN\1740 medically_3\RB\1740 refractory_4\JJ\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 underwent_8\VBD\109660 stereotactic_9\JJ\1740 posteromedial_10\JJ\1740 pallidotomy_11\NN\1740 between_12\IN\1740 august_13\NNP\15209706 1993_14\CD\1740 and_15\CC\1740 february_16\NNP\15209706 1997_17\CD\1740 for_18\IN\1740 treatment_19\NN\654885 of_20\IN\1740 <e2>bradykinesia</e2>_21\NN\1740 ,_22\,\1740 rigidity_23\NN\5023233 ,_24\,\1740 and_25\CC\1740 <e1>l-dopa-induced</e1>_26\VBN\1740 dyskinesias_27\NNS\14084880 ._28\.\1740
D007980_D009127 NONE 51_0\CD\1740 patients_1\NNS\9898892 with_2\IN\1740 medically_3\RB\1740 refractory_4\JJ\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 underwent_8\VBD\109660 stereotactic_9\JJ\1740 posteromedial_10\JJ\1740 pallidotomy_11\NN\1740 between_12\IN\1740 august_13\NNP\15209706 1993_14\CD\1740 and_15\CC\1740 february_16\NNP\15209706 1997_17\CD\1740 for_18\IN\1740 treatment_19\NN\654885 of_20\IN\1740 bradykinesia_21\NN\1740 ,_22\,\1740 <e2>rigidity</e2>_23\NN\5023233 ,_24\,\1740 and_25\CC\1740 <e1>l-dopa-induced</e1>_26\VBN\1740 dyskinesias_27\NNS\14084880 ._28\.\1740
D007980_D004409 CID 51_0\CD\1740 patients_1\NNS\9898892 with_2\IN\1740 medically_3\RB\1740 refractory_4\JJ\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 underwent_8\VBD\109660 stereotactic_9\JJ\1740 posteromedial_10\JJ\1740 pallidotomy_11\NN\1740 between_12\IN\1740 august_13\NNP\15209706 1993_14\CD\1740 and_15\CC\1740 february_16\NNP\15209706 1997_17\CD\1740 for_18\IN\1740 treatment_19\NN\654885 of_20\IN\1740 bradykinesia_21\NN\1740 ,_22\,\1740 rigidity_23\NN\5023233 ,_24\,\1740 and_25\CC\1740 <e1>l-dopa-induced</e1>_26\VBN\1740 <e2>dyskinesias</e2>_27\NNS\14084880 ._28\.\1740
25907210
D010755_D009369 NONE incidence_0\NN\13821570 of_1\IN\1740 solid_2\JJ\1740 <e2>tumours</e2>_3\NNS\14234074 among_4\IN\1740 pesticide_5\NN\14806838 applicators_6\NNS\3183080 exposed_7\VBN\2110927 to_8\TO\1740 the_9\DT\1740 <e1>organophosphate</e1>_10\JJ\1740 insecticide_11\NN\14980215 diazinon_12\NN\1740 in_13\IN\13603305 the_14\DT\1740 agricultural_15\NNP\1740 health_16\NNP\14447525 study_17\NNP\635850 :_18\:\1740 an_19\DT\6697703 updated_20\JJ\1740 analysis_21\NN\633864 ._22\.\1740
D010755_D009369 NONE objective_0\NN\5980875 :_1\:\1740 diazinon_2\NNP\1740 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 <e1>organophosphate</e1>_6\JJ\1740 insecticide_7\NN\14980215 with_8\IN\1740 genotoxic_9\JJ\1740 properties_10\NNS\32613 ,_11\,\1740 was_12\VBD\836236 previously_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 lung_16\NN\5528060 cancer_17\NN\14239425 in_18\IN\13603305 the_19\DT\1740 agricultural_20\NNP\1740 health_21\NNP\14447525 study_22\NNP\635850 (_23\-LRB-\1740 ahs_24\NN\1740 )_25\-RRB-\1740 cohort_26\NN\8184861 ,_27\,\1740 but_28\CC\1740 few_29\JJ\1740 other_30\JJ\1740 epidemiological_31\JJ\1740 studies_32\NNS\635850 have_33\VBP\2108377 examined_34\VBN\789138 diazinon-associated_35\JJ\1740 <e2>cancer</e2>_36\NN\14239425 risk_37\NN\14541044 ._38\.\1740
D003976_D009369 NONE incidence_0\NN\13821570 of_1\IN\1740 solid_2\JJ\1740 <e2>tumours</e2>_3\NNS\14234074 among_4\IN\1740 pesticide_5\NN\14806838 applicators_6\NNS\3183080 exposed_7\VBN\2110927 to_8\TO\1740 the_9\DT\1740 organophosphate_10\JJ\1740 insecticide_11\NN\14980215 <e1>diazinon</e1>_12\NN\1740 in_13\IN\13603305 the_14\DT\1740 agricultural_15\NNP\1740 health_16\NNP\14447525 study_17\NNP\635850 :_18\:\1740 an_19\DT\6697703 updated_20\JJ\1740 analysis_21\NN\633864 ._22\.\1740
D003976_D009369 NONE objective_0\NN\5980875 :_1\:\1740 <e1>diazinon</e1>_2\NNP\1740 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 organophosphate_6\JJ\1740 insecticide_7\NN\14980215 with_8\IN\1740 genotoxic_9\JJ\1740 properties_10\NNS\32613 ,_11\,\1740 was_12\VBD\836236 previously_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 lung_16\NN\5528060 cancer_17\NN\14239425 in_18\IN\13603305 the_19\DT\1740 agricultural_20\NNP\1740 health_21\NNP\14447525 study_22\NNP\635850 (_23\-LRB-\1740 ahs_24\NN\1740 )_25\-RRB-\1740 cohort_26\NN\8184861 ,_27\,\1740 but_28\CC\1740 few_29\JJ\1740 other_30\JJ\1740 epidemiological_31\JJ\1740 studies_32\NNS\635850 have_33\VBP\2108377 examined_34\VBN\789138 diazinon-associated_35\JJ\1740 <e2>cancer</e2>_36\NN\14239425 risk_37\NN\14541044 ._38\.\1740
D003976_D009369 NONE objective_0\NN\5980875 :_1\:\1740 diazinon_2\NNP\1740 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 organophosphate_6\JJ\1740 insecticide_7\NN\14980215 with_8\IN\1740 genotoxic_9\JJ\1740 properties_10\NNS\32613 ,_11\,\1740 was_12\VBD\836236 previously_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 lung_16\NN\5528060 cancer_17\NN\14239425 in_18\IN\13603305 the_19\DT\1740 agricultural_20\NNP\1740 health_21\NNP\14447525 study_22\NNP\635850 (_23\-LRB-\1740 ahs_24\NN\1740 )_25\-RRB-\1740 cohort_26\NN\8184861 ,_27\,\1740 but_28\CC\1740 few_29\JJ\1740 other_30\JJ\1740 epidemiological_31\JJ\1740 studies_32\NNS\635850 have_33\VBP\2108377 examined_34\VBN\789138 <e1>diazinon-associated</e1>_35\JJ\1740 <e2>cancer</e2>_36\NN\14239425 risk_37\NN\14541044 ._38\.\1740
D003976_D009369 NONE we_0\PRP\1740 used_1\VBD\1156834 updated_2\JJ\1740 <e1>diazinon</e1>_3\NN\1740 exposure_4\NN\5042871 and_5\CC\1740 <e2>cancer</e2>_6\NN\14239425 incidence_7\NN\13821570 information_8\NN\6598915 to_9\TO\1740 evaluate_10\VB\670261 solid_11\JJ\1740 tumour_12\NN\14234074 risk_13\NN\14541044 in_14\IN\13603305 the_15\DT\1740 ahs_16\NN\1740 ._17\.\1740
D003976_D009369 NONE we_0\PRP\1740 used_1\VBD\1156834 updated_2\JJ\1740 <e1>diazinon</e1>_3\NN\1740 exposure_4\NN\5042871 and_5\CC\1740 cancer_6\NN\14239425 incidence_7\NN\13821570 information_8\NN\6598915 to_9\TO\1740 evaluate_10\VB\670261 solid_11\JJ\1740 <e2>tumour</e2>_12\NN\14234074 risk_13\NN\14541044 in_14\IN\13603305 the_15\DT\1740 ahs_16\NN\1740 ._17\.\1740
D003976_D009369 NONE methods_0\NNS\5616786 :_1\:\1740 male_2\JJ\1740 pesticide_3\NN\14806838 applicators_4\NNS\3183080 in_5\IN\13603305 iowa_6\NNP\9669125 and_7\CC\1740 north_8\NNP\13831000 carolina_9\NNP\1740 reported_10\VBD\831651 lifetime_11\NN\15113229 <e1>diazinon</e1>_12\NN\1740 use_13\NN\407535 at_14\IN\14622893 enrolment_15\NN\49003 (_16\-LRB-\1740 1993_17\CD\1740 -_18\SYM\1740 1997_19\CD\1740 )_20\-RRB-\1740 and_21\CC\1740 follow-up_22\JJ\1740 (_23\-LRB-\1740 1998_24\CD\1740 -_25\SYM\1740 2005_26\CD\1740 )_27\-RRB-\1740 ;_28\:\1740 <e2>cancer</e2>_29\NN\14239425 incidence_30\NN\13821570 was_31\VBD\836236 assessed_32\VBN\670261 through_33\IN\1740 2010(north_34\NN\1740 carolina)/2011(iowa_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
D003976_D008175 CID objective_0\NN\5980875 :_1\:\1740 <e1>diazinon</e1>_2\NNP\1740 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 organophosphate_6\JJ\1740 insecticide_7\NN\14980215 with_8\IN\1740 genotoxic_9\JJ\1740 properties_10\NNS\32613 ,_11\,\1740 was_12\VBD\836236 previously_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 <e2>lung_16\NN\5528060 cancer</e2>_17\NN\14239425 in_18\IN\13603305 the_19\DT\1740 agricultural_20\NNP\1740 health_21\NNP\14447525 study_22\NNP\635850 (_23\-LRB-\1740 ahs_24\NN\1740 )_25\-RRB-\1740 cohort_26\NN\8184861 ,_27\,\1740 but_28\CC\1740 few_29\JJ\1740 other_30\JJ\1740 epidemiological_31\JJ\1740 studies_32\NNS\635850 have_33\VBP\2108377 examined_34\VBN\789138 diazinon-associated_35\JJ\1740 cancer_36\NN\14239425 risk_37\NN\14541044 ._38\.\1740
D003976_D008175 CID objective_0\NN\5980875 :_1\:\1740 diazinon_2\NNP\1740 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 organophosphate_6\JJ\1740 insecticide_7\NN\14980215 with_8\IN\1740 genotoxic_9\JJ\1740 properties_10\NNS\32613 ,_11\,\1740 was_12\VBD\836236 previously_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 <e2>lung_16\NN\5528060 cancer</e2>_17\NN\14239425 in_18\IN\13603305 the_19\DT\1740 agricultural_20\NNP\1740 health_21\NNP\14447525 study_22\NNP\635850 (_23\-LRB-\1740 ahs_24\NN\1740 )_25\-RRB-\1740 cohort_26\NN\8184861 ,_27\,\1740 but_28\CC\1740 few_29\JJ\1740 other_30\JJ\1740 epidemiological_31\JJ\1740 studies_32\NNS\635850 have_33\VBP\2108377 examined_34\VBN\789138 <e1>diazinon-associated</e1>_35\JJ\1740 cancer_36\NN\14239425 risk_37\NN\14541044 ._38\.\1740
D003976_D008175 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 observed_3\VBD\2163746 elevated_4\JJ\1740 <e2>lung_5\NN\5528060 cancer</e2>_6\NN\14239425 risks_7\NNS\14541044 (_8\-LRB-\1740 n=283_9\CD\1740 )_10\-RRB-\1740 among_11\IN\1740 applicators_12\NNS\3183080 with_13\IN\1740 the_14\DT\1740 greatest_15\JJS\1740 number_16\NN\5107765 of_17\IN\1740 lt_18\NN\1740 (_19\-LRB-\1740 rr=1.60_20\NN\1740 ;_21\:\1740 95_22\CD\1740 %_23\NN\1740 ci_24\NN\13635336 1.11_25\CD\1740 to_26\TO\1740 2.31_27\CD\1740 ;_28\:\1740 ptrend=0.02_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 iw_32\JJ\1740 days_33\NNS\15140892 of_34\IN\1740 <e1>diazinon</e1>_35\NN\1740 use_36\NN\407535 (_37\-LRB-\1740 rr=1.41_38\NNP\1740 ;_39\:\1740 95_40\CD\1740 %_41\NN\1740 ci_42\NN\13635336 0.98_43\CD\1740 to_44\TO\1740 2.04_45\CD\1740 ;_46\:\1740 ptrend=0.08_47\NN\1740 )_48\-RRB-\1740 ._49\.\1740
D003976_D008175 CID conclusions_0\NNS\5837957 :_1\:\1740 our_2\PRP$\1740 updated_3\JJ\1740 evaluation_4\NN\874067 of_5\IN\1740 <e1>diazinon</e1>_6\NN\1740 provides_7\VBZ\2199590 additional_8\JJ\1740 evidence_9\NN\5816287 of_10\IN\1740 an_11\DT\6697703 association_12\NN\8008335 with_13\IN\1740 <e2>lung_14\NN\5528060 cancer</e2>_15\NN\14239425 risk_16\NN\14541044 ._17\.\1740
D010755_D008175 NONE objective_0\NN\5980875 :_1\:\1740 diazinon_2\NNP\1740 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 <e1>organophosphate</e1>_6\JJ\1740 insecticide_7\NN\14980215 with_8\IN\1740 genotoxic_9\JJ\1740 properties_10\NNS\32613 ,_11\,\1740 was_12\VBD\836236 previously_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 <e2>lung_16\NN\5528060 cancer</e2>_17\NN\14239425 in_18\IN\13603305 the_19\DT\1740 agricultural_20\NNP\1740 health_21\NNP\14447525 study_22\NNP\635850 (_23\-LRB-\1740 ahs_24\NN\1740 )_25\-RRB-\1740 cohort_26\NN\8184861 ,_27\,\1740 but_28\CC\1740 few_29\JJ\1740 other_30\JJ\1740 epidemiological_31\JJ\1740 studies_32\NNS\635850 have_33\VBP\2108377 examined_34\VBN\789138 diazinon-associated_35\JJ\1740 cancer_36\NN\14239425 risk_37\NN\14541044 ._38\.\1740
2173761
D019806_D007022 CID vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 <e2>hypotension</e2>_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 <e1>cromakalim</e1>_11\NN\1740 and_12\CC\1740 pinacidil_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 tachycardia_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
D019806_D013610 CID vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 hypotension_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 <e1>cromakalim</e1>_11\NN\1740 and_12\CC\1740 pinacidil_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 <e2>tachycardia</e2>_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
D020110_D007022 CID vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 <e2>hypotension</e2>_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 cromakalim_11\NN\1740 and_12\CC\1740 <e1>pinacidil</e1>_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 tachycardia_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
D020110_D013610 CID vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 hypotension_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 cromakalim_11\NN\1740 and_12\CC\1740 <e1>pinacidil</e1>_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 <e2>tachycardia</e2>_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
D000319_D007022 NONE vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 <e2>hypotension</e2>_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 cromakalim_11\NN\1740 and_12\CC\1740 pinacidil_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 <e1>beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade</e1>_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 tachycardia_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
D018727_D007022 NONE vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 <e2>hypotension</e2>_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 cromakalim_11\NN\1740 and_12\CC\1740 pinacidil_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 <e1>beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade</e1>_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 tachycardia_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
D000319_D013610 NONE vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 hypotension_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 cromakalim_11\NN\1740 and_12\CC\1740 pinacidil_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 <e1>beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade</e1>_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 <e2>tachycardia</e2>_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
D018727_D013610 NONE vasodilation_0\NN\365995 of_1\IN\1740 large_2\JJ\1740 and_3\CC\1740 small_4\JJ\1740 coronary_5\JJ\1740 vessels_6\NNS\5246511 and_7\CC\1740 hypotension_8\NN\14057371 induced_9\VBN\1627355 by_10\IN\1740 cromakalim_11\NN\1740 and_12\CC\1740 pinacidil_13\NN\1740 were_14\VBD\836236 not_15\RB\1740 affected_16\VBN\126264 by_17\IN\1740 prior_18\JJ\1740 combined_19\JJ\1740 <e1>beta_20\NN\6828818 adrenergic_21\JJ\1740 and_22\CC\1740 muscarinic_23\NN\1740 receptors_24\NNS\5225602 blockade</e1>_25\NN\952963 but_26\CC\1740 drug-induced_27\JJ\1740 <e2>tachycardia</e2>_28\NN\14110674 was_29\VBD\836236 abolished_30\VBN\1740 ._31\.\1740
10390729
D011188_D009069 NONE in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 <e1>k(+)-channel</e1>_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 morphine-induced_16\JJ\1740 <e2>hypoactivity</e2>_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 k(+)-channel_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 morphine-induced_24\JJ\1740 secondary_25\JJ\1740 hyperactivity_26\NN\14052403 ._27\.\1740
D011188_D009069 NONE in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 k(+)-channel_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 morphine-induced_16\JJ\1740 <e2>hypoactivity</e2>_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 <e1>k(+)-channel</e1>_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 morphine-induced_24\JJ\1740 secondary_25\JJ\1740 hyperactivity_26\NN\14052403 ._27\.\1740
D011188_D009069 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 <e1>k(+)-channels</e1>_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 <e2>hypoactivity</e2>_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 hyperactivity_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D011188_D009069 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 <e2>hypoactivity</e2>_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 hyperactivity_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 <e1>k(+)-channels</e1>_32\NN\1740 ._33\.\1740
D011188_D006948 NONE in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 <e1>k(+)-channel</e1>_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 morphine-induced_16\JJ\1740 hypoactivity_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 k(+)-channel_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 morphine-induced_24\JJ\1740 secondary_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 ._27\.\1740
D011188_D006948 NONE in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 k(+)-channel_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 morphine-induced_16\JJ\1740 hypoactivity_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 <e1>k(+)-channel</e1>_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 morphine-induced_24\JJ\1740 secondary_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 ._27\.\1740
D011188_D006948 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 <e1>k(+)-channels</e1>_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 hypoactivity_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D011188_D006948 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 hypoactivity_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 <e1>k(+)-channels</e1>_32\NN\1740 ._33\.\1740
D009020_D009069 NONE in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 k(+)-channel_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 <e1>morphine-induced</e1>_16\JJ\1740 <e2>hypoactivity</e2>_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 k(+)-channel_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 morphine-induced_24\JJ\1740 secondary_25\JJ\1740 hyperactivity_26\NN\14052403 ._27\.\1740
D009020_D009069 NONE in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 k(+)-channel_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 morphine-induced_16\JJ\1740 <e2>hypoactivity</e2>_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 k(+)-channel_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 <e1>morphine-induced</e1>_24\JJ\1740 secondary_25\JJ\1740 hyperactivity_26\NN\14052403 ._27\.\1740
D009020_D009069 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 <e1>morphine-induced</e1>_18\JJ\1740 <e2>hypoactivity</e2>_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 hyperactivity_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D009020_D009069 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 <e2>hypoactivity</e2>_19\NN\1740 whereas_20\IN\1740 <e1>morphine-induced</e1>_21\JJ\1740 hyperactivity_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D009020_D006948 CID in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 k(+)-channel_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 <e1>morphine-induced</e1>_16\JJ\1740 hypoactivity_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 k(+)-channel_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 morphine-induced_24\JJ\1740 secondary_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 ._27\.\1740
D009020_D006948 CID in_0\IN\13603305 the_1\DT\1740 motor_2\NN\3699975 activity_3\NN\30358 test_4\NN\5798043 measured_5\VBN\697589 with_6\IN\1740 an_7\DT\6697703 animex-activity_8\JJ\1740 meter_9\NN\13649268 neither_10\CC\1740 of_11\IN\1740 the_12\DT\1740 k(+)-channel_13\NN\1740 blockers_14\NNS\10101634 affected_15\VBD\126264 morphine-induced_16\JJ\1740 hypoactivity_17\NN\1740 ,_18\,\1740 but_19\CC\1740 both_20\DT\1740 k(+)-channel_21\NN\1740 blockers_22\NNS\10101634 prevented_23\VBD\1740 <e1>morphine-induced</e1>_24\JJ\1740 secondary_25\JJ\1740 <e2>hyperactivity</e2>_26\NN\14052403 ._27\.\1740
D009020_D006948 CID it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 <e1>morphine-induced</e1>_18\JJ\1740 hypoactivity_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D009020_D006948 CID it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 hypoactivity_19\NN\1740 whereas_20\IN\1740 <e1>morphine-induced</e1>_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D011803_D009069 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 <e2>hypoactivity</e2>_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 hyperactivity_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 <e1>quinine-</e1>_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D011803_D006948 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 hypoactivity_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 <e1>quinine-</e1>_29\NN\1740 and_30\CC\1740 4-aminopyridine-sensitive_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D015761_D009069 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 <e2>hypoactivity</e2>_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 hyperactivity_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 <e1>4-aminopyridine-sensitive</e1>_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
D015761_D006948 NONE it_0\PRP\6125041 is_1\VBZ\836236 also_2\RB\1740 suggested_3\VBN\1010118 that_4\IN\1740 the_5\DT\1740 blockade_6\NN\952963 of_7\IN\1740 k(+)-channels_8\NN\1740 sensitive_9\JJ\1740 to_10\TO\1740 these_11\DT\1740 blockers_12\NNS\10101634 is_13\VBZ\836236 not_14\RB\1740 sufficient_15\JJ\1740 to_16\TO\1740 prevent_17\VB\1740 morphine-induced_18\JJ\1740 hypoactivity_19\NN\1740 whereas_20\IN\1740 morphine-induced_21\JJ\1740 <e2>hyperactivity</e2>_22\NN\14052403 seems_23\VBZ\2604760 to_24\TO\1740 be_25\VB\836236 connected_26\VBN\628491 to_27\TO\1740 both_28\CC\1740 quinine-_29\NN\1740 and_30\CC\1740 <e1>4-aminopyridine-sensitive</e1>_31\JJ\1740 k(+)-channels_32\NN\1740 ._33\.\1740
25119790
D003474_D007674 NONE <e1>curcumin</e1>_0\NN\1740 prevents_1\VBZ\1740 maleate-induced_2\JJ\1740 <e2>nephrotoxicity</e2>_3\NN\1740 :_4\:\1740 relation_5\NN\2137 to_6\TO\1740 hemodynamic_7\JJ\1740 alterations_8\NNS\7283608 ,_9\,\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 ,_12\,\1740 mitochondrial_13\JJ\1740 oxygen_14\NN\14622893 consumption_15\NN\13440063 and_16\CC\1740 activity_17\NN\30358 of_18\IN\1740 respiratory_19\JJ\1740 complex_20\NN\5869584 i._21\NN\1740
D003474_D007674 NONE the_0\DT\1740 potential_1\JJ\1740 protective_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 the_5\DT\1740 dietary_6\JJ\1740 antioxidant_7\JJ\1740 <e1>curcumin</e1>_8\NN\1740 (_9\-LRB-\1740 120_10\CD\13745420 mg/kg/day_11\NN\1740 for_12\IN\1740 6_13\CD\13741022 days_14\NNS\15140892 )_15\-RRB-\1740 against_16\IN\1740 the_17\DT\1740 <e2>renal_18\JJ\1740 injury</e2>_19\NN\14052046 induced_20\VBN\1627355 by_21\IN\1740 maleate_22\NN\2718811 was_23\VBD\836236 evaluated_24\VBN\670261 ._25\.\1740
D003474_D007674 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>curcumin</e1>_4\NN\1740 is_5\VBZ\836236 able_6\JJ\1740 to_7\TO\1740 attenuate_8\VB\224901 in_9\FW\13603305 vivo_10\FW\1740 maleate-induced_11\JJ\1740 <e2>nephropathy</e2>_12\NN\14573196 and_13\CC\1740 in_14\FW\13603305 vitro_15\FW\1740 cell_16\NN\3080309 damage_17\NN\7296428 ._18\.\1740
C030272_D007674 CID curcumin_0\NN\1740 prevents_1\VBZ\1740 <e1>maleate-induced</e1>_2\JJ\1740 <e2>nephrotoxicity</e2>_3\NN\1740 :_4\:\1740 relation_5\NN\2137 to_6\TO\1740 hemodynamic_7\JJ\1740 alterations_8\NNS\7283608 ,_9\,\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 ,_12\,\1740 mitochondrial_13\JJ\1740 oxygen_14\NN\14622893 consumption_15\NN\13440063 and_16\CC\1740 activity_17\NN\30358 of_18\IN\1740 respiratory_19\JJ\1740 complex_20\NN\5869584 i._21\NN\1740
C030272_D007674 CID the_0\DT\1740 potential_1\JJ\1740 protective_2\JJ\1740 effect_3\NN\34213 of_4\IN\1740 the_5\DT\1740 dietary_6\JJ\1740 antioxidant_7\JJ\1740 curcumin_8\NN\1740 (_9\-LRB-\1740 120_10\CD\13745420 mg/kg/day_11\NN\1740 for_12\IN\1740 6_13\CD\13741022 days_14\NNS\15140892 )_15\-RRB-\1740 against_16\IN\1740 the_17\DT\1740 <e2>renal_18\JJ\1740 injury</e2>_19\NN\14052046 induced_20\VBN\1627355 by_21\IN\1740 <e1>maleate</e1>_22\NN\2718811 was_23\VBD\836236 evaluated_24\VBN\670261 ._25\.\1740
C030272_D007674 CID <e1>maleate-induced</e1>_0\JJ\1740 <e2>renal_1\JJ\1740 injury</e2>_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 glucose_18\NN\14710501 ,_19\,\1740 sodium_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 kidney_37\NN\5333259 injury_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 necrosis_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
C030272_D007674 CID <e1>maleate-induced</e1>_0\JJ\1740 renal_1\JJ\1740 injury_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 glucose_18\NN\14710501 ,_19\,\1740 sodium_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 <e2>kidney_37\NN\5333259 injury</e2>_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 necrosis_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
C030272_D007674 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 curcumin_4\NN\1740 is_5\VBZ\836236 able_6\JJ\1740 to_7\TO\1740 attenuate_8\VB\224901 in_9\FW\13603305 vivo_10\FW\1740 <e1>maleate-induced</e1>_11\JJ\1740 <e2>nephropathy</e2>_12\NN\14573196 and_13\CC\1740 in_14\FW\13603305 vitro_15\FW\1740 cell_16\NN\3080309 damage_17\NN\7296428 ._18\.\1740
D010100_D007674 NONE curcumin_0\NN\1740 prevents_1\VBZ\1740 maleate-induced_2\JJ\1740 <e2>nephrotoxicity</e2>_3\NN\1740 :_4\:\1740 relation_5\NN\2137 to_6\TO\1740 hemodynamic_7\JJ\1740 alterations_8\NNS\7283608 ,_9\,\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 ,_12\,\1740 mitochondrial_13\JJ\1740 <e1>oxygen</e1>_14\NN\14622893 consumption_15\NN\13440063 and_16\CC\1740 activity_17\NN\30358 of_18\IN\1740 respiratory_19\JJ\1740 complex_20\NN\5869584 i._21\NN\1740
C030272_D011507 CID tubular_0\JJ\1740 <e2>proteinuria</e2>_1\NN\14299637 and_2\CC\1740 oxidative_3\JJ\1740 stress_4\NN\7083732 were_5\VBD\836236 induced_6\VBN\1627355 by_7\IN\1740 a_8\DT\13649268 single_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 <e1>maleate</e1>_12\NN\2718811 (_13\-LRB-\1740 400_14\CD\1740 mg/kg_15\NN\1740 )_16\-RRB-\1740 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
C030272_D009336 CID <e1>maleate-induced</e1>_0\JJ\1740 renal_1\JJ\1740 injury_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 glucose_18\NN\14710501 ,_19\,\1740 sodium_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 kidney_37\NN\5333259 injury_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 <e2>necrosis</e2>_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
D005947_D007674 NONE maleate-induced_0\JJ\1740 <e2>renal_1\JJ\1740 injury</e2>_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 <e1>glucose</e1>_18\NN\14710501 ,_19\,\1740 sodium_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 kidney_37\NN\5333259 injury_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 necrosis_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
D005947_D007674 NONE maleate-induced_0\JJ\1740 renal_1\JJ\1740 injury_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 <e1>glucose</e1>_18\NN\14710501 ,_19\,\1740 sodium_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 <e2>kidney_37\NN\5333259 injury</e2>_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 necrosis_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
D005947_D009336 NONE maleate-induced_0\JJ\1740 renal_1\JJ\1740 injury_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 <e1>glucose</e1>_18\NN\14710501 ,_19\,\1740 sodium_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 kidney_37\NN\5333259 injury_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 <e2>necrosis</e2>_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
D012964_D007674 NONE maleate-induced_0\JJ\1740 <e2>renal_1\JJ\1740 injury</e2>_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 glucose_18\NN\14710501 ,_19\,\1740 <e1>sodium</e1>_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 kidney_37\NN\5333259 injury_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 necrosis_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
D012964_D007674 NONE maleate-induced_0\JJ\1740 renal_1\JJ\1740 injury_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 glucose_18\NN\14710501 ,_19\,\1740 <e1>sodium</e1>_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 <e2>kidney_37\NN\5333259 injury</e2>_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 necrosis_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
D012964_D009336 NONE maleate-induced_0\JJ\1740 renal_1\JJ\1740 injury_2\NN\14052046 included_3\VBD\690614 increase_4\NN\13576355 in_5\IN\13603305 renal_6\JJ\1740 vascular_7\JJ\1740 resistance_8\NN\37396 and_9\CC\1740 in_10\IN\13603305 the_11\DT\1740 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 total_15\JJ\1740 protein_16\NN\14944888 ,_17\,\1740 glucose_18\NN\14710501 ,_19\,\1740 <e1>sodium</e1>_20\NN\14625458 ,_21\,\1740 neutrophil_22\NN\5449959 gelatinase-associated_23\JJ\1740 lipocalin_24\NN\1740 (_25\-LRB-\1740 ngal_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 n-acetyl_29\JJ\1740 b-d-glucosaminidase_30\NN\1740 (_31\-LRB-\1740 nag_32\NN\9631463 )_33\-RRB-\1740 ,_34\,\1740 upregulation_35\NN\1740 of_36\IN\1740 kidney_37\NN\5333259 injury_38\NN\14052046 molecule_39\NN\9465459 (kim)-1_40\NN\1740 ,_41\,\1740 decrease_42\VB\169651 in_43\IN\13603305 renal_44\JJ\1740 blood_45\NN\5397468 flow_46\NN\7311115 and_47\CC\1740 claudin-2_48\NN\1740 expression_49\NN\4679549 besides_50\IN\1740 of_51\IN\1740 <e2>necrosis</e2>_52\NN\11444117 and_53\CC\1740 apoptosis_54\NN\11486178 of_55\IN\1740 tubular_56\JJ\1740 cells_57\NNS\3080309 on_58\IN\1740 24_59\CD\13745420 h._60\NN\1740 oxidative_61\JJ\1740 stress_62\NN\7083732 was_63\VBD\836236 determined_64\VBN\1645601 by_65\IN\1740 measuring_66\VBG\697589 the_67\DT\1740 oxidation_68\NN\13447361 of_69\IN\1740 lipids_70\NNS\14944888 and_71\CC\1740 proteins_72\NNS\14944888 and_73\CC\1740 diminution_74\NN\13458571 in_75\IN\13603305 renal_76\JJ\1740 nrf2_77\NN\1740 levels_78\NNS\4916342 ._79\.\1740
24434397
D014148_D012640 NONE <e1>tranexamic_0\JJ\1740 acid</e1>_1\NN\14818238 overdosage-induced_2\JJ\1740 generalized_3\JJ\1740 <e2>seizure</e2>_4\NN\14081375 in_5\IN\13603305 renal_6\JJ\1740 failure_7\NN\66216 ._8\.\1740
D014148_D012640 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 precipitating_3\NN\1740 cause_4\NN\7323922 of_5\IN\1740 <e2>convulsions</e2>_6\NNS\14081375 was_7\VBD\836236 believed_8\VBN\686447 to_9\TO\1740 be_10\VB\836236 an_11\DT\6697703 overdose_12\NN\1740 of_13\IN\1740 <e1>tna</e1>_14\NNP\1740 ._15\.\1740
D014148_D051437 NONE <e1>tranexamic_0\JJ\1740 acid</e1>_1\NN\14818238 overdosage-induced_2\JJ\1740 generalized_3\JJ\1740 seizure_4\NN\14081375 in_5\IN\13603305 <e2>renal_6\JJ\1740 failure</e2>_7\NN\66216 ._8\.\1740
D014148_D006470 NONE <e1>tranexamic_0\JJ\1740 acid</e1>_1\NN\14818238 (_2\-LRB-\1740 tna_3\NN\1740 )_4\-RRB-\1740 1_5\CD\13741022 g_6\NN\13717155 8-hourly_7\RB\1740 was_8\VBD\836236 administered_9\VBN\2436349 to_10\IN\1740 her_11\PRP\1740 to_12\TO\1740 control_13\VB\2422663 <e2>bleeding</e2>_14\VBG\104868 per_15\IN\1740 vaginum_16\NN\1740 ._17\.\1740
D014148_D006470 NONE tranexamic_0\JJ\1740 acid_1\NN\14818238 (_2\-LRB-\1740 <e1>tna</e1>_3\NN\1740 )_4\-RRB-\1740 1_5\CD\13741022 g_6\NN\13717155 8-hourly_7\RB\1740 was_8\VBD\836236 administered_9\VBN\2436349 to_10\IN\1740 her_11\PRP\1740 to_12\TO\1740 control_13\VB\2422663 <e2>bleeding</e2>_14\VBG\104868 per_15\IN\1740 vaginum_16\NN\1740 ._17\.\1740
D014148_D004830 CID two_0\CD\13741022 hours_1\NNS\15118228 after_2\IN\1740 the_3\DT\1740 sixth_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 <e1>tna</e1>_7\NN\1740 ,_8\,\1740 she_9\PRP\1740 had_10\VBD\2108377 an_11\DT\6697703 episode_12\NN\7283608 of_13\IN\1740 generalized_14\JJ\1740 <e2>tonic_15\JJ\1740 clonic_16\NN\1740 convulsions</e2>_17\NNS\14081375 ._18\.\1740
D014148_D062787 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 precipitating_3\NN\1740 cause_4\NN\7323922 of_5\IN\1740 convulsions_6\NNS\14081375 was_7\VBD\836236 believed_8\VBN\686447 to_9\TO\1740 be_10\VB\836236 an_11\DT\6697703 <e2>overdose</e2>_12\NN\1740 of_13\IN\1740 <e1>tna</e1>_14\NNP\1740 ._15\.\1740
8135424
D005442_D012640 CID <e1>flumazenil</e1>_0\NN\1740 induces_1\VBZ\1627355 <e2>seizures</e2>_2\NNS\14081375 and_3\CC\1740 death_4\NN\7296428 in_5\IN\13603305 mixed_6\JJ\1740 cocaine-diazepam_7\JJ\1740 intoxications_8\NNS\14034177 ._9\.\1740
D005442_D012640 CID study_0\NN\635850 hypothesis_1\NN\7162194 :_2\:\1740 administration_3\NN\1133281 of_4\IN\1740 the_5\DT\1740 benzodiazepine_6\NN\3771443 antagonist_7\NN\7846 <e1>flumazenil</e1>_8\NN\1740 may_9\MD\15209706 unmask_10\VB\853195 <e2>seizures</e2>_11\NNS\14081375 in_12\IN\13603305 mixed_13\JJ\1740 cocaine-benzodiazepine_14\JJ\1740 intoxication_15\NN\14034177 ._16\.\1740
D005442_D012640 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>flumazenil</e1>_2\NNP\1740 can_3\MD\3094503 unmask_4\VB\853195 <e2>seizures</e2>_5\NNS\14081375 and_6\CC\1740 increase_7\VB\169651 the_8\DT\1740 incidence_9\NN\13821570 of_10\IN\1740 death_11\NN\7296428 in_12\IN\13603305 a_13\DT\13649268 model_14\NN\5888929 of_15\IN\1740 combined_16\JJ\1740 cocaine-diazepam_17\JJ\1740 intoxications_18\NNS\14034177 ._19\.\1740
D003042_D012640 CID flumazenil_0\NN\1740 induces_1\VBZ\1627355 <e2>seizures</e2>_2\NNS\14081375 and_3\CC\1740 death_4\NN\7296428 in_5\IN\13603305 mixed_6\JJ\1740 <e1>cocaine-diazepam</e1>_7\JJ\1740 intoxications_8\NNS\14034177 ._9\.\1740
D003042_D012640 CID study_0\NN\635850 hypothesis_1\NN\7162194 :_2\:\1740 administration_3\NN\1133281 of_4\IN\1740 the_5\DT\1740 benzodiazepine_6\NN\3771443 antagonist_7\NN\7846 flumazenil_8\NN\1740 may_9\MD\15209706 unmask_10\VB\853195 <e2>seizures</e2>_11\NNS\14081375 in_12\IN\13603305 mixed_13\JJ\1740 <e1>cocaine-benzodiazepine</e1>_14\JJ\1740 intoxication_15\NN\14034177 ._16\.\1740
D003042_D012640 CID conclusion_0\NN\5837957 :_1\:\1740 flumazenil_2\NNP\1740 can_3\MD\3094503 unmask_4\VB\853195 <e2>seizures</e2>_5\NNS\14081375 and_6\CC\1740 increase_7\VB\169651 the_8\DT\1740 incidence_9\NN\13821570 of_10\IN\1740 death_11\NN\7296428 in_12\IN\13603305 a_13\DT\13649268 model_14\NN\5888929 of_15\IN\1740 combined_16\JJ\1740 <e1>cocaine-diazepam</e1>_17\JJ\1740 intoxications_18\NNS\14034177 ._19\.\1740
D003975_D012640 CID flumazenil_0\NN\1740 induces_1\VBZ\1627355 <e2>seizures</e2>_2\NNS\14081375 and_3\CC\1740 death_4\NN\7296428 in_5\IN\13603305 mixed_6\JJ\1740 <e1>cocaine-diazepam</e1>_7\JJ\1740 intoxications_8\NNS\14034177 ._9\.\1740
D003975_D012640 CID conclusion_0\NN\5837957 :_1\:\1740 flumazenil_2\NNP\1740 can_3\MD\3094503 unmask_4\VB\853195 <e2>seizures</e2>_5\NNS\14081375 and_6\CC\1740 increase_7\VB\169651 the_8\DT\1740 incidence_9\NN\13821570 of_10\IN\1740 death_11\NN\7296428 in_12\IN\13603305 a_13\DT\13649268 model_14\NN\5888929 of_15\IN\1740 combined_16\JJ\1740 <e1>cocaine-diazepam</e1>_17\JJ\1740 intoxications_18\NNS\14034177 ._19\.\1740
D001569_D012640 NONE study_0\NN\635850 hypothesis_1\NN\7162194 :_2\:\1740 administration_3\NN\1133281 of_4\IN\1740 the_5\DT\1740 <e1>benzodiazepine</e1>_6\NN\3771443 antagonist_7\NN\7846 flumazenil_8\NN\1740 may_9\MD\15209706 unmask_10\VB\853195 <e2>seizures</e2>_11\NNS\14081375 in_12\IN\13603305 mixed_13\JJ\1740 cocaine-benzodiazepine_14\JJ\1740 intoxication_15\NN\14034177 ._16\.\1740
D001569_D012640 NONE study_0\NN\635850 hypothesis_1\NN\7162194 :_2\:\1740 administration_3\NN\1133281 of_4\IN\1740 the_5\DT\1740 benzodiazepine_6\NN\3771443 antagonist_7\NN\7846 flumazenil_8\NN\1740 may_9\MD\15209706 unmask_10\VB\853195 <e2>seizures</e2>_11\NNS\14081375 in_12\IN\13603305 mixed_13\JJ\1740 <e1>cocaine-benzodiazepine</e1>_14\JJ\1740 intoxication_15\NN\14034177 ._16\.\1740
24333387
D013311_D020258 NONE glial_0\JJ\1740 activation_1\NN\13561719 and_2\CC\1740 post-synaptic_3\JJ\1740 <e2>neurotoxicity</e2>_4\NN\1740 :_5\:\1740 the_6\DT\1740 key_7\JJ\1740 events_8\NNS\23100 in_9\IN\13603305 <e1>streptozotocin</e1>_10\NN\1740 (_11\-LRB-\1740 icv_12\NN\1740 )_13\-RRB-\1740 induced_14\VBD\1627355 memory_15\NN\5926676 impairment_16\NN\7296428 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D013311_D020258 NONE <e1>stz</e1>_0\NN\1740 treatment_1\NN\654885 showed_2\VBD\2137132 decrease_3\NN\7296428 expression_4\NN\4679549 of_5\IN\1740 post_6\NN\8621598 synaptic_7\JJ\1740 markers_8\NNS\21939 camkiia_9\NN\1740 and_10\CC\1740 psd-95_11\NN\1740 ,_12\,\1740 while_13\IN\15122231 ,_14\,\1740 expression_15\NN\4679549 of_16\IN\1740 pre_17\JJ\1740 synaptic_18\JJ\1740 markers_19\NNS\21939 (_20\-LRB-\1740 synaptophysin_21\NN\1740 and_22\CC\1740 snap-25_23\VB\1740 )_24\-RRB-\1740 remains_25\VBZ\2604760 unaltered_26\JJ\1740 indicating_27\VBG\952524 selective_28\JJ\1740 post_29\NN\8621598 synaptic_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D013311_D020258 NONE oral_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 memantine_3\NN\1740 (_4\-LRB-\1740 10mg/kg_5\NN\1740 )_6\-RRB-\1740 and_7\CC\1740 ibuprofen_8\NN\3828465 (_9\-LRB-\1740 50_10\CD\13745420 mg/kg_11\NN\1740 )_12\-RRB-\1740 daily_13\RB\1740 for_14\IN\1740 13_15\CD\13745420 days_16\NNS\15140892 attenuated_17\VBD\224901 <e1>stz</e1>_18\NN\1740 induced_19\JJ\1740 glial_20\JJ\1740 activation_21\NN\13561719 ,_22\,\1740 apoptotic_23\JJ\1740 cell_24\NN\3080309 death_25\NN\7296428 and_26\CC\1740 post_27\VB\1356370 synaptic_28\JJ\1740 <e2>neurotoxicity</e2>_29\NN\1740 in_30\IN\13603305 rat_31\NN\2329401 brain_32\NN\5462674 ._33\.\1740
D013311_D020258 NONE present_0\JJ\1740 study_1\NN\635850 clearly_2\RB\1740 suggests_3\VBZ\1010118 that_4\IN\1740 glial_5\JJ\1740 activation_6\NN\13561719 and_7\CC\1740 post_8\NN\8621598 synaptic_9\JJ\1740 <e2>neurotoxicity</e2>_10\NN\1740 are_11\VBP\836236 the_12\DT\1740 key_13\JJ\1740 factors_14\NNS\7326557 in_15\IN\13603305 <e1>stz</e1>_16\NN\1740 induced_17\JJ\1740 memory_18\NN\5926676 impairment_19\NN\7296428 and_20\CC\1740 neuronal_21\JJ\1740 cell_22\NN\3080309 death_23\NN\7296428 ._24\.\1740
D013311_D008569 CID glial_0\JJ\1740 activation_1\NN\13561719 and_2\CC\1740 post-synaptic_3\JJ\1740 neurotoxicity_4\NN\1740 :_5\:\1740 the_6\DT\1740 key_7\JJ\1740 events_8\NNS\23100 in_9\IN\13603305 <e1>streptozotocin</e1>_10\NN\1740 (_11\-LRB-\1740 icv_12\NN\1740 )_13\-RRB-\1740 induced_14\VBD\1627355 <e2>memory_15\NN\5926676 impairment</e2>_16\NN\7296428 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D013311_D008569 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 glial_7\JJ\1740 activation_8\NN\13561719 and_9\CC\1740 post_10\VBP\1356370 synaptic_11\JJ\1740 toxicity_12\NN\13576101 in_13\IN\13603305 icv_14\NN\1740 <e1>streptozotocin</e1>_15\NN\1740 (_16\-LRB-\1740 stz_17\NN\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 <e2>memory_20\NN\5926676 impaired</e2>_21\JJ\1740 rats_22\NNS\2329401 was_23\VBD\836236 explored_24\VBN\789138 ._25\.\1740
D013311_D008569 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 glial_7\JJ\1740 activation_8\NN\13561719 and_9\CC\1740 post_10\VBP\1356370 synaptic_11\JJ\1740 toxicity_12\NN\13576101 in_13\IN\13603305 icv_14\NN\1740 streptozotocin_15\NN\1740 (_16\-LRB-\1740 <e1>stz</e1>_17\NN\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 <e2>memory_20\NN\5926676 impaired</e2>_21\JJ\1740 rats_22\NNS\2329401 was_23\VBD\836236 explored_24\VBN\789138 ._25\.\1740
D013311_D008569 CID in_0\IN\13603305 experiment_1\NN\641820 set_2\VBN\1850315 up_3\RP\1740 1_4\CD\13741022 :_5\:\1740 <e2>memory_6\NN\5926676 deficit</e2>_7\NN\5113133 was_8\VBD\836236 found_9\VBN\2426171 in_10\IN\13603305 morris_11\NNP\1740 water_12\NN\14618834 maze_13\NN\4377057 test_14\NN\5798043 on_15\IN\1740 14_16\CD\13745420 -_17\SYM\1740 16_18\CD\13745420 days_19\NNS\15140892 after_20\IN\1740 <e1>stz</e1>_21\NN\1740 (_22\-LRB-\1740 icv_23\NN\1740 ;_24\:\1740 3mg/kg_25\NN\1740 )_26\-RRB-\1740 administration_27\NN\1133281 ._28\.\1740
D013311_D008569 CID present_0\JJ\1740 study_1\NN\635850 clearly_2\RB\1740 suggests_3\VBZ\1010118 that_4\IN\1740 glial_5\JJ\1740 activation_6\NN\13561719 and_7\CC\1740 post_8\NN\8621598 synaptic_9\JJ\1740 neurotoxicity_10\NN\1740 are_11\VBP\836236 the_12\DT\1740 key_13\JJ\1740 factors_14\NNS\7326557 in_15\IN\13603305 <e1>stz</e1>_16\NN\1740 induced_17\JJ\1740 <e2>memory_18\NN\5926676 impairment</e2>_19\NN\7296428 and_20\CC\1740 neuronal_21\JJ\1740 cell_22\NN\3080309 death_23\NN\7296428 ._24\.\1740
D013311_D064420 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 glial_7\JJ\1740 activation_8\NN\13561719 and_9\CC\1740 post_10\VBP\1356370 synaptic_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 in_13\IN\13603305 icv_14\NN\1740 <e1>streptozotocin</e1>_15\NN\1740 (_16\-LRB-\1740 stz_17\NN\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 memory_20\NN\5926676 impaired_21\JJ\1740 rats_22\NNS\2329401 was_23\VBD\836236 explored_24\VBN\789138 ._25\.\1740
D013311_D064420 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 the_4\DT\1740 role_5\NN\719494 of_6\IN\1740 glial_7\JJ\1740 activation_8\NN\13561719 and_9\CC\1740 post_10\VBP\1356370 synaptic_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 in_13\IN\13603305 icv_14\NN\1740 streptozotocin_15\NN\1740 (_16\-LRB-\1740 <e1>stz</e1>_17\NN\1740 )_18\-RRB-\1740 induced_19\VBD\1627355 memory_20\NN\5926676 impaired_21\JJ\1740 rats_22\NNS\2329401 was_23\VBD\836236 explored_24\VBN\789138 ._25\.\1740
D013311_D064420 NONE <e1>stz</e1>_0\NN\1740 also_1\RB\1740 significantly_2\RB\1740 increased_3\VBD\169651 the_4\DT\1740 level_5\NN\4916342 of_6\IN\1740 ros_7\NN\6894544 ,_8\,\1740 nitrite_9\JJ\1740 ,_10\,\1740 ca(2_11\NN\1740 +_12\CC\1740 )_13\-RRB-\1740 and_14\CC\1740 reduced_15\VBD\441445 the_16\DT\1740 mitochondrial_17\JJ\1740 activity_18\NN\30358 in_19\IN\13603305 synaptosomal_20\JJ\1740 preparation_21\NN\407535 illustrating_22\VBG\955601 free_23\JJ\1740 radical_24\JJ\1740 generation_25\NN\7942152 and_26\CC\1740 <e2>excitotoxicity</e2>_27\NN\1740 ._28\.\1740
D013311_D007249 CID <e1>stz</e1>_0\NN\1740 causes_1\VBZ\1617192 increased_2\VBN\169651 expression_3\NN\4679549 of_4\IN\1740 gfap_5\NN\1740 ,_6\,\1740 cd11b_7\NN\1740 and_8\CC\1740 tnf-a_9\NN\1740 indicating_10\VBG\952524 glial_11\JJ\1740 activation_12\NN\13561719 and_13\CC\1740 <e2>neuroinflammation</e2>_14\NN\1740 ._15\.\1740
D009573_D064420 NONE stz_0\NN\1740 also_1\RB\1740 significantly_2\RB\1740 increased_3\VBD\169651 the_4\DT\1740 level_5\NN\4916342 of_6\IN\1740 ros_7\NN\6894544 ,_8\,\1740 <e1>nitrite</e1>_9\JJ\1740 ,_10\,\1740 ca(2_11\NN\1740 +_12\CC\1740 )_13\-RRB-\1740 and_14\CC\1740 reduced_15\VBD\441445 the_16\DT\1740 mitochondrial_17\JJ\1740 activity_18\NN\30358 in_19\IN\13603305 synaptosomal_20\JJ\1740 preparation_21\NN\407535 illustrating_22\VBG\955601 free_23\JJ\1740 radical_24\JJ\1740 generation_25\NN\7942152 and_26\CC\1740 <e2>excitotoxicity</e2>_27\NN\1740 ._28\.\1740
D002118_D064420 NONE stz_0\NN\1740 also_1\RB\1740 significantly_2\RB\1740 increased_3\VBD\169651 the_4\DT\1740 level_5\NN\4916342 of_6\IN\1740 ros_7\NN\6894544 ,_8\,\1740 nitrite_9\JJ\1740 ,_10\,\1740 <e1>ca(2</e1>_11\NN\1740 +_12\CC\1740 )_13\-RRB-\1740 and_14\CC\1740 reduced_15\VBD\441445 the_16\DT\1740 mitochondrial_17\JJ\1740 activity_18\NN\30358 in_19\IN\13603305 synaptosomal_20\JJ\1740 preparation_21\NN\407535 illustrating_22\VBG\955601 free_23\JJ\1740 radical_24\JJ\1740 generation_25\NN\7942152 and_26\CC\1740 <e2>excitotoxicity</e2>_27\NN\1740 ._28\.\1740
D008559_D020258 NONE oral_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>memantine</e1>_3\NN\1740 (_4\-LRB-\1740 10mg/kg_5\NN\1740 )_6\-RRB-\1740 and_7\CC\1740 ibuprofen_8\NN\3828465 (_9\-LRB-\1740 50_10\CD\13745420 mg/kg_11\NN\1740 )_12\-RRB-\1740 daily_13\RB\1740 for_14\IN\1740 13_15\CD\13745420 days_16\NNS\15140892 attenuated_17\VBD\224901 stz_18\NN\1740 induced_19\JJ\1740 glial_20\JJ\1740 activation_21\NN\13561719 ,_22\,\1740 apoptotic_23\JJ\1740 cell_24\NN\3080309 death_25\NN\7296428 and_26\CC\1740 post_27\VB\1356370 synaptic_28\JJ\1740 <e2>neurotoxicity</e2>_29\NN\1740 in_30\IN\13603305 rat_31\NN\2329401 brain_32\NN\5462674 ._33\.\1740
D007052_D020258 NONE oral_0\JJ\1740 treatment_1\NN\654885 with_2\IN\1740 memantine_3\NN\1740 (_4\-LRB-\1740 10mg/kg_5\NN\1740 )_6\-RRB-\1740 and_7\CC\1740 <e1>ibuprofen</e1>_8\NN\3828465 (_9\-LRB-\1740 50_10\CD\13745420 mg/kg_11\NN\1740 )_12\-RRB-\1740 daily_13\RB\1740 for_14\IN\1740 13_15\CD\13745420 days_16\NNS\15140892 attenuated_17\VBD\224901 stz_18\NN\1740 induced_19\JJ\1740 glial_20\JJ\1740 activation_21\NN\13561719 ,_22\,\1740 apoptotic_23\JJ\1740 cell_24\NN\3080309 death_25\NN\7296428 and_26\CC\1740 post_27\VB\1356370 synaptic_28\JJ\1740 <e2>neurotoxicity</e2>_29\NN\1740 in_30\IN\13603305 rat_31\NN\2329401 brain_32\NN\5462674 ._33\.\1740
24587916
D003907_D006973 CID antioxidant_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 bovine_3\JJ\1740 lactoferrin_4\NN\1740 on_5\IN\1740 <e1>dexamethasone-induced</e1>_6\JJ\1740 <e2>hypertension</e2>_7\NN\14057371 in_8\IN\13603305 rat_9\NN\2329401 ._10\.\1740
D003907_D006973 CID <e1>dexamethasone-</e1>_0\NN\1740 (_1\-LRB-\1740 dex-_2\NN\1740 )_3\-RRB-\1740 induced_4\JJ\1740 <e2>hypertension</e2>_5\NN\14057371 is_6\VBZ\836236 associated_7\VBN\628491 with_8\IN\1740 enhanced_9\VBN\227165 oxidative_10\JJ\1740 stress_11\NN\7083732 ._12\.\1740
D003907_D006973 CID dexamethasone-_0\NN\1740 (_1\-LRB-\1740 <e1>dex-</e1>_2\NN\1740 )_3\-RRB-\1740 induced_4\JJ\1740 <e2>hypertension</e2>_5\NN\14057371 is_6\VBZ\836236 associated_7\VBN\628491 with_8\IN\1740 enhanced_9\VBN\227165 oxidative_10\JJ\1740 stress_11\NN\7083732 ._12\.\1740
D003907_D006973 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 ,_3\,\1740 we_4\PRP\1740 investigated_5\VBD\644583 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 chronic_9\JJ\1740 administration_10\NN\1133281 of_11\IN\1740 lf_12\NN\5056490 on_13\IN\1740 oxidative_14\JJ\1740 stress_15\NN\7083732 and_16\CC\1740 <e2>hypertension</e2>_17\NN\14057371 upon_18\IN\1740 <e1>dex</e1>_19\NN\1740 administration_20\NN\1133281 ._21\.\1740
D003907_D006973 CID lf_0\NN\5056490 lowered_1\JJ\1740 (_2\-LRB-\1740 p_3\NN\14622893 <_4\XX\1740 0.01_5\CD\1740 )_6\-RRB-\1740 and_7\CC\1740 dose_8\NN\3740161 dependently_9\RB\1740 prevented_10\VBN\1740 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.001_14\CD\1740 )_15\-RRB-\1740 <e1>dex-induced</e1>_16\JJ\1740 <e2>hypertension</e2>_17\NN\14057371 ._18\.\1740
D003907_D006973 CID chronic_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 lf_3\NN\5056490 strongly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 blood_7\NN\5397468 pressure_8\NN\11419404 and_9\CC\1740 production_10\NN\30358 of_11\IN\1740 ros_12\NN\6894544 and_13\CC\1740 improved_14\VBD\126264 antioxidant_15\JJ\1740 capacity_16\NN\5202497 in_17\IN\13603305 <e1>dex-induced</e1>_18\JJ\1740 <e2>hypertension</e2>_19\NN\14057371 ,_20\,\1740 suggesting_21\VBG\1010118 the_22\DT\1740 role_23\NN\719494 of_24\IN\1740 inhibition_25\NN\1068773 of_26\IN\1740 oxidative_27\JJ\1740 stress_28\NN\7083732 as_29\IN\14622893 another_30\DT\1740 mechanism_31\NN\13446390 of_32\IN\1740 antihypertensive_33\JJ\1740 action_34\NN\30358 of_35\IN\1740 lf_36\NN\5056490 ._37\.\1740
D006861_D015431 NONE lf_0\NN\5056490 prevented_1\VBD\1740 body_2\NN\19128 <e2>weight_3\NN\5009170 loss</e2>_4\NN\13252973 and_5\CC\1740 significantly_6\RB\1740 reduced_7\VBD\441445 the_8\DT\1740 elevated_9\JJ\1740 plasma_10\NN\5398023 <e1>h2o2</e1>_11\NN\1740 and_12\CC\1740 increased_13\VBD\169651 frap_14\NNP\1740 values_15\NNS\5941423 ._16\.\1740
23952588
D007980_D004409 CID risk_0\NN\14541044 factors_1\NNS\7326557 and_2\CC\1740 predictors_3\NNS\10756433 of_4\IN\1740 <e1>levodopa-induced</e1>_5\JJ\1740 <e2>dyskinesia</e2>_6\NN\14084880 among_7\IN\1740 multiethnic_8\JJ\1740 malaysians_9\NNPS\9641757 with_10\IN\1740 parkinson_11\NNP\1740 's_12\POS\1740 disease_13\NN\14061805 ._14\.\1740
D007980_D004409 CID chronic_0\JJ\1740 pulsatile_1\JJ\1740 <e1>levodopa</e1>_2\NN\14604959 therapy_3\NN\657604 for_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 (_8\-LRB-\1740 pd_9\NN\14625458 )_10\-RRB-\1740 leads_11\VBZ\1752884 to_12\TO\1740 the_13\DT\1740 development_14\NN\248977 of_15\IN\1740 motor_16\NN\3699975 fluctuations_17\NNS\7345593 and_18\CC\1740 <e2>dyskinesia</e2>_19\NN\14084880 ._20\.\1740
D007980_D004409 CID we_0\PRP\1740 studied_1\VBD\630380 the_2\DT\1740 prevalence_3\NN\4764412 and_4\CC\1740 predictors_5\NNS\10756433 of_6\IN\1740 <e1>levodopa-induced</e1>_7\JJ\1740 <e2>dyskinesia</e2>_8\NN\14084880 among_9\IN\1740 multiethnic_10\JJ\1740 malaysian_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 pd_14\NN\14625458 ._15\.\1740
D007980_D004409 CID <e2>dyskinesia</e2>_0\NNP\14084880 was_1\VBD\836236 present_2\JJ\1740 in_3\IN\13603305 44_4\CD\1740 %_5\NN\1740 (_6\-LRB-\1740 n_7\NN\14622893 =_8\JJ\1740 42_9\CD\1740 )_10\-RRB-\1740 with_11\IN\1740 median_12\JJ\1740 <e1>levodopa</e1>_13\NN\14604959 therapy_14\NN\657604 of_15\IN\1740 3_16\CD\13741022 years_17\NNS\15144371 ._18\.\1740
D007980_D004409 CID patients_0\NNS\9898892 with_1\IN\1740 <e2>dyskinesia</e2>_2\NN\14084880 had_3\VBD\2108377 lower_4\JJR\1740 onset_5\NN\7325190 age_6\NN\4916342 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.001_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 longer_13\JJR\1740 duration_14\NN\15113229 of_15\IN\1740 <e1>levodopa</e1>_16\NN\14604959 therapy_17\NN\657604 (_18\-LRB-\1740 p_19\NN\14622893 <_20\XX\1740 0.001_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 longer_24\JJR\1740 disease_25\NN\14061805 duration_26\NN\15113229 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 0.001_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 higher_33\JJR\1740 total_34\JJ\1740 daily_35\JJ\1740 levodopa_36\NN\14604959 dose_37\NN\3740161 (_38\-LRB-\1740 p_39\NN\14622893 <_40\XX\1740 0.001_41\CD\1740 )_42\-RRB-\1740 ,_43\,\1740 and_44\CC\1740 higher_45\JJR\1740 total_46\JJ\1740 updrs_47\NN\1740 scores_48\NNS\13757724 (_49\-LRB-\1740 p_50\NN\14622893 =_51\JJ\1740 0.005_52\CD\1740 )_53\-RRB-\1740 than_54\IN\1740 patients_55\NNS\9898892 without_56\IN\1740 dyskinesia_57\NN\14084880 ._58\.\1740
D007980_D004409 CID patients_0\NNS\9898892 with_1\IN\1740 dyskinesia_2\NN\14084880 had_3\VBD\2108377 lower_4\JJR\1740 onset_5\NN\7325190 age_6\NN\4916342 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.001_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 longer_13\JJR\1740 duration_14\NN\15113229 of_15\IN\1740 <e1>levodopa</e1>_16\NN\14604959 therapy_17\NN\657604 (_18\-LRB-\1740 p_19\NN\14622893 <_20\XX\1740 0.001_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 longer_24\JJR\1740 disease_25\NN\14061805 duration_26\NN\15113229 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 0.001_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 higher_33\JJR\1740 total_34\JJ\1740 daily_35\JJ\1740 levodopa_36\NN\14604959 dose_37\NN\3740161 (_38\-LRB-\1740 p_39\NN\14622893 <_40\XX\1740 0.001_41\CD\1740 )_42\-RRB-\1740 ,_43\,\1740 and_44\CC\1740 higher_45\JJR\1740 total_46\JJ\1740 updrs_47\NN\1740 scores_48\NNS\13757724 (_49\-LRB-\1740 p_50\NN\14622893 =_51\JJ\1740 0.005_52\CD\1740 )_53\-RRB-\1740 than_54\IN\1740 patients_55\NNS\9898892 without_56\IN\1740 <e2>dyskinesia</e2>_57\NN\14084880 ._58\.\1740
D007980_D004409 CID patients_0\NNS\9898892 with_1\IN\1740 <e2>dyskinesia</e2>_2\NN\14084880 had_3\VBD\2108377 lower_4\JJR\1740 onset_5\NN\7325190 age_6\NN\4916342 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.001_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 longer_13\JJR\1740 duration_14\NN\15113229 of_15\IN\1740 levodopa_16\NN\14604959 therapy_17\NN\657604 (_18\-LRB-\1740 p_19\NN\14622893 <_20\XX\1740 0.001_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 longer_24\JJR\1740 disease_25\NN\14061805 duration_26\NN\15113229 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 0.001_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 higher_33\JJR\1740 total_34\JJ\1740 daily_35\JJ\1740 <e1>levodopa</e1>_36\NN\14604959 dose_37\NN\3740161 (_38\-LRB-\1740 p_39\NN\14622893 <_40\XX\1740 0.001_41\CD\1740 )_42\-RRB-\1740 ,_43\,\1740 and_44\CC\1740 higher_45\JJR\1740 total_46\JJ\1740 updrs_47\NN\1740 scores_48\NNS\13757724 (_49\-LRB-\1740 p_50\NN\14622893 =_51\JJ\1740 0.005_52\CD\1740 )_53\-RRB-\1740 than_54\IN\1740 patients_55\NNS\9898892 without_56\IN\1740 dyskinesia_57\NN\14084880 ._58\.\1740
D007980_D004409 CID patients_0\NNS\9898892 with_1\IN\1740 dyskinesia_2\NN\14084880 had_3\VBD\2108377 lower_4\JJR\1740 onset_5\NN\7325190 age_6\NN\4916342 (_7\-LRB-\1740 p_8\NN\14622893 <_9\XX\1740 0.001_10\CD\1740 )_11\-RRB-\1740 ,_12\,\1740 longer_13\JJR\1740 duration_14\NN\15113229 of_15\IN\1740 levodopa_16\NN\14604959 therapy_17\NN\657604 (_18\-LRB-\1740 p_19\NN\14622893 <_20\XX\1740 0.001_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 longer_24\JJR\1740 disease_25\NN\14061805 duration_26\NN\15113229 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 0.001_30\CD\1740 )_31\-RRB-\1740 ,_32\,\1740 higher_33\JJR\1740 total_34\JJ\1740 daily_35\JJ\1740 <e1>levodopa</e1>_36\NN\14604959 dose_37\NN\3740161 (_38\-LRB-\1740 p_39\NN\14622893 <_40\XX\1740 0.001_41\CD\1740 )_42\-RRB-\1740 ,_43\,\1740 and_44\CC\1740 higher_45\JJR\1740 total_46\JJ\1740 updrs_47\NN\1740 scores_48\NNS\13757724 (_49\-LRB-\1740 p_50\NN\14622893 =_51\JJ\1740 0.005_52\CD\1740 )_53\-RRB-\1740 than_54\IN\1740 patients_55\NNS\9898892 without_56\IN\1740 <e2>dyskinesia</e2>_57\NN\14084880 ._58\.\1740
D007980_D004409 CID the_0\DT\1740 three_1\CD\13741022 significant_2\JJ\1740 predictors_3\NNS\10756433 of_4\IN\1740 <e2>dyskinesia</e2>_5\NN\14084880 were_6\VBD\836236 duration_7\NN\15113229 of_8\IN\1740 <e1>levodopa</e1>_9\NN\14604959 therapy_10\NN\657604 ,_11\,\1740 onset_12\NN\7325190 age_13\NN\4916342 ,_14\,\1740 and_15\CC\1740 total_16\JJ\1740 daily_17\JJ\1740 levodopa_18\NN\14604959 dose_19\NN\3740161 ._20\.\1740
D007980_D004409 CID the_0\DT\1740 three_1\CD\13741022 significant_2\JJ\1740 predictors_3\NNS\10756433 of_4\IN\1740 <e2>dyskinesia</e2>_5\NN\14084880 were_6\VBD\836236 duration_7\NN\15113229 of_8\IN\1740 levodopa_9\NN\14604959 therapy_10\NN\657604 ,_11\,\1740 onset_12\NN\7325190 age_13\NN\4916342 ,_14\,\1740 and_15\CC\1740 total_16\JJ\1740 daily_17\JJ\1740 <e1>levodopa</e1>_18\NN\14604959 dose_19\NN\3740161 ._20\.\1740
D007980_D004409 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 prevalence_3\NN\4764412 of_4\IN\1740 <e1>levodopa-induced</e1>_5\JJ\1740 <e2>dyskinesia</e2>_6\NN\14084880 in_7\IN\13603305 our_8\PRP$\1740 patients_9\NNS\9898892 was_10\VBD\836236 44_11\CD\1740 %_12\NN\1740 ._13\.\1740
D007980_D010300 NONE risk_0\NN\14541044 factors_1\NNS\7326557 and_2\CC\1740 predictors_3\NNS\10756433 of_4\IN\1740 <e1>levodopa-induced</e1>_5\JJ\1740 dyskinesia_6\NN\14084880 among_7\IN\1740 multiethnic_8\JJ\1740 malaysians_9\NNPS\9641757 with_10\IN\1740 <e2>parkinson_11\NNP\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 ._14\.\1740
D007980_D010300 NONE chronic_0\JJ\1740 pulsatile_1\JJ\1740 <e1>levodopa</e1>_2\NN\14604959 therapy_3\NN\657604 for_4\IN\1740 <e2>parkinson_5\NN\1740 's_6\POS\1740 disease</e2>_7\NN\14061805 (_8\-LRB-\1740 pd_9\NN\14625458 )_10\-RRB-\1740 leads_11\VBZ\1752884 to_12\TO\1740 the_13\DT\1740 development_14\NN\248977 of_15\IN\1740 motor_16\NN\3699975 fluctuations_17\NNS\7345593 and_18\CC\1740 dyskinesia_19\NN\14084880 ._20\.\1740
D007980_D010300 NONE chronic_0\JJ\1740 pulsatile_1\JJ\1740 <e1>levodopa</e1>_2\NN\14604959 therapy_3\NN\657604 for_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 (_8\-LRB-\1740 <e2>pd</e2>_9\NN\14625458 )_10\-RRB-\1740 leads_11\VBZ\1752884 to_12\TO\1740 the_13\DT\1740 development_14\NN\248977 of_15\IN\1740 motor_16\NN\3699975 fluctuations_17\NNS\7345593 and_18\CC\1740 dyskinesia_19\NN\14084880 ._20\.\1740
D007980_D010300 NONE we_0\PRP\1740 studied_1\VBD\630380 the_2\DT\1740 prevalence_3\NN\4764412 and_4\CC\1740 predictors_5\NNS\10756433 of_6\IN\1740 <e1>levodopa-induced</e1>_7\JJ\1740 dyskinesia_8\NN\14084880 among_9\IN\1740 multiethnic_10\JJ\1740 malaysian_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>pd</e2>_14\NN\14625458 ._15\.\1740
D007980_D010300 NONE methods_0\NNS\5616786 :_1\:\1740 this_2\DT\1740 is_3\VBZ\836236 a_4\DT\13649268 cross-sectional_5\JJ\1740 study_6\NN\635850 involving_7\VBG\2676054 95_8\CD\1740 patients_9\NNS\9898892 with_10\IN\1740 <e2>pd</e2>_11\NN\14625458 on_12\IN\1740 uninterrupted_13\JJ\1740 <e1>levodopa</e1>_14\NN\14604959 therapy_15\NN\657604 for_16\IN\1740 at_17\IN\14622893 least_18\JJS\1740 6_19\CD\13741022 months_20\NNS\15113229 ._21\.\1740
24588023
D014148_D012640 CID the_0\DT\1740 association_1\NN\8008335 between_2\IN\1740 <e1>tranexamic_3\JJ\1740 acid</e1>_4\NN\14818238 and_5\CC\1740 <e2>convulsive</e2>_6\JJ\1740 seizures_7\NNS\14081375 after_8\IN\1740 cardiac_9\JJ\1740 surgery_10\NN\6045562 :_11\:\1740 a_12\DT\13649268 multivariate_13\JJ\1740 analysis_14\NN\633864 in_15\IN\13603305 11_16\CD\13745420 529_17\CD\1740 patients_18\NNS\9898892 ._19\.\1740
D014148_D012640 CID the_0\DT\1740 association_1\NN\8008335 between_2\IN\1740 <e1>tranexamic_3\JJ\1740 acid</e1>_4\NN\14818238 and_5\CC\1740 convulsive_6\JJ\1740 <e2>seizures</e2>_7\NNS\14081375 after_8\IN\1740 cardiac_9\JJ\1740 surgery_10\NN\6045562 :_11\:\1740 a_12\DT\13649268 multivariate_13\JJ\1740 analysis_14\NN\633864 in_15\IN\13603305 11_16\CD\13745420 529_17\CD\1740 patients_18\NNS\9898892 ._19\.\1740
D014148_D012640 CID independent_0\JJ\1740 predictors_1\NNS\10756433 of_2\IN\1740 postoperative_3\JJ\1740 <e2>seizures</e2>_4\NNS\14081375 included_5\VBD\690614 age_6\NN\4916342 ,_7\,\1740 female_8\NN\15388 sex_9\NN\13440063 ,_10\,\1740 redo_11\NN\1740 cardiac_12\JJ\1740 surgery_13\NN\6045562 ,_14\,\1740 calcification_15\NN\13446390 of_16\IN\1740 ascending_17\VBG\1835496 aorta_18\NN\5333777 ,_19\,\1740 congestive_20\JJ\1740 heart_21\NN\5919034 failure_22\NN\66216 ,_23\,\1740 deep_24\JJ\1740 hypothermic_25\JJ\1740 circulatory_26\JJ\1740 arrest_27\NN\88481 ,_28\,\1740 duration_29\NN\15113229 of_30\IN\1740 aortic_31\JJ\1740 cross-clamp_32\NN\1740 and_33\CC\1740 <e1>tranexamic_34\JJ\1740 acid</e1>_35\NN\14818238 ._36\.\1740
D014148_D012640 CID when_0\WRB\1740 tested_1\VBN\670261 in_2\IN\13603305 a_3\DT\13649268 multivariate_4\JJ\1740 regression_5\NN\14501726 analysis_6\NN\633864 ,_7\,\1740 <e1>tranexamic_8\NN\1740 acid</e1>_9\NN\14818238 was_10\VBD\836236 a_11\DT\13649268 strong_12\JJ\1740 independent_13\JJ\1740 predictor_14\NN\10756433 of_15\IN\1740 <e2>seizures</e2>_16\NNS\14081375 (_17\-LRB-\1740 or_18\NN\3541091 14.3_19\CD\1740 ,_20\,\1740 95_21\CD\1740 %_22\NN\1740 ci_23\NN\13635336 5.5_24\CD\1740 -_25\SYM\1740 36.7_26\CD\1740 ;_27\:\1740 p_28\NN\14622893 <_29\XX\1740 0.001_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D014148_D012640 CID as_0\IN\14622893 <e1>tranexamic_1\JJ\1740 acid</e1>_2\NN\14818238 is_3\VBZ\836236 the_4\DT\1740 only_5\JJ\1740 modifiable_6\JJ\1740 factor_7\NN\7326557 ,_8\,\1740 its_9\PRP$\6125041 administration_10\NN\1133281 ,_11\,\1740 particularly_12\RB\1740 in_13\IN\13603305 doses_14\NNS\3740161 exceeding_15\VBG\2673965 80_16\CD\13745420 mg.kg(-1_17\CD\1740 )_18\-RRB-\1740 ,_19\,\1740 should_20\MD\1740 be_21\VB\836236 weighed_22\VBN\2704349 against_23\IN\1740 the_24\DT\1740 risk_25\NN\14541044 of_26\IN\1740 postoperative_27\JJ\1740 <e2>seizures</e2>_28\NNS\14081375 ._29\.\1740
D014148_D006333 NONE independent_0\JJ\1740 predictors_1\NNS\10756433 of_2\IN\1740 postoperative_3\JJ\1740 seizures_4\NNS\14081375 included_5\VBD\690614 age_6\NN\4916342 ,_7\,\1740 female_8\NN\15388 sex_9\NN\13440063 ,_10\,\1740 redo_11\NN\1740 cardiac_12\JJ\1740 surgery_13\NN\6045562 ,_14\,\1740 calcification_15\NN\13446390 of_16\IN\1740 ascending_17\VBG\1835496 aorta_18\NN\5333777 ,_19\,\1740 <e2>congestive_20\JJ\1740 heart_21\NN\5919034 failure</e2>_22\NN\66216 ,_23\,\1740 deep_24\JJ\1740 hypothermic_25\JJ\1740 circulatory_26\JJ\1740 arrest_27\NN\88481 ,_28\,\1740 duration_29\NN\15113229 of_30\IN\1740 aortic_31\JJ\1740 cross-clamp_32\NN\1740 and_33\CC\1740 <e1>tranexamic_34\JJ\1740 acid</e1>_35\NN\14818238 ._36\.\1740
D014148_D007035 NONE independent_0\JJ\1740 predictors_1\NNS\10756433 of_2\IN\1740 postoperative_3\JJ\1740 seizures_4\NNS\14081375 included_5\VBD\690614 age_6\NN\4916342 ,_7\,\1740 female_8\NN\15388 sex_9\NN\13440063 ,_10\,\1740 redo_11\NN\1740 cardiac_12\JJ\1740 surgery_13\NN\6045562 ,_14\,\1740 calcification_15\NN\13446390 of_16\IN\1740 ascending_17\VBG\1835496 aorta_18\NN\5333777 ,_19\,\1740 congestive_20\JJ\1740 heart_21\NN\5919034 failure_22\NN\66216 ,_23\,\1740 deep_24\JJ\1740 <e2>hypothermic</e2>_25\JJ\1740 circulatory_26\JJ\1740 arrest_27\NN\88481 ,_28\,\1740 duration_29\NN\15113229 of_30\IN\1740 aortic_31\JJ\1740 cross-clamp_32\NN\1740 and_33\CC\1740 <e1>tranexamic_34\JJ\1740 acid</e1>_35\NN\14818238 ._36\.\1740
24040781
C107135_D011507 CID an_0\DT\6697703 unexpected_1\JJ\1740 diagnosis_2\NN\152018 in_3\IN\13603305 a_4\DT\13649268 renal-transplant_5\JJ\1740 patient_6\NN\9898892 with_7\IN\1740 <e2>proteinuria</e2>_8\NN\14299637 treated_9\VBN\2376958 with_10\IN\1740 <e1>everolimus</e1>_11\NN\1740 :_12\:\1740 al_13\NN\14625458 amyloidosis_14\NN\14061805 ._15\.\1740
C107135_D011507 CID in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 we_3\PRP\1740 report_4\VBP\831651 the_5\DT\1740 unexpected_6\JJ\1740 diagnosis_7\NN\152018 of_8\IN\1740 amyloidosis_9\NN\14061805 in_10\IN\13603305 a_11\DT\13649268 renal-transplant_12\JJ\1740 patient_13\NN\9898892 with_14\IN\1740 pre-transplant_15\JJ\1740 monoclonal_16\JJ\1740 gammapathy_17\NN\1740 of_18\IN\1740 undetermined_19\JJ\1740 significance_20\NN\5168261 who_21\WP\8299493 developed_22\VBD\1753788 <e2>proteinuria</e2>_23\NN\14299637 after_24\IN\1740 conversion_25\NN\7359599 from_26\IN\1740 tacrolimus_27\NN\1740 to_28\TO\1740 <e1>everolimus</e1>_29\NN\1740 ._30\.\1740
C107135_D000686 CID an_0\DT\6697703 unexpected_1\JJ\1740 diagnosis_2\NN\152018 in_3\IN\13603305 a_4\DT\13649268 renal-transplant_5\JJ\1740 patient_6\NN\9898892 with_7\IN\1740 proteinuria_8\NN\14299637 treated_9\VBN\2376958 with_10\IN\1740 <e1>everolimus</e1>_11\NN\1740 :_12\:\1740 <e2>al</e2>_13\NN\14625458 amyloidosis_14\NN\14061805 ._15\.\1740
C107135_D000686 CID an_0\DT\6697703 unexpected_1\JJ\1740 diagnosis_2\NN\152018 in_3\IN\13603305 a_4\DT\13649268 renal-transplant_5\JJ\1740 patient_6\NN\9898892 with_7\IN\1740 proteinuria_8\NN\14299637 treated_9\VBN\2376958 with_10\IN\1740 <e1>everolimus</e1>_11\NN\1740 :_12\:\1740 al_13\NN\14625458 <e2>amyloidosis</e2>_14\NN\14061805 ._15\.\1740
C107135_D000686 CID in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 we_3\PRP\1740 report_4\VBP\831651 the_5\DT\1740 unexpected_6\JJ\1740 diagnosis_7\NN\152018 of_8\IN\1740 <e2>amyloidosis</e2>_9\NN\14061805 in_10\IN\13603305 a_11\DT\13649268 renal-transplant_12\JJ\1740 patient_13\NN\9898892 with_14\IN\1740 pre-transplant_15\JJ\1740 monoclonal_16\JJ\1740 gammapathy_17\NN\1740 of_18\IN\1740 undetermined_19\JJ\1740 significance_20\NN\5168261 who_21\WP\8299493 developed_22\VBD\1753788 proteinuria_23\NN\14299637 after_24\IN\1740 conversion_25\NN\7359599 from_26\IN\1740 tacrolimus_27\NN\1740 to_28\TO\1740 <e1>everolimus</e1>_29\NN\1740 ._30\.\1740
D020123_D011507 NONE <e2>proteinuria</e2>_0\NNP\14299637 is_1\VBZ\836236 an_2\DT\6697703 expected_3\VBN\670261 complication_4\NN\1073995 in_5\IN\13603305 transplant_6\NN\5267548 patients_7\NNS\9898892 treated_8\VBN\2376958 with_9\IN\1740 mammalian_10\JJ\1740 target_11\NN\7258332 of_12\IN\1740 <e1>rapamycin</e1>_13\NN\1740 inhibitors_14\NNS\20090 (_15\-LRB-\1740 mtor-i_16\NNS\1740 )_17\-RRB-\1740 ._18\.\1740
D016559_D000686 NONE in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 we_3\PRP\1740 report_4\VBP\831651 the_5\DT\1740 unexpected_6\JJ\1740 diagnosis_7\NN\152018 of_8\IN\1740 <e2>amyloidosis</e2>_9\NN\14061805 in_10\IN\13603305 a_11\DT\13649268 renal-transplant_12\JJ\1740 patient_13\NN\9898892 with_14\IN\1740 pre-transplant_15\JJ\1740 monoclonal_16\JJ\1740 gammapathy_17\NN\1740 of_18\IN\1740 undetermined_19\JJ\1740 significance_20\NN\5168261 who_21\WP\8299493 developed_22\VBD\1753788 proteinuria_23\NN\14299637 after_24\IN\1740 conversion_25\NN\7359599 from_26\IN\1740 <e1>tacrolimus</e1>_27\NN\1740 to_28\TO\1740 everolimus_29\NN\1740 ._30\.\1740
D016559_D011507 NONE in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 we_3\PRP\1740 report_4\VBP\831651 the_5\DT\1740 unexpected_6\JJ\1740 diagnosis_7\NN\152018 of_8\IN\1740 amyloidosis_9\NN\14061805 in_10\IN\13603305 a_11\DT\13649268 renal-transplant_12\JJ\1740 patient_13\NN\9898892 with_14\IN\1740 pre-transplant_15\JJ\1740 monoclonal_16\JJ\1740 gammapathy_17\NN\1740 of_18\IN\1740 undetermined_19\JJ\1740 significance_20\NN\5168261 who_21\WP\8299493 developed_22\VBD\1753788 <e2>proteinuria</e2>_23\NN\14299637 after_24\IN\1740 conversion_25\NN\7359599 from_26\IN\1740 <e1>tacrolimus</e1>_27\NN\1740 to_28\TO\1740 everolimus_29\NN\1740 ._30\.\1740
6728873
D002110_D012640 CID five_0\CD\13741022 phenotypic_1\JJ\1740 characteristics_2\NNS\5849040 --_3\:\1740 locomotor_4\NN\1740 activity_5\NN\30358 ,_6\,\1740 righting_7\NN\1740 ability_8\NN\4723816 ,_9\,\1740 <e2>clonic_10\JJ\1740 seizure</e2>_11\JJ\1740 induction_12\NN\7450842 ,_13\,\1740 stress-induced_14\JJ\1740 lethality_15\NN\4790449 ,_16\,\1740 death_17\NN\7296428 without_18\IN\1740 external_19\JJ\1740 stress_20\NN\7083732 --_21\:\1740 were_22\VBD\836236 scored_23\VBN\1111028 at_24\IN\14622893 various_25\JJ\1740 <e1>caffeine</e1>_26\NN\14712692 doses_27\NNS\3740161 in_28\IN\13603305 drug-naive_29\JJ\1740 animals_30\NNS\4475 under_31\IN\1740 empirically_32\RB\1740 optimized_33\VBN\473572 ,_34\,\1740 rigidly_35\RB\1740 constant_36\JJ\1740 experimental_37\JJ\1740 conditions_38\NNS\14512817 ._39\.\1740
-1_D064420 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 behavioral_4\JJ\1740 <e2>toxicity</e2>_5\NN\13576101 testing_6\NN\639556 of_7\IN\1740 <e1>alkylxanthines</e1>_8\NNS\1740 in_9\IN\13603305 a_10\DT\13649268 single_11\JJ\1740 mouse_12\NN\2329401 strain_13\NN\7358060 may_14\MD\15209706 be_15\VB\836236 misleading_16\VBG\1999798 and_17\CC\1740 suggest_18\VBP\1010118 that_19\IN\1740 toxic_20\JJ\1740 responses_21\NNS\11410625 of_22\IN\1740 the_23\DT\1740 central_24\JJ\1740 nervous_25\JJ\1740 system_26\NN\3575240 to_27\TO\1740 this_28\DT\1740 class_29\NN\7951464 of_30\IN\1740 compounds_31\NNS\5869584 are_32\VBP\836236 genetically_33\RB\1740 influenced_34\VBN\137313 in_35\IN\13603305 mammals_36\NNS\1471682 ._37\.\1740
3375885
D007213_D006947 CID <e2>hyperkalemia</e2>_0\NN\14299637 induced_1\VBN\1627355 by_2\IN\1740 <e1>indomethacin</e1>_3\NN\3828465 and_4\CC\1740 naproxen_5\NN\3828465 and_6\CC\1740 reversed_7\VBN\109660 by_8\IN\1740 fludrocortisone_9\NN\1740 ._10\.\1740
D007213_D006947 CID we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 <e2>hyperkalemia</e2>_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 <e1>indomethacin</e1>_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D007213_D006947 CID because_0\IN\1740 he_1\PRP\14622893 was_2\VBD\836236 unable_3\JJ\1740 to_4\TO\1740 discontinue_5\VB\2609764 nonsteroidal_6\JJ\1740 anti-inflammatory_7\JJ\1740 drug_8\NN\14778436 therapy_9\NN\657604 ,_10\,\1740 fludrocortisone_11\NN\1740 was_12\VBD\836236 added_13\VBN\156601 ,_14\,\1740 correcting_15\VBG\138508 the_16\DT\1740 <e2>hyperkalemia</e2>_17\NN\14299637 and_18\CC\1740 allowing_19\VBG\797697 <e1>indomethacin</e1>_20\NN\3828465 therapy_21\NN\657604 to_22\TO\1740 be_23\VB\836236 continued_24\VBN\2367363 safely_25\RB\1740 ._26\.\1740
D009288_D006947 CID <e2>hyperkalemia</e2>_0\NN\14299637 induced_1\VBN\1627355 by_2\IN\1740 indomethacin_3\NN\3828465 and_4\CC\1740 <e1>naproxen</e1>_5\NN\3828465 and_6\CC\1740 reversed_7\VBN\109660 by_8\IN\1740 fludrocortisone_9\NN\1740 ._10\.\1740
D009288_D006947 CID we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 <e2>hyperkalemia</e2>_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 <e1>naproxen</e1>_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D005438_D006947 NONE <e2>hyperkalemia</e2>_0\NN\14299637 induced_1\VBN\1627355 by_2\IN\1740 indomethacin_3\NN\3828465 and_4\CC\1740 naproxen_5\NN\3828465 and_6\CC\1740 reversed_7\VBN\109660 by_8\IN\1740 <e1>fludrocortisone</e1>_9\NN\1740 ._10\.\1740
D005438_D006947 NONE because_0\IN\1740 he_1\PRP\14622893 was_2\VBD\836236 unable_3\JJ\1740 to_4\TO\1740 discontinue_5\VB\2609764 nonsteroidal_6\JJ\1740 anti-inflammatory_7\JJ\1740 drug_8\NN\14778436 therapy_9\NN\657604 ,_10\,\1740 <e1>fludrocortisone</e1>_11\NN\1740 was_12\VBD\836236 added_13\VBN\156601 ,_14\,\1740 correcting_15\VBG\138508 the_16\DT\1740 <e2>hyperkalemia</e2>_17\NN\14299637 and_18\CC\1740 allowing_19\VBG\797697 indomethacin_20\NN\3828465 therapy_21\NN\657604 to_22\TO\1740 be_23\VB\836236 continued_24\VBN\2367363 safely_25\RB\1740 ._26\.\1740
D008528_D001172 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 <e2>rheumatoid_7\JJ\1740 arthritis</e2>_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 <e1>mefenamic_13\JJ\1740 acid</e1>_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D008528_D007674 CID we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 <e1>mefenamic_13\JJ\1740 acid</e1>_14\NN\14818238 <e2>nephropathy</e2>_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D008528_D006947 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 <e1>mefenamic_13\JJ\1740 acid</e1>_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 <e2>hyperkalemia</e2>_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D008528_D006994 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 <e1>mefenamic_13\JJ\1740 acid</e1>_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 <e2>hypoaldosteronism</e2>_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D007213_D001172 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 <e2>rheumatoid_7\JJ\1740 arthritis</e2>_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 <e1>indomethacin</e1>_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D007213_D007674 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 <e2>nephropathy</e2>_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 <e1>indomethacin</e1>_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D007213_D006994 CID we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 <e2>hypoaldosteronism</e2>_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 <e1>indomethacin</e1>_26\NN\3828465 and_27\CC\1740 naproxen_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D009288_D001172 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 <e2>rheumatoid_7\JJ\1740 arthritis</e2>_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 <e1>naproxen</e1>_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D009288_D007674 NONE we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 <e2>nephropathy</e2>_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 hypoaldosteronism_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 <e1>naproxen</e1>_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D009288_D006994 CID we_0\PRP\1740 have_1\VBP\2108377 described_2\VBN\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 severe_6\JJ\1740 rheumatoid_7\JJ\1740 arthritis_8\NN\14171682 and_9\CC\1740 a_10\DT\13649268 history_11\NN\15120823 of_12\IN\1740 mefenamic_13\JJ\1740 acid_14\NN\14818238 nephropathy_15\NN\14573196 in_16\IN\13603305 whom_17\WP\1740 hyperkalemia_18\NN\14299637 and_19\CC\1740 inappropriate_20\JJ\1740 <e2>hypoaldosteronism</e2>_21\NN\1740 were_22\VBD\836236 caused_23\VBN\1617192 by_24\IN\1740 both_25\CC\1740 indomethacin_26\NN\3828465 and_27\CC\1740 <e1>naproxen</e1>_28\NN\3828465 ,_29\,\1740 without_30\IN\1740 major_31\JJ\1740 decline_32\NN\13458571 in_33\IN\13603305 renal_34\JJ\1740 function_35\NN\13783581 ._36\.\1740
D011453_D007674 NONE it_0\PRP\6125041 is_1\VBZ\836236 likely_2\JJ\1740 that_3\IN\1740 preexisting_4\VBG\2603699 <e2>renal_5\JJ\1740 disease</e2>_6\NN\14061805 predisposed_7\VBD\680841 this_8\DT\1740 patient_9\NN\9898892 to_10\TO\1740 type_11\NN\5839024 iv_12\CD\13741022 renal_13\JJ\1740 tubular_14\JJ\1740 acidosis_15\NN\14204950 with_16\IN\1740 <e1>prostaglandin</e1>_17\NN\5414534 synthetase_18\NN\1740 inhibitors_19\NNS\20090 ._20\.\1740
D011453_D006994 NONE it_0\PRP\6125041 is_1\VBZ\836236 likely_2\JJ\1740 that_3\IN\1740 preexisting_4\VBG\2603699 renal_5\JJ\1740 disease_6\NN\14061805 predisposed_7\VBD\680841 this_8\DT\1740 patient_9\NN\9898892 to_10\TO\1740 <e2>type_11\NN\5839024 iv_12\CD\13741022 renal_13\JJ\1740 tubular_14\JJ\1740 acidosis</e2>_15\NN\14204950 with_16\IN\1740 <e1>prostaglandin</e1>_17\NN\5414534 synthetase_18\NN\1740 inhibitors_19\NNS\20090 ._20\.\1740
9538487
D008094_D006944 CID <e2>hyperosmolar_0\JJ\1740 nonketotic_1\JJ\1740 coma</e2>_2\NN\5678932 precipitated_3\VBN\1642924 by_4\IN\1740 <e1>lithium-induced</e1>_5\JJ\1740 nephrogenic_6\JJ\1740 diabetes_7\NNS\14075199 insipidus_8\NN\1740 ._9\.\1740
D008094_D006944 CID a_0\DT\13649268 45-year-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 with_4\IN\1740 a_5\DT\13649268 10-year_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 manic_9\JJ\1740 depression_10\NN\14373582 treated_11\VBN\2376958 with_12\IN\1740 <e1>lithium</e1>_13\NN\14625458 ,_14\,\1740 was_15\VBD\836236 admitted_16\VBN\822367 with_17\IN\1740 <e2>hyperosmolar_18\JJ\1740 ,_19\,\1740 nonketotic_20\JJ\1740 coma</e2>_21\NN\5678932 ._22\.\1740
D008094_D018500 CID hyperosmolar_0\JJ\1740 nonketotic_1\JJ\1740 coma_2\NN\5678932 precipitated_3\VBN\1642924 by_4\IN\1740 <e1>lithium-induced</e1>_5\JJ\1740 <e2>nephrogenic_6\JJ\1740 diabetes_7\NNS\14075199 insipidus</e2>_8\NN\1740 ._9\.\1740
D008094_D018500 CID after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 hyperglycaemia_3\NN\14299637 ,_4\,\1740 he_5\PRP\14622893 remained_6\VBD\2604760 polyuric_7\JJ\1740 despite_8\IN\7501545 normal_9\JJ\1740 blood_10\NN\5397468 glucose_11\NN\14710501 concentrations_12\NNS\4916342 ;_13\:\1740 water_14\NN\14618834 deprivation_15\NN\14493145 testing_16\NN\639556 indicated_17\VBD\952524 <e2>nephrogenic_18\JJ\1740 diabetes_19\NNS\14075199 insipidus</e2>_20\NN\1740 ,_21\,\1740 likely_22\JJ\1740 to_23\TO\1740 be_24\VB\836236 <e1>lithium-induced</e1>_25\JJ\1740 ._26\.\1740
D008094_D001714 NONE a_0\DT\13649268 45-year-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 with_4\IN\1740 a_5\DT\13649268 10-year_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 <e2>manic_9\JJ\1740 depression</e2>_10\NN\14373582 treated_11\VBN\2376958 with_12\IN\1740 <e1>lithium</e1>_13\NN\14625458 ,_14\,\1740 was_15\VBD\836236 admitted_16\VBN\822367 with_17\IN\1740 hyperosmolar_18\JJ\1740 ,_19\,\1740 nonketotic_20\JJ\1740 coma_21\NN\5678932 ._22\.\1740
D005947_D011141 NONE he_0\PRP\14622893 gave_1\VBD\2327200 a_2\DT\13649268 five-year_3\JJ\1740 history_4\NN\15120823 of_5\IN\1740 <e2>polyuria</e2>_6\NN\14113228 and_7\CC\1740 polydipsia_8\NN\14040660 ,_9\,\1740 during_10\IN\1740 which_11\WDT\1740 time_12\NN\7308889 urinalysis_13\NN\646833 had_14\VBD\2108377 been_15\VBN\836236 negative_16\JJ\1740 for_17\IN\1740 <e1>glucose</e1>_18\NN\14710501 ._19\.\1740
D005947_D011141 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 hyperglycaemia_3\NN\14299637 ,_4\,\1740 he_5\PRP\14622893 remained_6\VBD\2604760 <e2>polyuric</e2>_7\JJ\1740 despite_8\IN\7501545 normal_9\JJ\1740 blood_10\NN\5397468 <e1>glucose</e1>_11\NN\14710501 concentrations_12\NNS\4916342 ;_13\:\1740 water_14\NN\14618834 deprivation_15\NN\14493145 testing_16\NN\639556 indicated_17\VBD\952524 nephrogenic_18\JJ\1740 diabetes_19\NNS\14075199 insipidus_20\NN\1740 ,_21\,\1740 likely_22\JJ\1740 to_23\TO\1740 be_24\VB\836236 lithium-induced_25\JJ\1740 ._26\.\1740
D005947_D059606 NONE he_0\PRP\14622893 gave_1\VBD\2327200 a_2\DT\13649268 five-year_3\JJ\1740 history_4\NN\15120823 of_5\IN\1740 polyuria_6\NN\14113228 and_7\CC\1740 <e2>polydipsia</e2>_8\NN\14040660 ,_9\,\1740 during_10\IN\1740 which_11\WDT\1740 time_12\NN\7308889 urinalysis_13\NN\646833 had_14\VBD\2108377 been_15\VBN\836236 negative_16\JJ\1740 for_17\IN\1740 <e1>glucose</e1>_18\NN\14710501 ._19\.\1740
D005947_-1 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 <e2>hyperglycaemia</e2>_3\NN\14299637 ,_4\,\1740 he_5\PRP\14622893 remained_6\VBD\2604760 polyuric_7\JJ\1740 despite_8\IN\7501545 normal_9\JJ\1740 blood_10\NN\5397468 <e1>glucose</e1>_11\NN\14710501 concentrations_12\NNS\4916342 ;_13\:\1740 water_14\NN\14618834 deprivation_15\NN\14493145 testing_16\NN\639556 indicated_17\VBD\952524 nephrogenic_18\JJ\1740 diabetes_19\NNS\14075199 insipidus_20\NN\1740 ,_21\,\1740 likely_22\JJ\1740 to_23\TO\1740 be_24\VB\836236 lithium-induced_25\JJ\1740 ._26\.\1740
D005947_D018500 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 hyperglycaemia_3\NN\14299637 ,_4\,\1740 he_5\PRP\14622893 remained_6\VBD\2604760 polyuric_7\JJ\1740 despite_8\IN\7501545 normal_9\JJ\1740 blood_10\NN\5397468 <e1>glucose</e1>_11\NN\14710501 concentrations_12\NNS\4916342 ;_13\:\1740 water_14\NN\14618834 deprivation_15\NN\14493145 testing_16\NN\639556 indicated_17\VBD\952524 <e2>nephrogenic_18\JJ\1740 diabetes_19\NNS\14075199 insipidus</e2>_20\NN\1740 ,_21\,\1740 likely_22\JJ\1740 to_23\TO\1740 be_24\VB\836236 lithium-induced_25\JJ\1740 ._26\.\1740
D008094_-1 NONE after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 <e2>hyperglycaemia</e2>_3\NN\14299637 ,_4\,\1740 he_5\PRP\14622893 remained_6\VBD\2604760 polyuric_7\JJ\1740 despite_8\IN\7501545 normal_9\JJ\1740 blood_10\NN\5397468 glucose_11\NN\14710501 concentrations_12\NNS\4916342 ;_13\:\1740 water_14\NN\14618834 deprivation_15\NN\14493145 testing_16\NN\639556 indicated_17\VBD\952524 nephrogenic_18\JJ\1740 diabetes_19\NNS\14075199 insipidus_20\NN\1740 ,_21\,\1740 likely_22\JJ\1740 to_23\TO\1740 be_24\VB\836236 <e1>lithium-induced</e1>_25\JJ\1740 ._26\.\1740
D008094_D011141 CID after_0\IN\1740 recovery_1\NN\7357388 from_2\IN\1740 hyperglycaemia_3\NN\14299637 ,_4\,\1740 he_5\PRP\14622893 remained_6\VBD\2604760 <e2>polyuric</e2>_7\JJ\1740 despite_8\IN\7501545 normal_9\JJ\1740 blood_10\NN\5397468 glucose_11\NN\14710501 concentrations_12\NNS\4916342 ;_13\:\1740 water_14\NN\14618834 deprivation_15\NN\14493145 testing_16\NN\639556 indicated_17\VBD\952524 nephrogenic_18\JJ\1740 diabetes_19\NNS\14075199 insipidus_20\NN\1740 ,_21\,\1740 likely_22\JJ\1740 to_23\TO\1740 be_24\VB\836236 <e1>lithium-induced</e1>_25\JJ\1740 ._26\.\1740
2239937
D002119_D006934 CID etiology_0\NN\7326557 of_1\IN\1740 <e2>hypercalcemia</e2>_2\NN\14299637 in_3\IN\13603305 hemodialysis_4\JJ\1740 patients_5\NNS\9898892 on_6\IN\1740 <e1>calcium_7\NN\14625458 carbonate</e1>_8\NN\15010703 therapy_9\NN\657604 ._10\.\1740
D002119_D006934 CID fourteen_0\CD\13745420 of_1\IN\1740 39_2\CD\1740 dialysis_3\NN\646833 patients_4\NNS\9898892 (_5\-LRB-\1740 36_6\CD\1740 %_7\NN\1740 )_8\-RRB-\1740 became_9\VBD\146138 <e2>hypercalcemic</e2>_10\JJ\1740 after_11\IN\1740 switching_12\NN\191142 to_13\TO\1740 <e1>calcium_14\NN\14625458 carbonate</e1>_15\NN\15010703 as_16\IN\14622893 their_17\PRP$\1740 principal_18\JJ\1740 phosphate_19\NN\15010703 binder_20\NN\3496892 ._21\.\1740
D010710_D006934 NONE fourteen_0\CD\13745420 of_1\IN\1740 39_2\CD\1740 dialysis_3\NN\646833 patients_4\NNS\9898892 (_5\-LRB-\1740 36_6\CD\1740 %_7\NN\1740 )_8\-RRB-\1740 became_9\VBD\146138 <e2>hypercalcemic</e2>_10\JJ\1740 after_11\IN\1740 switching_12\NN\191142 to_13\TO\1740 calcium_14\NN\14625458 carbonate_15\NN\15010703 as_16\IN\14622893 their_17\PRP$\1740 principal_18\JJ\1740 <e1>phosphate</e1>_19\NN\15010703 binder_20\NN\3496892 ._21\.\1740
D002118_D006934 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 identify_3\VB\699815 risk_4\NN\14541044 factors_5\NNS\7326557 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 development_9\NN\248977 of_10\IN\1740 <e2>hypercalcemia</e2>_11\NN\14299637 ,_12\,\1740 indirect_13\JJ\1740 parameters_14\NNS\5858936 of_15\IN\1740 intestinal_16\JJ\1740 <e1>calcium</e1>_17\NN\14625458 reabsorption_18\NN\13526110 and_19\CC\1740 bone_20\NN\5286536 turnover_21\NN\13819207 rate_22\NN\13815152 in_23\IN\13603305 these_24\DT\1740 14_25\CD\13745420 patients_26\NNS\9898892 were_27\VBD\836236 compared_28\VBN\644583 with_29\IN\1740 results_30\NNS\34213 in_31\IN\13603305 14_32\CD\13745420 eucalcemic_33\JJ\1740 patients_34\NNS\9898892 matched_35\VBN\2664769 for_36\IN\1740 age_37\NN\4916342 ,_38\,\1740 sex_39\NN\13440063 ,_40\,\1740 length_41\NN\5093581 of_42\IN\1740 time_43\NN\7308889 on_44\IN\1740 dialysis_45\NN\646833 ,_46\,\1740 and_47\CC\1740 etiology_48\NN\7326557 of_49\IN\1740 renal_50\JJ\1740 disease_51\NN\14061805 ._52\.\1740
D002118_D006934 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 experiencing_3\VBG\2108377 <e2>hypercalcemic</e2>_4\JJ\1740 episodes_5\NNS\7283608 with_6\IN\1740 peak_7\JJ\1740 <e1>calcium</e1>_8\NN\14625458 values_9\NNS\5941423 of_10\IN\1740 2.7_11\CD\1740 to_12\TO\1740 3.8_13\CD\1740 mmol/l_14\NN\1740 (_15\-LRB-\1740 10.7_16\CD\1740 to_17\TO\1740 15.0_18\CD\1740 mg/dl_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 patients_22\NNS\9898892 in_23\IN\13603305 the_24\DT\1740 hypercalcemic_25\JJ\1740 group_26\NN\2137 exhibited_27\VBD\2632167 a_28\DT\13649268 significant_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 the_32\DT\1740 mean_33\NN\6021761 calcium_34\NN\14625458 concentration_35\NN\4916342 obtained_36\VBN\2210855 during_37\IN\1740 6_38\CD\13741022 months_39\NNS\15113229 before_40\IN\1740 the_41\DT\1740 switch_42\NN\3096960 ,_43\,\1740 compared_44\VBN\644583 with_45\IN\1740 the_46\DT\1740 mean_47\NN\6021761 value_48\NN\5856066 obtained_49\VBN\2210855 during_50\IN\1740 the_51\DT\1740 7_52\CD\13741022 months_53\NNS\15113229 of_54\IN\1740 observation_55\NN\996969 after_56\IN\1740 the_57\DT\1740 switch_58\NN\3096960 (_59\-LRB-\1740 2.4_60\CD\1740 +/-_61\CC\1740 0.03_62\CD\1740 to_63\TO\1740 2.5_64\CD\1740 +/-_65\CC\1740 0.03_66\CD\1740 mmol/l_67\NN\1740 [_68\-LRB-\1740 9.7_69\CD\1740 +/-_70\CC\1740 0.2_71\CD\1740 to_72\TO\1740 10.2_73\CD\1740 +/-_74\CC\1740 0.1_75\CD\1740 mg/dl_76\NN\1740 ]_77\-RRB-\1740 ,_78\,\1740 p_79\NN\14622893 =_80\JJ\1740 0.006_81\CD\1740 )_82\-RRB-\1740 ._83\.\1740
D002118_D006934 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 experiencing_3\VBG\2108377 hypercalcemic_4\JJ\1740 episodes_5\NNS\7283608 with_6\IN\1740 peak_7\JJ\1740 <e1>calcium</e1>_8\NN\14625458 values_9\NNS\5941423 of_10\IN\1740 2.7_11\CD\1740 to_12\TO\1740 3.8_13\CD\1740 mmol/l_14\NN\1740 (_15\-LRB-\1740 10.7_16\CD\1740 to_17\TO\1740 15.0_18\CD\1740 mg/dl_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 patients_22\NNS\9898892 in_23\IN\13603305 the_24\DT\1740 <e2>hypercalcemic</e2>_25\JJ\1740 group_26\NN\2137 exhibited_27\VBD\2632167 a_28\DT\13649268 significant_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 the_32\DT\1740 mean_33\NN\6021761 calcium_34\NN\14625458 concentration_35\NN\4916342 obtained_36\VBN\2210855 during_37\IN\1740 6_38\CD\13741022 months_39\NNS\15113229 before_40\IN\1740 the_41\DT\1740 switch_42\NN\3096960 ,_43\,\1740 compared_44\VBN\644583 with_45\IN\1740 the_46\DT\1740 mean_47\NN\6021761 value_48\NN\5856066 obtained_49\VBN\2210855 during_50\IN\1740 the_51\DT\1740 7_52\CD\13741022 months_53\NNS\15113229 of_54\IN\1740 observation_55\NN\996969 after_56\IN\1740 the_57\DT\1740 switch_58\NN\3096960 (_59\-LRB-\1740 2.4_60\CD\1740 +/-_61\CC\1740 0.03_62\CD\1740 to_63\TO\1740 2.5_64\CD\1740 +/-_65\CC\1740 0.03_66\CD\1740 mmol/l_67\NN\1740 [_68\-LRB-\1740 9.7_69\CD\1740 +/-_70\CC\1740 0.2_71\CD\1740 to_72\TO\1740 10.2_73\CD\1740 +/-_74\CC\1740 0.1_75\CD\1740 mg/dl_76\NN\1740 ]_77\-RRB-\1740 ,_78\,\1740 p_79\NN\14622893 =_80\JJ\1740 0.006_81\CD\1740 )_82\-RRB-\1740 ._83\.\1740
D002118_D006934 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 experiencing_3\VBG\2108377 <e2>hypercalcemic</e2>_4\JJ\1740 episodes_5\NNS\7283608 with_6\IN\1740 peak_7\JJ\1740 calcium_8\NN\14625458 values_9\NNS\5941423 of_10\IN\1740 2.7_11\CD\1740 to_12\TO\1740 3.8_13\CD\1740 mmol/l_14\NN\1740 (_15\-LRB-\1740 10.7_16\CD\1740 to_17\TO\1740 15.0_18\CD\1740 mg/dl_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 patients_22\NNS\9898892 in_23\IN\13603305 the_24\DT\1740 hypercalcemic_25\JJ\1740 group_26\NN\2137 exhibited_27\VBD\2632167 a_28\DT\13649268 significant_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 the_32\DT\1740 mean_33\NN\6021761 <e1>calcium</e1>_34\NN\14625458 concentration_35\NN\4916342 obtained_36\VBN\2210855 during_37\IN\1740 6_38\CD\13741022 months_39\NNS\15113229 before_40\IN\1740 the_41\DT\1740 switch_42\NN\3096960 ,_43\,\1740 compared_44\VBN\644583 with_45\IN\1740 the_46\DT\1740 mean_47\NN\6021761 value_48\NN\5856066 obtained_49\VBN\2210855 during_50\IN\1740 the_51\DT\1740 7_52\CD\13741022 months_53\NNS\15113229 of_54\IN\1740 observation_55\NN\996969 after_56\IN\1740 the_57\DT\1740 switch_58\NN\3096960 (_59\-LRB-\1740 2.4_60\CD\1740 +/-_61\CC\1740 0.03_62\CD\1740 to_63\TO\1740 2.5_64\CD\1740 +/-_65\CC\1740 0.03_66\CD\1740 mmol/l_67\NN\1740 [_68\-LRB-\1740 9.7_69\CD\1740 +/-_70\CC\1740 0.2_71\CD\1740 to_72\TO\1740 10.2_73\CD\1740 +/-_74\CC\1740 0.1_75\CD\1740 mg/dl_76\NN\1740 ]_77\-RRB-\1740 ,_78\,\1740 p_79\NN\14622893 =_80\JJ\1740 0.006_81\CD\1740 )_82\-RRB-\1740 ._83\.\1740
D002118_D006934 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 experiencing_3\VBG\2108377 hypercalcemic_4\JJ\1740 episodes_5\NNS\7283608 with_6\IN\1740 peak_7\JJ\1740 calcium_8\NN\14625458 values_9\NNS\5941423 of_10\IN\1740 2.7_11\CD\1740 to_12\TO\1740 3.8_13\CD\1740 mmol/l_14\NN\1740 (_15\-LRB-\1740 10.7_16\CD\1740 to_17\TO\1740 15.0_18\CD\1740 mg/dl_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 patients_22\NNS\9898892 in_23\IN\13603305 the_24\DT\1740 <e2>hypercalcemic</e2>_25\JJ\1740 group_26\NN\2137 exhibited_27\VBD\2632167 a_28\DT\13649268 significant_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 the_32\DT\1740 mean_33\NN\6021761 <e1>calcium</e1>_34\NN\14625458 concentration_35\NN\4916342 obtained_36\VBN\2210855 during_37\IN\1740 6_38\CD\13741022 months_39\NNS\15113229 before_40\IN\1740 the_41\DT\1740 switch_42\NN\3096960 ,_43\,\1740 compared_44\VBN\644583 with_45\IN\1740 the_46\DT\1740 mean_47\NN\6021761 value_48\NN\5856066 obtained_49\VBN\2210855 during_50\IN\1740 the_51\DT\1740 7_52\CD\13741022 months_53\NNS\15113229 of_54\IN\1740 observation_55\NN\996969 after_56\IN\1740 the_57\DT\1740 switch_58\NN\3096960 (_59\-LRB-\1740 2.4_60\CD\1740 +/-_61\CC\1740 0.03_62\CD\1740 to_63\TO\1740 2.5_64\CD\1740 +/-_65\CC\1740 0.03_66\CD\1740 mmol/l_67\NN\1740 [_68\-LRB-\1740 9.7_69\CD\1740 +/-_70\CC\1740 0.2_71\CD\1740 to_72\TO\1740 10.2_73\CD\1740 +/-_74\CC\1740 0.1_75\CD\1740 mg/dl_76\NN\1740 ]_77\-RRB-\1740 ,_78\,\1740 p_79\NN\14622893 =_80\JJ\1740 0.006_81\CD\1740 )_82\-RRB-\1740 ._83\.\1740
D002118_D007674 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 identify_3\VB\699815 risk_4\NN\14541044 factors_5\NNS\7326557 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 development_9\NN\248977 of_10\IN\1740 hypercalcemia_11\NN\14299637 ,_12\,\1740 indirect_13\JJ\1740 parameters_14\NNS\5858936 of_15\IN\1740 intestinal_16\JJ\1740 <e1>calcium</e1>_17\NN\14625458 reabsorption_18\NN\13526110 and_19\CC\1740 bone_20\NN\5286536 turnover_21\NN\13819207 rate_22\NN\13815152 in_23\IN\13603305 these_24\DT\1740 14_25\CD\13745420 patients_26\NNS\9898892 were_27\VBD\836236 compared_28\VBN\644583 with_29\IN\1740 results_30\NNS\34213 in_31\IN\13603305 14_32\CD\13745420 eucalcemic_33\JJ\1740 patients_34\NNS\9898892 matched_35\VBN\2664769 for_36\IN\1740 age_37\NN\4916342 ,_38\,\1740 sex_39\NN\13440063 ,_40\,\1740 length_41\NN\5093581 of_42\IN\1740 time_43\NN\7308889 on_44\IN\1740 dialysis_45\NN\646833 ,_46\,\1740 and_47\CC\1740 etiology_48\NN\7326557 of_49\IN\1740 <e2>renal_50\JJ\1740 disease</e2>_51\NN\14061805 ._52\.\1740
2625524
D006220_D012640 NONE <e1>haloperidol</e1>_0\NNP\3713736 failed_1\VBD\1798936 to_2\TO\1740 prevent_3\VB\1740 amphetamine-induced_4\JJ\1740 <e2>seizures</e2>_5\NNS\14081375 ,_6\,\1740 but_7\CC\1740 did_8\VBD\1640855 lower_9\JJR\1740 the_10\DT\1740 mortality_11\NN\5054863 rate_12\NN\13815152 at_13\IN\14622893 most_14\JJS\1740 doses_15\NNS\3740161 tested_16\VBN\670261 ._17\.\1740
D006220_D012640 NONE <e1>haloperidol</e1>_0\NNP\3713736 decreased_1\VBD\169651 the_2\DT\1740 incidence_3\NN\13821570 of_4\IN\1740 cocaine-induced_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 at_7\IN\14622893 the_8\DT\1740 two_9\CD\13741022 highest_10\JJS\1740 doses_11\NNS\3740161 ,_12\,\1740 but_13\CC\1740 the_14\DT\1740 lowering_15\NN\351638 of_16\IN\1740 the_17\DT\1740 mortality_18\NN\5054863 rate_19\NN\13815152 did_20\VBD\1640855 not_21\RB\1740 reach_22\VB\2005948 statistical_23\JJ\1740 significance_24\NN\5168261 at_25\IN\14622893 any_26\DT\1740 dose_27\NN\3740161 ._28\.\1740
D006220_D012640 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 a_3\DT\13649268 protective_4\JJ\1740 role_5\NN\719494 for_6\IN\1740 the_7\DT\1740 central_8\JJ\1740 dopamine_9\NN\14807737 blocker_10\NN\10101634 <e1>haloperidol</e1>_11\NN\3713736 against_12\IN\1740 death_13\NN\7296428 from_14\IN\1740 high-dose_15\JJ\1740 amphetamine_16\NN\3248958 exposure_17\NN\5042871 without_18\IN\1740 reducing_19\VBG\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 <e2>seizures</e2>_23\NNS\14081375 ._24\.\1740
D006220_D012640 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>haloperidol</e1>_3\NN\3713736 demonstrated_4\VBD\2137132 an_5\DT\6697703 ability_6\NN\4723816 to_7\TO\1740 reduce_8\VB\441445 cocaine-induced_9\JJ\1740 <e2>seizures</e2>_10\NNS\14081375 without_11\IN\1740 significantly_12\RB\1740 reducing_13\VBG\441445 mortality_14\NN\5054863 ._15\.\1740
D000661_D012640 CID haloperidol_0\NNP\3713736 failed_1\VBD\1798936 to_2\TO\1740 prevent_3\VB\1740 <e1>amphetamine-induced</e1>_4\JJ\1740 <e2>seizures</e2>_5\NNS\14081375 ,_6\,\1740 but_7\CC\1740 did_8\VBD\1640855 lower_9\JJR\1740 the_10\DT\1740 mortality_11\NN\5054863 rate_12\NN\13815152 at_13\IN\14622893 most_14\JJS\1740 doses_15\NNS\3740161 tested_16\VBN\670261 ._17\.\1740
D000661_D012640 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 a_3\DT\13649268 protective_4\JJ\1740 role_5\NN\719494 for_6\IN\1740 the_7\DT\1740 central_8\JJ\1740 dopamine_9\NN\14807737 blocker_10\NN\10101634 haloperidol_11\NN\3713736 against_12\IN\1740 death_13\NN\7296428 from_14\IN\1740 high-dose_15\JJ\1740 <e1>amphetamine</e1>_16\NN\3248958 exposure_17\NN\5042871 without_18\IN\1740 reducing_19\VBG\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 <e2>seizures</e2>_23\NNS\14081375 ._24\.\1740
D003042_D012640 CID haloperidol_0\NNP\3713736 decreased_1\VBD\169651 the_2\DT\1740 incidence_3\NN\13821570 of_4\IN\1740 <e1>cocaine-induced</e1>_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 at_7\IN\14622893 the_8\DT\1740 two_9\CD\13741022 highest_10\JJS\1740 doses_11\NNS\3740161 ,_12\,\1740 but_13\CC\1740 the_14\DT\1740 lowering_15\NN\351638 of_16\IN\1740 the_17\DT\1740 mortality_18\NN\5054863 rate_19\NN\13815152 did_20\VBD\1640855 not_21\RB\1740 reach_22\VB\2005948 statistical_23\JJ\1740 significance_24\NN\5168261 at_25\IN\14622893 any_26\DT\1740 dose_27\NN\3740161 ._28\.\1740
D003042_D012640 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 haloperidol_3\NN\3713736 demonstrated_4\VBD\2137132 an_5\DT\6697703 ability_6\NN\4723816 to_7\TO\1740 reduce_8\VB\441445 <e1>cocaine-induced</e1>_9\JJ\1740 <e2>seizures</e2>_10\NNS\14081375 without_11\IN\1740 significantly_12\RB\1740 reducing_13\VBG\441445 mortality_14\NN\5054863 ._15\.\1740
D004298_D012640 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 a_3\DT\13649268 protective_4\JJ\1740 role_5\NN\719494 for_6\IN\1740 the_7\DT\1740 central_8\JJ\1740 <e1>dopamine</e1>_9\NN\14807737 blocker_10\NN\10101634 haloperidol_11\NN\3713736 against_12\IN\1740 death_13\NN\7296428 from_14\IN\1740 high-dose_15\JJ\1740 amphetamine_16\NN\3248958 exposure_17\NN\5042871 without_18\IN\1740 reducing_19\VBG\441445 the_20\DT\1740 incidence_21\NN\13821570 of_22\IN\1740 <e2>seizures</e2>_23\NNS\14081375 ._24\.\1740
11299446
C027429_D010302 CID worsening_0\NN\13457378 of_1\IN\1740 <e2>parkinsonism</e2>_2\NNP\14085708 after_3\IN\1740 the_4\DT\1740 use_5\NN\407535 of_6\IN\1740 <e1>veralipride</e1>_7\NN\1740 for_8\IN\1740 treatment_9\NN\654885 of_10\IN\1740 menopause_11\NN\15116532 :_12\:\1740 case_13\NN\7283608 report_14\NN\6470073 ._15\.\1740
C027429_D010302 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 female_3\JJ\1740 patient_4\NN\9898892 with_5\IN\1740 stable_6\JJ\1740 <e2>parkinson_7\NNP\1740 's_8\POS\1740 disease</e2>_9\NN\14061805 who_10\WP\8299493 has_11\VBZ\2108377 shown_12\VBN\2137132 a_13\DT\13649268 marked_14\JJ\1740 worsening_15\NN\13457378 of_16\IN\1740 her_17\PRP$\1740 motor_18\NN\3699975 functions_19\NNS\13783581 following_20\VBG\1835496 therapy_21\NN\657604 of_22\IN\1740 menopause_23\NN\15116532 related_24\JJ\1740 symptoms_25\NNS\5823932 with_26\IN\1740 <e1>veralipride</e1>_27\NN\1740 ,_28\,\1740 as_29\RB\1740 well_30\RB\1740 as_31\IN\14622893 the_32\DT\1740 improvement_33\NN\7359599 of_34\IN\1740 her_35\PRP$\1740 symptoms_36\NNS\5823932 back_37\RB\1740 to_38\TO\1740 baseline_39\NN\7260623 after_40\IN\1740 discontinuation_41\NN\209943 of_42\IN\1740 the_43\DT\1740 drug_44\NN\14778436 ._45\.\1740
3831029
C037293_D006333 NONE improvement_0\NN\7359599 by_1\IN\1740 <e1>denopamine</e1>_2\NN\1740 (_3\-LRB-\1740 ta-064_4\NN\1740 )_5\-RRB-\1740 of_6\IN\1740 pentobarbital-induced_7\JJ\1740 <e2>cardiac_8\JJ\1740 failure</e2>_9\NN\66216 in_10\IN\13603305 the_11\DT\1740 dog_12\NN\2083346 heart-lung_13\JJ\1740 preparation_14\NN\407535 ._15\.\1740
C037293_D006333 NONE improvement_0\NN\7359599 by_1\IN\1740 denopamine_2\NN\1740 (_3\-LRB-\1740 <e1>ta-064</e1>_4\NN\1740 )_5\-RRB-\1740 of_6\IN\1740 pentobarbital-induced_7\JJ\1740 <e2>cardiac_8\JJ\1740 failure</e2>_9\NN\66216 in_10\IN\13603305 the_11\DT\1740 dog_12\NN\2083346 heart-lung_13\JJ\1740 preparation_14\NN\407535 ._15\.\1740
C037293_D006333 NONE the_0\DT\1740 efficacy_1\NN\5199286 of_2\IN\1740 <e1>denopamine</e1>_3\NN\1740 ,_4\,\1740 an_5\DT\6697703 orally_6\RB\1740 active_7\JJ\1740 beta_8\NN\6828818 1-adrenoceptor_9\NN\1740 agonist_10\NN\9613191 ,_11\,\1740 in_12\IN\13603305 improving_13\VBG\126264 <e2>cardiac_14\JJ\1740 failure</e2>_15\NN\66216 was_16\VBD\836236 assessed_17\VBN\670261 in_18\IN\13603305 dog_19\NN\2083346 heart-lung_20\JJ\1740 preparations_21\NNS\407535 ._22\.\1740
C037293_D006333 NONE the_0\DT\1740 results_1\NNS\34213 warrant_2\VBP\1012073 clinical_3\JJ\1740 trials_4\NNS\786195 of_5\IN\1740 <e1>denopamine</e1>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 <e2>cardiac_11\JJ\1740 failure</e2>_12\NN\66216 ._13\.\1740
D010424_D006333 CID improvement_0\NN\7359599 by_1\IN\1740 denopamine_2\NN\1740 (_3\-LRB-\1740 ta-064_4\NN\1740 )_5\-RRB-\1740 of_6\IN\1740 <e1>pentobarbital-induced</e1>_7\JJ\1740 <e2>cardiac_8\JJ\1740 failure</e2>_9\NN\66216 in_10\IN\13603305 the_11\DT\1740 dog_12\NN\2083346 heart-lung_13\JJ\1740 preparation_14\NN\407535 ._15\.\1740
C037293_D001145 NONE no_0\DT\7204911 <e2>arrhythmias</e2>_1\NNS\14103288 were_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 these_5\DT\1740 doses_6\NNS\3740161 of_7\IN\1740 <e1>denopamine</e1>_8\NN\1740 ._9\.\1740
2974281
D011433_D006332 NONE subacute_0\NN\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>propranolol</e1>_3\NN\1740 and_4\CC\1740 b_5\NN\1355326 24/76_6\CD\1740 on_7\IN\1740 isoproterenol-induced_8\JJ\1740 rat_9\NN\2329401 <e2>heart_10\NN\5919034 hypertrophy</e2>_11\NN\14365950 in_12\IN\13603305 correlation_13\NN\13841213 with_14\IN\1740 blood_15\NN\5397468 pressure_16\NN\11419404 ._17\.\1740
D011433_D006332 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 investigations_3\NNS\5797597 did_4\VBD\1640855 not_5\RB\1740 provide_6\VB\2199590 any_7\DT\1740 evidence_8\NN\5816287 that_9\IN\1740 the_10\DT\1740 beta-receptor_11\NN\1740 blockers_12\NNS\10101634 <e1>propranolol</e1>_13\NN\1740 and_14\CC\1740 b_15\NN\1355326 24/76_16\CD\1740 have_17\VBP\2108377 the_18\DT\1740 potency_19\NN\5196375 to_20\TO\1740 prevent_21\VB\1740 isoproterenol_22\NN\3740161 from_23\IN\1740 producing_24\VBG\1617192 <e2>heart_25\NN\5919034 hypertrophy</e2>_26\NN\14365950 ._27\.\1740
D007545_D006332 CID subacute_0\NN\1740 effects_1\NNS\13245626 of_2\IN\1740 propranolol_3\NN\1740 and_4\CC\1740 b_5\NN\1355326 24/76_6\CD\1740 on_7\IN\1740 <e1>isoproterenol-induced</e1>_8\JJ\1740 rat_9\NN\2329401 <e2>heart_10\NN\5919034 hypertrophy</e2>_11\NN\14365950 in_12\IN\13603305 correlation_13\NN\13841213 with_14\IN\1740 blood_15\NN\5397468 pressure_16\NN\11419404 ._17\.\1740
D007545_D006332 CID the_0\DT\1740 studies_1\NNS\635850 were_2\VBD\836236 performed_3\VBN\2367363 using_4\VBG\1156834 an_5\DT\6697703 experimental_6\JJ\1740 model_7\NN\5888929 of_8\IN\1740 <e1>isoproterenol-induced</e1>_9\JJ\1740 <e2>heart_10\NN\5919034 hypertrophy</e2>_11\NN\14365950 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
D007545_D006332 CID thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 investigations_3\NNS\5797597 did_4\VBD\1640855 not_5\RB\1740 provide_6\VB\2199590 any_7\DT\1740 evidence_8\NN\5816287 that_9\IN\1740 the_10\DT\1740 beta-receptor_11\NN\1740 blockers_12\NNS\10101634 propranolol_13\NN\1740 and_14\CC\1740 b_15\NN\1355326 24/76_16\CD\1740 have_17\VBP\2108377 the_18\DT\1740 potency_19\NN\5196375 to_20\TO\1740 prevent_21\VB\1740 <e1>isoproterenol</e1>_22\NN\3740161 from_23\IN\1740 producing_24\VBG\1617192 <e2>heart_25\NN\5919034 hypertrophy</e2>_26\NN\14365950 ._27\.\1740
D009952_D006332 NONE it_0\PRP\6125041 was_1\VBD\836236 possible_2\JJ\1740 to_3\TO\1740 suppress_4\VB\2510337 the_5\DT\1740 increased_6\VBN\169651 <e1>ornithine</e1>_7\NN\14601829 decarboxylase_8\NN\14732946 activity_9\NN\30358 with_10\IN\1740 both_11\DT\1740 beta-blockers_12\NNS\1740 in_13\IN\13603305 <e2>hypertrophied_14\VBN\230746 hearts</e2>_15\NNS\496167 ,_16\,\1740 but_17\CC\1740 there_18\EX\27167 was_19\VBD\836236 no_20\DT\7204911 effect_21\NN\34213 on_22\IN\1740 the_23\DT\1740 heart_24\NN\5919034 mass_25\NN\13575869 ._26\.\1740
D011433_D006984 NONE neither_0\DT\1740 <e1>propranolol</e1>_1\NN\1740 nor_2\CC\1740 b_3\NN\1355326 24/76_4\CD\1740 could_5\MD\1740 stop_6\VB\2452885 the_7\DT\1740 changes_8\NNS\7283608 in_9\IN\13603305 the_10\DT\1740 characteristic_11\JJ\1740 myosin_12\NN\15022171 isoenzyme_13\NN\1740 pattern_14\NN\5726345 of_15\IN\1740 the_16\DT\1740 <e2>hypertrophied</e2>_17\VBN\230746 rat_18\NN\2329401 heart_19\NN\5919034 ._20\.\1740
24100257
C089750_D054549 CID <e2>takotsubo_0\VBN\1740 syndrome</e2>_1\NN\5870365 (_2\-LRB-\1740 or_3\CC\3541091 apical_4\JJ\1740 ballooning_5\NN\302394 syndrome_6\NN\5870365 )_7\-RRB-\1740 secondary_8\JJ\1740 to_9\IN\1740 <e1>zolmitriptan</e1>_10\NNP\1740 ._11\.\1740
C089750_D054549 CID takotsubo_0\VBN\1740 syndrome_1\NN\5870365 (_2\-LRB-\1740 or_3\CC\3541091 <e2>apical_4\JJ\1740 ballooning_5\NN\302394 syndrome</e2>_6\NN\5870365 )_7\-RRB-\1740 secondary_8\JJ\1740 to_9\IN\1740 <e1>zolmitriptan</e1>_10\NNP\1740 ._11\.\1740
C089750_D054549 CID extensive_0\JJ\1740 literature_1\NN\6362953 search_2\NN\407535 revealed_3\VBD\2137132 multiple_4\JJ\1740 cases_5\NNS\7283608 of_6\IN\1740 coronary_7\JJ\1740 artery_8\NN\5417975 vasospasm_9\NN\1740 secondary_10\JJ\1740 to_11\TO\1740 <e1>zolmitriptan</e1>_12\NN\1740 ,_13\,\1740 but_14\CC\1740 none_15\NN\15228378 of_16\IN\1740 the_17\DT\1740 cases_18\NNS\7283608 were_19\VBD\836236 associated_20\VBN\628491 with_21\IN\1740 <e2>ts</e2>_22\NN\14999913 ._23\.\1740
C089750_D008881 NONE detailed_0\JJ\1740 history_1\NN\15120823 obtained_2\VBN\2210855 retrospectively_3\RB\1740 revealed_4\VBD\2137132 that_5\IN\1740 the_6\DT\1740 patient_7\NN\9898892 took_8\VBD\2367363 <e1>zolmitriptan</e1>_9\NN\1740 sparingly_10\RB\1740 only_11\RB\1740 when_12\WRB\1740 she_13\PRP\1740 had_14\VBD\2108377 <e2>migraines</e2>_15\NNS\14326607 ._16\.\1740 but_17\CC\1740 before_18\IN\1740 this_19\DT\1740 event_20\NN\23100 ,_21\,\1740 she_22\PRP\1740 was_23\VBD\836236 taking_24\VBG\2367363 zolmitriptan_25\NN\1740 2_26\CD\13741022 -_27\SYM\1740 3_28\CD\13741022 times_29\NNS\15113229 daily_30\RB\1740 for_31\IN\1740 several_32\JJ\1740 days_33\NNS\15140892 because_34\IN\1740 of_35\IN\1740 a_36\DT\13649268 persistent_37\JJ\1740 migraine_38\NN\14326607 headache_39\NN\5829480 ._40\.\1740
C089750_D008881 NONE detailed_0\JJ\1740 history_1\NN\15120823 obtained_2\VBN\2210855 retrospectively_3\RB\1740 revealed_4\VBD\2137132 that_5\IN\1740 the_6\DT\1740 patient_7\NN\9898892 took_8\VBD\2367363 <e1>zolmitriptan</e1>_9\NN\1740 sparingly_10\RB\1740 only_11\RB\1740 when_12\WRB\1740 she_13\PRP\1740 had_14\VBD\2108377 migraines_15\NNS\14326607 ._16\.\1740 but_17\CC\1740 before_18\IN\1740 this_19\DT\1740 event_20\NN\23100 ,_21\,\1740 she_22\PRP\1740 was_23\VBD\836236 taking_24\VBG\2367363 zolmitriptan_25\NN\1740 2_26\CD\13741022 -_27\SYM\1740 3_28\CD\13741022 times_29\NNS\15113229 daily_30\RB\1740 for_31\IN\1740 several_32\JJ\1740 days_33\NNS\15140892 because_34\IN\1740 of_35\IN\1740 a_36\DT\13649268 persistent_37\JJ\1740 <e2>migraine_38\NN\14326607 headache</e2>_39\NN\5829480 ._40\.\1740
C089750_D008881 NONE detailed_0\JJ\1740 history_1\NN\15120823 obtained_2\VBN\2210855 retrospectively_3\RB\1740 revealed_4\VBD\2137132 that_5\IN\1740 the_6\DT\1740 patient_7\NN\9898892 took_8\VBD\2367363 zolmitriptan_9\NN\1740 sparingly_10\RB\1740 only_11\RB\1740 when_12\WRB\1740 she_13\PRP\1740 had_14\VBD\2108377 <e2>migraines</e2>_15\NNS\14326607 ._16\.\1740 but_17\CC\1740 before_18\IN\1740 this_19\DT\1740 event_20\NN\23100 ,_21\,\1740 she_22\PRP\1740 was_23\VBD\836236 taking_24\VBG\2367363 <e1>zolmitriptan</e1>_25\NN\1740 2_26\CD\13741022 -_27\SYM\1740 3_28\CD\13741022 times_29\NNS\15113229 daily_30\RB\1740 for_31\IN\1740 several_32\JJ\1740 days_33\NNS\15140892 because_34\IN\1740 of_35\IN\1740 a_36\DT\13649268 persistent_37\JJ\1740 migraine_38\NN\14326607 headache_39\NN\5829480 ._40\.\1740
C089750_D008881 NONE detailed_0\JJ\1740 history_1\NN\15120823 obtained_2\VBN\2210855 retrospectively_3\RB\1740 revealed_4\VBD\2137132 that_5\IN\1740 the_6\DT\1740 patient_7\NN\9898892 took_8\VBD\2367363 zolmitriptan_9\NN\1740 sparingly_10\RB\1740 only_11\RB\1740 when_12\WRB\1740 she_13\PRP\1740 had_14\VBD\2108377 migraines_15\NNS\14326607 ._16\.\1740 but_17\CC\1740 before_18\IN\1740 this_19\DT\1740 event_20\NN\23100 ,_21\,\1740 she_22\PRP\1740 was_23\VBD\836236 taking_24\VBG\2367363 <e1>zolmitriptan</e1>_25\NN\1740 2_26\CD\13741022 -_27\SYM\1740 3_28\CD\13741022 times_29\NNS\15113229 daily_30\RB\1740 for_31\IN\1740 several_32\JJ\1740 days_33\NNS\15140892 because_34\IN\1740 of_35\IN\1740 a_36\DT\13649268 persistent_37\JJ\1740 <e2>migraine_38\NN\14326607 headache</e2>_39\NN\5829480 ._40\.\1740
C089750_D003329 CID extensive_0\JJ\1740 literature_1\NN\6362953 search_2\NN\407535 revealed_3\VBD\2137132 multiple_4\JJ\1740 cases_5\NNS\7283608 of_6\IN\1740 <e2>coronary_7\JJ\1740 artery_8\NN\5417975 vasospasm</e2>_9\NN\1740 secondary_10\JJ\1740 to_11\TO\1740 <e1>zolmitriptan</e1>_12\NN\1740 ,_13\,\1740 but_14\CC\1740 none_15\NN\15228378 of_16\IN\1740 the_17\DT\1740 cases_18\NNS\7283608 were_19\VBD\836236 associated_20\VBN\628491 with_21\IN\1740 ts_22\NN\14999913 ._23\.\1740
15987266
D003513_D004827 NONE growth-associated_0\JJ\1740 protein_1\NN\14944888 43_2\CD\1740 expression_3\NN\4679549 in_4\IN\13603305 hippocampal_5\NN\1740 molecular_6\JJ\1740 layer_7\NN\21939 of_8\IN\1740 chronic_9\JJ\1740 <e2>epileptic</e2>_10\JJ\1740 rats_11\NNS\2329401 treated_12\VBN\2376958 with_13\IN\1740 <e1>cycloheximide</e1>_14\NN\1740 ._15\.\1740
D010862_D013226 CID to_0\TO\1740 investigate_1\VB\644583 how_2\WRB\1740 gap43_3\NN\1740 expression_4\NN\4679549 (_5\-LRB-\1740 gap43-ir_6\NN\1740 )_7\-RRB-\1740 correlates_8\VBZ\2657219 with_9\IN\1740 mfs_10\NN\5056490 ,_11\,\1740 we_12\PRP\1740 assessed_13\VBD\670261 the_14\DT\1740 intensity_15\NN\5090441 (_16\-LRB-\1740 densitometry_17\NN\996969 )_18\-RRB-\1740 and_19\CC\1740 extension_20\NN\15272029 (_21\-LRB-\1740 width_22\NN\5093581 )_23\-RRB-\1740 of_24\IN\1740 gap43-ir_25\NN\1740 in_26\IN\13603305 the_27\DT\1740 inner_28\JJ\1740 molecular_29\JJ\1740 layer_30\NN\21939 of_31\IN\1740 the_32\DT\1740 dentate_33\NN\1740 gyrus_34\NN\5225602 (_35\-LRB-\1740 iml_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 rats_39\NNS\2329401 subject_40\JJ\1740 to_41\TO\1740 <e2>status_42\NN\24720 epilepticus</e2>_43\NN\1740 induced_44\VBN\1627355 by_45\IN\1740 <e1>pilocarpine</e1>_46\NN\14712692 (_47\-LRB-\1740 pilo_48\NN\1740 )_49\-RRB-\1740 ,_50\,\1740 previously_51\RB\1740 injected_52\VBN\81072 or_53\CC\3541091 not_54\RB\1740 with_55\IN\1740 cycloheximide_56\NN\1740 (_57\-LRB-\1740 chx_58\NN\1740 )_59\-RRB-\1740 ,_60\,\1740 which_61\WDT\1740 has_62\VBZ\2108377 been_63\VBN\836236 shown_64\VBN\2137132 to_65\TO\1740 inhibit_66\VB\2510337 mfs_67\NNP\5056490 ._68\.\1740
D010862_D013226 CID to_0\TO\1740 investigate_1\VB\644583 how_2\WRB\1740 gap43_3\NN\1740 expression_4\NN\4679549 (_5\-LRB-\1740 gap43-ir_6\NN\1740 )_7\-RRB-\1740 correlates_8\VBZ\2657219 with_9\IN\1740 mfs_10\NN\5056490 ,_11\,\1740 we_12\PRP\1740 assessed_13\VBD\670261 the_14\DT\1740 intensity_15\NN\5090441 (_16\-LRB-\1740 densitometry_17\NN\996969 )_18\-RRB-\1740 and_19\CC\1740 extension_20\NN\15272029 (_21\-LRB-\1740 width_22\NN\5093581 )_23\-RRB-\1740 of_24\IN\1740 gap43-ir_25\NN\1740 in_26\IN\13603305 the_27\DT\1740 inner_28\JJ\1740 molecular_29\JJ\1740 layer_30\NN\21939 of_31\IN\1740 the_32\DT\1740 dentate_33\NN\1740 gyrus_34\NN\5225602 (_35\-LRB-\1740 iml_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 rats_39\NNS\2329401 subject_40\JJ\1740 to_41\TO\1740 <e2>status_42\NN\24720 epilepticus</e2>_43\NN\1740 induced_44\VBN\1627355 by_45\IN\1740 pilocarpine_46\NN\14712692 (_47\-LRB-\1740 <e1>pilo</e1>_48\NN\1740 )_49\-RRB-\1740 ,_50\,\1740 previously_51\RB\1740 injected_52\VBN\81072 or_53\CC\3541091 not_54\RB\1740 with_55\IN\1740 cycloheximide_56\NN\1740 (_57\-LRB-\1740 chx_58\NN\1740 )_59\-RRB-\1740 ,_60\,\1740 which_61\WDT\1740 has_62\VBZ\2108377 been_63\VBN\836236 shown_64\VBN\2137132 to_65\TO\1740 inhibit_66\VB\2510337 mfs_67\NNP\5056490 ._68\.\1740
D003513_D013226 NONE to_0\TO\1740 investigate_1\VB\644583 how_2\WRB\1740 gap43_3\NN\1740 expression_4\NN\4679549 (_5\-LRB-\1740 gap43-ir_6\NN\1740 )_7\-RRB-\1740 correlates_8\VBZ\2657219 with_9\IN\1740 mfs_10\NN\5056490 ,_11\,\1740 we_12\PRP\1740 assessed_13\VBD\670261 the_14\DT\1740 intensity_15\NN\5090441 (_16\-LRB-\1740 densitometry_17\NN\996969 )_18\-RRB-\1740 and_19\CC\1740 extension_20\NN\15272029 (_21\-LRB-\1740 width_22\NN\5093581 )_23\-RRB-\1740 of_24\IN\1740 gap43-ir_25\NN\1740 in_26\IN\13603305 the_27\DT\1740 inner_28\JJ\1740 molecular_29\JJ\1740 layer_30\NN\21939 of_31\IN\1740 the_32\DT\1740 dentate_33\NN\1740 gyrus_34\NN\5225602 (_35\-LRB-\1740 iml_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 rats_39\NNS\2329401 subject_40\JJ\1740 to_41\TO\1740 <e2>status_42\NN\24720 epilepticus</e2>_43\NN\1740 induced_44\VBN\1627355 by_45\IN\1740 pilocarpine_46\NN\14712692 (_47\-LRB-\1740 pilo_48\NN\1740 )_49\-RRB-\1740 ,_50\,\1740 previously_51\RB\1740 injected_52\VBN\81072 or_53\CC\3541091 not_54\RB\1740 with_55\IN\1740 <e1>cycloheximide</e1>_56\NN\1740 (_57\-LRB-\1740 chx_58\NN\1740 )_59\-RRB-\1740 ,_60\,\1740 which_61\WDT\1740 has_62\VBZ\2108377 been_63\VBN\836236 shown_64\VBN\2137132 to_65\TO\1740 inhibit_66\VB\2510337 mfs_67\NNP\5056490 ._68\.\1740
D003513_D013226 NONE to_0\TO\1740 investigate_1\VB\644583 how_2\WRB\1740 gap43_3\NN\1740 expression_4\NN\4679549 (_5\-LRB-\1740 gap43-ir_6\NN\1740 )_7\-RRB-\1740 correlates_8\VBZ\2657219 with_9\IN\1740 mfs_10\NN\5056490 ,_11\,\1740 we_12\PRP\1740 assessed_13\VBD\670261 the_14\DT\1740 intensity_15\NN\5090441 (_16\-LRB-\1740 densitometry_17\NN\996969 )_18\-RRB-\1740 and_19\CC\1740 extension_20\NN\15272029 (_21\-LRB-\1740 width_22\NN\5093581 )_23\-RRB-\1740 of_24\IN\1740 gap43-ir_25\NN\1740 in_26\IN\13603305 the_27\DT\1740 inner_28\JJ\1740 molecular_29\JJ\1740 layer_30\NN\21939 of_31\IN\1740 the_32\DT\1740 dentate_33\NN\1740 gyrus_34\NN\5225602 (_35\-LRB-\1740 iml_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 rats_39\NNS\2329401 subject_40\JJ\1740 to_41\TO\1740 <e2>status_42\NN\24720 epilepticus</e2>_43\NN\1740 induced_44\VBN\1627355 by_45\IN\1740 pilocarpine_46\NN\14712692 (_47\-LRB-\1740 pilo_48\NN\1740 )_49\-RRB-\1740 ,_50\,\1740 previously_51\RB\1740 injected_52\VBN\81072 or_53\CC\3541091 not_54\RB\1740 with_55\IN\1740 cycloheximide_56\NN\1740 (_57\-LRB-\1740 <e1>chx</e1>_58\NN\1740 )_59\-RRB-\1740 ,_60\,\1740 which_61\WDT\1740 has_62\VBZ\2108377 been_63\VBN\836236 shown_64\VBN\2137132 to_65\TO\1740 inhibit_66\VB\2510337 mfs_67\NNP\5056490 ._68\.\1740
19728177
D000082_D017114 CID method_0\NN\5616786 :_1\:\1740 case-based_2\JJ\1740 observations_3\NNS\996969 from_4\IN\1740 a_5\DT\13649268 medical_6\JJ\1740 intensive_7\JJ\1740 care_8\NN\575741 unit_9\NN\13576101 (_10\-LRB-\1740 micu_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 a_14\DT\13649268 tertiary_15\JJ\1740 care_16\NN\575741 facility_17\NN\21939 in_18\IN\13603305 a_19\DT\13649268 27-year-old_20\JJ\1740 female_21\NN\15388 with_22\IN\1740 <e2>fhf</e2>_23\NN\1740 from_24\IN\1740 <e1>acetaminophen</e1>_25\NN\2707683 and_26\CC\1740 resultant_27\JJ\1740 cerebral_28\JJ\1740 edema_29\NN\14315192 ._30\.\1740
D000082_D017114 CID initial_0\JJ\1740 evaluation_1\NN\874067 confirmed_2\VBD\1011725 <e2>fhf</e2>_3\NN\1740 from_4\IN\1740 <e1>acetaminophen</e1>_5\NN\2707683 and_6\CC\1740 cerebral_7\JJ\1740 edema_8\NN\14315192 ._9\.\1740
D000082_D017114 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 <e2>fhf</e2>_5\NN\1740 and_6\CC\1740 cerebral_7\JJ\1740 edema_8\NN\14315192 from_9\IN\1740 <e1>acetaminophen</e1>_10\JJ\1740 overdose_11\NN\1740 ,_12\,\1740 prolonged_13\JJ\1740 therapeutic_14\JJ\1740 hypothermia_15\NN\14034177 could_16\MD\1740 potentially_17\RB\1740 be_18\VB\836236 used_19\VBN\1156834 as_20\IN\14622893 a_21\DT\13649268 life_22\NN\13954253 saving_23\NN\37396 therapy_24\NN\657604 and_25\CC\1740 a_26\DT\13649268 bridge_27\NN\4341686 to_28\TO\1740 hepatic_29\JJ\1740 and_30\CC\1740 neurological_31\JJ\1740 recovery_32\NN\7357388 ._33\.\1740
D000082_D001929 CID method_0\NN\5616786 :_1\:\1740 case-based_2\JJ\1740 observations_3\NNS\996969 from_4\IN\1740 a_5\DT\13649268 medical_6\JJ\1740 intensive_7\JJ\1740 care_8\NN\575741 unit_9\NN\13576101 (_10\-LRB-\1740 micu_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 a_14\DT\13649268 tertiary_15\JJ\1740 care_16\NN\575741 facility_17\NN\21939 in_18\IN\13603305 a_19\DT\13649268 27-year-old_20\JJ\1740 female_21\NN\15388 with_22\IN\1740 fhf_23\NN\1740 from_24\IN\1740 <e1>acetaminophen</e1>_25\NN\2707683 and_26\CC\1740 resultant_27\JJ\1740 <e2>cerebral_28\JJ\1740 edema</e2>_29\NN\14315192 ._30\.\1740
D000082_D001929 CID initial_0\JJ\1740 evaluation_1\NN\874067 confirmed_2\VBD\1011725 fhf_3\NN\1740 from_4\IN\1740 <e1>acetaminophen</e1>_5\NN\2707683 and_6\CC\1740 <e2>cerebral_7\JJ\1740 edema</e2>_8\NN\14315192 ._9\.\1740
D000082_D001929 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 fhf_5\NN\1740 and_6\CC\1740 <e2>cerebral_7\JJ\1740 edema</e2>_8\NN\14315192 from_9\IN\1740 <e1>acetaminophen</e1>_10\JJ\1740 overdose_11\NN\1740 ,_12\,\1740 prolonged_13\JJ\1740 therapeutic_14\JJ\1740 hypothermia_15\NN\14034177 could_16\MD\1740 potentially_17\RB\1740 be_18\VB\836236 used_19\VBN\1156834 as_20\IN\14622893 a_21\DT\13649268 life_22\NN\13954253 saving_23\NN\37396 therapy_24\NN\657604 and_25\CC\1740 a_26\DT\13649268 bridge_27\NN\4341686 to_28\TO\1740 hepatic_29\JJ\1740 and_30\CC\1740 neurological_31\JJ\1740 recovery_32\NN\7357388 ._33\.\1740
D000082_D064420 NONE results_0\NNS\34213 :_1\:\1740 our_2\PRP$\1740 patient_3\NN\9898892 was_4\VBD\836236 admitted_5\VBN\822367 to_6\TO\1740 the_7\DT\1740 micu_8\NN\1740 after_9\IN\1740 being_10\VBG\836236 found_11\VBN\2426171 unresponsive_12\JJ\1740 with_13\IN\1740 presumed_14\VBN\719734 <e2>toxicity</e2>_15\NN\13576101 from_16\IN\1740 <e1>acetaminophen</e1>_17\NN\2707683 which_18\WDT\1740 was_19\VBD\836236 ingested_20\VBN\597915 over_21\IN\5867413 a_22\DT\13649268 2-day_23\JJ\1740 period_24\NN\13575869 ._25\.\1740
D000082_D062787 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 fhf_5\NN\1740 and_6\CC\1740 cerebral_7\JJ\1740 edema_8\NN\14315192 from_9\IN\1740 <e1>acetaminophen</e1>_10\JJ\1740 <e2>overdose</e2>_11\NN\1740 ,_12\,\1740 prolonged_13\JJ\1740 therapeutic_14\JJ\1740 hypothermia_15\NN\14034177 could_16\MD\1740 potentially_17\RB\1740 be_18\VB\836236 used_19\VBN\1156834 as_20\IN\14622893 a_21\DT\13649268 life_22\NN\13954253 saving_23\NN\37396 therapy_24\NN\657604 and_25\CC\1740 a_26\DT\13649268 bridge_27\NN\4341686 to_28\TO\1740 hepatic_29\JJ\1740 and_30\CC\1740 neurological_31\JJ\1740 recovery_32\NN\7357388 ._33\.\1740
D000082_D007035 NONE conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 fhf_5\NN\1740 and_6\CC\1740 cerebral_7\JJ\1740 edema_8\NN\14315192 from_9\IN\1740 <e1>acetaminophen</e1>_10\JJ\1740 overdose_11\NN\1740 ,_12\,\1740 prolonged_13\JJ\1740 therapeutic_14\JJ\1740 <e2>hypothermia</e2>_15\NN\14034177 could_16\MD\1740 potentially_17\RB\1740 be_18\VB\836236 used_19\VBN\1156834 as_20\IN\14622893 a_21\DT\13649268 life_22\NN\13954253 saving_23\NN\37396 therapy_24\NN\657604 and_25\CC\1740 a_26\DT\13649268 bridge_27\NN\4341686 to_28\TO\1740 hepatic_29\JJ\1740 and_30\CC\1740 neurological_31\JJ\1740 recovery_32\NN\7357388 ._33\.\1740
19531695
D005424_D003693 CID <e2>delirium</e2>_0\NN\14391660 in_1\IN\13603305 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 toxic_5\JJ\1740 <e1>flecainide</e1>_6\NN\2715941 plasma_7\NN\5398023 concentrations_8\NNS\4916342 :_9\:\1740 the_10\DT\1740 role_11\NN\719494 of_12\IN\1740 a_13\DT\13649268 pharmacokinetic_14\JJ\1740 drug_15\NN\14778436 interaction_16\NN\37396 with_17\IN\1740 paroxetine_18\NN\1740 ._19\.\1740
D005424_D003693 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>flecainide-induced</e1>_7\JJ\1740 <e2>delirium</e2>_8\NN\14391660 associated_9\VBN\628491 with_10\IN\1740 a_11\DT\13649268 pharmacokinetic_12\JJ\1740 drug_13\NN\14778436 interaction_14\NN\37396 with_15\IN\1740 paroxetine_16\NN\1740 ._17\.\1740
D005424_D003693 CID discussion_0\NN\6252138 :_1\:\1740 <e1>flecainide</e1>_2\NNP\2715941 and_3\CC\1740 pharmacologically_4\RB\1740 similar_5\JJ\1740 agents_6\NNS\7347 that_7\WDT\1740 interact_8\VBP\2367363 with_9\IN\1740 sodium_10\NN\14625458 channels_11\NNS\6251781 may_12\MD\15209706 cause_13\VB\1617192 <e2>delirium</e2>_14\NN\14391660 in_15\IN\13603305 susceptible_16\JJ\1740 patients_17\NNS\9898892 ._18\.\1740
D005424_D003693 CID a_0\DT\13649268 medline_1\NN\4402746 search_2\NN\407535 (_3\-LRB-\1740 1966-january_4\JJ\1740 2009_5\CD\1740 )_6\-RRB-\1740 revealed_7\VBD\2137132 one_8\CD\13741022 in_9\FW\13603305 vivo_10\FW\1740 pharmacokinetic_11\JJ\1740 study_12\NN\635850 on_13\IN\1740 the_14\DT\1740 interaction_15\NN\37396 between_16\IN\1740 <e1>flecainide</e1>_17\NN\2715941 ,_18\,\1740 a_19\DT\13649268 cyp2d6_20\NN\1740 substrate_21\NN\19613 ,_22\,\1740 and_23\CC\1740 paroxetine_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 cyp2d6_27\NN\1740 inhibitor_28\NN\20090 ,_29\,\1740 as_30\RB\1740 well_31\RB\1740 as_32\IN\14622893 3_33\CD\13741022 case_34\NN\7283608 reports_35\NNS\6470073 of_36\IN\1740 flecainide-induced_37\JJ\1740 <e2>delirium</e2>_38\NN\14391660 ._39\.\1740
D005424_D003693 CID a_0\DT\13649268 medline_1\NN\4402746 search_2\NN\407535 (_3\-LRB-\1740 1966-january_4\JJ\1740 2009_5\CD\1740 )_6\-RRB-\1740 revealed_7\VBD\2137132 one_8\CD\13741022 in_9\FW\13603305 vivo_10\FW\1740 pharmacokinetic_11\JJ\1740 study_12\NN\635850 on_13\IN\1740 the_14\DT\1740 interaction_15\NN\37396 between_16\IN\1740 flecainide_17\NN\2715941 ,_18\,\1740 a_19\DT\13649268 cyp2d6_20\NN\1740 substrate_21\NN\19613 ,_22\,\1740 and_23\CC\1740 paroxetine_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 cyp2d6_27\NN\1740 inhibitor_28\NN\20090 ,_29\,\1740 as_30\RB\1740 well_31\RB\1740 as_32\IN\14622893 3_33\CD\13741022 case_34\NN\7283608 reports_35\NNS\6470073 of_36\IN\1740 <e1>flecainide-induced</e1>_37\JJ\1740 <e2>delirium</e2>_38\NN\14391660 ._39\.\1740
D005424_D003693 CID according_0\VBG\2657219 to_1\IN\1740 the_2\DT\1740 naranjo_3\NNP\1740 probability_4\NN\33615 scale_5\NN\7260623 ,_6\,\1740 <e1>flecainide</e1>_7\NN\2715941 was_8\VBD\836236 the_9\DT\1740 probable_10\JJ\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 patient_14\NN\9898892 's_15\POS\1740 <e2>delirium</e2>_16\NN\14391660 ;_17\:\1740 the_18\DT\1740 horn_19\NNP\3827536 drug_20\NNP\14778436 interaction_21\NNP\37396 probability_22\NNP\33615 scale_23\NN\7260623 indicates_24\VBZ\952524 a_25\DT\13649268 possible_26\JJ\1740 pharmacokinetic_27\JJ\1740 drug_28\NN\14778436 interaction_29\NN\37396 between_30\IN\1740 flecainide_31\NN\2715941 and_32\CC\1740 paroxetine_33\NN\1740 ._34\.\1740
D005424_D003693 CID according_0\VBG\2657219 to_1\IN\1740 the_2\DT\1740 naranjo_3\NNP\1740 probability_4\NN\33615 scale_5\NN\7260623 ,_6\,\1740 flecainide_7\NN\2715941 was_8\VBD\836236 the_9\DT\1740 probable_10\JJ\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 patient_14\NN\9898892 's_15\POS\1740 <e2>delirium</e2>_16\NN\14391660 ;_17\:\1740 the_18\DT\1740 horn_19\NNP\3827536 drug_20\NNP\14778436 interaction_21\NNP\37396 probability_22\NNP\33615 scale_23\NN\7260623 indicates_24\VBZ\952524 a_25\DT\13649268 possible_26\JJ\1740 pharmacokinetic_27\JJ\1740 drug_28\NN\14778436 interaction_29\NN\37396 between_30\IN\1740 <e1>flecainide</e1>_31\NN\2715941 and_32\CC\1740 paroxetine_33\NN\1740 ._34\.\1740
D005424_D003693 CID conclusions_0\NNS\5837957 :_1\:\1740 supratherapeutic_2\JJ\1740 <e1>flecainide</e1>_3\JJ\1740 plasma_4\NN\5398023 concentrations_5\NNS\4916342 may_6\MD\15209706 cause_7\VB\1617192 <e2>delirium</e2>_8\NN\14391660 ._9\.\1740
D017374_D003693 CID <e2>delirium</e2>_0\NN\14391660 in_1\IN\13603305 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 toxic_5\JJ\1740 flecainide_6\NN\2715941 plasma_7\NN\5398023 concentrations_8\NNS\4916342 :_9\:\1740 the_10\DT\1740 role_11\NN\719494 of_12\IN\1740 a_13\DT\13649268 pharmacokinetic_14\JJ\1740 drug_15\NN\14778436 interaction_16\NN\37396 with_17\IN\1740 <e1>paroxetine</e1>_18\NN\1740 ._19\.\1740
D017374_D003693 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 flecainide-induced_7\JJ\1740 <e2>delirium</e2>_8\NN\14391660 associated_9\VBN\628491 with_10\IN\1740 a_11\DT\13649268 pharmacokinetic_12\JJ\1740 drug_13\NN\14778436 interaction_14\NN\37396 with_15\IN\1740 <e1>paroxetine</e1>_16\NN\1740 ._17\.\1740
D017374_D003693 CID a_0\DT\13649268 medline_1\NN\4402746 search_2\NN\407535 (_3\-LRB-\1740 1966-january_4\JJ\1740 2009_5\CD\1740 )_6\-RRB-\1740 revealed_7\VBD\2137132 one_8\CD\13741022 in_9\FW\13603305 vivo_10\FW\1740 pharmacokinetic_11\JJ\1740 study_12\NN\635850 on_13\IN\1740 the_14\DT\1740 interaction_15\NN\37396 between_16\IN\1740 flecainide_17\NN\2715941 ,_18\,\1740 a_19\DT\13649268 cyp2d6_20\NN\1740 substrate_21\NN\19613 ,_22\,\1740 and_23\CC\1740 <e1>paroxetine</e1>_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 cyp2d6_27\NN\1740 inhibitor_28\NN\20090 ,_29\,\1740 as_30\RB\1740 well_31\RB\1740 as_32\IN\14622893 3_33\CD\13741022 case_34\NN\7283608 reports_35\NNS\6470073 of_36\IN\1740 flecainide-induced_37\JJ\1740 <e2>delirium</e2>_38\NN\14391660 ._39\.\1740
D017374_D003693 CID according_0\VBG\2657219 to_1\IN\1740 the_2\DT\1740 naranjo_3\NNP\1740 probability_4\NN\33615 scale_5\NN\7260623 ,_6\,\1740 flecainide_7\NN\2715941 was_8\VBD\836236 the_9\DT\1740 probable_10\JJ\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 patient_14\NN\9898892 's_15\POS\1740 <e2>delirium</e2>_16\NN\14391660 ;_17\:\1740 the_18\DT\1740 horn_19\NNP\3827536 drug_20\NNP\14778436 interaction_21\NNP\37396 probability_22\NNP\33615 scale_23\NN\7260623 indicates_24\VBZ\952524 a_25\DT\13649268 possible_26\JJ\1740 pharmacokinetic_27\JJ\1740 drug_28\NN\14778436 interaction_29\NN\37396 between_30\IN\1740 flecainide_31\NN\2715941 and_32\CC\1740 <e1>paroxetine</e1>_33\NN\1740 ._34\.\1740
D005424_D001281 NONE <e1>flecainide</e1>_0\NNP\2715941 had_1\VBD\2108377 been_2\VBN\836236 started_3\VBN\2009433 2_4\CD\13741022 weeks_5\NNS\15113229 prior_6\RB\1740 for_7\IN\1740 <e2>atrial_8\JJ\1740 fibrillation</e2>_9\NN\14361664 ._10\.\1740
D012964_D003693 NONE discussion_0\NN\6252138 :_1\:\1740 flecainide_2\NNP\2715941 and_3\CC\1740 pharmacologically_4\RB\1740 similar_5\JJ\1740 agents_6\NNS\7347 that_7\WDT\1740 interact_8\VBP\2367363 with_9\IN\1740 <e1>sodium</e1>_10\NN\14625458 channels_11\NNS\6251781 may_12\MD\15209706 cause_13\VB\1617192 <e2>delirium</e2>_14\NN\14391660 in_15\IN\13603305 susceptible_16\JJ\1740 patients_17\NNS\9898892 ._18\.\1740
D005424_D064420 NONE because_0\IN\1740 <e2>toxicity</e2>_1\NN\13576101 may_2\MD\15209706 occur_3\VB\2623529 when_4\WRB\1740 <e1>flecainide</e1>_5\NN\2715941 is_6\VBZ\836236 prescribed_7\VBN\748282 with_8\IN\1740 paroxetine_9\NN\1740 and_10\CC\1740 other_11\JJ\1740 potent_12\JJ\1740 cyp2d6_13\NN\1740 inhibitors_14\NNS\20090 ,_15\,\1740 flecainide_16\JJ\1740 plasma_17\NN\5398023 concentrations_18\NNS\4916342 should_19\MD\1740 be_20\VB\836236 monitored_21\VBN\2169352 closely_22\RB\1740 with_23\IN\1740 commencement_24\NN\15180528 of_25\IN\1740 cyp2d6_26\NN\1740 inhibitors_27\NNS\20090 ._28\.\1740
D005424_D064420 NONE because_0\IN\1740 <e2>toxicity</e2>_1\NN\13576101 may_2\MD\15209706 occur_3\VB\2623529 when_4\WRB\1740 flecainide_5\NN\2715941 is_6\VBZ\836236 prescribed_7\VBN\748282 with_8\IN\1740 paroxetine_9\NN\1740 and_10\CC\1740 other_11\JJ\1740 potent_12\JJ\1740 cyp2d6_13\NN\1740 inhibitors_14\NNS\20090 ,_15\,\1740 <e1>flecainide</e1>_16\JJ\1740 plasma_17\NN\5398023 concentrations_18\NNS\4916342 should_19\MD\1740 be_20\VB\836236 monitored_21\VBN\2169352 closely_22\RB\1740 with_23\IN\1740 commencement_24\NN\15180528 of_25\IN\1740 cyp2d6_26\NN\1740 inhibitors_27\NNS\20090 ._28\.\1740
D017374_D064420 NONE because_0\IN\1740 <e2>toxicity</e2>_1\NN\13576101 may_2\MD\15209706 occur_3\VB\2623529 when_4\WRB\1740 flecainide_5\NN\2715941 is_6\VBZ\836236 prescribed_7\VBN\748282 with_8\IN\1740 <e1>paroxetine</e1>_9\NN\1740 and_10\CC\1740 other_11\JJ\1740 potent_12\JJ\1740 cyp2d6_13\NN\1740 inhibitors_14\NNS\20090 ,_15\,\1740 flecainide_16\JJ\1740 plasma_17\NN\5398023 concentrations_18\NNS\4916342 should_19\MD\1740 be_20\VB\836236 monitored_21\VBN\2169352 closely_22\RB\1740 with_23\IN\1740 commencement_24\NN\15180528 of_25\IN\1740 cyp2d6_26\NN\1740 inhibitors_27\NNS\20090 ._28\.\1740
6631522
C013102_D066126 NONE our_0\PRP$\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 changes_5\NNS\7283608 leading_6\VBG\1752884 to_7\TO\1740 an_8\DT\6697703 alteration_9\NN\7283608 of_10\IN\1740 myocardial_11\JJ\1740 dynamic_12\NN\9179776 imaging_13\NN\5765159 with_14\IN\1740 <e1>i-131_15\NN\1740 ha</e1>_16\NN\13888491 are_17\VBP\836236 not_18\RB\1740 the_19\DT\1740 initiating_20\VBG\1617192 factor_21\NN\7326557 in_22\IN\13603305 doxorubicin_23\NN\2716866 <e2>cardiotoxicity</e2>_24\NN\1740 ._25\.\1740
D004317_D066126 CID our_0\PRP$\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 changes_5\NNS\7283608 leading_6\VBG\1752884 to_7\TO\1740 an_8\DT\6697703 alteration_9\NN\7283608 of_10\IN\1740 myocardial_11\JJ\1740 dynamic_12\NN\9179776 imaging_13\NN\5765159 with_14\IN\1740 i-131_15\NN\1740 ha_16\NN\13888491 are_17\VBP\836236 not_18\RB\1740 the_19\DT\1740 initiating_20\VBG\1617192 factor_21\NN\7326557 in_22\IN\13603305 <e1>doxorubicin</e1>_23\NN\2716866 <e2>cardiotoxicity</e2>_24\NN\1740 ._25\.\1740
25951420
D010126_D010300 CID associations_0\NNS\8008335 of_1\IN\1740 <e1>ozone</e1>_2\NN\14877585 and_3\CC\1740 pm2.5_4\NN\1740 concentrations_5\NNPS\4916342 with_6\IN\1740 <e2>parkinson_7\NNP\1740 's_8\POS\1740 disease</e2>_9\NNP\14061805 among_10\IN\1740 participants_11\NNS\9816771 in_12\IN\13603305 the_13\DT\1740 agricultural_14\NNP\1740 health_15\NNP\14447525 study_16\NNP\635850 ._17\.\1740
D010126_D010300 CID objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 describes_4\VBZ\1001294 associations_5\NNS\8008335 of_6\IN\1740 <e1>ozone</e1>_7\NN\14877585 and_8\CC\1740 fine_9\JJ\1740 particulate_10\JJ\1740 matter_11\NN\5670710 with_12\IN\1740 <e2>parkinson_13\NN\1740 's_14\POS\1740 disease</e2>_15\NN\14061805 observed_16\VBN\2163746 among_17\IN\1740 farmers_18\NNS\9614315 in_19\IN\13603305 north_20\NNP\13831000 carolina_21\NNP\1740 and_22\CC\1740 iowa_23\NNP\9669125 ._24\.\1740
D010126_D010300 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 observed_3\VBD\2163746 positive_4\JJ\1740 associations_5\NNS\8008335 of_6\IN\1740 <e2>parkinson_7\NN\1740 's_8\POS\1740 disease</e2>_9\NN\14061805 with_10\IN\1740 <e1>ozone</e1>_11\NN\14877585 (_12\-LRB-\1740 odds_13\NNS\4756635 ratio_14\NN\13815152 =_15\JJ\1740 1.39_16\CD\1740 ;_17\:\1740 95_18\CD\1740 %_19\NN\1740 ci_20\NN\13635336 :_21\:\1740 0.98_22\CD\1740 to_23\TO\1740 1.98_24\CD\1740 )_25\-RRB-\1740 and_26\CC\1740 fine_27\JJ\1740 particulate_28\JJ\1740 matter_29\NN\5670710 (_30\-LRB-\1740 odds_31\NNS\4756635 ratio_32\NN\13815152 =_33\JJ\1740 1.34_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 :_39\:\1740 0.93_40\CD\1740 to_41\TO\1740 1.93_42\CD\1740 )_43\-RRB-\1740 in_44\IN\13603305 north_45\NNP\13831000 carolina_46\NNP\1740 but_47\CC\1740 not_48\RB\1740 in_49\IN\13603305 iowa_50\NNP\9669125 ._51\.\1740
D052638_D010300 CID objective_0\NN\5980875 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 describes_4\VBZ\1001294 associations_5\NNS\8008335 of_6\IN\1740 ozone_7\NN\14877585 and_8\CC\1740 fine_9\JJ\1740 <e1>particulate_10\JJ\1740 matter</e1>_11\NN\5670710 with_12\IN\1740 <e2>parkinson_13\NN\1740 's_14\POS\1740 disease</e2>_15\NN\14061805 observed_16\VBN\2163746 among_17\IN\1740 farmers_18\NNS\9614315 in_19\IN\13603305 north_20\NNP\13831000 carolina_21\NNP\1740 and_22\CC\1740 iowa_23\NNP\9669125 ._24\.\1740
D052638_D010300 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 observed_3\VBD\2163746 positive_4\JJ\1740 associations_5\NNS\8008335 of_6\IN\1740 <e2>parkinson_7\NN\1740 's_8\POS\1740 disease</e2>_9\NN\14061805 with_10\IN\1740 ozone_11\NN\14877585 (_12\-LRB-\1740 odds_13\NNS\4756635 ratio_14\NN\13815152 =_15\JJ\1740 1.39_16\CD\1740 ;_17\:\1740 95_18\CD\1740 %_19\NN\1740 ci_20\NN\13635336 :_21\:\1740 0.98_22\CD\1740 to_23\TO\1740 1.98_24\CD\1740 )_25\-RRB-\1740 and_26\CC\1740 fine_27\JJ\1740 <e1>particulate_28\JJ\1740 matter</e1>_29\NN\5670710 (_30\-LRB-\1740 odds_31\NNS\4756635 ratio_32\NN\13815152 =_33\JJ\1740 1.34_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 :_39\:\1740 0.93_40\CD\1740 to_41\TO\1740 1.93_42\CD\1740 )_43\-RRB-\1740 in_44\IN\13603305 north_45\NNP\13831000 carolina_46\NNP\1740 but_47\CC\1740 not_48\RB\1740 in_49\IN\13603305 iowa_50\NNP\9669125 ._51\.\1740
11395263
D000431_D009203 NONE the_0\DT\1740 cardioprotective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 the_4\DT\1740 <e1>ethanol</e1>_5\NN\14708720 extract_6\NN\14589223 of_7\IN\1740 picrorrhiza_8\NNP\1740 kurroa_9\NN\1740 rhizomes_10\NNS\13129165 and_11\CC\1740 roots_12\NNS\13920429 (_13\-LRB-\1740 pk_14\NN\1740 )_15\-RRB-\1740 on_16\IN\1740 isoproterenol-induced_17\JJ\1740 <e2>myocardial_18\JJ\1740 infarction</e2>_19\NN\14204950 in_20\IN\13603305 rats_21\NNS\2329401 with_22\IN\1740 respect_23\NN\5817845 to_24\TO\1740 lipid_25\NN\14944888 metabolism_26\NN\13526110 in_27\IN\13603305 serum_28\NN\5397468 and_29\CC\1740 heart_30\NN\5919034 tissue_31\NN\5220461 has_32\VBZ\2108377 been_33\VBN\836236 investigated_34\VBN\644583 ._35\.\1740
D007545_D009203 CID the_0\DT\1740 cardioprotective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 the_4\DT\1740 ethanol_5\NN\14708720 extract_6\NN\14589223 of_7\IN\1740 picrorrhiza_8\NNP\1740 kurroa_9\NN\1740 rhizomes_10\NNS\13129165 and_11\CC\1740 roots_12\NNS\13920429 (_13\-LRB-\1740 pk_14\NN\1740 )_15\-RRB-\1740 on_16\IN\1740 <e1>isoproterenol-induced</e1>_17\JJ\1740 <e2>myocardial_18\JJ\1740 infarction</e2>_19\NN\14204950 in_20\IN\13603305 rats_21\NNS\2329401 with_22\IN\1740 respect_23\NN\5817845 to_24\TO\1740 lipid_25\NN\14944888 metabolism_26\NN\13526110 in_27\IN\13603305 serum_28\NN\5397468 and_29\CC\1740 heart_30\NN\5919034 tissue_31\NN\5220461 has_32\VBZ\2108377 been_33\VBN\836236 investigated_34\VBN\644583 ._35\.\1740
D007545_D009203 CID oral_0\JJ\1740 pre-treatment_1\NN\1740 with_2\IN\1740 pk_3\NN\1740 (_4\-LRB-\1740 80_5\CD\13745420 mg_6\NN\13717155 kg(-1_7\NN\1740 )_8\-RRB-\1740 day(-1_9\NN\1740 )_10\-RRB-\1740 for_11\IN\1740 15_12\CD\13745420 days_13\NNS\15140892 )_14\-RRB-\1740 significantly_15\RB\1740 prevented_16\VBD\1740 the_17\DT\1740 <e1>isoproterenol-induced</e1>_18\JJ\1740 <e2>myocardial_19\JJ\1740 infarction</e2>_20\NN\14204950 and_21\CC\1740 maintained_22\VBD\2202928 the_23\DT\1740 rats_24\NNS\2329401 at_25\IN\14622893 near_26\IN\1740 normal_27\JJ\1740 status_28\NN\24720 ._29\.\1740
2907577
-1_D058186 NONE effect_0\NN\34213 of_1\IN\1740 <e1>alkylxanthines</e1>_2\NNS\1740 on_3\IN\1740 gentamicin-induced_4\JJ\1740 <e2>acute_5\JJ\1740 renal_6\JJ\1740 failure</e2>_7\NN\66216 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
-1_D058186 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 three_8\CD\13741022 <e1>alkylxanthines</e1>_9\NNS\1740 with_10\IN\1740 different_11\JJ\1740 potencies_12\NNS\5196375 as_13\IN\14622893 adenosine_14\NN\14964367 antagonists_15\NNS\7846 8-phenyltheophylline_16\NN\1740 ,_17\,\1740 theophylline_18\NN\2905612 and_19\CC\1740 enprofylline_20\NN\1740 ,_21\,\1740 were_22\VBD\836236 examined_23\VBN\789138 in_24\IN\13603305 rats_25\NNS\2329401 developing_26\VBG\1753788 <e2>acute_27\JJ\1740 renal_28\JJ\1740 failure</e2>_29\NN\66216 after_30\IN\1740 4_31\CD\13741022 daily_32\JJ\1740 injections_33\NNS\320852 of_34\IN\1740 gentamicin_35\NN\2716866 (_36\-LRB-\1740 200_37\CD\1740 mg_38\NN\13717155 kg-1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
-1_D058186 NONE the_0\DT\1740 lack_1\NN\14449126 of_2\IN\1740 any_3\DT\1740 consistent_4\JJ\1740 protective_5\JJ\1740 effect_6\NN\34213 noted_7\VBN\1009240 with_8\IN\1740 the_9\DT\1740 <e1>alkylxanthines</e1>_10\NNS\1740 tested_11\VBN\670261 in_12\IN\13603305 the_13\DT\1740 present_14\JJ\1740 study_15\NN\635850 indicates_16\VBZ\952524 that_17\IN\1740 adenosine_18\NN\14964367 plays_19\VBZ\1072262 little_20\JJ\1740 ,_21\,\1740 if_22\IN\1740 any_23\DT\1740 ,_24\,\1740 pathophysiological_25\JJ\1740 role_26\NN\719494 in_27\IN\13603305 gentamicin-induced_28\JJ\1740 <e2>arf</e2>_29\NN\1740 ._30\.\1740
D005839_D058186 CID effect_0\NN\34213 of_1\IN\1740 alkylxanthines_2\NNS\1740 on_3\IN\1740 <e1>gentamicin-induced</e1>_4\JJ\1740 <e2>acute_5\JJ\1740 renal_6\JJ\1740 failure</e2>_7\NN\66216 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D005839_D058186 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 three_8\CD\13741022 alkylxanthines_9\NNS\1740 with_10\IN\1740 different_11\JJ\1740 potencies_12\NNS\5196375 as_13\IN\14622893 adenosine_14\NN\14964367 antagonists_15\NNS\7846 8-phenyltheophylline_16\NN\1740 ,_17\,\1740 theophylline_18\NN\2905612 and_19\CC\1740 enprofylline_20\NN\1740 ,_21\,\1740 were_22\VBD\836236 examined_23\VBN\789138 in_24\IN\13603305 rats_25\NNS\2329401 developing_26\VBG\1753788 <e2>acute_27\JJ\1740 renal_28\JJ\1740 failure</e2>_29\NN\66216 after_30\IN\1740 4_31\CD\13741022 daily_32\JJ\1740 injections_33\NNS\320852 of_34\IN\1740 <e1>gentamicin</e1>_35\NN\2716866 (_36\-LRB-\1740 200_37\CD\1740 mg_38\NN\13717155 kg-1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D005839_D058186 CID the_0\DT\1740 lack_1\NN\14449126 of_2\IN\1740 any_3\DT\1740 consistent_4\JJ\1740 protective_5\JJ\1740 effect_6\NN\34213 noted_7\VBN\1009240 with_8\IN\1740 the_9\DT\1740 alkylxanthines_10\NNS\1740 tested_11\VBN\670261 in_12\IN\13603305 the_13\DT\1740 present_14\JJ\1740 study_15\NN\635850 indicates_16\VBZ\952524 that_17\IN\1740 adenosine_18\NN\14964367 plays_19\VBZ\1072262 little_20\JJ\1740 ,_21\,\1740 if_22\IN\1740 any_23\DT\1740 ,_24\,\1740 pathophysiological_25\JJ\1740 role_26\NN\719494 in_27\IN\13603305 <e1>gentamicin-induced</e1>_28\JJ\1740 <e2>arf</e2>_29\NN\1740 ._30\.\1740
D000241_D007511 NONE <e1>adenosine</e1>_0\JJ\1740 antagonists_1\NNS\7846 have_2\VBP\2108377 been_3\VBN\836236 previously_4\RB\1740 shown_5\VBN\2137132 to_6\TO\1740 be_7\VB\836236 of_8\IN\1740 benefit_9\NN\13278375 in_10\IN\13603305 some_11\DT\1740 <e2>ischaemic</e2>_12\JJ\1740 and_13\CC\1740 nephrotoxic_14\JJ\1740 models_15\NNS\5888929 of_16\IN\1740 acute_17\JJ\1740 renal_18\JJ\1740 failure_19\NN\66216 (_20\-LRB-\1740 arf_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000241_D007674 NONE <e1>adenosine</e1>_0\JJ\1740 antagonists_1\NNS\7846 have_2\VBP\2108377 been_3\VBN\836236 previously_4\RB\1740 shown_5\VBN\2137132 to_6\TO\1740 be_7\VB\836236 of_8\IN\1740 benefit_9\NN\13278375 in_10\IN\13603305 some_11\DT\1740 ischaemic_12\JJ\1740 and_13\CC\1740 <e2>nephrotoxic</e2>_14\JJ\1740 models_15\NNS\5888929 of_16\IN\1740 acute_17\JJ\1740 renal_18\JJ\1740 failure_19\NN\66216 (_20\-LRB-\1740 arf_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000241_D058186 NONE <e1>adenosine</e1>_0\JJ\1740 antagonists_1\NNS\7846 have_2\VBP\2108377 been_3\VBN\836236 previously_4\RB\1740 shown_5\VBN\2137132 to_6\TO\1740 be_7\VB\836236 of_8\IN\1740 benefit_9\NN\13278375 in_10\IN\13603305 some_11\DT\1740 ischaemic_12\JJ\1740 and_13\CC\1740 nephrotoxic_14\JJ\1740 models_15\NNS\5888929 of_16\IN\1740 <e2>acute_17\JJ\1740 renal_18\JJ\1740 failure</e2>_19\NN\66216 (_20\-LRB-\1740 arf_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000241_D058186 NONE <e1>adenosine</e1>_0\JJ\1740 antagonists_1\NNS\7846 have_2\VBP\2108377 been_3\VBN\836236 previously_4\RB\1740 shown_5\VBN\2137132 to_6\TO\1740 be_7\VB\836236 of_8\IN\1740 benefit_9\NN\13278375 in_10\IN\13603305 some_11\DT\1740 ischaemic_12\JJ\1740 and_13\CC\1740 nephrotoxic_14\JJ\1740 models_15\NNS\5888929 of_16\IN\1740 acute_17\JJ\1740 renal_18\JJ\1740 failure_19\NN\66216 (_20\-LRB-\1740 <e2>arf</e2>_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000241_D058186 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 three_8\CD\13741022 alkylxanthines_9\NNS\1740 with_10\IN\1740 different_11\JJ\1740 potencies_12\NNS\5196375 as_13\IN\14622893 <e1>adenosine</e1>_14\NN\14964367 antagonists_15\NNS\7846 8-phenyltheophylline_16\NN\1740 ,_17\,\1740 theophylline_18\NN\2905612 and_19\CC\1740 enprofylline_20\NN\1740 ,_21\,\1740 were_22\VBD\836236 examined_23\VBN\789138 in_24\IN\13603305 rats_25\NNS\2329401 developing_26\VBG\1753788 <e2>acute_27\JJ\1740 renal_28\JJ\1740 failure</e2>_29\NN\66216 after_30\IN\1740 4_31\CD\13741022 daily_32\JJ\1740 injections_33\NNS\320852 of_34\IN\1740 gentamicin_35\NN\2716866 (_36\-LRB-\1740 200_37\CD\1740 mg_38\NN\13717155 kg-1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D000241_D058186 NONE the_0\DT\1740 lack_1\NN\14449126 of_2\IN\1740 any_3\DT\1740 consistent_4\JJ\1740 protective_5\JJ\1740 effect_6\NN\34213 noted_7\VBN\1009240 with_8\IN\1740 the_9\DT\1740 alkylxanthines_10\NNS\1740 tested_11\VBN\670261 in_12\IN\13603305 the_13\DT\1740 present_14\JJ\1740 study_15\NN\635850 indicates_16\VBZ\952524 that_17\IN\1740 <e1>adenosine</e1>_18\NN\14964367 plays_19\VBZ\1072262 little_20\JJ\1740 ,_21\,\1740 if_22\IN\1740 any_23\DT\1740 ,_24\,\1740 pathophysiological_25\JJ\1740 role_26\NN\719494 in_27\IN\13603305 gentamicin-induced_28\JJ\1740 <e2>arf</e2>_29\NN\1740 ._30\.\1740
C028322_D058186 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 three_8\CD\13741022 alkylxanthines_9\NNS\1740 with_10\IN\1740 different_11\JJ\1740 potencies_12\NNS\5196375 as_13\IN\14622893 adenosine_14\NN\14964367 antagonists_15\NNS\7846 <e1>8-phenyltheophylline</e1>_16\NN\1740 ,_17\,\1740 theophylline_18\NN\2905612 and_19\CC\1740 enprofylline_20\NN\1740 ,_21\,\1740 were_22\VBD\836236 examined_23\VBN\789138 in_24\IN\13603305 rats_25\NNS\2329401 developing_26\VBG\1753788 <e2>acute_27\JJ\1740 renal_28\JJ\1740 failure</e2>_29\NN\66216 after_30\IN\1740 4_31\CD\13741022 daily_32\JJ\1740 injections_33\NNS\320852 of_34\IN\1740 gentamicin_35\NN\2716866 (_36\-LRB-\1740 200_37\CD\1740 mg_38\NN\13717155 kg-1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D013806_D058186 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 three_8\CD\13741022 alkylxanthines_9\NNS\1740 with_10\IN\1740 different_11\JJ\1740 potencies_12\NNS\5196375 as_13\IN\14622893 adenosine_14\NN\14964367 antagonists_15\NNS\7846 8-phenyltheophylline_16\NN\1740 ,_17\,\1740 <e1>theophylline</e1>_18\NN\2905612 and_19\CC\1740 enprofylline_20\NN\1740 ,_21\,\1740 were_22\VBD\836236 examined_23\VBN\789138 in_24\IN\13603305 rats_25\NNS\2329401 developing_26\VBG\1753788 <e2>acute_27\JJ\1740 renal_28\JJ\1740 failure</e2>_29\NN\66216 after_30\IN\1740 4_31\CD\13741022 daily_32\JJ\1740 injections_33\NNS\320852 of_34\IN\1740 gentamicin_35\NN\2716866 (_36\-LRB-\1740 200_37\CD\1740 mg_38\NN\13717155 kg-1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
C034347_D058186 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 three_8\CD\13741022 alkylxanthines_9\NNS\1740 with_10\IN\1740 different_11\JJ\1740 potencies_12\NNS\5196375 as_13\IN\14622893 adenosine_14\NN\14964367 antagonists_15\NNS\7846 8-phenyltheophylline_16\NN\1740 ,_17\,\1740 theophylline_18\NN\2905612 and_19\CC\1740 <e1>enprofylline</e1>_20\NN\1740 ,_21\,\1740 were_22\VBD\836236 examined_23\VBN\789138 in_24\IN\13603305 rats_25\NNS\2329401 developing_26\VBG\1753788 <e2>acute_27\JJ\1740 renal_28\JJ\1740 failure</e2>_29\NN\66216 after_30\IN\1740 4_31\CD\13741022 daily_32\JJ\1740 injections_33\NNS\320852 of_34\IN\1740 gentamicin_35\NN\2716866 (_36\-LRB-\1740 200_37\CD\1740 mg_38\NN\13717155 kg-1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D014508_D009336 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 assessed_3\VBN\670261 by_4\IN\1740 biochemical_5\JJ\1740 (_6\-LRB-\1740 plasma_7\NN\5398023 <e1>urea</e1>_8\NN\14727670 and_9\CC\1740 creatinine_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 functional_13\JJ\1740 (_14\-LRB-\1740 urine_15\NN\14853947 analysis_16\NN\633864 and_17\CC\1740 [3h]inulin_18\NN\1740 and_19\CC\1740 [14c]p-aminohippuric_20\XX\1740 acid_21\NN\14818238 clearances_22\NNS\5089947 )_23\-RRB-\1740 and_24\CC\1740 morphological_25\JJ\1740 (_26\-LRB-\1740 degree_27\NN\4916342 of_28\IN\1740 <e2>necrosis</e2>_29\NN\11444117 )_30\-RRB-\1740 indices_31\NNS\13850304 ._32\.\1740
D003404_D009336 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 assessed_3\VBN\670261 by_4\IN\1740 biochemical_5\JJ\1740 (_6\-LRB-\1740 plasma_7\NN\5398023 urea_8\NN\14727670 and_9\CC\1740 <e1>creatinine</e1>_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 functional_13\JJ\1740 (_14\-LRB-\1740 urine_15\NN\14853947 analysis_16\NN\633864 and_17\CC\1740 [3h]inulin_18\NN\1740 and_19\CC\1740 [14c]p-aminohippuric_20\XX\1740 acid_21\NN\14818238 clearances_22\NNS\5089947 )_23\-RRB-\1740 and_24\CC\1740 morphological_25\JJ\1740 (_26\-LRB-\1740 degree_27\NN\4916342 of_28\IN\1740 <e2>necrosis</e2>_29\NN\11444117 )_30\-RRB-\1740 indices_31\NNS\13850304 ._32\.\1740
D010130_D009336 NONE renal_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 assessed_3\VBN\670261 by_4\IN\1740 biochemical_5\JJ\1740 (_6\-LRB-\1740 plasma_7\NN\5398023 urea_8\NN\14727670 and_9\CC\1740 creatinine_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 functional_13\JJ\1740 (_14\-LRB-\1740 urine_15\NN\14853947 analysis_16\NN\633864 and_17\CC\1740 [3h]inulin_18\NN\1740 and_19\CC\1740 <e1>[14c]p-aminohippuric_20\XX\1740 acid</e1>_21\NN\14818238 clearances_22\NNS\5089947 )_23\-RRB-\1740 and_24\CC\1740 morphological_25\JJ\1740 (_26\-LRB-\1740 degree_27\NN\4916342 of_28\IN\1740 <e2>necrosis</e2>_29\NN\11444117 )_30\-RRB-\1740 indices_31\NNS\13850304 ._32\.\1740
2983630
D002110_D016584 NONE increased_0\VBN\169651 anxiogenic_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>caffeine</e1>_4\NN\14712692 in_5\IN\13603305 <e2>panic_6\NN\7519253 disorders</e2>_7\NNS\14034177 ._8\.\1740
D002110_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>caffeine</e1>_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 <e2>panic_45\NN\7519253 attacks</e2>_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D002110_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>caffeine</e1>_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 <e2>panic_48\JJ\1740 disorder</e2>_49\NN\14034177 ._50\.\1740
D002110_D016584 NONE seventy-one_0\CD\1740 percent_1\NN\13815742 of_2\IN\1740 the_3\DT\1740 patients_4\NNS\9898892 reported_5\VBD\831651 that_6\IN\1740 the_7\DT\1740 behavioral_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>caffeine</e1>_11\NN\14712692 were_12\VBD\836236 similar_13\JJ\1740 to_14\TO\1740 those_15\DT\1740 experienced_16\VBN\2108377 during_17\IN\1740 <e2>panic_18\NN\7519253 attacks</e2>_19\NNS\955060 ._20\.\1740
D002110_D016584 NONE because_0\IN\1740 <e1>caffeine</e1>_1\NN\14712692 is_2\VBZ\836236 an_3\DT\6697703 adenosine_4\NN\14964367 receptor_5\NN\5225602 antagonist_6\NN\7846 ,_7\,\1740 these_8\DT\1740 results_9\NNS\34213 suggest_10\VBP\1010118 that_11\IN\1740 some_12\DT\1740 <e2>panic_13\JJ\1740 disorder</e2>_14\NN\14034177 patients_15\NNS\9898892 may_16\MD\15209706 have_17\VB\2108377 abnormalities_18\NNS\14034177 in_19\IN\13603305 neuronal_20\JJ\1740 systems_21\NNS\3575240 involving_22\VBG\2676054 adenosine_23\NN\14964367 ._24\.\1740
D002110_D000379 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>caffeine</e1>_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 <e2>agoraphobia</e2>_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D008734_D000379 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1>_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 <e2>agoraphobia</e2>_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D008734_D000379 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 <e1>mhpg</e1>_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 <e2>agoraphobia</e2>_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D008734_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1>_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 <e2>panic_45\NN\7519253 attacks</e2>_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D008734_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1>_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 <e2>panic_48\JJ\1740 disorder</e2>_49\NN\14034177 ._50\.\1740
D008734_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 <e1>mhpg</e1>_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 <e2>panic_45\NN\7519253 attacks</e2>_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D008734_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 <e1>mhpg</e1>_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 cortisol_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 <e2>panic_48\JJ\1740 disorder</e2>_49\NN\14034177 ._50\.\1740
D006854_D000379 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 <e1>cortisol</e1>_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 <e2>agoraphobia</e2>_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D006854_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 <e1>cortisol</e1>_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 <e2>panic_45\NN\7519253 attacks</e2>_46\NNS\955060 or_47\CC\3541091 panic_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D006854_D016584 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 oral_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 caffeine_6\NN\14712692 (_7\-LRB-\1740 10_8\CD\13745420 mg/kg_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 behavioral_12\JJ\1740 ratings_13\NNS\5733583 ,_14\,\1740 somatic_15\JJ\1740 symptoms_16\NNS\5823932 ,_17\,\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 plasma_21\NN\5398023 levels_22\NNS\4916342 of_23\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740 (_25\-LRB-\1740 mhpg_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 <e1>cortisol</e1>_29\NN\14751417 were_30\VBD\836236 determined_31\VBN\1645601 in_32\IN\13603305 17_33\CD\13745420 healthy_34\JJ\1740 subjects_35\NNS\6598915 and_36\CC\1740 21_37\CD\13745420 patients_38\NNS\9898892 meeting_39\VBG\1182709 dsm-iii_40\NN\1740 criteria_41\NNS\13577171 for_42\IN\1740 agoraphobia_43\NN\14381416 with_44\IN\1740 panic_45\NN\7519253 attacks_46\NNS\955060 or_47\CC\3541091 <e2>panic_48\JJ\1740 disorder</e2>_49\NN\14034177 ._50\.\1740
D002110_D001008 CID <e1>caffeine</e1>_0\NN\14712692 produced_1\VBD\1617192 significantly_2\RB\1740 greater_3\JJR\1740 increases_4\NNS\13576355 in_5\IN\13603305 subject-rated_6\JJ\1740 <e2>anxiety</e2>_7\NN\14373582 ,_8\,\1740 nervousness_9\RB\1740 ,_10\,\1740 fear_11\NN\7480068 ,_12\,\1740 nausea_13\NN\14299637 ,_14\,\1740 palpitations_15\NNS\14299637 ,_16\,\1740 restlessness_17\NN\4773351 ,_18\,\1740 and_19\CC\1740 tremors_20\NNS\345926 in_21\IN\13603305 the_22\DT\1740 patients_23\NNS\9898892 compared_24\VBN\644583 with_25\IN\1740 healthy_26\JJ\1740 subjects_27\NNS\6598915 ._28\.\1740
D002110_D001008 CID patients_0\NNS\9898892 with_1\IN\1740 <e2>anxiety_2\NN\14373582 disorders</e2>_3\NNS\14034177 may_4\MD\15209706 benefit_5\VB\2210855 by_6\IN\1740 avoiding_7\VBG\2452885 <e1>caffeine-containing</e1>_8\JJ\1740 foods_9\NNS\20090 and_10\CC\1740 beverages_11\NNS\21265 ._12\.\1740
D002110_D009325 CID <e1>caffeine</e1>_0\NN\14712692 produced_1\VBD\1617192 significantly_2\RB\1740 greater_3\JJR\1740 increases_4\NNS\13576355 in_5\IN\13603305 subject-rated_6\JJ\1740 anxiety_7\NN\14373582 ,_8\,\1740 nervousness_9\RB\1740 ,_10\,\1740 fear_11\NN\7480068 ,_12\,\1740 <e2>nausea</e2>_13\NN\14299637 ,_14\,\1740 palpitations_15\NNS\14299637 ,_16\,\1740 restlessness_17\NN\4773351 ,_18\,\1740 and_19\CC\1740 tremors_20\NNS\345926 in_21\IN\13603305 the_22\DT\1740 patients_23\NNS\9898892 compared_24\VBN\644583 with_25\IN\1740 healthy_26\JJ\1740 subjects_27\NNS\6598915 ._28\.\1740
D002110_-1 NONE <e1>caffeine</e1>_0\NN\14712692 produced_1\VBD\1617192 significantly_2\RB\1740 greater_3\JJR\1740 increases_4\NNS\13576355 in_5\IN\13603305 subject-rated_6\JJ\1740 anxiety_7\NN\14373582 ,_8\,\1740 nervousness_9\RB\1740 ,_10\,\1740 fear_11\NN\7480068 ,_12\,\1740 nausea_13\NN\14299637 ,_14\,\1740 <e2>palpitations</e2>_15\NNS\14299637 ,_16\,\1740 restlessness_17\NN\4773351 ,_18\,\1740 and_19\CC\1740 tremors_20\NNS\345926 in_21\IN\13603305 the_22\DT\1740 patients_23\NNS\9898892 compared_24\VBN\644583 with_25\IN\1740 healthy_26\JJ\1740 subjects_27\NNS\6598915 ._28\.\1740
D002110_D011595 NONE <e1>caffeine</e1>_0\NN\14712692 produced_1\VBD\1617192 significantly_2\RB\1740 greater_3\JJR\1740 increases_4\NNS\13576355 in_5\IN\13603305 subject-rated_6\JJ\1740 anxiety_7\NN\14373582 ,_8\,\1740 nervousness_9\RB\1740 ,_10\,\1740 fear_11\NN\7480068 ,_12\,\1740 nausea_13\NN\14299637 ,_14\,\1740 palpitations_15\NNS\14299637 ,_16\,\1740 <e2>restlessness</e2>_17\NN\4773351 ,_18\,\1740 and_19\CC\1740 tremors_20\NNS\345926 in_21\IN\13603305 the_22\DT\1740 patients_23\NNS\9898892 compared_24\VBN\644583 with_25\IN\1740 healthy_26\JJ\1740 subjects_27\NNS\6598915 ._28\.\1740
D002110_D014202 CID <e1>caffeine</e1>_0\NN\14712692 produced_1\VBD\1617192 significantly_2\RB\1740 greater_3\JJR\1740 increases_4\NNS\13576355 in_5\IN\13603305 subject-rated_6\JJ\1740 anxiety_7\NN\14373582 ,_8\,\1740 nervousness_9\RB\1740 ,_10\,\1740 fear_11\NN\7480068 ,_12\,\1740 nausea_13\NN\14299637 ,_14\,\1740 palpitations_15\NNS\14299637 ,_16\,\1740 restlessness_17\NN\4773351 ,_18\,\1740 and_19\CC\1740 <e2>tremors</e2>_20\NNS\345926 in_21\IN\13603305 the_22\DT\1740 patients_23\NNS\9898892 compared_24\VBN\644583 with_25\IN\1740 healthy_26\JJ\1740 subjects_27\NNS\6598915 ._28\.\1740
D002110_D009421 NONE because_0\IN\1740 <e1>caffeine</e1>_1\NN\14712692 is_2\VBZ\836236 an_3\DT\6697703 adenosine_4\NN\14964367 receptor_5\NN\5225602 antagonist_6\NN\7846 ,_7\,\1740 these_8\DT\1740 results_9\NNS\34213 suggest_10\VBP\1010118 that_11\IN\1740 some_12\DT\1740 panic_13\JJ\1740 disorder_14\NN\14034177 patients_15\NNS\9898892 may_16\MD\15209706 have_17\VB\2108377 <e2>abnormalities_18\NNS\14034177 in_19\IN\13603305 neuronal_20\JJ\1740 systems</e2>_21\NNS\3575240 involving_22\VBG\2676054 adenosine_23\NN\14964367 ._24\.\1740
D000241_D016584 NONE because_0\IN\1740 caffeine_1\NN\14712692 is_2\VBZ\836236 an_3\DT\6697703 <e1>adenosine</e1>_4\NN\14964367 receptor_5\NN\5225602 antagonist_6\NN\7846 ,_7\,\1740 these_8\DT\1740 results_9\NNS\34213 suggest_10\VBP\1010118 that_11\IN\1740 some_12\DT\1740 <e2>panic_13\JJ\1740 disorder</e2>_14\NN\14034177 patients_15\NNS\9898892 may_16\MD\15209706 have_17\VB\2108377 abnormalities_18\NNS\14034177 in_19\IN\13603305 neuronal_20\JJ\1740 systems_21\NNS\3575240 involving_22\VBG\2676054 adenosine_23\NN\14964367 ._24\.\1740
D000241_D016584 NONE because_0\IN\1740 caffeine_1\NN\14712692 is_2\VBZ\836236 an_3\DT\6697703 adenosine_4\NN\14964367 receptor_5\NN\5225602 antagonist_6\NN\7846 ,_7\,\1740 these_8\DT\1740 results_9\NNS\34213 suggest_10\VBP\1010118 that_11\IN\1740 some_12\DT\1740 <e2>panic_13\JJ\1740 disorder</e2>_14\NN\14034177 patients_15\NNS\9898892 may_16\MD\15209706 have_17\VB\2108377 abnormalities_18\NNS\14034177 in_19\IN\13603305 neuronal_20\JJ\1740 systems_21\NNS\3575240 involving_22\VBG\2676054 <e1>adenosine</e1>_23\NN\14964367 ._24\.\1740
D000241_D009421 NONE because_0\IN\1740 caffeine_1\NN\14712692 is_2\VBZ\836236 an_3\DT\6697703 <e1>adenosine</e1>_4\NN\14964367 receptor_5\NN\5225602 antagonist_6\NN\7846 ,_7\,\1740 these_8\DT\1740 results_9\NNS\34213 suggest_10\VBP\1010118 that_11\IN\1740 some_12\DT\1740 panic_13\JJ\1740 disorder_14\NN\14034177 patients_15\NNS\9898892 may_16\MD\15209706 have_17\VB\2108377 <e2>abnormalities_18\NNS\14034177 in_19\IN\13603305 neuronal_20\JJ\1740 systems</e2>_21\NNS\3575240 involving_22\VBG\2676054 adenosine_23\NN\14964367 ._24\.\1740
D000241_D009421 NONE because_0\IN\1740 caffeine_1\NN\14712692 is_2\VBZ\836236 an_3\DT\6697703 adenosine_4\NN\14964367 receptor_5\NN\5225602 antagonist_6\NN\7846 ,_7\,\1740 these_8\DT\1740 results_9\NNS\34213 suggest_10\VBP\1010118 that_11\IN\1740 some_12\DT\1740 panic_13\JJ\1740 disorder_14\NN\14034177 patients_15\NNS\9898892 may_16\MD\15209706 have_17\VB\2108377 <e2>abnormalities_18\NNS\14034177 in_19\IN\13603305 neuronal_20\JJ\1740 systems</e2>_21\NNS\3575240 involving_22\VBG\2676054 <e1>adenosine</e1>_23\NN\14964367 ._24\.\1740
9128918
D004298_D006966 NONE chronic_0\JJ\1740 <e2>hyperprolactinemia</e2>_1\NN\1740 and_2\CC\1740 changes_3\NNS\7283608 in_4\IN\13603305 <e1>dopamine</e1>_5\NN\14807737 neurons_6\NNS\5430628 ._7\.\1740
D004298_D006966 NONE <e2>hyperprolactinemia</e2>_0\NNP\1740 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 treatment_4\NN\654885 with_5\IN\1740 haloperidol_6\NN\3713736 ,_7\,\1740 a_8\DT\13649268 <e1>dopamine</e1>_9\NN\14807737 receptor_10\NN\5225602 antagonist_11\NN\7846 ,_12\,\1740 and_13\CC\1740 palkovits_14\NNS\1740 '_15\POS\1740 microdissection_16\NN\1740 technique_17\NN\5660268 in_18\IN\13603305 combination_19\NN\7951464 with_20\IN\1740 high-performance_21\JJ\1740 liquid_22\JJ\1740 chromatography_23\NN\13518963 was_24\VBD\836236 used_25\VBN\1156834 to_26\TO\1740 measure_27\VB\697589 neurotransmitter_28\NN\14807410 concentrations_29\NNS\4916342 in_30\IN\13603305 several_31\JJ\1740 areas_32\NNS\8630985 of_33\IN\1740 the_34\DT\1740 brain_35\NN\5462674 ._36\.\1740
D004298_D006966 NONE after_0\IN\1740 6_1\CD\13741022 months_2\NNS\15113229 of_3\IN\1740 <e2>hyperprolactinemia</e2>_4\NN\1740 ,_5\,\1740 <e1>dopamine</e1>_6\NN\14807737 (_7\-LRB-\1740 da_8\NN\10484858 )_9\-RRB-\1740 concentrations_10\NNS\4916342 in_11\IN\13603305 the_12\DT\1740 median_13\JJ\1740 eminence_14\NN\13948441 (_15\-LRB-\1740 me_16\NN\1740 )_17\-RRB-\1740 increased_18\VBD\169651 by_19\IN\1740 84_20\CD\1740 %_21\NN\1740 over_22\IN\5867413 the_23\DT\1740 control_24\NN\5190804 group_25\NN\2137 ._26\.\1740
D004298_D006966 NONE after_0\IN\1740 6_1\CD\13741022 months_2\NNS\15113229 of_3\IN\1740 <e2>hyperprolactinemia</e2>_4\NN\1740 ,_5\,\1740 dopamine_6\NN\14807737 (_7\-LRB-\1740 <e1>da</e1>_8\NN\10484858 )_9\-RRB-\1740 concentrations_10\NNS\4916342 in_11\IN\13603305 the_12\DT\1740 median_13\JJ\1740 eminence_14\NN\13948441 (_15\-LRB-\1740 me_16\NN\1740 )_17\-RRB-\1740 increased_18\VBD\169651 by_19\IN\1740 84_20\CD\1740 %_21\NN\1740 over_22\IN\5867413 the_23\DT\1740 control_24\NN\5190804 group_25\NN\2137 ._26\.\1740
D004298_D006966 NONE nine_0\CD\13741022 months_1\NNS\15113229 of_2\IN\1740 <e2>hyperprolactinemia</e2>_3\NN\1740 produced_4\VBD\1617192 a_5\DT\13649268 50_6\CD\13745420 %_7\NN\1740 increase_8\NN\13576355 in_9\IN\13603305 <e1>da</e1>_10\NN\10484858 concentrations_11\NNS\4916342 in_12\IN\13603305 the_13\DT\1740 me_14\NN\1740 over_15\IN\5867413 the_16\DT\1740 control_17\NN\5190804 group_18\NN\2137 ._19\.\1740
D004298_D006966 NONE however_0\RB\1740 ,_1\,\1740 <e1>da</e1>_2\NN\10484858 response_3\NN\11410625 was_4\VBD\836236 lost_5\VBN\1794668 if_6\IN\1740 a_7\DT\13649268 9-month_8\JJ\1740 long_9\JJ\1740 haloperidol-induced_10\JJ\1740 <e2>hyperprolactinemia</e2>_11\NN\1740 was_12\VBD\836236 followed_13\VBN\1835496 by_14\IN\1740 a_15\DT\13649268 1_16\CD\13741022 1/2_17\CD\1740 month-long_18\JJ\1740 extremely_19\RB\1740 high_20\JJ\1740 increase_21\NN\13576355 in_22\IN\13603305 serum_23\NN\5397468 prl_24\NN\1740 levels_25\NNS\4916342 produced_26\VBN\1617192 by_27\IN\1740 implantation_28\NN\13526110 of_29\IN\1740 mmq_30\NN\1740 cells_31\NNS\3080309 under_32\IN\1740 the_33\DT\1740 kidney_34\NN\5333259 capsule_35\NN\3094503 ._36\.\1740
D004298_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 <e1>da</e1>_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D004298_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 <e1>da</e1>_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
D004298_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 <e1>da</e1>_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D004298_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 <e1>da</e1>_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
D006220_D006966 CID <e2>hyperprolactinemia</e2>_0\NNP\1740 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 treatment_4\NN\654885 with_5\IN\1740 <e1>haloperidol</e1>_6\NN\3713736 ,_7\,\1740 a_8\DT\13649268 dopamine_9\NN\14807737 receptor_10\NN\5225602 antagonist_11\NN\7846 ,_12\,\1740 and_13\CC\1740 palkovits_14\NNS\1740 '_15\POS\1740 microdissection_16\NN\1740 technique_17\NN\5660268 in_18\IN\13603305 combination_19\NN\7951464 with_20\IN\1740 high-performance_21\JJ\1740 liquid_22\JJ\1740 chromatography_23\NN\13518963 was_24\VBD\836236 used_25\VBN\1156834 to_26\TO\1740 measure_27\VB\697589 neurotransmitter_28\NN\14807410 concentrations_29\NNS\4916342 in_30\IN\13603305 several_31\JJ\1740 areas_32\NNS\8630985 of_33\IN\1740 the_34\DT\1740 brain_35\NN\5462674 ._36\.\1740
D006220_D006966 CID however_0\RB\1740 ,_1\,\1740 da_2\NN\10484858 response_3\NN\11410625 was_4\VBD\836236 lost_5\VBN\1794668 if_6\IN\1740 a_7\DT\13649268 9-month_8\JJ\1740 long_9\JJ\1740 <e1>haloperidol-induced</e1>_10\JJ\1740 <e2>hyperprolactinemia</e2>_11\NN\1740 was_12\VBD\836236 followed_13\VBN\1835496 by_14\IN\1740 a_15\DT\13649268 1_16\CD\13741022 1/2_17\CD\1740 month-long_18\JJ\1740 extremely_19\RB\1740 high_20\JJ\1740 increase_21\NN\13576355 in_22\IN\13603305 serum_23\NN\5397468 prl_24\NN\1740 levels_25\NNS\4916342 produced_26\VBN\1617192 by_27\IN\1740 implantation_28\NN\13526110 of_29\IN\1740 mmq_30\NN\1740 cells_31\NNS\3080309 under_32\IN\1740 the_33\DT\1740 kidney_34\NN\5333259 capsule_35\NN\3094503 ._36\.\1740
D009638_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 <e1>norepinephrine</e1>_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D009638_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 <e1>norepinephrine</e1>_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
D009638_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 <e1>ne</e1>_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D009638_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 <e1>ne</e1>_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
D012701_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 <e1>serotonin</e1>_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D012701_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 <e1>serotonin</e1>_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
D012701_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 <e1>5-ht</e1>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D012701_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 <e1>5-ht</e1>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
D006897_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 <e1>5-hydroxyindoleacetic_62\JJ\1740 acid</e1>_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D006897_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 <e1>5-hydroxyindoleacetic_62\JJ\1740 acid</e1>_63\NN\14818238 (_64\-LRB-\1740 5-hiaa_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
D006897_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 <e1>5-hiaa</e1>_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 <e2>hyperprolactinemia</e2>_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 hyperprolactinemia_86\NN\1740 ._87\.\1740
D006897_D006966 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 change_3\NN\7283608 in_4\IN\13603305 the_5\DT\1740 levels_6\NNS\4916342 of_7\IN\1740 da_8\NN\10484858 ,_9\,\1740 norepinephrine_10\NN\14807929 (_11\-LRB-\1740 ne_12\NN\14622893 )_13\-RRB-\1740 ,_14\,\1740 serotonin_15\NN\14807737 (_16\-LRB-\1740 5-ht_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 or_20\CC\3541091 their_21\PRP$\1740 metabolites_22\NNS\20090 in_23\IN\13603305 the_24\DT\1740 arcuate_25\JJ\1740 nucleus_26\NN\5445668 (_27\-LRB-\1740 an_28\NN\6697703 )_29\-RRB-\1740 ,_30\,\1740 medial_31\JJ\1740 preoptic_32\JJ\1740 area_33\NN\8630985 (_34\-LRB-\1740 mpa_35\NN\1740 )_36\-RRB-\1740 ,_37\,\1740 caudate_38\NN\5497363 putamen_39\NNS\5497363 (_40\-LRB-\1740 cp_41\NN\1740 )_42\-RRB-\1740 ,_43\,\1740 substantia_44\RB\1740 nigra_45\JJ\1740 (_46\-LRB-\1740 sn_47\NN\14625458 )_48\-RRB-\1740 ,_49\,\1740 and_50\CC\1740 zona_51\NN\5225602 incerta_52\NN\1740 (_53\-LRB-\1740 zi_54\NN\1740 )_55\-RRB-\1740 ,_56\,\1740 except_57\IN\1740 for_58\IN\1740 a_59\DT\13649268 decrease_60\NN\7296428 in_61\IN\13603305 5-hydroxyindoleacetic_62\JJ\1740 acid_63\NN\14818238 (_64\-LRB-\1740 <e1>5-hiaa</e1>_65\JJ\1740 )_66\-RRB-\1740 in_67\IN\13603305 the_68\DT\1740 an_69\NN\6697703 after_70\IN\1740 6-months_71\NNS\1740 of_72\IN\1740 hyperprolactinemia_73\NN\1740 and_74\CC\1740 an_75\DT\6697703 increase_76\NN\13576355 in_77\IN\13603305 da_78\NN\10484858 concentrations_79\NNS\4916342 in_80\IN\13603305 the_81\DT\1740 an_82\NNP\6697703 after_83\IN\1740 9-months_84\NNS\1740 of_85\IN\1740 <e2>hyperprolactinemia</e2>_86\NN\1740 ._87\.\1740
11936424
C055603_D007674 NONE <e1>temocapril</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 long-acting_3\JJ\1740 non-sh_4\NN\1740 group_5\NN\2137 angiotensin_6\NN\4522421 converting_7\NN\1740 enzyme_8\NN\14723628 inhibitor_9\NN\20090 ,_10\,\1740 modulates_11\VBZ\1724459 <e2>glomerular_12\JJ\1740 injury</e2>_13\NN\14052046 in_14\IN\13603305 chronic_15\JJ\1740 puromycin_16\NN\1740 aminonucleoside_17\NN\1740 nephrosis_18\NN\14304060 ._19\.\1740
C055603_D009401 NONE <e1>temocapril</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 long-acting_3\JJ\1740 non-sh_4\NN\1740 group_5\NN\2137 angiotensin_6\NN\4522421 converting_7\NN\1740 enzyme_8\NN\14723628 inhibitor_9\NN\20090 ,_10\,\1740 modulates_11\VBZ\1724459 glomerular_12\JJ\1740 injury_13\NN\14052046 in_14\IN\13603305 chronic_15\JJ\1740 puromycin_16\NN\1740 aminonucleoside_17\NN\1740 <e2>nephrosis</e2>_18\NN\14304060 ._19\.\1740
C055603_D009401 NONE it_0\PRP\6125041 appears_1\VBZ\2604760 that_2\IN\1740 <e1>temocapril</e1>_3\NN\1740 was_4\VBD\836236 effective_5\JJ\1740 in_6\IN\13603305 retarding_7\VBG\438495 renal_8\JJ\1740 progression_9\NN\8457976 and_10\CC\1740 protected_11\VBD\1127795 renal_12\JJ\1740 function_13\NN\13783581 in_14\IN\13603305 pan_15\NN\3101986 <e2>neprotic</e2>_16\JJ\1740 rats_17\NNS\2329401 ._18\.\1740
D000809_D007674 NONE temocapril_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 long-acting_3\JJ\1740 non-sh_4\NN\1740 group_5\NN\2137 <e1>angiotensin</e1>_6\NN\4522421 converting_7\NN\1740 enzyme_8\NN\14723628 inhibitor_9\NN\20090 ,_10\,\1740 modulates_11\VBZ\1724459 <e2>glomerular_12\JJ\1740 injury</e2>_13\NN\14052046 in_14\IN\13603305 chronic_15\JJ\1740 puromycin_16\NN\1740 aminonucleoside_17\NN\1740 nephrosis_18\NN\14304060 ._19\.\1740
D000809_D009401 NONE temocapril_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 long-acting_3\JJ\1740 non-sh_4\NN\1740 group_5\NN\2137 <e1>angiotensin</e1>_6\NN\4522421 converting_7\NN\1740 enzyme_8\NN\14723628 inhibitor_9\NN\20090 ,_10\,\1740 modulates_11\VBZ\1724459 glomerular_12\JJ\1740 injury_13\NN\14052046 in_14\IN\13603305 chronic_15\JJ\1740 puromycin_16\NN\1740 aminonucleoside_17\NN\1740 <e2>nephrosis</e2>_18\NN\14304060 ._19\.\1740
D011692_D007674 NONE temocapril_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 long-acting_3\JJ\1740 non-sh_4\NN\1740 group_5\NN\2137 angiotensin_6\NN\4522421 converting_7\NN\1740 enzyme_8\NN\14723628 inhibitor_9\NN\20090 ,_10\,\1740 modulates_11\VBZ\1724459 <e2>glomerular_12\JJ\1740 injury</e2>_13\NN\14052046 in_14\IN\13603305 chronic_15\JJ\1740 <e1>puromycin_16\NN\1740 aminonucleoside</e1>_17\NN\1740 nephrosis_18\NN\14304060 ._19\.\1740
D011692_D009401 CID temocapril_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 long-acting_3\JJ\1740 non-sh_4\NN\1740 group_5\NN\2137 angiotensin_6\NN\4522421 converting_7\NN\1740 enzyme_8\NN\14723628 inhibitor_9\NN\20090 ,_10\,\1740 modulates_11\VBZ\1724459 glomerular_12\JJ\1740 injury_13\NN\14052046 in_14\IN\13603305 chronic_15\JJ\1740 <e1>puromycin_16\NN\1740 aminonucleoside</e1>_17\NN\1740 <e2>nephrosis</e2>_18\NN\14304060 ._19\.\1740
D011692_D009401 CID <e2>nephrosis</e2>_0\NN\14304060 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 injection_4\NN\320852 of_5\IN\1740 <e1>pan</e1>_6\NN\3101986 (_7\-LRB-\1740 15mg/100_8\CD\1740 g_9\NN\13717155 body_10\NN\19128 weight_11\NN\5009170 )_12\-RRB-\1740 in_13\IN\13603305 male_14\JJ\1740 sprague-dawley_15\NN\1740 (_16\-LRB-\1740 sd_17\NN\1740 )_18\-RRB-\1740 rats_19\NNS\2329401 ._20\.\1740
D011692_D009401 CID it_0\PRP\6125041 appears_1\VBZ\2604760 that_2\IN\1740 temocapril_3\NN\1740 was_4\VBD\836236 effective_5\JJ\1740 in_6\IN\13603305 retarding_7\VBG\438495 renal_8\JJ\1740 progression_9\NN\8457976 and_10\CC\1740 protected_11\VBD\1127795 renal_12\JJ\1740 function_13\NN\13783581 in_14\IN\13603305 <e1>pan</e1>_15\NN\3101986 <e2>neprotic</e2>_16\JJ\1740 rats_17\NNS\2329401 ._18\.\1740
C055603_D011507 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>temocapril</e1>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 <e2>proteinuria</e2>_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
C055603_D011507 NONE <e1>temocapril</e1>_0\NN\1740 did_1\VBD\1640855 not_2\RB\1740 attenuate_3\VB\224901 <e2>proteinuria</e2>_4\NN\14299637 at_5\IN\14622893 8_6\CD\13741022 days_7\NNS\15140892 ,_8\,\1740 but_9\CC\1740 it_10\PRP\6125041 did_11\VBD\1640855 markedly_12\RB\1740 lower_13\VB\1850315 it_14\PRP\6125041 from_15\IN\1740 weeks_16\NNS\15113229 4_17\CD\13741022 to_18\TO\1740 20_19\CD\13745420 ._20\.\1740
C055603_D006984 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>temocapril</e1>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 <e2>hypertrophy</e2>_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
C055603_D005921 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>temocapril</e1>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 <e2>glomerulosclerosis</e2>_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
C055603_D009404 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>temocapril</e1>_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 <e2>nephrotic</e2>_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D000809_D011507 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 <e1>angiotensin</e1>_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 <e2>proteinuria</e2>_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D000809_D006984 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 <e1>angiotensin</e1>_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 <e2>hypertrophy</e2>_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D000809_D005921 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 <e1>angiotensin</e1>_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 <e2>glomerulosclerosis</e2>_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D000809_D009404 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 <e1>angiotensin</e1>_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 <e2>nephrotic</e2>_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D011507 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 <e2>proteinuria</e2>_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 <e1>puromycin_38\NN\1740 aminonucleoside</e1>_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D011507 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 <e2>proteinuria</e2>_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 <e1>pan</e1>_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D006984 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 <e2>hypertrophy</e2>_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 <e1>puromycin_38\NN\1740 aminonucleoside</e1>_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D006984 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 <e2>hypertrophy</e2>_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 <e1>pan</e1>_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D005921 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 <e2>glomerulosclerosis</e2>_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 <e1>puromycin_38\NN\1740 aminonucleoside</e1>_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D005921 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 <e2>glomerulosclerosis</e2>_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 <e1>pan</e1>_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 nephrotic_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D005921 NONE the_0\DT\1740 <e2>glomerulosclerosis</e2>_1\NN\1740 index_2\NN\13850304 (_3\-LRB-\1740 gsi_4\NN\1740 )_5\-RRB-\1740 was_6\VBD\836236 6.21_7\CD\1740 %_8\NN\1740 at_9\IN\14622893 4_10\CD\13741022 weeks_11\NNS\15113229 and_12\CC\1740 respectively_13\RB\1740 25.35_14\CD\1740 %_15\NN\1740 and_16\CC\1740 30.49_17\CD\1740 %_18\NN\1740 at_19\IN\14622893 14_20\CD\13745420 and_21\CC\1740 20_22\CD\13745420 weeks_23\NNS\15113229 in_24\IN\13603305 the_25\DT\1740 <e1>pan</e1>_26\NN\3101986 group_27\NN\2137 ._28\.\1740
D011692_D009404 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 <e1>puromycin_38\NN\1740 aminonucleoside</e1>_39\NN\1740 (_40\-LRB-\1740 pan_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 <e2>nephrotic</e2>_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
D011692_D009404 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 determine_8\VB\1645601 whether_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 temocapril_13\NN\1740 ,_14\,\1740 a_15\DT\13649268 long-acting_16\JJ\1740 non-sh_17\NN\1740 group_18\NN\2137 angiotensin_19\NN\4522421 converting_20\NN\1740 enzyme_21\NN\14723628 (_22\-LRB-\1740 ace_23\NN\13741022 )_24\-RRB-\1740 inhibitor_25\NN\20090 ,_26\,\1740 reduced_27\VBN\441445 proteinuria_28\NN\14299637 ,_29\,\1740 inhibited_30\VBD\2510337 glomerular_31\JJ\1740 hypertrophy_32\NN\14365950 and_33\CC\1740 prevented_34\VBD\1740 glomerulosclerosis_35\NN\1740 in_36\IN\13603305 chronic_37\JJ\1740 puromycin_38\NN\1740 aminonucleoside_39\NN\1740 (_40\-LRB-\1740 <e1>pan</e1>_41\NN\3101986 )_42\-RRB-\1740 -_43\HYPH\1740 induced_44\VBN\1627355 <e2>nephrotic</e2>_45\JJ\1740 rats_46\NNS\2329401 ._47\.\1740
24923469
7492040
D008012_D009203 NONE clinical_0\JJ\1740 safety_1\NN\13920835 of_2\IN\1740 <e1>lidocaine</e1>_3\NN\3681148 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 cocaine-associated_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 ._10\.\1740
D008012_D009203 NONE study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 safety_6\NN\13920835 of_7\IN\1740 <e1>lidocaine</e1>_8\NN\3681148 in_9\IN\13603305 the_10\DT\1740 setting_11\NN\8567235 of_12\IN\1740 cocaine-induced_13\JJ\1740 <e2>myocardial_14\JJ\1740 infarction</e2>_15\NN\14204950 (_16\-LRB-\1740 mi_17\NN\14207561 )_18\-RRB-\1740 ._19\.\1740
D008012_D009203 NONE study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 safety_6\NN\13920835 of_7\IN\1740 <e1>lidocaine</e1>_8\NN\3681148 in_9\IN\13603305 the_10\DT\1740 setting_11\NN\8567235 of_12\IN\1740 cocaine-induced_13\JJ\1740 myocardial_14\JJ\1740 infarction_15\NN\14204950 (_16\-LRB-\1740 <e2>mi</e2>_17\NN\14207561 )_18\-RRB-\1740 ._19\.\1740
D008012_D009203 NONE participants_0\NNS\9816771 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 cocaine-associated_4\JJ\1740 <e2>mi</e2>_5\NN\14207561 who_6\WP\8299493 received_7\VBD\2210855 <e1>lidocaine</e1>_8\NN\3681148 in_9\IN\13603305 the_10\DT\1740 emergency_11\NN\7417644 department_12\NN\8220714 ._13\.\1740
D008012_D009203 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 <e1>lidocaine</e1>_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 <e2>mi</e2>_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D009203 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 <e2>mi</e2>_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>lidocaine</e1>_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D009203 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 <e1>lidocaine</e1>_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 <e2>mi</e2>_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D008012_D009203 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>lidocaine</e1>_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 <e2>mi</e2>_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D003042_D009203 CID clinical_0\JJ\1740 safety_1\NN\13920835 of_2\IN\1740 lidocaine_3\NN\3681148 in_4\IN\13603305 patients_5\NNS\9898892 with_6\IN\1740 <e1>cocaine-associated</e1>_7\JJ\1740 <e2>myocardial_8\JJ\1740 infarction</e2>_9\NN\14204950 ._10\.\1740
D003042_D009203 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 safety_6\NN\13920835 of_7\IN\1740 lidocaine_8\NN\3681148 in_9\IN\13603305 the_10\DT\1740 setting_11\NN\8567235 of_12\IN\1740 <e1>cocaine-induced</e1>_13\JJ\1740 <e2>myocardial_14\JJ\1740 infarction</e2>_15\NN\14204950 (_16\-LRB-\1740 mi_17\NN\14207561 )_18\-RRB-\1740 ._19\.\1740
D003042_D009203 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 safety_6\NN\13920835 of_7\IN\1740 lidocaine_8\NN\3681148 in_9\IN\13603305 the_10\DT\1740 setting_11\NN\8567235 of_12\IN\1740 <e1>cocaine-induced</e1>_13\JJ\1740 myocardial_14\JJ\1740 infarction_15\NN\14204950 (_16\-LRB-\1740 <e2>mi</e2>_17\NN\14207561 )_18\-RRB-\1740 ._19\.\1740
D003042_D009203 CID participants_0\NNS\9816771 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 <e1>cocaine-associated</e1>_4\JJ\1740 <e2>mi</e2>_5\NN\14207561 who_6\WP\8299493 received_7\VBD\2210855 lidocaine_8\NN\3681148 in_9\IN\13603305 the_10\DT\1740 emergency_11\NN\7417644 department_12\NN\8220714 ._13\.\1740
D003042_D009203 CID results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 <e2>mi</e2>_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D003042_D009203 CID conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 <e1>cocaine</e1>_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 <e2>mi</e2>_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D003042_D009203 CID conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 <e1>cocaine-associated</e1>_19\JJ\1740 <e2>mi</e2>_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D008012_D001919 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 <e1>lidocaine</e1>_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 <e2>bradydysrhythmias</e2>_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D001919 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 <e2>bradydysrhythmias</e2>_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>lidocaine</e1>_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D017180 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 <e1>lidocaine</e1>_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 <e2>ventricular_22\JJ\1740 tachycardia</e2>_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D017180 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 <e2>ventricular_22\JJ\1740 tachycardia</e2>_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>lidocaine</e1>_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D014693 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 <e1>lidocaine</e1>_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 <e2>ventricular_26\JJ\1740 fibrillation</e2>_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D014693 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 <e2>ventricular_26\JJ\1740 fibrillation</e2>_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>lidocaine</e1>_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D012640 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 <e1>lidocaine</e1>_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 <e2>seizures</e2>_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D012640 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 cocaine-associated_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 <e2>seizures</e2>_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>lidocaine</e1>_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D003042_D001919 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 <e2>bradydysrhythmias</e2>_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D003042_D017180 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 <e2>ventricular_22\JJ\1740 tachycardia</e2>_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D003042_D014693 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 <e2>ventricular_26\JJ\1740 fibrillation</e2>_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 seizures_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D003042_D012640 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 29_3\CD\13745420 patients_4\NNS\9898892 who_5\WP\8299493 received_6\VBD\2210855 lidocaine_7\NN\3681148 in_8\IN\13603305 the_9\DT\1740 setting_10\NN\8567235 of_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 mi_13\NN\14207561 ,_14\,\1740 no_15\DT\7204911 patient_16\NN\9898892 died_17\VBD\146138 ;_18\:\1740 exhibited_19\VBD\2632167 bradydysrhythmias_20\NNS\1740 ,_21\,\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 ,_24\,\1740 or_25\CC\3541091 ventricular_26\JJ\1740 fibrillation_27\NN\14361664 ;_28\:\1740 or_29\CC\3541091 experienced_30\JJ\1740 <e2>seizures</e2>_31\NNS\14081375 after_32\IN\1740 administration_33\NN\1133281 of_34\IN\1740 lidocaine_35\NN\3681148 (_36\-LRB-\1740 95_37\CD\1740 %_38\NN\1740 confidence_39\NN\5697135 interval_40\NN\33615 ,_41\,\1740 0_42\CD\13741022 %_43\NN\1740 to_44\TO\1740 11_45\CD\13745420 %_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D008012_D064420 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 <e1>lidocaine</e1>_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 <e2>toxicity</e2>_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D008012_D064420 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 <e2>toxicity</e2>_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>lidocaine</e1>_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D008012_D002318 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 <e1>lidocaine</e1>_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
D008012_D002318 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>lidocaine</e1>_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
D008012_D002493 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 <e1>lidocaine</e1>_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
D008012_D002493 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>lidocaine</e1>_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
D003042_D064420 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 <e1>cocaine</e1>_9\NN\3492717 <e2>toxicity</e2>_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D003042_D064420 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 <e2>toxicity</e2>_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 <e1>cocaine-associated</e1>_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity_31\NN\13576101 ._32\.\1740
D003042_D002318 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 <e1>cocaine</e1>_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
D003042_D002318 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 <e1>cocaine-associated</e1>_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
D003042_D002493 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 <e1>cocaine</e1>_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 cocaine-associated_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
D003042_D002493 NONE conclusion_0\NN\5837957 :_1\:\1740 despite_2\IN\7501545 theoretical_3\JJ\1740 concerns_4\NNS\5682950 that_5\IN\1740 lidocaine_6\NN\3681148 may_7\MD\15209706 enhance_8\VB\227165 cocaine_9\NN\3492717 toxicity_10\NN\13576101 ,_11\,\1740 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 lidocaine_15\NN\3681148 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 <e1>cocaine-associated</e1>_19\JJ\1740 mi_20\NN\14207561 was_21\VBD\836236 not_22\RB\1740 associated_23\VBN\628491 with_24\IN\1740 significant_25\JJ\1740 <e2>cardiovascular_26\JJ\1740 or_27\CC\3541091 central_28\JJ\1740 nervous_29\JJ\1740 system_30\NN\3575240 toxicity</e2>_31\NN\13576101 ._32\.\1740
17035713
C004656_D007674 NONE <e1>chloroacetaldehyde</e1>_0\NN\1740 as_1\IN\14622893 a_2\DT\13649268 sulfhydryl_3\NN\1740 reagent_4\NN\14779550 :_5\:\1740 the_6\DT\1740 role_7\NN\719494 of_8\IN\1740 critical_9\JJ\1740 thiol_10\NN\1740 groups_11\NNS\2137 in_12\IN\13603305 ifosfamide_13\NN\1740 <e2>nephropathy</e2>_14\NN\14573196 ._15\.\1740
C004656_D007674 NONE <e1>chloroacetaldehyde</e1>_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 <e2>renal_19\JJ\1740 damage</e2>_20\NN\7296428 following_21\VBG\1835496 anti-tumor_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
C004656_D007674 NONE chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 <e1>caa</e1>_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 <e2>renal_19\JJ\1740 damage</e2>_20\NN\7296428 following_21\VBG\1835496 anti-tumor_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
-1_D007674 NONE chloroacetaldehyde_0\NN\1740 as_1\IN\14622893 a_2\DT\13649268 <e1>sulfhydryl</e1>_3\NN\1740 reagent_4\NN\14779550 :_5\:\1740 the_6\DT\1740 role_7\NN\719494 of_8\IN\1740 critical_9\JJ\1740 thiol_10\NN\1740 groups_11\NNS\2137 in_12\IN\13603305 ifosfamide_13\NN\1740 <e2>nephropathy</e2>_14\NN\14573196 ._15\.\1740
D013438_D007674 NONE chloroacetaldehyde_0\NN\1740 as_1\IN\14622893 a_2\DT\13649268 sulfhydryl_3\NN\1740 reagent_4\NN\14779550 :_5\:\1740 the_6\DT\1740 role_7\NN\719494 of_8\IN\1740 critical_9\JJ\1740 <e1>thiol</e1>_10\NN\1740 groups_11\NNS\2137 in_12\IN\13603305 ifosfamide_13\NN\1740 <e2>nephropathy</e2>_14\NN\14573196 ._15\.\1740
D007069_D007674 CID chloroacetaldehyde_0\NN\1740 as_1\IN\14622893 a_2\DT\13649268 sulfhydryl_3\NN\1740 reagent_4\NN\14779550 :_5\:\1740 the_6\DT\1740 role_7\NN\719494 of_8\IN\1740 critical_9\JJ\1740 thiol_10\NN\1740 groups_11\NNS\2137 in_12\IN\13603305 <e1>ifosfamide</e1>_13\NN\1740 <e2>nephropathy</e2>_14\NN\14573196 ._15\.\1740
D007069_D007674 CID chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 <e1>ifosfamide</e1>_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 <e2>renal_19\JJ\1740 damage</e2>_20\NN\7296428 following_21\VBG\1835496 anti-tumor_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
D007069_D007674 CID chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 <e1>ifo</e1>_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 <e2>renal_19\JJ\1740 damage</e2>_20\NN\7296428 following_21\VBG\1835496 anti-tumor_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
D007069_D007674 CID chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 <e2>renal_19\JJ\1740 damage</e2>_20\NN\7296428 following_21\VBG\1835496 anti-tumor_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 <e1>ifo</e1>_25\NN\1740 ._26\.\1740
D007069_D007674 CID therefore_0\RB\1740 ,_1\,\1740 urinary_2\JJ\1740 acidification_3\NN\13518963 could_4\MD\1740 be_5\VB\836236 an_6\DT\6697703 option_7\NN\6480506 to_8\TO\1740 prevent_9\VB\1740 <e1>ifo</e1>_10\NN\1740 <e2>nephropathy</e2>_11\NN\14573196 in_12\IN\13603305 patients_13\NNS\9898892 ._14\.\1740
C004656_D009369 NONE <e1>chloroacetaldehyde</e1>_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 renal_19\JJ\1740 damage_20\NN\7296428 following_21\VBG\1835496 <e2>anti-tumor</e2>_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
C004656_D009369 NONE chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 <e1>caa</e1>_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 renal_19\JJ\1740 damage_20\NN\7296428 following_21\VBG\1835496 <e2>anti-tumor</e2>_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
D007069_D009369 NONE chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 <e1>ifosfamide</e1>_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 renal_19\JJ\1740 damage_20\NN\7296428 following_21\VBG\1835496 <e2>anti-tumor</e2>_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
D007069_D009369 NONE chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 <e1>ifo</e1>_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 renal_19\JJ\1740 damage_20\NN\7296428 following_21\VBG\1835496 <e2>anti-tumor</e2>_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 ifo_25\NN\1740 ._26\.\1740
D007069_D009369 NONE chloroacetaldehyde_0\NN\1740 (_1\-LRB-\1740 caa_2\NNP\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 metabolite_6\NN\20090 of_7\IN\1740 the_8\DT\1740 alkylating_9\VBG\1740 agent_10\NN\7347 ifosfamide_11\NN\1740 (_12\-LRB-\1740 ifo_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 putatively_16\RB\1740 responsible_17\JJ\1740 for_18\IN\1740 renal_19\JJ\1740 damage_20\NN\7296428 following_21\VBG\1835496 <e2>anti-tumor</e2>_22\JJ\1740 therapy_23\NN\657604 with_24\IN\1740 <e1>ifo</e1>_25\NN\1740 ._26\.\1740
C004656_D064420 NONE <e2>toxicity</e2>_0\NN\13576101 of_1\IN\1740 <e1>caa</e1>_2\NNP\1740 was_3\VBD\836236 determined_4\VBN\1645601 by_5\IN\1740 protein_6\NN\14944888 content_7\NN\7951464 ,_8\,\1740 cell_9\NN\3080309 number_10\NN\5107765 ,_11\,\1740 ldh_12\NN\1740 release_13\NN\3748886 ,_14\,\1740 trypan_15\VBP\1740 blue_16\JJ\1740 exclusion_17\NN\13927383 assay_18\NN\5733583 and_19\CC\1740 caspase-3_20\NN\1740 activity_21\NN\30358 ._22\.\1740
C004656_D064420 NONE thus_0\RB\1740 ,_1\,\1740 <e1>caa</e1>_2\NNP\1740 directly_3\RB\1740 reacts_4\VBZ\2367363 with_5\IN\1740 cellular_6\JJ\1740 protein_7\NN\14944888 and_8\CC\1740 non-protein_9\JJ\1740 thiols_10\NNS\1740 ,_11\,\1740 mediating_12\VBG\761713 its_13\PRP$\6125041 <e2>toxicity</e2>_14\NN\13576101 on_15\IN\1740 hrptec_16\NNP\1740 ._17\.\1740
D014343_D064420 NONE <e2>toxicity</e2>_0\NN\13576101 of_1\IN\1740 caa_2\NNP\1740 was_3\VBD\836236 determined_4\VBN\1645601 by_5\IN\1740 protein_6\NN\14944888 content_7\NN\7951464 ,_8\,\1740 cell_9\NN\3080309 number_10\NN\5107765 ,_11\,\1740 ldh_12\NN\1740 release_13\NN\3748886 ,_14\,\1740 <e1>trypan_15\VBP\1740 blue</e1>_16\JJ\1740 exclusion_17\NN\13927383 assay_18\NN\5733583 and_19\CC\1740 caspase-3_20\NN\1740 activity_21\NN\30358 ._22\.\1740
C004656_D009336 NONE <e1>caa</e1>_0\NNP\1740 reduced_1\VBD\441445 hrptec_2\NN\1740 cell_3\NN\3080309 number_4\NN\5107765 and_5\CC\1740 protein_6\NN\14944888 ,_7\,\1740 induced_8\VBD\1627355 a_9\DT\13649268 loss_10\NN\13252973 in_11\IN\13603305 free_12\JJ\1740 intracellular_13\JJ\1740 thiols_14\NNS\1740 and_15\CC\1740 an_16\DT\6697703 increase_17\NN\13576355 in_18\IN\13603305 <e2>necrosis</e2>_19\NN\11444117 markers_20\NNS\21939 ._21\.\1740
C004656_D009336 NONE acidification_0\NN\13518963 ,_1\,\1740 which_2\WDT\1740 slowed_3\VBD\151689 the_4\DT\1740 reaction_5\NN\13446390 of_6\IN\1740 <e1>caa</e1>_7\NN\1740 with_8\IN\1740 thiol_9\NN\1740 donors_10\NNS\9608709 ,_11\,\1740 could_12\MD\1740 also_13\RB\1740 attenuate_14\VB\224901 effects_15\NNS\13245626 of_16\IN\1740 caa_17\NN\1740 on_18\IN\1740 <e2>necrosis</e2>_19\NN\11444117 markers_20\NNS\21939 ,_21\,\1740 thiol_22\NN\1740 depletion_23\NN\351638 and_24\CC\1740 cysteine_25\NN\14601829 protease_26\NN\14732946 inhibition_27\NN\1068773 in_28\IN\13603305 living_29\VBG\2655135 cells_30\NNS\3080309 ._31\.\1740
C004656_D009336 NONE acidification_0\NN\13518963 ,_1\,\1740 which_2\WDT\1740 slowed_3\VBD\151689 the_4\DT\1740 reaction_5\NN\13446390 of_6\IN\1740 caa_7\NN\1740 with_8\IN\1740 thiol_9\NN\1740 donors_10\NNS\9608709 ,_11\,\1740 could_12\MD\1740 also_13\RB\1740 attenuate_14\VB\224901 effects_15\NNS\13245626 of_16\IN\1740 <e1>caa</e1>_17\NN\1740 on_18\IN\1740 <e2>necrosis</e2>_19\NN\11444117 markers_20\NNS\21939 ,_21\,\1740 thiol_22\NN\1740 depletion_23\NN\351638 and_24\CC\1740 cysteine_25\NN\14601829 protease_26\NN\14732946 inhibition_27\NN\1068773 in_28\IN\13603305 living_29\VBG\2655135 cells_30\NNS\3080309 ._31\.\1740
D013438_D009336 NONE caa_0\NNP\1740 reduced_1\VBD\441445 hrptec_2\NN\1740 cell_3\NN\3080309 number_4\NN\5107765 and_5\CC\1740 protein_6\NN\14944888 ,_7\,\1740 induced_8\VBD\1627355 a_9\DT\13649268 loss_10\NN\13252973 in_11\IN\13603305 free_12\JJ\1740 intracellular_13\JJ\1740 <e1>thiols</e1>_14\NNS\1740 and_15\CC\1740 an_16\DT\6697703 increase_17\NN\13576355 in_18\IN\13603305 <e2>necrosis</e2>_19\NN\11444117 markers_20\NNS\21939 ._21\.\1740
D013438_D009336 NONE acidification_0\NN\13518963 ,_1\,\1740 which_2\WDT\1740 slowed_3\VBD\151689 the_4\DT\1740 reaction_5\NN\13446390 of_6\IN\1740 caa_7\NN\1740 with_8\IN\1740 <e1>thiol</e1>_9\NN\1740 donors_10\NNS\9608709 ,_11\,\1740 could_12\MD\1740 also_13\RB\1740 attenuate_14\VB\224901 effects_15\NNS\13245626 of_16\IN\1740 caa_17\NN\1740 on_18\IN\1740 <e2>necrosis</e2>_19\NN\11444117 markers_20\NNS\21939 ,_21\,\1740 thiol_22\NN\1740 depletion_23\NN\351638 and_24\CC\1740 cysteine_25\NN\14601829 protease_26\NN\14732946 inhibition_27\NN\1068773 in_28\IN\13603305 living_29\VBG\2655135 cells_30\NNS\3080309 ._31\.\1740
D013438_D009336 NONE acidification_0\NN\13518963 ,_1\,\1740 which_2\WDT\1740 slowed_3\VBD\151689 the_4\DT\1740 reaction_5\NN\13446390 of_6\IN\1740 caa_7\NN\1740 with_8\IN\1740 thiol_9\NN\1740 donors_10\NNS\9608709 ,_11\,\1740 could_12\MD\1740 also_13\RB\1740 attenuate_14\VB\224901 effects_15\NNS\13245626 of_16\IN\1740 caa_17\NN\1740 on_18\IN\1740 <e2>necrosis</e2>_19\NN\11444117 markers_20\NNS\21939 ,_21\,\1740 <e1>thiol</e1>_22\NN\1740 depletion_23\NN\351638 and_24\CC\1740 cysteine_25\NN\14601829 protease_26\NN\14732946 inhibition_27\NN\1068773 in_28\IN\13603305 living_29\VBG\2655135 cells_30\NNS\3080309 ._31\.\1740
D003545_D009336 NONE acidification_0\NN\13518963 ,_1\,\1740 which_2\WDT\1740 slowed_3\VBD\151689 the_4\DT\1740 reaction_5\NN\13446390 of_6\IN\1740 caa_7\NN\1740 with_8\IN\1740 thiol_9\NN\1740 donors_10\NNS\9608709 ,_11\,\1740 could_12\MD\1740 also_13\RB\1740 attenuate_14\VB\224901 effects_15\NNS\13245626 of_16\IN\1740 caa_17\NN\1740 on_18\IN\1740 <e2>necrosis</e2>_19\NN\11444117 markers_20\NNS\21939 ,_21\,\1740 thiol_22\NN\1740 depletion_23\NN\351638 and_24\CC\1740 <e1>cysteine</e1>_25\NN\14601829 protease_26\NN\14732946 inhibition_27\NN\1068773 in_28\IN\13603305 living_29\VBG\2655135 cells_30\NNS\3080309 ._31\.\1740
D013438_D064420 NONE thus_0\RB\1740 ,_1\,\1740 caa_2\NNP\1740 directly_3\RB\1740 reacts_4\VBZ\2367363 with_5\IN\1740 cellular_6\JJ\1740 protein_7\NN\14944888 and_8\CC\1740 non-protein_9\JJ\1740 <e1>thiols</e1>_10\NNS\1740 ,_11\,\1740 mediating_12\VBG\761713 its_13\PRP$\6125041 <e2>toxicity</e2>_14\NN\13576101 on_15\IN\1740 hrptec_16\NNP\1740 ._17\.\1740
9831002
D008774_D009459 CID <e2>neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome</e2>_2\NN\5870365 and_3\CC\1740 <e1>methylphenidate</e1>_4\NN\4320126 ._5\.\1740
D008774_D009459 CID a_0\DT\13649268 1-year-old_1\JJ\1740 female_2\NN\15388 presented_3\VBN\2137132 with_4\IN\1740 <e2>neuroleptic_5\JJ\1740 malignant_6\JJ\1740 syndrome</e2>_7\NN\5870365 probably_8\RB\1740 caused_9\VBN\1617192 by_10\IN\1740 <e1>methylphenidate</e1>_11\NN\4320126 ._12\.\1740
D008774_D009459 CID this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 reported_4\VBN\831651 patient_5\NN\9898892 with_6\IN\1740 <e2>neuroleptic_7\JJ\1740 malignant_8\JJ\1740 syndrome</e2>_9\NN\5870365 probably_10\RB\1740 caused_11\VBN\1617192 by_12\IN\1740 <e1>methylphenidate</e1>_13\NN\4320126 ._14\.\1740
24072398
D008694_D020258 NONE a_0\DT\13649268 single_1\JJ\1740 <e2>neurotoxic</e2>_2\JJ\1740 dose_3\NN\3740161 of_4\IN\1740 <e1>methamphetamine</e1>_5\NN\2704153 induces_6\VBZ\1627355 a_7\DT\13649268 long-lasting_8\JJ\1740 depressive-like_9\JJ\1740 behaviour_10\NN\14006945 in_11\IN\13603305 mice_12\NNS\2329401 ._13\.\1740
D008694_D003866 CID a_0\DT\13649268 single_1\JJ\1740 neurotoxic_2\JJ\1740 dose_3\NN\3740161 of_4\IN\1740 <e1>methamphetamine</e1>_5\NN\2704153 induces_6\VBZ\1627355 a_7\DT\13649268 long-lasting_8\JJ\1740 <e2>depressive-like</e2>_9\JJ\1740 behaviour_10\NN\14006945 in_11\IN\13603305 mice_12\NNS\2329401 ._13\.\1740
D008694_D003866 CID <e1>methamphetamine</e1>_0\NNP\2704153 (_1\-LRB-\1740 meth_2\NN\2704153 )_3\-RRB-\1740 triggers_4\VBZ\1641914 a_5\DT\13649268 disruption_6\NN\1066163 of_7\IN\1740 the_8\DT\1740 monoaminergic_9\JJ\1740 system_10\NN\3575240 and_11\CC\1740 meth_12\NN\2704153 abuse_13\NN\418025 leads_14\VBZ\1752884 to_15\TO\1740 negative_16\JJ\1740 emotional_17\JJ\1740 states_18\NNS\8491826 including_19\VBG\690614 <e2>depressive_20\JJ\1740 symptoms</e2>_21\NNS\5823932 during_22\IN\1740 drug_23\NN\14778436 withdrawal_24\NN\7206096 ._25\.\1740
D008694_D003866 CID methamphetamine_0\NNP\2704153 (_1\-LRB-\1740 <e1>meth</e1>_2\NN\2704153 )_3\-RRB-\1740 triggers_4\VBZ\1641914 a_5\DT\13649268 disruption_6\NN\1066163 of_7\IN\1740 the_8\DT\1740 monoaminergic_9\JJ\1740 system_10\NN\3575240 and_11\CC\1740 meth_12\NN\2704153 abuse_13\NN\418025 leads_14\VBZ\1752884 to_15\TO\1740 negative_16\JJ\1740 emotional_17\JJ\1740 states_18\NNS\8491826 including_19\VBG\690614 <e2>depressive_20\JJ\1740 symptoms</e2>_21\NNS\5823932 during_22\IN\1740 drug_23\NN\14778436 withdrawal_24\NN\7206096 ._25\.\1740
D008694_D003866 CID methamphetamine_0\NNP\2704153 (_1\-LRB-\1740 meth_2\NN\2704153 )_3\-RRB-\1740 triggers_4\VBZ\1641914 a_5\DT\13649268 disruption_6\NN\1066163 of_7\IN\1740 the_8\DT\1740 monoaminergic_9\JJ\1740 system_10\NN\3575240 and_11\CC\1740 <e1>meth</e1>_12\NN\2704153 abuse_13\NN\418025 leads_14\VBZ\1752884 to_15\TO\1740 negative_16\JJ\1740 emotional_17\JJ\1740 states_18\NNS\8491826 including_19\VBG\690614 <e2>depressive_20\JJ\1740 symptoms</e2>_21\NNS\5823932 during_22\IN\1740 drug_23\NN\14778436 withdrawal_24\NN\7206096 ._25\.\1740
D008694_D003866 CID however_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 currently_4\RB\1740 unknown_5\JJ\1740 if_6\IN\1740 the_7\DT\1740 acute_8\JJ\1740 toxic_9\JJ\1740 dosage_10\NN\13576355 of_11\IN\1740 <e1>meth</e1>_12\NN\2704153 also_13\RB\1740 causes_14\VBZ\1617192 a_15\DT\13649268 long-lasting_16\JJ\1740 <e2>depressive</e2>_17\JJ\1740 phenotype_18\NN\4933544 and_19\CC\1740 persistent_20\JJ\1740 monoaminergic_21\JJ\1740 deficits_22\NNS\5113133 ._23\.\1740
D008694_D003866 CID thus_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 now_3\RB\1740 assessed_4\VBD\670261 the_5\DT\1740 <e2>depressive-like</e2>_6\JJ\1740 behaviour_7\NN\14006945 in_8\IN\13603305 mice_9\NNS\2329401 at_10\IN\14622893 early_11\JJ\1740 and_12\CC\1740 long-term_13\JJ\1740 periods_14\NNS\13575869 following_15\VBG\1835496 a_16\DT\13649268 single_17\JJ\1740 high_18\JJ\1740 <e1>meth</e1>_19\NN\2704153 dose_20\NN\3740161 (_21\-LRB-\1740 30_22\CD\13745420 mg/kg_23\NN\1740 ,_24\,\1740 i.p._25\RB\1740 )_26\-RRB-\1740 ._27\.\1740
D008694_D003866 CID this_0\DT\1740 <e2>depressive-like</e2>_1\JJ\1740 profile_2\NN\6999802 induced_3\VBN\1627355 by_4\IN\1740 <e1>meth</e1>_5\NN\2704153 was_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 a_9\DT\13649268 marked_10\JJ\1740 depletion_11\NN\351638 of_12\IN\1740 frontostriatal_13\JJ\1740 dopaminergic_14\JJ\1740 and_15\CC\1740 serotonergic_16\JJ\1740 neurotransmission_17\NN\1740 ,_18\,\1740 indicated_19\VBN\952524 by_20\IN\1740 a_21\DT\13649268 reduction_22\NN\351485 in_23\IN\13603305 the_24\DT\1740 levels_25\NNS\4916342 of_26\IN\1740 dopamine_27\NN\14807737 ,_28\,\1740 dopac_29\NN\1740 and_30\CC\1740 hva_31\NN\1740 ,_32\,\1740 tyrosine_33\NN\14601829 hydroxylase_34\NN\1740 and_35\CC\1740 serotonin_36\NN\14807737 ,_37\,\1740 observed_38\VBN\2163746 at_39\IN\14622893 both_40\CC\1740 3_41\CD\13741022 and_42\CC\1740 49_43\CD\1740 days_44\NNS\15140892 post-administration_45\JJ\1740 ._46\.\1740
D008694_D003866 CID these_0\DT\1740 findings_1\NNS\7951464 demonstrate_2\VBP\2137132 for_3\IN\1740 the_4\DT\1740 first_5\JJ\1740 time_6\NN\7308889 that_7\WDT\1740 a_8\DT\13649268 single_9\JJ\1740 high_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 <e1>meth</e1>_13\NN\2704153 induces_14\VBZ\1627355 long-lasting_15\JJ\1740 <e2>depressive-like</e2>_16\JJ\1740 behaviour_17\NN\14006945 in_18\IN\13603305 mice_19\NNS\2329401 associated_20\VBN\628491 with_21\IN\1740 a_22\DT\13649268 persistent_23\JJ\1740 disruption_24\NN\1066163 of_25\IN\1740 frontostriatal_26\JJ\1740 dopaminergic_27\JJ\1740 and_28\CC\1740 serotonergic_29\JJ\1740 homoeostasis_30\NN\1740 ._31\.\1740
D004298_D003866 NONE this_0\DT\1740 <e2>depressive-like</e2>_1\JJ\1740 profile_2\NN\6999802 induced_3\VBN\1627355 by_4\IN\1740 meth_5\NN\2704153 was_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 a_9\DT\13649268 marked_10\JJ\1740 depletion_11\NN\351638 of_12\IN\1740 frontostriatal_13\JJ\1740 dopaminergic_14\JJ\1740 and_15\CC\1740 serotonergic_16\JJ\1740 neurotransmission_17\NN\1740 ,_18\,\1740 indicated_19\VBN\952524 by_20\IN\1740 a_21\DT\13649268 reduction_22\NN\351485 in_23\IN\13603305 the_24\DT\1740 levels_25\NNS\4916342 of_26\IN\1740 <e1>dopamine</e1>_27\NN\14807737 ,_28\,\1740 dopac_29\NN\1740 and_30\CC\1740 hva_31\NN\1740 ,_32\,\1740 tyrosine_33\NN\14601829 hydroxylase_34\NN\1740 and_35\CC\1740 serotonin_36\NN\14807737 ,_37\,\1740 observed_38\VBN\2163746 at_39\IN\14622893 both_40\CC\1740 3_41\CD\13741022 and_42\CC\1740 49_43\CD\1740 days_44\NNS\15140892 post-administration_45\JJ\1740 ._46\.\1740
D015102_D003866 NONE this_0\DT\1740 <e2>depressive-like</e2>_1\JJ\1740 profile_2\NN\6999802 induced_3\VBN\1627355 by_4\IN\1740 meth_5\NN\2704153 was_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 a_9\DT\13649268 marked_10\JJ\1740 depletion_11\NN\351638 of_12\IN\1740 frontostriatal_13\JJ\1740 dopaminergic_14\JJ\1740 and_15\CC\1740 serotonergic_16\JJ\1740 neurotransmission_17\NN\1740 ,_18\,\1740 indicated_19\VBN\952524 by_20\IN\1740 a_21\DT\13649268 reduction_22\NN\351485 in_23\IN\13603305 the_24\DT\1740 levels_25\NNS\4916342 of_26\IN\1740 dopamine_27\NN\14807737 ,_28\,\1740 <e1>dopac</e1>_29\NN\1740 and_30\CC\1740 hva_31\NN\1740 ,_32\,\1740 tyrosine_33\NN\14601829 hydroxylase_34\NN\1740 and_35\CC\1740 serotonin_36\NN\14807737 ,_37\,\1740 observed_38\VBN\2163746 at_39\IN\14622893 both_40\CC\1740 3_41\CD\13741022 and_42\CC\1740 49_43\CD\1740 days_44\NNS\15140892 post-administration_45\JJ\1740 ._46\.\1740
D006719_D003866 NONE this_0\DT\1740 <e2>depressive-like</e2>_1\JJ\1740 profile_2\NN\6999802 induced_3\VBN\1627355 by_4\IN\1740 meth_5\NN\2704153 was_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 a_9\DT\13649268 marked_10\JJ\1740 depletion_11\NN\351638 of_12\IN\1740 frontostriatal_13\JJ\1740 dopaminergic_14\JJ\1740 and_15\CC\1740 serotonergic_16\JJ\1740 neurotransmission_17\NN\1740 ,_18\,\1740 indicated_19\VBN\952524 by_20\IN\1740 a_21\DT\13649268 reduction_22\NN\351485 in_23\IN\13603305 the_24\DT\1740 levels_25\NNS\4916342 of_26\IN\1740 dopamine_27\NN\14807737 ,_28\,\1740 dopac_29\NN\1740 and_30\CC\1740 <e1>hva</e1>_31\NN\1740 ,_32\,\1740 tyrosine_33\NN\14601829 hydroxylase_34\NN\1740 and_35\CC\1740 serotonin_36\NN\14807737 ,_37\,\1740 observed_38\VBN\2163746 at_39\IN\14622893 both_40\CC\1740 3_41\CD\13741022 and_42\CC\1740 49_43\CD\1740 days_44\NNS\15140892 post-administration_45\JJ\1740 ._46\.\1740
D014443_D003866 NONE this_0\DT\1740 <e2>depressive-like</e2>_1\JJ\1740 profile_2\NN\6999802 induced_3\VBN\1627355 by_4\IN\1740 meth_5\NN\2704153 was_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 a_9\DT\13649268 marked_10\JJ\1740 depletion_11\NN\351638 of_12\IN\1740 frontostriatal_13\JJ\1740 dopaminergic_14\JJ\1740 and_15\CC\1740 serotonergic_16\JJ\1740 neurotransmission_17\NN\1740 ,_18\,\1740 indicated_19\VBN\952524 by_20\IN\1740 a_21\DT\13649268 reduction_22\NN\351485 in_23\IN\13603305 the_24\DT\1740 levels_25\NNS\4916342 of_26\IN\1740 dopamine_27\NN\14807737 ,_28\,\1740 dopac_29\NN\1740 and_30\CC\1740 hva_31\NN\1740 ,_32\,\1740 <e1>tyrosine</e1>_33\NN\14601829 hydroxylase_34\NN\1740 and_35\CC\1740 serotonin_36\NN\14807737 ,_37\,\1740 observed_38\VBN\2163746 at_39\IN\14622893 both_40\CC\1740 3_41\CD\13741022 and_42\CC\1740 49_43\CD\1740 days_44\NNS\15140892 post-administration_45\JJ\1740 ._46\.\1740
D012701_D003866 NONE this_0\DT\1740 <e2>depressive-like</e2>_1\JJ\1740 profile_2\NN\6999802 induced_3\VBN\1627355 by_4\IN\1740 meth_5\NN\2704153 was_6\VBD\836236 accompanied_7\VBN\1835496 by_8\IN\1740 a_9\DT\13649268 marked_10\JJ\1740 depletion_11\NN\351638 of_12\IN\1740 frontostriatal_13\JJ\1740 dopaminergic_14\JJ\1740 and_15\CC\1740 serotonergic_16\JJ\1740 neurotransmission_17\NN\1740 ,_18\,\1740 indicated_19\VBN\952524 by_20\IN\1740 a_21\DT\13649268 reduction_22\NN\351485 in_23\IN\13603305 the_24\DT\1740 levels_25\NNS\4916342 of_26\IN\1740 dopamine_27\NN\14807737 ,_28\,\1740 dopac_29\NN\1740 and_30\CC\1740 hva_31\NN\1740 ,_32\,\1740 tyrosine_33\NN\14601829 hydroxylase_34\NN\1740 and_35\CC\1740 <e1>serotonin</e1>_36\NN\14807737 ,_37\,\1740 observed_38\VBN\2163746 at_39\IN\14622893 both_40\CC\1740 3_41\CD\13741022 and_42\CC\1740 49_43\CD\1740 days_44\NNS\15140892 post-administration_45\JJ\1740 ._46\.\1740
18801087
D000638_D055370 CID <e1>amiodarone-related</e1>_0\JJ\1740 <e2>pulmonary_1\JJ\1740 mass</e2>_2\NN\13575869 and_3\CC\1740 unique_4\JJ\1740 membranous_5\JJ\1740 glomerulonephritis_6\NN\14113798 in_7\IN\13603305 a_8\DT\13649268 patient_9\NN\9898892 with_10\IN\1740 valvular_11\JJ\1740 heart_12\NN\5919034 disease_13\NN\14061805 :_14\:\1740 diagnostic_15\NNP\1740 pitfall_16\NN\5686955 and_17\CC\1740 new_18\JJ\1740 findings_19\NNS\7951464 ._20\.\1740
D000638_D055370 CID reported_0\VBN\831651 herein_1\RB\1740 is_2\VBZ\836236 an_3\DT\6697703 autopsy_4\JJ\1740 case_5\NN\7283608 of_6\IN\1740 valvular_7\JJ\1740 heart_8\NN\5919034 disease_9\NN\14061805 ,_10\,\1740 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 a_16\DT\13649268 <e2>lung_17\NN\5528060 mass</e2>_18\NN\13575869 (_19\-LRB-\1740 1.5_20\CD\1740 cm_21\NNS\13649268 in_22\IN\13603305 diameter_23\NN\5129201 )_24\-RRB-\1740 and_25\CC\1740 proteinuria_26\NN\14299637 (_27\-LRB-\1740 2.76_28\CD\1740 g/day_29\NN\1740 )_30\-RRB-\1740 after_31\IN\1740 treatment_32\NN\654885 with_33\IN\1740 <e1>amiodarone</e1>_34\NN\2715941 for_35\IN\1740 a_36\DT\13649268 long_37\JJ\1740 time_38\NN\7308889 ._39\.\1740
D000638_D055370 CID the_0\DT\1740 <e2>lung_1\NN\5528060 mass</e2>_2\NN\13575869 was_3\VBD\836236 highly_4\RB\1740 suspected_5\VBN\916909 to_6\TO\1740 be_7\VB\836236 lung_8\NN\5528060 cancer_9\NN\14239425 on_10\IN\1740 ct_11\NN\901316 and_12\CC\1740 positron_13\NN\9199341 emission_14\NN\44455 tomography_15\NN\900375 ,_16\,\1740 but_17\CC\1740 histologically_18\RB\1740 the_19\DT\1740 lesion_20\NN\14204950 was_21\VBD\836236 composed_22\VBN\2620587 of_23\IN\1740 lymphoplasmacytic_24\JJ\1740 infiltrates_25\NNS\1740 in_26\IN\13603305 alveolar_27\JJ\1740 walls_28\NNS\3894379 and_29\CC\1740 intra-alveolar_30\JJ\1740 accumulation_31\NN\13497135 of_32\IN\1740 foamy_33\NN\1740 macrophages_34\NNS\5450888 containing_35\VBG\2632940 characteristic_36\JJ\1740 myelinoid_37\JJ\1740 bodies_38\NNS\19128 ,_39\,\1740 indicating_40\VBG\952524 that_41\IN\1740 it_42\PRP\6125041 was_43\VBD\836236 an_44\DT\6697703 <e1>amiodarone-related</e1>_45\JJ\1740 lesion_46\NN\14204950 ._47\.\1740
D000638_D055370 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 highlights_3\VBZ\514463 the_4\DT\1740 possibility_5\NN\5944958 that_6\IN\1740 differential_7\JJ\1740 diagnosis_8\NN\152018 between_9\IN\1740 an_10\DT\6697703 <e1>amiodarone-related</e1>_11\JJ\1740 <e2>pulmonary_12\JJ\1740 lesion</e2>_13\NN\14204950 and_14\CC\1740 a_15\DT\13649268 neoplasm_16\NN\14234074 can_17\MD\3094503 be_18\VB\836236 very_19\RB\1740 difficult_20\JJ\1740 radiologically_21\RB\1740 ,_22\,\1740 and_23\CC\1740 suggests_24\VBZ\1010118 that_25\IN\1740 membranous_26\JJ\1740 glomerulonephritis_27\NN\14113798 might_28\MD\5029706 be_29\VB\836236 another_30\DT\1740 possible_31\JJ\1740 complication_32\NN\1073995 of_33\IN\1740 amiodarone_34\JJ\1740 treatment_35\NN\654885 ._36\.\1740
D000638_D055370 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 highlights_3\VBZ\514463 the_4\DT\1740 possibility_5\NN\5944958 that_6\IN\1740 differential_7\JJ\1740 diagnosis_8\NN\152018 between_9\IN\1740 an_10\DT\6697703 amiodarone-related_11\JJ\1740 <e2>pulmonary_12\JJ\1740 lesion</e2>_13\NN\14204950 and_14\CC\1740 a_15\DT\13649268 neoplasm_16\NN\14234074 can_17\MD\3094503 be_18\VB\836236 very_19\RB\1740 difficult_20\JJ\1740 radiologically_21\RB\1740 ,_22\,\1740 and_23\CC\1740 suggests_24\VBZ\1010118 that_25\IN\1740 membranous_26\JJ\1740 glomerulonephritis_27\NN\14113798 might_28\MD\5029706 be_29\VB\836236 another_30\DT\1740 possible_31\JJ\1740 complication_32\NN\1073995 of_33\IN\1740 <e1>amiodarone</e1>_34\JJ\1740 treatment_35\NN\654885 ._36\.\1740
D000638_D015433 CID <e1>amiodarone-related</e1>_0\JJ\1740 pulmonary_1\JJ\1740 mass_2\NN\13575869 and_3\CC\1740 unique_4\JJ\1740 <e2>membranous_5\JJ\1740 glomerulonephritis</e2>_6\NN\14113798 in_7\IN\13603305 a_8\DT\13649268 patient_9\NN\9898892 with_10\IN\1740 valvular_11\JJ\1740 heart_12\NN\5919034 disease_13\NN\14061805 :_14\:\1740 diagnostic_15\NNP\1740 pitfall_16\NN\5686955 and_17\CC\1740 new_18\JJ\1740 findings_19\NNS\7951464 ._20\.\1740
D000638_D015433 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 highlights_3\VBZ\514463 the_4\DT\1740 possibility_5\NN\5944958 that_6\IN\1740 differential_7\JJ\1740 diagnosis_8\NN\152018 between_9\IN\1740 an_10\DT\6697703 <e1>amiodarone-related</e1>_11\JJ\1740 pulmonary_12\JJ\1740 lesion_13\NN\14204950 and_14\CC\1740 a_15\DT\13649268 neoplasm_16\NN\14234074 can_17\MD\3094503 be_18\VB\836236 very_19\RB\1740 difficult_20\JJ\1740 radiologically_21\RB\1740 ,_22\,\1740 and_23\CC\1740 suggests_24\VBZ\1010118 that_25\IN\1740 <e2>membranous_26\JJ\1740 glomerulonephritis</e2>_27\NN\14113798 might_28\MD\5029706 be_29\VB\836236 another_30\DT\1740 possible_31\JJ\1740 complication_32\NN\1073995 of_33\IN\1740 amiodarone_34\JJ\1740 treatment_35\NN\654885 ._36\.\1740
D000638_D015433 CID the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 highlights_3\VBZ\514463 the_4\DT\1740 possibility_5\NN\5944958 that_6\IN\1740 differential_7\JJ\1740 diagnosis_8\NN\152018 between_9\IN\1740 an_10\DT\6697703 amiodarone-related_11\JJ\1740 pulmonary_12\JJ\1740 lesion_13\NN\14204950 and_14\CC\1740 a_15\DT\13649268 neoplasm_16\NN\14234074 can_17\MD\3094503 be_18\VB\836236 very_19\RB\1740 difficult_20\JJ\1740 radiologically_21\RB\1740 ,_22\,\1740 and_23\CC\1740 suggests_24\VBZ\1010118 that_25\IN\1740 <e2>membranous_26\JJ\1740 glomerulonephritis</e2>_27\NN\14113798 might_28\MD\5029706 be_29\VB\836236 another_30\DT\1740 possible_31\JJ\1740 complication_32\NN\1073995 of_33\IN\1740 <e1>amiodarone</e1>_34\JJ\1740 treatment_35\NN\654885 ._36\.\1740
D000638_D006349 NONE <e1>amiodarone-related</e1>_0\JJ\1740 pulmonary_1\JJ\1740 mass_2\NN\13575869 and_3\CC\1740 unique_4\JJ\1740 membranous_5\JJ\1740 glomerulonephritis_6\NN\14113798 in_7\IN\13603305 a_8\DT\13649268 patient_9\NN\9898892 with_10\IN\1740 <e2>valvular_11\JJ\1740 heart_12\NN\5919034 disease</e2>_13\NN\14061805 :_14\:\1740 diagnostic_15\NNP\1740 pitfall_16\NN\5686955 and_17\CC\1740 new_18\JJ\1740 findings_19\NNS\7951464 ._20\.\1740
D000638_D006349 NONE reported_0\VBN\831651 herein_1\RB\1740 is_2\VBZ\836236 an_3\DT\6697703 autopsy_4\JJ\1740 case_5\NN\7283608 of_6\IN\1740 <e2>valvular_7\JJ\1740 heart_8\NN\5919034 disease</e2>_9\NN\14061805 ,_10\,\1740 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 a_16\DT\13649268 lung_17\NN\5528060 mass_18\NN\13575869 (_19\-LRB-\1740 1.5_20\CD\1740 cm_21\NNS\13649268 in_22\IN\13603305 diameter_23\NN\5129201 )_24\-RRB-\1740 and_25\CC\1740 proteinuria_26\NN\14299637 (_27\-LRB-\1740 2.76_28\CD\1740 g/day_29\NN\1740 )_30\-RRB-\1740 after_31\IN\1740 treatment_32\NN\654885 with_33\IN\1740 <e1>amiodarone</e1>_34\NN\2715941 for_35\IN\1740 a_36\DT\13649268 long_37\JJ\1740 time_38\NN\7308889 ._39\.\1740
D000638_D001145 NONE <e1>amiodarone</e1>_0\NN\2715941 is_1\VBZ\836236 an_2\DT\6697703 <e2>anti-arrhythmic</e2>_3\JJ\1740 drug_4\NN\14778436 for_5\IN\1740 life-threatening_6\JJ\1740 tachycardia_7\NN\14110674 ,_8\,\1740 but_9\CC\1740 various_10\JJ\1740 adverse_11\JJ\1740 effects_12\NNS\13245626 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 ._16\.\1740
D000638_D013610 NONE <e1>amiodarone</e1>_0\NN\2715941 is_1\VBZ\836236 an_2\DT\6697703 anti-arrhythmic_3\JJ\1740 drug_4\NN\14778436 for_5\IN\1740 life-threatening_6\JJ\1740 <e2>tachycardia</e2>_7\NN\14110674 ,_8\,\1740 but_9\CC\1740 various_10\JJ\1740 adverse_11\JJ\1740 effects_12\NNS\13245626 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 ._16\.\1740
D000638_D011507 NONE reported_0\VBN\831651 herein_1\RB\1740 is_2\VBZ\836236 an_3\DT\6697703 autopsy_4\JJ\1740 case_5\NN\7283608 of_6\IN\1740 valvular_7\JJ\1740 heart_8\NN\5919034 disease_9\NN\14061805 ,_10\,\1740 in_11\IN\13603305 a_12\DT\13649268 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 a_16\DT\13649268 lung_17\NN\5528060 mass_18\NN\13575869 (_19\-LRB-\1740 1.5_20\CD\1740 cm_21\NNS\13649268 in_22\IN\13603305 diameter_23\NN\5129201 )_24\-RRB-\1740 and_25\CC\1740 <e2>proteinuria</e2>_26\NN\14299637 (_27\-LRB-\1740 2.76_28\CD\1740 g/day_29\NN\1740 )_30\-RRB-\1740 after_31\IN\1740 treatment_32\NN\654885 with_33\IN\1740 <e1>amiodarone</e1>_34\NN\2715941 for_35\IN\1740 a_36\DT\13649268 long_37\JJ\1740 time_38\NN\7308889 ._39\.\1740
D000638_D008175 NONE the_0\DT\1740 lung_1\NN\5528060 mass_2\NN\13575869 was_3\VBD\836236 highly_4\RB\1740 suspected_5\VBN\916909 to_6\TO\1740 be_7\VB\836236 <e2>lung_8\NN\5528060 cancer</e2>_9\NN\14239425 on_10\IN\1740 ct_11\NN\901316 and_12\CC\1740 positron_13\NN\9199341 emission_14\NN\44455 tomography_15\NN\900375 ,_16\,\1740 but_17\CC\1740 histologically_18\RB\1740 the_19\DT\1740 lesion_20\NN\14204950 was_21\VBD\836236 composed_22\VBN\2620587 of_23\IN\1740 lymphoplasmacytic_24\JJ\1740 infiltrates_25\NNS\1740 in_26\IN\13603305 alveolar_27\JJ\1740 walls_28\NNS\3894379 and_29\CC\1740 intra-alveolar_30\JJ\1740 accumulation_31\NN\13497135 of_32\IN\1740 foamy_33\NN\1740 macrophages_34\NNS\5450888 containing_35\VBG\2632940 characteristic_36\JJ\1740 myelinoid_37\JJ\1740 bodies_38\NNS\19128 ,_39\,\1740 indicating_40\VBG\952524 that_41\IN\1740 it_42\PRP\6125041 was_43\VBD\836236 an_44\DT\6697703 <e1>amiodarone-related</e1>_45\JJ\1740 lesion_46\NN\14204950 ._47\.\1740
D000638_D009369 NONE the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 highlights_3\VBZ\514463 the_4\DT\1740 possibility_5\NN\5944958 that_6\IN\1740 differential_7\JJ\1740 diagnosis_8\NN\152018 between_9\IN\1740 an_10\DT\6697703 <e1>amiodarone-related</e1>_11\JJ\1740 pulmonary_12\JJ\1740 lesion_13\NN\14204950 and_14\CC\1740 a_15\DT\13649268 <e2>neoplasm</e2>_16\NN\14234074 can_17\MD\3094503 be_18\VB\836236 very_19\RB\1740 difficult_20\JJ\1740 radiologically_21\RB\1740 ,_22\,\1740 and_23\CC\1740 suggests_24\VBZ\1010118 that_25\IN\1740 membranous_26\JJ\1740 glomerulonephritis_27\NN\14113798 might_28\MD\5029706 be_29\VB\836236 another_30\DT\1740 possible_31\JJ\1740 complication_32\NN\1073995 of_33\IN\1740 amiodarone_34\JJ\1740 treatment_35\NN\654885 ._36\.\1740
D000638_D009369 NONE the_0\DT\1740 present_1\JJ\1740 case_2\NN\7283608 highlights_3\VBZ\514463 the_4\DT\1740 possibility_5\NN\5944958 that_6\IN\1740 differential_7\JJ\1740 diagnosis_8\NN\152018 between_9\IN\1740 an_10\DT\6697703 amiodarone-related_11\JJ\1740 pulmonary_12\JJ\1740 lesion_13\NN\14204950 and_14\CC\1740 a_15\DT\13649268 <e2>neoplasm</e2>_16\NN\14234074 can_17\MD\3094503 be_18\VB\836236 very_19\RB\1740 difficult_20\JJ\1740 radiologically_21\RB\1740 ,_22\,\1740 and_23\CC\1740 suggests_24\VBZ\1010118 that_25\IN\1740 membranous_26\JJ\1740 glomerulonephritis_27\NN\14113798 might_28\MD\5029706 be_29\VB\836236 another_30\DT\1740 possible_31\JJ\1740 complication_32\NN\1073995 of_33\IN\1740 <e1>amiodarone</e1>_34\JJ\1740 treatment_35\NN\654885 ._36\.\1740
20927253
D019386_D010146 CID diffuse_0\JJ\1740 skeletal_1\JJ\1740 <e2>pain</e2>_2\NN\14299637 after_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>alendronate</e1>_6\NN\3740161 ._7\.\1740
D019386_D010146 CID we_0\PRP\1740 presented_1\VBD\2137132 a_2\DT\13649268 patient_3\NN\9898892 admitted_4\VBN\822367 to_5\TO\1740 our_6\PRP$\1740 out-patient_7\JJ\1740 clinic_8\NN\8053905 with_9\IN\1740 diffuse_10\JJ\1740 skeletal_11\JJ\1740 <e2>pain</e2>_12\NN\14299637 after_13\IN\1740 three_14\CD\13741022 consecutive_15\JJ\1740 administration_16\NN\1133281 of_17\IN\1740 <e1>alendronate</e1>_18\NN\3740161 ._19\.\1740
D004164_D010024 NONE background_0\NN\4921011 :_1\:\1740 <e2>osteoporosis</e2>_2\NN\14204950 is_3\VBZ\836236 caused_4\VBN\1617192 by_5\IN\1740 bone_6\NN\5286536 resorption_7\NN\13526110 in_8\IN\13603305 excess_9\NN\5119367 of_10\IN\1740 bone_11\NN\5286536 formation_12\NN\7938773 ,_13\,\1740 and_14\CC\1740 <e1>bisphosphonates</e1>_15\NNS\1740 ,_16\,\1740 are_17\VBP\836236 used_18\VBN\1156834 to_19\TO\1740 inhibit_20\VB\2510337 bone_21\NN\5286536 resorption_22\NN\13526110 ._23\.\1740
D004164_D010024 NONE conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 <e2>osteoporosis</e2>_7\NN\14204950 can_8\MD\3094503 report_9\VB\831651 pain_10\NN\14299637 ,_11\,\1740 and_12\CC\1740 <e1>bisphosphonate-related</e1>_13\JJ\1740 pain_14\NN\14299637 should_15\MD\1740 also_16\RB\1740 be_17\VB\836236 considered_18\VBN\689344 before_19\IN\1740 ascribing_20\VBG\670261 this_21\DT\1740 complaint_22\NN\14052403 to_23\TO\1740 osteoporosis_24\NN\14204950 ._25\.\1740
D004164_D010024 NONE conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 osteoporosis_7\NN\14204950 can_8\MD\3094503 report_9\VB\831651 pain_10\NN\14299637 ,_11\,\1740 and_12\CC\1740 <e1>bisphosphonate-related</e1>_13\JJ\1740 pain_14\NN\14299637 should_15\MD\1740 also_16\RB\1740 be_17\VB\836236 considered_18\VBN\689344 before_19\IN\1740 ascribing_20\VBG\670261 this_21\DT\1740 complaint_22\NN\14052403 to_23\TO\1740 <e2>osteoporosis</e2>_24\NN\14204950 ._25\.\1740
D019386_D010024 NONE <e1>alendronate</e1>_0\NNP\3740161 ,_1\,\1740 a_2\DT\13649268 biphosphonate_3\NN\1740 ,_4\,\1740 is_5\VBZ\836236 effective_6\JJ\1740 for_7\IN\1740 both_8\CC\1740 the_9\DT\1740 treatment_10\NN\654885 and_11\CC\1740 prevention_12\NN\1073995 of_13\IN\1740 <e2>osteoporosis</e2>_14\NN\14204950 in_15\IN\13603305 postmenopausal_16\JJ\1740 women_17\NNS\9605289 ._18\.\1740
-1_D010024 NONE alendronate_0\NNP\3740161 ,_1\,\1740 a_2\DT\13649268 <e1>biphosphonate</e1>_3\NN\1740 ,_4\,\1740 is_5\VBZ\836236 effective_6\JJ\1740 for_7\IN\1740 both_8\CC\1740 the_9\DT\1740 treatment_10\NN\654885 and_11\CC\1740 prevention_12\NN\1073995 of_13\IN\1740 <e2>osteoporosis</e2>_14\NN\14204950 in_15\IN\13603305 postmenopausal_16\JJ\1740 women_17\NNS\9605289 ._18\.\1740
D004164_D010146 NONE conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 osteoporosis_7\NN\14204950 can_8\MD\3094503 report_9\VB\831651 <e2>pain</e2>_10\NN\14299637 ,_11\,\1740 and_12\CC\1740 <e1>bisphosphonate-related</e1>_13\JJ\1740 pain_14\NN\14299637 should_15\MD\1740 also_16\RB\1740 be_17\VB\836236 considered_18\VBN\689344 before_19\IN\1740 ascribing_20\VBG\670261 this_21\DT\1740 complaint_22\NN\14052403 to_23\TO\1740 osteoporosis_24\NN\14204950 ._25\.\1740
D004164_D010146 NONE conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 osteoporosis_7\NN\14204950 can_8\MD\3094503 report_9\VB\831651 pain_10\NN\14299637 ,_11\,\1740 and_12\CC\1740 <e1>bisphosphonate-related</e1>_13\JJ\1740 <e2>pain</e2>_14\NN\14299637 should_15\MD\1740 also_16\RB\1740 be_17\VB\836236 considered_18\VBN\689344 before_19\IN\1740 ascribing_20\VBG\670261 this_21\DT\1740 complaint_22\NN\14052403 to_23\TO\1740 osteoporosis_24\NN\14204950 ._25\.\1740
24902786
D013739_D008569 NONE <e1>testosterone</e1>_0\NN\14747587 ameliorates_1\VBZ\126264 streptozotocin-induced_2\JJ\1740 <e2>memory_3\NN\5926676 impairment</e2>_4\NN\7296428 in_5\IN\13603305 male_6\JJ\1740 rats_7\NNS\2329401 ._8\.\1740
D013739_D008569 NONE aim_0\NN\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>testosterone</e1>_7\NN\14747587 on_8\IN\1740 streptozotocin_9\NN\1740 (stz)-induced_10\JJ\1740 <e2>memory_11\NN\5926676 impairment</e2>_12\NN\7296428 in_13\IN\13603305 male_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D013739_D008569 NONE administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 <e2>impaired_8\VBD\258857 the_9\DT\1740 memory</e2>_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 <e1>testosterone</e1>_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 memory_26\NN\5926676 impairment_27\NN\7296428 ._28\.\1740
D013739_D008569 NONE administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 impaired_8\VBD\258857 the_9\DT\1740 memory_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 <e1>testosterone</e1>_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
D013739_D008569 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>testosterone</e1>_2\NN\14747587 administration_3\NN\1133281 ameliorates_4\VBZ\126264 stz-_5\NN\1740 and_6\CC\1740 castration-induced_7\JJ\1740 <e2>memory_8\NN\5926676 impairment</e2>_9\NN\7296428 in_10\IN\13603305 male_11\JJ\1740 wistar_12\NNP\1740 rats_13\NNS\2329401 ._14\.\1740
D013311_D008569 CID testosterone_0\NN\14747587 ameliorates_1\VBZ\126264 <e1>streptozotocin-induced</e1>_2\JJ\1740 <e2>memory_3\NN\5926676 impairment</e2>_4\NN\7296428 in_5\IN\13603305 male_6\JJ\1740 rats_7\NNS\2329401 ._8\.\1740
D013311_D008569 CID aim_0\NN\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 testosterone_7\NN\14747587 on_8\IN\1740 <e1>streptozotocin</e1>_9\NN\1740 (stz)-induced_10\JJ\1740 <e2>memory_11\NN\5926676 impairment</e2>_12\NN\7296428 in_13\IN\13603305 male_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D013311_D008569 CID aim_0\NN\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 testosterone_7\NN\14747587 on_8\IN\1740 streptozotocin_9\NN\1740 <e1>(stz)-induced</e1>_10\JJ\1740 <e2>memory_11\NN\5926676 impairment</e2>_12\NN\7296428 in_13\IN\13603305 male_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D013311_D008569 CID administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 <e2>impaired_8\VBD\258857 the_9\DT\1740 memory</e2>_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 <e1>stz-</e1>_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 memory_26\NN\5926676 impairment_27\NN\7296428 ._28\.\1740
D013311_D008569 CID administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 impaired_8\VBD\258857 the_9\DT\1740 memory_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 <e1>stz-</e1>_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
D013311_D008569 CID conclusion_0\NN\5837957 :_1\:\1740 testosterone_2\NN\14747587 administration_3\NN\1133281 ameliorates_4\VBZ\126264 <e1>stz-</e1>_5\NN\1740 and_6\CC\1740 castration-induced_7\JJ\1740 <e2>memory_8\NN\5926676 impairment</e2>_9\NN\7296428 in_10\IN\13603305 male_11\JJ\1740 wistar_12\NNP\1740 rats_13\NNS\2329401 ._14\.\1740
D005485_D008569 CID administration_0\NN\1133281 of_1\IN\1740 <e1>flutamide</e1>_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 <e2>impaired_8\VBD\258857 the_9\DT\1740 memory</e2>_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 memory_26\NN\5926676 impairment_27\NN\7296428 ._28\.\1740
D005485_D008569 CID administration_0\NN\1133281 of_1\IN\1740 <e1>flutamide</e1>_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 impaired_8\VBD\258857 the_9\DT\1740 memory_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
C067431_D008569 CID administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 <e1>letrozole</e1>_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 <e2>impaired_8\VBD\258857 the_9\DT\1740 memory</e2>_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 memory_26\NN\5926676 impairment_27\NN\7296428 ._28\.\1740
C067431_D008569 CID administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 <e1>letrozole</e1>_4\NN\1740 or_5\CC\3541091 tamoxifen_6\NN\2714883 significantly_7\RB\1740 impaired_8\VBD\258857 the_9\DT\1740 memory_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
D013629_D008569 CID administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 <e1>tamoxifen</e1>_6\NN\2714883 significantly_7\RB\1740 <e2>impaired_8\VBD\258857 the_9\DT\1740 memory</e2>_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 memory_26\NN\5926676 impairment_27\NN\7296428 ._28\.\1740
D013629_D008569 CID administration_0\NN\1133281 of_1\IN\1740 flutamide_2\NN\1740 ,_3\,\1740 letrozole_4\NN\1740 or_5\CC\3541091 <e1>tamoxifen</e1>_6\NN\2714883 significantly_7\RB\1740 impaired_8\VBD\258857 the_9\DT\1740 memory_10\NN\5926676 in_11\IN\13603305 intact_12\JJ\1740 rats_13\NNS\2329401 ,_14\,\1740 and_15\CC\1740 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 testosterone_19\NN\14747587 replacement_20\NN\196485 in_21\IN\13603305 improving_22\VBG\126264 stz-_23\NN\1740 and_24\CC\1740 castration-induced_25\JJ\1740 <e2>memory_26\NN\5926676 impairment</e2>_27\NN\7296428 ._28\.\1740
8160791
D005839_D007674 CID mechanisms_0\NNS\13446390 for_1\IN\1740 protective_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 free_5\JJ\1740 radical_6\NN\9465459 scavengers_7\NNS\14779550 on_8\IN\1740 <e1>gentamicin-mediated</e1>_9\JJ\1740 <e2>nephropathy</e2>_10\NN\14573196 in_11\IN\13603305 rats_12\NNS\2329401 ._13\.\1740
D005839_D007674 CID studies_0\NNS\635850 were_1\VBD\836236 performed_2\VBN\2367363 to_3\TO\1740 examine_4\VB\789138 the_5\DT\1740 mechanisms_6\NNS\13446390 for_7\IN\1740 the_8\DT\1740 protective_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 free_12\JJ\1740 radical_13\NN\9465459 scavengers_14\NNS\14779550 on_15\IN\1740 <e1>gentamicin</e1>_16\NN\2716866 (gm)-mediated_17\NN\1740 <e2>nephropathy</e2>_18\NN\14573196 ._19\.\1740
D005839_D007674 CID studies_0\NNS\635850 were_1\VBD\836236 performed_2\VBN\2367363 to_3\TO\1740 examine_4\VB\789138 the_5\DT\1740 mechanisms_6\NNS\13446390 for_7\IN\1740 the_8\DT\1740 protective_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 free_12\JJ\1740 radical_13\NN\9465459 scavengers_14\NNS\14779550 on_15\IN\1740 gentamicin_16\NN\2716866 <e1>(gm)-mediated</e1>_17\NN\1740 <e2>nephropathy</e2>_18\NN\14573196 ._19\.\1740
D005839_D007674 CID administration_0\NN\1133281 of_1\IN\1740 <e1>gm</e1>_2\NNP\13717155 at_3\IN\14622893 40_4\CD\13745420 mg/kg_5\NN\1740 sc_6\NN\14625458 for_7\IN\1740 13_8\CD\13745420 days_9\NNS\15140892 to_10\TO\1740 rats_11\NNS\2329401 induced_12\VBD\1627355 a_13\DT\13649268 significant_14\JJ\1740 reduction_15\NN\351485 in_16\IN\13603305 renal_17\JJ\1740 blood_18\NN\5397468 flow_19\NN\7311115 (_20\-LRB-\1740 rbf_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 inulin_24\JJ\1740 clearance_25\NN\5089947 (_26\-LRB-\1740 cin_27\NNS\1740 )_28\-RRB-\1740 as_29\RB\1740 well_30\RB\1740 as_31\IN\14622893 marked_32\JJ\1740 <e2>tubular_33\JJ\1740 damage</e2>_34\NN\7296428 ._35\.\1740
D005839_D007674 CID a_0\DT\13649268 significant_1\JJ\1740 reduction_2\NN\351485 in_3\IN\13603305 urinary_4\JJ\1740 guanosine_5\NN\14964367 3',5'-cyclic_6\JJ\1740 monophosphate_7\NN\1740 (_8\-LRB-\1740 cgmp_9\NN\1740 )_10\-RRB-\1740 excretion_11\NN\13466586 and_12\CC\1740 a_13\DT\13649268 significant_14\JJ\1740 increase_15\NN\13576355 in_16\IN\13603305 renal_17\JJ\1740 cortical_18\JJ\1740 renin_19\NN\14999106 and_20\CC\1740 endothelin-1_21\NN\1740 contents_22\NNS\6481320 were_23\VBD\836236 also_24\RB\1740 observed_25\VBN\2163746 in_26\IN\13603305 <e1>gm-mediated</e1>_27\JJ\1740 <e2>nephropathy</e2>_28\NN\14573196 ._29\.\1740
D005839_D007674 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 both_6\CC\1740 sod_7\NN\9335240 and_8\CC\1740 dmtu_9\NN\1740 have_10\VBP\2108377 protective_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 <e1>gm-mediated</e1>_14\JJ\1740 <e2>nephropathy</e2>_15\NN\14573196 ,_16\,\1740 2_17\LS\13741022 )_18\-RRB-\1740 the_19\DT\1740 mechanisms_20\NNS\13446390 for_21\IN\1740 the_22\DT\1740 protective_23\JJ\1740 effects_24\NNS\13245626 differ_25\VBP\1740 for_26\IN\1740 sod_27\NN\9335240 and_28\CC\1740 dmtu_29\NN\1740 ,_30\,\1740 and_31\CC\1740 3_32\LS\13741022 )_33\-RRB-\1740 superoxide_34\NN\14971519 anions_35\NNS\9315159 play_36\VBP\1072262 a_37\DT\13649268 critical_38\JJ\1740 role_39\NN\719494 in_40\IN\13603305 gm-induced_41\JJ\1740 renal_42\JJ\1740 vasoconstriction_43\NN\1149911 ._44\.\1740
D005839_D007674 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 both_6\CC\1740 sod_7\NN\9335240 and_8\CC\1740 dmtu_9\NN\1740 have_10\VBP\2108377 protective_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 gm-mediated_14\JJ\1740 <e2>nephropathy</e2>_15\NN\14573196 ,_16\,\1740 2_17\LS\13741022 )_18\-RRB-\1740 the_19\DT\1740 mechanisms_20\NNS\13446390 for_21\IN\1740 the_22\DT\1740 protective_23\JJ\1740 effects_24\NNS\13245626 differ_25\VBP\1740 for_26\IN\1740 sod_27\NN\9335240 and_28\CC\1740 dmtu_29\NN\1740 ,_30\,\1740 and_31\CC\1740 3_32\LS\13741022 )_33\-RRB-\1740 superoxide_34\NN\14971519 anions_35\NNS\9315159 play_36\VBP\1072262 a_37\DT\13649268 critical_38\JJ\1740 role_39\NN\719494 in_40\IN\13603305 <e1>gm-induced</e1>_41\JJ\1740 renal_42\JJ\1740 vasoconstriction_43\NN\1149911 ._44\.\1740
D006152_D007674 NONE a_0\DT\13649268 significant_1\JJ\1740 reduction_2\NN\351485 in_3\IN\13603305 urinary_4\JJ\1740 <e1>guanosine_5\NN\14964367 3',5'-cyclic_6\JJ\1740 monophosphate</e1>_7\NN\1740 (_8\-LRB-\1740 cgmp_9\NN\1740 )_10\-RRB-\1740 excretion_11\NN\13466586 and_12\CC\1740 a_13\DT\13649268 significant_14\JJ\1740 increase_15\NN\13576355 in_16\IN\13603305 renal_17\JJ\1740 cortical_18\JJ\1740 renin_19\NN\14999106 and_20\CC\1740 endothelin-1_21\NN\1740 contents_22\NNS\6481320 were_23\VBD\836236 also_24\RB\1740 observed_25\VBN\2163746 in_26\IN\13603305 gm-mediated_27\JJ\1740 <e2>nephropathy</e2>_28\NN\14573196 ._29\.\1740
D006152_D007674 NONE a_0\DT\13649268 significant_1\JJ\1740 reduction_2\NN\351485 in_3\IN\13603305 urinary_4\JJ\1740 guanosine_5\NN\14964367 3',5'-cyclic_6\JJ\1740 monophosphate_7\NN\1740 (_8\-LRB-\1740 <e1>cgmp</e1>_9\NN\1740 )_10\-RRB-\1740 excretion_11\NN\13466586 and_12\CC\1740 a_13\DT\13649268 significant_14\JJ\1740 increase_15\NN\13576355 in_16\IN\13603305 renal_17\JJ\1740 cortical_18\JJ\1740 renin_19\NN\14999106 and_20\CC\1740 endothelin-1_21\NN\1740 contents_22\NNS\6481320 were_23\VBD\836236 also_24\RB\1740 observed_25\VBN\2163746 in_26\IN\13603305 gm-mediated_27\JJ\1740 <e2>nephropathy</e2>_28\NN\14573196 ._29\.\1740
C038983_D007674 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>dmtu</e1>_3\NN\1740 significantly_4\RB\1740 reduced_5\VBD\441445 the_6\DT\1740 <e2>tubular_7\JJ\1740 damage</e2>_8\NN\7296428 and_9\CC\1740 lipid_10\NN\14944888 peroxidation_11\NN\1740 ,_12\,\1740 but_13\CC\1740 it_14\PRP\6125041 did_15\VBD\1640855 not_16\RB\1740 affect_17\VB\126264 renal_18\JJ\1740 hemodynamics_19\NNS\6080522 and_20\CC\1740 vasoactive_21\JJ\1740 substances_22\NNS\20827 ._23\.\1740
C038983_D007674 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 both_6\CC\1740 sod_7\NN\9335240 and_8\CC\1740 <e1>dmtu</e1>_9\NN\1740 have_10\VBP\2108377 protective_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 gm-mediated_14\JJ\1740 <e2>nephropathy</e2>_15\NN\14573196 ,_16\,\1740 2_17\LS\13741022 )_18\-RRB-\1740 the_19\DT\1740 mechanisms_20\NNS\13446390 for_21\IN\1740 the_22\DT\1740 protective_23\JJ\1740 effects_24\NNS\13245626 differ_25\VBP\1740 for_26\IN\1740 sod_27\NN\9335240 and_28\CC\1740 dmtu_29\NN\1740 ,_30\,\1740 and_31\CC\1740 3_32\LS\13741022 )_33\-RRB-\1740 superoxide_34\NN\14971519 anions_35\NNS\9315159 play_36\VBP\1072262 a_37\DT\13649268 critical_38\JJ\1740 role_39\NN\719494 in_40\IN\13603305 gm-induced_41\JJ\1740 renal_42\JJ\1740 vasoconstriction_43\NN\1149911 ._44\.\1740
C038983_D007674 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 both_6\CC\1740 sod_7\NN\9335240 and_8\CC\1740 dmtu_9\NN\1740 have_10\VBP\2108377 protective_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 gm-mediated_14\JJ\1740 <e2>nephropathy</e2>_15\NN\14573196 ,_16\,\1740 2_17\LS\13741022 )_18\-RRB-\1740 the_19\DT\1740 mechanisms_20\NNS\13446390 for_21\IN\1740 the_22\DT\1740 protective_23\JJ\1740 effects_24\NNS\13245626 differ_25\VBP\1740 for_26\IN\1740 sod_27\NN\9335240 and_28\CC\1740 <e1>dmtu</e1>_29\NN\1740 ,_30\,\1740 and_31\CC\1740 3_32\LS\13741022 )_33\-RRB-\1740 superoxide_34\NN\14971519 anions_35\NNS\9315159 play_36\VBP\1072262 a_37\DT\13649268 critical_38\JJ\1740 role_39\NN\719494 in_40\IN\13603305 gm-induced_41\JJ\1740 renal_42\JJ\1740 vasoconstriction_43\NN\1149911 ._44\.\1740
D013481_D007674 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 both_6\CC\1740 sod_7\NN\9335240 and_8\CC\1740 dmtu_9\NN\1740 have_10\VBP\2108377 protective_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 gm-mediated_14\JJ\1740 <e2>nephropathy</e2>_15\NN\14573196 ,_16\,\1740 2_17\LS\13741022 )_18\-RRB-\1740 the_19\DT\1740 mechanisms_20\NNS\13446390 for_21\IN\1740 the_22\DT\1740 protective_23\JJ\1740 effects_24\NNS\13245626 differ_25\VBP\1740 for_26\IN\1740 sod_27\NN\9335240 and_28\CC\1740 dmtu_29\NN\1740 ,_30\,\1740 and_31\CC\1740 3_32\LS\13741022 )_33\-RRB-\1740 <e1>superoxide</e1>_34\NN\14971519 anions_35\NNS\9315159 play_36\VBP\1072262 a_37\DT\13649268 critical_38\JJ\1740 role_39\NN\719494 in_40\IN\13603305 gm-induced_41\JJ\1740 renal_42\JJ\1740 vasoconstriction_43\NN\1149911 ._44\.\1740
8701013
D015738_D003693 CID <e1>famotidine-associated</e1>_0\JJ\1740 <e2>delirium</e2>_1\NN\14391660 ._2\.\1740
D015738_D003693 CID although_0\IN\1740 all_1\DT\1740 of_2\IN\1740 the_3\DT\1740 currently_4\RB\1740 available_5\JJ\1740 h2-receptor_6\JJ\1740 antagonists_7\NNS\7846 have_8\VBP\2108377 shown_9\VBN\2137132 the_10\DT\1740 propensity_11\NN\7498854 to_12\TO\1740 cause_13\VB\1617192 <e2>delirium</e2>_14\NN\14391660 ,_15\,\1740 only_16\RB\1740 two_17\CD\13741022 previously_18\RB\1740 reported_19\VBN\831651 cases_20\NNS\7283608 have_21\VBP\2108377 been_22\VBN\836236 associated_23\VBN\628491 with_24\IN\1740 <e1>famotidine</e1>_25\NN\3522239 ._26\.\1740
D015738_D003693 CID the_0\DT\1740 authors_1\NNS\9610660 report_2\VBP\831651 on_3\IN\1740 six_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 <e1>famotidine-associated</e1>_7\JJ\1740 <e2>delirium</e2>_8\NN\14391660 in_9\IN\13603305 hospitalized_10\VBN\2348568 patients_11\NNS\9898892 who_12\WP\8299493 cleared_13\VBD\126264 completely_14\RB\1740 upon_15\IN\1740 removal_16\NN\383606 of_17\IN\1740 famotidine_18\NN\3522239 ._19\.\1740
D015738_D003693 CID the_0\DT\1740 authors_1\NNS\9610660 report_2\VBP\831651 on_3\IN\1740 six_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 famotidine-associated_7\JJ\1740 <e2>delirium</e2>_8\NN\14391660 in_9\IN\13603305 hospitalized_10\VBN\2348568 patients_11\NNS\9898892 who_12\WP\8299493 cleared_13\VBD\126264 completely_14\RB\1740 upon_15\IN\1740 removal_16\NN\383606 of_17\IN\1740 <e1>famotidine</e1>_18\NN\3522239 ._19\.\1740
D015738_D014456 NONE <e1>famotidine</e1>_0\NNP\3522239 is_1\VBZ\836236 a_2\DT\13649268 histamine_3\NN\14739004 h2-receptor_4\NN\1740 antagonist_5\NN\7846 used_6\VBN\1156834 in_7\IN\13603305 inpatient_8\JJ\1740 settings_9\NNS\8567235 for_10\IN\1740 prevention_11\NN\1073995 of_12\IN\1740 stress_13\NN\7083732 <e2>ulcers</e2>_14\NNS\14211294 and_15\CC\1740 is_16\VBZ\836236 showing_17\VBG\2137132 increasing_18\VBG\169651 popularity_19\NN\4723816 because_20\IN\1740 of_21\IN\1740 its_22\PRP$\6125041 low_23\JJ\1740 cost_24\NN\13275288 ._25\.\1740
24684312
D018698_D006930 NONE intradermal_0\JJ\1740 <e1>glutamate</e1>_1\NN\15010703 and_2\CC\1740 capsaicin_3\NN\15032661 injections_4\NNS\320852 :_5\:\1740 intra-_6\NN\1740 and_7\CC\1740 interindividual_8\JJ\1740 variability_9\NN\4733640 of_10\IN\1740 provoked_11\VBN\1617192 <e2>hyperalgesia</e2>_12\NN\1740 and_13\CC\1740 allodynia_14\NN\1740 ._15\.\1740
D018698_D006930 NONE intradermal_0\JJ\1740 <e1>glutamate</e1>_1\NN\15010703 and_2\CC\1740 capsaicin_3\NN\15032661 injections_4\NNS\320852 :_5\:\1740 intra-_6\NN\1740 and_7\CC\1740 interindividual_8\JJ\1740 variability_9\NN\4733640 of_10\IN\1740 provoked_11\VBN\1617192 hyperalgesia_12\NN\1740 and_13\CC\1740 <e2>allodynia</e2>_14\NN\1740 ._15\.\1740
D018698_D006930 NONE intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 <e1>glutamate</e1>_3\NN\15010703 and_4\CC\1740 capsaicin_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 pain_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 <e2>hyperalgesia</e2>_16\NN\1740 and_17\CC\1740 allodynia_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 pain_24\NN\14299637 disorders_25\NNS\14034177 ._26\.\1740
D018698_D006930 NONE intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 <e1>glutamate</e1>_3\NN\15010703 and_4\CC\1740 capsaicin_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 pain_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 <e2>allodynia</e2>_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 pain_24\NN\14299637 disorders_25\NNS\14034177 ._26\.\1740
D018698_D006930 NONE secondary_0\JJ\1740 pinprick_1\NN\14406573 <e2>hyperalgesia</e2>_2\NN\1740 was_3\VBD\836236 observed_4\VBN\2163746 as_5\IN\14622893 a_6\DT\13649268 marked_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 the_10\DT\1740 visual_11\JJ\1740 analogue_12\NN\4743605 scale_13\NN\7260623 (_14\-LRB-\1740 vas_15\NN\5246511 )_16\-RRB-\1740 response_17\NN\11410625 to_18\TO\1740 von_19\NN\1740 frey_20\NNP\1740 gauges_21\NNS\3733925 60_22\CD\13745420 and_23\CC\1740 100_24\CD\13745420 g_25\NN\13717155 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.001_29\CD\1740 )_30\-RRB-\1740 after_31\IN\1740 <e1>glutamate</e1>_32\JJ\1740 injection_33\NN\320852 ._34\.\1740
D018698_D006930 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>glutamate</e1>_3\NN\15010703 and_4\CC\1740 capsaicin_5\NN\15032661 yield_6\NN\913705 reproducible_7\JJ\1740 <e2>hyperalgesic</e2>_8\JJ\1740 and_9\CC\1740 allodynic_10\JJ\1740 responses_11\NNS\11410625 ,_12\,\1740 and_13\CC\1740 the_14\DT\1740 present_15\JJ\1740 model_16\NN\5888929 is_17\VBZ\836236 well_18\RB\1740 suited_19\JJ\1740 for_20\IN\1740 basic_21\JJ\1740 research_22\NN\633864 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 for_27\IN\1740 assessing_28\VBG\670261 the_29\DT\1740 modulation_30\NN\7044917 of_31\IN\1740 central_32\JJ\1740 phenomena_33\NNS\29677 ._34\.\1740
D018698_D006930 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>glutamate</e1>_3\NN\15010703 and_4\CC\1740 capsaicin_5\NN\15032661 yield_6\NN\913705 reproducible_7\JJ\1740 hyperalgesic_8\JJ\1740 and_9\CC\1740 <e2>allodynic</e2>_10\JJ\1740 responses_11\NNS\11410625 ,_12\,\1740 and_13\CC\1740 the_14\DT\1740 present_15\JJ\1740 model_16\NN\5888929 is_17\VBZ\836236 well_18\RB\1740 suited_19\JJ\1740 for_20\IN\1740 basic_21\JJ\1740 research_22\NN\633864 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 for_27\IN\1740 assessing_28\VBG\670261 the_29\DT\1740 modulation_30\NN\7044917 of_31\IN\1740 central_32\JJ\1740 phenomena_33\NNS\29677 ._34\.\1740
D002211_D006930 CID intradermal_0\JJ\1740 glutamate_1\NN\15010703 and_2\CC\1740 <e1>capsaicin</e1>_3\NN\15032661 injections_4\NNS\320852 :_5\:\1740 intra-_6\NN\1740 and_7\CC\1740 interindividual_8\JJ\1740 variability_9\NN\4733640 of_10\IN\1740 provoked_11\VBN\1617192 <e2>hyperalgesia</e2>_12\NN\1740 and_13\CC\1740 allodynia_14\NN\1740 ._15\.\1740
D002211_D006930 CID intradermal_0\JJ\1740 glutamate_1\NN\15010703 and_2\CC\1740 <e1>capsaicin</e1>_3\NN\15032661 injections_4\NNS\320852 :_5\:\1740 intra-_6\NN\1740 and_7\CC\1740 interindividual_8\JJ\1740 variability_9\NN\4733640 of_10\IN\1740 provoked_11\VBN\1617192 hyperalgesia_12\NN\1740 and_13\CC\1740 <e2>allodynia</e2>_14\NN\1740 ._15\.\1740
D002211_D006930 CID intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 glutamate_3\NN\15010703 and_4\CC\1740 <e1>capsaicin</e1>_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 pain_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 <e2>hyperalgesia</e2>_16\NN\1740 and_17\CC\1740 allodynia_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 pain_24\NN\14299637 disorders_25\NNS\14034177 ._26\.\1740
D002211_D006930 CID intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 glutamate_3\NN\15010703 and_4\CC\1740 <e1>capsaicin</e1>_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 pain_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 <e2>allodynia</e2>_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 pain_24\NN\14299637 disorders_25\NNS\14034177 ._26\.\1740
D002211_D006930 CID for_0\IN\1740 <e1>capsaicin</e1>_1\NN\15032661 ,_2\,\1740 secondary_3\JJ\1740 pinprick_4\JJ\1740 <e2>hyperalgesia</e2>_5\NN\1740 was_6\VBD\836236 detected_7\VBN\2163746 with_8\IN\1740 all_9\DT\1740 von_10\NN\1740 frey_11\NN\1740 gauges_12\NNS\3733925 (_13\-LRB-\1740 p_14\NN\14622893 <_15\XX\1740 0.001_16\CD\1740 )_17\-RRB-\1740 ._18\.\1740
D002211_D006930 CID <e1>capsaicin</e1>_0\NN\15032661 injection_1\NN\320852 was_2\VBD\836236 reproducible_3\JJ\1740 for_4\IN\1740 <e2>secondary_5\JJ\1740 hyperalgesia</e2>_6\NN\1740 (_7\-LRB-\1740 icc_8\NN\8338847 >_9\NN\1740 0.70_10\CD\1740 )_11\-RRB-\1740 and_12\CC\1740 allodynia_13\NN\1740 (_14\-LRB-\1740 icc_15\NN\8338847 >_16\NN\1740 0.71_17\CD\1740 )_18\-RRB-\1740 ._19\.\1740
D002211_D006930 CID <e1>capsaicin</e1>_0\NN\15032661 injection_1\NN\320852 was_2\VBD\836236 reproducible_3\JJ\1740 for_4\IN\1740 secondary_5\JJ\1740 hyperalgesia_6\NN\1740 (_7\-LRB-\1740 icc_8\NN\8338847 >_9\NN\1740 0.70_10\CD\1740 )_11\-RRB-\1740 and_12\CC\1740 <e2>allodynia</e2>_13\NN\1740 (_14\-LRB-\1740 icc_15\NN\8338847 >_16\NN\1740 0.71_17\CD\1740 )_18\-RRB-\1740 ._19\.\1740
D002211_D006930 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 glutamate_3\NN\15010703 and_4\CC\1740 <e1>capsaicin</e1>_5\NN\15032661 yield_6\NN\913705 reproducible_7\JJ\1740 <e2>hyperalgesic</e2>_8\JJ\1740 and_9\CC\1740 allodynic_10\JJ\1740 responses_11\NNS\11410625 ,_12\,\1740 and_13\CC\1740 the_14\DT\1740 present_15\JJ\1740 model_16\NN\5888929 is_17\VBZ\836236 well_18\RB\1740 suited_19\JJ\1740 for_20\IN\1740 basic_21\JJ\1740 research_22\NN\633864 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 for_27\IN\1740 assessing_28\VBG\670261 the_29\DT\1740 modulation_30\NN\7044917 of_31\IN\1740 central_32\JJ\1740 phenomena_33\NNS\29677 ._34\.\1740
D002211_D006930 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 glutamate_3\NN\15010703 and_4\CC\1740 <e1>capsaicin</e1>_5\NN\15032661 yield_6\NN\913705 reproducible_7\JJ\1740 hyperalgesic_8\JJ\1740 and_9\CC\1740 <e2>allodynic</e2>_10\JJ\1740 responses_11\NNS\11410625 ,_12\,\1740 and_13\CC\1740 the_14\DT\1740 present_15\JJ\1740 model_16\NN\5888929 is_17\VBZ\836236 well_18\RB\1740 suited_19\JJ\1740 for_20\IN\1740 basic_21\JJ\1740 research_22\NN\633864 ,_23\,\1740 as_24\RB\1740 well_25\RB\1740 as_26\IN\14622893 for_27\IN\1740 assessing_28\VBG\670261 the_29\DT\1740 modulation_30\NN\7044917 of_31\IN\1740 central_32\JJ\1740 phenomena_33\NNS\29677 ._34\.\1740
D018698_D010146 NONE intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 <e1>glutamate</e1>_3\NN\15010703 and_4\CC\1740 capsaicin_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 <e2>pain</e2>_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 allodynia_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 pain_24\NN\14299637 disorders_25\NNS\14034177 ._26\.\1740
D018698_D013001 NONE intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 <e1>glutamate</e1>_3\NN\15010703 and_4\CC\1740 capsaicin_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 pain_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 allodynia_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 <e2>pain_24\NN\14299637 disorders</e2>_25\NNS\14034177 ._26\.\1740
D002211_D010146 NONE intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 glutamate_3\NN\15010703 and_4\CC\1740 <e1>capsaicin</e1>_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 <e2>pain</e2>_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 allodynia_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 pain_24\NN\14299637 disorders_25\NNS\14034177 ._26\.\1740
D002211_D013001 NONE intradermal_0\JJ\1740 injections_1\NNS\320852 of_2\IN\1740 glutamate_3\NN\15010703 and_4\CC\1740 <e1>capsaicin</e1>_5\NN\15032661 are_6\VBP\836236 attractive_7\JJ\1740 to_8\TO\1740 use_9\VB\1156834 in_10\IN\13603305 human_11\JJ\1740 experimental_12\JJ\1740 pain_13\NN\14299637 models_14\NNS\5888929 because_15\IN\1740 hyperalgesia_16\NN\1740 and_17\CC\1740 allodynia_18\JJ\1740 mimic_19\JJ\1740 isolated_20\VBN\2512305 aspects_21\NNS\5849789 of_22\IN\1740 clinical_23\JJ\1740 <e2>pain_24\NN\14299637 disorders</e2>_25\NNS\14034177 ._26\.\1740
3925479
D006220_D002375 CID evidence_0\NN\5816287 for_1\IN\1740 a_2\DT\13649268 cholinergic_3\JJ\1740 role_4\NN\719494 in_5\IN\13603305 <e1>haloperidol-induced</e1>_6\JJ\1740 <e2>catalepsy</e2>_7\NN\14023236 ._8\.\1740
D006220_D002375 CID low_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 pilocarpine_3\NN\14712692 caused_4\VBD\1617192 a_5\DT\13649268 pronounced_6\JJ\1740 enhancement_7\NN\248977 of_8\IN\1740 the_9\DT\1740 <e2>catalepsy</e2>_10\NN\14023236 that_11\WDT\1740 was_12\VBD\836236 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 dopaminergic_16\JJ\1740 blocker_17\NN\10101634 ,_18\,\1740 <e1>haloperidol</e1>_19\VB\1740 ._20\.\1740
D006220_D002375 CID a_0\DT\13649268 muscarinic_1\NN\1740 receptor_2\NN\5225602 blocker_3\NN\10101634 ,_4\,\1740 atropine_5\NN\14712692 ,_6\,\1740 disrupted_7\VBN\362348 <e1>haloperidol-induced</e1>_8\JJ\1740 <e2>catalepsy</e2>_9\NN\14023236 ._10\.\1740
D006220_D002375 CID intracranial_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 an_3\DT\6697703 acetylcholine-synthesis_4\JJ\1740 inhibitor_5\NN\20090 ,_6\,\1740 hemicholinium_7\NN\1740 ,_8\,\1740 prevented_9\VBD\1740 the_10\DT\1740 <e2>catalepsy</e2>_11\NN\14023236 that_12\WDT\1740 is_13\VBZ\836236 usually_14\RB\1740 induced_15\VBN\1627355 by_16\IN\1740 <e1>haloperidol</e1>_17\NN\3713736 ._18\.\1740
D006220_D002375 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 the_3\DT\1740 hypothesis_4\NN\7162194 that_5\IN\1740 the_6\DT\1740 <e2>catalepsy</e2>_7\NN\14023236 that_8\WDT\1740 is_9\VBZ\836236 produced_10\VBN\1617192 by_11\IN\1740 neuroleptics_12\NNS\4470232 such_13\JJ\1740 as_14\IN\14622893 <e1>haloperidol</e1>_15\NN\3713736 is_16\VBZ\836236 actually_17\RB\1740 mediated_18\VBN\761713 by_19\IN\1740 intrinsic_20\JJ\1740 central_21\JJ\1740 cholinergic_22\NN\1740 systems_23\NNS\3575240 ._24\.\1740
D014150_D002375 NONE experiments_0\NNS\641820 in_1\IN\13603305 mice_2\NNS\2329401 tested_3\VBD\670261 previous_4\JJ\1740 evidence_5\NN\5816287 that_6\IN\1740 activation_7\NN\13561719 of_8\IN\1740 cholinergic_9\JJ\1740 systems_10\NNS\3575240 promotes_11\VBZ\2556126 <e2>catalepsy</e2>_12\NN\14023236 and_13\CC\1740 that_14\IN\1740 cholinergic_15\NN\1740 mechanisms_16\NNS\13446390 need_17\VBP\2604760 to_18\TO\1740 be_19\VB\836236 intact_20\JJ\1740 for_21\IN\1740 full_22\JJ\1740 expression_23\NN\4679549 of_24\IN\1740 <e1>neuroleptic-induced</e1>_25\JJ\1740 catalepsy_26\NN\14023236 ._27\.\1740
D014150_D002375 NONE experiments_0\NNS\641820 in_1\IN\13603305 mice_2\NNS\2329401 tested_3\VBD\670261 previous_4\JJ\1740 evidence_5\NN\5816287 that_6\IN\1740 activation_7\NN\13561719 of_8\IN\1740 cholinergic_9\JJ\1740 systems_10\NNS\3575240 promotes_11\VBZ\2556126 catalepsy_12\NN\14023236 and_13\CC\1740 that_14\IN\1740 cholinergic_15\NN\1740 mechanisms_16\NNS\13446390 need_17\VBP\2604760 to_18\TO\1740 be_19\VB\836236 intact_20\JJ\1740 for_21\IN\1740 full_22\JJ\1740 expression_23\NN\4679549 of_24\IN\1740 <e1>neuroleptic-induced</e1>_25\JJ\1740 <e2>catalepsy</e2>_26\NN\14023236 ._27\.\1740
D014150_D002375 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 the_3\DT\1740 hypothesis_4\NN\7162194 that_5\IN\1740 the_6\DT\1740 <e2>catalepsy</e2>_7\NN\14023236 that_8\WDT\1740 is_9\VBZ\836236 produced_10\VBN\1617192 by_11\IN\1740 <e1>neuroleptics</e1>_12\NNS\4470232 such_13\JJ\1740 as_14\IN\14622893 haloperidol_15\NN\3713736 is_16\VBZ\836236 actually_17\RB\1740 mediated_18\VBN\761713 by_19\IN\1740 intrinsic_20\JJ\1740 central_21\JJ\1740 cholinergic_22\NN\1740 systems_23\NNS\3575240 ._24\.\1740
D010862_D002375 CID large_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 the_3\DT\1740 cholinomimetic_4\JJ\1740 ,_5\,\1740 <e1>pilocarpine</e1>_6\NN\14712692 ,_7\,\1740 could_8\MD\1740 induce_9\VB\1627355 <e2>catalepsy</e2>_10\NN\14023236 when_11\WRB\1740 peripheral_12\JJ\1740 cholinergic_13\NN\1740 receptors_14\NNS\5225602 were_15\VBD\836236 blocked_16\VBN\1476483 ._17\.\1740
D010862_D002375 CID low_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>pilocarpine</e1>_3\NN\14712692 caused_4\VBD\1617192 a_5\DT\13649268 pronounced_6\JJ\1740 enhancement_7\NN\248977 of_8\IN\1740 the_9\DT\1740 <e2>catalepsy</e2>_10\NN\14023236 that_11\WDT\1740 was_12\VBD\836236 induced_13\VBN\1627355 by_14\IN\1740 the_15\DT\1740 dopaminergic_16\JJ\1740 blocker_17\NN\10101634 ,_18\,\1740 haloperidol_19\VB\1740 ._20\.\1740
D001285_D002375 NONE a_0\DT\13649268 muscarinic_1\NN\1740 receptor_2\NN\5225602 blocker_3\NN\10101634 ,_4\,\1740 <e1>atropine</e1>_5\NN\14712692 ,_6\,\1740 disrupted_7\VBN\362348 haloperidol-induced_8\JJ\1740 <e2>catalepsy</e2>_9\NN\14023236 ._10\.\1740
D000109_D002375 NONE intracranial_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 an_3\DT\6697703 <e1>acetylcholine-synthesis</e1>_4\JJ\1740 inhibitor_5\NN\20090 ,_6\,\1740 hemicholinium_7\NN\1740 ,_8\,\1740 prevented_9\VBD\1740 the_10\DT\1740 <e2>catalepsy</e2>_11\NN\14023236 that_12\WDT\1740 is_13\VBZ\836236 usually_14\RB\1740 induced_15\VBN\1627355 by_16\IN\1740 haloperidol_17\NN\3713736 ._18\.\1740
D006426_D002375 NONE intracranial_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 an_3\DT\6697703 acetylcholine-synthesis_4\JJ\1740 inhibitor_5\NN\20090 ,_6\,\1740 <e1>hemicholinium</e1>_7\NN\1740 ,_8\,\1740 prevented_9\VBD\1740 the_10\DT\1740 <e2>catalepsy</e2>_11\NN\14023236 that_12\WDT\1740 is_13\VBZ\836236 usually_14\RB\1740 induced_15\VBN\1627355 by_16\IN\1740 haloperidol_17\NN\3713736 ._18\.\1740
25084821
C069541_D009503 CID <e1>quetiapine-induced</e1>_0\JJ\1740 <e2>neutropenia</e2>_1\NN\14196405 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 with_6\IN\1740 hepatocellular_7\JJ\1740 carcinoma_8\NN\14239918 ._9\.\1740
C069541_D009503 CID objective_0\NN\5980875 :_1\:\1740 <e1>quetiapine</e1>_2\NNP\1740 is_3\VBZ\836236 a_4\DT\13649268 dibenzothiazepine_5\NN\1740 derivative_6\JJ\1740 ,_7\,\1740 similar_8\JJ\1740 to_9\TO\1740 clozapine_10\NN\3713736 ,_11\,\1740 which_12\WDT\1740 has_13\VBZ\2108377 the_14\DT\1740 highest_15\JJS\1740 risk_16\NN\14541044 of_17\IN\1740 causing_18\VBG\1617192 blood_19\NN\5397468 dyscrasias_20\NNS\14052046 ,_21\,\1740 especially_22\RB\1740 <e2>neutropenia</e2>_23\JJ\1740 ._24\.\1740
C069541_D009503 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 hepatocellular_6\JJ\1740 carcinoma_7\NN\14239918 that_8\WDT\1740 developed_9\VBD\1753788 <e2>neutropenia</e2>_10\NN\14196405 after_11\IN\1740 treatment_12\NN\654885 with_13\IN\1740 <e1>quetiapine</e1>_14\NN\1740 is_15\VBZ\836236 described_16\VBN\1001294 here_17\RB\1740 ._18\.\1740
C069541_D009503 CID conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 <e2>neutropenia</e2>_3\NN\14196405 is_4\VBZ\836236 not_5\RB\1740 a_6\DT\13649268 common_7\JJ\1740 side_8\NN\8630039 effect_9\NN\34213 of_10\IN\1740 <e1>quetiapine</e1>_11\NN\1740 ,_12\,\1740 physicians_13\NNS\10305802 should_14\MD\1740 be_15\VB\836236 cautious_16\JJ\1740 about_17\IN\1740 its_18\PRP$\6125041 presentation_19\NN\1027379 and_20\CC\1740 associated_21\VBN\628491 risk_22\NN\14541044 factors_23\NNS\7326557 ._24\.\1740
C069541_D001714 NONE <e1>quetiapine-induced</e1>_0\JJ\1740 neutropenia_1\NN\14196405 in_2\IN\13603305 a_3\DT\13649268 <e2>bipolar</e2>_4\JJ\1740 patient_5\NN\9898892 with_6\IN\1740 hepatocellular_7\JJ\1740 carcinoma_8\NN\14239918 ._9\.\1740
C069541_D006528 NONE <e1>quetiapine-induced</e1>_0\JJ\1740 neutropenia_1\NN\14196405 in_2\IN\13603305 a_3\DT\13649268 bipolar_4\JJ\1740 patient_5\NN\9898892 with_6\IN\1740 <e2>hepatocellular_7\JJ\1740 carcinoma</e2>_8\NN\14239918 ._9\.\1740
C069541_D006528 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 <e2>hepatocellular_6\JJ\1740 carcinoma</e2>_7\NN\14239918 that_8\WDT\1740 developed_9\VBD\1753788 neutropenia_10\NN\14196405 after_11\IN\1740 treatment_12\NN\654885 with_13\IN\1740 <e1>quetiapine</e1>_14\NN\1740 is_15\VBZ\836236 described_16\VBN\1001294 here_17\RB\1740 ._18\.\1740
C069541_D006402 NONE objective_0\NN\5980875 :_1\:\1740 <e1>quetiapine</e1>_2\NNP\1740 is_3\VBZ\836236 a_4\DT\13649268 dibenzothiazepine_5\NN\1740 derivative_6\JJ\1740 ,_7\,\1740 similar_8\JJ\1740 to_9\TO\1740 clozapine_10\NN\3713736 ,_11\,\1740 which_12\WDT\1740 has_13\VBZ\2108377 the_14\DT\1740 highest_15\JJS\1740 risk_16\NN\14541044 of_17\IN\1740 causing_18\VBG\1617192 <e2>blood_19\NN\5397468 dyscrasias</e2>_20\NNS\14052046 ,_21\,\1740 especially_22\RB\1740 neutropenia_23\JJ\1740 ._24\.\1740
D003024_D006402 NONE objective_0\NN\5980875 :_1\:\1740 quetiapine_2\NNP\1740 is_3\VBZ\836236 a_4\DT\13649268 dibenzothiazepine_5\NN\1740 derivative_6\JJ\1740 ,_7\,\1740 similar_8\JJ\1740 to_9\TO\1740 <e1>clozapine</e1>_10\NN\3713736 ,_11\,\1740 which_12\WDT\1740 has_13\VBZ\2108377 the_14\DT\1740 highest_15\JJS\1740 risk_16\NN\14541044 of_17\IN\1740 causing_18\VBG\1617192 <e2>blood_19\NN\5397468 dyscrasias</e2>_20\NNS\14052046 ,_21\,\1740 especially_22\RB\1740 neutropenia_23\JJ\1740 ._24\.\1740
D003024_D009503 NONE objective_0\NN\5980875 :_1\:\1740 quetiapine_2\NNP\1740 is_3\VBZ\836236 a_4\DT\13649268 dibenzothiazepine_5\NN\1740 derivative_6\JJ\1740 ,_7\,\1740 similar_8\JJ\1740 to_9\TO\1740 <e1>clozapine</e1>_10\NN\3713736 ,_11\,\1740 which_12\WDT\1740 has_13\VBZ\2108377 the_14\DT\1740 highest_15\JJS\1740 risk_16\NN\14541044 of_17\IN\1740 causing_18\VBG\1617192 blood_19\NN\5397468 dyscrasias_20\NNS\14052046 ,_21\,\1740 especially_22\RB\1740 <e2>neutropenia</e2>_23\JJ\1740 ._24\.\1740
C069541_D007970 CID she_0\PRP\1740 developed_1\VBD\1753788 <e2>leucopenia</e2>_2\NN\14189204 after_3\IN\1740 being_4\VBG\836236 treated_5\VBN\2376958 with_6\IN\1740 <e1>quetiapine</e1>_7\NN\1740 ._8\.\1740
C069541_D008107 NONE <e2>hepatic_0\JJ\1740 dysfunction</e2>_1\NN\14204950 may_2\MD\15209706 be_3\VB\836236 one_4\CD\13741022 of_5\IN\1740 the_6\DT\1740 possible_7\JJ\1740 risk_8\NN\14541044 factors_9\NNS\7326557 ,_10\,\1740 and_11\CC\1740 concomitant_12\JJ\1740 fever_13\NN\14299637 may_14\MD\15209706 be_15\VB\836236 a_16\DT\13649268 diagnostic_17\JJ\1740 marker_18\NN\21939 for_19\IN\1740 adverse_20\JJ\1740 reaction_21\NN\13446390 to_22\IN\1740 <e1>quetiapine</e1>_23\NN\1740 ._24\.\1740
C069541_D005334 CID hepatic_0\JJ\1740 dysfunction_1\NN\14204950 may_2\MD\15209706 be_3\VB\836236 one_4\CD\13741022 of_5\IN\1740 the_6\DT\1740 possible_7\JJ\1740 risk_8\NN\14541044 factors_9\NNS\7326557 ,_10\,\1740 and_11\CC\1740 concomitant_12\JJ\1740 <e2>fever</e2>_13\NN\14299637 may_14\MD\15209706 be_15\VB\836236 a_16\DT\13649268 diagnostic_17\JJ\1740 marker_18\NN\21939 for_19\IN\1740 adverse_20\JJ\1740 reaction_21\NN\13446390 to_22\IN\1740 <e1>quetiapine</e1>_23\NN\1740 ._24\.\1740
18341442
C026098_C562694 NONE <e1>levetiracetam</e1>_0\NN\1740 as_1\IN\14622893 an_2\DT\6697703 adjunct_3\NN\9312645 to_4\TO\1740 phenobarbital_5\JJ\1740 treatment_6\NN\654885 in_7\IN\13603305 cats_8\NNS\2120997 with_9\IN\1740 suspected_10\VBN\916909 <e2>idiopathic_11\JJ\1740 epilepsy</e2>_12\NN\14085708 ._13\.\1740
C026098_C562694 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 pharmacokinetics_4\NNS\6054892 ,_5\,\1740 efficacy_6\NN\5199286 ,_7\,\1740 and_8\CC\1740 tolerability_9\NN\1740 of_10\IN\1740 oral_11\JJ\1740 <e1>levetiracetam</e1>_12\NN\1740 administered_13\VBN\2436349 as_14\IN\14622893 an_15\DT\6697703 adjunct_16\NN\9312645 to_17\TO\1740 phenobarbital_18\JJ\1740 treatment_19\NN\654885 in_20\IN\13603305 cats_21\NNS\2120997 with_22\IN\1740 poorly_23\RB\1740 controlled_24\VBN\2422663 suspected_25\VBN\916909 <e2>idiopathic_26\JJ\1740 epilepsy</e2>_27\NN\14085708 ._28\.\1740
C026098_C562694 NONE conclusions_0\NNS\5837957 and_1\CC\1740 clinical_2\NN\1740 relevance_3\NN\13791389 :_4\:\1740 results_5\NNS\34213 suggested_6\VBD\1010118 that_7\IN\1740 <e1>levetiracetam</e1>_8\NN\1740 is_9\VBZ\836236 well_10\RB\1740 tolerated_11\VBN\802318 in_12\IN\13603305 cats_13\NNS\2120997 and_14\CC\1740 may_15\MD\15209706 be_16\VB\836236 useful_17\JJ\1740 as_18\IN\14622893 an_19\DT\6697703 adjunct_20\NN\9312645 to_21\TO\1740 phenobarbital_22\JJ\1740 treatment_23\NN\654885 in_24\IN\13603305 cats_25\NNS\2120997 with_26\IN\1740 <e2>idiopathic_27\JJ\1740 epilepsy</e2>_28\NN\14085708 ._29\.\1740
D010634_C562694 NONE levetiracetam_0\NN\1740 as_1\IN\14622893 an_2\DT\6697703 adjunct_3\NN\9312645 to_4\TO\1740 <e1>phenobarbital</e1>_5\JJ\1740 treatment_6\NN\654885 in_7\IN\13603305 cats_8\NNS\2120997 with_9\IN\1740 suspected_10\VBN\916909 <e2>idiopathic_11\JJ\1740 epilepsy</e2>_12\NN\14085708 ._13\.\1740
D010634_C562694 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 pharmacokinetics_4\NNS\6054892 ,_5\,\1740 efficacy_6\NN\5199286 ,_7\,\1740 and_8\CC\1740 tolerability_9\NN\1740 of_10\IN\1740 oral_11\JJ\1740 levetiracetam_12\NN\1740 administered_13\VBN\2436349 as_14\IN\14622893 an_15\DT\6697703 adjunct_16\NN\9312645 to_17\TO\1740 <e1>phenobarbital</e1>_18\JJ\1740 treatment_19\NN\654885 in_20\IN\13603305 cats_21\NNS\2120997 with_22\IN\1740 poorly_23\RB\1740 controlled_24\VBN\2422663 suspected_25\VBN\916909 <e2>idiopathic_26\JJ\1740 epilepsy</e2>_27\NN\14085708 ._28\.\1740
D010634_C562694 NONE animals_0\NNS\4475 :_1\:\1740 12_2\CD\13745420 cats_3\NNS\2120997 suspected_4\VBN\916909 to_5\TO\1740 have_6\VB\2108377 <e2>idiopathic_7\JJ\1740 epilepsy</e2>_8\NN\14085708 that_9\WDT\1740 was_10\VBD\836236 poorly_11\RB\1740 controlled_12\VBN\2422663 with_13\IN\1740 <e1>phenobarbital</e1>_14\JJ\1740 or_15\CC\3541091 that_16\DT\1740 had_17\VBD\2108377 unacceptable_18\JJ\1740 adverse_19\JJ\1740 effects_20\NNS\13245626 when_21\WRB\1740 treated_22\VBN\2376958 with_23\IN\1740 phenobarbital_24\JJ\1740 ._25\.\1740
D010634_C562694 NONE animals_0\NNS\4475 :_1\:\1740 12_2\CD\13745420 cats_3\NNS\2120997 suspected_4\VBN\916909 to_5\TO\1740 have_6\VB\2108377 <e2>idiopathic_7\JJ\1740 epilepsy</e2>_8\NN\14085708 that_9\WDT\1740 was_10\VBD\836236 poorly_11\RB\1740 controlled_12\VBN\2422663 with_13\IN\1740 phenobarbital_14\JJ\1740 or_15\CC\3541091 that_16\DT\1740 had_17\VBD\2108377 unacceptable_18\JJ\1740 adverse_19\JJ\1740 effects_20\NNS\13245626 when_21\WRB\1740 treated_22\VBN\2376958 with_23\IN\1740 <e1>phenobarbital</e1>_24\JJ\1740 ._25\.\1740
D010634_C562694 NONE conclusions_0\NNS\5837957 and_1\CC\1740 clinical_2\NN\1740 relevance_3\NN\13791389 :_4\:\1740 results_5\NNS\34213 suggested_6\VBD\1010118 that_7\IN\1740 levetiracetam_8\NN\1740 is_9\VBZ\836236 well_10\RB\1740 tolerated_11\VBN\802318 in_12\IN\13603305 cats_13\NNS\2120997 and_14\CC\1740 may_15\MD\15209706 be_16\VB\836236 useful_17\JJ\1740 as_18\IN\14622893 an_19\DT\6697703 adjunct_20\NN\9312645 to_21\TO\1740 <e1>phenobarbital</e1>_22\JJ\1740 treatment_23\NN\654885 in_24\IN\13603305 cats_25\NNS\2120997 with_26\IN\1740 <e2>idiopathic_27\JJ\1740 epilepsy</e2>_28\NN\14085708 ._29\.\1740
C026098_D012640 NONE <e2>seizure</e2>_0\NN\14081375 frequencies_1\VBZ\1740 before_2\IN\1740 and_3\CC\1740 after_4\IN\1740 initiation_5\NN\7450842 of_6\IN\1740 <e1>levetiracetam</e1>_7\NN\1740 treatment_8\NN\654885 were_9\VBD\836236 compared_10\VBN\644583 ,_11\,\1740 and_12\CC\1740 adverse_13\JJ\1740 effects_14\NNS\13245626 were_15\VBD\836236 recorded_16\VBN\2225492 ._17\.\1740
C026098_D012640 NONE median_0\JJ\1740 <e2>seizure</e2>_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 <e1>levetiracetam</e1>_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 <e1>levetiracetam</e1>_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 <e2>seizures/mo</e2>_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 <e1>levetiracetam</e1>_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 <e2>seizure</e2>_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 <e1>levetiracetam</e1>_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 <e2>seizures/mo</e2>_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 <e1>levetiracetam</e1>_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 <e2>seizure</e2>_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 <e2>seizure</e2>_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>levetiracetam</e1>_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 <e2>seizures/mo</e2>_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>levetiracetam</e1>_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 <e2>seizure</e2>_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>levetiracetam</e1>_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>levetiracetam</e1>_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 <e2>seizures/mo</e2>_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>levetiracetam</e1>_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 levetiracetam_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 <e2>seizure</e2>_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 <e2>seizure</e2>_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 <e1>levetiracetam</e1>_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 <e2>seizures/mo</e2>_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 <e1>levetiracetam</e1>_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 <e2>seizure</e2>_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 <e1>levetiracetam</e1>_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 <e2>seizures/mo</e2>_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 <e1>levetiracetam</e1>_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 seizure_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C026098_D012640 NONE median_0\JJ\1740 seizure_1\NN\14081375 frequency_2\NN\15286249 prior_3\RB\1740 to_4\TO\1740 treatment_5\NN\654885 with_6\IN\1740 levetiracetam_7\NN\1740 (_8\-LRB-\1740 2.1_9\CD\1740 seizures/mo_10\NN\1740 )_11\-RRB-\1740 was_12\VBD\836236 significantly_13\RB\1740 higher_14\JJR\1740 than_15\IN\1740 median_16\JJ\1740 seizure_17\JJ\1740 frequency_18\NN\15286249 after_19\IN\1740 initiation_20\NN\7450842 of_21\IN\1740 levetiracetam_22\NN\1740 treatment_23\NN\654885 (_24\-LRB-\1740 0.42_25\CD\1740 seizures/mo_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 and_29\CC\1740 7_30\CD\13741022 of_31\IN\1740 10_32\CD\13745420 cats_33\NNS\2120997 were_34\VBD\836236 classified_35\VBN\657260 as_36\IN\14622893 having_37\VBG\2108377 responded_38\VBN\2367363 to_39\TO\1740 <e1>levetiracetam</e1>_40\NN\1740 treatment_41\NN\654885 (_42\-LRB-\1740 ie_43\FW\1740 ,_44\,\1740 reduction_45\NN\351485 in_46\IN\13603305 <e2>seizure</e2>_47\JJ\1740 frequency_48\NN\15286249 of_49\IN\1740 >_50\NNP\1740 or=50_51\NNP\1740 %_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
24341598
D012965_D007674 NONE comparison_0\NN\635850 of_1\IN\1740 effects_2\NNS\13245626 of_3\IN\1740 isotonic_4\JJ\1740 <e1>sodium_5\NN\14625458 chloride</e1>_6\NN\14818238 with_7\IN\1740 diltiazem_8\NN\2938514 in_9\IN\13603305 prevention_10\NN\1073995 of_11\IN\1740 contrast-induced_12\JJ\1740 <e2>nephropathy</e2>_13\NN\14573196 ._14\.\1740
D004110_D007674 NONE comparison_0\NN\635850 of_1\IN\1740 effects_2\NNS\13245626 of_3\IN\1740 isotonic_4\JJ\1740 sodium_5\NN\14625458 chloride_6\NN\14818238 with_7\IN\1740 <e1>diltiazem</e1>_8\NN\2938514 in_9\IN\13603305 prevention_10\NN\1073995 of_11\IN\1740 contrast-induced_12\JJ\1740 <e2>nephropathy</e2>_13\NN\14573196 ._14\.\1740
D003287_D007674 NONE comparison_0\NN\635850 of_1\IN\1740 effects_2\NNS\13245626 of_3\IN\1740 isotonic_4\JJ\1740 sodium_5\NN\14625458 chloride_6\NN\14818238 with_7\IN\1740 diltiazem_8\NN\2938514 in_9\IN\13603305 prevention_10\NN\1073995 of_11\IN\1740 <e1>contrast-induced</e1>_12\JJ\1740 <e2>nephropathy</e2>_13\NN\14573196 ._14\.\1740
D003287_D007674 NONE introduction_0\NN\235435 and_1\CC\1740 objective_2\NN\5980875 :_3\:\1740 <e1>contrast-induced</e1>_4\JJ\1740 <e2>nephropathy</e2>_5\NN\14573196 (_6\-LRB-\1740 cin_7\NN\1740 )_8\-RRB-\1740 significantly_9\RB\1740 increases_10\VBZ\169651 the_11\DT\1740 morbidity_12\NN\13826959 and_13\CC\1740 mortality_14\NN\5054863 of_15\IN\1740 patients_16\NNS\9898892 ._17\.\1740
D003287_D058186 CID among_0\IN\1740 a_1\DT\13649268 total_2\NN\3553 of_3\IN\1740 60_4\CD\13745420 patients_5\NNS\9898892 included_6\VBN\690614 in_7\IN\13603305 the_8\DT\1740 study_9\NN\635850 ,_10\,\1740 16_11\CD\13745420 patients_12\NNS\9898892 developed_13\VBD\1753788 <e2>acute_14\JJ\1740 renal_15\JJ\1740 failure</e2>_16\NN\66216 (_17\-LRB-\1740 arf_18\NN\1740 )_19\-RRB-\1740 on_20\IN\1740 the_21\DT\1740 second_22\JJ\1740 day_23\NN\15154774 after_24\IN\1740 <e1>contrast</e1>_25\NN\13854649 material_26\NN\19613 was_27\VBD\836236 injected_28\VBN\81072 (_29\-LRB-\1740 26.6_30\CD\1740 %_31\NN\1740 )_32\-RRB-\1740 ._33\.\1740
D003287_D058186 CID among_0\IN\1740 a_1\DT\13649268 total_2\NN\3553 of_3\IN\1740 60_4\CD\13745420 patients_5\NNS\9898892 included_6\VBN\690614 in_7\IN\13603305 the_8\DT\1740 study_9\NN\635850 ,_10\,\1740 16_11\CD\13745420 patients_12\NNS\9898892 developed_13\VBD\1753788 acute_14\JJ\1740 renal_15\JJ\1740 failure_16\NN\66216 (_17\-LRB-\1740 <e2>arf</e2>_18\NN\1740 )_19\-RRB-\1740 on_20\IN\1740 the_21\DT\1740 second_22\JJ\1740 day_23\NN\15154774 after_24\IN\1740 <e1>contrast</e1>_25\NN\13854649 material_26\NN\19613 was_27\VBD\836236 injected_28\VBN\81072 (_29\-LRB-\1740 26.6_30\CD\1740 %_31\NN\1740 )_32\-RRB-\1740 ._33\.\1740
17028363
D000880_D058186 NONE <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 associated_3\VBN\628491 with_4\IN\1740 prolonged_5\JJ\1740 intake_6\NN\13440063 of_7\IN\1740 slimming_8\VBG\1740 pills_9\NNS\4424218 containing_10\VBG\2632940 <e1>anthraquinones</e1>_11\NNS\1740 ._12\.\1740
D000880_D058186 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 23-year-old_3\JJ\1740 woman_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 <e2>acute_7\JJ\1740 renal_8\JJ\1740 failure</e2>_9\NN\66216 following_10\VBG\1835496 prolonged_11\JJ\1740 use_12\NN\407535 of_13\IN\1740 a_14\DT\13649268 proprietary_15\JJ\1740 chinese_16\JJ\1740 herbal_17\JJ\1740 slimming_18\NN\1740 pill_19\NN\4424218 that_20\WDT\1740 contained_21\VBD\2632940 <e1>anthraquinone</e1>_22\NN\1740 derivatives_23\NNS\5802185 ,_24\,\1740 extracted_25\VBN\173338 from_26\IN\1740 rhizoma_27\NNP\1740 rhei_28\NNP\1740 (_29\-LRB-\1740 rhubarb_30\NNS\7707451 )_31\-RRB-\1740 ._32\.\1740
D000880_D058186 NONE although_0\IN\1740 a_1\DT\13649268 causal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 an_8\DT\6697703 <e1>anthraquinone-containing</e1>_9\JJ\1740 herbal_10\JJ\1740 agent_11\NN\7347 and_12\CC\1740 <e2>renal_13\JJ\1740 injury</e2>_14\NN\14052046 remains_15\VBZ\2604760 to_16\TO\1740 be_17\VB\836236 proven_18\VBN\2604760 ,_19\,\1740 phytotherapy-associated_20\JJ\1740 interstitial_21\JJ\1740 nephropathy_22\NN\14573196 should_23\MD\1740 be_24\VB\836236 considered_25\VBN\689344 in_26\IN\13603305 patients_27\NNS\9898892 who_28\WP\8299493 present_29\VBP\2137132 with_30\IN\1740 unexplained_31\JJ\1740 renal_32\JJ\1740 failure_33\NN\66216 ._34\.\1740
D004365_D007674 NONE <e2>nephropathy</e2>_0\NNP\14573196 caused_1\VBN\1617192 by_2\IN\1740 <e1>chinese_3\JJ\1740 herbs</e1>_4\NNS\13083586 has_5\VBZ\2108377 previously_6\RB\1740 been_7\VBN\836236 reported_8\VBN\831651 ,_9\,\1740 usually_10\RB\1740 involving_11\VBG\2676054 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 aristolochic_15\JJ\1740 acids_16\NNS\14818238 ._17\.\1740
D034341_D007674 NONE <e2>nephropathy</e2>_0\NNP\14573196 caused_1\VBN\1617192 by_2\IN\1740 chinese_3\JJ\1740 herbs_4\NNS\13083586 has_5\VBZ\2108377 previously_6\RB\1740 been_7\VBN\836236 reported_8\VBN\831651 ,_9\,\1740 usually_10\RB\1740 involving_11\VBG\2676054 the_12\DT\1740 use_13\NN\407535 of_14\IN\1740 <e1>aristolochic_15\JJ\1740 acids</e1>_16\NNS\14818238 ._17\.\1740
D004365_D058186 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 23-year-old_3\JJ\1740 woman_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 <e2>acute_7\JJ\1740 renal_8\JJ\1740 failure</e2>_9\NN\66216 following_10\VBG\1835496 prolonged_11\JJ\1740 use_12\NN\407535 of_13\IN\1740 a_14\DT\13649268 proprietary_15\JJ\1740 <e1>chinese_16\JJ\1740 herbal</e1>_17\JJ\1740 slimming_18\NN\1740 pill_19\NN\4424218 that_20\WDT\1740 contained_21\VBD\2632940 anthraquinone_22\NN\1740 derivatives_23\NNS\5802185 ,_24\,\1740 extracted_25\VBN\173338 from_26\IN\1740 rhizoma_27\NNP\1740 rhei_28\NNP\1740 (_29\-LRB-\1740 rhubarb_30\NNS\7707451 )_31\-RRB-\1740 ._32\.\1740
D004008_D058186 CID the_0\DT\1740 <e2>renal_1\JJ\1740 injury</e2>_2\NN\14052046 was_3\VBD\836236 probably_4\RB\1740 aggravated_5\VBN\126264 by_6\IN\1740 the_7\DT\1740 concomitant_8\JJ\1740 intake_9\NN\13440063 of_10\IN\1740 a_11\DT\13649268 non-steroidal_12\JJ\1740 anti-inflammatory_13\JJ\1740 drug_14\NN\14778436 ,_15\,\1740 <e1>diclofenac</e1>_16\VBD\1740 ._17\.\1740
D000880_D007674 NONE although_0\IN\1740 a_1\DT\13649268 causal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 an_8\DT\6697703 <e1>anthraquinone-containing</e1>_9\JJ\1740 herbal_10\JJ\1740 agent_11\NN\7347 and_12\CC\1740 renal_13\JJ\1740 injury_14\NN\14052046 remains_15\VBZ\2604760 to_16\TO\1740 be_17\VB\836236 proven_18\VBN\2604760 ,_19\,\1740 phytotherapy-associated_20\JJ\1740 interstitial_21\JJ\1740 <e2>nephropathy</e2>_22\NN\14573196 should_23\MD\1740 be_24\VB\836236 considered_25\VBN\689344 in_26\IN\13603305 patients_27\NNS\9898892 who_28\WP\8299493 present_29\VBP\2137132 with_30\IN\1740 unexplained_31\JJ\1740 renal_32\JJ\1740 failure_33\NN\66216 ._34\.\1740
D000880_D051437 NONE although_0\IN\1740 a_1\DT\13649268 causal_2\JJ\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 use_6\NN\407535 of_7\IN\1740 an_8\DT\6697703 <e1>anthraquinone-containing</e1>_9\JJ\1740 herbal_10\JJ\1740 agent_11\NN\7347 and_12\CC\1740 renal_13\JJ\1740 injury_14\NN\14052046 remains_15\VBZ\2604760 to_16\TO\1740 be_17\VB\836236 proven_18\VBN\2604760 ,_19\,\1740 phytotherapy-associated_20\JJ\1740 interstitial_21\JJ\1740 nephropathy_22\NN\14573196 should_23\MD\1740 be_24\VB\836236 considered_25\VBN\689344 in_26\IN\13603305 patients_27\NNS\9898892 who_28\WP\8299493 present_29\VBP\2137132 with_30\IN\1740 unexplained_31\JJ\1740 <e2>renal_32\JJ\1740 failure</e2>_33\NN\66216 ._34\.\1740
24911645
C573355_D012640 NONE behavioral_0\JJ\1740 and_1\CC\1740 neurochemical_2\JJ\1740 studies_3\NNS\635850 in_4\IN\13603305 mice_5\NNS\2329401 pretreated_6\VBN\1740 with_7\IN\1740 <e1>garcinielliptone_8\NN\1740 fc</e1>_9\NN\1740 in_10\IN\13603305 pilocarpine-induced_11\JJ\1740 <e2>seizures</e2>_12\NNS\14081375 ._13\.\1740
C573355_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 <e1>gfc</e1>_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 <e2>seizure</e2>_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 seizures_59\NNS\14081375 ._60\.\1740
C573355_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 <e1>gfc</e1>_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 seizure_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 <e2>seizures</e2>_59\NNS\14081375 ._60\.\1740
C573355_D012640 NONE <e1>gfc</e1>_0\NN\1740 produced_1\VBD\1617192 an_2\DT\6697703 increased_3\VBN\169651 latency_4\NN\15269513 to_5\TO\1740 first_6\RB\1740 <e2>seizure</e2>_7\VB\1740 ,_8\,\1740 at_9\IN\14622893 doses_10\NNS\3740161 25mg/kg_11\NN\1740 (_12\-LRB-\1740 20.12_13\CD\1740 +_14\CC\1740 2.20_15\CD\1740 min_16\NN\15154774 )_17\-RRB-\1740 ,_18\,\1740 50mg/kg_19\NN\1740 (_20\-LRB-\1740 20.95_21\CD\1740 +_22\CC\1740 2.21_23\CD\1740 min_24\NN\15154774 )_25\-RRB-\1740 or_26\CC\3541091 75_27\CD\1740 mg/kg_28\NN\1740 (_29\-LRB-\1740 23.43_30\CD\1740 +_31\CC\1740 1.99_32\CD\1740 min_33\NN\15154774 )_34\-RRB-\1740 when_35\WRB\1740 compared_36\VBN\644583 with_37\IN\1740 seized_38\JJ\1740 mice_39\NNS\2329401 ._40\.\1740
C573355_D012640 NONE the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>gfc</e1>_4\NN\1740 can_5\MD\3094503 exert_6\VB\1158872 anticonvulsant_7\JJ\1740 activity_8\NN\30358 and_9\CC\1740 reduce_10\VB\441445 the_11\DT\1740 frequency_12\NN\15286249 of_13\IN\1740 installation_14\NN\235435 of_15\IN\1740 pilocarpine-induced_16\JJ\1740 status_17\NN\24720 epilepticus_18\NN\1740 ,_19\,\1740 as_20\IN\14622893 demonstrated_21\VBN\2137132 by_22\IN\1740 increase_23\NN\13576355 in_24\IN\13603305 latency_25\NN\15269513 to_26\TO\1740 first_27\RB\1740 <e2>seizure</e2>_28\VB\1740 and_29\CC\1740 decrease_30\VB\169651 in_31\IN\13603305 mortality_32\NN\5054863 rate_33\NN\13815152 of_34\IN\1740 animals_35\NNS\4475 ._36\.\1740
D010862_D012640 CID behavioral_0\JJ\1740 and_1\CC\1740 neurochemical_2\JJ\1740 studies_3\NNS\635850 in_4\IN\13603305 mice_5\NNS\2329401 pretreated_6\VBN\1740 with_7\IN\1740 garcinielliptone_8\NN\1740 fc_9\NN\1740 in_10\IN\13603305 <e1>pilocarpine-induced</e1>_11\JJ\1740 <e2>seizures</e2>_12\NNS\14081375 ._13\.\1740
D010862_D012640 CID the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 gfc_4\NN\1740 can_5\MD\3094503 exert_6\VB\1158872 anticonvulsant_7\JJ\1740 activity_8\NN\30358 and_9\CC\1740 reduce_10\VB\441445 the_11\DT\1740 frequency_12\NN\15286249 of_13\IN\1740 installation_14\NN\235435 of_15\IN\1740 <e1>pilocarpine-induced</e1>_16\JJ\1740 status_17\NN\24720 epilepticus_18\NN\1740 ,_19\,\1740 as_20\IN\14622893 demonstrated_21\VBN\2137132 by_22\IN\1740 increase_23\NN\13576355 in_24\IN\13603305 latency_25\NN\15269513 to_26\TO\1740 first_27\RB\1740 <e2>seizure</e2>_28\VB\1740 and_29\CC\1740 decrease_30\VB\169651 in_31\IN\13603305 mortality_32\NN\5054863 rate_33\NN\13815152 of_34\IN\1740 animals_35\NNS\4475 ._36\.\1740
D000596_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 <e2>seizure</e2>_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 <e1>amino_30\NN\14621446 acid</e1>_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 seizures_59\NNS\14081375 ._60\.\1740
D000596_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 seizure_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 <e1>amino_30\NN\14621446 acid</e1>_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 <e2>seizures</e2>_59\NNS\14081375 ._60\.\1740
D005680_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 <e2>seizure</e2>_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 <e1>r-aminobutyric_33\NN\1740 acid</e1>_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 seizures_59\NNS\14081375 ._60\.\1740
D005680_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 seizure_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 <e1>r-aminobutyric_33\NN\1740 acid</e1>_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 <e2>seizures</e2>_59\NNS\14081375 ._60\.\1740
D005680_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 <e2>seizure</e2>_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 <e1>gaba</e1>_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 seizures_59\NNS\14081375 ._60\.\1740
D005680_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 seizure_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 <e1>gaba</e1>_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 <e2>seizures</e2>_59\NNS\14081375 ._60\.\1740
D018698_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 <e2>seizure</e2>_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 <e1>glutamine</e1>_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 seizures_59\NNS\14081375 ._60\.\1740
D018698_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 seizure_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 <e1>glutamine</e1>_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 <e2>seizures</e2>_59\NNS\14081375 ._60\.\1740
D001224_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 <e2>seizure</e2>_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 <e1>aspartate</e1>_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 seizures_59\NNS\14081375 ._60\.\1740
D001224_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 seizure_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 <e1>aspartate</e1>_41\NN\1740 and_42\CC\1740 glutathione_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 <e2>seizures</e2>_59\NNS\14081375 ._60\.\1740
D005978_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 <e2>seizure</e2>_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 <e1>glutathione</e1>_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 seizures_59\NNS\14081375 ._60\.\1740
D005978_D012640 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 aimed_3\VBN\1987160 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 gfc_7\NN\1740 effects_8\NNS\13245626 at_9\IN\14622893 doses_10\NNS\3740161 of_11\IN\1740 25_12\CD\13745420 ,_13\,\1740 50_14\CD\13745420 or_15\CC\3541091 75_16\CD\1740 mg/kg_17\NN\1740 on_18\IN\1740 seizure_19\JJ\1740 parameters_20\NNS\5858936 to_21\TO\1740 determine_22\VB\1645601 their_23\PRP$\1740 anticonvulsant_24\JJ\1740 activity_25\NN\30358 and_26\CC\1740 its_27\PRP$\6125041 effects_28\NNS\13245626 on_29\IN\1740 amino_30\NN\14621446 acid_31\NN\14818238 (_32\-LRB-\1740 r-aminobutyric_33\NN\1740 acid_34\NN\14818238 (_35\-LRB-\1740 gaba_36\NN\14601829 )_37\-RRB-\1740 ,_38\,\1740 glutamine_39\NN\14601829 ,_40\,\1740 aspartate_41\NN\1740 and_42\CC\1740 <e1>glutathione</e1>_43\NN\1740 )_44\-RRB-\1740 levels_45\NNS\4916342 as_46\RB\1740 well_47\RB\1740 as_48\IN\14622893 on_49\IN\1740 acetylcholinesterase_50\NN\1740 (_51\-LRB-\1740 ache_52\NN\14322699 )_53\-RRB-\1740 activity_54\NN\30358 in_55\IN\13603305 mice_56\NNS\2329401 hippocampus_57\NN\5462674 after_58\IN\1740 <e2>seizures</e2>_59\NNS\14081375 ._60\.\1740
C573355_D013226 NONE the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>gfc</e1>_4\NN\1740 can_5\MD\3094503 exert_6\VB\1158872 anticonvulsant_7\JJ\1740 activity_8\NN\30358 and_9\CC\1740 reduce_10\VB\441445 the_11\DT\1740 frequency_12\NN\15286249 of_13\IN\1740 installation_14\NN\235435 of_15\IN\1740 pilocarpine-induced_16\JJ\1740 <e2>status_17\NN\24720 epilepticus</e2>_18\NN\1740 ,_19\,\1740 as_20\IN\14622893 demonstrated_21\VBN\2137132 by_22\IN\1740 increase_23\NN\13576355 in_24\IN\13603305 latency_25\NN\15269513 to_26\TO\1740 first_27\RB\1740 seizure_28\VB\1740 and_29\CC\1740 decrease_30\VB\169651 in_31\IN\13603305 mortality_32\NN\5054863 rate_33\NN\13815152 of_34\IN\1740 animals_35\NNS\4475 ._36\.\1740
D010862_D013226 CID the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 gfc_4\NN\1740 can_5\MD\3094503 exert_6\VB\1158872 anticonvulsant_7\JJ\1740 activity_8\NN\30358 and_9\CC\1740 reduce_10\VB\441445 the_11\DT\1740 frequency_12\NN\15286249 of_13\IN\1740 installation_14\NN\235435 of_15\IN\1740 <e1>pilocarpine-induced</e1>_16\JJ\1740 <e2>status_17\NN\24720 epilepticus</e2>_18\NN\1740 ,_19\,\1740 as_20\IN\14622893 demonstrated_21\VBN\2137132 by_22\IN\1740 increase_23\NN\13576355 in_24\IN\13603305 latency_25\NN\15269513 to_26\TO\1740 first_27\RB\1740 seizure_28\VB\1740 and_29\CC\1740 decrease_30\VB\169651 in_31\IN\13603305 mortality_32\NN\5054863 rate_33\NN\13815152 of_34\IN\1740 animals_35\NNS\4475 ._36\.\1740
1905439
D016595_D003693 CID <e2>delirium</e2>_0\NN\14391660 in_1\IN\13603305 an_2\DT\6697703 elderly_3\JJ\1740 woman_4\NN\9605289 possibly_5\RB\1740 associated_6\VBN\628491 with_7\IN\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>misoprostol</e1>_10\NN\1740 ._11\.\1740
D016595_D003693 CID her_0\PRP$\1740 <e2>delirium</e2>_1\NN\14391660 significantly_2\RB\1740 improved_3\VBD\126264 after_4\IN\1740 <e1>misoprostol</e1>_5\NN\1740 was_6\VBD\836236 discontinued_7\VBN\2609764 and_8\CC\1740 her_9\PRP$\1740 mental_10\JJ\1740 status_11\NN\24720 returned_12\VBD\1835496 to_13\TO\1740 normal_14\JJ\1740 within_15\IN\1740 a_16\DT\13649268 week_17\NN\15113229 ._18\.\1740
D016595_D003693 CID because_0\IN\1740 no_1\DT\7204911 other_2\JJ\1740 factors_3\NNS\7326557 related_4\JJ\1740 to_5\TO\1740 this_6\DT\1740 patient_7\NN\9898892 changed_8\VBD\46534 significantly_9\RB\1740 ,_10\,\1740 the_11\DT\1740 <e2>delirium</e2>_12\NN\14391660 experienced_13\VBN\2108377 by_14\IN\1740 this_15\DT\1740 patient_16\NN\9898892 possibly_17\RB\1740 resulted_18\VBD\2633881 from_19\IN\1740 <e1>misoprostol</e1>_20\NN\1740 therapy_21\NN\657604 ._22\.\1740
D016595_D006261 NONE <e1>misoprostol</e1>_0\NN\1740 has_1\VBZ\2108377 been_2\VBN\836236 associated_3\VBN\628491 with_4\IN\1740 adverse_5\JJ\1740 reactions_6\NNS\13446390 ,_7\,\1740 including_8\VBG\690614 gastrointestinal_9\JJ\1740 symptoms_10\NNS\5823932 ,_11\,\1740 gynecologic_12\JJ\1740 problems_13\NNS\14408086 ,_14\,\1740 and_15\CC\1740 <e2>headache</e2>_16\VB\1740 ._17\.\1740
12059909
D003520_D064420 NONE delayed_0\VBN\439958 <e2>toxicity</e2>_1\NN\13576101 of_2\IN\1740 <e1>cyclophosphamide</e1>_3\NN\1740 on_4\IN\1740 the_5\DT\1740 bladder_6\NN\5515670 of_7\IN\1740 dba/2_8\NN\1740 and_9\CC\1740 c57bl/6_10\NN\1740 female_11\JJ\1740 mouse_12\NN\2329401 ._13\.\1740
D003520_D064420 NONE early_0\JJ\1740 <e1>cy</e1>_1\NN\1740 <e2>toxicity</e2>_2\NN\13576101 caused_3\VBD\1617192 a_4\DT\13649268 typical_5\JJ\1740 haemorrhagic_6\JJ\1740 cystitis_7\NN\14566129 in_8\IN\13603305 both_9\DT\1740 strains_10\NNS\7358060 that_11\WDT\1740 was_12\VBD\836236 completely_13\RB\1740 repaired_14\VBN\205885 in_15\IN\13603305 about_16\RB\1740 7_17\CD\13741022 -_18\SYM\1740 10_19\CD\13745420 days_20\NNS\15140892 ._21\.\1740
D003520_D064420 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 delayed_4\VBN\439958 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 <e1>cy</e1>_7\NN\1740 in_8\IN\13603305 female_9\JJ\1740 dba/2_10\NN\1740 mice_11\NNS\2329401 causes_12\VBZ\1617192 a_13\DT\13649268 bladder_14\NN\5515670 pathology_15\NN\6045562 that_16\WDT\1740 is_17\VBZ\836236 not_18\RB\1740 observed_19\VBN\2163746 in_20\IN\13603305 c57bl/6_21\NN\1740 mice_22\NNS\2329401 ._23\.\1740
D003520_D006470 CID early_0\JJ\1740 <e1>cy</e1>_1\NN\1740 toxicity_2\NN\13576101 caused_3\VBD\1617192 a_4\DT\13649268 typical_5\JJ\1740 <e2>haemorrhagic</e2>_6\JJ\1740 cystitis_7\NN\14566129 in_8\IN\13603305 both_9\DT\1740 strains_10\NNS\7358060 that_11\WDT\1740 was_12\VBD\836236 completely_13\RB\1740 repaired_14\VBN\205885 in_15\IN\13603305 about_16\RB\1740 7_17\CD\13741022 -_18\SYM\1740 10_19\CD\13745420 days_20\NNS\15140892 ._21\.\1740
D003520_D003556 CID early_0\JJ\1740 <e1>cy</e1>_1\NN\1740 toxicity_2\NN\13576101 caused_3\VBD\1617192 a_4\DT\13649268 typical_5\JJ\1740 haemorrhagic_6\JJ\1740 <e2>cystitis</e2>_7\NN\14566129 in_8\IN\13603305 both_9\DT\1740 strains_10\NNS\7358060 that_11\WDT\1740 was_12\VBD\836236 completely_13\RB\1740 repaired_14\VBN\205885 in_15\IN\13603305 about_16\RB\1740 7_17\CD\13741022 -_18\SYM\1740 10_19\CD\13745420 days_20\NNS\15140892 ._21\.\1740
D003520_D003556 CID after_0\IN\1740 30_1\CD\13745420 days_2\NNS\15140892 of_3\IN\1740 <e1>cy</e1>_4\NN\1740 injection_5\NN\320852 ulcerous_6\JJ\1740 and_7\CC\1740 non-ulcerous_8\JJ\1740 forms_9\NNS\6286395 of_10\IN\1740 chronic_11\JJ\1740 <e2>cystitis</e2>_12\NN\14566129 appeared_13\VBD\2604760 in_14\IN\13603305 86_15\CD\1740 %_16\NN\1740 of_17\IN\1740 dba/2_18\NN\1740 mice_19\NNS\2329401 but_20\CC\1740 only_21\RB\1740 in_22\IN\13603305 4_23\CD\13741022 %_24\NN\1740 of_25\IN\1740 c57bl/6_26\NN\1740 mice_27\NNS\2329401 ._28\.\1740
26002693
C031763_D015464 NONE <e1>1,3-butadiene</e1>_0\NN\1740 ,_1\,\1740 <e2>cml</e2>_2\NN\1740 and_3\CC\1740 the_4\DT\1740 t(9:22_5\NN\1740 )_6\-RRB-\1740 translocation_7\NN\13526110 :_8\:\1740 a_9\DT\13649268 reality_10\NN\5984584 check_11\VBP\644583 ._12\.\1740
C031763_D015464 NONE unassigned_0\NNS\1740 :_1\:\1740 epidemiological_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 <e1>1,3-butadiene</e1>_5\NN\1740 have_6\VBP\2108377 suggest_7\VBP\1010118 that_8\IN\1740 exposures_9\NNS\5042871 to_10\TO\1740 humans_11\NNS\31264 are_12\VBP\836236 associated_13\VBN\628491 with_14\IN\1740 <e2>chronic_15\JJ\1740 myeloid_16\JJ\1740 leukemia</e2>_17\NN\14239918 (_18\-LRB-\1740 cml_19\NN\1740 )_20\-RRB-\1740 ._21\.\1740
C031763_D015464 NONE unassigned_0\NNS\1740 :_1\:\1740 epidemiological_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 <e1>1,3-butadiene</e1>_5\NN\1740 have_6\VBP\2108377 suggest_7\VBP\1010118 that_8\IN\1740 exposures_9\NNS\5042871 to_10\TO\1740 humans_11\NNS\31264 are_12\VBP\836236 associated_13\VBN\628491 with_14\IN\1740 chronic_15\JJ\1740 myeloid_16\JJ\1740 leukemia_17\NN\14239918 (_18\-LRB-\1740 <e2>cml</e2>_19\NN\1740 )_20\-RRB-\1740 ._21\.\1740
3289726
D005047_D009422 NONE <e2>acute_0\JJ\1740 neurologic_1\JJ\1740 dysfunction</e2>_2\NN\14204950 after_3\IN\1740 high-dose_4\JJ\1740 <e1>etoposide</e1>_5\NN\1740 therapy_6\NN\657604 for_7\IN\1740 malignant_8\JJ\1740 glioma_9\NN\14236743 ._10\.\1740
D005047_D005910 NONE acute_0\JJ\1740 neurologic_1\JJ\1740 dysfunction_2\NN\14204950 after_3\IN\1740 high-dose_4\JJ\1740 <e1>etoposide</e1>_5\NN\1740 therapy_6\NN\657604 for_7\IN\1740 <e2>malignant_8\JJ\1740 glioma</e2>_9\NN\14236743 ._10\.\1740
D005047_D005910 NONE this_0\DT\1740 complication_1\NN\1073995 appears_2\VBZ\2604760 to_3\TO\1740 represent_4\VB\2664769 a_5\DT\13649268 significant_6\JJ\1740 new_7\JJ\1740 toxicity_8\NN\13576101 of_9\IN\1740 high-dose_10\JJ\1740 <e1>etoposide</e1>_11\NN\1740 therapy_12\NN\657604 for_13\IN\1740 <e2>malignant_14\JJ\1740 glioma</e2>_15\NN\14236743 ._16\.\1740
D005047_D009369 NONE <e1>etoposide</e1>_0\NN\1740 (_1\-LRB-\1740 vp-16_2\NN\1740 -_3\HYPH\1740 213_4\CD\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 many_13\JJ\1740 solid_14\JJ\1740 <e2>tumors</e2>_15\NNS\14234074 and_16\CC\1740 hematologic_17\JJ\1740 malignancies_18\NNS\14070360 ._19\.\1740
D005047_D009369 NONE etoposide_0\NN\1740 (_1\-LRB-\1740 <e1>vp-16_2\NN\1740 -_3\HYPH\1740 213</e1>_4\CD\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 many_13\JJ\1740 solid_14\JJ\1740 <e2>tumors</e2>_15\NNS\14234074 and_16\CC\1740 hematologic_17\JJ\1740 malignancies_18\NNS\14070360 ._19\.\1740
D005047_D019337 NONE <e1>etoposide</e1>_0\NN\1740 (_1\-LRB-\1740 vp-16_2\NN\1740 -_3\HYPH\1740 213_4\CD\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 many_13\JJ\1740 solid_14\JJ\1740 tumors_15\NNS\14234074 and_16\CC\1740 <e2>hematologic_17\JJ\1740 malignancies</e2>_18\NNS\14070360 ._19\.\1740
D005047_D019337 NONE etoposide_0\NN\1740 (_1\-LRB-\1740 <e1>vp-16_2\NN\1740 -_3\HYPH\1740 213</e1>_4\CD\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 in_9\IN\13603305 the_10\DT\1740 treatment_11\NN\654885 of_12\IN\1740 many_13\JJ\1740 solid_14\JJ\1740 tumors_15\NNS\14234074 and_16\CC\1740 <e2>hematologic_17\JJ\1740 malignancies</e2>_18\NNS\14070360 ._19\.\1740
D005047_D064420 NONE this_0\DT\1740 complication_1\NN\1073995 appears_2\VBZ\2604760 to_3\TO\1740 represent_4\VB\2664769 a_5\DT\13649268 significant_6\JJ\1740 new_7\JJ\1740 <e2>toxicity</e2>_8\NN\13576101 of_9\IN\1740 high-dose_10\JJ\1740 <e1>etoposide</e1>_11\NN\1740 therapy_12\NN\657604 for_13\IN\1740 malignant_14\JJ\1740 glioma_15\NN\14236743 ._16\.\1740
1615846
D015248_D006951 NONE <e1>gemfibrozil-lovastatin</e1>_0\JJ\1740 therapy_1\NN\657604 for_2\IN\1740 primary_3\JJ\1740 <e2>hyperlipoproteinemias</e2>_4\NNS\14084502 ._5\.\1740
D008148_D006951 NONE <e1>gemfibrozil-lovastatin</e1>_0\JJ\1740 therapy_1\NN\657604 for_2\IN\1740 primary_3\JJ\1740 <e2>hyperlipoproteinemias</e2>_4\NNS\14084502 ._5\.\1740
D015248_D006949 NONE the_0\DT\1740 specific_1\JJ\1740 aim_2\NN\5980875 of_3\IN\1740 this_4\DT\1740 retrospective_5\JJ\1740 ,_6\,\1740 observational_7\JJ\1740 study_8\NN\635850 was_9\VBD\836236 to_10\TO\1740 assess_11\VB\670261 safety_12\NN\13920835 and_13\CC\1740 efficacy_14\NN\5199286 of_15\IN\1740 long-term_16\JJ\1740 (_17\-LRB-\1740 21_18\CD\13745420 months/patient_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 open-label_22\RB\1740 ,_23\,\1740 <e1>gemfibrozil-lovastatin</e1>_24\NN\1740 treatment_25\NN\654885 in_26\IN\13603305 80_27\CD\13745420 patients_28\NNS\9898892 with_29\IN\1740 primary_30\JJ\1740 mixed_31\JJ\1740 <e2>hyperlipidemia</e2>_32\NN\14299637 (_33\-LRB-\1740 68_34\CD\1740 %_35\NN\1740 of_36\IN\1740 whom_37\WP\1740 had_38\VBD\2108377 atherosclerotic_39\JJ\1740 vascular_40\JJ\1740 disease_41\NN\14061805 )_42\-RRB-\1740 ._43\.\1740
D015248_D002340 NONE the_0\DT\1740 specific_1\JJ\1740 aim_2\NN\5980875 of_3\IN\1740 this_4\DT\1740 retrospective_5\JJ\1740 ,_6\,\1740 observational_7\JJ\1740 study_8\NN\635850 was_9\VBD\836236 to_10\TO\1740 assess_11\VB\670261 safety_12\NN\13920835 and_13\CC\1740 efficacy_14\NN\5199286 of_15\IN\1740 long-term_16\JJ\1740 (_17\-LRB-\1740 21_18\CD\13745420 months/patient_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 open-label_22\RB\1740 ,_23\,\1740 <e1>gemfibrozil-lovastatin</e1>_24\NN\1740 treatment_25\NN\654885 in_26\IN\13603305 80_27\CD\13745420 patients_28\NNS\9898892 with_29\IN\1740 primary_30\JJ\1740 mixed_31\JJ\1740 hyperlipidemia_32\NN\14299637 (_33\-LRB-\1740 68_34\CD\1740 %_35\NN\1740 of_36\IN\1740 whom_37\WP\1740 had_38\VBD\2108377 <e2>atherosclerotic_39\JJ\1740 vascular_40\JJ\1740 disease</e2>_41\NN\14061805 )_42\-RRB-\1740 ._43\.\1740
D008148_D006949 NONE the_0\DT\1740 specific_1\JJ\1740 aim_2\NN\5980875 of_3\IN\1740 this_4\DT\1740 retrospective_5\JJ\1740 ,_6\,\1740 observational_7\JJ\1740 study_8\NN\635850 was_9\VBD\836236 to_10\TO\1740 assess_11\VB\670261 safety_12\NN\13920835 and_13\CC\1740 efficacy_14\NN\5199286 of_15\IN\1740 long-term_16\JJ\1740 (_17\-LRB-\1740 21_18\CD\13745420 months/patient_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 open-label_22\RB\1740 ,_23\,\1740 <e1>gemfibrozil-lovastatin</e1>_24\NN\1740 treatment_25\NN\654885 in_26\IN\13603305 80_27\CD\13745420 patients_28\NNS\9898892 with_29\IN\1740 primary_30\JJ\1740 mixed_31\JJ\1740 <e2>hyperlipidemia</e2>_32\NN\14299637 (_33\-LRB-\1740 68_34\CD\1740 %_35\NN\1740 of_36\IN\1740 whom_37\WP\1740 had_38\VBD\2108377 atherosclerotic_39\JJ\1740 vascular_40\JJ\1740 disease_41\NN\14061805 )_42\-RRB-\1740 ._43\.\1740
D008148_D002340 NONE the_0\DT\1740 specific_1\JJ\1740 aim_2\NN\5980875 of_3\IN\1740 this_4\DT\1740 retrospective_5\JJ\1740 ,_6\,\1740 observational_7\JJ\1740 study_8\NN\635850 was_9\VBD\836236 to_10\TO\1740 assess_11\VB\670261 safety_12\NN\13920835 and_13\CC\1740 efficacy_14\NN\5199286 of_15\IN\1740 long-term_16\JJ\1740 (_17\-LRB-\1740 21_18\CD\13745420 months/patient_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 open-label_22\RB\1740 ,_23\,\1740 <e1>gemfibrozil-lovastatin</e1>_24\NN\1740 treatment_25\NN\654885 in_26\IN\13603305 80_27\CD\13745420 patients_28\NNS\9898892 with_29\IN\1740 primary_30\JJ\1740 mixed_31\JJ\1740 hyperlipidemia_32\NN\14299637 (_33\-LRB-\1740 68_34\CD\1740 %_35\NN\1740 of_36\IN\1740 whom_37\WP\1740 had_38\VBD\2108377 <e2>atherosclerotic_39\JJ\1740 vascular_40\JJ\1740 disease</e2>_41\NN\14061805 )_42\-RRB-\1740 ._43\.\1740
D003401_D009220 NONE <e2>myositis</e2>_0\NNP\14336539 ,_1\,\1740 attributable_2\JJ\1740 to_3\TO\1740 the_4\DT\1740 drug_5\NN\14778436 combination_6\NN\7951464 and_7\CC\1740 symptomatic_8\JJ\1740 enough_9\RB\1740 to_10\TO\1740 discontinue_11\VB\2609764 it_12\PRP\6125041 ,_13\,\1740 occurred_14\VBD\2623529 in_15\IN\13603305 3_16\CD\13741022 %_17\NN\1740 of_18\IN\1740 patients_19\NNS\9898892 ,_20\,\1740 and_21\CC\1740 in_22\IN\13603305 1_23\CD\13741022 %_24\NN\1740 with_25\IN\1740 concurrent_26\JJ\1740 high_27\JJ\1740 <e1>creatine</e1>_28\NN\14601829 phosphokinase_29\NN\1740 (_30\-LRB-\1740 769_31\CD\1740 u/liter_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 no_35\DT\7204911 patients_36\NNS\9898892 had_37\VBD\2108377 rhabdomyolysis_38\NN\1740 or_39\CC\3541091 myoglobinuria_40\NNS\14299637 ._41\.\1740
D003401_D012206 NONE myositis_0\NNP\14336539 ,_1\,\1740 attributable_2\JJ\1740 to_3\TO\1740 the_4\DT\1740 drug_5\NN\14778436 combination_6\NN\7951464 and_7\CC\1740 symptomatic_8\JJ\1740 enough_9\RB\1740 to_10\TO\1740 discontinue_11\VB\2609764 it_12\PRP\6125041 ,_13\,\1740 occurred_14\VBD\2623529 in_15\IN\13603305 3_16\CD\13741022 %_17\NN\1740 of_18\IN\1740 patients_19\NNS\9898892 ,_20\,\1740 and_21\CC\1740 in_22\IN\13603305 1_23\CD\13741022 %_24\NN\1740 with_25\IN\1740 concurrent_26\JJ\1740 high_27\JJ\1740 <e1>creatine</e1>_28\NN\14601829 phosphokinase_29\NN\1740 (_30\-LRB-\1740 769_31\CD\1740 u/liter_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 no_35\DT\7204911 patients_36\NNS\9898892 had_37\VBD\2108377 <e2>rhabdomyolysis</e2>_38\NN\1740 or_39\CC\3541091 myoglobinuria_40\NNS\14299637 ._41\.\1740
D003401_D009212 NONE myositis_0\NNP\14336539 ,_1\,\1740 attributable_2\JJ\1740 to_3\TO\1740 the_4\DT\1740 drug_5\NN\14778436 combination_6\NN\7951464 and_7\CC\1740 symptomatic_8\JJ\1740 enough_9\RB\1740 to_10\TO\1740 discontinue_11\VB\2609764 it_12\PRP\6125041 ,_13\,\1740 occurred_14\VBD\2623529 in_15\IN\13603305 3_16\CD\13741022 %_17\NN\1740 of_18\IN\1740 patients_19\NNS\9898892 ,_20\,\1740 and_21\CC\1740 in_22\IN\13603305 1_23\CD\13741022 %_24\NN\1740 with_25\IN\1740 concurrent_26\JJ\1740 high_27\JJ\1740 <e1>creatine</e1>_28\NN\14601829 phosphokinase_29\NN\1740 (_30\-LRB-\1740 769_31\CD\1740 u/liter_32\NN\1740 )_33\-RRB-\1740 ;_34\:\1740 no_35\DT\7204911 patients_36\NNS\9898892 had_37\VBD\2108377 rhabdomyolysis_38\NN\1740 or_39\CC\3541091 <e2>myoglobinuria</e2>_40\NNS\14299637 ._41\.\1740
17384765
D004113_D003072 CID <e1>succimer</e1>_0\NN\1740 chelation_1\NN\29677 improves_2\NNS\1740 learning_3\NN\5701944 ,_4\,\1740 attention_5\NN\5701944 ,_6\,\1740 and_7\CC\1740 arousal_8\JJ\1740 regulation_9\NN\6652242 in_10\IN\13603305 lead-exposed_11\JJ\1740 rats_12\NNS\2329401 but_13\CC\1740 produces_14\VBZ\1617192 lasting_15\VBG\2704349 <e2>cognitive_16\JJ\1740 impairment</e2>_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 absence_20\NN\14449405 of_21\IN\1740 lead_22\JJ\1740 exposure_23\NN\5042871 ._24\.\1740
D004113_D003072 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>succimer</e1>_3\NN\1740 treatment_4\NN\654885 of_5\IN\1740 rats_6\NNS\2329401 not_7\RB\1740 previously_8\RB\1740 exposed_9\VBN\2110927 to_10\TO\1740 pb_11\NN\14625458 produced_12\VBN\1617192 lasting_13\NN\1740 and_14\CC\1740 pervasive_15\JJ\1740 <e2>cognitive_16\JJ\1740 and_17\CC\1740 affective_18\JJ\1740 dysfunction</e2>_19\NN\14204950 comparable_20\JJ\1740 in_21\IN\13603305 magnitude_22\NN\4916342 to_23\TO\1740 that_24\DT\1740 produced_25\VBN\1617192 by_26\IN\1740 the_27\DT\1740 higher_28\JJR\1740 pb_29\NN\14625458 exposure_30\NN\5042871 regimen_31\NN\5898568 ._32\.\1740
D007854_D003072 NONE succimer_0\NN\1740 chelation_1\NN\29677 improves_2\NNS\1740 learning_3\NN\5701944 ,_4\,\1740 attention_5\NN\5701944 ,_6\,\1740 and_7\CC\1740 arousal_8\JJ\1740 regulation_9\NN\6652242 in_10\IN\13603305 <e1>lead-exposed</e1>_11\JJ\1740 rats_12\NNS\2329401 but_13\CC\1740 produces_14\VBZ\1617192 lasting_15\VBG\2704349 <e2>cognitive_16\JJ\1740 impairment</e2>_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 absence_20\NN\14449405 of_21\IN\1740 lead_22\JJ\1740 exposure_23\NN\5042871 ._24\.\1740
D007854_D003072 NONE succimer_0\NN\1740 chelation_1\NN\29677 improves_2\NNS\1740 learning_3\NN\5701944 ,_4\,\1740 attention_5\NN\5701944 ,_6\,\1740 and_7\CC\1740 arousal_8\JJ\1740 regulation_9\NN\6652242 in_10\IN\13603305 lead-exposed_11\JJ\1740 rats_12\NNS\2329401 but_13\CC\1740 produces_14\VBZ\1617192 lasting_15\VBG\2704349 <e2>cognitive_16\JJ\1740 impairment</e2>_17\NN\7296428 in_18\IN\13603305 the_19\DT\1740 absence_20\NN\14449405 of_21\IN\1740 <e1>lead</e1>_22\JJ\1740 exposure_23\NN\5042871 ._24\.\1740
D007854_D003072 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 succimer_3\NN\1740 treatment_4\NN\654885 of_5\IN\1740 rats_6\NNS\2329401 not_7\RB\1740 previously_8\RB\1740 exposed_9\VBN\2110927 to_10\TO\1740 <e1>pb</e1>_11\NN\14625458 produced_12\VBN\1617192 lasting_13\NN\1740 and_14\CC\1740 pervasive_15\JJ\1740 <e2>cognitive_16\JJ\1740 and_17\CC\1740 affective_18\JJ\1740 dysfunction</e2>_19\NN\14204950 comparable_20\JJ\1740 in_21\IN\13603305 magnitude_22\NN\4916342 to_23\TO\1740 that_24\DT\1740 produced_25\VBN\1617192 by_26\IN\1740 the_27\DT\1740 higher_28\JJR\1740 pb_29\NN\14625458 exposure_30\NN\5042871 regimen_31\NN\5898568 ._32\.\1740
D007854_D003072 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 succimer_3\NN\1740 treatment_4\NN\654885 of_5\IN\1740 rats_6\NNS\2329401 not_7\RB\1740 previously_8\RB\1740 exposed_9\VBN\2110927 to_10\TO\1740 pb_11\NN\14625458 produced_12\VBN\1617192 lasting_13\NN\1740 and_14\CC\1740 pervasive_15\JJ\1740 <e2>cognitive_16\JJ\1740 and_17\CC\1740 affective_18\JJ\1740 dysfunction</e2>_19\NN\14204950 comparable_20\JJ\1740 in_21\IN\13603305 magnitude_22\NN\4916342 to_23\TO\1740 that_24\DT\1740 produced_25\VBN\1617192 by_26\IN\1740 the_27\DT\1740 higher_28\JJR\1740 <e1>pb</e1>_29\NN\14625458 exposure_30\NN\5042871 regimen_31\NN\5898568 ._32\.\1740
D007854_D003072 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 are_3\VBP\836236 the_4\DT\1740 first_5\JJ\1740 data_6\NNS\7951464 ,_7\,\1740 to_8\TO\1740 our_9\PRP$\1740 knowledge_10\NN\23100 ,_11\,\1740 to_12\TO\1740 show_13\VB\2137132 that_14\IN\1740 treatment_15\NN\654885 with_16\IN\1740 any_17\DT\1740 chelating_18\VBG\2621395 agent_19\NN\7347 can_20\MD\3094503 alleviate_21\VB\205885 <e2>cognitive_22\JJ\1740 deficits</e2>_23\NNS\5113133 due_24\JJ\1740 to_25\TO\1740 <e1>pb</e1>_26\NN\14625458 exposure_27\NN\5042871 ._28\.\1740
D007854_D007855 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 designed_6\VBN\1631534 to_7\TO\1740 answer_8\VB\1009240 these_9\DT\1740 questions_10\NNS\7193184 ,_11\,\1740 using_12\VBG\1156834 a_13\DT\13649268 rodent_14\JJ\1740 model_15\NN\5888929 of_16\IN\1740 early_17\JJ\1740 childhood_18\NN\15144371 <e1>pb</e1>_19\NN\14625458 exposure_20\NN\5042871 and_21\CC\1740 treatment_22\NN\654885 with_23\IN\1740 succimer_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 widely_27\RB\1740 used_28\VBN\1156834 chelating_29\VBG\2621395 agent_30\NN\7347 for_31\IN\1740 the_32\DT\1740 treatment_33\NN\654885 of_34\IN\1740 <e2>pb_35\NN\14625458 poisoning</e2>_36\NN\14034177 ._37\.\1740
D004113_D007855 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 present_3\JJ\1740 study_4\NN\635850 was_5\VBD\836236 designed_6\VBN\1631534 to_7\TO\1740 answer_8\VB\1009240 these_9\DT\1740 questions_10\NNS\7193184 ,_11\,\1740 using_12\VBG\1156834 a_13\DT\13649268 rodent_14\JJ\1740 model_15\NN\5888929 of_16\IN\1740 early_17\JJ\1740 childhood_18\NN\15144371 pb_19\NN\14625458 exposure_20\NN\5042871 and_21\CC\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>succimer</e1>_24\NN\1740 ,_25\,\1740 a_26\DT\13649268 widely_27\RB\1740 used_28\VBN\1156834 chelating_29\VBG\2621395 agent_30\NN\7347 for_31\IN\1740 the_32\DT\1740 treatment_33\NN\654885 of_34\IN\1740 <e2>pb_35\NN\14625458 poisoning</e2>_36\NN\14034177 ._37\.\1740
D007854_D007859 CID results_0\NNS\34213 :_1\:\1740 <e1>pb</e1>_2\NN\14625458 exposure_3\NN\5042871 produced_4\VBD\1617192 lasting_5\VBG\2704349 <e2>impairments_6\NNS\7296428 in_7\IN\13603305 learning_8\NN\5701944 ,_9\,\1740 attention_10\NN\5701944 ,_11\,\1740 inhibitory_12\JJ\1740 control_13\NN\5190804 ,_14\,\1740 and_15\CC\1740 arousal_16\JJ\1740 regulation</e2>_17\NN\6652242 ,_18\,\1740 paralleling_19\VBG\2657219 the_20\DT\1740 areas_21\NNS\8630985 of_22\IN\1740 dysfunction_23\NN\14204950 seen_24\VBN\2106506 in_25\IN\13603305 pb-exposed_26\JJ\1740 children_27\NNS\9622049 ._28\.\1740
D007854_D007859 CID results_0\NNS\34213 :_1\:\1740 pb_2\NN\14625458 exposure_3\NN\5042871 produced_4\VBD\1617192 lasting_5\VBG\2704349 <e2>impairments_6\NNS\7296428 in_7\IN\13603305 learning_8\NN\5701944 ,_9\,\1740 attention_10\NN\5701944 ,_11\,\1740 inhibitory_12\JJ\1740 control_13\NN\5190804 ,_14\,\1740 and_15\CC\1740 arousal_16\JJ\1740 regulation</e2>_17\NN\6652242 ,_18\,\1740 paralleling_19\VBG\2657219 the_20\DT\1740 areas_21\NNS\8630985 of_22\IN\1740 dysfunction_23\NN\14204950 seen_24\VBN\2106506 in_25\IN\13603305 <e1>pb-exposed</e1>_26\JJ\1740 children_27\NNS\9622049 ._28\.\1740
D007854_D019958 CID results_0\NNS\34213 :_1\:\1740 <e1>pb</e1>_2\NN\14625458 exposure_3\NN\5042871 produced_4\VBD\1617192 lasting_5\VBG\2704349 <e2>impairments_6\NNS\7296428 in_7\IN\13603305 learning_8\NN\5701944 ,_9\,\1740 attention_10\NN\5701944 ,_11\,\1740 inhibitory_12\JJ\1740 control_13\NN\5190804 ,_14\,\1740 and_15\CC\1740 arousal_16\JJ\1740 regulation</e2>_17\NN\6652242 ,_18\,\1740 paralleling_19\VBG\2657219 the_20\DT\1740 areas_21\NNS\8630985 of_22\IN\1740 dysfunction_23\NN\14204950 seen_24\VBN\2106506 in_25\IN\13603305 pb-exposed_26\JJ\1740 children_27\NNS\9622049 ._28\.\1740
D007854_D019958 CID results_0\NNS\34213 :_1\:\1740 pb_2\NN\14625458 exposure_3\NN\5042871 produced_4\VBD\1617192 lasting_5\VBG\2704349 <e2>impairments_6\NNS\7296428 in_7\IN\13603305 learning_8\NN\5701944 ,_9\,\1740 attention_10\NN\5701944 ,_11\,\1740 inhibitory_12\JJ\1740 control_13\NN\5190804 ,_14\,\1740 and_15\CC\1740 arousal_16\JJ\1740 regulation</e2>_17\NN\6652242 ,_18\,\1740 paralleling_19\VBG\2657219 the_20\DT\1740 areas_21\NNS\8630985 of_22\IN\1740 dysfunction_23\NN\14204950 seen_24\VBN\2106506 in_25\IN\13603305 <e1>pb-exposed</e1>_26\JJ\1740 children_27\NNS\9622049 ._28\.\1740
D004113_D019964 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>succimer</e1>_3\NN\1740 treatment_4\NN\654885 of_5\IN\1740 rats_6\NNS\2329401 not_7\RB\1740 previously_8\RB\1740 exposed_9\VBN\2110927 to_10\TO\1740 pb_11\NN\14625458 produced_12\VBN\1617192 lasting_13\NN\1740 and_14\CC\1740 pervasive_15\JJ\1740 <e2>cognitive_16\JJ\1740 and_17\CC\1740 affective_18\JJ\1740 dysfunction</e2>_19\NN\14204950 comparable_20\JJ\1740 in_21\IN\13603305 magnitude_22\NN\4916342 to_23\TO\1740 that_24\DT\1740 produced_25\VBN\1617192 by_26\IN\1740 the_27\DT\1740 higher_28\JJR\1740 pb_29\NN\14625458 exposure_30\NN\5042871 regimen_31\NN\5898568 ._32\.\1740
D007854_D019964 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 succimer_3\NN\1740 treatment_4\NN\654885 of_5\IN\1740 rats_6\NNS\2329401 not_7\RB\1740 previously_8\RB\1740 exposed_9\VBN\2110927 to_10\TO\1740 <e1>pb</e1>_11\NN\14625458 produced_12\VBN\1617192 lasting_13\NN\1740 and_14\CC\1740 pervasive_15\JJ\1740 <e2>cognitive_16\JJ\1740 and_17\CC\1740 affective_18\JJ\1740 dysfunction</e2>_19\NN\14204950 comparable_20\JJ\1740 in_21\IN\13603305 magnitude_22\NN\4916342 to_23\TO\1740 that_24\DT\1740 produced_25\VBN\1617192 by_26\IN\1740 the_27\DT\1740 higher_28\JJR\1740 pb_29\NN\14625458 exposure_30\NN\5042871 regimen_31\NN\5898568 ._32\.\1740
D007854_D019964 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 succimer_3\NN\1740 treatment_4\NN\654885 of_5\IN\1740 rats_6\NNS\2329401 not_7\RB\1740 previously_8\RB\1740 exposed_9\VBN\2110927 to_10\TO\1740 pb_11\NN\14625458 produced_12\VBN\1617192 lasting_13\NN\1740 and_14\CC\1740 pervasive_15\JJ\1740 <e2>cognitive_16\JJ\1740 and_17\CC\1740 affective_18\JJ\1740 dysfunction</e2>_19\NN\14204950 comparable_20\JJ\1740 in_21\IN\13603305 magnitude_22\NN\4916342 to_23\TO\1740 that_24\DT\1740 produced_25\VBN\1617192 by_26\IN\1740 the_27\DT\1740 higher_28\JJR\1740 <e1>pb</e1>_29\NN\14625458 exposure_30\NN\5042871 regimen_31\NN\5898568 ._32\.\1740
15625689
D007980_D010300 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 characterize_7\VB\609683 the_8\DT\1740 oropharyngeal_9\NN\1740 dynamics_10\NNS\6100236 in_11\IN\13603305 <e2>pd</e2>_12\NN\14625458 patients_13\NNS\9898892 with_14\IN\1740 and_15\CC\1740 without_16\IN\1740 <e1>levodopa-induced</e1>_17\JJ\1740 dyskinesia_18\NN\14084880 ._19\.\1740
D007980_D010300 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 a_3\DT\13649268 role_4\NN\719494 for_5\IN\1740 <e1>levodopa</e1>_6\NN\14604959 in_7\IN\13603305 the_8\DT\1740 oral_9\JJ\1740 phase_10\NN\15113229 of_11\IN\1740 deglutition_12\NN\838098 and_13\CC\1740 confirm_14\VBP\1011725 that_15\IN\1740 dysphagia_16\NN\14052403 is_17\VBZ\836236 not_18\RB\1740 a_19\DT\13649268 good_20\JJ\1740 predictor_21\NN\10756433 of_22\IN\1740 deglutition_23\NN\838098 alterations_24\NNS\7283608 in_25\IN\13603305 <e2>pd</e2>_26\NN\14625458 ._27\.\1740
D007980_D004409 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 characterize_7\VB\609683 the_8\DT\1740 oropharyngeal_9\NN\1740 dynamics_10\NNS\6100236 in_11\IN\13603305 pd_12\NN\14625458 patients_13\NNS\9898892 with_14\IN\1740 and_15\CC\1740 without_16\IN\1740 <e1>levodopa-induced</e1>_17\JJ\1740 <e2>dyskinesia</e2>_18\NN\14084880 ._19\.\1740
D007980_D004409 CID in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 <e2>dyskinetic</e2>_5\JJ\1740 patients_6\NNS\9898892 performed_7\VBN\2367363 better_8\RBR\1740 in_9\IN\13603305 swallowing_10\VBG\1156834 function_11\NN\13783581 ,_12\,\1740 which_13\WDT\1740 could_14\MD\1740 be_15\VB\836236 explained_16\VBN\831651 on_17\IN\1740 the_18\DT\1740 basis_19\NN\13790712 of_20\IN\1740 a_21\DT\13649268 greater_22\JJR\1740 <e1>levodopa</e1>_23\NN\14604959 dose_24\NN\3740161 ._25\.\1740
D007980_D003680 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 a_3\DT\13649268 role_4\NN\719494 for_5\IN\1740 <e1>levodopa</e1>_6\NN\14604959 in_7\IN\13603305 the_8\DT\1740 oral_9\JJ\1740 phase_10\NN\15113229 of_11\IN\1740 deglutition_12\NN\838098 and_13\CC\1740 confirm_14\VBP\1011725 that_15\IN\1740 <e2>dysphagia</e2>_16\NN\14052403 is_17\VBZ\836236 not_18\RB\1740 a_19\DT\13649268 good_20\JJ\1740 predictor_21\NN\10756433 of_22\IN\1740 deglutition_23\NN\838098 alterations_24\NNS\7283608 in_25\IN\13603305 pd_26\NN\14625458 ._27\.\1740
448423
D000614_D013345 NONE recurrent_0\JJ\1740 <e2>subarachnoid_1\JJ\1740 hemorrhage</e2>_2\NN\14285662 associated_3\VBN\628491 with_4\IN\1740 <e1>aminocaproic_5\JJ\1740 acid</e1>_6\NN\14818238 therapy_7\NN\657604 and_8\CC\1740 acute_9\JJ\1740 renal_10\JJ\1740 artery_11\NN\5417975 thrombosis_12\NN\14100769 ._13\.\1740
D000614_D007674 NONE recurrent_0\JJ\1740 subarachnoid_1\JJ\1740 hemorrhage_2\NN\14285662 associated_3\VBN\628491 with_4\IN\1740 <e1>aminocaproic_5\JJ\1740 acid</e1>_6\NN\14818238 therapy_7\NN\657604 and_8\CC\1740 <e2>acute_9\JJ\1740 renal_10\JJ\1740 artery_11\NN\5417975 thrombosis</e2>_12\NN\14100769 ._13\.\1740
D015119_D013345 CID <e1>epsilon_0\NN\6828818 aminocaproic_1\JJ\1740 acid</e1>_2\NN\14818238 (_3\-LRB-\1740 eaca_4\NN\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 to_9\TO\1740 prevent_10\VB\1740 rebleeding_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>subarachnoid_15\JJ\1740 hemorrhage</e2>_16\NN\14285662 (_17\-LRB-\1740 sah_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D015119_D013345 CID <e1>epsilon_0\NN\6828818 aminocaproic_1\JJ\1740 acid</e1>_2\NN\14818238 (_3\-LRB-\1740 eaca_4\NN\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 to_9\TO\1740 prevent_10\VB\1740 rebleeding_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 subarachnoid_15\JJ\1740 hemorrhage_16\NN\14285662 (_17\-LRB-\1740 <e2>sah</e2>_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D015119_D013345 CID epsilon_0\NN\6828818 aminocaproic_1\JJ\1740 acid_2\NN\14818238 (_3\-LRB-\1740 <e1>eaca</e1>_4\NN\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 to_9\TO\1740 prevent_10\VB\1740 rebleeding_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>subarachnoid_15\JJ\1740 hemorrhage</e2>_16\NN\14285662 (_17\-LRB-\1740 sah_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D015119_D013345 CID epsilon_0\NN\6828818 aminocaproic_1\JJ\1740 acid_2\NN\14818238 (_3\-LRB-\1740 <e1>eaca</e1>_4\NN\1740 )_5\-RRB-\1740 has_6\VBZ\2108377 been_7\VBN\836236 used_8\VBN\1156834 to_9\TO\1740 prevent_10\VB\1740 rebleeding_11\NN\1740 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 subarachnoid_15\JJ\1740 hemorrhage_16\NN\14285662 (_17\-LRB-\1740 <e2>sah</e2>_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D015119_D013345 CID these_0\DT\1740 complications_1\NNS\1073995 have_2\VBP\2108377 included_3\VBN\690614 clinical_4\JJ\1740 deterioration_5\NN\14560612 and_6\CC\1740 intracranial_7\JJ\1740 vascular_8\JJ\1740 thrombosis_9\NN\14100769 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>sah</e2>_13\NN\1740 ,_14\,\1740 arteriolar_15\JJ\1740 and_16\CC\1740 capillary_17\JJ\1740 fibrin_18\NN\14728724 thrombi_19\NN\5402091 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 fibrinolytic_23\JJ\1740 syndromes_24\NNS\5870365 treated_25\VBN\2376958 with_26\IN\1740 <e1>eaca</e1>_27\NN\1740 ,_28\,\1740 or_29\CC\3541091 other_30\JJ\1740 thromboembolic_31\NN\1740 phenomena_32\NNS\29677 ._33\.\1740
D015119_D013345 CID this_0\DT\1740 occlusion_1\NN\14081375 occurred_2\VBD\2623529 after_3\IN\1740 <e1>eaca</e1>_4\NN\1740 therapy_5\NN\657604 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 with_9\IN\1740 <e2>sah</e2>_10\NN\1740 and_11\CC\1740 histopathological_12\JJ\1740 documentation_13\NN\6650070 of_14\IN\1740 recurrent_15\JJ\1740 sah_16\NN\1740 ._17\.\1740
D015119_D013345 CID this_0\DT\1740 occlusion_1\NN\14081375 occurred_2\VBD\2623529 after_3\IN\1740 <e1>eaca</e1>_4\NN\1740 therapy_5\NN\657604 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 with_9\IN\1740 sah_10\NN\1740 and_11\CC\1740 histopathological_12\JJ\1740 documentation_13\NN\6650070 of_14\IN\1740 recurrent_15\JJ\1740 <e2>sah</e2>_16\NN\1740 ._17\.\1740
D015119_D013927 CID although_0\IN\1740 this_1\DT\1740 agent_2\NN\7347 does_3\VBZ\1640855 decrease_4\VB\169651 the_5\DT\1740 frequency_6\NN\15286249 of_7\IN\1740 rebleeding_8\NN\1740 ,_9\,\1740 several_10\JJ\1740 reports_11\NNS\6470073 have_12\VBP\2108377 described_13\VBN\1001294 <e2>thrombotic</e2>_14\JJ\1740 complications_15\NNS\1073995 of_16\IN\1740 <e1>eaca</e1>_17\NN\1740 therapy_18\NN\657604 ._19\.\1740
D015119_D013927 CID these_0\DT\1740 complications_1\NNS\1073995 have_2\VBP\2108377 included_3\VBN\690614 clinical_4\JJ\1740 deterioration_5\NN\14560612 and_6\CC\1740 intracranial_7\JJ\1740 vascular_8\JJ\1740 thrombosis_9\NN\14100769 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 sah_13\NN\1740 ,_14\,\1740 arteriolar_15\JJ\1740 and_16\CC\1740 capillary_17\JJ\1740 fibrin_18\NN\14728724 <e2>thrombi</e2>_19\NN\5402091 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 fibrinolytic_23\JJ\1740 syndromes_24\NNS\5870365 treated_25\VBN\2376958 with_26\IN\1740 <e1>eaca</e1>_27\NN\1740 ,_28\,\1740 or_29\CC\3541091 other_30\JJ\1740 thromboembolic_31\NN\1740 phenomena_32\NNS\29677 ._33\.\1740
D015119_D013927 CID since_0\IN\1740 intravascular_1\JJ\1740 fibrin_2\NN\14728724 <e2>thrombi</e2>_3\NN\5402091 are_4\VBP\836236 often_5\RB\1740 observed_6\VBN\2163746 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 fibrinolytic_10\JJ\1740 disorders_11\NNS\14034177 ,_12\,\1740 <e1>eaca</e1>_13\NN\1740 should_14\MD\1740 not_15\RB\1740 be_16\VB\836236 implicated_17\VBN\2677097 in_18\IN\13603305 the_19\DT\1740 pathogenesis_20\NN\13533470 of_21\IN\1740 fibrin_22\NN\14728724 thrombi_23\NN\5402091 in_24\IN\13603305 patients_25\NNS\9898892 with_26\IN\1740 disseminated_27\JJ\1740 intravascular_28\JJ\1740 coagulation_29\NN\13518963 or_30\CC\3541091 other_31\JJ\1740 "_32\``\1740 consumption_33\NN\13440063 coagulopathies_34\NNS\1740 ._35\.\1740 "_36\''\1740 this_37\DT\1740 report_38\NN\6470073 describes_39\VBZ\1001294 subtotal_40\JJ\1740 infarction_41\NN\14204950 of_42\IN\1740 the_43\DT\1740 kidney_44\NN\5333259 due_45\IN\5174653 to_46\TO\1740 thrombosis_47\NN\14100769 of_48\IN\1740 a_49\DT\13649268 normal_50\JJ\1740 renal_51\JJ\1740 artery_52\NN\5417975 ._53\.\1740
D015119_D013927 CID since_0\IN\1740 intravascular_1\JJ\1740 fibrin_2\NN\14728724 thrombi_3\NN\5402091 are_4\VBP\836236 often_5\RB\1740 observed_6\VBN\2163746 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 fibrinolytic_10\JJ\1740 disorders_11\NNS\14034177 ,_12\,\1740 <e1>eaca</e1>_13\NN\1740 should_14\MD\1740 not_15\RB\1740 be_16\VB\836236 implicated_17\VBN\2677097 in_18\IN\13603305 the_19\DT\1740 pathogenesis_20\NN\13533470 of_21\IN\1740 fibrin_22\NN\14728724 <e2>thrombi</e2>_23\NN\5402091 in_24\IN\13603305 patients_25\NNS\9898892 with_26\IN\1740 disseminated_27\JJ\1740 intravascular_28\JJ\1740 coagulation_29\NN\13518963 or_30\CC\3541091 other_31\JJ\1740 "_32\``\1740 consumption_33\NN\13440063 coagulopathies_34\NNS\1740 ._35\.\1740 "_36\''\1740 this_37\DT\1740 report_38\NN\6470073 describes_39\VBZ\1001294 subtotal_40\JJ\1740 infarction_41\NN\14204950 of_42\IN\1740 the_43\DT\1740 kidney_44\NN\5333259 due_45\IN\5174653 to_46\TO\1740 thrombosis_47\NN\14100769 of_48\IN\1740 a_49\DT\13649268 normal_50\JJ\1740 renal_51\JJ\1740 artery_52\NN\5417975 ._53\.\1740
D015119_D020767 CID these_0\DT\1740 complications_1\NNS\1073995 have_2\VBP\2108377 included_3\VBN\690614 clinical_4\JJ\1740 deterioration_5\NN\14560612 and_6\CC\1740 <e2>intracranial_7\JJ\1740 vascular_8\JJ\1740 thrombosis</e2>_9\NN\14100769 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 sah_13\NN\1740 ,_14\,\1740 arteriolar_15\JJ\1740 and_16\CC\1740 capillary_17\JJ\1740 fibrin_18\NN\14728724 thrombi_19\NN\5402091 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 fibrinolytic_23\JJ\1740 syndromes_24\NNS\5870365 treated_25\VBN\2376958 with_26\IN\1740 <e1>eaca</e1>_27\NN\1740 ,_28\,\1740 or_29\CC\3541091 other_30\JJ\1740 thromboembolic_31\NN\1740 phenomena_32\NNS\29677 ._33\.\1740
D015119_D013923 NONE these_0\DT\1740 complications_1\NNS\1073995 have_2\VBP\2108377 included_3\VBN\690614 clinical_4\JJ\1740 deterioration_5\NN\14560612 and_6\CC\1740 intracranial_7\JJ\1740 vascular_8\JJ\1740 thrombosis_9\NN\14100769 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 sah_13\NN\1740 ,_14\,\1740 arteriolar_15\JJ\1740 and_16\CC\1740 capillary_17\JJ\1740 fibrin_18\NN\14728724 thrombi_19\NN\5402091 in_20\IN\13603305 patients_21\NNS\9898892 with_22\IN\1740 fibrinolytic_23\JJ\1740 syndromes_24\NNS\5870365 treated_25\VBN\2376958 with_26\IN\1740 <e1>eaca</e1>_27\NN\1740 ,_28\,\1740 or_29\CC\3541091 other_30\JJ\1740 <e2>thromboembolic_31\NN\1740 phenomena</e2>_32\NNS\29677 ._33\.\1740
D015119_D004211 NONE since_0\IN\1740 intravascular_1\JJ\1740 fibrin_2\NN\14728724 thrombi_3\NN\5402091 are_4\VBP\836236 often_5\RB\1740 observed_6\VBN\2163746 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 fibrinolytic_10\JJ\1740 disorders_11\NNS\14034177 ,_12\,\1740 <e1>eaca</e1>_13\NN\1740 should_14\MD\1740 not_15\RB\1740 be_16\VB\836236 implicated_17\VBN\2677097 in_18\IN\13603305 the_19\DT\1740 pathogenesis_20\NN\13533470 of_21\IN\1740 fibrin_22\NN\14728724 thrombi_23\NN\5402091 in_24\IN\13603305 patients_25\NNS\9898892 with_26\IN\1740 <e2>disseminated_27\JJ\1740 intravascular_28\JJ\1740 coagulation</e2>_29\NN\13518963 or_30\CC\3541091 other_31\JJ\1740 "_32\``\1740 consumption_33\NN\13440063 coagulopathies_34\NNS\1740 ._35\.\1740 "_36\''\1740 this_37\DT\1740 report_38\NN\6470073 describes_39\VBZ\1001294 subtotal_40\JJ\1740 infarction_41\NN\14204950 of_42\IN\1740 the_43\DT\1740 kidney_44\NN\5333259 due_45\IN\5174653 to_46\TO\1740 thrombosis_47\NN\14100769 of_48\IN\1740 a_49\DT\13649268 normal_50\JJ\1740 renal_51\JJ\1740 artery_52\NN\5417975 ._53\.\1740
D015119_D004211 NONE since_0\IN\1740 intravascular_1\JJ\1740 fibrin_2\NN\14728724 thrombi_3\NN\5402091 are_4\VBP\836236 often_5\RB\1740 observed_6\VBN\2163746 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 fibrinolytic_10\JJ\1740 disorders_11\NNS\14034177 ,_12\,\1740 <e1>eaca</e1>_13\NN\1740 should_14\MD\1740 not_15\RB\1740 be_16\VB\836236 implicated_17\VBN\2677097 in_18\IN\13603305 the_19\DT\1740 pathogenesis_20\NN\13533470 of_21\IN\1740 fibrin_22\NN\14728724 thrombi_23\NN\5402091 in_24\IN\13603305 patients_25\NNS\9898892 with_26\IN\1740 disseminated_27\JJ\1740 intravascular_28\JJ\1740 coagulation_29\NN\13518963 or_30\CC\3541091 other_31\JJ\1740 "_32\``\1740 <e2>consumption_33\NN\13440063 coagulopathies</e2>_34\NNS\1740 ._35\.\1740 "_36\''\1740 this_37\DT\1740 report_38\NN\6470073 describes_39\VBZ\1001294 subtotal_40\JJ\1740 infarction_41\NN\14204950 of_42\IN\1740 the_43\DT\1740 kidney_44\NN\5333259 due_45\IN\5174653 to_46\TO\1740 thrombosis_47\NN\14100769 of_48\IN\1740 a_49\DT\13649268 normal_50\JJ\1740 renal_51\JJ\1740 artery_52\NN\5417975 ._53\.\1740
D015119_D007238 NONE since_0\IN\1740 intravascular_1\JJ\1740 fibrin_2\NN\14728724 thrombi_3\NN\5402091 are_4\VBP\836236 often_5\RB\1740 observed_6\VBN\2163746 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 fibrinolytic_10\JJ\1740 disorders_11\NNS\14034177 ,_12\,\1740 <e1>eaca</e1>_13\NN\1740 should_14\MD\1740 not_15\RB\1740 be_16\VB\836236 implicated_17\VBN\2677097 in_18\IN\13603305 the_19\DT\1740 pathogenesis_20\NN\13533470 of_21\IN\1740 fibrin_22\NN\14728724 thrombi_23\NN\5402091 in_24\IN\13603305 patients_25\NNS\9898892 with_26\IN\1740 disseminated_27\JJ\1740 intravascular_28\JJ\1740 coagulation_29\NN\13518963 or_30\CC\3541091 other_31\JJ\1740 "_32\``\1740 consumption_33\NN\13440063 coagulopathies_34\NNS\1740 ._35\.\1740 "_36\''\1740 this_37\DT\1740 report_38\NN\6470073 describes_39\VBZ\1001294 subtotal_40\JJ\1740 <e2>infarction</e2>_41\NN\14204950 of_42\IN\1740 the_43\DT\1740 kidney_44\NN\5333259 due_45\IN\5174653 to_46\TO\1740 thrombosis_47\NN\14100769 of_48\IN\1740 a_49\DT\13649268 normal_50\JJ\1740 renal_51\JJ\1740 artery_52\NN\5417975 ._53\.\1740
D015119_D007674 CID since_0\IN\1740 intravascular_1\JJ\1740 fibrin_2\NN\14728724 thrombi_3\NN\5402091 are_4\VBP\836236 often_5\RB\1740 observed_6\VBN\2163746 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 fibrinolytic_10\JJ\1740 disorders_11\NNS\14034177 ,_12\,\1740 <e1>eaca</e1>_13\NN\1740 should_14\MD\1740 not_15\RB\1740 be_16\VB\836236 implicated_17\VBN\2677097 in_18\IN\13603305 the_19\DT\1740 pathogenesis_20\NN\13533470 of_21\IN\1740 fibrin_22\NN\14728724 thrombi_23\NN\5402091 in_24\IN\13603305 patients_25\NNS\9898892 with_26\IN\1740 disseminated_27\JJ\1740 intravascular_28\JJ\1740 coagulation_29\NN\13518963 or_30\CC\3541091 other_31\JJ\1740 "_32\``\1740 consumption_33\NN\13440063 coagulopathies_34\NNS\1740 ._35\.\1740 "_36\''\1740 this_37\DT\1740 report_38\NN\6470073 describes_39\VBZ\1001294 subtotal_40\JJ\1740 infarction_41\NN\14204950 of_42\IN\1740 the_43\DT\1740 kidney_44\NN\5333259 due_45\IN\5174653 to_46\TO\1740 <e2>thrombosis_47\NN\14100769 of_48\IN\1740 a_49\DT\13649268 normal_50\JJ\1740 renal_51\JJ\1740 artery</e2>_52\NN\5417975 ._53\.\1740
8755612
D004967_D009369 NONE genetic_0\JJ\1740 separation_1\NN\24720 of_2\IN\1740 <e2>tumor</e2>_3\NN\14234074 growth_4\NN\13526110 and_5\CC\1740 hemorrhagic_6\JJ\1740 phenotypes_7\NNS\4933544 in_8\IN\13603305 an_9\DT\6697703 <e1>estrogen-induced</e1>_10\JJ\1740 tumor_11\NN\14234074 ._12\.\1740
D004967_D009369 NONE genetic_0\JJ\1740 separation_1\NN\24720 of_2\IN\1740 tumor_3\NN\14234074 growth_4\NN\13526110 and_5\CC\1740 hemorrhagic_6\JJ\1740 phenotypes_7\NNS\4933544 in_8\IN\13603305 an_9\DT\6697703 <e1>estrogen-induced</e1>_10\JJ\1740 <e2>tumor</e2>_11\NN\14234074 ._12\.\1740
D004967_D006470 NONE genetic_0\JJ\1740 separation_1\NN\24720 of_2\IN\1740 tumor_3\NN\14234074 growth_4\NN\13526110 and_5\CC\1740 <e2>hemorrhagic</e2>_6\JJ\1740 phenotypes_7\NNS\4933544 in_8\IN\13603305 an_9\DT\6697703 <e1>estrogen-induced</e1>_10\JJ\1740 tumor_11\NN\14234074 ._12\.\1740
D004967_D006470 NONE chronic_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>estrogen</e1>_3\NN\14745635 to_4\IN\1740 the_5\DT\1740 fischer_6\NNP\1740 344_7\CD\1740 (_8\-LRB-\1740 f344_9\NN\1740 )_10\-RRB-\1740 rat_11\NN\2329401 induces_12\VBZ\1627355 growth_13\NN\13526110 of_14\IN\1740 large_15\JJ\1740 ,_16\,\1740 <e2>hemorrhagic</e2>_17\JJ\1740 pituitary_18\JJ\1740 tumors_19\NNS\14234074 ._20\.\1740
D004967_D010911 NONE chronic_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>estrogen</e1>_3\NN\14745635 to_4\IN\1740 the_5\DT\1740 fischer_6\NNP\1740 344_7\CD\1740 (_8\-LRB-\1740 f344_9\NN\1740 )_10\-RRB-\1740 rat_11\NN\2329401 induces_12\VBZ\1627355 growth_13\NN\13526110 of_14\IN\1740 large_15\JJ\1740 ,_16\,\1740 hemorrhagic_17\JJ\1740 <e2>pituitary_18\JJ\1740 tumors</e2>_19\NNS\14234074 ._20\.\1740
D004054_D006470 NONE ten_0\CD\13745420 weeks_1\NNS\15113229 of_2\IN\1740 <e1>diethylstilbestrol</e1>_3\NN\14749794 (_4\-LRB-\1740 des_5\NN\14749794 )_6\-RRB-\1740 treatment_7\NN\654885 caused_8\VBD\1617192 female_9\JJ\1740 f344_10\NN\1740 rat_11\NN\2329401 pituitaries_12\NNS\5329735 to_13\TO\1740 grow_14\VB\109660 to_15\IN\1740 an_16\DT\6697703 average_17\NN\6021499 of_18\IN\1740 109.2_19\CD\1740 +/-_20\CC\1740 6.3_21\CD\1740 mg_22\NN\13717155 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 se_26\NN\14724645 )_27\-RRB-\1740 versus_28\CC\1740 11.3_29\CD\1740 +/-_30\CC\1740 1.4_31\CD\1740 mg_32\NN\13717155 for_33\IN\1740 untreated_34\JJ\1740 rats_35\NNS\2329401 ,_36\,\1740 and_37\CC\1740 to_38\TO\1740 become_39\VB\146138 highly_40\RB\1740 <e2>hemorrhagic</e2>_41\JJ\1740 ._42\.\1740
D004054_D006470 NONE ten_0\CD\13745420 weeks_1\NNS\15113229 of_2\IN\1740 diethylstilbestrol_3\NN\14749794 (_4\-LRB-\1740 <e1>des</e1>_5\NN\14749794 )_6\-RRB-\1740 treatment_7\NN\654885 caused_8\VBD\1617192 female_9\JJ\1740 f344_10\NN\1740 rat_11\NN\2329401 pituitaries_12\NNS\5329735 to_13\TO\1740 grow_14\VB\109660 to_15\IN\1740 an_16\DT\6697703 average_17\NN\6021499 of_18\IN\1740 109.2_19\CD\1740 +/-_20\CC\1740 6.3_21\CD\1740 mg_22\NN\13717155 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 se_26\NN\14724645 )_27\-RRB-\1740 versus_28\CC\1740 11.3_29\CD\1740 +/-_30\CC\1740 1.4_31\CD\1740 mg_32\NN\13717155 for_33\IN\1740 untreated_34\JJ\1740 rats_35\NNS\2329401 ,_36\,\1740 and_37\CC\1740 to_38\TO\1740 become_39\VB\146138 highly_40\RB\1740 <e2>hemorrhagic</e2>_41\JJ\1740 ._42\.\1740
D004054_D006470 NONE however_0\RB\1740 ,_1\,\1740 while_2\IN\15122231 <e1>des-induced</e1>_3\JJ\1740 pituitary_4\JJ\1740 growth_5\NN\13526110 exhibited_6\VBD\2632167 quantitative_7\JJ\1740 ,_8\,\1740 additive_9\JJ\1740 inheritance_10\NN\77419 ,_11\,\1740 the_12\DT\1740 <e2>hemorrhagic</e2>_13\JJ\1740 phenotype_14\NN\4933544 exhibited_15\VBD\2632167 recessive_16\JJ\1740 ,_17\,\1740 epistatic_18\JJ\1740 inheritance_19\NN\77419 ._20\.\1740
12452552
D018967_D007676 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>chronic_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 (_6\-LRB-\1740 crf_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome_12\NN\5870365 (_13\-LRB-\1740 nms_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 <e1>risperidone</e1>_19\NN\1740 and_20\CC\1740 levomepromazine_21\NN\1740 ._22\.\1740
D018967_D007676 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 chronic_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 <e2>crf</e2>_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome_12\NN\5870365 (_13\-LRB-\1740 nms_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 <e1>risperidone</e1>_19\NN\1740 and_20\CC\1740 levomepromazine_21\NN\1740 ._22\.\1740
D018967_D009459 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 chronic_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 crf_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 <e2>neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome</e2>_12\NN\5870365 (_13\-LRB-\1740 nms_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 <e1>risperidone</e1>_19\NN\1740 and_20\CC\1740 levomepromazine_21\NN\1740 ._22\.\1740
D018967_D009459 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 chronic_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 crf_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome_12\NN\5870365 (_13\-LRB-\1740 <e2>nms</e2>_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 <e1>risperidone</e1>_19\NN\1740 and_20\CC\1740 levomepromazine_21\NN\1740 ._22\.\1740
D008728_D007676 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>chronic_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 (_6\-LRB-\1740 crf_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome_12\NN\5870365 (_13\-LRB-\1740 nms_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 risperidone_19\NN\1740 and_20\CC\1740 <e1>levomepromazine</e1>_21\NN\1740 ._22\.\1740
D008728_D007676 NONE a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 chronic_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 <e2>crf</e2>_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome_12\NN\5870365 (_13\-LRB-\1740 nms_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 risperidone_19\NN\1740 and_20\CC\1740 <e1>levomepromazine</e1>_21\NN\1740 ._22\.\1740
D008728_D009459 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 chronic_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 crf_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 <e2>neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome</e2>_12\NN\5870365 (_13\-LRB-\1740 nms_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 risperidone_19\NN\1740 and_20\CC\1740 <e1>levomepromazine</e1>_21\NN\1740 ._22\.\1740
D008728_D009459 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 chronic_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 (_6\-LRB-\1740 crf_7\NN\1740 )_8\-RRB-\1740 developed_9\VBD\1753788 neuroleptic_10\JJ\1740 malignant_11\JJ\1740 syndrome_12\NN\5870365 (_13\-LRB-\1740 <e2>nms</e2>_14\NN\13649268 )_15\-RRB-\1740 after_16\IN\1740 administration_17\NN\1133281 of_18\IN\1740 risperidone_19\NN\1740 and_20\CC\1740 <e1>levomepromazine</e1>_21\NN\1740 ._22\.\1740
24126708
D007980_D010300 NONE association_0\NN\8008335 of_1\IN\1740 common_2\JJ\1740 genetic_3\JJ\1740 variants_4\NNS\7366289 of_5\IN\1740 homer1_6\NN\1740 gene_7\NN\8459252 with_8\IN\1740 <e1>levodopa</e1>_9\NN\14604959 adverse_10\JJ\1740 effects_11\NNS\13245626 in_12\IN\13603305 <e2>parkinson_13\NN\1740 's_14\POS\1740 disease</e2>_15\NN\14061805 patients_16\NNS\9898892 ._17\.\1740
D007980_D010300 NONE <e1>levodopa</e1>_0\NN\14604959 is_1\VBZ\836236 the_2\DT\1740 most_3\RBS\1740 effective_4\JJ\1740 symptomatic_5\JJ\1740 therapy_6\NN\657604 for_7\IN\1740 <e2>parkinson_8\NN\1740 's_9\POS\1740 disease</e2>_10\NN\14061805 ,_11\,\1740 but_12\CC\1740 its_13\PRP$\6125041 chronic_14\JJ\1740 use_15\NN\407535 could_16\MD\1740 lead_17\VB\1752884 to_18\TO\1740 chronic_19\JJ\1740 adverse_20\JJ\1740 outcomes_21\NNS\7291312 ,_22\,\1740 such_23\JJ\1740 as_24\IN\14622893 motor_25\NN\3699975 fluctuations_26\NNS\7345593 ,_27\,\1740 dyskinesia_28\NN\14084880 and_29\CC\1740 visual_30\JJ\1740 hallucinations_31\NNS\14376855 ._32\.\1740
D007980_D004409 CID <e1>levodopa</e1>_0\NN\14604959 is_1\VBZ\836236 the_2\DT\1740 most_3\RBS\1740 effective_4\JJ\1740 symptomatic_5\JJ\1740 therapy_6\NN\657604 for_7\IN\1740 parkinson_8\NN\1740 's_9\POS\1740 disease_10\NN\14061805 ,_11\,\1740 but_12\CC\1740 its_13\PRP$\6125041 chronic_14\JJ\1740 use_15\NN\407535 could_16\MD\1740 lead_17\VB\1752884 to_18\TO\1740 chronic_19\JJ\1740 adverse_20\JJ\1740 outcomes_21\NNS\7291312 ,_22\,\1740 such_23\JJ\1740 as_24\IN\14622893 motor_25\NN\3699975 fluctuations_26\NNS\7345593 ,_27\,\1740 <e2>dyskinesia</e2>_28\NN\14084880 and_29\CC\1740 visual_30\JJ\1740 hallucinations_31\NNS\14376855 ._32\.\1740
D007980_D006212 CID <e1>levodopa</e1>_0\NN\14604959 is_1\VBZ\836236 the_2\DT\1740 most_3\RBS\1740 effective_4\JJ\1740 symptomatic_5\JJ\1740 therapy_6\NN\657604 for_7\IN\1740 parkinson_8\NN\1740 's_9\POS\1740 disease_10\NN\14061805 ,_11\,\1740 but_12\CC\1740 its_13\PRP$\6125041 chronic_14\JJ\1740 use_15\NN\407535 could_16\MD\1740 lead_17\VB\1752884 to_18\TO\1740 chronic_19\JJ\1740 adverse_20\JJ\1740 outcomes_21\NNS\7291312 ,_22\,\1740 such_23\JJ\1740 as_24\IN\14622893 motor_25\NN\3699975 fluctuations_26\NNS\7345593 ,_27\,\1740 dyskinesia_28\NN\14084880 and_29\CC\1740 <e2>visual_30\JJ\1740 hallucinations</e2>_31\NNS\14376855 ._32\.\1740
11708428
D011241_D001008 CID <e1>prednisone</e1>_0\NN\2721538 induces_1\VBZ\1627355 <e2>anxiety</e2>_2\NN\14373582 and_3\CC\1740 glial_4\JJ\1740 cerebral_5\JJ\1740 changes_6\NNS\7283608 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D011241_D001008 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 whether_4\IN\1740 <e1>prednisone</e1>_5\NN\2721538 (_6\-LRB-\1740 pdn_7\NN\1740 )_8\-RRB-\1740 produces_9\VBZ\1617192 <e2>anxiety</e2>_10\NN\14373582 and/or_11\CC\1740 cerebral_12\JJ\1740 glial_13\JJ\1740 changes_14\NNS\7283608 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D011241_D001008 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 whether_4\IN\1740 prednisone_5\NN\2721538 (_6\-LRB-\1740 <e1>pdn</e1>_7\NN\1740 )_8\-RRB-\1740 produces_9\VBZ\1617192 <e2>anxiety</e2>_10\NN\14373582 and/or_11\CC\1740 cerebral_12\JJ\1740 glial_13\JJ\1740 changes_14\NNS\7283608 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D011241_D001008 CID results_0\NNS\34213 :_1\:\1740 <e2>anxiety</e2>_2\NNP\14373582 was_3\VBD\836236 documented_4\VBN\1000214 in_5\IN\13603305 both_6\DT\1740 groups_7\NNS\2137 of_8\IN\1740 <e1>pdn</e1>_9\NN\1740 treated_10\JJ\1740 rats_11\NNS\2329401 compared_12\VBN\644583 with_13\IN\1740 controls_14\NNS\5190804 ._15\.\1740
D011241_D001008 CID conclusion_0\NN\5837957 :_1\:\1740 subacute_2\NN\1740 exposure_3\NN\5042871 to_4\TO\1740 <e1>pdn</e1>_5\NN\1740 induced_6\VBD\1627355 <e2>anxiety</e2>_7\NN\14373582 and_8\CC\1740 reactivity_9\NN\5652926 of_10\IN\1740 microglia_11\NNS\5467054 ._12\.\1740
1858969
D004049_D004660 CID five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>encephalitis</e2>_3\NN\14336539 during_4\IN\1740 treatment_5\NN\654885 of_6\IN\1740 loiasis_7\NN\1740 with_8\IN\1740 <e1>diethylcarbamazine</e1>_9\NN\1740 ._10\.\1740
D004049_D004660 CID five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>encephalitis</e2>_3\NN\14336539 following_4\VBG\1835496 treatment_5\NN\654885 with_6\IN\1740 <e1>diethylcarbamazine</e1>_7\NN\1740 (_8\-LRB-\1740 dec_9\NN\15209706 )_10\-RRB-\1740 were_11\VBD\836236 observed_12\VBN\2163746 in_13\IN\13603305 congolese_14\JJ\1740 patients_15\NNS\9898892 with_16\IN\1740 loa_17\NN\1740 loa_18\JJ\1740 filariasis_19\NN\14070360 ._20\.\1740
D004049_D004660 CID five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>encephalitis</e2>_3\NN\14336539 following_4\VBG\1835496 treatment_5\NN\654885 with_6\IN\1740 diethylcarbamazine_7\NN\1740 (_8\-LRB-\1740 <e1>dec</e1>_9\NN\15209706 )_10\-RRB-\1740 were_11\VBD\836236 observed_12\VBN\2163746 in_13\IN\13603305 congolese_14\JJ\1740 patients_15\NNS\9898892 with_16\IN\1740 loa_17\NN\1740 loa_18\JJ\1740 filariasis_19\NN\14070360 ._20\.\1740
D004049_D008118 NONE five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 encephalitis_3\NN\14336539 during_4\IN\1740 treatment_5\NN\654885 of_6\IN\1740 <e2>loiasis</e2>_7\NN\1740 with_8\IN\1740 <e1>diethylcarbamazine</e1>_9\NN\1740 ._10\.\1740
D004049_D005368 NONE five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 encephalitis_3\NN\14336539 following_4\VBG\1835496 treatment_5\NN\654885 with_6\IN\1740 <e1>diethylcarbamazine</e1>_7\NN\1740 (_8\-LRB-\1740 dec_9\NN\15209706 )_10\-RRB-\1740 were_11\VBD\836236 observed_12\VBN\2163746 in_13\IN\13603305 congolese_14\JJ\1740 patients_15\NNS\9898892 with_16\IN\1740 loa_17\NN\1740 loa_18\JJ\1740 <e2>filariasis</e2>_19\NN\14070360 ._20\.\1740
D004049_D005368 NONE five_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 encephalitis_3\NN\14336539 following_4\VBG\1835496 treatment_5\NN\654885 with_6\IN\1740 diethylcarbamazine_7\NN\1740 (_8\-LRB-\1740 <e1>dec</e1>_9\NN\15209706 )_10\-RRB-\1740 were_11\VBD\836236 observed_12\VBN\2163746 in_13\IN\13603305 congolese_14\JJ\1740 patients_15\NNS\9898892 with_16\IN\1740 loa_17\NN\1740 loa_18\JJ\1740 <e2>filariasis</e2>_19\NN\14070360 ._20\.\1740
6615679
D013999_D001919 CID intraoperative_0\JJ\1740 <e2>bradycardia</e2>_1\NN\14110674 and_2\CC\1740 hypotension_3\NN\14057371 associated_4\VBN\628491 with_5\IN\1740 <e1>timolol</e1>_6\CD\2832168 and_7\CC\1740 pilocarpine_8\NN\14712692 eye_9\NN\5299178 drops_10\NNS\13899200 ._11\.\1740
D013999_D001919 CID a_0\DT\13649268 69-yr-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 who_4\WP\8299493 was_5\VBD\836236 concurrently_6\RB\1740 being_7\VBG\836236 treated_8\VBN\2376958 with_9\IN\1740 pilocarpine_10\NN\14712692 nitrate_11\NN\14818238 and_12\CC\1740 <e1>timolol_13\CD\2832168 maleate</e1>_14\JJ\1740 eye_15\NN\5299178 drops_16\NNS\13899200 ,_17\,\1740 developed_18\VBD\1753788 a_19\DT\13649268 <e2>bradycardia</e2>_20\NN\14110674 and_21\CC\1740 became_22\VBD\146138 hypotensive_23\JJ\1740 during_24\IN\1740 halothane_25\NN\3570838 anaesthesia_26\NN\14034177 ._27\.\1740
D013999_D007022 CID intraoperative_0\JJ\1740 bradycardia_1\NN\14110674 and_2\CC\1740 <e2>hypotension</e2>_3\NN\14057371 associated_4\VBN\628491 with_5\IN\1740 <e1>timolol</e1>_6\CD\2832168 and_7\CC\1740 pilocarpine_8\NN\14712692 eye_9\NN\5299178 drops_10\NNS\13899200 ._11\.\1740
D013999_D007022 CID a_0\DT\13649268 69-yr-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 who_4\WP\8299493 was_5\VBD\836236 concurrently_6\RB\1740 being_7\VBG\836236 treated_8\VBN\2376958 with_9\IN\1740 pilocarpine_10\NN\14712692 nitrate_11\NN\14818238 and_12\CC\1740 <e1>timolol_13\CD\2832168 maleate</e1>_14\JJ\1740 eye_15\NN\5299178 drops_16\NNS\13899200 ,_17\,\1740 developed_18\VBD\1753788 a_19\DT\13649268 bradycardia_20\NN\14110674 and_21\CC\1740 became_22\VBD\146138 <e2>hypotensive</e2>_23\JJ\1740 during_24\IN\1740 halothane_25\NN\3570838 anaesthesia_26\NN\14034177 ._27\.\1740
D010862_D001919 CID intraoperative_0\JJ\1740 <e2>bradycardia</e2>_1\NN\14110674 and_2\CC\1740 hypotension_3\NN\14057371 associated_4\VBN\628491 with_5\IN\1740 timolol_6\CD\2832168 and_7\CC\1740 <e1>pilocarpine</e1>_8\NN\14712692 eye_9\NN\5299178 drops_10\NNS\13899200 ._11\.\1740
D010862_D001919 CID a_0\DT\13649268 69-yr-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 who_4\WP\8299493 was_5\VBD\836236 concurrently_6\RB\1740 being_7\VBG\836236 treated_8\VBN\2376958 with_9\IN\1740 <e1>pilocarpine_10\NN\14712692 nitrate</e1>_11\NN\14818238 and_12\CC\1740 timolol_13\CD\2832168 maleate_14\JJ\1740 eye_15\NN\5299178 drops_16\NNS\13899200 ,_17\,\1740 developed_18\VBD\1753788 a_19\DT\13649268 <e2>bradycardia</e2>_20\NN\14110674 and_21\CC\1740 became_22\VBD\146138 hypotensive_23\JJ\1740 during_24\IN\1740 halothane_25\NN\3570838 anaesthesia_26\NN\14034177 ._27\.\1740
D010862_D007022 CID intraoperative_0\JJ\1740 bradycardia_1\NN\14110674 and_2\CC\1740 <e2>hypotension</e2>_3\NN\14057371 associated_4\VBN\628491 with_5\IN\1740 timolol_6\CD\2832168 and_7\CC\1740 <e1>pilocarpine</e1>_8\NN\14712692 eye_9\NN\5299178 drops_10\NNS\13899200 ._11\.\1740
D010862_D007022 CID a_0\DT\13649268 69-yr-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 who_4\WP\8299493 was_5\VBD\836236 concurrently_6\RB\1740 being_7\VBG\836236 treated_8\VBN\2376958 with_9\IN\1740 <e1>pilocarpine_10\NN\14712692 nitrate</e1>_11\NN\14818238 and_12\CC\1740 timolol_13\CD\2832168 maleate_14\JJ\1740 eye_15\NN\5299178 drops_16\NNS\13899200 ,_17\,\1740 developed_18\VBD\1753788 a_19\DT\13649268 bradycardia_20\NN\14110674 and_21\CC\1740 became_22\VBD\146138 <e2>hypotensive</e2>_23\JJ\1740 during_24\IN\1740 halothane_25\NN\3570838 anaesthesia_26\NN\14034177 ._27\.\1740
D006221_D001919 NONE a_0\DT\13649268 69-yr-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 who_4\WP\8299493 was_5\VBD\836236 concurrently_6\RB\1740 being_7\VBG\836236 treated_8\VBN\2376958 with_9\IN\1740 pilocarpine_10\NN\14712692 nitrate_11\NN\14818238 and_12\CC\1740 timolol_13\CD\2832168 maleate_14\JJ\1740 eye_15\NN\5299178 drops_16\NNS\13899200 ,_17\,\1740 developed_18\VBD\1753788 a_19\DT\13649268 <e2>bradycardia</e2>_20\NN\14110674 and_21\CC\1740 became_22\VBD\146138 hypotensive_23\JJ\1740 during_24\IN\1740 <e1>halothane</e1>_25\NN\3570838 anaesthesia_26\NN\14034177 ._27\.\1740
D006221_D001919 NONE it_0\PRP\6125041 is_1\VBZ\836236 postulated_2\VBN\756338 that_3\IN\1740 this_4\DT\1740 action_5\NN\30358 may_6\MD\15209706 have_7\VB\2108377 been_8\VBN\836236 enhanced_9\VBN\227165 during_10\IN\1740 <e1>halothane</e1>_11\NN\3570838 anaesthesia_12\NN\14034177 with_13\IN\1740 resultant_14\JJ\1740 <e2>bradycardia</e2>_15\NN\14110674 and_16\CC\1740 hypotension_17\NN\14057371 ._18\.\1740
D006221_D007022 NONE a_0\DT\13649268 69-yr-old_1\JJ\1740 man_2\NN\9605289 ,_3\,\1740 who_4\WP\8299493 was_5\VBD\836236 concurrently_6\RB\1740 being_7\VBG\836236 treated_8\VBN\2376958 with_9\IN\1740 pilocarpine_10\NN\14712692 nitrate_11\NN\14818238 and_12\CC\1740 timolol_13\CD\2832168 maleate_14\JJ\1740 eye_15\NN\5299178 drops_16\NNS\13899200 ,_17\,\1740 developed_18\VBD\1753788 a_19\DT\13649268 bradycardia_20\NN\14110674 and_21\CC\1740 became_22\VBD\146138 <e2>hypotensive</e2>_23\JJ\1740 during_24\IN\1740 <e1>halothane</e1>_25\NN\3570838 anaesthesia_26\NN\14034177 ._27\.\1740
D006221_D007022 NONE it_0\PRP\6125041 is_1\VBZ\836236 postulated_2\VBN\756338 that_3\IN\1740 this_4\DT\1740 action_5\NN\30358 may_6\MD\15209706 have_7\VB\2108377 been_8\VBN\836236 enhanced_9\VBN\227165 during_10\IN\1740 <e1>halothane</e1>_11\NN\3570838 anaesthesia_12\NN\14034177 with_13\IN\1740 resultant_14\JJ\1740 bradycardia_15\NN\14110674 and_16\CC\1740 <e2>hypotension</e2>_17\NN\14057371 ._18\.\1740
24088636
C098010_D009901 CID <e1>linezolid-induced</e1>_0\JJ\1740 <e2>optic_1\NN\5299178 neuropathy</e2>_2\JJ\1740 ._3\.\1740
C098010_D014786 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 progressive_5\JJ\1740 <e2>loss_6\NN\13252973 of_7\IN\1740 vision</e2>_8\NN\5767733 associated_9\VBN\628491 with_10\IN\1740 <e1>linezolid</e1>_11\JJ\1740 therapy_12\NN\657604 ._13\.\1740
C098010_D014786 NONE a_0\DT\13649268 45-year-old_1\JJ\1740 male_2\JJ\1740 patient_3\NN\9898892 who_4\WP\8299493 was_5\VBD\836236 on_6\IN\1740 treatment_7\NN\654885 with_8\IN\1740 multiple_9\JJ\1740 second-line_10\JJ\1740 anti-tuberculous_11\JJ\1740 drugs_12\NNS\14778436 including_13\VBG\690614 <e1>linezolid</e1>_14\JJ\1740 and_15\CC\1740 ethambutol_16\NN\1740 for_17\IN\1740 extensively_18\RB\1740 drug-resistant_19\JJ\1740 tuberculosis_20\NN\14127211 (_21\-LRB-\1740 xdr-tb_22\NN\1740 )_23\-RRB-\1740 presented_24\VBD\2137132 to_25\IN\1740 us_26\PRP\14964590 with_27\IN\1740 painless_28\JJ\1740 progressive_29\JJ\1740 <e2>loss_30\NN\13252973 of_31\IN\1740 vision</e2>_32\NN\5767733 in_33\IN\13603305 both_34\DT\1740 eyes_35\NNS\5945642 ._36\.\1740
C098010_D054908 NONE a_0\DT\13649268 45-year-old_1\JJ\1740 male_2\JJ\1740 patient_3\NN\9898892 who_4\WP\8299493 was_5\VBD\836236 on_6\IN\1740 treatment_7\NN\654885 with_8\IN\1740 multiple_9\JJ\1740 second-line_10\JJ\1740 anti-tuberculous_11\JJ\1740 drugs_12\NNS\14778436 including_13\VBG\690614 <e1>linezolid</e1>_14\JJ\1740 and_15\CC\1740 ethambutol_16\NN\1740 for_17\IN\1740 <e2>extensively_18\RB\1740 drug-resistant_19\JJ\1740 tuberculosis</e2>_20\NN\14127211 (_21\-LRB-\1740 xdr-tb_22\NN\1740 )_23\-RRB-\1740 presented_24\VBD\2137132 to_25\IN\1740 us_26\PRP\14964590 with_27\IN\1740 painless_28\JJ\1740 progressive_29\JJ\1740 loss_30\NN\13252973 of_31\IN\1740 vision_32\NN\5767733 in_33\IN\13603305 both_34\DT\1740 eyes_35\NNS\5945642 ._36\.\1740
C098010_D054908 NONE a_0\DT\13649268 45-year-old_1\JJ\1740 male_2\JJ\1740 patient_3\NN\9898892 who_4\WP\8299493 was_5\VBD\836236 on_6\IN\1740 treatment_7\NN\654885 with_8\IN\1740 multiple_9\JJ\1740 second-line_10\JJ\1740 anti-tuberculous_11\JJ\1740 drugs_12\NNS\14778436 including_13\VBG\690614 <e1>linezolid</e1>_14\JJ\1740 and_15\CC\1740 ethambutol_16\NN\1740 for_17\IN\1740 extensively_18\RB\1740 drug-resistant_19\JJ\1740 tuberculosis_20\NN\14127211 (_21\-LRB-\1740 <e2>xdr-tb</e2>_22\NN\1740 )_23\-RRB-\1740 presented_24\VBD\2137132 to_25\IN\1740 us_26\PRP\14964590 with_27\IN\1740 painless_28\JJ\1740 progressive_29\JJ\1740 loss_30\NN\13252973 of_31\IN\1740 vision_32\NN\5767733 in_33\IN\13603305 both_34\DT\1740 eyes_35\NNS\5945642 ._36\.\1740
D004977_D054908 NONE a_0\DT\13649268 45-year-old_1\JJ\1740 male_2\JJ\1740 patient_3\NN\9898892 who_4\WP\8299493 was_5\VBD\836236 on_6\IN\1740 treatment_7\NN\654885 with_8\IN\1740 multiple_9\JJ\1740 second-line_10\JJ\1740 anti-tuberculous_11\JJ\1740 drugs_12\NNS\14778436 including_13\VBG\690614 linezolid_14\JJ\1740 and_15\CC\1740 <e1>ethambutol</e1>_16\NN\1740 for_17\IN\1740 <e2>extensively_18\RB\1740 drug-resistant_19\JJ\1740 tuberculosis</e2>_20\NN\14127211 (_21\-LRB-\1740 xdr-tb_22\NN\1740 )_23\-RRB-\1740 presented_24\VBD\2137132 to_25\IN\1740 us_26\PRP\14964590 with_27\IN\1740 painless_28\JJ\1740 progressive_29\JJ\1740 loss_30\NN\13252973 of_31\IN\1740 vision_32\NN\5767733 in_33\IN\13603305 both_34\DT\1740 eyes_35\NNS\5945642 ._36\.\1740
D004977_D054908 NONE a_0\DT\13649268 45-year-old_1\JJ\1740 male_2\JJ\1740 patient_3\NN\9898892 who_4\WP\8299493 was_5\VBD\836236 on_6\IN\1740 treatment_7\NN\654885 with_8\IN\1740 multiple_9\JJ\1740 second-line_10\JJ\1740 anti-tuberculous_11\JJ\1740 drugs_12\NNS\14778436 including_13\VBG\690614 linezolid_14\JJ\1740 and_15\CC\1740 <e1>ethambutol</e1>_16\NN\1740 for_17\IN\1740 extensively_18\RB\1740 drug-resistant_19\JJ\1740 tuberculosis_20\NN\14127211 (_21\-LRB-\1740 <e2>xdr-tb</e2>_22\NN\1740 )_23\-RRB-\1740 presented_24\VBD\2137132 to_25\IN\1740 us_26\PRP\14964590 with_27\IN\1740 painless_28\JJ\1740 progressive_29\JJ\1740 loss_30\NN\13252973 of_31\IN\1740 vision_32\NN\5767733 in_33\IN\13603305 both_34\DT\1740 eyes_35\NNS\5945642 ._36\.\1740
D004977_D014786 NONE a_0\DT\13649268 45-year-old_1\JJ\1740 male_2\JJ\1740 patient_3\NN\9898892 who_4\WP\8299493 was_5\VBD\836236 on_6\IN\1740 treatment_7\NN\654885 with_8\IN\1740 multiple_9\JJ\1740 second-line_10\JJ\1740 anti-tuberculous_11\JJ\1740 drugs_12\NNS\14778436 including_13\VBG\690614 linezolid_14\JJ\1740 and_15\CC\1740 <e1>ethambutol</e1>_16\NN\1740 for_17\IN\1740 extensively_18\RB\1740 drug-resistant_19\JJ\1740 tuberculosis_20\NN\14127211 (_21\-LRB-\1740 xdr-tb_22\NN\1740 )_23\-RRB-\1740 presented_24\VBD\2137132 to_25\IN\1740 us_26\PRP\14964590 with_27\IN\1740 painless_28\JJ\1740 progressive_29\JJ\1740 <e2>loss_30\NN\13252973 of_31\IN\1740 vision</e2>_32\NN\5767733 in_33\IN\13603305 both_34\DT\1740 eyes_35\NNS\5945642 ._36\.\1740
D004977_D009901 NONE <e1>ethambutol-induced</e1>_0\JJ\1740 <e2>toxic_1\JJ\1740 optic_2\JJ\1740 neuropathy</e2>_3\NN\14204950 was_4\VBD\836236 suspected_5\VBN\916909 and_6\CC\1740 tablet_7\NN\4233405 ethambutol_8\NN\1740 was_9\VBD\836236 withdrawn_10\VBN\1835496 ._11\.\1740
D004977_D009901 NONE ethambutol-induced_0\JJ\1740 <e2>toxic_1\JJ\1740 optic_2\JJ\1740 neuropathy</e2>_3\NN\14204950 was_4\VBD\836236 suspected_5\VBN\916909 and_6\CC\1740 tablet_7\NN\4233405 <e1>ethambutol</e1>_8\NN\1740 was_9\VBD\836236 withdrawn_10\VBN\1835496 ._11\.\1740
D004977_D015354 NONE <e2>deterioration_0\NN\14560612 of_1\IN\1740 vision</e2>_2\NN\5767733 occurred_3\VBD\2623529 despite_4\IN\7501545 withdrawal_5\NN\7206096 of_6\IN\1740 <e1>ethambutol</e1>_7\NN\1740 ._8\.\1740
24727461
C005975_D028361 NONE <e1>hydroxytyrosol</e1>_0\JJ\1740 ameliorates_1\NNS\1740 oxidative_2\JJ\1740 stress_3\NN\7083732 and_4\CC\1740 <e2>mitochondrial_5\JJ\1740 dysfunction</e2>_6\NN\14204950 in_7\IN\13603305 doxorubicin-induced_8\JJ\1740 cardiotoxicity_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 breast_13\NN\5225090 cancer_14\NN\14239425 ._15\.\1740
C005975_D066126 NONE <e1>hydroxytyrosol</e1>_0\JJ\1740 ameliorates_1\NNS\1740 oxidative_2\JJ\1740 stress_3\NN\7083732 and_4\CC\1740 mitochondrial_5\JJ\1740 dysfunction_6\NN\14204950 in_7\IN\13603305 doxorubicin-induced_8\JJ\1740 <e2>cardiotoxicity</e2>_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 breast_13\NN\5225090 cancer_14\NN\14239425 ._15\.\1740
C005975_D066126 NONE herein_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 investigate_3\VBP\644583 whether_4\IN\1740 doxorubicin-associated_5\JJ\1740 chronic_6\JJ\1740 <e2>cardiac_7\JJ\1740 toxicity</e2>_8\NN\13576101 can_9\MD\3094503 be_10\VB\836236 ameliorated_11\VBN\126264 with_12\IN\1740 the_13\DT\1740 antioxidant_14\JJ\1740 <e1>hydroxytyrosol</e1>_15\NN\1740 in_16\IN\13603305 rats_17\NNS\2329401 with_18\IN\1740 breast_19\NN\5225090 cancer_20\NN\14239425 ._21\.\1740
C005975_D001943 NONE <e1>hydroxytyrosol</e1>_0\JJ\1740 ameliorates_1\NNS\1740 oxidative_2\JJ\1740 stress_3\NN\7083732 and_4\CC\1740 mitochondrial_5\JJ\1740 dysfunction_6\NN\14204950 in_7\IN\13603305 doxorubicin-induced_8\JJ\1740 cardiotoxicity_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 <e2>breast_13\NN\5225090 cancer</e2>_14\NN\14239425 ._15\.\1740
C005975_D001943 NONE herein_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 investigate_3\VBP\644583 whether_4\IN\1740 doxorubicin-associated_5\JJ\1740 chronic_6\JJ\1740 cardiac_7\JJ\1740 toxicity_8\NN\13576101 can_9\MD\3094503 be_10\VB\836236 ameliorated_11\VBN\126264 with_12\IN\1740 the_13\DT\1740 antioxidant_14\JJ\1740 <e1>hydroxytyrosol</e1>_15\NN\1740 in_16\IN\13603305 rats_17\NNS\2329401 with_18\IN\1740 <e2>breast_19\NN\5225090 cancer</e2>_20\NN\14239425 ._21\.\1740
C005975_D001943 NONE thirty-six_0\CD\1740 rats_1\NNS\2329401 bearing_2\VBG\2630189 <e2>breast_3\NN\5225090 tumors</e2>_4\NNS\14234074 induced_5\VBN\1627355 chemically_6\RB\1740 were_7\VBD\836236 divided_8\VBN\140123 into_9\IN\1740 4_10\CD\13741022 groups_11\NNS\2137 :_12\:\1740 control_13\NN\5190804 ,_14\,\1740 <e1>hydroxytyrosol</e1>_15\JJ\1740 (_16\-LRB-\1740 0.5mg/kg_17\CD\1740 ,_18\,\1740 5days/week_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 doxorubicin_22\NN\2716866 (_23\-LRB-\1740 1mg/kg/week_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 doxorubicin_28\NN\2716866 plus_29\CC\4723816 hydroxytyrosol_30\JJ\1740 ._31\.\1740
C005975_D001943 NONE thirty-six_0\CD\1740 rats_1\NNS\2329401 bearing_2\VBG\2630189 <e2>breast_3\NN\5225090 tumors</e2>_4\NNS\14234074 induced_5\VBN\1627355 chemically_6\RB\1740 were_7\VBD\836236 divided_8\VBN\140123 into_9\IN\1740 4_10\CD\13741022 groups_11\NNS\2137 :_12\:\1740 control_13\NN\5190804 ,_14\,\1740 hydroxytyrosol_15\JJ\1740 (_16\-LRB-\1740 0.5mg/kg_17\CD\1740 ,_18\,\1740 5days/week_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 doxorubicin_22\NN\2716866 (_23\-LRB-\1740 1mg/kg/week_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 doxorubicin_28\NN\2716866 plus_29\CC\4723816 <e1>hydroxytyrosol</e1>_30\JJ\1740 ._31\.\1740
D004317_D028361 NONE hydroxytyrosol_0\JJ\1740 ameliorates_1\NNS\1740 oxidative_2\JJ\1740 stress_3\NN\7083732 and_4\CC\1740 <e2>mitochondrial_5\JJ\1740 dysfunction</e2>_6\NN\14204950 in_7\IN\13603305 <e1>doxorubicin-induced</e1>_8\JJ\1740 cardiotoxicity_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 breast_13\NN\5225090 cancer_14\NN\14239425 ._15\.\1740
D004317_D028361 NONE <e1>doxorubicin</e1>_0\NNP\2716866 causes_1\VBZ\1617192 significant_2\JJ\1740 cardiotoxicity_3\NN\1740 characterized_4\VBN\609683 by_5\IN\1740 marked_6\JJ\1740 increases_7\NNS\13576355 in_8\IN\13603305 oxidative_9\JJ\1740 stress_10\NN\7083732 and_11\CC\1740 <e2>mitochondrial_12\JJ\1740 dysfunction</e2>_13\NN\14204950 ._14\.\1740
D004317_D066126 NONE hydroxytyrosol_0\JJ\1740 ameliorates_1\NNS\1740 oxidative_2\JJ\1740 stress_3\NN\7083732 and_4\CC\1740 mitochondrial_5\JJ\1740 dysfunction_6\NN\14204950 in_7\IN\13603305 <e1>doxorubicin-induced</e1>_8\JJ\1740 <e2>cardiotoxicity</e2>_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 breast_13\NN\5225090 cancer_14\NN\14239425 ._15\.\1740
D004317_D066126 NONE <e1>doxorubicin</e1>_0\NNP\2716866 causes_1\VBZ\1617192 significant_2\JJ\1740 <e2>cardiotoxicity</e2>_3\NN\1740 characterized_4\VBN\609683 by_5\IN\1740 marked_6\JJ\1740 increases_7\NNS\13576355 in_8\IN\13603305 oxidative_9\JJ\1740 stress_10\NN\7083732 and_11\CC\1740 mitochondrial_12\JJ\1740 dysfunction_13\NN\14204950 ._14\.\1740
D004317_D066126 NONE herein_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 investigate_3\VBP\644583 whether_4\IN\1740 <e1>doxorubicin-associated</e1>_5\JJ\1740 chronic_6\JJ\1740 <e2>cardiac_7\JJ\1740 toxicity</e2>_8\NN\13576101 can_9\MD\3094503 be_10\VB\836236 ameliorated_11\VBN\126264 with_12\IN\1740 the_13\DT\1740 antioxidant_14\JJ\1740 hydroxytyrosol_15\NN\1740 in_16\IN\13603305 rats_17\NNS\2329401 with_18\IN\1740 breast_19\NN\5225090 cancer_20\NN\14239425 ._21\.\1740
D004317_D001943 NONE hydroxytyrosol_0\JJ\1740 ameliorates_1\NNS\1740 oxidative_2\JJ\1740 stress_3\NN\7083732 and_4\CC\1740 mitochondrial_5\JJ\1740 dysfunction_6\NN\14204950 in_7\IN\13603305 <e1>doxorubicin-induced</e1>_8\JJ\1740 cardiotoxicity_9\NN\1740 in_10\IN\13603305 rats_11\NNS\2329401 with_12\IN\1740 <e2>breast_13\NN\5225090 cancer</e2>_14\NN\14239425 ._15\.\1740
D004317_D001943 NONE herein_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 investigate_3\VBP\644583 whether_4\IN\1740 <e1>doxorubicin-associated</e1>_5\JJ\1740 chronic_6\JJ\1740 cardiac_7\JJ\1740 toxicity_8\NN\13576101 can_9\MD\3094503 be_10\VB\836236 ameliorated_11\VBN\126264 with_12\IN\1740 the_13\DT\1740 antioxidant_14\JJ\1740 hydroxytyrosol_15\NN\1740 in_16\IN\13603305 rats_17\NNS\2329401 with_18\IN\1740 <e2>breast_19\NN\5225090 cancer</e2>_20\NN\14239425 ._21\.\1740
D004317_D001943 NONE thirty-six_0\CD\1740 rats_1\NNS\2329401 bearing_2\VBG\2630189 <e2>breast_3\NN\5225090 tumors</e2>_4\NNS\14234074 induced_5\VBN\1627355 chemically_6\RB\1740 were_7\VBD\836236 divided_8\VBN\140123 into_9\IN\1740 4_10\CD\13741022 groups_11\NNS\2137 :_12\:\1740 control_13\NN\5190804 ,_14\,\1740 hydroxytyrosol_15\JJ\1740 (_16\-LRB-\1740 0.5mg/kg_17\CD\1740 ,_18\,\1740 5days/week_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 <e1>doxorubicin</e1>_22\NN\2716866 (_23\-LRB-\1740 1mg/kg/week_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 doxorubicin_28\NN\2716866 plus_29\CC\4723816 hydroxytyrosol_30\JJ\1740 ._31\.\1740
D004317_D001943 NONE thirty-six_0\CD\1740 rats_1\NNS\2329401 bearing_2\VBG\2630189 <e2>breast_3\NN\5225090 tumors</e2>_4\NNS\14234074 induced_5\VBN\1627355 chemically_6\RB\1740 were_7\VBD\836236 divided_8\VBN\140123 into_9\IN\1740 4_10\CD\13741022 groups_11\NNS\2137 :_12\:\1740 control_13\NN\5190804 ,_14\,\1740 hydroxytyrosol_15\JJ\1740 (_16\-LRB-\1740 0.5mg/kg_17\CD\1740 ,_18\,\1740 5days/week_19\JJ\1740 )_20\-RRB-\1740 ,_21\,\1740 doxorubicin_22\NN\2716866 (_23\-LRB-\1740 1mg/kg/week_24\CD\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 <e1>doxorubicin</e1>_28\NN\2716866 plus_29\CC\4723816 hydroxytyrosol_30\JJ\1740 ._31\.\1740
D004317_D009369 NONE oxidative_0\JJ\1740 stress_1\NN\7083732 is_2\VBZ\836236 involved_3\VBN\2676054 in_4\IN\13603305 several_5\JJ\1740 processes_6\NNS\407535 including_7\VBG\690614 <e2>cancer</e2>_8\NN\14239425 ,_9\,\1740 aging_10\NN\13526110 and_11\CC\1740 cardiovascular_12\JJ\1740 disease_13\NN\14061805 ,_14\,\1740 and_15\CC\1740 has_16\VBZ\2108377 been_17\VBN\836236 shown_18\VBN\2137132 to_19\TO\1740 potentiate_20\VB\229605 the_21\DT\1740 therapeutic_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 drugs_25\NNS\14778436 such_26\JJ\1740 as_27\IN\14622893 <e1>doxorubicin</e1>_28\NN\2716866 ._29\.\1740
D004317_D002318 NONE oxidative_0\JJ\1740 stress_1\NN\7083732 is_2\VBZ\836236 involved_3\VBN\2676054 in_4\IN\13603305 several_5\JJ\1740 processes_6\NNS\407535 including_7\VBG\690614 cancer_8\NN\14239425 ,_9\,\1740 aging_10\NN\13526110 and_11\CC\1740 <e2>cardiovascular_12\JJ\1740 disease</e2>_13\NN\14061805 ,_14\,\1740 and_15\CC\1740 has_16\VBZ\2108377 been_17\VBN\836236 shown_18\VBN\2137132 to_19\TO\1740 potentiate_20\VB\229605 the_21\DT\1740 therapeutic_22\JJ\1740 effect_23\NN\34213 of_24\IN\1740 drugs_25\NNS\14778436 such_26\JJ\1740 as_27\IN\14622893 <e1>doxorubicin</e1>_28\NN\2716866 ._29\.\1740
C005975_D006331 NONE <e1>hydroxytyrosol</e1>_0\NNP\1740 improved_1\VBD\126264 the_2\DT\1740 <e2>cardiac_3\JJ\1740 disturbances</e2>_4\NNS\407535 enhanced_5\VBN\227165 by_6\IN\1740 doxorubicin_7\NN\2716866 by_8\IN\1740 significantly_9\RB\1740 reducing_10\VBG\441445 the_11\DT\1740 percentage_12\NN\13815742 of_13\IN\1740 altered_14\JJ\1740 mitochondria_15\NN\5445668 and_16\CC\1740 oxidative_17\JJ\1740 damage_18\NN\7296428 ._19\.\1740
C005975_D006331 NONE this_0\DT\1740 study_1\NN\635850 demonstrates_2\VBZ\2137132 that_3\IN\1740 <e1>hydroxytyrosol</e1>_4\JJ\1740 protect_5\NN\1740 rat_6\NN\2329401 <e2>heart_7\NN\5919034 damage</e2>_8\NN\7296428 provoked_9\VBN\1617192 by_10\IN\1740 doxorubicin_11\NN\2716866 decreasing_12\VBG\169651 oxidative_13\JJ\1740 damage_14\NN\7296428 and_15\CC\1740 mitochondrial_16\JJ\1740 alterations_17\NNS\7283608 ._18\.\1740
D004317_D006331 CID hydroxytyrosol_0\NNP\1740 improved_1\VBD\126264 the_2\DT\1740 <e2>cardiac_3\JJ\1740 disturbances</e2>_4\NNS\407535 enhanced_5\VBN\227165 by_6\IN\1740 <e1>doxorubicin</e1>_7\NN\2716866 by_8\IN\1740 significantly_9\RB\1740 reducing_10\VBG\441445 the_11\DT\1740 percentage_12\NN\13815742 of_13\IN\1740 altered_14\JJ\1740 mitochondria_15\NN\5445668 and_16\CC\1740 oxidative_17\JJ\1740 damage_18\NN\7296428 ._19\.\1740
D004317_D006331 CID this_0\DT\1740 study_1\NN\635850 demonstrates_2\VBZ\2137132 that_3\IN\1740 hydroxytyrosol_4\JJ\1740 protect_5\NN\1740 rat_6\NN\2329401 <e2>heart_7\NN\5919034 damage</e2>_8\NN\7296428 provoked_9\VBN\1617192 by_10\IN\1740 <e1>doxorubicin</e1>_11\NN\2716866 decreasing_12\VBG\169651 oxidative_13\JJ\1740 damage_14\NN\7296428 and_15\CC\1740 mitochondrial_16\JJ\1740 alterations_17\NNS\7283608 ._18\.\1740
1424076
D014750_D007177 CID <e2>syndrome_0\NN\5870365 of_1\IN\1740 inappropriate_2\JJ\1740 secretion_3\NN\13526110 of_4\IN\1740 antidiuretic_5\JJ\1740 hormone</e2>_6\NN\5404728 after_7\IN\1740 infusional_8\JJ\1740 <e1>vincristine</e1>_9\NN\3917455 ._10\.\1740
D014750_D007177 CID evaluation_0\NN\874067 revealed_1\VBD\2137132 the_2\DT\1740 <e2>syndrome_3\NN\5870365 of_4\IN\1740 inappropriate_5\JJ\1740 secretion_6\NN\13526110 of_7\IN\1740 antidiuretic_8\JJ\1740 hormone</e2>_9\NN\5404728 ,_10\,\1740 which_11\WDT\1740 was_12\VBD\836236 attributed_13\VBN\670261 to_14\TO\1740 the_15\DT\1740 <e1>vincristine</e1>_16\NN\3917455 infusion_17\NN\14589223 ._18\.\1740
D014750_D009101 NONE a_0\DT\13649268 77-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 refractory_4\JJ\1740 <e2>multiple_5\JJ\1740 myeloma</e2>_6\NN\14239425 was_7\VBD\836236 treated_8\VBN\2376958 with_9\IN\1740 a_10\DT\13649268 4-day_11\JJ\1740 continuous_12\JJ\1740 intravenous_13\JJ\1740 infusion_14\NN\14589223 of_15\IN\1740 <e1>vincristine</e1>_16\NN\3917455 and_17\CC\1740 doxorubicin_18\NN\2716866 and_19\CC\1740 4_20\CD\13741022 days_21\NNS\15140892 of_22\IN\1740 oral_23\JJ\1740 dexamethasone_24\NN\2721538 ._25\.\1740
D004317_D009101 NONE a_0\DT\13649268 77-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 refractory_4\JJ\1740 <e2>multiple_5\JJ\1740 myeloma</e2>_6\NN\14239425 was_7\VBD\836236 treated_8\VBN\2376958 with_9\IN\1740 a_10\DT\13649268 4-day_11\JJ\1740 continuous_12\JJ\1740 intravenous_13\JJ\1740 infusion_14\NN\14589223 of_15\IN\1740 vincristine_16\NN\3917455 and_17\CC\1740 <e1>doxorubicin</e1>_18\NN\2716866 and_19\CC\1740 4_20\CD\13741022 days_21\NNS\15140892 of_22\IN\1740 oral_23\JJ\1740 dexamethasone_24\NN\2721538 ._25\.\1740
D003907_D009101 NONE a_0\DT\13649268 77-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 refractory_4\JJ\1740 <e2>multiple_5\JJ\1740 myeloma</e2>_6\NN\14239425 was_7\VBD\836236 treated_8\VBN\2376958 with_9\IN\1740 a_10\DT\13649268 4-day_11\JJ\1740 continuous_12\JJ\1740 intravenous_13\JJ\1740 infusion_14\NN\14589223 of_15\IN\1740 vincristine_16\NN\3917455 and_17\CC\1740 doxorubicin_18\NN\2716866 and_19\CC\1740 4_20\CD\13741022 days_21\NNS\15140892 of_22\IN\1740 oral_23\JJ\1740 <e1>dexamethasone</e1>_24\NN\2721538 ._25\.\1740
24554916
D010758_D002779 CID <e2>cholestatic</e2>_0\JJ\1740 presentation_1\NN\1027379 of_2\IN\1740 yellow_3\JJ\1740 <e1>phosphorus</e1>_4\NN\14622893 poisoning_5\NN\14034177 ._6\.\1740
D010758_D002779 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 <e1>phosphorus</e1>_6\NN\14622893 poisoning_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 <e2>cholestasis</e2>_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 cholestasis_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 phosphorus_32\NN\14622893 hepatotoxicity_33\NN\1740 ._34\.\1740
D010758_D002779 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 <e1>phosphorus</e1>_6\NN\14622893 poisoning_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 cholestasis_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 <e2>cholestasis</e2>_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 phosphorus_32\NN\14622893 hepatotoxicity_33\NN\1740 ._34\.\1740
D010758_D002779 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 phosphorus_6\NN\14622893 poisoning_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 <e2>cholestasis</e2>_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 cholestasis_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 <e1>phosphorus</e1>_32\NN\14622893 hepatotoxicity_33\NN\1740 ._34\.\1740
D010758_D002779 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 phosphorus_6\NN\14622893 poisoning_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 cholestasis_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 <e2>cholestasis</e2>_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 <e1>phosphorus</e1>_32\NN\14622893 hepatotoxicity_33\NN\1740 ._34\.\1740
D010758_D011041 NONE cholestatic_0\JJ\1740 presentation_1\NN\1027379 of_2\IN\1740 yellow_3\JJ\1740 <e1>phosphorus</e1>_4\NN\14622893 <e2>poisoning</e2>_5\NN\14034177 ._6\.\1740
D010758_D011041 NONE <e2>poisoning</e2>_0\JJ\1740 with_1\IN\1740 yellow_2\JJ\1740 <e1>phosphorus</e1>_3\NN\14622893 classically_4\RB\1740 manifests_5\VBZ\1015244 with_6\IN\1740 acute_7\JJ\1740 hepatitis_8\NN\14127211 leading_9\VBG\1752884 to_10\TO\1740 acute_11\JJ\1740 liver_12\NN\5298729 failure_13\NN\66216 which_14\WDT\1740 may_15\MD\15209706 need_16\VB\2604760 liver_17\NN\5298729 transplantation_18\NN\671351 ._19\.\1740
D010758_D011041 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 <e1>phosphorus</e1>_6\NN\14622893 <e2>poisoning</e2>_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 cholestasis_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 cholestasis_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 phosphorus_32\NN\14622893 hepatotoxicity_33\NN\1740 ._34\.\1740
D010758_D011041 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 phosphorus_6\NN\14622893 <e2>poisoning</e2>_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 cholestasis_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 cholestasis_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 <e1>phosphorus</e1>_32\NN\14622893 hepatotoxicity_33\NN\1740 ._34\.\1740
D010758_D056486 NONE yellow_0\NN\4959672 <e1>phosphorus</e1>_1\NN\14622893 ,_2\,\1740 a_3\DT\13649268 component_4\NN\5867413 of_5\IN\1740 certain_6\JJ\1740 pesticide_7\NN\14806838 pastes_8\NNS\14588492 and_9\CC\1740 fireworks_10\NNS\14853392 ,_11\,\1740 is_12\VBZ\836236 well_13\RB\1740 known_14\VBN\2110220 to_15\TO\1740 cause_16\VB\1617192 <e2>hepatotoxicity</e2>_17\NN\1740 ._18\.\1740
D010758_D056486 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 <e1>phosphorus</e1>_6\NN\14622893 poisoning_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 cholestasis_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 cholestasis_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 phosphorus_32\NN\14622893 <e2>hepatotoxicity</e2>_33\NN\1740 ._34\.\1740
D010758_D056486 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 yellow_5\JJ\1740 phosphorus_6\NN\14622893 poisoning_7\NN\14034177 in_8\IN\13603305 which_9\WDT\1740 a_10\DT\13649268 patient_11\NN\9898892 presented_12\VBN\2137132 with_13\IN\1740 florid_14\JJ\1740 clinical_15\JJ\1740 features_16\NNS\5849040 of_17\IN\1740 cholestasis_18\NN\14052403 highlighting_19\VBG\514463 the_20\DT\1740 fact_21\NN\5816287 that_22\IN\1740 cholestasis_23\NN\14052403 can_24\MD\3094503 rarely_25\RB\1740 be_26\VB\836236 a_27\DT\13649268 presenting_28\JJ\1740 feature_29\NN\5849040 of_30\IN\1740 yellow_31\NN\4959672 <e1>phosphorus</e1>_32\NN\14622893 <e2>hepatotoxicity</e2>_33\NN\1740 ._34\.\1740
D010758_D006505 CID poisoning_0\JJ\1740 with_1\IN\1740 yellow_2\JJ\1740 <e1>phosphorus</e1>_3\NN\14622893 classically_4\RB\1740 manifests_5\VBZ\1015244 with_6\IN\1740 <e2>acute_7\JJ\1740 hepatitis</e2>_8\NN\14127211 leading_9\VBG\1752884 to_10\TO\1740 acute_11\JJ\1740 liver_12\NN\5298729 failure_13\NN\66216 which_14\WDT\1740 may_15\MD\15209706 need_16\VB\2604760 liver_17\NN\5298729 transplantation_18\NN\671351 ._19\.\1740
D010758_D017114 CID poisoning_0\JJ\1740 with_1\IN\1740 yellow_2\JJ\1740 <e1>phosphorus</e1>_3\NN\14622893 classically_4\RB\1740 manifests_5\VBZ\1015244 with_6\IN\1740 acute_7\JJ\1740 hepatitis_8\NN\14127211 leading_9\VBG\1752884 to_10\TO\1740 <e2>acute_11\JJ\1740 liver_12\NN\5298729 failure</e2>_13\NN\66216 which_14\WDT\1740 may_15\MD\15209706 need_16\VB\2604760 liver_17\NN\5298729 transplantation_18\NN\671351 ._19\.\1740
24571687
D020927_D019462 CID <e2>vasovagal_0\NN\1740 syncope</e2>_1\NN\7478169 and_2\CC\1740 severe_3\JJ\1740 bradycardia_4\NN\14110674 following_5\VBG\1835496 intranasal_6\JJ\1740 <e1>dexmedetomidine</e1>_7\NN\1740 for_8\IN\1740 pediatric_9\JJ\1740 procedural_10\JJ\1740 sedation_11\NN\14034177 ._12\.\1740
D020927_D001919 CID vasovagal_0\NN\1740 syncope_1\NN\7478169 and_2\CC\1740 severe_3\JJ\1740 <e2>bradycardia</e2>_4\NN\14110674 following_5\VBG\1835496 intranasal_6\JJ\1740 <e1>dexmedetomidine</e1>_7\NN\1740 for_8\IN\1740 pediatric_9\JJ\1740 procedural_10\JJ\1740 sedation_11\NN\14034177 ._12\.\1740
D020927_D001919 CID we_0\PRP\1740 report_1\VBP\831651 syncope_2\NN\7478169 and_3\CC\1740 <e2>bradycardia</e2>_4\NN\14110674 in_5\IN\13603305 an_6\DT\6697703 11-year-old_7\JJ\1740 girl_8\NN\10787470 following_9\VBG\1835496 administration_10\NN\1133281 of_11\IN\1740 intranasal_12\JJ\1740 <e1>dexmedetomidine</e1>_13\NN\1740 for_14\IN\1740 sedation_15\NN\14034177 for_16\IN\1740 a_17\DT\13649268 voiding_18\VBG\2477334 cystourethrogram_19\NN\1740 ._20\.\1740
D020927_D013575 NONE we_0\PRP\1740 report_1\VBP\831651 <e2>syncope</e2>_2\NN\7478169 and_3\CC\1740 bradycardia_4\NN\14110674 in_5\IN\13603305 an_6\DT\6697703 11-year-old_7\JJ\1740 girl_8\NN\10787470 following_9\VBG\1835496 administration_10\NN\1133281 of_11\IN\1740 intranasal_12\JJ\1740 <e1>dexmedetomidine</e1>_13\NN\1740 for_14\IN\1740 sedation_15\NN\14034177 for_16\IN\1740 a_17\DT\13649268 voiding_18\VBG\2477334 cystourethrogram_19\NN\1740 ._20\.\1740
8312983
D005473_D003693 CID <e2>delirium</e2>_0\NN\14391660 during_1\IN\1740 <e1>fluoxetine</e1>_2\NN\4169152 treatment_3\NN\654885 ._4\.\1740
D005473_D003693 CID in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 acute_9\JJ\1740 hyperkinetic_10\JJ\1740 <e2>delirium</e2>_11\NN\14391660 connected_12\VBN\628491 with_13\IN\1740 a_14\DT\13649268 high_15\JJ\1740 serum_16\NN\5397468 total_17\JJ\1740 <e1>fluoxetine</e1>_18\NN\4169152 (_19\-LRB-\1740 fluoxetine_20\NN\4169152 plus_21\CC\4723816 desmethylfluoxetine_22\NN\1740 )_23\-RRB-\1740 concentration_24\NN\4916342 ._25\.\1740
D005473_D003693 CID in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 acute_9\JJ\1740 hyperkinetic_10\JJ\1740 <e2>delirium</e2>_11\NN\14391660 connected_12\VBN\628491 with_13\IN\1740 a_14\DT\13649268 high_15\JJ\1740 serum_16\NN\5397468 total_17\JJ\1740 fluoxetine_18\NN\4169152 (_19\-LRB-\1740 <e1>fluoxetine</e1>_20\NN\4169152 plus_21\CC\4723816 desmethylfluoxetine_22\NN\1740 )_23\-RRB-\1740 concentration_24\NN\4916342 ._25\.\1740
D015283_D006970 NONE in_0\IN\13603305 some_1\DT\1740 cases_2\NNS\7283608 ,_3\,\1740 a_4\DT\13649268 high_5\JJ\1740 serum_6\NN\5397468 concentration_7\NN\4916342 of_8\IN\1740 <e1>citalopram</e1>_9\NN\1740 (_10\-LRB-\1740 >_11\NNS\1740 600_12\CD\1740 nmol/l_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 has_18\VBZ\2108377 been_19\VBN\836236 associated_20\VBN\628491 with_21\IN\1740 increased_22\VBN\169651 <e2>somnolence</e2>_23\NN\14015731 and_24\CC\1740 movement_25\NN\191142 difficulties_26\NNS\621627 ._27\.\1740
D015283_D020820 NONE in_0\IN\13603305 some_1\DT\1740 cases_2\NNS\7283608 ,_3\,\1740 a_4\DT\13649268 high_5\JJ\1740 serum_6\NN\5397468 concentration_7\NN\4916342 of_8\IN\1740 <e1>citalopram</e1>_9\NN\1740 (_10\-LRB-\1740 >_11\NNS\1740 600_12\CD\1740 nmol/l_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 elderly_16\JJ\1740 patients_17\NNS\9898892 has_18\VBZ\2108377 been_19\VBN\836236 associated_20\VBN\628491 with_21\IN\1740 increased_22\VBN\169651 somnolence_23\NN\14015731 and_24\CC\1740 <e2>movement_25\NN\191142 difficulties</e2>_26\NNS\621627 ._27\.\1740
D005473_D006948 CID in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 acute_9\JJ\1740 <e2>hyperkinetic</e2>_10\JJ\1740 delirium_11\NN\14391660 connected_12\VBN\628491 with_13\IN\1740 a_14\DT\13649268 high_15\JJ\1740 serum_16\NN\5397468 total_17\JJ\1740 <e1>fluoxetine</e1>_18\NN\4169152 (_19\-LRB-\1740 fluoxetine_20\NN\4169152 plus_21\CC\4723816 desmethylfluoxetine_22\NN\1740 )_23\-RRB-\1740 concentration_24\NN\4916342 ._25\.\1740
D005473_D006948 CID in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 acute_9\JJ\1740 <e2>hyperkinetic</e2>_10\JJ\1740 delirium_11\NN\14391660 connected_12\VBN\628491 with_13\IN\1740 a_14\DT\13649268 high_15\JJ\1740 serum_16\NN\5397468 total_17\JJ\1740 fluoxetine_18\NN\4169152 (_19\-LRB-\1740 <e1>fluoxetine</e1>_20\NN\4169152 plus_21\CC\4723816 desmethylfluoxetine_22\NN\1740 )_23\-RRB-\1740 concentration_24\NN\4916342 ._25\.\1740
C036139_D006948 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 acute_9\JJ\1740 <e2>hyperkinetic</e2>_10\JJ\1740 delirium_11\NN\14391660 connected_12\VBN\628491 with_13\IN\1740 a_14\DT\13649268 high_15\JJ\1740 serum_16\NN\5397468 total_17\JJ\1740 fluoxetine_18\NN\4169152 (_19\-LRB-\1740 fluoxetine_20\NN\4169152 plus_21\CC\4723816 <e1>desmethylfluoxetine</e1>_22\NN\1740 )_23\-RRB-\1740 concentration_24\NN\4916342 ._25\.\1740
C036139_D003693 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 patient_7\NN\9898892 with_8\IN\1740 acute_9\JJ\1740 hyperkinetic_10\JJ\1740 <e2>delirium</e2>_11\NN\14391660 connected_12\VBN\628491 with_13\IN\1740 a_14\DT\13649268 high_15\JJ\1740 serum_16\NN\5397468 total_17\JJ\1740 fluoxetine_18\NN\4169152 (_19\-LRB-\1740 fluoxetine_20\NN\4169152 plus_21\CC\4723816 <e1>desmethylfluoxetine</e1>_22\NN\1740 )_23\-RRB-\1740 concentration_24\NN\4916342 ._25\.\1740
12372954
D009530_D009395 CID acute_0\JJ\1740 <e2>interstitial_1\JJ\1740 nephritis</e2>_2\NN\14113228 due_3\JJ\1740 to_4\TO\1740 <e1>nicergoline</e1>_5\NN\1740 (_6\-LRB-\1740 sermion_7\NNP\1740 )_8\-RRB-\1740 ._9\.\1740
D009530_D009395 CID acute_0\JJ\1740 <e2>interstitial_1\JJ\1740 nephritis</e2>_2\NN\14113228 due_3\JJ\1740 to_4\TO\1740 nicergoline_5\NN\1740 (_6\-LRB-\1740 <e1>sermion</e1>_7\NNP\1740 )_8\-RRB-\1740 ._9\.\1740
D009530_D009395 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 <e2>interstitial_6\JJ\1740 nephritis</e2>_7\NN\14113228 (_8\-LRB-\1740 ain_9\NN\1740 )_10\-RRB-\1740 due_11\JJ\1740 to_12\TO\1740 <e1>nicergoline</e1>_13\NN\1740 (_14\-LRB-\1740 sermion_15\NNP\1740 )_16\-RRB-\1740 ._17\.\1740
D009530_D009395 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 interstitial_6\JJ\1740 nephritis_7\NN\14113228 (_8\-LRB-\1740 <e2>ain</e2>_9\NN\1740 )_10\-RRB-\1740 due_11\JJ\1740 to_12\TO\1740 <e1>nicergoline</e1>_13\NN\1740 (_14\-LRB-\1740 sermion_15\NNP\1740 )_16\-RRB-\1740 ._17\.\1740
D009530_D009395 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 <e2>interstitial_6\JJ\1740 nephritis</e2>_7\NN\14113228 (_8\-LRB-\1740 ain_9\NN\1740 )_10\-RRB-\1740 due_11\JJ\1740 to_12\TO\1740 nicergoline_13\NN\1740 (_14\-LRB-\1740 <e1>sermion</e1>_15\NNP\1740 )_16\-RRB-\1740 ._17\.\1740
D009530_D009395 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 interstitial_6\JJ\1740 nephritis_7\NN\14113228 (_8\-LRB-\1740 <e2>ain</e2>_9\NN\1740 )_10\-RRB-\1740 due_11\JJ\1740 to_12\TO\1740 nicergoline_13\NN\1740 (_14\-LRB-\1740 <e1>sermion</e1>_15\NNP\1740 )_16\-RRB-\1740 ._17\.\1740
D009530_D009395 CID to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 report_8\NN\6470073 of_9\IN\1740 <e1>nicergoline-associated</e1>_10\JJ\1740 <e2>ain</e2>_11\NN\1740 ._12\.\1740
D009530_D012170 NONE before_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 he_3\PRP\14622893 had_4\VBD\2108377 been_5\VBN\836236 taking_6\VBG\2367363 <e1>nicergoline</e1>_7\NN\1740 and_8\CC\1740 bendazac_9\NN\1740 lysine_10\NN\14605787 due_11\JJ\1740 to_12\TO\1740 <e2>retinal_13\JJ\1740 vein_14\NN\5417975 occlusion</e2>_15\NN\14081375 at_16\IN\14622893 ophthalmologic_17\JJ\1740 department_18\NN\8220714 ._19\.\1740
C036067_D012170 NONE before_0\IN\1740 admission_1\NN\49003 ,_2\,\1740 he_3\PRP\14622893 had_4\VBD\2108377 been_5\VBN\836236 taking_6\VBG\2367363 nicergoline_7\NN\1740 and_8\CC\1740 <e1>bendazac_9\NN\1740 lysine</e1>_10\NN\14605787 due_11\JJ\1740 to_12\TO\1740 <e2>retinal_13\JJ\1740 vein_14\NN\5417975 occlusion</e2>_15\NN\14081375 at_16\IN\14622893 ophthalmologic_17\JJ\1740 department_18\NN\8220714 ._19\.\1740
1564030
D005473_D001714 CID <e2>mania</e2>_0\NNP\9180259 associated_1\VBN\628491 with_2\IN\1740 <e1>fluoxetine</e1>_3\NN\4169152 treatment_4\NN\654885 in_5\IN\13603305 adolescents_6\NNS\9622049 ._7\.\1740
D005473_D001714 CID generally_0\RB\1740 safe_1\JJ\1740 and_2\CC\1740 well_3\RB\1740 tolerated_4\VBN\802318 by_5\IN\1740 adults_6\NNS\7846 ,_7\,\1740 <e1>fluoxetine</e1>_8\NN\4169152 has_9\VBZ\2108377 been_10\VBN\836236 reported_11\VBN\831651 to_12\TO\1740 induce_13\VB\1627355 <e2>mania</e2>_14\NN\9180259 ._15\.\1740
D005473_D001714 CID the_0\DT\1740 cases_1\NNS\7283608 of_2\IN\1740 five_3\CD\13741022 depressed_4\JJ\1740 adolescents_5\NNS\9622049 ,_6\,\1740 14_7\CD\13745420 -_8\SYM\1740 16_9\CD\13745420 years_10\NNS\15144371 of_11\IN\1740 age_12\NN\4916342 ,_13\,\1740 who_14\WP\8299493 developed_15\VBD\1753788 <e2>mania</e2>_16\NN\9180259 during_17\IN\1740 pharmacotherapy_18\NN\1740 with_19\IN\1740 <e1>fluoxetine</e1>_20\NN\4169152 ,_21\,\1740 are_22\VBP\836236 reported_23\VBN\831651 here_24\RB\1740 ._25\.\1740
D005473_D001714 CID apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 <e2>mania</e2>_7\NN\9180259 or_8\CC\3541091 hypomania_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 depression_28\NN\14373582 with_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 affective_37\JJ\1740 disorder_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 bipolar_41\JJ\1740 disorder_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 bipolar_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D005473_D001714 CID apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 mania_7\NN\9180259 or_8\CC\3541091 <e2>hypomania</e2>_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 depression_28\NN\14373582 with_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 affective_37\JJ\1740 disorder_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 bipolar_41\JJ\1740 disorder_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 bipolar_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D005473_D001714 CID apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 mania_7\NN\9180259 or_8\CC\3541091 hypomania_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 depression_28\NN\14373582 with_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 affective_37\JJ\1740 disorder_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 <e2>bipolar_41\JJ\1740 disorder</e2>_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 bipolar_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D005473_D001714 CID apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 mania_7\NN\9180259 or_8\CC\3541091 hypomania_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 depression_28\NN\14373582 with_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 affective_37\JJ\1740 disorder_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 bipolar_41\JJ\1740 disorder_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 <e2>bipolar_48\JJ\1740 disorder</e2>_49\NN\14034177 ._50\.\1740
D005473_D001714 CID further_0\RB\1740 study_1\NN\635850 is_2\VBZ\836236 needed_3\VBN\2604760 to_4\TO\1740 determine_5\VB\1645601 the_6\DT\1740 optimal_7\JJ\1740 dosage_8\NN\13576355 and_9\CC\1740 to_10\TO\1740 identify_11\VB\699815 risk_12\NN\14541044 factors_13\NNS\7326557 that_14\WDT\1740 increase_15\VBP\169651 individual_16\JJ\1740 vulnerability_17\NN\14540765 to_18\TO\1740 <e1>fluoxetine</e1>_19\NN\4169152 induced_20\JJ\1740 <e2>mania</e2>_21\NN\9180259 in_22\IN\13603305 adolescents_23\NNS\9622049 ._24\.\1740
D005473_D003866 NONE <e1>fluoxetine</e1>_0\NNP\4169152 ,_1\,\1740 a_2\DT\13649268 selective_3\JJ\1740 serotonin_4\NN\14807737 reuptake_5\NN\13571580 inhibitor_6\NN\20090 ,_7\,\1740 is_8\VBZ\836236 gaining_9\VBG\2238085 increased_10\VBN\169651 acceptance_11\NN\6193203 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 adolescent_16\JJ\1740 <e2>depression</e2>_17\NN\14373582 ._18\.\1740
D005473_D003866 NONE the_0\DT\1740 cases_1\NNS\7283608 of_2\IN\1740 five_3\CD\13741022 <e2>depressed</e2>_4\JJ\1740 adolescents_5\NNS\9622049 ,_6\,\1740 14_7\CD\13745420 -_8\SYM\1740 16_9\CD\13745420 years_10\NNS\15144371 of_11\IN\1740 age_12\NN\4916342 ,_13\,\1740 who_14\WP\8299493 developed_15\VBD\1753788 mania_16\NN\9180259 during_17\IN\1740 pharmacotherapy_18\NN\1740 with_19\IN\1740 <e1>fluoxetine</e1>_20\NN\4169152 ,_21\,\1740 are_22\VBP\836236 reported_23\VBN\831651 here_24\RB\1740 ._25\.\1740
D005473_D003866 NONE apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 mania_7\NN\9180259 or_8\CC\3541091 hypomania_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 <e2>depression</e2>_28\NN\14373582 with_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 affective_37\JJ\1740 disorder_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 bipolar_41\JJ\1740 disorder_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 bipolar_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D012701_D003866 NONE fluoxetine_0\NNP\4169152 ,_1\,\1740 a_2\DT\13649268 selective_3\JJ\1740 <e1>serotonin</e1>_4\NN\14807737 reuptake_5\NN\13571580 inhibitor_6\NN\20090 ,_7\,\1740 is_8\VBZ\836236 gaining_9\VBG\2238085 increased_10\VBN\169651 acceptance_11\NN\6193203 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 adolescent_16\JJ\1740 <e2>depression</e2>_17\NN\14373582 ._18\.\1740
D005473_D001289 NONE apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 mania_7\NN\9180259 or_8\CC\3541091 hypomania_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 <e2>attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder</e2>_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 depression_28\NN\14373582 with_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 affective_37\JJ\1740 disorder_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 bipolar_41\JJ\1740 disorder_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 bipolar_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D005473_D011618 NONE apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 mania_7\NN\9180259 or_8\CC\3541091 hypomania_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 depression_28\NN\14373582 with_29\IN\1740 <e2>psychotic</e2>_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 affective_37\JJ\1740 disorder_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 bipolar_41\JJ\1740 disorder_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 bipolar_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
D005473_D019964 NONE apparent_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 for_3\IN\1740 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 mania_7\NN\9180259 or_8\CC\3541091 hypomania_9\NN\1740 during_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 pharmacotherapy_12\NN\1740 in_13\IN\13603305 this_14\DT\1740 population_15\NN\7942152 were_16\VBD\836236 the_17\DT\1740 combination_18\NN\7951464 of_19\IN\1740 attention-deficit_20\JJ\1740 hyperactivity_21\NN\14052403 disorder_22\NN\14034177 and_23\CC\1740 affective_24\JJ\1740 instability_25\NN\13972797 ;_26\:\1740 major_27\JJ\1740 depression_28\NN\14373582 with_29\IN\1740 psychotic_30\JJ\1740 features_31\NNS\5849040 ;_32\:\1740 a_33\DT\13649268 family_34\NN\8189659 history_35\NN\15120823 of_36\IN\1740 <e2>affective_37\JJ\1740 disorder</e2>_38\NN\14034177 ,_39\,\1740 especially_40\RB\1740 bipolar_41\JJ\1740 disorder_42\NN\14034177 ;_43\:\1740 and_44\CC\1740 a_45\DT\13649268 diagnosis_46\NN\152018 of_47\IN\1740 bipolar_48\JJ\1740 disorder_49\NN\14034177 ._50\.\1740
19553912
D020123_D000740 CID posttransplant_0\JJ\1740 <e2>anemia</e2>_1\NN\14189204 :_2\:\1740 the_3\DT\1740 role_4\NN\719494 of_5\IN\1740 <e1>sirolimus</e1>_6\NN\1740 ._7\.\1740
D020123_D000740 CID <e1>sirolimus</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 mammalian_3\JJ\1740 target_4\NN\7258332 of_5\IN\1740 rapamycin_6\NN\1740 inhibitor_7\NN\20090 ,_8\,\1740 has_9\VBZ\2108377 been_10\VBN\836236 implicated_11\VBN\2677097 as_12\IN\14622893 playing_13\VBG\1072262 a_14\DT\13649268 special_15\JJ\1740 role_16\NN\719494 in_17\IN\13603305 posttransplant_18\JJ\1740 <e2>anemia</e2>_19\NN\14189204 ._20\.\1740
D020123_D000740 CID sirolimus_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 mammalian_3\JJ\1740 target_4\NN\7258332 of_5\IN\1740 <e1>rapamycin</e1>_6\NN\1740 inhibitor_7\NN\20090 ,_8\,\1740 has_9\VBZ\2108377 been_10\VBN\836236 implicated_11\VBN\2677097 as_12\IN\14622893 playing_13\VBG\1072262 a_14\DT\13649268 special_15\JJ\1740 role_16\NN\719494 in_17\IN\13603305 posttransplant_18\JJ\1740 <e2>anemia</e2>_19\NN\14189204 ._20\.\1740
D020123_D000740 CID this_0\DT\1740 review_1\NN\5733583 considers_2\NNS\1740 <e2>anemia</e2>_3\NN\14189204 associated_4\VBN\628491 with_5\IN\1740 <e1>sirolimus</e1>_6\NN\1740 ,_7\,\1740 including_8\VBG\690614 its_9\PRP$\6125041 presentation_10\NN\1027379 ,_11\,\1740 mechanisms_12\NNS\13446390 ,_13\,\1740 and_14\CC\1740 management_15\NN\1123598 ._16\.\1740
17496739
C085143_D012640 NONE <e1>piperacillin/tazobactam-induced</e1>_0\JJ\1740 <e2>seizure</e2>_1\NN\14081375 rapidly_2\RB\1740 reversed_3\VBN\109660 by_4\IN\1740 high_5\JJ\1740 flux_6\NN\15286249 hemodialysis_7\NN\649760 in_8\IN\13603305 a_9\DT\13649268 patient_10\NN\9898892 on_11\IN\1740 peritoneal_12\JJ\1740 dialysis_13\NN\646833 ._14\.\1740
D010878_D020258 NONE despite_0\IN\7501545 popular_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 <e1>piperacillin</e1>_4\NN\3910033 ,_5\,\1740 the_6\DT\1740 dire_7\JJ\1740 <e2>neurotoxicity</e2>_8\NN\1740 associated_9\VBN\628491 with_10\IN\1740 piperacillin_11\NN\3910033 still_12\RB\1740 goes_13\VBZ\2367363 unrecognized_14\JJ\1740 ,_15\,\1740 leading_16\VBG\1752884 to_17\IN\1740 a_18\DT\13649268 delay_19\NN\15271008 in_20\IN\13603305 appropriate_21\JJ\1740 management_22\NN\1123598 ._23\.\1740
D010878_D020258 NONE despite_0\IN\7501545 popular_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 piperacillin_4\NN\3910033 ,_5\,\1740 the_6\DT\1740 dire_7\JJ\1740 <e2>neurotoxicity</e2>_8\NN\1740 associated_9\VBN\628491 with_10\IN\1740 <e1>piperacillin</e1>_11\NN\3910033 still_12\RB\1740 goes_13\VBZ\2367363 unrecognized_14\JJ\1740 ,_15\,\1740 leading_16\VBG\1752884 to_17\IN\1740 a_18\DT\13649268 delay_19\NN\15271008 in_20\IN\13603305 appropriate_21\JJ\1740 management_22\NN\1123598 ._23\.\1740
C085143_D007676 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 57-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 <e2>end-stage_6\JJ\1740 renal_7\JJ\1740 disease</e2>_8\NN\14061805 receiving_9\VBG\2210855 continuous_10\JJ\1740 ambulatory_11\JJ\1740 peritoneal_12\NN\1740 dialysis_13\NN\646833 (_14\-LRB-\1740 capd_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 who_18\WP\8299493 developed_19\VBD\1753788 slurred_20\VBN\1724459 speech_21\NN\7160883 ,_22\,\1740 tremor_23\NN\345926 ,_24\,\1740 bizarre_25\JJ\1740 behavior_26\NN\407535 ,_27\,\1740 progressive_28\JJ\1740 mental_29\JJ\1740 confusion_30\NN\13972797 ,_31\,\1740 and_32\CC\1740 2_33\CD\13741022 episodes_34\NNS\7283608 of_35\IN\1740 generalized_36\VBN\634472 tonic-clonic_37\JJ\1740 seizure_38\NN\14081375 (_39\-LRB-\1740 gtcs_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 5_43\CD\13741022 doses_44\NNS\3740161 of_45\IN\1740 <e1>piperacillin/tazobactam</e1>_46\NN\1740 (_47\-LRB-\1740 2_48\CD\13741022 g/250_49\NN\1740 mg_50\NN\13717155 )_51\-RRB-\1740 were_52\VBD\836236 given_53\VBN\2327200 for_54\IN\1740 bronchiectasis_55\NN\1740 with_56\IN\1740 secondary_57\JJ\1740 infection_58\NN\14052046 ._59\.\1740
C085143_D014202 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 57-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 end-stage_6\JJ\1740 renal_7\JJ\1740 disease_8\NN\14061805 receiving_9\VBG\2210855 continuous_10\JJ\1740 ambulatory_11\JJ\1740 peritoneal_12\NN\1740 dialysis_13\NN\646833 (_14\-LRB-\1740 capd_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 who_18\WP\8299493 developed_19\VBD\1753788 slurred_20\VBN\1724459 speech_21\NN\7160883 ,_22\,\1740 <e2>tremor</e2>_23\NN\345926 ,_24\,\1740 bizarre_25\JJ\1740 behavior_26\NN\407535 ,_27\,\1740 progressive_28\JJ\1740 mental_29\JJ\1740 confusion_30\NN\13972797 ,_31\,\1740 and_32\CC\1740 2_33\CD\13741022 episodes_34\NNS\7283608 of_35\IN\1740 generalized_36\VBN\634472 tonic-clonic_37\JJ\1740 seizure_38\NN\14081375 (_39\-LRB-\1740 gtcs_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 5_43\CD\13741022 doses_44\NNS\3740161 of_45\IN\1740 <e1>piperacillin/tazobactam</e1>_46\NN\1740 (_47\-LRB-\1740 2_48\CD\13741022 g/250_49\NN\1740 mg_50\NN\13717155 )_51\-RRB-\1740 were_52\VBD\836236 given_53\VBN\2327200 for_54\IN\1740 bronchiectasis_55\NN\1740 with_56\IN\1740 secondary_57\JJ\1740 infection_58\NN\14052046 ._59\.\1740
C085143_D003221 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 57-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 end-stage_6\JJ\1740 renal_7\JJ\1740 disease_8\NN\14061805 receiving_9\VBG\2210855 continuous_10\JJ\1740 ambulatory_11\JJ\1740 peritoneal_12\NN\1740 dialysis_13\NN\646833 (_14\-LRB-\1740 capd_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 who_18\WP\8299493 developed_19\VBD\1753788 slurred_20\VBN\1724459 speech_21\NN\7160883 ,_22\,\1740 tremor_23\NN\345926 ,_24\,\1740 bizarre_25\JJ\1740 behavior_26\NN\407535 ,_27\,\1740 progressive_28\JJ\1740 mental_29\JJ\1740 <e2>confusion</e2>_30\NN\13972797 ,_31\,\1740 and_32\CC\1740 2_33\CD\13741022 episodes_34\NNS\7283608 of_35\IN\1740 generalized_36\VBN\634472 tonic-clonic_37\JJ\1740 seizure_38\NN\14081375 (_39\-LRB-\1740 gtcs_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 5_43\CD\13741022 doses_44\NNS\3740161 of_45\IN\1740 <e1>piperacillin/tazobactam</e1>_46\NN\1740 (_47\-LRB-\1740 2_48\CD\13741022 g/250_49\NN\1740 mg_50\NN\13717155 )_51\-RRB-\1740 were_52\VBD\836236 given_53\VBN\2327200 for_54\IN\1740 bronchiectasis_55\NN\1740 with_56\IN\1740 secondary_57\JJ\1740 infection_58\NN\14052046 ._59\.\1740
C085143_D004830 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 57-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 end-stage_6\JJ\1740 renal_7\JJ\1740 disease_8\NN\14061805 receiving_9\VBG\2210855 continuous_10\JJ\1740 ambulatory_11\JJ\1740 peritoneal_12\NN\1740 dialysis_13\NN\646833 (_14\-LRB-\1740 capd_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 who_18\WP\8299493 developed_19\VBD\1753788 slurred_20\VBN\1724459 speech_21\NN\7160883 ,_22\,\1740 tremor_23\NN\345926 ,_24\,\1740 bizarre_25\JJ\1740 behavior_26\NN\407535 ,_27\,\1740 progressive_28\JJ\1740 mental_29\JJ\1740 confusion_30\NN\13972797 ,_31\,\1740 and_32\CC\1740 2_33\CD\13741022 episodes_34\NNS\7283608 of_35\IN\1740 generalized_36\VBN\634472 <e2>tonic-clonic_37\JJ\1740 seizure</e2>_38\NN\14081375 (_39\-LRB-\1740 gtcs_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 5_43\CD\13741022 doses_44\NNS\3740161 of_45\IN\1740 <e1>piperacillin/tazobactam</e1>_46\NN\1740 (_47\-LRB-\1740 2_48\CD\13741022 g/250_49\NN\1740 mg_50\NN\13717155 )_51\-RRB-\1740 were_52\VBD\836236 given_53\VBN\2327200 for_54\IN\1740 bronchiectasis_55\NN\1740 with_56\IN\1740 secondary_57\JJ\1740 infection_58\NN\14052046 ._59\.\1740
C085143_D004830 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 57-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 end-stage_6\JJ\1740 renal_7\JJ\1740 disease_8\NN\14061805 receiving_9\VBG\2210855 continuous_10\JJ\1740 ambulatory_11\JJ\1740 peritoneal_12\NN\1740 dialysis_13\NN\646833 (_14\-LRB-\1740 capd_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 who_18\WP\8299493 developed_19\VBD\1753788 slurred_20\VBN\1724459 speech_21\NN\7160883 ,_22\,\1740 tremor_23\NN\345926 ,_24\,\1740 bizarre_25\JJ\1740 behavior_26\NN\407535 ,_27\,\1740 progressive_28\JJ\1740 mental_29\JJ\1740 confusion_30\NN\13972797 ,_31\,\1740 and_32\CC\1740 2_33\CD\13741022 episodes_34\NNS\7283608 of_35\IN\1740 generalized_36\VBN\634472 tonic-clonic_37\JJ\1740 seizure_38\NN\14081375 (_39\-LRB-\1740 <e2>gtcs</e2>_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 5_43\CD\13741022 doses_44\NNS\3740161 of_45\IN\1740 <e1>piperacillin/tazobactam</e1>_46\NN\1740 (_47\-LRB-\1740 2_48\CD\13741022 g/250_49\NN\1740 mg_50\NN\13717155 )_51\-RRB-\1740 were_52\VBD\836236 given_53\VBN\2327200 for_54\IN\1740 bronchiectasis_55\NN\1740 with_56\IN\1740 secondary_57\JJ\1740 infection_58\NN\14052046 ._59\.\1740
C085143_D004830 CID despite_0\IN\7501545 the_1\DT\1740 use_2\NN\407535 of_3\IN\1740 antiepileptic_4\JJ\1740 agents_5\NNS\7347 ,_6\,\1740 another_7\DT\1740 <e2>gtcs</e2>_8\NN\1740 episode_9\NN\7283608 recurred_10\VBN\339934 after_11\IN\1740 the_12\DT\1740 sixth_13\JJ\1740 dose_14\NN\3740161 of_15\IN\1740 <e1>piperacillin/tazobactam</e1>_16\NN\1740 ._17\.\1740
C085143_D001987 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 57-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 end-stage_6\JJ\1740 renal_7\JJ\1740 disease_8\NN\14061805 receiving_9\VBG\2210855 continuous_10\JJ\1740 ambulatory_11\JJ\1740 peritoneal_12\NN\1740 dialysis_13\NN\646833 (_14\-LRB-\1740 capd_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 who_18\WP\8299493 developed_19\VBD\1753788 slurred_20\VBN\1724459 speech_21\NN\7160883 ,_22\,\1740 tremor_23\NN\345926 ,_24\,\1740 bizarre_25\JJ\1740 behavior_26\NN\407535 ,_27\,\1740 progressive_28\JJ\1740 mental_29\JJ\1740 confusion_30\NN\13972797 ,_31\,\1740 and_32\CC\1740 2_33\CD\13741022 episodes_34\NNS\7283608 of_35\IN\1740 generalized_36\VBN\634472 tonic-clonic_37\JJ\1740 seizure_38\NN\14081375 (_39\-LRB-\1740 gtcs_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 5_43\CD\13741022 doses_44\NNS\3740161 of_45\IN\1740 <e1>piperacillin/tazobactam</e1>_46\NN\1740 (_47\-LRB-\1740 2_48\CD\13741022 g/250_49\NN\1740 mg_50\NN\13717155 )_51\-RRB-\1740 were_52\VBD\836236 given_53\VBN\2327200 for_54\IN\1740 <e2>bronchiectasis</e2>_55\NN\1740 with_56\IN\1740 secondary_57\JJ\1740 infection_58\NN\14052046 ._59\.\1740
C085143_D060085 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 57-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 end-stage_6\JJ\1740 renal_7\JJ\1740 disease_8\NN\14061805 receiving_9\VBG\2210855 continuous_10\JJ\1740 ambulatory_11\JJ\1740 peritoneal_12\NN\1740 dialysis_13\NN\646833 (_14\-LRB-\1740 capd_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 who_18\WP\8299493 developed_19\VBD\1753788 slurred_20\VBN\1724459 speech_21\NN\7160883 ,_22\,\1740 tremor_23\NN\345926 ,_24\,\1740 bizarre_25\JJ\1740 behavior_26\NN\407535 ,_27\,\1740 progressive_28\JJ\1740 mental_29\JJ\1740 confusion_30\NN\13972797 ,_31\,\1740 and_32\CC\1740 2_33\CD\13741022 episodes_34\NNS\7283608 of_35\IN\1740 generalized_36\VBN\634472 tonic-clonic_37\JJ\1740 seizure_38\NN\14081375 (_39\-LRB-\1740 gtcs_40\NN\1740 )_41\-RRB-\1740 after_42\IN\1740 5_43\CD\13741022 doses_44\NNS\3740161 of_45\IN\1740 <e1>piperacillin/tazobactam</e1>_46\NN\1740 (_47\-LRB-\1740 2_48\CD\13741022 g/250_49\NN\1740 mg_50\NN\13717155 )_51\-RRB-\1740 were_52\VBD\836236 given_53\VBN\2327200 for_54\IN\1740 bronchiectasis_55\NN\1740 with_56\IN\1740 <e2>secondary_57\JJ\1740 infection</e2>_58\NN\14052046 ._59\.\1740
D000641_D007964 NONE the_0\DT\1740 laboratory_1\NN\4602044 data_2\NNS\7951464 revealed_3\VBD\2137132 normal_4\JJ\1740 plasma_5\NN\5398023 electrolyte_6\NN\14589223 and_7\CC\1740 <e1>ammonia</e1>_8\JJ\1740 levels_9\NNS\4916342 but_10\CC\1740 <e2>leukocytosis</e2>_11\NN\14189204 ._12\.\1740
D010878_D001927 NONE <e1>piperacillin-induced</e1>_0\JJ\1740 <e2>encephalopathy</e2>_1\JJ\1740 should_2\MD\1740 be_3\VB\836236 considered_4\VBN\689344 in_5\IN\13603305 any_6\DT\1740 uremic_7\JJ\1740 patients_8\NNS\9898892 with_9\IN\1740 unexplained_10\JJ\1740 neurological_11\JJ\1740 manifestations_12\NNS\7321772 ._13\.\1740
D010878_D001927 NONE capd_0\NN\1740 is_1\VBZ\836236 inefficient_2\JJ\1740 in_3\IN\13603305 removing_4\VBG\2012344 <e1>piperacillin</e1>_5\NN\3910033 ,_6\,\1740 whereas_7\IN\1740 hemodialysis_8\NN\649760 can_9\MD\3094503 rapidly_10\RB\1740 terminate_11\VB\126264 the_12\DT\1740 piperacillin-induced_13\JJ\1740 <e2>encephalopathy</e2>_14\JJ\1740 ._15\.\1740
D010878_D001927 NONE capd_0\NN\1740 is_1\VBZ\836236 inefficient_2\JJ\1740 in_3\IN\13603305 removing_4\VBG\2012344 piperacillin_5\NN\3910033 ,_6\,\1740 whereas_7\IN\1740 hemodialysis_8\NN\649760 can_9\MD\3094503 rapidly_10\RB\1740 terminate_11\VB\126264 the_12\DT\1740 <e1>piperacillin-induced</e1>_13\JJ\1740 <e2>encephalopathy</e2>_14\JJ\1740 ._15\.\1740
D010878_D006463 NONE <e1>piperacillin-induced</e1>_0\JJ\1740 encephalopathy_1\JJ\1740 should_2\MD\1740 be_3\VB\836236 considered_4\VBN\689344 in_5\IN\13603305 any_6\DT\1740 <e2>uremic</e2>_7\JJ\1740 patients_8\NNS\9898892 with_9\IN\1740 unexplained_10\JJ\1740 neurological_11\JJ\1740 manifestations_12\NNS\7321772 ._13\.\1740
12119460
D005472_D013274 NONE high-dose_0\JJ\1740 <e1>5-fluorouracil</e1>_1\NN\1740 /_2\:\1740 folinic_3\JJ\1740 acid_4\NN\14818238 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 three-weekly_8\JJ\1740 mitomycin_9\NN\2716866 c_10\NN\13714184 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 advanced_15\JJ\1740 <e2>gastric_16\JJ\1740 cancer</e2>_17\NN\14239425 ._18\.\1740
D005472_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 <e1>5-fluorouracil</e1>_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 <e2>gastric_27\JJ\1740 cancer</e2>_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D005472_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 <e1>5-fluorouracil</e1>_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 <e2>agc</e2>_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D005472_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 <e1>5-fu</e1>_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 <e2>gastric_27\JJ\1740 cancer</e2>_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D005472_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 <e1>5-fu</e1>_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 <e2>agc</e2>_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D005472_D013274 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 from_4\IN\1740 february_5\NNP\15209706 ,_6\,\1740 1998_7\CD\1740 to_8\IN\1740 september_9\NNP\15209706 ,_10\,\1740 2000_11\CD\1740 we_12\PRP\1740 recruited_13\VBD\2471690 33_14\CD\1740 patients_15\NNS\9898892 with_16\IN\1740 <e2>agc</e2>_17\NN\1740 to_18\TO\1740 receive_19\VB\2210855 weekly_20\JJ\1740 24-hour_21\JJ\1740 <e1>5-fu</e1>_22\NN\1740 2,600_23\CD\1740 mg/m(2_24\NN\1740 )_25\-RRB-\1740 preceded_26\VBN\2690708 by_27\IN\1740 2-hour_28\JJ\1740 fa_29\NN\6868043 500_30\CD\13745420 mg/m(2_31\NN\1740 )_32\-RRB-\1740 for_33\IN\1740 6_34\CD\13741022 weeks_35\NNS\15113229 ,_36\,\1740 followed_37\VBN\1835496 by_38\IN\1740 a_39\DT\13649268 2-week_40\JJ\1740 rest_41\NN\13809207 period_42\NN\13575869 ._43\.\1740
D005472_D013274 NONE conclusions_0\NNS\5837957 :_1\:\1740 high-dose_2\JJ\1740 <e1>5-fu/fa/mmc</e1>_3\NN\1740 is_4\VBZ\836236 an_5\DT\6697703 effective_6\JJ\1740 and_7\CC\1740 well-tolerated_8\JJ\1740 outpatient_9\JJ\1740 regimen_10\NN\5898568 for_11\IN\1740 <e2>agc</e2>_12\NN\1740 (_13\-LRB-\1740 objective_14\JJ\1740 response_15\NN\11410625 rate_16\NN\13815152 54.6_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D002955_D013274 NONE high-dose_0\JJ\1740 5-fluorouracil_1\NN\1740 /_2\:\1740 <e1>folinic_3\JJ\1740 acid</e1>_4\NN\14818238 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 three-weekly_8\JJ\1740 mitomycin_9\NN\2716866 c_10\NN\13714184 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 advanced_15\JJ\1740 <e2>gastric_16\JJ\1740 cancer</e2>_17\NN\14239425 ._18\.\1740
D002955_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 <e1>folinic_12\JJ\1740 acid</e1>_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 <e2>gastric_27\JJ\1740 cancer</e2>_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D002955_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 <e1>folinic_12\JJ\1740 acid</e1>_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 <e2>agc</e2>_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D002955_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 <e1>fa</e1>_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 <e2>gastric_27\JJ\1740 cancer</e2>_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D002955_D013274 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 <e1>fa</e1>_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 <e2>agc</e2>_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 toxicity_40\NN\13576101 ._41\.\1740
D002955_D013274 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 from_4\IN\1740 february_5\NNP\15209706 ,_6\,\1740 1998_7\CD\1740 to_8\IN\1740 september_9\NNP\15209706 ,_10\,\1740 2000_11\CD\1740 we_12\PRP\1740 recruited_13\VBD\2471690 33_14\CD\1740 patients_15\NNS\9898892 with_16\IN\1740 <e2>agc</e2>_17\NN\1740 to_18\TO\1740 receive_19\VB\2210855 weekly_20\JJ\1740 24-hour_21\JJ\1740 5-fu_22\NN\1740 2,600_23\CD\1740 mg/m(2_24\NN\1740 )_25\-RRB-\1740 preceded_26\VBN\2690708 by_27\IN\1740 2-hour_28\JJ\1740 <e1>fa</e1>_29\NN\6868043 500_30\CD\13745420 mg/m(2_31\NN\1740 )_32\-RRB-\1740 for_33\IN\1740 6_34\CD\13741022 weeks_35\NNS\15113229 ,_36\,\1740 followed_37\VBN\1835496 by_38\IN\1740 a_39\DT\13649268 2-week_40\JJ\1740 rest_41\NN\13809207 period_42\NN\13575869 ._43\.\1740
D002955_D013274 NONE conclusions_0\NNS\5837957 :_1\:\1740 high-dose_2\JJ\1740 <e1>5-fu/fa/mmc</e1>_3\NN\1740 is_4\VBZ\836236 an_5\DT\6697703 effective_6\JJ\1740 and_7\CC\1740 well-tolerated_8\JJ\1740 outpatient_9\JJ\1740 regimen_10\NN\5898568 for_11\IN\1740 <e2>agc</e2>_12\NN\1740 (_13\-LRB-\1740 objective_14\JJ\1740 response_15\NN\11410625 rate_16\NN\13815152 54.6_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D016685_D013274 NONE high-dose_0\JJ\1740 5-fluorouracil_1\NN\1740 /_2\:\1740 folinic_3\JJ\1740 acid_4\NN\14818238 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 three-weekly_8\JJ\1740 <e1>mitomycin_9\NN\2716866 c</e1>_10\NN\13714184 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 advanced_15\JJ\1740 <e2>gastric_16\JJ\1740 cancer</e2>_17\NN\14239425 ._18\.\1740
D016685_D013274 NONE conclusions_0\NNS\5837957 :_1\:\1740 high-dose_2\JJ\1740 <e1>5-fu/fa/mmc</e1>_3\NN\1740 is_4\VBZ\836236 an_5\DT\6697703 effective_6\JJ\1740 and_7\CC\1740 well-tolerated_8\JJ\1740 outpatient_9\JJ\1740 regimen_10\NN\5898568 for_11\IN\1740 <e2>agc</e2>_12\NN\1740 (_13\-LRB-\1740 objective_14\JJ\1740 response_15\NN\11410625 rate_16\NN\13815152 54.6_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D005472_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 <e1>5-fluorouracil</e1>_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 <e2>toxicity</e2>_40\NN\13576101 ._41\.\1740
D005472_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 <e1>5-fu</e1>_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 <e2>toxicity</e2>_40\NN\13576101 ._41\.\1740
D005472_D064420 NONE in_0\IN\13603305 a_1\DT\13649268 previous_2\JJ\1740 phase_3\NN\15113229 ii_4\CD\13741022 study_5\NN\635850 with_6\IN\1740 3-weekly_7\JJ\1740 bolus_8\NN\13899404 <e1>5-fu</e1>_9\NN\1740 ,_10\,\1740 fa_11\NN\6868043 and_12\CC\1740 mitomycin_13\NN\2716866 c_14\NN\13714184 (_15\-LRB-\1740 mmc_16\NN\1740 )_17\-RRB-\1740 we_18\PRP\1740 found_19\VBD\2426171 a_20\DT\13649268 low_21\JJ\1740 <e2>toxicity</e2>_22\NN\13576101 rate_23\NN\13815152 and_24\CC\1740 response_25\NN\11410625 rates_26\NNS\13308999 comparable_27\JJ\1740 to_28\IN\1740 those_29\DT\1740 of_30\IN\1740 regimens_31\NNS\5898568 such_32\JJ\1740 as_33\IN\14622893 elf_34\NN\9540430 ,_35\,\1740 fam_36\NN\1740 or_37\CC\3541091 famtx_38\NNP\1740 ,_39\,\1740 and_40\CC\1740 a_41\DT\13649268 promising_42\JJ\1740 median_43\JJ\1740 overall_44\JJ\1740 survival_45\NN\13961642 ._46\.\1740
D002955_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 <e1>folinic_12\JJ\1740 acid</e1>_13\NN\14818238 (_14\-LRB-\1740 fa_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 <e2>toxicity</e2>_40\NN\13576101 ._41\.\1740
D002955_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 24-hour_3\JJ\1740 continuous_4\JJ\1740 infusion_5\NN\14589223 of_6\IN\1740 5-fluorouracil_7\NN\1740 (_8\-LRB-\1740 5-fu_9\NN\1740 )_10\-RRB-\1740 and_11\CC\1740 folinic_12\JJ\1740 acid_13\NN\14818238 (_14\-LRB-\1740 <e1>fa</e1>_15\NN\6868043 )_16\-RRB-\1740 as_17\IN\14622893 part_18\NN\31921 of_19\IN\1740 several_20\JJ\1740 new_21\JJ\1740 multidrug_22\NN\1740 chemotherapy_23\NN\661091 regimens_24\NNS\5898568 in_25\IN\13603305 advanced_26\JJ\1740 gastric_27\JJ\1740 cancer_28\NN\14239425 (_29\-LRB-\1740 agc_30\NN\1740 )_31\-RRB-\1740 has_32\VBZ\2108377 shown_33\VBN\2137132 to_34\TO\1740 be_35\VB\836236 effective_36\JJ\1740 ,_37\,\1740 with_38\IN\1740 low_39\JJ\1740 <e2>toxicity</e2>_40\NN\13576101 ._41\.\1740
D002955_D064420 NONE in_0\IN\13603305 a_1\DT\13649268 previous_2\JJ\1740 phase_3\NN\15113229 ii_4\CD\13741022 study_5\NN\635850 with_6\IN\1740 3-weekly_7\JJ\1740 bolus_8\NN\13899404 5-fu_9\NN\1740 ,_10\,\1740 <e1>fa</e1>_11\NN\6868043 and_12\CC\1740 mitomycin_13\NN\2716866 c_14\NN\13714184 (_15\-LRB-\1740 mmc_16\NN\1740 )_17\-RRB-\1740 we_18\PRP\1740 found_19\VBD\2426171 a_20\DT\13649268 low_21\JJ\1740 <e2>toxicity</e2>_22\NN\13576101 rate_23\NN\13815152 and_24\CC\1740 response_25\NN\11410625 rates_26\NNS\13308999 comparable_27\JJ\1740 to_28\IN\1740 those_29\DT\1740 of_30\IN\1740 regimens_31\NNS\5898568 such_32\JJ\1740 as_33\IN\14622893 elf_34\NN\9540430 ,_35\,\1740 fam_36\NN\1740 or_37\CC\3541091 famtx_38\NNP\1740 ,_39\,\1740 and_40\CC\1740 a_41\DT\13649268 promising_42\JJ\1740 median_43\JJ\1740 overall_44\JJ\1740 survival_45\NN\13961642 ._46\.\1740
D016685_D064420 NONE in_0\IN\13603305 a_1\DT\13649268 previous_2\JJ\1740 phase_3\NN\15113229 ii_4\CD\13741022 study_5\NN\635850 with_6\IN\1740 3-weekly_7\JJ\1740 bolus_8\NN\13899404 5-fu_9\NN\1740 ,_10\,\1740 fa_11\NN\6868043 and_12\CC\1740 <e1>mitomycin_13\NN\2716866 c</e1>_14\NN\13714184 (_15\-LRB-\1740 mmc_16\NN\1740 )_17\-RRB-\1740 we_18\PRP\1740 found_19\VBD\2426171 a_20\DT\13649268 low_21\JJ\1740 <e2>toxicity</e2>_22\NN\13576101 rate_23\NN\13815152 and_24\CC\1740 response_25\NN\11410625 rates_26\NNS\13308999 comparable_27\JJ\1740 to_28\IN\1740 those_29\DT\1740 of_30\IN\1740 regimens_31\NNS\5898568 such_32\JJ\1740 as_33\IN\14622893 elf_34\NN\9540430 ,_35\,\1740 fam_36\NN\1740 or_37\CC\3541091 famtx_38\NNP\1740 ,_39\,\1740 and_40\CC\1740 a_41\DT\13649268 promising_42\JJ\1740 median_43\JJ\1740 overall_44\JJ\1740 survival_45\NN\13961642 ._46\.\1740
D016685_D064420 NONE in_0\IN\13603305 a_1\DT\13649268 previous_2\JJ\1740 phase_3\NN\15113229 ii_4\CD\13741022 study_5\NN\635850 with_6\IN\1740 3-weekly_7\JJ\1740 bolus_8\NN\13899404 5-fu_9\NN\1740 ,_10\,\1740 fa_11\NN\6868043 and_12\CC\1740 mitomycin_13\NN\2716866 c_14\NN\13714184 (_15\-LRB-\1740 <e1>mmc</e1>_16\NN\1740 )_17\-RRB-\1740 we_18\PRP\1740 found_19\VBD\2426171 a_20\DT\13649268 low_21\JJ\1740 <e2>toxicity</e2>_22\NN\13576101 rate_23\NN\13815152 and_24\CC\1740 response_25\NN\11410625 rates_26\NNS\13308999 comparable_27\JJ\1740 to_28\IN\1740 those_29\DT\1740 of_30\IN\1740 regimens_31\NNS\5898568 such_32\JJ\1740 as_33\IN\14622893 elf_34\NN\9540430 ,_35\,\1740 fam_36\NN\1740 or_37\CC\3541091 famtx_38\NNP\1740 ,_39\,\1740 and_40\CC\1740 a_41\DT\13649268 promising_42\JJ\1740 median_43\JJ\1740 overall_44\JJ\1740 survival_45\NN\13961642 ._46\.\1740
D002945_D006463 NONE it_0\PRP\6125041 may_1\MD\15209706 serve_2\VB\2669789 as_3\IN\14622893 an_4\DT\6697703 alternative_5\NN\5788149 to_6\IN\1740 <e1>cisplatin-containing</e1>_7\JJ\1740 regimens_8\NNS\5898568 ;_9\:\1740 however_10\RB\1740 ,_11\,\1740 it_12\PRP\6125041 has_13\VBZ\2108377 to_14\TO\1740 be_15\VB\836236 considered_16\VBN\689344 that_17\IN\1740 possibly_18\RB\1740 <e2>hus</e2>_19\NNP\1740 may_20\MD\15209706 occur_21\VB\2623529 ._22\.\1740
12912689
D016190_D012175 NONE ocular_0\JJ\1740 motility_1\NN\4773351 changes_2\NNS\7283608 after_3\IN\1740 subtenon_4\NN\1740 <e1>carboplatin</e1>_5\NN\1740 chemotherapy_6\NN\661091 for_7\IN\1740 <e2>retinoblastoma</e2>_8\NN\14239425 ._9\.\1740
D016190_D012175 NONE background_0\NN\4921011 :_1\:\1740 focal_2\JJ\1740 subtenon_3\NN\1740 <e1>carboplatin</e1>_4\NN\1740 injections_5\NNS\320852 have_6\VBP\2108377 recently_7\RB\1740 been_8\VBN\836236 used_9\VBN\1156834 as_10\IN\14622893 a_11\DT\13649268 presumably_12\RB\1740 toxicity-free_13\JJ\1740 adjunct_14\NN\9312645 to_15\TO\1740 systemic_16\JJ\1740 chemotherapy_17\NN\661091 for_18\IN\1740 intraocular_19\JJ\1740 <e2>retinoblastoma</e2>_20\NN\14239425 ._21\.\1740
D016190_D012175 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 noted_3\VBD\1009240 abnormal_4\JJ\1740 ocular_5\JJ\1740 motility_6\NN\4773351 in_7\IN\13603305 10_8\CD\13745420 consecutive_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 <e2>retinoblastoma</e2>_12\NN\14239425 who_13\WP\8299493 had_14\VBD\2108377 received_15\VBN\2210855 subtenon_16\NN\1740 <e1>carboplatin</e1>_17\NN\1740 ._18\.\1740
D016190_D012175 NONE results_0\NNS\34213 :_1\:\1740 limitation_2\NN\5846054 of_3\IN\1740 ocular_4\JJ\1740 motility_5\NN\4773351 was_6\VBD\836236 detected_7\VBN\2163746 in_8\IN\13603305 all_9\DT\1740 12_10\CD\13745420 eyes_11\NNS\5945642 of_12\IN\1740 10_13\CD\13745420 patients_14\NNS\9898892 treated_15\VBN\2376958 for_16\IN\1740 intraocular_17\JJ\1740 <e2>retinoblastoma</e2>_18\NN\14239425 with_19\IN\1740 1_20\CD\13741022 to_21\TO\1740 6_22\CD\13741022 injections_23\NNS\320852 of_24\IN\1740 subtenon_25\NN\1740 <e1>carboplatin</e1>_26\NN\1740 as_27\IN\14622893 part_28\NN\31921 of_29\IN\1740 multimodality_30\NN\1740 therapy_31\NN\657604 ._32\.\1740
D016190_D064420 NONE background_0\NN\4921011 :_1\:\1740 focal_2\JJ\1740 subtenon_3\NN\1740 <e1>carboplatin</e1>_4\NN\1740 injections_5\NNS\320852 have_6\VBP\2108377 recently_7\RB\1740 been_8\VBN\836236 used_9\VBN\1156834 as_10\IN\14622893 a_11\DT\13649268 presumably_12\RB\1740 <e2>toxicity-free</e2>_13\JJ\1740 adjunct_14\NN\9312645 to_15\TO\1740 systemic_16\JJ\1740 chemotherapy_17\NN\661091 for_18\IN\1740 intraocular_19\JJ\1740 retinoblastoma_20\NN\14239425 ._21\.\1740
D016190_D064420 NONE subtenon_0\NNP\1740 <e1>carboplatin</e1>_1\NN\1740 is_2\VBZ\836236 not_3\RB\1740 free_4\JJ\1740 of_5\IN\1740 <e2>toxicity</e2>_6\NN\13576101 ,_7\,\1740 and_8\CC\1740 its_9\PRP$\6125041 use_10\NN\407535 is_11\VBZ\836236 best_12\RBS\1740 restricted_13\JJ\1740 to_14\TO\1740 specific_15\JJ\1740 indications_16\NNS\33020 ._17\.\1740
D016190_D015835 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 our_4\PRP$\1740 clinical_5\JJ\1740 experience_6\NN\5984287 with_7\IN\1740 <e2>abnormal_8\JJ\1740 ocular_9\JJ\1740 motility</e2>_10\NN\4773351 in_11\IN\13603305 patients_12\NNS\9898892 treated_13\VBN\2376958 with_14\IN\1740 subtenon_15\NN\1740 <e1>carboplatin</e1>_16\NN\1740 chemotherapy_17\NN\661091 ._18\.\1740
D016190_D015835 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 noted_3\VBD\1009240 <e2>abnormal_4\JJ\1740 ocular_5\JJ\1740 motility</e2>_6\NN\4773351 in_7\IN\13603305 10_8\CD\13745420 consecutive_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 retinoblastoma_12\NN\14239425 who_13\WP\8299493 had_14\VBD\2108377 received_15\VBN\2210855 subtenon_16\NN\1740 <e1>carboplatin</e1>_17\NN\1740 ._18\.\1740
D016190_D005355 CID conclusions_0\NNS\5837957 :_1\:\1740 subtenon_2\NNP\1740 <e1>carboplatin</e1>_3\NN\1740 chemotherapy_4\NN\661091 is_5\VBZ\836236 associated_6\VBN\628491 with_7\IN\1740 significant_8\JJ\1740 <e2>fibrosis</e2>_9\NN\14204950 of_10\IN\1740 orbital_11\JJ\1740 soft_12\JJ\1740 tissues_13\NNS\5220461 ,_14\,\1740 leading_15\VBG\1752884 to_16\TO\1740 mechanical_17\JJ\1740 restriction_18\NN\5846054 of_19\IN\1740 eye_20\NN\5299178 movements_21\NNS\191142 and_22\CC\1740 making_23\VBG\126264 subsequent_24\JJ\1740 enucleation_25\NN\671351 difficult_26\JJ\1740 ._27\.\1740
9158667
D014212_D013927 CID <e2>thrombotic</e2>_0\JJ\1740 complications_1\NNS\1073995 in_2\IN\13603305 acute_3\JJ\1740 promyelocytic_4\JJ\1740 leukemia_5\NN\14239918 during_6\IN\1740 <e1>all-trans-retinoic_7\JJ\1740 acid</e1>_8\NN\14818238 therapy_9\NN\657604 ._10\.\1740
D014212_D015473 NONE thrombotic_0\JJ\1740 complications_1\NNS\1073995 in_2\IN\13603305 <e2>acute_3\JJ\1740 promyelocytic_4\JJ\1740 leukemia</e2>_5\NN\14239918 during_6\IN\1740 <e1>all-trans-retinoic_7\JJ\1740 acid</e1>_8\NN\14818238 therapy_9\NN\657604 ._10\.\1740
D014212_D015473 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 <e2>acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia</e2>_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 <e1>all-trans-retinoic_25\JJ\1740 acid</e1>_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_D015473 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 <e2>apl</e2>_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 <e1>all-trans-retinoic_25\JJ\1740 acid</e1>_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_D015473 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 <e2>acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia</e2>_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 <e1>atra</e1>_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_D015473 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 <e2>apl</e2>_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 <e1>atra</e1>_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_D015473 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 acute_5\JJ\1740 renal_6\JJ\1740 failure_7\NN\66216 in_8\IN\13603305 an_9\DT\6697703 <e2>apl</e2>_10\NN\1740 patient_11\NN\9898892 treated_12\VBN\2376958 with_13\IN\1740 <e1>atra</e1>_14\NN\1740 alone_15\RB\1740 ._16\.\1740
D014212_D015473 NONE this_0\DT\1740 case_1\NN\7283608 further_2\RB\1740 supports_3\VBZ\2199590 the_4\DT\1740 concern_5\NN\5682950 about_6\IN\1740 thromboembolic_7\NN\1740 complications_8\NNS\1073995 associated_9\VBN\628491 with_10\IN\1740 <e1>atra</e1>_11\NN\1740 therapy_12\NN\657604 in_13\IN\13603305 <e2>apl</e2>_14\NN\1740 patients_15\NNS\9898892 ._16\.\1740
D014212_D015473 NONE the_0\DT\1740 patients_1\NNS\9898892 ,_2\,\1740 a_3\DT\13649268 43-year-old_4\JJ\1740 man_5\NN\9605289 ,_6\,\1740 presented_7\VBD\2137132 all_8\PDT\1740 the_9\DT\1740 signs_10\NNS\6643763 and_11\CC\1740 symptoms_12\NNS\5823932 of_13\IN\1740 <e2>apl</e2>_14\NN\1740 and_15\CC\1740 was_16\VBD\836236 included_17\VBN\690614 in_18\IN\13603305 a_19\DT\13649268 treatment_20\NN\654885 protocol_21\NN\6652242 with_22\IN\1740 <e1>atra</e1>_23\NN\1740 ._24\.\1740
D014212_D015473 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>atra</e1>_3\NN\1740 is_4\VBZ\836236 a_5\DT\13649268 valid_6\JJ\1740 therapeutic_7\JJ\1740 choice_8\NN\5788149 for_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 <e2>apl</e2>_12\NN\1740 ,_13\,\1740 although_14\IN\1740 the_15\DT\1740 procoagulant_16\JJ\1740 tendency_17\NN\6193203 is_18\VBZ\836236 not_19\RB\1740 completely_20\RB\1740 corrected_21\VBN\138508 ._22\.\1740
D014212_D058186 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 <e1>all-trans-retinoic_25\JJ\1740 acid</e1>_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_D058186 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 <e1>atra</e1>_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_D058186 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>acute_5\JJ\1740 renal_6\JJ\1740 failure</e2>_7\NN\66216 in_8\IN\13603305 an_9\DT\6697703 apl_10\NN\1740 patient_11\NN\9898892 treated_12\VBN\2376958 with_13\IN\1740 <e1>atra</e1>_14\NN\1740 alone_15\RB\1740 ._16\.\1740
D014212_-1 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 <e2>occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels</e2>_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 <e1>all-trans-retinoic_25\JJ\1740 acid</e1>_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_-1 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 <e2>occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels</e2>_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 <e1>atra</e1>_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 tranexamic_31\JJ\1740 acid_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014148_D058186 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>acute_3\JJ\1740 renal_4\JJ\1740 failure</e2>_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 <e1>tranexamic_31\JJ\1740 acid</e1>_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014148_-1 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 <e2>occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels</e2>_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 <e1>tranexamic_31\JJ\1740 acid</e1>_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014148_D015473 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 <e2>acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia</e2>_19\NN\14239918 (_20\-LRB-\1740 apl_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 <e1>tranexamic_31\JJ\1740 acid</e1>_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014148_D015473 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 renal_4\JJ\1740 failure_5\NN\66216 ,_6\,\1740 due_7\JJ\1740 to_8\TO\1740 occlusion_9\NN\14081375 of_10\IN\1740 renal_11\JJ\1740 vessels_12\NNS\5246511 in_13\IN\13603305 a_14\DT\13649268 patient_15\NN\9898892 with_16\IN\1740 acute_17\JJ\1740 promyelocytic_18\JJ\1740 leukemia_19\NN\14239918 (_20\-LRB-\1740 <e2>apl</e2>_21\NN\1740 )_22\-RRB-\1740 treated_23\VBN\2376958 with_24\IN\1740 all-trans-retinoic_25\JJ\1740 acid_26\NN\14818238 (_27\-LRB-\1740 atra_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 <e1>tranexamic_31\JJ\1740 acid</e1>_32\NN\14818238 has_33\VBZ\2108377 been_34\VBN\836236 described_35\VBN\1001294 recently_36\RB\1740 ._37\.\1740
D014212_D013923 NONE this_0\DT\1740 case_1\NN\7283608 further_2\RB\1740 supports_3\VBZ\2199590 the_4\DT\1740 concern_5\NN\5682950 about_6\IN\1740 <e2>thromboembolic</e2>_7\NN\1740 complications_8\NNS\1073995 associated_9\VBN\628491 with_10\IN\1740 <e1>atra</e1>_11\NN\1740 therapy_12\NN\657604 in_13\IN\13603305 apl_14\NN\1740 patients_15\NNS\9898892 ._16\.\1740
D006493_D013927 NONE <e2>thrombotic</e2>_0\JJ\1740 events_1\NNS\23100 ,_2\,\1740 however_3\RB\1740 ,_4\,\1740 could_5\MD\1740 be_6\VB\836236 avoided_7\VBN\2452885 by_8\IN\1740 using_9\VBG\1156834 low-dose_10\JJ\1740 <e1>heparin</e1>_11\NN\2718259 ._12\.\1740
15265979
D000638_D056486 CID <e1>amiodarone</e1>_0\RB\1740 ,_1\,\1740 an_2\DT\6697703 efficacious_3\JJ\1740 and_4\CC\1740 widely_5\RB\1740 used_6\VBN\1156834 antiarrhythmic_7\JJ\1740 agent_8\NN\7347 ,_9\,\1740 has_10\VBZ\2108377 been_11\VBN\836236 reported_12\VBN\831651 to_13\TO\1740 cause_14\VB\1617192 <e2>hepatotoxicity</e2>_15\NN\1740 in_16\IN\13603305 some_17\DT\1740 patients_18\NNS\9898892 ._19\.\1740
D000638_D056486 CID these_0\DT\1740 results_1\NNS\34213 provide_2\VBP\2199590 important_3\JJ\1740 new_4\JJ\1740 mechanistic_5\JJ\1740 information_6\NN\6598915 regarding_7\VBG\689344 the_8\DT\1740 <e2>hepatotoxic</e2>_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 <e1>amiodarone</e1>_12\NN\2715941 and_13\CC\1740 indicate_14\VBP\952524 that_15\IN\1740 pparalpha_16\NN\1740 protects_17\VBZ\1127795 against_18\IN\1740 amiodarone-induced_19\JJ\1740 hepatotoxicity_20\NN\1740 ._21\.\1740
D000638_D056486 CID these_0\DT\1740 results_1\NNS\34213 provide_2\VBP\2199590 important_3\JJ\1740 new_4\JJ\1740 mechanistic_5\JJ\1740 information_6\NN\6598915 regarding_7\VBG\689344 the_8\DT\1740 hepatotoxic_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 <e1>amiodarone</e1>_12\NN\2715941 and_13\CC\1740 indicate_14\VBP\952524 that_15\IN\1740 pparalpha_16\NN\1740 protects_17\VBZ\1127795 against_18\IN\1740 amiodarone-induced_19\JJ\1740 <e2>hepatotoxicity</e2>_20\NN\1740 ._21\.\1740
D000638_D056486 CID these_0\DT\1740 results_1\NNS\34213 provide_2\VBP\2199590 important_3\JJ\1740 new_4\JJ\1740 mechanistic_5\JJ\1740 information_6\NN\6598915 regarding_7\VBG\689344 the_8\DT\1740 <e2>hepatotoxic</e2>_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 amiodarone_12\NN\2715941 and_13\CC\1740 indicate_14\VBP\952524 that_15\IN\1740 pparalpha_16\NN\1740 protects_17\VBZ\1127795 against_18\IN\1740 <e1>amiodarone-induced</e1>_19\JJ\1740 hepatotoxicity_20\NN\1740 ._21\.\1740
D000638_D056486 CID these_0\DT\1740 results_1\NNS\34213 provide_2\VBP\2199590 important_3\JJ\1740 new_4\JJ\1740 mechanistic_5\JJ\1740 information_6\NN\6598915 regarding_7\VBG\689344 the_8\DT\1740 hepatotoxic_9\JJ\1740 effects_10\NNS\13245626 of_11\IN\1740 amiodarone_12\NN\2715941 and_13\CC\1740 indicate_14\VBP\952524 that_15\IN\1740 pparalpha_16\NN\1740 protects_17\VBZ\1127795 against_18\IN\1740 <e1>amiodarone-induced</e1>_19\JJ\1740 <e2>hepatotoxicity</e2>_20\NN\1740 ._21\.\1740
D000638_D006529 CID <e1>amiodarone</e1>_0\NN\2715941 induced_1\VBD\1627355 <e2>hepatomegaly</e2>_2\NN\14501726 ,_3\,\1740 hepatocyte_4\NN\1740 microvesicular_5\JJ\1740 lipid_6\NN\14944888 accumulation_7\NN\13497135 ,_8\,\1740 and_9\CC\1740 a_10\DT\13649268 significant_11\JJ\1740 decrease_12\NN\7296428 in_13\IN\13603305 serum_14\NN\5397468 triglycerides_15\NNS\14885088 and_16\CC\1740 glucose_17\NN\14710501 ._18\.\1740
D000638_D006529 CID the_0\DT\1740 absence_1\NN\14449405 of_2\IN\1740 induction_3\NN\7450842 of_4\IN\1740 these_5\DT\1740 genes_6\NNS\8459252 as_7\RB\1740 well_8\RB\1740 as_9\IN\14622893 <e2>hepatomegaly</e2>_10\NN\14501726 in_11\IN\13603305 pparalpha_12\NN\1740 knockout_13\NN\10787470 [_14\-LRB-\1740 pparalpha-/-_15\NN\1740 ]_16\-RRB-\1740 mice_17\NNS\2329401 indicated_18\VBD\952524 that_19\IN\1740 the_20\DT\1740 effects_21\NNS\13245626 of_22\IN\1740 <e1>amiodarone</e1>_23\NN\2715941 were_24\VBD\836236 dependent_25\JJ\1740 upon_26\IN\1740 the_27\DT\1740 presence_28\NN\13954253 of_29\IN\1740 a_30\DT\13649268 functional_31\JJ\1740 pparalpha_32\NN\1740 gene_33\NN\8459252 ._34\.\1740
D014280_D006529 NONE amiodarone_0\NN\2715941 induced_1\VBD\1627355 <e2>hepatomegaly</e2>_2\NN\14501726 ,_3\,\1740 hepatocyte_4\NN\1740 microvesicular_5\JJ\1740 lipid_6\NN\14944888 accumulation_7\NN\13497135 ,_8\,\1740 and_9\CC\1740 a_10\DT\13649268 significant_11\JJ\1740 decrease_12\NN\7296428 in_13\IN\13603305 serum_14\NN\5397468 <e1>triglycerides</e1>_15\NNS\14885088 and_16\CC\1740 glucose_17\NN\14710501 ._18\.\1740
D005947_D006529 NONE amiodarone_0\NN\2715941 induced_1\VBD\1627355 <e2>hepatomegaly</e2>_2\NN\14501726 ,_3\,\1740 hepatocyte_4\NN\1740 microvesicular_5\JJ\1740 lipid_6\NN\14944888 accumulation_7\NN\13497135 ,_8\,\1740 and_9\CC\1740 a_10\DT\13649268 significant_11\JJ\1740 decrease_12\NN\7296428 in_13\IN\13603305 serum_14\NN\5397468 triglycerides_15\NNS\14885088 and_16\CC\1740 <e1>glucose</e1>_17\NN\14710501 ._18\.\1740
D000638_D015431 NONE compared_0\VBN\644583 to_1\TO\1740 wild-type_2\JJ\1740 mice_3\NNS\2329401 ,_4\,\1740 treatment_5\NN\654885 of_6\IN\1740 pparalpha-/-_7\NN\1740 mice_8\NNS\2329401 with_9\IN\1740 <e1>amiodarone</e1>_10\NN\2715941 resulted_11\VBD\2633881 in_12\IN\13603305 an_13\DT\6697703 increased_14\VBN\169651 rate_15\NN\13815152 and_16\CC\1740 extent_17\NN\13939892 of_18\IN\1740 total_19\JJ\1740 body_20\NN\19128 <e2>weight_21\NN\5009170 loss</e2>_22\NN\13252973 ._23\.\1740
D000638_D006528 NONE the_0\DT\1740 inability_1\NN\23271 of_2\IN\1740 <e1>amiodarone</e1>_3\NN\2715941 to_4\TO\1740 directly_5\RB\1740 activate_6\VB\1641914 either_7\CC\1740 human_8\JJ\1740 or_9\CC\3541091 mouse_10\NN\2329401 pparalpha_11\NN\1740 transiently_12\RB\1740 expressed_13\VBN\928630 in_14\IN\13603305 human_15\JJ\1740 hepg2_16\NN\1740 <e2>hepatoma</e2>_17\NN\14242337 cells_18\NNS\3080309 indicates_19\VBZ\952524 that_20\IN\1740 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 amiodarone_24\NN\2715941 on_25\IN\1740 the_26\DT\1740 function_27\NN\13783581 of_28\IN\1740 this_29\DT\1740 receptor_30\NN\5225602 were_31\VBD\836236 indirect_32\JJ\1740 ._33\.\1740
D000638_D006528 NONE the_0\DT\1740 inability_1\NN\23271 of_2\IN\1740 amiodarone_3\NN\2715941 to_4\TO\1740 directly_5\RB\1740 activate_6\VB\1641914 either_7\CC\1740 human_8\JJ\1740 or_9\CC\3541091 mouse_10\NN\2329401 pparalpha_11\NN\1740 transiently_12\RB\1740 expressed_13\VBN\928630 in_14\IN\13603305 human_15\JJ\1740 hepg2_16\NN\1740 <e2>hepatoma</e2>_17\NN\14242337 cells_18\NNS\3080309 indicates_19\VBZ\952524 that_20\IN\1740 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 <e1>amiodarone</e1>_24\NN\2715941 on_25\IN\1740 the_26\DT\1740 function_27\NN\13783581 of_28\IN\1740 this_29\DT\1740 receptor_30\NN\5225602 were_31\VBD\836236 indirect_32\JJ\1740 ._33\.\1740
1117341
D015119_D006943 CID <e2>hyperglycemic</e2>_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>amino</e1>_3\NN\14621446 compounds_4\NNS\5869584 structurally_5\RB\1740 related_6\JJ\1740 to_7\TO\1740 caproate_8\VB\1740 in_9\IN\13603305 rats_10\NNS\2329401 ._11\.\1740
D015119_D006943 CID the_0\DT\1740 chronic_1\JJ\1740 feeding_2\NN\838098 of_3\IN\1740 small_4\JJ\1740 amounts_5\NNS\13329641 (_6\-LRB-\1740 0.3_7\CD\1740 -_8\SYM\1740 3_9\CD\13741022 %_10\NN\1740 of_11\IN\1740 diet_12\JJ\1740 weight_13\NN\5009170 )_14\-RRB-\1740 of_15\IN\1740 certain_16\JJ\1740 <e1>amino</e1>_17\NN\14621446 derivatives_18\NNS\5802185 of_19\IN\1740 caproate_20\NN\1740 resulted_21\VBD\2633881 in_22\IN\13603305 <e2>hyperglycemia</e2>_23\NN\14299637 ,_24\,\1740 an_25\DT\6697703 elevated_26\JJ\1740 glucose_27\NN\14710501 tolerance_28\NN\5032565 curve_29\NN\13863771 and_30\CC\1740 ,_31\,\1740 occasionally_32\RB\1740 ,_33\,\1740 glucosuria_34\NNS\14267841 ._35\.\1740
C037652_D006943 NONE <e2>hyperglycemic</e2>_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 amino_3\NN\14621446 compounds_4\NNS\5869584 structurally_5\RB\1740 related_6\JJ\1740 to_7\TO\1740 <e1>caproate</e1>_8\VB\1740 in_9\IN\13603305 rats_10\NNS\2329401 ._11\.\1740
C037652_D006943 NONE the_0\DT\1740 chronic_1\JJ\1740 feeding_2\NN\838098 of_3\IN\1740 small_4\JJ\1740 amounts_5\NNS\13329641 (_6\-LRB-\1740 0.3_7\CD\1740 -_8\SYM\1740 3_9\CD\13741022 %_10\NN\1740 of_11\IN\1740 diet_12\JJ\1740 weight_13\NN\5009170 )_14\-RRB-\1740 of_15\IN\1740 certain_16\JJ\1740 amino_17\NN\14621446 derivatives_18\NNS\5802185 of_19\IN\1740 <e1>caproate</e1>_20\NN\1740 resulted_21\VBD\2633881 in_22\IN\13603305 <e2>hyperglycemia</e2>_23\NN\14299637 ,_24\,\1740 an_25\DT\6697703 elevated_26\JJ\1740 glucose_27\NN\14710501 tolerance_28\NN\5032565 curve_29\NN\13863771 and_30\CC\1740 ,_31\,\1740 occasionally_32\RB\1740 ,_33\,\1740 glucosuria_34\NNS\14267841 ._35\.\1740
D015119_D006030 NONE the_0\DT\1740 chronic_1\JJ\1740 feeding_2\NN\838098 of_3\IN\1740 small_4\JJ\1740 amounts_5\NNS\13329641 (_6\-LRB-\1740 0.3_7\CD\1740 -_8\SYM\1740 3_9\CD\13741022 %_10\NN\1740 of_11\IN\1740 diet_12\JJ\1740 weight_13\NN\5009170 )_14\-RRB-\1740 of_15\IN\1740 certain_16\JJ\1740 <e1>amino</e1>_17\NN\14621446 derivatives_18\NNS\5802185 of_19\IN\1740 caproate_20\NN\1740 resulted_21\VBD\2633881 in_22\IN\13603305 hyperglycemia_23\NN\14299637 ,_24\,\1740 an_25\DT\6697703 elevated_26\JJ\1740 glucose_27\NN\14710501 tolerance_28\NN\5032565 curve_29\NN\13863771 and_30\CC\1740 ,_31\,\1740 occasionally_32\RB\1740 ,_33\,\1740 <e2>glucosuria</e2>_34\NNS\14267841 ._35\.\1740
C037652_D006030 NONE the_0\DT\1740 chronic_1\JJ\1740 feeding_2\NN\838098 of_3\IN\1740 small_4\JJ\1740 amounts_5\NNS\13329641 (_6\-LRB-\1740 0.3_7\CD\1740 -_8\SYM\1740 3_9\CD\13741022 %_10\NN\1740 of_11\IN\1740 diet_12\JJ\1740 weight_13\NN\5009170 )_14\-RRB-\1740 of_15\IN\1740 certain_16\JJ\1740 amino_17\NN\14621446 derivatives_18\NNS\5802185 of_19\IN\1740 <e1>caproate</e1>_20\NN\1740 resulted_21\VBD\2633881 in_22\IN\13603305 hyperglycemia_23\NN\14299637 ,_24\,\1740 an_25\DT\6697703 elevated_26\JJ\1740 glucose_27\NN\14710501 tolerance_28\NN\5032565 curve_29\NN\13863771 and_30\CC\1740 ,_31\,\1740 occasionally_32\RB\1740 ,_33\,\1740 <e2>glucosuria</e2>_34\NNS\14267841 ._35\.\1740
D005947_D006943 NONE the_0\DT\1740 chronic_1\JJ\1740 feeding_2\NN\838098 of_3\IN\1740 small_4\JJ\1740 amounts_5\NNS\13329641 (_6\-LRB-\1740 0.3_7\CD\1740 -_8\SYM\1740 3_9\CD\13741022 %_10\NN\1740 of_11\IN\1740 diet_12\JJ\1740 weight_13\NN\5009170 )_14\-RRB-\1740 of_15\IN\1740 certain_16\JJ\1740 amino_17\NN\14621446 derivatives_18\NNS\5802185 of_19\IN\1740 caproate_20\NN\1740 resulted_21\VBD\2633881 in_22\IN\13603305 <e2>hyperglycemia</e2>_23\NN\14299637 ,_24\,\1740 an_25\DT\6697703 elevated_26\JJ\1740 <e1>glucose</e1>_27\NN\14710501 tolerance_28\NN\5032565 curve_29\NN\13863771 and_30\CC\1740 ,_31\,\1740 occasionally_32\RB\1740 ,_33\,\1740 glucosuria_34\NNS\14267841 ._35\.\1740
D005947_D006030 NONE the_0\DT\1740 chronic_1\JJ\1740 feeding_2\NN\838098 of_3\IN\1740 small_4\JJ\1740 amounts_5\NNS\13329641 (_6\-LRB-\1740 0.3_7\CD\1740 -_8\SYM\1740 3_9\CD\13741022 %_10\NN\1740 of_11\IN\1740 diet_12\JJ\1740 weight_13\NN\5009170 )_14\-RRB-\1740 of_15\IN\1740 certain_16\JJ\1740 amino_17\NN\14621446 derivatives_18\NNS\5802185 of_19\IN\1740 caproate_20\NN\1740 resulted_21\VBD\2633881 in_22\IN\13603305 hyperglycemia_23\NN\14299637 ,_24\,\1740 an_25\DT\6697703 elevated_26\JJ\1740 <e1>glucose</e1>_27\NN\14710501 tolerance_28\NN\5032565 curve_29\NN\13863771 and_30\CC\1740 ,_31\,\1740 occasionally_32\RB\1740 ,_33\,\1740 <e2>glucosuria</e2>_34\NNS\14267841 ._35\.\1740
19108278
D011433_D001145 NONE the_0\DT\1740 biological_1\JJ\1740 properties_2\NNS\32613 of_3\IN\1740 the_4\DT\1740 optical_5\JJ\1740 isomers_6\NNS\14818238 of_7\IN\1740 <e1>propranolol</e1>_8\NN\1740 and_9\CC\1740 their_10\PRP$\1740 effects_11\NNS\13245626 on_12\IN\1740 <e2>cardiac_13\JJ\1740 arrhythmias</e2>_14\NNS\14103288 ._15\.\1740
D011433_D001145 NONE both_0\DT\1740 isomers_1\NNS\14818238 of_2\IN\1740 <e1>propranolol</e1>_3\NN\1740 were_4\VBD\836236 capable_5\JJ\1740 of_6\IN\1740 preventing_7\VBG\1740 adrenaline-induced_8\JJ\1740 <e2>cardiac_9\JJ\1740 arrhythmias</e2>_10\NNS\14103288 in_11\IN\13603305 cats_12\NNS\2120997 anaesthetized_13\VBN\84738 with_14\IN\1740 halothane_15\NN\3570838 ,_16\,\1740 but_17\CC\1740 the_18\DT\1740 mean_19\NN\6021761 dose_20\NN\3740161 of_21\IN\1740 (-)-propranolol_22\NN\1740 was_23\VBD\836236 0.09+/-0.02_24\CD\1740 mg/kg_25\NN\1740 whereas_26\IN\1740 that_27\DT\1740 of_28\IN\1740 (+)-propranolol_29\NN\1740 was_30\VBD\836236 4.2+/-1.2_31\CD\1740 mg/kg_32\NN\1740 ._33\.\1740
D011433_D001145 NONE both_0\DT\1740 isomers_1\NNS\14818238 of_2\IN\1740 propranolol_3\NN\1740 were_4\VBD\836236 capable_5\JJ\1740 of_6\IN\1740 preventing_7\VBG\1740 adrenaline-induced_8\JJ\1740 <e2>cardiac_9\JJ\1740 arrhythmias</e2>_10\NNS\14103288 in_11\IN\13603305 cats_12\NNS\2120997 anaesthetized_13\VBN\84738 with_14\IN\1740 halothane_15\NN\3570838 ,_16\,\1740 but_17\CC\1740 the_18\DT\1740 mean_19\NN\6021761 dose_20\NN\3740161 of_21\IN\1740 <e1>(-)-propranolol</e1>_22\NN\1740 was_23\VBD\836236 0.09+/-0.02_24\CD\1740 mg/kg_25\NN\1740 whereas_26\IN\1740 that_27\DT\1740 of_28\IN\1740 (+)-propranolol_29\NN\1740 was_30\VBD\836236 4.2+/-1.2_31\CD\1740 mg/kg_32\NN\1740 ._33\.\1740
D011433_D001145 NONE both_0\DT\1740 isomers_1\NNS\14818238 of_2\IN\1740 propranolol_3\NN\1740 were_4\VBD\836236 capable_5\JJ\1740 of_6\IN\1740 preventing_7\VBG\1740 adrenaline-induced_8\JJ\1740 <e2>cardiac_9\JJ\1740 arrhythmias</e2>_10\NNS\14103288 in_11\IN\13603305 cats_12\NNS\2120997 anaesthetized_13\VBN\84738 with_14\IN\1740 halothane_15\NN\3570838 ,_16\,\1740 but_17\CC\1740 the_18\DT\1740 mean_19\NN\6021761 dose_20\NN\3740161 of_21\IN\1740 (-)-propranolol_22\NN\1740 was_23\VBD\836236 0.09+/-0.02_24\CD\1740 mg/kg_25\NN\1740 whereas_26\IN\1740 that_27\DT\1740 of_28\IN\1740 <e1>(+)-propranolol</e1>_29\NN\1740 was_30\VBD\836236 4.2+/-1.2_31\CD\1740 mg/kg_32\NN\1740 ._33\.\1740
D004837_D001145 CID both_0\DT\1740 isomers_1\NNS\14818238 of_2\IN\1740 propranolol_3\NN\1740 were_4\VBD\836236 capable_5\JJ\1740 of_6\IN\1740 preventing_7\VBG\1740 <e1>adrenaline-induced</e1>_8\JJ\1740 <e2>cardiac_9\JJ\1740 arrhythmias</e2>_10\NNS\14103288 in_11\IN\13603305 cats_12\NNS\2120997 anaesthetized_13\VBN\84738 with_14\IN\1740 halothane_15\NN\3570838 ,_16\,\1740 but_17\CC\1740 the_18\DT\1740 mean_19\NN\6021761 dose_20\NN\3740161 of_21\IN\1740 (-)-propranolol_22\NN\1740 was_23\VBD\836236 0.09+/-0.02_24\CD\1740 mg/kg_25\NN\1740 whereas_26\IN\1740 that_27\DT\1740 of_28\IN\1740 (+)-propranolol_29\NN\1740 was_30\VBD\836236 4.2+/-1.2_31\CD\1740 mg/kg_32\NN\1740 ._33\.\1740
D004837_D001145 CID blockade_0\NN\952963 of_1\IN\1740 <e2>arrhythmias</e2>_2\NNS\14103288 with_3\IN\1740 both_4\DT\1740 isomers_5\NNS\14818238 was_6\VBD\836236 surmountable_7\JJ\1740 by_8\IN\1740 increasing_9\VBG\169651 the_10\DT\1740 dose_11\NN\3740161 of_12\IN\1740 <e1>adrenaline.7</e1>_13\NN\1740 ._14\.\1740
D006221_D001145 CID both_0\DT\1740 isomers_1\NNS\14818238 of_2\IN\1740 propranolol_3\NN\1740 were_4\VBD\836236 capable_5\JJ\1740 of_6\IN\1740 preventing_7\VBG\1740 adrenaline-induced_8\JJ\1740 <e2>cardiac_9\JJ\1740 arrhythmias</e2>_10\NNS\14103288 in_11\IN\13603305 cats_12\NNS\2120997 anaesthetized_13\VBN\84738 with_14\IN\1740 <e1>halothane</e1>_15\NN\3570838 ,_16\,\1740 but_17\CC\1740 the_18\DT\1740 mean_19\NN\6021761 dose_20\NN\3740161 of_21\IN\1740 (-)-propranolol_22\NN\1740 was_23\VBD\836236 0.09+/-0.02_24\CD\1740 mg/kg_25\NN\1740 whereas_26\IN\1740 that_27\DT\1740 of_28\IN\1740 (+)-propranolol_29\NN\1740 was_30\VBD\836236 4.2+/-1.2_31\CD\1740 mg/kg_32\NN\1740 ._33\.\1740
D011433_D017180 NONE both_0\DT\1740 isomers_1\NNS\14818238 of_2\IN\1740 <e1>propranolol</e1>_3\NN\1740 were_4\VBD\836236 also_5\RB\1740 capable_6\JJ\1740 of_7\IN\1740 reversing_8\VBG\109660 <e2>ventricular_9\JJ\1740 tachycardia</e2>_10\NN\14110674 caused_11\VBN\1617192 by_12\IN\1740 ouabain_13\NN\1740 in_14\IN\13603305 anaesthetized_15\VBN\84738 cats_16\NNS\2120997 and_17\CC\1740 dogs_18\NNS\2083346 ._19\.\1740
D010042_D017180 CID both_0\DT\1740 isomers_1\NNS\14818238 of_2\IN\1740 propranolol_3\NN\1740 were_4\VBD\836236 also_5\RB\1740 capable_6\JJ\1740 of_7\IN\1740 reversing_8\VBG\109660 <e2>ventricular_9\JJ\1740 tachycardia</e2>_10\NN\14110674 caused_11\VBN\1617192 by_12\IN\1740 <e1>ouabain</e1>_13\NN\1740 in_14\IN\13603305 anaesthetized_15\VBN\84738 cats_16\NNS\2120997 and_17\CC\1740 dogs_18\NNS\2083346 ._19\.\1740
1451544
D017275_D006973 NONE <e1>isradipine</e1>_0\NN\1740 treatment_1\NN\654885 for_2\IN\1740 <e2>hypertension</e2>_3\NN\14057371 in_4\IN\13603305 general_5\JJ\1740 practice_6\NN\407535 in_7\IN\13603305 hong_8\NNP\1740 kong_9\NNP\1740 ._10\.\1740
D017275_D006261 CID the_0\DT\1740 main_1\JJ\1740 side-effects_2\NNS\1740 were_3\VBD\836236 <e2>headache</e2>_4\VBN\1740 ,_5\,\1740 dizziness_6\JJ\1740 ,_7\,\1740 palpitation_8\NN\14299637 and_9\CC\1740 flushing_10\VBG\281101 and_11\CC\1740 these_12\DT\1740 were_13\VBD\836236 not_14\RB\1740 more_15\RBR\1740 frequent_16\JJ\1740 than_17\IN\1740 reported_18\VBN\831651 in_19\IN\13603305 other_20\JJ\1740 studies_21\NNS\635850 with_22\IN\1740 <e1>isradipine</e1>_23\NN\1740 or_24\CC\3541091 with_25\IN\1740 placebo_26\NN\3740161 ._27\.\1740
D017275_D004244 CID the_0\DT\1740 main_1\JJ\1740 side-effects_2\NNS\1740 were_3\VBD\836236 headache_4\VBN\1740 ,_5\,\1740 <e2>dizziness</e2>_6\JJ\1740 ,_7\,\1740 palpitation_8\NN\14299637 and_9\CC\1740 flushing_10\VBG\281101 and_11\CC\1740 these_12\DT\1740 were_13\VBD\836236 not_14\RB\1740 more_15\RBR\1740 frequent_16\JJ\1740 than_17\IN\1740 reported_18\VBN\831651 in_19\IN\13603305 other_20\JJ\1740 studies_21\NNS\635850 with_22\IN\1740 <e1>isradipine</e1>_23\NN\1740 or_24\CC\3541091 with_25\IN\1740 placebo_26\NN\3740161 ._27\.\1740
D017275_-1 NONE the_0\DT\1740 main_1\JJ\1740 side-effects_2\NNS\1740 were_3\VBD\836236 headache_4\VBN\1740 ,_5\,\1740 dizziness_6\JJ\1740 ,_7\,\1740 <e2>palpitation</e2>_8\NN\14299637 and_9\CC\1740 flushing_10\VBG\281101 and_11\CC\1740 these_12\DT\1740 were_13\VBD\836236 not_14\RB\1740 more_15\RBR\1740 frequent_16\JJ\1740 than_17\IN\1740 reported_18\VBN\831651 in_19\IN\13603305 other_20\JJ\1740 studies_21\NNS\635850 with_22\IN\1740 <e1>isradipine</e1>_23\NN\1740 or_24\CC\3541091 with_25\IN\1740 placebo_26\NN\3740161 ._27\.\1740
D017275_D005483 CID the_0\DT\1740 main_1\JJ\1740 side-effects_2\NNS\1740 were_3\VBD\836236 headache_4\VBN\1740 ,_5\,\1740 dizziness_6\JJ\1740 ,_7\,\1740 palpitation_8\NN\14299637 and_9\CC\1740 <e2>flushing</e2>_10\VBG\281101 and_11\CC\1740 these_12\DT\1740 were_13\VBD\836236 not_14\RB\1740 more_15\RBR\1740 frequent_16\JJ\1740 than_17\IN\1740 reported_18\VBN\831651 in_19\IN\13603305 other_20\JJ\1740 studies_21\NNS\635850 with_22\IN\1740 <e1>isradipine</e1>_23\NN\1740 or_24\CC\3541091 with_25\IN\1740 placebo_26\NN\3740161 ._27\.\1740
1395192
D001971_D009203 CID recurrent_0\JJ\1740 <e2>myocardial_1\JJ\1740 infarction</e2>_2\NN\14204950 in_3\IN\13603305 a_4\DT\13649268 postpartum_5\NN\1740 patient_6\NN\9898892 receiving_7\VBG\2210855 <e1>bromocriptine</e1>_8\NN\1740 ._9\.\1740
D001971_D009203 CID <e1>bromocriptine</e1>_0\NN\1740 has_1\VBZ\2108377 been_2\VBN\836236 implicated_3\VBN\2677097 in_4\IN\13603305 several_5\JJ\1740 previous_6\JJ\1740 case_7\NN\7283608 reports_8\NNS\6470073 of_9\IN\1740 <e2>myocardial_10\JJ\1740 infarction</e2>_11\NN\14204950 in_12\IN\13603305 the_13\DT\1740 puerperium_14\NN\15113229 ._15\.\1740
3475563
D001507_D002180 CID rechallenge_0\NN\1740 of_1\IN\1740 patients_2\NNS\9898892 who_3\WP\8299493 developed_4\VBD\1753788 <e2>oral_5\JJ\1740 candidiasis</e2>_6\NN\14176895 or_7\CC\3541091 hoarseness_8\JJ\1740 with_9\IN\1740 <e1>beclomethasone_10\NN\1740 dipropionate</e1>_11\NN\1740 ._12\.\1740
D001507_D002180 CID of_0\IN\1740 158_1\CD\1740 asthmatic_2\JJ\1740 patients_3\NNS\9898892 who_4\WP\8299493 were_5\VBD\836236 placed_6\VBN\1850315 on_7\IN\1740 inhaled_8\VBN\1198101 <e1>beclomethasone</e1>_9\NN\1740 ,_10\,\1740 15_11\CD\13745420 (_12\-LRB-\1740 9.5_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 developed_16\VBD\1753788 either_17\CC\1740 hoarseness_18\NN\4988666 (_19\-LRB-\1740 8)_20\CD\1740 ,_21\,\1740 oral_22\JJ\1740 <e2>thrush</e2>_23\NN\14181713 (_24\-LRB-\1740 6_25\CD\13741022 )_26\-RRB-\1740 ,_27\,\1740 or_28\CC\3541091 both_29\DT\1740 (_30\-LRB-\1740 1_31\CD\13741022 )_32\-RRB-\1740 ._33\.\1740
D001507_D006685 CID rechallenge_0\NN\1740 of_1\IN\1740 patients_2\NNS\9898892 who_3\WP\8299493 developed_4\VBD\1753788 oral_5\JJ\1740 candidiasis_6\NN\14176895 or_7\CC\3541091 <e2>hoarseness</e2>_8\JJ\1740 with_9\IN\1740 <e1>beclomethasone_10\NN\1740 dipropionate</e1>_11\NN\1740 ._12\.\1740
D001507_D006685 CID of_0\IN\1740 158_1\CD\1740 asthmatic_2\JJ\1740 patients_3\NNS\9898892 who_4\WP\8299493 were_5\VBD\836236 placed_6\VBN\1850315 on_7\IN\1740 inhaled_8\VBN\1198101 <e1>beclomethasone</e1>_9\NN\1740 ,_10\,\1740 15_11\CD\13745420 (_12\-LRB-\1740 9.5_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 developed_16\VBD\1753788 either_17\CC\1740 <e2>hoarseness</e2>_18\NN\4988666 (_19\-LRB-\1740 8)_20\CD\1740 ,_21\,\1740 oral_22\JJ\1740 thrush_23\NN\14181713 (_24\-LRB-\1740 6_25\CD\13741022 )_26\-RRB-\1740 ,_27\,\1740 or_28\CC\3541091 both_29\DT\1740 (_30\-LRB-\1740 1_31\CD\13741022 )_32\-RRB-\1740 ._33\.\1740
D001507_D006685 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 patients_3\NNS\9898892 may_4\MD\15209706 be_5\VB\836236 restarted_6\VBN\1857717 on_7\IN\1740 inhaled_8\VBN\1198101 <e1>beclomethasone</e1>_9\NN\1740 when_10\WRB\1740 clinically_11\RB\1740 indicated_12\VBN\952524 ;_13\:\1740 however_14\RB\1740 ,_15\,\1740 because_16\IN\1740 of_17\IN\1740 the_18\DT\1740 high_19\JJ\1740 recurrence_20\NN\7342049 rate_21\NN\13815152 ,_22\,\1740 patients_23\NNS\9898892 who_24\WP\8299493 develop_25\VBP\1753788 <e2>hoarseness</e2>_26\NN\4988666 should_27\MD\1740 not_28\RB\1740 be_29\VB\836236 re-challenged_30\VBN\1740 ._31\.\1740
D001507_D006685 CID concomitant_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 oral_3\JJ\1740 prednisone_4\NN\2721538 and_5\CC\1740 topical_6\JJ\1740 <e1>beclomethasone</e1>_7\NN\1740 may_8\MD\15209706 increase_9\VB\169651 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 developing_13\VBG\1753788 <e2>hoarseness</e2>_14\NN\4988666 or_15\CC\3541091 candidiasis_16\NN\14176895 ._17\.\1740
D001507_D001249 NONE of_0\IN\1740 158_1\CD\1740 <e2>asthmatic</e2>_2\JJ\1740 patients_3\NNS\9898892 who_4\WP\8299493 were_5\VBD\836236 placed_6\VBN\1850315 on_7\IN\1740 inhaled_8\VBN\1198101 <e1>beclomethasone</e1>_9\NN\1740 ,_10\,\1740 15_11\CD\13745420 (_12\-LRB-\1740 9.5_13\CD\1740 %_14\NN\1740 )_15\-RRB-\1740 developed_16\VBD\1753788 either_17\CC\1740 hoarseness_18\NN\4988666 (_19\-LRB-\1740 8)_20\CD\1740 ,_21\,\1740 oral_22\JJ\1740 thrush_23\NN\14181713 (_24\-LRB-\1740 6_25\CD\13741022 )_26\-RRB-\1740 ,_27\,\1740 or_28\CC\3541091 both_29\DT\1740 (_30\-LRB-\1740 1_31\CD\13741022 )_32\-RRB-\1740 ._33\.\1740
D011241_D006685 NONE concomitant_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 oral_3\JJ\1740 <e1>prednisone</e1>_4\NN\2721538 and_5\CC\1740 topical_6\JJ\1740 beclomethasone_7\NN\1740 may_8\MD\15209706 increase_9\VB\169651 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 developing_13\VBG\1753788 <e2>hoarseness</e2>_14\NN\4988666 or_15\CC\3541091 candidiasis_16\NN\14176895 ._17\.\1740
D011241_D002177 NONE concomitant_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 oral_3\JJ\1740 <e1>prednisone</e1>_4\NN\2721538 and_5\CC\1740 topical_6\JJ\1740 beclomethasone_7\NN\1740 may_8\MD\15209706 increase_9\VB\169651 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 developing_13\VBG\1753788 hoarseness_14\NN\4988666 or_15\CC\3541091 <e2>candidiasis</e2>_16\NN\14176895 ._17\.\1740
D001507_D002177 NONE concomitant_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 oral_3\JJ\1740 prednisone_4\NN\2721538 and_5\CC\1740 topical_6\JJ\1740 <e1>beclomethasone</e1>_7\NN\1740 may_8\MD\15209706 increase_9\VB\169651 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 developing_13\VBG\1753788 hoarseness_14\NN\4988666 or_15\CC\3541091 <e2>candidiasis</e2>_16\NN\14176895 ._17\.\1740
11799346
D015662_D001714 CID <e1>cotrimoxazole</e1>_0\NNP\1740 ,_1\,\1740 metronidazole_2\NN\2723292 ,_3\,\1740 and_4\CC\1740 erythromycin_5\NN\2716866 were_6\VBD\836236 involved_7\VBN\2676054 in_8\IN\13603305 15_9\CD\13745420 reported_10\VBN\831651 <e2>manic</e2>_11\JJ\1740 episodes_12\NNS\7283608 ._13\.\1740
D008795_D001714 CID cotrimoxazole_0\NNP\1740 ,_1\,\1740 <e1>metronidazole</e1>_2\NN\2723292 ,_3\,\1740 and_4\CC\1740 erythromycin_5\NN\2716866 were_6\VBD\836236 involved_7\VBN\2676054 in_8\IN\13603305 15_9\CD\13745420 reported_10\VBN\831651 <e2>manic</e2>_11\JJ\1740 episodes_12\NNS\7283608 ._13\.\1740
D004917_D001714 CID cotrimoxazole_0\NNP\1740 ,_1\,\1740 metronidazole_2\NN\2723292 ,_3\,\1740 and_4\CC\1740 <e1>erythromycin</e1>_5\NN\2716866 were_6\VBD\836236 involved_7\VBN\2676054 in_8\IN\13603305 15_9\CD\13745420 reported_10\VBN\831651 <e2>manic</e2>_11\JJ\1740 episodes_12\NNS\7283608 ._13\.\1740
D017291_D001714 CID cases_0\NNS\7283608 reported_1\VBN\831651 by_2\IN\1740 the_3\DT\1740 fda_4\NNP\8337324 showed_5\VBD\2137132 <e1>clarithromycin</e1>_6\NN\1740 and_7\CC\1740 ciprofloxacin_8\NN\2716866 to_9\TO\1740 be_10\VB\836236 the_11\DT\1740 most_12\RBS\1740 frequently_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 the_16\DT\1740 development_17\NN\248977 of_18\IN\1740 <e2>mania</e2>_19\NN\9180259 ._20\.\1740
D002939_D001714 CID cases_0\NNS\7283608 reported_1\VBN\831651 by_2\IN\1740 the_3\DT\1740 fda_4\NNP\8337324 showed_5\VBD\2137132 clarithromycin_6\NN\1740 and_7\CC\1740 <e1>ciprofloxacin</e1>_8\NN\2716866 to_9\TO\1740 be_10\VB\836236 the_11\DT\1740 most_12\RBS\1740 frequently_13\RB\1740 associated_14\VBN\628491 with_15\IN\1740 the_16\DT\1740 development_17\NN\248977 of_18\IN\1740 <e2>mania</e2>_19\NN\9180259 ._20\.\1740
10764869
D016559_D009901 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 bilateral_3\JJ\1740 <e2>optic_4\NN\5299178 neuropathy</e2>_5\JJ\1740 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 on_9\IN\1740 <e1>tacrolimus</e1>_10\NN\1740 (_11\-LRB-\1740 fk506_12\NN\1740 )_13\-RRB-\1740 therapy_14\NN\657604 after_15\IN\1740 liver_16\NN\5298729 transplantation_17\NN\671351 ._18\.\1740
D016559_D009901 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 bilateral_3\JJ\1740 <e2>optic_4\NN\5299178 neuropathy</e2>_5\JJ\1740 in_6\IN\13603305 a_7\DT\13649268 patient_8\NN\9898892 on_9\IN\1740 tacrolimus_10\NN\1740 (_11\-LRB-\1740 <e1>fk506</e1>_12\NN\1740 )_13\-RRB-\1740 therapy_14\NN\657604 after_15\IN\1740 liver_16\NN\5298729 transplantation_17\NN\671351 ._18\.\1740
D016559_D009901 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 bilateral_7\JJ\1740 <e2>optic_8\NN\5299178 neuropathy</e2>_9\JJ\1740 in_10\IN\13603305 a_11\DT\13649268 patient_12\NN\9898892 receiving_13\VBG\2210855 <e1>tacrolimus</e1>_14\NN\1740 (_15\-LRB-\1740 fk_16\NN\1740 506_17\CD\1740 ,_18\,\1740 prograf_19\NNP\1740 ;_20\:\1740 fujisawa_21\NNP\1740 usa_22\NNP\8337324 ,_23\,\1740 inc_24\NNP\8403787 ,_25\,\1740 deerfield_26\NNP\1740 ,_27\,\1740 illinois_28\NNP\9646608 )_29\-RRB-\1740 for_30\IN\1740 immunosuppression_31\NN\13973990 after_32\IN\1740 orthotropic_33\JJ\1740 liver_34\NN\5298729 transplantation_35\NN\671351 ._36\.\1740
D016559_D009901 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 bilateral_7\JJ\1740 <e2>optic_8\NN\5299178 neuropathy</e2>_9\JJ\1740 in_10\IN\13603305 a_11\DT\13649268 patient_12\NN\9898892 receiving_13\VBG\2210855 tacrolimus_14\NN\1740 (_15\-LRB-\1740 <e1>fk_16\NN\1740 506</e1>_17\CD\1740 ,_18\,\1740 prograf_19\NNP\1740 ;_20\:\1740 fujisawa_21\NNP\1740 usa_22\NNP\8337324 ,_23\,\1740 inc_24\NNP\8403787 ,_25\,\1740 deerfield_26\NNP\1740 ,_27\,\1740 illinois_28\NNP\9646608 )_29\-RRB-\1740 for_30\IN\1740 immunosuppression_31\NN\13973990 after_32\IN\1740 orthotropic_33\JJ\1740 liver_34\NN\5298729 transplantation_35\NN\671351 ._36\.\1740
D016559_D009901 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>tacrolimus</e1>_2\NN\1740 and_3\CC\1740 other_4\JJ\1740 immunosuppressive_5\JJ\1740 agents_6\NNS\7347 may_7\MD\15209706 be_8\VB\836236 associated_9\VBN\628491 with_10\IN\1740 <e2>optic_11\JJ\1740 nerve_12\NN\5475681 toxicity</e2>_13\NN\13576101 ._14\.\1740
D016559_D015354 NONE <e2>deterioration_0\NN\14560612 of_1\IN\1740 vision</e2>_2\NN\5767733 occurred_3\VBD\2623529 despite_4\IN\7501545 discontinuation_5\NN\209943 of_6\IN\1740 the_7\DT\1740 <e1>tacrolimus</e1>_8\NN\1740 ._9\.\1740
24595967
D018817_D008569 CID <e2>dysfunctional_0\JJ\1740 overnight_1\JJ\1740 memory</e2>_2\NN\5926676 consolidation_3\NN\7373803 in_4\IN\13603305 <e1>ecstasy</e1>_5\NN\13985818 users_6\NNS\7846 ._7\.\1740
D018817_D008569 CID <e1>ecstasy</e1>_0\NNP\13985818 users_1\NNS\7846 demonstrated_2\VBD\2137132 <e2>impaired_3\JJ\1740 overnight_4\JJ\1740 memory</e2>_5\NN\5926676 consolidation_6\NN\7373803 ,_7\,\1740 a_8\DT\13649268 finding_9\NN\43195 that_10\WDT\1740 was_11\VBD\836236 more_12\RBR\1740 pronounced_13\JJ\1740 following_14\VBG\1835496 associative_15\JJ\1740 interference_16\NN\6660942 ._17\.\1740
D018817_D008569 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 <e1>ecstasy-associated</e1>_3\JJ\1740 dysfunction_4\NN\14204950 in_5\IN\13603305 fronto-temporal_6\JJ\1740 circuitry_7\NN\3278248 may_8\MD\15209706 underlie_9\VB\2604760 overnight_10\JJ\1740 consolidation_11\NN\7373803 <e2>memory_12\NN\5926676 impairments</e2>_13\NNS\7296428 in_14\IN\13603305 regular_15\JJ\1740 ecstasy_16\NN\13985818 users_17\NNS\7846 ._18\.\1740
D018817_D008569 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 ecstasy-associated_3\JJ\1740 dysfunction_4\NN\14204950 in_5\IN\13603305 fronto-temporal_6\JJ\1740 circuitry_7\NN\3278248 may_8\MD\15209706 underlie_9\VB\2604760 overnight_10\JJ\1740 consolidation_11\NN\7373803 <e2>memory_12\NN\5926676 impairments</e2>_13\NNS\7296428 in_14\IN\13603305 regular_15\JJ\1740 <e1>ecstasy</e1>_16\NN\13985818 users_17\NNS\7846 ._18\.\1740
D018817_D012893 CID previous_0\JJ\1740 studies_1\NNS\635850 indicate_2\VBP\952524 that_3\IN\1740 <e1>ecstasy</e1>_4\NN\13985818 users_5\NNS\7846 have_6\VBP\2108377 marked_7\VBN\1296462 and_8\CC\1740 persistent_9\JJ\1740 neurocognitive_10\JJ\1740 and_11\CC\1740 <e2>sleep-related_12\JJ\1740 impairments</e2>_13\NNS\7296428 ._14\.\1740
48835
D011433_D007003 NONE modification_0\NN\191142 by_1\IN\1740 <e1>propranolol</e1>_2\NN\1740 of_3\IN\1740 cardiovascular_4\JJ\1740 effects_5\NNS\13245626 of_6\IN\1740 induced_7\VBN\1627355 <e2>hypoglycaemia</e2>_8\NN\14299637 ._9\.\1740
17572393
D008550_D054220 NONE neuroprotective_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>melatonin</e1>_3\NN\5407119 upon_4\IN\1740 the_5\DT\1740 offspring_6\VBG\1740 cerebellar_7\NN\1740 cortex_8\NN\5462674 in_9\IN\13603305 the_10\DT\1740 rat_11\NN\2329401 model_12\NN\5888929 of_13\IN\1740 bcnu-induced_14\JJ\1740 <e2>cortical_15\JJ\1740 dysplasia</e2>_16\NN\14501726 ._17\.\1740
D008550_D054220 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 alterations_7\NNS\7283608 in_8\IN\13603305 offspring_9\VBG\1740 rat_10\NN\2329401 cerebellum_11\NN\5462674 induced_12\VBN\1627355 by_13\IN\1740 maternal_14\JJ\1740 exposure_15\NN\5042871 to_16\TO\1740 carmustine-[1,3-bis_17\NN\1740 (2-chloroethyl)-1-nitrosoure_18\NN\1740 ]_19\-RRB-\1740 (_20\-LRB-\1740 bcnu_21\NNS\1740 )_22\-RRB-\1740 and_23\CC\1740 to_24\TO\1740 investigate_25\VB\644583 the_26\DT\1740 effects_27\NNS\13245626 of_28\IN\1740 exogenous_29\JJ\1740 <e1>melatonin</e1>_30\NN\5407119 upon_31\IN\1740 cerebellar_32\JJ\1740 bcnu-induced_33\JJ\1740 <e2>cortical_34\JJ\1740 dysplasia</e2>_35\NN\14501726 ,_36\,\1740 using_37\VBG\1156834 histological_38\JJ\1740 and_39\CC\1740 biochemical_40\JJ\1740 analyses_41\NNS\633864 ._42\.\1740
D002330_D054220 CID neuroprotective_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 melatonin_3\NN\5407119 upon_4\IN\1740 the_5\DT\1740 offspring_6\VBG\1740 cerebellar_7\NN\1740 cortex_8\NN\5462674 in_9\IN\13603305 the_10\DT\1740 rat_11\NN\2329401 model_12\NN\5888929 of_13\IN\1740 <e1>bcnu-induced</e1>_14\JJ\1740 <e2>cortical_15\JJ\1740 dysplasia</e2>_16\NN\14501726 ._17\.\1740
D002330_D054220 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 alterations_7\NNS\7283608 in_8\IN\13603305 offspring_9\VBG\1740 rat_10\NN\2329401 cerebellum_11\NN\5462674 induced_12\VBN\1627355 by_13\IN\1740 maternal_14\JJ\1740 exposure_15\NN\5042871 to_16\TO\1740 <e1>carmustine-[1,3-bis</e1>_17\NN\1740 (2-chloroethyl)-1-nitrosoure_18\NN\1740 ]_19\-RRB-\1740 (_20\-LRB-\1740 bcnu_21\NNS\1740 )_22\-RRB-\1740 and_23\CC\1740 to_24\TO\1740 investigate_25\VB\644583 the_26\DT\1740 effects_27\NNS\13245626 of_28\IN\1740 exogenous_29\JJ\1740 melatonin_30\NN\5407119 upon_31\IN\1740 cerebellar_32\JJ\1740 bcnu-induced_33\JJ\1740 <e2>cortical_34\JJ\1740 dysplasia</e2>_35\NN\14501726 ,_36\,\1740 using_37\VBG\1156834 histological_38\JJ\1740 and_39\CC\1740 biochemical_40\JJ\1740 analyses_41\NNS\633864 ._42\.\1740
D002330_D054220 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 alterations_7\NNS\7283608 in_8\IN\13603305 offspring_9\VBG\1740 rat_10\NN\2329401 cerebellum_11\NN\5462674 induced_12\VBN\1627355 by_13\IN\1740 maternal_14\JJ\1740 exposure_15\NN\5042871 to_16\TO\1740 <e1>carmustine-[1,3-bis_17\NN\1740 (2-chloroethyl)-1-nitrosoure</e1>_18\NN\1740 ]_19\-RRB-\1740 (_20\-LRB-\1740 bcnu_21\NNS\1740 )_22\-RRB-\1740 and_23\CC\1740 to_24\TO\1740 investigate_25\VB\644583 the_26\DT\1740 effects_27\NNS\13245626 of_28\IN\1740 exogenous_29\JJ\1740 melatonin_30\NN\5407119 upon_31\IN\1740 cerebellar_32\JJ\1740 bcnu-induced_33\JJ\1740 <e2>cortical_34\JJ\1740 dysplasia</e2>_35\NN\14501726 ,_36\,\1740 using_37\VBG\1156834 histological_38\JJ\1740 and_39\CC\1740 biochemical_40\JJ\1740 analyses_41\NNS\633864 ._42\.\1740
D002330_D054220 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 alterations_7\NNS\7283608 in_8\IN\13603305 offspring_9\VBG\1740 rat_10\NN\2329401 cerebellum_11\NN\5462674 induced_12\VBN\1627355 by_13\IN\1740 maternal_14\JJ\1740 exposure_15\NN\5042871 to_16\TO\1740 carmustine-[1,3-bis_17\NN\1740 (2-chloroethyl)-1-nitrosoure_18\NN\1740 ]_19\-RRB-\1740 (_20\-LRB-\1740 <e1>bcnu</e1>_21\NNS\1740 )_22\-RRB-\1740 and_23\CC\1740 to_24\TO\1740 investigate_25\VB\644583 the_26\DT\1740 effects_27\NNS\13245626 of_28\IN\1740 exogenous_29\JJ\1740 melatonin_30\NN\5407119 upon_31\IN\1740 cerebellar_32\JJ\1740 bcnu-induced_33\JJ\1740 <e2>cortical_34\JJ\1740 dysplasia</e2>_35\NN\14501726 ,_36\,\1740 using_37\VBG\1156834 histological_38\JJ\1740 and_39\CC\1740 biochemical_40\JJ\1740 analyses_41\NNS\633864 ._42\.\1740
D002330_D054220 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 alterations_7\NNS\7283608 in_8\IN\13603305 offspring_9\VBG\1740 rat_10\NN\2329401 cerebellum_11\NN\5462674 induced_12\VBN\1627355 by_13\IN\1740 maternal_14\JJ\1740 exposure_15\NN\5042871 to_16\TO\1740 carmustine-[1,3-bis_17\NN\1740 (2-chloroethyl)-1-nitrosoure_18\NN\1740 ]_19\-RRB-\1740 (_20\-LRB-\1740 bcnu_21\NNS\1740 )_22\-RRB-\1740 and_23\CC\1740 to_24\TO\1740 investigate_25\VB\644583 the_26\DT\1740 effects_27\NNS\13245626 of_28\IN\1740 exogenous_29\JJ\1740 melatonin_30\NN\5407119 upon_31\IN\1740 cerebellar_32\JJ\1740 <e1>bcnu-induced</e1>_33\JJ\1740 <e2>cortical_34\JJ\1740 dysplasia</e2>_35\NN\14501726 ,_36\,\1740 using_37\VBG\1156834 histological_38\JJ\1740 and_39\CC\1740 biochemical_40\JJ\1740 analyses_41\NNS\633864 ._42\.\1740
D002330_D054220 CID histopathologically_0\RB\1740 ,_1\,\1740 typical_2\JJ\1740 findings_3\NNS\7951464 were_4\VBD\836236 observed_5\VBN\2163746 in_6\IN\13603305 the_7\DT\1740 cerebella_8\NN\5462674 from_9\IN\1740 the_10\DT\1740 control_11\NN\5190804 groups_12\NNS\2137 ,_13\,\1740 but_14\CC\1740 the_15\DT\1740 findings_16\NNS\7951464 consistent_17\JJ\1740 with_18\IN\1740 early_19\JJ\1740 embryonic_20\JJ\1740 development_21\NN\248977 were_22\VBD\836236 noted_23\VBN\1009240 in_24\IN\13603305 <e1>bcnu-exposed</e1>_25\JJ\1740 <e2>cortical_26\JJ\1740 dysplasia</e2>_27\NN\14501726 group_28\NN\2137 ._29\.\1740
12677626
C476513_D020258 NONE <e2>central_0\JJ\1740 nervous_1\JJ\1740 system_2\NN\3575240 toxicity</e2>_3\NN\13576101 following_4\VBG\1835496 the_5\DT\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>levobupivacaine</e1>_8\NN\1740 for_9\IN\1740 lumbar_10\JJ\1740 plexus_11\NN\5225602 block_12\NN\21939 :_13\:\1740 a_14\DT\13649268 report_15\NN\6470073 of_16\IN\1740 two_17\CD\13741022 cases_18\NNS\7283608 ._19\.\1740
C476513_D004830 CID we_0\PRP\1740 describe_1\VBP\1001294 2_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 <e2>grand_5\JJ\1740 mal_6\JJ\1740 seizures</e2>_7\NNS\14081375 following_8\VBG\1835496 accidental_9\JJ\1740 intravascular_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 <e1>levobupivacaine</e1>_13\NN\1740 ._14\.\1740
C476513_D004830 CID immediately_0\RB\1740 after_1\IN\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>levobupivacaine</e1>_5\NN\1740 0.5_6\CD\1740 %_7\NN\1740 with_8\IN\1740 epinephrine_9\NN\14807929 2.5_10\CD\1740 microgram/ml_11\NN\1740 ,_12\,\1740 the_13\DT\1740 patients_14\NNS\9898892 developed_15\VBD\1753788 <e2>grand_16\JJ\1740 mal_17\JJ\1740 seizures</e2>_18\NNS\14081375 ,_19\,\1740 despite_20\IN\7501545 negative_21\JJ\1740 aspiration_22\NN\4836268 for_23\IN\1740 blood_24\NN\5397468 and_25\CC\1740 no_26\DT\7204911 clinical_27\JJ\1740 signs_28\NNS\6643763 of_29\IN\1740 intravenous_30\JJ\1740 epinephrine_31\NN\14807929 administration_32\NN\1133281 ._33\.\1740
D004837_D004830 NONE immediately_0\RB\1740 after_1\IN\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 levobupivacaine_5\NN\1740 0.5_6\CD\1740 %_7\NN\1740 with_8\IN\1740 <e1>epinephrine</e1>_9\NN\14807929 2.5_10\CD\1740 microgram/ml_11\NN\1740 ,_12\,\1740 the_13\DT\1740 patients_14\NNS\9898892 developed_15\VBD\1753788 <e2>grand_16\JJ\1740 mal_17\JJ\1740 seizures</e2>_18\NNS\14081375 ,_19\,\1740 despite_20\IN\7501545 negative_21\JJ\1740 aspiration_22\NN\4836268 for_23\IN\1740 blood_24\NN\5397468 and_25\CC\1740 no_26\DT\7204911 clinical_27\JJ\1740 signs_28\NNS\6643763 of_29\IN\1740 intravenous_30\JJ\1740 epinephrine_31\NN\14807929 administration_32\NN\1133281 ._33\.\1740
D004837_D004830 NONE immediately_0\RB\1740 after_1\IN\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 levobupivacaine_5\NN\1740 0.5_6\CD\1740 %_7\NN\1740 with_8\IN\1740 epinephrine_9\NN\14807929 2.5_10\CD\1740 microgram/ml_11\NN\1740 ,_12\,\1740 the_13\DT\1740 patients_14\NNS\9898892 developed_15\VBD\1753788 <e2>grand_16\JJ\1740 mal_17\JJ\1740 seizures</e2>_18\NNS\14081375 ,_19\,\1740 despite_20\IN\7501545 negative_21\JJ\1740 aspiration_22\NN\4836268 for_23\IN\1740 blood_24\NN\5397468 and_25\CC\1740 no_26\DT\7204911 clinical_27\JJ\1740 signs_28\NNS\6643763 of_29\IN\1740 intravenous_30\JJ\1740 <e1>epinephrine</e1>_31\NN\14807929 administration_32\NN\1133281 ._33\.\1740
D013874_D012640 NONE the_0\DT\1740 <e2>seizures</e2>_1\NNS\14081375 were_2\VBD\836236 successfully_3\RB\1740 treated_4\VBN\2376958 with_5\IN\1740 <e1>sodium_6\NN\14625458 thiopental</e1>_7\NN\2792049 in_8\IN\13603305 addition_9\NN\3081021 to_10\TO\1740 succinylcholine_11\NN\3800001 in_12\IN\13603305 1_13\CD\13741022 patient_14\NN\9898892 ._15\.\1740
D013390_D012640 NONE the_0\DT\1740 <e2>seizures</e2>_1\NNS\14081375 were_2\VBD\836236 successfully_3\RB\1740 treated_4\VBN\2376958 with_5\IN\1740 sodium_6\NN\14625458 thiopental_7\NN\2792049 in_8\IN\13603305 addition_9\NN\3081021 to_10\TO\1740 <e1>succinylcholine</e1>_11\NN\3800001 in_12\IN\13603305 1_13\CD\13741022 patient_14\NN\9898892 ._15\.\1740
C476513_D066126 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 <e1>levobupivacaine</e1>_3\NN\1740 may_4\MD\15209706 have_5\VB\2108377 a_6\DT\13649268 safer_7\JJR\1740 <e2>cardiac_8\JJ\1740 toxicity</e2>_9\NN\13576101 profile_10\NN\6999802 than_11\IN\1740 racemic_12\JJ\1740 bupivacaine_13\NN\1740 ,_14\,\1740 if_15\IN\1740 adequate_16\JJ\1740 amounts_17\NNS\13329641 of_18\IN\1740 levobupivacaine_19\NN\1740 reach_20\VBP\2005948 the_21\DT\1740 circulation_22\NN\6253140 ,_23\,\1740 it_24\PRP\6125041 will_25\MD\5650329 result_26\VB\2633881 in_27\IN\13603305 convulsions_28\NNS\14081375 ._29\.\1740
C476513_D066126 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 levobupivacaine_3\NN\1740 may_4\MD\15209706 have_5\VB\2108377 a_6\DT\13649268 safer_7\JJR\1740 <e2>cardiac_8\JJ\1740 toxicity</e2>_9\NN\13576101 profile_10\NN\6999802 than_11\IN\1740 racemic_12\JJ\1740 bupivacaine_13\NN\1740 ,_14\,\1740 if_15\IN\1740 adequate_16\JJ\1740 amounts_17\NNS\13329641 of_18\IN\1740 <e1>levobupivacaine</e1>_19\NN\1740 reach_20\VBP\2005948 the_21\DT\1740 circulation_22\NN\6253140 ,_23\,\1740 it_24\PRP\6125041 will_25\MD\5650329 result_26\VB\2633881 in_27\IN\13603305 convulsions_28\NNS\14081375 ._29\.\1740
C476513_D012640 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 <e1>levobupivacaine</e1>_3\NN\1740 may_4\MD\15209706 have_5\VB\2108377 a_6\DT\13649268 safer_7\JJR\1740 cardiac_8\JJ\1740 toxicity_9\NN\13576101 profile_10\NN\6999802 than_11\IN\1740 racemic_12\JJ\1740 bupivacaine_13\NN\1740 ,_14\,\1740 if_15\IN\1740 adequate_16\JJ\1740 amounts_17\NNS\13329641 of_18\IN\1740 levobupivacaine_19\NN\1740 reach_20\VBP\2005948 the_21\DT\1740 circulation_22\NN\6253140 ,_23\,\1740 it_24\PRP\6125041 will_25\MD\5650329 result_26\VB\2633881 in_27\IN\13603305 <e2>convulsions</e2>_28\NNS\14081375 ._29\.\1740
C476513_D012640 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 levobupivacaine_3\NN\1740 may_4\MD\15209706 have_5\VB\2108377 a_6\DT\13649268 safer_7\JJR\1740 cardiac_8\JJ\1740 toxicity_9\NN\13576101 profile_10\NN\6999802 than_11\IN\1740 racemic_12\JJ\1740 bupivacaine_13\NN\1740 ,_14\,\1740 if_15\IN\1740 adequate_16\JJ\1740 amounts_17\NNS\13329641 of_18\IN\1740 <e1>levobupivacaine</e1>_19\NN\1740 reach_20\VBP\2005948 the_21\DT\1740 circulation_22\NN\6253140 ,_23\,\1740 it_24\PRP\6125041 will_25\MD\5650329 result_26\VB\2633881 in_27\IN\13603305 <e2>convulsions</e2>_28\NNS\14081375 ._29\.\1740
D002045_D066126 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 levobupivacaine_3\NN\1740 may_4\MD\15209706 have_5\VB\2108377 a_6\DT\13649268 safer_7\JJR\1740 <e2>cardiac_8\JJ\1740 toxicity</e2>_9\NN\13576101 profile_10\NN\6999802 than_11\IN\1740 racemic_12\JJ\1740 <e1>bupivacaine</e1>_13\NN\1740 ,_14\,\1740 if_15\IN\1740 adequate_16\JJ\1740 amounts_17\NNS\13329641 of_18\IN\1740 levobupivacaine_19\NN\1740 reach_20\VBP\2005948 the_21\DT\1740 circulation_22\NN\6253140 ,_23\,\1740 it_24\PRP\6125041 will_25\MD\5650329 result_26\VB\2633881 in_27\IN\13603305 convulsions_28\NNS\14081375 ._29\.\1740
D002045_D012640 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 levobupivacaine_3\NN\1740 may_4\MD\15209706 have_5\VB\2108377 a_6\DT\13649268 safer_7\JJR\1740 cardiac_8\JJ\1740 toxicity_9\NN\13576101 profile_10\NN\6999802 than_11\IN\1740 racemic_12\JJ\1740 <e1>bupivacaine</e1>_13\NN\1740 ,_14\,\1740 if_15\IN\1740 adequate_16\JJ\1740 amounts_17\NNS\13329641 of_18\IN\1740 levobupivacaine_19\NN\1740 reach_20\VBP\2005948 the_21\DT\1740 circulation_22\NN\6253140 ,_23\,\1740 it_24\PRP\6125041 will_25\MD\5650329 result_26\VB\2633881 in_27\IN\13603305 <e2>convulsions</e2>_28\NNS\14081375 ._29\.\1740
7727612
D008140_D009207 CID <e2>myoclonus</e2>_0\NNP\14360459 associated_1\VBN\628491 with_2\IN\1740 <e1>lorazepam</e1>_3\NN\2830852 therapy_4\NN\657604 in_5\IN\13603305 very-low-birth-weight_6\NN\1740 infants_7\NNS\9918248 ._8\.\1740
D008140_D009207 CID three_0\CD\13741022 young_1\JJ\1740 infants_2\NNS\9918248 ,_3\,\1740 all_4\DT\1740 of_5\IN\1740 birth_6\NN\15265518 weight_7\NN\5009170 <_8\XX\1740 1,500_9\CD\1740 g_10\NN\13717155 ,_11\,\1740 experienced_12\JJ\1740 <e2>myoclonus</e2>_13\NN\14360459 following_14\VBG\1835496 the_15\DT\1740 intravenous_16\JJ\1740 administration_17\NN\1133281 of_18\IN\1740 <e1>lorazepam</e1>_19\NN\2830852 ._20\.\1740
17543491
19293073
D001241_D003327 NONE in_0\IN\13603305 2002_1\CD\1740 ,_2\,\1740 the_3\DT\1740 u.s._4\NNP\8052549 preventive_5\NNP\4074482 services_6\NNPS\584367 task_7\NNP\575741 force_8\NNP\5194151 (_9\-LRB-\1740 uspstf_10\NN\1740 )_11\-RRB-\1740 strongly_12\RB\1740 recommended_13\VBD\875394 that_14\IN\1740 clinicians_15\NNS\10462860 discuss_16\VBP\1033527 <e1>aspirin</e1>_17\NN\2707683 with_18\IN\1740 adults_19\NNS\7846 who_20\WP\8299493 are_21\VBP\836236 at_22\IN\14622893 increased_23\VBN\169651 risk_24\NN\14541044 for_25\IN\1740 <e2>coronary_26\JJ\1740 heart_27\NN\5919034 disease</e2>_28\NN\14061805 ._29\.\1740
D001241_D009203 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 benefits_5\NNS\13278375 and_6\CC\1740 harms_7\NNS\14052046 of_8\IN\1740 taking_9\VBG\2367363 <e1>aspirin</e1>_10\NN\2707683 for_11\IN\1740 the_12\DT\1740 primary_13\JJ\1740 prevention_14\NN\1073995 of_15\IN\1740 <e2>myocardial_16\JJ\1740 infarctions</e2>_17\NNS\14204950 ,_18\,\1740 strokes_19\NNS\556313 ,_20\,\1740 and_21\CC\1740 death_22\NN\7296428 ._23\.\1740
D001241_D009203 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>aspirin</e1>_2\NN\2707683 reduces_3\VBZ\441445 the_4\DT\1740 risk_5\NN\14541044 for_6\IN\1740 <e2>myocardial_7\JJ\1740 infarction</e2>_8\NN\14204950 in_9\IN\13603305 men_10\NNS\8208016 and_11\CC\1740 strokes_12\NNS\556313 in_13\IN\13603305 women_14\NNS\9605289 ._15\.\1740
D001241_D020521 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 benefits_5\NNS\13278375 and_6\CC\1740 harms_7\NNS\14052046 of_8\IN\1740 taking_9\VBG\2367363 <e1>aspirin</e1>_10\NN\2707683 for_11\IN\1740 the_12\DT\1740 primary_13\JJ\1740 prevention_14\NN\1073995 of_15\IN\1740 myocardial_16\JJ\1740 infarctions_17\NNS\14204950 ,_18\,\1740 <e2>strokes</e2>_19\NNS\556313 ,_20\,\1740 and_21\CC\1740 death_22\NN\7296428 ._23\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 <e2>strokes</e2>_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 <e2>stroke</e2>_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 <e2>hemorrhagic_74\JJ\1740 strokes</e2>_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 <e2>strokes</e2>_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 <e2>stroke</e2>_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 <e2>hemorrhagic_74\JJ\1740 strokes</e2>_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 <e2>strokes</e2>_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 <e2>stroke</e2>_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 <e2>hemorrhagic_74\JJ\1740 strokes</e2>_75\NNS\556313 ?_76\.\1740
D001241_D020521 CID men_0\NNS\8208016 have_1\VBP\2108377 an_2\DT\6697703 increased_3\VBN\169651 risk_4\NN\14541044 for_5\IN\1740 <e2>hemorrhagic_6\JJ\1740 strokes</e2>_7\NNS\556313 with_8\IN\1740 <e1>aspirin</e1>_9\NN\2707683 use_10\NN\407535 ._11\.\1740
D001241_D020521 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>aspirin</e1>_2\NN\2707683 reduces_3\VBZ\441445 the_4\DT\1740 risk_5\NN\14541044 for_6\IN\1740 myocardial_7\JJ\1740 infarction_8\NN\14204950 in_9\IN\13603305 men_10\NNS\8208016 and_11\CC\1740 <e2>strokes</e2>_12\NNS\556313 in_13\IN\13603305 women_14\NNS\9605289 ._15\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 <e2>cardiovascular_29\JJ\1740 disease</e2>_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 <e2>cvd</e2>_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 <e2>cvd</e2>_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 <e2>cardiovascular_29\JJ\1740 disease</e2>_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 <e2>cvd</e2>_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 <e2>cvd</e2>_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 <e2>cardiovascular_29\JJ\1740 disease</e2>_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 <e2>cvd</e2>_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 <e2>cvd</e2>_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D002318 NONE data_0\NN\7951464 synthesis_1\NN\13446390 :_2\:\1740 new_3\JJ\1740 evidence_4\NN\5816287 from_5\IN\1740 1_6\CD\13741022 good-quality_7\NN\1740 rct_8\NN\1740 ,_9\,\1740 1_10\CD\13741022 good-quality_11\NN\1740 meta-analysis_12\NN\1740 ,_13\,\1740 and_14\CC\1740 2_15\CD\13741022 fair-quality_16\JJ\1740 subanalyses_17\NNS\1740 of_18\IN\1740 rcts_19\NNS\1740 demonstrates_20\VBZ\2137132 that_21\IN\1740 <e1>aspirin</e1>_22\NN\2707683 use_23\NN\407535 reduces_24\VBZ\441445 the_25\DT\1740 number_26\NN\5107765 of_27\IN\1740 <e2>cvd</e2>_28\NN\1740 events_29\NNS\23100 in_30\IN\13603305 patients_31\NNS\9898892 without_32\IN\1740 known_33\VBN\2110220 cvd_34\NNP\1740 ._35\.\1740
D001241_D002318 NONE data_0\NN\7951464 synthesis_1\NN\13446390 :_2\:\1740 new_3\JJ\1740 evidence_4\NN\5816287 from_5\IN\1740 1_6\CD\13741022 good-quality_7\NN\1740 rct_8\NN\1740 ,_9\,\1740 1_10\CD\13741022 good-quality_11\NN\1740 meta-analysis_12\NN\1740 ,_13\,\1740 and_14\CC\1740 2_15\CD\13741022 fair-quality_16\JJ\1740 subanalyses_17\NNS\1740 of_18\IN\1740 rcts_19\NNS\1740 demonstrates_20\VBZ\2137132 that_21\IN\1740 <e1>aspirin</e1>_22\NN\2707683 use_23\NN\407535 reduces_24\VBZ\441445 the_25\DT\1740 number_26\NN\5107765 of_27\IN\1740 cvd_28\NN\1740 events_29\NNS\23100 in_30\IN\13603305 patients_31\NNS\9898892 without_32\IN\1740 known_33\VBN\2110220 <e2>cvd</e2>_34\NNP\1740 ._35\.\1740
D001241_D002318 NONE <e1>aspirin</e1>_0\NN\2707683 does_1\VBZ\1640855 not_2\RB\1740 seem_3\VB\2604760 to_4\TO\1740 affect_5\VB\126264 <e2>cvd</e2>_6\NN\1740 mortality_7\NN\5054863 or_8\CC\3541091 all-cause_9\JJ\1740 mortality_10\NN\5054863 in_11\IN\13603305 either_12\DT\1740 men_13\NNS\8208016 or_14\CC\3541091 women_15\NNS\9605289 ._16\.\1740
D001241_D002318 NONE limitations_0\NNS\5846054 :_1\:\1740 new_2\JJ\1740 evidence_3\NN\5816287 on_4\IN\1740 <e1>aspirin</e1>_5\NN\2707683 for_6\IN\1740 the_7\DT\1740 primary_8\JJ\1740 prevention_9\NN\1073995 of_10\IN\1740 <e2>cvd</e2>_11\NNP\1740 is_12\VBZ\836236 limited_13\JJ\1740 ._14\.\1740
D001241_D006471 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 <e2>gastrointestinal_71\JJ\1740 bleeding</e2>_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D006471 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 <e2>gastrointestinal_71\JJ\1740 bleeding</e2>_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D006471 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 <e2>gastrointestinal_71\JJ\1740 bleeding</e2>_72\JJ\1740 or_73\CC\3541091 hemorrhagic_74\JJ\1740 strokes_75\NNS\556313 ?_76\.\1740
D001241_D006471 CID the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>aspirin</e1>_3\NN\2707683 for_4\IN\1740 primary_5\JJ\1740 prevention_6\NN\1073995 increases_7\VBZ\169651 the_8\DT\1740 risk_9\NN\14541044 for_10\IN\1740 major_11\JJ\1740 bleeding_12\JJ\1740 events_13\NNS\23100 ,_14\,\1740 primarily_15\RB\1740 <e2>gastrointestinal_16\JJ\1740 bleeding</e2>_17\NN\14285662 events_18\NNS\23100 ,_19\,\1740 in_20\IN\13603305 both_21\DT\1740 men_22\NNS\8208016 and_23\CC\1740 women_24\NNS\9605289 ._25\.\1740
D001241_D020300 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 <e1>aspirin</e1>_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 <e2>hemorrhagic_74\JJ\1740 strokes</e2>_75\NNS\556313 ?_76\.\1740
D001241_D020300 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 <e1>aspirin</e1>_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 aspirin_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 <e2>hemorrhagic_74\JJ\1740 strokes</e2>_75\NNS\556313 ?_76\.\1740
D001241_D020300 CID study_0\NN\635850 selection_1\NN\37396 :_2\:\1740 english-language_3\JJ\1740 randomized_4\JJ\1740 ,_5\,\1740 controlled_6\VBN\2422663 trials_7\NNS\786195 (_8\-LRB-\1740 rcts_9\NNS\1740 )_10\-RRB-\1740 ;_11\:\1740 case-control_12\JJ\1740 studies_13\NNS\635850 ;_14\:\1740 meta-analyses_15\NNS\1740 ;_16\:\1740 and_17\CC\1740 systematic_18\JJ\1740 reviews_19\NNS\5733583 of_20\IN\1740 aspirin_21\NN\2707683 versus_22\CC\1740 control_23\NN\5190804 for_24\IN\1740 the_25\DT\1740 primary_26\JJ\1740 prevention_27\NN\1073995 of_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 (_31\-LRB-\1740 cvd_32\NN\1740 )_33\-RRB-\1740 were_34\VBD\836236 selected_35\VBN\697589 to_36\TO\1740 answer_37\VB\1009240 the_38\DT\1740 following_39\VBG\1835496 questions_40\NNS\7193184 :_41\:\1740 does_42\VBZ\1640855 aspirin_43\NN\2707683 decrease_44\VB\169651 coronary_45\JJ\1740 heart_46\NN\5919034 events_47\NNS\23100 ,_48\,\1740 strokes_49\NNS\556313 ,_50\,\1740 death_51\NN\7296428 from_52\IN\1740 coronary_53\JJ\1740 heart_54\NN\5919034 events_55\NNS\23100 or_56\CC\3541091 stroke_57\NN\556313 ,_58\,\1740 or_59\CC\3541091 all-cause_60\JJ\1740 mortality_61\NN\5054863 in_62\IN\13603305 adults_63\NNS\7846 without_64\IN\1740 known_65\VBN\2110220 cvd_66\NNP\1740 ?_67\,\1740 does_68\VBZ\1640855 <e1>aspirin</e1>_69\NN\2707683 increase_70\VB\169651 gastrointestinal_71\JJ\1740 bleeding_72\JJ\1740 or_73\CC\3541091 <e2>hemorrhagic_74\JJ\1740 strokes</e2>_75\NNS\556313 ?_76\.\1740
D001241_D020300 CID men_0\NNS\8208016 have_1\VBP\2108377 an_2\DT\6697703 increased_3\VBN\169651 risk_4\NN\14541044 for_5\IN\1740 <e2>hemorrhagic_6\JJ\1740 strokes</e2>_7\NNS\556313 with_8\IN\1740 <e1>aspirin</e1>_9\NN\2707683 use_10\NN\407535 ._11\.\1740
D001241_D006470 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>aspirin</e1>_3\NN\2707683 for_4\IN\1740 primary_5\JJ\1740 prevention_6\NN\1073995 increases_7\VBZ\169651 the_8\DT\1740 risk_9\NN\14541044 for_10\IN\1740 major_11\JJ\1740 <e2>bleeding</e2>_12\JJ\1740 events_13\NNS\23100 ,_14\,\1740 primarily_15\RB\1740 gastrointestinal_16\JJ\1740 bleeding_17\NN\14285662 events_18\NNS\23100 ,_19\,\1740 in_20\IN\13603305 both_21\DT\1740 men_22\NNS\8208016 and_23\CC\1740 women_24\NNS\9605289 ._25\.\1740
D001241_D006470 NONE <e1>aspirin</e1>_0\NN\2707683 use_1\NN\407535 increases_2\VBZ\169651 the_3\DT\1740 risk_4\NN\14541044 for_5\IN\1740 serious_6\JJ\1740 <e2>bleeding</e2>_7\NN\14285662 events_8\NNS\23100 ._9\.\1740
3125850
D013390_D005207 CID increase_0\NN\13576355 in_1\IN\13603305 intragastric_2\JJ\1740 pressure_3\NN\11419404 during_4\IN\1740 <e1>suxamethonium-induced</e1>_5\JJ\1740 <e2>muscle_6\NN\5289601 fasciculations</e2>_7\NNS\14361664 in_8\IN\13603305 children_9\NNS\9622049 :_10\:\1740 inhibition_11\NN\1068773 by_12\IN\1740 alfentanil_13\JJ\1740 ._14\.\1740
D013390_D005207 CID the_0\DT\1740 incidence_1\NN\13821570 and_2\CC\1740 intensity_3\NN\5090441 of_4\IN\1740 <e2>muscle_5\NN\5289601 fasciculations</e2>_6\NNS\14361664 caused_7\VBN\1617192 by_8\IN\1740 <e1>suxamethonium</e1>_9\NN\1740 were_10\VBD\836236 significantly_11\RB\1740 greater_12\JJR\1740 in_13\IN\13603305 the_14\DT\1740 control_15\NN\5190804 than_16\IN\1740 in_17\IN\13603305 the_18\DT\1740 alfentanil_19\JJ\1740 group_20\NN\2137 ._21\.\1740
D013390_D005207 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 intragastric_4\JJ\1740 pressure_5\NN\11419404 increases_6\VBZ\169651 significantly_7\RB\1740 during_8\IN\1740 <e2>muscle_9\NN\5289601 fasciculations</e2>_10\NNS\14361664 caused_11\VBN\1617192 by_12\IN\1740 <e1>suxamethonium</e1>_13\NN\1740 in_14\IN\13603305 healthy_15\JJ\1740 children_16\NNS\9622049 ._17\.\1740
D013390_D005207 CID alfentanil_0\NN\1740 50_1\CD\13745420 micrograms_2\NNS\13717155 kg-1_3\NN\1740 effectively_4\RB\1740 inhibits_5\VBZ\2510337 the_6\DT\1740 incidence_7\NN\13821570 and_8\CC\1740 intensity_9\NN\5090441 of_10\IN\1740 <e1>suxamethonium-induced</e1>_11\JJ\1740 <e2>muscle_12\NN\5289601 fasciculations</e2>_13\NNS\14361664 ;_14\:\1740 moreover_15\RB\1740 ,_16\,\1740 intragastric_17\JJ\1740 pressure_18\NN\11419404 remains_19\VBZ\2604760 at_20\IN\14622893 its_21\PRP$\6125041 control_22\NN\5190804 value_23\NN\5856066 ._24\.\1740
D015760_D005207 NONE increase_0\NN\13576355 in_1\IN\13603305 intragastric_2\JJ\1740 pressure_3\NN\11419404 during_4\IN\1740 suxamethonium-induced_5\JJ\1740 <e2>muscle_6\NN\5289601 fasciculations</e2>_7\NNS\14361664 in_8\IN\13603305 children_9\NNS\9622049 :_10\:\1740 inhibition_11\NN\1068773 by_12\IN\1740 <e1>alfentanil</e1>_13\JJ\1740 ._14\.\1740
D015760_D005207 NONE the_0\DT\1740 incidence_1\NN\13821570 and_2\CC\1740 intensity_3\NN\5090441 of_4\IN\1740 <e2>muscle_5\NN\5289601 fasciculations</e2>_6\NNS\14361664 caused_7\VBN\1617192 by_8\IN\1740 suxamethonium_9\NN\1740 were_10\VBD\836236 significantly_11\RB\1740 greater_12\JJR\1740 in_13\IN\13603305 the_14\DT\1740 control_15\NN\5190804 than_16\IN\1740 in_17\IN\13603305 the_18\DT\1740 <e1>alfentanil</e1>_19\JJ\1740 group_20\NN\2137 ._21\.\1740
D015760_D005207 NONE the_0\DT\1740 intragastric_1\JJ\1740 pressure_2\NN\11419404 during_3\IN\1740 <e2>muscle_4\NN\5289601 fasciculations</e2>_5\NNS\14361664 was_6\VBD\836236 significantly_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 control_11\NN\5190804 group_12\NN\2137 (_13\-LRB-\1740 16_14\CD\13745420 +/-_15\CC\1740 0.7_16\CD\1740 (_17\-LRB-\1740 sem_18\NN\1740 )_19\-RRB-\1740 cm_20\NN\13649268 h2o_21\NN\14618834 )_22\-RRB-\1740 than_23\IN\1740 in_24\IN\13603305 the_25\DT\1740 <e1>alfentanil</e1>_26\JJ\1740 group_27\NN\2137 (_28\-LRB-\1740 7.7_29\CD\1740 +/-_30\CC\1740 1.5_31\CD\1740 (_32\-LRB-\1740 sem_33\NN\1740 )_34\-RRB-\1740 cm_35\NN\13649268 h2o_36\NN\14618834 )_37\-RRB-\1740 ._38\.\1740
D015760_D005207 NONE <e1>alfentanil</e1>_0\NN\1740 50_1\CD\13745420 micrograms_2\NNS\13717155 kg-1_3\NN\1740 effectively_4\RB\1740 inhibits_5\VBZ\2510337 the_6\DT\1740 incidence_7\NN\13821570 and_8\CC\1740 intensity_9\NN\5090441 of_10\IN\1740 suxamethonium-induced_11\JJ\1740 <e2>muscle_12\NN\5289601 fasciculations</e2>_13\NNS\14361664 ;_14\:\1740 moreover_15\RB\1740 ,_16\,\1740 intragastric_17\JJ\1740 pressure_18\NN\11419404 remains_19\VBZ\2604760 at_20\IN\14622893 its_21\PRP$\6125041 control_22\NN\5190804 value_23\NN\5856066 ._24\.\1740
D014867_D005207 NONE the_0\DT\1740 intragastric_1\JJ\1740 pressure_2\NN\11419404 during_3\IN\1740 <e2>muscle_4\NN\5289601 fasciculations</e2>_5\NNS\14361664 was_6\VBD\836236 significantly_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 control_11\NN\5190804 group_12\NN\2137 (_13\-LRB-\1740 16_14\CD\13745420 +/-_15\CC\1740 0.7_16\CD\1740 (_17\-LRB-\1740 sem_18\NN\1740 )_19\-RRB-\1740 cm_20\NN\13649268 <e1>h2o</e1>_21\NN\14618834 )_22\-RRB-\1740 than_23\IN\1740 in_24\IN\13603305 the_25\DT\1740 alfentanil_26\JJ\1740 group_27\NN\2137 (_28\-LRB-\1740 7.7_29\CD\1740 +/-_30\CC\1740 1.5_31\CD\1740 (_32\-LRB-\1740 sem_33\NN\1740 )_34\-RRB-\1740 cm_35\NN\13649268 h2o_36\NN\14618834 )_37\-RRB-\1740 ._38\.\1740
D014867_D005207 NONE the_0\DT\1740 intragastric_1\JJ\1740 pressure_2\NN\11419404 during_3\IN\1740 <e2>muscle_4\NN\5289601 fasciculations</e2>_5\NNS\14361664 was_6\VBD\836236 significantly_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 control_11\NN\5190804 group_12\NN\2137 (_13\-LRB-\1740 16_14\CD\13745420 +/-_15\CC\1740 0.7_16\CD\1740 (_17\-LRB-\1740 sem_18\NN\1740 )_19\-RRB-\1740 cm_20\NN\13649268 h2o_21\NN\14618834 )_22\-RRB-\1740 than_23\IN\1740 in_24\IN\13603305 the_25\DT\1740 alfentanil_26\JJ\1740 group_27\NN\2137 (_28\-LRB-\1740 7.7_29\CD\1740 +/-_30\CC\1740 1.5_31\CD\1740 (_32\-LRB-\1740 sem_33\NN\1740 )_34\-RRB-\1740 cm_35\NN\13649268 <e1>h2o</e1>_36\NN\14618834 )_37\-RRB-\1740 ._38\.\1740
19655282
D003042_D002637 CID coronary_0\JJ\1740 computerized_1\VBN\2327200 tomography_2\NN\900375 angiography_3\NN\904623 for_4\IN\1740 rapid_5\JJ\1740 discharge_6\NN\7283608 of_7\IN\1740 low-risk_8\JJ\1740 patients_9\NNS\9898892 with_10\IN\1740 <e1>cocaine-associated</e1>_11\JJ\1740 <e2>chest_12\NN\5220461 pain</e2>_13\NN\14299637 ._14\.\1740
D003042_D002637 CID background_0\NN\4921011 :_1\:\1740 most_2\JJS\1740 patients_3\NNS\9898892 presenting_4\VBG\2137132 to_5\IN\1740 emergency_6\NN\7417644 departments_7\NNS\8220714 (_8\-LRB-\1740 eds_9\NNS\4377057 )_10\-RRB-\1740 with_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 <e2>chest_13\JJ\1740 pain</e2>_14\NN\14299637 are_15\VBP\836236 admitted_16\VBN\822367 for_17\IN\1740 at_18\IN\14622893 least_19\JJS\1740 12_20\CD\13745420 hours_21\NNS\15118228 and_22\CC\1740 receive_23\VB\2210855 a_24\DT\13649268 "_25\``\1740 rule_26\VB\2441022 out_27\RP\1740 acute_28\JJ\1740 coronary_29\JJ\1740 syndrome_30\NN\5870365 "_31\''\1740 protocol_32\NN\6652242 ,_33\,\1740 often_34\RB\1740 with_35\IN\1740 noninvasive_36\JJ\1740 testing_37\NN\639556 prior_38\RB\1740 to_39\TO\1740 discharge_40\VB\1640855 ._41\.\1740
D003042_D002637 CID it_0\PRP\6125041 is_1\VBZ\836236 unclear_2\JJ\1740 whether_3\IN\1740 a_4\DT\13649268 coronary_5\JJ\1740 cta_6\NN\1740 strategy_7\NN\5902545 would_8\MD\1740 be_9\VB\836236 efficacious_10\JJ\1740 in_11\IN\13603305 <e1>cocaine-associated</e1>_12\JJ\1740 <e2>chest_13\JJ\1740 pain</e2>_14\NN\14299637 ,_15\,\1740 as_16\IN\14622893 coronary_17\JJ\1740 vasospasm_18\NN\1740 may_19\MD\15209706 account_20\VB\2604760 for_21\IN\1740 some_22\DT\1740 of_23\IN\1740 the_24\DT\1740 ischemia_25\NN\14195315 ._26\.\1740
D003042_D002637 CID we_0\PRP\1740 studied_1\VBD\630380 whether_2\IN\1740 a_3\DT\13649268 negative_4\JJ\1740 coronary_5\JJ\1740 cta_6\NN\1740 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 <e1>cocaine-associated</e1>_10\JJ\1740 <e2>chest_11\JJ\1740 pain</e2>_12\NN\14299637 could_13\MD\1740 identify_14\VB\699815 a_15\DT\13649268 subset_16\NN\7999699 safe_17\JJ\1740 for_18\IN\1740 discharge_19\NN\7283608 ._20\.\1740
D003042_D002637 CID results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 total_3\NN\3553 of_4\IN\1740 59_5\CD\1740 patients_6\NNS\9898892 with_7\IN\1740 <e1>cocaine-associated</e1>_8\JJ\1740 <e2>chest_9\JJ\1740 pain</e2>_10\NN\14299637 were_11\VBD\836236 evaluated_12\VBN\670261 ._13\.\1740
D003042_D002637 CID conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 <e1>cocaine-associated</e1>_3\JJ\1740 myocardial_4\JJ\1740 ischemia_5\NN\14195315 can_6\MD\3094503 result_7\VB\2633881 from_8\IN\1740 coronary_9\JJ\1740 vasoconstriction_10\NN\1149911 ,_11\,\1740 patients_12\NNS\9898892 with_13\IN\1740 cocaine_14\NN\3492717 associated_15\VBD\628491 <e2>chest_16\NN\5220461 pain</e2>_17\NN\14299637 ,_18\,\1740 a_19\DT\13649268 non-ischemic_20\JJ\1740 ecg_21\NN\7000195 ,_22\,\1740 and_23\CC\1740 a_24\DT\13649268 timi_25\NN\1740 risk_26\NN\14541044 score_27\NN\5736149 <_28\XX\1740 2_29\CD\13741022 may_30\MD\15209706 be_31\VB\836236 safely_32\RB\1740 discharged_33\VBN\1640855 from_34\IN\1740 the_35\DT\1740 ed_36\NN\14557898 after_37\IN\1740 a_38\DT\13649268 negative_39\JJ\1740 coronary_40\JJ\1740 cta_41\NN\1740 with_42\IN\1740 a_43\DT\13649268 low_44\JJ\1740 risk_45\NN\14541044 of_46\IN\1740 30-day_47\JJ\1740 adverse_48\JJ\1740 events_49\NNS\23100 ._50\.\1740
D003042_D002637 CID conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 cocaine-associated_3\JJ\1740 myocardial_4\JJ\1740 ischemia_5\NN\14195315 can_6\MD\3094503 result_7\VB\2633881 from_8\IN\1740 coronary_9\JJ\1740 vasoconstriction_10\NN\1149911 ,_11\,\1740 patients_12\NNS\9898892 with_13\IN\1740 <e1>cocaine</e1>_14\NN\3492717 associated_15\VBD\628491 <e2>chest_16\NN\5220461 pain</e2>_17\NN\14299637 ,_18\,\1740 a_19\DT\13649268 non-ischemic_20\JJ\1740 ecg_21\NN\7000195 ,_22\,\1740 and_23\CC\1740 a_24\DT\13649268 timi_25\NN\1740 risk_26\NN\14541044 score_27\NN\5736149 <_28\XX\1740 2_29\CD\13741022 may_30\MD\15209706 be_31\VB\836236 safely_32\RB\1740 discharged_33\VBN\1640855 from_34\IN\1740 the_35\DT\1740 ed_36\NN\14557898 after_37\IN\1740 a_38\DT\13649268 negative_39\JJ\1740 coronary_40\JJ\1740 cta_41\NN\1740 with_42\IN\1740 a_43\DT\13649268 low_44\JJ\1740 risk_45\NN\14541044 of_46\IN\1740 30-day_47\JJ\1740 adverse_48\JJ\1740 events_49\NNS\23100 ._50\.\1740
D003042_D054058 NONE background_0\NN\4921011 :_1\:\1740 most_2\JJS\1740 patients_3\NNS\9898892 presenting_4\VBG\2137132 to_5\IN\1740 emergency_6\NN\7417644 departments_7\NNS\8220714 (_8\-LRB-\1740 eds_9\NNS\4377057 )_10\-RRB-\1740 with_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 chest_13\JJ\1740 pain_14\NN\14299637 are_15\VBP\836236 admitted_16\VBN\822367 for_17\IN\1740 at_18\IN\14622893 least_19\JJS\1740 12_20\CD\13745420 hours_21\NNS\15118228 and_22\CC\1740 receive_23\VB\2210855 a_24\DT\13649268 "_25\``\1740 rule_26\VB\2441022 out_27\RP\1740 <e2>acute_28\JJ\1740 coronary_29\JJ\1740 syndrome</e2>_30\NN\5870365 "_31\''\1740 protocol_32\NN\6652242 ,_33\,\1740 often_34\RB\1740 with_35\IN\1740 noninvasive_36\JJ\1740 testing_37\NN\639556 prior_38\RB\1740 to_39\TO\1740 discharge_40\VB\1640855 ._41\.\1740
D003042_D003329 NONE it_0\PRP\6125041 is_1\VBZ\836236 unclear_2\JJ\1740 whether_3\IN\1740 a_4\DT\13649268 coronary_5\JJ\1740 cta_6\NN\1740 strategy_7\NN\5902545 would_8\MD\1740 be_9\VB\836236 efficacious_10\JJ\1740 in_11\IN\13603305 <e1>cocaine-associated</e1>_12\JJ\1740 chest_13\JJ\1740 pain_14\NN\14299637 ,_15\,\1740 as_16\IN\14622893 <e2>coronary_17\JJ\1740 vasospasm</e2>_18\NN\1740 may_19\MD\15209706 account_20\VB\2604760 for_21\IN\1740 some_22\DT\1740 of_23\IN\1740 the_24\DT\1740 ischemia_25\NN\14195315 ._26\.\1740
D003042_D007511 NONE it_0\PRP\6125041 is_1\VBZ\836236 unclear_2\JJ\1740 whether_3\IN\1740 a_4\DT\13649268 coronary_5\JJ\1740 cta_6\NN\1740 strategy_7\NN\5902545 would_8\MD\1740 be_9\VB\836236 efficacious_10\JJ\1740 in_11\IN\13603305 <e1>cocaine-associated</e1>_12\JJ\1740 chest_13\JJ\1740 pain_14\NN\14299637 ,_15\,\1740 as_16\IN\14622893 coronary_17\JJ\1740 vasospasm_18\NN\1740 may_19\MD\15209706 account_20\VB\2604760 for_21\IN\1740 some_22\DT\1740 of_23\IN\1740 the_24\DT\1740 <e2>ischemia</e2>_25\NN\14195315 ._26\.\1740
D003042_D007511 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 <e1>cocaine-associated</e1>_3\JJ\1740 myocardial_4\JJ\1740 ischemia_5\NN\14195315 can_6\MD\3094503 result_7\VB\2633881 from_8\IN\1740 coronary_9\JJ\1740 vasoconstriction_10\NN\1149911 ,_11\,\1740 patients_12\NNS\9898892 with_13\IN\1740 cocaine_14\NN\3492717 associated_15\VBD\628491 chest_16\NN\5220461 pain_17\NN\14299637 ,_18\,\1740 a_19\DT\13649268 <e2>non-ischemic</e2>_20\JJ\1740 ecg_21\NN\7000195 ,_22\,\1740 and_23\CC\1740 a_24\DT\13649268 timi_25\NN\1740 risk_26\NN\14541044 score_27\NN\5736149 <_28\XX\1740 2_29\CD\13741022 may_30\MD\15209706 be_31\VB\836236 safely_32\RB\1740 discharged_33\VBN\1640855 from_34\IN\1740 the_35\DT\1740 ed_36\NN\14557898 after_37\IN\1740 a_38\DT\13649268 negative_39\JJ\1740 coronary_40\JJ\1740 cta_41\NN\1740 with_42\IN\1740 a_43\DT\13649268 low_44\JJ\1740 risk_45\NN\14541044 of_46\IN\1740 30-day_47\JJ\1740 adverse_48\JJ\1740 events_49\NNS\23100 ._50\.\1740
D003042_D007511 NONE conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 cocaine-associated_3\JJ\1740 myocardial_4\JJ\1740 ischemia_5\NN\14195315 can_6\MD\3094503 result_7\VB\2633881 from_8\IN\1740 coronary_9\JJ\1740 vasoconstriction_10\NN\1149911 ,_11\,\1740 patients_12\NNS\9898892 with_13\IN\1740 <e1>cocaine</e1>_14\NN\3492717 associated_15\VBD\628491 chest_16\NN\5220461 pain_17\NN\14299637 ,_18\,\1740 a_19\DT\13649268 <e2>non-ischemic</e2>_20\JJ\1740 ecg_21\NN\7000195 ,_22\,\1740 and_23\CC\1740 a_24\DT\13649268 timi_25\NN\1740 risk_26\NN\14541044 score_27\NN\5736149 <_28\XX\1740 2_29\CD\13741022 may_30\MD\15209706 be_31\VB\836236 safely_32\RB\1740 discharged_33\VBN\1640855 from_34\IN\1740 the_35\DT\1740 ed_36\NN\14557898 after_37\IN\1740 a_38\DT\13649268 negative_39\JJ\1740 coronary_40\JJ\1740 cta_41\NN\1740 with_42\IN\1740 a_43\DT\13649268 low_44\JJ\1740 risk_45\NN\14541044 of_46\IN\1740 30-day_47\JJ\1740 adverse_48\JJ\1740 events_49\NNS\23100 ._50\.\1740
D003042_D017202 CID conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 <e1>cocaine-associated</e1>_3\JJ\1740 <e2>myocardial_4\JJ\1740 ischemia</e2>_5\NN\14195315 can_6\MD\3094503 result_7\VB\2633881 from_8\IN\1740 coronary_9\JJ\1740 vasoconstriction_10\NN\1149911 ,_11\,\1740 patients_12\NNS\9898892 with_13\IN\1740 cocaine_14\NN\3492717 associated_15\VBD\628491 chest_16\NN\5220461 pain_17\NN\14299637 ,_18\,\1740 a_19\DT\13649268 non-ischemic_20\JJ\1740 ecg_21\NN\7000195 ,_22\,\1740 and_23\CC\1740 a_24\DT\13649268 timi_25\NN\1740 risk_26\NN\14541044 score_27\NN\5736149 <_28\XX\1740 2_29\CD\13741022 may_30\MD\15209706 be_31\VB\836236 safely_32\RB\1740 discharged_33\VBN\1640855 from_34\IN\1740 the_35\DT\1740 ed_36\NN\14557898 after_37\IN\1740 a_38\DT\13649268 negative_39\JJ\1740 coronary_40\JJ\1740 cta_41\NN\1740 with_42\IN\1740 a_43\DT\13649268 low_44\JJ\1740 risk_45\NN\14541044 of_46\IN\1740 30-day_47\JJ\1740 adverse_48\JJ\1740 events_49\NNS\23100 ._50\.\1740
D003042_D017202 CID conclusions_0\NNS\5837957 :_1\:\1740 although_2\IN\1740 cocaine-associated_3\JJ\1740 <e2>myocardial_4\JJ\1740 ischemia</e2>_5\NN\14195315 can_6\MD\3094503 result_7\VB\2633881 from_8\IN\1740 coronary_9\JJ\1740 vasoconstriction_10\NN\1149911 ,_11\,\1740 patients_12\NNS\9898892 with_13\IN\1740 <e1>cocaine</e1>_14\NN\3492717 associated_15\VBD\628491 chest_16\NN\5220461 pain_17\NN\14299637 ,_18\,\1740 a_19\DT\13649268 non-ischemic_20\JJ\1740 ecg_21\NN\7000195 ,_22\,\1740 and_23\CC\1740 a_24\DT\13649268 timi_25\NN\1740 risk_26\NN\14541044 score_27\NN\5736149 <_28\XX\1740 2_29\CD\13741022 may_30\MD\15209706 be_31\VB\836236 safely_32\RB\1740 discharged_33\VBN\1640855 from_34\IN\1740 the_35\DT\1740 ed_36\NN\14557898 after_37\IN\1740 a_38\DT\13649268 negative_39\JJ\1740 coronary_40\JJ\1740 cta_41\NN\1740 with_42\IN\1740 a_43\DT\13649268 low_44\JJ\1740 risk_45\NN\14541044 of_46\IN\1740 30-day_47\JJ\1740 adverse_48\JJ\1740 events_49\NNS\23100 ._50\.\1740
24284476
D047310_D000647 NONE furthermore_0\RB\1740 ,_1\,\1740 <e1>apigenin</e1>_2\NN\1740 did_3\VBD\1640855 not_4\RB\1740 prevent_5\VB\1740 the_6\DT\1740 <e2>amnesia</e2>_7\NN\5669934 induced_8\VBN\1627355 by_9\IN\1740 scopolamine_10\NN\14712692 (_11\-LRB-\1740 1mg/kg_12\CD\1740 ,_13\,\1740 i.p._14\RB\1740 ,_15\,\1740 30_16\CD\13745420 min_17\NN\15154774 before_18\IN\1740 the_19\DT\1740 acquisition_20\NN\41899 )_21\-RRB-\1740 ._22\.\1740
D012601_D000647 CID furthermore_0\RB\1740 ,_1\,\1740 apigenin_2\NN\1740 did_3\VBD\1640855 not_4\RB\1740 prevent_5\VB\1740 the_6\DT\1740 <e2>amnesia</e2>_7\NN\5669934 induced_8\VBN\1627355 by_9\IN\1740 <e1>scopolamine</e1>_10\NN\14712692 (_11\-LRB-\1740 1mg/kg_12\CD\1740 ,_13\,\1740 i.p._14\RB\1740 ,_15\,\1740 30_16\CD\13745420 min_17\NN\15154774 before_18\IN\1740 the_19\DT\1740 acquisition_20\NN\41899 )_21\-RRB-\1740 ._22\.\1740
10985896
D004317_D010051 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 <e1>doxorubicin</e1>_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 platinum/paclitaxel-refractory_12\JJ\1740 <e2>ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers</e2>_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum_23\NN\5605944 ._24\.\1740
D004317_D010051 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 <e1>doxorubicin</e1>_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 <e2>ovarian_19\JJ\1740 cancer</e2>_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D010051 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 <e1>doxil</e1>_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 <e2>ovarian_19\JJ\1740 cancer</e2>_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D010051 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers</e2>_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 peritoneal_13\JJ\1740 carcinoma_14\NN\14239918 with_15\IN\1740 platinum/paclitaxel-refractory_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 <e1>doxorubicin</e1>_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D004317_D005185 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 <e1>doxorubicin</e1>_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 platinum/paclitaxel-refractory_12\JJ\1740 <e2>ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers</e2>_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum_23\NN\5605944 ._24\.\1740
D004317_D005185 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers</e2>_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 peritoneal_13\JJ\1740 carcinoma_14\NN\14239918 with_15\IN\1740 platinum/paclitaxel-refractory_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 <e1>doxorubicin</e1>_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D004317_D010534 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 <e1>doxorubicin</e1>_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 platinum/paclitaxel-refractory_12\JJ\1740 ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 <e2>carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum</e2>_23\NN\5605944 ._24\.\1740
D004317_D010534 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 <e2>peritoneal_13\JJ\1740 carcinoma</e2>_14\NN\14239918 with_15\IN\1740 platinum/paclitaxel-refractory_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 <e1>doxorubicin</e1>_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D010984_D010051 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>_12\JJ\1740 <e2>ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers</e2>_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum_23\NN\5605944 ._24\.\1740
D010984_D010051 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 <e1>platinum-resistant</e1>_18\JJ\1740 <e2>ovarian_19\JJ\1740 cancer</e2>_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D010984_D010051 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers</e2>_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 peritoneal_13\JJ\1740 carcinoma_14\NN\14239918 with_15\IN\1740 <e1>platinum/paclitaxel-refractory</e1>_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 doxorubicin_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D010984_D010051 NONE definite_0\JJ\1740 ,_1\,\1740 although_2\IN\1740 limited_3\JJ\1740 ,_4\,\1740 antineoplastic_5\JJ\1740 activity_6\NN\30358 is_7\VBZ\836236 observed_8\VBN\2163746 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 well-defined_12\JJ\1740 <e1>platinum-</e1>_13\NN\1740 and_14\CC\1740 paclitaxel-refractory_15\JJ\1740 <e2>ovarian_16\JJ\1740 cancer</e2>_17\NN\14239425 ._18\.\1740
D010984_D005185 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>_12\JJ\1740 <e2>ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers</e2>_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum_23\NN\5605944 ._24\.\1740
D010984_D005185 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers</e2>_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 peritoneal_13\JJ\1740 carcinoma_14\NN\14239918 with_15\IN\1740 <e1>platinum/paclitaxel-refractory</e1>_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 doxorubicin_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D010984_D010534 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>_12\JJ\1740 ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 <e2>carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum</e2>_23\NN\5605944 ._24\.\1740
D010984_D010534 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 <e2>peritoneal_13\JJ\1740 carcinoma</e2>_14\NN\14239918 with_15\IN\1740 <e1>platinum/paclitaxel-refractory</e1>_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 doxorubicin_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D017239_D010051 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>_12\JJ\1740 <e2>ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers</e2>_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum_23\NN\5605944 ._24\.\1740
D017239_D010051 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers</e2>_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 peritoneal_13\JJ\1740 carcinoma_14\NN\14239918 with_15\IN\1740 <e1>platinum/paclitaxel-refractory</e1>_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 doxorubicin_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D017239_D010051 NONE definite_0\JJ\1740 ,_1\,\1740 although_2\IN\1740 limited_3\JJ\1740 ,_4\,\1740 antineoplastic_5\JJ\1740 activity_6\NN\30358 is_7\VBZ\836236 observed_8\VBN\2163746 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 well-defined_12\JJ\1740 platinum-_13\NN\1740 and_14\CC\1740 <e1>paclitaxel-refractory</e1>_15\JJ\1740 <e2>ovarian_16\JJ\1740 cancer</e2>_17\NN\14239425 ._18\.\1740
D017239_D005185 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>_12\JJ\1740 <e2>ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers</e2>_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum_23\NN\5605944 ._24\.\1740
D017239_D005185 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers</e2>_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 peritoneal_13\JJ\1740 carcinoma_14\NN\14239918 with_15\IN\1740 <e1>platinum/paclitaxel-refractory</e1>_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 doxorubicin_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D017239_D010534 NONE phase_0\NN\15113229 2_1\CD\13741022 trial_2\NN\786195 of_3\IN\1740 liposomal_4\JJ\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 40_7\CD\13745420 mg/m(2_8\NN\1740 )_9\-RRB-\1740 )_10\-RRB-\1740 in_11\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>_12\JJ\1740 ovarian_13\JJ\1740 and_14\CC\1740 fallopian_15\JJ\1740 tube_16\NN\3089014 cancers_17\NNS\14239425 and_18\CC\1740 primary_19\JJ\1740 <e2>carcinoma_20\NN\14239918 of_21\IN\1740 the_22\DT\1740 peritoneum</e2>_23\NN\5605944 ._24\.\1740
D017239_D010534 NONE methods_0\NNS\5616786 and_1\CC\1740 materials_2\NNS\19613 :_3\:\1740 patients_4\NNS\9898892 with_5\IN\1740 ovarian_6\JJ\1740 or_7\CC\3541091 fallopian_8\JJ\1740 tube_9\NN\3089014 cancers_10\NNS\14239425 or_11\CC\3541091 primary_12\JJ\1740 <e2>peritoneal_13\JJ\1740 carcinoma</e2>_14\NN\14239918 with_15\IN\1740 <e1>platinum/paclitaxel-refractory</e1>_16\JJ\1740 disease_17\NN\14061805 (_18\-LRB-\1740 stable_19\JJ\1740 or_20\CC\3541091 progressive_21\JJ\1740 disease_22\NN\14061805 following_23\VBG\1835496 treatment_24\NN\654885 with_25\IN\1740 these_26\DT\1740 agents_27\NNS\7347 or_28\CC\3541091 previous_29\JJ\1740 objective_30\JJ\1740 response_31\NN\11410625 <3_32\IN\1740 months_33\NNS\15113229 in_34\IN\13603305 duration_35\NN\15113229 )_36\-RRB-\1740 were_37\VBD\836236 treated_38\VBN\2376958 with_39\IN\1740 liposomal_40\JJ\1740 doxorubicin_41\NN\2716866 at_42\IN\14622893 a_43\DT\13649268 dose_44\NN\3740161 of_45\IN\1740 40_46\CD\13745420 mg/m(2_47\NN\1740 )_48\-RRB-\1740 q_49\DT\6828818 4_50\CD\13741022 weeks_51\NNS\15113229 ._52\.\1740
D004317_D064420 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 <e1>doxorubicin</e1>_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 <e2>toxicity</e2>_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D064420 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 <e1>doxil</e1>_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 <e2>toxicity</e2>_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D064420 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 modified_3\VBN\109660 liposomal_4\JJ\1740 <e1>doxorubicin</e1>_5\NN\2716866 regimen_6\NN\5898568 results_7\VBZ\2633881 in_8\IN\13603305 less_9\JJR\1740 <e2>toxicity</e2>_10\NN\13576101 (_11\-LRB-\1740 stomatitis_12\NN\14336539 ,_13\,\1740 hand-foot_14\JJ\1740 syndrome_15\NN\5870365 )_16\-RRB-\1740 than_17\IN\1740 the_18\DT\1740 standard_19\JJ\1740 fda-approved_20\JJ\1740 dose_21\NN\3740161 schedule_22\NN\5898568 ._23\.\1740
D004317_D060831 CID background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 <e1>doxorubicin</e1>_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 <e2>erythrodysesthesia</e2>_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D060831 CID background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 <e1>doxorubicin</e1>_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 <e2>hand-foot_44\JJ\1740 syndrome</e2>_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D060831 CID background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 <e1>doxil</e1>_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 <e2>erythrodysesthesia</e2>_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D060831 CID background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 <e1>doxil</e1>_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 <e2>hand-foot_44\JJ\1740 syndrome</e2>_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D004317_D060831 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 modified_3\VBN\109660 liposomal_4\JJ\1740 <e1>doxorubicin</e1>_5\NN\2716866 regimen_6\NN\5898568 results_7\VBZ\2633881 in_8\IN\13603305 less_9\JJR\1740 toxicity_10\NN\13576101 (_11\-LRB-\1740 stomatitis_12\NN\14336539 ,_13\,\1740 <e2>hand-foot_14\JJ\1740 syndrome</e2>_15\NN\5870365 )_16\-RRB-\1740 than_17\IN\1740 the_18\DT\1740 standard_19\JJ\1740 fda-approved_20\JJ\1740 dose_21\NN\3740161 schedule_22\NN\5898568 ._23\.\1740
D004317_D013280 CID background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 <e1>doxorubicin</e1>_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 <e2>stomatitis</e2>_49\NN\14336539 ._50\.\1740
D004317_D013280 CID background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 <e1>doxil</e1>_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 platinum-resistant_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 <e2>stomatitis</e2>_49\NN\14336539 ._50\.\1740
D004317_D013280 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 modified_3\VBN\109660 liposomal_4\JJ\1740 <e1>doxorubicin</e1>_5\NN\2716866 regimen_6\NN\5898568 results_7\VBZ\2633881 in_8\IN\13603305 less_9\JJR\1740 toxicity_10\NN\13576101 (_11\-LRB-\1740 <e2>stomatitis</e2>_12\NN\14336539 ,_13\,\1740 hand-foot_14\JJ\1740 syndrome_15\NN\5870365 )_16\-RRB-\1740 than_17\IN\1740 the_18\DT\1740 standard_19\JJ\1740 fda-approved_20\JJ\1740 dose_21\NN\3740161 schedule_22\NN\5898568 ._23\.\1740
D010984_D064420 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 <e1>platinum-resistant</e1>_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 <e2>toxicity</e2>_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D010984_D060831 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 <e1>platinum-resistant</e1>_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 <e2>erythrodysesthesia</e2>_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D010984_D060831 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 <e1>platinum-resistant</e1>_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 <e2>hand-foot_44\JJ\1740 syndrome</e2>_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 stomatitis_49\NN\14336539 ._50\.\1740
D010984_D013280 NONE background_0\NN\4921011 :_1\:\1740 several_2\JJ\1740 studies_3\NNS\635850 have_4\VBP\2108377 demonstrated_5\VBN\2137132 liposomal_6\JJ\1740 doxorubicin_7\NN\2716866 (_8\-LRB-\1740 doxil_9\NN\1740 )_10\-RRB-\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 active_14\JJ\1740 antineoplastic_15\JJ\1740 agent_16\NN\7347 in_17\IN\13603305 <e1>platinum-resistant</e1>_18\JJ\1740 ovarian_19\JJ\1740 cancer_20\NN\14239425 ,_21\,\1740 with_22\IN\1740 dose_23\NN\3740161 limiting_24\NN\13796779 toxicity_25\NN\13576101 of_26\IN\1740 the_27\DT\1740 standard_28\JJ\1740 dosing_29\NN\1740 regimen_30\NN\5898568 (_31\-LRB-\1740 50_32\CD\13745420 mg/m(2_33\NN\1740 )_34\-RRB-\1740 q_35\DT\6828818 4_36\CD\13741022 weeks_37\NNS\15113229 )_38\-RRB-\1740 being_39\VBG\836236 severe_40\JJ\1740 erythrodysesthesia_41\NN\1740 (_42\-LRB-\1740 "_43\``\1740 hand-foot_44\JJ\1740 syndrome_45\NN\5870365 "_46\''\1740 )_47\-RRB-\1740 and_48\CC\1740 <e2>stomatitis</e2>_49\NN\14336539 ._50\.\1740
10939760
D013411_D058186 CID patterns_0\NNS\5726345 of_1\IN\1740 <e1>sulfadiazine</e1>_2\NN\4352070 <e2>acute_3\JJ\1740 nephrotoxicity</e2>_4\NN\1740 ._5\.\1740
D013411_D058186 CID <e1>sulfadiazine</e1>_0\NN\4352070 <e2>acute_1\JJ\1740 nephrotoxicity</e2>_2\NN\1740 is_3\VBZ\836236 reviving_4\VBG\22099 specially_5\RB\1740 because_6\IN\1740 of_7\IN\1740 its_8\PRP$\6125041 use_9\NN\407535 in_10\IN\13603305 toxoplasmosis_11\NN\14174549 in_12\IN\13603305 hiv-positive_13\JJ\1740 patients_14\NNS\9898892 ._15\.\1740
D013411_D014123 NONE <e1>sulfadiazine</e1>_0\NN\4352070 acute_1\JJ\1740 nephrotoxicity_2\NN\1740 is_3\VBZ\836236 reviving_4\VBG\22099 specially_5\RB\1740 because_6\IN\1740 of_7\IN\1740 its_8\PRP$\6125041 use_9\NN\407535 in_10\IN\13603305 <e2>toxoplasmosis</e2>_11\NN\14174549 in_12\IN\13603305 hiv-positive_13\JJ\1740 patients_14\NNS\9898892 ._15\.\1740
D013411_D009846 NONE under_0\IN\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>sulfadiazine</e1>_3\NN\4352070 they_4\PRP\1740 developed_5\VBD\1753788 <e2>oliguria</e2>_6\NN\14299637 ,_7\,\1740 abdominal_8\JJ\1740 pain_9\NN\14299637 ,_10\,\1740 renal_11\JJ\1740 failure_12\NN\66216 and_13\CC\1740 showed_14\VBD\2137132 multiple_15\JJ\1740 radiolucent_16\JJ\1740 renal_17\JJ\1740 calculi_18\NNS\9416076 in_19\IN\13603305 echography_20\NN\901083 ._21\.\1740
D013411_D015746 NONE under_0\IN\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>sulfadiazine</e1>_3\NN\4352070 they_4\PRP\1740 developed_5\VBD\1753788 oliguria_6\NN\14299637 ,_7\,\1740 <e2>abdominal_8\JJ\1740 pain</e2>_9\NN\14299637 ,_10\,\1740 renal_11\JJ\1740 failure_12\NN\66216 and_13\CC\1740 showed_14\VBD\2137132 multiple_15\JJ\1740 radiolucent_16\JJ\1740 renal_17\JJ\1740 calculi_18\NNS\9416076 in_19\IN\13603305 echography_20\NN\901083 ._21\.\1740
D013411_D051437 NONE under_0\IN\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>sulfadiazine</e1>_3\NN\4352070 they_4\PRP\1740 developed_5\VBD\1753788 oliguria_6\NN\14299637 ,_7\,\1740 abdominal_8\JJ\1740 pain_9\NN\14299637 ,_10\,\1740 <e2>renal_11\JJ\1740 failure</e2>_12\NN\66216 and_13\CC\1740 showed_14\VBD\2137132 multiple_15\JJ\1740 radiolucent_16\JJ\1740 renal_17\JJ\1740 calculi_18\NNS\9416076 in_19\IN\13603305 echography_20\NN\901083 ._21\.\1740
D013411_D007669 CID under_0\IN\1740 treatment_1\NN\654885 with_2\IN\1740 <e1>sulfadiazine</e1>_3\NN\4352070 they_4\PRP\1740 developed_5\VBD\1753788 oliguria_6\NN\14299637 ,_7\,\1740 abdominal_8\JJ\1740 pain_9\NN\14299637 ,_10\,\1740 renal_11\JJ\1740 failure_12\NN\66216 and_13\CC\1740 showed_14\VBD\2137132 multiple_15\JJ\1740 radiolucent_16\JJ\1740 <e2>renal_17\JJ\1740 calculi</e2>_18\NNS\9416076 in_19\IN\13603305 echography_20\NN\901083 ._21\.\1740
14748761
C030852_D009369 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 quantify_3\VB\947077 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 these_7\DT\1740 cardiac_8\JJ\1740 events_9\NNS\23100 ,_10\,\1740 we_11\PRP\1740 performed_12\VBD\2367363 a_13\DT\13649268 meta-analysis_14\NN\1740 of_15\IN\1740 clinical_16\JJ\1740 trials_17\NNS\786195 comparing_18\VBG\644583 <e1>vnr</e1>_19\NN\1740 with_20\IN\1740 other_21\JJ\1740 chemotherapeutic_22\JJ\1740 agents_23\NNS\7347 in_24\IN\13603305 the_25\DT\1740 treatment_26\NN\654885 of_27\IN\1740 various_28\JJ\1740 <e2>malignancies</e2>_29\NNS\14070360 ._30\.\1740
C030852_D009369 NONE randomized_0\JJ\1740 clinical_1\JJ\1740 trials_2\NNS\786195 comparing_3\VBG\644583 <e1>vnr</e1>_4\NN\1740 with_5\IN\1740 other_6\JJ\1740 drugs_7\NNS\14778436 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 <e2>cancer</e2>_12\NN\14239425 were_13\VBD\836236 searched_14\VBN\2131279 in_15\IN\13603305 medline_16\NN\4402746 ,_17\,\1740 embase_18\NN\1740 ,_19\,\1740 evidence-based_20\JJ\1740 medicine_21\NNP\6045562 reviews_22\NNPS\5733583 databases_23\NNS\6634376 and_24\CC\1740 the_25\DT\1740 cochrane_26\NNP\1740 library_27\NN\4105893 from_28\IN\1740 1987_29\CD\1740 to_30\IN\1740 2002_31\CD\1740 ._32\.\1740
C030852_D066126 CID the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 <e1>vnr</e1>_3\NN\1740 cardiac_4\NN\1740 events_5\NNS\23100 was_6\VBD\836236 similar_7\JJ\1740 to_8\TO\1740 vindesine_9\NN\1740 (_10\-LRB-\1740 vds_11\NN\14122235 )_12\-RRB-\1740 and_13\CC\1740 other_14\JJ\1740 <e2>cardiotoxic</e2>_15\JJ\1740 drugs_16\NNS\14778436 [_17\-LRB-\1740 fluorouracil_18\NN\2722166 ,_19\,\1740 anthracyclines_20\NNS\1740 ,_21\,\1740 gemcitabine_22\NN\1740 (_23\-LRB-\1740 gem_24\NN\2743547 )_25\-RRB-\1740 em_26\NN\13600404 leader_27\NN\7846 ]_28\-RRB-\1740 ._29\.\1740
D014751_D066126 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 vnr_3\NN\1740 cardiac_4\NN\1740 events_5\NNS\23100 was_6\VBD\836236 similar_7\JJ\1740 to_8\TO\1740 <e1>vindesine</e1>_9\NN\1740 (_10\-LRB-\1740 vds_11\NN\14122235 )_12\-RRB-\1740 and_13\CC\1740 other_14\JJ\1740 <e2>cardiotoxic</e2>_15\JJ\1740 drugs_16\NNS\14778436 [_17\-LRB-\1740 fluorouracil_18\NN\2722166 ,_19\,\1740 anthracyclines_20\NNS\1740 ,_21\,\1740 gemcitabine_22\NN\1740 (_23\-LRB-\1740 gem_24\NN\2743547 )_25\-RRB-\1740 em_26\NN\13600404 leader_27\NN\7846 ]_28\-RRB-\1740 ._29\.\1740
D014751_D066126 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 vnr_3\NN\1740 cardiac_4\NN\1740 events_5\NNS\23100 was_6\VBD\836236 similar_7\JJ\1740 to_8\TO\1740 vindesine_9\NN\1740 (_10\-LRB-\1740 <e1>vds</e1>_11\NN\14122235 )_12\-RRB-\1740 and_13\CC\1740 other_14\JJ\1740 <e2>cardiotoxic</e2>_15\JJ\1740 drugs_16\NNS\14778436 [_17\-LRB-\1740 fluorouracil_18\NN\2722166 ,_19\,\1740 anthracyclines_20\NNS\1740 ,_21\,\1740 gemcitabine_22\NN\1740 (_23\-LRB-\1740 gem_24\NN\2743547 )_25\-RRB-\1740 em_26\NN\13600404 leader_27\NN\7846 ]_28\-RRB-\1740 ._29\.\1740
D005472_D066126 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 vnr_3\NN\1740 cardiac_4\NN\1740 events_5\NNS\23100 was_6\VBD\836236 similar_7\JJ\1740 to_8\TO\1740 vindesine_9\NN\1740 (_10\-LRB-\1740 vds_11\NN\14122235 )_12\-RRB-\1740 and_13\CC\1740 other_14\JJ\1740 <e2>cardiotoxic</e2>_15\JJ\1740 drugs_16\NNS\14778436 [_17\-LRB-\1740 <e1>fluorouracil</e1>_18\NN\2722166 ,_19\,\1740 anthracyclines_20\NNS\1740 ,_21\,\1740 gemcitabine_22\NN\1740 (_23\-LRB-\1740 gem_24\NN\2743547 )_25\-RRB-\1740 em_26\NN\13600404 leader_27\NN\7846 ]_28\-RRB-\1740 ._29\.\1740
D018943_D066126 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 vnr_3\NN\1740 cardiac_4\NN\1740 events_5\NNS\23100 was_6\VBD\836236 similar_7\JJ\1740 to_8\TO\1740 vindesine_9\NN\1740 (_10\-LRB-\1740 vds_11\NN\14122235 )_12\-RRB-\1740 and_13\CC\1740 other_14\JJ\1740 <e2>cardiotoxic</e2>_15\JJ\1740 drugs_16\NNS\14778436 [_17\-LRB-\1740 fluorouracil_18\NN\2722166 ,_19\,\1740 <e1>anthracyclines</e1>_20\NNS\1740 ,_21\,\1740 gemcitabine_22\NN\1740 (_23\-LRB-\1740 gem_24\NN\2743547 )_25\-RRB-\1740 em_26\NN\13600404 leader_27\NN\7846 ]_28\-RRB-\1740 ._29\.\1740
C056507_D066126 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 vnr_3\NN\1740 cardiac_4\NN\1740 events_5\NNS\23100 was_6\VBD\836236 similar_7\JJ\1740 to_8\TO\1740 vindesine_9\NN\1740 (_10\-LRB-\1740 vds_11\NN\14122235 )_12\-RRB-\1740 and_13\CC\1740 other_14\JJ\1740 <e2>cardiotoxic</e2>_15\JJ\1740 drugs_16\NNS\14778436 [_17\-LRB-\1740 fluorouracil_18\NN\2722166 ,_19\,\1740 anthracyclines_20\NNS\1740 ,_21\,\1740 <e1>gemcitabine</e1>_22\NN\1740 (_23\-LRB-\1740 gem_24\NN\2743547 )_25\-RRB-\1740 em_26\NN\13600404 leader_27\NN\7846 ]_28\-RRB-\1740 ._29\.\1740
C056507_D066126 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 vnr_3\NN\1740 cardiac_4\NN\1740 events_5\NNS\23100 was_6\VBD\836236 similar_7\JJ\1740 to_8\TO\1740 vindesine_9\NN\1740 (_10\-LRB-\1740 vds_11\NN\14122235 )_12\-RRB-\1740 and_13\CC\1740 other_14\JJ\1740 <e2>cardiotoxic</e2>_15\JJ\1740 drugs_16\NNS\14778436 [_17\-LRB-\1740 fluorouracil_18\NN\2722166 ,_19\,\1740 anthracyclines_20\NNS\1740 ,_21\,\1740 gemcitabine_22\NN\1740 (_23\-LRB-\1740 <e1>gem</e1>_24\NN\2743547 )_25\-RRB-\1740 em_26\NN\13600404 leader_27\NN\7846 ]_28\-RRB-\1740 ._29\.\1740
3423103
D003000_D007022 CID participation_0\NN\1080366 of_1\IN\1740 a_2\DT\13649268 bulbospinal_3\JJ\1740 serotonergic_4\NN\1740 pathway_5\NN\5483677 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 brain_9\NN\5462674 in_10\IN\13603305 <e1>clonidine-induced</e1>_11\JJ\1740 <e2>hypotension</e2>_12\NN\14057371 and_13\CC\1740 bradycardia_14\NN\14110674 ._15\.\1740
D003000_D007022 CID the_0\DT\1740 <e1>clonidine-induced</e1>_1\JJ\1740 <e2>hypotension</e2>_2\NN\14057371 was_3\VBD\836236 antagonized_4\VBN\1787955 by_5\IN\1740 prior_6\JJ\1740 spinal_7\JJ\1740 transection_8\NN\1740 ,_9\,\1740 but_10\CC\1740 not_11\RB\1740 bilateral_12\JJ\1740 vagotomy_13\NN\1740 ._14\.\1740
D003000_D007022 CID the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 a_4\DT\13649268 bulbospinal_5\JJ\1740 serotonergic_6\NN\1740 pathway_7\NN\5483677 is_8\VBZ\836236 involved_9\VBN\2676054 in_10\IN\13603305 development_11\NN\248977 of_12\IN\1740 <e1>clonidine-induced</e1>_13\JJ\1740 <e2>hypotension</e2>_14\NN\14057371 and_15\CC\1740 bradycardia_16\NN\14110674 ._17\.\1740
D003000_D001919 CID participation_0\NN\1080366 of_1\IN\1740 a_2\DT\13649268 bulbospinal_3\JJ\1740 serotonergic_4\NN\1740 pathway_5\NN\5483677 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 brain_9\NN\5462674 in_10\IN\13603305 <e1>clonidine-induced</e1>_11\JJ\1740 hypotension_12\NN\14057371 and_13\CC\1740 <e2>bradycardia</e2>_14\NN\14110674 ._15\.\1740
D003000_D001919 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 the_5\DT\1740 <e1>clonidine-induced</e1>_6\JJ\1740 <e2>bradycardia</e2>_7\NN\14110674 was_8\VBD\836236 antagonized_9\VBN\1787955 by_10\IN\1740 prior_11\JJ\1740 bilateral_12\JJ\1740 vagotomy_13\NN\1740 ,_14\,\1740 but_15\CC\1740 not_16\RB\1740 spinal_17\JJ\1740 transection_18\NN\1740 ._19\.\1740
D003000_D001919 CID furthermore_0\RB\1740 ,_1\,\1740 selective_2\JJ\1740 destruction_3\NN\209943 of_4\IN\1740 the_5\DT\1740 spinal_6\JJ\1740 5-ht_7\NN\1740 nerves_8\NNS\14373582 ,_9\,\1740 produced_10\VBN\1617192 by_11\IN\1740 bilateral_12\JJ\1740 spinal_13\JJ\1740 injection_14\NN\320852 of_15\IN\1740 5,7-dihydroxytryptamine_16\NN\1740 ,_17\,\1740 reduced_18\VBD\441445 the_19\DT\1740 magnitude_20\NN\4916342 of_21\IN\1740 the_22\DT\1740 vasodepressor_23\NN\1740 or_24\CC\3541091 the_25\DT\1740 <e2>bradycardiac</e2>_26\NN\1740 responses_27\NNS\11410625 to_28\TO\1740 <e1>clonidine</e1>_29\NN\2721160 microinjected_30\VBN\1740 into_31\IN\1740 the_32\DT\1740 area_33\NN\8630985 near_34\IN\1740 the_35\DT\1740 ventrolateral_36\JJ\1740 surface_37\NN\21939 of_38\IN\1740 the_39\DT\1740 medulla_40\NN\14864360 oblongata_41\NNS\1740 in_42\IN\13603305 rats_43\NNS\2329401 ._44\.\1740
D003000_D001919 CID the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 a_4\DT\13649268 bulbospinal_5\JJ\1740 serotonergic_6\NN\1740 pathway_7\NN\5483677 is_8\VBZ\836236 involved_9\VBN\2676054 in_10\IN\13603305 development_11\NN\248977 of_12\IN\1740 <e1>clonidine-induced</e1>_13\JJ\1740 hypotension_14\NN\14057371 and_15\CC\1740 <e2>bradycardia</e2>_16\NN\14110674 ._17\.\1740
D012701_D001919 NONE furthermore_0\RB\1740 ,_1\,\1740 selective_2\JJ\1740 destruction_3\NN\209943 of_4\IN\1740 the_5\DT\1740 spinal_6\JJ\1740 <e1>5-ht</e1>_7\NN\1740 nerves_8\NNS\14373582 ,_9\,\1740 produced_10\VBN\1617192 by_11\IN\1740 bilateral_12\JJ\1740 spinal_13\JJ\1740 injection_14\NN\320852 of_15\IN\1740 5,7-dihydroxytryptamine_16\NN\1740 ,_17\,\1740 reduced_18\VBD\441445 the_19\DT\1740 magnitude_20\NN\4916342 of_21\IN\1740 the_22\DT\1740 vasodepressor_23\NN\1740 or_24\CC\3541091 the_25\DT\1740 <e2>bradycardiac</e2>_26\NN\1740 responses_27\NNS\11410625 to_28\TO\1740 clonidine_29\NN\2721160 microinjected_30\VBN\1740 into_31\IN\1740 the_32\DT\1740 area_33\NN\8630985 near_34\IN\1740 the_35\DT\1740 ventrolateral_36\JJ\1740 surface_37\NN\21939 of_38\IN\1740 the_39\DT\1740 medulla_40\NN\14864360 oblongata_41\NNS\1740 in_42\IN\13603305 rats_43\NNS\2329401 ._44\.\1740
D015116_D001919 NONE furthermore_0\RB\1740 ,_1\,\1740 selective_2\JJ\1740 destruction_3\NN\209943 of_4\IN\1740 the_5\DT\1740 spinal_6\JJ\1740 5-ht_7\NN\1740 nerves_8\NNS\14373582 ,_9\,\1740 produced_10\VBN\1617192 by_11\IN\1740 bilateral_12\JJ\1740 spinal_13\JJ\1740 injection_14\NN\320852 of_15\IN\1740 <e1>5,7-dihydroxytryptamine</e1>_16\NN\1740 ,_17\,\1740 reduced_18\VBD\441445 the_19\DT\1740 magnitude_20\NN\4916342 of_21\IN\1740 the_22\DT\1740 vasodepressor_23\NN\1740 or_24\CC\3541091 the_25\DT\1740 <e2>bradycardiac</e2>_26\NN\1740 responses_27\NNS\11410625 to_28\TO\1740 clonidine_29\NN\2721160 microinjected_30\VBN\1740 into_31\IN\1740 the_32\DT\1740 area_33\NN\8630985 near_34\IN\1740 the_35\DT\1740 ventrolateral_36\JJ\1740 surface_37\NN\21939 of_38\IN\1740 the_39\DT\1740 medulla_40\NN\14864360 oblongata_41\NNS\1740 in_42\IN\13603305 rats_43\NNS\2329401 ._44\.\1740
15094729
D020888_D014786 CID the_0\DT\1740 natural_1\JJ\1740 history_2\NN\15120823 of_3\IN\1740 <e1>vigabatrin</e1>_4\NN\1740 associated_5\VBN\628491 <e2>visual_6\JJ\1740 field_7\NN\8673395 defects</e2>_8\NNS\14462666 in_9\IN\13603305 patients_10\NNS\9898892 electing_11\VBG\674607 to_12\TO\1740 continue_13\VB\2367363 their_14\PRP$\1740 medication_15\NN\3247620 ._16\.\1740
D020888_D014786 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 natural_5\JJ\1740 history_6\NN\15120823 of_7\IN\1740 <e2>visual_8\JJ\1740 field_9\NN\8673395 defects</e2>_10\NNS\14462666 in_11\IN\13603305 a_12\DT\13649268 group_13\NN\2137 of_14\IN\1740 patients_15\NNS\9898892 known_16\VBN\2110220 to_17\TO\1740 have_18\VB\2108377 <e1>vigabatrin-associated</e1>_19\JJ\1740 changes_20\NNS\7283608 who_21\WP\8299493 elected_22\VBD\674607 to_23\TO\1740 continue_24\VB\2367363 the_25\DT\1740 medication_26\NN\3247620 because_27\IN\1740 of_28\IN\1740 good_29\JJ\1740 seizure_30\JJ\1740 control_31\NN\5190804 ._32\.\1740
D020888_D014786 CID conclusion_0\NN\5837957 :_1\:\1740 established_2\JJ\1740 <e2>visual_3\JJ\1740 field_4\NN\8673395 defects</e2>_5\NNS\14462666 presumed_6\VBN\719734 to_7\TO\1740 be_8\VB\836236 due_9\JJ\1740 to_10\TO\1740 <e1>vigabatrin</e1>_11\NN\1740 therapy_12\NN\657604 did_13\VBD\1640855 not_14\RB\1740 usually_15\RB\1740 progress_16\VB\252019 in_17\IN\13603305 spite_18\NN\7550369 of_19\IN\1740 continuing_20\VBG\2367363 use_21\NN\407535 of_22\IN\1740 the_23\DT\1740 medication_24\NN\3247620 ._25\.\1740
D020888_D014786 CID these_0\DT\1740 data_1\NNS\7951464 give_2\VBP\2327200 support_3\NN\407535 to_4\TO\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 the_8\DT\1740 pathogenesis_9\NN\13533470 of_10\IN\1740 <e1>vigabatrin-associated</e1>_11\JJ\1740 <e2>visual_12\JJ\1740 field_13\NN\8673395 defects</e2>_14\NNS\14462666 may_15\MD\15209706 be_16\VB\836236 an_17\DT\6697703 idiosyncratic_18\JJ\1740 adverse_19\JJ\1740 drug_20\NN\14778436 reaction_21\NN\13446390 rather_22\RB\1740 than_23\IN\1740 dose-dependent_24\JJ\1740 toxicity_25\NN\13576101 ._26\.\1740
D020888_D012640 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 natural_5\JJ\1740 history_6\NN\15120823 of_7\IN\1740 visual_8\JJ\1740 field_9\NN\8673395 defects_10\NNS\14462666 in_11\IN\13603305 a_12\DT\13649268 group_13\NN\2137 of_14\IN\1740 patients_15\NNS\9898892 known_16\VBN\2110220 to_17\TO\1740 have_18\VB\2108377 <e1>vigabatrin-associated</e1>_19\JJ\1740 changes_20\NNS\7283608 who_21\WP\8299493 elected_22\VBD\674607 to_23\TO\1740 continue_24\VB\2367363 the_25\DT\1740 medication_26\NN\3247620 because_27\IN\1740 of_28\IN\1740 good_29\JJ\1740 <e2>seizure</e2>_30\JJ\1740 control_31\NN\5190804 ._32\.\1740
D020888_D064420 NONE these_0\DT\1740 data_1\NNS\7951464 give_2\VBP\2327200 support_3\NN\407535 to_4\TO\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 the_8\DT\1740 pathogenesis_9\NN\13533470 of_10\IN\1740 <e1>vigabatrin-associated</e1>_11\JJ\1740 visual_12\JJ\1740 field_13\NN\8673395 defects_14\NNS\14462666 may_15\MD\15209706 be_16\VB\836236 an_17\DT\6697703 idiosyncratic_18\JJ\1740 adverse_19\JJ\1740 drug_20\NN\14778436 reaction_21\NN\13446390 rather_22\RB\1740 than_23\IN\1740 dose-dependent_24\JJ\1740 <e2>toxicity</e2>_25\NN\13576101 ._26\.\1740
1280707
D002045_D001145 CID after_0\IN\1740 determining_1\VBG\1645601 the_2\DT\1740 <e1>bupivacaine</e1>_3\NN\1740 ad50_4\NN\1740 (_5\-LRB-\1740 the_6\DT\1740 concentration_7\NN\4916342 of_8\IN\1740 bupivacaine_9\NN\1740 that_10\WDT\1740 caused_11\VBD\1617192 50_12\CD\13745420 %_13\NN\1740 of_14\IN\1740 all_15\DT\1740 beating_16\NN\1170962 rat_17\NN\2329401 heart_18\NN\5919034 myocyte_19\NN\1740 cultures_20\NNS\7966140 to_21\TO\1740 become_22\VB\146138 <e2>arrhythmic</e2>_23\JJ\1740 )_24\-RRB-\1740 ,_25\,\1740 we_26\PRP\1740 determined_27\VBD\1645601 the_28\DT\1740 effect_29\NN\34213 of_30\IN\1740 1-hour_31\NN\1740 progesterone_32\NN\14747338 hcl_33\NN\1740 exposure_34\NN\5042871 on_35\IN\1740 myocyte_36\NN\1740 contractile_37\NN\1740 rhythm_38\NN\15122011 ._39\.\1740
D002045_D001145 CID after_0\IN\1740 determining_1\VBG\1645601 the_2\DT\1740 bupivacaine_3\NN\1740 ad50_4\NN\1740 (_5\-LRB-\1740 the_6\DT\1740 concentration_7\NN\4916342 of_8\IN\1740 <e1>bupivacaine</e1>_9\NN\1740 that_10\WDT\1740 caused_11\VBD\1617192 50_12\CD\13745420 %_13\NN\1740 of_14\IN\1740 all_15\DT\1740 beating_16\NN\1170962 rat_17\NN\2329401 heart_18\NN\5919034 myocyte_19\NN\1740 cultures_20\NNS\7966140 to_21\TO\1740 become_22\VB\146138 <e2>arrhythmic</e2>_23\JJ\1740 )_24\-RRB-\1740 ,_25\,\1740 we_26\PRP\1740 determined_27\VBD\1645601 the_28\DT\1740 effect_29\NN\34213 of_30\IN\1740 1-hour_31\NN\1740 progesterone_32\NN\14747338 hcl_33\NN\1740 exposure_34\NN\5042871 on_35\IN\1740 myocyte_36\NN\1740 contractile_37\NN\1740 rhythm_38\NN\15122011 ._39\.\1740
D002045_D001145 CID potentiation_0\NN\13564910 of_1\IN\1740 <e1>bupivacaine</e1>_2\NN\1740 <e2>arrhythmia</e2>_3\NN\14103288 in_4\IN\13603305 myocyte_5\NN\1740 cultures_6\NNS\7966140 suggests_7\VBZ\1010118 that_8\IN\1740 this_9\DT\1740 effect_10\NN\34213 is_11\VBZ\836236 at_12\IN\14622893 least_13\JJS\1740 partly_14\RB\1740 mediated_15\VBN\761713 at_16\IN\14622893 the_17\DT\1740 myocyte_18\NN\1740 level_19\NN\4916342 ._20\.\1740
D011374_D001145 CID after_0\IN\1740 determining_1\VBG\1645601 the_2\DT\1740 bupivacaine_3\NN\1740 ad50_4\NN\1740 (_5\-LRB-\1740 the_6\DT\1740 concentration_7\NN\4916342 of_8\IN\1740 bupivacaine_9\NN\1740 that_10\WDT\1740 caused_11\VBD\1617192 50_12\CD\13745420 %_13\NN\1740 of_14\IN\1740 all_15\DT\1740 beating_16\NN\1170962 rat_17\NN\2329401 heart_18\NN\5919034 myocyte_19\NN\1740 cultures_20\NNS\7966140 to_21\TO\1740 become_22\VB\146138 <e2>arrhythmic</e2>_23\JJ\1740 )_24\-RRB-\1740 ,_25\,\1740 we_26\PRP\1740 determined_27\VBD\1645601 the_28\DT\1740 effect_29\NN\34213 of_30\IN\1740 1-hour_31\NN\1740 <e1>progesterone</e1>_32\NN\14747338 hcl_33\NN\1740 exposure_34\NN\5042871 on_35\IN\1740 myocyte_36\NN\1740 contractile_37\NN\1740 rhythm_38\NN\15122011 ._39\.\1740
D006851_D001145 NONE after_0\IN\1740 determining_1\VBG\1645601 the_2\DT\1740 bupivacaine_3\NN\1740 ad50_4\NN\1740 (_5\-LRB-\1740 the_6\DT\1740 concentration_7\NN\4916342 of_8\IN\1740 bupivacaine_9\NN\1740 that_10\WDT\1740 caused_11\VBD\1617192 50_12\CD\13745420 %_13\NN\1740 of_14\IN\1740 all_15\DT\1740 beating_16\NN\1170962 rat_17\NN\2329401 heart_18\NN\5919034 myocyte_19\NN\1740 cultures_20\NNS\7966140 to_21\TO\1740 become_22\VB\146138 <e2>arrhythmic</e2>_23\JJ\1740 )_24\-RRB-\1740 ,_25\,\1740 we_26\PRP\1740 determined_27\VBD\1645601 the_28\DT\1740 effect_29\NN\34213 of_30\IN\1740 1-hour_31\NN\1740 progesterone_32\NN\14747338 <e1>hcl</e1>_33\NN\1740 exposure_34\NN\5042871 on_35\IN\1740 myocyte_36\NN\1740 contractile_37\NN\1740 rhythm_38\NN\15122011 ._39\.\1740
7477981
D007980_D004409 NONE <e1>levodopa-induced</e1>_0\JJ\1740 <e2>dyskinesias</e2>_1\NNS\14084880 are_2\VBP\836236 improved_3\VBN\126264 by_4\IN\1740 fluoxetine_5\NN\4169152 ._6\.\1740
D007980_D004409 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 <e2>dyskinesias</e2>_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 <e1>levodopa-responsive</e1>_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D007980_D004409 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 fluoxetine_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 <e1>levodopa-</e1>_12\NN\1740 or_13\CC\3541091 dopamine_14\NN\14807737 agonist-induced_15\JJ\1740 <e2>dyskinesias</e2>_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 parkinsonian_19\JJ\1740 motor_20\NN\3699975 disability_21\NN\14547369 ._22\.\1740
D005473_D004409 CID levodopa-induced_0\JJ\1740 <e2>dyskinesias</e2>_1\NNS\14084880 are_2\VBP\836236 improved_3\VBN\126264 by_4\IN\1740 <e1>fluoxetine</e1>_5\NN\4169152 ._6\.\1740
D005473_D004409 CID we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 <e2>dyskinesias</e2>_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>fluoxetine</e1>_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D005473_D004409 CID after_0\IN\1740 <e1>fluoxetine</e1>_1\NN\4169152 treatment_2\NN\654885 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 significant_7\JJ\1740 47_8\CD\1740 %_9\NN\1740 improvement_10\NN\7359599 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.05_14\CD\1740 )_15\-RRB-\1740 of_16\IN\1740 apomorphine-induced_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 without_19\IN\1740 modification_20\NN\191142 of_21\IN\1740 parkinsonian_22\JJ\1740 motor_23\NN\3699975 disability_24\NN\14547369 ._25\.\1740
D005473_D004409 CID the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 <e1>fluoxetine</e1>_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 levodopa-_12\NN\1740 or_13\CC\3541091 dopamine_14\NN\14807737 agonist-induced_15\JJ\1740 <e2>dyskinesias</e2>_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 parkinsonian_19\JJ\1740 motor_20\NN\3699975 disability_21\NN\14547369 ._22\.\1740
D007980_D009069 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 <e2>motor_5\NN\3699975 disability</e2>_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 <e1>levodopa-responsive</e1>_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D007980_D009069 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 fluoxetine_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 <e1>levodopa-</e1>_12\NN\1740 or_13\CC\3541091 dopamine_14\NN\14807737 agonist-induced_15\JJ\1740 dyskinesias_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 parkinsonian_19\JJ\1740 <e2>motor_20\NN\3699975 disability</e2>_21\NN\14547369 ._22\.\1740
D007980_D010300 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 <e1>levodopa-responsive</e1>_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>parkinson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D007980_D010300 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 fluoxetine_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 <e1>levodopa-</e1>_12\NN\1740 or_13\CC\3541091 dopamine_14\NN\14807737 agonist-induced_15\JJ\1740 dyskinesias_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 <e2>parkinsonian</e2>_19\JJ\1740 motor_20\NN\3699975 disability_21\NN\14547369 ._22\.\1740
D004298_D009069 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 <e2>motor_5\NN\3699975 disability</e2>_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 <e1>dopamine</e1>_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D004298_D009069 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 fluoxetine_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 levodopa-_12\NN\1740 or_13\CC\3541091 <e1>dopamine</e1>_14\NN\14807737 agonist-induced_15\JJ\1740 dyskinesias_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 parkinsonian_19\JJ\1740 <e2>motor_20\NN\3699975 disability</e2>_21\NN\14547369 ._22\.\1740
D004298_D004409 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 <e2>dyskinesias</e2>_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 <e1>dopamine</e1>_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D004298_D004409 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 fluoxetine_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 levodopa-_12\NN\1740 or_13\CC\3541091 <e1>dopamine</e1>_14\NN\14807737 agonist-induced_15\JJ\1740 <e2>dyskinesias</e2>_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 parkinsonian_19\JJ\1740 motor_20\NN\3699975 disability_21\NN\14547369 ._22\.\1740
D004298_D010300 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>parkinson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 <e1>dopamine</e1>_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D004298_D010300 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 fluoxetine_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 levodopa-_12\NN\1740 or_13\CC\3541091 <e1>dopamine</e1>_14\NN\14807737 agonist-induced_15\JJ\1740 dyskinesias_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 <e2>parkinsonian</e2>_19\JJ\1740 motor_20\NN\3699975 disability_21\NN\14547369 ._22\.\1740
D001058_D009069 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 <e2>motor_5\NN\3699975 disability</e2>_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 <e1>apomorphine</e1>_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D001058_D009069 NONE after_0\IN\1740 fluoxetine_1\NN\4169152 treatment_2\NN\654885 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 significant_7\JJ\1740 47_8\CD\1740 %_9\NN\1740 improvement_10\NN\7359599 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.05_14\CD\1740 )_15\-RRB-\1740 of_16\IN\1740 <e1>apomorphine-induced</e1>_17\JJ\1740 dyskinesias_18\NNS\14084880 without_19\IN\1740 modification_20\NN\191142 of_21\IN\1740 parkinsonian_22\JJ\1740 <e2>motor_23\NN\3699975 disability</e2>_24\NN\14547369 ._25\.\1740
D001058_D004409 CID we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 <e2>dyskinesias</e2>_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 <e1>apomorphine</e1>_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D001058_D004409 CID after_0\IN\1740 fluoxetine_1\NN\4169152 treatment_2\NN\654885 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 significant_7\JJ\1740 47_8\CD\1740 %_9\NN\1740 improvement_10\NN\7359599 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.05_14\CD\1740 )_15\-RRB-\1740 of_16\IN\1740 <e1>apomorphine-induced</e1>_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 without_19\IN\1740 modification_20\NN\191142 of_21\IN\1740 parkinsonian_22\JJ\1740 motor_23\NN\3699975 disability_24\NN\14547369 ._25\.\1740
D001058_D010300 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>parkinson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 <e1>apomorphine</e1>_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 fluoxetine_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D001058_D010300 NONE after_0\IN\1740 fluoxetine_1\NN\4169152 treatment_2\NN\654885 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 significant_7\JJ\1740 47_8\CD\1740 %_9\NN\1740 improvement_10\NN\7359599 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.05_14\CD\1740 )_15\-RRB-\1740 of_16\IN\1740 <e1>apomorphine-induced</e1>_17\JJ\1740 dyskinesias_18\NNS\14084880 without_19\IN\1740 modification_20\NN\191142 of_21\IN\1740 <e2>parkinsonian</e2>_22\JJ\1740 motor_23\NN\3699975 disability_24\NN\14547369 ._25\.\1740
D005473_D009069 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 <e2>motor_5\NN\3699975 disability</e2>_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 parkinson_14\NN\1740 's_15\POS\1740 disease_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>fluoxetine</e1>_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D005473_D009069 NONE after_0\IN\1740 <e1>fluoxetine</e1>_1\NN\4169152 treatment_2\NN\654885 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 significant_7\JJ\1740 47_8\CD\1740 %_9\NN\1740 improvement_10\NN\7359599 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.05_14\CD\1740 )_15\-RRB-\1740 of_16\IN\1740 apomorphine-induced_17\JJ\1740 dyskinesias_18\NNS\14084880 without_19\IN\1740 modification_20\NN\191142 of_21\IN\1740 parkinsonian_22\JJ\1740 <e2>motor_23\NN\3699975 disability</e2>_24\NN\14547369 ._25\.\1740
D005473_D009069 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 <e1>fluoxetine</e1>_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 levodopa-_12\NN\1740 or_13\CC\3541091 dopamine_14\NN\14807737 agonist-induced_15\JJ\1740 dyskinesias_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 parkinsonian_19\JJ\1740 <e2>motor_20\NN\3699975 disability</e2>_21\NN\14547369 ._22\.\1740
D005473_D010300 NONE we_0\PRP\1740 evaluated_1\VBD\670261 the_2\DT\1740 severity_3\NN\5036394 of_4\IN\1740 motor_5\NN\3699975 disability_6\NN\14547369 and_7\CC\1740 dyskinesias_8\NNS\14084880 in_9\IN\13603305 seven_10\CD\13741022 levodopa-responsive_11\JJ\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>parkinson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 after_17\IN\1740 an_18\DT\6697703 acute_19\JJ\1740 challenge_20\NN\13927383 with_21\IN\1740 the_22\DT\1740 mixed_23\JJ\1740 dopamine_24\NN\14807737 agonist_25\NN\9613191 ,_26\,\1740 apomorphine_27\NN\3786417 ,_28\,\1740 before_29\IN\1740 and_30\CC\1740 after_31\IN\1740 the_32\DT\1740 administration_33\NN\1133281 of_34\IN\1740 <e1>fluoxetine</e1>_35\NN\4169152 (_36\-LRB-\1740 20_37\CD\13745420 mg_38\NN\13717155 twice_39\RB\1740 per_40\IN\1740 day_41\NN\15154774 )_42\-RRB-\1740 for_43\IN\1740 11_44\CD\13745420 +/-_45\CC\1740 1_46\CD\13741022 days_47\NNS\15140892 ._48\.\1740
D005473_D010300 NONE after_0\IN\1740 <e1>fluoxetine</e1>_1\NN\4169152 treatment_2\NN\654885 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 a_6\DT\13649268 significant_7\JJ\1740 47_8\CD\1740 %_9\NN\1740 improvement_10\NN\7359599 (_11\-LRB-\1740 p_12\NN\14622893 <_13\XX\1740 0.05_14\CD\1740 )_15\-RRB-\1740 of_16\IN\1740 apomorphine-induced_17\JJ\1740 dyskinesias_18\NNS\14084880 without_19\IN\1740 modification_20\NN\191142 of_21\IN\1740 <e2>parkinsonian</e2>_22\JJ\1740 motor_23\NN\3699975 disability_24\NN\14547369 ._25\.\1740
D005473_D010300 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 increased_4\VBN\169651 brain_5\NN\5462674 serotoninergic_6\NN\1740 transmission_7\NN\121166 with_8\IN\1740 <e1>fluoxetine</e1>_9\NN\4169152 may_10\MD\15209706 reduce_11\VB\441445 levodopa-_12\NN\1740 or_13\CC\3541091 dopamine_14\NN\14807737 agonist-induced_15\JJ\1740 dyskinesias_16\NNS\14084880 without_17\IN\1740 aggravating_18\VBG\126264 <e2>parkinsonian</e2>_19\JJ\1740 motor_20\NN\3699975 disability_21\NN\14547369 ._22\.\1740
18165598
D002045_D010146 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>bupivacaine</e1>_4\NN\1740 and_5\CC\1740 lidocaine_6\NN\3681148 on_7\IN\1740 prostaglandin_8\NN\5414534 e2_9\NN\1740 release_10\NN\3748886 ,_11\,\1740 cyclooxygenase_12\NN\14732946 gene_13\NN\8459252 expression_14\NN\4679549 and_15\CC\1740 <e2>pain</e2>_16\NN\14299637 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 pain_20\NN\14299637 model_21\NN\5888929 ._22\.\1740
D002045_D010146 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>bupivacaine</e1>_4\NN\1740 and_5\CC\1740 lidocaine_6\NN\3681148 on_7\IN\1740 prostaglandin_8\NN\5414534 e2_9\NN\1740 release_10\NN\3748886 ,_11\,\1740 cyclooxygenase_12\NN\14732946 gene_13\NN\8459252 expression_14\NN\4679549 and_15\CC\1740 pain_16\NN\14299637 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 <e2>pain</e2>_20\NN\14299637 model_21\NN\5888929 ._22\.\1740
D002045_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 <e1>bupivacaine/rofecoxib</e1>_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 <e2>pain</e2>_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 bupivacaine/placebo_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 pain_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 pge2_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
D002045_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 <e1>bupivacaine/rofecoxib</e1>_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 pain_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 bupivacaine/placebo_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 <e2>pain</e2>_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 pge2_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
D002045_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 bupivacaine/rofecoxib_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 <e2>pain</e2>_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 <e1>bupivacaine/placebo</e1>_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 pain_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 pge2_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
D002045_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 bupivacaine/rofecoxib_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 pain_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 <e1>bupivacaine/placebo</e1>_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 <e2>pain</e2>_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 pge2_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
D002045_D010146 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 <e1>bupivacaine</e1>_6\NN\1740 stimulates_7\VBZ\137313 cox-2_8\NN\14737847 gene_9\NN\8459252 expression_10\NN\4679549 after_11\IN\1740 tissue_12\NN\5220461 injury_13\NN\14052046 ,_14\,\1740 which_15\WDT\1740 is_16\VBZ\836236 associated_17\VBN\628491 with_18\IN\1740 higher_19\JJR\1740 pge2_20\NN\1740 production_21\NN\30358 and_22\CC\1740 <e2>pain</e2>_23\NN\14299637 after_24\IN\1740 the_25\DT\1740 local_26\JJ\1740 anesthetic_27\JJ\1740 effect_28\NN\34213 dissipates_29\NNS\1740 ._30\.\1740
D008012_D010146 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 bupivacaine_4\NN\1740 and_5\CC\1740 <e1>lidocaine</e1>_6\NN\3681148 on_7\IN\1740 prostaglandin_8\NN\5414534 e2_9\NN\1740 release_10\NN\3748886 ,_11\,\1740 cyclooxygenase_12\NN\14732946 gene_13\NN\8459252 expression_14\NN\4679549 and_15\CC\1740 <e2>pain</e2>_16\NN\14299637 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 pain_20\NN\14299637 model_21\NN\5888929 ._22\.\1740
D008012_D010146 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 bupivacaine_4\NN\1740 and_5\CC\1740 <e1>lidocaine</e1>_6\NN\3681148 on_7\IN\1740 prostaglandin_8\NN\5414534 e2_9\NN\1740 release_10\NN\3748886 ,_11\,\1740 cyclooxygenase_12\NN\14732946 gene_13\NN\8459252 expression_14\NN\4679549 and_15\CC\1740 pain_16\NN\14299637 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 <e2>pain</e2>_20\NN\14299637 model_21\NN\5888929 ._22\.\1740
D015232_D010146 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 bupivacaine_4\NN\1740 and_5\CC\1740 lidocaine_6\NN\3681148 on_7\IN\1740 <e1>prostaglandin_8\NN\5414534 e2</e1>_9\NN\1740 release_10\NN\3748886 ,_11\,\1740 cyclooxygenase_12\NN\14732946 gene_13\NN\8459252 expression_14\NN\4679549 and_15\CC\1740 <e2>pain</e2>_16\NN\14299637 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 pain_20\NN\14299637 model_21\NN\5888929 ._22\.\1740
D015232_D010146 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 bupivacaine_4\NN\1740 and_5\CC\1740 lidocaine_6\NN\3681148 on_7\IN\1740 <e1>prostaglandin_8\NN\5414534 e2</e1>_9\NN\1740 release_10\NN\3748886 ,_11\,\1740 cyclooxygenase_12\NN\14732946 gene_13\NN\8459252 expression_14\NN\4679549 and_15\CC\1740 pain_16\NN\14299637 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 <e2>pain</e2>_20\NN\14299637 model_21\NN\5888929 ._22\.\1740
D015232_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 bupivacaine/rofecoxib_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 <e2>pain</e2>_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 bupivacaine/placebo_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 pain_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 <e1>pge2</e1>_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
D015232_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 bupivacaine/rofecoxib_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 pain_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 bupivacaine/placebo_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 <e2>pain</e2>_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 <e1>pge2</e1>_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
D015232_D010146 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 bupivacaine_6\NN\1740 stimulates_7\VBZ\137313 cox-2_8\NN\14737847 gene_9\NN\8459252 expression_10\NN\4679549 after_11\IN\1740 tissue_12\NN\5220461 injury_13\NN\14052046 ,_14\,\1740 which_15\WDT\1740 is_16\VBZ\836236 associated_17\VBN\628491 with_18\IN\1740 higher_19\JJR\1740 <e1>pge2</e1>_20\NN\1740 production_21\NN\30358 and_22\CC\1740 <e2>pain</e2>_23\NN\14299637 after_24\IN\1740 the_25\DT\1740 local_26\JJ\1740 anesthetic_27\JJ\1740 effect_28\NN\34213 dissipates_29\NNS\1740 ._30\.\1740
D002045_D010149 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 describe_6\VBP\1001294 the_7\DT\1740 proinflammatory_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 <e1>bupivacaine</e1>_11\NN\1740 on_12\IN\1740 local_13\JJ\1740 prostaglandin_14\NN\5414534 e2_15\NN\1740 (_16\-LRB-\1740 pge2_17\NN\1740 )_18\-RRB-\1740 production_19\NN\30358 and_20\CC\1740 cyclooxygenase_21\NN\14732946 (_22\-LRB-\1740 cox_23\NN\14732946 )_24\-RRB-\1740 gene_25\NN\8459252 expression_26\NN\4679549 that_27\WDT\1740 increases_28\VBZ\169651 <e2>postoperative_29\JJ\1740 pain</e2>_30\NN\14299637 in_31\IN\13603305 human_32\JJ\1740 subjects_33\NNS\6598915 ._34\.\1740
D015232_D010149 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 describe_6\VBP\1001294 the_7\DT\1740 proinflammatory_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 bupivacaine_11\NN\1740 on_12\IN\1740 local_13\JJ\1740 <e1>prostaglandin_14\NN\5414534 e2</e1>_15\NN\1740 (_16\-LRB-\1740 pge2_17\NN\1740 )_18\-RRB-\1740 production_19\NN\30358 and_20\CC\1740 cyclooxygenase_21\NN\14732946 (_22\-LRB-\1740 cox_23\NN\14732946 )_24\-RRB-\1740 gene_25\NN\8459252 expression_26\NN\4679549 that_27\WDT\1740 increases_28\VBZ\169651 <e2>postoperative_29\JJ\1740 pain</e2>_30\NN\14299637 in_31\IN\13603305 human_32\JJ\1740 subjects_33\NNS\6598915 ._34\.\1740
D015232_D010149 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 describe_6\VBP\1001294 the_7\DT\1740 proinflammatory_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 bupivacaine_11\NN\1740 on_12\IN\1740 local_13\JJ\1740 prostaglandin_14\NN\5414534 e2_15\NN\1740 (_16\-LRB-\1740 <e1>pge2</e1>_17\NN\1740 )_18\-RRB-\1740 production_19\NN\30358 and_20\CC\1740 cyclooxygenase_21\NN\14732946 (_22\-LRB-\1740 cox_23\NN\14732946 )_24\-RRB-\1740 gene_25\NN\8459252 expression_26\NN\4679549 that_27\WDT\1740 increases_28\VBZ\169651 <e2>postoperative_29\JJ\1740 pain</e2>_30\NN\14299637 in_31\IN\13603305 human_32\JJ\1740 subjects_33\NNS\6598915 ._34\.\1740
C116926_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 <e1>bupivacaine/rofecoxib</e1>_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 <e2>pain</e2>_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 bupivacaine/placebo_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 pain_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 pge2_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
C116926_D010146 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 <e1>bupivacaine/rofecoxib</e1>_3\JJ\1740 group_4\NN\2137 reported_5\VBD\831651 significantly_6\RB\1740 less_7\RBR\1740 pain_8\JJ\1740 ,_9\,\1740 as_10\IN\14622893 assessed_11\VBN\670261 by_12\IN\1740 a_13\DT\13649268 visual_14\JJ\1740 analog_15\NN\4743605 scale_16\NN\7260623 ,_17\,\1740 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 other_21\JJ\1740 three_22\CD\13741022 treatment_23\NN\654885 groups_24\NNS\2137 over_25\IN\5867413 the_26\DT\1740 first_27\JJ\1740 4_28\CD\13741022 h._29\NN\1740 however_30\RB\1740 ,_31\,\1740 the_32\DT\1740 bupivacaine/placebo_33\NN\1740 group_34\NN\2137 reported_35\VBD\831651 significantly_36\RB\1740 more_37\JJR\1740 <e2>pain</e2>_38\NN\14299637 at_39\IN\14622893 24_40\CD\13745420 h_41\NN\14622893 and_42\CC\1740 pge2_43\NN\1740 levels_44\NNS\4916342 during_45\IN\1740 the_46\DT\1740 first_47\JJ\1740 4_48\CD\13741022 h_49\NN\14622893 were_50\VBD\836236 significantly_51\RB\1740 higher_52\JJR\1740 than_53\IN\1740 the_54\DT\1740 other_55\JJ\1740 three_56\CD\13741022 treatment_57\NN\654885 groups_58\NNS\2137 ._59\.\1740
D002045_D017695 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 <e1>bupivacaine</e1>_6\NN\1740 stimulates_7\VBZ\137313 cox-2_8\NN\14737847 gene_9\NN\8459252 expression_10\NN\4679549 after_11\IN\1740 <e2>tissue_12\NN\5220461 injury</e2>_13\NN\14052046 ,_14\,\1740 which_15\WDT\1740 is_16\VBZ\836236 associated_17\VBN\628491 with_18\IN\1740 higher_19\JJR\1740 pge2_20\NN\1740 production_21\NN\30358 and_22\CC\1740 pain_23\NN\14299637 after_24\IN\1740 the_25\DT\1740 local_26\JJ\1740 anesthetic_27\JJ\1740 effect_28\NN\34213 dissipates_29\NNS\1740 ._30\.\1740
D015232_D017695 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 bupivacaine_6\NN\1740 stimulates_7\VBZ\137313 cox-2_8\NN\14737847 gene_9\NN\8459252 expression_10\NN\4679549 after_11\IN\1740 <e2>tissue_12\NN\5220461 injury</e2>_13\NN\14052046 ,_14\,\1740 which_15\WDT\1740 is_16\VBZ\836236 associated_17\VBN\628491 with_18\IN\1740 higher_19\JJR\1740 <e1>pge2</e1>_20\NN\1740 production_21\NN\30358 and_22\CC\1740 pain_23\NN\14299637 after_24\IN\1740 the_25\DT\1740 local_26\JJ\1740 anesthetic_27\JJ\1740 effect_28\NN\34213 dissipates_29\NNS\1740 ._30\.\1740
